Oral	O
treponemes	B-bacteria
are	O
considered	O
to	O
be	O
important	O
in	O
the	O
development	O
and	O
progression	O
of	O
periodontal	O
diseases	O
.	O

We	O
investigated	O
the	O
mechanisms	O
of	O
recognition	O
and	O
activation	O
of	O
human	O
gingival	O
epithelial	O
cells	O
(	O
HGEC	O
)	O
with	O
the	O
oral	O
treponemes	B-bacteria
Treponema	B-bacteria
denticola	I-bacteria
,	O
Treponema	B-bacteria
vincentii	I-bacteria
,	O
and	O
Treponema	B-bacteria
medium	I-bacteria
and	O
their	O
outer	O
membrane	O
extracts	O
(	O
OMEs	O
)	O
.	O

T	B-bacteria
.	I-bacteria
vincentii	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
medium	I-bacteria
but	O
not	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
produced	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
in	O
an	O
HGEC	O
culture	O
.	O

Further	O
,	O
all	O
three	O
treponemes	B-bacteria
induced	O
IL	O
-	O
8	O
mRNA	O
expression	O
and	O
NF	O
-	O
kappaB	O
activation	O
in	O
HGEC	O
.	O

Among	O
them	O
,	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
especially	O
exhibited	O
trypsin	O
-	O
and	O
chymotrypsin	O
-	O
like	O
protease	O
activities	O
,	O
and	O
the	O
addition	O
of	O
chymostatin	O
,	O
a	O
chymotrypsin	O
protease	O
inhibitor	O
,	O
resulted	O
in	O
detectable	O
IL	O
-	O
8	O
production	O
by	O
HGEC	O
cultured	O
with	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
.	O

Additionally	O
,	O
IL	O
-	O
8	O
mRNA	O
expression	O
in	O
HGEC	O
cultured	O
with	O
the	O
three	O
treponemes	B-bacteria
and	O
their	O
OMEs	O
was	O
definitely	O
inhibited	O
by	O
the	O
mouse	O
anti	O
-	O
human	O
Toll	O
-	O
like	O
receptor	O
2	O
(	O
TLR2	O
)	O
monoclonal	O
antibody	O
TL2	O
.	O
1	O
.	O

These	O
findings	O
suggest	O
that	O
oral	O
treponemes	B-bacteria
and	O
their	O
OMEs	O
activate	O
HGEC	O
through	O
TLR2	O
.	O

Although	O
bacterial	O
DNA	O
(	O
bDNA	O
)	O
containing	O
unmethylated	O
CpG	O
motifs	O
stimulates	O
innate	O
immune	O
cells	O
through	O
Toll	O
-	O
like	O
receptor	O
9	O
(	O
TLR	O
-	O
9	O
)	O
,	O
its	O
precise	O
role	O
in	O
the	O
pathophysiology	O
of	O
diseases	O
is	O
still	O
equivocal	O
.	O

Here	O
we	O
examined	O
the	O
immunostimulatory	O
effects	O
of	O
DNA	O
extracted	O
from	O
periodontopathogenic	O
bacteria	O
.	O

A	O
major	O
role	O
in	O
the	O
etiology	O
of	O
periodontal	O
diseases	O
has	O
been	O
attributed	O
to	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
and	O
Peptostreptococcus	B-bacteria
micros	I-bacteria
.	O

We	O
therefore	O
isolated	O
DNA	O
from	O
these	O
bacteria	O
and	O
stimulated	O
murine	O
macrophages	O
and	O
human	O
gingival	O
fibroblasts	O
(	O
HGF	O
)	O
in	O
vitro	O
.	O

Furthermore	O
,	O
HEK	O
293	O
cells	O
transfected	O
with	O
human	O
TLR	O
-	O
9	O
were	O
also	O
stimulated	O
with	O
these	O
DNA	O
preparations	O
.	O

We	O
observed	O
that	O
DNA	O
from	O
these	O
pathogens	O
stimulates	O
macrophages	O
and	O
gingival	O
fibroblasts	O
to	O
produce	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
interleukin	O
-	O
6	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Methylation	O
of	O
the	O
CpG	O
motifs	O
abolished	O
the	O
observed	O
effects	O
.	O

Activation	O
of	O
HEK	O
293	O
cells	O
expressing	O
TLR	O
-	O
9	O
which	O
were	O
responsive	O
to	O
bDNA	O
but	O
not	O
to	O
lipopolysaccharide	O
confirmed	O
that	O
immunostimulation	O
was	O
achieved	O
by	O
bDNA	O
.	O

In	O
addition	O
,	O
the	O
examined	O
bDNA	O
differed	O
in	O
the	O
ability	O
to	O
stimulate	O
murine	O
macrophages	O
,	O
HGF	O
,	O
and	O
TLR	O
-	O
9	O
-	O
transfected	O
cells	O
.	O

DNA	O
from	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
elicited	O
a	O
potent	O
cytokine	O
response	O
,	O
while	O
DNA	O
from	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
micros	I-bacteria
showed	O
lower	O
immunostimulatory	O
activity	O
.	O

Taken	O
together	O
,	O
the	O
results	O
strongly	O
suggest	O
that	O
DNA	O
from	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
and	O
P	B-bacteria
.	I-bacteria
micros	I-bacteria
possesses	O
immunostimulatory	O
properties	O
in	O
regard	O
to	O
cytokine	O
secretion	O
by	O
macrophages	O
and	O
fibroblasts	O
.	O

These	O
stimulatory	O
effects	O
are	O
due	O
to	O
unmethylated	O
CpG	O
motifs	O
within	O
bDNA	O
and	O
differ	O
between	O
distinct	O
periodontopathogenic	O
bacteria	O
strains	O
.	O

Hence	O
,	O
immunostimulation	O
by	O
DNA	O
from	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
and	O
P	B-bacteria
.	I-bacteria
micros	I-bacteria
could	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
periodontal	O
diseases	O
.	O

Immunosuppressants	O
play	O
an	O
essential	O
role	O
in	O
transplantation	O
therapy	O
.	O

In	O
view	O
of	O
the	O
side	O
effects	O
,	O
e	O
.	O
g	O
.	O
gingival	O
overgrowth	O
,	O
the	O
present	O
in	O
vitro	O
study	O
was	O
performed	O
in	O
order	O
to	O
investigate	O
the	O
effect	O
of	O
selected	O
immunosuppressants	O
on	O
metabolic	O
activities	O
of	O
gingival	O
fibroblasts	O
.	O

Furthermore	O
,	O
the	O
effect	O
on	O
the	O
growth	O
of	O
six	O
oral	O
microorganisms	O
was	O
investigated	O
.	O

Human	O
gingival	O
fibroblasts	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
azathioprine	O
(	O
Aza	O
)	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
tacrolimus	O
(	O
Tac	O
)	O
or	O
mycophenolatmofetil	O
(	O
Myc	O
)	O
.	O

PGE	O
subset	O
2	O
release	O
was	O
determined	O
by	O
means	O
of	O
a	O
specific	O
competitive	O
enzyme	O
immunoassay	O
,	O
using	O
monoclonal	O
antibodies	O
specific	O
for	O
PGE	O
subset	O
2	O
(	O
clone	O
E2R1	O
)	O
.	O

The	O
protein	O
content	O
was	O
measured	O
spectrophotometrically	O
.	O

A	O
redox	O
indicator	O
system	O
was	O
employed	O
to	O
assess	O
the	O
proliferation	O
activity	O
.	O

In	O
an	O
additional	O
trial	O
the	O
growth	O
of	O
six	O
strains	O
of	O
oral	O
bacteria	O
(	O
A	B-bacteria
.	I-bacteria
viscosus	I-bacteria
T14V	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
H1	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
10449	I-bacteria
,	O
C	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
DR2001	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
Y4	I-bacteria
,	O
and	O
M	B-bacteria
.	I-bacteria
micros	I-bacteria
33270	I-bacteria
)	O
in	O
the	O
presence	O
of	O
the	O
immunosuppressants	O
was	O
measured	O
.	O

In	O
comparison	O
with	O
the	O
controls	O
,	O
the	O
PGE	O
subset	O
2	O
release	O
was	O
increased	O
by	O
39	O
.	O
3	O
%	O
following	O
incubation	O
with	O
Aza	O
,	O
and	O
by	O
77	O
.	O
0	O
%	O
with	O
CsA	O
.	O

The	O
protein	O
concentrations	O
(	O
1	O
g	O
immunosuppressant	O
/	O
ml	O
medium	O
)	O
were	O
reduced	O
by	O
26	O
.	O
0	O
%	O
for	O
Aza	O
and	O
17	O
.	O
0	O
%	O
for	O
Myc	O
.	O

Furthermore	O
,	O
a	O
drug	O
-	O
dependent	O
inhibition	O
in	O
the	O
cell	O
proliferation	O
rate	O
was	O
noted	O
after	O
an	O
incubation	O
period	O
of	O
6	O
hours	O
(	O
Aza	O
70	O
.	O
7	O
%	O
,	O
CsA	O
78	O
.	O
2	O
%	O
,	O
Myc	O
69	O
.	O
8	O
%	O
,	O
Tac	O
64	O
.	O
0	O
%	O
)	O
.	O

The	O
most	O
pronounced	O
growth	O
-	O
inhibiting	O
effects	O
were	O
observed	O
for	O
CsA	O
at	O
values	O
ranging	O
from	O
21	O
.	O
0	O
%	O
(	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
10449	I-bacteria
)	O
to	O
48	O
.	O
6	O
%	O
(	O
A	B-bacteria
.	I-bacteria
viscosus	I-bacteria
T14V	I-bacteria
)	O
growth	O
inhibition	O
.	O

The	O
present	O
study	O
with	O
common	O
immunsuppresants	O
demonstrated	O
both	O
a	O
medication	O
-	O
and	O
dose	O
-	O
dependent	O
alteration	O
in	O
the	O
metabolic	O
activity	O
of	O
gingival	O
fibroblasts	O
.	O

Furthermore	O
,	O
growth	O
-	O
inhibitory	O
effects	O
on	O
the	O
selected	O
bacterial	O
strains	O
could	O
be	O
observed	O
.	O

The	O
in	O
vitro	O
activity	O
of	O
faropenem	O
,	O
an	O
oral	O
penem	O
,	O
was	O
compared	O
with	O
those	O
of	O
penicillin	O
,	O
co	O
-	O
amoxiclav	O
,	O
cefoxitin	O
,	O
clindamycin	O
,	O
erythromycin	O
and	O
metronidazole	O
against	O
106	O
isolates	O
of	O
anaerobic	O
pathogens	O
involved	O
in	O
systemic	O
infections	O
.	O

The	O
organisms	O
tested	O
comprised	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
29	O
)	O
,	O
Prevotella	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
eight	O
)	O
,	O
Prevotella	B-bacteria
melaninogenica	I-bacteria
(	O
seven	O
)	O
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
(	O
five	O
)	O
,	O
Actinomyces	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
25	O
)	O
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
(	O
14	O
)	O
,	O
Peptostreptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
11	O
)	O
,	O
Bacteroides	B-bacteria
ureolyticus	I-bacteria
(	O
five	O
)	O
and	O
Bacteroides	B-bacteria
forsythus	I-bacteria
(	O
two	O
)	O
.	O

The	O
antimicrobial	O
properties	O
of	O
faropenem	O
were	O
investigated	O
by	O
studying	O
MICs	O
,	O
MBCs	O
,	O
time	O
-	O
kill	O
kinetics	O
and	O
post	O
-	O
antibiotic	O
effect	O
(	O
PAE	O
)	O
.	O

faropenem	O
highly	O
active	O
against	O
all	O
the	O
anaerobes	O
tested	O
(	O
MIC	O
(	O
90	O
)	O
<	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
L	O
)	O
and	O
was	O
bactericidal	O
against	O
both	O
beta	O
-	O
lactamase	O
-	O
positive	O
and	O
-	O
negative	O
anaerobes	O
,	O
with	O
a	O
maximum	O
bactericidal	O
effect	O
at	O
10	O
x	O
MIC	O
at	O
between	O
12	O
and	O
24	O
h	O
.	O
In	O
addition	O
,	O
faropenem	O
had	O
an	O
in	O
vitro	O
PAE	O
on	O
all	O
the	O
tested	O
isolates	O
and	O
this	O
was	O
not	O
influenced	O
by	O
beta	O
-	O
lactamase	O
production	O
.	O

faropenem	O
be	O
useful	O
for	O
treating	O
infections	O
caused	O
by	O
periodontal	O
bacteria	O
or	O
oral	O
flora	O
.	O

Members	O
of	O
the	O
uncultivated	O
bacterial	O
division	O
TM7	B-bacteria
have	O
been	O
detected	O
in	O
the	O
human	O
mouth	O
,	O
but	O
little	O
information	O
is	O
available	O
regarding	O
their	O
prevalence	O
and	O
diversity	O
at	O
this	O
site	O
.	O

Human	O
subgingival	O
plaque	O
samples	O
from	O
healthy	O
sites	O
and	O
sites	O
exhibiting	O
various	O
stages	O
of	O
periodontal	O
disease	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
TM7	B-bacteria
bacteria	I-bacteria
.	O

TM7	B-bacteria
ribosomal	O
DNA	O
(	O
rDNA	O
)	O
was	O
found	O
in	O
96	O
%	O
of	O
the	O
samples	O
,	O
and	O
it	O
accounted	O
for	O
approximately	O
0	O
.	O
3	O
%	O
,	O
on	O
average	O
,	O
of	O
all	O
bacterial	O
rDNA	O
in	O
the	O
samples	O
as	O
determined	O
by	O
real	O
-	O
time	O
quantitative	O
PCR	O
.	O

Two	O
new	O
phylotypes	O
of	O
this	O
division	O
were	O
identified	O
,	O
and	O
members	O
of	O
the	O
division	O
were	O
found	O
to	O
exhibit	O
filamentous	O
morphology	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

The	O
abundance	O
of	O
TM7	B-bacteria
rDNA	O
relative	O
to	O
total	O
bacterial	O
rDNA	O
was	O
higher	O
in	O
sites	O
with	O
mild	O
periodontitis	O
(	O
0	O
.	O
54	O
%	O
+	O
/	O
-	O
0	O
.	O
1	O
%	O
)	O
than	O
in	O
either	O
healthy	O
sites	O
(	O
0	O
.	O
21	O
%	O
+	O
/	O
-	O
0	O
.	O
05	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
or	O
sites	O
with	O
severe	O
periodontitis	O
(	O
0	O
.	O
29	O
%	O
+	O
/	O
-	O
0	O
.	O
06	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

One	O
division	O
subgroup	O
,	O
the	O
I025	O
phylotype	O
,	O
was	O
detected	O
in	O
1	O
of	O
18	O
healthy	O
samples	O
and	O
38	O
of	O
58	O
disease	O
samples	O
.	O

These	O
data	O
suggest	O
that	O
this	O
phylotype	O
,	O
and	O
the	O
TM7	B-bacteria
bacterial	O
division	O
in	O
general	O
,	O
may	O
play	O
a	O
role	O
in	O
the	O
multifactorial	O
process	O
leading	O
to	O
periodontitis	O
.	O

Dental	O
diseases	O
are	O
among	O
the	O
most	O
prevalent	O
and	O
costly	O
diseases	O
affecting	O
industrialized	O
societies	O
,	O
and	O
yet	O
are	O
highly	O
preventable	O
.	O

The	O
microflora	O
of	O
dental	O
plaque	O
biofilms	O
from	O
diseased	O
sites	O
is	O
distinct	O
from	O
that	O
found	O
in	O
health	O
,	O
although	O
the	O
putative	O
pathogens	O
can	O
often	O
be	O
detected	O
in	O
low	O
numbers	O
at	O
normal	O
sites	O
.	O

In	O
dental	O
caries	O
,	O
there	O
is	O
a	O
shift	O
towards	O
community	O
dominance	O
by	O
acidogenic	O
and	O
acid	O
-	O
tolerant	O
Gram	O
-	O
positive	O
bacteria	O
(	O
e	O
.	O
g	O
.	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
lactobacilli	B-bacteria
)	O
at	O
the	O
expense	O
of	O
the	O
acid	O
-	O
sensitive	O
species	O
associated	O
with	O
sound	O
enamel	O
.	O

In	O
contrast	O
,	O
the	O
numbers	O
and	O
proportions	O
of	O
obligately	O
anaerobic	O
bacteria	O
,	O
including	O
Gram	O
-	O
negative	O
proteolytic	O
species	O
,	O
increase	O
in	O
periodontal	O
diseases	O
.	O

Modelling	O
studies	O
using	O
defined	O
consortia	O
of	O
oral	O
bacteria	O
grown	O
in	O
planktonic	O
and	O
biofilm	O
systems	O
have	O
been	O
undertaken	O
to	O
identify	O
environmental	O
factors	O
responsible	O
for	O
driving	O
these	O
deleterious	O
shifts	O
in	O
the	O
plaque	O
microflora	O
.	O

Repeated	O
conditions	O
of	O
low	O
pH	O
(	O
rather	O
than	O
sugar	O
availability	O
per	O
se	O
)	O
selected	O
for	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
lactobacilli	B-bacteria
,	O
while	O
the	O
introduction	O
of	O
novel	O
host	O
proteins	O
and	O
glycoproteins	O
(	O
as	O
occurs	O
during	O
the	O
inflammatory	O
response	O
to	O
plaque	O
)	O
,	O
and	O
the	O
concomitant	O
rise	O
in	O
local	O
pH	O
,	O
enriched	O
for	O
Gram	O
-	O
negative	O
anaerobic	O
and	O
asaccharolytic	O
species	O
.	O

These	O
studies	O
emphasized	O
(	O
a	O
)	O
.	O
significant	O
properties	O
of	O
dental	O
plaque	O
as	O
both	O
a	O
biofilm	O
and	O
a	O
microbial	O
community	O
,	O
and	O
(	O
b	O
)	O
.	O
the	O
dynamic	O
relationship	O
existing	O
between	O
the	O
environment	O
and	O
the	O
composition	O
of	O
the	O
oral	O
microflora	O
.	O

This	O
research	O
resulted	O
in	O
a	O
novel	O
hypothesis	O
(	O
the	O
'	O
ecological	O
plaque	O
hypothesis	O
'	O
)	O
to	O
better	O
describe	O
the	O
relationship	O
between	O
plaque	O
bacteria	O
and	O
the	O
host	O
in	O
health	O
and	O
disease	O
.	O

Implicit	O
in	O
this	O
hypothesis	O
is	O
the	O
concept	O
that	O
disease	O
can	O
be	O
prevented	O
not	O
only	O
by	O
directly	O
inhibiting	O
the	O
putative	O
pathogens	O
,	O
but	O
also	O
by	O
interfering	O
with	O
the	O
environmental	O
factors	O
driving	O
the	O
selection	O
and	O
enrichment	O
of	O
these	O
bacteria	O
.	O

Thus	O
,	O
a	O
more	O
holistic	O
approach	O
can	O
be	O
taken	O
in	O
disease	O
control	O
and	O
management	O
strategies	O
.	O

Sample	O
groups	O
of	O
children	O
(	O
n	O
=	O
50	O
)	O
and	O
adults	O
(	O
n	O
=	O
38	O
)	O
were	O
selected	O
from	O
pools	O
of	O
207	O
children	O
,	O
(	O
11	O
-	O
13	O
-	O
year	O
olds	O
from	O
two	O
primary	O
schools	O
)	O
and	O
94	O
adults	O
(	O
25	O
-	O
44	O
-	O
year	O
olds	O
from	O
four	O
governmental	O
agencies	O
)	O
who	O
were	O
the	O
subjects	O
of	O
an	O
oral	O
health	O
survey	O
among	O
Tibetans	O
living	O
in	O
Lhasa	O
,	O
Tibet	O
Autonomous	O
Region	O
.	O

Mean	O
ages	O
of	O
the	O
study	O
groups	O
of	O
children	O
(	O
38	O
%	O
females	O
)	O
and	O
adults	O
(	O
61	O
%	O
females	O
)	O
were	O
11	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
and	O
37	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
1	O
years	O
,	O
respectively	O
.	O

All	O
had	O
lived	O
in	O
Tibet	O
since	O
birth	O
.	O

Oral	O
rinse	O
samples	O
were	O
selective	O
cultured	O
to	O
isolate	O
,	O
quantify	O
and	O
speciate	O
aerobic	O
and	O
facultatively	O
anaerobic	O
Gram	O
-	O
negative	O
rods	O
(	O
using	O
the	O
API	O
20E	O
kit	O
)	O
and	O
yeasts	O
(	O
using	O
API	O
20C	O
AUX	O
and	O
API	O
ZYM	O
kits	O
)	O
.	O

For	O
children	O
,	O
the	O
isolation	O
rates	O
for	O
oral	O
coliform	B-bacteria
bacteria	I-bacteria
and	O
yeasts	O
were	O
84	O
and	O
14	O
%	O
,	O
respectively	O
,	O
for	O
adults	O
,	O
the	O
respective	O
rates	O
were	O
26	O
and	O
40	O
%	O
.	O

The	O
corresponding	O
quantities	O
of	O
coliforms	B-bacteria
/	O
yeasts	O
for	O
children	O
and	O
adults	O
were	O
0	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
6	O
x	O
10	O
(	O
3	O
)	O
c	O
.	O
f	O
.	O
u	O
.	O
/	O
15	O
.	O
8	O
+	O
/	O
-	O
72	O
.	O
3	O
and	O
0	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
6	O
x	O
10	O
(	O
3	O
)	O
c	O
.	O
f	O
.	O
u	O
.	O
/	O
57	O
.	O
2	O
+	O
/	O
-	O
137	O
.	O
5c	O
.	O
f	O
.	O
u	O
.	O
per	O
millilitre	O
oral	O
rinse	O
,	O
respectively	O
.	O

Aerobic	O
and	O
facultatively	O
anaerobic	O
Gram	O
-	O
negative	O
rods	O
and	O
Stenotrophomonas	B-bacteria
maltophilia	I-bacteria
,	O
a	O
free	O
-	O
living	O
saprophytic	O
and	O
ubiquitous	O
bacterial	O
species	O
of	O
wide	O
geographic	O
distribution	O
,	O
were	O
significantly	O
more	O
frequently	O
recovered	O
from	O
the	O
children	O
'	O
s	O
oral	O
rinses	O
.	O

The	O
isolation	O
rates	O
of	O
facultatively	O
anaerobic	O
Gram	O
-	O
negative	O
rods	O
in	O
adults	O
and	O
yeasts	O
in	O
both	O
groups	O
were	O
similar	O
to	O
those	O
found	O
in	O
similar	O
cohorts	O
from	O
southern	O
China	O
in	O
earlier	O
studies	O
.	O

Randomly	O
amplified	O
polymeric	O
DNA	O
analysis	O
showed	O
that	O
the	O
S	B-bacteria
.	I-bacteria
maltophilia	I-bacteria
spp	I-bacteria
.	I-bacteria
isolated	O
from	O
children	O
were	O
of	O
several	O
different	O
clonal	O
types	O
and	O
were	O
school	O
specific	O
.	O

This	O
study	O
shows	O
that	O
the	O
colonisation	O
rate	O
of	O
facultatively	O
anaerobic	O
Gram	O
-	O
negative	O
rods	O
in	O
adults	O
and	O
yeasts	O
in	O
both	O
groups	O
are	O
similar	O
to	O
those	O
in	O
populations	O
living	O
at	O
lower	O
altitudes	O
,	O
the	O
native	O
young	O
,	O
urban	O
Tibetans	O
appear	O
to	O
exhibit	O
a	O
high	O
oral	O
carriage	O
rate	O
of	O
S	B-bacteria
.	I-bacteria
maltophilia	I-bacteria
spp	I-bacteria
.	O

The	O
objectives	O
of	O
the	O
study	O
were	O
to	O
investigate	O
the	O
antimicrobial	O
efficacy	O
,	O
over	O
time	O
,	O
of	O
combining	O
antibacterial	O
agents	O
with	O
a	O
glass	O
ionomer	O
cement	O
(	O
GIC	O
)	O
.	O

This	O
was	O
assessed	O
using	O
an	O
agar	O
diffusion	O
test	O
.	O

Chlorhexidine	O
hydrochloride	O
,	O
cetylpyridinium	O
chloride	O
,	O
cetrimide	O
and	O
benzalkonium	O
chloride	O
were	O
added	O
to	O
Fuji	O
IX	O
GIC	O
at	O
0	O
,	O
1	O
,	O
2	O
and	O
4	O
%	O
w	O
/	O
w	O
.	O

Antibacterial	O
-	O
GIC	O
specimens	O
were	O
placed	O
onto	O
agar	O
plates	O
inoculated	O
with	O
one	O
of	O
six	O
bacterial	O
species	O
(	O
Streptococcis	B-bacteria
,	O
Lactobacillus	B-bacteria
,	O
and	O
Actinomyces	B-bacteria
,	O
two	O
each	O
)	O
and	O
the	O
area	O
of	O
inhibition	O
calculated	O
after	O
24	O
h	O
incubation	O
.	O

The	O
experiment	O
was	O
repeated	O
weekly	O
and	O
at	O
week	O
11	O
the	O
surface	O
of	O
the	O
specimen	O
was	O
abraded	O
prior	O
to	O
replacing	O
on	O
inoculated	O
agar	O
plates	O
.	O

Control	O
specimens	O
of	O
the	O
GIC	O
produced	O
no	O
bacterial	O
inhibition	O
.	O

The	O
antibacterial	O
-	O
GIC	O
combination	O
specimens	O
showed	O
significant	O
inhibition	O
which	O
decreased	O
at	O
different	O
rates	O
over	O
the	O
test	O
period	O
.	O

Resurfacing	O
of	O
the	O
specimens	O
showed	O
a	O
dramatic	O
increase	O
of	O
antibacterial	O
action	O
similar	O
to	O
levels	O
produced	O
on	O
week	O
1	O
.	O

CT	O
-	O
GIC	O
showed	O
the	O
greatest	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
inhibitory	O
effect	O
throughout	O
the	O
experimental	O
period	O
for	O
4	O
out	O
of	O
6	O
test	O
bacteria	O
.	O

The	O
addition	O
of	O
antibacterial	O
agents	O
to	O
Fuji	O
IX	O
creates	O
a	O
GIC	O
material	O
with	O
significant	O
antimicrobial	O
action	O
in	O
vitro	O
which	O
is	O
dependent	O
on	O
concentration	O
and	O
type	O
of	O
antibacterial	O
agent	O
,	O
and	O
appears	O
to	O
be	O
associated	O
primarily	O
with	O
a	O
release	O
of	O
the	O
antibacterial	O
from	O
the	O
surface	O
layer	O
of	O
the	O
specimen	O
.	O

We	O
immunohistologically	O
examined	O
the	O
prevalence	O
and	O
localization	O
of	O
bacteria	O
invading	O
dentinal	O
tubules	O
of	O
the	O
roots	O
of	O
teeth	O
with	O
infected	O
canals	O
.	O

Forty	O
extracted	O
teeth	O
with	O
apical	O
lesions	O
were	O
selected	O
and	O
divided	O
into	O
two	O
groups	O
:	O
a	O
group	O
of	O
untreated	O
teeth	O
and	O
a	O
group	O
of	O
canal	O
-	O
enlarged	O
teeth	O
.	O

The	O
bacteria	O
in	O
the	O
specimens	O
were	O
detected	O
by	O
Brown	O
-	O
Brenn	O
stain	O
and	O
the	O
labeled	O
-	O
streptavidin	O
-	O
biotin	O
method	O
with	O
specific	O
antisera	O
for	O
16	O
-	O
bacteria	O
.	O

Seventy	O
percent	O
of	O
the	O
examined	O
teeth	O
showed	O
bacteria	O
invading	O
the	O
dentinal	O
tubules	O
of	O
the	O
roots	O
.	O

Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Eubacterium	B-bacteria
alactolyticum	I-bacteria
,	O
E	B-bacteria
.	I-bacteria
nodatum	I-bacteria
,	O
Lactobacillus	B-bacteria
casei	I-bacteria
,	O
and	O
Peptostreptococcus	B-bacteria
micros	I-bacteria
were	O
abundant	O
.	O

Even	O
in	O
the	O
canal	O
-	O
enlarged	O
group	O
,	O
invasion	O
of	O
bacteria	O
was	O
observed	O
in	O
65	O
%	O
of	O
teeth	O
.	O

This	O
study	O
revealed	O
the	O
actual	O
condition	O
of	O
bacteria	O
in	O
infected	O
root	O
dentin	O
and	O
suggested	O
that	O
the	O
canal	O
-	O
enlargement	O
procedure	O
could	O
not	O
completely	O
remove	O
all	O
the	O
bacteria	O
in	O
the	O
infected	O
dentinal	O
tubules	O
of	O
the	O
root	O
.	O

Mucositis	O
is	O
an	O
acute	O
inflammation	O
of	O
the	O
oral	O
mucosa	O
because	O
of	O
radiotherapy	O
and	O
/	O
or	O
chemotherapy	O
.	O

All	O
patients	O
receiving	O
radiotherapy	O
in	O
the	O
head	O
and	O
neck	O
region	O
develop	O
oral	O
mucositis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
effects	O
of	O
selective	O
oral	O
flora	O
elimination	O
on	O
radiotherapy	O
-	O
induced	O
oral	O
mucositis	O
,	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomised	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Sixty	O
-	O
five	O
patients	O
with	O
a	O
malignant	O
tumour	O
in	O
the	O
head	O
and	O
neck	O
regions	O
to	O
be	O
treated	O
with	O
primary	O
curative	O
or	O
postoperative	O
radiotherapy	O
participated	O
in	O
this	O
study	O
.	O

The	O
patients	O
received	O
either	O
the	O
active	O
lozenges	O
of	O
1	O
g	O
containing	O
polymyxin	O
E	O
2	O
mg	O
,	O
tobramycin	O
1	O
.	O
8	O
mg	O
and	O
amphotericin	O
B	O
10	O
mg	O
(	O
PTA	O
)	O
(	O
33	O
patients	O
)	O
or	O
the	O
placebo	O
lozenges	O
(	O
32	O
patients	O
)	O
,	O
four	O
times	O
daily	O
during	O
the	O
full	O
course	O
of	O
radiotherapy	O
.	O

Mucositis	O
,	O
changes	O
in	O
the	O
oral	O
flora	O
,	O
quality	O
of	O
feeding	O
and	O
changes	O
of	O
total	O
body	O
weight	O
were	O
assessed	O
.	O

Mucositis	O
score	O
did	O
not	O
differ	O
between	O
the	O
groups	O
during	O
the	O
first	O
5	O
weeks	O
of	O
radiotherapy	O
.	O

Nasogastric	O
tube	O
feeding	O
was	O
needed	O
in	O
six	O
patients	O
(	O
19	O
%	O
)	O
of	O
the	O
placebo	O
group	O
and	O
two	O
patients	O
(	O
6	O
%	O
)	O
of	O
the	O
PTA	O
group	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

Mean	O
weight	O
loss	O
after	O
5	O
weeks	O
of	O
radiation	O
was	O
less	O
in	O
the	O
PTA	O
group	O
(	O
1	O
.	O
3	O
kg	O
)	O
(	O
s	O
.	O
d	O
.	O

:	O
3	O
.	O
0	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
2	O
.	O
8	O
kg	O
)	O
(	O
s	O
.	O
d	O
.	O
:	O
2	O
.	O
9	O
)	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Colonisation	O
index	O
of	O
Candida	O
species	O
and	O
Gram	O
-	O
negative	O
bacilli	O
was	O
reduced	O
in	O
the	O
PTA	O
group	O
and	O
not	O
in	O
the	O
placebo	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

No	O
effect	O
on	O
other	O
microorganisms	O
was	O
detected	O
.	O

In	O
conclusion	O
,	O
selective	O
oral	O
flora	O
elimination	O
in	O
head	O
and	O
neck	O
irradiation	O
patients	O
does	O
not	O
prevent	O
the	O
development	O
of	O
severe	O
mucositis	O
.	O

Treponema	B-bacteria
have	O
been	O
implicated	O
recently	O
in	O
the	O
pathogenesis	O
of	O
digital	O
dermatitis	O
(	O
DD	O
)	O
and	O
contagious	O
ovine	O
digital	O
dermatitis	O
(	O
CODD	O
)	O
that	O
are	O
infectious	O
diseases	O
of	O
bovine	O
and	O
ovine	O
foot	O
tissues	O
,	O
respectively	O
.	O

Previous	O
analyses	O
of	O
treponemal	O
16S	O
rDNA	O
sequences	O
,	O
PCR	O
-	O
amplified	O
directly	O
from	O
DD	O
or	O
CODD	O
lesions	O
,	O
have	O
suggested	O
relatedness	O
of	O
animal	O
Treponema	B-bacteria
to	O
some	O
human	O
oral	O
Treponema	B-bacteria
species	I-bacteria
isolated	O
from	O
periodontal	O
tissues	O
.	O

In	O
this	O
study	O
a	O
range	O
of	O
adhesion	O
and	O
virulence	O
-	O
related	O
properties	O
of	O
three	O
animal	O
Treponema	B-bacteria
isolates	I-bacteria
have	O
been	O
compared	O
with	O
representative	O
human	O
oral	O
strains	O
of	O
Treponema	B-bacteria
denticola	I-bacteria
and	O
Treponema	B-bacteria
vincentii	I-bacteria
.	O

In	O
adhesion	O
assays	O
using	O
biotinylated	O
treponemal	O
cells	O
,	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
cells	O
bound	O
in	O
consistently	O
higher	O
numbers	O
to	O
fibronectin	O
,	O
laminin	O
,	O
collagen	O
type	O
I	O
,	O
gelatin	O
,	O
keratin	O
and	O
lactoferrin	O
than	O
did	O
T	B-bacteria
.	I-bacteria
vincentii	I-bacteria
or	O
animal	O
Treponema	B-bacteria
isolates	I-bacteria
.	O

However	O
,	O
animal	O
DD	O
strains	O
adhered	O
to	O
fibrinogen	O
at	O
equivalent	O
or	O
greater	O
levels	O
than	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
.	O

All	O
Treponema	B-bacteria
strains	I-bacteria
bound	O
to	O
the	O
amino	O
-	O
terminal	O
heparin	O
I	O
/	O
fibrin	O
I	O
domain	O
of	O
fibronectin	O
.	O

16S	O
rDNA	O
sequence	O
analyses	O
placed	O
ovine	O
strain	O
UB1090	B-bacteria
and	O
bovine	O
strain	O
UB1467	B-bacteria
within	O
a	O
cluster	O
that	O
was	O
phylogenetically	O
related	O
to	O
T	B-bacteria
.	I-bacteria
vincentii	I-bacteria
,	O
while	O
ovine	O
strain	O
UB1466	B-bacteria
appeared	O
more	O
closely	O
related	O
to	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
.	O

These	O
observations	O
correlated	O
with	O
phenotypic	O
properties	O
.	O

Thus	O
,	O
T	B-bacteria
.	I-bacteria
denticola	B-bacteria
ATCC	I-bacteria
35405	I-bacteria
,	O
GM	B-bacteria
-	I-bacteria
1	I-bacteria
,	O
and	O
Treponema	B-bacteria
UB1466	I-bacteria
had	O
similar	O
outer	O
-	O
membrane	O
protein	O
profiles	O
,	O
produced	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
CTLP	O
)	O
,	O
trypsin	O
-	O
like	O
protease	O
and	O
high	O
levels	O
of	O
proline	O
iminopeptidase	O
,	O
and	O
co	O
-	O
aggregated	O
with	O
human	O
oral	O
bacteria	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
Streptococcus	B-bacteria
crista	I-bacteria
.	O

Conversely	O
,	O
T	B-bacteria
.	I-bacteria
vincentii	I-bacteria
ATCC	I-bacteria
35580	I-bacteria
,	O
D2A	B-bacteria
-	I-bacteria
2	I-bacteria
,	O
and	O
animal	O
strains	O
UB1090	B-bacteria
and	O
UB1467	B-bacteria
did	O
not	O
express	O
CTLP	O
or	O
trypsin	O
-	O
like	O
protease	O
and	O
did	O
not	O
co	O
-	O
aggregate	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
or	O
S	B-bacteria
.	I-bacteria
crista	I-bacteria
.	O

Taken	O
collectively	O
,	O
these	O
results	O
suggest	O
that	O
human	O
oral	O
-	O
related	O
Treponema	B-bacteria
have	O
broad	O
host	O
specificity	O
and	O
that	O
similar	O
control	O
or	O
preventive	O
strategies	O
might	O
be	O
developed	O
for	O
human	O
and	O
animal	O
Treponema	B-bacteria
-	O
associated	O
infections	O
.	O

Whether	O
micro	O
-	O
organisms	O
can	O
live	O
in	O
periapical	O
endodontic	O
lesions	O
of	O
asymptomatic	O
teeth	O
is	O
under	O
debate	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
visualize	O
and	O
identify	O
micro	O
-	O
organisms	O
within	O
periapical	O
lesions	O
directly	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
in	O
combination	O
with	O
epifluorescence	O
and	O
confocal	O
laser	O
scanning	O
microscopy	O
(	O
CLSM	O
)	O
.	O

Thirty	O
-	O
nine	O
periapical	O
lesions	O
were	O
surgically	O
removed	O
,	O
fixed	O
,	O
embedded	O
in	O
cold	O
polymerizing	O
resin	O
and	O
sectioned	O
.	O

The	O
probe	O
EUB	O
338	O
,	O
specific	O
for	O
the	O
domain	O
Bacteria	O
,	O
was	O
used	O
together	O
with	O
a	O
number	O
of	O
species	O
-	O
specific	O
16S	O
rRNA	O
-	O
directed	O
oligonucleotide	O
probes	O
to	O
identify	O
bacteria	O
.	O

To	O
control	O
non	O
-	O
specific	O
binding	O
of	O
EUB	O
338	O
,	O
probe	O
NON	O
338	O
was	O
used	O
.	O

Alternatively	O
,	O
DAPI	O
(	O
4	O
'	O
,	O
6	O
'	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
)	O
staining	O
was	O
applied	O
to	O
record	O
prokaryotic	O
and	O
eukaryotic	O
DNA	O
in	O
the	O
specimens	O
.	O

Hybridization	O
with	O
NON	O
338	O
gave	O
no	O
signals	O
despite	O
background	O
fluorescence	O
of	O
the	O
tissue	O
.	O

The	O
eubacterial	O
probe	O
showed	O
bacteria	O
of	O
different	O
morphotypes	O
in	O
50	O
%	O
of	O
the	O
lesions	O
.	O

Rods	B-bacteria
,	O
spirochaetes	B-bacteria
and	O
cocci	B-bacteria
were	O
spread	O
out	O
in	O
areas	O
of	O
the	O
tissue	O
while	O
other	O
parts	O
seemed	O
bacteria	O
-	O
free	O
.	O

Bacteria	O
were	O
also	O
seen	O
to	O
co	O
-	O
aggregate	O
inside	O
the	O
tissue	O
,	O
forming	O
microcolonies	O
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
and	O
treponemes	B-bacteria
of	O
phylogenetic	O
Group	O
I	O
were	O
detected	O
with	O
specific	O
probes	O
.	O

In	O
addition	O
,	O
colonies	O
with	O
Streptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
seen	O
in	O
some	O
lesions	O
.	O

A	O
number	O
of	O
morphotypes	O
occurred	O
that	O
could	O
not	O
be	O
identified	O
with	O
the	O
specific	O
probes	O
used	O
,	O
indicating	O
the	O
presence	O
of	O
additional	O
bacterial	O
species	O
.	O

CLSM	O
confirmed	O
that	O
bacteria	O
were	O
located	O
in	O
different	O
layers	O
of	O
the	O
tissue	O
.	O

Accordingly	O
,	O
the	O
FISH	O
technique	O
demonstrated	O
mixed	O
consortia	O
of	O
bacteria	O
consisting	O
of	O
rods	O
,	O
spirochaetes	B-bacteria
and	O
cocci	B-bacteria
in	O
asymptomatic	O
periapical	O
lesions	O
of	O
root	O
-	O
filled	O
teeth	O
.	O

Nearly	O
all	O
infections	O
begin	O
at	O
a	O
mucous	O
membrane	O
site	O
.	O

Also	O
,	O
the	O
human	O
mucous	O
membranes	O
are	O
a	O
reservoir	O
for	O
many	O
pathogenic	O
bacteria	O
found	O
in	O
the	O
environment	O
(	O
that	O
is	O
,	O
pneumococci	B-bacteria
,	O
staphylococci	B-bacteria
,	O
streptococci	B-bacteria
)	O
,	O
some	O
of	O
which	O
are	O
resistant	O
to	O
antibiotics	O
.	O

Clearly	O
,	O
if	O
this	O
human	O
reservoir	O
can	O
be	O
reduced	O
or	O
eliminated	O
,	O
the	O
incidence	O
of	O
disease	O
will	O
be	O
markedly	O
reduced	O
.	O

However	O
,	O
compounds	O
designed	O
to	O
eliminate	O
this	O
reservoir	O
are	O
not	O
available	O
.	O

Towards	O
this	O
goal	O
,	O
we	O
have	O
exploited	O
the	O
highly	O
lethal	O
effects	O
of	O
bacteriophage	O
lytic	O
enzymes	O
(	O
lysins	O
)	O
to	O
specifically	O
destroy	O
disease	O
bacteria	O
on	O
mucous	O
membranes	O
.	O

Such	O
lysins	O
are	O
used	O
by	O
the	O
phage	O
to	O
release	O
their	O
progeny	O
at	O
the	O
end	O
of	O
their	O
replicative	O
cycle	O
.	O

We	O
have	O
identified	O
and	O
purified	O
these	O
enzymes	O
and	O
found	O
that	O
when	O
applied	O
externally	O
to	O
gram	O
-	O
positive	O
bacteria	O
,	O
they	O
are	O
killed	O
seconds	O
after	O
contact	O
.	O

For	O
example	O
,	O
10	O
(	O
7	O
)	O
S	B-bacteria
.	I-bacteria
pyogenes	I-bacteria
are	O
reduced	O
to	O
undetectable	O
levels	O
10	O
s	O
after	O
enzyme	O
addition	O
.	O

A	O
feature	O
of	O
these	O
enzymes	O
is	O
their	O
high	O
specificity	O
;	O
that	O
is	O
,	O
streptococcal	O
lysins	O
kill	O
streptococci	B-bacteria
and	O
streptococcal	O
lysins	O
kill	O
pneumococci	B-bacteria
without	O
effects	O
on	O
the	O
normal	O
flora	O
organisms	O
.	O

In	O
vivo	O
,	O
an	O
oral	O
colonization	O
model	O
for	O
S	B-bacteria
.	I-bacteria
pyogenes	I-bacteria
and	O
a	O
nasal	O
colonization	O
model	O
for	O
S	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
were	O
developed	O
to	O
test	O
the	O
capacity	O
of	O
the	O
lysins	O
to	O
kill	O
organisms	O
on	O
these	O
surfaces	O
.	O

In	O
both	O
cases	O
,	O
when	O
the	O
animals	O
were	O
pre	O
-	O
colonized	O
with	O
their	O
respective	O
bacteria	O
then	O
treated	O
with	O
a	O
small	O
amount	O
of	O
lysin	O
,	O
specific	O
for	O
the	O
colonizing	O
organism	O
,	O
all	O
the	O
animals	O
were	O
found	O
to	O
be	O
free	O
of	O
colonizing	O
bacteria	O
shortly	O
after	O
lysin	O
treatment	O
.	O

Thus	O
,	O
lysins	O
may	O
be	O
added	O
to	O
our	O
armamentarium	O
to	O
control	O
antibiotic	O
-	O
resistant	O
bacteria	O
.	O

To	O
date	O
,	O
there	O
have	O
been	O
relatively	O
few	O
studies	O
addressing	O
the	O
presence	O
and	O
expression	O
of	O
the	O
plasminogen	O
-	O
plasmin	O
system	O
at	O
the	O
site	O
of	O
bacterial	O
infection	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
black	O
-	O
pigmented	O
bacteria	O
on	O
the	O
expression	O
of	O
the	O
plasminogen	O
-	O
plasmin	O
system	O
in	O
human	O
pulp	O
and	O
osteoblastic	O
cells	O
.	O

The	O
supernatants	O
of	O
Porphyromonas	B-bacteria
endodontalis	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
were	O
used	O
to	O
evaluate	O
tissue	O
-	O
type	O
plasminogen	O
activator	O
(	O
t	O
-	O
PA	O
)	O
and	O
type	O
1	O
plasminogen	O
activator	O
inhibitor	O
(	O
PAI	O
-	O
1	O
)	O
gene	O
expression	O
in	O
human	O
pulp	O
and	O
osteoblastic	O
cells	O
.	O

The	O
levels	O
of	O
mRNA	O
were	O
quantitatively	O
measured	O
by	O
using	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

In	O
this	O
study	O
,	O
black	O
-	O
pigmented	O
bacteria	O
induced	O
not	O
only	O
t	O
-	O
PA	O
but	O
also	O
PAI	O
-	O
1	O
gene	O
expression	O
in	O
human	O
pulp	O
and	O
osteoblastic	O
cells	O
.	O

In	O
addition	O
,	O
the	O
ratio	O
of	O
t	O
-	O
PA	O
to	O
PAI	O
-	O
1	O
was	O
higher	O
in	O
human	O
pulp	O
and	O
osteoblastic	O
cells	O
stimulated	O
by	O
black	O
-	O
pigmented	O
bacteria	O
than	O
in	O
untreated	O
cell	O
cultures	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

A	O
fine	O
balance	O
exists	O
in	O
the	O
expression	O
of	O
components	O
of	O
the	O
plasminogen	O
-	O
plasmin	O
system	O
,	O
whereby	O
tissue	O
homeostasis	O
is	O
maintained	O
.	O

Black	O
-	O
pigmented	O
bacteria	O
activate	O
the	O
activator	O
-	O
inhibitor	O
system	O
in	O
human	O
pulp	O
and	O
osteoblastic	O
cells	O
through	O
unbalance	O
regulation	O
of	O
t	O
-	O
PA	O
and	O
PAI	O
-	O
1	O
,	O
which	O
might	O
result	O
in	O
an	O
uncontrolled	O
degradation	O
of	O
pulpal	O
and	O
periapical	O
tissues	O
.	O

The	O
oral	O
epithelium	O
is	O
continuously	O
exposed	O
to	O
a	O
variety	O
of	O
microbial	O
challenges	O
that	O
can	O
cause	O
infectious	O
diseases	O
such	O
as	O
periodontal	O
disease	O
.	O

Human	O
B	O
Defensin	O
-	O
2	O
(	O
hBD	O
-	O
2	O
)	O
is	O
a	O
cationic	O
antimicrobial	O
peptide	O
with	O
low	O
molecular	O
weight	O
,	O
which	O
is	O
inducible	O
from	O
oral	O
epithelial	O
cells	O
upon	O
either	O
bacterial	O
infection	O
or	O
stimulation	O
with	O
inflammatory	O
cytokines	O
.	O

This	O
peptide	O
has	O
a	O
broad	O
antimicrobial	O
spectrum	O
that	O
includes	O
gram	O
-	O
positive	O
bacteria	O
,	O
gram	O
-	O
negative	O
bacteria	O
,	O
and	O
fungi	O
.	O

Therefore	O
,	O
it	O
is	O
thought	O
that	O
hBD	O
-	O
2	O
plays	O
an	O
important	O
role	O
as	O
one	O
of	O
natural	O
immunities	O
to	O
bacterial	O
infection	O
.	O

However	O
,	O
its	O
activity	O
is	O
inhibited	O
by	O
body	O
fluids	O
such	O
as	O
serum	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
antibacterial	O
activity	O
of	O
synthetic	O
hBD	O
-	O
2	O
against	O
oral	O
bacteria	O
in	O
the	O
presence	O
of	O
saliva	O
or	O
serum	O
.	O

The	O
antibacterial	O
activity	O
of	O
synthetic	O
hBD	O
-	O
2	O
was	O
tested	O
against	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
and	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

Antibacterial	O
broth	O
assay	O
and	O
diffusion	O
assay	O
were	O
performed	O
in	O
vitro	O
.	O

The	O
antibacterial	O
activity	O
of	O
hBD	O
-	O
2	O
was	O
approximately	O
equal	O
to	O
that	O
of	O
minocycline	O
at	O
equimolar	O
concentrations	O
.	O

Furthermore	O
,	O
the	O
activity	O
of	O
hBD	O
-	O
2	O
remained	O
at	O
60	O
%	O
in	O
the	O
presence	O
of	O
80	O
%	O
saliva	O
,	O
whereas	O
no	O
activity	O
remained	O
in	O
the	O
presence	O
of	O
20	O
%	O
serum	O
.	O

Our	O
results	O
suggest	O
the	O
possibility	O
that	O
synthetic	O
hBD	O
-	O
2	O
could	O
be	O
useful	O
to	O
prevent	O
infection	O
by	O
periodontal	O
disease	O
.	O

Viable	O
counts	O
and	O
activities	O
of	O
sulfate	B-bacteria
-	I-bacteria
reducing	I-bacteria
bacteria	I-bacteria
(	O
SRB	B-bacteria
)	O
and	O
methanogenic	O
bacteria	O
were	O
determined	O
in	O
the	O
oral	O
cavities	O
of	O
eight	O
volunteers	O
.	O

Of	O
these	O
,	O
seven	O
harbored	O
viable	O
SRB	B-bacteria
populations	O
,	O
and	O
six	O
harbored	O
viable	O
methanogenic	O
bacterial	O
populations	O
.	O

Two	O
volunteers	O
classified	O
as	O
type	O
III	O
periodontal	O
patients	O
had	O
both	O
SRB	B-bacteria
and	O
methanogenic	O
bacteria	O
.	O

Six	O
separate	O
sites	O
were	O
sampled	O
:	O
posterior	O
tongue	O
,	O
anterior	O
tongue	O
,	O
mid	O
-	O
buccal	O
mucosa	O
,	O
vestibular	O
mucosa	O
,	O
supragingival	O
plaque	O
,	O
and	O
subgingival	O
plaque	O
.	O

The	O
SRB	B-bacteria
was	O
found	O
in	O
all	O
areas	O
in	O
one	O
volunteer	O
,	O
and	O
it	O
was	O
mostly	O
present	O
in	O
posterior	O
tongue	O
,	O
anterior	O
tongue	O
,	O
supragingival	O
,	O
and	O
subgingival	O
plaques	O
in	O
many	O
volunteers	O
.	O

The	O
methanogenic	O
bacteria	O
were	O
mostly	O
found	O
in	O
supragingival	O
and	O
subgingival	O
plaques	O
.	O

The	O
activities	O
of	O
sulfate	O
reduction	O
and	O
methane	O
production	O
were	O
determined	O
in	O
randomly	O
selected	O
isolates	O
.	O

A	O
clinical	O
procedure	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
short	O
-	O
term	O
and	O
extended	O
use	O
of	O
a	O
triclosan	O
/	O
copolymer	O
dentifrice	O
and	O
a	O
commercial	O
fluoride	O
dentifrice	O
on	O
oral	O
bacteria	O
,	O
including	O
those	O
producing	O
hydrogen	O
sulfide	O
.	O

Healthy	O
adults	O
volunteered	O
for	O
this	O
double	O
-	O
blind	O
,	O
crossover	O
design	O
clinical	O
study	O
and	O
provided	O
saliva	O
samples	O
for	O
culturing	O
on	O
enriched	O
and	O
indicator	O
media	O
to	O
enumerate	O
all	O
salivary	O
bacteria	O
and	O
those	O
producing	O
hydrogen	O
sulfide	O
(	O
odorigenic	O
)	O
,	O
respectively	O
.	O

Subjects	O
brushed	O
with	O
an	O
assigned	O
dentifrice	O
for	O
7	O
d	O
and	O
were	O
sampled	O
on	O
day	O
8	O
to	O
assess	O
the	O
long	O
-	O
term	O
effects	O
on	O
bacteria	O
.	O

Extended	O
use	O
of	O
the	O
triclosan	O
/	O
copolymer	O
dentifrice	O
resulted	O
in	O
a	O
49	O
%	O
and	O
66	O
%	O
reduction	O
of	O
salivary	O
and	O
odorigenic	O
bacteria	O
,	O
respectively	O
,	O
compared	O
with	O
the	O
fluoride	O
dentifrice	O
.	O

To	O
examine	O
short	O
-	O
term	O
effects	O
,	O
subjects	O
subsequently	O
brushed	O
with	O
their	O
assigned	O
dentifrice	O
and	O
were	O
sampled	O
at	O
2	O
h	O
and	O
4	O
h	O
post	O
-	O
brushing	O
.	O

At	O
2	O
h	O
and	O
4	O
h	O
post	O
-	O
brushing	O
,	O
the	O
triclosan	O
/	O
copolymer	O
dentifrice	O
resulted	O
in	O
a	O
62	O
%	O
and	O
52	O
%	O
decrease	O
for	O
salivary	O
bacteria	O
and	O
79	O
%	O
and	O
72	O
%	O
decrease	O
for	O
odorigenic	O
bacteria	O
,	O
respectively	O
,	O
vs	O
.	O
the	O
fluoride	O
dentifrice	O
.	O

The	O
results	O
indicate	O
a	O
significant	O
decrease	O
of	O
all	O
salivary	O
bacteria	O
and	O
hydrogen	O
sulfide	O
-	O
producing	O
odorigenic	O
bacteria	O
following	O
use	O
of	O
the	O
triclosan	O
/	O
copolymer	O
dentifrice	O
and	O
explain	O
previous	O
results	O
on	O
the	O
efficacy	O
of	O
this	O
dentifrice	O
on	O
oral	O
malodor	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
predominant	O
flora	O
associated	O
with	O
pericoronitis	O
in	O
third	O
molars	O
and	O
to	O
investigate	O
the	O
presence	O
of	O
beta	O
-	O
lactamase	O
-	O
producing	O
strains	O
.	O

The	O
third	O
molars	O
in	O
26	O
adults	O
were	O
evaluated	O
by	O
cultures	O
with	O
nonselective	O
media	O
and	O
with	O
selective	O
media	O
containing	O
amoxicillin	O
,	O
pristinamycin	O
,	O
spiramycin	O
,	O
metronidazole	O
,	O
and	O
spiramycin	O
plus	O
metronidazole	O
.	O

In	O
the	O
majority	O
of	O
cases	O
(	O
19	O
/	O
26	O
)	O
,	O
the	O
flora	O
found	O
in	O
an	O
anaerobic	O
atmosphere	O
predominated	O
.	O

Obligate	O
anaerobes	O
were	O
present	O
in	O
21	O
of	O
the	O
26	O
samples	O
.	O

The	O
bacteria	O
most	O
commonly	O
detected	O
were	O
alpha	B-bacteria
-	I-bacteria
hemolytic	I-bacteria
streptococci	I-bacteria
(	O
26	O
/	O
26	O
)	O
and	O
the	O
genera	O
Prevotella	B-bacteria
(	O
15	O
/	O
26	O
)	O
,	O
Veillonella	B-bacteria
(	O
15	O
/	O
26	O
)	O
,	O
Bacteroides	B-bacteria
(	O
9	O
/	O
26	O
)	O
,	O
and	O
Capnocytophaga	B-bacteria
(	O
9	O
/	O
26	O
)	O
.	O

Amoxicillin	O
and	O
pristinamycin	O
were	O
the	O
most	O
active	O
in	O
reducing	O
the	O
anaerobic	O
cultivable	O
counts	O
.	O

beta	O
-	O
Lactamase	O
-	O
producing	O
strains	O
were	O
detected	O
in	O
9	O
samples	O
and	O
were	O
mostly	O
bacteria	O
of	O
the	O
genera	O
Prevotella	B-bacteria
,	O
Staphylococcus	B-bacteria
,	O
and	O
Bacteroides	B-bacteria
.	O

These	O
results	O
highlight	O
(	O
1	O
)	O
the	O
diversity	O
of	O
the	O
microflora	O
associated	O
with	O
pericoronitis	O
and	O
the	O
importance	O
of	O
the	O
anaerobic	O
flora	O
and	O
(	O
2	O
)	O
the	O
existence	O
of	O
selection	O
pressure	O
related	O
to	O
the	O
use	O
of	O
beta	O
-	O
lactams	O
that	O
may	O
culminate	O
in	O
failure	O
of	O
prescribed	O
penicillins	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
screened	O
149	O
subjects	O
and	O
established	O
four	O
groups	O
high	O
or	O
low	O
for	O
salivary	O
killing	O
of	O
oral	O
bacteria	O
,	O
and	O
for	O
aggregation	O
and	O
live	O
and	O
dead	O
adherence	O
of	O
oral	O
bacteria	O
(	O
as	O
a	O
combined	O
factor	O
)	O
.	O

Caries	O
scores	O
were	O
significantly	O
lower	O
in	O
both	O
High	O
Aggregation	O
-	O
Adherence	O
groups	O
.	O

In	O
this	O
study	O
we	O
looked	O
at	O
the	O
effects	O
of	O
those	O
differences	O
in	O
salivary	O
function	O
on	O
the	O
quantity	O
and	O
diversity	O
of	O
oral	O
biofilm	O
streptococci	B-bacteria
.	O

Subjects	O
from	O
those	O
four	O
groups	O
were	O
recalled	O
for	O
collection	O
of	O
overnight	O
oral	O
biofilm	O
from	O
buccal	O
upper	O
centra	O
incisors	O
,	O
lingual	O
lower	O
central	O
incisors	O
,	O
buccal	O
upper	O
and	O
lower	O
first	O
molars	O
,	O
and	O
lingual	O
upper	O
and	O
lower	O
first	O
molars	O
.	O

At	O
each	O
site	O
,	O
groups	O
were	O
compared	O
for	O
total	O
biofilm	O
(	O
by	O
DNA	O
concentration	O
)	O
,	O
total	O
streptococci	B-bacteria
(	O
by	O
quantitative	O
PCR	O
)	O
,	O
and	O
streptococcal	B-bacteria
diversity	O
(	O
by	O
Streptococcus	B-bacteria
-	O
specific	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
)	O
.	O

Total	O
biofilm	O
DNA	O
and	O
total	O
streptococci	B-bacteria
were	O
correlated	O
.	O

Both	O
were	O
highest	O
on	O
buccal	O
molar	O
surfaces	O
and	O
lowest	O
on	O
lingual	O
lower	O
central	O
incisors	O
,	O
and	O
both	O
were	O
significantly	O
lower	O
in	O
the	O
High	O
Aggregation	O
-	O
Adherence	O
groups	O
(	O
particularly	O
at	O
the	O
buccal	O
molar	O
site	O
)	O
.	O

Fifty	O
distinct	O
bands	O
were	O
observed	O
in	O
denaturing	O
gradient	O
gels	O
.	O

There	O
was	O
great	O
diversity	O
within	O
and	O
between	O
sites	O
.	O

Three	O
major	O
bands	O
were	O
present	O
in	O
almost	O
every	O
person	O
at	O
every	O
site	O
.	O

Densities	O
for	O
two	O
of	O
those	O
bands	O
were	O
significantly	O
lower	O
in	O
both	O
High	O
Aggregation	O
-	O
Adherence	O
groups	O
.	O

Other	O
less	O
-	O
prevalent	O
bands	O
also	O
showed	O
the	O
same	O
pattern	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
our	O
caries	O
results	O
in	O
suggesting	O
that	O
differences	O
in	O
salivary	O
function	O
can	O
influence	O
the	O
quantity	O
and	O
composition	O
of	O
streptococci	B-bacteria
in	O
oral	O
biofilms	O
.	O

Dental	O
plaque	O
from	O
76	O
children	O
without	O
amalgam	O
restorations	O
was	O
screened	O
for	O
bacteria	O
resistant	O
to	O
mercuric	O
chloride	O
.	O

Seventy	O
-	O
one	O
per	O
cent	O
of	O
the	O
children	O
harboured	O
mercury	O
-	O
resistant	O
oral	O
bacteria	O
and	O
the	O
median	O
percentage	O
of	O
the	O
total	O
oral	O
microflora	O
resistant	O
to	O
mercuric	O
chloride	O
was	O
0	O
.	O
007	O
%	O
(	O
range	O
0	O
-	O
5	O
.	O
3	O
%	O
)	O
.	O

Eighty	O
-	O
seven	O
mercury	O
-	O
resistant	O
bacteria	O
were	O
isolated	O
and	O
86	O
%	O
of	O
these	O
were	O
streptococci	B-bacteria
with	O
Streptococcus	B-bacteria
mitis	I-bacteria
predominating	O
.	O

Sixty	O
per	O
cent	O
of	O
the	O
mercury	O
-	O
resistant	O
isolates	O
were	O
also	O
resistant	O
to	O
at	O
least	O
one	O
of	O
the	O
four	O
antibiotics	O
tested	O
(	O
penicillin	O
,	O
ampicillin	O
,	O
erythromycin	O
and	O
tetracycline	O
)	O
with	O
resistance	O
to	O
tetracycline	O
(	O
40	O
%	O
of	O
isolates	O
)	O
most	O
frequently	O
encountered	O
.	O

Chronic	O
maxillary	O
sinusitis	O
is	O
a	O
chronic	O
inflammatory	O
condition	O
in	O
which	O
the	O
role	O
of	O
microbial	O
infection	O
remains	O
undefined	O
.	O

Bacteria	O
have	O
been	O
isolated	O
from	O
chronically	O
inflamed	O
sinuses	O
;	O
however	O
,	O
their	O
role	O
in	O
the	O
chronicity	O
of	O
inflammation	O
is	O
unknown	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
bacteria	O
are	O
present	O
in	O
clinical	O
samples	O
from	O
chronic	O
maxillary	O
sinusitis	O
and	O
to	O
assess	O
the	O
diversity	O
of	O
the	O
flora	O
present	O
.	O

Washes	O
and	O
/	O
or	O
tissue	O
samples	O
from	O
endoscopic	O
sinus	O
surgery	O
on	O
11	O
patients	O
with	O
chronic	O
maxillary	O
sinusitis	O
were	O
subjected	O
to	O
PCR	O
amplification	O
of	O
bacterial	O
16S	O
rDNA	O
using	O
three	O
universal	O
primer	O
pairs	O
,	O
followed	O
by	O
cloning	O
and	O
sequencing	O
.	O

The	O
samples	O
were	O
also	O
assessed	O
for	O
the	O
presence	O
of	O
bacteria	O
and	O
fungi	O
by	O
conventional	O
culture	O
methods	O
.	O

Viable	O
bacteria	O
and	O
/	O
or	O
bacterial	O
16S	O
rDNA	O
were	O
detected	O
from	O
maxillary	O
sinus	O
samples	O
of	O
five	O
of	O
the	O
11	O
patients	O
examined	O
(	O
45	O
%	O
)	O
.	O

Three	O
sinus	O
samples	O
were	O
positive	O
by	O
both	O
PCR	O
and	O
culture	O
methods	O
,	O
one	O
was	O
positive	O
only	O
by	O
PCR	O
,	O
and	O
one	O
only	O
by	O
culture	O
.	O

Thirteen	O
bacterial	O
species	O
were	O
identified	O
:	O
Abiotrophia	B-bacteria
defectiva	I-bacteria
,	O
Enterococcus	B-bacteria
avium	I-bacteria
,	O
Eubacterium	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Granulicatella	B-bacteria
elegans	I-bacteria
,	O
Neisseria	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Prevotella	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
,	O
Serratia	B-bacteria
marcescens	I-bacteria
,	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
Stenotrophomonas	B-bacteria
maltophilia	I-bacteria
,	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
/	O
Streptococcus	I-bacteria
oralis	I-bacteria
and	O
Streptococcus	B-bacteria
sp	I-bacteria
.	O

Fungi	O
were	O
not	O
detected	O
.	O

In	O
one	O
patient	O
Streptococcus	B-bacteria
mitis	I-bacteria
/	O
Streptococcus	B-bacteria
oralis	I-bacteria
,	O
and	O
in	O
another	O
patient	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
,	O
were	O
detected	O
from	O
both	O
the	O
sinus	O
and	O
the	O
oral	O
cavity	O
using	O
species	O
-	O
specific	O
PCR	O
primers	O
.	O

These	O
results	O
suggest	O
that	O
both	O
aerobic	O
and	O
anaerobic	O
bacteria	O
can	O
be	O
detected	O
in	O
nearly	O
half	O
of	O
chronic	O
maxillary	O
sinusitis	O
cases	O
.	O

In	O
a	O
previous	O
study	O
we	O
showed	O
that	O
prolonged	O
nasogastric	O
tube	O
feeding	O
is	O
associated	O
with	O
pathogenic	O
oral	O
flora	O
.	O

To	O
reexamine	O
the	O
impact	O
of	O
prolonged	O
nasogastric	O
tube	O
feeding	O
on	O
the	O
oral	O
microbiota	O
and	O
to	O
explore	O
the	O
salivary	O
flow	O
and	O
composition	O
in	O
elderly	O
patients	O
in	O
long	O
-	O
term	O
care	O
.	O

We	O
compared	O
a	O
group	O
of	O
elderly	O
patients	O
fed	O
by	O
nasogastric	O
tube	O
with	O
a	O
control	O
group	O
of	O
elderly	O
patients	O
in	O
long	O
-	O
term	O
care	O
who	O
are	O
fed	O
orally	O
.	O

Bacteriologic	O
studies	O
were	O
performed	O
by	O
culturing	O
samples	O
from	O
the	O
oropharynx	O
.	O

Saliva	O
studies	O
included	O
quantitative	O
and	O
biochemical	O
analysis	O
of	O
basal	O
and	O
stimulated	O
salivary	O
flow	O
.	O

Bacteriologic	O
studies	O
performed	O
in	O
90	O
patients	O
revealed	O
a	O
significantly	O
higher	O
prevalence	O
of	O
gram	O
-	O
negative	O
bacteria	O
in	O
prolonged	O
nasogastric	O
tube	O
feeding	O
patients	O
(	O
73	O
%	O
vs	O
.	O
13	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

It	O
is	O
emphasized	O
that	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
and	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
were	O
commonly	O
and	O
exclusively	O
isolated	O
from	O
the	O
oral	O
flora	O
of	O
the	O
nasogastric	O
-	O
tube	O
fed	O
patients	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
the	O
saliva	O
studies	O
performed	O
on	O
23	O
nasogastric	O
-	O
tube	O
fed	O
and	O
21	O
control	O
patients	O
,	O
basal	O
and	O
stimulated	O
salivary	O
flow	O
was	O
not	O
significantly	O
different	O
in	O
the	O
two	O
groups	O
,	O
however	O
the	O
ratio	O
of	O
stimulated	O
to	O
basal	O
flow	O
was	O
reduced	O
in	O
the	O
nasogastric	O
-	O
tube	O
fed	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Significant	O
differences	O
were	O
also	O
found	O
in	O
the	O
concentrations	O
of	O
sodium	O
,	O
amylase	O
,	O
phosphor	O
and	O
magnesium	O
.	O

Noteworthy	O
was	O
the	O
concentration	O
of	O
uric	O
acid	O
,	O
the	O
main	O
non	O
-	O
enzymatic	O
antioxidant	O
of	O
saliva	O
,	O
which	O
was	O
significantly	O
lower	O
in	O
nasogastric	O
-	O
tube	O
fed	O
patients	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
prolonged	O
nasogastric	O
tube	O
feeding	O
is	O
associated	O
with	O
pathologic	O
colonization	O
of	O
the	O
oroparynx	O
and	O
with	O
alterations	O
in	O
the	O
saliva	O
that	O
are	O
related	O
to	O
the	O
risk	O
of	O
aspiration	O
pneumonia	O
.	O

Further	O
research	O
is	O
called	O
for	O
,	O
as	O
well	O
as	O
a	O
thorough	O
revision	O
of	O
the	O
existing	O
oral	O
cleansing	O
procedures	O
in	O
these	O
patients	O
.	O

Lactobacilli	B-bacteria
were	O
considered	O
the	O
prime	O
cariogenic	O
microorganisms	O
until	O
phylogenetic	O
related	O
bacteria	O
,	O
mutans	B-bacteria
streptococci	I-bacteria
,	O
were	O
associated	O
with	O
caries	O
.	O

Today	O
,	O
lactobacilli	B-bacteria
are	O
still	O
considered	O
a	O
factor	O
in	O
determining	O
the	O
predisposition	O
to	O
develop	O
cavities	O
.	O

As	O
a	O
first	O
step	O
in	O
colonization	O
,	O
microorganisms	O
adhere	O
to	O
oral	O
tissues	O
.	O

Based	O
on	O
this	O
fact	O
,	O
the	O
purpose	O
of	O
our	O
study	O
was	O
to	O
determine	O
if	O
there	O
was	O
a	O
statistical	O
association	O
or	O
difference	O
related	O
to	O
the	O
state	O
of	O
oral	O
health	O
with	O
the	O
surface	O
characteristics	O
of	O
lactobacilli	B-bacteria
.	O

Patients	O
were	O
classified	O
as	O
caries	O
-	O
free	O
and	O
caries	O
-	O
active	O
.	O

Interviews	O
were	O
performed	O
to	O
establish	O
the	O
nutritional	O
and	O
oral	O
hygiene	O
habits	O
.	O

The	O
previously	O
reported	O
characteristics	O
of	O
isolated	O
lactobacilli	B-bacteria
'	O
s	O
quantification	O
and	O
association	O
to	O
dental	O
tissues	O
were	O
determined	O
.	O

Although	O
the	O
nutritional	O
habits	O
for	O
caries	O
-	O
free	O
and	O
caries	O
-	O
active	O
patients	O
were	O
similar	O
,	O
the	O
patients	O
'	O
oral	O
hygiene	O
and	O
dental	O
care	O
determined	O
differences	O
in	O
risk	O
indices	O
.	O

The	O
number	O
of	O
lactobacilli	B-bacteria
was	O
statistically	O
lower	O
in	O
saliva	O
of	O
subjects	O
with	O
good	O
oral	O
health	O
.	O

Certain	O
species	O
of	O
lactobacilli	B-bacteria
could	O
not	O
be	O
associated	O
to	O
specific	O
areas	O
of	O
the	O
mouth	O
,	O
although	O
some	O
species	O
could	O
be	O
localized	O
.	O

Lactobacilli	B-bacteria
from	O
caries	O
active	O
(	O
CA	O
)	O
subjects	O
showed	O
a	O
greater	O
ability	O
to	O
adhere	O
to	O
hydrophobic	O
substances	O
,	O
had	O
a	O
greater	O
salt	O
agglutination	O
property	O
,	O
and	O
showed	O
lower	O
production	O
of	O
inhibitory	O
substances	O
.	O

Lactobacilli	B-bacteria
from	O
caries	O
free	O
(	O
CF	O
)	O
subjects	O
were	O
better	O
able	O
to	O
inhibit	O
oral	O
,	O
potentially	O
pathogenic	O
,	O
microorganisms	O
.	O

These	O
studies	O
prove	O
that	O
preliminary	O
differences	O
between	O
oral	O
lactobacilli	B-bacteria
in	O
CF	O
and	O
CA	O
patients	O
exist	O
.	O

Non	O
-	O
specific	O
and	O
specific	O
adhesion	O
mechanisms	O
in	O
bacteria	O
should	O
be	O
further	O
demonstrated	O
.	O

Mucosal	O
immunization	O
should	O
be	O
an	O
excellent	O
method	O
of	O
preventing	O
respiratory	O
infections	O
because	O
the	O
local	O
immunoglobulin	O
A	O
antibodies	O
can	O
neutralize	O
the	O
invading	O
pathogens	O
at	O
the	O
site	O
of	O
entry	O
.	O

Because	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
a	O
normal	O
inhabitant	O
of	O
the	O
human	O
oral	O
cavity	O
,	O
can	O
naturally	O
elicit	O
a	O
mucosal	O
immune	O
response	O
,	O
it	O
has	O
been	O
a	O
prime	O
candidate	O
for	O
investigations	O
as	O
a	O
live	O
oral	O
vaccine	O
vector	O
for	O
immunization	O
against	O
respiratory	O
infections	O
.	O

Antigens	O
from	O
a	O
number	O
of	O
respiratory	O
bacteria	O
,	O
such	O
as	O
Bordetella	B-bacteria
pertussis	I-bacteria
,	O
and	O
one	O
virus	O
have	O
been	O
expressed	O
extracellularly	O
or	O
on	O
the	O
cell	O
surface	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
.	O

The	O
antigens	O
expressed	O
were	O
single	O
or	O
multiple	O
proteins	O
from	O
one	O
or	O
more	O
pathogens	O
.	O

The	O
recombinant	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
expressing	O
surface	O
-	O
localized	O
heterologous	O
antigens	O
could	O
colonize	O
and	O
persist	O
in	O
the	O
oral	O
cavity	O
of	O
mice	O
and	O
rats	O
.	O

Oral	O
colonization	O
induced	O
a	O
mucosal	O
immunoglobulin	O
A	O
response	O
and	O
,	O
in	O
some	O
instances	O
,	O
also	O
a	O
systemic	O
immunoglobulin	O
G	O
response	O
to	O
the	O
heterologous	O
antigens	O
.	O

When	O
given	O
parenterally	O
,	O
the	O
heterologous	O
antigens	O
generated	O
a	O
systemic	O
immunoglobulin	O
G	O
response	O
.	O

These	O
findings	O
indicate	O
that	O
antigens	O
expressed	O
by	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
are	O
immunogenic	O
.	O

A	O
new	O
approach	O
to	O
the	O
use	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
as	O
a	O
vaccine	O
vector	O
is	O
to	O
modulate	O
immune	O
responses	O
by	O
co	O
-	O
expressing	O
cytokines	O
with	O
the	O
antigen	O
.	O

The	O
ability	O
to	O
express	O
antigens	O
from	O
respiratory	O
pathogens	O
and	O
induce	O
immune	O
responses	O
during	O
oral	O
colonization	O
suggests	O
that	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
may	O
be	O
developed	O
into	O
a	O
live	O
vector	O
for	O
oral	O
immunization	O
against	O
respiratory	O
infections	O
.	O

The	O
major	O
challenge	O
ahead	O
is	O
to	O
find	O
ways	O
to	O
achieve	O
a	O
high	O
level	O
of	O
immune	O
response	O
following	O
oral	O
colonization	O
.	O

Chavez	O
de	O
Paz	O
LE	O
,	O
Dahlen	O
G	O
,	O
Molander	O
A	O
,	O
Moller	O
A	O
,	O
Bergenholtz	O
G	O
.	O
Bacteria	O
recovered	O
from	O
teeth	O
with	O
apical	O
periodontitis	O
after	O
antimicrobial	O
endodontic	O
treatment	O
.	O

International	O
Endodontic	O
Journal	O
,	O
36	O
,	O
500	O
-	O
508	O
,	O
2003	O
.	O

To	O
determine	O
whether	O
there	O
is	O
a	O
pattern	O
for	O
certain	O
bacteria	O
to	O
remain	O
after	O
chemo	O
-	O
mechanical	O
treatment	O
of	O
root	O
canals	O
in	O
teeth	O
with	O
apical	O
periodontitis	O
.	O

Consecutive	O
root	O
-	O
canal	O
samples	O
of	O
200	O
teeth	O
receiving	O
root	O
-	O
canal	O
treatment	O
,	O
referred	O
from	O
general	O
practitioners	O
and	O
endodontic	O
specialists	O
for	O
analyses	O
of	O
cultivable	O
microbes	O
,	O
were	O
studied	O
prospectively	O
.	O

To	O
be	O
included	O
,	O
samples	O
had	O
to	O
be	O
taken	O
at	O
a	O
treatment	O
session	O
subsequent	O
to	O
the	O
one	O
at	O
which	O
endodontic	O
therapy	O
was	O
initiated	O
.	O

All	O
samples	O
were	O
from	O
teeth	O
that	O
either	O
presented	O
with	O
clinical	O
or	O
radiographic	O
evidence	O
of	O
apical	O
periodontitis	O
or	O
both	O
.	O

Bacteriological	O
findings	O
were	O
linked	O
to	O
clinical	O
and	O
radiographic	O
parameters	O
including	O
status	O
of	O
the	O
root	O
canal	O
prior	O
to	O
treatment	O
,	O
namely	O
,	O
vital	O
pulp	O
,	O
necrotic	O
pulp	O
or	O
root	O
filled	O
.	O

A	O
total	O
of	O
248	O
strains	O
were	O
isolated	O
from	O
107	O
teeth	O
giving	O
bacterial	O
growth	O
.	O

Gram	O
-	O
positives	O
predominated	O
(	O
85	O
%	O
)	O
.	O

Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
22	O
%	O
)	O
,	O
nonmutans	B-bacteria
streptococci	I-bacteria
(	O
18	O
%	O
)	O
,	O
and	O
Enterococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
12	O
%	O
)	O
were	O
the	O
most	O
common	O
isolates	O
.	O

Gram	O
-	O
negative	O
anaerobes	O
were	O
relatively	O
sporadic	O
.	O

Large	O
radiographic	O
bone	O
lesions	O
,	O
persistent	O
pain	O
and	O
use	O
of	O
intracanal	O
calcium	O
hydroxide	O
dressing	O
correlated	O
with	O
bacterial	O
presence	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Once	O
established	O
,	O
nonmutans	B-bacteria
streptococci	I-bacteria
,	O
enterococci	B-bacteria
and	O
lactobacilli	B-bacteria
appear	O
to	O
survive	O
commonly	O
following	O
root	O
-	O
canal	O
treatment	O
of	O
teeth	O
with	O
clinical	O
and	O
radiographical	O
signs	O
of	O
apical	O
periodontitis	O
.	O

Oral	O
streptococci	B-bacteria
are	O
present	O
in	O
large	O
numbers	O
in	O
dental	O
plaque	O
and	O
several	O
types	O
interact	O
with	O
the	O
enamel	O
salivary	O
pellicle	O
to	O
form	O
a	O
biofilm	O
on	O
tooth	O
surfaces	O
.	O

The	O
respective	O
affinity	O
of	O
individual	O
streptococci	B-bacteria
for	O
salivary	O
components	O
has	O
an	O
influence	O
on	O
the	O
etiologic	O
properties	O
of	O
oral	O
biofilm	O
in	O
the	O
development	O
of	O
dental	O
caries	O
.	O

We	O
studied	O
real	O
-	O
time	O
biospecific	O
interactions	O
between	O
oral	O
streptococci	B-bacteria
and	O
salivary	O
components	O
utilizing	O
biosensor	O
technology	O
to	O
analyze	O
surface	O
plasmon	O
resonance	O
.	O

Streptococcus	B-bacteria
sanguis	I-bacteria
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
showed	O
significant	O
responses	O
for	O
binding	O
to	O
salivary	O
components	O
,	O
in	O
comparison	O
with	O
other	O
bacteria	O
.	O

Further	O
,	O
the	O
association	O
rates	O
(	O
4	O
.	O
1	O
x	O
10	O
-	O
11	O
/	O
bacterium	O
)	O
and	O
dissociation	O
rate	O
(	O
5	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
9	O
x	O
10	O
-	O
3	O
Second	O
(	O
s	O
)	O
-	O
1	O
)	O
were	O
higher	O
for	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
than	O
for	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
(	O
2	O
.	O
4	O
x	O
10	O
-	O
11	O
and	O
2	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
8	O
x	O
10	O
-	O
3	O
)	O
and	O
Streptococcus	B-bacteria
mitis	I-bacteria
(	O
1	O
.	O
3	O
x	O
10	O
-	O
11	O
and	O
3	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
3	O
x	O
10	O
-	O
3	O
)	O
.	O

However	O
,	O
the	O
association	O
equilibrium	O
constants	O
(	O
8	O
.	O
2	O
S	O
/	O
bacterium	O
)	O
for	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
was	O
2	O
times	O
higher	O
in	O
than	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
(	O
3	O
.	O
8	O
)	O
and	O
slightly	O
higher	O
than	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
(	O
7	O
.	O
2	O
)	O
.	O

These	O
findings	O
may	O
provide	O
useful	O
information	O
regarding	O
the	O
mechanism	O
of	O
early	O
biofilm	O
formation	O
by	O
streptococci	B-bacteria
on	O
the	O
tooth	O
surface	O
.	O

This	O
article	O
describes	O
the	O
microbiology	O
,	O
diagnosis	O
,	O
and	O
management	O
of	O
human	O
and	O
animal	O
bite	O
wound	O
infections	O
.	O

Various	O
organisms	O
can	O
be	O
recovered	O
from	O
bite	O
wounds	O
that	O
generally	O
result	O
from	O
aerobic	O
and	O
anaerobic	O
microbial	O
flora	O
of	O
the	O
oral	O
cavity	O
of	O
the	O
biting	O
animal	O
,	O
rather	O
than	O
the	O
victim	O
'	O
s	O
own	O
skin	O
flora	O
.	O

The	O
role	O
of	O
anaerobes	O
in	O
bite	O
wound	O
infections	O
has	O
been	O
increasingly	O
appreciated	O
.	O

Anaerobes	O
were	O
isolated	O
from	O
more	O
than	O
two	O
thirds	O
of	O
human	O
and	O
animal	O
bite	O
wound	O
infections	O
,	O
especially	O
those	O
associated	O
with	O
abscess	O
formation	O
.	O

This	O
article	O
describes	O
several	O
of	O
the	O
organisms	O
found	O
in	O
the	O
bites	O
of	O
various	O
species	O
.	O

In	O
addition	O
to	O
local	O
wound	O
infection	O
,	O
other	O
complications	O
may	O
occur	O
,	O
including	O
lymphangitis	O
,	O
local	O
abscess	O
,	O
septic	O
arthritis	O
,	O
tenosynovitis	O
,	O
and	O
osteomyelitis	O
.	O

Rare	O
complications	O
include	O
endocarditis	O
,	O
meningitis	O
,	O
brain	O
abscess	O
,	O
and	O
sepsis	O
with	O
disseminated	O
intravascular	O
coagulation	O
,	O
especially	O
in	O
immunocompromised	O
individuals	O
.	O

Wound	O
management	O
includes	O
the	O
administration	O
of	O
proper	O
local	O
care	O
and	O
the	O
use	O
of	O
proper	O
antimicrobial	O
agents	O
when	O
needed	O
.	O

The	O
mucosal	O
secretory	O
proteins	O
,	O
such	O
as	O
the	O
salivary	O
proteins	O
,	O
play	O
a	O
key	O
role	O
in	O
the	O
acquisition	O
and	O
regulation	O
of	O
the	O
mucosal	O
microflora	O
.	O

Most	O
notably	O
,	O
some	O
microorganisms	O
utilize	O
the	O
host	O
'	O
s	O
secretory	O
proteins	O
to	O
adhere	O
to	O
the	O
mucosa	O
;	O
a	O
first	O
step	O
in	O
colonization	O
and	O
infection	O
.	O

The	O
secretory	O
proteins	O
also	O
influence	O
colonization	O
by	O
affecting	O
the	O
binding	O
among	O
microorganisms	O
,	O
a	O
process	O
denoted	O
as	O
coadherence	O
.	O

Previously	O
we	O
reported	O
that	O
acute	O
stressors	O
cause	O
specific	O
changes	O
in	O
saliva	O
composition	O
.	O

The	O
present	O
study	O
investigated	O
to	O
what	O
extent	O
these	O
changes	O
influence	O
saliva	O
-	O
mediated	O
microbial	O
adherence	O
and	O
coadherence	O
(	O
ex	O
vivo	O
)	O
.	O

Thirty	O
-	O
two	O
male	O
undergraduates	O
provided	O
unstimulated	O
saliva	O
before	O
and	O
during	O
a	O
control	O
condition	O
and	O
two	O
stressors	O
:	O
A	O
memory	O
test	O
and	O
a	O
surgery	O
video	O
presentation	O
.	O

We	O
used	O
saliva	O
-	O
coated	O
microplates	O
to	O
test	O
the	O
adherence	O
of	O
bacteria	O
for	O
which	O
the	O
oral	O
cavity	O
is	O
either	O
a	O
natural	O
reservoir	O
(	O
eg	O
,	O
viridans	B-bacteria
streptococci	I-bacteria
)	O
or	O
a	O
portal	O
of	O
entry	O
(	O
eg	O
,	O
Helicobacter	B-bacteria
pylori	I-bacteria
)	O
.	O

We	O
also	O
tested	O
the	O
saliva	O
-	O
mediated	O
co	O
-	O
adherence	O
between	O
Streptococcus	B-bacteria
gordonii	I-bacteria
and	O
the	O
yeast	O
Candida	O
albicans	O
.	O

Correlation	O
analyses	O
were	O
performed	O
to	O
determine	O
the	O
relationships	O
between	O
changes	O
in	O
microbial	O
adherence	O
and	O
the	O
concentrations	O
of	O
potential	O
salivary	O
ligands	O
,	O
viz	O
.	O

cystatin	O
S	O
,	O
the	O
mucins	O
MUC5B	O
and	O
MUC7	O
,	O
S	O
-	O
IgA	O
,	O
lactoferrin	O
,	O
alpha	O
-	O
amylase	O
,	O
and	O
total	O
salivary	O
protein	O
.	O

During	O
the	O
memory	O
test	O
,	O
saliva	O
-	O
mediated	O
adhesion	O
of	O
Streptococcus	B-bacteria
sanguis	I-bacteria
,	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
and	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
increased	O
,	O
whereas	O
the	O
coadherence	O
of	O
C	O
.	O
albicans	O
with	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
decreased	O
.	O

During	O
the	O
surgical	O
video	O
presentation	O
the	O
saliva	O
-	O
mediated	O
adherence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
,	O
and	O
Streptococcus	B-bacteria
mitis	I-bacteria
increased	O
.	O

These	O
changes	O
were	O
independent	O
of	O
salivary	O
flow	O
rate	O
,	O
but	O
correlated	O
with	O
specific	O
changes	O
in	O
salivary	O
protein	O
composition	O
.	O

The	O
results	O
show	O
that	O
even	O
moderate	O
stressors	O
,	O
by	O
altering	O
the	O
activity	O
of	O
the	O
mucosal	O
secretory	O
glands	O
,	O
may	O
affect	O
microbial	O
colonization	O
processes	O
such	O
as	O
adherence	O
and	O
coadherence	O
.	O

This	O
study	O
hereby	O
presents	O
a	O
mechanism	O
by	O
which	O
stress	O
may	O
affect	O
the	O
mucosal	O
microflora	O
and	O
susceptibility	O
to	O
infectious	O
disease	O
.	O

The	O
accurate	O
classification	O
of	O
oral	O
Actinomyces	B-bacteria
isolates	I-bacteria
as	O
one	O
species	O
is	O
difficult	O
.	O

Out	O
of	O
18	O
Actinomyces	B-bacteria
isolates	I-bacteria
forming	O
red	O
colonies	O
on	O
brain	O
heart	O
blood	O
agar	O
,	O
12	O
could	O
be	O
straightforwardly	O
assigned	O
as	O
Actinomyces	B-bacteria
odontolyticus	I-bacteria
by	O
biochemical	O
,	O
morphological	O
,	O
and	O
chemotaxonomic	O
characteristics	O
.	O

For	O
the	O
remaining	O
six	O
isolates	O
,	O
the	O
results	O
of	O
the	O
different	O
identification	O
methods	O
were	O
inconsistent	O
.	O

By	O
sequencing	O
a	O
16S	O
ribosomal	O
DNA	O
fragment	O
by	O
a	O
rapid	O
mass	O
spectrometric	O
method	O
,	O
all	O
isolates	O
could	O
be	O
identified	O
unambiguously	O
as	O
A	B-bacteria
.	I-bacteria
odontolyticus	I-bacteria
.	O

This	O
result	O
proves	O
the	O
importance	O
of	O
red	O
colony	O
pigmentation	O
on	O
brain	O
heart	O
blood	O
agar	O
together	O
with	O
the	O
characteristic	O
cell	O
morphology	O
for	O
unequivocal	O
assignment	O
of	O
oral	O
Actinomyces	B-bacteria
isolates	I-bacteria
to	O
the	O
species	O
A	B-bacteria
.	I-bacteria
odontolyticus	I-bacteria
.	O

The	O
oral	O
cavity	O
is	O
a	O
reservoir	O
for	O
colonization	O
and	O
infection	O
of	O
systemic	O
organs	O
by	O
pathogenic	O
bacteria	O
.	O

It	O
is	O
understood	O
that	O
aging	O
,	O
tooth	O
eruption	O
,	O
hormonal	O
changes	O
,	O
active	O
disease	O
,	O
oral	O
hygiene	O
,	O
and	O
other	O
factors	O
have	O
an	O
influence	O
on	O
biofilm	O
formation	O
and	O
bacterial	O
accumulation	O
in	O
the	O
oral	O
cavity	O
.	O

To	O
understand	O
the	O
influence	O
of	O
systemic	O
health	O
care	O
on	O
microfloral	O
changes	O
,	O
we	O
conducted	O
epidemiological	O
studies	O
of	O
nursing	O
home	O
residents	O
in	O
an	O
attempt	O
to	O
elucidate	O
the	O
relationship	O
between	O
underlying	O
systemic	O
diseases	O
and	O
the	O
isolation	O
frequency	O
of	O
oral	O
opportunistic	O
pathogens	O
.	O

The	O
prevalence	O
of	O
bacteria	O
and	O
fungi	O
causing	O
pneumonia	O
in	O
association	O
with	O
oral	O
biofilm	O
bacteria	O
were	O
determined	O
using	O
detection	O
culture	O
plates	O
.	O

The	O
influences	O
of	O
gender	O
,	O
age	O
,	O
denture	O
-	O
wearing	O
status	O
,	O
number	O
of	O
teeth	O
,	O
and	O
bedridden	O
status	O
in	O
the	O
patients	O
residing	O
in	O
nursing	O
homes	O
were	O
then	O
analyzed	O
.	O

The	O
isolation	O
frequency	O
rates	O
of	O
Candida	O
albicans	O
,	O
Pseudomonadaceae	B-bacteria
,	O
Staphylococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
and	O
some	O
strains	O
of	O
Enterobacteriaceae	B-bacteria
in	O
plaque	O
samples	O
,	O
as	O
well	O
as	O
C	O
.	O
albicans	O
and	O
Xanthomonas	B-bacteria
maltophilia	I-bacteria
in	O
samples	O
from	O
the	O
pharynx	O
,	O
were	O
significantly	O
higher	O
in	O
those	O
requiring	O
systemic	O
care	O
(	O
mean	O
age	O
83	O
.	O
9	O
years	O
)	O
than	O
in	O
those	O
who	O
did	O
not	O
require	O
such	O
care	O
(	O
mean	O
71	O
.	O
0	O
years	O
)	O
.	O

In	O
particular	O
,	O
the	O
frequencies	O
of	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
C	O
.	O
albicans	O
,	O
and	O
Serratia	B-bacteria
marcescens	I-bacteria
in	O
plaque	O
were	O
significantly	O
higher	O
in	O
those	O
who	O
were	O
bedridden	O
.	O

Furthermore	O
,	O
the	O
isolation	O
of	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
,	O
and	O
/	O
or	O
C	O
.	O
albicans	O
in	O
plaque	O
was	O
significantly	O
associated	O
with	O
heart	O
disease	O
.	O

The	O
coexistence	O
of	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
C	O
.	O
albicans	O
in	O
elderly	O
with	O
10	O
-	O
19	O
teeth	O
is	O
a	O
potential	O
indicator	O
of	O
high	O
risk	O
for	O
pneumonia	O
and	O
heart	O
disease	O
.	O

Therefore	O
,	O
attention	O
to	O
oral	O
hygiene	O
and	O
professional	O
care	O
for	O
removing	O
the	O
indicators	O
may	O
diminish	O
the	O
occurrence	O
of	O
systemic	O
disease	O
in	O
the	O
elderly	O
requiring	O
systemic	O
care	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
oral	O
status	O
of	O
children	O
suffering	O
from	O
end	O
-	O
stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
with	O
the	O
aim	O
of	O
determining	O
the	O
causes	O
of	O
low	O
caries	O
prevalence	O
in	O
this	O
population	O
(	O
using	O
the	O
CRT	O
bacteria	O
and	O
buffer	O
test	O
)	O
,	O
and	O
compared	O
results	O
with	O
a	O
control	O
group	O
(	O
n	O
=	O
38	O
)	O
.	O

In	O
the	O
study	O
group	O
,	O
there	O
were	O
38	O
children	O
(	O
aged	O
4	O
-	O
17	O
years	O
)	O
who	O
were	O
being	O
treated	O
in	O
pediatric	O
nephrology	O
units	O
at	O
three	O
different	O
hospitals	O
in	O
Izmir	O
,	O
Turkey	O
.	O

The	O
study	O
and	O
control	O
groups	O
did	O
not	O
significantly	O
differ	O
in	O
daily	O
tooth	O
brushing	O
frequency	O
and	O
periodic	O
dental	O
check	O
-	O
up	O
frequency	O
.	O

Severe	O
enamel	O
hypoplasia	O
was	O
present	O
in	O
the	O
study	O
group	O
.	O

Dmft	O
,	O
DMFT	O
,	O
gingival	O
and	O
plaque	O
indices	O
were	O
compared	O
statistically	O
in	O
mixed	O
dentition	O
stage	O
with	O
the	O
control	O
group	O
and	O
dmft	O
and	O
gingival	O
status	O
showed	O
a	O
statistically	O
significant	O
difference	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
differences	O
among	O
groups	O
for	O
DMFT	O
and	O
plaque	O
indices	O
were	O
not	O
statistically	O
significant	O
.	O

In	O
the	O
study	O
group	O
,	O
high	O
salivary	O
buffer	O
capacity	O
was	O
found	O
in	O
89	O
.	O
5	O
%	O
of	O
patients	O
.	O

Salivary	O
levels	O
of	O
cariogenic	O
streptococcus	B-bacteria
mutans	I-bacteria
and	O
lactobacilli	B-bacteria
in	O
the	O
study	O
group	O
were	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
.	O

In	O
conclusion	O
,	O
probably	O
due	O
to	O
increased	O
concentrations	O
of	O
antibacterial	O
chemicals	O
such	O
as	O
urea	O
in	O
the	O
saliva	O
of	O
children	O
with	O
ESRD	O
,	O
decreased	O
levels	O
of	O
cariogenic	O
microorganisms	O
were	O
detected	O
.	O

Therefore	O
,	O
although	O
dental	O
treatment	O
need	O
is	O
not	O
high	O
,	O
these	O
children	O
should	O
receive	O
dental	O
health	O
education	O
,	O
including	O
oral	O
hygiene	O
instruction	O
,	O
in	O
order	O
to	O
improve	O
their	O
overall	O
oral	O
health	O
.	O

It	O
has	O
been	O
suggested	O
that	O
between	O
3	O
%	O
and	O
13	O
%	O
of	O
the	O
cerebral	O
abscesses	O
(	O
CA	O
)	O
are	O
presumably	O
associated	O
to	O
oral	O
infections	O
or	O
dental	O
procedures	O
.	O

Determine	O
the	O
prevalence	O
of	O
CA	O
of	O
oral	O
origin	O
,	O
discussing	O
their	O
clinical	O
and	O
microbiological	O
characteristics	O
.	O

Retrospectively	O
,	O
54	O
cases	O
of	O
CA	O
diagnosed	O
in	O
3	O
hospitals	O
of	O
Galicia	O
between	O
2001	O
and	O
2002	O
were	O
reviewed	O
.	O

A	O
presumed	O
oral	O
portal	O
of	O
entry	O
was	O
recorded	O
in	O
6	O
patients	O
(	O
11	O
.	O
1	O
%	O
)	O
;	O
4	O
cases	O
were	O
associated	O
to	O
oral	O
infections	O
and	O
the	O
remaining	O
2	O
had	O
received	O
dental	O
treatment	O
in	O
the	O
months	O
prior	O
to	O
the	O
onset	O
of	O
symptoms	O
.	O

Half	O
of	O
the	O
patients	O
showed	O
irrelevant	O
medical	O
record	O
,	O
2	O
had	O
had	O
previous	O
extracranial	O
abscesses	O
and	O
1	O
presented	O
a	O
type	O
A	O
immunoglobulin	O
deficiency	O
.	O

In	O
4	O
cases	O
,	O
the	O
microbiological	O
analysis	O
was	O
positive	O
and	O
typical	O
oral	O
bacteria	O
(	O
Streptococcus	B-bacteria
viridans	I-bacteria
and	O
Peptostreptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
)	O
were	O
identified	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
a	O
significant	O
number	O
of	O
CA	O
are	O
probably	O
of	O
oral	O
origin	O
.	O

In	O
consequence	O
,	O
to	O
maintain	O
a	O
good	O
oral	O
health	O
status	O
is	O
important	O
and	O
specific	O
prophylactic	O
measures	O
before	O
any	O
dental	O
procedure	O
should	O
be	O
applied	O
,	O
especially	O
in	O
patients	O
with	O
risk	O
recognized	O
factors	O
.	O

Veillonella	B-bacteria
spp	I-bacteria
.	I-bacteria
are	O
early	O
colonizing	O
inhabitants	O
in	O
the	O
mouth	O
.	O

As	O
part	O
of	O
studies	O
on	O
penicillin	O
resistance	O
among	O
oral	O
indigenous	O
anaerobic	O
microbiota	O
in	O
childhood	O
,	O
the	O
aim	O
of	O
the	O
present	O
longitudinal	O
study	O
was	O
to	O
examine	O
the	O
emergence	O
of	O
resistant	O
strains	O
in	O
Veillonella	B-bacteria
populations	O
.	O

Altogether	O
305	O
Veillonella	B-bacteria
isolates	I-bacteria
from	O
saliva	O
of	O
49	O
healthy	O
infants	O
followed	O
from	O
2	O
to	O
24	O
months	O
of	O
age	O
were	O
examined	O
for	O
their	O
in	O
vitro	O
susceptibility	O
to	O
penicillin	O
G	O
and	O
,	O
further	O
,	O
20	O
penicillin	O
-	O
resistant	O
isolates	O
representing	O
5	O
MIC	O
categories	O
to	O
ampicillin	O
,	O
amoxicillin	O
,	O
amoxicillin	O
/	O
clavulanate	O
,	O
cefoxitin	O
,	O
and	O
beta	O
-	O
lactamase	O
production	O
.	O

In	O
infants	O
positive	O
for	O
oral	O
Veillonella	B-bacteria
,	O
the	O
recovery	O
rate	O
of	O
penicillin	O
-	O
resistant	O
(	O
MIC	O
>	O
/	O
=	O
2	O
microg	O
/	O
ml	O
)	O
strains	O
increased	O
with	O
age	O
up	O
to	O
68	O
%	O
,	O
however	O
,	O
most	O
infants	O
simultaneously	O
harbored	O
penicillin	O
-	O
susceptible	O
strains	O
.	O

During	O
the	O
follow	O
-	O
up	O
,	O
the	O
MIC	O
(	O
50	O
)	O
increased	O
from	O
0	O
.	O
5	O
microg	O
/	O
ml	O
to	O
2	O
microg	O
/	O
ml	O
.	O

In	O
addition	O
to	O
penicillin	O
G	O
,	O
8	O
/	O
20	O
strains	O
also	O
showed	O
reduced	O
susceptibility	O
to	O
ampicillin	O
and	O
/	O
or	O
amoxicillin	O
but	O
none	O
produced	O
beta	O
-	O
lactamase	O
.	O

Our	O
study	O
suggests	O
other	O
mechanisms	O
than	O
enzymatic	O
degradation	O
of	O
beta	O
-	O
lactam	O
ring	O
for	O
resistance	O
of	O
oral	O
Veillonella	B-bacteria
to	O
penicillin	O
.	O

The	O
complete	O
2	O
,	O
343	O
,	O
479	O
-	O
bp	O
genome	O
sequence	O
of	O
the	O
gram	O
-	O
negative	O
,	O
pathogenic	O
oral	O
bacterium	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
strain	I-bacteria
W83	I-bacteria
,	O
a	O
major	O
contributor	O
to	O
periodontal	O
disease	O
,	O
was	O
determined	O
.	O

Whole	O
-	O
genome	O
comparative	O
analysis	O
with	O
other	O
available	O
complete	O
genome	O
sequences	O
confirms	O
the	O
close	O
relationship	O
between	O
the	O
Cytophaga	B-bacteria
-	I-bacteria
Flavobacteria	I-bacteria
-	I-bacteria
Bacteroides	I-bacteria
(	O
CFB	B-bacteria
)	O
phylum	O
and	O
the	O
green	O
-	O
sulfur	O
bacteria	O
.	O

Within	O
the	O
CFB	B-bacteria
phyla	I-bacteria
,	O
the	O
genomes	O
most	O
similar	O
to	O
that	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
are	O
those	O
of	O
Bacteroides	B-bacteria
thetaiotaomicron	I-bacteria
and	O
B	B-bacteria
.	I-bacteria
fragilis	I-bacteria
.	O

Outside	O
of	O
the	O
CFB	B-bacteria
phyla	I-bacteria
the	O
most	O
similar	O
genome	O
to	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
is	O
that	O
of	O
Chlorobium	B-bacteria
tepidum	I-bacteria
,	O
supporting	O
the	O
previous	O
phylogenetic	O
studies	O
that	O
indicated	O
that	O
the	O
Chlorobia	B-bacteria
and	O
CFB	B-bacteria
phyla	I-bacteria
are	O
related	O
,	O
albeit	O
distantly	O
.	O

Genome	O
analysis	O
of	O
strain	O
W83	O
reveals	O
a	O
range	O
of	O
pathways	O
and	O
virulence	O
determinants	O
that	O
relate	O
to	O
the	O
novel	O
biology	O
of	O
this	O
oral	O
pathogen	O
.	O

Among	O
these	O
determinants	O
are	O
at	O
least	O
six	O
putative	O
hemagglutinin	O
-	O
like	O
genes	O
and	O
36	O
previously	O
unidentified	O
peptidases	O
.	O

Genome	O
analysis	O
also	O
reveals	O
that	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
can	O
metabolize	O
a	O
range	O
of	O
amino	O
acids	O
and	O
generate	O
a	O
number	O
of	O
metabolic	O
end	O
products	O
that	O
are	O
toxic	O
to	O
the	O
human	O
host	O
or	O
human	O
gingival	O
tissue	O
and	O
contribute	O
to	O
the	O
development	O
of	O
periodontal	O
disease	O
.	O

It	O
has	O
recently	O
been	O
shown	O
that	O
human	O
salivary	O
glands	O
constitutively	O
express	O
CD14	O
,	O
an	O
important	O
molecule	O
in	O
innate	O
immunity	O
,	O
and	O
that	O
a	O
soluble	O
form	O
of	O
CD14	O
is	O
secreted	O
in	O
saliva	O
.	O

The	O
concentration	O
of	O
CD14	O
in	O
parotid	O
(	O
a	O
serous	O
gland	O
)	O
saliva	O
was	O
comparable	O
to	O
that	O
in	O
normal	O
serum	O
and	O
10	O
-	O
fold	O
the	O
amount	O
in	O
whole	O
saliva	O
,	O
although	O
the	O
physiological	O
function	O
of	O
saliva	O
CD14	O
remained	O
unclear	O
.	O

Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
is	O
a	O
periodontopathic	O
bacterium	O
and	O
is	O
able	O
to	O
invade	O
oral	O
epithelial	O
cells	O
.	O

The	O
present	O
study	O
showed	O
that	O
upon	O
exposure	O
to	O
live	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
Y4	I-bacteria
for	O
2	O
h	O
,	O
human	O
oral	O
epithelial	O
HSC	O
-	O
2	O
cells	O
produced	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
for	O
a	O
further	O
24	O
h	O
and	O
whole	O
saliva	O
augmented	O
the	O
production	O
induced	O
by	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
Y4	I-bacteria
.	O

Parotid	O
saliva	O
showed	O
a	O
more	O
pronounced	O
effect	O
on	O
the	O
production	O
of	O
IL	O
-	O
8	O
than	O
whole	O
saliva	O
.	O

Neither	O
saliva	O
preparation	O
itself	O
had	O
IL	O
-	O
8	O
-	O
inducing	O
activity	O
.	O

Parotid	O
saliva	O
exhibited	O
antibacterial	O
activity	O
against	O
a	O
low	O
concentration	O
of	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
Y4	I-bacteria
,	O
but	O
recombinant	O
CD14	O
did	O
not	O
show	O
the	O
activity	O
.	O

The	O
internalization	O
of	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
Y4	I-bacteria
into	O
HSC	O
-	O
2	O
cells	O
was	O
inhibited	O
by	O
cytochalasin	O
B	O
,	O
indicating	O
that	O
the	O
process	O
was	O
actin	O
dependent	O
,	O
and	O
depletion	O
of	O
CD14	O
from	O
parotid	O
saliva	O
inhibited	O
the	O
invasion	O
and	O
,	O
as	O
a	O
consequence	O
,	O
inhibited	O
production	O
of	O
IL	O
-	O
8	O
.	O

Furthermore	O
,	O
human	O
recombinant	O
CD14	O
augmented	O
invasion	O
and	O
IL	O
-	O
8	O
production	O
.	O

These	O
results	O
suggest	O
that	O
saliva	O
CD14	O
promoted	O
the	O
invasion	O
of	O
oral	O
epithelial	O
cells	O
by	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
and	O
consequently	O
augmented	O
the	O
production	O
of	O
IL	O
-	O
8	O
,	O
playing	O
an	O
important	O
role	O
in	O
innate	O
immunity	O
in	O
the	O
oral	O
cavity	O
.	O

The	O
in	O
vitro	O
activities	O
of	O
human	O
beta	O
-	O
defensin	O
3	O
(	O
hBD	O
-	O
3	O
)	O
alone	O
or	O
combined	O
with	O
lysozyme	O
,	O
metronidazole	O
,	O
amoxicillin	O
,	O
and	O
chlorhexidine	O
were	O
investigated	O
with	O
the	O
oral	O
bacteria	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
.	O

hBD	O
-	O
3	O
showed	O
bactericidal	O
activity	O
against	O
all	O
of	O
the	O
bacterial	O
species	O
tested	O
.	O

The	O
bactericidal	O
effect	O
was	O
enhanced	O
when	O
the	O
peptide	O
was	O
used	O
in	O
combination	O
with	O
the	O
antimicrobial	O
agents	O
mentioned	O
above	O
.	O

Cysteine	O
proteinases	O
(	O
gingipains	O
)	O
from	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
are	O
considered	O
key	O
virulence	O
factors	O
of	O
severe	O
periodontitis	O
and	O
host	O
immune	O
evasion	O
.	O

Since	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
on	O
gingival	O
epithelium	O
is	O
indispensable	O
in	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
migration	O
at	O
the	O
site	O
of	O
periodontitis	O
,	O
we	O
examined	O
the	O
effects	O
of	O
gingipains	O
on	O
the	O
expression	O
of	O
ICAM	O
-	O
1	O
on	O
human	O
oral	O
epithelial	O
cell	O
lines	O
(	O
KB	O
and	O
HSC	O
-	O
2	O
)	O
by	O
flow	O
cytometry	O
and	O
Western	O
blotting	O
.	O

We	O
found	O
that	O
three	O
purified	O
forms	O
of	O
gingipains	O
efficiently	O
reduced	O
ICAM	O
-	O
1	O
expression	O
on	O
the	O
cells	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

Gingipains	O
reduced	O
the	O
expression	O
on	O
fixed	O
cells	O
and	O
degraded	O
the	O
ICAM	O
-	O
1	O
in	O
the	O
cell	O
membranes	O
,	O
indicating	O
that	O
the	O
reduction	O
resulted	O
from	O
direct	O
proteolysis	O
.	O

They	O
then	O
disturbed	O
the	O
ICAM	O
-	O
1	O
-	O
dependent	O
adhesion	O
of	O
PMNs	O
to	O
the	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
gingipains	O
cleave	O
ICAM	O
-	O
1	O
on	O
oral	O
epithelial	O
cells	O
,	O
consequently	O
disrupting	O
PMN	O
-	O
oral	O
epithelial	O
cell	O
interaction	O
,	O
and	O
are	O
involved	O
in	O
immune	O
evasion	O
by	O
the	O
bacterium	O
in	O
periodontal	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
a	O
16S	O
rDNA	O
-	O
based	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
nPCR	O
)	O
assay	O
to	O
investigate	O
the	O
occurrence	O
of	O
Campylobacter	B-bacteria
gracilis	I-bacteria
in	O
oral	O
infections	O
.	O

Samples	O
were	O
collected	O
from	O
ten	O
infected	O
root	O
canals	O
,	O
ten	O
cases	O
of	O
acute	O
periradicular	O
abscesses	O
and	O
eight	O
cases	O
of	O
adult	O
marginal	O
periodontitis	O
.	O

DNA	O
extracted	O
from	O
the	O
samples	O
was	O
initially	O
amplified	O
using	O
universal	O
16S	O
rDNA	O
primers	O
.	O

A	O
second	O
round	O
of	O
amplification	O
used	O
the	O
first	O
PCR	O
products	O
to	O
detect	O
C	B-bacteria
.	I-bacteria
gracilis	I-bacteria
using	O
oligonucleotide	O
primers	O
designed	O
from	O
species	O
-	O
specific	O
16S	O
rDNA	O
signature	O
sequences	O
.	O

The	O
nPCR	O
assay	O
used	O
in	O
this	O
study	O
showed	O
a	O
detection	O
limit	O
of	O
10	O
C	B-bacteria
.	I-bacteria
gracilis	I-bacteria
cells	O
and	O
no	O
cross	O
-	O
reactivity	O
was	O
observed	O
with	O
nontarget	O
bacteria	O
.	O

C	B-bacteria
.	I-bacteria
gracilis	I-bacteria
was	O
detected	O
in	O
the	O
three	O
types	O
of	O
oral	O
infections	O
investigated	O
-	O
4	O
/	O
10	O
infected	O
root	O
canals	O
;	O
2	O
/	O
10	O
acute	O
periradicular	O
abscesses	O
;	O
and	O
1	O
/	O
8	O
subgingival	O
specimens	O
from	O
adult	O
periodontitis	O
.	O

The	O
method	O
proposed	O
in	O
this	O
study	O
showed	O
both	O
high	O
sensitivity	O
and	O
high	O
specificity	O
to	O
directly	O
detect	O
C	B-bacteria
.	I-bacteria
gracilis	I-bacteria
in	O
samples	O
from	O
root	O
canal	O
infections	O
,	O
abscesses	O
,	O
and	O
subgingival	O
plaque	O
.	O

Our	O
findings	O
confirmed	O
that	O
C	B-bacteria
.	I-bacteria
gracilis	I-bacteria
may	O
be	O
a	O
member	O
of	O
the	O
microbiota	O
associated	O
with	O
distinct	O
oral	O
infections	O
,	O
and	O
its	O
specific	O
role	O
in	O
such	O
diseases	O
requires	O
further	O
clarification	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
perform	O
a	O
quantitative	O
and	O
qualitative	O
analysis	O
of	O
oral	O
carriage	O
of	O
staphylococci	B-bacteria
in	O
a	O
range	O
of	O
oral	O
specimens	O
from	O
patients	O
admitted	O
to	O
a	O
regional	O
burns	O
unit	O
.	O

The	O
study	O
recruited	O
28	O
patients	O
and	O
reasons	O
for	O
admittance	O
were	O
:	O
burns	O
(	O
46	O
%	O
)	O
,	O
skin	O
grafting	O
(	O
39	O
%	O
)	O
,	O
lacerations	O
(	O
7	O
%	O
)	O
,	O
scalding	O
(	O
4	O
%	O
)	O
and	O
necrotizing	O
fasciitis	O
(	O
4	O
%	O
)	O
.	O

No	O
patient	O
had	O
smoke	O
inhalation	O
injuries	O
or	O
trauma	O
to	O
the	O
oro	O
-	O
pharynx	O
.	O

There	O
were	O
five	O
patients	O
from	O
whom	O
methicillin	B-bacteria
-	I-bacteria
sensitive	I-bacteria
S	I-bacteria
.	I-bacteria
aureus	I-bacteria
(	O
MRSA	B-bacteria
)	O
could	O
be	O
detected	O
in	O
oral	O
specimens	O
.	O

For	O
three	O
patients	O
only	O
the	O
wound	O
and	O
oral	O
specimens	O
were	O
positive	O
for	O
MRSA	B-bacteria
.	O

In	O
one	O
patient	O
only	O
the	O
oral	O
specimens	O
were	O
positive	O
for	O
MRSA	B-bacteria
.	O

There	O
were	O
five	O
patients	O
from	O
whom	O
methicillin	B-bacteria
-	I-bacteria
sensitive	I-bacteria
S	I-bacteria
.	I-bacteria
aureus	I-bacteria
(	O
MRSA	B-bacteria
)	O
could	O
be	O
detected	O
in	O
the	O
oral	O
specimens	O
.	O

In	O
one	O
patient	O
only	O
the	O
oral	O
specimens	O
were	O
positive	O
for	O
MSSA	B-bacteria
.	O

Staphylococci	B-bacteria
could	O
be	O
recovered	O
from	O
the	O
dental	O
plaque	O
,	O
denture	O
and	O
toothbrush	O
specimens	O
with	O
a	O
mean	O
count	O
of	O
1	O
.	O
1	O
x	O
10	O
(	O
4	O
)	O
cfu	O
/	O
mL	O
(	O
range	O
20	O
-	O
5	O
.	O
3	O
x	O
10	O
(	O
4	O
)	O
)	O
,	O
5	O
.	O
4	O
x	O
10	O
(	O
3	O
)	O
(	O
range	O
40	O
-	O
2	O
.	O
1	O
x	O
10	O
(	O
4	O
)	O
)	O
and	O
264	O
cfu	O
/	O
mL	O
(	O
range	O
20	O
-	O
500	O
)	O
,	O
respectively	O
.	O

Both	O
MSSA	B-bacteria
and	O
MRSA	B-bacteria
could	O
be	O
recovered	O
from	O
these	O
specimen	O
types	O
.	O

In	O
one	O
patient	O
only	O
the	O
toothbrush	O
was	O
positive	O
for	O
MRSA	B-bacteria
and	O
all	O
other	O
oral	O
specimens	O
were	O
negative	O
.	O

This	O
study	O
suggests	O
that	O
staphylococci	B-bacteria
are	O
not	O
infrequent	O
colonizers	O
of	O
the	O
oral	O
cavity	O
,	O
and	O
that	O
this	O
site	O
may	O
serve	O
as	O
a	O
potential	O
reservoir	O
for	O
transmission	O
to	O
other	O
body	O
sites	O
.	O

The	O
prevalence	O
of	O
tetracycline	O
-	O
resistant	O
oral	O
bacteria	O
in	O
healthy	O
4	O
-	O
and	O
6	O
-	O
year	O
-	O
old	O
children	O
who	O
had	O
not	O
received	O
antibiotics	O
during	O
the	O
3	O
months	O
prior	O
to	O
sampling	O
was	O
investigated	O
.	O

Of	O
the	O
47	O
children	O
sampled	O
,	O
46	O
harboured	O
tetracycline	O
-	O
resistant	O
bacteria	O
.	O

The	O
median	O
proportion	O
of	O
cultivable	O
anaerobic	O
and	O
aerobic	O
oral	O
bacteria	O
resistant	O
to	O
tetracycline	O
was	O
1	O
.	O
1	O
%	O
and	O
the	O
MIC50	O
of	O
these	O
was	O
64	O
microg	O
ml	O
(	O
-	O
1	O
)	O
.	O

The	O
majority	O
(	O
56	O
%	O
)	O
of	O
tetracycline	O
-	O
resistant	O
bacteria	O
were	O
resistant	O
to	O
at	O
least	O
one	O
other	O
antibiotic	O
,	O
usually	O
erythromycin	O
.	O

The	O
most	O
commonly	O
identified	O
tetracycline	O
-	O
resistant	O
bacteria	O
were	O
the	O
oral	O
streptococci	B-bacteria
(	O
65	O
%	O
)	O
,	O
the	O
next	O
most	O
prevalent	O
groups	O
were	O
Veillonella	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
10	O
%	O
)	O
and	O
Neisseria	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
9	O
%	O
)	O
.	O

The	O
most	O
frequently	O
identified	O
tetracycline	O
resistance	O
determinant	O
was	O
tet	O
(	O
M	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
have	O
shown	O
that	O
tetracycline	O
-	O
resistant	O
oral	O
bacteria	O
were	O
widespread	O
amongst	O
the	O
children	O
studied	O
.	O

Naturally	O
occurring	O
antimicrobial	O
peptides	O
have	O
emerged	O
as	O
alternative	O
classes	O
of	O
antimicrobials	O
.	O

In	O
general	O
,	O
these	O
antimicrobial	O
peptides	O
exhibit	O
selectivity	O
for	O
prokaryotes	O
and	O
minimize	O
the	O
problems	O
of	O
engendering	O
microbial	O
resistance	O
.	O

As	O
an	O
alternative	O
method	O
to	O
search	O
for	O
more	O
effective	O
broad	O
-	O
spectrum	O
peptide	O
antimicrobials	O
,	O
investigators	O
have	O
developed	O
peptide	O
libraries	O
by	O
using	O
synthetic	O
combinatorial	O
technology	O
.	O

A	O
novel	O
decapeptide	O
,	O
KKVVFKVKFK	O
(	O
KSL	O
)	O
,	O
has	O
been	O
identified	O
that	O
shows	O
a	O
broad	O
range	O
of	O
antibacterial	O
activity	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
efficacy	O
of	O
this	O
antimicrobial	O
peptide	O
in	O
killing	O
selected	O
strains	O
of	O
oral	O
pathogens	O
and	O
resident	O
saliva	O
bacteria	O
collected	O
from	O
human	O
subjects	O
.	O

Cytotoxic	O
activity	O
of	O
KSL	O
against	O
mammalian	O
cells	O
and	O
the	O
structural	O
features	O
of	O
this	O
decapeptide	O
were	O
also	O
investigated	O
,	O
the	O
latter	O
by	O
using	O
two	O
-	O
dimensional	O
NMR	O
in	O
aqueous	O
and	O
DMSO	O
solutions	O
.	O

MICs	O
of	O
KSL	O
for	O
the	O
majority	O
of	O
oral	O
bacteria	O
tested	O
in	O
vitro	O
ranged	O
from	O
3	O
to	O
100	O
microg	O
ml	O
(	O
-	O
1	O
)	O
.	O

Minimal	O
bactericidal	O
concentrations	O
of	O
KSL	O
were	O
,	O
in	O
general	O
,	O
within	O
one	O
to	O
two	O
dilutions	O
of	O
the	O
MICs	O
.	O

KSL	O
exhibited	O
an	O
ED	O
(	O
99	O
)	O
(	O
the	O
dose	O
at	O
which	O
99	O
%	O
killing	O
was	O
observed	O
after	O
15	O
min	O
at	O
37	O
degrees	O
C	O
)	O
of	O
6	O
.	O
25	O
microg	O
ml	O
(	O
-	O
1	O
)	O
against	O
selected	O
strains	O
of	O
Lactobacillus	B-bacteria
salivarius	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
gordonii	I-bacteria
and	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
.	O

In	O
addition	O
,	O
KSL	O
damaged	O
bacterial	O
cell	O
membranes	O
and	O
caused	O
1	O
.	O
05	O
log	O
units	O
reduction	O
of	O
viability	O
counts	O
of	O
saliva	O
bacteria	O
.	O

In	O
vitro	O
toxicity	O
studies	O
showed	O
that	O
KSL	O
,	O
at	O
concentrations	O
up	O
to	O
1	O
mg	O
ml	O
(	O
-	O
1	O
)	O
,	O
did	O
not	O
induce	O
cell	O
death	O
or	O
compromise	O
the	O
membrane	O
integrity	O
of	O
human	O
gingival	O
fibroblasts	O
.	O

NMR	O
studies	O
suggest	O
that	O
KSL	O
adopts	O
an	O
alpha	O
-	O
helical	O
structure	O
in	O
DMSO	O
solution	O
,	O
which	O
mimics	O
the	O
polar	O
aprotic	O
membrane	O
environment	O
,	O
whereas	O
it	O
remains	O
unstructured	O
in	O
aqueous	O
medium	O
.	O

This	O
study	O
shows	O
that	O
KSL	O
may	O
be	O
a	O
useful	O
antimicrobial	O
agent	O
for	O
inhibiting	O
the	O
growth	O
of	O
oral	O
bacteria	O
that	O
are	O
associated	O
with	O
caries	O
development	O
and	O
early	O
plaque	O
formation	O
.	O

Microbial	O
interactions	O
with	O
host	O
molecules	O
,	O
and	O
programmed	O
responses	O
to	O
host	O
environmental	O
stimuli	O
,	O
are	O
critical	O
for	O
colonization	O
and	O
initiation	O
of	O
pathogenesis	O
.	O

Bacteria	O
of	O
the	O
genus	O
Streptococcus	B-bacteria
are	O
primary	O
colonizers	O
of	O
the	O
human	O
mouth	O
.	O

They	O
express	O
multiple	O
cell	O
-	O
surface	O
adhesins	O
that	O
bind	O
salivary	O
components	O
and	O
other	O
oral	O
bacteria	O
and	O
enable	O
the	O
development	O
of	O
polymicrobial	O
biofilms	O
associated	O
with	O
tooth	O
decay	O
and	O
periodontal	O
disease	O
.	O

However	O
,	O
the	O
mechanisms	O
by	O
which	O
streptococci	B-bacteria
invade	O
dentine	O
to	O
infect	O
the	O
tooth	O
pulp	O
and	O
periapical	O
tissues	O
are	O
poorly	O
understood	O
.	O

Here	O
we	O
show	O
that	O
production	O
of	O
the	O
antigen	O
I	O
/	O
II	O
(	O
AgI	O
/	O
II	O
)	O
family	O
polypeptide	O
adhesin	O
and	O
invasin	O
SspA	O
in	O
Streptococcus	B-bacteria
gordonii	I-bacteria
is	O
specifically	O
upregulated	O
in	O
response	O
to	O
a	O
collagen	O
type	O
I	O
signal	O
,	O
minimally	O
the	O
tri	O
-	O
peptide	O
Gly	O
-	O
Pro	O
-	O
Xaa	O
(	O
where	O
Xaa	O
is	O
hydroxyproline	O
or	O
alanine	O
)	O
.	O

Increased	O
AgI	O
/	O
II	O
polypeptide	O
expression	O
promotes	O
bacterial	O
adhesion	O
and	O
extended	O
growth	O
of	O
streptococcal	O
cell	O
chains	O
along	O
collagen	O
type	O
I	O
fibrils	O
that	O
are	O
characteristically	O
found	O
within	O
dentinal	O
tubules	O
.	O

These	O
observations	O
define	O
a	O
new	O
model	O
of	O
host	O
matrix	O
signal	O
-	O
induced	O
tissue	O
penetration	O
by	O
bacteria	O
and	O
open	O
the	O
way	O
for	O
novel	O
therapy	O
opportunities	O
for	O
oral	O
invasive	O
diseases	O
.	O

Oral	O
epithelium	O
may	O
play	O
a	O
regulatory	O
role	O
in	O
local	O
immune	O
responses	O
when	O
interacting	O
with	O
bacteria	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
selected	O
bacterial	O
pathogens	O
found	O
in	O
periodontal	O
and	O
endodontic	O
infections	O
on	O
oral	O
epithelial	O
cells	O
.	O

Expression	O
of	O
cell	O
surface	O
molecules	O
(	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
Class	O
II	O
,	O
CD54	O
,	O
CD70	O
,	O
CD80	O
and	O
CD86	O
)	O
and	O
secretion	O
of	O
inflammatory	O
cytokines	O
(	O
interleukin	O
(	O
IL	O
)	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
)	O
in	O
response	O
to	O
selected	O
bacterial	O
challenge	O
were	O
examined	O
on	O
an	O
immortalized	O
oral	O
epithelial	O
cell	O
line	O
,	O
HOK	O
-	O
18A	O
and	O
a	O
skin	O
epithelial	O
cell	O
line	O
,	O
HaCaT	O
.	O

Actinomyces	B-bacteria
viscosus	I-bacteria
,	O
Actinomyces	B-bacteria
israelii	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
primary	O
human	O
periradicular	O
exudate	O
from	O
a	O
granuloma	O
were	O
co	O
-	O
cultured	O
with	O
epithelial	O
cells	O
for	O
4	O
or	O
24	O
h	O
.	O
Subsequently	O
,	O
cell	O
surface	O
expression	O
of	O
MHC	O
Class	O
II	O
,	O
CD54	O
,	O
CD70	O
,	O
CD80	O
and	O
CD86	O
,	O
along	O
with	O
pro	O
-	O
inflammatory	O
cytokine	O
levels	O
were	O
determined	O
using	O
flow	O
cytometry	O
,	O
ELISA	O
and	O
RT	O
-	O
PCR	O
.	O

Results	O
indicated	O
that	O
the	O
selected	O
oral	O
bacteria	O
have	O
greater	O
effects	O
on	O
oral	O
versus	O
skin	O
epithelial	O
cells	O
.	O

F	I-bacteria
.	I-bacteria
nucleatum	I-bacteria
increased	O
MHC	O
Class	O
II	O
and	O
CD54	O
(	O
ICAM	O
-	O
1	O
)	O
cell	O
surface	O
expression	O
on	O
HOK	O
-	O
18A	O
and	O
HaCaT	O
cells	O
.	O

A	O
.	O
israelii	O
also	O
had	O
enhancing	O
effects	O
on	O
the	O
expression	O
of	O
CD54	O
and	O
MHC	O
Class	O
II	O
.	O

A	B-bacteria
.	I-bacteria
israelii	I-bacteria
and	O
LPS	O
induced	O
a	O
2	O
.	O
8	O
-	O
fold	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
4	O
.	O
4	O
-	O
fold	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
TNF	O
-	O
alpha	O
secretion	O
,	O
respectively	O
,	O
while	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
and	O
LPS	O
induced	O
a	O
10	O
-	O
fold	O
(	O
P	O
<	O
0	O
.	O
0004	O
)	O
and	O
6	O
-	O
fold	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
IL	O
-	O
1beta	O
secretion	O
,	O
respectively	O
by	O
HOK	O
-	O
18A	O
.	O

Interestingly	O
,	O
CD70	O
,	O
CD80	O
,	O
and	O
CD86	O
were	O
generally	O
decreased	O
upon	O
bacteria	O
and	O
LPS	O
challenge	O
on	O
HOK	O
-	O
18A	O
.	O

The	O
effects	O
of	O
increased	O
MHC	O
Class	O
II	O
and	O
decreased	O
CD70	O
were	O
also	O
evident	O
with	O
challenge	O
of	O
human	O
periradicular	O
exudate	O
on	O
HOK	O
-	O
18A	O
.	O

The	O
implications	O
of	O
the	O
study	O
are	O
unique	O
in	O
that	O
oral	O
epithelial	O
cells	O
may	O
play	O
both	O
activating	O
and	O
inhibitory	O
roles	O
in	O
the	O
host	O
immune	O
response	O
towards	O
infection	O
by	O
oral	O
bacteria	O
.	O

We	O
introduce	O
a	O
concept	O
of	O
'	O
dormancy	O
'	O
where	O
the	O
differential	O
expression	O
of	O
key	O
cell	O
surface	O
antigens	O
on	O
oral	O
epithelial	O
cells	O
may	O
keep	O
the	O
recruited	O
immune	O
effector	O
cells	O
in	O
a	O
state	O
of	O
unresponsiveness	O
,	O
thus	O
contributing	O
to	O
the	O
long	O
term	O
quiescent	O
period	O
observed	O
in	O
many	O
periodontal	O
and	O
endodontic	O
lesions	O
.	O

Human	O
beta	O
-	O
defensin	O
-	O
2	O
,	O
and	O
-	O
3	O
(	O
hBD	O
-	O
2	O
,	O
-	O
3	O
)	O
are	O
small	O
inducible	O
antimicrobial	O
peptides	O
involved	O
in	O
host	O
defense	O
.	O

Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
a	O
gram	O
-	O
negative	O
facultative	O
anaerobe	O
,	O
is	O
frequently	O
associated	O
with	O
oral	O
disease	O
in	O
humans	O
.	O

A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
strain	O
JP2	B-bacteria
,	O
was	O
examined	O
for	O
its	O
ability	O
to	O
modulate	O
hBD	O
-	O
2	O
and	O
-	O
3	O
gene	O
expression	O
in	O
normal	O
human	O
oral	O
epithelial	O
cells	O
(	O
NHOECs	O
)	O
and	O
in	O
OKF6	O
/	O
Tert	O
cells	O
,	O
an	O
immortalized	O
cell	O
line	O
derived	O
from	O
human	O
oral	O
epithelial	O
cells	O
.	O

Stimulation	O
of	O
both	O
cell	O
types	O
by	O
live	O
bacteria	O
,	O
at	O
a	O
minimal	O
bacteria	O
/	O
cell	O
ratio	O
of	O
500	O
:	O
1	O
,	O
resulted	O
in	O
increased	O
hBD	O
-	O
3	O
gene	O
expression	O
.	O

This	O
was	O
not	O
evinced	O
for	O
hBD	O
-	O
2	O
in	O
either	O
cell	O
type	O
with	O
live	O
bacteria	O
,	O
even	O
at	O
bacteria	O
/	O
cell	O
ratios	O
exceeding	O
500	O
:	O
1	O
.	O

The	O
increased	O
hBD	O
-	O
3	O
gene	O
expression	O
was	O
dependent	O
upon	O
viable	O
bacteria	O
,	O
and	O
not	O
their	O
lipopolysaccharides	O
(	O
LPS	O
)	O
,	O
since	O
heat	O
-	O
killed	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
did	O
not	O
induce	O
hBD	O
-	O
3	O
transcript	O
expression	O
.	O

The	O
overall	O
similarity	O
between	O
results	O
obtained	O
in	O
OKF6	O
/	O
Tert	O
cells	O
and	O
NHOECs	O
suggest	O
that	O
the	O
OKF6	O
/	O
Tert	O
cell	O
line	O
may	O
be	O
a	O
useful	O
tool	O
in	O
the	O
study	O
of	O
beta	O
-	O
defensin	O
expression	O
in	O
oral	O
epithelium	O
.	O

The	O
in	O
vitro	O
activity	O
of	O
Melaleuca	O
alternifolia	O
(	O
tea	O
tree	O
)	O
oil	O
against	O
161	O
isolates	O
of	O
oral	O
bacteria	O
from	O
15	O
genera	O
was	O
determined	O
.	O

Minimum	O
inhibitory	O
concentrations	O
(	O
MIC	O
)	O
and	O
minimum	O
bactericidal	O
concentrations	O
(	O
MBC	O
)	O
ranged	O
from	O
0	O
.	O
003	O
to	O
2	O
.	O
0	O
%	O
(	O
v	O
/	O
v	O
)	O
.	O

MIC90	O
values	O
were	O
1	O
.	O
0	O
%	O
(	O
v	O
/	O
v	O
)	O
for	O
Actinomyces	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
and	O
Streptococcus	B-bacteria
sanguis	I-bacteria
,	O
and	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
for	O
Prevotella	B-bacteria
spp	I-bacteria
.	O

Isolates	O
of	O
Porphyromonas	B-bacteria
,	O
Prevotella	B-bacteria
and	O
Veillonella	B-bacteria
had	O
the	O
lowest	O
MICs	O
and	O
MBCs	O
,	O
and	O
isolates	O
of	O
Streptococcus	B-bacteria
,	O
Fusobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
had	O
the	O
highest	O
.	O

Time	O
kill	O
studies	O
with	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
showed	O
that	O
treatment	O
with	O
>	O
or	O
=	O
0	O
.	O
5	O
%	O
tea	O
tree	O
oil	O
caused	O
decreases	O
in	O
viability	O
of	O
>	O
3	O
log	O
colony	O
forming	O
units	O
/	O
ml	O
after	O
only	O
30	O
s	O
,	O
and	O
viable	O
organisms	O
were	O
not	O
detected	O
after	O
5	O
min	O
.	O

These	O
studies	O
indicate	O
that	O
a	O
range	O
of	O
oral	O
bacteria	O
are	O
susceptible	O
to	O
tea	O
tree	O
oil	O
,	O
suggesting	O
that	O
tea	O
tree	O
oil	O
may	O
be	O
of	O
use	O
in	O
oral	O
healthcare	O
products	O
and	O
in	O
the	O
maintenance	O
of	O
oral	O
hygiene	O
.	O

Bacterial	O
effects	O
on	O
in	O
vitro	O
mineralization	O
of	O
human	O
periodontal	O
fibroblasts	O
(	O
HPF	O
)	O
have	O
not	O
yet	O
been	O
examined	O
in	O
great	O
detail	O
.	O

In	O
our	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
soluble	O
extracts	O
of	O
the	O
periodontopathic	O
bacteria	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Bacteroides	B-bacteria
forsythus	I-bacteria
and	O
,	O
Treponema	B-bacteria
denticola	I-bacteria
on	O
cell	O
proliferation	O
,	O
mineralization	O
,	O
as	O
well	O
as	O
on	O
osteoblastic	O
markers	O
present	O
in	O
HPF	O
cultured	O
in	O
vitro	O
,	O
such	O
as	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
activity	O
and	O
collagen	O
content	O
.	O

Periodontal	O
fibroblasts	O
stimulated	O
by	O
B	O
-	O
glycerophosphate	O
,	O
ascorbic	O
acid	O
and	O
dexamethasone	O
(	O
BAD	O
)	O
or	O
by	O
dexamethasone	O
and	O
ascorbic	O
acid	O
(	O
DA	O
)	O
were	O
compared	O
to	O
unstimulated	O
cells	O
.	O

During	O
the	O
cultivation	O
period	O
,	O
the	O
stimulation	O
of	O
HPF	O
by	O
combined	O
dexamethasone	O
and	O
ascorbic	O
acid	O
(	O
DA	O
)	O
had	O
a	O
strong	O
inductive	O
effect	O
on	O
proliferation	O
,	O
ALP	O
activity	O
and	O
collagen	O
formation	O
.	O

The	O
extracts	O
obtained	O
from	O
the	O
periodontal	O
pathogens	O
had	O
a	O
suppressing	O
effect	O
on	O
the	O
proliferation	O
rate	O
of	O
HPF	O
.	O

The	O
extracts	O
from	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
B	B-bacteria
.	I-bacteria
forsythus	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
caused	O
a	O
decrease	O
in	O
ALP	O
activity	O
within	O
24	O
h	O
of	O
application	O
.	O

While	O
extracts	O
obtained	O
from	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
B	B-bacteria
.	I-bacteria
forsythus	I-bacteria
induced	O
a	O
reduction	O
in	O
collagen	O
content	O
in	O
BAD	O
-	O
and	O
DA	O
-	O
stimulated	O
HPF	O
cells	O
,	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
extracts	O
led	O
to	O
an	O
increase	O
in	O
collagen	O
.	O

Our	O
data	O
suggest	O
that	O
specific	O
periodontopathic	O
bacteria	O
may	O
suppress	O
tissue	O
regeneration	O
in	O
vivo	O
not	O
only	O
by	O
activating	O
host	O
defense	O
mechanisms	O
but	O
also	O
directly	O
via	O
a	O
suppression	O
of	O
growth	O
and	O
differentiation	O
of	O
HPF	O
and	O
a	O
reduction	O
in	O
the	O
extracellular	O
collagen	O
matrix	O
.	O

For	O
the	O
process	O
of	O
pocket	O
formation	O
,	O
not	O
even	O
the	O
direct	O
influence	O
of	O
viable	O
bacteria	O
seems	O
to	O
be	O
necessary	O
.	O

Additionally	O
,	O
long	O
-	O
distance	O
effects	O
of	O
bacteria	O
harboured	O
in	O
periodontal	O
pockets	O
or	O
in	O
root	O
canals	O
may	O
be	O
of	O
importance	O
.	O

Six	O
strains	O
of	O
anaerobic	O
,	O
Gram	O
-	O
negative	O
coccobacilli	O
isolated	O
from	O
the	O
root	O
canals	O
of	O
patients	O
with	O
endodontic	O
infections	O
(	O
five	O
strains	O
)	O
and	O
from	O
a	O
deep	O
periodontal	O
pocket	O
(	O
one	O
strain	O
)	O
were	O
subjected	O
to	O
a	O
comprehensive	O
range	O
of	O
phenotypic	O
and	O
genetic	O
tests	O
and	O
were	O
found	O
to	O
comprise	O
a	O
homogeneous	O
group	O
.	O

Following	O
16S	O
rRNA	O
gene	O
sequence	O
analysis	O
,	O
they	O
were	O
found	O
to	O
be	O
most	O
closely	O
related	O
to	O
Dialister	B-bacteria
pneumosintes	I-bacteria
,	O
with	O
93	O
%	O
sequence	O
similarity	O
between	O
the	O
two	O
taxa	O
.	O

A	O
novel	O
species	O
,	O
Dialister	B-bacteria
invisus	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
is	O
proposed	O
.	O

Biochemically	O
,	O
the	O
species	O
is	O
largely	O
unreactive	O
and	O
is	O
asaccharolytic	O
,	O
with	O
only	O
traces	O
of	O
acetate	O
and	O
propionate	O
detected	O
as	O
metabolic	O
end	O
-	O
products	O
.	O

The	O
G	O
+	O
C	O
content	O
of	O
the	O
DNA	O
of	O
D	O
.	O
invisus	O
strains	O
is	O
45	O
-	O
46	O
mol	O
%	O
.	O

The	O
type	O
strain	O
is	O
E7	O
.	O
25	O
(	O
T	O
)	O
(	O
=	O
CCUG	B-bacteria
47026	I-bacteria
(	O
T	O
)	O
=	O
DSM	B-bacteria
15470	I-bacteria
(	O
T	O
)	O
)	O
.	O

To	O
investigate	O
whether	O
human	O
breast	O
milk	O
contains	O
potentially	O
probiotic	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
,	O
and	O
therefore	O
,	O
whether	O
it	O
can	O
be	O
considered	O
a	O
synbiotic	O
food	O
.	O

Study	O
design	O
Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
were	O
isolated	O
from	O
milk	O
,	O
mammary	O
areola	O
,	O
and	O
breast	O
skin	O
of	O
eight	O
healthy	O
mothers	O
and	O
oral	O
swabs	O
and	O
feces	O
of	O
their	O
respective	O
breast	O
-	O
fed	O
infants	O
.	O

Some	O
isolates	O
(	O
178	O
from	O
each	O
mother	O
and	O
newborn	O
pair	O
)	O
were	O
randomly	O
selected	O
and	O
submitted	O
to	O
randomly	O
amplified	O
polymorphic	O
DNA	O
(	O
RAPD	O
)	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
and	O
those	O
that	O
displayed	O
identical	O
RAPD	O
patterns	O
were	O
identified	O
by	O
16S	O
rDNA	O
sequencing	O
.	O

Within	O
each	O
mother	O
and	O
newborn	O
pair	O
,	O
some	O
rod	O
-	O
shaped	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
isolated	O
from	O
mammary	O
areola	O
,	O
breast	O
milk	O
,	O
and	O
infant	O
oral	O
swabs	O
and	O
feces	O
displayed	O
identical	O
RAPD	O
profiles	O
.	O

All	O
of	O
them	O
,	O
independently	O
from	O
the	O
mother	O
and	O
child	O
pair	O
,	O
were	O
identified	O
as	O
Lactobacillus	B-bacteria
gasseri	I-bacteria
.	O

Similarly	O
,	O
among	O
coccoid	B-bacteria
lactic	I-bacteria
acid	I-bacteria
bacteria	I-bacteria
from	O
these	O
different	O
sources	O
,	O
some	O
shared	O
an	O
identical	O
RAPD	O
pattern	O
and	O
were	O
identified	O
as	O
Enterococcus	B-bacteria
faecium	I-bacteria
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
isolated	O
from	O
breast	O
skin	O
shared	O
RAPD	O
profiles	O
with	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
of	O
the	O
other	O
sources	O
.	O

Breast	O
-	O
feeding	O
can	O
be	O
a	O
significant	O
source	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
to	O
the	O
infant	O
gut	O
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
present	O
in	O
milk	O
may	O
have	O
an	O
endogenous	O
origin	O
and	O
may	O
not	O
be	O
the	O
result	O
of	O
contamination	O
from	O
the	O
surrounding	O
breast	O
skin	O
.	O

To	O
analyze	O
the	O
relationship	O
between	O
Helicobacter	B-bacteria
pylori	I-bacteria
(	O
Hp	B-bacteria
)	O
in	O
oral	O
cavity	O
and	O
the	O
Hp	B-bacteria
infection	O
in	O
stomach	O
.	O

102	O
patients	O
with	O
gastric	O
Hp	B-bacteria
infection	O
and	O
periodontitis	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

DNA	O
was	O
extracted	O
from	O
subgingival	O
plaques	O
,	O
mouthwashes	O
and	O
stomach	O
mucosa	O
samples	O
by	O
using	O
the	O
glass	O
-	O
milk	O
(	O
SiO2	O
)	O
purification	O
method	O
.	O

To	O
identify	O
the	O
presence	O
of	O
Hp	B-bacteria
in	O
these	O
samples	O
,	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
was	O
carried	O
out	O
,	O
and	O
two	O
pairs	O
of	O
oligonucleotide	O
primer	O
were	O
used	O
to	O
amplify	O
a	O
portion	O
of	O
gene	O
urease	O
C	O
and	O
gene	O
cag	O
A	O
of	O
Hp	B-bacteria
.	O

The	O
rate	O
of	O
Hp	B-bacteria
detected	O
in	O
oral	O
cavity	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
positive	O
Hp	B-bacteria
in	O
stomach	O
(	O
43	O
.	O
1	O
%	O
,	O
n	O
=	O
58	O
)	O
than	O
in	O
those	O
with	O
negative	O
Hp	B-bacteria
in	O
stomach	O
(	O
22	O
.	O
7	O
%	O
,	O
n	O
=	O
44	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

After	O
the	O
treatment	O
for	O
gastric	O
Hp	B-bacteria
infection	O
for	O
4	O
weeks	O
,	O
the	O
eradication	O
rate	O
of	O
Hp	B-bacteria
in	O
stomach	O
was	O
lower	O
,	O
but	O
only	O
slightly	O
in	O
patients	O
with	O
positive	O
oral	O
Hp	B-bacteria
(	O
16	O
/	O
25	O
,	O
64	O
%	O
)	O
than	O
in	O
those	O
with	O
negative	O
oral	O
Hp	B-bacteria
(	O
24	O
/	O
33	O
,	O
72	O
.	O
7	O
%	O
)	O
.	O

However	O
,	O
this	O
difference	O
became	O
apparent	O
(	O
36	O
.	O
0	O
%	O
vs	O
63	O
.	O
6	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
one	O
year	O
of	O
the	O
treatment	O
.	O

The	O
effectiveness	O
of	O
the	O
eradication	O
therapy	O
for	O
gastric	O
Hp	B-bacteria
infection	O
is	O
affected	O
by	O
the	O
presence	O
of	O
Hp	B-bacteria
in	O
oral	O
cavity	O
.	O

Oral	O
colonization	O
of	O
Hp	B-bacteria
may	O
imply	O
that	O
there	O
is	O
a	O
risk	O
of	O
the	O
relapses	O
of	O
gastric	O
and	O
duodenal	O
Hp	B-bacteria
infection	O
and	O
ulcer	O
after	O
the	O
antibiotics	O
treatment	O
for	O
the	O
eradication	O
of	O
Hp	B-bacteria
.	O

The	O
feasibility	O
of	O
recovering	O
and	O
genotypically	O
comparing	O
oral	O
bacteria	O
from	O
bitemarks	O
for	O
forensic	O
purposes	O
was	O
assessed	O
experimentally	O
.	O

Volunteers	O
firmly	O
bit	O
their	O
own	O
upper	O
arms	O
and	O
bitemarks	O
were	O
sampled	O
at	O
intervals	O
to	O
recover	O
viable	O
Streptococcus	B-bacteria
isolates	I-bacteria
.	O

The	O
recoverability	O
of	O
bacteria	O
decreased	O
over	O
time	O
but	O
an	O
average	O
of	O
more	O
than	O
one	O
thousand	O
viable	O
organisms	O
was	O
recovered	O
24	O
hrs	O
after	O
biting	O
,	O
provided	O
the	O
site	O
remained	O
relatively	O
undisturbed	O
.	O

Physical	O
exertion	O
,	O
manual	O
rubbing	O
and	O
application	O
of	O
moisturizing	O
lotion	O
all	O
decreased	O
bacterial	O
recoverability	O
compared	O
to	O
controls	O
.	O

Streptococci	B-bacteria
could	O
also	O
be	O
recovered	O
from	O
bites	O
inflicted	O
on	O
various	O
fabrics	O
.	O

Genomic	O
profiles	O
(	O
DNA	O
`	O
`	O
fingerprints	O
'	O
'	O
)	O
of	O
bacteria	O
recovered	O
from	O
bitemarks	O
could	O
be	O
identified	O
exclusively	O
with	O
those	O
from	O
the	O
teeth	O
of	O
the	O
individual	O
responsible	O
.	O

These	O
findings	O
suggest	O
that	O
a	O
bacterial	O
genotyping	O
approach	O
to	O
bitemark	O
analysis	O
could	O
have	O
forensic	O
application	O
in	O
situations	O
where	O
the	O
perpetrator	O
'	O
s	O
DNA	O
can	O
not	O
be	O
recovered	O
from	O
an	O
oral	O
contact	O
site	O
.	O

The	O
innate	O
immune	O
response	O
is	O
critical	O
for	O
the	O
epithelial	O
antimicrobial	O
barrier	O
.	O

The	O
human	O
beta	O
-	O
defensins	O
are	O
small	O
,	O
cationic	O
antimicrobial	O
peptides	O
that	O
are	O
made	O
by	O
epithelial	O
cells	O
and	O
that	O
play	O
a	O
role	O
in	O
mucosal	O
and	O
skin	O
defenses	O
.	O

Human	O
beta	O
-	O
defensin	O
1	O
(	O
hBD	O
-	O
1	O
)	O
is	O
expressed	O
constitutively	O
in	O
epithelial	O
tissues	O
,	O
whereas	O
hBD	O
-	O
2	O
and	O
hBD	O
-	O
3	O
are	O
expressed	O
in	O
response	O
to	O
bacterial	O
stimuli	O
or	O
inflammation	O
.	O

Previous	O
studies	O
showed	O
that	O
hBD	O
-	O
2	O
was	O
induced	O
by	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
cell	O
wall	O
extract	O
without	O
the	O
involvement	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
,	O
which	O
typically	O
are	O
associated	O
with	O
innate	O
immunity	O
and	O
inflammation	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
characterize	O
signaling	O
pathways	O
involved	O
in	O
hBD	O
-	O
2	O
induction	O
in	O
response	O
to	O
commensal	O
and	O
pathogenic	O
bacteria	O
.	O

Cultured	O
human	O
oral	O
and	O
foreskin	O
keratinocytes	O
were	O
treated	O
separately	O
with	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
and	O
p38	O
and	O
then	O
stimulated	O
with	O
oral	O
commensal	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
oral	O
pathogens	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
skin	O
commensal	O
Staphylococcus	B-bacteria
epidermidis	I-bacteria
,	O
or	O
skin	O
pathogen	O
Streptococcus	B-bacteria
pyogenes	I-bacteria
.	O

Different	O
bacteria	O
induced	O
different	O
levels	O
of	O
hBD	O
-	O
2	O
and	O
in	O
response	O
to	O
the	O
various	O
inhibitors	O
tested	O
,	O
although	O
certain	O
common	O
patterns	O
were	O
observed	O
for	O
commensal	O
-	O
and	O
pathogen	O
-	O
stimulated	O
cells	O
.	O

hBD	O
-	O
2	O
induction	O
by	O
all	O
bacteria	O
tested	O
was	O
partially	O
or	O
completely	O
blocked	O
by	O
inhibitors	O
of	O
the	O
JNK	O
and	O
p38	O
pathways	O
.	O

However	O
,	O
in	O
addition	O
,	O
hBD	O
-	O
2	O
induction	O
by	O
pathogenic	O
bacteria	O
in	O
both	O
oral	O
and	O
foreskin	O
keratinocytes	O
was	O
blocked	O
by	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
results	O
indicate	O
that	O
commensal	O
and	O
pathogenic	O
bacteria	O
utilize	O
different	O
pathways	O
in	O
hBD	O
-	O
2	O
induction	O
and	O
suggest	O
that	O
epithelial	O
cells	O
from	O
different	O
body	O
sites	O
have	O
common	O
signaling	O
mechanisms	O
to	O
distinguish	O
between	O
commensal	O
and	O
pathogenic	O
bacteria	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
organisms	O
are	O
occasionally	O
isolated	O
from	O
the	O
blood	O
of	O
patients	O
with	O
infective	O
endocarditis	O
,	O
though	O
the	O
mechanisms	O
of	O
invasion	O
and	O
survival	O
remain	O
to	O
be	O
elucidated	O
.	O

Two	O
of	O
four	O
blood	O
isolates	O
from	O
patients	O
with	O
bacteremia	O
or	O
infective	O
endocarditis	O
(	O
strains	O
TW295	B-bacteria
and	O
TW871	B-bacteria
)	O
were	O
serologically	O
untypeable	O
by	O
immunodiffusion	O
testing	O
,	O
which	O
was	O
due	O
to	O
a	O
lack	O
of	O
the	O
glucose	O
side	O
chain	O
of	O
the	O
serotype	O
-	O
specific	O
polysaccharide	O
antigen	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Immunodiffusion	O
analyses	O
using	O
antisera	O
against	O
these	O
strains	O
demonstrated	O
that	O
2	O
of	O
100	O
isolates	O
from	O
100	O
subjects	O
showed	O
a	O
positive	O
reaction	O
,	O
while	O
further	O
analysis	O
of	O
2500	O
isolates	O
from	O
50	O
subjects	O
revealed	O
that	O
all	O
50	O
isolates	O
from	O
a	O
single	O
subject	O
were	O
not	O
reactive	O
with	O
anti	O
-	O
c	O
,	O
-	O
e	O
,	O
and	O
-	O
f	O
antisera	O
,	O
though	O
they	O
were	O
reactive	O
with	O
anti	O
-	O
TW295	O
and	O
-	O
TW871	O
antisera	O
.	O

The	O
oral	O
isolates	O
showed	O
biological	O
properties	O
similar	O
to	O
those	O
of	O
the	O
reference	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
strain	I-bacteria
MT8148	I-bacteria
,	O
including	O
high	O
levels	O
of	O
sucrose	O
-	O
dependent	O
adhesion	O
and	O
cellular	O
hydrophobicity	O
,	O
along	O
with	O
expression	O
of	O
glucosyltransferases	O
and	O
a	O
protein	O
antigen	O
,	O
PA	O
.	O
We	O
designated	O
these	O
organisms	O
serotype	O
k	O
.	O
A	O
glucose	O
side	O
chain	O
-	O
defective	O
mutant	O
strain	O
was	O
then	O
constructed	O
by	O
insertional	O
inactivation	O
of	O
the	O
gluA	O
gene	O
of	O
strain	O
MT8148	B-bacteria
,	O
which	O
showed	O
biological	O
properties	O
similar	O
to	O
those	O
of	O
serotype	O
k	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Serotype	O
k	O
oral	O
isolates	O
were	O
less	O
susceptible	O
to	O
phagocytosis	O
,	O
as	O
were	O
the	O
gluA	O
-	O
inactivated	O
mutant	O
of	O
strain	O
MT8148	B-bacteria
and	O
blood	O
isolates	O
.	O

These	O
results	O
indicate	O
that	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
serotype	I-bacteria
k	I-bacteria
strains	I-bacteria
are	O
present	O
in	O
the	O
oral	O
cavity	O
in	O
humans	O
and	O
may	O
be	O
able	O
to	O
survive	O
longer	O
in	O
blood	O
owing	O
to	O
their	O
low	O
susceptibility	O
to	O
phagocytosis	O
.	O

A	O
retrospective	O
analysis	O
of	O
laboratory	O
data	O
to	O
investigate	O
the	O
isolation	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
from	O
the	O
oral	O
cavity	O
and	O
facial	O
area	O
in	O
specimens	O
submitted	O
to	O
a	O
regional	O
diagnostic	O
oral	O
microbiology	O
laboratory	O
.	O

A	O
hand	O
search	O
of	O
laboratory	O
records	O
for	O
a	O
three	O
-	O
year	O
period	O
(	O
1998	O
-	O
2000	O
)	O
was	O
performed	O
for	O
specimens	O
submitted	O
to	O
the	O
regional	O
diagnostic	O
oral	O
microbiology	O
laboratory	O
based	O
at	O
Glasgow	O
Dental	O
Hospital	O
and	O
School	O
.	O

Data	O
were	O
collected	O
from	O
forms	O
where	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
was	O
isolated	O
.	O

These	O
data	O
included	O
demographics	O
,	O
referral	O
source	O
,	O
specimen	O
type	O
,	O
methicillin	O
susceptibility	O
and	O
clinical	O
details	O
.	O

For	O
the	O
period	O
1998	O
-	O
2000	O
,	O
there	O
were	O
5	O
,	O
005	O
specimens	O
submitted	O
to	O
the	O
laboratory	O
.	O

S	B-bacteria
.	I-bacteria
aureus	I-bacteria
was	O
isolated	O
from	O
1	O
,	O
017	O
specimens	O
,	O
of	O
which	O
967	O
(	O
95	O
%	O
)	O
were	O
sensitive	O
to	O
methicillin	O
(	O
MSSA	B-bacteria
)	O
and	O
50	O
(	O
5	O
%	O
)	O
were	O
resistant	O
to	O
methicillin	O
(	O
MRSA	B-bacteria
)	O
.	O

The	O
1	O
,	O
017	O
specimens	O
were	O
provided	O
from	O
615	O
patients	O
.	O

MRSA	B-bacteria
was	O
isolated	O
from	O
37	O
(	O
6	O
%	O
)	O
of	O
patients	O
.	O

There	O
was	O
an	O
increasing	O
incidence	O
of	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
with	O
age	O
,	O
particularly	O
in	O
the	O
>	O
70	O
years	O
age	O
group	O
.	O

The	O
most	O
common	O
specimen	O
from	O
which	O
MSSA	B-bacteria
was	O
isolated	O
was	O
an	O
oral	O
rinse	O
(	O
38	O
%	O
)	O
whilst	O
for	O
MRSA	B-bacteria
isolates	I-bacteria
this	O
was	O
a	O
tongue	O
swab	O
(	O
28	O
%	O
)	O
.	O

The	O
clinical	O
condition	O
most	O
commonly	O
reported	O
for	O
MSSA	B-bacteria
isolates	I-bacteria
was	O
angular	O
cheilitis	O
(	O
22	O
%	O
)	O
.	O

Erythema	O
,	O
swelling	O
,	O
pain	O
or	O
burning	O
of	O
the	O
oral	O
mucosa	O
was	O
the	O
clinical	O
condition	O
most	O
commonly	O
reported	O
for	O
MRSA	B-bacteria
isolates	I-bacteria
(	O
16	O
%	O
)	O
.	O

Patients	O
from	O
whom	O
the	O
MSSA	B-bacteria
isolates	I-bacteria
were	O
recovered	O
were	O
most	O
commonly	O
(	O
55	O
%	O
)	O
seen	O
in	O
the	O
oral	O
medicine	O
clinic	O
at	O
the	O
dental	O
hospital	O
,	O
whilst	O
patients	O
with	O
MRSA	B-bacteria
were	O
more	O
commonly	O
seen	O
in	O
primary	O
care	O
settings	O
such	O
as	O
nursing	O
homes	O
,	O
hospices	O
and	O
general	O
dental	O
practice	O
(	O
51	O
%	O
)	O
.	O

In	O
line	O
with	O
more	O
recent	O
surveys	O
,	O
this	O
retrospective	O
study	O
suggests	O
that	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
may	O
be	O
a	O
more	O
frequent	O
isolate	O
from	O
the	O
oral	O
cavity	O
than	O
hitherto	O
suspected	O
.	O

A	O
small	O
proportion	O
of	O
the	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
isolates	I-bacteria
were	O
MRSA	B-bacteria
.	O

There	O
were	O
insufficient	O
data	O
available	O
to	O
determine	O
whether	O
the	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
isolates	I-bacteria
were	O
colonising	O
or	O
infecting	O
the	O
oral	O
cavity	O
.	O

However	O
,	O
the	O
role	O
of	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
in	O
several	O
diseases	O
of	O
the	O
oral	O
mucosa	O
merits	O
further	O
investigation	O
.	O

Calcific	O
aortic	O
stenosis	O
is	O
a	O
major	O
public	O
health	O
problem	O
in	O
the	O
United	O
States	O
.	O

The	O
mechanism	O
of	O
calcification	O
remains	O
unclear	O
.	O

The	O
hypothesis	O
that	O
low	O
grade	O
chronic	O
or	O
recurrent	O
bacterial	O
endocarditis	O
with	O
specific	O
calcifiable	O
bacteria	O
is	O
a	O
cause	O
of	O
calcification	O
of	O
the	O
aortic	O
valves	O
was	O
investigated	O
using	O
an	O
animal	O
model	O
.	O

Such	O
bacteria	O
are	O
typically	O
present	O
as	O
part	O
of	O
the	O
normal	O
human	O
oral	O
flora	O
.	O

Forty	O
New	O
Zealand	O
white	O
rabbits	O
were	O
divided	O
into	O
four	O
groups	O
:	O
group	O
1	O
,	O
control	O
(	O
1	O
ml	O
of	O
normal	O
saline	O
)	O
;	O
group	O
2	O
,	O
Corynebacterium	B-bacteria
matruchotti	I-bacteria
100	O
,	O
000	O
colonies	O
;	O
group	O
3	O
,	O
Streptococcus	B-bacteria
sanguis	I-bacteria
II	I-bacteria
10	I-bacteria
colonies	O
;	O
and	O
group	O
4	O
,	O
C	B-bacteria
matruchotti	I-bacteria
100	O
,	O
000	O
colonies	O
plus	O
S	B-bacteria
sanguis	I-bacteria
II	I-bacteria
10	O
colonies	O
.	O

Animals	O
were	O
inoculated	O
with	O
bacteria	O
through	O
a	O
flexible	O
catheter	O
placed	O
through	O
the	O
aortic	O
valve	O
through	O
a	O
right	O
carotid	O
cut	O
down	O
.	O

Inoculations	O
were	O
repeated	O
every	O
3	O
days	O
the	O
first	O
2	O
weeks	O
and	O
then	O
twice	O
a	O
week	O
thereafter	O
.	O

At	O
postmortem	O
examination	O
the	O
aortic	O
valves	O
were	O
harvested	O
,	O
embedded	O
in	O
paraffin	O
,	O
and	O
stained	O
with	O
von	O
Kossa	O
stain	O
.	O

They	O
were	O
also	O
examined	O
by	O
scanning	O
and	O
transmission	O
electron	O
micrography	O
.	O

Group	O
4	O
had	O
93	O
.	O
3	O
%	O
large	O
calcifications	O
(	O
confluent	O
calcium	O
densities	O
that	O
are	O
easily	O
recognized	O
with	O
minimal	O
magnification	O
)	O
and	O
6	O
.	O
6	O
%	O
small	O
microcalcifications	O
(	O
dustlike	O
microscopic	O
particles	O
requiring	O
a	O
compound	O
microscope	O
to	O
appreciate	O
)	O
of	O
the	O
aortic	O
valves	O
.	O

Group	O
3	O
exhibited	O
large	O
calcification	O
in	O
20	O
%	O
and	O
small	O
in	O
40	O
%	O
of	O
the	O
aortic	O
valves	O
.	O

Group	O
1	O
and	O
group	O
2	O
had	O
no	O
evidence	O
of	O
calcification	O
.	O

These	O
results	O
suggest	O
that	O
recurrent	O
low	O
-	O
grade	O
endocarditis	O
from	O
calcifying	O
oral	O
bacteria	O
,	O
particularly	O
when	O
occurring	O
with	O
synergistic	O
strains	O
,	O
may	O
be	O
one	O
cause	O
of	O
calcific	O
aortic	O
stenosis	O
.	O

Some	O
oral	O
anaerobes	O
from	O
the	O
Streptococcus	B-bacteria
milleri	I-bacteria
strain	I-bacteria
group	O
were	O
found	O
to	O
secrete	O
human	O
specific	O
hemolytic	O
toxin	O
,	O
which	O
was	O
detected	O
when	O
bacteria	O
were	O
cultured	O
in	O
Todd	O
-	O
Hewitt	O
broth	O
and	O
Brain	O
Heart	O
Infusion	O
broth	O
.	O

The	O
toxin	O
elicited	O
by	O
the	O
Streptococcus	B-bacteria
intermedius	I-bacteria
strain	I-bacteria
was	O
partially	O
fractionated	O
by	O
ammonium	O
sulfate	O
precipitation	O
.	O

Preincubation	O
with	O
glutathione	O
or	O
cysteine	O
showed	O
significant	O
inhibiting	O
effects	O
;	O
however	O
,	O
no	O
effects	O
were	O
seen	O
with	O
dithiothreitol	O
or	O
beta	O
-	O
mercaptoethanol	O
,	O
and	O
cholesterol	O
was	O
a	O
weak	O
inhibitor	O
.	O

Five	O
kinds	O
of	O
protease	O
inhibitor	O
had	O
no	O
effect	O
on	O
the	O
hemolytic	O
activity	O
,	O
and	O
rabbit	O
preimmune	O
and	O
immune	O
sera	O
against	O
the	O
bacterial	O
cells	O
showed	O
weak	O
inhibition	O
at	O
a	O
similar	O
level	O
.	O

Digestion	O
with	O
trypsin	O
,	O
chymotrypsin	O
,	O
proteinase	O
-	O
K	O
,	O
subtilisin	O
and	O
pronase	O
-	O
P	O
brought	O
about	O
a	O
rise	O
in	O
activity	O
,	O
followed	O
by	O
a	O
decrease	O
during	O
long	O
-	O
term	O
incubation	O
.	O

Other	O
enzymes	O
tested	O
showed	O
no	O
effects	O
.	O

Further	O
,	O
the	O
presence	O
of	O
the	O
intermedilysin	O
gene	O
in	O
the	O
portion	O
with	O
hemolytic	O
activity	O
was	O
not	O
identified	O
by	O
polymerase	O
chain	O
reaction	O
.	O

The	O
authors	O
studied	O
the	O
bacterial	O
flora	O
of	O
the	O
dog	O
oral	O
cavity	O
and	O
of	O
bite	O
wounds	O
,	O
Aerobic	O
bacteria	O
were	O
isolated	O
from	O
mouth	O
swabs	O
of	O
16	O
normal	O
and	O
5	O
rabid	O
dogs	O
as	O
well	O
as	O
from	O
infected	O
dog	O
-	O
bite	O
wounds	O
from	O
18	O
patients	O
.	O

A	O
total	O
of	O
20	O
different	O
microbial	O
species	O
were	O
recovered	O
from	O
mouth	O
swab	O
cultures	O
.	O

The	O
most	O
frequently	O
isolated	O
organisms	O
were	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
ssp	I-bacteria
pneumoniae	I-bacteria
,	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
Citrobacter	B-bacteria
freundii	I-bacteria
,	O
Enterobacter	B-bacteria
cloacae	I-bacteria
,	O
Acinetobacter	B-bacteria
calcoaceticus	I-bacteria
,	O
and	O
Pasteurella	B-bacteria
species	I-bacteria
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
aerobic	O
bacterial	O
flora	O
between	O
rabid	O
and	O
nonrabid	O
dogs	O
.	O

From	O
the	O
cultures	O
of	O
the	O
bite	O
wound	O
swabs	O
,	O
the	O
authors	O
found	O
that	O
almost	O
all	O
of	O
the	O
organisms	O
identified	O
were	O
part	O
of	O
the	O
normal	O
oral	O
flora	O
of	O
the	O
dog	O
.	O

One	O
or	O
more	O
aerobic	O
bacteria	O
were	O
isolated	O
from	O
the	O
infected	O
dog	O
-	O
bite	O
wounds	O
.	O

Two	O
patients	O
had	O
four	O
,	O
3	O
had	O
three	O
,	O
4	O
had	O
two	O
,	O
and	O
6	O
had	O
one	O
of	O
the	O
nine	O
organisms	O
in	O
their	O
wounds	O
.	O

The	O
predominant	O
species	O
of	O
bacteria	O
involved	O
in	O
infection	O
of	O
bite	O
wounds	O
were	O
,	O
as	O
follows	O
:	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
Pasteurella	B-bacteria
multocida	I-bacteria
,	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
,	O
Moraxella	B-bacteria
species	I-bacteria
,	O
Pasteurella	B-bacteria
canis	I-bacteria
,	O
and	O
Enterobacter	B-bacteria
cloacae	I-bacteria
.	O

However	O
,	O
three	O
wound	O
cultures	O
had	O
no	O
aerobic	O
bacterial	O
growth	O
.	O

The	O
results	O
of	O
this	O
study	O
show	O
that	O
the	O
infected	O
bite	O
wounds	O
may	O
contain	O
a	O
mixed	O
bacterial	O
flora	O
that	O
colonize	O
human	O
skin	O
and	O
the	O
oral	O
cavity	O
of	O
dogs	O
.	O

Oral	O
streptococci	B-bacteria
are	O
primary	O
colonisers	O
of	O
the	O
tooth	O
surface	O
and	O
are	O
abundant	O
in	O
dental	O
plaque	O
biofilms	O
.	O

Bacteria	O
growing	O
in	O
these	O
relatively	O
dense	O
,	O
surface	O
-	O
associated	O
communities	O
are	O
phenotypically	O
quite	O
distinct	O
from	O
their	O
planktonic	O
counterparts	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
develop	O
a	O
method	O
to	O
investigate	O
biofilm	O
-	O
specific	O
surface	O
protein	O
expression	O
by	O
Streptococcus	B-bacteria
sanguis	I-bacteria
to	O
help	O
provide	O
a	O
better	O
understanding	O
of	O
the	O
critical	O
events	O
in	O
plaque	O
development	O
.	O

Biofilm	O
cells	O
were	O
grown	O
on	O
the	O
surface	O
of	O
glass	O
beads	O
in	O
a	O
biofilm	O
device	O
fed	O
with	O
mucin	O
-	O
containing	O
artificial	O
saliva	O
.	O

Planktonic	O
cells	O
were	O
grown	O
in	O
continuous	O
culture	O
at	O
approximately	O
the	O
same	O
growth	O
rate	O
.	O

Surface	O
hydrophobicity	O
of	O
biofilm	O
and	O
planktonic	O
cells	O
was	O
determined	O
by	O
hexadecane	O
partitioning	O
,	O
and	O
expression	O
of	O
streptococcal	B-bacteria
fibronectin	O
adhesin	O
CshA	O
was	O
determined	O
in	O
ELISA	O
using	O
specific	O
antiserum	O
.	O

Antisera	O
raised	O
to	O
glutaraldehyde	O
-	O
fixed	O
whole	O
biofilm	O
or	O
planktonic	O
grown	O
cells	O
were	O
used	O
to	O
screen	O
an	O
expression	O
library	O
of	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
genomic	O
DNA	O
,	O
and	O
isolated	O
clones	O
were	O
sequenced	O
.	O

Phenotypic	O
analysis	O
of	O
biofilm	O
and	O
planktonic	O
cells	O
confirmed	O
that	O
mode	O
of	O
growth	O
affected	O
surface	O
properties	O
of	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
.	O

Thus	O
,	O
hydrophobicity	O
and	O
CshA	O
expression	O
was	O
significantly	O
elevated	O
in	O
biofilm	O
cells	O
.	O

Library	O
screening	O
with	O
biofilm	O
antiserum	O
yielded	O
32	O
recombinant	O
clones	O
representing	O
21	O
different	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
proteins	O
involved	O
in	O
adhesion	O
and	O
colonisation	O
,	O
carbohydrate	O
utilisation	O
or	O
bacterial	O
metabolism	O
.	O

In	O
differential	O
analysis	O
of	O
four	O
selected	O
Escherichia	B-bacteria
coli	I-bacteria
clones	O
,	O
biofilm	O
antiserum	O
reacted	O
five	O
times	O
stronger	O
than	O
planktonic	O
antiserum	O
with	O
cell	O
-	O
free	O
extracts	O
of	O
clones	O
encoding	O
homologues	O
of	O
CshA	O
and	O
Cna	O
collagen	O
adhesin	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
suggesting	O
that	O
these	O
surface	O
proteins	O
are	O
up	O
-	O
regulated	O
in	O
biofilm	O
cells	O
.	O

In	O
contrast	O
,	O
both	O
antisera	O
reacted	O
equally	O
strongly	O
with	O
cell	O
-	O
free	O
extracts	O
of	O
the	O
remaining	O
two	O
clones	O
(	O
encoding	O
dihydrofolate	O
synthase	O
and	O
an	O
unknown	O
protein	O
)	O
.	O

The	O
method	O
described	O
represents	O
a	O
useful	O
means	O
for	O
determining	O
bacterial	O
protein	O
expression	O
in	O
biofilms	O
based	O
on	O
a	O
combination	O
of	O
molecular	O
and	O
immunological	O
techniques	O
.	O

Surface	O
expression	O
of	O
putative	O
fibronectin	O
and	O
collagen	O
adhesins	O
was	O
up	O
-	O
regulated	O
in	O
biofilm	O
cells	O
.	O

Human	O
beta	O
-	O
defensins	O
2	O
and	O
3	O
(	O
HBD	O
-	O
2	O
and	O
HBD	O
-	O
3	O
)	O
are	O
inducible	O
peptides	O
present	O
at	O
sites	O
of	O
infection	O
in	O
the	O
oral	O
cavity	O
.	O

A	O
few	O
studies	O
have	O
reported	O
broad	O
-	O
spectrum	O
antimicrobial	O
activity	O
for	O
both	O
peptides	O
.	O

However	O
,	O
no	O
comprehensive	O
study	O
has	O
thoroughly	O
investigated	O
their	O
potential	O
against	O
oral	O
pathogens	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
effectiveness	O
of	O
HBD	O
-	O
2	O
and	O
HBD	O
-	O
3	O
against	O
a	O
collection	O
of	O
oral	O
organisms	O
(	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Peptostreptococcus	B-bacteria
micros	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
Actinomyces	B-bacteria
israelii	I-bacteria
,	O
Streptococcus	B-bacteria
sanguis	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Candida	O
tropicalis	O
,	O
Candida	O
parapsilosis	O
,	O
Candida	O
krusei	O
,	O
Candida	O
glabrata	O
,	O
and	O
Candida	O
albicans	O
)	O
.	O

Radial	O
diffusion	O
assays	O
were	O
used	O
to	O
test	O
HBD	O
-	O
2	O
and	O
HBD	O
-	O
3	O
activities	O
against	O
at	O
least	O
three	O
strains	O
of	O
each	O
species	O
.	O

There	O
was	O
significant	O
variability	O
in	O
MICs	O
,	O
which	O
was	O
strain	O
specific	O
rather	O
than	O
species	O
specific	O
.	O

MICs	O
ranged	O
from	O
3	O
.	O
9	O
to	O
>	O
250	O
micro	O
g	O
/	O
ml	O
for	O
HBD	O
-	O
2	O
and	O
from	O
1	O
.	O
4	O
to	O
>	O
250	O
micro	O
g	O
/	O
ml	O
for	O
HBD	O
-	O
3	O
.	O

HBD	O
-	O
3	O
demonstrated	O
greater	O
antimicrobial	O
activity	O
and	O
was	O
effective	O
against	O
a	O
broader	O
array	O
of	O
organisms	O
.	O

Overall	O
,	O
aerobes	O
were	O
100	O
%	O
susceptible	O
to	O
HBD	O
-	O
2	O
and	O
HBD	O
-	O
3	O
,	O
whereas	O
only	O
21	O
.	O
4	O
and	O
50	O
%	O
of	O
the	O
anaerobes	O
were	O
susceptible	O
to	O
HBD	O
-	O
2	O
and	O
HBD	O
-	O
3	O
,	O
respectively	O
.	O

HBD	O
-	O
2	O
and	O
HBD	O
-	O
3	O
also	O
demonstrated	O
strain	O
-	O
specific	O
activity	O
against	O
the	O
Candida	O
species	O
evaluated	O
.	O

Interestingly	O
,	O
an	O
association	O
between	O
HBD	O
-	O
2	O
and	O
HBD	O
-	O
3	O
activities	O
was	O
noted	O
.	O

This	O
suggests	O
that	O
the	O
two	O
peptides	O
may	O
have	O
similar	O
mechanisms	O
yet	O
utilize	O
distinct	O
pathways	O
.	O

The	O
lack	O
of	O
activity	O
against	O
specific	O
anaerobic	O
strains	O
and	O
Candida	O
warrants	O
further	O
investigation	O
of	O
the	O
potential	O
resistance	O
mechanisms	O
of	O
these	O
organisms	O
.	O

Finally	O
,	O
the	O
significant	O
variability	O
between	O
strains	O
underlies	O
the	O
importance	O
of	O
testing	O
multiple	O
strains	O
when	O
evaluating	O
activities	O
of	O
antimicrobial	O
peptides	O
.	O

To	O
compare	O
the	O
protective	O
activity	O
of	O
liver	O
injury	O
induced	O
by	O
D	O
-	O
galactosamine	O
(	O
GalN	O
)	O
between	O
Huangqin	O
-	O
Tang	O
and	O
their	O
metabolites	O
by	O
human	O
intestinal	O
bacteria	O
(	O
HIB	O
)	O
.	O

The	O
liver	O
injuries	O
in	O
conventional	O
and	O
pseudo	O
-	O
germfree	O
mice	O
were	O
induced	O
by	O
GalN	O
.	O

After	O
oral	O
administration	O
of	O
Huangqin	O
-	O
Tang	O
and	O
their	O
metabolites	O
mixtures	O
by	O
HIB	O
,	O
the	O
serum	O
transaminase	O
(	O
ALT	O
and	O
AST	O
)	O
activities	O
were	O
detected	O
.	O

In	O
conventional	O
mice	O
,	O
large	O
and	O
medium	O
doses	O
(	O
20	O
and	O
10	O
g	O
.	O
kg	O
-	O
1	O
)	O
of	O
Huangqin	O
-	O
Tang	O
decoction	O
significantly	O
reduced	O
the	O
increase	O
of	O
serum	O
ALT	O
activity	O
after	O
18	O
h	O
GalN	O
treatment	O
.	O

In	O
pseudo	O
-	O
germfree	O
mice	O
,	O
metabolites	O
significantly	O
reduced	O
the	O
ALT	O
levels	O
.	O

However	O
,	O
Huangqing	O
-	O
Tang	O
did	O
n	O
'	O
t	O
affect	O
the	O
ALT	O
levels	O
in	O
this	O
kind	O
of	O
mice	O
.	O

To	O
all	O
of	O
the	O
animals	O
,	O
AST	O
levels	O
remained	O
the	O
same	O
after	O
oral	O
Huangqin	O
-	O
tang	O
or	O
their	O
metabolites	O
.	O

The	O
metabolism	O
by	O
intestinal	O
bacteria	O
plays	O
a	O
role	O
in	O
pharmacological	O
effects	O
of	O
constituents	O
of	O
Chinese	O
herbal	O
medicine	O
.	O

The	O
metabolites	O
of	O
the	O
constituents	O
by	O
intestinal	O
bacteria	O
were	O
the	O
real	O
active	O
components	O
in	O
vivo	O
.	O

Oral	O
streptococci	B-bacteria
are	O
major	O
constituents	O
of	O
dental	O
plaque	O
,	O
and	O
their	O
prevalence	O
is	O
implicated	O
in	O
various	O
pathologies	O
.	O

Therefore	O
,	O
accurate	O
identification	O
of	O
oral	O
streptococci	B-bacteria
would	O
be	O
valuable	O
for	O
studies	O
of	O
cariogenic	O
plaque	O
and	O
for	O
diagnostic	O
use	O
in	O
infective	O
endocarditis	O
.	O

Many	O
oral	O
streptococci	B-bacteria
possess	O
glucosyltransferase	O
enzymes	O
that	O
synthesize	O
glucan	O
,	O
which	O
is	O
an	O
obligate	O
component	O
of	O
dental	O
plaque	O
.	O

We	O
established	O
a	O
rapid	O
and	O
precise	O
method	O
to	O
identify	O
oral	O
streptococci	B-bacteria
by	O
PCR	O
using	O
the	O
species	O
-	O
specific	O
region	O
from	O
the	O
glucosyltransferase	O
gene	O
.	O

With	O
the	O
species	O
-	O
specific	O
primers	O
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
,	O
and	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
could	O
be	O
successfully	O
distinguished	O
.	O

Further	O
,	O
we	O
developed	O
a	O
simple	O
method	O
to	O
extract	O
the	O
bacterial	O
DNA	O
from	O
saliva	O
.	O

Using	O
the	O
resultant	O
DNA	O
as	O
a	O
template	O
,	O
the	O
proposed	O
PCR	O
detection	O
was	O
performed	O
.	O

Their	O
distribution	O
was	O
in	O
accord	O
with	O
results	O
of	O
conventional	O
biochemical	O
tests	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
present	O
PCR	O
method	O
is	O
useful	O
for	O
the	O
analysis	O
of	O
oral	O
streptococci	B-bacteria
and	O
can	O
be	O
successfully	O
used	O
in	O
clinical	O
applications	O
to	O
identify	O
pathogenic	O
bacteria	O
associated	O
with	O
oral	O
infectious	O
disease	O
and	O
/	O
or	O
endocarditis	O
.	O

Fusobacterium	B-bacteria
nucleatum	I-bacteria
is	O
a	O
gram	O
-	O
negative	O
anaerobe	O
ubiquitous	O
to	O
the	O
oral	O
cavity	O
.	O

It	O
is	O
associated	O
with	O
periodontal	O
disease	O
.	O

It	O
is	O
also	O
associated	O
with	O
preterm	O
birth	O
and	O
has	O
been	O
isolated	O
from	O
the	O
amniotic	O
fluid	O
,	O
placenta	O
,	O
and	O
chorioamnionic	O
membranes	O
of	O
women	O
delivering	O
prematurely	O
.	O

Periodontal	O
disease	O
is	O
a	O
newly	O
recognized	O
risk	O
factor	O
for	O
preterm	O
birth	O
.	O

This	O
study	O
examined	O
the	O
possible	O
mechanism	O
underlying	O
the	O
link	O
between	O
these	O
two	O
diseases	O
.	O

F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
strains	I-bacteria
isolated	O
from	O
amniotic	O
fluids	O
and	O
placentas	O
along	O
with	O
those	O
isolated	O
from	O
orally	O
related	O
sources	O
invaded	O
both	O
epithelial	O
and	O
endothelial	O
cells	O
.	O

The	O
invasive	O
ability	O
may	O
enable	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
to	O
colonize	O
and	O
infect	O
the	O
pregnant	O
uterus	O
.	O

Transient	O
bacteremia	O
caused	O
by	O
periodontal	O
infection	O
may	O
facilitate	O
bacterial	O
transmission	O
from	O
the	O
oral	O
cavity	O
to	O
the	O
uterus	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
intravenously	O
injected	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
into	O
pregnant	O
CF	O
-	O
1	O
mice	O
.	O

The	O
injection	O
resulted	O
in	O
premature	O
delivery	O
,	O
stillbirths	O
,	O
and	O
nonsustained	O
live	O
births	O
.	O

The	O
bacterial	O
infection	O
was	O
restricted	O
inside	O
the	O
uterus	O
,	O
without	O
spreading	O
systemically	O
.	O

F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
was	O
first	O
detected	O
in	O
the	O
blood	O
vessels	O
in	O
murine	O
placentas	O
.	O

Invasion	O
of	O
the	O
endothelial	O
cells	O
lining	O
the	O
blood	O
vessels	O
was	O
observed	O
.	O

The	O
bacteria	O
then	O
crossed	O
the	O
endothelium	O
,	O
proliferated	O
in	O
surrounding	O
tissues	O
,	O
and	O
finally	O
spread	O
to	O
the	O
amniotic	O
fluid	O
.	O

The	O
pattern	O
of	O
infection	O
paralleled	O
that	O
in	O
humans	O
.	O

This	O
study	O
represents	O
the	O
first	O
evidence	O
that	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
may	O
be	O
transmitted	O
hematogenously	O
to	O
the	O
placenta	O
and	O
cause	O
adverse	O
pregnancy	O
outcomes	O
.	O

The	O
results	O
strengthen	O
the	O
link	O
between	O
periodontal	O
disease	O
and	O
preterm	O
birth	O
.	O

Our	O
study	O
also	O
indicates	O
that	O
invasion	O
may	O
be	O
an	O
important	O
virulence	O
mechanism	O
for	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
to	O
infect	O
the	O
placenta	O
.	O

We	O
examined	O
the	O
antimicrobial	O
effects	O
of	O
human	O
beta	O
-	O
defensin	O
-	O
2	O
(	O
hBD	O
-	O
2	O
)	O
on	O
17	O
species	O
of	O
oral	O
streptococci	B-bacteria
to	O
investigate	O
the	O
involvement	O
of	O
antimicrobial	O
peptide	O
activity	O
in	O
oral	O
microflora	O
development	O
and	O
the	O
clinical	O
use	O
of	O
the	O
antimicrobial	O
peptide	O
for	O
oral	O
microflora	O
control	O
.	O

Oral	O
streptococci	B-bacteria
exhibit	O
diverse	O
levels	O
of	O
susceptibility	O
to	O
human	O
beta	O
-	O
defensin	O
-	O
2	O
(	O
hBD	O
-	O
2	O
)	O
.	O

Two	O
major	O
cariogenic	O
bacterial	O
species	O
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
(	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
)	O
and	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
,	O
were	O
found	O
to	O
be	O
susceptible	O
to	O
the	O
peptide	O
,	O
indicating	O
that	O
it	O
is	O
a	O
potential	O
therapeutic	O
agent	O
for	O
preventing	O
dental	O
caries	O
.	O

S	B-bacteria
.	I-bacteria
mitis	I-bacteria
exhibited	O
the	O
lowest	O
susceptibility	O
to	O
the	O
peptide	O
.	O

S	B-bacteria
.	I-bacteria
mitis	I-bacteria
is	O
a	O
major	O
indigenous	O
bacterium	O
in	O
the	O
oral	O
microflora	O
,	O
and	O
our	O
results	O
suggest	O
that	O
it	O
might	O
possess	O
a	O
certain	O
resistance	O
mechanism	O
against	O
hBD	O
-	O
2	O
.	O

To	O
study	O
dynamic	O
relation	O
between	O
periodontal	O
pathogens	O
and	O
cariogenic	O
bacteria	O
under	O
analogous	O
oral	O
environment	O
.	O

Eight	O
periodontopathic	O
and	O
cariogenic	O
bacteria	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
Pg	B-bacteria
)	O
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
Aa	B-bacteria
)	O
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
(	O
Fn	B-bacteria
)	O
,	O
Provotella	B-bacteria
intermedium	I-bacteria
(	O
Pi	B-bacteria
)	O
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
(	O
Sm	B-bacteria
)	O
,	O
Streptococcus	B-bacteria
sanguis	I-bacteria
(	O
Ss	B-bacteria
)	O
,	O
Actinomyces	B-bacteria
viscosus	I-bacteria
(	O
Av	B-bacteria
)	O
and	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
(	O
La	B-bacteria
)	O
were	O
used	O
.	O

These	O
eight	O
strains	O
were	O
cultured	O
in	O
modified	O
chemostat	O
under	O
analogous	O
oral	O
environment	O
which	O
contained	O
600	O
ml	O
modified	O
BM	O
medium	O
supplemented	O
with	O
2	O
.	O
5	O
g	O
/	O
L	O
porcine	O
gastric	O
mucin	O
,	O
respectively	O
.	O

After	O
1	O
,	O
24	O
,	O
48	O
and	O
96	O
h	O
,	O
optical	O
sectioning	O
of	O
plaque	O
biofilms	O
on	O
removable	O
and	O
replaceable	O
hydroxyapatite	O
disks	O
was	O
analyzed	O
by	O
the	O
combination	O
of	O
live	O
bacterial	O
Gram	O
fluorescence	O
staining	O
and	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

Biofilm	O
thickness	O
and	O
reconstruction	O
of	O
the	O
three	O
-	O
dimensional	O
architecture	O
of	O
plaque	O
biofilms	O
were	O
made	O
.	O

Biofilm	O
thickness	O
increased	O
significantly	O
with	O
time	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Biofilms	O
of	O
Aa	B-bacteria
were	O
thinner	O
than	O
those	O
of	O
Ss	O
and	O
eight	O
-	O
specie	O
biofilms	O
were	O
thicker	O
than	O
those	O
formed	O
by	O
Ss	B-bacteria
and	O
Aa	B-bacteria
per	O
time	O
point	O
.	O

Three	O
-	O
dimensional	O
images	O
showed	O
periodontal	O
pathogens	O
mainly	O
occurred	O
in	O
cariogenic	O
bacterial	O
complex	O
or	O
on	O
the	O
biofilm	O
surface	O
.	O

Gram	O
-	O
positive	O
cariogenic	O
species	O
initially	O
predominated	O
in	O
artificial	O
plaque	O
,	O
followed	O
by	O
the	O
increasing	O
proportions	O
of	O
Gram	O
-	O
negative	O
periodontal	O
pathogens	O
.	O

The	O
relation	O
between	O
microecological	O
balance	O
among	O
bacteria	O
and	O
diseases	O
is	O
worthy	O
of	O
further	O
studies	O
.	O

It	O
is	O
difficult	O
to	O
permanently	O
change	O
the	O
composition	O
of	O
the	O
complex	O
intestinal	O
microflora	O
of	O
the	O
adult	O
.	O

Orally	O
administered	O
probiotic	O
bacteria	O
produce	O
only	O
temporary	O
colonization	O
of	O
the	O
intestine	O
in	O
patients	O
with	O
a	O
fully	O
developed	O
gut	O
microflora	O
.	O

The	O
gastrointestinal	O
tract	O
of	O
a	O
healthy	O
fetus	O
is	O
sterile	O
.	O

During	O
the	O
birth	O
process	O
and	O
rapidly	O
thereafter	O
,	O
microbes	O
from	O
the	O
mother	O
and	O
the	O
surrounding	O
environment	O
colonize	O
the	O
gastrointestinal	O
tract	O
until	O
a	O
dense	O
,	O
complex	O
microflora	O
develops	O
.	O

Probiotic	O
bacteria	O
have	O
been	O
shown	O
to	O
beneficially	O
influence	O
the	O
intestinal	O
and	O
systemic	O
immune	O
system	O
and	O
mediate	O
protection	O
against	O
nosocomial	O
infections	O
affecting	O
the	O
neonate	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
oral	O
administration	O
of	O
the	O
probiotic	O
micro	O
-	O
organism	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
strain	I-bacteria
GG	I-bacteria
(	O
L	B-bacteria
.	I-bacteria
GG	I-bacteria
)	O
to	O
the	O
pregnant	O
woman	O
leads	O
to	O
colonization	O
of	O
the	O
newborn	O
infant	O
.	O

The	O
authors	O
identified	O
six	O
women	O
who	O
were	O
taking	O
L	B-bacteria
.	I-bacteria
GG	I-bacteria
during	O
late	O
pregnancy	O
.	O

None	O
of	O
the	O
children	O
received	O
L	B-bacteria
.	I-bacteria
GG	I-bacteria
after	O
birth	O
,	O
and	O
their	O
mothers	O
discontinued	O
its	O
consumption	O
at	O
the	O
time	O
of	O
delivery	O
.	O

L	B-bacteria
.	I-bacteria
GG	I-bacteria
concentration	O
in	O
fecal	O
samples	O
was	O
determined	O
by	O
colony	O
morphology	O
and	O
molecular	O
analysis	O
.	O

In	O
all	O
four	O
children	O
delivered	O
vaginally	O
and	O
in	O
one	O
of	O
two	O
children	O
delivered	O
by	O
cesarean	O
section	O
,	O
L	B-bacteria
.	I-bacteria
GG	I-bacteria
was	O
present	O
in	O
fecal	O
samples	O
at	O
1	O
and	O
6	O
months	O
of	O
age	O
.	O

Three	O
children	O
remained	O
colonized	O
for	O
at	O
least	O
12	O
months	O
,	O
and	O
in	O
two	O
children	O
L	B-bacteria
.	I-bacteria
GG	I-bacteria
was	O
detected	O
in	O
fecal	O
samples	O
at	O
24	O
months	O
of	O
age	O
.	O

Three	O
mothers	O
were	O
tested	O
1	O
month	O
post	O
partum	O
and	O
no	O
L	B-bacteria
.	I-bacteria
GG	I-bacteria
was	O
present	O
in	O
fecal	O
samples	O
.	O

No	O
L	B-bacteria
.	I-bacteria
GG	I-bacteria
was	O
found	O
in	O
one	O
of	O
these	O
women	O
24	O
months	O
post	O
partum	O
.	O

There	O
was	O
no	O
L	B-bacteria
.	I-bacteria
GG	I-bacteria
detectable	O
in	O
stools	O
of	O
the	O
siblings	O
of	O
two	O
children	O
at	O
the	O
2	O
-	O
year	O
and	O
3	O
-	O
years	O
after	O
birth	O
of	O
the	O
index	O
child	O
.	O

L	B-bacteria
.	I-bacteria
GG	I-bacteria
was	O
not	O
isolated	O
from	O
the	O
stools	O
of	O
children	O
whose	O
mothers	O
were	O
not	O
taking	O
L	B-bacteria
.	I-bacteria
GG	I-bacteria
.	O

Temporary	O
colonization	O
of	O
an	O
infant	O
with	O
L	B-bacteria
.	I-bacteria
GG	I-bacteria
may	O
be	O
possible	O
by	O
colonizing	O
the	O
pregnant	O
mother	O
before	O
delivery	O
.	O

Colonization	O
is	O
stable	O
for	O
as	O
long	O
as	O
6	O
months	O
,	O
and	O
in	O
unexplained	O
circumstances	O
may	O
persist	O
for	O
as	O
long	O
as	O
24	O
months	O
.	O

Peculiarities	O
of	O
quantitative	O
and	O
qualitative	O
composition	O
of	O
microbiocenosis	O
of	O
the	O
oral	O
cavity	O
in	O
healthy	O
children	O
and	O
children	O
with	O
chronic	O
aphthous	O
recurrent	O
stomatitis	O
have	O
been	O
studied	O
.	O

Strains	O
of	O
microorganisms	O
(	O
n	O
=	O
259	O
)	O
have	O
been	O
isolated	O
and	O
identified	O
.	O

The	O
results	O
obtained	O
showed	O
that	O
the	O
studied	O
biotope	O
is	O
characterised	O
by	O
a	O
wide	O
spectrum	O
of	O
isolated	O
microflora	O
.	O

The	O
growth	O
of	O
microorganism	O
association	O
is	O
observed	O
in	O
all	O
the	O
studied	O
samples	O
.	O

The	O
analysis	O
of	O
genus	O
and	O
species	O
composition	O
of	O
microbiocenosis	O
of	O
the	O
mucous	O
membrane	O
indicated	O
that	O
streptococci	B-bacteria
,	O
neiserii	B-bacteria
,	O
corynebacteria	B-bacteria
,	O
enterococci	B-bacteria
,	O
lactobacilli	B-bacteria
,	O
epidermal	B-bacteria
staphylococci	I-bacteria
and	O
candidas	O
were	O
distinguished	O
as	O
to	O
isolation	O
frequency	O
among	O
the	O
isolated	O
strains	O
.	O

These	O
bacteria	O
were	O
isolated	O
from	O
oral	O
cavity	O
of	O
healthy	O
and	O
sick	O
children	O
,	O
but	O
their	O
quantity	O
in	O
1	O
mm2	O
of	O
sick	O
children	O
mucosa	O
prevailed	O
,	O
except	O
for	O
Streptococcus	B-bacteria
salivarius	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
and	O
Lactobacillus	B-bacteria
sp	I-bacteria
.	I-bacteria
their	O
quantity	O
was	O
far	O
less	O
.	O

Golden	O
staphylococci	B-bacteria
,	O
escherichia	B-bacteria
,	O
klebsiella	B-bacteria
,	O
clostridia	B-bacteria
,	O
hemophilic	B-bacteria
rods	I-bacteria
and	O
campylobacteria	B-bacteria
were	O
isolated	O
from	O
sick	O
children	O
only	O
.	O

Microflora	O
of	O
oral	O
cavity	O
of	O
people	O
of	O
45	O
-	O
65	O
years	O
with	O
removable	O
denture	O
and	O
children	O
with	O
acute	O
herpetic	O
stomatitis	O
,	O
its	O
dependence	O
upon	O
the	O
degree	O
of	O
local	O
immunity	O
,	O
presence	O
and	O
severity	O
of	O
inflammatory	O
process	O
have	O
been	O
studied	O
.	O

Percentage	O
of	O
leucocyte	O
subpopulations	O
activity	O
of	O
bactericide	O
enzymes	O
of	O
granulocytes	O
,	O
average	O
anticolonization	O
ratio	O
,	O
correlation	O
of	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
,	O
degree	O
of	O
colonization	O
with	O
Candida	O
fungi	O
have	O
been	O
determined	O
is	O
smear	O
-	O
simprints	O
of	O
mucous	O
membrane	O
.	O

The	O
intensity	O
of	O
growth	O
of	O
optional	O
anaerobic	O
microorganisms	O
has	O
been	O
investigated	O
in	O
bacteriological	O
studies	O
of	O
material	O
taken	O
from	O
mucous	O
membrane	O
.	O

Their	O
identification	O
has	O
been	O
performed	O
using	O
morphological	O
-	O
cultural	O
and	O
biochemical	O
indices	O
.	O

Significant	O
changes	O
in	O
microbiocenosis	O
of	O
oral	O
cavity	O
such	O
as	O
disappearance	O
of	O
autochthonous	O
microflora	O
,	O
appearance	O
and	O
intensive	O
growth	O
of	O
pathogenic	O
and	O
opportunistic	O
microorganisms	O
are	O
to	O
be	O
observed	O
in	O
conditions	O
of	O
decrease	O
of	O
non	O
-	O
specific	O
resistance	O
and	O
presence	O
of	O
inflammatory	O
process	O
in	O
persons	O
with	O
removable	O
denture	O
and	O
acute	O
herpetic	O
stomatitis	O
.	O

Cranberry	O
juice	O
is	O
known	O
to	O
inhibit	O
bacterial	O
adhesion	O
.	O

We	O
examined	O
the	O
inhibitory	O
effect	O
of	O
cranberry	O
juice	O
on	O
the	O
adhesion	O
of	O
oral	O
streptococci	B-bacteria
strains	I-bacteria
labeled	O
with	O
[	O
3H	O
]	O
-	O
thymidine	O
to	O
saliva	O
-	O
coated	O
hydroxyapatite	O
beads	O
(	O
s	O
-	O
HA	O
)	O
.	O

When	O
the	O
bacterial	O
cells	O
were	O
momentarily	O
exposed	O
to	O
cranberry	O
juice	O
,	O
their	O
adherence	O
to	O
s	O
-	O
HA	O
decreased	O
significantly	O
compared	O
with	O
the	O
control	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Their	O
hydrophobicity	O
also	O
decreased	O
dependently	O
with	O
the	O
concentration	O
of	O
cranberry	O
juice	O
.	O

We	O
also	O
evaluated	O
the	O
inhibitory	O
effect	O
of	O
cranberry	O
juice	O
on	O
biofilm	O
formation	O
.	O

By	O
using	O
a	O
microplate	O
system	O
,	O
we	O
found	O
that	O
the	O
high	O
molecular	O
mass	O
constituents	O
of	O
cranberry	O
juice	O
inhibited	O
the	O
biofilm	O
formation	O
of	O
the	O
tested	O
streptococci	B-bacteria
.	O

The	O
inhibitory	O
activity	O
was	O
related	O
to	O
the	O
reduction	O
of	O
the	O
hydrophobicity	O
.	O

The	O
present	O
findings	O
suggest	O
that	O
cranberry	O
juice	O
component	O
(	O
s	O
)	O
can	O
inhibit	O
colonization	O
by	O
oral	O
streptococci	B-bacteria
to	O
the	O
tooth	O
surface	O
and	O
can	O
thus	O
slow	O
development	O
of	O
dental	O
plaque	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
triclosan	O
exposure	O
on	O
the	O
antimicrobial	O
susceptibilities	O
of	O
numerically	O
important	O
dental	O
bacteria	O
.	O

A	O
gradient	O
plate	O
technique	O
was	O
used	O
to	O
expose	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
,	O
Neisseria	B-bacteria
subflava	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
Prevotella	B-bacteria
nigrescens	I-bacteria
,	O
Streptococcus	B-bacteria
oralis	I-bacteria
,	O
Streptococcus	B-bacteria
sanguis	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Veillonella	B-bacteria
dispar	I-bacteria
repeatedly	O
to	O
escalating	O
,	O
sublethal	O
concentrations	O
of	O
triclosan	O
.	O

Escherichia	B-bacteria
coli	I-bacteria
ATCC	I-bacteria
8739	I-bacteria
was	O
included	O
as	O
an	O
organism	O
showing	O
the	O
triclosan	O
resistance	O
development	O
trait	O
.	O

MIC	O
values	O
towards	O
chlorhexidine	O
,	O
metronidazole	O
and	O
tetracycline	O
were	O
determined	O
before	O
and	O
after	O
biocide	O
exposure	O
.	O

N	B-bacteria
.	I-bacteria
subflava	I-bacteria
,	O
Pr	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
Po	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
were	O
highly	O
susceptible	O
to	O
triclosan	O
(	O
MIC	O
range	O
0	O
.	O
1	O
-	O
3	O
.	O
9	O
mg	O
/	O
L	O
)	O
,	O
whereas	O
the	O
lactobacillus	B-bacteria
and	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
were	O
less	O
susceptible	O
(	O
MIC	O
range	O
15	O
.	O
6	O
-	O
20	O
.	O
8	O
mg	O
/	O
L	O
)	O
.	O

Triclosan	O
exposure	O
resulted	O
in	O
a	O
highly	O
significant	O
(	O
approximately	O
400	O
-	O
fold	O
)	O
reduction	O
in	O
triclosan	O
susceptibility	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
for	O
the	O
positive	O
control	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
,	O
although	O
its	O
MICs	O
towards	O
chlorhexidine	O
,	O
metronidazole	O
and	O
tetracycline	O
were	O
not	O
significantly	O
altered	O
.	O

Minor	O
(	O
approximately	O
two	O
-	O
fold	O
)	O
decreases	O
in	O
triclosan	O
susceptibility	O
(	O
MIC	O
)	O
occurred	O
for	O
Pr	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
and	O
in	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
(	O
MBC	O
)	O
.	O

Mean	O
changes	O
in	O
susceptibilities	O
(	O
MIC	O
and	O
MBC	O
)	O
of	O
the	O
oral	O
species	O
to	O
chlorhexidine	O
,	O
metronidazole	O
and	O
tetracycline	O
did	O
not	O
exceed	O
two	O
-	O
fold	O
,	O
although	O
chlorhexidine	O
MBCs	O
for	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
were	O
markedly	O
,	O
but	O
transiently	O
,	O
increased	O
.	O

These	O
data	O
fail	O
to	O
demonstrate	O
biologically	O
significant	O
drug	O
resistance	O
in	O
triclosan	O
-	O
exposed	O
bacteria	O
and	O
suggest	O
that	O
markedly	O
decreased	O
triclosan	O
susceptibility	O
,	O
although	O
confirmed	O
for	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
,	O
is	O
not	O
a	O
universal	O
phenomenon	O
.	O

Other	O
bacteria	O
possibly	O
possess	O
more	O
susceptible	O
targets	O
than	O
FabI	O
that	O
are	O
highly	O
conserved	O
,	O
which	O
may	O
govern	O
triclosan	O
activity	O
.	O

Previously	O
,	O
we	O
screened	O
149	O
subjects	O
and	O
established	O
four	O
groups	O
high	O
or	O
low	O
for	O
salivary	O
killing	O
of	O
oral	O
bacteria	O
,	O
and	O
for	O
aggregation	O
and	O
live	O
and	O
dead	O
adherence	O
of	O
oral	O
bacteria	O
(	O
as	O
a	O
combined	O
factor	O
)	O
.	O

Caries	O
scores	O
were	O
significantly	O
lower	O
in	O
both	O
High	O
Aggregation	O
-	O
Adherence	O
groups	O
.	O

Subsequently	O
,	O
we	O
found	O
that	O
supragingival	O
total	O
biofilm	O
DNA	O
,	O
total	O
streptococci	B-bacteria
and	O
two	O
major	O
streptococcal	O
rRNA	O
variants	O
also	O
were	O
significantly	O
lower	O
in	O
the	O
High	O
Aggregation	O
-	O
Adherence	O
groups	O
.	O

In	O
this	O
study	O
,	O
we	O
looked	O
at	O
the	O
effects	O
of	O
those	O
differences	O
in	O
salivary	O
function	O
on	O
three	O
periodontal	O
pathogens	O
.	O

Quantitative	O
PCR	O
was	O
used	O
to	O
determine	O
levels	O
of	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
Tannerella	B-bacteria
forsythensis	I-bacteria
(	O
formerly	O
Bacteroides	B-bacteria
forsythus	I-bacteria
)	O
in	O
stored	O
DNA	O
extracts	O
of	O
overnight	O
supragingival	O
biofilm	O
collected	O
from	O
buccal	O
upper	O
central	O
incisors	O
(	O
UC	O
)	O
,	O
lingual	O
lower	O
central	O
incisors	O
(	O
LC	O
)	O
and	O
buccal	O
upper	O
and	O
lower	O
first	O
molars	O
(	O
BM	O
)	O
and	O
lingual	O
upper	O
and	O
lower	O
first	O
molars	O
(	O
LM	O
)	O
of	O
subjects	O
in	O
the	O
four	O
groups	O
.	O

A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
were	O
almost	O
completely	O
absent	O
from	O
these	O
samples	O
.	O

T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
was	O
found	O
in	O
11	O
of	O
35	O
persons	O
at	O
the	O
buccal	O
molar	O
site	O
.	O

Only	O
two	O
of	O
those	O
subjects	O
were	O
in	O
the	O
High	O
Aggregation	O
-	O
Adherence	O
groups	O
,	O
and	O
that	O
difference	O
was	O
statistically	O
significant	O
.	O

The	O
mean	O
quantity	O
of	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
also	O
was	O
significantly	O
lower	O
in	O
the	O
High	O
Aggregation	O
-	O
Adherence	O
groups	O
.	O

The	O
difference	O
between	O
the	O
Low	O
and	O
High	O
Aggregation	O
-	O
Adherence	O
groups	O
might	O
reflect	O
direct	O
interactions	O
of	O
salivary	O
proteins	O
with	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
.	O

Alternatively	O
,	O
the	O
higher	O
levels	O
of	O
total	O
biofilm	O
and	O
total	O
streptococci	B-bacteria
seen	O
in	O
the	O
Low	O
Aggregation	O
-	O
Adherence	O
groups	O
might	O
create	O
a	O
favourable	O
environment	O
for	O
early	O
secondary	O
colonization	O
of	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
.	O

The	O
incidence	O
of	O
oral	O
candidosis	O
has	O
increased	O
in	O
recent	O
years	O
,	O
largely	O
as	O
a	O
result	O
of	O
the	O
emergence	O
of	O
human	O
immunodeficiency	O
virus	O
infection	O
and	O
the	O
more	O
widespread	O
use	O
of	O
immunosuppressive	O
chemotherapy	O
.	O

This	O
development	O
has	O
been	O
associated	O
with	O
a	O
need	O
for	O
more	O
reliable	O
methods	O
for	O
the	O
detection	O
of	O
Candida	O
.	O

The	O
present	O
study	O
assessed	O
the	O
performance	O
of	O
a	O
real	O
-	O
time	O
PCR	O
and	O
two	O
block	O
-	O
based	O
PCRs	O
for	O
the	O
detection	O
of	O
Candida	O
in	O
193	O
concentrated	O
oral	O
rinse	O
culture	O
(	O
CRC	O
)	O
specimens	O
.	O

A	O
total	O
of	O
102	O
CRC	O
specimens	O
were	O
positive	O
by	O
culture	O
for	O
Candida	O
;	O
and	O
96	O
,	O
90	O
,	O
and	O
75	O
of	O
these	O
were	O
also	O
positive	O
by	O
real	O
-	O
time	O
,	O
N18	O
-	O
specific	O
,	O
and	O
internal	O
transcribed	O
spacer	O
(	O
ITS	O
)	O
-	O
specific	O
PCRs	O
,	O
respectively	O
.	O

The	O
five	O
false	O
-	O
negative	O
results	O
by	O
the	O
real	O
-	O
time	O
PCR	O
were	O
all	O
non	O
-	O
Candida	O
albicans	O
positive	O
by	O
culture	O
.	O

Of	O
the	O
91	O
culture	O
-	O
negative	O
CRC	O
specimens	O
,	O
20	O
,	O
41	O
,	O
and	O
44	O
were	O
positive	O
by	O
the	O
real	O
-	O
time	O
PCR	O
and	O
the	O
N18	O
-	O
and	O
ITS	O
-	O
specific	O
PCRs	O
,	O
respectively	O
.	O

All	O
three	O
PCRs	O
detected	O
fungal	O
DNA	O
in	O
8	O
culture	O
-	O
negative	O
CRC	O
specimens	O
,	O
with	O
a	O
further	O
30	O
being	O
positive	O
by	O
two	O
of	O
the	O
three	O
PCRs	O
.	O

A	O
total	O
of	O
32	O
CRC	O
specimens	O
were	O
Candida	O
free	O
by	O
all	O
methods	O
.	O

In	O
summary	O
,	O
a	O
real	O
-	O
time	O
PCR	O
that	O
provides	O
a	O
sensitive	O
,	O
specific	O
,	O
and	O
rapid	O
alternative	O
technique	O
for	O
detection	O
of	O
Candida	O
in	O
the	O
mouth	O
is	O
described	O
.	O

The	O
mouths	O
of	O
three	O
human	O
infants	O
were	O
examined	O
from	O
birth	O
to	O
age	O
2	O
years	O
to	O
detect	O
colonization	O
of	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
genospecies	I-bacteria
1	I-bacteria
and	I-bacteria
2	I-bacteria
.	O

These	O
bacteria	O
did	O
not	O
colonize	O
until	O
after	O
tooth	O
eruption	O
.	O

The	O
diversity	O
of	O
posteruption	O
isolates	O
was	O
determined	O
by	O
ribotyping	O
.	O

Using	O
immunoblotting	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
we	O
determined	O
the	O
reactivity	O
of	O
secretory	O
immunoglobulin	O
A	O
(	O
SIgA	O
)	O
antibodies	O
in	O
saliva	O
samples	O
collected	O
from	O
each	O
infant	O
before	O
and	O
after	O
colonization	O
against	O
cell	O
wall	O
proteins	O
from	O
their	O
own	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
strains	I-bacteria
and	O
carbohydrates	O
from	O
standard	O
A	B-bacteria
.		I-bacteria
naeslundii	I-bacteria
genospecies	I-bacteria
1	I-bacteria
and	I-bacteria
2	I-bacteria
strains	I-bacteria
.	O

A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
genospecies	I-bacteria
1	I-bacteria
and	I-bacteria
2	I-bacteria
carbohydrate	O
-	O
reactive	O
SIgA	O
antibodies	O
were	O
not	O
detected	O
in	O
any	O
saliva	O
sample	O
.	O

However	O
,	O
SIgA	O
antibodies	O
reactive	O
with	O
cell	O
wall	O
proteins	O
were	O
present	O
in	O
saliva	O
before	O
these	O
bacteria	O
colonized	O
the	O
mouth	O
.	O

These	O
antibodies	O
could	O
be	O
almost	O
completely	O
removed	O
by	O
absorption	O
with	O
A	B-bacteria
.	I-bacteria
odontolyticus	I-bacteria
,	O
a	O
species	O
known	O
to	O
colonize	O
the	O
human	O
mouth	O
shortly	O
after	O
birth	O
.	O

However	O
,	O
after	O
colonization	O
by	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
genospecies	I-bacteria
1	I-bacteria
and	I-bacteria
2	I-bacteria
,	O
specific	O
antibodies	O
were	O
induced	O
that	O
could	O
not	O
be	O
removed	O
by	O
absorption	O
with	O
A	B-bacteria
.	I-bacteria
odontolyticus	I-bacteria
.	O

Cluster	O
analysis	O
of	O
the	O
patterns	O
of	O
reactivity	O
of	O
postcolonization	O
salivary	O
antibodies	O
from	O
each	O
infant	O
with	O
antigens	O
from	O
their	O
own	O
strains	O
showed	O
that	O
not	O
only	O
could	O
these	O
antibodies	O
discriminate	O
among	O
strains	O
but	O
antibodies	O
in	O
saliva	O
samples	O
collected	O
at	O
different	O
times	O
showed	O
different	O
reactivity	O
patterns	O
.	O

Overall	O
,	O
these	O
data	O
suggest	O
that	O
,	O
although	O
much	O
of	O
the	O
salivary	O
SIgA	O
antibodies	O
reactive	O
with	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
genospecies	I-bacteria
1	I-bacteria
and	I-bacteria
2	I-bacteria
are	O
directed	O
against	O
genus	O
-	O
specific	O
or	O
more	O
broadly	O
cross	O
-	O
reactive	O
antigens	O
,	O
species	O
,	O
genospecies	O
,	O
and	O
possibly	O
strain	O
-	O
specific	O
antibodies	O
are	O
induced	O
in	O
response	O
to	O
colonization	O
.	O

Hydrolytic	O
degradation	O
by	O
-	O
products	O
associated	O
with	O
the	O
constitutive	O
monomers	O
2	O
,	O
2	O
-	O
bis	O
[	O
4	O
-	O
(	O
2	O
-	O
hydroxy	O
-	O
3	O
-	O
methacryloxypropoxy	O
)	O
phenyl	O
]	O
propane	O
(	O
bis	O
-	O
GMA	O
)	O
,	O
bisphenol	O
A	O
polyethylene	O
glycol	O
diether	O
dimethacrylate	O
(	O
bis	O
-	O
EMA	O
)	O
,	O
and	O
triethylene	O
glycol	O
dimethacrylate	O
(	O
TEDGMA	O
)	O
used	O
in	O
dental	O
restorative	O
composites	O
include	O
bis	O
-	O
hydroxy	O
-	O
propoxyphenyl	O
propane	O
(	O
bis	O
-	O
HPPP	O
)	O
,	O
ethoxylated	O
bisphenol	O
A	O
(	O
E	O
-	O
bisPA	O
)	O
,	O
methacrylic	O
acid	O
(	O
MA	O
)	O
,	O
and	O
triethylene	O
glycol	O
(	O
TEG	O
)	O
.	O

These	O
products	O
are	O
generated	O
from	O
the	O
interaction	O
of	O
human	O
salivary	O
esterases	O
with	O
the	O
composites	O
.	O

Recent	O
findings	O
have	O
indicated	O
that	O
TEGDMA	O
has	O
the	O
ability	O
to	O
modulate	O
oral	O
bacteria	O
but	O
it	O
is	O
unclear	O
which	O
components	O
of	O
TEGDMA	O
are	O
related	O
to	O
the	O
observed	O
effects	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
influence	O
of	O
TEGDMA	O
derived	O
degradation	O
products	O
MA	O
and	O
TEG	O
on	O
the	O
growth	O
of	O
three	O
strains	O
of	O
oral	O
bacteria	O
:	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
strains	I-bacteria
NG8	I-bacteria
and	O
JH1005	B-bacteria
,	O
and	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
AT2	I-bacteria
.	O

Bacterial	O
growth	O
rates	O
were	O
measured	O
at	O
37	O
degrees	O
C	O
,	O
and	O
pH	O
values	O
of	O
5	O
.	O
5	O
(	O
representative	O
of	O
cariogenic	O
state	O
)	O
or	O
7	O
.	O
0	O
at	O
concentrations	O
of	O
0	O
-	O
50mmol	O
/	O
l	O
for	O
MA	O
(	O
Sigma	O
,	O
US	O
)	O
and	O
0	O
-	O
100mmol	O
/	O
l	O
for	O
TEG	O
(	O
Sigma	O
,	O
US	O
)	O
.	O

It	O
was	O
found	O
that	O
at	O
pH	O
5	O
.	O
5	O
TEG	O
significantly	O
stimulated	O
the	O
growth	O
of	O
both	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
strains	I-bacteria
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
concentration	O
range	O
of	O
0	O
.	O
5	O
-	O
10	O
.	O
0mmol	O
/	O
l	O
and	O
stimulated	O
the	O
growth	O
of	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
AT2	I-bacteria
for	O
the	O
entire	O
concentration	O
range	O
tested	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

TEG	O
(	O
above	O
50mmol	O
/	O
1	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
doubling	O
times	O
of	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
at	O
pH	O
of	O
7	O
.	O
0	O
and	O
it	O
inhibited	O
the	O
growth	O
of	O
both	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
strains	I-bacteria
above	O
50mmol	O
/	O
l	O
at	O
the	O
same	O
pH	O
value	O
.	O

At	O
pH	O
5	O
.	O
5	O
MA	O
inhibited	O
the	O
growth	O
of	O
all	O
three	O
strains	O
with	O
increasing	O
concentration	O
.	O

At	O
neutral	O
pH	O
,	O
the	O
growth	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
NG8	I-bacteria
strain	I-bacteria
was	O
significantly	O
reduced	O
by	O
MA	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
above	O
10mmol	O
/	O
l	O
.	O

In	O
summary	O
,	O
these	O
results	O
indicate	O
that	O
TEG	O
and	O
MA	O
modulate	O
the	O
growth	O
rate	O
of	O
important	O
oral	O
bacteria	O
in	O
a	O
concentration	O
and	O
pH	O
dependent	O
manner	O
.	O

Two	O
bacterial	O
strains	O
,	O
EHS11	B-bacteria
(	O
T	O
)	O
and	O
EPSA11	B-bacteria
(	O
T	O
)	O
,	O
which	O
were	O
isolated	O
from	O
the	O
human	O
oral	O
cavity	O
,	O
were	O
characterized	O
in	O
terms	O
of	O
phenotypic	O
and	O
biochemical	O
characteristics	O
,	O
cellular	O
fatty	O
acid	O
profiles	O
and	O
phylogenetic	O
position	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequence	O
analysis	O
.	O

16S	O
rRNA	O
gene	O
sequence	O
analysis	O
showed	O
that	O
each	O
of	O
the	O
isolates	O
belonged	O
to	O
a	O
novel	O
species	O
of	O
the	O
genus	O
Prevotella	B-bacteria
.	O

Strain	O
EHS11	B-bacteria
(	O
T	O
)	O
was	O
related	O
to	O
Prevotella	B-bacteria
loescheii	I-bacteria
(	O
about	O
95	O
%	O
similarity	O
)	O
,	O
whereas	O
strain	O
EPSA11	B-bacteria
(	O
T	O
)	O
was	O
related	O
to	O
Prevotella	B-bacteria
oris	I-bacteria
(	O
about	O
94	O
%	O
similarity	O
)	O
.	O

Both	O
strains	O
were	O
obligately	O
anaerobic	O
,	O
non	O
-	O
pigmented	O
,	O
non	O
-	O
spore	O
-	O
forming	O
,	O
non	O
-	O
motile	O
,	O
Gram	O
-	O
negative	O
rods	O
.	O

The	O
cellular	O
fatty	O
acid	O
composition	O
of	O
strain	O
EPSA11	B-bacteria
(	O
T	O
)	O
was	O
very	O
similar	O
to	O
that	O
of	O
P	B-bacteria
.	I-bacteria
oris	I-bacteria
JCM	I-bacteria
8540	I-bacteria
(	O
T	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
cellular	O
fatty	O
acid	O
composition	O
of	O
strain	O
EHS11	B-bacteria
(	O
T	O
)	O
was	O
significantly	O
different	O
from	O
those	O
of	O
other	O
Prevotella	B-bacteria
species	I-bacteria
.	O

The	O
predominant	O
fatty	O
acids	O
in	O
strain	O
EHS11	B-bacteria
(	O
T	O
)	O
are	O
C	O
(	O
18	O
:	O
1	O
)	O
omega9c	O
,	O
C	O
(	O
16	O
:	O
0	O
)	O
and	O
C	O
(	O
16	O
:	O
0	O
)	O
3	O
-	O
OH	O
,	O
whereas	O
other	O
Prevotella	B-bacteria
species	I-bacteria
,	O
except	O
for	O
P	B-bacteria
.	I-bacteria
loescheii	I-bacteria
JCM	I-bacteria
8530	I-bacteria
(	O
T	O
)	O
,	O
possess	O
anteiso	O
-	O
C	O
(	O
15	O
:	O
0	O
)	O
,	O
iso	O
-	O
C	O
(	O
17	O
:	O
0	O
)	O
3	O
-	O
OH	O
and	O
C	O
(	O
18	O
:	O
1	O
)	O
omega9c	O
.	O

The	O
predominant	O
fatty	O
acids	O
in	O
P	B-bacteria
.	I-bacteria
loescheii	I-bacteria
JCM	I-bacteria
8530	I-bacteria
(	O
T	O
)	O
are	O
anteiso	O
-	O
C	O
(	O
15	O
:	O
0	O
)	O
,	O
C	O
(	O
16	O
:	O
0	O
)	O
and	O
C	O
(	O
18	O
:	O
1	O
)	O
omega9c	O
.	O

DNA	O
-	O
DNA	O
hybridization	O
experiments	O
revealed	O
a	O
genomic	O
distinction	O
of	O
strains	O
EHS11	B-bacteria
(	O
T	O
)	O
and	O
EPSA11	B-bacteria
(	O
T	O
)	O
from	O
P	B-bacteria
.	I-bacteria
loescheii	I-bacteria
JCM	I-bacteria
8530	I-bacteria
(	O
T	O
)	O
and	O
P	B-bacteria
.	I-bacteria
oris	I-bacteria
JCM	I-bacteria
8540	I-bacteria
(	O
T	O
)	O
.	O

On	O
the	O
basis	O
of	O
these	O
data	O
,	O
two	O
novel	O
Prevotella	B-bacteria
species	I-bacteria
are	O
proposed	O
:	O
Prevotella	B-bacteria
shahii	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
and	O
Prevotella	B-bacteria
salivae	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	O

The	O
type	O
strains	O
of	O
P	B-bacteria
.	I-bacteria
shahii	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
salivae	I-bacteria
are	O
EHS11	B-bacteria
(	O
T	O
)	O
(	O
=	O
JCM	B-bacteria
12083	I-bacteria
(	O
T	O
)	O
=	O
DSM	B-bacteria
15611	I-bacteria
(	O
T	O
)	O
)	O
and	O
EPSA11	B-bacteria
(	O
T	O
)	O
(	O
=	O
JCM	B-bacteria
12084	I-bacteria
(	O
T	O
)	O
=	O
DSM	B-bacteria
15606	I-bacteria
(	O
T	O
)	O
)	O
,	O
respectively	O
.	O

Terminal	O
RFLP	O
(	O
T	O
-	O
RFLP	O
)	O
analysis	O
was	O
used	O
to	O
investigate	O
changes	O
in	O
the	O
oral	O
microbiota	O
in	O
saliva	O
and	O
subgingival	O
plaque	O
samples	O
from	O
one	O
patient	O
with	O
aggressive	O
periodontitis	O
(	O
subject	O
A	O
)	O
and	O
two	O
patients	O
with	O
chronic	O
periodontitis	O
(	O
subjects	O
B	O
and	O
C	O
)	O
before	O
and	O
3	O
months	O
after	O
periodontal	O
treatment	O
.	O

Substantial	O
changes	O
in	O
the	O
T	O
-	O
RFLP	O
patterns	O
of	O
subgingival	O
plaque	O
samples	O
of	O
subjects	O
B	O
and	O
C	O
were	O
noted	O
after	O
3	O
months	O
of	O
improved	O
oral	O
hygiene	O
and	O
full	O
-	O
mouth	O
supra	O
-	O
and	O
subgingival	O
scaling	O
and	O
root	O
planing	O
.	O

However	O
,	O
there	O
was	O
little	O
change	O
in	O
the	O
subgingival	O
microbiota	O
of	O
subject	O
A	O
.	O

Although	O
the	O
proportions	O
of	O
terminal	O
restriction	O
fragments	O
(	O
T	O
-	O
RFs	O
)	O
larger	O
than	O
1000	O
bp	O
were	O
notable	O
in	O
the	O
T	O
-	O
RFLP	O
patterns	O
generated	O
after	O
digestion	O
with	O
HhaI	O
of	O
the	O
samples	O
from	O
two	O
subjects	O
before	O
treatment	O
(	O
subject	O
B	O
,	O
35	O
.	O
5	O
%	O
;	O
subject	O
C	O
,	O
29	O
.	O
6	O
%	O
)	O
,	O
the	O
proportions	O
of	O
these	O
T	O
-	O
RFs	O
were	O
significantly	O
reduced	O
or	O
not	O
detected	O
after	O
treatment	O
(	O
subject	O
B	O
,	O
none	O
;	O
subject	O
C	O
,	O
4	O
.	O
1	O
%	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
showed	O
a	O
significant	O
change	O
in	O
the	O
proportions	O
of	O
target	O
bacteria	O
in	O
subgingival	O
plaque	O
samples	O
of	O
subject	O
B	O
.	O

After	O
3	O
months	O
,	O
the	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
population	O
was	O
markedly	O
reduced	O
(	O
3	O
.	O
1	O
x	O
10	O
(	O
-	O
3	O
)	O
%	O
)	O
,	O
whereas	O
the	O
proportion	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
before	O
treatment	O
was	O
7	O
.	O
6	O
%	O
.	O

The	O
proportions	O
of	O
Tannerella	B-bacteria
forsythensis	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
and	O
Treponema	B-bacteria
socranskii	I-bacteria
were	O
also	O
markedly	O
diminished	O
after	O
treatment	O
.	O

Similarly	O
,	O
the	O
proportion	O
of	O
the	O
T	O
-	O
RF	O
presumed	O
to	O
represent	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
was	O
5	O
.	O
9	O
%	O
and	O
became	O
undetectable	O
after	O
3	O
months	O
.	O

Analysis	O
of	O
16S	O
rRNA	O
gene	O
clone	O
libraries	O
from	O
subgingival	O
plaque	O
samples	O
of	O
subject	O
B	O
before	O
and	O
after	O
treatment	O
showed	O
a	O
notable	O
change	O
in	O
the	O
subgingival	O
microbiota	O
.	O

These	O
results	O
were	O
in	O
agreement	O
with	O
the	O
T	O
-	O
RFLP	O
analysis	O
data	O
and	O
showed	O
that	O
the	O
T	O
-	O
RFs	O
larger	O
than	O
1000	O
bp	O
represent	O
Peptostreptococcus	B-bacteria
species	I-bacteria
.	O

Our	O
results	O
indicate	O
that	O
T	O
-	O
RFLP	O
analysis	O
is	O
useful	O
for	O
evaluation	O
of	O
the	O
effects	O
of	O
medical	O
treatment	O
of	O
periodontitis	O
.	O

Once	O
established	O
,	O
early	O
-	O
colonizing	O
bacterial	O
species	O
tend	O
to	O
persist	O
in	O
the	O
mouth	O
.	O

To	O
obtain	O
detailed	O
information	O
on	O
the	O
population	O
dynamics	O
of	O
early	O
-	O
colonizing	O
oral	O
anaerobes	O
,	O
we	O
examined	O
the	O
clonal	O
diversity	O
and	O
persistence	O
of	O
clones	O
among	O
oral	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
populations	O
during	O
the	O
first	O
2	O
yrs	O
of	O
life	O
.	O

Consecutive	O
salivary	O
samples	O
from	O
12	O
infants	O
,	O
collected	O
at	O
2	O
,	O
6	O
,	O
12	O
,	O
18	O
,	O
and	O
24	O
mos	O
of	O
age	O
,	O
yielded	O
a	O
total	O
of	O
546	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
isolates	I-bacteria
for	O
clonal	O
typing	O
with	O
arbitrarily	O
primed	O
PCR	O
(	O
AP	O
-	O
PCR	O
)	O
.	O

Up	O
to	O
7	O
AP	O
-	O
PCR	O
types	O
were	O
simultaneously	O
detected	O
in	O
each	O
sample	O
.	O

In	O
11	O
out	O
of	O
the	O
12	O
infants	O
examined	O
,	O
AP	O
-	O
PCR	O
types	O
persisted	O
for	O
up	O
to	O
1	O
yr	O
.	O
Strain	O
turnover	O
rate	O
was	O
high	O
during	O
the	O
first	O
year	O
of	O
life	O
,	O
but	O
then	O
the	O
occurrence	O
of	O
persistent	O
clones	O
increased	O
.	O

This	O
study	O
indicates	O
a	O
wide	O
genetic	O
diversity	O
within	O
the	O
species	O
and	O
provides	O
evidence	O
for	O
the	O
increasing	O
persistence	O
of	O
F	O
.	O
nucleatum	O
clones	O
in	O
the	O
oral	O
cavity	O
with	O
age	O
.	O

Colonization	O
of	O
the	O
tooth	O
surface	O
by	O
actinomyces	B-bacteria
and	O
viridans	B-bacteria
group	I-bacteria
streptococci	I-bacteria
involves	O
the	O
attachment	O
of	O
these	O
bacteria	O
to	O
adsorbed	O
salivary	O
components	O
of	O
the	O
acquired	O
enamel	O
pellicle	O
.	O

The	O
hypothesis	O
that	O
this	O
attachment	O
depends	O
on	O
specific	O
adhesins	O
has	O
now	O
been	O
assessed	O
from	O
the	O
binding	O
of	O
bacteria	O
with	O
well	O
-	O
defined	O
adhesive	O
properties	O
to	O
blots	O
of	O
SDS	O
-	O
PAGE	O
-	O
separated	O
parotid	O
and	O
submandibular	O
-	O
sublingual	O
(	O
SM	O
-	O
SL	O
)	O
saliva	O
.	O

Streptococcus	B-bacteria
sanguis	I-bacteria
and	O
type	B-bacteria
2	I-bacteria
fimbriated	I-bacteria
Actinomyces	I-bacteria
naeslundii	I-bacteria
,	O
which	O
bound	O
terminal	O
sialic	O
acid	O
and	O
Galbeta1	O
-	O
3GalNAc	O
,	O
respectively	O
,	O
recognized	O
only	O
a	O
few	O
SM	O
-	O
SL	O
salivary	O
components	O
,	O
primarily	O
MG2	O
.	O

In	O
contrast	O
,	O
type	O
1	O
fimbriated	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
,	O
which	O
bound	O
purified	O
proline	O
-	O
rich	O
proteins	O
(	O
PRPs	O
)	O
,	O
recognized	O
several	O
other	O
components	O
from	O
both	O
SM	O
-	O
SL	O
and	O
parotid	O
saliva	O
.	O

Significantly	O
,	O
bacteria	O
that	O
lacked	O
PRP	O
-	O
binding	O
and	O
the	O
lectin	O
-	O
like	O
activities	O
detected	O
by	O
binding	O
to	O
MG2	O
failed	O
to	O
bind	O
any	O
immobilized	O
salivary	O
component	O
.	O

These	O
findings	O
suggest	O
the	O
involvement	O
of	O
specific	O
adhesins	O
in	O
bacterial	O
recognition	O
of	O
many	O
adsorbed	O
salivary	O
proteins	O
and	O
glycoproteins	O
.	O

The	O
oral	O
environment	O
contains	O
many	O
different	O
types	O
of	O
microorganisms	O
,	O
including	O
both	O
Gram	O
-	O
negative	O
and	O
Gram	O
-	O
positive	O
cocci	O
,	O
bacilli	O
,	O
and	O
spirochetes	O
.	O

From	O
the	O
ecological	O
point	O
of	O
view	O
,	O
the	O
oral	O
cavity	O
is	O
a	O
perfect	O
niche	O
for	O
certain	O
bacteria	O
such	O
as	O
lactobacilli	B-bacteria
because	O
they	O
interact	O
,	O
forming	O
different	O
types	O
of	O
communities	O
.	O

Lactobacilli	B-bacteria
have	O
been	O
associated	O
with	O
the	O
generation	O
of	O
caries	O
in	O
some	O
reports	O
,	O
secondary	O
to	O
the	O
cariogenic	O
Streptococcus	B-bacteria
.	O

In	O
previous	O
papers	O
,	O
the	O
isolation	O
and	O
identification	O
of	O
145	O
strains	O
from	O
healthy	O
subjects	O
and	O
from	O
subjects	O
with	O
active	O
caries	O
were	O
performed	O
.	O

Strains	O
were	O
characterized	O
by	O
their	O
surface	O
properties	O
and	O
also	O
by	O
the	O
production	O
of	O
inhibitory	O
substances	O
.	O

From	O
all	O
the	O
strains	O
,	O
one	O
isolated	O
from	O
the	O
teeth	O
of	O
healthy	O
patients	O
and	O
another	O
from	O
a	O
patient	O
with	O
caries	O
,	O
sharing	O
some	O
surface	O
properties	O
,	O
were	O
selected	O
for	O
further	O
study	O
of	O
their	O
adhesion	O
properties	O
in	O
an	O
experimental	O
model	O
by	O
using	O
hydroxylapatite	O
beads	O
.	O

Adhesion	O
is	O
the	O
first	O
step	O
in	O
the	O
association	O
of	O
microorganisms	O
with	O
surfaces	O
or	O
mucous	O
membranes	O
.	O

The	O
first	O
approach	O
is	O
a	O
nonspecific	O
interaction	O
of	O
both	O
surfaces	O
;	O
later	O
some	O
other	O
types	O
of	O
interactions	O
can	O
occur	O
,	O
involving	O
more	O
specific	O
mediators	O
of	O
adhesions	O
.	O

Many	O
different	O
assays	O
are	O
available	O
to	O
study	O
the	O
adhesion	O
phenomenon	O
;	O
some	O
of	O
them	O
use	O
predictive	O
characteristics	O
,	O
and	O
others	O
use	O
experimental	O
models	O
resembling	O
the	O
in	O
vivo	O
situation	O
.	O

Two	O
model	O
systems	O
predominate	O
.	O

The	O
most	O
widely	O
used	O
has	O
been	O
saliva	O
-	O
coated	O
hydroxylapatite	O
or	O
hydroxylapatite	O
coated	O
with	O
buffers	O
,	O
proteins	O
,	O
and	O
other	O
substances	O
.	O

In	O
an	O
attempt	O
to	O
increase	O
knowledge	O
of	O
the	O
mechanisms	O
of	O
adhesion	O
of	O
oral	O
lactobacilli	B-bacteria
with	O
hard	O
surfaces	O
,	O
this	O
chapter	O
describes	O
an	O
experimental	O
model	O
for	O
studing	O
the	O
adhesion	O
between	O
lactobacilli	B-bacteria
and	O
hard	O
tissues	O
represented	O
by	O
hydroxylapatite	O
,	O
the	O
component	O
most	O
abundant	O
in	O
the	O
teeth	O
.	O

The	O
following	O
steps	O
were	O
performed	O
:	O
1	O
.	O
Obtaining	O
the	O
microorganisms	O
.	O
2	O
.	O
Preparation	O
of	O
the	O
hydroxylapatite	O
beads	O
.	O

3	O
.	O
Adhesion	O
assay	O
.	O
Commensal	O
microflora	O
(	O
normal	O
microflora	O
,	O
indigenous	O
microbiota	O
)	O
consists	O
of	O
those	O
micro	O
-	O
organisms	O
,	O
which	O
are	O
present	O
on	O
body	O
surfaces	O
covered	O
by	O
epithelial	O
cells	O
and	O
are	O
exposed	O
to	O
the	O
external	O
environment	O
(	O
gastrointestinal	O
and	O
respiratory	O
tract	O
,	O
vagina	O
,	O
skin	O
,	O
etc	O
.	O
)	O
.	O

The	O
number	O
of	O
bacteria	O
colonising	O
mucosal	O
and	O
skin	O
surfaces	O
exceeds	O
the	O
number	O
of	O
cells	O
forming	O
human	O
body	O
.	O

Commensal	O
bacteria	O
co	O
-	O
evolved	O
with	O
their	O
hosts	O
,	O
however	O
,	O
under	O
specific	O
conditions	O
they	O
are	O
able	O
to	O
overcome	O
protective	O
host	O
responses	O
and	O
exert	O
pathologic	O
effects	O
.	O

Resident	O
bacteria	O
form	O
complex	O
ecosystems	O
,	O
whose	O
diversity	O
is	O
enormous	O
.	O

The	O
most	O
abundant	O
microflora	O
is	O
present	O
in	O
the	O
distal	O
parts	O
of	O
the	O
gut	O
;	O
the	O
majority	O
of	O
the	O
intestinal	O
bacteria	O
are	O
Gram	O
-	O
negative	O
anaerobes	O
.	O

More	O
than	O
50	O
%	O
of	O
intestinal	O
bacteria	O
can	O
not	O
be	O
cultured	O
by	O
conventional	O
microbiological	O
techniques	O
.	O

Molecular	O
biological	O
methods	O
help	O
in	O
analysing	O
the	O
structural	O
and	O
functional	O
complexity	O
of	O
the	O
microflora	O
and	O
in	O
identifying	O
its	O
components	O
.	O

Resident	O
microflora	O
contains	O
a	O
number	O
of	O
components	O
able	O
to	O
activate	O
innate	O
and	O
adaptive	O
immunity	O
.	O

Unlimited	O
immune	O
activation	O
in	O
response	O
to	O
signals	O
from	O
commensal	O
bacteria	O
could	O
pose	O
the	O
risk	O
of	O
inflammation	O
;	O
immune	O
responses	O
to	O
mucosal	O
microbiota	O
therefore	O
require	O
a	O
precise	O
regulatory	O
control	O
.	O

The	O
mucosal	O
immune	O
system	O
has	O
developed	O
specialised	O
regulatory	O
,	O
anti	O
-	O
inflammatory	O
mechanisms	O
for	O
eliminating	O
or	O
tolerating	O
non	O
-	O
dangerous	O
,	O
food	O
and	O
airborne	O
antigens	O
and	O
commensal	O
micro	O
-	O
organisms	O
(	O
oral	O
,	O
mucosal	O
tolerance	O
)	O
.	O

However	O
,	O
at	O
the	O
same	O
time	O
the	O
mucosal	O
immune	O
system	O
must	O
provide	O
local	O
defense	O
mechanisms	O
against	O
environmental	O
threats	O
(	O
e	O
.	O
g	O
.	O
invading	O
pathogens	O
)	O
.	O

This	O
important	O
requirement	O
is	O
fulfilled	O
by	O
several	O
mechanisms	O
of	O
mucosal	O
immunity	O
:	O
strongly	O
developed	O
innate	O
defense	O
mechanisms	O
ensuring	O
appropriate	O
function	O
of	O
the	O
mucosal	O
barrier	O
,	O
existence	O
of	O
unique	O
types	O
of	O
lymphocytes	O
and	O
their	O
products	O
,	O
transport	O
of	O
polymeric	O
immunoglobulins	O
through	O
epithelial	O
cells	O
into	O
secretions	O
(	O
sIgA	O
)	O
and	O
migration	O
and	O
homing	O
of	O
cells	O
originating	O
from	O
the	O
mucosal	O
organised	O
tissues	O
in	O
mucosae	O
and	O
exocrine	O
glands	O
.	O

The	O
important	O
role	O
of	O
commensal	O
bacteria	O
in	O
development	O
of	O
optimally	O
functioning	O
mucosal	O
immune	O
system	O
was	O
demonstrated	O
in	O
germ	O
-	O
free	O
animals	O
(	O
using	O
gnotobiological	O
techniques	O
)	O
.	O

Involvement	O
of	O
commensal	O
microflora	O
and	O
its	O
components	O
with	O
strong	O
immunoactivating	O
properties	O
(	O
e	O
.	O
g	O
.	O
LPS	O
,	O
peptidoglycans	O
,	O
superantigens	O
,	O
bacterial	O
DNA	O
,	O
Hsp	O
)	O
in	O
etiopathogenetic	O
mechanism	O
of	O
various	O
complex	O
,	O
multifactorial	O
and	O
multigenic	O
diseases	O
,	O
including	O
inflammatory	O
bowel	O
diseases	O
,	O
periodontal	O
disease	O
,	O
rheumatoid	O
arthritis	O
,	O
atherosclerosis	O
,	O
allergy	O
,	O
multiorgan	O
failure	O
,	O
colon	O
cancer	O
has	O
been	O
recently	O
suggested	O
.	O

Animal	O
models	O
of	O
human	O
diseases	O
reared	O
in	O
defined	O
gnotobiotic	O
conditions	O
are	O
helping	O
to	O
elucidate	O
the	O
aetiology	O
of	O
these	O
frequent	O
disorders	O
.	O

An	O
improved	O
understanding	O
of	O
commensal	O
bacteria	O
-	O
host	O
interactions	O
employing	O
germ	O
-	O
free	O
animal	O
models	O
with	O
selective	O
colonisation	O
strategies	O
combined	O
with	O
modern	O
molecular	O
techniques	O
could	O
bring	O
new	O
insights	O
into	O
the	O
mechanisms	O
of	O
mucosal	O
immunity	O
and	O
also	O
into	O
pathogenetic	O
mechanisms	O
of	O
several	O
infectious	O
,	O
inflammatory	O
,	O
autoimmune	O
and	O
neoplastic	O
diseases	O
.	O

Regulation	O
of	O
microflora	O
composition	O
(	O
e	O
.	O
g	O
.	O
by	O
probiotics	O
and	O
prebiotics	O
)	O
offers	O
the	O
possibility	O
to	O
influence	O
the	O
development	O
of	O
mucosal	O
and	O
systemic	O
immunity	O
but	O
it	O
can	O
play	O
a	O
role	O
also	O
in	O
prevention	O
and	O
treatment	O
of	O
some	O
diseases	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
sampling	O
methods	O
for	O
recovery	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
(	O
MS	B-bacteria
)	O
and	O
lactobacilli	B-bacteria
(	O
LB	B-bacteria
)	O
in	O
children	O
9	O
to	O
36	O
months	O
of	O
age	O
.	O

Tongue	O
and	O
plaque	O
specimens	O
collected	O
on	O
cotton	O
swabs	O
and	O
stimulated	O
saliva	O
were	O
diluted	O
and	O
plated	O
on	O
selective	O
and	O
nonselective	O
media	O
.	O

Tongue	O
specimens	O
on	O
a	O
swab	O
and	O
mouth	O
mirror	O
were	O
inoculated	O
directly	O
on	O
selective	O
agar	O
media	O
(	O
MS	B-bacteria
only	O
)	O
.	O

Sampling	O
methods	O
were	O
compared	O
by	O
frequency	O
of	O
recovery	O
of	O
MS	B-bacteria
or	O
LB	B-bacteria
,	O
correlation	O
of	O
microbial	O
counts	O
with	O
dmfs	O
scores	O
,	O
and	O
potential	O
of	O
specific	O
microbial	O
counts	O
to	O
predict	O
caries	O
presence	O
or	O
absence	O
.	O

The	O
mean	O
dmfs	O
score	O
of	O
87	O
subjects	O
was	O
6	O
.	O
3	O
;	O
48	O
subjects	O
were	O
caries	O
free	O
.	O

Levels	O
of	O
MS	B-bacteria
and	O
LB	B-bacteria
were	O
consistently	O
higher	O
in	O
plaque	O
than	O
in	O
other	O
sampling	O
techniques	O
(	O
P	O
<	O
.	O
001	O
)	O
,	O
and	O
frequencies	O
of	O
recovery	O
of	O
MS	B-bacteria
were	O
highest	O
in	O
plaque	O
(	O
P	O
<	O
.	O
041	O
)	O
and	O
tongue	O
(	O
P	O
<	O
.	O
006	O
)	O
.	O

Frequency	O
of	O
LB	B-bacteria
recovery	O
did	O
not	O
differ	O
significantly	O
between	O
sampling	O
methods	O
.	O

Counts	O
of	O
MS	B-bacteria
or	O
LB	B-bacteria
in	O
total	O
subjects	O
and	O
subjects	O
aged	O
9	O
to	O
24	O
months	O
correlated	O
positively	O
with	O
dmfs	O
scores	O
(	O
P	O
<	O
.	O
028	O
)	O
.	O

Threshold	O
levels	O
of	O
MS	B-bacteria
which	O
were	O
predictive	O
of	O
presence	O
of	O
caries	O
were	O
:	O
(	O
1	O
)	O
plaque	O
=	O
>	O
2x10	O
(	O
5	O
)	O
;	O
(	O
2	O
)	O
tongue	O
=	O
>	O
10	O
(	O
4	O
)	O
;	O
(	O
3	O
)	O
saliva	O
=	O
>	O
10	O
(	O
5	O
)	O
;	O
(	O
4	O
)	O
mirror	O
=	O
>	O
50	O
;	O
and	O
(	O
5	O
)	O
swab	O
=	O
>	O
50	O
.	O

Comparable	O
levels	O
of	O
LB	B-bacteria
were	O
:	O
plaque	O
,	O
>	O
10	O
(	O
3	O
)	O
;	O
tongue	O
,	O
>	O
10	O
(	O
2	O
)	O
and	O
saliva	O
,	O
>	O
10	O
(	O
3	O
)	O
.	O

Specificities	O
associated	O
with	O
these	O
predictions	O
were	O
higher	O
than	O
sensitivities	O
for	O
all	O
sampling	O
methods	O
.	O

(	O
1	O
)	O
All	O
sampling	O
methods	O
were	O
adequate	O
for	O
microbial	O
risk	O
assessment	O
tests	O
in	O
children	O
under	O
3	O
years	O
of	O
age	O
;	O
(	O
2	O
)	O
MS	B-bacteria
was	O
a	O
stronger	O
indicator	O
of	O
caries	O
status	O
than	O
LB	B-bacteria
.	O

Recent	O
studies	O
suggest	O
that	O
normal	O
human	O
oral	O
keratinocytes	O
(	O
NHOKs	O
)	O
can	O
be	O
infected	O
by	O
HIV	O
-	O
1	O
,	O
and	O
alcohol	O
can	O
enhance	O
HIV	O
infection	O
and	O
replication	O
in	O
lymphocytes	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
possibility	O
that	O
alcohol	O
might	O
facilitate	O
HIV	O
-	O
1	O
infection	O
of	O
NHOKs	O
by	O
up	O
-	O
regulating	O
cell	O
surface	O
expression	O
of	O
the	O
coreceptor	O
,	O
CXCR4	O
.	O

Alcohol	O
enhanced	O
in	O
vitro	O
infection	O
of	O
NHOKs	O
by	O
CXCR4	O
-	O
tropic	O
strains	O
of	O
HIV	O
-	O
1	O
as	O
indicated	O
by	O
synthesis	O
of	O
viral	O
reverse	O
transcripts	O
and	O
production	O
of	O
p24gag	O
protein	O
.	O

Alcohol	O
had	O
no	O
effect	O
on	O
CXCR4	O
gene	O
expression	O
or	O
on	O
total	O
cellular	O
complements	O
of	O
CXCR4	O
protein	O
.	O

However	O
,	O
alcohol	O
did	O
enhance	O
the	O
fraction	O
of	O
total	O
CXCR4	O
expressed	O
on	O
the	O
cell	O
surface	O
relative	O
to	O
intracellular	O
stores	O
.	O

Alcohol	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
cell	O
surface	O
CXCR4	O
expression	O
and	O
HIV	O
-	O
1	O
infectivity	O
could	O
be	O
blocked	O
by	O
SDF	O
-	O
1alpha	O
-	O
mediated	O
internalization	O
.	O

These	O
data	O
suggest	O
that	O
alcohol	O
may	O
influence	O
oral	O
HIV	O
transmission	O
by	O
altering	O
the	O
cellular	O
compartmentalization	O
of	O
CXCR4	O
in	O
cells	O
of	O
the	O
oral	O
cavity	O
.	O

To	O
observe	O
the	O
dynamic	O
changes	O
of	O
oral	O
microflora	O
early	O
colonized	O
in	O
infants	O
.	O

The	O
oral	O
swab	O
samples	O
for	O
the	O
study	O
were	O
taken	O
in	O
1	O
day	O
,	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
months	O
after	O
birth	O
from	O
12	O
healthy	O
neonates	O
.	O

By	O
choosing	O
suitable	O
diluted	O
concentration	O
,	O
the	O
samples	O
were	O
incubated	O
aerobically	O
,	O
facultative	O
anaerobically	O
and	O
anaerobically	O
.	O

The	O
strains	O
were	O
identified	O
by	O
observing	O
colony	O
characteristics	O
,	O
Gram	O
staining	O
and	O
biochemical	O
tests	O
.	O

S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
was	O
the	O
most	O
frequent	O
microflora	O
,	O
followed	O
by	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
occurred	O
in	O
oral	O
cavity	O
after	O
tooth	O
eruption	O
.	O

Veillonella	B-bacteria
spp	I-bacteria
.	I-bacteria
can	O
be	O
detected	O
in	O
oral	O
cavity	O
of	O
1	O
-	O
month	O
-	O
old	O
babies	O
,	O
A	B-bacteria
.	I-bacteria
odontolyticus	I-bacteria
was	O
isolated	O
from	O
8	O
.	O
3	O
%	O
infants	O
of	O
more	O
than	O
3	O
months	O
old	O
.	O

L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
maintained	O
the	O
lower	O
prevalence	O
in	O
oral	O
cavity	O
of	O
babies	O
.	O

Leptotrichia	B-bacteria
buccalis	I-bacteria
and	O
Capnocytophaga	B-bacteria
spp	I-bacteria
.	I-bacteria
occurred	O
in	O
oral	O
cavity	O
of	O
some	O
dentate	O
infants	O
.	O

S	B-bacteria
.	I-bacteria
solivarius	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
are	O
predominant	O
species	O
in	O
oral	O
cavity	O
of	O
the	O
infants	O
,	O
Veillonella	B-bacteria
spp	I-bacteria
.	I-bacteria
is	O
the	O
first	O
and	O
the	O
most	O
anaerobic	O
species	O
appeared	O
in	O
oral	O
cavity	O
of	O
healthy	O
babies	O
.	O

A	B-bacteria
.	I-bacteria
odontolyticus	I-bacteria
is	O
the	O
first	O
actinomyces	B-bacteria
detected	O
in	O
oral	O
cavity	O
.	O

With	O
the	O
increasing	O
months	O
,	O
kind	O
and	O
amount	O
of	O
microflora	O
increase	O
dramatically	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
ozonated	O
water	O
on	O
oral	O
microorganisms	O
and	O
dental	O
plaque	O
.	O

Almost	O
no	O
microorganisms	O
were	O
detected	O
after	O
being	O
treated	O
with	O
ozonated	O
water	O
(	O
4	O
mg	O
/	O
l	O
)	O
for	O
10	O
s	O
.	O
To	O
estimate	O
the	O
ozonated	O
water	O
-	O
treated	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
bacterial	O
cells	O
were	O
stained	O
with	O
LIVE	O
/	O
DEAD	O
BacLight	O
Bacterial	O
Viability	O
Kit	O
.	O

Fluorescence	O
microscopic	O
analysis	O
revealed	O
that	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
cells	O
were	O
killed	O
instantaneously	O
in	O
ozonated	O
water	O
.	O

Some	O
breakage	O
of	O
ozonated	O
water	O
-	O
treated	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
was	O
found	O
by	O
electron	O
microscopy	O
.	O

When	O
the	O
experimental	O
dental	O
plaque	O
was	O
exposed	O
to	O
ozonated	O
water	O
,	O
the	O
number	O
of	O
viable	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
remarkably	O
decreased	O
.	O

Ozonated	O
water	O
strongly	O
inhibited	O
the	O
accumulation	O
of	O
experimental	O
dental	O
plaque	O
in	O
vitro	O
.	O

After	O
the	O
dental	O
plaque	O
samples	O
from	O
human	O
subjects	O
were	O
exposed	O
to	O
ozonated	O
water	O
in	O
vitro	O
,	O
almost	O
no	O
viable	O
bacterial	O
cells	O
were	O
detected	O
.	O

These	O
results	O
suggest	O
that	O
ozonated	O
water	O
should	O
be	O
useful	O
in	O
reducing	O
the	O
infections	O
caused	O
by	O
oral	O
microorganisms	O
in	O
dental	O
plaque	O
.	O

Dental	O
plaque	O
is	O
composed	O
of	O
a	O
biofilm	O
community	O
of	O
microorganisms	O
on	O
teeth	O
that	O
coats	O
the	O
oral	O
cavity	O
,	O
including	O
attaching	O
to	O
the	O
teeth	O
,	O
and	O
provides	O
a	O
protective	O
reservoir	O
for	O
oral	O
microbial	O
pathogens	O
,	O
which	O
are	O
the	O
primary	O
cause	O
of	O
persistent	O
and	O
chronic	O
infectious	O
diseases	O
.	O

Oral	O
streptococci	B-bacteria
are	O
pioneering	O
organisms	O
that	O
play	O
an	O
important	O
role	O
in	O
biofilm	O
formation	O
on	O
tooth	O
surfaces	O
as	O
well	O
as	O
being	O
primary	O
causative	O
agents	O
of	O
dental	O
caries	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
E2f1	O
gene	O
in	O
susceptibility	O
to	O
dry	O
mouth	O
and	O
bacterial	O
adherence	O
of	O
oral	O
streptococci	B-bacteria
to	O
tooth	O
surfaces	O
in	O
animal	O
model	O
experiments	O
.	O

A	O
mutation	O
of	O
the	O
E2f1	O
gene	O
in	O
mice	O
is	O
known	O
to	O
cause	O
enhanced	O
T	O
-	O
lymphocyte	O
proliferation	O
,	O
leading	O
to	O
testicular	O
atrophy	O
,	O
splenomegaly	O
,	O
salivary	O
gland	O
dysplasia	O
,	O
and	O
other	O
systemic	O
and	O
organ	O
-	O
specific	O
autoimmunity	O
.	O

We	O
found	O
a	O
decreased	O
volume	O
of	O
saliva	O
production	O
and	O
protein	O
production	O
rate	O
,	O
along	O
with	O
increased	O
amylase	O
activity	O
,	O
IgA	O
concentration	O
,	O
and	O
mucin	O
1	O
concentration	O
in	O
E2F	O
-	O
1	O
(	O
-	O
/	O
-	O
)	O
mice	O
as	O
compared	O
with	O
the	O
control	O
C57BL	O
/	O
6	O
mice	O
.	O

Further	O
,	O
we	O
quantified	O
the	O
recolonization	O
of	O
oral	O
streptococci	B-bacteria
in	O
E2F	O
-	O
1	O
(	O
-	O
/	O
-	O
)	O
mice	O
and	O
found	O
that	O
a	O
higher	O
number	O
of	O
some	O
oral	O
streptococci	B-bacteria
were	O
colonized	O
on	O
the	O
teeth	O
of	O
these	O
mice	O
.	O

In	O
particular	O
,	O
following	O
oral	O
ingestion	O
of	O
1	O
%	O
sucrose	O
in	O
water	O
,	O
the	O
colonization	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
increased	O
in	O
comparison	O
with	O
other	O
streptococci	B-bacteria
.	O

Our	O
results	O
suggest	O
that	O
the	O
E2f1	O
gene	O
may	O
affect	O
susceptibility	O
for	O
oral	O
biofilm	O
formation	O
by	O
streptococci	B-bacteria
in	O
humans	O
with	O
dry	O
mouth	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
is	O
an	O
important	O
gastrointestinal	O
pathogen	O
associated	O
with	O
gastritis	O
,	O
peptic	O
ulcers	O
,	O
and	O
an	O
increased	O
risk	O
of	O
gastric	O
carcinoma	O
.	O

The	O
oral	O
cavity	O
has	O
been	O
indicated	O
as	O
a	O
possible	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
reservoir	O
,	O
and	O
may	O
therefore	O
be	O
involved	O
in	O
the	O
reinfection	O
of	O
the	O
stomach	O
which	O
sometimes	O
follows	O
treatment	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
prevalence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
as	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
in	O
the	O
oral	O
cavity	O
of	O
periodontitis	O
patients	O
testing	O
positive	O
for	O
this	O
bacterium	O
in	O
the	O
stomach	O
.	O

Thirty	O
adult	O
patients	O
with	O
alterations	O
of	O
the	O
superior	O
digestive	O
tract	O
,	O
testing	O
urease	O
positive	O
after	O
endoscopy	O
and	O
biopsy	O
,	O
were	O
selected	O
.	O

A	O
full	O
-	O
mouth	O
periodontal	O
examination	O
was	O
performed	O
in	O
every	O
patient	O
and	O
the	O
subjects	O
were	O
allocated	O
to	O
two	O
groups	O
:	O
gingivitis	O
(	O
15	O
patients	O
)	O
and	O
chronic	O
periodontitis	O
(	O
15	O
patients	O
)	O
.	O

plaque	O
and	O
saliva	O
samples	O
collected	O
from	O
each	O
patient	O
were	O
stored	O
in	O
0	O
.	O
5	O
ml	O
of	O
TE	O
buffer	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
samples	O
by	O
the	O
boiling	O
method	O
and	O
was	O
evaluated	O
for	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
using	O
the	O
PCR	O
method	O
.	O

JW	O
22	O
/	O
23	O
primers	O
were	O
used	O
.	O

The	O
DNA	O
of	O
ATCC	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
43629	I-bacteria
(	O
positive	O
control	O
)	O
and	O
water	O
(	O
negative	O
control	O
)	O
were	O
used	O
for	O
controlling	O
the	O
reactions	O
.	O

Of	O
the	O
30	O
evaluated	O
patients	O
,	O
13	O
(	O
43	O
.	O
3	O
%	O
)	O
harbored	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
mouth	O
.	O

The	O
bacterium	O
was	O
not	O
found	O
on	O
the	O
dorsum	O
of	O
the	O
tongue	O
of	O
any	O
patient	O
,	O
but	O
was	O
found	O
in	O
saliva	O
in	O
three	O
patients	O
(	O
10	O
%	O
)	O
,	O
in	O
the	O
supragingival	O
plaque	O
in	O
six	O
patients	O
(	O
20	O
%	O
)	O
,	O
and	O
in	O
the	O
subgingival	O
plaque	O
in	O
eight	O
patients	O
(	O
26	O
.	O
6	O
%	O
)	O
.	O

The	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
similar	O
in	O
the	O
gingivitis	O
and	O
chronic	O
periodontitis	O
groups	O
.	O

In	O
conclusion	O
,	O
a	O
high	O
percentage	O
of	O
patients	O
harbored	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
their	O
mouth	O
.	O

The	O
bacterium	O
was	O
detected	O
in	O
saliva	O
,	O
supragingival	O
and	O
subgingival	O
plaque	O
,	O
suggesting	O
that	O
these	O
sites	O
may	O
be	O
considered	O
reservoirs	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
urease	O
-	O
positive	O
patients	O
.	O

The	O
comparative	O
in	O
vitro	O
activities	O
of	O
11	O
iodonium	O
salt	O
compounds	O
,	O
0	O
.	O
12	O
%	O
chlorhexidine	O
,	O
and	O
four	O
antimicrobial	O
agents	O
against	O
322	O
anaerobic	O
and	O
fastidious	O
potential	O
dental	O
and	O
periodontal	O
bacterial	O
pathogens	O
were	O
studied	O
.	O

Iodonium	O
salts	O
3	O
,	O
4	O
,	O
5	O
,	O
9	O
,	O
and	O
10	O
had	O
in	O
vitro	O
activities	O
comparable	O
to	O
that	O
of	O
chlorhexidine	O
against	O
most	O
isolates	O
.	O

These	O
compounds	O
may	O
be	O
suitable	O
for	O
incorporation	O
into	O
an	O
oral	O
mouthwash	O
.	O

To	O
evaluate	O
the	O
relationship	O
between	O
oral	O
bacteria	O
species	O
detection	O
and	O
volatile	O
sulphide	O
compounds	O
(	O
VSC	O
)	O
concentration	O
in	O
the	O
elderly	O
.	O

Cross	O
-	O
sectional	O
microbiological	O
and	O
clinical	O
VSC	O
examination	O
of	O
elderly	O
.	O

Sixty	O
-	O
seven	O
elderly	O
people	O
aged	O
75	O
,	O
who	O
were	O
functionally	O
independent	O
and	O
dentate	O
.	O

VSC	O
(	O
H2S	O
and	O
CH3SH	O
)	O
concentrations	O
in	O
the	O
mouth	O
air	O
of	O
subjects	O
were	O
measured	O
using	O
portable	O
gas	O
chromatography	O
.	O

Oral	O
bacteria	O
samples	O
were	O
taken	O
from	O
dental	O
plaque	O
and	O
identification	O
of	O
bacteria	O
species	O
was	O
accomplished	O
using	O
standard	O
methods	O
.	O

Fewer	O
than	O
20	O
%	O
of	O
subjects	O
showed	O
more	O
than	O
10	O
ng	O
/	O
10	O
ml	O
of	O
H2S	O
(	O
severe	O
odour	O
level	O
)	O
.	O

The	O
detection	O
rate	O
of	O
P	B-bacteria
.	I-bacteria
melaninogenica	I-bacteria
was	O
significantly	O
higher	O
in	O
elderly	O
people	O
with	O
more	O
than	O
10	O
ng	O
/	O
10	O
ml	O
(	O
p	O
=	O
0	O
.	O
043	O
)	O
levels	O
.	O

Fusobacterium	B-bacteria
had	O
a	O
tendency	O
to	O
be	O
found	O
in	O
those	O
with	O
more	O
than	O
10	O
ng	O
/	O
10	O
ml	O
,	O
but	O
a	O
significant	O
relation	O
was	O
not	O
found	O
.	O

The	O
results	O
suggest	O
that	O
Fusobacterium	B-bacteria
and	O
P	B-bacteria
.	I-bacteria
melaninogenica	I-bacteria
may	O
be	O
involved	O
in	O
the	O
production	O
of	O
H2S	O
in	O
the	O
oral	O
cavity	O
of	O
elderly	O
people	O
.	O

Microbial	O
communities	O
within	O
the	O
human	O
oral	O
cavity	O
are	O
dynamic	O
associations	O
of	O
more	O
than	O
500	O
bacterial	O
species	O
that	O
form	O
biofilms	O
on	O
the	O
soft	O
and	O
hard	O
tissues	O
of	O
the	O
mouth	O
.	O

Understanding	O
the	O
development	O
and	O
spatial	O
organization	O
of	O
oral	O
biofilms	O
has	O
been	O
facilitated	O
by	O
the	O
use	O
of	O
in	O
vitro	O
models	O
.	O

We	O
used	O
a	O
saliva	O
-	O
conditioned	O
flow	O
cell	O
,	O
with	O
saliva	O
as	O
the	O
sole	O
nutritional	O
source	O
,	O
as	O
a	O
model	O
to	O
examine	O
the	O
development	O
of	O
multispecies	O
biofilm	O
communities	O
from	O
an	O
inoculum	O
containing	O
the	O
coaggregation	O
partners	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
Veillonella	B-bacteria
atypica	I-bacteria
,	O
and	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
.	O

Biofilms	O
inoculated	O
with	O
individual	O
species	O
in	O
a	O
sequential	O
order	O
were	O
compared	O
with	O
biofilms	O
inoculated	O
with	O
coaggregates	O
of	O
the	O
four	O
species	O
.	O

Our	O
results	O
indicated	O
that	O
flow	O
cells	O
inoculated	O
sequentially	O
produced	O
biofilms	O
with	O
larger	O
biovolumes	O
compared	O
to	O
those	O
biofilms	O
inoculated	O
with	O
coaggregates	O
.	O

Individual	O
-	O
species	O
biovolumes	O
within	O
the	O
four	O
-	O
species	O
communities	O
also	O
differed	O
between	O
the	O
two	O
modes	O
of	O
inoculation	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
with	O
genus	O
-	O
and	O
species	O
-	O
specific	O
probes	O
revealed	O
that	O
the	O
majority	O
of	O
cells	O
in	O
both	O
sequentially	O
and	O
coaggregate	O
-	O
inoculated	O
biofilms	O
were	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
,	O
regardless	O
of	O
the	O
inoculation	O
order	O
.	O

However	O
,	O
the	O
representation	O
of	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
and	O
V	B-bacteria
.	I-bacteria
atypica	I-bacteria
was	O
significantly	O
higher	O
in	O
biofilms	O
inoculated	O
with	O
coaggregates	O
compared	O
to	O
sequentially	O
inoculated	O
biofilms	O
.	O

Thus	O
,	O
these	O
results	O
indicate	O
that	O
the	O
development	O
of	O
multispecies	O
biofilm	O
communities	O
is	O
influenced	O
by	O
coaggregations	O
preformed	O
in	O
planktonic	O
phase	O
.	O

Coaggregating	O
bacteria	O
such	O
as	O
certain	O
streptococci	B-bacteria
are	O
especially	O
adapted	O
to	O
primary	O
colonization	O
of	O
saliva	O
-	O
conditioned	O
surfaces	O
independent	O
of	O
the	O
mode	O
of	O
inoculation	O
and	O
order	O
of	O
addition	O
in	O
the	O
multispecies	O
inoculum	O
.	O

Preformed	O
coaggregations	O
favor	O
other	O
bacterial	O
strains	O
and	O
may	O
facilitate	O
symbiotic	O
relationships	O
.	O

To	O
isolate	O
bacteriophages	O
lytic	O
for	O
oral	O
pathogens	O
from	O
human	O
saliva	O
,	O
dental	O
plaque	O
and	O
mature	O
biofilms	O
constituted	O
from	O
saliva	O
-	O
derived	O
bacteria	O
.	O

Saliva	O
and	O
dental	O
plaque	O
samples	O
from	O
healthy	O
volunteers	O
and	O
from	O
patients	O
with	O
gingivitis	O
and	O
periodontitis	O
were	O
examined	O
for	O
the	O
presence	O
of	O
lytic	O
bacteriophages	O
using	O
a	O
panel	O
of	O
oral	O
pathogens	O
and	O
bacteria	O
isolated	O
from	O
the	O
samples	O
.	O

Samples	O
were	O
also	O
enriched	O
for	O
bacteriophage	O
using	O
static	O
culture	O
techniques	O
and	O
mature	O
biofilms	O
.	O

A	O
limited	O
number	O
of	O
samples	O
contained	O
bacteriophage	O
particles	O
that	O
were	O
visualized	O
using	O
electron	O
microscopy	O
.	O

Cultures	O
yielded	O
phage	O
infecting	O
non	O
-	O
oral	O
bacteria	O
(	O
Proteus	B-bacteria
mirabilis	I-bacteria
)	O
but	O
no	O
bacteriophage	O
specific	O
for	O
recognized	O
oral	O
pathogens	O
were	O
found	O
.	O

Some	O
micro	O
-	O
organisms	O
from	O
the	O
oral	O
microflora	O
elaborated	O
antibacterial	O
substances	O
that	O
inhibited	O
growth	O
of	O
other	O
residents	O
of	O
the	O
oral	O
cavity	O
.	O

Unlike	O
other	O
ecosystems	O
,	O
the	O
composition	O
of	O
the	O
oral	O
cavity	O
does	O
not	O
appear	O
to	O
be	O
heavily	O
influenced	O
by	O
interactions	O
between	O
bacteriophages	O
and	O
their	O
hosts	O
.	O

Bacteriophage	O
for	O
control	O
of	O
oral	O
infections	O
may	O
need	O
to	O
be	O
obtained	O
from	O
other	O
sources	O
.	O

Antibacterial	O
substances	O
derived	O
from	O
some	O
members	O
of	O
the	O
oral	O
microflora	O
warrant	O
investigation	O
as	O
potential	O
antibiotics	O
.	O

Mercury	O
-	O
resistant	O
bacteria	O
isolated	O
from	O
the	O
oral	O
cavities	O
of	O
children	O
carried	O
one	O
of	O
two	O
types	O
of	O
merA	O
gene	O
that	O
appear	O
to	O
have	O
evolved	O
from	O
a	O
common	O
ancestor	O
.	O

Streptococcus	B-bacteria
oralis	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
and	O
a	O
few	O
other	O
species	O
had	O
merA	O
genes	O
that	O
were	O
very	O
similar	O
to	O
merA	O
of	O
Bacillus	B-bacteria
cereus	I-bacteria
strain	I-bacteria
RC607	I-bacteria
.	O

Unlike	O
the	O
B	B-bacteria
.	I-bacteria
cereus	I-bacteria
RC607	I-bacteria
merA	O
gene	O
,	O
however	O
,	O
the	O
streptococcal	O
merA	O
genes	O
were	O
not	O
carried	O
on	O
Tn5084	O
-	O
like	O
transposons	O
.	O

Instead	O
,	O
comparisons	O
with	O
microbial	O
genomic	O
sequences	O
suggest	O
the	O
merA	O
gene	O
is	O
located	O
on	O
a	O
novel	O
type	O
II	O
transposon	O
.	O

Coagulase	B-bacteria
-	I-bacteria
negative	I-bacteria
staphylococci	B-bacteria
and	O
Streptococcus	B-bacteria
parasanguis	I-bacteria
had	O
identical	O
merA	O
genes	O
that	O
represent	O
a	O
new	O
merA	O
variant	O
.	O

The	O
alanine	O
-	O
rich	O
repeating	O
region	O
(	O
A	O
-	O
region	O
)	O
in	O
the	O
surface	O
protein	O
antigen	O
(	O
PAc	O
)	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
has	O
received	O
much	O
attention	O
as	O
an	O
antigenic	O
component	O
for	O
vaccines	O
against	O
dental	O
caries	O
.	O

The	O
PAc	O
(	O
residue	O
361	O
-	O
386	O
)	O
peptide	O
in	O
the	O
A	O
-	O
region	O
possesses	O
a	O
multiple	O
binding	O
motif	O
(	O
L	O
-	O
-	O
V	O
-	O
K	O
-	O
-	O
A	O
)	O
to	O
various	O
HLA	O
-	O
DR	O
molecules	O
and	O
a	O
B	O
-	O
cell	O
core	O
epitope	O
(	O
-	O
Y	O
-	O
-	O
-	O
L	O
-	O
-	O
Y	O
-	O
-	O
-	O
-	O
)	O
that	O
recognizes	O
the	O
inhibiting	O
antibody	O
to	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
PAc	O
(	O
361	O
-	O
386	O
)	O
peptide	O
in	O
humans	O
and	O
regulators	O
of	O
induction	O
of	O
the	O
anti	O
-	O
PAc	O
(	O
361	O
-	O
386	O
)	O
peptide	O
IgA	O
antibody	O
(	O
aPPA	O
)	O
in	O
saliva	O
.	O

The	O
PAc	O
(	O
361	O
-	O
386	O
)	O
peptide	O
was	O
confirmed	O
as	O
an	O
ideal	O
peptide	O
antigen	O
for	O
induction	O
of	O
the	O
inhibiting	O
antibody	O
to	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
in	O
151	O
healthy	O
human	O
subjects	O
(	O
36	O
.	O
6	O
+	O
/	O
-	O
12	O
.	O
6	O
years	O
old	O
)	O
by	O
quantitative	O
analyses	O
of	O
oral	O
bacteria	O
and	O
ELISA	O
,	O
as	O
the	O
aPPA	O
titre	O
in	O
human	O
saliva	O
decreased	O
significantly	O
in	O
an	O
age	O
-	O
dependent	O
manner	O
.	O

Homozygous	O
DRB1	O
*	O
0405	O
and	O
1502	O
,	O
and	O
heterozygous	O
DRB1	O
*	O
0405	O
/	O
1502	O
showed	O
a	O
negative	O
association	O
with	O
production	O
of	O
aPPA	O
and	O
tended	O
to	O
reduce	O
the	O
number	O
of	O
total	O
streptococci	B-bacteria
in	O
saliva	O
.	O

In	O
contrast	O
,	O
the	O
DRB1	O
*	O
1501	O
allele	O
was	O
significantly	O
correlated	O
with	O
a	O
high	O
level	O
of	O
induction	O
of	O
the	O
antibodies	O
,	O
and	O
also	O
tended	O
to	O
reduce	O
lactobacilli	B-bacteria
and	O
mutans	B-bacteria
streptococci	I-bacteria
.	O

Further	O
,	O
peptide	O
immunogenicity	O
was	O
confirmed	O
in	O
NOD	O
-	O
SCID	O
mice	O
grafted	O
with	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
interplay	O
between	O
regulators	O
such	O
as	O
age	O
,	O
DRB1	O
genotype	O
,	O
cytokines	O
,	O
and	O
peptide	O
immunogenicity	O
may	O
provide	O
a	O
potential	O
means	O
for	O
developing	O
a	O
vaccine	O
useful	O
for	O
the	O
prevention	O
of	O
dental	O
caries	O
as	O
well	O
as	O
their	O
diagnosis	O
.	O

Oral	O
streptococci	B-bacteria
play	O
a	O
large	O
role	O
in	O
dental	O
biofilm	O
formation	O
,	O
and	O
several	O
types	O
interact	O
as	O
early	O
colonizers	O
with	O
the	O
enamel	O
salivary	O
pellicle	O
to	O
form	O
the	O
primary	O
biofilm	O
,	O
as	O
well	O
as	O
to	O
incorporate	O
other	O
bacteria	O
on	O
tooth	O
surfaces	O
.	O

Interactions	O
of	O
surface	O
molecules	O
of	O
individual	O
streptococci	B-bacteria
with	O
the	O
salivary	O
pellicle	O
on	O
the	O
tooth	O
surface	O
have	O
an	O
influence	O
on	O
the	O
etiological	O
properties	O
of	O
an	O
oral	O
biofilm	O
.	O

To	O
elucidate	O
the	O
molecular	O
interactions	O
of	O
streptococci	B-bacteria
with	O
salivary	O
components	O
,	O
binding	O
between	O
surface	O
protein	O
(	O
SspB	O
and	O
PAg	O
)	O
peptides	O
of	O
Streptococcus	B-bacteria
gordonii	I-bacteria
and	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
were	O
investigated	O
by	O
utilizing	O
BIAcore	O
biosensor	O
technology	O
.	O

The	O
analogous	O
peptide	O
[	O
change	O
of	O
T	O
at	O
position	O
400	O
to	O
K	O
in	O
SspB	O
(	O
390	O
-	O
402	O
)	O
,	O
resulting	O
in	O
the	O
SspB	O
(	O
390	O
-	O
T400K	O
-	O
402	O
)	O
peptide	O
]	O
from	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
showed	O
the	O
greatest	O
response	O
for	O
binding	O
to	O
salivary	O
components	O
and	O
inhibited	O
the	O
binding	O
of	O
Streptococcus	B-bacteria
sanguis	I-bacteria
by	O
more	O
than	O
50	O
%	O
in	O
a	O
competitive	O
inhibition	O
assay	O
in	O
a	O
comparison	O
with	O
other	O
SspB	O
and	O
PAg	O
peptides	O
.	O

This	O
peptide	O
also	O
bound	O
to	O
the	O
high	O
-	O
molecular	O
-	O
weight	O
protein	O
complex	O
of	O
salivary	O
components	O
and	O
the	O
agglutinin	O
(	O
gp340	O
/	O
DMBT1	O
)	O
peptide	O
(	O
scavenger	O
receptor	O
cysteine	O
-	O
rich	O
domain	O
peptide	O
2	O
[	O
SRCRP	O
2	O
]	O
)	O
.	O

In	O
addition	O
,	O
the	O
SspB	O
(	O
390	O
-	O
T400K	O
-	O
402	O
)	O
peptide	O
was	O
visualized	O
by	O
two	O
surface	O
positive	O
charges	O
in	O
connection	O
with	O
the	O
positively	O
charged	O
residues	O
,	O
in	O
which	O
lysine	O
was	O
a	O
key	O
residue	O
for	O
binding	O
.	O

Therefore	O
,	O
the	O
region	O
containing	O
lysine	O
may	O
have	O
binding	O
activity	O
in	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
,	O
and	O
the	O
SRCRP	O
2	O
region	O
may	O
function	O
as	O
a	O
receptor	O
for	O
the	O
binding	O
.	O

These	O
findings	O
may	O
provide	O
useful	O
information	O
regarding	O
the	O
molecular	O
mechanism	O
of	O
early	O
biofilm	O
formation	O
by	O
streptococci	B-bacteria
on	O
tooth	O
surfaces	O
.	O

Dental	O
plaque	O
samples	O
from	O
40	O
children	O
were	O
screened	O
for	O
the	O
presence	O
of	O
bacteria	O
resistant	O
to	O
amoxicillin	O
.	O

Fifteen	O
children	O
had	O
used	O
amoxicillin	O
and	O
25	O
had	O
not	O
used	O
any	O
antibiotic	O
in	O
the	O
3	O
months	O
prior	O
to	O
sample	O
collection	O
.	O

All	O
(	O
100	O
%	O
)	O
of	O
the	O
children	O
harbored	O
amoxicillin	O
-	O
resistant	O
oral	O
bacteria	O
.	O

The	O
median	O
percentage	O
of	O
the	O
total	O
cultivable	O
oral	O
microbiota	O
resistant	O
to	O
amoxicillin	O
was	O
2	O
.	O
4	O
%	O
(	O
range	O
,	O
0	O
.	O
1	O
to	O
14	O
.	O
3	O
%	O
)	O
in	O
children	O
without	O
amoxicillin	O
use	O
and	O
10	O
.	O
9	O
%	O
(	O
range	O
,	O
0	O
.	O
8	O
to	O
97	O
.	O
3	O
%	O
)	O
in	O
children	O
with	O
amoxicillin	O
use	O
,	O
with	O
the	O
latter	O
value	O
being	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
total	O
of	O
224	O
amoxicillin	O
-	O
resistant	O
bacteria	O
were	O
isolated	O
and	O
comprised	O
three	O
main	O
genera	O
:	O
Haemophilus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Streptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
and	O
Veillonella	B-bacteria
spp	I-bacteria
.	O

The	O
biodiversity	O
of	O
the	O
amoxicillin	O
-	O
resistant	O
microbiota	O
was	O
similar	O
among	O
the	O
isolates	O
from	O
children	O
with	O
and	O
without	O
previous	O
antibiotic	O
use	O
.	O

The	O
amoxicillin	O
MIC	O
at	O
which	O
90	O
%	O
of	O
the	O
isolates	O
were	O
inhibited	O
for	O
isolates	O
from	O
children	O
who	O
had	O
used	O
amoxicillin	O
in	O
the	O
previous	O
3	O
months	O
was	O
higher	O
(	O
64	O
mg	O
liter	O
(	O
-	O
1	O
)	O
)	O
than	O
that	O
obtained	O
for	O
the	O
isolates	O
from	O
subjects	O
who	O
had	O
not	O
used	O
antibiotics	O
(	O
16	O
mg	O
liter	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
majority	O
of	O
the	O
amoxicillin	O
-	O
resistant	O
isolates	O
(	O
65	O
%	O
)	O
were	O
also	O
resistant	O
to	O
at	O
least	O
one	O
of	O
the	O
three	O
antibiotics	O
tested	O
(	O
penicillin	O
,	O
erythromycin	O
,	O
and	O
tetracycline	O
)	O
,	O
with	O
resistance	O
to	O
penicillin	O
(	O
51	O
%	O
of	O
isolates	O
)	O
being	O
the	O
most	O
frequently	O
encountered	O
.	O

However	O
,	O
significantly	O
more	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
of	O
the	O
amoxicillin	O
-	O
resistant	O
isolates	O
from	O
subjects	O
with	O
previous	O
amoxicillin	O
use	O
were	O
also	O
resistant	O
to	O
erythromycin	O
.	O

This	O
study	O
has	O
demonstrated	O
that	O
a	O
diverse	O
collection	O
of	O
amoxicillin	O
-	O
resistant	O
bacteria	O
is	O
present	O
in	O
the	O
oral	O
cavity	O
and	O
that	O
the	O
number	O
,	O
proportions	O
,	O
MICs	O
,	O
and	O
resistance	O
to	O
erythromycin	O
can	O
significantly	O
increase	O
with	O
amoxicillin	O
use	O
.	O

Motile	O
bacteria	O
often	O
use	O
sophisticated	O
chemotaxis	O
signaling	O
systems	O
to	O
direct	O
their	O
movements	O
.	O

In	O
general	O
,	O
bacterial	O
chemotactic	O
signal	O
transduction	O
pathways	O
have	O
three	O
basic	O
elements	O
:	O
(	O
1	O
)	O
signal	O
reception	O
by	O
bacterial	O
chemoreceptors	O
located	O
on	O
the	O
membrane	O
;	O
(	O
2	O
)	O
signal	O
transduction	O
to	O
relay	O
the	O
signals	O
from	O
membrane	O
receptors	O
to	O
the	O
motor	O
;	O
and	O
(	O
3	O
)	O
signal	O
adaptation	O
to	O
desensitize	O
the	O
initial	O
signal	O
input	O
.	O

The	O
chemotaxis	O
proteins	O
involved	O
in	O
these	O
signal	O
transduction	O
pathways	O
have	O
been	O
identified	O
and	O
extensively	O
studied	O
,	O
especially	O
in	O
the	O
enterobacteria	B-bacteria
Escherichia	B-bacteria
coli	I-bacteria
and	O
Salmonella	B-bacteria
enterica	I-bacteria
serovar	I-bacteria
typhimurium	I-bacteria
.	O

Chemotaxis	O
-	O
guided	O
bacterial	O
movements	O
enable	O
bacteria	O
to	O
adapt	O
better	O
to	O
their	O
natural	O
habitats	O
via	O
moving	O
toward	O
favorable	O
conditions	O
and	O
away	O
from	O
hostile	O
surroundings	O
.	O

A	O
variety	O
of	O
oral	O
microbes	O
exhibits	O
motility	O
and	O
chemotaxis	O
,	O
behaviors	O
that	O
may	O
play	O
important	O
roles	O
in	O
bacterial	O
survival	O
and	O
pathogenesis	O
in	O
the	O
oral	O
cavity	O
.	O

The	O
innate	O
immune	O
response	O
is	O
of	O
pivotal	O
importance	O
in	O
defending	O
the	O
mucosal	O
barriers	O
of	O
the	O
body	O
against	O
pathogenic	O
attack	O
.	O

The	O
list	O
of	O
proteins	O
that	O
contribute	O
to	O
this	O
defense	O
mechanism	O
is	O
constantly	O
being	O
updated	O
.	O

In	O
this	O
review	O
we	O
introduce	O
a	O
novel	O
family	O
of	O
secreted	O
proteins	O
,	O
palate	O
,	O
lung	O
,	O
and	O
nasal	O
epithelium	O
clones	O
(	O
PLUNCs	O
)	O
,	O
that	O
are	O
expressed	O
in	O
the	O
mouth	O
,	O
nose	O
and	O
upper	O
airways	O
of	O
humans	O
,	O
mice	O
,	O
rats	O
and	O
cows	O
.	O

In	O
humans	O
,	O
PLUNC	O
genes	O
are	O
located	O
in	O
a	O
compact	O
cluster	O
on	O
chromosome	O
20	O
,	O
with	O
similar	O
loci	O
being	O
found	O
in	O
synteneic	O
locations	O
in	O
other	O
species	O
.	O

The	O
protein	O
products	O
of	O
this	O
gene	O
cluster	O
are	O
predicted	O
to	O
be	O
structural	O
homologues	O
of	O
the	O
human	O
lipopolysaccharide	O
binding	O
proteins	O
,	O
lipopolysaccharide	O
binding	O
-	O
protein	O
(	O
LBP	O
)	O
and	O
bacterial	O
permeability	O
-	O
increasing	O
protein	O
(	O
BPI	O
)	O
,	O
which	O
are	O
known	O
mediators	O
of	O
host	O
defense	O
against	O
Gram	O
-	O
negative	O
bacteria	O
.	O

On	O
the	O
basis	O
of	O
these	O
observations	O
we	O
outline	O
why	O
we	O
believe	O
PLUNC	O
proteins	O
mediate	O
host	O
defense	O
functions	O
in	O
the	O
oral	O
,	O
nasal	O
and	O
respiratory	O
epithelia	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
relationship	O
between	O
oral	O
bacterial	O
colonization	O
and	O
oral	O
motor	O
dysfunction	O
.	O

Oral	O
motor	O
dysfunction	O
(	O
swallowing	O
and	O
speech	O
disorders	O
)	O
and	O
detection	O
of	O
oral	O
bacterial	O
species	O
from	O
dental	O
plaque	O
in	O
55	O
elderly	O
persons	O
who	O
had	O
remained	O
hospitalized	O
for	O
more	O
than	O
3	O
months	O
were	O
investigated	O
and	O
statistically	O
analyzed	O
.	O

The	O
detection	O
rates	O
of	O
methicillin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Staphylococcus	I-bacteria
aureus	I-bacteria
(	O
MRSA	B-bacteria
)	O
,	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
,	O
Streptococcus	B-bacteria
agalactiae	I-bacteria
,	O
and	O
Stenotrophomonas	B-bacteria
maltophilia	I-bacteria
were	O
significantly	O
higher	O
in	O
subjects	O
with	O
than	O
in	O
those	O
without	O
a	O
swallowing	O
disorder	O
.	O

A	O
similar	O
result	O
was	O
found	O
with	O
regard	O
to	O
the	O
presence	O
of	O
a	O
speech	O
disorder	O
.	O

About	O
half	O
of	O
subjects	O
who	O
had	O
oral	O
motor	O
dysfunction	O
and	O
hypoalbuminemia	O
had	O
colonization	O
by	O
MRSA	B-bacteria
and	O
/	O
or	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
.	O

These	O
results	O
suggest	O
that	O
the	O
combination	O
of	O
oral	O
motor	O
dysfunction	O
and	O
hypoalbminemia	O
elevated	O
the	O
risk	O
of	O
opportunistic	O
microorganisms	O
colonization	O
in	O
the	O
oral	O
cavity	O
of	O
elderly	O
patients	O
hospitalized	O
over	O
the	O
long	O
term	O
.	O

Clinical	O
studies	O
have	O
demonstrated	O
the	O
considerable	O
effects	O
of	O
chlorhexidine	O
on	O
dental	O
plaque	O
and	O
oral	O
microbiota	O
as	O
well	O
as	O
improvements	O
in	O
indices	O
of	O
oral	O
health	O
.	O

This	O
investigation	O
examined	O
the	O
efficacy	O
of	O
lower	O
concentrations	O
of	O
chlorhexidine	O
.	O

Mouthrinses	O
with	O
0	O
.	O
03	O
%	O
,	O
0	O
.	O
06	O
%	O
,	O
0	O
.	O
12	O
%	O
chlorhexidine	O
and	O
a	O
control	O
rinse	O
without	O
chlorhexidine	O
were	O
examined	O
.	O

Alamar	O
blue	O
,	O
an	O
oxidation	O
-	O
reduction	O
dye	O
with	O
fluorescent	O
end	O
-	O
points	O
proportional	O
to	O
bacterial	O
viability	O
,	O
was	O
used	O
to	O
determine	O
bacterial	O
viability	O
.	O

Further	O
clinical	O
studies	O
examined	O
the	O
effects	O
of	O
these	O
rinses	O
on	O
salivary	O
bacteria	O
and	O
on	O
bacteria	O
producing	O
hydrogen	O
sulfide	O
(	O
H	O
(	O
2	O
)	O
S	O
)	O
and	O
implicated	O
in	O
halitosis	O
.	O

In	O
laboratory	O
tests	O
,	O
a	O
significant	O
dose	O
-	O
dependent	O
effect	O
was	O
observed	O
with	O
Actinomyces	B-bacteria
viscosus	I-bacteria
as	O
a	O
model	O
system	O
using	O
the	O
Alamar	O
blue	O
procedure	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Clinical	O
studies	O
examined	O
the	O
effects	O
1	O
.	O
5	O
h	O
and	O
3	O
h	O
post	O
-	O
treatment	O
on	O
salivary	O
bacteria	O
and	O
bacteria	O
producing	O
H	O
(	O
2	O
)	O
S	O
.	O

The	O
first	O
study	O
compared	O
the	O
control	O
rinse	O
with	O
the	O
0	O
.	O
03	O
%	O
and	O
0	O
.	O
06	O
%	O
chlorhexidine	O
rinses	O
;	O
a	O
second	O
study	O
compared	O
the	O
effects	O
of	O
the	O
control	O
rinse	O
and	O
the	O
0	O
.	O
06	O
%	O
and	O
0	O
.	O
12	O
%	O
chlorhexidine	O
mouthrinses	O
.	O

In	O
both	O
studies	O
,	O
chlorhexidine	O
rinses	O
demonstrated	O
significant	O
dose	O
-	O
dependent	O
effects	O
post	O
-	O
treatment	O
on	O
salivary	O
bacteria	O
vs	O
.	O
the	O
control	O
rinse	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Significant	O
decreases	O
in	O
H	O
(	O
2	O
)	O
S	O
-	O
producing	O
bacteria	O
were	O
noted	O
with	O
these	O
chlorhexidine	O
rinses	O
vs	O
.	O
the	O
control	O
rinse	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
results	O
highlight	O
the	O
dose	O
-	O
dependent	O
relationships	O
noted	O
in	O
laboratory	O
and	O
clinical	O
tests	O
which	O
have	O
potential	O
implications	O
for	O
the	O
use	O
of	O
lower	O
doses	O
of	O
chlorhexidine	O
to	O
inhibit	O
oral	O
bacteria	O
,	O
including	O
those	O
implicated	O
in	O
halitosis	O
.	O

Four	O
oral	O
bacterial	O
strains	O
,	O
of	O
which	O
two	O
are	O
considered	O
aciduric	O
and	O
two	O
are	O
considered	O
acid	O
-	O
sensitive	O
,	O
were	O
grown	O
under	O
glucose	O
-	O
limiting	O
conditions	O
in	O
chemostats	O
to	O
determine	O
whether	O
their	O
membrane	O
fatty	O
acid	O
profiles	O
were	O
altered	O
in	O
response	O
to	O
environmental	O
acidification	O
.	O

Streptococcus	B-bacteria
gordonii	I-bacteria
DL1	I-bacteria
,	O
as	O
well	O
as	O
the	O
aciduric	O
strains	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
57	I-bacteria
.	I-bacteria
I	I-bacteria
,	O
and	O
Lactobacillus	B-bacteria
casei	I-bacteria
4646	I-bacteria
increased	O
the	O
levels	O
of	O
mono	O
-	O
unsaturated	O
membrane	O
fatty	O
acids	O
.	O

The	O
non	O
-	O
aciduric	O
strain	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
10904	I-bacteria
did	O
not	O
alter	O
its	O
membrane	O
composition	O
in	O
response	O
to	O
pH	O
values	O
examined	O
here	O
.	O

Thus	O
,	O
in	O
response	O
to	O
low	O
pH	O
,	O
aciduric	O
oral	O
bacteria	O
alter	O
their	O
membrane	O
composition	O
to	O
contain	O
increased	O
levels	O
of	O
long	O
-	O
chained	O
,	O
mono	O
-	O
unsaturated	O
fatty	O
acids	O
.	O

This	O
suggests	O
that	O
membrane	O
fatty	O
acid	O
adaptation	O
is	O
a	O
common	O
mechanism	O
utilized	O
by	O
bacteria	O
to	O
withstand	O
environmental	O
stress	O
.	O

Fourteen	O
strains	O
of	O
Gram	O
-	O
negative	O
,	O
anaerobic	O
,	O
fluoroquinolone	O
-	O
resistant	O
,	O
non	O
-	O
sporulating	O
rods	O
were	O
isolated	O
from	O
various	O
infections	O
in	O
cats	O
and	O
dogs	O
,	O
as	O
well	O
as	O
from	O
wounds	O
in	O
humans	O
after	O
cat	O
-	O
or	O
dog	O
-	O
bites	O
.	O

These	O
strains	O
were	O
characterized	O
by	O
sequencing	O
of	O
the	O
16S	O
-	O
23S	O
rDNA	O
internal	O
transcribed	O
spacer	O
(	O
ITS	O
)	O
regions	O
,	O
16S	O
rDNA	O
,	O
DNA	O
-	O
DNA	O
hybridization	O
,	O
phylogenetic	O
analysis	O
,	O
and	O
phenotypic	O
tests	O
.	O

The	O
results	O
indicate	O
that	O
the	O
novel	O
strains	O
belong	O
to	O
a	O
distinct	O
species	O
,	O
closely	O
related	O
to	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
.	O

The	O
species	O
Fusobacterium	B-bacteria
canifelinum	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
is	O
proposed	O
,	O
with	O
strain	O
ATCC	B-bacteria
BAA	I-bacteria
689T	I-bacteria
as	O
the	O
type	O
strain	O
.	O

The	O
control	O
of	O
oral	O
malodor	O
is	O
well	O
-	O
recognized	O
in	O
efforts	O
to	O
improve	O
oral	O
health	O
.	O

Antimicrobial	O
formulations	O
can	O
mitigate	O
oral	O
malodor	O
,	O
however	O
,	O
procedures	O
to	O
assess	O
effects	O
on	O
oral	O
bacteria	O
including	O
those	O
implicated	O
in	O
halitosis	O
are	O
unavailable	O
.	O

This	O
investigation	O
examined	O
the	O
antimicrobial	O
effects	O
of	O
a	O
new	O
liquid	O
triclosan	O
/	O
copolymer	O
dentifrice	O
(	O
test	O
)	O
formulation	O
that	O
demonstrated	O
significant	O
inhibition	O
of	O
oral	O
malodor	O
in	O
previous	O
organoleptic	O
clinical	O
studies	O
.	O

Procedures	O
compared	O
antimicrobial	O
effects	O
of	O
the	O
test	O
and	O
control	O
formulations	O
on	O
a	O
range	O
of	O
oral	O
micro	O
-	O
organisms	O
including	O
members	O
implicated	O
in	O
halitosis	O
,	O
substantive	O
antimicrobial	O
effects	O
of	O
formulations	O
with	O
hydroxyapatite	O
as	O
a	O
surrogate	O
for	O
human	O
teeth	O
and	O
ex	O
vivo	O
effects	O
on	O
oral	O
bacteria	O
from	O
human	O
volunteers	O
.	O

With	O
Actinomyces	B-bacteria
viscosus	I-bacteria
,	O
as	O
a	O
model	O
system	O
,	O
the	O
test	O
formulation	O
demonstrated	O
a	O
dose	O
-	O
dependent	O
effect	O
.	O

At	O
these	O
concentrations	O
the	O
test	O
formulation	O
provided	O
significant	O
antimicrobial	O
effects	O
on	O
13	O
strains	O
of	O
oral	O
bacteria	O
including	O
those	O
implicated	O
in	O
bad	O
breath	O
at	O
selected	O
posttreatment	O
time	O
points	O
.	O

Treatment	O
of	O
hydroxyapatite	O
by	O
the	O
test	O
dentifrice	O
resulted	O
in	O
a	O
significant	O
and	O
substantive	O
antimicrobial	O
effect	O
vs	O
.	O
controls	O
.	O

Oral	O
bacteria	O
from	O
subjects	O
treated	O
ex	O
vivo	O
with	O
the	O
test	O
dentifrice	O
resulted	O
in	O
significant	O
reductions	O
in	O
cultivable	O
oral	O
bacteria	O
and	O
odorigenic	O
bacteria	O
producing	O
hydrogen	O
sulfide	O
.	O

In	O
summary	O
,	O
microbiological	O
methods	O
adapted	O
to	O
study	O
odorigenic	O
bacteria	O
demonstrate	O
the	O
significant	O
antimicrobial	O
effects	O
of	O
the	O
test	O
(	O
triclosan	O
/	O
copolymer	O
)	O
dentifrice	O
with	O
laboratory	O
and	O
clinical	O
strains	O
of	O
oral	O
bacteria	O
implicated	O
in	O
bad	O
breath	O
.	O

A	O
range	O
of	O
opportunistic	O
pathogens	O
have	O
been	O
associated	O
with	O
dental	O
unit	O
water	O
systems	O
(	O
DUWS	O
)	O
,	O
particularly	O
in	O
the	O
biofilms	O
that	O
can	O
line	O
the	O
tubing	O
.	O

This	O
study	O
therefore	O
aimed	O
to	O
assess	O
the	O
microbiology	O
of	O
DUWS	O
and	O
biofilms	O
in	O
general	O
dental	O
practices	O
across	O
seven	O
European	O
countries	O
,	O
including	O
the	O
United	O
Kingdom	O
(	O
UK	O
)	O
,	O
Ireland	O
(	O
IRL	O
)	O
,	O
Greece	O
(	O
GR	O
)	O
,	O
Spain	O
(	O
ES	O
)	O
,	O
Germany	O
(	O
D	O
)	O
,	O
Denmark	O
(	O
DK	O
)	O
and	O
the	O
Netherlands	O
(	O
NL	O
)	O
.	O

Water	O
supplied	O
by	O
51	O
%	O
of	O
237	O
dental	O
unit	O
water	O
lines	O
exceeded	O
current	O
American	O
Dental	O
Association	O
recommendations	O
of	O
<	O
or	O
=	O
200	O
colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
ml	O
(	O
-	O
1	O
)	O
.	O

Microbiological	O
loading	O
of	O
the	O
source	O
waters	O
was	O
between	O
0	O
(	O
Denmark	O
,	O
the	O
Netherlands	O
and	O
Spain	O
)	O
and	O
4	O
.	O
67	O
(	O
IRL	O
)	O
log	O
CFU	O
ml	O
(	O
-	O
1	O
)	O
;	O
water	O
line	O
samples	O
from	O
the	O
DUWS	O
ranged	O
from	O
1	O
.	O
52	O
(	O
ES	O
)	O
to	O
2	O
.	O
79	O
(	O
GR	O
)	O
log	O
CFU	O
ml	O
(	O
-	O
1	O
)	O
;	O
and	O
biofilm	O
counts	O
ranged	O
from	O
1	O
.	O
49	O
(	O
GR	O
)	O
to	O
3	O
.	O
22	O
(	O
DK	O
)	O
log	O
CFU	O
.	O
cm	O
(	O
-	O
2	O
)	O
.	O

Opportunistic	O
pathogens	O
such	O
as	O
legionellae	O
(	O
DK	O
and	O
ES	O
)	O
,	O
including	O
Legionella	B-bacteria
pneumophila	I-bacteria
SG1	I-bacteria
(	O
DK	O
and	O
GR	O
)	O
,	O
and	O
Mycobacterium	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
DK	O
,	O
NL	O
,	O
GR	O
,	O
D	O
and	O
ES	O
)	O
were	O
recovered	O
occasionally	O
.	O

Presumptive	O
oral	O
streptococci	B-bacteria
(	O
ES	O
and	O
NL	O
)	O
,	O
oral	O
anaerobes	O
(	O
GR	O
)	O
,	O
Candida	O
spp	O
.	O
(	O
UK	O
,	O
NL	O
and	O
ES	O
)	O
and	O
blood	O
(	O
GR	O
and	O
IRL	O
)	O
were	O
detected	O
at	O
relatively	O
low	O
frequencies	O
,	O
but	O
their	O
presence	O
indicated	O
a	O
failure	O
of	O
the	O
3	O
-	O
in	O
-	O
1	O
antiretraction	O
valve	O
,	O
leading	O
to	O
back	O
siphonage	O
of	O
oral	O
fluids	O
into	O
the	O
water	O
and	O
biofilm	O
phase	O
.	O

These	O
findings	O
confirm	O
that	O
a	O
substantial	O
proportion	O
of	O
DUWS	O
have	O
high	O
levels	O
of	O
microbial	O
contamination	O
,	O
irrespective	O
of	O
country	O
,	O
type	O
of	O
equipment	O
and	O
source	O
water	O
.	O

The	O
study	O
emphasizes	O
the	O
need	O
for	O
effective	O
mechanisms	O
to	O
reduce	O
the	O
microbial	O
burden	O
within	O
DUWS	O
,	O
and	O
highlights	O
the	O
risk	O
of	O
occupational	O
exposure	O
and	O
cross	O
-	O
infection	O
in	O
general	O
dental	O
practice	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
oral	O
epithelial	O
cells	O
via	O
two	O
cytokines	O
(	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
alpha	O
)	O
and	O
one	O
chemokine	O
(	O
IL	O
-	O
8	O
)	O
in	O
local	O
defences	O
against	O
live	O
yeast	O
(	O
Candida	O
albicans	O
)	O
and	O
bacteria	O
(	O
Streptococcus	B-bacteria
salivarius	I-bacteria
)	O
using	O
an	O
engineered	O
human	O
oral	O
mucosa	O
model	O
.	O

We	O
report	O
that	O
the	O
yeast	O
changed	O
from	O
the	O
blastospore	O
to	O
the	O
hyphal	O
form	O
and	O
induced	O
significant	O
tissue	O
disorganization	O
at	O
later	O
contact	O
periods	O
(	O
24	O
and	O
48	O
h	O
)	O
compared	O
to	O
the	O
bacteria	O
.	O

However	O
,	O
this	O
effect	O
did	O
not	O
reduce	O
the	O
viability	O
or	O
total	O
number	O
of	O
epithelial	O
cells	O
.	O

Gene	O
activation	O
analyses	O
revealed	O
that	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
and	O
TNF	O
-	O
alpha	O
mRNA	O
levels	O
rose	O
in	O
tissues	O
in	O
contact	O
with	O
live	O
C	O
.	O
albicans	O
or	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
.	O

Gene	O
activation	O
was	O
followed	O
by	O
an	O
upregulation	O
of	O
protein	O
secretion	O
.	O

IL	O
-	O
6	O
levels	O
were	O
higher	O
after	O
contact	O
with	O
C	O
.	O
albicans	O
than	O
with	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
.	O

IL	O
-	O
8	O
levels	O
after	O
contact	O
with	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
were	O
higher	O
than	O
with	O
C	O
.	O
albicans	O
.	O

Our	O
study	O
suggests	O
that	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
is	O
more	O
efficient	O
at	O
inducing	O
proinflammatory	O
mediator	O
release	O
than	O
C	O
.	O
albicans	O
.	O

These	O
results	O
provide	O
additional	O
evidence	O
for	O
the	O
contribution	O
of	O
oral	O
epithelial	O
cells	O
to	O
the	O
inflammatory	O
response	O
against	O
fungi	O
and	O
bacteria	O
.	O

Controversy	O
exists	O
concerning	O
the	O
association	O
between	O
oral	O
bacteria	O
and	O
infection	O
of	O
hemodialysis	O
(	O
HD	O
)	O
shunts	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
extent	O
to	O
which	O
oral	O
bacteria	O
are	O
associated	O
with	O
vascular	O
access	O
site	O
infections	O
in	O
a	O
group	O
of	O
HD	O
patients	O
.	O

STUDY	O
Microbial	O
blood	O
culture	O
data	O
for	O
87	O
HD	O
patients	O
were	O
collected	O
:	O
53	O
via	O
chart	O
review	O
(	O
retrospective	O
)	O
,	O
and	O
34	O
with	O
newly	O
suspected	O
vascular	O
access	O
infections	O
(	O
prospective	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
nature	O
(	O
i	O
.	O
e	O
.	O
,	O
species	O
)	O
of	O
the	O
bacteria	O
recovered	O
from	O
blood	O
cultures	O
of	O
subjects	O
with	O
vascular	O
access	O
infection	O
,	O
specifically	O
those	O
bacteria	O
considered	O
to	O
be	O
oral	O
flora	O
.	O

The	O
predominant	O
bacteria	O
reported	O
to	O
cause	O
HD	O
vascular	O
access	O
infections	O
were	O
Staphylococcus	B-bacteria
(	O
48	O
.	O
6	O
%	O
)	O
and	O
Enterococcus	B-bacteria
(	O
17	O
.	O
6	O
%	O
)	O
species	O
.	O

Most	O
infections	O
occurred	O
in	O
hemodialysis	O
catheters	O
(	O
89	O
%	O
)	O
compared	O
with	O
AV	O
grafts	O
(	O
11	O
%	O
)	O
and	O
AV	O
fistulas	O
(	O
0	O
%	O
)	O
.	O

The	O
subclavian	O
venous	O
access	O
(	O
41	O
%	O
)	O
and	O
the	O
internal	O
jugular	O
venous	O
access	O
(	O
38	O
.	O
9	O
%	O
)	O
were	O
more	O
commonly	O
infected	O
than	O
other	O
sites	O
.	O

None	O
of	O
the	O
bacteria	O
identified	O
by	O
blood	O
cultures	O
were	O
considered	O
to	O
be	O
oral	O
flora	O
.	O

The	O
results	O
suggest	O
that	O
oral	O
bacteria	O
rarely	O
,	O
if	O
ever	O
,	O
cause	O
vascular	O
access	O
infections	O
in	O
hemodialysis	O
patients	O
.	O

It	O
is	O
not	O
well	O
known	O
how	O
periodontopathic	O
bacteria	O
colonize	O
in	O
the	O
oral	O
cavity	O
during	O
childhood	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
distribution	O
of	O
periodontopathic	O
bacteria	O
in	O
oral	O
cavities	O
of	O
children	O
and	O
their	O
parents	O
and	O
the	O
relationship	O
between	O
the	O
bacterial	O
findings	O
and	O
clinical	O
parameters	O
.	O

Fifty	O
-	O
six	O
children	O
(	O
mean	O
age	O
:	O
8	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
5	O
,	O
range	O
:	O
1	O
-	O
15	O
years	O
)	O
,	O
including	O
15	O
with	O
deciduous	O
dentition	O
,	O
26	O
with	O
mixed	O
dentition	O
and	O
15	O
with	O
permanent	O
dentition	O
,	O
and	O
their	O
parents	O
participated	O
in	O
this	O
study	O
.	O

Whole	O
saliva	O
and	O
dental	O
plaque	O
of	O
the	O
children	O
and	O
whole	O
saliva	O
of	O
their	O
parents	O
were	O
collected	O
for	O
detection	O
of	O
seven	O
species	O
of	O
periodontopathic	O
bacteria	O
(	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
(	O
Bacteroides	B-bacteria
forsythus	I-bacteria
)	O
,	O
Campylobacter	B-bacteria
rectus	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Prevotella	B-bacteria
nigrescens	I-bacteria
and	O
Treponema	B-bacteria
denticola	I-bacteria
)	O
using	O
the	O
polymerase	O
chain	O
reaction	O
method	O
.	O

Clinical	O
parameters	O
including	O
simplified	O
Oral	O
Hygiene	O
Index	O
and	O
Papillary	O
-	O
Marginal	O
-	O
Attachment	O
Index	O
were	O
recorded	O
for	O
the	O
children	O
and	O
their	O
accompanied	O
parents	O
.	O

The	O
detection	O
frequencies	O
of	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
,	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
in	O
the	O
oral	O
cavities	O
of	O
children	O
were	O
42	O
.	O
9	O
%	O
,	O
94	O
.	O
6	O
%	O
,	O
42	O
.	O
9	O
%	O
,	O
48	O
.	O
2	O
%	O
,	O
1	O
.	O
8	O
%	O
and	O
8	O
.	O
9	O
%	O
,	O
respectively	O
.	O

T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
were	O
detected	O
more	O
frequently	O
in	O
the	O
saliva	O
of	O
parents	O
(	O
54	O
.	O
8	O
%	O
,	O
54	O
.	O
8	O
%	O
,	O
88	O
.	O
1	O
%	O
,	O
respectively	O
)	O
than	O
in	O
the	O
saliva	O
of	O
children	O
(	O
25	O
.	O
5	O
%	O
,	O
7	O
.	O
3	O
%	O
,	O
41	O
.	O
8	O
%	O
,	O
respectively	O
)	O
.	O

Different	O
detection	O
frequencies	O
of	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
were	O
found	O
among	O
the	O
oral	O
cavities	O
of	O
children	O
with	O
deciduous	O
,	O
mixed	O
and	O
permanent	O
dentitions	O
.	O

In	O
mixed	O
dentition	O
,	O
females	O
harbored	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
more	O
frequently	O
than	O
males	O
did	O
.	O

Children	O
who	O
harbored	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
showed	O
high	O
scores	O
for	O
oral	O
debris	O
measurement	O
by	O
simplified	O
Oral	O
Hygiene	O
Index	O
.	O

T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
were	O
detected	O
more	O
frequently	O
in	O
children	O
whose	O
parents	O
were	O
positive	O
for	O
these	O
pathogens	O
than	O
in	O
children	O
whose	O
parents	O
were	O
negative	O
.	O

High	O
plaque	O
retention	O
seems	O
to	O
promote	O
the	O
colonization	O
of	O
periodontal	O
pathogens	O
in	O
the	O
oral	O
cavities	O
of	O
children	O
.	O

T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
were	O
detected	O
more	O
frequently	O
in	O
the	O
oral	O
cavities	O
of	O
children	O
whose	O
parents	O
already	O
harbored	O
these	O
bacteria	O
.	O

Familial	O
transmission	O
of	O
these	O
bacteria	O
is	O
suggested	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
isolate	O
and	O
identify	O
alkali	O
-	O
resistant	O
bacteria	O
from	O
the	O
dentin	O
of	O
infected	O
root	O
canals	O
.	O

Bacteria	O
from	O
homogenized	O
dentin	O
powder	O
made	O
up	O
from	O
infected	O
root	O
canal	O
walls	O
from	O
human	O
teeth	O
were	O
cultured	O
on	O
buffer	O
-	O
enriched	O
Brain	O
Heart	O
Infusion	O
agar	O
supplemented	O
with	O
4	O
%	O
sheep	O
blood	O
(	O
BHI	O
-	O
blood	O
agar	O
)	O
,	O
adjusted	O
to	O
pH	O
7	O
.	O
0	O
,	O
9	O
.	O
0	O
or	O
10	O
.	O
0	O
.	O

Incubation	O
took	O
place	O
for	O
7	O
days	O
at	O
37	O
degrees	O
C	O
in	O
an	O
anaerobic	O
glove	O
box	O
.	O

Bacterial	O
strains	O
selected	O
according	O
to	O
colony	O
and	O
morphology	O
were	O
subcultured	O
in	O
buffer	O
-	O
enriched	O
BHI	O
broth	O
adjusted	O
to	O
pH	O
9	O
.	O
0	O
,	O
10	O
.	O
0	O
or	O
11	O
.	O
0	O
to	O
confirm	O
their	O
growth	O
as	O
alkali	O
-	O
resistant	O
bacteria	O
.	O

Polymerase	O
chain	O
reaction	O
amplification	O
using	O
specific	O
primer	O
sets	O
and	O
16S	O
rDNA	O
sequence	O
analysis	O
was	O
performed	O
for	O
identification	O
of	O
alkali	O
-	O
resistant	O
isolates	O
.	O

In	O
the	O
present	O
study	O
,	O
37	O
teeth	O
extracted	O
from	O
37	O
patients	O
were	O
used	O
for	O
preparation	O
of	O
the	O
dentin	O
powder	O
samples	O
.	O

Bacteria	O
were	O
detected	O
in	O
25	O
samples	O
when	O
standard	O
BHI	O
-	O
blood	O
agars	O
(	O
pH	O
7	O
.	O
0	O
)	O
were	O
used	O
.	O

Of	O
these	O
,	O
29	O
strains	O
from	O
15	O
samples	O
were	O
alkali	O
resistant	O
,	O
25	O
strains	O
growing	O
at	O
pH	O
9	O
.	O
0	O
and	O
4	O
at	O
pH	O
10	O
.	O
0	O
.	O

The	O
alkali	O
-	O
resistant	O
strains	O
included	O
Enterococcus	B-bacteria
faecium	I-bacteria
(	O
10	O
strains	O
)	O
and	O
Enterococcus	B-bacteria
faecalis	I-bacteria
(	O
2	O
strains	O
)	O
,	O
Enterobacter	B-bacteria
cancerogenus	I-bacteria
(	O
1	O
strains	O
)	O
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
(	O
1	O
strains	O
)	O
,	O
Klebsiella	B-bacteria
ornithinolytica	I-bacteria
(	O
2	O
strains	O
)	O
,	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
(	O
2	O
strains	O
)	O
,	O
Streptococcus	B-bacteria
anginosus	I-bacteria
(	O
2	O
strains	O
)	O
,	O
Streptococcus	B-bacteria
constellatus	I-bacteria
(	O
3	O
strains	O
)	O
,	O
and	O
Streptococcus	B-bacteria
mitis	I-bacteria
(	O
2	O
strains	O
)	O
.	O

Three	O
strains	O
were	O
also	O
identified	O
as	O
bacteria	O
of	O
genus	O
Firmicutes	B-bacteria
or	O
Staphylococcus	B-bacteria
at	O
the	O
genus	O
level	O
.	O

The	O
present	O
study	O
showed	O
that	O
many	O
bacterial	O
species	O
in	O
infected	O
root	O
canal	O
dentin	O
were	O
alkali	O
-	O
resistant	O
at	O
pH	O
9	O
.	O
0	O
and	O
/	O
or	O
pH	O
10	O
.	O
0	O
,	O
and	O
belonged	O
mainly	O
to	O
the	O
genus	O
Enterococcus	B-bacteria
.	O

oral	O
treponemes	B-bacteria
are	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
periodontal	O
disease	O
.	O

We	O
have	O
previously	O
shown	O
that	O
Treponema	B-bacteria
denticola	I-bacteria
ATCC	I-bacteria
type	I-bacteria
strains	I-bacteria
and	O
strain	O
GM	O
-	O
1	O
are	O
resistant	O
to	O
killing	O
by	O
human	O
beta	O
-	O
defensins	O
(	O
hbetaD	O
)	O
-	O
1	O
and	O
-	O
2	O
.	O

We	O
hypothesize	O
that	O
resistance	O
to	O
beta	O
-	O
defensins	O
is	O
a	O
common	O
feature	O
of	O
oral	O
treponemes	B-bacteria
,	O
which	O
allows	O
colonization	O
and	O
persistence	O
in	O
the	O
oral	O
cavity	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
additional	O
isolates	O
of	O
T	O
.	O
denticola	O
,	O
as	O
well	O
as	O
six	O
other	O
species	O
of	O
treponemes	B-bacteria
,	O
for	O
resistance	O
to	O
hbetaD	O
-	O
1	O
,	O
-	O
2	O
and	O
-	O
3	O
.	O

We	O
also	O
examined	O
the	O
four	O
ATCC	B-bacteria
strains	I-bacteria
of	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
and	O
strain	O
GM	B-bacteria
-	I-bacteria
1	I-bacteria
for	O
resistance	O
to	O
hbetaD	O
-	O
3	O
.	O

Resistance	O
was	O
determined	O
by	O
motility	O
and	O
Blue	O
assays	O
for	O
metabolic	O
activity	O
.	O

All	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
strains	I-bacteria
tested	O
were	O
resistant	O
to	O
hbetaD	O
-	O
1	O
,	O
-	O
2	O
and	O
-	O
3	O
,	O
with	O
the	O
exception	O
of	O
strain	O
Ambigua	O
,	O
which	O
was	O
sensitive	O
to	O
hbetaD	O
-	O
2	O
and	O
-	O
3	O
.	O

All	O
other	O
treponemes	B-bacteria
except	O
Treponema	B-bacteria
vincentii	I-bacteria
were	O
resistant	O
to	O
hbetaD	O
-	O
1	O
.	O

Treponema	B-bacteria
pectinovorum	I-bacteria
sensitive	O
to	O
hbetaD	O
-	O
2	O
,	O
while	O
T	B-bacteria
.	I-bacteria
vincentii	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
pectinovorum	I-bacteria
and	O
Treponema	B-bacteria
maltophilum	I-bacteria
were	O
sensitive	O
to	O
hbetaD	O
-	O
3	O
.	O

Escherichia	B-bacteria
coli	I-bacteria
was	O
used	O
as	O
a	O
control	O
organism	O
and	O
was	O
killed	O
by	O
all	O
three	O
defensins	O
.	O

Resistance	O
to	O
the	O
constitutively	O
expressed	O
hbetaD	O
-	O
1	O
may	O
assist	O
treponemes	B-bacteria
in	O
initial	O
colonization	O
of	O
epithelial	O
surfaces	O
,	O
while	O
resistance	O
to	O
the	O
inducible	O
hbetaD	O
-	O
2	O
and	O
-	O
3	O
would	O
allow	O
some	O
treponemes	B-bacteria
to	O
survive	O
in	O
active	O
periodontal	O
lesions	O
.	O

Dental	O
caries	O
prevention	O
programs	O
using	O
chlorhexidine	O
(	O
CHX	O
)	O
have	O
been	O
proposed	O
,	O
but	O
CHX	O
'	O
s	O
effect	O
in	O
reducing	O
levels	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
(	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
)	O
appears	O
to	O
last	O
for	O
only	O
a	O
few	O
months	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
attempt	O
to	O
eradicate	O
mutans	B-bacteria
streptococci	I-bacteria
from	O
the	O
oral	O
cavity	O
using	O
intensive	O
professional	O
mechanical	O
tooth	O
cleaning	O
(	O
PMTC	O
)	O
and	O
topical	O
application	O
of	O
CHX	O
in	O
custom	O
-	O
made	O
trays	O
.	O

Seven	O
adult	O
dentate	O
subjects	O
participated	O
in	O
this	O
study	O
(	O
mean	O
age	O
53	O
.	O
7	O
+	O
/	O
-	O
5	O
.	O
6	O
,	O
age	O
range	O
46	O
to	O
62	O
,	O
mean	O
DMFT	O
,	O
9	O
.	O
1	O
+	O
/	O
-	O
4	O
.	O
2	O
)	O
.	O

For	O
each	O
subject	O
,	O
PMTC	O
was	O
carried	O
out	O
eight	O
times	O
within	O
ten	O
days	O
.	O

After	O
each	O
PMTC	O
,	O
1	O
%	O
CHX	O
was	O
applied	O
twice	O
to	O
the	O
tooth	O
surface	O
using	O
custom	O
-	O
made	O
trays	O
.	O

In	O
addition	O
,	O
as	O
home	O
treatment	O
,	O
subjects	O
were	O
required	O
to	O
carry	O
out	O
tooth	O
brushing	O
three	O
times	O
a	O
day	O
,	O
and	O
apply	O
0	O
.	O
2	O
%	O
CHX	O
in	O
custom	O
trays	O
after	O
brushing	O
in	O
the	O
morning	O
and	O
evening	O
.	O

In	O
addition	O
,	O
subjects	O
rinsed	O
with	O
0	O
.	O
2	O
%	O
CHX	O
solution	O
after	O
lunch	O
.	O

Salivary	O
levels	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
were	O
evaluated	O
using	O
Dentocult	O
-	O
SM	O
at	O
baseline	O
and	O
on	O
days	O
9	O
,	O
20	O
,	O
70	O
,	O
120	O
.	O

Mutans	B-bacteria
streptococci	I-bacteria
were	O
eradicated	O
by	O
day	O
120	O
from	O
4	O
of	O
the	O
7	O
seven	O
subjects	O
participating	O
in	O
this	O
study	O
.	O

Those	O
3	O
subjects	O
still	O
harboring	O
mutans	B-bacteria
streptococci	I-bacteria
exhibited	O
deep	O
periodontal	O
pocketing	O
.	O

Eradication	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
from	O
the	O
oral	O
cavity	O
is	O
feasible	O
using	O
a	O
combination	O
of	O
CHX	O
application	O
in	O
custom	O
-	O
made	O
trays	O
and	O
intensive	O
PMTC	O
.	O

During	O
investigation	O
of	O
adhesive	O
properties	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
it	O
was	O
found	O
out	O
that	O
11	O
strains	O
adhered	O
to	O
buccal	O
intestinal	O
and	O
vaginal	O
epithelium	O
of	O
human	O
.	O

The	O
highest	O
adhesive	O
activity	O
was	O
detected	O
in	O
enterococci	B-bacteria
(	O
adhesive	O
index	O
7	O
.	O
75	O
-	O
14	O
.	O
26	O
)	O
,	O
lower	O
one	O
-	O
-	O
in	O
streptococci	B-bacteria
(	O
6	O
.	O
40	O
-	O
9	O
.	O
16	O
)	O
.	O

In	O
lactobacilli	B-bacteria
adhesive	O
properties	O
manifested	O
in	O
different	O
ways	O
:	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
strains	I-bacteria
adhered	O
more	O
often	O
to	O
buccal	O
epithelium	O
(	O
2	O
.	O
58	O
-	O
4	O
.	O
60	O
)	O
and	O
rarely	O
-	O
-	O
to	O
intestinal	O
and	O
vaginal	O
.	O

L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
manifested	O
high	O
adhesive	O
activity	O
(	O
8	O
.	O
03	O
-	O
9	O
.	O
69	O
)	O
to	O
buccal	O
epithelium	O
and	O
lower	O
one	O
-	O
-	O
to	O
the	O
rest	O
of	O
epithelium	O
types	O
.	O

Monosaccharide	O
composition	O
of	O
glycocalix	O
of	O
6	O
strains	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
was	O
studied	O
to	O
understand	O
the	O
adhesion	O
mechanism	O
.	O

It	O
was	O
shown	O
that	O
surface	O
structures	O
of	O
this	O
microorganism	O
interact	O
with	O
plant	O
lectins	O
,	O
specific	O
to	O
certain	O
monosaccharides	O
.	O

Nosocomial	O
pneumonia	O
remains	O
a	O
common	O
complication	O
in	O
patients	O
undergoing	O
endotracheal	O
intubation	O
.	O

This	O
study	O
examined	O
the	O
transport	O
of	O
bacteria	O
into	O
the	O
trachea	O
during	O
endotracheal	O
intubation	O
,	O
and	O
evaluated	O
the	O
effects	O
of	O
gargling	O
with	O
povidone	O
-	O
iodine	O
on	O
bacterial	O
contamination	O
of	O
the	O
tip	O
of	O
the	O
intubation	O
tube	O
.	O

In	O
the	O
gargling	O
group	O
,	O
patients	O
gargled	O
with	O
25	O
mL	O
of	O
povidone	O
-	O
iodine	O
(	O
2	O
.	O
5	O
mg	O
.	O
mL	O
(	O
-	O
1	O
)	O
)	O
.	O

In	O
the	O
control	O
group	O
,	O
patients	O
gargled	O
with	O
25	O
mL	O
of	O
tap	O
water	O
.	O

Before	O
tracheal	O
intubation	O
,	O
microorganisms	O
were	O
obtained	O
from	O
the	O
posterior	O
wall	O
of	O
the	O
patient	O
'	O
s	O
pharynx	O
using	O
sterile	O
cotton	O
swabs	O
.	O

After	O
anesthesia	O
,	O
all	O
patients	O
were	O
extubated	O
and	O
bacteria	O
contaminating	O
the	O
tip	O
of	O
the	O
tracheal	O
tube	O
were	O
sampled	O
and	O
cultured	O
.	O

Before	O
orotracheal	O
intubation	O
,	O
all	O
19	O
patients	O
who	O
gargled	O
with	O
tap	O
water	O
(	O
control	O
group	O
)	O
had	O
bacterial	O
colonization	O
on	O
the	O
posterior	O
walls	O
of	O
the	O
pharynx	O
.	O

This	O
group	O
included	O
five	O
patients	O
who	O
had	O
methicillin	B-bacteria
-	I-bacteria
resistant	I-bacteria
staphylococcus	I-bacteria
aureus	I-bacteria
(	O
MRSA	B-bacteria
)	O
in	O
their	O
nasal	O
cavity	O
preoperatively	O
and	O
MRSA	B-bacteria
was	O
also	O
detected	O
in	O
the	O
pharynx	O
of	O
four	O
patients	O
.	O

Bacterial	O
colonization	O
was	O
observed	O
in	O
all	O
19	O
patients	O
who	O
gargled	O
with	O
povidone	O
-	O
iodine	O
(	O
gargling	O
group	O
)	O
and	O
four	O
patients	O
carried	O
MRSA	B-bacteria
in	O
their	O
nasal	O
cavity	O
,	O
although	O
no	O
MRSA	B-bacteria
was	O
detected	O
in	O
the	O
pharynx	O
.	O

In	O
the	O
control	O
group	O
,	O
all	O
the	O
patients	O
had	O
bacterial	O
colonization	O
at	O
the	O
tip	O
of	O
the	O
tube	O
after	O
extubation	O
.	O

Additionally	O
,	O
MRSA	B-bacteria
was	O
detected	O
in	O
two	O
of	O
the	O
four	O
patients	O
.	O

In	O
the	O
gargling	O
group	O
,	O
povidone	O
-	O
iodine	O
eradicated	O
general	O
bacteria	O
and	O
MRSA	B-bacteria
colonies	O
in	O
the	O
pharynx	O
before	O
intubation	O
and	O
at	O
the	O
tip	O
of	O
the	O
tube	O
after	O
extubation	O
.	O

Gargling	O
with	O
povidone	O
-	O
iodine	O
before	O
oral	O
intubation	O
reduces	O
the	O
transport	O
of	O
bacteria	O
into	O
the	O
trachea	O
.	O

Previous	O
analysis	O
of	O
the	O
microbiology	O
of	O
advanced	O
caries	O
by	O
culture	O
and	O
real	O
-	O
time	O
PCR	O
emphasized	O
the	O
high	O
incidence	O
and	O
abundance	O
of	O
gram	O
-	O
negative	O
anaerobic	O
species	O
,	O
particularly	O
Prevotella	O
-	O
like	O
bacteria	O
.	O

The	O
diversity	O
of	O
Prevotella	O
-	O
like	O
bacteria	O
was	O
further	O
explored	O
by	O
analyzing	O
pooled	O
bacterial	O
DNA	O
from	O
lesions	O
of	O
carious	O
dentine	O
.	O

This	O
was	O
achieved	O
by	O
amplification	O
of	O
a	O
region	O
of	O
the	O
16S	O
ribosomal	O
DNA	O
with	O
a	O
Prevotella	B-bacteria
genus	O
-	O
specific	O
forward	O
primer	O
and	O
a	O
universal	O
bacterial	O
reverse	O
primer	O
,	O
followed	O
by	O
cloning	O
and	O
sequencing	O
.	O

Cultured	O
Prevotella	B-bacteria
species	I-bacteria
commonly	O
associated	O
with	O
oral	O
tissues	O
constituted	O
only	O
12	O
%	O
of	O
the	O
Prevotella	B-bacteria
clones	O
isolated	O
from	O
advanced	O
carious	O
lesions	O
.	O

The	O
remaining	O
88	O
%	O
consisted	O
of	O
a	O
diverse	O
range	O
of	O
phylotypes	O
.	O

These	O
included	O
five	O
clusters	O
of	O
previously	O
recognized	O
but	O
uncultured	O
oral	O
Prevotella	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
a	O
major	O
cluster	O
containing	O
Prevotella	O
-	O
like	O
bacteria	O
most	O
closely	O
related	O
to	O
uncharacterized	O
rumen	O
bacteria	O
.	O

Cluster	O
-	O
specific	O
primers	O
were	O
designed	O
,	O
and	O
the	O
numbers	O
of	O
bacteria	O
within	O
clusters	O
were	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
,	O
confirming	O
the	O
abundance	O
of	O
these	O
organisms	O
.	O

The	O
data	O
indicated	O
that	O
advanced	O
dental	O
caries	O
provides	O
a	O
unique	O
environment	O
for	O
a	O
complex	O
array	O
of	O
novel	O
and	O
uncultured	O
Prevotella	B-bacteria
and	O
Prevotella	O
-	O
like	O
bacteria	O
which	O
,	O
in	O
some	O
cases	O
,	O
may	O
dominate	O
the	O
diverse	O
polymicrobial	O
community	O
associated	O
with	O
the	O
disease	O
.	O

To	O
compare	O
five	O
different	O
commercial	O
mouth	O
rinses	O
with	O
chlorhexidine	O
(	O
CHX	O
)	O
with	O
respect	O
to	O
their	O
anti	O
-	O
halitosis	O
effect	O
and	O
anti	O
-	O
microbial	O
activity	O
on	O
salivary	O
bacterial	O
counts	O
,	O
following	O
a	O
standardised	O
research	O
protocol	O
.	O

And	O
secondly	O
,	O
to	O
validate	O
the	O
study	O
model	O
proposed	O
in	O
the	O
evaluation	O
of	O
patients	O
suffering	O
from	O
halitosis	O
.	O

PATIENTS	O
AND	O
Ten	O
volunteers	O
,	O
with	O
a	O
healthy	O
oral	O
status	O
,	O
were	O
enrolled	O
in	O
a	O
double	O
-	O
blind	O
,	O
cross	O
-	O
over	O
design	O
,	O
using	O
sterile	O
saline	O
as	O
negative	O
control	O
and	O
five	O
CHX	O
-	O
containing	O
mouth	O
rinses	O
:	O
0	O
.	O
12	O
%	O
CHX	O
alone	O
(	O
CHX	O
+	O
NO	O
)	O
,	O
plus	O
alcohol	O
(	O
CHX	O
+	O
ALC	O
)	O
,	O
plus	O
0	O
.	O
05	O
%	O
cetylpiridinium	O
chloride	O
(	O
CHX	O
+	O
CPC	O
)	O
,	O
plus	O
sodium	O
fluoride	O
(	O
CHX	O
+	O
NaF	O
)	O
,	O
and	O
0	O
.	O
05	O
%	O
CHX	O
plus	O
0	O
.	O
05	O
%	O
CPC	O
,	O
plus	O
0	O
.	O
14	O
%	O
zinc	O
lactate	O
(	O
CHX	O
+	O
Zn	O
)	O
.	O

The	O
levels	O
of	O
whole	O
-	O
mouth	O
volatile	O
sulphur	O
compounds	O
(	O
VSCs	O
)	O
were	O
measured	O
by	O
means	O
of	O
a	O
sulphide	O
monitor	O
at	O
baseline	O
,	O
1	O
and	O
5	O
h	O
after	O
rinsing	O
with	O
the	O
assigned	O
product	O
.	O

Baseline	O
measurements	O
also	O
included	O
an	O
organoleptic	O
assessment	O
and	O
the	O
recording	O
of	O
the	O
tongue	O
-	O
coating	O
index	O
.	O

Aerobic	O
and	O
anaerobic	O
salivary	O
bacterial	O
counts	O
were	O
also	O
obtained	O
by	O
collecting	O
unstimulated	O
saliva	O
samples	O
at	O
the	O
same	O
evaluation	O
times	O
,	O
and	O
processed	O
by	O
culturing	O
techniques	O
.	O

Analysis	O
of	O
variance	O
was	O
used	O
to	O
evaluate	O
whether	O
significant	O
differences	O
existed	O
among	O
groups	O
,	O
at	O
each	O
evaluation	O
point	O
,	O
or	O
in	O
changes	O
between	O
evaluations	O
.	O

No	O
significant	O
differences	O
were	O
detected	O
at	O
baseline	O
,	O
with	O
VSC	O
levels	O
ranging	O
between	O
190	O
and	O
227	O
parts	O
per	O
billion	O
(	O
p	O
.	O
p	O
.	O
b	O
.	O
)	O

After	O
rinsing	O
,	O
VSC	O
levels	O
were	O
reduced	O
with	O
all	O
products	O
(	O
except	O
saline	O
)	O
,	O
after	O
1	O
h	O
.	O
Significant	O
differences	O
at	O
1	O
h	O
were	O
detected	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
,	O
corresponding	O
to	O
a	O
lower	O
amount	O
of	O
p	O
.	O
p	O
.	O
b	O
.	O

(	O
109	O
)	O
in	O
(	O
CHX	O
+	O
Zn	O
)	O
as	O
compared	O
with	O
the	O
other	O
groups	O
(	O
except	O
CHX	O
+	O
NO	O
)	O
.	O

At	O
5	O
h	O
,	O
VSC	O
levels	O
were	O
lower	O
for	O
CHX	O
+	O
CPC	O
and	O
CHX	O
+	O
Zn	O
(	O
155	O
and	O
169	O
,	O
respectively	O
)	O
,	O
while	O
the	O
other	O
groups	O
showed	O
levels	O
higher	O
than	O
220	O
p	O
.	O
p	O
.	O
b	O
.	O

With	O
respect	O
to	O
aerobic	O
salivary	O
bacterial	O
counts	O
,	O
CHX	O
+	O
CPC	O
demonstrated	O
the	O
lowest	O
percentage	O
of	O
survival	O
(	O
6	O
%	O
after	O
1	O
h	O
and	O
18	O
%	O
after	O
5	O
h	O
)	O
.	O

For	O
anaerobic	O
bacterial	O
counts	O
,	O
again	O
CHX	O
+	O
CPC	O
demonstrated	O
the	O
lowest	O
percentage	O
of	O
survival	O
(	O
10	O
%	O
at	O
1	O
h	O
and	O
23	O
%	O
at	O
5	O
h	O
)	O
,	O
together	O
with	O
CHX	O
+	O
ALC	O
(	O
18	O
%	O
of	O
survival	O
at	O
5	O
h	O
)	O
.	O

However	O
,	O
salivary	O
counts	O
and	O
VSCs	O
were	O
only	O
significantly	O
correlated	O
at	O
baseline	O
,	O
but	O
not	O
after	O
treatment	O
.	O

Important	O
differences	O
can	O
be	O
expected	O
from	O
different	O
CHX	O
formulations	O
,	O
in	O
relation	O
to	O
both	O
their	O
anti	O
-	O
halitosis	O
effect	O
and	O
anti	O
-	O
microbial	O
activity	O
in	O
saliva	O
.	O

Formulations	O
that	O
combine	O
CHX	O
and	O
CPC	O
achieved	O
the	O
best	O
results	O
,	O
and	O
a	O
formulation	O
combining	O
CHX	O
with	O
NaF	O
resulted	O
in	O
the	O
poorest	O
.	O

Glucansucrases	O
of	O
oral	O
streptococci	B-bacteria
and	O
Leuconostoc	B-bacteria
mesenteroides	I-bacteria
have	O
a	O
common	O
pattern	O
of	O
structural	O
organization	O
and	O
characteristically	O
contain	O
a	O
domain	O
with	O
a	O
series	O
of	O
tandem	O
amino	O
acid	O
repeats	O
in	O
which	O
certain	O
residues	O
are	O
highly	O
conserved	O
,	O
particularly	O
aromatic	O
amino	O
acids	O
and	O
glycine	O
.	O

In	O
some	O
glucosyltransferases	O
(	O
GTFs	O
)	O
the	O
repeat	O
region	O
has	O
been	O
identified	O
as	O
a	O
glucan	O
binding	O
domain	O
(	O
GBD	O
)	O
.	O

Such	O
GBDs	O
are	O
also	O
found	O
in	O
several	O
glucan	O
binding	O
proteins	O
(	O
GBP	O
)	O
of	O
oral	O
streptococci	B-bacteria
that	O
do	O
not	O
have	O
glucansucrase	O
activity	O
.	O

Alignment	O
of	O
the	O
amino	O
acid	O
sequences	O
of	O
20	O
glucansucrases	O
and	O
GBP	O
showed	O
the	O
widespread	O
conservation	O
of	O
the	O
33	O
-	O
residue	O
A	O
repeat	O
first	O
identified	O
in	O
GtfI	O
of	O
Streptococcus	B-bacteria
downei	I-bacteria
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
individual	O
highly	O
conserved	O
residues	O
in	O
recombinant	O
GBD	O
of	O
GtfI	O
demonstrated	O
the	O
importance	O
of	O
the	O
first	O
tryptophan	O
and	O
the	O
tyrosine	O
-	O
phenylalanine	O
pair	O
in	O
the	O
binding	O
of	O
dextran	O
,	O
as	O
well	O
as	O
the	O
essential	O
contribution	O
of	O
a	O
basic	O
residue	O
(	O
arginine	O
or	O
lysine	O
)	O
.	O

A	O
microplate	O
binding	O
assay	O
was	O
developed	O
to	O
measure	O
the	O
binding	O
affinity	O
of	O
recombinant	O
GBDs	O
.	O

GBD	O
of	O
GtfI	O
was	O
shown	O
to	O
be	O
capable	O
of	O
binding	O
glucans	O
with	O
predominantly	O
alpha	O
-	O
1	O
,	O
3	O
or	O
alpha	O
-	O
1	O
,	O
6	O
links	O
,	O
as	O
well	O
as	O
alternating	O
alpha	O
-	O
1	O
,	O
3	O
and	O
alpha	O
-	O
1	O
,	O
6	O
links	O
(	O
alternan	O
)	O
.	O

Western	O
blot	O
experiments	O
using	O
biotinylated	O
dextran	O
or	O
alternan	O
as	O
probes	O
demonstrated	O
a	O
difference	O
between	O
the	O
binding	O
of	O
streptococcal	O
GTF	O
and	O
GBP	O
and	O
that	O
of	O
Leuconostoc	B-bacteria
glucansucrases	I-bacteria
.	O

Experimental	O
data	O
and	O
bioinformatics	O
analysis	O
showed	O
that	O
the	O
A	O
repeat	O
motif	O
is	O
distinct	O
from	O
the	O
20	O
-	O
residue	O
CW	O
motif	O
,	O
which	O
also	O
has	O
conserved	O
aromatic	O
amino	O
acids	O
and	O
glycine	O
and	O
which	O
occurs	O
in	O
the	O
choline	O
-	O
binding	O
proteins	O
of	O
Streptococcus	B-bacteria
pneumoniae	I-bacteria
and	O
other	O
organisms	O
.	O

Because	O
oral	O
infections	O
are	O
common	O
,	O
the	O
physician	O
must	O
understand	O
the	O
underlying	O
etiology	O
,	O
pathogeny	O
,	O
and	O
other	O
variables	O
that	O
determine	O
how	O
these	O
processes	O
evolve	O
in	O
order	O
to	O
choose	O
the	O
most	O
appropriate	O
antibiotic	O
drug	O
.	O

The	O
special	O
characteristics	O
of	O
the	O
oral	O
cavity	O
determine	O
the	O
make	O
-	O
up	O
of	O
the	O
microflora	O
that	O
lives	O
there	O
.	O

Different	O
anaerobic	O
species	O
belonging	O
to	O
the	O
Peptostreptococcus	B-bacteria
,	O
Prevotella	B-bacteria
,	O
Fusobacterium	B-bacteria
,	O
Gemella	B-bacteria
,	O
and	O
Porphyromonas	B-bacteria
genera	I-bacteria
are	O
of	O
particular	O
interest	O
,	O
as	O
are	O
the	O
aerobic	O
species	O
Streptococcus	B-bacteria
,	O
Staphylococcus	B-bacteria
,	O
and	O
Corynebacterium	B-bacteria
.	O

Each	O
of	O
these	O
microorganisms	O
occupies	O
a	O
different	O
microniche	O
within	O
the	O
oral	O
cavity	O
,	O
and	O
the	O
prevailing	O
balance	O
is	O
upset	O
when	O
conditions	O
become	O
modified	O
as	O
a	O
result	O
of	O
illness	O
or	O
due	O
to	O
dental	O
interventions	O
such	O
as	O
tooth	O
extraction	O
or	O
tooth	O
scaling	O
and	O
polishing	O
.	O

Pathogenic	O
or	O
opportunistic	O
bacteria	O
(	O
Actinomyces	B-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
species	I-bacteria
,	O
etc	O
.	O
)	O
can	O
develop	O
in	O
these	O
conditions	O
,	O
as	O
can	O
yeasts	O
(	O
Candida	O
sp	O
.	O
,	O
Histoplasma	O
capsulatum	O
)	O
,	O
virus	O
(	O
herpes	O
simplex	O
,	O
papilomavirus	O
)	O
,	O
and	O
parasites	O
(	O
Entamoeba	O
gingivalis	O
,	O
Trichomonas	O
tenax	O
)	O
.	O

When	O
infection	O
occurs	O
,	O
the	O
patients	O
s	O
immune	O
system	O
reacts	O
by	O
means	O
of	O
inborn	O
immunity	O
(	O
non	O
-	O
specific	O
)	O
and	O
acquired	O
immunity	O
(	O
specific	O
)	O
.	O

Empirical	O
treatment	O
is	O
administered	O
that	O
should	O
be	O
based	O
on	O
etiological	O
data	O
and	O
on	O
the	O
antimicrobial	O
sensitivity	O
of	O
the	O
pathogen	O
that	O
is	O
causing	O
the	O
infection	O
.	O

However	O
,	O
oral	O
microflora	O
sensitivity	O
to	O
different	O
antibiotics	O
is	O
currently	O
declining	O
and	O
there	O
is	O
a	O
noticeable	O
trend	O
towards	O
resistances	O
.	O

As	O
a	O
consequence	O
of	O
all	O
this	O
,	O
the	O
treatment	O
of	O
oral	O
infections	O
must	O
also	O
aim	O
to	O
restore	O
the	O
ecological	O
balance	O
of	O
the	O
oral	O
cavity	O
and	O
to	O
minimize	O
the	O
emergence	O
of	O
resistance	O
in	O
the	O
microorganisms	O
present	O
in	O
the	O
mouth	O
.	O

Hence	O
,	O
epidemiological	O
oral	O
pathogen	O
sensitivity	O
studies	O
must	O
be	O
conducted	O
,	O
fostering	O
the	O
administration	O
of	O
appropriate	O
antibiotics	O
at	O
proper	O
doses	O
and	O
keeping	O
specialists	O
abreast	O
of	O
the	O
latest	O
trends	O
.	O

In	O
recent	O
decades	O
,	O
oral	O
infections	O
comprise	O
one	O
of	O
the	O
most	O
common	O
pathologies	O
in	O
the	O
general	O
population	O
,	O
due	O
in	O
large	O
part	O
to	O
infectious	O
complications	O
associated	O
with	O
poor	O
oral	O
hygiene	O
.	O

This	O
in	O
turn	O
,	O
translates	O
into	O
an	O
increased	O
need	O
and	O
demand	O
for	O
dental	O
care	O
,	O
while	O
at	O
the	O
same	O
time	O
,	O
it	O
requires	O
that	O
the	O
professional	O
accurately	O
understand	O
the	O
etiological	O
factors	O
involved	O
,	O
as	O
well	O
as	O
the	O
pathogeny	O
and	O
different	O
variables	O
that	O
determine	O
the	O
specificity	O
of	O
these	O
kinds	O
of	O
infections	O
,	O
so	O
as	O
to	O
be	O
able	O
to	O
choose	O
the	O
appropriate	O
antimicrobial	O
drugs	O
for	O
proper	O
treatment	O
.	O

Halitosis	O
refers	O
to	O
the	O
condition	O
of	O
offensive	O
mouth	O
odour	O
.	O

More	O
than	O
90	O
%	O
of	O
cases	O
of	O
halitosis	O
originate	O
from	O
the	O
oral	O
cavity	O
.	O

The	O
implicated	O
bacteria	O
(	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
and	O
Tannerella	B-bacteria
forsythensis	I-bacteria
)	O
are	O
located	O
in	O
stagnant	O
areas	O
in	O
the	O
oral	O
cavity	O
,	O
such	O
as	O
the	O
dorsal	O
surface	O
of	O
tongue	O
,	O
periodontal	O
pockets	O
,	O
and	O
interproximal	O
areas	O
.	O

These	O
bacteria	O
proteolyse	O
the	O
amino	O
acids	O
releasing	O
volatile	O
sulphur	O
compounds	O
.	O

The	O
management	O
of	O
halitosis	O
involves	O
determining	O
and	O
eliminating	O
the	O
causes	O
,	O
which	O
includes	O
identifying	O
any	O
contributory	O
factors	O
,	O
because	O
certain	O
medical	O
conditions	O
are	O
also	O
associated	O
with	O
characteristic	O
smells	O
.	O

Professional	O
advice	O
should	O
be	O
given	O
on	O
oral	O
hygiene	O
and	O
diet	O
,	O
and	O
treatments	O
should	O
include	O
dental	O
scaling	O
,	O
and	O
root	O
planing	O
of	O
the	O
associated	O
periodontal	O
pockets	O
to	O
reduce	O
the	O
bacterial	O
loading	O
.	O

In	O
addition	O
to	O
the	O
normal	O
oral	O
hygiene	O
practice	O
,	O
tongue	O
cleaning	O
and	O
use	O
of	O
mouthwash	O
are	O
advocated	O
.	O

This	O
paper	O
discusses	O
the	O
common	O
aetiological	O
factors	O
,	O
classification	O
of	O
oral	O
halitosis	O
,	O
and	O
its	O
treatment	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
is	O
a	O
gram	O
-	O
negative	O
,	O
microaerophilic	O
rod	O
-	O
shaped	O
bacteria	O
that	O
lives	O
beneath	O
the	O
gastric	O
mucous	O
layer	O
,	O
on	O
the	O
surface	O
of	O
epithelial	O
cells	O
.	O

Stomach	O
infection	O
with	O
this	O
organism	O
causes	O
inflammation	O
of	O
the	O
gastric	O
mucosa	O
,	O
which	O
can	O
lead	O
to	O
gastritis	O
,	O
duodenal	O
or	O
gastric	O
ulcer	O
and	O
even	O
in	O
rare	O
cases	O
to	O
gastric	O
carcinoma	O
or	O
MALT	O
lymphoma	O
.	O

Approximately	O
50	O
%	O
of	O
the	O
world	O
'	O
s	O
population	O
is	O
believed	O
to	O
be	O
infected	O
with	O
H	O
.	O
pylori	O
.	O

Most	O
infections	O
is	O
probably	O
acquired	O
in	O
childhood	O
,	O
but	O
the	O
exact	O
route	O
of	O
transmission	O
is	O
unknown	O
.	O

It	O
has	O
been	O
speculated	O
that	O
dental	O
plaque	O
might	O
harbour	O
Helicobacter	B-bacteria
pylori	I-bacteria
and	O
,	O
therefore	O
,	O
might	O
be	O
a	O
source	O
of	O
gastric	O
infection	O
.	O

In	O
order	O
to	O
address	O
this	O
issue	O
we	O
studied	O
the	O
relationships	O
between	O
oral	O
and	O
gastric	O
infections	O
with	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
100	O
subjects	O
.	O

Gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
was	O
determined	O
by	O
(	O
13	O
)	O
C	O
-	O
urea	O
breath	O
test	O
(	O
UBT	O
)	O
and	O
the	O
presence	O
of	O
the	O
bacteria	O
in	O
oral	O
cavity	O
was	O
monitored	O
by	O
the	O
culture	O
from	O
the	O
saliva	O
and	O
from	O
dental	O
plaque	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
found	O
in	O
the	O
stomach	O
in	O
51	O
%	O
of	O
studied	O
individuals	O
,	O
while	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
found	O
in	O
54	O
%	O
(	O
in	O
saliva	O
)	O
and	O
in	O
48	O
.	O
3	O
%	O
(	O
in	O
gingival	O
pockets	O
)	O
,	O
the	O
difference	O
was	O
not	O
statistical	O
significant	O
(	O
p	O
=	O
NS	O
)	O
.	O

Interestingly	O
,	O
anti	O
-	O
Hp	O
IgA	O
was	O
found	O
in	O
84	O
%	O
of	O
studied	O
individuals	O
.	O

No	O
relationship	O
was	O
found	O
between	O
the	O
presence	O
of	O
the	O
bacteria	O
in	O
the	O
oral	O
cavity	O
and	O
the	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
gastric	O
infection	O
.	O

54	O
.	O
9	O
%	O
of	O
subjects	O
with	O
stomach	O
infection	O
showed	O
concomitant	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
saliva	O
.	O

52	O
.	O
3	O
%	O
of	O
examined	O
subjects	O
with	O
negative	O
UBT	O
-	O
test	O
revealed	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
culture	O
from	O
the	O
saliva	O
.	O

The	O
X	O
(	O
2	O
)	O
value	O
of	O
relationship	O
between	O
UBT	O
and	O
culture	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
saliva	O
was	O
0	O
.	O
029	O
(	O
p	O
=	O
0	O
.	O
9	O
)	O
.	O

Similarly	O
,	O
no	O
relationship	O
was	O
found	O
between	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
stomach	O
and	O
in	O
the	O
dental	O
plaque	O
(	O
X2	O
=	O
0	O
.	O
6	O
)	O
;	O
p	O
=	O
0	O
.	O
4	O
)	O
.	O

As	O
expected	O
,	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
dental	O
plaque	O
was	O
significantly	O
correlated	O
with	O
the	O
presence	O
of	O
bacteria	O
in	O
the	O
saliva	O
(	O
X2	O
=	O
18	O
.	O
4	O
;	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

We	O
also	O
compared	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
saliva	O
of	O
patients	O
with	O
and	O
without	O
teeth	O
.	O

The	O
cultured	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
found	O
in	O
63	O
.	O
7	O
%	O
of	O
patients	O
without	O
teeth	O
and	O
in	O
52	O
.	O
9	O
%	O
of	O
patients	O
with	O
teeth	O
.	O

This	O
indicates	O
that	O
the	O
presence	O
of	O
teeth	O
does	O
not	O
seem	O
to	O
affect	O
the	O
occurrence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
saliva	O
.	O

We	O
conclude	O
that	O
oral	O
activity	O
contamination	O
with	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
occurs	O
at	O
similar	O
degree	O
to	O
that	O
in	O
the	O
stomach	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
correlation	O
between	O
the	O
occurrence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
stomach	O
and	O
in	O
the	O
oral	O
cavity	O
indicating	O
that	O
other	O
factors	O
,	O
like	O
susceptibility	O
to	O
infection	O
due	O
to	O
acid	O
environment	O
in	O
the	O
stomach	O
may	O
be	O
the	O
major	O
factor	O
in	O
gastric	O
infection	O
with	O
that	O
bacteria	O
,	O
while	O
oral	O
cavity	O
may	O
serve	O
only	O
as	O
transient	O
food	O
-	O
related	O
contamination	O
without	O
clear	O
relation	O
to	O
gastric	O
infection	O
.	O

Prevotella	B-bacteria
species	I-bacteria
are	O
a	O
major	O
component	O
of	O
the	O
oral	O
microflora	O
and	O
some	O
have	O
been	O
implicated	O
in	O
various	O
forms	O
of	O
periodontal	O
disease	O
.	O

Despite	O
the	O
importance	O
of	O
understanding	O
the	O
prevalence	O
of	O
these	O
organisms	O
in	O
the	O
oral	O
microflora	O
,	O
no	O
rapid	O
,	O
simultaneous	O
detection	O
system	O
for	O
these	O
species	O
has	O
been	O
reported	O
.	O

This	O
study	O
developed	O
a	O
multiplex	O
polymerase	O
chain	O
reaction	O
assay	O
for	O
the	O
simultaneous	O
detection	O
of	O
four	O
oral	O
black	O
-	O
pigmented	O
Prevotella	B-bacteria
species	I-bacteria
in	O
various	O
oral	O
specimens	O
.	O

This	O
assay	O
will	O
be	O
useful	O
for	O
determining	O
the	O
prevalence	O
of	O
these	O
organisms	O
in	O
the	O
oral	O
ecosystem	O
.	O

Furthermore	O
,	O
this	O
assay	O
system	O
should	O
prove	O
a	O
useful	O
tool	O
for	O
analyzing	O
the	O
role	O
of	O
black	O
-	O
pigmented	O
Prevotella	B-bacteria
species	I-bacteria
in	O
the	O
mouth	O
.	O

Previously	O
,	O
we	O
used	O
in	O
situ	O
hybridization	O
and	O
confocal	O
microscopy	O
to	O
detect	O
the	O
periodontal	O
pathogens	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
and	O
Tannerella	B-bacteria
forsythensis	I-bacteria
within	O
buccal	O
epithelial	O
cells	O
taken	O
directly	O
from	O
the	O
mouth	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
the	O
intracellular	O
flora	O
of	O
buccal	O
cells	O
is	O
polymicrobial	O
.	O

Mixtures	O
containing	O
a	O
red	O
fluorescent	O
universal	O
probe	O
paired	O
with	O
green	O
fluorescent	O
versions	O
of	O
either	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
-	O
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
-	O
,	O
or	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
-	O
specific	O
probes	O
were	O
hybridized	O
with	O
buccal	O
cells	O
collected	O
from	O
each	O
of	O
38	O
healthy	O
humans	O
.	O

We	O
verified	O
co	O
-	O
localization	O
of	O
probe	O
pairs	O
within	O
cells	O
by	O
generating	O
three	O
-	O
dimensional	O
reconstructions	O
.	O

Intracellular	O
bacteria	O
were	O
detected	O
in	O
every	O
subject	O
.	O

Each	O
cell	O
that	O
was	O
labeled	O
with	O
a	O
species	O
-	O
specific	O
probe	O
also	O
contained	O
bacteria	O
recognized	O
only	O
by	O
the	O
universal	O
probe	O
.	O

Bacteria	O
labeled	O
with	O
specific	O
probes	O
often	O
occupied	O
smaller	O
regions	O
within	O
larger	O
masses	O
of	O
bacteria	O
.	O

Those	O
findings	O
suggest	O
that	O
future	O
studies	O
of	O
invasion	O
by	O
oral	O
bacteria	O
may	O
need	O
to	O
include	O
microbial	O
consortia	O
.	O

Induction	O
of	O
resistance	O
of	O
oral	O
anaerobes	O
to	O
the	O
effects	O
of	O
human	O
beta	O
-	O
defensin	O
1	O
(	O
hbetaD	O
-	O
1	O
)	O
to	O
hbetaD	O
-	O
4	O
was	O
investigated	O
by	O
pretreating	O
cells	O
with	O
either	O
sublethal	O
levels	O
of	O
defensins	O
or	O
environmental	O
factors	O
,	O
followed	O
by	O
a	O
challenge	O
with	O
lethal	O
levels	O
of	O
defensins	O
.	O

Cultures	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
were	O
(	O
i	O
)	O
pretreated	O
with	O
defensins	O
at	O
1	O
ng	O
/	O
ml	O
,	O
(	O
ii	O
)	O
heated	O
to	O
42	O
degrees	O
C	O
(	O
heat	O
stress	O
)	O
,	O
(	O
iii	O
)	O
exposed	O
to	O
normal	O
atmosphere	O
(	O
oxidative	O
stress	O
)	O
,	O
or	O
(	O
iv	O
)	O
exposed	O
to	O
1	O
mM	O
hydrogen	O
peroxide	O
(	O
peroxide	O
stress	O
)	O
.	O

Samples	O
(	O
10	O
microl	O
)	O
were	O
distributed	O
among	O
the	O
wells	O
of	O
sterile	O
384	O
-	O
well	O
plates	O
containing	O
hbetaD	O
-	O
1	O
to	O
-	O
4	O
(	O
100	O
microg	O
/	O
ml	O
)	O
.	O

Plates	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
36	O
h	O
in	O

an	O
anaerobe	O
chamber	O
.	O

Growth	O
inhibition	O
was	O
determined	O
by	O
a	O
system	O
that	O
measures	O
the	O
total	O
nucleic	O
acid	O
of	O
a	O
sample	O
with	O
a	O
DNA	O
binding	O
dye	O
.	O

The	O
MICs	O
of	O
the	O
four	O
defensins	O
for	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
were	O
3	O
to	O
12	O
microg	O
/	O
ml	O
.	O

We	O
found	O
that	O
sublethal	O
levels	O
of	O
the	O
defensins	O
and	O
heat	O
and	O
peroxide	O
stress	O
,	O
but	O
not	O
oxidative	O
stress	O
,	O
induced	O
resistance	O
to	O
100	O
microg	O
of	O
defensin	O
per	O
ml	O
in	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

Resistance	O
induced	O
by	O
sublethal	O
levels	O
of	O
hbetaD	O
-	O
2	O
lasted	O
90	O
min	O
,	O
and	O
the	O
resistance	O
induced	O
by	O
each	O
defensin	O
was	O
effective	O
against	O
the	O
other	O
three	O
.	O

Multiple	O
strains	O
exposed	O
to	O
hbetaD	O
-	O
2	O
all	O
evidenced	O
resistance	O
induction	O
.	O

Defensin	O
resistance	O
is	O
vital	O
to	O
the	O
pathogenic	O
potential	O
of	O
several	O
human	O
pathogens	O
.	O

This	O
is	O
the	O
first	O
report	O
describing	O
the	O
induction	O
of	O
defensin	O
resistance	O
in	O
the	O
oral	O
periodontal	O
pathogen	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

Such	O
resistance	O
may	O
have	O
an	O
effect	O
on	O
the	O
ability	O
of	O
oral	O
pathogens	O
to	O
persist	O
in	O
the	O
mouth	O
and	O
to	O
withstand	O
innate	O
human	O
immunity	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
has	O
been	O
recognized	O
as	O
an	O
important	O
etiological	O
agent	O
in	O
human	O
dental	O
caries	O
.	O

Some	O
strains	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
also	O
produce	O
bacteriocins	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
demonstrate	O
that	O
bacteriocin	O
production	O
by	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
strains	I-bacteria
GS5	I-bacteria
and	O
BM71	B-bacteria
was	O
mediated	O
by	O
quorum	O
sensing	O
,	O
which	O
is	O
dependent	O
on	O
a	O
competence	O
-	O
stimulating	O
peptide	O
(	O
CSP	O
)	O
signaling	O
system	O
encoded	O
by	O
the	O
com	O
genes	O
.	O

We	O
also	O
demonstrated	O
that	O
interactions	O
with	O
some	O
other	O
oral	O
streptococci	B-bacteria
interfered	O
with	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
bacteriocin	O
production	O
both	O
in	O
broth	O
and	O
in	O
biofilms	O
.	O

The	O
inhibition	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
bacteriocin	O
production	O
by	O
oral	O
bacteria	O
was	O
stronger	O
in	O
biofilms	O
than	O
in	O
broth	O
.	O

Using	O
transposon	O
Tn916	O
mutagenesis	O
,	O
we	O
identified	O
a	O
gene	O
(	O
sgc	O
;	O
named	O
for	O
Streptococcus	B-bacteria
gordonii	I-bacteria
challisin	I-bacteria
)	O
responsible	O
for	O
the	O
inhibition	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
bacteriocin	O
production	O
by	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
Challis	O
.	O

Interruption	O
of	O
the	O
sgc	O
gene	O
in	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
Challis	O
resulted	O
in	O
attenuated	O
inhibition	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
bacteriocin	O
production	O
.	O

The	O
supernatant	O
fluids	O
from	O
the	O
sgc	O
mutant	O
did	O
not	O
inactivate	O
the	O
exogenous	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
CSP	O
as	O
did	O
those	O
from	O
the	O
parent	O
strain	O
Challis	O
.	O

S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
Challis	O
did	O
not	O
inactivate	O
bacteriocin	O
produced	O
by	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
GS5	I-bacteria
.	O

Because	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
uses	O
quorum	O
sensing	O
to	O
regulate	O
virulence	O
,	O
strategies	O
designed	O
to	O
interfere	O
with	O
these	O
signaling	O
systems	O
may	O
have	O
broad	O
applicability	O
for	O
biological	O
control	O
of	O
this	O
caries	O
-	O
causing	O
organism	O
.	O

Direct	O
person	O
-	O
to	O
-	O
person	O
transmission	O
of	O
periodontal	O
bacteria	O
through	O
saliva	O
has	O
recently	O
been	O
widely	O
reported	O
and	O
dental	O
units	O
have	O
been	O
demonstrated	O
to	O
retract	O
saliva	O
from	O
patients	O
under	O
treatment	O
and	O
to	O
release	O
it	O
into	O
the	O
mouths	O
of	O
subjects	O
undergoing	O
the	O
next	O
operation	O
.	O

In	O
this	O
study	O
the	O
presence	O
of	O
a	O
group	O
of	O
periodontal	O
pathogenic	O
bacteria	O
inside	O
waterlines	O
in	O
dental	O
units	O
was	O
investigated	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
based	O
methods	O
.	O

Briefly	O
,	O
18	O
dental	O
units	O
of	O
three	O
different	O
manufacturers	O
were	O
studied	O
.	O

Dental	O
units	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
their	O
prevalent	O
use	O
in	O
routine	O
practice	O
.	O

The	O
first	O
group	O
consisted	O
of	O
nine	O
dental	O
units	O
characterized	O
by	O
the	O
frequent	O
use	O
of	O
high	O
-	O
speed	O
dental	O
hand	O
-	O
pieces	O
directly	O
inside	O
the	O
mouth	O
and	O
in	O
contact	O
with	O
patients	O
'	O
saliva	O
.	O

The	O
second	O
group	O
,	O
as	O
a	O
control	O
,	O
consisted	O
of	O
nine	O
dental	O
units	O
where	O
high	O
-	O
speed	O
dental	O
hand	O
-	O
pieces	O
were	O
not	O
in	O
use	O
.	O

A	O
one	O
cm	O
section	O
of	O
the	O
waterline	O
tubing	O
connected	O
to	O
the	O
high	O
-	O
speed	O
hand	O
-	O
piece	O
was	O
removed	O
from	O
each	O
dental	O
unit	O
to	O
evaluate	O
the	O
presence	O
of	O
DNA	O
of	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Bacteroides	B-bacteria
forsythus	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
.	O

Two	O
specimens	O
were	O
positive	O
for	O
Prevotella	B-bacteria
intermedia	I-bacteria
DNA	O
.	O

All	O
the	O
positive	O
results	O
were	O
from	O
samples	O
obtained	O
from	O
dental	O
units	O
categorised	O
in	O
the	O
first	O
group	O
.	O

These	O
findings	O
clearly	O
suggest	O
that	O
dental	O
units	O
have	O
the	O
potential	O
to	O
transmit	O
periodontal	O
pathogens	O
.	O

Manufacturers	O
should	O
be	O
invited	O
to	O
design	O
dental	O
units	O
that	O
incorporate	O
automated	O
devices	O
to	O
disinfect	O
DUWLs	O
between	O
patients	O
with	O
minimal	O
effort	O
by	O
dental	O
staff	O
.	O

The	O
aim	O
of	O
this	O
investigation	O
was	O
to	O
evaluate	O
the	O
prevalence	O
of	O
Candida	O
and	O
Enterobacteriaceae	B-bacteria
in	O
a	O
group	O
of	O
adolescents	O
during	O
fixed	O
orthodontic	O
appliance	O
(	O
FOA	O
)	O
therapy	O
.	O

The	O
experimental	O
group	O
was	O
recruited	O
from	O
a	O
larger	O
sample	O
of	O
orthodontic	O
patients	O
who	O
were	O
clinically	O
examined	O
once	O
to	O
obtain	O
baseline	O
data	O
before	O
active	O
treatment	O
.	O

The	O
group	O
comprised	O
27	O
subjects	O
;	O
13	O
males	O
,	O
14	O
females	O
(	O
mean	O
age	O
15	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
3	O
years	O
)	O
.	O

Thereafter	O
,	O
the	O
experimental	O
group	O
was	O
examined	O
three	O
times	O
during	O
a	O
3	O
month	O
follow	O
-	O
up	O
period	O
after	O
insertion	O
of	O
the	O
FOA	O
.	O

The	O
whole	O
mouth	O
plaque	O
score	O
was	O
obtained	O
,	O
and	O
the	O
oral	O
cavity	O
was	O
then	O
sampled	O
for	O
Candida	O
species	O
and	O
Enterobacteriaceae	B-bacteria
using	O
three	O
different	O
microbiological	O
culture	O
techniques	O
,	O
namely	O
the	O
oral	O
rinse	O
,	O
pooled	O
plaque	O
and	O
the	O
imprint	O
culture	O
.	O
A	O
significant	O
increase	O
in	O
candidal	O
numbers	O
was	O
observed	O
after	O
FOA	O
insertion	O
when	O
the	O
imprint	O
technique	O
was	O
used	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
although	O
the	O
overall	O
candidal	O
prevalence	O
rates	O
obtained	O
using	O
the	O
oral	O
rinse	O
and	O
pooled	O
plaque	O
techniques	O
did	O
not	O
demonstrate	O
such	O
a	O
change	O
.	O

The	O
predominant	O
Candida	O
species	O
isolated	O
was	O
C	O
.	O
albicans	O
and	O
the	O
number	O
of	O
coliform	B-bacteria
carriers	O
significantly	O
increased	O
after	O
the	O
insertion	O
of	O
a	O
FOA	O
,	O
as	O
detected	O
by	O
the	O
oral	O
rinse	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
pooled	O
plaque	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
techniques	O
.	O

In	O
total	O
,	O
eight	O
coliform	B-bacteria
species	I-bacteria
were	O
isolated	O
following	O
FOA	O
therapy	O
compared	O
with	O
the	O
three	O
species	O
isolated	O
before	O
insertion	O
of	O
the	O
appliance	O
.	O

The	O
results	O
also	O
revealed	O
a	O
significant	O
increase	O
in	O
plaque	O
index	O
due	O
to	O
the	O
introduction	O
of	O
a	O
FOA	O
.	O

Taken	O
together	O
,	O
these	O
data	O
imply	O
that	O
insertion	O
of	O
a	O
FOA	O
is	O
likely	O
to	O
promote	O
oral	O
carriage	O
of	O
Candida	O
and	O
coliform	B-bacteria
species	I-bacteria
.	O

Furthermore	O
,	O
it	O
appears	O
that	O
routine	O
oral	O
hygiene	O
instruction	O
and	O
information	O
on	O
appliance	O
hygiene	O
given	O
to	O
these	O
patients	O
may	O
not	O
necessarily	O
reduce	O
plaque	O
accumulation	O
and	O
possible	O
attendant	O
effects	O
.	O

Further	O
work	O
with	O
a	O
larger	O
cohort	O
is	O
required	O
to	O
confirm	O
these	O
findings	O
.	O

Cecropin	O
-	O
XJ	O
belongs	O
to	O
cecropin	O
-	O
B	O
,	O
which	O
is	O
the	O
most	O
potent	O
antibacterial	O
peptide	O
found	O
naturally	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
cecropin	O
-	O
XJ	O
on	O
growth	O
and	O
adherence	O
of	O
oral	O
cariogenic	O
bacteria	O
.	O

Four	O
oral	O
cariogenic	O
bacteria	O
(	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
Actinomyces	B-bacteria
viscosus	I-bacteria
and	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
)	O
were	O
chosen	O
for	O
this	O
experiment	O
.	O

The	O
minimal	O
inhibitory	O
concentrations	O
(	O
MICs	O
)	O
and	O
reductive	O
percent	O
of	O
bacterial	O
growth	O
were	O
used	O
to	O
assay	O
the	O
antibacterial	O
activity	O
of	O
cecropin	O
-	O
XJ	O
.	O

Mammalian	O
cytotoxicity	O
of	O
cecropin	O
-	O
XJ	O
was	O
tested	O
with	O
human	O
periodontal	O
membrane	O
fibroblasts	O
by	O
tetrazolium	O
(	O
MTT	O
)	O
colorimetric	O
assay	O
.	O

The	O
bacterial	O
morphological	O
changes	O
induced	O
by	O
cecropin	O
-	O
XJ	O
were	O
examined	O
on	O
scanning	O
electron	O
microscope	O
(	O
SEM	O
)	O
.	O

The	O
influence	O
of	O
cecropin	O
-	O
XJ	O
on	O
bacterial	O
adhesion	O
to	O
saliva	O
-	O
coated	O
hydroxyapatite	O
(	O
S	O
-	O
HA	O
)	O
was	O
measured	O
by	O
scintillation	O
counting	O
.	O

The	O
MICs	O
of	O
cecropin	O
-	O
XJ	O
for	O
inhibition	O
of	O
the	O
growth	O
of	O
four	O
bacteria	O
ranged	O
from	O
4	O
.	O
0	O
to	O
42	O
.	O
8	O
micromol	O
/	O
L	O
with	O
the	O
highest	O
susceptible	O
to	O
A	O
.	O
naeslundii	O
and	O
the	O
lowest	O
susceptible	O
to	O
L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
.	O

At	O
pH	O
6	O
.	O
8	O
,	O
5	O
.	O
5	O
and	O
8	O
.	O
2	O
,	O
1	O
/	O
2	O
MIC	O
of	O
cecropin	O
-	O
XJ	O
reduced	O
the	O
number	O
of	O
viable	O
bacteria	O
by	O
40	O
.	O
9	O
%	O
,	O
67	O
.	O
8	O
%	O
and	O
32	O
.	O
8	O
%	O
for	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
by	O
28	O
.	O
1	O
%	O
,	O
57	O
.	O
2	O
%	O
and	O
37	O
.	O
9	O
%	O
for	O
L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
.	O

The	O
activities	O
against	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
increased	O
at	O
pH	O
5	O
.	O
5	O
compared	O
with	O
pH	O
6	O
.	O
8	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

In	O
present	O
of	O
50	O
%	O
saliva	O
,	O
1	O
/	O
2	O
MIC	O
of	O
the	O
peptide	O
decreased	O
the	O
direct	O
count	O
of	O
viable	O
cells	O
by	O
29	O
.	O
2	O
%	O
and	O
14	O
.	O
4	O
%	O
for	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
01	O
and	O
P	O
>	O
0	O
.	O
05	O
,	O
respectively	O
)	O
,	O
whereas	O
almost	O
no	O
reduction	O
counts	O
were	O
detected	O
in	O
the	O
presence	O
of	O
20	O
%	O
serum	O
for	O
both	O
bacteria	O
(	O
P	O
>	O
0	O
.	O
05	O
,	O
respectively	O
)	O
.	O

Mammalian	O
cytotoxicity	O
of	O
cecropin	O
-	O
XJ	O
from	O
1	O
.	O
0	O
to	O
100	O
micromol	O
/	O
L	O
exhibited	O
no	O
cytotoxicity	O
against	O
human	O
periodontal	O
membrane	O
fibroblasts	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

Bacterial	O
morphological	O
changes	O
induced	O
by	O
MIC	O
of	O
cecropin	O
-	O
XJ	O
examined	O
on	O
SEM	O
showed	O
cell	O
surface	O
disruption	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
A	O
.	O
naeslundii	O
adhesion	O
to	O
S	O
-	O
HA	O
decreased	O
significantly	O
with	O
MIC	O
of	O
cecropin	O
-	O
XJ	O
for	O
10	O
and	O
20	O
minutes	O
(	O
P	O
=	O
0	O
.	O
001	O
and	O
0	O
.	O
000	O
,	O
respectively	O
)	O
,	O
and	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
viscosus	I-bacteria
to	O
S	O
-	O
HA	O
decreased	O
significantly	O
with	O
MIC	O
of	O
cecropin	O
-	O
XJ	O
for	O
20	O
minutes	O
(	O
P	O
=	O
0	O
.	O
000	O
,	O
respectively	O
)	O
.	O

Cecropin	O
-	O
XJ	O
exhibited	O
bactericidal	O
action	O
against	O
cariogenic	O
pathogens	O
,	O
and	O
the	O
antibacterial	O
activity	O
enhanced	O
in	O
the	O
acid	O
environment	O
.	O

The	O
results	O
also	O
demonstrate	O
that	O
cecropin	O
-	O
XJ	O
prevents	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
actinomyces	B-bacteria
adsorption	O
to	O
S	O
-	O
HA	O
.	O

These	O
findings	O
suggest	O
that	O
Cecropin	O
-	O
XJ	O
may	O
have	O
potential	O
to	O
prevent	O
caries	O
.	O

It	O
is	O
hypothesized	O
that	O
the	O
enterosalivary	O
nitrate	O
circulation	O
encourages	O
nitrate	O
reducing	O
bacteria	O
to	O
reside	O
within	O
the	O
oral	O
cavity	O
.	O

Nitrite	O
production	O
may	O
then	O
limit	O
the	O
growth	O
of	O
acidogenic	O
bacteria	O
as	O
a	O
result	O
of	O
the	O
production	O
of	O
antimicrobial	O
oxides	O
of	O
nitrogen	O
,	O
including	O
nitric	O
oxide	O
.	O

This	O
study	O
was	O
carried	O
out	O
with	O
10	O
subjects	O
to	O
characterize	O
oral	O
nitrate	O
reduction	O
and	O
identify	O
the	O
bacteria	O
responsible	O
.	O

Nitrate	O
reduction	O
varied	O
between	O
individuals	O
(	O
mean	O
85	O
.	O
4	O
+	O
/	O
-	O
15	O
.	O
9	O
nmol	O
nitrite	O
min	O
(	O
-	O
1	O
)	O
with	O
10	O
ml	O
1	O
mm	O
KNO	O
(	O
3	O
)	O
mouth	O
wash	O
)	O
and	O
was	O
found	O
to	O
be	O
concentrated	O
at	O
the	O
rear	O
of	O
the	O
tongue	O
dorsal	O
surface	O
.	O

Nitrate	O
reductase	O
positive	O
isolates	O
identified	O
,	O
using	O
16S	O
rDNA	O
sequencing	O
,	O
from	O
the	O
tongue	O
comprised	O
Veillonella	B-bacteria
atypica	I-bacteria
(	O
34	O
%	O
)	O
,	O
Veillonella	B-bacteria
dispar	I-bacteria
(	O
24	O
%	O
)	O
,	O
Actinomyces	B-bacteria
odontolyticus	I-bacteria
(	O
21	O
%	O
)	O
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
(	O
2	O
%	O
)	O
,	O
Rothia	B-bacteria
mucilaginosa	I-bacteria
(	O
10	O
%	O
)	O
,	O
Rothia	B-bacteria
dentocariosa	I-bacteria
(	O
3	O
%	O
)	O
and	O
Staphylococcus	B-bacteria
epidermidis	I-bacteria
(	O
5	O
%	O
)	O
.	O

Nitrite	O
production	O
rates	O
,	O
using	O
intact	O
and	O
permeabilized	O
cells	O
,	O
of	O
the	O
major	O
tongue	O
nitrate	O
reducers	O
were	O
determined	O
in	O
the	O
presence	O
of	O
methyl	O
and	O
benzyl	O
viologen	O
.	O

Under	O
anaerobic	O
conditions	O
in	O
the	O
presence	O
of	O
nitrate	O
,	O
rates	O
in	O
decreasing	O
order	O
were	O
:	O
A	B-bacteria
.	I-bacteria
odontolyticus	I-bacteria
>	O
R	B-bacteria
.	I-bacteria
mucilaginosa	I-bacteria
>	O
R	B-bacteria
.	I-bacteria
dentocariosa	I-bacteria
>	O
V	B-bacteria
.	I-bacteria
dispar	I-bacteria
>	O
V	B-bacteria
.	I-bacteria
atypica	I-bacteria
.	O

In	O
conclusion	O
,	O
Veillonella	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
found	O
to	O
be	O
the	O
most	O
prevalent	O
taxa	O
isolated	O
and	O
thus	O
may	O
make	O
a	O
major	O
contribution	O
to	O
nitrate	O
reduction	O
in	O
the	O
oral	O
cavity	O
.	O

Bone	O
necrosis	O
secondary	O
to	O
radiation	O
was	O
previously	O
attributed	O
to	O
trauma	O
of	O
devitalized	O
bone	O
and	O
microbiological	O
sepsis	O
.	O

However	O
,	O
conventional	O
microbiological	O
technique	O
has	O
failed	O
to	O
demonstrate	O
microorganisms	O
throughout	O
osteoradionecrotic	O
bone	O
,	O
claimed	O
to	O
be	O
hypoxic	O
,	O
hypovascular	O
and	O
hypocellular	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
such	O
bone	O
for	O
bacteria	O
using	O
DNA	O
-	O
DNA	O
hybridization	O
.	O

Compared	O
to	O
standard	O
culture	O
methods	O
this	O
technique	O
enables	O
the	O
investigation	O
of	O
a	O
vast	O
number	O
of	O
bacteria	O
in	O
a	O
fairly	O
short	O
time	O
.	O

Twelve	O
deep	O
medullary	O
specimens	O
from	O
resected	O
radionecrotic	O
mandibles	O
were	O
studied	O
.	O

A	O
multitude	O
of	O
bacterial	O
species	O
were	O
detected	O
,	O
most	O
of	O
them	O
anaerobic	O
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
was	O
the	O
most	O
predominant	O
organism	O
,	O
followed	O
by	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
subspecies	I-bacteria
polymorphum	I-bacteria
.	O

All	O
samples	O
contained	O
Actinomyces	B-bacteria
,	O
Prevotella	B-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
bacteria	O
,	O
particularly	O
anaerobes	O
,	O
may	O
play	O
a	O
more	O
fundamental	O
role	O
in	O
the	O
pathophysiology	O
of	O
osteoradionecrosis	O
than	O
being	O
merely	O
surface	O
contaminants	O
.	O

Glycoproteins	O
display	O
carbohydrate	O
facets	O
that	O
serve	O
as	O
adhesion	O
receptors	O
for	O
cells	O
including	O
leukocytes	O
and	O
bacterial	O
cells	O
.	O

Our	O
aim	O
was	O
to	O
understand	O
the	O
role	O
of	O
the	O
specialized	O
carbohydrate	O
motifs	O
carried	O
by	O
highly	O
glycosylated	O
human	O
salivary	O
proteins	O
in	O
regulating	O
the	O
oral	O
ecology	O
.	O

To	O
date	O
,	O
our	O
structural	O
studies	O
suggest	O
that	O
these	O
molecules	O
display	O
a	O
wide	O
array	O
of	O
oligosaccharide	O
structures	O
,	O
including	O
many	O
species	O
with	O
highly	O
charged	O
and	O
/	O
or	O
fucosylated	O
termini	O
.	O

Here	O
,	O
we	O
used	O
an	O
immunoblot	O
approach	O
to	O
gain	O
additional	O
information	O
about	O
the	O
nature	O
of	O
these	O
oligosaccharides	O
.	O

The	O
results	O
showed	O
that	O
MG1	O
and	O
the	O
salivary	O
agglutinin	O
express	O
the	O
MECA	O
-	O
79	O
epitope	O
,	O
an	O
unusual	O
sulfated	O
carbohydrate	O
structure	O
that	O
belongs	O
to	O
an	O
important	O
class	O
of	O
high	O
-	O
affinity	O
(	O
endothelial	O
)	O
L	O
-	O
selectin	O
ligands	O
.	O

Unexpectedly	O
,	O
we	O
discovered	O
that	O
in	O
many	O
women	O
the	O
expression	O
of	O
this	O
epitope	O
is	O
hormonally	O
regulated	O
.	O

Additional	O
experiments	O
revealed	O
that	O
MG1	O
,	O
MG2	O
,	O
and	O
the	O
salivary	O
agglutinin	O
also	O
present	O
Lewis	O
blood	O
group	O
antigens	O
,	O
the	O
exact	O
repertoire	O
varying	O
on	O
an	O
individual	O
basis	O
.	O

In	O
parallel	O
,	O
we	O
explored	O
the	O
functions	O
of	O
these	O
carbohydrate	O
motifs	O
.	O

Using	O
an	O
assay	O
that	O
detects	O
L	O
-	O
selectin	O
ligands	O
,	O
we	O
found	O
that	O
the	O
subset	O
of	O
MECA	O
-	O
79	O
-	O
reactive	O
oligosaccharides	O
displayed	O
on	O
salivary	O
molecules	O
specifically	O
bind	O
an	O
L	O
-	O
selectin	O
/	O
Fc	O
chimera	O
.	O

In	O
contrast	O
,	O
the	O
Lewis	O
blood	O
group	O
structures	O
are	O
receptors	O
for	O
many	O
strains	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
,	O
an	O
organism	O
that	O
is	O
implicated	O
in	O
the	O
development	O
of	O
gastric	O
ulcers	O
and	O
cancer	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
MG1	O
,	O
MG2	O
,	O
and	O
the	O
salivary	O
agglutinin	O
play	O
important	O
roles	O
in	O
governing	O
leukocyte	O
and	O
bacterial	O
adhesion	O
.	O

Our	O
findings	O
suggest	O
novel	O
strategies	O
,	O
based	O
on	O
the	O
relevant	O
carbohydrate	O
structures	O
,	O
for	O
promoting	O
or	O
inhibiting	O
these	O
processes	O
.	O

Expression	O
of	O
the	O
phosphorylcholine	O
(	O
PC	O
)	O
epitope	O
was	O
examined	O
in	O
48	O
viridans	B-bacteria
streptococcal	I-bacteria
strains	I-bacteria
,	O
including	O
Streptococcus	B-bacteria
pneumoniae	I-bacteria
R36a	I-bacteria
as	O
the	O
positive	O
control	O
,	O
and	O
their	O
immunogenicity	O
to	O
induce	O
an	O
S	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
-	O
cross	O
-	O
reactive	O
response	O
was	O
evaluated	O
in	O
mice	O
.	O

Thirteen	O
strains	O
were	O
found	O
to	O
express	O
the	O
PC	O
epitope	O
,	O
while	O
no	O
obvious	O
association	O
was	O
found	O
between	O
the	O
taxonomic	O
categories	O
and	O
PC	O
expression	O
.	O

Serum	O
antibody	O
responses	O
to	O
S	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
cells	O
were	O
induced	O
in	O
mice	O
by	O
intraperitoneal	O
injection	O
of	O
the	O
PC	O
-	O
positive	O
,	O
but	O
not	O
PC	O
-	O
negative	O
,	O
strains	O
.	O

The	O
cross	O
-	O
reactive	O
antibodies	O
induced	O
by	O
non	O
-	O
pneumococcal	O
oral	O
streptococci	B-bacteria
were	O
readily	O
inhibited	O
by	O
free	O
hapten	O
PC	O
.	O

IgM	O
was	O
the	O
sole	O
isotype	O
of	O
the	O
anti	O
-	O
pneumococcal	O
and	O
anti	O
-	O
PC	O
antibodies	O
,	O
and	O
the	O
phenomenon	O
of	O
immunological	O
memory	O
was	O
not	O
observed	O
.	O

Since	O
the	O
anti	O
-	O
PC	O
antibody	O
is	O
critically	O
important	O
for	O
resistance	O
against	O
pneumococcal	O
infection	O
in	O
mice	O
,	O
the	O
present	O
results	O
indicate	O
the	O
possibility	O
that	O
PC	O
-	O
expressing	O
oral	O
commensal	O
bacteria	O
have	O
a	O
significant	O
influence	O
on	O
the	O
hosts	O
'	O
responsiveness	O
to	O
S	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
.	O

Antifungal	O
prophylactic	O
therapy	O
in	O
oncology	O
patients	O
has	O
favors	O
the	O
emergence	O
of	O
diverse	O
species	O
of	O
Candida	O
.	O

In	O
the	O
present	O
study	O
32	O
clinic	O
isolates	O
of	O
Candida	O
spp	O
.	O
,	O
recovered	O
from	O
oral	O
cavity	O
,	O
were	O
evaluated	O
testing	O
their	O
susceptibility	O
to	O
diverse	O
antifungals	O
by	O
means	O
of	O
the	O
microdilution	O
method	O
according	O
with	O
the	O
document	O
M	O
-	O
27A	O
of	O
the	O
National	O
Committee	O
for	O
Clinical	O
Laboratory	O
Standards	O
(	O
NCCLS	O
)	O
.	O

The	O
response	O
to	O
antifungals	O
was	O
then	O
compared	O
with	O
SSCP	O
patterns	O
of	O
the	O
gene	O
ERG11	O
,	O
hoping	O
to	O
find	O
mutations	O
in	O
this	O
gene	O
linked	O
to	O
resistance	O
to	O
the	O
azole	O
antifungals	O
from	O
samples	O
of	O
clinical	O
origin	O
.	O

Three	O
SSCP	O
genotypes	O
with	O
diverse	O
response	O
to	O
different	O
antifungals	O
were	O
found	O
.	O

This	O
study	O
suggested	O
that	O
a	O
link	O
of	O
mutations	O
in	O
the	O
ERG11	O
gene	O
of	O
Candida	O
albicans	O
and	O
antifungal	O
resistance	O
was	O
not	O
supported	O
by	O
this	O
data	O
.	O

In	O
addition	O
,	O
the	O
isolates	O
were	O
also	O
classified	O
by	O
conventional	O
methods	O
and	O
their	O
genetic	O
diversity	O
evaluated	O
by	O
means	O
of	O
SSCP	O
analysis	O
and	O
evaluation	O
of	O
their	O
ITS2	O
regions	O
,	O
identifying	O
eight	O
SSCP	O
genotypes	O
.	O

This	O
technique	O
has	O
the	O
potential	O
to	O
be	O
a	O
more	O
sensitive	O
method	O
for	O
taxonomic	O
classification	O
.	O

To	O
validate	O
perfused	O
,	O
inline	O
,	O
filter	O
-	O
based	O
fermentation	O
systems	O
(	O
multiple	O
Sorbarod	O
devices	O
,	O
MSD	O
)	O
for	O
their	O
ability	O
to	O
maintain	O
stable	O
oral	O
bacterial	O
communities	O
.	O

MSD	O
enable	O
replicate	O
(	O
n	O
=	O
5	O
)	O
microcosm	O
biofilms	O
(	O
BF	O
)	O
to	O
be	O
established	O
and	O
sampled	O
,	O
together	O
with	O
their	O
perfusates	O
(	O
PA	O
,	O
cells	O
in	O
eluted	O
medium	O
)	O
.	O

Fresh	O
saliva	O
from	O
human	O
volunteers	O
was	O
used	O
to	O
inoculate	O
MSD	O
,	O
incubated	O
in	O
an	O
anaerobic	O
cabinet	O
and	O
perfused	O
with	O
artificial	O
saliva	O
at	O
7	O
ml	O
h	O
(	O
-	O
1	O
)	O
.	O

BF	O
within	O
Sorbarod	O
filters	O
and	O
cells	O
eluted	O
in	O
the	O
PA	O
were	O
analysed	O
at	O
24	O
-	O
h	O
intervals	O
by	O
differential	O
bacteriological	O
culture	O
and	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
(	O
CKB	O
,	O
40	O
oral	O
species	O
)	O
.	O

Dynamic	O
stability	O
was	O
apparent	O
after	O
2	O
-	O
3	O
days	O
within	O
both	O
BF	O
and	O
PA	O
as	O
evidenced	O
by	O
culture	O
,	O
CKB	O
data	O
and	O
pH	O
measurements	O
.	O

BF	O
harboured	O
large	O
numbers	O
of	O
anaerobic	O
species	O
and	O
facultative	O
anaerobes	O
[	O
ca	O
10	O
-	O
11	O
log10	O
colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
/	O
filter	O
]	O
comprising	O
considerable	O
numbers	O
of	O
streptococci	B-bacteria
and	O
Gram	O
-	O
negative	O
species	O
.	O

PA	O
contained	O
ca	O
9	O
-	O
10	O
log	O
(	O
10	O
)	O
CFU	O
ml	O
(	O
-	O
1	O
)	O
suggesting	O
an	O
apparent	O
mean	O
growth	O
rate	O
of	O
0	O
.	O
1	O
h	O
(	O
-	O
1	O
)	O
for	O
the	O
BF	O
,	O
as	O
a	O
whole	O
corresponding	O
to	O
a	O
mean	O
generation	O
time	O
of	O
10	O
h	O
.	O
CKB	O
analysis	O
revealed	O
considerable	O
bacterial	O
diversity	O
within	O
the	O
respective	O
MSD	O
.	O

Inter	O
-	O
individual	O
variations	O
in	O
the	O
relative	O
species	O
abundance	O
of	O
inocula	O
was	O
broadly	O
reproduced	O
in	O
the	O
MSD	O
(	O
BF	O
and	O
PA	O
)	O
,	O
although	O
considerable	O
variation	O
was	O
apparent	O
between	O
triplicate	O
models	O
established	O
using	O
saliva	O
from	O
one	O
saliva	O
donor	O
or	O
from	O
three	O
individual	O
donors	O
.	O

The	O
dominance	O
of	O
Gram	O
-	O
negative	O
species	O
,	O
indicated	O
by	O
culture	O
was	O
supported	O
by	O
CKB	O
analysis	O
(	O
major	O
species	O
,	O
Prevotella	B-bacteria
melaninogenica	I-bacteria
and	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
)	O
.	O

Data	O
obtained	O
from	O
the	O
various	O
analytical	O
approaches	O
showed	O
a	O
high	O
degree	O
of	O
congruence	O
.	O

The	O
MSD	O
enables	O
the	O
maintenance	O
of	O
complex	O
,	O
stable	O
salivary	O
microcosms	O
and	O
represents	O
a	O
simple	O
,	O
reproducible	O
tool	O
for	O
modelling	O
individual	O
oral	O
bacterial	O
ecosystems	O
.	O

This	O
study	O
demonstrates	O
the	O
utility	O
of	O
the	O
MSD	O
for	O
studying	O
the	O
micro	O
-	O
ecology	O
of	O
the	O
oral	O
cavity	O
.	O

The	O
main	O
cause	O
of	O
acute	O
diverticulitis	O
is	O
the	O
abnormal	O
accumulation	O
of	O
fecal	O
bacteria	O
within	O
the	O
diverticular	O
lumen	O
,	O
leading	O
to	O
a	O
balancing	O
between	O
normal	O
probiotic	O
microflora	O
and	O
pathogenic	O
species	O
;	O
Gram	O
negative	O
Entero	O
-	O
bacteriaceae	O
,	O
mainly	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
Proteus	B-bacteria
spp	I-bacteria
,	O
are	O
the	O
genders	O
that	O
usually	O
cause	O
the	O
disease	O
-	O
related	O
symptoms	O
,	O
due	O
to	O
their	O
ability	O
to	O
adhere	O
to	O
intestinal	O
mucosa	O
.	O

The	O
intestine	O
is	O
well	O
known	O
as	O
the	O
largest	O
human	O
lymphoepithelial	O
organ	O
and	O
daily	O
produces	O
more	O
antibodies	O
,	O
mainly	O
secretory	O
IgAs	O
,	O
than	O
do	O
all	O
other	O
lymphoid	O
tissues	O
.	O

IgAs	O
have	O
different	O
immune	O
and	O
anti	O
-	O
inflammatory	O
properties	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
verify	O
the	O
efficacy	O
of	O
an	O
oral	O
immunostimulant	O
highly	O
-	O
purified	O
,	O
polymicrobial	O
lysate	O
in	O
the	O
prevention	O
of	O
recurrent	O
attacks	O
of	O
diverticulitis	O
and	O
in	O
the	O
improvement	O
of	O
symptoms	O
.	O

The	O
study	O
was	O
carried	O
out	O
on	O
83	O
consecutive	O
patients	O
suffering	O
from	O
recurrent	O
symptomatic	O
acute	O
diverticulitis	O
and	O
with	O
at	O
least	O
2	O
attacks	O
in	O
the	O
previous	O
year	O
;	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
(	O
group	O
A	O
)	O
an	O
oral	O
polybacterial	O
lysate	O
suspension	O
or	O
to	O
a	O
no	O
-	O
treatment	O
clinical	O
follow	O
-	O
up	O
as	O
controls	O
(	O
group	O
B	O
)	O
.	O

A	O
total	O
of	O
76	O
patients	O
(	O
41	O
in	O
group	O
A	O
and	O
35	O
in	O
group	O
B	O
)	O
terminated	O
the	O
study	O
period	O
.	O

the	O
sums	O
of	O
the	O
scores	O
for	O
symptoms	O
,	O
reported	O
on	O
day	O
schedules	O
,	O
were	O
calculated	O
and	O
examined	O
by	O
means	O
of	O
ANOVA	O
statistical	O
analysis	O
.	O

Statistical	O
differences	O
between	O
group	O
A	O
vs	O
group	O
B	O
were	O
recorded	O
after	O
1	O
month	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
3	O
months	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
of	O
treatment	O
with	O
the	O
oral	O
polybacterial	O
lysate	O
suspension	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
administration	O
of	O
an	O
oral	O
enterovaccine	O
for	O
the	O
prophylaxis	O
of	O
recurrent	O
diverticulitis	O
is	O
effective	O
and	O
well	O
tolerated	O
,	O
probably	O
due	O
to	O
a	O
direct	O
stimulation	O
of	O
IgA	O
-	O
mediated	O
mucosal	O
defences	O
.	O

We	O
studied	O
the	O
pheno	O
-	O
and	O
genotypes	O
of	O
an	O
oral	O
Granulicatella	B-bacteria
elegans	I-bacteria
strain	I-bacteria
in	O
comparison	O
with	O
those	O
of	O
a	O
blood	O
-	O
derived	O
isolate	O
which	O
caused	O
infective	O
endocarditis	O
.	O

The	O
two	O
isolates	O
exhibited	O
identical	O
biochemical	O
characteristics	O
and	O
had	O
the	O
same	O
drug	O
MICs	O
.	O

Their	O
genotypes	O
were	O
indistinguishable	O
,	O
indicating	O
that	O
these	O
were	O
from	O
the	O
same	O
clone	O
.	O

The	O
transmission	O
of	O
G	B-bacteria
.	I-bacteria
elegans	I-bacteria
from	O
the	O
oral	O
cavity	O
thus	O
should	O
be	O
noted	O
as	O
a	O
possible	O
cause	O
of	O
infective	O
endocarditis	O
.	O

It	O
is	O
well	O
-	O
known	O
that	O
some	O
periodontopathic	O
bacteria	O
,	O
especially	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
(	O
formerly	O
Bacteroides	B-bacteria
forsythus	I-bacteria
or	O
Tan	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
)	O
,	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
,	O
actively	O
produce	O
volatile	O
sulfur	O
compounds	O
(	O
VSCs	O
)	O
,	O
such	O
as	O
H2S	O
and	O
CH3SH	O
.	O

We	O
previously	O
reported	O
a	O
qualitative	O
relationship	O
between	O
periodontopathic	O
bacteria	O
and	O
VSCs	O
;	O
however	O
,	O
a	O
quantitative	O
analysis	O
of	O
periodontopathic	O
bacteria	O
in	O
oral	O
specimens	O
is	O
required	O
for	O
further	O
characterization	O
of	O
the	O
relationship	O
between	O
oral	O
bacteria	O
and	O
VSCs	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
a	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
for	O
the	O
quantitative	O
analysis	O
of	O
VSC	O
-	O
producing	O
bacteria	O
in	O
oral	O
specimens	O
.	O

Specimens	O
were	O
collected	O
from	O
22	O
patients	O
who	O
visited	O
the	O
Preventive	O
Dentistry	O
and	O
Breath	O
Odor	O
Clinic	O
of	O
Kyushu	O
Dental	O
College	O
.	O

A	O
real	O
-	O
time	O
PCR	O
assay	O
using	O
the	O
TaqMan	O
system	O
,	O
based	O
on	O
the	O
5	O
'	O
-	O
3	O
'	O
exonuclease	O
activity	O
of	O
Taq	O
polymerase	O
,	O
was	O
employed	O
for	O
the	O
quantitative	O
analysis	O
of	O
periodontopathic	O
bacteria	O
that	O
produce	O
VSCs	O
.	O

Using	O
real	O
-	O
time	O
PCR	O
,	O
we	O
performed	O
a	O
quantitative	O
analysis	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
,	O
Tan	B-bacteria
.	I-bacteria
forsythia	I-bacteria
,	O
and	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
in	O
the	O
saliva	O
,	O
on	O
the	O
tongue	O
coat	O
,	O
and	O
in	O
the	O
subgingival	O
plaque	O
of	O
patients	O
with	O
oral	O
malodor	O
.	O

Real	O
-	O
time	O
PCR	O
using	O
the	O
TaqMan	O
system	O
can	O
be	O
used	O
for	O
the	O
quantitative	O
analysis	O
of	O
VSC	O
-	O
producing	O
oral	O
bacteria	O
.	O

To	O
evaluate	O
the	O
efficacy	O
of	O
antimicrobial	O
therapy	O
in	O
oral	O
odontogenic	O
infections	O
using	O
estimated	O
pharmacokinetic	O
/	O
pharmacodynamic	O
parameters	O
or	O
efficacy	O
indices	O
,	O
and	O
to	O
compare	O
pharmacokinetic	O
/	O
pharmacodynamic	O
breakpoints	O
with	O
National	O
Committee	O
for	O
Clinical	O
Laboratory	O
Standards	O
'	O
(	O
NCCLS	O
)	O
breakpoints	O
.	O

Retrospective	O
literature	O
search	O
to	O
obtain	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
values	O
,	O
pharmacokinetic	O
parameters	O
of	O
antimicrobials	O
and	O
NCCLS	O
breakpoints	O
.	O

Pharmacokinetic	O
simulations	O
were	O
carried	O
out	O
using	O
WinNonlin	O
software	O
(	O
Pharsight	O
Corporation	O
,	O
Mountain	O
View	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
antimicrobials	O
with	O
time	O
-	O
dependent	O
activity	O
,	O
the	O
time	O
that	O
the	O
plasma	O
drug	O
concentration	O
exceeds	O
the	O
MIC	O
as	O
the	O
percentage	O
of	O
dose	O
interval	O
at	O
steady	O
state	O
was	O
calculated	O
.	O

For	O
antimicrobials	O
with	O
concentration	O
-	O
dependent	O
activity	O
,	O
the	O
total	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
over	O
24	O
hours	O
at	O
steady	O
state	O
divided	O
by	O
the	O
MIC	O
was	O
calculated	O
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
breakpoints	O
were	O
calculated	O
according	O
to	O
these	O
parameters	O
.	O

Only	O
amoxicillin	O
/	O
clavulanic	O
acid	O
and	O
clindamycin	O
showed	O
adequate	O
efficacy	O
indices	O
against	O
the	O
most	O
commonly	O
isolated	O
bacteria	O
in	O
odontogenic	O
infections	O
.	O

Metronidazole	O
reached	O
good	O
indices	O
against	O
anaerobes	O
only	O
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
susceptibility	O
breakpoints	O
do	O
not	O
coincide	O
exactly	O
with	O
NCCLS	O
breakpoints	O
.	O

Owing	O
to	O
the	O
scarcity	O
of	O
double	O
-	O
blind	O
,	O
clinical	O
trials	O
on	O
the	O
use	O
of	O
antimicrobials	O
in	O
endodontics	O
,	O
this	O
study	O
may	O
be	O
useful	O
in	O
determining	O
the	O
best	O
antimicrobial	O
treatment	O
in	O
these	O
infections	O
.	O

However	O
,	O
as	O
we	O
have	O
not	O
used	O
concentration	O
data	O
in	O
infected	O
tissue	O
to	O
determine	O
pharmacokinetic	O
/	O
pharmacodynamic	O
indices	O
,	O
it	O
would	O
be	O
necessary	O
to	O
design	O
clinical	O
trials	O
in	O
order	O
to	O
confirm	O
these	O
results	O
.	O

Apoptosis	O
is	O
critical	O
in	O
the	O
pathogenesis	O
of	O
several	O
infectious	O
diseases	O
.	O

The	O
induction	O
of	O
apoptosis	O
was	O
assessed	O
in	O
mouse	O
lymph	O
node	O
cells	O
by	O
four	O
bacteria	O
recovered	O
from	O
infected	O
human	O
dental	O
pulp	O
:	O
Gemella	B-bacteria
morbillorum	I-bacteria
,	O
Clostridium	B-bacteria
butyricum	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
and	O
Bifidobacterium	B-bacteria
adolescentis	I-bacteria
.	O

Smaller	O
lymph	O
nodes	O
and	O
smaller	O
numbers	O
of	O
cells	O
were	O
observed	O
after	O
experimental	O
dental	O
pulp	O
infection	O
with	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
,	O
suggesting	O
that	O
this	O
bacterium	O
induces	O
cell	O
death	O
.	O

Apoptosis	O
was	O
evaluated	O
by	O
determination	O
of	O
cell	O
ploidy	O
and	O
detection	O
of	O
DNA	O
degradation	O
in	O
cells	O
cultured	O
with	O
killed	O
bacteria	O
.	O

Paraformaldehyde	O
-	O
killed	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
and	O
heat	O
-	O
killed	O
G	B-bacteria
.	I-bacteria
morbillorum	I-bacteria
induced	O
substantial	O
cell	O
death	O
,	O
while	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
and	O
B	B-bacteria
.	I-bacteria
adolescentis	I-bacteria
induced	O
cell	O
death	O
at	O
lower	O
levels	O
.	O

No	O
bacterial	O
preparations	O
induced	O
apoptosis	O
in	O
cells	O
from	O
mice	O
genetically	O
deficient	O
for	O
tumour	O
necrosis	O
factor	O
receptor	O
p55	O
(	O
TNFRp55	O
)	O
,	O
implicating	O
this	O
receptor	O
directly	O
or	O
indirectly	O
as	O
a	O
mediator	O
in	O
the	O
process	O
.	O

It	O
was	O
concluded	O
that	O
apoptosis	O
may	O
be	O
induced	O
during	O
periapical	O
lesions	O
of	O
pulpal	O
origin	O
.	O

The	O
objective	O
of	O
this	O
randomized	O
,	O
crossover	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
a	O
newly	O
designed	O
manual	O
toothbrush	O
(	O
Colgate	O
360	O
degrees	O
)	O
to	O
two	O
commercially	O
available	O
manual	O
toothbrushes	O
(	O
Oral	O
-	O
B	O
Indicator	O
and	O
Oral	O
-	O
B	O
CrossAction	O
)	O
and	O
a	O
battery	O
-	O
powered	O
toothbrush	O
(	O
Crest	O
SpinBrush	O
PRO	O
)	O
for	O
their	O
ability	O
to	O
reduce	O
hydrogen	O
-	O
sulfide	O
-	O
forming	O
bacteria	O
on	O
the	O
tongue	O
.	O

After	O
a	O
washout	O
period	O
,	O
subjects	O
arrived	O
at	O
the	O
clinical	O
site	O
for	O
baseline	O
sampling	O
without	O
performing	O
dental	O
hygiene	O
,	O
eating	O
,	O
or	O
drinking	O
.	O

Subjects	O
sampled	O
the	O
left	O
side	O
of	O
their	O
tongue	O
with	O
a	O
cotton	O
swab	O
.	O

Subjects	O
brushed	O
for	O
1	O
minute	O
with	O
the	O
assigned	O
test	O
toothbrush	O
and	O
regular	O
fluoride	O
toothpaste	O
.	O

Those	O
using	O
the	O
Colgate	O
360	O
degrees	O
toothbrush	O
were	O
instructed	O
to	O
clean	O
their	O
tongue	O
with	O
the	O
implement	O
on	O
the	O
back	O
of	O
the	O
brush	O
head	O
for	O
10	O
seconds	O
.	O

After	O
2	O
hours	O
,	O
the	O
subjects	O
returned	O
to	O
the	O
clinical	O
site	O
having	O
refrained	O
from	O
dental	O
hygiene	O
,	O
eating	O
,	O
and	O
drinking	O
for	O
posttreatment	O
sampling	O
,	O
this	O
time	O
sampling	O
the	O
right	O
side	O
of	O
their	O
tongue	O
.	O

After	O
a	O
minimum	O
2	O
-	O
day	O
washout	O
period	O
,	O
subjects	O
repeated	O
the	O
same	O
regimen	O
using	O
the	O
other	O
toothbrushes	O
.	O

Collected	O
tongue	O
samples	O
were	O
dispersed	O
in	O
sterile	O
water	O
,	O
serially	O
diluted	O
in	O
sterile	O
phosphate	O
-	O
buffered	O
saline	O
,	O
and	O
plated	O
in	O
duplicate	O
onto	O
lead	O
acetate	O
agar	O
.	O

When	O
plated	O
on	O
this	O
medium	O
,	O
bacteria	O
that	O
produce	O
hydrogen	O
sulfide	O
appear	O
as	O
dark	O
-	O
pigmented	O
colonies	O
.	O

After	O
72	O
hours	O
of	O
incubation	O
,	O
the	O
dark	O
colonies	O
were	O
counted	O
,	O
expressed	O
as	O
log	O
colony	O
-	O
forming	O
units	O
/	O
mL	O
,	O
and	O
reduction	O
from	O
baseline	O
was	O
calculated	O
.	O

Thirty	O
-	O
one	O
adult	O
men	O
and	O
women	O
completed	O
the	O
clinical	O
study	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
baseline	O
hydrogen	O
-	O
sulfide	O
-	O
forming	O
bacteria	O
levels	O
.	O

Posttreatment	O
,	O
the	O
log	O
reduction	O
of	O
bacteria	O
was	O
0	O
.	O
80	O
,	O
0	O
.	O
41	O
,	O
0	O
.	O
33	O
,	O
and	O
0	O
.	O
44	O
for	O
the	O
Colgate	O
360	O
degrees	O
,	O
Oral	O
-	O
B	O
Indicator	O
,	O
Crest	O
SpinBrush	O
PRO	O
,	O
and	O
Oral	O
-	O
B	O
CrossAction	O
,	O
respectively	O
.	O

Statistical	O
analysis	O
indicated	O
that	O
the	O
Colgate	O
360	O
toothbrush	O
was	O
statistically	O
significantly	O
better	O
(	O
P	O
<	O
.	O
05	O
)	O
than	O
the	O
3	O
commercial	O
toothbrushes	O
in	O
reducing	O
the	O
levels	O
of	O
hydrogen	O
-	O
sulfide	O
-	O
forming	O
bacteria	O
on	O
the	O
tongue	O
.	O

We	O
have	O
found	O
that	O
broadband	O
light	O
(	O
380	O
to	O
520	O
nm	O
)	O
rapidly	O
and	O
selectively	O
kills	O
oral	O
black	O
-	O
pigmented	O
bacteria	O
(	O
BPB	O
)	O
in	O
pure	O
cultures	O
and	O
in	O
dental	O
plaque	O
samples	O
obtained	O
from	O
human	O
subjects	O
with	O
chronic	O
periodontitis	O
.	O

We	O
hypothesize	O
that	O
this	O
killing	O
effect	O
is	O
a	O
result	O
of	O
light	O
excitation	O
of	O
their	O
endogenous	O
porphyrins	O
.	O

Cultures	O
of	O
Prevotella	B-bacteria
intermedia	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
were	O
killed	O
by	O
4	O
.	O
2	O
J	O
/	O
cm2	O
,	O
whereas	O
P	B-bacteria
.	I-bacteria
melaninogenica	I-bacteria
required	O
21	O
J	O
/	O
cm2	O
.	O

Exposure	O
to	O
light	O
with	O
a	O
fluence	O
of	O
42	O
J	O
/	O
cm2	O
produced	O
99	O
%	O
killing	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

High	O
-	O
performance	O
liquid	O
chromatography	O
demonstrated	O
the	O
presence	O
of	O
various	O
amounts	O
of	O
different	O
porphyrin	O
molecules	O
in	O
BPB	O
.	O

The	O
amounts	O
of	O
endogenous	O
porphyrin	O
in	O
BPB	O
were	O
267	O
(	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
)	O
,	O
47	O
(	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
)	O
,	O
41	O
(	O
P	B-bacteria
.	I-bacteria
melaninogenica	I-bacteria
)	O
,	O
and	O
2	O
.	O
2	O
(	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
)	O
ng	O
/	O
mg	O
.	O

Analysis	O
of	O
bacteria	O
in	O
dental	O
plaque	O
samples	O
by	O
DNA	O
-	O
DNA	O
hybridization	O
for	O
40	O
taxa	O
before	O
and	O
after	O
phototherapy	O
showed	O
that	O
the	O
growth	O
of	O
the	O
four	O
BPB	O
was	O
decreased	O
by	O
2	O
and	O
3	O
times	O
after	O
irradiation	O
at	O
energy	O
fluences	O
of	O
4	O
.	O
2	O
and	O
21	O
J	O
/	O
cm2	O
,	O
respectively	O
,	O
whereas	O
the	O
growth	O
of	O
the	O
remaining	O
36	O
microorganisms	O
was	O
decreased	O
by	O
1	O
.	O
5	O
times	O
at	O
both	O
energy	O
fluences	O
.	O

The	O
present	O
study	O
suggests	O
that	O
intraoral	O
light	O
exposure	O
may	O
be	O
used	O
to	O
control	O
BPB	O
growth	O
and	O
possibly	O
benefit	O
patients	O
with	O
periodontal	O
disease	O
.	O

Autologous	O
stem	O
cell	O
transplantation	O
has	O
augmented	O
treatment	O
successes	O
.	O

However	O
,	O
high	O
-	O
dose	O
chemotherapy	O
is	O
still	O
accompanied	O
by	O
dose	O
-	O
limiting	O
toxicities	O
,	O
for	O
example	O
,	O
severe	O
mucositis	O
.	O

Mucosal	O
lesions	O
serve	O
as	O
portals	O
of	O
entry	O
for	O
infections	O
.	O

In	O
order	O
to	O
reduce	O
the	O
oral	O
microbial	O
burden	O
,	O
we	O
prospectively	O
evaluated	O
the	O
microbiological	O
impact	O
of	O
a	O
complex	O
regimen	O
of	O
mouth	O
rinses	O
consisting	O
of	O
concomitantly	O
applied	O
polyene	O
antifungals	O
,	O
povidone	O
-	O
iodine	O
,	O
chlorhexidine	O
,	O
sage	O
tea	O
,	O
and	O
prophylactic	O
ciprofloxacin	O
and	O
fluconazole	O
.	O

A	O
total	O
of	O
15	O
patients	O
were	O
enrolled	O
into	O
this	O
longitudinal	O
evaluation	O
.	O

Colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
were	O
quantitated	O
from	O
saliva	O
,	O
buccal	O
and	O
palatinal	O
swabs	O
during	O
high	O
-	O
dose	O
chemotherapy	O
and	O
autologous	O
stem	O
cell	O
transplantation	O
.	O

The	O
number	O
of	O
CFU	O
did	O
not	O
show	O
any	O
significant	O
changes	O
after	O
initiation	O
of	O
the	O
mouth	O
rinses	O
and	O
the	O
prophylactic	O
antibiotics	O
.	O

The	O
median	O
CFU	O
count	O
was	O
268	O
x	O
10	O
(	O
6	O
)	O
/	O
ml	O
saliva	O
before	O
chemotherapy	O
and	O
decreased	O
after	O
initiation	O
of	O
intravenous	O
antibiotics	O
only	O
.	O

Neither	O
prophylactic	O
nor	O
therapeutic	O
antifungals	O
significantly	O
reduced	O
the	O
number	O
of	O
cultures	O
positive	O
for	O
yeasts	O
.	O

Since	O
90	O
%	O
of	O
our	O
patients	O
had	O
febrile	O
neutropenia	O
at	O
some	O
time	O
point	O
during	O
the	O
observation	O
period	O
,	O
the	O
approach	O
evaluated	O
can	O
not	O
be	O
recommended	O
as	O
prophylaxis	O
of	O
febrile	O
neutropenia	O
as	O
such	O
.	O

Two	O
studies	O
were	O
conducted	O
to	O
determine	O
the	O
antimicrobial	O
effect	O
of	O
rinsing	O
with	O
an	O
essential	O
oil	O
-	O
containing	O
mouth	O
rinse	O
12	O
h	O
after	O
a	O
single	O
rinse	O
and	O
12	O
h	O
after	O
2	O
weeks	O
of	O
twice	O
daily	O
rinsing	O
,	O
during	O
the	O
daytime	O
and	O
overnight	O
.	O

These	O
studies	O
utilized	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
crossover	O
design	O
.	O

Following	O
baseline	O
sampling	O
of	O
bacteria	O
from	O
supragingival	O
plaque	O
and	O
the	O
dorsum	O
of	O
the	O
tongue	O
,	O
subjects	O
began	O
twice	O
-	O
daily	O
rinsing	O
with	O
either	O
an	O
essential	O
oil	O
mouth	O
rinse	O
containing	O
0	O
.	O
09	O
%	O
zinc	O
chloride	O
(	O
Tartar	O
Control	O
Listerine	O
Antiseptic	O
)	O
or	O
a	O
negative	O
control	O
rinse	O
.	O

Bacterial	O
sampling	O
was	O
repeated	O
12	O
h	O
after	O
the	O
first	O
rinse	O
,	O
and	O
again	O
12	O
h	O
after	O
the	O
final	O
rinse	O
14	O
days	O
later	O
.	O

The	O
sampling	O
schedule	O
was	O
adjusted	O
according	O
to	O
whether	O
the	O
study	O
was	O
investigating	O
daytime	O
or	O
overnight	O
activity	O
.	O

Samples	O
were	O
plated	O
on	O
Schaedlers	O
medium	O
(	O
total	O
anaerobes	O
)	O
,	O
Schaedlers	O
Nalidixic	O
/	O
Vancomycin	O
medium	O
(	O
Gram	O
-	O
negative	O
anaerobes	O
)	O
,	O
and	O
OOPS	O
medium	O
(	O
volatile	O
sulphur	O
compound	O
(	O
VSC	O
)	O
-	O
producing	O
organisms	O
)	O
.	O

Inter	O
-	O
group	O
log10	O
transformed	O
colony	O
-	O
forming	O
units	O
/	O
ml	O
counts	O
from	O
samples	O
of	O
supragingival	O
plaque	O
and	O
tongue	O
swabs	O
on	O
each	O
of	O
the	O
three	O
media	O
were	O
compared	O
by	O
analysis	O
of	O
covariance	O
.	O

The	O
mean	O
bacterial	O
counts	O
in	O
subjects	O
using	O
the	O
essential	O
oil	O
mouth	O
rinse	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
005	O
)	O
than	O
mean	O
counts	O
in	O
subjects	O
using	O
the	O
control	O
rinse	O
in	O
all	O
the	O
comparisons	O
,	O
i	O
.	O
e	O
.	O
,	O
tongue	O
and	O
supragingival	O
plaque	O
samples	O
on	O
each	O
of	O
three	O
media	O
at	O
two	O
sampling	O
periods	O
in	O
the	O
daytime	O
and	O
overnight	O
study	O
,	O
respectively	O
.	O

Mean	O
bacterial	O
count	O
percent	O
reductions	O
for	O
plaque	O
samples	O
ranged	O
from	O
56	O
.	O
3	O
to	O
95	O
.	O
3	O
;	O
percent	O
reductions	O
for	O
tongue	O
samples	O
ranged	O
from	O
61	O
.	O
1	O
to	O
96	O
.	O
1	O
.	O

There	O
was	O
a	O
trend	O
to	O
higher	O
reductions	O
after	O
14	O
days	O
'	O
rinsing	O
than	O
after	O
the	O
initial	O
rinse	O
.	O

Rinsing	O
with	O
the	O
essential	O
oil	O
mouth	O
rinse	O
can	O
have	O
long	O
-	O
lasting	O
effects	O
in	O
reducing	O
anaerobic	O
bacteria	O
overall	O
as	O
well	O
as	O
Gram	O
-	O
negative	O
anaerobes	O
and	O
VSC	O
-	O
producing	O
bacteria	O
.	O

The	O
significant	O
reductions	O
in	O
numbers	O
of	O
these	O
bacteria	O
produced	O
by	O
the	O
essential	O
oil	O
mouth	O
rinse	O
,	O
both	O
in	O
plaque	O
and	O
on	O
the	O
dorsum	O
of	O
the	O
tongue	O
,	O
can	O
play	O
a	O
key	O
role	O
in	O
explaining	O
the	O
essential	O
oil	O
mouth	O
rinse	O
'	O
s	O
effectiveness	O
in	O
reducing	O
supragingival	O
plaque	O
and	O
gingivitis	O
as	O
well	O
as	O
its	O
effectiveness	O
in	O
controlling	O
intrinsic	O
oral	O
malodor	O
over	O
prolonged	O
periods	O
.	O

Psychological	O
stress	O
is	O
known	O
to	O
increase	O
the	O
circulating	O
levels	O
of	O
the	O
catecholamine	O
hormones	O
noradrenaline	O
and	O
adrenaline	O
,	O
which	O
have	O
been	O
shown	O
to	O
influence	O
the	O
growth	O
of	O
a	O
large	O
number	O
of	O
bacterial	O
species	O
by	O
acting	O
in	O
a	O
siderophore	O
-	O
like	O
manner	O
or	O
by	O
inducing	O
the	O
production	O
of	O
novel	O
autoinducers	O
of	O
growth	O
.	O

As	O
we	O
have	O
previously	O
demonstrated	O
that	O
periodontal	O
organisms	O
display	O
differing	O
growth	O
responses	O
to	O
noradrenaline	O
and	O
adrenaline	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
these	O
growth	O
effects	O
were	O
based	O
upon	O
either	O
siderophore	O
-	O
like	O
or	O
autoinducer	O
mechanisms	O
.	O

Initial	O
inocula	O
of	O
43	O
microbial	O
organisms	O
normally	O
found	O
within	O
the	O
subgingival	O
biofilm	O
were	O
established	O
under	O
anaerobic	O
conditions	O
(	O
35	O
degrees	O
C	O
)	O
.	O

Each	O
strain	O
was	O
re	O
-	O
inoculated	O
into	O
a	O
serum	O
-	O
based	O
minimal	O
medium	O
and	O
growth	O
was	O
assessed	O
by	O
optical	O
density	O
(	O
OD	O
(	O
600	O
nm	O
)	O
)	O
with	O
test	O
and	O
control	O
cultures	O
performed	O
in	O
triplicate	O
.	O

Test	O
cultures	O
were	O
supplemented	O
with	O
either	O
50	O
mum	O
ferric	O
nitrate	O
or	O
a	O
previously	O
described	O
Escherichia	B-bacteria
coli	I-bacteria
autoinducer	O
of	O
growth	O
.	O

Significant	O
growth	O
effects	O
for	O
supplementation	O
with	O
ferric	O
nitrate	O
(	O
13	O
species	O
responding	O
positively	O
)	O
and	O
E	B-bacteria
.	I-bacteria
coli	O
autoinducer	O
(	O
24	O
species	O
responding	O
positively	O
)	O
were	O
observed	O
,	O
with	O
differences	O
in	O
growth	O
response	O
within	O
bacterial	O
species	O
and	O
within	O
microbial	O
complexes	O
.	O

When	O
data	O
for	O
all	O
organisms	O
were	O
compared	O
with	O
published	O
responses	O
to	O
catecholamines	O
there	O
were	O
only	O
weak	O
correlations	O
with	O
Fe	O
(	O
r	O
=	O
0	O
.	O
28	O
)	O
and	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
autoinducer	O
(	O
r	O
=	O
0	O
.	O
34	O
)	O
responses	O
.	O

However	O
,	O
large	O
positive	O
responses	O
(	O
>	O
25	O
%	O
increase	O
)	O
to	O
free	O
Fe	O
and	O
/	O
or	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
autoinducer	O
were	O
significantly	O
more	O
prevalent	O
in	O
the	O
group	O
of	O
organisms	O
(	O
n	O
=	O
12	O
)	O
known	O
to	O
exhibit	O
similar	O
responses	O
to	O
catecholamine	O
hormones	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
chi2	O
=	O
4	O
.	O
56	O
)	O
.	O

The	O
results	O
support	O
the	O
view	O
that	O
catecholamines	O
may	O
exert	O
their	O
effects	O
on	O
subgingival	O
organisms	O
by	O
initiating	O
autoinducer	O
production	O
,	O
or	O
simply	O
by	O
acting	O
in	O
a	O
siderophore	O
-	O
like	O
manner	O
,	O
scavenging	O
bound	O
iron	O
from	O
the	O
local	O
environment	O
.	O

It	O
is	O
possible	O
that	O
autoinducer	O
mechanisms	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
response	O
of	O
oral	O
microorganisms	O
to	O
stress	O
hormones	O
,	O
thereby	O
contributing	O
to	O
the	O
clinical	O
course	O
of	O
stress	O
-	O
associated	O
periodontal	O
diseases	O
.	O

We	O
isolated	O
bacteria	O
from	O
periodontal	O
sites	O
and	O
mixed	O
saliva	O
in	O
eight	O
patients	O
with	O
Behcet	O
'	O
s	O
disease	O
and	O
surveyed	O
them	O
to	O
determine	O
whether	O
they	O
produced	O
heat	O
shock	O
proteins	O
(	O
HSPs	O
)	O
and	O
superantigen	O
.	O

Cultivable	O
bacterial	O
compositions	O
from	O
periodontal	O
sites	O
and	O
saliva	O
were	O
examined	O
by	O
anaerobic	O
culture	O
using	O
blood	O
agar	O
plates	O
.	O

Gram	O
-	O
negative	O
anaerobic	O
rods	O
such	O
as	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
and	O
Capnocytophaga	B-bacteria
species	I-bacteria
were	O
predominant	O
in	O
the	O
isolates	O
from	O
the	O
subgingival	O
plaque	O
samples	O
.	O

The	O
Streptococcus	B-bacteria
mitis	I-bacteria
group	O
was	O
the	O
most	O
common	O
type	O
isolated	O
from	O
the	O
saliva	O
samples	O
.	O

To	O
detect	O
the	O
production	O
of	O
HSPs	O
,	O
Western	O
blot	O
analyses	O
were	O
performed	O
using	O
a	O
polyclonal	O
rabbit	O
antibody	O
to	O
Escherichia	B-bacteria
coli	I-bacteria
DnaK	O
and	O
a	O
monoclonal	O
antibody	O
to	O
Helicobacter	B-bacteria
pylori	I-bacteria
Gro	O
-	O
EL	O
.	O

Sonic	O
extracts	O
of	O
27	O
of	O
the	O
strains	O
(	O
79	O
.	O
4	O
%	O
)	O
reacted	O
with	O
the	O
antibody	O
against	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
DnaK	O
.	O

Nine	O
of	O
these	O
34	O
strains	O
(	O
26	O
.	O
5	O
%	O
)	O
were	O
found	O
to	O
produce	O
HSPs	O
that	O
reacted	O
with	O
antibody	O
to	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
Gro	O
-	O
EL	O
.	O

A	O
total	O
of	O
54	O
isolates	O
were	O
examined	O
for	O
superantigen	O
activity	O
against	O
human	O
peripheral	O
leukocytes	O
.	O

Twenty	O
-	O
five	O
gram	O
-	O
negative	O
clinical	O
strains	O
isolated	O
from	O
chronic	O
periodontitis	O
lesions	O
and	O
20	O
ATCC	B-bacteria
strains	I-bacteria
of	O
microorganisms	O
were	O
also	O
examined	O
.	O

We	O
could	O
not	O
detect	O
any	O
superantigen	O
activity	O
in	O
500x	O
diluted	O
supernatant	O
of	O
the	O
strains	O
isolated	O
from	O
the	O
eight	O
patients	O
with	O
Behcet	O
'	O
s	O
disease	O
.	O

The	O
present	O
study	O
indicates	O
that	O
the	O
anaerobic	O
strains	O
isolated	O
from	O
the	O
oral	O
cavity	O
of	O
these	O
patients	O
produce	O
HSPs	O
,	O
the	O
production	O
being	O
related	O
to	O
Bechet	O
'	O
s	O
disease	O
.	O

Peptidoglycan	O
recognition	O
proteins	O
(	O
PGRPs	O
)	O
,	O
a	O
novel	O
family	O
of	O
pattern	O
recognition	O
molecules	O
(	O
PRMs	O
)	O
in	O
innate	O
immunity	O
conserved	O
from	O
insects	O
to	O
mammals	O
,	O
recognize	O
bacterial	O
cell	O
wall	O
peptidoglycan	O
(	O
PGN	O
)	O
and	O
are	O
suggested	O
to	O
act	O
as	O
anti	O
-	O
bacterial	O
factors	O
.	O

In	O
humans	O
,	O
four	O
kinds	O
of	O
PGRPs	O
(	O
PGRP	O
-	O
L	O
,	O
-	O
Ialpha	O
,	O
-	O
Ibeta	O
and	O
-	O
S	O
)	O
have	O
been	O
cloned	O
and	O
all	O
four	O
human	O
PGRPs	O
bind	O
PGN	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
possible	O
regulation	O
of	O
the	O
expression	O
of	O
PGRPs	O
in	O
oral	O
epithelial	O
cells	O
upon	O
stimulation	O
with	O
chemically	O
synthesized	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
(	O
PAMPs	O
)	O
in	O
bacterial	O
cell	O
surface	O
components	O
:	O
Escherichia	O
coli	O
-	O
type	O
tryacyl	O
lipopeptide	O
(	O
Pam3CSSNA	O
)	O
,	O
E	O
.	O
coli	O
-	O
type	O
lipid	O
A	O
(	O
LA	O
-	O
15	O
-	O
PP	O
)	O
,	O
diaminopimelic	O
acid	O
containing	O
desmuramyl	O
peptide	O
(	O
gamma	O
-	O
D	O
-	O
glutamyl	O
-	O
meso	O
-	O
DAP	O
;	O
iE	O
-	O
DAP	O
)	O
,	O
and	O
muramyldipeptide	O
(	O
MDP	O
)	O
.	O

These	O
synthetic	O
PAMPs	O
markedly	O
upregulated	O
the	O
mRNA	O
expression	O
of	O
the	O
four	O
PGRPs	O
and	O
cell	O
surface	O
expression	O
of	O
PGRP	O
-	O
Ialpha	O
and	O
-	O
Ibeta	O
,	O
but	O
did	O
not	O
induce	O
either	O
mRNA	O
expression	O
or	O
secretion	O
of	O
inflammatory	O
cytokines	O
,	O
in	O
oral	O
epithelial	O
cells	O
.	O

Suppression	O
of	O
the	O
expression	O
of	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
2	O
,	O
TLR4	O
,	O
nucleotide	O
-	O
binding	O
oligomerization	O
domain	O
(	O
NOD	O
)	O
1	O
and	O
NOD2	O
by	O
RNA	O
interference	O
specifically	O
inhibited	O
the	O
upregulation	O
of	O
PGRP	O
mRNA	O
expression	O
induced	O
by	O
Pam3CSSNA	O
,	O
LA	O
-	O
15	O
-	O
PP	O
,	O
iE	O
-	O
DAP	O
and	O
MDP	O
respectively	O
.	O

These	O
PAMPs	O
definitely	O
activated	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
in	O
the	O
epithelial	O
cells	O
,	O
and	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
clearly	O
prevented	O
the	O
induction	O
of	O
PGRP	O
mRNA	O
expression	O
induced	O
by	O
these	O
PAMPs	O
in	O
the	O
cells	O
.	O

These	O
findings	O
suggested	O
that	O
bacterial	O
PAMPs	O
induced	O
the	O
expression	O
of	O
PGRPs	O
,	O
but	O
not	O
proinflammatory	O
cytokines	O
,	O
in	O
oral	O
epithelial	O
cells	O
,	O
and	O
the	O
PGRPs	O
might	O
be	O
involved	O
in	O
host	O
defence	O
against	O
bacterial	O
invasion	O
without	O
accompanying	O
inflammatory	O
responses	O
.	O

oral	O
treponemes	B-bacteria
are	O
well	O
-	O
known	O
as	O
causative	O
agents	O
of	O
periodontal	O
disease	O
;	O
however	O
,	O
the	O
details	O
have	O
not	O
been	O
fully	O
clarified	O
.	O

Here	O
,	O
we	O
examined	O
the	O
effects	O
of	O
Treponema	B-bacteria
medium	I-bacteria
glycoconjugate	O
on	O
the	O
activation	O
of	O
human	O
gingival	O
fibroblasts	O
using	O
phenol	O
-	O
water	O
extracts	O
from	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
subsp	I-bacteria
.	I-bacteria
nucleatum	I-bacteria
,	O
and	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
.	O

The	O
phenol	O
-	O
water	O
extracts	O
activated	O
human	O
gingival	O
fibroblasts	O
to	O
mediate	O
IL	O
-	O
8	O
production	O
,	O
as	O
well	O
as	O
IL	O
-	O
8	O
mRNA	O
expression	O
,	O
phosphorylation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
,	O
and	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
.	O

T	B-bacteria
.	I-bacteria
medium	I-bacteria
glycoconjugate	O
exhibited	O
no	O
activation	O
of	O
human	O
gingival	O
fibroblasts	O
,	O
while	O
phenol	O
-	O
water	O
extract	O
-	O
induced	O
activation	O
of	O
human	O
gingival	O
fibroblasts	O
was	O
clearly	O
inhibited	O
by	O
T	B-bacteria
.	I-bacteria
medium	I-bacteria
glycoconjugate	O
.	O

Furthermore	O
,	O
binding	O
of	O
biotinylated	O
phenol	O
-	O
water	O
extracts	O
to	O
CD14	O
in	O
the	O
presence	O
of	O
LPS	O
-	O
binding	O
protein	O
was	O
blocked	O
with	O
T	B-bacteria
.	I-bacteria
medium	I-bacteria
glycoconjugate	O
.	O

These	O
results	O
suggest	O
that	O
T	B-bacteria
.	I-bacteria
medium	I-bacteria
glycoconjugate	O
has	O
an	O
inhibitory	O
effect	O
on	O
host	O
cell	O
activation	O
by	O
periodontopathic	O
bacteria	O
caused	O
by	O
binding	O
to	O
CD14	O
-	O
and	O
LPS	O
-	O
binding	O
protein	O
.	O

Enterococcus	B-bacteria
faecalis	I-bacteria
is	O
consistently	O
associated	O
with	O
recurrent	O
root	O
canal	O
infections	O
.	O

Only	O
low	O
concentrations	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
in	O
the	O
human	O
mouth	O
have	O
been	O
demonstrated	O
by	O
culture	O
techniques	O
.	O

Quantitative	O
detection	O
strategies	O
more	O
sensitive	O
than	O
culturing	O
,	O
such	O
as	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
,	O
could	O
provide	O
more	O
illuminating	O
data	O
.	O

Thirty	O
outpatients	O
attending	O
the	O
University	O
of	O
Michigan	O
Graduate	O
Endodontic	O
Clinic	O
for	O
endodontic	O
treatment	O
provided	O
oral	O
rinse	O
samples	O
that	O
were	O
analysed	O
for	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
using	O
qPCR	O
and	O
microbiological	O
culturing	O
.	O

A	O
SYBR	O
Green	O
I	O
qPCR	O
protocol	O
was	O
developed	O
for	O
the	O
quantifiable	O
detection	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
and	O
total	O
bacteria	O
in	O
oral	O
rinse	O
samples	O
using	O
primers	O
designed	O
to	O
target	O
the	O
16S	O
rRNA	O
gene	O
.	O

Annealing	O
temperature	O
and	O
primer	O
,	O
magnesium	O
ion	O
,	O
and	O
dimethyl	O
sulfoxide	O
concentrations	O
were	O
investigated	O
for	O
optimisation	O
of	O
the	O
protocol	O
;	O
a	O
minimum	O
sensitivity	O
limit	O
of	O
23	O
rRNA	O
copies	O
(	O
an	O
estimated	O
six	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
cells	O
)	O
was	O
established	O
for	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
in	O
pure	O
culture	O
,	O
and	O
104	O
rRNA	O
copies	O
(	O
an	O
estimated	O
26	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
cells	O
)	O
in	O
mixed	O
culture	O
.	O

In	O
qPCR	O
assays	O
,	O
based	O
on	O
extrapolation	O
from	O
estimated	O
rRNA	O
gene	O
copy	O
numbers	O
,	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
comprised	O
0	O
.	O
0006	O
-	O
0	O
.	O
0047	O
%	O
of	O
a	O
total	O
bacteria	O
load	O
that	O
ranged	O
from	O
5	O
.	O
92	O
x	O
10	O
(	O
5	O
)	O
to	O
5	O
.	O
69	O
x	O
10	O
(	O
7	O
)	O
cells	O
/	O
ml	O
of	O
oral	O
rinse	O
.	O

E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
was	O
detected	O
in	O
five	O
(	O
17	O
%	O
)	O
samples	O
in	O
concentrations	O
from	O
114	O
to	O
490	O
cells	O
/	O
ml	O
.	O

In	O
parallel	O
culture	O
assays	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
were	O
detected	O
in	O
only	O
two	O
samples	O
(	O
7	O
%	O
)	O
of	O
the	O
five	O
identified	O
by	O
qPCR	O
and	O
in	O
concentrations	O
30	O
and	O
240	O
CFU	O
/	O
ml	O
.	O

qPCR	O
reported	O
a	O
higher	O
incidence	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
in	O
oral	O
rinse	O
samples	O
than	O
culture	O
techniques	O
and	O
afforded	O
greater	O
sensitivity	O
.	O

The	O
application	O
of	O
molecular	O
,	O
mainly	O
16S	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
-	O
based	O
approaches	O
enables	O
researchers	O
to	O
bypass	O
the	O
cultivation	O
step	O
and	O
has	O
proven	O
its	O
usefulness	O
in	O
studying	O
the	O
microbial	O
composition	O
in	O
a	O
variety	O
of	O
ecosystems	O
,	O
including	O
the	O
human	O
oral	O
cavity	O
.	O

In	O
this	O
mini	O
-	O
review	O
,	O
we	O
describe	O
the	O
impact	O
of	O
these	O
culture	O
-	O
independent	O
approaches	O
on	O
our	O
knowledge	O
of	O
the	O
ecology	O
of	O
the	O
human	O
oral	O
cavity	O
and	O
provide	O
directions	O
for	O
future	O
studies	O
that	O
should	O
emphasize	O
the	O
role	O
of	O
specific	O
strains	O
,	O
species	O
and	O
groups	O
of	O
microbes	O
in	O
periodontal	O
disease	O
.	O

Recent	O
findings	O
are	O
summarized	O
to	O
elucidate	O
the	O
relationship	O
between	O
periodontal	O
disease	O
and	O
human	O
oral	O
microbiota	O
,	O
including	O
as	O
-	O
yet	O
-	O
to	O
-	O
be	O
-	O
cultured	O
organisms	O
.	O

The	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
was	O
developed	O
to	O
detect	O
and	O
quantify	O
periodontopathic	O
bacteria	O
,	O
such	O
as	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
(	O
formerly	O
Bacteroides	B-bacteria
forsythus	I-bacteria
)	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
.	O

The	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
technique	O
allowed	O
enumeration	O
of	O
large	O
numbers	O
of	O
species	O
in	O
very	O
large	O
numbers	O
of	O
samples	O
.	O

16S	O
rRNA	O
gene	O
clone	O
library	O
analysis	O
revealed	O
the	O
diversity	O
of	O
human	O
oral	O
microbiota	O
and	O
the	O
existence	O
of	O
as	O
-	O
yet	O
-	O
to	O
-	O
be	O
-	O
cultured	O
organisms	O
that	O
are	O
presumed	O
periodontal	O
pathogens	O
.	O

In	O
addition	O
,	O
terminal	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
T	O
-	O
RFLP	O
)	O
analysis	O
was	O
applied	O
for	O
assessment	O
of	O
diversity	O
of	O
human	O
oral	O
microbiota	O
.	O

Culture	O
-	O
independent	O
approaches	O
are	O
useful	O
for	O
studying	O
the	O
microbial	O
ecology	O
in	O
the	O
human	O
oral	O
cavity	O
and	O
should	O
be	O
useful	O
in	O
the	O
future	O
to	O
elucidate	O
the	O
etiology	O
of	O
periodontal	O
disease	O
.	O

The	O
description	O
of	O
the	O
new	O
species	O
Cardiobacterium	B-bacteria
valvarum	I-bacteria
prompted	O
a	O
search	O
for	O
additional	O
strains	O
of	O
the	O
organism	O
.	O

Here	O
we	O
report	O
characterization	O
of	O
four	O
oral	O
Cardiobacterium	B-bacteria
strains	I-bacteria
from	O
the	O
Culture	O
Collection	O
of	O
the	O
University	O
of	O
Goteborg	O
.	O

The	O
16S	O
rRNA	O
gene	O
sequences	O
of	O
the	O
organisms	O
exhibited	O
99	O
.	O
6	O
%	O
to	O
99	O
.	O
3	O
%	O
homology	O
with	O
Cardiobacterium	B-bacteria
valvarum	I-bacteria
.	O

The	O
cellular	O
fatty	O
acid	O
profiles	O
,	O
electrophoretic	O
patterns	O
of	O
whole	O
-	O
cell	O
proteins	O
,	O
growth	O
rate	O
and	O
nutritional	O
requirement	O
,	O
colonial	O
and	O
cellular	O
morphology	O
,	O
and	O
biochemical	O
reactions	O
were	O
also	O
similar	O
to	O
those	O
of	O
C	B-bacteria
.	I-bacteria
valvarum	I-bacteria
.	O

These	O
results	O
thus	O
classify	O
these	O
organisms	O
as	O
oral	O
strains	O
of	O
C	B-bacteria
.	I-bacteria
valvarum	I-bacteria
.	O

All	O
strains	O
were	O
susceptible	O
to	O
many	O
antibiotics	O
tested	O
.	O

The	O
description	O
of	O
the	O
species	O
was	O
emended	O
.	O

C	B-bacteria
.	I-bacteria
valvarum	I-bacteria
is	O
a	O
rare	O
cause	O
of	O
endocarditis	O
,	O
and	O
its	O
relationship	O
with	O
periodontal	O
diseases	O
may	O
need	O
investigation	O
.	O

Oral	O
Campylobacter	B-bacteria
species	I-bacteria
are	O
rarely	O
reported	O
to	O
cause	O
extraoral	O
infections	O
.	O

Here	O
we	O
present	O
three	O
cases	O
of	O
extraoral	O
abscess	O
caused	O
by	O
an	O
oral	O
Campylobacter	B-bacteria
sp	I-bacteria
.	I-bacteria
and	O
a	O
Streptococcus	B-bacteria
sp	I-bacteria
.	O

The	O
Campylobacter	B-bacteria
species	I-bacteria
were	O
all	O
isolated	O
anaerobically	O
and	O
identified	O
by	O
sequencing	O
analysis	O
of	O
the	O
16S	O
rRNA	O
gene	O
.	O

The	O
cases	O
included	O
a	O
breast	O
abscess	O
caused	O
by	O
Campylobacter	B-bacteria
rectus	I-bacteria
and	O
a	O
non	O
-	O
group	O
A	O
beta	B-bacteria
-	I-bacteria
hemolytic	I-bacteria
streptococcus	I-bacteria
in	O
a	O
patient	O
with	O
lymphoma	O
,	O
a	O
liver	O
abscess	O
caused	O
by	O
Campylobacter	B-bacteria
curvus	I-bacteria
and	O
an	O
alpha	B-bacteria
-	I-bacteria
hemolytic	I-bacteria
streptococcus	I-bacteria
in	O
a	O
patient	O
with	O
complicated	O
ovarian	O
cancer	O
,	O
and	O
a	O
postobstructive	O
bronchial	O
abscess	O
caused	O
by	O
C	B-bacteria
.	I-bacteria
curvus	I-bacteria
and	O
group	O
C	O
beta	B-bacteria
-	I-bacteria
hemolytic	I-bacteria
Streptococcus	I-bacteria
constellatus	I-bacteria
in	O
a	O
patient	O
with	O
lung	O
cancer	O
.	O

The	O
abscesses	O
were	O
drained	O
or	O
resected	O
,	O
and	O
the	O
patients	O
were	O
treated	O
with	O
antibiotics	O
with	O
full	O
resolution	O
of	O
the	O
lesions	O
.	O

The	O
C	B-bacteria
.	I-bacteria
curvus	I-bacteria
cases	O
are	O
likely	O
the	O
first	O
reported	O
infections	O
by	O
this	O
organism	O
,	O
and	O
the	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
case	O
represents	O
the	O
second	O
such	O
reported	O
extraoral	O
infection	O
.	O

This	O
paper	O
describes	O
some	O
of	O
the	O
work	O
done	O
in	O
the	O
author	O
'	O
s	O
laboratory	O
over	O
the	O
past	O
35	O
years	O
.	O

The	O
research	O
covers	O
the	O
following	O
areas	O
:	O
the	O
physiology	O
of	O
oral	O
streptococci	B-bacteria
and	O
their	O
interactions	O
;	O
the	O
physiology	O
of	O
some	O
Gram	O
-	O
negative	O
anaerobes	O
and	O
their	O
interactions	O
in	O
relation	O
to	O
periodontal	O
diseases	O
;	O
preventing	O
the	O
major	O
dental	O
diseases	O
;	O
and	O
the	O
future	O
of	O
oral	O
microbiology	O
.	O

Antimicrobial	O
peptides	O
are	O
one	O
of	O
the	O
factors	O
involved	O
in	O
innate	O
immunity	O
.	O

The	O
susceptibility	O
of	O
periodontopathogenic	O
and	O
cariogenic	O
bacteria	O
to	O
the	O
major	O
antimicrobial	O
peptides	O
produced	O
by	O
epithelia	O
was	O
investigated	O
.	O

Synthetic	O
antimicrobial	O
peptides	O
of	O
human	O
beta	O
-	O
defensin	O
-	O
1	O
(	O
hBD1	O
)	O
,	O
hBD2	O
,	O
hBD3	O
and	O
LL37	O
(	O
CAP18	O
)	O
were	O
evaluated	O
for	O
their	O
antimicrobial	O
activity	O
against	O
oral	O
bacteria	O
.	O

They	O
included	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
20	O
strains	O
)	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
6	O
)	O
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
(	O
7	O
)	O
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
(	O
7	O
)	O
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
(	O
5	O
)	O
,	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
(	O
5	O
)	O
,	O
Streptococcus	B-bacteria
salivarius	I-bacteria
(	O
5	O
)	O
,	O
Streptococcus	B-bacteria
sanguis	I-bacteria
(	O
4	O
)	O
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
(	O
2	O
)	O
and	O
Lactobacillus	B-bacteria
casei	I-bacteria
(	O
1	O
)	O
.	O

Although	O
the	O
four	O
peptides	O
had	O
bactericidal	O
activity	O
against	O
all	O
bacteria	O
tested	O
,	O
the	O
degree	O
of	O
antibacterial	O
activity	O
was	O
variable	O
against	O
the	O
different	O
strains	O
and	O
species	O
.	O

The	O
antibacterial	O
activity	O
of	O
hBD1	O
was	O
lower	O
than	O
that	O
of	O
the	O
other	O
peptides	O
.	O

Among	O
the	O
bacteria	O
tested	O
in	O
this	O
study	O
,	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
was	O
highly	O
susceptible	O
to	O
hBD3	O
and	O
LL37	O
,	O
and	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
was	O
highly	O
susceptible	O
to	O
hBD3	O
.	O

We	O
measured	O
the	O
Zeta	O
-	O
potential	O
,	O
representing	O
the	O
net	O
charge	O
of	O
whole	O
bacteria	O
,	O
to	O
study	O
the	O
relationship	O
between	O
susceptibility	O
to	O
cationic	O
peptide	O
and	O
the	O
net	O
charge	O
of	O
the	O
bacteria	O
.	O

Although	O
we	O
found	O
some	O
correlation	O
in	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
strains	I-bacteria
,	O
we	O
did	O
not	O
find	O
a	O
definite	O
correlation	O
with	O
all	O
the	O
bacterial	O
species	O
.	O

These	O
results	O
indicate	O
that	O
beta	O
-	O
defensins	O
and	O
LL37	O
have	O
versatile	O
antibacterial	O
activity	O
against	O
oral	O
bacteria	O
.	O

Transcriptional	O
profiling	O
,	O
bioinformatics	O
,	O
statistical	O
and	O
ontology	O
tools	O
were	O
used	O
to	O
uncover	O
and	O
dissect	O
genes	O
and	O
pathways	O
of	O
human	O
gingival	O
epithelial	O
cells	O
that	O
are	O
modulated	O
upon	O
interaction	O
with	O
the	O
periodontal	O
pathogens	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
.	O

Consistent	O
with	O
their	O
biological	O
and	O
clinical	O
differences	O
,	O
the	O
common	O
core	O
transcriptional	O
response	O
of	O
epithelial	O
cells	O
to	O
both	O
organisms	O
was	O
very	O
limited	O
,	O
and	O
organism	O
-	O
specific	O
responses	O
predominated	O
.	O

A	O
large	O
number	O
of	O
differentially	O
regulated	O
genes	O
linked	O
to	O
the	O
P53	O
apoptotic	O
network	O
were	O
found	O
with	O
both	O
organisms	O
,	O
which	O
was	O
consistent	O
with	O
the	O
pro	O
-	O
apoptotic	O
phenotype	O
observed	O
with	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
and	O
anti	O
-	O
apoptotic	O
phenotype	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

Furthermore	O
,	O
with	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
the	O
induction	O
of	O
apoptosis	O
did	O
not	O
appear	O
to	O
be	O
Fas	O
-	O
or	O
TNF	O
(	O
alpha	O
)	O
-	O
mediated	O
.	O

Linkage	O
of	O
specific	O
bacterial	O
components	O
to	O
host	O
pathways	O
and	O
networks	O
provided	O
additional	O
insight	O
into	O
the	O
pathogenic	O
process	O
.	O

Comparison	O
of	O
the	O
transcriptional	O
responses	O
of	O
epithelial	O
cells	O
challenged	O
with	O
parental	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
or	O
with	O
a	O
mutant	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
deficient	O
in	O
production	O
of	O
major	O
fimbriae	O
,	O
which	O
are	O
required	O
for	O
optimal	O
invasion	O
,	O
showed	O
major	O
expression	O
differences	O
that	O
reverberated	O
throughout	O
the	O
host	O
cell	O
transcriptome	O
.	O

In	O
contrast	O
,	O
gene	O
ORF859	O
in	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
which	O
may	O
play	O
a	O
role	O
in	O
intracellular	O
homeostasis	O
,	O
had	O
a	O
more	O
subtle	O
effect	O
on	O
the	O
transcriptome	O
.	O

These	O
studies	O
help	O
unravel	O
the	O
complex	O
and	O
dynamic	O
interactions	O
between	O
host	O
epithelial	O
cells	O
and	O
endogenous	O
bacteria	O
that	O
can	O
cause	O
opportunistic	O
infections	O
.	O

Garlic	O
(	O
Allium	O
sativum	O
)	O
has	O
long	O
been	O
known	O
to	O
have	O
antibacterial	O
,	O
antifungal	O
and	O
antiviral	O
properties	O
but	O
there	O
are	O
few	O
data	O
on	O
its	O
effects	O
against	O
oral	O
bacterial	O
species	O
particularly	O
putative	O
periodontal	O
pathogens	O
or	O
their	O
enzymes	O
.	O

Filter	O
sterilised	O
,	O
aqueous	O
extract	O
of	O
garlic	O
was	O
tested	O
for	O
ability	O
to	O
inhibit	O
the	O
growth	O
of	O
a	O
range	O
of	O
oral	O
species	O
and	O
to	O
inhibit	O
the	O
trypsin	O
-	O
like	O
and	O
total	O
protease	O
activity	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
.	O

The	O
garlic	O
extract	O
(	O
57	O
.	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
,	O
containing	O
220	O
microg	O
/	O
ml	O
allicin	O
)	O
inhibited	O
the	O
growth	O
and	O
killed	O
most	O
of	O
the	O
organisms	O
tested	O
.	O

In	O
general	O
,	O
the	O
minimal	O
inhibitory	O
and	O
minimum	O
bactericidal	O
concentrations	O
for	O
the	O
Gram	O
-	O
negative	O
strains	O
(	O
garlic	O
MIC	O
range	O
35	O
.	O
7	O
-	O
1	O
.	O
1	O
mg	O
/	O
ml	O
;	O
allicin	O
mean	O
MIC	O
4	O
.	O
1	O
microg	O
/	O
ml	O
;	O
mean	O
MBC	O
7	O
.	O
9	O
microg	O
/	O
ml	O
)	O
were	O
lower	O
than	O
those	O
for	O
the	O
Gram	O
-	O
positive	O
strains	O
tested	O
(	O
garlic	O
MIC	O
range	O
142	O
.	O
7	O
-	O
35	O
.	O
7	O
mg	O
/	O
ml	O
;	O
allicin	O
mean	O
MIC	O
27	O
.	O
5	O
microg	O
/	O
ml	O
;	O
mean	O
MBC	O
91	O
.	O
9	O
microg	O
/	O
ml	O
)	O
.	O

Also	O
,	O
of	O
the	O
organisms	O
tested	O
,	O
the	O
putative	O
periodontal	O
pathogens	O
had	O
among	O
the	O
lowest	O
MICs	O
(	O
17	O
.	O
8	O
-	O
1	O
.	O
1	O
mg	O
/	O
ml	O
garlic	O
)	O
and	O
MBCs	O
(	O
35	O
.	O
7	O
-	O
1	O
.	O
1	O
mg	O
/	O
ml	O
garlic	O
)	O
.	O

Time	O
-	O
kill	O
curves	O
for	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
ginigvalis	I-bacteria
,	O
showed	O
that	O
killing	O
of	O
the	O
latter	O
started	O
almost	O
immediately	O
,	O
whereas	O
there	O
was	O
a	O
delay	O
before	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
was	O
killed	O
.	O

The	O
garlic	O
extract	O
also	O
inhibited	O
the	O
trypsin	O
-	O
like	O
and	O
total	O
protease	O
activity	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
by	O
92	O
.	O
7	O
%	O
and	O
94	O
.	O
88	O
%	O
,	O
respectively	O
.	O

These	O
data	O
indicate	O
that	O
garlic	O
extract	O
inhibits	O
the	O
growth	O
of	O
oral	O
pathogens	O
and	O
certain	O
proteases	O
and	O
so	O
may	O
have	O
therapeutic	O
value	O
,	O
particularly	O
for	O
periodontitis	O
.	O

The	O
aims	O
of	O
this	O
study	O
are	O
to	O
describe	O
the	O
relationships	O
between	O
IgG	O
antibodies	O
to	O
17	O
oral	O
organisms	O
and	O
atherosclerosis	O
as	O
indexed	O
by	O
carotid	O
intima	O
-	O
medial	O
wall	O
thickness	O
(	O
IMT	O
)	O
and	O
to	O
evaluate	O
the	O
role	O
of	O
smoking	O
.	O

Our	O
study	O
is	O
based	O
on	O
a	O
subset	O
of	O
participants	O
in	O
the	O
Atherosclerosis	O
Risk	O
in	O
Communities	O
(	O
ARIC	O
)	O
Study	O
,	O
who	O
received	O
a	O
complete	O
periodontal	O
examination	O
during	O
visit	O
4	O
(	O
1996	O
-	O
1998	O
)	O
.	O

The	O
outcome	O
was	O
mean	O
carotid	O
IMT	O
>	O
/	O
=	O
1mm	O
assessed	O
by	O
B	O
-	O
mode	O
ultrasound	O
.	O

The	O
exposures	O
were	O
serum	O
IgG	O
antibody	O
levels	O
against	O
17	O
periodontal	O
organisms	O
using	O
a	O
whole	O
bacterial	O
checkerboard	O
immunoblotting	O
technique	O
.	O

Evaluation	O
of	O
all	O
17	O
antibodies	O
indicated	O
that	O
antibody	O
to	O
Campylobacter	B-bacteria
rectus	I-bacteria
resulted	O
in	O
the	O
best	O
-	O
fitting	O
model	O
(	O
OR	O
=	O
2	O
.	O
3	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
83	O
-	O
2	O
.	O
84	O
)	O
and	O
individuals	O
with	O
both	O
high	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
and	O
Peptostreptococcus	B-bacteria
micros	I-bacteria
titers	O
had	O
almost	O
twice	O
the	O
prevalence	O
of	O
IMT	O
>	O
/	O
=	O
1mm	O
than	O
those	O
with	O
only	O
a	O
high	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
antibody	O
(	O
8	O
.	O
3	O
%	O
versus	O
16	O
.	O
3	O
%	O
)	O
.	O

Stratification	O
by	O
smoking	O
indicated	O
that	O
all	O
microbial	O
models	O
significant	O
for	O
smokers	O
were	O
also	O
significant	O
for	O
never	O
smokers	O
except	O
for	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
p	O
=	O
0	O
.	O
08	O
)	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
report	O
a	O
relationship	O
between	O
IgG	O
antibody	O
reactive	O
to	O
oral	O
organisms	O
and	O
subclinical	O
atherosclerosis	O
with	O
significant	O
relationships	O
evident	O
in	O
both	O
ever	O
and	O
never	O
smokers	O
.	O

To	O
detect	O
enterococci	B-bacteria
,	O
enteric	O
bacteria	O
and	O
yeast	O
species	O
from	O
the	O
canals	O
of	O
teeth	O
with	O
primary	O
endodontic	O
infections	O
before	O
and	O
after	O
canal	O
preparation	O
and	O
to	O
test	O
the	O
antibiotic	O
susceptibility	O
of	O
enterococcal	B-bacteria
strains	I-bacteria
isolated	O
from	O
infected	O
root	O
canals	O
.	O

Twenty	O
-	O
five	O
single	O
-	O
rooted	O
teeth	O
with	O
pulp	O
necrosis	O
,	O
intact	O
pulp	O
chambers	O
and	O
periradicular	O
lesions	O
were	O
selected	O
for	O
study	O
.	O

Samples	O
were	O
collected	O
from	O
canals	O
before	O
and	O
after	O
instrumentation	O
.	O

Amongst	O
isolated	O
microorganisms	O
from	O
infected	O
root	O
canals	O
only	O
enterococci	B-bacteria
,	O
enteric	O
bacteria	O
and	O
yeasts	O
were	O
identified	O
by	O
biochemical	O
tests	O
.	O

The	O
in	O
vitro	O
antimicrobial	O
susceptibility	O
of	O
isolated	O
enterococci	B-bacteria
strains	I-bacteria
was	O
evaluated	O
by	O
the	O
Etest	O
system	O
.	O

Microorganisms	O
were	O
isolated	O
from	O
92	O
%	O
of	O
the	O
samples	O
following	O
intracoronal	O
access	O
,	O
22	O
%	O
were	O
enterococci	B-bacteria
,	O
enteric	O
bacteria	O
or	O
yeast	O
species	O
.	O

After	O
biomechanical	O
preparation	O
,	O
these	O
species	O
were	O
no	O
longer	O
detected	O
.	O

After	O
7	O
days	O
without	O
intracanal	O
dressing	O
,	O
100	O
%	O
of	O
the	O
canals	O
contained	O
microorganisms	O
,	O
52	O
%	O
of	O
which	O
were	O
target	O
species	O
.	O

However	O
,	O
after	O
using	O
paramonochlorophenol	O
[	O
PRP	O
(	O
2	O
.	O
0	O
g	O
)	O
,	O
Rinosoro	O
and	O
polyethylene	O
glycol	O
(	O
400	O
equal	O
parts	O
up	O
to	O
100	O
mL	O
)	O
]	O
as	O
an	O
intracanal	O
dressing	O
for	O
7	O
days	O
,	O
enteric	O
bacteria	O
and	O
yeasts	O
were	O
not	O
detected	O
;	O
only	O
enterococci	B-bacteria
were	O
still	O
present	O
.	O

All	O
strains	O
of	O
enterococci	B-bacteria
were	O
susceptible	O
to	O
ampicillin	O
,	O
but	O
exhibited	O
variable	O
susceptibility	O
to	O
rifampin	O
and	O
ciprofloxacin	O
.	O

Enterococci	B-bacteria
,	O
enteric	O
bacteria	O
and	O
yeasts	O
were	O
present	O
in	O
primary	O
endodontic	O
infections	O
.	O

Enterococci	B-bacteria
,	O
particularly	O
Enterococcus	B-bacteria
faecalis	I-bacteria
and	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
were	O
resistant	O
to	O
removal	O
by	O
root	O
canal	O
preparation	O
followed	O
by	O
intracanal	O
dressing	O
.	O

To	O
inquire	O
into	O
the	O
effect	O
of	O
different	O
of	O
Nidus	O
Vespae	O
extract	O
(	O
NVE	O
)	O
on	O
growth	O
and	O
acid	O
production	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
sanguis	I-bacteria
and	O
Actinomyces	B-bacteria
viscosus	I-bacteria
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
ATCC	I-bacteria
25175	I-bacteria
,	O
Streptococcus	B-bacteria
sanguis	I-bacteria
ATCC	I-bacteria
10556	I-bacteria
and	O
Actinomyces	B-bacteria
viscosus	I-bacteria
ATCC	I-bacteria
19246	I-bacteria
were	O
chosen	O
as	O
the	O
experimental	O
bacteria	O
.	O

Four	O
extracts	O
of	O
Nidus	O
Vespae	O
were	O
prepared	O
and	O
then	O
the	O
effects	O
of	O
these	O
Nidus	O
Vespae	O
extracts	O
on	O
the	O
acid	O
production	O
were	O
determined	O
.	O

All	O
of	O
Nidus	O
Vespae	O
extracts	O
could	O
inhibit	O
the	O
growth	O
the	O
of	O
the	O
three	O
strains	O
,	O
and	O
NVE1	O
,	O
NVE3	O
,	O
NVE4	O
could	O
inhibit	O
the	O
acid	O
production	O
of	O
the	O
three	O
strains	O
,	O
NVE2	O
could	O
inhibit	O
the	O
acid	O
production	O
of	O
Actinomyces	B-bacteria
viscosus	I-bacteria
.	O

Four	O
extracts	O
of	O
Nidus	O
Vespae	O
could	O
inhibit	O
the	O
acid	O
production	O
of	O
three	O
bacteria	O
strains	O
.	O

Noninvasive	O
in	O
situ	O
detection	O
of	O
suspected	O
cariogenic	O
bacterial	O
species	O
within	O
dental	O
biofilms	O
could	O
facilitate	O
monitoring	O
of	O
the	O
dynamic	O
change	O
of	O
oral	O
microbial	O
flora	O
and	O
assist	O
in	O
the	O
assessment	O
of	O
the	O
treatment	O
efficacy	O
of	O
therapeutic	O
agents	O
.	O

In	O
this	O
study	O
,	O
we	O
explore	O
the	O
possibility	O
to	O
use	O
three	O
well	O
-	O
characterized	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
against	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
and	O
Lactobacillus	B-bacteria
casei	I-bacteria
to	O
identify	O
these	O
three	O
important	O
members	O
of	O
the	O
oral	O
microbial	O
community	O
in	O
the	O
complex	O
environment	O
of	O
oral	O
biofilms	O
.	O

These	O
MAbs	O
,	O
which	O
were	O
conjugated	O
to	O
different	O
fluorescent	O
labels	O
and	O
visualized	O
with	O
confocal	O
laser	O
scanning	O
microscopy	O
(	O
CLSM	O
)	O
,	O
proved	O
to	O
be	O
an	O
useful	O
tool	O
to	O
identify	O
the	O
three	O
species	O
of	O
interest	O
(	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
,	O
and	O
L	B-bacteria
.	I-bacteria
casei	I-bacteria
)	O
under	O
various	O
experimental	O
conditions	O
including	O
in	O
vitro	O
and	O
in	O
vivo	O
derived	O
oral	O
biofilms	O
.	O

Manifold	O
addition	O
of	O
the	O
MAbs	O
on	O
consecutive	O
days	O
did	O
not	O
alter	O
the	O
biofilm	O
structure	O
thus	O
allowing	O
monitoring	O
of	O
the	O
same	O
biofilm	O
over	O
extended	O
time	O
periods	O
.	O

Using	O
this	O
MAb	O
-	O
based	O
method	O
the	O
effect	O
of	O
sucrose	O
challenge	O
on	O
the	O
biofilm	O
composition	O
and	O
the	O
distribution	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
,	O
and	O
L	B-bacteria
.	I-bacteria
casei	I-bacteria
were	O
examined	O
.	O

S	B-bacteria
.	I-bacteria
mutans	I-bacteria
was	O
found	O
to	O
be	O
the	O
predominant	O
species	O
under	O
the	O
various	O
biofilm	O
conditions	O
tested	O
.	O

These	O
studies	O
indicate	O
that	O
MAbs	O
based	O
bacterial	O
detection	O
with	O
CLSM	O
is	O
a	O
versatile	O
tool	O
which	O
permits	O
new	O
insights	O
into	O
the	O
ecology	O
of	O
oral	O
biofilm	O
development	O
.	O

To	O
investigate	O
the	O
microbial	O
contents	O
presented	O
on	O
the	O
surface	O
of	O
mucosa	O
in	O
the	O
oral	O
cavity	O
of	O
patients	O
who	O
accepted	O
radiotherapy	O
,	O
and	O
to	O
provide	O
the	O
evidences	O
of	O
controlling	O
post	O
-	O
radiotherapeutic	O
infections	O
.	O

32	O
patients	O
(	O
19	O
males	O
and	O
13	O
females	O
)	O
aged	O
from	O
37	O
-	O
72	O
received	O
radiotherapy	O
after	O
oral	O
squamous	O
cell	O
carcinomas	O
operation	O
were	O
selected	O
.	O

Samples	O
of	O
saliva	O
were	O
obtained	O
from	O
the	O
radiated	O
center	O
and	O
opposite	O
mucosa	O
before	O
and	O
after	O
radiotherapy	O
.	O

The	O
detective	O
amount	O
,	O
detective	O
ratio	O
and	O
constituent	O
ratio	O
were	O
analysed	O
by	O
cultivation	O
and	O
identification	O
.	O

Streptococci	B-bacteria
,	O
Candida	O
albicans	O
and	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
significantly	O
increased	O
on	O
both	O
sides	O
of	O
the	O
oral	O
mucosa	O
while	O
Neisseria	B-bacteria
and	O
Actinobacillus	B-bacteria
decreased	O
on	O
radiated	O
region	O
after	O
the	O
radiotherapy	O
.	O

Radiotherapy	O
has	O
great	O
effects	O
on	O
oral	O
bacteria	O
and	O
pathogenic	O
organism	O
may	O
play	O
a	O
role	O
in	O
post	O
-	O
radiotherapy	O
infections	O
.	O

It	O
is	O
necessary	O
to	O
do	O
bacteria	O
culture	O
and	O
choose	O
sensitive	O
antibiotics	O
regularly	O
for	O
post	O
-	O
radiotherapeutic	O
patients	O
.	O

This	O
review	O
describes	O
current	O
knowledge	O
on	O
probiotic	O
bacteriotherapy	O
from	O
the	O
oral	O
health	O
perspective	O
.	O

Recent	O
experimental	O
studies	O
and	O
results	O
from	O
randomized	O
controlled	O
trials	O
have	O
shown	O
that	O
certain	O
gut	O
bacteria	O
,	O
in	O
particular	O
species	O
of	O
Lactobacillus	B-bacteria
and	O
Bifidobacterium	B-bacteria
,	O
may	O
exert	O
beneficial	O
effects	O
in	O
the	O
oral	O
cavity	O
by	O
inhibiting	O
cariogenic	O
streptococci	B-bacteria
and	O
Candida	O
sp	O
.	O

Probiotics	O
have	O
been	O
successfully	O
used	O
to	O
control	O
gastro	O
-	O
intestinal	O
diseases	O
.	O

They	O
also	O
appear	O
to	O
alleviate	O
symptoms	O
of	O
allergy	O
and	O
diseases	O
with	O
immunological	O
pathology	O
.	O

The	O
mechanisms	O
of	O
probiotic	O
action	O
appear	O
to	O
link	O
with	O
colonization	O
resistance	O
and	O
immune	O
modulation	O
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
can	O
produce	O
different	O
antimicrobial	O
components	O
such	O
as	O
organic	O
acids	O
,	O
hydrogen	O
peroxide	O
,	O
carbon	O
peroxide	O
,	O
diacetyl	O
,	O
low	O
molecular	O
weight	O
antimicrobial	O
substances	O
,	O
bacteriocins	O
,	O
and	O
adhesion	O
inhibitors	O
,	O
which	O
also	O
affect	O
oral	O
microflora	O
.	O

However	O
,	O
data	O
is	O
still	O
sparse	O
on	O
the	O
probiotic	O
action	O
in	O
the	O
oral	O
cavity	O
.	O

More	O
information	O
is	O
needed	O
on	O
the	O
colonization	O
of	O
probiotics	O
in	O
the	O
mouth	O
and	O
their	O
possible	O
effect	O
on	O
and	O
within	O
oral	O
biofilms	O
.	O

There	O
is	O
every	O
reason	O
to	O
believe	O
that	O
the	O
putative	O
probiotic	O
mechanisms	O
of	O
action	O
are	O
the	O
same	O
in	O
the	O
mouth	O
as	O
they	O
are	O
in	O
other	O
parts	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

Because	O
of	O
the	O
increasing	O
global	O
problem	O
with	O
antimicrobial	O
drug	O
resistance	O
,	O
the	O
concept	O
of	O
probiotic	O
therapy	O
is	O
interesting	O
and	O
pertinent	O
,	O
and	O
merits	O
further	O
research	O
in	O
the	O
fields	O
of	O
oral	O
medicine	O
and	O
dentistry	O
.	O

Zinc	O
is	O
used	O
in	O
oral	O
care	O
products	O
as	O
an	O
antiplaque	O
/	O
antigingivitis	O
agent	O
.	O

Our	O
objective	O
was	O
to	O
assess	O
the	O
antimicrobial	O
actions	O
of	O
zinc	O
against	O
oral	O
anaerobes	O
associated	O
with	O
gingivitis	O
,	O
specifically	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
with	O
focus	O
on	O
catabolism	O
and	O
oxidative	O
metabolism	O
.	O

The	O
oral	O
anaerobes	O
were	O
grown	O
in	O
complex	O
medium	O
in	O
an	O
anaerobic	O
chamber	O
,	O
harvested	O
by	O
centrifugation	O
and	O
used	O
directly	O
for	O
experiments	O
with	O
suspensions	O
.	O

Biofilm	O
growth	O
involved	O
super	O
-	O
infection	O
by	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
of	O
an	O
initial	O
biofilm	O
formed	O
by	O
Streptococcus	B-bacteria
sanguis	I-bacteria
.	O

Zn	O
(	O
2	O
+	O
)	O
inhibited	O
catabolism	O
of	O
glutamate	O
,	O
glutamyl	O
-	O
glutamate	O
,	O
glucose	O
and	O
fructose	O
by	O
F	O
.	O
nucleatum	O
cells	O
in	O
suspensions	O
with	O
ID	O
(	O
50	O
)	O
values	O
,	O
respectively	O
,	O
of	O
0	O
.	O
05	O
,	O
0	O
.	O
005	O
,	O
0	O
.	O
01	O
and	O
0	O
.	O
01	O
mM	O
.	O

The	O
ID	O
(	O
50	O
)	O
value	O
for	O
inhibition	O
of	O
glutamate	O
catabolism	O
by	O
biofilms	O
was	O
0	O
.	O
10	O
mM	O
.	O

Inhibition	O
of	O
glutamate	O
catabolism	O
could	O
be	O
related	O
to	O
inhibition	O
of	O
substrate	O
uptake	O
and	O
of	O
2	O
-	O
oxoglutarate	O
reductase	O
.	O

Zn	O
(	O
2	O
+	O
)	O
also	O
inhibited	O
catabolism	O
of	O
aspartate	O
or	O
aspartyl	O
-	O
aspartate	O
by	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
with	O
ID	O
(	O
50	O
)	O
values	O
of	O
0	O
.	O
07	O
and	O
about	O
0	O
.	O
03	O
mM	O
,	O
respectively	O
.	O

Respiration	O
of	O
intact	O
cells	O
of	O
F	O
.	O
nucleatum	O
and	O
NADH	O
oxidase	O
in	O
cell	O
extracts	O
were	O
sensitive	O
to	O
zinc	O
with	O
ID	O
(	O
50	O
)	O
values	O
,	O
respectively	O
,	O
of	O
about	O
1	O
.	O
0	O
and	O
1	O
.	O
4	O
mM	O
.	O

Zinc	O
also	O
inhibited	O
production	O
of	O
hydrogen	O
peroxide	O
by	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
(	O
ID	O
(	O
50	O
)	O
=	O
ca	O
.	O
0	O
.	O
04	O
mM	O
.	O
)	O

but	O
at	O
high	O
concentrations	O
acted	O
to	O
potentiate	O
and	O
enhance	O
peroxide	O
killing	O
of	O
the	O
anaerobe	O
.	O

Zn	O
(	O
2	O
+	O
)	O
is	O
a	O
potent	O
inhibitor	O
of	O
catabolism	O
by	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
including	O
catabolism	O
of	O
peptides	O
,	O
which	O
can	O
be	O
degraded	O
to	O
yield	O
inflammatory	O
metabolic	O
end	O
products	O
.	O

Zn	O
(	O
2	O
+	O
)	O
also	O
inhibits	O
O	O
(	O
2	O
)	O
metabolism	O
of	O
F	O
.	O
nucleatum	O
by	O
about	O
50	O
%	O
and	O
hydrogen	O
peroxide	O
production	O
nearly	O
completely	O
but	O
also	O
enhances	O
killing	O
by	O
peroxide	O
added	O
to	O
cells	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
levels	O
of	O
occurrence	O
and	O
number	O
of	O
aerobic	O
bacteria	O
hemolysing	O
and	O
non	O
-	O
hemolysing	O
,	O
anaerobic	O
bacteria	O
,	O
streptococci	B-bacteria
hemolysing	O
and	O
non	O
-	O
hemolysing	O
,	O
staphylococci	B-bacteria
,	O
and	O
bacteria	O
responsible	O
for	O
tooth	O
decay	O
(	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
)	O
on	O
oral	O
cavity	O
in	O
children	O
and	O
adults	O
.	O

The	O
results	O
obtained	O
indicate	O
the	O
difference	O
of	O
the	O
level	O
of	O
occurrence	O
of	O
,	O
aerobic	O
bacteria	O
hemolysing	O
and	O
non	O
-	O
hemolysing	O
,	O
anaerobic	O
bacteria	O
,	O
streptococci	B-bacteria
hemolysing	O
and	O
non	O
-	O
hemolysing	O
,	O
staphylococci	B-bacteria
,	O
and	O
bacteria	O
responsible	O
for	O
tooth	O
decay	O
(	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
)	O
was	O
not	O
statistically	O
significant	O
in	O
either	O
group	O
.	O

The	O
counts	O
and	O
average	O
values	O
of	O
the	O
counts	O
for	O
aerobic	O
bacteria	O
non	O
-	O
hemolysing	O
,	O
anaerobic	O
bacteria	O
,	O
streptococci	B-bacteria
hemolysing	O
and	O
non	O
-	O
hemolysing	O
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
turned	O
out	O
to	O
be	O
statistically	O
significantly	O
larger	O
in	O
adults	O
than	O
in	O
children	O
.	O

However	O
for	O
aerobic	O
bacteria	O
hemolysing	O
,	O
staphylococci	B-bacteria
and	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
the	O
difference	O
of	O
the	O
counts	O
was	O
not	O
statistically	O
significant	O
in	O
either	O
group	O
.	O

The	O
comparative	O
in	O
vitro	O
potency	O
of	O
XRP2868	O
,	O
a	O
new	O
oral	O
semisynthetic	O
streptogramin	O
antibiotic	O
,	O
was	O
evaluated	O
against	O
gram	O
-	O
positive	O
bacteria	O
.	O

XRP2868	O
inhibited	O
all	O
staphylococci	B-bacteria
at	O
<	O
or	O
=	O
1	O
microg	O
/	O
ml	O
and	O
all	O
non	O
-	O
pneumococcal	O
streptococci	I-bacteria
at	O
<	O
or	O
=	O
0	O
.	O
25	O
microg	O
/	O
ml	O
and	O
was	O
fourfold	O
more	O
potent	O
than	O
quinupristin	O
-	O
dalfopristin	O
against	O
Staphylococcus	B-bacteria
aureus	I-bacteria
and	O
Enterococcus	B-bacteria
faecium	I-bacteria
.	O

The	O
purpose	O
of	O
the	O
present	O
investigation	O
was	O
to	O
determine	O
if	O
the	O
salivary	O
counts	O
of	O
40	O
common	O
oral	O
bacteria	O
in	O
subjects	O
with	O
an	O
oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
lesion	O
would	O
differ	O
from	O
those	O
found	O
in	O
cancer	O
-	O
free	O
(	O
OSCC	O
-	O
free	O
)	O
controls	O
.	O

Unstimulated	O
saliva	O
samples	O
were	O
collected	O
from	O
229	O
OSCC	O
-	O
free	O
and	O
45	O
OSCC	O
subjects	O
and	O
evaluated	O
for	O
their	O
content	O
of	O
40	O
common	O
oral	O
bacteria	O
using	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
.	O

DNA	O
counts	O
per	O
ml	O
saliva	O
were	O
determined	O
for	O
each	O
species	O
,	O
averaged	O
across	O
subjects	O
in	O
the	O
2	O
subject	O
groups	O
,	O
and	O
significance	O
of	O
differences	O
between	O
groups	O
determined	O
using	O
the	O
Mann	O
-	O
Whitney	O
test	O
and	O
adjusted	O
for	O
multiple	O
comparisons	O
.	O

Diagnostic	O
sensitivity	O
and	O
specificity	O
in	O
detection	O
of	O
OSCC	O
by	O
levels	O
of	O
salivary	O
organisms	O
were	O
computed	O
and	O
comparisons	O
made	O
separately	O
between	O
a	O
non	O
-	O
matched	O
group	O
of	O
45	O
OSCC	O
subjects	O
and	O
229	O
controls	O
and	O
a	O
group	O
of	O
45	O
OSCC	O
subjects	O
and	O
45	O
controls	O
matched	O
by	O
age	O
,	O
gender	O
and	O
smoking	O
history	O
.	O

Counts	O
of	O
3	O
of	O
the	O
40	O
species	O
tested	O
,	O
Capnocytophaga	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
melaninogenica	I-bacteria
and	O
Streptococcus	B-bacteria
mitis	I-bacteria
,	O
were	O
elevated	O
in	O
the	O
saliva	O
of	O
individuals	O
with	O
OSCC	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

When	O
tested	O
as	O
diagnostic	O
markers	O
the	O
3	O
species	O
were	O
found	O
to	O
predict	O
80	O
%	O
of	O
cancer	O
cases	O
(	O
sensitivity	O
)	O
while	O
excluding	O
83	O
%	O
of	O
controls	O
(	O
specificity	O
)	O
in	O
the	O
non	O
-	O
matched	O
group	O
.	O

Diagnostic	O
sensitivity	O
and	O
specificity	O
in	O
the	O
matched	O
group	O
were	O
80	O
%	O
and	O
82	O
%	O
respectively	O
.	O

High	O
salivary	O
counts	O
of	O
C	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
melaninogenica	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
may	O
be	O
diagnostic	O
indicators	O
of	O
OSCC	O
.	O

Heat	O
shock	O
proteins	O
(	O
HSP	O
)	O
are	O
released	O
by	O
cells	O
in	O
response	O
to	O
stress	O
signals	O
.	O

It	O
is	O
hypothesized	O
that	O
pathogenic	O
bacteria	O
stimulate	O
the	O
cells	O
in	O
the	O
periodontium	O
to	O
up	O
-	O
regulate	O
the	O
expression	O
of	O
HSP60	O
,	O
which	O
would	O
stimulate	O
macrophages	O
,	O
and	O
possibly	O
other	O
cells	O
,	O
to	O
produce	O
proinflammatory	O
cytokines	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
oral	O
keratinocytes	O
responded	O
to	O
recombinant	O
human	O
HSP60	O
and	O
to	O
identify	O
the	O
signalling	O
pathways	O
involved	O
.	O

In	O
addition	O
,	O
whether	O
oral	O
keratinocytes	O
are	O
a	O
source	O
of	O
endogenous	O
HSP60	O
was	O
also	O
investigated	O
.	O

RT	O
-	O
PCR	O
revealed	O
that	O
rhHSP60	O
induced	O
expression	O
of	O
the	O
IL	O
-	O
1beta	O
gene	O
in	O
the	O
Human	O
Oral	O
Keratinocyte	O
(	O
HOK	O
-	O
16B	O
)	O
cell	O
line	O
and	O
it	O
was	O
highest	O
at	O
the	O
lowest	O
concentration	O
used	O
(	O
0	O
.	O
1	O
microg	O
/	O
ml	O
)	O
.	O

These	O
responses	O
were	O
mediated	O
via	O
activation	O
of	O
p44	O
/	O
42	O
MAP	O
-	O
kinases	O
and	O
to	O
a	O
lesser	O
extend	O
the	O
MAP	O
-	O
kinase	O
SAP	O
/	O
JNK	O
.	O

Similar	O
data	O
was	O
obtained	O
from	O
analysis	O
of	O
intracellular	O
signalling	O
pathways	O
in	O
HOK	O
-	O
16B	O
cells	O
by	O
rhHSP70	O
and	O
LPS	O
(	O
from	O
both	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
the	O
oral	O
pathogen	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
)	O
.	O

However	O
,	O
there	O
was	O
little	O
activation	O
of	O
p38	O
by	O
rhHSP60	O
.	O

Blocking	O
of	O
the	O
p44	O
/	O
42	O
pathway	O
decreased	O
HSP60	O
-	O
induced	O
IL	O
-	O
1beta	O
gene	O
expression	O
and	O
protein	O
secretion	O
.	O

In	O
addition	O
,	O
we	O
discovered	O
that	O
self	O
-	O
HSP60	O
proteins	O
were	O
constitutively	O
secreted	O
by	O
HOK	O
-	O
16B	O
cells	O
.	O

Secretion	O
of	O
self	O
-	O
HSP60	O
was	O
up	O
-	O
regulated	O
in	O
cells	O
treated	O
with	O
LPS	O
from	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
but	O
down	O
-	O
regulated	O
with	O
LPS	O
from	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
.	O

To	O
summarize	O
,	O
oral	O
keratinocytes	O
respond	O
to	O
exogenous	O
HSP60	O
by	O
triggering	O
expression	O
of	O
the	O
inflammatory	O
cytokine	O
IL	O
-	O
1beta	O
through	O
activation	O
of	O
p44	O
/	O
42	O
MAP	O
kinase	O
.	O

Oral	O
keratinocytes	O
are	O
also	O
a	O
source	O
for	O
self	O
-	O
HSP60	O
and	O
the	O
secretion	O
of	O
this	O
protein	O
may	O
be	O
differentially	O
modified	O
by	O
LPS	O
from	O
different	O
bacterial	O
species	O
.	O

These	O
results	O
highlight	O
the	O
importance	O
of	O
oral	O
keratinocytes	O
and	O
HSPs	O
in	O
the	O
development	O
of	O
an	O
immune	O
response	O
against	O
bacterial	O
infection	O
.	O

Endodontic	O
infections	O
have	O
been	O
traditionally	O
studied	O
by	O
culture	O
methods	O
,	O
but	O
recent	O
reports	O
showing	O
that	O
over	O
50	O
%	O
of	O
the	O
oral	O
microbiota	O
is	O
still	O
uncultivable	O
(	O
B	O
.	O
J	O
.	O
Paster	O
et	O
al	O
.	O
,	O
J	O
.	O
Bacteriol	O
.	O
183	O
:	O
3770	O
-	O
3783	O
,	O
2001	O
)	O
raise	O
the	O
possibility	O
that	O
many	O
endodontic	O
pathogens	O
remain	O
unknown	O
.	O

This	O
study	O
intended	O
to	O
investigate	O
the	O
prevalence	O
of	O
several	O
uncultivated	O
oral	O
phylotypes	O
,	O
as	O
well	O
as	O
newly	O
named	O
species	O
in	O
primary	O
or	O
persistent	O
endodontic	O
infections	O
associated	O
with	O
chronic	O
periradicular	O
diseases	O
.	O

Samples	O
were	O
taken	O
from	O
the	O
root	O
canals	O
of	O
21	O
untreated	O
teeth	O
and	O
22	O
root	O
-	O
filled	O
teeth	O
,	O
all	O
of	O
them	O
with	O
radiographic	O
evidence	O
of	O
periradicular	O
bone	O
destruction	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
directly	O
from	O
each	O
sample	O
,	O
and	O
16S	O
rRNA	O
gene	O
-	O
based	O
nested	O
or	O
heminested	O
PCR	O
assays	O
were	O
used	O
to	O
determine	O
the	O
presence	O
of	O
13	O
species	O
or	O
phylotypes	O
of	O
bacteria	O
.	O

Species	O
-	O
specific	O
primers	O
had	O
already	O
been	O
validated	O
in	O
the	O
literature	O
or	O
were	O
developed	O
by	O
aligning	O
closely	O
related	O
16S	O
rRNA	O
gene	O
sequences	O
.	O

Species	O
specificity	O
for	O
each	O
primer	O
pair	O
was	O
confirmed	O
by	O
running	O
PCRs	O
against	O
a	O
panel	O
of	O
several	O
oral	O
bacteria	O
and	O
by	O
sequencing	O
DNA	O
from	O
representative	O
positive	O
samples	O
.	O

All	O
species	O
or	O
phylotypes	O
were	O
detected	O
in	O
at	O
least	O
one	O
case	O
of	O
primary	O
infections	O
.	O

The	O
most	O
prevalent	O
species	O
or	O
phylotypes	O
found	O
in	O
primary	O
infections	O
were	O
Dialister	B-bacteria
invisus	I-bacteria
(	O
81	O
%	O
)	O
,	O
Synergistes	B-bacteria
oral	I-bacteria
clone	I-bacteria
BA121	I-bacteria
(	O
33	O
%	O
)	O
,	O
and	O
Olsenella	B-bacteria
uli	I-bacteria
(	O
33	O
%	O
)	O
.	O

Of	O
the	O
target	O
bacteria	O
,	O
only	O
these	O
three	O
species	O
were	O
detected	O
in	O
persistent	O
infections	O
.	O

Detection	O
of	O
uncultivated	O
phylotypes	O
and	O
newly	O
named	O
species	O
in	O
infected	O
root	O
canals	O
suggests	O
that	O
there	O
are	O
previously	O
unrecognized	O
bacteria	O
that	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
periradicular	O
diseases	O
.	O

Diverse	O
methylotrophic	O
bacteria	O
were	O
isolated	O
from	O
the	O
tongue	O
,	O
and	O
supra	O
-	O
and	O
subgingival	O
plaque	O
in	O
the	O
mouths	O
of	O
volunteers	O
and	O
patients	O
with	O
periodontitis	O
.	O

One	O
-	O
carbon	O
compounds	O
such	O
as	O
dimethylsulfide	O
in	O
the	O
mouth	O
are	O
likely	O
to	O
be	O
used	O
as	O
growth	O
substrates	O
for	O
these	O
organisms	O
.	O

Methylotrophic	O
strains	O
of	O
Bacillus	B-bacteria
,	O
Brevibacterium	B-bacteria
casei	I-bacteria
,	O
Hyphomicrobium	B-bacteria
sulfonivorans	I-bacteria
,	O
Methylobacterium	B-bacteria
,	O
Micrococcus	B-bacteria
luteus	I-bacteria
and	O
Variovorax	B-bacteria
paradoxus	I-bacteria
were	O
characterized	O
physiologically	O
and	O
by	O
their	O
16S	O
rRNA	O
gene	O
sequences	O
.	O

The	O
type	O
strain	O
of	O
B	B-bacteria
.	I-bacteria
casei	I-bacteria
was	O
shown	O
to	O
be	O
methylotrophic	O
.	O

Enzymes	O
of	O
methylotrophic	O
metabolism	O
were	O
characterized	O
in	O
some	O
strains	O
,	O
and	O
activities	O
consistent	O
with	O
growth	O
using	O
known	O
pathways	O
of	O
C1	O
-	O
compound	O
metabolism	O
demonstrated	O
.	O

Genomic	O
DNA	O
from	O
18	O
tongue	O
and	O
dental	O
plaque	O
samples	O
from	O
nine	O
volunteers	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
using	O
primers	O
for	O
the	O
16S	O
rRNA	O
gene	O
of	O
Methylobacterium	O
and	O
the	O
mxaF	O
gene	O
of	O
methanol	O
dehydrogenase	O
.	O

MxaF	O
was	O
detected	O
in	O
all	O
nine	O
volunteers	O
,	O
and	O
Methylobacterium	B-bacteria
was	O
detected	O
in	O
seven	O
.	O

Methylotrophic	O
activity	O
is	O
thus	O
a	O
feature	O
of	O
the	O
oral	O
bacterial	O
community	O
.	O

Recent	O
studies	O
have	O
suggested	O
that	O
infectious	O
organisms	O
play	O
a	O
role	O
in	O
vascular	O
diseases	O
.	O

In	O
this	O
study	O
,	O
to	O
explore	O
a	O
possible	O
link	O
between	O
oral	O
infection	O
and	O
Buerger	O
disease	O
,	O
we	O
investigated	O
whether	O
oral	O
(	O
periodontal	O
)	O
bacteria	O
were	O
present	O
in	O
occluded	O
arteries	O
removed	O
from	O
patients	O
with	O
characteristic	O
Buerger	O
disease	O
.	O

Fourteen	O
male	O
patients	O
with	O
a	O
smoking	O
history	O
who	O
had	O
developed	O
characteristics	O
of	O
Buerger	O
disease	O
before	O
the	O
age	O
of	O
50	O
years	O
were	O
included	O
in	O
this	O
study	O
.	O

Occluded	O
arteries	O
,	O
including	O
superficial	O
femoral	O
(	O
n	O
=	O
4	O
)	O
,	O
popliteal	O
(	O
n	O
=	O
2	O
)	O
,	O
anterior	O
tibial	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
posterior	O
tibial	O
(	O
n	O
=	O
4	O
)	O
arteries	O
,	O
were	O
removed	O
and	O
studied	O
.	O

A	O
periodontist	O
performed	O
a	O
periodontal	O
examination	O
on	O
each	O
patient	O
and	O
collected	O
dental	O
plaque	O
and	O
saliva	O
samples	O
from	O
them	O
at	O
the	O
same	O
time	O
.	O

The	O
polymerase	O
chain	O
reaction	O
method	O
was	O
applied	O
to	O
detect	O
whether	O
seven	O
species	O
of	O
periodontal	O
bacteria	O
-	O
-	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
,	O
Campylobacter	B-bacteria
rectus	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
and	O
Prevotella	B-bacteria
nigrescens	I-bacteria
-	O
-	O
were	O
present	O
in	O
the	O
occluded	O
arteries	O
and	O
oral	O
samples	O
.	O

In	O
addition	O
,	O
arterial	O
specimens	O
from	O
seven	O
control	O
patients	O
were	O
examined	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

DNA	O
of	O
oral	O
bacteria	O
was	O
detected	O
in	O
13	O
of	O
14	O
arterial	O
samples	O
and	O
all	O
oral	O
samples	O
of	O
patients	O
with	O
Buerger	O
disease	O
.	O

Treponema	B-bacteria
denticola	I-bacteria
was	O
found	O
in	O
12	O
arterial	O
and	O
all	O
oral	O
samples	O
.	O

Campylobacter	B-bacteria
rectus	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
,	O
and	O
Prevotella	B-bacteria
nigrescens	I-bacteria
were	O
found	O
in	O
14	O
%	O
to	O
43	O
%	O
of	O
the	O
arterial	O
samples	O
and	O
71	O
%	O
to	O
100	O
%	O
of	O
the	O
oral	O
samples	O
.	O

A	O
pathologic	O
examination	O
revealed	O
that	O
arterial	O
specimens	O
showed	O
the	O
characteristics	O
of	O
an	O
intermediate	O
-	O
chronic	O
-	O
stage	O
or	O
chronic	O
-	O
stage	O
lesion	O
of	O
Buerger	O
disease	O
.	O

All	O
14	O
patients	O
with	O
Buerger	O
disease	O
had	O
moderate	O
to	O
severe	O
periodontitis	O
.	O

None	O
of	O
the	O
control	O
arterial	O
samples	O
was	O
positive	O
for	O
periodontal	O
bacteria	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
identify	O
oral	O
microorganisms	O
in	O
the	O
lesions	O
of	O
Buerger	O
disease	O
.	O

Our	O
findings	O
suggest	O
a	O
possible	O
etiologic	O
link	O
between	O
Buerger	O
disease	O
and	O
chronic	O
infections	O
such	O
as	O
oral	O
bacterial	O
infections	O
.	O

Eleven	O
strains	O
of	O
anaerobic	O
Gram	O
-	O
negative	O
bacilli	O
isolated	O
from	O
the	O
human	O
oral	O
cavity	O
were	O
subjected	O
to	O
a	O
comprehensive	O
range	O
of	O
phenotypic	O
and	O
genotypic	O
tests	O
and	O
were	O
found	O
to	O
comprise	O
two	O
homogeneous	O
groups	O
,	O
designated	O
E2	O
and	O
E4	O
.	O

16S	O
rRNA	O
gene	O
sequence	O
analysis	O
revealed	O
that	O
members	O
of	O
both	O
groups	O
belonged	O
to	O
the	O
genus	O
Prevotella	B-bacteria
but	O
were	O
distinct	O
from	O
any	O
species	O
with	O
validly	O
published	O
names	O
.	O

This	O
distinction	O
was	O
confirmed	O
by	O
DNA	O
-	O
DNA	O
hybridization	O
and	O
phenotypic	O
tests	O
.	O

Two	O
novel	O
species	O
are	O
therefore	O
proposed	O
:	O
Prevotella	B-bacteria
marshii	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
(	O
group	O
E2	O
)	O
and	O
Prevotella	B-bacteria
baroniae	I-bacteria
(	O
group	O
E4	O
)	O
.	O

Both	O
species	O
are	O
saccharolytic	O
;	O
the	O
end	O
-	O
products	O
of	O
fermentation	O
for	O
P	O
.	O
marshii	O
are	O
acetic	O
,	O
propionic	O
and	O
succinic	O
acids	O
,	O
while	O
P	B-bacteria
.	I-bacteria
baroniae	I-bacteria
produces	O
acetic	O
and	O
succinic	O
acids	O
with	O
minor	O
amounts	O
of	O
isovaleric	O
and	O
isobutyric	O
acids	O
.	O

The	O
G	O
+	O
C	O
content	O
of	O
the	O
DNA	O
of	O
the	O
type	O
strain	O
of	O
Prevotella	B-bacteria
marshii	I-bacteria
is	O
51	O
mol	O
%	O
and	O
that	O
of	O
Prevotella	B-bacteria
baroniae	I-bacteria
is	O
52	O
mol	O
%	O
.	O

The	O
type	O
strain	O
for	O
P	B-bacteria
.	I-bacteria
marshii	I-bacteria
is	O
E9	B-bacteria
.	I-bacteria
34	I-bacteria
(	O
T	O
)	O
(	O
=	O
DSM	B-bacteria
16973	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
50419	I-bacteria
(	O
T	O
)	O
)	O
and	O
that	O
for	O
P	B-bacteria
.	I-bacteria
baroniae	I-bacteria
is	O
E9	B-bacteria
.	I-bacteria
33	I-bacteria
(	O
T	O
)	O
(	O
=	O
DSM	B-bacteria
16972	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
50418	I-bacteria
(	O
T	O
)	O
)	O
.	O

Timely	O
initiation	O
of	O
antibiotic	O
therapy	O
is	O
crucial	O
for	O
severe	O
infection	O
.	O

Appropriate	O
antibiotic	O
therapy	O
is	O
often	O
delayed	O
for	O
nosocomial	O
infections	O
caused	O
by	O
antibiotic	O
-	O
resistant	O
bacteria	O
.	O

The	O
relationship	O
between	O
knowledge	O
of	O
colonization	O
caused	O
by	O
antibiotic	O
-	O
resistant	O
gram	O
-	O
negative	O
bacteria	O
(	O
ABR	O
-	O
GNB	O
)	O
and	O
rate	O
of	O
appropriate	O
initial	O
antibiotic	O
therapy	O
for	O
subsequent	O
bacteremia	O
was	O
evaluated	O
.	O

Retrospective	O
cohort	O
study	O
.	O

Fifty	O
-	O
four	O
-	O
bed	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
of	O
a	O
university	O
hospital	O
.	O

In	O
this	O
unit	O
,	O
colonization	O
surveillance	O
is	O
performed	O
through	O
routine	O
site	O
-	O
specific	O
surveillance	O
cultures	O
(	O
urine	O
,	O
mouth	O
,	O
trachea	O
,	O
and	O
anus	O
)	O
.	O

Additional	O
cultures	O
are	O
performed	O
when	O
presumed	O
clinically	O
relevant	O
.	O

ICU	O
patients	O
with	O
nosocomial	O
bacteremia	O
caused	O
by	O
ABR	O
-	O
GNB	O
.	O

Infectious	O
and	O
microbiological	O
characteristics	O
and	O
rates	O
of	O
appropriate	O
antibiotic	O
therapy	O
were	O
compared	O
between	O
patients	O
with	O
and	O
without	O
colonization	O
prior	O
to	O
bacteremia	O
.	O

Prior	O
colonization	O
was	O
defined	O
as	O
the	O
presence	O
(	O
detected	O
>	O
or	O
=	O
2	O
days	O
before	O
the	O
onset	O
of	O
bacteremia	O
)	O
of	O
the	O
same	O
ABR	O
-	O
GNB	O
in	O
colonization	O
and	O
subsequent	O
blood	O
cultures	O
.	O

During	O
the	O
study	O
period	O
,	O
157	O
episodes	O
of	O
bacteremia	O
caused	O
by	O
ABR	O
-	O
GNB	O
were	O
suitable	O
for	O
evaluation	O
.	O

One	O
hundred	O
seventeen	O
episodes	O
of	O
bacteremia	O
(	O
74	O
.	O
5	O
%	O
)	O
were	O
preceded	O
by	O
colonization	O
.	O

Appropriate	O
empiric	O
antibiotic	O
therapy	O
(	O
started	O
within	O
24	O
hours	O
)	O
was	O
administered	O
for	O
74	O
.	O
4	O
%	O
of	O
these	O
episodes	O
versus	O
55	O
.	O
0	O
%	O
of	O
the	O
episodes	O
that	O
occurred	O
without	O
prior	O
colonization	O
.	O

Appropriate	O
therapy	O
was	O
administered	O
within	O
48	O
hours	O
for	O
all	O
episodes	O
preceded	O
by	O
colonization	O
versus	O
90	O
.	O
0	O
%	O
of	O
episodes	O
without	O
prior	O
colonization	O
.	O

Knowledge	O
of	O
colonization	O
status	O
prior	O
to	O
infection	O
is	O
associated	O
with	O
higher	O
rates	O
of	O
appropriate	O
therapy	O
for	O
patients	O
with	O
bacteremia	O
caused	O
by	O
ABR	O
-	O
GNB	O
.	O

To	O
investigate	O
the	O
maintenance	O
of	O
tetracycline	O
-	O
resistant	O
oral	O
bacteria	O
and	O
the	O
genes	O
encoding	O
tetracycline	O
resistance	O
in	O
these	O
bacteria	O
in	O
children	O
(	O
aged	O
4	O
-	O
-	O
6	O
years	O
)	O
over	O
a	O
period	O
of	O
12	O
months	O
.	O

Plaque	O
and	O
saliva	O
samples	O
were	O
taken	O
from	O
26	O
children	O
.	O

Tetracycline	O
-	O
resistant	O
bacteria	O
were	O
isolated	O
and	O
identified	O
.	O

The	O
types	O
of	O
resistance	O
genes	O
and	O
their	O
genetic	O
locations	O
were	O
also	O
determined	O
.	O

Fifteen	O
out	O
of	O
18	O
children	O
harboured	O
tetracycline	O
-	O
resistant	O
(	O
defined	O
as	O
having	O
a	O
MIC	O
>	O
or	O
=	O
8	O
mg	O
/	O
L	O
)	O
oral	O
bacteria	O
at	O
all	O
three	O
time	O
points	O
.	O

The	O
median	O
percentage	O
of	O
tetracycline	O
-	O
resistant	O
bacteria	O
at	O
0	O
,	O
6	O
and	O
12	O
months	O
was	O
1	O
.	O
37	O
,	O
1	O
.	O
37	O
and	O
0	O
.	O
85	O
%	O
,	O
respectively	O
;	O
these	O
were	O
not	O
significantly	O
different	O
.	O

The	O
MIC	O
(	O
50	O
)	O
of	O
the	O
group	O
was	O
64	O
mg	O
/	O
L	O
at	O
all	O
three	O
time	O
points	O
compared	O
with	O
the	O
MIC	O
(	O
90	O
)	O
,	O
which	O
was	O
64	O
mg	O
/	O
L	O
at	O
0	O
months	O
,	O
and	O
128	O
mg	O
/	O
L	O
at	O
6	O
and	O
12	O
months	O
.	O

The	O
most	O
prevalent	O
resistant	O
species	O
were	O
streptococci	B-bacteria
(	O
68	O
%	O
)	O
,	O
which	O
were	O
isolated	O
at	O
all	O
three	O
time	O
points	O
in	O
13	O
children	O
.	O

The	O
most	O
prevalent	O
gene	O
encoding	O
tetracycline	O
resistance	O
was	O
tet	O
(	O
M	O
)	O
and	O
this	O
was	O
found	O
in	O
different	O
species	O
at	O
all	O
three	O
time	O
points	O
.	O

For	O
the	O
first	O
time	O
,	O
tet	O
(	O
32	O
)	O
was	O
found	O
in	O
Streptococcus	B-bacteria
parasanguinis	I-bacteria
and	O
Eubacterium	B-bacteria
saburreum	I-bacteria
.	O

PCR	O
and	O
Southern	O
-	O
blot	O
analysis	O
(	O
on	O
isolates	O
from	O
three	O
of	O
the	O
children	O
)	O
showed	O
that	O
the	O
tet	O
(	O
M	O
)	O
gene	O
was	O
located	O
on	O
a	O
Tn916	O
-	O
like	O
element	O
and	O
could	O
be	O
detected	O
at	O
all	O
three	O
time	O
points	O
,	O
in	O
four	O
different	O
genera	O
,	O
Streptococcus	B-bacteria
,	O
Granulicatella	B-bacteria
,	O
Veillonella	B-bacteria
and	O
Neisseria	B-bacteria
.	O

The	O
results	O
of	O
this	O
study	O
show	O
that	O
tetracycline	O
-	O
resistant	O
bacteria	O
and	O
tet	O
(	O
M	O
)	O
are	O
maintained	O
within	O
the	O
indigenous	O
oral	O
microbiota	O
of	O
children	O
,	O
even	O
though	O
they	O
are	O
unlikely	O
to	O
have	O
been	O
directly	O
exposed	O
to	O
tetracycline	O
.	O

The	O
presence	O
and	O
maturity	O
of	O
the	O
salivary	O
pellicle	O
influences	O
microbial	O
adhesion	O
and	O
its	O
tenacity	O
in	O
the	O
oral	O
cavity	O
,	O
posing	O
a	O
challenge	O
to	O
different	O
plaque	O
-	O
control	O
systems	O
.	O

Some	O
plaque	O
-	O
control	O
systems	O
rely	O
on	O
surface	O
-	O
tension	O
forces	O
arising	O
from	O
passing	O
microbubbles	O
sprayed	O
over	O
the	O
pellicle	O
.	O

Passage	O
of	O
such	O
bubbles	O
is	O
accompanied	O
by	O
a	O
high	O
fluid	O
flow	O
,	O
but	O
systematic	O
studies	O
are	O
lacking	O
on	O
the	O
contribution	O
of	O
fluid	O
flow	O
vs	O
.	O
microbubbles	O
towards	O
plaque	O
removal	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
detachment	O
efficacy	O
of	O
laminar	O
fluid	O
flow	O
(	O
wall	O
shear	O
rates	O
11	O
,	O
000	O
-	O
16	O
,	O
000	O
s	O
(	O
-	O
1	O
)	O
)	O
,	O
with	O
and	O
without	O
microbubbles	O
,	O
towards	O
the	O
detachment	O
of	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
T14V	I-bacteria
-	I-bacteria
J1	I-bacteria
and	O
Streptococcus	B-bacteria
oralis	I-bacteria
J22	I-bacteria
,	O
and	O
their	O
coadhering	O
aggregates	O
,	O
from	O
salivary	O
pellicles	O
formed	O
over	O
2	O
h	O
or	O
16	O
h	O
from	O
reconstituted	O
human	O
whole	O
saliva	O
.	O

Microbubbles	O
in	O
a	O
fluid	O
flow	O
were	O
more	O
efficient	O
at	O
inducing	O
single	O
bacterial	O
detachment	O
,	O
resulting	O
in	O
almost	O
complete	O
(	O
97	O
%	O
)	O
removal	O
for	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
J22	I-bacteria
and	O
a	O
15	O
-	O
fold	O
increase	O
in	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
T14V	I-bacteria
-	I-bacteria
J1	I-bacteria
removal	O
as	O
compared	O
to	O
the	O
detachment	O
caused	O
by	O
fluid	O
flow	O
alone	O
.	O

A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
was	O
more	O
difficult	O
to	O
remove	O
and	O
apparently	O
formed	O
the	O
strongest	O
bonds	O
with	O
high	O
-	O
molecular	O
-	O
weight	O
proteins	O
in	O
16	O
-	O
h	O
pellicles	O
.	O

The	O
detachment	O
of	O
coaggregates	O
after	O
2	O
min	O
left	O
a	O
substantial	O
amount	O
of	O
adhered	O
bacterial	O
mass	O
,	O
including	O
more	O
than	O
60	O
%	O
of	O
singly	O
attached	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
on	O
the	O
pellicle	O
surface	O
,	O
providing	O
nucleation	O
sites	O
for	O
the	O
de	O
novo	O
adhesion	O
of	O
coadhering	O
streptococci	B-bacteria
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
identify	O
hydrogen	O
sulfide	O
(	O
H2S	O
)	O
-	O
producing	O
bacteria	O
among	O
tongue	O
biofilm	O
microflora	O
and	O
to	O
investigate	O
the	O
relationship	O
between	O
bacterial	O
flora	O
and	O
H2S	O
levels	O
in	O
mouth	O
air	O
.	O

Oral	O
malodour	O
levels	O
in	O
10	O
subjects	O
(	O
age	O
21	O
-	O
56	O
years	O
)	O
were	O
assessed	O
by	O
gas	O
chromatography	O
,	O
and	O
Breathtron	O
and	O
organoleptic	O
scores	O
.	O

Based	O
on	O
these	O
assessments	O
,	O
subjects	O
were	O
divided	O
into	O
two	O
groups	O
:	O
an	O
odour	O
group	O
and	O
a	O
no	O
/	O
low	O
odour	O
group	O
.	O

Tongue	O
coatings	O
were	O
sampled	O
and	O
spread	O
onto	O
Fastidious	O
Anaerobe	O
Agar	O
plates	O
containing	O
0	O
.	O
05	O
%	O
cysteine	O
,	O
0	O
.	O
12	O
%	O
glutathione	O
and	O
0	O
.	O
02	O
%	O
lead	O
acetate	O
,	O
and	O
were	O
then	O
incubated	O
anaerobically	O
at	O
37	O
degrees	O
C	O
for	O
2	O
weeks	O
.	O

Bacteria	O
forming	O
black	O
or	O
grey	O
colonies	O
were	O
selected	O
as	O
H2S	O
-	O
producing	O
phenotypes	O
.	O

The	O
numbers	O
of	O
total	O
bacteria	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
H2S	O
-	O
producing	O
bacteria	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
odour	O
group	O
were	O
significantly	O
larger	O
than	O
those	O
in	O
the	O
no	O
/	O
low	O
odour	O
group	O
.	O

Bacteria	O
forming	O
black	O
or	O
grey	O
colonies	O
(	O
126	O
isolates	O
from	O
the	O
odour	O
group	O
;	O
242	O
isolates	O
from	O
the	O
no	O
/	O
low	O
odour	O
group	O
)	O
were	O
subcultured	O
,	O
confirmed	O
as	O
producing	O
H2S	O
and	O
identified	O
according	O
to	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

Species	O
of	O
Veillonella	B-bacteria
(	O
38	O
.	O
1	O
%	O
in	O
odour	O
group	O
;	O
46	O
.	O
3	O
%	O
in	O
no	O
/	O
low	O
odour	O
group	O
)	O
,	O
Actinomyces	B-bacteria
(	O
25	O
.	O
4	O
%	O
;	O
17	O
.	O
7	O
%	O
)	O
and	O
Prevotella	B-bacteria
(	O
10	O
.	O
3	O
%	O
;	O
7	O
.	O
8	O
%	O
)	O
were	O
the	O
predominant	O
H2S	O
-	O
producing	O
bacteria	O
in	O
both	O
the	O
odour	O
and	O
no	O
/	O
low	O
odour	O
groups	O
.	O

These	O
results	O
suggest	O
that	O
an	O
increase	O
in	O
the	O
number	O
of	O
H2S	O
-	O
producing	O
bacteria	O
in	O
the	O
tongue	O
biofilm	O
is	O
responsible	O
for	O
oral	O
malodour	O
,	O
although	O
the	O
bacterial	O
composition	O
of	O
tongue	O
biofilm	O
was	O
similar	O
between	O
the	O
two	O
groups	O
.	O

Thorough	O
examination	O
of	O
114	O
young	O
men	O
of	O
pre	O
-	O
constriction	O
military	O
training	O
age	O
disclosed	O
that	O
possibility	O
of	O
oral	O
cavity	O
pathology	O
development	O
is	O
mainly	O
determined	O
by	O
the	O
indices	O
DMFT	O
,	O
PMA	O
,	O
OHI	O
-	O
S	O
and	O
the	O
following	O
parameters	O
of	O
mixed	O
saliva	O
-	O
-	O
basic	O
salivary	O
flow	O
,	O
pH	O
and	O
Lactobacillus	B-bacteria
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
amounts	O
.	O

The	O
degree	O
of	O
these	O
factors	O
changes	O
expressed	O
in	O
scores	O
identifies	O
groups	O
of	O
low	O
,	O
medium	O
and	O
high	O
probability	O
of	O
stomatologic	O
pathology	O
development	O
and	O
basing	O
on	O
this	O
to	O
individualize	O
curative	O
and	O
preventive	O
measures	O
.	O

The	O
accumulation	O
of	O
microorganisms	O
in	O
dental	O
plaque	O
is	O
related	O
to	O
the	O
etiology	O
of	O
caries	O
and	O
periodontal	O
disease	O
,	O
with	O
a	O
high	O
prevalence	O
worldwide	O
.	O

The	O
prophylactic	O
measures	O
include	O
the	O
use	O
of	O
chemical	O
agents	O
as	O
NaF	O
and	O
chlorhexidine	O
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
are	O
members	O
of	O
the	O
normal	O
microbiota	O
of	O
the	O
oral	O
cavity	O
being	O
discussed	O
with	O
regard	O
to	O
their	O
beneficial	O
or	O
detrimental	O
effect	O
in	O
this	O
environment	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
determine	O
the	O
growth	O
of	O
some	O
species	O
of	O
Lactobacillus	B-bacteria
at	O
different	O
concentrations	O
of	O
NaF	O
and	O
chlorhexidine	O
.	O

The	O
strains	O
were	O
isolated	O
from	O
both	O
caries	O
-	O
free	O
and	O
caries	O
patients	O
.	O

Their	O
growth	O
parameters	O
were	O
evaluated	O
by	O
the	O
application	O
of	O
the	O
Gompertz	O
model	O
to	O
the	O
experimental	O
data	O
of	O
optical	O
density	O
as	O
a	O
measurement	O
of	O
growth	O
.	O

The	O
degree	O
of	O
inhibition	O
of	O
the	O
growth	O
of	O
all	O
of	O
the	O
lactobacilli	B-bacteria
studied	O
was	O
different	O
,	O
depending	O
on	O
each	O
particular	O
strain	O
.	O

NaF	O
at	O
1	O
mmol	O
x	O
L	O
(	O
-	O
1	O
)	O
inhibited	O
between	O
5	O
%	O
and	O
46	O
%	O
,	O
at	O
5	O
mmol	O
x	O
L	O
(	O
-	O
1	O
)	O
between	O
13	O
%	O
and	O
65	O
%	O
,	O
and	O
at	O
20	O
mmol	O
x	O
L	O
(	O
-	O
1	O
)	O
between	O
57	O
%	O
and	O
84	O
%	O
.	O

CHX	O
at	O
higher	O
concentrations	O
(	O
197	O
and	O
98	O
mmol	O
x	O
L	O
(	O
-	O
1	O
)	O
showed	O
a	O
complete	O
inhibition	O
of	O
some	O
of	O
the	O
strains	O
.	O

The	O
significance	O
of	O
the	O
results	O
was	O
evaluated	O
by	O
the	O
application	O
of	O
a	O
multivariate	O
analysis	O
and	O
also	O
compared	O
with	O
the	O
inhibition	O
of	O
pathogenic	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
with	O
lactobacilli	B-bacteria
strains	I-bacteria
from	O
collection	O
cultures	O
.	O

The	O
presence	O
of	O
selected	O
bacteria	O
(	O
Enterococcus	B-bacteria
faecalis	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
)	O
in	O
infected	O
root	O
canals	O
was	O
studied	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assays	O
,	O
and	O
the	O
association	O
of	O
bacteria	O
with	O
clinical	O
signs	O
of	O
endodontic	O
disease	O
was	O
assessed	O
.	O

The	O
null	O
hypothesis	O
,	O
that	O
no	O
difference	O
could	O
be	O
observed	O
between	O
clinical	O
signs	O
of	O
apical	O
periodontitis	O
and	O
a	O
specific	O
bacterial	O
strain	O
,	O
was	O
tested	O
.	O

Microbial	O
samples	O
were	O
obtained	O
from	O
62	O
teeth	O
in	O
54	O
patients	O
with	O
endodontic	O
disease	O
.	O

For	O
each	O
tooth	O
,	O
clinical	O
data	O
including	O
patient	O
symptoms	O
were	O
collected	O
.	O

Teeth	O
were	O
categorized	O
by	O
diagnosis	O
as	O
having	O
acute	O
apical	O
periodontitis	O
(	O
AAP	O
,	O
teeth	O
with	O
clinical	O
symptoms	O
but	O
no	O
periapical	O
radiolucency	O
,	O
n	O
=	O
22	O
)	O
,	O
chronic	O
apical	O
periodontitis	O
(	O
CAP	O
,	O
teeth	O
with	O
radiolucency	O
but	O
no	O
clinical	O
symptoms	O
,	O
n	O
=	O
15	O
)	O
or	O
exacerbated	O
apical	O
periodontitis	O
(	O
EAP	O
,	O
teeth	O
with	O
symptoms	O
and	O
radiolucency	O
,	O
n	O
=	O
25	O
)	O
.	O

Seventy	O
-	O
one	O
percent	O
of	O
cases	O
were	O
primary	O
endodontic	O
infections	O
,	O
and	O
29	O
%	O
were	O
recurrent	O
(	O
'	O
secondary	O
'	O
)	O
endodontic	O
infections	O
(	O
failing	O
cases	O
)	O
.	O

PCR	O
assays	O
were	O
used	O
to	O
detect	O
the	O
presence	O
of	O
the	O
selected	O
bacteria	O
.	O

T	B-bacteria
.	I-bacteria
denticola	I-bacteria
and	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
were	O
each	O
detected	O
in	O
15	O
of	O
62	O
samples	O
(	O
24	O
%	O
)	O
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
in	O
8	O
samples	O
(	O
13	O
%	O
)	O
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
in	O
5	O
samples	O
(	O
8	O
%	O
)	O
,	O
and	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
in	O
4	O
samples	O
(	O
7	O
%	O
)	O
.	O

T	B-bacteria
.	I-bacteria
denticola	I-bacteria
was	O
detected	O
in	O
56	O
%	O
of	O
teeth	O
with	O
EAP	O
.	O

E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
was	O
found	O
in	O
60	O
%	O
of	O
teeth	O
with	O
CAP	O
and	O
in	O
72	O
%	O
of	O
teeth	O
with	O
secondary	O
infection	O
.	O

Statistical	O
analysis	O
demonstrated	O
an	O
association	O
of	O
CAP	O
and	O
secondary	O
endodontic	O
infection	O
with	O
the	O
presence	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
.	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

EAP	O
was	O
associated	O
with	O
the	O
presence	O
of	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

T	B-bacteria
.	I-bacteria
denticola	I-bacteria
was	O
associated	O
with	O
symptomatic	O
endodontic	O
disease	O
in	O
the	O
presence	O
of	O
apical	O
bone	O
resorption	O
.	O

E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
was	O
associated	O
with	O
treatment	O
failures	O
.	O

We	O
suggest	O
that	O
these	O
species	O
may	O
play	O
critical	O
roles	O
in	O
endodontic	O
pathology	O
.	O

Until	O
today	O
,	O
human	O
stomach	O
is	O
the	O
only	O
recognized	O
habitat	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
.	O

However	O
,	O
recruitment	O
of	O
DNA	O
-	O
based	O
methods	O
has	O
made	O
possible	O
the	O
detection	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
water	O
and	O
oral	O
cavity	O
,	O
thus	O
suggesting	O
fecal	O
-	O
oral	O
and	O
oral	O
-	O
oral	O
routes	O
for	O
transmission	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
,	O
respectively	O
.	O

In	O
this	O
study	O
,	O
yeast	O
has	O
been	O
proposed	O
as	O
a	O
common	O
vector	O
for	O
transmission	O
of	O
H	B-bacteria
pylori	I-bacteria
.	O

Thus	O
designed	O
primers	O
were	O
recruited	O
to	O
target	O
16S	O
rDNA	O
and	O
cagA	O
genes	O
in	O
the	O
oral	O
yeasts	O
by	O
PCR	O
.	O

MATERIALS	O
AND	O
Eighteen	O
yeasts	O
were	O
examined	O
microscopically	O
for	O
the	O
presence	O
of	O
bacterial	O
-	O
like	O
bodies	O
.	O

DNAs	O
were	O
extracted	O
from	O
oral	O
yeasts	O
using	O
phenol	O
-	O
chloroform	O
method	O
.	O

Amplification	O
conditions	O
were	O
optimized	O
as	O
33	O
cycles	O
and	O
annealing	O
temperatures	O
of	O
63	O
degrees	O
C	O
for	O
16S	O
rDNA	O
and	O
51	O
degrees	O
C	O
and	O
52	O
degrees	O
C	O
for	O
cagA	O
gene	O
which	O
was	O
targeted	O
in	O
two	O
steps	O
.	O

DNAs	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
and	O
Saccharomyces	O
cerevisiae	O
were	O
used	O
as	O
controls	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
of	O
two	O
genes	O
from	O
one	O
yeast	O
and	O
from	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
were	O
cloned	O
in	O
pCAP	O
and	O
subsequently	O
subcloned	O
in	O
pSK	O
+	O
and	O
were	O
sequenced	O
.	O

Bacterial	O
-	O
like	O
bodies	O
were	O
observed	O
in	O
all	O
oral	O
yeasts	O
.	O

The	O
amplified	O
products	O
of	O
16S	O
rDNA	O
from	O
all	O
oral	O
yeasts	O
were	O
homologous	O
in	O
size	O
with	O
those	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

Fifteen	O
out	O
of	O
eighteen	O
(	O
83	O
%	O
)	O
yeasts	O
contained	O
cagA	O
gene	O
,	O
homologous	O
to	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

CagA	O
was	O
not	O
amplified	O
from	O
three	O
yeasts	O
and	O
S	B-bacteria
.	I-bacteria
cerevisiae	I-bacteria
.	O

Analysis	O
of	O
the	O
sequenced	O
products	O
of	O
16S	O
rDNA	O
and	O
cagA	O
from	O
one	O
oral	O
yeast	O
showed	O
98	O
%	O
homology	O
with	O
those	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

The	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
inside	O
the	O
yeast	O
was	O
indicated	O
by	O
light	O
microscopy	O
and	O
PCR	O
.	O

It	O
appears	O
that	O
yeasts	O
,	O
which	O
are	O
abundant	O
in	O
nature	O
and	O
thrive	O
the	O
mucosal	O
surfaces	O
of	O
human	O
,	O
might	O
serve	O
as	O
reservoirs	O
and	O
vehicles	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

The	O
functions	O
of	O
epithelial	O
cells	O
are	O
more	O
than	O
a	O
physical	O
selective	O
barrier	O
for	O
protection	O
from	O
mucosal	O
pathogens	O
.	O

The	O
epithelial	O
response	O
regulated	O
by	O
host	O
-	O
microorganism	O
interaction	O
may	O
change	O
due	O
to	O
histological	O
and	O
physiological	O
differences	O
between	O
sterile	O
and	O
nonsterile	O
sites	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
presence	O
of	O
a	O
difference	O
between	O
bactericidal	O
capacities	O
of	O
urinary	O
and	O
oral	O
epithelial	O
cells	O
against	O
different	O
strains	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

Oral	O
epithelial	O
cells	O
were	O
collected	O
from	O
unstimulated	O
saliva	O
and	O
uroepithelial	O
cells	O
were	O
collected	O
from	O
urine	O
of	O
eight	O
healthy	O
volunteers	O
.	O

E	B-bacteria
.	I-bacteria
coli	I-bacteria
K12	I-bacteria
and	I-bacteria
O75	I-bacteria
strains	I-bacteria
and	O
epithelial	O
cells	O
were	O
prepared	O
for	O
the	O
experiment	O
,	O
added	O
to	O
microplates	O
and	O
incubated	O
for	O
one	O
hour	O
.	O

The	O
growth	O
of	O
bacteria	O
was	O
detected	O
by	O
the	O
quantitative	O
colony	O
counting	O
method	O
.	O

Antibacterial	O
effects	O
of	O
the	O
oral	O
and	O
urinary	O
epithelial	O
cells	O
against	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
K12	I-bacteria
and	I-bacteria
O75	I-bacteria
strains	I-bacteria
were	O
49	O
.	O
8	O
%	O
,	O
34	O
.	O
7	O
%	O
,	O
45	O
.	O
7	O
%	O
and	O
29	O
.	O
2	O
%	O
,	O
respectively	O
.	O

As	O
a	O
result	O
,	O
it	O
was	O
detected	O
that	O
the	O
antibacterial	O
activity	O
of	O
oral	O
epithelial	O
cells	O
to	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
K12	I-bacteria
and	I-bacteria
O75	I-bacteria
were	O
higher	O
than	O
urinary	O
epithelial	O
cells	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
the	O
number	O
of	O
polymorphonuclear	O
leukocytes	O
(	O
PMNL	O
)	O
and	O
the	O
number	O
of	O
selected	O
bacteria	O
in	O
human	O
oral	O
cavity	O
.	O

Sixty	O
one	O
healthy	O
people	O
(	O
periodontal	O
index	O
of	O
Russel	O
'	O
s	O
did	O
not	O
exceed	O
0	O
.	O
2	O
)	O
,	O
aged	O
22	O
-	O
26	O
were	O
investigated	O
.	O

PMNL	O
were	O
isolated	O
by	O
rinsing	O
oral	O
cavity	O
with	O
isotonic	O
,	O
buffered	O
NaCl	O
solution	O
.	O

Nonstimulated	O
whole	O
saliva	O
was	O
bacteriologically	O
examined	O
.	O

The	O
number	O
of	O
PMNL	O
,	O
which	O
was	O
obtained	O
from	O
mouth	O
of	O
examined	O
people	O
was	O
between	O
100	O
,	O
000	O
and	O
4	O
,	O
200	O
,	O
000	O
in	O
100	O
mL	O
of	O
rinsings	O
.	O

Usually	O
,	O
i	O
.	O
e	O
.	O
in	O
34	O
%	O
of	O
cases	O
,	O
the	O
number	O
was	O
between	O
500	O
,	O
000	O
-	O
1	O
,	O
000	O
,	O
000	O
.	O

Streptococci	B-bacteria
were	O
isolated	O
from	O
all	O
tested	O
people	O
and	O
their	O
number	O
was	O
the	O
biggest	O
.	O

Almost	O
in	O
all	O
cases	O
there	O
were	O
isolated	O
cariogenic	O
bacteria	O
-	O
-	O
Streptococcus	B-bacteria
mutans	I-bacteria
(	O
95	O
%	O
)	O
and	O
lactobacilli	B-bacteria
(	O
93	O
%	O
)	O
.	O

Haemophili	B-bacteria
,	O
staphylococci	B-bacteria
,	O
including	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
were	O
found	O
relatively	O
often	O
(	O
in	O
86	O
%	O
,	O
86	O
%	O
and	O
52	O
%	O
respectively	O
)	O
.	O

Gram	O
-	O
negative	O
enteric	O
rods	O
were	O
rarely	O
isolated	O
(	O
33	O
%	O
)	O
and	O
were	O
the	O
least	O
numerous	O
group	O
of	O
all	O
.	O

It	O
has	O
been	O
stated	O
,	O
that	O
there	O
is	O
a	O
comparatively	O
strong	O
negative	O
correlation	O
between	O
the	O
number	O
of	O
PMNL	O
in	O
oral	O
cavity	O
and	O
the	O
number	O
of	O
streptococci	B-bacteria
(	O
r	O
=	O
-	O
0	O
.	O
55	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
haemophili	B-bacteria
(	O
r	O
=	O
-	O
0	O
.	O
564	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
staphylococci	B-bacteria
(	O
r	O
=	O
-	O
0	O
.	O
538	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
lactobacilli	B-bacteria
(	O
r	O
=	O
-	O
0	O
.	O
407	O
;	O
p	O
=	O
0	O
.	O
0017	O
)	O
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
(	O
r	O
=	O
-	O
0	O
.	O
483	O
;	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

The	O
results	O
suggest	O
that	O
PMNL	O
are	O
one	O
of	O
the	O
factors	O
controlling	O
the	O
number	O
of	O
some	O
bacteria	O
in	O
human	O
oral	O
cavity	O
.	O

To	O
examine	O
the	O
isolation	O
frequency	O
and	O
the	O
carriage	O
of	O
yeasts	O
,	O
Enterobacteriaceae	B-bacteria
,	O
Staphylococcus	B-bacteria
and	O
Enterococcus	B-bacteria
species	I-bacteria
in	O
oral	O
samples	O
from	O
elderly	O
Greeks	O
living	O
alone	O
or	O
in	O
institutions	O
.	O

Ageing	O
may	O
promote	O
changes	O
in	O
the	O
oral	O
ecosystem	O
,	O
which	O
lead	O
to	O
colonisation	O
of	O
the	O
mouth	O
by	O
microbes	O
found	O
less	O
commonly	O
or	O
only	O
transiently	O
in	O
younger	O
subjects	O
.	O

Previous	O
studies	O
indicate	O
a	O
geographical	O
variation	O
in	O
the	O
isolation	O
frequency	O
of	O
such	O
bacteria	O
in	O
elderly	O
populations	O
.	O

Medical	O
and	O
dental	O
records	O
were	O
obtained	O
from	O
66	O
attenders	O
at	O
elderly	O
people	O
'	O
s	O
day	O
centres	O
(	O
EPDC	O
)	O
,	O
and	O
82	O
residents	O
of	O
elderly	O
people	O
'	O
s	O
homes	O
(	O
EPH	O
)	O
,	O
66	O
-	O
95	O
years	O
old	O
.	O

Mucosa	O
smear	O
samples	O
were	O
cultured	O
on	O
appropriate	O
media	O
for	O
enumeration	O
of	O
the	O
above	O
species	O
.	O

Microbial	O
identification	O
was	O
performed	O
by	O
conventional	O
microbiological	O
tests	O
.	O

The	O
results	O
were	O
analysed	O
using	O
the	O
Multiple	O
Correspondence	O
Analysis	O
(	O
MCA	O
)	O
,	O
ANOVA	O
and	O
other	O
traditional	O
statistical	O
tests	O
.	O

No	O
statistically	O
significant	O
association	O
was	O
found	O
between	O
the	O
place	O
of	O
residence	O
and	O
the	O
wearing	O
of	O
dentures	O
.	O

The	O
isolation	O
frequencies	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
Enterococcus	B-bacteria
and	O
Enterobacteriaceae	B-bacteria
species	I-bacteria
were	O
21	O
.	O
6	O
,	O
20	O
.	O
3	O
and	O
7	O
.	O
4	O
%	O
respectively	O
.	O

MCA	O
,	O
and	O
further	O
statistical	O
analysis	O
,	O
revealed	O
that	O
the	O
place	O
of	O
residence	O
affected	O
the	O
isolation	O
frequency	O
of	O
years	O
(	O
54	O
.	O
9	O
%	O
in	O
EPH	O
vs	O
.	O
37	O
.	O
9	O
%	O
in	O
EPDC	O
)	O
.	O

Moreover	O
,	O
ANOVA	O
showed	O
that	O
living	O
in	O
EPH	O
increased	O
the	O
carriage	O
of	O
yeasts	O
.	O

Elderly	O
Greeks	O
exhibit	O
a	O
moderate	O
to	O
high	O
oral	O
carriage	O
of	O
transient	O
bacteria	O
compared	O
with	O
other	O
elderly	O
populations	O
.	O

Living	O
in	O
EPH	O
seems	O
to	O
increase	O
both	O
the	O
isolation	O
frequency	O
and	O
carriage	O
of	O
yeasts	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
antimicrobial	O
effect	O
of	O
essential	O
oil	O
-	O
containing	O
oral	O
strips	O
on	O
different	O
species	O
of	O
the	O
oral	O
microbiota	O
.	O

Saliva	O
samples	O
were	O
collected	O
from	O
20	O
subjects	O
with	O
good	O
oral	O
health	O
,	O
diluted	O
and	O
plated	O
onto	O
blood	O
agar	O
medium	O
.	O

The	O
subjects	O
were	O
asked	O
to	O
place	O
the	O
strip	O
(	O
Listerine	O
PocketPaks	O
)	O
on	O
the	O
tongue	O
allowing	O
it	O
to	O
dissolve	O
.	O

After	O
30	O
minutes	O
,	O
new	O
saliva	O
samples	O
were	O
collected	O
again	O
and	O
the	O
plates	O
with	O
the	O
samples	O
were	O
incubated	O
under	O
anaerobic	O
conditions	O
at	O
37	O
degrees	O
C	O
for	O
seven	O
days	O
.	O

Colony	O
counts	O
(	O
CFU	O
/	O
mL	O
)	O
were	O
determined	O
for	O
each	O
sample	O
.	O

The	O
colonies	O
on	O
the	O
plates	O
were	O
washed	O
with	O
1	O
mL	O
of	O
TE	O
buffer	O
,	O
and	O
the	O
bacterial	O
suspensions	O
were	O
processed	O
for	O
the	O
identification	O
of	O
24	O
species	O
by	O
DNA	O
probes	O
and	O
the	O
Checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
method	O
.	O

Differences	O
in	O
total	O
counts	O
,	O
prevalence	O
,	O
and	O
levels	O
of	O
the	O
species	O
evaluated	O
before	O
and	O
after	O
placement	O
of	O
the	O
strips	O
were	O
determined	O
by	O
Wilcoxon	O
sign	O
rank	O
and	O
Chi	O
-	O
square	O
tests	O
.	O

A	O
modest	O
increase	O
in	O
the	O
total	O
bacterial	O
number	O
in	O
saliva	O
from	O
1	O
.	O
4	O
x	O
10	O
(	O
8	O
)	O
to	O
1	O
.	O
7	O
x	O
10	O
(	O
8	O
)	O
bacterial	O
cells	O
was	O
observed	O
30	O
minutes	O
after	O
the	O
strip	O
placement	O
,	O
although	O
this	O
change	O
was	O
not	O
significant	O
(	O
p	O
=	O
0	O
.	O
632	O
)	O
.	O

Most	O
of	O
the	O
species	O
reduced	O
in	O
frequency	O
and	O
/	O
or	O
levels	O
,	O
including	O
the	O
pathogens	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
,	O
E	B-bacteria
.	I-bacteria
corrodens	I-bacteria
,	O
Fusobacterium	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
and	O
S	B-bacteria
.	I-bacteria
noxia	I-bacteria
,	O
as	O
well	O
as	O
the	O
beneficial	O
species	O
A	B-bacteria
.	I-bacteria
meyeri	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
georgia	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
gerencseriae	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
odontolyticus	I-bacteria
,	O
and	O
P	B-bacteria
.	I-bacteria
acnes	I-bacteria
after	O
strip	O
placement	O
.	O

In	O
contrast	O
,	O
A	B-bacteria
.	I-bacteria
viscosus	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
melaninogenica	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
micros	I-bacteria
,	O
Streptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
,	O
and	O
V	B-bacteria
.	I-bacteria
parvula	I-bacteria
presented	O
an	O
increase	O
in	O
prevalence	O
and	O
/	O
or	O
levels	O
.	O

These	O
changes	O
were	O
not	O
statistically	O
significant	O
after	O
adjusting	O
for	O
multiple	O
comparisons	O
(	O
p	O
>	O
0	O
.	O
0022	O
)	O
.	O

The	O
use	O
of	O
the	O
essential	O
oil	O
-	O
containing	O
oral	O
strips	O
resulted	O
in	O
a	O
short	O
-	O
term	O
small	O
increase	O
in	O
the	O
total	O
number	O
of	O
salivary	O
microorganisms	O
.	O

In	O
addition	O
,	O
a	O
not	O
significant	O
decrease	O
of	O
certain	O
periodontopathogens	O
,	O
and	O
an	O
increase	O
in	O
species	O
compatible	O
with	O
oral	O
health	O
were	O
observed	O
.	O

To	O
analyse	O
the	O
microbial	O
flora	O
in	O
specific	O
sites	O
in	O
20	O
dentate	O
(	O
>	O
or	O
=	O
16	O
teeth	O
)	O
subjects	O
with	O
hyposalivation	O
due	O
to	O
medicines	O
or	O
of	O
unknown	O
origin	O
and	O
in	O
20	O
controls	O
matched	O
according	O
to	O
age	O
,	O
sex	O
and	O
number	O
of	O
teeth	O
.	O

The	O
microbial	O
samples	O
were	O
analysed	O
for	O
the	O
following	O
micro	O
-	O
organisms	O
:	O
mutans	B-bacteria
streptococci	I-bacteria
,	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
Actinomyces	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
associated	O
with	O
the	O
development	O
of	O
caries	O
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
/	O
Prevotella	B-bacteria
nigrescens	I-bacteria
,	O
associated	O
with	O
plaque	O
accumulation	O
and	O
gingivitis	O
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
frequently	O
found	O
in	O
elevated	O
numbers	O
in	O
periodontitis	O
sites	O
and	O
Candida	O
albicans	O
,	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
enterics	B-bacteria
and	O
enterococci	B-bacteria
,	O
associated	O
with	O
mucosal	O
infections	O
.	O

The	O
total	O
microbial	O
count	O
was	O
also	O
registered	O
,	O
together	O
with	O
the	O
total	O
number	O
of	O
streptococci	B-bacteria
,	O
associated	O
with	O
good	O
oral	O
health	O
.	O

In	O
the	O
hyposalivation	O
group	O
,	O
the	O
mean	O
age	O
was	O
54	O
+	O
/	O
-	O
8	O
years	O
and	O
the	O
mean	O
number	O
of	O
teeth	O
25	O
+	O
/	O
-	O
3	O
.	O

The	O
unstimulated	O
secretion	O
rate	O
was	O
0	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
04	O
mL	O
/	O
min	O
and	O
the	O
stimulated	O
secretion	O
rate	O
0	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
51	O
mL	O
/	O
min	O
.	O

Compared	O
with	O
the	O
controls	O
,	O
the	O
hyposalivation	O
group	O
tended	O
to	O
harbour	O
a	O
lower	O
number	O
and	O
proportion	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
on	O
the	O
tongue	O
,	O
and	O
an	O
increased	O
number	O
of	O
enterococci	B-bacteria
in	O
the	O
vestibular	O
region	O
.	O

In	O
the	O
supragingival	O
plaque	O
,	O
the	O
numbers	O
of	O
Strepococcus	B-bacteria
mutans	I-bacteria
and	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
significantly	O
increased	O
and	O
the	O
number	O
of	O
C	O
.	O
albicans	O
tended	O
to	O
be	O
increased	O
.	O

The	O
results	O
indicate	O
that	O
subjects	O
with	O
hyposalivation	O
due	O
to	O
medicines	O
or	O
of	O
unknown	O
origin	O
have	O
a	O
supragingival	O
plaque	O
associated	O
with	O
the	O
development	O
of	O
caries	O
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
a	O
periodontopathic	O
bacterium	O
,	O
is	O
known	O
to	O
invade	O
oral	O
epithelial	O
cells	O
in	O
periodontal	O
lesions	O
,	O
although	O
the	O
mechanism	O
is	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
goat	O
polyclonal	O
anti	O
-	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
anti	O
-	O
ICAM	O
-	O
1	O
)	O
antibody	O
inhibited	O
the	O
invasion	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
into	O
KB	O
cells	O
(	O
human	O
oral	O
epithelial	O
cells	O
)	O
.	O

Further	O
,	O
the	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
fimbria	O
,	O
a	O
pathogenic	O
adhesion	O
molecule	O
,	O
bound	O
to	O
recombinant	O
human	O
ICAM	O
-	O
1	O
,	O
as	O
shown	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
was	O
also	O
found	O
to	O
colocalize	O
with	O
ICAM	O
-	O
1	O
on	O
KB	O
cells	O
,	O
as	O
seen	O
with	O
an	O
immunofluorescence	O
microscope	O
,	O
and	O
the	O
knockdown	O
of	O
ICAM	O
-	O
1	O
in	O
KB	O
cells	O
resulted	O
in	O
the	O
inhibition	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
invasion	O
by	O
RNA	O
interference	O
.	O

In	O
addition	O
,	O
methyl	O
-	O
beta	O
-	O
cyclodextrin	O
,	O
a	O
cholesterol	O
-	O
binding	O
agent	O
,	O
inhibited	O
the	O
colocalization	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
with	O
ICAM	O
-	O
1	O
and	O
invasion	O
by	O
the	O
microorganism	O
.	O

The	O
colocalization	O
of	O
caveolin	O
-	O
1	O
,	O
a	O
caveolar	O
marker	O
protein	O
,	O
on	O
KB	O
cells	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
was	O
also	O
shown	O
,	O
and	O
the	O
knockdown	O
of	O
caveolin	O
-	O
1	O
in	O
KB	O
cells	O
caused	O
a	O
reduced	O
level	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
invasion	O
.	O

These	O
results	O
suggest	O
that	O
ICAM	O
-	O
1	O
and	O
caveolae	O
are	O
required	O
for	O
the	O
invasion	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
into	O
human	O
oral	O
epithelial	O
cells	O
,	O
and	O
these	O
molecules	O
appear	O
to	O
be	O
associated	O
with	O
the	O
primary	O
stages	O
of	O
the	O
development	O
and	O
progression	O
of	O
chronic	O
periodontitis	O
.	O

Streptococcus	B-bacteria
mitis	I-bacteria
bv	I-bacteria
.	I-bacteria
1	I-bacteria
is	O
a	O
pioneer	O
colonizer	O
of	O
the	O
human	O
oral	O
cavity	O
.	O

Studies	O
of	O
its	O
population	O
dynamics	O
within	O
parents	O
and	O
their	O
infants	O
and	O
within	O
neonates	O
have	O
shown	O
extensive	O
diversity	O
within	O
and	O
between	O
subjects	O
.	O

We	O
examined	O
the	O
genetic	O
diversity	O
and	O
clonal	O
turnover	O
of	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
bv	I-bacteria
.	I-bacteria
1	I-bacteria
isolated	O
from	O
the	O
cheeks	O
,	O
tongue	O
,	O
and	O
primary	O
incisors	O
of	O
four	O
infants	O
from	O
birth	O
to	O
1	O
year	O
of	O
age	O
.	O

In	O
addition	O
,	O
we	O
compared	O
the	O
clonotypes	O
of	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
bv	I-bacteria
.	I-bacteria
1	I-bacteria
isolated	O
from	O
their	O
mothers	O
'	O
saliva	O
collected	O
in	O
parallel	O
to	O
determine	O
whether	O
the	O
mother	O
was	O
the	O
origin	O
of	O
the	O
clones	O
colonizing	O
her	O
infant	O
.	O

Of	O
859	O
isolates	O
obtained	O
from	O
the	O
infants	O
,	O
568	O
were	O
unique	O
clones	O
.	O

Each	O
of	O
the	O
surfaces	O
examined	O
,	O
whether	O
shedding	O
or	O
nonshedding	O
,	O
displayed	O
the	O
same	O
degree	O
of	O
diversity	O
.	O

Among	O
the	O
four	O
infants	O
it	O
was	O
rare	O
to	O
detect	O
the	O
same	O
clone	O
colonizing	O
more	O
than	O
one	O
surface	O
at	O
a	O
given	O
visit	O
.	O

There	O
was	O
little	O
evidence	O
for	O
persistence	O
of	O
clones	O
,	O
but	O
when	O
clones	O
were	O
isolated	O
on	O
multiple	O
visits	O
they	O
were	O
not	O
always	O
found	O
on	O
the	O
same	O
surface	O
.	O

A	O
similar	O
degree	O
of	O
clonal	O
diversity	O
of	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
bv	I-bacteria
.	I-bacteria
1	I-bacteria
was	O
observed	O
in	O
the	O
mothers	O
'	O
saliva	O
as	O
in	O
their	O
infants	O
'	O
mouths	O
.	O

Clones	O
common	O
to	O
both	O
infant	O
and	O
mothers	O
'	O
saliva	O
were	O
found	O
infrequently	O
suggesting	O
that	O
this	O
is	O
not	O
the	O
origin	O
of	O
the	O
infants	O
'	O
clones	O
.	O

It	O
is	O
unclear	O
whether	O
mucosal	O
immunity	O
exerts	O
the	O
environmental	O
pressure	O
driving	O
the	O
genetic	O
diversity	O
and	O
clonal	O
turnover	O
of	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
bv	I-bacteria
.	I-bacteria
1	I-bacteria
,	O
which	O
may	O
be	O
mechanisms	O
employed	O
by	O
this	O
bacterium	O
to	O
evade	O
immune	O
elimination	O
.	O

Bacteriocins	O
are	O
bacteriocidal	O
proteinaceous	O
molecules	O
produced	O
by	O
the	O
Gram	O
-	O
positive	O
bacteria	O
not	O
active	O
against	O
the	O
produced	O
strain	O
.	O

Many	O
investigations	O
have	O
revealed	O
that	O
certain	O
bacteria	O
using	O
antibacterial	O
or	O
the	O
inhibitory	O
substance	O
inhibit	O
some	O
other	O
bacteria	O
.	O

A	O
study	O
was	O
conducted	O
in	O
a	O
group	O
of	O
60	O
children	O
to	O
ascertain	O
whether	O
any	O
correlation	O
exists	O
between	O
the	O
proportion	O
of	O
salivary	O
bacteria	O
inhibiting	O
and	O
stimulating	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
the	O
oral	O
health	O
indices	O
(	O
DMFT	O
,	O
deft	O
and	O
Community	O
Periodontal	O
Index	O
of	O
Treatment	O
Needs	O
)	O
.	O

A	O
definite	O
inverse	O
correlation	O
was	O
observed	O
between	O
the	O
percentage	O
of	O
salivary	O
inhibiting	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
untreated	O
carious	O
teeth	O
(	O
UCT	O
)	O
.	O

Postoperative	O
maxillary	O
cyst	O
(	O
POMC	O
)	O
is	O
known	O
to	O
occur	O
as	O
a	O
delayed	O
complication	O
of	O
radical	O
maxillary	O
sinus	O
surgery	O
,	O
such	O
as	O
Caldwell	O
-	O
Luc	O
surgery	O
.	O

The	O
cyst	O
gradually	O
expands	O
with	O
no	O
symptoms	O
over	O
a	O
period	O
of	O
years	O
,	O
and	O
then	O
occasionally	O
causes	O
swelling	O
and	O
pain	O
in	O
the	O
buccal	O
region	O
and	O
/	O
or	O
the	O
mucogingival	O
fold	O
.	O

It	O
is	O
probable	O
that	O
bacterial	O
infection	O
affects	O
the	O
progression	O
of	O
POMC	O
symptoms	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
bacterial	O
density	O
and	O
to	O
examine	O
the	O
presence	O
of	O
20	O
oral	O
bacteria	O
in	O
POMC	O
fluids	O
.	O

POMC	O
fluids	O
(	O
4	O
purulent	O
,	O
2	O
mucous	O
and	O
4	O
serous	O
)	O
were	O
sampled	O
from	O
10	O
subjects	O
(	O
aged	O
43	O
-	O
77	O
years	O
)	O
.	O

Bacterial	O
quantification	O
and	O
detection	O
were	O
performed	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
nested	O
PCR	O
based	O
on	O
bacterial	O
16S	O
rRNA	O
genes	O
,	O
respectively	O
.	O

Bacterial	O
DNA	O
was	O
detected	O
in	O
all	O
samples	O
and	O
the	O
average	O
concentrations	O
of	O
bacterial	O
DNA	O
were	O
5	O
.	O
9	O
(	O
purulent	O
)	O
,	O
0	O
.	O
5	O
(	O
mucous	O
)	O
,	O
and	O
0	O
.	O
7	O
(	O
serous	O
)	O
ng	O
/	O
mg	O
of	O
sample	O
.	O

Twelve	O
bacterial	O
species	O
,	O
including	O
anginosus	B-bacteria
streptococci	I-bacteria
,	O
known	O
to	O
be	O
associated	O
with	O
abscess	O
formation	O
,	O
were	O
detected	O
in	O
the	O
purulent	O
fluids	O
,	O
while	O
two	O
and	O
five	O
species	O
were	O
detected	O
in	O
the	O
mucous	O
and	O
serous	O
fluids	O
,	O
respectively	O
.	O

Purulent	O
fluids	O
contained	O
numerous	O
bacteria	O
of	O
various	O
types	O
,	O
thus	O
suggesting	O
that	O
oral	O
bacteria	O
may	O
cause	O
symptoms	O
such	O
as	O
pain	O
in	O
POMC	O
with	O
purulent	O
fluids	O
.	O

Mucous	O
and	O
serous	O
fluids	O
also	O
contained	O
bacteria	O
,	O
although	O
their	O
numbers	O
were	O
small	O
,	O
thus	O
suggesting	O
an	O
association	O
between	O
bacteria	O
and	O
progression	O
of	O
POMC	O
.	O

Lactobacilli	B-bacteria
are	O
known	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
maintenance	O
of	O
health	O
by	O
stimulating	O
natural	O
immunity	O
and	O
contributing	O
to	O
the	O
balance	O
of	O
microflora	O
.	O

However	O
,	O
their	O
role	O
in	O
chronic	O
periodontitis	O
is	O
unclear	O
.	O

We	O
aimed	O
to	O
identify	O
oral	O
lactobacilli	B-bacteria
in	O
chronic	O
periodontitis	O
and	O
periodontally	O
healthy	O
subjects	O
,	O
and	O
to	O
determine	O
their	O
antimicrobial	O
activity	O
against	O
putative	O
oral	O
pathogens	O
.	O

A	O
total	O
of	O
238	O
Lactobacillus	B-bacteria
isolates	I-bacteria
from	O
the	O
saliva	O
and	O
subgingival	O
sites	O
of	O
20	O
chronic	O
periodontitis	O
and	O
15	O
healthy	O
subjects	O
were	O
collected	O
.	O

In	O
all	O
,	O
115	O
strains	O
were	O
identified	O
using	O
rapid	O
amplified	O
ribosomal	O
DNA	O
restriction	O
analysis	O
.	O

Antimicrobial	O
activity	O
against	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
was	O
assessed	O
.	O

Lactobacilli	B-bacteria
belonging	O
to	O
10	O
species	O
were	O
identified	O
.	O

The	O
most	O
prevalent	O
strains	O
in	O
healthy	O
persons	O
were	O
Lactobacillus	B-bacteria
gasseri	I-bacteria
and	O
Lactobacillus	B-bacteria
fermentum	I-bacteria
and	O
in	O
chronic	O
periodontitis	O
patients	O
,	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
.	O

Obligately	O
homofermentatives	O
,	O
particularly	O
L	B-bacteria
.	I-bacteria
gasseri	I-bacteria
,	O
were	O
less	O
prevalent	O
in	O
chronic	O
periodontitis	O
patients	O
compared	O
with	O
healthy	O
subjects	O
(	O
8	O
%	O
vs	O
.	O
64	O
%	O
for	O
L	B-bacteria
.	I-bacteria
gasseri	I-bacteria
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Sixty	O
-	O
nine	O
percent	O
of	O
tested	O
lactobacilli	B-bacteria
inhibited	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
88	O
%	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
82	O
%	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
65	O
%	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
.	O

The	O
strongest	O
antimicrobial	O
activity	O
was	O
associated	O
with	O
Lactobacillus	B-bacteria
paracasei	I-bacteria
,	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
,	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
,	O
and	O
Lactobacillus	B-bacteria
salivarius	I-bacteria
.	O

The	O
strains	O
from	O
periodontally	O
healthy	O
patients	O
showed	O
a	O
lower	O
antimicrobial	O
activity	O
against	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
than	O
the	O
strains	O
from	O
chronic	O
periodontitis	O
patients	O
.	O

The	O
composition	O
of	O
oral	O
lactoflora	O
in	O
chronic	O
periodontitis	O
and	O
healthy	O
subjects	O
differs	O
,	O
with	O
a	O
higher	O
prevalence	O
of	O
homofermentative	O
lactobacilli	B-bacteria
,	O
particularly	O
L	B-bacteria
.	I-bacteria
gasseri	I-bacteria
,	O
in	O
the	O
latter	O
group	O
.	O

Both	O
homo	O
-	O
and	O
heterofermentative	O
oral	O
lactobacilli	B-bacteria
suppress	O
the	O
growth	O
of	O
periodontal	O
pathogens	O
,	O
but	O
the	O
antimicrobial	O
properties	O
are	O
strain	O
,	O
species	O
and	O
origin	O
specific	O
.	O

Recent	O
evidence	O
from	O
molecular	O
genetic	O
studies	O
has	O
revealed	O
that	O
oral	O
Treponema	B-bacteria
species	I-bacteria
are	O
involved	O
in	O
infections	O
of	O
endodontic	O
origin	O
.	O

This	O
study	O
assessed	O
the	O
occurrence	O
of	O
two	O
newly	O
named	O
oral	O
treponemes	B-bacteria
-	O
Treponema	B-bacteria
parvum	I-bacteria
and	O
Treponema	B-bacteria
putidum	I-bacteria
-	O
in	O
primary	O
endodontic	O
infections	O
using	O
a	O
culture	O
-	O
independent	O
identification	O
technique	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
directly	O
from	O
clinical	O
samples	O
,	O
and	O
a	O
16S	O
rRNA	O
gene	O
-	O
based	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
was	O
used	O
to	O
determine	O
the	O
presence	O
of	O
T	B-bacteria
.	I-bacteria
parvum	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
putidum	I-bacteria
.	O

Species	O
-	O
specific	O
primer	O
pairs	O
were	O
developed	O
by	O
aligning	O
closely	O
related	O
16S	O
rRNA	O
gene	O
sequences	O
.	O

The	O
specificity	O
for	O
each	O
primer	O
pair	O
was	O
validated	O
by	O
running	O
PCR	O
against	O
a	O
panel	O
of	O
oral	O
bacteria	O
and	O
by	O
sequence	O
analysis	O
of	O
PCR	O
products	O
from	O
positive	O
clinical	O
samples	O
.	O

T	B-bacteria
.	I-bacteria
parvum	I-bacteria
was	O
detected	O
in	O
52	O
%	O
of	O
the	O
root	O
canals	O
associated	O
with	O
chronic	O
apical	O
periodontitis	O
,	O
in	O
20	O
%	O
of	O
the	O
cases	O
diagnosed	O
as	O
acute	O
apical	O
periodontitis	O
,	O
and	O
in	O
no	O
abscessed	O
case	O
.	O

In	O
general	O
,	O
T	B-bacteria
.	I-bacteria
parvum	I-bacteria
was	O
detected	O
in	O
26	O
%	O
of	O
the	O
samples	O
from	O
primary	O
endodontic	O
infections	O
.	O

T	B-bacteria
.	I-bacteria
putidum	I-bacteria
was	O
found	O
in	O
only	O
one	O
case	O
of	O
acute	O
apical	O
periodontitis	O
(	O
2	O
%	O
of	O
the	O
total	O
number	O
of	O
cases	O
investigated	O
)	O
.	O

The	O
devised	O
nested	O
PCR	O
protocol	O
was	O
able	O
to	O
identify	O
both	O
T	B-bacteria
.	I-bacteria
parvum	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
putidum	I-bacteria
directly	O
in	O
clinical	O
samples	O
and	O
demonstrated	O
that	O
these	O
two	O
treponemes	B-bacteria
can	O
take	O
part	O
in	O
endodontic	O
infections	O
.	O

This	O
study	O
assessed	O
,	O
for	O
forensic	O
purposes	O
,	O
the	O
feasibility	O
of	O
genotypically	O
matching	O
oral	O
streptococci	B-bacteria
recovered	O
from	O
recent	O
human	O
bite	O
marks	O
with	O
those	O
from	O
the	O
teeth	O
of	O
the	O
biter	O
.	O

Streptococci	B-bacteria
were	O
isolated	O
from	O
the	O
incisors	O
of	O
eight	O
volunteers	O
.	O

Arbitrarily	O
primed	O
PCR	O
(	O
AP	O
-	O
PCR	O
)	O
distinguished	O
106	O
streptococcal	O
genotypes	O
among	O
the	O
participants	O
,	O
each	O
harbouring	O
at	O
least	O
eight	O
distinct	O
strains	O
.	O

In	O
a	O
crime	O
simulation	O
,	O
a	O
sample	O
from	O
an	O
experimental	O
bite	O
mark	O
was	O
analysed	O
by	O
an	O
experimenter	O
unaware	O
of	O
its	O
origin	O
.	O

The	O
bacteria	O
were	O
unambiguously	O
matched	O
to	O
the	O
biter	O
by	O
comparing	O
the	O
amplicon	O
profiles	O
with	O
those	O
from	O
the	O
eight	O
participants	O
.	O

In	O
contrast	O
,	O
bacteria	O
from	O
an	O
additional	O
bite	O
mark	O
(	O
not	O
generated	O
by	O
one	O
of	O
the	O
original	O
participants	O
)	O
could	O
not	O
be	O
matched	O
to	O
any	O
of	O
the	O
eight	O
participants	O
.	O

Between	O
20	O
and	O
78	O
%	O
of	O
catalogued	O
bacterial	O
genotypes	O
were	O
recovered	O
12	O
months	O
later	O
from	O
each	O
participant	O
.	O

Throughout	O
the	O
study	O
period	O
,	O
none	O
of	O
the	O
bacterial	O
genotypes	O
were	O
shared	O
between	O
participants	O
.	O

Streptococci	B-bacteria
isolated	O
from	O
recent	O
bite	O
marks	O
can	O
be	O
catalogued	O
by	O
AP	O
-	O
PCR	O
and	O
matched	O
to	O
the	O
teeth	O
responsible	O
for	O
the	O
bite	O
.	O

The	O
study	O
provides	O
'	O
proof	O
of	O
concept	O
'	O
that	O
genotypic	O
analysis	O
of	O
streptococci	B-bacteria
from	O
bite	O
marks	O
may	O
provide	O
valuable	O
forensic	O
evidence	O
in	O
situations	O
where	O
the	O
perpetrator	O
'	O
s	O
DNA	O
can	O
not	O
be	O
recovered	O
.	O

We	O
have	O
shown	O
that	O
buccal	O
epithelial	O
cells	O
(	O
BEC	O
)	O
from	O
humans	O
can	O
contain	O
a	O
polymicrobial	O
intracellular	O
flora	O
.	O

Members	O
of	O
that	O
flora	O
can	O
induce	O
proinflammatory	O
responses	O
.	O

However	O
,	O
our	O
subjects	O
all	O
had	O
healthy	O
oral	O
mucosa	O
.	O

This	O
might	O
reflect	O
tolerance	O
of	O
bacterial	O
invasion	O
by	O
live	O
BEC	O
.	O

Alternatively	O
,	O
inflammation	O
might	O
not	O
occur	O
if	O
invaded	O
cells	O
were	O
mostly	O
dead	O
,	O
and	O
thus	O
unable	O
to	O
mount	O
a	O
response	O
.	O

This	O
study	O
addressed	O
that	O
issue	O
,	O
by	O
determining	O
the	O
vital	O
status	O
of	O
BEC	O
and	O
the	O
bacteria	O
associated	O
with	O
them	O
.	O

Initial	O
experiments	O
indicated	O
that	O
BEC	O
were	O
anomalously	O
permeable	O
to	O
the	O
DNA	O
stain	O
propidium	O
iodide	O
.	O

We	O
used	O
that	O
property	O
to	O
develop	O
a	O
protocol	O
that	O
combined	O
the	O
DNA	O
stains	O
SYTO	O
9	O
and	O
propidium	O
iodide	O
(	O
indicators	O
of	O
bacterial	O
viability	O
)	O
with	O
the	O
esterase	O
substrate	O
calcein	O
blue	O
AM	O
(	O
an	O
indicator	O
of	O
BEC	O
viability	O
)	O
,	O
and	O
Annexin	O
V	O
Alexa	O
Fluor	O
647	O
conjugate	O
(	O
an	O
apoptosis	O
marker	O
)	O
.	O

That	O
protocol	O
was	O
applied	O
to	O
BEC	O
collected	O
from	O
36	O
human	O
subjects	O
.	O

On	O
average	O
,	O
70	O
%	O
of	O
BEC	O
displayed	O
calcein	O
blue	O
staining	O
,	O
with	O
no	O
binding	O
of	O
Annexin	O
V	O
,	O
25	O
%	O
showed	O
signs	O
of	O
apoptosis	O
,	O
and	O
5	O
%	O
did	O
not	O
stain	O
with	O
calcein	O
blue	O
.	O

The	O
mean	O
percent	O
of	O
BEC	O
with	O
live	O
cell	O
-	O
associated	O
bacteria	O
was	O
29	O
%	O
.	O

Collectively	O
,	O
25	O
%	O
of	O
total	O
BEC	O
displayed	O
calcein	O
blue	O
staining	O
and	O
live	O
(	O
SYTO	O
9	O
stained	O
)	O
bacteria	O
.	O

Only	O
1	O
%	O
of	O
total	O
BEC	O
were	O
negative	O
for	O
calcein	O
blue	O
and	O
associated	O
with	O
live	O
bacteria	O
.	O

Our	O
findings	O
suggest	O
that	O
live	O
BEC	O
are	O
tolerant	O
of	O
bacterial	O
invasion	O
.	O

This	O
may	O
be	O
due	O
to	O
complex	O
interactions	O
between	O
members	O
of	O
the	O
polymicrobial	O
flora	O
and	O
their	O
host	O
BEC	O
.	O

To	O
measure	O
antibacterial	O
action	O
of	O
photoactivated	O
disinfection	O
(	O
PAD	O
)	O
on	O
endodontic	O
bacteria	O
in	O
planktonic	O
suspension	O
and	O
root	O
canals	O
.	O

Four	O
bacteria	O
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Peptostreptococcus	B-bacteria
micros	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
and	O
Streptococcus	B-bacteria
intermedius	I-bacteria
,	O
were	O
tested	O
in	O
suspension	O
.	O

After	O
mixing	O
equal	O
volumes	O
of	O
Tolonium	O
chloride	O
and	O
bacterial	O
suspension	O
for	O
60s	O
,	O
each	O
200	O
microL	O
of	O
concentration	O
(	O
>	O
10	O
(	O
6	O
)	O
cfu	O
mL	O
(	O
-	O
1	O
)	O
)	O
was	O
irradiated	O
with	O
light	O
at	O
633	O
+	O
/	O
-	O
2	O
nm	O
.	O

Each	O
energy	O
dose	O
/	O
Tolonium	O
chloride	O
concentration	O
combination	O
was	O
tested	O
eight	O
times	O
,	O
with	O
controls	O
.	O

Prepared	O
root	O
canals	O
in	O
Training	O
Blocs	O
and	O
extracted	O
human	O
teeth	O
were	O
inoculated	O
with	O
S	B-bacteria
.	I-bacteria
intermedius	I-bacteria
followed	O
by	O
10	O
mg	O
L	O
(	O
-	O
1	O
)	O
Tolonium	O
chloride	O
or	O
saline	O
.	O

Bacteria	O
in	O
canals	O
were	O
sampled	O
before	O
and	O
after	O
light	O
irradiation	O
.	O

Student	O
t	O
-	O
test	O
assessed	O
significance	O
of	O
changes	O
in	O
viable	O
bacteria	O
produced	O
by	O
treatment	O
of	O
either	O
light	O
or	O
Tolonium	O
chloride	O
alone	O
and	O
light	O
/	O
Tolonium	O
chloride	O
combinations	O
.	O

In	O
suspension	O
,	O
reductions	O
in	O
bacteria	O
were	O
highly	O
significant	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
for	O
light	O
/	O
Tolonium	O
chloride	O
combinations	O
compared	O
to	O
light	O
or	O
Tolonium	O
chloride	O
alone	O
.	O

Maximum	O
mean	O
log	O
reductions	O
of	O
1	O
.	O
14	O
(	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
)	O
,	O
2	O
.	O
48	O
(	O
P	B-bacteria
.	I-bacteria
micros	I-bacteria
)	O
,	O
2	O
.	O
81	O
(	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
)	O
and	O
6	O
.	O
73	O
(	O
S	B-bacteria
.	I-bacteria
intermedius	I-bacteria
)	O
were	O
at	O
4	O
.	O
8	O
J	O
/	O
20	O
mg	O
L	O
(	O
-	O
1	O
)	O
.	O

Antibacterial	O
action	O
was	O
increased	O
by	O
energy	O
dose	O
increase	O
(	O
not	O
always	O
significantly	O
)	O
,	O
but	O
not	O
by	O
Tolonium	O
chloride	O
concentration	O
.	O

In	O
control	O
canals	O
mean	O
log	O
reductions	O
of	O
0	O
.	O
42	O
(	O
Blocs	O
)	O
and	O
0	O
.	O
38	O
(	O
teeth	O
)	O
from	O
initial	O
levels	O
were	O
not	O
significant	O
.	O

PAD	O
mean	O
log	O
reductions	O
of	O
2	O
.	O
40	O
(	O
Blocs	O
)	O
and	O
2	O
.	O
01	O
(	O
teeth	O
)	O
were	O
highly	O
significant	O
.	O

Changes	O
for	O
PAD	O
/	O
energy	O
dose	O
combinations	O
were	O
not	O
significant	O
.	O

PAD	O
killed	O
endodontic	O
bacteria	O
at	O
statistically	O
significant	O
levels	O
compared	O
to	O
controls	O
.	O

Kills	O
varied	O
with	O
bacterial	O
species	O
.	O

The	O
purposes	O
of	O
the	O
study	O
presented	O
are	O
to	O
identify	O
the	O
microbial	O
content	O
of	O
the	O
collected	O
bone	O
debris	O
and	O
to	O
determine	O
the	O
antibacterial	O
efficiency	O
of	O
chlorhexidine	O
mouth	O
rinse	O
in	O
reducing	O
the	O
microbial	O
content	O
of	O
the	O
collected	O
bone	O
debris	O
.	O

Twenty	O
-	O
five	O
patients	O
who	O
had	O
asymptomatic	O
fully	O
impacted	O
mandibular	O
third	O
molars	O
bilaterally	O
underwent	O
surgical	O
removal	O
for	O
prophylactic	O
and	O
orthodontic	O
considerations	O
.	O

Immediately	O
before	O
surgery	O
all	O
patients	O
rinsed	O
with	O
10	O
mL	O
of	O
their	O
assigned	O
solution	O
(	O
chlorhexidine	O
or	O
sterile	O
saline	O
)	O
for	O
2	O
minutes	O
.	O

Before	O
surgical	O
removal	O
of	O
the	O
teeth	O
,	O
bone	O
debris	O
was	O
collected	O
with	O
a	O
stringent	O
aspiration	O
protocol	O
from	O
the	O
ramus	O
by	O
bone	O
filter	O
.	O

The	O
microbial	O
content	O
of	O
the	O
bone	O
debris	O
was	O
assessed	O
and	O
the	O
bacterial	O
levels	O
between	O
the	O
2	O
groups	O
were	O
compared	O
statistically	O
.	O

All	O
samples	O
from	O
both	O
groups	O
(	O
chlorhexidine	O
or	O
sterile	O
saline	O
)	O
yielded	O
viable	O
microorganisms	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
mean	O
/	O
median	O
colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
/	O
g	O
values	O
of	O
both	O
group	O
samples	O
,	O
for	O
aerobes	O
(	O
Streptococcus	B-bacteria
salivarius	I-bacteria
)	O
and	O
anaerobes	O
(	O
Bacteroides	B-bacteria
,	O
Peptococcus	B-bacteria
,	O
Peptostreptococcus	B-bacteria
,	O
and	O
Veillonella	B-bacteria
species	I-bacteria
)	O
.	O

With	O
regard	O
to	O
total	O
microorganisms	O
,	O
the	O
mean	O
CFU	O
/	O
g	O
derived	O
from	O
the	O
chlorhexidine	O
group	O
samples	O
were	O
1	O
.	O
5	O
x	O
10	O
(	O
8	O
)	O
CFU	O
/	O
g	O
per	O
bone	O
sample	O
compared	O
with	O
1	O
.	O
5	O
x	O
10	O
(	O
9	O
)	O
CFU	O
/	O
g	O
for	O
the	O
sterile	O
saline	O
control	O
group	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Although	O
chlorhexidine	O
rinsing	O
immediately	O
before	O
surgery	O
reduced	O
the	O
levels	O
of	O
total	O
microorganisms	O
when	O
compared	O
with	O
stringent	O
aspiration	O
protocol	O
alone	O
,	O
it	O
has	O
not	O
been	O
found	O
effective	O
on	O
aerobic	O
Streptococcus	B-bacteria
salivarius	I-bacteria
and	O
,	O
importantly	O
,	O
on	O
anaerobes	O
.	O

The	O
reduced	O
bacterial	O
levels	O
may	O
still	O
carry	O
high	O
infectious	O
risk	O
and	O
may	O
lead	O
to	O
failure	O
in	O
autogenous	O
grafting	O
procedures	O
in	O
oral	O
surgery	O
.	O

Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
adult	O
periodontitis	O
share	O
common	O
pathogenetic	O
mechanisms	O
and	O
immunologic	O
and	O
pathological	O
findings	O
.	O

One	O
oral	O
pathogen	O
strongly	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
periodontal	O
disease	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
possesses	O
a	O
unique	O
microbial	O
enzyme	O
,	O
peptidylarginine	O
deiminase	O
(	O
PAD	O
)	O
,	O
the	O
human	O
equivalent	O
of	O
which	O
has	O
been	O
identified	O
as	O
a	O
susceptibility	O
factor	O
for	O
RA	O
.	O

We	O
suggest	O
that	O
individuals	O
predisposed	O
to	O
periodontal	O
infection	O
are	O
exposed	O
to	O
antigens	O
generated	O
by	O
PAD	O
,	O
with	O
de	O
-	O
iminated	O
fibrin	O
as	O
a	O
likely	O
candidate	O
,	O
which	O
become	O
systemic	O
immunogens	O
and	O
lead	O
to	O
intraarticular	O
inflammation	O
.	O

PAD	O
engendered	O
antigens	O
lead	O
to	O
production	O
of	O
rheumatoid	O
factor	O
-	O
containing	O
immune	O
complexes	O
and	O
provoke	O
local	O
inflammation	O
,	O
both	O
in	O
gingiva	O
and	O
synovium	O
via	O
Fc	O
and	O
C5a	O
receptors	O
.	O

To	O
assess	O
antimicrobial	O
activities	O
of	O
aqueous	O
crude	O
khat	O
(	O
Catha	O
edulis	O
)	O
extracts	O
against	O
a	O
panel	O
of	O
oral	O
microorganisms	O
and	O
to	O
test	O
their	O
ability	O
to	O
modify	O
bacterial	O
resistance	O
to	O
tetracycline	O
and	O
penicillin	O
in	O
vitro	O
.	O

Lyophilized	O
aqueous	O
extracts	O
were	O
prepared	O
from	O
three	O
khat	O
cultivars	O
.	O

The	O
agar	O
dilution	O
method	O
of	O
the	O
NCCLS	O
was	O
used	O
to	O
test	O
the	O
extracts	O
,	O
at	O
concentrations	O
of	O
20	O
-	O
1	O
.	O
25	O
mg	O
/	O
ml	O
,	O
against	O
33	O
oral	O
strains	O
.	O

MIC	O
was	O
defined	O
as	O
the	O
lowest	O
concentration	O
at	O
which	O
there	O
was	O
no	O
visible	O
growth	O
.	O

Slight	O
growth	O
was	O
defined	O
as	O
marked	O
growth	O
reduction	O
(	O
MGR	O
)	O
.	O

The	O
E	O
-	O
test	O
was	O
used	O
to	O
determine	O
the	O
MICs	O
of	O
tetracycline	O
and	O
penicillin	O
-	O
G	O
for	O
three	O
resistant	O
strains	O
in	O
absence	O
and	O
presence	O
of	O
a	O
sub	O
-	O
MIC	O
of	O
the	O
khat	O
extracts	O
(	O
5mg	O
/	O
ml	O
)	O
.	O

Eighteen	O
strains	O
(	O
55	O
%	O
)	O
were	O
sensitive	O
to	O
the	O
extracts	O
(	O
MICs	O
5	O
-	O
20	O
mg	O
/	O
ml	O
)	O
.	O

Most	O
of	O
these	O
were	O
periodontal	O
pathogens	O
with	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
Tannerella	B-bacteria
forsythensis	I-bacteria
being	O
the	O
most	O
susceptible	O
(	O
MIC	O
5	O
-	O
10mg	O
/	O
ml	O
)	O
.	O

Veillonella	B-bacteria
parvula	I-bacteria
,	O
Actinomyces	B-bacteria
israelii	I-bacteria
and	O
some	O
streptococci	B-bacteria
were	O
not	O
sensitive	O
.	O

Except	O
for	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
that	O
showed	O
MGR	O
at	O
1mg	O
/	O
ml	O
,	O
cariogenic	O
species	O
were	O
neither	O
sensitive	O
.	O

The	O
extracts	O
were	O
active	O
against	O
Streptococcus	B-bacteria
pyogenes	I-bacteria
(	O
MIC	O
10	O
-	O
20	O
mg	O
/	O
ml	O
)	O
but	O
not	O
against	O
Candida	O
albicans	O
and	O
Staphylococcus	B-bacteria
aureus	I-bacteria
.	O

The	O
presence	O
of	O
the	O
khat	O
extracts	O
at	O
a	O
sub	O
-	O
MIC	O
resulted	O
in	O
a	O
2	O
-	O
4	O
-	O
fold	O
potentiation	O
of	O
the	O
tested	O
antibiotics	O
against	O
the	O
resistant	O
strains	O
.	O

Khat	O
has	O
water	O
-	O
soluble	O
constituents	O
possessing	O
selective	O
antibacterial	O
activity	O
against	O
oral	O
bacteria	O
.	O

There	O
is	O
preliminary	O
evidence	O
for	O
presence	O
of	O
an	O
antibiotic	O
resistance	O
-	O
modifying	O
component	O
.	O

Further	O
investigation	O
is	O
needed	O
to	O
identify	O
the	O
active	O
components	O
and	O
assess	O
their	O
clinical	O
relevance	O
.	O

We	O
analyzed	O
the	O
distribution	O
of	O
10	O
periodontal	O
bacteria	O
species	O
(	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Prevotella	B-bacteria
nigrescens	I-bacteria
,	O
Campylobacter	B-bacteria
rectus	I-bacteria
,	O
Eikenella	B-bacteria
corrodens	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Capnocytophaga	B-bacteria
ochracea	I-bacteria
,	O
Capnocytophaga	B-bacteria
sputigena	I-bacteria
,	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
)	O
in	O
children	O
,	O
and	O
then	O
compared	O
their	O
distribution	O
in	O
those	O
children	O
and	O
their	O
mothers	O
,	O
with	O
special	O
attention	O
given	O
to	O
three	O
of	O
the	O
species	O
known	O
as	O
the	O
red	O
complex	O
(	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
,	O
and	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
)	O
whose	O
presence	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
conditions	O
related	O
to	O
periodontal	O
diseases	O
.	O

One	O
hundred	O
thirteen	O
pairs	O
of	O
children	O
and	O
their	O
mothers	O
were	O
randomly	O
selected	O
from	O
patients	O
treated	O
at	O
the	O
Pedodontic	O
Clinic	O
of	O
Osaka	O
University	O
Dental	O
Hospital	O
.	O

Saliva	O
samples	O
were	O
taken	O
at	O
the	O
second	O
visit	O
prior	O
to	O
receiving	O
professional	O
tooth	O
brushing	O
instruction	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
each	O
saliva	O
sample	O
,	O
followed	O
by	O
a	O
polymerase	O
chain	O
reaction	O
assay	O
with	O
species	O
-	O
specific	O
sets	O
of	O
primers	O
.	O

A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
was	O
the	O
most	O
frequently	O
detected	O
species	O
in	O
the	O
mothers	O
,	O
followed	O
by	O
C	B-bacteria
.	I-bacteria
sputigena	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
and	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
,	O
while	O
C	B-bacteria
.	I-bacteria
sputigena	I-bacteria
had	O
the	O
highest	O
detection	O
rate	O
,	O
followed	O
by	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
in	O
the	O
children	O
.	O

The	O
detection	O
rate	O
of	O
the	O
red	O
complex	O
species	O
in	O
children	O
whose	O
mothers	O
possessed	O
the	O
same	O
species	O
was	O
significantly	O
higher	O
than	O
in	O
those	O
whose	O
mothers	O
did	O
not	O
possess	O
them	O
.	O

Our	O
results	O
indicate	O
a	O
correlation	O
between	O
the	O
presence	O
of	O
periodontal	O
bacteria	O
in	O
children	O
and	O
their	O
mothers	O
,	O
while	O
the	O
presence	O
of	O
red	O
complex	O
bacteria	O
in	O
children	O
was	O
highly	O
associated	O
with	O
that	O
in	O
their	O
mothers	O
.	O

Bacteria	O
were	O
isolated	O
from	O
the	O
dental	O
plaques	O
of	O
nine	O
dogs	O
and	O
a	O
sample	O
of	O
pooled	O
saliva	O
from	O
five	O
other	O
dogs	O
and	O
were	O
then	O
identified	O
by	O
comparative	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

Among	O
339	O
isolates	O
,	O
84	O
different	O
phylotypes	O
belonging	O
to	O
37	O
genera	O
were	O
identified	O
.	O

Approximately	O
half	O
of	O
the	O
phylotypes	O
were	O
identified	O
to	O
the	O
species	O
level	O
,	O
and	O
28	O
%	O
of	O
these	O
were	O
considered	O
members	O
of	O
the	O
indigenous	O
oral	O
microbiota	O
of	O
humans	O
.	O

The	O
16S	O
rRNA	O
gene	O
sequences	O
of	O
the	O
remaining	O
44	O
phylotypes	O
were	O
not	O
represented	O
in	O
GenBank	O
,	O
and	O
most	O
of	O
these	O
phylotypes	O
were	O
tentatively	O
identified	O
as	O
candidate	O
new	O
species	O
.	O

The	O
genera	O
most	O
frequently	O
isolated	O
from	O
saliva	O
were	O
Actinomyces	B-bacteria
(	O
26	O
%	O
)	O
,	O
Streptococcus	B-bacteria
(	O
18	O
%	O
)	O
,	O
and	O
Granulicatella	B-bacteria
(	O
17	O
%	O
)	O
.	O

The	O
genera	O
most	O
frequently	O
isolated	O
from	O
plaque	O
were	O
Porphyromonas	B-bacteria
(	O
20	O
%	O
)	O
,	O
Actinomyces	B-bacteria
(	O
12	O
%	O
)	O
,	O
and	O
Neisseria	B-bacteria
(	O
10	O
%	O
)	O
.	O

A	O
comparison	O
of	O
the	O
DNA	O
sequences	O
from	O
this	O
study	O
with	O
sequences	O
of	O
the	O
human	O
microbiota	O
available	O
in	O
GenBank	O
showed	O
that	O
,	O
on	O
average	O
,	O
canine	O
and	O
human	O
microbiotas	O
differed	O
by	O
almost	O
7	O
%	O
in	O
the	O
16S	O
rRNA	O
gene	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
has	O
shown	O
that	O
the	O
cultivable	O
oral	O
microbiotas	O
of	O
dogs	O
and	O
humans	O
show	O
significant	O
differences	O
.	O

More	O
than	O
700	O
bacterial	O
species	O
or	O
phylotypes	O
,	O
of	O
which	O
over	O
50	O
%	O
have	O
not	O
been	O
cultivated	O
,	O
have	O
been	O
detected	O
in	O
the	O
oral	O
cavity	O
.	O

Our	O
purposes	O
were	O
(	O
i	O
)	O
to	O
utilize	O
culture	O
-	O
independent	O
molecular	O
techniques	O
to	O
extend	O
our	O
knowledge	O
on	O
the	O
breadth	O
of	O
bacterial	O
diversity	O
in	O
the	O
healthy	O
human	O
oral	O
cavity	O
,	O
including	O
not	O
-	O
yet	O
-	O
cultivated	O
bacteria	O
species	O
,	O
and	O
(	O
ii	O
)	O
to	O
determine	O
the	O
site	O
and	O
subject	O
specificity	O
of	O
bacterial	O
colonization	O
.	O

Nine	O
sites	O
from	O
five	O
clinically	O
healthy	O
subjects	O
were	O
analyzed	O
.	O

Sites	O
included	O
tongue	O
dorsum	O
,	O
lateral	O
sides	O
of	O
tongue	O
,	O
buccal	O
epithelium	O
,	O
hard	O
palate	O
,	O
soft	O
palate	O
,	O
supragingival	O
plaque	O
of	O
tooth	O
surfaces	O
,	O
subgingival	O
plaque	O
,	O
maxillary	O
anterior	O
vestibule	O
,	O
and	O
tonsils	O
.	O

16S	O
rRNA	O
genes	O
from	O
sample	O
DNA	O
were	O
amplified	O
,	O
cloned	O
,	O
and	O
transformed	O
into	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

Sequences	O
of	O
16S	O
rRNA	O
genes	O
were	O
used	O
to	O
determine	O
species	O
identity	O
or	O
closest	O
relatives	O
.	O

In	O
2	O
,	O
589	O
clones	O
,	O
141	O
predominant	O
species	O
were	O
detected	O
,	O
of	O
which	O
over	O
60	O
%	O
have	O
not	O
been	O
cultivated	O
.	O

Thirteen	O
new	O
phylotypes	O
were	O
identified	O
.	O

Species	O
common	O
to	O
all	O
sites	O
belonged	O
to	O
the	O
genera	O
Gemella	B-bacteria
,	O
Granulicatella	B-bacteria
,	O
Streptococcus	B-bacteria
,	O
and	O
Veillonella	B-bacteria
.	O

While	O
some	O
species	O
were	O
subject	O
specific	O
and	O
detected	O
in	O
most	O
sites	O
,	O
other	O
species	O
were	O
site	O
specific	O
.	O

Most	O
sites	O
possessed	O
20	O
to	O
30	O
different	O
predominant	O
species	O
,	O
and	O
the	O
number	O
of	O
predominant	O
species	O
from	O
all	O
nine	O
sites	O
per	O
individual	O
ranged	O
from	O
34	O
to	O
72	O
.	O

Species	O
typically	O
associated	O
with	O
periodontitis	O
and	O
caries	O
were	O
not	O
detected	O
.	O

There	O
is	O
a	O
distinctive	O
predominant	O
bacterial	O
flora	O
of	O
the	O
healthy	O
oral	O
cavity	O
that	O
is	O
highly	O
diverse	O
and	O
site	O
and	O
subject	O
specific	O
.	O

It	O
is	O
important	O
to	O
fully	O
define	O
the	O
human	O
microflora	O
of	O
the	O
healthy	O
oral	O
cavity	O
before	O
we	O
can	O
understand	O
the	O
role	O
of	O
bacteria	O
in	O
oral	O
disease	O
.	O

Oral	O
malodour	O
is	O
considered	O
to	O
be	O
caused	O
by	O
the	O
proteolytic	O
activity	O
of	O
anaerobic	O
Gram	O
-	O
negative	O
oral	O
bacteria	O
.	O

In	O
a	O
previous	O
study	O
,	O
it	O
was	O
shown	O
that	O
these	O
bacteria	O
were	O
susceptible	O
to	O
blue	O
light	O
(	O
wavelengths	O
of	O
400	O
-	O
500	O
nm	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
blue	O
light	O
on	O
malodour	O
production	O
by	O
mixed	O
oral	O
microflora	O
was	O
tested	O
in	O
a	O
salivary	O
incubation	O
assay	O
.	O

Whole	O
saliva	O
samples	O
were	O
exposed	O
to	O
a	O
xenon	O
light	O
source	O
for	O
30	O
,	O
60	O
,	O
120	O
and	O
240	O
s	O
,	O
equivalent	O
to	O
fluences	O
of	O
34	O
,	O
68	O
,	O
137	O
and	O
274	O
J	O
cm	O
(	O
-	O
2	O
)	O
,	O
respectively	O
.	O

Malodour	O
was	O
scored	O
by	O
two	O
judges	O
.	O

The	O
levels	O
of	O
volatile	O
sulfide	O
compounds	O
(	O
VSC	O
)	O
were	O
measured	O
using	O
a	O
sulfide	O
monitor	O
(	O
Halimeter	O
)	O
,	O
the	O
microbial	O
population	O
was	O
assessed	O
using	O
viable	O
counts	O
and	O
microscopy	O
,	O
salivary	O
protein	O
degradation	O
was	O
followed	O
by	O
SDS	O
-	O
PAGE	O
densitometry	O
and	O
VSC	O
-	O
producing	O
bacteria	O
were	O
demonstrated	O
using	O
a	O
differential	O
agar	O
.	O

The	O
results	O
showed	O
that	O
the	O
exposure	O
of	O
mixed	O
salivary	O
microflora	O
to	O
blue	O
light	O
caused	O
a	O
reduction	O
in	O
malodour	O
production	O
concomitant	O
with	O
a	O
selective	O
inhibitory	O
effect	O
on	O
the	O
population	O
of	O
Gram	O
-	O
negative	O
oral	O
bacteria	O
.	O

These	O
results	O
suggest	O
that	O
light	O
exposure	O
might	O
have	O
clinical	O
applications	O
for	O
the	O
treatment	O
of	O
oral	O
malodour	O
.	O

Current	O
treatment	O
options	O
in	O
patients	O
with	O
primary	O
and	O
secondary	O
hyperoxaluria	O
are	O
limited	O
and	O
do	O
not	O
always	O
lead	O
to	O
sufficient	O
reduction	O
in	O
urinary	O
oxalate	O
excretion	O
.	O

Intestinal	O
oxalate	O
degrading	O
bacteria	O
are	O
capable	O
of	O
degrading	O
oxalate	O
to	O
CO	O
(	O
2	O
)	O
and	O
formate	O
,	O
the	O
latter	O
being	O
further	O
metabolized	O
and	O
excreted	O
via	O
the	O
feces	O
.	O

It	O
is	O
speculated	O
,	O
that	O
both	O
endogenously	O
produced	O
,	O
as	O
well	O
as	O
dietary	O
oxalate	O
can	O
be	O
significantly	O
removed	O
via	O
the	O
intestinal	O
tract	O
.	O

Oxalobacter	B-bacteria
formigenes	I-bacteria
,	O
an	O
obligate	O
anaerobic	O
microbe	O
normally	O
found	O
in	O
the	O
intestinal	O
tract	O
has	O
one	O
oxalate	O
degrading	O
enzyme	O
,	O
oxalyl	O
-	O
CoA	O
decarboxylase	O
,	O
which	O
is	O
also	O
found	O
in	O
Bifidobacterium	B-bacteria
lactis	I-bacteria
.	O

Other	O
bacteria	O
with	O
possible	O
oxalate	O
degrading	O
potency	O
are	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
,	O
as	O
well	O
as	O
Enterococcus	B-bacteria
faecalis	I-bacteria
and	O
Eubacterium	B-bacteria
lentum	I-bacteria
.	O

However	O
,	O
specific	O
therapeutic	O
studies	O
on	O
humans	O
are	O
scarce	O
and	O
,	O
except	O
for	O
Oxalobacter	B-bacteria
,	O
data	O
are	O
not	O
congruent	O
.	O

We	O
found	O
the	O
oral	O
application	O
of	O
Oxalobacter	B-bacteria
successful	O
in	O
patients	O
with	O
primary	O
hyperoxaluria	O
.	O

However	O
,	O
long	O
-	O
term	O
post	O
-	O
treatment	O
follow	O
-	O
up	O
of	O
1	O
-	O
2	O
years	O
showed	O
that	O
constant	O
intestinal	O
colonization	O
is	O
not	O
achieved	O
in	O
most	O
patients	O
.	O

In	O
one	O
patient	O
with	O
constant	O
colonization	O
,	O
urinary	O
oxalate	O
excretion	O
normalized	O
over	O
time	O
.	O

Short	O
-	O
term	O
studies	O
with	O
other	O
bacteria	O
such	O
as	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
did	O
not	O
show	O
a	O
specific	O
reduction	O
in	O
urinary	O
oxalate	O
excretion	O
.	O

O	O
.	O
formigenes	O
might	O
be	O
a	O
promising	O
new	O
therapeutic	O
tool	O
in	O
patients	O
with	O
primary	O
and	O
secondary	O
hyperoxaluria	O
.	O

A	O
novel	O
mouthrinse	O
(	O
IND	O
61	O
,	O
164	O
)	O
containing	O
essential	O
oils	O
and	O
extracts	O
from	O
four	O
plant	O
species	O
(	O
Melaleuca	O
alternifolia	O
,	O
Leptospermum	O
scoparium	O
,	O
Calendula	O
officinalis	O
and	O
Camellia	O
sinensis	O
)	O
were	O
tested	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
safety	O
,	O
palatability	O
and	O
preliminary	O
efficacy	O
of	O
the	O
rinse	O
.	O

Fifteen	O
subjects	O
completed	O
the	O
Phase	O
I	O
safety	O
study	O
.	O

Seventeen	O
subjects	O
completed	O
the	O
Phase	O
II	O
randomized	O
placebo	O
-	O
controlled	O
study	O
.	O

Plaque	O
was	O
collected	O
,	O
gingival	O
and	O
plaque	O
indices	O
were	O
recorded	O
(	O
baseline	O
,	O
6	O
weeks	O
,	O
and	O
12	O
weeks	O
)	O
.	O

The	O
relative	O
abundance	O
of	O
two	O
periodontal	O
pathogens	O
(	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Tanerella	B-bacteria
forsythensis	I-bacteria
)	O
was	O
determined	O
utilizing	O
digoxigenin	O
-	O
labeled	O
DNA	O
probes	O
.	O

ANCOVA	O
was	O
used	O
at	O
the	O
p	O
=	O
0	O
.	O
05	O
level	O
of	O
significance	O
.	O

Two	O
subjects	O
reported	O
a	O
minor	O
adverse	O
event	O
.	O

One	O
subject	O
withdrew	O
from	O
the	O
study	O
.	O

Several	O
subjects	O
objected	O
to	O
the	O
taste	O
of	O
the	O
test	O
rinse	O
but	O
continued	O
treatment	O
.	O

Differences	O
between	O
gingival	O
index	O
,	O
plaque	O
index	O
or	O
relative	O
abundance	O
of	O
either	O
bacterial	O
species	O
did	O
not	O
reach	O
statistical	O
significance	O
when	O
comparing	O
nine	O
placebo	O
subjects	O
with	O
eight	O
test	O
rinse	O
subjects	O
.	O

Subjects	O
exposed	O
to	O
the	O
test	O
rinse	O
experienced	O
no	O
abnormal	O
oral	O
lesions	O
,	O
altered	O
vital	O
signs	O
,	O
changes	O
in	O
liver	O
,	O
kidney	O
,	O
or	O
bone	O
marrow	O
function	O
.	O

Larger	O
scale	O
studies	O
would	O
be	O
necessary	O
to	O
determine	O
the	O
efficacy	O
and	O
oral	O
health	O
benefits	O
of	O
the	O
test	O
rinse	O
.	O

Human	O
dental	O
plaque	O
is	O
thought	O
to	O
contribute	O
to	O
disease	O
,	O
not	O
only	O
in	O
the	O
oral	O
cavity	O
but	O
also	O
at	O
other	O
body	O
sites	O
.	O

To	O
investigate	O
the	O
pathogenicity	O
of	O
dental	O
plaque	O
in	O
tissues	O
remote	O
from	O
the	O
mouth	O
,	O
we	O
examined	O
the	O
ability	O
of	O
human	O
supragingival	O
dental	O
plaque	O
to	O
induce	O
infective	O
endocarditis	O
(	O
IE	O
)	O
in	O
rats	O
.	O

In	O
total	O
,	O
15	O
out	O
of	O
27	O
catheterized	O
rats	O
survived	O
after	O
intravenous	O
injections	O
with	O
human	O
supragingival	O
dental	O
plaque	O
suspensions	O
containing	O
3	O
x	O
10	O
(	O
6	O
)	O
colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
of	O
bacterial	O
cells	O
.	O

In	O
surviving	O
rats	O
,	O
infected	O
vegetations	O
were	O
formed	O
in	O
all	O
except	O
one	O
rat	O
.	O

The	O
microbial	O
composition	O
of	O
the	O
infected	O
vegetations	O
was	O
different	O
from	O
that	O
of	O
the	O
respective	O
dental	O
plaque	O
inocula	O
,	O
with	O
Streptococcus	B-bacteria
oralis	I-bacteria
comprising	O
the	O
majority	O
of	O
the	O
isolates	O
.	O

In	O
rats	O
affected	O
with	O
endocarditis	O
,	O
the	O
aortic	O
sinus	O
was	O
filled	O
with	O
fibrinous	O
vegetation	O
containing	O
bacteria	O
.	O

Inflammatory	O
cells	O
infiltrated	O
the	O
aortic	O
valve	O
,	O
the	O
aorta	O
adjacent	O
to	O
the	O
valve	O
,	O
and	O
the	O
cardiac	O
muscles	O
.	O

The	O
inoculation	O
of	O
catheterized	O
rats	O
with	O
a	O
cell	O
suspension	O
of	O
S	O
.	O
oralis	O
isolate	O
(	O
5	O
x	O
10	O
(	O
6	O
)	O
CFU	O
)	O
was	O
not	O
lethal	O
but	O
capable	O
of	O
inducing	O
endocarditis	O
in	O
all	O
animals	O
.	O

The	O
results	O
suggest	O
that	O
if	O
dental	O
plaque	O
were	O
introduced	O
into	O
the	O
bloodstream	O
,	O
it	O
could	O
serve	O
as	O
a	O
potent	O
source	O
of	O
bacteria	O
causing	O
IE	O
in	O
humans	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
(	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
)	O
is	O
an	O
important	O
gastrointestinal	O
pathogen	O
associated	O
with	O
gastritis	O
as	O
well	O
as	O
gastric	O
or	O
duodenal	O
ulcers	O
and	O
gastric	O
cancer	O
.	O

The	O
oral	O
cavity	O
has	O
been	O
considered	O
as	O
a	O
potential	O
reservoir	O
for	O
the	O
gastric	O
infection	O
and	O
reinfection	O
.	O

The	O
objective	O
of	O
our	O
studies	O
was	O
to	O
evaluate	O
the	O
influence	O
of	O
oral	O
H	O
.	O
pylori	O
for	O
the	O
stomach	O
infection	O
and	O
the	O
release	O
of	O
gut	O
hormones	O
affecting	O
food	O
intake	O
such	O
as	O
ghrelin	O
and	O
gastric	O
secretion	O
such	O
as	O
gastrin	O
.	O

Additionally	O
,	O
the	O
contribution	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
periodontal	O
disease	O
has	O
been	O
examined	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
in	O
stomach	O
was	O
assessed	O
by	O
(	O
13	O
)	O
C	O
-	O
Urease	O
Breath	O
Test	O
and	O
presence	O
of	O
the	O
bacteria	O
in	O
oral	O
cavity	O
by	O
culture	O
.	O

The	O
periodontal	O
status	O
was	O
measured	O
by	O
pockets	O
depth	O
with	O
the	O
periodontal	O
probe	O
.	O

We	O
estimated	O
the	O
serum	O
level	O
of	O
IgG	O
anti	O
-	O
H	O
.	O
pylori	O
,	O
anti	O
-	O
VacA	O
,	O
anti	O
-	O
CagA	O
,	O
ghrelin	O
,	O
gastrin	O
,	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
8	O
in	O
blood	O
and	O
the	O
level	O
of	O
IgA	O
anti	O
-	O
H	O
.	O
pylori	O
in	O
saliva	O
.	O

The	O
presence	O
of	O
H	O
.	O
pylori	O
in	O
oral	O
cavity	O
was	O
detected	O
in	O
54	O
.	O
1	O
%	O
of	O
examined	O
individuals	O
,	O
whereas	O
the	O
H	O
.	O
pylori	O
gastric	O
infection	O
in	O
tested	O
group	O
was	O
found	O
in	O
51	O
%	O
cases	O
.	O

However	O
,	O
the	O
correlation	O
analysis	O
between	O
those	O
two	O
groups	O
of	O
patients	O
involving	O
together	O
about	O
100	O
subjects	O
showed	O
that	O
within	O
the	O
group	O
of	O
patients	O
with	O
positive	O
gastric	O
H	O
.	O
pylori	O
infection	O
only	O
45	O
.	O
1	O
%	O
did	O
not	O
show	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
saliva	O
and	O
43	O
.	O
1	O
%	O
showed	O
no	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
supragingival	O
plaque	O
.	O

In	O
line	O
of	O
these	O
findings	O
patients	O
who	O
did	O
not	O
have	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
,	O
53	O
.	O
2	O
%	O
showed	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
saliva	O
and	O
42	O
.	O
9	O
%	O
in	O
supragingival	O
plaques	O
.	O

Serum	O
level	O
of	O
ghrelin	O
and	O
gastrin	O
in	O
subjects	O
with	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
inoculation	O
but	O
without	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
were	O
not	O
significantly	O
different	O
from	O
those	O
without	O
the	O
presence	O
of	O
this	O
germ	O
in	O
oral	O
cavity	O
.	O

In	O
contrast	O
,	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
resulted	O
in	O
significant	O
reduction	O
in	O
serum	O
ghrelin	O
levels	O
and	O
significant	O
elevation	O
of	O
gastrin	O
as	O
compared	O
to	O
those	O
who	O
were	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
negative	O
.	O

We	O
concluded	O
that	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
alone	O
does	O
not	O
seem	O
to	O
serve	O
as	O
bacterium	O
sanctuary	O
for	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
and	O
,	O
unlike	O
gastric	O
infection	O
,	O
it	O
fails	O
to	O
affect	O
serum	O
levels	O
of	O
hormones	O
stimulating	O
appetitive	O
behaviour	O
such	O
as	O
ghrelin	O
and	O
gastric	O
acid	O
secretion	O
such	O
as	O
gastrin	O
.	O

The	O
aim	O
of	O
this	O
prospective	O
study	O
was	O
to	O
evaluate	O
the	O
long	O
term	O
change	O
in	O
oral	O
pathogens	O
following	O
radiation	O
therapy	O
.	O

Twenty	O
-	O
two	O
patients	O
with	O
planned	O
radiation	O
therapy	O
(	O
>	O
30	O
Gy	O
)	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
were	O
included	O
.	O

Before	O
radiation	O
therapy	O
,	O
after	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
samples	O
from	O
the	O
deepest	O
periodontal	O
pocket	O
were	O
drawn	O
.	O

Five	O
major	O
periodontal	O
pathogens	O
were	O
studied	O
using	O
DNA	O
probes	O
(	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Bacteriodes	B-bacteria
forsythus	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
)	O
.	O

Stimulated	O
saliva	O
was	O
sampled	O
for	O
the	O
microbiologic	O
study	O
of	O
caries	O
pathogens	O
(	O
streptococci	B-bacteria
and	O
lactobacilli	B-bacteria
)	O
.	O

Plaque	O
index	O
and	O
decayed	O
,	O
missing	O
,	O
filled	O
tooth	O
surfaces	O
(	O
DMF	O
-	O
S	O
)	O
were	O
recorded	O
.	O

A	O
normalisation	O
of	O
the	O
caries	O
bacteria	O
is	O
not	O
found	O
correlating	O
to	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
affected	O
teeth	O
(	O
DMF	O
-	O
S	O
)	O
from	O
80	O
.	O
7	O
to	O
88	O
.	O
5	O
after	O
12	O
months	O
.	O

The	O
plaque	O
index	O
remained	O
unchanged	O
.	O

The	O
incidence	O
of	O
periodontal	O
pathogens	O
did	O
not	O
significantly	O
change	O
during	O
the	O
follow	O
up	O
.	O

In	O
contrast	O
to	O
radiation	O
caries	O
there	O
seems	O
to	O
be	O
no	O
microbiological	O
evidence	O
for	O
`	O
`	O
radiation	O
periodontitis	O
'	O
'	O
.	O

Despite	O
of	O
the	O
intensive	O
oral	O
hygiene	O
no	O
reduction	O
of	O
the	O
high	O
number	O
of	O
caries	O
pathogens	O
is	O
found	O
,	O
which	O
leads	O
to	O
a	O
high	O
risk	O
of	O
tooth	O
decay	O
even	O
12	O
months	O
after	O
radiation	O
.	O

To	O
evaluate	O
the	O
number	O
of	O
bacteria	O
extruded	O
apically	O
from	O
extracted	O
teeth	O
ex	O
vivo	O
after	O
canal	O
instrumentation	O
using	O
the	O
two	O
engine	O
-	O
driven	O
techniques	O
utilizing	O
nickel	O
-	O
titanium	O
instruments	O
(	O
ProTaper	O
and	O
System	O
GT	O
)	O
.	O

Forty	O
extracted	O
single	O
-	O
rooted	O
human	O
mandibular	O
premolar	O
teeth	O
were	O
used	O
.	O

Access	O
cavities	O
were	O
prepared	O
and	O
root	O
canals	O
were	O
then	O
contaminated	O
with	O
a	O
suspension	O
of	O
Enterococcus	B-bacteria
faecalis	I-bacteria
and	O
dried	O
.	O

The	O
contaminated	O
roots	O
were	O
divided	O
into	O
two	O
experimental	O
groups	O
of	O
15	O
teeth	O
each	O
and	O
one	O
control	O
group	O
of	O
10	O
teeth	O
.	O

Group	O
1	O
,	O
ProTaper	O
group	O
:	O
the	O
root	O
canals	O
were	O
instrumented	O
using	O
ProTaper	O
instruments	O
.	O

Group	O
2	O
,	O
System	O
GT	O
group	O
:	O
the	O
root	O
canals	O
were	O
instrumented	O
using	O
System	O
GT	O
instruments	O
.	O

Group	O
3	O
,	O
control	O
group	O
:	O
no	O
instrumentation	O
was	O
attempted	O
.	O

Bacteria	O
extruded	O
from	O
the	O
apical	O
foramen	O
during	O
instrumentation	O
were	O
collected	O
into	O
vials	O
.	O

The	O
microbiological	O
samples	O
from	O
the	O
vials	O
were	O
incubated	O
in	O
culture	O
media	O
for	O
24	O
h	O
.	O
Colonies	O
of	O
bacteria	O
were	O
counted	O
and	O
the	O
results	O
were	O
given	O
as	O
number	O
of	O
colony	O
-	O
forming	O
units	O
.	O

The	O
data	O
obtained	O
were	O
analysed	O
using	O
the	O
Kruskal	O
-	O
Wallis	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
and	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
,	O
with	O
alpha	O
=	O
0	O
.	O
05	O
as	O
the	O
level	O
for	O
statistical	O
significance	O
.	O

There	O
was	O
no	O
significant	O
difference	O
as	O
to	O
the	O
number	O
of	O
extruded	O
bacteria	O
between	O
the	O
ProTaper	O
and	O
System	O
GT	O
engine	O
-	O
driven	O
systems	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

Both	O
engine	O
-	O
driven	O
nickel	O
-	O
titanium	O
systems	O
extruded	O
bacteria	O
through	O
the	O
apical	O
foramen	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
component	O
that	O
causes	O
the	O
disease	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
which	O
shows	O
great	O
resemblance	O
to	O
periodontitis	O
in	O
a	O
pathologic	O
context	O
.	O

Within	O
this	O
study	O
,	O
the	O
pathogen	O
-	O
specific	O
IgG	O
levels	O
formed	O
against	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
FDC	I-bacteria
381	I-bacteria
,	O
Prevotella	B-bacteria
melaninogenica	I-bacteria
ATCC	I-bacteria
25845	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
Y4	I-bacteria
,	O
Bacteroides	B-bacteria
forsythus	I-bacteria
ATCC	I-bacteria
43047	I-bacteria
,	O
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
25611	I-bacteria
oral	O
bacteria	O
were	O
researched	O
from	O
the	O
blood	O
serum	O
samples	O
of	O
30	O
RA	O
patients	O
and	O
20	O
healthy	O
controls	O
with	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
method	O
.	O

The	O
IgG	O
levels	O
of	O
P	B-bacteria
gingivalis	I-bacteria
,	O
P	B-bacteria
intermedia	I-bacteria
,	O
P	B-bacteria
melaninogenica	I-bacteria
,	O
and	O
B	B-bacteria
forsythus	I-bacteria
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
RA	O
patients	O
when	O
compared	O
with	O
those	O
of	O
the	O
controls	O
.	O

Of	O
the	O
other	O
bacteria	O
antibodies	O
,	O
A	B-bacteria
actinomycetemcomitans	I-bacteria
was	O
not	O
found	O
at	O
greater	O
levels	O
in	O
RA	O
serum	O
samples	O
in	O
comparison	O
with	O
the	O
healthy	O
samples	O
.	O

The	O
antibodies	O
formed	O
against	O
P	B-bacteria
gingivalis	I-bacteria
,	O
P	B-bacteria
intermedia	I-bacteria
,	O
P	B-bacteria
melaninogenica	I-bacteria
,	O
and	O
B	B-bacteria
forsythus	I-bacteria
could	O
be	O
important	O
to	O
the	O
etiopathogenesis	O
of	O
RA	O
.	O

A	O
significant	O
proportion	O
of	O
oral	O
bacteria	O
are	O
unable	O
to	O
undergo	O
cultivation	O
by	O
existing	O
techniques	O
.	O

In	O
this	O
regard	O
,	O
the	O
microbiota	O
from	O
root	O
canals	O
still	O
requires	O
complementary	O
characterization	O
.	O

The	O
present	O
study	O
aimed	O
at	O
the	O
identification	O
of	O
bacteria	O
by	O
sequence	O
analysis	O
of	O
16S	O
rDNA	O
clone	O
libraries	O
from	O
seven	O
endodontically	O
infected	O
teeth	O
.	O

Samples	O
were	O
collected	O
from	O
the	O
root	O
canals	O
,	O
subjected	O
to	O
the	O
PCR	O
with	O
universal	O
16S	O
rDNA	O
primers	O
,	O
cloned	O
and	O
partially	O
sequenced	O
.	O

Clones	O
were	O
clustered	O
into	O
groups	O
of	O
closely	O
related	O
sequences	O
(	O
phylotypes	O
)	O
and	O
identification	O
to	O
the	O
species	O
level	O
was	O
performed	O
by	O
comparative	O
analysis	O
with	O
the	O
GenBank	O
,	O
EMBL	O
and	O
DDBJ	O
databases	O
,	O
according	O
to	O
a	O
98	O
%	O
minimum	O
identity	O
.	O

All	O
samples	O
were	O
positive	O
for	O
bacteria	O
and	O
the	O
number	O
of	O
phylotypes	O
detected	O
per	O
subject	O
varied	O
from	O
two	O
to	O
14	O
.	O

The	O
majority	O
of	O
taxa	O
(	O
65	O
.	O
2	O
%	O
)	O
belonged	O
to	O
the	O
phylum	O
Firmicutes	B-bacteria
of	O
the	O
Gram	O
-	O
positive	O
bacteria	O
,	O
followed	O
by	O
Proteobacteria	B-bacteria
(	O
10	O
.	O
9	O
%	O
)	O
,	O
Spirochaetes	B-bacteria
(	O
4	O
.	O
3	O
%	O
)	O
,	O
Bacteroidetes	B-bacteria
(	O
6	O
.	O
5	O
%	O
)	O
,	O
Actinobacteria	B-bacteria
(	O
2	O
.	O
2	O
%	O
)	O
and	O
Deferribacteres	B-bacteria
(	O
2	O
.	O
2	O
%	O
)	O
.	O

A	O
total	O
of	O
46	O
distinct	O
taxonomic	O
units	O
was	O
identified	O
.	O

Four	O
clones	O
with	O
low	O
similarity	O
to	O
sequences	O
previously	O
deposited	O
in	O
the	O
databases	O
were	O
sequenced	O
to	O
nearly	O
full	O
extent	O
and	O
were	O
classified	O
taxonomically	O
as	O
novel	O
representatives	O
of	O
the	O
order	O
Clostridiales	B-bacteria
,	O
including	O
a	O
putative	O
novel	O
species	O
of	O
Mogibacterium	B-bacteria
.	O

The	O
identification	O
of	O
novel	O
phylotypes	O
associated	O
with	O
endodontic	O
infections	O
suggests	O
that	O
the	O
endodontium	O
may	O
still	O
harbour	O
a	O
relevant	O
proportion	O
of	O
uncharacterized	O
taxa	O
.	O

An	O
evaluation	O
is	O
made	O
of	O
bacterial	O
species	O
and	O
susceptibility	O
to	O
various	O
antibiotics	O
used	O
in	O
application	O
to	O
odontogenic	O
infections	O
of	O
periapical	O
location	O
and	O
in	O
pericoronitis	O
of	O
the	O
lower	O
third	O
molar	O
,	O
with	O
the	O
aim	O
of	O
optimizing	O
the	O
antibiotherapy	O
of	O
such	O
infections	O
and	O
thus	O
preventing	O
unnecessary	O
side	O
effects	O
and	O
over	O
-	O
treatment	O
.	O

Sixty	O
-	O
four	O
patients	O
with	O
odontogenic	O
infection	O
were	O
selected	O
on	O
the	O
basis	O
of	O
a	O
series	O
of	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O

Samples	O
were	O
collected	O
from	O
lesions	O
under	O
maximally	O
aseptic	O
conditions	O
,	O
avoiding	O
oral	O
saprophytic	O
contamination	O
.	O

The	O
samples	O
were	O
cultured	O
and	O
incubated	O
under	O
aerobic	O
and	O
anaerobic	O
conditions	O
,	O
followed	O
by	O
bacteriological	O
identification	O
and	O
antibiotic	O
susceptibility	O
testing	O
.	O

A	O
total	O
of	O
184	O
bacterial	O
strains	O
were	O
isolated	O
and	O
identified	O
,	O
comprising	O
grampositive	O
facultative	O
anaerobes	O
(	O
68	O
%	O
)	O
,	O
gramnegative	O
strict	O
anaerobes	O
(	O
30	O
%	O
)	O
and	O
grampositive	O
facultative	O
anaerobes	O
(	O
2	O
%	O
)	O
.	O

Regardless	O
of	O
the	O
origin	O
of	O
the	O
odontogenic	O
infection	O
,	O
the	O
causal	O
bacteria	O
yielded	O
the	O
best	O
results	O
in	O
terms	O
of	O
increased	O
sensitivity	O
and	O
lesser	O
resistance	O
with	O
amoxicillin	O
/	O
clavulanate	O
and	O
amoxicillin	O
,	O
respectively	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
are	O
increasingly	O
numerous	O
reports	O
in	O
the	O
literature	O
of	O
growing	O
bacterial	O
resistance	O
to	O
antibiotics	O
in	O
infectious	O
processes	O
affecting	O
non	O
-	O
buccodental	O
territories	O
.	O

This	O
same	O
tendency	O
has	O
not	O
been	O
observed	O
in	O
relation	O
to	O
oral	O
infections	O
,	O
though	O
important	O
resistance	O
has	O
been	O
documented	O
for	O
certain	O
concrete	O
antibiotics	O
.	O

According	O
to	O
our	O
results	O
,	O
the	O
common	O
-	O
use	O
antibiotics	O
with	O
the	O
greatest	O
sensitivity	O
and	O
lowest	O
resistance	O
were	O
shown	O
to	O
be	O
amoxicillin	O
/	O
clavulanate	O
followed	O
by	O
amoxicillin	O
alone	O
.	O

In	O
various	O
immunopathologic	O
conditions	O
,	O
bacterial	O
flora	O
induce	O
an	O
immune	O
response	O
which	O
results	O
in	O
inflammatory	O
manifestations	O
,	O
e	O
.	O
g	O
.	O
periapical	O
granuloma	O
.	O

Dendritic	O
cells	O
provide	O
the	O
main	O
orchestration	O
of	O
specific	O
immune	O
responses	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
test	O
the	O
capacity	O
of	O
distinct	O
oral	O
bacterial	O
antigens	O
(	O
prepared	O
from	O
Streptococcus	B-bacteria
mitis	I-bacteria
,	O
Propionibacterium	B-bacteria
acnes	I-bacteria
,	O
and	O
Bacteroides	B-bacteria
spp	I-bacteria
.	I-bacteria
)	O
to	O
prime	O
human	O
dendritic	O
cells	O
for	O
stimulation	O
of	O
the	O
T	O
-	O
lymphocyte	O
response	O
.	O

To	O
assess	O
the	O
T	O
-	O
lymphocyte	O
response	O
,	O
the	O
expression	O
of	O
CD25	O
,	O
CD69	O
,	O
intracellular	O
interferon	O
gamma	O
(	O
cIFN	O
-	O
gamma	O
)	O
,	O
and	O
intracellular	O
interleukin	O
4	O
(	O
cIL	O
-	O
4	O
)	O
was	O
determined	O
.	O

Dendritic	O
cells	O
were	O
prepared	O
from	O
leukocyte	O
buffy	O
coat	O
from	O
healthy	O
blood	O
donors	O
.	O

Monocytes	O
were	O
stimulated	O
with	O
IL	O
-	O
4	O
and	O
GM	O
-	O
CSF	O
and	O
dendritic	O
cells	O
activated	O
with	O
bacterial	O
lysates	O
.	O

Cell	O
suspensions	O
contained	O
up	O
to	O
90	O
%	O
dendritic	O
cells	O
,	O
which	O
represented	O
2	O
-	O
12	O
%	O
of	O
the	O
initial	O
number	O
of	O
mononuclear	O
cells	O
.	O

Lymphocyte	O
subsets	O
that	O
developed	O
in	O
lymphocyte	O
cultures	O
after	O
1	O
week	O
of	O
stimulation	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

Dendritic	O
cells	O
,	O
primed	O
with	O
antigens	O
of	O
Bacteroides	B-bacteria
fragilis	I-bacteria
have	O
shown	O
significantly	O
higher	O
activation	O
and	O
expression	O
of	O
intercellular	O
IFN	O
-	O
gamma	O
by	O
T	O
lymphocytes	O
compared	O
to	O
negative	O
controls	O
.	O

The	O
dendritic	O
cells	O
primed	O
with	O
antigens	O
of	O
P	B-bacteria
.	I-bacteria
acnes	I-bacteria
had	O
no	O
effect	O
on	O
T	O
-	O
lymphocyte	O
activation	O
or	O
cytokine	O
production	O
;	O
instead	O
they	O
induced	O
differentiation	O
of	O
T	O
lymphocytes	O
into	O
CD25bright	O
cells	O
(	O
regulatory	O
T	O
cells	O
)	O
with	O
a	O
potentially	O
inhibitory	O
effect	O
on	O
immune	O
response	O
.	O

Dendritic	O
cells	O
primed	O
with	O
antigens	O
of	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
induced	O
increased	O
expression	O
of	O
cIL	O
-	O
4	O
.	O

We	O
conclude	O
that	O
commensal	O
oral	O
bacteria	O
antigens	O
prepared	O
from	O
B	B-bacteria
.	I-bacteria
fragilis	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
,	O
and	O
P	B-bacteria
.	I-bacteria
acnes	I-bacteria
prime	O
human	O
dendritic	O
cells	O
to	O
induce	O
Th1	O
,	O
Th2	O
,	O
and	O
T	O
(	O
reg	O
)	O
differentiation	O
,	O
respectively	O
.	O

This	O
may	O
advance	O
our	O
understanding	O
of	O
immunopathologic	O
manifestations	O
in	O
the	O
oral	O
cavity	O
and	O
offer	O
new	O
possibilities	O
for	O
redirecting	O
immune	O
responses	O
in	O
mucosal	O
vaccination	O
.	O

To	O
establish	O
whether	O
an	O
intra	O
-	O
oral	O
lubricating	O
device	O
for	O
dry	O
mouth	O
alters	O
the	O
oral	O
environment	O
.	O

A	O
single	O
-	O
blind	O
randomized	O
cross	O
-	O
over	O
study	O
.	O

Twenty	O
-	O
nine	O
dentate	O
subjects	O
from	O
the	O
Sjogren	O
'	O
s	O
syndrome	O
clinic	O
attended	O
on	O
five	O
occasions	O
at	O
4	O
-	O
week	O
intervals	O
.	O

They	O
were	O
randomized	O
,	O
having	O
the	O
device	O
fitted	O
on	O
either	O
the	O
second	O
or	O
the	O
fourth	O
visit	O
for	O
the	O
experimental	O
period	O
,	O
whilst	O
using	O
their	O
preferred	O
method	O
of	O
lubrication	O
throughout	O
the	O
rest	O
of	O
the	O
study	O
.	O

The	O
preferred	O
methods	O
of	O
lubrication	O
were	O
either	O
water	O
(	O
group	O
1	O
,	O
n	O
=	O
10	O
)	O
or	O
saliva	O
substitute	O
(	O
group	O
2	O
,	O
n	O
=	O
9	O
)	O
or	O
sugar	O
-	O
free	O
chewing	O
gum	O
(	O
group	O
3	O
,	O
n	O
=	O
10	O
)	O
.	O

At	O
each	O
visit	O
microbiological	O
,	O
unstimulated	O
and	O
stimulated	O
saliva	O
samples	O
were	O
collected	O
.	O

Dry	O
mouth	O
score	O
,	O
speech	O
test	O
and	O
periodontal	O
indices	O
were	O
recorded	O
.	O

The	O
water	O
lubrication	O
group	O
(	O
1	O
)	O
had	O
a	O
resting	O
salivary	O
flow	O
greater	O
than	O
lubrication	O
groups	O
(	O
2	O
and	O
3	O
)	O
by	O
post	O
-	O
ANOVA	O
contrasts	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
postdevice	O
data	O
also	O
demonstrated	O
a	O
salivary	O
flow	O
greater	O
than	O
lubrication	O
group	O
(	O
3	O
)	O
by	O
post	O
-	O
ANOVA	O
contrasts	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
epithelial	O
cell	O
count	O
using	O
the	O
Spearman	O
correlation	O
was	O
high	O
,	O
possibly	O
reflecting	O
increased	O
viscosity	O
of	O
the	O
saliva	O
(	O
P	O
=	O
0	O
.	O
044	O
)	O
.	O

The	O
speech	O
test	O
indicated	O
that	O
the	O
experimental	O
subjects	O
had	O
difficulty	O
in	O
speaking	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

This	O
was	O
slightly	O
easier	O
postdevice	O
wear	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
(	O
P	O
=	O
0	O
.	O
009	O
)	O
and	O
Lactobacillus	B-bacteria
(	O
P	O
=	O
0	O
.	O
058	O
)	O
increased	O
in	O
the	O
salivary	O
after	O
wearing	O
the	O
device	O
.	O

Salivary	O
flow	O
rate	O
,	O
Candida	O
albicans	O
,	O
oral	O
dryness	O
,	O
speaking	O
and	O
periodontal	O
indices	O
were	O
unchanged	O
.	O

The	O
oral	O
environment	O
was	O
altered	O
by	O
wearing	O
a	O
lubricating	O
device	O
with	O
an	O
increase	O
in	O
the	O
numbers	O
of	O
Strep	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
Lactobacillus	B-bacteria
.	O

Clinical	O
dryness	O
and	O
speech	O
test	O
correlated	O
with	O
the	O
mean	O
whole	O
salivary	O
flow	O
suggesting	O
a	O
screening	O
method	O
for	O
xerostomia	O
.	O

Ecological	O
studies	O
indicate	O
that	O
most	O
Lactobacillus	B-bacteria
species	I-bacteria
found	O
in	O
the	O
human	O
gastrointestinal	O
tract	O
are	O
likely	O
to	O
be	O
transient	O
(	O
allochthonous	O
)	O
,	O
originating	O
from	O
either	O
the	O
oral	O
cavity	O
or	O
food	O
.	O

In	O
order	O
to	O
investigate	O
if	O
oral	O
lactobacilli	B-bacteria
constitute	O
a	O
part	O
of	O
the	O
faecal	O
Lactobacillus	B-bacteria
biota	I-bacteria
,	O
the	O
Lactobacillus	B-bacteria
biota	I-bacteria
of	O
saliva	O
and	O
faeces	O
of	O
three	O
human	O
subjects	O
were	O
investigated	O
and	O
compared	O
at	O
two	O
time	O
-	O
points	O
in	O
a	O
3	O
-	O
months	O
interval	O
.	O

Bacteriological	O
culture	O
,	O
performed	O
by	O
incubation	O
under	O
standard	O
(	O
37	O
degrees	O
C	O
,	O
anaerobic	O
)	O
and	O
alternative	O
(	O
30	O
degrees	O
C	O
,	O
microaerobic	O
)	O
conditions	O
,	O
as	O
well	O
as	O
PCR	O
-	O
DGGE	O
with	O
group	O
-	O
specific	O
primers	O
were	O
used	O
to	O
characterize	O
the	O
predominant	O
lactobacilli	B-bacteria
.	O

Cell	O
counts	O
varied	O
among	O
the	O
subjects	O
and	O
over	O
time	O
,	O
reaching	O
up	O
to	O
10	O
(	O
7	O
)	O
CFU	O
/	O
ml	O
in	O
saliva	O
and	O
5	O
x	O
10	O
(	O
6	O
)	O
CFU	O
/	O
g	O
in	O
faecal	O
samples	O
.	O

The	O
species	O
composition	O
of	O
the	O
Lactobacillus	B-bacteria
biota	I-bacteria
of	O
human	O
saliva	O
and	O
faeces	O
was	O
found	O
to	O
be	O
subject	O
-	O
specific	O
and	O
fluctuated	O
to	O
some	O
degree	O
,	O
but	O
the	O
species	O
Lactobacillus	B-bacteria
gasseri	I-bacteria
,	O
Lactobacillus	B-bacteria
paracasei	I-bacteria
,	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
and	O
Lactobacillus	B-bacteria
vaginalis	I-bacteria
were	O
detected	O
at	O
both	O
time	O
-	O
points	O
in	O
saliva	O
and	O
faecal	O
samples	O
of	O
individual	O
subjects	O
.	O

RAPD	O
-	O
PCR	O
analysis	O
indicated	O
that	O
several	O
strains	O
of	O
these	O
species	O
were	O
present	O
both	O
in	O
the	O
oral	O
cavity	O
and	O
in	O
the	O
faecal	O
samples	O
of	O
the	O
same	O
subject	O
.	O

Oral	O
isolates	O
of	O
the	O
species	O
L	B-bacteria
.	I-bacteria
gasseri	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
vaginalis	I-bacteria
showing	O
identical	O
RAPD	O
types	O
were	O
found	O
to	O
persist	O
over	O
time	O
,	O
suggesting	O
that	O
these	O
species	O
are	O
autochthonous	O
to	O
the	O
oral	O
cavity	O
.	O

Our	O
results	O
together	O
with	O
recent	O
published	O
data	O
give	O
strong	O
evidence	O
that	O
some	O
lactobacilli	B-bacteria
found	O
in	O
human	O
faeces	O
are	O
allochthonous	O
to	O
the	O
intestine	O
and	O
originate	O
from	O
the	O
oral	O
cavity	O
.	O

There	O
are	O
conflicting	O
data	O
on	O
the	O
occurrence	O
of	O
Enterococcus	B-bacteria
faecalis	I-bacteria
in	O
the	O
oral	O
cavity	O
of	O
endodontic	O
patients	O
.	O

This	O
study	O
investigated	O
the	O
prevalence	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
in	O
multi	O
-	O
site	O
oral	O
samples	O
(	O
n	O
=	O
136	O
)	O
from	O
41	O
endodontic	O
patients	O
using	O
culture	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

Additionally	O
,	O
culturable	O
strains	O
were	O
investigated	O
for	O
virulence	O
traits	O
.	O

Overall	O
,	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
was	O
detected	O
in	O
at	O
least	O
one	O
tongue	O
,	O
oral	O
rinse	O
,	O
or	O
gingival	O
sulcus	O
sample	O
in	O
68	O
%	O
of	O
patients	O
and	O
in	O
the	O
root	O
canals	O
only	O
in	O
5	O
%	O
of	O
patients	O
.	O

In	O
21	O
patients	O
from	O
whom	O
samples	O
were	O
obtained	O
from	O
all	O
four	O
sites	O
,	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
was	O
detected	O
in	O
more	O
tongue	O
than	O
gingival	O
sulcus	O
,	O
oral	O
rinse	O
,	O
and	O
root	O
canal	O
samples	O
(	O
43	O
,	O
14	O
,	O
10	O
,	O
and	O
10	O
%	O
,	O
respectively	O
;	O
p	O
=	O
0	O
.	O
0148	O
,	O
chi	O
(	O
2	O
)	O
)	O
,	O
and	O
in	O
proportionally	O
greater	O
numbers	O
of	O
patients	O
with	O
gingivitis	O
/	O
periodontitis	O
compared	O
to	O
healthy	O
periodontium	O
(	O
73	O
%	O
versus	O
20	O
%	O
;	O
p	O
=	O
0	O
.	O
03	O
,	O
Fisher	O
'	O
s	O
exact	O
test	O
)	O
.	O

PCR	O
was	O
more	O
sensitive	O
than	O
culture	O
in	O
detecting	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
in	O
oral	O
samples	O
(	O
32	O
%	O
and	O
4	O
%	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
0001	O
,	O
McNemar	O
'	O
s	O
test	O
)	O
.	O

Multiple	O
virulence	O
traits	O
were	O
identified	O
in	O
culturable	O
strains	O
.	O

The	O
oral	O
health	O
of	O
dependent	O
residents	O
at	O
special	O
facilities	O
has	O
often	O
been	O
reported	O
as	O
being	O
poor	O
,	O
but	O
it	O
is	O
difficult	O
to	O
relate	O
oral	O
health	O
to	O
general	O
health	O
and	O
define	O
the	O
need	O
for	O
oral	O
health	O
care	O
.	O

Microbiological	O
analyses	O
of	O
the	O
oral	O
flora	O
have	O
been	O
suggested	O
as	O
a	O
suitable	O
method	O
for	O
evaluating	O
oral	O
health	O
in	O
this	O
group	O
of	O
patients	O
.	O

A	O
study	O
was	O
performed	O
at	O
a	O
nursing	O
facility	O
where	O
33	O
individuals	O
participated	O
.	O

The	O
aim	O
was	O
to	O
describe	O
their	O
oral	O
flora	O
in	O
relation	O
to	O
other	O
health	O
variables	O
and	O
to	O
classify	O
the	O
residents	O
on	O
different	O
risk	O
levels	O
.	O

An	O
oral	O
examination	O
of	O
the	O
residents	O
was	O
made	O
at	O
the	O
facility	O
,	O
together	O
with	O
a	O
3	O
-	O
day	O
food	O
record	O
and	O
an	O
oral	O
microbiological	O
analysis	O
.	O

The	O
analysis	O
classified	O
the	O
residents	O
in	O
different	O
categories	O
according	O
to	O
both	O
acid	O
-	O
producing	O
bacteria	O
and	O
the	O
flora	O
correlated	O
with	O
a	O
reduction	O
in	O
general	O
health	O
.	O

The	O
categories	O
were	O
based	O
on	O
previous	O
studies	O
conducted	O
at	O
the	O
Department	O
of	O
Microbiology	O
(	O
Faculty	O
of	O
Odontology	O
in	O
Goteborg	O
)	O
.	O

The	O
present	O
study	O
revealed	O
that	O
the	O
level	O
for	O
acid	O
-	O
producing	O
bacteria	O
was	O
high	O
in	O
12	O
individuals	O
and	O
the	O
micriobial	O
level	O
according	O
to	O
decreased	O
general	O
health	O
was	O
high	O
in	O
seven	O
individuals	O
.	O

A	O
high	O
level	O
of	O
acid	O
-	O
producing	O
bacteria	O
was	O
related	O
to	O
functional	O
impairment	O
,	O
which	O
was	O
in	O
turn	O
related	O
to	O
nutritional	O
problems	O
and	O
help	O
with	O
oral	O
hygiene	O
.	O

The	O
microbial	O
level	O
according	O
to	O
the	O
reduction	O
in	O
general	O
health	O
did	O
not	O
significantly	O
correlate	O
with	O
other	O
variables	O
.	O

To	O
date	O
,	O
it	O
appears	O
that	O
the	O
dentists	O
'	O
war	O
against	O
dental	O
caries	O
has	O
no	O
end	O
in	O
sight	O
due	O
to	O
the	O
fact	O
that	O
dentists	O
lack	O
any	O
genuine	O
offensive	O
firepower	O
.	O

Make	O
no	O
mistake	O
,	O
the	O
defense	O
has	O
drastically	O
improved	O
as	O
dentists	O
have	O
shifted	O
the	O
focus	O
more	O
toward	O
the	O
preventive	O
aspects	O
of	O
dental	O
care	O
.	O

But	O
defense	O
by	O
itself	O
can	O
not	O
defeat	O
the	O
enemy	O
;	O
at	O
best	O
,	O
it	O
can	O
maintain	O
the	O
status	O
quo	O
.	O

In	O
order	O
to	O
defeat	O
the	O
enemy	O
,	O
one	O
must	O
study	O
and	O
understand	O
the	O
enemy	O
,	O
to	O
know	O
its	O
strengths	O
and	O
weaknesses	O
,	O
and	O
to	O
strike	O
at	O
those	O
points	O
of	O
vulnerability	O
.	O

The	O
aim	O
of	O
this	O
research	O
is	O
to	O
identify	O
and	O
characterize	O
genes	O
that	O
are	O
responsible	O
for	O
observed	O
virulence	O
factors	O
in	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
which	O
is	O
the	O
primary	O
pathogen	O
involved	O
in	O
the	O
development	O
of	O
dental	O
caries	O
.	O

Once	O
there	O
is	O
a	O
more	O
defined	O
understanding	O
of	O
the	O
many	O
virulence	O
factors	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
there	O
will	O
be	O
a	O
much	O
more	O
valuable	O
insight	O
into	O
its	O
role	O
in	O
the	O
ecology	O
of	O
the	O
oral	O
cavity	O
.	O

Eventually	O
,	O
this	O
knowledge	O
could	O
enable	O
dentists	O
to	O
convert	O
the	O
bacterial	O
`	O
`	O
weaponry	O
'	O
'	O
into	O
its	O
own	O
arsenal	O
,	O
which	O
could	O
then	O
be	O
innovatively	O
employed	O
as	O
preventive	O
,	O
diagnostic	O
,	O
and	O
therapeutic	O
agents	O
to	O
treat	O
oral	O
bacterial	O
-	O
related	O
diseases	O
.	O

Our	O
study	O
aimed	O
to	O
evaluate	O
the	O
oral	O
cavity	O
as	O
a	O
reservoir	O
from	O
where	O
Helicobacter	B-bacteria
pylori	I-bacteria
may	O
be	O
transmitted	O
.	O

Histology	O
and	O
PCR	O
amplification	O
were	O
performed	O
.	O

Eighty	O
-	O
four	O
percent	O
of	O
the	O
stomach	O
biopsies	O
tested	O
positive	O
;	O
however	O
,	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
not	O
detected	O
in	O
dental	O
samples	O
,	O
indicating	O
the	O
absence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
within	O
the	O
oral	O
cavity	O
.	O

The	O
genus	O
Lactobacillus	B-bacteria
has	O
been	O
associated	O
with	O
dental	O
caries	O
in	O
humans	O
,	O
although	O
it	O
is	O
seldom	O
speciated	O
due	O
to	O
lack	O
of	O
simple	O
and	O
nonlaborious	O
identification	O
methods	O
.	O

A	O
considerable	O
heterogeneity	O
among	O
Lactobacillus	B-bacteria
species	I-bacteria
has	O
been	O
demonstrated	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
develop	O
simple	O
methods	O
combining	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
amplified	O
16S	O
rRNA	O
(	O
16S	O
rRNA	O
gene	O
PCR	O
-	O
RFLP	O
)	O
and	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
for	O
the	O
identification	O
of	O
13	O
reference	O
strains	O
of	O
Lactobacillus	B-bacteria
.	O

The	O
16S	O
rRNA	O
gene	O
sequences	O
were	O
amplified	O
by	O
PCR	O
using	O
universal	O
primers	O
and	O
digestion	O
of	O
PCR	O
products	O
with	O
the	O
restriction	O
endonucleases	O
,	O
HpaII	O
and	O
HaeIII	O
.	O

The	O
16S	O
rRNA	O
gene	O
PCR	O
-	O
RFLP	O
is	O
reproducible	O
and	O
has	O
been	O
proved	O
to	O
be	O
useful	O
for	O
differentiating	O
Lactobacillus	B-bacteria
strains	I-bacteria
to	O
species	O
level	O
.	O

Seventy	O
-	O
seven	O
Lactobacillus	B-bacteria
isolates	I-bacteria
from	O
a	O
Thai	O
population	O
were	O
used	O
to	O
show	O
the	O
applicability	O
of	O
the	O
identification	O
test	O
.	O

PCR	O
-	O
RFLP	O
alone	O
had	O
limitations	O
,	O
because	O
the	O
RFLP	O
patterns	O
of	O
Lactobacillus	B-bacteria
casei	I-bacteria
and	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
and	O
of	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
and	O
Lactobacillus	B-bacteria
crispatus	I-bacteria
showed	O
similar	O
patterns	O
;	O
however	O
,	O
these	O
could	O
be	O
differentiated	O
by	O
SDS	O
-	O
PAGE	O
.	O

Of	O
the	O
77	O
isolates	O
,	O
38	O
were	O
identified	O
as	O
Lactobacillus	B-bacteria
fermentum	I-bacteria
,	O
25	O
as	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
,	O
5	O
as	O
Lactobacillus	B-bacteria
salivarius	I-bacteria
,	O
5	O
as	O
L	B-bacteria
.	I-bacteria
casei	I-bacteria
,	O
3	O
as	O
L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
and	O
1	O
as	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
.	O

16S	O
rRNA	O
gene	O
PCR	O
-	O
RFLP	O
,	O
using	O
HpaII	O
and	O
HaeIII	O
,	O
together	O
with	O
SDS	O
-	O
PAGE	O
protein	O
profiles	O
could	O
be	O
an	O
alternative	O
method	O
for	O
the	O
identification	O
of	O
oral	O
Lactobacillus	B-bacteria
strains	I-bacteria
to	O
species	O
level	O
,	O
and	O
may	O
be	O
applicable	O
for	O
large	O
-	O
scale	O
studies	O
on	O
the	O
association	O
of	O
Lactobacillus	B-bacteria
to	O
dental	O
caries	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
use	O
terminal	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
and	O
the	O
16S	O
rRNA	O
gene	O
clone	O
library	O
to	O
investigate	O
the	O
diversity	O
of	O
the	O
microbiota	O
associated	O
with	O
asymptomatic	O
and	O
symptomatic	O
endodontic	O
infections	O
and	O
to	O
compare	O
the	O
bacterial	O
community	O
structure	O
in	O
these	O
two	O
clinical	O
conditions	O
.	O

Samples	O
were	O
taken	O
from	O
asymptomatic	O
endodontic	O
infections	O
associated	O
with	O
chronic	O
periradicular	O
lesions	O
and	O
from	O
symptomatic	O
infections	O
clinically	O
diagnosed	O
as	O
acute	O
abscesses	O
.	O

16S	O
rRNA	O
genes	O
from	O
DNA	O
isolated	O
from	O
clinical	O
samples	O
were	O
used	O
to	O
construct	O
clone	O
libraries	O
or	O
were	O
subjected	O
to	O
terminal	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
.	O

Sequence	O
analysis	O
of	O
186	O
clones	O
revealed	O
42	O
taxa	O
;	O
23	O
(	O
55	O
%	O
)	O
were	O
uncultivated	O
phylotypes	O
,	O
of	O
which	O
seven	O
were	O
unique	O
to	O
endodontic	O
infections	O
.	O

Clone	O
sequencing	O
and	O
terminal	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
revealed	O
that	O
the	O
most	O
commonly	O
detected	O
taxa	O
were	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
(	O
including	O
terminal	O
restriction	O
fragment	O
types	O
1	O
and	O
2	O
)	O
,	O
Peptostreptococcus	B-bacteria
micros	I-bacteria
/	O
Peptostreptococcus	I-bacteria
sp	I-bacteria
.	I-bacteria
oral	I-bacteria
clone	I-bacteria
AJ062	I-bacteria
/	O
BS044	B-bacteria
/	O
FG014	B-bacteria
,	O
Prevotella	B-bacteria
species	I-bacteria
,	O
Dialister	B-bacteria
species	I-bacteria
,	O
Mogibacterium	B-bacteria
species	I-bacteria
,	O
Lachnospiraceae	B-bacteria
oral	I-bacteria
clone	I-bacteria
55A	I-bacteria
-	I-bacteria
34	I-bacteria
,	O
Filifactor	B-bacteria
alocis	I-bacteria
,	O
Megasphaera	B-bacteria
sp	I-bacteria
.	I-bacteria
oral	I-bacteria
clone	I-bacteria
CS025	I-bacteria
/	I-bacteria
BS073	I-bacteria
,	O
and	O
Veillonella	B-bacteria
sp	I-bacteria
.	I-bacteria
oral	I-bacteria
clone	I-bacteria
BP1	I-bacteria
-	I-bacteria
85	I-bacteria
/	O
Veillonella	B-bacteria
dispar	I-bacteria
/	O
V	B-bacteria
.	I-bacteria
parvula	I-bacteria
.	O

Bacteroides	B-bacteria
-	I-bacteria
like	I-bacteria
sp	I-bacteria
.	I-bacteria
oral	I-bacteria
clone	I-bacteria
X083	I-bacteria
/	O
Bacteroidales	B-bacteria
oral	I-bacteria
clone	I-bacteria
MCE7	I-bacteria
_	I-bacteria
20	I-bacteria
and	O
Dialister	B-bacteria
sp	I-bacteria
.	I-bacteria
oral	I-bacteria
clone	I-bacteria
BS016	I-bacteria
/	I-bacteria
MCE7	I-bacteria
_	I-bacteria
134	I-bacteria
were	O
detected	O
only	O
in	O
asymptomatic	O
teeth	O
.	O

On	O
the	O
other	O
hand	O
,	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
terminal	O
restriction	O
fragment	O
type	O
2	O
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Dialister	B-bacteria
pneumosintes	I-bacteria
,	O
and	O
some	O
phylotypes	O
were	O
exclusively	O
detected	O
in	O
symptomatic	O
samples	O
.	O

Bacterial	O
profiles	O
of	O
symptomatic	O
endodontic	O
infections	O
generated	O
by	O
terminal	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
were	O
clearly	O
different	O
from	O
those	O
of	O
asymptomatic	O
infections	O
.	O

Overall	O
,	O
the	O
average	O
number	O
of	O
terminal	O
restriction	O
fragments	O
in	O
symptomatic	O
samples	O
was	O
significantly	O
larger	O
than	O
in	O
asymptomatic	O
samples	O
.	O

Molecular	O
analysis	O
of	O
the	O
microbiota	O
associated	O
with	O
symptomatic	O
or	O
asymptomatic	O
endodontic	O
infections	O
indicates	O
that	O
the	O
endodontic	O
bacterial	O
diversity	O
is	O
greater	O
than	O
previously	O
described	O
by	O
culture	O
methods	O
and	O
that	O
the	O
structure	O
of	O
the	O
microbiota	O
differ	O
significantly	O
between	O
asymptomatic	O
and	O
symptomatic	O
infections	O
.	O

Lactobacillus	B-bacteria
rhamnosus	I-bacteria
GG	I-bacteria
(	O
LGG	B-bacteria
)	O
is	O
one	O
of	O
the	O
most	O
widely	O
studied	O
probiotic	O
bacterial	O
strain	O
.	O

The	O
benefits	O
of	O
LGG	B-bacteria
treatment	O
in	O
gastrointestinal	O
disorders	O
are	O
well	O
documented	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
LGG	B-bacteria
can	O
be	O
detected	O
in	O
the	O
oral	O
cavity	O
after	O
discontinuation	O
of	O
administration	O
of	O
a	O
product	O
prepared	O
with	O
this	O
bacterium	O
.	O

56	O
volunteers	O
consumed	O
Gefilus	O
juice	O
(	O
Valio	O
Ltd	O
,	O
Helsinki	O
,	O
Finland	O
)	O
containing	O
LGG	B-bacteria
during	O
a	O
14	O
-	O
day	O
trial	O
period	O
.	O

Saliva	O
samples	O
were	O
collected	O
and	O
cultured	O
onto	O
MRS	O
agar	O
after	O
a	O
clearance	O
period	O
and	O
then	O
daily	O
after	O
a	O
2	O
-	O
week	O
intervention	O
period	O
for	O
as	O
long	O
as	O
LGG	B-bacteria
was	O
found	O
.	O

LGG	B-bacteria
-	O
like	O
colonies	O
were	O
analyzed	O
in	O
saliva	O
samples	O
,	O
identified	O
by	O
characteristic	O
colony	O
morphology	O
,	O
a	O
lactose	O
fermentation	O
test	O
,	O
and	O
PCR	O
with	O
specific	O
primers	O
.	O

LGG	B-bacteria
was	O
not	O
able	O
to	O
colonize	O
the	O
oral	O
cavity	O
.	O

It	O
could	O
only	O
be	O
temporarily	O
detected	O
.	O

In	O
one	O
female	O
subject	O
,	O
however	O
,	O
whose	O
medical	O
history	O
revealed	O
use	O
of	O
LGG	B-bacteria
in	O
childhood	O
,	O
the	O
bacterium	O
was	O
detected	O
in	O
all	O
saliva	O
samples	O
taken	O
up	O
to	O
5	O
months	O
.	O

(	O
She	O
was	O
excluded	O
from	O
the	O
intervention	O
trial	O
)	O
.	O

Permanent	O
colonization	O
of	O
LGG	B-bacteria
in	O
the	O
oral	O
cavity	O
is	O
improbable	O
but	O
seems	O
possible	O
in	O
individual	O
cases	O
.	O

In	O
order	O
to	O
estimate	O
the	O
clinical	O
efficacy	O
of	O
a	O
povidone	O
-	O
iodine	O
oral	O
antiseptic	O
(	O
PVP	O
-	O
I	O
)	O
on	O
oral	O
bacterial	O
infectious	O
diseases	O
,	O
we	O
studied	O
the	O
effect	O
of	O
oral	O
organic	O
matter	O
on	O
the	O
in	O
vitro	O
killing	O
activity	O
of	O
PVP	O
-	O
I	O
.	O

In	O
addition	O
,	O
we	O
compared	O
the	O
in	O
vitro	O
short	O
-	O
time	O
killing	O
activity	O
of	O
PVP	O
-	O
I	O
with	O
those	O
of	O
other	O
oral	O
antiseptics	O
using	O
mouth	O
-	O
washing	O
and	O
gargling	O
samples	O
collected	O
from	O
healthy	O
volunteers	O
.	O

When	O
any	O
of	O
the	O
mouth	O
-	O
washing	O
and	O
gargling	O
samples	O
was	O
used	O
,	O
the	O
standard	O
(	O
0	O
.	O
23	O
-	O
0	O
.	O
47	O
%	O
)	O
or	O
lower	O
concentrations	O
of	O
PVP	O
-	O
I	O
killed	O
methicillin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Staphylococcus	I-bacteria
aureus	I-bacteria
(	O
MRSA	B-bacteria
)	O
and	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
,	O
including	O
multidrug	O
-	O
resistant	O
strains	O
,	O
within	O
15	O
-	O
60	O
s	O
in	O
the	O
presence	O
of	O
oral	O
organic	O
matter	O
.	O

0	O
.	O
02	O
%	O
benzethonium	O
chloride	O
(	O
BEC	O
)	O
and	O
0	O
.	O
002	O
%	O
chlorhexidine	O
gluconate	O
(	O
CHG	O
)	O
did	O
not	O
show	O
effects	O
against	O
MRSA	B-bacteria
and	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
(	O
including	O
multidrug	O
-	O
resistant	O
strains	O
)	O
in	O
mouth	O
-	O
washing	O
and	O
gargling	O
samples	O
even	O
after	O
60	O
s	O
.	O
The	O
above	O
-	O
mentioned	O
results	O
show	O
that	O
the	O
in	O
vitro	O
killing	O
activity	O
of	O
the	O
standard	O
concentration	O
of	O
PVP	O
-	O
I	O
was	O
hardly	O
affected	O
by	O
the	O
oral	O
organic	O
matter	O
and	O
that	O
a	O
mouth	O
-	O
washing	O
or	O
gargling	O
solution	O
containing	O
PVP	O
-	O
I	O
has	O
a	O
stronger	O
bactericidal	O
activity	O
than	O
BEC	O
and	O
CHG	O
.	O

Although	O
mouth	O
-	O
washing	O
and	O
gargling	O
samples	O
were	O
obtained	O
from	O
healthy	O
individuals	O
in	O
this	O
study	O
,	O
PVP	O
-	O
I	O
may	O
be	O
used	O
for	O
protection	O
against	O
infections	O
in	O
patients	O
with	O
various	O
diseases	O
,	O
if	O
proper	O
concentrations	O
and	O
usage	O
are	O
encouraged	O
.	O

A	O
total	O
of	O
8	O
strains	O
of	O
6	O
bacterial	O
species	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
ATCC33277	I-bacteria
and	I-bacteria
TDC286	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
ATCC29523	I-bacteria
and	I-bacteria
JP2	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
No	I-bacteria
.	I-bacteria
2	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
ATCC43937	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
ATCC25611	I-bacteria
and	O
Streptococcus	B-bacteria
anginosus	I-bacteria
ATCC33397	I-bacteria
,	O
were	O
treated	O
with	O
povidone	O
-	O
iodine	O
(	O
PVP	O
-	O
I	O
)	O
gargle	O
(	O
PVP	O
-	O
I	O
:	O
0	O
.	O
47	O
and	O
0	O
.	O
23	O
%	O
w	O
/	O
v	O
)	O
or	O
chlorhexidine	O
gluconate	O
(	O
CHG	O
)	O
gargle	O
(	O
CHG	O
:	O
0	O
.	O
002	O
%	O
w	O
/	O
v	O
)	O
for	O
15	O
,	O
30	O
or	O
60	O
s	O
,	O
after	O
which	O
they	O
were	O
inoculated	O
into	O
various	O
media	O
,	O
cultured	O
and	O
counted	O
for	O
residual	O
bacteria	O
.	O

At	O
both	O
concentrations	O
,	O
PVP	O
-	O
I	O
gargle	O
reduced	O
the	O
viable	O
cell	O
count	O
of	O
all	O
8	O
bacterial	O
strains	O
to	O
below	O
the	O
measurable	O
limit	O
within	O
15	O
s	O
.	O
By	O
contrast	O
,	O
there	O
were	O
more	O
than	O
1	O
,	O
000	O
viable	O
colonies	O
60	O
s	O
following	O
treatment	O
with	O
the	O
CHG	O
gargle	O
.	O

The	O
results	O
demonstrate	O
that	O
povidone	O
-	O
iodine	O
gargle	O
has	O
rapid	O
bactericidal	O
activity	O
against	O
the	O
causative	O
bacteria	O
of	O
periodontal	O
disease	O
.	O

An	O
evaluation	O
on	O
the	O
applicability	O
of	O
Mitis	B-bacteria
Salivarius	I-bacteria
agar	O
(	O
MS	B-bacteria
)	O
medium	O
,	O
commonly	O
used	O
for	O
the	O
detection	O
of	O
oral	O
streptococci	B-bacteria
in	O
human	O
and	O
animals	O
,	O
to	O
dog	O
specimens	O
and	O
the	O
development	O
of	O
a	O
new	O
selective	O
medium	O
for	O
isolating	O
streptococci	B-bacteria
from	O
the	O
canine	O
oral	O
cavity	O
are	O
described	O
.	O

Oral	O
samples	O
from	O
dogs	O
were	O
cultured	O
on	O
MS	B-bacteria
medium	O
under	O
anaerobic	O
conditions	O
.	O

The	O
predominant	O
facultative	O
anaerobic	O
bacteria	O
on	O
MS	B-bacteria
plates	O
were	O
gram	O
-	O
negative	O
rods	O
.	O

Selectivity	O
of	O
streptococci	B-bacteria
on	O
MS	B-bacteria
medium	O
was	O
21	O
.	O
2	O
%	O
.	O

A	O
new	O
selective	O
medium	O
,	O
designated	O
MS	O
-	O
CAN	O
-	O
AE	O
,	O
was	O
developed	O
for	O
the	O
isolation	O
of	O
streptococci	B-bacteria
from	O
the	O
canine	O
oral	O
cavity	O
.	O

The	O
average	O
growth	O
recovery	O
of	O
laboratory	O
and	O
clinically	O
isolated	O
strains	O
of	O
streptococci	B-bacteria
on	O
MS	O
-	O
CAN	O
-	O
AE	O
medium	O
was	O
84	O
.	O
1	O
%	O
of	O
that	O
on	O
MS	B-bacteria
medium	O
.	O

Gram	O
-	O
positive	O
rods	O
and	O
gram	O
-	O
negative	O
rods	O
and	O
cocci	O
rarely	O
grew	O
on	O
the	O
MS	O
-	O
CAN	O
-	O
AE	O
.	O

The	O
selectivity	O
of	O
MS	O
-	O
CAN	O
-	O
AE	O
was	O
95	O
.	O
0	O
%	O
for	O
clinical	O
samples	O
.	O

MS	O
-	O
CAN	O
-	O
AE	O
medium	O
will	O
be	O
helpful	O
for	O
investigations	O
of	O
streptococci	B-bacteria
in	O
the	O
canine	O
oral	O
cavity	O
.	O

To	O
study	O
the	O
inhibition	O
of	O
compound	O
lightyellow	O
sophora	O
root	O
collutory	O
on	O
oral	O
bacteria	O
.	O

The	O
standard	O
strains	O
of	O
common	O
oral	O
bacteria	O
were	O
cultured	O
and	O
proliferated	O
by	O
corresponding	O
media	O
in	O
vitro	O
.	O

The	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
,	O
MIC	O
(	O
50	O
)	O
,	O
MIC	O
(	O
90	O
)	O
of	O
compound	O
lightyellow	O
sophora	O
root	O
collutory	O
were	O
determined	O
.	O

The	O
bacteriostatic	O
effects	O
were	O
determined	O
by	O
the	O
plating	O
method	O
.	O

The	O
MIC	O
of	O
compound	O
lightyellow	O
sophora	O
root	O
collutory	O
were	O
lower	O
than	O
the	O
stock	O
solution	O
concentration	O
.	O

It	O
was	O
showed	O
that	O
compound	O
lightyellow	O
sophora	O
root	O
collutory	O
had	O
the	O
same	O
effect	O
as	O
tea	O
polyphenol	O
on	O
oral	O
bacteria	O
.	O

To	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
compound	O
lightyellow	O
sophora	O
root	O
collutory	O
inhibited	O
the	O
bacteria	O
growth	O
more	O
obviously	O
than	O
tea	O
polyphenol	O
.	O

The	O
result	O
showed	O
that	O
there	O
was	O
no	O
remarkable	O
difference	O
between	O
the	O
compound	O
lightyellow	O
sophora	O
root	O
collutory	O
and	O
tea	O
polyphenol	O
by	O
the	O
plating	O
method	O
.	O

Compound	O
lightyellow	O
sophora	O
root	O
collutory	O
can	O
inhibit	O
the	O
oral	O
bacteria	O
growth	O
obviously	O
.	O

To	O
determine	O
whether	O
dosing	O
with	O
bacteriocin	O
-	O
producing	O
Streptococcus	B-bacteria
salivarius	I-bacteria
following	O
an	O
antimicrobial	O
mouthwash	O
effects	O
a	O
change	O
in	O
oral	O
malodour	O
parameters	O
and	O
in	O
the	O
composition	O
of	O
the	O
oral	O
microbiota	O
of	O
subjects	O
with	O
halitosis	O
.	O

Twenty	O
-	O
three	O
subjects	O
with	O
halitosis	O
undertook	O
a	O
3	O
-	O
day	O
regimen	O
of	O
chlorhexidine	O
(	O
CHX	O
)	O
mouth	O
rinsing	O
,	O
followed	O
at	O
intervals	O
by	O
the	O
use	O
of	O
lozenges	O
containing	O
either	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
K12	I-bacteria
or	O
placebo	O
.	O

Assessment	O
of	O
the	O
subjects	O
'	O
volatile	O
sulphur	O
compound	O
(	O
VSC	O
)	O
levels	O
1	O
week	O
after	O
treatment	O
initiation	O
showed	O
that	O
85	O
%	O
of	O
the	O
K12	O
-	O
treated	O
group	O
and	O
30	O
%	O
of	O
the	O
placebo	O
group	O
had	O
substantial	O
(	O
>	O
100	O
ppb	O
)	O
reductions	O
.	O

The	O
bacterial	O
composition	O
of	O
the	O
saliva	O
was	O
monitored	O
by	O
culture	O
and	O
PCR	O
-	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
PCR	O
-	O
DGGE	O
)	O
.	O

Changes	O
in	O
the	O
PCR	O
-	O
DGGE	O
profiles	O
occurred	O
in	O
most	O
subjects	O
following	O
K12	B-bacteria
treatment	O
.	O

In	O
vitro	O
testing	O
showed	O
that	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
K12	I-bacteria
suppressed	O
the	O
growth	O
of	O
black	O
-	O
pigmented	O
bacteria	O
in	O
saliva	O
samples	O
and	O
also	O
in	O
various	O
reference	O
strains	O
of	O
bacteria	O
implicated	O
in	O
halitosis	O
.	O

Administration	O
of	O
bacteriocin	O
-	O
producing	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
after	O
an	O
oral	O
antimicrobial	O
mouthwash	O
reduces	O
oral	O
VSC	O
levels	O
.	O

The	O
outcome	O
of	O
this	O
preliminary	O
study	O
indicates	O
that	O
the	O
replacement	O
of	O
bacteria	O
implicated	O
in	O
halitosis	O
by	O
colonization	O
with	O
competitive	O
bacteria	O
such	O
as	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
K12	I-bacteria
may	O
provide	O
an	O
effective	O
strategy	O
to	O
reduce	O
the	O
severity	O
of	O
halitosis	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
(	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
)	O
infection	O
spreads	O
from	O
person	O
-	O
to	O
-	O
person	O
,	O
however	O
the	O
precise	O
mode	O
of	O
transmission	O
(	O
oral	O
-	O
oral	O
,	O
fecal	O
-	O
oral	O
or	O
gastro	O
-	O
gastric	O
)	O
is	O
hitherto	O
not	O
known	O
.	O

Gaining	O
understanding	O
into	O
the	O
spread	O
of	O
the	O
bacterium	O
might	O
be	O
useful	O
in	O
identifying	O
high	O
-	O
risk	O
populations	O
,	O
especially	O
in	O
areas	O
that	O
have	O
high	O
rates	O
of	O
gastric	O
malignancies	O
or	O
peptic	O
ulcer	O
.	O

In	O
this	O
review	O
,	O
the	O
authors	O
analyze	O
the	O
aspects	O
concerning	O
the	O
plausibility	O
for	O
the	O
fecal	O
-	O
oral	O
route	O
on	O
the	O
basis	O
of	O
the	O
available	O
data	O
.	O

Since	O
the	O
discovery	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
(	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
)	O
,	O
much	O
progress	O
has	O
been	O
made	O
worldwide	O
in	O
the	O
field	O
of	O
its	O
epidemiology	O
.	O

In	O
spite	O
of	O
these	O
advancements	O
,	O
many	O
aspects	O
of	O
epidemiology	O
still	O
remain	O
unclear	O
,	O
particularly	O
among	O
populations	O
with	O
low	O
socio	O
-	O
economic	O
status	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
elucidate	O
the	O
different	O
routes	O
of	O
transmission	O
of	O
H	B-bacteria
.		I-bacteria
pylori	I-bacteria
in	O
the	O
Hyderabad	O
(	O
South	O
India	O
)	O
population	O
and	O
to	O
investigate	O
the	O
impact	O
of	O
certain	O
factors	O
,	O
such	O
as	O
age	O
,	O
gender	O
,	O
and	O
lifestyle	O
.	O

Samples	O
used	O
for	O
the	O
study	O
included	O
saliva	O
and	O
biopsy	O
samples	O
of	O
400	O
symptomatic	O
subjects	O
from	O
Hyderabad	O
,	O
India	O
.	O

The	O
patients	O
were	O
retrospectively	O
grouped	O
,	O
based	O
on	O
histopathology	O
of	O
the	O
biopsy	O
and	O
16S	O
rRNA	O
amplification	O
of	O
both	O
saliva	O
and	O
biopsy	O
as	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
positive	O
and	O
negative	O
.	O

This	O
study	O
showed	O
that	O
the	O
prevalence	O
of	O
H	O
.	O
pylori	O
in	O
both	O
saliva	O
and	O
biopsy	O
samples	O
increased	O
with	O
age	O
.	O

In	O
addition	O
,	O
the	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
was	O
found	O
more	O
commonly	O
in	O
the	O
saliva	O
and	O
biopsy	O
samples	O
among	O
males	O
(	O
64	O
percent	O
and	O
60	O
percent	O
,	O
respectively	O
)	O
than	O
females	O
(	O
53	O
.	O
3	O
percent	O
and	O
64	O
percent	O
,	O
respectively	O
)	O
.	O

Similarly	O
,	O
71	O
.	O
6	O
percent	O
and	O
73	O
.	O
5	O
percent	O
of	O
those	O
who	O
consumed	O
municipal	O
water	O
acquired	O
H	O
.	O
pylori	O
(	O
which	O
were	O
respectively	O
found	O
in	O
their	O
saliva	O
and	O
biopsy	O
samples	O
)	O
compared	O
to	O
a	O
lesser	O
proportion	O
(	O
12	O
.	O
6	O
percent	O
and	O
12	O
.	O
6	O
percent	O
,	O
respectively	O
)	O
of	O
those	O
who	O
consumed	O
boiled	O
or	O
filtered	O
water	O
.	O

The	O
study	O
also	O
found	O
that	O
subjects	O
who	O
preferred	O
home	O
-	O
cooked	O
food	O
(	O
57	O
.	O
1	O
percent	O
and	O
57	O
.	O
7	O
percent	O
)	O
showed	O
a	O
lower	O
prevalence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
saliva	O
and	O
biopsy	O
samples	O
,	O
respectively	O
,	O
compared	O
to	O
those	O
(	O
80	O
percent	O
and	O
88	O
percent	O
)	O
who	O
frequently	O
ate	O
out	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
besides	O
the	O
oral	O
-	O
oral	O
route	O
,	O
the	O
transmission	O
of	O
H	O
.	O
pylori	O
also	O
takes	O
place	O
through	O
the	O
consumption	O
of	O
food	O
prepared	O
under	O
unhygienic	O
conditions	O
.	O

Consumption	O
of	O
municipal	O
tap	O
water	O
also	O
has	O
a	O
high	O
impact	O
in	O
the	O
transmission	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

Bacterial	O
invasion	O
of	O
host	O
epithelial	O
cells	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
periodontal	O
diseases	O
;	O
however	O
,	O
the	O
interactions	O
between	O
subgingival	O
species	O
and	O
the	O
gingival	O
crevice	O
cells	O
are	O
not	O
fully	O
understood	O
.	O

This	O
study	O
determined	O
the	O
prevalence	O
of	O
a	O
group	O
of	O
oral	O
bacterial	O
species	O
on	O
or	O
in	O
epithelial	O
cells	O
derived	O
from	O
periodontal	O
pockets	O
and	O
the	O
gingival	O
crevice	O
of	O
subjects	O
with	O
periodontitis	O
.	O

Samples	O
of	O
epithelial	O
cells	O
were	O
obtained	O
from	O
120	O
sites	O
with	O
periodontal	O
pockets	O
>	O
or	O
=	O
4	O
mm	O
and	O
92	O
periodontally	O
healthy	O
sites	O
from	O
49	O
patients	O
(	O
mean	O
age	O
46	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
years	O
;	O
43	O
%	O
males	O
)	O
with	O
chronic	O
periodontitis	O
.	O

Bacteria	O
in	O
or	O
on	O
epithelial	O
cells	O
were	O
separated	O
from	O
unattached	O
bacteria	O
by	O
Percoll	O
density	O
-	O
gradient	O
centrifugation	O
.	O

The	O
presence	O
and	O
levels	O
of	O
33	O
oral	O
species	O
were	O
determined	O
in	O
epithelial	O
cell	O
samples	O
by	O
whole	O
genomic	O
DNA	O
probes	O
and	O
the	O
checkerboard	O
method	O
.	O

The	O
most	O
frequently	O
detected	O
species	O
were	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
42	O
%	O
)	O
,	O
Treponema	B-bacteria
denticola	I-bacteria
(	O
38	O
%	O
)	O
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
(	O
37	O
%	O
)	O
,	O
Streptococcus	B-bacteria
intermedius	I-bacteria
(	O
36	O
%	O
)	O
,	O
Campylobacter	B-bacteria
rectus	I-bacteria
(	O
35	O
%	O
)	O
,	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
(	O
35	O
%	O
)	O
and	O
Streptococcus	B-bacteria
oralis	I-bacteria
(	O
34	O
%	O
)	O
.	O

Species	O
of	O
Actinomyces	B-bacteria
were	O
found	O
in	O
low	O
prevalence	O
and	O
levels	O
.	O

The	O
data	O
indicated	O
that	O
there	O
were	O
more	O
micro	O
-	O
organisms	O
on	O
or	O
in	O
epithelial	O
cells	O
obtained	O
from	O
periodontal	O
pockets	O
than	O
from	O
healthy	O
sulci	O
;	O
however	O
,	O
no	O
significant	O
differences	O
regarding	O
the	O
percentage	O
and	O
level	O
of	O
any	O
specific	O
species	O
were	O
found	O
between	O
these	O
sites	O
.	O

Veillonella	B-bacteria
parvula	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
,	O
Streptococcus	B-bacteria
gordonii	I-bacteria
and	O
Streptococcus	B-bacteria
mitis	I-bacteria
tended	O
to	O
be	O
more	O
prevalent	O
in	O
sites	O
without	O
disease	O
.	O

These	O
findings	O
demonstrated	O
that	O
a	O
wide	O
range	O
of	O
oral	O
species	O
may	O
be	O
detected	O
on	O
or	O
in	O
crevicular	O
epithelial	O
cells	O
from	O
sites	O
with	O
periodontitis	O
and	O
from	O
periodontally	O
healthy	O
sulci	O
.	O

Seven	O
strains	O
of	O
anaerobic	O
Gram	O
-	O
positive	O
cocci	O
isolated	O
from	O
human	O
oral	O
sites	O
were	O
subjected	O
to	O
a	O
comprehensive	O
range	O
of	O
phenotypic	O
and	O
genotypic	O
tests	O
.	O

16S	O
rRNA	O
gene	O
sequence	O
analysis	O
revealed	O
that	O
the	O
strains	O
constituted	O
a	O
homogeneous	O
group	O
that	O
was	O
distinct	O
from	O
species	O
with	O
validly	O
published	O
names	O
,	O
but	O
related	O
to	O
Peptostreptococcus	B-bacteria
anaerobius	I-bacteria
.	O

All	O
oral	O
strains	O
tested	O
belonged	O
to	O
this	O
group	O
,	O
whereas	O
all	O
non	O
-	O
oral	O
strains	O
studied	O
were	O
confirmed	O
as	O
P	B-bacteria
.	I-bacteria
anaerobius	I-bacteria
.	O

A	O
novel	O
species	O
,	O
Peptostreptococcus	B-bacteria
stomatis	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
is	O
proposed	O
to	O
accommodate	O
these	O
oral	O
strains	O
.	O

P	B-bacteria
.	I-bacteria
stomatis	I-bacteria
is	O
weakly	O
saccharolytic	O
and	O
produces	O
acetic	O
,	O
butyric	O
,	O
isobutyric	O
,	O
isovaleric	O
and	O
isocaproic	O
acids	O
as	O
end	O
products	O
of	O
fermentation	O
.	O

The	O
type	O
strain	O
of	O
P	B-bacteria
.	I-bacteria
stomatis	I-bacteria
is	O
W2278T	B-bacteria
(	O
=	O
DSM	B-bacteria
17678T	I-bacteria
=	O
CCUG	B-bacteria
51858T	I-bacteria
)	O
;	O
the	O
G	O
+	O
C	O
content	O
of	O
the	O
DNA	O
of	O
this	O
strain	O
is	O
36	O
mol	O
%	O
.	O

Intrauterine	O
infection	O
is	O
a	O
recognized	O
cause	O
of	O
preterm	O
birth	O
.	O

The	O
infectious	O
organisms	O
are	O
believed	O
to	O
originate	O
primarily	O
from	O
the	O
vaginal	O
tract	O
and	O
secondarily	O
from	O
other	O
parts	O
of	O
the	O
body	O
.	O

It	O
is	O
plausible	O
that	O
microbes	O
in	O
the	O
oral	O
cavity	O
can	O
be	O
transmitted	O
to	O
the	O
pregnant	O
uterus	O
.	O

However	O
,	O
direct	O
evidence	O
supporting	O
such	O
a	O
transmission	O
is	O
lacking	O
.	O

In	O
this	O
study	O
,	O
amniotic	O
fluids	O
of	O
34	O
pregnant	O
women	O
were	O
examined	O
by	O
PCR	O
using	O
16S	O
and	O
23S	O
rRNA	O
universally	O
conserved	O
primers	O
.	O

Bacterial	O
DNA	O
was	O
amplified	O
from	O
the	O
only	O
patient	O
with	O
clinical	O
intrauterine	O
infection	O
and	O
histologic	O
necrotizing	O
acute	O
and	O
chronic	O
chorioamnionitis	O
.	O

One	O
strain	O
,	O
Bergeyella	B-bacteria
sp	I-bacteria
.	I-bacteria
clone	I-bacteria
AF14	I-bacteria
,	O
was	O
detected	O
and	O
was	O
99	O
.	O
7	O
%	O
identical	O
to	O
a	O
previously	O
reported	O
uncultivated	O
oral	O
Bergeyella	B-bacteria
strain	I-bacteria
,	O
clone	B-bacteria
AK152	I-bacteria
,	O
at	O
the	O
16S	O
rRNA	O
level	O
.	O

The	O
same	O
strain	O
was	O
detected	O
in	O
the	O
subgingival	O
plaque	O
of	O
the	O
patient	O
but	O
not	O
in	O
her	O
vaginal	O
tract	O
.	O

The	O
16S	O
-	O
23S	O
rRNA	O
sequence	O
of	O
clone	O
AF14	O
matched	O
exactly	O
with	O
the	O
sequences	O
amplified	O
from	O
the	O
patient	O
'	O
s	O
subgingival	O
plaque	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
Bergeyella	B-bacteria
strain	I-bacteria
identified	O
in	O
the	O
patient	O
'	O
s	O
intrauterine	O
infection	O
originated	O
from	O
the	O
oral	O
cavity	O
.	O

This	O
is	O
the	O
first	O
direct	O
evidence	O
of	O
oral	O
-	O
utero	O
microbial	O
transmission	O
.	O

The	O
patient	O
'	O
s	O
periodontal	O
health	O
during	O
pregnancy	O
was	O
unclear	O
.	O

She	O
did	O
not	O
have	O
detectable	O
periodontal	O
disease	O
during	O
postpartum	O
examination	O
.	O

Bergeyella	B-bacteria
spp	I-bacteria
.	I-bacteria
had	O
not	O
been	O
previously	O
associated	O
with	O
preterm	O
birth	O
and	O
were	O
detected	O
in	O
subgingival	O
plaque	O
of	O
women	O
without	O
clinical	O
levels	O
of	O
intrauterine	O
infection	O
.	O

Uncultivated	O
species	O
may	O
be	O
overlooked	O
opportunistic	O
pathogens	O
in	O
preterm	O
birth	O
.	O

This	O
study	O
sheds	O
new	O
light	O
on	O
the	O
implication	O
of	O
oral	O
bacteria	O
in	O
preterm	O
birth	O
.	O

The	O
initial	O
microbial	O
colonization	O
of	O
tooth	O
surfaces	O
is	O
a	O
repeatable	O
and	O
selective	O
process	O
,	O
with	O
certain	O
bacterial	O
species	O
predominating	O
in	O
the	O
nascent	O
biofilm	O
.	O

Characterization	O
of	O
the	O
initial	O
microflora	O
is	O
the	O
first	O
step	O
in	O
understanding	O
interactions	O
among	O
community	O
members	O
that	O
shape	O
ensuing	O
biofilm	O
development	O
.	O

Using	O
molecular	O
methods	O
and	O
a	O
retrievable	O
enamel	O
chip	O
model	O
,	O
we	O
characterized	O
the	O
microbial	O
diversity	O
of	O
early	O
dental	O
biofilms	O
in	O
three	O
subjects	O
.	O

A	O
total	O
of	O
531	O
16S	O
rRNA	O
gene	O
sequences	O
were	O
analyzed	O
,	O
and	O
97	O
distinct	O
phylotypes	O
were	O
identified	O
.	O

Microbial	O
community	O
composition	O
was	O
shown	O
to	O
be	O
statistically	O
different	O
among	O
subjects	O
.	O

In	O
all	O
subjects	O
,	O
however	O
,	O
4	O
-	O
h	O
and	O
8	O
-	O
h	O
communities	O
were	O
dominated	O
by	O
Streptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
belonging	O
to	O
the	O
Streptococcus	B-bacteria
oralis	I-bacteria
/	O
Streptococcus	B-bacteria
mitis	I-bacteria
group	O
.	O

Other	O
frequently	O
observed	O
genera	O
(	O
comprising	O
at	O
least	O
5	O
%	O
of	O
clone	O
sequences	O
in	O
at	O
least	O
one	O
of	O
the	O
six	O
clone	O
libraries	O
)	O
were	O
Actinomyces	B-bacteria
,	O
Gemella	B-bacteria
,	O
Granulicatella	B-bacteria
,	O
Neisseria	B-bacteria
,	O
Prevotella	B-bacteria
,	O
Rothia	B-bacteria
,	O
and	O
Veillonella	B-bacteria
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
confirmed	O
that	O
the	O
proportion	O
of	O
Streptococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
sequences	O
in	O
the	O
clone	O
libraries	O
coincided	O
with	O
the	O
proportion	O
of	O
streptococcus	B-bacteria
probe	O
-	O
positive	O
organisms	O
on	O
the	O
chip	O
.	O

FISH	O
also	O
revealed	O
that	O
,	O
in	O
the	O
undisturbed	O
plaque	O
,	O
not	O
only	O
Streptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
but	O
also	O
the	O
rarer	O
Prevotella	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
usually	O
seen	O
in	O
small	O
multigeneric	O
clusters	O
of	O
cells	O
.	O

This	O
study	O
shows	O
that	O
the	O
initial	O
dental	O
plaque	O
community	O
of	O
each	O
subject	O
is	O
unique	O
in	O
terms	O
of	O
diversity	O
and	O
composition	O
.	O

Repetitive	O
and	O
distinctive	O
community	O
composition	O
within	O
subjects	O
suggests	O
that	O
the	O
spatiotemporal	O
interactions	O
and	O
ecological	O
shifts	O
that	O
accompany	O
biofilm	O
maturation	O
also	O
occur	O
in	O
a	O
subject	O
-	O
dependent	O
manner	O
.	O

Streptococcus	B-bacteria
salivarius	I-bacteria
is	O
a	O
prominent	O
member	O
of	O
the	O
oral	O
microbiota	O
and	O
has	O
excellent	O
potential	O
for	O
use	O
as	O
a	O
probiotic	O
targeting	O
the	O
oral	O
cavity	O
.	O

In	O
this	O
report	O
we	O
document	O
safety	O
data	O
relating	O
to	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
K12	I-bacteria
,	O
including	O
assessment	O
of	O
its	O
antibiogram	O
,	O
metabolic	O
profiles	O
,	O
and	O
virulence	O
determinants	O
,	O
and	O
we	O
examine	O
the	O
microbial	O
composition	O
of	O
saliva	O
following	O
the	O
dosing	O
of	O
subjects	O
with	O
K12	B-bacteria
.	O

Ventilator	O
-	O
associated	O
pneumonia	O
(	O
VAP	O
)	O
is	O
the	O
most	O
frequently	O
occurring	O
nosocomial	O
infection	O
associated	O
with	O
increased	O
morbidity	O
and	O
mortality	O
.	O

Although	O
oral	O
decontamination	O
with	O
antibiotics	O
reduces	O
incidences	O
of	O
VAP	O
,	O
it	O
is	O
not	O
recommended	O
because	O
of	O
potential	O
selection	O
of	O
antibiotic	O
-	O
resistant	O
pathogens	O
.	O

We	O
hypothesized	O
that	O
oral	O
decontamination	O
with	O
either	O
chlorhexidine	O
(	O
CHX	O
,	O
2	O
%	O
)	O
or	O
CHX	O
/	O
colistin	O
(	O
CHX	O
/	O
COL	O
,	O
2	O
%	O
/	O
2	O
%	O
)	O
would	O
reduce	O
and	O
postpone	O
development	O
of	O
VAP	O
,	O
and	O
oral	O
and	O
endotracheal	O
colonization	O
.	O

To	O
determine	O
the	O
effect	O
of	O
oral	O
decontamination	O
with	O
CHX	O
or	O
CHX	O
/	O
COL	O
on	O
VAP	O
incidence	O
and	O
time	O
to	O
development	O
of	O
VAP	O
.	O

Consecutive	O
patients	O
needing	O
mechanical	O
ventilation	O
for	O
48	O
h	O
or	O
more	O
were	O
enrolled	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
with	O
three	O
arms	O
:	O
CHX	O
,	O
CHX	O
/	O
COL	O
,	O
and	O
placebo	O
(	O
PLAC	O
)	O
.	O

Trial	O
medication	O
was	O
applied	O
every	O
6	O
h	O
into	O
the	O
buccal	O
cavity	O
.	O

Oropharyngeal	O
swabs	O
were	O
obtained	O
daily	O
and	O
quantitatively	O
analyzed	O
for	O
gram	O
-	O
positive	O
and	O
gram	O
-	O
negative	O
microorganisms	O
.	O

Endotracheal	O
colonization	O
was	O
monitored	O
twice	O
weekly	O
.	O

Of	O
385	O
patients	O
included	O
,	O
130	O
received	O
PLAC	O
,	O
127	O
CHX	O
and	O
128	O
CHX	O
/	O
COL	O
.	O

Baseline	O
characteristics	O
were	O
comparable	O
.	O

The	O
daily	O
risk	O
of	O
VAP	O
was	O
reduced	O
in	O
both	O
treatment	O
groups	O
compared	O
with	O
PLAC	O
:	O
65	O
%	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
0	O
.	O
352	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0	O
.	O
160	O
,	O
0	O
.	O

791	O
;	O
p	O
=	O
0	O
.	O
012	O
)	O
for	O
CHX	O
and	O
55	O
%	O
(	O
HR	O
=	O
0	O
.	O
454	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
224	O
,	O
0	O
.	O

925	O
;	O
p	O
=	O
0	O
.	O
030	O
)	O
for	O
CHX	O
/	O
COL	O
.	O

CHX	O
/	O
COL	O
provided	O
significant	O
reduction	O
in	O
oropharyngeal	O
colonization	O
with	O
both	O
gram	O
-	O
negative	O
and	O
gram	O
-	O
positive	O
microorganisms	O
,	O
whereas	O
CHX	O
mostly	O
affected	O
gram	O
-	O
positive	O
microorganisms	O
.	O

Endotracheal	O
colonization	O
was	O
reduced	O
for	O
CHX	O
/	O
COL	O
patients	O
and	O
to	O
a	O
lesser	O
extent	O
for	O
CHX	O
patients	O
.	O

No	O
differences	O
in	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
intensive	O
care	O
unit	O
stay	O
,	O
or	O
intensive	O
care	O
unit	O
survival	O
could	O
be	O
demonstrated	O
.	O

Topical	O
oral	O
decontamination	O
with	O
CHX	O
or	O
CHX	O
/	O
COL	O
reduces	O
the	O
incidence	O
of	O
VAP	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
eight	O
aerobic	O
and	O
anaerobic	O
oral	O
commensal	O
bacterial	O
species	O
on	O
in	O
vitro	O
Candida	O
albicans	O
biofilm	O
development	O
.	O

A	O
single	O
isolate	O
of	O
C	O
.	O
albicans	O
2560	O
g	O
,	O
and	O
eight	O
different	O
species	O
of	O
oral	O
bacteria	O
comprising	O
,	O
Actinomyces	B-bacteria
israelii	I-bacteria
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
Prevotella	B-bacteria
nigrescens	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
,	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
and	O
Streptococcus	B-bacteria
intermedius	I-bacteria
were	O
studied	O
using	O
an	O
in	O
vitro	O
biofilm	O
assay	O
.	O

Biofilm	O
formation	O
was	O
quantified	O
in	O
terms	O
of	O
the	O
ability	O
of	O
Candida	O
to	O
grow	O
on	O
polystyrene	O
plastic	O
surfaces	O
co	O
-	O
cultured	O
with	O
the	O
foregoing	O
bacteria	O
.	O

A	O
viable	O
cell	O
count	O
was	O
used	O
to	O
quantify	O
the	O
sessile	O
yeast	O
growth	O
and	O
scanning	O
electron	O
microscopy	O
was	O
employed	O
to	O
confirm	O
and	O
visualize	O
biofilm	O
formation	O
.	O

Co	O
-	O
culture	O
with	O
differing	O
concentrations	O
of	O
bacteria	O
had	O
variable	O
effects	O
on	O
Candida	O
biofilm	O
formation	O
.	O

Co	O
-	O
culture	O
with	O
the	O
highest	O
concentrations	O
of	O
each	O
of	O
the	O
foregoing	O
bacteria	O
resulted	O
in	O
a	O
consistent	O
reduction	O
in	O
the	O
yeast	O
counts	O
in	O
the	O
candidal	O
biofilm	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
except	O
for	O
L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
and	O
,	O
S	B-bacteria
.	I-bacteria
intermedius	I-bacteria
co	O
-	O
cultures	O
.	O

Further	O
,	O
on	O
regression	O
analysis	O
a	O
significant	O
negative	O
correlation	O
between	O
the	O
co	O
-	O
culture	O
concentration	O
of	O
either	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
or	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
viable	O
yeast	O
counts	O
in	O
the	O
biofilm	O
was	O
noted	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
although	O
this	O
was	O
not	O
evident	O
for	O
the	O
other	O
bacterial	O
species	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
,	O
quantitative	O
and	O
qualitative	O
nature	O
of	O
the	O
bacteria	O
modulate	O
C	O
.	O
albicans	O
biofilm	O
formation	O
in	O
mixed	O
species	O
environments	O
such	O
as	O
the	O
oral	O
cavity	O
.	O

We	O
investigated	O
cellular	O
and	O
humoral	O
immune	O
responses	O
to	O
oral	O
biofilm	O
bacteria	O
,	O
including	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
anginosus	I-bacteria
,	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
,	O
and	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
in	O
NOD	O
/	O
SCID	O
mice	O
immunized	O
with	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
hu	O
-	O
PBMC	O
-	O
NOD	O
/	O
SCID	O
mice	O
)	O
to	O
explore	O
the	O
pathogenicity	O
of	O
each	O
of	O
those	O
organisms	O
in	O
dental	O
and	O
oral	O
inflammatory	O
diseases	O
.	O

hu	O
-	O
PBMC	O
-	O
NOD	O
/	O
SCID	O
mice	O
were	O
immunized	O
by	O
intraperitoneal	O
injections	O
with	O
the	O
whole	O
cells	O
of	O
the	O
streptococci	B-bacteria
once	O
a	O
week	O
for	O
3	O
weeks	O
.	O

FACS	O
analyses	O
were	O
used	O
to	O
determine	O
the	O
percentages	O
of	O
various	O
hu	O
-	O
T	O
cell	O
types	O
,	O
as	O
well	O
as	O
intracellular	O
cytokine	O
production	O
of	O
interleukin	O
-	O
4	O
and	O
interferon	O
-	O
gamma	O
.	O

Serum	O
IgG	O
and	O
IgM	O
antibody	O
levels	O
in	O
response	O
to	O
the	O
streptococci	B-bacteria
were	O
also	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

S	B-bacteria
.	I-bacteria
anginosus	I-bacteria
induced	O
a	O
significant	O
amount	O
of	O
the	O
proinflammatory	O
cytokine	O
interferon	O
-	O
gamma	O
in	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
in	O
comparison	O
with	O
the	O
other	O
streptococci	B-bacteria
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
differences	O
between	O
the	O
streptococci	B-bacteria
in	O
interleukin	O
-	O
4	O
production	O
by	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
after	O
inoculation	O
.	O

Further	O
,	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
significantly	O
induced	O
human	O
anti	O
-	O
S	O
.	O
mutans	O
IgG	O
,	O
IgG	O
(	O
1	O
)	O
,	O
IgG	O
(	O
2	O
)	O
,	O
and	O
IgM	O
antibodies	O
in	O
comparison	O
with	O
the	O
other	O
organisms	O
.	O

In	O
conclusion	O
,	O
S	B-bacteria
.	I-bacteria
anginosus	I-bacteria
up	O
-	O
regulated	O
Th1	O
and	O
Tc1	O
cells	O
,	O
and	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
led	O
to	O
increasing	O
levels	O
of	O
their	O
antibodies	O
,	O
which	O
was	O
associated	O
with	O
the	O
induction	O
of	O
Th2	O
cells	O
.	O

These	O
results	O
may	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
human	O
lymphocyte	O
interactions	O
to	O
biofilm	O
bacteria	O
,	O
along	O
with	O
their	O
impact	O
on	O
dental	O
and	O
mucosal	O
inflammatory	O
diseases	O
,	O
as	O
well	O
as	O
endocarditis	O
.	O

Oropharyngeal	O
candidiasis	O
is	O
emerging	O
as	O
a	O
serious	O
health	O
problem	O
in	O
the	O
elderly	O
as	O
well	O
as	O
other	O
chronically	O
immunosuppressed	O
patient	O
populations	O
.	O

Several	O
approaches	O
have	O
been	O
used	O
to	O
study	O
the	O
interactions	O
between	O
Candida	O
and	O
the	O
oral	O
mucosa	O
in	O
vitro	O
.	O

Recently	O
,	O
three	O
-	O
dimensional	O
organotypic	O
systems	O
of	O
the	O
oral	O
mucosa	O
have	O
been	O
developed	O
,	O
which	O
provide	O
an	O
organizational	O
complexity	O
that	O
is	O
between	O
the	O
culture	O
of	O
single	O
cell	O
types	O
and	O
organ	O
cultures	O
in	O
vivo	O
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
development	O
of	O
a	O
novel	O
three	O
-	O
dimensional	O
system	O
of	O
the	O
human	O
oral	O
mucosa	O
based	O
on	O
an	O
immortalized	O
oral	O
keratinocyte	O
cell	O
line	O
.	O

Unlike	O
the	O
commercially	O
available	O
cell	O
line	O
systems	O
,	O
this	O
system	O
also	O
contains	O
a	O
connective	O
tissue	O
cell	O
component	O
,	O
which	O
ensures	O
the	O
quality	O
and	O
resemblance	O
of	O
the	O
tissue	O
model	O
to	O
the	O
human	O
oral	O
masticatory	O
mucosa	O
and	O
submucosa	O
.	O

Using	O
a	O
panel	O
of	O
Candida	O
albicans	O
strains	O
with	O
variable	O
virulence	O
in	O
vivo	O
,	O
we	O
showed	O
that	O
the	O
extent	O
of	O
tissue	O
damage	O
,	O
fungal	O
invasion	O
and	O
host	O
inflammatory	O
response	O
in	O
this	O
system	O
was	O
proportional	O
to	O
the	O
well	O
-	O
documented	O
in	O
vivo	O
virulence	O
potential	O
of	O
these	O
strains	O
.	O

Therefore	O
,	O
this	O
investigation	O
has	O
added	O
another	O
useful	O
tool	O
in	O
the	O
study	O
of	O
host	O
pathogen	O
interactions	O
in	O
oral	O
candidiasis	O
.	O

To	O
examine	O
the	O
efficacy	O
of	O
the	O
multiple	O
Sorbarod	O
device	O
(	O
MSD	O
)	O
for	O
the	O
reproduction	O
of	O
inter	O
-	O
individual	O
variations	O
in	O
oral	O
microbiotas	O
.	O

The	O
MSD	O
supports	O
sessile	O
growth	O
on	O
parallel	O
cellulose	O
filters	O
,	O
perfused	O
with	O
artificial	O
saliva	O
.	O

This	O
enables	O
biofilms	O
(	O
BF	O
)	O
to	O
be	O
grown	O
and	O
sampled	O
,	O
together	O
with	O
released	O
cells	O
in	O
eluted	O
medium	O
(	O
perfusates	O
,	O
PAs	O
)	O
.	O

Two	O
sets	O
of	O
triplicate	O
MSDs	O
were	O
established	O
.	O

One	O
set	O
was	O
inoculated	O
using	O
fresh	O
saliva	O
from	O
three	O
separate	O
volunteers	O
;	O
the	O
second	O
set	O
was	O
inoculated	O
from	O
one	O
saliva	O
donor	O
.	O

Both	O
were	O
incubated	O
in	O
an	O
anaerobic	O
cabinet	O
.	O

BF	O
and	O
PA	O
were	O
analysed	O
at	O
24	O
-	O
h	O
intervals	O
by	O
PCR	O
-	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
of	O
16S	O
rDNA	O
.	O

Hierarchical	O
dendrograms	O
were	O
constructed	O
in	O
order	O
to	O
sort	O
community	O
fingerprints	O
over	O
time	O
,	O
based	O
on	O
community	O
relatedness	O
.	O

The	O
MSD	O
supported	O
complex	O
oral	O
communities	O
,	O
as	O
evidenced	O
by	O
DGGE	O
(	O
>	O
20	O
distinct	O
DGGE	O
bands	O
)	O
and	O
confocal	O
scanning	O
laser	O
microscopy	O
.	O

DGGE	O
band	O
sequencing	O
revealed	O
bacteriological	O
diversity	O
and	O
a	O
high	O
incidence	O
of	O
anaerobic	O
species	O
,	O
including	O
Prevotella	B-bacteria
sp	I-bacteria
.	O

Dendrograms	O
demonstrated	O
marked	O
inter	O
-	O
individual	O
variation	O
in	O
the	O
relative	O
species	O
abundance	O
within	O
salivary	O
inocula	O
from	O
different	O
volunteers	O
(	O
DV	O
)	O
and	O
each	O
associated	O
MSD	O
(	O
all	O
>	O
45	O
%	O
,	O
majority	O
c	O
.	O
85	O
%	O
concordance	O
)	O
.	O

Less	O
variation	O
was	O
shown	O
between	O
triplicate	O
models	O
established	O
using	O
saliva	O
from	O
a	O
single	O
volunteer	O
(	O
SV	O
)	O
(	O
all	O
>	O
58	O
%	O
;	O
majority	O
c	O
.	O
95	O
%	O
concordance	O
)	O
.	O

PAs	O
clustered	O
together	O
with	O
the	O
associated	O
biofilms	O
and	O
inocula	O
in	O
the	O
majority	O
of	O
cases	O
for	O
the	O
DV	O
MSDs	O
whilst	O
SV	O
MSD	O
community	O
profiles	O
clustered	O
between	O
replicate	O
MSDs	O
.	O

Data	O
indicate	O
that	O
marked	O
inter	O
-	O
individual	O
variations	O
in	O
human	O
salivary	O
composition	O
can	O
be	O
partially	O
replicated	O
in	O
individualized	O
MSD	O
microcosms	O
.	O
This	O
study	O
demonstrates	O
the	O
in	O
vitro	O
reproduction	O
of	O
individual	O
oral	O
microbiotas	O
and	O
suggests	O
that	O
taking	O
inter	O
-	O
individual	O
variability	O
into	O
account	O
will	O
increase	O
the	O
relevance	O
of	O
microcosm	O
studies	O
.	O

Triclosan	O
(	O
TCS	O
)	O
exposure	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
selects	O
for	O
tolerant	O
clones	O
,	O
mutated	O
in	O
their	O
enoyl	O
-	O
acyl	O
carrier	O
protein	O
reductase	O
(	O
FabI	O
)	O
.	O

It	O
has	O
been	O
inferred	O
that	O
this	O
phenomenon	O
is	O
widespread	O
amongst	O
bacterial	O
genera	O
and	O
might	O
be	O
associated	O
with	O
resistance	O
to	O
third	O
party	O
agents	O
.	O

Ex	O
-	O
situ	O
,	O
low	O
passage	O
isolates	O
of	O
enteric	O
,	O
human	O
axilla	O
,	O
human	O
oral	O
origin	O
and	O
bacteria	O
isolated	O
from	O
a	O
domestic	O
drain	O
,	O
together	O
with	O
selected	O
type	O
cultures	O
were	O
exposed	O
to	O
escalating	O
concentrations	O
of	O
TCS	O
over	O
10	O
passages	O
using	O
a	O
gradient	O
plate	O
technique	O
.	O

One	O
fresh	O
faecal	O
isolate	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
was	O
included	O
as	O
a	O
positive	O
control	O
.	O

TCS	O
susceptibility	O
was	O
determined	O
for	O
all	O
strains	O
before	O
and	O
after	O
exposure	O
,	O
whilst	O
enteric	O
isolates	O
were	O
additionally	O
assessed	O
for	O
susceptibility	O
towards	O
chlorhexidine	O
,	O
tetracycline	O
,	O
chloramphenicol	O
,	O
nalidixic	O
acid	O
and	O
ciprofloxacin	O
,	O
and	O
the	O
oral	O
isolates	O
towards	O
chlorhexidine	O
,	O
tetracycline	O
and	O
metronidazole	O
.	O

Triclosan	O
exposure	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
markedly	O
decreased	O
TCS	O
susceptibility	O
.	O

TCS	O
susceptibility	O
also	O
decreased	O
for	O
Klebsiella	B-bacteria
oxytoca	I-bacteria
,	O
Aranicola	B-bacteria
proteolyticus	I-bacteria
and	O
Stenotrophomonas	B-bacteria
maltophilia	I-bacteria
.	O

Susceptibility	O
of	O
the	O
remaining	O
35	O
strains	O
to	O
TCS	O
and	O
the	O
other	O
test	O
agents	O
remained	O
unchanged	O
.	O

These	O
data	O
suggest	O
that	O
selection	O
for	O
high	O
level	O
resistance	O
by	O
TCS	O
exposure	O
is	O
not	O
widespread	O
and	O
appears	O
to	O
be	O
confined	O
to	O
certain	O
enteric	O
bacteria	O
,	O
especially	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
.	O

Change	O
in	O
TCS	O
susceptibility	O
did	O
not	O
affect	O
susceptibility	O
towards	O
chemically	O
unrelated	O
antimicrobials	O
.	O

Acquired	O
high	O
-	O
level	O
TCS	O
resistance	O
is	O
not	O
a	O
widespread	O
phenomenon	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
if	O
the	O
oral	O
cavity	O
of	O
chronic	O
periodontitis	O
patients	O
can	O
harbor	O
Helicobacter	B-bacteria
pylori	I-bacteria
after	O
systemic	O
eradication	O
therapy	O
.	O

Samples	O
of	O
30	O
patients	O
(	O
15	O
with	O
gingivitis	O
and	O
15	O
with	O
chronic	O
periodontitis	O
)	O
positive	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
stomach	O
were	O
evaluated	O
.	O

Samples	O
were	O
collected	O
3	O
months	O
after	O
triple	O
systemic	O
antibiotic	O
therapy	O
from	O
saliva	O
,	O
microbiota	O
from	O
the	O
dorsum	O
of	O
the	O
tongue	O
,	O
supra	O
-	O
and	O
sub	O
-	O
gingival	O
plaque	O
as	O
well	O
as	O
gastric	O
biopsies	O
.	O

DNA	O
of	O
each	O
sample	O
was	O
extracted	O
by	O
the	O
boiling	O
method	O
and	O
used	O
as	O
a	O
template	O
in	O
polymerase	O
chain	O
reaction	O
with	O
the	O
primers	O
JW22	O
/	O
23	O
.	O

Eighteen	O
patients	O
(	O
60	O
%	O
)	O
harboured	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
their	O
mouths	O
.	O

Five	O
patients	O
(	O
16	O
.	O
6	O
%	O
)	O
were	O
positive	O
in	O
saliva	O
,	O
two	O
(	O
6	O
.	O
6	O
%	O
)	O
on	O
the	O
dorsum	O
of	O
the	O
tongue	O
,	O
nine	O
(	O
30	O
%	O
)	O
in	O
supra	O
-	O
gingival	O
plaque	O
,	O
14	O
(	O
46	O
.	O
6	O
%	O
)	O
in	O
sub	O
-	O
gingival	O
plaque	O
and	O
three	O
(	O
10	O
%	O
)	O
in	O
the	O
stomach	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
study	O
groups	O
.	O

Eradication	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
after	O
therapy	O
was	O
more	O
effective	O
for	O
the	O
stomach	O
than	O
for	O
the	O
mouth	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Mouths	O
of	O
patients	O
with	O
gingivitis	O
or	O
with	O
chronic	O
periodontitis	O
,	O
who	O
are	O
positive	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
their	O
stomachs	O
,	O
may	O
be	O
considered	O
as	O
reservoirs	O
of	O
these	O
bacteria	O
.	O

To	O
study	O
the	O
role	O
of	O
fibrinogen	O
molecule	O
in	O
the	O
pathogenesis	O
of	O
periodontal	O
diseases	O
.	O

An	O
in	O
vitro	O
cell	O
culture	O
model	O
was	O
used	O
.	O

Methyl	O
-	O
(	O
3	O
)	O
H	O
Thymidine	O
radiolabeled	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	I-bacteria
Pg	I-bacteria
)	I-bacteria
ATCC	I-bacteria
33277	I-bacteria
were	O
examined	O
for	O
their	O
ability	O
to	O
adhere	O
to	O
and	O
invade	O
the	O
confluent	O
monolayers	O
of	O
human	O
oral	O
epithelial	O
KB	O
cells	O
with	O
or	O
without	O
exogenous	O
human	O
fibrinogens	O
by	O
scintillation	O
spectrometry	O
.	O

The	O
addition	O
of	O
exogenous	O
fibrinogens	O
made	O
more	O
amount	O
of	O
and	O
higher	O
ratios	O
of	O
adhesive	O
and	O
invasive	O
Pg	B-bacteria
,	O
in	O
contrast	O
to	O
the	O
group	O
without	O
exogenous	O
fibrinogen	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

At	O
different	O
concentrations	O
of	O
exogenous	O
fibrinogen	O
,	O
the	O
amount	O
and	O
ratios	O
of	O
adhesive	O
and	O
invasive	O
Pg	B-bacteria
varied	O
significantly	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
007	O
)	O
.	O

The	O
higher	O
concentrations	O
of	O
exogenous	O
fibrinogen	O
was	O
added	O
,	O
the	O
greater	O
amount	O
and	O
ratios	O
of	O
adhesive	O
and	O
invasive	O
Pg	B-bacteria
were	O
found	O
.	O

Fibrinogen	O
promotes	O
the	O
adherence	O
of	O
Pg	B-bacteria
to	O
human	O
oral	O
epithelial	O
cells	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
periodontal	O
diseases	O
.	O

(	O
1	O
)	O
To	O
investigate	O
the	O
prevalence	O
of	O
oral	B-bacteria
streptococci	I-bacteria
(	O
OS	B-bacteria
)	O
and	O
biological	O
indicators	O
of	O
water	O
contamination	O
by	O
oral	O
fluids	O
in	O
water	O
from	O
dental	O
unit	O
water	O
lines	O
(	O
DUWs	O
)	O
by	O
detection	O
and	O
quantification	O
and	O
of	O
saprophytes	O
indigenous	O
to	O
the	O
oral	O
cavity	O
.	O

(	O
2	O
)	O
To	O
test	O
whether	O
measurement	O
of	O
the	O
total	O
cultivable	O
mesophilic	O
flora	O
(	O
TCF	O
)	O
,	O
the	O
parameter	O
commonly	O
used	O
to	O
monitor	O
water	O
quality	O
in	O
DUWs	O
,	O
is	O
an	O
effective	O
predictor	O
for	O
OS	B-bacteria
contamination	O
.	O

Survey	O
of	O
21	O
dental	O
units	O
equipped	O
with	O
antiretraction	O
devices	O
.	O

Water	O
samples	O
were	O
collected	O
from	O
air	O
-	O
water	O
syringes	O
,	O
cup	O
fillers	O
,	O
tap	O
water	O
,	O
and	O
before	O
and	O
during	O
the	O
working	O
day	O
.	O

Units	O
were	O
from	O
7	O
public	O
dental	O
offices	O
selected	O
for	O
convenience	O
from	O
among	O
those	O
in	O
proximity	O
of	O
the	O
microbiological	O
laboratory	O
.	O

For	O
detection	O
of	O
OS	B-bacteria
,	O
samples	O
were	O
plated	O
on	O
an	O
enriched	O
medium	O
,	O
to	O
revitalize	O
the	O
organisms	O
.	O

Colonies	O
were	O
subcultured	O
on	O
a	O
selective	O
medium	O
and	O
biochemically	O
identified	O
(	O
lower	O
detection	O
limit	O
,	O
1	O
cfu	O
/	O
mL	O
)	O
.	O

For	O
measurement	O
of	O
the	O
TCF	O
,	O
samples	O
were	O
plated	O
on	O
a	O
nutrient	O
-	O
poor	O
medium	O
.	O

Cultures	O
with	O
colony	O
counts	O
greater	O
than	O
200	O
cfu	O
/	O
mL	O
were	O
considered	O
to	O
be	O
TCF	O
positive	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
TCF	O
positivity	O
in	O
predicting	O
OS	B-bacteria
detection	O
was	O
calculated	O
.	O

Prevalence	O
rates	O
for	O
OS	B-bacteria
contamination	O
and	O
for	O
TCF	O
positivity	O
were	O
,	O
respectively	O
,	O
34	O
.	O
4	O
%	O
(	O
11	O
of	O
32	O
samples	O
)	O
and	O
25	O
.	O
0	O
%	O
(	O
8	O
of	O
32	O
samples	O
)	O
for	O
syringes	O
,	O
27	O
.	O
8	O
%	O
(	O
10	O
of	O
36	O
samples	O
)	O
and	O
8	O
.	O
3	O
%	O
(	O
3	O
of	O
36	O
samples	O
)	O
for	O
cup	O
fillers	O
,	O
and	O
0	O
.	O
0	O
%	O
(	O
0	O
of	O
7	O
samples	O
)	O
for	O
tap	O
water	O
.	O

OS	B-bacteria
contamination	O
levels	O
ranged	O
from	O
1	O
to	O
6	O
cfu	O
/	O
mL	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
between	O
samples	O
obtained	O
before	O
and	O
during	O
the	O
working	O
day	O
.	O

TCF	O
positivity	O
did	O
not	O
predict	O
OS	B-bacteria
contamination	O
effectively	O
,	O
because	O
of	O
low	O
sensitivity	O
.	O

Given	O
the	O
absence	O
of	O
OS	B-bacteria
in	O
tap	O
water	O
,	O
the	O
reported	O
prevalence	O
of	O
OS	B-bacteria
contamination	O
suggests	O
that	O
oral	O
fluids	O
are	O
aspirated	O
during	O
dental	O
therapy	O
with	O
relatively	O
high	O
frequency	O
and	O
that	O
DUWs	O
can	O
potentially	O
expose	O
successive	O
patients	O
to	O
bloodborne	O
cross	O
-	O
infections	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
prevalence	O
of	O
oral	O
bacteria	O
on	O
the	O
dorsum	O
of	O
the	O
tongue	O
.	O

In	O
addition	O
,	O
the	O
relationship	O
between	O
the	O
number	O
of	O
teeth	O
and	O
the	O
microflora	O
present	O
on	O
the	O
coating	O
of	O
the	O
tongue	O
in	O
a	O
population	O
of	O
85	O
-	O
year	O
-	O
old	O
people	O
was	O
assessed	O
.	O

Two	O
hundred	O
and	O
five	O
individuals	O
(	O
89	O
males	O
,	O
116	O
females	O
)	O
from	O
the	O
same	O
geographical	O
area	O
who	O
were	O
85	O
years	O
of	O
age	O
were	O
examined	O
.	O

Five	O
periodontopathic	O
bacteria	O
(	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
)	O
and	O
one	O
cariogenic	O
bacterium	O
(	O
Streptococcus	B-bacteria
mutans	I-bacteria
)	O
were	O
analysed	O
using	O
a	O
polymerase	O
chain	O
reaction	O
assay	O
of	O
tongue	O
samples	O
from	O
the	O
population	O
.	O

Periodontal	O
bacteria	O
-	O
positive	O
individuals	O
have	O
more	O
teeth	O
than	O
that	O
of	O
periodontal	O
bacteria	O
-	O
negative	O
people	O
.	O

Between	O
the	O
periodontal	O
bacteria	O
-	O
positive	O
and	O
-	O
negative	O
individuals	O
,	O
there	O
were	O
significant	O
differences	O
in	O
the	O
mean	O
number	O
of	O
teeth	O
for	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
and	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
(	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
while	O
there	O
were	O
no	O
significant	O
differences	O
for	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
(	O
p	O
=	O
0	O
.	O
998	O
)	O
or	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
(	O
p	O
=	O
0	O
.	O
147	O
)	O
.	O

A	O
wide	O
range	O
of	O
species	O
,	O
including	O
anaerobes	O
,	O
was	O
detected	O
in	O
85	O
-	O
year	O
-	O
old	O
subjects	O
.	O

It	O
was	O
found	O
that	O
the	O
detection	O
of	O
periodontal	O
bacteria	O
on	O
the	O
tongue	O
coating	O
increased	O
with	O
the	O
number	O
of	O
teeth	O
.	O

There	O
was	O
a	O
positive	O
relationship	O
between	O
the	O
tooth	O
number	O
and	O
periodontopathic	O
bacteria	O
,	O
except	O
for	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
.	O

These	O
results	O
suggest	O
that	O
tongue	O
care	O
is	O
essential	O
for	O
preventing	O
oral	O
disease	O
and	O
needs	O
to	O
be	O
part	O
of	O
any	O
oral	O
care	O
programme	O
in	O
elderly	O
people	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
emphasize	O
that	O
particular	O
stains	O
on	O
the	O
third	O
cervical	O
of	O
the	O
buccal	O
and	O
lingual	O
surfaces	O
in	O
mixed	O
dentition	O
,	O
called	O
`	O
`	O
black	O
stain	O
.	O
'	O
'	O

Previous	O
research	O
showed	O
the	O
microbiological	O
etiology	O
of	O
this	O
discoloration	O
by	O
chromogen	O
bacterias	O
.	O

Our	O
study	O
shows	O
bacteria	O
spp	O
involved	O
in	O
stains	O
by	O
means	O
of	O
PCR	O
process	O
and	O
electrophoresis	O
gel	O
on	O
the	O
agarose	O
medium	O
.	O

Sample	O
was	O
formed	O
by	O
100	O
subject	O
with	O
black	O
stain	O
and	O
100	O
control	O
subjects	O
stain	O
-	O
free	O
.	O

A	O
statistical	O
analysis	O
(	O
SPSS	O
10	O
.	O
0	O
)	O
using	O
X2	O
was	O
performed	O
in	O
this	O
study	O
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
Prevotella	B-bacteria
melaninogenica	I-bacteria
,	O
were	O
not	O
involved	O
in	O
both	O
in	O
black	O
stain	O
subjects	O
and	O
in	O
the	O
control	O
.	O

On	O
the	O
contrary	O
,	O
Actinomyces	B-bacteria
could	O
be	O
involved	O
in	O
the	O
pigmentation	O
process	O
.	O

Antimicrobial	O
peptides	O
are	O
components	O
of	O
the	O
innate	O
immunity	O
that	O
play	O
an	O
important	O
role	O
in	O
systemic	O
and	O
oral	O
health	O
.	O

The	O
antibacterial	O
activity	O
of	O
the	O
amphibian	O
-	O
derived	O
K4	O
-	O
S4	O
(	O
1	O
-	O
15	O
)	O
a	O
antimicrobial	O
peptide	O
was	O
tested	O
against	O
oral	O
pathogens	O
associated	O
with	O
caries	O
and	O
periodontitis	O
and	O
compared	O
with	O
the	O
activities	O
of	O
the	O
human	O
-	O
derived	O
antimicrobial	O
peptides	O
LL	O
-	O
37	O
and	O
dhvar4a	O
.	O

Growth	O
inhibition	O
of	O
planktonic	O
bacteria	O
was	O
tested	O
using	O
standard	O
microdilution	O
assays	O
.	O

Live	O
/	O
Dead	O
staining	O
followed	O
by	O
confocal	O
scanning	O
laser	O
microscopy	O
(	O
CSLM	O
)	O
was	O
used	O
to	O
determine	O
the	O
bactericidal	O
effect	O
of	O
K4	O
-	O
S4	O
(	O
1	O
-	O
15	O
)	O
a	O
on	O
Streptococcus	B-bacteria
mutans	I-bacteria
attached	O
to	O
a	O
glass	O
surface	O
or	O
grown	O
as	O
biofilm	O
.	O

The	O
cariogenic	O
species	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
,	O
Lactobacillus	B-bacteria
paracasei	I-bacteria
and	O
Actinomyces	B-bacteria
viscosus	I-bacteria
were	O
resistant	O
to	O
LL	O
-	O
37	O
found	O
in	O
the	O
oral	O
cavity	O
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
was	O
the	O
species	O
most	O
resistant	O
to	O
the	O
three	O
tested	O
peptides	O
.	O

K4	O
-	O
S4	O
(	O
1	O
-	O
15	O
)	O
a	O
demonstrated	O
the	O
highest	O
activity	O
against	O
the	O
tested	O
planktonic	O
bacteria	O
.	O

In	O
addition	O
,	O
K4	O
-	O
S4	O
(	O
1	O
-	O
15	O
)	O
a	O
was	O
bactericidal	O
to	O
surface	O
-	O
attached	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
as	O
well	O
as	O
to	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
biofilms	O
grown	O
in	O
vitro	O
.	O

However	O
,	O
surface	O
attachment	O
increased	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
resistance	O
to	O
the	O
antimicrobial	O
peptide	O
.	O

Our	O
results	O
support	O
growing	O
evidence	O
suggesting	O
the	O
use	O
of	O
antimicrobial	O
peptides	O
for	O
prevention	O
and	O
treatment	O
of	O
oral	O
disease	O
.	O

To	O
isolate	O
and	O
characterise	O
Streptococcus	B-bacteria
mutans	I-bacteria
from	O
Irish	O
saliva	O
samples	O
and	O
to	O
assess	O
their	O
sensitivity	O
to	O
a	O
food	O
-	O
grade	O
preparation	O
of	O
the	O
lantibiotic	O
,	O
lacticin	O
3147	O
,	O
produced	O
by	O
Lactococcus	B-bacteria
lactis	I-bacteria
DPC3147	I-bacteria
.	O

Saliva	O
samples	O
collected	O
from	O
children	O
with	O
varying	O
oral	O
health	O
status	O
were	O
screened	O
on	O
Mitis	O
Salivarius	O
agar	O
for	O
the	O
presence	O
of	O
pathogenic	O
streptococci	B-bacteria
.	O

Following	O
selective	O
plating	O
,	O
16S	O
rDNA	O
sequencing	O
and	O
Pulsed	O
Field	O
Gel	O
Electrophoresis	O
(	O
PFGE	O
)	O
,	O
15	O
distinct	O
strains	O
of	O
Strep	B-bacteria
.	I-bacteria
mutans	I-bacteria
were	O
identified	O
.	O

These	O
were	O
grouped	O
according	O
to	O
their	O
relative	O
sensitivity	O
to	O
lacticin	O
3147	O
which	O
ranged	O
from	O
0	O
.	O
78	O
to	O
6	O
.	O
25	O
%	O
;	O
relative	O
to	O
a	O
sensitive	O
indicator	O
strain	O
,	O
Lactococcus	B-bacteria
lactis	I-bacteria
ssp	I-bacteria
.	I-bacteria
lactis	I-bacteria
HP	I-bacteria
.	O

Inhibition	O
of	O
indicator	O
Strep	B-bacteria
.	I-bacteria
mutans	I-bacteria
strains	I-bacteria
from	O
sensitive	O
,	O
intermediate	O
and	O
tolerant	O
groupings	O
were	O
assessed	O
in	O
microtitre	O
plate	O
assays	O
with	O
increasing	O
concentrations	O
of	O
lacticin	O
3147	O
.	O

The	O
concentration	O
of	O
lacticin	O
3147	O
required	O
to	O
give	O
50	O
%	O
growth	O
inhibition	O
correlated	O
with	O
their	O
relative	O
sensitivities	O
(	O
as	O
assayed	O
by	O
well	O
diffusion	O
methodology	O
)	O
and	O
ranged	O
from	O
1280	O
to	O
5120	O
AU	O
ml	O
(	O
-	O
1	O
)	O
.	O

Concentrated	O
preparations	O
of	O
lacticin	O
3147	O
caused	O
a	O
rapid	O
killing	O
of	O
Strep	B-bacteria
.	I-bacteria
mutans	I-bacteria
strains	I-bacteria
in	O
broth	O
.	O

Moreover	O
,	O
in	O
human	O
saliva	O
deliberately	O
spiked	O
with	O
Strep	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
the	O
pathogenic	O
was	O
eliminated	O
(	O
initial	O
inoculum	O
of	O
10	O
(	O
5	O
)	O
)	O
in	O
the	O
presence	O
of	O
40	O
,	O
000	O
AU	O
ml	O
(	O
-	O
1	O
)	O
of	O
lacticin	O
3147	O
.	O

Furthermore	O
,	O
a	O
food	O
-	O
grade	O
lacticin	O
3147	O
spray	O
dried	O
powder	O
ingredient	O
was	O
assessed	O
for	O
the	O
inhibition	O
of	O
Strep	B-bacteria
.	I-bacteria
mutans	I-bacteria
in	O
human	O
saliva	O
,	O
spiked	O
with	O
a	O
strain	O
of	O
intermediate	O
sensitivity	O
,	O
resulting	O
in	O
up	O
to	O
a	O
4	O
-	O
log	O
reduction	O
in	O
counts	O
after	O
20	O
min	O
.	O

A	O
food	O
grade	O
preparation	O
of	O
lacticin	O
3147	O
was	O
effective	O
in	O
the	O
inhibition	O
of	O
oral	O
Strep	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

The	O
inhibition	O
of	O
oral	O
streptococci	B-bacteria
by	O
food	O
grade	O
preparations	O
of	O
lacticin	O
3147	O
may	O
offer	O
novel	O
opportunities	O
for	O
the	O
development	O
of	O
lacticin	O
3147	O
as	O
an	O
anti	O
-	O
cariogenic	O
agent	O
particularly	O
in	O
the	O
area	O
of	O
functional	O
foods	O
for	O
the	O
improvement	O
of	O
oral	O
health	O
.	O

Streptococci	B-bacteria
are	O
the	O
primary	O
component	O
of	O
the	O
multispecies	O
oral	O
biofilm	O
known	O
as	O
supragingival	O
dental	O
plaque	O
;	O
they	O
grow	O
by	O
fermentation	O
of	O
sugars	O
to	O
organic	O
acids	O
,	O
e	O
.	O
g	O
.	O
,	O
lactic	O
acid	O
.	O

Veillonellae	O
,	O
a	O
ubiquitous	O
component	O
of	O
early	O
plaque	O
,	O
are	O
unable	O
to	O
use	O
sugars	O
;	O
they	O
ferment	O
organic	O
acids	O
,	O
such	O
as	O
lactate	O
,	O
to	O
a	O
mixture	O
of	O
shorter	O
-	O
chain	O
-	O
length	O
acids	O
,	O
CO	O
(	O
2	O
)	O
,	O
and	O
hydrogen	O
.	O

Certain	O
veillonellae	B-bacteria
bind	O
to	O
(	O
coaggregate	O
with	O
)	O
streptococci	B-bacteria
in	O
vitro	O
.	O

We	O
show	O
that	O
,	O
between	O
4	O
and	O
8	O
hours	O
into	O
plaque	O
development	O
,	O
the	O
dominant	O
strains	O
of	O
Veillonella	B-bacteria
change	O
in	O
their	O
phenotypic	O
characteristics	O
(	O
coaggregation	O
and	O
antibody	O
reactivity	O
)	O
as	O
well	O
as	O
in	O
their	O
genotypic	O
characteristics	O
(	O
16S	O
RNA	O
gene	O
sequences	O
as	O
well	O
as	O
strain	O
level	O
fingerprint	O
patterns	O
)	O
.	O

This	O
succession	O
is	O
coordinated	O
with	O
the	O
development	O
of	O
mixed	O
-	O
species	O
bacterial	O
colonies	O
.	O

Changes	O
in	O
community	O
structure	O
can	O
occur	O
very	O
rapidly	O
in	O
natural	O
biofilm	O
development	O
,	O
and	O
we	O
suggest	O
that	O
this	O
process	O
may	O
influence	O
evolution	O
within	O
this	O
ecosystem	O
.	O

Epithelial	O
cells	O
(	O
EC	O
)	O
have	O
an	O
important	O
role	O
in	O
the	O
constitution	O
of	O
both	O
innate	O
and	O
acquired	O
immune	O
responses	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
alterations	O
of	O
bactericidal	O
effects	O
and	O
cytokine	O
production	O
patterns	O
of	O
human	O
oral	O
epithelial	O
cells	O
(	O
OEC	O
)	O
against	O
different	O
doses	O
of	O
Streptococcus	B-bacteria
pyogenes	I-bacteria
.	O

For	O
this	O
purpose	O
,	O
OEC	O
have	O
been	O
stimulated	O
with	O
S	B-bacteria
.	I-bacteria
pyogenes	I-bacteria
with	O
an	O
effector	O
/	O
target	O
(	O
E	O
/	O
T	O
)	O
cell	O
ratio	O
of	O
1	O
/	O
1	O
,	O
1	O
/	O
100	O
,	O
1	O
/	O
1	O
.	O
000	O
and	O
1	O
/	O
10	O
.	O
000	O
,	O
and	O
bactericidal	O
effects	O
and	O
interleukin	O
(	O
IL	O
)	O
-	O
6	O
,	O
IL	O
-	O
8	O
and	O
IL	O
-	O
10	O
levels	O
were	O
detected	O
in	O
the	O
first	O
and	O
sixth	O
hours	O
of	O
incubation	O
.	O

The	O
mean	O
rates	O
of	O
bactericidal	O
effect	O
detected	O
in	O
the	O
first	O
and	O
sixth	O
hours	O
were	O
38	O
.	O
7	O
%	O
and	O
54	O
.	O
5	O
%	O
,	O
respectively	O
.	O

The	O
bactericidal	O
effects	O
observed	O
at	O
1	O
/	O
1	O
E	O
/	O
T	O
cell	O
ratio	O
in	O
the	O
first	O
hour	O
,	O
and	O
at	O
1	O
/	O
1	O
and	O
1	O
/	O
100	O
E	O
/	O
T	O
cell	O
ratio	O
in	O
the	O
the	O
sixth	O
hour	O
were	O
found	O
significantly	O
higher	O
then	O
the	O
other	O
cells	O
ratios	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Time	O
-	O
and	O
dose	O
-	O
depended	O
differences	O
were	O
detected	O
in	O
the	O
cytokine	O
responses	O
of	O
OEC	O
for	O
different	O
S	B-bacteria
.	I-bacteria
pyogenes	I-bacteria
concentrations	O
.	O

IL	O
-	O
6	O
levels	O
produced	O
by	O
stimulated	O
OEC	O
were	O
found	O
higher	O
,	O
and	O
IL	O
-	O
8	O
levels	O
were	O
found	O
lower	O
then	O
the	O
levels	O
which	O
were	O
produced	O
by	O
unstimulated	O
OEC	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
respectively	O
)	O
in	O
the	O
first	O
hour	O
,	O
while	O
there	O
were	O
no	O
change	O
in	O
IL	O
-	O
10	O
levels	O
after	O
stimulation	O
with	O
different	O
bacterial	O
concentrations	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

At	O
the	O
sixth	O
hour	O
there	O
were	O
no	O
differences	O
in	O
the	O
IL	O
-	O
6	O
levels	O
produced	O
by	O
stimulated	O
and	O
unstimulated	O
cells	O
,	O
while	O
the	O
levels	O
of	O
IL	O
-	O
8	O
produced	O
by	O
stimulated	O
cells	O
were	O
found	O
lower	O
then	O
the	O
levels	O
produced	O
by	O
unstimulated	O
cells	O
in	O
the	O
E	O
/	O
T	O
cell	O
ratio	O
of	O
1	O
/	O
100	O
,	O
1	O
/	O
1000	O
and	O
1	O
/	O
10	O
.	O
000	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

Nevertheless	O
IL	O
-	O
10	O
levels	O
in	O
the	O
E	O
/	O
T	O
cell	O
ratio	O
of	O
1	O
/	O
100	O
and	O
1	O
/	O
1	O
.	O
000	O
were	O
statistically	O
higher	O
then	O
the	O
levels	O
produced	O
by	O
unstimulated	O
cells	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

As	O
a	O
result	O
OEC	O
stimulated	O
with	O
S	B-bacteria
.	I-bacteria
pyogenes	I-bacteria
showed	O
dose	O
dependent	O
manner	O
in	O
bactericidal	O
effect	O
and	O
cytokine	O
production	O
.	O

It	O
is	O
suggested	O
that	O
epithelial	O
cells	O
stimulation	O
with	O
different	O
doses	O
of	O
antigen	O
contributed	O
to	O
the	O
immune	O
system	O
activation	O
or	O
tolerance	O
.	O

Benzimidazoles	O
are	O
widely	O
used	O
as	O
proton	O
-	O
pump	O
inhibitors	O
to	O
control	O
stomach	O
hyperacidity	O
and	O
have	O
been	O
found	O
also	O
to	O
have	O
antimicrobial	O
actions	O
against	O
Helicobacter	B-bacteria
pylori	I-bacteria
and	O
oral	O
streptococci	B-bacteria
.	O

Our	O
primary	O
aim	O
was	O
to	O
determine	O
if	O
they	O
are	O
active	O
also	O
against	O
oral	O
anaerobes	O
associated	O
with	O
gingivitis	O
.	O

Our	O
major	O
focus	O
was	O
on	O
catabolism	O
because	O
it	O
leads	O
to	O
production	O
of	O
inflammatory	O
metabolites	O
such	O
as	O
butyrate	O
and	O
ammonia	O
.	O

The	O
benzimidazoles	O
are	O
effective	O
in	O
the	O
protonated	O
form	O
at	O
acid	O
pH	O
values	O
and	O
cause	O
irreversible	O
inhibition	O
of	O
enzymes	O
associated	O
with	O
formation	O
of	O
drug	O
-	O
target	O
disulfide	O
bonds	O
.	O

Fusobacterium	B-bacteria
nucleatum	I-bacteria
ATCC	I-bacteria
25586	I-bacteria
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
ATCC	I-bacteria
25611	I-bacteria
were	O
grown	O
anaerobically	O
in	O
suspension	O
cultures	O
,	O
harvested	O
,	O
washed	O
and	O
exposed	O
to	O
the	O
benzimidazole	O
lansoprazole	O
at	O
pH	O
values	O
of	O
4	O
or	O
5	O
before	O
being	O
washed	O
and	O
used	O
for	O
standard	O
assays	O
to	O
detect	O
inhibition	O
of	O
catabolic	O
functions	O
,	O
uptake	O
of	O
the	O
agent	O
and	O
lethality	O
.	O

Lansoprazole	O
was	O
found	O
to	O
be	O
a	O
bacteriostatic	O
,	O
multi	O
-	O
target	O
antimicrobial	O
against	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
under	O
anaerobic	O
conditions	O
inhibitory	O
for	O
amino	O
acid	O
fermentation	O
and	O
also	O
for	O
glycolysis	O
of	O
glucose	O
or	O
fructose	O
.	O

ID	O
(	O
50	O
)	O
values	O
for	O
fermentation	O
of	O
amino	O
acids	O
and	O
dipeptides	O
by	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
ranged	O
from	O
0	O
.	O
05	O
mM	O
for	O
lysine	O
to	O
0	O
.	O
25	O
mM	O
for	O
serine	O
.	O

Fructose	O
catabolism	O
was	O
highly	O
sensitive	O
with	O
an	O
ID	O
(	O
50	O
)	O
value	O
of	O
0	O
.	O
03	O
mM	O
apparently	O
related	O
to	O
high	O
sensitivity	O
of	O
the	O
phosphoenolpyruvate	O
:	O
fructose	O
phosphotransferase	O
system	O
,	O
while	O
the	O
ID	O
(	O
50	O
)	O
for	O
glucose	O
catabolism	O
by	O
intact	O
cells	O
was	O
some	O
0	O
.	O
07	O
mM	O
.	O

Fermentation	O
of	O
aspartate	O
or	O
aspartylaspartate	O
by	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
was	O
found	O
to	O
be	O
lansoprazole	O
-	O
sensitive	O
with	O
ID	O
(	O
50	O
)	O
values	O
of	O
about	O
0	O
.	O
18	O
and	O
0	O
.	O
20	O
mM	O
,	O
respectively	O
.	O

Catabolism	O
of	O
amino	O
acids	O
,	O
dipeptides	O
and	O
sugars	O
by	O
oral	O
anaerobes	O
associated	O
with	O
gingivitis	O
are	O
sensitive	O
to	O
the	O
inhibitory	O
actions	O
of	O
lansoprazole	O
.	O

Thus	O
,	O
catabolic	O
pathways	O
are	O
potential	O
targets	O
for	O
use	O
of	O
benzimidazoles	O
against	O
bacteria	O
involved	O
in	O
gingivitis	O
.	O

Most	O
infections	O
of	O
the	O
oral	O
cavity	O
,	O
including	O
the	O
major	O
dental	O
diseases	O
caries	O
and	O
periodontitis	O
,	O
are	O
opportunistic	O
in	O
nature	O
.	O

They	O
are	O
caused	O
or	O
maintained	O
by	O
microorganisms	O
of	O
the	O
resident	O
or	O
transient	O
flora	O
normally	O
present	O
in	O
low	O
numbers	O
and	O
not	O
pathogenic	O
,	O
but	O
in	O
certain	O
circumstances	O
develop	O
infections	O
.	O

Mucosal	O
infections	O
have	O
some	O
degree	O
of	O
specificity	O
[	O
e	O
.	O
g	O
.	O

Candida	O
spp	O
.	O
,	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
and	O
enterics	B-bacteria
]	O
and	O
a	O
microbiological	O
test	O
can	O
be	O
interpreted	O
accurately	O
for	O
clinical	O
diagnosis	O
and	O
choice	O
of	O
treatment	O
.	O

Subepithelial	O
or	O
deep	O
infections	O
,	O
however	O
,	O
include	O
a	O
number	O
of	O
species	O
from	O
the	O
resident	O
flora	O
,	O
mainly	O
anaerobes	O
whose	O
role	O
in	O
the	O
infections	O
is	O
difficult	O
to	O
interpret	O
.	O

However	O
,	O
microbiological	O
tests	O
and	O
the	O
presence	O
of	O
certain	O
bacterial	O
species	O
could	O
be	O
used	O
for	O
treatment	O
control	O
,	O
risk	O
-	O
evaluation	O
and	O
even	O
for	O
patient	O
motivation	O
in	O
the	O
prevention	O
of	O
these	O
diseases	O
.	O

Microbiological	O
diagnosis	O
can	O
be	O
used	O
in	O
general	O
practice	O
for	O
several	O
purposes	O
and	O
in	O
various	O
situations	O
that	O
can	O
be	O
of	O
great	O
value	O
for	O
the	O
dental	O
patient	O
.	O

Carbohydrate	O
antigen	O
detection	O
,	O
nucleic	O
acid	O
probe	O
detection	O
,	O
and	O
bacterial	O
culture	O
are	O
commonly	O
used	O
to	O
confirm	O
group	B-bacteria
A	I-bacteria
streptococcus	I-bacteria
(	O
GAS	B-bacteria
)	O
pharyngitis	O
.	O

Compared	O
to	O
standard	O
throat	O
swab	O
specimens	O
,	O
the	O
sensitivities	O
of	O
these	O
tests	O
with	O
mouth	O
specimens	O
are	O
poor	O
.	O

When	O
testing	O
for	O
GAS	B-bacteria
pharyngitis	O
,	O
the	O
throat	O
remains	O
the	O
optimum	O
site	O
for	O
sampling	O
.	O

Tetracycline	O
resistance	O
is	O
commonly	O
found	O
in	O
endodontic	O
bacteria	O
.	O

One	O
of	O
the	O
most	O
common	O
tetracycline	O
-	O
resistance	O
genes	O
is	O
tet	O
(	O
M	O
)	O
,	O
which	O
is	O
often	O
encoded	O
on	O
the	O
broad	O
-	O
host	O
-	O
range	O
conjugative	O
transposon	O
Tn916	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
whether	O
tet	O
(	O
M	O
)	O
was	O
present	O
in	O
bacteria	O
isolated	O
from	O
endodontic	O
patients	O
at	O
the	O
Eastman	O
Dental	O
Institute	O
and	O
whether	O
this	O
gene	O
was	O
carried	O
on	O
the	O
transferable	O
conjugative	O
transposon	O
Tn916	O
.	O

The	O
cultivable	O
microflora	O
isolated	O
from	O
15	O
endodontic	O
patients	O
was	O
screened	O
for	O
resistance	O
to	O
tetracycline	O
.	O

Polymerase	O
chain	O
reactions	O
for	O
tet	O
(	O
M	O
)	O
and	O
for	O
unique	O
regions	O
of	O
Tn916	O
were	O
carried	O
out	O
on	O
the	O
DNA	O
of	O
all	O
tetracycline	O
-	O
resistant	O
bacteria	O
.	O

Filter	O
-	O
mating	O
experiments	O
were	O
used	O
to	O
see	O
if	O
transfer	O
of	O
any	O
Tn916	O
-	O
like	O
elements	O
could	O
occur	O
.	O

Eight	O
out	O
of	O
15	O
tetracycline	O
-	O
resistant	O
bacteria	O
isolated	O
were	O
shown	O
to	O
possess	O
tet	O
(	O
M	O
)	O
.	O

Furthermore	O
,	O
four	O
of	O
these	O
eight	O
were	O
shown	O
to	O
possess	O
the	O
Tn916	O
-	O
unique	O
regions	O
linked	O
to	O
the	O
tet	O
(	O
M	O
)	O
gene	O
.	O

Transfer	O
experiments	O
demonstrated	O
that	O
a	O
Neisseria	B-bacteria
sp	I-bacteria
.	I-bacteria
donor	O
could	O
transfer	O
an	O
extremely	O
unstable	O
Tn916	O
-	O
like	O
element	O
to	O
Enterococcus	B-bacteria
faecalis	I-bacteria
.	O

The	O
tet	O
(	O
M	O
)	O
gene	O
is	O
present	O
in	O
the	O
majority	O
of	O
tetracycline	O
-	O
resistant	O
bacteria	O
isolated	O
in	O
this	O
study	O
and	O
the	O
conjugative	O
transposon	O
Tn916	O
has	O
been	O
shown	O
to	O
be	O
responsible	O
for	O
the	O
support	O
and	O
transfer	O
of	O
this	O
gene	O
in	O
some	O
of	O
the	O
bacteria	O
isolated	O
.	O

Opportunistic	O
infections	O
in	O
the	O
oral	O
cavity	O
of	O
the	O
elderly	O
may	O
increase	O
the	O
incidence	O
of	O
systemic	O
disease	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
differences	O
in	O
the	O
oral	O
bacterial	O
flora	O
between	O
dependent	O
elderly	O
(	O
inpatients	O
)	O
and	O
independent	O
elderly	O
(	O
community	O
-	O
dwelling	O
residents	O
)	O
.	O

After	O
multiple	O
variables	O
were	O
taken	O
into	O
account	O
,	O
inpatients	O
had	O
significantly	O
lower	O
detection	O
rates	O
than	O
community	O
-	O
dwelling	O
residents	O
for	O
alpha	B-bacteria
-	I-bacteria
streptococci	I-bacteria
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
Neisseria	B-bacteria
(	O
p	O
0	O
.	O
004	O
)	O
,	O
and	O
higher	O
detection	O
rates	O
for	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
(	O
p	O
0	O
.	O
024	O
)	O
,	O
methicillin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Staphylococcus	I-bacteria
aureus	I-bacteria
(	O
MRSA	B-bacteria
)	O
(	O
p	O
0	O
.	O
011	O
)	O
and	O
Actinomyces	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
p	O
0	O
.	O
005	O
)	O
.	O

Among	O
inpatients	O
,	O
the	O
requirement	O
for	O
a	O
high	O
degree	O
of	O
care	O
was	O
related	O
negatively	O
to	O
detection	O
of	O
alpha	B-bacteria
-	I-bacteria
streptococci	I-bacteria
,	O
but	O
was	O
related	O
significantly	O
to	O
detection	O
of	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
(	O
p	O
0	O
.	O
018	O
)	O
or	O
MRSA	B-bacteria
(	O
p	O
0	O
.	O
004	O
)	O
.	O

Tube	O
-	O
fed	O
inpatients	O
had	O
a	O
significantly	O
lower	O
detection	O
rate	O
for	O
alpha	B-bacteria
-	I-bacteria
streptococci	I-bacteria
(	O
p	O
0	O
.	O
041	O
)	O
and	O
a	O
higher	O
detection	O
rate	O
for	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
(	O
p	O
0	O
.	O
004	O
)	O
than	O
those	O
who	O
did	O
not	O
require	O
tube	O
feeding	O
.	O

Inpatients	O
with	O
a	O
history	O
of	O
antibiotic	O
use	O
had	O
a	O
significantly	O
lower	O
detection	O
rate	O
for	O
alpha	B-bacteria
-	I-bacteria
streptococci	I-bacteria
(	O
p	O
0	O
.	O
049	O
)	O
and	O
a	O
higher	O
detection	O
rate	O
for	O
MRSA	B-bacteria
(	O
p	O
0	O
.	O
007	O
)	O
than	O
those	O
without	O
a	O
history	O
of	O
antibiotic	O
use	O
.	O

The	O
detection	O
rates	O
for	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
or	O
MRSA	B-bacteria
in	O
inpatients	O
without	O
alpha	B-bacteria
-	I-bacteria
streptococci	I-bacteria
were	O
higher	O
than	O
in	O
inpatients	O
with	O
alpha	B-bacteria
-	I-bacteria
streptococci	I-bacteria
after	O
controlling	O
for	O
age	O
and	O
gender	O
(	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
,	O
p	O
0	O
.	O
006	O
;	O
MRSA	B-bacteria
,	O
p	O
0	O
.	O
001	O
)	O
.	O

Overall	O
,	O
detection	O
of	O
alpha	B-bacteria
-	I-bacteria
streptococci	I-bacteria
had	O
an	O
inverse	O
correlation	O
with	O
the	O
detection	O
of	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
and	O
MRSA	B-bacteria
in	O
the	O
oral	O
cavity	O
and	O
is	O
likely	O
to	O
be	O
an	O
indicator	O
of	O
pathogenic	O
bacterial	O
infection	O
.	O

Peptidoglycans	O
(	O
PGNs	O
)	O
are	O
ubiquitous	O
constituents	O
of	O
bacterial	O
cell	O
walls	O
and	O
exhibit	O
various	O
immunobiological	O
activities	O
.	O

Two	O
types	O
of	O
minimum	O
essential	O
PGN	O
structures	O
for	O
immunobiological	O
activities	O
were	O
chemically	O
synthesized	O
and	O
designated	O
as	O
muramyldipeptide	O
;	O
N	O
-	O
acetylmuramyl	O
-	O
L	O
-	O
alanyl	O
-	O
D	O
-	O
isoglutamine	O
(	O
MDP	O
)	O
and	O
gamma	O
-	O
D	O
-	O
glutamyl	O
-	O
meso	O
-	O
diaminopimelic	O
acid	O
(	O
iE	O
-	O
DAP	O
)	O
,	O
which	O
are	O
common	O
constituents	O
of	O
both	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
,	O
as	O
well	O
as	O
most	O
Gram	O
-	O
negative	O
and	O
some	O
Gram	O
-	O
positive	O
bacteria	O
,	O
respectively	O
.	O

Recently	O
,	O
intracellular	O
receptors	O
for	O
MDP	O
and	O
iE	O
-	O
DAP	O
have	O
been	O
demonstrated	O
to	O
be	O
nucleotide	O
-	O
binding	O
oligomerization	O
domain	O
(	O
NOD	O
)	O
1	O
and	O
NOD2	O
,	O
respectively	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
chemically	O
synthesized	O
meso	O
-	O
DAP	O
itself	O
activated	O
human	O
epithelial	O
cells	O
from	O
various	O
tissues	O
,	O
through	O
NOD1	O
to	O
generate	O
antibacterial	O
factors	O
,	O
PGN	O
recognition	O
proteins	O
and	O
beta	O
-	O
defensin	O
2	O
,	O
and	O
cytokines	O
in	O
specified	O
cases	O
,	O
although	O
the	O
activities	O
of	O
meso	O
-	O
DAP	O
were	O
generally	O
weaker	O
than	O
those	O
of	O
known	O
NOD	O
agonists	O
.	O

However	O
,	O
stereoisomers	O
of	O
meso	O
-	O
DAP	O
,	O
LL	O
-	O
DAP	O
,	O
and	O
DD	O
-	O
DAP	O
were	O
only	O
slightly	O
activated	O
or	O
remained	O
inactive	O
,	O
respectively	O
.	O

Synthetic	O
meso	O
-	O
lanthionine	O
,	O
which	O
is	O
another	O
diamino	O
-	O
type	O
amino	O
acid	O
specific	O
to	O
PGN	O
of	O
the	O
specified	O
Gram	O
-	O
negative	O
bacteria	O
,	O
was	O
also	O
recognized	O
by	O
NOD1	O
.	O

In	O
human	O
monocytic	O
cells	O
,	O
in	O
the	O
presence	O
of	O
cytochalasin	O
D	O
meso	O
-	O
DAP	O
induced	O
slightly	O
but	O
significantly	O
increased	O
production	O
of	O
cytokines	O
,	O
although	O
the	O
cells	O
did	O
not	O
respond	O
to	O
meso	O
-	O
DAP	O
in	O
the	O
absent	O
of	O
cytochalasin	O
D	O
.	O
Our	O
findings	O
suggest	O
that	O
NOD1	O
is	O
a	O
special	O
sentinel	O
molecule	O
,	O
especially	O
in	O
the	O
epithelial	O
barrier	O
,	O
allowing	O
the	O
intracellular	O
detection	O
of	O
bacteria	O
through	O
recognizing	O
meso	O
-	O
DAP	O
or	O
comparable	O
moiety	O
of	O
PGN	O
from	O
specified	O
bacteria	O
in	O
cooperation	O
with	O
NOD2	O
,	O
thereby	O
playing	O
a	O
key	O
role	O
in	O
innate	O
immunity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
serum	O
antibody	O
responses	O
to	O
periodontal	O
pathogens	O
after	O
single	O
-	O
visit	O
full	O
-	O
mouth	O
ultrasonic	O
debridement	O
and	O
quadrant	O
-	O
wise	O
therapy	O
.	O

Thirty	O
-	O
six	O
subjects	O
with	O
chronic	O
periodontitis	O
were	O
randomized	O
into	O
three	O
groups	O
:	O
quadrant	O
-	O
wise	O
debridement	O
in	O
four	O
visits	O
,	O
one	O
-	O
visit	O
full	O
-	O
mouth	O
debridement	O
with	O
water	O
and	O
with	O
povidone	O
iodine	O
.	O

Blood	O
samples	O
were	O
collected	O
before	O
and	O
immediately	O
after	O
treatment	O
and	O
1	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
therapy	O
.	O

Serum	O
antibody	O
titres	O
and	O
avidity	O
to	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
and	O
Treponema	B-bacteria
denticola	I-bacteria
were	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
thiocyanate	O
ELISA	O
,	O
respectively	O
.	O

IgG	O
titres	O
to	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
significantly	O
decreased	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
in	O
full	O
-	O
mouth	O
debridement	O
with	O
water	O
group	O
,	O
while	O
significant	O
reductions	O
were	O
seen	O
only	O
at	O
3	O
and	O
6	O
months	O
after	O
quadrant	O
-	O
wise	O
debridement	O
.	O

Both	O
full	O
-	O
mouth	O
groups	O
showed	O
significant	O
reduction	O
in	O
IgG	O
titres	O
to	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
at	O
3	O
and	O
6	O
months	O
.	O

Significant	O
increases	O
in	O
antibody	O
avidity	O
to	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
were	O
noted	O
3	O
months	O
following	O
full	O
-	O
mouth	O
debridement	O
with	O
povidone	O
.	O

Both	O
full	O
-	O
mouth	O
and	O
quadrant	O
treatments	O
generally	O
resulted	O
in	O
a	O
decrease	O
in	O
antibody	O
titres	O
and	O
increase	O
in	O
antibody	O
avidity	O
.	O

Full	O
-	O
mouth	O
debridement	O
induced	O
an	O
earlier	O
reduction	O
of	O
IgG	O
titre	O
to	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
than	O
quadrant	O
-	O
wise	O
therapy	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
oral	O
cavity	O
condition	O
,	O
identify	O
microorganisms	O
and	O
evaluate	O
interrelation	O
between	O
protozoans	O
,	O
bacteria	O
and	O
fungi	O
occurring	O
in	O
mouths	O
of	O
insuline	O
treated	O
diabetics	O
.	O

30	O
men	O
and	O
women	O
,	O
25	O
-	O
60	O
years	O
old	O
,	O
were	O
clinically	O
assessed	O
for	O
their	O
oral	O
cavity	O
condition	O
including	O
pH	O
range	O
.	O

Fifteen	O
of	O
them	O
were	O
the	O
insuline	O
treated	O
diabetics	O
.	O

Swabs	O
taken	O
of	O
different	O
sites	O
of	O
periodontium	O
,	O
dental	O
plaques	O
and	O
dental	O
pockets	O
collected	O
from	O
each	O
patients	O
were	O
used	O
for	O
detection	O
and	O
identification	O
of	O
protozoans	O
,	O
bacteria	O
and	O
fungi	O
.	O

Mucosal	O
inflammation	O
,	O
dental	O
caries	O
,	O
loose	O
teeth	O
,	O
periodontitis	O
were	O
observed	O
in	O
the	O
diabetic	O
patients	O
,	O
whereas	O
the	O
oral	O
cavities	O
were	O
generally	O
in	O
better	O
condition	O
in	O
the	O
control	O
patients	O
.	O

Prevalence	O
of	O
the	O
protozoan	O
parasites	O
Entamoeba	O
gingivalis	O
and	O
Trichomonas	O
tenax	O
was	O
higher	O
in	O
the	O
control	O
patients	O
than	O
in	O
the	O
diabetics	O
(	O
26	O
.	O
6	O
%	O
and	O
13	O
.	O
3	O
%	O
,	O
respectively	O
)	O
.	O

Fecal	O
bacteria	O
Enterococcus	B-bacteria
fecalis	I-bacteria
,	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
,	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
occurred	O
with	O
significantly	O
higher	O
frequency	O
in	O
the	O
insuline	O
treated	O
patients	O
(	O
60	O
%	O
)	O
than	O
in	O
the	O
control	O
(	O
6	O
.	O
6	O
%	O
)	O
.	O

Various	O
Candida	O
albicans	O
strains	O
were	O
more	O
often	O
found	O
in	O
the	O
diabetic	O
(	O
53	O
.	O
2	O
%	O
)	O
than	O
in	O
the	O
control	O
patients	O
(	O
13	O
.	O
3	O
%	O
)	O
.	O

The	O
results	O
of	O
our	O
studies	O
show	O
a	O
clear	O
interrelation	O
between	O
alteration	O
of	O
oral	O
health	O
and	O
the	O
occurrence	O
of	O
microorganisms	O
in	O
the	O
insuline	O
treated	O
diabetics	O
.	O

Metabolic	O
disease	O
that	O
causes	O
serious	O
multi	O
-	O
organ	O
disturbances	O
as	O
well	O
as	O
insulinotherapy	O
are	O
the	O
very	O
important	O
factors	O
changing	O
oral	O
cavity	O
ecology	O
of	O
the	O
persons	O
with	O
diabetes	O
mellitus	O
;	O
decresed	O
pH	O
(	O
the	O
average	O
5	O
.	O
5	O
)	O
may	O
inhibit	O
development	O
of	O
infection	O
with	O
protozoans	O
in	O
the	O
oral	O
cavity	O
of	O
these	O
patients	O
and	O
favour	O
subclinical	O
infections	O
with	O
other	O
microorganisms	O
.	O

Thus	O
,	O
in	O
the	O
insuline	O
treated	O
diabetics	O
,	O
examination	O
of	O
mouths	O
with	O
regard	O
to	O
the	O
occurrence	O
of	O
opportunistic	O
fecal	O
bacteria	O
and	O
fungi	O
,	O
particularly	O
before	O
a	O
therapy	O
with	O
antibiotics	O
is	O
strongly	O
recommended	O
.	O

Alcohol	O
is	O
a	O
well	O
documented	O
risk	O
factor	O
for	O
upper	O
digestive	O
tract	O
cancers	O
.	O

It	O
has	O
been	O
shown	O
that	O
acetaldehyde	O
,	O
the	O
first	O
metabolite	O
of	O
ethanol	O
is	O
carcinogenic	O
.	O

The	O
role	O
of	O
microbes	O
in	O
the	O
production	O
of	O
acetaldehyde	O
to	O
the	O
oral	O
cavity	O
has	O
previously	O
been	O
described	O
in	O
several	O
studies	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
aim	O
was	O
to	O
investigate	O
the	O
capability	O
of	O
viridans	B-bacteria
group	I-bacteria
streptococci	I-bacteria
of	O
normal	O
oral	O
flora	O
to	O
produce	O
acetaldehyde	O
in	O
vitro	O
during	O
ethanol	O
incubation	O
.	O

Furthermore	O
,	O
the	O
aim	O
was	O
to	O
measure	O
the	O
alcohol	O
dehydrogenase	O
(	O
ADH	O
)	O
activity	O
of	O
the	O
bacteria	O
.	O

Eight	O
clinical	O
strains	O
and	O
eight	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
)	O
strains	O
of	O
viridans	B-bacteria
group	I-bacteria
streptococci	I-bacteria
were	O
selected	O
for	O
the	O
study	O
.	O

Bacterial	O
suspensions	O
were	O
incubated	O
in	O
two	O
different	O
ethanol	O
concentrations	O
,	O
11	O
mM	O
and	O
1100	O
mM	O
and	O
the	O
acetaldehyde	O
was	O
measured	O
by	O
gas	O
chromatography	O
.	O

ADH	O
-	O
activity	O
was	O
measured	O
by	O
using	O
a	O
sensitive	O
spectroscopy	O
.	O

The	O
results	O
show	O
significant	O
differences	O
between	O
the	O
bacterial	O
strains	O
regarding	O
acetaldehyde	O
production	O
capability	O
and	O
the	O
detected	O
ADH	O
-	O
activity	O
.	O

In	O
particular	O
,	O
clinical	O
strain	O
of	O
Streptococcus	B-bacteria
salivarius	I-bacteria
,	O
both	O
clinical	O
and	O
culture	O
collection	O
strains	O
of	O
Streptococcus	B-bacteria
intermedius	I-bacteria
and	O
culture	O
collection	O
strain	O
of	O
Streptococcus	B-bacteria
mitis	I-bacteria
produced	O
high	O
amounts	O
of	O
acetaldehyde	O
in	O
11	O
mM	O
and	O
1100	O
mM	O
ethanol	O
incubation	O
.	O

All	O
these	O
four	O
bacterial	O
strains	O
also	O
showed	O
significant	O
ADH	O
-	O
enzyme	O
activity	O
.	O

Twelve	O
other	O
strains	O
were	O
found	O
to	O
be	O
low	O
acetaldehyde	O
producers	O
.	O

Consequently	O
,	O
our	O
study	O
shows	O
that	O
viridans	B-bacteria
group	I-bacteria
streptococci	I-bacteria
may	O
play	O
a	O
role	O
in	O
metabolizing	O
ethanol	O
to	O
carcinogenic	O
acetaldehyde	O
in	O
the	O
mouth	O
.	O

The	O
observation	O
supports	O
the	O
concept	O
of	O
a	O
novel	O
mechanism	O
in	O
the	O
pathogenesis	O
of	O
oral	O
cancer	O
.	O

Twelve	O
out	O
of	O
96	O
Veillonella	B-bacteria
spp	I-bacteria
.	I-bacteria
isolated	O
from	O
oral	O
samples	O
harbored	O
tetracycline	O
resistance	O
genes	O
.	O

The	O
most	O
common	O
resistance	O
gene	O
was	O
tet	O
(	O
M	O
)	O
.	O

A	O
tet	O
(	O
M	O
)	O
-	O
positive	O
Veillonella	B-bacteria
dispar	I-bacteria
strain	I-bacteria
was	O
shown	O
to	O
transfer	O
a	O
Tn916	O
-	O
like	O
element	O
to	O
four	O
Streptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
by	O
conjugation	O
at	O
a	O
frequency	O
of	O
5	O
.	O
2	O
x	O
10	O
(	O
-	O
6	O
)	O
to	O
4	O
.	O
5	O
x	O
10	O
(	O
-	O
5	O
)	O
per	O
recipient	O
.	O

At	O
this	O
time	O
in	O
the	O
USA	O
there	O
are	O
no	O
antimicrobials	O
with	O
specific	O
indications	O
for	O
oral	O
infections	O
,	O
and	O
many	O
of	O
those	O
currently	O
used	O
have	O
limited	O
efficacy	O
against	O
oral	O
anaerobic	O
strains	O
.	O

We	O
tested	O
the	O
activity	O
of	O
azithromycin	O
against	O
a	O
broad	O
range	O
of	O
anaerobic	O
oral	O
pathogens	O
and	O
,	O
at	O
pH	O
8	O
,	O
found	O
it	O
to	O
be	O
effective	O
against	O
98	O
%	O
of	O
strains	O
,	O
including	O
all	O
fusobacteria	B-bacteria
and	O
beta	O
-	O
lactamase	O
-	O
producing	O
strains	O
of	O
Prevotella	B-bacteria
spp	I-bacteria
.	O

All	O
strains	O
of	O
Eikenella	B-bacteria
corrodens	I-bacteria
were	O
also	O
susceptible	O
to	O
azithromycin	O
but	O
resistant	O
to	O
erythromycin	O
,	O
clindamycin	O
,	O
metronidazole	O
and	O
cefalexin	O
.	O

Other	O
comparator	O
agents	O
were	O
penicillin	O
,	O
amoxicillin	O
/	O
clavulanic	O
acid	O
,	O
tetracycline	O
,	O
levofloxacin	O
and	O
ciprofloxacin	O
.	O

Minimum	O
inhibitory	O
concentrations	O
obtained	O
on	O
agar	O
adjusted	O
to	O
pH	O
8	O
were	O
generally	O
one	O
dilution	O
lower	O
than	O
those	O
obtained	O
on	O
agar	O
at	O
pH	O
7	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
infection	O
is	O
common	O
in	O
people	O
.	O

However	O
,	O
the	O
existence	O
of	O
extra	O
gastric	O
reservoirs	O
and	O
transmission	O
routes	O
remain	O
controversial	O
in	O
the	O
field	O
.	O

Because	O
the	O
oral	O
cavity	O
has	O
been	O
proposed	O
as	O
a	O
reservoir	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
,	O
a	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
dental	O
plaque	O
and	O
saliva	O
.	O

The	O
results	O
were	O
asociated	O
with	O
those	O
obtained	O
in	O
the	O
gastric	O
biopsy	O
.	O

Ninety	O
-	O
seven	O
dyspeptic	O
and	O
fifty	O
asymptomatic	O
patients	O
were	O
studied	O
and	O
samples	O
taken	O
for	O
biopsy	O
,	O
dental	O
plaque	O
and	O
saliva	O
.	O

The	O
gastric	O
biopsies	O
were	O
evaluated	O
using	O
microbiology	O
and	O
histology	O
methods	O
.	O

Cultures	O
and	O
urease	O
tests	O
were	O
carried	O
out	O
on	O
the	O
oral	O
cavity	O
samples	O
and	O
included	O
pretreatment	O
methods	O
using	O
urea	O
and	O
HCl	O
.	O

The	O
frequency	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
for	O
all	O
the	O
patients	O
evaluated	O
was	O
75	O
.	O
5	O
%	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
not	O
isolated	O
in	O
saliva	O
or	O
dental	O
plaque	O
in	O
any	O
of	O
the	O
two	O
groups	O
studied	O
with	O
or	O
without	O
sample	O
pretreatment	O
.	O

The	O
urease	O
test	O
in	O
dental	O
plaque	O
was	O
positive	O
in	O
99	O
.	O
3	O
%	O
of	O
the	O
patients	O
and	O
89	O
.	O
8	O
%	O
in	O
saliva	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
infection	O
prevalence	O
by	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
dyspeptic	O
or	O
not	O
dyspeptic	O
patients	O
.	O

The	O
obtained	O
results	O
suggest	O
that	O
the	O
methodology	O
used	O
for	O
the	O
detection	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
is	O
not	O
sufficiently	O
sensitive	O
for	O
the	O
determination	O
of	O
the	O
microorganism	O
in	O
the	O
oral	O
cavity	O
.	O

The	O
bacterial	O
division	O
Synergistes	B-bacteria
represents	O
a	O
poorly	O
characterized	O
phylotype	O
of	O
which	O
only	O
a	O
few	O
isolates	O
have	O
been	O
cultured	O
,	O
primarily	O
from	O
natural	O
environments	O
.	O

Recent	O
detection	O
of	O
Synergistes	O
-	O
like	O
sequence	O
types	O
in	O
periodontal	O
pockets	O
and	O
caries	O
lesions	O
of	O
humans	O
prompted	O
us	O
to	O
search	O
the	O
R	O
.	O
M	O
.	O
Alden	O
culture	O
collection	O
(	O
Santa	O
Monica	O
,	O
Calif	O
.	O
)	O
for	O
biochemically	O
unidentifiable	O
,	O
slow	O
-	O
growing	O
,	O
obligately	O
anaerobic	O
gram	O
-	O
negative	O
bacilli	O
.	O

Here	O
we	O
report	O
on	O
five	O
clinical	O
isolates	O
cultured	O
from	O
peritoneal	O
fluid	O
and	O
two	O
isolates	O
from	O
soft	O
-	O
tissue	O
infections	O
that	O
together	O
constitute	O
three	O
separate	O
evolutionary	O
lineages	O
within	O
the	O
phylogenetic	O
radiation	O
of	O
the	O
division	O
Synergistes	B-bacteria
.	O

One	O
of	O
these	O
clusters	O
was	O
formed	O
by	O
the	O
peritoneal	O
isolates	O
and	O
had	O
an	O
85	O
%	O
similarity	O
to	O
Synergistes	B-bacteria
jonesii	I-bacteria
,	O
the	O
first	O
described	O
Synergistes	B-bacteria
species	I-bacteria
,	O
which	O
was	O
isolated	O
from	O
the	O
rumen	O
of	O
a	O
goat	O
.	O

The	O
isolates	O
from	O
soft	O
-	O
tissue	O
infections	O
,	O
on	O
the	O
other	O
hand	O
,	O
formed	O
two	O
distinct	O
lineages	O
moderately	O
related	O
to	O
each	O
other	O
with	O
a	O
similarity	O
of	O
approximately	O
78	O
%	O
.	O

In	O
addition	O
,	O
by	O
using	O
a	O
newly	O
designed	O
16S	O
rRNA	O
gene	O
-	O
based	O
PCR	O
assay	O
with	O
intended	O
target	O
specificity	O
for	O
Synergistes	B-bacteria
,	O
we	O
found	O
that	O
the	O
dominant	O
phylotype	O
from	O
a	O
fecal	O
sample	O
was	O
nearly	O
identical	O
to	O
that	O
of	O
the	O
strains	O
obtained	O
from	O
peritonitis	O
.	O

Conversely	O
,	O
sequence	O
types	O
detected	O
in	O
periodontal	O
pockets	O
formed	O
a	O
separate	O
cluster	O
that	O
shared	O
a	O
similarity	O
of	O
only	O
80	O
%	O
with	O
the	O
soft	O
-	O
tissue	O
isolates	O
.	O

These	O
findings	O
suggest	O
a	O
high	O
diversity	O
of	O
medically	O
important	O
Synergistes	B-bacteria
clades	O
that	O
apparently	O
are	O
unique	O
to	O
individual	O
ecological	O
niches	O
in	O
the	O
human	O
body	O
.	O

In	O
conclusion	O
,	O
we	O
now	O
have	O
available	O
the	O
first	O
characterized	O
human	O
isolates	O
of	O
the	O
division	O
Synergistes	B-bacteria
which	O
are	O
colonizing	O
,	O
and	O
probably	O
infecting	O
,	O
several	O
sites	O
in	O
the	O
human	O
body	O
.	O

Malodour	O
has	O
been	O
correlated	O
with	O
the	O
concentration	O
of	O
volatile	O
sulphur	O
compounds	O
produced	O
in	O
the	O
oral	O
cavity	O
by	O
metabolic	O
activity	O
of	O
bacteria	O
colonizing	O
the	O
periodontal	O
sites	O
and	O
the	O
dorsum	O
of	O
the	O
tongue	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
detect	O
malodour	O
in	O
mouth	O
air	O
organoleptically	O
and	O
using	O
a	O
portable	O
sulphide	O
monitor	O
and	O
to	O
correlate	O
it	O
with	O
the	O
clinical	O
parameters	O
,	O
halitosis	O
linked	O
toxins	O
and	O
BANA	O
,	O
using	O
tongue	O
and	O
subgingival	O
plaque	O
samples	O
.	O

The	O
halitosis	O
grading	O
is	O
also	O
correlated	O
with	O
the	O
microbial	O
colonies	O
of	O
the	O
subgingival	O
plaque	O
sample	O
.	O

20	O
patients	O
with	O
chronic	O
periodontitis	O
with	O
5	O
-	O
7	O
mm	O
pocket	O
depth	O
,	O
radiographic	O
evidence	O
of	O
bone	O
loss	O
and	O
presence	O
of	O
oral	O
malodour	O
participated	O
in	O
this	O
study	O
.	O

Assessment	O
of	O
mouth	O
air	O
was	O
done	O
organoleptically	O
and	O
by	O
using	O
a	O
portable	O
sulphide	O
monitor	O
.	O

The	O
clinical	O
parameter	O
,	O
plaque	O
index	O
(	O
PI	O
)	O
,	O
gingival	O
index	O
(	O
GI	O
)	O
,	O
gingival	O
bleeding	O
index	O
(	O
BI	O
)	O
,	O
were	O
obtained	O
from	O
all	O
the	O
areas	O
.	O

Samples	O
for	O
BANA	O
and	O
to	O
detect	O
halitosis	O
linked	O
toxins	O
were	O
taken	O
from	O
the	O
dorsal	O
surface	O
of	O
the	O
tongue	O
and	O
periodontal	O
pockets	O
ranging	O
5	O
-	O
7	O
mm	O
.	O

Halitosis	O
related	O
microbial	O
colonies	O
were	O
identified	O
using	O
anaerobic	O
culturing	O
from	O
the	O
subgingival	O
plaque	O
.	O

The	O
scores	O
of	O
PI	O
,	O
GI	O
,	O
BI	O
and	O
sample	O
that	O
tested	O
positive	O
for	O
halitosis	O
linked	O
toxins	O
and	O
with	O
the	O
halitosis	O
grading	O
were	O
not	O
significant	O
.	O

The	O
presence	O
of	O
tongue	O
coating	O
and	O
the	O
halitosis	O
grading	O
and	O
toxin	O
levels	O
were	O
significant	O
.	O

BANA	O
has	O
shown	O
to	O
be	O
non	O
contributory	O
due	O
to	O
technical	O
problems	O
.	O

Anaerobic	O
culture	O
has	O
shown	O
to	O
identify	O
Streptococcus	B-bacteria
,	O
Bacteroides	B-bacteria
,	O
Fusobacterium	B-bacteria
,	O
Porphyromonas	B-bacteria
and	O
Prevotella	B-bacteria
colonies	O
.	O

The	O
results	O
confirmed	O
that	O
there	O
was	O
no	O
correlation	O
between	O
the	O
clinical	O
parameters	O
,	O
halitosis	O
linked	O
toxins	O
and	O
halitosis	O
grading	O
.	O

The	O
microbial	O
colonies	O
have	O
shown	O
to	O
correlate	O
with	O
the	O
presence	O
of	O
oral	O
malodour	O
.	O

The	O
degree	O
of	O
adhesion	O
and	O
colonization	O
was	O
studied	O
among	O
27	O
patients	O
with	O
generalized	O
paradontitis	O
of	O
moderate	O
severity	O
and	O
in	O
remission	O
stage	O
.	O

All	O
these	O
patients	O
had	O
different	O
material	O
teeth	O
prostheses	O
.	O

12	O
patients	O
had	O
acrylic	O
plastic	O
`	O
`	O
Ftorax	O
'	O
'	O
material	O
prostheses	O
and	O
15	O
of	O
them	O
polypropylenes	O
prostheses	O
.	O

Prostheses	O
prepared	O
from	O
acryl	O
plastic	O
were	O
intensively	O
colonized	O
by	O
stable	O
microflora	O
of	O
oral	O
cavity	O
,	O
as	O
well	O
as	O
by	O
paradontopathogens	O
,	O
whereas	O
usage	O
of	O
polypropylenes	O
prostheses	O
is	O
rather	O
effective	O
for	O
patients	O
with	O
paradontitis	O
,	O
because	O
it	O
is	O
followed	O
by	O
partial	O
recovery	O
of	O
stable	O
microflora	O
and	O
lack	O
of	O
secretion	O
of	O
parodontopathogenic	O
types	O
,	O
such	O
as	O
actynomycetes	B-bacteria
,	O
prevotellae	B-bacteria
,	O
fusobacteria	B-bacteria
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
anatomical	O
spaces	O
and	O
causative	O
micro	O
-	O
organisms	O
responsible	O
for	O
deep	O
fascial	O
space	O
head	O
and	O
neck	O
infections	O
and	O
evaluate	O
the	O
resistance	O
of	O
antibiotics	O
used	O
in	O
the	O
treatment	O
of	O
these	O
infections	O
.	O

A	O
6	O
-	O
year	O
retrospective	O
study	O
evaluated	O
hospital	O
records	O
of	O
103	O
patients	O
.	O

All	O
patients	O
in	O
this	O
study	O
underwent	O
surgical	O
incision	O
and	O
drainage	O
,	O
received	O
IV	O
antibiotics	O
,	O
and	O
had	O
culture	O
and	O
sensitivity	O
performed	O
.	O

Patient	O
demographics	O
reviewed	O
were	O
gender	O
,	O
age	O
,	O
involved	O
fascial	O
space	O
(	O
s	O
)	O
,	O
micro	O
-	O
organisms	O
identified	O
and	O
antibiotic	O
resistance	O
from	O
culture	O
and	O
sensitivity	O
testing	O
.	O

There	O
were	O
56	O
male	O
(	O
54	O
%	O
)	O
and	O
47	O
(	O
46	O
%	O
)	O
female	O
patients	O
.	O

The	O
submandibular	O
space	O
was	O
the	O
most	O
frequent	O
location	O
for	O
a	O
single	O
space	O
abscess	O
(	O
30	O
%	O
)	O
,	O
followed	O
by	O
the	O
buccal	O
space	O
(	O
27	O
.	O
5	O
%	O
)	O
and	O
the	O
lateral	O
pharyngeal	O
space	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

Sixty	O
-	O
three	O
patients	O
presented	O
with	O
multiple	O
space	O
involvement	O
,	O
totaling	O
142	O
spaces	O
involved	O
.	O

A	O
total	O
of	O
269	O
bacterial	O
strains	O
were	O
isolated	O
from	O
103	O
patients	O
.	O

The	O
bacteria	O
were	O
found	O
to	O
be	O
63	O
.	O
5	O
%	O
gram	O
-	O
positive	O
.	O

Gram	O
-	O
positive	O
cocci	O
were	O
isolated	O
57	O
.	O
7	O
%	O
of	O
specimens	O
and	O
gram	O
-	O
negative	O
rods	O
were	O
isolated	O
in	O
33	O
%	O
of	O
cultures	O
.	O

There	O
were	O
178	O
aerobes	O
(	O
65	O
.	O
7	O
%	O
)	O
and	O
91	O
anaerobes	O
(	O
34	O
.	O
3	O
%	O
)	O
isolated	O
.	O

The	O
most	O
common	O
bacteria	O
isolated	O
were	O
Viridans	B-bacteria
streptococci	I-bacteria
,	O
Provetella	B-bacteria
,	O
Staphylococci	B-bacteria
,	O
and	O
Peptostreptococcus	B-bacteria
.	O

culture	O
and	O
sensitivity	O
testing	O
were	O
reviewed	O
on	O
101	O
patients	O
.	O

Patients	O
who	O
underwent	O
surgical	O
incision	O
and	O
drainage	O
in	O
the	O
operating	O
room	O
had	O
a	O
tendency	O
for	O
involvement	O
of	O
multiple	O
space	O
abscesses	O
with	O
the	O
submandibular	O
space	O
,	O
submental	O
,	O
and	O
lateral	O
pharyngeal	O
spaces	O
effected	O
most	O
frequently	O
.	O

culture	O
and	O
sensitivity	O
testing	O
commonly	O
showed	O
greater	O
growth	O
in	O
aerobes	O
(	O
65	O
.	O
7	O
%	O
)	O
than	O
in	O
anaerobes	O
.	O

Gram	O
positive	O
cocci	O
and	O
gram	O
negative	O
rods	O
had	O
the	O
greatest	O
growth	O
percentage	O
in	O
cultures	O
.	O

The	O
aim	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
30	O
%	O
ethanolic	O
extract	O
of	O
Bulgarian	O
propolis	O
on	O
94	O
clinical	O
anaerobic	O
strains	O
.	O

The	O
strains	O
were	O
tested	O
by	O
both	O
agar	O
-	O
well	O
diffusion	O
(	O
wells	O
,	O
7	O
mm	O
diameter	O
)	O
and	O
disk	O
-	O
diffusion	O
methods	O
.	O

Only	O
15	O
%	O
of	O
Clostridium	B-bacteria
-	O
,	O
3	O
.	O
3	O
%	O
of	O
other	O
Gram	O
-	O
positive	O
-	O
and	O
9	O
.	O
1	O
%	O
of	O
Gram	O
-	O
negative	O
anaerobic	O
strains	O
were	O
not	O
inhibited	O
by	O
30	O
microL	O
propolis	O
extract	O
per	O
well	O
.	O

Propolis	O
extract	O
was	O
more	O
active	O
than	O
the	O
ethanol	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

By	O
30	O
microL	O
extract	O
per	O
well	O
,	O
mean	O
inhibitory	O
diameters	O
of	O
the	O
clostridia	B-bacteria
,	O
other	O
Gram	O
-	O
positive	O
-	O
and	O
Gram	O
-	O
negative	O
anaerobes	O
were	O
11	O
.	O
5	O
,	O
13	O
.	O
1	O
,	O
and	O
11	O
.	O
3	O
mm	O
,	O
and	O
those	O
by	O
90	O
microL	O
were	O
16	O
,	O
18	O
.	O
1	O
and	O
15	O
.	O
4	O
mm	O
,	O
respectively	O
.	O

Mean	O
inhibitory	O
diameters	O
of	O
all	O
strains	O
by	O
30	O
and	O
90	O
microL	O
ethanol	O
were	O
only	O
8	O
.	O
4	O
and	O
9	O
.	O
5	O
mm	O
.	O

By	O
30	O
microL	O
propolis	O
extract	O
per	O
well	O
,	O
inhibitory	O
diameters	O
of	O
15	O
mm	O
or	O
more	O
were	O
more	O
common	O
in	O
Gram	O
-	O
positive	O
(	O
32	O
%	O
)	O
than	O
in	O
Gram	O
-	O
negative	O
bacteria	O
(	O
13	O
.	O
6	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Moist	O
propolis	O
disks	O
inhibited	O
more	O
strains	O
(	O
89	O
.	O
4	O
%	O
)	O
than	O
dried	O
disks	O
(	O
68	O
.	O
1	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Most	O
(	O
81	O
.	O
8	O
%	O
)	O
Bacteroides	B-bacteria
fragilis	I-bacteria
group	I-bacteria
strains	I-bacteria
and	O
75	O
%	O
of	O
clostridial	B-bacteria
strains	I-bacteria
were	O
inhibited	O
by	O
moist	O
EEP	O
disks	O
.	O

Bulgarian	O
propolis	O
was	O
active	O
against	O
most	O
anaerobic	O
strains	O
of	O
different	O
genera	O
.	O

In	O
addition	O
to	O
oral	O
pathogens	O
,	O
an	O
activity	O
of	O
propolis	O
against	O
Clostridium	B-bacteria
,	O
Bacteroides	B-bacteria
and	O
Propionibacterium	B-bacteria
species	I-bacteria
was	O
observed	O
.	O

The	O
results	O
could	O
motivate	O
a	O
higher	O
medical	O
interest	O
and	O
further	O
trials	O
for	O
evaluating	O
the	O
use	O
of	O
bee	O
glue	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
some	O
anaerobic	O
infections	O
such	O
as	O
oral	O
,	O
skin	O
and	O
wound	O
diseases	O
.	O

Most	O
probiotic	O
products	O
are	O
consumed	O
orally	O
and	O
hence	O
it	O
is	O
feasible	O
that	O
the	O
bacteria	O
in	O
these	O
products	O
may	O
also	O
attach	O
to	O
oral	O
surfaces	O
;	O
however	O
,	O
the	O
effects	O
of	O
these	O
bacteria	O
on	O
the	O
oral	O
ecosystem	O
are	O
mostly	O
unknown	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
the	O
oral	O
colonization	O
potential	O
of	O
different	O
probiotic	O
,	O
dairy	O
,	O
and	O
fecal	O
Lactobacillus	B-bacteria
and	O
Bifidobacterium	B-bacteria
strains	I-bacteria
in	O
vitro	O
.	O

The	O
binding	O
of	O
17	O
Lactobacillus	B-bacteria
and	O
seven	O
Bifidobacterium	B-bacteria
strains	I-bacteria
to	O
hydroxyapatite	O
and	O
microtitre	O
wells	O
coated	O
with	O
human	O
saliva	O
was	O
tested	O
.	O

Binding	O
of	O
selected	O
strains	O
to	O
human	O
buccal	O
epithelial	O
cells	O
and	O
co	O
-	O
adherence	O
with	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
were	O
also	O
investigated	O
.	O

In	O
addition	O
,	O
the	O
survival	O
in	O
sterilized	O
human	O
whole	O
saliva	O
was	O
examined	O
.	O

There	O
was	O
a	O
large	O
variation	O
in	O
binding	O
to	O
saliva	O
-	O
coated	O
surfaces	O
and	O
buccal	O
epithelial	O
cells	O
but	O
all	O
strains	O
survived	O
in	O
saliva	O
.	O

The	O
binding	O
pattern	O
of	O
the	O
probiotics	O
did	O
not	O
differ	O
from	O
the	O
binding	O
of	O
the	O
fecal	O
strains	O
.	O

F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
altered	O
the	O
binding	O
of	O
both	O
the	O
low	O
-	O
binding	O
bifidobacteria	B-bacteria
and	O
the	O
high	O
-	O
binding	O
lactobacilli	B-bacteria
.	O

The	O
differences	O
in	O
binding	O
in	O
vitro	O
may	O
indicate	O
that	O
there	O
are	O
also	O
differences	O
in	O
the	O
persistence	O
of	O
the	O
different	O
probiotic	O
strains	O
in	O
the	O
oral	O
cavity	O
in	O
vivo	O
.	O

Colonization	O
of	O
Candida	O
albicans	O
on	O
oral	O
surfaces	O
can	O
serve	O
as	O
a	O
reservoir	O
for	O
disseminated	O
infections	O
,	O
such	O
as	O
aspiration	O
pneumonia	O
and	O
gastrointestinal	O
infection	O
,	O
particularly	O
in	O
the	O
immunocompromised	O
host	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
salivary	O
and	O
serum	O
pellicles	O
on	O
C	O
.	O
albicans	O
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
,	O
Lactobacillus	B-bacteria
and	O
Actinomyces	B-bacteria
colonization	O
on	O
type	O
I	O
collagen	O
,	O
a	O
major	O
organic	O
component	O
of	O
periodontal	O
ligaments	O
.	O

The	O
colonization	O
potential	O
of	O
two	O
isolates	O
each	O
of	O
C	O
.	O
albicans	O
,	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
,	O
and	O
a	O
single	O
isolate	O
each	O
of	O
Lactobacillus	B-bacteria
and	O
Actinomyces	B-bacteria
to	O
uncoated	O
(	O
control	O
)	O
,	O
saliva	O
-	O
coated	O
or	O
serum	O
-	O
coated	O
type	O
I	O
collagen	O
plates	O
(	O
surface	O
area	O
143	O
mm	O
(	O
2	O
)	O
,	O
Cell	O
Disk	O
;	O
Sumitomo	O
,	O
Tokyo	O
,	O
Japan	O
)	O
was	O
examined	O
using	O
a	O
bioluminescent	O
adenosine	O
triphosphate	O
assay	O
based	O
on	O
firefly	O
luciferase	O
-	O
luciferin	O
system	O
.	O

The	O
results	O
revealed	O
that	O
with	O
mutans	B-bacteria
streptococci	I-bacteria
,	O
a	O
saliva	O
pellicle	O
was	O
significantly	O
more	O
effective	O
in	O
promoting	O
bacterial	O
colonization	O
compared	O
with	O
the	O
pellicle	O
-	O
free	O
collagen	O
disc	O
,	O
and	O
the	O
serum	O
-	O
coated	O
sample	O
significantly	O
inhibited	O
the	O
colonization	O
of	O
streptococci	B-bacteria
(	O
anova	O
;	O
P	O
<	O
0b01	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
case	O
of	O
C	O
.	O
albicans	O
,	O
Lactobacillus	B-bacteria
and	O
Actinomyces	B-bacteria
isolates	I-bacteria
,	O
a	O
serum	O
pellicle	O
was	O
significantly	O
more	O
effective	O
in	O
promoting	O
the	O
colonization	O
,	O
followed	O
by	O
saliva	O
pellicle	O
and	O
uncoated	O
specimen	O
(	O
anova	O
;	O
P	O
<	O
0b01	O
)	O
.	O

These	O
results	O
suggested	O
that	O
crevicular	O
fluid	O
rich	O
in	O
seruminous	O
components	O
would	O
promote	O
the	O
colonization	O
of	O
Candida	O
,	O
Lactobacillus	B-bacteria
and	O
Actinomyces	B-bacteria
on	O
type	O
I	O
collagen	O
as	O
opposed	O
to	O
streptococci	B-bacteria
which	O
showed	O
greater	O
avidity	O
to	O
saliva	O
-	O
coated	O
collagen	O
.	O

This	O
study	O
investigated	O
the	O
antibacterial	O
effect	O
of	O
electrolyzed	O
water	O
on	O
oral	O
bacteria	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Tap	O
water	O
was	O
electrolyzed	O
in	O
a	O
water	O
vessel	O
using	O
platinum	O
cell	O
technology	O
.	O

The	O
electrolyzed	O
tap	O
water	O
(	O
called	O
Puri	O
-	O
water	O
)	O
was	O
put	O
in	O
contact	O
with	O
five	O
major	O
periodontopathogens	O
or	O
toothbrushes	O
contaminated	O
with	O
these	O
bacteria	O
for	O
30	O
sec	O
.	O

In	O
addition	O
,	O
Puri	O
-	O
water	O
was	O
used	O
as	O
a	O
mouthwash	O
for	O
30	O
sec	O
in	O
16	O
subjects	O
and	O
the	O
antibacterial	O
effect	O
on	O
salivary	O
bacteria	O
was	O
evaluated	O
.	O

Puri	O
-	O
water	O
significantly	O
reduced	O
the	O
growth	O
of	O
all	O
periodontopathogens	O
in	O
culture	O
and	O
on	O
toothbrushes	O
,	O
and	O
that	O
of	O
aerobic	O
and	O
anaerobic	O
bacteria	O
in	O
saliva	O
,	O
when	O
compared	O
to	O
the	O
effect	O
of	O
tap	O
water	O
.	O

It	O
also	O
significantly	O
reduced	O
mutans	B-bacteria
streptococci	I-bacteria
growing	O
on	O
mitis	O
salivarius	O
-	O
bacitracin	O
agar	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
electrolyzed	O
tap	O
water	O
is	O
effective	O
as	O
a	O
mouthwash	O
and	O
for	O
toothbrush	O
disinfection	O
.	O

Anaerobic	O
infections	O
are	O
common	O
and	O
can	O
cause	O
diseases	O
associated	O
with	O
severe	O
morbidity	O
,	O
but	O
are	O
easily	O
overlooked	O
in	O
clinical	O
settings	O
.	O

Both	O
the	O
relatively	O
small	O
number	O
of	O
infections	O
due	O
to	O
exogenous	O
anaerobes	O
and	O
the	O
much	O
larger	O
number	O
of	O
infections	O
involving	O
anaerobic	O
species	O
that	O
are	O
originally	O
members	O
of	O
the	O
normal	O
flora	O
,	O
may	O
lead	O
to	O
a	O
life	O
-	O
threatening	O
situation	O
unless	O
appropriate	O
treatment	O
is	O
instituted	O
.	O

Special	O
laboratory	O
procedures	O
are	O
needed	O
for	O
the	O
isolation	O
,	O
identification	O
and	O
susceptibility	O
testing	O
of	O
this	O
diverse	O
group	O
of	O
bacteria	O
.	O

Since	O
many	O
anaerobes	O
grow	O
more	O
slowly	O
than	O
the	O
facultative	O
or	O
aerobic	O
bacteria	O
,	O
and	O
particularly	O
since	O
clinical	O
specimens	O
yielding	O
anaerobic	O
bacteria	O
commonly	O
contain	O
several	O
organisms	O
and	O
often	O
very	O
complex	O
mixtures	O
of	O
aerobic	O
and	O
anaerobic	O
bacteria	O
,	O
considerable	O
time	O
may	O
elapse	O
before	O
the	O
laboratory	O
is	O
able	O
to	O
provide	O
a	O
final	O
report	O
.	O

Species	O
definition	O
based	O
on	O
phenotypic	O
features	O
is	O
often	O
time	O
-	O
consuming	O
and	O
is	O
not	O
always	O
easy	O
to	O
carry	O
out	O
.	O

Molecular	O
genetic	O
methods	O
may	O
help	O
in	O
the	O
everyday	O
clinical	O
microbiological	O
practice	O
in	O
laboratories	O
dealing	O
with	O
the	O
diagnostics	O
of	O
anaerobic	O
infections	O
.	O

Methods	O
have	O
been	O
introduced	O
for	O
species	O
diagnostics	O
,	O
such	O
as	O
16S	O
rRNA	O
PCR	O
-	O
RFLP	O
profile	O
determination	O
,	O
which	O
can	O
help	O
to	O
distinguish	O
species	O
of	O
Bacteroides	B-bacteria
,	O
Prevotella	B-bacteria
,	O
Actinomyces	B-bacteria
,	O
etc	O
.	O
that	O
are	O
otherwise	O
difficult	O
to	O
differentiate	O
.	O

The	O
use	O
of	O
DNA	O
-	O
DNA	O
hybridization	O
and	O
the	O
sequencing	O
of	O
special	O
regions	O
of	O
the	O
16S	O
rRNA	O
have	O
revealed	O
fundamental	O
taxonomic	O
changes	O
among	O
anaerobic	O
bacteria	O
.	O

Some	O
anaerobic	O
bacteria	O
are	O
extremely	O
slow	O
growing	O
or	O
not	O
cultivatable	O
at	O
all	O
.	O

To	O
detect	O
them	O
in	O
special	O
infections	O
involving	O
flora	O
changes	O
due	O
to	O
oral	O
malignancy	O
or	O
periodontitis	O
,	O
for	O
instance	O
,	O
a	O
PCR	O
-	O
based	O
hybridization	O
technique	O
is	O
used	O
.	O

Molecular	O
methods	O
have	O
demonstrated	O
the	O
spread	O
of	O
specific	O
resistance	O
genes	O
among	O
the	O
most	O
important	O
anaerobic	O
bacteria	O
,	O
the	O
members	O
of	O
the	O
Bacteroides	B-bacteria
genus	I-bacteria
.	O

Their	O
detection	O
and	O
investigation	O
of	O
the	O
IS	O
elements	O
involved	O
in	O
their	O
expression	O
may	O
facilitate	O
following	O
of	O
the	O
spread	O
of	O
antibiotic	O
resistance	O
among	O
anaerobic	O
bacteria	O
involved	O
in	O
infections	O
and	O
in	O
the	O
normal	O
flora	O
members	O
.	O

Molecular	O
methods	O
(	O
a	O
search	O
for	O
toxin	O
genes	O
and	O
ribotyping	O
)	O
may	O
promote	O
a	O
better	O
understanding	O
of	O
the	O
pathogenic	O
features	O
of	O
some	O
anaerobic	O
infections	O
,	O
such	O
as	O
the	O
nosocomial	O
diarrhoea	O
caused	O
by	O
C	O
.	O
difficile	O
and	O
its	O
spread	O
in	O
the	O
hospital	O
environment	O
and	O
the	O
community	O
.	O

The	O
investigation	O
of	O
toxin	O
production	O
at	O
a	O
molecular	O
level	O
helps	O
in	O
the	O
detection	O
of	O
new	O
toxin	O
types	O
.	O

This	O
mini	O
-	O
review	O
surveys	O
some	O
of	O
the	O
results	O
obtained	O
by	O
our	O
group	O
and	O
others	O
using	O
molecular	O
genetic	O
methods	O
in	O
anaerobic	O
diagnostics	O
.	O

Bacillus	B-bacteria
thuringiensis	I-bacteria
is	O
the	O
most	O
widely	O
applied	O
biological	O
insecticide	O
and	O
is	O
used	O
to	O
manage	O
insects	O
that	O
affect	O
forestry	O
and	O
agriculture	O
and	O
transmit	O
human	O
and	O
animal	O
pathogens	O
.	O

This	O
ubiquitous	O
spore	O
-	O
forming	O
bacterium	O
kills	O
insect	O
larvae	O
largely	O
through	O
the	O
action	O
of	O
insecticidal	O
crystal	O
proteins	O
and	O
is	O
commonly	O
deployed	O
as	O
a	O
direct	O
bacterial	O
spray	O
.	O

Moreover	O
,	O
plants	O
engineered	O
with	O
the	O
cry	O
genes	O
encoding	O
the	O
B	B-bacteria
.	I-bacteria
thuringiensis	I-bacteria
crystal	O
proteins	O
are	O
the	O
most	O
widely	O
cultivated	O
transgenic	O
crops	O
.	O

For	O
decades	O
,	O
the	O
mechanism	O
of	O
insect	O
killing	O
has	O
been	O
assumed	O
to	O
be	O
toxin	O
-	O
mediated	O
lysis	O
of	O
the	O
gut	O
epithelial	O
cells	O
,	O
which	O
leads	O
to	O
starvation	O
,	O
or	O
B	B-bacteria
.	I-bacteria
thuringiensis	I-bacteria
septicemia	O
.	O

Here	O
,	O
we	O
report	O
that	O
B	B-bacteria
.	I-bacteria
thuringiensis	I-bacteria
does	O
not	O
kill	O
larvae	O
of	O
the	O
gypsy	O
moth	O
in	O
the	O
absence	O
of	O
indigenous	O
midgut	O
bacteria	O
.	O

Elimination	O
of	O
the	O
gut	O
microbial	O
community	O
by	O
oral	O
administration	O
of	O
antibiotics	O
abolished	O
B	B-bacteria
.	I-bacteria
thuringiensis	I-bacteria
insecticidal	O
activity	O
,	O
and	O
reestablishment	O
of	O
an	O
Enterobacter	B-bacteria
sp	I-bacteria
.	I-bacteria
that	O
normally	O
resides	O
in	O
the	O
midgut	O
microbial	O
community	O
restored	O
B	O
.	O
thuringiensis	O
-	O
mediated	O
killing	O
.	O

Escherichia	B-bacteria
coli	I-bacteria
engineered	O
to	O
produce	O
the	O
B	B-bacteria
.	I-bacteria
thuringiensis	I-bacteria
insecticidal	O
toxin	O
killed	O
gypsy	O
moth	O
larvae	O
irrespective	O
of	O
the	O
presence	O
of	O
other	O
bacteria	O
in	O
the	O
midgut	O
.	O

However	O
,	O
when	O
the	O
engineered	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
was	O
heat	O
-	O
killed	O
and	O
then	O
fed	O
to	O
the	O
larvae	O
,	O
the	O
larvae	O
did	O
not	O
die	O
in	O
the	O
absence	O
of	O
the	O
indigenous	O
midgut	O
bacteria	O
.	O

E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
the	O
Enterobacter	B-bacteria
sp	I-bacteria
.	I-bacteria
achieved	O
high	O
populations	O
in	O
hemolymph	O
,	O
in	O
contrast	O
to	O
B	B-bacteria
.	I-bacteria
thuringiensis	I-bacteria
,	O
which	O
appeared	O
to	O
die	O
in	O
hemolymph	O
.	O

Our	O
results	O
demonstrate	O
that	O
B	B-bacteria
.	I-bacteria
thuringiensis	I-bacteria
-	O
induced	O
mortality	O
depends	O
on	O
enteric	O
bacteria	O
.	O

In	O
this	O
investigation	O
,	O
the	O
urine	O
samples	O
obtained	O
in	O
a	O
single	O
oral	O
-	O
dose	O
pharmacokinetic	O
study	O
were	O
examined	O
for	O
their	O
bactericidal	O
activity	O
against	O
a	O
range	O
of	O
relevant	O
urinary	O
tract	O
pathogens	O
.	O

Six	O
healthy	O
volunteers	O
received	O
a	O
single	O
oral	O
dose	O
of	O
ten	O
oral	O
antibiotics	O
available	O
in	O
Croatia	O
.	O

Urine	O
samples	O
were	O
taken	O
every	O
2	O
h	O
during	O
the	O
whole	O
dosing	O
interval	O
of	O
the	O
particular	O
antibiotic	O
.	O

The	O
urinary	O
bactericidal	O
activity	O
was	O
tested	O
by	O
determination	O
of	O
urinary	O
bactericidal	O
titers	O
.	O

All	O
antibiotics	O
showed	O
a	O
significant	O
urinary	O
bactericidal	O
activity	O
against	O
non	O
-	O
extended	O
spectrum	O
beta	O
-	O
lactamase	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
Proteus	B-bacteria
mirabilis	I-bacteria
.	O

Fluoroquinolones	O
displayed	O
high	O
and	O
persisting	O
levels	O
of	O
urinary	O
bactericidal	O
activity	O
against	O
all	O
gram	O
-	O
negative	O
bacteria	O
and	O
Staphylococcus	B-bacteria
saprophyticus	I-bacteria
.	O

Average	O
urinary	O
bactericidal	O
activity	O
can	O
be	O
predicted	O
from	O
in	O
vitro	O
susceptibility	O
testing	O
,	O
but	O
we	O
expect	O
that	O
there	O
will	O
be	O
patients	O
with	O
a	O
low	O
level	O
of	O
urinary	O
bactericidal	O
activity	O
.	O

The	O
authors	O
compared	O
the	O
in	O
vivo	O
antimicrobial	O
effects	O
on	O
microorganisms	O
from	O
dental	O
plaque	O
,	O
saliva	O
and	O
the	O
tongue	O
in	O
subjects	O
who	O
used	O
a	O
triclosan	O
/	O
copolymer	O
dentifrice	O
and	O
a	O
fluoride	O
dentifrice	O
(	O
control	O
)	O
.	O

The	O
authors	O
assigned	O
15	O
subjects	O
randomly	O
to	O
the	O
control	O
dentifrice	O
or	O
the	O
triclosan	O
/	O
copolymer	O
dentifrice	O
for	O
twice	O
-	O
daily	O
use	O
for	O
one	O
week	O
.	O

They	O
collected	O
samples	O
of	O
plaque	O
,	O
saliva	O
and	O
tongue	O
scrapings	O
six	O
and	O
12	O
hours	O
after	O
the	O
final	O
brushing	O
.	O

They	O
analyzed	O
colony	O
-	O
forming	O
units	O
of	O
Veillonella	B-bacteria
species	I-bacteria
,	O
Fusobacteria	B-bacteria
species	I-bacteria
,	O
total	O
cultivable	O
anaerobes	O
and	O
hydrogen	O
sulfide	O
(	O
H	O
(	O
2	O
)	O
S	O
)	O
-	O
producing	O
bacteria	O
.	O

A	O
one	O
-	O
week	O
washout	O
followed	O
.	O

The	O
authors	O
repeated	O
the	O
protocol	O
with	O
the	O
second	O
dentifrice	O
.	O

The	O
results	O
showed	O
no	O
differences	O
at	O
baseline	O
.	O

Significant	O
reductions	O
(	O
88	O
to	O
96	O
percent	O
)	O
in	O
oral	O
anaerobic	O
bacteria	O
were	O
observed	O
in	O
the	O
triclosan	O
/	O
copolymer	O
group	O
six	O
and	O
12	O
hours	O
after	O
brushing	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
=	O
.	O
001	O
)	O
.	O

Fusobacteria	B-bacteria
decreased	O
by	O
77	O
to	O
92	O
percent	O
and	O
Veillonella	B-bacteria
decreased	O
by	O
84	O
to	O
89	O
percent	O
six	O
and	O
12	O
hours	O
after	O
brushing	O
in	O
the	O
triclosan	O
/	O
copolymer	O
group	O
versus	O
the	O
control	O
group	O
.	O

The	O
triclosan	O
/	O
copolymer	O
group	O
also	O
demonstrated	O
a	O
significant	O
decrease	O
in	O
H	O
(	O
2	O
)	O
S	O
-	O
producing	O
bacteria	O
six	O
and	O
12	O
hours	O
after	O
brushing	O
(	O
74	O
to	O
85	O
percent	O
)	O
(	O
P	O
=	O
.	O
001	O
)	O
.	O

Brushing	O
with	O
the	O
triclosan	O
/	O
copolymer	O
dentifrice	O
resulted	O
in	O
significant	O
reductions	O
in	O
microorganisms	O
from	O
the	O
three	O
sites	O
compared	O
with	O
the	O
control	O
dentifrice	O
.	O

:	O
The	O
triclosan	O
/	O
copolymer	O
dentifrice	O
produced	O
sustained	O
effects	O
on	O
oral	O
bacteria	O
for	O
12	O
hours	O
.	O

To	O
determine	O
antibacterial	O
activity	O
of	O
chewing	O
mastic	O
gum	O
against	O
the	O
salivary	O
levels	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
the	O
total	O
number	O
of	O
viable	O
bacteria	O
,	O
and	O
lactobacilli	B-bacteria
in	O
patients	O
undergoing	O
therapy	O
with	O
fixed	O
orthodontic	O
appliances	O
.	O

In	O
this	O
study	O
,	O
the	O
levels	O
of	O
S	B-bacteria
mutans	I-bacteria
,	O
lactobacilli	B-bacteria
,	O
and	O
total	O
cultivated	O
bacteria	O
were	O
measured	O
before	O
and	O
after	O
chewing	O
mastic	O
gum	O
.	O

The	O
antibacterial	O
effects	O
of	O
chewing	O
mastic	O
gum	O
against	O
these	O
microorganisms	O
in	O
saliva	O
were	O
compared	O
with	O
a	O
placebo	O
gum	O
.	O

The	O
counts	O
for	O
orthodontically	O
treated	O
patients	O
were	O
evaluated	O
before	O
chewing	O
gum	O
;	O
just	O
after	O
chewing	O
gum	O
;	O
and	O
after	O
45	O
,	O
75	O
,	O
105	O
,	O
and	O
135	O
minutes	O
.	O

Saliva	O
samples	O
taken	O
from	O
the	O
patients	O
were	O
inoculated	O
onto	O
trypticase	O
-	O
yeast	O
-	O
cystine	O
-	O
bacitracin	O
agar	O
for	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
onto	O
Rogosa	O
agar	O
for	O
lactobacilli	B-bacteria
.	O

The	O
agar	O
plates	O
were	O
incubated	O
for	O
48	O
hours	O
anaerobically	O
at	O
37	O
degrees	O
C	O
.	O
The	O
total	O
number	O
of	O
viable	O
bacteria	O
was	O
then	O
counted	O
.	O

Just	O
after	O
chewing	O
the	O
mastic	O
gum	O
for	O
15	O
minutes	O
,	O
a	O
significant	O
decrease	O
of	O
total	O
bacteria	O
and	O
S	B-bacteria
mutans	I-bacteria
was	O
observed	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
reduction	O
in	O
lactobacilli	B-bacteria
was	O
not	O
significant	O
at	O
later	O
first	O
stage	O
(	O
P	O
>	O
.	O
05	O
)	O
.	O

However	O
,	O
at	O
the	O
end	O
of	O
135	O
minutes	O
,	O
there	O
were	O
significantly	O
fewer	O
S	B-bacteria
mutans	I-bacteria
(	O
P	O
<	O
.	O
001	O
)	O
,	O
total	O
viable	O
bacteria	O
(	O
P	O
<	O
.	O
001	O
)	O
,	O
and	O
lactobacilli	B-bacteria
(	O
P	O
<	O
.	O
001	O
)	O
in	O
the	O
oral	O
cavity	O
after	O
chewing	O
mastic	O
gum	O
than	O
after	O
chewing	O
paraffin	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
results	O
show	O
that	O
chewing	O
mastic	O
gum	O
decreased	O
the	O
total	O
viable	O
bacteria	O
,	O
S	B-bacteria
mutans	I-bacteria
,	O
and	O
lactobacilli	B-bacteria
in	O
saliva	O
in	O
orthodontically	O
treated	O
patients	O
with	O
fixed	O
appliances	O
.	O

Chewing	O
mastic	O
gum	O
might	O
be	O
useful	O
in	O
preventing	O
caries	O
lesions	O
.	O

The	O
mode	O
of	O
acquisition	O
of	O
gastric	O
Helicobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
infection	O
in	O
dogs	O
has	O
not	O
been	O
determined	O
.	O

It	O
is	O
suspected	O
that	O
oral	O
-	O
oral	O
and	O
faecal	O
-	O
oral	O
transmission	O
may	O
be	O
involved	O
.	O

The	O
present	O
study	O
sought	O
to	O
determine	O
if	O
Helicobacter	B-bacteria
spp	I-bacteria
.	O

DNA	O
is	O
present	O
in	O
the	O
oral	O
cavity	O
of	O
healthy	O
and	O
vomiting	O
dogs	O
.	O

Thirty	O
-	O
eight	O
pet	O
dogs	O
(	O
27	O
vomiting	O
and	O
11	O
clinically	O
healthy	O
)	O
were	O
studied	O
.	O

The	O
presence	O
of	O
Helicobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
was	O
determined	O
by	O
single	O
and	O
nested	O
PCR	O
evaluation	O
of	O
DNA	O
extracted	O
from	O
saliva	O
,	O
dental	O
plaque	O
and	O
gastric	O
biopsy	O
samples	O
.	O

Helicobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
DNA	O
was	O
detected	O
by	O
nested	O
PCR	O
in	O
36	O
(	O
94	O
.	O
7	O
%	O
)	O
gastric	O
biopsies	O
,	O
17	O
(	O
44	O
.	O
7	O
%	O
)	O
dental	O
plaque	O
and	O
19	O
(	O
50	O
%	O
)	O
saliva	O
samples	O
out	O
of	O
the	O
38	O
dogs	O
examined	O
.	O

Overall	O
27	O
(	O
71	O
.	O
1	O
%	O
)	O
dogs	O
screened	O
by	O
nested	O
PCR	O
were	O
found	O
to	O
harbour	O
Helicobacter	B-bacteria
spp	I-bacteria
.	O

DNA	O
in	O
the	O
oral	O
cavity	O
(	O
dental	O
plaque	O
and	O
/	O
or	O
saliva	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
prevalence	O
of	O
Helicobacter	B-bacteria
spp	I-bacteria
.	O

DNA	O
in	O
the	O
oral	O
cavity	O
of	O
vomiting	O
and	O
healthy	O
dogs	O
,	O
and	O
the	O
time	O
from	O
vomiting	O
to	O
oral	O
sampling	O
did	O
not	O
have	O
significant	O
impact	O
.	O

This	O
study	O
confirms	O
the	O
high	O
prevalence	O
of	O
gastric	O
Helicobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
infection	O
in	O
dogs	O
,	O
and	O
reveals	O
that	O
Helicobacter	B-bacteria
spp	I-bacteria
.	O

DNA	O
is	O
detectable	O
in	O
the	O
oral	O
cavity	O
of	O
over	O
70	O
%	O
of	O
dogs	O
.	O

These	O
findings	O
support	O
the	O
possibility	O
of	O
oral	O
-	O
oral	O
transmission	O
between	O
dogs	O
and	O
that	O
the	O
canine	O
oral	O
cavity	O
may	O
act	O
as	O
source	O
of	O
non	B-bacteria
-	I-bacteria
pylori	I-bacteria
Helicobacter	I-bacteria
spp	I-bacteria
.	I-bacteria
infection	O
fors	O
humans	O
.	O

There	O
are	O
numerous	O
studies	O
suggesting	O
that	O
inflammation	O
of	O
the	O
oral	O
cavity	O
caused	O
by	O
bacteria	O
or	O
fungi	O
is	O
accompanied	O
by	O
gastric	O
inflammation	O
.	O

This	O
is	O
particularly	O
relevant	O
in	O
patients	O
using	O
complete	O
dentures	O
.	O

Since	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
cavity	O
can	O
be	O
easily	O
discovered	O
by	O
bacteria	O
culture	O
and	O
that	O
in	O
the	O
stomach	O
by	O
(	O
13	O
)	O
C	O
urea	O
breath	O
test	O
(	O
UBT	O
)	O
and	O
histology	O
of	O
gastric	O
endoscopic	O
biopsy	O
samples	O
it	O
is	O
reasonably	O
to	O
state	O
that	O
the	O
majority	O
of	O
the	O
patients	O
show	O
the	O
presence	O
of	O
bacterium	O
in	O
oral	O
cavity	O
and	O
active	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
.	O

When	O
comparing	O
,	O
however	O
,	O
the	O
bacteria	O
culture	O
originating	O
from	O
the	O
oral	O
mucosa	O
to	O
those	O
from	O
the	O
gastric	O
mucosa	O
,	O
employing	O
molecular	O
biology	O
examination	O
,	O
such	O
as	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
we	O
found	O
that	O
the	O
oral	O
bacteria	O
and	O
those	O
originating	O
from	O
stomach	O
are	O
completely	O
different	O
,	O
suggesting	O
that	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
may	O
be	O
present	O
only	O
transiently	O
in	O
oral	O
cavity	O
and	O
does	O
not	O
play	O
major	O
role	O
in	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
.	O

Thus	O
,	O
oral	O
cavity	O
does	O
not	O
serve	O
as	O
bacterial	O
reservoir	O
to	O
infect	O
gastric	O
mucosa	O
.	O

Most	O
important	O
finding	O
of	O
our	O
study	O
is	O
that	O
patients	O
with	O
recognized	O
inflammation	O
in	O
the	O
oral	O
cavity	O
in	O
the	O
form	O
of	O
stomatitis	O
prothetica	O
hyperplasica	O
both	O
fibrosa	O
as	O
well	O
as	O
papillaris	O
showed	O
in	O
nearly	O
100	O
%	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
,	O
usually	O
without	O
the	O
presence	O
of	O
the	O
same	O
bacterium	O
in	O
the	O
oral	O
cavity	O
,	O
suggesting	O
that	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
affects	O
oral	O
mucosa	O
at	O
distance	O
by	O
some	O
,	O
as	O
yet	O
,	O
unknown	O
mechanism	O
.	O

To	O
assess	O
caries	O
risk	O
and	O
check	O
the	O
presence	O
of	O
four	O
commonly	O
found	O
oral	O
cariogenic	O
bacteria	O
in	O
`	O
`	O
8020	O
'	O
'	O
achievers	O
.	O

Initial	O
report	O
based	O
on	O
Japan	O
'	O
s	O
newly	O
implemented	O
`	O
`	O
8020	O
'	O
'	O
campaign	O
,	O
which	O
aims	O
to	O
promote	O
health	O
and	O
awareness	O
in	O
older	O
people	O
.	O

Simply	O
stated	O
,	O
the	O
goal	O
is	O
,	O
at	O
80	O
years	O
,	O
to	O
maintain	O
20	O
teeth	O
.	O

Healthy	O
community	O
-	O
dwelling	O
elderly	O
individuals	O
of	O
Okayama	O
Prefecture	O
,	O
Japan	O
.	O

One	O
hundred	O
sixty	O
individuals	O
aged	O
80	O
and	O
older	O
with	O
20	O
of	O
their	O
own	O
natural	O
teeth	O
.	O

General	O
and	O
oral	O
health	O
conditions	O
,	O
caries	O
risk	O
assessment	O
using	O
the	O
Cariostat	O
method	O
,	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
detection	O
of	O
four	O
oral	O
cariogenic	O
bacteria	O
.	O

The	O
participants	O
had	O
an	O
average	O
of	O
24	O
.	O
7	O
teeth	O
,	O
of	O
which	O
12	O
.	O
1	O
were	O
sound	O
,	O
12	O
.	O
2	O
were	O
treated	O
,	O
and	O
0	O
.	O
4	O
were	O
untreated	O
.	O

Based	O
on	O
Cariostat	O
scores	O
,	O
64	O
.	O
4	O
%	O
had	O
low	O
caries	O
risk	O
.	O

Using	O
PCR	O
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
,	O
Lactobacillus	B-bacteria
casei	I-bacteria
,	O
and	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
were	O
detected	O
in	O
51	O
.	O
3	O
%	O
,	O
23	O
.	O
1	O
%	O
,	O
40	O
%	O
,	O
and	O
25	O
%	O
of	O
the	O
participants	O
,	O
respectively	O
.	O

S	B-bacteria
.	I-bacteria
mutans	I-bacteria
(	O
P	O
<	O
.	O
001	O
)	O
,	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
(	O
P	O
=	O
.	O
002	O
)	O
,	O
L	B-bacteria
.	I-bacteria
casei	I-bacteria
(	O
P	O
<	O
.	O
001	O
)	O
,	O
and	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
(	O
P	O
=	O
.	O
001	O
)	O
deoxyribonucleic	O
acid	O
band	O
was	O
detected	O
more	O
in	O
participants	O
with	O
high	O
caries	O
risk	O
scores	O
.	O

Participants	O
with	O
low	O
caries	O
risk	O
scores	O
had	O
low	O
prevalence	O
of	O
cariogenic	O
bacteria	O
,	O
20	O
or	O
more	O
sound	O
teeth	O
,	O
and	O
fewer	O
missing	O
teeth	O
.	O

Incorporating	O
caries	O
risk	O
assessment	O
,	O
using	O
the	O
Cariostat	O
and	O
PCR	O
analysis	O
,	O
in	O
the	O
`	O
`	O
8020	O
'	O
'	O
campaign	O
in	O
health	O
systems	O
worldwide	O
will	O
contribute	O
to	O
a	O
better	O
life	O
for	O
the	O
aging	O
society	O
,	O
initiate	O
research	O
interest	O
regarding	O
the	O
program	O
,	O
and	O
improve	O
current	O
health	O
policies	O
.	O

A	O
variety	O
of	O
oxalate	O
-	O
degrading	O
bacteria	O
including	O
Oxalobacter	B-bacteria
formigenes	I-bacteria
and	O
some	O
species	O
of	O
Bifidobacterium	B-bacteria
are	O
known	O
to	O
colonize	O
the	O
human	O
intestinal	O
tract	O
.	O

Oral	O
lactosucrose	O
supplementation	O
promotes	O
the	O
growth	O
of	O
Bifidobacterium	B-bacteria
in	O
the	O
human	O
intestine	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
oral	O
lactosucrose	O
supplementation	O
on	O
enteric	O
oxalate	O
-	O
degrading	O
bacteria	O
in	O
twelve	O
healthy	O
men	O
(	O
age	O
ranging	O
from	O
25	O
to	O
39	O
years	O
)	O
.	O

Lactosucrose	O
was	O
orally	O
administered	O
10	O
g	O
daily	O
for	O
2	O
weeks	O
without	O
restriction	O
of	O
dietary	O
intake	O
.	O

The	O
total	O
number	O
of	O
oxalate	O
-	O
degrading	O
bacteria	O
in	O
feces	O
and	O
the	O
24	O
-	O
hour	O
urinary	O
excretion	O
of	O
oxalate	O
were	O
examined	O
before	O
and	O
after	O
lactosucrose	O
supplementation	O
.	O

The	O
total	O
number	O
of	O
oxalate	O
degrading	O
-	O
bacteria	O
was	O
significantly	O
increased	O
by	O
lactosucrose	O
supplementation	O
(	O
9	O
.	O
20	O
+	O
/	O
-	O
0	O
.	O
44	O
versus	O
9	O
.	O
77	O
+	O
/	O
-	O
0	O
.	O
46	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
although	O
there	O
was	O
no	O
significant	O
change	O
in	O
the	O
urinary	O
oxalate	O
excretion	O
.	O

The	O
oxalate	O
degrading	O
-	O
bacteria	O
isolated	O
from	O
feces	O
was	O
biochemically	O
identified	O
as	O
Bifidobacterium	B-bacteria
adolescentis	I-bacteria
.	O

In	O
conclusion	O
,	O
oral	O
supplementation	O
of	O
10	O
g	O
lactosucrose	O
daily	O
for	O
2	O
weeks	O
was	O
effective	O
in	O
multiplying	O
oxalate	O
-	O
degrading	O
bacteria	O
,	O
but	O
not	O
in	O
reducing	O
urinary	O
oxalate	O
excretion	O
under	O
free	O
non	O
-	O
restricted	O
dietary	O
intake	O
.	O

In	O
addition	O
,	O
it	O
was	O
suggested	O
that	O
various	O
species	O
of	O
Bifidobacterium	B-bacteria
were	O
related	O
to	O
degradation	O
of	O
oxalate	O
in	O
the	O
human	O
intestine	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
explore	O
the	O
physiological	O
and	O
antigenic	O
diversity	O
of	O
a	O
large	O
number	O
of	O
Streptococcus	B-bacteria
mitis	I-bacteria
biovar	I-bacteria
1	I-bacteria
isolates	I-bacteria
in	O
order	O
to	O
begin	O
to	O
determine	O
whether	O
these	O
properties	O
contribute	O
to	O
species	O
persistence	O
.	O

S	B-bacteria
.	I-bacteria
mitis	I-bacteria
biovar	I-bacteria
1	I-bacteria
was	O
collected	O
from	O
four	O
infants	O
from	O
birth	O
to	O
the	O
first	O
year	O
of	O
age	O
.	O

At	O
each	O
of	O
eight	O
to	O
nine	O
visits	O
,	O
60	O
isolates	O
each	O
were	O
obtained	O
from	O
the	O
cheeks	O
,	O
tongue	O
and	O
incisors	O
(	O
once	O
erupted	O
)	O
yielding	O
4440	O
in	O
total	O
.	O

These	O
were	O
tested	O
for	O
production	O
of	O
neuraminidase	O
,	O
beta1	O
-	O
N	O
-	O
acetylglucosaminidase	O
,	O
beta1	O
-	O
N	O
-	O
acetylgalactosaminidase	O
,	O
IgA1	O
protease	O
and	O
amylase	O
-	O
binding	O
.	O

Antigenic	O
diversity	O
was	O
examined	O
by	O
ELISA	O
and	O
Western	O
immunoblotting	O
using	O
antisera	O
raised	O
against	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
biovar	I-bacteria
1	I-bacteria
NCTC	I-bacteria
12261	I-bacteria
(	O
T	O
)	O
and	O
SK145	B-bacteria
.	O

Three	O
thousand	O
three	O
hundred	O
and	O
thirty	O
(	O
75	O
%	O
)	O
of	O
the	O
isolates	O
were	O
identified	O
as	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
biovar	I-bacteria
1	I-bacteria
and	O
3144	B-bacteria
(	O
94	O
.	O
4	O
%	O
)	O
could	O
be	O
divided	O
into	O
four	O
large	O
phenotypic	O
groups	O
based	O
on	O
glycosidase	O
production	O
.	O

Fifty	O
-	O
four	O
percent	O
of	O
the	O
isolates	O
produced	O
IgA1	O
protease	O
,	O
but	O
production	O
was	O
disproportionate	O
among	O
the	O
phenotypes	O
.	O

Between	O
one	O
-	O
third	O
and	O
one	O
-	O
half	O
of	O
the	O
strains	O
of	O
each	O
phenotype	O
bound	O
salivary	O
alpha	O
-	O
amylase	O
.	O

Antisera	O
against	O
strains	O
NCTC	B-bacteria
12261	I-bacteria
(	O
T	O
)	O
and	O
SK145	B-bacteria
displayed	O
different	O
patterns	O
of	O
reactivity	O
with	O
randomly	O
selected	O
representatives	O
of	O
the	O
four	O
phenotypes	O
.	O

S	B-bacteria
.	I-bacteria
mitis	I-bacteria
biovar	I-bacteria
1	I-bacteria
is	O
physiologically	O
and	O
antigenically	O
diverse	O
,	O
properties	O
which	O
could	O
aid	O
strains	O
in	O
avoiding	O
host	O
immunity	O
and	O
promote	O
re	O
-	O
colonization	O
of	O
a	O
habitat	O
or	O
transfer	O
to	O
a	O
new	O
habitat	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
plays	O
a	O
significant	O
role	O
in	O
gastric	O
disease	O
.	O

However	O
,	O
the	O
presence	O
of	O
this	O
bacterium	O
in	O
the	O
oral	O
cavity	O
remains	O
controversial	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
detect	O
and	O
quantify	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
29	O
different	O
sites	O
of	O
the	O
oral	O
cavity	O
in	O
non	O
-	O
dyspeptic	O
subjects	O
by	O
means	O
of	O
real	O
-	O
time	O
polymerase	O
chain	O
reactions	O
(	O
PCR	O
)	O
.	O

Ten	O
subjects	O
without	O
gastric	O
symptoms	O
were	O
studied	O
.	O

Samples	O
from	O
unstimulated	O
saliva	O
,	O
three	O
sites	O
of	O
the	O
tongue	O
,	O
oral	O
mucosa	O
,	O
and	O
12	O
sites	O
of	O
both	O
supragingival	O
and	O
subgingival	O
plaque	O
were	O
collected	O
from	O
each	O
subject	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
oral	O
samples	O
and	O
analysed	O
for	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
by	O
real	O
-	O
time	O
PCR	O
(	O
LightCycler	O
)	O
using	O
JW23	O
/	O
22	O
primers	O
which	O
targeted	O
the	O
16S	O
rRNA	O
gene	O
.	O

DNA	O
from	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
DSM	I-bacteria
4867	I-bacteria
was	O
used	O
as	O
a	O
positive	O
control	O
.	O

Amplification	O
efficiency	O
for	O
the	O
LightCycler	O
2	O
.	O
0	O
runs	O
ranged	O
from	O
1	O
.	O
8	O
to	O
2	O
.	O
4	O
.	O

Melting	O
curve	O
analysis	O
identified	O
all	O
the	O
positive	O
control	O
capillaries	O
,	O
which	O
contained	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
reference	O
DNA	O
,	O
as	O
a	O
single	O
and	O
narrow	O
peak	O
at	O
a	O
melting	O
temperature	O
between	O
84	O
.	O
5	O
and	O
84	O
.	O
9	O
degrees	O
C	O
.	O
All	O
the	O
negative	O
control	O
capillaries	O
with	O
no	O
template	O
control	O
and	O
the	O
29	O
oral	O
samples	O
from	O
each	O
subject	O
showed	O
either	O
no	O
melting	O
peaks	O
or	O
broad	O
melting	O
peaks	O
below	O
80	O
degrees	O
C	O
,	O
which	O
were	O
considered	O
as	O
primer	O
dimers	O
.	O

Therefore	O
,	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
not	O
detected	O
from	O
any	O
of	O
the	O
290	O
oral	O
samples	O
.	O

As	O
a	O
conclusion	O
,	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
seems	O
not	O
to	O
be	O
permanently	O
present	O
in	O
the	O
oral	O
cavity	O
of	O
a	O
non	O
-	O
dyspeptic	O
population	O
.	O

The	O
oral	O
streptococci	B-bacteria
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
Streptococcus	B-bacteria
gordonii	I-bacteria
and	O
Streptococcus	B-bacteria
oralis	I-bacteria
are	O
common	O
aetiological	O
agents	O
of	O
infective	O
endocarditis	O
,	O
and	O
their	O
ability	O
to	O
adhere	O
to	O
and	O
induce	O
the	O
aggregation	O
of	O
platelets	O
is	O
thought	O
to	O
be	O
a	O
virulence	O
trait	O
.	O

The	O
platelet	O
glycoprotein	O
GPIbalpha	O
has	O
been	O
implicated	O
as	O
the	O
adhesion	O
receptor	O
for	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
,	O
but	O
it	O
is	O
not	O
known	O
if	O
this	O
is	O
the	O
case	O
for	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
and	O
other	O
species	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
GPIbalpha	O
-	O
interactive	O
capability	O
of	O
a	O
range	O
of	O
oral	O
streptococci	B-bacteria
and	O
to	O
determine	O
the	O
relationship	O
between	O
this	O
capability	O
and	O
their	O
ability	O
to	O
interact	O
with	O
the	O
salivary	O
constituents	O
that	O
they	O
would	O
encounter	O
in	O
their	O
normal	O
habitat	O
.	O

All	O
platelet	O
-	O
adhesive	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
strains	I-bacteria
and	O
most	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
strains	I-bacteria
adhered	O
in	O
a	O
GPIbalpha	O
-	O
dependent	O
manner	O
,	O
but	O
strains	O
of	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
,	O
Streptococcus	B-bacteria
cristatus	I-bacteria
,	O
Streptococcus	B-bacteria
parasanguinis	I-bacteria
and	O
Streptococcus	B-bacteria
mitis	I-bacteria
had	O
no	O
direct	O
affinity	O
for	O
platelets	O
.	O

Those	O
strains	O
that	O
were	O
able	O
to	O
bind	O
GPIbalpha	O
also	O
bound	O
to	O
the	O
low	O
-	O
molecular	O
-	O
weight	O
submandibular	O
salivary	O
mucin	O
,	O
MG2	O
,	O
and	O
this	O
interaction	O
was	O
sialic	O
acid	O
-	O
dependent	O
.	O

The	O
data	O
suggest	O
that	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
may	O
be	O
efficient	O
colonizers	O
of	O
platelet	O
vegetations	O
because	O
of	O
their	O
adaptation	O
to	O
recognize	O
sialylated	O
salivary	O
mucins	O
.	O

In	O
contrast	O
,	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
does	O
not	O
interact	O
with	O
platelets	O
and	O
so	O
is	O
likely	O
to	O
colonize	O
vegetations	O
through	O
an	O
as	O
yet	O
unidentified	O
mechanism	O
.	O

Halitosis	O
can	O
be	O
a	O
crippling	O
social	O
problem	O
,	O
and	O
standard	O
dental	O
treatments	O
and	O
mouthwashes	O
often	O
provide	O
only	O
temporary	O
relief	O
.	O

The	O
mouth	O
is	O
home	O
to	O
hundreds	O
of	O
bacterial	O
species	O
that	O
produce	O
several	O
fetid	O
substances	O
as	O
a	O
result	O
of	O
protein	O
degradation	O
.	O

Volatile	O
sulfur	O
compound	O
(	O
VSC	O
)	O
-	O
producing	O
bacteria	O
colonizing	O
the	O
lingual	O
dorsum	O
have	O
recently	O
been	O
implicated	O
in	O
the	O
generation	O
of	O
halitosis	O
.	O

Detection	O
of	O
VSCs	O
,	O
such	O
as	O
methylmercaptan	O
and	O
hydrogen	O
sulfite	O
,	O
via	O
organoleptic	O
and	O
objective	O
methods	O
,	O
can	O
aid	O
in	O
the	O
identification	O
of	O
their	O
source	O
.	O

Following	O
comprehensive	O
evaluation	O
for	O
possible	O
causes	O
,	O
most	O
halitosis	O
in	O
patients	O
seen	O
in	O
an	O
ENT	O
practice	O
can	O
be	O
localized	O
to	O
the	O
tongue	O
.	O

We	O
review	O
methods	O
of	O
diagnosis	O
and	O
treatment	O
of	O
oral	O
malodor	O
from	O
the	O
overgrowth	O
of	O
proteolytic	O
,	O
anaerobic	O
,	O
gram	O
-	O
negative	O
bacteria	O
on	O
the	O
crevices	O
of	O
the	O
lingual	O
dorsum	O
.	O

Bacteriologic	O
analysis	O
of	O
biofilm	O
and	O
scraped	O
specimens	O
obtained	O
from	O
the	O
lingual	O
dorsum	O
and	O
other	O
oral	O
sites	O
,	O
primarily	O
gingival	O
pockets	O
and	O
tonsillar	O
crypts	O
,	O
can	O
identify	O
VSC	O
-	O
producing	O
bacteria	O
.	O

Porphyromonas	B-bacteria
,	O
Prevotella	B-bacteria
,	O
Actinobacillus	B-bacteria
,	O
and	O
Fusobacterium	B-bacteria
species	I-bacteria
are	O
the	O
most	O
common	O
organisms	O
identified	O
.	O

Halitosis	O
is	O
an	O
oral	O
phenomenon	O
,	O
with	O
almost	O
no	O
cases	O
originating	O
distal	O
to	O
the	O
tonsils	O
.	O

Halitosis	O
arising	O
from	O
the	O
lingual	O
dorsum	O
secondary	O
to	O
overpopulated	O
VSC	O
-	O
producing	O
bacteria	O
can	O
be	O
successfully	O
managed	O
with	O
a	O
combination	O
of	O
mechanical	O
cleansing	O
using	O
tongue	O
brushes	O
or	O
scrapes	O
and	O
chemical	O
solutions	O
containing	O
essential	O
oils	O
,	O
zinc	O
chloride	O
,	O
and	O
cetylpyridinium	O
chloride	O
.	O

The	O
hygiene	O
hypothesis	O
contends	O
that	O
fewer	O
opportunities	O
for	O
infection	O
have	O
led	O
to	O
increases	O
in	O
the	O
prevalences	O
of	O
asthma	O
and	O
other	O
allergic	O
diseases	O
.	O

This	O
study	O
evaluated	O
the	O
association	O
between	O
asthma	O
,	O
wheeze	O
,	O
and	O
hay	O
fever	O
and	O
antibodies	O
to	O
2	O
oral	O
bacteria	O
associated	O
with	O
periodontal	O
disease	O
.	O

Data	O
were	O
obtained	O
from	O
the	O
Third	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
.	O

Serum	O
levels	O
of	O
IgG	O
antibodies	O
to	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
were	O
quantified	O
by	O
enzyme	O
-	O
linked	O
immunoassays	O
in	O
9385	O
subjects	O
age	O
12	O
years	O
and	O
older	O
.	O

The	O
outcomes	O
were	O
current	O
asthma	O
,	O
wheeze	O
,	O
and	O
hay	O
fever	O
.	O

Odds	O
ratios	O
(	O
ORs	O
)	O
representing	O
a	O
1	O
-	O
log	O
-	O
unit	O
increase	O
in	O
IgG	O
concentrations	O
were	O
estimated	O
with	O
logistic	O
regression	O
.	O

ORs	O
were	O
adjusted	O
for	O
8	O
confounders	O
and	O
weighted	O
to	O
represent	O
the	O
US	O
population	O
.	O

For	O
each	O
disease	O
outcome	O
,	O
geometric	O
mean	O
antibody	O
concentrations	O
were	O
higher	O
in	O
persons	O
without	O
the	O
disease	O
outcome	O
than	O
with	O
the	O
disease	O
outcome	O
.	O

For	O
a	O
1	O
-	O
log	O
-	O
unit	O
increase	O
in	O
P	B-bacteria
gingivalis	I-bacteria
antibody	O
concentration	O
,	O
adjusted	O
ORs	O
were	O
0	O
.	O
41	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
20	O
-	O
0	O
.	O
87	O
)	O
for	O
asthma	O
,	O
0	O
.	O
43	O
(	O
0	O
.	O
23	O
-	O
0	O
.	O
78	O
)	O
for	O
wheeze	O
,	O
and	O
0	O
.	O
45	O
(	O
0	O
.	O
23	O
-	O
0	O
.	O
93	O
)	O
for	O
hay	O
fever	O
.	O

For	O
A	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
those	O
ORs	O
were	O
0	O
.	O
56	O
(	O
0	O
.	O
19	O
-	O
1	O
.	O
72	O
)	O
,	O
0	O
.	O
39	O
(	O
0	O
.	O
17	O
-	O
0	O
.	O
86	O
)	O
,	O
and	O
0	O
.	O
48	O
(	O
0	O
.	O
23	O
-	O
1	O
.	O
03	O
)	O
,	O
respectively	O
.	O

Consistent	O
with	O
the	O
hygiene	O
hypothesis	O
,	O
higher	O
concentrations	O
of	O
IgG	O
antibodies	O
to	O
P	B-bacteria
gingivalis	I-bacteria
were	O
significantly	O
associated	O
with	O
lower	O
prevalences	O
of	O
asthma	O
,	O
wheeze	O
,	O
and	O
hay	O
fever	O
,	O
and	O
higher	O
concentrations	O
of	O
IgG	O
antibodies	O
to	O
A	B-bacteria
actinomycetemcomitans	I-bacteria
were	O
significantly	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
wheeze	O
.	O

Colonization	O
of	O
the	O
oral	O
cavity	O
by	O
bacteria	O
and	O
other	O
microbes	O
might	O
play	O
a	O
protective	O
role	O
in	O
the	O
etiology	O
of	O
allergic	O
disease	O
.	O

Aortic	O
aneurysms	O
are	O
common	O
vascular	O
conditions	O
that	O
cause	O
considerable	O
morbidity	O
and	O
mortality	O
.	O

Understanding	O
of	O
the	O
mechanisms	O
involved	O
in	O
the	O
pathogenesis	O
of	O
the	O
condition	O
remains	O
limited	O
.	O

Recently	O
,	O
infection	O
has	O
been	O
suggested	O
as	O
possible	O
contributor	O
in	O
the	O
development	O
of	O
the	O
disease	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
aortic	O
aneurysms	O
for	O
the	O
presence	O
of	O
bacterial	O
DNA	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
targeting	O
the	O
16S	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
gene	O
,	O
followed	O
by	O
cloning	O
and	O
sequencing	O
.	O

Universal	O
eubacterial	O
primers	O
were	O
used	O
to	O
amplify	O
16S	O
rRNA	O
bacterial	O
genes	O
in	O
10	O
specimens	O
from	O
arterial	O
walls	O
of	O
aortic	O
aneurysms	O
.	O

Subsequently	O
,	O
PCR	O
amplicons	O
were	O
cloned	O
into	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
sequencing	O
of	O
the	O
cloned	O
inserts	O
was	O
used	O
to	O
determine	O
species	O
identity	O
or	O
closest	O
relatives	O
by	O
comparison	O
with	O
known	O
sequences	O
in	O
GenBank	O
.	O

Sequences	O
of	O
Stenotrophomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
including	O
S	B-bacteria
.	I-bacteria
maltophilia	I-bacteria
(	O
formerly	O
Pseudomonas	B-bacteria
homology	I-bacteria
group	I-bacteria
V	I-bacteria
)	O
were	O
detected	O
in	O
six	O
aneurysm	O
samples	O
.	O

Propionibacterium	B-bacteria
acnes	I-bacteria
was	O
identified	O
in	O
five	O
samples	O
,	O
and	O
Brevundimonas	B-bacteria
diminuta	I-bacteria
(	O
formerly	O
P	B-bacteria
.	I-bacteria
diminuta	I-bacteria
)	O
in	O
four	O
samples	O
.	O

Other	O
species	O
previously	O
assigned	O
to	O
the	O
Pseudomonas	B-bacteria
genus	I-bacteria
such	O
as	O
Comamonas	B-bacteria
testosteroni	I-bacteria
,	O
Delftia	B-bacteria
acidovorans	I-bacteria
,	O
Burkholderia	B-bacteria
cepacia	I-bacteria
,	O
Herbaspirillum	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
and	O
Acidovorax	B-bacteria
sp	I-bacteria
.	I-bacteria
were	O
also	O
detected	O
.	O

Some	O
clones	O
fell	O
into	O
other	O
environmental	O
species	O
,	O
including	O
Methylobacterium	B-bacteria
sp	I-bacteria
.	I-bacteria
and	O
Bradyrhizobium	B-bacteria
elkanii	I-bacteria
,	O
and	O
others	O
represented	O
bacteria	O
that	O
have	O
not	O
yet	O
been	O
cultivated	O
.	O

DNA	O
sequences	O
from	O
oral	O
bacteria	O
,	O
including	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
and	O
Leptotrichia	B-bacteria
buccalis	I-bacteria
were	O
detected	O
.	O

Sequences	O
from	O
Prevotella	B-bacteria
melaninogenica	I-bacteria
and	O
Lactobacillus	B-bacteria
delbrueckii	I-bacteria
,	O
which	O
are	O
commonly	O
found	O
in	O
both	O
mouth	O
and	O
gastrointestinal	O
tract	O
,	O
were	O
also	O
detected	O
.	O

Additional	O
species	O
included	O
Dermacoccus	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
Corynebacterium	B-bacteria
vitaeruminis	I-bacteria
.	O

A	O
wide	O
variety	O
of	O
bacteria	O
,	O
including	O
oral	O
bacteria	O
,	O
was	O
found	O
to	O
colonize	O
aortic	O
aneurysms	O
and	O
may	O
play	O
a	O
role	O
in	O
their	O
development	O
.	O

Several	O
of	O
these	O
microorganisms	O
have	O
not	O
yet	O
been	O
cultivated	O
.	O

Although	O
Chlamydophila	B-bacteria
pneumoniae	I-bacteria
has	O
been	O
detected	O
in	O
aneurysmal	O
walls	O
,	O
its	O
exact	O
role	O
in	O
the	O
condition	O
remains	O
inconclusive	O
.	O

Overall	O
,	O
there	O
is	O
scarce	O
information	O
about	O
the	O
role	O
of	O
microorganisms	O
in	O
aneurysmal	O
disease	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
molecular	O
genetics	O
to	O
detect	O
a	O
diversity	O
of	O
bacteria	O
in	O
arterial	O
walls	O
of	O
aortic	O
aneurysms	O
.	O

The	O
presence	O
of	O
multiple	O
microorganisms	O
in	O
aneurysmal	O
disease	O
may	O
have	O
implications	O
for	O
chemoprophylaxis	O
and	O
antibiotic	O
treatment	O
if	O
directed	O
only	O
at	O
C	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
.	O

We	O
have	O
already	O
reported	O
that	O
chitosan	O
inhibited	O
the	O
growth	O
of	O
cariogenic	O
bacteria	O
in	O
vitro	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
whether	O
chewing	O
gum	O
,	O
containing	O
chitosan	O
,	O
can	O
effectively	O
suppressed	O
the	O
growth	O
of	O
oral	O
bacteria	O
(	O
total	O
bacteria	O
,	O
total	O
Streptococci	B-bacteria
,	O
mutans	B-bacteria
streptococci	I-bacteria
(	O
MS	B-bacteria
)	O
)	O
in	O
saliva	O
.	O

Fifty	O
healthy	O
subjects	O
,	O
ranging	O
in	O
age	O
from	O
19	O
to	O
32	O
years	O
,	O
were	O
recruited	O
from	O
among	O
the	O
staff	O
and	O
students	O
of	O
Nagasaki	O
University	O
School	O
of	O
Dentistry	O
.	O

For	O
the	O
slab	O
of	O
gum	O
study	O
,	O
the	O
subjects	O
chewed	O
gum	O
for	O
5	O
min	O
and	O
then	O
rested	O
for	O
5	O
min	O
.	O

Each	O
subject	O
chewed	O
a	O
total	O
of	O
eight	O
pieces	O
of	O
gum	O
,	O
which	O
was	O
either	O
supplemented	O
with	O
or	O
without	O
chitosan	O
,	O
for	O
a	O
total	O
of	O
80	O
min	O
.	O

Two	O
different	O
types	O
of	O
gums	O
were	O
examined	O
with	O
at	O
least	O
1	O
week	O
as	O
a	O
rest	O
period	O
in	O
between	O
treatments	O
.	O

This	O
in	O
vivo	O
study	O
was	O
carried	O
out	O
by	O
the	O
double	O
blind	O
comparison	O
test	O
.	O

The	O
amount	O
of	O
oral	O
bacteria	O
was	O
found	O
to	O
significantly	O
decrease	O
in	O
the	O
chitosan	O
group	O
.	O

Especially	O
,	O
the	O
number	O
of	O
MS	B-bacteria
were	O
maintained	O
at	O
about	O
a	O
20	O
%	O
level	O
in	O
comparison	O
to	O
that	O
before	O
gum	O
chewing	O
,	O
even	O
at	O
1h	O
after	O
gum	O
chewing	O
.	O

These	O
findings	O
suggest	O
that	O
a	O
supplementation	O
of	O
chitosan	O
to	O
gum	O
is	O
an	O
effective	O
method	O
for	O
controlling	O
the	O
number	O
of	O
cariogenic	O
bacteria	O
in	O
situations	O
where	O
it	O
is	O
difficult	O
to	O
brush	O
one	O
'	O
s	O
teeth	O
,	O
such	O
as	O
when	O
an	O
individual	O
is	O
away	O
from	O
home	O
all	O
day	O
or	O
participating	O
in	O
outdoor	O
training	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
impact	O
of	O
haematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
on	O
Helicobacter	B-bacteria
pylori	I-bacteria
colonization	O
of	O
the	O
oral	O
mucosa	O
by	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
nested	O
-	O
PCR	O
)	O
.	O

Forty	O
six	O
consecutive	O
patients	O
submitted	O
to	O
HSCT	O
and	O
46	O
healthy	O
volunteers	O
were	O
included	O
in	O
the	O
study	O
.	O

Oral	O
swabs	O
were	O
taken	O
from	O
the	O
oral	O
mucosa	O
of	O
the	O
patients	O
and	O
control	O
group	O
.	O

The	O
medical	O
records	O
of	O
the	O
patients	O
were	O
reviewed	O
and	O
the	O
following	O
information	O
was	O
retrieved	O
:	O
gender	O
and	O
age	O
of	O
the	O
patient	O
,	O
donor	O
gender	O
,	O
primary	O
disease	O
,	O
stem	O
cell	O
source	O
(	O
bone	O
marrow	O
or	O
blood	O
stem	O
cells	O
)	O
,	O
leukocyte	O
,	O
neutrophil	O
and	O
platelet	O
counts	O
,	O
and	O
chronic	O
graft	O
versus	O
host	O
disease	O
(	O
cGVHD	O
)	O
of	O
salivary	O
glands	O
.	O

The	O
results	O
demonstrated	O
an	O
increased	O
frequency	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
mucosa	O
of	O
HSCT	O
patients	O
compared	O
to	O
controls	O
(	O
rho	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
mucosa	O
was	O
not	O
related	O
to	O
the	O
severity	O
of	O
cGVHD	O
.	O

The	O
median	O
counts	O
of	O
platelet	O
/	O
mm3	O
,	O
leukocytes	O
/	O
mm3	O
and	O
neutrophils	O
/	O
mm3	O
in	O
the	O
group	O
of	O
HSCT	O
patients	O
positive	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
were	O
not	O
statistically	O
different	O
from	O
those	O
of	O
the	O
patients	O
negative	O
for	O
it	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
shows	O
increased	O
frequency	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
mucosa	O
of	O
HSCT	O
patients	O
compared	O
to	O
non	O
-	O
transplanted	O
healthy	O
volunteers	O
.	O

Salivary	O
nitrate	O
is	O
positively	O
correlated	O
with	O
plasma	O
nitrate	O
and	O
its	O
level	O
is	O
9	O
times	O
the	O
plasma	O
level	O
after	O
nitrate	O
loading	O
.	O

Nitrate	O
in	O
saliva	O
is	O
known	O
to	O
be	O
reduced	O
to	O
nitrite	O
by	O
oral	O
bacteria	O
.	O

Nitrate	O
and	O
nitrite	O
levels	O
in	O
saliva	O
are	O
3	O
-	O
5	O
times	O
those	O
in	O
serum	O
in	O
physiological	O
conditions	O
respectively	O
in	O
our	O
previous	O
study	O
.	O

The	O
biological	O
functions	O
of	O
high	O
salivary	O
nitrate	O
and	O
nitrite	O
are	O
still	O
not	O
well	O
understood	O
.	O

The	O
aim	O
of	O
this	O
in	O
vitro	O
study	O
was	O
to	O
investigate	O
the	O
antimicrobial	O
effects	O
of	O
nitrate	O
and	O
nitrite	O
on	O
main	O
oral	O
pathogens	O
under	O
acidic	O
conditions	O
.	O

Six	O
common	O
oral	O
pathogens	O
including	O
Streptococcus	B-bacteria
mutans	I-bacteria
NCTC	I-bacteria
10449	I-bacteria
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
ATCC	I-bacteria
4646	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
ATCC	I-bacteria
33277	I-bacteria
,	O
Capnocytophaga	B-bacteria
gingivalis	I-bacteria
ATCC	I-bacteria
33624	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
ATCC	I-bacteria
10953	I-bacteria
,	O
and	O
Candida	O
albicans	O
ATCC	O
10231	O
were	O
cultured	O
in	O
liquid	O
medium	O
.	O

Sodium	O
nitrate	O
or	O
sodium	O
nitrite	O
was	O
added	O
to	O
the	O
medium	O
to	O
final	O
concentrations	O
of	O
0	O
,	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
and	O
10	O
mmol	O
/	O
L	O
.	O

All	O
of	O
the	O
microorganisms	O
were	O
incubated	O
for	O
24	O
to	O
48	O
hours	O
.	O

The	O
optical	O
densities	O
(	O
OD	O
)	O
of	O
cell	O
suspensions	O
were	O
determined	O
and	O
the	O
cultures	O
were	O
transferred	O
to	O
solid	O
nutrient	O
broth	O
medium	O
to	O
observe	O
the	O
minimum	O
inhibitory	O
concentration	O
and	O
minimum	O
bactericidal	O
/	O
fungicidal	O
concentration	O
for	O
the	O
six	O
tested	O
pathogens	O
.	O

Nitrite	O
at	O
concentrations	O
of	O
0	O
.	O
5	O
to	O
10	O
mmol	O
/	O
L	O
had	O
an	O
inhibitory	O
effect	O
on	O
all	O
tested	O
organisms	O
at	O
low	O
pH	O
values	O
.	O

The	O
antimicrobial	O
effect	O
of	O
nitrite	O
increased	O
with	O
the	O
acidity	O
of	O
the	O
medium	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
NCTC	I-bacteria
10449	I-bacteria
was	O
highly	O
sensitive	O
to	O
nitrite	O
at	O
low	O
pH	O
values	O
.	O

Lactobacillus	B-bacteria
acidophilus	I-bacteria
ATCC	I-bacteria
4646	I-bacteria
and	O
Candida	O
albicans	O
ATCC	B-bacteria
10231	I-bacteria
were	O
relatively	O
resistant	O
to	O
acidified	O
nitrite	O
.	O

Nitrate	O
at	O
the	O
given	O
concentrations	O
and	O
under	O
acidic	O
conditions	O
had	O
no	O
inhibitory	O
effect	O
on	O
the	O
growth	O
of	O
any	O
of	O
the	O
tested	O
pathogens	O
.	O

Nitrite	O
,	O
at	O
a	O
concentration	O
equal	O
to	O
that	O
in	O
human	O
saliva	O
,	O
is	O
both	O
cytocidal	O
and	O
cytostatic	O
to	O
six	O
principal	O
oral	O
pathogens	O
in	O
vitro	O
,	O
whereas	O
nitrate	O
at	O
a	O
similar	O
concentration	O
has	O
no	O
antimicrobial	O
effect	O
on	O
these	O
organisms	O
.	O

As	O
the	O
result	O
of	O
the	O
study	O
of	O
stomatological	O
status	O
indices	O
in	O
children	O
with	O
gastroduodenal	O
pathology	O
associated	O
with	O
Helicobacter	B-bacteria
pylori	I-bacteria
it	O
was	O
established	O
that	O
caries	O
incidence	O
in	O
children	O
did	O
not	O
depend	O
upon	O
contamination	O
while	O
caries	O
prevalence	O
in	O
examined	O
children	O
unlike	O
caries	O
incidence	O
was	O
associated	O
with	O
HP	O
-	O
status	O
of	O
the	O
oral	O
cavity	O
.	O

Patients	O
with	O
concomitant	O
gastroduodenal	O
pathology	O
had	O
frequently	O
periodontal	O
disease	O
(	O
PD	O
)	O
.	O

In	O
children	O
with	O
chronic	O
antral	O
gastritis	O
associated	O
with	O
Helicobacter	B-bacteria
pylori	I-bacteria
clinical	O
manifestations	O
were	O
poor	O
and	O
tended	O
towards	O
inflammatory	O
process	O
chronicity	O
.	O

All	O
the	O
patients	O
had	O
chronic	O
catarrhal	O
gingivitis	O
.	O

In	O
children	O
with	O
Helicobacter	B-bacteria
pylori	I-bacteria
associated	O
pathology	O
of	O
GIT	O
it	O
proceeded	O
with	O
100	O
%	O
contamination	O
of	O
gingival	O
mucous	O
membrane	O
by	O
Helicobacter	B-bacteria
pylori	I-bacteria
as	O
shown	O
by	O
bacterioscopic	O
study	O
.	O

For	O
nearly	O
a	O
century	O
,	O
lactobacilli	B-bacteria
(	O
LB	B-bacteria
)	O
in	O
the	O
oral	O
cavity	O
have	O
been	O
generally	O
associated	O
with	O
dental	O
caries	O
.	O

Here	O
,	O
we	O
characterized	O
the	O
LB	B-bacteria
isolated	O
from	O
the	O
saliva	O
of	O
6	O
women	O
with	O
active	O
caries	O
using	O
genetic	O
-	O
based	O
taxonomical	O
identification	O
methods	O
.	O

From	O
each	O
subject	O
,	O
30	O
isolates	O
growing	O
on	O
Rogosa	O
medium	O
and	O
presumed	O
to	O
be	O
LB	B-bacteria
were	O
analyzed	O
.	O

Of	O
the	O
180	O
isolates	O
,	O
176	O
were	O
further	O
characterized	O
by	O
biotyping	O
,	O
DNA	O
melting	O
points	O
,	O
DNA	O
chromosomal	O
fingerprinting	O
,	O
genotyping	O
,	O
and	O
phylogenetic	O
cluster	O
assessment	O
.	O

We	O
found	O
a	O
total	O
of	O
30	O
unique	O
genotypes	O
of	O
LB	B-bacteria
in	O
the	O
saliva	O
of	O
caries	O
-	O
active	O
women	O
,	O
with	O
each	O
woman	O
harboring	O
between	O
2	O
and	O
8	O
distinct	O
genotypes	O
.	O

Although	O
Lactobacillus	B-bacteria
vaginalis	I-bacteria
,	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
,	O
and	O
L	B-bacteria
.	I-bacteria
salivarius	I-bacteria
were	O
found	O
in	O
4	O
of	O
6	O
of	O
the	O
subjects	O
,	O
results	O
from	O
other	O
studies	O
using	O
comparable	O
methods	O
show	O
an	O
entirely	O
different	O
array	O
of	O
LB	B-bacteria
associated	O
with	O
caries	O
.	O

These	O
collective	O
observations	O
lead	O
us	O
to	O
surmise	O
that	O
LB	B-bacteria
associated	O
with	O
dental	O
caries	O
are	O
likely	O
exogenous	O
and	O
opportunistic	O
colonizers	O
,	O
arising	O
from	O
food	O
or	O
other	O
reservoirs	O
outside	O
the	O
oral	O
cavity	O
.	O

In	O
this	O
longitudinal	O
study	O
,	O
patients	O
with	O
fixed	O
orthodontic	O
appliances	O
served	O
as	O
models	O
to	O
determine	O
whether	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
and	O
total	O
streptococci	B-bacteria
increased	O
after	O
treatment	O
,	O
and	O
whether	O
treatment	O
affected	O
bacterial	O
invasion	O
into	O
the	O
adjacent	O
buccal	O
epithelial	O
cells	O
(	O
BEC	O
)	O
.	O

Supragingival	O
plaque	O
,	O
subgingival	O
plaque	O
,	O
and	O
BEC	O
were	O
collected	O
from	O
27	O
patients	O
before	O
and	O
at	O
least	O
4	O
weeks	O
after	O
placement	O
of	O
orthodontic	O
fixed	O
appliances	O
.	O

Total	O
sample	O
DNA	O
was	O
determined	O
,	O
and	O
bacteria	O
were	O
assayed	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
.	O

The	O
BEC	O
were	O
also	O
examined	O
by	O
confocal	O
microscopy	O
after	O
fluorescent	O
in	O
-	O
situ	O
hybridization	O
to	O
visually	O
detect	O
the	O
presence	O
of	O
each	O
species	O
bacteria	O
in	O
BEC	O
.	O

Total	O
DNA	O
in	O
supragingival	O
and	O
subgingival	O
plaque	O
increased	O
after	O
appliance	O
placement	O
(	O
P	O
=	O
.	O
005	O
)	O
.	O

There	O
was	O
also	O
a	O
significant	O
increase	O
in	O
supragingival	O
streptococci	B-bacteria
(	O
P	O
=	O
.	O
0002	O
)	O
.	O

By	O
confocal	O
microscopy	O
,	O
a	O
trend	O
toward	O
fewer	O
buccal	O
cells	O
recovered	O
was	O
found	O
after	O
appliance	O
placement	O
,	O
and	O
there	O
was	O
a	O
significant	O
increase	O
in	O
the	O
percentage	O
of	O
buccal	O
cells	O
containing	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
(	O
P	O
=	O
.	O
0058	O
)	O
.	O

Appliance	O
placement	O
appeared	O
to	O
increase	O
buccal	O
cell	O
susceptibility	O
to	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
invasion	O
.	O

This	O
might	O
be	O
due	O
to	O
physical	O
trauma	O
or	O
to	O
leaching	O
of	O
metals	O
from	O
the	O
appliances	O
.	O

High	O
level	O
of	O
hydrogen	O
peroxide	O
was	O
produced	O
by	O
S	B-bacteria
.	I-bacteria
oligofermentans	I-bacteria
,	O
a	O
novel	O
oral	O
streptococcus	B-bacteria
isolated	O
from	O
human	O
oral	O
cavity	O
previously	O
in	O
our	O
laboratory	O
.	O

To	O
characterize	O
the	O
hydrogen	O
peroxide	O
production	O
by	O
S	B-bacteria
.	I-bacteria
oligofermentans	I-bacteria
,	O
hydrogen	O
peroxide	O
yields	O
at	O
different	O
growth	O
phases	O
and	O
from	O
different	O
substrates	O
were	O
assayed	O
.	O

The	O
results	O
turned	O
out	O
that	O
hydrogen	O
peroxide	O
production	O
started	O
at	O
the	O
beginning	O
of	O
logarithmic	O
phase	O
,	O
and	O
reached	O
the	O
maximal	O
yield	O
at	O
the	O
early	O
stationary	O
phase	O
.	O

Peptone	O
and	O
yeast	O
extract	O
could	O
be	O
the	O
main	O
substrates	O
for	O
hydrogen	O
peroxide	O
production	O
.	O

Moreover	O
,	O
lactate	O
,	O
as	O
a	O
fermentative	O
product	O
of	O
glucose	O
,	O
can	O
be	O
another	O
substrate	O
for	O
hydrogen	O
peroxide	O
production	O
.	O

Furthermore	O
three	O
oxidases	O
activities	O
possibly	O
associated	O
with	O
H2O2	O
production	O
were	O
assayed	O
,	O
and	O
both	O
activities	O
of	O
lactate	O
oxidase	O
and	O
NADH	O
oxidase	O
were	O
detected	O
under	O
aerobic	O
condition	O
,	O
while	O
pyruvate	O
oxidase	O
activity	O
was	O
not	O
detected	O
in	O
the	O
permeabilized	O
cells	O
of	O
S	B-bacteria
.	I-bacteria
oligofermentans	I-bacteria
,	O
implying	O
that	O
S	B-bacteria
.	I-bacteria
oligofermentans	I-bacteria
could	O
mainly	O
rely	O
on	O
the	O
two	O
enzymes	O
activities	O
for	O
H2O2	O
production	O
.	O

There	O
is	O
increasing	O
prevalence	O
of	O
root	O
caries	O
.	O

We	O
hypothesized	O
different	O
biofilms	O
will	O
cause	O
varying	O
demineralization	O
in	O
cementum	O
.	O

This	O
study	O
investigated	O
the	O
extent	O
of	O
demineralization	O
of	O
cementum	O
by	O
oral	O
biofilm	O
formed	O
from	O
three	O
major	O
cariogenic	O
microorganisms	O
:	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
and	O
Actinomyces	B-bacteria
israelii	I-bacteria
.	O

Sound	O
cementum	O
tooth	O
blocks	O
were	O
incubated	O
with	O
mono	O
-	O
,	O
bi	O
-	O
,	O
and	O
tri	O
-	O
species	O
combinations	O
of	O
the	O
bacteria	O
under	O
investigation	O
.	O

MATERIALS	O
AND	O
The	O
matrix	O
(	O
amide	O
I	O
)	O
and	O
phosphate	O
content	O
of	O
the	O
lesions	O
was	O
analyzed	O
by	O
Fourier	O
-	O
transform	O
infrared	O
spectroscopy	O
(	O
FTIR	O
)	O
,	O
and	O
calcium	O
and	O
phosphorus	O
levels	O
were	O
analyzed	O
by	O
scanning	O
electron	O
microscopy	O
and	O
energy	O
-	O
dispersive	O
spectroscopy	O
(	O
SEM	O
-	O
EDX	O
)	O
.	O

The	O
log	O
[	O
amide	O
I	O
:	O
HPO	O
(	O
4	O
)	O
(	O
2	O
-	O
)	O
absorbance	O
]	O
values	O
showed	O
that	O
A	B-bacteria
.	I-bacteria
israelii	I-bacteria
mono	O
-	O
culture	O
caused	O
significantly	O
more	O
demineralization	O
than	O
the	O
other	O
bacterial	O
cultures	O
.	O

log	O
[	O
Ca	O
:	O
P	O
]	O
showed	O
that	O
all	O
carious	O
lesions	O
were	O
confined	O
to	O
the	O
cementum	O
.	O

Oral	O
biofilm	O
arising	O
from	O
bacterial	O
species	O
A	B-bacteria
.	I-bacteria
israelii	I-bacteria
alone	O
was	O
the	O
most	O
cariogenic	O
of	O
those	O
tested	O
and	O
produced	O
the	O
most	O
demineralization	O
in	O
incipient	O
carious	O
lesions	O
in	O
cementum	O
.	O

It	O
is	O
thought	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cancer	O
chemotherapy	O
-	O
associated	O
mucositis	O
is	O
caused	O
in	O
part	O
by	O
changes	O
in	O
the	O
oral	O
bacterial	O
microflora	O
.	O

This	O
systematic	O
review	O
examined	O
the	O
role	O
of	O
oral	O
bacterial	O
microflora	O
changes	O
in	O
the	O
development	O
of	O
oral	O
mucositis	O
during	O
chemotherapy	O
.	O

Thirteen	O
prospective	O
clinical	O
trials	O
were	O
identified	O
,	O
involving	O
300	O
patients	O
with	O
13	O
different	O
cancer	O
diagnoses	O
.	O

There	O
was	O
great	O
variability	O
in	O
patient	O
populations	O
,	O
bacterial	O
sample	O
collection	O
methodology	O
,	O
and	O
oral	O
sample	O
sites	O
.	O

No	O
clear	O
pattern	O
regarding	O
qualitative	O
and	O
quantitative	O
oral	O
flora	O
changes	O
emerged	O
among	O
these	O
studies	O
.	O

The	O
most	O
frequent	O
Gram	O
-	O
negative	O
species	O
isolated	O
during	O
chemotherapy	O
were	O
from	O
the	O
Enterobacteriaceae	B-bacteria
family	I-bacteria
,	O
Pseudomonas	B-bacteria
sp	I-bacteria
.	I-bacteria
and	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
.	O

The	O
most	O
common	O
Gram	O
-	O
positive	O
species	O
isolated	O
were	O
Staphylococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
and	O
Streptococcus	B-bacteria
sp	I-bacteria
.	O

Five	O
studies	O
assessed	O
the	O
role	O
of	O
oral	O
flora	O
changes	O
in	O
the	O
genesis	O
of	O
oral	O
mucosal	O
changes	O
,	O
with	O
no	O
consensus	O
among	O
them	O
.	O

More	O
detailed	O
studies	O
are	O
required	O
to	O
understand	O
the	O
relationship	O
between	O
chemotherapy	O
,	O
alterations	O
in	O
the	O
nature	O
and	O
magnitude	O
of	O
the	O
oral	O
microflora	O
,	O
and	O
the	O
presence	O
of	O
mucositis	O
.	O

To	O
investigate	O
the	O
presence	O
of	O
oral	O
bacterial	O
DNAs	O
in	O
serum	O
and	O
synovial	O
fluid	O
(	O
SF	O
)	O
of	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
.	O

Serum	O
and	O
SF	O
samples	O
from	O
16	O
RA	O
patients	O
,	O
14	O
PsA	O
patients	O
,	O
and	O
9	O
osteoarthritis	O
(	O
controls	O
)	O
patients	O
were	O
extracted	O
for	O
oral	O
bacterial	O
DNA	O
.	O

This	O
was	O
used	O
in	O
a	O
checkerboard	O
DNA	O
-	O
DNA	O
-	O
hybridization	O
set	O
up	O
,	O
to	O
identify	O
40	O
different	O
bacteria	O
.	O

Mean	O
number	O
+	O
/	O
-	O
standard	O
deviation	O
(	O
SD	O
)	O
of	O
oral	O
bacterial	O
species	O
in	O
sera	O
were	O
6	O
.	O
2	O
(	O
3	O
.	O
2	O
)	O
in	O
the	O
RA	O
group	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
and	O
5	O
.	O
4	O
(	O
2	O
.	O
7	O
)	O
in	O
the	O
PsA	O
group	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
compared	O
to	O
2	O
.	O
1	O
(	O
1	O
.	O
7	O
)	O
in	O
the	O
controls	O
.	O

Periodontitis	O
associated	O
species	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
Prevotella	B-bacteria
nigrescens	I-bacteria
were	O
exclusively	O
detected	O
in	O
RA	O
and	O
PsA	O
.	O

Mean	O
number	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
oral	O
bacterial	O
species	O
in	O
SF	O
were	O
14	O
.	O
0	O
(	O
6	O
.	O
8	O
)	O
in	O
the	O
RA	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
19	O
.	O
4	O
(	O
7	O
.	O
1	O
)	O
in	O
the	O
PsA	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
compared	O
to	O
4	O
.	O
0	O
(	O
1	O
.	O
7	O
)	O
in	O
controls	O
.	O

P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
were	O
exclusively	O
identified	O
in	O
RA	O
and	O
PsA	O
SF	O
.	O

Higher	O
means	O
of	O
DNAs	O
were	O
found	O
in	O
RA	O
SF	O
compared	O
to	O
RA	O
serum	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
in	O
PsA	O
SF	O
compared	O
to	O
PsA	O
serum	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Higher	O
concentrations	O
of	O
bacterial	O
DNAs	O
were	O
found	O
in	O
RA	O
and	O
PsA	O
compared	O
to	O
controls	O
.	O

Higher	O
variety	O
and	O
concentrations	O
of	O
oral	O
bacterial	O
DNAs	O
were	O
found	O
in	O
SF	O
compared	O
to	O
serum	O
of	O
RA	O
and	O
PsA	O
patients	O
.	O

These	O
findings	O
indicate	O
that	O
synovial	O
inflammation	O
in	O
RA	O
and	O
PsA	O
may	O
favor	O
trapping	O
of	O
oral	O
bacterial	O
DNAs	O
,	O
suggesting	O
a	O
perpetuating	O
effect	O
of	O
oral	O
pathogens	O
in	O
joint	O
disease	O
.	O

Nitroethane	O
inhibits	O
the	O
growth	O
of	O
certain	O
zoonotic	O
pathogens	O
such	O
as	O
Campylobacter	B-bacteria
and	O
Salmonella	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
foodborne	O
pathogens	O
estimated	O
to	O
cause	O
millions	O
of	O
human	O
infections	O
each	O
year	O
,	O
and	O
enhances	O
the	O
Salmonella	B-bacteria
-	O
and	O
Escherichia	B-bacteria
coli	I-bacteria
-	O
killing	O
effect	O
of	O
an	O
experimental	O
chlorate	O
product	O
being	O
developed	O
as	O
a	O
feed	O
additive	O
to	O
kill	O
these	O
bacteria	O
immediately	O
pre	O
-	O
harvest	O
.	O

Limited	O
studies	O
have	O
shown	O
that	O
nitroethane	O
inhibits	O
ruminal	O
methane	O
production	O
,	O
which	O
represents	O
a	O
loss	O
of	O
2	O
-	O
12	O
%	O
of	O
the	O
host	O
'	O
s	O
gross	O
energy	O
intake	O
and	O
contributes	O
to	O
global	O
warming	O
and	O
destruction	O
of	O
the	O
ozone	O
layer	O
.	O

The	O
present	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
effects	O
of	O
14	O
-	O
day	O
oral	O
nitroethane	O
administration	O
,	O
0	O
(	O
0X	O
)	O
,	O
80	O
(	O
1X	O
)	O
or	O
160	O
(	O
2X	O
)	O
mg	O
nitroethane	O
/	O
kg	O
body	O
weight	O
per	O
day	O
on	O
ruminal	O
and	O
fecal	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
Campylobacter	B-bacteria
,	O
ruminal	O
and	O
fecal	O
methane	O
-	O
producing	O
and	O
nitroethane	O
-	O
reducing	O
activity	O
,	O
whole	O
animal	O
methane	O
emissions	O
,	O
and	O
ruminal	O
and	O
fecal	O
fermentation	O
balance	O
in	O
Holstein	O
steers	O
(	O
n	O
=	O
6	O
per	O
treatment	O
)	O
averaging	O
403	O
+	O
/	O
-	O
26	O
(	O
SD	O
)	O
kg	O
BW	O
.	O

An	O
experimental	O
chlorate	O
product	O
was	O
fed	O
the	O
day	O
following	O
the	O
last	O
nitroethane	O
administration	O
to	O
determine	O
effects	O
on	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
Campylobacter	B-bacteria
.	O

The	O
experimental	O
chlorate	O
product	O
decreased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
fecal	O
,	O
but	O
not	O
ruminal	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
E	O
.	O
coli	O
concentrations	O
by	O
1000	O
-	O
and	O
10	O
-	O
fold	O
by	O
24	O
and	O
48	O
h	O
,	O
respectively	O
,	O
after	O
chlorate	O
feeding	O
when	O
compared	O
to	O
pre	O
-	O
treatment	O
concentrations	O
(	O
>	O
5	O
.	O
7	O
log	O
(	O
10	O
)	O
colony	O
forming	O
units	O
/	O
g	O
)	O
.	O

No	O
effects	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
of	O
nitroethane	O
or	O
the	O
experimental	O
chlorate	O
product	O
were	O
observed	O
on	O
fecal	O
Campylobacter	B-bacteria
concentrations	O
;	O
Campylobacter	B-bacteria
were	O
not	O
recovered	O
from	O
ruminal	O
contents	O
.	O

Nitroethane	O
treatment	O
decreased	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
ruminal	O
(	O
8	O
.	O
46	O
,	O
7	O
.	O
91	O
and	O
4	O
.	O
74	O
+	O
/	O
-	O
0	O
.	O
78	O
micromol	O
/	O
g	O
/	O
h	O
)	O
and	O
fecal	O
(	O
3	O
.	O
90	O
,	O
1	O
.	O
36	O
and	O
1	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
50	O
micromol	O
/	O
g	O
/	O
h	O
)	O
methane	O
-	O
producing	O
activity	O
for	O
treatments	O
0X	O
,	O
1X	O
and	O
2X	O
,	O
respectively	O
.	O

Administration	O
of	O
nitroethane	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
nitroethane	O
-	O
reducing	O
activity	O
in	O
ruminal	O
,	O
but	O
not	O
fecal	O
samples	O
.	O

Day	O
of	O
study	O
affected	O
ruminal	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
but	O
not	O
fecal	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
methane	O
-	O
producing	O
and	O
nitroethane	O
-	O
reducing	O
activities	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
;	O
treatment	O
by	O
day	O
interactions	O
were	O
not	O
observed	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

Ruminal	O
accumulations	O
of	O
acetate	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
2X	O
-	O
treated	O
steers	O
when	O
compared	O
with	O
0X	O
-	O
and	O
1X	O
-	O
treated	O
steers	O
,	O
but	O
no	O
effect	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
of	O
nitroethane	O
was	O
observed	O
on	O
propionate	O
,	O
butyrate	O
or	O
the	O
acetate	O
to	O
propionate	O
ratio	O
.	O

Whole	O
animal	O
methane	O
emissions	O
,	O
expressed	O
as	O
L	O
/	O
day	O
or	O
as	O
a	O
proportion	O
of	O
gross	O
energy	O
intake	O
(	O
%	O
GEI	O
)	O
,	O
were	O
unaffected	O
by	O
nitroethane	O
treatment	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
,	O
and	O
were	O
not	O
correlated	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
with	O
ruminal	O
methane	O
-	O
producing	O
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
oral	O
nitroethane	O
administration	O
reduces	O
ruminal	O
methane	O
-	O
producing	O
activity	O
but	O
suggest	O
that	O
a	O
microbial	O
adaptation	O
,	O
likely	O
due	O
to	O
an	O
in	O
situ	O
enrichment	O
of	O
ruminal	O
nitroethane	O
-	O
reducing	O
bacteria	O
,	O
may	O
cause	O
depletion	O
of	O
nitroethane	O
,	O
at	O
least	O
at	O
the	O
1X	O
administration	O
dose	O
,	O
to	O
concentrations	O
too	O
low	O
to	O
be	O
effective	O
.	O

Further	O
research	O
is	O
warranted	O
to	O
determine	O
if	O
the	O
optimization	O
of	O
dosage	O
of	O
nitroethane	O
or	O
related	O
nitrocompouds	O
can	O
maintain	O
the	O
enteropathogen	O
control	O
and	O
anti	O
-	O
methanogen	O
effect	O
in	O
fed	O
steers	O
.	O

Involvement	O
of	O
the	O
oral	O
mucosa	O
can	O
occur	O
in	O
lepromatous	O
leprosy	O
;	O
however	O
,	O
lesions	O
in	O
the	O
oral	O
mucosa	O
of	O
paucibacillary	O
patients	O
have	O
not	O
been	O
previously	O
observed	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
determine	O
whether	O
clinical	O
and	O
subclinical	O
lesions	O
exist	O
in	O
oral	O
mucosa	O
in	O
nontreated	O
paucibacillary	O
leprosy	O
patients	O
,	O
using	O
clinical	O
and	O
histopathological	O
examination	O
.	O

A	O
clinical	O
and	O
histopathological	O
study	O
involving	O
30	O
untreated	O
paucibacillary	O
leprosy	O
patients	O
was	O
conducted	O
.	O

All	O
patients	O
underwent	O
biopsies	O
of	O
the	O
buccal	O
mucosa	O
,	O
soft	O
palate	O
,	O
and	O
tongue	O
.	O

When	O
acid	O
-	O
fast	O
bacilli	O
in	O
association	O
with	O
inflammatory	O
infiltrate	O
,	O
granulomatous	O
or	O
not	O
,	O
were	O
encountered	O
,	O
it	O
was	O
considered	O
`	O
`	O
specific	O
'	O
'	O
involvement	O
of	O
the	O
oral	O
mucosa	O
;	O
and	O
`	O
`	O
nonspecific	O
'	O
'	O
involvement	O
when	O
the	O
bacilli	O
were	O
not	O
encountered	O
.	O

Eight	O
nonspecific	O
chronic	O
inflammatory	O
reactions	O
and	O
1	O
granulomatous	O
inflammatory	O
process	O
without	O
acid	O
-	O
fast	O
bacilli	O
were	O
detected	O
.	O

Paucibacillary	O
leprosy	O
patients	O
do	O
not	O
exhibit	O
specific	O
,	O
clinical	O
or	O
subclinical	O
,	O
involvement	O
in	O
the	O
oral	O
mucosa	O
;	O
nonspecific	O
alterations	O
occur	O
even	O
in	O
the	O
absence	O
of	O
signs	O
and	O
symptoms	O
.	O

The	O
bactericidal	O
efficacy	O
of	O
diode	O
lasers	O
has	O
already	O
been	O
demonstrated	O
in	O
vitro	O
.	O

We	O
investigated	O
the	O
reduction	O
of	O
aerobe	O
bacteria	O
-	O
colonizing	O
rough	O
titanium	O
samples	O
in	O
biofilms	O
intraorally	O
grown	O
-	O
by	O
diode	O
lasers	O
of	O
different	O
wave	O
lengths	O
.	O

Twenty	O
-	O
two	O
volunteers	O
participated	O
in	O
the	O
trial	O
.	O

They	O
were	O
fitted	O
for	O
10	O
days	O
with	O
custom	O
-	O
made	O
intraoral	O
plastic	O
splints	O
carrying	O
titanium	O
sleeves	O
.	O

A	O
part	O
of	O
the	O
sleeves	O
was	O
then	O
irradiated	O
with	O
diode	O
lasers	O
in	O
different	O
modes	O
.	O

The	O
other	O
part	O
remained	O
non	O
-	O
irradiated	O
and	O
served	O
as	O
control	O
.	O

Directly	O
after	O
irradiation	O
,	O
the	O
sleeves	O
were	O
swabbed	O
and	O
the	O
gained	O
bacteria	O
were	O
first	O
examined	O
microscopically	O
and	O
then	O
were	O
cultured	O
under	O
aerobic	O
conditions	O
.	O

The	O
bacteria	O
in	O
the	O
controls	O
and	O
in	O
the	O
treated	O
samples	O
were	O
quantified	O
.	O

A	O
comparison	O
with	O
the	O
controls	O
revealed	O
a	O
marked	O
overall	O
reduction	O
of	O
bacterial	O
colonization	O
in	O
all	O
irradiated	O
sleeves	O
.	O

Continuous	O
irradiation	O
for	O
20	O
s	O
reduced	O
bacteria	O
counts	O
by	O
99	O
.	O
67	O
%	O
at	O
810	O
nm	O
and	O
99	O
.	O
58	O
%	O
at	O
980	O
nm	O
.	O

Repeating	O
the	O
20	O
s	O
exposure	O
five	O
times	O
reduced	O
counts	O
by	O
99	O
.	O
98	O
%	O
at	O
810	O
nm	O
and	O
by	O
99	O
.	O
39	O
%	O
at	O
980	O
nm	O
.	O

A	O
98	O
.	O
86	O
%	O
reduction	O
was	O
seen	O
after	O
irradiation	O
in	O
pulsed	O
mode	O
.	O

A	O
further	O
analysis	O
in	O
respect	O
of	O
different	O
isolated	O
bacteria	O
revealed	O
that	O
the	O
streptococci	B-bacteria
group	O
was	O
reduced	O
by	O
99	O
.	O
29	O
-	O
99	O
.	O
99	O
%	O
,	O
while	O
the	O
staphylococci	B-bacteria
group	O
was	O
reduced	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
range	O
94	O
.	O
67	O
-	O
99	O
.	O
99	O
%	O
.	O

The	O
results	O
are	O
of	O
clinical	O
relevance	O
.	O

In	O
comparison	O
with	O
the	O
mean	O
bacterial	O
counts	O
of	O
the	O
untreated	O
samples	O
,	O
all	O
irradiation	O
programs	O
studied	O
in	O
this	O
investigation	O
reduced	O
mean	O
bacterial	O
colonization	O
in	O
a	O
biofilm	O
on	O
intraoral	O
rough	O
titanium	O
surfaces	O
by	O
more	O
than	O
98	O
%	O
.	O

The	O
actual	O
extent	O
of	O
reduction	O
was	O
dependent	O
on	O
the	O
bacteria	O
species	O
as	O
well	O
as	O
on	O
the	O
irradiation	O
mode	O
.	O

Under	O
physiological	O
conditions	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
are	O
involved	O
in	O
the	O
remodeling	O
and	O
turnover	O
of	O
periodontal	O
tissue	O
and	O
their	O
activity	O
is	O
tightly	O
regulated	O
by	O
tissue	O
inhibitors	O
of	O
metalloproteinases	O
(	O
TIMPs	O
)	O
.	O

Disturbances	O
in	O
the	O
balance	O
between	O
MMPs	O
and	O
TIMPs	O
may	O
result	O
in	O
excessive	O
tissue	O
destruction	O
.	O

We	O
previously	O
used	O
an	O
engineered	O
human	O
oral	O
mucosa	O
(	O
EHOM	O
)	O
model	O
to	O
demonstrate	O
that	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
a	O
major	O
etiological	O
agent	O
of	O
periodontitis	O
,	O
infiltrates	O
connective	O
tissue	O
and	O
induces	O
significant	O
loss	O
of	O
attachment	O
of	O
the	O
stratified	O
epithelium	O
from	O
the	O
basement	O
membrane	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
on	O
the	O
expression	O
and	O
production	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
TIMP	O
-	O
1	O
,	O
and	O
TIMP	O
-	O
2	O
by	O
oral	O
fibroblasts	O
and	O
epithelial	O
cells	O
.	O

The	O
EHOM	O
model	O
was	O
infected	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
ATCC	I-bacteria
33277	I-bacteria
or	O
its	O
derivative	O
gingipain	O
-	O
null	O
mutant	O
(	O
KDP128	O
)	O
for	O
different	O
periods	O
of	O
time	O
.	O

MMP	O
and	O
TIMP	O
mRNA	O
expression	O
was	O
evaluated	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
,	O
while	O
protein	O
secretion	O
into	O
the	O
culture	O
medium	O
was	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
.	O

P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
significantly	O
up	O
-	O
regulated	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
mRNA	O
expression	O
by	O
oral	O
epithelial	O
cells	O
.	O

This	O
MMP	O
gene	O
activation	O
was	O
paralleled	O
by	O
TIMP	O
-	O
2	O
gene	O
activation	O
.	O

However	O
,	O
only	O
MMP	O
-	O
9	O
mRNA	O
expression	O
was	O
significantly	O
enhanced	O
by	O
the	O
gingipain	O
-	O
null	O
mutant	O
.	O

At	O
8	O
and	O
24	O
h	O
post	O
-	O
infection	O
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
increased	O
significantly	O
the	O
MMP	O
-	O
9	O
protein	O
level	O
compared	O
to	O
the	O
uninfected	O
EHOM	O
model	O
.	O

The	O
present	O
study	O
reports	O
the	O
ability	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
to	O
regulate	O
MMP	O
and	O
TIMP	O
production	O
by	O
oral	O
cells	O
,	O
a	O
phenomenon	O
that	O
may	O
contribute	O
to	O
tissue	O
destruction	O
.	O

Nail	O
biting	O
is	O
a	O
common	O
oral	O
habit	O
in	O
children	O
and	O
young	O
adults	O
.	O

However	O
,	O
its	O
effect	O
on	O
the	O
oral	O
carriage	O
of	O
Enterobacteriaceae	B-bacteria
is	O
unclear	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
differences	O
in	O
prevalence	O
of	O
Enterobacteriaceae	B-bacteria
in	O
saliva	O
samples	O
from	O
subjects	O
with	O
and	O
without	O
a	O
nail	O
-	O
biting	O
habit	O
.	O

Saliva	O
samples	O
were	O
taken	O
from	O
25	O
subjects	O
who	O
were	O
nail	O
-	O
biters	O
and	O
34	O
subjects	O
with	O
no	O
oral	O
habit	O
.	O

The	O
mean	O
chronological	O
age	O
for	O
all	O
subjects	O
was	O
13	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
9	O
years	O
.	O

The	O
saliva	O
samples	O
were	O
studied	O
microbiologically	O
.	O

A	O
Pearson	O
chi	O
-	O
squared	O
test	O
was	O
performed	O
to	O
compare	O
the	O
prevalence	O
of	O
Enterobacteriaceae	B-bacteria
in	O
the	O
saliva	O
samples	O
of	O
the	O
subjects	O
with	O
and	O
without	O
nail	O
-	O
biting	O
habits	O
.	O

Statistically	O
significant	O
differences	O
were	O
found	O
in	O
the	O
prevalence	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
total	O
Enterobacteriaceae	B-bacteria
between	O
both	O
groups	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

E	B-bacteria
.	I-bacteria
coli	I-bacteria
,	O
Enterobacter	B-bacteria
aerogenes	I-bacteria
,	O
Enterobacter	B-bacteria
cloacae	I-bacteria
and	O
Enterobacter	B-bacteria
gergoviae	I-bacteria
were	O
found	O
in	O
the	O
saliva	O
samples	O
of	O
19	O
of	O
the	O
25	O
nail	O
-	O
biting	O
subjects	O
(	O
76	O
%	O
)	O
,	O
whereas	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
,	O
E	B-bacteria
.	I-bacteria
aerogenes	I-bacteria
and	O
E	B-bacteria
.	I-bacteria
cloacae	I-bacteria
were	O
detected	O
in	O
the	O
saliva	O
samples	O
of	O
only	O
nine	O
of	O
the	O
34	O
subjects	O
who	O
were	O
not	O
nail	O
-	O
biters	O
(	O
26	O
.	O
5	O
%	O
)	O
.	O

According	O
to	O
the	O
results	O
of	O
the	O
present	O
study	O
,	O
the	O
Enterobacteriaceae	B-bacteria
were	O
more	O
prevalent	O
in	O
the	O
oral	O
cavities	O
of	O
children	O
with	O
nail	O
-	O
biting	O
habits	O
than	O
in	O
children	O
with	O
no	O
oral	O
habit	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
eradication	O
from	O
the	O
oral	O
cavity	O
is	O
more	O
difficult	O
than	O
from	O
the	O
stomach	O
.	O

Thus	O
,	O
if	O
the	O
bacterium	O
survives	O
the	O
antibacterial	O
therapy	O
in	O
the	O
oral	O
cavity	O
,	O
it	O
would	O
be	O
able	O
to	O
re	O
-	O
infect	O
the	O
stomach	O
within	O
a	O
few	O
weeks	O
.	O

Since	O
oral	O
health	O
status	O
could	O
correspond	O
to	O
oral	O
infection	O
with	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
,	O
the	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
oral	O
health	O
and	O
oral	O
hygiene	O
practices	O
affect	O
the	O
efficacy	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
from	O
the	O
stomach	O
.	O

The	O
study	O
was	O
performed	O
in	O
137	O
patients	O
with	O
peptic	O
ulcer	O
who	O
had	O
undergone	O
a	O
7	O
-	O
day	O
course	O
of	O
eradication	O
treatment	O
with	O
one	O
of	O
two	O
sets	O
of	O
drugs	O
:	O
1	O
,	O
omeprazole	O
,	O
amoxicillin	O
,	O
and	O
tinidazole	O
or	O
2	O
,	O
omeprazole	O
,	O
clarithromycin	O
,	O
and	O
tinidazole	O
.	O

The	O
efficacy	O
of	O
H	O
.	O
pylori	O
eradication	O
from	O
the	O
stomach	O
was	O
evaluated	O
at	O
the	O
second	O
gastroscopy	O
4	O
weeks	O
after	O
cessation	O
of	O
eradication	O
therapy	O
by	O
means	O
of	O
two	O
methods	O
:	O
rapid	O
urease	O
test	O
and	O
histology	O
.	O

The	O
examination	O
of	O
natural	O
dentition	O
and	O
prosthetic	O
restorations	O
as	O
well	O
as	O
the	O
assessment	O
of	O
hygienic	O
procedures	O
referring	O
to	O
natural	O
dentition	O
and	O
dentures	O
accompanied	O
the	O
second	O
gastroscopy	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
efficacy	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
from	O
the	O
stomach	O
and	O
the	O
number	O
of	O
natural	O
teeth	O
,	O
decayed	O
teeth	O
,	O
use	O
of	O
dentures	O
,	O
debris	O
index	O
,	O
or	O
periodontal	O
index	O
.	O

However	O
,	O
an	O
association	O
between	O
eradication	O
success	O
and	O
some	O
oral	O
hygiene	O
procedures	O
were	O
noted	O
.	O

Unexpectedly	O
,	O
in	O
patients	O
treated	O
with	O
omeprazole	O
,	O
amoxicillin	O
and	O
tinidazole	O
,	O
the	O
removal	O
of	O
dental	O
prosthesis	O
for	O
the	O
night	O
and	O
brushing	O
the	O
natural	O
teeth	O
twice	O
a	O
day	O
or	O
more	O
reduced	O
the	O
efficacy	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
from	O
the	O
stomach	O
.	O

Oral	O
health	O
and	O
oral	O
hygiene	O
practices	O
seem	O
unlikely	O
to	O
increase	O
the	O
efficacy	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
from	O
the	O
stomach	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
(	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
)	O
is	O
an	O
important	O
pathogen	O
in	O
gastritis	O
,	O
peptic	O
ulcer	O
and	O
possibly	O
gastric	O
cancer	O
,	O
but	O
several	O
questions	O
remain	O
unanswered	O
.	O

Particularly	O
how	O
the	O
organism	O
is	O
transmitted	O
and	O
what	O
is	O
the	O
relationship	O
between	O
oral	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
and	O
the	O
gastric	O
infection	O
.	O

Accordingly	O
,	O
we	O
aimed	O
to	O
characterize	O
the	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
oral	O
cavity	O
and	O
to	O
evaluate	O
its	O
relationship	O
to	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
.	O

Out	O
of	O
total	O
100	O
screened	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
female	O
subjects	O
(	O
40	O
to	O
85	O
y	O
)	O
,	O
49	O
patients	O
(	O
pts	O
)	O
,	O
who	O
had	O
positive	O
C	O
-	O
urea	O
breath	O
test	O
(	O
UBT	O
)	O
and	O
dyspeptic	O
symptoms	O
,	O
agreed	O
for	O
1	O
week	O
regimen	O
of	O
triple	O
anti	O
-	O
H	O
.	O
pylori	O
therapy	O
.	O

The	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
oral	O
cavity	O
was	O
assessed	O
using	O
bacterial	O
culture	O
from	O
saliva	O
and	O
gingival	O
pockets	O
.	O

Gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
was	O
estimated	O
using	O
capsulated	O
C	O
-	O
urea	O
breath	O
test	O
and	O
plasma	O
anti	O
-	O
H	O
.	O
pylori	O
IgG	O
and	O
saliva	O
IgA	O
antibodies	O
.	O

In	O
addition	O
,	O
plasma	O
gastrin	O
,	O
ghrelin	O
,	O
and	O
pepsinogen	O
I	O
were	O
measured	O
by	O
radioimmunoassay	O
.	O

In	O
selected	O
patients	O
,	O
gastroscopy	O
was	O
additionally	O
performed	O
and	O
gastric	O
biopsy	O
samples	O
were	O
taken	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
random	O
amplification	O
of	O
polymorphic	O
DNA	O
genetic	O
profiling	O
.	O

The	O
triple	O
therapy	O
resulted	O
in	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
in	O
79	O
%	O
pts	O
,	O
along	O
with	O
significant	O
decrease	O
of	O
plasma	O
gastrin	O
combined	O
with	O
an	O
increase	O
in	O
plasma	O
ghrelin	O
and	O
pepsinogen	O
I	O
(	O
PgI	O
)	O
levels	O
and	O
a	O
marked	O
alleviation	O
of	O
dyspeptic	O
symptoms	O
.	O

In	O
contrast	O
to	O
gastric	O
effects	O
,	O
the	O
eradication	O
therapy	O
failed	O
to	O
cause	O
any	O
changes	O
in	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
oral	O
cavity	O
.	O

Moreover	O
no	O
relationship	O
was	O
observed	O
between	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
oral	O
cavity	O
and	O
the	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
.	O

In	O
line	O
with	O
these	O
findings	O
,	O
no	O
relationship	O
between	O
gastric	O
and	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
found	O
using	O
genetic	O
profiling	O
by	O
random	O
amplification	O
of	O
polymorphic	O
DNA	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
detected	O
both	O
in	O
the	O
oral	O
cavity	O
and	O
the	O
stomach	O
but	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
had	O
no	O
relation	O
to	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
and	O
remained	O
unaffected	O
by	O
eradication	O
of	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

Structure	O
of	O
bacterial	O
microflora	O
of	O
periodontal	O
pocket	O
using	O
classical	O
cultural	O
and	O
molecular	O
genetic	O
methods	O
(	O
PCR	O
and	O
RT	O
-	O
PCR	O
assays	O
)	O
was	O
studied	O
in	O
patients	O
with	O
chronic	O
generalized	O
severe	O
or	O
intermediate	O
periodontitis	O
in	O
acute	O
phase	O
and	O
in	O
healthy	O
subjects	O
.	O

Structure	O
of	O
viral	O
and	O
fungal	O
microflora	O
using	O
PCR	O
or	O
ELISA	O
assays	O
was	O
studied	O
also	O
.	O

Markers	O
of	O
Gram	O
-	O
negative	O
bacteria	O
(	O
B	B-bacteria
.	I-bacteria
forsithus	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
actinomicetemcommitans	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
)	O
were	O
detected	O
with	O
different	O
rates	O
.	O

Rate	O
of	O
detection	O
of	O
pigment	O
-	O
forming	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
was	O
significantly	O
higher	O
when	O
PCR	O
assay	O
was	O
used	O
compared	O
with	O
traditional	O
bacteriologic	O
method	O
.	O

Detection	O
rate	O
of	O
Candida	O
albicans	O
DNA	O
in	O
tooth	O
-	O
gingival	O
fluid	O
was	O
virtually	O
not	O
different	O
from	O
one	O
when	O
cultural	O
method	O
was	O
used	O
.	O

PCR	O
assay	O
is	O
recommended	O
as	O
laboratory	O
method	O
for	O
detection	O
of	O
DNA	O
of	O
microorganisms	O
associated	O
with	O
inflammatory	O
diseases	O
of	O
oral	O
mucosa	O
and	O
periodontium	O
.	O

Trauma	O
intensive	O
care	O
unit	O
(	O
TICU	O
)	O
patients	O
requiring	O
mechanical	O
respiratory	O
support	O
frequently	O
develop	O
ventilator	O
-	O
associated	O
pneumonia	O
(	O
VAP	O
)	O
.	O

Oral	O
and	O
oropharyngeal	O
bacteria	O
are	O
believed	O
to	O
be	O
responsible	O
for	O
many	O
cases	O
of	O
VAP	O
,	O
but	O
definitive	O
evidence	O
of	O
this	O
relationship	O
is	O
lacking	O
.	O

Earlier	O
studies	O
used	O
conventional	O
culture	O
-	O
based	O
methods	O
for	O
identification	O
of	O
bacterial	O
pathogens	O
,	O
but	O
these	O
methods	O
are	O
insufficient	O
,	O
as	O
some	O
bacteria	O
may	O
be	O
uncultivable	O
or	O
difficult	O
to	O
grow	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
use	O
a	O
culture	O
-	O
independent	O
molecular	O
approach	O
to	O
analyze	O
and	O
compare	O
the	O
bacterial	O
species	O
colonizing	O
the	O
oral	O
cavity	O
and	O
the	O
lungs	O
of	O
TICU	O
patients	O
who	O
developed	O
VAP	O
.	O

Bacterial	O
samples	O
were	O
acquired	O
from	O
the	O
dorsal	O
tongue	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
of	O
16	O
patients	O
.	O

Bacterial	O
DNA	O
was	O
extracted	O
,	O
and	O
the	O
16S	O
rRNA	O
genes	O
were	O
PCR	O
amplified	O
,	O
cloned	O
into	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
and	O
sequenced	O
.	O

The	O
sequencing	O
data	O
revealed	O
the	O
following	O
:	O
(	O
i	O
)	O
a	O
wide	O
diversity	O
of	O
bacterial	O
species	O
in	O
both	O
the	O
oral	O
and	O
pulmonary	O
sites	O
,	O
some	O
of	O
them	O
novel	O
;	O
(	O
ii	O
)	O
known	O
and	O
putative	O
respiratory	O
pathogens	O
colonizing	O
both	O
the	O
oral	O
cavity	O
and	O
lungs	O
of	O
14	O
patients	O
;	O
and	O
(	O
iii	O
)	O
a	O
number	O
of	O
bacterial	O
pathogens	O
(	O
e	O
.	O
g	O
.	O
,	O
Dialister	B-bacteria
pneumosintes	I-bacteria
,	O
Haemophilus	B-bacteria
segnis	I-bacteria
,	O
Gemella	B-bacteria
morbillorum	I-bacteria
,	O
and	O
Pseudomonas	B-bacteria
fluorescens	I-bacteria
)	O
in	O
lung	O
samples	O
that	O
had	O
not	O
been	O
reported	O
previously	O
at	O
this	O
site	O
when	O
culture	O
-	O
based	O
methods	O
were	O
used	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
dorsal	O
surface	O
of	O
the	O
tongue	O
serves	O
as	O
a	O
potential	O
reservoir	O
for	O
bacterial	O
species	O
involved	O
in	O
VAP	O
.	O

Furthermore	O
,	O
it	O
is	O
clear	O
that	O
the	O
diversity	O
of	O
bacterial	O
pathogens	O
for	O
VAP	O
is	O
far	O
more	O
complex	O
than	O
the	O
current	O
literature	O
suggests	O
.	O

The	O
aim	O
of	O
this	O
cross	O
-	O
sectional	O
study	O
was	O
to	O
evaluate	O
the	O
periodontal	O
status	O
and	O
oral	O
microbiological	O
patterns	O
of	O
a	O
population	O
with	O
end	O
-	O
stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
,	O
undergoing	O
haemodialysis	O
(	O
HD	O
)	O
.	O

This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
,	O
involving	O
52	O
patients	O
from	O
the	O
Nephrology	O
Department	O
and	O
52	O
matched	O
control	O
subjects	O
.	O

The	O
subjects	O
had	O
a	O
periodontal	O
clinical	O
examination	O
;	O
subgingival	O
plaque	O
samples	O
were	O
taken	O
and	O
analysed	O
using	O
a	O
semiquantitative	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
test	O
to	O
detect	O
Porphyromas	B-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Prevotella	B-bacteria
nigrescens	I-bacteria
and	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
.	O

Subgingival	O
plaque	O
and	O
saliva	O
samples	O
were	O
studied	O
for	O
Candida	O
and	O
Enterobacteriaceae	B-bacteria
.	O

Most	O
of	O
the	O
104	O
subjects	O
had	O
some	O
degree	O
of	O
loss	O
of	O
periodontal	O
attachment	O
(	O
LPA	O
)	O
>	O
or	O
=	O
3	O
mm	O
[	O
11	O
(	O
10	O
.	O
5	O
%	O
)	O
had	O
severe	O
LPA	O
;	O
16	O
(	O
15	O
.	O
4	O
%	O
)	O
moderate	O
LPA	O
;	O
and	O
64	O
(	O
61	O
.	O
5	O
%	O
)	O
mild	O
LPA	O
]	O
.	O

Only	O
13	O
subjects	O
(	O
12	O
.	O
5	O
%	O
)	O
presented	O
good	O
periodontal	O
health	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
between	O
the	O
HD	O
patients	O
and	O
the	O
control	O
group	O
regarding	O
bleeding	O
index	O
,	O
number	O
of	O
teeth	O
,	O
or	O
percentage	O
of	O
LPA	O
>	O
or	O
=	O
3	O
mm	O
.	O

However	O
,	O
a	O
statistically	O
significant	O
difference	O
was	O
seen	O
in	O
the	O
degree	O
of	O
oral	O
hygiene	O
.	O

On	O
the	O
basis	O
of	O
the	O
findings	O
presented	O
here	O
,	O
we	O
can	O
not	O
associate	O
ESRD	O
with	O
more	O
severe	O
periodontal	O
destruction	O
.	O

Although	O
HD	O
patients	O
presented	O
a	O
higher	O
number	O
of	O
periodontopathic	O
microorganisms	O
than	O
the	O
matched	O
controls	O
,	O
a	O
prolonged	O
duration	O
of	O
HD	O
did	O
not	O
bear	O
a	O
statistically	O
significant	O
relationship	O
with	O
the	O
percentage	O
of	O
sites	O
with	O
LPA	O
>	O
or	O
=	O
3	O
mm	O
,	O
specific	O
microbiota	O
or	O
composition	O
of	O
biofilm	O
.	O

To	O
study	O
the	O
short	O
-	O
term	O
microbiological	O
changes	O
following	O
full	O
-	O
mouth	O
compared	O
with	O
quadrant	O
wise	O
scaling	O
and	O
root	O
planing	O
(	O
FMRP	O
and	O
QRP	O
)	O
as	O
well	O
as	O
long	O
-	O
term	O
effects	O
.	O

Twenty	O
patients	O
with	O
chronic	O
periodontitis	O
were	O
randomized	O
into	O
a	O
test	O
group	O
treated	O
in	O
two	O
sessions	O
with	O
subgingival	O
scaling	O
and	O
root	O
planing	O
within	O
24	O
h	O
(	O
FMRP	O
)	O
and	O
a	O
control	O
group	O
treated	O
quadrant	O
by	O
quadrant	O
in	O
four	O
sessions	O
at	O
intervals	O
of	O
one	O
week	O
(	O
QRP	O
)	O
.	O

Microbiological	O
samples	O
were	O
taken	O
in	O
the	O
two	O
deepest	O
pockets	O
of	O
the	O
maxillary	O
right	O
quadrant	O
immediately	O
before	O
treatment	O
and	O
after	O
1	O
day	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
and	O
24	O
weeks	O
.	O

The	O
samples	O
were	O
evaluated	O
by	O
real	O
-	O
time	O
PCR	O
for	O
quantification	O
of	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
ssp	I-bacteria
.	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
,	O
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
as	O
well	O
as	O
for	O
total	O
bacterial	O
counts	O
(	O
TBC	O
)	O
.	O

Treatment	O
resulted	O
in	O
a	O
TBC	O
median	O
log	O
reduction	O
of	O
0	O
.	O
75	O
(	O
FMRP	O
)	O
and	O
0	O
.	O
72	O
(	O
QRP	O
)	O
.	O

There	O
were	O
no	O
differences	O
between	O
groups	O
either	O
for	O
the	O
short	O
term	O
(	O
1	O
day	O
-	O
4	O
weeks	O
)	O
(	O
analysis	O
of	O
variance	O
:	O
p	O
=	O
0	O
.	O
3150	O
)	O
or	O
for	O
long	O
term	O
(	O
4	O
-	O
24	O
weeks	O
)	O
(	O
analysis	O
of	O
variance	O
:	O
p	O
=	O
0	O
.	O
9671	O
)	O
.	O

Likewise	O
,	O
no	O
differences	O
were	O
detected	O
for	O
selected	O
target	O
bacteria	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
showed	O
similar	O
microbiological	O
outcomes	O
following	O
both	O
treatment	O
modalities	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
lactobacilli	B-bacteria
from	O
the	O
human	O
oral	O
cavity	O
as	O
a	O
potential	O
source	O
of	O
probiotic	O
strains	O
.	O

Samples	O
were	O
collected	O
from	O
four	O
different	O
locations	O
within	O
the	O
oral	O
cavity	O
:	O
surface	O
of	O
healthy	O
tooth	O
,	O
oral	O
mucous	O
membrane	O
,	O
surface	O
of	O
tooth	O
decay	O
and	O
deep	O
tooth	O
decay	O
.	O

On	O
the	O
basis	O
of	O
morphological	O
and	O
biochemical	O
properties	O
eight	O
categories	O
were	O
formed	O
and	O
26	O
isolates	O
were	O
selected	O
for	O
further	O
characterization	O
.	O

The	O
isolates	O
were	O
determined	O
as	O
Lactobacillus	B-bacteria
sp	I-bacteria
.	I-bacteria
using	O
primers	O
specific	O
for	O
16S	O
rDNA	O
.	O

Sequencing	O
of	O
16S	O
rDNA	O
genes	O
and	O
repetitive	O
sequence	O
-	O
based	O
polymerase	O
chain	O
reactions	O
were	O
used	O
for	O
determination	O
to	O
species	O
and	O
subspecies	O
levels	O
.	O

Predominant	O
species	O
were	O
Lactobacillus	B-bacteria
fermentum	I-bacteria
,	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
,	O
Lactobacillus	B-bacteria
salivarius	I-bacteria
and	O
Lactobacillus	B-bacteria
paracasei	I-bacteria
subsp	I-bacteria
.	I-bacteria
paracasei	I-bacteria
,	O
while	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
Lactobacillus	B-bacteria
cellobiosus	I-bacteria
,	O
Lactobacillus	B-bacteria
delbrueckii	I-bacteria
subsp	I-bacteria
.	I-bacteria
lactis	I-bacteria
and	O
Lactobacillus	B-bacteria
gasseri	I-bacteria
were	O
also	O
present	O
.	O

The	O
isolates	O
Lactobacillus	B-bacteria
salivarius	I-bacteria
BGHO1	I-bacteria
,	O
Lactobacillus	B-bacteria
fermentum	I-bacteria
BGHO36	I-bacteria
and	I-bacteria
BGHO64	I-bacteria
,	O
Lactobacillus	B-bacteria
gasseri	I-bacteria
BGHO89	I-bacteria
and	O
Lactobacillus	B-bacteria
delbrueckii	I-bacteria
subsp	I-bacteria
.	I-bacteria
lactis	I-bacteria
BGHO99	I-bacteria
exhibited	O
antagonistic	O
action	O
on	O
the	O
growth	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
Enterococcus	B-bacteria
faecalis	I-bacteria
,	O
Micrococcus	B-bacteria
flavus	I-bacteria
,	O
Salmonella	B-bacteria
enteritidis	I-bacteria
,	O
Streptococcus	B-bacteria
pneumoniae	I-bacteria
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
but	O
not	O
on	O
growth	O
of	O
Candida	O
albicans	O
.	O

Moreover	O
,	O
the	O
isolates	O
L	B-bacteria
.	I-bacteria
salivarius	I-bacteria
BGHO1	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
gasseri	I-bacteria
BGHO89	I-bacteria
were	O
tolerant	O
to	O
low	O
pH	O
and	O
high	O
concentration	O
of	O
bile	O
salts	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
imply	O
that	O
L	B-bacteria
.	I-bacteria
salivarius	I-bacteria
BGHO1	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
gasseri	I-bacteria
BGHO89	I-bacteria
might	O
be	O
subjects	O
for	O
additional	O
investigation	O
as	O
potential	O
probiotic	O
strains	O
.	O

The	O
bacteriocin	O
producer	O
Streptococcus	B-bacteria
salivarius	I-bacteria
K12	I-bacteria
is	O
used	O
as	O
a	O
probiotic	O
targeting	O
the	O
oral	O
cavity	O
,	O
so	O
our	O
study	O
aimed	O
to	O
assess	O
whether	O
its	O
dispersal	O
and	O
persistence	O
could	O
be	O
monitored	O
using	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
.	O

To	O
this	O
end	O
,	O
we	O
designed	O
polymerase	O
chain	O
reaction	O
primers	O
and	O
a	O
hybridization	O
probe	O
specifically	O
targeting	O
salA	O
,	O
which	O
encodes	O
for	O
the	O
prepropeptide	O
of	O
salivaricin	O
A	O
.	O

Using	O
a	O
single	O
individual	O
as	O
our	O
subject	O
,	O
we	O
administered	O
four	O
lozenges	O
of	O
K12	B-bacteria
Throat	O
Guard	O
per	O
day	O
over	O
3	O
days	O
,	O
then	O
measured	O
salA	O
gene	O
levels	O
for	O
16	O
different	O
oral	O
sites	O
at	O
six	O
different	O
intervals	O
over	O
35	O
days	O
.	O

Four	O
samples	O
each	O
from	O
gingival	O
sulci	O
and	O
from	O
teeth	O
all	O
remained	O
negative	O
.	O

In	O
contrast	O
,	O
in	O
saliva	O
and	O
at	O
all	O
mucosal	O
membranes	O
K12	B-bacteria
was	O
detected	O
,	O
but	O
with	O
varying	O
amounts	O
and	O
time	O
profiles	O
.	O

Relatively	O
high	O
salA	O
gene	O
copy	O
numbers	O
,	O
calibrated	O
on	O
the	O
basis	O
of	O
colony	O
-	O
forming	O
units	O
,	O
were	O
seen	O
on	O
the	O
tongue	O
(	O
maximum	O
4	O
.	O
6	O
x	O
10	O
(	O
4	O
)	O
/	O
swab	O
at	O
day	O
4	O
)	O
,	O
in	O
stimulated	O
saliva	O
(	O
2	O
.	O
4	O
x	O
10	O
(	O
4	O
)	O
/	O
ml	O
,	O
day	O
4	O
)	O
and	O
on	O
buccal	O
membranes	O
(	O
1	O
.	O
3	O
x	O
10	O
(	O
4	O
)	O
/	O
swab	O
,	O
day	O
8	O
)	O
.	O

K12	B-bacteria
was	O
present	O
on	O
both	O
sides	O
of	O
the	O
pharynx	O
but	O
asymmetrically	O
in	O
both	O
quantity	O
and	O
duration	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
developed	O
a	O
real	O
-	O
time	O
quantitative	O
-	O
polymerase	O
chain	O
reaction	O
for	O
counting	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
K12	I-bacteria
at	O
various	O
sites	O
in	O
the	O
oral	O
cavity	O
.	O

In	O
the	O
individual	O
studied	O
,	O
K12	B-bacteria
could	O
be	O
detected	O
at	O
the	O
mucosal	O
membranes	O
for	O
as	O
long	O
as	O
3	O
weeks	O
,	O
but	O
with	O
steadily	O
decreasing	O
numbers	O
after	O
day	O
8	O
.	O

Thus	O
,	O
K12	B-bacteria
may	O
have	O
the	O
potential	O
to	O
control	O
oral	O
bacterial	O
infections	O
only	O
when	O
the	O
uptake	O
is	O
repeated	O
frequently	O
.	O

The	O
ability	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
to	O
promote	O
coagulation	O
prompted	O
the	O
hypothesis	O
that	O
pro	O
-	O
inflammatory	O
cytokines	O
induced	O
by	O
oral	O
streptococci	B-bacteria
might	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
viridans	O
endocarditis	O
.	O

We	O
used	O
supernatant	O
fluids	O
from	O
peripheral	O
blood	O
mononuclear	O
monocyte	O
(	O
PBMC	O
)	O
cultures	O
,	O
stimulated	O
for	O
just	O
4	O
-	O
6	O
hrs	O
with	O
representative	O
streptococcal	B-bacteria
isolates	I-bacteria
,	O
to	O
study	O
cytokines	O
that	O
promoted	O
endothelial	O
tissue	O
factor	O
(	O
TF	O
)	O
activity	O
.	O

Neutralizing	O
antibodies	O
demonstrated	O
that	O
interleukin	O
-	O
1beta	O
(	O
IL	O
-	O
1beta	O
)	O
was	O
a	O
major	O
early	O
endothelial	O
TF	O
inducer	O
,	O
and	O
that	O
recombinant	O
IL	O
-	O
1beta	O
was	O
comparable	O
with	O
the	O
supernatant	O
fluid	O
in	O
activity	O
.	O

IL	O
-	O
1beta	O
-	O
rich	O
supernatant	O
fluids	O
from	O
oral	O
streptococci	B-bacteria
-	O
stimulated	O
or	O
lipopolysaccharide	O
-	O
stimulated	O
PBMC	O
cultures	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
endothelial	O
ICAM	O
-	O
1	O
and	O
E	O
-	O
selectin	O
.	O

These	O
molecules	O
could	O
help	O
trap	O
TF	O
-	O
producing	O
monocytes	O
or	O
dendritic	O
cells	O
bearing	O
streptococci	B-bacteria
at	O
the	O
site	O
.	O

Thus	O
,	O
the	O
rapid	O
IL	O
-	O
1beta	O
-	O
inducing	O
capacity	O
of	O
oral	O
streptococci	B-bacteria
could	O
facilitate	O
the	O
early	O
deposition	O
of	O
bacteria	O
in	O
fibrin	O
clots	O
and	O
promote	O
endocarditis	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
special	O
oral	O
care	O
using	O
a	O
toothbrush	O
with	O
combined	O
irrigation	O
and	O
suctioning	O
functions	O
,	O
along	O
with	O
povidone	O
-	O
iodine	O
to	O
treat	O
oral	O
bacteria	O
and	O
mucositis	O
,	O
in	O
esophageal	O
cancer	O
patients	O
undergoing	O
chemoradiotherapy	O
.	O

In	O
the	O
special	O
care	O
group	O
,	O
oral	O
hygiene	O
was	O
performed	O
3	O
days	O
a	O
week	O
after	O
dinner	O
.	O

Bacteria	O
in	O
saliva	O
and	O
plague	O
samples	O
were	O
measured	O
at	O
various	O
sampling	O
points	O
after	O
chemoradiotherapy	O
.	O

The	O
incidence	O
of	O
mucositis	O
was	O
significantly	O
reduced	O
in	O
the	O
special	O
care	O
group	O
in	O
comparison	O
with	O
the	O
control	O
group	O
.	O

Total	O
streptococci	B-bacteria
were	O
significantly	O
decreased	O
in	O
the	O
opportunistic	O
pathogens	O
-	O
positive	O
and	O
lower	O
-	O
level	O
mutans	B-bacteria
streptococci	I-bacteria
control	O
group	O
during	O
chemoradiotherapy	O
,	O
but	O
they	O
were	O
not	O
reduced	O
in	O
the	O
opportunistic	O
pathogens	O
-	O
negative	O
and	O
higher	O
-	O
level	O
mutans	B-bacteria
streptococci	I-bacteria
control	O
groups	O
or	O
in	O
the	O
special	O
care	O
group	O
.	O

Our	O
results	O
showed	O
that	O
a	O
special	O
oral	O
care	O
regimen	O
enabled	O
the	O
total	O
population	O
of	O
streptococci	B-bacteria
microflora	O
to	O
remain	O
stable	O
,	O
was	O
negatively	O
correlated	O
with	O
opportunistic	O
pathogens	O
and	O
positively	O
correlated	O
with	O
mutans	B-bacteria
streptococci	I-bacteria
infection	O
,	O
and	O
prevented	O
the	O
development	O
of	O
mucositis	O
.	O

A	O
significant	O
amount	O
of	O
evidence	O
has	O
been	O
accumulated	O
to	O
show	O
that	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
function	O
as	O
sensors	O
for	O
microbial	O
invasion	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
how	O
signalling	O
triggered	O
by	O
TLRs	O
leads	O
to	O
the	O
phagocytosis	O
of	O
pathogens	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
stimulation	O
of	O
TLR2	O
mainly	O
with	O
the	O
lipopeptide	O
FSL	O
-	O
1	O
plays	O
a	O
role	O
in	O
the	O
phagocytosis	O
of	O
pathogens	O
by	O
macrophages	O
.	O

FSL	O
-	O
1	O
enhanced	O
the	O
phagocytosis	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
to	O
a	O
markedly	O
greater	O
extent	O
than	O
it	O
did	O
that	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
but	O
did	O
not	O
enhance	O
the	O
phagocytosis	O
of	O
latex	O
beads	O
.	O

FSL	O
-	O
1	O
stimulation	O
resulted	O
in	O
enhanced	O
phagocytosis	O
of	O
bacteria	O
by	O
macrophages	O
from	O
TLR2	O
(	O
+	O
/	O
+	O
)	O
mice	O
but	O
not	O
by	O
those	O
from	O
TLR2	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Chinese	O
hamster	O
ovary	O
cells	O
stably	O
expressing	O
TLR2	O
failed	O
to	O
phagocytose	O
these	O
bacteria	O
,	O
but	O
the	O
cells	O
expressing	O
CD14	O
did	O
.	O

FSL	O
-	O
1	O
induced	O
upregulation	O
of	O
the	O
expression	O
of	O
phagocytic	O
receptors	O
,	O
including	O
MSR1	O
,	O
CD36	O
,	O
DC	O
-	O
SIGN	O
and	O
Dectin	O
-	O
1	O
in	O
THP	O
-	O
1	O
cells	O
.	O

Human	O
embryonic	O
kidney	O
293	O
cells	O
transfected	O
with	O
DC	O
-	O
SIGN	O
and	O
MSR1	O
phagocytosed	O
these	O
bacteria	O
.	O

These	O
results	O
suggest	O
that	O
the	O
FSL	O
-	O
1	O
-	O
induced	O
enhancement	O
of	O
phagocytosis	O
of	O
bacteria	O
by	O
macrophages	O
may	O
be	O
explained	O
partly	O
by	O
the	O
upregulation	O
of	O
scavenger	O
receptors	O
and	O
the	O
C	O
-	O
type	O
lectins	O
through	O
TLR2	O
-	O
mediated	O
signalling	O
pathways	O
,	O
and	O
that	O
TLR2	O
by	O
itself	O
does	O
not	O
function	O
as	O
a	O
phagocytic	O
receptor	O
.	O

The	O
efficacy	O
of	O
a	O
novel	O
synthetic	O
antimicrobial	O
peptide	O
(	O
WLBU2	O
)	O
was	O
evaluated	O
against	O
three	O
oral	O
microorganisms	O
(	O
grown	O
planktonically	O
)	O
:	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
.	O

WLBU2	O
killed	O
all	O
three	O
species	O
,	O
with	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
being	O
the	O
most	O
susceptible	O
.	O

WLBU2	O
also	O
reduced	O
the	O
bacterial	O
burden	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
biofilms	O
.	O

Recently	O
,	O
the	O
clinical	O
additive	O
value	O
of	O
a	O
highly	O
concentrated	O
chlorhexidine	O
(	O
CHX	O
)	O
varnish	O
,	O
when	O
applied	O
subgingivally	O
as	O
an	O
adjunct	O
to	O
scaling	O
and	O
root	O
planing	O
,	O
was	O
described	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
microbiological	O
impact	O
of	O
a	O
treatment	O
strategy	O
for	O
chronic	O
periodontitis	O
based	O
on	O
a	O
combination	O
of	O
same	O
-	O
day	O
full	O
-	O
mouth	O
root	O
planing	O
and	O
subgingival	O
CHX	O
varnish	O
administration	O
.	O

A	O
randomized	O
,	O
controlled	O
,	O
single	O
-	O
blind	O
,	O
parallel	O
trial	O
was	O
conducted	O
on	O
33	O
non	O
-	O
smoking	O
chronic	O
periodontitis	O
patients	O
.	O

The	O
control	O
group	O
received	O
oral	O
hygiene	O
instructions	O
and	O
same	O
-	O
day	O
full	O
-	O
mouth	O
root	O
planing	O
.	O

The	O
test	O
group	O
received	O
the	O
same	O
instructions	O
and	O
treatment	O
;	O
however	O
,	O
all	O
pockets	O
also	O
were	O
disinfected	O
using	O
a	O
supersaturated	O
CHX	O
varnish	O
.	O

Subgingival	O
plaque	O
samples	O
were	O
collected	O
from	O
the	O
deepest	O
site	O
per	O
quadrant	O
in	O
each	O
patient	O
at	O
baseline	O
and	O
after	O
1	O
,	O
3	O
,	O
and	O
6	O
months	O
.	O

Pooled	O
sample	O
analysis	O
was	O
performed	O
using	O
a	O
multiplex	O
polymerase	O
chain	O
reaction	O
-	O
based	O
method	O
for	O
the	O
identification	O
of	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
Aa	B-bacteria
)	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
Pg	B-bacteria
)	O
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
(	O
Tf	B-bacteria
)	O
,	O
Treponema	B-bacteria
denticola	I-bacteria
(	O
Td	B-bacteria
)	O
,	O
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
(	O
Pi	B-bacteria
)	O
.	O

In	O
terms	O
of	O
detection	O
frequency	O
and	O
bacterial	O
levels	O
,	O
significant	O
,	O
mainly	O
temporary	O
,	O
reductions	O
from	O
baseline	O
were	O
found	O
in	O
both	O
groups	O
.	O

When	O
a	O
comparison	O
was	O
made	O
between	O
the	O
control	O
and	O
the	O
test	O
group	O
,	O
significant	O
differences	O
in	O
the	O
detection	O
frequency	O
of	O
Tf	B-bacteria
(	O
P	O
=	O
0	O
.	O
024	O
)	O
and	O
Td	B-bacteria
(	O
P	O
=	O
0	O
.	O
024	O
)	O
,	O
which	O
favored	O
the	O
test	O
group	O
,	O
were	O
found	O
at	O
1	O
month	O
.	O

A	O
similar	O
phenomenon	O
was	O
seen	O
for	O
Td	B-bacteria
(	O
P	O
=	O
0	O
.	O
031	O
)	O
based	O
on	O
bacterial	O
levels	O
.	O

An	O
important	O
trend	O
toward	O
lower	O
Tf	O
levels	O
in	O
the	O
test	O
group	O
also	O
was	O
found	O
at	O
1	O
month	O
(	O
P	O
=	O
0	O
.	O
052	O
)	O
.	O

Compared	O
to	O
baseline	O
levels	O
,	O
microbiological	O
benefits	O
in	O
the	O
test	O
group	O
seemed	O
to	O
be	O
maintained	O
,	O
at	O
least	O
in	O
part	O
,	O
over	O
a	O
6	O
-	O
month	O
period	O
.	O

In	O
contrast	O
,	O
all	O
microbial	O
levels	O
had	O
relapsed	O
in	O
the	O
control	O
group	O
at	O
study	O
termination	O
.	O

The	O
microbiological	O
results	O
of	O
the	O
present	O
study	O
promote	O
the	O
subgingival	O
administration	O
of	O
a	O
highly	O
concentrated	O
CHX	O
varnish	O
as	O
an	O
adjunct	O
to	O
same	O
-	O
day	O
full	O
-	O
mouth	O
root	O
planing	O
.	O

By	O
using	O
fluorescence	O
microscopy	O
,	O
fluorescently	O
labeled	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
W50	I-bacteria
was	O
shown	O
to	O
adhere	O
to	O
oral	O
epithelial	O
(	O
KB	O
)	O
cells	O
as	O
discrete	O
cells	O
or	O
small	O
cell	O
aggregates	O
,	O
whereas	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
ATCC	I-bacteria
33277	I-bacteria
bound	O
as	O
large	O
cell	O
aggregates	O
.	O

Flow	O
cytometric	O
analysis	O
showed	O
that	O
for	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
W50	I-bacteria
there	O
was	O
a	O
logarithmic	O
relationship	O
between	O
the	O
bacterial	O
cell	O
ratio	O
(	O
BCR	O
)	O
,	O
that	O
is	O
the	O
number	O
of	O
bacterial	O
cells	O
to	O
KB	O
cells	O
,	O
and	O
the	O
percentage	O
of	O
KB	O
cells	O
with	O
W50	B-bacteria
cells	O
attached	O
.	O

This	O
percentage	O
of	O
KB	O
cells	O
with	O
W50	B-bacteria
attached	O
reached	O
a	O
plateau	O
of	O
approximately	O
84	O
%	O
cells	O
at	O
a	O
BCR	O
of	O
500	O
:	O
1	O
.	O

In	O
contrast	O
,	O
a	O
quadratic	O
relationship	O
was	O
observed	O
between	O
BCR	O
and	O
the	O
percentage	O
of	O
KB	O
cells	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
ATCC	I-bacteria
33277	I-bacteria
attached	O
,	O
reaching	O
a	O
maximum	O
of	O
47	O
%	O
at	O
a	O
BCR	O
of	O
100	O
:	O
1	O
but	O
decreasing	O
to	O
7	O
%	O
at	O
a	O
BCR	O
of	O
1	O
,	O
000	O
:	O
1	O
.	O

The	O
lower	O
binding	O
of	O
ATCC	B-bacteria
33277	I-bacteria
at	O
high	O
cell	O
concentrations	O
was	O
attributed	O
to	O
autoaggregation	O
.	O

P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
W50	I-bacteria
cells	O
treated	O
with	O
an	O
inhibitor	O
(	O
Nalpha	O
-	O
p	O
-	O
tosyl	O
-	O
L	O
-	O
lysine	O
chloromethyl	O
ketone	O
[	O
TLCK	O
]	O
)	O
of	O
its	O
RgpA	O
-	O
Kgp	O
proteinase	O
-	O
adhesin	O
complex	O
exhibited	O
significantly	O
reduced	O
binding	O
to	O
KB	O
cells	O
than	O
to	O
untreated	O
cells	O
,	O
suggesting	O
a	O
role	O
for	O
proteinase	O
activity	O
in	O
binding	O
to	O
KB	O
cells	O
.	O

Competitive	O
inhibition	O
with	O
purified	O
proteinase	O
-	O
active	O
and	O
TLCK	O
-	O
inactivated	O
RgpA	O
-	O
Kgp	O
complex	O
significantly	O
decreased	O
the	O
adherence	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
W50	I-bacteria
cells	O
to	O
KB	O
cells	O
.	O

Furthermore	O
,	O
isogenic	O
mutants	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
W50	I-bacteria
lacking	O
the	O
kgp	O
gene	O
product	O
,	O
but	O
not	O
the	O
rgpA	O
or	O
rgpB	O
gene	O
products	O
,	O
exhibited	O
significantly	O
decreased	O
adherence	O
to	O
KB	O
cells	O
compared	O
to	O
the	O
wild	O
type	O
.	O

To	O
investigate	O
the	O
molecular	O
effects	O
of	O
the	O
periodontopathogens	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
(	O
FN	B-bacteria
)	O
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
PG	B-bacteria
)	O
on	O
the	O
oral	O
epithelium	O
,	O
the	O
H400	O
oral	O
epithelial	O
cell	O
line	O
was	O
cultured	O
in	O
the	O
presence	O
of	O
non	O
-	O
viable	O
bacteria	O
.	O

Following	O
confirmation	O
of	O
the	O
presence	O
of	O
transcripts	O
for	O
the	O
bacterial	O
pattern	O
recognition	O
receptors	O
in	O
H400	O
cells	O
,	O
Toll	O
-	O
like	O
receptors	O
-	O
2	O
,	O
-	O
4	O
and	O
-	O
9	O
,	O
and	O
components	O
of	O
the	O
NF	O
-	O
kappaB	O
signalling	O
pathway	O
,	O
immunocytochemical	O
analyses	O
were	O
performed	O
showing	O
that	O
NF	O
-	O
kappaB	O
was	O
activated	O
within	O
1	O
h	O
of	O
exposure	O
to	O
both	O
periodontopathogens	O
.	O

A	O
significantly	O
greater	O
number	O
of	O
NF	O
-	O
kappaB	O
nuclear	O
translocations	O
were	O
apparent	O
following	O
H400	O
cell	O
exposure	O
to	O
FN	B-bacteria
as	O
compared	O
with	O
PG	B-bacteria
.	O

Gene	O
expression	O
analyses	O
indicated	O
that	O
transcripts	O
known	O
to	O
be	O
regulated	O
by	O
the	O
NF	O
-	O
kappaB	O
pathway	O
,	O
including	O
cytokines	O
/	O
chemokines	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
8	O
,	O
MCP	O
-	O
1	O
/	O
CCL2	O
and	O
GM	O
-	O
CSF	O
,	O
were	O
up	O
-	O
regulated	O
following	O
4	O
and	O
24	O
h	O
of	O
exposure	O
to	O
both	O
periodontopathogens	O
.	O

In	O
addition	O
,	O
H400	O
periodontopathogen	O
exposure	O
resulted	O
in	O
differential	O
regulation	O
of	O
transcripts	O
for	O
several	O
cytokeratin	O
gene	O
family	O
members	O
.	O

Consistent	O
with	O
the	O
immunocytochemical	O
data	O
,	O
microarray	O
results	O
indicated	O
that	O
FN	B-bacteria
induced	O
a	O
greater	O
number	O
of	O
gene	O
expression	O
changes	O
than	O
PG	B-bacteria
following	O
24	O
h	O
of	O
exposure	O
,	O
609	O
and	O
409	O
genes	O
,	O
respectively	O
.	O

Ninety	O
-	O
one	O
genes	O
were	O
commonly	O
differentially	O
expressed	O
by	O
both	O
periodontopathogens	O
and	O
represented	O
biological	O
processes	O
commonly	O
associated	O
with	O
periodontitis	O
.	O

Gene	O
expression	O
analyses	O
by	O
reserve	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
of	O
molecules	O
identified	O
from	O
the	O
microarray	O
data	O
sets	O
,	O
including	O
Heme	O
oxygenase	O
-	O
1	O
,	O
lysyl	O
oxidase	O
,	O
SOD2	O
,	O
CCL20	O
and	O
calprotectin	O
components	O
,	O
confirmed	O
their	O
differential	O
expression	O
profiles	O
induced	O
by	O
the	O
two	O
periodontopathogens	O
.	O

FN	B-bacteria
and	O
PG	B-bacteria
have	O
clearly	O
different	O
molecular	O
effects	O
on	O
oral	O
epithelial	O
cells	O
,	O
potentially	O
highlighting	O
the	O
importance	O
of	O
the	O
composition	O
of	O
the	O
plaque	O
biofilm	O
in	O
periodontitis	O
pathogenesis	O
.	O

In	O
2002	O
we	O
investigated	O
an	O
outbreak	O
comprising	O
231	O
patients	O
in	O
Norway	O
,	O
caused	O
by	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
and	O
linked	O
to	O
the	O
use	O
of	O
contaminated	O
mouth	O
swabs	O
called	O
Dent	O
-	O
O	O
-	O
Sept	O
.	O

Here	O
we	O
describe	O
the	O
extent	O
of	O
contamination	O
of	O
the	O
swabs	O
,	O
and	O
identify	O
critical	O
points	O
in	O
the	O
production	O
process	O
that	O
made	O
the	O
contamination	O
possible	O
,	O
in	O
order	O
to	O
prevent	O
future	O
outbreaks	O
.	O

Environmental	O
investigation	O
with	O
microbiological	O
examination	O
of	O
production	O
,	O
ingredients	O
and	O
product	O
,	O
molecular	O
typing	O
of	O
bacteria	O
and	O
a	O
system	O
audit	O
of	O
production	O
.	O

Of	O
the	O
1565	O
swabs	O
examined	O
from	O
149	O
different	O
production	O
batches	O
the	O
outbreak	O
strain	O
of	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
was	O
detected	O
in	O
76	O
swabs	O
from	O
12	O
batches	O
produced	O
in	O
2001	O
and	O
2002	O
.	O

In	O
total	O
more	O
than	O
250	O
swabs	O
were	O
contaminated	O
with	O
one	O
or	O
more	O
microbial	O
species	O
.	O

P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
was	O
detected	O
from	O
different	O
spots	O
along	O
the	O
production	O
line	O
.	O

The	O
audit	O
revealed	O
serious	O
breeches	O
of	O
production	O
regulations	O
.	O

Health	O
care	O
institutions	O
reported	O
non	O
-	O
proper	O
use	O
of	O
the	O
swabs	O
and	O
weaknesses	O
in	O
their	O
purchasing	O
systems	O
.	O

Biofilm	O
formation	O
in	O
the	O
wet	O
part	O
of	O
the	O
production	O
is	O
the	O
most	O
plausible	O
explanation	O
for	O
the	O
continuous	O
contamination	O
of	O
the	O
swabs	O
with	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
over	O
a	O
period	O
of	O
at	O
least	O
30	O
weeks	O
.	O

When	O
not	O
abiding	O
to	O
production	O
regulations	O
fatal	O
consequences	O
for	O
the	O
users	O
may	O
ensue	O
.	O

For	O
the	O
most	O
vulnerable	O
patient	O
groups	O
only	O
documented	O
quality	O
-	O
controlled	O
,	O
high	O
-	O
level	O
disinfected	O
products	O
and	O
items	O
should	O
be	O
used	O
in	O
the	O
oropharynx	O
.	O

The	O
DNA	O
sequence	O
flanking	O
a	O
tet	O
(	O
W	O
)	O
gene	O
in	O
an	O
oral	O
Rothia	B-bacteria
sp	I-bacteria
.	I-bacteria
was	O
determined	O
.	O

The	O
gene	O
was	O
linked	O
to	O
two	O
different	O
transposases	O
,	O
and	O
these	O
were	O
flanked	O
by	O
two	O
almost	O
identical	O
mef	O
(	O
macrolide	O
efflux	O
)	O
genes	O
.	O

This	O
structure	O
was	O
found	O
in	O
4	O
out	O
of	O
20	O
tet	O
(	O
W	O
)	O
-	O
containing	O
oral	O
bacteria	O
investigated	O
.	O

Uncaria	O
tomentosa	O
is	O
considered	O
a	O
medicinal	O
plant	O
used	O
over	O
centuries	O
by	O
the	O
peruvian	O
population	O
as	O
an	O
alternative	O
treatment	O
for	O
several	O
diseases	O
.	O

Many	O
microorganisms	O
usually	O
inhabit	O
the	O
human	O
oral	O
cavity	O
and	O
under	O
certain	O
conditions	O
can	O
become	O
etiologic	O
agents	O
of	O
diseases	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
antimicrobial	O
activity	O
of	O
different	O
concentrations	O
of	O
Uncaria	O
tomentosa	O
on	O
different	O
strains	O
of	O
microorganisms	O
isolated	O
from	O
the	O
human	O
oral	O
cavity	O
.	O

Micropulverized	O
Uncaria	O
tomentosa	O
was	O
tested	O
in	O
vitro	O
to	O
determine	O
the	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
on	O
selected	O
microbial	O
strains	O
.	O

The	O
tested	O
strains	O
were	O
oral	O
clinical	O
isolates	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Staphylococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Candida	O
albicans	O
,	O
Enterobacteriaceae	B-bacteria
and	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
.	O

The	O
tested	O
concentrations	O
of	O
Uncaria	O
tomentosa	O
ranged	O
from	O
0	O
.	O
25	O
-	O
5	O
%	O
in	O
Mueller	O
-	O
Hinton	O
agar	O
.	O

Three	O
percent	O
Uncaria	O
tomentosa	O
inhibited	O
8	O
%	O
of	O
Enterobacteriaceae	B-bacteria
isolates	I-bacteria
,	O
52	O
%	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
96	O
%	O
of	O
Staphylococcus	B-bacteria
spp	I-bacteria
.	O

The	O
tested	O
concentrations	O
did	O
not	O
present	O
inhibitory	O
effect	O
on	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
and	O
C	O
.	O
albicans	O
.	O

It	O
could	O
be	O
concluded	O
that	O
micropulverized	O
Uncaria	O
tomentosa	O
presented	O
antimicrobial	O
activity	O
on	O
Enterobacteriaceae	B-bacteria
,	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
Staphylococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
isolates	I-bacteria
.	O

In	O
addition	O
to	O
saliva	O
,	O
other	O
oral	O
components	O
such	O
as	O
gingival	O
crevicular	O
fluid	O
,	O
epithelial	O
cells	O
,	O
bacteria	O
,	O
breath	O
,	O
and	O
dental	O
plaque	O
have	O
diagnostic	O
potential	O
.	O

For	O
oral	O
diseases	O
such	O
as	O
caries	O
and	O
periodontal	O
disease	O
,	O
visual	O
diagnosis	O
is	O
usually	O
adequate	O
,	O
but	O
objective	O
diagnostic	O
tests	O
with	O
predictive	O
value	O
are	O
desired	O
.	O

Therefore	O
,	O
prediction	O
models	O
like	O
the	O
Cariogram	O
have	O
been	O
developed	O
that	O
also	O
include	O
oral	O
aspects	O
such	O
as	O
saliva	O
secretion	O
,	O
buffering	O
capacity	O
,	O
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
counts	O
for	O
the	O
prediction	O
of	O
caries	O
.	O

Correlation	O
studies	O
on	O
salivary	O
components	O
and	O
caries	O
have	O
not	O
been	O
conclusive	O
,	O
but	O
correlation	O
studies	O
on	O
functional	O
aspects	O
,	O
such	O
as	O
saliva	O
-	O
induced	O
bacterial	O
aggregation	O
and	O
caries	O
,	O
look	O
promising	O
.	O

Modern	O
proteomic	O
techniques	O
make	O
it	O
possible	O
to	O
study	O
simultaneously	O
the	O
many	O
salivary	O
components	O
involved	O
in	O
these	O
functions	O
.	O

Neutrophils	O
,	O
monocytes	O
,	O
and	O
dendritic	O
cells	O
(	O
DC	O
)	O
are	O
phenotypically	O
and	O
functionally	O
related	O
phagocytes	O
whose	O
presence	O
in	O
infected	O
tissues	O
is	O
critical	O
to	O
host	O
survival	O
.	O

Their	O
overlapping	O
expression	O
pattern	O
of	O
surface	O
molecules	O
,	O
the	O
differentiation	O
capacity	O
of	O
monocytes	O
,	O
and	O
the	O
presence	O
of	O
monocyte	O
subsets	O
underscores	O
the	O
complexity	O
of	O
understanding	O
the	O
role	O
of	O
these	O
cells	O
during	O
infection	O
.	O

In	O
this	O
study	O
we	O
use	O
five	O
-	O
to	O
seven	O
-	O
color	O
flow	O
cytometry	O
to	O
assess	O
the	O
phenotype	O
and	O
function	O
of	O
monocytes	O
recruited	O
to	O
Peyer	O
'	O
s	O
patches	O
(	O
PP	O
)	O
and	O
mesenteric	O
lymph	O
nodes	O
(	O
MLN	O
)	O
after	O
oral	O
Salmonella	B-bacteria
infection	O
of	O
mice	O
.	O

The	O
data	O
show	O
that	O
CD68	O
(	O
high	O
)	O
Gr	O
-	O
1	O
(	O
int	O
)	O
(	O
intermediate	O
)	O
monocytes	O
,	O
along	O
with	O
CD68	O
(	O
int	O
)	O
Gr	O
-	O
1	O
(	O
high	O
)	O
neutrophils	O
,	O
rapidly	O
accumulate	O
in	O
PP	O
and	O
MLN	O
.	O

The	O
monocytes	O
have	O
increased	O
MHC	O
-	O
II	O
and	O
costimulatory	O
molecule	O
expression	O
and	O
,	O
in	O
contrast	O
to	O
neutrophils	O
and	O
DC	O
,	O
produce	O
inducible	O
NO	O
synthase	O
.	O

Although	O
neutrophils	O
and	O
monocytes	O
from	O
infected	O
mice	O
produce	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1beta	O
upon	O
ex	O
vivo	O
culture	O
,	O
DC	O
do	O
not	O
.	O

In	O
addition	O
,	O
although	O
recruited	O
monocytes	O
internalize	O
Salmonella	B-bacteria
in	O
vitro	O
and	O
in	O
vivo	O
they	O
did	O
not	O
induce	O
the	O
proliferation	O
of	O
OT	O
-	O
II	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
after	O
coincubation	O
with	O
Salmonella	B-bacteria
expressing	O
OVA	O
despite	O
their	O
ability	O
to	O
activate	O
OT	O
-	O
II	O
cells	O
when	O
pulsed	O
with	O
the	O
OVA	O
(	O
323	O
-	O
339	O
)	O
peptide	O
.	O

We	O
also	O
show	O
that	O
recruited	O
monocytes	O
enter	O
the	O
PP	O
of	O
infected	O
mice	O
independently	O
of	O
the	O
mucosal	O
address	O
in	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
MAdCAM	O
-	O
1	O
)	O
.	O

Finally	O
,	O
recruited	O
but	O
not	O
resident	O
monocytes	O
increase	O
in	O
the	O
blood	O
of	O
orally	O
infected	O
mice	O
,	O
and	O
MHC	O
-	O
II	O
up	O
-	O
regulation	O
,	O
but	O
not	O
TNF	O
-	O
alpha	O
or	O
iNOS	O
production	O
,	O
occur	O
already	O
in	O
the	O
blood	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
describe	O
the	O
accumulation	O
and	O
function	O
of	O
monocyte	O
subsets	O
in	O
the	O
blood	O
and	O
GALT	O
during	O
oral	O
Salmonella	B-bacteria
infection	O
.	O

Cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
who	O
are	O
chronically	O
infected	O
with	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
make	O
serum	O
antibodies	O
to	O
bacterial	O
surface	O
LPS	O
as	O
well	O
as	O
other	O
pseudomonas	B-bacteria
antigens	O
.	O

This	O
study	O
investigated	O
the	O
feasibility	O
of	O
using	O
oral	O
fluid	O
samples	O
for	O
the	O
detection	O
of	O
pseudomonas	B-bacteria
antibodies	O
in	O
CF	O
patients	O
and	O
compared	O
these	O
results	O
with	O
corresponding	O
serum	O
antibodies	O
.	O

Most	O
strains	O
of	O
P	O
.	O
aeruginosa	O
produce	O
two	O
forms	O
of	O
LPS	O
molecule	O
,	O
termed	O
A	O
-	O
band	O
(	O
described	O
as	O
a	O
common	O
antigen	O
)	O
and	O
B	O
-	O
band	O
(	O
O	O
-	O
serotype	O
-	O
specific	O
antigen	O
)	O
,	O
apparently	O
bound	O
to	O
a	O
common	O
core	O
oligosaccharide	O
moiety	O
.	O

A	O
-	O
band	O
LPS	O
was	O
demonstrated	O
in	O
45	O
out	O
of	O
49	O
clinical	O
isolates	O
of	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotting	O
with	O
a	O
specific	O
antibody	O
.	O

Oral	O
fluids	O
were	O
collected	O
from	O
17	O
adult	O
CF	O
patients	O
,	O
all	O
of	O
whom	O
were	O
sputum	O
culture	O
positive	O
for	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
(	O
13	O
also	O
provided	O
serum	O
samples	O
)	O
,	O
11	O
primary	O
ciliary	O
dyskinesia	O
(	O
PCD	O
)	O
patients	O
and	O
37	O
healthy	O
volunteers	O
.	O

Antibodies	O
to	O
A	O
-	O
band	O
LPS	O
were	O
detected	O
by	O
immunoblotting	O
in	O
all	O
of	O
the	O
CF	O
patients	O
'	O
oral	O
fluids	O
but	O
10	O
of	O
the	O
volunteer	O
samples	O
gave	O
weak	O
reactions	O
with	O
immunoblotting	O
.	O

Six	O
of	O
the	O
PCD	O
patients	O
gave	O
a	O
weak	O
reaction	O
with	O
A	O
-	O
band	O
antibodies	O
and	O
only	O
one	O
demonstrated	O
antibodies	O
to	O
core	O
LPS	O
.	O

In	O
a	O
quantitative	O
ELISA	O
,	O
15	O
of	O
the	O
17	O
CF	O
patients	O
'	O
oral	O
fluids	O
were	O
shown	O
to	O
contain	O
antibodies	O
to	O
A	O
-	O
band	O
LPS	O
,	O
whilst	O
none	O
of	O
the	O
volunteer	O
samples	O
contained	O
antibodies	O
to	O
A	O
-	O
band	O
LPS	O
.	O

All	O
serum	O
samples	O
from	O
the	O
CF	O
patients	O
were	O
positive	O
by	O
both	O
methods	O
.	O

Thus	O
this	O
is	O
a	O
sensitive	O
procedure	O
for	O
the	O
detection	O
of	O
antibodies	O
to	O
A	O
-	O
band	O
LPS	O
of	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
in	O
oral	O
fluid	O
and	O
serum	O
from	O
patients	O
with	O
CF	O
.	O

Interactions	O
between	O
oral	O
bacteria	O
and	O
gingival	O
epithelial	O
cells	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
periodontal	O
diseases	O
.	O

This	O
study	O
used	O
in	O
situ	O
hybridization	O
with	O
16	O
rRNA	O
probes	O
and	O
confocal	O
microscopy	O
to	O
detect	O
the	O
periodontal	O
pathogens	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
within	O
epithelial	O
cells	O
from	O
periodontal	O
pockets	O
,	O
gingival	O
crevice	O
,	O
and	O
buccal	O
mucosa	O
collected	O
from	O
subjects	O
with	O
chronic	O
periodontitis	O
(	O
n	O
=	O
14	O
)	O
and	O
good	O
periodontal	O
health	O
(	O
n	O
=	O
8	O
)	O
.	O

Each	O
green	O
fluorescent	O
species	O
-	O
specific	O
and	O
universal	O
probe	O
was	O
hybridized	O
with	O
all	O
58	O
epithelial	O
samples	O
from	O
the	O
22	O
patients	O
.	O

The	O
samples	O
were	O
observed	O
by	O
confocal	O
microscopy	O
to	O
confirm	O
the	O
intracellular	O
localization	O
of	O
oral	O
species	O
of	O
bacteria	O
.	O

The	O
mean	O
frequency	O
of	O
detection	O
and	O
number	O
of	O
intracellular	O
bacteria	O
per	O
epithelial	O
cell	O
were	O
computed	O
for	O
each	O
sample	O
.	O

The	O
frequency	O
of	O
cells	O
with	O
internalized	O
bacteria	O
was	O
higher	O
in	O
samples	O
from	O
the	O
gingival	O
crevice	O
than	O
in	O
samples	O
from	O
the	O
oral	O
mucosa	O
.	O

Epithelial	O
cells	O
from	O
all	O
subjects	O
harbored	O
intracellular	O
bacteria	O
;	O
however	O
,	O
patients	O
with	O
periodontitis	O
presented	O
significantly	O
higher	O
counts	O
of	O
bacteria	O
per	O
cell	O
than	O
periodontally	O
healthy	O
individuals	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Periodontal	O
pathogens	O
showed	O
a	O
trend	O
to	O
be	O
detected	O
in	O
higher	O
numbers	O
in	O
epithelial	O
cells	O
from	O
periodontitis	O
patients	O
.	O

In	O
particular	O
,	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
were	O
significantly	O
more	O
prevalent	O
in	O
periodontal	O
pocket	O
cells	O
than	O
healthy	O
sulci	O
and	O
buccal	O
cell	O
samples	O
in	O
the	O
periodontitis	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Those	O
findings	O
indicate	O
that	O
crevicular	O
and	O
buccal	O
cells	O
present	O
internalized	O
bacteria	O
,	O
regardless	O
of	O
periodontal	O
status	O
.	O

However	O
,	O
higher	O
bacterial	O
loads	O
are	O
detected	O
in	O
cells	O
from	O
subjects	O
with	O
periodontitis	O
.	O

Clinical	O
,	O
epidemiological	O
and	O
microbiological	O
examinations	O
of	O
adult	O
patients	O
with	O
periodontal	O
disease	O
.	O

The	O
study	O
of	O
population	O
consisted	O
of	O
21	O
subjects	O
(	O
13	O
female	O
and	O
8	O
male	O
)	O
aged	O
38	O
-	O
58	O
years	O
,	O
treated	O
in	O
the	O
Outpatient	O
Department	O
of	O
Periodontology	O
.	O

Dental	O
examinations	O
were	O
performed	O
at	O
an	O
artificial	O
light	O
and	O
using	O
a	O
WHO	O
periodontometer	O
,	O
a	O
mirror	O
and	O
a	O
probe	O
.	O

Periodontal	O
status	O
was	O
assessed	O
by	O
determination	O
of	O
the	O
probing	O
pocket	O
depth	O
(	O
CPI	O
)	O
,	O
gingival	O
state	O
(	O
GSBI	O
according	O
to	O
Muhlemann	O
and	O
Son	O
)	O
,	O
and	O
oral	O
hygiene	O
index	O
(	O
according	O
to	O
Silness	O
and	O
Loe	O
)	O
.	O

Material	O
for	O
microbiological	O
examination	O
was	O
collected	O
from	O
subgingival	O
and	O
supragingival	O
plaques	O
of	O
each	O
patient	O
.	O

Additionally	O
,	O
pus	O
was	O
obtained	O
from	O
8	O
patients	O
and	O
periodontal	O
pocket	O
fluid	O
from	O
2	O
patients	O
.	O

The	O
samples	O
were	O
examined	O
for	O
the	O
presence	O
of	O
aerobic	O
and	O
anaerobic	O
bacteria	O
and	O
Candida	O
yeasts	O
.	O

Standard	O
procedures	O
were	O
used	O
for	O
culture	O
and	O
identification	O
of	O
bacteria	O
and	O
fungi	O
.	O

Candida	O
yeasts	O
were	O
not	O
isolated	O
from	O
adults	O
with	O
periodontal	O
disease	O
.	O

In	O
19	O
/	O
21	O
patients	O
,	O
cultures	O
of	O
both	O
aerobic	O
and	O
anaerobic	O
bacteria	O
from	O
subgingival	O
and	O
supragingival	O
plaque	O
samples	O
were	O
positive	O
.	O

A	O
total	O
of	O
42	O
bacterial	O
strains	O
were	O
isolated	O
from	O
subgingival	O
plaques	O
,	O
of	O
which	O
24	O
(	O
57	O
.	O
1	O
%	O
)	O
belonged	O
to	O
7	O
anaerobic	O
species	O
and	O
18	O
(	O
42	O
.	O
9	O
%	O
)	O
to	O
12	O
aerobic	O
species	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

There	O
were	O
more	O
aerobic	O
(	O
33	O
/	O
53	O
;	O
62	O
.	O
3	O
%	O
)	O
than	O
anaerobic	O
bacteria	O
(	O
20	O
/	O
53	O
;	O
37	O
.	O
7	O
%	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
supragingival	O
plaques	O
.	O

Anaerobes	O
were	O
isolated	O
more	O
frequently	O
than	O
aerobes	O
from	O
the	O
abscess	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

1	O
)	O
In	O
adult	O
patients	O
with	O
periodontal	O
disease	O
,	O
Gram	O
-	O
positive	O
anaerobes	O
,	O
including	O
Peptostreptococcus	B-bacteria
,	O
were	O
the	O
predominant	O
bacteria	O
in	O
the	O
subgingival	O
plaque	O
.	O

2	O
)	O
While	O
in	O
the	O
supragingival	O
plaque	O
,	O
Gram	O
-	O
positive	O
aerobic	O
cocci	O
(	O
Streptococcus	B-bacteria
and	O
Staphylococcus	B-bacteria
)	O
were	O
predominant	O
.	O

Determination	O
of	O
bacterial	O
composition	O
in	O
the	O
oral	O
cavity	O
of	O
patients	O
with	O
removable	O
dentures	O
and	O
with	O
own	O
dentition	O
(	O
without	O
dentures	O
)	O
.	O

Bacteriological	O
investigations	O
were	O
performed	O
in	O
55	O
patients	O
from	O
the	O
department	O
of	O
internal	O
medicine	O
(	O
32	O
diabetic	O
patients	O
)	O
and	O
40	O
patients	O
treated	O
in	O
surgical	O
department	O
(	O
25	O
patients	O
with	O
malignancy	O
)	O
.	O

Palate	O
mucosa	O
and	O
tongue	O
dorsa	O
swabs	O
were	O
collected	O
from	O
two	O
groups	O
of	O
patients	O
,	O
and	O
additionally	O
swabs	O
from	O
mucosal	O
part	O
of	O
denture	O
surfaces	O
in	O
prosthetic	O
patients	O
.	O

Cultures	O
in	O
oxygenic	O
and	O
microaerophilic	O
(	O
5	O
%	O
CO2	O
)	O
conditions	O
were	O
conducted	O
on	O
solid	O
non	O
-	O
selective	O
and	O
selective	O
media	O
as	O
well	O
as	O
media	O
enriched	O
with	O
5	O
%	O
sheep	O
blood	O
.	O

Standard	O
procedures	O
of	O
bacterial	O
culture	O
and	O
identification	O
were	O
applied	O
.	O

Among	O
95	O
of	O
examined	O
patients	O
,	O
57	O
(	O
60	O
.	O
0	O
%	O
)	O
with	O
removable	O
dentures	O
and	O
38	O
(	O
40	O
.	O
0	O
%	O
)	O
had	O
their	O
own	O
dentition	O
.	O

As	O
far	O
as	O
prosthetic	O
patients	O
were	O
concerned	O
,	O
the	O
rate	O
of	O
bacterial	O
isolations	O
from	O
palate	O
,	O
tongue	O
dorsa	O
and	O
denture	O
plaque	O
swabs	O
were	O
generally	O
comparable	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
;	O
in	O
number	O
and	O
species	O
compositions	O
.	O

Statistically	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
bacterial	O
composition	O
of	O
denture	O
plaques	O
,	O
palate	O
and	O
tongue	O
dorsa	O
in	O
patients	O
with	O
and	O
without	O
abdominal	O
cancers	O
.	O

Patients	O
without	O
cancer	O
did	O
not	O
reveal	O
staphylococci	B-bacteria
and	O
enteric	O
bacteria	O
in	O
the	O
samples	O
from	O
a	O
various	O
sites	O
of	O
their	O
oral	O
cavities	O
.	O

These	O
bacteria	O
were	O
most	O
common	O
in	O
cancer	O
patients	O
.	O

Similar	O
(	O
in	O
number	O
and	O
species	O
)	O
composition	O
of	O
bacteria	O
occurred	O
in	O
palate	O
and	O
tongue	O
swabs	O
in	O
patients	O
without	O
dentures	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
incidence	O
rate	O
of	O
aerobic	O
bacteria	O
in	O
denture	O
plaques	O
and	O
palatal	O
mucosa	O
of	O
patients	O
with	O
(	O
37	O
/	O
57	O
;	O
64	O
.	O
9	O
%	O
)	O
and	O
without	O
(	O
20	O
/	O
57	O
;	O
35	O
.	O
1	O
%	O
)	O
denture	O
associated	O
stomatitis	O
were	O
comparable	O
(	O
except	O
for	O
Neisseria	B-bacteria
spp	I-bacteria
.	I-bacteria
)	O
.	O

1	O
)	O
Generally	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
species	O
composition	O
of	O
bacteria	O
isolated	O
from	O
the	O
hard	O
palate	O
and	O
tongue	O
dorsa	O
in	O
patients	O
with	O
and	O
without	O
removable	O
dentures	O
.	O

2	O
)	O
Staphylococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
Gram	O
-	O
negative	O
enteric	O
bacilli	O
were	O
isolated	O
more	O
often	O
from	O
denture	O
plaque	O
,	O
palate	O
and	O
tongue	O
dorsa	O
of	O
cancer	O
patients	O
than	O
from	O
patients	O
without	O
cancer	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

3	O
)	O
Staphylococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
was	O
isolated	O
more	O
frequently	O
from	O
denture	O
plaques	O
of	O
diabetic	O
patients	O
compared	O
with	O
non	O
-	O
diabetic	O
patients	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

4	O
)	O
No	O
significant	O
differences	O
observed	O
in	O
isolation	O
frequencies	O
(	O
%	O
)	O
of	O
aerobic	O
bacteria	O
in	O
denture	O
plaques	O
and	O
palatal	O
mucosa	O
of	O
patients	O
with	O
and	O
without	O
denture	O
associated	O
stomatitis	O
.	O

To	O
evaluate	O
the	O
hypothesis	O
that	O
food	O
-	O
borne	O
viable	O
Enterococcus	B-bacteria
faecalis	I-bacteria
cells	O
could	O
enter	O
the	O
root	O
canal	O
space	O
via	O
coronal	O
leakage	O
.	O

In	O
a	O
simulated	O
oral	O
environment	O
under	O
mastication	O
the	O
capacity	O
of	O
a	O
calcium	O
sulphate	O
-	O
based	O
temporary	O
filling	O
material	O
(	O
Cavit	O
W	O
)	O
to	O
prevent	O
leakage	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
from	O
a	O
cheese	O
through	O
the	O
endodontic	O
access	O
cavity	O
into	O
the	O
pulp	O
chamber	O
was	O
assessed	O
.	O

Standardized	O
class	O
I	O
access	O
cavities	O
were	O
prepared	O
in	O
human	O
maxillary	O
molars	O
.	O

These	O
were	O
filled	O
with	O
Cavit	O
of	O
either	O
2	O
or	O
4	O
mm	O
thickness	O
(	O
n	O
=	O
16	O
,	O
each	O
)	O
.	O

Empty	O
access	O
cavities	O
served	O
as	O
positive	O
,	O
teeth	O
filled	O
with	O
a	O
light	O
-	O
curing	O
composite	O
material	O
acted	O
as	O
negative	O
controls	O
(	O
n	O
=	O
8	O
,	O
each	O
)	O
.	O

A	O
cheese	O
containing	O
viable	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
cells	O
was	O
placed	O
on	O
the	O
occlusal	O
aspects	O
of	O
test	O
and	O
control	O
teeth	O
,	O
which	O
were	O
subsequently	O
subjected	O
to	O
680	O
mastication	O
loads	O
per	O
day	O
for	O
1	O
week	O
in	O
a	O
masticator	O
device	O
perfused	O
with	O
artificial	O
saliva	O
at	O
37	O
degrees	O
C	O
.	O
Leakage	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
from	O
the	O
cheese	O
into	O
the	O
pulp	O
chamber	O
was	O
assessed	O
by	O
culture	O
on	O
a	O
kanamycin	O
aesculin	O
azide	O
agar	O
and	O
compared	O
between	O
groups	O
using	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

All	O
of	O
the	O
positive	O
controls	O
showed	O
pure	O
growth	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
.	O

In	O
addition	O
,	O
one	O
of	O
the	O
negative	O
control	O
teeth	O
leaked	O
.	O

The	O
4	O
mm	O
application	O
of	O
Cavit	O
prevented	O
leakage	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
significantly	O
better	O
than	O
the	O
corresponding	O
2	O
mm	O
application	O
:	O
1	O
of	O
16	O
specimens	O
compared	O
with	O
6	O
of	O
16	O
specimens	O
had	O
leakage	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
current	O
results	O
substantiate	O
the	O
suspicion	O
that	O
food	O
-	O
derived	O
microbiota	O
could	O
enter	O
the	O
necrotic	O
root	O
canal	O
system	O
via	O
microleakage	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluated	O
the	O
prevalence	O
rate	O
of	O
oral	O
viridans	B-bacteria
group	I-bacteria
streptococci	I-bacteria
(	O
VGS	B-bacteria
)	O
and	O
their	O
susceptibilities	O
to	O
some	O
antibiotics	O
in	O
healthy	O
children	O
.	O

Samples	O
of	O
pharyngeal	O
swabs	O
and	O
supragingival	O
dental	O
plaques	O
for	O
microbiological	O
studies	O
were	O
collected	O
from	O
206	O
healthy	O
children	O
,	O
aged	O
4	O
-	O
18	O
years	O
.	O

Additionally	O
,	O
75	O
samples	O
of	O
carious	O
lesions	O
from	O
children	O
with	O
dental	O
caries	O
were	O
included	O
.	O

The	O
streptococci	B-bacteria
were	O
isolated	O
and	O
identified	O
using	O
standard	O
methods	O
and	O
commercial	O
identification	O
kits	O
.	O

For	O
performance	O
of	O
antibacterial	O
susceptibility	O
testing	O
of	O
VGS	B-bacteria
strains	I-bacteria
disk	O
diffusion	O
and	O
/	O
or	O
breakpoints	O
procedures	O
were	O
used	O
according	O
to	O
NCCLS	O
standards	O
and	O
criteria	O
.	O

A	O
total	O
of	O
425	O
VGS	B-bacteria
strains	I-bacteria
were	O
tested	O
against	O
penicillin	O
,	O
ampicillin	O
,	O
erythromycin	O
,	O
clindamycin	O
,	O
tetracycline	O
,	O
doxycycline	O
,	O
ciprofloxacin	O
and	O
vancomycin	O
.	O

A	O
total	O
of	O
239	O
VGS	B-bacteria
strains	I-bacteria
belonging	O
to	O
8	O
species	O
from	O
pharyngeal	O
swabs	O
of	O
192	O
(	O
93	O
.	O
2	O
%	O
)	O
children	O
were	O
isolated	O
.	O

VGS	B-bacteria
strains	I-bacteria
from	O
supragingival	O
plaques	O
were	O
isolated	O
in	O
149	O
(	O
72	O
.	O
3	O
%	O
)	O
healthy	O
children	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
from	O
carious	O
lesions	O
in	O
37	O
(	O
49	O
.	O
3	O
%	O
)	O
children	O
with	O
dental	O
caries	O
.	O

VGS	B-bacteria
strains	I-bacteria
of	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
species	I-bacteria
were	O
isolated	O
most	O
frequently	O
from	O
4	O
-	O
5	O
year	O
old	O
as	O
compared	O
to	O
12	O
and	O
18	O
year	O
old	O
children	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
S	B-bacteria
.	I-bacteria
vestibularis	I-bacteria
strains	I-bacteria
isolated	O
most	O
often	O
in	O
12	O
year	O
old	O
ones	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Among	O
425	O
VGS	B-bacteria
strains	I-bacteria
,	O
high	O
level	O
of	O
penicillin	O
resistance	O
(	O
MIC	O
>	O
or	O
=	O
2	O
.	O
0	O
mg	O
/	O
L	O
)	O
was	O
shown	O
in	O
71	O
(	O
16	O
.	O
7	O
%	O
)	O
strains	O
,	O
33	O
(	O
46	O
.	O
5	O
%	O
)	O
of	O
them	O
belonged	O
to	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
species	I-bacteria
.	O

VGS	B-bacteria
strains	I-bacteria
were	O
also	O
resistant	O
to	O
erythromycin	O
(	O
23	O
.	O
5	O
%	O
)	O
,	O
clindamycin	O
(	O
23	O
.	O
1	O
%	O
)	O
,	O
tetracyclines	O
(	O
T	O
-	O
52	O
%	O
,	O
DOX	O
-	O
16	O
%	O
)	O
,	O
gentamycin	O
(	O
25	O
.	O
9	O
%	O
)	O
and	O
ciprofloxacin	O
(	O
55	O
.	O
2	O
%	O
)	O
.	O

All	O
VGS	B-bacteria
strains	I-bacteria
were	O
vancomycin	O
-	O
susceptible	O
.	O

1	O
.	O
In	O
the	O
oral	O
cavities	O
of	O
healthy	O
children	O
,	O
approximately	O
98	O
%	O
of	O
streptococci	B-bacteria
belonged	O
to	O
two	O
VGS	B-bacteria
groups	O
,	O
i	O
.	O
e	O
.	O
mitis	B-bacteria
and	I-bacteria
salivarius	I-bacteria
groups	I-bacteria
.	O

Streptococci	B-bacteria
of	I-bacteria
mutans	I-bacteria
and	I-bacteria
anginosus	I-bacteria
groups	I-bacteria
were	O
isolated	O
sporadically	O
(	O
2	O
%	O
)	O
.	O

2	O
.	O

We	O
observed	O
difference	O
in	O
susceptibility	O
to	O
penicillin	O
and	O
other	O
antibiotics	O
between	O
the	O
various	O
species	O
of	O
viridans	B-bacteria
groups	I-bacteria
streptococci	I-bacteria
.	O

Mitis	I-bacteria
group	I-bacteria
strains	I-bacteria
(	O
except	O
S	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
)	O
were	O
more	O
frequently	O
penicillin	O
-	O
resistant	O
(	O
23	O
%	O
)	O
in	O
comparison	O
to	O
salivarius	O
group	O
of	O
VGS	B-bacteria
strains	I-bacteria
(	O
9	O
%	O
)	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

Respiratory	O
infection	O
is	O
a	O
major	O
cause	O
of	O
death	O
in	O
the	O
elderly	O
.	O

We	O
have	O
evaluated	O
the	O
role	O
of	O
professional	O
oral	O
health	O
care	O
(	O
POHC	O
)	O
by	O
dental	O
hygienists	O
in	O
reducing	O
respiratory	O
infections	O
in	O
elderly	O
persons	O
requiring	O
nursing	O
care	O
.	O

Two	O
populations	O
of	O
elderly	O
persons	O
,	O
one	O
receiving	O
POHC	O
and	O
one	O
not	O
,	O
were	O
examined	O
to	O
determine	O
numbers	O
of	O
microorganisms	O
,	O
potent	O
pathogens	O
of	O
respiratory	O
infection	O
,	O
enzymatic	O
activity	O
in	O
saliva	O
,	O
fevers	O
,	O
prevalence	O
of	O
fatal	O
aspiration	O
pneumonia	O
and	O
prevalence	O
of	O
influenza	O
.	O

In	O
the	O
first	O
population	O
,	O
we	O
found	O
a	O
high	O
prevalence	O
of	O
potent	O
respiratory	O
pathogens	O
such	O
as	O
Staphylococcus	B-bacteria
species	I-bacteria
,	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
and	O
Candida	O
albicans	O
.	O

Patients	O
who	O
received	O
POHC	O
showed	O
a	O
lower	O
prevalence	O
for	O
these	O
pathogens	O
than	O
those	O
who	O
did	O
not	O
.	O

The	O
ratio	O
of	O
fatal	O
aspiration	O
pneumonia	O
in	O
POHC	O
patients	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
patients	O
without	O
POHC	O
(	O
non	O
-	O
POHC	O
)	O
over	O
a	O
24	O
-	O
month	O
period	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
prevalence	O
of	O
a	O
fever	O
of	O
37	O
.	O
8	O
degrees	O
C	O
or	O
more	O
in	O
POHC	O
patients	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
non	O
-	O
POHC	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
the	O
second	O
study	O
population	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
POHC	O
on	O
infection	O
with	O
influenza	O
over	O
a	O
6	O
-	O
month	O
period	O
.	O

In	O
the	O
POHC	O
group	O
,	O
neuraminidase	O
and	O
trypsin	O
-	O
like	O
protease	O
activities	O
decreased	O
,	O
and	O
one	O
of	O
98	O
patients	O
was	O
diagnosed	O
with	O
influenza	O
;	O
whereas	O
,	O
in	O
the	O
non	O
-	O
POHC	O
group	O
,	O
nine	O
of	O
92	O
patients	O
were	O
diagnosed	O
with	O
influenza	O
.	O

The	O
relative	O
risk	O
of	O
developing	O
influenza	O
while	O
under	O
POHC	O
was	O
0	O
.	O
1	O
(	O
95	O
%	O
CI	O
0	O
.	O
01	O
-	O
0	O
.	O
81	O
,	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O

These	O
results	O
suggest	O
that	O
POHC	O
by	O
dental	O
hygienists	O
is	O
effective	O
in	O
preventing	O
respiratory	O
infections	O
in	O
elderly	O
persons	O
requiring	O
nursing	O
care	O
.	O

A	O
total	O
of	O
270	O
viridans	B-bacteria
group	I-bacteria
streptococci	I-bacteria
(	O
VS	B-bacteria
)	O
isolated	O
from	O
healthy	O
children	O
,	O
identified	O
to	O
the	O
species	O
level	O
,	O
were	O
tested	O
for	O
their	O
susceptibilities	O
to	O
penicillin	O
,	O
imipenem	O
,	O
erythromycin	O
,	O
and	O
vancomycin	O
.	O

A	O
total	O
of	O
270	O
isolates	O
and	O
1	O
,	O
080	O
organism	O
-	O
antibiotic	O
combinations	O
were	O
evaluated	O
.	O

The	O
overall	O
susceptibility	O
rates	O
of	O
all	O
isolates	O
obtained	O
by	O
the	O
Etest	O
(	O
ET	O
)	O
versus	O
agar	O
dilution	O
(	O
AD	O
)	O
were	O
60	O
.	O
4	O
%	O
versus	O
61	O
.	O
8	O
%	O
for	O
penicillin	O
,	O
63	O
.	O
8	O
%	O
versus	O
63	O
.	O
9	O
%	O
for	O
erythromycin	O
,	O
90	O
.	O
6	O
%	O
versus	O
96	O
%	O
for	O
vancomycin	O
,	O
and	O
99	O
.	O
1	O
%	O
versus	O
96	O
.	O
0	O
%	O
for	O
imipenem	O
,	O
respectively	O
.	O

Major	O
discrepancies	O
occurred	O
in	O
the	O
testing	O
of	O
the	O
susceptibility	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
to	O
vancomycin	O
,	O
with	O
59	O
.	O
5	O
%	O
(	O
ET	O
)	O
versus	O
100	O
%	O
(	O
AD	O
)	O
,	O
followed	O
by	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
,	O
with	O
84	O
.	O
1	O
%	O
versus	O
100	O
%	O
;	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
,	O
with	O
82	O
.	O
1	O
%	O
versus	O
96	O
.	O
4	O
%	O
;	O
and	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
,	O
with	O
90	O
%	O
versus	O
100	O
%	O
,	O
respectively	O
.	O

There	O
were	O
also	O
differences	O
in	O
the	O
rates	O
of	O
susceptibility	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
66	O
.	O
5	O
%	O
(	O
ET	O
)	O
versus	O
85	O
.	O
1	O
%	O
(	O
AD	O
)	O
,	O
and	O
S	B-bacteria
.	I-bacteria
intermedius	I-bacteria
,	O
82	O
.	O
9	O
%	O
versus	O
72	O
.	O
1	O
%	O
,	O
respectively	O
,	O
to	O
penicillin	O
.	O

General	O
agreement	O
between	O
the	O
results	O
of	O
ET	O
and	O
AD	O
was	O
obtained	O
for	O
973	O
organism	O
-	O
antibiotic	O
combinations	O
out	O
of	O
1	O
,	O
080	O
antibiotic	O
combinations	O
,	O
i	O
.	O
e	O
.	O
,	O
90	O
.	O
1	O
%	O
.	O

Very	O
major	O
errors	O
were	O
found	O
for	O
6	O
.	O
8	O
%	O
of	O
isolates	O
,	O
and	O
major	O
errors	O
were	O
found	O
for	O
3	O
.	O
2	O
%	O
of	O
isolates	O
;	O
the	O
minor	O
errors	O
were	O
negligible	O
.	O

Agreement	O
between	O
the	O
results	O
of	O
the	O
two	O
methods	O
was	O
98	O
.	O
7	O
%	O
for	O
penicillin	O
,	O
94	O
.	O
6	O
%	O
for	O
vancomycin	O
,	O
96	O
.	O
9	O
%	O
for	O
imipenem	O
,	O
and	O
99	O
.	O
9	O
%	O
for	O
erythromycin	O
.	O

The	O
highest	O
rate	O
of	O
very	O
major	O
errors	O
was	O
for	O
vancomycin	O
,	O
at	O
5	O
.	O
4	O
%	O
.	O

The	O
ET	O
appears	O
to	O
be	O
as	O
efficient	O
as	O
AD	O
for	O
susceptibility	O
testing	O
of	O
VS	O
,	O
except	O
for	O
vancomycin	O
,	O
where	O
very	O
major	O
errors	O
in	O
the	O
results	O
were	O
relatively	O
high	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
influence	O
of	O
oral	O
hygiene	O
instruction	O
(	O
OHI	O
)	O
on	O
oral	O
hygiene	O
status	O
and	O
on	O
the	O
reduction	O
of	O
inducing	O
bacteria	O
(	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
)	O
in	O
30	O
subjects	O
(	O
12	O
males	O
and	O
18	O
females	O
)	O
with	O
an	O
age	O
range	O
from	O
10	O
to	O
14	O
years	O
.	O

The	O
patients	O
were	O
instructed	O
on	O
how	O
to	O
carry	O
out	O
effective	O
oral	O
hygiene	O
close	O
to	O
brackets	O
and	O
ligatures	O
,	O
and	O
in	O
the	O
use	O
of	O
dental	O
floss	O
for	O
cleaning	O
spaces	O
around	O
brackets	O
,	O
between	O
the	O
teeth	O
and	O
under	O
archwires	O
.	O

The	O
plaque	O
index	O
(	O
PI	O
)	O
was	O
used	O
to	O
measure	O
oral	O
hygiene	O
status	O
,	O
and	O
the	O
level	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
was	O
determined	O
using	O
the	O
colour	O
reaction	O
time	O
test	O
before	O
and	O
after	O
1	O
month	O
of	O
OHI	O
.	O

Statistical	O
analysis	O
included	O
a	O
Student	O
'	O
s	O
t	O
-	O
test	O
and	O
chi	O
-	O
square	O
test	O
.	O

The	O
results	O
showed	O
that	O
OHI	O
significantly	O
improved	O
oral	O
hygiene	O
.	O

The	O
percentage	O
of	O
patients	O
with	O
a	O
PI	O
exceeding	O
1	O
decreased	O
from	O
23	O
.	O
3	O
to	O
10	O
per	O
cent	O
and	O
for	O
those	O
with	O
a	O
PI	O
below	O
0	O
.	O
1	O
it	O
increased	O
from	O
20	O
to	O
60	O
per	O
cent	O
.	O

The	O
level	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
was	O
not	O
reduced	O
.	O

The	O
percentage	O
of	O
subjects	O
with	O
excessive	O
levels	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
(	O
above	O
10	O
(	O
6	O
)	O
bacteria	O
in	O
1	O
ml	O
of	O
saliva	O
)	O
decreased	O
after	O
OHI	O
but	O
only	O
from	O
73	O
.	O
3	O
to	O
70	O
per	O
cent	O
.	O

For	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
a	O
level	O
above	O
10	O
(	O
5	O
)	O
of	O
bacteria	O
in	O
1	O
ml	O
of	O
saliva	O
was	O
found	O
for	O
all	O
subjects	O
at	O
both	O
time	O
points	O
.	O

Patients	O
with	O
fixed	O
appliances	O
,	O
trained	O
in	O
scrupulous	O
tooth	O
cleaning	O
,	O
remain	O
at	O
risk	O
of	O
developing	O
caries	O
and	O
should	O
be	O
carefully	O
monitored	O
.	O

Effect	O
of	O
Bactisporin	O
-	O
-	O
a	O
probiotic	O
,	O
containing	O
spores	O
of	O
aerobic	O
Bacillus	B-bacteria
subtilis	I-bacteria
3H	I-bacteria
bacterium	I-bacteria
-	O
-	O
for	O
complex	O
treatment	O
of	O
patients	O
with	O
nosocomial	O
urinary	O
tract	O
infections	O
was	O
studied	O
.	O

68	O
Cultures	O
of	O
different	O
species	O
of	O
conditionally	O
pathogenic	O
bacteria	O
were	O
isolated	O
from	O
urine	O
of	O
the	O
patients	O
.	O

Susceptibility	O
of	O
the	O
isolated	O
cultures	O
to	O
antibiotics	O
before	O
and	O
after	O
application	O
of	O
B	B-bacteria
.	I-bacteria
subtilis	I-bacteria
3H	I-bacteria
metabolites	O
was	O
determined	O
.	O

The	O
metabolites	O
were	O
accumulated	O
on	O
potato	O
-	O
glucose	O
agar	O
(	O
PGA	O
)	O
while	O
bacterium	O
was	O
cultivated	O
on	O
kapron	O
membranes	O
placed	O
on	O
surface	O
of	O
the	O
medium	O
.	O

Influence	O
of	O
obtained	O
metabolites	O
on	O
isolated	O
strains	O
was	O
assessed	O
by	O
cultivation	O
of	O
each	O
strain	O
in	O
metabolites	O
-	O
rich	O
PGA	O
during	O
24	O
h	O
.	O
Metabolites	O
of	O
B	B-bacteria
.	I-bacteria
subtilis	I-bacteria
led	O
to	O
decrease	O
in	O
resistance	O
of	O
isolated	O
uropathogenic	O
microflora	O
to	O
antibiotics	O
.	O

Use	O
of	O
Bactisporin	O
in	O
complex	O
treatment	O
of	O
nosocomial	O
urinary	O
tract	O
infections	O
resulted	O
in	O
accelerated	O
elimination	O
of	O
causative	O
microorganism	O
.	O

To	O
investigate	O
the	O
association	O
of	O
recurrent	O
aphthous	O
ulcer	O
(	O
RAU	O
)	O
with	O
Helicobacter	B-bacteria
pylori	I-bacteria
(	O
Hp	B-bacteria
)	O
infection	O
and	O
digestive	O
diseases	O
.	O

Saliva	O
samples	O
were	O
collected	O
from	O
82	O
patients	O
with	O
RAU	O
and	O
74	O
healthy	O
volunteers	O
for	O
Hp	B-bacteria
detection	O
with	O
PCR	O
.	O

The	O
positivity	O
rates	O
of	O
HP	B-bacteria
differed	O
significantly	O
between	O
RAU	O
patients	O
and	O
healthy	O
volunteers	O
(	O
43	O
.	O
9	O
%	O
vs	O
16	O
.	O
2	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
82	O
RAU	O
patients	O
,	O
22	O
(	O
26	O
.	O
82	O
%	O
)	O
were	O
identified	O
to	O
have	O
gastritis	O
and	O
peptic	O
ulcer	O
,	O
whereas	O
only	O
7	O
out	O
of	O
the	O
74	O
healthy	O
volunteers	O
(	O
10	O
.	O
45	O
%	O
)	O
had	O
such	O
digestive	O
diseases	O
,	O
showing	O
significant	O
difference	O
between	O
them	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Hp	B-bacteria
might	O
in	O
some	O
way	O
associate	O
with	O
RAU	O
,	O
which	O
in	O
turn	O
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
digestive	O
diseases	O
.	O

Wine	O
contains	O
a	O
number	O
of	O
biologically	O
active	O
compounds	O
with	O
beneficial	O
effects	O
on	O
human	O
health	O
.	O

The	O
antibacterial	O
action	O
of	O
commercial	O
red	O
and	O
white	O
wines	O
against	O
oral	O
streptococci	B-bacteria
responsible	O
for	O
caries	O
development	O
and	O
against	O
S	B-bacteria
.	I-bacteria
pyogenes	I-bacteria
responsible	O
for	O
pharyngitis	O
was	O
studied	O
.	O

Its	O
postcontact	O
effect	O
against	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
was	O
also	O
studied	O
.	O

Both	O
wines	O
displayed	O
activity	O
.	O

The	O
compounds	O
responsible	O
for	O
such	O
activities	O
were	O
succinic	O
,	O
malic	O
,	O
lactic	O
,	O
tartaric	O
,	O
citric	O
,	O
and	O
acetic	O
acid	O
.	O

The	O
synthetic	O
mixtures	O
of	O
the	O
organic	O
acids	O
tested	O
at	O
the	O
concentrations	O
found	O
in	O
wine	O
had	O
greater	O
antibacterial	O
activity	O
than	O
the	O
beverages	O
,	O
indicating	O
that	O
in	O
wine	O
they	O
are	O
inhibited	O
by	O
other	O
components	O
.	O

Wine	O
polyphenols	O
displayed	O
no	O
activity	O
against	O
oral	O
streptococci	B-bacteria
or	O
S	B-bacteria
.	I-bacteria
pyogenes	I-bacteria
.	O

Findings	O
show	O
that	O
wine	O
is	O
active	O
against	O
oral	O
streptococci	B-bacteria
and	O
S	B-bacteria
.	I-bacteria
pyogenes	I-bacteria
and	O
suggest	O
that	O
it	O
enhances	O
oral	O
health	O
.	O

Patients	O
undergoing	O
allogeneic	O
stem	O
cell	O
transplantation	O
are	O
at	O
high	O
risk	O
for	O
infection	O
with	O
a	O
variety	O
of	O
pathogens	O
during	O
different	O
phases	O
of	O
the	O
procedure	O
.	O

Human	O
infections	O
due	O
to	O
Bartonella	B-bacteria
spp	I-bacteria
.	I-bacteria
are	O
viewed	O
as	O
emerging	O
diseases	O
typical	O
in	O
,	O
although	O
not	O
exclusive	O
to	O
,	O
immunosuppressed	O
patients	O
,	O
in	O
particular	O
those	O
with	O
AIDS	O
,	O
organ	O
transplants	O
and	O
haematological	O
malignancies	O
.	O

We	O
describe	O
four	O
patients	O
,	O
three	O
children	O
and	O
one	O
adult	O
,	O
who	O
developed	O
vegetating	O
papillomatous	O
lesions	O
exclusively	O
on	O
the	O
oral	O
mucosae	O
.	O

They	O
shared	O
a	O
history	O
of	O
haematological	O
malignancy	O
and	O
allogeneic	O
bone	O
marrow	O
/	O
stem	O
cell	O
transplantation	O
,	O
and	O
later	O
developed	O
chronic	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
,	O
also	O
involving	O
the	O
oral	O
mucosae	O
.	O

Histopathologically	O
,	O
the	O
vegetating	O
lesions	O
were	O
characterized	O
by	O
a	O
diffuse	O
neoangiogenesis	O
,	O
granulation	O
-	O
like	O
tissue	O
,	O
and	O
a	O
mixed	O
cell	O
infiltrate	O
predominantly	O
composed	O
of	O
neutrophils	O
.	O

Gram	O
-	O
negative	O
bacteria	O
were	O
found	O
in	O
the	O
endothelial	O
cells	O
of	O
the	O
vessels	O
in	O
the	O
deeper	O
portion	O
of	O
the	O
corium	O
by	O
electron	O
microscopy	O
.	O

In	O
three	O
cases	O
,	O
DNA	O
of	O
B	B-bacteria
.	I-bacteria
henselae	I-bacteria
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
and	O
confirmed	O
by	O
sequencing	O
of	O
the	O
PCR	O
products	O
.	O

All	O
the	O
lesions	O
healed	O
after	O
systemic	O
antibiotic	O
therapy	O
,	O
although	O
some	O
recurred	O
after	O
months	O
,	O
and	O
regressed	O
again	O
after	O
systemic	O
antibiotic	O
treatment	O
associated	O
with	O
conservative	O
surgical	O
excision	O
.	O

The	O
paper	O
describes	O
an	O
optimized	O
technique	O
for	O
DNA	O
isolation	O
from	O
the	O
Streptococcus	B-bacteria
mutans	I-bacteria
cultures	O
and	O
from	O
the	O
clinical	O
samples	O
including	O
proteinase	O
K	O
treatment	O
and	O
detergent	O
lysis	O
,	O
followed	O
by	O
sorbent	O
-	O
based	O
enrichment	O
.	O

This	O
technique	O
was	O
employed	O
for	O
isolating	O
DNA	O
from	O
the	O
periodontal	O
bacteria	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
and	O
Bacteroides	B-bacteria
forsythus	I-bacteria
.	O

A	O
multiplex	O
PCR	O
technique	O
was	O
adapted	O
for	O
large	O
-	O
scale	O
studies	O
of	O
clinical	O
samples	O
.	O

An	O
original	O
PCR	O
method	O
was	O
developed	O
for	O
the	O
semiquantitative	O
detection	O
of	O
Str	O
.	O

mutans	O
,	O
showing	O
the	O
sensitivity	O
of	O
100	O
genome	O
copies	O
per	O
reaction	O
.	O

Extensive	O
studies	O
of	O
approximately	O
2	O
,	O
000	O
individuals	O
have	O
demonstrated	O
that	O
these	O
methods	O
are	O
applicable	O
to	O
the	O
study	O
of	O
the	O
dental	O
and	O
gingival	O
microflora	O
in	O
the	O
biological	O
sample	O
from	O
the	O
oral	O
cavity	O
of	O
persons	O
with	O
dental	O
diseases	O
from	O
various	O
age	O
groups	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
aerobic	O
and	O
anaerobic	O
microbiology	O
of	O
acute	O
maxillary	O
sinusitis	O
of	O
odontogenic	O
origin	O
presenting	O
with	O
periodontal	O
infection	O
in	O
children	O
.	O

Aspirates	O
of	O
18	O
acutely	O
infected	O
maxillary	O
sinuses	O
that	O
were	O
associated	O
with	O
odontogenic	O
infection	O
in	O
children	O
who	O
presented	O
with	O
periorbital	O
cellulitis	O
were	O
processed	O
for	O
aerobic	O
and	O
anaerobic	O
bacteria	O
.	O

A	O
total	O
of	O
54	O
isolates	O
were	O
recovered	O
(	O
3	O
.	O
0	O
per	O
specimen	O
)	O
:	O
13	O
aerobic	O
and	O
facultative	O
(	O
0	O
.	O
7	O
per	O
specimen	O
)	O
and	O
41	O
anaerobic	O
(	O
2	O
.	O
3	O
per	O
specimen	O
)	O
.	O

The	O
number	O
of	O
isolates	O
per	O
specimen	O
varied	O
from	O
1	O
to	O
4	O
.	O

Aerobic	O
and	O
facultative	O
organisms	O
alone	O
were	O
recovered	O
in	O
2	O
specimens	O
(	O
11	O
%	O
)	O
,	O
anaerobes	O
only	O
in	O
7	O
(	O
39	O
%	O
)	O
,	O
and	O
mixed	O
aerobic	O
and	O
anaerobic	O
bacteria	O
in	O
9	O
(	O
50	O
%	O
)	O
.	O

The	O
predominant	O
aerobic	O
and	O
facultative	O
organisms	O
were	O
alpha	B-bacteria
-	I-bacteria
hemolytic	I-bacteria
streptococci	I-bacteria
(	O
4	O
)	O
,	O
microaerophilic	B-bacteria
streptococci	I-bacteria
(	O
3	O
)	O
,	O
and	O
Streptococcus	B-bacteria
pyogenes	I-bacteria
and	O
Staphylococcus	B-bacteria
aureus	I-bacteria
(	O
2	O
each	O
)	O
.	O

The	O
predominant	O
anaerobic	O
bacteria	O
were	O
anaerobic	O
gram	O
-	O
negative	O
bacilli	O
(	O
17	O
)	O
,	O
Peptostreptococcus	B-bacteria
spp	I-bacteria
(	O
11	O
)	O
,	O
Fusobacterium	B-bacteria
spp	I-bacteria
(	O
8	O
)	O
,	O
and	O
Propionibacterium	B-bacteria
acnes	I-bacteria
(	O
2	O
)	O
.	O

Twelve	O
beta	O
-	O
lactamase	O
-	O
producing	O
bacteria	O
were	O
recovered	O
from	O
9	O
specimens	O
(	O
50	O
%	O
)	O
.	O

This	O
study	O
demonstrates	O
the	O
unique	O
aerobic	O
and	O
anaerobic	O
microbiological	O
features	O
of	O
acute	O
maxillary	O
sinusitis	O
of	O
odontogenic	O
origin	O
presenting	O
with	O
periorbital	O
cellulitis	O
in	O
children	O
.	O

Oral	O
epithelia	O
are	O
constantly	O
exposed	O
to	O
non	O
-	O
pathogenic	O
(	O
commensal	O
)	O
bacteria	O
,	O
but	O
generally	O
remain	O
healthy	O
and	O
uninflamed	O
.	O

Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
an	O
oral	O
commensal	O
bacterium	O
,	O
strongly	O
induces	O
human	O
beta	O
-	O
defensin	O
-	O
2	O
(	O
hBD2	O
)	O
,	O
an	O
antimicrobial	O
and	O
immunomodulatory	O
peptide	O
,	O
in	O
gingival	O
epithelial	O
cells	O
(	O
GECs	O
)	O
.	O

hBD2	O
is	O
also	O
expressed	O
in	O
normal	O
oral	O
tissue	O
leading	O
to	O
the	O
hypothesis	O
that	O
oral	O
epithelia	O
are	O
in	O
an	O
activated	O
state	O
with	O
respect	O
to	O
innate	O
immune	O
responses	O
under	O
normal	O
in	O
vivo	O
conditions	O
.	O

In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
global	O
gene	O
expression	O
was	O
evaluated	O
in	O
GECs	O
in	O
response	O
to	O
stimulation	O
by	O
an	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
cell	O
wall	O
(	O
FnCW	O
)	O
preparation	O
and	O
to	O
hBD2	O
peptide	O
.	O

FnCW	O
treatment	O
altered	O
829	O
genes	O
,	O
while	O
hBD2	O
altered	O
209	O
genes	O
(	O
P	O
<	O
0	O
.	O
005	O
,	O
ANOVA	O
)	O
.	O

Many	O
induced	O
genes	O
were	O
associated	O
with	O
the	O
gene	O
ontology	O
categories	O
of	O
immune	O
responses	O
and	O
defence	O
responses	O
.	O

Consistent	O
with	O
the	O
hypothesis	O
,	O
similar	O
responses	O
were	O
activated	O
by	O
commensal	O
bacteria	O
and	O
hBD2	O
.	O

These	O
responses	O
included	O
up	O
-	O
regulation	O
of	O
common	O
antimicrobial	O
effectors	O
and	O
chemokines	O
,	O
and	O
down	O
-	O
regulation	O
of	O
proliferation	O
markers	O
.	O

In	O
addition	O
,	O
FnCW	O
up	O
-	O
regulated	O
multiple	O
protease	O
inhibitors	O
,	O
and	O
suppressed	O
NF	O
-	O
kappaB	O
function	O
and	O
the	O
ubiquitin	O
/	O
proteasome	O
system	O
.	O

These	O
global	O
changes	O
may	O
protect	O
the	O
tissue	O
from	O
inflammatory	O
damage	O
.	O

Both	O
FnCW	O
and	O
hBD2	O
also	O
up	O
-	O
regulated	O
genes	O
that	O
may	O
enhance	O
the	O
epithelial	O
barrier	O
.	O

The	O
findings	O
suggest	O
that	O
both	O
commensal	O
bacteria	O
and	O
hBD2	O
activate	O
protective	O
responses	O
of	O
GECs	O
and	O
play	O
an	O
important	O
role	O
in	O
immune	O
modulation	O
in	O
the	O
oral	O
cavity	O
.	O

Antagonistic	O
abilities	O
may	O
confer	O
ecological	O
advantages	O
for	O
micro	O
-	O
organisms	O
in	O
competitive	O
ecosystems	O
.	O

However	O
,	O
reports	O
regarding	O
this	O
phenomenon	O
in	O
Eikenella	B-bacteria
corrodens	I-bacteria
are	O
not	O
available	O
.	O

Nineteen	O
E	B-bacteria
.	I-bacteria
corrodens	I-bacteria
strains	I-bacteria
,	O
isolated	O
from	O
the	O
oral	O
cavity	O
of	O
human	O
beings	O
without	O
periodontal	O
disease	O
(	O
n	O
=	O
5	O
)	O
and	O
with	O
aggressive	O
(	O
n	O
=	O
9	O
)	O
and	O
chronic	O
(	O
n	O
=	O
5	O
)	O
periodontitis	O
,	O
as	O
well	O
as	O
a	O
reference	O
strain	O
(	O
E	B-bacteria
.	I-bacteria
corrodens	I-bacteria
ATCC23834	I-bacteria
)	O
,	O
were	O
evaluated	O
for	O
antagonistic	O
activity	O
.	O

The	O
following	O
indicators	O
were	O
used	O
:	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
FDC381	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
ATCC25611	I-bacteria
,	O
Actinomyces	B-bacteria
israelii	I-bacteria
ATCC12102	I-bacteria
,	O
Eubacterium	B-bacteria
lentum	I-bacteria
ATCC25559	I-bacteria
,	O
Peptostreptococcus	B-bacteria
anaerobius	I-bacteria
ATCC27337	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
FDCY4	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
ATCC10953	I-bacteria
,	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
ATCC10557	I-bacteria
,	O
Streptococcus	B-bacteria
uberis	I-bacteria
ATCC9927	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
IM	I-bacteria
/	I-bacteria
UFRJ	I-bacteria
,	O
Staphylococcus	B-bacteria
aureus	I-bacteria
ATCC33591	I-bacteria
and	O
Candida	O
albicans	O
ATCC18804	O
.	O

All	O
the	O
strains	O
showed	O
antagonism	O
against	O
at	O
least	O
one	O
of	O
the	O
indicator	O
strains	O
.	O

This	O
phenomenon	O
was	O
more	O
frequently	O
observed	O
for	O
strains	O
isolated	O
from	O
patients	O
with	O
chronic	O
periodontitis	O
(	O
36	O
.	O
4	O
%	O
)	O
,	O
than	O
those	O
from	O
healthy	O
subjects	O
(	O
20	O
.	O
6	O
%	O
)	O
and	O
those	O
with	O
aggressive	O
periodontitis	O
(	O
10	O
.	O
8	O
%	O
)	O
.	O

The	O
heterogeneous	O
antagonistic	O
spectrum	O
exhibited	O
by	O
E	B-bacteria
.	I-bacteria
corrodens	I-bacteria
isolates	I-bacteria
suggests	O
their	O
ability	O
to	O
produce	O
more	O
than	O
one	O
antagonistic	O
substance	O
,	O
whose	O
ecological	O
relevance	O
is	O
yet	O
to	O
be	O
demonstrated	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
antagonistic	O
compound	O
production	O
by	O
E	B-bacteria
.	I-bacteria
corrodens	I-bacteria
and	O
its	O
relationships	O
with	O
the	O
clinical	O
status	O
of	O
the	O
patients	O
.	O

Strong	O
epidemiological	O
,	O
genetic	O
and	O
biochemical	O
evidence	O
indicates	O
that	O
local	O
acetaldehyde	O
exposure	O
is	O
a	O
major	O
factor	O
behind	O
gastrointestinal	O
cancers	O
especially	O
associated	O
with	O
alcohol	O
drinking	O
and	O
smoking	O
.	O

Thus	O
,	O
reducing	O
the	O
exposure	O
to	O
carcinogenic	O
acetaldehyde	O
either	O
by	O
decreasing	O
the	O
production	O
or	O
by	O
eliminating	O
acetaldehyde	O
locally	O
might	O
offer	O
a	O
preventive	O
strategy	O
against	O
acetaldehyde	O
-	O
induced	O
gastrointestinal	O
cancers	O
.	O

Thiol	O
products	O
,	O
such	O
as	O
the	O
amino	O
acid	O
cysteine	O
,	O
are	O
known	O
to	O
be	O
able	O
to	O
protect	O
against	O
acetaldehyde	O
toxicity	O
.	O

Cysteine	O
is	O
able	O
to	O
bind	O
acetaldehyde	O
efficiently	O
by	O
forming	O
a	O
stable	O
thiazolidine	O
-	O
carboxylic	O
acid	O
compound	O
.	O

Special	O
cysteine	O
preparations	O
(	O
such	O
as	O
lozenge	O
and	O
chewing	O
gum	O
)	O
have	O
already	O
been	O
developed	O
to	O
bind	O
smoking	O
and	O
alcohol	O
drinking	O
derived	O
acetaldehyde	O
from	O
the	O
oral	O
cavity	O
.	O

Most	O
importantly	O
,	O
these	O
type	O
of	O
drug	O
formulations	O
offer	O
a	O
novel	O
method	O
for	O
intervention	O
studies	O
aimed	O
to	O
resolve	O
the	O
eventual	O
role	O
of	O
acetaldehyde	O
in	O
the	O
pathogenesis	O
of	O
upper	O
digestive	O
tract	O
cancers	O
.	O

Acetaldehyde	O
exposure	O
could	O
also	O
be	O
influenced	O
by	O
modifying	O
the	O
acetaldehyde	O
producing	O
microbiota	O
.	O

With	O
regard	O
to	O
the	O
upper	O
digestive	O
tract	O
,	O
acetaldehyde	O
production	O
from	O
ingested	O
ethanol	O
could	O
be	O
significantly	O
reduced	O
by	O
using	O
an	O
antiseptic	O
mouthwash	O
,	O
chlorhexidine	O
.	O

In	O
the	O
large	O
intestine	O
acetaldehyde	O
production	O
could	O
be	O
markedly	O
decreased	O
either	O
by	O
reducing	O
the	O
Gram	O
-	O
negative	O
microbes	O
by	O
ciprofloxacin	O
antibiotic	O
or	O
by	O
lowering	O
the	O
intraluminal	O
pH	O
by	O
lactulose	O
.	O

Enterococci	B-bacteria
are	O
rarely	O
found	O
in	O
the	O
healthy	O
human	O
oral	O
cavity	O
,	O
yet	O
they	O
are	O
strongly	O
associated	O
with	O
filled	O
root	O
canals	O
.	O

The	O
origin	O
of	O
these	O
enterococci	B-bacteria
remains	O
unknown	O
.	O

Our	O
hypothesis	O
is	O
that	O
they	O
are	O
transient	O
food	O
-	O
born	O
colonizers	O
under	O
healthy	O
conditions	O
.	O

This	O
pilot	O
study	O
reinvestigated	O
the	O
prevalence	O
of	O
enterococci	B-bacteria
in	O
the	O
oral	O
cavity	O
of	O
healthy	O
volunteers	O
,	O
screened	O
cheese	O
samples	O
for	O
enterococci	B-bacteria
and	O
investigated	O
colonization	O
of	O
the	O
oral	O
cavity	O
after	O
ingestion	O
of	O
an	O
enterocci	O
-	O
positive	O
cheese	O
.	O

Concentrated	O
oral	O
rinse	O
samples	O
were	O
collected	O
from	O
a	O
cohort	O
of	O
50	O
dental	O
students	O
and	O
proved	O
negative	O
for	O
viable	O
enterococci	B-bacteria
.	O

Twenty	O
cheese	O
samples	O
were	O
obtained	O
from	O
local	O
supermarkets	O
.	O

Enterococci	B-bacteria
were	O
cultured	O
and	O
identified	O
using	O
standard	O
methods	O
.	O

Viable	O
enterococci	B-bacteria
were	O
detected	O
in	O
one	O
of	O
five	O
specimens	O
of	O
Swiss	O
Tilsiter	O
,	O
three	O
of	O
five	O
samples	O
of	O
French	O
soft	O
cheese	O
,	O
one	O
of	O
five	O
Mozzarella	O
samples	O
and	O
one	O
of	O
five	O
Feta	O
samples	O
.	O

Eight	O
volunteers	O
from	O
the	O
cohort	O
consumed	O
10	O
g	O
of	O
a	O
cheese	O
with	O
high	O
Enterococcus	B-bacteria
faecalis	I-bacteria
load	O
.	O

Oral	O
rinse	O
samples	O
were	O
collected	O
before	O
and	O
1	O
,	O
10	O
and	O
100	O
min	O
after	O
cheese	O
ingestion	O
.	O

One	O
minute	O
after	O
ingestion	O
,	O
a	O
median	O
of	O
5	O
,	O
480	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
colony	O
-	O
forming	O
units	O
was	O
recovered	O
from	O
the	O
oral	O
rinse	O
samples	O
.	O

Bacterial	O
counts	O
were	O
reduced	O
after	O
10	O
min	O
,	O
had	O
dropped	O
after	O
100	O
min	O
to	O
levels	O
that	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
different	O
from	O
the	O
1	O
-	O
min	O
and	O
10	O
-	O
min	O
scores	O
and	O
were	O
below	O
the	O
detection	O
limit	O
after	O
1	O
week	O
.	O

These	O
findings	O
suggest	O
that	O
colonization	O
of	O
the	O
healthy	O
oral	O
cavity	O
by	O
enterococci	B-bacteria
is	O
transitional	O
,	O
but	O
at	O
the	O
same	O
time	O
add	O
weight	O
to	O
our	O
hypothesis	O
that	O
enterococcal	O
root	O
canal	O
infections	O
could	O
be	O
food	O
-	O
borne	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
current	O
antimicrobial	O
susceptibility	O
of	O
the	O
principle	O
anaerobic	O
pathogens	O
involved	O
in	O
dentoalveolar	O
infection	O
,	O
to	O
13	O
oral	O
antibiotics	O
,	O
and	O
to	O
assess	O
the	O
value	O
of	O
each	O
antibiotic	O
in	O
the	O
management	O
of	O
the	O
infection	O
.	O

A	O
total	O
of	O
800	O
isolates	O
from	O
patients	O
with	O
dentoalveolar	O
infection	O
(	O
Prevotella	B-bacteria
species	I-bacteria
,	O
Fusobacterium	B-bacteria
species	I-bacteria
,	O
Porphyromonas	B-bacteria
species	I-bacteria
and	O
Peptostreptococcus	B-bacteria
micros	I-bacteria
)	O
were	O
tested	O
for	O
their	O
susceptibility	O
to	O
amoxicillin	O
,	O
amoxicillin	O
/	O
clavulanate	O
,	O
cefaclor	O
,	O
cefuroxime	O
,	O
cefcapene	O
,	O
cefdinir	O
,	O
erythromycin	O
,	O
azithromycin	O
,	O
telithromycin	O
,	O
minocycline	O
,	O
levofloxacin	O
,	O
clindamycin	O
,	O
and	O
metronidazole	O
using	O
an	O
agar	O
dilution	O
method	O
.	O

Although	O
the	O
majority	O
of	O
Fusobacterium	B-bacteria
strains	I-bacteria
were	O
resistant	O
to	O
erythromycin	O
,	O
azithromycin	O
,	O
and	O
telithromycin	O
,	O
the	O
remaining	O
antibiotics	O
demonstrated	O
a	O
high	O
level	O
of	O
antimicrobial	O
activity	O
.	O

P	B-bacteria
.	I-bacteria
micros	I-bacteria
and	O
Porphyromonas	B-bacteria
species	I-bacteria
exhibited	O
high	O
susceptibility	O
to	O
all	O
antibiotics	O
tested	O
in	O
this	O
study	O
.	O

In	O
the	O
case	O
of	O
Prevotella	B-bacteria
species	I-bacteria
,	O
resistance	O
to	O
amoxicillin	O
occurred	O
in	O
34	O
%	O
of	O
isolates	O
and	O
all	O
of	O
these	O
resistant	O
strains	O
were	O
found	O
to	O
produce	O
beta	O
-	O
lactamase	O
.	O

Susceptibility	O
of	O
Prevotella	B-bacteria
strains	I-bacteria
to	O
cefaclor	O
,	O
cefuroxime	O
,	O
cefcapene	O
,	O
cefdinir	O
,	O
erythromycin	O
,	O
azithromycin	O
,	O
and	O
minocycline	O
was	O
found	O
to	O
correlate	O
with	O
amoxicillin	O
susceptibility	O
.	O

Amoxicillin	O
/	O
clavulanate	O
,	O
telithromycin	O
,	O
clindamycin	O
,	O
and	O
metronidazole	O
exhibited	O
high	O
antimicrobial	O
activity	O
even	O
against	O
amoxicillin	O
-	O
resistant	O
strains	O
of	O
Prevotella	B-bacteria
species	I-bacteria
.	O

Amoxicillin	O
would	O
still	O
be	O
advocated	O
therefore	O
as	O
being	O
a	O
suitable	O
first	O
-	O
line	O
agent	O
,	O
while	O
reduced	O
susceptibility	O
of	O
Prevotella	B-bacteria
strains	I-bacteria
remains	O
a	O
matter	O
of	O
concern	O
with	O
penicillins	O
.	O

Amoxicillin	O
/	O
clavulanate	O
,	O
clindamycin	O
,	O
and	O
metronidazole	O
are	O
useful	O
alternatives	O
in	O
combating	O
the	O
anaerobic	O
bacteria	O
involved	O
in	O
dentoalveolar	O
infection	O
.	O

To	O
determine	O
the	O
distribution	O
of	O
pathogens	O
on	O
cattle	O
hides	O
at	O
the	O
feedlot	O
,	O
samples	O
were	O
collected	O
from	O
six	O
hide	O
surface	O
locations	O
(	O
back	O
,	O
flank	O
,	O
hock	O
,	O
neck	O
,	O
perineum	O
,	O
and	O
ventrum	O
)	O
,	O
the	O
oral	O
cavity	O
,	O
the	O
rectal	O
-	O
anal	O
junction	O
,	O
and	O
the	O
feces	O
of	O
feedlot	O
cattle	O
and	O
subjected	O
to	O
Escherichia	B-bacteria
coli	I-bacteria
0157	I-bacteria
detection	O
via	O
culture	O
methods	O
and	O
to	O
Salmonella	B-bacteria
detection	O
via	O
PCR	O
.	O

E	B-bacteria
.	I-bacteria
coli	I-bacteria
0157	I-bacteria
was	O
isolated	O
from	O
one	O
or	O
more	O
of	O
the	O
sampling	O
locations	O
from	O
31	O
(	O
42	O
.	O
5	O
%	O
)	O
of	O
the	O
73	O
animals	O
sampled	O
.	O

Location	O
-	O
specific	O
prevalence	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
0157	I-bacteria
was	O
5	O
%	O
for	O
back	O
samples	O
,	O
5	O
%	O
for	O
flank	O
samples	O
,	O
12	O
%	O
for	O
hock	O
samples	O
,	O
7	O
%	O
for	O
neck	O
samples	O
,	O
12	O
%	O
for	O
perineum	O
samples	O
,	O
8	O
%	O
for	O
ventrum	O
samples	O
,	O
1	O
%	O
for	O
oral	O
cavity	O
samples	O
,	O
4	O
%	O
for	O
rectal	O
-	O
anal	O
junction	O
swabs	O
,	O
and	O
23	O
%	O
for	O
fecal	O
grab	O
samples	O
.	O

Salmonella	B-bacteria
was	O
isolated	O
from	O
one	O
or	O
more	O
of	O
these	O
sample	O
locations	O
from	O
100	O
%	O
(	O
50	O
of	O
50	O
samples	O
)	O
of	O
all	O
animals	O
sampled	O
.	O

Location	O
-	O
specific	O
prevalence	O
of	O
Salmonella	B-bacteria
was	O
76	O
%	O
for	O
back	O
samples	O
,	O
74	O
%	O
for	O
flank	O
samples	O
,	O
94	O
%	O
for	O
hock	O
samples	O
,	O
76	O
%	O
for	O
neck	O
samples	O
,	O
88	O
%	O
for	O
perineum	O
samples	O
,	O
86	O
%	O
for	O
ventrum	O
samples	O
,	O
94	O
%	O
for	O
oral	O
cavity	O
samples	O
,	O
64	O
%	O
for	O
rectal	O
-	O
anal	O
junction	O
swabs	O
,	O
and	O
50	O
%	O
for	O
fecal	O
grab	O
samples	O
.	O

The	O
sampling	O
locations	O
that	O
maximized	O
the	O
likelihood	O
of	O
finding	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
0157	I-bacteria
and	O
Salmonella	B-bacteria
(	O
84	O
and	O
96	O
%	O
,	O
respectively	O
)	O
if	O
the	O
animal	O
was	O
positive	O
at	O
one	O
sampling	O
location	O
or	O
more	O
were	O
the	O
hock	O
,	O
perineum	O
,	O
and	O
fecal	O
grab	O
.	O

These	O
data	O
suggest	O
that	O
the	O
use	O
of	O
multiple	O
sample	O
locations	O
is	O
useful	O
when	O
isolating	O
these	O
pathogens	O
from	O
feedlot	O
cattle	O
.	O

Focusing	O
on	O
one	O
sampling	O
location	O
may	O
underestimate	O
the	O
prevalence	O
.	O

Enhanced	O
delivery	O
of	O
bifidobacteria	B-bacteria
and	O
fecal	O
changes	O
were	O
compared	O
following	O
multiple	O
oral	O
administrations	O
of	O
protected	O
bifidobacteria	O
-	O
loaded	O
alginate	O
poly	O
-	O
l	O
-	O
lysine	O
microparticles	O
(	O
bap	O
-	O
microparticles	O
)	O
and	O
unprotected	O
bifidobacteria	B-bacteria
cultures	O
over	O
a	O
period	O
of	O
1	O
month	O
to	O
healthy	O
human	O
volunteers	O
as	O
preliminary	O
in	O
vivo	O
studies	O
.	O

When	O
bap	O
-	O
microparticles	O
were	O
orally	O
administered	O
,	O
enhanced	O
delivery	O
of	O
bifidobacteria	B-bacteria
was	O
achieved	O
.	O

The	O
viability	O
of	O
the	O
bifidobacteria	B-bacteria
was	O
significantly	O
increased	O
approximately	O
11	O
.	O
5	O
-	O
30	O
times	O
(	O
1	O
.	O
06	O
-	O
1	O
.	O
48	O
log	O
cycles	O
)	O
during	O
the	O
ingestion	O
period	O
when	O
compared	O
with	O
the	O
bifidobacteria	B-bacteria
culture	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
other	O
gut	O
microflora	O
such	O
as	O
bifidobacteria	B-bacteria
,	O
enterobacteriaceae	B-bacteria
,	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
,	O
and	O
staphylococci	B-bacteria
in	O
feces	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Encapsulated	O
bifidobacteria	B-bacteria
resulted	O
in	O
more	O
frequent	O
defecation	O
and	O
decreased	O
fecal	O
viscosity	O
.	O

The	O
`	O
`	O
Synergistes	B-bacteria
'	O
'	O
group	O
of	O
organisms	O
are	O
a	O
phylogenetic	O
cluster	O
of	O
Gram	O
-	O
negative	O
anaerobes	O
related	O
to	O
Synergistes	B-bacteria
jonesii	I-bacteria
,	O
sufficiently	O
distinct	O
from	O
all	O
other	O
phyla	O
to	O
be	O
considered	O
a	O
distinct	O
phylum	O
or	O
Division	O
.	O

They	O
are	O
widely	O
distributed	O
in	O
nature	O
although	O
normally	O
only	O
a	O
minor	O
constituent	O
of	O
the	O
bacterial	O
community	O
in	O
each	O
habitat	O
.	O

They	O
have	O
evolved	O
to	O
adapt	O
to	O
each	O
habitat	O
,	O
and	O
therefore	O
exhibit	O
a	O
wide	O
range	O
of	O
physiological	O
and	O
biochemical	O
characteristics	O
,	O
although	O
all	O
cultivable	O
taxa	O
so	O
far	O
studied	O
have	O
the	O
ability	O
to	O
degrade	O
amino	O
acids	O
.	O

They	O
are	O
found	O
in	O
the	O
human	O
mouth	O
where	O
they	O
appear	O
to	O
be	O
more	O
numerous	O
in	O
tooth	O
and	O
gum	O
disease	O
than	O
health	O
.	O

They	O
have	O
also	O
been	O
found	O
in	O
the	O
human	O
gut	O
and	O
soft	O
tissue	O
infections	O
.	O

Their	O
role	O
in	O
human	O
disease	O
has	O
yet	O
to	O
be	O
established	O
but	O
improved	O
knowledge	O
of	O
the	O
characteristics	O
that	O
enable	O
their	O
identification	O
should	O
increase	O
the	O
likelihood	O
of	O
their	O
recognition	O
when	O
present	O
at	O
diseased	O
sites	O
.	O

An	O
in	O
vitro	O
plaque	O
model	O
based	O
on	O
the	O
use	O
of	O
human	O
salivary	O
bacteria	O
and	O
tooth	O
-	O
like	O
surfaces	O
was	O
previously	O
developed	O
for	O
studying	O
the	O
formation	O
of	O
oral	O
biofilm	O
and	O
its	O
use	O
for	O
pre	O
-	O
clinical	O
testing	O
of	O
candidate	O
antimicrobial	O
or	O
antiplaque	O
agents	O
.	O

In	O
this	O
study	O
,	O
a	O
quantitative	O
Taqman	O
PCR	O
assay	O
(	O
QPCR	O
)	O
was	O
developed	O
to	O
compare	O
the	O
bacterial	O
compositions	O
of	O
in	O
vitro	O
biofilms	O
to	O
parent	O
saliva	O
samples	O
,	O
and	O
to	O
determine	O
the	O
relative	O
contributions	O
of	O
different	O
species	O
in	O
the	O
formation	O
of	O
the	O
oral	O
biofilm	O
.	O

In	O
addition	O
,	O
the	O
growth	O
inhibition	O
of	O
saliva	O
-	O
derived	O
plaque	O
was	O
evaluated	O
by	O
chlorhexidine	O
.	O

With	O
this	O
assay	O
,	O
which	O
consisted	O
of	O
primer	O
/	O
probe	O
sets	O
targeting	O
either	O
16S	O
rDNA	O
sequences	O
present	O
in	O
public	O
databases	O
or	O
cloned	O
ribosomal	O
intergenic	O
spacer	O
region	O
(	O
ISR	O
)	O
sequences	O
,	O
15	O
oral	O
bacteria	O
derived	O
from	O
saliva	O
as	O
well	O
as	O
those	O
that	O
were	O
responsible	O
for	O
biofilm	O
formation	O
in	O
an	O
in	O
vitro	O
plaque	O
model	O
were	O
rapidly	O
identified	O
and	O
quantified	O
.	O

Among	O
the	O
target	O
organisms	O
were	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Eikenella	B-bacteria
corrodens	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
Micromonas	B-bacteria
micros	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
,	O
and	O
Veillonella	B-bacteria
parvula	I-bacteria
.	O

Primer	O
and	O
probe	O
sets	O
developed	O
were	O
both	O
sensitive	O
and	O
specific	O
.	O

The	O
relative	O
profiles	O
of	O
a	O
number	O
of	O
bacteria	O
in	O
45	O
-	O
h	O
-	O
old	O
biofilms	O
were	O
determined	O
and	O
,	O
when	O
compared	O
to	O
saliva	O
samples	O
,	O
it	O
was	O
found	O
that	O
most	O
of	O
the	O
bacteria	O
identified	O
in	O
saliva	O
also	O
populated	O
the	O
in	O
vitro	O
plaque	O
,	O
including	O
some	O
anaerobes	O
.	O

Brief	O
exposure	O
of	O
biofilms	O
to	O
chlorhexidine	O
resulted	O
in	O
significant	O
losses	O
in	O
viability	O
.	O

This	O
new	O
broad	O
spectrum	O
QPCR	O
assay	O
in	O
combination	O
with	O
the	O
in	O
vitro	O
plaque	O
model	O
will	O
be	O
of	O
significant	O
value	O
in	O
the	O
quantitative	O
study	O
of	O
the	O
microbial	O
composition	O
of	O
human	O
saliva	O
,	O
saliva	O
-	O
derived	O
plaque	O
,	O
and	O
pre	O
-	O
clinical	O
evaluation	O
of	O
potential	O
antimicrobial	O
and	O
antiplaque	O
molecules	O
.	O

Sutures	O
used	O
in	O
oral	O
surgery	O
should	O
avoid	O
or	O
limit	O
bacterial	O
adhesion	O
and	O
proliferation	O
to	O
those	O
parts	O
exposed	O
to	O
oral	O
fluids	O
.	O

Hence	O
,	O
microbial	O
colonization	O
on	O
various	O
intraoral	O
suture	O
materials	O
from	O
patients	O
undergoing	O
dental	O
surgery	O
was	O
compared	O
.	O

PATIENTS	O
AND	O
During	O
dentoalveolar	O
surgery	O
,	O
various	O
suture	O
materials	O
were	O
used	O
in	O
60	O
patients	O
,	O
who	O
were	O
randomly	O
divided	O
into	O
5	O
groups	O
of	O
12	O
.	O

In	O
each	O
group	O
,	O
silk	O
was	O
placed	O
intraorally	O
in	O
association	O
with	O
a	O
different	O
type	O
of	O
suture	O
(	O
ie	O
,	O
Supramid	O
,	O
Synthofil	O
,	O
Ethibond	O
Excel	O
,	O
Ti	O
-	O
cron	O
,	O
Monocryl	O
)	O
at	O
the	O
same	O
site	O
to	O
compare	O
microbial	O
colonization	O
intraindividually	O
.	O

Eight	O
days	O
postoperatively	O
,	O
the	O
sutures	O
were	O
removed	O
,	O
and	O
adhered	O
micro	O
-	O
organisms	O
were	O
isolated	O
,	O
counted	O
,	O
and	O
identified	O
through	O
enzymatic	O
activities	O
and	O
fermentation	O
of	O
sugars	O
.	O

In	O
all	O
60	O
patients	O
,	O
silk	O
sutures	O
exhibited	O
the	O
smallest	O
affinity	O
toward	O
the	O
adhesion	O
of	O
bacteria	O
compared	O
with	O
considerable	O
proliferation	O
with	O
nonresorbable	O
multifilament	O
sutures	O
(	O
Supramid	O
,	O
Synthofil	O
,	O
Ethibond	O
Excel	O
,	O
Ti	O
-	O
cron	O
)	O
.	O

On	O
the	O
contrary	O
,	O
the	O
microbial	O
load	O
was	O
significantly	O
lower	O
when	O
absorbable	O
monofilament	O
Monocryl	O
was	O
used	O
.	O

A	O
greater	O
quantity	O
of	O
bacteria	O
was	O
found	O
on	O
nonresorbable	O
sutures	O
than	O
on	O
absorbable	O
ones	O
,	O
and	O
nearly	O
2	O
times	O
more	O
facultative	O
anaerobic	O
bacteria	O
were	O
isolated	O
in	O
total	O
.	O

Our	O
results	O
show	O
that	O
bacteria	O
adhere	O
with	O
different	O
affinity	O
to	O
various	O
types	O
of	O
suture	O
materials	O
.	O

Absorbable	O
silk	O
and	O
Monocryl	O
exhibited	O
the	O
smallest	O
number	O
of	O
adherent	O
bacteria	O
.	O

Colonization	O
by	O
pathogens	O
on	O
sutures	O
leads	O
to	O
the	O
recommendation	O
that	O
sutures	O
should	O
be	O
removed	O
as	O
early	O
as	O
possible	O
after	O
surgery	O
is	O
performed	O
,	O
to	O
eliminate	O
or	O
to	O
limit	O
the	O
reservoir	O
for	O
oral	O
pathogens	O
.	O

This	O
recommendation	O
is	O
dependent	O
on	O
whether	O
the	O
suture	O
is	O
absorbable	O
.	O

The	O
objective	O
of	O
this	O
trial	O
was	O
to	O
measure	O
the	O
antimicrobial	O
effects	O
of	O
a	O
minocycline	O
HCl	O
microsphere	O
(	O
MM	O
)	O
local	O
drug	O
-	O
delivery	O
system	O
when	O
used	O
as	O
an	O
adjunct	O
to	O
scaling	O
and	O
root	O
planing	O
(	O
SRP	O
)	O
.	O

DNA	O
probe	O
analysis	O
for	O
40	O
bacteria	O
was	O
used	O
to	O
evaluate	O
the	O
oral	O
bacteria	O
of	O
127	O
subjects	O
with	O
moderate	O
to	O
advanced	O
chronic	O
periodontitis	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
SRP	O
alone	O
(	O
N	O
=	O
65	O
)	O
or	O
MM	O
+	O
SRP	O
(	O
N	O
=	O
62	O
)	O
.	O

The	O
primary	O
endpoints	O
of	O
this	O
study	O
were	O
changes	O
in	O
numbers	O
and	O
proportions	O
of	O
the	O
red	B-bacteria
-	I-bacteria
complex	I-bacteria
bacteria	I-bacteria
(	O
RCB	B-bacteria
)	O
and	O
the	O
sum	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
(	O
formally	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
)	O
,	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
relative	O
to	O
40	O
oral	O
bacteria	O
at	O
each	O
test	O
site	O
from	O
baseline	O
to	O
day	O
30	O
.	O

Numbers	O
of	O
RCB	B-bacteria
from	O
the	O
five	O
test	O
sites	O
were	O
averaged	O
to	O
provide	O
a	O
value	O
for	O
each	O
subject	O
.	O

MM	O
+	O
SRP	O
reduced	O
the	O
proportion	O
of	O
RCB	B-bacteria
by	O
6	O
.	O
49	O
%	O
and	O
the	O
numbers	O
by	O
9	O
.	O
4	O
x	O
10	O
(	O
5	O
)	O
.	O

The	O
reduction	O
in	O
RCB	B-bacteria
proportions	O
and	O
numbers	O
by	O
SRP	O
alone	O
(	O
5	O
.	O
03	O
%	O
and	O
5	O
.	O
1	O
x	O
10	O
(	O
5	O
)	O
,	O
respectively	O
)	O
was	O
significantly	O
less	O
.	O

In	O
addition	O
,	O
MM	O
+	O
SRP	O
reduced	O
probing	O
depth	O
by	O
1	O
.	O
38	O
mm	O
(	O
compared	O
to	O
1	O
.	O
01	O
mm	O
by	O
SRP	O
alone	O
)	O
,	O
bleeding	O
on	O
probing	O
was	O
reduced	O
by	O
25	O
.	O
2	O
%	O
(	O
compared	O
to	O
13	O
.	O
8	O
%	O
by	O
SRP	O
alone	O
)	O
,	O
and	O
a	O
clinical	O
attachment	O
level	O
gain	O
of	O
1	O
.	O
16	O
mm	O
(	O
compared	O
to	O
0	O
.	O
80	O
mm	O
by	O
SRP	O
alone	O
)	O
was	O
achieved	O
.	O

These	O
observations	O
support	O
the	O
hypothesis	O
that	O
RCBs	B-bacteria
are	O
responsible	O
for	O
periodontal	O
disease	O
and	O
that	O
local	O
antimicrobial	O
therapy	O
using	O
MM	O
+	O
SRP	O
effectively	O
reduces	O
numbers	O
of	O
RCBs	B-bacteria
and	O
their	O
proportions	O
to	O
a	O
greater	O
extent	O
than	O
SRP	O
alone	O
.	O

The	O
authors	O
examined	O
the	O
tongue	O
bacteria	O
associated	O
with	O
oral	O
halitosis	O
(	O
bad	O
breath	O
originating	O
from	O
the	O
oral	O
cavity	O
)	O
,	O
focusing	O
on	O
noncultivable	O
bacteria	O
-	O
bacteria	O
that	O
can	O
not	O
be	O
identified	O
by	O
bacterial	O
culture	O
techniques	O
.	O

The	O
authors	O
took	O
samples	O
from	O
the	O
dorsal	O
tongue	O
surface	O
of	O
eight	O
adult	O
subjects	O
with	O
halitosis	O
and	O
five	O
control	O
subjects	O
who	O
did	O
not	O
have	O
halitosis	O
.	O

They	O
identified	O
the	O
bacteria	O
in	O
these	O
samples	O
by	O
using	O
both	O
anaerobic	O
culture	O
and	O
direct	O
amplification	O
of	O
16S	O
ribosomal	O
DNA	O
,	O
a	O
method	O
that	O
can	O
identify	O
both	O
cultivable	O
and	O
noncultivable	O
microorganisms	O
.	O

They	O
analyzed	O
the	O
resulting	O
microbiological	O
data	O
using	O
chi	O
(	O
2	O
)	O
and	O
correlation	O
coefficient	O
tests	O
.	O

Clinical	O
measures	O
of	O
halitosis	O
were	O
correlated	O
highly	O
with	O
each	O
other	O
and	O
with	O
tongue	O
coating	O
scores	O
.	O

Of	O
4	O
,	O
088	O
isolates	O
and	O
phylotypes	O
identified	O
from	O
the	O
13	O
subjects	O
,	O
32	O
species	O
including	O
13	O
noncultivable	O
species	O
were	O
found	O
only	O
in	O
subjects	O
with	O
halitosis	O
.	O

Solobacterium	B-bacteria
moorei	I-bacteria
was	O
present	O
in	O
all	O
subjects	O
with	O
halitosis	O
but	O
not	O
in	O
any	O
control	O
subjects	O
.	O

Subjects	O
with	O
halitosis	O
harbor	O
some	O
bacterial	O
species	O
on	O
their	O
dorsal	O
tongue	O
surfaces	O
that	O
are	O
distinct	O
from	O
bacterial	O
species	O
found	O
in	O
control	O
subjects	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
halitosis	O
has	O
a	O
microbial	O
etiology	O
.	O

Like	O
other	O
oral	O
diseases	O
with	O
microbial	O
etiology	O
,	O
halitosis	O
may	O
be	O
amenable	O
to	O
specific	O
and	O
nonspecific	O
antimicrobial	O
therapy	O
targeted	O
toward	O
the	O
bacteria	O
associated	O
with	O
it	O
.	O

Because	O
of	O
its	O
excellent	O
osteogenic	O
potential	O
,	O
autogenous	O
bone	O
is	O
the	O
preferred	O
grafting	O
material	O
for	O
dental	O
procedures	O
;	O
however	O
,	O
bone	O
collected	O
in	O
osseous	O
coagulum	O
traps	O
is	O
subject	O
to	O
contamination	O
by	O
oral	O
bacteria	O
.	O

This	O
study	O
assessed	O
bacterial	O
contamination	O
of	O
osseous	O
coagulum	O
and	O
tested	O
treatments	O
for	O
reducing	O
contamination	O
.	O

Fifty	O
bone	O
samples	O
from	O
patients	O
undergoing	O
implant	O
osteotomy	O
procedures	O
were	O
collected	O
in	O
osseous	O
coagulum	O
traps	O
,	O
divided	O
into	O
groups	O
of	O
10	O
,	O
and	O
rinsed	O
with	O
normal	O
saline	O
,	O
0	O
.	O
12	O
%	O
chlorhexidine	O
,	O
or	O
50	O
mg	O
/	O
mL	O
tetracycline	O
.	O

Twenty	O
control	O
samples	O
received	O
no	O
treatment	O
.	O

The	O
bone	O
samples	O
were	O
plated	O
in	O
triplicate	O
on	O
selective	O
and	O
differential	O
media	O
to	O
assay	O
aerobic	O
and	O
anaerobic	O
bacteria	O
and	O
potential	O
bacterial	O
pathogens	O
,	O
including	O
staphylococci	B-bacteria
,	O
streptococci	B-bacteria
,	O
enterics	B-bacteria
,	O
and	O
black	O
-	O
pigmented	O
bacteria	O
(	O
BPB	O
)	O
.	O

Inoculations	O
were	O
performed	O
with	O
an	O
Autoplate	O
4000	O
,	O
and	O
plates	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
either	O
aerobically	O
or	O
in	O
a	O
Coy	O
anaerobic	O
chamber	O
.	O

Bacteria	O
were	O
isolated	O
from	O
all	O
samples	O
.	O

In	O
control	O
samples	O
,	O
the	O
mean	O
colony	O
-	O
forming	O
units	O
(	O
cfu	O
)	O
per	O
milliliter	O
of	O
suspended	O
osseous	O
coagulum	O
was	O
6	O
.	O
5	O
x	O
10	O
(	O
4	O
)	O
+	O
/	O
-	O
9	O
.	O
6	O
x	O
10	O
(	O
4	O
)	O
in	O
aerobic	O
cultures	O
and	O
4	O
.	O
8	O
x	O
10	O
(	O
4	O
)	O
+	O
/	O
-	O
6	O
.	O
9	O
x	O
10	O
(	O
4	O
)	O
in	O
anaerobic	O
cultures	O
.	O

Viridans	B-bacteria
streptococci	I-bacteria
were	O
isolated	O
from	O
46	O
samples	O
,	O
with	O
a	O
mean	O
of	O
2	O
.	O
9	O
x	O
10	O
(	O
4	O
)	O
+	O
/	O
-	O
4	O
.	O
1	O
x	O
10	O
(	O
4	O
)	O
cfu	O
/	O
mL	O
.	O

Enterics	O
were	O
in	O
16	O
samples	O
with	O
cfu	O
ranging	O
from	O
200	O
cfu	O
/	O
mL	O
to	O
3	O
.	O
4	O
x	O
10	O
(	O
4	O
)	O
cfu	O
/	O
mL	O
.	O

Mannitol	O
nonfermenting	B-bacteria
staphylococci	I-bacteria
were	O
found	O
in	O
one	O
sample	O
at	O
106	O
cfu	O
/	O
mL	O
.	O

BPB	O
were	O
not	O
isolated	O
.	O

A	O
Mann	O
-	O
Whitney	O
U	O
test	O
with	O
significance	O
set	O
at	O
P	O
=	O
.	O
05	O
determined	O
that	O
the	O
only	O
statistically	O
significant	O
reductions	O
in	O
bacterial	O
numbers	O
occurred	O
in	O
tetracycline	O
-	O
treated	O
samples	O
of	O
anaerobic	O
bacteria	O
(	O
5	O
-	O
fold	O
decrease	O
,	O
P	O
=	O
.	O
02	O
)	O
and	O
aerobic	O
bacteria	O
(	O
6	O
-	O
fold	O
decrease	O
,	O
P	O
=	O
.	O
01	O
)	O
.	O

Tetracycline	O
treatments	O
effected	O
a	O
7	O
-	O
fold	O
decrease	O
in	O
streptococci	B-bacteria
,	O
but	O
the	O
difference	O
was	O
not	O
significant	O
(	O
P	O
=	O
.	O
07	O
)	O
.	O

These	O
data	O
indicate	O
significant	O
bacterial	O
contamination	O
of	O
bone	O
collected	O
in	O
osseous	O
coagulum	O
traps	O
and	O
justify	O
further	O
research	O
into	O
methods	O
for	O
eliminating	O
that	O
contamination	O
.	O

Primary	O
infection	O
of	O
oral	O
epithelial	O
cells	O
by	O
HIV	O
-	O
1	O
,	O
if	O
it	O
occurs	O
,	O
could	O
promote	O
systemic	O
infection	O
.	O

Most	O
primary	O
systemic	O
infections	O
are	O
associated	O
with	O
R5	O
-	O
type	O
HIV	O
-	O
1	O
targeting	O
the	O
R5	O
-	O
specific	O
coreceptor	O
CCR5	O
,	O
which	O
is	O
not	O
usually	O
expressed	O
on	O
oral	O
keratinocytes	O
.	O

Because	O
coinfection	O
with	O
other	O
microbes	O
has	O
been	O
suggested	O
to	O
modulate	O
cellular	O
infection	O
by	O
HIV	O
-	O
1	O
,	O
we	O
hypothesized	O
that	O
oral	O
keratinocytes	O
may	O
up	O
-	O
regulate	O
CCR5	O
in	O
response	O
to	O
the	O
oral	O
endogenous	O
pathogen	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
by	O
cysteine	O
-	O
protease	O
(	O
gingipains	O
)	O
activation	O
of	O
the	O
protease	O
-	O
activated	O
receptors	O
(	O
PARs	O
)	O
or	O
LPS	O
signaling	O
through	O
the	O
TLRs	O
.	O

The	O
OKF6	O
/	O
TERT	O
-	O
2	O
-	O
immortalized	O
normal	O
human	O
oral	O
keratinocyte	O
line	O
expressed	O
CXCR4	O
,	O
whereas	O
CCR5	O
was	O
not	O
detectable	O
.	O

When	O
exposed	O
to	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
ATCC	I-bacteria
33277	I-bacteria
,	O
TERT	O
-	O
2	O
cells	O
induced	O
greater	O
time	O
-	O
dependent	O
expression	O
of	O
CCR5	O
-	O
specific	O
mRNA	O
and	O
surface	O
coreceptors	O
than	O
CXCR4	O
.	O

By	O
comparing	O
arg	O
-	O
(	O
Rgp	O
)	O
and	O
lys	O
-	O
gingipain	O
(	O
Kgp	O
)	O
mutants	O
,	O
a	O
mutant	O
deficient	O
in	O
both	O
proteases	O
,	O
and	O
the	O
action	O
of	O
trypsin	O
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
Rgp	O
was	O
strongly	O
suggested	O
to	O
cleave	O
PAR	O
-	O
1	O
and	O
PAR	O
-	O
2	O
to	O
up	O
-	O
regulate	O
CCR5	O
.	O

CCR5	O
was	O
also	O
slightly	O
up	O
-	O
regulated	O
by	O
an	O
isogenic	O
gingipain	O
-	O
deficient	O
mutant	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
nongingipain	O
-	O
mediated	O
mechanism	O
.	O

Purified	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
LPS	O
also	O
up	O
-	O
regulated	O
CCR5	O
.	O

Blocking	O
TLR2	O
and	O
TLR4	O
receptors	O
with	O
Abs	O
attenuated	O
induction	O
of	O
CCR5	O
,	O
suggesting	O
LPS	O
signaling	O
through	O
TLRs	O
.	O

P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
therefore	O
,	O
selectively	O
up	O
-	O
regulated	O
CCR5	O
by	O
two	O
independent	O
signaling	O
pathways	O
,	O
Rgp	O
acting	O
on	O
PAR	O
-	O
1	O
and	O
PAR	O
-	O
2	O
,	O
and	O
LPS	O
on	O
TLR2	O
and	O
TLR4	O
.	O

By	O
inducing	O
CCR5	O
expression	O
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
coinfection	O
could	O
promote	O
selective	O
R5	O
-	O
type	O
HIV	O
-	O
1	O
infection	O
of	O
oral	O
keratinocytes	O
.	O

To	O
assess	O
the	O
effectiveness	O
of	O
0	O
.	O
2	O
%	O
chlorhexidine	O
gluconate	O
mouth	O
rinse	O
on	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
lactobacilli	B-bacteria
in	O
orthodontic	O
patients	O
with	O
fixed	O
appliances	O
.	O

Twenty	O
patients	O
,	O
aged	O
13	O
-	O
18	O
,	O
with	O
fixed	O
orthodontic	O
appliances	O
participated	O
in	O
the	O
study	O
.	O

The	O
levels	O
of	O
S	B-bacteria
mutans	I-bacteria
and	O
lactobacilli	B-bacteria
in	O
saliva	O
samples	O
were	O
evaluated	O
at	O
four	O
stages	O
:	O
at	O
the	O
beginning	O
of	O
the	O
orthodontic	O
treatment	O
,	O
at	O
least	O
2	O
weeks	O
after	O
the	O
bonding	O
of	O
brackets	O
,	O
1	O
week	O
after	O
the	O
introduction	O
of	O
0	O
.	O
2	O
%	O
chlorhexidine	O
gluconate	O
mouth	O
rinse	O
,	O
and	O
at	O
the	O
fourth	O
week	O
.	O

The	O
changes	O
in	O
S	B-bacteria
mutans	I-bacteria
and	O
lactobacilli	B-bacteria
levels	O
were	O
analyzed	O
via	O
Wilcoxon	O
test	O
.	O

Increases	O
in	O
bacterial	O
levels	O
of	O
S	B-bacteria
mutans	I-bacteria
and	O
lactobacilli	B-bacteria
were	O
detected	O
after	O
the	O
orthodontic	O
appliances	O
were	O
bonded	O
.	O

A	O
significant	O
decrease	O
in	O
S	B-bacteria
mutans	I-bacteria
levels	O
was	O
observed	O
1	O
week	O
after	O
the	O
introduction	O
of	O
chlorhexidine	O
mouth	O
rinse	O
.	O

An	O
0	O
.	O
2	O
%	O
chlorhexidine	O
gluconate	O
mouth	O
rinse	O
decreased	O
S	B-bacteria
mutans	I-bacteria
levels	O
,	O
but	O
had	O
no	O
effect	O
on	O
lactobacilli	B-bacteria
levels	O
.	O

This	O
paper	O
aims	O
to	O
critically	O
review	O
current	O
knowledge	O
about	O
the	O
key	O
factors	O
involved	O
in	O
oral	O
colonization	O
of	O
the	O
cariogenic	O
group	O
of	O
bacteria	O
,	O
mutans	B-bacteria
streptococci	I-bacteria
(	O
MS	B-bacteria
)	O
in	O
young	O
children	O
.	O

MS	B-bacteria
,	O
consisting	O
mainly	O
of	O
the	O
species	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
,	O
are	O
commonly	O
cultured	O
from	O
the	O
mouths	O
of	O
infants	O
,	O
with	O
prevalence	O
of	O
infection	O
ranging	O
from	O
around	O
30	O
per	O
cent	O
in	O
3	O
month	O
old	O
predentate	O
children	O
to	O
over	O
80	O
per	O
cent	O
in	O
24	O
month	O
old	O
children	O
with	O
primary	O
teeth	O
.	O

MS	B-bacteria
is	O
usually	O
transmitted	O
to	O
children	O
through	O
their	O
mothers	O
,	O
and	O
the	O
risk	O
of	O
transmission	O
increases	O
with	O
high	O
maternal	O
salivary	O
levels	O
of	O
MS	B-bacteria
and	O
frequent	O
inoculation	O
.	O

Factors	O
that	O
affect	O
the	O
colonization	O
of	O
MS	B-bacteria
may	O
be	O
divided	O
into	O
bacterial	O
virulence	O
,	O
host	O
-	O
related	O
and	O
environmental	O
factors	O
.	O

Complex	O
interaction	O
among	O
these	O
factors	O
determine	O
the	O
success	O
and	O
timing	O
of	O
MS	B-bacteria
colonization	O
in	O
the	O
child	O
.	O

As	O
clinical	O
studies	O
have	O
shown	O
that	O
caries	O
risk	O
is	O
correlated	O
with	O
age	O
at	O
which	O
initial	O
MS	B-bacteria
colonization	O
occurred	O
,	O
strategies	O
for	O
the	O
prevention	O
of	O
dental	O
caries	O
should	O
include	O
timely	O
control	O
of	O
colonization	O
of	O
the	O
cariogenic	O
bacteria	O
in	O
the	O
mouths	O
of	O
young	O
children	O
.	O

Oral	O
administration	O
of	O
artificial	O
cell	O
microcapsules	O
has	O
been	O
proposed	O
for	O
various	O
therapy	O
procedures	O
using	O
biologically	O
active	O
materials	O
.	O

Recently	O
we	O
have	O
designed	O
novel	O
APPPA	O
microcapsules	O
using	O
alginate	O
,	O
poly	O
-	O
L	O
-	O
lysine	O
,	O
pectin	O
,	O
poly	O
-	O
L	O
-	O
lysine	O
and	O
alginate	O
that	O
have	O
shown	O
superior	O
oral	O
delivery	O
features	O
.	O

This	O
article	O
investigates	O
,	O
in	O
-	O
vitro	O
using	O
a	O
computer	O
controlled	O
dynamic	O
gastrointestinal	O
(	O
GI	O
)	O
model	O
,	O
effects	O
of	O
APPPA	O
microcapsules	O
on	O
health	O
of	O
gastrointestinal	O
(	O
GI	O
)	O
microbial	O
flora	O
.	O

The	O
impact	O
of	O
APPPA	O
microcapsules	O
on	O
GI	O
bacterial	O
population	O
,	O
total	O
anaerobes	O
,	O
total	O
aerobes	O
,	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Lactobacillus	B-bacteria
sp	I-bacteria
.	I-bacteria
and	O
Staphylococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
has	O
been	O
analyzed	O
.	O

In	O
addition	O
,	O
the	O
effects	O
of	O
microcapsules	O
on	O
GI	O
microbial	O
extracellular	O
enzymatic	O
activities	O
have	O
been	O
investigated	O
.	O

Result	O
shows	O
the	O
altered	O
activities	O
of	O
microbial	O
flora	O
and	O
enzymes	O
due	O
to	O
the	O
use	O
of	O
APPPA	O
microcapsule	O
.	O

The	O
most	O
disparity	O
is	O
observed	O
in	O
the	O
colon	O
ascendans	O
microbial	O
activities	O
.	O

This	O
study	O
would	O
have	O
significant	O
impact	O
on	O
future	O
microcapsule	O
design	O
.	O

However	O
,	O
further	O
in	O
-	O
vivo	O
studies	O
are	O
required	O
.	O

The	O
inhibitory	O
role	O
of	O
TNF	O
-	O
alpha	O
on	O
survival	O
of	O
naive	O
and	O
IL	O
-	O
2	O
treated	O
NK	O
cells	O
has	O
been	O
demonstrated	O
in	O
the	O
past	O
.	O

However	O
,	O
its	O
effect	O
on	O
the	O
function	O
of	O
these	O
cells	O
against	O
tumor	O
cells	O
,	O
in	O
particular	O
against	O
oral	O
tumors	O
has	O
not	O
been	O
established	O
.	O

We	O
investigated	O
the	O
significance	O
of	O
secreted	O
TNF	O
-	O
alpha	O
in	O
death	O
and	O
functional	O
loss	O
of	O
splenocytes	O
and	O
NK	O
cells	O
in	O
ex	O
-	O
vivo	O
cultures	O
with	O
oral	O
tumors	O
.	O

Oral	O
tumors	O
trigger	O
potent	O
secretion	O
of	O
TNF	O
-	O
alpha	O
by	O
human	O
and	O
murine	O
immune	O
effectors	O
.	O

Absence	O
of	O
TNF	O
-	O
alpha	O
increases	O
the	O
cytotoxic	O
activity	O
and	O
secretion	O
of	O
IFN	O
-	O
gamma	O
by	O
IL	O
-	O
2	O
treated	O
splenocytes	O
and	O
NK	O
cells	O
in	O
co	O
-	O
cultures	O
with	O
MOK	O
L2D1	O
+	O
/	O
p53	O
-	O
/	O
-	O
oral	O
tumor	O
cells	O
.	O

IL	O
-	O
2	O
treated	O
splenocytes	O
and	O
NK	O
cells	O
from	O
TNF	O
-	O
alpha	O
-	O
/	O
-	O
mice	O
survive	O
and	O
proliferate	O
more	O
when	O
compared	O
to	O
cells	O
from	O
TNF	O
-	O
alpha	O
+	O
/	O
+	O
mice	O
.	O

Cell	O
death	O
induced	O
by	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
,	O
an	O
oral	O
bacteria	O
,	O
in	O
TNF	O
-	O
alpha	O
-	O
/	O
-	O
splenocytes	O
are	O
considerably	O
lower	O
than	O
that	O
induced	O
in	O
TNF	O
-	O
alpha	O
+	O
/	O
+	O
splenocytes	O
where	O
potent	O
release	O
of	O
TNF	O
-	O
alpha	O
is	O
reproducibly	O
observed	O
.	O

Addition	O
of	O
exogenous	O
rTNF	O
-	O
alpha	O
to	O
IL	O
-	O
2	O
treated	O
splenocytes	O
and	O
NK	O
cells	O
decreased	O
survival	O
and	O
function	O
of	O
splenocytes	O
and	O
NK	O
cells	O
obtained	O
from	O
TNF	O
-	O
alpha	O
-	O
/	O
-	O
mice	O
against	O
oral	O
tumors	O
.	O

These	O
findings	O
suggest	O
that	O
potent	O
induction	O
of	O
TNF	O
-	O
alpha	O
during	O
interaction	O
of	O
immune	O
effectors	O
with	O
oral	O
tumors	O
and	O
/	O
or	O
oral	O
bacteria	O
is	O
an	O
important	O
factor	O
in	O
decreasing	O
the	O
function	O
and	O
survival	O
of	O
cytotoxic	O
immune	O
effectors	O
.	O

Strategies	O
to	O
neutralize	O
TNF	O
-	O
alpha	O
may	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
oral	O
cancers	O
.	O

Probiotics	O
have	O
been	O
extensively	O
studied	O
for	O
their	O
health	O
-	O
promoting	O
effects	O
.	O

The	O
main	O
field	O
of	O
research	O
has	O
been	O
in	O
the	O
gastrointestinal	O
tract	O
.	O

However	O
,	O
in	O
the	O
past	O
few	O
years	O
probiotics	O
have	O
also	O
been	O
investigated	O
in	O
the	O
oral	O
health	O
perspective	O
,	O
which	O
is	O
the	O
topic	O
of	O
the	O
present	O
review	O
.	O

We	O
discuss	O
the	O
mechanisms	O
of	O
bacterial	O
adhesion	O
,	O
potential	O
of	O
probiotics	O
in	O
oral	O
cavity	O
colonization	O
,	O
interspecies	O
interactions	O
,	O
and	O
possible	O
effects	O
on	O
immunomodulation	O
,	O
and	O
means	O
of	O
probiotic	O
administration	O
.	O

We	O
suggest	O
that	O
probiotic	O
treatment	O
of	O
diseases	O
other	O
than	O
dental	O
caries	O
and	O
periodontal	O
disease	O
should	O
also	O
be	O
systematically	O
investigated	O
.	O

In	O
general	O
,	O
hardly	O
any	O
randomized	O
controlled	O
trials	O
have	O
been	O
conducted	O
in	O
this	O
area	O
and	O
the	O
studies	O
on	O
probiotics	O
vs	O
oral	O
health	O
are	O
still	O
in	O
their	O
cradle	O
.	O

Hence	O
,	O
much	O
more	O
investigations	O
are	O
called	O
for	O
before	O
any	O
evidence	O
-	O
based	O
conclusions	O
can	O
be	O
drawn	O
:	O
if	O
or	O
not	O
probiotic	O
therapy	O
can	O
be	O
recommended	O
for	O
oral	O
health	O
purposes	O
.	O

Assessment	O
of	O
the	O
presence	O
of	O
probiotic	O
bacteria	O
in	O
feces	O
after	O
oral	O
ingestion	O
.	O

Probiotic	O
bacteria	O
are	O
said	O
to	O
have	O
beneficial	O
effects	O
on	O
the	O
host	O
.	O

As	O
a	O
precondition	O
for	O
any	O
effect	O
,	O
probiotic	O
strains	O
must	O
survive	O
passage	O
through	O
the	O
gastrointestinal	O
tract	O
.	O

The	O
feces	O
of	O
seven	O
volunteers	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
probiotic	O
strains	O
after	O
one	O
week	O
'	O
s	O
oral	O
ingestion	O
of	O
each	O
of	O
six	O
commercially	O
available	O
products	O
:	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
Nissle	I-bacteria
0	O
.	O
5	O
-	O
5	O
x	O
10	O
(	O
9	O
)	O
cells	O
(	O
Mutaflor	O
)	O
,	O
Enterococcus	B-bacteria
faecium	I-bacteria
SF	I-bacteria
68	I-bacteria
7	O
.	O
5	O
x	O
10	O
(	O
7	O
)	O
cells	O
(	O
Bioflorin	O
)	O
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
and	O
Bifidobacterium	B-bacteria
infantis	I-bacteria
both	O
1	O
x	O
10	O
(	O
9	O
)	O
cells	O
(	O
Infloran	O
)	O
,	O
Lactobacillus	B-bacteria
gasseri	I-bacteria
and	O
Bifidobacterium	B-bacteria
longum	I-bacteria
both	O
1	O
x	O
10	O
(	O
8	O
)	O
cells	O
(	O
Omniflora	O
)	O
,	O
Lactobacillus	B-bacteria
casei	I-bacteria
rhamnosus	I-bacteria
1	O
x	O
10	O
(	O
9	O
)	O
cells	O
(	O
Antibiophilus	O
)	O
,	O
and	O
yoghurt	O
enriched	O
with	O
Lactobacillus	B-bacteria
casei	I-bacteria
Immunitas	O
1	O
x	O
10	O
(	O
10	O
)	O
cells	O
(	O
Actimel	O
)	O
.	O

Ten	O
colonies	O
were	O
selected	O
from	O
each	O
stool	O
sample	O
,	O
and	O
DNA	O
was	O
extracted	O
and	O
typed	O
using	O
random	O
amplification	O
of	O
polymorphic	O
DNA	O
(	O
RAPD	O
)	O
.	O

Typing	O
patterns	O
of	O
the	O
ingested	O
probiotics	O
and	O
the	O
fecal	O
isolates	O
were	O
compared	O
.	O

Fingerprints	O
identical	O
to	O
the	O
ingested	O
probiotic	O
strains	O
were	O
recovered	O
from	O
fecal	O
samples	O
of	O
4	O
/	O
7	O
volunteers	O
after	O
one	O
week	O
of	O
Mutaflor	O
,	O
from	O
4	O
/	O
6	O
after	O
taking	O
Bioflorin	O
,	O
and	O
from	O
1	O
/	O
6	O
after	O
Infloran	O
.	O

Cultivation	O
of	O
strains	O
of	O
the	O
same	O
species	O
from	O
fecal	O
specimens	O
was	O
negative	O
after	O
consumption	O
of	O
Antibiophilus	O
,	O
Omniflora	O
and	O
Actimel	O
.	O

After	O
oral	O
consumption	O
of	O
probiotics	O
,	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
enterococci	B-bacteria
could	O
be	O
detected	O
in	O
stool	O
samples	O
(	O
57	O
%	O
and	O
67	O
%	O
,	O
respectively	O
)	O
.	O

In	O
contrast	O
,	O
with	O
only	O
one	O
exception	O
,	O
ingested	O
lactobacilli	B-bacteria
and	O
bifidobacteria	B-bacteria
could	O
not	O
be	O
detected	O
in	O
human	O
feces	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
susceptibility	O
of	O
nonperiodontopathic	O
and	O
periodontopathic	O
bacteria	O
to	O
major	O
defense	O
mechanisms	O
for	O
bacterial	O
clearance	O
in	O
gingival	O
sulcus	O
.	O

Twenty	O
strains	O
of	O
13	O
oral	O
bacterial	O
species	O
were	O
studied	O
for	O
their	O
susceptibility	O
to	O
phagocytosis	O
by	O
human	O
neutrophils	O
and	O
to	O
the	O
antimicrobial	O
peptides	O
LL	O
-	O
37	O
and	O
human	O
beta	O
defensin	O
-	O
3	O
.	O

The	O
minimum	O
inhibitory	O
concentrations	O
of	O
LL	O
-	O
37	O
and	O
human	O
beta	O
defensin	O
-	O
3	O
were	O
determined	O
by	O
a	O
liquid	O
dilution	O
assay	O
,	O
and	O
susceptibility	O
to	O
phagocytosis	O
was	O
examined	O
by	O
a	O
flow	O
cytometric	O
phagocytosis	O
assay	O
.	O

The	O
minimum	O
inhibitory	O
concentrations	O
of	O
LL	O
-	O
37	O
and	O
human	O
beta	O
defensin	O
-	O
3	O
varied	O
greatly	O
,	O
depending	O
on	O
the	O
strain	O
and	O
species	O
.	O

Although	O
a	O
significant	O
difference	O
between	O
the	O
non	O
-	O
and	O
periodontopathic	O
groups	O
was	O
not	O
observed	O
,	O
the	O
red	O
-	O
complex	O
bacteria	O
were	O
more	O
resistant	O
to	O
LL	O
-	O
37	O
than	O
the	O
others	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
.	O

The	O
susceptibility	O
of	O
oral	O
bacteria	O
to	O
phagocytosis	O
was	O
quite	O
variable	O
,	O
depending	O
on	O
the	O
species	O
but	O
not	O
on	O
the	O
strains	O
.	O

The	O
periodontopathic	O
bacteria	O
,	O
especially	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
and	O
the	O
red	O
-	O
complex	O
triad	O
,	O
were	O
more	O
resistant	O
to	O
phagocytosis	O
than	O
were	O
the	O
nonperiodontopathic	O
bacteria	O
(	O
p	O
=	O
0	O
.	O
0003	O
)	O
.	O

In	O
addition	O
,	O
bacteria	O
resistant	O
both	O
to	O
antimicrobial	O
peptides	O
and	O
to	O
phagocytosis	O
were	O
more	O
common	O
in	O
the	O
periodontopathic	O
group	O
.	O

Our	O
results	O
indicate	O
that	O
immune	O
evasion	O
may	O
contribute	O
to	O
the	O
pathogenicity	O
of	O
some	O
periodontopathic	O
bacteria	O
.	O

Antimicrobial	O
peptides	O
(	O
AMPs	O
)	O
are	O
naturally	O
occurring	O
,	O
broad	O
-	O
spectrum	O
antimicrobial	O
agents	O
that	O
have	O
recently	O
been	O
examined	O
for	O
their	O
utility	O
as	O
therapeutic	O
antibiotics	O
.	O

Unfortunately	O
,	O
they	O
are	O
expensive	O
to	O
produce	O
and	O
are	O
often	O
sensitive	O
to	O
protease	O
digestion	O
.	O

To	O
address	O
this	O
problem	O
,	O
we	O
have	O
examined	O
the	O
activity	O
of	O
a	O
peptide	O
mimetic	O
whose	O
design	O
was	O
based	O
on	O
the	O
structure	O
of	O
magainin	O
,	O
exhibiting	O
its	O
amphiphilic	O
structure	O
.	O

We	O
demonstrate	O
that	O
this	O
compound	O
,	O
meta	O
-	O
phenylene	O
ethynylene	O
(	O
mPE	O
)	O
,	O
exhibits	O
antimicrobial	O
activity	O
at	O
nanomolar	O
concentrations	O
against	O
a	O
variety	O
of	O
bacterial	O
and	O
Candida	O
species	O
found	O
in	O
oral	O
infections	O
.	O

Since	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
an	O
etiological	O
agent	O
of	O
dental	O
caries	O
,	O
colonizes	O
the	O
tooth	O
surface	O
and	O
forms	O
a	O
biofilm	O
,	O
we	O
quantified	O
the	O
activity	O
of	O
this	O
compound	O
against	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
growing	O
under	O
conditions	O
that	O
favor	O
biofilm	O
formation	O
.	O

Our	O
results	O
indicate	O
that	O
mPE	O
can	O
prevent	O
the	O
formation	O
of	O
a	O
biofilm	O
at	O
nanomolar	O
concentrations	O
.	O

Incubation	O
with	O
5	O
nM	O
mPE	O
prevents	O
further	O
growth	O
of	O
the	O
biofilm	O
,	O
and	O
100	O
nM	O
mPE	O
reduces	O
viable	O
bacteria	O
in	O
the	O
biofilm	O
by	O
3	O
logs	O
.	O

Structure	O
-	O
function	O
analyses	O
suggest	O
that	O
mPE	O
inhibits	O
the	O
bioactivity	O
of	O
lipopolysaccharide	O
and	O
binds	O
DNA	O
at	O
equimolar	O
ratios	O
,	O
suggesting	O
that	O
it	O
may	O
act	O
both	O
as	O
a	O
membrane	O
-	O
active	O
molecule	O
,	O
similar	O
to	O
magainin	O
,	O
and	O
as	O
an	O
intracellular	O
antibiotic	O
,	O
similar	O
to	O
other	O
AMPs	O
.	O

We	O
conclude	O
that	O
mPE	O
and	O
similar	O
molecules	O
display	O
great	O
potential	O
for	O
development	O
as	O
therapeutic	O
antimicrobials	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
exhibits	O
extensive	O
genotypic	O
diversity	O
,	O
but	O
the	O
role	O
of	O
this	O
variation	O
is	O
poorly	O
understood	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
number	O
and	O
distribution	O
of	O
genotypes	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
isolated	O
from	O
caries	O
-	O
active	O
and	O
caries	O
-	O
free	O
children	O
and	O
to	O
evaluate	O
some	O
of	O
their	O
phenotypic	O
traits	O
.	O

Stimulated	O
saliva	O
,	O
tongue	O
surface	O
and	O
biofilms	O
over	O
sound	O
and	O
carious	O
teeth	O
surfaces	O
were	O
sampled	O
from	O
10	O
caries	O
-	O
free	O
and	O
11	O
caries	O
-	O
active	O
children	O
aged	O
5	O
-	O
8	O
years	O
.	O

A	O
total	O
of	O
339	O
isolates	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
were	O
genotyped	O
by	O
arbitrarily	O
primed	O
polymerase	O
chain	O
reaction	O
using	O
OPA2	O
primer	O
.	O

One	O
isolate	O
from	O
each	O
genotype	O
was	O
tested	O
for	O
its	O
acid	O
susceptibility	O
and	O
its	O
ability	O
to	O
form	O
a	O
biofilm	O
.	O

Fifty	O
-	O
one	O
distinct	O
genotypes	O
were	O
determined	O
,	O
one	O
to	O
three	O
genotypes	O
in	O
each	O
oral	O
sample	O
.	O

A	O
single	O
genotype	O
was	O
detected	O
in	O
seven	O
children	O
,	O
whereas	O
the	O
remaining	O
14	O
children	O
exhibited	O
two	O
to	O
seven	O
genotypes	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
number	O
of	O
genotypes	O
detected	O
in	O
caries	O
-	O
free	O
and	O
caries	O
-	O
active	O
children	O
.	O

No	O
correlation	O
was	O
observed	O
between	O
the	O
number	O
of	O
genotypes	O
and	O
the	O
mutans	B-bacteria
streptococci	I-bacteria
salivary	O
levels	O
.	O

Five	O
of	O
the	O
six	O
high	O
biofilm	O
-	O
forming	O
genotypes	O
were	O
obtained	O
from	O
caries	O
-	O
active	O
children	O
,	O
although	O
the	O
differences	O
in	O
biofilm	O
formation	O
between	O
isolates	O
from	O
caries	O
-	O
free	O
and	O
caries	O
-	O
active	O
children	O
were	O
not	O
statistically	O
significant	O
.	O

Genotypes	O
with	O
low	O
susceptibility	O
to	O
acid	O
challenge	O
were	O
statistically	O
more	O
frequent	O
among	O
isolates	O
from	O
caries	O
-	O
active	O
children	O
than	O
among	O
those	O
from	O
caries	O
-	O
free	O
children	O
.	O

The	O
present	O
data	O
suggested	O
that	O
there	O
were	O
differences	O
in	O
the	O
distribution	O
of	O
genotypes	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
according	O
to	O
the	O
oral	O
site	O
and	O
that	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
populations	O
differ	O
in	O
their	O
acid	O
susceptibility	O
and	O
ability	O
to	O
form	O
biofilms	O
,	O
factors	O
allowing	O
their	O
colonization	O
of	O
sucrose	O
-	O
rich	O
environments	O
.	O

Autoinducer	O
-	O
2	O
(	O
AI	O
-	O
2	O
)	O
is	O
a	O
widespread	O
communication	O
-	O
signal	O
molecule	O
that	O
allows	O
bacteria	O
to	O
sense	O
and	O
react	O
to	O
environmental	O
factors	O
.	O

In	O
some	O
streptococci	B-bacteria
AI	O
-	O
2	O
is	O
reported	O
to	O
be	O
involved	O
in	O
virulence	O
expression	O
and	O
biofilm	O
formation	O
.	O

It	O
has	O
earlier	O
been	O
shown	O
that	O
the	O
alga	O
Delisea	O
pulchra	O
produces	O
bromated	O
furanones	O
,	O
which	O
prevent	O
bacterial	O
colonization	O
of	O
the	O
algae	O
.	O

We	O
have	O
previously	O
published	O
a	O
novel	O
and	O
simple	O
synthesis	O
of	O
(	O
Z	O
)	O
-	O
5	O
-	O
bromomethylene	O
-	O
2	O
(	O
5H	O
)	O
-	O
furanone	O
.	O

In	O
this	O
study	O
we	O
showed	O
that	O
our	O
synthesized	O
furanone	O
inhibited	O
biofilm	O
formation	O
and	O
bioluminescence	O
induction	O
by	O
Streptococcus	B-bacteria
anginosus	I-bacteria
,	O
Streptococcus	B-bacteria
intermedius	I-bacteria
,	O
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
as	O
well	O
as	O
bioluminescence	O
induction	O
by	O
Vibrio	B-bacteria
harveyi	I-bacteria
BB152	I-bacteria
.	O

We	O
suggest	O
that	O
the	O
effect	O
is	O
linked	O
to	O
interference	O
with	O
the	O
AI	O
-	O
2	O
signaling	O
pathway	O
because	O
adding	O
furanone	O
to	O
the	O
medium	O
had	O
no	O
effect	O
on	O
the	O
ability	O
of	O
the	O
AI	O
-	O
2	O
-	O
defective	O
S	O
.	O
anginosus	O
luxS	O
and	O
S	B-bacteria
.	I-bacteria
intermedius	I-bacteria
luxS	O
mutants	O
to	O
form	O
biofilms	O
.	O

Biofilms	O
are	O
complex	O
aggregations	O
of	O
microorganisms	O
attached	O
to	O
a	O
surface	O
.	O

The	O
formation	O
of	O
biofilms	O
might	O
facilitate	O
certain	O
survival	O
and	O
virulence	O
characteristics	O
under	O
some	O
situations	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
the	O
ability	O
of	O
Enterococcus	B-bacteria
faecalis	I-bacteria
to	O
form	O
biofilms	O
is	O
related	O
to	O
the	O
source	O
of	O
the	O
strains	O
.	O

E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
strains	I-bacteria
recovered	O
from	O
root	O
canals	O
(	O
n	O
=	O
33	O
)	O
,	O
the	O
oral	O
cavity	O
(	O
n	O
=	O
21	O
)	O
,	O
and	O
non	O
-	O
oral	O
/	O
non	O
-	O
endodontic	O
sources	O
(	O
n	O
=	O
16	O
)	O
were	O
studied	O
.	O

Biofilms	O
were	O
grown	O
in	O
tryptic	O
soy	O
broth	O
in	O
96	O
-	O
well	O
plates	O
for	O
24	O
hours	O
at	O
37	O
degrees	O
C	O
,	O
fixed	O
with	O
Bouin	O
'	O
s	O
fixative	O
,	O
and	O
stained	O
with	O
1	O
%	O
crystal	O
violet	O
.	O

Optical	O
density	O
at	O
570	O
nm	O
(	O
OD	O
(	O
570	O
)	O
)	O
was	O
measured	O
by	O
using	O
a	O
microtiter	O
plate	O
reader	O
.	O

Experiments	O
were	O
performed	O
in	O
quadruplicate	O
on	O
three	O
occasions	O
and	O
mean	O
OD	O
(	O
570	O
)	O
readings	O
determined	O
for	O
each	O
strain	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
groups	O
(	O
p	O
=	O
0	O
.	O
066	O
,	O
Kruskal	O
-	O
Wallis	O
)	O
.	O

Within	O
the	O
root	O
canal	O
and	O
oral	O
isolates	O
there	O
were	O
no	O
significant	O
associations	O
between	O
biofilm	O
formation	O
and	O
the	O
presence	O
of	O
the	O
virulence	O
determinants	O
asa	O
,	O
cylA	O
,	O
esp	O
,	O
and	O
gelE	O
.	O

Salivary	O
occurrence	O
of	O
periodontopathic	O
bacteria	O
is	O
of	O
interest	O
especially	O
in	O
children	O
as	O
a	O
risk	O
indicator	O
for	O
the	O
transmission	O
,	O
development	O
and	O
control	O
of	O
periodontal	O
disease	O
.	O

We	O
assessed	O
the	O
prevalence	O
of	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Prevotella	B-bacteria
nigrescens	I-bacteria
and	O
Treponema	B-bacteria
denticola	I-bacteria
as	O
microbial	O
complexes	O
in	O
the	O
saliva	O
of	O
children	O
with	O
mixed	O
dentition	O
and	O
healthy	O
gingiva	O
.	O

Paraffin	O
-	O
stimulated	O
saliva	O
samples	O
were	O
collected	O
from	O
41	O
children	O
(	O
22	O
boys	O
and	O
19	O
girls	O
)	O
,	O
aged	O
6	O
-	O
13	O
years	O
old	O
.	O

Gingival	O
health	O
was	O
determined	O
during	O
the	O
initial	O
screening	O
exam	O
.	O

The	O
test	O
bacteria	O
were	O
identified	O
using	O
a	O
16S	O
rRNA	O
-	O
based	O
PCR	O
analysis	O
.	O

P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
was	O
the	O
most	O
frequent	O
species	O
(	O
80	O
%	O
)	O
,	O
followed	O
by	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
(	O
32	O
%	O
)	O
,	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
(	O
24	O
%	O
)	O
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
(	O
12	O
%	O
)	O
.	O

P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
were	O
not	O
detected	O
.	O

P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
was	O
also	O
common	O
species	O
in	O
combinations	O
.	O

Paired	O
and	O
triple	O
bacterial	O
combinations	O
were	O
found	O
in	O
24	O
%	O
and	O
20	O
%	O
of	O
all	O
children	O
,	O
respectively	O
.	O

There	O
was	O
no	O
positive	O
association	O
between	O
bacterial	O
combinations	O
in	O
colonization	O
and	O
subject	O
'	O
s	O
gender	O
(	O
P	O
>	O
0	O
.	O
05	O
,	O
Fisher	O
exact	O
test	O
)	O
.	O

The	O
salivary	O
presence	O
of	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
but	O
not	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
can	O
occur	O
in	O
childhood	O
without	O
clinical	O
signs	O
of	O
gingival	O
disease	O
.	O

Thus	O
,	O
the	O
possible	O
risk	O
of	O
bacterial	O
transmissions	O
through	O
saliva	O
and	O
,	O
the	O
need	O
to	O
screen	O
for	O
periodontal	O
pathogens	O
should	O
be	O
considered	O
before	O
mixed	O
dentition	O
.	O

To	O
evaluate	O
our	O
hypothesis	O
that	O
non	O
-	O
pathogenic	O
bacterial	O
flora	O
inhibit	O
later	O
colonization	O
with	O
methicillin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Staphylococcus	I-bacteria
aureus	I-bacteria
(	O
MRSA	B-bacteria
)	O
in	O
extremely	O
low	O
birth	O
weight	O
(	O
ELBW	O
)	O
infants	O
,	O
we	O
performed	O
a	O
retrospective	O
investigation	O
of	O
the	O
association	O
between	O
non	O
-	O
pathogenic	O
bacterial	O
flora	O
and	O
later	O
inhibition	O
of	O
colonization	O
by	O
MRSA	B-bacteria
in	O
ELBW	O
infants	O
.	O

A	O
total	O
of	O
110	O
preterm	O
infants	O
with	O
birth	O
weight	O
<	O
1	O
,	O
000	O
g	O
admitted	O
to	O
the	O
Neonatal	O
Intensive	O
Care	O
Unit	O
of	O
Nagano	O
Children	O
'	O
s	O
Hospital	O
from	O
January	O
1997	O
to	O
December	O
2003	O
were	O
analyzed	O
retrospectively	O
with	O
regard	O
to	O
colonization	O
by	O
MRSA	B-bacteria
during	O
hospitalization	O
.	O

We	O
investigated	O
the	O
incidence	O
of	O
MRSA	B-bacteria
colonization	O
in	O
56	O
infants	O
with	O
non	O
-	O
pathogenic	O
bacterial	O
flora	O
in	O
the	O
oral	O
cavity	O
during	O
the	O
first	O
week	O
after	O
birth	O
and	O
compared	O
them	O
with	O
54	O
infants	O
lacking	O
non	O
-	O
pathogenic	O
bacteria	O
.	O

Incidence	O
rate	O
of	O
colonization	O
by	O
MRSA	B-bacteria
at	O
postnatal	O
week	O
6	O
was	O
significantly	O
lower	O
in	O
infants	O
with	O
non	O
-	O
pathogenic	O
bacterial	O
flora	O
in	O
the	O
oral	O
cavity	O
(	O
32	O
.	O
1	O
%	O
)	O
than	O
in	O
infants	O
without	O
such	O
bacteria	O
during	O
the	O
first	O
week	O
of	O
life	O
(	O
77	O
.	O
8	O
%	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
present	O
results	O
suggest	O
an	O
important	O
role	O
for	O
non	O
-	O
pathogenic	O
bacterial	O
flora	O
in	O
the	O
oral	O
cavity	O
during	O
early	O
life	O
in	O
prevention	O
of	O
later	O
MRSA	B-bacteria
colonization	O
in	O
ELBW	O
infants	O
.	O

Flavors	O
and	O
natural	O
botanic	O
extracts	O
are	O
often	O
used	O
in	O
chewing	O
gum	O
and	O
compressed	O
mints	O
for	O
breath	O
freshening	O
and	O
relief	O
of	O
oral	O
malodor	O
.	O

The	O
oral	O
malodor	O
is	O
a	O
result	O
of	O
bacterial	O
putrification	O
of	O
proteinaceous	O
materials	O
from	O
food	O
or	O
saliva	O
.	O

In	O
this	O
study	O
,	O
magnolia	O
bark	O
extract	O
(	O
MBE	O
)	O
and	O
its	O
two	O
main	O
components	O
,	O
magnolol	O
and	O
honokiol	O
,	O
were	O
evaluated	O
by	O
the	O
minimum	O
inhibition	O
concentration	O
(	O
MIC	O
)	O
test	O
.	O

The	O
inhibitory	O
effect	O
of	O
MBE	O
mint	O
was	O
further	O
evaluated	O
by	O
a	O
kill	O
-	O
time	O
assay	O
study	O
.	O

In	O
addition	O
,	O
an	O
in	O
vivo	O
study	O
was	O
performed	O
on	O
nine	O
healthy	O
volunteers	O
postlunch	O
.	O

Saliva	O
samples	O
were	O
taken	O
before	O
and	O
after	O
subjects	O
consumed	O
mints	O
and	O
gum	O
,	O
with	O
and	O
without	O
MBE	O
.	O

Listerine	O
mouthwash	O
was	O
included	O
as	O
a	O
positive	O
control	O
.	O

The	O
testing	O
results	O
indicated	O
that	O
MBE	O
and	O
its	O
two	O
main	O
constituents	O
demonstrated	O
a	O
strong	O
germ	O
-	O
kill	O
effect	O
against	O
bacteria	O
responsible	O
for	O
halitosis	O
and	O
also	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
bacteria	O
involved	O
in	O
dental	O
caries	O
formation	O
.	O

The	O
MIC	O
of	O
magnolol	O
,	O
honokiol	O
,	O
and	O
MBE	O
on	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
and	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
ranged	O
from	O
8	O
to	O
31	O
microg	O
/	O
mL	O
.	O

Kill	O
-	O
time	O
assay	O
results	O
indicated	O
that	O
mints	O
containing	O
0	O
.	O
2	O
%	O
MBE	O
reduced	O
more	O
than	O
99	O
.	O
9	O
%	O
of	O
three	O
oral	O
bacteria	O
within	O
5	O
min	O
of	O
treatment	O
.	O

The	O
in	O
vivo	O
study	O
demonstrated	O
that	O
MBE	O
containing	O
mints	O
reduced	O
total	O
salivary	O
bacteria	O
by	O
61	O
.	O
6	O
%	O
at	O
30	O
min	O
and	O
33	O
.	O
8	O
%	O
at	O
60	O
min	O
postconsumption	O
.	O

In	O
comparison	O
,	O
the	O
flavorless	O
mint	O
reduced	O
total	O
salivary	O
bacteria	O
by	O
3	O
.	O
6	O
%	O
at	O
30	O
min	O
and	O
increased	O
total	O
bacteria	O
by	O
47	O
.	O
9	O
%	O
at	O
60	O
min	O
.	O

The	O
MBE	O
containing	O
chewing	O
gum	O
reduced	O
total	O
salivary	O
bacteria	O
by	O
43	O
.	O
0	O
%	O
at	O
40	O
min	O
,	O
while	O
placebo	O
gum	O
reduced	O
total	O
salivary	O
bacteria	O
by	O
18	O
.	O
0	O
%	O
.	O

In	O
conclusion	O
,	O
MBE	O
demonstrated	O
a	O
significant	O
antibacterial	O
activity	O
against	O
organisms	O
responsible	O
for	O
oral	O
malodor	O
and	O
can	O
be	O
incorporated	O
in	O
compressed	O
mints	O
and	O
chewing	O
gum	O
for	O
improved	O
breath	O
-	O
freshening	O
benefits	O
.	O

The	O
mechanisms	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
by	O
bacteria	O
in	O
the	O
oral	O
cavity	O
are	O
still	O
not	O
clearly	O
defined	O
but	O
salivary	O
streptococci	B-bacteria
have	O
been	O
reported	O
to	O
generate	O
NO	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
mechanism	O
of	O
nitrite	O
metabolism	O
and	O
generation	O
of	O
NO	O
by	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
a	O
major	O
pathogen	O
of	O
dental	O
caries	O
.	O

We	O
searched	O
the	O
genomic	O
database	O
of	O
oral	O
pathogens	O
for	O
nitrite	O
reductase	O
and	O
used	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
to	O
clone	O
the	O
nirJ	O
gene	O
from	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
GS5	I-bacteria
.	O

His	O
-	O
tagged	O
recombinant	O
NirJ	O
protein	O
was	O
expressed	O
in	O
Escherichia	B-bacteria
coli	I-bacteria
BL21	I-bacteria
and	O
characterized	O
.	O

We	O
constructed	O
a	O
nirJ	O
gene	O
-	O
disrupted	O
mutant	O
strain	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
(	O
DeltanirJ	O
)	O
to	O
analyze	O
the	O
physiological	O
significance	O
of	O
nirJ	O
.	O

S	B-bacteria
.	I-bacteria
mutans	I-bacteria
generates	O
NO	O
from	O
nitrite	O
,	O
probably	O
as	O
a	O
result	O
of	O
the	O
possession	O
of	O
nitrite	O
reductase	O
.	O

We	O
cloned	O
the	O
nirJ	O
gene	O
from	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
GS5	I-bacteria
by	O
PCR	O
.	O

The	O
recombinant	O
NirJ	O
protein	O
catalyzed	O
the	O
reduction	O
of	O
nitrite	O
with	O
a	O
K	O
(	O
m	O
)	O
value	O
of	O
3	O
.	O
37	O
microM	O
and	O
a	O
specific	O
activity	O
of	O
2	O
.	O
5	O
micromol	O
/	O
min	O
/	O
mg	O
of	O
protein	O
at	O
37	O
degrees	O
C	O
.	O
Biochemical	O
analysis	O
revealed	O
that	O
the	O
nitrite	O
-	O
reducing	O
activity	O
of	O
the	O
mutant	O
(	O
DeltanirJ	O
)	O
strain	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
strain	O
.	O

The	O
growth	O
of	O
the	O
mutant	O
strain	O
,	O
but	O
not	O
of	O
the	O
wild	O
-	O
type	O
strain	O
,	O
was	O
strongly	O
suppressed	O
by	O
the	O
presence	O
of	O
physiological	O
levels	O
of	O
nitrite	O
(	O
approximately	O
0	O
.	O
2	O
mM	O
)	O
in	O
saliva	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
elimination	O
of	O
nitrite	O
and	O
/	O
or	O
the	O
generation	O
of	O
NO	O
are	O
important	O
for	O
the	O
survival	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
in	O
the	O
oral	O
cavity	O
.	O

Elimination	O
of	O
methicillin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Staphylococcus	I-bacteria
aureus	I-bacteria
(	O
MRSA	B-bacteria
)	O
is	O
of	O
critical	O
importance	O
in	O
oral	O
and	O
maxillofacial	O
surgery	O
because	O
control	O
is	O
very	O
difficult	O
once	O
infection	O
of	O
an	O
oral	O
tumor	O
or	O
oral	O
wound	O
with	O
MRSA	B-bacteria
is	O
established	O
.	O

We	O
retrospectively	O
investigated	O
the	O
risk	O
factors	O
for	O
acquiring	O
MRSA	B-bacteria
in	O
518	O
patients	O
with	O
oral	O
cancer	O
among	O
1	O
,	O
877	O
inpatients	O
in	O
our	O
department	O
between	O
1984	O
and	O
2005	O
.	O

The	O
patients	O
with	O
oral	O
cancer	O
demonstrated	O
a	O
high	O
rate	O
of	O
MRSA	B-bacteria
colonization	O
and	O
infection	O
(	O
77	O
.	O
8	O
%	O
)	O
relative	O
to	O
the	O
population	O
as	O
a	O
whole	O
with	O
MRSA	B-bacteria
isolated	O
percentage	O
in	O
our	O
department	O
after	O
1991	O
.	O

The	O
risk	O
factors	O
for	O
MRSA	B-bacteria
in	O
oral	O
cancer	O
patients	O
are	O
also	O
related	O
to	O
systemic	O
diseases	O
and	O
physiological	O
and	O
iatrogenic	O
conditions	O
,	O
including	O
cerebrovascular	O
diseases	O
(	O
77	O
.	O
8	O
%	O
)	O
,	O
peripheral	O
arterial	O
catheterization	O
(	O
69	O
.	O
2	O
%	O
)	O
,	O
diabetes	O
(	O
50	O
.	O
0	O
%	O
)	O
,	O
tracheotomy	O
(	O
50	O
.	O
0	O
%	O
)	O
,	O
renal	O
failure	O
(	O
50	O
.	O
0	O
%	O
)	O
,	O
long	O
-	O
term	O
broad	O
-	O
spectrum	O
antibiotic	O
use	O
(	O
45	O
.	O
7	O
%	O
)	O
,	O
and	O
malnutrition	O
(	O
43	O
.	O
3	O
%	O
)	O
.	O

However	O
,	O
the	O
highest	O
risk	O
of	O
MRSA	B-bacteria
seems	O
to	O
be	O
related	O
to	O
poor	O
hygienic	O
care	O
.	O

Beginning	O
in	O
1999	O
,	O
we	O
implemented	O
a	O
strategy	O
for	O
reducing	O
infection	O
by	O
MRSA	B-bacteria
that	O
included	O
nasal	O
mupirocin	O
ointment	O
for	O
patients	O
at	O
high	O
risk	O
of	O
MRSA	B-bacteria
;	O
since	O
then	O
,	O
the	O
detection	O
rate	O
has	O
decreased	O
.	O

We	O
suggest	O
that	O
the	O
administration	O
of	O
nasal	O
mupirocin	O
ointment	O
and	O
provision	O
of	O
scrupulous	O
hygienic	O
care	O
for	O
high	O
-	O
risk	O
patients	O
are	O
useful	O
and	O
effective	O
measures	O
for	O
decreasing	O
the	O
incidence	O
of	O
MRSA	B-bacteria
infection	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
is	O
the	O
etiologic	O
agent	O
of	O
dental	O
caries	O
and	O
is	O
a	O
causative	O
agent	O
of	O
infective	O
endocarditis	O
.	O

While	O
the	O
mechanisms	O
by	O
which	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
cells	O
colonize	O
heart	O
tissue	O
is	O
not	O
clear	O
,	O
it	O
is	O
thought	O
that	O
bacterial	O
binding	O
to	O
extracellular	O
matrix	O
and	O
blood	O
components	O
is	O
crucial	O
in	O
the	O
development	O
of	O
endocarditis	O
.	O

Previously	O
,	O
we	O
have	O
demonstrated	O
that	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
cells	O
have	O
the	O
capacity	O
to	O
bind	O
and	O
activate	O
plasminogen	O
to	O
plasmin	O
.	O

Here	O
we	O
report	O
the	O
first	O
cloning	O
and	O
characterization	O
of	O
an	O
alpha	O
-	O
enolase	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
that	O
binds	O
plasminogen	O
.	O

The	O
functional	O
identity	O
of	O
the	O
purified	O
recombinant	O
alpha	O
-	O
enolase	O
protein	O
was	O
confirmed	O
by	O
its	O
ability	O
to	O
catalyze	O
the	O
conversion	O
of	O
2	O
-	O
phosphoglycerate	O
to	O
phosphoenolpyruvate	O
.	O

The	O
protein	O
exhibited	O
a	O
Km	O
of	O
9	O
.	O
5	O
mM	O
and	O
a	O
Vmax	O
of	O
31	O
.	O
0	O
mM	O
/	O
min	O
/	O
mg	O
.	O

The	O
alpha	O
-	O
enolase	O
protein	O
was	O
localized	O
in	O
the	O
cytoplasmic	O
,	O
cell	O
wall	O
and	O
extracellular	O
fractions	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Binding	O
studies	O
using	O
an	O
immunoblot	O
analysis	O
revealed	O
that	O
human	O
plasminogen	O
binds	O
to	O
the	O
enolase	O
enzyme	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

These	O
findings	O
identify	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
alpha	O
-	O
enolase	O
as	O
a	O
binding	O
molecule	O
used	O
by	O
this	O
oral	O
pathogen	O
to	O
interact	O
with	O
the	O
blood	O
component	O
,	O
plasminogen	O
.	O

Further	O
studies	O
of	O
this	O
interaction	O
may	O
be	O
critical	O
to	O
understand	O
the	O
pathogenesis	O
of	O
endocarditis	O
caused	O
by	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Plasma	O
and	O
salivary	O
amoxicillin	O
(	O
AMO	O
)	O
concentrations	O
were	O
quantified	O
following	O
a	O
single	O
oral	O
dose	O
(	O
875	O
mg	O
)	O
of	O
two	O
formulations	O
of	O
AMO	O
(	O
Amoxicillin	O
-	O
EMS	O
Sigma	O
Pharma	O
and	O
Amoxil	O
BD	O
875	O
mg	O
)	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
amoxicillin	O
against	O
oral	O
microorganisms	O
was	O
accessed	O
.	O

The	O
open	O
,	O
randomized	O
,	O
two	O
-	O
period	O
crossover	O
study	O
was	O
carried	O
out	O
in	O
20	O
volunteers	O
.	O

Saliva	O
and	O
blood	O
samples	O
were	O
collected	O
at	O
0	O
,	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
and	O
12	O
h	O
after	O
drug	O
administration	O
,	O
and	O
quantified	O
using	O
HPLC	O
-	O
ESI	O
-	O
MS	O
and	O
HPLC	O
,	O
respectively	O
.	O

Streptococci	B-bacteria
counts	O
,	O
anaerobe	O
counts	O
and	O
total	O
microorganism	O
counts	O
were	O
obtained	O
.	O

No	O
differences	O
were	O
observed	O
between	O
formulations	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
in	O
the	O
plasma	O
and	O
salivary	O
AMO	O
concentrations	O
and	O
the	O
pharmacokinetic	O
parameters	O
(	O
C	O
(	O
max	O
)	O
,	O
t	O
(	O
max	O
)	O
,	O
AUC	O
(	O
0	O
-	O
8	O
)	O
,	O
and	O
AUC	O
(	O
0	O
-	O
infinity	O
)	O
)	O
also	O
showed	O
no	O
statistically	O
significant	O
differences	O
between	O
formulations	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Microorganism	O
counts	O
for	O
the	O
two	O
formulations	O
at	O
all	O
sampling	O
times	O
did	O
not	O
differ	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
but	O
all	O
microorganism	O
counts	O
at	O
60	O
min	O
post	O
-	O
dose	O
showed	O
a	O
significant	O
decrease	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Amoxicillin	O
was	O
effective	O
in	O
reducing	O
oral	O
microorganism	O
levels	O
up	O
to	O
12	O
h	O
post	O
-	O
dose	O
.	O

Oral	O
epithelium	O
is	O
a	O
stratified	O
squamous	O
epithelium	O
that	O
functions	O
as	O
the	O
barrier	O
between	O
the	O
outside	O
environment	O
and	O
the	O
host	O
.	O

In	O
the	O
oral	O
cavity	O
,	O
epithelial	O
tissues	O
are	O
constantly	O
exposed	O
to	O
a	O
variety	O
of	O
bacteria	O
,	O
but	O
most	O
individuals	O
maintain	O
healthy	O
homeostasis	O
.	O

Epithelial	O
cells	O
contribute	O
to	O
the	O
innate	O
host	O
response	O
,	O
and	O
antimicrobial	O
peptide	O
expression	O
in	O
all	O
human	O
epithelia	O
,	O
including	O
oral	O
epithelia	O
,	O
is	O
an	O
important	O
part	O
of	O
this	O
epithelial	O
function	O
.	O

These	O
antimicrobial	O
peptides	O
have	O
a	O
broad	O
spectrum	O
of	O
activity	O
against	O
both	O
Gram	O
-	O
negative	O
and	O
Gram	O
-	O
positive	O
bacteria	O
as	O
well	O
as	O
against	O
yeast	O
and	O
viruses	O
.	O

In	O
humans	O
these	O
antimicrobial	O
peptides	O
include	O
defensins	O
and	O
a	O
cathelicidin	O
family	O
member	O
LL	O
-	O
37	O
in	O
skin	O
and	O
oral	O
mucosa	O
and	O
other	O
epithelia	O
.	O

The	O
human	O
defensins	O
include	O
the	O
alpha	O
-	O
defensins	O
of	O
intestinal	O
and	O
neutrophil	O
origin	O
,	O
and	O
the	O
beta	O
-	O
defensins	O
of	O
skin	O
and	O
oral	O
mucosa	O
and	O
other	O
epithelia	O
.	O

Present	O
studies	O
have	O
identified	O
specific	O
signaling	O
routes	O
that	O
pathogens	O
and	O
commensals	O
take	O
in	O
stimulating	O
these	O
innate	O
immune	O
responses	O
,	O
and	O
this	O
may	O
open	O
the	O
way	O
for	O
development	O
of	O
new	O
therapeutic	O
agents	O
for	O
periodontal	O
diseases	O
.	O

A	O
recent	O
study	O
indicated	O
that	O
Neisseria	B-bacteria
subflava	I-bacteria
,	O
one	O
of	O
the	O
commensal	O
Neisseria	B-bacteria
species	I-bacteria
,	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
emergence	O
of	O
Neisseria	B-bacteria
gonorrhoeae	I-bacteria
strains	I-bacteria
with	O
chromosomally	O
mediated	O
resistance	O
to	O
penicillin	O
or	O
cephalosporin	O
by	O
the	O
horizontal	O
genetic	O
exchange	O
of	O
penA	O
genes	O
encoding	O
the	O
target	O
site	O
for	O
penicillin	O
or	O
cephalosporin	O
.	O

The	O
present	O
investigation	O
examined	O
the	O
antimicrobial	O
susceptibility	O
of	O
45	O
isolates	O
of	O
N	B-bacteria
.	I-bacteria
subflava	I-bacteria
from	O
the	O
oral	O
cavities	O
of	O
Japanese	O
men	O
and	O
women	O
to	O
various	O
agents	O
used	O
for	O
the	O
treatment	O
of	O
gonococcal	O
infections	O
.	O

Of	O
the	O
45	O
isolates	O
,	O
40	O
(	O
88	O
.	O
9	O
%	O
)	O
and	O
4	O
(	O
8	O
.	O
8	O
%	O
)	O
were	O
intermediately	O
resistant	O
and	O
resistant	O
to	O
penicillin	O
,	O
respectively	O
,	O
with	O
the	O
minimal	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
(	O
50	O
)	O
and	O
MIC	O
(	O
90	O
)	O
of	O
penicillin	O
being	O
0	O
.	O
5	O
mg	O
/	O
l	O
and	O
1	O
mg	O
/	O
l	O
,	O
respectively	O
.	O

Of	O
the	O
45	O
isolates	O
,	O
13	O
(	O
28	O
.	O
9	O
%	O
)	O
and	O
14	O
(	O
31	O
.	O
1	O
%	O
)	O
were	O
resistant	O
to	O
tetracycline	O
and	O
ciprofloxacin	O
,	O
respectively	O
,	O
and	O
3	O
(	O
6	O
.	O
7	O
%	O
)	O
showed	O
reduced	O
susceptibility	O
to	O
cefixime	O
(	O
although	O
the	O
susceptibility	O
category	O
was	O
not	O
determined	O
)	O
.	O

These	O
results	O
indicate	O
that	O
several	O
isolates	O
of	O
N	B-bacteria
.	I-bacteria
subflava	I-bacteria
have	O
acquired	O
resistance	O
or	O
intermediate	O
resistance	O
to	O
various	O
antimicrobial	O
agents	O
,	O
including	O
penicillin	O
,	O
cephalosporin	O
,	O
tetracycline	O
,	O
and	O
ciprofloxacin	O
.	O

The	O
present	O
study	O
may	O
thus	O
confirm	O
that	O
N	O
.	O
subflava	O
may	O
be	O
involved	O
in	O
the	O
emergence	O
of	O
N	B-bacteria
.	I-bacteria
gonorrhoeae	I-bacteria
strains	I-bacteria
with	O
either	O
intermediate	O
or	O
total	O
resistance	O
to	O
penicillin	O
or	O
cephalosporin	O
by	O
the	O
horizontal	O
genetic	O
exchange	O
of	O
the	O
penA	O
gene	O
.	O

Granulicatella	B-bacteria
elegans	I-bacteria
is	O
a	O
member	O
of	O
normal	O
human	O
oral	O
flora	O
and	O
is	O
thought	O
to	O
be	O
a	O
potent	O
pathogen	O
in	O
endocarditis	O
,	O
especially	O
so	O
-	O
called	O
`	O
`	O
culture	O
-	O
negative	O
'	O
'	O
endocarditis	O
.	O

To	O
elucidate	O
the	O
pathogenicity	O
of	O
this	O
microorganism	O
in	O
inflammatory	O
diseases	O
,	O
the	O
effect	O
of	O
the	O
extracellular	O
products	O
of	O
this	O
bacteria	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
was	O
examined	O
.	O

Culture	O
supernatants	O
produced	O
by	O
oral	O
isolates	O
of	O
G	B-bacteria
.	I-bacteria
elegans	I-bacteria
strongly	O
inhibited	O
the	O
proliferation	O
of	O
PBMC	O
stimulated	O
by	O
the	O
T	O
-	O
cell	O
mitogens	O
phytohemagglutinin	O
-	O
P	O
,	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
,	O
concanavalin	O
A	O
,	O
and	O
staphylococcal	O
enterotoxin	O
B	O
.	O
Purification	O
of	O
the	O
active	O
extracellular	O
product	O
revealed	O
that	O
a	O
fraction	O
containing	O
proteins	O
of	O
approximately	O
47	O
kDa	O
showing	O
arginine	O
deiminase	O
activity	O
contributed	O
to	O
the	O
inhibition	O
of	O
PBMC	O
proliferation	O
.	O

In	O
order	O
to	O
characterize	O
the	O
bacterial	O
microbiota	O
present	O
within	O
oral	O
cancerous	O
lesions	O
,	O
tumorous	O
and	O
non	O
-	O
tumorous	O
mucosal	O
tissue	O
specimens	O
(	O
approx	O
.	O

1	O
cm	O
(	O
3	O
)	O
)	O
were	O
harvested	O
from	O
ten	O
oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
patients	O
at	O
the	O
time	O
of	O
surgery	O
.	O

Any	O
microbial	O
contamination	O
on	O
the	O
surface	O
of	O
the	O
specimens	O
was	O
eliminated	O
by	O
immersion	O
in	O
Betadine	O
and	O
washing	O
with	O
PBS	O
.	O

Bacteria	O
were	O
visualized	O
within	O
sections	O
of	O
the	O
OSCC	O
by	O
performing	O
fluorescent	O
in	O
situ	O
hybridization	O
with	O
the	O
universal	O
oligonucleotide	O
probe	O
,	O
EUB338	O
.	O

DNA	O
was	O
extracted	O
from	O
each	O
aseptically	O
macerated	O
tissue	O
specimen	O
using	O
a	O
commercial	O
kit	O
.	O

This	O
was	O
then	O
used	O
as	O
template	O
for	O
PCR	O
with	O
three	O
sets	O
of	O
primers	O
,	O
targeting	O
the	O
16S	O
rRNA	O
genes	O
of	O
Spirochaetes	B-bacteria
,	O
Bacteroidetes	B-bacteria
and	O
the	O
domain	O
Bacteria	O
.	O

PCR	O
products	O
were	O
differentiated	O
by	O
TA	O
cloning	O
and	O
bacterial	O
species	O
were	O
identified	O
by	O
partial	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
gene	O
fragments	O
.	O

A	O
total	O
of	O
70	O
distinct	O
taxa	O
was	O
detected	O
:	O
52	O
different	O
phylotypes	O
isolated	O
from	O
the	O
tumorous	O
tissues	O
,	O
and	O
37	O
taxa	O
from	O
within	O
the	O
non	O
-	O
tumorous	O
specimens	O
.	O

Differences	O
between	O
the	O
composition	O
of	O
the	O
microbiotas	O
within	O
the	O
tumorous	O
and	O
non	O
-	O
tumorous	O
mucosae	O
were	O
apparent	O
,	O
possibly	O
indicating	O
selective	O
growth	O
of	O
bacteria	O
within	O
carcinoma	O
tissue	O
.	O

Most	O
taxa	O
isolated	O
from	O
within	O
the	O
tumour	O
tissue	O
represented	O
saccharolytic	O
and	O
aciduric	O
species	O
.	O

Whether	O
the	O
presence	O
of	O
these	O
bacteria	O
within	O
the	O
mucosa	O
has	O
any	O
bearing	O
on	O
the	O
carcinogenic	O
process	O
is	O
a	O
concept	O
worthy	O
of	O
further	O
investigation	O
.	O

Three	O
strains	O
of	O
anaerobic	O
Gram	O
-	O
negative	O
bacilli	O
isolated	O
from	O
human	O
oral	O
sites	O
were	O
subjected	O
to	O
a	O
comprehensive	O
range	O
of	O
phenotypic	O
and	O
genotypic	O
tests	O
and	O
were	O
found	O
to	O
comprise	O
a	O
homogeneous	O
group	O
.	O

16S	O
rRNA	O
gene	O
sequence	O
analysis	O
revealed	O
the	O
strains	O
to	O
constitute	O
a	O
novel	O
group	O
within	O
the	O
genus	O
Prevotella	B-bacteria
,	O
most	O
closely	O
related	O
to	O
Prevotella	B-bacteria
oris	I-bacteria
and	O
Prevotella	B-bacteria
salivae	I-bacteria
.	O

A	O
novel	O
species	O
,	O
Prevotella	B-bacteria
maculosa	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
is	O
proposed	O
to	O
accommodate	O
these	O
strains	O
.	O

Prevotella	B-bacteria
maculosa	I-bacteria
is	O
saccharolytic	O
and	O
produces	O
acetic	O
and	O
succinic	O
acids	O
as	O
end	O
products	O
of	O
fermentation	O
.	O

The	O
G	O
+	O
C	O
content	O
of	O
the	O
DNA	O
of	O
the	O
type	O
strain	O
is	O
48	O
mol	O
%	O
.	O

The	O
type	O
strain	O
of	O
Prevotella	B-bacteria
maculosa	I-bacteria
is	O
W1609	B-bacteria
(	O
T	O
)	O
(	O
=	O
DSM	B-bacteria
19339	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
54766	I-bacteria
(	O
T	O
)	O
)	O
.	O

Periodontitis	O
is	O
a	O
common	O
oral	O
disease	O
produced	O
by	O
bacterial	O
species	O
that	O
reside	O
in	O
the	O
subgingival	O
plaque	O
.	O

These	O
microorganisms	O
have	O
been	O
associated	O
to	O
atherosclerosis	O
and	O
it	O
is	O
suggested	O
that	O
periodontitis	O
is	O
a	O
cardiovascular	O
risk	O
factor	O
.	O

To	O
isolate	O
periodontal	O
bacteria	O
from	O
blood	O
and	O
atheroma	O
samples	O
,	O
from	O
patients	O
with	O
atherosclerosis	O
and	O
periodontitis	O
.	O

Twelve	O
patients	O
with	O
periodontitis	O
and	O
a	O
clinical	O
diagnosis	O
of	O
atherosclerosis	O
and	O
12	O
patients	O
with	O
periodontitis	O
but	O
without	O
atherosclerosis	O
were	O
studied	O
.	O

Blood	O
samples	O
were	O
obtained	O
immediately	O
before	O
and	O
after	O
scaling	O
and	O
root	O
planing	O
.	O

The	O
samples	O
were	O
incubated	O
in	O
aerobic	O
and	O
anaerobic	O
conditions	O
.	O

One	O
week	O
after	O
scaling	O
,	O
atheromatous	O
plaques	O
were	O
obtained	O
during	O
endarterectomy	O
in	O
the	O
12	O
patients	O
with	O
atherosclerosis	O
.	O

These	O
were	O
homogenized	O
and	O
cultured	O
for	O
aerobic	O
and	O
anaerobic	O
bacteria	O
.	O

Microorganisms	O
were	O
identified	O
by	O
means	O
ofPCR	O
.	O

Five	O
patients	O
with	O
and	O
two	O
without	O
atherosclerosis	O
,	O
had	O
bacteremia	O
after	O
scaling	O
and	O
root	O
planing	O
.	O

Bacterial	O
species	O
isolated	O
from	O
blood	O
samples	O
were	O
the	O
same	O
found	O
in	O
periodontic	O
pockets	O
.	O

Four	O
atheromatous	O
plaques	O
of	O
patients	O
with	O
bacteremia	O
yielded	O
positive	O
cultures	O
.	O

The	O
isolated	O
bacteria	O
were	O
the	O
same	O
found	O
in	O
blood	O
samples	O
and	O
periodontal	O
pockets	O
.	O

Bacteremia	O
occurred	O
in	O
seven	O
of	O
24	O
patients	O
after	O
scaling	O
and	O
root	O
planing	O
.	O

In	O
four	O
patients	O
,	O
the	O
same	O
species	O
found	O
in	O
periodontic	O
pockets	O
and	O
blood	O
cultures	O
were	O
detected	O
in	O
atherosclerotic	O
plaques	O
obtained	O
one	O
week	O
after	O
the	O
dental	O
procedure	O
.	O

To	O
investigate	O
a	O
possible	O
peroral	O
route	O
of	O
infective	O
endocarditis	O
(	O
IE	O
)	O
,	O
the	O
occurrence	O
of	O
staphylococci	B-bacteria
in	O
the	O
oral	O
cavity	O
was	O
examined	O
using	O
saliva	O
and	O
supragingival	O
plaque	O
specimens	O
from	O
56	O
systemically	O
and	O
periodontally	O
healthy	O
adults	O
aged	O
22	O
-	O
43	O
years	O
old	O
(	O
27	O
.	O
1	O
+	O
/	O
-	O
5	O
.	O
3	O
)	O
.	O

Nine	O
Staphylococcus	B-bacteria
species	I-bacteria
and	O
334	O
isolates	O
were	O
identified	O
.	O

In	O
saliva	O
,	O
the	O
total	O
occurrence	O
rate	O
was	O
83	O
.	O
9	O
%	O
and	O
the	O
total	O
number	O
of	O
bacteria	O
was	O
10	O
(	O
2	O
)	O
-	O
10	O
(	O
4	O
)	O
c	O
.	O
f	O
.	O
u	O
.	O

ml	O
(	O
-	O
1	O
)	O
.	O

Staphylococcus	B-bacteria
aureus	I-bacteria
was	O
the	O
most	O
frequent	O
species	O
(	O
46	O
.	O
4	O
%	O
)	O
,	O
followed	O
by	O
Staphylococcus	B-bacteria
epidermidis	I-bacteria
(	O
41	O
.	O
1	O
%	O
)	O
and	O
others	O
(	O
Staphylococcus	B-bacteria
hominis	I-bacteria
,	O
Staphylococcus	B-bacteria
warneri	I-bacteria
,	O
Staphylococcus	B-bacteria
intermedius	I-bacteria
,	O
Staphylococcus	B-bacteria
capitis	I-bacteria
,	O
Staphylococcus	B-bacteria
haemolyticus	I-bacteria
,	O
Staphylococcus	B-bacteria
lugdunensis	I-bacteria
and	O
Staphylococcus	B-bacteria
gallinarum	I-bacteria
,	O
isolation	O
frequencies	O
ranging	O
in	O
order	O
from	O
12	O
.	O
5	O
to	O
1	O
.	O
8	O
%	O
)	O
.	O

A	O
similar	O
isolation	O
tendency	O
was	O
observed	O
in	O
supragingival	O
plaque	O
,	O
with	O
a	O
total	O
occurrence	O
rate	O
of	O
73	O
.	O
2	O
%	O
and	O
amounts	O
of	O
bacteria	O
ranging	O
from	O
10	O
(	O
2	O
)	O
to	O
10	O
(	O
5	O
)	O
c	O
.	O
f	O
.	O
u	O
.	O
g	O
(	O
-	O
1	O
)	O
.	O

Four	O
common	O
Staphylococcus	B-bacteria
species	I-bacteria
(	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
epidermidis	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
lugdunensis	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
hominis	I-bacteria
)	O
were	O
isolated	O
from	O
nasal	O
swab	O
samples	O
taken	O
from	O
the	O
oral	O
staphylococci	O
-	O
positive	O
subjects	O
.	O

Genotyping	O
of	O
all	O
18	O
combinations	O
of	O
oral	O
-	O
and	O
nasal	O
-	O
derived	O
isolates	O
by	O
PFGE	O
indicated	O
that	O
identical	O
clones	O
or	O
close	O
relatives	O
were	O
commonly	O
distributed	O
in	O
these	O
two	O
cavities	O
.	O

Since	O
the	O
provision	O
of	O
micro	O
-	O
organisms	O
from	O
the	O
nasal	O
cavity	O
was	O
shown	O
and	O
occurrence	O
rates	O
in	O
the	O
oral	O
cavity	O
were	O
adequate	O
,	O
these	O
results	O
suggest	O
a	O
possible	O
peroral	O
route	O
of	O
staphylococcal	B-bacteria
IE	O
,	O
as	O
in	O
cases	O
of	O
viridans	B-bacteria
streptococcal	I-bacteria
IE	O
.	O

Triterpene	O
acids	O
(	O
ursolic	O
,	O
oleanoic	O
,	O
gypsogenic	O
,	O
and	O
sumaresinolic	O
acids	O
)	O
isolated	O
from	O
Miconia	O
species	O
,	O
along	O
with	O
a	O
mixture	O
of	O
ursolic	O
and	O
oleanolic	O
acids	O
and	O
a	O
mixture	O
of	O
maslinic	O
and	O
2	O
-	O
a	O
-	O
hydroxyursolic	O
acids	O
,	O
as	O
well	O
as	O
ursolic	O
acid	O
derivatives	O
were	O
evaluated	O
against	O
the	O
following	O
microorganisms	O
:	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
,	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
Streptococcus	B-bacteria
salivarius	I-bacteria
,	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
,	O
and	O
Enterococcus	B-bacteria
faecalis	I-bacteria
,	O
which	O
are	O
potentially	O
responsible	O
for	O
the	O
formation	O
of	O
dental	O
caries	O
in	O
humans	O
.	O

The	O
microdilution	O
method	O
was	O
used	O
for	O
the	O
determination	O
of	O
the	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
during	O
the	O
evaluation	O
of	O
the	O
antibacterial	O
activity	O
.	O

All	O
the	O
isolated	O
compounds	O
,	O
mixtures	O
,	O
and	O
semi	O
-	O
synthetic	O
derivatives	O
displayed	O
activity	O
against	O
all	O
the	O
tested	O
bacteria	O
,	O
showing	O
that	O
they	O
are	O
promising	O
antiplaque	O
and	O
anticaries	O
agents	O
.	O

Ursolic	O
and	O
oleanolic	O
acids	O
displayed	O
the	O
most	O
intense	O
antibacterial	O
effect	O
,	O
with	O
MIC	O
values	O
ranging	O
from	O
30	O
microg	O
/	O
mL	O
to	O
80	O
microg	O
/	O
mL	O
.	O

The	O
MIC	O
values	O
of	O
ursolic	O
acid	O
derivatives	O
,	O
as	O
well	O
as	O
those	O
obtained	O
for	O
the	O
mixture	O
of	O
ursolic	O
and	O
oleanolic	O
acids	O
showed	O
that	O
these	O
compounds	O
do	O
not	O
have	O
higher	O
antibacterial	O
activity	O
when	O
compared	O
with	O
the	O
activity	O
observed	O
with	O
either	O
ursolic	O
acid	O
or	O
oleanolic	O
acid	O
alone	O
.	O

With	O
regard	O
to	O
the	O
structure	O
-	O
activity	O
relationship	O
of	O
triterpene	O
acids	O
and	O
derivatives	O
,	O
it	O
is	O
suggested	O
that	O
both	O
hydroxy	O
and	O
carboxy	O
groups	O
present	O
in	O
the	O
triterpenes	O
are	O
important	O
for	O
their	O
antibacterial	O
activity	O
against	O
oral	O
pathogens	O
.	O

Extracts	O
or	O
alkaloids	O
isolated	O
from	O
Mahonia	O
aquifolium	O
exhibit	O
antimicrobial	O
activity	O
against	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
,	O
fungi	O
,	O
and	O
protozoa	O
.	O

In	O
this	O
study	O
the	O
bacteriostatic	O
and	O
bacteriocidal	O
activities	O
of	O
a	O
M	O
.	O
aquifolium	O
extract	O
and	O
two	O
of	O
its	O
major	O
alkaloids	O
,	O
berberine	O
chloride	O
and	O
oxyacanthine	O
sulphate	O
,	O
were	O
tested	O
in	O
vitro	O
against	O
nine	O
different	O
oral	O
bacteria	O
.	O

Minimum	O
inhibitory	O
concentrations	O
were	O
in	O
the	O
range	O
from	O
<	O
or	O
=	O
0	O
.	O
0031	O
%	O
to	O
0	O
.	O
1993	O
%	O
for	O
the	O
M	O
.	O
aquifolium	O
extract	O
,	O
from	O
0	O
.	O
002	O
%	O
to	O
>	O
0	O
.	O
125	O
%	O
for	O
berberine	O
chloride	O
,	O
and	O
from	O
0	O
.	O
0156	O
%	O
to	O
>	O
0	O
.	O
0625	O
%	O
for	O
oxyacanthine	O
sulphate	O
.	O

The	O
values	O
for	O
the	O
minimum	O
bactericidal	O
concentrations	O
were	O
in	O
the	O
same	O
range	O
,	O
indicating	O
that	O
the	O
test	O
substances	O
most	O
probably	O
acted	O
in	O
a	O
bactericidal	O
manner	O
.	O

The	O
most	O
susceptible	O
bacterium	O
against	O
all	O
three	O
test	O
substances	O
was	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
.	O

The	O
oral	O
epithelium	O
functions	O
as	O
a	O
mechanical	O
and	O
protective	O
barrier	O
to	O
resist	O
bacterial	O
infection	O
.	O

beta	O
-	O
Defensins	O
are	O
a	O
group	O
of	O
antimicrobial	O
peptides	O
mainly	O
produced	O
by	O
epithelial	O
cells	O
of	O
many	O
organs	O
including	O
skin	O
,	O
lung	O
,	O
kidney	O
,	O
pancreas	O
,	O
uterus	O
,	O
eye	O
,	O
and	O
nasal	O
and	O
oral	O
mucosa	O
.	O

This	O
review	O
focuses	O
on	O
beta	O
-	O
defensins	O
(	O
BDs	O
)	O
in	O
oral	O
epithelia	O
and	O
discusses	O
their	O
importance	O
in	O
oral	O
epithelial	O
health	O
and	O
disease	O
.	O

BDs	O
exhibit	O
antimicrobial	O
activity	O
against	O
oral	O
microbes	O
including	O
periodontitis	O
-	O
related	O
bacteria	O
,	O
Candida	O
,	O
and	O
papilloma	O
virus	O
.	O

Alterative	O
expression	O
of	O
BDs	O
was	O
observed	O
in	O
oral	O
epithelial	O
diseases	O
,	O
including	O
oral	O
inflammatory	O
lesions	O
with	O
and	O
without	O
microbial	O
infection	O
and	O
oral	O
cancer	O
.	O

BDs	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
oral	O
infectious	O
diseases	O
,	O
ulcerative	O
lesions	O
,	O
and	O
cancer	O
.	O

BDs	O
play	O
an	O
important	O
role	O
in	O
protection	O
against	O
oral	O
microbes	O
and	O
may	O
be	O
used	O
in	O
clinical	O
applications	O
.	O

Probiotics	O
are	O
living	O
micro	O
-	O
organisms	O
added	O
to	O
food	O
which	O
beneficially	O
affect	O
the	O
host	O
by	O
improving	O
its	O
intestinal	O
microbial	O
balance	O
.	O

This	O
paper	O
aims	O
to	O
present	O
a	O
general	O
background	O
on	O
probiotics	O
and	O
its	O
health	O
effects	O
in	O
children	O
,	O
and	O
to	O
examine	O
the	O
evidence	O
for	O
oral	O
colonization	O
and	O
the	O
possible	O
impact	O
on	O
oral	O
health	O
in	O
children	O
and	O
young	O
adults	O
.	O

For	O
delivery	O
and	O
general	O
health	O
effects	O
,	O
recent	O
systematic	O
reviews	O
,	O
meta	O
-	O
analyses	O
,	O
and	O
other	O
relevant	O
papers	O
were	O
used	O
.	O

Concerning	O
oral	O
installation	O
and	O
oral	O
effects	O
,	O
a	O
broad	O
search	O
for	O
publications	O
in	O
English	O
was	O
conducted	O
through	O
February	O
2007	O
in	O
PubMed	O
.	O

Studies	O
describing	O
an	O
installation	O
or	O
intervention	O
trial	O
in	O
humans	O
with	O
a	O
controlled	O
design	O
and	O
an	O
oral	O
endpoint	O
measure	O
were	O
considered	O
.	O

Fourteen	O
papers	O
with	O
dental	O
focus	O
were	O
identified	O
,	O
of	O
which	O
two	O
were	O
narrative	O
reviews	O
.	O

Only	O
one	O
study	O
of	O
dental	O
interest	O
was	O
conducted	O
in	O
children	O
.	O

Four	O
papers	O
dealt	O
with	O
oral	O
installation	O
of	O
probiotic	O
bacteria	O
,	O
and	O
although	O
detectable	O
levels	O
were	O
found	O
in	O
saliva	O
shortly	O
after	O
intake	O
,	O
the	O
studies	O
failed	O
to	O
demonstrate	O
a	O
long	O
-	O
term	O
installation	O
.	O

Seven	O
papers	O
evaluated	O
the	O
effect	O
of	O
lactobacilli	B-bacteria
-	O
or	O
bifidobacteria	B-bacteria
-	O
derived	O
probiotics	O
on	O
the	O
salivary	O
levels	O
of	O
caries	O
-	O
associated	O
bacteria	O
in	O
placebo	O
-	O
controlled	O
designs	O
.	O

All	O
but	O
one	O
reported	O
a	O
hampering	O
effect	O
on	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
/	O
or	O
yeast	O
.	O

The	O
single	O
study	O
carried	O
out	O
in	O
early	O
childhood	O
reported	O
a	O
significant	O
caries	O
reduction	O
in	O
3	O
-	O
to	O
4	O
-	O
year	O
-	O
old	O
children	O
after	O
7	O
months	O
of	O
daily	O
consumption	O
of	O
probiotic	O
milk	O
.	O

Bacteriotheraphy	O
in	O
the	O
form	O
of	O
probiotic	O
bacteria	O
with	O
an	O
inhibitory	O
effect	O
on	O
oral	O
pathogens	O
is	O
a	O
promising	O
concept	O
,	O
especially	O
in	O
childhood	O
,	O
but	O
this	O
may	O
not	O
necessarily	O
lead	O
to	O
improved	O
oral	O
health	O
.	O

Further	O
placebo	O
controlled	O
trials	O
that	O
assess	O
carefully	O
selected	O
and	O
defined	O
probiotic	O
strains	O
using	O
standardized	O
outcomes	O
are	O
needed	O
before	O
any	O
clinical	O
recommendations	O
can	O
be	O
made	O
.	O

To	O
investigate	O
prospectively	O
the	O
qualitative	O
and	O
quantitative	O
changes	O
in	O
oral	O
carriage	O
of	O
yeasts	O
and	O
coliforms	B-bacteria
in	O
southern	O
Chinese	O
people	O
suffering	O
from	O
stroke	O
.	O

In	O
56	O
elderly	O
people	O
suffering	O
from	O
stroke	O
in	O
a	O
rehabilitation	O
unit	O
of	O
a	O
general	O
medical	O
hospital	O
in	O
Hong	O
Kong	O
,	O
oral	O
microbiological	O
sampling	O
using	O
a	O
combined	O
imprint	O
culture	O
,	O
oral	O
rinse	O
approach	O
and	O
clinical	O
assessment	O
was	O
made	O
during	O
the	O
acute	O
stroke	O
phase	O
,	O
on	O
hospital	O
discharge	O
and	O
6	O
months	O
later	O
.	O

The	O
oral	O
carriage	O
of	O
yeasts	O
increased	O
significantly	O
during	O
acute	O
stroke	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
coliform	B-bacteria
carriage	O
did	O
not	O
.	O

A	O
reduction	O
in	O
oral	O
carriage	O
of	O
yeasts	O
was	O
found	O
on	O
hospital	O
discharge	O
and	O
6	O
months	O
later	O
and	O
in	O
coliforms	B-bacteria
at	O
the	O
6	O
-	O
month	O
assessment	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Candida	O
albicans	O
and	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
were	O
the	O
predominant	O
yeast	O
and	O
coliform	B-bacteria
respectively	O
.	O

Stroke	O
-	O
related	O
difficulty	O
in	O
tooth	O
brushing	O
and	O
denture	O
wearing	O
were	O
associated	O
with	O
higher	O
oral	O
yeast	O
carriage	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

We	O
also	O
report	O
here	O
for	O
the	O
first	O
time	O
that	O
the	O
use	O
of	O
aspirin	O
was	O
associated	O
with	O
lower	O
oral	O
yeast	O
carriage	O
in	O
people	O
suffering	O
from	O
stroke	O
.	O

Oral	O
yeast	O
carriage	O
was	O
closely	O
linked	O
to	O
the	O
level	O
of	O
stroke	O
-	O
related	O
functional	O
disability	O
that	O
improved	O
over	O
time	O
but	O
had	O
not	O
totally	O
resolved	O
6	O
months	O
after	O
hospital	O
discharge	O
.	O

The	O
oral	O
reservoir	O
of	O
yeasts	O
and	O
coliforms	B-bacteria
in	O
people	O
suffering	O
from	O
stroke	O
is	O
noteworthy	O
by	O
care	O
providers	O
as	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
may	O
cause	O
aspiration	O
pneumonia	O
.	O

Proton	O
pump	O
inhibitors	O
(	O
PPI	O
)	O
used	O
to	O
suppress	O
acid	O
secretion	O
in	O
the	O
stomach	O
are	O
among	O
the	O
most	O
widely	O
prescribed	O
medications	O
.	O

There	O
is	O
emerging	O
evidence	O
of	O
proton	O
secretion	O
elsewhere	O
in	O
the	O
aerodigestive	O
tract	O
,	O
and	O
acidic	O
microenvironments	O
are	O
integral	O
to	O
oral	O
flora	O
such	O
as	O
Lactobacillus	B-bacteria
.	O

The	O
hypothesis	O
of	O
this	O
study	O
is	O
that	O
the	O
growth	O
rate	O
and	O
morphology	O
of	O
oral	O
Lactobacillus	B-bacteria
strains	I-bacteria
are	O
effected	O
by	O
PPIs	O
.	O

Nineteen	O
different	O
strains	O
of	O
Lactobacilli	B-bacteria
were	O
inoculated	O
in	O
microtiter	O
plates	O
at	O
pH	O
of	O
4	O
.	O
5	O
to	O
6	O
.	O
5	O
and	O
exposed	O
to	O
twofold	O
dilutions	O
of	O
pantoprazole	O
at	O
a	O
range	O
of	O
2	O
.	O
5	O
mg	O
/	O
mL	O
to	O
2	O
.	O
5	O
microg	O
/	O
mL	O
.	O

Bacterial	O
growth	O
was	O
monitored	O
,	O
and	O
the	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
of	O
the	O
drug	O
was	O
determined	O
for	O
the	O
strains	O
most	O
sensitive	O
to	O
pantoprazole	O
.	O

In	O
the	O
unexposed	O
(	O
control	O
)	O
group	O
,	O
nine	O
Lactobacilli	B-bacteria
strains	I-bacteria
were	O
affected	O
by	O
pH	O
changes	O
from	O
6	O
.	O
5	O
to	O
4	O
.	O
5	O
.	O

In	O
the	O
group	O
exposed	O
to	O
pantoprazole	O
,	O
9	O
of	O
the	O
19	O
Lactobacilli	B-bacteria
strains	I-bacteria
were	O
found	O
to	O
have	O
an	O
MIC	O
below	O
625	O
microg	O
/	O
mL	O
,	O
with	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
14917	I-bacteria
being	O
the	O
most	O
sensitive	O
(	O
MIC	O
=	O
20	O
microg	O
/	O
mL	O
)	O
.	O

In	O
some	O
strains	O
,	O
such	O
as	O
L	B-bacteria
.	I-bacteria
s	I-bacteria
.	I-bacteria
salivarius	I-bacteria
11741	I-bacteria
,	O
Gram	O
-	O
staining	O
revealed	O
conformational	O
changes	O
in	O
the	O
bacteria	O
when	O
grown	O
in	O
the	O
presence	O
of	O
pantoprazole	O
.	O

Growth	O
rates	O
and	O
morphology	O
of	O
oral	O
Lactobacillus	B-bacteria
are	O
affected	O
by	O
the	O
pH	O
of	O
the	O
environment	O
.	O

Pantoprazole	O
at	O
supraphysiologic	O
doses	O
further	O
affects	O
growth	O
rates	O
and	O
conformation	O
in	O
some	O
strains	O
.	O

The	O
balance	O
of	O
oral	O
flora	O
and	O
upper	O
digestive	O
tract	O
homeostasis	O
may	O
be	O
affected	O
by	O
unexpected	O
targets	O
of	O
PPI	O
pharmacotherapy	O
,	O
with	O
possible	O
unanticipated	O
consequences	O
.	O
(	O
i	O
)	O
To	O
assess	O
the	O
pattern	O
of	O
early	O
bacterial	O
colonization	O
on	O
titanium	O
oral	O
implants	O
after	O
installation	O
,	O
at	O
12	O
weeks	O
and	O
at	O
12	O
months	O
,	O
(	O
ii	O
)	O
to	O
compare	O
the	O
microbiota	O
at	O
submucosal	O
implant	O
sites	O
and	O
adjacent	O
subgingival	O
tooth	O
sites	O
and	O
(	O
iii	O
)	O
to	O
assess	O
whether	O
or	O
not	O
early	O
colonization	O
was	O
predictive	O
of	O
12	O
-	O
month	O
colonization	O
patterns	O
.	O

Submucosal	O
/	O
subgingival	O
plaque	O
samples	O
from	O
17	O
titanium	O
oral	O
implants	O
and	O
adjacent	O
teeth	O
were	O
analyzed	O
by	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
30	O
min	O
,	O
12	O
weeks	O
and	O
12	O
months	O
after	O
implant	O
installation	O
.	O

At	O
12	O
months	O
,	O
none	O
of	O
the	O
inserted	O
implants	O
had	O
been	O
lost	O
or	O
presented	O
with	O
signs	O
of	O
peri	O
-	O
implantitis	O
.	O

The	O
distribution	O
of	O
sites	O
at	O
implants	O
and	O
teeth	O
with	O
bleeding	O
on	O
probing	O
varied	O
between	O
2	O
%	O
and	O
11	O
%	O
.	O

Probing	O
pocket	O
depths	O
<	O
or	O
=	O
3	O
mm	O
were	O
found	O
at	O
75	O
%	O
of	O
implant	O
sites	O
.	O

At	O
12	O
months	O
,	O
the	O
sum	O
of	O
the	O
bacterial	O
counts	O
of	O
40	O
species	O
was	O
statistically	O
significantly	O
higher	O
at	O
tooth	O
compared	O
with	O
implant	O
sites	O
(	O
mean	O
difference	O
:	O
34	O
.	O
4	O
x	O
10	O
(	O
5	O
)	O
,	O
95	O
%	O
confidence	O
interval	O
-	O
0	O
.	O
4	O
to	O
69	O
.	O
4	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
12	O
months	O
,	O
higher	O
individual	O
bacterial	O
counts	O
at	O
tooth	O
sites	O
were	O
found	O
for	O
7	O
/	O
40	O
species	O
compared	O
with	O
implant	O
sites	O
.	O

Detection	O
or	O
lack	O
of	O
detection	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
at	O
implant	O
sites	O
at	O
12	O
weeks	O
resulted	O
in	O
the	O
highest	O
positive	O
(	O
e	O
.	O
g	O
.	O
80	O
%	O
)	O
and	O
negative	O
(	O
e	O
.	O
g	O
.	O
90	O
%	O
)	O
predictive	O
values	O
,	O
respectively	O
.	O

Between	O
12	O
weeks	O
and	O
12	O
months	O
,	O
the	O
prevalence	O
of	O
Tannerella	B-bacteria
forsythia	I-bacteria
increased	O
statistically	O
significantly	O
at	O
implant	O
sites	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Lack	O
of	O
detection	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
at	O
12	O
weeks	O
yielded	O
a	O
negative	O
predictive	O
value	O
of	O
93	O
.	O
1	O
%	O
of	O
this	O
microorganism	O
being	O
undetectable	O
at	O
implant	O
sites	O
at	O
12	O
months	O
.	O

Within	O
the	O
limits	O
of	O
this	O
study	O
,	O
the	O
findings	O
showed	O
(	O
i	O
)	O
a	O
few	O
differences	O
in	O
the	O
prevalence	O
of	O
bacterial	O
species	O
between	O
implant	O
and	O
adjacent	O
tooth	O
sites	O
at	O
12	O
months	O
and	O
(	O
ii	O
)	O
high	O
positive	O
and	O
negative	O
predictive	O
values	O
for	O
selected	O
bacterial	O
species	O
.	O

To	O
determine	O
the	O
effectiveness	O
of	O
oral	O
decontamination	O
with	O
2	O
%	O
chlorhexidine	O
solution	O
for	O
the	O
prevention	O
of	O
ventilator	O
-	O
associated	O
pneumonia	O
(	O
VAP	O
)	O
.	O

Randomized	O
controlled	O
trial	O
and	O
meta	O
-	O
analysis	O
.	O

A	O
tertiary	O
care	O
university	O
hospital	O
in	O
Bangkok	O
,	O
Thailand	O
.	O

Adult	O
patients	O
who	O
received	O
mechanical	O
ventilation	O
and	O
who	O
were	O
hospitalized	O
in	O
intensive	O
care	O
units	O
and	O
general	O
medical	O
wards	O
.	O

The	O
patients	O
were	O
randomized	O
to	O
receive	O
oral	O
decontamination	O
with	O
2	O
%	O
chlorhexidine	O
solution	O
or	O
normal	O
saline	O
solution	O
4	O
times	O
per	O
day	O
until	O
their	O
endotracheal	O
tubes	O
were	O
removed	O
.	O

The	O
outcome	O
measures	O
were	O
the	O
development	O
of	O
VAP	O
and	O
oropharyngeal	O
colonization	O
with	O
gram	O
-	O
negative	O
bacilli	O
.	O

Meta	O
-	O
analysis	O
was	O
performed	O
by	O
combining	O
the	O
results	O
of	O
the	O
present	O
study	O
with	O
those	O
from	O
another	O
randomized	O
controlled	O
trial	O
that	O
also	O
used	O
a	O
2	O
%	O
chlorhexidine	O
formulation	O
for	O
oral	O
decontamination	O
.	O

The	O
characteristics	O
of	O
the	O
patients	O
in	O
the	O
chlorhexidine	O
group	O
(	O
n	O
=	O
102	O
)	O
and	O
the	O
normal	O
saline	O
group	O
(	O
n	O
=	O
105	O
)	O
were	O
not	O
significantly	O
different	O
.	O

The	O
incidence	O
of	O
VAP	O
in	O
the	O
chlorhexidine	O
group	O
was	O
4	O
.	O
9	O
%	O
(	O
5	O
of	O
102	O
)	O
,	O
and	O
the	O
incidence	O
in	O
the	O
normal	O
saline	O
group	O
was	O
11	O
.	O
4	O
%	O
(	O
12	O
of	O
105	O
)	O
(	O
P	O
=	O
.	O
08	O
)	O
.	O

The	O
rate	O
of	O
VAP	O
in	O
the	O
chlorhexidine	O
group	O
was	O
7	O
episodes	O
per	O
1	O
,	O
000	O
ventilator	O
-	O
days	O
,	O
and	O
the	O
rate	O
in	O
the	O
normal	O
saline	O
group	O
was	O
21	O
episodes	O
per	O
1	O
,	O
000	O
ventilator	O
-	O
days	O
(	O
P	O
=	O
.	O
04	O
)	O
.	O

Irritation	O
of	O
the	O
oral	O
mucosa	O
was	O
observed	O
in	O
10	O
(	O
9	O
.	O
8	O
%	O
)	O
of	O
the	O
patients	O
in	O
the	O
chlorhexidine	O
group	O
and	O
in	O
1	O
(	O
0	O
.	O
9	O
%	O
)	O
of	O
the	O
patients	O
in	O
the	O
normal	O
saline	O
group	O
(	O
P	O
=	O
.	O
001	O
)	O
.	O

Oropharyngeal	O
colonization	O
with	O
gram	O
-	O
negative	O
bacilli	O
was	O
either	O
reduced	O
or	O
delayed	O
in	O
the	O
chlorhexidine	O
group	O
.	O

Overall	O
mortality	O
of	O
the	O
patients	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O

Meta	O
-	O
analysis	O
of	O
2	O
randomized	O
controlled	O
trials	O
revealed	O
an	O
overall	O
relative	O
risk	O
of	O
VAP	O
for	O
patients	O
in	O
the	O
chlorhexidine	O
group	O
of	O
0	O
.	O
53	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
31	O
-	O
0	O
.	O
90	O
;	O
P	O
=	O
.	O
02	O
)	O
.	O

Oral	O
decontamination	O
with	O
2	O
%	O
chlorhexidine	O
solution	O
is	O
an	O
effective	O
and	O
safe	O
method	O
for	O
preventing	O
VAP	O
in	O
patients	O
who	O
receive	O
mechanical	O
ventilation	O
.	O

Oral	O
microbes	O
that	O
colonize	O
in	O
the	O
mouths	O
of	O
humans	O
contribute	O
to	O
disease	O
susceptibility	O
,	O
but	O
it	O
is	O
unclear	O
if	O
host	O
genetic	O
factors	O
mediate	O
colonization	O
.	O

We	O
therefore	O
tested	O
the	O
hypothesis	O
that	O
the	O
levels	O
at	O
which	O
oral	O
microbes	O
colonize	O
in	O
the	O
mouth	O
are	O
heritable	O
.	O

Dental	O
plaque	O
biofilms	O
were	O
sampled	O
from	O
intact	O
tooth	O
surfaces	O
of	O
118	O
caries	O
-	O
free	O
twins	O
.	O

An	O
additional	O
86	O
caries	O
-	O
active	O
twins	O
were	O
sampled	O
for	O
plaque	O
from	O
carious	O
lesions	O
and	O
intact	O
tooth	O
surfaces	O
.	O

Using	O
a	O
reverse	O
capture	O
checkerboard	O
assay	O
the	O
relative	O
abundance	O
of	O
82	O
bacterial	O
species	O
was	O
determined	O
.	O

An	O
integrative	O
computational	O
predictive	O
model	O
determined	O
microbial	O
abundance	O
patterns	O
of	O
microbial	O
species	O
in	O
caries	O
-	O
free	O
twins	O
as	O
compared	O
to	O
caries	O
-	O
active	O
twins	O
.	O

Heritability	O
estimates	O
were	O
calculated	O
for	O
the	O
relative	O
microbial	O
abundance	O
levels	O
of	O
the	O
microbial	O
species	O
in	O
both	O
groups	O
.	O

The	O
levels	O
of	O
10	O
species	O
were	O
significantly	O
different	O
in	O
healthy	O
individuals	O
than	O
in	O
caries	O
-	O
active	O
individuals	O
,	O
including	O
,	O
A	B-bacteria
.	I-bacteria
defectiva	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
parasanguinis	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
/	I-bacteria
oralis	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
cristatus	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
,	O
Streptococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
clone	I-bacteria
CH016	I-bacteria
,	O
G	B-bacteria
.	I-bacteria
morbillorum	I-bacteria
and	O
G	B-bacteria
.	I-bacteria
haemolysans	I-bacteria
.	O

Moderate	O
to	O
high	O
heritability	O
estimates	O
were	O
found	O
for	O
these	O
species	O
(	O
h	O
(	O
2	O
)	O
=	O
56	O
%	O
-	O
80	O
%	O
,	O
p	O
<	O
.	O
0001	O
)	O
.	O

Similarity	O
of	O
the	O
overall	O
oral	O
microbial	O
flora	O
was	O
also	O
evident	O
in	O
caries	O
-	O
free	O
twins	O
from	O
multivariate	O
distance	O
matrix	O
regression	O
analysis	O
.	O

It	O
appears	O
that	O
genetic	O
and	O
/	O
or	O
familial	O
factors	O
significantly	O
contribute	O
to	O
the	O
colonization	O
of	O
oral	O
beneficial	O
species	O
in	O
twins	O
.	O

To	O
identify	O
the	O
predictors	O
of	O
early	O
childhood	O
caries	O
and	O
urgent	O
dental	O
treatment	O
need	O
among	O
primarily	O
African	O
-	O
American	O
children	O
in	O
child	O
care	O
centers	O
in	O
the	O
Delta	O
region	O
of	O
Mississippi	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
replicate	O
predictors	O
of	O
caries	O
and	O
urgent	O
dental	O
treatment	O
needs	O
that	O
were	O
identified	O
in	O
an	O
earlier	O
study	O
conducted	O
in	O
Delta	O
child	O
care	O
centers	O
and	O
to	O
assess	O
additional	O
caries	O
risk	O
factors	O
not	O
collected	O
in	O
the	O
original	O
study	O
.	O

Children	O
in	O
19	O
child	O
care	O
centers	O
were	O
examined	O
by	O
the	O
dentists	O
,	O
and	O
the	O
parents	O
provided	O
data	O
on	O
oral	O
health	O
practices	O
,	O
oral	O
health	O
history	O
,	O
and	O
on	O
children	O
'	O
s	O
oral	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
.	O

The	O
dentists	O
also	O
assessed	O
visible	O
plaque	O
and	O
tested	O
levels	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
.	O

Predictors	O
of	O
caries	O
and	O
treatment	O
need	O
among	O
children	O
24	O
to	O
71	O
months	O
of	O
age	O
were	O
examined	O
using	O
logistic	O
regression	O
.	O

Two	O
parent	O
predictors	O
of	O
caries	O
identified	O
in	O
the	O
earlier	O
study	O
(	O
parent	O
flossing	O
and	O
soft	O
/	O
sugary	O
drink	O
consumption	O
)	O
were	O
not	O
predictive	O
in	O
the	O
current	O
study	O
.	O

Parent	O
history	O
of	O
abscess	O
continued	O
to	O
predict	O
their	O
child	O
'	O
s	O
urgent	O
need	O
for	O
treatment	O
.	O

Young	O
children	O
'	O
s	O
level	O
of	O
salivary	O
mutans	B-bacteria
streptococci	I-bacteria
,	O
maxillary	O
incisor	O
visible	O
plaque	O
,	O
and	O
parents	O
'	O
reports	O
of	O
child	O
oral	O
health	O
-	O
related	O
QOL	O
measures	O
predicted	O
the	O
presence	O
of	O
both	O
caries	O
and	O
urgent	O
treatment	O
need	O
.	O

Some	O
expected	O
predictors	O
,	O
such	O
as	O
frequency	O
of	O
child	O
'	O
s	O
toothbrushing	O
,	O
were	O
not	O
predictive	O
of	O
caries	O
.	O

Parental	O
abscess	O
and	O
parent	O
'	O
s	O
report	O
of	O
the	O
child	O
'	O
s	O
oral	O
health	O
-	O
related	O
OOL	O
are	O
risk	O
indicators	O
for	O
poor	O
oral	O
health	O
outcomes	O
that	O
could	O
be	O
used	O
by	O
nondental	O
personnel	O
to	O
identify	O
young	O
children	O
in	O
need	O
of	O
early	O
preventive	O
intervention	O
and	O
dental	O
referral	O

Even	O
though	O
animal	O
models	O
have	O
limitations	O
,	O
they	O
are	O
often	O
superior	O
to	O
in	O
vitro	O
or	O
clinical	O
studies	O
in	O
addressing	O
mechanistic	O
questions	O
and	O
serve	O
as	O
an	O
essential	O
link	O
between	O
hypotheses	O
and	O
human	O
patients	O
.	O

Periodontal	O
disease	O
can	O
be	O
viewed	O
as	O
a	O
process	O
that	O
involves	O
four	O
major	O
stages	O
:	O
bacterial	O
colonization	O
,	O
invasion	O
,	O
induction	O
of	O
a	O
destructive	O
host	O
response	O
in	O
connective	O
tissue	O
and	O
a	O
repair	O
process	O
that	O
reduces	O
the	O
extent	O
of	O
tissue	O
breakdown	O
.	O

Animal	O
studies	O
should	O
be	O
evaluated	O
in	O
terms	O
of	O
their	O
capacity	O
to	O
test	O
specific	O
hypotheses	O
rather	O
than	O
their	O
fidelity	O
to	O
all	O
aspects	O
of	O
periodontal	O
disease	O
initiation	O
and	O
progression	O
.	O

Thus	O
,	O
each	O
of	O
the	O
models	O
described	O
below	O
can	O
be	O
adapted	O
to	O
test	O
discrete	O
components	O
of	O
these	O
four	O
major	O
steps	O
,	O
but	O
not	O
all	O
of	O
them	O
.	O

This	O
review	O
describes	O
five	O
different	O
animal	O
models	O
that	O
are	O
appropriate	O
for	O
examining	O
components	O
of	O
host	O
-	O
bacteria	O
interactions	O
that	O
can	O
lead	O
to	O
breakdown	O
of	O
hard	O
and	O
soft	O
connective	O
tissue	O
or	O
conditions	O
that	O
limit	O
its	O
repair	O
as	O
follows	O
:	O
the	O
mouse	O
calvarial	O
model	O
,	O
murine	O
oral	O
gavage	O
models	O
with	O
or	O
without	O
adoptive	O
transfer	O
of	O
human	O
lymphocytes	O
,	O
rat	O
ligature	O
model	O
and	O
rat	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
feeding	O
model	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
causes	O
dental	O
caries	O
and	O
infective	O
endocarditis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
genomic	O
diversity	O
among	O
serotype	O
c	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
laboratory	O
and	O
clinical	O
strains	O
and	O
to	O
characterize	O
the	O
genetic	O
events	O
involved	O
.	O

A	O
genome	O
-	O
based	O
approach	O
using	O
PFGE	O
coupled	O
with	O
Southern	O
hybridization	O
was	O
employed	O
to	O
examine	O
a	O
total	O
of	O
58	O
serotype	O
c	O
oral	O
and	O
blood	O
isolates	O
and	O
seven	O
laboratory	O
strains	O
and	O
to	O
compare	O
them	O
with	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
UA159	I-bacteria
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
the	O
phenotypic	O
characteristics	O
of	O
the	O
strains	O
tested	O
,	O
except	O
that	O
some	O
of	O
the	O
strains	O
exhibited	O
smooth	O
rather	O
than	O
rough	O
colony	O
morphology	O
.	O

In	O
contrast	O
,	O
PFGE	O
profiles	O
of	O
clinical	O
isolates	O
,	O
from	O
either	O
diseased	O
or	O
healthy	O
subjects	O
,	O
exhibited	O
diverse	O
patterns	O
,	O
suggesting	O
that	O
recombination	O
or	O
point	O
mutations	O
occurred	O
frequently	O
in	O
vivo	O
.	O

Diverse	O
PFGE	O
patterns	O
,	O
with	O
various	O
lengths	O
of	O
insertions	O
and	O
deletions	O
,	O
could	O
be	O
detected	O
even	O
within	O
a	O
localized	O
chromosomal	O
region	O
between	O
rRNA	O
operons	O
.	O

Comparative	O
analysis	O
using	O
Southern	O
hybridization	O
with	O
specific	O
markers	O
revealed	O
that	O
a	O
large	O
chromosomal	O
inversion	O
had	O
also	O
occurred	O
between	O
rrn	O
operons	O
in	O
25	O
strains	O
.	O

To	O
analyse	O
the	O
microbial	O
flora	O
in	O
specific	O
oral	O
sites	O
in	O
13	O
dentate	O
subjects	O
,	O
6	O
-	O
8	O
months	O
after	O
completed	O
radiation	O
therapy	O
(	O
RT	O
group	O
)	O
and	O
in	O
13	O
matched	O
controls	O
.	O

The	O
microflora	O
on	O
the	O
tongue	O
,	O
buccal	O
mucosa	O
,	O
vestibulum	O
,	O
supragingival	O
plaque	O
and	O
subgingival	O
region	O
was	O
analysed	O
using	O
duplicate	O
sampling	O
and	O
cultivation	O
technique	O
.	O

A	O
clinical	O
examination	O
was	O
also	O
performed	O
.	O

Candida	O
albicans	O
was	O
found	O
in	O
one	O
or	O
more	O
sites	O
in	O
54	O
%	O
of	O
the	O
RT	O
subjects	O
and	O
in	O
15	O
%	O
of	O
the	O
controls	O
.	O

In	O
three	O
RT	O
subjects	O
,	O
C	O
.	O
albicans	O
was	O
found	O
at	O
all	O
four	O
sites	O
analysed	O
.	O

An	O
unexpected	O
finding	O
was	O
that	O
enterococci	B-bacteria
were	O
found	O
in	O
all	O
RT	O
subjects	O
and	O
in	O
high	O
number	O
in	O
38	O
%	O
.	O

None	O
of	O
the	O
controls	O
harboured	O
enterococci	B-bacteria
.	O

In	O
supragingival	O
plaque	O
,	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
detected	O
in	O
92	O
%	O
of	O
the	O
RT	O
subjects	O
and	O
the	O
number	O
and	O
proportion	O
of	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
extremely	O
high	O
compared	O
with	O
the	O
controls	O
.	O

Mutans	B-bacteria
streptococci	I-bacteria
were	O
detected	O
in	O
high	O
numbers	O
in	O
31	O
%	O
of	O
the	O
RT	O
subjects	O
,	O
while	O
they	O
were	O
not	O
detected	O
in	O
23	O
%	O
.	O

The	O
microbial	O
results	O
explain	O
why	O
some	O
RT	O
subjects	O
have	O
an	O
increased	O
susceptibility	O
to	O
oral	O
diseases	O
and	O
stress	O
that	O
site	O
-	O
specific	O
microbial	O
analysis	O
is	O
an	O
important	O
diagnostic	O
tool	O
when	O
planning	O
oral	O
health	O
preventive	O
care	O
for	O
RT	O
subjects	O
.	O

Although	O
Streptococcus	B-bacteria
mutans	I-bacteria
has	O
been	O
implicated	O
as	O
a	O
major	O
etiological	O
agent	O
of	O
dental	O
caries	O
,	O
our	O
cross	O
-	O
sectional	O
preliminary	O
study	O
indicated	O
that	O
10	O
%	O
of	O
subjects	O
with	O
rampant	O
caries	O
in	O
permanent	O
teeth	O
do	O
not	O
have	O
detectable	O
levels	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Our	O
aims	O
were	O
to	O
use	O
molecular	O
methods	O
to	O
detect	O
all	O
bacterial	O
species	O
associated	O
with	O
caries	O
in	O
primary	O
and	O
permanent	O
teeth	O
and	O
to	O
determine	O
the	O
bacterial	O
profiles	O
associated	O
with	O
different	O
disease	O
states	O
.	O

Plaque	O
was	O
collected	O
from	O
39	O
healthy	O
controls	O
and	O
from	O
intact	O
enamel	O
and	O
white	O
-	O
spot	O
lesions	O
,	O
dentin	O
lesions	O
,	O
and	O
deep	O
-	O
dentin	O
lesions	O
in	O
each	O
of	O
51	O
subjects	O
with	O
severe	O
caries	O
.	O

16S	O
rRNA	O
genes	O
were	O
PCR	O
amplified	O
,	O
cloned	O
,	O
and	O
sequenced	O
to	O
determine	O
species	O
identities	O
.	O

In	O
a	O
reverse	O
-	O
capture	O
checkerboard	O
assay	O
,	O
243	O
samples	O
were	O
analyzed	O
for	O
110	O
prevalent	O
bacterial	O
species	O
.	O

A	O
sequencing	O
analysis	O
of	O
1	O
,	O
285	O
16S	O
rRNA	O
clones	O
detected	O
197	O
bacterial	O
species	O
/	O
phylotypes	O
,	O
of	O
which	O
50	O
%	O
were	O
not	O
cultivable	O
.	O

Twenty	O
-	O
two	O
new	O
phylotypes	O
were	O
identified	O
.	O

PROC	O
MIXED	O
tests	O
revealed	O
health	O
-	O
and	O
disease	O
-	O
associated	O
species	O
.	O

In	O
subjects	O
with	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
additional	O
species	O
,	O
e	O
.	O
g	O
.	O
,	O
species	O
of	O
the	O
genera	O
Atopobium	B-bacteria
,	O
Propionibacterium	B-bacteria
,	O
and	O
Lactobacillus	B-bacteria
,	O
were	O
present	O
at	O
significantly	O
higher	O
levels	O
than	O
those	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Bifidobacterium	B-bacteria
dentium	I-bacteria
,	O
and	O
low	O
-	O
pH	O
non	O
-	O
S	O
.	O
mutans	B-bacteria
streptococci	I-bacteria
were	O
predominant	O
in	O
subjects	O
with	O
no	O
detectable	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Actinomyces	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
non	O
-	O
S	O
.	O
mutans	B-bacteria
streptococci	I-bacteria
were	O
predominant	O
in	O
white	O
-	O
spot	O
lesions	O
,	O
while	O
known	O
acid	O
producers	O
were	O
found	O
at	O
their	O
highest	O
levels	O
later	O
in	O
disease	O
.	O

Bacterial	O
profiles	O
change	O
with	O
disease	O
states	O
and	O
differ	O
between	O
primary	O
and	O
secondary	O
dentitions	O
.	O

Bacterial	O
species	O
other	O
than	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
e	O
.	O
g	O
.	O
,	O
species	O
of	O
the	O
genera	O
Veillonella	B-bacteria
,	O
Lactobacillus	B-bacteria
,	O
Bifidobacterium	B-bacteria
,	O
and	O
Propionibacterium	B-bacteria
,	O
low	O
-	O
pH	O
non	B-bacteria
-	I-bacteria
S	I-bacteria
.	I-bacteria
mutans	I-bacteria
streptococci	I-bacteria
,	O
Actinomyces	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
and	O
Atopobium	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
likely	O
play	O
important	O
roles	O
in	O
caries	O
progression	O
.	O

Bacteria	O
of	O
the	O
genus	O
Capnocytophaga	B-bacteria
form	O
part	O
of	O
the	O
resident	O
oral	O
flora	O
in	O
children	O
and	O
adults	O
.	O

They	O
are	O
recognized	O
as	O
opportunistic	O
pathogens	O
of	O
various	O
extra	O
-	O
oral	O
infections	O
.	O

The	O
significance	O
of	O
individual	O
species	O
in	O
periodontal	O
and	O
extra	O
-	O
oral	O
diseases	O
is	O
unclear	O
,	O
due	O
to	O
the	O
inability	O
of	O
conventional	O
phenotypic	O
tests	O
to	O
identify	O
clinical	O
isolates	O
to	O
species	O
level	O
.	O

Aiming	O
at	O
a	O
clear	O
distinction	O
between	O
species	O
,	O
we	O
undertook	O
a	O
phylogenetic	O
study	O
of	O
a	O
collection	O
of	O
102	O
Capnocytophaga	B-bacteria
strains	I-bacteria
including	O
62	O
oral	O
isolates	O
from	O
children	O
and	O
40	O
reference	O
strains	O
from	O
oral	O
and	O
extra	O
-	O
oral	O
infections	O
representing	O
the	O
five	O
known	O
,	O
human	O
,	O
oral	O
Capnocytophaga	B-bacteria
species	I-bacteria
.	O

The	O
phylogeny	O
was	O
estimated	O
on	O
the	O
basis	O
of	O
multilocus	O
enzyme	O
electrophoresis	O
(	O
MLEE	O
)	O
of	O
12	O
intracellular	O
,	O
housekeeping	O
enzymes	O
and	O
by	O
partial	O
16S	O
rRNA	O
gene	O
sequencing	O
,	O
and	O
was	O
compared	O
to	O
phenotypic	O
characteristics	O
.	O

The	O
clustering	O
profiles	O
in	O
the	O
MLEE	O
and	O
sequence	O
-	O
based	O
dendrograms	O
were	O
concordant	O
and	O
allowed	O
identification	O
of	O
isolates	O
to	O
species	O
level	O
,	O
based	O
on	O
co	O
-	O
clustering	O
with	O
reference	O
strains	O
.	O

The	O
study	O
confirmed	O
Capnocytophaga	B-bacteria
ochracea	I-bacteria
and	O
Capnocytophaga	B-bacteria
sputigena	I-bacteria
as	O
separate	O
species	O
,	O
and	O
underlined	O
the	O
problems	O
of	O
distinguishing	O
between	O
them	O
by	O
conventional	O
phenotypic	O
tests	O
.	O

The	O
presence	O
of	O
two	O
distinct	O
clusters	O
of	O
oral	O
isolates	O
from	O
children	O
indicated	O
the	O
existence	O
of	O
novel	O
species	O
,	O
supported	O
by	O
analysis	O
of	O
near	O
-	O
full	O
-	O
length	O
16S	O
rRNA	O
gene	O
sequences	O
and	O
by	O
DNA	O
-	O
DNA	O
hybridization	O
results	O
.	O

One	O
cluster	O
of	O
weakly	O
saccharolytic	O
isolates	O
without	O
the	O
ability	O
to	O
ferment	O
sucrose	O
is	O
proposed	O
as	O
Capnocytophaga	B-bacteria
leadbetteri	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
(	O
type	O
strain	O
AHN8855	B-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
51857	I-bacteria
(	O
T	O
)	O
=	O
NCTC	B-bacteria
13375	I-bacteria
(	O
T	O
)	O
)	O
.	O

Another	O
cluster	O
not	O
phenotypically	O
distinguishable	O
from	O
C	B-bacteria
.	I-bacteria
ochracea	I-bacteria
and	O
C	B-bacteria
.	I-bacteria
sputigena	I-bacteria
is	O
designated	O
Capnocytophaga	B-bacteria
genospecies	I-bacteria
AHN8471	I-bacteria
(	O
represented	O
by	O
strain	O
AHN8471	B-bacteria
=	O
CCUG	B-bacteria
51856	I-bacteria
=	O
NCTC	B-bacteria
13374	I-bacteria
)	O
.	O

The	O
roles	O
of	O
the	O
'	O
classical	O
'	O
Actinomyces	B-bacteria
spp	I-bacteria
.	I-bacteria
as	O
colonizers	O
of	O
oral	O
cavities	O
of	O
man	O
and	O
animals	O
,	O
in	O
development	O
of	O
intra	O
-	O
oral	O
infections	O
and	O
as	O
agents	O
of	O
actinomycosis	O
have	O
been	O
well	O
documented	O
.	O

This	O
mini	O
-	O
review	O
focuses	O
on	O
perceptions	O
of	O
human	O
colonization	O
and	O
infection	O
that	O
have	O
emerged	O
in	O
the	O
past	O
decade	O
,	O
largely	O
as	O
a	O
result	O
of	O
advances	O
in	O
classification	O
,	O
identification	O
and	O
direct	O
detection	O
from	O
clinical	O
material	O
.	O

Arguably	O
,	O
of	O
the	O
greatest	O
importance	O
is	O
the	O
recognition	O
of	O
actinomycosis	O
as	O
a	O
major	O
factor	O
and	O
indicator	O
of	O
poor	O
prognosis	O
in	O
both	O
infected	O
osteoradionecrosis	O
and	O
bisphosphonate	O
-	O
associated	O
osteonecrosis	O
of	O
the	O
jaws	O
.	O

Among	O
recently	O
described	O
species	O
,	O
Actinomyces	B-bacteria
graevenitzii	I-bacteria
has	O
been	O
isolated	O
almost	O
exclusively	O
from	O
oral	O
and	O
respiratory	O
sites	O
and	O
may	O
be	O
a	O
causative	O
agent	O
of	O
actinomycosis	O
.	O

Conversely	O
,	O
several	O
other	O
Actinomyces	B-bacteria
spp	I-bacteria
.	I-bacteria
are	O
isolated	O
commonly	O
from	O
superficial	O
soft	O
tissue	O
infections	O
.	O

Members	O
of	O
the	O
genus	O
Actinobaculum	B-bacteria
,	O
which	O
is	O
closely	O
related	O
to	O
Actinomyces	B-bacteria
,	O
are	O
strongly	O
associated	O
with	O
urosepsis	O
.	O

Isolation	O
and	O
identification	O
of	O
Actinomyces	B-bacteria
and	O
related	O
genera	O
by	O
conventional	O
methods	O
remain	O
difficult	O
.	O

Diagnosis	O
is	O
commonly	O
belated	O
and	O
based	O
solely	O
upon	O
histological	O
findings	O
.	O

Development	O
of	O
direct	O
detection	O
methods	O
may	O
aid	O
patient	O
management	O
and	O
further	O
elucidate	O
clinical	O
associations	O
.	O

A	O
microscopic	O
method	O
for	O
noninvasively	O
visualizing	O
the	O
action	O
of	O
an	O
antimicrobial	O
agent	O
inside	O
a	O
biofilm	O
was	O
developed	O
and	O
applied	O
to	O
describe	O
spatial	O
and	O
temporal	O
patterns	O
of	O
mouthrinse	O
activity	O
on	O
model	O
oral	O
biofilms	O
.	O

Three	O
species	O
biofilms	O
of	O
Streptococcus	B-bacteria
oralis	I-bacteria
,	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
and	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
were	O
grown	O
in	O
glass	O
capillary	O
flow	O
cells	O
.	O

Bacterial	O
cells	O
were	O
stained	O
with	O
the	O
fluorogenic	O
esterase	O
substrate	O
Calcien	O
AM	O
(	O
CAM	O
)	O
.	O

Loss	O
of	O
green	O
fluorescence	O
upon	O
exposure	O
to	O
an	O
antimicrobial	O
formulation	O
was	O
subsequently	O
imaged	O
by	O
time	O
-	O
lapse	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

When	O
an	O
antimicrobial	O
mouthrinse	O
containing	O
chlorhexidine	O
digluconate	O
was	O
administered	O
,	O
a	O
gradual	O
loss	O
of	O
green	O
fluorescence	O
was	O
observed	O
that	O
began	O
at	O
the	O
periphery	O
of	O
cell	O
clusters	O
where	O
they	O
adjoined	O
the	O
flowing	O
bulk	O
fluid	O
and	O
progressed	O
inward	O
over	O
a	O
time	O
period	O
of	O
several	O
minutes	O
.	O

Image	O
analysis	O
was	O
performed	O
to	O
quantify	O
a	O
penetration	O
velocity	O
of	O
4	O
mum	O
/	O
min	O
.	O

An	O
enzyme	O
-	O
based	O
antimicrobial	O
formulation	O
led	O
to	O
a	O
gradual	O
,	O
continually	O
slowing	O
loss	O
of	O
fluorescence	O
in	O
a	O
pattern	O
that	O
was	O
qualitatively	O
different	O
from	O
the	O
behavior	O
observed	O
with	O
chlorhexidine	O
.	O

Ethanol	O
at	O
11	O
.	O
6	O
%	O
had	O
little	O
effect	O
on	O
the	O
biofilm	O
.	O

None	O
of	O
these	O
treatments	O
resulted	O
in	O
the	O
removal	O
of	O
biomass	O
from	O
the	O
biofilm	O
.	O

Most	O
methods	O
to	O
measure	O
or	O
visualize	O
antimicrobial	O
action	O
in	O
biofilms	O
are	O
destructive	O
.	O

Spatial	O
information	O
is	O
important	O
because	O
biofilms	O
are	O
known	O
for	O
their	O
structural	O
and	O
physiological	O
heterogeneity	O
.	O

The	O
CAM	O
staining	O
technique	O
has	O
the	O
potential	O
to	O
provide	O
information	O
about	O
the	O
rate	O
of	O
antimicrobial	O
penetration	O
,	O
the	O
presence	O
of	O
tolerant	O
subpopulations	O
,	O
and	O
the	O
extent	O
of	O
biomass	O
removal	O
effected	O
by	O
a	O
treatment	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
wild	O
-	O
thyme	O
(	O
Thymus	O
serpyllum	O
)	O
hydrosol	O
had	O
a	O
preserving	O
effect	O
against	O
spoilage	O
of	O
freshwater	O
fish	O
.	O

Sensorial	O
characteristics	O
,	O
chemical	O
freshness	O
indicator	O
contents	O
,	O
and	O
microbial	O
counts	O
(	O
total	O
aerobes	O
,	O
psychrotrophics	O
,	O
Enterobacteriaceae	B-bacteria
,	O
fecal	B-bacteria
coliform	I-bacteria
bacteria	I-bacteria
,	O
Aeromonas	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
and	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
)	O
of	O
whole	O
ungutted	O
and	O
gutted	O
Transcaucasian	O
barb	O
(	O
Capoeta	O
capoeta	O
capoeta	O
Guldenstaedt	O
,	O
1772	O
)	O
stored	O
on	O
ice	O
produced	O
from	O
wild	O
-	O
thyme	O
hydrosol	O
and	O
tap	O
water	O
at	O
4	O
degrees	O
C	O
for	O
20	O
days	O
were	O
compared	O
.	O

The	O
results	O
did	O
not	O
reveal	O
any	O
significant	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
differences	O
in	O
the	O
microbial	O
counts	O
,	O
sensorial	O
characteristics	O
,	O
pH	O
,	O
and	O
total	O
volatile	O
basic	O
nitrogen	O
values	O
between	O
gutted	O
and	O
ungutted	O
groups	O
.	O

Sensory	O
evaluation	O
and	O
microbiological	O
and	O
chemical	O
analyses	O
indicated	O
that	O
the	O
storage	O
of	O
the	O
fish	O
on	O
ice	O
produced	O
from	O
wild	O
-	O
thyme	O
hydrosol	O
had	O
a	O
significant	O
increase	O
in	O
shelf	O
life	O
by	O
at	O
least	O
15	O
to	O
20	O
days	O
.	O

Frequent	O
occurrence	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
in	O
the	O
human	O
gastrointestinal	O
tract	O
and	O
its	O
persistence	O
due	O
to	O
unsuccessful	O
antimicrobial	O
therapy	O
might	O
be	O
related	O
to	O
a	O
stage	O
in	O
the	O
life	O
cycle	O
of	O
H	O
.	O
pylori	O
in	O
which	O
the	O
bacterium	O
establishes	O
itself	O
as	O
an	O
intracellular	O
symbiont	O
in	O
yeast	O
.	O

In	O
this	O
study	O
,	O
occurrence	O
of	O
non	O
-	O
culturable	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
yeast	O
was	O
assessed	O
by	O
targeting	O
vacuolating	O
cytotoxin	O
A	O
(	O
vacA	O
s1s2	O
)	O
and	O
ureAB	O
genes	O
in	O
the	O
total	O
DNAs	O
of	O
yeasts	O
.	O

DNAs	O
were	O
extracted	O
from	O
13	O
oral	O
yeasts	O
in	O
which	O
bacterium	O
-	O
like	O
bodies	O
,	O
suspected	O
to	O
be	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
,	O
were	O
observed	O
microscopically	O
.	O

Primers	O
were	O
recruited	O
to	O
amplify	O
vacA	O
s1s2	O
and	O
ureAB	O
genes	O
.	O

DNAs	O
from	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
and	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
were	O
used	O
as	O
controls	O
.	O

The	O
amplicons	O
from	O
one	O
yeast	O
and	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
were	O
sequenced	O
.	O

Yeasts	O
were	O
identified	O
as	O
Candida	O
albicans	O
.	O

Fragments	O
of	O
vacA	O
s1s2	O
and	O
ureAB	O
genes	O
were	O
amplified	O
from	O
13	O
yeasts	O
.	O

The	O
size	O
of	O
PCR	O
products	O
was	O
286	O
bp	O
for	O
vacA	O
s1s2	O
gene	O
and	O
406	O
bp	O
for	O
ureAB	O
gene	O
.	O

Similar	O
bands	O
were	O
obtained	O
from	O
the	O
control	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
,	O
and	O
the	O
results	O
for	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
were	O
negative	O
.	O

The	O
data	O
from	O
sequencing	O
of	O
PCR	O
products	O
showed	O
about	O
98	O
%	O
homology	O
between	O
the	O
genes	O
amplified	O
from	O
yeast	O
and	O
those	O
from	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

The	O
results	O
of	O
this	O
study	O
showed	O
the	O
intracellular	O
occurrence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
yeast	O
.	O

This	O
endosymbiotic	O
relationship	O
might	O
explain	O
the	O
persistence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
cavity	O
,	O
the	O
consequence	O
of	O
which	O
could	O
be	O
reinoculation	O
of	O
the	O
stomach	O
by	O
the	O
bacterium	O
and	O
spread	O
of	O
infection	O
among	O
human	O
populations	O
.	O

Type	O
1	O
diabetes	O
mellitus	O
(	O
T1DM	O
)	O
is	O
an	O
auto	O
-	O
immune	O
disease	O
while	O
oral	O
administrating	O
its	O
autoantigens	O
could	O
be	O
a	O
treatment	O
of	O
T1DM	O
.	O

To	O
express	O
human	O
insulin	O
gene	O
(	O
ins	O
)	O
in	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
for	O
oral	O
vaccine	O
,	O
ins	O
gene	O
was	O
replaced	O
by	O
LAB	B-bacteria
bias	O
codon	O
and	O
an	O
8	O
-	O
amino	O
-	O
acid	O
-	O
residue	O
linker	O
peptide	O
forming	O
a	O
beta	O
-	O
turn	O
was	O
designed	O
to	O
link	O
insulin	O
chain	O
A	O
and	O
B	O
.	O

After	O
synthesized	O
by	O
primer	O
annealing	O
method	O
,	O
the	O
whole	O
ins	O
gene	O
was	O
fused	O
with	O
signal	O
peptide	O
sequence	O
SP	O
(	O
Usp45	O
)	O
,	O
subcloned	O
into	O
a	O
LAB	B-bacteria
secretory	O
expressive	O
vector	O
pSW501	O
and	O
then	O
introduced	O
to	O
Lactococcus	B-bacteria
lactis	I-bacteria
(	I-bacteria
L	I-bacteria
.	I-bacteria
lactis	I-bacteria
)	I-bacteria
MG1363	I-bacteria
and	O
Lactobacillus	B-bacteria
casei	I-bacteria
(	I-bacteria
Lb	I-bacteria
.	I-bacteria
casei	I-bacteria
)	I-bacteria
ATCC27092	I-bacteria
respectively	O
.	O

Western	O
blot	O
showed	O
that	O
the	O
expression	O
product	O
(	O
SP	O
(	O
Usp45	O
)	O
-	O
INS	O
protein	O
)	O
targeted	O
mainly	O
at	O
the	O
cell	O
wall	O
while	O
little	O
was	O
found	O
in	O
cytoplasm	O
or	O
supernatant	O
.	O

The	O
highest	O
expression	O
level	O
emerged	O
in	O
exponential	O
phase	O
when	O
the	O
optical	O
density	O
at	O
600nm	O
of	O
the	O
culture	O
was	O
0	O
.	O
4	O
.	O

The	O
culture	O
of	O
the	O
recombinant	O
strain	O
Lb	B-bacteria
.	I-bacteria
casei	I-bacteria
/	O
pSW501	B-bacteria
was	O
administered	O
to	O
non	O
-	O
obese	O
diabetic	O
(	O
NOD	O
)	O
mice	O
orally	O
.	O

ELISA	O
and	O
Western	O
blot	O
results	O
showed	O
that	O
the	O
recombinant	O
strain	O
could	O
induce	O
SP	O
(	O
Usp45	O
)	O
-	O
INS	O
-	O
specific	O
antibodies	O
and	O
raise	O
IL	O
-	O
4	O
level	O
(	O
38	O
.	O
583	O
+	O
/	O
-	O
2	O
.	O
083	O
pg	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
mice	O
'	O
s	O
sera	O
.	O

Expression	O
of	O
insulin	O
in	O
the	O
food	O
-	O
grade	O
vehicle	O
LAB	B-bacteria
could	O
induce	O
oral	O
immune	O
tolerance	O
in	O
NOD	O
mice	O
and	O
protect	O
it	O
from	O
pancreas	O
injury	O
,	O
suggesting	O
it	O
might	O
be	O
a	O
new	O
way	O
to	O
the	O
treatment	O
of	O
T1DM	O
.	O

The	O
incorporation	O
of	O
antibacterial	O
agents	O
into	O
adhesive	O
systems	O
has	O
been	O
proposed	O
to	O
eliminate	O
residual	O
bacteria	O
from	O
dentine	O
.	O

This	O
study	O
used	O
the	O
agar	O
diffusion	O
method	O
to	O
evaluate	O
the	O
antibacterial	O
activity	O
of	O
Clearfil	O
Protect	O
Bond	O
(	O
CPB	O
)	O
,	O
Clearfil	O
SE	O
Bond	O
(	O
CSEB	O
)	O
,	O
Clearfil	O
Tri	O
-	O
S	O
Bond	O
(	O
C3SB	O
)	O
and	O
Xeno	O
-	O
III	O
(	O
XIII	O
)	O
self	O
-	O
etching	O
adhesive	O
systems	O
,	O
with	O
or	O
without	O
light	O
-	O
activation	O
,	O
against	O
cariogenic	O
bacteria	O
,	O
and	O
to	O
assess	O
the	O
influence	O
of	O
human	O
dentine	O
on	O
the	O
antibacterial	O
activity	O
of	O
these	O
materials	O
.	O

An	O
aliquot	O
of	O
10	O
microl	O
per	O
material	O
(	O
and	O
individual	O
components	O
)	O
were	O
pipetted	O
onto	O
paper	O
and	O
dentine	O
discs	O
distributed	O
in	O
Petri	O
dishes	O
containing	O
bacterial	O
culture	O
in	O
BHI	O
agar	O
.	O

Positive	O
control	O
was	O
0	O
.	O
2	O
%	O
chlorhexidine	O
digluconate	O
(	O
CHX	O
)	O
.	O

After	O
incubation	O
,	O
the	O
adhesive	O
components	O
of	O
CPB	O
and	O
CSEB	O
,	O
liquid	O
A	O
of	O
XIII	O
and	O
C3SB	O
did	O
not	O
present	O
antibacterial	O
activity	O
when	O
applied	O
to	O
paper	O
discs	O
.	O

The	O
non	O
-	O
light	O
-	O
activated	O
CPB	O
primer	O
+	O
adhesive	O
promoted	O
the	O
greatest	O
inhibition	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
with	O
light	O
-	O
activation	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
primer	O
+	O
adhesive	O
and	O
primer	O
alone	O
.	O

For	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
CPB	O
primer	O
presented	O
the	O
greatest	O
antibacterial	O
activity	O
in	O
both	O
light	O
-	O
activation	O
conditions	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Regarding	O
the	O
dentine	O
discs	O
,	O
only	O
CHX	O
promoted	O
an	O
inhibitory	O
effect	O
,	O
though	O
less	O
intense	O
than	O
on	O
paper	O
discs	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CHX	O
presented	O
greater	O
antibacterial	O
activity	O
against	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
than	O
against	O
L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Light	O
-	O
activation	O
significantly	O
reduced	O
the	O
antibacterial	O
activity	O
of	O
the	O
self	O
-	O
etching	O
adhesive	O
systems	O
;	O
MDPB	O
incorporation	O
contributed	O
to	O
the	O
effect	O
of	O
adhesive	O
systems	O
against	O
cariogenic	O
bacteria	O
;	O
the	O
components	O
eluted	O
from	O
the	O
adhesive	O
systems	O
were	O
not	O
capable	O
to	O
diffuse	O
through	O
400	O
microm	O
-	O
thick	O
dentine	O
disc	O
to	O
exert	O
their	O
antibacterial	O
activity	O
against	O
cariogenic	O
bacteria	O
.	O

Cathelicidins	O
are	O
antimicrobial	O
peptides	O
found	O
in	O
epithelial	O
and	O
mucosal	O
tissues	O
as	O
well	O
as	O
the	O
secondary	O
granules	O
of	O
neutrophils	O
.	O

SMAP29	O
,	O
a	O
sheep	O
cathelicidin	O
,	O
has	O
differential	O
antimicrobial	O
properties	O
against	O
various	O
pathogens	O
,	O
including	O
periodontal	O
organisms	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
antimicrobial	O
properties	O
and	O
cytotoxicity	O
of	O
SMAP29	O
,	O
SMAP28	O
,	O
and	O
three	O
congeners	O
(	O
SMAP18A	O
,	O
SMAP18D	O
,	O
and	O
SMAP14A	O
)	O
.	O

The	O
peptides	O
at	O
concentrations	O
ranging	O
from	O
0	O
.	O
25	O
to	O
250	O
microg	O
/	O
ml	O
were	O
tested	O
for	O
their	O
activity	O
against	O
multiple	O
strains	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
sanguis	I-bacteria
,	O
Actinomyces	B-bacteria
israelii	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Peptostreptococcus	B-bacteria
micros	I-bacteria
,	O
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
using	O
a	O
radial	O
diffusion	O
assay	O
.	O

Cytotoxicity	O
of	O
keratinocytes	O
was	O
evaluated	O
by	O
measuring	O
lactate	O
dehydrogenase	O
release	O
after	O
incubation	O
with	O
the	O
individual	O
peptides	O
.	O

SMAP28	O
,	O
thought	O
to	O
be	O
the	O
biologically	O
active	O
peptide	O
,	O
was	O
the	O
most	O
potent	O
antimicrobial	O
(	O
range	O
of	O
minimum	O
inhibitory	O
concentrations	O
0	O
.	O
06	O
-	O
7	O
.	O
03	O
microg	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
however	O
,	O
the	O
activity	O
of	O
SMAP28	O
and	O
SMAP29	O
was	O
strongly	O
associated	O
(	O
r	O
=	O
0	O
.	O
933	O
)	O
.	O

The	O
congeners	O
also	O
demonstrated	O
antimicrobial	O
activity	O
against	O
the	O
bacteria	O
tested	O
(	O
range	O
of	O
minimum	O
inhibitory	O
concnetrations	O
0	O
.	O
21	O
-	O
79	O
microg	O
/	O
ml	O
)	O
.	O

Overall	O
,	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
was	O
the	O
most	O
susceptible	O
organism	O
,	O
while	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
was	O
the	O
least	O
susceptible	O
.	O

Keratinocyte	O
cytotoxicity	O
was	O
dependent	O
on	O
peptide	O
length	O
and	O
dose	O
.	O

SMAP28	O
was	O
the	O
most	O
cytotoxic	O
,	O
while	O
SMAP14A	O
was	O
the	O
least	O
cytotoxic	O
.	O

The	O
antimicrobial	O
activities	O
against	O
oral	O
microorganisms	O
and	O
the	O
minimal	O
toxicity	O
seen	O
in	O
this	O
study	O
suggest	O
that	O
the	O
congeners	O
of	O
SMAP29	O
may	O
serve	O
as	O
an	O
alternative	O
to	O
traditional	O
antibiotics	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
periodontal	O
and	O
other	O
oral	O
diseases	O
.	O

Intestinal	O
lactobacilli	B-bacteria
have	O
been	O
successfully	O
used	O
as	O
probiotics	O
to	O
treat	O
gastrointestinal	O
disorders	O
,	O
but	O
only	O
limited	O
data	O
are	O
available	O
for	O
the	O
probiotic	O
properties	O
of	O
oral	O
lactobacilli	B-bacteria
to	O
combat	O
oral	O
diseases	O
.	O

We	O
aimed	O
to	O
characterize	O
oral	O
lactobacilli	B-bacteria
for	O
their	O
potential	O
probiotic	O
properties	O
according	O
to	O
the	O
international	O
guidelines	O
for	O
the	O
evaluation	O
of	O
probiotics	O
,	O
and	O
to	O
select	O
potential	O
probiotic	O
strains	O
for	O
oral	O
health	O
.	O

The	O
study	O
included	O
67	O
salivary	O
and	O
subgingival	O
lactobacilli	B-bacteria
of	O
10	O
species	O
,	O
isolated	O
from	O
healthy	O
humans	O
.	O

All	O
strains	O
were	O
identified	O
using	O
amplified	O
ribosomal	O
DNA	O
restriction	O
analysis	O
,	O
tested	O
for	O
antimicrobial	O
activity	O
against	O
oral	O
pathogens	O
,	O
tolerance	O
of	O
low	O
pH	O
and	O
bile	O
content	O
.	O

Thereafter	O
,	O
the	O
lysozyme	O
tolerance	O
and	O
antibiotic	O
susceptibility	O
of	O
22	O
potential	O
probiotic	O
strains	O
were	O
assessed	O
.	O

The	O
majority	O
of	O
strains	O
suppressed	O
the	O
growth	O
of	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
but	O
none	O
inhibited	O
Candida	O
albicans	O
.	O

The	O
lowest	O
pH	O
tolerated	O
by	O
lactobacilli	B-bacteria
following	O
4	O
h	O
of	O
incubation	O
was	O
pH	O
2	O
.	O
5	O
,	O
but	O
none	O
of	O
the	O
strains	O
grew	O
at	O
this	O
pH	O
.	O

All	O
strains	O
tolerated	O
a	O
high	O
concentration	O
of	O
lysozyme	O
(	O
10	O
mg	O
/	O
ml	O
)	O
and	O
half	O
of	O
the	O
strains	O
tolerated	O
a	O
high	O
concentration	O
of	O
human	O
bile	O
[	O
5	O
%	O
volume	O
/	O
volume	O
(	O
V	O
/	O
V	O
)	O
]	O
.	O

Four	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
and	O
two	O
Lactobacillus	B-bacteria
oris	I-bacteria
strains	I-bacteria
expressed	O
resistance	O
to	O
tetracycline	O
and	O
/	O
or	O
doxycycline	O
.	O

Strains	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
,	O
Lactobacillus	B-bacteria
paracasei	I-bacteria
,	O
Lactobacillus	B-bacteria
salivarius	I-bacteria
,	O
and	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
expressed	O
both	O
high	O
antimicrobial	O
activity	O
and	O
high	O
tolerance	O
of	O
environmental	O
stress	O
.	O

The	O
absence	O
of	O
transferable	O
antibiotic	O
-	O
resistance	O
genes	O
in	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
strains	I-bacteria
remains	O
to	O
be	O
confirmed	O
.	O

These	O
results	O
suggest	O
a	O
potential	O
for	O
oral	O
lactobacilli	B-bacteria
to	O
be	O
used	O
as	O
probiotics	O
for	O
oral	O
health	O
.	O

It	O
is	O
unclear	O
when	O
the	O
initial	O
colonization	O
by	O
periodontal	O
pathogens	O
occurs	O
in	O
the	O
oral	O
cavity	O
.	O

Therefore	O
,	O
we	O
report	O
here	O
the	O
association	O
between	O
specific	O
age	O
groups	O
and	O
the	O
time	O
when	O
the	O
initial	O
colonization	O
by	O
periodontal	O
pathogens	O
occurs	O
in	O
the	O
oral	O
cavity	O
in	O
such	O
groups	O
.	O

Findings	O
are	O
based	O
on	O
an	O
epidemiological	O
analysis	O
of	O
the	O
prevalence	O
of	O
five	O
periodontal	O
pathogens	O
in	O
the	O
oral	O
cavities	O
of	O
a	O
wide	O
range	O
of	O
age	O
populations	O
,	O
from	O
newborn	O
to	O
elderly	O
,	O
who	O
were	O
randomly	O
selected	O
in	O
a	O
geographic	O
region	O
of	O
Brazil	O
.	O

These	O
periodontal	O
pathogens	O
include	O
Campylobacter	B-bacteria
rectus	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
and	O
were	O
analyzed	O
in	O
the	O
bacterial	O
samples	O
isolated	O
from	O
gingival	O
sulcus	O
,	O
the	O
dorsum	O
of	O
the	O
tongue	O
,	O
and	O
cheek	O
mucosa	O
of	O
diverse	O
age	O
groups	O
,	O
using	O
a	O
bacterial	O
DNA	O
-	O
specific	O
PCR	O
method	O
.	O

Results	O
indicated	O
that	O
there	O
are	O
distinct	O
age	O
-	O
related	O
groups	O
where	O
initial	O
colonization	O
by	O
the	O
five	O
periodontal	O
pathogens	O
examined	O
in	O
this	O
study	O
can	O
be	O
detected	O
and	O
that	O
the	O
presence	O
of	O
teeth	O
is	O
a	O
permissive	O
factor	O
for	O
colonization	O
by	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
and	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
.	O

Although	O
it	O
remains	O
unclear	O
exactly	O
how	O
or	O
when	O
target	O
pathogens	O
colonize	O
healthy	O
subjects	O
,	O
an	O
understanding	O
of	O
age	O
-	O
related	O
groups	O
does	O
provide	O
a	O
potentially	O
useful	O
tool	O
in	O
the	O
early	O
detection	O
and	O
prevention	O
of	O
periodontitis	O
in	O
healthy	O
individuals	O
.	O

To	O
assess	O
the	O
level	O
of	O
antibiotic	O
resistance	O
of	O
viridans	B-bacteria
streptococci	I-bacteria
in	O
the	O
oral	O
flora	O
of	O
children	O
with	O
a	O
history	O
of	O
rheumatic	O
fever	O
,	O
receiving	O
long	O
-	O
term	O
monthly	O
intramuscular	O
benzathine	O
penicillin	O
G	O
prophylaxis	O
.	O

PATIENTS	O
AND	O
Oral	O
swabs	O
from	O
patients	O
receiving	O
monthly	O
penicillin	O
G	O
prophylaxis	O
for	O
rheumatic	O
fever	O
were	O
cultured	O
and	O
tested	O
for	O
viridans	B-bacteria
streptococci	I-bacteria
.	O

The	O
E	O
-	O
test	O
was	O
used	O
to	O
test	O
susceptibility	O
to	O
penicillin	O
G	O
,	O
clindamycin	O
,	O
clarithromycin	O
and	O
rifampin	O
.	O

Findings	O
were	O
compared	O
with	O
samples	O
from	O
healthy	O
children	O
who	O
had	O
not	O
been	O
exposed	O
to	O
antibiotic	O
treatment	O
for	O
at	O
least	O
2	O
months	O
.	O

Twenty	O
-	O
six	O
patients	O
and	O
20	O
control	O
children	O
were	O
included	O
in	O
the	O
study	O
.	O

Duration	O
of	O
intramuscular	O
antibiotic	O
treatment	O
ranged	O
from	O
5	O
months	O
to	O
13	O
.	O
5	O
years	O
.	O

Sixty	O
isolates	O
of	O
viridans	B-bacteria
streptococci	I-bacteria
species	I-bacteria
were	O
obtained	O
,	O
with	O
a	O
similar	O
distribution	O
in	O
the	O
two	O
groups	O
.	O

Intermediate	O
resistance	O
to	O
penicillin	O
(	O
MIC	O
0	O
.	O
25	O
-	O
2	O
mg	O
/	O
L	O
)	O
was	O
documented	O
in	O
10	O
of	O
the	O
32	O
isolates	O
(	O
31	O
.	O
2	O
%	O
)	O
in	O
the	O
study	O
group	O
,	O
and	O
high	O
resistance	O
in	O
none	O
,	O
compared	O
to	O
seven	O
of	O
28	O
isolates	O
(	O
25	O
%	O
)	O
with	O
intermediate	O
or	O
high	O
resistance	O
in	O
the	O
control	O
group	O
(	O
p	O
=	O
NS	O
)	O
.	O

All	O
isolates	O
in	O
the	O
study	O
group	O
and	O
all	O
but	O
one	O
in	O
the	O
control	O
group	O
were	O
susceptible	O
to	O
clindamycin	O
,	O
and	O
all	O
isolates	O
from	O
both	O
groups	O
were	O
susceptible	O
to	O
rifampin	O
.	O

One	O
isolate	O
(	O
3	O
.	O
1	O
%	O
)	O
in	O
the	O
study	O
group	O
and	O
two	O
(	O
7	O
.	O
1	O
%	O
)	O
in	O
the	O
control	O
group	O
were	O
resistant	O
to	O
clarithromycin	O
.	O

Monthly	O
Intramuscular	O
penicillin	O
prophylaxis	O
has	O
no	O
effect	O
on	O
the	O
antibiotic	O
susceptibility	O
of	O
viridans	B-bacteria
streptococci	I-bacteria
in	O
oral	O
flora	O
in	O
children	O
with	O
a	O
history	O
of	O
rheumatic	O
fever	O
,	O
receiving	O
secondary	O
prophylaxis	O
after	O
rheumatic	O
fever	O
,	O
regardless	O
of	O
the	O
duration	O
of	O
treatment	O
.	O

A	O
broad	O
variety	O
of	O
microbes	O
are	O
present	O
in	O
atherosclerotic	O
plaques	O
and	O
chronic	O
bacterial	O
infection	O
increases	O
the	O
risk	O
of	O
atherosclerosis	O
by	O
mechanisms	O
that	O
have	O
remained	O
vague	O
.	O

One	O
possible	O
mechanism	O
is	O
that	O
bacteria	O
or	O
bacterial	O
products	O
activate	O
plaque	O
mast	O
cells	O
that	O
are	O
known	O
to	O
participate	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
.	O

Here	O
,	O
we	O
show	O
by	O
real	O
-	O
time	O
PCR	O
analysis	O
and	O
ELISA	O
that	O
Chlamydia	B-bacteria
pneumoniae	I-bacteria
(	O
Cpn	B-bacteria
)	O
and	O
a	O
periodontal	O
pathogen	O
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
Aa	B-bacteria
)	O
,	O
both	O
induce	O
a	O
time	O
and	O
concentration	O
-	O
dependent	O
expression	O
and	O
secretion	O
of	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
,	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
)	O
by	O
cultured	O
human	O
peripheral	O
blood	O
-	O
derived	O
mast	O
cells	O
,	O
but	O
not	O
anti	O
-	O
inflammatory	O
molecules	O
,	O
such	O
as	O
IL	O
-	O
10	O
or	O
transforming	O
growth	O
factor	O
beta	O
1	O
(	O
TGF	O
-	O
beta	O
1	O
)	O
.	O

The	O
IL	O
-	O
8	O
and	O
MCP	O
-	O
1	O
responses	O
were	O
immediate	O
,	O
whereas	O
the	O
onset	O
of	O
TNF	O
-	O
alpha	O
secretion	O
was	O
delayed	O
.	O

The	O
Cpn	O
-	O
mediated	O
pro	O
-	O
inflammatory	O
effect	O
was	O
attenuated	O
when	O
the	O
bacteria	O
were	O
inactivated	O
by	O
UV	O
-	O
treatment	O
.	O

Human	O
monocyte	O
-	O
derived	O
macrophages	O
that	O
were	O
pre	O
-	O
infected	O
with	O
Cpn	O
also	O
induced	O
a	O
significant	O
pro	O
-	O
inflammatory	O
response	O
in	O
human	O
mast	O
cells	O
,	O
both	O
in	O
cocultures	O
and	O
when	O
preconditioned	O
media	O
from	O
Cpn	O
-	O
infected	O
macrophages	O
were	O
used	O
.	O

Intranasal	O
and	O
intravenous	O
administration	O
of	O
live	O
Cpn	B-bacteria
and	O
Aa	B-bacteria
,	O
respectively	O
induced	O
an	O
accumulation	O
of	O
activated	O
mast	O
cells	O
in	O
the	O
aortic	O
sinus	O
of	O
apolipoprotein	O
E	O
-	O
deficient	O
mice	O
,	O
however	O
,	O
with	O
varying	O
responses	O
in	O
the	O
systemic	O
levels	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
TNF	O
-	O
alpha	O
.	O

Pro	O
-	O
atherogenic	O
Cpn	B-bacteria
and	O
Aa	B-bacteria
induce	O
a	O
pro	O
-	O
inflammatory	O
response	O
in	O
cultured	O
human	O
connective	O
tissue	O
-	O
type	O
mast	O
cells	O
and	O
activation	O
of	O
mouse	O
aortic	O
mast	O
cells	O
in	O
vivo	O
.	O

Plasminogen	O
binding	O
by	O
bacteria	O
is	O
a	O
virulence	O
factor	O
important	O
for	O
the	O
entry	O
and	O
dissemination	O
of	O
bacteria	O
in	O
the	O
body	O
.	O

A	O
wide	O
variety	O
of	O
bacteria	O
bind	O
plasminogen	O
,	O
including	O
both	O
organisms	O
causing	O
disease	O
and	O
components	O
of	O
the	O
normal	O
oral	O
flora	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
characteristics	O
of	O
plasminogen	O
binding	O
by	O
six	O
clinical	O
isolates	O
of	O
oral	O
streptococci	B-bacteria
from	O
both	O
dental	O
plaque	O
and	O
inflammatory	O
lesions	O
.	O

All	O
the	O
strains	O
bound	O
plasminogen	O
with	O
approximately	O
the	O
same	O
affinity	O
,	O
and	O
binding	O
was	O
specific	O
and	O
lysine	O
-	O
dependent	O
as	O
evidenced	O
by	O
its	O
inhibition	O
by	O
epsilon	O
-	O
aminocaproic	O
acid	O
.	O

All	O
of	O
the	O
test	O
strains	O
were	O
capable	O
of	O
activating	O
bound	O
plasminogen	O
to	O
plasmin	O
without	O
the	O
addition	O
of	O
a	O
plasminogen	O
activator	O
,	O
and	O
subsequent	O
analysis	O
revealed	O
the	O
presence	O
of	O
streptokinase	O
in	O
all	O
strains	O
.	O

However	O
,	O
the	O
streptococci	B-bacteria
exhibited	O
fibrinolytic	O
activity	O
only	O
in	O
the	O
presence	O
of	O
plasminogen	O
and	O
this	O
could	O
be	O
inhibited	O
by	O
the	O
addition	O
of	O
epsilon	O
-	O
aminocaproic	O
acid	O
.	O

SDS	O
-	O
PAGE	O
and	O
2D	O
gel	O
electrophoresis	O
coupled	O
with	O
plasminogen	O
ligand	O
blotting	O
showed	O
that	O
only	O
a	O
subset	O
of	O
the	O
total	O
proteins	O
(	O
2	O
-	O
15	O
)	O
were	O
involved	O
in	O
the	O
binding	O
of	O
plasminogen	O
.	O

Partial	O
identification	O
of	O
the	O
binding	O
proteins	O
revealed	O
that	O
four	O
glycolytic	O
enzymes	O
,	O
enolase	O
,	O
phosphoglycerate	O
kinase	O
,	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
and	O
phosphoglycerate	O
mutase	O
,	O
were	O
predominant	O
in	O
binding	O
plasminogen	O
.	O

The	O
binding	O
of	O
plasminogen	O
by	O
bacteria	O
from	O
pus	O
did	O
not	O
differ	O
from	O
that	O
of	O
the	O
strains	O
from	O
supragingival	O
plaque	O
.	O

The	O
findings	O
illustrate	O
how	O
apparently	O
innocuous	O
commensal	O
bacteria	O
are	O
capable	O
of	O
utilizing	O
a	O
mechanism	O
that	O
is	O
generally	O
regarded	O
as	O
being	O
of	O
importance	O
to	O
pathogenicity	O
and	O
suggest	O
an	O
additional	O
role	O
of	O
plasminogen	O
binding	O
.	O

Coaggregation	O
assays	O
were	O
performed	O
to	O
investigate	O
interactions	O
between	O
oral	O
Bifidobacterium	B-bacteria
adolescentis	I-bacteria
and	O
other	O
oral	O
bacterial	O
species	O
.	O

Bifidobacterium	B-bacteria
adolescentis	I-bacteria
OLB6410	I-bacteria
isolated	O
from	O
the	O
saliva	O
of	O
healthy	O
humans	O
did	O
not	O
coaggregate	O
with	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
JCM8350	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
OLS3293	I-bacteria
,	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
JCM5708	I-bacteria
,	O
Veillonella	B-bacteria
parvula	I-bacteria
ATCC17745	I-bacteria
or	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
OB7124	I-bacteria
,	O
but	O
it	O
did	O
coaggregate	O
with	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
JCM8532	I-bacteria
.	O

Subsequent	O
examination	O
of	O
biofilm	O
formation	O
on	O
saliva	O
-	O
coated	O
hydroxyapatite	O
discs	O
using	O
FISH	O
revealed	O
that	O
B	B-bacteria
.	I-bacteria
adolescentis	I-bacteria
OLB6410	I-bacteria
could	O
not	O
directly	O
adhere	O
to	O
the	O
coated	O
discs	O
.	O

It	O
did	O
,	O
however	O
,	O
adhere	O
to	O
biofilms	O
of	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
,	O
V	B-bacteria
.	I-bacteria
parvula	I-bacteria
,	O
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
,	O
although	O
it	O
did	O
not	O
coaggregate	O
with	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
nor	O
with	O
V	B-bacteria
.	I-bacteria
parvula	I-bacteria
.	O

These	O
results	O
suggest	O
that	O
the	O
adhesion	O
of	O
B	B-bacteria
.	I-bacteria
adolescentis	I-bacteria
to	O
tooth	O
surfaces	O
is	O
mediated	O
by	O
other	O
oral	O
bacteria	O
.	O

Heat	O
-	O
or	O
proteinase	O
K	O
-	O
treated	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
could	O
not	O
coaggregate	O
with	O
B	B-bacteria
.	I-bacteria
adolescentis	I-bacteria
.	O

Similarly	O
,	O
the	O
coaggregation	O
and	O
coadhesion	O
of	O
proteinase	O
K	O
-	O
treated	O
B	B-bacteria
.	I-bacteria
adolescentis	I-bacteria
were	O
strongly	O
inhibited	O
.	O

It	O
is	O
therefore	O
probable	O
that	O
proteinaceous	O
factors	O
on	O
the	O
cellular	O
surface	O
of	O
B	B-bacteria
.	I-bacteria
adolescentis	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
are	O
involved	O
in	O
their	O
interaction	O
.	O

The	O
data	O
presented	O
in	O
this	O
study	O
add	O
to	O
our	O
understanding	O
of	O
bifidobacterial	B-bacteria
colonization	O
in	O
the	O
human	O
oral	O
cavity	O
.	O

Oral	O
biofilms	O
are	O
associated	O
with	O
the	O
most	O
common	O
infections	O
of	O
the	O
oral	O
cavity	O
.	O

Bacteria	O
embedded	O
in	O
the	O
biofilms	O
are	O
less	O
sensitive	O
to	O
antibacterial	O
agents	O
than	O
planktonic	O
bacteria	O
are	O
.	O

Recently	O
,	O
an	O
antibacterial	O
synergic	O
effect	O
of	O
noncoherent	O
blue	O
light	O
and	O
hydrogen	O
peroxide	O
(	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
)	O
on	O
planktonic	O
Streptococcus	B-bacteria
mutans	I-bacteria
was	O
demonstrated	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
effect	O
of	O
a	O
combination	O
of	O
light	O
and	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
on	O
the	O
vitality	O
and	O
gene	O
expression	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
embedded	O
in	O
biofilm	O
.	O

Biofilms	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
were	O
exposed	O
to	O
visible	O
light	O
(	O
wavelengths	O
,	O
400	O
to	O
500	O
nm	O
)	O
for	O
30	O
or	O
60	O
s	O
(	O
equivalent	O
to	O
34	O
or	O
68	O
J	O
/	O
cm	O
(	O
2	O
)	O
)	O
in	O
the	O
presence	O
of	O
3	O
to	O
300	O
mM	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
.	O

The	O
antibacterial	O
effect	O
was	O
assessed	O
by	O
microbial	O
counts	O
of	O
each	O
treated	O
sample	O
compared	O
with	O
that	O
of	O
the	O
control	O
.	O

The	O
effect	O
of	O
light	O
combined	O
with	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
on	O
the	O
different	O
layers	O
of	O
the	O
biofilm	O
was	O
evaluated	O
by	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

Gene	O
expression	O
was	O
determined	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
.	O

Our	O
results	O
show	O
that	O
noncoherent	O
light	O
,	O
in	O
combination	O
with	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
,	O
has	O
a	O
synergistic	O
antibacterial	O
effect	O
through	O
all	O
of	O
the	O
layers	O
of	O
the	O
biofilm	O
.	O

Furthermore	O
,	O
this	O
treatment	O
was	O
more	O
effective	O
against	O
bacteria	O
in	O
biofilm	O
than	O
against	O
planktonic	O
bacteria	O
.	O

The	O
combined	O
light	O
and	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
treatment	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
several	O
genes	O
such	O
as	O
gtfB	O
,	O
brp	O
,	O
smu630	O
,	O
and	O
comDE	O
but	O
did	O
not	O
affect	O
relA	O
and	O
ftf	O
.	O

The	O
ability	O
of	O
noncoherent	O
visible	O
light	O
in	O
combination	O
with	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
to	O
affect	O
bacteria	O
in	O
deep	O
layers	O
of	O
the	O
biofilm	O
suggests	O
that	O
this	O
treatment	O
may	O
be	O
applied	O
in	O
biofilm	O
-	O
related	O
diseases	O
as	O
a	O
minimally	O
invasive	O
antibacterial	O
procedure	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
causes	O
peptic	O
ulcer	O
disease	O
and	O
gastric	O
cancer	O
,	O
and	O
the	O
oral	O
cavity	O
is	O
likely	O
to	O
serve	O
as	O
a	O
reservoir	O
for	O
this	O
pathogen	O
.	O

We	O
investigated	O
the	O
binding	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
to	O
the	O
mucins	O
covering	O
the	O
mucosal	O
surfaces	O
in	O
the	O
niches	O
along	O
the	O
oral	O
to	O
gastric	O
infection	O
route	O
and	O
during	O
gastric	O
disease	O
and	O
modeled	O
the	O
outcome	O
of	O
these	O
interactions	O
.	O

A	O
panel	O
of	O
seven	O
H	B-bacteria
.	I-bacteria
pylori		I-bacteria
strains	I-bacteria
with	O
defined	O
binding	O
properties	O
was	O
used	O
to	O
identify	O
binding	O
to	O
human	O
mucins	O
from	O
saliva	O
,	O
gastric	O
juice	O
,	O
cardia	O
,	O
corpus	O
,	O
and	O
antrum	O
of	O
healthy	O
stomachs	O
and	O
of	O
stomachs	O
affected	O
by	O
gastritis	O
at	O
pH	O
7	O
.	O
4	O
and	O
3	O
.	O
0	O
using	O
a	O
microtiter	O
-	O
based	O
method	O
.	O

H	O
.	O
pylori	O
binding	O
to	O
mucins	O
differed	O
substantially	O
with	O
the	O
anatomic	O
site	O
,	O
mucin	O
type	O
,	O
pH	O
,	O
gastritis	O
status	O
,	O
and	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
strain	I-bacteria
all	O
having	O
effect	O
on	O
binding	O
.	O

Mucins	O
from	O
saliva	O
and	O
gastric	O
juice	O
displayed	O
the	O
most	O
diverse	O
binding	O
patterns	O
,	O
involving	O
four	O
modes	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
adhesion	O
and	O
the	O
MUC5B	O
,	O
MUC7	O
,	O
and	O
MUC5AC	O
mucins	O
as	O
well	O
as	O
the	O
salivary	O
agglutinin	O
.	O

Binding	O
occurred	O
via	O
the	O
blood	O
-	O
group	O
antigen	O
-	O
binding	O
adhesin	O
(	O
BabA	O
)	O
,	O
the	O
sialic	O
acid	O
-	O
binding	O
adhesin	O
(	O
SabA	O
)	O
,	O
a	O
charge	O
/	O
low	O
pH	O
-	O
dependent	O
mechanism	O
,	O
and	O
a	O
novel	O
saliva	O
-	O
binding	O
adhesin	O
.	O

In	O
the	O
healthy	O
gastric	O
mucus	O
layer	O
only	O
BabA	O
and	O
acid	O
/	O
charge	O
affect	O
binding	O
to	O
the	O
mucins	O
,	O
whereas	O
in	O
gastritis	O
,	O
the	O
BabA	O
/	O
Le	O
(	O
b	O
)	O
-	O
dependent	O
binding	O
to	O
MUC5AC	O
remained	O
,	O
and	O
SabA	O
and	O
low	O
pH	O
binding	O
increased	O
.	O

The	O
four	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
adhesion	O
modes	O
binding	O
to	O
mucins	O
are	O
likely	O
to	O
play	O
different	O
roles	O
during	O
colonization	O
of	O
the	O
oral	O
to	O
gastric	O
niches	O
and	O
during	O
long	O
-	O
term	O
infection	O
.	O

Compare	O
the	O
microbial	O
profiles	O
on	O
the	O
tongue	O
dorsum	O
in	O
patients	O
with	O
halitosis	O
and	O
control	O
subjects	O
in	O
a	O
UK	O
population	O
using	O
culture	O
-	O
independent	O
techniques	O
.	O

Halitosis	O
patients	O
were	O
screened	O
according	O
to	O
our	O
recently	O
developed	O
recruitment	O
protocol	O
.	O

Scrapings	O
from	O
the	O
tongue	O
dorsum	O
were	O
obtained	O
for	O
12	O
control	O
subjects	O
and	O
20	O
halitosis	O
patients	O
.	O

Bacteria	O
were	O
identified	O
by	O
PCR	O
amplification	O
,	O
cloning	O
and	O
sequencing	O
of	O
16S	O
rRNA	O
genes	O
.	O

The	O
predominant	O
species	O
found	O
in	O
the	O
control	O
samples	O
were	O
Lysobacter	O
-	O
type	O
species	O
,	O
Streptococcus	B-bacteria
salivarius	I-bacteria
,	O
Veillonella	B-bacteria
dispar	I-bacteria
,	O
unidentified	O
oral	O
bacterium	O
,	O
Actinomyces	B-bacteria
odontolyticus	I-bacteria
,	O
Atopobium	B-bacteria
parvulum	I-bacteria
and	O
Veillonella	B-bacteria
atypica	I-bacteria
.	O

In	O
the	O
halitosis	O
samples	O
,	O
Lysobacter	O
-	O
type	O
species	O
,	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
,	O
Prevotella	B-bacteria
melaninogenica	I-bacteria
,	O
unidentified	O
oral	O
bacterium	O
,	O
Prevotella	B-bacteria
veroralis	I-bacteria
and	O
Prevotella	B-bacteria
pallens	I-bacteria
were	O
the	O
most	O
commonly	O
found	O
species	O
.	O

For	O
the	O
control	O
samples	O
,	O
13	O
-	O
16	O
(	O
4	O
.	O
7	O
-	O
5	O
.	O
8	O
%	O
)	O
of	O
276	O
clones	O
represented	O
uncultured	O
species	O
,	O
whereas	O
in	O
the	O
halitosis	O
samples	O
,	O
this	O
proportion	O
increased	O
to	O
6	O
.	O
5	O
-	O
9	O
.	O
6	O
%	O
(	O
36	O
-	O
53	O
of	O
553	O
clones	O
)	O
.	O

In	O
the	O
control	O
samples	O
,	O
22	O
(	O
8	O
.	O
0	O
%	O
)	O
of	O
276	O
clones	O
represented	O
potentially	O
novel	O
phylotypes	O
,	O
and	O
in	O
the	O
halitosis	O
samples	O
,	O
this	O
figure	O
was	O
39	O
(	O
7	O
.	O
1	O
%	O
)	O
of	O
553	O
clones	O
.	O

The	O
microflora	O
associated	O
with	O
the	O
tongue	O
dorsum	O
is	O
complex	O
in	O
both	O
the	O
control	O
and	O
halitosis	O
groups	O
,	O
but	O
several	O
key	O
species	O
predominate	O
in	O
both	O
groups	O
.	O

The	O
oral	O
cavity	O
presents	O
numerous	O
surfaces	O
for	O
microbial	O
colonization	O
.	O

These	O
surfaces	O
produce	O
biofilms	O
of	O
differing	O
complexities	O
unique	O
to	O
each	O
individual	O
.	O

Several	O
studies	O
have	O
looked	O
at	O
biofilms	O
in	O
dentate	O
patients	O
.	O

There	O
has	O
been	O
limited	O
research	O
regarding	O
biofilms	O
on	O
dentures	O
or	O
soft	O
tissues	O
of	O
edentulous	O
patients	O
.	O

The	O
purpose	O
of	O
the	O
present	O
investigation	O
was	O
to	O
provide	O
meaningful	O
data	O
describing	O
microbial	O
ecological	O
relationships	O
in	O
the	O
oral	O
cavity	O
of	O
edentulous	O
patients	O
and	O
to	O
evaluate	O
the	O
microbiota	O
on	O
hard	O
and	O
soft	O
tissue	O
surfaces	O
and	O
saliva	O
in	O
edentulous	O
patients	O
wearing	O
complete	O
dentures	O
.	O

MATERIALS	O
AND	O
Sixty	O
-	O
one	O
edentulous	O
subjects	O
with	O
complete	O
maxillary	O
and	O
mandibular	O
dentures	O
were	O
recruited	O
.	O

`	O
`	O
Supragingival	O
'	O
'	O
biofilm	O
samples	O
were	O
taken	O
from	O
28	O
denture	O
teeth	O
for	O
each	O
subject	O
.	O

Biofilm	O
samples	O
were	O
also	O
taken	O
from	O
the	O
dorsal	O
,	O
lateral	O
,	O
and	O
ventral	O
surfaces	O
of	O
the	O
tongue	O
,	O
floor	O
of	O
mouth	O
,	O
buccal	O
mucosa	O
,	O
hard	O
palate	O
,	O
vestibule	O
/	O
lip	O
,	O
`	O
`	O
attached	O
gingiva	O
,	O
'	O
'	O
and	O
saliva	O
.	O

Samples	O
were	O
individually	O
analyzed	O
for	O
their	O
content	O
of	O
41	O
bacterial	O
species	O
using	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
.	O

Levels	O
and	O
proportions	O
of	O
each	O
species	O
were	O
determined	O
for	O
every	O
sample	O
location	O
.	O

Periodontal	O
pathogens	O
such	O
as	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
were	O
clearly	O
present	O
in	O
the	O
samples	O
from	O
the	O
edentulous	O
subjects	O
.	O

Microbial	O
profiles	O
in	O
samples	O
from	O
the	O
soft	O
tissue	O
surfaces	O
differed	O
among	O
site	O
locations	O
.	O

Samples	O
from	O
the	O
dorsum	O
of	O
the	O
tongue	O
exhibited	O
the	O
highest	O
bacterial	O
counts	O
followed	O
by	O
the	O
`	O
`	O
attached	O
gingiva	O
'	O
'	O
and	O
the	O
lateral	O
surfaces	O
of	O
the	O
tongue	O
,	O
while	O
the	O
lowest	O
mean	O
counts	O
were	O
found	O
in	O
samples	O
from	O
the	O
buccal	O
mucosa	O
and	O
labial	O
vestibules	O
.	O

Using	O
cluster	O
analysis	O
of	O
the	O
proportions	O
of	O
the	O
test	O
species	O
,	O
three	O
clusters	O
were	O
formed	O
.	O

The	O
first	O
cluster	O
comprised	O
saliva	O
,	O
supragingival	O
plaque	O
,	O
and	O
the	O
lateral	O
and	O
dorsal	O
surfaces	O
of	O
the	O
tongue	O
.	O

The	O
second	O
cluster	O
comprised	O
the	O
other	O
six	O
soft	O
tissue	O
surfaces	O
.	O

Species	O
on	O
the	O
denture	O
palate	O
formed	O
a	O
third	O
cluster	O
.	O

One	O
of	O
the	O
major	O
findings	O
in	O
this	O
study	O
was	O
the	O
detection	O
of	O
periodontal	O
pathogens	O
,	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
in	O
the	O
edentulous	O
subjects	O
,	O
as	O
these	O
species	O
were	O
thought	O
to	O
disappear	O
after	O
removal	O
of	O
all	O
natural	O
teeth	O
.	O

This	O
finding	O
has	O
implications	O
regarding	O
future	O
dental	O
treatment	O
and	O
the	O
general	O
health	O
of	O
individuals	O
.	O

Distinct	O
patterns	O
of	O
microbial	O
colonization	O
were	O
seen	O
on	O
the	O
different	O
soft	O
tissue	O
surfaces	O
.	O

Thus	O
,	O
this	O
investigation	O
provided	O
the	O
first	O
step	O
in	O
defining	O
the	O
organisms	O
that	O
are	O
associated	O
with	O
edentulous	O
patients	O
on	O
both	O
soft	O
(	O
mucosa	O
)	O
and	O
hard	O
surfaces	O
(	O
denture	O
)	O
.	O

The	O
study	O
also	O
provided	O
meaningful	O
data	O
that	O
described	O
microbial	O
ecological	O
relationships	O
in	O
the	O
oral	O
cavity	O
of	O
edentulous	O
subjects	O
.	O

The	O
authors	O
believe	O
that	O
this	O
study	O
is	O
the	O
first	O
comprehensive	O
assessment	O
of	O
the	O
microbiota	O
in	O
the	O
complete	O
denture	O
-	O
wearing	O
subject	O
.	O

To	O
examine	O
phylogenetic	O
identity	O
and	O
metabolic	O
activity	O
of	O
individual	O
cells	O
in	O
complex	O
microbial	O
communities	O
,	O
we	O
developed	O
a	O
method	O
which	O
combines	O
rRNA	O
-	O
based	O
in	O
situ	O
hybridization	O
with	O
stable	O
isotope	O
imaging	O
based	O
on	O
nanometer	O
-	O
scale	O
secondary	O
-	O
ion	O
mass	O
spectrometry	O
(	O
NanoSIMS	O
)	O
.	O

Fluorine	O
or	O
bromine	O
atoms	O
were	O
introduced	O
into	O
cells	O
via	O
16S	O
rRNA	O
-	O
targeted	O
probes	O
,	O
which	O
enabled	O
phylogenetic	O
identification	O
of	O
individual	O
cells	O
by	O
NanoSIMS	O
imaging	O
.	O

To	O
overcome	O
the	O
natural	O
fluorine	O
and	O
bromine	O
backgrounds	O
,	O
we	O
modified	O
the	O
current	O
catalyzed	O
reporter	O
deposition	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
technique	O
by	O
using	O
halogen	O
-	O
containing	O
fluorescently	O
labeled	O
tyramides	O
as	O
substrates	O
for	O
the	O
enzymatic	O
tyramide	O
deposition	O
.	O

Thereby	O
,	O
we	O
obtained	O
an	O
enhanced	O
element	O
labeling	O
of	O
microbial	O
cells	O
by	O
FISH	O
(	O
EL	O
-	O
FISH	O
)	O
.	O

The	O
relative	O
cellular	O
abundance	O
of	O
fluorine	O
or	O
bromine	O
after	O
EL	O
-	O
FISH	O
exceeded	O
natural	O
background	O
concentrations	O
by	O
up	O
to	O
180	O
-	O
fold	O
and	O
allowed	O
us	O
to	O
distinguish	O
target	O
from	O
non	O
-	O
target	O
cells	O
in	O
NanoSIMS	O
fluorine	O
or	O
bromine	O
images	O
.	O

The	O
method	O
was	O
optimized	O
on	O
single	O
cells	O
of	O
axenic	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
Vibrio	B-bacteria
cholerae	I-bacteria
cultures	O
.	O

EL	O
-	O
FISH	O
/	O
NanoSIMS	O
was	O
then	O
applied	O
to	O
study	O
interrelationships	O
in	O
a	O
dual	O
-	O
species	O
consortium	O
consisting	O
of	O
a	O
filamentous	B-bacteria
cyanobacterium	I-bacteria
and	O
a	O
heterotrophic	B-bacteria
alphaproteobacterium	I-bacteria
.	O

We	O
also	O
evaluated	O
the	O
method	O
on	O
complex	O
microbial	O
aggregates	O
obtained	O
from	O
human	O
oral	O
biofilms	O
.	O

In	O
both	O
samples	O
,	O
we	O
found	O
evidence	O
for	O
metabolic	O
interactions	O
by	O
visualizing	O
the	O
fate	O
of	O
substrates	O
labeled	O
with	O
(	O
13	O
)	O
C	O
-	O
carbon	O
and	O
(	O
15	O
)	O
N	O
-	O
nitrogen	O
,	O
while	O
individual	O
cells	O
were	O
identified	O
simultaneously	O
by	O
halogen	O
labeling	O
via	O
EL	O
-	O
FISH	O
.	O

Our	O
novel	O
approach	O
will	O
facilitate	O
further	O
studies	O
of	O
the	O
ecophysiology	O
of	O
known	O
and	O
uncultured	O
microorganisms	O
in	O
complex	O
environments	O
and	O
communities	O
.	O

Studies	O
have	O
suggested	O
that	O
oral	O
bone	O
loss	O
is	O
independently	O
influenced	O
by	O
local	O
and	O
systemic	O
factors	O
,	O
including	O
osteoporosis	O
.	O

This	O
cross	O
-	O
sectional	O
study	O
of	O
1256	O
post	O
-	O
menopausal	O
women	O
,	O
recruited	O
from	O
the	O
Buffalo	O
center	O
of	O
the	O
Women	O
'	O
s	O
Health	O
Initiative	O
Observational	O
Study	O
,	O
evaluated	O
the	O
influence	O
of	O
oral	O
infection	O
and	O
age	O
on	O
the	O
associations	O
between	O
osteoporosis	O
and	O
oral	O
bone	O
loss	O
.	O

Systemic	O
bone	O
density	O
was	O
measured	O
by	O
dual	O
-	O
energy	O
x	O
-	O
ray	O
absorptiometry	O
.	O

Alveolar	O
crestal	O
height	O
was	O
measured	O
from	O
standardized	O
dental	O
radiographs	O
.	O

Oral	O
infection	O
was	O
assessed	O
from	O
subgingival	O
plaque	O
samples	O
.	O

Total	O
forearm	O
density	O
[	O
beta	O
(	O
SE	O
)	O
=	O
-	O
0	O
.	O
931	O
(	O
0	O
.	O
447	O
)	O
,	O
p	O
=	O
0	O
.	O
038	O
]	O
and	O
presence	O
of	O
Tannerella	B-bacteria
forsythensis	I-bacteria
[	O
beta	O
(	O
SE	O
)	O
=	O
0	O
.	O
125	O
(	O
0	O
.	O
051	O
)	O
,	O
p	O
=	O
0	O
.	O
015	O
]	O
were	O
independently	O
associated	O
with	O
mean	O
alveolar	O
height	O
among	O
women	O
aged	O
<	O
70	O
years	O
after	O
confounder	O
adjustment	O
.	O

Women	O
aged	O
70	O
+	O
years	O
had	O
worse	O
oral	O
bone	O
loss	O
,	O
in	O
general	O
,	O
but	O
neither	O
bone	O
density	O
nor	O
oral	O
infection	O
was	O
significantly	O
associated	O
with	O
mean	O
alveolar	O
height	O
in	O
this	O
age	O
group	O
.	O

Systemic	O
bone	O
density	O
and	O
oral	O
infection	O
independently	O
influenced	O
oral	O
bone	O
loss	O
in	O
post	O
-	O
menopausal	O
women	O
aged	O
<	O
70	O
years	O
.	O

Systemic	O
infection	O
with	O
HIV	O
occurs	O
infrequently	O
through	O
the	O
oral	O
route	O
.	O

The	O
frequency	O
of	O
occurrence	O
may	O
be	O
increased	O
by	O
concomitant	O
bacterial	O
infection	O
of	O
the	O
oral	O
tissues	O
,	O
since	O
co	O
-	O
infection	O
and	O
inflammation	O
of	O
some	O
cell	O
types	O
increases	O
HIV	O
-	O
1	O
replication	O
.	O

A	O
putative	O
periodontal	O
pathogen	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
selectively	O
up	O
-	O
regulates	O
expression	O
of	O
the	O
HIV	O
-	O
1	O
coreceptor	O
CCR5	O
on	O
oral	O
keratinocytes	O
.	O

We	O
,	O
therefore	O
,	O
hypothesized	O
that	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
modulates	O
the	O
outcome	O
of	O
HIV	O
infection	O
in	O
oral	O
epithelial	O
cells	O
.	O

Oral	O
and	O
tonsil	O
epithelial	O
cells	O
were	O
pre	O
-	O
incubated	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
and	O
inoculated	O
with	O
either	O
an	O
X4	O
-	O
or	O
R5	O
-	O
type	O
HIV	O
-	O
1	O
.	O

Between	O
6	O
and	O
48	O
hours	O
post	O
-	O
inoculation	O
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
selectively	O
increased	O
the	O
infectivity	O
of	O
R5	O
-	O
tropic	O
HIV	O
-	O
1	O
from	O
oral	O
and	O
tonsil	O
keratinocytes	O
;	O
infectivity	O
of	O
X4	O
-	O
tropic	O
HIV	O
-	O
1	O
remained	O
unchanged	O
.	O

Oral	O
keratinocytes	O
appeared	O
to	O
harbor	O
infectious	O
HIV	O
-	O
1	O
,	O
with	O
no	O
evidence	O
of	O
productive	O
infection	O
.	O

HIV	O
-	O
1	O
was	O
harbored	O
at	O
highest	O
levels	O
during	O
the	O
first	O
6	O
hours	O
after	O
HIV	O
exposure	O
and	O
decreased	O
to	O
barely	O
detectable	O
levels	O
at	O
48	O
hours	O
.	O

HIV	O
did	O
not	O
appear	O
to	O
co	O
-	O
localize	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
which	O
increased	O
selective	O
R5	O
-	O
tropic	O
HIV	O
-	O
1	O
trans	O
infection	O
from	O
keratinocytes	O
to	O
permissive	O
cells	O
.	O

When	O
CCR5	O
was	O
selectively	O
blocked	O
,	O
HIV	O
-	O
1	O
trans	O
infection	O
was	O
reduced	O
.	O

P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
up	O
-	O
regulation	O
of	O
CCR5	O
increases	O
trans	O
infection	O
of	O
harbored	O
R5	O
-	O
tropic	O
HIV	O
-	O
1	O
from	O
oral	O
keratinocytes	O
to	O
permissive	O
cells	O
.	O

Oral	O
infections	O
such	O
as	O
periodontitis	O
may	O
,	O
therefore	O
,	O
increase	O
risk	O
for	O
oral	O
infection	O
and	O
dissemination	O
of	O
R5	O
-	O
tropic	O
HIV	O
-	O
1	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
prevalence	O
and	O
levels	O
of	O
salivary	O
microorganisms	O
in	O
HIV	O
-	O
positive	O
children	O
,	O
and	O
their	O
correlation	O
to	O
HIV	O
status	O
,	O
oral	O
lesions	O
,	O
and	O
salivary	O
IgA	O
levels	O
.	O

Forty	O
-	O
two	O
HIV	O
-	O
positive	O
and	O
36	O
control	O
children	O
were	O
clinically	O
examined	O
,	O
had	O
their	O
saliva	O
collected	O
and	O
processed	O
for	O
the	O
microbiological	O
analysis	O
of	O
38	O
bacterial	O
taxa	O
by	O
the	O
checkerboard	O
method	O
,	O
and	O
salivary	O
IgA	O
quantification	O
by	O
ELISA	O
.	O

The	O
majority	O
of	O
the	O
species	O
tested	O
were	O
more	O
prevalent	O
in	O
control	O
children	O
than	O
in	O
the	O
HIV	O
group	O
.	O

Mean	O
concentration	O
of	O
total	O
salivary	O
IgA	O
was	O
similar	O
in	O
both	O
groups	O
.	O

High	O
levels	O
of	O
Veillonella	B-bacteria
parvula	I-bacteria
were	O
found	O
in	O
children	O
with	O
cheilitis	O
and	O
herpes	O
.	O

Tannerella	B-bacteria
forsythia	I-bacteria
,	O
Eikenella	B-bacteria
Corrodens	I-bacteria
,	O
and	O
Propionibacterium	B-bacteria
acnes	I-bacteria
were	O
prevalent	O
in	O
children	O
with	O
gingivitis	O
,	O
while	O
Fusobacterium	B-bacteria
periodonticum	I-bacteria
,	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
and	O
Streptococcus	B-bacteria
oralis	I-bacteria
were	O
significantly	O
more	O
frequent	O
in	O
children	O
with	O
no	O
oral	O
lesions	O
.	O

Significant	O
negative	O
correlations	O
between	O
salivary	O
IgA	O
levels	O
and	O
Eubacterium	B-bacteria
nodatum	I-bacteria
and	O
oral	O
streptococci	B-bacteria
were	O
observed	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

HIV	O
-	O
seropositive	O
children	O
presented	O
significantly	O
lower	O
prevalence	O
and	O
levels	O
of	O
several	O
bacterial	O
species	O
in	O
saliva	O
;	O
HIV	O
-	O
positive	O
children	O
are	O
able	O
to	O
mount	O
a	O
mucosal	O
immune	O
response	O
;	O
HIV	O
-	O
seropositive	O
children	O
under	O
highly	O
active	O
antiretroviral	O
therapy	O
presented	O
low	O
prevalence	O
of	O
oral	O
lesions	O
.	O

Viral	O
and	O
bacterial	O
associations	O
appear	O
to	O
be	O
implicated	O
in	O
the	O
development	O
of	O
periodontal	O
infections	O
.	O

Little	O
information	O
is	O
available	O
describing	O
the	O
periodontopathic	O
agents	O
in	O
root	O
canals	O
with	O
necrotic	O
pulp	O
.	O

In	O
this	O
study	O
,	O
the	O
occurrence	O
and	O
the	O
combinations	O
among	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
and	O
Dialister	B-bacteria
pneumosintes	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
in	O
patients	O
with	O
chronic	O
periodontitis	O
and	O
necrotic	O
pulp	O
were	O
evaluated	O
.	O

Clinical	O
samples	O
from	O
healthy	O
subjects	O
and	O
patients	O
with	O
periodontal	O
or	O
pulp	O
infections	O
were	O
analyzed	O
using	O
a	O
nested	O
polymeras	O
chain	O
reaction	O
PCR	O
to	O
detect	O
HSV	O
and	O
PCR	O
to	O
detect	O
the	O
3	O
periodontal	O
bacteria	O
.	O

The	O
presence	O
of	O
Tannerella	B-bacteria
forsythia	I-bacteria
and	O
Treponema	B-bacteria
denticola	I-bacteria
was	O
observed	O
in	O
healthy	O
,	O
chronic	O
periodontitis	O
,	O
and	O
necrotic	O
pulp	O
patients	O
.	O

HSV	O
was	O
observed	O
in	O
periodontitis	O
and	O
necrotic	O
pulp	O
patients	O
,	O
and	O
no	O
healthy	O
subject	O
harbored	O
D	O
.	O
pneumosintes	O
or	O
HSV	O
.	O

The	O
occurrence	O
of	O
Tannerella	B-bacteria
forsythia	I-bacteria
was	O
not	O
statistically	O
significant	O
in	O
patients	O
with	O
necrotic	O
pulp	O
(	O
P	O
=	O
0	O
.	O
704	O
)	O
.	O

Periodontal	O
bacteria	O
were	O
observed	O
varying	O
from	O
10	O
.	O
3	O
%	O
to	O
20	O
.	O
7	O
%	O
in	O
chronic	O
periodontitis	O
and	O
necrotic	O
pulp	O
patients	O
.	O

The	O
presence	O
of	O
Treponema	B-bacteria
denticola	I-bacteria
-	O
HSV	O
association	O
was	O
predominant	O
in	O
patients	O
showing	O
necrotic	O
pulp	O
(	O
24	O
.	O
1	O
%	O
)	O
;	O
however	O
,	O
HSV	O
alone	O
was	O
observed	O
in	O
one	O
patient	O
with	O
periodontitis	O
and	O
in	O
another	O
patient	O
with	O
necrotic	O
pulp	O
.	O

The	O
presence	O
of	O
double	O
association	O
among	O
bacteria	O
or	O
bacteria	O
-	O
HSV	O
could	O
indicate	O
a	O
role	O
in	O
both	O
periodontitis	O
and	O
necrotic	O
pulp	O
,	O
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
-	O
Treponema	B-bacteria
denticola	I-bacteria
-	O
HSV	O
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
-	O
D	B-bacteria
.	I-bacteria
pneumosintes	I-bacteria
-	O
Treponema	B-bacteria
denticola	I-bacteria
-	O
HSV	O
associations	O
might	O
be	O
important	O
in	O
periodontitis	O
.	O

To	O
evaluate	O
the	O
influence	O
of	O
doxycycline	O
therapy	O
on	O
the	O
composition	O
and	O
antibiotic	O
susceptibility	O
of	O
intestinal	O
bifidobacteria	B-bacteria
.	O

Faecal	O
samples	O
were	O
collected	O
from	O
nine	O
subjects	O
receiving	O
doxycycline	O
therapy	O
and	O
ten	O
control	O
subjects	O
,	O
and	O
analysed	O
for	O
bifidobacteria	B-bacteria
by	O
culturing	O
and	O
PCR	O
-	O
DGGE	O
(	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
)	O
.	O

A	O
marked	O
decrease	O
in	O
the	O
diversity	O
(	O
average	O
number	O
of	O
amplicons	O
detected	O
by	O
PCR	O
-	O
DGGE	O
0	O
.	O
8	O
in	O
the	O
antibiotic	O
vs	O
4	O
.	O
3	O
in	O
the	O
control	O
group	O
)	O
of	O
Bifidobacterium	B-bacteria
populations	O
was	O
observed	O
during	O
doxycycline	O
therapy	O
.	O

The	O
proportion	O
of	O
a	O
tetracycline	O
-	O
resistant	O
bifidobacterial	O
population	O
was	O
higher	O
in	O
the	O
antibiotic	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
83	O
%	O
vs	O
26	O
%	O
)	O
.	O

Based	O
on	O
the	O
tet	O
gene	O
PCR	O
,	O
resistance	O
could	O
be	O
associated	O
with	O
the	O
presence	O
of	O
tet	O
(	O
W	O
)	O
.	O

In	O
two	O
subjects	O
,	O
strains	O
representing	O
highly	O
similar	O
genetic	O
fingerprints	O
but	O
different	O
tetracycline	O
susceptibilities	O
were	O
detected	O
.	O

A	O
mutation	O
causing	O
lack	O
of	O
functionality	O
in	O
the	O
tet	O
(	O
W	O
)	O
was	O
observed	O
in	O
one	O
of	O
the	O
susceptible	O
strains	O
.	O

Doxycycline	O
therapy	O
had	O
a	O
drastic	O
effect	O
on	O
the	O
diversity	O
and	O
tetracycline	O
susceptibility	O
of	O
intestinal	O
Bifidobacterium	B-bacteria
populations	O
.	O

The	O
use	O
of	O
broad	O
-	O
spectrum	O
antibiotics	O
increased	O
the	O
pool	O
of	O
tetracycline	O
-	O
resistant	O
commensal	O
bacteria	O
in	O
the	O
intestine	O
.	O

The	O
detection	O
of	O
resistance	O
genes	O
alone	O
is	O
not	O
sufficient	O
for	O
the	O
evaluation	O
of	O
bacterial	O
antibiotic	O
resistance	O
.	O

Model	O
systems	O
with	O
oral	O
bacteria	O
from	O
dental	O
plaque	O
have	O
demonstrated	O
that	O
the	O
utilization	O
of	O
complex	O
glycoproteins	O
as	O
a	O
food	O
source	O
can	O
not	O
be	O
undertaken	O
by	O
single	O
species	O
but	O
requires	O
concerted	O
degradation	O
by	O
a	O
multi	O
-	O
species	O
consortium	O
,	O
with	O
each	O
member	O
contributing	O
one	O
or	O
a	O
few	O
hydrolytic	O
enzymes	O
.	O

Unlike	O
previous	O
studies	O
,	O
the	O
aim	O
of	O
the	O
present	O
investigation	O
was	O
to	O
explore	O
the	O
ability	O
of	O
fresh	O
dental	O
plaque	O
to	O
degrade	O
salivary	O
mucin	O
,	O
MUC5B	O
,	O
isolated	O
by	O
methods	O
designed	O
to	O
retain	O
intact	O
the	O
natural	O
polymeric	O
structure	O
and	O
physiological	O
conformation	O
,	O
in	O
an	O
attempt	O
to	O
mimic	O
the	O
naturally	O
occurring	O
interaction	O
between	O
the	O
oral	O
microbiota	O
and	O
salivary	O
mucins	O
.	O

Human	O
salivary	O
MUC5B	O
was	O
isolated	O
from	O
whole	O
saliva	O
by	O
density	O
-	O
gradient	O
centrifugation	O
and	O
incubated	O
with	O
freshly	O
isolated	O
supragingival	O
dental	O
plaque	O
with	O
samples	O
subjected	O
to	O
fluorescent	O
staining	O
for	O
viability	O
and	O
metabolic	O
activity	O
.	O

In	O
addition	O
,	O
the	O
degradation	O
of	O
MUC5B	O
oligosaccharide	O
side	O
chains	O
was	O
studied	O
using	O
a	O
lectin	O
assay	O
,	O
recognizing	O
three	O
different	O
carbohydrate	O
epitopes	O
commonly	O
found	O
on	O
mucin	O
oligosaccharide	O
side	O
chains	O
.	O

The	O
addition	O
of	O
purified	O
salivary	O
MUC5B	O
elicited	O
a	O
strong	O
metabolic	O
response	O
from	O
the	O
biofilm	O
cells	O
,	O
whereas	O
individual	O
strains	O
of	O
Streptococcus	B-bacteria
oralis	I-bacteria
and	O
Streptococcus	B-bacteria
gordonii	I-bacteria
isolated	O
from	O
the	O
same	O
plaque	O
were	O
not	O
able	O
to	O
utilize	O
the	O
MUC5B	O
.	O

The	O
degradation	O
of	O
terminal	O
saccharide	O
moieties	O
on	O
the	O
MUC5B	O
was	O
demonstrated	O
by	O
a	O
marked	O
decrease	O
in	O
both	O
sialic	O
acid	O
and	O
fucose	O
reactivity	O
.	O

These	O
results	O
have	O
shown	O
that	O
dental	O
plaque	O
is	O
capable	O
of	O
utilizing	O
human	O
salivary	O
MUC5B	O
as	O
a	O
nutrient	O
source	O
,	O
a	O
process	O
possibly	O
requiring	O
the	O
synergistic	O
degradation	O
of	O
the	O
molecule	O
by	O
a	O
consortium	O
of	O
oral	O
bacteria	O
in	O
the	O
plaque	O
community	O
.	O

Lactobacillus	B-bacteria
salivarius	I-bacteria
BGHO1	I-bacteria
,	O
a	O
human	O
oral	O
isolate	O
with	O
antagonistic	O
activity	O
against	O
growth	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
pneumoniae	I-bacteria
,	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
Enterococcus	B-bacteria
faecalis	I-bacteria
,	O
Micrococcus	B-bacteria
flavus	I-bacteria
,	O
and	O
Salmonella	B-bacteria
enteritidis	I-bacteria
,	O
probably	O
produces	O
more	O
than	O
one	O
proteinaceous	O
antimicrobial	O
substance	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
the	O
purification	O
of	O
a	O
bacteriocin	O
,	O
named	O
LS1	O
,	O
produced	O
by	O
L	B-bacteria
.	I-bacteria
salivarius	I-bacteria
BGHO1	I-bacteria
.	O

A	O
simple	O
and	O
fast	O
procedure	O
for	O
bacteriocin	O
purification	O
was	O
developed	O
,	O
consisting	O
of	O
reverse	O
-	O
phase	O
chromatography	O
of	O
the	O
ammonium	O
sulfate	O
precipitate	O
of	O
cell	O
-	O
free	O
culture	O
supernatant	O
by	O
fast	O
protein	O
liquid	O
chromatography	O
and	O
high	O
-	O
performance	O
liquid	O
chromatography	O
,	O
followed	O
by	O
tricine	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
,	O
with	O
the	O
subsequent	O
extraction	O
of	O
bacteriocin	O
from	O
the	O
gel	O
.	O

The	O
supernatant	O
of	O
L	B-bacteria
.	I-bacteria
salivarius	I-bacteria
BGHO1	I-bacteria
culture	O
retained	O
its	O
antimicrobial	O
activity	O
after	O
boiling	O
in	O
a	O
water	O
bath	O
for	O
15	O
min	O
.	O

Its	O
antimicrobial	O
activity	O
was	O
also	O
maintained	O
even	O
after	O
treatment	O
for	O
20	O
min	O
at	O
121	O
degrees	O
C	O
in	O
an	O
autoclave	O
.	O

Bacteriocin	O
LS1	O
was	O
purified	O
to	O
homogeneity	O
.	O

The	O
molecular	O
mass	O
of	O
bacteriocin	O
LS1	O
was	O
estimated	O
to	O
be	O
approximately	O
10	O
kDa	O
,	O
based	O
on	O
tricine	O
SDS	O
-	O
PAGE	O
.	O

During	O
purification	O
,	O
another	O
compound	O
with	O
antimicrobial	O
activity	O
,	O
produced	O
by	O
L	B-bacteria
.	I-bacteria
salivarius	I-bacteria
BGHO1	I-bacteria
,	O
was	O
detected	O
.	O

The	O
molecular	O
mass	O
of	O
this	O
compound	O
was	O
estimated	O
to	O
be	O
approximately	O
5	O
kDa	O
,	O
based	O
on	O
tricine	O
SDS	O
-	O
PAGE	O
.	O

Our	O
results	O
imply	O
that	O
LS1	O
is	O
most	O
probably	O
a	O
new	O
bacteriocin	O
,	O
different	O
from	O
previously	O
described	O
bacteriocins	O
produced	O
by	O
L	B-bacteria
.	I-bacteria
salivarius	I-bacteria
strains	I-bacteria
.	O

The	O
purification	O
of	O
bacteriocin	O
LS1	O
enabled	O
the	O
further	O
characterization	O
of	O
LS1	O
on	O
both	O
the	O
molecular	O
and	O
genetic	O
levels	O
.	O

Bacteraemia	O
,	O
defined	O
as	O
the	O
presence	O
of	O
viable	O
bacteria	O
in	O
the	O
circulating	O
blood	O
can	O
result	O
in	O
bloodstream	O
infection	O
,	O
which	O
is	O
one	O
of	O
the	O
most	O
frequent	O
and	O
challenging	O
hospital	O
-	O
acquired	O
infections	O
.	O

Bacteraemia	O
occurs	O
in	O
healthy	O
populations	O
with	O
manipulation	O
of	O
the	O
oral	O
mucosa	O
,	O
including	O
toothbrushing	O
.	O

Oral	O
care	O
is	O
commonly	O
administered	O
to	O
mechanically	O
ventilated	O
patients	O
,	O
it	O
is	O
important	O
to	O
determine	O
whether	O
this	O
practice	O
contributes	O
to	O
the	O
incidence	O
of	O
bacteraemia	O
.	O

This	O
paper	O
reviews	O
the	O
literature	O
on	O
the	O
link	O
between	O
the	O
manipulation	O
of	O
the	O
oral	O
cavity	O
and	O
the	O
development	O
of	O
bacteraemia	O
in	O
mechanically	O
ventilated	O
adults	O
.	O

Searches	O
were	O
conducted	O
using	O
Medline	O
,	O
and	O
the	O
Cochrane	O
Library	O
databases	O
.	O

Article	O
inclusion	O
criteria	O
were	O
(	O
1	O
)	O
a	O
focus	O
on	O
mechanical	O
ventilation	O
and	O
critical	O
illness	O
,	O
(	O
2	O
)	O
human	O
subjects	O
,	O
(	O
3	O
)	O
adult	O
subjects	O
,	O
and	O
(	O
4	O
)	O
publication	O
in	O
English	O
(	O
or	O
available	O
English	O
translation	O
)	O
.	O

Nine	O
articles	O
met	O
inclusion	O
criteria	O
and	O
were	O
critiqued	O
.	O

All	O
relied	O
upon	O
clinical	O
data	O
as	O
outcome	O
measures	O
;	O
many	O
were	O
retrospective	O
.	O

The	O
three	O
organisms	O
most	O
often	O
associated	O
with	O
nosocomial	O
bloodstream	O
infections	O
were	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
coagulase	B-bacteria
negative	I-bacteria
staphylococci	I-bacteria
,	O
and	O
Enterococcus	B-bacteria
species	I-bacteria
.	O

Establishing	O
the	O
origin	O
of	O
bacteraemia	O
was	O
problematic	O
in	O
most	O
studies	O
.	O

Additional	O
research	O
is	O
needed	O
to	O
understand	O
the	O
relationship	O
of	O
oral	O
care	O
practices	O
to	O
bacteraemia	O
in	O
mechanically	O
ventilated	O
adults	O
.	O

Evidence	O
is	O
accumulating	O
that	O
oral	O
bacteria	O
are	O
associated	O
with	O
myocardial	O
infarctions	O
(	O
MI	O
)	O
.	O

We	O
were	O
interested	O
in	O
studying	O
the	O
differences	O
in	O
the	O
association	O
between	O
single	O
bacteria	O
or	O
bacteria	O
in	O
combination	O
and	O
the	O
relation	O
to	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
.	O

We	O
examined	O
the	O
levels	O
of	O
antibodies	O
against	O
four	O
major	O
periodontal	O
pathogens	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
PG	B-bacteria
)	O
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
AA	B-bacteria
)	O
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
(	O
TF	B-bacteria
)	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
(	O
TD	B-bacteria
)	O
and	O
CRP	O
in	O
548	O
men	O
with	O
a	O
self	O
-	O
reported	O
history	O
of	O
MI	O
to	O
625	O
controls	O
who	O
took	O
part	O
in	O
the	O
Oslo	O
II	O
study	O
in	O
2000	O
.	O

The	O
mean	O
levels	O
of	O
bacterial	O
antibodies	O
were	O
higher	O
for	O
the	O
cases	O
than	O
the	O
controls	O
,	O
but	O
not	O
significant	O
as	O
standard	O
deviations	O
were	O
large	O
.	O

The	O
level	O
of	O
CRP	O
was	O
higher	O
in	O
the	O
cases	O
than	O
the	O
controls	O
(	O
p	O
=	O
0	O
.	O
010	O
)	O
.	O

Logistic	O
regression	O
analyses	O
comparing	O
the	O
upper	O
quartile	O
value	O
with	O
the	O
lower	O
value	O
of	O
one	O
of	O
either	O
four	O
antibodies	O
(	O
anti	O
-	O
AA	O
,	O
anti	O
-	O
TF	O
,	O
anti	O
-	O
TD	O
and	O
anti	O
-	O
PG	O
)	O
were	O
significantly	O
associated	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
with	O
MI	O
.	O

Equivalent	O
analyses	O
of	O
either	O
three	O
bacteria	O
showed	O
significant	O
associations	O
for	O
anti	O
-	O
AA	O
,	O
anti	O
-	O
TD	O
and	O
anti	O
-	O
PG	O
(	O
p	O
=	O
0	O
.	O
036	O
)	O
and	O
anti	O
-	O
AA	O
,	O
anti	O
-	O
PG	O
and	O
anti	O
-	O
TF	O
(	O
p	O
=	O
0	O
.	O
040	O
)	O
.	O

CRP	O
showed	O
an	O
increased	O
relative	O
risk	O
with	O
increasing	O
quartile	O
value	O
;	O
trend	O
,	O
p	O
=	O
0	O
.	O
016	O
,	O
but	O
not	O
in	O
multivariate	O
analysis	O
including	O
the	O
oral	O
antigens	O
.	O

No	O
single	O
bacterium	O
but	O
rather	O
combinations	O
were	O
related	O
to	O
increasing	O
relative	O
risk	O
for	O
MI	O
independent	O
of	O
known	O
cardiovascular	O
risk	O
factors	O
.	O

To	O
define	O
the	O
relationship	O
between	O
salivary	O
SIgA	O
antibodies	O
and	O
commensal	O
oral	O
bacteria	O
,	O
we	O
examined	O
the	O
reactivity	O
of	O
SIgA	O
antibodies	O
from	O
the	O
saliva	O
of	O
four	O
infants	O
with	O
their	O
own	O
colonizing	O
Streptococcus	B-bacteria
mitis	I-bacteria
biovar	I-bacteria
1	I-bacteria
(	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
bv	I-bacteria
1	I-bacteria
)	O
clones	O
(	O
ribotypes	O
)	O
.	O

Immunoblot	O
analysis	O
was	O
used	O
to	O
examine	O
reactivity	O
of	O
these	O
antibodies	O
with	O
persistent	O
ribotypes	O
isolated	O
from	O
the	O
mouths	O
of	O
the	O
infants	O
over	O
the	O
first	O
year	O
postpartum	O
.	O

Results	O
showed	O
that	O
the	O
pattern	O
of	O
SIgA	O
antibody	O
reactivity	O
with	O
the	O
majority	O
of	O
clones	O
increased	O
in	O
complexity	O
after	O
colonization	O
but	O
that	O
most	O
additional	O
bands	O
were	O
common	O
to	O
other	O
clones	O
,	O
indicating	O
that	O
they	O
represented	O
shared	O
antigens	O
.	O

However	O
,	O
unique	O
bands	O
were	O
identified	O
in	O
75	O
%	O
of	O
the	O
selected	O
persistent	O
clones	O
.	O

We	O
hypothesized	O
that	O
if	O
strain	O
-	O
specific	O
SIgA	O
antibody	O
was	O
induced	O
in	O
response	O
to	O
colonization	O
of	O
a	O
particular	O
clone	O
and	O
contributed	O
to	O
its	O
elimination	O
from	O
the	O
mouth	O
,	O
then	O
the	O
appearance	O
of	O
unique	O
bands	O
would	O
immediately	O
precede	O
the	O
disappearance	O
of	O
the	O
strain	O
.	O

Seventy	O
-	O
three	O
percent	O
of	O
all	O
unique	O
bands	O
identified	O
in	O
the	O
study	O
fulfilled	O
this	O
criterion	O
.	O

Because	O
the	O
mouth	O
is	O
an	O
open	O
,	O
dynamic	O
environment	O
and	O
multiple	O
factors	O
are	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
immune	O
response	O
at	O
mucosal	O
surfaces	O
,	O
it	O
may	O
not	O
be	O
possible	O
to	O
conclusively	O
define	O
the	O
relationship	O
between	O
SIgA	O
antibody	O
and	O
commensal	O
bacteria	O
.	O

However	O
,	O
our	O
data	O
provide	O
evidence	O
that	O
SIgA	O
antibody	O
,	O
reactive	O
with	O
unique	O
antigens	O
of	O
their	O
own	O
colonizing	O
strains	O
,	O
is	O
produced	O
in	O
infants	O
and	O
may	O
point	O
to	O
a	O
role	O
of	O
this	O
antibody	O
in	O
regulating	O
colonization	O
by	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
bv	I-bacteria
1	I-bacteria
.	O

The	O
effects	O
of	O
oral	O
commensal	O
streptococci	B-bacteria
(	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
,	O
and	O
Streptococcus	B-bacteria
salivarius	I-bacteria
)	O
on	O
biofilm	O
formation	O
by	O
cariogenic	O
mutans	B-bacteria
streptococci	I-bacteria
(	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
)	O
were	O
investigated	O
.	O

Cell	O
suspensions	O
were	O
cultured	O
on	O
96	O
-	O
well	O
microtiter	O
plates	O
coated	O
with	O
or	O
without	O
salivary	O
components	O
(	O
SC	O
)	O
,	O
and	O
in	O
flow	O
cell	O
systems	O
coated	O
with	O
SC	O
in	O
tryptic	O
soy	O
broth	O
including	O
0	O
.	O
25	O
%	O
sucrose	O
without	O
dextrose	O
(	O
TSB	O
)	O
.	O

The	O
resultant	O
biofilm	O
formations	O
were	O
stained	O
using	O
safranin	O
or	O
a	O
LIVE	O
/	O
DEAD	O
BacLight	O
Viability	O
Kit	O
,	O
and	O
examined	O
with	O
absorbance	O
at	O
492	O
nm	O
or	O
using	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

Mutans	B-bacteria
streptococci	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
biofilms	O
were	O
formed	O
significantly	O
on	O
the	O
polystyrene	O
surfaces	O
in	O
TSB	O
.	O

Further	O
,	O
in	O
combination	O
cultures	O
,	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
formed	O
a	O
sufficient	O
biofilm	O
when	O
cultured	O
with	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

However	O
,	O
when	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
was	O
cultured	O
with	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
,	O
biofilm	O
formation	O
was	O
slightly	O
inhibited	O
.	O

S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
also	O
inhibited	O
biofilm	O
formation	O
in	O
the	O
culture	O
with	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
,	O
but	O
not	O
when	O
cultured	O
with	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

S	B-bacteria
.	I-bacteria
mitis	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
collapsed	O
the	O
biofilm	O
morphology	O
and	O
inhibited	O
volume	O
development	O
in	O
some	O
conditions	O
when	O
cultured	O
with	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
or	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
.	O

Biofilm	O
formation	O
by	O
mutans	B-bacteria
streptococci	I-bacteria
was	O
challenged	O
and	O
collapsed	O
on	O
the	O
whole	O
by	O
culturing	O
with	O
each	O
of	O
the	O
other	O
oral	O
streptococci	B-bacteria
.	O

These	O
results	O
indicate	O
that	O
co	O
-	O
culturing	O
of	O
multiple	O
species	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
other	O
oral	O
streptococci	B-bacteria
has	O
physical	O
effects	O
related	O
to	O
previous	O
attachment	O
and	O
colonization	O
on	O
the	O
surface	O
,	O
as	O
well	O
as	O
biological	O
effects	O
to	O
regulate	O
biofilm	O
formation	O
.	O

We	O
identified	O
oral	O
bacterial	O
species	O
in	O
blood	O
cultures	O
following	O
single	O
-	O
tooth	O
extraction	O
and	O
tooth	O
brushing	O
.	O

Sequence	O
analysis	O
of	O
16S	O
rRNA	O
genes	O
identified	O
98	O
different	O
bacterial	O
species	O
recovered	O
from	O
151	O
bacteremic	O
subjects	O
.	O

Of	O
interest	O
,	O
48	O
of	O
the	O
isolates	O
represented	O
19	O
novel	O
species	O
of	O
Prevotella	B-bacteria
,	O
Fusobacterium	B-bacteria
,	O
Streptococcus	B-bacteria
,	O
Actinomyces	B-bacteria
,	O
Capnocytophaga	B-bacteria
,	O
Selenomonas	B-bacteria
,	O
and	O
Veillonella	B-bacteria
.	O

This	O
study	O
investigated	O
whether	O
an	O
improvement	O
in	O
periodontal	O
health	O
resulted	O
in	O
changes	O
in	O
the	O
prevalence	O
of	O
periodontopathogenic	O
bacteria	O
in	O
saliva	O
and	O
tongue	O
coatings	O
and	O
a	O
reduction	O
in	O
volatile	O
sulfur	O
compounds	O
(	O
VSCs	O
:	O
H	O
(	O
2	O
)	O
S	O
and	O
CH	O
(	O
3	O
)	O
SH	O
)	O
linked	O
to	O
oral	O
malodour	O
.	O

The	O
subjects	O
were	O
35	O
patients	O
who	O
visited	O
the	O
breath	O
odour	O
clinic	O
of	O
Kyushu	O
Dental	O
College	O
,	O
Japan	O
.	O

Their	O
mean	O
age	O
was	O
51	O
.	O
2	O
+	O
/	O
-	O
18	O
.	O
3	O
years	O
(	O
mean	O
+	O
/	O
-	O
sd	O
)	O
.	O

A	O
clinical	O
examination	O
performed	O
at	O
baseline	O
and	O
2	O
months	O
after	O
periodontal	O
treatment	O
assessed	O
VSCs	O
in	O
mouth	O
air	O
using	O
gas	O
chromatography	O
,	O
periodontal	O
probing	O
depth	O
and	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
in	O
all	O
subjects	O
;	O
saliva	O
and	O
tongue	O
coatings	O
were	O
also	O
collected	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
samples	O
,	O
and	O
the	O
proportions	O
of	O
five	O
periodontopathogenic	O
bacteria	O
(	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
and	O
Prevotella	B-bacteria
nigrescens	I-bacteria
)	O
were	O
investigated	O
using	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

The	O
subjects	O
were	O
classified	O
into	O
four	O
groups	O
based	O
on	O
the	O
presence	O
of	O
a	O
periodontal	O
pocket	O
of	O
more	O
than	O
4	O
mm	O
(	O
PD	O
)	O
and	O
VSCs	O
above	O
the	O
organoleptic	O
threshold	O
level	O
(	O
VSCT	O
)	O
as	O
follows	O
:	O
-	O
PD	O
/	O
-	O
VSCT	O
group	O
,	O
subjects	O
without	O
PD	O
or	O
VSCT	O
;	O
-	O
PD	O
/	O
+	O
VSCT	O
group	O
,	O
those	O
without	O
PD	O
but	O
with	O
VSCT	O
;	O
+	O
PD	O
/	O
-	O
VSCT	O
group	O
,	O
those	O
with	O
PD	O
but	O
without	O
VSCT	O
;	O
and	O
+	O
PD	O
/	O
+	O
VSCT	O
group	O
,	O
those	O
with	O
PD	O
and	O
VSCT	O
.	O

Although	O
the	O
mean	O
PD	O
values	O
in	O
the	O
+	O
PD	O
/	O
-	O
VSCT	O
and	O
+	O
PD	O
/	O
+	O
VSCT	O
groups	O
,	O
BOP	O
in	O
the	O
+	O
PD	O
/	O
+	O
VSCT	O
group	O
,	O
and	O
H	O
(	O
2	O
)	O
S	O
and	O
CH	O
(	O
3	O
)	O
SH	O
concentrations	O
in	O
the	O
-	O
PD	O
/	O
+	O
VSCT	O
and	O
+	O
PD	O
/	O
+	O
VSCT	O
groups	O
were	O
greater	O
than	O
in	O
the	O
other	O
groups	O
at	O
baseline	O
,	O
we	O
found	O
no	O
significant	O
difference	O
among	O
the	O
four	O
groups	O
after	O
periodontal	O
treatment	O
.	O

The	O
proportion	O
of	O
periodontopathogenic	O
bacteria	O
in	O
saliva	O
was	O
higher	O
in	O
the	O
+	O
PD	O
/	O
-	O
VSCT	O
and	O
+	O
PD	O
/	O
+	O
VSCT	O
groups	O
than	O
in	O
the	O
-	O
PD	O
/	O
-	O
VSCT	O
and	O
-	O
PD	O
/	O
+	O
VSCT	O
groups	O
at	O
baseline	O
and	O
after	O
treatment	O
,	O
but	O
the	O
proportions	O
of	O
bacteria	O
in	O
saliva	O
after	O
treatment	O
were	O
reduced	O
compared	O
to	O
the	O
baseline	O
.	O

Furthermore	O
,	O
the	O
differences	O
in	O
the	O
proportions	O
of	O
the	O
five	O
target	O
bacteria	O
in	O
the	O
tongue	O
coating	O
were	O
not	O
as	O
apparent	O
as	O
those	O
in	O
saliva	O
at	O
baseline	O
or	O
after	O
treatment	O
.	O

The	O
prevalence	O
of	O
periodontopathogenic	O
bacteria	O
in	O
saliva	O
may	O
reflect	O
periodontal	O
health	O
status	O
and	O
influence	O
VSC	O
levels	O
in	O
mouth	O
air	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
while	O
performing	O
the	O
(	O
14	O
)	O
C	O
-	O
urea	O
breath	O
test	O
(	O
(	O
14	O
)	O
C	O
-	O
UBT	O
)	O
for	O
the	O
detection	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
(	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
)	O
,	O
there	O
is	O
possibility	O
of	O
false	O
-	O
positive	O
results	O
due	O
to	O
the	O
other	O
urease	O
producing	O
bacteria	O
present	O
in	O
oropharynx	O
,	O
if	O
breath	O
samples	O
are	O
obtained	O
within	O
30	O
min	O
after	O
administration	O
of	O
non	O
-	O
capsulated	O
(	O
14	O
)	O
C	O
-	O
urea	O
.	O

Therefore	O
,	O
we	O
have	O
exclusively	O
evaluated	O
the	O
kinetics	O
of	O
(	O
14	O
)	O
carbon	O
dioxide	O
(	O
(	O
14	O
)	O
CO	O
(	O
2	O
)	O
)	O
excretion	O
by	O
oral	O
commensal	O
flora	O
to	O
theoretically	O
propose	O
optimum	O
breath	O
collection	O
timings	O
for	O
(	O
14	O
)	O
C	O
-	O
UBT	O
.	O

Multiple	O
breath	O
samples	O
up	O
to	O
15	O
min	O
were	O
collected	O
in	O
0	O
.	O
25	O
mmol	O
benzethonium	O
hydroxide	O
from	O
25	O
healthy	O
volunteers	O
after	O
they	O
withheld	O
37	O
kBq	O
(	O
1	O
muCi	O
)	O
of	O
(	O
14	O
)	O
C	O
-	O
urea	O
in	O
their	O
mouths	O
for	O
15	O
s	O
and	O
then	O
expectorated	O
the	O
tracer	O
.	O

The	O
test	O
was	O
repeated	O
on	O
the	O
same	O
subjects	O
without	O
and	O
with	O
mouth	O
cleansing	O
protocols	O
.	O

Breath	O
(	O
14	O
)	O
CO	O
(	O
2	O
)	O
content	O
was	O
measured	O
by	O
the	O
Liquid	O
Scintillation	O
Counter	O
(	O
1409	O
;	O
Wallac	O
,	O
Turku	O
,	O
Finland	O
)	O
and	O
results	O
were	O
expressed	O
as	O
(	O
14	O
)	O
CO	O
(	O
2	O
)	O
excretion	O
per	O
mmol	O
breath	O
CO	O
(	O
2	O
)	O
(	O
%	O
administered	O
dose	O
)	O
.	O

Peak	O
breath	O
radioactivity	O
at	O
1	O
min	O
in	O
the	O
former	O
protocol	O
was	O
3	O
.	O
53	O
times	O
higher	O
than	O
the	O
latter	O
which	O
declined	O
subsequently	O
with	O
a	O
half	O
time	O
of	O
1	O
min	O
and	O
2	O
.	O
5	O
min	O
,	O
and	O
reached	O
baseline	O
levels	O
by	O
15	O
and	O
10	O
min	O
,	O
respectively	O
.	O

The	O
peak	O
radioactivity	O
(	O
100	O
%	O
)	O
at	O
1	O
min	O
declined	O
by	O
94	O
%	O
and	O
97	O
.	O
8	O
%	O
in	O
the	O
former	O
and	O
later	O
protocols	O
,	O
respectively	O
,	O
at	O
15	O
min	O
.	O

Although	O
magnitude	O
of	O
the	O
peak	O
varied	O
in	O
different	O
subjects	O
,	O
the	O
shape	O
of	O
curve	O
remained	O
almost	O
similar	O
in	O
all	O
cases	O
.	O

Without	O
mouth	O
cleansing	O
,	O
oral	O
micro	O
flora	O
excreted	O
more	O
(	O
14	O
)	O
CO	O
(	O
2	O
)	O
up	O
to	O
15	O
min	O
after	O
administration	O
of	O
non	O
-	O
capsulated	O
(	O
14	O
)	O
C	O
-	O
urea	O
.	O

Therefore	O
,	O
it	O
is	O
proposed	O
that	O
two	O
breath	O
samples	O
may	O
be	O
obtained	O
either	O
at	O
15	O
and	O
20	O
min	O
without	O
or	O
at	O
10	O
and	O
15	O
min	O
with	O
mouth	O
cleansing	O
protocols	O
for	O
reliable	O
analysis	O
of	O
(	O
14	O
)	O
C	O
-	O
UBT	O
data	O
for	O
H	O
.	O
pylori	O
detection	O
.	O

The	O
induction	O
of	O
tissue	O
-	O
destructive	O
molecules	O
from	O
neutrophils	O
by	O
periodontopathic	O
bacteria	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
mechanisms	O
of	O
periodontal	O
destruction	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
ability	O
to	O
stimulate	O
neutrophils	O
is	O
an	O
authentic	O
characteristic	O
of	O
periodontopathic	O
bacteria	O
.	O

We	O
evaluated	O
,	O
along	O
with	O
phagocytosis	O
,	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
matrix	O
metalloproteinase	O
-	O
8	O
(	O
MMP	O
-	O
8	O
)	O
,	O
and	O
interleukin	O
-	O
1beta	O
by	O
neutrophils	O
in	O
response	O
to	O
non	O
-	O
periodontopathic	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
and	O
periodontopathic	O
bacteria	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
and	O
Treponema	B-bacteria
denticola	I-bacteria
,	O
in	O
the	O
absence	O
or	O
presence	O
of	O
antibodies	O
.	O

Phagocytosis	O
,	O
the	O
death	O
of	O
neutrophils	O
,	O
and	O
intracellular	O
ROS	O
production	O
were	O
measured	O
by	O
flow	O
cytometry	O
and	O
the	O
concentrations	O
of	O
MMP	O
-	O
8	O
and	O
interleukin	O
-	O
1beta	O
secreted	O
into	O
medium	O
were	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
induced	O
greater	O
production	O
of	O
ROS	O
,	O
MMP	O
-	O
8	O
,	O
and	O
interleukin	O
-	O
1beta	O
than	O
did	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
.	O

The	O
levels	O
of	O
tissue	O
-	O
destructive	O
molecules	O
produced	O
by	O
neutrophils	O
had	O
a	O
positive	O
correlation	O
with	O
phagocytosis	O
.	O

Opsonization	O
of	O
bacteria	O
with	O
antibodies	O
significantly	O
increased	O
phagocytosis	O
and	O
ROS	O
production	O
and	O
release	O
,	O
thus	O
increasing	O
both	O
bacterial	O
clearance	O
and	O
potential	O
tissue	O
damage	O
.	O

The	O
ability	O
of	O
oral	O
bacteria	O
to	O
induce	O
tissue	O
-	O
destructive	O
molecules	O
from	O
neutrophils	O
is	O
not	O
an	O
inherent	O
characteristic	O
of	O
periodontopathic	O
bacteria	O
,	O
which	O
would	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
neutrophils	O
in	O
periodontal	O
destruction	O
.	O

To	O
investigate	O
foam	O
generation	O
during	O
brushing	O
,	O
and	O
the	O
oral	O
debris	O
and	O
bacteria	O
removal	O
efficacy	O
of	O
an	O
experimental	O
gel	O
-	O
to	O
-	O
foam	O
dentifrice	O
compared	O
to	O
a	O
commercially	O
-	O
available	O
dentifrice	O
after	O
brushing	O
.	O

Thirty	O
-	O
four	O
subjects	O
participated	O
in	O
this	O
blinded	O
,	O
crossover	O
study	O
.	O

After	O
a	O
wash	O
-	O
out	O
period	O
prior	O
to	O
each	O
session	O
of	O
product	O
use	O
,	O
subjects	O
reported	O
to	O
the	O
site	O
having	O
abstained	O
from	O
oral	O
hygiene	O
,	O
eating	O
and	O
drinking	O
from	O
22	O
:	O
00	O
h	O
on	O
the	O
evening	O
prior	O
to	O
treatment	O
visits	O
.	O

The	O
subjects	O
brushed	O
with	O
a	O
weighed	O
dose	O
of	O
assigned	O
paste	O
and	O
were	O
asked	O
to	O
expectorate	O
their	O
toothpaste	O
slurry	O
into	O
a	O
collection	O
vessel	O
at	O
30	O
and	O
60	O
seconds	O
during	O
supervised	O
brushing	O
.	O

The	O
expectorated	O
foam	O
was	O
measured	O
immediately	O
,	O
after	O
which	O
subjects	O
rinsed	O
with	O
10	O
ml	O
of	O
sterile	O
water	O
and	O
expectorated	O
into	O
the	O
same	O
vessel	O
.	O

Samples	O
were	O
placed	O
on	O
ice	O
and	O
immediately	O
transported	O
to	O
the	O
laboratory	O
for	O
analysis	O
.	O

Bacteria	O
(	O
total	O
anaerobes	O
and	O
VSC	O
-	O
producing	O
bacteria	O
)	O
were	O
enumerated	O
using	O
appropriate	O
selective	O
media	O
.	O

To	O
calculate	O
the	O
amount	O
of	O
debris	O
,	O
a	O
measured	O
portion	O
of	O
the	O
sample	O
was	O
deposited	O
onto	O
a	O
pre	O
-	O
weighed	O
dish	O
and	O
weighed	O
.	O

Dishes	O
were	O
dried	O
thoroughly	O
and	O
weighed	O
again	O
after	O
cooling	O
.	O

Use	O
of	O
the	O
gel	O
-	O
to	O
-	O
foam	O
dentifrice	O
resulted	O
in	O
105	O
%	O
greater	O
foam	O
volume	O
compared	O
with	O
use	O
of	O
the	O
control	O
dentifrice	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Further	O
,	O
the	O
gel	O
-	O
to	O
-	O
foam	O
dentifrice	O
removed	O
15	O
.	O
77	O
%	O
more	O
debris	O
than	O
the	O
control	O
dentifrice	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
0342	O
)	O
.	O

There	O
was	O
greater	O
removal	O
of	O
total	O
anaerobes	O
and	O
VSC	O
-	O
producing	O
bacteria	O
by	O
the	O
gel	O
-	O
to	O
-	O
foam	O
dentifrice	O
versus	O
the	O
control	O
dentifrice	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
)	O
.	O

Single	O
use	O
of	O
a	O
gel	O
-	O
to	O
-	O
foam	O
dentifrice	O
generated	O
a	O
greater	O
volume	O
of	O
foam	O
and	O
removed	O
a	O
greater	O
amount	O
of	O
oral	O
debris	O
and	O
bacteria	O
during	O
brushing	O
than	O
a	O
standard	O
dentifrice	O
.	O

To	O
investigate	O
the	O
topographic	O
distribution	O
of	O
bacterial	O
types	O
and	O
loads	O
associated	O
with	O
mid	O
-	O
morning	O
oral	O
malodour	O
on	O
the	O
tongue	O
surface	O
.	O

Fifty	O
subjects	O
with	O
good	O
oral	O
health	O
and	O
at	O
least	O
20	O
natural	O
uncrowned	O
teeth	O
were	O
included	O
.	O

Samples	O
were	O
taken	O
with	O
sterile	O
brushes	O
from	O
the	O
dorsal	O
anterior	O
(	O
DA	O
)	O
,	O
dorsal	O
middle	O
(	O
DM	O
)	O
,	O
dorsal	O
posterior	O
(	O
DP	O
)	O
,	O
dorsal	O
posterior	O
to	O
the	O
circumvallate	O
papillae	O
(	O
DPCP	O
)	O
,	O
lateral	O
posterior	O
(	O
LP	O
)	O
and	O
ventral	O
posterior	O
(	O
VP	O
)	O
tongue	O
surfaces	O
.	O

Samples	O
were	O
cultured	O
on	O
appropriate	O
media	O
for	O
anaerobic	O
bacteria	O
,	O
aerobic	O
bacteria	O
,	O
Gram	O
-	O
negative	O
anaerobic	O
bacteria	O
,	O
volatile	O
sulphur	O
compound	O
(	O
VSC	O
)	O
-	O
producing	O
bacteria	O
and	O
Streptococcus	B-bacteria
saliuarius	I-bacteria
.	O

Malodour	O
was	O
assessed	O
by	O
trained	O
judges	O
on	O
an	O
intensity	O
basis	O
.	O

The	O
counts	O
of	O
all	O
bacterial	O
groups	O
were	O
consistently	O
highest	O
at	O
the	O
DPCP	O
surface	O
.	O

Mean	O
VSC	O
-	O
producing	O
bacterial	O
counts	O
(	O
colony	O
forming	O
units	O
/	O
brush	O
x10	O
(	O
5	O
)	O
)	O
were	O
1	O
.	O
45	O
,	O
5	O
.	O
67	O
,	O
32	O
.	O
52	O
,	O
88	O
.	O
94	O
,	O
6	O
.	O
46	O
and	O
0	O
.	O
33	O
at	O
DA	O
,	O
DM	O
,	O
DP	O
,	O
DPCP	O
,	O
LP	O
and	O
VP	O
surfaces	O
,	O
respectively	O
.	O

Anaerobic	O
,	O
Gram	O
-	O
negative	O
and	O
VSC	O
counts	O
at	O
DPCP	O
surfaces	O
increased	O
with	O
malodour	O
intensity	O
,	O
whereas	O
aerobic	O
and	O
S	B-bacteria
.	I-bacteria
saliuarius	I-bacteria
counts	O
decreased	O
;	O
however	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

It	O
is	O
concluded	O
that	O
the	O
DPCP	O
area	O
consistently	O
carries	O
the	O
highest	O
load	O
of	O
bacteria	O
capable	O
of	O
contributing	O
to	O
oral	O
malodour	O
.	O

The	O
study	O
demonstrates	O
that	O
tongue	O
surfaces	O
not	O
accessible	O
to	O
routine	O
oral	O
hygiene	O
procedures	O
can	O
significantly	O
contribute	O
to	O
oral	O
malodour	O
.	O

We	O
isolated	O
oral	O
bacteria	O
that	O
coexisted	O
with	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
in	O
a	O
hamster	O
periodontitis	O
model	O
.	O

As	O
predominant	O
bacteria	O
in	O
the	O
periodontitis	O
site	O
,	O
Collinsella	O
-	O
reltaed	O
strains	O
,	O
Eubacterium	O
-	O
reltaed	O
strains	O
,	O
Streptococcus	O
suis	O
-	O
related	O
strains	O
,	O
and	O
Veillonella	O
parvula	O
-	O
reltaed	O
strains	O
were	O
detected	O
.	O

In	O
addition	O
,	O
Actinomyces	B-bacteria
,	O
Bacteroides	B-bacteria
,	O
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
were	O
also	O
isolated	O
predominantly	O
.	O

The	O
results	O
suggest	O
that	O
the	O
bacterial	O
composition	O
of	O
the	O
periodontitis	O
site	O
in	O
hamsters	O
is	O
complex	O
,	O
as	O
in	O
human	O
periodontitis	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
compound	O
light	O
yellow	O
Sophora	O
root	O
collutory	O
on	O
oral	O
erosive	O
lichen	O
planus	O
and	O
analyze	O
the	O
salivary	O
microbial	O
contents	O
and	O
proportion	O
.	O

30	O
patients	O
with	O
oral	O
erosive	O
lichen	O
planus	O
were	O
chosen	O
and	O
treated	O
with	O
compound	O
light	O
yellow	O
Sophora	O
root	O
collutory	O
.	O

Pain	O
index	O
and	O
clinical	O
symptoms	O
were	O
observed	O
,	O
the	O
changes	O
of	O
quantity	O
and	O
proportion	O
of	O
salivary	O
bacteria	O
were	O
investigated	O
before	O
and	O
after	O
taking	O
drugs	O
.	O

SAS6	O
.	O
12	O
software	O
package	O
was	O
used	O
for	O
statistical	O
analysis	O
.	O

The	O
extravasate	O
and	O
congest	O
of	O
the	O
erosive	O
mucous	O
membrane	O
were	O
relieved	O
.	O

The	O
pain	O
caused	O
by	O
erosion	O
were	O
significantly	O
relieved	O
after	O
taking	O
the	O
drugs	O
.	O

The	O
quantity	O
of	O
oral	O
Staphylococcus	B-bacteria
was	O
significantly	O
decreased	O
after	O
taking	O
the	O
drugs	O
.	O

Oral	O
Staphylococcus	B-bacteria
can	O
be	O
inhibited	O
by	O
light	O
yellow	O
Sophora	O
root	O
collutory	O
.	O

The	O
use	O
of	O
compound	O
light	O
yellow	O
Sophora	O
root	O
collutory	O
is	O
one	O
of	O
the	O
safe	O
and	O
effective	O
local	O
therapies	O
on	O
oral	O
lichen	O
planus	O
.	O

In	O
recent	O
years	O
,	O
patients	O
have	O
benefited	O
from	O
the	O
development	O
of	O
better	O
and	O
more	O
esthetic	O
materials	O
,	O
including	O
all	O
-	O
ceramics	O
dental	O
restorative	O
materials	O
.	O

Dental	O
plaque	O
formation	O
on	O
teeth	O
and	O
restorative	O
materials	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
oral	O
diseases	O
.	O

This	O
study	O
investigates	O
initial	O
adhesion	O
of	O
stationary	O
phase	O
streptococcal	B-bacteria
species	I-bacteria
to	O
different	O
all	O
-	O
ceramics	O
dental	O
restorative	O
materials	O
.	O

The	O
saliva	O
-	O
coated	O
materials	O
were	O
incubated	O
with	O
the	O
bacteria	O
for	O
1	O
h	O
in	O
an	O
in	O
vitro	O
flow	O
chamber	O
which	O
mimics	O
environmental	O
conditions	O
in	O
the	O
oral	O
cavity	O
.	O

Number	O
and	O
vitality	O
of	O
adhering	O
bacteria	O
were	O
determined	O
microscopically	O
after	O
staining	O
.	O

Surface	O
roughness	O
and	O
the	O
composition	O
of	O
the	O
materials	O
had	O
no	O
distinctive	O
influence	O
on	O
bacterial	O
adhesion	O
.	O

However	O
,	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
adhered	O
about	O
tenfold	O
less	O
numerous	O
to	O
all	O
materials	O
than	O
the	O
other	O
streptococcal	B-bacteria
species	I-bacteria
.	O

Further	O
,	O
there	O
was	O
a	O
correlation	O
between	O
bacterial	O
vitality	O
and	O
materials	O
'	O
glass	O
content	O
.	O

The	O
results	O
showed	O
that	O
early	O
plaque	O
formation	O
was	O
influenced	O
predominantly	O
by	O
the	O
presence	O
of	O
the	O
salivary	O
pellicle	O
rather	O
than	O
by	O
material	O
dependent	O
parameters	O
whereas	O
the	O
composition	O
of	O
the	O
all	O
-	O
ceramics	O
appeared	O
to	O
have	O
influenced	O
the	O
percentage	O
of	O
viable	O
cells	O
during	O
the	O
adhesion	O
process	O
.	O

This	O
presented	O
in	O
vitro	O
technique	O
may	O
provide	O
a	O
useful	O
model	O
to	O
study	O
the	O
influence	O
of	O
different	O
parameters	O
on	O
adherence	O
of	O
oral	O
streptococcal	B-bacteria
species	I-bacteria
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
initially	O
colonizes	O
the	O
oral	O
cavity	O
by	O
interacting	O
with	O
organisms	O
in	O
supragingival	O
plaque	O
,	O
such	O
as	O
the	O
oralis	O
group	O
of	O
oral	O
streptococci	B-bacteria
.	O

This	O
interaction	O
involves	O
the	O
association	O
of	O
the	O
streptococcal	O
antigen	O
I	O
/	O
II	O
with	O
the	O
minor	O
fimbrial	O
antigen	O
(	O
Mfa1	O
)	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

Our	O
previous	O
studies	O
showed	O
that	O
a	O
peptide	O
(	O
BAR	O
)	O
derived	O
from	O
antigen	O
I	O
/	O
II	O
inhibits	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
adherence	O
and	O
subsequent	O
biofilm	O
formation	O
on	O
streptococcal	O
substrates	O
.	O

In	O
addition	O
,	O
screening	O
a	O
combinatorial	O
peptide	O
library	O
identified	O
select	O
amino	O
acid	O
substitutions	O
in	O
the	O
NITVK	O
active	O
region	O
of	O
BAR	O
that	O
increased	O
the	O
adherence	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
to	O
streptococci	B-bacteria
.	O

Here	O
we	O
report	O
that	O
incorporating	O
these	O
residues	O
in	O
a	O
synthetic	O
peptide	O
results	O
in	O
more	O
-	O
potent	O
inhibition	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
adherence	O
and	O
biofilm	O
formation	O
(	O
I	O
(	O
50	O
)	O
[	O
50	O
%	O
inhibition	O
]	O
at	O
0	O
.	O
52	O
microM	O
versus	O
I	O
(	O
50	O
)	O
at	O
1	O
.	O
25	O
microM	O
for	O
BAR	O
)	O
.	O

In	O
addition	O
,	O
a	O
second	O
structural	O
motif	O
in	O
BAR	O
,	O
comprised	O
of	O
the	O
amino	O
acids	O
KKVQDLLKK	O
,	O
was	O
shown	O
to	O
contribute	O
to	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
adherence	O
to	O
streptococci	B-bacteria
.	O

Consistent	O
with	O
this	O
,	O
the	O
KKVQDLLKK	O
and	O
NITVK	O
motifs	O
are	O
conserved	O
only	O
in	O
antigen	O
I	O
/	O
II	O
proteins	O
expressed	O
by	O
the	O
oralis	O
group	O
of	O
streptococci	B-bacteria
,	O
which	O
interact	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

Interestingly	O
,	O
the	O
primary	O
and	O
secondary	O
structures	O
and	O
the	O
functional	O
characteristics	O
of	O
the	O
amphipathic	O
VQDLL	O
core	O
alpha	O
-	O
helix	O
resemble	O
the	O
consensus	O
nuclear	O
receptor	O
(	O
NR	O
)	O
box	O
protein	O
-	O
protein	O
interacting	O
domain	O
sequence	O
(	O
LXXLL	O
)	O
of	O
eukaryotes	O
.	O

BAR	O
peptides	O
containing	O
amino	O
acid	O
substitutions	O
with	O
the	O
potential	O
to	O
disrupt	O
the	O
secondary	O
structure	O
of	O
VQDLL	O
were	O
less	O
-	O
effective	O
inhibitors	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
adherence	O
and	O
biofilm	O
formation	O
,	O
suggesting	O
that	O
the	O
alpha	O
-	O
helical	O
character	O
of	O
VQDLL	O
is	O
important	O
.	O

Furthermore	O
,	O
replacing	O
the	O
lysines	O
that	O
flank	O
VQDLL	O
with	O
acidic	O
amino	O
acids	O
also	O
reduced	O
inhibitory	O
activity	O
,	O
suggesting	O
that	O
the	O
association	O
of	O
VQDLL	O
with	O
Mfa1	O
may	O
be	O
stabilized	O
by	O
a	O
charge	O
clamp	O
.	O

These	O
results	O
indicate	O
that	O
the	O
Mfa1	O
-	O
interacting	O
interface	O
of	O
streptococcal	B-bacteria
antigen	O
I	O
/	O
II	O
encompasses	O
both	O
the	O
KKVQDLLKK	O
and	O
NITVK	O
motif	O
and	O
suggest	O
that	O
the	O
adherence	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
to	O
streptococci	B-bacteria
is	O
driven	O
by	O
a	O
protein	O
-	O
protein	O
interaction	O
domain	O
that	O
resembles	O
the	O
eukaryotic	O
NR	O
box	O
.	O

Thus	O
,	O
both	O
motifs	O
must	O
be	O
taken	O
into	O
account	O
in	O
designing	O
potential	O
peptidomimetics	O
that	O
target	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
adherence	O
and	O
biofilm	O
formation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
two	O
different	O
methods	O
of	O
identifying	O
oral	O
bacteri	O
from	O
blood	O
samples	O
after	O
dental	O
extractions	O
.	O

Blood	O
cultures	O
were	O
taken	O
before	O
,	O
during	O
,	O
and	O
after	O
a	O
single	O
tooth	O
extraction	O
in	O
30	O
subjects	O
and	O
cultured	O
using	O
aerobic	O
and	O
anaerobic	O
Bactec	O
media	O
.	O

Positive	O
cultures	O
from	O
22	O
subjects	O
were	O
subcultured	O
on	O
selective	O
and	O
nonselective	O
media	O
,	O
resulting	O
in	O
58	O
isolates	O
.	O

Bacterial	O
identification	O
was	O
performed	O
by	O
biochemical	O
analysis	O
and	O
sequence	O
analysis	O
of	O
16S	O
rRNA	O
gene	O
.	O

Of	O
the	O
58	O
isolates	O
,	O
only	O
10	O
(	O
17	O
%	O
)	O
were	O
the	O
same	O
species	O
by	O
both	O
methods	O
.	O

Thirty	O
-	O
two	O
(	O
55	O
%	O
)	O
belonged	O
to	O
the	O
same	O
genus	O
but	O
different	O
species	O
,	O
and	O
16	O
(	O
28	O
%	O
)	O
showed	O
no	O
correlation	O
at	O
all	O
.	O

There	O
were	O
31	O
and	O
40	O
diverse	O
species	O
by	O
the	O
biochemical	O
and	O
the	O
sequencing	O
methods	O
,	O
respectively	O
.	O

Streptococci	B-bacteria
were	O
the	O
dominant	O
species	O
.	O

DNA	O
sequencing	O
results	O
in	O
more	O
accurate	O
identification	O
and	O
a	O
more	O
diverse	O
population	O
of	O
bacteria	O
from	O
bacteremia	O
following	O
dental	O
extractions	O
.	O

Silent	O
aspiration	O
of	O
oropharyngeal	O
pathogenic	O
organisms	O
is	O
a	O
significant	O
risk	O
factor	O
causing	O
pneumonia	O
in	O
the	O
elderly	O
.	O

We	O
hypothesized	O
that	O
regular	O
oral	O
hygiene	O
care	O
will	O
affect	O
the	O
presence	O
of	O
oropharyngeal	O
bacteria	O
.	O

Professional	O
cleaning	O
of	O
the	O
oral	O
cavity	O
and	O
/	O
or	O
the	O
gargling	O
of	O
a	O
disinfectant	O
liquid	O
solution	O
was	O
performed	O
over	O
a	O
five	O
-	O
month	O
period	O
in	O
three	O
facilities	O
for	O
the	O
dependent	O
elderly	O
.	O

Total	O
oropharyngeal	O
bacteria	O
,	O
streptococci	B-bacteria
,	O
staphylococci	B-bacteria
,	O
Candida	O
,	O
Pseudomonas	B-bacteria
,	O
and	O
black	O
-	O
pigmented	O
Bacteroides	B-bacteria
species	I-bacteria
were	O
monitored	O
.	O

The	O
levels	O
of	O
these	O
oropharyngeal	O
bacteria	O
decreased	O
or	O
disappeared	O
after	O
weekly	O
professional	O
oral	O
health	O
care	O
,	O
i	O
.	O
e	O
.	O
,	O
cleaning	O
of	O
teeth	O
,	O
dentures	O
,	O
tongue	O
,	O
and	O
oral	O
mucous	O
membrane	O
by	O
dental	O
hygienists	O
.	O

After	O
lunch	O
,	O
gargling	O
with	O
povidone	O
iodine	O
was	O
shown	O
to	O
be	O
less	O
effective	O
than	O
professional	O
oral	O
care	O
.	O

These	O
findings	O
indicate	O
that	O
weekly	O
professional	O
mechanical	O
cleaning	O
of	O
the	O
oral	O
cavity	O
,	O
rather	O
than	O
a	O
daily	O
chemical	O
disinfection	O
of	O
the	O
mouth	O
,	O
can	O
be	O
an	O
important	O
strategy	O
to	O
prevent	O
aspiration	O
pneumonia	O
in	O
the	O
dependent	O
elderly	O
.	O

Oral	O
viridans	B-bacteria
streptococci	I-bacteria
are	O
a	O
reservoir	O
of	O
resistance	O
genes	O
for	O
pathogens	O
.	O

Through	O
prolonged	O
exposure	O
,	O
long	O
-	O
acting	O
macrolides	O
(	O
e	O
.	O
g	O
.	O
,	O
azithromycin	O
)	O
may	O
induce	O
the	O
resistance	O
of	O
the	O
commensals	O
to	O
macrolides	O
more	O
frequently	O
than	O
macrolides	O
with	O
a	O
shorter	O
half	O
-	O
life	O
(	O
e	O
.	O
g	O
.	O
,	O
clarithromycin	O
)	O
.	O

In	O
a	O
prospective	O
,	O
randomized	O
,	O
evaluator	O
-	O
blinded	O
trial	O
in	O
healthy	O
volunteers	O
receiving	O
standard	O
courses	O
of	O
either	O
azithromycin	O
(	O
n	O
=	O
20	O
)	O
or	O
clarithromycin	O
(	O
n	O
=	O
20	O
)	O
,	O
we	O
compared	O
the	O
susceptibility	O
of	O
oral	O
viridans	B-bacteria
streptococci	I-bacteria
to	O
macrolides	O
over	O
a	O
period	O
of	O
12	O
weeks	O
.	O

There	O
was	O
a	O
significant	O
temporal	O
increase	O
in	O
the	O
numbers	O
of	O
resistant	O
isolates	O
in	O
both	O
groups	O
(	O
p	O
<	O
0	O
.	O
0005	O
at	O
week	O
1	O
)	O
.	O

The	O
proportion	O
of	O
macrolide	O
-	O
resistant	O
isolates	O
over	O
time	O
was	O
significantly	O
higher	O
following	O
azithromycin	O
treatment	O
(	O
p	O
=	O
0	O
.	O
0005	O
)	O
,	O
but	O
returned	O
to	O
baseline	O
values	O
until	O
week	O
12	O
in	O
both	O
groups	O
.	O

Temporal	O
differential	O
effects	O
of	O
azithromycin	O
and	O
clarithromycin	O
on	O
the	O
induction	O
of	O
resistance	O
were	O
observed	O
and	O
need	O
to	O
be	O
investigated	O
regarding	O
their	O
effect	O
on	O
co	O
-	O
colonizing	O
pathogens	O
.	O

A	O
relationship	O
between	O
the	O
distribution	O
of	O
periodontal	O
bacteria	O
species	O
and	O
malodor	O
in	O
children	O
has	O
not	O
been	O
sufficiently	O
investigated	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
presence	O
of	O
3	O
periodontopathic	O
bacteria	O
(	O
Prevotella	B-bacteria
spp	I-bacteria
.	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
melaninogenica	I-bacteria
)	O
in	O
the	O
supragingival	O
plaques	O
of	O
3	O
to	O
16	O
-	O
year	O
-	O
old	O
children	O
with	O
different	O
oral	O
health	O
conditions	O
and	O
oral	O
malodor	O
.	O

The	O
number	O
of	O
decayed	O
and	O
filled	O
primary	O
teeth	O
(	O
df	O
)	O
and	O
Decayed	O
,	O
Missing	O
and	O
Filled	O
permanent	O
teeth	O
(	O
DMF	O
)	O
,	O
Papillary	O
Marginal	O
and	O
Attached	O
gingivitis	O
(	O
PMA	O
)	O
index	O
,	O
Oral	O
Hygiene	O
Index	O
(	O
OHI	O
)	O
,	O
and	O
oral	O
malodor	O
of	O
each	O
subject	O
were	O
determined	O
prior	O
to	O
the	O
collection	O
of	O
supragingival	O
plaques	O
.	O

Three	O
periodontopathic	O
bacteria	O
(	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
melaninogenica	I-bacteria
)	O
in	O
supragingival	O
plaques	O
were	O
detected	O
by	O
using	O
an	O
immunoslot	O
blot	O
assay	O
with	O
monoclonal	O
antibodies	O
specific	O
for	O
each	O
microorganism	O
.	O

The	O
frequencies	O
of	O
periodontopathic	O
bacteria	O
in	O
children	O
with	O
and	O
without	O
caries	O
were	O
not	O
significantly	O
different	O
from	O
each	O
other	O
.	O

Positivity	O
for	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
but	O
not	O
for	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
or	O
P	B-bacteria
.	I-bacteria
melaninogenica	I-bacteria
was	O
correlated	O
with	O
oral	O
malodor	O
.	O

Oral	O
malodor	O
was	O
also	O
correlated	O
with	O
the	O
debris	O
index	O
,	O
a	O
component	O
of	O
OHI	O
.	O

The	O
group	O
with	O
the	O
higher	O
OHI	O
showed	O
a	O
higher	O
prevalence	O
of	O
periodontopathic	O
bacteria	O
.	O

For	O
the	O
3	O
periodontopathic	O
bacteria	O
in	O
the	O
subjects	O
tested	O
,	O
plaques	O
positive	O
for	O
any	O
of	O
them	O
were	O
not	O
age	O
related	O
.	O

However	O
the	O
frequencies	O
of	O
all	O
3	O
periodontopathic	O
bacteria	O
were	O
the	O
highest	O
in	O
the	O
3	O
-	O
6	O
-	O
year	O
olds	O
.	O

The	O
supragingival	O
plaques	O
in	O
children	O
can	O
harbor	O
3	O
species	O
of	O
periodontopathic	O
bacteria	O
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
,	O
and	O
P	B-bacteria
.	I-bacteria
melaninogenica	I-bacteria
.	O

The	O
aim	O
of	O
this	O
in	O
vitro	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
nicotine	O
,	O
cotinine	O
,	O
and	O
caffeine	O
on	O
the	O
viability	O
of	O
some	O
oral	O
bacterial	O
species	O
.	O

It	O
also	O
evaluated	O
the	O
ability	O
of	O
these	O
bacteria	O
to	O
metabolize	O
those	O
substances	O
.	O

Single	O
-	O
species	O
biofilms	O
of	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
or	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
and	O
dual	O
-	O
species	O
biofilms	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
-	O
-	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
-	O
-	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
were	O
grown	O
on	O
hydroxyapatite	O
discs	O
.	O

Seven	O
species	O
were	O
studied	O
as	O
planktonic	O
cells	O
,	O
including	O
Streptococcus	B-bacteria
oralis	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
,	O
Propionibacterium	B-bacteria
acnes	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
and	O
the	O
species	O
mentioned	O
above	O
.	O

The	O
viability	O
of	O
planktonic	O
cells	O
and	O
biofilms	O
was	O
analyzed	O
by	O
susceptibility	O
tests	O
and	O
time	O
-	O
kill	O
assays	O
,	O
respectively	O
,	O
against	O
different	O
concentrations	O
of	O
nicotine	O
,	O
cotinine	O
,	O
and	O
caffeine	O
.	O

High	O
-	O
performance	O
liquid	O
chromatography	O
was	O
performed	O
to	O
quantify	O
nicotine	O
,	O
cotinine	O
,	O
and	O
caffeine	O
concentrations	O
in	O
the	O
culture	O
media	O
after	O
the	O
assays	O
.	O

Susceptibility	O
tests	O
and	O
viability	O
assays	O
showed	O
that	O
nicotine	O
,	O
cotinine	O
,	O
and	O
caffeine	O
can	O
not	O
reduce	O
or	O
stimulate	O
bacterial	O
growth	O
.	O

High	O
-	O
performance	O
liquid	O
chromatography	O
results	O
showed	O
that	O
nicotine	O
,	O
cotinine	O
,	O
and	O
caffeine	O
concentrations	O
were	O
not	O
altered	O
after	O
bacteria	O
exposure	O
.	O

These	O
findings	O
indicate	O
that	O
nicotine	O
,	O
cotinine	O
,	O
and	O
caffeine	O
,	O
in	O
the	O
concentrations	O
used	O
,	O
can	O
not	O
affect	O
significantly	O
the	O
growth	O
of	O
these	O
oral	O
bacterial	O
strains	O
.	O

Moreover	O
,	O
these	O
species	O
do	O
not	O
seem	O
to	O
metabolize	O
these	O
substances	O
.	O

To	O
evaluate	O
the	O
efficacy	O
of	O
common	O
antiseptic	O
mouth	O
rinses	O
and	O
octenidine	O
dihydrochloride	O
(	O
OCT	O
)	O
.	O

The	O
antibacterial	O
activities	O
of	O
antiseptics	O
against	O
total	O
and	O
cariogenic	O
bacteria	O
(	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Lactobacillus	B-bacteria
species	I-bacteria
)	O
in	O
saliva	O
were	O
studied	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

After	O
unstimulated	O
saliva	O
was	O
collected	O
,	O
one	O
of	O
the	O
mouth	O
rinse	O
solutions	O
was	O
applied	O
for	O
30seconds	O
.	O

Saliva	O
samples	O
were	O
collected	O
15	O
,	O
30	O
,	O
60	O
,	O
and	O
120min	O
later	O
and	O
evaluated	O
for	O
their	O
bacterial	O
count	O
.	O

OCT	O
had	O
a	O
significantly	O
greater	O
inhibitory	O
effect	O
on	O
the	O
studied	O
bacteria	O
than	O
0	O
.	O
2	O
%	O
chlorhexidine	O
gluconate	O
(	O
CHX	O
)	O
and	O
7	O
.	O
5	O
%	O
polyvinylpyrrolidone	O
-	O
iodine	O
complex	O
(	O
PVP	O
-	O
I	O
)	O
from	O
15min	O
to	O
120min	O
following	O
the	O
application	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
antiseptic	O
efficacy	O
of	O
0	O
.	O
2	O
%	O
CHX	O
on	O
total	O
bacteria	O
and	O
Lactobacillus	B-bacteria
species	I-bacteria
was	O
very	O
similar	O
to	O
the	O
efficacy	O
observed	O
with	O
7	O
.	O
5	O
%	O
PVP	O
-	O
I	O
mouth	O
solution	O
from	O
15min	O
up	O
to	O
120min	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
was	O
completely	O
inhibited	O
by	O
0	O
.	O
15mg	O
/	O
ml	O
PVP	O
-	O
I	O
,	O
0	O
.	O
5mg	O
/	O
ml	O
CHX	O
,	O
and	O
0	O
.	O
1mg	O
/	O
ml	O
OCT	O
concentrations	O
,	O
while	O
Streptococcus	B-bacteria
salivarius	I-bacteria
was	O
inhibited	O
by	O
0	O
.	O
15mg	O
/	O
ml	O
PVP	O
-	O
I	O
,	O
2mg	O
/	O
ml	O
CHX	O
,	O
and	O
0	O
.	O
8mg	O
/	O
ml	O
OCT	O
concentrations	O
.	O

Lactococcus	B-bacteria
lactis	I-bacteria
subspecies	I-bacteria
lactis	I-bacteria
was	O
inhibited	O
with	O
0	O
.	O
00313mg	O
/	O
ml	O
OCT	O
,	O
30mg	O
/	O
ml	O
PVP	O
-	O
I	O
,	O
and	O
0	O
.	O
0063mg	O
/	O
ml	O
CHX	O
concentrations	O
.	O

OCT	O
compared	O
favorably	O
with	O
CHX	O
and	O
PVP	O
-	O
I	O
in	O
its	O
antibacterial	O
effects	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Leptotrichia	B-bacteria
species	I-bacteria
typically	O
colonize	O
the	O
oral	O
cavity	O
and	O
genitourinary	O
tract	O
.	O

These	O
anaerobic	O
bacteria	O
belong	O
to	O
the	O
normal	O
flora	O
of	O
humans	O
and	O
are	O
seldom	O
found	O
in	O
clinically	O
significant	O
specimens	O
.	O

However	O
,	O
on	O
rare	O
occasions	O
,	O
Leptotrichia	B-bacteria
has	O
been	O
isolated	O
from	O
blood	O
cultures	O
of	O
patients	O
with	O
lesions	O
in	O
the	O
oral	O
mucosa	O
,	O
in	O
particular	O
from	O
patients	O
with	O
neutropenia	O
.	O

These	O
organisms	O
should	O
be	O
considered	O
potential	O
pathogens	O
in	O
neutropenic	O
patients	O
,	O
especially	O
when	O
breaks	O
in	O
the	O
mucosal	O
barriers	O
are	O
present	O
through	O
which	O
they	O
frequently	O
spread	O
to	O
the	O
bloodstream	O
.	O

Leptotrichia	B-bacteria
has	O
also	O
been	O
recovered	O
from	O
immunocompetent	O
persons	O
,	O
e	O
.	O
g	O
.	O
patients	O
with	O
endocarditis	O
.	O

Although	O
their	O
role	O
in	O
infections	O
remains	O
elusive	O
and	O
not	O
much	O
is	O
known	O
,	O
they	O
have	O
been	O
suggested	O
as	O
emerging	O
pathogens	O
.	O

The	O
present	O
review	O
deals	O
with	O
taxonomy	O
,	O
diagnosis	O
,	O
clinical	O
importance	O
,	O
pathogenesis	O
,	O
host	O
defence	O
,	O
infection	O
control	O
,	O
and	O
spectrum	O
of	O
Leptotrichia	B-bacteria
infections	O
,	O
and	O
ends	O
with	O
a	O
few	O
typical	O
case	O
reports	O
.	O

Currently	O
,	O
six	O
species	O
have	O
been	O
validly	O
published	O
,	O
but	O
a	O
number	O
of	O
yet	O
uncultivable	O
species	O
exist	O
.	O

Molecular	O
methods	O
recovering	O
uncultivable	O
species	O
should	O
be	O
used	O
to	O
get	O
a	O
real	O
idea	O
of	O
their	O
role	O
as	O
pathogens	O
.	O

Coaggregation	O
is	O
believed	O
to	O
facilitate	O
the	O
integration	O
of	O
new	O
bacterial	O
species	O
into	O
polymicrobial	O
communities	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
coaggregation	O
between	O
and	O
among	O
human	O
oral	O
and	O
enteric	O
bacteria	O
.	O

Stationary	O
phase	O
cultures	O
of	O
10	O
oral	O
and	O
10	O
enteric	O
species	O
,	O
chosen	O
on	O
the	O
basis	O
of	O
numerical	O
and	O
ecological	O
significance	O
in	O
their	O
respective	O
environments	O
together	O
with	O
their	O
ease	O
of	O
cultivation	O
,	O
were	O
tested	O
using	O
a	O
quantitative	O
spectrophotometric	O
coaggregation	O
assay	O
in	O
all	O
possible	O
pairwise	O
combinations	O
to	O
provide	O
quantitative	O
coaggregation	O
scores	O
.	O

While	O
40	O
%	O
of	O
possible	O
partnerships	O
coaggregated	O
strongly	O
for	O
oral	O
strains	O
,	O
strong	O
interactions	O
between	O
oral	O
and	O
gut	O
strains	O
were	O
considerably	O
less	O
common	O
(	O
4	O
%	O
incidence	O
)	O
.	O

Coaggregation	O
scores	O
were	O
also	O
weak	O
between	O
members	O
of	O
the	O
intestinal	O
microbiota	O
(	O
7	O
%	O
incidence	O
)	O
,	O
apart	O
from	O
Bacteroides	B-bacteria
fragilis	I-bacteria
with	O
Clostridium	B-bacteria
perfringens	I-bacteria
,	O
and	O
Bifidobacterium	B-bacteria
adolescentis	I-bacteria
withenteric	O
C	I-bacteria
.	I-bacteria
perfringens	I-bacteria
.	O

Oral	O
and	O
intestinal	O
bacteria	O
did	O
not	O
strongly	O
interact	O
,	O
apart	O
from	O
B	B-bacteria
.	I-bacteria
adolescentis	I-bacteria
with	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
with	O
C	B-bacteria
.	I-bacteria
perfringens	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
with	O
Lactobacillus	B-bacteria
paracasei	I-bacteria
.	O

Heating	O
and	O
sugar	O
-	O
addition	O
experiments	O
indicated	O
that	O
similar	O
to	O
oral	O
microorganisms	O
,	O
interactions	O
within	O
intestinal	O
bacteria	O
and	O
between	O
intestinal	O
and	O
oral	O
strains	O
were	O
mediated	O
by	O
lectin	O
-	O
carbohydrate	O
interactions	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
oral	O
mucosal	O
lesions	O
,	O
microbial	O
changes	O
,	O
and	O
taste	O
disturbances	O
induced	O
by	O
adjuvant	O
chemotherapy	O
(	O
CT	O
)	O
in	O
breast	O
cancer	O
patients	O
during	O
and	O
1	O
year	O
after	O
treatment	O
.	O

Forty	O
-	O
five	O
consecutive	O
breast	O
cancer	O
patients	O
,	O
eligible	O
for	O
adjuvant	O
CT	O
with	O
cyclophosphamide	O
,	O
epirubicin	O
or	O
methotrexate	O
,	O
and	O
5	O
-	O
fluorouracil	O
were	O
followed	O
before	O
,	O
during	O
,	O
6	O
months	O
and	O
1	O
year	O
after	O
CT	O
and	O
were	O
compared	O
to	O
a	O
control	O
group	O
of	O
31	O
breast	O
cancer	O
patients	O
not	O
receiving	O
adjuvant	O
CT	O
.	O
During	O
CT	O
,	O
oral	O
mucosal	O
lesions	O
developed	O
including	O
erythema	O
(	O
n	O
=	O
10	O
,	O
22	O
%	O
)	O
and	O
ulceration	O
(	O
n	O
=	O
7	O
,	O
16	O
%	O
)	O
.	O

Five	O
patients	O
(	O
11	O
%	O
)	O
were	O
diagnosed	O
with	O
oral	O
candidosis	O
.	O

Scores	O
of	O
dental	O
bacterial	O
plaque	O
and	O
gingival	O
inflammation	O
increased	O
during	O
CT	O
and	O
the	O
oral	O
microbial	O
composition	O
changed	O
towards	O
a	O
more	O
acidophilic	O
flora	O
.	O

Taste	O
disturbances	O
were	O
experienced	O
by	O
84	O
%	O
(	O
n	O
=	O
38	O
)	O
of	O
the	O
patients	O
in	O
the	O
CT	O
group	O
.	O

In	O
breast	O
cancer	O
patients	O
,	O
moderate	O
-	O
intensive	O
adjuvant	O
CT	O
caused	O
oral	O
mucosal	O
lesions	O
,	O
oral	O
candidosis	O
,	O
taste	O
disturbances	O
and	O
a	O
more	O
acidophilic	O
oral	O
microflora	O
.	O

These	O
adverse	O
effects	O
were	O
temporary	O
and	O
the	O
majority	O
of	O
the	O
patients	O
were	O
mildly	O
affected	O
.	O

A	O
powder	O
preparation	O
of	O
the	O
oral	O
probiotic	O
Streptococcus	B-bacteria
salivarius	I-bacteria
K12	I-bacteria
has	O
been	O
given	O
to	O
19	O
young	O
otitis	O
media	O
-	O
prone	O
children	O
following	O
a	O
3	O
-	O
day	O
course	O
of	O
amoxicillin	O
administered	O
as	O
a	O
preliminary	O
to	O
ventilation	O
tube	O
placement	O
.	O

In	O
two	O
subjects	O
,	O
the	O
use	O
of	O
strain	O
K12	B-bacteria
appeared	O
to	O
effect	O
the	O
expansion	O
of	O
an	O
indigenous	O
population	O
of	O
inhibitory	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
.	O

In	O
other	O
children	O
,	O
strain	O
K12	B-bacteria
colonisation	O
extended	O
beyond	O
the	O
oral	O
cavity	O
to	O
also	O
include	O
the	O
nasopharynx	O
or	O
adenoid	O
tissue	O
.	O

The	O
relatively	O
low	O
proportion	O
(	O
33	O
%	O
)	O
of	O
subjects	O
that	O
colonised	O
was	O
attributed	O
to	O
failure	O
of	O
the	O
amoxicillin	O
pre	O
-	O
treatment	O
to	O
sufficiently	O
reduce	O
the	O
indigenous	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
populations	O
prior	O
to	O
dosing	O
with	O
strain	O
K12	B-bacteria
powder	O
.	O

Porphyromonas	B-bacteria
species	I-bacteria
are	O
frequently	O
isolated	O
from	O
the	O
oral	O
cavity	O
and	O
are	O
associated	O
with	O
periodontal	O
disease	O
in	O
both	O
animals	O
and	O
humans	O
.	O

Black	O
,	O
pigmented	O
Porphyromonas	B-bacteria
spp	I-bacteria
.	I-bacteria
isolated	O
from	O
the	O
gingival	O
margins	O
of	O
selected	O
wild	O
and	O
captive	O
Australian	O
marsupials	O
with	O
varying	O
degrees	O
of	O
periodontal	O
disease	O
(	O
brushtail	O
possums	O
,	O
koalas	O
and	O
macropods	O
)	O
were	O
compared	O
phylogenetically	O
to	O
Porphyromonas	B-bacteria
strains	I-bacteria
from	O
non	O
-	O
marsupials	O
(	O
bear	O
,	O
wolf	O
,	O
coyote	O
,	O
cats	O
and	O
dogs	O
)	O
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
strains	I-bacteria
from	O
humans	O
using	O
16S	O
rRNA	O
gene	O
sequence	O
analysis	O
.	O

The	O
results	O
of	O
the	O
phylogenetic	O
analysis	O
identified	O
three	O
distinct	O
groups	O
of	O
strains	O
.	O

A	O
monophyletic	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
group	O
(	O
Group	O
1	O
)	O
contained	O
only	O
strains	O
isolated	O
from	O
humans	O
and	O
a	O
Porphyromonas	B-bacteria
gulae	I-bacteria
group	O
(	O
Group	O
2	O
)	O
was	O
divided	O
into	O
three	O
distinct	O
subclades	O
,	O
each	O
containing	O
both	O
marsupial	O
and	O
non	O
-	O
marsupial	O
strains	O
.	O

Group	O
3	O
,	O
which	O
contained	O
only	O
marsupial	O
strains	O
,	O
including	O
all	O
six	O
strains	O
isolated	O
from	O
captive	O
koalas	O
,	O
was	O
genetically	O
distinct	O
from	O
P	B-bacteria
.	I-bacteria
gulae	I-bacteria
and	O
may	O
constitute	O
a	O
new	O
Porphyromonas	B-bacteria
species	I-bacteria
.	O

This	O
study	O
investigated	O
the	O
influence	O
of	O
urease	O
-	O
positive	O
non	O
-	O
Helicobacter	B-bacteria
pylori	I-bacteria
bacteria	O
on	O
the	O
results	O
of	O
a	O
urea	O
breath	O
test	O
(	O
UBT	O
)	O
to	O
evaluate	O
the	O
diagnostic	O
utility	O
of	O
a	O
UBT	O
using	O
film	O
-	O
coated	O
[	O
(	O
13	O
)	O
C	O
]	O
urea	O
tablets	O
.	O

The	O
UBT	O
was	O
performed	O
in	O
102	O
patients	O
treated	O
with	O
a	O
proton	O
pump	O
inhibitor	O
and	O
antibiotics	O
for	O
the	O
eradication	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

Urease	O
-	O
producing	O
bacteria	O
other	O
than	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
were	O
isolated	O
and	O
identified	O
from	O
the	O
oral	O
cavity	O
and	O
stomach	O
.	O

In	O
4	O
/	O
102	O
patients	O
,	O
the	O
UBT	O
gave	O
false	O
-	O
positive	O
results	O
.	O

These	O
false	O
-	O
positive	O
results	O
were	O
found	O
to	O
be	O
caused	O
by	O
the	O
presence	O
of	O
urease	O
-	O
positive	O
bacteria	O
in	O
the	O
oral	O
cavity	O
and	O
stomach	O
.	O

Five	O
bacterial	O
species	O
with	O
urease	O
activity	O
(	O
Proteus	B-bacteria
mirabilis	I-bacteria
,	O
Citrobacter	B-bacteria
freundii	I-bacteria
,	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
,	O
Enterobacter	B-bacteria
cloacae	I-bacteria
and	O
Staphylococcus	B-bacteria
aureus	I-bacteria
)	O
were	O
subsequently	O
isolated	O
from	O
the	O
oral	O
cavity	O
and	O
/	O
or	O
stomach	O
.	O

As	O
there	O
was	O
no	O
correlation	O
between	O
the	O
in	O
vitro	O
urease	O
activity	O
of	O
urease	O
-	O
positive	O
non	O
-	O
H	O
.	O
pylori	O
bacteria	O
and	O
the	O
UBT	O
value	O
,	O
and	O
all	O
of	O
the	O
patients	O
with	O
a	O
false	O
-	O
positive	O
UBT	O
result	O
were	O
suffering	O
from	O
atrophic	O
gastritis	O
,	O
it	O
is	O
possible	O
that	O
the	O
false	O
-	O
positive	O
results	O
in	O
the	O
UBT	O
were	O
a	O
result	O
of	O
colonization	O
of	O
urease	O
-	O
positive	O
bacteria	O
and	O
gastric	O
hypochlorhydric	O
conditions	O
.	O

Thus	O
,	O
for	O
the	O
diagnosis	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
using	O
a	O
UBT	O
,	O
the	O
influence	O
of	O
stomach	O
bacteria	O
must	O
be	O
considered	O
when	O
interpreting	O
the	O
results	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
confirm	O
further	O
the	O
efficacy	O
and	O
safety	O
of	O
levofloxacin	O
in	O
patients	O
with	O
chronic	O
bacterial	O
prostatitis	O
(	O
CBP	O
)	O
in	O
Europe	O
.	O

Men	O
with	O
a	O
history	O
of	O
CBP	O
were	O
enrolled	O
in	O
a	O
prospective	O
,	O
multinational	O
(	O
eight	O
countries	O
)	O
,	O
open	O
-	O
label	O
study	O
to	O
receive	O
levofloxacin	O
500	O
mg	O
once	O
daily	O
per	O
os	O
(	O
p	O
.	O
o	O
.	O
)	O

for	O
28	O
days	O
.	O

Patients	O
were	O
followed	O
for	O
6	O
months	O
.	O

A	O
total	O
of	O
117	O
patients	O
were	O
treated	O
.	O

Gram	O
-	O
negative	O
bacteria	O
were	O
identified	O
in	O
57	O
/	O
106	O
patients	O
(	O
mainly	O
Escherichia	B-bacteria
coli	I-bacteria
(	O
n	O
=	O
37	O
)	O
)	O
and	O
Gram	O
-	O
positive	O
bacteria	O
in	O
60	O
/	O
106	O
patients	O
(	O
mainly	O
Enterococcus	B-bacteria
faecalis	I-bacteria
(	O
n	O
=	O
18	O
)	O
and	O
Staphylococcus	B-bacteria
epidermidis	I-bacteria
(	O
n	O
=	O
14	O
)	O
)	O
.	O

Among	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
(	O
n	O
=	O
116	O
)	O
,	O
the	O
clinical	O
success	O
rate	O
(	O
cured	O
and	O
improved	O
patients	O
)	O
was	O
92	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
84	O
.	O
8	O
-	O
96	O
.	O
5	O
%	O
)	O
,	O
77	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
68	O
.	O
2	O
-	O
84	O
.	O
9	O
%	O
)	O
,	O
66	O
.	O
0	O
%	O
(	O
95	O
%	O
CI	O
56	O
.	O
2	O
-	O
75	O
.	O
0	O
%	O
)	O
and	O
61	O
.	O
9	O
%	O
(	O
95	O
%	O
CI	O
51	O
.	O
9	O
-	O
71	O
.	O
2	O
%	O
)	O
at	O
5	O
-	O
12	O
days	O
,	O
1	O
month	O
,	O
3	O
months	O
and	O
6	O
months	O
post	O
treatment	O
.	O

The	O
microbiological	O
eradication	O
rate	O
according	O
to	O
evaluation	O
scheme	O
II	O
was	O
82	O
/	O
98	O
(	O
83	O
.	O
7	O
%	O
,	O
95	O
%	O
CI	O
74	O
.	O
8	O
-	O
90	O
.	O
4	O
%	O
)	O
at	O
1	O
month	O
and	O
the	O
continued	O
eradication	O
rate	O
was	O
52	O
/	O
57	O
(	O
91	O
.	O
2	O
%	O
,	O
95	O
%	O
CI	O
80	O
.	O
7	O
-	O
97	O
.	O
1	O
%	O
)	O
at	O
6	O
months	O
post	O
treatment	O
.	O

Comparison	O
of	O
four	O
classification	O
schemes	O
showed	O
similar	O
results	O
.	O

Thus	O
,	O
the	O
present	O
investigation	O
is	O
suitably	O
comparable	O
in	O
methods	O
and	O
results	O
to	O
previous	O
studies	O
.	O

Levofloxacin	O
was	O
well	O
tolerated	O
.	O

Four	O
patients	O
(	O
3	O
.	O
4	O
%	O
)	O
discontinued	O
therapy	O
due	O
to	O
adverse	O
events	O
and	O
15	O
patients	O
(	O
12	O
.	O
8	O
%	O
)	O
experienced	O
at	O
least	O
one	O
adverse	O
event	O
.	O

Levofloxacin	O
500	O
mg	O
p	O
.	O
o	O
.	O
once	O
daily	O
for	O
28	O
days	O
is	O
clinically	O
and	O
microbiologically	O
effective	O
in	O
the	O
treatment	O
of	O
CBP	O
caused	O
by	O
susceptible	O
pathogens	O
and	O
is	O
well	O
tolerated	O
.	O

Hydroxychavicol	O
isolated	O
from	O
the	O
chloroform	O
extraction	O
of	O
aqueous	O
extract	O
of	O
Piper	O
betle	O
leaves	O
showed	O
inhibitory	O
activity	O
against	O
oral	O
cavity	O
pathogens	O
.	O

It	O
exhibited	O
an	O
inhibitory	O
effect	O
on	O
all	O
of	O
the	O
oral	O
cavity	O
pathogens	O
tested	O
(	O
MICs	O
of	O
62	O
.	O
5	O
to	O
500	O
microg	O
/	O
ml	O
)	O
with	O
a	O
minimal	O
bactericidal	O
concentration	O
that	O
was	O
twofold	O
greater	O
than	O
the	O
inhibitory	O
concentration	O
.	O

Hydroxychavicol	O
exhibited	O
concentration	O
-	O
dependent	O
killing	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
ATCC	I-bacteria
25175	I-bacteria
up	O
to	O
4x	O
MIC	O
and	O
also	O
prevented	O
the	O
formation	O
of	O
water	O
-	O
insoluble	O
glucan	O
.	O

Interestingly	O
,	O
hydroxychavicol	O
exhibited	O
an	O
extended	O
postantibiotic	O
effect	O
of	O
6	O
to	O
7	O
h	O
and	O
prevented	O
the	O
emergence	O
of	O
mutants	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
ATCC	I-bacteria
25175	I-bacteria
and	O
Actinomyces	B-bacteria
viscosus	I-bacteria
ATCC	I-bacteria
15987	I-bacteria
at	O
2x	O
MIC	O
.	O

Furthermore	O
,	O
it	O
also	O
inhibited	O
the	O
growth	O
of	O
biofilms	O
generated	O
by	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
A	B-bacteria
.	I-bacteria
viscosus	I-bacteria
and	O
reduced	O
the	O
preformed	O
biofilms	O
by	O
these	O
bacteria	O
.	O

Increased	O
uptake	O
of	O
propidium	O
iodide	O
by	O
hydroxychavicol	O
-	O
treated	O
cells	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
A	B-bacteria
.	I-bacteria
viscosus	I-bacteria
indicated	O
that	O
hydroxychavicol	O
probably	O
works	O
through	O
the	O
disruption	O
of	O
the	O
permeability	O
barrier	O
of	O
microbial	O
membrane	O
structures	O
.	O

Hydroxychavicol	O
also	O
exhibited	O
potent	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
.	O

This	O
was	O
evident	O
from	O
its	O
concentration	O
-	O
dependent	O
inhibition	O
of	O
lipid	O
peroxidation	O
and	O
significant	O
suppression	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
expression	O
in	O
human	O
neutrophils	O
.	O

Its	O
efficacy	O
against	O
adherent	O
cells	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
in	O
water	O
-	O
insoluble	O
glucan	O
in	O
the	O
presence	O
of	O
sucrose	O
suggests	O
that	O
hydroxychavicol	O
would	O
be	O
a	O
useful	O
compound	O
for	O
the	O
development	O
of	O
antibacterial	O
agents	O
against	O
oral	O
pathogens	O
and	O
that	O
it	O
has	O
great	O
potential	O
for	O
use	O
in	O
mouthwash	O
for	O
preventing	O
and	O
treating	O
oral	O
infections	O
.	O

The	O
use	O
of	O
probiotic	O
bacteria	O
is	O
increasing	O
worldwide	O
and	O
at	O
least	O
some	O
of	O
them	O
can	O
transiently	O
colonize	O
the	O
oral	O
cavity	O
.	O

Several	O
studies	O
have	O
shown	O
that	O
probiotic	O
bacteria	O
,	O
which	O
are	O
often	O
thought	O
of	O
in	O
relation	O
only	O
to	O
intestinal	O
health	O
,	O
can	O
also	O
affect	O
the	O
oral	O
ecology	O
,	O
but	O
the	O
mechanisms	O
for	O
this	O
are	O
largely	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
in	O
vitro	O
if	O
the	O
probiotic	O
bacteria	O
used	O
in	O
commercial	O
products	O
affect	O
the	O
protein	O
composition	O
of	O
the	O
salivary	O
pellicle	O
and	O
the	O
adherence	O
of	O
other	O
oral	O
bacteria	O
.	O

salivary	O
pellicle	O
on	O
hydroxyapatite	O
and	O
the	O
adhesion	O
of	O
two	O
oral	O
streptococci	B-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
were	O
used	O
as	O
a	O
model	O
.	O

Probiotic	O
bacteria	O
that	O
bound	O
to	O
saliva	O
-	O
coated	O
hydroxyapatite	O
reduced	O
the	O
adhesion	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
but	O
the	O
inhibitory	O
effect	O
on	O
the	O
adherence	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
was	O
weaker	O
.	O

salivary	O
pellicle	O
protein	O
composition	O
was	O
modified	O
by	O
all	O
the	O
strains	O
tested	O
.	O

The	O
modifications	O
in	O
the	O
pellicle	O
affected	O
the	O
adherence	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
but	O
not	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
.	O

Two	O
of	O
the	O
proteins	O
missing	O
from	O
the	O
pellicles	O
made	O
of	O
saliva	O
-	O
treated	O
with	O
the	O
probiotic	O
bacteria	O
were	O
identified	O
as	O
salivary	O
agglutinin	O
gp340	O
and	O
salivary	O
peroxidase	O
.	O

All	O
bacterial	O
strains	O
bound	O
salivary	O
agglutinin	O
gp340	O
.	O

The	O
ability	O
of	O
the	O
probiotic	O
bacteria	O
to	O
degrade	O
peroxidase	O
was	O
demonstrated	O
with	O
purified	O
bovine	O
lactoperoxidase	O
and	O
two	O
of	O
the	O
probiotic	O
strains	O
.	O

This	O
in	O
vitro	O
study	O
showed	O
that	O
probiotic	O
strains	O
used	O
in	O
commercial	O
products	O
may	O
affect	O
the	O
oral	O
ecology	O
by	O
specifically	O
preventing	O
the	O
adherence	O
of	O
other	O
bacteria	O
and	O
by	O
modifying	O
the	O
protein	O
composition	O
of	O
the	O
salivary	O
pellicle	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
a	O
novel	O
conjugative	O
transposon	O
Tn6009	O
composed	O
of	O
a	O
Tn916	O
linked	O
to	O
a	O
Staphylococcus	B-bacteria
aureus	I-bacteria
mer	O
operon	O
in	O
representative	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
isolated	O
in	O
Nigeria	O
and	O
Portugal	O
.	O

Eighty	O
-	O
three	O
Gram	O
-	O
positive	O
and	O
34	O
Gram	O
-	O
negative	O
bacteria	O
were	O
screened	O
for	O
the	O
presence	O
of	O
the	O
Tn6009	O
using	O
DNA	O
-	O
DNA	O
hybridization	O
,	O
PCR	O
,	O
hybridization	O
of	O
PCR	O
products	O
,	O
sequencing	O
and	O
mating	O
experiments	O
by	O
established	O
procedures	O
.	O

Forty	O
-	O
three	O
oral	O
and	O
23	O
urine	O
Gram	O
-	O
negative	O
and	O
Gram	O
-	O
positive	O
isolates	O
carried	O
the	O
Tn6009	O
.	O

Sequencing	O
was	O
performed	O
to	O
verify	O
the	O
direct	O
linkage	O
between	O
the	O
mer	O
resistance	O
genes	O
and	O
the	O
tet	O
(	O
M	O
)	O
gene	O
.	O

A	O
Nigerian	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
,	O
isolated	O
from	O
a	O
urinary	O
tract	O
infection	O
patient	O
,	O
and	O
one	O
commensal	O
isolate	O
from	O
each	O
of	O
the	O
other	O
Tn6009	O
-	O
positive	O
genera	O
,	O
Serratia	B-bacteria
liquefaciens	I-bacteria
,	O
Pseudomonas	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Enterococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
and	O
Streptococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
isolated	O
from	O
the	O
oral	O
and	O
urine	O
samples	O
of	O
healthy	O
Portuguese	O
children	O
,	O
were	O
able	O
to	O
act	O
as	O
donors	O
and	O
conjugally	O
transfer	O
the	O
Tn6009	O
to	O
the	O
Enterococcus	B-bacteria
faecalis	I-bacteria
JH2	I-bacteria
-	I-bacteria
2	I-bacteria
recipient	O
,	O
resulting	O
in	O
tetracycline	O
-	O
and	O
mercury	O
-	O
resistant	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
transconjugants	O
.	O

This	O
study	O
reports	O
a	O
novel	O
non	O
-	O
composite	O
conjugative	O
transposon	O
Tn6009	O
containing	O
a	O
Tn916	O
element	O
linked	O
to	O
an	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
mer	O
operon	O
carrying	O
genes	O
coding	O
for	O
inorganic	O
mercury	O
resistance	O
(	O
merA	O
)	O
,	O
an	O
organic	O
mercury	O
resistance	O
(	O
merB	O
)	O
,	O
a	O
regulatory	O
protein	O
(	O
merR	O
)	O
and	O
a	O
mercury	O
transporter	O
(	O
merT	O
)	O
.	O

This	O
transposon	O
was	O
identified	O
in	O
66	O
isolates	O
from	O
two	O
Gram	O
-	O
positive	O
and	O
three	O
Gram	O
-	O
negative	O
genera	O
and	O
is	O
the	O
first	O
transposon	O
in	O
the	O
Tn916	O
family	O
to	O
carry	O
the	O
Gram	O
-	O
positive	O
mer	O
genes	O
directly	O
linked	O
to	O
the	O
tet	O
(	O
M	O
)	O
gene	O
.	O

Bacterial	O
vaginosis	O
frequently	O
persists	O
after	O
treatment	O
.	O

The	O
role	O
of	O
newly	O
defined	O
bacterial	O
vaginosis	O
-	O
associated	O
bacteria	O
(	O
BVAB	O
)	O
,	O
which	O
have	O
a	O
specificity	O
for	O
this	O
condition	O
of	O
97	O
%	O
or	O
greater	O
,	O
has	O
not	O
been	O
assessed	O
.	O

To	O
define	O
risks	O
for	O
bacterial	O
vaginosis	O
persistence	O
,	O
including	O
pretreatment	O
detection	O
of	O
specific	O
vaginal	O
bacteria	O
,	O
among	O
women	O
reporting	O
sex	O
with	O
women	O
.	O

Observational	O
cohort	O
study	O
.	O

University	O
-	O
based	O
research	O
clinic	O
.	O

335	O
women	O
age	O
16	O
to	O
29	O
years	O
reporting	O
sex	O
with	O
at	O
least	O
1	O
woman	O
in	O
the	O
past	O
year	O
.	O

Participants	O
were	O
recruited	O
through	O
advertisements	O
and	O
provider	O
referral	O
.	O

Bacterial	O
vaginosis	O
was	O
treated	O
with	O
intravaginal	O
metronidazole	O
gel	O
(	O
0	O
.	O
75	O
%	O
)	O
,	O
37	O
.	O
5	O
mg	O
nightly	O
for	O
5	O
nights	O
.	O

Species	O
-	O
specific	O
16S	O
recombinant	O
DNA	O
polymerase	O
chain	O
reaction	O
assays	O
targeting	O
17	O
bacterial	O
species	O
were	O
applied	O
to	O
vaginal	O
fluid	O
obtained	O
at	O
baseline	O
.	O

Test	O
of	O
cure	O
by	O
clinical	O
criteria	O
and	O
Gram	O
stain	O
analysis	O
and	O
repeated	O
polymerase	O
chain	O
reaction	O
assays	O
of	O
vaginal	O
fluid	O
were	O
performed	O
1	O
month	O
after	O
treatment	O
,	O
and	O
interim	O
behaviors	O
were	O
assessed	O
by	O
using	O
computer	O
-	O
assisted	O
self	O
-	O
interview	O
.	O

Of	O
335	O
women	O
,	O
24	O
%	O
of	O
whom	O
also	O
reported	O
sex	O
with	O
men	O
within	O
3	O
months	O
before	O
enrollment	O
,	O
131	O
(	O
39	O
%	O
)	O
had	O
bacterial	O
vaginosis	O
.	O

In	O
the	O
120	O
(	O
92	O
%	O
)	O
women	O
who	O
returned	O
for	O
follow	O
-	O
up	O
,	O
the	O
incidence	O
of	O
persistent	O
bacterial	O
vaginosis	O
was	O
26	O
%	O
and	O
was	O
statistically	O
significantly	O
higher	O
in	O
women	O
with	O
baseline	O
detection	O
of	O
3	O
Clostridiales	B-bacteria
bacteria	I-bacteria
,	O
designated	O
as	O
BVAB1	O
(	O
risk	O
ratio	O
,	O
2	O
.	O
0	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
to	O
4	O
.	O
0	O
]	O
)	O
,	O
BVAB2	O
(	O
risk	O
ratio	O
,	O
8	O
.	O
7	O
[	O
CI	O
,	O
2	O
.	O
5	O
to	O
infinity	O
]	O
)	O
,	O
or	O
BVAB3	O
(	O
risk	O
ratio	O
,	O
3	O
.	O
1	O
[	O
CI	O
,	O
1	O
.	O
7	O
to	O
5	O
.	O
8	O
]	O
)	O
;	O
Peptoniphilus	B-bacteria
lacrimalis	I-bacteria
(	O
risk	O
ratio	O
,	O
3	O
.	O
5	O
[	O
CI	O
,	O
1	O
.	O
6	O
to	O
15	O
.	O
5	O
]	O
)	O
;	O
and	O
Megasphaera	B-bacteria
phylotype	I-bacteria
2	I-bacteria
(	O
risk	O
ratio	O
,	O
3	O
.	O
4	O
[	O
CI	O
,	O
1	O
.	O
4	O
to	O
5	O
.	O
5	O
]	O
)	O
.	O

Persistence	O
was	O
lower	O
with	O
treatment	O
adherence	O
(	O
risk	O
ratio	O
,	O
0	O
.	O
4	O
[	O
0	O
.	O
2	O
to	O
0	O
.	O
9	O
]	O
)	O
.	O

Detection	O
of	O
these	O
bacteria	O
at	O
the	O
test	O
-	O
of	O
-	O
cure	O
visit	O
was	O
associated	O
with	O
persistence	O
,	O
whereas	O
posttreatment	O
sexual	O
activity	O
was	O
not	O
.	O

LIMITATIONS	O
:	O
Findings	O
may	O
not	O
be	O
generalizable	O
to	O
women	O
who	O
have	O
sex	O
only	O
with	O
men	O
,	O
or	O
to	O
women	O
whose	O
bacterial	O
vaginosis	O
is	O
treated	O
with	O
oral	O
antibiotics	O
.	O

The	O
study	O
may	O
be	O
too	O
small	O
and	O
may	O
involve	O
a	O
population	O
that	O
is	O
too	O
highly	O
selected	O
to	O
draw	O
definitive	O
conclusions	O
about	O
associations	O
of	O
persistent	O
infection	O
with	O
posttreatment	O
sexual	O
behaviors	O
.	O

Persistent	O
bacterial	O
vaginosis	O
is	O
associated	O
with	O
several	O
bacteria	O
in	O
the	O
Clostridiales	B-bacteria
order	O
,	O
Megasphaera	B-bacteria
phylotype	I-bacteria
2	I-bacteria
,	O
and	O
P	B-bacteria
.	I-bacteria
lacrimalis	I-bacteria
,	O
suggesting	O
that	O
vaginal	O
microbiology	O
at	O
diagnosis	O
may	O
determine	O
risk	O
for	O
antibiotic	O
failure	O
.	O

The	O
ability	O
of	O
oral	O
bacteria	O
to	O
enter	O
a	O
non	O
-	O
growing	O
state	O
is	O
believed	O
to	O
be	O
an	O
important	O
mechanism	O
for	O
survival	O
in	O
the	O
starved	O
micro	O
-	O
environments	O
of	O
the	O
oral	O
cavity	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
reactivation	O
of	O
nutrient	O
-	O
deprived	O
cells	O
of	O
two	O
oral	O
bacteria	O
in	O
biofilms	O
,	O
Streptococcus	B-bacteria
anginosus	I-bacteria
and	O
Lactobacillus	B-bacteria
salivarius	I-bacteria
.	O

Non	O
-	O
growing	O
cells	O
were	O
generated	O
by	O
incubation	O
in	O
10	O
mM	O
potassium	O
phosphate	O
buffer	O
for	O
24	O
h	O
and	O
the	O
results	O
were	O
compared	O
to	O
those	O
of	O
planktonic	O
cultures	O
.	O

When	O
both	O
types	O
of	O
cells	O
were	O
shifted	O
from	O
a	O
rich	O
,	O
peptone	O
-	O
yeast	O
extract	O
-	O
glucose	O
(	O
PYG	O
)	O
medium	O
to	O
buffer	O
for	O
24	O
h	O
,	O
dehydrogenase	O
and	O
esterase	O
activity	O
measured	O
by	O
the	O
fluorescent	O
dyes	O
5	O
-	O
cyano	O
-	O
2	O
,	O
3	O
-	O
ditolyl	O
-	O
tetrazolium	O
chloride	O
(	O
CTC	O
)	O
and	O
fluorescein	O
diacetate	O
(	O
FDA	O
)	O
,	O
respectively	O
,	O
was	O
absent	O
in	O
both	O
species	O
.	O

However	O
,	O
the	O
membranes	O
of	O
the	O
vast	O
majority	O
of	O
nutrient	O
-	O
deprived	O
cells	O
remained	O
intact	O
as	O
assessed	O
by	O
LIVE	O
/	O
DEAD	O
staining	O
.	O

Metabolic	O
reactivation	O
of	O
the	O
nutrient	O
-	O
deprived	O
biofilm	O
cells	O
was	O
not	O
observed	O
for	O
at	O
least	O
48	O
h	O
following	O
addition	O
of	O
fresh	O
PYG	O
medium	O
,	O
whereas	O
the	O
non	O
-	O
growing	O
planktonic	O
cultures	O
of	O
the	O
same	O
two	O
strains	O
were	O
in	O
rapid	O
growth	O
in	O
less	O
than	O
2	O
h	O
.	O
At	O
72	O
h	O
,	O
the	O
S	B-bacteria
.	I-bacteria
anginosus	I-bacteria
biofilm	O
cells	O
had	O
recovered	O
78	O
%	O
of	O
the	O
dehydrogenase	O
activity	O
and	O
61	O
%	O
of	O
the	O
esterase	O
activity	O
and	O
the	O
biomass	O
mm	O
(	O
-	O
2	O
)	O
had	O
increased	O
by	O
30	O
-	O
35	O
%	O
.	O

With	O
L	B-bacteria
.	I-bacteria
salivarius	I-bacteria
at	O
72	O
h	O
,	O
the	O
biofilms	O
had	O
recovered	O
56	O
%	O
and	O
75	O
%	O
of	O
dehydrogenase	O
and	O
esterase	O
activity	O
,	O
respectively	O
.	O

Reactivation	O
of	O
both	O
species	O
in	O
biofilms	O
was	O
enhanced	O
by	O
removal	O
of	O
glucose	O
from	O
PYG	O
,	O
and	O
S	B-bacteria
.	I-bacteria
anginosus	I-bacteria
cells	O
were	O
particularly	O
responsive	O
to	O
yeast	O
extract	O
(	O
YE	O
)	O
medium	O
.	O

The	O
data	O
suggest	O
that	O
the	O
low	O
reactivity	O
of	O
non	O
-	O
growing	O
biofilm	O
cells	O
to	O
the	O
introduction	O
of	O
fresh	O
nutrients	O
may	O
be	O
a	O
survival	O
strategy	O
employed	O
by	O
micro	O
-	O
organisms	O
in	O
the	O
oral	O
cavity	O
.	O

Many	O
neuropeptides	O
are	O
similar	O
in	O
size	O
,	O
amino	O
acid	O
composition	O
and	O
charge	O
to	O
antimicrobial	O
peptides	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
whether	O
the	O
neuropeptides	O
substance	O
P	O
(	O
SP	O
)	O
,	O
neurokinin	O
A	O
(	O
NKA	O
)	O
,	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
,	O
neuropeptide	O
Y	O
(	O
NPY	O
)	O
and	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
,	O
displayed	O
antimicrobial	O
activity	O
against	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
Enterococcus	B-bacteria
faecalis	I-bacteria
,	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
and	O
Candida	O
albicans	O
.	O

SP	O
,	O
NPY	O
,	O
VIP	O
and	O
CGRP	O
displayed	O
variable	O
degrees	O
of	O
antimicrobial	O
activity	O
against	O
all	O
the	O
pathogens	O
tested	O
with	O
the	O
exception	O
of	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
.	O

These	O
antimicrobial	O
activities	O
add	O
a	O
further	O
dimension	O
to	O
the	O
immunomodulatory	O
roles	O
for	O
neuropeptides	O
in	O
the	O
inflammatory	O
and	O
immune	O
responses	O
.	O

Glucosyltransferases	O
(	O
GTF	O
)	O
play	O
an	O
important	O
role	O
in	O
the	O
adherence	O
of	O
bacteria	O
to	O
acquired	O
pellicle	O
.	O

Cocoa	O
bean	O
husk	O
extract	O
(	O
CBHE	O
)	O
has	O
been	O
shown	O
to	O
possess	O
anti	O
-	O
glucosyltransferase	O
and	O
antibacterial	O
activity	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
effect	O
of	O
CBHE	O
on	O
plaque	O
accumulation	O
and	O
mutans	B-bacteria
streptococcus	I-bacteria
count	O
when	O
used	O
as	O
a	O
mouth	O
rinse	O
by	O
children	O
.	O

Scaling	O
of	O
the	O
teeth	O
of	O
the	O
selected	O
children	O
was	O
done	O
and	O
the	O
children	O
were	O
instructed	O
to	O
refrain	O
from	O
their	O
routine	O
oral	O
hygiene	O
practices	O
till	O
the	O
morning	O
of	O
the	O
fourth	O
day	O
;	O
they	O
were	O
instead	O
given	O
a	O
placebo	O
mouth	O
rinse	O
for	O
use	O
during	O
this	O
period	O
.	O

On	O
the	O
fourth	O
day	O
,	O
saliva	O
was	O
collected	O
from	O
each	O
subject	O
for	O
microbiological	O
analysis	O
and	O
plaque	O
was	O
disclosed	O
and	O
scored	O
using	O
the	O
modified	O
Quigley	O
and	O
Hein	O
plaque	O
index	O
;	O
later	O
,	O
the	O
teeth	O
were	O
cleaned	O
.	O

After	O
1	O
week	O
,	O
scaling	O
of	O
the	O
subjects	O
was	O
done	O
and	O
they	O
were	O
given	O
CBHE	O
mouth	O
rinse	O
to	O
rinse	O
their	O
mouth	O
,	O
following	O
the	O
above	O
protocol	O
.	O

The	O
data	O
was	O
statistically	O
analyzed	O
using	O
Wilcoxon	O
'	O
s	O
signed	O
rank	O
test	O
.	O

There	O
was	O
a	O
20	O
.	O
9	O
%	O
decrease	O
in	O
mutans	B-bacteria
streptococci	I-bacteria
counts	O
and	O
a	O
49	O
.	O
6	O
%	O
decrease	O
in	O
plaque	O
scores	O
in	O
the	O
CBHE	O
group	O
as	O
compared	O
to	O
the	O
placebo	O
group	O
,	O
which	O
was	O
highly	O
significant	O
(	O
P	O
value	O
Conclusion	O
:	O
CBHE	O
is	O
highly	O
effective	O
in	O
reducing	O
mutans	B-bacteria
streptococci	I-bacteria
counts	O
and	O
plaque	O
deposition	O
when	O
used	O
as	O
a	O
mouth	O
rinse	O
by	O
children	O
.	O

People	O
living	O
without	O
piped	O
water	O
and	O
sewer	O
can	O
be	O
at	O
increased	O
risk	O
for	O
diseases	O
transmitted	O
via	O
the	O
fecal	O
-	O
oral	O
route	O
.	O

One	O
rural	O
Alaskan	O
community	O
that	O
relies	O
on	O
hauling	O
water	O
into	O
homes	O
and	O
sewage	O
from	O
homes	O
was	O
studied	O
to	O
determine	O
the	O
pathways	O
of	O
fecal	O
contamination	O
of	O
drinking	O
water	O
and	O
the	O
human	O
environment	O
so	O
that	O
barriers	O
can	O
be	O
established	O
to	O
protect	O
health	O
.	O

Samples	O
were	O
tested	O
for	O
the	O
fecal	O
indicator	O
,	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
and	O
the	O
less	O
specific	O
indicator	O
group	O
,	O
total	O
coliforms	B-bacteria
.	O

Shoes	O
transported	O
fecal	O
contamination	O
from	O
outside	O
to	O
floor	O
material	O
inside	O
buildings	O
.	O

Contamination	O
in	O
puddles	O
on	O
the	O
road	O
,	O
in	O
conjunction	O
with	O
contamination	O
found	O
on	O
all	O
-	O
terrain	O
vehicle	O
(	O
ATV	O
)	O
tires	O
,	O
supports	O
vehicle	O
traffic	O
as	O
a	O
mechanism	O
for	O
transporting	O
contamination	O
from	O
the	O
dumpsite	O
or	O
other	O
source	O
areas	O
to	O
the	O
rest	O
of	O
the	O
community	O
.	O

The	O
abundance	O
of	O
fecal	O
bacteria	O
transported	O
around	O
the	O
community	O
on	O
shoes	O
and	O
ATV	O
tires	O
suggests	O
that	O
centralized	O
measures	O
for	O
waste	O
disposal	O
as	O
well	O
as	O
shoe	O
removal	O
in	O
buildings	O
could	O
improve	O
sanitation	O
and	O
health	O
in	O
the	O
community	O
.	O

Bacterial	O
glycosyltransferases	O
have	O
drawn	O
growing	O
attention	O
as	O
economical	O
enzymes	O
for	O
oligosaccharide	O
synthesis	O
,	O
with	O
their	O
easy	O
expression	O
and	O
relatively	O
broad	O
substrate	O
specificity	O
.	O

Here	O
,	O
we	O
characterized	O
a	O
glycosyltransferase	O
homolog	O
(	O
Fnu	O
_	O
GT	O
)	O
from	O
a	O
human	O
oral	O
pathogen	O
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
.	O

Bioinformatic	O
analysis	O
showed	O
that	O
Fnu	O
_	O
GT	O
belongs	O
to	O
the	O
glycosyltransferases	O
family	O
II	O
.	O

The	O
recombinant	O
Fnu	O
_	O
GT	O
(	O
rFnu	O
_	O
GT	O
)	O
expressed	O
in	O
Escherichia	B-bacteria
coli	I-bacteria
displayed	O
the	O
highest	O
glycosylation	O
activity	O
when	O
UDP	O
-	O
galactose	O
(	O
Gal	O
)	O
was	O
used	O
as	O
a	O
donor	O
nucleotide	O
-	O
sugar	O
with	O
heptose	O
or	O
Nacetylglucosamine	O
(	O
GlcNAc	O
)	O
as	O
an	O
acceptor	O
sugar	O
.	O

Interestingly	O
,	O
rFnu	O
_	O
GT	O
transferred	O
the	O
galactose	O
moiety	O
of	O
UDP	O
-	O
Gal	O
to	O
a	O
nonreducing	O
terminal	O
GlcNAc	O
attached	O
to	O
the	O
trimannosyl	O
core	O
glycan	O
,	O
indicating	O
its	O
potential	O
as	O
an	O
enzyme	O
for	O
humantype	O
N	O
-	O
glycan	O
synthesis	O
.	O

The	O
aim	O
of	O
the	O
study	O
is	O
was	O
to	O
evaluate	O
anaerobic	O
periodontal	O
microbes	O
in	O
120	O
postpartum	O
mothers	O
.	O

Group	O
I	O
consisted	O
of	O
mothers	O
with	O
a	O
birth	O
weight	O
of	O
less	O
than	O
2	O
,	O
500g	O
and	O
gestational	O
age	O
<	O
37	O
weeks	O
.	O

Group	O
II	O
included	O
mothers	O
with	O
normal	O
birth	O
weight	O
infants	O
.	O

All	O
women	O
in	O
both	O
of	O
groups	O
were	O
subjected	O
to	O
a	O
full	O
-	O
mouth	O
periodontal	O
examination	O
to	O
determine	O
a	O
periodontal	O
status	O
.	O

The	O
microbial	O
investigation	O
for	O
anaerobic	O
bacteria	O
of	O
deepest	O
periodontal	O
pockets	O
was	O
performed	O
in	O
35	O
cases	O
of	O
periodontits	O
.	O

A	O
significantly	O
higher	O
incidence	O
of	O
preterm	O
low	O
birth	O
weight	O
cases	O
in	O
patiens	O
with	O
periodontitis	O
was	O
documented	O
.	O

In	O
addition	O
higher	O
variety	O
of	O
anaerobic	O
bacteria	O
of	O
periodontal	O
pockets	O
in	O
mothers	O
with	O
preterm	O
low	O
birth	O
weight	O
infants	O
comparison	O
to	O
control	O
group	O
was	O
observed	O
.	O

Genes	O
encoding	O
virulence	O
determinants	O
are	O
transferred	O
between	O
species	O
in	O
many	O
different	O
environments	O
.	O

In	O
this	O
review	O
we	O
describe	O
gene	O
transfer	O
events	O
to	O
and	O
from	O
different	O
species	O
of	O
bacteria	O
,	O
from	O
bacteria	O
to	O
plants	O
,	O
and	O
from	O
plants	O
to	O
bacteria	O
.	O

Examples	O
of	O
the	O
setting	O
for	O
these	O
transfer	O
events	O
include	O
:	O
the	O
GI	O
tract	O
,	O
the	O
rumen	O
,	O
the	O
oral	O
cavity	O
,	O
and	O
in	O
food	O
matrixes	O
.	O

As	O
a	O
case	O
study	O
,	O
the	O
flux	O
of	O
virulence	O
factors	O
from	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
O157	I-bacteria
:	I-bacteria
H7	I-bacteria
is	O
described	O
as	O
an	O
example	O
of	O
gene	O
flow	O
in	O
the	O
environment	O
.	O

Implants	O
showing	O
signs	O
of	O
peri	O
-	O
implantitis	O
harbor	O
a	O
microbiota	O
similar	O
to	O
that	O
of	O
periodontitis	O
-	O
affected	O
teeth	O
.	O

This	O
case	O
report	O
describes	O
the	O
subgingival	O
microbiota	O
of	O
a	O
45	O
-	O
year	O
-	O
old	O
female	O
with	O
advanced	O
periodontitis	O
before	O
and	O
after	O
complete	O
edentulation	O
and	O
reconstruction	O
with	O
dental	O
implants	O
.	O

A	O
3	O
-	O
month	O
healing	O
period	O
post	O
extraction	O
passed	O
before	O
implants	O
were	O
placed	O
using	O
a	O
two	O
-	O
stage	O
submerged	O
implant	O
protocol	O
.	O

At	O
4	O
-	O
to	O
6	O
-	O
month	O
recall	O
visits	O
after	O
definitive	O
prosthetic	O
reconstruction	O
,	O
some	O
implant	O
sites	O
showed	O
bleeding	O
on	O
probing	O
and	O
localized	O
mucositis	O
.	O

Microbiological	O
culture	O
of	O
three	O
inflamed	O
peri	O
-	O
implant	O
sites	O
showed	O
an	O
almost	O
identical	O
spectrum	O
of	O
pathogens	O
,	O
including	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
and	O
other	O
major	O
pathogenic	O
bacteria	O
characteristic	O
of	O
aggressive	O
periodontitis	O
.	O

As	O
natural	O
teeth	O
were	O
absent	O
for	O
8	O
months	O
,	O
this	O
case	O
report	O
suggests	O
that	O
periodontal	O
pathogens	O
can	O
be	O
retained	O
for	O
a	O
prolonged	O
period	O
of	O
time	O
in	O
nondental	O
sites	O
,	O
from	O
where	O
they	O
can	O
later	O
colonize	O
and	O
compromise	O
the	O
health	O
of	O
dental	O
implants	O
.	O

The	O
therapeutic	O
implications	O
of	O
this	O
finding	O
are	O
discussed	O
.	O

Leprosy	O
is	O
a	O
chronic	O
infection	O
caused	O
by	O
Mycobacterium	B-bacteria
leprae	I-bacteria
,	O
a	O
bacillus	O
that	O
presents	O
a	O
peculiar	O
tropism	O
for	O
the	O
skin	O
and	O
peripheral	O
nerves	O
.	O

The	O
clinical	O
spectrum	O
of	O
leprosy	O
ranges	O
from	O
the	O
tuberculoid	O
form	O
(	O
TT	O
)	O
to	O
the	O
disseminative	O
and	O
progressive	O
lepromatous	O
form	O
(	O
LL	O
)	O
.	O

Oral	O
lesions	O
are	O
rare	O
but	O
,	O
when	O
present	O
,	O
occur	O
in	O
the	O
lepromatous	O
form	O
.	O

This	O
article	O
describes	O
the	O
clinical	O
and	O
microscopic	O
findings	O
of	O
three	O
cases	O
of	O
LL	O
with	O
oral	O
manifestations	O
.	O

All	O
patients	O
had	O
the	O
lepromatous	O
form	O
and	O
their	O
leprosy	O
-	O
specific	O
oral	O
lesions	O
occurred	O
in	O
the	O
palate	O
.	O

The	O
diagnosis	O
was	O
based	O
on	O
clinical	O
,	O
serological	O
and	O
histopathological	O
findings	O
,	O
and	O
multidrug	O
therapy	O
for	O
multibacillary	O
leprosy	O
was	O
started	O
and	O
continued	O
for	O
24	O
months	O
.	O

All	O
patients	O
completed	O
treatment	O
,	O
but	O
developed	O
reaction	O
episodes	O
which	O
were	O
treated	O
with	O
prednisone	O
and	O
/	O
or	O
thalidomide	O
.	O

The	O
authors	O
emphasize	O
the	O
importance	O
of	O
oral	O
mucosa	O
evaluation	O
by	O
a	O
dental	O
health	O
professional	O
during	O
patient	O
care	O
since	O
oral	O
lesions	O
may	O
act	O
as	O
a	O
source	O
of	O
infection	O
.	O

Two	O
kaurane	O
diterpenes	O
,	O
ent	O
-	O
kaur	O
-	O
16	O
(	O
17	O
)	O
-	O
en	O
-	O
19	O
-	O
oic	O
acid	O
(	O
KA	O
)	O
and	O
15	O
-	O
beta	O
-	O
isovaleryloxy	O
-	O
ent	O
-	O
kaur	O
-	O
16	O
(	O
17	O
)	O
-	O
en	O
-	O
19	O
-	O
oic	O
acid	O
(	O
KA	O
-	O
Ival	O
)	O
,	O
isolated	O
from	O
Aspilia	O
foliacea	O
,	O
and	O
the	O
methyl	O
ester	O
derivative	O
of	O
KA	O
(	O
KA	O
-	O
Me	O
)	O
were	O
evaluated	O
against	O
oral	O
pathogens	O
.	O

KA	O
was	O
the	O
most	O
active	O
compound	O
,	O
with	O
MIC	O
values	O
of	O
10	O
microg	O
mL	O
(	O
-	O
1	O
)	O
against	O
the	O
following	O
microorganisms	O
:	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
,	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
and	O
Lactobacillus	B-bacteria
casei	I-bacteria
.	O

However	O
,	O
KA	O
did	O
not	O
show	O
significant	O
activity	O
against	O
Streptococcus	B-bacteria
salivarius	I-bacteria
and	O
Enterococcus	B-bacteria
faecalis	I-bacteria
,	O
with	O
MIC	O
values	O
equal	O
to	O
100	O
and	O
200	O
microg	O
mL	O
(	O
-	O
1	O
)	O
,	O
respectively	O
.	O

Our	O
results	O
show	O
that	O
KA	O
has	O
potential	O
to	O
be	O
used	O
as	O
a	O
prototype	O
for	O
the	O
discovery	O
of	O
new	O
effective	O
anti	O
-	O
infection	O
agents	O
against	O
microorganisms	O
responsible	O
for	O
caries	O
and	O
periodontal	O
diseases	O
.	O

Moreover	O
,	O
these	O
results	O
allow	O
to	O
conclude	O
that	O
minor	O
structural	O
differences	O
among	O
these	O
diterpenes	O
significantly	O
influence	O
their	O
antimicrobial	O
activity	O
,	O
bringing	O
new	O
perspectives	O
to	O
studies	O
on	O
the	O
structure	O
-	O
activity	O
relationship	O
of	O
this	O
type	O
of	O
metabolites	O
with	O
respect	O
to	O
caries	O
and	O
periodontal	O
diseases	O
.	O

Ethanol	O
extracts	O
of	O
eight	O
plant	O
species	O
used	O
traditionally	O
in	O
South	O
Africa	O
for	O
the	O
treatment	O
of	O
oral	O
diseases	O
were	O
investigated	O
for	O
in	O
vitro	O
antimicrobial	O
activity	O
against	O
oral	O
pathogens	O
namely	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
Actinomyces	B-bacteria
israelii	I-bacteria
,	O
Candida	O
albicans	O
,	O
Porphyromonus	B-bacteria
gingivalis	I-bacteria
,	O
Privotella	B-bacteria
intermedia	I-bacteria
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
using	O
the	O
disk	O
diffusion	O
method	O
.	O

Minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
and	O
minimum	O
bactericidal	O
concentration	O
(	O
MBC	O
)	O
of	O
ethanol	O
extracts	O
were	O
determined	O
against	O
these	O
microorganisms	O
using	O
micro	O
dilution	O
.	O

The	O
cytotoxicity	O
and	O
therapeutic	O
index	O
(	O
TI	O
)	O
of	O
selected	O
active	O
extracts	O
were	O
also	O
determined	O
.	O

Out	O
of	O
eight	O
plants	O
,	O
six	O
(	O
Annona	O
senegalensis	O
,	O
Englerophytum	O
magalismontanum	O
,	O
Dicerocarym	O
senecioides	O
,	O
Euclea	O
divinorum	O
,	O
Euclea	O
natalensis	O
,	O
Solanum	O
panduriforme	O
and	O
Parinari	O
curatellifolia	O
)	O
exhibited	O
MIC	O
values	O
ranging	O
from	O
25	O
.	O
0	O
mg	O
/	O
ml	O
to	O
0	O
.	O
8	O
mg	O
/	O
ml	O
.	O

Gram	O
negative	O
bacteria	O
were	O
found	O
to	O
be	O
more	O
resistant	O
to	O
the	O
plant	O
extracts	O
than	O
Gram	O
positive	O
bacteria	O
,	O
except	O
for	O
Euclea	O
natalensis	O
which	O
inhibited	O
all	O
three	O
Gram	O
negative	O
bacteria	O
tested	O
in	O
this	O
study	O
.	O

All	O
plant	O
extracts	O
showed	O
moderate	O
cytotoxicity	O
on	O
the	O
Vero	O
cell	O
line	O
.	O

The	O
fifty	O
percent	O
inhibitory	O
concentration	O
(	O
IC	O
(	O
50	O
)	O
)	O
of	O
all	O
plants	O
tested	O
range	O
from	O
92	O
.	O
3	O
to	O
285	O
.	O
1	O
microg	O
/	O
ml	O
.	O

Mucosal	O
surfaces	O
are	O
the	O
primary	O
oral	O
reservoirs	O
of	O
Candida	O
species	O
,	O
but	O
these	O
species	O
can	O
also	O
be	O
found	O
in	O
subgingival	O
biofilm	O
.	O

The	O
present	O
study	O
investigated	O
the	O
genetic	O
diversity	O
and	O
production	O
of	O
exoenzymes	O
of	O
C	O
.	O
albicans	O
and	O
C	O
.	O
dubliniensis	O
isolated	O
from	O
the	O
oral	O
cavity	O
of	O
systemically	O
healthy	O
patients	O
with	O
periodontitis	O
.	O

Fifty	O
-	O
three	O
patients	O
were	O
analysed	O
.	O

Samples	O
were	O
collected	O
from	O
three	O
oral	O
cavity	O
sites	O
(	O
periodontal	O
pocket	O
,	O
gingival	O
sulci	O
and	O
oral	O
mucosa	O
)	O
,	O
plated	O
and	O
,	O
after	O
isolation	O
,	O
suspect	O
strains	O
of	O
C	O
.	O
albicans	O
and	O
C	O
.	O
dubliniensis	O
were	O
identified	O
by	O
PCR	O
.	O

The	O
genetic	O
diversity	O
of	O
the	O
isolates	O
was	O
evaluated	O
by	O
RAPD	O
and	O
the	O
activities	O
of	O
the	O
secreted	O
aspartyl	O
proteinases	O
and	O
phospholipases	O
were	O
evaluated	O
by	O
the	O
agar	O
plate	O
method	O
.	O

Twenty	O
-	O
one	O
patients	O
showed	O
positive	O
results	O
for	O
Candida	O
spp	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
genders	O
,	O
or	O
between	O
sites	O
.	O

C	O
.	O
albicans	O
was	O
the	O
most	O
frequently	O
found	O
specie	O
,	O
while	O
C	O
.	O
dubliniensis	O
was	O
isolated	O
from	O
the	O
periodontal	O
pocket	O
of	O
only	O
one	O
patient	O
.	O

Sixteen	O
genotypes	O
were	O
detected	O
among	O
the	O
C	O
.	O
albicans	O
isolates	O
,	O
and	O
one	O
among	O
the	O
C	O
.	O
dubliniensis	O
isolates	O
.	O

The	O
similarity	O
coefficient	O
(	O
S	O
(	O
SM	O
)	O
)	O
values	O
among	O
the	O
C	O
.	O
albicans	O
genotypes	O
ranged	O
from	O
0	O
.	O
684	O
to	O
1	O
.	O
0	O
with	O
an	O
average	O
of	O
0	O
.	O
905	O
+	O
/	O
-	O
0	O
.	O
074	O
.	O

All	O
isolates	O
produced	O
high	O
levels	O
of	O
Saps	O
and	O
most	O
of	O
them	O
produced	O
high	O
levels	O
of	O
phospholipases	O
.	O

No	O
relationship	O
was	O
found	O
between	O
the	O
genotypes	O
and	O
the	O
pattern	O
of	O
enzymatic	O
production	O
.	O

There	O
was	O
no	O
association	O
between	O
specific	O
genotypes	O
and	O
their	O
site	O
of	O
isolation	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
genetically	O
homogeneous	O
strains	O
of	O
C	O
.	O
albicans	O
are	O
present	O
in	O
the	O
oral	O
cavity	O
of	O
patients	O
with	O
periodontitis	O
and	O
that	O
these	O
strains	O
are	O
capable	O
of	O
producing	O
high	O
levels	O
of	O
exoenzyme	O
.	O

The	O
chewing	O
stick	O
(	O
miswak	O
)	O
is	O
used	O
for	O
oral	O
hygiene	O
in	O
many	O
parts	O
of	O
the	O
world	O
.	O

In	O
addition	O
to	O
the	O
mechanical	O
removal	O
of	O
plaque	O
,	O
an	O
antibacterial	O
effect	O
has	O
been	O
postulated	O
;	O
however	O
,	O
tests	O
of	O
miswak	O
extract	O
from	O
Salvadora	O
persica	O
(	O
Arak	O
)	O
disclosed	O
only	O
low	O
to	O
moderate	O
antibacterial	O
effects	O
.	O

This	O
may	O
be	O
attributable	O
to	O
the	O
extraction	O
process	O
.	O

Our	O
aim	O
was	O
to	O
test	O
in	O
vitro	O
the	O
antibacterial	O
effect	O
of	O
miswak	O
pieces	O
,	O
without	O
extraction	O
,	O
on	O
bacteria	O
implicated	O
in	O
the	O
etiology	O
of	O
periodontitis	O
and	O
caries	O
.	O

Miswak	O
pieces	O
were	O
standardized	O
by	O
size	O
and	O
weight	O
(	O
0	O
.	O
07	O
and	O
0	O
.	O
14	O
g	O
)	O
and	O
tested	O
against	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
previously	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
)	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
and	O
,	O
as	O
a	O
reference	O
,	O
Haemophilus	B-bacteria
influenzae	I-bacteria
.	O

The	O
miswak	O
pieces	O
were	O
tested	O
in	O
two	O
ways	O
:	O
embedded	O
in	O
the	O
agar	O
plate	O
or	O
suspended	O
above	O
the	O
agar	O
plate	O
.	O

The	O
inhibitory	O
effect	O
was	O
most	O
pronounced	O
on	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
and	O
H	B-bacteria
.	I-bacteria
influenzae	I-bacteria
,	O
less	O
on	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
and	O
least	O
on	O
L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
.	O

Suspended	O
miswak	O
had	O
comparable	O
or	O
stronger	O
effects	O
than	O
miswak	O
embedded	O
in	O
agar	O
.	O

The	O
0	O
.	O
14	O
-	O
g	O
suspended	O
miswak	O
exhibited	O
significantly	O
greater	O
inhibition	O
on	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
and	O
H	B-bacteria
.	I-bacteria
influenzae	I-bacteria
than	O
the	O
0	O
.	O
14	O
-	O
g	O
miswak	O
embedded	O
in	O
agar	O
(	O
P	O
<	O
0	O
.	O
01	O
and	O
P	O
<	O
0	O
.	O
001	O
,	O
respectively	O
)	O
.	O

Miswak	O
embedded	O
in	O
agar	O
or	O
suspended	O
above	O
the	O
agar	O
plate	O
had	O
strong	O
antibacterial	O
effects	O
against	O
all	O
bacteria	O
tested	O
.	O

The	O
antibacterial	O
effect	O
of	O
suspended	O
miswak	O
pieces	O
suggests	O
the	O
presence	O
of	O
volatile	O
active	O
antibacterial	O
compounds	O
.	O

Three	O
strains	O
of	O
anaerobic	O
,	O
variably	O
pigmenting	O
,	O
Gram	O
-	O
negative	O
bacilli	O
isolated	O
from	O
human	O
oral	O
mucosal	O
tissue	O
were	O
subjected	O
to	O
a	O
comprehensive	O
range	O
of	O
phenotypic	O
and	O
genotypic	O
tests	O
and	O
were	O
found	O
to	O
comprise	O
a	O
homogeneous	O
group	O
.	O

16S	O
rRNA	O
gene	O
sequence	O
analysis	O
and	O
DNA	O
-	O
DNA	O
hybridization	O
revealed	O
that	O
the	O
strains	O
constituted	O
a	O
novel	O
group	O
within	O
the	O
genus	O
Prevotella	B-bacteria
,	O
being	O
most	O
closely	O
related	O
to	O
Prevotella	B-bacteria
melaninogenica	I-bacteria
and	O
Prevotella	B-bacteria
veroralis	I-bacteria
.	O

A	O
novel	O
species	O
,	O
Prevotella	B-bacteria
histicola	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
is	O
proposed	O
to	O
accommodate	O
these	O
strains	O
.	O

Prevotella	B-bacteria
histicola	I-bacteria
is	O
saccharolytic	O
and	O
produces	O
acetic	O
acid	O
and	O
succinic	O
acid	O
as	O
major	O
end	O
products	O
of	O
fermentation	O
and	O
trace	O
to	O
minor	O
amounts	O
of	O
isovaleric	O
acid	O
and	O
lactic	O
acid	O
.	O

The	O
G	O
+	O
C	O
content	O
of	O
the	O
DNA	O
of	O
the	O
type	O
strain	O
is	O
43	O
mol	O
%	O
.	O

The	O
type	O
strain	O
of	O
Prevotella	B-bacteria
histicola	I-bacteria
is	O
T05	B-bacteria
-	I-bacteria
04T	I-bacteria
(	O
=	O
DSM	B-bacteria
19854T	I-bacteria
=	O
CCUG	B-bacteria
55407T	I-bacteria
)	O
.	O

There	O
is	O
now	O
strong	O
evidence	O
that	O
probiotic	O
bacteria	O
can	O
regulate	O
inflammatory	O
immune	O
responses	O
.	O

Here	O
,	O
we	O
analyzed	O
whether	O
oral	O
supplementation	O
with	O
the	O
probiotic	O
bacterial	O
strain	O
Lactobacillus	B-bacteria
johnsonii	I-bacteria
(	O
La1	B-bacteria
)	O
could	O
interfere	O
with	O
skin	O
immune	O
status	O
following	O
UV	O
exposure	O
.	O

A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
controlled	O
clinical	O
trial	O
was	O
conducted	O
with	O
54	O
healthy	O
volunteers	O
receiving	O
either	O
La1	B-bacteria
or	O
placebo	O
,	O
during	O
six	O
weeks	O
prior	O
to	O
solar	O
-	O
simulated	O
UV	O
irradiation	O
.	O

Blister	O
roofs	O
and	O
skin	O
biopsies	O
were	O
recovered	O
1	O
,	O
4	O
and	O
10	O
days	O
after	O
UV	O
exposure	O
from	O
un	O
-	O
irradiated	O
and	O
irradiated	O
skin	O
and	O
used	O
for	O
immunohistochemical	O
analysis	O
and	O
mixed	O
epidermal	O
cell	O
lymphocyte	O
reaction	O
(	O
MECLR	O
)	O
,	O
respectively	O
.	O

La1	B-bacteria
supplementation	O
did	O
not	O
prevent	O
the	O
UV	O
-	O
induced	O
phenotypic	O
maturation	O
of	O
Langerhans	O
cells	O
(	O
LCs	O
)	O
or	O
the	O
decrease	O
in	O
MECLR	O
in	O
irradiated	O
skin	O
samples	O
,	O
one	O
day	O
post	O
-	O
irradiation	O
.	O

On	O
day	O
4	O
,	O
MECLR	O
was	O
still	O
decreased	O
in	O
the	O
placebo	O
group	O
,	O
with	O
a	O
parallel	O
reduction	O
in	O
the	O
CD1a	O
LC	O
marker	O
in	O
irradiated	O
epidermis	O
.	O

In	O
contrast	O
,	O
the	O
allostimulatory	O
capacity	O
of	O
epidermal	O
cells	O
was	O
totally	O
recovered	O
in	O
the	O
La1	B-bacteria
group	O
correlating	O
with	O
the	O
normalization	O
of	O
CD1a	O
expression	O
within	O
the	O
epidermis	O
.	O

For	O
the	O
first	O
time	O
,	O
the	O
results	O
provide	O
evidence	O
that	O
ingested	O
probiotic	O
bacteria	O
accelerate	O
the	O
recovery	O
of	O
skin	O
immune	O
homeostasis	O
after	O
UV	O
-	O
induced	O
immunosuppression	O
.	O

The	O
oral	O
cavity	O
has	O
been	O
suspected	O
as	O
an	O
extra	O
-	O
gastroduodenal	O
reservoir	O
for	O
Helicobacter	B-bacteria
pylori	I-bacteria
infection	O
and	O
transmission	O
,	O
but	O
conflicting	O
evidence	O
exists	O
regarding	O
the	O
occurrence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
mouth	O
,	O
independently	O
of	O
stomach	O
colonization	O
.	O

Ninety	O
-	O
four	O
gastric	O
biopsy	O
patients	O
were	O
analysed	O
for	O
the	O
concurrent	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
mouth	O
and	O
stomach	O
.	O

Samples	O
were	O
collected	O
from	O
different	O
areas	O
within	O
the	O
mouth	O
and	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
DNA	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
verified	O
by	O
sequencing	O
.	O

Helicobacter	O
pylori	O
-	O
specific	O
serology	O
was	O
performed	O
,	O
and	O
stomach	O
colonization	O
was	O
determined	O
by	O
culture	O
.	O

In	O
addition	O
,	O
relevant	O
dental	O
and	O
periodontal	O
parameters	O
,	O
as	O
well	O
as	O
general	O
health	O
parameters	O
,	O
were	O
recorded	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
was	O
found	O
in	O
the	O
stomach	O
of	O
29	O
patients	O
and	O
in	O
the	O
oral	O
cavity	O
of	O
16	O
patients	O
.	O

In	O
only	O
six	O
patients	O
was	O
the	O
bacterium	O
detected	O
simultaneously	O
in	O
the	O
stomach	O
and	O
mouth	O
.	O

Notably	O
,	O
the	O
10	O
patients	O
in	O
whom	O
the	O
bacterium	O
was	O
found	O
solely	O
in	O
the	O
mouth	O
did	O
not	O
have	O
serum	O
antibodies	O
to	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

The	O
occurrence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
mouth	O
was	O
found	O
to	O
be	O
correlated	O
neither	O
to	O
any	O
general	O
or	O
oral	O
health	O
parameters	O
,	O
nor	O
to	O
any	O
particular	O
site	O
of	O
collection	O
.	O

This	O
study	O
shows	O
that	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
can	O
occur	O
in	O
the	O
oral	O
cavity	O
independently	O
of	O
stomach	O
colonization	O
.	O

The	O
aim	O
of	O
this	O
randomized	O
double	O
-	O
blinded	O
preliminary	O
study	O
was	O
to	O
evaluate	O
the	O
clinical	O
and	O
microbiological	O
long	O
-	O
term	O
effects	O
of	O
an	O
essential	O
-	O
oil	O
-	O
containing	O
mouth	O
rinse	O
as	O
the	O
active	O
agent	O
utilized	O
in	O
the	O
`	O
`	O
one	O
-	O
stage	O
full	O
-	O
mouth	O
disinfection	O
protocol	O
.	O
'	O
'	O

Probing	O
pocket	O
depth	O
and	O
plaque	O
and	O
gingival	O
indices	O
were	O
evaluated	O
by	O
the	O
same	O
calibrated	O
examiner	O
in	O
all	O
teeth	O
of	O
20	O
moderate	O
chronic	O
periodontitis	O
subjects	O
.	O

Presence	O
of	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
and	O
Tannerella	B-bacteria
forsythensis	I-bacteria
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
in	O
nonstimulated	O
saliva	O
,	O
tongue	O
dorsum	O
,	O
and	O
pooled	O
subgingival	O
samples	O
.	O

The	O
subjects	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
full	O
-	O
mouth	O
disinfection	O
plus	O
essential	O
oils	O
(	O
Listerine	O
)	O
or	O
full	O
-	O
mouth	O
disinfection	O
plus	O
placebo	O
.	O

Clinical	O
and	O
microbial	O
parameters	O
were	O
evaluated	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
45	O
(	O
T1	O
)	O
and	O
180	O
(	O
T2	O
)	O
days	O
after	O
therapy	O
and	O
analyzed	O
using	O
analysis	O
of	O
variance	O
,	O
Student	O
t	O
,	O
and	O
Wilcoxon	O
tests	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
groups	O
regarding	O
clinical	O
measurements	O
at	O
baseline	O
.	O

However	O
,	O
in	O
the	O
later	O
examinations	O
,	O
T1	O
and	O
T2	O
,	O
the	O
test	O
group	O
always	O
presented	O
higher	O
reductions	O
of	O
pocket	O
depth	O
,	O
plaque	O
index	O
,	O
and	O
gingival	O
index	O
compared	O
to	O
the	O
control	O
group	O
.	O

The	O
essential	O
-	O
oils	O
group	O
revealed	O
significant	O
reduction	O
on	O
occurrence	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
in	O
saliva	O
comparing	O
baseline	O
and	O
45	O
days	O
;	O
this	O
difference	O
still	O
remain	O
at	O
180	O
days	O
.	O

The	O
essential	O
-	O
oil	O
-	O
containing	O
mouth	O
rinse	O
demonstrated	O
beneficial	O
effects	O
on	O
clinical	O
parameters	O
.	O

Microbiological	O
findings	O
were	O
less	O
consistent	O
.	O

The	O
results	O
of	O
this	O
preliminary	O
study	O
suggest	O
further	O
investigations	O
.	O

The	O
antimicrobial	O
and	O
biofilm	O
formation	O
preventive	O
properties	O
of	O
Mentha	O
piperita	O
and	O
Rosmarinus	O
officinalis	O
essential	O
oils	O
and	O
chlorhexidine	O
were	O
assessed	O
against	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Streptococcus	B-bacteria
pyogenes	I-bacteria
.	O

26	O
and	O
20	O
compounds	O
were	O
identified	O
by	O
GC	O
and	O
GC	O
-	O
MS	B-bacteria
analysis	O
in	O
hydrodistilled	O
oils	O
from	O
M	O
.	O
piperita	O
and	O
R	O
.	O
officinalis	O
,	O
respectively	O
.	O

The	O
minimal	O
bactericidal	O
concentrations	O
(	O
MBC	O
)	O
of	O
the	O
M	O
.	O
piperita	O
and	O
R	O
.	O
officinalis	O
oils	O
and	O
chlorhexidine	O
were	O
(	O
6000	O
,	O
2000	O
,	O
8000	O
ppm	O
)	O
and	O
(	O
1000	O
,	O
4000	O
,	O
1000	O
ppm	O
)	O
for	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
pyogenes	I-bacteria
,	O
respectively	O
.	O

The	O
decimal	O
reduction	O
time	O
(	O
D	O
)	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
exposed	O
to	O
the	O
oils	O
at	O
their	O
MBC	O
levels	O
was	O
2	O
.	O
8	O
min	O
while	O
chlorhexidine	O
showed	O
a	O
longer	O
time	O
.	O

The	O
D	O
values	O
of	O
S	B-bacteria
.	I-bacteria
pyogenes	I-bacteria
on	O
exposure	O
to	O
the	O
MBC	O
levels	O
of	O
M	O
.	O
piperita	O
and	O
R	O
.	O
officinalis	O
oils	O
and	O
of	O
chlorhexidine	O
were	O
2	O
.	O
14	O
,	O
4	O
.	O
28	O
and	O
2	O
.	O
8	O
min	O
,	O
indicating	O
a	O
higher	O
efficacy	O
of	O
M	O
.	O
piperita	O
oil	O
.	O

Biofilm	O
formation	O
was	O
performed	O
by	O
growing	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
culture	O
with	O
and	O
without	O
essential	O
oils	O
in	O
LB	B-bacteria
medium	O
in	O
polystyrene	O
tubes	O
.	O

In	O
vitro	O
biofilm	O
inhibitory	O
properties	O
were	O
in	O
the	O
order	O
M	O
.	O
piperita	O
>	O
R	O
.	O
officinalis	O
>	O
chlorhexidine	O
.	O

In	O
vivo	O
experiments	O
on	O
the	O
antibiofilm	O
properties	O
revealed	O
that	O
all	O
concentrations	O
of	O
the	O
oils	O
were	O
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
more	O
effective	O
than	O
chlorhexidine	O
.	O

In	O
conclusion	O
,	O
essential	O
oils	O
may	O
be	O
considered	O
as	O
safe	O
agents	O
in	O
the	O
development	O
of	O
novel	O
antibiofilm	O
agents	O
.	O

to	O
compare	O
the	O
concentration	O
and	O
serotype	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
in	O
saliva	O
of	O
Down	O
syndrome	O
(	O
DS	O
)	O
,	O
mental	O
retarded	O
(	O
MR	O
)	O
and	O
healthy	O
control	O
(	O
C	O
)	O
individuals	O
of	O
the	O
Region	O
Metropolitana	O
Sur	O
of	O
Santiago	O
of	O
Chile	O
.	O

Hundred	O
and	O
seventy	O
nine	O
male	O
and	O
females	O
children	O
and	O
adolescents	O
,	O
aged	O
between	O
5	O
to	O
19	O
years	O
,	O
59	O
DS	O
,	O
60	O
MR	O
and	O
60	O
C	O
were	O
studied	O
.	O

Saliva	O
samples	O
were	O
cultured	O
in	O
TYCSB	O
agar	O
for	O
quantification	O
,	O
biochemical	O
and	O
serological	O
tests	O
.	O

ANOVA	O
and	O
Chi	O
-	O
square	O
for	O
homogeneity	O
tests	O
were	O
applied	O
.	O

C	O
,	O
DS	O
and	O
MR	O
presented	O
Streptococcus	B-bacteria
mutans	I-bacteria
(	O
serotypes	O
c	O
,	O
e	O
,	O
f	O
)	O
and	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
(	O
d	O
,	O
g	O
,	O
h	O
)	O
,	O
but	O
only	O
among	O
DS	O
and	O
MR	O
non	O
-	O
typifiable	O
(	O
No	O
-	O
tip	O
)	O
Streptococcus	B-bacteria
mutans	I-bacteria
were	O
found	O
.	O

MR	O
and	O
DS	O
showed	O
higher	O
bacteria	O
concentration	O
scores	O
than	O
C	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Serotypes	O
showed	O
a	O
significant	O
heterogeneity	O
of	O
concentration	O
scores	O
:	O
d	O
,	O
g	O
,	O
h	O
showed	O
the	O
highest	O
and	O
No	O
-	O
tip	O
the	O
lowest	O
one	O
(	O
P	O
=	O
0	O
.	O
037	O
)	O
.	O

No	O
-	O
tip	O
bacteria	O
were	O
absent	O
in	O
C	O
and	O
present	O
in	O
MR	O
and	O
DS	O
;	O
this	O
result	O
indicates	O
different	O
immune	O
and	O
ecological	O
conditions	O
among	O
these	O
human	O
groups	O
.	O

The	O
score	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
in	O
saliva	O
was	O
higher	O
in	O
DS	O
and	O
MR	O
than	O
in	O
C	O
.	O

Probiotics	O
are	O
frequently	O
used	O
for	O
multiple	O
objectives	O
and	O
the	O
majority	O
of	O
applications	O
are	O
performed	O
both	O
in	O
human	O
beings	O
and	O
in	O
different	O
animals	O
.	O

The	O
specificity	O
of	O
species	O
showed	O
by	O
the	O
members	O
of	O
the	O
indigenous	O
microbiotia	O
led	O
us	O
to	O
isolate	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
from	O
their	O
natural	O
bovine	O
ecosystems	O
and	O
to	O
select	O
those	O
with	O
probiotic	O
potentiality	O
.	O

The	O
beneficial	O
probiotic	O
LAB	B-bacteria
were	O
isolated	O
from	O
the	O
vaginal	O
tract	O
and	O
mammary	O
gland	O
of	O
adult	O
heifers	O
,	O
faeces	O
and	O
oral	O
cavity	O
of	O
newborn	O
calves	O
.	O

Bacterial	O
strains	O
and	O
their	O
numbers	O
varied	O
in	O
each	O
tract	O
under	O
study	O
.	O

Their	O
surface	O
properties	O
,	O
evaluated	O
using	O
the	O
MATH	O
test	O
,	O
revealed	O
that	O
the	O
higher	O
number	O
of	O
low	O
hydrophobic	O
strains	O
were	O
isolated	O
from	O
vaginal	O
tract	O
,	O
mammary	O
gland	O
or	O
faeces	O
.	O

The	O
capability	O
of	O
autoaggregation	O
also	O
differed	O
with	O
higher	O
degree	O
in	O
those	O
isolated	O
from	O
vagina	O
,	O
whereas	O
those	O
that	O
originated	O
in	O
the	O
mammary	O
gland	O
or	O
faeces	O
showed	O
low	O
autoaggregation	O
characteristics	O
.	O

The	O
production	O
of	O
antagonistic	O
substances	O
showed	O
that	O
the	O
production	O
of	O
hydrogen	O
peroxide	O
was	O
higher	O
in	O
the	O
strains	O
isolated	O
from	O
the	O
vaginal	O
tract	O
,	O
while	O
those	O
able	O
to	O
produce	O
organic	O
acid	O
were	O
isolated	O
from	O
all	O
the	O
environments	O
.	O

A	O
few	O
strains	O
were	O
able	O
to	O
produce	O
bacteriocins	O
and	O
were	O
isolated	O
only	O
from	O
the	O
mammary	O
gland	O
and	O
faeces	O
,	O
but	O
not	O
from	O
the	O
vaginal	O
tract	O
.	O

Further	O
studies	O
are	O
being	O
performed	O
to	O
complete	O
the	O
functional	O
characterization	O
of	O
the	O
strains	O
in	O
order	O
to	O
evaluate	O
their	O
survival	O
in	O
the	O
environmental	O
conditions	O
of	O
each	O
tract	O
.	O

Finally	O
,	O
the	O
selected	O
strains	O
could	O
be	O
combined	O
for	O
the	O
design	O
of	O
probiotic	O
products	O
to	O
be	O
used	O
both	O
in	O
adult	O
cows	O
and	O
in	O
neonates	O
,	O
based	O
on	O
the	O
host	O
-	O
specificity	O
,	O
due	O
to	O
their	O
autochthonous	O
origin	O
and	O
their	O
potential	O
use	O
in	O
the	O
tract	O
where	O
they	O
were	O
isolated	O
.	O

Human	O
beta	O
-	O
defensin	O
-	O
3	O
(	O
HBD3	O
)	O
,	O
an	O
endogenous	O
antimicrobial	O
peptide	O
,	O
has	O
strong	O
broad	O
-	O
spectrum	O
antimicrobial	O
activity	O
.	O

This	O
study	O
aimed	O
to	O
obtain	O
recombinant	O
HBD3	O
(	O
rHBD3	O
)	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
the	O
antimicrobial	O
characteristics	O
of	O
HBD3	O
may	O
offer	O
an	O
advantage	O
over	O
conventional	O
medicine	O
in	O
reducing	O
intracanal	O
bacteria	O
.	O

Genetic	O
engineering	O
was	O
used	O
to	O
obtain	O
active	O
rHBD3	O
and	O
analysis	O
revealed	O
that	O
it	O
exhibited	O
a	O
broad	O
spectrum	O
of	O
antibacterial	O
activity	O
at	O
low	O
micromolar	O
concentrations	O
against	O
not	O
only	O
Staphylococcus	B-bacteria
aureus	I-bacteria
and	O
Escherichia	B-bacteria
coli	I-bacteria
but	O
also	O
against	O
some	O
critical	O
pathogenic	O
microbes	O
in	O
infected	O
root	O
canals	O
,	O
including	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Prevotella	B-bacteria
melaninogenica	I-bacteria
,	O
Peptostreptococcus	B-bacteria
anaerobius	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
Enterococcus	B-bacteria
faecalis	I-bacteria
and	O
Candida	O
albicans	O
.	O

In	O
an	O
in	O
vitro	O
antibacterial	O
experiment	O
,	O
rHBD3	O
significantly	O
eliminated	O
pathogenic	O
bacteria	O
in	O
root	O
canals	O
.	O

The	O
ratio	O
of	O
bacterial	O
death	O
was	O
up	O
to	O
98	O
%	O
.	O

We	O
conclude	O
that	O
HBD3	O
has	O
the	O
potential	O
to	O
eliminate	O
bacteria	O
effectively	O
and	O
rapidly	O
in	O
the	O
local	O
microenvironment	O
of	O
the	O
root	O
canal	O
system	O
and	O
that	O
it	O
may	O
contribute	O
to	O
successful	O
endodontic	O
treatment	O
.	O

To	O
facilitate	O
the	O
identification	O
of	O
anaerobes	O
cultivated	O
from	O
periodontal	O
disease	O
,	O
whole	O
cell	O
bacterial	O
identification	O
by	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
-	O
MS	O
)	O
was	O
evaluated	O
.	O

A	O
total	O
of	O
84	O
strains	O
(	O
nine	O
reference	O
strains	O
and	O
75	O
recent	O
clinical	O
isolates	O
from	O
33	O
patients	O
with	O
aggressive	O
periodontitis	O
)	O
previously	O
identified	O
with	O
phenotypic	O
methods	O
were	O
used	O
.	O

All	O
the	O
references	O
and	O
10	O
clinical	O
isolates	O
belonging	O
to	O
the	O
same	O
species	O
as	O
the	O
reference	O
strains	O
were	O
genotypically	O
identified	O
by	O
sequence	O
analysis	O
of	O
the	O
16S	O
ribosomal	O
RNA	O
gene	O
.	O

All	O
the	O
strains	O
were	O
then	O
analyzed	O
using	O
MALDI	O
-	O
TOF	O
-	O
MS	O
.	O

The	O
reference	O
strains	O
of	O
anaerobic	O
bacteria	O
used	O
showed	O
characteristic	O
MALDI	O
-	O
TOF	O
-	O
MS	O
spectra	O
with	O
peaks	O
between	O
m	O
/	O
z	O
2000	O
and	O
up	O
to	O
about	O
m	O
/	O
z	O
13	O
,	O
000	O
.	O

On	O
visual	O
inspection	O
,	O
the	O
similarity	O
of	O
spectra	O
produced	O
by	O
strains	O
of	O
a	O
single	O
genus	O
could	O
be	O
recognized	O
.	O

Obvious	O
differences	O
between	O
spectra	O
produced	O
by	O
strains	O
of	O
different	O
species	O
were	O
also	O
easily	O
noticed	O
.	O

The	O
reproducibility	O
of	O
the	O
method	O
was	O
proved	O
by	O
the	O
similarity	O
of	O
spectra	O
belonging	O
to	O
the	O
same	O
species	O
.	O

The	O
spectra	O
of	O
the	O
Prevotella	B-bacteria
intermedia	I-bacteria
strains	I-bacteria
identified	O
with	O
MALDI	O
clustered	O
together	O
and	O
clustered	O
separately	O
from	O
the	O
spectra	O
of	O
Prevotella	B-bacteria
nigrescens	I-bacteria
,	O
proving	O
that	O
MALDI	O
-	O
TOF	O
-	O
MS	O
is	O
an	O
accurate	O
method	O
that	O
is	O
capable	O
of	O
separating	O
these	O
two	O
species	O
.	O

The	O
quality	O
of	O
clustering	O
was	O
characterized	O
by	O
calculating	O
an	O
inconsistency	O
coefficient	O
(	O
Our	O
results	O
suggest	O
that	O
MALDI	O
-	O
TOF	O
-	O
MS	O
might	O
become	O
a	O
useful	O
method	O
for	O
the	O
identification	O
of	O
anaerobic	O
bacteria	O
,	O
especially	O
for	O
those	O
that	O
can	O
not	O
be	O
readily	O
identified	O
by	O
biochemical	O
analysis	O
.	O

It	O
may	O
become	O
an	O
attractive	O
system	O
even	O
for	O
the	O
routine	O
identification	O
of	O
clinical	O
isolates	O
.	O

A	O
poorly	O
described	O
bacterium	O
,	O
Campylobacter	B-bacteria
rectus	I-bacteria
,	O
has	O
been	O
implicated	O
as	O
an	O
etiological	O
agent	O
of	O
periodontal	O
disease	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
use	O
a	O
comparative	O
genomics	O
approach	O
to	O
identify	O
genes	O
that	O
contribute	O
to	O
the	O
lifestyle	O
of	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
as	O
an	O
oral	O
pathogen	O
.	O

Suppressive	O
subtractive	O
hybridization	O
was	O
used	O
to	O
identify	O
genes	O
encoded	O
by	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
ATCC	I-bacteria
33238	I-bacteria
,	O
but	O
not	O
present	O
in	O
the	O
genome	O
of	O
a	O
related	O
Campylobacter	B-bacteria
species	I-bacteria
,	O
Campylobacter	B-bacteria
jejuni	I-bacteria
ATCC	I-bacteria
11168	I-bacteria
.	O

Suppressive	O
subtractive	O
hybridization	O
identified	O
154	O
unique	O
DNA	O
sequences	O
from	O
the	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
genome	O
.	O

Ninety	O
-	O
two	O
of	O
the	O
154	O
clones	O
were	O
classified	O
as	O
C	O
.	O
rectus	O
-	O
specific	O
,	O
as	O
they	O
did	O
not	O
show	O
significant	O
sequence	O
homology	O
to	O
genes	O
identified	O
in	O
any	O
strain	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
(	O
blast	O
E	O
-	O
value	O
>	O
1E	O
-	O
3	O
)	O
.	O

blast	O
analysis	O
predicted	O
that	O
the	O
92	O
C	O
.	O
rectus	O
-	O
specific	O
gene	O
fragments	O
play	O
a	O
role	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
including	O
signal	O
transduction	O
mechanisms	O
(	O
histidine	O
kinase	O
,	O
response	O
regulators	O
,	O
diguanylate	O
cyclases	O
,	O
chemotaxis	O
receptor	O
)	O
and	O
potentially	O
virulence	O
(	O
S	O
-	O
layer	O
RTX	O
and	O
cysteine	O
desulfhydrase	O
)	O
.	O

Further	O
analysis	O
of	O
the	O
C	O
.	O
rectus	O
-	O
specific	O
clones	O
showed	O
that	O
10	O
genes	O
had	O
Campylobacter	B-bacteria
homologues	O
that	O
were	O
only	O
found	O
in	O
species	O
that	O
commonly	O
reside	O
within	O
the	O
oral	O
cavity	O
of	O
humans	O
and	O
10	O
other	O
fragments	O
shared	O
homology	O
only	O
with	O
non	O
-	O
campylobacter	O
organisms	O
.	O

These	O
data	O
provide	O
the	O
first	O
substantial	O
insights	O
into	O
the	O
genomic	O
content	O
of	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
,	O
a	O
significant	O
oral	O
pathogen	O
.	O

The	O
genes	O
identified	O
in	O
this	O
study	O
are	O
a	O
valuable	O
resource	O
for	O
initiating	O
new	O
research	O
on	O
the	O
virulence	O
of	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
during	O
periodontitis	O
.	O

Ginger	O
(	O
Zingiber	O
officinale	O
Roscoe	O
)	O
has	O
been	O
used	O
widely	O
as	O
a	O
food	O
spice	O
and	O
an	O
herbal	O
medicine	O
.	O

In	O
particular	O
,	O
its	O
gingerol	O
-	O
related	O
components	O
have	O
been	O
reported	O
to	O
possess	O
antimicrobial	O
and	O
antifungal	O
properties	O
,	O
as	O
well	O
as	O
several	O
pharmaceutical	O
properties	O
.	O

However	O
,	O
the	O
effective	O
ginger	O
constituents	O
that	O
inhibit	O
the	O
growth	O
of	O
oral	O
bacteria	O
associated	O
with	O
periodontitis	O
in	O
the	O
human	O
oral	O
cavity	O
have	O
not	O
been	O
elucidated	O
.	O

This	O
study	O
revealed	O
that	O
the	O
ethanol	O
and	O
n	O
-	O
hexane	O
extracts	O
of	O
ginger	O
exhibited	O
antibacterial	O
activities	O
against	O
three	O
anaerobic	O
Gram	O
-	O
negative	O
bacteria	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
ATCC	I-bacteria
53978	I-bacteria
,	O
Porphyromonas	B-bacteria
endodontalis	I-bacteria
ATCC	I-bacteria
35406	I-bacteria
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
ATCC	I-bacteria
25611	I-bacteria
,	O
causing	O
periodontal	O
diseases	O
.	O

Thereafter	O
,	O
five	O
ginger	O
constituents	O
were	O
isolated	O
by	O
a	O
preparative	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
method	O
from	O
the	O
active	O
silica	O
-	O
gel	O
column	O
chromatography	O
fractions	O
,	O
elucidated	O
their	O
structures	O
by	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
and	O
electrospray	O
ionization	O
mass	O
spectrometry	O
and	O
their	O
antibacterial	O
activity	O
evaluated	O
.	O

In	O
conclusion	O
,	O
two	O
highly	O
alkylated	O
gingerols	O
,	O
[	O
10	O
]	O
-	O
gingerol	O
and	O
[	O
12	O
]	O
-	O
gingerol	O
effectively	O
inhibited	O
the	O
growth	O
of	O
these	O
oral	O
pathogens	O
at	O
a	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
range	O
of	O
6	O
-	O
30	O
microg	O
/	O
mL	O
.	O

These	O
ginger	O
compounds	O
also	O
killed	O
the	O
oral	O
pathogens	O
at	O
a	O
minimum	O
bactericidal	O
concentration	O
(	O
MBC	O
)	O
range	O
of	O
4	O
-	O
20	O
microg	O
/	O
mL	O
,	O
but	O
not	O
the	O
other	O
ginger	O
compounds	O
5	O
-	O
acetoxy	O
-	O
[	O
6	O
]	O
-	O
gingerol	O
,	O
3	O
,	O
5	O
-	O
diacetoxy	O
-	O
[	O
6	O
]	O
-	O
gingerdiol	O
and	O
galanolactone	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
semi	O
fermented	O
and	O
non	O
fermented	O
Camellia	O
sinensis	O
extracts	O
(	O
Black	O
and	O
Green	O
tea	O
)	O
and	O
comparison	O
between	O
them	O
against	O
Streptococcus	B-bacteria
mutans	I-bacteria
ATCC	I-bacteria
25175	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
ATCC	I-bacteria
9811	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sanguis	I-bacteria
ATCC	I-bacteria
10556	I-bacteria
that	O
are	O
responsible	O
for	O
dental	O
caries	O
and	O
bacteremias	O
following	O
dental	O
manipulations	O
.	O

Minimum	O
inhibitory	O
concentrations	O
of	O
both	O
tea	O
extracts	O
were	O
assessed	O
by	O
Well	O
diffusion	O
and	O
Broth	O
dilution	O
methods	O
and	O
examination	O
of	O
cell	O
adherence	O
(	O
Biofilm	O
inhibitory	O
concentrations	O
)	O
was	O
observed	O
on	O
glass	O
slides	O
under	O
phase	O
contrast	O
microscope	O
and	O
colony	O
counts	O
from	O
glass	O
beads	O
.	O

Concentration	O
of	O
1	O
mg	O
mL	O
(	O
-	O
1	O
)	O
of	O
semi	O
fermented	O
tea	O
extract	O
was	O
completely	O
biofilm	O
inhibitor	O
but	O
biofilm	O
formation	O
by	O
these	O
bacteria	O
was	O
seen	O
7	O
days	O
after	O
treatment	O
with	O
1	O
mg	O
mL	O
(	O
-	O
1	O
)	O
of	O
non	O
fermented	O
Camellia	O
sinensis	O
on	O
glass	O
beads	O
and	O
BIC	O
for	O
oral	O
streptococci	B-bacteria
treated	O
with	O
this	O
extract	O
was	O
1	O
.	O
5	O
,	O
2	O
.	O
5	O
mg	O
mL	O
(	O
-	O
1	O
)	O
of	O
semi	O
fermented	O
and	O
3	O
mg	O
mL	O
(	O
-	O
1	O
)	O
of	O
non	O
fermented	O
extracts	O
had	O
bactericidal	O
effect	O
on	O
these	O
bacteria	O
.	O

Semi	O
fermented	O
and	O
non	O
fermented	O
Camellia	O
sinensis	O
extracts	O
were	O
able	O
to	O
prevent	O
growth	O
of	O
oral	O
streptococci	B-bacteria
.	O

Therefore	O
dental	O
caries	O
significantly	O
reduce	O
and	O
the	O
efficiency	O
of	O
semi	O
fermented	O
tea	O
was	O
higher	O
due	O
to	O
rich	O
content	O
of	O
volatile	O
components	O
rather	O
than	O
non	O
fermented	O
extracts	O
.	O

We	O
present	O
a	O
novel	O
concept	O
on	O
carcinogenesis	O
mediated	O
by	O
oral	O
microbiota	O
.	O

Oral	O
micro	O
-	O
organisms	O
are	O
capable	O
of	O
metabolizing	O
alcohol	O
to	O
acetaldehyde	O
.	O

This	O
finding	O
casts	O
light	O
on	O
the	O
observed	O
association	O
between	O
poor	O
oral	O
hygiene	O
and	O
oral	O
cancer	O
.	O

Ethanol	O
,	O
as	O
such	O
,	O
is	O
not	O
carcinogenic	O
,	O
but	O
its	O
first	O
metabolite	O
acetaldehyde	O
is	O
indisputably	O
carcinogenic	O
.	O

Several	O
gastro	O
-	O
intestinal	O
microbial	O
species	O
possess	O
the	O
enzyme	O
alcohol	O
dehydrogenase	O
(	O
ADH	O
)	O
,	O
which	O
is	O
also	O
the	O
enzyme	O
responsible	O
for	O
alcohol	O
metabolism	O
in	O
the	O
liver	O
.	O

In	O
oral	O
microbiota	O
,	O
we	O
observed	O
that	O
species	O
such	O
as	O
the	O
ubiquitous	O
viridans	B-bacteria
streptococci	I-bacteria
and	O
Candida	O
also	O
possess	O
ADH	O
.	O

Ethanol	O
can	O
be	O
detected	O
in	O
the	O
mouth	O
hours	O
after	O
the	O
consumption	O
of	O
alcoholic	O
beverages	O
.	O

Patients	O
with	O
poor	O
oral	O
health	O
status	O
have	O
shown	O
higher	O
salivary	O
acetaldehyde	O
concentrations	O
than	O
those	O
with	O
better	O
oral	O
health	O
.	O

It	O
is	O
thus	O
understandable	O
that	O
ADH	O
-	O
containing	O
micro	O
-	O
organisms	O
in	O
the	O
mouth	O
present	O
a	O
risk	O
for	O
carcinogenic	O
acetaldehyde	O
production	O
,	O
with	O
subsequent	O
potential	O
for	O
the	O
development	O
of	O
oral	O
cancer	O
,	O
particularly	O
among	O
heavy	O
drinkers	O
.	O

In	O
this	O
article	O
,	O
we	O
briefly	O
review	O
this	O
area	O
of	O
investigation	O
and	O
conclude	O
by	O
highlighting	O
some	O
future	O
possibilities	O
for	O
the	O
control	O
of	O
carcinogenesis	O
.	O

Generally	O
,	O
mechanical	O
plaque	O
control	O
without	O
chemical	O
support	O
is	O
insufficient	O
to	O
prevent	O
oral	O
diseases	O
,	O
and	O
an	O
ongoing	O
quest	O
exists	O
for	O
new	O
antimicrobials	O
for	O
use	O
in	O
oral	O
healthcare	O
.	O

Chitosans	O
are	O
polycationic	O
,	O
naturally	O
occurring	O
antimicrobials	O
that	O
are	O
rapidly	O
finding	O
their	O
way	O
into	O
oral	O
healthcare	O
.	O

In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
pellicle	O
treatment	O
with	O
chitosan	O
on	O
bacterial	O
adhesion	O
and	O
growth	O
.	O

Chitosan	O
caused	O
a	O
reduction	O
in	O
bacterial	O
adhesion	O
and	O
was	O
responsible	O
for	O
bacterial	O
death	O
upon	O
contact	O
compared	O
with	O
a	O
buffer	O
control	O
.	O

Exposure	O
of	O
adhering	O
bacteria	O
to	O
a	O
chitosan	O
solution	O
or	O
a	O
buffer	O
control	O
did	O
not	O
cause	O
detachment	O
,	O
but	O
the	O
chitosan	O
solution	O
left	O
a	O
small	O
proportion	O
of	O
the	O
adhering	O
bacteria	O
alive	O
.	O

Growth	O
after	O
exposure	O
to	O
chitosan	O
was	O
similar	O
to	O
(	O
Streptococcus	B-bacteria
mutans	I-bacteria
ATCC700610	I-bacteria
,	O
Streptococcus	B-bacteria
oralis	I-bacteria
HM1	I-bacteria
,	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
HG1025	I-bacteria
)	O
or	O
less	O
than	O
(	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
NS	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
HM1	I-bacteria
)	O
that	O
of	O
the	O
control	O
,	O
while	O
biofilm	O
viability	O
after	O
chitosan	O
treatment	O
was	O
lower	O
than	O
that	O
of	O
the	O
control	O
,	O
except	O
for	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
HM1	I-bacteria
.	O

Therefore	O
,	O
chitosan	O
is	O
a	O
promising	O
antimicrobial	O
for	O
use	O
in	O
oral	O
healthcare	O
.	O

A	O
multitude	O
of	O
molecular	O
methods	O
are	O
currently	O
used	O
for	O
identification	O
and	O
characterization	O
of	O
oral	O
biofilms	O
or	O
for	O
community	O
profiling	O
.	O

However	O
,	O
multiplex	O
PCR	O
techniques	O
that	O
are	O
able	O
to	O
routinely	O
identify	O
several	O
species	O
in	O
a	O
single	O
assay	O
are	O
not	O
available	O
.	O

Multiplex	O
Ligation	O
-	O
dependent	O
Probe	O
Amplification	O
(	O
MLPA	O
)	O
identifies	O
up	O
to	O
45	O
unique	O
fragments	O
in	O
a	O
single	O
tube	O
PCR	O
.	O

Here	O
we	O
report	O
a	O
novel	O
use	O
of	O
MLPA	O
in	O
the	O
relative	O
quantification	O
of	O
targeted	O
microorganisms	O
in	O
a	O
community	O
of	O
oral	O
microbiota	O
.	O

We	O
designed	O
9	O
species	O
specific	O
probes	O
for	O
:	O
Actinomyces	B-bacteria
gerencseriae	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
Actinomyces	B-bacteria
odontolyticus	I-bacteria
,	O
Candida	O
albicans	O
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
Rothia	B-bacteria
dentocariosa	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
and	O
Veillonella	B-bacteria
parvula	I-bacteria
;	O
and	O
genus	O
specific	O
probes	O
for	O
selected	O
oral	O
Streptococci	B-bacteria
and	O
Lactobacilli	B-bacteria
based	O
on	O
their	O
16S	O
rDNA	O
sequences	O
.	O

MLPA	O
analysis	O
of	O
DNA	O
pooled	O
from	O
the	O
strains	O
showed	O
the	O
expected	O
specific	O
MLPA	O
products	O
.	O

Relative	O
quantification	O
of	O
a	O
serial	O
dilution	O
of	O
equimolar	O
DNA	O
showed	O
that	O
as	O
little	O
as	O
10	O
pg	O
templates	O
can	O
be	O
detected	O
with	O
clearly	O
discernible	O
signals	O
.	O

Moreover	O
,	O
a	O
2	O
to	O
7	O
%	O
divergence	O
in	O
relative	O
signal	O
ratio	O
of	O
amplified	O
probes	O
observed	O
from	O
normalized	O
peak	O
area	O
values	O
suggests	O
MLPA	O
can	O
be	O
a	O
cheaper	O
alternative	O
to	O
using	O
qPCR	O
for	O
quantification	O
.	O

We	O
observed	O
2	O
to	O
6	O
fold	O
fluctuations	O
in	O
signal	O
intensities	O
of	O
MLPA	O
products	O
in	O
DNAs	O
isolated	O
from	O
multispecies	O
biofilms	O
grown	O
in	O
various	O
media	O
for	O
various	O
culture	O
times	O
.	O

Furthermore	O
,	O
MLPA	O
analyses	O
of	O
DNA	O
isolated	O
from	O
saliva	O
obtained	O
from	O
different	O
donors	O
gave	O
a	O
varying	O
number	O
and	O
intensity	O
of	O
signals	O
.	O

This	O
clearly	O
shows	O
the	O
usefulness	O
of	O
MLPA	O
in	O
a	O
quantitative	O
description	O
of	O
microbial	O
shifts	O
.	O

In	O
the	O
last	O
decade	O
,	O
as	O
a	O
result	O
of	O
the	O
widespread	O
use	O
of	O
PCR	O
and	O
DNA	O
sequencing	O
,	O
16S	O
rDNA	O
sequencing	O
has	O
played	O
a	O
pivotal	O
role	O
in	O
the	O
accurate	O
identification	O
of	O
bacterial	O
isolates	O
and	O
the	O
discovery	O
of	O
novel	O
bacteria	O
in	O
clinical	O
microbiology	O
laboratories	O
.	O

For	O
bacterial	O
identification	O
,	O
16S	O
rDNA	O
sequencing	O
is	O
particularly	O
important	O
in	O
the	O
case	O
of	O
bacteria	O
with	O
unusual	O
phenotypic	O
profiles	O
,	O
rare	O
bacteria	O
,	O
slow	O
-	O
growing	O
bacteria	O
,	O
uncultivable	O
bacteria	O
and	O
culture	O
-	O
negative	O
infections	O
.	O

Not	O
only	O
has	O
it	O
provided	O
insights	O
into	O
aetiologies	O
of	O
infectious	O
disease	O
,	O
but	O
it	O
also	O
helps	O
clinicians	O
in	O
choosing	O
antibiotics	O
and	O
in	O
determining	O
the	O
duration	O
of	O
treatment	O
and	O
infection	O
control	O
procedures	O
.	O

With	O
the	O
use	O
of	O
16S	O
rDNA	O
sequencing	O
,	O
215	O
novel	O
bacterial	O
species	O
,	O
29	O
of	O
which	O
belong	O
to	O
novel	O
genera	O
,	O
have	O
been	O
discovered	O
from	O
human	O
specimens	O
in	O
the	O
past	O
7	O
years	O
of	O
the	O
21st	O
century	O
(	O
2001	O
-	O
2007	O
)	O
.	O

One	O
hundred	O
of	O
the	O
215	O
novel	O
species	O
,	O
15	O
belonging	O
to	O
novel	O
genera	O
,	O
have	O
been	O
found	O
in	O
four	O
or	O
more	O
subjects	O
.	O

The	O
largest	O
number	O
of	O
novel	O
species	O
discovered	O
were	O
of	O
the	O
genera	O
Mycobacterium	B-bacteria
(	O
n	O
=	O
12	O
)	O
and	O
Nocardia	B-bacteria
(	O
n	O
=	O
6	O
)	O
.	O

The	O
oral	O
cavity	O
/	O
dental	O
-	O
related	O
specimens	O
(	O
n	O
=	O
19	O
)	O
and	O
the	O
gastrointestinal	O
tract	O
(	O
n	O
=	O
26	O
)	O
were	O
the	O
most	O
important	O
sites	O
for	O
discovery	O
and	O
/	O
or	O
reservoirs	O
of	O
novel	O
species	O
.	O

Among	O
the	O
100	O
novel	O
species	O
,	O
Streptococcus	B-bacteria
sinensis	I-bacteria
,	O
Laribacter	B-bacteria
hongkongensis	I-bacteria
,	O
Clostridium	B-bacteria
hathewayi	I-bacteria
and	O
Borrelia	B-bacteria
spielmanii	I-bacteria
have	O
been	O
most	O
thoroughly	O
characterized	O
,	O
with	O
the	O
reservoirs	O
and	O
routes	O
of	O
transmission	O
documented	O
,	O
and	O
S	O
.	O
sinensis	O
,	O
L	O
.	O
hongkongensis	O
and	O
C	O
.	O
hathewayi	O
have	O
been	O
found	O
globally	O
.	O

One	O
of	O
the	O
greatest	O
hurdles	O
in	O
putting	O
16S	O
rDNA	O
sequencing	O
into	O
routine	O
use	O
in	O
clinical	O
microbiology	O
laboratories	O
is	O
automation	O
of	O
the	O
technology	O
.	O

The	O
only	O
step	O
that	O
can	O
be	O
automated	O
at	O
the	O
moment	O
is	O
input	O
of	O
the	O
16S	O
rDNA	O
sequence	O
of	O
the	O
bacterial	O
isolate	O
for	O
identification	O
into	O
one	O
of	O
the	O
software	O
packages	O
that	O
will	O
generate	O
the	O
result	O
of	O
the	O
identity	O
of	O
the	O
isolate	O
on	O
the	O
basis	O
of	O
its	O
sequence	O
database	O
.	O

However	O
,	O
studies	O
on	O
the	O
accuracy	O
of	O
the	O
software	O
packages	O
have	O
given	O
highly	O
varied	O
results	O
,	O
and	O
interpretation	O
of	O
results	O
remains	O
difficult	O
for	O
most	O
technicians	O
,	O
and	O
even	O
for	O
clinical	O
microbiologists	O
.	O

To	O
fully	O
utilize	O
16S	O
rDNA	O
sequencing	O
in	O
clinical	O
microbiology	O
,	O
better	O
guidelines	O
are	O
needed	O
for	O
interpretation	O
of	O
the	O
identification	O
results	O
,	O
and	O
additional	O
/	O
supplementary	O
methods	O
are	O
necessary	O
for	O
bacterial	O
species	O
that	O
can	O
not	O
be	O
identified	O
confidently	O
by	O
16S	O
rDNA	O
sequencing	O
alone	O
.	O

To	O
obtain	O
deeper	O
insights	O
into	O
the	O
etiology	O
of	O
oral	O
disease	O
,	O
an	O
understanding	O
of	O
the	O
composition	O
of	O
the	O
surrounding	O
bacterial	O
environments	O
that	O
lead	O
to	O
health	O
or	O
disease	O
is	O
required	O
,	O
which	O
is	O
attracting	O
increasing	O
attention	O
.	O

In	O
this	O
study	O
,	O
the	O
bacterial	O
compositions	O
in	O
the	O
saliva	O
of	O
200	O
subjects	O
aged	O
15	O
-	O
40	O
years	O
were	O
depicted	O
as	O
peak	O
patterns	O
by	O
terminal	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
T	O
-	O
RFLP	O
)	O
analysis	O
of	O
16S	O
rRNA	O
genes	O
.	O

The	O
subjects	O
were	O
classified	O
into	O
three	O
clusters	O
by	O
partitioning	O
around	O
medoids	O
clustering	O
based	O
on	O
their	O
T	O
-	O
RFLP	O
profiles	O
,	O
and	O
the	O
clinical	O
oral	O
health	O
parameters	O
of	O
the	O
clusters	O
were	O
compared	O
.	O

The	O
clustering	O
of	O
the	O
T	O
-	O
RFLP	O
profiles	O
in	O
this	O
study	O
was	O
mainly	O
based	O
on	O
differences	O
in	O
the	O
abundance	O
distribution	O
of	O
the	O
dominant	O
terminal	O
restriction	O
fragments	O
(	O
TRFs	O
)	O
detected	O
in	O
most	O
of	O
the	O
subjects	O
.	O

Predicted	O
from	O
the	O
sizes	O
of	O
the	O
TRFs	O
,	O
the	O
characteristically	O
more	O
predominant	O
members	O
of	O
each	O
were	O
Prevotella	B-bacteria
and	O
Veillonella	B-bacteria
species	I-bacteria
in	O
cluster	O
I	O
;	O
Streptococcus	B-bacteria
species	I-bacteria
in	O
cluster	O
II	O
and	O
Neisseria	B-bacteria
,	O
Haemophilus	B-bacteria
or	O
Aggregatibacter	B-bacteria
species	I-bacteria
and	O
Porphyromonas	B-bacteria
species	I-bacteria
in	O
cluster	O
III	O
.	O

The	O
parameters	O
associated	O
with	O
periodontal	O
disease	O
were	O
significantly	O
different	O
among	O
the	O
clusters	O
.	O

Clusters	O
I	O
and	O
II	O
had	O
a	O
higher	O
percentage	O
of	O
sites	O
of	O
periodontal	O
pockets	O
greater	O
than	O
4	O
mm	O
than	O
cluster	O
III	O
,	O
and	O
cluster	O
I	O
contained	O
sites	O
exhibiting	O
bleeding	O
on	O
probing	O
more	O
often	O
than	O
cluster	O
II	O
or	O
III	O
;	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
other	O
parameters	O
.	O

These	O
results	O
suggest	O
that	O
the	O
abundance	O
distribution	O
of	O
commensal	O
bacteria	O
in	O
saliva	O
is	O
correlated	O
with	O
periodontal	O
health	O
,	O
and	O
might	O
be	O
involved	O
in	O
the	O
susceptibility	O
of	O
an	O
individual	O
to	O
periodontal	O
disease	O
.	O

The	O
microbiota	O
of	O
the	O
human	O
oral	O
mucosa	O
consists	O
of	O
a	O
myriad	O
of	O
bacterial	O
species	O
that	O
normally	O
exist	O
in	O
commensal	O
harmony	O
with	O
the	O
host	O
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
an	O
aetiological	O
agent	O
in	O
severe	O
forms	O
of	O
periodontitis	O
(	O
a	O
chronic	O
inflammatory	O
disease	O
)	O
,	O
is	O
a	O
prominent	O
component	O
of	O
the	O
oral	O
microbiome	O
and	O
a	O
successful	O
colonizer	O
of	O
the	O
oral	O
epithelium	O
.	O

This	O
Gram	O
-	O
negative	O
anaerobe	O
can	O
also	O
exist	O
within	O
the	O
host	O
epithelium	O
without	O
the	O
existence	O
of	O
overt	O
disease	O
.	O

Gingival	O
epithelial	O
cells	O
,	O
the	O
outer	O
lining	O
of	O
the	O
gingival	O
mucosa	O
,	O
which	O
function	O
as	O
an	O
important	O
part	O
of	O
the	O
innate	O
immune	O
system	O
,	O
are	O
among	O
the	O
first	O
host	O
cells	O
colonized	O
by	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

This	O
review	O
describes	O
recent	O
studies	O
implicating	O
the	O
co	O
-	O
existence	O
and	O
intracellular	O
adaptation	O
of	O
the	O
organism	O
in	O
these	O
target	O
host	O
cells	O
.	O

Specifically	O
,	O
recent	O
findings	O
on	O
the	O
putative	O
mechanisms	O
of	O
persistence	O
,	O
intercellular	O
dissemination	O
and	O
opportunism	O
are	O
highlighted	O
.	O

These	O
new	O
findings	O
may	O
also	O
represent	O
an	O
original	O
and	O
valuable	O
model	O
for	O
mechanistic	O
characterization	O
of	O
other	O
successful	O
host	O
-	O
adapted	O
,	O
self	O
-	O
limiting	O
,	O
persistent	O
intracellular	O
bacteria	O
in	O
human	O
epithelial	O
tissues	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
colonization	O
of	O
Campylobacter	B-bacteria
rectus	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
previously	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
)	O
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
(	O
previously	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
)	O
in	O
the	O
tongue	O
and	O
cheek	O
of	O
newborns	O
and	O
elderly	O
individuals	O
with	O
no	O
teeth	O
.	O

Seventy	O
-	O
four	O
edentulous	O
subjects	O
were	O
included	O
in	O
this	O
cross	O
-	O
sectional	O
study	O
.	O

Microbiologic	O
samples	O
were	O
taken	O
from	O
the	O
dorsum	O
of	O
the	O
tongue	O
and	O
cheek	O
mucosa	O
of	O
all	O
individuals	O
and	O
analyzed	O
using	O
a	O
bacterial	O
DNA	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O

C	B-bacteria
.	I-bacteria
rectus	I-bacteria
was	O
the	O
most	O
prevalent	O
species	O
in	O
both	O
groups	O
(	O
20	O
.	O
9	O
%	O
in	O
the	O
cheek	O
of	O
newborns	O
,	O
and	O
77	O
.	O
4	O
%	O
in	O
the	O
tongue	O
of	O
elderly	O
subjects	O
)	O
.	O

P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
43	O
newborns	O
;	O
however	O
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
was	O
recovered	O
from	O
the	O
tongue	O
and	O
cheek	O
(	O
3	O
.	O
2	O
%	O
)	O
of	O
elderly	O
individuals	O
,	O
whereas	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
was	O
detected	O
in	O
the	O
tongue	O
(	O
9	O
.	O
6	O
%	O
)	O
and	O
cheek	O
(	O
3	O
.	O
2	O
%	O
)	O
of	O
elderly	O
individuals	O
.	O

T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
was	O
detected	O
in	O
newborns	O
as	O
well	O
as	O
elderly	O
individuals	O
,	O
although	O
the	O
highest	O
prevalence	O
was	O
observed	O
in	O
the	O
tongue	O
of	O
newborns	O
(	O
6	O
.	O
9	O
%	O
)	O
and	O
elderly	O
(	O
9	O
.	O
6	O
%	O
)	O
individuals	O
.	O

A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
was	O
not	O
found	O
in	O
the	O
tongue	O
of	O
newborns	O
,	O
but	O
we	O
observed	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
in	O
the	O
cheek	O
(	O
2	O
.	O
3	O
%	O
)	O
of	O
newborns	O
and	O
in	O
the	O
tongue	O
(	O
12	O
.	O
9	O
%	O
)	O
and	O
cheek	O
(	O
6	O
.	O
4	O
%	O
)	O
of	O
elderly	O
patients	O
.	O

Although	O
we	O
did	O
not	O
detect	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
in	O
newborns	O
,	O
periodontal	O
pathogens	O
could	O
be	O
detected	O
from	O
the	O
oral	O
mucous	O
membranes	O
of	O
edentulous	O
individuals	O
.	O

Our	O
results	O
suggest	O
that	O
major	O
attention	O
should	O
be	O
paid	O
to	O
edentulous	O
individuals	O
as	O
an	O
important	O
measure	O
in	O
the	O
prevention	O
of	O
the	O
initial	O
colonization	O
of	O
natural	O
teeth	O
and	O
dental	O
implants	O
by	O
periodontal	O
pathogens	O
.	O

Changes	O
in	O
the	O
levels	O
of	O
female	O
sex	O
hormones	O
during	O
the	O
menstrual	O
cycle	O
may	O
cause	O
cyclic	O
differences	O
in	O
subgingival	O
bacterial	O
colonization	O
patterns	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
hormonal	O
changes	O
in	O
the	O
menstrual	O
cycle	O
cause	O
changes	O
in	O
the	O
oral	O
microbiota	O
.	O

Bacterial	O
plaque	O
samples	O
were	O
collected	O
in	O
20	O
systemically	O
and	O
periodontally	O
healthy	O
women	O
using	O
no	O
hormonal	O
contraceptives	O
(	O
test	O
group	O
)	O
over	O
a	O
period	O
of	O
6	O
weeks	O
.	O

Twenty	O
age	O
-	O
matched	O
systemically	O
and	O
periodontally	O
healthy	O
men	O
were	O
assigned	O
to	O
the	O
control	O
group	O
.	O

Samples	O
were	O
processed	O
by	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
assay	O
,	O
and	O
74	O
species	O
were	O
analyzed	O
.	O

No	O
cyclic	O
pattern	O
of	O
bacterial	O
colonization	O
was	O
identified	O
for	O
any	O
of	O
the	O
74	O
species	O
studied	O
in	O
women	O
not	O
using	O
hormonal	O
contraceptives	O
.	O

Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
previously	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
)	O
(	O
Y4	B-bacteria
)	O
was	O
common	O
at	O
the	O
beginning	O
of	O
menstruation	O
(	O
mean	O
:	O
32	O
%	O
)	O
and	O
increased	O
during	O
the	O
following	O
2	O
weeks	O
(	O
36	O
%	O
)	O
in	O
women	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

No	O
cyclic	O
differences	O
in	O
bacterial	O
presence	O
were	O
found	O
among	O
the	O
men	O
(	O
P	O
values	O
varied	O
between	O
0	O
.	O
14	O
and	O
0	O
.	O
98	O
)	O
.	O

Men	O
presented	O
with	O
significantly	O
higher	O
bacterial	O
counts	O
for	O
40	O
of	O
74	O
species	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
including	O
Staphylococcus	B-bacteria
aureus	I-bacteria
and	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
but	O
not	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
P	O
=	O
0	O
.	O
15	O
)	O
or	O
Tannerella	B-bacteria
forsythia	I-bacteria
(	O
previously	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
)	O
(	O
P	O
=	O
0	O
.	O
42	O
)	O
.	O

During	O
a	O
menstruation	O
period	O
,	O
cyclic	O
variation	O
in	O
the	O
subgingival	O
microbiota	O
of	O
periodontally	O
healthy	O
women	O
of	O
child	O
-	O
bearing	O
age	O
who	O
were	O
not	O
using	O
oral	O
hormonal	O
contraceptives	O
could	O
not	O
be	O
confirmed	O
.	O

Male	O
control	O
subjects	O
presented	O
with	O
higher	O
levels	O
of	O
many	O
species	O
but	O
also	O
without	O
a	O
cyclic	O
pattern	O
.	O

The	O
presence	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
.	O

in	O
the	O
oral	O
cavity	O
remains	O
controversial	O
and	O
the	O
most	O
appropriate	O
method	O
for	O
detection	O
of	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
has	O
yet	O
to	O
be	O
established	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
four	O
different	O
primer	O
sets	O
on	O
the	O
detection	O
of	O
H	B-bacteria
.	I-bacteria
pylor	I-bacteria
in	O
gastric	O
biopsies	O
and	O
oral	O
samples	O
using	O
real	O
-	O
time	O
PCR	O
.	O

Gastric	O
biopsy	O
and	O
oral	O
samples	O
were	O
collected	O
from	O
eight	O
patients	O
with	O
gastric	O
symptoms	O
.	O

DNA	O
from	O
clinical	O
samples	O
was	O
extracted	O
and	O
analyzed	O
for	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
by	O
real	O
-	O
time	O
PCR	O
(	O
LightCycler	O
2	O
.	O
0	O
)	O
using	O
four	O
pairs	O
of	O
primers	O
which	O
targeted	O
16S	O
rRNA	O
(	O
16S	O
rRNA	O
#	O
295	O
;	O
16S	O
rRNA	O
#	O
120	O
)	O
or	O
glmM	O
(	O
glmM	O
#	O
294	O
;	O
glmM	O
#	O
722	O
)	O
DNA	O
genes	O
.	O

Three	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
strains	I-bacteria
and	O
three	O
clinical	O
isolates	O
served	O
as	O
reference	O
.	O

The	O
specificities	O
of	O
the	O
four	O
primer	O
pairs	O
were	O
examined	O
for	O
seven	O
oral	O
microorganisms	O
and	O
two	O
Helicobacter	B-bacteria
non	I-bacteria
-	I-bacteria
pylori	I-bacteria
species	I-bacteria
.	O

Primer	O
pair	O
16S	O
rRNA	O
#	O
120	O
showed	O
an	O
acceptable	O
specificity	O
and	O
a	O
high	O
sensitivity	O
.	O

Primer	O
pairs	O
glmM	O
#	O
294	O
and	O
glmM	O
#	O
722	O
demonstrated	O
a	O
high	O
specificity	O
but	O
a	O
low	O
sensitivity	O
and	O
primer	O
pair	O
16S	O
rRNA	O
#	O
295	O
demonstrated	O
a	O
poor	O
specificity	O
but	O
acceptable	O
sensitivity	O
.	O

Four	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
positive	O
gastric	O
biopsies	O
were	O
demonstrated	O
by	O
culture	O
,	O
histology	O
and	O
real	O
-	O
time	O
PCR	O
with	O
primer	O
pairs	O
16S	O
rRNA	O
#	O
295	O
or	O
16S	O
rRNA	O
#	O
120	O
.	O

No	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
detected	O
in	O
oral	O
samples	O
,	O
either	O
by	O
culture	O
or	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Of	O
the	O
four	O
different	O
primer	O
pairs	O
examined	O
,	O
16S	O
rRNA	O
#	O
120	O
was	O
the	O
most	O
appropriate	O
to	O
detect	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
clinical	O
samples	O
using	O
real	O
-	O
time	O
PCR	O
.	O

Conventional	O
culture	O
methods	O
and	O
Multiplex	O
PCR	O
,	O
both	O
of	O
which	O
we	O
have	O
been	O
used	O
for	O
a	O
long	O
time	O
in	O
our	O
clinical	O
microbiology	O
laboratory	O
,	O
were	O
compared	O
for	O
their	O
ability	O
to	O
detect	O
a	O
selected	O
panel	O
of	O
periodontopathic	O
bacteria	O
:	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Campylobacter	B-bacteria
rectus	I-bacteria
,	O
Eikenella	B-bacteria
corrodens	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
.	O

Tests	O
were	O
performed	O
in	O
a	O
single	O
subgingival	O
sample	O
taken	O
from	O
a	O
periodontal	O
diseased	O
site	O
with	O
a	O
probing	O
depth	O
equal	O
to	O
or	O
greater	O
than	O
6mm	O
.	O

The	O
results	O
were	O
compared	O
site	O
-	O
by	O
-	O
site	O
,	O
taking	O
into	O
account	O
the	O
quality	O
and	O
the	O
presence	O
or	O
absence	O
of	O
pathogens	O
.	O

529	O
samples	O
of	O
subgingival	O
plaque	O
were	O
analysed	O
and	O
the	O
prevalence	O
of	O
the	O
six	O
species	O
monitored	O
varied	O
in	O
relation	O
to	O
the	O
species	O
itself	O
and	O
the	O
method	O
of	O
detection	O
.	O

The	O
most	O
represented	O
species	O
is	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
,	O
with	O
a	O
percentage	O
of	O
positive	O
variability	O
between	O
44	O
.	O
9	O
%	O
PCR	O
and	O
46	O
.	O
5	O
%	O
culture	O
test	O
.	O

Generally	O
,	O
the	O
lowest	O
prevalence	O
was	O
determined	O
by	O
culture	O
test	O
,	O
with	O
the	O
exception	O
of	O
E	B-bacteria
.	I-bacteria
corrodens	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
,	O
which	O
,	O
unlike	O
other	O
bacteria	O
,	O
have	O
been	O
seen	O
in	O
higher	O
percentages	O
in	O
culture	O
with	O
respect	O
to	O
PCR	O
.	O

For	O
both	O
methods	O
,	O
there	O
was	O
a	O
good	O
degree	O
of	O
accuracy	O
in	O
the	O
determination	O
of	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
,	O
E	B-bacteria
.	I-bacteria
corrodens	I-bacteria
,	O
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

It	O
becomes	O
weak	O
for	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
.	O

Both	O
culture	O
and	O
PCR	O
techniques	O
introduced	O
many	O
methodological	O
problems	O
when	O
applied	O
in	O
oral	O
microbiology	O
,	O
but	O
the	O
ideal	O
technique	O
for	O
accurate	O
detection	O
of	O
pathogens	O
in	O
subgingival	O
plaque	O
samples	O
has	O
yet	O
to	O
be	O
developed	O
.	O

This	O
crossover	O
design	O
clinical	O
study	O
compared	O
the	O
anti	O
-	O
microbial	O
effects	O
of	O
a	O
new	O
1	O
%	O
zinc	O
citrate	O
dentifrice	O
with	O
a	O
control	O
formulation	O
.	O

Thirty	O
adults	O
completed	O
a	O
washout	O
phase	O
and	O
baseline	O
samples	O
of	O
dental	O
plaque	O
,	O
buccal	O
mucosa	O
,	O
tongue	O
,	O
saliva	O
,	O
and	O
plaque	O
collected	O
to	O
enumerate	O
anaerobes	O
and	O
streptococci	B-bacteria
.	O

Subjects	O
were	O
randomly	O
assigned	O
a	O
test	O
dentifrice	O
to	O
use	O
for	O
the	O
next	O
13	O
days	O
.	O

Oral	O
samples	O
similar	O
to	O
the	O
baseline	O
were	O
collected	O
on	O
day	O
14	O
prior	O
to	O
oral	O
hygiene	O
for	O
microbial	O
analysis	O
.	O

The	O
subject	O
then	O
placed	O
a	O
custom	O
intra	O
-	O
oral	O
stent	O
with	O
hydroxyapatite	O
(	O
HA	O
)	O
squares	O
and	O
brushed	O
their	O
teeth	O
with	O
their	O
assigned	O
dentifrice	O
.	O

Oral	O
samples	O
and	O
HA	O
squares	O
were	O
collected	O
5	O
h	O
later	O
for	O
microbial	O
analyses	O
.	O

This	O
completed	O
the	O
study	O
with	O
one	O
test	O
dentifrice	O
.	O

The	O
entire	O
study	O
was	O
repeated	O
with	O
the	O
alternate	O
dentifrice	O
after	O
a	O
second	O
washout	O
phase	O
.	O

Whereas	O
baseline	O
samples	O
demonstrated	O
no	O
significant	O
differences	O
in	O
microbial	O
parameters	O
between	O
the	O
two	O
treatment	O
groups	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
,	O
subjects	O
provided	O
the	O
zinc	O
citrate	O
dentifrice	O
demonstrated	O
24	O
-	O
52	O
%	O
reductions	O
in	O
anaerobic	O
bacteria	O
and	O
streptococci	B-bacteria
on	O
day	O
14	O
versus	O
the	O
control	O
paste	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
the	O
5	O
-	O
h	O
post	O
-	O
brushing	O
samples	O
,	O
subjects	O
provided	O
the	O
zinc	O
citrate	O
toothpaste	O
demonstrated	O
27	O
-	O
49	O
%	O
reductions	O
for	O
anaerobic	O
bacteria	O
and	O
streptococci	B-bacteria
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Additionally	O
,	O
in	O
situ	O
microbial	O
biofilm	O
formation	O
on	O
HA	O
disks	O
was	O
significantly	O
inhibited	O
amongst	O
the	O
zinc	O
citrate	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Significant	O
reductions	O
in	O
anaerobic	O
bacteria	O
and	O
streptococci	B-bacteria
were	O
observed	O
amongst	O
all	O
intra	O
-	O
oral	O
locations	O
along	O
with	O
in	O
situ	O
biofilm	O
formation	O
after	O
use	O
of	O
the	O
zinc	O
citrate	O
dentifrice	O
.	O

Apical	O
periodontitis	O
is	O
an	O
infectious	O
disease	O
caused	O
by	O
microorganisms	O
colonizing	O
the	O
root	O
canal	O
system	O
.	O

For	O
an	O
optimal	O
outcome	O
of	O
the	O
endodontic	O
treatment	O
to	O
be	O
achieved	O
,	O
bacterial	O
populations	O
within	O
the	O
root	O
canal	O
should	O
be	O
ideally	O
eliminated	O
or	O
at	O
least	O
significantly	O
reduced	O
to	O
levels	O
that	O
are	O
compatible	O
with	O
periradicular	O
tissue	O
healing	O
.	O

If	O
bacteria	O
persist	O
after	O
chemomechanical	O
preparation	O
supplemented	O
or	O
not	O
with	O
an	O
intracanal	O
medication	O
,	O
there	O
is	O
an	O
increased	O
risk	O
of	O
adverse	O
outcome	O
of	O
the	O
endodontic	O
treatment	O
.	O

Therefore	O
,	O
bacterial	O
presence	O
in	O
the	O
root	O
canal	O
at	O
the	O
time	O
of	O
filling	O
has	O
been	O
shown	O
to	O
be	O
a	O
risk	O
factor	O
for	O
posttreatment	O
apical	O
periodontitis	O
.	O

About	O
100	O
species	O
/	O
phylotypes	O
have	O
already	O
been	O
detected	O
in	O
postinstrumentation	O
and	O
/	O
or	O
postmedication	O
samples	O
,	O
and	O
gram	O
-	O
positive	O
bacteria	O
are	O
the	O
most	O
dominant	O
.	O

However	O
,	O
it	O
remains	O
to	O
be	O
determined	O
by	O
longitudinal	O
studies	O
if	O
any	O
species	O
/	O
phylotypes	O
persisting	O
after	O
treatment	O
procedures	O
can	O
influence	O
outcome	O
.	O

This	O
review	O
article	O
discusses	O
diverse	O
aspects	O
of	O
bacterial	O
persistence	O
after	O
treatment	O
,	O
including	O
the	O
microbiology	O
,	O
bacterial	O
strategies	O
to	O
persist	O
,	O
the	O
requisites	O
for	O
persisting	O
bacteria	O
to	O
affect	O
the	O
outcome	O
,	O
and	O
future	O
directions	O
of	O
research	O
in	O
this	O
field	O
.	O

The	O
microbial	O
community	O
present	O
in	O
the	O
human	O
mouth	O
is	O
engaged	O
in	O
a	O
complex	O
network	O
of	O
diverse	O
metabolic	O
activities	O
.	O

In	O
addition	O
to	O
serving	O
as	O
energy	O
and	O
building	O
-	O
block	O
sources	O
,	O
metabolites	O
are	O
key	O
players	O
in	O
interspecies	O
and	O
host	O
-	O
pathogen	O
interactions	O
.	O

Metabolites	O
are	O
also	O
implicated	O
in	O
triggering	O
the	O
local	O
inflammatory	O
response	O
,	O
which	O
can	O
affect	O
systemic	O
conditions	O
such	O
as	O
atherosclerosis	O
,	O
obesity	O
,	O
and	O
diabetes	O
.	O

While	O
the	O
genome	O
of	O
several	O
oral	O
pathogens	O
has	O
been	O
sequenced	O
,	O
quantitative	O
understanding	O
of	O
the	O
metabolic	O
functions	O
of	O
any	O
oral	O
pathogen	O
at	O
the	O
system	O
level	O
has	O
not	O
been	O
explored	O
yet	O
.	O

Here	O
we	O
pursue	O
the	O
computational	O
construction	O
and	O
analysis	O
of	O
the	O
genome	O
-	O
scale	O
metabolic	O
network	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
a	O
gram	O
-	O
negative	O
anaerobe	O
that	O
is	O
endemic	O
in	O
the	O
human	O
population	O
and	O
largely	O
responsible	O
for	O
adult	O
periodontitis	O
.	O

Integrating	O
information	O
from	O
the	O
genome	O
,	O
online	O
databases	O
,	O
and	O
literature	O
screening	O
,	O
we	O
built	O
a	O
stoichiometric	O
model	O
that	O
encompasses	O
679	O
metabolic	O
reactions	O
.	O

By	O
using	O
flux	O
balance	O
approaches	O
and	O
automated	O
network	O
visualization	O
,	O
we	O
analyze	O
the	O
growth	O
capacity	O
under	O
amino	O
-	O
acid	O
-	O
rich	O
medium	O
and	O
provide	O
evidence	O
that	O
amino	O
acid	O
preference	O
and	O
cytotoxic	O
by	O
-	O
product	O
secretion	O
rates	O
are	O
suitably	O
reproduced	O
by	O
the	O
model	O
.	O

To	O
provide	O
further	O
insight	O
into	O
the	O
basic	O
metabolic	O
functions	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
suggest	O
potential	O
drug	O
targets	O
,	O
we	O
study	O
systematically	O
how	O
the	O
network	O
responds	O
to	O
any	O
reaction	O
knockout	O
.	O

We	O
focus	O
specifically	O
on	O
the	O
lipopolysaccharide	O
biosynthesis	O
pathway	O
and	O
identify	O
eight	O
putative	O
targets	O
,	O
one	O
of	O
which	O
has	O
been	O
recently	O
verified	O
experimentally	O
.	O

The	O
current	O
model	O
,	O
which	O
is	O
amenable	O
to	O
further	O
experimental	O
testing	O
and	O
refinements	O
,	O
could	O
prove	O
useful	O
in	O
evaluating	O
the	O
oral	O
microbiome	O
dynamics	O
and	O
in	O
the	O
development	O
of	O
novel	O
biomedical	O
applications	O
.	O

Oral	O
epithelial	O
cells	O
may	O
be	O
invaded	O
by	O
a	O
polymicrobial	O
intracellular	O
flora	O
,	O
including	O
pathogens	O
together	O
with	O
commensals	O
.	O

Various	O
oral	O
pathogens	O
can	O
induce	O
the	O
production	O
of	O
interleukin	O
-	O
8	O
,	O
a	O
potent	O
neutrophil	O
chemotractant	O
,	O
in	O
oral	O
epithelial	O
cells	O
.	O

Evidence	O
from	O
the	O
gut	O
suggests	O
that	O
commensal	O
species	O
may	O
modulate	O
inflammatory	O
responses	O
to	O
pathogens	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
interleukin	O
-	O
8	O
responses	O
of	O
oral	O
epithelial	O
cells	O
to	O
an	O
oral	O
pro	O
-	O
inflammatory	O
species	O
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
in	O
combination	O
with	O
an	O
oral	O
commensal	O
,	O
Streptococcus	B-bacteria
cristatus	I-bacteria
.	O

KB	O
,	O
TERT	O
-	O
2	O
,	O
TR146	O
and	O
SCC15	O
cells	O
were	O
cocultured	O
with	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
cristatus	I-bacteria
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
at	O
37	O
degrees	O
C	O
in	O
5	O
%	O
CO2	O
under	O
various	O
conditions	O
.	O

The	O
mRNA	O
expression	O
of	O
interleukin	O
-	O
8	O
was	O
analyzed	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
protein	O
secretion	O
was	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
alone	O
evoked	O
a	O
potent	O
interleukin	O
-	O
8	O
response	O
,	O
whereas	O
S	O
.	O
cristatus	O
alone	O
did	O
not	O
induce	O
significant	O
interleukin	O
-	O
8	O
expression	O
in	O
oral	O
epithelial	O
cells	O
.	O

When	O
present	O
together	O
,	O
S	B-bacteria
.	I-bacteria
cristatus	I-bacteria
attenuated	O
the	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
-	O
induced	O
interleukin	O
-	O
8	O
production	O
in	O
the	O
four	O
oral	O
epithelial	O
cell	O
lines	O
to	O
varying	O
degrees	O
.	O

The	O
inhibitory	O
effect	O
of	O
S	B-bacteria
.	I-bacteria
cristatus	I-bacteria
was	O
independent	O
of	O
its	O
viability	O
and	O
its	O
co	O
-	O
aggregation	O
with	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
,	O
was	O
not	O
related	O
to	O
soluble	O
bacterial	O
products	O
and	O
appeared	O
to	O
require	O
bacterial	O
contact	O
with	O
epithelial	O
cells	O
.	O

Similar	O
effects	O
were	O
seen	O
with	O
several	O
other	O
species	O
of	O
oral	O
streptococci	B-bacteria
.	O

Our	O
data	O
suggest	O
that	O
S	B-bacteria
.	I-bacteria
cristatus	I-bacteria
may	O
exert	O
immunomodulatory	O
effects	O
on	O
the	O
interleukin	O
-	O
8	O
response	O
of	O
oral	O
epithelial	O
cells	O
to	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
challenge	O
.	O

To	O
study	O
the	O
distribution	O
and	O
drug	O
resistance	O
of	O
the	O
isolated	O
bacteria	O
from	O
children	O
with	O
acute	O
respiratory	O
infection	O
(	O
ARI	O
)	O
in	O
Dalian	O
.	O

Between	O
January	O
2006	O
and	O
February	O
2007	O
,	O
930	O
children	O
with	O
ARI	O
were	O
enrolled	O
,	O
including	O
364	O
with	O
acute	O
upper	O
respiratory	O
infection	O
(	O
AURI	O
)	O
,	O
and	O
566	O
with	O
acute	O
lower	O
respiratory	O
infection	O
(	O
ALRI	O
)	O
.	O

The	O
AURI	O
children	O
,	O
who	O
did	O
not	O
receive	O
antimicrobial	O
agent	O
treatment	O
or	O
received	O
oral	O
antimicrobial	O
agents	O
1	O
-	O
2	O
times	O
,	O
had	O
bacterial	O
cultures	O
of	O
pharyngeal	O
swab	O
.	O

The	O
ALRI	O
children	O
,	O
who	O
received	O
intravenous	O
antibacterial	O
agents	O
more	O
than	O
3	O
days	O
,	O
had	O
bacterial	O
cultures	O
of	O
sputum	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
.	O

Isolated	O
bacteria	O
were	O
identified	O
by	O
the	O
ATB	O
system	O
(	O
Bio	O
-	O
Merieux	O
,	O
France	O
)	O
.	O

Antimicrobial	O
susceptibility	O
testing	O
was	O
carried	O
out	O
by	O
means	O
of	O
Kirby	O
-	O
bauer	O
.	O

A	O
total	O
of	O
404	O
isolates	O
(	O
43	O
.	O
4	O
%	O
)	O
were	O
identified	O
.	O

Haemophilus	B-bacteria
influenzae	I-bacteria
,	O
Haemophilus	B-bacteria
parainfluenzae	I-bacteria
and	O
Streptococcus	B-bacteria
pneumoniae	I-bacteria
accounted	O
for	O
22	O
.	O
5	O
%	O
,	O
12	O
.	O
1	O
%	O
and	O
7	O
.	O
4	O
%	O
respectively	O
.	O

In	O
the	O
isolates	O
from	O
AURI	O
,	O
Haemophilus	B-bacteria
influenzae	I-bacteria
,	O
Haemophilus	B-bacteria
parainfluenzae	I-bacteria
and	O
Streptococcus	B-bacteria
pneumoniae	I-bacteria
accounted	O
for	O
43	O
.	O
9	O
%	O
,	O
22	O
.	O
0	O
%	O
and	O
9	O
.	O
1	O
%	O
respectively	O
;	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Klebsiella	B-bacteria
pneumonia	I-bacteria
and	O
Nonfermenters	B-bacteria
accounted	O
for	O
4	O
.	O
5	O
%	O
,	O
8	O
.	O
3	O
%	O
and	O
3	O
.	O
0	O
%	O
respectively	O
.	O

In	O
the	O
isolates	O
from	O
ALRI	O
,	O
Haemophilus	B-bacteria
influenzae	I-bacteria
,	O
Haemophilus	B-bacteria
parainfluenzae	I-bacteria
and	O
Streptococcus	B-bacteria
pneumoniae	I-bacteria
accounted	O
for	O
12	O
.	O
1	O
%	O
,	O
7	O
.	O
4	O
%	O
and	O
6	O
.	O
6	O
%	O
respectively	O
;	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
and	O
Nonfermenters	B-bacteria
accounted	O
for	O
16	O
.	O
9	O
%	O
,	O
13	O
.	O
2	O
%	O
and	O
21	O
.	O
8	O
%	O
respectively	O
.	O

The	O
resistant	O
rates	O
of	O
Haemophilus	B-bacteria
to	O
ampicillin	O
and	O
TMP	O
-	O
SMZ	O
were	O
29	O
.	O
3	O
%	O
and	O
32	O
.	O
9	O
%	O
respectively	O
,	O
and	O
to	O
amoxicillin	O
-	O
clavulanic	O
acid	O
,	O
cefalotin	O
,	O
cefaclor	O
,	O
cefuroxime	O
and	O
cefotaxime	O
were	O
12	O
.	O
1	O
%	O
,	O
10	O
.	O
0	O
%	O
,	O
10	O
.	O
0	O
%	O
,	O
11	O
.	O
4	O
%	O
and	O
5	O
.	O
7	O
%	O
,	O
respectively	O
.	O

The	O
resistant	O
rate	O
of	O
Haemophilus	B-bacteria
to	O
ampicillin	O
,	O
amoxicillin	O
-	O
clavulanic	O
acid	O
,	O
cefaclor	O
,	O
tetracycine	O
and	O
TMP	O
-	O
SMZ	O
in	O
the	O
ALRI	O
group	O
were	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
AURI	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
0	O
.	O
01	O
)	O
.	O

In	O
Dalian	O
,	O
Haemophilus	B-bacteria
was	O
the	O
main	O
isolate	O
of	O
children	O
with	O
ARI	O
.	O

The	O
distribution	O
of	O
bacteria	O
was	O
different	O
between	O
ALRI	O
and	O
AURI	O
.	O

In	O
ALRI	O
,	O
Gram	O
-	O
negative	O
bacilli	O
were	O
in	O
a	O
higher	O
proportion	O
,	O
and	O
the	O
resistant	O
rates	O
of	O
Haemophilus	B-bacteria
influenzae	I-bacteria
and	O
Haemophilus	B-bacteria
parainfluenzae	I-bacteria
to	O
ampicillin	O
,	O
amoxicillin	O
-	O
clavulanic	O
acid	O
and	O
cefaclor	O
were	O
higher	O
.	O

Parotid	O
secretory	O
protein	O
(	O
PSP	O
)	O
(	O
SPLUNC2	O
)	O
,	O
a	O
potential	O
host	O
-	O
defense	O
protein	O
related	O
to	O
bactericidal	O
/	O
permeability	O
-	O
increasing	O
protein	O
(	O
BPI	O
)	O
,	O
was	O
used	O
as	O
a	O
template	O
to	O
design	O
antibacterial	O
peptides	O
.	O

Based	O
on	O
the	O
structure	O
of	O
BPI	O
,	O
new	O
PSP	O
peptides	O
were	O
designed	O
and	O
tested	O
for	O
antibacterial	O
activity	O
.	O

The	O
peptides	O
did	O
not	O
exhibit	O
significant	O
bactericidal	O
activity	O
or	O
inhibit	O
growth	O
but	O
the	O
peptide	O
GL	O
-	O
13	O
induced	O
bacterial	O
matting	O
,	O
suggesting	O
passive	O
agglutination	O
of	O
bacteria	O
.	O

GL	O
-	O
13	O
was	O
shown	O
to	O
agglutinate	O
the	O
Gram	O
negative	O
bacteria	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
and	O
Aggregatibacter	B-bacteria
(	I-bacteria
Actinobacillus	I-bacteria
)	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
Gram	O
positive	O
Streptococcus	B-bacteria
gordonii	I-bacteria
and	O
uncoated	O
sheep	O
erythrocytes	O
.	O

Bacterial	O
agglutination	O
was	O
time	O
and	O
dose	O
-	O
dependent	O
and	O
involved	O
hydrophobic	O
interactions	O
.	O

Variant	O
forms	O
of	O
GL	O
-	O
13	O
revealed	O
that	O
agglutination	O
also	O
depended	O
on	O
the	O
number	O
of	O
amine	O
groups	O
on	O
the	O
peptide	O
.	O

GL	O
-	O
13	O
inhibited	O
the	O
adhesion	O
of	O
bacteria	O
to	O
plastic	O
surfaces	O
and	O
the	O
peptide	O
prevented	O
the	O
spread	O
of	O
P	B-bacteria
.	I-bacteria
aeruginos	I-bacteria
infection	O
in	O
a	O
lettuce	O
leaf	O
model	O
,	O
suggesting	O
that	O
GL	O
-	O
13	O
is	O
active	O
in	O
vivo	O
.	O

Moreover	O
,	O
GL	O
-	O
13	O
-	O
induced	O
agglutination	O
enhanced	O
the	O
phagocytosis	O
of	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
by	O
RAW	O
264	O
.	O
7	O
macrophage	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
GL	O
-	O
13	O
represents	O
a	O
class	O
of	O
antimicrobial	O
peptides	O
,	O
which	O
do	O
not	O
directly	O
kill	O
bacteria	O
but	O
instead	O
reduce	O
bacterial	O
adhesion	O
and	O
promote	O
agglutination	O
,	O
leading	O
to	O
increased	O
clearance	O
by	O
host	O
phagocytic	O
cells	O
.	O

Such	O
peptides	O
may	O
cause	O
less	O
bacterial	O
resistance	O
than	O
traditional	O
antibiotic	O
peptides	O
.	O

tet	O
(	O
32	O
)	O
Was	O
identified	O
in	O
three	O
bacterial	O
isolates	O
and	O
in	O
metagenomic	O
DNA	O
from	O
the	O
human	O
oral	O
cavity	O
.	O

The	O
regions	O
immediately	O
flanking	O
the	O
gene	O
were	O
found	O
to	O
have	O
similarities	O
to	O
the	O
mobile	O
elements	O
TnB1230	O
from	O
Butyrivibrio	B-bacteria
fibrisolvens	I-bacteria
,	O
ATE	O
-	O
3	O
from	O
Arcanobacterium	B-bacteria
pyogenes	I-bacteria
,	O
and	O
CTn5	O
from	O
Clostridium	B-bacteria
difficile	I-bacteria
.	O

Dental	O
caries	O
is	O
among	O
the	O
more	O
prevalent	O
chronic	O
human	O
infections	O
for	O
which	O
an	O
effective	O
human	O
vaccine	O
has	O
not	O
yet	O
been	O
achieved	O
.	O

Enolase	O
from	O
Streptococcus	B-bacteria
sobrinus	I-bacteria
has	O
been	O
identified	O
as	O
an	O
immunomodulatory	O
protein	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
recombinant	O
enolase	O
(	O
rEnolase	O
)	O
as	O
a	O
target	O
antigen	O
and	O
assessed	O
its	O
therapeutic	O
effect	O
in	O
a	O
rat	O
model	O
of	O
Dental	O
caries	O
.	O

Wistar	O
rats	O
that	O
were	O
fed	O
a	O
cariogenic	O
solid	O
diet	O
on	O
day	O
18	O
after	O
birth	O
were	O
orally	O
infected	O
with	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
on	O
day	O
19	O
after	O
birth	O
and	O
for	O
5	O
consecutive	O
days	O
thereafter	O
.	O

Five	O
days	O
after	O
infection	O
and	O
,	O
again	O
,	O
3	O
weeks	O
later	O
,	O
rEnolase	O
plus	O
alum	O
adjuvant	O
was	O
delivered	O
into	O
the	O
oral	O
cavity	O
of	O
the	O
rats	O
.	O

A	O
sham	O
-	O
immunized	O
group	O
of	O
rats	O
was	O
contemporarily	O
treated	O
with	O
adjuvant	O
alone	O
.	O

In	O
the	O
rEnolase	O
-	O
immunized	O
rats	O
,	O
increased	O
levels	O
of	O
salivary	O
IgA	O
and	O
IgG	O
antibodies	O
specific	O
for	O
this	O
recombinant	O
protein	O
were	O
detected	O
.	O

A	O
significant	O
decrease	O
in	O
sulcal	O
,	O
proximal	O
enamel	O
,	O
and	O
Dental	O
caries	O
scores	O
was	O
observed	O
in	O
these	O
animals	O
,	O
compared	O
with	O
sham	O
-	O
immunized	O
control	O
animals	O
.	O

No	O
detectable	O
histopathologic	O
alterations	O
were	O
observed	O
in	O
all	O
immunized	O
animals	O
.	O

Furthermore	O
,	O
the	O
antibodies	O
produced	O
against	O
bacterial	O
enolase	O
did	O
not	O
react	O
with	O
human	O
enolase	O
.	O

Overall	O
,	O
these	O
results	O
indicate	O
that	O
rEnolase	O
could	O
be	O
a	O
promising	O
and	O
safe	O
candidate	O
for	O
testing	O
in	O
trials	O
of	O
vaccines	O
against	O
Dental	O
caries	O
in	O
humans	O
.	O

The	O
genome	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
harbours	O
13	O
two	O
-	O
component	O
signal	O
transduction	O
systems	O
(	O
TCSTSs	O
)	O
.	O

Of	O
these	O
,	O
a	O
peptide	O
-	O
mediated	O
quorum	O
-	O
sensing	O
system	O
,	O
ComCDE	O
,	O
and	O
the	O
HK	O
/	O
RR11	O
two	O
-	O
component	O
system	O
are	O
well	O
known	O
to	O
regulate	O
several	O
virulence	O
-	O
associated	O
traits	O
in	O
in	O
vitro	O
experiments	O
,	O
including	O
genetic	O
competence	O
,	O
bacteriocin	O
production	O
,	O
biofilm	O
formation	O
and	O
stress	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
hypothesis	O
that	O
inactivation	O
of	O
ComCDE	O
,	O
HK	O
/	O
RR11	O
or	O
both	O
systems	O
would	O
attenuate	O
the	O
virulence	O
and	O
cariogenicity	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

The	O
results	O
showed	O
that	O
simultaneous	O
inactivation	O
of	O
both	O
signal	O
transduction	O
systems	O
additively	O
attenuated	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
virulence	O
and	O
cariogenicity	O
,	O
since	O
inactivation	O
of	O
either	O
of	O
these	O
systems	O
alone	O
did	O
not	O
result	O
in	O
the	O
same	O
degree	O
of	O
effect	O
.	O

The	O
double	O
deletion	O
mutant	O
SMcde	O
-	O
hk11	O
was	O
defective	O
in	O
genetic	O
competence	O
,	O
had	O
a	O
reduced	O
acid	O
production	O
,	O
was	O
unable	O
to	O
grow	O
at	O
pH	O
5	O
.	O
0	O
and	O
formed	O
an	O
abnormal	O
biofilm	O
with	O
reduced	O
biomass	O
.	O

Animal	O
studies	O
showed	O
that	O
this	O
mutant	O
had	O
reduced	O
capabilities	O
for	O
oral	O
colonization	O
,	O
succession	O
and	O
initiation	O
of	O
dental	O
caries	O
.	O

A	O
competitive	O
index	O
(	O
CI	O
)	O
analysis	O
using	O
a	O
mixed	O
-	O
infection	O
animal	O
model	O
revealed	O
that	O
all	O
the	O
mutants	O
,	O
particularly	O
SMcde	O
-	O
hk11	O
,	O
had	O
reduced	O
fitness	O
in	O
their	O
ecological	O
niches	O
and	O
were	O
unable	O
to	O
compete	O
with	O
the	O
wild	O
-	O
type	O
strain	O
for	O
persistence	O
in	O
dental	O
biofilms	O
.	O

The	O
evidence	O
from	O
this	O
study	O
suggests	O
that	O
the	O
ComCDE	O
and	O
HK	O
/	O
RR11	O
signal	O
transduction	O
systems	O
can	O
be	O
considered	O
to	O
be	O
novel	O
targets	O
for	O
the	O
development	O
of	O
strategies	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
infections	O
.	O

Little	O
is	O
known	O
regarding	O
the	O
factors	O
that	O
affect	O
the	O
microbial	O
composition	O
of	O
supragingival	O
biofilms	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
tooth	O
location	O
affects	O
the	O
microbial	O
composition	O
of	O
supragingival	O
plaque	O
beyond	O
the	O
effect	O
due	O
to	O
plaque	O
mass	O
as	O
reflected	O
by	O
total	O
DNA	O
probe	O
count	O
.	O

Supragingival	O
plaque	O
samples	O
were	O
taken	O
from	O
the	O
mesiobuccal	O
aspect	O
of	O
each	O
tooth	O
in	O
187	O
subjects	O
(	O
n	O
=	O
4745	O
samples	O
)	O
.	O

All	O
samples	O
were	O
individually	O
analyzed	O
for	O
their	O
content	O
of	O
40	O
bacterial	O
species	O
using	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
.	O

Significance	O
of	O
differences	O
in	O
mean	O
species	O
counts	O
and	O
proportions	O
were	O
determined	O
among	O
tooth	O
surfaces	O
and	O
six	O
tooth	O
type	O
categories	O
:	O
molars	O
,	O
bicuspids	O
,	O
incisors	O
/	O
canines	O
in	O
the	O
mandible	O
and	O
maxilla	O
separately	O
using	O
the	O
Kruskal	O
-	O
Wallis	O
test	O
.	O

Stepwise	O
multiple	O
linear	O
regression	O
was	O
employed	O
to	O
examine	O
the	O
relationship	O
between	O
species	O
proportions	O
and	O
total	O
DNA	O
probe	O
count	O
,	O
tooth	O
location	O
,	O
periodontal	O
and	O
smoking	O
status	O
,	O
age	O
and	O
sex	O
.	O

All	O
species	O
differed	O
significantly	O
among	O
tooth	O
types	O
and	O
among	O
the	O
six	O
tooth	O
categories	O
.	O

Higher	O
plaque	O
levels	O
were	O
seen	O
on	O
molars	O
and	O
lower	O
incisors	O
.	O

Some	O
differences	O
observed	O
between	O
tooth	O
types	O
could	O
be	O
partly	O
explained	O
by	O
the	O
level	O
of	O
plaque	O
.	O

Teeth	O
with	O
high	O
plaque	O
mass	O
exhibited	O
high	O
levels	O
of	O
Capnocytophaga	B-bacteria
gingivalis	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
genospecies	I-bacteria
2	I-bacteria
,	O
Campylobacter	B-bacteria
rectus	I-bacteria
and	O
Campylobacter	B-bacteria
showae	I-bacteria
.	O

However	O
,	O
certain	O
species	O
,	O
such	O
as	O
Veillonella	B-bacteria
parvula	I-bacteria
and	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
differed	O
significantly	O
at	O
different	O
tooth	O
locations	O
despite	O
similarities	O
in	O
plaque	O
mass	O
.	O

Twenty	O
of	O
the	O
test	O
species	O
exhibited	O
a	O
significant	O
association	O
with	O
tooth	O
location	O
after	O
adjusting	O
for	O
total	O
DNA	O
probe	O
count	O
and	O
subject	O
level	O
factors	O
.	O

While	O
plaque	O
mass	O
was	O
associated	O
with	O
differences	O
in	O
proportions	O
of	O
many	O
species	O
in	O
supragingival	O
biofilms	O
,	O
tooth	O
location	O
also	O
was	O
strongly	O
associated	O
with	O
species	O
proportions	O
in	O
both	O
univariate	O
and	O
multivariate	O
analyses	O
.	O

Treating	O
a	O
carious	O
tooth	O
in	O
children	O
with	O
high	O
caries	O
experience	O
by	O
providing	O
a	O
restoration	O
does	O
not	O
cure	O
the	O
disease	O
.	O

If	O
the	O
unfavorable	O
oral	O
environment	O
that	O
caused	O
the	O
cavity	O
persists	O
so	O
will	O
the	O
disease	O
and	O
more	O
restorations	O
will	O
be	O
required	O
in	O
future	O
.	O

Treating	O
the	O
oral	O
infection	O
by	O
reducing	O
the	O
number	O
of	O
cariogenic	O
microorganisms	O
and	O
establishing	O
a	O
favorable	O
oral	O
environment	O
to	O
promote	O
predominantly	O
remineralization	O
of	O
tooth	O
structure	O
over	O
time	O
will	O
stop	O
the	O
caries	O
process	O
.	O

The	O
present	O
study	O
was	O
conducted	O
:	O
(	O
1	O
)	O
To	O
evaluate	O
the	O
efficacy	O
of	O
povidone	O
-	O
iodine	O
and	O
chlorhexidine	O
mouth	O
rinses	O
on	O
plaque	O
Streptococcus	B-bacteria
mutans	I-bacteria
when	O
used	O
as	O
an	O
adjunct	O
to	O
restoration	O
.	O

(	O
2	O
)	O
To	O
compare	O
the	O
anti	O
-	O
microbial	O
effect	O
of	O
1	O
%	O
povidone	O
-	O
iodine	O
and	O
0	O
.	O
2	O
%	O
chlorhexidine	O
mouth	O
rinses	O
on	O
plaque	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
count	O
.	O

STUDY	O
Forty	O
-	O
five	O
study	O
participants	O
in	O
the	O
age	O
group	O
of	O
6	O
-	O
12	O
years	O
with	O
dmft	O
(	O
decay	O
component	O
)	O
of	O
three	O
or	O
four	O
were	O
selected	O
from	O
one	O
government	O
school	O
in	O
Bangalore	O
city	O
.	O

They	O
were	O
divided	O
into	O
three	O
groups	O
after	O
the	O
restorative	O
treatment	O
.	O

Group	O
-	O
A	O
,	O
Group	O
-	O
B	O
,	O
and	O
Group	O
-	O
C	O
received	O
1	O
%	O
povidone	O
-	O
iodine	O
mouth	O
rinse	O
,	O
0	O
.	O
2	O
%	O
chlorhexidine	O
mouth	O
rinse	O
and	O
placebo	O
mouth	O
rinse	O
,	O
respectively	O
,	O
twice	O
daily	O
for	O
14	O
days	O
.	O

The	O
plaque	O
sample	O
was	O
collected	O
and	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
count	O
was	O
estimated	O
at	O
six	O
phases	O
:	O
(	O
1	O
)	O
Baseline	O
,	O
(	O
2	O
)	O
3	O
weeks	O
after	O
restoration	O
,	O
(	O
3	O
)	O
First	O
day	O
after	O
mouth	O
rinse	O
therapy	O
,	O
(	O
4	O
)	O
15	O
days	O
after	O
mouth	O
rinse	O
therapy	O
,	O
(	O
5	O
)	O
1	O
month	O
and	O
(	O
6	O
)	O
3	O
months	O
after	O
mouth	O
rinse	O
therapy	O
After	O
the	O
restoration	O
the	O
percentage	O
change	O
in	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
count	O
was	O
28	O
.	O
4	O
%	O
.	O

Immediately	O
after	O
mouth	O
rinse	O
therapy	O
there	O
was	O
significant	O
reduction	O
in	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
count	O
in	O
all	O
the	O
three	O
groups	O
.	O

After	O
which	O
the	O
count	O
started	O
to	O
increase	O
gradually	O
and	O
after	O
3	O
months	O
the	O
bacterial	O
counts	O
in	O
the	O
povidone	O
-	O
iodine	O
group	O
and	O
placebo	O
group	O
were	O
almost	O
near	O
the	O
postrestorative	O
count	O
.	O

Mouth	O
rinses	O
can	O
be	O
used	O
as	O
adjunct	O
to	O
restoration	O
for	O
short	O
duration	O
as	O
temporary	O
measure	O
in	O
reduction	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
count	O
and	O
restorations	O
provide	O
longer	O
effect	O
.	O

In	O
case	O
a	O
mouth	O
rinse	O
has	O
to	O
be	O
used	O
,	O
chlorhexidine	O
can	O
be	O
recommended	O
as	O
it	O
has	O
shown	O
to	O
have	O
better	O
effect	O
than	O
Povidone	O
-	O
iodine	O
and	O
placebo	O
.	O

Periodontitis	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
cardiovascular	O
diseases	O
(	O
CVD	O
)	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
poorly	O
understood	O
.	O

Recently	O
,	O
we	O
showed	O
that	O
platelets	O
from	O
periodontitis	O
patients	O
are	O
more	O
activated	O
than	O
those	O
from	O
controls	O
.	O

Given	O
the	O
regularly	O
occurring	O
bacteremic	O
episodes	O
in	O
periodontitis	O
patients	O
,	O
we	O
hypothesized	O
that	O
platelets	O
and	O
/	O
or	O
leukocytes	O
from	O
periodontitis	O
patients	O
are	O
more	O
sensitive	O
to	O
stimulation	O
by	O
oral	O
bacteria	O
,	O
in	O
particular	O
the	O
known	O
periodontal	O
pathogens	O
,	O
than	O
platelets	O
from	O
control	O
subjects	O
.	O

Three	O
-	O
color	O
flow	O
cytometry	O
analysis	O
was	O
performed	O
to	O
quantify	O
activation	O
of	O
platelets	O
(	O
P	O
-	O
selectin	O
,	O
PAC	O
-	O
1	O
,	O
CD63	O
)	O
and	O
leukocytes	O
(	O
CD11b	O
)	O
in	O
whole	O
blood	O
from	O
patients	O
with	O
periodontitis	O
(	O
n	O
=	O
19	O
)	O
and	O
controls	O
(	O
n	O
=	O
18	O
)	O
,	O
with	O
and	O
without	O
stimulation	O
by	O
oral	O
bacteria	O
.	O

Phagocytosis	O
was	O
assessed	O
by	O
using	O
green	O
-	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
-	O
expressing	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
Aa	B-bacteria
)	O
.	O

Neutrophils	O
and	O
monocytes	O
were	O
activated	O
by	O
all	O
species	O
of	O
oral	O
bacteria	O
tested	O
,	O
but	O
no	O
differences	O
were	O
observed	O
between	O
patients	O
and	O
controls	O
.	O

In	O
response	O
to	O
several	O
species	O
of	O
oral	O
bacteria	O
,	O
platelets	O
from	O
periodontitis	O
patients	O
showed	O
,	O
compared	O
with	O
controls	O
,	O
increased	O
exposure	O
of	O
P	O
-	O
selectin	O
(	O
P	O
=	O
0	O
.	O
027	O
)	O
and	O
increased	O
formation	O
of	O
platelet	O
-	O
monocyte	O
complexes	O
(	O
P	O
=	O
0	O
.	O
040	O
)	O
.	O

Platelet	O
-	O
leukocyte	O
complexes	O
bound	O
and	O
/	O
or	O
phagocytosed	O
more	O
GFP	O
-	O
Aa	O
than	O
platelet	O
-	O
free	O
leukocytes	O
(	O
for	O
neutrophils	O
and	O
monocytes	O
,	O
in	O
both	O
patients	O
and	O
controls	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
periodontitis	O
,	O
increased	O
platelet	O
response	O
to	O
oral	O
bacteria	O
is	O
paralleled	O
by	O
increased	O
formation	O
of	O
platelet	O
-	O
leukocyte	O
complexes	O
with	O
elevated	O
capacity	O
for	O
bacterial	O
clearance	O
.	O

We	O
speculate	O
that	O
activated	O
platelets	O
and	O
leukocytes	O
might	O
contribute	O
to	O
increased	O
atherothrombotic	O
activity	O
.	O

Ventilator	O
-	O
associated	O
pneumonia	O
(	O
VAP	O
)	O
is	O
usually	O
caused	O
by	O
aspiration	O
of	O
pathogenic	O
bacteria	O
from	O
the	O
oropharynx	O
.	O

Oral	O
decontamination	O
with	O
antiseptics	O
,	O
such	O
as	O
chlorhexidine	O
(	O
CHX	O
)	O
or	O
antibiotics	O
,	O
has	O
been	O
used	O
as	O
prophylaxis	O
against	O
this	O
complication	O
.	O

We	O
hypothesised	O
that	O
the	O
probiotic	O
bacteria	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
299	I-bacteria
(	O
Lp299	B-bacteria
)	O
would	O
be	O
as	O
efficient	O
as	O
CHX	O
in	O
reducing	O
the	O
pathogenic	O
bacterial	O
load	O
in	O
the	O
oropharynx	O
of	O
tracheally	O
intubated	O
,	O
mechanically	O
ventilated	O
,	O
critically	O
ill	O
patients	O
.	O

Fifty	O
critically	O
ill	O
patients	O
on	O
mechanical	O
ventilation	O
were	O
randomised	O
to	O
either	O
oral	O
mechanical	O
cleansing	O
followed	O
by	O
washing	O
with	O
0	O
.	O
1	O
%	O
CHX	O
solution	O
or	O
to	O
the	O
same	O
cleansing	O
procedure	O
followed	O
by	O
oral	O
application	O
of	O
an	O
emulsion	O
of	O
Lp299	B-bacteria
.	O

Samples	O
for	O
microbiological	O
analyses	O
were	O
taken	O
from	O
the	O
oropharynx	O
and	O
trachea	O
at	O
inclusion	O
and	O
at	O
defined	O
intervals	O
thereafter	O
.	O

Potentially	O
pathogenic	O
bacteria	O
that	O
were	O
not	O
present	O
at	O
inclusion	O
were	O
identified	O
in	O
oropharyngeal	O
samples	O
from	O
eight	O
of	O
the	O
patients	O
treated	O
with	O
Lp299	O
and	O
13	O
of	O
those	O
treated	O
with	O
CHX	O
(	O
p	O
=	O
0	O
.	O
13	O
)	O
.	O

Analysis	O
of	O
tracheal	O
samples	O
yielded	O
similar	O
results	O
.	O

Lp299	B-bacteria
was	O
recovered	O
from	O
the	O
oropharynx	O
of	O
all	O
patients	O
in	O
the	O
Lp299	B-bacteria
group	O
.	O

In	O
this	O
pilot	O
study	O
,	O
we	O
found	O
no	O
difference	O
between	O
the	O
effect	O
of	O
Lp299	B-bacteria
and	O
CHX	O
used	O
in	O
oral	O
care	O
procedures	O
,	O
when	O
we	O
examined	O
the	O
effects	O
of	O
those	O
agents	O
on	O
colonisation	O
of	O
potentially	O
pathogenic	O
bacteria	O
in	O
the	O
oropharynx	O
of	O
intubated	O
,	O
mechanically	O
ventilated	O
patients	O
.	O

Processing	O
of	O
bronchoscopes	O
after	O
a	O
physical	O
examination	O
has	O
to	O
eliminate	O
all	O
micro	O
-	O
organisms	O
that	O
could	O
have	O
contaminated	O
the	O
endoscope	O
and	O
that	O
may	O
harm	O
the	O
following	O
patient	O
.	O

The	O
aim	O
of	O
this	O
analysis	O
is	O
to	O
define	O
those	O
micro	O
-	O
organisms	O
that	O
may	O
contaminate	O
the	O
bronchoscope	O
during	O
the	O
examination	O
and	O
that	O
may	O
cause	O
disease	O
in	O
other	O
patients	O
.	O

Research	O
of	O
literature	O
and	O
analysis	O
of	O
laboratory	O
data	O
.	O

During	O
the	O
passage	O
of	O
the	O
respiratory	O
tract	O
the	O
bronchoscope	O
will	O
be	O
contaminated	O
by	O
the	O
physiological	O
flora	O
of	O
oral	O
cavity	O
,	O
nasopharynx	O
,	O
trachea	O
,	O
bronchi	O
,	O
and	O
pulmonary	O
tissues	O
.	O

Whilst	O
the	O
oral	O
cavity	O
,	O
the	O
nasopharynx	O
and	O
the	O
pharynx	O
are	O
the	O
habitat	O
for	O
a	O
great	O
variety	O
of	O
bacteria	O
the	O
lower	O
respiratory	O
tract	O
is	O
virtually	O
free	O
of	O
micro	O
-	O
organisms	O
.	O

However	O
,	O
in	O
ventilated	O
patients	O
trachea	O
and	O
bronchi	O
can	O
become	O
colonized	O
as	O
the	O
result	O
of	O
bypassing	O
the	O
cleansing	O
effect	O
of	O
the	O
ciliated	O
epithelium	O
.	O

In	O
addition	O
all	O
agents	O
that	O
can	O
cause	O
bronchitis	O
or	O
pneumonia	O
in	O
immunocompromised	O
or	O
otherwise	O
healthy	O
individuals	O
are	O
potential	O
contaminants	O
of	O
bronchoscopes	O
.	O

These	O
microorganisms	O
include	O
bacteria	O
,	O
mycobacteria	B-bacteria
,	O
yeasts	O
and	O
moulds	O
,	O
enveloped	O
and	O
non	O
-	O
enveloped	O
viruses	O
and	O
rarely	O
parasites	O
.	O

The	O
bronchoscopic	O
procedure	O
can	O
result	O
in	O
epithelial	O
injury	O
with	O
subsequent	O
bleeding	O
.	O

Therefore	O
,	O
all	O
blood	O
-	O
borne	O
pathogens	O
,	O
e	O
.	O
g	O
.	O
HIV	O
or	O
HBV	O
are	O
also	O
potential	O
contaminants	O
of	O
the	O
bronchoscope	O
.	O

There	O
are	O
several	O
reports	O
of	O
transmission	O
of	O
micro	O
-	O
organisms	O
due	O
to	O
incomplete	O
or	O
faulty	O
cleaning	O
and	O
disinfection	O
procedures	O
of	O
bronchoscopes	O
.	O

These	O
incidents	O
include	O
nearly	O
all	O
classes	O
of	O
micro	O
-	O
organisms	O
but	O
not	O
parasites	O
or	O
viruses	O
.	O

However	O
,	O
the	O
incubation	O
period	O
of	O
viruses	O
can	O
be	O
long	O
and	O
the	O
association	O
between	O
bronchoscopy	O
and	O
infection	O
may	O
be	O
obscure	O
.	O

Endospore	O
forming	O
micro	O
-	O
organisms	O
and	O
parasites	O
are	O
not	O
part	O
of	O
the	O
normal	O
flora	O
of	O
the	O
respiratory	O
tract	O
and	O
may	O
rarely	O
cause	O
disease	O
,	O
usually	O
only	O
in	O
severely	O
immunocompromised	O
patients	O
,	O
but	O
transmission	O
of	O
such	O
organisms	O
by	O
bronchoscopy	O
has	O
never	O
been	O
reported	O
.	O

The	O
antimicrobial	O
activity	O
of	O
the	O
disinfection	O
process	O
,	O
including	O
chemical	O
disinfectants	O
for	O
endoscopes	O
has	O
to	O
include	O
bacteria	O
,	O
fungi	O
and	O
viruses	O
.	O

Sporicidal	O
activity	O
may	O
be	O
only	O
warranted	O
in	O
specific	O
patient	O
populations	O
,	O
i	O
.	O
e	O
.	O
after	O
bronchoscopy	O
of	O
suspected	O
anthrax	O
patients	O
or	O
before	O
examination	O
of	O
severely	O
immunocompromised	O
patients	O
.	O

To	O
investigate	O
the	O
probiotic	O
characteristics	O
of	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
(	I-bacteria
L	I-bacteria
.	I-bacteria
plantarum	I-bacteria
)	I-bacteria
HO	I-bacteria
-	I-bacteria
69	I-bacteria
in	O
oral	O
cavity	O
.	O

The	O
adhesion	O
ratios	O
to	O
teeth	O
and	O
dentine	O
surface	O
were	O
determined	O
by	O
in	O
vitro	O
models	O
.	O

Hydrophobicity	O
and	O
surface	O
charges	O
were	O
measured	O
by	O
MATH	O
method	O
.	O

Inhibitory	O
activity	O
was	O
measured	O
by	O
agar	O
well	O
diffusion	O
method	O
.	O

The	O
adhesion	O
ratios	O
to	O
hard	O
tissue	O
were	O
quite	O
low	O
.	O

The	O
hydrophobicity	O
and	O
surface	O
charges	O
were	O
high	O
,	O
and	O
it	O
exhibited	O
inhibitory	O
activity	O
against	O
some	O
pathogens	O
.	O

The	O
probability	O
is	O
low	O
for	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
HO	I-bacteria
-	I-bacteria
69	I-bacteria
to	O
initiate	O
or	O
accelerate	O
dental	O
caries	O
.	O

It	O
shows	O
broad	O
-	O
spectrum	O
inhibitory	O
activity	O
and	O
is	O
potential	O
probiotics	O
applied	O
in	O
oral	O
cavity	O
.	O

In	O
this	O
paper	O
we	O
have	O
developed	O
a	O
model	O
of	O
antimicrobial	O
effect	O
of	O
gramicidin	O
S	O
.	O
This	O
model	O
has	O
allowed	O
us	O
to	O
predict	O
the	O
dependence	O
of	O
antimicrobial	O
effect	O
of	O
the	O
drug	O
applied	O
as	O
oral	O
melting	O
tablets	O
on	O
dosage	O
,	O
time	O
of	O
resorption	O
and	O
minimal	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
of	O
the	O
drug	O
characterizing	O
its	O
ability	O
to	O
kill	O
different	O
bacteria	O
.	O

The	O
model	O
has	O
been	O
employed	O
to	O
optimize	O
dosing	O
regime	O
of	O
gramicidin	O
S	O
containing	O
drug	O
Grammidin	O
.	O

Efficacy	O
of	O
the	O
drug	O
has	O
been	O
studied	O
for	O
the	O
diverse	O
gram	O
-	O
positive	O
and	O
gram	O
-	O
negative	O
bacteria	O
with	O
different	O
MIC	O
.	O

The	O
number	O
of	O
bacteria	O
located	O
in	O
the	O
oral	O
cavity	O
and	O
killed	O
by	O
one	O
-	O
pass	O
administration	O
of	O
the	O
drug	O
(	O
resolution	O
of	O
one	O
tablet	O
)	O
has	O
been	O
calculated	O
under	O
condition	O
of	O
various	O
dosing	O
regimes	O
.	O

Based	O
on	O
the	O
simulation	O
results	O
it	O
has	O
been	O
found	O
that	O
(	O
1	O
)	O
twofold	O
prolongation	O
of	O
prescribed	O
resorption	O
time	O
(	O
from	O
30	O
to	O
60min	O
)	O
of	O
the	O
tablet	O
comprising	O
standard	O
dosage	O
of	O
3mg	O
of	O
gramicidin	O
S	O
results	O
in	O
1	O
.	O
5	O
-	O
fold	O
increase	O
in	O
efficacy	O
,	O
(	O
2	O
)	O
1	O
.	O
5	O
-	O
fold	O
decrease	O
in	O
gramicidin	O
S	O
dosage	O
(	O
from	O
3	O
to	O
2mg	O
per	O
administration	O
)	O
under	O
condition	O
of	O
holding	O
prescribed	O
resorption	O
time	O
(	O
30min	O
)	O
does	O
not	O
lead	O
to	O
any	O
considerable	O
decrease	O
in	O
the	O
efficacy	O
of	O
the	O
drug	O
.	O

Lactobacillus	B-bacteria
paracasei	I-bacteria
KW3110	I-bacteria
is	O
a	O
strain	O
which	O
has	O
been	O
reported	O
to	O
possess	O
a	O
strong	O
antiallergic	O
activity	O
.	O

Since	O
many	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
have	O
shown	O
to	O
be	O
useful	O
as	O
the	O
probiotics	O
,	O
the	O
possibility	O
of	O
this	O
strain	O
for	O
use	O
as	O
a	O
probiotic	O
was	O
studied	O
.	O

An	O
in	O
vitro	O
test	O
showed	O
that	O
this	O
strain	O
is	O
strong	O
enough	O
to	O
survive	O
in	O
the	O
gastric	O
juice	O
.	O

In	O
addition	O
,	O
this	O
strain	O
showed	O
exceptionally	O
strong	O
adherence	O
to	O
human	O
intestinal	O
epithelial	O
cells	O
,	O
Caco	O
-	O
2	O
and	O
HT29	O
compared	O
to	O
normal	O
L	B-bacteria
.	I-bacteria
paracasei	I-bacteria
strains	I-bacteria
.	O

Human	O
oral	O
administration	O
testing	O
of	O
L	B-bacteria
.	I-bacteria
paracasei	I-bacteria
KW3110	I-bacteria
showed	O
that	O
this	O
strain	O
survived	O
in	O
the	O
human	O
gut	O
and	O
increased	O
the	O
number	O
of	O
bifidobacteria	B-bacteria
and	O
lactobacilli	B-bacteria
in	O
the	O
fecal	O
samples	O
of	O
the	O
subjects	O
.	O

In	O
addition	O
,	O
KW	B-bacteria
3110	I-bacteria
was	O
detected	O
in	O
50	O
%	O
of	O
the	O
subjects	O
up	O
to	O
1	O
week	O
after	O
the	O
end	O
of	O
the	O
administration	O
test	O
.	O

These	O
results	O
showed	O
that	O
L	B-bacteria
.	I-bacteria
paracasei	I-bacteria
KW3110	I-bacteria
has	O
a	O
strong	O
ability	O
to	O
survive	O
in	O
and	O
colonize	O
the	O
human	O
gut	O
and	O
improve	O
the	O
human	O
intestinal	O
microflora	O
.	O

Pseudomonas	B-bacteria
aeruginosa	I-bacteria
is	O
an	O
important	O
opportunistic	O
bacterial	O
pathogen	O
,	O
causing	O
infections	O
of	O
the	O
respiratory	O
and	O
other	O
organ	O
systems	O
in	O
susceptible	O
hosts	O
.	O

P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
infection	O
is	O
initiated	O
by	O
adhesion	O
to	O
and	O
invasion	O
of	O
mucosal	O
epithelial	O
cells	O
.	O

The	O
failure	O
of	O
host	O
defenses	O
to	O
eliminate	O
P	O
.	O
aeruginosa	O
from	O
mucosal	O
surfaces	O
results	O
in	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
proliferation	O
,	O
sometimes	O
followed	O
by	O
overt	O
infection	O
and	O
tissue	O
destruction	O
.	O

There	O
is	O
growing	O
evidence	O
that	O
associates	O
poor	O
oral	O
health	O
and	O
respiratory	O
infection	O
.	O

An	O
in	O
vitro	O
model	O
system	O
for	O
bacterial	O
invasion	O
of	O
respiratory	O
epithelial	O
cells	O
was	O
used	O
to	O
investigate	O
the	O
influence	O
of	O
oral	O
bacteria	O
on	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
epithelial	O
cell	O
invasion	O
.	O

Oral	O
pathogens	O
including	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
and	O
Aggregatibacter	B-bacteria
(	I-bacteria
Actinobacillus	I-bacteria
)	I-bacteria
actinomycetemcomitans	I-bacteria
increased	O
invasion	O
of	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
into	O
HEp	O
-	O
2	O
cells	O
from	O
one	O
-	O
to	O
threefold	O
.	O

In	O
contrast	O
,	O
non	O
-	O
pathogenic	O
oral	O
bacteria	O
such	O
as	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
and	O
Streptococcus	B-bacteria
gordonii	I-bacteria
showed	O
no	O
significant	O
influence	O
on	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
invasion	O
.	O

P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
together	O
with	O
oral	O
bacteria	O
stimulated	O
greater	O
cytokine	O
production	O
from	O
HEp	O
-	O
2	O
cells	O
than	O
did	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
alone	O
.	O

P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
in	O
combination	O
with	O
periodontal	O
pathogens	O
also	O
increased	O
apoptosis	O
of	O
HEp	O
-	O
2	O
cells	O
and	O
induced	O
elevated	O
caspase	O
-	O
3	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
oral	O
bacteria	O
,	O
especially	O
periodontal	O
pathogens	O
,	O
may	O
foster	O
P	B-bacteria
.	I-bacteria
aeruginos	I-bacteria
invasion	O
into	O
respiratory	O
epithelial	O
cells	O
to	O
enhance	O
host	O
cell	O
cytokine	O
release	O
and	O
apoptosis	O
.	O

Many	O
of	O
the	O
protective	O
immune	O
responses	O
of	O
old	O
people	O
are	O
impaired	O
and	O
this	O
leads	O
to	O
an	O
increased	O
risk	O
of	O
oral	O
bacterial	O
infections	O
.	O

Little	O
is	O
known	O
about	O
the	O
interaction	O
between	O
the	O
systemic	O
immune	O
response	O
on	O
one	O
hand	O
and	O
oral	O
infections	O
and	O
oral	O
diseases	O
on	O
the	O
other	O
.	O

Here	O
,	O
we	O
conducted	O
an	O
epidemiological	O
study	O
of	O
the	O
independent	O
elderly	O
to	O
determine	O
the	O
relationships	O
between	O
activated	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
oral	O
bacterial	O
infections	O
:	O
oral	O
diseases	O
such	O
as	O
dental	O
caries	O
and	O
periodontal	O
disease	O
.	O

One	O
hundred	O
independent	O
elderly	O
people	O
aged	O
77	O
years	O
old	O
(	O
53	O
males	O
,	O
47	O
females	O
)	O
were	O
examined	O
.	O

Blood	O
samples	O
were	O
drawn	O
,	O
and	O
activated	O
NK	O
cells	O
were	O
evaluated	O
using	O
CD16	O
,	O
CD56	O
,	O
and	O
CD69	O
monoclonal	O
antibodies	O
with	O
flow	O
cytometry	O
.	O

Bacterial	O
counts	O
for	O
oral	O
streptococci	B-bacteria
,	O
lactobacillus	B-bacteria
,	O
and	O
opportunistic	O
pathogens	O
were	O
performed	O
using	O
culture	O
techniques	O
.	O

Oral	O
disease	O
examinations	O
were	O
performed	O
by	O
dentists	O
.	O

A	O
larger	O
percentage	O
of	O
CD69	O
(	O
+	O
)	O
NK	O
cells	O
(	O
CD16	O
(	O
+	O
)	O
CD56	O
(	O
+	O
)	O
)	O
showed	O
significant	O
correlations	O
to	O
the	O
isolation	O
numbers	O
of	O
total	O
streptococci	B-bacteria
(	O
r	O
=	O
0	O
.	O
409	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
the	O
species	O
numbers	O
of	O
opportunistic	O
pathogens	O
(	O
r	O
=	O
-	O
0	O
.	O
318	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
the	O
numbers	O
of	O
decayed	O
teeth	O
(	O
r	O
=	O
-	O
0	O
.	O
223	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
the	O
amount	O
of	O
bridge	O
work	O
(	O
r	O
=	O
0	O
.	O
219	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
higher	O
proportion	O
of	O
CD69	O
(	O
+	O
)	O
NK	O
cells	O
is	O
associated	O
with	O
the	O
incidence	O
of	O
dental	O
caries	O
and	O
the	O
number	O
of	O
opportunistic	O
pathogens	O
and	O
total	O
streptococci	B-bacteria
in	O
the	O
oral	O
cavity	O
of	O
the	O
elderly	O
.	O

This	O
suggests	O
that	O
the	O
proportionate	O
number	O
of	O
CD69	O
(	O
+	O
)	O
NK	O
cells	O
may	O
be	O
a	O
useful	O
indicator	O
for	O
oral	O
infection	O
in	O
elderly	O
subjects	O
.	O

Lactobacilli	B-bacteria
were	O
isolated	O
from	O
oral	O
cavity	O
of	O
healthy	O
children	O
and	O
identified	O
by	O
using	O
standard	O
bacteriological	O
methods	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
show	O
the	O
prevalent	O
of	O
Lactobacilli	B-bacteria
in	O
the	O
oral	O
cavity	O
and	O
to	O
emphasis	O
on	O
the	O
antagonistic	O
activity	O
of	O
oral	O
Lactobacilli	B-bacteria
on	O
oral	O
pathogens	O
.	O

Our	O
results	O
revealed	O
that	O
a	O
variety	O
of	O
lactobacillus	B-bacteria
species	I-bacteria
were	O
inhabited	O
the	O
healthy	O
oral	O
cavity	O
of	O
children	O
and	O
quantitative	O
assay	O
using	O
Lactobacillus	B-bacteria
filtered	O
supernatant	O
is	O
more	O
reliable	O
than	O
Lactobacillus	B-bacteria
non	O
filtered	O
supernatant	O
for	O
screening	O
of	O
in	O
vitro	O
antagonistic	O
activity	O
.	O

Recent	O
studies	O
suggest	O
an	O
association	O
between	O
sciatica	O
and	O
Propionibacterium	B-bacteria
acnes	I-bacteria
.	O

`	O
`	O
Modic	O
type	O
I	O
changes	O
'	O
'	O
in	O
the	O
vertebrae	O
are	O
closely	O
associated	O
with	O
sciatica	O
and	O
lower	O
back	O
pain	O
,	O
and	O
recent	O
studies	O
have	O
questioned	O
the	O
ability	O
of	O
conventional	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
to	O
differentiate	O
between	O
degenerative	O
Modic	O
type	O
I	O
changes	O
and	O
vertebral	O
abnormalities	O
caused	O
by	O
infection	O
.	O

To	O
test	O
whether	O
bacteria	O
could	O
be	O
cultured	O
from	O
biopsies	O
of	O
Modic	O
type	O
I	O
changes	O
.	O

Twenty	O
-	O
four	O
consecutive	O
patients	O
with	O
Modic	O
type	O
I	O
changes	O
in	O
lumbar	O
vertebrae	O
had	O
a	O
biopsy	O
taken	O
from	O
the	O
affected	O
vertebra	O
by	O
a	O
strict	O
aseptic	O
procedure	O
.	O

The	O
biopsy	O
was	O
split	O
into	O
two	O
specimens	O
,	O
which	O
were	O
inoculated	O
into	O
thioglycolate	O
agar	O
tubes	O
in	O
the	O
surgical	O
theatre	O
and	O
transported	O
to	O
the	O
microbiology	O
laboratory	O
.	O

In	O
the	O
laboratory	O
,	O
one	O
specimen	O
was	O
streaked	O
onto	O
plates	O
and	O
analyzed	O
for	O
anaerobic	O
and	O
aerobic	O
culture	O
.	O

The	O
other	O
tube	O
was	O
left	O
unopened	O
and	O
incubated	O
directly	O
.	O

Plates	O
and	O
tubes	O
were	O
incubated	O
for	O
2	O
weeks	O
and	O
observed	O
for	O
visible	O
growth	O
.	O

None	O
of	O
the	O
biopsies	O
yielded	O
growth	O
of	O
anaerobic	O
bacteria	O
.	O

In	O
one	O
patient	O
,	O
both	O
biopsies	O
yielded	O
growth	O
of	O
Staphylococcus	B-bacteria
epidermidis	I-bacteria
,	O
and	O
in	O
another	O
patient	O
coagulase	O
-	O
negative	O
staphylococci	B-bacteria
were	O
isolated	O
from	O
one	O
biopsy	O
.	O

Both	O
patients	O
received	O
oral	O
antibiotics	O
without	O
convincing	O
effect	O
on	O
symptoms	O
.	O

Our	O
results	O
showed	O
no	O
evidence	O
of	O
bacteria	O
in	O
vertebrae	O
with	O
Modic	O
type	O
I	O
changes	O
.	O

The	O
isolation	O
of	O
staphylococci	B-bacteria
from	O
two	O
patients	O
probably	O
represented	O
contamination	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
strict	O
supragingival	O
plaque	O
control	O
on	O
the	O
subgingival	O
microbiota	O
in	O
smokers	O
and	O
never	O
-	O
smokers	O
.	O

Research	O
into	O
the	O
impact	O
of	O
supragingival	O
plaque	O
control	O
on	O
the	O
number	O
of	O
subgingival	O
bacteria	O
has	O
resulted	O
in	O
contradictory	O
findings	O
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
has	O
been	O
suggested	O
as	O
a	O
valid	O
alternative	O
to	O
current	O
microbiologic	O
methods	O
based	O
on	O
bacteria	O
cultures	O
.	O

Forty	O
-	O
five	O
subjects	O
with	O
chronic	O
periodontitis	O
were	O
selected	O
.	O

Twenty	O
-	O
four	O
of	O
them	O
had	O
never	O
smoked	O
,	O
and	O
21	O
were	O
active	O
smokers	O
.	O

Four	O
sites	O
per	O
patient	O
were	O
selected	O
for	O
sampling	O
.	O

Supragingival	O
debridement	O
was	O
performed	O
at	O
baseline	O
,	O
and	O
the	O
subjects	O
received	O
weekly	O
instructions	O
on	O
oral	O
hygiene	O
for	O
180	O
days	O
.	O

A	O
clinical	O
examination	O
and	O
subgingival	O
plaque	O
sampling	O
were	O
carried	O
out	O
at	O
baseline	O
and	O
at	O
30	O
,	O
90	O
,	O
and	O
180	O
days	O
.	O

A	O
real	O
-	O
time	O
PCR	O
assay	O
was	O
used	O
to	O
detect	O
and	O
quantify	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Parvimonas	B-bacteria
micra	I-bacteria
(	O
previously	O
Peptostreptococcus	B-bacteria
micros	I-bacteria
or	O
Micromonas	B-bacteria
micros	I-bacteria
)	O
,	O
Dialister	B-bacteria
pneumosintes	I-bacteria
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
previously	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
)	O
,	O
and	O
the	O
total	O
bacteria	O
load	O
(	O
eubacteria	O
)	O
in	O
the	O
subgingival	O
samples	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
linear	O
models	O
adjusted	O
for	O
the	O
clustering	O
of	O
observations	O
within	O
individuals	O
.	O

Smokers	O
and	O
never	O
-	O
smokers	O
exhibited	O
a	O
similar	O
and	O
significant	O
reduction	O
in	O
total	O
bacteria	O
counts	O
over	O
time	O
.	O

Irrespective	O
of	O
smoking	O
status	O
,	O
deep	O
sites	O
consistently	O
harbored	O
greater	O
quantities	O
of	O
total	O
bacteria	O
throughout	O
the	O
study	O
.	O

Higher	O
numbers	O
of	O
the	O
bacteria	O
investigated	O
were	O
associated	O
with	O
bleeding	O
on	O
probing	O
.	O

Supragingival	O
plaque	O
control	O
markedly	O
reduced	O
subgingival	O
microbiota	O
counts	O
in	O
smokers	O
and	O
never	O
-	O
smokers	O
.	O

The	O
bacterial	O
colonization	O
of	O
the	O
oral	O
mucosa	O
was	O
evaluated	O
in	O
patients	O
with	O
asymptomatic	O
oral	O
lichen	O
planus	O
(	O
OLP	O
)	O
and	O
compared	O
to	O
the	O
microbiologic	O
status	O
in	O
mucosally	O
healthy	O
subjects	O
.	O

Bacteria	O
from	O
patients	O
with	O
clinically	O
and	O
histopathologically	O
diagnosed	O
OLP	O
from	O
the	O
Stomatology	O
Service	O
,	O
Department	O
of	O
Oral	O
Surgery	O
and	O
Stomatology	O
,	O
School	O
of	O
Dental	O
Medicine	O
,	O
University	O
of	O
Bern	O
,	O
were	O
collected	O
with	O
a	O
non	O
-	O
invasive	O
swab	O
system	O
.	O

Samples	O
were	O
taken	O
from	O
OLP	O
lesions	O
on	O
the	O
gingiva	O
and	O
from	O
non	O
-	O
affected	O
sites	O
on	O
the	O
contralateral	O
side	O
of	O
the	O
mouth	O
.	O

The	O
control	O
population	O
did	O
not	O
have	O
OLP	O
and	O
was	O
recruited	O
from	O
the	O
student	O
clinic	O
.	O

All	O
samples	O
were	O
processed	O
with	O
the	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
method	O
using	O
well	O
-	O
defined	O
bacterial	O
species	O
for	O
the	O
analysis	O
.	O

Significantly	O
higher	O
bacterial	O
counts	O
of	O
Bacteroides	B-bacteria
ureolyticus	I-bacteria
(	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
Dialister	B-bacteria
species	I-bacteria
(	O
sp	O
.	O
)	O

(	O
P	O
=	O
0	O
.	O
006	O
)	O
,	O
Staphylococcus	B-bacteria
haemolyticus	I-bacteria
(	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
and	O
Streptococcus	B-bacteria
agalactiae	I-bacteria
(	O
P	O
=	O
0	O
.	O
006	O
)	O
were	O
found	O
in	O
samples	O
taken	O
from	O
OLP	O
lesions	O
compared	O
to	O
sites	O
with	O
no	O
clinical	O
evidence	O
of	O
OLP	O
.	O

Significantly	O
higher	O
bacterial	O
counts	O
were	O
found	O
for	O
Capnocytophaga	B-bacteria
sputigena	I-bacteria
,	O
Eikenella	B-bacteria
corrodens	I-bacteria
,	O
Lactobacillus	B-bacteria
crispatus	I-bacteria
,	O
Mobiluncus	B-bacteria
curtisii	I-bacteria
,	O
Neisseria	B-bacteria
mucosa	I-bacteria
,	O
Prevotella	B-bacteria
bivia	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
and	O
S	B-bacteria
.	I-bacteria
agalactiae	I-bacteria
at	O
sites	O
with	O
lesions	O
in	O
subjects	O
with	O
OLP	O
compared	O
to	O
sites	O
in	O
control	O
subjects	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Microbiologic	O
differences	O
were	O
found	O
between	O
sites	O
with	O
OLP	O
and	O
sites	O
in	O
subjects	O
without	O
a	O
diagnosis	O
of	O
OLP	O
.	O

Specifically	O
,	O
higher	O
counts	O
of	O
staphylococci	B-bacteria
and	O
S	B-bacteria
.	I-bacteria
agalactiae	I-bacteria
were	O
found	O
in	O
OLP	O
lesions	O
.	O

Bacteriological	O
air	O
sampling	O
was	O
conducted	O
at	O
25	O
dental	O
units	O
during	O
restorative	O
treatment	O
sessions	O
before	O
and	O
after	O
disinfection	O
of	O
dental	O
unit	O
waterlines	O
(	O
DUWL	O
)	O
with	O
hydrogen	O
peroxide	O
.	O

Air	O
samples	O
for	O
determining	O
the	O
concentration	O
and	O
species	O
composition	O
of	O
aerobic	O
and	O
facultatively	O
anaerobic	O
bacteria	O
were	O
collected	O
with	O
the	O
portable	O
Reuter	O
Centrifugal	O
Sampler	O
(	O
RCS	O
Plus	O
)	O
in	O
the	O
dental	O
operation	O
area	O
close	O
to	O
patient	O
'	O
s	O
mouth	O
.	O

Large	O
concentrations	O
of	O
airborne	O
bacteria	O
in	O
the	O
range	O
of	O
0	O
.	O
35	O
-	O
40	O
.	O
08	O
x	O
10	O
(	O
3	O
)	O
cfu	O
/	O
m	O
(	O
3	O
)	O
(	O
median	O
=	O
1	O
.	O
63	O
x	O
10	O
(	O
3	O
)	O
cfu	O
/	O
m	O
(	O
3	O
)	O
)	O
were	O
recorded	O
before	O
DUWL	O
disinfection	O
.	O

After	O
disinfection	O
,	O
the	O
concentrations	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
ranging	O
from	O
0	O
.	O
51	O
-	O
3	O
.	O
82	O
x	O
10	O
(	O
3	O
)	O
cfu	O
/	O
m	O
(	O
3	O
)	O
(	O
median	O
=	O
0	O
.	O
9	O
x	O
10	O
(	O
3	O
)	O
cfu	O
/	O
m	O
(	O
3	O
)	O
)	O
.	O

Streptococci	B-bacteria
were	O
most	O
numerous	O
among	O
airborne	O
bacteria	O
before	O
DUWL	O
disinfection	O
,	O
forming	O
79	O
.	O
23	O
%	O
of	O
total	O
isolates	O
.	O

The	O
remaining	O
isolates	O
were	O
staphylococci	B-bacteria
/	O
micrococci	B-bacteria
(	O
15	O
.	O
7	O
%	O
)	O
,	O
corynebacteria	B-bacteria
(	O
2	O
.	O
3	O
%	O
)	O
,	O
endospore	O
-	O
forming	O
bacilli	O
(	O
1	O
.	O
45	O
%	O
)	O
,	O
Gram	O
-	O
negative	O
bacteria	O
(	O
1	O
.	O
31	O
%	O
)	O
,	O
and	O
actinomycetes	B-bacteria
(	O
0	O
.	O
01	O
%	O
)	O
.	O

After	O
DUWL	O
disinfection	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
numbers	O
of	O
streptococci	B-bacteria
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
Gram	O
-	O
negative	O
bacteria	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
was	O
noted	O
,	O
while	O
the	O
numbers	O
of	O
other	O
types	O
of	O
bacteria	O
were	O
unaffected	O
.	O

Altogether	O
,	O
50	O
species	O
or	O
genera	O
of	O
bacteria	O
were	O
identified	O
in	O
the	O
examined	O
air	O
samples	O
before	O
and	O
after	O
DUWL	O
disinfection	O
.	O

Of	O
these	O
,	O
36	O
species	O
or	O
genera	O
are	O
considered	O
potentially	O
pathogenic	O
,	O
as	O
a	O
potential	O
cause	O
of	O
infection	O
,	O
allergic	O
disease	O
or	O
intoxication	O
.	O

In	O
conclusion	O
,	O
the	O
high	O
pollution	O
of	O
dental	O
operation	O
area	O
with	O
bacteria	O
indicates	O
a	O
need	O
for	O
use	O
of	O
preventive	O
measures	O
protecting	O
dental	O
staff	O
and	O
patients	O
,	O
such	O
as	O
DUWL	O
disinfection	O
that	O
proved	O
efficient	O
in	O
decrease	O
of	O
exposure	O
in	O
the	O
present	O
study	O
.	O

Periodontitis	O
is	O
an	O
inflammatory	O
disease	O
of	O
the	O
supporting	O
tissues	O
of	O
teeth	O
and	O
is	O
a	O
major	O
cause	O
of	O
tooth	O
loss	O
in	O
adults	O
.	O

The	O
onset	O
and	O
progression	O
of	O
periodontal	O
disease	O
is	O
attributed	O
to	O
the	O
presence	O
of	O
elevated	O
levels	O
of	O
a	O
consortium	O
of	O
pathogenic	O
bacteria	O
.	O

Gram	O
negative	O
bacteria	O
,	O
mainly	O
strict	O
anaerobes	O
,	O
play	O
the	O
major	O
role	O
.	O

The	O
present	O
study	O
aimed	O
to	O
assess	O
the	O
presence	O
of	O
the	O
main	O
types	O
of	O
microorganisms	O
involved	O
in	O
the	O
aetiopathogenesis	O
of	O
periodontal	O
disease	O
:	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Eikenella	B-bacteria
corrodens	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
,	O
Tanerella	B-bacteria
forsythia	I-bacteria
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
in	O
different	O
samples	O
collected	O
from	O
the	O
oral	O
cavity	O
of	O
90	O
patients	O
diagnosed	O
with	O
Periodontitis	O
.	O

Bacterial	O
DNA	O
detection	O
was	O
performed	O
in	O
diverse	O
biological	O
materials	O
,	O
namely	O
in	O
dental	O
plaque	O
,	O
gingival	O
tissue	O
and	O
saliva	O
,	O
by	O
means	O
of	O
multiplex	O
PCR	O
,	O
a	O
technique	O
that	O
allows	O
simultaneous	O
identification	O
of	O
two	O
different	O
bacterial	O
genomes	O
.	O

In	O
the	O
dental	O
plaque	O
of	O
the	O
Periodontitis	O
patients	O
,	O
Treponema	B-bacteria
denticola	I-bacteria
dominated	O
.	O

In	O
the	O
gingival	O
tissue	O
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
and	O
Treponema	B-bacteria
denticola	I-bacteria
were	O
the	O
microbiota	O
most	O
frequently	O
detected	O
,	O
whilst	O
in	O
saliva	O
Treponema	B-bacteria
denticola	I-bacteria
and	O
Eikenella	B-bacteria
corrodens	I-bacteria
were	O
found	O
with	O
the	O
highest	O
percentage	O
.	O

The	O
identification	O
of	O
microorganisms	O
by	O
multiplex	O
PCR	O
is	O
specific	O
and	O
sensitive	O
.	O

Rapid	O
and	O
precise	O
assessment	O
of	O
different	O
types	O
of	O
periodontopathogens	O
is	O
extremely	O
important	O
for	O
early	O
detection	O
of	O
the	O
infection	O
and	O
consequently	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
periodontal	O
disease	O
.	O

In	O
everyday	O
clinical	O
practice	O
,	O
for	O
routine	O
bacterial	O
evaluation	O
in	O
patients	O
with	O
periodontal	O
disease	O
,	O
the	O
dental	O
plaque	O
is	O
the	O
most	O
suitable	O
biological	O
material	O
,	O
because	O
it	O
is	O
the	O
richest	O
in	O
periodontal	O
bacteria	O
.	O

Dental	O
caries	O
in	O
babies	O
and	O
toddlers	O
is	O
called	O
Early	O
Childhood	O
Caries	O
(	O
ECC	O
)	O
.	O

It	O
is	O
an	O
infectious	O
and	O
transmissible	O
die	O
-	O
to	O
-	O
bacterial	O
disease	O
.	O

Detailed	O
knowledge	O
regarding	O
the	O
acquisition	O
and	O
transmission	O
of	O
infectious	O
agents	O
facilitates	O
a	O
more	O
comprehensive	O
approach	O
toward	O
prevention	O
.	O

Mutans	B-bacteria
streptococci	I-bacteria
are	O
important	O
organisms	O
in	O
the	O
initiation	O
and	O
progression	O
of	O
dental	O
caries	O
.	O

Recent	O
evidence	O
demonstrates	O
that	O
these	O
bacteria	O
are	O
found	O
in	O
the	O
mouths	O
of	O
pre	O
-	O
dentate	O
infants	O
and	O
are	O
acquired	O
via	O
vertical	O
and	O
/	O
or	O
horizontal	O
transmission	O
from	O
human	O
reservoirs	O
.	O

This	O
information	O
should	O
facilitate	O
the	O
focusing	O
of	O
clinical	O
interventions	O
that	O
prevent	O
or	O
delay	O
infant	O
infection	O
,	O
thereby	O
reducing	O
the	O
prevalence	O
of	O
dental	O
caries	O
(	O
ECC	O
)	O
in	O
babies	O
and	O
toddlers	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
observe	O
the	O
coexistence	O
of	O
periodontal	O
bacteria	O
DNA	O
(	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Tannerella	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
)	O
in	O
coronary	O
atheromatous	O
plaques	O
and	O
subgingival	O
plaques	O
in	O
patients	O
scheduled	O
for	O
coronary	O
artery	O
bypass	O
graft	O
.	O

Coronary	O
atheromatous	O
plaque	O
and	O
subgingival	O
plaque	O
samples	O
were	O
obtained	O
from	O
51	O
patients	O
and	O
examined	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
technique	O
with	O
specific	O
primers	O
for	O
periodontal	O
bacteria	O
.	O

P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
(	O
33	O
%	O
)	O
,	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
(	O
31	O
%	O
)	O
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
(	O
18	O
%	O
)	O
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
(	O
12	O
%	O
)	O
were	O
detected	O
while	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
was	O
negative	O
and	O
not	O
found	O
in	O
coronary	O
atheromatous	O
plaques	O
;	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
(	O
84	O
%	O
)	O
,	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
(	O
78	O
%	O
)	O
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
(	O
59	O
%	O
)	O
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
(	O
39	O
%	O
)	O
and	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
(	O
22	O
%	O
)	O
were	O
detected	O
in	O
subgingival	O
plaque	O
samples	O
.	O

Coexistence	O
of	O
periodontal	O
bacteria	O
DNA	O
in	O
coronary	O
atheromatous	O
and	O
subgingival	O
plaque	O
samples	O
was	O
evidenced	O
in	O
32	O
patients	O
.	O

The	O
coexistence	O
of	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
,	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
in	O
coronary	O
atheromatous	O
plaques	O
and	O
the	O
subgingival	O
plaque	O
samples	O
in	O
CAD	O
patients	O
could	O
suggest	O
a	O
potential	O
role	O
for	O
periodontal	O
pathogenic	O
bacteria	O
in	O
atherosclerosis	O
disease	O
process	O
.	O

Maternal	O
periodontitis	O
has	O
emerged	O
as	O
a	O
putative	O
risk	O
factor	O
for	O
preterm	O
births	O
in	O
humans	O
.	O

The	O
periodontitis	O
-	O
associated	O
dental	O
biofilm	O
is	O
thought	O
to	O
serve	O
as	O
an	O
important	O
source	O
of	O
oral	O
bacteria	O
and	O
related	O
virulence	O
factors	O
that	O
hematogenously	O
disseminate	O
and	O
affect	O
the	O
fetoplacental	O
unit	O
;	O
however	O
the	O
underlying	O
biological	O
mechanisms	O
are	O
yet	O
to	O
be	O
fully	O
elucidated	O
.	O

This	O
study	O
hypothesized	O
that	O
an	O
oral	O
infection	O
with	O
the	O
human	O
periodontal	O
pathogens	O
Campylobacter	B-bacteria
rectus	I-bacteria
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
is	O
able	O
to	O
induce	O
fetal	O
growth	O
restriction	O
,	O
placental	O
inflammation	O
and	O
enhance	O
Toll	O
-	O
like	O
receptors	O
type	O
4	O
(	O
TLR4	O
)	O
expression	O
in	O
a	O
murine	O
pregnancy	O
model	O
.	O

Female	O
Balb	O
/	O
C	O
mice	O
(	O
n	O
=	O
40	O
)	O
were	O
orally	O
infected	O
with	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
and	O
/	O
or	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
over	O
a	O
16	O
-	O
week	O
period	O
and	O
mated	O
once	O
/	O
week	O
.	O

Pregnant	O
mice	O
were	O
sacrificed	O
at	O
embryonic	O
day	O
(	O
E	O
)	O
16	O
.	O
5	O
and	O
placentas	O
were	O
collected	O
and	O
analyzed	O
for	O
TLR4	O
mRNA	O
levels	O
and	O
qualitative	O
protein	O
expression	O
by	O
real	O
-	O
time	O
PCR	O
and	O
immunofluorescence	O
.	O

TLR4	O
mRNA	O
expression	O
was	O
found	O
to	O
be	O
increased	O
in	O
the	O
C	O
.	O
rectus	O
-	O
infected	O
group	O
(	O
1	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
886	O
-	O
fold	O
difference	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
ANOVA	O
)	O
compared	O
to	O
controls	O
.	O

Microscopic	O
analysis	O
of	O
murine	O
placentas	O
showed	O
enhanced	O
immunofluorescence	O
of	O
TLR4	O
in	O
trophoblasts	O
,	O
mainly	O
in	O
the	O
placental	O
labyrinth	O
layer	O
.	O

Also	O
,	O
combined	O
oral	O
infection	O
with	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
significantly	O
reduced	O
the	O
overall	O
fecundity	O
compared	O
to	O
controls	O
(	O
16	O
.	O
7	O
%	O
vs	O
.	O
75	O
%	O
,	O
infected	O
vs	O
.	O
non	O
-	O
infected	O
mice	O
respectively	O
,	O
P	O
=	O
0	O
.	O
03	O
,	O
Kaplan	O
-	O
Meier	O
)	O
.	O

The	O
results	O
supported	O
an	O
enhanced	O
placental	O
TLR4	O
expression	O
after	O
oral	O
infection	O
with	O
periodontal	O
pathogens	O
.	O

The	O
TLR4	O
pathway	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
preterm	O
births	O
;	O
therefore	O
the	O
abnormal	O
regulation	O
of	O
placental	O
TLR4	O
may	O
give	O
new	O
insights	O
into	O
how	O
maternal	O
periodontitis	O
and	O
periodontal	O
pathogens	O
might	O
be	O
linked	O
to	O
placental	O
inflammation	O
and	O
preterm	O
birth	O
pathogenesis	O
.	O

This	O
study	O
examined	O
the	O
ability	O
of	O
methyl	O
gallate	O
(	O
MG	O
)	O
and	O
gallic	O
acid	O
(	O
GA	O
)	O
,	O
the	O
main	O
compounds	O
of	O
gallo	O
-	O
tannins	O
in	O
Galla	O
Rhois	O
,	O
to	O
inhibit	O
the	O
proliferation	O
of	O
oral	O
bacterial	O
and	O
the	O
in	O
vitro	O
formation	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
biofilms	O
.	O

The	O
antimicrobial	O
activities	O
of	O
these	O
compounds	O
were	O
evaluated	O
in	O
vitro	O
using	O
the	O
broth	O
microdilution	O
method	O
and	O
a	O
beaker	O
-	O
wire	O
test	O
.	O

Both	O
MG	O
and	O
GA	O
had	O
inhibitory	O
effects	O
on	O
the	O
growth	O
of	O
cariogenic	O
(	O
MIC	O
<	O
8	O
mg	O
/	O
ml	O
)	O
and	O
periodontopathic	O
bacteria	O
(	O
MIC	O
=	O
1	O
mg	O
/	O
ml	O
)	O
.	O

Moreover	O
,	O
these	O
compounds	O
significantly	O
inhibited	O
the	O
in	O
vitro	O
formation	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
biofilms	O
(	O
MG	O
,	O
1	O
mg	O
/	O
ml	O
;	O
GA	O
,	O
4	O
mg	O
/	O
ml	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

MG	O
was	O
more	O
effective	O
in	O
inhibiting	O
bacterial	O
growth	O
and	O
the	O
formation	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
biofilm	O
than	O
GA	O
.	O

In	O
conclusion	O
,	O
MG	O
and	O
GA	O
can	O
inhibit	O
the	O
growth	O
of	O
oral	O
pathogens	O
and	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
biofilm	O
formation	O
,	O
and	O
may	O
be	O
used	O
to	O
prevent	O
the	O
formation	O
of	O
oral	O
biofilms	O
.	O

We	O
evaluated	O
the	O
ability	O
of	O
a	O
dual	O
-	O
species	O
community	O
of	O
oral	O
bacteria	O
to	O
produce	O
the	O
universal	O
signalling	O
molecule	O
,	O
autoinducer	O
-	O
2	O
(	O
AI	O
-	O
2	O
)	O
,	O
in	O
saliva	O
-	O
fed	O
biofilms	O
.	O

Streptococcus	B-bacteria
oralis	I-bacteria
34	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
34	I-bacteria
luxS	I-bacteria
mutant	I-bacteria
and	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
T14V	I-bacteria
were	O
grown	O
as	O
single	O
-	O
and	O
dual	O
-	O
species	O
biofilms	O
within	O
sorbarods	O
fed	O
with	O
25	O
%	O
human	O
saliva	O
.	O

AI	O
-	O
2	O
concentration	O
in	O
biofilm	O
effluents	O
was	O
determined	O
by	O
the	O
Vibrio	B-bacteria
harveyi	I-bacteria
BB170	I-bacteria
bioluminescence	O
assay	O
.	O

After	O
homogenizing	O
the	O
sorbarods	O
to	O
release	O
biofilm	O
cells	O
,	O
cell	O
numbers	O
were	O
determined	O
by	O
fluorometric	O
analysis	O
of	O
fluorescent	O
antibody	O
-	O
labelled	O
cells	O
.	O

After	O
48	O
h	O
,	O
dual	O
-	O
species	O
biofilm	O
communities	O
of	O
interdigitated	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
34	I-bacteria
and	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
T14V	I-bacteria
contained	O
3	O
.	O
2	O
x	O
10	O
(	O
9	O
)	O
cells	O
:	O
fivefold	O
more	O
than	O
single	O
-	O
species	O
biofilms	O
.	O

However	O
,	O
these	O
48	O
-	O
h	O
dual	O
-	O
species	O
biofilms	O
exhibited	O
the	O
lowest	O
concentration	O
ratio	O
of	O
AI	O
-	O
2	O
to	O
cell	O
density	O
.	O

Oral	O
bacteria	O
produce	O
AI	O
-	O
2	O
in	O
saliva	O
-	O
fed	O
biofilms	O
.	O

The	O
decrease	O
of	O
more	O
than	O
10	O
-	O
fold	O
in	O
concentration	O
ratio	O
seen	O
between	O
1	O
and	O
48	O
h	O
in	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
34	I-bacteria
-	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
T14V	I-bacteria
biofilms	O
suggests	O
that	O
peak	O
production	O
of	O
AI	O
-	O
2	O
occurs	O
early	O
and	O
is	O
followed	O
by	O
a	O
very	O
low	O
steady	O
-	O
state	O
level	O
.	O

High	O
oral	O
bacterial	O
biofilm	O
densities	O
may	O
be	O
achieved	O
by	O
inter	O
-	O
species	O
AI	O
-	O
2	O
signalling	O
.	O

We	O
propose	O
that	O
low	O
concentrations	O
of	O
AI	O
-	O
2	O
contribute	O
to	O
the	O
establishment	O
of	O
oral	O
commensal	O
biofilm	O
communities	O
.	O

Oral	O
bacteria	O
,	O
including	O
cariogenic	O
and	O
periodontal	O
pathogens	O
,	O
are	O
thought	O
to	O
be	O
etiological	O
factors	O
in	O
the	O
development	O
of	O
cardiovascular	O
diseases	O
.	O

To	O
define	O
this	O
relationship	O
,	O
we	O
analyzed	O
the	O
distribution	O
of	O
oral	O
bacterial	O
species	O
in	O
cardiovascular	O
specimens	O
.	O

Following	O
acceptance	O
into	O
the	O
study	O
,	O
203	O
consecutive	O
patients	O
were	O
analyzed	O
,	O
from	O
whom	O
82	O
aortic	O
valve	O
specimens	O
,	O
35	O
mitral	O
valve	O
specimens	O
,	O
and	O
86	O
aortic	O
aneurysmal	O
wall	O
specimens	O
,	O
of	O
which	O
16	O
contained	O
aneurysmal	O
thrombus	O
tissues	O
,	O
were	O
obtained	O
.	O

In	O
addition	O
,	O
a	O
total	O
of	O
58	O
dental	O
plaque	O
specimens	O
were	O
collected	O
from	O
the	O
same	O
group	O
of	O
patients	O
who	O
underwent	O
heart	O
valve	O
replacement	O
or	O
removal	O
of	O
aortic	O
aneurysms	O
.	O

Bacterial	O
DNA	O
was	O
extracted	O
from	O
both	O
cardiovascular	O
tissues	O
and	O
dental	O
plaque	O
in	O
those	O
cases	O
and	O
then	O
species	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
assays	O
were	O
used	O
to	O
analyze	O
the	O
occurrences	O
of	O
six	O
oral	O
streptococcal	B-bacteria
and	O
six	O
periodontal	O
bacterial	O
species	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
was	O
the	O
most	O
frequently	O
detected	O
species	O
in	O
the	O
cardiovascular	O
specimens	O
,	O
followed	O
by	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
.	O

As	O
for	O
dental	O
plaque	O
specimens	O
from	O
patients	O
who	O
underwent	O
cardiovascular	O
operations	O
,	O
most	O
of	O
the	O
tested	O
periodontitis	O
-	O
related	O
species	O
as	O
well	O
as	O
oral	O
streptococci	B-bacteria
were	O
detected	O
at	O
high	O
frequencies	O
.	O

Furthermore	O
,	O
the	O
positive	O
rate	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
in	O
cardiovascular	O
specimens	O
from	O
patients	O
whose	O
dental	O
plaque	O
specimens	O
were	O
also	O
positive	O
for	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
was	O
78	O
%	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
any	O
other	O
tested	O
species	O
when	O
the	O
same	O
analysis	O
was	O
performed	O
.	O

Our	O
results	O
suggest	O
that	O
specific	O
oral	O
bacterial	O
species	O
,	O
such	O
as	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
are	O
related	O
to	O
bacteremia	O
and	O
may	O
be	O
etiologic	O
factors	O
for	O
the	O
development	O
of	O
cardiovascular	O
diseases	O
.	O

Quantative	O
confocal	O
laser	O
scanning	O
microscopy	O
(	O
CLSM	O
)	O
in	O
combination	O
with	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
may	O
help	O
to	O
increase	O
our	O
knowledge	O
about	O
biofilm	O
formation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
evaluate	O
a	O
stereological	O
method	O
for	O
quantification	O
of	O
bacteria	O
in	O
intact	O
biofilm	O
.	O

The	O
method	O
was	O
applied	O
in	O
a	O
quantitative	O
study	O
of	O
the	O
proportion	O
of	O
streptococci	B-bacteria
relative	O
to	O
other	O
bacteria	O
in	O
initial	O
in	O
-	O
situ	O
-	O
grown	O
dental	O
biofilms	O
as	O
a	O
function	O
of	O
time	O
.	O

Biofilms	O
were	O
collected	O
on	O
standardized	O
glass	O
slabs	O
mounted	O
in	O
intra	O
-	O
oral	O
appliances	O
and	O
worn	O
by	O
10	O
individuals	O
for	O
6	O
,	O
12	O
,	O
24	O
,	O
and	O
48	O
h	O
.	O
Biofilms	O
were	O
analysed	O
using	O
CLSM	O
.	O

Quantification	O
of	O
bacteria	O
labelled	O
with	O
16S	O
ribosomal	O
RNA	O
oligonucleotide	O
probes	O
was	O
performed	O
with	O
stereological	O
tools	O
:	O
the	O
unbiased	O
counting	O
frame	O
and	O
the	O
two	O
-	O
dimensional	O
fractionator	O
.	O

Results	O
showed	O
a	O
notable	O
increase	O
in	O
the	O
total	O
number	O
of	O
bacteria	O
and	O
streptococci	B-bacteria
over	O
time	O
,	O
with	O
a	O
considerable	O
inter	O
-	O
individual	O
variation	O
at	O
each	O
time	O
-	O
point	O
.	O

After	O
48	O
h	O
there	O
was	O
a	O
12	O
.	O
5	O
-	O
fold	O
difference	O
between	O
individuals	O
in	O
the	O
total	O
number	O
of	O
bacteria	O
and	O
a	O
12	O
.	O
6	O
-	O
fold	O
difference	O
in	O
the	O
number	O
of	O
streptococci	B-bacteria
.	O

The	O
number	O
of	O
streptococci	B-bacteria
exceeded	O
that	O
of	O
other	O
bacteria	O
and	O
over	O
the	O
examination	O
period	O
there	O
was	O
a	O
relatively	O
constant	O
relationship	O
between	O
the	O
number	O
of	O
streptococci	B-bacteria
and	O
other	O
bacteria	O
(	O
streptococci	B-bacteria
vs	O
.	O
non	B-bacteria
-	I-bacteria
streptococci	I-bacteria
:	O
median	O
15	O
.	O
2	O
;	O
minimum	O
1	O
.	O
0	O
;	O
maximum	O
89	O
.	O
3	O
)	O
.	O

The	O
study	O
demonstrates	O
that	O
the	O
combined	O
use	O
of	O
FISH	O
and	O
stereology	O
is	O
a	O
relevant	O
and	O
reliable	O
tool	O
for	O
obtaining	O
unbiased	O
information	O
about	O
the	O
numerical	O
contributions	O
of	O
specific	O
bacterial	O
populations	O
during	O
early	O
biofilm	O
formation	O
.	O

Although	O
commensal	O
bacteria	O
are	O
known	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
proper	O
maturation	O
of	O
the	O
immune	O
system	O
of	O
their	O
mammalian	O
hosts	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
this	O
immunomodulation	O
are	O
poorly	O
characterized	O
.	O

The	O
present	O
review	O
summarizes	O
recent	O
findings	O
in	O
the	O
field	O
and	O
describes	O
new	O
knowledge	O
on	O
the	O
interplay	O
of	O
the	O
innate	O
and	O
adaptive	O
arms	O
of	O
the	O
immune	O
response	O
induced	O
by	O
symbiotic	O
bacterial	O
carbohydrate	O
antigens	O
.	O

Commensal	O
bacteria	O
in	O
the	O
intestine	O
not	O
only	O
interact	O
directly	O
with	O
dendritic	O
cells	O
but	O
also	O
engage	O
in	O
cross	O
-	O
talk	O
with	O
epithelial	O
cells	O
.	O

These	O
interactions	O
lead	O
to	O
the	O
induction	O
of	O
tolerogenic	O
antigen	O
-	O
presenting	O
cells	O
in	O
the	O
lamina	O
propria	O
and	O
ultimately	O
to	O
the	O
regulation	O
of	O
functional	O
maturation	O
of	O
effector	O
T	O
cells	O
.	O

Upon	O
recognition	O
of	O
capsular	O
polysaccharide	O
antigens	O
of	O
commensal	O
bacteria	O
by	O
dendritic	O
cells	O
(	O
through	O
toll	O
-	O
like	O
receptor	O
2	O
)	O
,	O
innate	O
immune	O
responses	O
facilitate	O
and	O
act	O
in	O
conjunction	O
with	O
adaptive	O
responses	O
to	O
promote	O
optimal	O
Th1	O
polarization	O
.	O

In	O
contrast	O
,	O
adaptive	O
immunoglobulin	O
A	O
responses	O
to	O
symbiotic	O
bacteria	O
regulate	O
the	O
magnitude	O
of	O
oxidative	O
innate	O
immune	O
responses	O
in	O
the	O
mucosa	O
as	O
well	O
as	O
bacterial	O
epitope	O
expression	O
in	O
the	O
lumen	O
.	O

Accumulating	O
evidence	O
is	O
elucidating	O
surface	O
carbohydrate	O
structures	O
of	O
symbiotic	O
bacteria	O
that	O
drive	O
the	O
modulation	O
of	O
the	O
intestinal	O
immune	O
system	O
,	O
resulting	O
in	O
mature	O
,	O
balanced	O
immune	O
responses	O
and	O
oral	O
tolerance	O
.	O

Seven	O
pimarane	O
type	O
-	O
diterpenes	O
re	O
-	O
isolated	O
from	O
Viguiera	O
arenaria	O
Baker	O
and	O
two	O
semi	O
-	O
synthetic	O
pimarane	O
derivatives	O
were	O
evaluated	O
in	O
vitro	O
against	O
the	O
following	O
main	O
microorganisms	O
responsible	O
for	O
dental	O
caries	O
:	O
Streptococcus	B-bacteria
salivarius	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
and	O
Lactobacillus	B-bacteria
casei	I-bacteria
.	O

The	O
compounds	O
ent	O
-	O
pimara	O
-	O
8	O
(	O
14	O
)	O
,	O
15	O
-	O
dien	O
-	O
19	O
-	O
oic	O
acid	O
(	O
PA	O
)	O
;	O
ent	O
-	O
8	O
(	O
14	O
)	O
,	O
15	O
-	O
pimaradien	O
-	O
3beta	O
-	O
ol	O
;	O
ent	O
-	O
15	O
-	O
pimarene	O
-	O
8beta	O
,	O
19	O
-	O
diol	O
;	O
ent	O
-	O
8	O
(	O
14	O
)	O
,	O
15	O
-	O
pimaradien	O
-	O
3beta	O
-	O
acetoxy	O
and	O
the	O
sodium	O
salt	O
derivative	O
of	O
PA	O
were	O
the	O
most	O
active	O
compounds	O
,	O
displaying	O
MIC	O
values	O
ranging	O
from	O
2	O
to	O
8	O
microg	O
mL	O
(	O
-	O
1	O
)	O
.	O

Thus	O
,	O
this	O
class	O
of	O
compounds	O
seems	O
promising	O
as	O
a	O
class	O
of	O
new	O
effective	O
anticariogenic	O
agents	O
.	O

Furthermore	O
,	O
our	O
results	O
also	O
allow	O
us	O
to	O
conclude	O
that	O
minor	O
structural	O
differences	O
among	O
these	O
diterpenes	O
significantly	O
influence	O
their	O
antimicrobial	O
activity	O
,	O
bringing	O
new	O
perspectives	O
to	O
the	O
discovery	O
of	O
new	O
natural	O
compounds	O
that	O
could	O
be	O
employed	O
in	O
the	O
development	O
of	O
oral	O
care	O
products	O
.	O

To	O
evaluate	O
the	O
number	O
of	O
bacteria	O
extruded	O
apically	O
from	O
extracted	O
teeth	O
ex	O
vivo	O
after	O
canal	O
instrumentation	O
using	O
a	O
manual	O
technique	O
and	O
three	O
engine	O
-	O
driven	O
techniques	O
utilizing	O
nickel	O
-	O
titanium	O
instruments	O
(	O
K3	O
,	O
RaCe	O
,	O
and	O
FlexMaster	O
)	O
.	O

Seventy	O
extracted	O
human	O
mandibular	O
premolar	O
teeth	O
with	O
similar	O
dimensions	O
were	O
used	O
.	O

Access	O
cavities	O
were	O
prepared	O
and	O
root	O
canals	O
were	O
then	O
contaminated	O
with	O
a	O
suspension	O
of	O
Enterococcus	B-bacteria
faecalis	I-bacteria
and	O
then	O
dried	O
.	O

The	O
contaminated	O
roots	O
were	O
divided	O
into	O
four	O
experimental	O
groups	O
of	O
15	O
teeth	O
each	O
and	O
one	O
control	O
group	O
of	O
10	O
teeth	O
.	O

G1	O
.	O

RaCe	O
group	O
:	O
the	O
root	O
canals	O
were	O
instrumented	O
using	O
RaCe	O
instruments	O
.	O

G2	O
.	O

K3	O
group	O
:	O
the	O
root	O
canals	O
were	O
instrumented	O
using	O
K3	O
instruments	O
.	O

G3	O
.	O

FlexMaster	O
group	O
:	O
the	O
root	O
canals	O
were	O
instrumented	O
using	O
FlexMaster	O
instruments	O
.	O

G4	O
.	O

Manual	O
technique	O
group	O
:	O
the	O
root	O
canals	O
were	O
instrumented	O
using	O
K	O
-	O
type	O
stainless	O
steel	O
instruments	O
.	O

G5	O
.	O

no	O
instrumentation	O
was	O
attempted	O
.	O

Bacteria	O
extruded	O
from	O
the	O
apical	O
foramen	O
during	O
instrumentation	O
were	O
collected	O
into	O
vials	O
.	O

The	O
resultant	O
microbiological	O
samples	O
were	O
removed	O
from	O
the	O
vials	O
and	O
then	O
incubated	O
in	O
culture	O
media	O
for	O
24	O
h	O
.	O
The	O
number	O
of	O
colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
was	O
determined	O
for	O
each	O
sample	O
.	O

The	O
data	O
obtained	O
were	O
analysed	O
using	O
the	O
Kruskal	O
-	O
Wallis	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
and	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
,	O
with	O
alpha	O
=	O
0	O
.	O
05	O
as	O
the	O
level	O
for	O
statistical	O
significance	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
experimental	O
-	O
control	O
and	O
engine	O
-	O
driven	O
-	O
manual	O
technique	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
manual	O
technique	O
was	O
associated	O
with	O
the	O
greatest	O
extrusion	O
of	O
microorganism	O
.	O

All	O
instrumentation	O
techniques	O
extruded	O
intracanal	O
bacteria	O
apically	O
.	O

No	O
significant	O
difference	O
was	O
found	O
in	O
the	O
number	O
of	O
CFU	O
among	O
the	O
engine	O
-	O
driven	O
techniques	O
;	O
manual	O
techniques	O
extruded	O
significantly	O
more	O
microorganisms	O
.	O

The	O
current	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
prevalence	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
cavity	O
of	O
a	O
Chinese	O
population	O
.	O

Nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
used	O
to	O
investigate	O
whether	O
individuals	O
with	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
show	O
more	O
possibility	O
of	O
gastric	O
infection	O
and	O
to	O
examine	O
the	O
relationship	O
between	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
and	O
the	O
presence	O
of	O
the	O
bacteria	O
in	O
the	O
oral	O
cavity	O
.	O

A	O
total	O
of	O
443	O
dyspeptic	O
patients	O
participated	O
in	O
the	O
study	O
.	O

Gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
was	O
detected	O
by	O
the	O
rapid	O
urease	O
test	O
and	O
histology	O
with	O
Giemsa	O
staining	O
,	O
PCR	O
,	O
or	O
smear	O
examination	O
,	O
whereas	O
the	O
presence	O
of	O
the	O
bacteria	O
in	O
the	O
oral	O
cavity	O
was	O
observed	O
by	O
nested	O
PCR	O
from	O
dental	O
plaque	O
.	O

Relevant	O
periodontal	O
and	O
dental	O
parameters	O
were	O
recorded	O
in	O
the	O
process	O
of	O
oral	O
examination	O
.	O

Of	O
the	O
443	O
study	O
patients	O
,	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
found	O
in	O
the	O
dental	O
plaque	O
of	O
263	O
(	O
59	O
.	O
4	O
%	O
)	O
and	O
the	O
stomach	O
of	O
273	O
(	O
61	O
.	O
6	O
%	O
)	O
.	O

Additionally	O
,	O
in	O
all	O
four	O
age	O
groups	O
,	O
the	O
prevalence	O
of	O
gastric	O
infection	O
was	O
significantly	O
higher	O
among	O
the	O
patients	O
with	O
positive	O
tests	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
their	O
dental	O
plaque	O
than	O
in	O
the	O
patients	O
with	O
no	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
their	O
dental	O
plaque	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
oral	O
cavity	O
may	O
be	O
a	O
potential	O
reservoir	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
,	O
and	O
the	O
prevalence	O
of	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
approximated	O
that	O
of	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
studied	O
population	O
.	O

Furthermore	O
,	O
a	O
close	O
relationship	O
may	O
exist	O
between	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
cavity	O
and	O
bacteria	O
in	O
the	O
stomach	O
or	O
gastric	O
infection	O
,	O
and	O
dyspeptic	O
patients	O
with	O
gastric	O
infection	O
are	O
more	O
likely	O
to	O
harbor	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
their	O
oral	O
cavity	O
.	O

Saliva	O
may	O
become	O
a	O
potential	O
source	O
of	O
contamination	O
through	O
vertical	O
and	O
horizontal	O
transmissions	O
as	O
well	O
as	O
cross	O
-	O
infections	O
.	O

This	O
study	O
aims	O
to	O
use	O
saliva	O
as	O
a	O
screening	O
tool	O
to	O
detect	O
putative	O
periodontal	O
pathogens	O
in	O
a	O
young	O
population	O
with	O
fairly	O
good	O
oral	O
hygiene	O
.	O

Stimulated	O
saliva	O
samples	O
were	O
obtained	O
from	O
134	O
dental	O
students	O
(	O
20	O
.	O
5	O
+	O
/	O
-	O
1	O
years	O
,	O
range	O
18	O
-	O
22	O
years	O
)	O
.	O

Among	O
those	O
,	O
77	O
subjects	O
also	O
completed	O
a	O
periodontal	O
examination	O
including	O
attachment	O
loss	O
,	O
modified	O
dental	O
,	O
gingival	O
and	O
plaque	O
indices	O
(	O
AL	O
,	O
mDI	O
,	O
GI	O
and	O
PI	O
)	O
.	O

The	O
test	O
bacteria	O
were	O
identified	O
using	O
a	O
16S	O
rRNA	O
-	O
based	O
PCR	O
detection	O
method	O
.	O

One	O
or	O
more	O
of	O
the	O
test	O
bacteria	O
was	O
found	O
in	O
67	O
%	O
of	O
the	O
subjects	O
.	O

Prevotella	B-bacteria
nigrescens	I-bacteria
was	O
detected	O
as	O
single	O
bacterium	O
in	O
16	O
%	O
of	O
the	O
subjects	O
followed	O
by	O
Treponema	B-bacteria
denticola	I-bacteria
(	O
4	O
%	O
)	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
2	O
%	O
)	O
,	O
Aggregatibacter	B-bacteria
(	I-bacteria
formerly	I-bacteria
Actinobacillus	I-bacteria
)	I-bacteria
actinomycetemcomitans	I-bacteria
(	O
1	O
%	O
)	O
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
(	O
1	O
%	O
)	O
.	O

Two	O
or	O
more	O
pathogens	O
were	O
detected	O
in	O
42	O
%	O
of	O
the	O
subjects	O
.	O

Clinical	O
examination	O
revealed	O
health	O
with	O
no	O
attachment	O
loss	O
(	O
AL	O
)	O
in	O
84	O
%	O
of	O
the	O
students	O
.	O

In	O
no	O
AL	O
group	O
,	O
38	O
%	O
of	O
the	O
students	O
were	O
pathogen	O
free	O
while	O
this	O
was	O
25	O
%	O
for	O
students	O
in	O
localized	O
AL	O
group	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
association	O
between	O
the	O
detection	O
of	O
salivary	O
periodontal	O
pathogen	O
in	O
general	O
and	O
higher	O
PI	O
(	O
p	O
=	O
0	O
.	O
018	O
)	O
and	O
GI	O
(	O
p	O
=	O
0	O
.	O
043	O
)	O
.	O

Within	O
the	O
limits	O
of	O
this	O
study	O
,	O
it	O
is	O
possible	O
to	O
detect	O
all	O
six	O
periodontal	O
pathogens	O
in	O
the	O
saliva	O
of	O
dental	O
students	O
.	O

Although	O
a	O
correlation	O
can	O
be	O
observed	O
between	O
the	O
presence	O
of	O
salivary	O
periodontal	O
pathogen	O
and	O
clinical	O
signs	O
of	O
inflammation	O
such	O
as	O
plaque	O
accumulation	O
and	O
gingival	O
bleeding	O
,	O
detection	O
of	O
specific	O
bacteria	O
in	O
saliva	O
is	O
not	O
related	O
to	O
the	O
presence	O
of	O
localized	O
AL	O
based	O
on	O
the	O
presented	O
study	O
population	O
.	O

To	O
determine	O
characteristics	O
of	O
microbial	O
associations	O
and	O
degree	O
of	O
oral	O
cavity	O
colonization	O
by	O
different	O
biotopes	O
in	O
healthy	O
adolescents	O
and	O
patients	O
with	O
chronic	O
gastroduodenitis	O
.	O

Saliva	O
,	O
dental	O
deposit	O
,	O
content	O
of	O
tooth	O
-	O
gingival	O
cavity	O
and	O
material	O
from	O
buccal	O
and	O
lingual	O
mucous	O
surfaces	O
of	O
24	O
healthy	O
adolescents	O
and	O
29	O
patients	O
of	O
the	O
same	O
age	O
with	O
gastroduodenitis	O
were	O
used	O
for	O
bacteriological	O
analysis	O
.	O

Inoculation	O
were	O
made	O
on	O
the	O
following	O
growth	O
media	O
:	O
yolk	O
-	O
salt	O
agar	O
,	O
Endo	O
,	O
Saburo	O
,	O
MRS	O
as	O
well	O
as	O
on	O
Columbia	O
and	O
Saedler	O
blood	O
agars	O
.	O

It	O
was	O
shown	O
that	O
rate	O
of	O
isolation	O
of	O
peptostreptococci	B-bacteria
from	O
oral	O
cavity	O
of	O
patients	O
was	O
90	O
%	O
lower	O
compared	O
with	O
controls	O
;	O
rate	O
of	O
isolation	O
of	O
lactobacilli	B-bacteria
,	O
Veillonella	B-bacteria
,	O
and	O
stomatococci	B-bacteria
was	O
30	O
%	O
lower	O
,	O
whereas	O
hemolytic	O
Porphyromonas	B-bacteria
,	O
staphylococci	B-bacteria
and	O
streptococci	B-bacteria
were	O
isolated	O
20	O
%	O
more	O
frequently	O
.	O

Concentration	O
of	O
peptostreptococci	B-bacteria
and	O
streptococci	B-bacteria
was	O
7	O
.	O
0	O
lg	O
CFU	O
/	O
ml	O
,	O
whereas	O
concentration	O
of	O
Porphyromonas	B-bacteria
,	O
Veillonella	B-bacteria
,	O
peptococci	B-bacteria
and	O
staphylococci	B-bacteria
was	O
6	O
.	O
0	O
lg	O
CFU	O
/	O
ml	O
,	O
Neisseria	B-bacteria
-	O
-	O
5	O
.	O
0	O
lg	O
CFU	O
/	O
ml	O
,	O
stomatococci	B-bacteria
,	O
bacilli	O
and	O
Candida	O
fungi	O
-	O
-	O
4	O
.	O
5	O
lg	O
CFU	O
/	O
ml	O
.	O

Decrease	O
of	O
concentration	O
of	O
lactobacilli	B-bacteria
to	O
4	O
.	O
0	O
lg	O
CFU	O
/	O
ml	O
was	O
noted	O
.	O

Compared	O
with	O
healthy	O
group	O
of	O
children	O
,	O
widened	O
spectrum	O
of	O
microorganisms	O
in	O
all	O
studied	O
biotopes	O
of	O
oral	O
cavity	O
was	O
observed	O
in	O
patients	O
with	O
chronic	O
gastroduodenitis	O
;	O
species	O
belonging	O
to	O
pathogenic	O
microflora	O
were	O
detected	O
in	O
patients	O
more	O
frequently	O
and	O
in	O
more	O
quantities	O
.	O

Microbial	O
spectrum	O
and	O
non	O
-	O
specific	O
as	O
well	O
as	O
specific	O
IgA1	O
protease	O
activity	O
of	O
isolated	O
microorganisms	O
were	O
investigated	O
in	O
gingival	O
liquid	O
of	O
patients	O
with	O
periodontitis	O
.	O

Microorganisms	O
from	O
the	O
gingival	O
liqud	O
of	O
these	O
patients	O
belonged	O
to	O
conditional	O
-	O
pathogenic	O
obligate	O
and	O
facultatively	O
anaerobic	O
bacteria	O
.	O

24	O
strains	O
of	O
microorganisms	O
have	O
been	O
identified	O
.	O

Nonspecific	O
proteolytic	O
activity	O
was	O
found	O
in	O
the	O
following	O
microorganisms	O
:	O
Actinomyces	B-bacteria
israelii	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
Aerococcus	B-bacteria
viridans	I-bacteria
,	O
Bifidobacterium	B-bacteria
longum	I-bacteria
,	O
Neisseria	B-bacteria
subflave	I-bacteria
,	O
Streptococcus	B-bacteria
parvulus	I-bacteria
,	O
Eubacterium	B-bacteria
alactolyticum	I-bacteria
,	O
Lactobaccilus	B-bacteria
catenoforme	I-bacteria
,	O
Bacillus	B-bacteria
spp	I-bacteria
.	O

Specific	O
IgA1	O
-	O
protease	O
activity	O
and	O
lack	O
of	O
proteolytic	O
activity	O
towards	O
IgG	O
was	O
found	O
in	O
Streptococcus	B-bacteria
acidominimus	I-bacteria
,	O
Streptococcus	B-bacteria
hansenii	I-bacteria
,	O
Streptococcus	B-bacteria
salivarius	I-bacteria
,	O
Leptotrychia	B-bacteria
buccalis	I-bacteria
,	O
Staphylococcus	B-bacteria
haemolyticus	I-bacteria
and	O
Neisseria	B-bacteria
sicca	I-bacteria
.	O

No	O
proteolytic	O
activity	O
was	O
found	O
in	O
cultivation	O
medium	O
of	O
Eubacterium	B-bacteria
alactolyticum	I-bacteria
(	O
1	O
strain	O
)	O
,	O
Prevotella	B-bacteria
buccalis	I-bacteria
,	O
Aerococcus	B-bacteria
viridans	I-bacteria
and	O
Streptococcus	B-bacteria
sanguis	I-bacteria
.	O

Nucleic	O
acid	O
amplification	O
tests	O
are	O
sensitive	O
and	O
specific	O
for	O
identifying	O
Mycobacterium	B-bacteria
tuberculosis	I-bacteria
in	O
sputum	O
smear	O
-	O
positive	O
populations	O
,	O
but	O
they	O
are	O
less	O
sensitive	O
in	O
sputum	O
smear	O
-	O
negative	O
populations	O
.	O

Few	O
studies	O
have	O
assessed	O
their	O
performance	O
among	O
patients	O
infected	O
with	O
HIV	O
,	O
and	O
no	O
studies	O
have	O
assessed	O
their	O
performance	O
with	O
oral	O
wash	O
specimens	O
,	O
which	O
may	O
be	O
easier	O
to	O
obtain	O
than	O
sputum	O
samples	O
.	O

We	O
performed	O
a	O
prospective	O
study	O
involving	O
127	O
adults	O
from	O
2	O
populations	O
who	O
were	O
undergoing	O
evaluation	O
for	O
respiratory	O
complaints	O
at	O
Mulago	O
Hospital	O
in	O
Kampala	O
,	O
Uganda	O
.	O

We	O
obtained	O
and	O
tested	O
sputum	O
samples	O
for	O
Mycobacterium	B-bacteria
tuberculosis	I-bacteria
,	O
and	O
we	O
simultaneously	O
obtained	O
oral	O
wash	O
specimens	O
to	O
test	O
for	O
M	B-bacteria
.	I-bacteria
tuberculosis	I-bacteria
DNA	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
a	O
novel	O
locus	O
,	O
the	O
secA1	O
gene	O
.	O

A	O
positive	O
mycobacterial	O
culture	O
of	O
sputum	O
was	O
used	O
to	O
define	O
cases	O
of	O
tuberculosis	O
;	O
we	O
calculated	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
PCR	O
assay	O
with	O
sputum	O
or	O
oral	O
wash	O
specimens	O
in	O
reference	O
to	O
the	O
standard	O
of	O
sputum	O
culture	O
results	O
.	O

Tuberculosis	O
(	O
75	O
[	O
59	O
%	O
]	O
of	O
127	O
patients	O
)	O
and	O
HIV	O
infection	O
(	O
58	O
[	O
46	O
%	O
]	O
of	O
126	O
patients	O
)	O
were	O
both	O
common	O
in	O
the	O
study	O
population	O
.	O

PCR	O
of	O
sputum	O
samples	O
was	O
highly	O
sensitive	O
(	O
sensitivity	O
,	O
99	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
93	O
%	O
-	O
100	O
%	O
)	O
and	O
specific	O
(	O
specificity	O
,	O
88	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
77	O
%	O
-	O
96	O
%	O
)	O
for	O
detection	O
of	O
pulmonary	O
tuberculosis	O
and	O
performed	O
well	O
among	O
HIV	O
-	O
infected	O
patients	O
and	O
among	O
patients	O
with	O
negative	O
sputum	O
smear	O
results	O
.	O

PCR	O
of	O
oral	O
wash	O
specimens	O
was	O
less	O
sensitive	O
(	O
sensitivity	O
,	O
73	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
62	O
%	O
-	O
83	O
%	O
)	O
but	O
also	O
detected	O
a	O
substantial	O
proportion	O
of	O
tuberculosis	O
cases	O
.	O

PCR	O
targeting	O
the	O
secA1	O
gene	O
was	O
highly	O
sensitive	O
and	O
specific	O
for	O
identifying	O
M	B-bacteria
.	I-bacteria
tuberculosis	I-bacteria
in	O
sputum	O
samples	O
,	O
independent	O
of	O
smear	O
or	O
HIV	O
infection	O
status	O
.	O

Oral	O
washes	O
showed	O
promise	O
as	O
an	O
easily	O
obtained	O
respiratory	O
specimen	O
for	O
tuberculosis	O
diagnosis	O
.	O

PCR	O
of	O
sputum	O
for	O
detection	O
of	O
the	O
secA1	O
gene	O
could	O
be	O
a	O
rapid	O
,	O
effective	O
diagnostic	O
tool	O
for	O
tuberculosis	O
referral	O
centers	O
.	O

Knowledge	O
of	O
the	O
colonization	O
patterns	O
and	O
composition	O
of	O
the	O
oral	O
microbiota	O
can	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
disease	O
initiation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
distribution	O
of	O
selected	O
cariogenic	O
bacteria	O
in	O
samples	O
from	O
five	O
different	O
oral	O
habitats	O
in	O
young	O
Greek	O
children	O
.	O

Ninety	O
-	O
three	O
children	O
3	O
-	O
12	O
years	O
old	O
(	O
mean	O
+	O
SD	O
7	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
5	O
)	O
(	O
60	O
.	O
2	O
%	O
male	O
,	O
39	O
.	O
8	O
%	O
female	O
)	O
participated	O
and	O
split	O
into	O
three	O
different	O
age	O
groups	O
:	O
primary	O
(	O
3	O
-	O
6	O
years	O
)	O
,	O
early	O
mixed	O
(	O
6	O
-	O
9	O
years	O
)	O
,	O
and	O
mixed	O
dentition	O
(	O
9	O
-	O
12	O
years	O
)	O
.	O

Samples	O
for	O
bacterial	O
enumeration	O
were	O
taken	O
from	O
saliva	O
,	O
supragingival	O
and	O
subgingival	O
plaque	O
,	O
tongue	O
dorsum	O
,	O
and	O
soft	O
tissues	O
from	O
each	O
child	O
,	O
and	O
were	O
further	O
analysed	O
using	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
.	O

Mean	O
counts	O
and	O
proportions	O
of	O
all	O
the	O
test	O
bacteria	O
differed	O
significantly	O
among	O
sample	O
locations	O
.	O

Cariogenic	O
bacteria	O
were	O
present	O
in	O
almost	O
all	O
healthy	O
children	O
.	O

Mean	O
proportions	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
isolated	O
from	O
soft	O
tissue	O
and	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
from	O
soft	O
tissue	O
,	O
subgingival	O
and	O
saliva	O
samples	O
increased	O
significantly	O
with	O
age	O
,	O
whereas	O
the	O
opposite	O
was	O
seen	O
for	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
.	O

Cariogenic	O
bacteria	O
were	O
present	O
in	O
almost	O
all	O
young	O
children	O
.	O

Soft	O
tissues	O
,	O
saliva	O
,	O
and	O
tongue	O
were	O
more	O
often	O
colonized	O
by	O
cariogenic	O
streptococcal	B-bacteria
species	I-bacteria
than	O
teeth	O
.	O

These	O
surfaces	O
may	O
serve	O
as	O
reservoirs	O
for	O
oral	O
pathogens	O
,	O
requiring	O
attention	O
during	O
preventive	O
interventions	O
.	O

As	O
modern	O
humans	O
(	O
Homo	O
sapiens	O
)	O
migrated	O
out	O
of	O
Africa	O
to	O
different	O
parts	O
of	O
the	O
world	O
,	O
their	O
obligate	O
indigenous	O
bacterial	O
biota	O
accompanied	O
them	O
.	O

As	O
both	O
evolved	O
,	O
the	O
accumulations	O
of	O
mutations	O
in	O
their	O
DNA	O
can	O
reveal	O
their	O
phylogenies	O
.	O

Here	O
,	O
we	O
describe	O
the	O
evolutionary	O
history	O
of	O
an	O
indigenous	O
bacteria	O
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
from	O
the	O
oral	O
cavity	O
.	O

Using	O
several	O
genetic	O
markers	O
,	O
four	O
distinct	O
clusters	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
genetic	O
traits	O
coincide	O
with	O
individuals	O
of	O
distinct	O
geographic	O
or	O
racial	O
groups	O
comprised	O
of	O
two	O
African	O
clades	O
and	O
an	O
Asian	O
and	O
a	O
Caucasian	O
clade	O
.	O

The	O
evolutionary	O
lineage	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
is	O
in	O
agreement	O
with	O
anthropological	O
artifacts	O
marking	O
the	O
trail	O
of	O
human	O
migrations	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
Arcobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
in	O
different	O
biological	O
samples	O
from	O
domestic	O
cats	O
in	O
Southern	O
Italy	O
by	O
using	O
a	O
species	O
-	O
specific	O
PCR	O
assay	O
and	O
thus	O
to	O
elucidate	O
their	O
potential	O
significance	O
as	O
sources	O
of	O
human	O
infection	O
.	O

We	O
investigated	O
the	O
prevalence	O
of	O
Arcobacter	B-bacteria
DNA	O
in	O
oral	O
swabs	O
,	O
in	O
peripheral	O
blood	O
samples	O
and	O
fine	O
needle	O
lymph	O
node	O
aspirate	O
specimens	O
from	O
85	O
cats	O
of	O
which	O
17	O
were	O
clinically	O
healthy	O
and	O
68	O
had	O
clinical	O
signs	O
of	O
oral	O
disease	O
or	O
lymphadenomegaly	O
.	O

Overall	O
,	O
molecular	O
analysis	O
has	O
shown	O
that	O
Arcobacter	O
-	O
specific	O
DNA	O
was	O
found	O
in	O
78	O
.	O
8	O
%	O
(	O
67	O
of	O
85	O
)	O
of	O
all	O
the	O
cats	O
.	O

In	O
the	O
67	O
Arcobacter	O
-	O
positive	O
cats	O
,	O
66	O
(	O
77	O
.	O
6	O
%	O
)	O
and	O
29	O
(	O
34	O
.	O
1	O
%	O
)	O
were	O
found	O
positive	O
for	O
Arcobacter	B-bacteria
butzleri	I-bacteria
and	O
Arcobacter	B-bacteria
cryaerophilus	I-bacteria
,	O
respectively	O
.	O

None	O
of	O
the	O
examined	O
samples	O
gave	O
a	O
PCR	O
product	O
for	O
Arcobacter	B-bacteria
skirrowii	I-bacteria
.	O

This	O
study	O
demonstrates	O
that	O
pet	O
cats	O
commonly	O
carry	O
Arcobacter	B-bacteria
in	O
the	O
oral	O
cavity	O
.	O

According	O
to	O
the	O
clinical	O
data	O
,	O
the	O
Arcobacter	B-bacteria
detection	O
results	O
showed	O
no	O
significant	O
difference	O
between	O
cats	O
with	O
oral	O
pathology	O
and	O
those	O
suffering	O
from	O
other	O
different	O
pathologies	O
.	O

Pet	O
cats	O
harbour	O
Arcobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
may	O
play	O
a	O
role	O
in	O
their	O
dissemination	O
in	O
the	O
domestic	O
habitat	O
.	O

The	O
high	O
prevalence	O
in	O
a	O
limited	O
number	O
of	O
cat	O
samples	O
in	O
this	O
study	O
may	O
be	O
of	O
significance	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
the	O
one	O
-	O
stage	O
full	O
-	O
mouth	O
disinfection	O
(	O
FMD	O
)	O
provides	O
greater	O
clinical	O
and	O
microbiological	O
improvement	O
compared	O
with	O
full	O
-	O
mouth	O
scaling	O
and	O
root	O
planing	O
(	O
FM	O
-	O
SRP	O
)	O
within	O
24	O
h	O
and	O
quadrant	O
scaling	O
and	O
root	O
planing	O
(	O
Q	O
-	O
SRP	O
)	O
in	O
patients	O
with	O
generalized	O
chronic	O
periodontitis	O
.	O

Twenty	O
-	O
eight	O
patients	O
were	O
randomized	O
into	O
three	O
groups	O
.	O

25	O
patients	O
completed	O
the	O
study	O
and	O
were	O
the	O
basis	O
for	O
analysis	O
.	O

The	O
Q	O
-	O
SRP	O
group	O
was	O
scaled	O
quadrant	O
-	O
wise	O
at	O
1	O
-	O
week	O
intervals	O
.	O

The	O
other	O
groups	O
received	O
a	O
one	O
-	O
stage	O
full	O
-	O
mouth	O
scaling	O
with	O
(	O
FMD	O
)	O
and	O
without	O
(	O
FM	O
-	O
SRP	O
)	O
chlorhexidine	O
.	O

At	O
baseline	O
,	O
after	O
1	O
,	O
2	O
,	O
4	O
and	O
8	O
months	O
clinical	O
parameters	O
were	O
recorded	O
and	O
microbiological	O
analysis	O
was	O
performed	O
.	O

All	O
three	O
treatment	O
modalities	O
resulted	O
in	O
significant	O
clinical	O
improvement	O
at	O
any	O
time	O
.	O

There	O
were	O
only	O
group	O
differences	O
after	O
1	O
and	O
2	O
months	O
:	O
in	O
the	O
FM	O
-	O
SRP	O
group	O
was	O
a	O
significantly	O
higher	O
reduction	O
of	O
probing	O
depth	O
and	O
bleeding	O
on	O
probing	O
compared	O
with	O
the	O
other	O
two	O
groups	O
.	O

The	O
bacteria	O
could	O
be	O
reduced	O
in	O
every	O
group	O
although	O
this	O
reduction	O
was	O
only	O
significant	O
for	O
Prevotella	B-bacteria
intermedia	I-bacteria
in	O
the	O
FMD	O
group	O
8	O
months	O
after	O
treatment	O
.	O

All	O
three	O
treatment	O
modalities	O
lead	O
to	O
an	O
improvement	O
of	O
the	O
clinical	O
and	O
microbiological	O
parameters	O
,	O
however	O
,	O
without	O
significant	O
group	O
differences	O
after	O
8	O
months	O
.	O

Alkali	O
generation	O
by	O
oral	O
bacteria	O
plays	O
a	O
key	O
role	O
in	O
plaque	O
pH	O
homeostasis	O
and	O
may	O
be	O
a	O
major	O
impediment	O
to	O
the	O
development	O
of	O
dental	O
caries	O
.	O

To	O
determine	O
if	O
the	O
capacity	O
of	O
oral	O
samples	O
to	O
produce	O
ammonia	O
from	O
arginine	O
or	O
urea	O
was	O
related	O
to	O
caries	O
experience	O
,	O
the	O
arginine	O
deiminase	O
system	O
(	O
ADS	O
)	O
and	O
urease	O
activity	O
in	O
saliva	O
and	O
dental	O
plaque	O
samples	O
were	O
measured	O
in	O
45	O
adult	O
subjects	O
.	O

The	O
subjects	O
were	O
divided	O
into	O
three	O
groups	O
according	O
to	O
caries	O
status	O
;	O
13	O
caries	O
-	O
free	O
(	O
CF	O
)	O
individuals	O
(	O
decayed	O
,	O
missing	O
,	O
and	O
filled	O
teeth	O
=	O
0	O
)	O
;	O
21	O
caries	O
-	O
active	O
(	O
CA	O
)	O
individuals	O
(	O
decayed	O
teeth	O
>	O
or	O
=	O
4	O
)	O
;	O
and	O
11	O
caries	O
-	O
experienced	O
(	O
CE	O
)	O
individuals	O
(	O
decayed	O
teeth	O
=	O
0	O
;	O
missing	O
and	O
filled	O
teeth	O
>	O
0	O
)	O
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
quantify	O
the	O
proportion	O
of	O
certain	O
acid	O
-	O
or	O
alkali	O
-	O
producing	O
organisms	O
in	O
the	O
samples	O
.	O

The	O
amount	O
of	O
ammonia	O
generated	O
from	O
the	O
test	O
substrates	O
by	O
plaque	O
samples	O
was	O
generally	O
higher	O
than	O
that	O
produced	O
by	O
salivary	O
samples	O
in	O
all	O
groups	O
.	O

Significantly	O
higher	O
levels	O
of	O
salivary	O
ADS	O
activity	O
and	O
plaque	O
urease	O
activity	O
were	O
observed	O
in	O
CF	O
subjects	O
compared	O
to	O
CA	O
subjects	O
(	O
P	O
=	O
0	O
.	O
0004	O
and	O
P	O
=	O
0	O
.	O
014	O
,	O
respectively	O
)	O
.	O

The	O
proportions	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
from	O
saliva	O
and	O
dental	O
plaque	O
of	O
CA	O
subjects	O
were	O
significantly	O
higher	O
than	O
those	O
from	O
the	O
CF	O
group	O
(	O
P	O
=	O
0	O
.	O
0153	O
and	O
P	O
=	O
0	O
.	O
0009	O
,	O
respectively	O
)	O
.	O

In	O
the	O
CA	O
group	O
,	O
there	O
was	O
an	O
inverse	O
relationship	O
between	O
urease	O
activity	O
and	O
the	O
levels	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

This	O
study	O
supports	O
the	O
theory	O
that	O
increased	O
caries	O
risk	O
is	O
associated	O
with	O
reduced	O
alkali	O
-	O
generating	O
capacity	O
of	O
the	O
bacteria	O
colonizing	O
the	O
oral	O
cavity	O
;	O
providing	O
compelling	O
evidence	O
to	O
further	O
our	O
understanding	O
of	O
oral	O
alkali	O
-	O
generation	O
in	O
health	O
and	O
disease	O
.	O

The	O
oral	O
cavity	O
harbors	O
a	O
diverse	O
and	O
complex	O
microbial	O
community	O
.	O

Bacteria	O
accumulate	O
on	O
both	O
the	O
hard	O
and	O
soft	O
oral	O
tissues	O
in	O
sessile	O
biofilms	O
and	O
engage	O
the	O
host	O
in	O
an	O
intricate	O
cellular	O
dialog	O
,	O
which	O
normally	O
constrains	O
the	O
bacteria	O
to	O
a	O
state	O
of	O
commensal	O
harmony	O
.	O

Dendritic	O
cells	O
(	O
DCs	O
)	O
are	O
likely	O
to	O
balance	O
tolerance	O
and	O
active	O
immunity	O
to	O
commensal	O
microorganisms	O
as	O
part	O
of	O
chronic	O
inflammatory	O
responses	O
.	O

While	O
the	O
role	O
played	O
by	O
DCs	O
in	O
maintaining	O
intestinal	O
homeostasis	O
has	O
been	O
investigated	O
extensively	O
,	O
relatively	O
little	O
is	O
known	O
about	O
DC	O
responses	O
to	O
oral	O
bacteria	O
.	O

In	O
this	O
study	O
,	O
we	O
pulsed	O
human	O
monocyte	O
-	O
derived	O
immature	O
DCs	O
(	O
iDCs	O
)	O
with	O
cell	O
wall	O
extracts	O
from	O
pathogenic	O
and	O
commensal	O
gram	O
-	O
positive	O
or	O
gram	O
-	O
negative	O
oral	O
bacteria	O
.	O

Although	O
all	O
bacterial	O
extracts	O
tested	O
induced	O
iDCs	O
to	O
mature	O
and	O
produce	O
cytokines	O
/	O
chemokines	O
including	O
interleukin	O
-	O
12p40	O
,	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
)	O
,	O
the	O
most	O
important	O
factor	O
for	O
programming	O
DCs	O
by	O
oral	O
bacteria	O
was	O
whether	O
they	O
were	O
gram	O
-	O
positive	O
or	O
gram	O
-	O
negative	O
,	O
not	O
whether	O
they	O
were	O
commensal	O
or	O
pathogenic	O
.	O

In	O
general	O
,	O
gram	O
-	O
negative	O
oral	O
bacteria	O
,	O
except	O
for	O
periodontopathic	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
stimulated	O
DC	O
maturation	O
and	O
cytokine	O
production	O
at	O
lower	O
concentrations	O
than	O
gram	O
-	O
positive	O
oral	O
bacteria	O
.	O

The	O
threshold	O
of	O
bacteria	O
needed	O
to	O
stimulate	O
chemokine	O
production	O
was	O
100	O
-	O
fold	O
to	O
1000	O
-	O
fold	O
lower	O
than	O
that	O
needed	O
to	O
induce	O
cytokines	O
.	O

In	O
addition	O
,	O
very	O
low	O
doses	O
of	O
oral	O
commensal	O
bacteria	O
triggered	O
monocytes	O
to	O
migrate	O
toward	O
DC	O
-	O
derived	O
MCP	O
-	O
1	O
.	O

Oral	O
commensal	O
and	O
pathogenic	O
bacteria	O
do	O
not	O
differ	O
qualitatively	O
in	O
how	O
they	O
program	O
DCs	O
.	O

DC	O
-	O
derived	O
MCP	O
-	O
1	O
induced	O
in	O
response	O
to	O
oral	O
commensal	O
bacteria	O
may	O
play	O
a	O
role	O
,	O
at	O
least	O
in	O
part	O
,	O
in	O
the	O
maintenance	O
of	O
oral	O
tissue	O
integrity	O
by	O
attracting	O
monocytes	O
.	O

Ceragenin	O
CSA	O
-	O
13	O
is	O
a	O
bile	O
-	O
acid	O
-	O
based	O
mimic	O
of	O
endogenous	O
antimicrobial	O
peptides	O
and	O
shares	O
a	O
mechanism	O
of	O
action	O
with	O
many	O
of	O
these	O
antimicrobial	O
agents	O
.	O

Because	O
CSA	O
-	O
13	O
is	O
not	O
peptide	O
based	O
,	O
it	O
is	O
not	O
a	O
substrate	O
for	O
the	O
proteases	O
that	O
are	O
found	O
in	O
the	O
oral	O
cavity	O
,	O
which	O
are	O
capable	O
of	O
degrading	O
antimicrobial	O
peptides	O
.	O

Furthermore	O
,	O
the	O
simplicity	O
of	O
the	O
ceragenins	O
makes	O
them	O
easier	O
to	O
prepare	O
and	O
purify	O
than	O
antimicrobial	O
peptides	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
antimicrobial	O
activities	O
of	O
CSA	O
-	O
13	O
against	O
oral	O
pathogens	O
and	O
found	O
that	O
this	O
compound	O
was	O
bactericidal	O
against	O
all	O
of	O
the	O
strains	O
tested	O
.	O

The	O
strains	O
used	O
were	O
isolates	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Porphyromonas	B-bacteria
species	I-bacteria
.	O

Minimum	O
inhibitory	O
concentrations	O
(	O
MIC	O
)	O
were	O
determined	O
using	O
agar	O
dilution	O
methods	O
.	O

In	O
susceptibility	O
testing	O
,	O
viable	O
counts	O
were	O
determined	O
after	O
incubation	O
with	O
CSA	O
-	O
13	O
.	O

CSA	O
-	O
13	O
was	O
potent	O
against	O
all	O
23	O
strains	O
tested	O
with	O
MICs	O
of	O
1	O
-	O
8	O
microg	O
/	O
ml	O
for	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
1	O
-	O
16	O
microg	O
/	O
ml	O
for	O
24	O
strains	O
of	O
the	O
genus	O
Porphyromonas	B-bacteria
.	O

The	O
MIC	O
(	O
50	O
)	O
was	O
2	O
and	O
the	O
MIC	O
(	O
90	O
)	O
was	O
8	O
mug	O
/	O
ml	O
for	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

MIC	O
ranges	O
for	O
protease	O
-	O
positive	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
cangingivalis	I-bacteria
were	O
2	O
-	O
16	O
microg	O
/	O
ml	O
,	O
and	O
1	O
-	O
2	O
microg	O
/	O
ml	O
for	O
protease	O
-	O
negative	O
P	B-bacteria
.	I-bacteria
circumdentaria	I-bacteria
.	O

CSA	O
-	O
13	O
interacted	O
with	O
lipopolysaccharide	O
-	O
sensitized	O
erythrocytes	O
at	O
a	O
concentration	O
of	O
5	O
.	O
0	O
-	O
20	O
.	O
0	O
microg	O
/	O
ml	O
.	O

CSA	O
-	O
13	O
displays	O
broad	O
-	O
spectrum	O
activity	O
against	O
cariogenic	O
and	O
periodontopathic	O
bacteria	O
.	O

CSA	O
-	O
13	O
was	O
effective	O
against	O
protease	O
-	O
positive	O
Porphyromonas	B-bacteria
.	O

It	O
was	O
shown	O
to	O
bind	O
to	O
erythrocytes	O
coated	O
with	O
lipopolysaccharide	O
and	O
lipoteichoic	O
acid	O
from	O
diverse	O
bacterial	O
strains	O
.	O

These	O
results	O
suggest	O
that	O
CSA	O
-	O
13	O
may	O
be	O
useful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
oral	O
microbial	O
diseases	O
.	O

Actinomyces	B-bacteria
naeslundii	I-bacteria
is	O
an	O
important	O
early	O
colonizer	O
in	O
the	O
oral	O
biofilm	O
and	O
consists	O
of	O
three	O
genospecies	O
(	O
1	O
,	O
2	O
and	O
WVA	O
963	O
)	O
which	O
can	O
not	O
be	O
readily	O
differentiated	O
using	O
conventional	O
phenotypic	O
testing	O
or	O
on	O
the	O
basis	O
of	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

We	O
have	O
investigated	O
a	O
representative	O
collection	O
of	O
type	O
and	O
reference	O
strains	O
and	O
clinical	O
and	O
oral	O
isolates	O
(	O
n	O
=	O
115	O
)	O
and	O
determined	O
the	O
partial	O
gene	O
sequences	O
of	O
six	O
housekeeping	O
genes	O
(	O
atpA	O
,	O
rpoB	O
,	O
pgi	O
,	O
metG	O
,	O
gltA	O
and	O
gyrA	O
)	O
.	O

These	O
sequences	O
identified	O
the	O
three	O
genospecies	O
and	O
differentiated	O
them	O
from	O
Actinomyces	B-bacteria
viscosus	I-bacteria
isolated	O
from	O
rodents	O
.	O

The	O
partial	O
sequences	O
of	O
atpA	O
and	O
metG	O
gave	O
best	O
separation	O
of	O
the	O
three	O
genospecies	O
.	O

A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
genospecies	I-bacteria
1	I-bacteria
and	I-bacteria
2	I-bacteria
formed	O
two	O
distinct	O
clusters	O
,	O
well	O
separated	O
from	O
both	O
genospecies	O
WVA	B-bacteria
963	I-bacteria
and	O
A	B-bacteria
.	I-bacteria
viscosus	I-bacteria
.	O

Analysis	O
of	O
the	O
same	O
genes	O
in	O
other	O
oral	O
Actinomyces	B-bacteria
species	I-bacteria
(	O
Actinomyces	B-bacteria
gerencseriae	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
israelii	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
meyeri	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
odontolyticus	I-bacteria
and	O
A	B-bacteria
.	I-bacteria
georgiae	I-bacteria
)	O
indicated	O
that	O
,	O
when	O
sequence	O
data	O
were	O
obtained	O
,	O
these	O
species	O
each	O
exhibited	O
<	O
90	O
%	O
similarity	O
with	O
the	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
genospecies	O
.	O

Based	O
on	O
these	O
data	O
,	O
we	O
propose	O
the	O
name	O
Actinomyces	B-bacteria
oris	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
(	O
type	O
strain	O
ATCC	B-bacteria
27044	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
34288	I-bacteria
(	O
T	O
)	O
)	O
for	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
genospecies	I-bacteria
2	I-bacteria
and	O
Actinomyces	B-bacteria
johnsonii	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
(	O
type	O
strain	O
ATCC	B-bacteria
49338	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
34287	I-bacteria
(	O
T	O
)	O
)	O
for	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
genospecies	I-bacteria
WVA	I-bacteria
963	I-bacteria
.	O

A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
genospecies	I-bacteria
1	I-bacteria
should	O
remain	O
as	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
sensu	O
stricto	O
,	O
with	O
the	O
type	O
strain	O
ATCC	B-bacteria
12104	I-bacteria
(	O
T	O
)	O
=	O
NCTC	B-bacteria
10301	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
2238	I-bacteria
(	O
T	O
)	O
.	O

The	O
gut	O
associated	O
lymphoid	O
tissue	O
(	O
GALT	O
)	O
is	O
anatomical	O
and	O
functionally	O
divided	O
in	O
inductive	O
and	O
effectors	O
sites	O
.	O

In	O
previous	O
works	O
we	O
demonstrated	O
that	O
non	O
-	O
pathogenic	O
bacteria	O
with	O
probiotic	O
characteristics	O
can	O
improve	O
the	O
gut	O
mucosal	O
immune	O
system	O
,	O
with	O
an	O
increase	O
in	O
the	O
number	O
of	O
IgA	O
and	O
cytokines	O
producing	O
cells	O
in	O
the	O
effector	O
site	O
of	O
the	O
intestine	O
.	O

In	O
the	O
present	O
work	O
we	O
studied	O
the	O
effect	O
of	O
non	O
-	O
pathogenic	O
Gram	O
(	O
+	O
)	O
,	O
Gram	O
(	O
-	O
)	O
bacteria	O
and	O
a	O
Gram	O
(	O
+	O
)	O
probiotic	O
strain	O
on	O
the	O
inductor	O
site	O
(	O
PP	O
)	O
after	O
the	O
oral	O
administration	O
to	O
BALB	O
/	O
c	O
mice	O
.	O

We	O
also	O
studied	O
some	O
signals	O
induced	O
by	O
the	O
assayed	O
strain	O
in	O
the	O
effectors	O
site	O
,	O
such	O
as	O
the	O
enzyme	O
calcineurin	O
and	O
TLR	O
-	O
9	O
as	O
a	O
way	O
to	O
understand	O
the	O
mechanisms	O
induced	O
in	O
such	O
bacterial	O
stimulation	O
.	O

The	O
implicance	O
of	O
the	O
lipoteichoic	O
acid	O
(	O
LTA	O
)	O
in	O
the	O
immunostimulation	O
was	O
analyzed	O
.	O

All	O
strains	O
increased	O
the	O
number	O
of	O
IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
(	O
+	O
)	O
cells	O
,	O
but	O
not	O
of	O
IL	O
-	O
10	O
(	O
+	O
)	O
cells	O
in	O
the	O
total	O
population	O
of	O
PP	O
.	O

The	O
release	O
of	O
IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
was	O
only	O
induced	O
by	O
LPS	O
stimulation	O
.	O

All	O
assayed	O
strains	O
increased	O
the	O
number	O
of	O
calcineurin	O
(	O
+	O
)	O
cells	O
,	O
while	O
only	O
Gram	O
(	O
+	O
)	O
strains	O
increased	O
the	O
number	O
of	O
TLR	O
-	O
9	O
(	O
+	O
)	O
cells	O
.	O

The	O
immunostimulatory	O
properties	O
of	O
the	O
purified	O
LTA	O
from	O
Gram	O
(	O
+	O
)	O
strains	O
was	O
evaluated	O
on	O
a	O
monocyte	O
-	O
macrophage	O
U937	O
cell	O
line	O
.	O

These	O
cells	O
showed	O
capacity	O
to	O
release	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
10	O
in	O
response	O
to	O
all	O
LTA	O
assayed	O
in	O
a	O
dose	O
-	O
dependent	O
way	O
.	O

Gram	O
(	O
+	O
)	O
strains	O
induced	O
signals	O
through	O
the	O
calcineurin	O
enzyme	O
able	O
to	O
activate	O
the	O
transcriptional	O
factor	O
NFAT	O
and	O
through	O
TLR	O
-	O
9	O
.	O

The	O
LTA	O
molecule	O
from	O
Gram	O
(	O
+	O
)	O
strains	O
would	O
not	O
be	O
the	O
only	O
structure	O
involved	O
in	O
the	O
immunostimulatory	O
properties	O
observed	O
,	O
specially	O
for	O
the	O
probiotic	O
strain	O
.	O

Periodontitis	O
is	O
the	O
major	O
cause	O
of	O
tooth	O
loss	O
in	O
adults	O
and	O
is	O
linked	O
to	O
systemic	O
illnesses	O
,	O
such	O
as	O
cardiovascular	O
disease	O
and	O
stroke	O
.	O

The	O
development	O
of	O
rapid	O
point	O
-	O
of	O
-	O
care	O
(	O
POC	O
)	O
chairside	O
diagnostics	O
has	O
the	O
potential	O
for	O
the	O
early	O
detection	O
of	O
periodontal	O
infection	O
and	O
progression	O
to	O
identify	O
incipient	O
disease	O
and	O
reduce	O
health	O
care	O
costs	O
.	O

However	O
,	O
validation	O
of	O
effective	O
diagnostics	O
requires	O
the	O
identification	O
and	O
verification	O
of	O
biomarkers	O
correlated	O
with	O
disease	O
progression	O
.	O

This	O
clinical	O
study	O
sought	O
to	O
determine	O
the	O
ability	O
of	O
putative	O
host	O
-	O
and	O
microbially	O
derived	O
biomarkers	O
to	O
identify	O
periodontal	O
disease	O
status	O
from	O
whole	O
saliva	O
and	O
plaque	O
biofilm	O
.	O

One	O
hundred	O
human	O
subjects	O
were	O
equally	O
recruited	O
into	O
a	O
healthy	O
/	O
gingivitis	O
group	O
or	O
a	O
periodontitis	O
population	O
.	O

Whole	O
saliva	O
was	O
collected	O
from	O
all	O
subjects	O
and	O
analyzed	O
using	O
antibody	O
arrays	O
to	O
measure	O
the	O
levels	O
of	O
multiple	O
proinflammatory	O
cytokines	O
and	O
bone	O
resorptive	O
/	O
turnover	O
markers	O
.	O

Salivary	O
biomarker	O
data	O
were	O
correlated	O
to	O
comprehensive	O
clinical	O
,	O
radiographic	O
,	O
and	O
microbial	O
plaque	O
biofilm	O
levels	O
measured	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
for	O
the	O
generation	O
of	O
models	O
for	O
periodontal	O
disease	O
identification	O
.	O

Significantly	O
elevated	O
levels	O
of	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-	O
8	O
and	O
-	O
9	O
were	O
found	O
in	O
subjects	O
with	O
advanced	O
periodontitis	O
with	O
Random	O
Forest	O
importance	O
scores	O
of	O
7	O
.	O
1	O
and	O
5	O
.	O
1	O
,	O
respectively	O
.	O

The	O
generation	O
of	O
receiver	O
operating	O
characteristic	O
curves	O
demonstrated	O
that	O
permutations	O
of	O
salivary	O
biomarkers	O
and	O
pathogen	O
biofilm	O
values	O
augmented	O
the	O
prediction	O
of	O
disease	O
category	O
.	O

Multiple	O
combinations	O
of	O
salivary	O
biomarkers	O
(	O
especially	O
MMP	O
-	O
8	O
and	O
-	O
9	O
and	O
osteoprotegerin	O
)	O
combined	O
with	O
red	O
-	O
complex	O
anaerobic	O
periodontal	O
pathogens	O
(	O
such	O
as	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
or	O
Treponema	B-bacteria
denticola	I-bacteria
)	O
provided	O
highly	O
accurate	O
predictions	O
of	O
periodontal	O
disease	O
category	O
.	O

Elevated	O
salivary	O
MMP	O
-	O
8	O
and	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
biofilm	O
levels	O
displayed	O
robust	O
combinatorial	O
characteristics	O
in	O
predicting	O
periodontal	O
disease	O
severity	O
(	O
area	O
under	O
the	O
curve	O
=	O
0	O
.	O
88	O
;	O
odds	O
ratio	O
=	O
24	O
.	O
6	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
5	O
.	O
2	O
to	O
116	O
.	O
5	O
)	O
.	O

Using	O
qPCR	O
and	O
sensitive	O
immunoassays	O
,	O
we	O
identified	O
host	O
-	O
and	O
bacterially	O
derived	O
biomarkers	O
correlated	O
with	O
periodontal	O
disease	O
.	O

This	O
approach	O
offers	O
significant	O
potential	O
for	O
the	O
discovery	O
of	O
biomarker	O
signatures	O
useful	O
in	O
the	O
development	O
of	O
rapid	O
POC	O
chairside	O
diagnostics	O
for	O
oral	O
and	O
systemic	O
diseases	O
.	O

Studies	O
are	O
ongoing	O
to	O
apply	O
this	O
approach	O
to	O
the	O
longitudinal	O
predictions	O
of	O
disease	O
activity	O
.	O

Measurement	O
of	O
salivary	O
IgA	O
antibody	O
(	O
PAc	O
-	O
peptide	O
antibody	O
,	O
PPA	O
)	O
to	O
amino	O
acid	O
residues	O
361	O
-	O
386	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
PAc	O
,	O
which	O
possess	O
a	O
multiple	O
binding	O
motif	O
to	O
various	O
HLA	O
-	O
DR	O
molecules	O
and	O
a	O
B	O
-	O
cell	O
epitope	O
that	O
recognises	O
the	O
inhibiting	O
antibody	O
to	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
is	O
an	O
indicator	O
for	O
the	O
population	O
numbers	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
(	O
MS	B-bacteria
)	O
in	O
human	O
saliva	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
role	O
of	O
PPA	O
in	O
infection	O
control	O
of	O
MS	B-bacteria
after	O
professional	O
oral	O
hygiene	O
care	O
.	O

Thirty	O
-	O
nine	O
dependently	O
living	O
institutionalised	O
elderly	O
subjects	O
(	O
75	O
.	O
9	O
+	O
/	O
-	O
7	O
.	O
5	O
years	O
;	O
10	O
males	O
,	O
29	O
females	O
)	O
participated	O
in	O
the	O
study	O
.	O

The	O
measurements	O
of	O
PPA	O
,	O
MS	B-bacteria
,	O
total	O
streptococci	B-bacteria
(	O
TS	B-bacteria
)	O
and	O
lactobacilli	B-bacteria
(	O
LB	B-bacteria
)	O
were	O
performed	O
by	O
ELISA	O
and	O
culture	O
techniques	O
from	O
saliva	O
,	O
plaque	O
and	O
tongue	O
samples	O
from	O
the	O
elderly	O
.	O

After	O
treatment	O
using	O
professional	O
oral	O
care	O
,	O
the	O
numbers	O
of	O
MS	B-bacteria
decreased	O
significantly	O
at	O
6	O
months	O
in	O
saliva	O
and	O
tongue	O
samples	O
from	O
the	O
group	O
not	O
having	O
PPA	O
in	O
comparison	O
with	O
the	O
primary	O
data	O
;	O
whereas	O
in	O
the	O
PPA	O
-	O
detected	O
group	O
,	O
a	O
significant	O
decrease	O
in	O
MS	B-bacteria
number	O
was	O
shown	O
immediately	O
following	O
professional	O
care	O
at	O
1	O
-	O
12	O
months	O
in	O
all	O
samples	O
.	O

There	O
was	O
little	O
difference	O
in	O
the	O
numbers	O
of	O
LB	B-bacteria
at	O
any	O
of	O
the	O
time	O
points	O
.	O

The	O
numbers	O
of	O
TS	O
decreased	O
rapidly	O
in	O
PPA	O
-	O
not	O
detected	O
group	O
in	O
comparison	O
with	O
the	O
PPA	O
-	O
detected	O
group	O
.	O

PPA	O
may	O
be	O
more	O
effective	O
for	O
controlling	O
MS	B-bacteria
number	O
in	O
the	O
oral	O
cavity	O
after	O
professional	O
treatment	O
.	O

The	O
measurement	O
of	O
PPA	O
may	O
be	O
used	O
for	O
preventive	O
instruction	O
to	O
dental	O
caries	O
at	O
the	O
chair	O
side	O
in	O
the	O
clinical	O
setting	O
.	O

The	O
study	O
was	O
conducted	O
to	O
evaluate	O
a	O
new	O
cefixime	O
-	O
clavulanic	O
acid	O
combination	O
for	O
in	O
vitro	O
susceptibility	O
towards	O
gram	O
-	O
negative	O
bacteria	O
.	O

A	O
total	O
of	O
220	O
isolates	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
,	O
Pseudomonas	B-bacteria
aeroginosa	I-bacteria
,	O
Acinetobacter	B-bacteria
spp	I-bacteria
,	O
Salmonella	B-bacteria
enterica	I-bacteria
serovar	I-bacteria
Typhi	I-bacteria
and	O
Salmonella	B-bacteria
enterica	I-bacteria
serovar	I-bacteria
Typhimurium	I-bacteria
were	O
included	O
in	O
the	O
study	O
.	O

The	O
isolates	O
were	O
tested	O
for	O
susceptibility	O
towards	O
the	O
new	O
combination	O
antimicrobial	O
molecule	O
cefixime	O
with	O
clavulanic	O
acid	O
by	O
disk	O
diffusion	O
and	O
Epsilometer	O
strip	O
(	O
E	O
-	O
strip	O
)	O
Minimum	O
Inhibitary	O
Concentration	O
(	O
MIC	O
)	O
method	O
.	O

Of	O
the	O
101	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
isolates	I-bacteria
,	O
62	O
.	O
4	O
%	O
were	O
found	O
to	O
be	O
extended	O
spectrum	O
beta	O
-	O
lactamase	O
(	O
ESBL	O
)	O
producers	O
.	O

Almost	O
half	O
of	O
these	O
were	O
from	O
the	O
community	O
and	O
55	O
.	O
6	O
%	O
were	O
hospital	O
isolates	O
.	O

Of	O
the	O
ESBL	O
isolates	O
,	O
19	O
%	O
were	O
AmpC	O
(	O
cephalosporinases	O
that	O
are	O
poorly	O
inhibited	O
by	O
beta	O
lactamase	O
inhibitor	O
)	O
producers	O
while	O
the	O
remaining	O
81	O
%	O
were	O
non	O
AmpC	O
ESBL	O
producers	O
.	O

The	O
AmpC	O
producers	O
were	O
resistant	O
to	O
both	O
cefixime	O
and	O
the	O
combination	O
,	O
while	O
the	O
non	O
-	O
AmpC	O
producers	O
were	O
sensitive	O
to	O
the	O
combination	O
.	O

The	O
addition	O
of	O
clavulanate	O
to	O
cefixime	O
did	O
not	O
improve	O
the	O
sensitivities	O
of	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
and	O
Acinetobacter	B-bacteria
isolates	I-bacteria
.	O

There	O
were	O
no	O
ESBL	O
isolates	O
among	O
the	O
S	B-bacteria
.	I-bacteria
Typhi	I-bacteria
isolates	I-bacteria
,	O
all	O
of	O
which	O
were	O
sensitive	O
to	O
cefixime	O
.	O

Of	O
the	O
S	B-bacteria
.	I-bacteria
Typhimurium	I-bacteria
,	O
88	O
.	O
9	O
%	O
were	O
ESBL	O
producers	O
and	O
all	O
of	O
these	O
were	O
resistant	O
to	O
cefixime	O
but	O
sensitive	O
to	O
the	O
combination	O
.	O

The	O
combination	O
of	O
cefixime	O
with	O
clavulanic	O
acid	O
offers	O
the	O
advantage	O
of	O
oral	O
administration	O
and	O
appears	O
to	O
be	O
a	O
viable	O
option	O
for	O
the	O
treatment	O
of	O
uncomplicated	O
community	O
acquired	O
infections	O
caused	O
by	O
non	O
-	O
AmpC	O
ESBL	O
producing	O
gram	O
-	O
negative	O
bacteria	O
.	O

Adrenomedullin	O
(	O
ADM	O
)	O
promotes	O
epithelial	O
cell	O
proliferation	O
and	O
antimicrobial	O
activity	O
in	O
the	O
gastrointestinal	O
tract	O
.	O

Since	O
ADM	O
is	O
also	O
present	O
in	O
saliva	O
,	O
it	O
was	O
the	O
objective	O
of	O
our	O
study	O
to	O
investigate	O
the	O
role	O
of	O
salivary	O
ADM	O
in	O
the	O
maintenance	O
of	O
oral	O
health	O
.	O

We	O
found	O
mRNA	O
for	O
ADM	O
and	O
the	O
specific	O
receptors	O
CRLR	O
-	O
RAMP2	O
and	O
CRLR	O
-	O
RAMP3	O
expressed	O
by	O
the	O
salivary	O
glands	O
and	O
by	O
oral	O
keratinocytes	O
.	O

The	O
hormone	O
was	O
detected	O
in	O
the	O
glandular	O
tissues	O
by	O
western	O
blot	O
,	O
being	O
slightly	O
bigger	O
than	O
the	O
synthetic	O
peptide	O
,	O
indicating	O
a	O
posttranslational	O
modification	O
.	O

ADM	O
was	O
localized	O
using	O
immunohistochemistry	O
and	O
immunofluorescence	O
.	O

Staining	O
specific	O
for	O
ADM	O
was	O
observed	O
near	O
the	O
cell	O
nuclei	O
of	O
the	O
salivary	O
ducts	O
and	O
acini	O
.	O

There	O
was	O
no	O
correlation	O
between	O
ADM	O
from	O
matched	O
saliva	O
and	O
serum	O
of	O
healthy	O
volunteers	O
.	O

The	O
physiological	O
role	O
of	O
salivary	O
ADM	O
in	O
the	O
oral	O
cavity	O
was	O
investigated	O
by	O
incubating	O
buccal	O
keratinocytes	O
with	O
ADM	O
and	O
measurement	O
of	O
the	O
cell	O
proliferation	O
using	O
bromodeoxyuridine	O
(	O
BrDU	O
)	O
assays	O
.	O

There	O
was	O
a	O
significant	O
,	O
dose	O
dependent	O
increase	O
(	O
up	O
to	O
5	O
-	O
fold	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
of	O
the	O
BrDU	O
incorporation	O
after	O
stimulation	O
with	O
ADM	O
(	O
1	O
.	O
5	O
to	O
50	O
ng	O
/	O
mL	O
)	O
.	O

The	O
antibacterial	O
properties	O
of	O
salivary	O
ADM	O
was	O
studied	O
by	O
incubation	O
of	O
Gram	O
+	O
and	O
Gram	O
-	O
bacteria	O
and	O
yeast	O
,	O
isolated	O
from	O
human	O
oral	O
flora	O
,	O
with	O
ADM	O
(	O
0	O
.	O
01	O
-	O
1000	O
ng	O
/	O
mL	O
)	O
for	O
24	O
h	O
.	O
Bacterial	O
growth	O
was	O
inhibited	O
dose	O
dependently	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
whereas	O
the	O
yeast	O
was	O
not	O
affected	O
.	O

This	O
finding	O
was	O
consistent	O
when	O
using	O
radial	O
growth	O
inhibition	O
test	O
on	O
agarose	O
plates	O
as	O
well	O
as	O
photometric	O
measurement	O
in	O
microtiter	O
plates	O
.	O

Our	O
findings	O
suggest	O
an	O
important	O
role	O
of	O
salivary	O
ADM	O
in	O
the	O
maintenance	O
of	O
oral	O
health	O
,	O
being	O
involved	O
as	O
well	O
as	O
in	O
oral	O
cell	O
proliferation	O
and	O
anti	O
-	O
bacterial	O
defense	O
.	O

Four	O
strains	O
of	O
anaerobic	O
Gram	O
-	O
negative	O
bacilli	O
isolated	O
from	O
the	O
human	O
mouth	O
were	O
characterized	O
using	O
a	O
variety	O
of	O
phenotypic	O
and	O
genotypic	O
tests	O
.	O

The	O
strains	O
were	O
found	O
to	O
comprise	O
a	O
homogeneous	O
group	O
and	O
16S	O
rRNA	O
gene	O
sequence	O
analysis	O
revealed	O
them	O
to	O
be	O
distinct	O
from	O
but	O
related	O
to	O
a	O
loose	O
cluster	O
of	O
Prevotella	B-bacteria
species	I-bacteria
including	O
Prevotella	B-bacteria
buccalis	I-bacteria
,	O
Prevotella	B-bacteria
nanceiensis	I-bacteria
and	O
Prevotella	B-bacteria
marshii	I-bacteria
.	O

A	O
novel	O
species	O
,	O
Prevotella	B-bacteria
micans	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
is	O
proposed	O
to	O
accommodate	O
these	O
strains	O
.	O

Prevotella	B-bacteria
micans	I-bacteria
is	O
saccharolytic	O
and	O
produces	O
acetic	O
,	O
isovaleric	O
and	O
succinic	O
acids	O
and	O
minor	O
amounts	O
of	O
isobutyric	O
acid	O
as	O
end	O
products	O
of	O
fermentation	O
.	O

The	O
G	O
+	O
C	O
content	O
of	O
the	O
DNA	O
of	O
the	O
type	O
strain	O
is	O
46	O
mol	O
%	O
.	O

The	O
type	O
strain	O
of	O
Prevotella	B-bacteria
micans	I-bacteria
is	O
E7	B-bacteria
.	I-bacteria
56	I-bacteria
(	O
T	O
)	O
(	O
=	O
DSM	B-bacteria
21469	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
56105	I-bacteria
(	O
T	O
)	O
)	O
.	O

Results	O
of	O
study	O
of	O
microecological	O
disorders	O
in	O
oral	O
cavity	O
of	O
patients	O
with	O
non	O
-	O
specific	O
ulcerative	O
colitis	O
(	O
NSUC	O
)	O
and	O
Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
and	O
control	O
subjects	O
(	O
patients	O
with	O
hypertension	O
)	O
.	O

Condition	O
of	O
mucosa	O
was	O
assessed	O
on	O
the	O
basis	O
of	O
morphological	O
data	O
and	O
electrophoretic	O
mobility	O
of	O
cell	O
nuclei	O
,	O
whereas	O
structure	O
of	O
microbiocenosis	O
and	O
metabolic	O
activity	O
of	O
microflora	O
-	O
-	O
on	O
the	O
basis	O
of	O
saliva	O
bacterial	O
culture	O
and	O
contents	O
and	O
profile	O
of	O
volatile	O
fat	O
acids	O
in	O
it	O
.	O

Detection	O
rate	O
of	O
negative	O
charge	O
of	O
the	O
cell	O
nuclei	O
(	O
decrease	O
of	O
functional	O
activity	O
of	O
epithelium	O
)	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
NSUC	O
and	O
CD	O
(	O
66	O
.	O
6	O
%	O
)	O
compared	O
with	O
controls	O
(	O
10	O
%	O
)	O
.	O

This	O
fact	O
was	O
directly	O
related	O
with	O
hypercolonization	O
of	O
oral	O
cavity	O
by	O
Gram	O
-	O
negative	O
microflora	O
.	O

Lesions	O
of	O
mucosa	O
which	O
are	O
characteristic	O
of	O
NSUC	O
and	O
CD	O
and	O
determined	O
by	O
pathologic	O
immune	O
mechanisms	O
correlated	O
with	O
quantity	O
of	O
pathogenic	O
microflora	O
(	O
Staphylococcus	B-bacteria
aureus	I-bacteria
and	O
Candida	O
)	O
.	O

Marked	O
differences	O
of	O
chromatograms	O
'	O
patterns	O
were	O
observed	O
in	O
patients	O
with	O
NSUC	O
and	O
CD	O
indicating	O
the	O
suppression	O
of	O
anaerobic	O
microflora	O
in	O
patients	O
with	O
CD	O
and	O
hypercolonization	O
of	O
oral	O
cavity	O
by	O
anaerobic	O
microflora	O
in	O
majority	O
of	O
patients	O
with	O
NSUC	O
.	O

Members	O
of	O
the	O
phylum	O
`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
have	O
frequently	O
been	O
detected	O
in	O
the	O
human	O
oral	O
cavity	O
at	O
sites	O
of	O
dental	O
disease	O
,	O
but	O
they	O
have	O
rarely	O
been	O
detected	O
in	O
studies	O
of	O
oral	O
health	O
.	O

Only	O
two	O
oral	O
`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
taxa	O
are	O
cultivable	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
investigate	O
the	O
diversity	O
of	O
`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
in	O
the	O
oral	O
cavity	O
,	O
to	O
establish	O
whether	O
`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
taxa	O
are	O
more	O
strongly	O
associated	O
with	O
periodontitis	O
than	O
with	O
oral	O
health	O
,	O
and	O
to	O
visualize	O
unculturable	O
`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
in	O
situ	O
.	O

Sixty	O
samples	O
(	O
saliva	O
,	O
dental	O
plaque	O
,	O
and	O
mucosal	O
swabs	O
)	O
were	O
collected	O
from	O
five	O
subjects	O
with	O
periodontitis	O
and	O
five	O
periodontally	O
healthy	O
controls	O
.	O

Using	O
phylum	O
-	O
specific	O
16S	O
rRNA	O
gene	O
primers	O
,	O
`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
were	O
identified	O
by	O
PCR	O
,	O
cloning	O
,	O
and	O
sequencing	O
of	O
48	O
clones	O
per	O
PCR	O
-	O
positive	O
sample	O
.	O

Subgingival	O
plaque	O
samples	O
were	O
labeled	O
with	O
probes	O
targeting	O
rRNA	O
of	O
unculturable	O
oral	O
`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
using	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Analysis	O
of	O
1	O
,	O
664	O
clones	O
revealed	O
12	O
`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
at	O
the	O
99	O
%	O
sequence	O
identity	O
level	O
,	O
5	O
of	O
which	O
were	O
novel	O
.	O

`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
OTU	O
4	O
.	O
2	O
was	O
found	O
in	O
significantly	O
more	O
subjects	O
with	O
periodontitis	O
than	O
controls	O
(	O
P	O
=	O
0	O
.	O
048	O
)	O
and	O
was	O
more	O
abundant	O
in	O
subgingival	O
plaque	O
at	O
diseased	O
sites	O
than	O
at	O
healthy	O
sites	O
in	O
subjects	O
with	O
periodontitis	O
(	O
P	O
=	O
0	O
.	O
019	O
)	O
or	O
controls	O
(	O
P	O
=	O
0	O
.	O
019	O
)	O
.	O

FISH	O
analysis	O
revealed	O
that	O
unculturable	O
oral	O
`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
cells	O
were	O
large	O
curved	O
bacilli	O
.	O

The	O
human	O
oral	O
cavity	O
harbors	O
a	O
diverse	O
population	O
of	O
`	O
`	O
Synergistetes	B-bacteria
.	O
'	O
'	O

`	O
`	O
Synergistetes	B-bacteria
'	O
'	O
OTU	O
4	O
.	O
2	O
is	O
associated	O
with	O
periodontitis	O
and	O
may	O
have	O
a	O
pathogenic	O
role	O
.	O

Parvimonas	B-bacteria
micra	I-bacteria
are	O
gram	O
positive	O
anaerobic	O
cocci	O
isolated	O
from	O
the	O
oral	O
cavity	O
and	O
frequently	O
related	O
to	O
polymicrobial	O
infections	O
in	O
humans	O
.	O

Despite	O
reports	O
about	O
phenotypic	O
differences	O
,	O
the	O
genotypic	O
variation	O
of	O
P	B-bacteria
.	I-bacteria
micra	I-bacteria
and	O
its	O
role	O
in	O
virulence	O
are	O
still	O
not	O
elucidated	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
genotypic	O
diversity	O
of	O
P	B-bacteria
.	I-bacteria
micra	I-bacteria
isolates	I-bacteria
obtained	O
from	O
the	O
subgingival	O
biofilm	O
of	O
subjects	O
with	O
different	O
periodontal	O
conditions	O
and	O
to	O
correlate	O
these	O
findings	O
with	O
phenotypic	O
traits	O
.	O

Three	O
reference	O
strains	O
and	O
35	O
isolates	O
of	O
P	B-bacteria
.	I-bacteria
micra	I-bacteria
were	O
genotyped	O
by	O
16S	O
rRNA	O
PCR	O
-	O
RFLP	O
and	O
phenotypic	O
traits	O
such	O
as	O
collagenase	O
production	O
,	O
elastolytic	O
and	O
hemolytic	O
activities	O
were	O
evaluated	O
.	O

16S	O
rRNA	O
PCR	O
-	O
RFLP	O
showed	O
that	O
P	B-bacteria
.	I-bacteria
micra	I-bacteria
could	O
be	O
grouped	O
into	O
two	O
main	O
clusters	O
:	O
C1	O
and	O
C2	O
;	O
cluster	O
C1	O
harbored	O
three	O
genotypes	O
(	O
HG1259	O
-	O
like	O
,	O
HG1467	O
-	O
like	O
and	O
ICBMO583	O
-	O
like	O
)	O
while	O
cluster	O
C2	O
harbored	O
two	O
genotypes	O
(	O
ATCC33270	O
-	O
like	O
and	O
ICBMO36	O
)	O
.	O

A	O
wide	O
variability	O
in	O
collagenolytic	O
activity	O
intensities	O
was	O
observed	O
among	O
all	O
isolates	O
,	O
while	O
elastolytic	O
activity	O
was	O
detected	O
in	O
only	O
two	O
isolates	O
.	O

There	O
was	O
an	O
association	O
between	O
hemolytic	O
activity	O
in	O
rabbit	O
erythrocytes	O
and	O
cluster	O
C2	O
.	O

There	O
was	O
an	O
association	O
between	O
hemolytic	O
activity	O
in	O
rabbit	O
erythrocytes	O
and	O
cluster	O
C1	O
.	O

Although	O
these	O
data	O
suggest	O
a	O
possible	O
association	O
between	O
P	B-bacteria
.	I-bacteria
micra	I-bacteria
genetic	O
diversity	O
and	O
their	O
pathogenic	O
potential	O
,	O
further	O
investigations	O
are	O
needed	O
to	O
confirm	O
this	O
hypothesis	O
.	O

We	O
examined	O
the	O
associations	O
between	O
preterm	O
birth	O
and	O
low	O
birth	O
weight	O
and	O
maternal	O
caries	O
history	O
,	O
maternal	O
periodontal	O
status	O
,	O
and	O
salivary	O
levels	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
Lactobacilli	B-bacteria
.	O

This	O
study	O
was	O
a	O
matched	O
case	O
-	O
control	O
study	O
in	O
women	O
during	O
their	O
pregnancy	O
or	O
up	O
to	O
8	O
weeks	O
after	O
delivery	O
.	O

SUBJECTS	O
AND	O
Thirty	O
-	O
four	O
women	O
delivering	O
before	O
37	O
weeks	O
gestation	O
were	O
recruited	O
along	O
with	O
73	O
term	O
controls	O
matched	O
for	O
age	O
and	O
race	O
/	O
ethnicity	O
.	O

Demographic	O
and	O
obstetric	O
information	O
was	O
collected	O
from	O
questionnaires	O
and	O
medical	O
records	O
and	O
oral	O
examinations	O
along	O
with	O
commercial	O
salivary	O
tests	O
were	O
completed	O
within	O
the	O
study	O
groups	O
.	O

The	O
main	O
outcome	O
variables	O
were	O
the	O
preterm	O
birth	O
and	O
low	O
birth	O
weight	O
status	O
.	O

The	O
independent	O
variables	O
measured	O
were	O
the	O
salivary	O
levels	O
of	O
Lactobacilli	B-bacteria
and	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
the	O
caries	O
and	O
periodontal	O
status	O
of	O
the	O
subjects	O
.	O

The	O
odds	O
ratio	O
comparing	O
low	O
levels	O
of	O
bacteria	O
in	O
preterm	O
mothers	O
and	O
controls	O
was	O
statistically	O
significant	O
for	O
Lactobacilli	B-bacteria
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
3	O
.	O
45	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
27	O
to	O
10	O
.	O
00	O
)	O
and	O
almost	O
significant	O
for	O
mutans	B-bacteria
streptococci	I-bacteria
(	O
OR	O
=	O
2	O
.	O
63	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
95	O
to	O
8	O
.	O
33	O
)	O
.	O

Clinical	O
caries	O
and	O
periodontal	O
disease	O
measures	O
did	O
not	O
differ	O
significantly	O
between	O
groups	O
.	O

Within	O
the	O
limitation	O
of	O
our	O
study	O
,	O
low	O
levels	O
of	O
Lactobacilli	B-bacteria
in	O
saliva	O
were	O
found	O
to	O
be	O
associated	O
with	O
preterm	O
birth	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
describe	O
the	O
bacterial	O
diversity	O
in	O
the	O
oral	O
cavity	O
of	O
the	O
elderly	O
without	O
root	O
caries	O
using	O
bacterial	O
microarrays	O
,	O
and	O
to	O
determine	O
the	O
site	O
-	O
and	O
subject	O
-	O
specificity	O
of	O
bacterial	O
colonization	O
.	O

Samples	O
were	O
collected	O
from	O
the	O
tongue	O
dorsum	O
,	O
mucosa	O
of	O
the	O
buccal	O
fold	O
,	O
hard	O
palate	O
,	O
supragingival	O
plaque	O
from	O
sound	O
root	O
surfaces	O
,	O
and	O
subgingival	O
plaque	O
from	O
the	O
same	O
roots	O
.	O

A	O
new	O
16	O
S	O
rRNA	O
gene	O
-	O
based	O
microarray	O
method	O
was	O
used	O
for	O
the	O
simultaneous	O
detection	O
of	O
approximately	O
300	O
bacterial	O
species	O
.	O

Overall	O
,	O
175	O
species	O
and	O
clusters	O
were	O
detected	O
,	O
representing	O
eight	O
phyla	O
.	O

Species	O
belonging	O
to	O
the	O
genera	O
Streptococcus	B-bacteria
,	O
Veillonella	B-bacteria
,	O
and	O
Fusobacterium	B-bacteria
were	O
common	O
in	O
all	O
sites	O
.	O

The	O
number	O
of	O
species	O
per	O
subject	O
varied	O
from	O
51	O
to	O
81	O
.	O

Statistical	O
analyses	O
revealed	O
about	O
40	O
species	O
or	O
clusters	O
with	O
significant	O
associations	O
with	O
at	O
least	O
one	O
of	O
the	O
sites	O
.	O

The	O
bacterial	O
diversity	O
was	O
highest	O
in	O
the	O
cheek	O
and	O
palate	O
regions	O
.	O

Species	O
typically	O
associated	O
with	O
caries	O
and	O
periodontitis	O
were	O
detected	O
rarely	O
or	O
not	O
at	O
all	O
.	O

The	O
oral	O
bacterial	O
flora	O
of	O
the	O
elderly	O
appears	O
to	O
be	O
diverse	O
,	O
and	O
,	O
to	O
a	O
large	O
extent	O
,	O
site	O
-	O
rather	O
than	O
subject	O
-	O
specific	O
.	O

Surface	O
adhesion	O
plays	O
an	O
essential	O
part	O
in	O
the	O
survival	O
of	O
the	O
commensal	O
organism	O
Streptococcus	B-bacteria
gordonii	I-bacteria
in	O
the	O
oral	O
cavity	O
as	O
well	O
as	O
during	O
opportunistic	O
infections	O
such	O
as	O
endocarditis	O
.	O

At	O
least	O
two	O
types	O
of	O
cell	O
surface	O
protein	O
involved	O
in	O
adhesion	O
are	O
found	O
on	O
the	O
surface	O
of	O
Gram	O
-	O
positive	O
bacteria	O
:	O
those	O
anchored	O
via	O
an	O
LPXTG	O
motif	O
by	O
the	O
enzyme	O
sortase	O
A	O
(	O
SrtA	O
)	O
and	O
those	O
associated	O
with	O
the	O
cell	O
surface	O
by	O
,	O
as	O
yet	O
,	O
unknown	O
mechanisms	O
.	O

In	O
srtA	O
(	O
-	O
)	O
mutants	O
,	O
LPXTG	O
-	O
containing	O
proteins	O
have	O
been	O
shown	O
to	O
be	O
released	O
rather	O
than	O
cross	O
-	O
linked	O
to	O
the	O
cell	O
wall	O
.	O

We	O
have	O
therefore	O
used	O
2D	O
gel	O
electrophoresis	O
of	O
released	O
proteins	O
from	O
an	O
srtA	O
(	O
-	O
)	O
mutant	O
as	O
well	O
as	O
the	O
wild	O
-	O
type	O
strain	O
,	O
followed	O
by	O
peptide	O
identification	O
by	O
MS	B-bacteria
,	O
to	O
identify	O
a	O
set	O
of	O
novel	O
proteins	O
predicted	O
to	O
be	O
present	O
on	O
the	O
surface	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
DL1	I-bacteria
.	O

This	O
includes	O
two	O
large	O
LPXTG	O
-	O
linked	O
proteins	O
(	O
SGO	O
_	O
0707	O
and	O
SGO	O
_	O
1487	O
)	O
,	O
which	O
both	O
contain	O
tandemly	O
repeated	O
sequences	O
similar	O
to	O
those	O
present	O
in	O
known	O
fibrillar	O
adhesins	O
.	O

A	O
5	O
'	O
-	O
nucleotidase	O
and	O
a	O
protein	O
with	O
a	O
putative	O
collagen	O
-	O
binding	O
domain	O
,	O
both	O
containing	O
LPXTG	O
motifs	O
,	O
were	O
also	O
identified	O
.	O

Anchorless	O
proteins	O
with	O
known	O
chaperone	O
,	O
stress	O
response	O
and	O
elongation	O
factor	O
functions	O
,	O
apparently	O
responsible	O
for	O
bacterial	O
binding	O
to	O
keratinocytes	O
and	O
saliva	O
-	O
coated	O
surfaces	O
in	O
the	O
absence	O
of	O
the	O
LPXTG	O
-	O
linked	O
adhesins	O
,	O
were	O
also	O
associated	O
with	O
the	O
cell	O
surface	O
.	O

These	O
data	O
reveal	O
a	O
range	O
of	O
proteins	O
to	O
be	O
present	O
on	O
the	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
DL1	I-bacteria
cell	O
surface	O
,	O
the	O
expression	O
of	O
which	O
plays	O
an	O
important	O
role	O
in	O
adhesion	O
to	O
epithelia	O
and	O
which	O
represent	O
likely	O
candidates	O
for	O
novel	O
virulence	O
factors	O
in	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
microbiologically	O
analyze	O
oral	O
mucosal	O
samples	O
collected	O
during	O
2	O
years	O
from	O
patients	O
with	O
oral	O
mucosal	O
complaints	O
.	O

Mucosal	O
scraping	O
samples	O
were	O
taken	O
from	O
297	O
patients	O
and	O
semiquantified	O
by	O
culture	O
for	O
detection	O
of	O
opportunistic	O
microorganisms	O
e	O
.	O
g	O
.	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
enterococci	B-bacteria
,	O
aerobic	O
Gram	O
-	O
negative	O
bacilli	O
(	O
AGNB	O
)	O
and	O
yeasts	O
.	O

Antibiotic	O
susceptibility	O
test	O
was	O
performed	O
.	O

Altogether	O
297	O
patients	O
were	O
sampled	O
(	O
mean	O
age	O
56	O
.	O
8	O
+	O
/	O
-	O
20	O
.	O
7	O
)	O
.	O

Among	O
the	O
110	O
patients	O
with	O
known	O
medical	O
condition	O
,	O
48	O
were	O
systemically	O
immunocompromised	O
,	O
35	O
had	O
systemic	O
diseases	O
,	O
and	O
27	O
had	O
only	O
local	O
oral	O
complaints	O
.	O

Opportunists	O
in	O
moderate	O
growth	O
or	O
more	O
were	O
present	O
commonly	O
in	O
all	O
three	O
groups	O
and	O
most	O
frequent	O
in	O
the	O
immunocompromised	O
patients	O
(	O
66	O
.	O
7	O
%	O
)	O
.	O

Candida	O
species	O
were	O
the	O
most	O
frequent	O
opportunist	O
(	O
68	O
.	O
8	O
%	O
)	O
,	O
however	O
,	O
their	O
level	O
was	O
low	O
and	O
combinations	O
with	O
bacterial	O
opportunists	O
were	O
common	O
(	O
39	O
.	O
6	O
%	O
)	O
.	O

All	O
bacterial	O
opportunists	O
tested	O
were	O
antibiotic	O
multiresistant	O
.	O

Follow	O
-	O
up	O
samples	O
were	O
collected	O
in	O
23	O
cases	O
out	O
of	O
which	O
seven	O
showed	O
still	O
presence	O
of	O
opportunists	O
in	O
heavy	O
growth	O
despite	O
repeated	O
treatment	O
with	O
ciprofloxacin	O
.	O

This	O
study	O
showed	O
a	O
frequent	O
presence	O
of	O
bacterial	O
and	O
fungal	O
opportunists	O
in	O
patients	O
with	O
oral	O
mucosal	O
complaints	O
,	O
which	O
were	O
most	O
common	O
in	O
immunocompromised	O
individuals	O
,	O
however	O
,	O
also	O
frequent	O
in	O
patients	O
with	O
local	O
oral	O
complaints	O
only	O
.	O

Systematic	O
evaluation	O
of	O
different	O
treatment	O
strategies	O
is	O
needed	O
.	O

Polyphenols	O
are	O
antibacterial	O
and	O
anti	O
-	O
oxidative	O
natural	O
agents	O
.	O

The	O
present	O
in	O
situ	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
different	O
polyphenolic	O
beverages	O
on	O
initial	O
bacterial	O
adherence	O
to	O
enamel	O
in	O
the	O
oral	O
cavity	O
.	O

Initial	O
biofilm	O
formation	O
was	O
performed	O
on	O
bovine	O
enamel	O
specimens	O
mounted	O
buccally	O
on	O
individual	O
upper	O
jaw	O
splints	O
and	O
carried	O
by	O
six	O
subjects	O
.	O

After	O
1	O
min	O
of	O
pellicle	O
formation	O
,	O
oral	O
rinses	O
with	O
black	O
tea	O
,	O
green	O
tea	O
,	O
grape	O
juice	O
,	O
Cistus	O
tea	O
or	O
red	O
wine	O
were	O
performed	O
for	O
10	O
min	O
.	O

Afterwards	O
the	O
slabs	O
were	O
carried	O
for	O
another	O
19	O
or	O
109	O
min	O
,	O
respectively	O
.	O

Samples	O
exposed	O
to	O
the	O
oral	O
fluids	O
for	O
30	O
and	O
120	O
min	O
served	O
as	O
controls	O
.	O

Following	O
intraoral	O
exposure	O
,	O
the	O
slabs	O
were	O
rinsed	O
with	O
saline	O
solution	O
.	O

The	O
amount	O
of	O
adherent	O
bacteria	O
was	O
determined	O
with	O
DAPI	O
-	O
staining	O
(	O
4	O
'	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
)	O
and	O
with	O
fluorescence	O
-	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
of	O
eubacteria	O
and	O
streptococci	B-bacteria
.	O

Rinses	O
with	O
all	O
beverages	O
reduced	O
the	O
amount	O
of	O
detectable	O
bacteria	O
.	O

Lowest	O
number	O
of	O
adherent	O
bacteria	O
was	O
found	O
following	O
rinses	O
with	O
red	O
wine	O
,	O
Cistus	O
tea	O
and	O
black	O
tea	O
as	O
measured	O
with	O
DAPI	O
(	O
up	O
to	O
66	O
%	O
reduction	O
of	O
adherent	O
bacteria	O
vs	O
.	O
controls	O
)	O
.	O

Also	O
FISH	O
revealed	O
significant	O
impact	O
of	O
most	O
tested	O
beverages	O
.	O

Rinses	O
with	O
certain	O
polyphenolic	O
beverages	O
as	O
well	O
as	O
consumption	O
of	O
these	O
foodstuffs	O
may	O
contribute	O
to	O
prevention	O
of	O
biofilm	O
induced	O
diseases	O
in	O
the	O
oral	O
cavity	O
.	O

To	O
establish	O
the	O
effects	O
of	O
three	O
factors	O
:	O
previous	O
caries	O
experience	O
;	O
colonization	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
;	O
and	O
final	O
pH	O
on	O
autologous	O
lactobacilli	O
-	O
mediated	O
inhibition	O
against	O
a	O
panel	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
in	O
young	O
subjects	O
with	O
different	O
caries	O
experiences	O
.	O

The	O
inhibition	O
capacity	O
was	O
determined	O
by	O
the	O
use	O
of	O
the	O
agar	O
overlay	O
method	O
and	O
the	O
final	O
pH	O
in	O
culture	O
medium	O
was	O
measured	O
after	O
20	O
h	O
.	O
Using	O
a	O
logistic	O
regression	O
model	O
,	O
the	O
risk	O
of	O
having	O
an	O
incomplete	O
lactobacilli	O
-	O
mediated	O
inhibition	O
was	O
calculated	O
.	O

All	O
three	O
factors	O
significantly	O
influenced	O
the	O
interference	O
outcome	O
in	O
the	O
order	O
;	O
final	O
pH	O
of	O
the	O
Lactobacillus	B-bacteria
strains	I-bacteria
,	O
oral	O
colonization	O
of	O
autologous	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
caries	O
experience	O
.	O

A	O
high	O
risk	O
occurred	O
at	O
a	O
lower	O
pH	O
and	O
at	O
a	O
wider	O
pH	O
range	O
for	O
individuals	O
with	O
previous	O
caries	O
experience	O
and	O
autologous	O
colonization	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
compared	O
with	O
caries	O
-	O
free	O
subjects	O
who	O
were	O
not	O
colonized	O
.	O

At	O
a	O
final	O
pH	O
of	O
4	O
.	O
0	O
,	O
this	O
risk	O
was	O
approximately	O
eight	O
times	O
higher	O
than	O
that	O
of	O
the	O
latter	O
group	O
.	O

Two	O
mutans	B-bacteria
Streptococcus	I-bacteria
strains	I-bacteria
in	O
the	O
test	O
panel	O
demonstrated	O
high	O
individual	O
predictive	O
values	O
of	O
inhibition	O
mediated	O
by	O
oral	O
lactobacilli	B-bacteria
.	O

Generation	O
of	O
a	O
low	O
pH	O
either	O
directly	O
via	O
organic	O
acid	O
production	O
and	O
/	O
or	O
production	O
of	O
bacteriocins	O
or	O
metabolites	O
at	O
a	O
low	O
pH	O
may	O
promote	O
mutans	B-bacteria
Streptococcus	I-bacteria
growth	O
inhibition	O
,	O
in	O
vitro	O
.	O

Furthermore	O
,	O
a	O
shift	O
of	O
pH	O
range	O
for	O
the	O
risk	O
of	O
incomplete	O
inhibition	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
suggests	O
a	O
less	O
effective	O
inhibition	O
at	O
a	O
wider	O
pH	O
range	O
for	O
naturally	O
occurring	O
lactobacilli	B-bacteria
from	O
individuals	O
with	O
earlier	O
caries	O
experience	O
containing	O
own	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Four	O
strains	O
of	O
anaerobic	O
,	O
Gram	O
-	O
negative	O
bacilli	O
isolated	O
from	O
the	O
human	O
oral	O
cavity	O
were	O
subjected	O
to	O
a	O
comprehensive	O
range	O
of	O
phenotypic	O
and	O
genotypic	O
tests	O
and	O
were	O
found	O
to	O
comprise	O
a	O
homogeneous	O
group	O
distinct	O
from	O
any	O
species	O
with	O
validly	O
published	O
names	O
.	O

16S	O
rRNA	O
and	O
23S	O
rRNA	O
gene	O
sequence	O
analyses	O
and	O
DNA	O
-	O
DNA	O
reassociation	O
data	O
revealed	O
that	O
the	O
strains	O
constituted	O
a	O
novel	O
group	O
within	O
the	O
phylum	O
'	O
Synergistetes	B-bacteria
'	O
and	O
were	O
most	O
closely	O
related	O
to	O
Jonquetella	B-bacteria
anthropi	I-bacteria
.	O

Two	O
libraries	O
of	O
randomly	O
cloned	O
DNA	O
were	O
prepared	O
from	O
strain	O
W5455	B-bacteria
(	O
T	O
)	O
and	O
were	O
sequenced	O
to	O
provide	O
a	O
genome	O
survey	O
as	O
a	O
resource	O
for	O
metagenomic	O
studies	O
.	O

A	O
new	O
genus	O
and	O
novel	O
species	O
,	O
Pyramidobacter	B-bacteria
piscolens	I-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
is	O
proposed	O
to	O
accommodate	O
these	O
strains	O
.	O

The	O
genus	O
Pyramidobacter	B-bacteria
comprises	O
strains	O
that	O
are	O
anaerobic	O
,	O
non	O
-	O
motile	O
,	O
asaccharolytic	O
bacilli	O
that	O
produce	O
acetic	O
and	O
isovaleric	O
acids	O
and	O
minor	O
to	O
trace	O
amounts	O
of	O
propionic	O
,	O
isobutyric	O
,	O
succinic	O
and	O
phenylacetic	O
acids	O
as	O
end	O
products	O
of	O
metabolism	O
.	O

P	B-bacteria
.	I-bacteria
piscolens	I-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
produced	O
hydrogen	O
sulphide	O
but	O
was	O
otherwise	O
largely	O
biochemically	O
unreactive	O
.	O

Growth	O
was	O
stimulated	O
by	O
the	O
addition	O
of	O
glycine	O
to	O
broth	O
media	O
.	O

The	O
G	O
+	O
C	O
content	O
of	O
the	O
DNA	O
of	O
the	O
type	O
strain	O
was	O
59	O
mol	O
%	O
.	O

The	O
type	O
strain	O
of	O
Pyramidobacter	B-bacteria
piscolens	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
is	O
W5455	B-bacteria
(	O
T	O
)	O
(	O
=	O
DSM	B-bacteria
21147	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
55836	I-bacteria
(	O
T	O
)	O
)	O
.	O

The	O
combined	O
use	O
of	O
confocal	O
laser	O
scanning	O
microscopy	O
(	O
CLSM	O
)	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
offers	O
new	O
opportunities	O
for	O
analysis	O
of	O
the	O
spatial	O
relationships	O
and	O
temporal	O
changes	O
of	O
specific	O
members	O
of	O
the	O
microbiota	O
of	O
intact	O
dental	O
biofilms	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
patterns	O
of	O
colonization	O
and	O
population	O
dynamics	O
of	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
compared	O
to	O
streptococci	B-bacteria
and	O
other	O
bacteria	O
during	O
the	O
initial	O
48	O
h	O
of	O
biofilm	O
formation	O
in	O
the	O
oral	O
cavity	O
.	O

Biofilms	O
developed	O
on	O
standardized	O
glass	O
slabs	O
mounted	O
in	O
intra	O
-	O
oral	O
appliances	O
worn	O
by	O
ten	O
individuals	O
for	O
6	O
,	O
12	O
,	O
24	O
and	O
48	O
h	O
.	O
The	O
biofilms	O
were	O
subsequently	O
labelled	O
with	O
probes	O
against	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
(	O
ACT476	B-bacteria
)	O
,	O
streptococci	B-bacteria
(	O
STR405	B-bacteria
)	O
or	O
all	O
bacteria	O
(	O
EUB338	O
)	O
,	O
and	O
were	O
analysed	O
by	O
CLSM	O
.	O

Labelled	O
bacteria	O
were	O
quantified	O
by	O
stereological	O
tools	O
.	O

The	O
results	O
showed	O
a	O
notable	O
increase	O
in	O
the	O
number	O
of	O
streptococci	B-bacteria
and	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
over	O
time	O
,	O
with	O
a	O
tendency	O
towards	O
a	O
slower	O
growth	O
rate	O
for	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
compared	O
with	O
streptococci	B-bacteria
.	O

A	O
.	O
naeslundii	O
was	O
located	O
mainly	O
in	O
the	O
inner	O
part	O
of	O
the	O
multilayered	O
biofilm	O
,	O
indicating	O
that	O
it	O
is	O
one	O
of	O
the	O
species	O
that	O
attaches	O
directly	O
to	O
the	O
acquired	O
pellicle	O
.	O

The	O
participation	O
of	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
in	O
the	O
initial	O
stages	O
of	O
dental	O
biofilm	O
formation	O
may	O
have	O
important	O
ecological	O
consequences	O
.	O

TGF	O
-	O
beta1	O
exerts	O
diverse	O
functions	O
in	O
tooth	O
development	O
and	O
tissue	O
repair	O
,	O
but	O
its	O
role	O
in	O
microbial	O
defenses	O
of	O
the	O
tooth	O
is	O
not	O
well	O
-	O
understood	O
.	O

Odontoblasts	O
extending	O
their	O
cellular	O
processes	O
into	O
the	O
dentin	O
are	O
the	O
first	O
cells	O
to	O
recognize	O
signals	O
from	O
TGF	O
-	O
beta1	O
and	O
bacteria	O
in	O
carious	O
dentin	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
role	O
of	O
TGF	O
-	O
beta1	O
in	O
modulating	O
odontoblast	O
responses	O
to	O
oral	O
bacteria	O
.	O

We	O
show	O
that	O
these	O
responses	O
depend	O
upon	O
the	O
expression	O
levels	O
of	O
microbial	O
recognition	O
receptors	O
TLR2	O
and	O
TLR4	O
on	O
the	O
cell	O
surface	O
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
and	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
activated	O
both	O
TLRs	O
,	O
but	O
TLR4	O
played	O
a	O
greater	O
role	O
.	O

Lack	O
of	O
cell	O
-	O
surface	O
TLR2	O
was	O
associated	O
with	O
poor	O
response	O
to	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Enterococcus	B-bacteria
faecalis	I-bacteria
,	O
and	O
Lactobacillus	B-bacteria
casei	I-bacteria
.	O

TGF	O
-	O
beta1	O
inhibited	O
TLR2	O
and	O
TLR4	O
expression	O
and	O
attenuated	O
odontoblast	O
responses	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
balance	O
between	O
TLR	O
-	O
mediated	O
inflammation	O
and	O
TGF	O
-	O
beta1	O
anti	O
-	O
inflammatory	O
activity	O
plays	O
an	O
important	O
role	O
in	O
pulpal	O
inflammation	O
.	O

This	O
study	O
was	O
performed	O
to	O
detect	O
the	O
opportunistic	O
bacteria	O
and	O
fungi	O
from	O
the	O
oral	O
cavities	O
of	O
orthodontic	O
patients	O
and	O
examine	O
the	O
ability	O
of	O
the	O
organisms	O
to	O
adhere	O
to	O
saliva	O
-	O
coated	O
metallic	O
brackets	O
.	O

Opportunistic	O
bacteria	O
and	O
fungi	O
were	O
isolated	O
from	O
58	O
patients	O
(	O
orthodontic	O
group	O
:	O
42	O
;	O
non	O
-	O
orthodontic	O
group	O
:	O
16	O
)	O
using	O
culture	O
methods	O
and	O
were	O
identified	O
based	O
on	O
their	O
biochemical	O
and	O
enzymatic	O
profiles	O
.	O

Seven	O
opportunistic	O
and	O
four	O
streptococcal	B-bacteria
strains	I-bacteria
were	O
tested	O
for	O
their	O
ability	O
to	O
adhere	O
to	O
saliva	O
-	O
coated	O
metallic	O
brackets	O
.	O

More	O
opportunistic	O
bacteria	O
and	O
fungi	O
were	O
detected	O
in	O
the	O
orthodontic	O
group	O
than	O
in	O
the	O
non	O
-	O
orthodontic	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Opportunistic	O
bacteria	O
adhered	O
to	O
saliva	O
-	O
coated	O
metallic	O
brackets	O
to	O
the	O
same	O
degree	O
as	O
oral	O
streptococci	B-bacteria
.	O

The	O
isolation	O
frequencies	O
of	O
opportunistic	O
bacteria	O
and	O
fungi	O
increase	O
during	O
orthodontic	O
treatment	O
,	O
suggesting	O
the	O
importance	O
of	O
paying	O
special	O
attention	O
to	O
oral	O
hygiene	O
in	O
orthodontic	O
patients	O
to	O
prevent	O
periodontal	O
disease	O
and	O
the	O
aggravation	O
of	O
systemic	O
disease	O
in	O
immunocompromised	O
conditions	O
.	O

Knowledge	O
of	O
the	O
early	O
oral	O
colonization	O
patterns	O
could	O
provide	O
a	O
better	O
understanding	O
of	O
oral	O
biofilm	O
development	O
and	O
disease	O
initiation	O
that	O
in	O
turn	O
could	O
be	O
the	O
basis	O
for	O
early	O
preventive	O
programmes	O
.	O

Microbial	O
samples	O
were	O
collected	O
from	O
five	O
different	O
oral	O
habitats	O
from	O
a	O
total	O
of	O
93	O
children	O
(	O
age	O
3	O
-	O
12	O
years	O
)	O
,	O
attending	O
the	O
Dental	O
School	O
of	O
the	O
University	O
of	O
Athens	O
,	O
who	O
were	O
split	O
into	O
three	O
age	O
groups	O
.	O

A	O
total	O
of	O
38	O
microbial	O
species	O
were	O
sought	O
out	O
by	O
the	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
technique	O
.	O

All	O
of	O
the	O
test	O
species	O
,	O
except	O
Parvimonas	B-bacteria
micra	I-bacteria
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
differed	O
significantly	O
among	O
sample	O
locations	O
providing	O
quite	O
distinct	O
microbial	O
profiles	O
for	O
the	O
different	O
oral	O
surfaces	O
.	O

Supragingival	O
and	O
subgingival	O
plaque	O
had	O
similar	O
profiles	O
and	O
exhibited	O
higher	O
proportions	O
of	O
Actinomyces	B-bacteria
species	I-bacteria
and	O
Green	O
complex	O
while	O
soft	O
tissue	O
samples	O
were	O
dominated	O
by	O
streptococci	B-bacteria
of	O
the	O
Yellow	O
complex	O
.	O

The	O
profiles	O
of	O
the	O
tongue	O
dorsum	O
and	O
saliva	O
were	O
also	O
similar	O
.	O

Many	O
of	O
the	O
species	O
were	O
in	O
similar	O
proportions	O
in	O
all	O
three	O
age	O
groups	O
for	O
a	O
given	O
location	O
.	O

Periodontal	O
pathogens	O
showed	O
increases	O
in	O
proportions	O
with	O
increasing	O
age	O
.	O

Specifically	O
,	O
the	O
Red	O
complex	O
species	O
(	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
)	O
showed	O
a	O
significant	O
increase	O
in	O
proportion	O
with	O
age	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
all	O
sample	O
locations	O
.	O

The	O
results	O
showed	O
a	O
pattern	O
of	O
colonization	O
in	O
children	O
similar	O
to	O
that	O
previously	O
found	O
in	O
adults	O
.	O

Differences	O
in	O
the	O
profile	O
between	O
age	O
groups	O
suggest	O
a	O
gradual	O
maturation	O
of	O
the	O
oral	O
microbiota	O
,	O
with	O
it	O
being	O
made	O
up	O
of	O
an	O
increasing	O
number	O
of	O
Orange	O
and	O
Red	O
complex	O
species	O
.	O

We	O
investigated	O
receptor	O
activator	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
ligand	O
(	O
RANKL	O
)	O
expression	O
by	O
B	O
lymphocytes	O
during	O
early	O
and	O
late	O
aspects	O
of	O
the	O
immune	O
response	O
to	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
a	O
gram	O
-	O
negative	O
,	O
anaerobic	O
bacterium	O
associated	O
with	O
aggressive	O
periodontal	O
disease	O
.	O

Expression	O
of	O
messenger	O
RNA	O
transcripts	O
(	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
Toll	O
-	O
like	O
receptors	O
4	O
and	O
9	O
,	O
interleukins	O
4	O
and	O
10	O
,	O
and	O
RANKL	O
)	O
involved	O
in	O
early	O
(	O
1	O
-	O
day	O
)	O
and	O
late	O
(	O
10	O
-	O
day	O
)	O
responses	O
in	O
cultured	O
rat	O
splenocytes	O
was	O
examined	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

The	O
immune	O
cell	O
distribution	O
(	O
T	O
,	O
B	O
,	O
and	O
natural	O
killer	O
cells	O
and	O
macrophages	O
)	O
in	O
cultured	O
rat	O
splenocytes	O
and	O
RANKL	O
expression	O
in	O
B	O
cells	O
were	O
determined	O
by	O
flow	O
cytometric	O
analyses	O
.	O

B	O
-	O
cell	O
capacity	O
for	O
induction	O
of	O
osteoclast	O
differentiation	O
was	O
evaluated	O
by	O
coculture	O
with	O
RAW	O
264	O
.	O
7	O
cells	O
followed	O
by	O
a	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
(	O
TRAP	O
)	O
activity	O
assay	O
.	O

The	O
expression	O
levels	O
of	O
interleukins	O
4	O
and	O
10	O
in	O
cultured	O
cells	O
were	O
not	O
changed	O
in	O
the	O
presence	O
of	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
until	O
cultured	O
for	O
3	O
days	O
,	O
and	O
peaked	O
after	O
7	O
days	O
.	O

After	O
culture	O
for	O
10	O
days	O
,	O
the	O
percentages	O
of	O
B	O
and	O
T	O
cells	O
,	O
the	O
overall	O
RANKL	O
messenger	O
RNA	O
transcripts	O
,	O
and	O
the	O
percentage	O
of	O
RANKL	O
-	O
expressing	O
immunoglobulin	O
G	O
-	O
positive	O
cells	O
were	O
significantly	O
increased	O
in	O
the	O
presence	O
of	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
.	O

These	O
increases	O
were	O
considerably	O
greater	O
in	O
cells	O
isolated	O
from	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
-	O
immunized	O
animals	O
than	O
from	O
non	O
-	O
immunized	O
animals	O
.	O

RAW	O
264	O
.	O
7	O
cells	O
demonstrated	O
significantly	O
increased	O
TRAP	O
activity	O
when	O
cocultured	O
with	O
B	O
cells	O
from	O
A	O
.	O
actinomycetemcomitans	O
-	O
immunized	O
animals	O
.	O

The	O
addition	O
of	O
human	O
osteoprotegerin	O
-	O
Fc	O
to	O
the	O
culture	O
significantly	O
diminished	O
such	O
increases	O
.	O

This	O
study	O
suggests	O
that	O
B	O
-	O
lymphocyte	O
involvement	O
in	O
the	O
immune	O
response	O
to	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
through	O
upregulation	O
of	O
RANKL	O
expression	O
potentially	O
contribute	O
to	O
bone	O
resorption	O
in	O
periodontal	O
disease	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
infection	O
is	O
very	O
prevalent	O
in	O
Brazil	O
,	O
infecting	O
almost	O
65	O
%	O
of	O
the	O
population	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
presence	O
of	O
this	O
bacterium	O
in	O
the	O
oral	O
cavity	O
of	O
patients	O
with	O
functional	O
dyspepsia	O
(	O
epigastric	O
pain	O
syndrome	O
)	O
,	O
establish	O
the	O
main	O
sites	O
of	O
infection	O
in	O
the	O
mouth	O
,	O
and	O
assess	O
the	O
frequency	O
of	O
cagA	O
and	O
vacA	O
genotypes	O
of	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

All	O
43	O
outpatients	O
with	O
epigastric	O
pain	O
syndrome	O
,	O
who	O
entered	O
the	O
study	O
,	O
were	O
submitted	O
to	O
upper	O
gastrointestinal	O
endoscopy	O
to	O
rule	O
out	O
organic	O
diseases	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
infection	O
in	O
the	O
stomach	O
was	O
confirmed	O
by	O
a	O
rapid	O
urease	O
test	O
and	O
urea	O
breath	O
tests	O
.	O

Samples	O
of	O
saliva	O
,	O
the	O
tongue	O
dorsum	O
and	O
supragingival	O
dental	O
plaque	O
were	O
collected	O
from	O
the	O
oral	O
cavity	O
of	O
each	O
subject	O
and	O
subgingival	O
dental	O
plaque	O
samples	O
were	O
collected	O
from	O
the	O
patients	O
with	O
periodontitis	O
;	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
was	O
verified	O
by	O
polymerase	O
chain	O
reaction	O
using	O
primers	O
that	O
amplify	O
the	O
DNA	O
sequence	O
of	O
a	O
species	O
-	O
specific	O
antigen	O
present	O
in	O
all	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
strains	I-bacteria
;	O
primers	O
that	O
amplify	O
a	O
region	O
of	O
urease	O
gene	O
,	O
and	O
primers	O
for	O
cagA	O
and	O
vacA	O
(	O
m1	O
,	O
m2	O
,	O
s1a	O
,	O
s1b	O
,	O
s2	O
)	O
genotyping	O
.	O

Thirty	O
patients	O
harbored	O
H	O
.	O
pylori	O
in	O
the	O
stomach	O
,	O
but	O
it	O
was	O
not	O
possible	O
to	O
detect	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
any	O
oral	O
samples	O
using	O
P1	O
/	O
P2	O
and	O
Urease	O
A	O
/	O
B	O
.	O

The	O
genotype	O
cagA	O
was	O
also	O
negative	O
in	O
all	O
samples	O
and	O
vacA	O
genotype	O
could	O
not	O
be	O
characterized	O
(	O
s	O
-	O
m	O
-	O
)	O
.	O

The	O
oral	O
cavity	O
may	O
not	O
be	O
a	O
reservoir	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
patients	O
with	O
epigastric	O
pain	O
syndrome	O
,	O
the	O
bacterium	O
being	O
detected	O
exclusively	O
in	O
the	O
stomach	O
.	O

Streptococcus	B-bacteria
oralis	I-bacteria
is	O
a	O
member	O
of	O
the	O
normal	O
human	O
oral	O
microbiota	O
,	O
capable	O
of	O
opportunistic	O
pathogenicity	O
;	O
like	O
related	O
oral	O
streptococci	B-bacteria
,	O
it	O
exhibits	O
appreciable	O
phenotypic	O
and	O
genetic	O
variation	O
.	O

A	O
multilocus	O
sequence	O
typing	O
(	O
MLST	O
)	O
scheme	O
for	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
was	O
developed	O
and	O
the	O
resultant	O
data	O
analysed	O
to	O
examine	O
the	O
population	O
structure	O
of	O
the	O
species	O
.	O

Analysis	O
of	O
113	O
isolates	O
,	O
confirmed	O
as	O
belonging	O
to	O
the	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
/	I-bacteria
mitis	I-bacteria
group	O
by	O
16S	O
rRNA	O
gene	O
sequencing	O
,	O
characterized	O
the	O
population	O
as	O
highly	O
diverse	O
and	O
undergoing	O
inter	O
-	O
and	O
intra	O
-	O
species	O
recombination	O
with	O
a	O
probable	O
clonal	O
complex	O
structure	O
.	O

ClonalFrame	O
analysis	O
of	O
these	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
isolates	I-bacteria
along	O
with	O
examples	O
of	O
Streptococcus	B-bacteria
pneumoniae	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
and	O
Streptococcus	B-bacteria
pseudopneumoniae	I-bacteria
grouped	O
the	O
named	O
species	O
into	O
distinct	O
,	O
coherent	O
populations	O
and	O
did	O
not	O
support	O
the	O
clustering	O
of	O
S	B-bacteria
.	I-bacteria
pseudopneumoniae	I-bacteria
with	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
as	O
reported	O
previously	O
using	O
distance	O
-	O
based	O
methods	O
.	O

Analysis	O
of	O
the	O
individual	O
loci	O
suggested	O
that	O
this	O
discrepancy	O
was	O
due	O
to	O
the	O
possible	O
hybrid	O
nature	O
of	O
S	B-bacteria
.	I-bacteria
pseudopneumoniae	I-bacteria
.	O

This	O
randomized	O
clinical	O
trial	O
evaluated	O
the	O
effects	O
of	O
an	O
essential	O
oils	O
-	O
containing	O
mouthrinse	O
for	O
full	O
-	O
mouth	O
disinfection	O
.	O

Fifty	O
patients	O
were	O
assigned	O
to	O
receive	O
full	O
-	O
mouth	O
disinfection	O
with	O
either	O
essential	O
oils	O
or	O
placebo	O
.	O

At	O
baseline	O
,	O
2	O
and	O
6	O
months	O
of	O
treatment	O
the	O
primary	O
outcomes	O
probing	O
depth	O
(	O
PD	O
)	O
,	O
plaque	O
index	O
(	O
PlI	O
)	O
and	O
modified	O
gingival	O
index	O
(	O
MGI	O
)	O
were	O
monitored	O
.	O

Additional	O
monitoring	O
included	O
bacterial	O
presence	O
(	O
by	O
polymerase	O
chain	O
reaction	O
)	O
in	O
subgingival	O
,	O
saliva	O
and	O
tongue	O
samples	O
;	O
flows	O
,	O
pH	O
,	O
total	O
protein	O
and	O
alkaline	O
phosphatase	O
salivary	O
levels	O
.	O

The	O
following	O
statistics	O
were	O
used	O
:	O
ANOVA	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
,	O
chi	O
(	O
2	O
)	O
and	O
Kruskal	O
-	O
Wallis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Mean	O
PD	O
>	O
or	O
=	O
3	O
.	O
5	O
mm	O
was	O
reduced	O
over	O
time	O
in	O
both	O
the	O
placebo	O
and	O
the	O
test	O
groups	O
,	O
but	O
there	O
was	O
no	O
difference	O
in	O
PD	O
reduction	O
between	O
groups	O
at	O
2	O
and	O
6	O
months	O
.	O

At	O
2	O
and	O
6	O
months	O
,	O
PlI	O
and	O
MGI	O
showed	O
greater	O
reductions	O
in	O
the	O
test	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

Porphyromona	B-bacteria
gingivalis	I-bacteria
was	O
not	O
reduced	O
in	O
any	O
site	O
.	O

At	O
6	O
months	O
,	O
Campylobacter	B-bacteria
rectus	I-bacteria
increased	O
in	O
both	O
groups	O
,	O
while	O
Tannerella	B-bacteria
forsythensis	I-bacteria
decreased	O
subgingivally	O
in	O
the	O
test	O
group	O
.	O

S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
increased	O
,	O
except	O
subgingivally	O
,	O
in	O
the	O
placebo	O
group	O
.	O

Salivary	O
pH	O
and	O
flows	O
were	O
not	O
altered	O
.	O

Total	O
protein	O
reduced	O
only	O
in	O
the	O
test	O
group	O
.	O

Alkaline	O
phosphatase	O
did	O
not	O
change	O
in	O
either	O
group	O
.	O

Essential	O
oils	O
for	O
full	O
-	O
mouth	O
disinfection	O
showed	O
clinical	O
benefits	O
,	O
namely	O
reducing	O
plaque	O
and	O
gingival	O
inflammation	O
without	O
altering	O
basic	O
salivary	O
parameters	O
.	O

To	O
purify	O
and	O
partially	O
characterize	O
a	O
bacteriocin	O
produced	O
by	O
a	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
strain	I-bacteria
.	O
Following	O
protein	O
precipitation	O
the	O
effect	O
of	O
different	O
treatments	O
on	O
a	O
bacteriocin	O
produced	O
by	O
a	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
strain	I-bacteria
named	O
P12	B-bacteria
.	I-bacteria
2	I-bacteria
isolated	O
from	O
a	O
patient	O
with	O
periodontitis	O
was	O
evaluated	O
.	O

The	O
antagonistic	O
activity	O
of	O
the	O
intracellular	O
fraction	O
obtained	O
at	O
80	O
%	O
ammonium	O
sulphate	O
was	O
preserved	O
at	O
pH	O
values	O
from	O
6	O
.	O
0	O
to	O
9	O
.	O
0	O
and	O
showed	O
to	O
be	O
sensitive	O
to	O
high	O
temperatures	O
and	O
to	O
treatment	O
with	O
proteases	O
.	O

The	O
fraction	O
was	O
submitted	O
to	O
sequential	O
steps	O
of	O
gel	O
filtration	O
,	O
ion	O
exchange	O
,	O
and	O
reverse	O
phase	O
chromatography	O
,	O
and	O
SDS	O
-	O
PAGE	O
.	O

Data	O
obtained	O
by	O
mass	O
spectrometry	O
revealed	O
that	O
the	O
molecular	O
mass	O
of	O
the	O
protein	O
was	O
27	O
,	O
296	O
Da	O
.	O

For	O
the	O
first	O
time	O
a	O
bacteriocin	O
produced	O
by	O
a	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
strain	I-bacteria
was	O
purified	O
and	O
characterized	O
.	O

This	O
is	O
the	O
first	O
description	O
on	O
characterization	O
of	O
a	O
bacteriocin	O
produced	O
by	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
.	O

It	O
is	O
possible	O
that	O
the	O
bacteriocin	O
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
population	O
levels	O
of	O
periodontopathic	O
organisms	O
.	O

Bacteria	O
settled	O
in	O
the	O
apical	O
root	O
canal	O
are	O
in	O
a	O
privileged	O
position	O
to	O
inflict	O
damage	O
to	O
the	O
periradicular	O
tissues	O
.	O

Therefore	O
,	O
the	O
species	O
identified	O
in	O
this	O
region	O
can	O
be	O
of	O
special	O
relevance	O
for	O
the	O
pathogenesis	O
of	O
apical	O
periodontitis	O
.	O

This	O
study	O
investigated	O
the	O
occurrence	O
and	O
levels	O
of	O
several	O
bacterial	O
taxa	O
in	O
the	O
apical	O
root	O
canal	O
of	O
teeth	O
with	O
apical	O
periodontitis	O
.	O

DNA	O
extracts	O
from	O
samples	O
taken	O
from	O
the	O
apical	O
part	O
of	O
the	O
root	O
canal	O
of	O
extracted	O
teeth	O
evincing	O
chronic	O
apical	O
periodontitis	O
lesions	O
served	O
as	O
templates	O
for	O
analysis	O
of	O
the	O
presence	O
and	O
levels	O
of	O
28	O
bacterial	O
species	O
/	O
phylotypes	O
using	O
a	O
16S	O
ribosomal	O
RNA	O
gene	O
-	O
based	O
reverse	O
-	O
capture	O
checkerboard	O
hybridization	O
assay	O
.	O

Bacterial	O
DNA	O
was	O
detected	O
in	O
19	O
out	O
of	O
20	O
samples	O
.	O

Detected	O
taxa	O
included	O
Pseudoramibacter	B-bacteria
alactolyticus	I-bacteria
(	O
32	O
%	O
)	O
,	O
Bacteroidetes	B-bacteria
clone	I-bacteria
X083	I-bacteria
(	O
26	O
%	O
)	O
,	O
Streptococcus	B-bacteria
species	I-bacteria
(	O
21	O
%	O
)	O
,	O
Olsenella	B-bacteria
uli	I-bacteria
(	O
10	O
.	O
5	O
%	O
)	O
,	O
Synergistes	B-bacteria
clone	I-bacteria
BA121	I-bacteria
(	O
10	O
.	O
5	O
%	O
)	O
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
(	O
10	O
.	O
5	O
%	O
)	O
,	O
Porphyromonas	B-bacteria
endodontalis	I-bacteria
(	O
10	O
.	O
5	O
%	O
)	O
,	O
Dialister	B-bacteria
clone	I-bacteria
BS016	I-bacteria
(	O
5	O
%	O
)	O
,	O
Filifactor	B-bacteria
alocis	I-bacteria
(	O
5	O
%	O
)	O
,	O
Parvimonas	B-bacteria
micra	I-bacteria
(	O
5	O
%	O
)	O
,	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
(	O
5	O
%	O
)	O
.	O

Of	O
these	O
,	O
only	O
Bacteroidetes	B-bacteria
clone	I-bacteria
X083	I-bacteria
and	O
Synergistes	B-bacteria
clone	I-bacteria
BA121	I-bacteria
were	O
found	O
at	O
levels	O
above	O
10	O
(	O
5	O
)	O
.	O

Occurrence	O
of	O
these	O
bacterial	O
taxa	O
in	O
the	O
apical	O
part	O
of	O
infected	O
root	O
canals	O
indicates	O
their	O
potential	O
pathogenetic	O
role	O
in	O
the	O
etiology	O
of	O
apical	O
periodontitis	O
.	O

The	O
oral	O
microbial	O
flora	O
comprises	O
one	O
of	O
the	O
most	O
diverse	O
human	O
-	O
associated	O
biofilms	O
.	O

Its	O
development	O
is	O
heavily	O
influenced	O
by	O
oral	O
streptococci	B-bacteria
,	O
which	O
are	O
considered	O
the	O
main	O
group	O
of	O
early	O
colonizers	O
.	O

Their	O
initial	O
attachment	O
determines	O
the	O
composition	O
of	O
later	O
colonizers	O
in	O
the	O
oral	O
biofilm	O
and	O
impacts	O
the	O
health	O
or	O
disease	O
status	O
of	O
the	O
host	O
.	O

Thus	O
,	O
the	O
role	O
of	O
streptococci	B-bacteria
in	O
the	O
development	O
of	O
oral	O
diseases	O
is	O
best	O
described	O
in	O
the	O
context	O
of	O
bacterial	O
ecology	O
,	O
which	O
itself	O
is	O
further	O
influenced	O
by	O
interactions	O
with	O
host	O
epithelial	O
cells	O
,	O
the	O
immune	O
system	O
,	O
and	O
salivary	O
components	O
.	O

The	O
tractability	O
of	O
the	O
oral	O
biofilm	O
makes	O
it	O
an	O
excellent	O
model	O
system	O
for	O
studies	O
of	O
complex	O
,	O
biofilm	O
-	O
associated	O
polymicrobial	O
diseases	O
.	O

Using	O
this	O
system	O
,	O
numerous	O
cooperative	O
and	O
antagonistic	O
bacterial	O
interactions	O
have	O
been	O
demonstrated	O
to	O
occur	O
within	O
the	O
community	O
and	O
with	O
the	O
host	O
.	O

In	O
this	O
review	O
,	O
several	O
recent	O
identified	O
interactions	O
are	O
presented	O
.	O

The	O
oral	O
microbial	O
consortium	O
is	O
the	O
most	O
characterized	O
polymicrobial	O
microbial	O
community	O
associated	O
with	O
the	O
human	O
host	O
.	O

Extensive	O
sampling	O
of	O
both	O
microbial	O
and	O
tissue	O
samples	O
has	O
demonstrated	O
that	O
there	O
is	O
a	O
strong	O
association	O
between	O
the	O
type	O
of	O
microbial	O
community	O
found	O
in	O
the	O
gingival	O
crevice	O
and	O
the	O
status	O
of	O
innate	O
host	O
mediator	O
expression	O
.	O

The	O
strong	O
clinical	O
association	O
between	O
the	O
microbial	O
community	O
and	O
the	O
innate	O
host	O
response	O
in	O
both	O
clinically	O
healthy	O
and	O
diseased	O
tissue	O
suggests	O
that	O
the	O
oral	O
consortium	O
has	O
a	O
direct	O
effect	O
on	O
periodontal	O
tissue	O
expression	O
of	O
innate	O
defense	O
mediators	O
.	O

A	O
preliminary	O
study	O
in	O
germ	O
-	O
free	O
mice	O
has	O
demonstrated	O
that	O
the	O
oral	O
commensal	O
consortium	O
has	O
direct	O
effect	O
on	O
IL	O
-	O
1beta	O
expression	O
,	O
indicating	O
that	O
this	O
microbial	O
community	O
may	O
contribute	O
to	O
the	O
strong	O
protective	O
status	O
of	O
healthy	O
gingival	O
tissue	O
.	O

Likewise	O
,	O
the	O
lipopolysaccharide	O
composition	O
and	O
invasion	O
characteristics	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
an	O
oral	O
bacterium	O
strongly	O
associated	O
with	O
periodontitis	O
,	O
suggest	O
that	O
it	O
may	O
be	O
a	O
keystone	O
member	O
of	O
the	O
oral	O
microbial	O
community	O
and	O
facilitate	O
a	O
destructive	O
change	O
in	O
the	O
protective	O
gingival	O
innate	O
host	O
status	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
whether	O
the	O
oral	O
administration	O
of	O
lactobacilli	B-bacteria
could	O
change	O
the	O
bacterial	O
population	O
in	O
supra	O
/	O
subgingival	O
plaque	O
.	O

Sixty	O
-	O
six	O
healthy	O
volunteers	O
without	O
severe	O
periodontitis	O
were	O
randomized	O
into	O
two	O
groups	O
to	O
receive	O
lactobacilli	B-bacteria
or	O
placebo	O
for	O
8	O
weeks	O
(	O
8W	O
)	O
:	O
the	O
test	O
group	O
(	O
n	O
=	O
34	O
)	O
received	O
2	O
.	O
01	O
x	O
10	O
(	O
9	O
)	O
CFU	O
/	O
day	O
of	O
Lactobacillus	B-bacteria
salivarius	I-bacteria
WB21	I-bacteria
and	O
xylitol	O
in	O
tablets	O
;	O
the	O
control	O
group	O
(	O
n	O
=	O
32	O
)	O
received	O
placebo	O
with	O
xylitol	O
.	O

Supra	O
/	O
subgingival	O
plaque	O
samples	O
were	O
collected	O
at	O
the	O
baseline	O
and	O
after	O
4	O
weeks	O
(	O
4W	O
)	O
and	O
8W	O
.	O

The	O
bacterial	O
amounts	O
in	O
plaque	O
samples	O
were	O
analysed	O
by	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

The	O
numerical	O
sum	O
of	O
five	O
selected	O
periodontopathic	O
bacteria	O
in	O
the	O
test	O
group	O
was	O
decreased	O
significantly	O
in	O
subgingival	O
plaque	O
at	O
4W	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
3	O
.	O
13	O
,	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
=	O
1	O
.	O
28	O
-	O
7	O
.	O
65	O
,	O
p	O
=	O
0	O
.	O
012	O
]	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
significantly	O
higher	O
odds	O
were	O
obtained	O
for	O
the	O
reduction	O
of	O
Tannerella	B-bacteria
forsythia	I-bacteria
in	O
subgingival	O
plaque	O
of	O
the	O
test	O
group	O
at	O
both	O
4W	O
(	O
OR	O
=	O
6	O
.	O
69	O
,	O
95	O
%	O
CI	O
=	O
2	O
.	O
51	O
-	O
17	O
.	O
9	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
8W	O
(	O
OR	O
=	O
3	O
.	O
67	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
45	O
-	O
9	O
.	O
26	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

Oral	O
administration	O
of	O
probiotic	O
lactobacilli	B-bacteria
reduced	O
the	O
numerical	O
sum	O
of	O
five	O
selected	O
periodontopathic	O
bacteria	O
and	O
could	O
contribute	O
to	O
the	O
beneficial	O
effects	O
on	O
periodontal	O
conditions	O
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
is	O
a	O
periodontal	O
pathogen	O
that	O
resides	O
in	O
a	O
complex	O
multispecies	O
microbial	O
biofilm	O
community	O
known	O
as	O
dental	O
plaque	O
.	O

Confocal	O
laser	O
scanning	O
microscopy	O
showed	O
that	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
can	O
assemble	O
into	O
communities	O
in	O
vitro	O
with	O
Streptococcus	B-bacteria
gordonii	I-bacteria
and	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
common	O
constituents	O
of	O
dental	O
plaque	O
.	O

Whole	O
cell	O
quantitative	O
proteomics	O
,	O
along	O
with	O
mutant	O
construction	O
and	O
analysis	O
,	O
were	O
conducted	O
to	O
investigate	O
how	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
adapts	O
to	O
this	O
three	O
species	O
community	O
.	O

1156	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
proteins	O
were	O
detected	O
qualitatively	O
during	O
comparison	O
of	O
the	O
three	O
species	O
model	O
community	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
incubated	O
alone	O
under	O
the	O
same	O
conditions	O
.	O

Integration	O
of	O
spectral	O
counting	O
and	O
summed	O
signal	O
intensity	O
analyses	O
of	O
the	O
dataset	O
showed	O
that	O
403	O
proteins	O
were	O
down	O
-	O
regulated	O
and	O
89	O
proteins	O
up	O
-	O
regulated	O
.	O

The	O
proteomics	O
results	O
were	O
inspected	O
manually	O
and	O
an	O
ontology	O
analysis	O
conducted	O
using	O
DAVID	O
.	O

Significant	O
decreases	O
were	O
seen	O
in	O
proteins	O
involved	O
in	O
cell	O
shape	O
and	O
the	O
formation	O
of	O
the	O
cell	O
envelope	O
,	O
as	O
well	O
as	O
thiamine	O
,	O
cobalamin	O
,	O
and	O
pyrimidine	O
synthesis	O
and	O
DNA	O
repair	O
.	O

An	O
overall	O
increase	O
was	O
seen	O
in	O
proteins	O
involved	O
in	O
protein	O
synthesis	O
.	O

HmuR	O
,	O
a	O
TonB	O
dependent	O
outer	O
membrane	O
receptor	O
,	O
was	O
up	O
-	O
regulated	O
in	O
the	O
community	O
and	O
an	O
hmuR	O
deficient	O
mutant	O
was	O
deficient	O
in	O
three	O
species	O
community	O
formation	O
,	O
but	O
was	O
unimpaired	O
in	O
its	O
ability	O
to	O
form	O
mono	O
-	O
or	O
dual	O
-	O
species	O
biofilms	O
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
can	O
assemble	O
into	O
a	O
heterotypic	O
community	O
with	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
,	O
and	O
that	O
a	O
community	O
lifestyle	O
provides	O
physiologic	O
support	O
for	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

Proteins	O
such	O
as	O
HmuR	O
,	O
that	O
are	O
up	O
-	O
regulated	O
,	O
can	O
be	O
necessary	O
for	O
community	O
structure	O
.	O

To	O
investigate	O
the	O
correlation	O
between	O
the	O
changes	O
in	O
oral	O
microflora	O
and	O
recurrent	O
oral	O
ulcers	O
(	O
ROU	O
)	O
.	O

Salivary	O
sample	O
were	O
collected	O
from	O
ROU	O
patients	O
with	O
oral	O
ulcers	O
(	O
group	O
T	O
)	O
and	O
those	O
with	O
ulcer	O
healing	O
(	O
group	O
C	O
)	O
as	O
well	O
as	O
from	O
ROU	O
-	O
free	O
individuals	O
(	O
group	O
N	O
)	O
.	O

The	O
quantity	O
of	O
3	O
common	O
bacteria	O
(	O
Streptococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Veillonella	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
and	O
Neisseria	B-bacteria
sp	I-bacteria
.	I-bacteria
)	O

in	O
the	O
salivary	O
samples	O
was	O
detected	O
and	O
compared	O
between	O
the	O
3	O
groups	O
.	O

The	O
quantities	O
of	O
Streptococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
(	O
7	O
.	O
30	O
-	O
/	O
+	O
0	O
.	O
89	O
copies	O
/	O
ml	O
)	O
and	O
Veillonella	B-bacteria
sp	I-bacteria
.	I-bacteria
(	O
8	O
.	O
29	O
-	O
/	O
+	O
0	O
.	O
77	O
copies	O
/	O
ml	O
)	O
in	O
group	O
T	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
group	O
N	O
(	O
8	O
.	O
15	O
-	O
/	O
+	O
0	O
.	O
55	O
and	O
8	O
.	O
93	O
-	O
/	O
+	O
0	O
.	O
76	O
copies	O
/	O
ml	O
,	O
respectively	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
but	O
similar	O
with	O
those	O
in	O
group	O
C	O
.	O
The	O
quantity	O
of	O
Streptococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
(	O
7	O
.	O
51	O
-	O
/	O
+	O
0	O
.	O
81	O
copies	O
/	O
ml	O
)	O
in	O
group	O
C	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
group	O
N	O
(	O
8	O
.	O
15	O
-	O
/	O
+	O
0	O
.	O
55	O
copies	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
but	O
the	O
quantity	O
of	O
Veillonella	B-bacteria
sp	I-bacteria
.	I-bacteria
was	O
similar	O
between	O
the	O
two	O
groups	O
.	O

No	O
significant	O
difference	O
were	O
found	O
in	O
the	O
quantity	O
of	O
Neisseria	B-bacteria
sp	I-bacteria
.	I-bacteria
between	O
the	O
3	O
groups	O
.	O

The	O
quantity	O
of	O
oral	O
microflora	O
differs	O
significantly	O
between	O
patients	O
with	O
recurrent	O
oral	O
ulcers	O
and	O
normal	O
individuals	O
,	O
suggesting	O
a	O
possible	O
correlation	O
between	O
oral	O
microfora	O
and	O
recurrent	O
oral	O
ulcers	O
.	O

Separation	O
of	O
bacterial	O
DNA	O
from	O
human	O
DNA	O
in	O
clinical	O
samples	O
may	O
have	O
an	O
important	O
impact	O
on	O
downstream	O
applications	O
,	O
involving	O
microbial	O
diagnostic	O
systems	O
.	O

We	O
evaluated	O
two	O
commercially	O
available	O
reagents	O
(	O
MolYsis	O
)	O
,	O
Molzym	O
GmbH	O
&	O
Co	O
.	O
KG	O
,	O
Bremen	O
and	O
Pureprove	O
,	O
SIRS	O
-	O
Lab	O
GmbH	O
,	O
Jena	O
,	O
both	O
Germany	O
)	O
for	O
their	O
potential	O
to	O
isolate	O
and	O
purify	O
bacterial	O
DNA	O
from	O
human	O
DNA	O
.	O

We	O
chose	O
oral	O
samples	O
,	O
which	O
usually	O
contain	O
very	O
high	O
amounts	O
of	O
both	O
human	O
and	O
bacterial	O
cells	O
.	O

Three	O
different	O
DNA	O
preparations	O
each	O
were	O
made	O
from	O
eight	O
caries	O
and	O
eight	O
periodontal	O
specimens	O
using	O
the	O
two	O
reagents	O
above	O
and	O
a	O
conventional	O
DNA	O
extraction	O
strategy	O
as	O
reference	O
.	O

Based	O
on	O
target	O
-	O
specific	O
real	O
-	O
time	O
-	O
quantitative	O
PCR	O
assays	O
we	O
compared	O
the	O
reduction	O
of	O
human	O
DNA	O
versus	O
loss	O
of	O
bacterial	O
DNA	O
.	O

Human	O
DNA	O
was	O
monitored	O
by	O
targeting	O
the	O
beta	O
-	O
2	O
-	O
microglobulin	O
gene	O
,	O
while	O
bacteria	O
were	O
monitored	O
by	O
targeting	O
16S	O
rDNA	O
(	O
total	O
bacteria	O
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
)	O
or	O
the	O
glycosyltransferase	O
gene	O
(	O
Streptococcus	B-bacteria
mutans	I-bacteria
)	O
.	O

We	O
found	O
that	O
in	O
most	O
cases	O
at	O
least	O
90	O
%	O
of	O
human	O
DNA	O
could	O
successfully	O
be	O
removed	O
,	O
with	O
complete	O
removal	O
in	O
eight	O
of	O
16	O
cases	O
using	O
MolYsis	O
,	O
and	O
two	O
(	O
of	O
16	O
)	O
cases	O
using	O
Pureprove	O
.	O

Conversely	O
,	O
detection	O
of	O
bacterial	O
DNA	O
was	O
possible	O
in	O
all	O
cases	O
with	O
a	O
recovery	O
rate	O
generally	O
ranging	O
from	O
35	O
%	O
to	O
50	O
%	O
.	O

In	O
conclusion	O
,	O
both	O
strategies	O
have	O
the	O
potential	O
to	O
reduce	O
background	O
interference	O
from	O
the	O
host	O
DNA	O
which	O
may	O
be	O
of	O
remarkable	O
value	O
for	O
nucleic	O
-	O
acid	O
based	O
microbial	O
diagnostic	O
systems	O
.	O

To	O
evaluate	O
the	O
in	O
vitro	O
abilities	O
of	O
probiotic	O
bacteria	O
derived	O
from	O
consumer	O
products	O
to	O
coaggregate	O
with	O
caries	O
-	O
associated	O
mutans	B-bacteria
streptococci	I-bacteria
.	O

Six	O
lactobacillus	B-bacteria
strains	I-bacteria
(	O
L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
(	O
CCUG	B-bacteria
5917	I-bacteria
)	O
,	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
299v	I-bacteria
,	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
GG	I-bacteria
and	O
LB21	B-bacteria
,	O
L	B-bacteria
.	I-bacteria
paracasei	I-bacteria
F19	I-bacteria
,	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
PTA5289	I-bacteria
)	O
were	O
cultivated	O
under	O
anaerobic	O
conditions	O
at	O
37	O
degrees	O
C	O
in	O
Man	O
Rogosa	O
Sharpe	O
(	O
MSB	O
)	O
broth	O
for	O
24	O
h	O
.	O
Four	O
strains	O
of	O
human	O
streptococci	B-bacteria
(	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
Ingbritt	O
,	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
(	O
ATCC	B-bacteria
25175	I-bacteria
)	O
,	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
GS	I-bacteria
-	I-bacteria
5	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
sobrinus	I-bacteria
(	O
ATCC	B-bacteria
33478	I-bacteria
)	O
were	O
similarly	O
grown	O
in	O
Brain	O
Heart	O
Infusion	O
(	O
BHI	O
)	O
broth	O
.	O

A	O
gastrointestinal	O
pathogen	O
(	O
Escherichia	B-bacteria
coli	I-bacteria
)	O
was	O
aerobically	O
cultivated	O
on	O
BHI	O
broth	O
as	O
a	O
positive	O
control	O
.	O

After	O
incubation	O
,	O
the	O
bacteria	O
were	O
aerobically	O
harvested	O
,	O
washed	O
,	O
and	O
suspended	O
in	O
10	O
mmol	O
/	O
l	O
phosphate	O
-	O
buffered	O
saline	O
(	O
pH	O
7	O
.	O
2	O
)	O
.	O

The	O
probiotic	O
strains	O
were	O
characterized	O
with	O
the	O
API	O
50	O
CH	O
system	O
to	O
confirm	O
their	O
identity	O
.	O

Coaggregation	O
was	O
determined	O
by	O
spectrophotometry	O
in	O
mixtures	O
and	O
bacterial	O
suspensions	O
alone	O
after	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
24	O
h	O
and	O
expressed	O
as	O
the	O
aggregation	O
ratio	O
(	O
%	O
)	O
.	O

All	O
probiotic	O
strains	O
showed	O
coaggregation	O
abilities	O
with	O
the	O
oral	O
pathogens	O
and	O
the	O
results	O
were	O
strain	O
specific	O
and	O
dependent	O
on	O
time	O
.	O

S	B-bacteria
.	I-bacteria
mutans	I-bacteria
GS	I-bacteria
-	I-bacteria
5	I-bacteria
exhibited	O
a	O
significantly	O
higher	O
ability	O
to	O
coaggregate	O
with	O
all	O
the	O
probiotic	O
strains	O
than	O
the	O
other	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
.	O

The	O
differences	O
among	O
the	O
probiotic	O
strains	O
were	O
modest	O
with	O
L	B-bacteria
.	I-bacteria
acidophilus	I-bacteria
being	O
the	O
most	O
prone	O
and	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
LB21	I-bacteria
the	O
least	O
prone	O
to	O
coaggregate	O
with	O
the	O
oral	O
streptococci	B-bacteria
.	O

The	O
results	O
demonstrated	O
different	O
abilities	O
of	O
lactobacilli	O
-	O
derived	O
probiotic	O
bacteria	O
to	O
coaggregate	O
with	O
selected	O
oral	O
streptococci	B-bacteria
.	O

Aggregation	O
assays	O
may	O
be	O
a	O
useful	O
complement	O
for	O
screening	O
of	O
probiotic	O
candidates	O
with	O
possible	O
anti	O
-	O
caries	O
properties	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
ATCC	I-bacteria
55730	I-bacteria
can	O
be	O
detected	O
in	O
the	O
oral	O
cavity	O
after	O
discontinuation	O
of	O
administration	O
of	O
a	O
product	O
prepared	O
with	O
this	O
bacterium	O
.	O

The	O
study	O
consisted	O
of	O
three	O
2	O
-	O
week	O
periods	O
:	O
clearance	O
period	O
,	O
intervention	O
period	O
,	O
and	O
post	O
-	O
treatment	O
period	O
.	O

Twenty	O
-	O
five	O
volunteers	O
consumed	O
a	O
chewable	O
tablet	O
of	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
ATCC	I-bacteria
55730	I-bacteria
(	O
10	O
(	O
8	O
)	O
cfu	O
/	O
tablet	O
)	O
during	O
a	O
14	O
-	O
day	O
trial	O
period	O
.	O

Saliva	O
samples	O
were	O
collected	O
and	O
cultured	O
onto	O
MRS	O
agar	O
after	O
a	O
clearance	O
period	O
of	O
2	O
weeks	O
and	O
then	O
daily	O
after	O
a	O
2	O
-	O
week	O
intervention	O
period	O
for	O
as	O
long	O
as	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
was	O
found	O
.	O

Lactobacillus	B-bacteria
reuteri	I-bacteria
colonies	O
were	O
analysed	O
in	O
saliva	O
samples	O
.	O

The	O
analysis	O
was	O
performed	O
using	O
selective	O
media	O
for	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
followed	O
by	O
confirmation	O
using	O
the	O
specific	O
detection	O
of	O
reuterin	O
produced	O
by	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
.	O

The	O
number	O
of	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
carriers	O
decreased	O
gradually	O
,	O
and	O
after	O
1	O
week	O
only	O
8	O
%	O
of	O
the	O
subjects	O
harboured	O
the	O
bacterium	O
.	O

After	O
5	O
weeks	O
,	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
was	O
not	O
detected	O
in	O
any	O
of	O
the	O
subjects	O
.	O

Consuming	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
for	O
2	O
weeks	O
does	O
not	O
seem	O
to	O
be	O
sufficient	O
for	O
permanent	O
colonization	O
of	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
in	O
the	O
oral	O
cavity	O
.	O

To	O
conduct	O
a	O
pilot	O
human	O
clinical	O
trial	O
to	O
assess	O
the	O
safety	O
and	O
to	O
test	O
the	O
ability	O
of	O
a	O
probiotic	O
mouthwash	O
,	O
ProBiora	O
(	O
3	O
)	O
,	O
to	O
affect	O
the	O
levels	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
certain	O
known	O
periodontal	O
pathogens	O
in	O
the	O
mouth	O
when	O
administered	O
twice	O
daily	O
over	O
a	O
period	O
of	O
4	O
weeks	O
.	O
The	O
mouthwash	O
contained	O
three	O
specific	O
strains	O
of	O
naturally	O
occurring	O
oral	O
bacteria	O
and	O
was	O
tested	O
at	O
two	O
dose	O
levels	O
:	O
10	O
(	O
6	O
)	O
and	O
10	O
(	O
8	O
)	O
colony	O
forming	O
units	O
each	O
of	O
Strep	B-bacteria
.	I-bacteria
oralis	I-bacteria
strain	I-bacteria
KJ3sm	I-bacteria
,	O
Strep	B-bacteria
.	I-bacteria
uberis	I-bacteria
strain	I-bacteria
KJ2sm	I-bacteria
,	O
and	O
the	O
spontaneous	O
lactic	O
acid	O
-	O
deficient	O
variant	O
of	O
Strep	B-bacteria
.	I-bacteria
rattus	I-bacteria
,	O
strain	O
JH145	B-bacteria
.	O

Substantial	O
decreases	O
in	O
the	O
levels	O
of	O
the	O
marker	O
bacteria	O
were	O
observed	O
.	O

No	O
safety	O
issues	O
were	O
noted	O
with	O
the	O
twice	O
daily	O
application	O
of	O
this	O
mouthwash	O
.	O

Despite	O
the	O
small	O
number	O
of	O
subjects	O
and	O
the	O
use	O
of	O
young	O
,	O
orally	O
healthy	O
adults	O
,	O
along	O
with	O
the	O
inherent	O
variability	O
in	O
the	O
microbiological	O
measurements	O
,	O
the	O
probiotic	O
mouthwash	O
was	O
able	O
to	O
substantially	O
affect	O
the	O
levels	O
of	O
dental	O
pathogens	O
in	O
saliva	O
and	O
periodontal	O
pathogens	O
in	O
subgingival	O
plaque	O
.	O

The	O
results	O
of	O
this	O
pilot	O
human	O
study	O
suggest	O
that	O
the	O
probiotic	O
mouthwash	O
product	O
may	O
be	O
safe	O
for	O
daily	O
use	O
as	O
an	O
aid	O
in	O
maintaining	O
both	O
dental	O
and	O
periodontal	O
health	O
.	O

Microbial	O
association	O
distinctive	O
features	O
and	O
colonization	O
degree	O
of	O
different	O
oral	O
cavity	O
biotope	O
were	O
established	O
in	O
healthy	O
teenagers	O
and	O
patients	O
with	O
chronic	O
gastritis	O
and	O
gastroduodenitis	O
.	O

There	O
were	O
studied	O
mucous	O
membrane	O
surfaces	O
of	O
cheek	O
,	O
tongue	O
,	O
content	O
of	O
gingival	O
crevice	O
,	O
oral	O
fluid	O
and	O
dental	O
plaque	O
of	O
24	O
healthy	O
persons	O
of	O
the	O
age	O
12	O
-	O
17	O
years	O
and	O
29	O
patients	O
of	O
the	O
same	O
age	O
with	O
gastritis	O
and	O
gastroduodenitis	O
.	O

On	O
the	O
mucous	O
membranes	O
of	O
the	O
ill	O
teenagers	O
there	O
were	O
found	O
Porphiromonas	O
type	O
bacteria	O
,	O
20	O
%	O
more	O
Staphylococcus	B-bacteria
,	O
90	O
%	O
less	O
Peptostreptococcus	B-bacteria
,	O
30	O
%	O
less	O
Lactobacillus	B-bacteria
,	O
20	O
%	O
less	O
Veillonella	B-bacteria
and	O
Stomatococcus	B-bacteria
.	O

In	O
saliva	O
anaerobic	O
Peptostreptococcus	B-bacteria
and	O
facultative	O
anaerobic	O
Streptococcus	B-bacteria
(	O
7	O
lg	O
COE	O
/	O
ml	O
)	O
;	O
Porphiromonas	B-bacteria
,	O
Veillonella	B-bacteria
,	O
Peptococcus	B-bacteria
and	O
Staphylococcus	B-bacteria
(	O
6	O
lg	O
COE	O
/	O
ml	O
)	O
;	O
Neisseria	B-bacteria
(	O
5	O
lg	O
COE	O
/	O
ml	O
)	O
;	O
Stomatococcus	B-bacteria
,	O
Enterobacteriaceae	B-bacteria
and	O
Bacillus	B-bacteria
(	O
4	O
.	O
6	O
lg	O
COE	O
/	O
ml	O
)	O
;	O
Lactobacillus	B-bacteria
and	O
Candida	O
(	O
4	O
lg	O
COE	O
/	O
ml	O
)	O
predominated	O
.	O

In	O
patients	O
with	O
chronic	O
pathology	O
in	O
all	O
tested	O
biotopes	O
there	O
was	O
found	O
the	O
increase	O
of	O
the	O
whole	O
microbiota	O
spectra	O
(	O
representatives	O
of	O
opportunistic	O
pathogenic	O
microfiora	O
were	O
detected	O
more	O
often	O
)	O
as	O
well	O
as	O
the	O
bacteria	O
number	O
if	O
compared	O
with	O
healthy	O
teenagers	O
.	O

Our	O
study	O
demonstrates	O
that	O
staurosporine	O
(	O
STS	O
)	O
,	O
a	O
protein	O
kinase	O
inhibitor	O
from	O
Streptomyces	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
induces	O
apoptosis	O
in	O
human	O
papillomavirus	O
positive	O
oral	O
carcinoma	O
cells	O
(	O
KB	O
)	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

Growth	O
inhibition	O
studies	O
revealed	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
approximately	O
100	O
nM	O
.	O

STS	O
induced	O
marked	O
nuclear	O
fragmentation	O
and	O
inter	O
-	O
nucleosomal	O
cleavage	O
compared	O
to	O
untreated	O
cells	O
.	O

It	O
also	O
caused	O
dose	O
dependent	O
disruption	O
of	O
mitochondrial	O
membrane	O
potential	O
and	O
activation	O
of	O
caspase	O
-	O
3	O
,	O
indicating	O
involvement	O
of	O
mitochondria	O
-	O
mediated	O
cell	O
death	O
signaling	O
in	O
KB	O
cell	O
apoptosis	O
.	O

We	O
found	O
time	O
-	O
dependent	O
arrest	O
of	O
the	O
KB	O
cells	O
at	O
G2	O
/	O
M	O
phase	O
of	O
cell	O
cycle	O
.	O

Using	O
fluorescence	O
microscopy	O
,	O
we	O
have	O
further	O
shown	O
that	O
STS	O
treatment	O
disrupts	O
microtubules	O
and	O
reorganizes	O
F	O
-	O
actin	O
after	O
6h	O
exposure	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
STS	O
induces	O
mitochondria	O
-	O
mediated	O
KB	O
cell	O
apoptosis	O
at	O
G2	O
/	O
M	O
phase	O
by	O
altering	O
cell	O
cytoskeletal	O
network	O
.	O

Bacterial	O
vaginosis	O
(	O
BV	O
)	O
is	O
a	O
common	O
condition	O
that	O
is	O
associated	O
with	O
preterm	O
birth	O
and	O
acquisition	O
of	O
complex	O
communities	O
of	O
vaginal	O
bacteria	O
that	O
include	O
several	O
fastidious	O
species	O
.	O

Treatment	O
of	O
BV	O
in	O
pregnancy	O
has	O
mixed	O
effects	O
on	O
the	O
risk	O
of	O
preterm	O
delivery	O
,	O
which	O
some	O
hypothesize	O
is	O
due	O
to	O
variable	O
antibiotic	O
efficacy	O
for	O
the	O
fastidious	O
bacteria	O
.	O

Both	O
oral	O
and	O
intravaginal	O
metronidazole	O
can	O
be	O
used	O
to	O
treat	O
bacterial	O
vaginosis	O
in	O
pregnancy	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
impact	O
of	O
different	O
routes	O
of	O
antibiotic	O
administration	O
on	O
concentrations	O
of	O
fastidious	O
vaginal	O
bacteria	O
.	O

This	O
was	O
a	O
sub	O
-	O
study	O
of	O
a	O
larger	O
randomized	O
trial	O
of	O
oral	O
versus	O
vaginal	O
metronidazole	O
for	O
treatment	O
of	O
BV	O
in	O
pregnancy	O
.	O

Fifty	O
-	O
three	O
women	O
were	O
evaluated	O
,	O
including	O
30	O
women	O
who	O
received	O
oral	O
metronidazole	O
and	O
23	O
who	O
received	O
intravaginal	O
metronidazole	O
.	O

Bacterial	O
taxon	O
-	O
specific	O
quantitative	O
PCR	O
assays	O
were	O
used	O
to	O
measure	O
concentrations	O
of	O
bacterial	O
vaginosis	O
associated	O
bacterium	O
(	O
BVAB	O
)	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
Gardnerella	B-bacteria
vaginalis	I-bacteria
,	O
Atopobium	B-bacteria
species	I-bacteria
,	O
Leptotrichia	B-bacteria
/	I-bacteria
Sneathia	I-bacteria
species	I-bacteria
,	O
Megasphaera	B-bacteria
species	I-bacteria
,	O
and	O
Lactobacillus	B-bacteria
crispatus	I-bacteria
before	O
and	O
after	O
antibiotic	O
treatment	O
.	O

Concentrations	O
of	O
Leptotrichia	B-bacteria
and	O
Sneathia	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
the	O
fastidious	O
Clostridia	O
-	O
like	O
bacterium	O
designated	O
BVAB1	O
decreased	O
significantly	O
with	O
oral	O
(	O
p	O
=	O
.	O
002	O
,	O
p	O
=	O
.	O
02	O
)	O
but	O
not	O
vaginal	O
therapy	O
(	O
p	O
=	O
.	O
141	O
,	O
p	O
=	O
.	O
126	O
)	O
.	O

The	O
fastidious	O
bacterium	O
BVAB3	O
did	O
not	O
significantly	O
decrease	O
with	O
either	O
treatment	O
.	O

Concentrations	O
of	O
Atopobium	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
reportedly	O
resistant	O
to	O
metronidazole	O
in	O
vitro	O
,	O
dropped	O
significantly	O
with	O
oral	O
(	O
p	O
=	O
.	O
002	O
)	O
and	O
vaginal	O
(	O
p	O
=	O
.	O
001	O
)	O
treatment	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
magnitude	O
of	O
change	O
in	O
bacterial	O
concentrations	O
between	O
oral	O
and	O
vaginal	O
treatment	O
arms	O
for	O
any	O
of	O
the	O
bacterial	O
species	O
.	O

Lactobacillus	B-bacteria
crispatus	I-bacteria
concentrations	O
did	O
not	O
change	O
.	O

Both	O
oral	O
and	O
vaginal	O
metronidazole	O
therapy	O
in	O
pregnant	O
women	O
result	O
in	O
a	O
significant	O
decrease	O
in	O
concentrations	O
of	O
most	O
BV	O
-	O
associated	O
anaerobic	O
bacteria	O
,	O
with	O
the	O
exception	O
that	O
Leptotrichia	B-bacteria
,	O
Sneathia	B-bacteria
and	O
BVAB1	B-bacteria
do	O
not	O
significantly	O
decrease	O
with	O
vaginal	O
metronidazole	O
therapy	O
.	O

These	O
data	O
suggest	O
that	O
the	O
route	O
of	O
antibiotic	O
administration	O
has	O
a	O
minor	O
impact	O
on	O
bacterial	O
eradication	O
in	O
pregnant	O
women	O
with	O
BV	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
number	O
NCT00153517	O
.	O

The	O
bacterial	O
colonization	O
of	O
teeth	O
by	O
Streptococcus	B-bacteria
mutans	I-bacteria
(	O
StrepM	B-bacteria
)	O
represents	O
a	O
major	O
risk	O
factor	O
for	O
the	O
development	O
of	O
dental	O
caries	O
.	O

At	O
present	O
,	O
no	O
clinical	O
studies	O
have	O
explored	O
the	O
effect	O
of	O
a	O
combined	O
mechanical	O
-	O
chemical	O
antisepsis	O
protocol	O
in	O
a	O
periodontally	O
-	O
healthy	O
population	O
and	O
the	O
pattern	O
of	O
recolonization	O
of	O
StrepM	B-bacteria
in	O
subjects	O
whose	O
StrepM	B-bacteria
infection	O
was	O
successfully	O
eradicated	O
.	O

The	O
present	O
study	O
was	O
designed	O
in	O
order	O
to	O
1	O
)	O
determine	O
the	O
salivary	O
and	O
plaque	O
changes	O
in	O
StrepM	B-bacteria
content	O
after	O
a	O
combined	O
mechanical	O
/	O
chemical	O
antisepsis	O
protocol	O
;	O
and	O
2	O
)	O
evaluate	O
the	O
pattern	O
of	O
recolonization	O
when	O
StrepM	B-bacteria
was	O
successfully	O
eradicated	O
from	O
saliva	O
and	O
plaque	O
.	O

Thirty	O
-	O
five	O
periodontally	O
-	O
healthy	O
and	O
caries	O
-	O
susceptible	O
subjects	O
successfully	O
entered	O
and	O
concluded	O
the	O
study	O
.	O

At	O
baseline	O
,	O
non	O
-	O
surgical	O
periodontal	O
therapy	O
was	O
performed	O
according	O
to	O
the	O
principles	O
of	O
full	O
mouth	O
disinfection	O
.	O

Adjunctive	O
home	O
-	O
based	O
rinsing	O
with	O
a	O
0	O
.	O
2	O
%	O
chlorhexidine	O
mouthrinse	O
was	O
requested	O
for	O
the	O
following	O
week	O
.	O

StrepM	B-bacteria
concentration	O
was	O
assessed	O
in	O
saliva	O
and	O
plaque	O
at	O
the	O
initial	O
contact	O
appointment	O
,	O
at	O
baseline	O
,	O
and	O
1	O
-	O
week	O
,	O
1	O
-	O
month	O
,	O
3	O
-	O
month	O
and	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

A	O
significant	O
effect	O
of	O
'	O
'	O
time	O
'	O
'	O
on	O
StrepM	B-bacteria
concentration	O
in	O
saliva	O
and	O
plaque	O
was	O
observed	O
(	O
P	O
<	O
0	O
.	O
000	O
)	O
.	O

In	O
subjects	O
with	O
successful	O
eradication	O
of	O
StrepM	B-bacteria
at	O
1	O
week	O
(	O
N	O
=	O
17	O
plaque	O
samples	O
)	O
,	O
StrepM	B-bacteria
infection	O
recurrence	O
occurred	O
within	O
3	O
-	O
6	O
months	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
demonstrated	O
that	O
1	O
)	O
the	O
application	O
of	O
the	O
investigated	O
mechanical	O
/	O
chemical	O
antisepsis	O
protocol	O
can	O
effectively	O
reduce	O
StrepM	B-bacteria
colonies	O
in	O
saliva	O
and	O
plaque	O
of	O
periodontally	O
healthy	O
subjects	O
;	O
and	O
2	O
)	O
in	O
plaque	O
samples	O
,	O
StrepM	B-bacteria
infection	O
recurrence	O
tends	O
to	O
occur	O
within	O
3	O
-	O
6	O
months	O
.	O

To	O
determine	O
the	O
absolute	O
and	O
relative	O
antibacterial	O
activity	O
of	O
octenidine	O
dihydrochloride	O
(	O
OCT	O
)	O
against	O
total	O
and	O
cariogenic	O
bacteria	O
in	O
saliva	O
samples	O
of	O
patients	O
with	O
fixed	O
orthodontic	O
appliances	O
during	O
5	O
days	O
of	O
usage	O
.	O

The	O
study	O
group	O
consisted	O
of	O
5	O
male	O
and	O
13	O
female	O
subjects	O
who	O
were	O
selected	O
from	O
patients	O
in	O
the	O
Clinic	O
of	O
Orthodontics	O
.	O

Each	O
patient	O
was	O
given	O
physiologic	O
saline	O
(	O
PS	O
)	O
,	O
chlorhexidine	O
gluconate	O
(	O
CHX	O
)	O
,	O
polyvinylpyrrolidone	O
-	O
iodine	O
complex	O
(	O
PVP	O
-	O
I	O
)	O
,	O
and	O
OCT	O
every	O
morning	O
for	O
5	O
days	O
,	O
each	O
separated	O
by	O
a	O
2	O
-	O
week	O
interval	O
.	O

Total	O
and	O
cariogenic	O
bacteria	O
in	O
saliva	O
samples	O
of	O
orthodontically	O
treated	O
patients	O
with	O
fixed	O
appliances	O
were	O
collected	O
during	O
5	O
days	O
of	O
usage	O
.	O

Unstimulated	O
saliva	O
was	O
collected	O
as	O
a	O
baseline	O
sample	O
.	O

Saliva	O
samples	O
were	O
collected	O
at	O
15	O
minutes	O
,	O
and	O
on	O
the	O
second	O
,	O
third	O
,	O
and	O
fifth	O
day	O
after	O
rinsing	O
the	O
mouth	O
with	O
any	O
of	O
the	O
solutions	O
for	O
30	O
seconds	O
,	O
and	O
bacterial	O
counts	O
were	O
detected	O
.	O

OCT	O
showed	O
an	O
ultimate	O
reduction	O
of	O
total	O
viable	O
oral	O
bacteria	O
,	O
Lactobacillus	B-bacteria
species	I-bacteria
,	O
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
in	O
vivo	O
.	O

OCT	O
also	O
had	O
a	O
significantly	O
greater	O
inhibitory	O
effect	O
than	O
0	O
.	O
2	O
%	O
CHX	O
and	O
7	O
.	O
5	O
%	O
PVP	O
-	O
I	O
,	O
from	O
the	O
beginning	O
of	O
the	O
study	O
until	O
the	O
fifth	O
day	O
after	O
the	O
orthodontic	O
appliances	O
were	O
bonded	O
(	O
P	O
<	O
.	O
1	O
)	O
.	O

OCT	O
compared	O
favorably	O
with	O
respect	O
to	O
CHX	O
and	O
PVP	O
-	O
I	O
complex	O
in	O
orthodontically	O
treated	O
patients	O
with	O
fixed	O
appliances	O
(	O
P	O
<	O
/	O
=	O
.	O
1	O
)	O
.	O

Infective	O
endocarditis	O
(	O
IE	O
)	O
is	O
a	O
rare	O
but	O
life	O
-	O
threatening	O
infection	O
.	O

Bacteremia	O
with	O
organisms	O
known	O
to	O
cause	O
IE	O
occurs	O
commonly	O
in	O
association	O
with	O
invasive	O
dental	O
origin	O
.	O

Despite	O
daily	O
oral	O
activities	O
as	O
well	O
as	O
professional	O
dental	O
treatments	O
inducing	O
bacteremia	O
and	O
the	O
dental	O
bacteremia	O
as	O
a	O
risk	O
factor	O
of	O
IE	O
,	O
the	O
details	O
of	O
dental	O
bacteria	O
in	O
the	O
pathogenesis	O
of	O
IE	O
are	O
far	O
from	O
elucidation	O
to	O
date	O
.	O

How	O
do	O
a	O
few	O
microorganisms	O
survive	O
host	O
defenses	O
or	O
escape	O
from	O
antibiotic	O
attacking	O
to	O
seed	O
target	O
organs	O
and	O
cause	O
distant	O
infections	O
?	O

Why	O
are	O
Gram	O
-	O
positive	O
bacteria	O
more	O
frequently	O
detected	O
than	O
Gram	O
-	O
negative	O
bacteria	O
in	O
IE	O
?	O

Cell	O
wall	O
-	O
deficient	O
bacteria	O
(	O
CWDB	O
)	O
were	O
traditionally	O
defined	O
as	O
bacteria	O
with	O
altered	O
morphology	O
and	O
consistent	O
with	O
damaged	O
or	O
absent	O
cell	O
wall	O
structures	O
identified	O
by	O
EM	O
.	O

A	O
number	O
of	O
case	O
reports	O
and	O
laboratory	O
studies	O
suggest	O
that	O
CWDB	O
may	O
be	O
found	O
in	O
the	O
peripheral	O
blood	O
of	O
patients	O
with	O
IE	O
,	O
and	O
may	O
also	O
be	O
demonstrated	O
in	O
vegetations	O
on	O
the	O
valves	O
of	O
patients	O
with	O
IE	O
.	O

CWDB	O
,	O
in	O
vitro	O
,	O
are	O
resistant	O
to	O
antibiotics	O
that	O
act	O
on	O
cell	O
wall	O
biosynthesis	O
.	O

Recent	O
studies	O
indicate	O
that	O
the	O
Streptococcus	B-bacteria
mutans	I-bacteria
(	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
)	O
strains	O
,	O
the	O
major	O
cariogenic	O
bacterium	O
,	O
isolated	O
from	O
the	O
infected	O
valve	O
were	O
deficient	O
in	O
some	O
wall	O
-	O
associated	O
proteins	O
which	O
are	O
main	O
cariogenic	O
virulence	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
and	O
the	O
deficient	O
stains	O
exhibited	O
less	O
susceptible	O
to	O
antibiotics	O
that	O
act	O
on	O
cell	O
wall	O
biosynthesis	O
.	O

Further	O
,	O
the	O
cloned	O
deficient	O
mutans	O
were	O
less	O
susceptible	O
to	O
phagocytosis	O
by	O
human	O
polymorphonuclear	O
leukocytes	O
but	O
to	O
possess	O
higher	O
platelet	O
aggregation	O
properties	O
than	O
their	O
parent	O
strains	O
.	O

As	O
outlined	O
above	O
,	O
we	O
hypothesize	O
that	O
defect	O
of	O
cell	O
wall	O
construction	O
may	O
shield	O
oral	O
bacteria	O
'	O
s	O
survival	O
in	O
bloodstream	O
and	O
cause	O
IE	O
.	O

The	O
oral	O
cavity	O
has	O
been	O
considered	O
a	O
potential	O
reservoir	O
for	O
Helicobacter	B-bacteria
pylori	I-bacteria
(	O
H	B-bacteria
pylori	I-bacteria
)	O
,	O
from	O
where	O
the	O
organism	O
causes	O
recurrent	O
gastric	O
infections	O
.	O

With	O
this	O
case	O
-	O
control	O
study	O
we	O
tried	O
to	O
evaluate	O
the	O
role	O
of	O
H	B-bacteria
pylori	I-bacteria
in	O
the	O
etiology	O
of	O
mucosal	O
inflammation	O
,	O
a	O
condition	O
that	O
compounds	O
the	O
morbid	O
state	O
associated	O
with	O
oral	O
submucous	O
fibrosis	O
(	O
OSF	O
)	O
.	O

Subjects	O
(	O
n	O
=	O
150	O
)	O
were	O
selected	O
following	O
institutional	O
regulations	O
on	O
sample	O
collection	O
and	O
grouped	O
into	O
test	O
cases	O
and	O
positive	O
and	O
negative	O
controls	O
based	O
on	O
the	O
presence	O
of	O
mucosal	O
fibrosis	O
and	O
inflammation	O
.	O

The	O
negative	O
controls	O
had	O
none	O
of	O
the	O
clinical	O
signs	O
.	O

All	O
patients	O
underwent	O
an	O
oral	O
examination	O
as	O
well	O
as	O
tests	O
to	O
assess	O
oral	O
hygiene	O
/	O
periodontal	O
disease	O
status	O
;	O
a	O
rapid	O
urease	O
test	O
(	O
RUT	O
)	O
of	O
plaque	O
samples	O
was	O
also	O
done	O
to	O
estimate	O
the	O
H	B-bacteria
pylori	I-bacteria
bacterial	O
load	O
.	O

We	O
used	O
univariate	O
and	O
mutivariate	O
logistic	O
regression	O
for	O
statistical	O
analysis	O
of	O
the	O
data	O
and	O
calculated	O
the	O
odds	O
ratios	O
to	O
assess	O
the	O
risk	O
posed	O
by	O
the	O
different	O
variables	O
.	O

The	O
RUT	O
results	O
differed	O
significantly	O
between	O
the	O
groups	O
,	O
reflecting	O
the	O
variations	O
in	O
the	O
bacterial	O
loads	O
in	O
each	O
category	O
.	O

The	O
test	O
was	O
positive	O
in	O
52	O
%	O
in	O
the	O
positive	O
controls	O
(	O
where	O
nonspecific	O
inflammation	O
of	O
oral	O
mucosa	O
was	O
seen	O
unassociated	O
with	O
fibrosis	O
)	O
,	O
in	O
46	O
%	O
of	O
the	O
test	O
cases	O
,	O
and	O
in	O
18	O
%	O
of	O
the	O
negative	O
controls	O
(	O
healthy	O
volunteers	O
)	O
(	O
chi2	O
=	O
13	O
.	O
887	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
positive	O
correlation	O
was	O
seen	O
between	O
the	O
oral	O
hygiene	O
/	O
periodontal	O
disease	O
indices	O
and	O
RUT	O
reactivity	O
in	O
all	O
the	O
three	O
groups	O
.	O

The	O
contribution	O
of	O
the	O
H	B-bacteria
pylori	I-bacteria
in	O
dental	O
plaque	O
to	O
mucosal	O
inflammation	O
and	O
periodontal	O
disease	O
was	O
significant	O
.	O

Logistic	O
regression	O
analysis	O
showed	O
gastrointestinal	O
disease	O
and	O
poor	O
oral	O
hygiene	O
as	O
being	O
the	O
greatest	O
risk	O
factors	O
for	O
bacterial	O
colonization	O
,	O
irrespective	O
of	O
the	O
subject	O
groups	O
.	O

A	O
positive	O
correlation	O
exists	O
between	O
RUT	O
reactivity	O
and	O
the	O
frequency	O
of	O
mucosal	O
inflammation	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
evaluate	O
the	O
association	O
between	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
periodontopathic	O
bacteria	O
.	O

Clinical	O
studies	O
of	O
RA	O
and	O
periodontal	O
disease	O
have	O
provided	O
evidence	O
for	O
a	O
significant	O
association	O
between	O
the	O
two	O
disorders	O
.	O

Patients	O
with	O
long	O
-	O
standing	O
active	O
RA	O
have	O
a	O
substantially	O
increased	O
frequency	O
of	O
periodontal	O
disease	O
compared	O
with	O
that	O
among	O
healthy	O
subjects	O
.	O

High	O
levels	O
of	O
oral	O
anaerobic	O
bacterial	O
antibodies	O
have	O
been	O
found	O
in	O
the	O
serum	O
and	O
synovial	O
fluid	O
of	O
RA	O
patients	O
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
,	O
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
have	O
been	O
identified	O
in	O
RA	O
synovial	O
fluid	O
.	O

Ornidazole	O
,	O
levofloxacin	O
,	O
and	O
clarithromycin	O
are	O
used	O
in	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
anaerobic	O
bacteria	O
.	O

These	O
antibiotics	O
have	O
been	O
shown	O
to	O
be	O
effective	O
against	O
RA	O
.	O

The	O
evidence	O
in	O
this	O
review	O
indicates	O
that	O
oral	O
bacteria	O
directly	O
associate	O
with	O
etiopathogenesis	O
of	O
RA	O
.	O

The	O
degradation	O
of	O
complex	O
substrates	O
,	O
like	O
salivary	O
mucins	O
,	O
requires	O
an	O
arsenal	O
of	O
glycosidases	O
and	O
proteases	O
to	O
sequentially	O
degrade	O
the	O
oligosaccharides	O
and	O
polypeptide	O
backbone	O
.	O

The	O
mucin	O
MUC5B	O
is	O
a	O
complex	O
oligomeric	O
glycoprotein	O
,	O
heterogeneous	O
in	O
molecular	O
mass	O
(	O
14	O
-	O
40	O
x	O
10	O
(	O
6	O
)	O
Da	O
)	O
,	O
with	O
a	O
diverse	O
repertoire	O
of	O
oligosaccharides	O
,	O
differing	O
in	O
composition	O
and	O
charge	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
proteolytic	O
degradation	O
of	O
the	O
mucin	O
polypeptide	O
backbone	O
could	O
be	O
identified	O
and	O
if	O
cooperation	O
of	O
dental	O
biofilm	O
bacteria	O
was	O
required	O
.	O

Cooperative	O
bacteria	O
-	O
mediated	O
proteolysis	O
of	O
MUC5B	O
was	O
determined	O
by	O
comparing	O
individual	O
species	O
and	O
mixed	O
consortia	O
of	O
strains	O
isolated	O
from	O
supragingival	O
plaque	O
,	O
and	O
freshly	O
harvested	O
supragingival	O
plaque	O
.	O

Proteolytic	O
activity	O
was	O
analysed	O
using	O
fluorescent	O
labelled	O
substrate	O
and	O
by	O
visualizing	O
mucin	O
degradation	O
by	O
SDS	O
-	O
PAGE	O
.	O

Dental	O
plaque	O
degraded	O
the	O
polypeptide	O
backbone	O
of	O
the	O
salivary	O
MUC5B	O
mucin	O
.	O

The	O
mucin	O
was	O
also	O
degraded	O
by	O
a	O
specific	O
consortium	O
of	O
isolated	O
species	O
from	O
supragingival	O
plaque	O
,	O
although	O
individual	O
species	O
and	O
other	O
consortia	O
did	O
not	O
.	O

Certain	O
bacteria	O
in	O
supragingival	O
dental	O
plaque	O
therefore	O
cooperate	O
as	O
a	O
consortium	O
to	O
proteolyse	O
human	O
salivary	O
MUC5B	O
and	O
hydrolyse	O
glycosides	O
.	O

Recent	O
progress	O
in	O
identification	O
of	O
oral	O
microorganisms	O
has	O
shown	O
that	O
the	O
oropharynx	O
can	O
be	O
a	O
site	O
of	O
origin	O
for	O
dissemination	O
of	O
pathogenic	O
organisms	O
to	O
distant	O
body	O
sites	O
,	O
such	O
as	O
the	O
lungs	O
.	O

To	O
compare	O
the	O
oropharyngeal	O
microbiological	O
profile	O
,	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
and	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
of	O
children	O
receiving	O
mechanical	O
ventilation	O
who	O
had	O
pharmacological	O
or	O
nonpharmacological	O
oral	O
care	O
.	O

A	O
randomized	O
and	O
controlled	O
study	O
was	O
performed	O
in	O
a	O
pediatric	O
intensive	O
unit	O
in	O
Sao	O
Paulo	O
,	O
Brazil	O
.	O

A	O
total	O
of	O
56	O
children	O
were	O
randomly	O
assigned	O
to	O
an	O
experimental	O
group	O
(	O
n	O
=	O
27	O
,	O
48	O
%	O
)	O
that	O
received	O
oral	O
care	O
with	O
use	O
of	O
0	O
.	O
12	O
%	O
chlorhexidine	O
digluconate	O
or	O
a	O
control	O
group	O
(	O
n	O
=	O
29	O
,	O
52	O
%	O
)	O
that	O
received	O
oral	O
care	O
without	O
an	O
antiseptic	O
.	O

Oropharyngeal	O
secretions	O
were	O
collected	O
and	O
cultured	O
on	O
days	O
0	O
,	O
2	O
,	O
and	O
4	O
,	O
and	O
at	O
discharge	O
.	O

The	O
2	O
groups	O
had	O
similar	O
demographic	O
characteristics	O
,	O
preexisting	O
underlying	O
diseases	O
,	O
and	O
pharmacological	O
,	O
nutritional	O
,	O
and	O
ventilatory	O
support	O
.	O

Gram	O
-	O
negative	O
bacteria	O
were	O
the	O
predominant	O
pathogens	O
:	O
Acinetobacter	B-bacteria
baumannii	I-bacteria
,	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
,	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
,	O
and	O
Enter	O
-	O
obacter	O
species	O
.	O

The	O
2	O
groups	O
did	O
not	O
differ	O
significantly	O
in	O
the	O
colonization	O
of	O
normal	O
(	O
P	O
=	O
.	O
72	O
)	O
or	O
pathogenic	O
(	O
P	O
=	O
.	O
62	O
)	O
flora	O
,	O
in	O
the	O
duration	O
of	O
mechanical	O
ventilation	O
(	O
P	O
=	O
.	O
67	O
)	O
,	O
or	O
in	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
(	O
P	O
=	O
.	O
22	O
)	O
.	O

Use	O
of	O
chlorhexidine	O
combined	O
with	O
nonpharmacological	O
oral	O
care	O
did	O
not	O
decrease	O
the	O
colonization	O
profile	O
,	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
or	O
length	O
of	O
stay	O
in	O
critically	O
ill	O
children	O
receiving	O
mechanical	O
ventilation	O
.	O

Although	O
oral	O
health	O
affects	O
systemic	O
health	O
,	O
studies	O
of	O
oral	O
health	O
during	O
intubation	O
among	O
critically	O
ill	O
neuroscience	O
patients	O
are	O
lacking	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
oral	O
care	O
on	O
intracranial	O
pressure	O
among	O
critically	O
ill	O
patients	O
in	O
a	O
neuroscience	O
intensive	O
care	O
unit	O
is	O
unknown	O
.	O

To	O
describe	O
changes	O
in	O
oral	O
health	O
and	O
development	O
of	O
ventilator	O
-	O
associated	O
pneumonia	O
during	O
intubation	O
among	O
patients	O
in	O
a	O
neuroscience	O
intensive	O
care	O
unit	O
and	O
to	O
assess	O
the	O
influence	O
of	O
oral	O
care	O
on	O
intracranial	O
pressure	O
.	O

Data	O
on	O
45	O
consecutive	O
intubated	O
patients	O
admitted	O
to	O
a	O
neuroscience	O
intensive	O
care	O
unit	O
during	O
1	O
year	O
were	O
collected	O
by	O
using	O
oral	O
cultures	O
and	O
the	O
Oral	O
Assessment	O
Guide	O
throughout	O
intubation	O
and	O
48	O
hours	O
after	O
extubation	O
.	O

Occurrence	O
of	O
ventilator	O
-	O
associated	O
pneumonia	O
and	O
intracranial	O
pressures	O
associated	O
with	O
oral	O
care	O
were	O
recorded	O
.	O

Oral	O
health	O
,	O
assessed	O
by	O
the	O
Oral	O
Assessment	O
Guide	O
,	O
deteriorated	O
significantly	O
during	O
intubation	O
and	O
improved	O
to	O
almost	O
baseline	O
levels	O
48	O
hours	O
after	O
extubation	O
.	O

During	O
intubation	O
,	O
occurrence	O
of	O
oral	O
gram	O
-	O
negative	O
bacteria	O
and	O
yeast	O
increased	O
.	O

The	O
incidence	O
of	O
ventilator	O
-	O
associated	O
pneumonia	O
was	O
24	O
%	O
among	O
patients	O
enrolled	O
for	O
4	O
to	O
10	O
days	O
.	O

During	O
or	O
after	O
879	O
instances	O
of	O
oral	O
care	O
,	O
overall	O
intracranial	O
pressure	O
did	O
not	O
increase	O
.	O

Among	O
30	O
instances	O
in	O
which	O
intracranial	O
pressure	O
was	O
greater	O
than	O
20	O
mm	O
Hg	O
before	O
oral	O
care	O
,	O
pressure	O
decreased	O
during	O
and	O
30	O
minutes	O
after	O
the	O
procedure	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

Intubation	O
may	O
contribute	O
to	O
worsening	O
of	O
oral	O
health	O
among	O
patients	O
in	O
neuroscience	O
intensive	O
care	O
units	O
.	O

Execution	O
of	O
oral	O
care	O
does	O
not	O
seem	O
to	O
affect	O
intracranial	O
pressure	O
adversely	O
.	O

Oral	O
care	O
should	O
be	O
explored	O
further	O
to	O
promote	O
good	O
oral	O
and	O
systemic	O
health	O
in	O
patients	O
in	O
neuroscience	O
intensive	O
care	O
units	O
and	O
to	O
determine	O
its	O
effect	O
on	O
ventilator	O
-	O
associated	O
pneumonia	O
.	O

Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
a	O
commensal	O
opportunistic	O
oral	O
bacterium	O
,	O
is	O
capable	O
of	O
invading	O
gingival	O
epithelial	O
cells	O
,	O
but	O
the	O
entrance	O
into	O
human	O
primary	O
oral	O
fibroblast	O
cells	O
has	O
not	O
been	O
documented	O
.	O

This	O
study	O
evaluated	O
the	O
ability	O
of	O
three	O
strains	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
(	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
ssp	I-bacteria
.	I-bacteria
nucleatum	I-bacteria
,	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
ssp	I-bacteria
.	I-bacteria
polymorphum	I-bacteria
,	O
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
ssp	I-bacteria
.	I-bacteria
vincentii	I-bacteria
)	O
to	O
enter	O
gingival	O
fibroblasts	O
(	O
GFs	O
)	O
and	O
periodontal	O
ligament	O
fibroblasts	O
(	O
PLFs	O
)	O
.	O

GFs	O
and	O
PLFs	O
were	O
cocultured	O
for	O
various	O
periods	O
of	O
time	O
with	O
different	O
strains	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
.	O

Scanning	O
and	O
transmission	O
electron	O
microscopy	O
,	O
together	O
with	O
confocal	O
laser	O
scanning	O
microscopy	O
,	O
were	O
used	O
to	O
visualize	O
the	O
entrance	O
and	O
presence	O
of	O
bacteria	O
in	O
host	O
cells	O
.	O

Flow	O
cytometry	O
was	O
performed	O
to	O
compare	O
the	O
load	O
of	O
internalized	O
bacteria	O
in	O
GFs	O
and	O
PLFs	O
exposed	O
for	O
3	O
and	O
5	O
hours	O
to	O
live	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
labeled	O
with	O
fluorescein	O
isothiocyanate	O
.	O

All	O
three	O
strains	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
were	O
found	O
entering	O
and	O
located	O
in	O
the	O
cytoplasm	O
of	O
GFs	O
and	O
PLFs	O
after	O
1	O
hour	O
of	O
exposure	O
.	O

Flow	O
cytometry	O
tests	O
revealed	O
a	O
significant	O
increase	O
in	O
the	O
fluorescent	O
signal	O
,	O
compared	O
to	O
baseline	O
,	O
derived	O
from	O
bacteria	O
internalized	O
in	O
fibroblasts	O
exposed	O
for	O
3	O
hours	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
;	O
a	O
further	O
increase	O
was	O
found	O
at	O
5	O
hours	O
.	O

The	O
greatest	O
bacterial	O
mass	O
in	O
exposed	O
fibroblasts	O
of	O
both	O
types	O
was	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
ssp	I-bacteria
.	I-bacteria
polymorphum	I-bacteria
;	O
the	O
smallest	O
was	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
ssp	I-bacteria
.	I-bacteria
vincentii	I-bacteria
.	O

Although	O
not	O
statistically	O
significant	O
,	O
PLFs	O
had	O
a	O
higher	O
bacterial	O
load	O
than	O
corresponding	O
GFs	O
.	O

F	I-bacteria
.	I-bacteria
nucleatum	I-bacteria
was	O
capable	O
of	O
entering	O
GFs	O
and	O
PLFs	O
in	O
a	O
manner	O
that	O
is	O
dependent	O
on	O
the	O
cell	O
type	O
and	O
the	O
bacterial	O
strain	O
.	O

In	O
vitro	O
plaque	O
removal	O
studies	O
require	O
biofilm	O
models	O
that	O
resemble	O
in	O
vivo	O
dental	O
plaque	O
.	O

Here	O
,	O
we	O
compare	O
contact	O
and	O
non	O
-	O
contact	O
removal	O
of	O
single	O
and	O
dual	O
-	O
species	O
biofilms	O
as	O
well	O
as	O
of	O
biofilms	O
grown	O
from	O
human	O
whole	O
saliva	O
in	O
vitro	O
using	O
different	O
biofilm	O
models	O
.	O

Bacteria	O
were	O
adhered	O
to	O
a	O
salivary	O
pellicle	O
for	O
2	O
h	O
or	O
grown	O
after	O
adhesion	O
for	O
16	O
h	O
,	O
after	O
which	O
,	O
their	O
removal	O
was	O
evaluated	O
.	O

In	O
a	O
contact	O
mode	O
,	O
no	O
differences	O
were	O
observed	O
between	O
the	O
manual	O
,	O
rotating	O
,	O
or	O
sonic	O
brushing	O
;	O
and	O
removal	O
was	O
on	O
average	O
39	O
%	O
,	O
84	O
%	O
,	O
and	O
95	O
%	O
for	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
oralis	I-bacteria
,	O
and	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
,	O
respectively	O
,	O
and	O
90	O
%	O
and	O
54	O
%	O
for	O
the	O
dual	O
-	O
and	O
multi	O
-	O
species	O
biofilms	O
,	O
respectively	O
.	O

However	O
,	O
in	O
a	O
non	O
-	O
contact	O
mode	O
,	O
rotating	O
and	O
sonic	O
brushes	O
still	O
removed	O
considerable	O
numbers	O
of	O
bacteria	O
(	O
24	O
-	O
40	O
%	O
)	O
,	O
while	O
the	O
manual	O
brush	O
as	O
a	O
control	O
(	O
5	O
-	O
11	O
%	O
)	O
did	O
not	O
.	O

Single	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
and	O
dual	O
-	O
species	O
(	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
)	O
biofilms	O
were	O
more	O
difficult	O
to	O
remove	O
after	O
16	O
h	O
growth	O
than	O
after	O
2	O
h	O
adhesion	O
(	O
on	O
average	O
,	O
62	O
%	O
and	O
93	O
%	O
for	O
16	O
-	O
and	O
2	O
-	O
h	O
-	O
old	O
biofilms	O
,	O
respectively	O
)	O
,	O
while	O
in	O
contrast	O
,	O
biofilms	O
grown	O
from	O
whole	O
saliva	O
were	O
easier	O
to	O
remove	O
(	O
97	O
%	O
after	O
16	O
h	O
and	O
54	O
%	O
after	O
2	O
h	O
of	O
growth	O
)	O
.	O

Considering	O
the	O
strong	O
adhesion	O
of	O
dual	O
-	O
species	O
biofilms	O
and	O
their	O
easier	O
more	O
reproducible	O
growth	O
compared	O
with	O
biofilms	O
grown	O
from	O
whole	O
saliva	O
,	O
dual	O
-	O
species	O
biofilms	O
of	O
A	B-bacteria
.	I-bacteria
naeslundii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
are	O
suggested	O
to	O
be	O
preferred	O
for	O
use	O
in	O
mechanical	O
plaque	O
removal	O
studies	O
in	O
vitro	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
Enterococcus	B-bacteria
faecalis	I-bacteria
isolates	I-bacteria
from	O
endodontic	O
patients	O
(	O
from	O
saliva	O
and	O
from	O
a	O
root	O
canal	O
)	O
are	O
able	O
to	O
prevail	O
against	O
salivary	O
bacteria	O
when	O
grown	O
in	O
coculture	O
in	O
a	O
biofilm	O
reactor	O
.	O

Saliva	O
that	O
was	O
tested	O
to	O
be	O
free	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
was	O
used	O
as	O
the	O
inoculum	O
.	O

The	O
fate	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
was	O
examined	O
by	O
using	O
culture	O
techniques	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

The	O
root	O
canal	O
isolate	O
accounted	O
for	O
37	O
.	O
4	O
%	O
of	O
the	O
biofilm	O
and	O
31	O
.	O
9	O
%	O
of	O
the	O
planktonic	O
phase	O
when	O
examined	O
by	O
the	O
culture	O
technique	O
,	O
whereas	O
the	O
proportions	O
examined	O
by	O
FISH	O
showed	O
15	O
.	O
3	O
%	O
in	O
the	O
biofilm	O
and	O
11	O
.	O
7	O
%	O
in	O
the	O
planktonic	O
phase	O
.	O

The	O
saliva	O
isolate	O
(	O
as	O
examined	O
by	O
the	O
culture	O
technique	O
)	O
accounted	O
for	O
32	O
.	O
4	O
%	O
in	O
the	O
biofilm	O
and	O
27	O
.	O
1	O
%	O
in	O
the	O
planktonic	O
phase	O
,	O
respectively	O
,	O
compared	O
with	O
14	O
.	O
1	O
%	O
in	O
the	O
biofilm	O
and	O
9	O
.	O
5	O
%	O
in	O
the	O
planktonic	O
phase	O
when	O
examined	O
by	O
FISH	O
analysis	O
.	O

These	O
results	O
led	O
to	O
the	O
suggestion	O
that	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
could	O
persist	O
in	O
the	O
biofilm	O
of	O
the	O
human	O
oral	O
cavity	O
.	O

Because	O
of	O
the	O
ubiquitous	O
presence	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
,	O
root	O
canal	O
infections	O
may	O
arise	O
from	O
different	O
sources	O
.	O

Members	O
of	O
the	O
genus	O
Veillonella	B-bacteria
can	O
not	O
be	O
reliably	O
distinguished	O
by	O
their	O
biochemical	O
characteristics	O
and	O
phenotypic	O
features	O
.	O

Moreover	O
,	O
DNA	O
-	O
DNA	O
hybridization	O
and	O
sequence	O
analyses	O
of	O
the	O
16S	O
ribosomal	O
RNA	O
gene	O
including	O
random	O
fragment	O
length	O
polymorphism	O
analysis	O
,	O
are	O
complex	O
and	O
time	O
-	O
consuming	O
procedures	O
that	O
are	O
not	O
well	O
-	O
suited	O
to	O
identifying	O
oral	O
species	O
of	O
Veillonella	B-bacteria
:	O
Veillonella	B-bacteria
atypica	I-bacteria
,	O
Veillonella	B-bacteria
denticariosi	I-bacteria
,	O
Veillonella	B-bacteria
dispar	I-bacteria
,	O
Veillonella	B-bacteria
parvula	I-bacteria
,	O
and	O
Veillonella	B-bacteria
rogosae	I-bacteria
.	O

In	O
this	O
study	O
,	O
five	O
forward	O
primers	O
and	O
a	O
reverse	O
primer	O
were	O
designed	O
for	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
according	O
to	O
the	O
partial	O
sequences	O
of	O
the	O
rpoB	O
genes	O
of	O
these	O
oral	O
Veillonella	B-bacteria
species	I-bacteria
.	O

The	O
forward	O
primers	O
were	O
species	O
-	O
specific	O
for	O
these	O
five	O
Veillonella	B-bacteria
species	I-bacteria
,	O
and	O
could	O
produce	O
specific	O
amplicons	O
when	O
used	O
together	O
with	O
reverse	O
primer	O
and	O
individual	O
DNA	O
templates	O
of	O
these	O
species	O
in	O
PCR	O
.	O

These	O
primer	O
pairs	O
were	O
also	O
found	O
to	O
discriminate	O
between	O
the	O
respective	O
species	O
,	O
and	O
the	O
Veillonella	B-bacteria
strains	I-bacteria
isolated	O
from	O
human	O
oral	O
cavities	O
were	O
successfully	O
assigned	O
to	O
one	O
of	O
the	O
five	O
oral	O
species	O
of	O
the	O
genus	O
Veillonella	B-bacteria
based	O
on	O
their	O
specific	O
products	O
by	O
PCR	O
.	O

A	O
simple	O
two	O
-	O
step	O
PCR	O
procedure	O
using	O
the	O
five	O
sets	O
of	O
primer	O
pairs	O
developed	O
in	O
the	O
present	O
study	O
is	O
a	O
rapid	O
and	O
reliable	O
method	O
for	O
the	O
identification	O
of	O
the	O
recognized	O
oral	O
Veillonella	B-bacteria
species	I-bacteria
.	O

In	O
this	O
study	O
,	O
the	O
bacteriostatic	O
effect	O
of	O
Piper	O
betle	O
and	O
Psidium	O
guajava	O
extracts	O
on	O
selected	O
early	O
dental	O
plaque	O
bacteria	O
was	O
investigated	O
based	O
on	O
changes	O
in	O
the	O
doubling	O
time	O
(	O
g	O
)	O
and	O
specific	O
growth	O
rates	O
(	O
micro	O
)	O
.	O

Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
and	O
Actinomyces	B-bacteria
sp	I-bacteria
.	I-bacteria
were	O
cultured	O
in	O
Brain	O
Heart	O
Infusion	O
(	O
BHI	O
)	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
extracts	O
.	O

The	O
growth	O
of	O
bacteria	O
was	O
monitored	O
periodically	O
every	O
15	O
min	O
over	O
a	O
period	O
of	O
9	O
h	O
to	O
allow	O
for	O
a	O
complete	O
growth	O
cycle	O
.	O

Growth	O
profiles	O
of	O
the	O
bacteria	O
in	O
the	O
presence	O
of	O
the	O
extracts	O
were	O
compared	O
to	O
those	O
in	O
the	O
absence	O
and	O
deviation	O
in	O
the	O
g	O
and	O
micro	O
were	O
determined	O
and	O
analyzed	O
.	O

It	O
was	O
found	O
that	O
the	O
g	O
and	O
mu	O
were	O
affected	O
by	O
both	O
extracts	O
.	O

At	O
4	O
mg	O
mL	O
(	O
-	O
1	O
)	O
of	O
P	O
.	O
betle	O
the	O
g	O
-	O
values	O
for	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
were	O
increased	O
by	O
12	O
.	O
0	O
-	O
and	O
10	O
.	O
4	O
-	O
fold	O
,	O
respectively	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
similar	O
concentration	O
P	O
.	O
guajava	O
increased	O
the	O
g	O
-	O
value	O
by	O
1	O
.	O
8	O
-	O
and	O
2	O
.	O
6	O
-	O
fold	O
,	O
respectively	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
effect	O
on	O
Actinomyces	B-bacteria
sp	I-bacteria
.	I-bacteria
was	O
observed	O
at	O
a	O
much	O
lower	O
magnitude	O
.	O

It	O
appears	O
that	O
P	O
.	O
betle	O
and	O
P	O
.	O
guajava	O
extracts	O
have	O
bacteriostatic	O
effect	O
on	O
the	O
plaque	O
bacteria	O
by	O
creating	O
a	O
stressed	O
environment	O
that	O
had	O
suppressed	O
the	O
growth	O
and	O
propagation	O
of	O
the	O
cells	O
.	O

Within	O
the	O
context	O
of	O
the	O
dental	O
plaque	O
,	O
this	O
would	O
ensure	O
the	O
attainment	O
of	O
thin	O
and	O
healthy	O
plaque	O
.	O

Thus	O
,	O
decoctions	O
of	O
these	O
plants	O
would	O
be	O
suitable	O
if	O
used	O
in	O
the	O
control	O
of	O
dental	O
plaque	O
.	O

The	O
world	O
-	O
wide	O
explosion	O
of	O
overweight	O
people	O
has	O
been	O
called	O
an	O
epidemic	O
.	O

The	O
inflammatory	O
nature	O
of	O
obesity	O
is	O
widely	O
recognized	O
.	O

Could	O
it	O
really	O
be	O
an	O
epidemic	O
involving	O
an	O
infectious	O
agent	O
?	O

In	O
this	O
climate	O
of	O
concern	O
over	O
the	O
increasing	O
prevalence	O
of	O
overweight	O
conditions	O
in	O
our	O
society	O
,	O
we	O
focus	O
on	O
the	O
possible	O
role	O
of	O
oral	O
bacteria	O
as	O
a	O
potential	O
direct	O
contributor	O
to	O
obesity	O
.	O

To	O
investigate	O
this	O
possibility	O
,	O
we	O
measured	O
salivary	O
bacterial	O
populations	O
of	O
overweight	O
women	O
.	O

Saliva	O
was	O
collected	O
from	O
313	O
women	O
with	O
a	O
body	O
mass	O
index	O
between	O
27	O
and	O
32	O
,	O
and	O
bacterial	O
populations	O
were	O
measured	O
by	O
DNA	O
probe	O
analysis	O
.	O

Levels	O
in	O
this	O
group	O
were	O
compared	O
with	O
data	O
from	O
a	O
population	O
of	O
232	O
healthy	O
individuals	O
from	O
periodontal	O
disease	O
studies	O
.	O

The	O
median	O
percentage	O
difference	O
of	O
7	O
of	O
the	O
40	O
bacterial	O
species	O
measured	O
was	O
greater	O
than	O
2	O
%	O
in	O
the	O
saliva	O
of	O
overweight	O
women	O
.	O

Classification	O
tree	O
analysis	O
of	O
salivary	O
microbiological	O
composition	O
revealed	O
that	O
98	O
.	O
4	O
%	O
of	O
the	O
overweight	O
women	O
could	O
be	O
identified	O
by	O
the	O
presence	O
of	O
a	O
single	O
bacterial	O
species	O
(	O
Selenomonas	B-bacteria
noxia	I-bacteria
)	O
at	O
levels	O
greater	O
than	O
1	O
.	O
05	O
%	O
of	O
the	O
total	O
salivary	O
bacteria	O
.	O

Analysis	O
of	O
these	O
data	O
suggests	O
that	O
the	O
composition	O
of	O
salivary	O
bacteria	O
changes	O
in	O
overweight	O
women	O
.	O

It	O
seems	O
likely	O
that	O
these	O
bacterial	O
species	O
could	O
serve	O
as	O
biological	O
indicators	O
of	O
a	O
developing	O
overweight	O
condition	O
.	O

Of	O
even	O
greater	O
interest	O
,	O
and	O
the	O
subject	O
of	O
future	O
research	O
,	O
is	O
the	O
possibility	O
that	O
oral	O
bacteria	O
may	O
participate	O
in	O
the	O
pathology	O
that	O
leads	O
to	O
obesity	O
.	O

Beach	O
sand	O
contains	O
fecal	O
indicator	O
bacteria	O
,	O
often	O
in	O
densities	O
greatly	O
exceeding	O
the	O
adjacent	O
swimming	O
waters	O
.	O

We	O
examined	O
the	O
transferability	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
F	O
+	O
coliphage	O
(	O
MS2	O
)	O
from	O
beach	O
sand	O
to	O
hands	O
in	O
order	O
to	O
estimate	O
the	O
potential	O
subsequent	O
health	O
risk	O
.	O

Sand	O
with	O
high	O
initial	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
concentrations	O
was	O
collected	O
from	O
a	O
Chicago	O
beach	O
.	O

Individuals	O
manipulated	O
the	O
sand	O
for	O
60	O
seconds	O
,	O
and	O
rinse	O
water	O
was	O
analysed	O
for	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
coliphage	O
.	O

E	B-bacteria
.	I-bacteria
coli	I-bacteria
densities	O
transferred	O
were	O
correlated	O
with	O
density	O
in	O
sand	O
rather	O
than	O
surface	O
area	O
of	O
an	O
individual	O
'	O
s	O
hand	O
,	O
and	O
the	O
amount	O
of	O
coliphage	O
transferred	O
from	O
seeded	O
sand	O
was	O
different	O
among	O
individuals	O
.	O

In	O
sequential	O
rinsing	O
,	O
percentage	O
reduction	O
was	O
92	O
%	O
for	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
98	O
%	O
for	O
coliphage	O
.	O

Using	O
dose	O
-	O
response	O
estimates	O
developed	O
for	O
swimming	O
water	O
,	O
it	O
was	O
determined	O
that	O
the	O
number	O
of	O
individuals	O
per	O
thousand	O
that	O
would	O
develop	O
gastrointestinal	O
symptoms	O
would	O
be	O
11	O
if	O
all	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
on	O
the	O
fingertip	O
were	O
ingested	O
or	O
33	O
if	O
all	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
on	O
the	O
hand	O
were	O
ingested	O
.	O

These	O
results	O
suggest	O
that	O
beach	O
sand	O
may	O
be	O
an	O
important	O
medium	O
for	O
microbial	O
exposure	O
;	O
bacteria	O
transfer	O
is	O
related	O
to	O
initial	O
concentration	O
in	O
the	O
sand	O
;	O
and	O
rinsing	O
may	O
be	O
effective	O
in	O
limiting	O
oral	O
exposure	O
to	O
sand	O
-	O
borne	O
microbes	O
of	O
human	O
concern	O
.	O

Photodynamic	O
therapy	O
has	O
been	O
advocated	O
as	O
an	O
alternative	O
to	O
antimicrobial	O
agents	O
to	O
suppress	O
subgingival	O
species	O
and	O
to	O
treat	O
periodontitis	O
.	O

Bacteria	O
located	O
within	O
dense	O
biofilms	O
,	O
such	O
as	O
those	O
encountered	O
in	O
dental	O
plaque	O
,	O
have	O
been	O
found	O
to	O
be	O
relatively	O
resistant	O
to	O
antimicrobial	O
therapy	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
photodynamic	O
therapy	O
to	O
reduce	O
the	O
number	O
of	O
bacteria	O
in	O
biofilms	O
by	O
comparing	O
the	O
photodynamic	O
effects	O
of	O
methylene	O
blue	O
on	O
human	O
dental	O
plaque	O
microorganisms	O
in	O
the	O
planktonic	O
phase	O
and	O
in	O
biofilms	O
.	O

Dental	O
plaque	O
samples	O
were	O
obtained	O
from	O
10	O
subjects	O
with	O
chronic	O
periodontitis	O
.	O

Suspensions	O
of	O
plaque	O
microorganisms	O
from	O
five	O
subjects	O
were	O
sensitized	O
with	O
methylene	O
blue	O
(	O
25	O
microg	O
/	O
mL	O
)	O
for	O
5	O
min	O
then	O
exposed	O
to	O
red	O
light	O
.	O

Multispecies	O
microbial	O
biofilms	O
developed	O
from	O
the	O
same	O
plaque	O
samples	O
were	O
also	O
exposed	O
to	O
methylene	O
blue	O
(	O
25	O
microg	O
/	O
mL	O
)	O
and	O
the	O
same	O
light	O
conditions	O
as	O
their	O
planktonic	O
counterparts	O
.	O

In	O
a	O
second	O
set	O
of	O
experiments	O
,	O
biofilms	O
were	O
developed	O
with	O
plaque	O
bacteria	O
from	O
five	O
subjects	O
,	O
sensitized	O
with	O
25	O
or	O
50	O
microg	O
/	O
mL	O
of	O
methylene	O
blue	O
and	O
then	O
exposed	O
to	O
red	O
light	O
.	O

After	O
photodynamic	O
therapy	O
,	O
survival	O
fractions	O
were	O
calculated	O
by	O
counting	O
the	O
number	O
of	O
colony	O
-	O
forming	O
units	O
.	O

Photodynamic	O
therapy	O
killed	O
approximately	O
63	O
%	O
of	O
bacteria	O
present	O
in	O
suspension	O
.	O

By	O
contrast	O
,	O
in	O
biofilms	O
,	O
photodynamic	O
therapy	O
had	O
much	O
less	O
of	O
an	O
effect	O
on	O
the	O
viability	O
of	O
bacteria	O
(	O
32	O
%	O
maximal	O
killing	O
)	O
.	O

Oral	O
bacteria	O
in	O
biofilms	O
are	O
affected	O
less	O
by	O
photodynamic	O
therapy	O
than	O
bacteria	O
in	O
the	O
planktonic	O
phase	O
.	O

The	O
antibacterial	O
effect	O
of	O
photodynamic	O
therapy	O
is	O
reduced	O
in	O
biofilm	O
bacteria	O
but	O
not	O
to	O
the	O
same	O
degree	O
as	O
has	O
been	O
reported	O
for	O
treatment	O
with	O
antibiotics	O
under	O
similar	O
conditions	O
.	O

Three	O
strains	O
of	O
anaerobic	O
,	O
pleomorphic	O
,	O
Gram	O
-	O
positive	O
-	O
staining	O
bacilli	O
,	O
which	O
were	O
isolated	O
from	O
human	O
carious	O
dentine	O
,	O
were	O
subjected	O
to	O
a	O
comprehensive	O
range	O
of	O
phenotypic	O
and	O
genotypic	O
tests	O
and	O
were	O
found	O
to	O
comprise	O
a	O
homogeneous	O
group	O
.	O

The	O
strains	O
were	O
saccharolytic	O
and	O
produced	O
acetic	O
and	O
propionic	O
acids	O
in	O
large	O
amounts	O
,	O
and	O
succinic	O
acid	O
in	O
moderate	O
amounts	O
,	O
as	O
the	O
end	O
products	O
of	O
fermentation	O
.	O

16S	O
rRNA	O
gene	O
and	O
RpoB	O
protein	O
sequence	O
analyses	O
revealed	O
that	O
the	O
strains	O
constituted	O
a	O
novel	O
group	O
within	O
the	O
genus	O
Propionibacterium	B-bacteria
,	O
most	O
closely	O
related	O
to	O
Propionibacterium	B-bacteria
australiense	I-bacteria
but	O
sharing	O
only	O
8	O
%	O
DNA	O
-	O
DNA	O
relatedness	O
with	O
the	O
type	O
strain	O
of	O
that	O
species	O
.	O

Therefore	O
,	O
a	O
novel	O
species	O
,	O
Propionibacterium	B-bacteria
acidifaciens	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
is	O
proposed	O
to	O
accommodate	O
these	O
strains	O
.	O

The	O
DNA	O
G	O
+	O
C	O
content	O
of	O
the	O
type	O
strain	O
is	O
70	O
mol	O
%	O
.	O

The	O
type	O
strain	O
is	O
C3M	B-bacteria
_	I-bacteria
31	I-bacteria
(	O
T	O
)	O
(	O
=	O
DSM	B-bacteria
21887	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
57100	I-bacteria
(	O
T	O
)	O
)	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
monitor	O
changes	O
in	O
oral	O
health	O
and	O
oral	O
biofilm	O
composition	O
in	O
vivo	O
during	O
an	O
experiment	O
simulating	O
prehistoric	O
lifestyle	O
and	O
diet	O
and	O
poor	O
oral	O
hygiene	O
.	O

Thirteen	O
subjects	O
lived	O
for	O
a	O
period	O
of	O
8	O
weeks	O
under	O
Neolithic	O
conditions	O
.	O

The	O
following	O
clinical	O
parameters	O
were	O
recorded	O
before	O
and	O
after	O
the	O
project	O
:	O
gingival	O
and	O
plaque	O
index	O
(	O
Loe	O
and	O
Silness	O
,	O
Acta	O
Odontol	O
Scand	O
21	O
:	O
533	O
,	O
1963	O
;	O
Silness	O
and	O
Loe	O
,	O
Acta	O
Odontol	O
Scand	O
22	O
:	O
121	O
-	O
135	O
,	O
1964	O
)	O
,	O
probing	O
pocket	O
depth	O
,	O
and	O
bleeding	O
upon	O
probing	O
.	O

In	O
addition	O
,	O
supragingival	O
plaque	O
samples	O
were	O
collected	O
both	O
before	O
and	O
after	O
the	O
project	O
and	O
were	O
analysed	O
quantitatively	O
using	O
multiplex	O
fluorescence	O
in	O
situ	O
hybridization	O
and	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

The	O
following	O
plaque	O
bacteria	O
were	O
evaluated	O
:	O
Streptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Veillonella	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
and	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
.	O

The	O
plaque	O
index	O
increased	O
significantly	O
from	O
1	O
.	O
12	O
up	O
to	O
1	O
.	O
55	O
over	O
the	O
8	O
-	O
week	O
period	O
(	O
gingival	O
index	O
before	O
,	O
0	O
.	O
46	O
;	O
after	O
,	O
0	O
.	O
93	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
strong	O
correlation	O
of	O
both	O
indices	O
was	O
recorded	O
before	O
(	O
r	O
=	O
0	O
.	O
77	O
)	O
and	O
after	O
(	O
r	O
=	O
0	O
.	O
83	O
)	O
participation	O
in	O
the	O
study	O
.	O

Each	O
of	O
the	O
children	O
in	O
the	O
study	O
showed	O
a	O
progression	O
of	O
carious	O
lesions	O
and	O
/	O
or	O
new	O
areas	O
of	O
demineralisation	O
.	O

The	O
probing	O
pocket	O
depth	O
and	O
bleeding	O
upon	O
probing	O
were	O
not	O
affected	O
.	O

All	O
subjects	O
yielded	O
an	O
intra	O
-	O
individual	O
shift	O
in	O
biofilm	O
composition	O
.	O

The	O
proportion	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
decreased	O
across	O
all	O
subjects	O
.	O

The	O
proportion	O
of	O
Veillonella	B-bacteria
spp	I-bacteria
.	I-bacteria
increased	O
among	O
the	O
children	O
.	O

Poor	O
oral	O
hygiene	O
and	O
change	O
of	O
diet	O
lead	O
to	O
an	O
increase	O
in	O
oral	O
plaque	O
and	O
gingival	O
inflammation	O
.	O

The	O
inter	O
-	O
individual	O
comparison	O
indicated	O
a	O
shift	O
in	O
bacterial	O
composition	O
.	O

Bacillus	B-bacteria
subtilis	I-bacteria
is	O
an	O
effective	O
probiotic	O
product	O
for	O
prevention	O
of	O
enteric	O
infections	O
both	O
in	O
humans	O
and	O
animals	O
.	O

We	O
hypothesized	O
that	O
a	O
mouth	O
rinse	O
containing	O
Bacillus	B-bacteria
subtilis	I-bacteria
should	O
adhere	O
to	O
and	O
colonize	O
part	O
of	O
the	O
oral	O
bacteria	O
on	O
periodontal	O
tissue	O
.	O

The	O
rinsing	O
ability	O
of	O
Extraction	O
300E	O
(	O
containing	O
Bacillus	B-bacteria
subtilis	I-bacteria
:	O
E	O
-	O
300	O
)	O
was	O
compared	O
with	O
that	O
of	O
a	O
mouth	O
wash	O
liquid	O
,	O
Neosteline	O
Green	O
(	O
benzethonium	O
chloride	O
;	O
NG	O
)	O
that	O
is	O
commonly	O
used	O
in	O
Japan	O
.	O

Compared	O
with	O
NG	O
rinsing	O
,	O
E	O
-	O
300	O
rinsing	O
resulted	O
in	O
a	O
marked	O
change	O
in	O
the	O
BANA	O
-	O
score	O
.	O

The	O
mean	O
BANA	O
values	O
(	O
score	O
+	O
/	O
-	O
SD	O
)	O
over	O
the	O
course	O
of	O
the	O
study	O
from	O
0	O
to	O
30	O
days	O
were	O
1	O
.	O
52	O
+	O
/	O
-	O
0	O
.	O
51	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
1	O
)	O
and	O
0	O
.	O
30	O
+	O
/	O
-	O
0	O
.	O
47	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
for	O
E	O
-	O
300	O
,	O
and	O
1	O
.	O
56	O
+	O
/	O
-	O
0	O
.	O
51	O
and	O
0	O
.	O
93	O
+	O
/	O
-	O
0	O
.	O
68	O
for	O
NG	O
,	O
respectively	O
.	O

Gingival	O
Index	O
also	O
had	O
improvement	O
,	O
while	O
probing	O
pocket	O
depth	O
and	O
bleeding	O
on	O
probing	O
showed	O
small	O
improvements	O
.	O

Mouth	O
rinsing	O
with	O
E	O
-	O
300	O
significantly	O
reduced	O
periodontal	O
pathogens	O
compared	O
with	O
NG	O
.	O

These	O
results	O
suggest	O
that	O
Bacillus	B-bacteria
subtilis	I-bacteria
is	O
an	O
appropriate	O
mouth	O
rinse	O
for	O
patients	O
with	O
periodontitis	O
.	O

Two	O
anaerobic	O
,	O
pigmented	O
,	O
non	O
-	O
spore	O
-	O
forming	O
,	O
Gram	O
-	O
stain	O
-	O
negative	O
,	O
rod	O
-	O
shaped	O
strains	O
isolated	O
from	O
the	O
human	O
oral	O
cavity	O
,	O
OMA31	O
(	O
T	O
)	O
and	O
OMA130	O
,	O
were	O
characterized	O
by	O
determining	O
their	O
phenotypic	O
and	O
biochemical	O
features	O
,	O
cellular	O
fatty	O
acid	O
profiles	O
and	O
phylogenetic	O
positions	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequence	O
analysis	O
.	O

16S	O
rRNA	O
gene	O
sequence	O
analysis	O
showed	O
that	O
the	O
new	O
isolates	O
belonged	O
to	O
a	O
single	O
species	O
of	O
the	O
genus	O
Prevotella	B-bacteria
.	O

The	O
two	O
isolates	O
showed	O
100	O
%	O
16S	O
rRNA	O
gene	O
sequence	O
similarity	O
with	O
each	O
other	O
and	O
were	O
most	O
closely	O
related	O
to	O
Prevotella	B-bacteria
intermedia	I-bacteria
ATCC	I-bacteria
25611	I-bacteria
(	O
T	O
)	O
with	O
96	O
.	O
4	O
%	O
16S	O
rRNA	O
gene	O
sequence	O
similarity	O
;	O
the	O
next	O
most	O
closely	O
related	O
strains	O
to	O
the	O
isolates	O
were	O
Prevotella	B-bacteria
pallens	I-bacteria
AHN	I-bacteria
10371	I-bacteria
(	O
T	O
)	O
(	O
96	O
.	O
1	O
%	O
)	O
and	O
Prevotella	B-bacteria
falsenii	I-bacteria
JCM	I-bacteria
15124	I-bacteria
(	O
T	O
)	O
(	O
95	O
.	O
3	O
%	O
)	O
.	O

Phenotypic	O
and	O
biochemical	O
characteristics	O
of	O
the	O
isolates	O
were	O
the	O
same	O
as	O
those	O
of	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
JCM	I-bacteria
12248	I-bacteria
(	O
T	O
)	O
,	O
P	B-bacteria
.	I-bacteria
falsenii	I-bacteria
JCM	I-bacteria
15124	I-bacteria
(	O
T	O
)	O
and	O
Prevotella	B-bacteria
nigrescens	I-bacteria
JCM	I-bacteria
12250	I-bacteria
(	O
T	O
)	O
.	O

The	O
isolates	O
could	O
be	O
differentiated	O
from	O
P	B-bacteria
.	I-bacteria
pallens	I-bacteria
JCM	I-bacteria
11140	I-bacteria
(	O
T	O
)	O
by	O
mannose	O
fermentation	O
and	O
alpha	O
-	O
fucosidase	O
activity	O
.	O

Conventional	O
biochemical	O
tests	O
were	O
unable	O
to	O
differentiate	O
the	O
new	O
isolates	O
from	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
falsenii	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
.	O

However	O
,	O
hsp60	O
gene	O
sequence	O
analysis	O
suggested	O
that	O
strain	O
OMA31	B-bacteria
(	O
T	O
)	O
was	O
not	O
a	O
representative	O
of	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
pallens	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
falsenii	I-bacteria
or	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
.	O

Based	O
on	O
these	O
data	O
,	O
a	O
novel	O
species	O
of	O
the	O
genus	O
Prevotella	B-bacteria
,	O
Prevotella	B-bacteria
aurantiaca	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
is	O
proposed	O
,	O
with	O
OMA31	B-bacteria
(	O
T	O
)	O
(	O
=	O
JCM	B-bacteria
15754	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
57723	I-bacteria
(	O
T	O
)	O
)	O
as	O
the	O
type	O
strain	O
.	O

Lichen	O
planus	O
(	O
LP	O
)	O
is	O
a	O
mucocutaneous	O
disease	O
of	O
unknown	O
aetiology	O
,	O
which	O
may	O
involve	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
mucosa	O
.	O

The	O
association	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
with	O
LP	O
has	O
been	O
a	O
subject	O
of	O
debate	O
.	O

To	O
investigate	O
upper	O
GI	O
findings	O
and	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
GI	O
mucosa	O
and	O
oral	O
LP	O
(	O
OLP	O
)	O
.	O

Oral	O
biopsies	O
from	O
20	O
patients	O
with	O
erosive	O
OLP	O
and	O
20	O
with	O
non	O
-	O
erosive	O
OLP	O
were	O
investigated	O
for	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
by	O
histopathological	O
examination	O
and	O
PCR	O
.	O

Upper	O
GI	O
endoscopy	O
and	O
GI	O
mucosal	O
biopsies	O
were	O
examined	O
for	O
LP	O
lesions	O
and	O
/	O
or	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

The	O
endoscopic	O
findings	O
of	O
both	O
groups	O
were	O
oesophagitis	O
,	O
antral	O
gastritis	O
and	O
duodenitis	O
.	O

No	O
LP	O
or	O
LP	O
-	O
like	O
changes	O
were	O
found	O
in	O
the	O
upper	O
GI	O
mucosa	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
found	O
by	O
histopathological	O
examination	O
in	O
the	O
gastric	O
mucosa	O
of	O
18	O
patients	O
(	O
45	O
%	O
)	O
,	O
with	O
equal	O
distribution	O
in	O
both	O
the	O
control	O
and	O
study	O
groups	O
.	O

Positive	O
PCR	O
results	O
were	O
obtained	O
from	O
biopsy	O
specimens	O
of	O
oral	O
lesions	O
in	O
all	O
patients	O
with	O
erosive	O
OLP	O
and	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
stomach	O
(	O
9	O
patients	O
)	O
,	O
but	O
in	O
none	O
of	O
the	O
patients	O
with	O
non	O
-	O
erosive	O
OLP	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

We	O
did	O
not	O
find	O
any	O
difference	O
in	O
symptoms	O
,	O
endoscopic	O
findings	O
and	O
histopathological	O
results	O
between	O
patients	O
with	O
erosive	O
and	O
non	O
-	O
erosive	O
OLP	O
.	O

However	O
,	O
the	O
concomitant	O
presence	O
of	O
erosive	O
OLP	O
,	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
nucleic	O
acid	O
in	O
erosive	O
OLP	O
and	O
the	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
organisms	O
in	O
gastric	O
mucosa	O
implies	O
a	O
possible	O
pathogenic	O
connection	O
between	O
this	O
bacterium	O
and	O
erosive	O
OLP	O
.	O

A	O
predominant	O
kgp	O
biovar	O
colonized	O
subgingival	O
sites	O
and	O
buccal	O
and	O
tongue	O
mucosa	O
in	O
45	O
of	O
56	O
adults	O
in	O
an	O
isolated	O
community	O
.	O

The	O
presence	O
of	O
biovars	O
381	O
,	O
W83	O
,	O
and	O
W83v	O
,	O
but	O
not	O
HG66	O
,	O
correlated	O
with	O
the	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
load	O
at	O
diseased	O
sites	O
.	O

Biovars	O
W83	O
and	O
W83v	O
poorly	O
colonized	O
tongue	O
and	O
buccal	O
mucosa	O
.	O

to	O
determine	O
the	O
simultaneous	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
both	O
the	O
oral	O
cavity	O
and	O
gastric	O
mucosal	O
in	O
patients	O
suffering	O
digestive	O
pathologies	O
and	O
to	O
establish	O
the	O
possible	O
association	O
between	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
cavity	O
and	O
the	O
gingivoperiodontal	O
pathology	O
.	O

Patients	O
with	O
gastric	O
symptoms	O
(	O
case	O
group	O
)	O
and	O
asymptomatic	O
patients	O
(	O
control	O
group	O
)	O
seen	O
at	O
the	O
Gastroenterology	O
Department	O
of	O
Dr	O
.	O
Julio	O
C	O
.	O
Perrando	O
Hospital	O
(	O
Resistencia	O
,	O
Argentina	O
)	O
were	O
selected	O
.	O

Dental	O
plaque	O
and	O
saliva	O
samples	O
from	O
both	O
groups	O
were	O
obtained	O
.	O

In	O
the	O
case	O
group	O
,	O
gastric	O
biopsy	O
samples	O
were	O
also	O
taken	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
detected	O
in	O
gastric	O
biopsies	O
by	O
histological	O
stains	O
,	O
and	O
Polymerase	O
Chain	O
Reaction	O
(	O
PCR	O
)	O
was	O
carried	O
out	O
on	O
the	O
oral	O
samples	O
.	O

Among	O
the	O
98	O
patients	O
(	O
43	O
cases	O
and	O
55	O
controls	O
)	O
,	O
196	O
oral	O
samples	O
(	O
saliva	O
98	O
,	O
dental	O
plaque	O
98	O
)	O
and	O
43	O
gastric	O
biopsias	O
were	O
obtained	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
detected	O
in	O
oral	O
samples	O
in	O
18	O
/	O
98	O
patients	O
,	O
in	O
gastric	O
biopsies	O
in	O
38	O
/	O
43	O
patients	O
,	O
and	O
in	O
both	O
samples	O
in	O
15	O
/	O
43	O
patients	O
.	O

The	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
cavity	O
of	O
patients	O
suffering	O
digestive	O
pathologies	O
is	O
more	O
frequent	O
in	O
those	O
patients	O
harbouring	O
a	O
gingivoperiodontal	O
disease	O
,	O
and	O
this	O
fact	O
could	O
represent	O
an	O
obstacle	O
for	O
the	O
eradication	O
of	O
the	O
bacterium	O
.	O

At	O
the	O
same	O
time	O
,	O
it	O
could	O
constitute	O
a	O
risk	O
factor	O
for	O
gastrointestinal	O
reinfection	O
after	O
treatment	O
.	O

Toxoplasma	O
gondii	O
is	O
a	O
universally	O
distributed	O
pathogen	O
that	O
infects	O
over	O
one	O
billion	O
people	O
worldwide	O
.	O

Host	O
resistance	O
to	O
this	O
protozoan	O
parasite	O
depends	O
on	O
a	O
Th1	O
immune	O
response	O
with	O
potent	O
production	O
of	O
the	O
cytokines	O
interleukin	O
-	O
12	O
and	O
interferon	O
gamma	O
.	O

Although	O
Toll	O
-	O
like	O
receptor	O
11	O
(	O
TLR11	O
)	O
plays	O
a	O
major	O
role	O
in	O
controlling	O
Th1	O
immunity	O
to	O
this	O
pathogen	O
in	O
mice	O
,	O
this	O
innate	O
immune	O
receptor	O
is	O
nonfunctional	O
in	O
humans	O
,	O
and	O
the	O
mechanisms	O
of	O
TLR11	O
-	O
independent	O
sensing	O
of	O
T	O
.	O
gondii	O
remain	O
elusive	O
.	O

Here	O
,	O
we	O
show	O
that	O
oral	O
infection	O
by	O
T	B-bacteria
.	I-bacteria
gondii	I-bacteria
triggers	O
a	O
TLR11	O
-	O
independent	O
but	O
MyD88	O
-	O
dependent	O
Th1	O
response	O
that	O
is	O
impaired	O
in	O
TLR2xTLR4	O
double	O
knockout	O
and	O
TLR9	O
single	O
knockout	O
mice	O
.	O

These	O
mucosal	O
innate	O
and	O
adaptive	O
immune	O
responses	O
to	O
T	B-bacteria
.	I-bacteria
gondii	I-bacteria
rely	O
on	O
the	O
indirect	O
stimulation	O
of	O
dendritic	O
cells	O
by	O
normal	O
gut	O
microflora	O
.	O

Thus	O
,	O
our	O
results	O
reveal	O
that	O
gut	O
commensal	O
bacteria	O
can	O
serve	O
as	O
molecular	O
adjuvants	O
during	O
parasitic	O
infection	O
,	O
providing	O
indirect	O
immunostimulation	O
that	O
protects	O
against	O
T	B-bacteria
.	I-bacteria
gondii	I-bacteria
in	O
the	O
absence	O
of	O
TLR11	O
.	O

Streptococcus	B-bacteria
is	O
a	O
dominant	O
genus	O
in	O
the	O
human	O
oral	O
cavity	O
,	O
making	O
up	O
about	O
20	O
%	O
of	O
the	O
more	O
than	O
800	O
species	O
of	O
bacteria	O
that	O
have	O
been	O
identified	O
,	O
and	O
about	O
80	O
%	O
of	O
the	O
early	O
biofilm	O
colonizers	O
.	O

Oral	O
streptococci	B-bacteria
include	O
both	O
health	O
-	O
compatible	O
(	O
e	O
.	O
g	O
.	O
Streptococcus	B-bacteria
gordonii	I-bacteria
and	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
)	O
and	O
pathogenic	O
strains	O
(	O
e	O
.	O
g	O
.	O
the	O
cariogenic	O
Streptococcus	B-bacteria
mutans	I-bacteria
)	O
.	O

Because	O
the	O
streptococci	B-bacteria
have	O
similar	O
metabolic	O
requirements	O
,	O
they	O
have	O
developed	O
defence	O
strategies	O
that	O
lead	O
to	O
antagonism	O
(	O
also	O
known	O
as	O
bacterial	O
interference	O
)	O
.	O

S	B-bacteria
.	I-bacteria
mutans	I-bacteria
expresses	O
bacteriocins	O
that	O
are	O
cytotoxic	O
toward	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
,	O
whereas	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
differentially	O
produce	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
(	O
under	O
aerobic	O
growth	O
conditions	O
)	O
,	O
which	O
is	O
relatively	O
toxic	O
toward	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Superimposed	O
on	O
the	O
inter	O
-	O
bacterial	O
combat	O
are	O
the	O
effects	O
of	O
the	O
host	O
defensive	O
mechanisms	O
.	O

We	O
report	O
here	O
on	O
the	O
multifarious	O
effects	O
of	O
bovine	O
lactoperoxidase	O
(	O
bLPO	O
)	O
on	O
the	O
antagonism	O
between	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
versus	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Some	O
of	O
the	O
effects	O
are	O
apparently	O
counterproductive	O
with	O
respect	O
to	O
maintaining	O
a	O
health	O
-	O
compatible	O
population	O
of	O
streptococci	B-bacteria
.	O

For	O
example	O
,	O
the	O
bLPO	O
system	O
(	O
comprised	O
of	O
bLPO	O
+	O
SCN	O
(	O
-	O
)	O
+	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
)	O
destroys	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
,	O
thereby	O
abolishing	O
the	O
ability	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
to	O
inhibit	O
the	O
growth	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Furthermore	O
,	O
bLPO	O
protein	O
(	O
with	O
or	O
without	O
its	O
substrate	O
)	O
inhibits	O
bacterial	O
growth	O
in	O
a	O
biofilm	O
assay	O
,	O
but	O
sucrose	O
negates	O
the	O
inhibitory	O
effects	O
of	O
the	O
bLPO	O
protein	O
,	O
thereby	O
facilitating	O
adherence	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
in	O
lieu	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
.	O

Our	O
findings	O
may	O
be	O
relevant	O
to	O
environmental	O
pressures	O
that	O
select	O
early	O
supragingival	O
colonizers	O
.	O

Human	O
cells	O
express	O
membrane	O
-	O
bound	O
complement	O
regulatory	O
proteins	O
to	O
prevent	O
complement	O
-	O
mediated	O
autologous	O
tissue	O
damage	O
.	O

In	O
this	O
study	O
,	O
we	O
hypothesized	O
that	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
the	O
major	O
etiological	O
agent	O
of	O
chronic	O
periodontitis	O
,	O
causes	O
the	O
shedding	O
or	O
proteolysis	O
of	O
the	O
complement	O
regulatory	O
protein	O
CD46	O
expressed	O
by	O
oral	O
epithelial	O
cells	O
.	O

Oral	O
epithelial	O
cells	O
were	O
treated	O
with	O
a	O
culture	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
before	O
measurement	O
of	O
membrane	O
-	O
bound	O
and	O
shedt	O
CD46	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

The	O
effect	O
of	O
soluble	O
recombinant	O
CD46	O
on	O
secretion	O
of	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
by	O
epithelial	O
cells	O
was	O
evaluated	O
by	O
ELISA	O
.	O

The	O
susceptibility	O
of	O
soluble	O
recombinant	O
CD46	O
to	O
proteolytic	O
degradation	O
by	O
cells	O
and	O
purified	O
Lys	O
-	O
gingipain	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
was	O
investigated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
/	O
western	O
immunoblotting	O
analysis	O
.	O

Oral	O
epithelial	O
cells	O
treated	O
with	O
a	O
culture	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
showed	O
a	O
lower	O
reactivity	O
with	O
antibodies	O
directed	O
to	O
CD46	O
.	O

ELISA	O
revealed	O
that	O
such	O
a	O
treatment	O
resulted	O
in	O
increased	O
amounts	O
of	O
CD46	O
in	O
the	O
conditioned	O
media	O
suggesting	O
that	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
caused	O
the	O
shedding	O
of	O
membrane	O
-	O
anchored	O
CD46	O
.	O

Stimulation	O
of	O
epithelial	O
cells	O
with	O
soluble	O
recombinant	O
CD46	O
induced	O
IL	O
-	O
8	O
secretion	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Whole	O
cells	O
and	O
purified	O
Lys	O
-	O
gingipain	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
degraded	O
recombinant	O
CD46	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

This	O
study	O
showed	O
the	O
ability	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
to	O
induce	O
the	O
shedding	O
/	O
proteolysis	O
of	O
CD46	O
from	O
the	O
surface	O
of	O
oral	O
epithelial	O
cells	O
.	O

This	O
may	O
render	O
host	O
cells	O
susceptible	O
to	O
the	O
complement	O
system	O
and	O
contribute	O
to	O
tissue	O
damage	O
and	O
the	O
inflammatory	O
process	O
in	O
periodontitis	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
can	O
integrate	O
into	O
T	O
cells	O
,	O
macrophages	O
and	O
dendritic	O
cells	O
resulting	O
in	O
a	O
latent	O
infection	O
.	O

Reports	O
have	O
also	O
demonstrated	O
that	O
various	O
microbial	O
and	O
host	O
cell	O
factors	O
can	O
trigger	O
HIV	O
reactivation	O
leading	O
to	O
HIV	O
recrudescence	O
,	O
potentially	O
undermining	O
highly	O
active	O
antiretroviral	O
therapies	O
.	O

This	O
study	O
evaluated	O
the	O
capacity	O
of	O
oral	O
bacteria	O
associated	O
with	O
chronic	O
periodontal	O
infections	O
to	O
stimulate	O
HIV	O
promoter	O
activation	O
in	O
various	O
cell	O
models	O
of	O
HIV	O
latency	O
.	O

T	O
cells	O
(	O
1G5	O
)	O
challenged	O
with	O
oral	O
bacteria	O
demonstrated	O
a	O
dose	O
-	O
response	O
of	O
HIV	O
promoter	O
activation	O
with	O
a	O
subset	O
of	O
the	O
bacteria	O
,	O
as	O
well	O
as	O
kinetics	O
that	O
were	O
generally	O
similar	O
irrespective	O
of	O
the	O
stimuli	O
.	O

Direct	O
bacterial	O
challenge	O
of	O
the	O
T	O
cells	O
resulted	O
in	O
increased	O
activation	O
of	O
approximately	O
1	O
.	O
5	O
-	O
to	O
7	O
-	O
fold	O
over	O
controls	O
.	O

Challenge	O
of	O
macrophages	O
(	O
BF24	O
)	O
indicated	O
different	O
kinetics	O
for	O
individual	O
bacteria	O
and	O
resulted	O
in	O
consistent	O
increases	O
in	O
promoter	O
activation	O
of	O
five	O
fold	O
to	O
six	O
fold	O
over	O
basal	O
levels	O
for	O
all	O
bacteria	O
except	O
Streptococcus	B-bacteria
mutans	I-bacteria
.	O

Dendritic	O
cells	O
showed	O
increases	O
in	O
HIV	O
reactivation	O
of	O
7	O
-	O
to	O
34	O
-	O
fold	O
specific	O
for	O
individual	O
species	O
of	O
bacteria	O
.	O

These	O
results	O
suggested	O
that	O
oral	O
bacteria	O
have	O
the	O
capability	O
to	O
reactivate	O
HIV	O
from	O
latently	O
infected	O
cells	O
,	O
showing	O
a	O
relationship	O
of	O
mature	O
dendritic	O
cells	O
>	O
immature	O
dendritic	O
cells	O
>	O
macrophages	O
>	O
or	O
=	O
T	O
cells	O
.	O

Expression	O
of	O
various	O
pattern	O
recognition	O
receptors	O
on	O
these	O
various	O
cell	O
types	O
may	O
provide	O
insight	O
into	O
the	O
primary	O
receptors	O
/	O
signaling	O
pathways	O
used	O
for	O
reactivation	O
by	O
the	O
bacteria	O
.	O

Lactoferrin	O
(	O
Lf	O
)	O
,	O
an	O
iron	O
-	O
binding	O
salivary	O
glycoprotein	O
,	O
plays	O
an	O
important	O
role	O
in	O
human	O
innate	O
defense	O
against	O
local	O
mucosal	O
infection	O
.	O

We	O
hypothesized	O
that	O
Lf	O
interferes	O
with	O
initial	O
oral	O
bacterial	O
attachment	O
to	O
surfaces	O
by	O
iron	O
sequestration	O
,	O
so	O
inhibiting	O
subsequent	O
biofilm	O
formation	O
.	O

The	O
objective	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
Lf	O
on	O
the	O
early	O
stages	O
of	O
single	O
-	O
species	O
and	O
multi	O
-	O
species	O
oral	O
biofilm	O
development	O
.	O

Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
were	O
used	O
in	O
this	O
study	O
.	O

Glass	O
disks	O
of	O
a	O
two	O
-	O
track	O
flow	O
cell	O
coated	O
with	O
flowing	O
artificial	O
saliva	O
(	O
0	O
.	O
3	O
ml	O
/	O
min	O
)	O
with	O
and	O
without	O
Lf	O
(	O
100	O
microg	O
/	O
ml	O
)	O
were	O
used	O
for	O
studying	O
bacterial	O
attachment	O
(	O
3	O
h	O
,	O
37	O
degrees	O
C	O
)	O
.	O

Attachment	O
was	O
also	O
examined	O
by	O
incubating	O
single	O
or	O
multiple	O
species	O
of	O
test	O
bacteria	O
(	O
10	O
(	O
7	O
)	O
colony	O
-	O
forming	O
units	O
/	O
ml	O
)	O
with	O
Lf	O
-	O
coated	O
(	O
20	O
-	O
100	O
microg	O
/	O
ml	O
)	O
and	O
uncoated	O
glass	O
slides	O
.	O

The	O
effects	O
of	O
beta	O
-	O
lactoglobulin	O
,	O
2	O
,	O
2	O
'	O
-	O
dipyridyl	O
(	O
25	O
-	O
100	O
microg	O
/	O
ml	O
)	O
,	O
an	O
iron	O
chelator	O
,	O
and	O
FeCl3	O
on	O
attachment	O
were	O
also	O
examined	O
.	O

Lf	O
inhibited	O
the	O
initial	O
attachment	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
(	O
50	O
.	O
3	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
not	O
that	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

However	O
,	O
the	O
attachment	O
of	O
a	O
dual	O
-	O
species	O
biofilm	O
containing	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
(	O
i	O
.	O
e	O
.	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
/	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
or	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
/	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
)	O
was	O
significantly	O
reduced	O
(	O
48	O
.	O
7	O
%	O
or	O
62	O
.	O
1	O
%	O
,	O
respectively	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
presence	O
of	O
Lf	O
.	O

beta	O
-	O
Lactoglobulin	O
did	O
not	O
affect	O
the	O
attachment	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
.	O

In	O
the	O
presence	O
of	O
100	O
microm	O
2	O
,	O
2	O
'	O
-	O
dipyridyl	O
,	O
attachment	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
was	O
reduced	O
by	O
53	O
.	O
87	O
%	O
.	O

No	O
reduction	O
in	O
attachment	O
was	O
noted	O
in	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
pretreated	O
with	O
Lf	O
(	O
100	O
microg	O
/	O
ml	O
)	O
and	O
FeCl3	O
(	O
20	O
-	O
200	O
microm	O
)	O
.	O

Lf	O
suppresses	O
initial	O
attachment	O
of	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
gordonii	I-bacteria
coaggregates	O
by	O
iron	O
sequestration	O
.	O

This	O
may	O
lead	O
to	O
subsequent	O
inhibition	O
of	O
oral	O
biofilm	O
development	O
.	O

Increasing	O
evidence	O
suggests	O
a	O
role	O
for	O
methanogenic	O
archaea	O
(	O
methanogens	O
)	O
in	O
human	O
health	O
and	O
disease	O
via	O
syntrophic	O
interactions	O
with	O
bacteria	O
.	O

Here	O
we	O
assessed	O
the	O
prevalence	O
and	O
distribution	O
of	O
methanogens	O
and	O
possible	O
associations	O
with	O
bacteria	O
in	O
oral	O
biofilms	O
.	O

Forty	O
-	O
four	O
periodontal	O
and	O
32	O
endodontic	O
samples	O
from	O
necrotic	O
teeth	O
with	O
radiographic	O
evidence	O
of	O
apical	O
periodontitis	O
were	O
analysed	O
.	O

Terminal	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
based	O
on	O
the	O
mcrA	O
gene	O
,	O
specific	O
to	O
methanogens	O
,	O
was	O
applied	O
.	O

The	O
prevalence	O
and	O
amounts	O
of	O
methanogens	O
in	O
endodontic	O
samples	O
were	O
compared	O
with	O
those	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
Treponema	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
Synergistes	B-bacteria
spp	I-bacteria
.	I-bacteria
based	O
on	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reactions	O
.	O

Besides	O
dominance	O
of	O
the	O
mcrA	O
gene	O
corresponding	O
to	O
Methanobrevibacter	B-bacteria
oralis	I-bacteria
,	O
one	O
mcrA	O
gene	O
type	O
,	O
for	O
which	O
no	O
cultivated	O
member	O
has	O
been	O
reported	O
previously	O
,	O
was	O
identified	O
in	O
five	O
periodontal	O
samples	O
and	O
one	O
endodontic	O
sample	O
.	O

Rates	O
of	O
non	O
-	O
synonymous	O
vs	O
.	O
synonymous	O
nucleotide	O
substitutions	O
suggest	O
that	O
this	O
mcrA	O
gene	O
type	O
codes	O
for	O
a	O
functionally	O
active	O
methyl	O
-	O
coenzyme	O
M	O
reductase	O
.	O

Methanobrevibacter	B-bacteria
smithii	I-bacteria
,	O
the	O
prominent	O
methanogent	O
in	O
the	O
human	O
gut	O
system	O
,	O
was	O
not	O
detected	O
.	O

Mean	O
proportions	O
of	O
methanogenst	O
were	O
comparable	O
to	O
Synergistes	B-bacteria
spp	I-bacteria
.	I-bacteria
ranging	O
from	O
0	O
.	O
5	O
to	O
1	O
.	O
0	O
%	O
of	O
the	O
total	O
microbial	O
community	O
.	O

Treponema	B-bacteria
spp	I-bacteria
.	I-bacteria
dominated	O
with	O
a	O
mean	O
proportion	O
of	O
10	O
%	O
,	O
while	O
the	O
mean	O
proportions	O
of	O
the	O
other	O
endodontic	O
pathogens	O
were	O
below	O
0	O
.	O
1	O
%	O
.	O

A	O
positive	O
association	O
between	O
methanogens	O
and	O
Synergistes	B-bacteria
spp	I-bacteria
.	I-bacteria
was	O
found	O
.	O

Our	O
data	O
provide	O
evidence	O
of	O
a	O
novel	O
,	O
as	O
yet	O
uncultured	O
methanogenict	O
phylotypet	O
in	O
association	O
with	O
oral	O
infections	O
,	O
and	O
indicate	O
possible	O
interactions	O
between	O
methanogenst	O
and	O
Synergistes	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
the	O
nature	O
of	O
which	O
deserves	O
further	O
investigation	O
.	O

This	O
study	O
compared	O
the	O
subgingival	O
microbiota	O
of	O
subjects	O
with	O
refractory	O
periodontitis	O
(	O
RP	O
)	O
to	O
those	O
in	O
subjects	O
with	O
treatable	O
periodontitis	O
(	O
GRs	O
=	O
good	O
responders	O
)	O
or	O
periodontal	O
health	O
(	O
PH	O
)	O
using	O
the	O
Human	O
Oral	O
Microbe	O
Identification	O
Microarray	O
(	O
HOMIM	O
)	O
.	O

At	O
baseline	O
,	O
subgingival	O
plaque	O
samples	O
were	O
taken	O
from	O
47	O
subjects	O
with	O
periodontitis	O
and	O
20	O
individuals	O
with	O
PH	O
and	O
analyzed	O
for	O
the	O
presence	O
of	O
300	O
species	O
by	O
HOMIM	O
.	O

The	O
subjects	O
with	O
periodontitis	O
were	O
classified	O
as	O
having	O
RP	O
(	O
n	O
=	O
17	O
)	O
based	O
on	O
mean	O
attachment	O
loss	O
(	O
AL	O
)	O
and	O
/	O
or	O
more	O
than	O
three	O
sites	O
with	O
AL	O
>	O
or	O
=	O
2	O
.	O
5	O
mm	O
after	O
scaling	O
and	O
root	O
planing	O
,	O
surgery	O
,	O
and	O
systemically	O
administered	O
amoxicillin	O
and	O
metronidazole	O
or	O
as	O
GRs	O
(	O
n	O
=	O
30	O
)	O
based	O
on	O
mean	O
attachment	O
gain	O
and	O
no	O
sites	O
with	O
AL	O
>	O
or	O
=	O
2	O
.	O
5	O
mm	O
after	O
treatment	O
.	O

Significant	O
differences	O
in	O
taxa	O
among	O
the	O
groups	O
were	O
sought	O
using	O
the	O
Kruskal	O
-	O
Wallis	O
and	O
chi	O
(	O
2	O
)	O
tests	O
.	O

More	O
species	O
were	O
detected	O
in	O
patients	O
with	O
disease	O
(	O
GR	O
or	O
RP	O
)	O
than	O
in	O
those	O
without	O
disease	O
(	O
PH	O
)	O
.	O

Subjects	O
with	O
RP	O
were	O
distinguished	O
from	O
GRs	O
or	O
those	O
with	O
PH	O
by	O
a	O
significantly	O
higher	O
frequency	O
of	O
putative	O
periodontal	O
pathogens	O
,	O
such	O
as	O
Parvimonas	B-bacteria
micra	I-bacteria
(	O
previously	O
Peptostreptococcus	B-bacteria
micros	I-bacteria
or	O
Micromonas	B-bacteria
micros	I-bacteria
)	O
,	O
Campylobacter	B-bacteria
gracilis	I-bacteria
,	O
Eubacterium	B-bacteria
nodatum	I-bacteria
,	O
Selenomonas	B-bacteria
noxia	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
(	O
previously	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
)	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Treponema	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
and	O
Eikenella	B-bacteria
corrodens	I-bacteria
,	O
as	O
well	O
as	O
unusual	O
species	O
(	O
Pseudoramibacter	B-bacteria
alactolyticus	I-bacteria
,	O
TM7	B-bacteria
spp	I-bacteria
.	I-bacteria
oral	I-bacteria
taxon	I-bacteria
[	I-bacteria
OT	I-bacteria
]	I-bacteria
346	I-bacteria
/	I-bacteria
356	I-bacteria
,	O
Bacteroidetes	B-bacteria
sp	I-bacteria
.	I-bacteria
OT	I-bacteria
272	I-bacteria
/	I-bacteria
274	I-bacteria
,	O
Solobacterium	B-bacteria
moorei	I-bacteria
,	O
Desulfobulbus	B-bacteria
sp	I-bacteria
.	I-bacteria
OT	I-bacteria
041	I-bacteria
,	O
Brevundimonas	B-bacteria
diminuta	I-bacteria
,	O
Sphaerocytophaga	B-bacteria
sp	I-bacteria
.	O

OT	B-bacteria
337	I-bacteria
,	O
Shuttleworthia	B-bacteria
satelles	I-bacteria
,	O
Filifactor	B-bacteria
alocis	I-bacteria
,	O
Dialister	B-bacteria
invisus	I-bacteria
/	I-bacteria
pneumosintes	I-bacteria
,	O
Granulicatella	B-bacteria
adiacens	I-bacteria
,	O
Mogibacterium	B-bacteria
timidum	I-bacteria
,	O
Veillonella	B-bacteria
atypica	I-bacteria
,	O
Mycoplasma	B-bacteria
salivarium	I-bacteria
,	O
Synergistes	B-bacteria
sp	I-bacteria
.	I-bacteria
cluster	I-bacteria
II	I-bacteria
,	O
and	O
Acidaminococcaceae	B-bacteria
[	I-bacteria
G	I-bacteria
-	I-bacteria
1	I-bacteria
]	I-bacteria
sp	I-bacteria
.	I-bacteria
OT	I-bacteria
132	I-bacteria
/	I-bacteria
150	I-bacteria
/	I-bacteria
155	I-bacteria
/	I-bacteria
148	I-bacteria
/	I-bacteria
135	I-bacteria
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Species	O
that	O
were	O
more	O
prevalent	O
in	O
subjects	O
with	O
PH	O
than	O
in	O
patients	O
with	O
periodontitis	O
included	O
Actinomyces	B-bacteria
sp	I-bacteria
.	I-bacteria
OT	I-bacteria
170	I-bacteria
,	O
Actinomyces	B-bacteria
spp	I-bacteria
.	I-bacteria
cluster	I-bacteria
I	I-bacteria
,	O
Capnocytophaga	B-bacteria
sputigena	I-bacteria
,	O
Cardiobacterium	B-bacteria
hominis	I-bacteria
,	O
Haemophilus	B-bacteria
parainfluenzae	I-bacteria
,	O
Lautropia	B-bacteria
mirabilis	I-bacteria
,	O
Propionibacterium	B-bacteria
propionicum	I-bacteria
,	O
Rothia	B-bacteria
dentocariosa	I-bacteria
/	I-bacteria
mucilaginosa	I-bacteria
,	O
and	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

As	O
determined	O
by	O
HOMIM	O
,	O
patients	O
with	O
RP	O
presented	O
a	O
distinct	O
microbial	O
profile	O
compared	O
to	O
patients	O
in	O
the	O
GR	O
and	O
PH	O
groups	O
.	O

We	O
have	O
analyzed	O
the	O
total	O
metagenomic	O
DNA	O
from	O
both	O
human	O
oral	O
and	O
fecal	O
samples	O
derived	O
from	O
healthy	O
volunteers	O
from	O
six	O
European	O
countries	O
to	O
determine	O
the	O
molecular	O
basis	O
for	O
tetracycline	O
and	O
erythromycin	O
resistance	O
.	O

We	O
have	O
determined	O
that	O
tet	O
(	O
M	O
)	O
and	O
tet	O
(	O
W	O
)	O
are	O
the	O
most	O
prevalent	O
tetracycline	O
resistance	O
genes	O
assayed	O
for	O
in	O
the	O
oral	O
and	O
fecal	O
metagenomes	O
,	O
respectively	O
.	O

Additionally	O
,	O
tet	O
(	O
Q	O
)	O
,	O
tet	O
(	O
O	O
)	O
,	O
and	O
tet	O
(	O
O	O
/	O
32	O
/	O
O	O
)	O
have	O
been	O
shown	O
to	O
be	O
common	O
.	O

We	O
have	O
also	O
shown	O
that	O
erm	O
(	O
B	O
)	O
,	O
erm	O
(	O
V	O
)	O
,	O
and	O
erm	O
(	O
E	O
)	O
are	O
common	O
erythromycin	O
resistance	O
genes	O
present	O
in	O
these	O
environments	O
.	O

Further	O
,	O
we	O
have	O
demonstrated	O
the	O
ubiquitous	O
presence	O
of	O
the	O
Tn916	O
integrase	O
in	O
the	O
oral	O
metagenomes	O
and	O
the	O
Tn4451	O
and	O
Tn1549	O
integrase	O
genes	O
within	O
the	O
fecal	O
metagenomes	O
.	O

To	O
characterize	O
the	O
clinical	O
manifestations	O
of	O
Actinomyces	O
-	O
associated	O
lesions	O
of	O
the	O
oral	O
mucosa	O
and	O
jawbones	O
,	O
and	O
to	O
correlate	O
the	O
clinical	O
course	O
and	O
treatment	O
requirements	O
with	O
the	O
findings	O
of	O
histomorphometric	O
analysis	O
.	O

The	O
study	O
was	O
a	O
10	O
-	O
year	O
retrospective	O
analysis	O
of	O
archived	O
cases	O
with	O
microscopic	O
identification	O
of	O
Actinomyces	B-bacteria
infection	O
.	O

Actinomyces	B-bacteria
colonies	O
were	O
identified	O
,	O
using	O
hematoxylin	O
-	O
eosin	O
,	O
Gram	O
,	O
and	O
periodic	O
acid	O
-	O
Schiff	O
stains	O
,	O
exhibiting	O
filamentous	O
morphology	O
with	O
color	O
variation	O
between	O
center	O
and	O
periphery	O
.	O

Only	O
colonies	O
with	O
adjacent	O
tissue	O
reaction	O
(	O
inflammation	O
,	O
fibrosis	O
)	O
were	O
analyzed	O
.	O

Actinomyces	B-bacteria
density	O
(	O
AD	O
)	O
was	O
calculated	O
by	O
dividing	O
total	O
number	O
of	O
colonies	O
by	O
tissue	O
surface	O
,	O
Actinomyces	B-bacteria
relative	O
surface	O
(	O
ARS	O
)	O
was	O
calculated	O
by	O
dividing	O
total	O
bacterial	O
surface	O
by	O
tissue	O
surface	O
.	O

The	O
study	O
included	O
106	O
cases	O
(	O
48	O
male	O
,	O
58	O
female	O
;	O
aged	O
13	O
-	O
84	O
years	O
,	O
mean	O
50	O
.	O
5	O
years	O
)	O
.	O

Cases	O
presented	O
a	O
wide	O
clinical	O
spectrum	O
,	O
involving	O
jawbone	O
and	O
/	O
or	O
oral	O
soft	O
tissues	O
.	O

Cases	O
included	O
osteomyelitis	O
associated	O
with	O
bisphosphonates	O
,	O
osteoradionecrosis	O
,	O
osteomyelitis	O
unrelated	O
to	O
radiation	O
or	O
bisphosphonates	O
,	O
periapical	O
lesions	O
,	O
odontogenic	O
cysts	O
,	O
periimplantitis	O
,	O
and	O
lesion	O
mimicking	O
periodontal	O
disease	O
.	O

The	O
AD	O
correlated	O
with	O
median	O
length	O
of	O
antibiotic	O
treatment	O
(	O
R	O
=	O
0	O
.	O
284	O
;	O
P	O
=	O
.	O
028	O
)	O
.	O

Because	O
we	O
were	O
able	O
to	O
identify	O
106	O
such	O
cases	O
,	O
the	O
results	O
indicate	O
that	O
Actinomyces	O
-	O
associated	O
lesions	O
may	O
not	O
be	O
as	O
rare	O
as	O
would	O
be	O
expected	O
from	O
the	O
relatively	O
low	O
number	O
of	O
cases	O
in	O
the	O
literature	O
.	O

Actinomyces	O
-	O
associated	O
lesions	O
presented	O
in	O
a	O
wide	O
spectrum	O
of	O
clinical	O
settings	O
and	O
a	O
variety	O
of	O
contributing	O
factors	O
.	O

Quantitative	O
analysis	O
of	O
the	O
number	O
of	O
bacterial	O
colonies	O
(	O
representing	O
bacterial	O
load	O
)	O
could	O
help	O
in	O
evaluating	O
the	O
aggressive	O
potential	O
of	O
the	O
lesion	O
and	O
help	O
in	O
treatment	O
planning	O
.	O

Dental	O
plaque	O
biofilms	O
are	O
colonized	O
by	O
respiratory	O
pathogens	O
in	O
mechanically	O
-	O
ventilated	O
intensive	O
care	O
unit	O
patients	O
.	O

Thus	O
,	O
improvements	O
in	O
oral	O
hygiene	O
in	O
these	O
patients	O
may	O
prevent	O
ventilator	O
-	O
associated	O
pneumonia	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
minimum	O
frequency	O
(	O
once	O
or	O
twice	O
a	O
day	O
)	O
for	O
0	O
.	O
12	O
%	O
chlorhexidine	O
gluconate	O
application	O
necessary	O
to	O
reduce	O
oral	O
colonization	O
by	O
pathogens	O
in	O
175	O
intubated	O
patients	O
in	O
a	O
trauma	O
intensive	O
care	O
unit	O
.	O

A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
tested	O
oral	O
topical	O
0	O
.	O
12	O
%	O
chlorhexidine	O
gluconate	O
or	O
placebo	O
(	O
vehicle	O
alone	O
)	O
,	O
applied	O
once	O
or	O
twice	O
a	O
day	O
by	O
staff	O
nurses	O
.	O

Quantitation	O
of	O
colonization	O
of	O
the	O
oral	O
cavity	O
by	O
respiratory	O
pathogens	O
(	O
teeth	O
/	O
denture	O
/	O
buccal	O
mucosa	O
)	O
was	O
measured	O
.	O

Subjects	O
were	O
recruited	O
from	O
1	O
March	O
,	O
2004	O
until	O
30	O
November	O
,	O
2007	O
.	O

While	O
175	O
subjects	O
were	O
randomized	O
,	O
microbiologic	O
baseline	O
data	O
was	O
available	O
for	O
146	O
subjects	O
,	O
with	O
115	O
subjects	O
having	O
full	O
outcome	O
assessment	O
after	O
at	O
least	O
48	O
hours	O
.	O

Chlorhexidine	O
reduced	O
the	O
number	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
but	O
not	O
the	O
total	O
number	O
of	O
enterics	B-bacteria
,	O
Pseudomonas	B-bacteria
or	O
Acinetobacter	B-bacteria
in	O
the	O
dental	O
plaque	O
of	O
test	O
subjects	O
.	O

A	O
non	O
-	O
significant	O
reduction	O
in	O
pneumonia	O
rate	O
was	O
noted	O
in	O
groups	O
treated	O
with	O
chlorhexidine	O
compared	O
with	O
the	O
placebo	O
group	O
(	O
OR	O
=	O
0	O
.	O
54	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
23	O
to	O
1	O
.	O
25	O
,	O
P	O
=	O
0	O
.	O
15	O
)	O
.	O

No	O
evidence	O
for	O
resistance	O
to	O
chlorhexidine	O
was	O
noted	O
,	O
and	O
no	O
adverse	O
events	O
were	O
observed	O
.	O

No	O
differences	O
were	O
noted	O
in	O
microbiologic	O
or	O
clinical	O
outcomes	O
between	O
treatment	O
arms	O
.	O

While	O
decontamination	O
of	O
the	O
oral	O
cavity	O
with	O
chlorhexidine	O
did	O
not	O
reduce	O
the	O
total	O
number	O
of	O
potential	O
respiratory	O
pathogens	O
,	O
it	O
did	O
reduce	O
the	O
number	O
of	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
in	O
dental	O
plaque	O
of	O
trauma	O
intensive	O
care	O
patients	O
.	O

The	O
human	O
gastrointestinal	O
tract	O
is	O
home	O
to	O
hundreds	O
of	O
species	O
of	O
bacteria	O
and	O
the	O
balance	O
between	O
beneficial	O
and	O
pathogenic	O
bacteria	O
plays	O
a	O
critical	O
role	O
in	O
human	O
health	O
and	O
disease	O
.	O

The	O
human	O
infant	O
,	O
however	O
,	O
is	O
born	O
with	O
a	O
sterile	O
gut	O
and	O
the	O
complex	O
gastrointestinal	O
host	O
/	O
bacterial	O
ecosystem	O
is	O
only	O
established	O
after	O
birth	O
by	O
rapid	O
bacterial	O
colonization	O
.	O

Composition	O
of	O
newborn	O
gut	O
flora	O
depends	O
on	O
several	O
factors	O
including	O
type	O
of	O
birth	O
(	O
Ceasarian	O
or	O
natural	O
)	O
,	O
manner	O
of	O
early	O
feeding	O
(	O
breast	O
milk	O
or	O
formula	O
)	O
,	O
and	O
exposure	O
to	O
local	O
,	O
physical	O
environment	O
.	O

Imbalance	O
in	O
normal	O
,	O
healthy	O
gut	O
flora	O
contributes	O
to	O
several	O
adult	O
human	O
diseases	O
including	O
inflammatory	O
bowel	O
(	O
ulcerative	O
colitis	O
and	O
Crohn	O
'	O
s	O
disease	O
)	O
and	O
Clostridium	B-bacteria
difficile	I-bacteria
associated	O
disease	O
,	O
and	O
early	O
childhood	O
diseases	O
such	O
as	O
necrotizing	O
enterocolitis	O
.	O

As	O
a	O
first	O
step	O
towards	O
characterization	O
of	O
the	O
role	O
of	O
gut	O
bacteria	O
in	O
human	O
health	O
and	O
disease	O
,	O
we	O
conducted	O
an	O
850	O
MHz	O
(	O
1	O
)	O
H	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
study	O
to	O
monitor	O
changes	O
in	O
metabolic	O
profiles	O
of	O
urine	O
and	O
fecal	O
extracts	O
of	O
15	O
mice	O
following	O
gut	O
sterilization	O
by	O
the	O
broad	O
-	O
spectrum	O
antibiotic	O
enrofloxacin	O
(	O
also	O
known	O
as	O
Baytril	O
)	O
.	O

Ten	O
metabolites	O
changed	O
in	O
urine	O
following	O
enrofloxacin	O
treatment	O
including	O
decreased	O
acetate	O
due	O
to	O
loss	O
of	O
microbial	O
catabolism	O
of	O
sugars	O
and	O
polysaccharides	O
,	O
decreased	O
trimethylamine	O
-	O
N	O
-	O
oxide	O
due	O
to	O
loss	O
of	O
microbial	O
catabolism	O
of	O
choline	O
,	O
and	O
increased	O
creatine	O
and	O
creatinine	O
due	O
to	O
loss	O
of	O
microbial	O
enzyme	O
degradation	O
.	O

Eight	O
metabolites	O
changed	O
in	O
fecal	O
extracts	O
of	O
mice	O
treated	O
with	O
enrofloxacin	O
including	O
depletion	O
of	O
amino	O
acids	O
produced	O
by	O
microbial	O
proteases	O
,	O
reduction	O
in	O
metabolites	O
generated	O
by	O
lactate	O
-	O
utilizing	O
bacteria	O
,	O
and	O
increased	O
urea	O
caused	O
by	O
loss	O
of	O
microbial	O
ureases	O
.	O

Mouth	O
dryness	O
is	O
one	O
of	O
the	O
major	O
problems	O
that	O
can	O
lead	O
to	O
several	O
oral	O
diseases	O
such	O
as	O
dental	O
caries	O
,	O
periodontitis	O
and	O
oral	O
infection	O
.	O

Mouth	O
dryness	O
has	O
also	O
been	O
associated	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
xerostomia	O
(	O
feeling	O
of	O
mouth	O
dryness	O
)	O
,	O
hyposalivation	O
(	O
the	O
reduction	O
of	O
saliva	O
)	O
,	O
and	O
oral	O
microbiota	O
in	O
Thai	O
patients	O
with	O
type	O
2	O
DM	O
.	O

One	O
hundred	O
and	O
fifty	O
-	O
four	O
ambulatory	O
patients	O
with	O
type	O
2	O
DM	O
and	O
50	O
non	O
-	O
diabetic	O
control	O
subjects	O
were	O
interviewed	O
for	O
symptoms	O
of	O
xerostomia	O
.	O

The	O
medical	O
records	O
of	O
these	O
subjects	O
were	O
reviewed	O
for	O
pertinent	O
medical	O
history	O
and	O
laboratory	O
investigations	O
regarding	O
their	O
diabetic	O
control	O
.	O

Oral	O
examination	O
and	O
measurement	O
of	O
hyposalivation	O
using	O
a	O
modified	O
Schirmer	O
test	O
(	O
MST	O
)	O
were	O
performed	O
The	O
presence	O
of	O
oral	O
microbial	O
flora	O
was	O
investigated	O
using	O
a	O
modified	O
dip	O
-	O
slide	O
test	O
.	O

The	O
prevalence	O
of	O
xerostomia	O
was	O
62	O
%	O
in	O
patients	O
with	O
type	O
2	O
DM	O
compared	O
with	O
36	O
%	O
in	O
the	O
nondiabetic	O
control	O
group	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
prevalence	O
of	O
hyposalivation	O
(	O
defined	O
as	O
MST	O
values	O
<	O
or	O
=	O
25	O
mm	O
at	O
3	O
min	O
)	O
was	O
46	O
%	O
in	O
the	O
patient	O
group	O
,	O
whereas	O
only	O
28	O
%	O
of	O
the	O
control	O
group	O
had	O
hyposalivation	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

Patients	O
with	O
hyposalivation	O
had	O
significantly	O
higher	O
numbers	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
,	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
and	O
Candida	O
spp	O
.	O
in	O
the	O
saliva	O
compared	O
with	O
those	O
without	O
hyposalivation	O
.	O

These	O
results	O
suggested	O
that	O
xerostomia	O
and	O
hyposalivation	O
were	O
prevalent	O
in	O
patients	O
with	O
type	O
2	O
DM	O
and	O
were	O
associated	O
with	O
higher	O
numbers	O
of	O
oral	O
pathogens	O
in	O
the	O
saliva	O
.	O

Betel	O
chewing	O
has	O
been	O
shown	O
to	O
predispose	O
to	O
periodontal	O
disease	O
and	O
oral	O
cancer	O
.	O

Studies	O
show	O
that	O
people	O
with	O
gum	O
disease	O
are	O
more	O
likely	O
to	O
test	O
positive	O
for	O
Helicobacter	B-bacteria
pylori	I-bacteria
(	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
)	O
.	O

It	O
is	O
not	O
known	O
if	O
the	O
lesions	O
produced	O
by	O
betel	O
quid	O
and	O
the	O
resulting	O
,	O
chemical	O
changes	O
predispose	O
to	O
colonization	O
by	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

Further	O
the	O
role	O
of	O
this	O
organism	O
in	O
oral	O
cancer	O
is	O
not	O
known	O
.	O

Our	O
objective	O
was	O
to	O
determine	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
oral	O
lesions	O
of	O
thirty	O
oral	O
cancer	O
patients	O
and	O
to	O
determine	O
the	O
presence	O
of	O
IgG	O
antibodies	O
to	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
oral	O
cancer	O
patients	O
who	O
are	O
betel	O
chewers	O
and	O
non	O
betel	O
chewers	O
,	O
healthy	O
betel	O
chewers	O
and	O
healthy	O
non	O
-	O
betel	O
chewers	O
and	O
to	O
compare	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
these	O
four	O
groups	O
.	O

This	O
case	O
control	O
study	O
was	O
conducted	O
at	O
the	O
Cancer	O
Institute	O
Maharagama	O
and	O
the	O
Department	O
of	O
Microbiology	O
,	O
Faculty	O
of	O
Medical	O
Sciences	O
,	O
University	O
of	O
Sri	O
Jayewardenepura	O
.	O

One	O
hundred	O
and	O
seventy	O
three	O
subjects	O
,	O
of	O
whom	O
fifty	O
three	O
were	O
patients	O
presenting	O
with	O
oral	O
cancer	O
to	O
the	O
Cancer	O
Institute	O
Maharagama	O
,	O
sixty	O
healthy	O
betel	O
chewers	O
and	O
sixty	O
healthy	O
non	O
-	O
betel	O
chewers	O
from	O
the	O
Religious	O
and	O
Welfare	O
Service	O
Centre	O
Maharagama	O
were	O
tested	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
by	O
serology	O
.	O

Thirty	O
oral	O
biopsies	O
from	O
oral	O
cancer	O
patients	O
were	O
cultured	O
under	O
microaerophilic	O
condition	O
to	O
isolate	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

The	O
statistic	O
used	O
was	O
Chi	O
-	O
square	O
test	O
.	O

Of	O
the	O
fifty	O
-	O
three	O
oral	O
cancer	O
patients	O
,	O
forty	O
-	O
four	O
were	O
betel	O
chewers	O
.	O

Among	O
the	O
53	O
oral	O
cancer	O
patients	O
examined	O
,	O
ten	O
of	O
forty	O
-	O
four	O
(	O
10	O
/	O
44	O
=	O
22	O
.	O
7	O
%	O
)	O
patients	O
who	O
are	O
betel	O
chewers	O
and	O
four	O
of	O
nine	O
(	O
4	O
/	O
9	O
=	O
44	O
.	O
4	O
%	O
)	O
patients	O
who	O
are	O
non	O
-	O
betel	O
chewers	O
were	O
detected	O
positive	O
for	O
IgG	O
antibody	O
against	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

In	O
the	O
healthy	O
group	O
(	O
betel	O
chewers	O
and	O
non	O
betel	O
chewers	O
)	O
ten	O
(	O
16	O
.	O
7	O
%	O
)	O
of	O
the	O
healthy	O
betel	O
chewers	O
tested	O
positive	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
by	O
serology	O
.	O

None	O
of	O
the	O
healthy	O
non	O
-	O
betel	O
chewers	O
tested	O
positive	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
Fourteen	O
[	O
26	O
.	O
4	O
%	O
]	O
of	O
oral	O
cancer	O
patients	O
tested	O
positive	O
for	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
by	O
serology	O
,	O
of	O
which	O
two	O
were	O
also	O
culture	O
positive	O
(	O
Only	O
thirty	O
samples	O
were	O
cultured	O
)	O
.	O

The	O
presence	O
of	O
H	B-bacteria
.	I-bacteria	O
pylori	I-bacteria
in	O
betel	O
chewers	O
(	O
with	O
or	O
without	O
cancer	O
)	O
compared	O
to	O
non	O
-	O
betel	O
chewers	O
was	O
statistically	O
significant	O
.	O

(	O
Chi	O
-	O
square	O
test	O
p	O
<	O
0	O
.	O
05	O
)	O
The	O
use	O
of	O
tobacco	O
and	O
areca	O
nut	O
in	O
betel	O
chewers	O
was	O
significant	O
with	O
the	O
presence	O
of	O
H	O
.	O
pylori	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
is	O
a	O
significant	O
higher	O
proportion	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
betel	O
chewers	O
compared	O
to	O
non	O
-	O
betel	O
chewers	O
but	O
not	O
between	O
oral	O
cancer	O
patients	O
compared	O
to	O
patients	O
without	O
oral	O
cancer	O
.	O

Hence	O
Betel	O
chewing	O
may	O
predispose	O
to	O
colonisation	O
with	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
digestive	O
tract	O
through	O
swallowing	O
the	O
quid	O
or	O
during	O
betel	O
chewing	O
.	O

We	O
present	O
a	O
case	O
series	O
of	O
5	O
patients	O
admitted	O
over	O
5	O
months	O
to	O
Queen	O
Elizabeth	O
Central	O
Hospital	O
who	O
had	O
sustained	O
injuries	O
from	O
a	O
crocodile	O
bite	O
.	O

Three	O
patients	O
required	O
amputation	O
of	O
a	O
limb	O
.	O

The	O
severe	O
soft	O
tissue	O
injury	O
associated	O
with	O
a	O
crocodile	O
bite	O
and	O
the	O
unusual	O
normal	O
oral	O
flora	O
of	O
the	O
crocodile	O
create	O
challenges	O
in	O
treatment	O
.	O

Progressive	O
tissue	O
destruction	O
and	O
haemolysis	O
are	O
complications	O
of	O
such	O
infected	O
wounds	O
.	O

An	O
antibiotic	O
regime	O
is	O
recommended	O
that	O
covers	O
gram	O
negative	O
rods	O
,	O
anaerobes	O
and	O
may	O
include	O
doxycycline	O
,	O
as	O
well	O
as	O
the	O
need	O
to	O
have	O
a	O
low	O
threshold	O
for	O
early	O
amputation	O
.	O

In	O
our	O
study	O
of	O
nursing	O
home	O
residents	O
with	O
clinically	O
suspected	O
urinary	O
tract	O
infection	O
who	O
did	O
not	O
require	O
the	O
use	O
of	O
an	O
indwelling	O
catheter	O
,	O
we	O
identified	O
bacteria	O
isolated	O
from	O
urine	O
samples	O
,	O
the	O
resistance	O
patterns	O
of	O
these	O
isolated	O
bacteria	O
,	O
and	O
the	O
antibiotic	O
therapy	O
prescribed	O
to	O
the	O
residents	O
.	O

Escherichia	B-bacteria
coli	I-bacteria
,	O
the	O
predominant	O
organism	O
isolated	O
,	O
frequently	O
was	O
resistant	O
to	O
commonly	O
prescribed	O
oral	O
antibiotics	O
.	O

Trimethoprim	O
-	O
sulfamethoxazole	O
remains	O
the	O
best	O
empiric	O
antimicrobial	O
therapy	O
for	O
a	O
urinary	O
tract	O
infection	O
,	O
but	O
nitrofurantoin	O
should	O
be	O
considered	O
if	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
is	O
identified	O
.	O

To	O
date	O
,	O
metagenomic	O
studies	O
have	O
relied	O
on	O
the	O
utilization	O
and	O
analysis	O
of	O
reads	O
obtained	O
using	O
454	O
pyrosequencing	O
to	O
replace	O
conventional	O
Sanger	O
sequencing	O
.	O

After	O
extensively	O
scanning	O
the	O
16S	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
gene	O
,	O
we	O
identified	O
the	O
V5	O
hypervariable	O
region	O
as	O
a	O
short	O
region	O
providing	O
reliable	O
identification	O
of	O
bacterial	O
sequences	O
available	O
in	O
public	O
databases	O
such	O
as	O
the	O
Human	O
Oral	O
Microbiome	O
Database	O
.	O

We	O
amplified	O
samples	O
from	O
the	O
oral	O
cavity	O
of	O
three	O
healthy	O
individuals	O
using	O
primers	O
covering	O
an	O
approximately	O
82	O
-	O
base	O
segment	O
of	O
the	O
V5	O
loop	O
,	O
and	O
sequenced	O
using	O
the	O
Illumina	O
technology	O
in	O
a	O
single	O
orientation	O
.	O

We	O
identified	O
135	O
genera	O
or	O
higher	O
taxonomic	O
ranks	O
from	O
the	O
resulting	O
1	O
,	O
373	O
,	O
824	O
sequences	O
.	O

While	O
the	O
abundances	O
of	O
the	O
most	O
common	O
phyla	O
(	O
Firmicutes	B-bacteria
,	O
Proteobacteria	B-bacteria
,	O
Actinobacteria	B-bacteria
,	O
Fusobacteria	B-bacteria
and	O
TM7	B-bacteria
)	O
are	O
largely	O
comparable	O
to	O
previous	O
studies	O
,	O
Bacteroidetes	B-bacteria
were	O
less	O
present	O
.	O

Potential	O
sources	O
for	O
this	O
difference	O
include	O
classification	O
bias	O
in	O
this	O
region	O
of	O
the	O
16S	O
rRNA	O
gene	O
,	O
human	O
sample	O
variation	O
,	O
sample	O
preparation	O
and	O
primer	O
bias	O
.	O

Using	O
an	O
Illumina	O
sequencing	O
approach	O
,	O
we	O
achieved	O
a	O
much	O
greater	O
depth	O
of	O
coverage	O
than	O
previous	O
oral	O
microbiota	O
studies	O
,	O
allowing	O
us	O
to	O
identify	O
several	O
taxa	O
not	O
yet	O
discovered	O
in	O
these	O
types	O
of	O
samples	O
,	O
and	O
to	O
assess	O
that	O
at	O
least	O
30	O
,	O
000	O
additional	O
reads	O
would	O
be	O
required	O
to	O
identify	O
only	O
one	O
additional	O
phylotype	O
.	O

The	O
evolution	O
of	O
high	O
-	O
throughput	O
sequencing	O
technologies1	O
,	O
and	O
their	O
subsequent	O
improvements	O
in	O
read	O
length	O
enable	O
the	O
utilization	O
of	O
different	O
platforms	O
for	O
studying	O
communities	O
of	O
complex	O
flora	O
.	O

Access	O
to	O
large	O
amounts	O
of	O
data	O
is	O
already	O
leading	O
to	O
a	O
better	O
representation	O
of	O
sample	O
diversity	O
at	O
a	O
reasonable	O
cost	O
.	O

Infection	O
of	O
Galleria	O
mellonella	O
by	O
feeding	O
a	O
mixture	O
of	O
Bacillus	B-bacteria
thuringiensis	I-bacteria
spores	O
or	O
vegetative	O
bacteria	O
in	O
association	O
with	O
the	O
toxin	O
Cry1C	O
results	O
in	O
high	O
levels	O
of	O
larval	O
mortality	O
.	O

Under	O
these	O
conditions	O
the	O
toxin	O
or	O
bacteria	O
have	O
minimal	O
effects	O
on	O
the	O
larva	O
when	O
inoculated	O
separately	O
.	O

In	O
order	O
to	O
evaluate	O
whether	O
G	O
.	O
mellonella	O
can	O
function	O
as	O
an	O
oral	O
infection	O
model	O
for	O
human	O
and	O
entomo	O
-	O
bacterial	O
pathogens	O
,	O
we	O
tested	O
strains	O
of	O
Bacillus	B-bacteria
cereus	I-bacteria
,	O
Bacillus	B-bacteria
anthracis	I-bacteria
,	O
Enterococcus	B-bacteria
faecalis	I-bacteria
,	O
Listeria	B-bacteria
monocytogenes	I-bacteria
,	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
and	O
a	O
Drosophila	B-bacteria
targeting	I-bacteria
Pseudomonas	I-bacteria
entomophila	I-bacteria
strain	I-bacteria
.	O

Six	O
B	B-bacteria
.	I-bacteria
cereus	I-bacteria
strains	I-bacteria
(	O
5	O
diarrheal	O
,	O
1	O
environmental	O
isolate	O
)	O
were	O
first	O
screened	O
in	O
2nd	O
instar	O
G	B-bacteria
.	I-bacteria
mellonella	I-bacteria
larvae	O
by	O
free	O
ingestion	O
and	O
four	O
of	O
them	O
were	O
analyzed	O
by	O
force	O
-	O
feeding	O
5th	O
instar	O
larvae	O
.	O

The	O
virulence	O
of	O
these	O
B	B-bacteria
.	I-bacteria
cereus	I-bacteria
strains	I-bacteria
did	O
not	O
differ	O
from	O
the	O
B	B-bacteria
.	I-bacteria
thuringiensis	I-bacteria
virulent	O
reference	O
strain	O
407Cry	O
(	O
-	O
)	O
with	O
the	O
exception	O
of	O
strain	O
D19	O
(	O
NVH391	O
/	O
98	O
)	O
that	O
showed	O
a	O
lower	O
virulence	O
.	O

Following	O
force	O
-	O
feeding	O
,	O
5th	O
instar	O
G	B-bacteria
.	I-bacteria
mellonella	I-bacteria
larvae	O
survived	O
infection	O
with	O
B	B-bacteria
.	I-bacteria
anthracis	I-bacteria
,	O
L	B-bacteria
.	I-bacteria
monocytogenes	I-bacteria
,	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
strains	I-bacteria
in	O
contrast	O
to	O
the	O
P	B-bacteria
.	I-bacteria
entomophila	I-bacteria
strain	I-bacteria
which	O
led	O
to	O
high	O
mortality	O
even	O
without	O
Cry1C	O
toxin	O
co	O
-	O
ingestion	O
.	O

Thus	O
,	O
specific	O
virulence	O
factors	O
adapted	O
to	O
the	O
insect	O
intestine	O
might	O
exist	O
in	O
B	B-bacteria
.	I-bacteria
thuringiensis	I-bacteria
/	O
B	I-bacteria
.	I-bacteria
cereus	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
entomophila	I-bacteria
.	O

This	O
suggests	O
a	O
co	O
-	O
evolution	O
between	O
host	O
and	O
pathogens	O
and	O
supports	O
the	O
close	O
links	O
between	O
B	B-bacteria
.	I-bacteria
thuringiensis	I-bacteria
and	O
B	B-bacteria
.	I-bacteria
cereus	I-bacteria
and	O
more	O
distant	O
links	O
to	O
their	O
relative	O
B	B-bacteria
.	I-bacteria
anthracis	I-bacteria
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
a	O
type	O
of	O
Gram	O
-	O
negative	O
periodontopathogen	O
,	O
causes	O
periodontal	O
disease	O
by	O
activating	O
intracellular	O
signaling	O
pathways	O
that	O
produce	O
excessive	O
inflammatory	O
responses	O
such	O
as	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
panduratin	O
A	O
,	O
a	O
chalcone	O
compound	O
isolated	O
from	O
Kaempferia	O
pandurata	O
ROXB	O
.	O
,	O
caused	O
the	O
decreased	O
levels	O
of	O
MMP	O
-	O
9	O
secretion	O
,	O
protein	O
,	O
and	O
gene	O
expression	O
in	O
human	O
oral	O
epidermoid	O
KB	O
cells	O
exposed	O
to	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
supernatant	O
.	O

In	O
this	O
study	O
,	O
we	O
clarified	O
if	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
mediated	O
MMP	O
-	O
9	O
expression	O
by	O
examining	O
the	O
effect	O
of	O
specific	O
MAPK	O
inhibitors	O
,	O
i	O
.	O
e	O
.	O

U0126	O
,	O
SB203580	O
,	O
and	O
SP600125	O
,	O
on	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
supernatant	O
-	O
stimulated	O
MMP	O
-	O
9	O
expression	O
in	O
KB	O
cells	O
.	O

We	O
next	O
elucidated	O
the	O
molecular	O
mechanism	O
by	O
which	O
panduratin	O
A	O
attenuated	O
signaling	O
pathways	O
involved	O
in	O
MMP	O
-	O
9	O
expression	O
by	O
performing	O
gelatin	O
zymography	O
,	O
Western	O
blotting	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
and	O
promoter	O
assays	O
.	O

Exposure	O
of	O
KB	O
cells	O
to	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
supernatant	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
MMP	O
-	O
9	O
protein	O
and	O
gene	O
,	O
and	O
activation	O
of	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
element	O
,	O
MAPK	O
phosphorylation	O
(	O
extracellular	O
signal	O
-	O
related	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
,	O
p38	O
,	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
)	O
,	O
and	O
transcription	O
factors	O
(	O
Elk1	O
,	O
c	O
-	O
Jun	O
,	O
and	O
c	O
-	O
Fos	O
)	O
.	O

A	O
JNK	O
inhibitor	O
(	O
SP600125	O
)	O
significantly	O
attenuated	O
MMP	O
-	O
9	O
gene	O
expression	O
and	O
AP	O
-	O
1	O
activity	O
in	O
KB	O
cells	O
in	O
response	O
to	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
supernatant	O
.	O

Similar	O
to	O
SP600125	O
,	O
panduratin	O
A	O
was	O
found	O
to	O
strongly	O
suppress	O
the	O
level	O
of	O
phosphorylated	O
JNK	O
and	O
block	O
AP	O
-	O
1	O
activity	O
in	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
supernatant	O
-	O
stimulated	O
KB	O
cells	O
.	O

In	O
summary	O
,	O
JNK	O
and	O
AP	O
-	O
1	O
are	O
the	O
major	O
signaling	O
for	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
supernatant	O
-	O
stimulated	O
MMP	O
-	O
9	O
expression	O
in	O
KB	O
cells	O
,	O
and	O
panduratin	O
A	O
markedly	O
down	O
-	O
regulates	O
MMP	O
-	O
9	O
expression	O
through	O
inhibition	O
of	O
these	O
signaling	O
.	O

Periodontitis	O
is	O
a	O
polymicrobial	O
infection	O
caused	O
by	O
selected	O
gram	O
-	O
negative	O
bacteria	O
including	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
.	O

Host	O
cell	O
invasion	O
by	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
has	O
been	O
proposed	O
as	O
a	O
possible	O
mechanism	O
of	O
pathogenesis	O
in	O
periodontitis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
influence	O
of	O
periodontopathogens	O
on	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
invasion	O
of	O
gingival	O
epithelial	O
cells	O
in	O
polymicrobial	O
infection	O
.	O

P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
was	O
tested	O
for	O
its	O
ability	O
to	O
invade	O
a	O
human	O
gingival	O
epithelial	O
cell	O
line	O
Ca9	O
-	O
22	O
in	O
co	O
-	O
infection	O
with	O
periodontopathogens	O
,	O
using	O
an	O
antibiotic	O
protection	O
assay	O
.	O

Among	O
the	O
pathogens	O
tested	O
,	O
only	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
demonstrated	O
the	O
ability	O
to	O
significantly	O
promote	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
invasion	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

This	O
increased	O
invasion	O
was	O
confirmed	O
by	O
confocal	O
scanning	O
laser	O
microscopy	O
utilizing	O
a	O
dual	O
labeling	O
technique	O
.	O

In	O
contrast	O
,	O
co	O
-	O
infection	O
with	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
or	O
Tannerella	B-bacteria
forsythia	I-bacteria
attenuated	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
invasion	O
.	O

The	O
fusobacterial	O
enhancement	O
of	O
host	O
cell	O
invasion	O
was	O
not	O
observed	O
in	O
co	O
-	O
incubation	O
with	O
other	O
periodontopathogens	O
tested	O
.	O

These	O
results	O
suggested	O
that	O
complex	O
synergistic	O
or	O
antagonistic	O
physiologic	O
mechanisms	O
are	O
intimately	O
involved	O
in	O
host	O
cell	O
invasion	O
by	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
in	O
polymicrobial	O
infection	O
.	O

To	O
investigate	O
the	O
patterns	O
of	O
microbial	O
infection	O
on	O
the	O
apical	O
external	O
root	O
surfaces	O
of	O
treated	O
and	O
untreated	O
teeth	O
associated	O
with	O
chronic	O
apical	O
periodontitis	O
and	O
to	O
study	O
bacteria	O
in	O
the	O
biofilm	O
in	O
order	O
to	O
find	O
out	O
the	O
species	O
,	O
constitution	O
and	O
origination	O
of	O
bacteria	O
in	O
periapical	O
biofilm	O
.	O

Ten	O
teeth	O
with	O
chronic	O
apical	O
periodontitis	O
from	O
patients	O
of	O
the	O
Department	O
of	O
Stomatology	O
of	O
People	O
'	O
s	O
Hospital	O
,	O
Peking	O
University	O
:	O
5	O
untreated	O
teeth	O
with	O
a	O
radiographically	O
visible	O
chronic	O
periradicular	O
lesions	O
and	O
5	O
teeth	O
with	O
extensive	O
carious	O
lesions	O
,	O
radiolucent	O
lesions	O
of	O
varying	O
sizes	O
and	O
attached	O
periradicular	O
tissues	O
were	O
selected	O
for	O
study	O
.	O

Using	O
aseptic	O
techniques	O
and	O
sterile	O
instruments	O
,	O
bacterial	O
samples	O
of	O
the	O
root	O
canals	O
were	O
taken	O
,	O
inoculated	O
and	O
separated	O
according	O
to	O
usual	O
practice	O
.	O

After	O
extraction	O
,	O
ten	O
teeth	O
were	O
fixed	O
and	O
the	O
apical	O
5	O
mm	O
portion	O
of	O
one	O
root	O
was	O
sectioned	O
.	O

Root	O
tips	O
were	O
dehydrated	O
,	O
sputter	O
coated	O
with	O
gold	O
,	O
and	O
then	O
examined	O
for	O
the	O
occurrence	O
of	O
bacteria	O
on	O
the	O
apical	O
root	O
surfaces	O
using	O
scanning	O
electron	O
microscope	O
.	O

Five	O
healthy	O
teeth	O
with	O
vital	O
pulp	O
were	O
used	O
as	O
controls	O
.	O

Microbial	O
study	O
showed	O
that	O
ten	O
specimens	O
yielded	O
bacterial	O
growth	O
.	O

The	O
most	O
prevalent	O
bacteria	O
were	O
P	B-bacteria
.	I-bacteria
micros	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nueleatum	I-bacteria
.	O

In	O
the	O
5	O
untreated	O
teeth	O
,	O
bacterial	O
cells	O
were	O
usually	O
observed	O
close	O
to	O
the	O
apical	O
foramen	O
in	O
only	O
1	O
specimen	O
.	O

Morphologically	O
,	O
these	O
bacteria	O
consisted	O
of	O
cocci	O
.	O

In	O
the	O
5	O
treated	O
teeth	O
,	O
a	O
dense	O
bacterial	O
aggregation	O
composed	O
mainly	O
of	O
cocci	O
and	O
rods	O
was	O
observed	O
surrounding	O
the	O
apical	O
foramen	O
of	O
all	O
specimens	O
.	O

Besides	O
rods	O
,	O
other	O
bacterial	O
morphological	O
types	O
were	O
recognized	O
,	O
including	O
coaggregations	O
of	O
cocci	O
and	O
filaments	O
,	O
characterizing	O
a	O
fully	O
developed	O
`	O
`	O
corn	O
-	O
cob	O
'	O
'	O
.	O

No	O
microorganisms	O
were	O
found	O
in	O
the	O
healthy	O
controls	O
.	O

Bacterial	O
biofilm	O
was	O
always	O
present	O
in	O
teeth	O
with	O
post	O
-	O
treatment	O
endodontic	O
disease	O
.	O

The	O
presence	O
of	O
apical	O
bacterial	O
biofilm	O
is	O
clinically	O
important	O
,	O
and	O
it	O
may	O
cause	O
failure	O
of	O
endodontic	O
treatment	O
as	O
a	O
consequence	O
of	O
persistent	O
infection	O
.	O

To	O
evaluate	O
the	O
safety	O
of	O
two	O
probiotic	O
bacterial	O
strains	O
,	O
Lactobacillus	B-bacteria
casei	I-bacteria
strain	I-bacteria
Shirota	I-bacteria
(	O
LcS	B-bacteria
)	O
and	O
Bifidobacterium	B-bacteria
breve	I-bacteria
strain	I-bacteria
Yakult	I-bacteria
(	O
BbY	B-bacteria
)	O
,	O
these	O
probiotics	O
were	O
orally	O
administered	O
to	O
Lewis	O
rats	O
with	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
,	O
the	O
experimental	O
model	O
of	O
human	O
multiple	O
sclerosis	O
.	O

We	O
examined	O
three	O
experimental	O
designs	O
by	O
combining	O
different	O
antigen	O
types	O
and	O
probiotic	O
administration	O
periods	O
:	O
(	O
1	O
)	O
EAE	O
was	O
induced	O
with	O
a	O
homogenate	O
of	O
guinea	O
pig	O
spinal	O
cord	O
as	O
the	O
sensitizing	O
antigen	O
,	O
and	O
LcS	B-bacteria
was	O
orally	O
administered	O
from	O
one	O
week	O
before	O
this	O
sensitization	O
until	O
the	O
end	O
of	O
the	O
experiment	O
;	O
(	O
2	O
)	O
EAE	O
was	O
induced	O
using	O
guinea	O
pig	O
originated	O
myelin	O
basic	O
protein	O
(	O
MBP	O
)	O
as	O
the	O
sensitizing	O
antigen	O
,	O
and	O
LcS	B-bacteria
was	O
orally	O
administered	O
from	O
one	O
week	O
before	O
this	O
sensitization	O
to	O
the	O
end	O
of	O
the	O
experiment	O
;	O
(	O
3	O
)	O
EAE	O
was	O
induced	O
using	O
guinea	O
pig	O
MBP	O
as	O
the	O
sensitizing	O
antigen	O
,	O
and	O
the	O
probiotic	O
strains	O
(	O
LcS	B-bacteria
and	O
BbY	B-bacteria
)	O
were	O
administered	O
starting	O
in	O
infancy	O
(	O
two	O
weeks	O
old	O
)	O
and	O
continued	O
until	O
the	O
end	O
of	O
the	O
experiment	O
.	O

In	O
experiment	O
1	O
,	O
oral	O
administration	O
of	O
LcS	B-bacteria
tended	O
to	O
suppress	O
the	O
development	O
of	O
neurological	O
symptoms	O
.	O

Differences	O
in	O
neurological	O
symptoms	O
between	O
the	O
control	O
group	O
and	O
the	O
administration	O
groups	O
did	O
not	O
reach	O
statistical	O
significance	O
in	O
experiments	O
2	O
and	O
3	O
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
neither	O
LcS	B-bacteria
nor	O
BbY	B-bacteria
exacerbates	O
autoimmune	O
disease	O
.	O

In	O
Mexico	O
,	O
more	O
than	O
80	O
%	O
of	O
the	O
population	O
is	O
infected	O
with	O
Helicobacter	B-bacteria
pylori	I-bacteria
.	O

The	O
frequency	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
detection	O
in	O
the	O
oral	O
cavity	O
is	O
unknown	O
,	O
as	O
its	O
relationship	O
with	O
gastroesophageal	O
pathology	O
.	O

To	O
detect	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
cavity	O
in	O
Mexican	O
population	O
by	O
PCR	O
and	O
to	O
determine	O
its	O
association	O
with	O
gastroesophageal	O
disease	O
.	O

Patients	O
were	O
divided	O
into	O
two	O
groups	O
with	O
different	O
clinic	O
conditions	O
from	O
whom	O
gastric	O
biopsy	O
,	O
dental	O
plaque	O
,	O
and	O
saliva	O
samples	O
were	O
taken	O
and	O
analyzed	O
.	O

The	O
first	O
group	O
comprised	O
of	O
hospitalized	O
patients	O
,	O
the	O
majority	O
of	O
whom	O
were	O
diagnosed	O
with	O
gastroesophageal	O
disease	O
,	O
while	O
the	O
second	O
group	O
was	O
selected	O
from	O
a	O
dental	O
clinic	O
(	O
ambulatory	O
population	O
)	O
the	O
majority	O
of	O
whom	O
appeared	O
to	O
be	O
healthy	O
subjects	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
detected	O
in	O
gastric	O
biopsy	O
,	O
dental	O
plaque	O
and	O
saliva	O
samples	O
by	O
PCR	O
using	O
a	O
set	O
of	O
specific	O
primers	O
for	O
the	O
signal	O
sequence	O
of	O
the	O
vacuolating	O
cytotoxin	O
gene	O
;	O
detection	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
general	O
was	O
higher	O
in	O
gastric	O
biopsy	O
and	O
dental	O
plaque	O
samples	O
than	O
in	O
saliva	O
samples	O
.	O

Detection	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
cavity	O
is	O
significantly	O
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
associated	O
with	O
patients	O
presenting	O
gastroesophageal	O
disease	O
,	O
while	O
healthy	O
subjects	O
and	O
those	O
with	O
other	O
non	O
-	O
gastric	O
disease	O
do	O
not	O
present	O
with	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
their	O
oral	O
cavity	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
detection	O
in	O
the	O
oral	O
cavity	O
is	O
associated	O
to	O
gastroesophageal	O
disease	O
.	O

In	O
addition	O
,	O
it	O
is	O
suggested	O
that	O
all	O
patients	O
presenting	O
gastric	O
symptoms	O
and	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
detection	O
in	O
the	O
oral	O
cavity	O
would	O
begin	O
bacterial	O
treatment	O
immediately	O
.	O

Mouse	O
prolactin	O
-	O
inducible	O
protein	O
(	O
mPIP	O
)	O
is	O
secreted	O
in	O
mouse	O
saliva	O
and	O
has	O
been	O
found	O
to	O
bind	O
oral	O
bacteria	O
,	O
showing	O
the	O
highest	O
affinity	O
for	O
streptococci	B-bacteria
.	O

Comparisons	O
between	O
the	O
oral	O
flora	O
of	O
mPIP	O
knockout	O
mice	O
and	O
their	O
wild	O
-	O
type	O
controls	O
showed	O
differences	O
in	O
the	O
genera	O
colonizing	O
the	O
two	O
groups	O
of	O
mice	O
.	O

These	O
findings	O
suggested	O
a	O
role	O
for	O
mPIP	O
in	O
the	O
colonization	O
of	O
the	O
mouse	O
oral	O
cavity	O
,	O
possibly	O
modulating	O
the	O
oral	O
flora	O
.	O

In	O
this	O
in	O
vitro	O
study	O
,	O
we	O
focused	O
on	O
the	O
contribution	O
of	O
this	O
protein	O
to	O
aggregation	O
of	O
oral	O
bacteria	O
,	O
a	O
process	O
thought	O
to	O
promote	O
the	O
clearance	O
of	O
bacteria	O
from	O
the	O
oral	O
cavity	O
,	O
and	O
one	O
that	O
could	O
influence	O
the	O
composition	O
of	O
the	O
oral	O
bacterial	O
community	O
.	O

The	O
aggregation	O
of	O
selected	O
human	O
and	O
mouse	O
oral	O
streptococci	B-bacteria
was	O
measured	O
spectrophotometrically	O
.	O

The	O
aggregation	O
of	O
oral	O
bacteria	O
by	O
saliva	O
from	O
mPIP	O
knockout	O
mice	O
,	O
which	O
lack	O
mPIP	O
,	O
was	O
compared	O
with	O
that	O
of	O
saliva	O
from	O
wild	O
-	O
type	O
mice	O
.	O

Both	O
wild	O
-	O
type	O
saliva	O
and	O
mPIP	O
knockout	O
mouse	O
saliva	O
induced	O
aggregation	O
of	O
human	O
strain	O
Streptococcus	B-bacteria
gordonii	I-bacteria
SK120	I-bacteria
and	O
mouse	O
streptococci	B-bacteria
strains	I-bacteria
M105	I-bacteria
/	I-bacteria
6	I-bacteria
and	O
M106	B-bacteria
/	I-bacteria
2	I-bacteria
.	O

Bacterial	O
aggregation	O
induced	O
by	O
the	O
saliva	O
of	O
wild	O
-	O
type	O
mice	O
was	O
significantly	O
higher	O
than	O
the	O
aggregation	O
induced	O
by	O
saliva	O
from	O
mPIP	O
knockout	O
mice	O
for	O
all	O
the	O
bacterial	O
strains	O
.	O

In	O
this	O
study	O
it	O
was	O
confirmed	O
that	O
mPIP	O
plays	O
a	O
role	O
in	O
the	O
aggregation	O
of	O
oral	O
bacteria	O
.	O

The	O
salivary	O
components	O
promoting	O
aggregation	O
of	O
oral	O
bacteria	O
are	O
considered	O
to	O
be	O
part	O
of	O
the	O
oral	O
defense	O
mechanisms	O
so	O
these	O
findings	O
provide	O
insight	O
into	O
a	O
possible	O
function	O
of	O
mPIP	O
in	O
host	O
defense	O
by	O
promoting	O
aggregation	O
of	O
oral	O
bacteria	O
.	O

Weak	O
oral	O
bacteria	O
,	O
such	O
as	O
periodontal	O
bacteria	O
,	O
have	O
been	O
found	O
in	O
various	O
vascular	O
lesions	O
,	O
including	O
atheroma	O
,	O
the	O
thrombus	O
of	O
the	O
occluded	O
artery	O
of	O
Buerger	O
'	O
s	O
disease	O
,	O
the	O
abdominal	O
aortic	O
aneurismal	O
wall	O
and	O
varicose	O
veins	O
.	O

Serum	O
titer	O
levels	O
of	O
each	O
bacterium	O
are	O
now	O
available	O
and	O
have	O
shown	O
a	O
significant	O
relationship	O
between	O
severity	O
and	O
individual	O
differences	O
.	O

The	O
Medline	O
and	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
databases	O
were	O
searched	O
to	O
identify	O
the	O
literature	O
currently	O
available	O
on	O
oral	O
bacteria	O
and	O
vascular	O
diseases	O
.	O

It	O
is	O
estimated	O
that	O
lymph	O
vessel	O
openings	O
trap	O
bacteria	O
en	O
route	O
from	O
the	O
mouth	O
to	O
the	O
bloodstream	O
and	O
then	O
carry	O
them	O
to	O
the	O
vein	O
of	O
the	O
venous	O
angle	O
near	O
the	O
supraclavicular	O
area	O
.	O

In	O
the	O
case	O
of	O
periodontal	O
bacteria	O
,	O
a	O
typical	O
bacterium	O
,	O
such	O
as	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
strongly	O
activates	O
platelets	O
and	O
makes	O
them	O
mass	O
,	O
including	O
the	O
bacteria	O
without	O
phagocytosis	O
.	O

Simultaneously	O
,	O
cytokines	O
and	O
serotonin	O
are	O
discharged	O
.	O

Platelet	O
engulfment	O
was	O
clearly	O
demonstrated	O
by	O
electron	O
microscopy	O
analysis	O
.	O

An	O
animal	O
study	O
using	O
rats	O
showed	O
the	O
formation	O
of	O
a	O
small	O
arterial	O
thrombus	O
after	O
continuous	O
intravenous	O
infusion	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
for	O
2	O
-	O
4	O
wk	O
.	O

Weak	O
oral	O
bacteria	O
,	O
such	O
as	O
periodontal	O
bacteria	O
,	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
various	O
vascular	O
diseases	O
,	O
such	O
as	O
Buerger	O
'	O
s	O
disease	O
,	O
atherosclerosis	O
and	O
varicose	O
veins	O
,	O
through	O
bacteremia	O
.	O

Dental	O
caries	O
disproportionately	O
affects	O
disadvantaged	O
subjects	O
.	O

This	O
study	O
hypothesized	O
that	O
there	O
were	O
greater	O
caries	O
extent	O
and	O
higher	O
levels	O
of	O
caries	O
-	O
associated	O
and	O
anaerobic	O
subgingival	O
bacterial	O
species	O
in	O
oral	O
samples	O
of	O
Hispanic	O
and	O
immigrant	O
children	O
compared	O
with	O
non	O
-	O
Hispanic	O
and	O
US	O
born	O
children	O
.	O

Children	O
from	O
a	O
school	O
-	O
based	O
dental	O
clinic	O
serving	O
a	O
community	O
with	O
a	O
large	O
Hispanic	O
component	O
were	O
examined	O
,	O
and	O
the	O
extent	O
of	O
caries	O
was	O
recorded	O
.	O

Microbial	O
samples	O
were	O
taken	O
from	O
teeth	O
and	O
the	O
tongues	O
of	O
children	O
.	O

Samples	O
were	O
analyzed	O
using	O
DNA	O
probes	O
to	O
18	O
oral	O
bacterial	O
species	O
.	O

Seventy	O
five	O
children	O
were	O
examined	O
.	O

Extent	O
of	O
caries	O
increased	O
with	O
child	O
age	O
in	O
immigrant	O
,	O
but	O
not	O
in	O
US	O
born	O
or	O
Hispanic	O
children	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
microbiota	O
based	O
on	O
ethnicity	O
or	O
whether	O
the	O
child	O
was	O
born	O
in	O
US	O
or	O
not	O
.	O

There	O
was	O
a	O
higher	O
species	O
detection	O
frequency	O
from	O
teeth	O
than	O
tongue	O
samples	O
.	O

Levels	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
other	O
Streptococcus	B-bacteria
spp	I-bacteria
increased	O
with	O
caries	O
extent	O
.	O

Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
and	O
Selenomonas	B-bacteria
spp	I-bacteria
were	O
detected	O
at	O
low	O
levels	O
in	O
these	O
children	O
.	O

We	O
conclude	O
that	O
,	O
while	O
there	O
was	O
a	O
high	O
rate	O
of	O
dental	O
caries	O
in	O
disadvantaged	O
school	O
children	O
,	O
there	O
were	O
no	O
differences	O
in	O
the	O
caries	O
-	O
associated	O
microbiota	O
,	O
including	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
based	O
on	O
ethnicity	O
or	O
immigration	O
status	O
.	O

Furthermore	O
,	O
while	O
anaerobic	O
subgingival	O
,	O
periodontal	O
pathogens	O
were	O
also	O
detected	O
in	O
children	O
,	O
there	O
was	O
no	O
difference	O
in	O
species	O
detection	O
based	O
on	O
ethnicity	O
or	O
immigration	O
status	O
.	O

Increased	O
levels	O
of	O
streptococci	B-bacteria
,	O
including	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
,	O
however	O
,	O
were	O
detected	O
with	O
high	O
caries	O
levels	O
.	O

This	O
suggested	O
that	O
while	O
it	O
is	O
beneficial	O
to	O
target	O
preventive	O
and	O
treatment	O
programs	O
to	O
disadvantaged	O
populations	O
,	O
there	O
is	O
likely	O
no	O
additional	O
benefit	O
to	O
focus	O
on	O
subgroups	O
within	O
a	O
population	O
already	O
at	O
high	O
risk	O
for	O
dental	O
disease	O
.	O

Human	O
odontoblasts	O
trigger	O
immune	O
response	O
s	O
to	O
oral	O
bacteria	O
that	O
invade	O
dental	O
tissues	O
during	O
the	O
caries	O
process	O
.	O

To	O
date	O
,	O
their	O
ability	O
to	O
regulate	O
the	O
expression	O
of	O
the	O
nucleotide	O
-	O
binding	O
domain	O
leucine	O
-	O
rich	O
repeat	O
containing	O
receptor	O
NOD2	O
when	O
challenged	O
by	O
Gram	O
-	O
positive	O
bacteria	O
is	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
NOD2	O
expression	O
in	O
healthy	O
and	O
inflamed	O
human	O
dental	O
pulps	O
challenged	O
by	O
bacteria	O
,	O
and	O
in	O
cultured	O
odontoblast	O
-	O
like	O
cells	O
stimulated	O
with	O
lipoteichoic	O
acid	O
(	O
LTA	O
)	O
,	O
a	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
2	O
agonist	O
which	O
is	O
specific	O
for	O
Gram	O
-	O
positive	O
bacteria	O
.	O

We	O
found	O
that	O
NOD2	O
gene	O
expression	O
was	O
significantly	O
up	O
-	O
regulated	O
in	O
pulps	O
with	O
acute	O
inflammation	O
compared	O
to	O
healthy	O
ones	O
.	O

In	O
vitro	O
,	O
LTA	O
augmented	O
NOD2	O
gene	O
expression	O
and	O
protein	O
level	O
in	O
odontoblast	O
-	O
like	O
cells	O
.	O

The	O
increase	O
was	O
more	O
pronounced	O
in	O
odontoblast	O
-	O
like	O
cells	O
compared	O
to	O
dental	O
pulp	O
fibroblasts	O
.	O

Blocking	O
experiments	O
in	O
odontoblast	O
-	O
like	O
cells	O
with	O
anti	O
-	O
TLR2	O
antibody	O
strongly	O
reduced	O
the	O
NOD2	O
gene	O
expression	O
increase	O
,	O
whereas	O
stimulation	O
with	O
the	O
synthetic	O
TLR2	O
ligand	O
Pam	O
(	O
2	O
)	O
CSK	O
(	O
4	O
)	O
confirmed	O
NOD2	O
gene	O
up	O
-	O
regulation	O
following	O
TLR2	O
engagement	O
.	O

These	O
data	O
suggest	O
that	O
NOD2	O
up	O
-	O
regulation	O
is	O
part	O
of	O
the	O
odontoblast	O
immune	O
response	O
to	O
Gram	O
-	O
positive	O
bacteria	O
and	O
might	O
be	O
important	O
in	O
protecting	O
human	O
dental	O
pulp	O
from	O
the	O
deleterious	O
effects	O
of	O
cariogenic	O
pathogens	O
.	O

Nitrogen	O
-	O
containing	O
bisphosphonates	O
such	O
as	O
zoledronic	O
acid	O
(	O
ZOL	O
)	O
and	O
pamidronate	O
have	O
been	O
widely	O
and	O
successfully	O
used	O
for	O
the	O
treatment	O
of	O
cancer	O
patients	O
with	O
bone	O
metastases	O
and	O
/	O
or	O
hypercalcemia	O
.	O

Accumulating	O
recent	O
reports	O
have	O
shown	O
that	O
cancer	O
patients	O
who	O
have	O
received	O
these	O
bisphosphonates	O
occasionally	O
manifest	O
bisphosphonate	O
-	O
related	O
osteonecrosis	O
of	O
the	O
jaw	O
(	O
BRONJ	O
)	O
following	O
dental	O
treatments	O
,	O
including	O
tooth	O
extraction	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
pathogenesis	O
of	O
BRONJ	O
to	O
date	O
.	O

Here	O
,	O
to	O
understand	O
the	O
underlying	O
pathogenesis	O
of	O
BRONJ	O
,	O
we	O
examined	O
the	O
effects	O
of	O
ZOL	O
on	O
wound	O
healing	O
of	O
the	O
tooth	O
extraction	O
socket	O
using	O
a	O
mouse	O
tooth	O
extraction	O
model	O
.	O

Histomorphometrical	O
analysis	O
revealed	O
that	O
the	O
amount	O
of	O
new	O
bone	O
and	O
the	O
numbers	O
of	O
blood	O
vessels	O
in	O
the	O
socket	O
were	O
significantly	O
decreased	O
in	O
ZOL	O
-	O
treated	O
mice	O
compared	O
to	O
control	O
mice	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
ZOL	O
significantly	O
inhibited	O
angiogenesis	O
induced	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
in	O
vivo	O
and	O
the	O
proliferation	O
of	O
endothelial	O
cells	O
in	O
culture	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
contrast	O
,	O
etidronate	O
,	O
a	O
non	O
-	O
nitrogen	O
-	O
containing	O
bisphosphonate	O
,	O
showed	O
no	O
effects	O
on	O
osteogenesis	O
and	O
angiogenesis	O
in	O
the	O
socket	O
.	O

ZOL	O
also	O
suppressed	O
the	O
migration	O
of	O
oral	O
epithelial	O
cells	O
,	O
which	O
is	O
a	O
crucial	O
step	O
for	O
tooth	O
socket	O
closure	O
.	O

In	O
addition	O
,	O
ZOL	O
promoted	O
the	O
adherence	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
to	O
hydroxyapatite	O
and	O
the	O
proliferation	O
of	O
oral	O
bacteria	O
obtained	O
from	O
healthy	O
individuals	O
,	O
suggesting	O
that	O
ZOL	O
may	O
increase	O
the	O
bacterial	O
infection	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
ZOL	O
delays	O
wound	O
healing	O
of	O
the	O
tooth	O
extraction	O
socket	O
by	O
inhibiting	O
osteogenesis	O
and	O
angiogenesis	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
ZOL	O
alters	O
oral	O
bacterial	O
behaviors	O
.	O

These	O
actions	O
of	O
ZOL	O
may	O
be	O
relevant	O
to	O
the	O
pathogenesis	O
of	O
BRONJ	O
.	O

To	O
evaluate	O
the	O
antimicrobial	O
activity	O
of	O
10	O
%	O
and	O
37	O
%	O
carbamide	O
peroxide	O
during	O
dental	O
bleaching	O
in	O
three	O
different	O
modes	O
.	O

This	O
five	O
-	O
week	O
double	O
-	O
blind	O
randomized	O
controlled	O
trial	O
included	O
32	O
volunteers	O
assigned	O
to	O
four	O
groups	O
(	O
n	O
=	O
8	O
)	O
.	O

Each	O
group	O
received	O
bleaching	O
agents	O
or	O
placebo	O
as	O
an	O
in	O
-	O
office	O
and	O
at	O
-	O
home	O
treatment	O
.	O

The	O
dental	O
bleaching	O
techniques	O
were	O
:	O
In	O
-	O
office	O
bleaching	O
(	O
37	O
%	O
carbamide	O
peroxide	O
:	O
CP37	O
)	O
;	O
at	O
-	O
home	O
bleaching	O
(	O
10	O
%	O
carbamide	O
peroxide	O
:	O
CP10	O
)	O
and	O
the	O
association	O
of	O
both	O
(	O
CP37	O
and	O
CP10	O
)	O
.	O

Saliva	O
samples	O
were	O
collected	O
right	O
before	O
(	O
baseline	O
)	O
,	O
right	O
after	O
,	O
12	O
hours	O
after	O
,	O
and	O
seven	O
days	O
after	O
the	O
treatment	O
.	O

Counts	O
of	O
total	O
microorganisms	O
,	O
Streptococci	B-bacteria
,	O
and	O
Mutans	B-bacteria
streptococci	I-bacteria
were	O
carried	O
out	O
.	O

Friedman	O
test	O
(	O
alpha	O
=	O
0	O
.	O
05	O
)	O
was	O
used	O
to	O
compare	O
the	O
microorganism	O
counts	O
.	O

The	O
number	O
of	O
the	O
all	O
oral	O
microorganisms	O
remained	O
stable	O
during	O
all	O
experiment	O
.	O

No	O
bleaching	O
agent	O
(	O
CP37	O
,	O
CP10	O
or	O
the	O
combination	O
of	O
both	O
)	O
was	O
able	O
to	O
reduce	O
the	O
oral	O
microorganisms	O
tested	O
.	O

Hydrogen	O
sulfide	O
is	O
one	O
of	O
the	O
predominant	O
volatile	O
sulfur	O
compounds	O
(	O
VSCs	O
)	O
produced	O
by	O
oral	O
bacteria	O
.	O

This	O
study	O
developed	O
and	O
evaluated	O
a	O
system	O
for	O
detecting	O
hydrogen	O
sulfide	O
production	O
by	O
oral	O
bacteria	O
.	O

L	O
-	O
methionine	O
-	O
alpha	O
-	O
deamino	O
-	O
gamma	O
-	O
mercaptomethane	O
-	O
lyase	O
(	O
METase	O
)	O
and	O
beta	O
carbon	O
-	O
sulfur	O
(	O
beta	O
C	O
-	O
S	O
)	O
lyase	O
were	O
used	O
to	O
degrade	O
homocysteine	O
and	O
cysteine	O
,	O
respectively	O
,	O
to	O
produce	O
hydrogen	O
sulfide	O
.	O

Enzymatic	O
reactions	O
resulting	O
in	O
hydrogen	O
sulfide	O
production	O
were	O
assayed	O
by	O
reaction	O
with	O
bismuth	O
trichloride	O
,	O
which	O
forms	O
a	O
black	O
precipitate	O
when	O
mixed	O
with	O
hydrogen	O
sulfide	O
.	O

The	O
enzymatic	O
activities	O
of	O
various	O
oral	O
bacteria	O
that	O
result	O
in	O
hydrogen	O
sulfide	O
production	O
and	O
the	O
capacity	O
of	O
bacteria	O
from	O
periodontal	O
sites	O
to	O
form	O
hydrogen	O
sulfide	O
in	O
reaction	O
mixtures	O
containing	O
L	O
-	O
cysteine	O
or	O
DL	O
-	O
homocysteine	O
were	O
assayed	O
.	O

With	O
L	O
-	O
cysteine	O
as	O
the	O
substrate	O
,	O
Streptococcus	B-bacteria
anginosus	I-bacteria
FW73	I-bacteria
produced	O
the	O
most	O
hydrogen	O
sulfide	O
,	O
whereas	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
American	I-bacteria
Type	I-bacteria
Culture	I-bacteria
Collection	I-bacteria
(	I-bacteria
ATCC	I-bacteria
)	I-bacteria
33277	I-bacteria
and	I-bacteria
W83	I-bacteria
and	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
ATCC	I-bacteria
10953	I-bacteria
produced	O
approximately	O
35	O
%	O
of	O
the	O
amount	O
produced	O
by	O
the	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
strains	I-bacteria
.	O

Finally	O
,	O
the	O
hydrogen	O
sulfide	O
found	O
in	O
subgingival	O
plaque	O
was	O
analyzed	O
.	O

Using	O
bismuth	O
trichloride	O
,	O
the	O
hydrogen	O
sulfide	O
produced	O
by	O
oral	O
bacteria	O
was	O
visually	O
detectable	O
as	O
a	O
black	O
precipitate	O
.	O

Hydrogen	O
sulfide	O
production	O
by	O
oral	O
bacteria	O
was	O
easily	O
analyzed	O
using	O
bismuth	O
trichloride	O
.	O

However	O
,	O
further	O
innovation	O
is	O
required	O
for	O
practical	O
use	O
.	O

To	O
investigate	O
if	O
oral	O
health	O
parameters	O
were	O
impaired	O
in	O
patients	O
with	O
myocardial	O
infarction	O
(	O
MI	O
)	O
and	O
if	O
there	O
was	O
an	O
association	O
with	O
serum	O
antibody	O
levels	O
against	O
the	O
periodontal	O
pathogens	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
Pg	B-bacteria
)	O
and	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
Aa	B-bacteria
)	O
.	O

A	O
case	O
-	O
control	O
study	O
consisting	O
of	O
100	O
patients	O
with	O
MI	O
and	O
100	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
from	O
the	O
same	O
geographic	O
area	O
was	O
investigated	O
regarding	O
oral	O
health	O
.	O

The	O
MI	O
group	O
had	O
significantly	O
more	O
periodontal	O
bone	O
loss	O
(	O
PBL	O
)	O
,	O
number	O
of	O
deepened	O
pockets	O
(	O
NDP	O
)	O
,	O
and	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
,	O
and	O
lower	O
number	O
of	O
teeth	O
(	O
NT	O
)	O
than	O
the	O
controls	O
.	O

After	O
adjustment	O
for	O
known	O
cardiovascular	O
risk	O
factors	O
NT	O
,	O
BOP	O
,	O
and	O
NDP	O
still	O
remained	O
significantly	O
related	O
to	O
MI	O
(	O
p	O
=	O
0	O
.	O
014	O
,	O
p	O
=	O
0	O
.	O
02	O
,	O
and	O
p	O
=	O
0	O
.	O
0069	O
,	O
respectively	O
)	O
.	O

IgG	O
antibody	O
levels	O
against	O
Pg	B-bacteria
were	O
higher	O
in	O
subjects	O
with	O
MI	O
(	O
p	O
=	O
0	O
.	O
043	O
)	O
,	O
as	O
well	O
as	O
in	O
those	O
with	O
>	O
4	O
deepened	O
pockets	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
BOP	O
>	O
20	O
%	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
PBL	O
(	O
p	O
=	O
0	O
.	O
0003	O
)	O
.	O

However	O
,	O
indicating	O
a	O
causal	O
pathway	O
,	O
the	O
relationship	O
between	O
MI	O
and	O
Pg	O
IgG	O
disappeared	O
when	O
the	O
oral	O
parameters	O
were	O
included	O
in	O
the	O
logistic	O
regression	O
model	O
(	O
p	O
=	O
0	O
.	O
69	O
)	O
.	O

No	O
correlation	O
was	O
seen	O
between	O
MI	O
and	O
Aa	O
in	O
the	O
present	O
study	O
.	O

Patients	O
with	O
MI	O
had	O
an	O
impaired	O
oral	O
health	O
compared	O
to	O
controls	O
.	O

Furthermore	O
,	O
IgG	O
levels	O
against	O
Pg	O
were	O
related	O
to	O
both	O
MI	O
and	O
oral	O
health	O
,	O
suggesting	O
this	O
pathogen	O
as	O
a	O
possible	O
link	O
between	O
oral	O
health	O
and	O
CVD	O
.	O

A	O
modified	O
titanium	O
surface	O
,	O
anodized	O
after	O
being	O
discharged	O
in	O
electrolytes	O
,	O
provides	O
antibacterial	O
activity	O
against	O
oral	O
bacteria	O
as	O
well	O
as	O
osteoconductivity	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
this	O
antibacterial	O
effect	O
against	O
oral	O
bacteria	O
is	O
still	O
unclear	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
whether	O
it	O
is	O
the	O
chloride	O
or	O
the	O
hydrophilicity	O
properties	O
of	O
the	O
anodized	O
titanium	O
,	O
which	O
is	O
effective	O
against	O
the	O
oral	O
bacteria	O
.	O

Titanium	O
plates	O
are	O
anodized	O
in	O
various	O
electrolytes	O
with	O
or	O
without	O
chloride	O
and	O
are	O
characterized	O
.	O

Then	O
the	O
survival	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
on	O
each	O
specimen	O
is	O
evaluated	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
peroxidation	O
effects	O
of	O
HClO	O
generated	O
from	O
the	O
TiCl	O
(	O
3	O
)	O
formed	O
on	O
the	O
titanium	O
surface	O
anodized	O
in	O
various	O
chloride	O
solutions	O
efficiently	O
killed	O
adherent	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
on	O
the	O
surface	O
whereas	O
the	O
presence	O
of	O
hydrophilicity	O
alone	O
do	O
not	O
demonstrate	O
antibacterial	O
activity	O
.	O

This	O
method	O
of	O
anodizing	O
titanium	O
surface	O
in	O
a	O
chloride	O
solution	O
may	O
provide	O
a	O
novel	O
strategy	O
for	O
use	O
in	O
orthopedic	O
or	O
dental	O
implant	O
systems	O
.	O

To	O
monitor	O
the	O
intra	O
-	O
oral	O
microbiological	O
changes	O
after	O
full	O
-	O
mouth	O
extraction	O
using	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
.	O

Nine	O
patients	O
with	O
severe	O
,	O
aggressive	O
periodontitis	O
,	O
for	O
whom	O
a	O
full	O
-	O
mouth	O
tooth	O
extraction	O
was	O
the	O
only	O
remaining	O
treatment	O
option	O
were	O
recruited	O
.	O

Before	O
and	O
6	O
months	O
after	O
extraction	O
,	O
microbial	O
samples	O
were	O
obtained	O
(	O
tongue	O
,	O
saliva	O
and	O
subgingival	O
plaque	O
)	O
and	O
analysed	O
by	O
qPCR	O
.	O

The	O
elimination	O
of	O
subgingival	O
niches	O
,	O
by	O
extraction	O
of	O
all	O
natural	O
teeth	O
,	O
resulted	O
in	O
a	O
3	O
-	O
log	O
reduction	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
and	O
more	O
modest	O
reductions	O
of	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
.	O

However	O
,	O
the	O
detection	O
frequencies	O
of	O
these	O
periodontopathogens	O
in	O
saliva	O
and	O
on	O
the	O
tongue	O
remained	O
unchanged	O
after	O
full	O
-	O
mouth	O
tooth	O
extraction	O
.	O

In	O
contrast	O
to	O
what	O
has	O
been	O
believed	O
so	O
far	O
,	O
full	O
-	O
mouth	O
tooth	O
extraction	O
does	O
not	O
result	O
in	O
eradication	O
of	O
all	O
periodontopathogens	O
but	O
only	O
in	O
a	O
significant	O
reduction	O
.	O

The	O
clinical	O
consequences	O
of	O
this	O
observation	O
remain	O
speculative	O
.	O

Hydrogen	O
sulfide	O
(	O
H	O
(	O
2	O
)	O
S	O
)	O
,	O
a	O
volatile	O
sulfur	O
compound	O
,	O
is	O
implicated	O
as	O
a	O
cause	O
of	O
inflammation	O
,	O
especially	O
when	O
it	O
is	O
produced	O
by	O
bacteria	O
colonizing	O
gastrointestinal	O
organs	O
.	O

However	O
,	O
it	O
is	O
unclear	O
if	O
H	O
(	O
2	O
)	O
S	O
produced	O
by	O
periodontal	O
pathogens	O
affects	O
the	O
inflammatory	O
responses	O
mediated	O
by	O
oral	O
/	O
gingival	O
epithelial	O
cells	O
.	O

Therefore	O
,	O
the	O
aims	O
of	O
this	O
study	O
were	O
(	O
1	O
)	O
to	O
compare	O
the	O
in	O
vitro	O
production	O
of	O
H	O
(	O
2	O
)	O
S	O
among	O
14	O
strains	O
of	O
oral	O
bacteria	O
and	O
(	O
2	O
)	O
to	O
evaluate	O
the	O
effects	O
of	O
H	O
(	O
2	O
)	O
S	O
on	O
inflammatory	O
response	O
induced	O
in	O
host	O
oral	O
/	O
gingival	O
epithelial	O
cells	O
.	O

Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
Pg	B-bacteria
)	O
produced	O
the	O
most	O
H	O
(	O
2	O
)	O
S	O
in	O
culture	O
,	O
which	O
,	O
in	O
turn	O
,	O
resulted	O
in	O
the	O
promotion	O
of	O
proinflammatory	O
cytokine	O
IL	O
-	O
8	O
from	O
both	O
gingival	O
and	O
oral	O
epithelial	O
cells	O
.	O

The	O
up	O
-	O
regulation	O
of	O
IL	O
-	O
8	O
expression	O
was	O
reproduced	O
by	O
the	O
exogenously	O
applied	O
H	O
(	O
2	O
)	O
S	O
.	O
Furthermore	O
,	O
the	O
mutant	O
strains	O
of	O
Pg	B-bacteria
that	O
do	O
not	O
produce	O
major	O
soluble	O
virulent	O
factors	O
,	O
i	O
.	O
e	O
.	O
gingipains	O
,	O
still	O
showed	O
the	O
production	O
of	O
H	O
(	O
2	O
)	O
S	O
,	O
as	O
well	O
as	O
the	O
promotion	O
of	O
epithelial	O
IL	O
-	O
8	O
production	O
,	O
which	O
was	O
abrogated	O
by	O
H	O
(	O
2	O
)	O
S	O
scavenging	O
reagents	O
.	O

These	O
results	O
demonstrated	O
that	O
Pg	B-bacteria
produces	O
a	O
concentration	O
of	O
H	O
(	O
2	O
)	O
S	O
capable	O
of	O
up	O
-	O
regulating	O
IL	O
-	O
8	O
expression	O
induced	O
in	O
gingival	O
and	O
oral	O
epithelial	O
cells	O
,	O
revealing	O
a	O
possible	O
mechanism	O
that	O
may	O
promote	O
the	O
inflammation	O
in	O
periodontal	O
disease	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
correlate	O
the	O
presence	O
of	O
Enterobacteriaceae	B-bacteria
,	O
Pseudomonadaceae	B-bacteria
,	O
Moraxellaceae	B-bacteria
and	O
Xanthomonadaceae	B-bacteria
on	O
the	O
posterior	O
dorsum	O
of	O
the	O
human	O
tongue	O
with	O
the	O
presence	O
of	O
tongue	O
coating	O
,	O
gender	O
,	O
age	O
,	O
smoking	O
habit	O
and	O
denture	O
use	O
.	O

Bacteria	O
were	O
isolated	O
from	O
the	O
posterior	O
tongue	O
dorsum	O
of	O
100	O
individuals	O
in	O
MacConkey	O
agar	O
medium	O
and	O
were	O
identified	O
by	O
the	O
API	O
20E	O
system	O
(	O
Biolab	O
-	O
Merieux	O
)	O
.	O

43	O
%	O
of	O
the	O
individuals	O
,	O
presented	O
the	O
target	O
microorganisms	O
on	O
the	O
tongue	O
dorsum	O
,	O
with	O
greater	O
prevalence	O
among	O
individuals	O
between	O
40	O
and	O
50	O
years	O
of	O
age	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
non	O
-	O
smokers	O
(	O
p	O
=	O
0	O
.	O
0485	O
)	O
.	O

A	O
higher	O
prevalence	O
of	O
Enterobacteriaceae	B-bacteria
and	O
Pseudomonadaceae	B-bacteria
was	O
observed	O
on	O
the	O
tongue	O
dorsum	O
of	O
the	O
individuals	O
evaluated	O
.	O

There	O
was	O
no	O
correlation	O
between	O
these	O
species	O
and	O
the	O
presence	O
and	O
thickness	O
of	O
tongue	O
coating	O
,	O
gender	O
and	O
presence	O
of	O
dentures	O
.	O

The	O
incidence	O
of	O
potential	O
periodontal	O
pathogens	O
(	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
formerly	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
nigrescens	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
and	O
Capnocytophaga	B-bacteria
ochracea	I-bacteria
)	O
was	O
monitored	O
in	O
patients	O
with	O
chronic	O
periodontitis	O
and	O
in	O
healthy	O
control	O
subjects	O
.	O

Two	O
types	O
of	O
studies	O
were	O
carried	O
out	O
in	O
which	O
the	O
composition	O
of	O
the	O
bacterial	O
communities	O
in	O
different	O
niches	O
of	O
the	O
same	O
oral	O
cavity	O
ecosystem	O
was	O
investigated	O
.	O

Fluctuation	O
or	O
at	O
least	O
pronounced	O
quantitative	O
changes	O
in	O
the	O
incidence	O
of	O
individual	O
species	O
in	O
time	O
were	O
documented	O
in	O
the	O
long	O
-	O
term	O
study	O
as	O
well	O
as	O
after	O
the	O
local	O
administration	O
of	O
antibacterial	O
drug	O
Chlo	O
-	O
Site	O
or	O
Metronidazole	O
.	O

Even	O
within	O
two	O
weeks	O
,	O
a	O
turnover	O
of	O
the	O
monitored	O
bacteria	O
in	O
separate	O
niches	O
of	O
the	O
oral	O
biotope	O
can	O
be	O
detected	O
.	O

A	O
relatively	O
high	O
incidence	O
of	O
the	O
tested	O
periopathogens	O
in	O
the	O
clinically	O
healthy	O
teeth	O
of	O
patients	O
implies	O
that	O
even	O
the	O
`	O
`	O
healthy	O
'	O
'	O
niches	O
in	O
the	O
periodontal	O
biotope	O
function	O
as	O
a	O
dynamic	O
reservoir	O
of	O
periopathogenic	O
microorganisms	O
.	O

This	O
should	O
be	O
kept	O
in	O
mind	O
when	O
a	O
local	O
application	O
of	O
antibacterial	O
compounds	O
is	O
used	O
in	O
the	O
therapy	O
of	O
periodontal	O
disease	O
.	O

To	O
assess	O
the	O
prevalence	O
of	O
oral	O
colonisation	O
by	O
bacterial	O
respiratory	O
pathogens	O
in	O
hospitalised	O
patients	O
.	O

Thirty	O
patients	O
undergoing	O
myocardium	O
revascularisation	O
surgery	O
were	O
evaluated	O
.	O

At	O
baseline	O
(	O
pre	O
-	O
operative	O
phase	O
)	O
,	O
full	O
-	O
mouth	O
clinical	O
periodontal	O
assessment	O
was	O
performed	O
.	O

Saliva	O
and	O
biofilm	O
samples	O
were	O
obtained	O
from	O
subjects	O
at	O
baseline	O
and	O
at	O
the	O
post	O
-	O
operative	O
phase	O
,	O
after	O
orotracheal	O
extubation	O
.	O

DNA	O
was	O
extracted	O
from	O
samples	O
and	O
species	O
of	O
Acinetobacter	B-bacteria
,	O
Pseudomonas	B-bacteria
,	O
Staphylococcus	B-bacteria
aureus	I-bacteria
and	O
Dialister	B-bacteria
pneumosintes	I-bacteria
were	O
detected	O
by	O
PCR	O
or	O
culture	O
(	O
for	O
staphylococci	B-bacteria
isolates	I-bacteria
)	O
.	O

Most	O
of	O
the	O
subjects	O
were	O
males	O
,	O
with	O
history	O
of	O
hypertension	O
and	O
smoking	O
.	O

Thirteen	O
were	O
edentulous	O
(	O
ED	O
)	O
and	O
17	O
were	O
dentate	O
(	O
DE	O
)	O
,	O
with	O
moderate	O
chronic	O
periodontitis	O
.	O

The	O
most	O
prevalent	O
bacteria	O
in	O
saliva	O
were	O
Staphylococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
85	O
.	O
7	O
%	O
)	O
,	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
83	O
.	O
8	O
%	O
)	O
,	O
and	O
Acinetobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
53	O
.	O
3	O
%	O
)	O
.	O

There	O
was	O
a	O
trend	O
for	O
D	O
.	O
pneumosintes	O
to	O
be	O
more	O
frequently	O
detected	O
in	O
DE	O
(	O
43	O
.	O
7	O
%	O
)	O
than	O
ED	O
(	O
11	O
.	O
5	O
%	O
)	O
patients	O
.	O

In	O
plaque	O
samples	O
,	O
DE	O
with	O
>	O
14	O
teeth	O
showed	O
a	O
higher	O
prevalence	O
of	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
(	O
100	O
%	O
)	O
than	O
individuals	O
with	O
<	O
or	O
=	O
14	O
teeth	O
(	O
69	O
.	O
1	O
%	O
;	O
p	O
=	O
0	O
.	O
048	O
)	O
.	O

Conversely	O
,	O
P	O
.	O
aeruginosa	O
was	O
more	O
prevalent	O
in	O
subjects	O
with	O
fewer	O
teeth	O
(	O
35	O
.	O
5	O
%	O
)	O
than	O
with	O
>	O
14	O
teeth	O
(	O
5	O
.	O
7	O
%	O
;	O
p	O
=	O
0	O
.	O
037	O
)	O
.	O

All	O
staphylococci	B-bacteria
isolates	I-bacteria
were	O
coagulase	O
-	O
negative	O
,	O
and	O
about	O
11	O
%	O
were	O
positive	O
for	O
the	O
mecA	O
gene	O
.	O

These	O
mecA	O
-	O
positive	O
isolates	O
showed	O
a	O
tendency	O
to	O
increase	O
in	O
all	O
samples	O
,	O
whereas	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
reduced	O
after	O
surgery	O
.	O

A	O
strong	O
correlation	O
between	O
the	O
presence	O
of	O
Acinetobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
was	O
observed	O
(	O
rho	O
=	O
0	O
.	O
886	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
oral	O
cavity	O
of	O
hospitalised	O
patients	O
harbours	O
high	O
frequencies	O
of	O
bacterial	O
respiratory	O
pathogens	O
,	O
supporting	O
its	O
potential	O
role	O
as	O
a	O
reservoir	O
for	O
these	O
species	O
.	O

Two	O
strains	O
of	O
anaerobic	O
,	O
Gram	O
-	O
stain	O
-	O
negative	O
bacilli	O
isolated	O
from	O
the	O
human	O
oral	O
cavity	O
(	O
D033B	O
-	O
12	O
-	O
2	O
(	O
T	O
)	O
and	O
D080A	O
-	O
01	O
)	O
were	O
subjected	O
to	O
a	O
comprehensive	O
range	O
of	O
phenotypic	O
and	O
genotypic	O
tests	O
and	O
were	O
found	O
to	O
be	O
distinct	O
from	O
any	O
previously	O
described	O
species	O
.	O

16S	O
rRNA	O
gene	O
sequence	O
analysis	O
revealed	O
that	O
the	O
strains	O
were	O
related	O
most	O
closely	O
to	O
the	O
type	O
strain	O
of	O
Prevotella	B-bacteria
marshii	I-bacteria
(	O
93	O
.	O
5	O
%	O
sequence	O
identity	O
)	O
.	O

The	O
novel	O
strains	O
were	O
saccharolytic	O
and	O
produced	O
acetic	O
acid	O
and	O
succinic	O
acid	O
as	O
end	O
products	O
of	O
fermentation	O
.	O

The	O
principal	O
cellular	O
long	O
-	O
chain	O
fatty	O
acids	O
were	O
C	O
(	O
1	O
)	O
(	O
6	O
)	O
:	O
(	O
0	O
)	O
)	O
,	O
iso	O
-	O
C	O
(	O
1	O
)	O
(	O
4	O
)	O
:	O
(	O
0	O
)	O
,	O
C	O
(	O
1	O
)	O
(	O
4	O
)	O
:	O
(	O
0	O
)	O
,	O
anteiso	O
-	O
C	O
(	O
1	O
)	O
(	O
5	O
)	O
:	O
(	O
0	O
)	O
,	O
iso	O
-	O
C	O
(	O
1	O
)	O
(	O
6	O
)	O
:	O
(	O
0	O
)	O
and	O
C	O
(	O
1	O
)	O
(	O
6	O
)	O
:	O
(	O
0	O
)	O
)	O
3	O
-	O
OH	O
.	O

The	O
G	O
+	O
C	O
content	O
of	O
the	O
DNA	O
of	O
strain	O
D033B	B-bacteria
-	I-bacteria
12	I-bacteria
-	I-bacteria
2	I-bacteria
(	O
T	O
)	O
was	O
44	O
mol	O
%	O
.	O

Strains	O
D033B	B-bacteria
-	I-bacteria
12	I-bacteria
-	I-bacteria
2	I-bacteria
(	O
T	O
)	O
and	O
D080A	B-bacteria
-	I-bacteria
01	I-bacteria
are	O
considered	O
to	O
represent	O
a	O
single	O
novel	O
species	O
of	O
the	O
genus	O
Prevotella	B-bacteria
,	O
for	O
which	O
the	O
name	O
Prevotella	B-bacteria
saccharolytica	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
is	O
proposed	O
.	O

The	O
type	O
strain	O
is	O
D033B	B-bacteria
-	O
12	O
-	O
2	O
(	O
T	O
)	O
(	O
=	O
DSM	B-bacteria
22473	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
57944	I-bacteria
(	O
T	O
)	O
)	O
.	O

We	O
reported	O
previously	O
that	O
Treponema	B-bacteria
denticola	I-bacteria
,	O
one	O
of	O
the	O
periodontal	O
pathogens	O
,	O
suppresses	O
the	O
expression	O
of	O
human	O
beta	O
-	O
defensins	O
(	O
HBDs	O
)	O
in	O
human	O
gingival	O
epithelial	O
cells	O
.	O

To	O
identify	O
the	O
mechanisms	O
involved	O
in	O
this	O
suppression	O
,	O
immortalized	O
and	O
normal	O
human	O
gingival	O
epithelial	O
cells	O
were	O
infected	O
with	O
live	O
or	O
heat	O
-	O
killed	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
for	O
24	O
h	O
,	O
and	O
then	O
the	O
expression	O
of	O
HBDs	O
was	O
examined	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Live	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
suppressed	O
the	O
expression	O
of	O
HBD	O
-	O
3	O
substantially	O
and	O
also	O
suppressed	O
the	O
expression	O
of	O
HBD	O
-	O
1	O
and	O
HBD	O
-	O
2	O
.	O

However	O
,	O
heat	O
-	O
killed	O
bacteria	O
did	O
not	O
produce	O
a	O
suppressive	O
effect	O
but	O
instead	O
slightly	O
upregulated	O
the	O
levels	O
of	O
HBD	O
-	O
2	O
and	O
HBD	O
-	O
3	O
.	O

In	O
contrast	O
to	O
live	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
,	O
which	O
reduced	O
the	O
activation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
and	O
NF	O
-	O
kappaB	O
within	O
an	O
hour	O
of	O
infection	O
,	O
heat	O
-	O
killed	O
bacteria	O
did	O
not	O
show	O
any	O
inhibitory	O
effect	O
on	O
the	O
MAPK	O
and	O
NF	O
-	O
kappaB	O
signaling	O
pathways	O
.	O

Knockdown	O
of	O
Toll	O
-	O
like	O
receptor	O
2	O
(	O
TLR2	O
)	O
via	O
RNA	O
interference	O
abolished	O
the	O
suppressive	O
effect	O
of	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
on	O
the	O
expression	O
of	O
HBD	O
-	O
3	O
.	O

Heat	O
-	O
killed	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
but	O
not	O
live	O
bacteria	O
could	O
activate	O
TLR2	O
in	O
CHO	O
/	O
CD14	O
/	O
TLR2	O
reporter	O
cells	O
,	O
suggesting	O
that	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
contains	O
a	O
heat	O
-	O
labile	O
inhibitor	O
(	O
s	O
)	O
of	O
TLR2	O
in	O
addition	O
to	O
ligands	O
recognized	O
by	O
TLR2	O
.	O

Indeed	O
,	O
live	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
was	O
able	O
to	O
inhibit	O
TLR2	O
activation	O
by	O
Pam	O
(	O
3	O
)	O
CSK	O
.	O

In	O
conclusion	O
,	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
suppressed	O
the	O
expression	O
of	O
HBD	O
-	O
3	O
by	O
inhibiting	O
the	O
TLR2	O
axis	O
in	O
gingival	O
epithelial	O
cells	O
.	O

These	O
results	O
may	O
provide	O
new	O
insight	O
into	O
the	O
pathogenesis	O
of	O
periodontitis	O
caused	O
by	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
.	O

Most	O
studies	O
examining	O
the	O
commensal	O
human	O
oral	O
microbiome	O
are	O
focused	O
on	O
disease	O
or	O
are	O
limited	O
in	O
methodology	O
.	O

In	O
order	O
to	O
diagnose	O
and	O
treat	O
diseases	O
at	O
an	O
early	O
and	O
reversible	O
stage	O
an	O
in	O
-	O
depth	O
definition	O
of	O
health	O
is	O
indispensible	O
.	O

The	O
aim	O
of	O
this	O
study	O
therefore	O
was	O
to	O
define	O
the	O
healthy	O
oral	O
microbiome	O
using	O
recent	O
advances	O
in	O
sequencing	O
technology	O
(	O
454	O
pyrosequencing	O
)	O
.	O

We	O
sampled	O
and	O
sequenced	O
microbiomes	O
from	O
several	O
intraoral	O
niches	O
(	O
dental	O
surfaces	O
,	O
cheek	O
,	O
hard	O
palate	O
,	O
tongue	O
and	O
saliva	O
)	O
in	O
three	O
healthy	O
individuals	O
.	O

Within	O
an	O
individual	O
oral	O
cavity	O
,	O
we	O
found	O
over	O
3600	O
unique	O
sequences	O
,	O
over	O
500	O
different	O
OTUs	O
or	O
`	O
`	O
species	O
-	O
level	O
'	O
'	O
phylotypes	O
(	O
sequences	O
that	O
clustered	O
at	O
3	O
%	O
genetic	O
difference	O
)	O
and	O
88	O
-	O
104	O
higher	O
taxa	O
(	O
genus	O
or	O
more	O
inclusive	O
taxon	O
)	O
.	O

The	O
predominant	O
taxa	O
belonged	O
to	O
Firmicutes	B-bacteria
(	O
genus	B-bacteria
Streptococcus	I-bacteria
,	O
family	B-bacteria
Veillonellaceae	I-bacteria
,	O
genus	B-bacteria
Granulicatella	I-bacteria
)	O
,	O
Proteobacteria	B-bacteria
(	O
genus	B-bacteria
Neisseria	I-bacteria
,	O
Haemophilus	B-bacteria
)	O
,	O
Actinobacteria	B-bacteria
(	O
genus	B-bacteria
Corynebacterium	I-bacteria
,	O
Rothia	B-bacteria
,	O
Actinomyces	B-bacteria
)	O
,	O
Bacteroidetes	B-bacteria
(	O
genus	B-bacteria
Prevotella	I-bacteria
,	O
Capnocytophaga	B-bacteria
,	O
Porphyromonas	B-bacteria
)	O
and	O
Fusobacteria	B-bacteria
(	O
genus	B-bacteria
Fusobacterium	I-bacteria
)	O
.	O
Each	O
individual	O
sample	O
harboured	O
on	O
average	O
266	O
`	O
`	O
species	O
-	O
level	O
'	O
'	O
phylotypes	O
(	O
SD	O
67	O
;	O
range	O
123	O
-	O
326	O
)	O
with	O
cheek	O
samples	O
being	O
the	O
least	O
diverse	O
and	O
the	O
dental	O
samples	O
from	O
approximal	O
surfaces	O
showing	O
the	O
highest	O
diversity	O
.	O

Principal	O
component	O
analysis	O
discriminated	O
the	O
profiles	O
of	O
the	O
samples	O
originating	O
from	O
shedding	O
surfaces	O
(	O
mucosa	O
of	O
tongue	O
,	O
cheek	O
and	O
palate	O
)	O
from	O
the	O
samples	O
that	O
were	O
obtained	O
from	O
solid	O
surfaces	O
(	O
teeth	O
)	O
.	O
There	O
was	O
a	O
large	O
overlap	O
in	O
the	O
higher	O
taxa	O
,	O
`	O
`	O
species	O
-	O
level	O
'	O
'	O
phylotypes	O
and	O
unique	O
sequences	O
among	O
the	O
three	O
microbiomes	O
:	O
84	O
%	O
of	O
the	O
higher	O
taxa	O
,	O
75	O
%	O
of	O
the	O
OTUs	O
and	O
65	O
%	O
of	O
the	O
unique	O
sequences	O
were	O
present	O
in	O
at	O
least	O
two	O
of	O
the	O
three	O
microbiomes	O
.	O

The	O
three	O
individuals	O
shared	O
1660	O
of	O
6315	O
unique	O
sequences	O
.	O

These	O
1660	O
sequences	O
(	O
the	O
`	O
`	O
core	O
microbiome	O
'	O
'	O
)	O
contributed	O
66	O
%	O
of	O
the	O
reads	O
.	O

The	O
overlapping	O
OTUs	O
contributed	O
to	O
94	O
%	O
of	O
the	O
reads	O
,	O
while	O
nearly	O
all	O
reads	O
(	O
99	O
.	O
8	O
%	O
)	O
belonged	O
to	O
the	O
shared	O
higher	O
taxa	O
.	O

We	O
obtained	O
the	O
first	O
insight	O
into	O
the	O
diversity	O
and	O
uniqueness	O
of	O
individual	O
oral	O
microbiomes	O
at	O
a	O
resolution	O
of	O
next	O
-	O
generation	O
sequencing	O
.	O

We	O
showed	O
that	O
a	O
major	O
proportion	O
of	O
bacterial	O
sequences	O
of	O
unrelated	O
healthy	O
individuals	O
is	O
identical	O
,	O
supporting	O
the	O
concept	O
of	O
a	O
core	O
microbiome	O
at	O
health	O
.	O

This	O
study	O
identified	O
the	O
bacterial	O
taxa	O
enduring	O
endodontic	O
treatment	O
procedures	O
by	O
using	O
a	O
combined	O
16S	O
ribosomal	O
RNA	O
-	O
based	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
reverse	O
-	O
capture	O
checkerboard	O
hybridization	O
approach	O
.	O

Samples	O
were	O
taken	O
from	O
infected	O
canals	O
of	O
15	O
teeth	O
with	O
apical	O
periodontitis	O
before	O
treatment	O
(	O
S1	O
)	O
,	O
after	O
chemomechanical	O
preparation	O
with	O
NaOCl	O
as	O
the	O
irrigant	O
(	O
S2	O
)	O
,	O
and	O
after	O
interappointment	O
medication	O
with	O
a	O
calcium	O
hydroxide	O
paste	O
(	O
S3	O
)	O
.	O

Bacterial	O
presence	O
was	O
first	O
screened	O
by	O
a	O
DNA	O
-	O
based	O
single	O
PCR	O
assay	O
.	O

RNA	O
extracts	O
were	O
subjected	O
to	O
RT	O
-	O
PCR	O
,	O
and	O
the	O
resulting	O
products	O
were	O
surveyed	O
for	O
the	O
presence	O
of	O
28	O
targeted	O
taxa	O
by	O
using	O
the	O
checkerboard	O
method	O
.	O

Bacteria	O
were	O
found	O
in	O
all	O
S1	O
samples	O
.	O

Detectable	O
levels	O
of	O
bacterial	O
ribosomal	O
RNA	O
,	O
used	O
as	O
an	O
indicator	O
of	O
viability	O
,	O
were	O
observed	O
in	O
60	O
%	O
of	O
the	O
cases	O
after	O
chemomechanical	O
preparation	O
and	O
53	O
%	O
after	O
intracanal	O
medication	O
.	O

The	O
most	O
prevalent	O
taxa	O
in	O
S1	O
were	O
Olsenella	B-bacteria
uli	I-bacteria
(	O
67	O
%	O
)	O
,	O
Pyramidobacter	B-bacteria
piscolens	I-bacteria
(	O
60	O
%	O
)	O
,	O
Streptococcus	B-bacteria
species	I-bacteria
(	O
53	O
%	O
)	O
,	O
and	O
Bacteroidetes	B-bacteria
clone	I-bacteria
X083	I-bacteria
(	O
53	O
%	O
)	O
.	O

Streptococcus	B-bacteria
species	I-bacteria
(	O
47	O
%	O
)	O
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
(	O
40	O
%	O
)	O
,	O
and	O
O	O
.	O
uli	O
(	O
33	O
%	O
)	O
prevailed	O
in	O
S2	O
,	O
whereas	O
Streptococcus	B-bacteria
species	I-bacteria
(	O
47	O
%	O
)	O
,	O
Propionibacterium	B-bacteria
acnes	I-bacteria
(	O
27	O
%	O
)	O
,	O
and	O
O	O
.	O
uli	O
(	O
27	O
%	O
)	O
were	O
the	O
most	O
frequent	O
taxa	O
in	O
S3	O
.	O

The	O
present	O
study	O
with	O
a	O
combined	O
molecular	O
approach	O
revealed	O
that	O
bacterial	O
diversity	O
was	O
overall	O
markedly	O
reduced	O
by	O
treatment	O
procedures	O
.	O

Although	O
bacterial	O
taxa	O
more	O
frequently	O
identified	O
in	O
post	O
-	O
treatment	O
samples	O
emerge	O
as	O
potential	O
risk	O
factors	O
for	O
persistent	O
disease	O
,	O
this	O
remains	O
to	O
be	O
determined	O
by	O
longitudinal	O
studies	O
.	O

Streptococcus	B-bacteria
sanguinis	I-bacteria
is	O
a	O
predominant	O
bacterium	O
in	O
the	O
human	O
oral	O
cavity	O
and	O
occasionally	O
causes	O
infective	O
endocarditis	O
.	O

We	O
identified	O
a	O
unique	O
cell	O
surface	O
polymeric	O
structure	O
named	O
pili	O
in	O
this	O
species	O
and	O
investigated	O
its	O
functions	O
in	O
regard	O
to	O
its	O
potential	O
virulence	O
.	O

Pili	O
of	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
strain	I-bacteria
SK36	I-bacteria
were	O
shown	O
to	O
be	O
composed	O
of	O
three	O
distinctive	O
pilus	O
proteins	O
(	O
PilA	O
,	O
PilB	O
,	O
and	O
PilC	O
)	O
,	O
and	O
a	O
pili	O
-	O
deficient	O
mutant	O
demonstrated	O
reduced	O
bacterial	O
adherence	O
to	O
HeLa	O
and	O
human	O
oral	O
epithelial	O
cells	O
.	O

PilC	O
showed	O
a	O
binding	O
ability	O
to	O
fibronectin	O
,	O
suggesting	O
that	O
pili	O
are	O
involved	O
in	O
colonization	O
by	O
this	O
species	O
.	O

In	O
addition	O
,	O
ATCC10556	O
,	O
a	O
standard	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
strain	I-bacteria
,	O
was	O
unable	O
to	O
produce	O
pili	O
due	O
to	O
defective	O
pilus	O
genes	O
,	O
which	O
indicates	O
a	O
diversity	O
of	O
pilus	O
expression	O
among	O
various	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
strains	I-bacteria
.	O

Shear	O
-	O
enhanced	O
adhesion	O
,	O
although	O
not	O
observed	O
for	O
fimbria	O
-	O
mediated	O
adhesion	O
of	O
oral	O
Actinomyces	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
was	O
noted	O
for	O
Hsa	O
-	O
mediated	O
adhesion	O
of	O
Streptococcus	B-bacteria
gordonii	I-bacteria
to	O
sialic	O
acid	O
-	O
containing	O
receptors	O
,	O
an	O
interaction	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
infective	O
endocarditis	O
.	O

Bifidobacteria	B-bacteria
,	O
one	O
of	O
the	O
relatively	O
dominant	O
components	O
of	O
the	O
human	O
intestinal	O
microbiota	O
,	O
are	O
considered	O
one	O
of	O
the	O
key	O
groups	O
of	O
beneficial	O
intestinal	O
bacteria	O
(	O
probiotic	O
bacteria	O
)	O
.	O

However	O
,	O
in	O
addition	O
to	O
health	O
-	O
promoting	O
taxa	O
,	O
the	O
genus	O
Bifidobacterium	B-bacteria
also	O
includes	O
Bifidobacterium	B-bacteria
dentium	I-bacteria
,	O
an	O
opportunistic	O
cariogenic	O
pathogen	O
.	O

The	O
genetic	O
basis	O
for	O
the	O
ability	O
of	O
B	B-bacteria
.	I-bacteria
dentium	I-bacteria
to	O
survive	O
in	O
the	O
oral	O
cavity	O
and	O
contribute	O
to	O
caries	O
development	O
is	O
not	O
understood	O
.	O

The	O
genome	O
of	O
B	B-bacteria
.	I-bacteria
dentium	I-bacteria
Bd1	I-bacteria
,	O
a	O
strain	O
isolated	O
from	O
dental	O
caries	O
,	O
was	O
sequenced	O
to	O
completion	O
to	O
uncover	O
a	O
single	O
circular	O
2	O
,	O
636	O
,	O
368	O
base	O
pair	O
chromosome	O
with	O
2	O
,	O
143	O
predicted	O
open	O
reading	O
frames	O
.	O

Annotation	O
of	O
the	O
genome	O
sequence	O
revealed	O
multiple	O
ways	O
in	O
which	O
B	B-bacteria
.	I-bacteria
dentium	I-bacteria
has	O
adapted	O
to	O
the	O
oral	O
environment	O
through	O
specialized	O
nutrient	O
acquisition	O
,	O
defences	O
against	O
antimicrobials	O
,	O
and	O
gene	O
products	O
that	O
increase	O
fitness	O
and	O
competitiveness	O
within	O
the	O
oral	O
niche	O
.	O

B	B-bacteria
.	I-bacteria
dentium	I-bacteria
Bd1	I-bacteria
was	O
shown	O
to	O
metabolize	O
a	O
wide	O
variety	O
of	O
carbohydrates	O
,	O
consistent	O
with	O
genome	O
-	O
based	O
predictions	O
,	O
while	O
colonization	O
and	O
persistence	O
factors	O
implicated	O
in	O
tissue	O
adhesion	O
,	O
acid	O
tolerance	O
,	O
and	O
the	O
metabolism	O
of	O
human	O
saliva	O
-	O
derived	O
compounds	O
were	O
also	O
identified	O
.	O

Global	O
transcriptome	O
analysis	O
demonstrated	O
that	O
many	O
of	O
the	O
genes	O
encoding	O
these	O
predicted	O
traits	O
are	O
highly	O
expressed	O
under	O
relevant	O
physiological	O
conditions	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
identify	O
,	O
through	O
various	O
genomic	O
approaches	O
,	O
specific	O
genetic	O
adaptations	O
of	O
a	O
Bifidobacterium	B-bacteria
taxon	I-bacteria
,	O
Bifidobacterium	B-bacteria
dentium	I-bacteria
Bd1	I-bacteria
,	O
to	O
a	O
lifestyle	O
as	O
a	O
cariogenic	O
microorganism	O
in	O
the	O
oral	O
cavity	O
.	O

In	O
silico	O
analysis	O
and	O
comparative	O
genomic	O
hybridization	O
experiments	O
clearly	O
reveal	O
a	O
high	O
level	O
of	O
genome	O
conservation	O
among	O
various	O
B	B-bacteria
.	I-bacteria
dentium	I-bacteria
strains	I-bacteria
.	O

The	O
data	O
indicate	O
that	O
the	O
genome	O
of	O
this	O
opportunistic	O
cariogen	O
has	O
evolved	O
through	O
a	O
very	O
limited	O
number	O
of	O
horizontal	O
gene	O
acquisition	O
events	O
,	O
highlighting	O
the	O
narrow	O
boundaries	O
that	O
separate	O
commensals	O
from	O
opportunistic	O
pathogens	O
.	O

Seasonal	O
changes	O
in	O
day	O
length	O
(	O
i	O
.	O
e	O
.	O
,	O
photoperiod	O
)	O
provide	O
animals	O
with	O
a	O
reliable	O
environmental	O
cue	O
to	O
determine	O
time	O
of	O
year	O
,	O
and	O
many	O
physiological	O
changes	O
occur	O
in	O
laboratory	O
animals	O
simply	O
by	O
extending	O
or	O
shortening	O
day	O
length	O
.	O

Male	O
Siberian	O
hamsters	O
(	O
Phodopus	O
sungorus	O
)	O
housed	O
in	O
long	O
summer	O
-	O
like	O
day	O
lengths	O
have	O
significantly	O
elevated	O
body	O
and	O
fat	O
masses	O
compared	O
to	O
short	O
-	O
day	O
hamsters	O
.	O

Because	O
others	O
have	O
demonstrated	O
that	O
the	O
intestinal	O
microbiota	O
of	O
humans	O
and	O
rodents	O
promotes	O
host	O
adiposity	O
,	O
we	O
hypothesized	O
that	O
photoperiod	O
-	O
induced	O
changes	O
in	O
body	O
and	O
fat	O
masses	O
could	O
be	O
associated	O
with	O
changes	O
in	O
the	O
microbial	O
composition	O
in	O
the	O
intestines	O
.	O

We	O
used	O
bacterial	O
tag	O
-	O
encoded	O
FLX	O
amplicon	O
pyrosequencing	O
(	O
bTEFAP	O
)	O
to	O
assess	O
microbial	O
diversity	O
in	O
the	O
cecal	O
contents	O
of	O
hamsters	O
;	O
long	O
days	O
significantly	O
increased	O
the	O
relative	O
abundance	O
of	O
bacteria	O
in	O
the	O
phylum	O
Proteobacteria	B-bacteria
.	O

This	O
effect	O
was	O
primarily	O
due	O
to	O
a	O
significant	O
increase	O
in	O
the	O
abundance	O
of	O
the	O
genus	O
Citrobacter	B-bacteria
,	O
with	O
both	O
the	O
abundance	O
of	O
Proteobacteria	B-bacteria
and	O
Citrobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
significantly	O
correlated	O
with	O
body	O
mass	O
and	O
with	O
inguinal	O
fat	O
mass	O
.	O

In	O
general	O
,	O
the	O
abundance	O
of	O
the	O
Firmicutes	B-bacteria
phylum	I-bacteria
was	O
inversely	O
associated	O
with	O
body	O
mass	O
.	O

These	O
data	O
indicate	O
that	O
the	O
intestinal	O
microbiota	O
are	O
responsive	O
to	O
changes	O
in	O
photoperiod	O
and	O
suggest	O
that	O
these	O
changes	O
may	O
in	O
part	O
influence	O
photoperiodic	O
changes	O
in	O
body	O
and	O
fat	O
masses	O
.	O

Epidemiologic	O
studies	O
of	O
periodontal	O
infection	O
as	O
a	O
risk	O
factor	O
for	O
cardiovascular	O
disease	O
often	O
use	O
clinical	O
periodontal	O
measures	O
as	O
a	O
surrogate	O
for	O
the	O
underlying	O
bacterial	O
exposure	O
of	O
interest	O
.	O

There	O
are	O
currently	O
no	O
methodological	O
studies	O
evaluating	O
which	O
clinical	O
periodontal	O
measures	O
best	O
reflect	O
the	O
levels	O
of	O
subgingival	O
bacterial	O
colonization	O
in	O
population	O
-	O
based	O
settings	O
.	O

We	O
investigated	O
the	O
characteristics	O
of	O
clinical	O
periodontal	O
definitions	O
that	O
were	O
most	O
representative	O
of	O
exposure	O
to	O
bacterial	O
species	O
that	O
are	O
believed	O
to	O
be	O
either	O
markers	O
,	O
or	O
themselves	O
etiologic	O
,	O
of	O
periodontal	O
disease	O
.	O

706	O
men	O
and	O
women	O
aged	O
>	O
or	O
=	O
55	O
years	O
,	O
residing	O
in	O
northern	O
Manhattan	O
were	O
enrolled	O
.	O

Using	O
DNA	O
-	O
DNA	O
checkerboard	O
hybridization	O
in	O
subgingival	O
biofilms	O
,	O
standardized	O
values	O
for	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
were	O
averaged	O
within	O
mouth	O
and	O
summed	O
to	O
define	O
`	O
`	O
bacterial	O
burden	O
'	O
'	O
.	O

Correlations	O
of	O
bacterial	O
burden	O
with	O
clinical	O
periodontal	O
constructs	O
defined	O
by	O
the	O
severity	O
and	O
extent	O
of	O
attachment	O
loss	O
(	O
AL	O
)	O
,	O
pocket	O
depth	O
(	O
PD	O
)	O
and	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
were	O
assessed	O
.	O

Clinical	O
periodontal	O
constructs	O
demonstrating	O
the	O
highest	O
correlations	O
with	O
bacterial	O
burden	O
were	O
:	O
i	O
)	O
percent	O
of	O
sites	O
with	O
BOP	O
(	O
r	O
=	O
0	O
.	O
62	O
)	O
;	O
ii	O
)	O
percent	O
of	O
sites	O
with	O
PD	O
>	O
or	O
=	O
3	O
mm	O
(	O
r	O
=	O
0	O
.	O
61	O
)	O
;	O
and	O
iii	O
)	O
number	O
of	O
sites	O
with	O
BOP	O
(	O
r	O
=	O
0	O
.	O
59	O
)	O
.	O

Increasing	O
PD	O
or	O
AL	O
severity	O
thresholds	O
consistently	O
attenuated	O
correlations	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
correlation	O
of	O
bacterial	O
burden	O
with	O
the	O
percent	O
of	O
sites	O
with	O
PD	O
>	O
or	O
=	O
8	O
mm	O
was	O
only	O
r	O
=	O
0	O
.	O
16	O
.	O

Clinical	O
exposure	O
definitions	O
of	O
periodontal	O
disease	O
should	O
incorporate	O
relatively	O
shallow	O
pockets	O
to	O
best	O
reflect	O
whole	O
mouth	O
exposure	O
to	O
bacterial	O
burden	O
.	O

It	O
has	O
been	O
suggested	O
that	O
use	O
of	O
systemic	O
antibiotics	O
should	O
be	O
limited	O
to	O
patients	O
with	O
specific	O
microbiologic	O
profiles	O
.	O

The	O
main	O
purpose	O
of	O
the	O
present	O
analysis	O
was	O
to	O
study	O
whether	O
microbiologic	O
testing	O
before	O
therapy	O
was	O
of	O
value	O
in	O
predicting	O
which	O
patients	O
would	O
specifically	O
benefit	O
from	O
adjunctive	O
amoxicillin	O
and	O
metronidazole	O
,	O
given	O
in	O
the	O
context	O
of	O
full	O
-	O
mouth	O
scaling	O
and	O
root	O
planing	O
(	O
SRP	O
)	O
within	O
48	O
hours	O
.	O

This	O
was	O
a	O
6	O
-	O
month	O
,	O
single	O
-	O
center	O
,	O
double	O
-	O
masked	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
longitudinal	O
study	O
.	O

Fifty	O
-	O
one	O
patients	O
received	O
full	O
-	O
mouth	O
periodontal	O
debridement	O
,	O
performed	O
within	O
48	O
hours	O
;	O
then	O
,	O
25	O
subjects	O
received	O
metronidazole	O
,	O
500	O
mg	O
,	O
and	O
amoxicillin	O
,	O
375	O
mg	O
,	O
three	O
times	O
a	O
day	O
for	O
7	O
days	O
,	O
and	O
26	O
received	O
a	O
placebo	O
(	O
control	O
group	O
)	O
.	O

Pooled	O
microbiologic	O
samples	O
were	O
taken	O
from	O
the	O
deepest	O
pocket	O
at	O
baseline	O
in	O
each	O
quadrant	O
before	O
and	O
6	O
months	O
after	O
treatment	O
.	O

Six	O
periodontal	O
pathogens	O
were	O
quantified	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Forty	O
-	O
seven	O
patients	O
were	O
followed	O
for	O
6	O
months	O
.	O

After	O
treatment	O
,	O
test	O
subjects	O
had	O
a	O
substantially	O
lower	O
mean	O
number	O
of	O
persisting	O
sites	O
with	O
probing	O
depth	O
>	O
4	O
mm	O
and	O
bleeding	O
on	O
probing	O
than	O
did	O
control	O
subjects	O
(	O
0	O
.	O
4	O
versus	O
3	O
.	O
0	O
;	O
P	O
=	O
0	O
.	O
005	O
;	O
month	O
6	O
)	O
.	O

Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
previously	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
)	O
could	O
not	O
be	O
detected	O
in	O
the	O
antibiotic	O
group	O
after	O
treatment	O
.	O

However	O
,	O
in	O
the	O
placebo	O
group	O
,	O
three	O
of	O
six	O
subjects	O
positive	O
for	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
continued	O
to	O
be	O
positive	O
.	O

Lower	O
frequencies	O
were	O
also	O
noted	O
in	O
the	O
test	O
group	O
for	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
P	O
=	O
0	O
.	O
013	O
)	O
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
(	O
previously	O
T	B-bacteria
.	I-bacteria
forsythensis	I-bacteria
)	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

However	O
,	O
even	O
subjects	O
testing	O
negative	O
for	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
at	O
baseline	O
had	O
a	O
significantly	O
better	O
primary	O
clinical	O
outcome	O
if	O
they	O
received	O
the	O
active	O
drugs	O
.	O

The	O
presence	O
of	O
six	O
putative	O
periodontal	O
pathogens	O
(	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
spp	I-bacteria
.	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
,	O
and	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
)	O
quantified	O
prior	O
to	O
therapy	O
was	O
not	O
correlated	O
with	O
the	O
outcome	O
of	O
full	O
-	O
mouth	O
SRP	O
with	O
or	O
without	O
amoxicillin	O
and	O
metronidazole	O
.	O

Excellent	O
clinical	O
results	O
in	O
the	O
antibiotics	O
group	O
were	O
obtained	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
six	O
classic	O
periodontal	O
periopathogens	O
prior	O
to	O
treatment	O
.	O

The	O
intestinal	O
ecosystem	O
is	O
formed	O
by	O
a	O
complex	O
,	O
yet	O
highly	O
characteristic	O
microbial	O
community	O
.	O

The	O
parameters	O
defining	O
whether	O
this	O
community	O
permits	O
invasion	O
of	O
a	O
new	O
bacterial	O
species	O
are	O
unclear	O
.	O

In	O
particular	O
,	O
inhibition	O
of	O
enteropathogen	O
infection	O
by	O
the	O
gut	O
microbiota	O
(	O
=	O
colonization	O
resistance	O
)	O
is	O
poorly	O
understood	O
.	O

To	O
analyze	O
the	O
mechanisms	O
of	O
microbiota	O
-	O
mediated	O
protection	O
from	O
Salmonella	B-bacteria
enterica	I-bacteria
induced	O
enterocolitis	O
,	O
we	O
used	O
a	O
mouse	O
infection	O
model	O
and	O
large	O
scale	O
high	O
-	O
throughput	O
pyrosequencing	O
.	O

In	O
contrast	O
to	O
conventional	O
mice	O
(	O
CON	O
)	O
,	O
mice	O
with	O
a	O
gut	O
microbiota	O
of	O
low	O
complexity	O
(	O
LCM	O
)	O
were	O
highly	O
susceptible	O
to	O
S	O
.	O
enterica	O
induced	O
colonization	O
and	O
enterocolitis	O
.	O

Colonization	O
resistance	O
was	O
partially	O
restored	O
in	O
LCM	O
-	O
animals	O
by	O
co	O
-	O
housing	O
with	O
conventional	O
mice	O
for	O
21	O
days	O
(	O
LCM	O
(	O
con21	O
)	O
)	O
.	O

16S	O
rRNA	O
sequence	O
analysis	O
comparing	O
LCM	O
,	O
LCM	O
(	O
con21	O
)	O
and	O
CON	O
gut	O
microbiota	O
revealed	O
that	O
gut	O
microbiota	O
complexity	O
increased	O
upon	O
conventionalization	O
and	O
correlated	O
with	O
increased	O
resistance	O
to	O
S	O
.	O
enterica	O
infection	O
.	O

Comparative	O
microbiota	O
analysis	O
of	O
mice	O
with	O
varying	O
degrees	O
of	O
colonization	O
resistance	O
allowed	O
us	O
to	O
identify	O
intestinal	O
ecosystem	O
characteristics	O
associated	O
with	O
susceptibility	O
to	O
S	B-bacteria
.	I-bacteria
enterica	I-bacteria
infection	O
.	O

Moreover	O
,	O
this	O
system	O
enabled	O
us	O
to	O
gain	O
further	O
insights	O
into	O
the	O
general	O
principles	O
of	O
gut	O
ecosystem	O
invasion	O
by	O
non	O
-	O
pathogenic	O
,	O
commensal	O
bacteria	O
.	O

Mice	O
harboring	O
high	O
commensal	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
densities	O
were	O
more	O
susceptible	O
to	O
S	B-bacteria
.	I-bacteria
enterica	I-bacteria
induced	O
gut	O
inflammation	O
.	O

Similarly	O
,	O
mice	O
with	O
high	O
titers	O
of	O
Lactobacilli	B-bacteria
were	O
more	O
efficiently	O
colonized	O
by	O
a	O
commensal	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
(	O
RR	B-bacteria
)	O
strain	O
after	O
oral	O
inoculation	O
.	O

Upon	O
examination	O
of	O
16S	O
rRNA	O
sequence	O
data	O
from	O
9	O
CON	O
mice	O
we	O
found	O
that	O
closely	O
related	O
phylotypes	O
generally	O
display	O
significantly	O
correlated	O
abundances	O
(	O
co	O
-	O
occurrence	O
)	O
,	O
more	O
so	O
than	O
distantly	O
related	O
phylotypes	O
.	O

Thus	O
,	O
in	O
essence	O
,	O
the	O
presence	O
of	O
closely	O
related	O
species	O
can	O
increase	O
the	O
chance	O
of	O
invasion	O
of	O
newly	O
incoming	O
species	O
into	O
the	O
gut	O
ecosystem	O
.	O

We	O
provide	O
evidence	O
that	O
this	O
principle	O
might	O
be	O
of	O
general	O
validity	O
for	O
invasion	O
of	O
bacteria	O
in	O
preformed	O
gut	O
ecosystems	O
.	O

This	O
might	O
be	O
of	O
relevance	O
for	O
human	O
enteropathogen	O
infections	O
as	O
well	O
as	O
therapeutic	O
use	O
of	O
probiotic	O
commensal	O
bacteria	O
.	O

To	O
explore	O
a	O
selected	O
-	O
media	O
of	O
Bifidobacterium	B-bacteria
from	O
oral	O
cavity	O
,	O
to	O
detect	O
the	O
distribution	O
of	O
Bifidobacterium	B-bacteria
in	O
different	O
sites	O
of	O
children	O
and	O
primarily	O
investigate	O
the	O
relationship	O
between	O
oral	O
Bifidobacterium	B-bacteria
and	O
early	O
childhood	O
caries	O
.	O

70	O
children	O
aged	O
from	O
3	O
to	O
5	O
-	O
year	O
-	O
old	O
were	O
selected	O
,	O
30	O
children	O
were	O
caries	O
-	O
free	O
and	O
40	O
were	O
severe	O
early	O
childhood	O
caries	O
(	O
S	O
-	O
ECC	O
)	O
.	O

Saliva	O
was	O
collected	O
and	O
plaque	O
samples	O
from	O
the	O
30	O
healthy	O
subjects	O
were	O
pooled	O
.	O

For	O
S	O
-	O
ECC	O
group	O
,	O
plaques	O
were	O
collected	O
separately	O
from	O
four	O
different	O
sites	O
as	O
follows	O
:	O
Saliva	O
,	O
surfaces	O
of	O
intact	O
enamel	O
,	O
surfaces	O
of	O
white	O
spot	O
-	O
lesions	O
,	O
and	O
deep	O
dentin	O
-	O
lesions	O
.	O

Samples	O
would	O
be	O
grown	O
in	O
the	O
selected	O
-	O
media	O
,	O
and	O
the	O
whole	O
DNA	O
of	O
bacteria	O
was	O
extracted	O
.	O

Polymerase	O
chain	O
reaction	O
was	O
performed	O
with	O
specific	O
primers	O
and	O
the	O
results	O
were	O
analyzed	O
by	O
the	O
electrophoresis	O
.	O

Bifidobacterium	B-bacteria
were	O
detected	O
0	O
in	O
the	O
caries	O
-	O
free	O
children	O
,	O
while	O
47	O
.	O
5	O
%	O
in	O
the	O
S	O
-	O
ECC	O
group	O
.	O

There	O
was	O
significant	O
difference	O
between	O
two	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
there	O
was	O
no	O
difference	O
between	O
different	O
sites	O
of	O
teeth	O
in	O
S	O
-	O
ECC	O
group	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

27	O
.	O
5	O
%	O
Bifidobacterium	B-bacteria
were	O
detected	O
in	O
saliva	O
,	O
27	O
.	O
5	O
%	O
on	O
surfaces	O
of	O
intact	O
enamel	O
,	O
20	O
.	O
0	O
%	O
on	O
surfaces	O
of	O
white	O
spot	O
-	O
lesions	O
and	O
22	O
.	O
5	O
%	O
in	O
deep	O
dentin	O
-	O
lesions	O
.	O

10	O
%	O
Bifidobacterium	B-bacteria
dentium	I-bacteria
were	O
detected	O
in	O
saliva	O
,	O
7	O
.	O
5	O
%	O
on	O
surfaces	O
of	O
intact	O
enamel	O
,	O
7	O
.	O
5	O
%	O
on	O
surfaces	O
of	O
white	O
spot	O
-	O
lesions	O
and	O
10	O
.	O
0	O
%	O
in	O
deep	O
dentin	O
-	O
lesions	O
.	O

One	O
type	O
of	O
modified	O
selected	O
media	O
of	O
Bifidobacterium	B-bacteria
in	O
oral	O
cavity	O
was	O
explored	O
.	O

Bifidobacterium	B-bacteria
may	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
the	O
S	O
-	O
ECC	O
and	O
has	O
nothing	O
to	O
do	O
with	O
different	O
sites	O
of	O
teeth	O
in	O
children	O
.	O

Members	O
of	O
the	O
phylum	O
Synergistetes	B-bacteria
have	O
been	O
demonstrated	O
in	O
several	O
environmental	O
ecosystems	O
and	O
mammalian	O
microflorae	O
by	O
culture	O
-	O
independent	O
methods	O
.	O

In	O
the	O
past	O
few	O
years	O
,	O
the	O
clinical	O
relevance	O
of	O
some	O
uncultivated	O
phylotypes	O
has	O
been	O
demonstrated	O
in	O
endodontic	O
infections	O
,	O
and	O
uncultured	O
Synergistetes	B-bacteria
have	O
been	O
demonstrated	O
in	O
human	O
mouth	O
,	O
gut	O
and	O
skin	O
microbiota	O
.	O

However	O
,	O
Synergistetes	B-bacteria
are	O
rarely	O
cultured	O
from	O
human	O
samples	O
,	O
and	O
only	O
17	O
isolates	O
are	O
currently	O
reported	O
.	O

Twelve	O
members	O
of	O
Synergistetes	B-bacteria
isolated	O
in	O
the	O
course	O
of	O
various	O
infectious	O
processes	O
,	O
including	O
3	O
Jonquetella	B-bacteria
anthropi	I-bacteria
,	O
2	O
Cloacibacillus	B-bacteria
evryensis	I-bacteria
,	O
2	O
Pyramidobacter	B-bacteria
piscolens	I-bacteria
and	O
5	O
unidentified	O
strains	O
,	O
as	O
well	O
as	O
56	O
clones	O
obtained	O
by	O
specific	O
PCR	O
from	O
the	O
normal	O
vaginal	O
microflora	O
,	O
were	O
studied	O
.	O

16S	O
rRNA	O
gene	O
-	O
based	O
phylogeny	O
showed	O
that	O
the	O
clones	O
were	O
grouped	O
into	O
3	O
clusters	O
,	O
corresponding	O
to	O
the	O
genus	O
Jonquetella	B-bacteria
,	O
P	B-bacteria
.	I-bacteria
piscolens	I-bacteria
and	O
one	O
novel	O
Synergistetes	B-bacteria
taxon	O
.	O

The	O
presence	O
and	O
diversity	O
of	O
Synergistetes	B-bacteria
were	O
reported	O
for	O
the	O
first	O
time	O
in	O
the	O
vaginal	O
microflora	O
.	O

Synergistetes	B-bacteria
were	O
found	O
in	O
healthy	O
patients	O
,	O
suggesting	O
that	O
they	O
could	O
play	O
a	O
functional	O
role	O
in	O
human	O
microflorae	O
,	O
but	O
may	O
also	O
act	O
as	O
opportunistic	O
pathogens	O
.	O

Studying	O
the	O
phylogenetic	O
relationships	O
between	O
environmental	O
and	O
mammalian	O
strains	O
and	O
clones	O
revealed	O
clearly	O
delineated	O
independent	O
lineages	O
according	O
to	O
the	O
origin	O
of	O
the	O
sequences	O
.	O

Campylobacter	B-bacteria
species	I-bacteria
(	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
,	O
C	B-bacteria
.	I-bacteria
fetus	I-bacteria
)	O
are	O
enteric	O
abortifacient	O
bacteria	O
in	O
humans	O
and	O
ungulates	O
.	O

Campylobacter	B-bacteria
rectus	I-bacteria
is	O
a	O
periodontal	O
pathogen	O
associated	O
with	O
human	O
fetal	O
exposure	O
and	O
adverse	O
pregnancy	O
outcomes	O
including	O
preterm	O
delivery	O
.	O

Experiments	O
in	O
pregnant	O
mice	O
have	O
demonstrated	O
that	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
can	O
translocate	O
from	O
a	O
distant	O
site	O
of	O
infection	O
to	O
the	O
placenta	O
to	O
induce	O
fetal	O
growth	O
restriction	O
and	O
impair	O
placental	O
development	O
.	O

However	O
,	O
placental	O
tissues	O
from	O
human	O
,	O
small	O
-	O
for	O
-	O
gestational	O
age	O
deliveries	O
have	O
not	O
been	O
reported	O
to	O
harbor	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
despite	O
evidence	O
of	O
maternal	O
infection	O
and	O
fetal	O
exposure	O
by	O
fetal	O
IgM	O
response	O
.	O

This	O
investigation	O
examined	O
the	O
temporal	O
relationship	O
between	O
the	O
placental	O
translocation	O
of	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
and	O
the	O
effects	O
on	O
fetal	O
growth	O
in	O
mice	O
.	O

BALB	O
/	O
c	O
mice	O
were	O
infected	O
at	O
gestational	O
day	O
E7	O
.	O
5	O
to	O
examine	O
placental	O
translocation	O
of	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
by	O
immunohistology	O
.	O

C	B-bacteria
.	I-bacteria
rectus	I-bacteria
significantly	O
decreased	O
fetoplacental	O
weight	O
at	O
E14	O
.	O
5	O
and	O
at	O
E16	O
.	O
5	O
.	O

C	B-bacteria
.	I-bacteria
rectus	I-bacteria
was	O
detected	O
in	O
63	O
%	O
of	O
placentas	O
at	O
E14	O
.	O
5	O
,	O
but	O
not	O
at	O
E16	O
.	O
5	O
.	O

In	O
in	O
vitro	O
trophoblast	O
invasion	O
assays	O
,	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
was	O
able	O
to	O
effectively	O
invade	O
human	O
trophoblasts	O
(	O
BeWo	O
)	O
but	O
not	O
murine	O
trophoblasts	O
(	O
SM9	O
-	O
1	O
)	O
,	O
and	O
showed	O
a	O
trend	O
for	O
more	O
invasiveness	O
than	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
.	O

C	B-bacteria
.	I-bacteria
rectus	I-bacteria
challenge	O
significantly	O
upregulated	O
both	O
mRNA	O
and	O
protein	O
levels	O
of	O
IL	O
-	O
6	O
and	O
TNFalpha	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
human	O
trophoblasts	O
,	O
but	O
did	O
not	O
increase	O
cytokine	O
expression	O
in	O
murine	O
cells	O
,	O
suggesting	O
a	O
correlation	O
between	O
invasion	O
and	O
cytokine	O
activation	O
.	O

In	O
conclusion	O
,	O
the	O
trophoblast	O
-	O
invasive	O
trait	O
of	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
that	O
appears	O
limited	O
to	O
human	O
trophoblasts	O
may	O
play	O
a	O
role	O
in	O
facilitating	O
bacterial	O
translocation	O
and	O
placental	O
inflammation	O
during	O
early	O
gestation	O
.	O

Intrauterine	O
infection	O
is	O
a	O
recognized	O
cause	O
of	O
adverse	O
pregnancy	O
outcome	O
,	O
but	O
the	O
source	O
of	O
infection	O
is	O
often	O
undetermined	O
.	O

We	O
report	O
a	O
case	O
of	O
stillbirth	O
caused	O
by	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
that	O
originated	O
in	O
the	O
mother	O
'	O
s	O
mouth	O
.	O

A	O
woman	O
with	O
pregnancy	O
-	O
associated	O
gingivitis	O
experienced	O
an	O
upper	O
respiratory	O
tract	O
infection	O
at	O
term	O
,	O
followed	O
by	O
stillbirth	O
a	O
few	O
days	O
later	O
.	O

F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
was	O
isolated	O
from	O
the	O
placenta	O
and	O
the	O
fetus	O
.	O

Examination	O
of	O
different	O
microbial	O
floras	O
from	O
the	O
mother	O
identified	O
the	O
same	O
clone	O
in	O
her	O
subgingival	O
plaque	O
but	O
not	O
in	O
the	O
supragingival	O
plaque	O
,	O
vagina	O
,	O
or	O
rectum	O
.	O

F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
may	O
have	O
translocated	O
from	O
the	O
mother	O
'	O
s	O
mouth	O
to	O
the	O
uterus	O
when	O
the	O
immune	O
system	O
was	O
weakened	O
during	O
the	O
respiratory	O
infection	O
.	O

This	O
case	O
sheds	O
light	O
on	O
patient	O
management	O
for	O
those	O
with	O
pregnancy	O
-	O
associated	O
gingivitis	O
.	O

Carious	O
tissue	O
fluoresces	O
with	O
a	O
wavelength	O
different	O
from	O
sound	O
tissue	O
when	O
stimulated	O
by	O
light	O
with	O
a	O
wavelength	O
of	O
655	O
nm	O
.	O

This	O
difference	O
is	O
thought	O
to	O
have	O
a	O
bacterial	O
origin	O
rather	O
than	O
indicating	O
demineralization	O
.	O

This	O
study	O
aimed	O
to	O
measure	O
fluorescence	O
emitted	O
by	O
normal	O
cultivable	O
caries	O
-	O
associated	O
bacterial	O
flora	O
and	O
typical	O
porphyrin	O
-	O
producing	O
bacteria	O
with	O
DIAGNOdent	O
,	O
and	O
to	O
verify	O
earlier	O
findings	O
that	O
demineralization	O
of	O
the	O
dental	O
hard	O
tissue	O
does	O
not	O
affect	O
DIAGNOdent	O
readings	O
.	O

Bacterial	O
samples	O
were	O
collected	O
from	O
five	O
occlusal	O
caries	O
lesions	O
in	O
three	O
subjects	O
.	O

From	O
these	O
,	O
mixed	O
anaerobic	O
flora	O
,	O
Lactobacilli	B-bacteria
and	O
mutans	B-bacteria
Streptococci	I-bacteria
were	O
cultured	O
in	O
up	O
to	O
three	O
different	O
kinds	O
of	O
culture	O
medium	O
.	O

Colonies	O
of	O
Lactobacilli	B-bacteria
and	O
mutans	B-bacteria
Streptococci	I-bacteria
were	O
also	O
measured	O
after	O
transferring	O
them	O
to	O
glass	O
slides	O
.	O

Laboratory	O
teaching	O
strains	O
of	O
Prevotella	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
Actinomyces	B-bacteria
odontolyticus	I-bacteria
were	O
cultured	O
anaerobically	O
and	O
fluorescence	O
measured	O
directly	O
after	O
an	O
appropriate	O
incubation	O
period	O
.	O

Sound	O
enamel	O
surfaces	O
of	O
15	O
extracted	O
premolars	O
were	O
demineralized	O
and	O
changes	O
in	O
fluorescence	O
measured	O
.	O

DIAGNOdent	O
readings	O
>	O
20	O
were	O
only	O
obtained	O
from	O
young	O
colonies	O
of	O
Prevotella	B-bacteria
and	O
from	O
colonies	O
of	O
mutans	B-bacteria
Streptococci	I-bacteria
cultured	O
on	O
mitis	O
-	O
salivarius	O
-	O
bacitracin	O
agar	O
.	O

Higher	O
measurements	O
were	O
obtained	O
as	O
the	O
bacterial	O
colonies	O
aged	O
.	O

Lower	O
measurements	O
were	O
obtained	O
after	O
transferring	O
colonies	O
to	O
glass	O
slides	O
.	O

Demineralization	O
of	O
enamel	O
did	O
not	O
affect	O
the	O
DIAGNOdent	O
measurements	O
.	O

The	O
change	O
in	O
fluorescence	O
measured	O
with	O
DIAGNOdent	O
has	O
a	O
bacterial	O
origin	O
rather	O
than	O
occurring	O
as	O
a	O
result	O
of	O
demineralization	O
.	O

The	O
measurements	O
are	O
presumably	O
dependent	O
on	O
bacterial	O
metabolites	O
rather	O
than	O
bacteria	O
themselves	O
,	O
and	O
probably	O
record	O
synergistic	O
effects	O
during	O
the	O
carious	O
process	O
rather	O
than	O
the	O
quantity	O
or	O
species	O
of	O
bacteria	O
involved	O
.	O

Eleven	O
clinical	O
strains	O
isolated	O
from	O
infected	O
wound	O
specimens	O
were	O
subjected	O
to	O
polyphasic	O
taxonomic	O
analysis	O
.	O

Sequence	O
analysis	O
of	O
the	O
16S	O
rRNA	O
gene	O
showed	O
that	O
all	O
11	O
strains	O
were	O
phylogenetically	O
related	O
to	O
Slackia	B-bacteria
exigua	I-bacteria
.	O

Additionally	O
,	O
conventional	O
and	O
biochemical	O
tests	O
of	O
6	O
of	O
the	O
11	O
strains	O
were	O
performed	O
as	O
supplementary	O
methods	O
to	O
obtain	O
phenotypic	O
identification	O
by	O
comparison	O
with	O
the	O
phenotypes	O
of	O
the	O
relevant	O
type	O
strains	O
.	O

S	B-bacteria
.	I-bacteria
exigua	I-bacteria
has	O
been	O
considered	O
an	O
oral	O
bacterial	O
species	O
in	O
the	O
family	O
Coriobacteriaceae	B-bacteria
.	O

This	O
organism	O
is	O
fastidious	O
and	O
grows	O
poorly	O
,	O
so	O
it	O
may	O
easily	O
be	O
overlooked	O
.	O

The	O
16S	O
rRNA	O
gene	O
sequences	O
and	O
the	O
biochemical	O
characteristics	O
of	O
four	O
of	O
the	O
S	B-bacteria
.	I-bacteria
exigua	I-bacteria
strains	O
isolated	O
for	O
this	O
study	O
from	O
various	O
infections	O
indicative	O
of	O
an	O
intestinal	O
source	O
were	O
almost	O
identical	O
to	O
those	O
of	O
the	O
validated	O
S	B-bacteria
.	I-bacteria
exigua	I-bacteria
type	O
strain	O
from	O
an	O
oral	O
source	O
and	O
two	O
of	O
the	O
S	B-bacteria
.	I-bacteria
exigua	I-bacteria
strains	O
from	O
oral	O
sources	O
evaluated	O
in	O
this	O
study	O
.	O

Thus	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
S	B-bacteria
.	I-bacteria
exigua	I-bacteria
species	O
can	O
be	O
isolated	O
from	O
extraoral	O
infections	O
as	O
well	O
as	O
from	O
oral	O
infections	O
.	O

The	O
profiles	O
of	O
susceptibility	O
to	O
selected	O
antimicrobials	O
of	O
this	O
species	O
were	O
also	O
investigated	O
for	O
the	O
first	O
time	O
.	O

Studies	O
with	O
cetylpyridinium	O
chloride	O
(	O
CPC	O
)	O
mouth	O
rinses	O
that	O
range	O
from	O
1	O
use	O
to	O
6	O
months	O
of	O
use	O
have	O
documented	O
the	O
clinical	O
efficacy	O
of	O
these	O
formulations	O
on	O
supragingival	O
plaque	O
and	O
gingivitis	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
a	O
commercially	O
available	O
mouth	O
rinse	O
containing	O
0	O
.	O
05	O
%	O
CPC	O
versus	O
a	O
fluoride	O
mouth	O
rinse	O
on	O
the	O
anaerobic	O
bacteria	O
found	O
in	O
dental	O
plaque	O
.	O

Antimicrobial	O
effects	O
on	O
the	O
organisms	O
of	O
the	O
supragingival	O
plaque	O
,	O
a	O
natural	O
biofilm	O
,	O
were	O
determined	O
after	O
1	O
use	O
and	O
after	O
14	O
days	O
of	O
use	O
of	O
each	O
mouth	O
rinse	O
.	O

After	O
enrollment	O
,	O
adult	O
subjects	O
from	O
China	O
completed	O
a	O
1	O
-	O
week	O
washout	O
period	O
and	O
provided	O
baseline	O
samples	O
of	O
supragingival	O
plaque	O
for	O
analysis	O
of	O
anaerobic	O
bacteria	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
commercially	O
available	O
mouth	O
rinse	O
formulated	O
with	O
0	O
.	O
05	O
%	O
CPC	O
or	O
a	O
fluoride	O
mouth	O
rinse	O
.	O

Subjects	O
were	O
assigned	O
to	O
each	O
group	O
according	O
to	O
a	O
computer	O
-	O
generated	O
randomization	O
sequence	O
.	O

They	O
were	O
instructed	O
to	O
rinse	O
with	O
20	O
mL	O
of	O
either	O
the	O
CPC	O
or	O
the	O
fluoride	O
mouth	O
rinse	O
for	O
30	O
seconds	O
.	O

Microbiologic	O
analyses	O
of	O
dental	O
plaque	O
samples	O
were	O
conducted	O
12	O
hours	O
after	O
the	O
first	O
use	O
of	O
assigned	O
mouth	O
rinse	O
.	O

Subjects	O
were	O
instructed	O
to	O
continue	O
twice	O
-	O
daily	O
rinsing	O
with	O
their	O
assigned	O
mouth	O
rinse	O
for	O
the	O
next	O
14	O
days	O
in	O
addition	O
to	O
brushing	O
their	O
teeth	O
with	O
a	O
commercial	O
fluoride	O
toothpaste	O
.	O

Dental	O
plaque	O
samples	O
for	O
microbiologic	O
analyses	O
were	O
collected	O
on	O
day	O
15	O
;	O
this	O
was	O
done	O
12	O
hours	O
after	O
the	O
final	O
use	O
of	O
the	O
assigned	O
mouth	O
rinses	O
.	O

A	O
dentist	O
conducted	O
oral	O
examinations	O
before	O
each	O
sample	O
collection	O
to	O
evaluate	O
hard	O
and	O
soft	O
tissue	O
health	O
over	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
study	O
included	O
117	O
adults	O
(	O
62	O
females	O
,	O
mean	O
age	O
,	O
28	O
.	O
70	O
years	O
;	O
55	O
males	O
,	O
mean	O
age	O
,	O
30	O
.	O
41	O
years	O
)	O
.	O

Subjects	O
rinsing	O
with	O
the	O
CPC	O
mouthwash	O
(	O
n	O
=	O
58	O
;	O
mean	O
age	O
,	O
29	O
.	O
41	O
years	O
)	O
reported	O
significant	O
reductions	O
in	O
anaerobic	O
bacteria	O
versus	O
those	O
issued	O
the	O
fluoride	O
rinse	O
(	O
n	O
=	O
59	O
;	O
mean	O
age	O
,	O
29	O
.	O
61	O
years	O
)	O
12	O
hours	O
after	O
1	O
use	O
and	O
12	O
hours	O
after	O
14	O
days	O
of	O
use	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
mean	O
percent	O
reduction	O
in	O
anaerobic	O
bacteria	O
between	O
the	O
CPC	O
mouth	O
rinse	O
and	O
the	O
fluoride	O
mouth	O
rinse	O
was	O
29	O
.	O
98	O
%	O
after	O
1	O
use	O
and	O
57	O
.	O
90	O
%	O
after	O
14	O
days	O
of	O
use	O
.	O

All	O
enrolled	O
subjects	O
completed	O
the	O
study	O
without	O
any	O
adverse	O
events	O
.	O

Use	O
of	O
the	O
CPC	O
mouth	O
rinse	O
was	O
associated	O
with	O
significant	O
reductions	O
in	O
the	O
anaerobic	O
bacteria	O
of	O
supragingival	O
plaque	O
compared	O
with	O
fluoride	O
mouth	O
rinse	O
use	O
in	O
these	O
adult	O
subjects	O
.	O

Bacterial	O
metabolites	O
demineralize	O
dental	O
hard	O
tissues	O
,	O
and	O
soluble	O
factors	O
lead	O
to	O
tertiary	O
dentinogenesis	O
in	O
the	O
area	O
of	O
the	O
dentin	O
-	O
pulp	O
complex	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
oral	O
bacteria	O
are	O
directly	O
involved	O
in	O
the	O
differentiation	O
of	O
dental	O
pulp	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
oral	O
bacterial	O
extracts	O
on	O
cellular	O
differentiation	O
in	O
human	O
dental	O
pulp	O
-	O
derived	O
cells	O
(	O
hDPC	O
)	O
.	O

The	O
hDPC	O
were	O
obtained	O
from	O
third	O
molar	O
teeth	O
,	O
and	O
the	O
cells	O
were	O
subcultured	O
.	O

The	O
sonicated	O
extracts	O
were	O
obtained	O
from	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
gram	O
-	O
negative	O
)	O
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
(	O
gram	O
-	O
positive	O
)	O
.	O

The	O
effect	O
of	O
bacterial	O
extracts	O
on	O
cellular	O
growth	O
and	O
differentiation	O
in	O
hDPC	O
were	O
tested	O
.	O

Alkaline	O
phosphatase	O
activity	O
and	O
bone	O
sialoprotein	O
(	O
BSP	O
)	O
gene	O
expression	O
were	O
increased	O
in	O
hDPC	O
exposed	O
to	O
low	O
concentrations	O
of	O
both	O
sonicated	O
extracts	O
,	O
whereas	O
the	O
activity	O
was	O
decreased	O
upon	O
exposure	O
to	O
high	O
concentrations	O
of	O
sonicated	O
extracts	O
from	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

This	O
is	O
the	O
first	O
evidence	O
that	O
oral	O
bacteria	O
have	O
a	O
positive	O
effect	O
on	O
cellular	O
differentiation	O
in	O
hPDC	O
.	O

Interactions	O
between	O
periodontal	O
bacteria	O
and	O
human	O
oral	O
epithelial	O
cells	O
can	O
lead	O
to	O
the	O
activation	O
and	O
expression	O
of	O
a	O
variety	O
of	O
inflammatory	O
mediators	O
in	O
epithelial	O
cells	O
.	O

Fusobacterium	B-bacteria
nucleatum	I-bacteria
is	O
a	O
filamentous	O
human	O
pathogen	O
that	O
is	O
strongly	O
associated	O
with	O
periodontal	O
diseases	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
methyl	O
gallate	O
(	O
MG	O
)	O
and	O
gallic	O
acid	O
(	O
GA	O
)	O
on	O
the	O
production	O
of	O
inflammatory	O
mediators	O
,	O
interleukin	O
(	O
IL	O
)	O
-	O
6	O
and	O
IL	O
-	O
8	O
,	O
by	O
oral	O
epithelial	O
cells	O
stimulated	O
by	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
.	O

In	O
a	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
live	O
F	O
.	O
nucleatum	O
induced	O
high	O
levels	O
of	O
gene	O
expression	O
and	O
protein	O
release	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
.	O

The	O
effects	O
of	O
MG	O
and	O
GA	O
were	O
examined	O
by	O
treating	O
KB	O
oral	O
epithelial	O
cells	O
with	O
MG	O
and	O
GA	O
and	O
stimulating	O
them	O
with	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
.	O

MG	O
and	O
GA	O
inhibited	O
significantly	O
the	O
increases	O
in	O
the	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
gene	O
and	O
protein	O
levels	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
Compounds	O
also	O
inhibited	O
the	O
growth	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
.	O

No	O
visible	O
effects	O
of	O
MG	O
and	O
GA	O
on	O
the	O
adhesion	O
and	O
invasion	O
of	O
KB	O
cells	O
by	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
were	O
observed	O
.	O

In	O
conclusion	O
,	O
both	O
MG	O
and	O
GA	O
inhibit	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
production	O
from	O
F	O
.	O
nucleatum	O
-	O
activated	O
KB	O
cells	O
.	O

Previous	O
research	O
has	O
shown	O
the	O
oxidizing	O
properties	O
and	O
microbiological	O
efficacies	O
of	O
chlorine	O
dioxide	O
(	O
ClO2	O
)	O
.	O

Its	O
clinical	O
efficacies	O
on	O
oral	O
malodor	O
have	O
been	O
evaluated	O
and	O
reported	O
only	O
in	O
short	O
duration	O
trials	O
,	O
moreover	O
,	O
no	O
clinical	O
studies	O
have	O
investigated	O
its	O
microbiological	O
efficacies	O
on	O
periodontal	O
and	O
malodorous	O
bacteria	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
inhibitory	O
effects	O
of	O
a	O
mouthwash	O
containing	O
ClO2	O
used	O
for	O
7	O
days	O
on	O
morning	O
oral	O
malodor	O
and	O
on	O
salivary	O
periodontal	O
and	O
malodorous	O
bacteria	O
.	O

A	O
randomized	O
,	O
double	O
blind	O
,	O
crossover	O
,	O
placebo	O
-	O
controlled	O
trial	O
was	O
conducted	O
among	O
15	O
healthy	O
male	O
volunteers	O
,	O
who	O
were	O
divided	O
into	O
2	O
groups	O
.	O

Subjects	O
were	O
instructed	O
to	O
rinse	O
with	O
the	O
experimental	O
mouthwash	O
containing	O
ClO2	O
or	O
the	O
placebo	O
mouthwash	O
,	O
without	O
ClO2	O
,	O
twice	O
per	O
day	O
for	O
7	O
days	O
.	O

After	O
a	O
one	O
week	O
washout	O
period	O
,	O
each	O
group	O
then	O
used	O
the	O
opposite	O
mouthwash	O
for	O
7	O
days	O
.	O

At	O
baseline	O
and	O
after	O
7	O
days	O
,	O
oral	O
malodor	O
was	O
evaluated	O
with	O
Organoleptic	O
measurement	O
(	O
OM	O
)	O
,	O
and	O
analyzed	O
the	O
concentrations	O
of	O
hydrogen	O
sulfide	O
(	O
H2S	O
)	O
,	O
methyl	O
mercaptan	O
(	O
CH3SH	O
)	O
and	O
dimethyl	O
sulfide	O
(	O
(	O
CH3	O
)	O
2S	O
)	O
,	O
the	O
main	O
VSCs	O
of	O
human	O
oral	O
malodor	O
,	O
were	O
assessed	O
by	O
gas	O
chromatography	O
(	O
GC	O
)	O
.	O

Clinical	O
outcome	O
variables	O
included	O
plaque	O
and	O
gingival	O
indices	O
,	O
and	O
tongue	O
coating	O
index	O
.	O

The	O
samples	O
of	O
saliva	O
were	O
microbiologically	O
investigated	O
.	O

Quantitative	O
and	O
qualitative	O
analyses	O
were	O
performed	O
using	O
the	O
polymerase	O
chain	O
reaction	O
-	O
Invader	O
method	O
.	O

RESULTS	O
AND	O
The	O
baseline	O
oral	O
condition	O
in	O
healthy	O
subjects	O
in	O
the	O
2	O
groups	O
did	O
not	O
differ	O
significantly	O
.	O

After	O
rinsing	O
with	O
the	O
mouthwash	O
containing	O
ClO2	O
for	O
7	O
days	O
,	O
morning	O
bad	O
breath	O
decreased	O
as	O
measured	O
by	O
the	O
OM	O
and	O
reduced	O
the	O
concentrations	O
of	O
H2S	O
,	O
CH3SH	O
and	O
(	O
CH3	O
)	O
2S	O
measured	O
by	O
GC	O
,	O
were	O
found	O
.	O

Moreover	O
ClO2	O
mouthwash	O
used	O
over	O
a	O
7	O
-	O
day	O
period	O
appeared	O
effective	O
in	O
reducing	O
plaque	O
,	O
tongue	O
coating	O
accumulation	O
and	O
the	O
counts	O
of	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
in	O
saliva	O
.	O

Future	O
research	O
is	O
needed	O
to	O
examine	O
long	O
-	O
term	O
effects	O
,	O
as	O
well	O
as	O
effects	O
on	O
periodontal	O
diseases	O
and	O
plaque	O
accumulation	O
in	O
a	O
well	O
-	O
defined	O
sample	O
of	O
halitosis	O
patients	O
and	O
broader	O
population	O
samples	O
.	O

ClinicalTrials	O
.	O
gov	O
NCT00748943	O
.	O

Fixed	O
orthodontic	O
appliances	O
can	O
alter	O
the	O
subgingival	O
microbiota	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
the	O
subgingival	O
microbiota	O
and	O
clinical	O
parameters	O
in	O
adolescent	O
subjects	O
at	O
sites	O
of	O
teeth	O
treated	O
with	O
orthodontic	O
bands	O
with	O
margins	O
at	O
(	O
OBM	O
)	O
or	O
below	O
the	O
gingival	O
margin	O
(	O
OBSM	O
)	O
,	O
or	O
with	O
brackets	O
(	O
OBR	O
)	O
.	O

Microbial	O
samples	O
were	O
collected	O
from	O
33	O
subjects	O
(	O
ages	O
,	O
12	O
-	O
18	O
years	O
)	O
in	O
treatment	O
more	O
than	O
6	O
months	O
.	O

The	O
microbiota	O
was	O
assessed	O
by	O
the	O
DNA	O
-	O
DNA	O
checkerboard	O
hybridization	O
method	O
.	O

Bacterial	O
samples	O
were	O
taken	O
from	O
83	O
OBR	O
,	O
103	O
OBSM	O
,	O
and	O
54	O
OBM	O
sites	O
.	O

Probing	O
pocket	O
depths	O
differed	O
by	O
orthodontic	O
type	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
with	O
mean	O
values	O
of	O
2	O
.	O
9	O
mm	O
(	O
SD	O
,	O
0	O
.	O
6	O
)	O
at	O
OBSM	O
sites	O
,	O
2	O
.	O
5	O
mm	O
(	O
SD	O
,	O
0	O
.	O
6	O
)	O
at	O
OBM	O
sites	O
,	O
and	O
2	O
.	O
3	O
mm	O
(	O
SD	O
,	O
0	O
.	O
5	O
)	O
at	O
OBR	O
sites	O
.	O

Only	O
Actinomyces	B-bacteria
israelii	I-bacteria
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
(	O
P	O
<	O
0	O
.	O
001	O
)	O
had	O
higher	O
levels	O
at	O
OBR	O
sites	O
,	O
whereas	O
Neisseria	B-bacteria
mucosa	I-bacteria
had	O
higher	O
levels	O
at	O
sites	O
treated	O
with	O
OBSM	O
or	O
OBM	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
was	O
found	O
in	O
25	O
%	O
of	O
sites	O
independent	O
of	O
the	O
appliance	O
.	O

Different	O
types	O
of	O
orthodontic	O
appliances	O
cause	O
minor	O
differences	O
in	O
the	O
subgingival	O
microbiota	O
(	O
A	B-bacteria
israelii	I-bacteria
and	O
A	B-bacteria
naeslundii	I-bacteria
)	O
and	O
higher	O
levels	O
at	O
sites	O
treated	O
with	O
orthodontic	O
brackets	O
.	O

More	O
sites	O
with	O
bleeding	O
on	O
probing	O
and	O
deeper	O
pockets	O
were	O
found	O
around	O
orthodontic	O
bands	O
.	O

Lactoferrin	O
(	O
LF	O
)	O
is	O
a	O
component	O
of	O
saliva	O
and	O
is	O
suspected	O
to	O
be	O
a	O
defense	O
factor	O
against	O
oral	O
pathogens	O
including	O
Streptococcus	B-bacteria
mutans	I-bacteria
and	O
Candida	O
albicans	O
.	O

Periodontitis	O
is	O
a	O
very	O
common	O
oral	O
disease	O
caused	O
by	O
periodontopathic	O
bacteria	O
.	O

Antimicrobial	O
activities	O
and	O
other	O
biological	O
effects	O
of	O
LF	O
against	O
representative	O
periodontopathic	O
bacteria	O
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
have	O
been	O
widely	O
studied	O
.	O

Association	O
of	O
polymorphisms	O
in	O
LF	O
with	O
incidence	O
of	O
aggressive	O
periodontitis	O
and	O
the	O
role	O
of	O
LF	O
in	O
the	O
gingival	O
crevicular	O
fluid	O
as	O
a	O
marker	O
of	O
periodontitis	O
severity	O
have	O
also	O
been	O
reported	O
.	O

Periodontopathic	O
bacteria	O
reside	O
as	O
a	O
biofilm	O
in	O
supragingival	O
and	O
subgingival	O
plaque	O
.	O

Our	O
recent	O
study	O
indicated	O
that	O
LF	O
exhibits	O
antibacterial	O
activity	O
against	O
planktonic	O
forms	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
at	O
higher	O
concentrations	O
,	O
and	O
furthermore	O
,	O
LF	O
effectively	O
inhibits	O
biofilm	O
formation	O
and	O
reduces	O
the	O
established	O
biofilm	O
of	O
these	O
bacteria	O
at	O
physiological	O
concentrations	O
.	O

A	O
small	O
-	O
scale	O
clinical	O
study	O
indicated	O
that	O
oral	O
administration	O
of	O
bovine	O
LF	O
reduces	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
in	O
the	O
subgingival	O
plaque	O
of	O
chronic	O
periodontitis	O
patients	O
.	O

LF	O
seems	O
to	O
be	O
a	O
biofilm	O
inhibitor	O
of	O
periodontopathic	O
bacteria	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

To	O
determine	O
the	O
influence	O
of	O
oral	O
status	O
on	O
halitosis	O
,	O
the	O
relationship	O
between	O
halitosis	O
and	O
periodontopathic	O
bacteria	O
present	O
in	O
plaque	O
on	O
the	O
tongue	O
and	O
the	O
subgingival	O
sulcus	O
was	O
examined	O
in	O
62	O
periodontally	O
healthy	O
adults	O
.	O

Halitosis	O
indicators	O
used	O
were	O
the	O
organoleptic	O
score	O
;	O
gas	O
chromatography	O
results	O
[	O
total	O
volatile	O
sulfur	O
compounds	O
(	O
VSCs	O
)	O
=	O
H	O
(	O
2	O
)	O
S	O
+	O
CH	O
(	O
3	O
)	O
SH	O
+	O
(	O
CH	O
(	O
3	O
)	O
)	O
(	O
2	O
)	O
S	O
]	O
;	O
Halimeter	O
values	O
;	O
and	O
the	O
results	O
of	O
three	O
clinical	O
tests	O
,	O
plaque	O
control	O
record	O
(	O
PlCR	O
)	O
,	O
plaque	O
index	O
(	O
PlI	O
)	O
,	O
and	O
tongue	O
coat	O
status	O
.	O

Significant	O
correlations	O
with	O
organoleptic	O
scores	O
was	O
observed	O
for	O
PlCR	O
,	O
PlI	O
,	O
tongue	O
coat	O
status	O
,	O
VSC	O
amounts	O
,	O
and	O
Halimeter	O
values	O
,	O
indicating	O
that	O
halitosis	O
in	O
periodontally	O
healthy	O
subjects	O
tended	O
to	O
originate	O
from	O
tongue	O
plaque	O
deposits	O
.	O

Polymerase	O
chain	O
reaction	O
analysis	O
was	O
used	O
to	O
detect	O
six	O
periodontopathic	O
bacteria	O
(	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
,	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
)	O
from	O
the	O
tongue	O
and	O
subgingival	O
plaque	O
.	O

Significant	O
effects	O
on	O
the	O
organoleptic	O
scores	O
,	O
tongue	O
coat	O
status	O
,	O
total	O
VSC	O
,	O
H	O
(	O
2	O
)	O
S	O
and	O
CH	O
(	O
3	O
)	O
SH	O
amounts	O
,	O
and	O
Halimeter	O
values	O
were	O
observed	O
only	O
for	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
and	O
only	O
in	O
the	O
tongue	O
plaque	O
,	O
not	O
in	O
the	O
subgingival	O
plaque	O
.	O

Thus	O
,	O
therapies	O
developed	O
to	O
inhibit	O
the	O
growth	O
of	O
these	O
bacteria	O
may	O
lead	O
to	O
future	O
treatments	O
of	O
halitosis	O
.	O

Distinguishing	O
expirated	O
bloodstains	O
(	O
blood	O
forced	O
by	O
airflow	O
out	O
of	O
the	O
nose	O
,	O
mouth	O
or	O
a	O
chest	O
wound	O
)	O
from	O
impact	O
spatter	O
(	O
blood	O
from	O
gunshots	O
,	O
explosives	O
,	O
blunt	O
force	O
trauma	O
and	O
/	O
or	O
machinery	O
accidents	O
)	O
is	O
an	O
important	O
challenge	O
in	O
forensic	O
science	O
.	O

Streptococcal	B-bacteria
bacteria	I-bacteria
are	O
only	O
found	O
in	O
the	O
human	O
mouth	O
and	O
saliva	O
.	O

This	O
study	O
developed	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
that	O
detects	O
DNA	O
from	O
these	O
bacteria	O
as	O
a	O
sensitive	O
tool	O
to	O
detect	O
the	O
presence	O
of	O
saliva	O
.	O

The	O
PCR	O
method	O
was	O
very	O
specific	O
to	O
human	O
oral	O
streptococci	B-bacteria
,	O
with	O
no	O
PCR	O
product	O
being	O
made	O
from	O
human	O
DNA	O
or	O
DNA	O
from	O
other	O
microbes	O
that	O
were	O
tested	O
.	O

It	O
was	O
also	O
very	O
sensitive	O
,	O
detecting	O
as	O
little	O
as	O
60	O
fg	O
of	O
target	O
DNA	O
.	O

The	O
PCR	O
amplification	O
gave	O
product	O
with	O
99	O
out	O
of	O
100	O
saliva	O
samples	O
tested	O
.	O

PCR	O
was	O
not	O
inhibited	O
by	O
the	O
presence	O
of	O
blood	O
and	O
could	O
detect	O
target	O
DNA	O
in	O
expirated	O
bloodstains	O
in	O
a	O
range	O
of	O
materials	O
and	O
for	O
up	O
to	O
92	O
days	O
after	O
deposit	O
on	O
cardboard	O
or	O
cotton	O
fabric	O
.	O

In	O
a	O
blind	O
trial	O
,	O
the	O
PCR	O
method	O
was	O
able	O
to	O
distinguish	O
three	O
mock	O
forensic	O
samples	O
that	O
contained	O
expirated	O
blood	O
from	O
four	O
that	O
did	O
not	O
.	O

Our	O
data	O
show	O
that	O
bacteria	O
present	O
in	O
the	O
oral	O
cavity	O
can	O
be	O
detected	O
in	O
bloodstains	O
that	O
contain	O
saliva	O
and	O
therefore	O
can	O
potentially	O
be	O
used	O
as	O
a	O
marker	O
in	O
forensic	O
work	O
to	O
distinguish	O
mouth	O
-	O
expirated	O
bloodstains	O
from	O
other	O
types	O
of	O
bloodstains	O
.	O

In	O
this	O
study	O
,	O
specific	O
sequences	O
within	O
three	O
genes	O
(	O
3D	O
,	O
VP4	O
and	O
2B	O
)	O
of	O
the	O
foot	O
-	O
and	O
-	O
mouth	O
disease	O
virus	O
(	O
FMDV	O
)	O
genome	O
were	O
determined	O
to	O
be	O
effective	O
RNAi	O
targets	O
.	O

These	O
sequences	O
are	O
highly	O
conserved	O
among	O
different	O
serotype	O
viruses	O
based	O
on	O
sequence	O
analysis	O
.	O

Small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
-	O
expressing	O
plasmids	O
(	O
p3D	O
-	O
NT19	O
,	O
p3D	O
-	O
NT56	O
,	O
pVP4	O
-	O
NT19	O
,	O
pVP4	O
-	O
NT65	O
and	O
p2B	O
-	O
NT25	O
)	O
were	O
constructed	O
to	O
express	O
siRNA	O
targeting	O
3D	O
,	O
VP4	O
and	O
2B	O
,	O
respectively	O
.	O

The	O
antiviral	O
potential	O
of	O
these	O
siRNA	O
for	O
various	O
FMDV	O
isolates	O
was	O
investigated	O
in	O
baby	O
hamster	O
kidney	O
(	O
BHK	O
-	O
21	O
)	O
cells	O
and	O
suckling	O
mice	O
.	O

The	O
results	O
show	O
that	O
these	O
siRNA	O
inhibited	O
virus	O
yield	O
10	O
-	O
to	O
300	O
-	O
fold	O
for	O
different	O
FMDV	O
isolates	O
of	O
serotype	O
O	O
and	O
serotype	O
Asia	O
I	O
at	O
48	O
h	O
post	O
infection	O
in	O
BHK	O
-	O
21	O
cells	O
compared	O
to	O
control	O
cells	O
.	O

In	O
suckling	O
mice	O
,	O
p3D	O
-	O
NT56	O
and	O
p2B	O
-	O
NT25	O
delayed	O
the	O
death	O
of	O
mice	O
.	O

Twenty	O
percent	O
to	O
40	O
%	O
of	O
the	O
animals	O
that	O
received	O
a	O
single	O
siRNA	O
dose	O
survived	O
5	O
days	O
post	O
infection	O
with	O
serotype	O
O	O
or	O
serotype	O
Asia	O
I	O
.	O

We	O
used	O
an	O
attenuated	O
Salmonella	B-bacteria
choleraesuis	I-bacteria
(	O
C500	O
)	O
vaccine	O
strain	O
,	O
to	O
carry	O
the	O
plasmid	O
that	O
expresses	O
siRNA	O
directed	O
against	O
the	O
polymerase	O
gene	O
3D	O
(	O
p3D	O
-	O
NT56	O
)	O
of	O
FMDV	O
.	O

We	O
used	O
guinea	O
pigs	O
to	O
evaluate	O
the	O
inhibitory	O
effects	O
of	O
recombinant	O
S	O
.	O
cho	O
(	O
p3D	O
-	O
NT56	O
/	O
S	O
.	O
cho	O
)	O
on	O
FMDV	O
infection	O
.	O

The	O
results	O
show	O
that	O
80	O
%	O
of	O
guinea	O
pigs	O
inoculated	O
with	O
10	O
(	O
9	O
)	O
CFU	O
of	O
p3D	O
-	O
NT56	O
/	O
S	O
.	O

cho	O
and	O
challenged	O
36	O
h	O
later	O
with	O
50	O
ID	O
(	O
50	O
)	O
of	O
homologous	O
FMDV	O
were	O
protected	O
.	O

We	O
also	O
measured	O
the	O
antiviral	O
activity	O
of	O
p3D	O
-	O
NT56	O
/	O
S	O
.	O
cho	O
in	O
swine	O
.	O

The	O
results	O
indicate	O
that	O
100	O
%	O
of	O
the	O
animals	O
treated	O
with	O
5	O
x	O
10	O
(	O
9	O
)	O
CFU	O
of	O
p3D	O
-	O
NT56	O
/	O
S	O
.	O
cho	O
were	O
protected	O
in	O
9	O
days	O
.	O

Although	O
many	O
clinical	O
trials	O
on	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
therapeutic	O
vaccines	O
have	O
been	O
performed	O
,	O
clinical	O
responses	O
have	O
not	O
been	O
consistent	O
.	O

We	O
have	O
addressed	O
mucosal	O
cytotoxic	O
cellular	O
immune	O
responses	O
to	O
HPV16	O
E7	O
after	O
oral	O
immunization	O
of	O
mice	O
with	O
recombinant	O
Lactobacillus	B-bacteria
casei	I-bacteria
expressing	O
HPV16	O
E7	O
(	O
LacE7	O
)	O
.	O

C57BL	O
/	O
6	O
mice	O
were	O
orally	O
exposed	O
to	O
0	O
.	O
1	O
-	O
100mg	O
/	O
head	O
of	O
attenuated	O
LacE7	O
or	O
vehicle	O
(	O
Lac	O
)	O
vaccines	O
at	O
weeks	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
8	O
.	O

Responses	O
to	O
subcutaneous	O
or	O
intramuscular	O
injection	O
of	O
an	O
HPV16	O
E7	O
fusion	O
protein	O
using	O
the	O
same	O
timing	O
protocol	O
were	O
used	O
for	O
comparison	O
.	O

Oral	O
immunization	O
with	O
LacE7	O
elicited	O
E7	O
-	O
specific	O
IFN	O
gamma	O
-	O
producing	O
cells	O
(	O
T	O
cells	O
with	O
E7	O
-	O
type	O
1	O
immune	O
responses	O
)	O
among	O
integrin	O
alpha	O
4	O
beta	O
7	O
(	O
+	O
)	O
mucosal	O
lymphocytes	O
collected	O
from	O
gut	O
mucosa	O
.	O

An	O
induction	O
of	O
E7	O
-	O
specific	O
granzyme	O
B	O
-	O
producing	O
cells	O
(	O
E7	O
-	O
CTL	O
)	O
exhibiting	O
killer	O
responses	O
toward	O
HPV16	O
E7	O
-	O
positive	O
cells	O
was	O
also	O
observed	O
.	O

The	O
induction	O
of	O
T	O
cells	O
with	O
specific	O
mucosal	O
E7	O
-	O
type	O
1	O
immune	O
responses	O
was	O
greater	O
after	O
oral	O
immunization	O
with	O
LacE7	O
when	O
compared	O
to	O
subcutaneous	O
or	O
intramuscular	O
antigen	O
delivery	O
.	O

Oral	O
immunization	O
with	O
Lactobacillus	B-bacteria
-	O
based	O
vaccines	O
was	O
also	O
able	O
to	O
induce	O
mucosal	O
cytotoxic	O
cellular	O
immune	O
responses	O
.	O

This	O
novel	O
approach	O
at	O
a	O
therapeutic	O
HPV	O
vaccine	O
may	O
achieve	O
more	O
effective	O
clinical	O
responses	O
through	O
its	O
induction	O
of	O
mucosal	O
E7	O
-	O
specific	O
CTL	O
.	O

Probiotics	O
or	O
health	O
-	O
beneficial	O
bacteria	O
have	O
only	O
recently	O
been	O
introduced	O
in	O
dentistry	O
and	O
oral	O
medicine	O
after	O
years	O
of	O
successful	O
use	O
in	O
mainly	O
gastro	O
-	O
intestinal	O
disorders	O
.	O

The	O
concept	O
of	O
bacteriotherapy	O
and	O
use	O
of	O
health	O
-	O
beneficial	O
micro	O
-	O
organisms	O
to	O
heal	O
diseases	O
or	O
support	O
immune	O
function	O
was	O
first	O
introduced	O
in	O
the	O
beginning	O
of	O
the	O
20th	O
century	O
.	O

Later	O
the	O
concept	O
lead	O
to	O
the	O
development	O
of	O
modem	O
dairy	O
industry	O
and	O
even	O
today	O
most	O
probiotic	O
strains	O
are	O
lactobacilli	B-bacteria
or	O
bifidobacteria	B-bacteria
used	O
in	O
milk	O
fermentation	O
.	O

The	O
mechanisms	O
of	O
probiotic	O
action	O
are	O
mainly	O
unknown	O
but	O
the	O
inter	O
-	O
microbial	O
species	O
interactions	O
are	O
supposed	O
to	O
play	O
a	O
key	O
role	O
in	O
this	O
together	O
with	O
their	O
immuno	O
-	O
stimulatory	O
effects	O
.	O

The	O
introduction	O
of	O
probiotic	O
bacteria	O
in	O
the	O
mouth	O
calls	O
for	O
ascertainment	O
of	O
their	O
particular	O
safety	O
.	O

Since	O
acid	O
production	O
from	O
sugar	O
is	O
detrimental	O
to	O
teeth	O
,	O
care	O
must	O
be	O
taken	O
not	O
to	O
select	O
strains	O
with	O
high	O
fermentation	O
capacity	O
.	O

The	O
first	O
randomized	O
controlled	O
trials	O
have	O
nevertheless	O
shown	O
that	O
probiotics	O
may	O
control	O
dental	O
caries	O
in	O
children	O
due	O
to	O
their	O
inhibitory	O
action	O
against	O
cariogenic	O
streptococci	B-bacteria
.	O

Less	O
evidence	O
exists	O
on	O
their	O
role	O
in	O
periodontal	O
disease	O
or	O
oral	O
yeast	O
infections	O
.	O

Furthermore	O
the	O
best	O
vehicles	O
for	O
oral	O
probiotic	O
applications	O
need	O
to	O
be	O
assessed	O
.	O

So	O
far	O
mainly	O
dairy	O
products	O
have	O
been	O
investigated	O
but	O
other	O
means	O
such	O
as	O
probiotics	O
in	O
chewing	O
gums	O
or	O
lozenges	O
have	O
also	O
been	O
studied	O
.	O

From	O
the	O
clinical	O
practitioner	O
'	O
s	O
point	O
of	O
view	O
direct	O
recommendations	O
for	O
the	O
use	O
of	O
probiotics	O
can	O
not	O
yet	O
be	O
given	O
.	O

However	O
,	O
scientific	O
evidence	O
so	O
far	O
indicates	O
that	O
probiotic	O
therapy	O
may	O
be	O
a	O
reality	O
also	O
in	O
dentistry	O
and	O
oral	O
medicine	O
in	O
the	O
future	O
.	O

The	O
periodontal	O
pathogens	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
are	O
strongly	O
associated	O
with	O
periodontal	O
disease	O
and	O
are	O
highly	O
prevalent	O
in	O
humans	O
with	O
periodontitis	O
.	O

Porphyromonas	B-bacteria
and	O
Tannerella	B-bacteria
spp	I-bacteria
.	I-bacteria
have	O
also	O
been	O
isolated	O
from	O
the	O
oral	O
cavity	O
of	O
cats	O
.	O

The	O
oral	O
microflora	O
in	O
animals	O
was	O
compared	O
with	O
those	O
in	O
humans	O
in	O
earlier	O
studies	O
,	O
but	O
no	O
studies	O
are	O
available	O
on	O
the	O
comparison	O
of	O
the	O
oral	O
microflora	O
from	O
pets	O
and	O
their	O
respective	O
owners	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
presence	O
of	O
these	O
bacteria	O
in	O
the	O
oral	O
microflora	O
of	O
cats	O
and	O
their	O
owners	O
,	O
since	O
animal	O
to	O
human	O
transmission	O
,	O
or	O
vice	O
versa	O
,	O
of	O
oral	O
pathogens	O
could	O
have	O
public	O
health	O
implications	O
.	O

This	O
study	O
investigated	O
the	O
prevalence	O
of	O
Porphyromonas	B-bacteria
gulae	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
and	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
in	O
the	O
oral	O
microflora	O
of	O
cats	O
and	O
their	O
owners	O
,	O
using	O
culture	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

All	O
Porphyromonas	B-bacteria
isolates	I-bacteria
from	O
cats	O
(	O
n	O
=	O
64	O
)	O
were	O
catalase	O
positive	O
,	O
whereas	O
the	O
Porphyromonas	B-bacteria
isolates	I-bacteria
from	O
owners	O
(	O
n	O
=	O
7	O
)	O
were	O
catalase	O
negative	O
,	O
suggesting	O
that	O
the	O
isolates	O
from	O
cats	O
were	O
P	B-bacteria
.	I-bacteria
gulae	I-bacteria
whereas	O
those	O
from	O
the	O
owners	O
were	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
was	O
recovered	O
from	O
both	O
cats	O
(	O
n	O
=	O
63	O
)	O
and	O
owners	O
(	O
n	O
=	O
31	O
)	O
;	O
the	O
proportion	O
of	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
relative	O
to	O
the	O
total	O
CFU	O
was	O
higher	O
in	O
cats	O
with	O
periodontitis	O
than	O
in	O
cats	O
without	O
periodontal	O
disease	O
.	O

Genotyping	O
of	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
isolates	I-bacteria
(	O
n	O
=	O
54	O
)	O
in	O
six	O
cat	O
/	O
owner	O
couples	O
showed	O
that	O
in	O
one	O
cat	O
/	O
owner	O
couple	O
the	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
isolates	I-bacteria
(	O
n	O
=	O
6	O
)	O
were	O
identical	O
.	O

These	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
isolates	I-bacteria
were	O
all	O
catalase	O
positive	O
,	O
which	O
led	O
us	O
to	O
hypothesize	O
that	O
transmission	O
from	O
cats	O
to	O
owners	O
had	O
occurred	O
and	O
that	O
cats	O
may	O
be	O
a	O
reservoir	O
of	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
.	O

Periodontitis	O
and	O
caries	O
are	O
infectious	O
diseases	O
of	O
the	O
oral	O
cavity	O
in	O
which	O
oral	O
biofilms	O
play	O
a	O
causative	O
role	O
.	O

Moreover	O
,	O
oral	O
biofilms	O
are	O
widely	O
studied	O
as	O
model	O
systems	O
for	O
bacterial	O
adhesion	O
,	O
biofilm	O
development	O
,	O
and	O
biofilm	O
resistance	O
to	O
antibiotics	O
,	O
due	O
to	O
their	O
widespread	O
presence	O
and	O
accessibility	O
.	O

Despite	O
descriptions	O
of	O
initial	O
plaque	O
formation	O
on	O
the	O
tooth	O
surface	O
,	O
studies	O
on	O
mature	O
plaque	O
and	O
plaque	O
structure	O
below	O
the	O
gum	O
are	O
limited	O
to	O
landmark	O
studies	O
from	O
the	O
1970s	O
,	O
without	O
appreciating	O
the	O
breadth	O
of	O
microbial	O
diversity	O
in	O
the	O
plaque	O
.	O

We	O
used	O
fluorescent	O
in	O
situ	O
hybridization	O
to	O
localize	O
in	O
vivo	O
the	O
most	O
abundant	O
species	O
from	O
different	O
phyla	O
and	O
species	O
associated	O
with	O
periodontitis	O
on	O
seven	O
embedded	O
teeth	O
obtained	O
from	O
four	O
different	O
subjects	O
.	O

The	O
data	O
showed	O
convincingly	O
the	O
dominance	O
of	O
Actinomyces	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Spirochaetes	B-bacteria
,	O
and	O
Synergistetes	B-bacteria
in	O
subgingival	O
plaque	O
.	O

The	O
latter	O
proved	O
to	O
be	O
new	O
with	O
a	O
possibly	O
important	O
role	O
in	O
host	O
-	O
pathogen	O
interaction	O
due	O
to	O
its	O
localization	O
in	O
close	O
proximity	O
to	O
immune	O
cells	O
.	O

The	O
present	O
study	O
identified	O
for	O
the	O
first	O
time	O
in	O
vivo	O
that	O
Lactobacillus	B-bacteria
sp	I-bacteria
.	I-bacteria
are	O
the	O
central	O
cells	O
of	O
bacterial	O
aggregates	O
in	O
subgingival	O
plaque	O
,	O
and	O
that	O
Streptococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
and	O
the	O
yeast	O
Candida	O
albicans	O
form	O
corncob	O
structures	O
in	O
supragingival	O
plaque	O
.	O

Finally	O
,	O
periodontal	O
pathogens	O
colonize	O
already	O
formed	O
biofilms	O
and	O
form	O
microcolonies	O
therein	O
.	O

These	O
in	O
vivo	O
observations	O
on	O
oral	O
biofilms	O
provide	O
a	O
clear	O
vision	O
on	O
biofilm	O
architecture	O
and	O
the	O
spatial	O
distribution	O
of	O
predominant	O
species	O
.	O

Irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
reflects	O
several	O
pathogenetic	O
entities	O
including	O
a	O
subgroup	O
with	O
low	O
-	O
grade	O
colonic	O
inflammation	O
.	O

We	O
propose	O
that	O
pathogenic	O
bacteria	O
act	O
as	O
triggers	O
and	O
that	O
disturbances	O
of	O
commensal	O
bacteria	O
maintain	O
low	O
-	O
grade	O
inflammation	O
,	O
that	O
in	O
turn	O
leads	O
to	O
dysfunction	O
in	O
the	O
gut	O
or	O
brain	O
.	O

Studies	O
were	O
performed	O
in	O
mice	O
under	O
specific	O
pathogen	O
-	O
free	O
conditions	O
.	O

Visceral	O
pain	O
was	O
assessed	O
by	O
the	O
visceromotor	O
response	O
and	O
motility	O
was	O
assessed	O
by	O
in	O
vivo	O
fluoroscopy	O
and	O
in	O
vitro	O
by	O
muscle	O
contractility	O
.	O

Brain	O
chemistry	O
was	O
assessed	O
by	O
in	O
situ	O
hybridization	O
and	O
behavior	O
by	O
standard	O
tests	O
.	O

The	O
microbiota	O
was	O
monitored	O
using	O
16s	O
-	O
based	O
RT	O
-	O
PCR	O
and	O
DGGE	O
.	O

Mice	O
transiently	O
infected	O
with	O
the	O
nematode	O
Trichinella	O
spiralis	O
exhibited	O
changes	O
in	O
motility	O
and	O
in	O
visceral	O
perception	O
that	O
persisted	O
for	O
up	O
to	O
6	O
weeks	O
post	O
-	O
infection	O
.	O

This	O
was	O
accompanied	O
by	O
alterations	O
in	O
the	O
microbiota	O
and	O
an	O
upregulation	O
of	O
cyclooxygenase	O
-	O
2	O
which	O
could	O
be	O
reversed	O
by	O
treatment	O
with	O
anti	O
-	O
inflammatory	O
agents	O
or	O
selected	O
probiotics	O
.	O

To	O
investigate	O
the	O
contribution	O
of	O
the	O
microbiota	O
,	O
we	O
treated	O
mice	O
with	O
oral	O
antibiotics	O
and	O
monitored	O
visceral	O
perception	O
and	O
behavior	O
.	O

Antibiotic	O
therapy	O
produced	O
substantial	O
changes	O
in	O
the	O
microbiota	O
,	O
a	O
small	O
increment	O
in	O
inflammatory	O
activity	O
and	O
an	O
increase	O
in	O
substance	O
P	O
or	O
pain	O
perception	O
.	O

Oral	O
,	O
but	O
not	O
systemic	O
antibiotic	O
treatment	O
,	O
produced	O
changes	O
in	O
brain	O
chemistry	O
and	O
an	O
increase	O
in	O
anxiety	O
-	O
like	O
behavior	O
.	O

These	O
studies	O
provide	O
proof	O
of	O
concept	O
that	O
pathogenic	O
microbes	O
can	O
induce	O
persistent	O
gut	O
dysfunction	O
and	O
that	O
changes	O
in	O
microbial	O
composition	O
of	O
the	O
gut	O
can	O
maintain	O
gut	O
dysfunction	O
as	O
well	O
as	O
induce	O
behavioral	O
changes	O
reminiscent	O
of	O
the	O
psychiatric	O
comorbidity	O
that	O
occurs	O
in	O
up	O
to	O
60	O
%	O
of	O
irritable	O
bowel	O
syndrome	O
patients	O
.	O

Protease	O
-	O
activated	O
receptors	O
(	O
PARs	O
)	O
,	O
nucleotide	O
-	O
binding	O
oligomerization	O
domain	O
(	O
NOD	O
)	O
receptors	O
and	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
play	O
a	O
role	O
in	O
innate	O
immunity	O
,	O
but	O
little	O
is	O
known	O
about	O
interaction	O
between	O
these	O
receptors	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
how	O
silencing	O
one	O
receptor	O
affects	O
the	O
expression	O
of	O
other	O
receptors	O
and	O
downstream	O
innate	O
immune	O
markers	O
in	O
response	O
to	O
bacteria	O
.	O

Human	O
gingival	O
epithelial	O
cells	O
(	O
GECs	O
)	O
were	O
transfected	O
with	O
siRNA	O
specific	O
for	O
PAR1	O
or	O
PAR2	O
,	O
then	O
stimulated	O
with	O
periopathogen	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
bridging	O
organism	O
between	O
pathogens	O
and	O
non	O
-	O
pathogens	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
or	O
non	O
-	O
pathogen	O
Streptococcus	B-bacteria
gordonii	I-bacteria
.	O

PAR1	O
or	O
PAR2	O
knock	O
-	O
down	O
resulted	O
in	O
up	O
-	O
regulated	O
NOD1	O
and	O
NOD2	O
expression	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
or	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
stimulation	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
as	O
well	O
as	O
enhanced	O
TLR2	O
and	O
TLR4	O
expression	O
when	O
cells	O
were	O
stimulated	O
by	O
bacteria	O
that	O
utilize	O
TLR2	O
or	O
TLR4	O
,	O
respectively	O
.	O

Involvement	O
of	O
PARs	O
for	O
induction	O
of	O
CC	O
chemokine	O
ligand	O
20	O
(	O
CCL20	O
)	O
,	O
a	O
cytokine	O
with	O
antimicrobial	O
properties	O
,	O
was	O
observed	O
following	O
stimulation	O
of	O
the	O
three	O
bacterial	O
species	O
.	O

Furthermore	O
,	O
results	O
from	O
multiple	O
cytokine	O
ELISA	O
array	O
showed	O
receptors	O
utilized	O
in	O
the	O
induction	O
of	O
various	O
innate	O
immune	O
markers	O
are	O
tailored	O
to	O
individual	O
bacterium	O
tested	O
.	O

Our	O
data	O
suggest	O
complex	O
interplay	O
of	O
several	O
receptors	O
is	O
required	O
for	O
appropriate	O
innate	O
immune	O
responses	O
to	O
the	O
different	O
types	O
of	O
bacteria	O
present	O
within	O
the	O
oral	O
cavity	O
and	O
that	O
receptor	O
expression	O
itself	O
is	O
altered	O
depending	O
on	O
which	O
organism	O
the	O
cell	O
encounters	O
.	O

To	O
compare	O
the	O
effects	O
of	O
a	O
new	O
gel	O
-	O
to	O
-	O
foam	O
dentifrice	O
to	O
two	O
standard	O
fluoride	O
control	O
dentifrices	O
on	O
foam	O
generation	O
,	O
levels	O
of	O
total	O
viable	O
anaerobes	O
and	O
total	O
viable	O
volatile	O
sulfur	O
compound	O
(	O
VSC	O
)	O
-	O
producing	O
bacteria	O
in	O
expectorate	O
after	O
brushing	O
.	O

36	O
subjects	O
participated	O
in	O
this	O
investigator	O
-	O
blind	O
,	O
randomized	O
,	O
crossover	O
study	O
.	O

After	O
a	O
1	O
-	O
week	O
wash	O
-	O
out	O
period	O
prior	O
to	O
each	O
product	O
use	O
,	O
participants	O
reported	O
to	O
the	O
test	O
site	O
having	O
refrained	O
from	O
oral	O
hygiene	O
,	O
eating	O
and	O
drinking	O
on	O
the	O
morning	O
prior	O
to	O
the	O
visit	O
.	O

Subjects	O
brushed	O
with	O
a	O
full	O
ribbon	O
of	O
assigned	O
dentifrice	O
(	O
Aquafresh	O
Iso	O
-	O
active	O
,	O
Aquafresh	O
Extreme	O
Clean	O
or	O
Aquafresh	O
Fresh	O
&	O
Minty	O
)	O
,	O
then	O
expectorated	O
the	O
slurry	O
into	O
a	O
collection	O
vessel	O
after	O
30	O
and	O
60	O
seconds	O
of	O
supervised	O
brushing	O
.	O

Total	O
foam	O
volume	O
was	O
immediately	O
measured	O
.	O

Subjects	O
then	O
rinsed	O
with	O
sterile	O
water	O
for	O
10	O
seconds	O
and	O
expectorated	O
into	O
the	O
same	O
vessel	O
,	O
which	O
was	O
processed	O
for	O
microbiological	O
analysis	O
.	O

Total	O
viable	O
anaerobes	O
and	O
total	O
viable	O
VSC	O
-	O
producing	O
bacteria	O
were	O
enumerated	O
using	O
appropriate	O
selective	O
media	O
.	O

No	O
statistically	O
significant	O
difference	O
was	O
indicated	O
between	O
the	O
gel	O
-	O
to	O
-	O
foam	O
dentifrice	O
and	O
either	O
of	O
the	O
control	O
dentifrices	O
with	O
respect	O
to	O
the	O
level	O
of	O
total	O
viable	O
anaerobes	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
level	O
of	O
total	O
viable	O
VSC	O
-	O
producing	O
bacteria	O
was	O
statistically	O
significantly	O
lower	O
for	O
the	O
gel	O
-	O
to	O
-	O
foam	O
dentifrice	O
(	O
Aquafresh	O
Iso	O
-	O
active	O
)	O
than	O
for	O
one	O
of	O
the	O
control	O
dentifrices	O
(	O
Aquafresh	O
Fresh	O
&	O
Minty	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
numerically	O
lower	O
for	O
the	O
gel	O
-	O
to	O
-	O
foam	O
dentifrice	O
than	O
for	O
the	O
other	O
control	O
dentifrice	O
(	O
Aquafresh	O
Extreme	O
Clean	O
)	O
(	O
P	O
=	O
0	O
.	O
0526	O
)	O
.	O

Use	O
of	O
the	O
gel	O
-	O
to	O
-	O
foam	O
dentifrice	O
resulted	O
in	O
statistically	O
significantly	O
greater	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
foam	O
generation	O
than	O
the	O
two	O
control	O
dentifrices	O
.	O

Oral	O
malodor	O
develops	O
mostly	O
from	O
the	O
metabolic	O
activities	O
of	O
indigenous	O
bacterial	O
populations	O
within	O
the	O
oral	O
cavity	O
,	O
but	O
whether	O
healthy	O
or	O
oral	O
malodor	O
-	O
related	O
patterns	O
of	O
the	O
global	O
bacterial	O
composition	O
exist	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
the	O
bacterial	O
compositions	O
in	O
the	O
saliva	O
of	O
240	O
subjects	O
complaining	O
of	O
oral	O
malodor	O
were	O
divided	O
into	O
groups	O
based	O
on	O
terminal	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
T	O
-	O
RFLP	O
)	O
profiles	O
using	O
hierarchical	O
cluster	O
analysis	O
,	O
and	O
the	O
patterns	O
of	O
the	O
microbial	O
community	O
composition	O
of	O
those	O
exhibiting	O
higher	O
and	O
lower	O
malodor	O
were	O
explored	O
.	O

Four	O
types	O
of	O
bacterial	O
community	O
compositions	O
were	O
detected	O
(	O
clusters	O
I	O
,	O
II	O
,	O
III	O
,	O
and	O
IV	O
)	O
.	O

Two	O
parameters	O
for	O
measuring	O
oral	O
malodor	O
intensity	O
(	O
the	O
concentration	O
of	O
volatile	O
sulfur	O
compounds	O
in	O
mouth	O
air	O
and	O
the	O
organoleptic	O
score	O
)	O
were	O
noticeably	O
lower	O
in	O
cluster	O
I	O
than	O
in	O
the	O
other	O
clusters	O
.	O

Using	O
multivariate	O
analysis	O
,	O
the	O
differences	O
in	O
the	O
levels	O
of	O
oral	O
malodor	O
were	O
significant	O
after	O
adjustment	O
for	O
potential	O
confounding	O
factors	O
such	O
as	O
total	O
bacterial	O
count	O
,	O
mean	O
periodontal	O
pocket	O
depth	O
,	O
and	O
tongue	O
coating	O
score	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Among	O
the	O
four	O
clusters	O
with	O
different	O
proportions	O
of	O
indigenous	O
members	O
,	O
the	O
T	O
-	O
RFLP	O
profiles	O
of	O
cluster	O
I	O
were	O
implicated	O
as	O
the	O
bacterial	O
populations	O
with	O
higher	O
proportions	O
of	O
Streptococcus	B-bacteria
,	O
Granulicatella	B-bacteria
,	O
Rothia	B-bacteria
,	O
and	O
Treponema	B-bacteria
species	I-bacteria
than	O
those	O
of	O
the	O
other	O
clusters	O
.	O

These	O
results	O
clearly	O
correlate	O
the	O
global	O
composition	O
of	O
indigenous	O
bacterial	O
populations	O
with	O
the	O
severity	O
of	O
oral	O
malodor	O
.	O

The	O
oral	O
cavity	O
may	O
represent	O
a	O
site	O
of	O
colonization	O
by	O
antibiotic	O
-	O
resistant	O
bacteria	O
,	O
such	O
as	O
methicillin	B-bacteria
-	I-bacteria
resistant	I-bacteria
staphylococci	I-bacteria
(	O
MRS	B-bacteria
)	O
.	O

To	O
define	O
the	O
prevalence	O
of	O
staphylococci	B-bacteria
and	O
MRS	B-bacteria
in	O
the	O
oral	O
cavity	O
,	O
an	O
observational	O
study	O
was	O
carried	O
out	O
in	O
the	O
city	O
of	O
Bari	O
(	O
Italy	O
)	O
.	O

Sixty	O
subjects	O
were	O
asked	O
to	O
provide	O
oral	O
samples	O
and	O
a	O
questionnaire	O
about	O
risk	O
factors	O
of	O
colonization	O
by	O
MRS	B-bacteria
.	O
An	O
enrichment	O
medium	O
specific	O
for	O
staphylococci	B-bacteria
was	O
used	O
for	O
the	O
isolation	O
.	O

Swabs	O
and	O
corresponding	O
questionnaires	O
were	O
available	O
from	O
36	O
out	O
of	O
60	O
patients	O
.	O

Staphylococci	B-bacteria
were	O
isolated	O
from	O
seven	O
out	O
of	O
36	O
samples	O
(	O
prevalence	O
19	O
.	O
4	O
%	O
)	O
.	O

Among	O
the	O
seven	O
staphylococcal	B-bacteria
isolates	I-bacteria
,	O
three	O
were	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
and	O
one	O
strain	O
,	O
belonging	O
to	O
S	B-bacteria
.	I-bacteria
epidermidis	I-bacteria
species	I-bacteria
,	O
was	O
found	O
to	O
be	O
MR	O
(	O
1	O
.	O
7	O
%	O
)	O
.	O

No	O
methicillin	B-bacteria
-	I-bacteria
resistant	I-bacteria
S	I-bacteria
.	I-bacteria
aureus	I-bacteria
were	O
isolated	O
.	O

Five	O
out	O
of	O
seven	O
staphylococcal	B-bacteria
isolates	I-bacteria
exhibited	O
resistance	O
to	O
more	O
than	O
two	O
classes	O
of	O
non	O
-	O
beta	O
-	O
lactams	O
antimicrobials	O
.	O

None	O
of	O
the	O
risk	O
factors	O
analysed	O
correlated	O
with	O
the	O
status	O
of	O
MRS	B-bacteria
carriers	O
,	O
except	O
the	O
presence	O
of	O
oral	O
disease	O
.	O

The	O
results	O
underline	O
the	O
potential	O
role	O
of	O
the	O
oral	O
cavity	O
as	O
a	O
reservoir	O
of	O
staphylococci	B-bacteria
.	O

Staphylococcus	B-bacteria
aureus	I-bacteria
is	O
an	O
important	O
pathogen	O
that	O
forms	O
biofilm	O
.	O

In	O
this	O
study	O
,	O
22	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
have	O
been	O
isolated	O
from	O
the	O
oral	O
cavity	O
of	O
Tunisian	O
children	O
and	O
investigated	O
for	O
slime	O
production	O
using	O
Congo	O
red	O
agar	O
method	O
(	O
CRA	O
)	O
and	O
semi	O
quantitative	O
adherence	O
assay	O
.	O

The	O
hydrophobicity	O
of	O
strains	O
was	O
evaluated	O
by	O
the	O
microbial	O
adhesion	O
to	O
solvent	O
(	O
MATS	O
)	O
test	O
.	O

The	O
adherence	O
of	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
to	O
Hep2	O
cells	O
was	O
examined	O
by	O
light	O
microscopy	O
.	O

The	O
genes	O
implicated	O
in	O
adhesion	O
(	O
icaA	O
,	O
icaD	O
,	O
fnbA	O
,	O
cna	O
,	O
clfA	O
)	O
were	O
detected	O
.	O

Polymerase	O
chain	O
reaction	O
was	O
used	O
.	O

The	O
affinity	O
to	O
hexadecane	O
was	O
low	O
proving	O
a	O
hydrophilic	O
character	O
of	O
all	O
the	O
studied	O
strains	O
.	O

Qualitative	O
biofilm	O
production	O
revealed	O
that	O
50	O
%	O
of	O
strains	O
were	O
slime	O
producers	O
.	O

The	O
result	O
of	O
OD	O
(	O
570	O
)	O
showed	O
that	O
four	O
strains	O
isolated	O
from	O
the	O
caries	O
-	O
active	O
children	O
were	O
highly	O
biofilm	O
positive	O
.	O

In	O
addition	O
,	O
50	O
%	O
of	O
strains	O
were	O
icaA	O
and	O
icaD	O
positive	O
.	O

The	O
fnbA	O
gene	O
was	O
present	O
in	O
59	O
.	O
1	O
%	O
of	O
isolated	O
strains	O
.	O

Furthermore	O
,	O
54	O
.	O
5	O
%	O
of	O
strains	O
harboured	O
the	O
cna	O
gene	O
,	O
9	O
.	O
1	O
%	O
were	O
clfA	O
positive	O
and	O
50	O
%	O
were	O
hla	O
positive	O
.	O

Quantitative	O
adherence	O
varied	O
considerably	O
among	O
the	O
tested	O
strains	O
.	O

All	O
strains	O
showed	O
adherence	O
to	O
Hep2	O
cells	O
.	O

However	O
,	O
the	O
level	O
of	O
adhesion	O
varied	O
between	O
strains	O
as	O
follows	O
.	O

Seven	O
strains	O
were	O
defined	O
as	O
moderately	O
adherent	O
,	O
nine	O
as	O
strongly	O
adherent	O
and	O
six	O
as	O
weakly	O
adherent	O
.	O

The	O
percentage	O
of	O
infected	O
cells	O
ranged	O
from	O
15	O
+	O
/	O
-	O
0	O
.	O
0376	O
(	O
B374	O
)	O
to	O
96	O
+	O
/	O
-	O
0	O
.	O
019	O
(	O
B295	O
)	O
and	O
the	O
total	O
number	O
of	O
bacteria	O
per	O
100	O
cells	O
ranged	O
from	O
15	O
+	O
/	O
-	O
5	O
.	O
1	O
(	O
B374	O
)	O
to	O
1824	O
+	O
/	O
-	O
30	O
.	O
1	O
(	O
B295	O
)	O
.	O

This	O
pilot	O
study	O
determined	O
the	O
profile	O
of	O
the	O
oral	O
bacterial	O
flora	O
in	O
an	O
outpatient	O
cancer	O
population	O
before	O
and	O
after	O
chemotherapy	O
using	O
molecular	O
techniques	O
.	O

We	O
recruited	O
9	O
newly	O
diagnosed	O
breast	O
cancer	O
patients	O
scheduled	O
for	O
induction	O
chemotherapy	O
.	O

All	O
were	O
seen	O
immediately	O
before	O
chemotherapy	O
,	O
and	O
7	O
to	O
14	O
days	O
later	O
.	O

At	O
both	O
visits	O
,	O
we	O
performed	O
oral	O
evaluations	O
and	O
obtained	O
mucositis	O
grading	O
(	O
with	O
the	O
World	O
Health	O
Organization	O
[	O
WHO	O
]	O
scale	O
)	O
,	O
absolute	O
neutrophil	O
counts	O
(	O
ANC	O
)	O
,	O
and	O
bacterial	O
samples	O
from	O
the	O
buccal	O
mucosa	O
.	O

Bacterial	O
DNA	O
was	O
isolated	O
,	O
and	O
16S	O
ribosomal	O
RNA	O
gene	O
clonal	O
libraries	O
were	O
constructed	O
.	O

Sequences	O
of	O
genes	O
in	O
the	O
library	O
were	O
used	O
to	O
determine	O
species	O
identity	O
by	O
comparison	O
to	O
known	O
sequences	O
.	O

After	O
chemotherapy	O
,	O
WHO	O
scores	O
of	O
0	O
and	O
1	O
were	O
in	O
3	O
and	O
6	O
patients	O
,	O
respectively	O
,	O
and	O
mean	O
ANC	O
(	O
+	O
/	O
-	O
SD	O
)	O
dropped	O
from	O
3326	O
+	O
/	O
-	O
463	O
to	O
1091	O
+	O
/	O
-	O
1082	O
cells	O
/	O
mm	O
(	O
3	O
)	O
.	O

From	O
pre	O
-	O
and	O
post	O
-	O
chemotherapy	O
samples	O
,	O
41	O
species	O
were	O
detected	O
,	O
with	O
a	O
predominance	O
of	O
Gemella	B-bacteria
haemolysans	I-bacteria
and	O
Streptococcus	B-bacteria
mitis	I-bacteria
.	O

More	O
than	O
85	O
%	O
of	O
species	O
have	O
not	O
been	O
previously	O
identified	O
in	O
chemotherapy	O
patients	O
.	O

Seven	O
species	O
appeared	O
exclusively	O
before	O
chemotherapy	O
and	O
25	O
after	O
chemotherapy	O
.	O

After	O
chemotherapy	O
,	O
the	O
number	O
of	O
species	O
per	O
patient	O
increased	O
by	O
a	O
mean	O
of	O
2	O
.	O
6	O
(	O
SD	O
=	O
4	O
.	O
7	O
,	O
P	O
=	O
.	O
052	O
)	O
.	O

We	O
identified	O
species	O
not	O
previously	O
identified	O
in	O
chemotherapy	O
patients	O
.	O

Our	O
results	O
suggest	O
a	O
shift	O
to	O
a	O
more	O
complex	O
oral	O
bacterial	O
profile	O
in	O
patients	O
undergoing	O
cancer	O
chemotherapy	O
.	O

Bacterial	O
and	O
host	O
cell	O
products	O
during	O
coinfections	O
of	O
Human	O
Immunodeficiency	O
Virus	O
type	O
1	O
-	O
positive	O
(	O
HIV	O
-	O
1	O
(	O
+	O
)	O
)	O
patients	O
regulate	O
HIV	O
-	O
1	O
recrudescence	O
in	O
latently	O
infected	O
cells	O
(	O
e	O
.	O
g	O
.	O

T	O
cells	O
,	O
monocytes	O
/	O
macrophages	O
)	O
,	O
impacting	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
failure	O
and	O
progression	O
of	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

A	O
high	O
frequency	O
of	O
oral	O
opportunistic	O
infections	O
(	O
e	O
.	O
g	O
.	O
periodontitis	O
)	O
in	O
HIV	O
-	O
1	O
(	O
+	O
)	O
patients	O
has	O
been	O
demonstrated	O
;	O
however	O
,	O
their	O
potential	O
to	O
impact	O
HIV	O
-	O
1	O
exacerbation	O
is	O
unclear	O
.	O

We	O
sought	O
to	O
determine	O
the	O
ability	O
of	O
supernatants	O
derived	O
from	O
oral	O
epithelial	O
cells	O
(	O
OKF4	O
)	O
and	O
human	O
gingival	O
fibroblasts	O
(	O
Gin	O
-	O
4	O
)	O
challenged	O
with	O
periodontal	O
pathogens	O
,	O
to	O
modulate	O
the	O
HIV	O
-	O
1	O
promoter	O
activation	O
in	O
monocytes	O
/	O
macrophages	O
.	O

BF24	O
monocytes	O
/	O
macrophages	O
transfected	O
with	O
the	O
HIV	O
-	O
1	O
promoter	O
driving	O
the	O
expression	O
of	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
were	O
stimulated	O
with	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
or	O
Treponema	B-bacteria
denticola	I-bacteria
in	O
the	O
presence	O
of	O
supernatants	O
from	O
OKF4	O
or	O
Gin4	O
cells	O
either	O
unstimulated	O
or	O
previously	O
pulsed	O
with	O
bacteria	O
.	O

CAT	O
levels	O
were	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
cytokine	O
production	O
was	O
evaluated	O
by	O
Luminex	O
beadlyte	O
assays	O
.	O

OKF4	O
and	O
Gin4	O
supernatants	O
enhanced	O
HIV	O
-	O
1	O
promoter	O
activation	O
particularly	O
related	O
to	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
challenge	O
.	O

An	O
additive	O
effect	O
was	O
observed	O
in	O
HIV	O
-	O
1	O
promoter	O
activation	O
when	O
monocytes	O
/	O
macrophages	O
were	O
simultaneously	O
stimulated	O
with	O
gingival	O
cell	O
supernatants	O
and	O
bacterial	O
extracts	O
.	O

OKF4	O
cells	O
produced	O
higher	O
levels	O
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
and	O
interleukins	O
-	O
6	O
and	O
-	O
8	O
in	O
response	O
to	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
.	O

Preincubation	O
of	O
OKF4	O
supernatants	O
with	O
anti	O
-	O
GM	O
-	O
CSF	O
reduced	O
the	O
additive	O
effect	O
in	O
periodontopathogen	O
-	O
induced	O
HIV	O
-	O
1	O
promoter	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
soluble	O
mediators	O
produced	O
by	O
gingival	O
resident	O
cells	O
in	O
response	O
to	O
periodontopathogens	O
could	O
contribute	O
to	O
HIV	O
-	O
1	O
promoter	O
activation	O
in	O
monocytes	O
/	O
macrophages	O
,	O
albeit	O
this	O
effect	O
is	O
most	O
notable	O
following	O
direct	O
stimulation	O
of	O
the	O
cells	O
with	O
oral	O
gram	O
-	O
negative	O
bacteria	O
.	O

The	O
presence	O
of	O
periodontal	O
pathogens	O
in	O
the	O
oral	O
cavity	O
may	O
impact	O
implant	O
survival	O
.	O

Therefore	O
,	O
this	O
study	O
aimed	O
to	O
determine	O
the	O
prevalence	O
of	O
Campylobacter	B-bacteria
rectus	I-bacteria
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
,	O
Eikenella	B-bacteria
corrodens	I-bacteria
and	O
Parvimonas	B-bacteria
micra	I-bacteria
in	O
a	O
specific	O
elderly	O
population	O
with	O
a	O
history	O
of	O
periodontitis	O
who	O
have	O
never	O
worn	O
dentures	O
.	O

Thirty	O
dentate	O
subjects	O
(	O
mean	O
age	O
61	O
.	O
7	O
+	O
/	O
-	O
7	O
.	O
05	O
years	O
)	O
and	O
30	O
edentulous	O
subjects	O
(	O
mean	O
age	O
65	O
.	O
8	O
+	O
/	O
-	O
8	O
.	O
05	O
years	O
)	O
were	O
included	O
in	O
this	O
cross	O
-	O
sectional	O
study	O
.	O

Microbiological	O
samples	O
of	O
cheek	O
mucosa	O
and	O
the	O
dorsum	O
of	O
the	O
tongue	O
were	O
taken	O
from	O
all	O
subjects	O
.	O

In	O
addition	O
,	O
sulcus	O
samples	O
were	O
taken	O
from	O
the	O
dentate	O
group	O
.	O

All	O
samples	O
were	O
analysed	O
using	O
a	O
bacterial	O
DNA	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O

All	O
the	O
pathogens	O
studied	O
were	O
detected	O
in	O
dentate	O
and	O
edentulous	O
subjects	O
.	O

When	O
cheek	O
and	O
tongue	O
samples	O
were	O
combined	O
,	O
C	B-bacteria
.	I-bacteria
rectus	I-bacteria
,	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
and	O
E	B-bacteria
.	I-bacteria
corrodens	I-bacteria
presented	O
with	O
a	O
similar	O
prevalence	O
in	O
both	O
groups	O
,	O
whereas	O
the	O
other	O
species	O
were	O
more	O
prevalent	O
specifically	O
in	O
the	O
dentate	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
dentate	O
subjects	O
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
were	O
present	O
in	O
higher	O
frequencies	O
in	O
the	O
cheek	O
mucosa	O
(	O
26	O
.	O
67	O
%	O
and	O
66	O
.	O
67	O
%	O
,	O
respectively	O
)	O
,	O
whereas	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
were	O
more	O
prevalent	O
in	O
the	O
tongue	O
samples	O
(	O
26	O
.	O
67	O
%	O
and	O
56	O
.	O
67	O
%	O
,	O
respectively	O
)	O
.	O

Periodontal	O
pathogens	O
may	O
persist	O
in	O
the	O
oral	O
cavity	O
of	O
edentulous	O
subjects	O
who	O
have	O
had	O
periodontal	O
disease	O
,	O
even	O
1	O
year	O
after	O
the	O
extraction	O
of	O
all	O
teeth	O
and	O
in	O
the	O
absence	O
of	O
other	O
hard	O
surfaces	O
in	O
the	O
mouth	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
clinically	O
and	O
microbiologically	O
evaluate	O
the	O
effect	O
of	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
as	O
a	O
full	O
-	O
mouth	O
procedure	O
in	O
Fusobacterium	O
nucleatum	O
-	O
infected	O
patients	O
with	O
periodontitis	O
.	O

In	O
the	O
present	O
study	O
,	O
PDT	O
is	O
administered	O
adjuvantly	O
after	O
scaling	O
and	O
root	O
planing	O
(	O
SRP	O
)	O
to	O
patients	O
with	O
localized	O
chronic	O
periodontitis	O
(	O
LCP	O
)	O
.	O

Twenty	O
-	O
four	O
patients	O
,	O
in	O
whom	O
only	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
was	O
detected	O
by	O
baseline	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
after	O
SRP	O
,	O
were	O
randomly	O
assigned	O
to	O
PDT	O
and	O
control	O
groups	O
.	O

PDT	O
was	O
carried	O
out	O
once	O
as	O
a	O
full	O
-	O
mouth	O
disinfection	O
in	O
the	O
test	O
group	O
.	O

The	O
control	O
group	O
was	O
treated	O
with	O
the	O
photosensitizer	O
solution	O
,	O
but	O
without	O
laser	O
irradiation	O
.	O

In	O
all	O
subjects	O
,	O
the	O
clinical	O
parameters	O
plaque	O
index	O
,	O
reddening	O
,	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
,	O
probing	O
depth	O
(	O
PD	O
)	O
,	O
gingival	O
recession	O
,	O
and	O
clinical	O
attachment	O
level	O
(	O
CAL	O
)	O
were	O
determined	O
at	O
the	O
baseline	O
examination	O
and	O
at	O
1	O
,	O
4	O
,	O
and	O
12	O
weeks	O
after	O
PDT	O
.	O

Quantitative	O
analysis	O
of	O
the	O
F	O
.	O
nucleatum	O
DNA	O
concentration	O
was	O
performed	O
by	O
competitive	O
PCR	O
.	O

All	O
clinical	O
indices	O
were	O
calculated	O
for	O
each	O
test	O
and	O
control	O
subject	O
as	O
were	O
the	O
median	O
and	O
interquartile	O
range	O
of	O
each	O
group	O
.	O

In	O
patients	O
with	O
LCP	O
who	O
received	O
PDT	O
treatment	O
,	O
significant	O
reductions	O
in	O
reddening	O
,	O
BOP	O
,	O
and	O
mean	O
PD	O
and	O
CAL	O
were	O
observed	O
during	O
the	O
observation	O
period	O
and	O
with	O
respect	O
to	O
controls	O
.	O

Four	O
and	O
12	O
weeks	O
after	O
PDT	O
,	O
the	O
mean	O
PD	O
and	O
CAL	O
showed	O
significant	O
differences	O
from	O
baseline	O
values	O
and	O
from	O
those	O
of	O
the	O
control	O
group	O
.	O

In	O
the	O
PDT	O
group	O
,	O
12	O
weeks	O
after	O
treatment	O
,	O
the	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
DNA	O
concentration	O
was	O
found	O
to	O
be	O
significantly	O
reduced	O
compared	O
to	O
the	O
baseline	O
level	O
.	O

The	O
results	O
of	O
this	O
study	O
show	O
that	O
the	O
adjuvant	O
application	O
of	O
the	O
described	O
PDT	O
method	O
is	O
appropriate	O
to	O
reduce	O
periodontal	O
inflammatory	O
symptoms	O
and	O
to	O
successfully	O
treat	O
infection	O
with	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
.	O

The	O
present	O
study	O
evaluates	O
the	O
survival	O
capability	O
of	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
strains	I-bacteria
in	O
an	O
aerobic	O
environment	O
and	O
compares	O
the	O
invasive	O
capability	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
in	O
biofilm	O
and	O
planktonic	O
forms	O
in	O
an	O
organotypic	O
cell	O
culture	O
(	O
OCC	O
)	O
model	O
.	O

Biofilms	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
American	I-bacteria
Type	I-bacteria
Culture	I-bacteria
Collection	I-bacteria
(	I-bacteria
ATCC	I-bacteria
)	I-bacteria
25586	I-bacteria
or	O
Anaerobe	B-bacteria
Helsinki	I-bacteria
Negative	I-bacteria
(	I-bacteria
AHN	I-bacteria
)	I-bacteria
9508	I-bacteria
were	O
produced	O
by	O
culturing	O
on	O
semipermeable	O
membranes	O
on	O
brucella	O
agar	O
plates	O
.	O

The	O
oxygen	O
tolerance	O
of	O
the	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
strains	I-bacteria
was	O
examined	O
by	O
incubating	O
3	O
-	O
day	O
-	O
old	O
anaerobically	O
grown	O
biofilms	O
in	O
an	O
aerobic	O
environment	O
(	O
CO	O
(	O
2	O
)	O
[	O
5	O
%	O
in	O
air	O
]	O
incubator	O
)	O
for	O
an	O
additional	O
48	O
hours	O
.	O

The	O
OCC	O
model	O
was	O
constructed	O
by	O
seeding	O
keratinocytes	O
on	O
a	O
fibroblast	O
-	O
containing	O
collagen	O
gel	O
.	O

In	O
invasion	O
assays	O
,	O
a	O
3	O
-	O
day	O
-	O
old	O
anaerobically	O
grown	O
biofilm	O
(	O
and	O
planktonic	O
bacteria	O
in	O
solution	O
as	O
the	O
control	O
)	O
was	O
placed	O
upside	O
down	O
on	O
the	O
top	O
of	O
OCC	O
and	O
incubated	O
under	O
5	O
%	O
CO	O
(	O
2	O
)	O
for	O
24	O
hours	O
.	O

Invasion	O
of	O
the	O
bacteria	O
and	O
morphologic	O
changes	O
in	O
OCC	O
were	O
assessed	O
using	O
hematoxylin	O
and	O
eosin	O
,	O
Ki	O
-	O
67	O
,	O
and	O
periodic	O
acid	O
-	O
Schiff	O
stainings	O
.	O

In	O
biofilms	O
,	O
both	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
strains	I-bacteria
continuously	O
increased	O
their	O
cell	O
numbers	O
in	O
an	O
aerobic	O
environment	O
for	O
48	O
hours	O
.	O

After	O
incubating	O
the	O
bacterial	O
biofilm	O
in	O
contact	O
with	O
the	O
OCC	O
model	O
,	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
AHN	I-bacteria
9508	I-bacteria
was	O
able	O
to	O
pass	O
through	O
the	O
epithelial	O
/	O
basement	O
membrane	O
barrier	O
and	O
invade	O
the	O
collagen	O
matrix	O
.	O

The	O
invasiveness	O
of	O
biofilm	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
ATCC	I-bacteria
25586	I-bacteria
was	O
limited	O
to	O
the	O
epithelium	O
.	O

Cytotoxic	O
effects	O
and	O
invasiveness	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
on	O
the	O
OCC	O
were	O
much	O
stronger	O
when	O
the	O
bacteria	O
were	O
in	O
biofilms	O
than	O
in	O
the	O
planktonic	O
form	O
.	O

Biofilm	O
formation	O
regulates	O
the	O
survival	O
and	O
invasiveness	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
in	O
an	O
aerobic	O
environment	O
.	O

During	O
oral	O
procedures	O
,	O
microorganisms	O
from	O
the	O
oral	O
cavity	O
may	O
contaminate	O
nearby	O
surfaces	O
.	O

The	O
authors	O
evaluated	O
the	O
efficacy	O
of	O
a	O
commercial	O
preprocedural	O
mouthrinse	O
containing	O
0	O
.	O
05	O
percent	O
cetylpyridinium	O
chloride	O
(	O
CPC	O
)	O
in	O
reducing	O
the	O
levels	O
and	O
composition	O
of	O
viable	O
bacteria	O
in	O
oral	O
spatter	O
.	O

The	O
authors	O
randomly	O
assigned	O
60	O
participants	O
receiving	O
oral	O
prophylaxis	O
with	O
an	O
ultrasonic	O
scaler	O
to	O
one	O
of	O
four	O
groups	O
:	O
a	O
preprocedural	O
rinse	O
solution	O
containing	O
0	O
.	O
05	O
percent	O
CPC	O
,	O
0	O
.	O
12	O
percent	O
chlorhexidine	O
(	O
CHX	O
)	O
or	O
water	O
,	O
or	O
no	O
rinsing	O
.	O

Airborne	O
microorganisms	O
were	O
collected	O
on	O
blood	O
agar	O
plates	O
.	O

The	O
composition	O
of	O
the	O
spatter	O
was	O
analyzed	O
for	O
39	O
oral	O
bacterial	O
species	O
by	O
means	O
of	O
checkerboard	O
DNA	O
-	O
DNA	O
hybridization	O
.	O

CPC	O
and	O
CHX	O
were	O
equally	O
effective	O
in	O
lowering	O
the	O
levels	O
of	O
spatter	O
bacteria	O
and	O
performed	O
better	O
than	O
water	O
and	O
no	O
rinsing	O
(	O
P	O
<	O
.	O
05	O
,	O
Kruskal	O
-	O
Wallis	O
test	O
)	O
.	O

The	O
composition	O
of	O
the	O
spatter	O
from	O
the	O
control	O
groups	O
showed	O
higher	O
proportions	O
(	O
P	O
<	O
.	O
05	O
,	O
Kruskal	O
-	O
Wallis	O
test	O
)	O
of	O
Fusobacterium	B-bacteria
species	I-bacteria
and	O
lower	O
proportions	O
of	O
Capnocytophaga	B-bacteria
species	I-bacteria
when	O
compared	O
with	O
the	O
spatter	O
from	O
the	O
CPC	O
and	O
CHX	O
groups	O
.	O

A	O
commercial	O
mouthrinse	O
containing	O
0	O
.	O
05	O
percent	O
CPC	O
when	O
used	O
as	O
a	O
preprocedural	O
mouthrinse	O
was	O
equally	O
effective	O
as	O
CHX	O
in	O
reducing	O
the	O
levels	O
of	O
spatter	O
bacteria	O
generated	O
during	O
ultrasonic	O
scaling	O
.	O

Owing	O
to	O
its	O
strong	O
antibacterial	O
effect	O
and	O
the	O
fact	O
that	O
it	O
has	O
fewer	O
side	O
effects	O
than	O
CHX	O
,	O
a	O
solution	O
containing	O
0	O
.	O
05	O
percent	O
CPC	O
may	O
be	O
a	O
good	O
alternative	O
to	O
that	O
containing	O
0	O
.	O
12	O
CHX	O
as	O
a	O
preprocedural	O
mouthrinse	O
used	O
to	O
help	O
decrease	O
the	O
level	O
of	O
contamination	O
in	O
spatter	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
effect	O
of	O
full	O
mouth	O
rehabilitation	O
on	O
the	O
amount	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
in	O
children	O
with	O
Early	O
Childhood	O
Caries	O
.	O

Thirty	O
-	O
nine	O
children	O
between	O
2	O
and	O
5	O
years	O
old	O
treated	O
under	O
general	O
anaesthesia	O
participated	O
in	O
this	O
study	O
.	O

Prior	O
to	O
treatment	O
two	O
baselines	O
samples	O
were	O
collected	O
,	O
one	O
of	O
dental	O
plaque	O
and	O
one	O
of	O
saliva	O
.	O

In	O
addition	O
,	O
samples	O
were	O
obtained	O
one	O
week	O
post	O
operatively	O
,	O
and	O
then	O
three	O
months	O
later	O
.	O

In	O
each	O
sampling	O
,	O
the	O
amount	O
and	O
the	O
concentration	O
(	O
cfu	O
/	O
ml	O
)	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
were	O
evaluated	O
.	O

The	O
findings	O
demonstrate	O
that	O
the	O
operative	O
procedures	O
under	O
general	O
anaesthesia	O
,	O
significantly	O
decrease	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
the	O
concentration	O
(	O
cfu	O
/	O
ml	O
)	O
and	O
the	O
amount	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
for	O
at	O
least	O
three	O
months	O
.	O

After	O
three	O
months	O
,	O
saliva	O
concentrations	O
and	O
plaque	O
colony	O
numbers	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
increased	O
significantly	O
in	O
relation	O
to	O
one	O
week	O
post	O
-	O
operatively	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

However	O
,	O
none	O
of	O
the	O
saliva	O
or	O
plaque	O
samples	O
collected	O
three	O
months	O
following	O
treatment	O
reached	O
the	O
pretreatment	O
levels	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
in	O
any	O
of	O
our	O
subjects	O
.	O

The	O
data	O
indicates	O
that	O
full	O
mouth	O
rehabilitation	O
under	O
general	O
anaesthesia	O
produces	O
a	O
statistically	O
significant	O
decrease	O
in	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
levels	O
for	O
at	O
least	O
three	O
months	O
.	O

The	O
indigenous	O
bacteria	O
create	O
natural	O
cohabitation	O
niches	O
together	O
with	O
mucosal	O
Abs	O
in	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tract	O
.	O

Here	O
we	O
report	O
that	O
opportunistic	O
bacteria	O
,	O
largely	O
Alcaligenes	B-bacteria
species	I-bacteria
,	O
specifically	O
inhabit	O
host	O
Peyer	O
'	O
s	O
patches	O
(	O
PPs	O
)	O
and	O
isolated	O
lymphoid	O
follicles	O
,	O
with	O
the	O
associated	O
preferential	O
induction	O
of	O
antigen	O
-	O
specific	O
mucosal	O
IgA	O
Abs	O
in	O
the	O
GI	O
tract	O
.	O

Alcaligenes	B-bacteria
were	O
identified	O
as	O
the	O
dominant	O
bacteria	O
on	O
the	O
interior	O
of	O
PPs	O
from	O
naive	O
,	O
specific	O
-	O
pathogen	O
-	O
free	O
but	O
not	O
from	O
germ	O
-	O
free	O
mice	O
.	O

Oral	O
transfer	O
of	O
intratissue	O
uncultured	O
Alcaligenes	B-bacteria
into	O
germ	O
-	O
free	O
mice	O
resulted	O
in	O
the	O
presence	O
of	O
Alcaligenes	B-bacteria
inside	O
the	O
PPs	O
of	O
recipients	O
.	O

This	O
result	O
was	O
further	O
supported	O
by	O
the	O
induction	O
of	O
antigen	O
-	O
specific	O
Ab	O
-	O
producing	O
cells	O
in	O
the	O
mucosal	O
(	O
e	O
.	O
g	O
.	O
,	O
PPs	O
)	O
but	O
not	O
systemic	O
compartment	O
(	O
e	O
.	O
g	O
.	O
,	O
spleen	O
)	O
.	O

The	O
preferential	O
presence	O
of	O
Alcaligenes	B-bacteria
inside	O
PPs	O
and	O
the	O
associated	O
induction	O
of	O
intestinal	O
secretory	O
IgA	O
Abs	O
were	O
also	O
observed	O
in	O
both	O
monkeys	O
and	O
humans	O
.	O

Localized	O
mucosal	O
Ab	O
-	O
mediated	O
symbiotic	O
immune	O
responses	O
were	O
supported	O
by	O
Alcaligenes	O
-	O
stimulated	O
CD11c	O
(	O
+	O
)	O
dendritic	O
cells	O
(	O
DCs	O
)	O
producing	O
the	O
Ab	O
-	O
enhancing	O
cytokines	O
TGF	O
-	O
beta	O
,	O
B	O
-	O
cell	O
-	O
activating	O
factor	O
belonging	O
to	O
the	O
TNF	O
family	O
,	O
and	O
IL	O
-	O
6	O
in	O
PPs	O
.	O

These	O
CD11c	O
(	O
+	O
)	O
DCs	O
did	O
not	O
migrate	O
beyond	O
the	O
draining	O
mesenteric	O
lymph	O
nodes	O
.	O

In	O
the	O
absence	O
of	O
antigen	O
-	O
specific	O
mucosal	O
Abs	O
,	O
the	O
presence	O
of	O
Alcaligenes	B-bacteria
in	O
PPs	O
was	O
greatly	O
diminished	O
.	O

Thus	O
,	O
indigenous	O
opportunistic	O
bacteria	O
uniquely	O
inhabit	O
PPs	O
,	O
leading	O
to	O
PP	O
-	O
DCs	O
-	O
initiated	O
,	O
local	O
antigen	O
-	O
specific	O
Ab	O
production	O
;	O
this	O
may	O
involve	O
the	O
creation	O
of	O
an	O
optimal	O
symbiotic	O
environment	O
on	O
the	O
interior	O
of	O
the	O
PPs	O
.	O

Increasing	O
awareness	O
of	O
hazards	O
associated	O
with	O
the	O
use	O
of	O
antibiotic	O
and	O
chemical	O
agents	O
has	O
accelerated	O
investigations	O
into	O
plants	O
and	O
their	O
extracts	O
as	O
new	O
sources	O
of	O
antimicrobial	O
agents	O
.	O

Therefore	O
,	O
this	O
study	O
aimed	O
at	O
determining	O
the	O
effects	O
of	O
oil	O
and	O
95	O
%	O
ethanol	O
extracts	O
of	O
Boesenbergia	O
pandurata	O
rhizomes	O
and	O
Piper	O
sarmentosum	O
leaf	O
against	O
four	O
oral	O
pathogens	O
which	O
were	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Lactobacillus	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
and	O
Candida	O
albicans	O
.	O

Employing	O
the	O
disc	O
diffusion	O
and	O
broth	O
microdilution	O
methods	O
,	O
the	O
results	O
showed	O
that	O
B	O
.	O
pandurata	O
oil	O
(	O
BPO	O
)	O
was	O
the	O
most	O
effective	O
extract	O
against	O
C	O
.	O
albicans	O
.	O

Time	O
-	O
kill	O
assay	O
with	O
the	O
BPO	O
demonstrated	O
killing	O
of	O
C	O
.	O
albicans	O
at	O
concentrations	O
equal	O
to	O
2	O
and	O
2	O
.	O
5	O
times	O
the	O
MIC	O
.	O

The	O
times	O
required	O
to	O
reach	O
the	O
fungicidal	O
endpoint	O
at	O
2	O
and	O
2	O
.	O
5	O
times	O
the	O
MIC	O
were	O
60	O
and	O
44	O
min	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
our	O
results	O
also	O
demonstrated	O
that	O
the	O
BPO	O
possesses	O
potent	O
anti	O
-	O
Candida	O
biofilm	O
activity	O
in	O
vitro	O
.	O

Therefore	O
,	O
the	O
BPO	O
could	O
be	O
considered	O
as	O
a	O
natural	O
antifungal	O
agent	O
against	O
Candida	O
infections	O
and	O
has	O
significant	O
potential	O
for	O
further	O
investigation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
influence	O
of	O
oral	O
contraceptive	O
(	O
OC	O
)	O
use	O
on	O
the	O
subgingival	O
occurrence	O
of	O
specific	O
periodontopathogens	O
and	O
the	O
host	O
'	O
s	O
periodontal	O
status	O
.	O

Ninety	O
-	O
two	O
females	O
aged	O
19	O
to	O
40	O
years	O
were	O
included	O
in	O
the	O
study	O
.	O

They	O
were	O
divided	O
into	O
two	O
groups	O
,	O
OC	O
users	O
and	O
non	O
-	O
users	O
,	O
and	O
subgrouped	O
according	O
to	O
the	O
most	O
severe	O
periodontal	O
condition	O
and	O
duration	O
of	O
OC	O
usage	O
.	O

A	O
pooled	O
subgingival	O
sample	O
from	O
each	O
subject	O
was	O
cultured	O
to	O
investigate	O
the	O
presence	O
of	O
Candida	O
species	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
previously	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
)	O
,	O
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
.	O

OC	O
users	O
,	O
particularly	O
smokers	O
,	O
show	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
prevalence	O
of	O
severe	O
periodontitis	O
.	O

OC	O
users	O
had	O
deeper	O
probing	O
depths	O
(	O
>	O
or	O
=	O
5	O
mm	O
)	O
than	O
non	O
-	O
users	O
.	O

Moreover	O
,	O
OC	O
users	O
had	O
higher	O
gingival	O
index	O
scores	O
and	O
clinical	O
attachment	O
loss	O
,	O
>	O
or	O
=	O
2	O
and	O
>	O
or	O
=	O
5	O
mm	O
,	O
respectively	O
,	O
than	O
non	O
-	O
users	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Patients	O
taking	O
OCs	O
had	O
significantly	O
higher	O
numbers	O
of	O
cultures	O
positive	O
for	O
Candida	O
.	O

Seven	O
Candida	O
species	O
were	O
isolated	O
.	O

Subgingival	O
Candida	O
was	O
associated	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
and	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
in	O
82	O
.	O
9	O
%	O
and	O
85	O
.	O
4	O
%	O
,	O
respectively	O
,	O
in	O
patients	O
taking	O
OCs	O
.	O

A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
was	O
isolated	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
periodontitis	O
and	O
was	O
associated	O
with	O
subgingival	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
and	O
Candida	O
.	O

OC	O
use	O
may	O
increase	O
the	O
risk	O
of	O
severe	O
periodontitis	O
and	O
seems	O
to	O
cause	O
a	O
selection	O
of	O
certain	O
Candida	O
species	O
in	O
periodontal	O
pockets	O
.	O

OC	O
users	O
showed	O
a	O
higher	O
prevalence	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
intermedia	I-bacteria
,	O
and	O
A	B-bacteria
.	I-bacteria
actinomycetemcomitans	I-bacteria
compared	O
to	O
non	O
-	O
users	O
.	O

C	O
.	O
albicans	O
,	O
C	O
.	O
parapsilosis	O
,	O
C	O
.	O
krusei	O
,	O
C	O
.	O
tropicalis	O
,	O
and	O
C	O
.	O
glabrata	O
were	O
the	O
species	O
with	O
the	O
ability	O
to	O
survive	O
in	O
the	O
conditions	O
created	O
by	O
the	O
sex	O
hormones	O
after	O
3	O
years	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
adhesion	O
and	O
invasion	O
of	O
periodontopathogenic	O
bacteria	O
in	O
varied	O
mixed	O
infections	O
and	O
the	O
release	O
of	O
interleukins	O
from	O
an	O
epithelial	O
cell	O
line	O
(	O
KB	O
cells	O
)	O
.	O

KB	O
cells	O
were	O
co	O
-	O
cultured	O
with	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
ATCC	I-bacteria
33277	I-bacteria
and	O
M5	B-bacteria
-	I-bacteria
1	I-bacteria
-	I-bacteria
2	I-bacteria
,	O
Tannerella	B-bacteria
forsythia	I-bacteria
ATCC	I-bacteria
43037	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
ATCC	I-bacteria
35405	I-bacteria
and	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
ATCC	I-bacteria
25586	I-bacteria
in	O
single	O
and	O
mixed	O
infections	O
.	O

The	O
numbers	O
of	O
adherent	O
and	O
internalized	O
bacteria	O
were	O
determined	O
up	O
to	O
18	O
h	O
after	O
bacterial	O
exposure	O
.	O

Additionally	O
,	O
the	O
mRNA	O
expression	O
and	O
concentrations	O
of	O
released	O
interleukin	O
(	O
IL	O
)	O
-	O
6	O
and	O
IL	O
-	O
8	O
were	O
measured	O
.	O

All	O
periodontopathogenic	O
bacteria	O
adhered	O
and	O
internalized	O
in	O
different	O
numbers	O
to	O
KB	O
cells	O
,	O
but	O
individually	O
without	O
any	O
evidence	O
of	O
co	O
-	O
aggregation	O
also	O
to	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
.	O

High	O
levels	O
of	O
epithelial	O
mRNA	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
were	O
detectable	O
after	O
all	O
bacterial	O
challenges	O
.	O

After	O
the	O
mixed	O
infection	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
ATCC	I-bacteria
33277	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
ATCC	I-bacteria
25586	I-bacteria
the	O
highest	O
levels	O
of	O
released	O
interleukins	O
were	O
found	O
.	O

No	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
were	O
detectable	O
after	O
the	O
mixed	O
infection	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
M5	I-bacteria
-	I-bacteria
1	I-bacteria
-	I-bacteria
2	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
ATCC	I-bacteria
25586	I-bacteria
and	O
the	O
fourfold	O
infection	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
ATCC	I-bacteria
33277	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
ATCC	I-bacteria
35405	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
forsythia	I-bacteria
ATCC	I-bacteria
43037	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
ATCC	I-bacteria
25586	I-bacteria
.	O

Anaerobic	O
periodontopathogenic	O
bacteria	O
promote	O
the	O
release	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
by	O
epithelial	O
cells	O
.	O

Despite	O
a	O
continuous	O
epithelial	O
expression	O
of	O
IL	O
-	O
8	O
mRNA	O
by	O
all	O
bacterial	O
infections	O
these	O
effects	O
are	O
temporary	O
because	O
of	O
the	O
time	O
-	O
dependent	O
degradation	O
of	O
cytokines	O
by	O
bacterial	O
proteases	O
.	O

Mixed	O
infections	O
have	O
a	O
stronger	O
virulence	O
potential	O
than	O
single	O
bacteria	O
.	O

Further	O
research	O
is	O
necessary	O
to	O
evaluate	O
the	O
role	O
of	O
mixed	O
infections	O
and	O
biofilms	O
in	O
the	O
pathogenesis	O
of	O
periodontitis	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
is	O
a	O
major	O
pathogen	O
of	O
dental	O
caries	O
and	O
occasionally	O
isolated	O
from	O
the	O
blood	O
of	O
patients	O
with	O
infective	O
endocarditis	O
,	O
though	O
the	O
association	O
of	O
its	O
cell	O
-	O
surface	O
glucosyltransferases	O
(	O
GTFB	O
,	O
GTFC	O
,	O
and	O
GTFD	O
)	O
with	O
pathogenicity	O
for	O
infective	O
endocarditis	O
remains	O
to	O
be	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
contribution	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
GTFs	O
to	O
platelet	O
aggregation	O
and	O
analysed	O
GTF	O
expression	O
profiles	O
in	O
a	O
large	O
number	O
of	O
clinical	O
oral	O
isolates	O
.	O

The	O
platelet	O
aggregation	O
properties	O
of	O
GTF	O
-	O
defective	O
isogenic	O
mutant	O
strains	O
constructed	O
from	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
reference	O
strain	O
MT8148	B-bacteria
were	O
evaluated	O
using	O
whole	O
blood	O
and	O
platelet	O
-	O
rich	O
plasma	O
(	O
PRP	O
)	O
taken	O
from	O
mice	O
,	O
as	O
well	O
as	O
human	O
PRP	O
.	O

In	O
addition	O
,	O
GTF	O
expression	O
profiles	O
for	O
396	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
strains	I-bacteria
isolated	O
from	O
the	O
oral	O
cavities	O
of	O
396	O
subjects	O
were	O
analysed	O
by	O
western	O
blotting	O
using	O
antisera	O
specific	O
for	O
each	O
GTF	O
.	O

The	O
platelet	O
aggregation	O
activities	O
of	O
the	O
GTF	O
-	O
defective	O
isogenic	O
mutants	O
were	O
significantly	O
lower	O
than	O
that	O
of	O
MT8148	B-bacteria
when	O
added	O
to	O
a	O
large	O
number	O
of	O
cells	O
.	O

Western	O
blotting	O
revealed	O
no	O
strains	O
without	O
GTF	O
expression	O
,	O
though	O
six	O
strains	O
had	O
alterations	O
of	O
GTFB	O
and	O
GTFC	O
as	O
compared	O
to	O
MT8148	B-bacteria
.	O

PCR	O
analyses	O
indicated	O
that	O
the	O
gtfB	O
-	O
gtfC	O
region	O
length	O
was	O
approximately	O
4	O
.	O
5	O
kb	O
shorter	O
in	O
those	O
strains	O
as	O
compared	O
to	O
MT8148	B-bacteria
.	O

These	O
were	O
designated	O
as	O
`	O
`	O
GTFBC	O
-	O
fusion	O
'	O
'	O
strains	O
and	O
they	O
demonstrated	O
lower	O
levels	O
of	O
platelet	O
aggregation	O
.	O

Our	O
findings	O
indicate	O
that	O
GTFs	O
are	O
associated	O
with	O
platelet	O
aggregation	O
.	O

Although	O
the	O
clinical	O
detection	O
frequency	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
strains	I-bacteria
with	O
altered	O
expressions	O
is	O
extremely	O
low	O
,	O
GTFBC	O
-	O
fusion	O
strains	O
have	O
activities	O
similar	O
to	O
GTF	O
-	O
defective	O
mutant	O
strains	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
is	O
an	O
important	O
factor	O
in	O
the	O
pathogenesis	O
of	O
numerous	O
diseases	O
including	O
gastro	O
-	O
intestinal	O
,	O
metabolic	O
and	O
vascular	O
disorders	O
.	O

Therefore	O
,	O
identification	O
of	O
individuals	O
at	O
risk	O
of	O
this	O
infection	O
remains	O
of	O
critical	O
importance	O
.	O

Dentists	O
and	O
dental	O
professionals	O
may	O
be	O
at	O
increased	O
risk	O
due	O
to	O
the	O
contact	O
with	O
oral	O
cavity	O
of	O
patients	O
with	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
the	O
oral	O
cavity	O
where	O
it	O
may	O
serve	O
as	O
reservoir	O
for	O
gastric	O
infections	O
and	O
participate	O
in	O
the	O
pathogenesis	O
oral	O
mucosal	O
lesions	O
and	O
ulceration	O
.	O

However	O
,	O
evidence	O
regarding	O
the	O
occurrence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infections	O
and	O
colonization	O
in	O
dentists	O
is	O
conflicting	O
,	O
but	O
has	O
been	O
based	O
mainly	O
on	O
serological	O
studies	O
,	O
which	O
carry	O
significant	O
limitations	O
.	O

Therefore	O
,	O
we	O
attempted	O
to	O
characterize	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
in	O
practising	O
dentists	O
in	O
relation	O
to	O
the	O
duration	O
of	O
their	O
work	O
as	O
dental	O
professionals	O
.	O

Moreover	O
,	O
apart	O
from	O
seropositivity	O
,	O
which	O
was	O
used	O
by	O
majority	O
of	O
previous	O
studies	O
,	O
we	O
have	O
performed	O
urea	O
-	O
breath	O
test	O
(	O
UBT	O
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
represent	O
active	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
in	O
stomach	O
as	O
well	O
as	O
the	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
culture	O
from	O
the	O
oral	O
cavity	O
.	O

We	O
found	O
that	O
while	O
the	O
occurrence	O
of	O
either	O
gastric	O
or	O
oral	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
dentists	O
is	O
not	O
greater	O
than	O
in	O
general	O
population	O
,	O
it	O
seems	O
that	O
in	O
male	O
dentists	O
there	O
is	O
a	O
greater	O
risk	O
of	O
gastric	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
.	O

Moreover	O
,	O
we	O
found	O
a	O
relationship	O
between	O
the	O
length	O
of	O
dentist	O
occupation	O
with	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
gingival	O
sulcus	O
.	O

In	O
conclusion	O
,	O
while	O
overall	O
occurrence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
dentists	O
did	O
not	O
differ	O
from	O
that	O
reported	O
for	O
stomach	O
or	O
oral	O
cavity	O
in	O
general	O
population	O
,	O
there	O
was	O
an	O
increased	O
occurrence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
male	O
dentists	O
and	O
the	O
presence	O
of	O
this	O
germ	O
in	O
the	O
oral	O
cavity	O
appears	O
to	O
be	O
related	O
to	O
the	O
length	O
of	O
professional	O
exposure	O
.	O

Oral	O
immunotherapy	O
with	O
inactivated	O
non	B-bacteria
-	I-bacteria
typeable	I-bacteria
Haemophilus	I-bacteria
influenzae	I-bacteria
(	O
NTHi	B-bacteria
)	O
prevents	O
exacerbations	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
but	O
the	O
mechanism	O
is	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
mechanism	O
of	O
protection	O
.	O

This	O
was	O
a	O
placebo	O
versus	O
active	O
prospective	O
study	O
over	O
3	O
months	O
in	O
64	O
smokers	O
.	O

The	O
active	O
treatment	O
was	O
three	O
courses	O
of	O
oral	O
NTHi	B-bacteria
given	O
at	O
monthly	O
intervals	O
,	O
followed	O
by	O
measurement	O
of	O
bacteriological	O
and	O
immunological	O
parameters	O
.	O

The	O
results	O
can	O
be	O
summarized	O
:	O
(	O
i	O
)	O
NTHi	O
-	O
specific	O
T	O
cells	O
increased	O
in	O
the	O
placebo	O
treatment	O
group	O
over	O
time	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
(	O
ii	O
)	O
the	O
T	O
`	O
cell	O
response	O
in	O
the	O
oral	O
NTHi	B-bacteria
group	O
started	O
earlier	O
than	O
that	O
in	O
the	O
placebo	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
and	O
(	O
iii	O
)	O
serum	O
NTHi	O
-	O
specific	O
immunoglobulin	O
(	O
Ig	O
)	O
G	O
had	O
significantly	O
greater	O
variation	O
in	O
the	O
placebo	O
group	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
increase	O
in	O
antibody	O
in	O
placebos	O
over	O
time	O
correlated	O
with	O
exposure	O
to	O
live	O
H	B-bacteria
.	I-bacteria
influenzae	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
determined	O
from	O
culture	O
of	O
gargles	O
;	O
(	O
iv	O
)	O
reduction	O
in	O
saliva	O
lysozyme	O
over	O
time	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
was	O
detected	O
only	O
in	O
the	O
oral	O
NTHi	B-bacteria
treatment	O
group	O
.	O

These	O
data	O
are	O
consistent	O
with	O
T	O
cell	O
priming	O
of	O
gut	O
lymphoid	O
tissue	O
by	O
aspiration	O
of	O
bronchus	O
content	O
into	O
the	O
gut	O
,	O
with	O
oral	O
immunotherapy	O
augmenting	O
this	O
process	O
leading	O
to	O
enhanced	O
bronchus	O
protection	O
.	O

The	O
evidence	O
for	O
protection	O
was	O
a	O
stable	O
IgG	O
antibody	O
level	O
through	O
the	O
study	O
in	O
the	O
oral	O
NTHi	B-bacteria
treatment	O
group	O
,	O
contrasting	O
with	O
an	O
increase	O
in	O
antibody	O
correlating	O
with	O
exposure	O
of	O
the	O
airways	O
to	O
H	B-bacteria
.	I-bacteria
influenzae	I-bacteria
in	O
the	O
placebo	O
group	O
.	O

Saliva	O
lysozyme	O
was	O
a	O
useful	O
biomarker	O
of	O
mucosal	O
inflammation	O
,	O
falling	O
after	O
oral	O
NTHi	B-bacteria
consistent	O
with	O
a	O
reduction	O
in	O
the	O
level	O
of	O
intralumenal	O
inflammation	O
.	O

This	O
study	O
examined	O
caries	O
level	O
,	O
amount	O
of	O
calculus	O
,	O
and	O
oral	O
microbial	O
environment	O
in	O
gastrostomy	O
tube	O
(	O
GT	O
)	O
-	O
fed	O
children	O
compared	O
with	O
healthy	O
children	O
and	O
children	O
with	O
disabilities	O
orally	O
fed	O
(	O
PO	O
)	O
.	O

STUDY	O
The	O
study	O
group	O
consisted	O
of	O
12	O
GT	O
-	O
fed	O
children	O
and	O
the	O
two	O
control	O
groups	O
consisted	O
of	O
16	O
children	O
with	O
disabilities	O
orally	O
fed	O
and	O
17	O
healthy	O
children	O
.	O

DMF	O
-	O
T	O
/	O
dmf	O
-	O
t	O
index	O
,	O
calculus	O
index	O
,	O
Mutans	B-bacteria
Streptococci	I-bacteria
(	O
MS	B-bacteria
)	O
,	O
Lactobacilli	B-bacteria
(	O
LB	B-bacteria
)	O
levels	O
and	O
salivary	O
buffer	O
capacity	O
were	O
examined	O
.	O

DMF	O
-	O
T	O
/	O
dmf	O
-	O
t	O
index	O
was	O
significantly	O
lower	O
in	O
the	O
tube	O
-	O
fed	O
group	O
.	O

Calculus	O
index	O
was	O
highest	O
in	O
the	O
tube	O
-	O
fed	O
group	O
.	O

MS	B-bacteria
and	O
LB	B-bacteria
levels	O
were	O
the	O
lowest	O
in	O
the	O
tube	O
-	O
fed	O
children	O
.	O

Correlation	O
was	O
found	O
between	O
MS	B-bacteria
and	O
DMF	O
-	O
T	O
/	O
dmf	O
-	O
t	O
.	O
Tube	O
-	O
fed	O
children	O
demonstrated	O
significantly	O
higher	O
calculus	O
levels	O
and	O
less	O
caries	O
,	O
MS	B-bacteria
,	O
and	O
LB	B-bacteria
levels	O
then	O
healthy	O
children	O
or	O
children	O
with	O
disabilities	O
eating	O
PO	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
smoking	O
cessation	O
alters	O
the	O
subgingival	O
microbial	O
profile	O
;	O
however	O
,	O
the	O
response	O
of	O
individual	O
bacteria	O
within	O
this	O
ecosystem	O
has	O
not	O
been	O
well	O
studied	O
.	O

The	O
aim	O
of	O
this	O
investigation	O
,	O
therefore	O
,	O
was	O
to	O
longitudinally	O
examine	O
the	O
effect	O
of	O
smoking	O
cessation	O
on	O
the	O
prevalence	O
and	O
levels	O
of	O
selected	O
subgingival	O
bacteria	O
using	O
molecular	O
approaches	O
for	O
bacterial	O
identification	O
and	O
enumeration	O
.	O

Subgingival	O
plaque	O
was	O
collected	O
from	O
22	O
smokers	O
at	O
the	O
baseline	O
and	O
12	O
months	O
following	O
periodontal	O
nonsurgical	O
management	O
and	O
smoking	O
cessation	O
counseling	O
.	O

The	O
prevalence	O
and	O
abundance	O
of	O
selected	O
organisms	O
were	O
examined	O
using	O
nested	O
PCR	O
and	O
multiplexed	O
bead	O
-	O
based	O
flow	O
cytometry	O
.	O

Eleven	O
subjects	O
successfully	O
quit	O
smoking	O
over	O
12	O
months	O
(	O
quitters	O
)	O
,	O
while	O
11	O
continued	O
to	O
smoke	O
throughout	O
(	O
smokers	O
)	O
.	O

Smoking	O
cessation	O
led	O
to	O
a	O
decrease	O
in	O
the	O
prevalence	O
of	O
Porphyromonas	B-bacteria
endodontalis	I-bacteria
and	O
Dialister	B-bacteria
pneumosintes	I-bacteria
at	O
12	O
months	O
and	O
in	O
the	O
levels	O
of	O
Parvimonas	B-bacteria
micra	I-bacteria
,	O
Filifactor	B-bacteria
alocis	I-bacteria
,	O
and	O
Treponema	B-bacteria
denticola	I-bacteria
.	O

Smoking	O
cessation	O
also	O
led	O
to	O
an	O
increase	O
in	O
the	O
levels	O
of	O
Veillonella	B-bacteria
parvula	I-bacteria
.	O

Following	O
nonsurgical	O
periodontal	O
therapy	O
and	O
smoking	O
cessation	O
,	O
the	O
subgingival	O
microbiome	O
is	O
recolonized	O
by	O
a	O
greater	O
number	O
of	O
health	O
-	O
associated	O
species	O
and	O
there	O
are	O
a	O
significantly	O
lower	O
prevalence	O
and	O
abundance	O
of	O
putative	O
periodontal	O
pathogens	O
.	O

The	O
results	O
indicate	O
a	O
critical	O
role	O
for	O
smoking	O
cessation	O
counseling	O
in	O
periodontal	O
therapy	O
for	O
smokers	O
in	O
order	O
to	O
effectively	O
alter	O
the	O
subgingival	O
microbiome	O
.	O

To	O
study	O
a	O
possible	O
influence	O
of	O
betel	O
chewing	O
on	O
the	O
composition	O
of	O
the	O
oral	O
microflora	O
in	O
plaque	O
and	O
saliva	O
and	O
on	O
oral	O
health	O
parameters	O
as	O
well	O
as	O
a	O
possible	O
betel	O
effect	O
on	O
oral	O
bacteria	O
in	O
vitro	O
.	O

Thirty	O
-	O
two	O
adults	O
(	O
16	O
betel	O
chewers	O
and	O
16	O
non	O
-	O
betel	O
-	O
chewing	O
controls	O
)	O
of	O
the	O
Karen	O
Hill	O
tribe	O
in	O
Thailand	O
were	O
investigated	O
.	O

Saliva	O
samples	O
and	O
2	O
pooled	O
supragingival	O
plaque	O
samples	O
were	O
taken	O
from	O
each	O
individual	O
for	O
microbial	O
analysis	O
with	O
culture	O
and	O
4	O
subgingival	O
samples	O
for	O
analysis	O
with	O
the	O
DNA	O
-	O
DNA	O
hybridization	O
method	O
against	O
12	O
periodontitis	O
associated	O
bacterial	O
species	O
.	O

Caries	O
(	O
DMFS	O
)	O
,	O
plaque	O
(	O
PlI	O
%	O
)	O
and	O
bleeding	O
on	O
probing	O
(	O
%	O
BoP	O
)	O
was	O
registered	O
as	O
well	O
as	O
number	O
of	O
sites	O
with	O
>	O
5mm	O
probing	O
pocket	O
depth	O
(	O
PPD	O
)	O
.	O

Water	O
extract	O
of	O
the	O
betel	O
(	O
areca	O
chatechu	O
)	O
nut	O
was	O
tested	O
for	O
its	O
antimicrobial	O
effect	O
in	O
vitro	O
against	O
10	O
oral	O
bacterial	O
species	O
with	O
the	O
agar	O
diffusion	O
method	O
.	O

An	O
antimicrobial	O
effect	O
of	O
betel	O
nut	O
water	O
extract	O
was	O
found	O
on	O
the	O
oral	O
microorganisms	O
in	O
vitro	O
.	O

The	O
levels	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
lactobacilli	B-bacteria
in	O
saliva	O
were	O
low	O
or	O
absent	O
in	O
both	O
chewers	O
and	O
controls	O
.	O

The	O
prevalence	O
of	O
the	O
periodontitis	O
associated	O
bacteria	O
was	O
>	O
90	O
%	O
.	O

Betel	O
chewers	O
had	O
significantly	O
lower	O
levels	O
of	O
some	O
bacteria	O
in	O
subgingival	O
plaque	O
(	O
Prevotella	B-bacteria
intermedia	I-bacteria
p	O
<	O
0	O
.	O
001	O
)	O
than	O
non	O
-	O
chewers	O
.	O

This	O
study	O
population	O
was	O
low	O
in	O
missing	O
teeth	O
(	O
mean	O
0	O
.	O
7	O
and	O
0	O
.	O
3	O
)	O
,	O
caries	O
decay	O
(	O
DS	O
2	O
.	O
1	O
vs	O
1	O
.	O
6	O
)	O
,	O
and	O
number	O
of	O
deep	O
pockets	O
(	O
mean	O
1	O
.	O
9	O
vs	O
1	O
.	O
3	O
)	O
.	O

Great	O
variation	O
in	O
oral	O
hygiene	O
(	O
PlI	O
and	O
BoP	O
)	O
between	O
the	O
subjects	O
was	O
seen	O
.	O

An	O
antimicrobial	O
effect	O
of	O
the	O
betel	O
nut	O
was	O
found	O
in	O
vitro	O
and	O
with	O
a	O
possible	O
effect	O
also	O
in	O
vivo	O
;	O
however	O
it	O
did	O
not	O
seem	O
to	O
influence	O
clinical	O
parameters	O
such	O
as	O
plaque	O
index	O
,	O
caries	O
prevalence	O
(	O
DMFS	O
)	O
,	O
bleeding	O
on	O
probing	O
and	O
number	O
of	O
deep	O
pockets	O
.	O

The	O
number	O
of	O
incidents	O
involving	O
sharks	O
and	O
humans	O
at	O
beaches	O
in	O
Recife	O
,	O
on	O
the	O
north	O
-	O
eastern	O
Brazilian	O
coast	O
,	O
is	O
among	O
the	O
highest	O
worldwide	O
.	O

In	O
addition	O
,	O
wound	O
infections	O
in	O
survivors	O
are	O
common	O
;	O
but	O
the	O
nature	O
and	O
risk	O
of	O
the	O
aetiological	O
agents	O
is	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
81	O
potential	O
bacterial	O
pathogens	O
were	O
identified	O
in	O
the	O
oral	O
cavity	O
of	O
sharks	O
involved	O
in	O
attacks	O
in	O
Recife	O
,	O
and	O
were	O
subjected	O
to	O
antibiotic	O
susceptibility	O
tests	O
using	O
the	O
standardized	O
disc	O
-	O
diffusion	O
method	O
.	O

The	O
majority	O
were	O
enterobacteria	B-bacteria
such	O
as	O
Enterobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Citrobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Proteus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Providencia	B-bacteria
alcalifaciens	I-bacteria
,	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Moellerella	B-bacteria
wisconcensis	I-bacteria
and	O
Leclercia	B-bacteria
adecarboxylata	I-bacteria
.	O

Other	O
Gram	O
-	O
negative	O
bacteria	O
included	O
Vibrio	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Burkholderia	B-bacteria
cepaciaQ	I-bacteria
,	O
Acinetobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	O

In	O
addition	O
,	O
coagulase	O
-	O
positive	O
and	O
coagulase	O
-	O
negative	O
Staphylococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Enterococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
Micrococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
identified	O
,	O
besides	O
Streptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
from	O
the	O
viridans	O
group	O
.	O

Resistance	O
was	O
especially	O
found	O
in	O
the	O
Proteus	B-bacteria
mirabilis	I-bacteria
and	O
Citrobacter	B-bacteria
freundii	I-bacteria
,	O
and	O
ranged	O
from	O
4	O
to	O
6	O
antibiotics	O
out	O
of	O
the	O
13	O
tested	O
.	O

Gentamicin	O
and	O
vancomycin	O
were	O
the	O
most	O
effective	O
against	O
Gram	O
-	O
positive	O
cocci	O
strains	O
,	O
whereas	O
levofloxacin	O
was	O
fully	O
inhibitory	O
against	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
.	O

These	O
data	O
are	O
discussed	O
in	O
light	O
of	O
a	O
retrospective	O
evaluation	O
of	O
the	O
medical	O
records	O
of	O
three	O
shark	O
victims	O
treated	O
at	O
Restauracao	O
Hospital	O
in	O
Recife	O
.	O

An	O
important	O
risk	O
factor	O
for	O
nosocomial	O
infection	O
in	O
an	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
is	O
prior	O
colonization	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
spectrum	O
of	O
bacterial	O
colonization	O
and	O
predisposing	O
risk	O
factors	O
in	O
patients	O
being	O
admitted	O
to	O
an	O
ICU	O
in	O
India	O
,	O
with	O
special	O
emphasis	O
on	O
extended	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
(	O
ESBL	O
)	O
-	O
and	O
metallo	O
-	O
beta	O
-	O
lactamase	O
(	O
MBL	O
)	O
-	O
producing	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Nasal	O
,	O
oral	O
and	O
rectal	O
swab	O
samples	O
were	O
collected	O
and	O
processed	O
for	O
isolation	O
of	O
ESBL	O
-	O
producing	O
Gram	O
-	O
negative	O
bacteria	O
and	O
MBL	O
-	O
producing	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
and	O
Acinetobacter	B-bacteria
species	I-bacteria
.	O

Bacterial	O
colonization	O
(	O
of	O
one	O
or	O
more	O
sites	O
)	O
on	O
admission	O
was	O
detected	O
in	O
51	O
out	O
of	O
96	O
patients	O
included	O
in	O
the	O
study	O
.	O

Non	O
-	O
fermenters	O
,	O
i	O
.	O
e	O
.	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
and	O
Acinetobacter	B-bacteria
baumannii	I-bacteria
,	O
were	O
the	O
most	O
common	O
colonizers	O
,	O
present	O
in	O
37	O
patients	O
,	O
with	O
simultaneous	O
colonization	O
in	O
12	O
patients	O
.	O

A	O
total	O
of	O
16	O
patients	O
were	O
colonized	O
with	O
MBL	O
-	O
producing	O
members	O
of	O
the	O
family	O
Enterobacteriaceae	B-bacteria
,	O
out	O
of	O
which	O
11	O
isolates	O
(	O
from	O
5	O
patients	O
)	O
were	O
also	O
carrying	O
ESBL	O
-	O
encoding	O
genes	O
.	O

As	O
for	O
MBLs	O
,	O
most	O
of	O
our	O
patients	O
have	O
shown	O
colonization	O
with	O
ESBL	O
-	O
producing	O
bacteria	O
.	O

On	O
admission	O
,	O
47	O
of	O
51	O
patients	O
(	O
92	O
%	O
)	O
have	O
been	O
colonized	O
by	O
ESBL	O
-	O
producing	O
members	O
of	O
the	O
family	O
Enterobacteriaceae	B-bacteria
,	O
at	O
one	O
or	O
more	O
of	O
the	O
three	O
anatomical	O
sites	O
.	O

The	O
most	O
common	O
MBL	O
subtype	O
was	O
bla	O
(	O
IMP	O
)	O
(	O
51	O
.	O
56	O
%	O
)	O
,	O
whereas	O
bla	O
(	O
CTX	O
)	O
was	O
the	O
most	O
common	O
gene	O
(	O
84	O
.	O
9	O
%	O
)	O
identified	O
among	O
ESBL	O
producers	O
.	O

Risk	O
factors	O
for	O
colonization	O
on	O
admission	O
to	O
the	O
ICU	O
were	O
hospitalization	O
for	O
more	O
than	O
48	O
h	O
,	O
use	O
of	O
>	O
or	O
=	O
3	O
groups	O
of	O
antibiotics	O
,	O
co	O
-	O
morbidities	O
and	O
mechanical	O
ventilation	O
for	O
more	O
than	O
48	O
h	O
prior	O
to	O
ICU	O
admission	O
.	O

There	O
is	O
an	O
increasing	O
incidence	O
of	O
MBLs	O
and	O
ESBLs	O
in	O
the	O
Indian	O
population	O
.	O

The	O
identified	O
risk	O
factors	O
can	O
be	O
used	O
as	O
a	O
guide	O
for	O
empiric	O
antibiotic	O
therapy	O
targeted	O
to	O
these	O
resistant	O
bacteria	O
.	O

Xylitol	O
-	O
sweetened	O
chewing	O
gum	O
has	O
cariostatic	O
properties	O
,	O
but	O
is	O
not	O
suitable	O
for	O
all	O
patients	O
.	O

This	O
study	O
evaluated	O
the	O
effect	O
of	O
xylitol	O
rinse	O
on	O
mutans	B-bacteria
streptococci	I-bacteria
(	O
MS	B-bacteria
)	O
levels	O
in	O
the	O
mouth	O
.	O

One	O
hundred	O
and	O
five	O
subjects	O
with	O
high	O
salivary	O
MS	B-bacteria
levels	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
.	O

Subjects	O
in	O
the	O
positive	O
control	O
group	O
(	O
N	O
=	O
35	O
)	O
chewed	O
two	O
xylitol	O
gum	O
pellets	O
for	O
at	O
least	O
5	O
minutes	O
three	O
times	O
daily	O
(	O
xylitol	O
dose	O
:	O
4	O
.	O
3g	O
/	O
day	O
)	O
.	O

The	O
experimental	O
group	O
(	O
N	O
=	O
36	O
)	O
rinsed	O
with	O
20	O
mL	O
of	O
an	O
aqueous	O
solution	O
of	O
xylitol	O
twice	O
daily	O
for	O
60	O
seconds	O
(	O
dose	O
:	O
4	O
.	O
4	O
g	O
/	O
day	O
)	O
.	O

The	O
negative	O
control	O
group	O
(	O
N	O
=	O
34	O
)	O
used	O
neither	O
product	O
.	O

No	O
attempt	O
was	O
made	O
to	O
change	O
the	O
subjects	O
'	O
diet	O
.	O

Mean	O
MS	B-bacteria
levels	O
at	O
baseline	O
were	O
5	O
.	O
6	O
(	O
0	O
.	O
1	O
)	O
in	O
positive	O
control	O
,	O
5	O
.	O
4	O
(	O
0	O
.	O
1	O
)	O
in	O
experimental	O
,	O
and	O
5	O
.	O
5	O
(	O
0	O
.	O
1	O
)	O
in	O
negative	O
control	O
groups	O
.	O

After	O
3	O
months	O
,	O
MS	B-bacteria
levels	O
were	O
4	O
.	O
4	O
(	O
0	O
.	O
2	O
)	O
,	O
4	O
.	O
4	O
(	O
0	O
.	O
2	O
)	O
,	O
and	O
4	O
.	O
9	O
(	O
0	O
.	O
2	O
)	O
,	O
respectively	O
.	O

Differences	O
between	O
groups	O
were	O
not	O
significant	O
by	O
ANOVA	O
(	O
p	O
=	O
.	O
2	O
)	O
;	O
however	O
,	O
MS	B-bacteria
levels	O
tended	O
to	O
be	O
lower	O
in	O
the	O
experimental	O
and	O
positive	O
control	O
groups	O
.	O

Xylitol	O
rinse	O
and	O
chewing	O
gum	O
caused	O
a	O
similar	O
but	O
statistically	O
insignificant	O
reduction	O
in	O
MS	B-bacteria
levels	O
in	O
the	O
mouth	O
.	O

The	O
research	O
described	O
here	O
was	O
aimed	O
at	O
the	O
selection	O
of	O
oral	O
bacteria	O
that	O
displayed	O
properties	O
compatible	O
with	O
their	O
potential	O
use	O
as	O
probiotics	O
for	O
the	O
pharyngeal	O
mucosa	O
.	O

We	O
included	O
in	O
the	O
study	O
56	O
bacteria	O
newly	O
isolated	O
from	O
the	O
pharynges	O
of	O
healthy	O
donors	O
,	O
which	O
were	O
identified	O
at	O
the	O
intraspecies	O
level	O
and	O
characterized	O
in	O
vitro	O
for	O
their	O
probiotic	O
potential	O
.	O

The	O
experiments	O
led	O
us	O
to	O
select	O
two	O
potential	O
probiotic	O
bacterial	O
strains	O
(	O
Streptococcus	B-bacteria
salivarius	I-bacteria
RS1	I-bacteria
and	O
ST3	B-bacteria
)	O
and	O
to	O
compare	O
them	O
with	O
the	O
prototype	O
oral	O
probiotic	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
strain	I-bacteria
K12	I-bacteria
.	O

All	O
three	O
strains	O
efficiently	O
bound	O
to	O
FaDu	O
human	O
epithelial	O
pharyngeal	O
cells	O
and	O
thereby	O
antagonized	O
Streptococcus	B-bacteria
pyogenes	I-bacteria
adhesion	O
and	O
growth	O
.	O

All	O
were	O
sensitive	O
to	O
a	O
variety	O
of	O
antibiotics	O
routinely	O
used	O
for	O
the	O
control	O
of	O
upper	O
respiratory	O
tract	O
infections	O
.	O

Immunological	O
in	O
vitro	O
testing	O
on	O
a	O
FaDu	O
layer	O
revealed	O
different	O
responses	O
to	O
RS1	B-bacteria
,	O
ST3	B-bacteria
,	O
and	O
K12	B-bacteria
.	O

RS1	B-bacteria
and	O
ST3	B-bacteria
modulated	O
NF	O
-	O
kappaB	O
activation	O
and	O
biased	O
proinflammatory	O
cytokines	O
at	O
baseline	O
and	O
after	O
interleukin	O
-	O
1beta	O
(	O
IL	O
-	O
1beta	O
)	O
induction	O
.	O

In	O
conclusion	O
,	O
we	O
suggest	O
that	O
the	O
selected	O
commensal	O
streptococci	B-bacteria
represent	O
potential	O
pharyngeal	O
probiotic	O
candidates	O
.	O

They	O
could	O
display	O
a	O
good	O
degree	O
of	O
adaptation	O
to	O
the	O
host	O
and	O
possess	O
potential	O
immunomodulatory	O
and	O
anti	O
-	O
inflammatory	O
properties	O
.	O

Our	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
potent	O
protective	O
effects	O
of	O
oral	O
administration	O
of	O
probiotic	O
Lactobacillus	B-bacteria
strains	I-bacteria
against	O
influenza	O
virus	O
(	O
Flu	O
)	O
infection	O
in	O
a	O
mouse	O
model	O
.	O

Lyophilized	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
GG	I-bacteria
(	O
LGG	B-bacteria
)	O
and	O
Lactobacillus	B-bacteria
gasseri	I-bacteria
TMC0356	I-bacteria
(	O
TMC0356	B-bacteria
)	O
were	O
orally	O
administered	O
to	O
BALB	O
/	O
c	O
mice	O
for	O
19	O
days	O
.	O

The	O
test	O
mice	O
were	O
intranasally	O
infected	O
with	O
Flu	O
A	O
/	O
PR	O
/	O
8	O
/	O
34	O
(	O
H1N1	O
)	O
on	O
day	O
14	O
,	O
and	O
any	O
changes	O
in	O
clinical	O
symptoms	O
were	O
monitored	O
.	O

After	O
6	O
days	O
of	O
infection	O
,	O
the	O
mice	O
were	O
killed	O
and	O
pulmonary	O
virus	O
titres	O
were	O
determined	O
.	O

The	O
clinical	O
symptom	O
scores	O
of	O
mice	O
administered	O
oral	O
LGG	B-bacteria
and	O
TMC0356	B-bacteria
were	O
significantly	O
ameliorated	O
,	O
compared	O
to	O
those	O
of	O
the	O
control	O
mice	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
pulmonary	O
virus	O
titres	O
of	O
the	O
mice	O
fed	O
LGG	B-bacteria
and	O
TMC0356	B-bacteria
were	O
also	O
significantly	O
decreased	O
compared	O
to	O
those	O
of	O
control	O
mice	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
results	O
indicate	O
that	O
oral	O
administration	O
of	O
lactobacilli	B-bacteria
,	O
such	O
as	O
LGG	B-bacteria
and	O
TMC0356	B-bacteria
,	O
might	O
protect	O
a	O
host	O
animal	O
against	O
Flu	O
infection	O
.	O

These	O
results	O
demonstrate	O
that	O
oral	O
administration	O
of	O
selected	O
lactobacilli	B-bacteria
might	O
protect	O
host	O
animals	O
from	O
Flu	O
infection	O
by	O
interactions	O
with	O
gut	O
immunity	O
.	O

Clinical	O
studies	O
with	O
dentifrices	O
formulated	O
with	O
antimicrobial	O
ingredients	O
typically	O
examine	O
the	O
effects	O
of	O
their	O
use	O
on	O
clinical	O
parameters	O
of	O
dental	O
plaque	O
and	O
gingivitis	O
.	O

The	O
effects	O
of	O
routine	O
use	O
of	O
these	O
formulations	O
on	O
the	O
microorganisms	O
found	O
in	O
the	O
distinct	O
regions	O
of	O
the	O
human	O
mouth	O
remain	O
unexplored	O
.	O

The	O
present	O
cross	O
-	O
over	O
design	O
clinical	O
study	O
compared	O
the	O
effects	O
of	O
brushing	O
with	O
a	O
recently	O
formulated	O
dentifrice	O
with	O
1	O
%	O
zinc	O
citrate	O
to	O
a	O
control	O
dentifrice	O
on	O
oral	O
bacteria	O
found	O
in	O
oral	O
niches	O
.	O

A	O
total	O
of	O
35	O
adults	O
completed	O
a	O
1	O
-	O
week	O
wash	O
-	O
out	O
phase	O
prior	O
to	O
providing	O
baseline	O
samples	O
of	O
dental	O
plaque	O
on	O
the	O
teeth	O
,	O
gums	O
,	O
saliva	O
and	O
scrapings	O
from	O
cheeks	O
and	O
tongue	O
to	O
quantify	O
anaerobic	O
bacteria	O
.	O

Subjects	O
brushed	O
twice	O
daily	O
with	O
a	O
randomly	O
assigned	O
test	O
dentifrice	O
for	O
the	O
next	O
13	O
days	O
.	O

On	O
the	O
14th	O
day	O
,	O
they	O
arrived	O
at	O
the	O
dental	O
clinic	O
prior	O
to	O
oral	O
hygiene	O
and	O
provided	O
samples	O
similar	O
to	O
baseline	O
samples	O
for	O
microbiological	O
examinations	O
.	O

Subjects	O
brushed	O
with	O
the	O
test	O
formulation	O
they	O
used	O
in	O
the	O
previous	O
13	O
days	O
,	O
prior	O
to	O
providing	O
additional	O
samples	O
at	O
5	O
-	O
h	O
post	O
-	O
brushing	O
for	O
microbial	O
assessments	O
.	O

An	O
additional	O
wash	O
-	O
out	O
phase	O
was	O
assigned	O
to	O
subjects	O
prior	O
to	O
completing	O
the	O
study	O
with	O
the	O
alternate	O
test	O
dentifrice	O
.	O

Analyses	O
of	O
log10	O
-	O
transformed	O
microbial	O
counts	O
indicated	O
no	O
statistical	O
differences	O
in	O
the	O
baseline	O
samples	O
from	O
each	O
oral	O
site	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
,	O
while	O
brushing	O
with	O
the	O
zinc	O
citrate	O
dentifrice	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
bacteria	O
in	O
each	O
post	O
-	O
brushing	O
oral	O
site	O
versus	O
the	O
control	O
paste	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Brushing	O
with	O
the	O
zinc	O
citrate	O
dentifrice	O
resulted	O
in	O
38	O
.	O
56	O
%	O
,	O
23	O
.	O
57	O
%	O
,	O
26	O
.	O
24	O
%	O
and	O
29	O
.	O
1	O
%	O
decreases	O
in	O
anaerobic	O
bacteria	O
from	O
dental	O
plaque	O
,	O
tongue	O
,	O
cheek	O
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
overnight	O
samples	O
collected	O
on	O
the	O
14th	O
day	O
versus	O
the	O
control	O
.	O

Similarly	O
,	O
the	O
5	O
-	O
h	O
post	O
-	O
brushing	O
samples	O
indicated	O
24	O
.	O
8	O
%	O
,	O
34	O
.	O
25	O
%	O
,	O
37	O
.	O
98	O
%	O
and	O
38	O
.	O
31	O
%	O
reductions	O
in	O
anaerobic	O
organisms	O
when	O
compared	O
with	O
control	O
.	O

Toothbrushing	O
with	O
the	O
zinc	O
citrate	O
formulation	O
resulted	O
in	O
significant	O
reductions	O
in	O
oral	O
bacteria	O
from	O
all	O
of	O
the	O
intraoral	O
locations	O
.	O

To	O
determine	O
the	O
antibacterial	O
activity	O
of	O
six	O
kinds	O
of	O
natural	O
herbs	O
in	O
Yunnan	O
on	O
normal	O
oral	O
predominant	O
bacteria	O
in	O
vitro	O
.	O

Agar	O
dilution	O
method	O
,	O
the	O
antimicrobial	O
susceptibility	O
testing	O
of	O
anaerobes	O
which	O
was	O
recommended	O
by	O
National	O
Committee	O
for	O
Clinical	O
Laboratory	O
Standard	O
(	O
NCCLs	O
)	O
,	O
was	O
used	O
to	O
determine	O
the	O
antimicrobial	O
susceptibility	O
of	O
herbs	O
to	O
21	O
kinds	O
of	O
oral	O
model	O
strains	O
and	O
clinical	O
isolates	O
.	O

The	O
results	O
were	O
expressed	O
by	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
.	O

All	O
six	O
kinds	O
of	O
herbs	O
were	O
effective	O
to	O
the	O
oral	O
predominant	O
bacteria	O
.	O

For	O
the	O
ten	O
kinds	O
of	O
cariogenic	O
bacteria	O
,	O
the	O
MIC	O
of	O
caesalpinia	O
sappan	O
lignum	O
was	O
between	O
5	O
-	O
10	O
mg	O
x	O
mL	O
(	O
-	O
1	O
)	O
,	O
and	O
the	O
MIC	O
of	O
other	O
herbs	O
was	O
above	O
20	O
mg	O
x	O
mL	O
(	O
-	O
1	O
)	O
.	O

For	O
the	O
eleven	O
kinds	O
of	O
predominant	O
bacteria	O
which	O
normally	O
involved	O
in	O
pulp	O
periapical	O
disease	O
and	O
periodontitis	O
,	O
the	O
MIC	O
of	O
caesalpinia	O
sappan	O
lignum	O
was	O
below	O
0	O
.	O
062	O
5	O
mg	O
x	O
mL	O
(	O
-	O
1	O
)	O
,	O
and	O
the	O
MIC	O
of	O
the	O
terminalia	O
chebula	O
retz	O
was	O
between	O
10	O
-	O
20	O
mg	O
x	O
mL	O
(	O
-	O
1	O
)	O
,	O
and	O
the	O
others	O
were	O
above	O
20	O
mg	O
x	O
mL	O
(	O
-	O
1	O
)	O
.	O

The	O
six	O
kinds	O
of	O
herbs	O
in	O
Yunnan	O
could	O
be	O
used	O
in	O
treatment	O
or	O
prevention	O
of	O
oral	O
bacterial	O
diseases	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
if	O
microbial	O
infection	O
was	O
a	O
significant	O
factor	O
in	O
patients	O
with	O
undiagnosed	O
craniofacial	O
pain	O
.	O

Of	O
the	O
150	O
patients	O
from	O
whom	O
intra	O
-	O
bony	O
cultures	O
were	O
obtained	O
,	O
23	O
different	O
groups	O
of	O
isolates	O
were	O
obtained	O
.	O

There	O
were	O
49	O
(	O
32	O
.	O
67	O
%	O
)	O
patients	O
whose	O
cultures	O
exhibited	O
growth	O
of	O
microbes	O
other	O
than	O
routine	O
oral	O
flora	O
,	O
mixed	O
skin	O
flora	O
or	O
routine	O
respiratory	O
flora	O
.	O

The	O
most	O
common	O
was	O
of	O
the	O
Streptococcus	B-bacteria
species	I-bacteria
(	O
11	O
or	O
22	O
.	O
91	O
%	O
)	O
of	O
the	O
49	O
.	O

Sixty	O
-	O
seven	O
(	O
67	O
)	O
(	O
44	O
.	O
67	O
%	O
)	O
of	O
the	O
total	O
cultures	O
demonstrated	O
the	O
growth	O
of	O
mixed	O
skin	O
flora	O
,	O
nineteen	O
(	O
12	O
.	O
67	O
%	O
)	O
demonstrated	O
the	O
growth	O
of	O
routine	O
respiratory	O
flora	O
and	O
sixteen	O
(	O
10	O
.	O
67	O
%	O
)	O
demonstrated	O
the	O
growth	O
of	O
routine	O
oral	O
flora	O
.	O

No	O
bacterial	O
isolates	O
were	O
found	O
in	O
16	O
(	O
10	O
.	O
67	O
%	O
)	O
cultures	O
.	O

The	O
most	O
common	O
histological	O
diagnoses	O
of	O
those	O
who	O
exhibited	O
pathogenic	O
microbial	O
growth	O
were	O
,	O
in	O
order	O
:	O
1	O
.	O
focal	O
osteoporotic	O
marrow	O
defect	O
;	O
2	O
.	O
ischemic	O
osteonecrosis	O
;	O
and	O
3	O
.	O
chronic	O
nonsuppurative	O
osteomyelitis	O
.	O

To	O
elucidate	O
the	O
effects	O
of	O
mucosal	O
care	O
on	O
colonization	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
infection	O
of	O
Candida	O
species	O
,	O
we	O
randomized	O
50	O
functionally	O
dependent	O
nursing	O
home	O
residents	O
,	O
mean	O
age	O
76	O
.	O
1	O
(	O
+	O
/	O
-	O
7	O
.	O
8	O
years	O
)	O
,	O
76	O
%	O
females	O
,	O
to	O
receive	O
oral	O
professional	O
care	O
with	O
or	O
without	O
mucosal	O
care	O
.	O

During	O
12	O
months	O
of	O
follow	O
-	O
up	O
,	O
significant	O
reduction	O
in	O
the	O
numbers	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
in	O
saliva	O
and	O
dental	O
plaque	O
samples	O
were	O
observed	O
in	O
both	O
treatment	O
groups	O
.	O

However	O
,	O
there	O
was	O
no	O
reduction	O
in	O
the	O
numbers	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
in	O
tongue	O
samples	O
in	O
the	O
non	O
-	O
mucosal	O
group	O
(	O
p	O
=	O
0	O
.	O
150	O
)	O
.	O

In	O
the	O
comparison	O
between	O
the	O
treatment	O
with	O
and	O
without	O
mucosal	O
care	O
,	O
the	O
treatment	O
with	O
mucosal	O
care	O
showed	O
a	O
significant	O
inhibition	O
effects	O
on	O
numbers	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
on	O
the	O
tongue	O
surface	O
at	O
6	O
months	O
after	O
the	O
treatment	O
as	O
compared	O
with	O
the	O
treatment	O
without	O
mucosal	O
care	O
(	O
p	O
=	O
0	O
.	O
043	O
)	O
.	O

Mucosal	O
care	O
was	O
not	O
associated	O
with	O
any	O
significant	O
reduction	O
in	O
the	O
rate	O
of	O
opportunistic	O
infection	O
with	O
Candida	O
species	O
in	O
any	O
of	O
the	O
three	O
sites	O
.	O

However	O
,	O
more	O
subjects	O
without	O
mucosal	O
care	O
had	O
Candida	O
infection	O
in	O
dental	O
plaque	O
during	O
the	O
follow	O
-	O
up	O
(	O
p	O
=	O
0	O
.	O
046	O
)	O
.	O

Professional	O
dental	O
care	O
with	O
(	O
versus	O
without	O
)	O
mucosal	O
care	O
had	O
no	O
effect	O
on	O
mutans	B-bacteria
streptococci	I-bacteria
colonization	O
in	O
saliva	O
or	O
plaque	O
.	O

Lack	O
of	O
mucosal	O
care	O
seemed	O
to	O
be	O
associated	O
with	O
higher	O
rates	O
opportunistic	O
infections	O
with	O
Candida	O
species	O
.	O

Two	O
strains	O
of	O
anaerobic	O
,	O
Gram	O
-	O
negative	O
bacilli	O
isolated	O
from	O
the	O
human	O
oral	O
cavity	O
were	O
subjected	O
to	O
a	O
comprehensive	O
range	O
of	O
phenotypic	O
and	O
genotypic	O
tests	O
and	O
were	O
found	O
to	O
belong	O
to	O
two	O
separate	O
taxa	O
.	O

Phylogenetic	O
analysis	O
of	O
full	O
-	O
length	O
16S	O
rRNA	O
gene	O
sequences	O
showed	O
that	O
the	O
strains	O
were	O
both	O
related	O
to	O
,	O
but	O
distinct	O
from	O
,	O
the	O
type	O
strain	O
of	O
Prevotella	B-bacteria
melaninogenica	I-bacteria
.	O

Two	O
novel	O
species	O
,	O
Prevotella	B-bacteria
fusca	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
and	O
Prevotella	B-bacteria
scopos	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
are	O
proposed	O
to	O
accommodate	O
these	O
strains	O
.	O

Both	O
strains	O
were	O
saccharolytic	O
and	O
produced	O
acetic	O
and	O
succinic	O
acids	O
,	O
with	O
lesser	O
amounts	O
of	O
lactic	O
and	O
isovaleric	O
acids	O
,	O
as	O
end	O
products	O
of	O
fermentation	O
,	O
and	O
both	O
were	O
sensitive	O
to	O
20	O
%	O
bile	O
.	O

The	O
principal	O
cellular	O
long	O
-	O
chain	O
fatty	O
acids	O
of	O
both	O
strains	O
were	O
ai	O
-	O
C	O
(	O
15	O
:	O
0	O
)	O
,	O
3	O
-	O
OH	O
i	O
-	O
C	O
(	O
17	O
:	O
0	O
)	O
,	O
3	O
-	O
OH	O
C	O
(	O
16	O
:	O
0	O
)	O
,	O
i	O
-	O
C	O
(	O
15	O
:	O
0	O
)	O
and	O
C	O
(	O
16	O
:	O
0	O
)	O
.	O

The	O
DNA	O
G	O
+	O
C	O
contents	O
of	O
the	O
type	O
strains	O
of	O
Prevotella	B-bacteria
fusca	I-bacteria
(	O
W1435	B-bacteria
(	O
T	O
)	O
=	O
DSM	B-bacteria
22504	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
57946	I-bacteria
(	O
T	O
)	O
)	O
and	O
Prevotella	B-bacteria
scopos	I-bacteria
(	O
W2052	B-bacteria
(	O
T	O
)	O
=	O
DSM	B-bacteria
22613	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
57945	I-bacteria
(	O
T	O
)	O
)	O
were	O
43	O
and	O
41	O
mol	O
%	O
,	O
respectively	O
.	O

The	O
two	O
species	O
could	O
be	O
differentiated	O
by	O
gelatin	O
hydrolysis	O
,	O
cellobiose	O
and	O
ribose	O
fermentation	O
,	O
and	O
production	O
of	O
beta	O
-	O
glucosidase	O
.	O

It	O
has	O
been	O
reported	O
that	O
DNA	O
of	O
oral	O
bacterial	O
species	O
,	O
such	O
as	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
was	O
detected	O
frequently	O
in	O
specimens	O
of	O
arteriosclerotic	O
vessels	O
.	O

However	O
,	O
the	O
source	O
of	O
DNA	O
,	O
whether	O
from	O
live	O
intact	O
bacteria	O
or	O
a	O
part	O
of	O
the	O
bacteria	O
,	O
has	O
not	O
been	O
identified	O
yet	O
.	O

Moreover	O
,	O
there	O
was	O
no	O
precise	O
evidence	O
concerning	O
involvement	O
of	O
oral	O
bacteria	O
in	O
the	O
progression	O
of	O
arteriosclerosis	O
.	O

We	O
tried	O
to	O
clarify	O
the	O
involvement	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
on	O
the	O
mechanisms	O
of	O
development	O
of	O
aortic	O
intimal	O
hyperplasia	O
.	O

Intravenous	O
administration	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
dramatically	O
induced	O
intimal	O
hyperplasia	O
in	O
the	O
mouse	O
model	O
with	O
photochemical	O
impairment	O
of	O
the	O
femoral	O
artery	O
.	O

However	O
there	O
were	O
no	O
changes	O
identified	O
in	O
the	O
mice	O
without	O
aortic	O
impairment	O
,	O
even	O
with	O
the	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
infection	O
.	O

Concomitantly	O
,	O
S100	O
calcium	O
-	O
binding	O
protein	O
A9	O
(	O
S100A9	O
)	O
and	O
the	O
embryonic	O
isoform	O
of	O
myosin	O
heavy	O
chain	O
(	O
SMemb	O
)	O
,	O
a	O
proliferative	O
phenotypic	O
marker	O
of	O
smooth	O
muscle	O
cells	O
,	O
were	O
significantly	O
overexpressed	O
on	O
the	O
surfaces	O
of	O
smooth	O
muscle	O
cells	O
present	O
in	O
the	O
injured	O
blood	O
vessels	O
.	O

Similarly	O
,	O
increased	O
expressions	O
of	O
S100A9	O
and	O
SMemb	O
proteins	O
were	O
observed	O
in	O
aneurismal	O
specimens	O
obtained	O
from	O
P	O
.	O
gingivalis	O
-	O
infected	O
patients	O
.	O

We	O
found	O
that	O
bacteremia	O
induced	O
by	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
leads	O
to	O
intimal	O
hyperplasia	O
associated	O
with	O
overexpressions	O
of	O
S100A9	O
and	O
SMemb	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
oral	O
-	O
hematogenous	O
spreading	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
is	O
a	O
causative	O
event	O
in	O
the	O
development	O
of	O
aortic	O
hyperplasia	O
in	O
periodontitis	O
patients	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
is	O
generally	O
known	O
as	O
a	O
pathogen	O
of	O
dental	O
caries	O
,	O
and	O
it	O
is	O
also	O
considered	O
to	O
cause	O
bacteremia	O
and	O
infective	O
endocarditis	O
(	O
IE	O
)	O
.	O

S	B-bacteria
.	I-bacteria
mutans	I-bacteria
was	O
previously	O
classified	O
into	O
3	O
serotypes	O
,	O
c	O
,	O
e	O
,	O
and	O
f	O
,	O
due	O
to	O
the	O
different	O
chemical	O
compositions	O
of	O
the	O
serotype	O
-	O
specific	O
polysaccharides	O
,	O
which	O
are	O
composed	O
of	O
a	O
rhamnose	O
backbone	O
and	O
glucose	O
side	O
chains	O
.	O

We	O
recently	O
designated	O
non	O
-	O
c	O
/	O
e	O
/	O
f	O
serotype	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
strains	I-bacteria
as	O
novel	O
serotype	O
k	O
,	O
which	O
is	O
characterized	O
by	O
a	O
drastic	O
reduction	O
in	O
the	O
amount	O
of	O
the	O
glucose	O
side	O
chain	O
.	O

A	O
common	O
biological	O
feature	O
of	O
novel	O
serotype	O
-	O
k	O
strains	O
is	O
a	O
lower	O
level	O
of	O
cariogenicity	O
due	O
to	O
alterations	O
of	O
several	O
major	O
cell	O
surface	O
protein	O
antigens	O
.	O

As	O
for	O
virulence	O
in	O
blood	O
,	O
these	O
strains	O
survive	O
in	O
blood	O
for	O
a	O
longer	O
duration	O
due	O
to	O
lower	O
antigenicity	O
,	O
while	O
the	O
detection	O
rate	O
of	O
all	O
strains	O
carrying	O
the	O
gene	O
encoding	O
collagen	O
-	O
binding	O
adhesin	O
has	O
been	O
shown	O
to	O
be	O
high	O
.	O

Furthermore	O
,	O
molecular	O
biological	O
analyses	O
of	O
infected	O
heart	O
valve	O
specimens	O
obtained	O
from	O
IE	O
patients	O
revealed	O
a	O
high	O
detection	O
rate	O
of	O
serotype	O
-	O
k	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
serotype	O
-	O
k	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
strains	I-bacteria
show	O
low	O
cariogenicity	O
but	O
high	O
virulence	O
in	O
blood	O
as	O
compared	O
to	O
the	O
other	O
serotypes	O
,	O
due	O
to	O
alterations	O
of	O
several	O
cell	O
surface	O
structures	O
.	O

Accumulating	O
evidence	O
suggests	O
the	O
involvement	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
(	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
)	O
,	O
a	O
periodontal	O
pathogen	O
,	O
in	O
cardiovascular	O
diseases	O
.	O

Clinical	O
specimens	O
of	O
aneurysmal	O
tissue	O
and	O
dental	O
plaque	O
collected	O
from	O
patients	O
infected	O
with	O
or	O
without	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
were	O
analyzed	O
.	O

The	O
number	O
of	O
aneurysms	O
in	O
the	O
distal	O
aorta	O
in	O
the	O
P	O
.	O
gingivalis	O
-	O
infected	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
non	O
-	O
infected	O
group	O
.	O

Cellular	O
accumulation	O
of	O
adipocytes	O
in	O
aneurysms	O
was	O
less	O
frequently	O
identified	O
in	O
the	O
infected	O
group	O
.	O

The	O
expression	O
of	O
embryonic	O
myosin	O
heavy	O
chain	O
isoform	O
,	O
a	O
phenotypic	O
marker	O
for	O
proliferative	O
smooth	O
muscle	O
cells	O
,	O
was	O
higher	O
in	O
the	O
P	O
.	O
gingivalis	O
-	O
infected	O
group	O
than	O
the	O
non	O
-	O
infected	O
group	O
.	O

Clinical	O
and	O
histopathological	O
features	O
of	O
aortic	O
aneurysms	O
associated	O
with	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
infection	O
are	O
different	O
from	O
those	O
present	O
in	O
non	O
-	O
infected	O
patients	O
.	O

The	O
major	O
characteristic	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
infection	O
associated	O
with	O
aneurysms	O
is	O
smooth	O
muscle	O
cell	O
proliferation	O
in	O
the	O
distal	O
aorta	O
.	O

Bifidobacteria	B-bacteria
are	O
aciduric	O
bacteria	O
that	O
might	O
play	O
a	O
role	O
in	O
the	O
caries	O
process	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
Bifidobacteria	B-bacteria
behave	O
as	O
caries	O
-	O
associated	O
organisms	O
,	O
as	O
predicted	O
by	O
the	O
ecological	O
plaque	O
hypothesis	O
,	O
we	O
determined	O
salivary	O
levels	O
of	O
Bifidobacteria	B-bacteria
and	O
caries	O
-	O
associated	O
organisms	O
for	O
156	O
older	O
adults	O
.	O

Salivary	O
levels	O
of	O
Bifidobacteria	B-bacteria
,	O
mutans	B-bacteria
streptococci	I-bacteria
,	O
lactobacilli	B-bacteria
,	O
and	O
yeasts	O
were	O
correlated	O
with	O
each	O
other	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
negatively	O
correlated	O
with	O
salivary	O
flow	O
rate	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
positively	O
correlated	O
with	O
plaque	O
index	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Salivary	O
Bifidobacteria	B-bacteria
levels	O
were	O
positively	O
associated	O
with	O
the	O
number	O
of	O
filled	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
decayed	O
(	O
p	O
=	O
0	O
.	O
036	O
)	O
tooth	O
surfaces	O
and	O
negatively	O
associated	O
with	O
number	O
of	O
teeth	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
salivary	O
flow	O
rate	O
(	O
p	O
=	O
0	O
.	O
049	O
)	O
.	O

In	O
regression	O
analyses	O
,	O
caries	O
experience	O
was	O
significantly	O
associated	O
with	O
only	O
salivary	O
Bifidobacteria	B-bacteria
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
yeast	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
levels	O
and	O
the	O
individual	O
'	O
s	O
age	O
(	O
p	O
=	O
0	O
.	O
021	O
)	O
.	O

Bifidobacteria	B-bacteria
should	O
be	O
regarded	O
as	O
caries	O
-	O
associated	O
organisms	O
whose	O
role	O
in	O
the	O
caries	O
process	O
and	O
as	O
markers	O
of	O
caries	O
risk	O
requires	O
further	O
investigation	O
.	O

A	O
straight	O
,	O
non	O
-	O
sporulating	O
,	O
Gram	O
-	O
variable	O
bacillus	O
(	O
HKU24	O
(	O
T	O
)	O
)	O
was	O
recovered	O
from	O
the	O
blood	O
culture	O
of	O
a	O
patient	O
with	O
metastatic	O
breast	O
carcinoma	O
.	O

After	O
repeated	O
subculturing	O
in	O
BACTEC	O
Plus	O
Anaerobic	O
/	O
F	O
blood	O
culture	O
broth	O
,	O
HKU24	O
(	O
T	O
)	O
grew	O
on	O
brucella	O
agar	O
as	O
non	O
-	O
hemolytic	O
,	O
pinpoint	O
colonies	O
after	O
96	O
h	O
of	O
incubation	O
at	O
37	O
degrees	O
C	O
in	O
an	O
anaerobic	O
environment	O
and	O
aerobic	O
environment	O
with	O
5	O
%	O
CO2	O
.	O

Growth	O
was	O
enhanced	O
with	O
a	O
streak	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
.	O

HKU24	O
(	O
T	O
)	O
was	O
non	O
-	O
motile	O
and	O
catalase	O
-	O
negative	O
,	O
but	O
positive	O
for	O
alkaline	O
phosphatase	O
,	O
beta	O
-	O
glucosidase	O
,	O
and	O
alpha	O
-	O
glucosidase	O
.	O

It	O
hydrolyzed	O
phenylphosphonate	O
and	O
reduced	O
resazurin	O
.	O

16S	O
rRNA	O
,	O
groEL	O
,	O
gyrB	O
,	O
recA	O
,	O
and	O
rpoB	O
sequencing	O
showed	O
that	O
HKU24	O
(	O
T	O
)	O
occupies	O
a	O
distinct	O
phylogenetic	O
position	O
among	O
the	O
Leptotrichia	B-bacteria
species	I-bacteria
,	O
being	O
most	O
closely	O
related	O
to	O
Leptotrichia	B-bacteria
trevisanii	I-bacteria
.	O

Using	O
HKU24	O
(	O
T	O
)	O
groEL	O
,	O
gyrB	O
,	O
recA	O
,	O
and	O
rpoB	O
gene	O
-	O
specific	O
primers	O
,	O
fragments	O
of	O
these	O
genes	O
were	O
amplified	O
from	O
one	O
of	O
20	O
oral	O
specimens	O
.	O

Based	O
on	O
phenotypic	O
and	O
genotypic	O
characteristics	O
,	O
we	O
propose	O
a	O
new	O
species	O
,	O
Leptotrichia	B-bacteria
hongkongensis	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
to	O
describe	O
this	O
bacterium	O
.	O

Endotracheal	O
(	O
ET	O
)	O
tubes	O
accumulate	O
a	O
biofilm	O
during	O
use	O
,	O
which	O
can	O
harbor	O
potentially	O
pathogenic	O
microorganisms	O
.	O

The	O
enrichment	O
of	O
pathogenic	O
strains	O
in	O
the	O
biofilm	O
may	O
lead	O
to	O
ventilator	O
-	O
associated	O
pneumonia	O
(	O
VAP	O
)	O
with	O
an	O
increased	O
morbidity	O
rate	O
in	O
intensive	O
care	O
units	O
.	O

We	O
used	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
and	O
gene	O
surveys	O
targeting	O
16S	O
rRNA	O
genes	O
to	O
quantify	O
and	O
identify	O
the	O
bacterial	O
community	O
to	O
detect	O
fastidious	O
/	O
nonculturable	O
organisms	O
present	O
among	O
extubated	O
ET	O
tubes	O
.	O

We	O
collected	O
eight	O
ET	O
tubes	O
with	O
intubation	O
periods	O
between	O
12	O
h	O
and	O
23	O
d	O
from	O
different	O
patients	O
in	O
a	O
surgical	O
and	O
a	O
medical	O
intensive	O
care	O
unit	O
.	O

Our	O
qPCR	O
data	O
showed	O
that	O
ET	O
tubes	O
were	O
colonized	O
within	O
24	O
h	O
.	O
However	O
,	O
the	O
variation	O
between	O
patients	O
was	O
too	O
high	O
to	O
find	O
a	O
positive	O
correlation	O
between	O
the	O
bacterial	O
load	O
and	O
intubation	O
period	O
.	O

We	O
obtained	O
1263	O
near	O
full	O
-	O
length	O
16S	O
rRNA	O
gene	O
sequences	O
from	O
the	O
diverse	O
bacterial	O
communities	O
.	O

Over	O
70	O
%	O
of	O
these	O
sequences	O
were	O
associated	O
with	O
genera	O
of	O
typical	O
oral	O
flora	O
,	O
while	O
only	O
6	O
%	O
were	O
associated	O
with	O
gastrointestinal	O
flora	O
.	O

The	O
most	O
common	O
genus	O
identified	O
was	O
Streptococcus	B-bacteria
(	O
348	O
/	O
1263	O
)	O
,	O
followed	O
by	O
Prevotella	B-bacteria
(	O
179	O
/	O
1263	O
)	O
,	O
and	O
Neisseria	B-bacteria
(	O
143	O
/	O
1263	O
)	O
with	O
the	O
highest	O
relative	O
concentrations	O
for	O
ET	O
tubes	O
with	O
short	O
intubation	O
periods	O
,	O
indicating	O
oral	O
inoculation	O
of	O
the	O
ET	O
tubes	O
.	O

Our	O
study	O
also	O
shows	O
that	O
even	O
though	O
potentially	O
pathogenic	O
bacteria	O
existed	O
in	O
ET	O
tube	O
biofilms	O
within	O
24	O
h	O
of	O
intubation	O
,	O
a	O
longer	O
intubation	O
period	O
increases	O
the	O
opportunity	O
for	O
these	O
organisms	O
to	O
proliferate	O
.	O

In	O
the	O
ET	O
tube	O
that	O
was	O
in	O
place	O
for	O
23	O
d	O
,	O
95	O
%	O
of	O
the	O
sequences	O
belonged	O
to	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
,	O
which	O
is	O
a	O
bacterial	O
pathogen	O
that	O
is	O
known	O
to	O
out	O
compete	O
commensal	O
bacteria	O
in	O
biofilms	O
,	O
especially	O
during	O
periods	O
of	O
antibiotic	O
treatment	O
.	O

Harboring	O
such	O
pathogens	O
in	O
ET	O
biofilms	O
may	O
increase	O
the	O
chance	O
of	O
VAP	O
,	O
and	O
should	O
be	O
aggressively	O
monitored	O
and	O
prevented	O
.	O

To	O
determine	O
the	O
pattern	O
of	O
oral	O
bacterial	O
flora	O
and	O
their	O
sensitivity	O
to	O
antibiotics	O
in	O
freshly	O
captured	O
native	O
snakes	O
in	O
Hong	O
Kong	O
SAR	O
,	O
People	O
'	O
s	O
Republic	O
of	O
China	O
.	O

Healthy	O
native	O
snakes	O
were	O
captured	O
and	O
kept	O
in	O
a	O
designated	O
centre	O
.	O

Snake	O
species	O
were	O
identified	O
by	O
experienced	O
herpetologists	O
.	O

Mouth	O
swabs	O
were	O
taken	O
by	O
the	O
veterinarian	O
using	O
strict	O
aseptic	O
techniques	O
.	O

The	O
snakes	O
were	O
released	O
back	O
to	O
the	O
wild	O
immediately	O
after	O
the	O
above	O
procedure	O
.	O

Swabs	O
were	O
sent	O
for	O
microbiological	O
studies	O
of	O
bacterial	O
culture	O
and	O
antibiotic	O
sensitivity	O
.	O

47	O
venomous	O
snakes	O
of	O
the	O
families	O
Colubridae	O
,	O
Elapidae	O
and	O
Viperidae	O
and	O
53	O
non	O
-	O
medically	O
important	O
snakes	O
were	O
captured	O
.	O

406	O
bacterial	O
isolates	O
of	O
72	O
different	O
species	O
were	O
cultured	O
:	O
these	O
included	O
gram	O
negative	O
and	O
positive	O
bacterial	O
species	O
and	O
also	O
anaerobic	O
bacterial	O
species	O
.	O

With	O
the	O
exception	O
of	O
the	O
white	O
-	O
lipped	O
pit	O
viper	O
(	O
Cryptelytrops	O
albolabris	O
)	O
,	O
venomous	O
snakes	O
harboured	O
more	O
pathogenic	O
bacteria	O
and	O
total	O
bacteria	O
species	O
compared	O
to	O
the	O
non	O
-	O
medically	O
important	O
species	O
.	O

Of	O
the	O
venomous	O
snakes	O
,	O
the	O
Chinese	O
cobra	O
(	O
Naja	O
atra	O
)	O
harboured	O
the	O
largest	O
number	O
of	O
bacterial	O
species	O
.	O

In	O
the	O
present	O
study	O
,	O
all	O
gram	O
negative	O
bacteria	O
associated	O
with	O
wound	O
infection	O
were	O
sensitive	O
to	O
levofloxacin	O
,	O
netilmicin	O
and	O
piperacillin	O
/	O
tazobactam	O
.	O

Many	O
gram	O
negative	O
bacteria	O
in	O
the	O
study	O
were	O
not	O
sensitive	O
to	O
cefuroxime	O
axetil	O
.	O

Amoxicillin	O
/	O
clavulanic	O
acid	O
was	O
an	O
appropriate	O
choice	O
to	O
cover	O
Enterococcus	B-bacteria
faecalis	I-bacteria
and	O
anaerobes	O
.	O

In	O
the	O
presence	O
of	O
wound	O
infection	O
from	O
snakebite	O
injury	O
in	O
Hong	O
Kong	O
,	O
first	O
line	O
empirical	O
antibiotics	O
include	O
amoxicillin	O
/	O
clavulanic	O
acid	O
plus	O
levofloxacin	O
.	O

Prophylactic	O
antibiotics	O
may	O
be	O
considered	O
in	O
selected	O
cases	O
of	O
Chinese	O
cobra	O
(	O
N	O
.	O
atra	O
)	O
bite	O
,	O
otherwise	O
prophylactic	O
antibiotics	O
are	O
not	O
recommended	O
in	O
snakebite	O
unless	O
tissue	O
necrosis	O
is	O
present	O
.	O

A	O
70	O
-	O
year	O
-	O
old	O
woman	O
who	O
had	O
for	O
five	O
years	O
been	O
treated	O
with	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
a	O
-	O
inhibitors	O
for	O
rheumatoid	O
arthritis	O
was	O
admitted	O
because	O
of	O
treatment	O
-	O
refractory	O
oral	O
ulcerations	O
and	O
persisting	O
considerable	O
soft	O
-	O
tissue	O
swelling	O
over	O
the	O
left	O
maxilla	O
.	O

Multiple	O
mucosal	O
biopsies	O
from	O
the	O
left	O
maxillary	O
sinus	O
revealed	O
necrotizing	O
granulomatous	O
inflammation	O
suspicious	O
of	O
mycobacterial	O
infection	O
.	O

This	O
was	O
subsequently	O
confirmed	O
in	O
concurrent	O
microbiological	O
cultures	O
and	O
ultimately	O
identified	O
as	O
Mycobacterium	B-bacteria
bovis	I-bacteria
.	O

This	O
species	O
of	O
the	O
mycobacterium	B-bacteria
tuberculosis	I-bacteria
complex	O
has	O
in	O
recent	O
times	O
rarely	O
been	O
seen	O
in	O
clinical	O
practice	O
in	O
Germany	O
.	O

On	O
further	O
questioning	O
the	O
patient	O
reported	O
that	O
she	O
had	O
been	O
treated	O
for	O
`	O
`	O
lung	O
disease	O
'	O
'	O
as	O
a	O
schoolgirl	O
.	O

The	O
patient	O
was	O
isolated	O
and	O
quadruple	O
therapy	O
with	O
isoniazide	O
(	O
INH	O
)	O
,	O
rifampin	O
(	O
RMP	O
)	O
,	O
ethambutol	O
(	O
EMB	O
)	O
and	O
pyrazinamide	O
(	O
PZA	O
)	O
was	O
initiated	O
.	O

Rapid	O
improvement	O
of	O
her	O
condition	O
occurred	O
within	O
two	O
weeks	O
.	O

When	O
microbiological	O
sub	O
-	O
typing	O
using	O
16s	O
-	O
RNA	O
sequencing	O
had	O
confirmed	O
M	B-bacteria
.	I-bacteria
bovis	I-bacteria
,	O
PZA	O
was	O
replaced	O
by	O
moxifloxacin	O
.	O

When	O
investigating	O
the	O
cause	O
of	O
treatment	O
-	O
refractory	O
infections	O
and	O
ulcerations	O
,	O
particularly	O
among	O
immunosuppressed	O
patients	O
,	O
consideration	O
should	O
always	O
be	O
given	O
to	O
mycobacterial	O
infections	O
.	O

Detailed	O
and	O
targeted	O
history	O
-	O
taking	O
is	O
vital	O
.	O

Use	O
of	O
oral	O
antiseptics	O
decreases	O
the	O
bacterial	O
load	O
in	O
the	O
oral	O
cavity	O
.	O

To	O
compare	O
the	O
antimicrobial	O
activity	O
of	O
3	O
novel	O
oral	O
antiseptics	O
with	O
that	O
of	O
chlorhexidine	O
,	O
which	O
is	O
considered	O
the	O
`	O
`	O
gold	O
standard	O
'	O
'	O
of	O
oral	O
hygiene	O
.	O

Comparative	O
in	O
vitro	O
study	O
.	O

Four	O
common	O
oral	O
microorganisms	O
(	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Candida	O
albicans	O
,	O
and	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
)	O
were	O
tested	O
under	O
standard	O
conditions	O
and	O
at	O
different	O
concentrations	O
,	O
by	O
use	O
of	O
a	O
broth	O
dilution	O
assay	O
and	O
an	O
agar	O
diffusion	O
assay	O
and	O
by	O
calculating	O
the	O
log10	O
reduction	O
factor	O
(	O
RF	O
)	O
.	O

The	O
antimicrobial	O
activity	O
of	O
each	O
antiseptic	O
was	O
assessed	O
by	O
counting	O
the	O
difference	O
in	O
bacterial	O
densities	O
(	O
ie	O
,	O
the	O
log10	O
number	O
of	O
colony	O
-	O
forming	O
units	O
of	O
bacteria	O
)	O
before	O
and	O
after	O
the	O
disinfection	O
process	O
.	O

The	O
oral	O
antiseptics	O
containing	O
octenidine	O
(	O
with	O
an	O
RF	O
in	O
the	O
range	O
of	O
7	O
.	O
1	O
-	O
8	O
.	O
24	O
CFU	O
/	O
mL	O
)	O
and	O
polyhexamethylene	O
biguanide	O
(	O
with	O
an	O
RF	O
in	O
the	O
range	O
of	O
7	O
.	O
1	O
-	O
8	O
.	O
24	O
CFU	O
/	O
mL	O
)	O
demonstrated	O
antimicrobial	O
activity	O
comparable	O
to	O
that	O
of	O
chlorhexidine	O
(	O
with	O
an	O
RF	O
in	O
the	O
range	O
of	O
1	O
.	O
03	O
-	O
8	O
.	O
24	O
CFU	O
/	O
mL	O
)	O
,	O
whereas	O
the	O
mouth	O
rinse	O
containing	O
Citroxx	O
(	O
Citroxx	O
Biosciences	O
;	O
with	O
an	O
RF	O
in	O
the	O
range	O
of	O
0	O
.	O
22	O
-	O
1	O
.	O
36	O
CFU	O
/	O
mL	O
)	O
showed	O
significantly	O
weaker	O
antimicrobial	O
efficacy	O
.	O

Overall	O
,	O
octenidine	O
and	O
polyhexamethylene	O
biguanide	O
were	O
more	O
active	O
at	O
lower	O
concentrations	O
.	O
conclusion	O
.	O

Oral	O
antiseptics	O
containing	O
the	O
antimicrobial	O
agent	O
octenidine	O
or	O
polyhexamethylene	O
biguanide	O
may	O
be	O
considered	O
as	O
potent	O
alternatives	O
to	O
chlorhexidine	O
-	O
based	O
preparations	O
.	O

This	O
investigation	O
assessed	O
regional	O
differences	O
in	O
dental	O
plaque	O
and	O
gingivitis	O
within	O
the	O
human	O
dentition	O
in	O
conjunction	O
with	O
microbiological	O
analyses	O
of	O
dental	O
plaque	O
.	O

Forty	O
-	O
one	O
adults	O
(	O
23	O
males	O
and	O
18	O
females	O
;	O
age	O
range	O
19	O
-	O
44	O
years	O
)	O
were	O
enrolled	O
,	O
and	O
a	O
calibrated	O
dental	O
examiner	O
completed	O
whole	O
mouth	O
examinations	O
for	O
dental	O
plaque	O
(	O
PI	O
)	O
and	O
gingivitis	O
(	O
GI	O
)	O
using	O
the	O
Turesky	O
modification	O
of	O
the	O
Quigley	O
-	O
Hein	O
Index	O
(	O
TMQH	O
)	O
and	O
the	O
L6e	O
-	O
Silness	O
(	O
LS	O
)	O
Index	O
,	O
respectively	O
.	O

Dental	O
plaque	O
samples	O
were	O
collected	O
from	O
the	O
anterior	O
surfaces	O
and	O
posterior	O
teeth	O
to	O
determine	O
viable	O
anaerobic	O
bacteria	O
.	O

During	O
this	O
visit	O
,	O
subjects	O
underwent	O
a	O
whole	O
mouth	O
dental	O
prophylaxis	O
and	O
were	O
provided	O
a	O
marketed	O
fluoride	O
dentifrice	O
for	O
twice	O
-	O
daily	O
oral	O
hygiene	O
.	O

Subjects	O
were	O
recalled	O
on	O
day	O
15	O
and	O
day	O
30	O
for	O
whole	O
mouth	O
assessments	O
of	O
PI	O
and	O
GI	O
,	O
followed	O
by	O
the	O
collection	O
of	O
dental	O
plaque	O
from	O
the	O
anterior	O
and	O
posterior	O
teeth	O
for	O
microbiological	O
analyses	O
during	O
these	O
visits	O
.	O

Low	O
plaque	O
and	O
gingival	O
scores	O
were	O
common	O
on	O
anterior	O
surfaces	O
,	O
in	O
contrast	O
to	O
greater	O
frequencies	O
of	O
higher	O
PI	O
and	O
GI	O
scores	O
on	O
the	O
posterior	O
regions	O
or	O
the	O
entire	O
dentition	O
.	O

Correspondingly	O
,	O
mean	O
scores	O
for	O
PI	O
and	O
GI	O
were	O
significantly	O
lower	O
among	O
the	O
anterior	O
surfaces	O
in	O
comparison	O
to	O
all	O
other	O
regions	O
of	O
the	O
mouth	O
(	O
posterior	O
,	O
Ramfjord	O
surfaces	O
,	O
or	O
the	O
entire	O
dentition	O
)	O
over	O
each	O
phase	O
of	O
the	O
study	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

While	O
prophylaxis	O
resulted	O
in	O
lower	O
clinical	O
scores	O
from	O
baseline	O
to	O
the	O
day	O
-	O
15	O
recall	O
visit	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
anterior	O
surfaces	O
demonstrated	O
lower	O
scores	O
than	O
posterior	O
regions	O
during	O
this	O
recall	O
visit	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Although	O
dental	O
plaque	O
scores	O
increased	O
from	O
the	O
day	O
-	O
15	O
to	O
the	O
day	O
-	O
30	O
evaluations	O
,	O
gingival	O
scores	O
maintained	O
broad	O
reductions	O
,	O
with	O
anterior	O
scores	O
consistently	O
lower	O
than	O
the	O
corresponding	O
posterior	O
regions	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Microbiological	O
analyses	O
indicated	O
significantly	O
lower	O
numbers	O
of	O
viable	O
bacteria	O
from	O
the	O
anterior	O
surfaces	O
in	O
comparison	O
to	O
posterior	O
regions	O
at	O
both	O
recall	O
visits	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Anterior	O
surfaces	O
routinely	O
demonstrated	O
lower	O
levels	O
of	O
dental	O
plaque	O
scores	O
than	O
the	O
other	O
regions	O
of	O
the	O
dentition	O
.	O

Higher	O
gingival	O
inflammation	O
levels	O
were	O
also	O
correlated	O
with	O
increased	O
plaque	O
deposits	O
associated	O
with	O
posterior	O
teeth	O
.	O

Microbiological	O
analyses	O
confirm	O
clinical	O
observations	O
with	O
significantly	O
higher	O
numbers	O
of	O
viable	O
bacteria	O
in	O
the	O
dental	O
plaque	O
collected	O
from	O
the	O
posterior	O
regions	O
.	O

The	O
human	O
dentition	O
demonstrates	O
significant	O
regional	O
differences	O
in	O
the	O
prevalence	O
of	O
dental	O
plaque	O
,	O
gingivitis	O
,	O
and	O
corresponding	O
anaerobic	O
bacteria	O
,	O
with	O
posterior	O
surfaces	O
consistently	O
reporting	O
higher	O
scores	O
than	O
the	O
anterior	O
regions	O
.	O

These	O
consistent	O
differences	O
should	O
be	O
taken	O
into	O
account	O
in	O
performing	O
plaque	O
and	O
gingivitis	O
studies	O
when	O
assessing	O
the	O
efficacy	O
of	O
oral	O
health	O
products	O
for	O
controlling	O
dental	O
health	O
.	O

periodontitis	O
is	O
a	O
bacterially	O
induced	O
chronic	O
inflammatory	O
disease	O
.	O

Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
,	O
which	O
could	O
recognize	O
microbial	O
pathogens	O
,	O
are	O
important	O
components	O
in	O
the	O
innate	O
and	O
adaptive	O
immune	O
systems	O
.	O

Both	O
qualitatively	O
and	O
quantitatively	O
distinct	O
immune	O
responses	O
might	O
result	O
from	O
different	O
bacteria	O
stimulation	O
and	O
the	O
triggering	O
of	O
different	O
TLRs	O
.	O

This	O
study	O
explores	O
the	O
interaction	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
and	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
(	O
previously	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
)	O
with	O
TLR2	O
and	O
TLR4	O
.	O

We	O
studied	O
the	O
gene	O
expression	O
changes	O
of	O
TLR2	O
and	O
TLR4	O
and	O
cytokine	O
production	O
(	O
interleukin	O
-	O
1beta	O
,	O
-	O
6	O
,	O
-	O
8	O
,	O
-	O
10	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
)	O
in	O
human	O
periodontal	O
ligament	O
cells	O
(	O
HPDLCs	O
)	O
stimulated	O
with	O
heat	O
-	O
killed	O
bacteria	O
or	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
lipopolysaccharide	O
(	O
LPS	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
monoclonal	O
antibodies	O
to	O
TLR2	O
or	O
TLR4	O
(	O
anti	O
-	O
TLR2	O
/	O
4	O
mAb	O
)	O
.	O

Both	O
test	O
bacteria	O
and	O
10	O
microg	O
/	O
ml	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
LPS	O
treatment	O
increased	O
the	O
gene	O
expression	O
of	O
TLR2	O
and	O
TLR4	O
and	O
cytokine	O
production	O
in	O
HPDLCs	O
.	O

In	O
addition	O
,	O
these	O
upregulations	O
could	O
be	O
blocked	O
by	O
anti	O
-	O
TLR2	O
/	O
4	O
mAb	O
.	O

However	O
,	O
the	O
expression	O
of	O
TLR4	O
mRNA	O
in	O
HPDLCs	O
stimulated	O
with	O
1	O
microg	O
/	O
ml	O
P	O
.	O
gingivalis	O
LPS	O
was	O
not	O
increased	O
.	O

No	O
differences	O
were	O
found	O
in	O
the	O
cytokine	O
production	O
caused	O
by	O
1	O
microg	O
/	O
ml	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
LPS	O
treatment	O
in	O
the	O
presence	O
or	O
absence	O
of	O
anti	O
-	O
TLR4	O
mAb	O
.	O

These	O
patterns	O
of	O
gene	O
expression	O
and	O
cytokine	O
production	O
indicate	O
that	O
Gram	O
-	O
negative	O
periodontal	O
bacteria	O
or	O
their	O
LPS	O
might	O
play	O
a	O
role	O
in	O
triggering	O
TLR2	O
and	O
/	O
or	O
TLR4	O
,	O
and	O
be	O
of	O
importance	O
for	O
the	O
immune	O
responses	O
in	O
periodontitis	O
.	O

Coagulase	B-bacteria
-	I-bacteria
negative	I-bacteria
staphylococci	I-bacteria
(	O
CoNS	B-bacteria
)	O
are	O
frequently	O
isolated	O
from	O
blood	O
cultures	O
of	O
hematopoietic	O
cell	O
transplantation	O
(	O
HCT	O
)	O
patients	O
.	O

Generally	O
,	O
the	O
use	O
of	O
central	O
venous	O
catheters	O
is	O
recognized	O
as	O
a	O
significant	O
risk	O
factor	O
for	O
CoNS	B-bacteria
infection	O
,	O
while	O
the	O
impact	O
of	O
CoNS	B-bacteria
infection	O
from	O
oral	O
ulcerative	O
mucositis	O
,	O
which	O
occurs	O
frequently	O
in	O
HCT	O
,	O
may	O
be	O
underestimated	O
.	O

Here	O
,	O
we	O
examined	O
the	O
bacteria	O
on	O
the	O
buccal	O
mucosa	O
after	O
HCT	O
.	O

Sixty	O
-	O
one	O
patients	O
were	O
examined	O
for	O
bacteria	O
on	O
the	O
buccal	O
mucosa	O
routinely	O
once	O
a	O
week	O
from	O
1	O
week	O
before	O
to	O
3	O
weeks	O
after	O
allogeneic	O
HCT	O
.	O

Subjects	O
were	O
divided	O
into	O
groups	O
with	O
short	O
and	O
long	O
periods	O
of	O
antibiotic	O
use	O
,	O
and	O
differences	O
in	O
bacterial	O
substitution	O
were	O
evaluated	O
.	O

The	O
relationships	O
between	O
type	O
of	O
HCT	O
(	O
conventional	O
HCT	O
or	O
RIST	O
)	O
and	O
bacterial	O
substitution	O
were	O
also	O
evaluated	O
.	O

The	O
changes	O
in	O
detection	O
frequencies	O
of	O
CoNS	B-bacteria
and	O
alpha	B-bacteria
-	I-bacteria
streptococci	I-bacteria
from	O
before	O
to	O
3	O
weeks	O
after	O
HCT	O
were	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
chi	O
(	O
2	O
)	O
test	O
)	O
:	O
14	O
.	O
5	O
-	O
53	O
.	O
3	O
%	O
and	O
92	O
.	O
7	O
-	O
53	O
.	O
1	O
%	O
,	O
respectively	O
.	O

Significant	O
bacterial	O
substitution	O
of	O
CoNS	B-bacteria
for	O
streptococci	B-bacteria
was	O
observed	O
in	O
the	O
long	O
-	O
term	O
antibiotic	O
use	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
chi	O
(	O
2	O
)	O
test	O
)	O
,	O
but	O
also	O
occurred	O
in	O
cases	O
with	O
short	O
-	O
term	O
or	O
no	O
antibiotic	O
use	O
.	O

No	O
relationships	O
between	O
type	O
of	O
HCT	O
(	O
conventional	O
HCT	O
or	O
RIST	O
)	O
were	O
observed	O
.	O

Bacterial	O
substitution	O
of	O
CoNS	B-bacteria
for	O
streptococci	B-bacteria
occurred	O
frequently	O
on	O
the	O
buccal	O
mucosa	O
after	O
HCT	O
.	O

In	O
addition	O
to	O
antibiotic	O
use	O
,	O
environmental	O
factors	O
may	O
be	O
involved	O
in	O
bacterial	O
substitution	O
.	O

It	O
is	O
important	O
to	O
consider	O
the	O
presence	O
of	O
oral	O
mucositis	O
in	O
CoNS	B-bacteria
infection	O
after	O
HCT	O
.	O

Approximately	O
10	O
-	O
20	O
%	O
of	O
Streptococcus	B-bacteria
mutans	I-bacteria
strains	I-bacteria
have	O
been	O
reported	O
to	O
possess	O
collagen	O
-	O
binding	O
properties	O
,	O
whereas	O
other	O
species	O
in	O
the	O
oral	O
cavity	O
with	O
those	O
properties	O
remain	O
to	O
be	O
elucidated	O
.	O

Aim	O
.	O

To	O
identify	O
strains	O
with	O
collagen	O
-	O
binding	O
properties	O
and	O
analyse	O
their	O
characteristics	O
in	O
comparison	O
with	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

A	O
total	O
of	O
110	O
expectorated	O
saliva	O
specimens	O
were	O
collected	O
from	O
55	O
pairs	O
of	O
mothers	O
and	O
their	O
children	O
.	O

Bacterial	O
strains	O
with	O
collagen	O
-	O
binding	O
properties	O
were	O
isolated	O
and	O
the	O
species	O
specified	O
.	O

In	O
addition	O
,	O
strains	O
with	O
collagen	O
-	O
binding	O
properties	O
isolated	O
from	O
mother	O
-	O
child	O
pairs	O
were	O
analysed	O
using	O
molecular	O
biological	O
approaches	O
.	O

The	O
detection	O
frequency	O
of	O
strains	O
with	O
collagen	O
-	O
binding	O
properties	O
was	O
shown	O
to	O
be	O
40	O
.	O
9	O
%	O
,	O
among	O
which	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
was	O
the	O
most	O
frequently	O
detected	O
,	O
followed	O
by	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
.	O

The	O
collagen	O
-	O
binding	O
activity	O
of	O
the	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
group	O
was	O
the	O
highest	O
,	O
followed	O
by	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
.	O

In	O
addition	O
,	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
strains	I-bacteria
from	O
3	O
and	O
1	O
mother	O
-	O
child	O
pairs	O
,	O
respectively	O
,	O
were	O
shown	O
to	O
be	O
the	O
same	O
clones	O
.	O

Our	O
results	O
indicate	O
that	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
salivarius	I-bacteria
are	O
major	O
species	O
with	O
collagen	O
-	O
binding	O
properties	O
in	O
the	O
oral	O
cavity	O
,	O
and	O
that	O
strains	O
with	O
such	O
properties	O
may	O
be	O
related	O
to	O
mother	O
-	O
child	O
transmission	O
.	O

The	O
microbiota	O
of	O
the	O
denture	O
plaque	O
biofilm	O
colonizing	O
the	O
fitting	O
surface	O
of	O
dentures	O
in	O
edentulous	O
subjects	O
with	O
healthy	O
palates	O
(	O
n	O
=	O
20	O
)	O
and	O
in	O
edentulous	O
subjects	O
with	O
denture	O
stomatitis	O
(	O
n	O
=	O
20	O
)	O
was	O
studied	O
.	O

The	O
numbers	O
of	O
bacteria	O
colonizing	O
the	O
dentures	O
of	O
healthy	O
subjects	O
was	O
significantly	O
less	O
than	O
the	O
numbers	O
colonizing	O
the	O
dentures	O
of	O
stomatitis	O
subjects	O
.	O

The	O
proportions	O
and	O
frequency	O
of	O
isolation	O
of	O
mutans	B-bacteria
streptococci	I-bacteria
,	O
lactobacilli	B-bacteria
,	O
bifidobacteria	B-bacteria
and	O
yeasts	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
greater	O
in	O
the	O
subjects	O
with	O
denture	O
stomatitis	O
.	O

The	O
proportions	O
of	O
these	O
organisms	O
in	O
the	O
denture	O
plaque	O
biofilm	O
of	O
the	O
subjects	O
with	O
denture	O
stomatitis	O
were	O
similar	O
to	O
those	O
found	O
in	O
carious	O
lesions	O
,	O
indicating	O
that	O
the	O
site	O
is	O
a	O
low	O
pH	O
environment	O
.	O

The	O
predominant	O
bifidobacterial	B-bacteria
species	I-bacteria
in	O
the	O
mouths	O
of	O
dentate	O
subjects	O
is	O
Bifidobacterium	B-bacteria
dentium	I-bacteria
but	O
in	O
the	O
edentulous	O
subjects	O
wearing	O
dentures	O
B	B-bacteria
.	I-bacteria
dentium	I-bacteria
was	O
isolated	O
from	O
only	O
one	O
of	O
the	O
20	O
subjects	O
with	O
denture	O
stomatitis	O
and	O
from	O
none	O
of	O
the	O
20	O
subjects	O
with	O
healthy	O
palates	O
.	O

Instead	O
,	O
Bifidobacterium	B-bacteria
breve	I-bacteria
,	O
Bifidobacterium	B-bacteria
scardovii	I-bacteria
and	O
Bifidobacterium	B-bacteria
longum	I-bacteria
subsp	I-bacteria
.	I-bacteria
longum	I-bacteria
were	O
isolated	O
.	O

Only	O
a	O
single	O
non	O
-	O
oral	O
bifidobacterial	B-bacteria
species	I-bacteria
was	O
isolated	O
from	O
each	O
individual	O
and	O
repetitive	O
extragenic	O
palindromic	O
-	O
and	O
BOX	O
-	O
polymerase	O
chain	O
reaction	O
typing	O
methods	O
indicated	O
that	O
the	O
same	O
genotypes	O
were	O
shared	O
between	O
subjects	O
.	O

Using	O
deferred	O
antagonism	O
spot	O
plate	O
assays	O
,	O
interspecies	O
inhibition	O
was	O
demonstrated	O
between	O
oral	O
isolates	O
of	O
B	B-bacteria
.	I-bacteria
dentium	I-bacteria
,	O
B	B-bacteria
.	I-bacteria
breve	I-bacteria
,	O
B	B-bacteria
.	I-bacteria
scardovii	I-bacteria
and	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
subsp	I-bacteria
.	I-bacteria
longum	I-bacteria
.	O

Here	O
we	O
have	O
shown	O
that	O
bifidobacteria	B-bacteria
and	O
caries	O
-	O
associated	O
microbiota	O
are	O
present	O
in	O
denture	O
plaque	O
at	O
levels	O
similar	O
to	O
those	O
of	O
carious	O
lesions	O
and	O
B	O
.	O
dentium	O
can	O
not	O
be	O
maintained	O
in	O
an	O
edentulous	O
mouth	O
.	O

This	O
study	O
is	O
to	O
assess	O
the	O
antibacterial	O
activity	O
of	O
omega	O
-	O
6	O
,	O
-	O
7	O
,	O
-	O
9	O
(	O
n	O
-	O
6	O
,	O
n	O
-	O
7	O
,	O
n	O
-	O
9	O
)	O
fatty	O
acids	O
against	O
various	O
oral	O
microorganisms	O
.	O

The	O
n	O
-	O
6	O
,	O
n	O
-	O
7	O
,	O
n	O
-	O
9	O
fatty	O
acids	O
,	O
such	O
as	O
gamma	O
-	O
linoleic	O
acid	O
(	O
GLA	O
)	O
,	O
linoleic	O
acid	O
(	O
LA	O
)	O
,	O
arachidonic	O
acid	O
(	O
ARA	O
)	O
,	O
palmitoleic	O
acid	O
(	O
PA	O
)	O
,	O
and	O
oleic	O
acid	O
(	O
OA	O
)	O
,	O
their	O
fatty	O
acid	O
ethyl	O
esters	O
,	O
GLA	O
-	O
EE	O
,	O
LA	O
-	O
EE	O
,	O
ARA	O
-	O
EE	O
,	O
PA	O
-	O
EE	O
,	O
OA	O
-	O
EE	O
,	O
and	O
their	O
fatty	O
acid	O
methyl	O
esters	O
,	O
GLA	O
-	O
ME	O
,	O
LA	O
-	O
ME	O
,	O
ARA	O
-	O
ME	O
,	O
PA	O
-	O
ME	O
,	O
OA	O
-	O
ME	O
,	O
were	O
investigated	O
for	O
antimicrobial	O
activity	O
against	O
oral	O
pathogens	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Candida	O
albicans	O
,	O
Aggregatibacter	B-bacteria
actinomycetemcomitans	I-bacteria
,	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
.	O

Various	O
concentrations	O
of	O
the	O
fatty	O
acids	O
,	O
their	O
methyl	O
and	O
ethyl	O
esters	O
were	O
tested	O
against	O
various	O
oral	O
pathogens	O
in	O
96	O
-	O
well	O
plates	O
and	O
blood	O
-	O
agar	O
plate	O
.	O

The	O
plates	O
were	O
incubated	O
anaerobically	O
or	O
aerobically	O
at	O
37	O
degrees	O
C	O
for	O
48h	O
,	O
and	O
the	O
colony	O
forming	O
units	O
(	O
CFU	O
)	O
were	O
determined	O
.	O

The	O
data	O
demonstrated	O
that	O
select	O
n	O
-	O
6	O
,	O
n	O
-	O
7	O
,	O
n	O
-	O
9	O
fatty	O
acids	O
and	O
their	O
esters	O
exhibited	O
strong	O
antimicrobial	O
activity	O
against	O
these	O
oral	O
microorganisms	O
,	O
demonstrating	O
some	O
specificity	O
for	O
individual	O
microbial	O
species	O
.	O

The	O
potential	O
use	O
or	O
the	O
combinations	O
of	O
the	O
n	O
-	O
6	O
,	O
n	O
-	O
7	O
,	O
n	O
-	O
9	O
fatty	O
acids	O
and	O
/	O
or	O
their	O
esters	O
,	O
provided	O
in	O
a	O
local	O
delivery	O
vehicle	O
to	O
infected	O
sites	O
in	O
the	O
oral	O
cavity	O
,	O
could	O
be	O
considered	O
as	O
an	O
additional	O
therapeutic	O
approach	O
to	O
improving	O
oral	O
health	O
.	O

Non	O
-	O
clinical	O
studies	O
,	O
focusing	O
on	O
the	O
pharmacodynamics	O
(	O
PD	O
)	O
,	O
pharmacokinetics	O
(	O
PK	O
)	O
and	O
safety	O
pharmacology	O
of	O
genetically	O
modified	O
Lactococcus	B-bacteria
lactis	I-bacteria
(	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
)	O
bacteria	O
,	O
engineered	O
to	O
secrete	O
human	O
Trefoil	O
Factor	O
1	O
(	O
hTFF1	O
)	O
,	O
were	O
performed	O
to	O
provide	O
proof	O
-	O
of	O
-	O
concept	O
for	O
the	O
treatment	O
of	O
oral	O
mucositis	O
(	O
OM	O
)	O
patients	O
.	O

L	B-bacteria
.	I-bacteria
lactis	I-bacteria
strain	I-bacteria
sAGX0085	I-bacteria
was	O
constructed	O
by	O
stably	O
inserting	O
an	O
htff1	O
expression	O
cassette	O
into	O
the	O
bacterial	O
genome	O
,	O
and	O
clinically	O
formulated	O
as	O
a	O
mouth	O
rinse	O
(	O
coded	O
AG013	O
)	O
.	O

PD	O
studies	O
,	O
using	O
different	O
oral	O
dosing	O
regimens	O
,	O
were	O
performed	O
in	O
a	O
clinically	O
relevant	O
hamster	O
model	O
for	O
radiation	O
-	O
induced	O
OM	O
.	O

The	O
PK	O
profile	O
was	O
assessed	O
in	O
healthy	O
hamsters	O
and	O
in	O
hamsters	O
with	O
radiation	O
-	O
induced	O
OM	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
safety	O
pharmacology	O
studies	O
were	O
conducted	O
,	O
in	O
pooled	O
,	O
complement	O
-	O
preserved	O
human	O
serum	O
,	O
and	O
in	O
neutropenic	O
hamsters	O
and	O
rats	O
respectively	O
.	O

Topical	O
administration	O
of	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
sAGX0085	I-bacteria
/	I-bacteria
AG013	I-bacteria
to	O
the	O
oral	O
mucosa	O
significantly	O
reduced	O
the	O
severity	O
and	O
course	O
of	O
radiation	O
-	O
induced	O
OM	O
.	O

PK	O
studies	O
demonstrated	O
that	O
both	O
living	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
bacteria	I-bacteria
,	O
as	O
well	O
as	O
the	O
hTFF1	O
secreted	O
,	O
could	O
be	O
recovered	O
from	O
the	O
administration	O
site	O
for	O
maximum	O
24h	O
post	O
-	O
dosing	O
,	O
without	O
systemic	O
exposure	O
.	O

The	O
in	O
vitro	O
and	O
in	O
vivo	O
safety	O
pharmacology	O
studies	O
confirmed	O
that	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
sAGX0085	I-bacteria
could	O
not	O
survive	O
in	O
systemic	O
circulation	O
,	O
not	O
even	O
under	O
neutropenic	O
conditions	O
.	O

The	O
results	O
from	O
the	O
PD	O
,	O
PK	O
and	O
safety	O
pharmacology	O
studies	O
reported	O
here	O
indicate	O
that	O
in	O
situ	O
secretion	O
of	O
hTFF1	O
by	O
topically	O
administered	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
bacteria	O
provides	O
a	O
safe	O
and	O
efficacious	O
therapeutic	O
tool	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
OM	O
.	O

The	O
human	O
oropharynx	O
is	O
a	O
reservoir	O
for	O
many	O
potential	O
pathogens	O
,	O
including	O
streptococcal	B-bacteria
species	I-bacteria
that	O
cause	O
endocarditis	O
.	O

Although	O
oropharyngeal	O
microbes	O
have	O
been	O
well	O
described	O
,	O
viral	O
communities	O
are	O
essentially	O
uncharacterized	O
.	O

We	O
conducted	O
a	O
metagenomic	O
study	O
to	O
determine	O
the	O
composition	O
of	O
oropharyngeal	O
DNA	O
viral	O
communities	O
(	O
both	O
phage	O
and	O
eukaryotic	O
viruses	O
)	O
in	O
healthy	O
individuals	O
and	O
to	O
evaluate	O
oropharyngeal	O
swabs	O
as	O
a	O
rapid	O
method	O
for	O
viral	O
detection	O
.	O

Viral	O
DNA	O
was	O
extracted	O
from	O
19	O
pooled	O
oropharyngeal	O
swabs	O
and	O
sequenced	O
.	O

Viral	O
communities	O
consisted	O
almost	O
exclusively	O
of	O
phage	O
,	O
and	O
complete	O
genomes	O
of	O
several	O
phage	O
were	O
recovered	O
,	O
including	O
Escherichia	B-bacteria
coli	I-bacteria
phage	O
T3	O
,	O
Propionibacterium	B-bacteria
acnes	I-bacteria
phage	O
PA6	O
,	O
and	O
Streptococcus	B-bacteria
mitis	I-bacteria
phage	O
SM1	O
.	O

Phage	O
relative	O
abundances	O
changed	O
dramatically	O
depending	O
on	O
whether	O
samples	O
were	O
chloroform	O
treated	O
or	O
filtered	O
to	O
remove	O
microbial	O
contamination	O
.	O

pblA	O
and	O
pblB	O
genes	O
of	O
phage	O
SM1	O
were	O
detected	O
in	O
the	O
metagenomes	O
.	O

pblA	O
and	O
pblB	O
mediate	O
the	O
attachment	O
of	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
to	O
platelets	O
and	O
play	O
a	O
significant	O
role	O
in	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
virulence	O
in	O
the	O
endocardium	O
,	O
but	O
have	O
never	O
previously	O
been	O
detected	O
in	O
the	O
oral	O
cavity	O
.	O

These	O
genes	O
were	O
also	O
identified	O
in	O
salivary	O
metagenomes	O
from	O
three	O
individuals	O
at	O
three	O
time	O
points	O
and	O
in	O
individual	O
saliva	O
samples	O
by	O
PCR	O
.	O

Additionally	O
,	O
we	O
demonstrate	O
that	O
phage	O
SM1	O
can	O
be	O
induced	O
by	O
commonly	O
ingested	O
substances	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
oral	O
cavity	O
is	O
a	O
reservoir	O
for	O
pblA	O
and	O
pblB	O
genes	O
and	O
for	O
phage	O
SM1	O
itself	O
.	O

Further	O
studies	O
will	O
determine	O
the	O
association	O
between	O
pblA	O
and	O
pblB	O
genes	O
in	O
the	O
oral	O
cavity	O
and	O
the	O
risk	O
of	O
endocarditis	O
.	O

The	O
oral	O
cavity	O
is	O
inhabited	O
by	O
over	O
500	O
different	O
bacterial	O
species	O
that	O
normally	O
exist	O
in	O
ecological	O
balance	O
both	O
with	O
each	O
other	O
and	O
with	O
the	O
host	O
.	O

When	O
this	O
equilibrium	O
is	O
disturbed	O
,	O
an	O
overgrowth	O
of	O
individual	O
organisms	O
can	O
occur	O
,	O
which	O
,	O
in	O
turn	O
,	O
can	O
lead	O
to	O
the	O
onset	O
of	O
pathological	O
processes	O
,	O
notably	O
dental	O
caries	O
and	O
periodontitis	O
.	O

Generally	O
,	O
bacteraemias	O
occur	O
more	O
frequently	O
in	O
individuals	O
with	O
periodontal	O
disease	O
,	O
and	O
these	O
bacteraemias	O
have	O
been	O
implicated	O
in	O
the	O
development	O
of	O
a	O
range	O
of	O
systemic	O
diseases	O
,	O
including	O
atherothrombotic	O
disorders	O
.	O

The	O
mechanism	O
underlying	O
this	O
relationship	O
remains	O
to	O
be	O
precisely	O
defined	O
,	O
although	O
studies	O
have	O
shown	O
a	O
link	O
between	O
bacteria	O
of	O
oral	O
origin	O
and	O
platelet	O
activation	O
.	O

Several	O
orally	O
derived	O
species	O
of	O
bacteria	O
interact	O
with	O
platelets	O
,	O
including	O
those	O
of	O
the	O
Streptococcus	B-bacteria
(	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
agalactiae	I-bacteria
,	O
Streptococcus	B-bacteria
pyogenes	I-bacteria
,	O
Streptococcus	B-bacteria
gordonii	I-bacteria
,	O
Streptococcus	B-bacteria
pneumoniae	I-bacteria
,	O
Streptococcus	B-bacteria
mitis	I-bacteria
)	O
and	O
Staphylococcus	B-bacteria
(	O
Staphylococcus	B-bacteria
epidermidis	I-bacteria
,	O
Staphylococcus	B-bacteria
capitis	I-bacteria
)	O
genera	O
,	O
as	O
well	O
as	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
.	O

In	O
addition	O
,	O
some	O
members	O
of	O
both	O
the	O
Streptococcus	B-bacteria
and	O
the	O
Staphylococcus	B-bacteria
genera	I-bacteria
,	O
as	O
well	O
as	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
can	O
activate	O
platelets	O
in	O
vitro	O
.	O

The	O
current	O
review	O
describes	O
the	O
heterogeneous	O
mechanisms	O
of	O
platelet	O
activation	O
employed	O
by	O
individual	O
bacterial	O
species	O
.	O

The	O
pathological	O
and	O
clinical	O
implications	O
of	O
platelet	O
activation	O
by	O
orally	O
derived	O
bacteria	O
are	O
discussed	O
.	O

Dentistry	O
has	O
undergone	O
a	O
shift	O
in	O
caries	O
management	O
toward	O
prevention	O
and	O
improved	O
oral	O
hygiene	O
and	O
diagnosis	O
.	O

Caries	O
prevention	O
now	O
represents	O
one	O
of	O
the	O
most	O
important	O
aspects	O
of	O
modern	O
dental	O
practice	O
.	O

The	O
purpose	O
of	O
this	O
cross	O
-	O
sectional	O
study	O
was	O
to	O
demonstrate	O
the	O
use	O
of	O
adenosine	O
triphosphate	O
-	O
(	O
ATP	O
-	O
)	O
driven	O
bioluminescence	O
as	O
an	O
innovative	O
tool	O
for	O
the	O
rapid	O
chairside	O
enumeration	O
of	O
oral	O
bacteria	O
(	O
including	O
plague	O
streptococci	B-bacteria
)	O
and	O
assessment	O
of	O
oral	O
hygiene	O
and	O
caries	O
risk	O
.	O

Thirty	O
-	O
three	O
pediatric	O
patients	O
(	O
7	O
-	O
to	O
12	O
-	O
year	O
-	O
old	O
males	O
and	O
females	O
)	O
were	O
examined	O
,	O
and	O
plague	O
specimens	O
,	O
in	O
addition	O
to	O
stimulated	O
saliva	O
,	O
were	O
collected	O
from	O
representative	O
teeth	O
within	O
each	O
quadrant	O
.	O

Oral	O
specimens	O
(	O
n	O
=	O
150	O
specimens	O
)	O
were	O
assessed	O
by	O
plating	O
on	O
enriched	O
and	O
selective	O
agars	O
,	O
to	O
enumerate	O
total	O
bacteria	O
and	O
streptococci	B-bacteria
,	O
and	O
subjected	O
to	O
adenosine	O
triphosphate	O
-	O
(	O
ATP	O
-	O
)	O
driven	O
bioluminescence	O
determinations	O
using	O
a	O
luciferase	O
-	O
based	O
assay	O
system	O
.	O

Statistical	O
correlations	O
,	O
linking	O
ATP	O
values	O
to	O
numbers	O
of	O
total	O
bacteria	O
,	O
oral	O
streptococci	B-bacteria
and	O
mutans	B-bacteria
streptococci	I-bacteria
,	O
yielded	O
highly	O
significant	O
r	O
values	O
of	O
0	O
.	O
854	O
,	O
0	O
.	O
840	O
,	O
and	O
0	O
.	O
796	O
,	O
respectively	O
Our	O
clinical	O
data	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
ATP	O
measurements	O
have	O
a	O
strong	O
statistical	O
association	O
with	O
bacterial	O
number	O
in	O
plague	O
and	O
saliva	O
specimens	O
,	O
including	O
numbers	O
for	O
oral	O
streptococci	B-bacteria
,	O
and	O
may	O
be	O
used	O
as	O
a	O
potential	O
assessment	O
tool	O
for	O
oral	O
hygiene	O
and	O
caries	O
risk	O
in	O
children	O
.	O

To	O
assess	O
the	O
distribution	O
of	O
elevated	O
antibody	O
titres	O
to	O
multiple	O
periodontal	O
bacteria	O
,	O
including	O
established	O
/	O
putative	O
pathogens	O
and	O
health	O
-	O
related	O
species	O
,	O
by	O
selected	O
demographic	O
,	O
behavioural	O
,	O
and	O
oral	O
-	O
and	O
general	O
health	O
-	O
related	O
characteristics	O
.	O

Data	O
from	O
8153	O
>	O
or	O
=	O
40	O
-	O
year	O
-	O
old	O
participants	O
from	O
the	O
third	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
were	O
used	O
,	O
including	O
1588	O
edentulous	O
individuals	O
.	O

We	O
used	O
checkerboard	O
immunoblotting	O
to	O
assess	O
serum	O
IgG	O
levels	O
to	O
19	O
periodontal	O
species	O
.	O

Thresholds	O
for	O
elevated	O
antibody	O
responses	O
were	O
defined	O
for	O
each	O
species	O
using	O
the	O
90th	O
percentile	O
titre	O
in	O
periodontal	O
healthy	O
participants	O
,	O
using	O
two	O
alternative	O
definitions	O
of	O
periodontitis	O
.	O

Edentulous	O
individuals	O
showed	O
lower	O
antibody	O
responses	O
than	O
dentate	O
participants	O
,	O
notably	O
for	O
titres	O
to	O
`	O
`	O
red	O
complex	O
'	O
'	O
species	O
and	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
.	O

Elevated	O
titres	O
to	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
were	O
twice	O
as	O
prevalent	O
in	O
participants	O
with	O
periodontitis	O
than	O
in	O
periodontal	O
healthy	O
individuals	O
.	O

Non	O
-	O
Hispanic	O
blacks	O
and	O
Mexican	O
-	O
Americans	O
were	O
more	O
likely	O
to	O
display	O
elevated	O
titres	O
for	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
compared	O
with	O
non	O
-	O
Hispanic	O
whites	O
(	O
22	O
.	O
9	O
%	O
versus	O
19	O
.	O
4	O
%	O
versus	O
9	O
.	O
5	O
%	O
)	O
.	O

Current	O
smokers	O
were	O
significantly	O
less	O
likely	O
to	O
exhibit	O
high	O
titres	O
to	O
multiple	O
bacteria	O
than	O
never	O
smokers	O
.	O

Demographic	O
,	O
behavioural	O
,	O
and	O
oral	O
-	O
and	O
general	O
health	O
-	O
related	O
characteristics	O
were	O
strong	O
determinants	O
of	O
systemic	O
antibody	O
responses	O
to	O
periodontal	O
bacteria	O
in	O
a	O
nationally	O
representative	O
sample	O
of	O
US	O
adults	O
.	O

Upon	O
delivery	O
,	O
the	O
neonate	O
is	O
exposed	O
for	O
the	O
first	O
time	O
to	O
a	O
wide	O
array	O
of	O
microbes	O
from	O
a	O
variety	O
of	O
sources	O
,	O
including	O
maternal	O
bacteria	O
.	O

Although	O
prior	O
studies	O
have	O
suggested	O
that	O
delivery	O
mode	O
shapes	O
the	O
microbiota	O
'	O
s	O
establishment	O
and	O
,	O
subsequently	O
,	O
its	O
role	O
in	O
child	O
health	O
,	O
most	O
researchers	O
have	O
focused	O
on	O
specific	O
bacterial	O
taxa	O
or	O
on	O
a	O
single	O
body	O
habitat	O
,	O
the	O
gut	O
.	O

Thus	O
,	O
the	O
initiation	O
stage	O
of	O
human	O
microbiome	O
development	O
remains	O
obscure	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
obtain	O
a	O
community	O
-	O
wide	O
perspective	O
on	O
the	O
influence	O
of	O
delivery	O
mode	O
and	O
body	O
habitat	O
on	O
the	O
neonate	O
'	O
s	O
first	O
microbiota	O
.	O

We	O
used	O
multiplexed	O
16S	O
rRNA	O
gene	O
pyrosequencing	O
to	O
characterize	O
bacterial	O
communities	O
from	O
mothers	O
and	O
their	O
newborn	O
babies	O
,	O
four	O
born	O
vaginally	O
and	O
six	O
born	O
via	O
Cesarean	O
section	O
.	O

Mothers	O
'	O
skin	O
,	O
oral	O
mucosa	O
,	O
and	O
vagina	O
were	O
sampled	O
1	O
h	O
before	O
delivery	O
,	O
and	O
neonates	O
'	O
skin	O
,	O
oral	O
mucosa	O
,	O
and	O
nasopharyngeal	O
aspirate	O
were	O
sampled	O
<	O
5	O
min	O
,	O
and	O
meconium	O
<	O
24	O
h	O
,	O
after	O
delivery	O
.	O

We	O
found	O
that	O
in	O
direct	O
contrast	O
to	O
the	O
highly	O
differentiated	O
communities	O
of	O
their	O
mothers	O
,	O
neonates	O
harbored	O
bacterial	O
communities	O
that	O
were	O
undifferentiated	O
across	O
multiple	O
body	O
habitats	O
,	O
regardless	O
of	O
delivery	O
mode	O
.	O

Our	O
results	O
also	O
show	O
that	O
vaginally	O
delivered	O
infants	O
acquired	O
bacterial	O
communities	O
resembling	O
their	O
own	O
mother	O
'	O
s	O
vaginal	O
microbiota	O
,	O
dominated	O
by	O
Lactobacillus	B-bacteria
,	O
Prevotella	B-bacteria
,	O
or	O
Sneathia	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
and	O
C	O
-	O
section	O
infants	O
harbored	O
bacterial	O
communities	O
similar	O
to	O
those	O
found	O
on	O
the	O
skin	O
surface	O
,	O
dominated	O
by	O
Staphylococcus	B-bacteria
,	O
Corynebacterium	B-bacteria
,	O
and	O
Propionibacterium	B-bacteria
spp	I-bacteria
.	O

These	O
findings	O
establish	O
an	O
important	O
baseline	O
for	O
studies	O
tracking	O
the	O
human	O
microbiome	O
'	O
s	O
successional	O
development	O
in	O
different	O
body	O
habitats	O
following	O
different	O
delivery	O
modes	O
,	O
and	O
their	O
associated	O
effects	O
on	O
infant	O
health	O
.	O

In	O
the	O
human	O
mouth	O
,	O
fungi	O
and	O
several	O
hundred	O
species	O
of	O
bacteria	O
coexist	O
.	O

Here	O
we	O
report	O
a	O
case	O
of	O
interkingdom	O
signaling	O
in	O
the	O
oral	O
cavity	O
:	O
A	O
compound	O
excreted	O
by	O
the	O
caries	O
bacterium	O
Streptococcus	B-bacteria
mutans	I-bacteria
inhibits	O
the	O
morphological	O
transition	O
from	O
yeast	O
to	O
hyphae	O
,	O
an	O
important	O
virulence	O
trait	O
,	O
in	O
the	O
opportunistic	O
fungus	O
Candida	O
albicans	O
.	O

The	O
compound	O
excreted	O
by	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
was	O
originally	O
studied	O
because	O
it	O
inhibited	O
signaling	O
by	O
the	O
universal	O
bacterial	O
signal	O
autoinducer	O
-	O
2	O
(	O
AI	O
-	O
2	O
)	O
,	O
determined	O
by	O
the	O
luminescence	O
of	O
a	O
Vibrio	B-bacteria
harveyi	I-bacteria
sensor	O
strain	O
.	O

The	O
inhibitor	O
was	O
purified	O
from	O
cell	O
-	O
free	O
culture	O
supernatants	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
guided	O
by	O
its	O
activity	O
.	O

Its	O
chemical	O
structure	O
was	O
elucidated	O
by	O
using	O
NMR	O
spectroscopy	O
and	O
GC	O
-	O
MS	B-bacteria
and	O
proved	O
to	O
be	O
trans	O
-	O
2	O
-	O
decenoic	O
acid	O
.	O

We	O
show	O
that	O
trans	O
-	O
2	O
-	O
decenoic	O
acid	O
does	O
not	O
inhibit	O
AI	O
-	O
2	O
-	O
specific	O
signaling	O
,	O
but	O
rather	O
the	O
luciferase	O
reaction	O
used	O
for	O
its	O
detection	O
.	O

A	O
potential	O
biological	O
role	O
of	O
trans	O
-	O
2	O
-	O
decenoic	O
acid	O
was	O
then	O
discovered	O
.	O

It	O
is	O
able	O
to	O
suppress	O
the	O
transition	O
from	O
yeast	O
to	O
hyphal	O
morphology	O
in	O
the	O
opportunistic	O
human	O
pathogen	O
Candida	O
albicans	O
at	O
concentrations	O
that	O
do	O
not	O
affect	O
growth	O
.	O

The	O
expression	O
of	O
HWP1	O
,	O
a	O
hyphal	O
-	O
specific	O
signature	O
gene	O
of	O
C	O
.	O
albicans	O
,	O
is	O
abolished	O
by	O
trans	O
-	O
2	O
-	O
decenoic	O
acid	O
.	O

trans	O
-	O
2	O
-	O
Decenoic	O
acid	O
is	O
structurally	O
similar	O
to	O
the	O
diffusible	O
signal	O
factor	O
(	O
DSF	O
)	O
family	O
of	O
interkingdom	O
-	O
signaling	O
molecules	O
and	O
is	O
the	O
first	O
member	O
of	O
this	O
family	O
from	O
a	O
Gram	O
-	O
positive	O
organism	O
(	O
Streptococcus	B-bacteria
DSF	I-bacteria
,	O
SDSF	B-bacteria
)	O
.	O

SDSF	B-bacteria
activity	O
was	O
also	O
found	O
in	O
S	B-bacteria
.	I-bacteria
mitis	I-bacteria
,	O
S	B-bacteria
.	I-bacteria
oralis	I-bacteria
,	O
and	O
S	B-bacteria
.	I-bacteria
sanguinis	I-bacteria
,	O
but	O
not	O
in	O
other	O
oral	O
bacteria	O
.	O

SDSF	B-bacteria
could	O
be	O
relevant	O
in	O
shaping	O
multispecies	O
Candida	O
bacteria	O
biofilms	O
in	O
the	O
human	O
body	O
.	O

Several	O
methods	O
for	O
determining	O
the	O
diversity	O
of	O
Lactobacillus	B-bacteria
spp	I-bacteria
were	O
evaluated	O
with	O
the	O
purpose	O
of	O
developing	O
a	O
realistic	O
approach	O
for	O
further	O
studies	O
.	O

The	O
patient	O
population	O
was	O
comprised	O
of	O
young	O
children	O
with	O
an	O
oral	O
disease	O
called	O
severe	O
early	O
childhood	O
caries	O
.	O

The	O
ultimate	O
goal	O
of	O
these	O
studies	O
was	O
to	O
ascertain	O
the	O
role	O
of	O
lactobacilli	B-bacteria
in	O
the	O
caries	O
process	O
.	O

To	O
accomplish	O
that	O
goal	O
,	O
we	O
evaluated	O
several	O
methods	O
and	O
approaches	O
for	O
determining	O
diversity	O
including	O
AP	O
-	O
PCR	O
,	O
chromosomal	O
DNA	O
fingerprinting	O
,	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
and	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

Central	O
to	O
these	O
methods	O
was	O
the	O
gathering	O
and	O
screening	O
of	O
isolates	O
from	O
cultivation	O
medium	O
.	O

Using	O
various	O
estimates	O
of	O
diversity	O
,	O
we	O
addressed	O
the	O
question	O
as	O
to	O
how	O
many	O
isolates	O
represent	O
the	O
overall	O
diversity	O
and	O
how	O
cultivation	O
compares	O
to	O
non	O
-	O
cultivation	O
techniques	O
.	O

Finally	O
,	O
we	O
proposed	O
a	O
working	O
approach	O
for	O
achieving	O
the	O
goals	O
outlined	O
framed	O
by	O
both	O
practical	O
constraints	O
in	O
terms	O
of	O
time	O
,	O
effort	O
and	O
efficacy	O
while	O
yielding	O
a	O
reliable	O
outcome	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
is	O
a	O
facultative	O
member	O
of	O
the	O
oral	O
plaque	O
and	O
is	O
associated	O
with	O
dental	O
caries	O
.	O

It	O
is	O
able	O
to	O
survive	O
long	O
periods	O
of	O
sugar	O
starvation	O
.	O

We	O
show	O
here	O
that	O
inactivation	O
of	O
pdhD	O
,	O
putatively	O
encoding	O
a	O
subunit	O
of	O
the	O
pyruvate	O
dehydrogenase	O
complex	O
,	O
impairs	O
survival	O
of	O
both	O
batch	O
cultures	O
and	O
biofilms	O
.	O

We	O
show	O
that	O
pdhD	O
and	O
the	O
downstream	O
genes	O
pdhA	O
,	O
pdhB	O
,	O
and	O
pdhC	O
form	O
an	O
operon	O
that	O
is	O
predominantly	O
transcribed	O
in	O
stationary	O
phase	O
.	O

Analysis	O
with	O
fluorescent	O
reporters	O
revealed	O
a	O
bimodal	O
expression	O
pattern	O
for	O
the	O
pdh	O
promoter	O
,	O
with	O
less	O
than	O
1	O
%	O
of	O
stationary	O
-	O
phase	O
populations	O
expressing	O
pdh	O
.	O

When	O
it	O
was	O
first	O
detected	O
,	O
after	O
1	O
day	O
of	O
sugar	O
starvation	O
in	O
batch	O
culture	O
,	O
expression	O
was	O
mostly	O
in	O
individual	O
bacteria	O
.	O

At	O
later	O
times	O
,	O
expressing	O
bacteria	O
were	O
often	O
in	O
chains	O
.	O

The	O
lengths	O
of	O
the	O
chains	O
increased	O
with	O
time	O
.	O

We	O
infer	O
that	O
the	O
pdh	O
-	O
expressing	O
subpopulation	O
is	O
able	O
grow	O
and	O
divide	O
and	O
to	O
persist	O
for	O
extended	O
times	O
in	O
stationary	O
phase	O
.	O

Laser	O
light	O
can	O
be	O
used	O
during	O
endodontic	O
procedures	O
to	O
sterilize	O
the	O
root	O
canal	O
by	O
destroying	O
bacteria	O
.	O

Previous	O
in	O
-	O
vitro	O
studies	O
that	O
investigated	O
the	O
mechanism	O
of	O
the	O
destruction	O
of	O
bacteria	O
inhabiting	O
the	O
root	O
canal	O
by	O
1	O
,	O
064	O
-	O
nm	O
Nd	O
:	O
YAG	O
and	O
808	O
-	O
nm	O
diode	O
laser	O
light	O
used	O
substrates	O
that	O
absorb	O
light	O
in	O
the	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
spectrum	O
.	O

These	O
substrates	O
heat	O
the	O
bacterial	O
microenvironment	O
,	O
which	O
possibly	O
contributes	O
to	O
cell	O
death	O
.	O

To	O
determine	O
the	O
direct	O
effect	O
of	O
laser	O
light	O
on	O
the	O
bacterial	O
sample	O
in	O
the	O
absence	O
of	O
detrimental	O
heating	O
,	O
a	O
sapphire	O
substrate	O
,	O
which	O
is	O
virtually	O
transparent	O
in	O
NIR	O
spectrum	O
,	O
was	O
inoculated	O
with	O
bacterial	O
samples	O
and	O
subjected	O
to	O
laser	O
irradiation	O
at	O
1	O
,	O
064	O
nm	O
(	O
1	O
.	O
5	O
W	O
,	O
15	O
Hz	O
)	O
and	O
at	O
808	O
nm	O
(	O
1	O
.	O
5	O
W	O
,	O
20	O
Hz	O
)	O
.	O

Enterococcus	B-bacteria
faecalis	I-bacteria
,	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
bacteria	I-bacteria
were	O
used	O
.	O

E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
and	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
were	O
largely	O
unaffected	O
by	O
laser	O
light	O
.	O

The	O
viability	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
a	O
pigmented	O
bacterium	O
,	O
was	O
directly	O
affected	O
by	O
both	O
NIR	O
wavelengths	O
(	O
a	O
57	O
%	O
decrease	O
of	O
viability	O
at	O
1	O
,	O
064	O
nm	O
and	O
a	O
31	O
%	O
decrease	O
at	O
808	O
nm	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
primary	O
mediator	O
of	O
cell	O
death	O
appears	O
to	O
be	O
the	O
interaction	O
between	O
NIR	O
laser	O
light	O
and	O
the	O
bacterial	O
microenvironment	O
,	O
most	O
likely	O
in	O
the	O
form	O
of	O
heating	O
.	O

Our	O
research	O
suggests	O
that	O
when	O
optimizing	O
the	O
efficacy	O
of	O
laser	O
-	O
assisted	O
endodontic	O
sterilization	O
of	O
the	O
root	O
canal	O
,	O
the	O
optical	O
characteristics	O
of	O
the	O
bacterial	O
microenvironment	O
play	O
a	O
key	O
role	O
,	O
as	O
nonpigmented	O
bacteria	O
appear	O
to	O
be	O
virtually	O
transparent	O
at	O
808	O
nm	O
and	O
1	O
,	O
064	O
nm	O
.	O

Histoplasmosis	O
is	O
a	O
deep	O
mycosis	O
caused	O
by	O
Histoplasma	O
capsulatum	O
,	O
which	O
is	O
endemic	O
in	O
many	O
areas	O
of	O
the	O
world	O
but	O
is	O
relatively	O
rare	O
in	O
China	O
.	O

Although	O
the	O
majority	O
of	O
cases	O
present	O
as	O
a	O
mild	O
to	O
moderate	O
flu	O
-	O
like	O
disease	O
requiring	O
only	O
supportive	O
therapy	O
,	O
approximately	O
1	O
%	O
of	O
patients	O
experience	O
more	O
serious	O
pulmonary	O
and	O
extrapulmonary	O
disease	O
,	O
which	O
can	O
be	O
life	O
-	O
threatening	O
if	O
diagnosis	O
is	O
delayed	O
or	O
the	O
treatment	O
is	O
not	O
initiated	O
rapidly	O
.	O

Definitive	O
diagnosis	O
is	O
usually	O
made	O
by	O
a	O
combination	O
of	O
culture	O
,	O
detection	O
of	O
the	O
organism	O
in	O
tissues	O
,	O
measurement	O
of	O
antibodies	O
,	O
and	O
detection	O
of	O
antigen	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
51	O
-	O
year	O
-	O
old	O
patient	O
who	O
presented	O
with	O
histoplasmosis	O
only	O
,	O
with	O
several	O
ulcerated	O
lesions	O
in	O
the	O
oral	O
cavity	O
and	O
without	O
HIV	O
infection	O
,	O
who	O
did	O
not	O
show	O
any	O
detectable	O
signs	O
and	O
symptoms	O
of	O
systemic	O
disease	O
or	O
extra	O
-	O
oral	O
manifestations	O
.	O

Histopathological	O
analysis	O
indicated	O
a	O
chronic	O
inflammatory	O
process	O
with	O
granulomas	O
with	O
yeast	O
-	O
like	O
organisms	O
.	O

Isolation	O
of	O
H	O
.	O
capsulatum	O
and	O
molecular	O
identification	O
provided	O
the	O
definitive	O
diagnosis	O
.	O

Treatment	O
with	O
oral	O
itraconazole	O
led	O
to	O
remission	O
of	O
the	O
oral	O
lesions	O
.	O

This	O
is	O
the	O
first	O
Chinese	O
case	O
report	O
of	O
localized	O
histoplasmosis	O
with	O
lesions	O
restricted	O
to	O
the	O
mouth	O
in	O
an	O
HIV	O
-	O
negative	O
patient	O
.	O

Oral	O
microbiota	O
plays	O
a	O
vital	O
role	O
in	O
maintaining	O
the	O
homeostasis	O
of	O
oral	O
cavity	O
.	O

Dental	O
caries	O
are	O
among	O
the	O
most	O
common	O
oral	O
diseases	O
in	O
children	O
and	O
pathogenic	O
bacteria	O
contribute	O
to	O
the	O
development	O
of	O
the	O
disease	O
.	O

However	O
,	O
the	O
overall	O
structure	O
of	O
bacterial	O
communities	O
in	O
the	O
oral	O
cavity	O
from	O
children	O
with	O
dental	O
caries	O
has	O
not	O
been	O
explored	O
deeply	O
heretofore	O
.	O

We	O
used	O
high	O
-	O
throughput	O
barcoded	O
pyrosequencing	O
and	O
PCR	O
-	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
to	O
examine	O
bacterial	O
diversity	O
of	O
oral	O
microbiota	O
in	O
saliva	O
and	O
supragingival	O
plaques	O
from	O
60	O
children	O
aged	O
3	O
to	O
6	O
years	O
old	O
with	O
and	O
without	O
dental	O
caries	O
from	O
China	O
.	O

The	O
multiplex	O
barcoded	O
pyrosequencing	O
was	O
performed	O
in	O
a	O
single	O
run	O
,	O
with	O
multiple	O
samples	O
tagged	O
uniquely	O
by	O
multiplex	O
identifiers	O
.	O

As	O
PCR	O
-	O
DGGE	O
analysis	O
is	O
a	O
conventional	O
molecular	O
ecological	O
approach	O
,	O
this	O
analysis	O
was	O
also	O
performed	O
on	O
the	O
same	O
samples	O
and	O
the	O
results	O
of	O
both	O
approaches	O
were	O
compared	O
.	O

A	O
total	O
of	O
186	O
,	O
787	O
high	O
-	O
quality	O
sequences	O
were	O
obtained	O
for	O
evaluating	O
bacterial	O
diversity	O
and	O
41	O
,	O
905	O
unique	O
sequences	O
represented	O
all	O
phylotypes	O
.	O

We	O
found	O
that	O
the	O
oral	O
microbiota	O
in	O
children	O
was	O
far	O
more	O
diverse	O
than	O
previous	O
studies	O
reported	O
,	O
and	O
more	O
than	O
200	O
genera	O
belonging	O
to	O
ten	O
phyla	O
were	O
found	O
in	O
the	O
oral	O
cavity	O
.	O

The	O
phylotypes	O
in	O
saliva	O
and	O
supragingival	O
plaques	O
were	O
significantly	O
different	O
and	O
could	O
be	O
divided	O
into	O
two	O
distinct	O
clusters	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
bacterial	O
diversity	O
in	O
oral	O
microbiome	O
analyzed	O
by	O
PCR	O
-	O
DGGE	O
and	O
barcoded	O
pyrosequencing	O
was	O
employed	O
to	O
cross	O
validate	O
the	O
data	O
sets	O
.	O

The	O
genera	O
of	O
Streptococcus	B-bacteria
,	O
Veillonella	B-bacteria
,	O
Actinomyces	B-bacteria
,	O
Granulicatella	B-bacteria
,	O
Leptotrichia	B-bacteria
,	O
and	O
Thiomonas	B-bacteria
in	O
plaques	O
were	O
significantly	O
associated	O
with	O
dental	O
caries	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
results	O
showed	O
that	O
there	O
was	O
no	O
one	O
specific	O
pathogen	O
but	O
rather	O
pathogenic	O
populations	O
in	O
plaque	O
that	O
significantly	O
correlated	O
with	O
dental	O
caries	O
.	O

The	O
enormous	O
diversity	O
of	O
oral	O
microbiota	O
allowed	O
for	O
a	O
better	O
understanding	O
of	O
oral	O
microecosystem	O
,	O
and	O
these	O
pathogenic	O
populations	O
in	O
plaque	O
provide	O
new	O
insights	O
into	O
the	O
etiology	O
of	O
dental	O
caries	O
and	O
suggest	O
new	O
targets	O
for	O
interventions	O
of	O
the	O
disease	O
.	O

This	O
study	O
was	O
designed	O
to	O
explore	O
the	O
biological	O
characteristics	O
of	O
a	O
new	O
oral	O
streptococcus	B-bacteria
species	I-bacteria
Streptococcus	B-bacteria
oligofermentans	I-bacteria
.	O

Plaque	O
samples	O
were	O
collected	O
from	O
caries	O
-	O
free	O
and	O
caries	O
-	O
active	O
subjects	O
.	O

S	B-bacteria
.	I-bacteria
oligofermentans	I-bacteria
was	O
selectively	O
grown	O
on	O
Mitis	O
salivarius	O
agar	O
plates	O
and	O
identified	O
by	O
using	O
2	O
-	O
step	O
PCR	O
and	O
was	O
isolated	O
from	O
38	O
%	O
of	O
18	O
subjects	O
.	O

Isolates	O
were	O
found	O
mostly	O
on	O
healthy	O
tooth	O
surfaces	O
.	O

S	B-bacteria
.	I-bacteria
oligofermentans	I-bacteria
had	O
weaker	O
abilities	O
in	O
acid	O
production	O
and	O
demineralizing	O
hydroxyapatite	O
.	O

When	O
Streptococcus	B-bacteria
mutans	I-bacteria
was	O
coincubated	O
with	O
S	B-bacteria
.	I-bacteria
oligofermentans	I-bacteria
,	O
total	O
number	O
,	O
acid	O
production	O
and	O
calcium	O
release	O
were	O
significantly	O
inhibited	O
.	O

In	O
conclusion	O
,	O
inhibition	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
could	O
be	O
a	O
beneficial	O
biological	O
characteristic	O
of	O
S	B-bacteria
.	I-bacteria
oligofermentans	I-bacteria
in	O
oral	O
microecology	O
.	O

Epithelial	O
cells	O
and	O
dendritic	O
cells	O
(	O
DCs	O
)	O
both	O
initiate	O
and	O
contribute	O
to	O
innate	O
immune	O
responses	O
to	O
bacteria	O
.	O

However	O
,	O
much	O
less	O
is	O
known	O
about	O
the	O
coordinated	O
regulation	O
of	O
innate	O
immune	O
responses	O
between	O
GECs	O
and	O
immune	O
cells	O
,	O
particularly	O
DCs	O
in	O
the	O
oral	O
cavity	O
.	O

The	O
present	O
study	O
was	O
conducted	O
to	O
investigate	O
whether	O
their	O
responses	O
are	O
coordinated	O
and	O
are	O
bacteria	O
-	O
specific	O
in	O
the	O
oral	O
cavity	O
.	O

The	O
beta	O
-	O
defensin	O
antimicrobial	O
peptides	O
hBD1	O
,	O
hBD2	O
and	O
hBD3	O
were	O
expressed	O
by	O
immature	O
DCs	O
as	O
well	O
as	O
gingival	O
epithelial	O
cells	O
(	O
GECs	O
)	O
.	O

HBD1	O
,	O
hBD2	O
and	O
hBD3	O
are	O
upregulated	O
in	O
DCs	O
while	O
hBD2	O
and	O
hBD3	O
are	O
upregulated	O
in	O
GECs	O
in	O
response	O
to	O
bacterial	O
stimulation	O
.	O

Responses	O
of	O
both	O
cell	O
types	O
were	O
bacteria	O
-	O
specific	O
,	O
as	O
demonstrated	O
by	O
distinctive	O
profiles	O
of	O
hBDs	O
mRNA	O
expression	O
and	O
secreted	O
cytokines	O
and	O
chemokines	O
in	O
response	O
to	O
cell	O
wall	O
preparations	O
of	O
various	O
bacteria	O
of	O
different	O
pathogenicity	O
:	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Actinomyces	B-bacteria
naeslundii	I-bacteria
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
.	O

The	O
regulation	O
of	O
expression	O
of	O
hBD2	O
,	O
IL	O
-	O
8	O
,	O
CXCL2	O
/	O
GRObeta	O
and	O
CCL	O
-	O
20	O
/	O
MIP3alpha	O
by	O
GECs	O
was	O
greatly	O
enhanced	O
by	O
conditioned	O
medium	O
from	O
bacterially	O
activated	O
DCs	O
.	O

This	O
enhancement	O
was	O
primarily	O
mediated	O
via	O
IL	O
-	O
1beta	O
,	O
since	O
induction	O
was	O
largely	O
attenuated	O
by	O
IL	O
-	O
1	O
receptor	O
antagonist	O
.	O

In	O
addition	O
,	O
the	O
defensins	O
influence	O
DCs	O
by	O
eliciting	O
differential	O
cytokine	O
and	O
chemokine	O
secretion	O
.	O

HBD2	O
significantly	O
induced	O
IL	O
-	O
6	O
,	O
while	O
hBD3	O
induced	O
MCP	O
-	O
1	O
to	O
approximately	O
the	O
same	O
extent	O
as	O
LPS	O
,	O
suggesting	O
a	O
unique	O
role	O
in	O
immune	O
responses	O
.	O

The	O
results	O
suggest	O
that	O
cytokines	O
,	O
chemokines	O
and	O
beta	O
-	O
defensins	O
are	O
involved	O
in	O
interaction	O
of	O
these	O
two	O
cell	O
types	O
,	O
and	O
the	O
responses	O
are	O
bacteria	O
-	O
specific	O
.	O

Differential	O
and	O
coordinated	O
regulation	O
between	O
GECs	O
and	O
DCs	O
may	O
be	O
important	O
in	O
regulation	O
of	O
innate	O
immune	O
homeostasis	O
and	O
response	O
to	O
pathogens	O
in	O
the	O
oral	O
cavity	O
.	O

The	O
human	O
mouth	O
is	O
host	O
to	O
a	O
diverse	O
collection	O
of	O
microorganisms	O
including	O
bacteria	O
,	O
viruses	O
,	O
fungi	O
and	O
protozoa	O
.	O

Recent	O
advances	O
using	O
molecular	O
methods	O
for	O
the	O
analysis	O
of	O
complex	O
bacterial	O
communities	O
have	O
demonstrated	O
the	O
richness	O
of	O
the	O
oral	O
bacterial	O
biota	O
and	O
the	O
presence	O
of	O
numerous	O
previously	O
undescribed	O
lineages	O
.	O

Dental	O
plaque	O
forms	O
in	O
a	O
structured	O
way	O
with	O
pioneer	O
species	O
able	O
to	O
colonise	O
pellicle	O
-	O
coated	O
enamel	O
followed	O
by	O
secondary	O
plaque	O
formers	O
such	O
as	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
that	O
have	O
the	O
capability	O
of	O
coaggregating	O
with	O
a	O
range	O
of	O
other	O
genera	O
and	O
species	O
.	O

The	O
mature	O
plaque	O
biofilm	O
has	O
many	O
features	O
of	O
multicellular	O
organisms	O
with	O
the	O
constituent	O
organisms	O
cooperating	O
to	O
make	O
nutrients	O
available	O
and	O
resist	O
environmental	O
stresses	O
,	O
and	O
communicating	O
to	O
regulate	O
their	O
overall	O
numbers	O
.	O

Control	O
of	O
the	O
oral	O
microbiota	O
to	O
prevent	O
disease	O
has	O
conventionally	O
been	O
by	O
mechanical	O
means	O
augmented	O
with	O
toothpastes	O
and	O
mouthrinses	O
,	O
but	O
improved	O
knowledge	O
of	O
oral	O
microbial	O
ecology	O
is	O
allowing	O
the	O
development	O
of	O
pre	O
and	O
pro	O
-	O
biotic	O
approaches	O
.	O

Other	O
possibilities	O
include	O
interference	O
with	O
the	O
plaque	O
formation	O
process	O
and	O
the	O
perturbation	O
of	O
bacterial	O
communication	O
networks	O
.	O

We	O
aimed	O
to	O
determine	O
oral	O
microflora	O
of	O
patients	O
on	O
long	O
-	O
term	O
hemodialysis	O
and	O
kidney	O
transplant	O
recipients	O
,	O
and	O
to	O
compare	O
them	O
with	O
individuals	O
without	O
kidney	O
disease	O
.	O

We	O
studied	O
on	O
3	O
groups	O
including	O
patients	O
on	O
at	O
least	O
6	O
months	O
of	O
hemodialysis	O
,	O
kidney	O
transplant	O
recipients	O
for	O
more	O
than	O
2	O
years	O
,	O
and	O
controls	O
with	O
a	O
normal	O
kidney	O
function	O
.	O

Staining	O
and	O
culture	O
were	O
applied	O
for	O
samples	O
from	O
the	O
dorsum	O
of	O
the	O
tongue	O
and	O
the	O
oral	O
floor	O
in	O
order	O
to	O
detect	O
aerobic	O
and	O
anaerobic	O
bacteria	O
and	O
Candida	O
.	O

The	O
participants	O
were	O
49	O
patients	O
on	O
hemodialysis	O
,	O
50	O
kidney	O
transplant	O
recipients	O
,	O
and	O
50	O
volunteers	O
in	O
the	O
control	O
group	O
.	O

The	O
abundance	O
of	O
Candida	O
was	O
significantly	O
higher	O
in	O
the	O
hemodialysis	O
and	O
transplant	O
groups	O
compared	O
with	O
the	O
control	O
group	O
.	O

The	O
mean	O
of	O
various	O
microorganisms	O
was	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
hemodialysis	O
group	O
than	O
the	O
control	O
group	O
(	O
P	O
=	O
.	O
03	O
)	O
;	O
however	O
,	O
the	O
frequency	O
of	O
these	O
microorganisms	O
in	O
the	O
transplant	O
group	O
was	O
lower	O
than	O
that	O
in	O
the	O
hemodialysis	O
group	O
.	O

Adjusting	O
for	O
confounding	O
factors	O
,	O
the	O
odds	O
of	O
having	O
Candida	O
in	O
the	O
hemodialysis	O
and	O
transplant	O
groups	O
were	O
3	O
.	O
54	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
21	O
to	O
10	O
.	O
41	O
)	O
and	O
3	O
.	O
49	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
27	O
to	O
9	O
.	O
18	O
)	O
times	O
higher	O
compared	O
to	O
the	O
control	O
group	O
,	O
respectively	O
.	O

Hemodialysis	O
and	O
kidney	O
transplantation	O
could	O
affect	O
oral	O
microflora	O
.	O

Candida	O
was	O
significantly	O
more	O
frequent	O
in	O
these	O
patients	O
compared	O
to	O
healthy	O
adults	O
.	O

Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Lactobacilli	B-bacteria
,	O
Porphyromonas	B-bacteria
,	O
and	O
Candida	O
is	O
seen	O
slightly	O
less	O
frequently	O
after	O
kidney	O
transplantation	O
,	O
which	O
might	O
be	O
in	O
favor	O
of	O
promising	O
effects	O
of	O
kidney	O
transplantation	O
on	O
oral	O
microflora	O
.	O

Within	O
the	O
same	O
human	O
gastrointestinal	O
tract	O
,	O
substantial	O
differences	O
in	O
the	O
bacterial	O
species	O
that	O
inhabit	O
oral	O
cavity	O
and	O
intestinal	O
tract	O
have	O
been	O
noted	O
.	O

Previous	O
research	O
primarily	O
attributed	O
the	O
differences	O
to	O
the	O
influences	O
of	O
host	O
environments	O
and	O
nutritional	O
availabilities	O
(	O
`	O
`	O
host	O
habitat	O
'	O
'	O
effect	O
)	O
.	O

Our	O
recent	O
study	O
indicated	O
that	O
,	O
other	O
than	O
the	O
host	O
habitat	O
effect	O
,	O
an	O
existing	O
microbial	O
community	O
could	O
impose	O
a	O
selective	O
pressure	O
on	O
incoming	O
foreign	O
bacterial	O
species	O
independent	O
of	O
host	O
-	O
mediated	O
selection	O
(	O
`	O
`	O
community	O
selection	O
'	O
'	O
effect	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
in	O
vitro	O
microbial	O
floras	O
representing	O
microorganisms	O
that	O
inhabit	O
the	O
oral	O
cavities	O
and	O
intestinal	O
tract	O
of	O
mice	O
in	O
combination	O
with	O
Escherichia	B-bacteria
coli	I-bacteria
as	O
a	O
model	O
intestinal	O
bacterium	O
and	O
demonstrated	O
that	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
displays	O
a	O
striking	O
community	O
preference	O
.	O

It	O
thrived	O
when	O
introduced	O
into	O
the	O
intestinal	O
microbial	O
community	O
and	O
survived	O
poorly	O
in	O
the	O
microbial	O
flora	O
of	O
foreign	O
origin	O
(	O
oral	O
community	O
)	O
.	O

A	O
more	O
detailed	O
examination	O
of	O
this	O
phenomenon	O
showed	O
that	O
the	O
oral	O
community	O
produced	O
oxygen	O
-	O
free	O
radicals	O
in	O
the	O
presence	O
of	O
wild	O
-	O
type	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
while	O
mutants	O
deficient	O
in	O
lipopolysaccharides	O
(	O
LPS	O
)	O
did	O
not	O
trigger	O
significant	O
production	O
of	O
these	O
cell	O
-	O
damaging	O
agents	O
.	O

Furthermore	O
,	O
mutants	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
defective	O
in	O
the	O
oxidative	O
stress	O
response	O
experienced	O
a	O
more	O
drastic	O
reduction	O
in	O
viability	O
when	O
cocultivated	O
with	O
the	O
oral	O
flora	O
,	O
while	O
the	O
exogenous	O
addition	O
of	O
the	O
antioxidant	O
vitamin	O
C	O
was	O
able	O
to	O
rescue	O
it	O
.	O

We	O
concluded	O
that	O
the	O
oral	O
-	O
derived	O
microbial	O
community	O
senses	O
the	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
LPS	O
and	O
kills	O
the	O
bacterium	O
with	O
oxygen	O
-	O
free	O
radicals	O
.	O

This	O
study	O
reveals	O
a	O
new	O
mechanism	O
of	O
community	O
invasion	O
resistance	O
employed	O
by	O
established	O
microflora	O
to	O
defend	O
their	O
domains	O
.	O

Dental	O
plaque	O
is	O
the	O
biofilm	O
found	O
naturally	O
on	O
teeth	O
.	O

Dental	O
plaque	O
is	O
also	O
implicated	O
in	O
dental	O
caries	O
,	O
which	O
is	O
associated	O
with	O
shifts	O
in	O
the	O
microbial	O
balance	O
of	O
the	O
biofilm	O
resulting	O
in	O
increased	O
proportions	O
of	O
acid	O
producing	O
and	O
acid	O
tolerating	O
bacteria	O
,	O
especially	O
(	O
but	O
not	O
exclusively	O
)	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
lactobacilli	B-bacteria
.	O

The	O
regular	O
intake	O
of	O
fermentable	O
dietary	O
sugars	O
,	O
or	O
impaired	O
saliva	O
flow	O
,	O
produces	O
persistent	O
conditions	O
of	O
low	O
pH	O
within	O
the	O
biofilm	O
,	O
which	O
selects	O
for	O
these	O
cariogenic	O
bacteria	O
.	O

Clinicians	O
should	O
prevent	O
this	O
disruption	O
to	O
the	O
natural	O
microbial	O
balance	O
of	O
the	O
biofilm	O
(	O
relevant	O
approaches	O
are	O
described	O
)	O
rather	O
than	O
merely	O
treating	O
its	O
consequences	O
by	O
restoring	O
cavities	O
.	O

This	O
study	O
investigated	O
the	O
antibacterial	O
effect	O
of	O
a	O
resin	O
composite	O
matrix	O
with	O
or	O
without	O
incorporated	O
triclosan	O
(	O
0	O
.	O
3	O
wt	O
%	O
)	O
on	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Actinomyces	B-bacteria
viscosus	I-bacteria
and	O
Lactobacillus	B-bacteria
casei	I-bacteria
.	O

In	O
the	O
quantitative	O
assay	O
,	O
bacterial	O
suspensions	O
were	O
filled	O
into	O
20	O
-	O
mul	O
cavities	O
within	O
temporary	O
restorative	O
resins	O
.	O

After	O
0	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
24	O
and	O
48	O
h	O
of	O
incubation	O
,	O
the	O
suspensions	O
were	O
removed	O
from	O
the	O
restoratives	O
and	O
the	O
numbers	O
of	O
viable	O
bacteria	O
were	O
determined	O
.	O

Bacterial	O
suspensions	O
incubated	O
without	O
restoratives	O
served	O
as	O
the	O
controls	O
.	O

Ten	O
replicates	O
were	O
carried	O
out	O
for	O
each	O
experiment	O
.	O

The	O
resin	O
composite	O
containing	O
triclosan	O
demonstrated	O
variable	O
degrees	O
of	O
antibacterial	O
activity	O
against	O
the	O
microorganisms	O
,	O
revealing	O
a	O
significant	O
inhibitory	O
effect	O
on	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
within	O
12	O
h	O
compared	O
to	O
the	O
control	O
.	O

The	O
viable	O
counts	O
of	O
A	B-bacteria
.	I-bacteria
viscosus	I-bacteria
significantly	O
decreased	O
after	O
24	O
h	O
.	O

A	O
significant	O
reduction	O
of	O
L	B-bacteria
.	I-bacteria
casei	I-bacteria
was	O
observed	O
after	O
48	O
h	O
.	O
The	O
unloaded	O
resin	O
composite	O
did	O
not	O
reveal	O
a	O
marked	O
antibacterial	O
effect	O
.	O

The	O
resin	O
composite	O
loaded	O
with	O
triclosan	O
might	O
be	O
beneficial	O
in	O
preventing	O
cavity	O
contamination	O
and	O
minimizing	O
the	O
risk	O
of	O
pulpal	O
irritation	O
in	O
the	O
short	O
-	O
term	O
.	O

The	O
oral	O
cavity	O
can	O
act	O
as	O
a	O
reservoir	O
of	O
certain	O
pathogens	O
that	O
can	O
cause	O
systemic	O
infections	O
.	O

The	O
periodontal	O
pocket	O
is	O
an	O
ecological	O
niche	O
appropriate	O
for	O
hosting	O
microorganisms	O
that	O
could	O
act	O
as	O
opportunistic	O
pathogens	O
.	O

The	O
ability	O
of	O
Staphylococcus	B-bacteria
spp	I-bacteria
and	O
Candida	O
spp	O
to	O
form	O
a	O
biofilm	O
and	O
live	O
within	O
certain	O
niches	O
allows	O
them	O
to	O
develop	O
mechanisms	O
that	O
increase	O
persistence	O
,	O
such	O
as	O
the	O
evasion	O
of	O
host	O
defenses	O
and	O
antibiotic	O
efficacy	O
.	O

These	O
microorganisms	O
can	O
easily	O
be	O
or	O
become	O
resistant	O
to	O
antibiotics	O
and	O
lead	O
to	O
superinfection	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
assess	O
the	O
presence	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
and	O
Staphylococcus	B-bacteria
spp	I-bacteria
in	O
biofilm	O
in	O
subgingival	O
plaque	O
and	O
oral	O
cavity	O
of	O
individuals	O
with	O
gingival	O
-	O
periodontal	O
disease	O
,	O
to	O
identify	O
isolates	O
and	O
the	O
relationship	O
with	O
Candida	O
spp	O
.	O

The	O
study	O
included	O
eighty	O
-	O
two	O
patients	O
,	O
aged	O
18	O
-	O
70	O
years	O
with	O
periodontal	O
disease	O
and	O
at	O
least	O
two	O
sites	O
with	O
probing	O
depth	O
>	O
or	O
=	O
3	O
mm	O
.	O

Participants	O
'	O
data	O
were	O
evaluated	O
individually	O
.	O

Subgingival	O
biofilm	O
samples	O
were	O
obtained	O
using	O
Gracey	O
curettes	O
7	O
/	O
8	O
,	O
after	O
supragingival	O
biofilm	O
removal	O
,	O
and	O
a	O
sample	O
from	O
the	O
oral	O
cavity	O
(	O
buccal	O
mucosa	O
,	O
tongue	O
and	O
cheek	O
mucosa	O
)	O
by	O
sterile	O
swab	O
.	O

Of	O
all	O
the	O
patients	O
studied	O
,	O
42	O
.	O
7	O
%	O
exhibited	O
Staphylococcus	B-bacteria
spp	I-bacteria
in	O
the	O
periodontal	O
pocket	O
and	O
69	O
.	O
5	O
%	O
in	O
the	O
oral	O
cavity	O
while	O
25	O
.	O
6	O
%	O
exhibited	O
Candida	O
spp	O
in	O
the	O
periodontal	O
pocket	O
and	O
42	O
.	O
7	O
%	O
in	O
the	O
oral	O
cavity	O
.	O

However	O
,	O
13	O
.	O
4	O
%	O
had	O
both	O
microorganisms	O
in	O
the	O
periodontal	O
pocket	O
and	O
36	O
.	O
6	O
%	O
in	O
the	O
oral	O
cavity	O
.	O

The	O
prevalence	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
was	O
13	O
.	O
4	O
%	O
in	O
the	O
periodontal	O
pocket	O
and	O
15	O
.	O
8	O
%	O
in	O
the	O
oral	O
cavity	O
.	O

Candida	O
albicans	O
was	O
the	O
most	O
prevalent	O
yeast	O
in	O
the	O
periodontal	O
pocket	O
(	O
76	O
.	O
2	O
%	O
)	O
and	O
in	O
the	O
oral	O
cavity	O
(	O
63	O
.	O
0	O
%	O
)	O
.	O

The	O
human	O
oral	O
cavity	O
contains	O
a	O
number	O
of	O
different	O
habitats	O
,	O
including	O
the	O
teeth	O
,	O
gingival	O
sulcus	O
,	O
tongue	O
,	O
cheeks	O
,	O
hard	O
and	O
soft	O
palates	O
,	O
and	O
tonsils	O
,	O
which	O
are	O
colonized	O
by	O
bacteria	O
.	O

The	O
oral	O
microbiome	O
is	O
comprised	O
of	O
over	O
600	O
prevalent	O
taxa	O
at	O
the	O
species	O
level	O
,	O
with	O
distinct	O
subsets	O
predominating	O
at	O
different	O
habitats	O
.	O

The	O
oral	O
microbiome	O
has	O
been	O
extensively	O
characterized	O
by	O
cultivation	O
and	O
culture	O
-	O
independent	O
molecular	O
methods	O
such	O
as	O
16S	O
rRNA	O
cloning	O
.	O

Unfortunately	O
,	O
the	O
vast	O
majority	O
of	O
unnamed	O
oral	O
taxa	O
are	O
referenced	O
by	O
clone	O
numbers	O
or	O
16S	O
rRNA	O
GenBank	O
accession	O
numbers	O
,	O
often	O
without	O
taxonomic	O
anchors	O
.	O

The	O
first	O
aim	O
of	O
this	O
research	O
was	O
to	O
collect	O
16S	O
rRNA	O
gene	O
sequences	O
into	O
a	O
curated	O
phylogeny	O
-	O
based	O
database	O
,	O
the	O
Human	O
Oral	O
Microbiome	O
Database	O
(	O
HOMD	O
)	O
,	O
and	O
make	O
it	O
web	O
accessible	O
(	O
www	O
.	O
homd	O
.	O
org	O
)	O
.	O

The	O
HOMD	O
includes	O
619	O
taxa	O
in	O
13	O
phyla	O
,	O
as	O
follows	O
:	O
Actinobacteria	B-bacteria
,	O
Bacteroidetes	B-bacteria
,	O
Chlamydiae	B-bacteria
,	O
Chloroflexi	B-bacteria
,	O
Euryarchaeota	B-bacteria
,	O
Firmicutes	B-bacteria
,	O
Fusobacteria	B-bacteria
,	O
Proteobacteria	B-bacteria
,	O
Spirochaetes	B-bacteria
,	O
SR1	B-bacteria
,	O
Synergistetes	B-bacteria
,	O
Tenericutes	B-bacteria
,	O
and	O
TM7	B-bacteria
.	O

The	O
second	O
aim	O
was	O
to	O
analyze	O
36	O
,	O
043	O
16S	O
rRNA	O
gene	O
clones	O
isolated	O
from	O
studies	O
of	O
the	O
oral	O
microbiota	O
to	O
determine	O
the	O
relative	O
abundance	O
of	O
taxa	O
and	O
identify	O
novel	O
candidate	O
taxa	O
.	O

The	O
analysis	O
identified	O
1	O
,	O
179	O
taxa	O
,	O
of	O
which	O
24	O
%	O
were	O
named	O
,	O
8	O
%	O
were	O
cultivated	O
but	O
unnamed	O
,	O
and	O
68	O
%	O
were	O
uncultivated	O
phylotypes	O
.	O

Upon	O
validation	O
,	O
434	O
novel	O
,	O
nonsingleton	O
taxa	O
will	O
be	O
added	O
to	O
the	O
HOMD	O
.	O

The	O
number	O
of	O
taxa	O
needed	O
to	O
account	O
for	O
90	O
%	O
,	O
95	O
%	O
,	O
or	O
99	O
%	O
of	O
the	O
clones	O
examined	O
is	O
259	O
,	O
413	O
,	O
and	O
875	O
,	O
respectively	O
.	O

The	O
HOMD	O
is	O
the	O
first	O
curated	O
description	O
of	O
a	O
human	O
-	O
associated	O
microbiome	O
and	O
provides	O
tools	O
for	O
use	O
in	O
understanding	O
the	O
role	O
of	O
the	O
microbiome	O
in	O
health	O
and	O
disease	O
.	O

To	O
characterize	O
the	O
normal	O
bacterial	O
flora	O
and	O
evaluate	O
the	O
presence	O
of	O
periodontopathogenic	O
bacteria	O
around	O
dental	O
implants	O
and	O
to	O
correlate	O
them	O
with	O
the	O
periodontal	O
flora	O
or	O
,	O
in	O
completely	O
edentulous	O
patients	O
,	O
the	O
alveolar	O
gingival	O
flora	O
.	O

Clinical	O
and	O
radiographic	O
parameters	O
were	O
recorded	O
to	O
exclude	O
peri	O
-	O
implantitis	O
in	O
34	O
partially	O
edentulous	O
and	O
19	O
completely	O
edentulous	O
patients	O
.	O

Partially	O
edentulous	O
patients	O
were	O
subdivided	O
into	O
two	O
subgroups	O
based	O
on	O
the	O
depth	O
of	O
the	O
periodontal	O
pocket	O
:	O
<	O
/	O
=	O
4	O
mm	O
(	O
n	O
=	O
19	O
)	O
and	O
>	O
4	O
mm	O
(	O
n	O
=	O
15	O
)	O
.	O

Microbial	O
samples	O
were	O
collected	O
from	O
peri	O
-	O
implant	O
sulci	O
,	O
the	O
deepest	O
periodontal	O
sulci	O
,	O
and	O
,	O
for	O
completely	O
edentulous	O
patients	O
,	O
from	O
the	O
alveolar	O
gingiva	O
.	O

Predominant	O
aerobic	O
bacteria	O
were	O
determined	O
by	O
microbiologic	O
culturing	O
,	O
and	O
multiplex	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
detect	O
five	O
periodontopathogenic	O
bacteria	O
:	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
and	O
Actinobacillus	B-bacteria
actinomycetemcomitans	I-bacteria
.	O

In	O
all	O
the	O
examined	O
patients	O
,	O
oral	O
streptococci	B-bacteria
were	O
the	O
most	O
frequent	O
aerobic	O
peri	O
-	O
implant	O
bacteria	O
.	O

The	O
frequency	O
of	O
four	O
periodontopathogenic	O
bacteria	O
in	O
tooth	O
sulci	O
(	O
A	B-bacteria
actino	I-bacteria
?	I-bacteria
mycetemcomitans	I-bacteria
,	O
P	B-bacteria
gingivalis	I-bacteria
,	O
T	B-bacteria
forsythensis	I-bacteria
,	O
T	B-bacteria
denticola	I-bacteria
)	O
was	O
significantly	O
higher	O
around	O
natural	O
teeth	O
with	O
deeper	O
periodontal	O
pockets	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
the	O
same	O
bacteria	O
in	O
peri	O
-	O
implant	O
sulci	O
in	O
the	O
two	O
partially	O
edentulous	O
subgroups	O
.	O

In	O
contrast	O
,	O
there	O
were	O
no	O
such	O
bacteria	O
in	O
the	O
peri	O
-	O
implant	O
sulci	O
or	O
the	O
alveolar	O
gingiva	O
of	O
completely	O
edentulous	O
patients	O
.	O

In	O
healthy	O
peri	O
-	O
implant	O
sulci	O
,	O
oral	O
streptococci	B-bacteria
constitute	O
the	O
predominant	O
bacterial	O
flora	O
.	O

In	O
partially	O
edentulous	O
patients	O
four	O
periodontopathogenic	O
bacteria	O
were	O
detected	O
around	O
implants	O
,	O
and	O
none	O
of	O
these	O
bacteria	O
were	O
found	O
around	O
implants	O
in	O
completely	O
edentulous	O
patients	O
.	O

The	O
antibacterial	O
properties	O
of	O
self	O
-	O
etching	O
adhesive	O
systems	O
constitute	O
an	O
important	O
issue	O
in	O
operative	O
dentistry	O
,	O
since	O
viable	O
bacteria	O
can	O
still	O
be	O
present	O
after	O
cavity	O
preparation	O
.	O

The	O
current	O
study	O
evaluated	O
the	O
antibacterial	O
activity	O
of	O
five	O
one	O
-	O
step	O
self	O
-	O
etching	O
adhesives	O
(	O
SEAs	O
)	O
and	O
four	O
self	O
-	O
etching	O
primers	O
(	O
SEPs	O
)	O
against	O
oral	O
streptococci	B-bacteria
.	O

Clearfil	O
S3	O
(	O
S3	O
)	O
,	O
One	O
-	O
Up	O
Bond	O
F	O
Plus	O
(	O
OU	O
)	O
,	O
Futurabond	O
NR	O
(	O
FB	O
)	O
,	O
GBond	O
(	O
GB	O
)	O
,	O
Xeno	O
IV	O
(	O
X4	O
)	O
,	O
Clearfil	O
SE	O
Bond	O
(	O
SE	O
)	O
,	O
Clearfil	O
Protect	O
Bond	O
(	O
PB	O
)	O
,	O
Adper	O
SE	O
Plus	O
(	O
AS	O
)	O
and	O
AdheSE	O
(	O
AD	O
)	O
were	O
tested	O
for	O
antibacterial	O
activity	O
against	O
five	O
streptococci	B-bacteria
species	I-bacteria
:	O
S	B-bacteria
oralis	I-bacteria
,	O
S	B-bacteria
sanguinis	I-bacteria
,	O
S	B-bacteria
cricetus	I-bacteria
,	O
S	B-bacteria
mutans	I-bacteria
and	O
S	B-bacteria
sobrinus	I-bacteria
.	O

Chlorhexidine	O
(	O
0	O
.	O
12	O
%	O
)	O
and	O
phosphoric	O
acid	O
(	O
37	O
%	O
)	O
gel	O
were	O
used	O
as	O
control	O
.	O

The	O
agar	O
diffusion	O
test	O
method	O
was	O
used	O
.	O

Plates	O
containing	O
BHI	O
agar	O
and	O
300	O
uL	O
of	O
bacterial	O
cell	O
suspension	O
(	O
0	O
.	O
5	O
MacFarland	O
)	O
were	O
prepared	O
.	O

Holes	O
6	O
mm	O
in	O
diameter	O
were	O
made	O
and	O
partially	O
filled	O
with	O
bacteriological	O
agar	O
.	O

Then	O
,	O
10	O
uL	O
of	O
each	O
SEA	O
or	O
SEP	O
was	O
dropped	O
and	O
the	O
plates	O
were	O
incubated	O
under	O
microaerophilic	O
atmosphere	O
at	O
37	O
degrees	O
C	O
for	O
48	O
hours	O
and	O
the	O
diameter	O
of	O
each	O
halo	O
was	O
registered	O
.	O

The	O
results	O
were	O
analyzed	O
by	O
two	O
-	O
way	O
ANOVA	O
and	O
Tukey	O
test	O
.	O

PB	O
exhibited	O
the	O
most	O
effective	O
antibacterial	O
activity	O
against	O
oral	O
streptococci	B-bacteria
.	O

The	O
performances	O
of	O
SE	O
and	O
FB	O
were	O
similar	O
or	O
better	O
than	O
chlorhexidine	O
for	O
all	O
bacteria	O
.	O

S3	O
,	O
X4	O
,	O
AS	O
,	O
AD	O
,	O
OU	O
and	O
GB	O
showed	O
significantly	O
lower	O
inhibition	O
values	O
.	O

Among	O
the	O
species	O
tested	O
,	O
S	B-bacteria
oralis	I-bacteria
was	O
the	O
most	O
sensitive	O
to	O
all	O
self	O
-	O
etching	O
adhesive	O
systems	O
;	O
on	O
the	O
other	O
hand	O
,	O
S	B-bacteria
cricetus	I-bacteria
,	O
S	B-bacteria
mutans	I-bacteria
and	O
S	B-bacteria
sobrinus	I-bacteria
were	O
more	O
resistant	O
.	O

Among	O
the	O
self	O
-	O
etching	O
adhesive	O
systems	O
evaluated	O
,	O
Clearfil	O
Protect	O
Bond	O
exhibited	O
the	O
most	O
effective	O
antibacterial	O
activity	O
against	O
oral	O
streptococci	B-bacteria
.	O

Colonization	O
of	O
periodontopathic	O
bacteria	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
systemic	O
diseases	O
.	O

However	O
,	O
few	O
studies	O
have	O
investigated	O
the	O
relationships	O
between	O
oral	O
status	O
factors	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HR	O
-	O
QOL	O
)	O
and	O
the	O
prevalence	O
of	O
such	O
bacteria	O
in	O
elderly	O
individuals	O
.	O

This	O
study	O
investigated	O
the	O
prevalence	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
,	O
Treponema	B-bacteria
denticola	I-bacteria
and	O
Tannerella	B-bacteria
forsythia	I-bacteria
in	O
165	O
community	O
-	O
dwelling	O
functionally	O
independent	O
85	O
-	O
year	O
-	O
old	O
Japanese	O
individuals	O
(	O
93	O
dentate	O
,	O
72	O
edentulous	O
)	O
and	O
the	O
relationship	O
to	O
oral	O
status	O
,	O
including	O
oral	O
malodour	O
and	O
HR	O
-	O
QOL	O
.	O

All	O
four	O
of	O
the	O
studied	O
periodontopathic	O
bacteria	O
were	O
found	O
more	O
frequently	O
in	O
tongue	O
coating	O
samples	O
from	O
dentate	O
than	O
edentulous	O
subjects	O
,	O
and	O
the	O
prevalence	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
and	O
Treponema	B-bacteria
denticola	I-bacteria
was	O
significantly	O
related	O
to	O
the	O
number	O
of	O
teeth	O
with	O
a	O
periodontal	O
pocket	O
depth	O
>	O
/	O
=	O
4	O
mm	O
.	O

These	O
results	O
suggest	O
the	O
existence	O
of	O
a	O
stable	O
circulation	O
of	O
periodontopathic	O
bacteria	O
between	O
the	O
gingival	O
sulcus	O
and	O
tongue	O
coating	O
over	O
time	O
with	O
teeth	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
teeth	O
with	O
a	O
deep	O
pocket	O
and	O
colonization	O
of	O
Treponema	B-bacteria
denticola	I-bacteria
were	O
positively	O
related	O
to	O
the	O
level	O
of	O
CH	O
(	O
3	O
)	O
SH	O
,	O
whilst	O
the	O
number	O
of	O
present	O
teeth	O
contributed	O
positively	O
to	O
HR	O
-	O
QOL	O
,	O
especially	O
with	O
regard	O
to	O
mental	O
health	O
.	O

In	O
conclusion	O
,	O
as	O
the	O
dentate	O
state	O
can	O
retain	O
colonization	O
of	O
periodontopathic	O
pathogens	O
in	O
the	O
oral	O
cavity	O
,	O
both	O
periodontal	O
treatment	O
and	O
tongue	O
care	O
are	O
important	O
for	O
maintaining	O
a	O
healthy	O
oral	O
status	O
in	O
the	O
elderly	O
,	O
and	O
possibly	O
result	O
in	O
avoidance	O
of	O
risk	O
for	O
tooth	O
loss	O
and	O
decline	O
in	O
HR	O
-	O
QOL	O
,	O
as	O
well	O
as	O
protecting	O
from	O
systemic	O
diseases	O
.	O

Beneficial	O
findings	O
concerning	O
probiotics	O
are	O
increasing	O
day	O
by	O
day	O
.	O

However	O
,	O
one	O
of	O
the	O
most	O
important	O
parameter	O
which	O
affects	O
the	O
probiotic	O
activity	O
of	O
a	O
microorganism	O
is	O
its	O
survival	O
during	O
the	O
gastroduodenal	O
transit	O
.	O

Some	O
microencapsulation	O
techniques	O
could	O
be	O
applied	O
to	O
bacterial	O
cells	O
to	O
improve	O
this	O
parameter	O
.	O

A	O
comparison	O
between	O
the	O
intestinal	O
colonization	O
by	O
microencapsulated	O
bacteria	O
and	O
the	O
same	O
not	O
microencapsulated	O
strains	O
has	O
been	O
conducted	O
in	O
a	O
double	O
blind	O
,	O
randomized	O
,	O
cross	O
-	O
over	O
study	O
.	O

The	O
study	O
(	O
April	O
to	O
July	O
2005	O
)	O
involved	O
44	O
healthy	O
volunteers	O
.	O

In	O
particular	O
,	O
participants	O
were	O
divided	O
into	O
2	O
groups	O
:	O
group	O
A	O
(	O
21	O
participants	O
)	O
received	O
a	O
mix	O
of	O
probiotic	O
strains	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
LP01	I-bacteria
(	O
LMG	B-bacteria
P	I-bacteria
-	I-bacteria
21021	I-bacteria
)	O
and	O
Bifidobacterium	B-bacteria
breve	I-bacteria
BR03	I-bacteria
(	O
DSM	B-bacteria
16604	I-bacteria
)	O
in	O
an	O
uncoated	O
form	O
,	O
group	O
B	O
(	O
23	O
participants	O
)	O
was	O
given	O
the	O
same	O
strains	O
microencapsulated	O
with	O
a	O
gastroresistant	O
material	O
.	O

The	O
not	O
microencapsulated	O
strains	O
were	O
administered	O
at	O
5	O
x	O
10	O
(	O
9	O
)	O
colony	O
forming	O
units	O
/	O
strain	O
/	O
d	O
for	O
21	O
days	O
,	O
whereas	O
the	O
microencapsulated	O
bacteria	O
were	O
given	O
at	O
1	O
x	O
10	O
(	O
9	O
)	O
colony	O
forming	O
units	O
/	O
strain	O
/	O
d	O
for	O
21	O
days	O
.	O

At	O
the	O
end	O
of	O
the	O
first	O
period	O
of	O
treatment	O
with	O
probiotics	O
a	O
3	O
weeks	O
washout	O
phase	O
has	O
been	O
included	O
in	O
the	O
study	O
protocol	O
.	O

At	O
the	O
end	O
of	O
the	O
washout	O
period	O
the	O
groups	O
were	O
crossed	O
:	O
in	O
detail	O
,	O
group	O
A	O
had	O
the	O
microencapsulated	O
and	O
group	O
B	O
the	O
uncoated	O
bacteria	O
.	O

The	O
administered	O
amounts	O
of	O
each	O
strain	O
were	O
the	O
same	O
as	O
the	O
first	O
treatment	O
.	O

The	O
quantitative	O
evaluation	O
of	O
intestinal	O
colonization	O
by	O
strains	O
microencapsulated	O
or	O
not	O
microencapsulated	O
was	O
made	O
by	O
fecal	O
samples	O
examination	O
at	O
the	O
beginning	O
of	O
the	O
clinical	O
trial	O
,	O
after	O
10	O
and	O
21	O
days	O
of	O
each	O
treatment	O
period	O
.	O

In	O
particular	O
,	O
fecal	O
heterofermentative	B-bacteria
Lactobacilli	I-bacteria
and	O
Bifidobacteria	B-bacteria
have	O
been	O
counted	O
.	O

A	O
statistically	O
significant	O
increase	O
in	O
the	O
fecal	O
amounts	O
of	O
Lactobacilli	B-bacteria
and	O
Bifidobacteria	B-bacteria
was	O
recorded	O
in	O
both	O
groups	O
at	O
the	O
end	O
of	O
each	O
treatment	O
compared	O
with	O
d0	O
or	O
d42	O
(	O
P	O
<	O
0	O
.	O
0001	O
and	O
P	O
<	O
0	O
.	O
0001	O
at	O
d21	O
,	O
P	O
<	O
0	O
.	O
0001	O
and	O
P	O
<	O
0	O
.	O
0001	O
at	O
d63	O
for	O
Lactobacilli	B-bacteria
and	O
Bifidobacteria	B-bacteria
,	O
respectively	O
)	O
,	O
confirming	O
the	O
ability	O
of	O
the	O
2	O
strains	O
to	O
colonize	O
the	O
human	O
gut	O
,	O
either	O
in	O
a	O
gastroprotected	O
form	O
or	O
not	O
.	O

Participants	O
treated	O
with	O
the	O
microencapsulated	O
bacteria	O
reported	O
a	O
kinetics	O
of	O
intestinal	O
colonization	O
quite	O
similar	O
to	O
participants	O
who	O
received	O
not	O
coated	O
strains	O
.	O

Probiotics	O
are	O
able	O
to	O
exert	O
many	O
different	O
beneficial	O
effects	O
on	O
the	O
human	O
host	O
.	O

These	O
effects	O
are	O
mediated	O
by	O
the	O
number	O
of	O
viable	O
cells	O
which	O
reach	O
the	O
gut	O
.	O

The	O
microencapsulation	O
technique	O
used	O
in	O
this	O
study	O
is	O
a	O
valid	O
strategy	O
to	O
significantly	O
improve	O
gastroresistance	O
of	O
strains	O
,	O
thus	O
enhancing	O
their	O
probiotic	O
activity	O
and	O
allowing	O
the	O
use	O
of	O
a	O
5	O
times	O
lower	O
amount	O
.	O

The	O
oral	O
and	O
dental	O
complications	O
arising	O
in	O
cancer	O
patients	O
can	O
be	O
attributable	O
to	O
the	O
malignant	O
disease	O
itself	O
and	O
to	O
the	O
various	O
modalities	O
of	O
cancer	O
therapy	O
.	O

Up	O
to	O
37	O
.	O
2	O
%	O
of	O
all	O
patients	O
receiving	O
cancer	O
chemotherapy	O
develop	O
acute	O
oral	O
complications	O
and	O
up	O
to	O
31	O
.	O
1	O
%	O
of	O
all	O
patients	O
receiving	O
cancer	O
radiotherapy	O
develop	O
acute	O
oral	O
manifestations	O
.	O

Oral	O
complications	O
may	O
result	O
in	O
significant	O
morbidity	O
,	O
impaired	O
nutrition	O
,	O
treatment	O
delays	O
,	O
and	O
dose	O
reductions	O
which	O
are	O
affecting	O
the	O
prognosis	O
of	O
the	O
primary	O
disease	O
.	O

We	O
investigated	O
312	O
cases	O
of	O
blood	O
dyscrasia	O
which	O
296	O
cases	O
had	O
oral	O
manifestations	O
(	O
86	O
.	O
2	O
%	O
)	O
.	O

They	O
had	O
a	O
mean	O
age	O
of	O
40	O
,	O
6	O
years	O
(	O
range	O
from	O
7	O
to	O
86	O
years	O
)	O
.	O

The	O
male	O
to	O
female	O
ratio	O
was	O
1	O
.	O
0	O
:	O
0	O
.	O
75	O
(	O
178	O
/	O
134	O
)	O
.	O

Data	O
were	O
statistically	O
analyzed	O
by	O
t	O
test	O
,	O
chi	O
-	O
square	O
,	O
Wilcoxon	O
,	O
Kruskal	O
-	O
Wallis	O
and	O
two	O
-	O
tailed	O
exact	O
Fischer	O
,	O
using	O
the	O
SPSS	O
program	O
,	O
at	O
a	O
significance	O
level	O
of	O
5	O
%	O
.	O

Oral	O
complications	O
are	O
frequently	O
encountered	O
in	O
patients	O
receiving	O
anticancer	O
therapy	O
and	O
these	O
complications	O
may	O
result	O
in	O
significant	O
morbidity	O
,	O
treatment	O
delays	O
,	O
dose	O
reductions	O
,	O
and	O
nutritional	O
deficiencies	O
.	O

The	O
acute	O
effects	O
of	O
anticancer	O
chemotherapy	O
upon	O
the	O
oral	O
cavity	O
include	O
mucositis	O
,	O
infection	O
,	O
hemorrhage	O
,	O
xerostomia	O
and	O
nutritional	O
deficiencies	O
.	O

Patients	O
which	O
undergo	O
radiotherapy	O
,	O
specific	O
in	O
head	O
and	O
neck	O
carcinomas	O
,	O
display	O
a	O
30	O
-	O
60	O
%	O
incidence	O
of	O
the	O
oral	O
manifestations	O
.	O

The	O
antineoplastic	O
therapy	O
will	O
interfere	O
with	O
the	O
turnover	O
of	O
the	O
epithelial	O
cells	O
,	O
followed	O
by	O
mucosal	O
injury	O
,	O
later	O
by	O
infections	O
,	O
due	O
to	O
indirect	O
invasion	O
of	O
Gram	O
-	O
negative	O
bacteria	O
and	O
fungal	O
species	O
,	O
as	O
most	O
of	O
the	O
anti	O
-	O
cancer	O
drugs	O
cause	O
immunological	O
changes	O
.	O

The	O
mucosal	O
surface	O
that	O
is	O
the	O
oral	O
cavity	O
may	O
provide	O
insight	O
into	O
the	O
immune	O
function	O
of	O
the	O
patient	O
.	O

Differential	O
diagnosis	O
is	O
important	O
as	O
many	O
disorders	O
may	O
manifest	O
themselves	O
similarly	O
in	O
the	O
buccal	O
area	O
.	O

Aggregatibacter	B-bacteria
(	I-bacteria
formerly	I-bacteria
Actinobacillus	I-bacteria
)	I-bacteria
actinomycetemcomitans	I-bacteria
,	O
Tannerella	B-bacteria
forsythensis	I-bacteria
and	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
to	O
a	O
lesser	O
extent	O
Prevotella	B-bacteria
intermedia	I-bacteria
and	O
Prevotella	B-bacteria
nigrescens	I-bacteria
,	O
are	O
Gram	O
-	O
negative	O
species	O
that	O
are	O
associated	O
with	O
destructive	O
periodontitis	O
.	O

Studies	O
from	O
different	O
parts	O
of	O
the	O
world	O
have	O
shown	O
variable	O
detection	O
rates	O
of	O
periodontal	O
organisms	O
.	O

Hardly	O
any	O
data	O
exist	O
on	O
their	O
carriage	O
in	O
children	O
living	O
in	O
the	O
Middle	O
East	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
detection	O
of	O
these	O
species	O
in	O
the	O
oral	O
cavity	O
of	O
240	O
generally	O
healthy	O
Kuwaiti	O
children	O
,	O
divided	O
into	O
five	O
age	O
groups	O
:	O
<	O
6	O
years	O
(	O
n	O
=	O
40	O
)	O
,	O
6	O
-	O
9	O
years	O
(	O
n	O
=	O
60	O
)	O
,	O
10	O
-	O
12	O
years	O
(	O
n	O
=	O
40	O
)	O
,	O
13	O
-	O
15	O
years	O
(	O
n	O
=	O
40	O
)	O
and	O
16	O
-	O
18	O
years	O
(	O
n	O
=	O
60	O
)	O
.	O

Saliva	O
was	O
used	O
as	O
the	O
microbiological	O
specimen	O
,	O
and	O
the	O
samples	O
were	O
analyzed	O
by	O
molecular	O
methods	O
using	O
multiplex	O
PCR	O
.	O

A	O
total	O
of	O
185	O
(	O
77	O
.	O
1	O
%	O
)	O
of	O
the	O
240	O
children	O
were	O
colonized	O
by	O
at	O
least	O
one	O
of	O
the	O
target	O
periodontal	O
bacteria	O
.	O

In	O
all	O
age	O
groups	O
,	O
P	B-bacteria
.	I-bacteria
nigrescens	I-bacteria
was	O
the	O
most	O
prominent	O
and	O
detected	O
in	O
saliva	O
of	O
15	O
%	O
,	O
32	O
%	O
,	O
63	O
%	O
,	O
50	O
%	O
,	O
and	O
47	O
%	O
of	O
the	O
children	O
at	O
the	O
five	O
age	O
groups	O
,	O
respectively	O
.	O

P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
was	O
detected	O
only	O
occasionally	O
.	O

Only	O
few	O
pathogens	O
were	O
found	O
before	O
the	O
permanent	O
dentition	O
,	O
i	O
.	O
e	O
.	O
at	O
the	O
age	O
of	O
<	O
6	O
years	O
.	O

The	O
highest	O
carriage	O
rates	O
were	O
from	O
the	O
groups	O
between	O
6	O
and	O
15	O
years	O
of	O
age	O
.	O

The	O
salivary	O
carriage	O
of	O
the	O
pathogens	O
was	O
essentially	O
similar	O
in	O
the	O
age	O
groups	O
of	O
10	O
-	O
12	O
years	O
and	O
13	O
-	O
15	O
years	O
.	O

In	O
conclusion	O
,	O
except	O
for	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
,	O
the	O
examined	O
periodontal	O
pathogens	O
are	O
relatively	O
common	O
findings	O
in	O
Kuwaiti	O
children	O
and	O
colonize	O
the	O
oral	O
cavity	O
from	O
childhood	O
onwards	O
.	O

Colonization	O
and	O
infection	O
of	O
the	O
human	O
host	O
by	O
opportunistic	O
pathogen	O
Candida	O
albicans	O
derive	O
from	O
an	O
ability	O
of	O
this	O
fungus	O
to	O
colonize	O
mucosal	O
tissues	O
and	O
prosthetic	O
devices	O
within	O
the	O
polymicrobial	O
communities	O
present	O
.	O

To	O
determine	O
the	O
functions	O
of	O
C	O
.	O
albicans	O
cell	O
wall	O
proteins	O
in	O
interactions	O
with	O
host	O
or	O
bacterial	O
molecules	O
,	O
Saccharomyces	O
cerevisiae	O
was	O
utilized	O
as	O
a	O
surrogate	O
host	O
to	O
express	O
C	O
.	O
albicans	O
cell	O
wall	O
proteins	O
Als3p	O
,	O
Eap1p	O
,	O
Hwp1p	O
,	O
and	O
Rbt1p	O
.	O

Salivary	O
pellicle	O
and	O
fibrinogen	O
were	O
identified	O
as	O
novel	O
substrata	O
for	O
Als3p	O
and	O
Hwp1p	O
,	O
while	O
only	O
Als3p	O
mediated	O
adherence	O
of	O
S	O
.	O
cerevisiae	O
to	O
basement	O
membrane	O
collagen	O
type	O
IV	O
.	O

Parental	O
S	B-bacteria
.	I-bacteria
cerevisiae	I-bacteria
cells	O
failed	O
to	O
form	O
biofilms	O
on	O
Salivary	O
pellicle	O
,	O
polystyrene	O
,	O
or	O
silicone	O
,	O
but	O
cells	O
expressing	O
Als3p	O
or	O
Hwp1p	O
exhibited	O
significant	O
attachment	O
to	O
each	O
surface	O
.	O

Virulence	O
factor	O
Rbt1p	O
also	O
conferred	O
lower	O
-	O
level	O
binding	O
to	O
Salivary	O
pellicle	O
and	O
polystyrene	O
.	O

S	O
.	O
cerevisiae	O
cells	O
expressing	O
Eap1p	O
formed	O
robust	O
biofilms	O
upon	O
polystyrene	O
surfaces	O
but	O
not	O
Salivary	O
pellicle	O
.	O

Proteins	O
Als3p	O
and	O
Eap1p	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
Hwp1p	O
,	O
conferred	O
upon	O
S	B-bacteria
.	I-bacteria
cerevisiae	I-bacteria
the	O
ability	O
to	O
bind	O
cells	O
of	O
the	O
oral	O
primary	O
colonizing	O
bacterium	O
Streptococcus	B-bacteria
gordonii	I-bacteria
.	O

These	O
interactions	O
,	O
which	O
occurred	O
independently	O
of	O
amyloid	O
aggregate	O
formation	O
,	O
provide	O
the	O
first	O
examples	O
of	O
specific	O
C	O
.	O
albicans	O
surface	O
proteins	O
serving	O
as	O
receptors	O
for	O
bacterial	O
adhesins	O
.	O

Streptococcus	B-bacteria
gordonii	I-bacteria
did	O
not	O
bind	O
parental	O
S	O
.	O
cerevisiae	O
or	O
cells	O
expressing	O
Rbt1p	O
.	O

Taken	O
collectively	O
,	O
these	O
data	O
suggest	O
that	O
a	O
network	O
of	O
cell	O
wall	O
proteins	O
comprising	O
Als3p	O
,	O
Hwp1p	O
,	O
and	O
Eap1p	O
,	O
with	O
complementary	O
adhesive	O
functions	O
,	O
promotes	O
interactions	O
of	O
C	O
.	O
albicans	O
with	O
host	O
and	O
bacterial	O
molecules	O
,	O
thus	O
leading	O
to	O
effective	O
colonization	O
within	O
polymicrobial	O
communities	O
.	O

The	O
aims	O
of	O
this	O
research	O
were	O
to	O
determine	O
the	O
prevalence	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
and	O
its	O
vacA	O
genotypes	O
in	O
oral	O
cavity	O
in	O
persons	O
without	O
dyspepsia	O
and	O
to	O
establish	O
the	O
association	O
between	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
oral	O
cavity	O
and	O
oral	O
hygiene	O
.	O

The	O
seroprevalence	O
of	O
anti	O
-	O
H	O
.	O
pylori	O
antibodies	O
and	O
its	O
associated	O
factors	O
were	O
analyzed	O
too	O
.	O

For	O
the	O
study	O
,	O
200	O
adults	O
without	O
dyspepsia	O
symptoms	O
were	O
selected	O
.	O

Dental	O
plaque	O
and	O
saliva	O
samples	O
from	O
each	O
subject	O
were	O
obtained	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
detection	O
in	O
oral	O
samples	O
was	O
carried	O
out	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
for	O
vacA	O
genotyping	O
a	O
semi	O
-	O
nested	O
and	O
nested	O
PCR	O
was	O
used	O
.	O

The	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
used	O
to	O
detect	O
anti	O
-	O
H	O
.	O
pylori	O
IgG	O
and	O
IgM	O
.	O

The	O
data	O
were	O
analyzed	O
with	O
Chi	O
square	O
and	O
Fisher	O
exact	O
test	O
and	O
the	O
statistical	O
significance	O
was	O
set	O
to	O
0	O
.	O
05	O
.	O

Of	O
200	O
subjects	O
tested	O
,	O
124	O
(	O
62	O
%	O
)	O
were	O
seropositive	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
was	O
detected	O
in	O
the	O
oral	O
cavity	O
of	O
34	O
subjects	O
(	O
17	O
%	O
)	O
and	O
vacA	O
allelotypes	O
were	O
typified	O
in	O
12	O
of	O
those	O
samples	O
.	O

The	O
s1	O
allele	O
was	O
detected	O
in	O
8	O
(	O
66	O
.	O
7	O
%	O
)	O
samples	O
and	O
in	O
one	O
of	O
them	O
m1	O
y	O
m2	O
alleles	O
were	O
found	O
.	O

In	O
four	O
subjects	O
vacA	O
m1	O
subtypes	O
were	O
found	O
and	O
in	O
two	O
of	O
those	O
both	O
m1	O
and	O
m2	O
alleles	O
were	O
detected	O
.	O

The	O
prevalence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
oral	O
cavity	O
was	O
higher	O
(	O
18	O
.	O
5	O
%	O
)	O
among	O
seropositive	O
subjects	O
compared	O
with	O
seronegative	O
persons	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
and	O
oral	O
hygiene	O
habits	O
.	O

The	O
presence	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
in	O
oral	O
cavity	O
is	O
more	O
frequent	O
in	O
seropositive	O
subjects	O
without	O
dyspepsia	O
symptoms	O
and	O
could	O
represent	O
the	O
source	O
of	O
gastric	O
infection	O
and	O
bacterial	O
transmission	O
.	O

The	O
data	O
suggest	O
that	O
more	O
than	O
one	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
strain	I-bacteria
may	O
exist	O
in	O
the	O
mouth	O
of	O
asymptomatic	O
persons	O
.	O

Colonization	O
of	O
surfaces	O
in	O
the	O
human	O
body	O
by	O
microorganisms	O
is	O
an	O
early	O
,	O
essential	O
,	O
step	O
in	O
the	O
initiation	O
of	O
infectious	O
disease	O
.	O

We	O
have	O
developed	O
in	O
vitro	O
assays	O
to	O
investigate	O
interactions	O
between	O
yeast	O
or	O
bacterial	O
cells	O
and	O
human	O
tissues	O
,	O
fluids	O
,	O
or	O
prostheses	O
.	O

Such	O
assays	O
can	O
be	O
used	O
to	O
identify	O
the	O
adhesins	O
,	O
ligands	O
,	O
and	O
receptors	O
involved	O
in	O
these	O
interactions	O
,	O
for	O
example	O
by	O
determining	O
which	O
components	O
of	O
the	O
microbe	O
or	O
human	O
tissue	O
/	O
fluid	O
interfere	O
with	O
adherence	O
in	O
the	O
assay	O
.	O

The	O
assays	O
can	O
also	O
be	O
applied	O
to	O
finding	O
ways	O
of	O
preventing	O
adhesion	O
,	O
and	O
subsequent	O
disease	O
,	O
by	O
investigating	O
the	O
effects	O
of	O
different	O
conditions	O
and	O
added	O
compounds	O
on	O
adherence	O
in	O
the	O
in	O
vitro	O
assays	O
.	O

We	O
describe	O
six	O
assays	O
for	O
measuring	O
adhesion	O
of	O
the	O
oral	O
yeast	O
Candida	O
albicans	O
,	O
a	O
common	O
commensal	O
and	O
opportunistic	O
pathogen	O
,	O
or	O
the	O
bacterium	O
Staphylococcus	B-bacteria
epidermidis	I-bacteria
,	O
which	O
is	O
not	O
normally	O
pathogenic	O
but	O
is	O
known	O
to	O
form	O
biofilms	O
on	O
medical	O
prostheses	O
.	O

The	O
assays	O
described	O
represent	O
two	O
approaches	O
to	O
investigating	O
adhesion	O
;	O
retention	O
at	O
a	O
fixed	O
time	O
point	O
following	O
liquid	O
washes	O
;	O
and	O
retention	O
against	O
a	O
continuous	O
flow	O
of	O
medium	O
.	O

Most	O
bacteria	O
in	O
nature	O
exist	O
in	O
multispecies	O
communities	O
known	O
as	O
biofilms	O
.	O

In	O
the	O
natural	O
habitat	O
where	O
resources	O
(	O
nutrient	O
,	O
space	O
,	O
etc	O
.	O
)	O

are	O
usually	O
limited	O
,	O
individual	O
species	O
must	O
compete	O
or	O
collaborate	O
with	O
other	O
neighboring	O
species	O
in	O
order	O
to	O
perpetuate	O
in	O
the	O
multispecies	O
community	O
.	O

The	O
human	O
oral	O
cavity	O
is	O
colonized	O
by	O
>	O
700	O
microbial	O
species	O
known	O
as	O
the	O
indigenous	O
microflora	O
.	O

This	O
indigenous	O
flora	O
normally	O
maintains	O
an	O
ecological	O
balance	O
through	O
antagonistic	O
as	O
well	O
as	O
mutualistic	O
interspecies	O
interactions	O
.	O

However	O
,	O
environmental	O
perturbation	O
may	O
disrupt	O
this	O
balance	O
,	O
leading	O
to	O
overgrowth	O
of	O
pathogenic	O
species	O
,	O
which	O
could	O
in	O
turn	O
initiate	O
diseases	O
such	O
as	O
dental	O
caries	O
(	O
tooth	O
decay	O
)	O
and	O
periodontitis	O
(	O
gum	O
disease	O
)	O
.	O

Understanding	O
the	O
mechanisms	O
of	O
diversity	O
maintenance	O
may	O
help	O
development	O
of	O
novel	O
approaches	O
to	O
manage	O
these	O
`	O
`	O
polymicrobial	O
diseases	O
.	O
'	O
'	O

In	O
this	O
chapter	O
,	O
we	O
will	O
focus	O
on	O
a	O
well	O
-	O
characterized	O
form	O
of	O
biochemical	O
warfare	O
:	O
bacteriocins	O
produced	O
by	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
a	O
primary	O
dental	O
caries	O
pathogen	O
,	O
and	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
produced	O
by	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
,	O
an	O
oral	O
commensal	O
.	O

We	O
will	O
describe	O
detailed	O
methodologies	O
on	O
the	O
competition	O
assay	O
,	O
isolation	O
,	O
purification	O
,	O
and	O
characterization	O
of	O
bacteriocins	O
.	O

The	O
microbiological	O
effects	O
of	O
biocidal	O
products	O
used	O
for	O
the	O
enhancement	O
of	O
oral	O
hygiene	O
relate	O
to	O
the	O
active	O
compound	O
(	O
s	O
)	O
as	O
well	O
as	O
other	O
formulation	O
components	O
.	O

Here	O
,	O
we	O
test	O
the	O
specificities	O
of	O
selected	O
actives	O
in	O
the	O
absence	O
of	O
multiple	O
excipients	O
.	O

Salivary	O
ecosystems	O
were	O
maintained	O
in	O
tissue	O
culture	O
plate	O
-	O
based	O
hydroxyapatite	O
disc	O
models	O
(	O
HDMs	O
)	O
and	O
modified	O
drip	O
-	O
flow	O
biofilm	O
reactors	O
(	O
MDFRs	O
)	O
.	O

Test	O
compounds	O
stannous	O
fluoride	O
(	O
SF	O
)	O
,	O
SDS	O
,	O
triclosan	O
(	O
TCS	O
)	O
,	O
zinc	O
lactate	O
(	O
ZL	O
)	O
and	O
ZL	O
with	O
SF	O
in	O
combination	O
(	O
ZLSF	O
)	O
were	O
delivered	O
to	O
the	O
HDMs	O
once	O
and	O
four	O
times	O
daily	O
for	O
6	O
days	O
to	O
MDFRs	O
.	O

Plaques	O
were	O
characterized	O
by	O
differential	O
viable	O
counting	O
and	O
PCR	O
-	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O

TCS	O
and	O
SDS	O
were	O
the	O
most	O
effective	O
compounds	O
against	O
HDM	O
plaques	O
,	O
significantly	O
reducing	O
total	O
viable	O
counts	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whilst	O
SF	O
,	O
ZL	O
and	O
ZLSF	O
were	O
comparatively	O
ineffective	O
.	O

TCS	O
exhibited	O
specificity	O
for	O
streptococci	B-bacteria
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
Gram	O
-	O
negative	O
anaerobes	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
following	O
a	O
single	O
dosing	O
and	O
also	O
on	O
repeated	O
dosing	O
in	O
MDFRs	O
.	O

In	O
contrast	O
to	O
single	O
exposures	O
,	O
multiple	O
dosing	O
with	O
ZLSF	O
also	O
significantly	O
reduced	O
all	O
bacterial	O
groups	O
,	O
whilst	O
SF	O
and	O
ZL	O
caused	O
significant	O
but	O
transient	O
reductions	O
.	O

According	O
to	O
PCR	O
-	O
DGGE	O
analyses	O
,	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
reductions	O
in	O
eubacterial	O
diversity	O
occurred	O
following	O
6	O
day	O
dosing	O
with	O
both	O
TCS	O
and	O
ZLSF	O
.	O

Concordance	O
of	O
MDFR	O
eubacterial	O
profiles	O
with	O
salivary	O
inocula	O
ranged	O
between	O
58	O
and	O
97	O
%	O
.	O

TCS	O
and	O
ZL	O
(	O
SF	O
)	O
exhibited	O
similar	O
specificities	O
to	O
those	O
reported	O
for	O
formulations	O
.	O

TCS	O
was	O
the	O
most	O
potent	O
antibacterial	O
,	O
after	O
single	O
and	O
multiple	O
dosage	O
regimens	O
.	O

Enterotoxigenic	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
(	O
ETEC	B-bacteria
)	O
is	O
an	O
important	O
cause	O
of	O
diarrheal	O
disease	O
and	O
deaths	O
among	O
children	O
in	O
developing	O
countries	O
and	O
the	O
major	O
cause	O
of	O
traveller	O
'	O
s	O
diarrhea	O
.	O

Since	O
surface	O
protein	O
colonization	O
factors	O
(	O
CFs	O
)	O
of	O
ETEC	B-bacteria
are	O
important	O
for	O
pathogenicity	O
and	O
immune	O
protection	O
is	O
mainly	O
mediated	O
by	O
locally	O
produced	O
IgA	O
antibodies	O
in	O
the	O
gut	O
,	O
much	O
effort	O
has	O
focused	O
on	O
the	O
development	O
of	O
an	O
oral	O
CF	O
-	O
based	O
vaccine	O
.	O

We	O
have	O
recently	O
described	O
the	O
development	O
of	O
recombinant	O
strains	O
over	O
-	O
expressing	O
CFA	O
/	O
I	O
;	O
the	O
most	O
prevalent	O
CF	O
among	O
human	O
clinical	O
ETEC	B-bacteria
isolates	I-bacteria
.	O

Here	O
,	O
non	O
-	O
toxigenic	O
recombinant	O
E	B-bacteria
.		I-bacteria
coli	I-bacteria
strains	I-bacteria
over	O
-	O
expressing	O
Coli	O
surface	O
antigen	O
2	O
(	O
CS2	O
)	O
,	O
CS4	O
,	O
CS5	O
,	O
and	O
CS6	O
,	O
either	O
alone	O
,	O
or	O
each	O
in	O
combination	O
with	O
CFA	O
/	O
I	O
were	O
constructed	O
by	O
cloning	O
the	O
genes	O
required	O
for	O
expression	O
and	O
assembly	O
of	O
each	O
CF	O
into	O
expression	O
vectors	O
harboring	O
a	O
strong	O
promoter	O
.	O

Immunological	O
assays	O
showed	O
that	O
recombinant	O
strains	O
expressing	O
single	O
CFs	O
produced	O
those	O
in	O
significantly	O
larger	O
amounts	O
than	O
did	O
corresponding	O
naturally	O
high	O
producing	O
reference	O
strains	O
.	O

Recombinant	O
strains	O
co	O
-	O
expressing	O
CFA	O
/	O
I	O
together	O
with	O
another	O
CF	O
also	O
expressed	O
significantly	O
larger	O
amounts	O
of	O
both	O
CFs	O
compared	O
with	O
the	O
corresponding	O
references	O
strains	O
.	O

Further	O
,	O
when	O
tested	O
in	O
mice	O
,	O
oral	O
immunization	O
with	O
formalin	O
-	O
killed	O
recombinant	O
bacteria	O
co	O
-	O
expressing	O
one	O
such	O
double	O
-	O
expression	O
CF	O
pair	O
,	O
CFA	O
/	O
I	O
+	O
CS2	O
,	O
induced	O
specific	O
serum	O
IgG	O
+	O
IgM	O
and	O
fecal	O
IgA	O
antibody	O
responses	O
against	O
both	O
CFs	O
exceeding	O
the	O
responses	O
induced	O
by	O
immunizations	O
with	O
natural	O
reference	O
strains	O
expressing	O
CFA	O
/	O
I	O
and	O
CS2	O
,	O
respectively	O
.	O

We	O
conclude	O
that	O
the	O
described	O
type	O
of	O
recombinant	O
bacteria	O
over	O
-	O
expressing	O
major	O
CFs	O
of	O
ETEC	B-bacteria
,	O
alone	O
or	O
in	O
combination	O
,	O
may	O
be	O
useful	O
as	O
candidate	O
strains	O
for	O
use	O
in	O
an	O
oral	O
whole	O
-	O
cell	O
CF	O
-	O
ETEC	O
vaccine	O
.	O

To	O
investigate	O
the	O
polymicrobial	O
infection	O
of	O
periodontal	O
disease	O
,	O
which	O
elicits	O
inflammatory	O
mediators	O
/	O
cytokines	O
/	O
chemokines	O
in	O
the	O
local	O
gingival	O
tissues	O
,	O
and	O
a	O
polybacterial	O
challenge	O
of	O
antigen	O
-	O
presenting	O
cells	O
,	O
e	O
.	O
g	O
.	O
macrophages	O
and	O
dendritic	O
cells	O
(	O
DCs	O
)	O
,	O
at	O
the	O
mucosal	O
surface	O
.	O

The	O
cytokine	O
/	O
chemokine	O
profiles	O
of	O
human	O
macrophages	O
and	O
DCs	O
in	O
response	O
to	O
polybacterial	O
challenges	O
were	O
investigated	O
.	O

Oral	O
Gram	O
-	O
negative	O
bacteria	O
elicited	O
significantly	O
greater	O
IL	O
-	O
8	O
levels	O
from	O
macrophages	O
,	O
compared	O
to	O
Gram	O
-	O
positive	O
bacteria	O
.	O

Gram	O
-	O
positive	O
bacteria	O
did	O
not	O
show	O
synergism	O
in	O
inducing	O
this	O
chemokine	O
from	O
macrophages	O
.	O

In	O
contrast	O
,	O
pairs	O
of	O
oral	O
Gram	O
-	O
negative	O
bacteria	O
elicited	O
synergistic	O
production	O
of	O
IL	O
-	O
8	O
by	O
macrophages	O
.	O

Similar	O
results	O
were	O
not	O
observed	O
with	O
TNFalpha	O
,	O
which	O
only	O
appeared	O
additive	O
with	O
the	O
polybacterial	O
challenge	O
.	O

Selected	O
Gram	O
-	O
negative	O
bacterial	O
pairs	O
synergized	O
in	O
IL	O
-	O
6	O
production	O
by	O
immature	O
DCs	O
.	O

In	O
mature	O
DCs	O
(	O
mDCs	O
)	O
,	O
a	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
/	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
and	O
Porphyromonas	B-bacteria
intermedia	I-bacteria
/	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
polybacterial	O
challenge	O
resulted	O
in	O
significant	O
synergism	O
for	O
IL	O
-	O
6	O
and	O
TNFalpha	O
levels	O
.	O

However	O
,	O
only	O
the	O
Pi	B-bacteria
/	O
Fn	B-bacteria
combination	O
synergized	O
for	O
IL	O
-	O
12	O
production	O
and	O
there	O
appeared	O
to	O
be	O
no	O
polybacterial	O
effect	O
on	O
IL	O
-	O
10	O
production	O
by	O
the	O
mDCs	O
.	O

These	O
results	O
indicate	O
that	O
a	O
polybacterial	O
challenge	O
of	O
cells	O
linking	O
innate	O
and	O
adaptive	O
immune	O
responses	O
results	O
in	O
varied	O
response	O
profiles	O
that	O
are	O
dependent	O
upon	O
the	O
characteristics	O
of	O
the	O
microorganisms	O
that	O
are	O
components	O
of	O
the	O
polybacterial	O
complex	O
.	O

The	O
nose	O
and	O
throat	O
are	O
important	O
sites	O
of	O
pathogen	O
colonization	O
,	O
yet	O
the	O
microbiota	O
of	O
both	O
is	O
relatively	O
unexplored	O
by	O
culture	O
-	O
independent	O
approaches	O
.	O

We	O
examined	O
the	O
bacterial	O
microbiota	O
of	O
the	O
nostril	O
and	O
posterior	O
wall	O
of	O
the	O
oropharynx	O
from	O
seven	O
healthy	O
adults	O
using	O
two	O
culture	O
-	O
independent	O
methods	O
,	O
a	O
16S	O
rRNA	O
gene	O
microarray	O
(	O
PhyloChip	O
)	O
and	O
16S	O
rRNA	O
gene	O
clone	O
libraries	O
.	O

While	O
the	O
bacterial	O
microbiota	O
of	O
the	O
oropharynx	O
was	O
richer	O
than	O
that	O
of	O
the	O
nostril	O
,	O
the	O
oropharyngeal	O
microbiota	O
varied	O
less	O
among	O
participants	O
than	O
did	O
nostril	O
microbiota	O
.	O

A	O
few	O
phyla	O
accounted	O
for	O
the	O
majority	O
of	O
the	O
bacteria	O
detected	O
at	O
each	O
site	O
:	O
Firmicutes	B-bacteria
and	O
Actinobacteria	B-bacteria
in	O
the	O
nostril	O
and	O
Firmicutes	B-bacteria
,	O
Proteobacteria	B-bacteria
,	O
and	O
Bacteroidetes	B-bacteria
in	O
the	O
oropharynx	O
.	O

Compared	O
to	O
culture	O
-	O
independent	O
surveys	O
of	O
microbiota	O
from	O
other	O
body	O
sites	O
,	O
the	O
microbiota	O
of	O
the	O
nostril	O
and	O
oropharynx	O
show	O
distinct	O
phylum	O
-	O
level	O
distribution	O
patterns	O
,	O
supporting	O
niche	O
-	O
specific	O
colonization	O
at	O
discrete	O
anatomical	O
sites	O
.	O

In	O
the	O
nostril	O
,	O
the	O
distribution	O
of	O
Actinobacteria	B-bacteria
and	O
Firmicutes	B-bacteria
was	O
reminiscent	O
of	O
that	O
of	O
skin	O
,	O
though	O
Proteobacteria	B-bacteria
were	O
much	O
less	O
prevalent	O
.	O

The	O
distribution	O
of	O
Firmicutes	B-bacteria
,	O
Proteobacteria	B-bacteria
,	O
and	O
Bacteroidetes	B-bacteria
in	O
the	O
oropharynx	O
was	O
most	O
similar	O
to	O
that	O
in	O
saliva	O
,	O
with	O
more	O
Proteobacteria	B-bacteria
than	O
in	O
the	O
distal	O
esophagus	O
or	O
mouth	O
.	O

While	O
Firmicutes	B-bacteria
were	O
prevalent	O
at	O
both	O
sites	O
,	O
distinct	O
families	O
within	O
this	O
phylum	O
dominated	O
numerically	O
in	O
each	O
.	O

At	O
both	O
sites	O
there	O
was	O
an	O
inverse	O
correlation	O
between	O
the	O
prevalences	O
of	O
Firmicutes	B-bacteria
and	O
another	O
phylum	O
:	O
in	O
the	O
oropharynx	O
,	O
Firmicutes	B-bacteria
and	O
Proteobacteria	B-bacteria
,	O
and	O
in	O
the	O
nostril	O
,	O
Firmicutes	B-bacteria
and	O
Actinobacteria	B-bacteria
.	O

In	O
the	O
nostril	O
,	O
this	O
inverse	O
correlation	O
existed	O
between	O
the	O
Firmicutes	B-bacteria
family	I-bacteria
Staphylococcaceae	B-bacteria
and	O
Actinobacteria	B-bacteria
families	I-bacteria
,	O
suggesting	O
potential	O
antagonism	O
between	O
these	O
groups	O
.	O

Oral	O
Bifidobacteriaceae	B-bacteria
,	O
Bifidobacterium	B-bacteria
dentium	I-bacteria
and	O
Bifidobacterium	B-bacteria
longum	I-bacteria
,	O
are	O
known	O
to	O
be	O
isolated	O
together	O
with	O
mutans	B-bacteria
streptococci	I-bacteria
and	O
lactobacilli	B-bacteria
from	O
caries	O
lesions	O
,	O
suggesting	O
that	O
these	O
Bifidobacteriaceae	B-bacteria
are	O
caries	O
associated	O
and	O
acid	O
resistant	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
effects	O
of	O
acidification	O
on	O
B	B-bacteria
.	I-bacteria
dentium	I-bacteria
and	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
,	O
and	O
to	O
compare	O
them	O
with	O
those	O
on	O
Streptococcus	B-bacteria
mutans	I-bacteria
,	O
Streptococcus	B-bacteria
sanguinis	I-bacteria
and	O
Lactobacillus	B-bacteria
paracasei	I-bacteria
.	O

Effects	O
of	O
acidification	O
,	O
growth	O
ability	O
in	O
a	O
complex	O
medium	O
at	O
a	O
pH	O
of	O
4	O
.	O
0	O
-	O
8	O
.	O
0	O
,	O
cell	O
viability	O
in	O
2	O
-	O
morpholinoethanesulfonic	O
acid	O
monohydrate	O
(	O
MES	O
)	O
-	O
KOH	O
buffer	O
at	O
pH	O
4	O
.	O
0	O
,	O
as	O
well	O
as	O
stability	O
of	O
intracellular	O
pH	O
(	O
pH	O
(	O
in	O
)	O
)	O
at	O
an	O
extracellular	O
pH	O
of	O
3	O
.	O
5	O
-	O
8	O
.	O
0	O
estimated	O
using	O
a	O
fluorescent	O
dye	O
,	O
5	O
(	O
6	O
)	O
-	O
carboxyfluorescein	O
diacetate	O
N	O
-	O
succinimidyl	O
ester	O
in	O
MES	O
-	O
KOH	O
,	O
3	O
-	O
(	O
N	O
-	O
morpholino	O
)	O
propanesulfonic	O
acid	O
-	O
KOH	O
or	O
N	O
,	O
N	O
-	O
bis	O
(	O
2	O
-	O
hydroxyethyl	O
)	O
glycine	O
-	O
KOH	O
buffer	O
,	O
were	O
investigated	O
.	O

B	B-bacteria
.	I-bacteria
longum	I-bacteria
grew	O
as	O
well	O
as	O
Streptococcus	B-bacteria
strains	I-bacteria
over	O
a	O
wide	O
pH	O
range	O
,	O
whereas	O
B	B-bacteria
.	I-bacteria
dentium	I-bacteria
grew	O
best	O
in	O
the	O
narrow	O
pH	O
range	O
around	O
neutral	O
.	O

The	O
cell	O
viability	O
of	O
B	B-bacteria
.	I-bacteria
dentium	I-bacteria
decreased	O
significantly	O
after	O
2	O
h	O
of	O
acidification	O
at	O
a	O
pH	O
of	O
4	O
.	O
0	O
,	O
but	O
this	O
was	O
significantly	O
less	O
than	O
that	O
of	O
the	O
Streptococcus	B-bacteria
and	O
Lactobacillus	B-bacteria
species	I-bacteria
,	O
whereas	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
maintained	O
almost	O
100	O
%	O
viability	O
.	O

The	O
pH	O
(	O
in	O
)	O
was	O
close	O
to	O
the	O
extracellular	O
pH	O
at	O
pH	O
of	O
5	O
.	O
5	O
-	O
7	O
.	O
5	O
in	O
the	O
Bifidobacterium	B-bacteria
and	O
Streptococcus	B-bacteria
strains	I-bacteria
,	O
while	O
at	O
a	O
pH	O
of	O
<	O
5	O
.	O
0	O
,	O
the	O
pH	O
(	O
in	O
)	O
was	O
higher	O
than	O
the	O
extracellular	O
pH	O
in	O
all	O
the	O
strains	O
,	O
but	O
the	O
pH	O
(	O
in	O
)	O
maintenance	O
ability	O
of	O
Bifidobacterium	B-bacteria
strains	I-bacteria
was	O
higher	O
than	O
that	O
of	O
the	O
Streptococcus	B-bacteria
strains	I-bacteria
.	O

The	O
high	O
survival	O
rate	O
and	O
pH	O
(	O
in	O
)	O
maintenance	O
ability	O
of	O
bifidobacteria	B-bacteria
comparable	O
to	O
that	O
of	O
S	B-bacteria
.	I-bacteria
mutans	I-bacteria
in	O
the	O
acidic	O
environment	O
may	O
account	O
for	O
why	O
bifidobacteria	B-bacteria
exist	O
as	O
stable	O
species	O
in	O
acidic	O
caries	O
lesions	O
together	O
with	O
mutans	B-bacteria
streptococci	I-bacteria
.	O

We	O
investigated	O
the	O
effect	O
of	O
the	O
bacterial	O
flora	O
of	O
the	O
nose	O
and	O
throat	O
on	O
the	O
outcome	O
of	O
the	O
initial	O
repairs	O
of	O
the	O
cleft	O
palate	O
in	O
the	O
presence	O
of	O
prophylactic	O
antibiotics	O
.	O

A	O
retrospective	O
review	O
of	O
90	O
procedures	O
in	O
66	O
patients	O
who	O
had	O
cleft	O
palate	O
repair	O
between	O
April	O
2005	O
and	O
June	O
2007	O
was	O
conducted	O
at	O
Booth	O
Hall	O
Children	O
'	O
s	O
Hospital	O
,	O
Manchester	O
,	O
U	O
.	O
K	O
.	O

Both	O
isolated	O
cleft	O
palate	O
and	O
cleft	O
lip	O
and	O
palate	O
patients	O
were	O
included	O
.	O

Exclusion	O
criteria	O
included	O
syndromic	O
cases	O
,	O
other	O
medical	O
disorders	O
,	O
and	O
revisions	O
of	O
previous	O
cleft	O
palate	O
repairs	O
.	O

Nose	O
and	O
throat	O
swabs	O
were	O
taken	O
on	O
admission	O
.	O

Benzyl	O
penicillin	O
and	O
flucloxacillin	O
were	O
given	O
perioperatively	O
.	O

The	O
occurrence	O
of	O
oronasal	O
fistulas	O
was	O
correlated	O
with	O
the	O
bacteria	O
grown	O
on	O
culture	O
.	O

The	O
oronasal	O
fistula	O
rate	O
was	O
15	O
.	O
9	O
%	O
.	O

The	O
highest	O
fistula	O
rate	O
in	O
procedures	O
with	O
positive	O
swabs	O
was	O
seen	O
with	O
Moraxella	B-bacteria
catarrhalis	I-bacteria
.	O

M	B-bacteria
.	I-bacteria
catarrhalis	I-bacteria
has	O
not	O
been	O
previously	O
recognized	O
as	O
a	O
pathogen	O
in	O
cleft	O
palate	O
repairs	O
.	O

This	O
study	O
demonstrates	O
a	O
higher	O
fistula	O
rate	O
in	O
procedures	O
positive	O
for	O
M	B-bacteria
.	I-bacteria
catarrhalis	I-bacteria
.	O

Other	O
factors	O
that	O
may	O
have	O
contributed	O
to	O
the	O
fistula	O
formation	O
include	O
the	O
severity	O
of	O
the	O
initial	O
cleft	O
and	O
technical	O
factors	O
.	O

Further	O
study	O
is	O
required	O
before	O
a	O
definitive	O
link	O
can	O
be	O
established	O
.	O

In	O
this	O
study	O
the	O
presence	O
of	O
periodontopathic	O
pathogens	O
in	O
atheromatous	O
plaques	O
removed	O
from	O
coronary	O
arteries	O
of	O
patients	O
with	O
chronic	O
periodontitis	O
and	O
periodontally	O
healthy	O
subjects	O
by	O
PCR	O
was	O
detected	O
.	O

Our	O
results	O
indicate	O
a	O
significant	O
association	O
between	O
the	O
presence	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
and	O
atheromas	O
,	O
and	O
the	O
periodontal	O
bacteria	O
in	O
oral	O
biofilm	O
may	O
find	O
a	O
way	O
to	O
reach	O
arteries	O
.	O

Prevotella	B-bacteria
species	I-bacteria
are	O
members	O
of	O
the	O
bacterial	O
oral	O
flora	O
and	O
are	O
opportunistic	O
pathogens	O
in	O
polymicrobial	O
infections	O
of	O
soft	O
tissues	O
.	O

Antibiotic	O
resistance	O
to	O
tetracyclines	O
is	O
common	O
in	O
these	O
bacteria	O
,	O
and	O
the	O
gene	O
encoding	O
this	O
resistance	O
has	O
been	O
previously	O
identified	O
as	O
tetQ	O
.	O

The	O
tetQ	O
gene	O
is	O
also	O
found	O
on	O
conjugative	O
transposons	O
in	O
the	O
intestinal	O
Bacteroides	B-bacteria
species	I-bacteria
;	O
whether	O
these	O
related	O
bacteria	O
have	O
transmitted	O
tetQ	O
to	O
Prevotella	B-bacteria
is	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
our	O
genetic	O
analysis	O
of	O
mobile	O
tetQ	O
elements	O
in	O
oral	O
Prevotella	B-bacteria
species	I-bacteria
.	O

Our	O
results	O
indicate	O
that	O
the	O
mobile	O
elements	O
encoding	O
tetQ	O
in	O
oral	O
species	O
are	O
distinct	O
from	O
those	O
found	O
in	O
the	O
Bacteroides	B-bacteria
.	O

The	O
intestinal	O
bacteria	O
may	O
act	O
as	O
a	O
reservoir	O
for	O
the	O
tetQ	O
gene	O
,	O
but	O
Prevotella	B-bacteria
has	O
incorporated	O
this	O
gene	O
into	O
an	O
IS21	O
-	O
family	O
transposon	O
.	O

This	O
transposon	O
is	O
present	O
in	O
Prevotella	B-bacteria
species	I-bacteria
from	O
more	O
than	O
one	O
geographical	O
location	O
,	O
implying	O
that	O
the	O
mechanism	O
of	O
tetQ	O
spread	O
between	O
oral	O
Prevotella	B-bacteria
species	I-bacteria
is	O
highly	O
conserved	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
cultivable	O
microorganisms	O
from	O
primary	O
teeth	O
with	O
necrotic	O
pulps	O
.	O

This	O
experimental	O
study	O
included	O
21	O
patients	O
of	O
both	O
sexes	O
between	O
4	O
and	O
7	O
years	O
of	O
age	O
with	O
necrotic	O
pulps	O
in	O
primary	O
teeth	O
.	O

Twenty	O
-	O
one	O
maxillary	O
and	O
mandibular	O
molars	O
containing	O
at	O
least	O
1	O
necrotic	O
canal	O
,	O
an	O
abscess	O
or	O
sinus	O
tract	O
,	O
one	O
or	O
more	O
radiolucent	O
areas	O
in	O
the	O
furcation	O
or	O
periapical	O
region	O
,	O
teeth	O
having	O
at	O
least	O
two	O
thirds	O
of	O
root	O
length	O
,	O
and	O
carious	O
lesions	O
directly	O
exposed	O
to	O
the	O
oral	O
environment	O
were	O
included	O
.	O

After	O
antisepsis	O
of	O
the	O
oral	O
cavity	O
,	O
anesthesia	O
of	O
the	O
affected	O
tooth	O
,	O
and	O
isolation	O
and	O
disinfection	O
of	O
the	O
operative	O
field	O
,	O
3	O
sterile	O
absorbent	O
paper	O
points	O
were	O
sequentially	O
placed	O
for	O
30	O
seconds	O
for	O
the	O
collection	O
of	O
samples	O
.	O

The	O
samples	O
were	O
immediately	O
processed	O
in	O
an	O
anaerobic	O
chamber	O
,	O
and	O
all	O
isolated	O
microorganisms	O
were	O
identified	O
.	O

Anaerobic	O
species	O
(	O
anaerobic	O
facultative	O
and	O
moderate	O
anaerobes	O
)	O
were	O
isolated	O
in	O
all	O
root	O
canals	O
;	O
68	O
.	O
4	O
%	O
of	O
root	O
canal	O
samples	O
studied	O
showed	O
a	O
polymicrobial	O
nature	O
.	O

Most	O
of	O
the	O
isolate	O
consisted	O
of	O
Bifidobacterium	B-bacteria
Spp2	I-bacteria
and	O
Streptococcus	B-bacteria
intermedius	I-bacteria
.	O

Other	O
less	O
frequently	O
encountered	O
species	O
were	O
Actinomyces	B-bacteria
israelii	I-bacteria
,	O
Bifidobacterium	B-bacteria
spp	I-bacteria
1	I-bacteria
,	O
Clostridium	B-bacteria
spp	I-bacteria
,	O
and	O
Candida	O
albicans	O
.	O

Results	O
indicate	O
the	O
existence	O
of	O
combinations	O
of	O
bacterial	O
species	O
in	O
root	O
canal	O
infections	O
of	O
the	O
primary	O
dentition	O
with	O
necrotic	O
pulps	O
,	O
anaerobic	O
bacteria	O
predominating	O
.	O

Protease	O
inhibitor	O
cocktails	O
are	O
routinely	O
added	O
to	O
clinical	O
samples	O
used	O
for	O
proteomic	O
studies	O
to	O
inactivate	O
proteases	O
.	O

As	O
these	O
same	O
samples	O
are	O
often	O
used	O
for	O
microbial	O
studies	O
,	O
we	O
determined	O
whether	O
the	O
addition	O
of	O
protease	O
inhibitors	O
could	O
affect	O
the	O
quantitative	O
or	O
qualitative	O
assessment	O
of	O
microbial	O
profiles	O
.	O

Twenty	O
-	O
two	O
saliva	O
samples	O
were	O
collected	O
and	O
processed	O
immediately	O
with	O
or	O
without	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	O
cocktail	O
.	O

The	O
gut	O
microbiome	O
influences	O
host	O
endocrine	O
functions	O
.	O

The	O
gut	O
microbiome	O
is	O
now	O
considered	O
as	O
an	O
organ	O
contributing	O
to	O
the	O
regulation	O
of	O
host	O
metabolism	O
.	O

Since	O
the	O
finding	O
of	O
the	O
existence	O
of	O
a	O
relationship	O
between	O
the	O
gut	O
microbiome	O
and	O
specific	O
diseases	O
,	O
numerous	O
studies	O
have	O
also	O
deciphered	O
molecular	O
mechanisms	O
explaining	O
how	O
gut	O
bacteria	O
dialogue	O
with	O
host	O
cells	O
and	O
eventually	O
shape	O
metabolism	O
.	O

Both	O
metagenomic	O
and	O
metabolomic	O
analyses	O
have	O
contributed	O
to	O
the	O
discovery	O
of	O
bacterial	O
-	O
derived	O
metabolites	O
acting	O
on	O
host	O
cells	O
.	O

In	O
this	O
review	O
,	O
we	O
examine	O
the	O
molecular	O
mechanisms	O
by	O
which	O
bacterial	O
metabolites	O
are	O
acting	O
as	O
paracrine	O
or	O
endocrine	O
factors	O
thereby	O
regulating	O
host	O
metabolism	O
.	O

We	O
highlight	O
the	O
impact	O
of	O
specific	O
short	O
chain	O
fatty	O
acids	O
on	O
the	O
secretion	O
of	O
gut	O
peptides	O
(	O
i	O
.	O
e	O
.	O
,	O
GLP	O
-	O
1	O
,	O
PYY	O
)	O
as	O
well	O
as	O
other	O
metabolites	O
produced	O
from	O
different	O
amino	O
acids	O
and	O
regulating	O
inflammation	O
,	O
glucose	O
metabolism	O
or	O
energy	O
homeostasis	O
.	O

We	O
also	O
discuss	O
the	O
role	O
of	O
gut	O
microbes	O
on	O
the	O
regulation	O
of	O
bioactive	O
lipids	O
that	O
belong	O
to	O
the	O
endocannabinoid	O
system	O
as	O
well	O
as	O
specific	O
neurotransmitters	O
(	O
e	O
.	O
g	O
.	O
,	O
GABA	O
,	O
serotonin	O
,	O
NO	O
)	O
.	O

Finally	O
,	O
we	O
review	O
the	O
role	O
of	O
specific	O
bacterial	O
components	O
(	O
i	O
.	O
e	O
.	O
,	O
ClpB	O
,	O
Amuc	O
_	O
1100	O
)	O
also	O
acting	O
as	O
endocrine	O
factors	O
and	O
eventually	O
controlling	O
host	O
metabolism	O
.	O

In	O
conclusion	O
,	O
this	O
review	O
summarizes	O
recent	O
state	O
-	O
of	O
-	O
the	O
art	O
aiming	O
at	O
providing	O
evidence	O
that	O
the	O
gut	O
microbiome	O
influences	O
host	O
endocrine	O
functions	O
via	O
several	O
bacterial	O
-	O
derived	O
metabolites	O
.	O

Gut	O
microbiota	O
and	O
chronic	O
exercise	O
in	O
diabetic	O
patients	O
:	O
not	O
only	O
bacteria	O
.	O

Gut	O
microbiome	O
dysbiosis	O
and	O
increased	O
intestinal	O
permeability	O
in	O
children	O
with	O
islet	O
autoimmunity	O
and	O
type	O
1	O
diabetes	O
:	O
a	O
prospective	O
cohort	O
study	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
To	O
investigate	O
the	O
longitudinal	O
relationship	O
between	O
the	O
gut	O
microbiome	O
,	O
circulating	O
short	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
and	O
intestinal	O
permeability	O
in	O
children	O
with	O
islet	O
autoimmunity	O
or	O
type	O
1	O
diabetes	O
and	O
controls	O
.	O

METHODS	O
:	O
We	O
analysed	O
the	O
gut	O
bacterial	O
microbiome	O
,	O
plasma	O
SCFAs	O
,	O
small	O
intestinal	O
permeability	O
and	O
dietary	O
intake	O
in	O
47	O
children	O
with	O
islet	O
autoimmunity	O
or	O
recent	O
-	O
onset	O
type	O
1	O
diabetes	O
and	O
in	O
41	O
unrelated	O
or	O
sibling	O
controls	O
over	O
a	O
median	O
(	O
range	O
)	O
of	O
13	O
(	O
2	O
-	O
34	O
)	O
months	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O
Children	O
with	O
multiple	O
islet	O
autoantibodies	O
(	O
>	O
/	O
=	O
2	O
IA	O
)	O
or	O
type	O
1	O
diabetes	O
had	O
gut	O
microbiome	O
dysbiosis	O
.	O

Anti	O
-	O
inflammatory	O
Prevotella	B-bacteria
and	O
Butyricimonas	B-bacteria
genera	I-bacteria
were	O
less	O
abundant	O
and	O
these	O
changes	O
were	O
not	O
explained	O
by	O
differences	O
in	O
diet	O
.	O

Small	O
intestinal	O
permeability	O
measured	O
by	O
blood	O
lactulose	O
:	O
rhamnose	O
ratio	O
was	O
higher	O
in	O
type	O
1	O
diabetes	O
.	O

Children	O
with	O
>	O
/	O
=	O
2	O
IA	O
who	O
progressed	O
to	O
type	O
1	O
diabetes	O
(	O
progressors	O
)	O
,	O
compared	O
to	O
those	O
who	O
did	O
not	O
progress	O
,	O
had	O
higher	O
intestinal	O
permeability	O
(	O
mean	O
[	O
SE	O
]	O
difference	O
+	O
5	O
.	O
14	O
[	O
2	O
.	O
0	O
]	O
,	O
95	O
%	O
CI	O
1	O
.	O
21	O
,	O
9	O
.	O
07	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
,	O
lower	O
within	O
-	O
sample	O
(	O
alpha	O
)	O
microbial	O
diversity	O
(	O
31	O
.	O
3	O
[	O
11	O
.	O
2	O
]	O
,	O
95	O
%	O
CI	O
9	O
.	O
3	O
,	O
53	O
.	O
3	O
,	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
and	O
lower	O
abundance	O
of	O
SCFA	O
-	O
producing	O
bacteria	O
.	O

Alpha	O
diversity	O
(	O
observed	O
richness	O
)	O
correlated	O
with	O
plasma	O
acetate	O
levels	O
in	O
all	O
groups	O
combined	O
(	O
regression	O
coeff	O
[	O
SE	O
]	O
0	O
.	O
57	O
[	O
0	O
.	O
21	O
]	O
,	O
95	O
%	O
CI	O
0	O
.	O
15	O
,	O
0	O
.	O
99	O
p	O
=	O
0	O
.	O
008	O
)	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
Children	O
with	O
>	O
/	O
=	O
2	O
IA	O
who	O
progress	O
to	O
diabetes	O
,	O
like	O
those	O
with	O
recent	O
-	O
onset	O
diabetes	O
,	O
have	O
gut	O
microbiome	O
dysbiosis	O
associated	O
with	O
increased	O
intestinal	O
permeability	O
.	O

Interventions	O
that	O
expand	O
gut	O
microbial	O
diversity	O
,	O
in	O
particular	O
SCFA	O
-	O
producing	O
bacteria	O
,	O
may	O
have	O
a	O
role	O
to	O
decrease	O
progression	O
to	O
diabetes	O
in	O
children	O
at	O
-	O
risk	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Deciphering	O
the	O
Chemical	O
Lexicon	O
of	O
Host	O
-	O
Gut	O
Microbiota	O
Interactions	O
.	O

The	O
human	O
intestine	O
harbors	O
an	O
immense	O
,	O
diverse	O
,	O
and	O
critical	O
population	O
of	O
bacteria	O
that	O
has	O
effects	O
on	O
numerous	O
aspects	O
of	O
host	O
physiology	O
,	O
immunity	O
,	O
and	O
disease	O
.	O

Emerging	O
evidence	O
suggests	O
that	O
many	O
of	O
the	O
interactions	O
between	O
the	O
host	O
and	O
the	O
gut	O
microbiota	O
are	O
mediated	O
via	O
the	O
microbial	O
metabolome	O
,	O
or	O
the	O
collection	O
of	O
small	O
-	O
molecule	O
metabolites	O
produced	O
by	O
intestinal	O
bacteria	O
.	O

This	O
review	O
summarizes	O
findings	O
from	O
recent	O
work	O
by	O
focusing	O
on	O
different	O
classes	O
of	O
metabolites	O
produced	O
by	O
the	O
gut	O
microbiota	O
and	O
their	O
effects	O
in	O
modulating	O
host	O
health	O
and	O
disease	O
.	O

These	O
metabolites	O
ultimately	O
serve	O
as	O
a	O
form	O
of	O
communication	O
between	O
the	O
gut	O
microbiome	O
and	O
the	O
host	O
,	O
and	O
a	O
better	O
understanding	O
of	O
this	O
chemical	O
language	O
could	O
potentially	O
lead	O
to	O
novel	O
strategies	O
for	O
treating	O
a	O
wide	O
variety	O
of	O
human	O
disorders	O
.	O

Targeting	O
gut	O
microbiota	O
as	O
a	O
possible	O
therapy	O
for	O
mastitis	O
.	O

Mastitis	O
,	O
a	O
disease	O
that	O
affects	O
both	O
dairy	O
herds	O
and	O
humans	O
,	O
is	O
recognized	O
as	O
the	O
most	O
common	O
source	O
of	O
losses	O
in	O
the	O
dairy	O
industry	O
.	O

Antibiotics	O
have	O
been	O
used	O
for	O
years	O
as	O
the	O
primary	O
treatment	O
for	O
mastitis	O
.	O

However	O
,	O
abuse	O
of	O
antibiotics	O
has	O
led	O
to	O
the	O
emergence	O
of	O
resistant	O
strains	O
and	O
the	O
presence	O
of	O
drug	O
residues	O
and	O
has	O
increased	O
the	O
difficulty	O
of	O
curing	O
this	O
disease	O
.	O

In	O
addition	O
,	O
antibiotics	O
kill	O
most	O
of	O
the	O
microbes	O
that	O
are	O
present	O
in	O
the	O
digestive	O
tract	O
,	O
leading	O
to	O
imbalances	O
in	O
the	O
gut	O
microbiome	O
and	O
destruction	O
of	O
the	O
ecosystem	O
that	O
is	O
normally	O
present	O
in	O
the	O
gut	O
.	O

Gut	O
microbiota	O
play	O
an	O
important	O
role	O
in	O
the	O
host	O
'	O
s	O
health	O
and	O
could	O
be	O
considered	O
the	O
`	O
`	O
second	O
brain	O
'	O
'	O
of	O
the	O
body	O
.	O

In	O
recent	O
years	O
,	O
the	O
gut	O
microbiota	O
and	O
their	O
metabolites	O
,	O
including	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
have	O
been	O
shown	O
to	O
participate	O
in	O
the	O
development	O
of	O
mastitis	O
.	O

LPS	O
is	O
the	O
main	O
component	O
of	O
the	O
cell	O
walls	O
of	O
gram	O
-	O
negative	O
bacteria	O
.	O

Overproduction	O
of	O
rumen	O
-	O
derived	O
LPS	O
injures	O
the	O
rumen	O
epithelium	O
,	O
resulting	O
in	O
the	O
entry	O
of	O
LPS	O
into	O
the	O
blood	O
and	O
damaged	O
liver	O
function	O
;	O
once	O
in	O
the	O
blood	O
,	O
it	O
circulates	O
into	O
the	O
mammary	O
gland	O
,	O
increasing	O
blood	O
-	O
barrier	O
permeability	O
and	O
leading	O
to	O
mammary	O
gland	O
inflammation	O
.	O

SCFAs	O
,	O
which	O
are	O
produced	O
by	O
gut	O
microbiota	O
as	O
fermentation	O
products	O
,	O
have	O
a	O
protective	O
effect	O
on	O
mammary	O
gland	O
inflammatory	O
responses	O
and	O
help	O
maintain	O
the	O
function	O
of	O
the	O
blood	O
-	O
milk	O
barrier	O
.	O

Recently	O
,	O
increasing	O
attention	O
has	O
been	O
focused	O
on	O
the	O
use	O
of	O
probiotics	O
as	O
a	O
promising	O
alternative	O
for	O
the	O
treatment	O
of	O
mastitis	O
.	O

This	O
review	O
summarizes	O
the	O
effects	O
of	O
the	O
gut	O
microbiome	O
and	O
its	O
metabolites	O
on	O
mastitis	O
as	O
well	O
as	O
the	O
current	O
of	O
probiotics	O
in	O
mastitis	O
.	O

This	O
work	O
may	O
provide	O
a	O
valuable	O
theoretical	O
foundation	O
for	O
the	O
development	O
of	O
fresh	O
ideas	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
mastitis	O
.	O

Gut	O
feelings	O
:	O
A	O
randomised	O
,	O
triple	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
probiotics	O
for	O
depressive	O
symptoms	O
.	O

BACKGROUND	O
:	O
Depression	O
is	O
the	O
leading	O
cause	O
of	O
disability	O
worldwide	O
;	O
with	O
evidence	O
suggesting	O
that	O
decreased	O
gut	O
barrier	O
function	O
and	O
inflammation	O
are	O
correlated	O
with	O
depressive	O
symptoms	O
.	O

We	O
conducted	O
a	O
clinical	O
trial	O
to	O
determine	O
the	O
effect	O
of	O
consumption	O
of	O
probiotic	O
supplements	O
(	O
Winclove	O
'	O
s	O
Ecologic	O
(	O
R	O
)	O
Barrier	O
)	O
on	O
depressive	O
symptoms	O
in	O
a	O
sample	O
of	O
participants	O
with	O
mild	O
to	O
severe	O
depression	O
.	O

METHOD	O
:	O
71	O
participants	O
were	O
randomly	O
allocated	O
to	O
either	O
probiotic	O
or	O
placebo	O
,	O
which	O
was	O
,	O
consumed	O
daily	O
over	O
eight	O
weeks	O
.	O

Pre	O
-	O
and	O
post	O
-	O
intervention	O
measures	O
of	O
symptoms	O
and	O
vulnerability	O
markers	O
of	O
depression	O
as	O
well	O
as	O
gut	O
microbiota	O
composition	O
were	O
compared	O
.	O

Clinical	O
trial	O
participants	O
were	O
also	O
compared	O
on	O
psychological	O
variables	O
and	O
gut	O
microbiota	O
composition	O
to	O
a	O
non	O
-	O
depressed	O
group	O
(	O
n	O
=	O
20	O
)	O
.	O

RESULTS	O
:	O
All	O
clinical	O
trial	O
participants	O
demonstrated	O
improvement	O
in	O
symptoms	O
,	O
suggesting	O
non	O
-	O
specific	O
therapeutic	O
effects	O
associated	O
with	O
weekly	O
monitoring	O
visits	O
.	O

Participants	O
in	O
the	O
probiotic	O
group	O
demonstrated	O
a	O
significantly	O
greater	O
reduction	O
in	O
cognitive	O
reactivity	O
compared	O
with	O
the	O
placebo	O
group	O
,	O
particularly	O
in	O
the	O
mild	O
/	O
moderate	O
subgroup	O
.	O

Probiotics	O
did	O
not	O
significantly	O
alter	O
the	O
microbiota	O
of	O
depressed	O
individuals	O
,	O
however	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
Ruminococcus	B-bacteria
gnavus	I-bacteria
and	O
one	O
depression	O
metric	O
.	O

LIMITATIONS	O
:	O
There	O
was	O
a	O
high	O
attrition	O
rate	O
,	O
which	O
may	O
be	O
attributed	O
to	O
weekly	O
monitoring	O
visits	O
.	O

Additionally	O
,	O
modulation	O
of	O
the	O
gut	O
microbiota	O
may	O
need	O
more	O
specific	O
testing	O
to	O
distinguish	O
subtle	O
changes	O
.	O

CONCLUSIONS	O
:	O
While	O
microbiota	O
composition	O
was	O
similar	O
between	O
all	O
groups	O
,	O
probiotics	O
did	O
affect	O
a	O
psychological	O
variable	O
associated	O
with	O
susceptibility	O
to	O
depression	O
.	O

Further	O
research	O
is	O
needed	O
to	O
investigate	O
how	O
probiotics	O
can	O
be	O
utilised	O
to	O
modify	O
mental	O
wellbeing	O
,	O
and	O
whether	O
they	O
can	O
act	O
as	O
an	O
adjunct	O
to	O
existing	O
treatments	O
.	O

Partial	O
Evaluation	O
of	O
Autochthonous	O
Probiotic	O
Potential	O
of	O
the	O
Gut	O
Microbiota	O
of	O
Seriola	O
lalandi	O
.	O

Seriola	O
lalandi	O
is	O
an	O
economically	O
important	O
species	O
that	O
is	O
globally	O
distributed	O
in	O
temperate	O
and	O
subtropical	O
marine	O
waters	O
.	O

Aquaculture	O
production	O
of	O
this	O
species	O
has	O
had	O
problems	O
associated	O
with	O
intensive	O
fish	O
farming	O
,	O
such	O
as	O
disease	O
outbreaks	O
or	O
nutritional	O
deficiencies	O
causing	O
high	O
mortality	O
.	O

Intestinal	O
microbiota	O
are	O
involved	O
in	O
many	O
processes	O
that	O
benefit	O
a	O
host	O
,	O
such	O
as	O
disease	O
control	O
,	O
stimulation	O
of	O
the	O
immune	O
response	O
,	O
and	O
the	O
promotion	O
of	O
nutrient	O
metabolism	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
in	O
vitro	O
probiotic	O
properties	O
of	O
bacteria	O
isolated	O
from	O
the	O
intestinal	O
content	O
of	O
wild	O
Seriola	O
lalandi	O
.	O

The	O
probiotic	O
potential	O
was	O
evaluated	O
in	O
terms	O
of	O
(	O
i	O
)	O
the	O
antimicrobial	O
activity	O
against	O
vibrios	O
causing	O
outbreaks	O
in	O
farmed	O
fish	O
;	O
(	O
ii	O
)	O
the	O
ability	O
to	O
stimulate	O
genes	O
related	O
to	O
an	O
innate	O
immune	O
response	O
in	O
fish	O
;	O
and	O
(	O
iii	O
)	O
antibiotic	O
resistance	O
.	O

Nineteen	O
isolates	O
identified	O
as	O
Pseudomonas	B-bacteria
,	O
Shewanella	B-bacteria
,	O
Psychrobacter	B-bacteria
,	O
and	O
Acinetobacter	B-bacteria
showed	O
antimicrobial	O
activity	O
and	O
significant	O
relative	O
expression	O
of	O
cytokines	O
,	O
serum	O
amyloid	O
A	O
protein	O
(	O
SAA	O
)	O
,	O
hepcidin	O
,	O
and	O
lysozyme	O
.	O

A	O
positive	O
correlation	O
was	O
observed	O
between	O
the	O
levels	O
of	O
expression	O
and	O
the	O
bacterial	O
load	O
after	O
24	O
h	O
of	O
exposure	O
.	O

Pseudomonas	B-bacteria
isolates	I-bacteria
showed	O
a	O
level	O
of	O
antibiotic	O
resistance	O
.	O

In	O
conclusion	O
,	O
isolates	O
of	O
the	O
genera	O
Shewanella	B-bacteria
,	O
Psychrobacter	B-bacteria
,	O
and	O
Acinetobacter	B-bacteria
could	O
serve	O
as	O
potential	O
probiotics	O
in	O
S	O
.	O
lalandi	O
culture	O
.	O

Breakdown	O
of	O
the	O
Paracellular	O
Tight	O
and	O
Adherens	O
Junctions	O
in	O
the	O
Gut	O
and	O
Blood	O
Brain	O
Barrier	O
and	O
Damage	O
to	O
the	O
Vascular	O
Barrier	O
in	O
Patients	O
with	O
Deficit	O
Schizophrenia	O
.	O

Deficit	O
schizophrenia	O
is	O
characterized	O
by	O
leaky	O
intestinal	O
tight	O
and	O
adherens	O
junctions	O
and	O
bacterial	O
translocation	O
.	O

Here	O
we	O
examine	O
whether	O
(	O
deficit	O
)	O
schizophrenia	O
is	O
accompanied	O
by	O
leaky	O
paracellular	O
,	O
transcellular	O
,	O
and	O
vascular	O
barriers	O
in	O
the	O
gut	O
and	O
blood	O
-	O
brain	O
barriers	O
.	O

We	O
measured	O
IgA	O
responses	O
to	O
occludin	O
,	O
claudin	O
-	O
5	O
,	O
E	O
-	O
cadherin	O
,	O
and	O
beta	O
-	O
catenin	O
(	O
paracellular	O
pathway	O
,	O
PARA	O
)	O
;	O
talin	O
,	O
actin	O
,	O
vinculin	O
,	O
and	O
epithelial	O
intermediate	O
filament	O
(	O
transcellular	O
pathway	O
,	O
TRANS	O
)	O
;	O
and	O
plasmalemma	O
vesicle	O
-	O
associated	O
protein	O
(	O
PLVAP	O
,	O
vascular	O
pathway	O
)	O
in	O
78	O
schizophrenia	O
patients	O
and	O
40	O
controls	O
.	O

IgA	O
responses	O
to	O
claudin	O
-	O
5	O
,	O
E	O
-	O
cadherin	O
,	O
and	O
beta	O
-	O
catenin	O
,	O
the	O
sum	O
of	O
the	O
four	O
PARA	O
proteins	O
,	O
and	O
the	O
ratio	O
PARA	O
/	O
TRANS	O
were	O
significantly	O
higher	O
in	O
deficit	O
schizophrenia	O
patients	O
than	O
in	O
nondeficit	O
schizophrenia	O
patients	O
and	O
controls	O
.	O

A	O
large	O
part	O
of	O
the	O
variance	O
in	O
PHEMN	O
(	O
psychosis	O
,	O
hostility	O
,	O
excitation	O
,	O
mannerism	O
,	O
and	O
negative	O
)	O
symptoms	O
,	O
psychomotor	O
retardation	O
,	O
formal	O
thought	O
disorders	O
,	O
verbal	O
fluency	O
,	O
word	O
list	O
memory	O
,	O
word	O
list	O
recall	O
,	O
and	O
executive	O
functions	O
was	O
explained	O
by	O
the	O
PARA	O
/	O
TRANS	O
ratio	O
coupled	O
with	O
plasma	O
IgA	O
responses	O
to	O
Gram	O
-	O
negative	O
bacteria	O
,	O
IgM	O
to	O
malondialdehyde	O
,	O
CCL	O
-	O
11	O
(	O
eotaxin	O
)	O
,	O
IgA	O
levels	O
of	O
the	O
ratio	O
of	O
noxious	O
to	O
more	O
protective	O
tryptophan	O
catabolites	O
(	O
NOX	O
/	O
PRO	O
TRYCATs	O
)	O
,	O
and	O
a	O
plasma	O
immune	O
activation	O
index	O
.	O

Moreover	O
,	O
IgA	O
levels	O
to	O
Gram	O
-	O
negative	O
bacteria	O
were	O
significantly	O
associated	O
with	O
IgA	O
to	O
E	O
-	O
cadherin	O
,	O
beta	O
-	O
catenin	O
,	O
and	O
PLVAP	O
,	O
while	O
IgA	O
levels	O
to	O
claudin	O
-	O
5	O
were	O
significantly	O
predicted	O
by	O
IgA	O
to	O
E	O
-	O
cadherin	O
,	O
NOX	O
/	O
PRO	O
TRYCAT	O
ratio	O
,	O
Gram	O
-	O
negative	O
bacteria	O
,	O
and	O
CCL11	O
.	O

The	O
phenomenology	O
of	O
the	O
deficit	O
syndrome	O
is	O
to	O
a	O
large	O
extent	O
explained	O
by	O
the	O
cumulative	O
effects	O
of	O
lowered	O
natural	O
IgM	O
,	O
breakdown	O
of	O
the	O
paracellular	O
and	O
vascular	O
pathways	O
,	O
increased	O
bacterial	O
translocation	O
,	O
peripheral	O
immune	O
-	O
inflammatory	O
responses	O
,	O
and	O
indices	O
of	O
BBB	O
breakdown	O
.	O

Microbiota	O
Metabolite	O
Short	O
-	O
Chain	O
Fatty	O
Acids	O
Facilitate	O
Mucosal	O
Adjuvant	O
Activity	O
of	O
Cholera	O
Toxin	O
through	O
GPR43	O
.	O

The	O
gut	O
microbiota	O
has	O
been	O
shown	O
critical	O
for	O
mucosal	O
adjuvant	O
activity	O
of	O
cholera	O
toxin	O
(	O
CT	O
)	O
,	O
a	O
potent	O
mucosal	O
adjuvant	O
.	O

However	O
,	O
the	O
mechanisms	O
involved	O
remain	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
depletion	O
of	O
gut	O
bacteria	O
significantly	O
decreased	O
mucosal	O
and	O
systemic	O
Ab	O
responses	O
in	O
mice	O
orally	O
immunized	O
with	O
OVA	O
and	O
CT	O
.	O

Feeding	O
mice	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
promoted	O
Ab	O
responses	O
elicited	O
by	O
CT	O
,	O
and	O
,	O
more	O
importantly	O
,	O
rescued	O
Ab	O
responses	O
in	O
antibiotic	O
-	O
treated	O
mice	O
.	O

In	O
addition	O
,	O
mice	O
deficient	O
in	O
GPR43	O
,	O
a	O
receptor	O
for	O
SCFAs	O
,	O
showed	O
impaired	O
adjuvant	O
activity	O
of	O
CT	O
.	O

Administering	O
CT	O
did	O
not	O
promote	O
SCFA	O
production	O
in	O
the	O
intestines	O
;	O
thus	O
,	O
SCFAs	O
facilitated	O
but	O
did	O
not	O
directly	O
mediate	O
the	O
adjuvant	O
activity	O
of	O
CT	O
.	O
SCFAs	O
promoted	O
B	O
cell	O
Ab	O
production	O
by	O
promoting	O
dendritic	O
cell	O
production	O
of	O
BAFF	O
and	O
ALDH1a2	O
,	O
which	O
induced	O
B	O
cell	O
expression	O
of	O
IFN	O
regulatory	O
factor	O
4	O
,	O
Blimp1	O
,	O
and	O
XBP1	O
,	O
the	O
plasma	O
B	O
cell	O
differentiation	O
-	O
related	O
genes	O
.	O

Furthermore	O
,	O
when	O
infected	O
with	O
Citrobacter	B-bacteria
rodentium	I-bacteria
,	O
GPR43	O
(	O
-	O
/	O
-	O
)	O
mice	O
exhibited	O
decreased	O
Ab	O
responses	O
and	O
were	O
more	O
susceptible	O
to	O
infection	O
,	O
whereas	O
the	O
administration	O
of	O
SCFAs	O
promoted	O
intestinal	O
Ab	O
responses	O
in	O
wild	O
-	O
type	O
mice	O
.	O

Our	O
study	O
thereby	O
demonstrated	O
a	O
critical	O
role	O
of	O
gut	O
microbiota	O
and	O
their	O
metabolite	O
SCFAs	O
in	O
promoting	O
mucosal	O
adjuvant	O
activity	O
of	O
CT	O
through	O
GPR43	O
.	O

Functional	O
characterization	O
of	O
a	O
subtilisin	O
-	O
like	O
serine	O
protease	O
from	O
Vibrio	B-bacteria
cholerae	I-bacteria
.	O

Vibrio	B-bacteria
cholerae	I-bacteria
,	O
the	O
causative	O
agent	O
of	O
the	O
human	O
diarrheal	O
disease	O
cholera	O
,	O
exports	O
numerous	O
enzymes	O
that	O
facilitate	O
its	O
adaptation	O
to	O
both	O
intestinal	O
and	O
aquatic	O
niches	O
.	O

These	O
secreted	O
enzymes	O
can	O
mediate	O
nutrient	O
acquisition	O
,	O
biofilm	O
assembly	O
,	O
and	O
V	B-bacteria
.	I-bacteria
cholerae	I-bacteria
interactions	O
with	O
its	O
host	O
.	O

We	O
recently	O
identified	O
a	O
V	O
.	O
cholerae	O
-	O
secreted	O
serine	O
protease	O
,	O
IvaP	O
,	O
that	O
is	O
active	O
in	O
V	O
.	O
cholerae	O
-	O
infected	O
rabbits	O
and	O
human	O
choleric	O
stool	O
.	O

IvaP	O
alters	O
the	O
activity	O
of	O
several	O
host	O
and	O
pathogen	O
enzymes	O
in	O
the	O
gut	O
and	O
,	O
along	O
with	O
other	O
secreted	O
V	B-bacteria
.	I-bacteria
cholerae	I-bacteria
proteases	O
,	O
decreases	O
binding	O
of	O
intelectin	O
,	O
an	O
intestinal	O
carbohydrate	O
-	O
binding	O
protein	O
,	O
to	O
V	B-bacteria
.	I-bacteria
cholerae	I-bacteria
in	O
vivo	O
IvaP	O
bears	O
homology	O
to	O
subtilisin	O
-	O
like	O
enzymes	O
,	O
a	O
large	O
family	O
of	O
serine	O
proteases	O
primarily	O
comprised	O
of	O
secreted	O
endopeptidases	O
.	O

Following	O
secretion	O
,	O
IvaP	O
is	O
cleaved	O
at	O
least	O
three	O
times	O
to	O
yield	O
a	O
truncated	O
enzyme	O
with	O
serine	O
hydrolase	O
activity	O
,	O
yet	O
little	O
is	O
known	O
about	O
the	O
mechanism	O
of	O
extracellular	O
maturation	O
.	O

Here	O
,	O
we	O
show	O
that	O
IvaP	O
maturation	O
requires	O
a	O
series	O
of	O
sequential	O
N	O
-	O
and	O
C	O
-	O
terminal	O
cleavage	O
events	O
congruent	O
with	O
the	O
enzyme	O
'	O
s	O
mosaic	O
protein	O
domain	O
structure	O
.	O

Using	O
a	O
catalytically	O
inactive	O
reporter	O
protein	O
,	O
we	O
determined	O
that	O
IvaP	O
can	O
be	O
partially	O
processed	O
in	O
trans	O
,	O
but	O
intramolecular	O
proteolysis	O
is	O
most	O
likely	O
required	O
to	O
generate	O
the	O
mature	O
enzyme	O
.	O

Unlike	O
many	O
other	O
subtilisin	O
-	O
like	O
enzymes	O
,	O
the	O
IvaP	O
cleavage	O
pattern	O
is	O
consistent	O
with	O
stepwise	O
processing	O
of	O
the	O
N	O
-	O
terminal	O
propeptide	O
,	O
which	O
could	O
temporarily	O
inhibit	O
,	O
and	O
be	O
cleaved	O
by	O
,	O
the	O
purified	O
enzyme	O
.	O

Furthermore	O
,	O
IvaP	O
was	O
able	O
to	O
cleave	O
purified	O
intelectin	O
,	O
which	O
inhibited	O
intelectin	O
binding	O
to	O
V	B-bacteria
.	I-bacteria
cholerae	I-bacteria
These	O
results	O
suggest	O
that	O
IvaP	O
plays	O
a	O
role	O
in	O
modulating	O
intelectin	O
-	O
V	B-bacteria
.	I-bacteria
cholerae	I-bacteria
interactions	O
.	O

Targeting	O
monocyte	O
-	O
intrinsic	O
enhancer	O
reprogramming	O
improves	O
immunotherapy	O
efficacy	O
in	O
hepatocellular	O
carcinoma	O
.	O

OBJECTIVE	O
:	O
Hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
,	O
mostly	O
developed	O
in	O
fibrotic	O
/	O
cirrhotic	O
liver	O
,	O
exhibits	O
relatively	O
low	O
responsiveness	O
to	O
immune	O
checkpoint	O
blockade	O
(	O
ICB	O
)	O
therapy	O
.	O

As	O
myeloid	O
-	O
derived	O
suppressor	O
cell	O
(	O
MDSC	O
)	O
is	O
pivotal	O
for	O
immunosuppression	O
,	O
we	O
investigated	O
its	O
role	O
and	O
regulation	O
in	O
the	O
fibrotic	O
microenvironment	O
with	O
an	O
aim	O
of	O
developing	O
mechanism	O
-	O
based	O
combination	O
immunotherapy	O
.	O

DESIGN	O
:	O
Functional	O
significance	O
of	O
MDSCs	O
was	O
evaluated	O
by	O
flow	O
cytometry	O
using	O
two	O
orthotopic	O
HCC	O
models	O
in	O
fibrotic	O
liver	O
setting	O
via	O
carbon	O
tetrachloride	O
or	O
high	O
-	O
fat	O
high	O
-	O
carbohydrate	O
diet	O
and	O
verified	O
by	O
clinical	O
specimens	O
.	O

Mechanistic	O
studies	O
were	O
conducted	O
in	O
human	O
hepatic	O
stellate	O
cell	O
(	O
HSC	O
)	O
-	O
peripheral	O
blood	O
mononuclear	O
cell	O
culture	O
systems	O
and	O
fibrotic	O
-	O
HCC	O
patient	O
-	O
derived	O
MDSCs	O
.	O

The	O
efficacy	O
of	O
single	O
or	O
combined	O
therapy	O
with	O
anti	O
-	O
programmed	O
death	O
-	O
1	O
-	O
ligand	O
-	O
1	O
(	O
anti	O
-	O
PD	O
-	O
L1	O
)	O
and	O
a	O
clinically	O
trialled	O
BET	O
bromodomain	O
inhibitor	O
i	O
-	O
BET762	O
was	O
determined	O
.	O

RESULTS	O
:	O
Accumulation	O
of	O
monocytic	O
MDSCs	O
(	O
M	O
-	O
MDSCs	O
)	O
,	O
but	O
not	O
polymorphonuclear	O
MDSCs	O
,	O
in	O
fibrotic	O
livers	O
significantly	O
correlated	O
with	O
reduced	O
tumour	O
-	O
infiltrating	O
lymphocytes	O
(	O
TILs	O
)	O
and	O
increased	O
tumorigenicity	O
in	O
both	O
mouse	O
models	O
.	O

In	O
human	O
HCCs	O
,	O
the	O
tumour	O
-	O
surrounding	O
fibrotic	O
livers	O
were	O
markedly	O
enriched	O
with	O
M	O
-	O
MDSC	O
,	O
with	O
its	O
surrogate	O
marker	O
CD33	O
significantly	O
associated	O
with	O
aggressive	O
tumour	O
phenotypes	O
and	O
poor	O
survival	O
rates	O
.	O

Mechanistically	O
,	O
activated	O
HSCs	O
induced	O
monocyte	O
-	O
intrinsic	O
p38	O
MAPK	O
signalling	O
to	O
trigger	O
enhancer	O
reprogramming	O
for	O
M	O
-	O
MDSC	O
development	O
and	O
immunosuppression	O
.	O

Treatment	O
with	O
p38	O
MAPK	O
inhibitor	O
abrogated	O
HSC	O
-	O
M	O
-	O
MDSC	O
crosstalk	O
to	O
prevent	O
HCC	O
growth	O
.	O

Concomitant	O
with	O
patient	O
-	O
derived	O
M	O
-	O
MDSC	O
suppression	O
by	O
i	O
-	O
BET762	O
,	O
combined	O
treatment	O
with	O
anti	O
-	O
PD	O
-	O
L1	O
synergistically	O
enhanced	O
TILs	O
,	O
resulting	O
in	O
tumour	O
eradication	O
and	O
prolonged	O
survival	O
in	O
the	O
fibrotic	O
-	O
HCC	O
mouse	O
model	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
signify	O
how	O
non	O
-	O
tumour	O
-	O
intrinsic	O
properties	O
in	O
the	O
desmoplastic	O
microenvironment	O
can	O
be	O
exploited	O
to	O
reinstate	O
immunosurveillance	O
,	O
providing	O
readily	O
translatable	O
combination	O
strategies	O
to	O
empower	O
HCC	O
immunotherapy	O
.	O

The	O
Immunomodulatory	O
Properties	O
of	O
Extracellular	O
Vesicles	O
Derived	O
from	O
Probiotics	O
:	O
A	O
Novel	O
Approach	O
for	O
the	O
Management	O
of	O
Gastrointestinal	O
Diseases	O
.	O

Probiotics	O
,	O
included	O
in	O
functional	O
foods	O
,	O
nutritional	O
supplements	O
,	O
or	O
nutraceuticals	O
,	O
exhibit	O
different	O
beneficial	O
effects	O
on	O
gut	O
function	O
.	O

They	O
are	O
extensively	O
used	O
to	O
improve	O
the	O
digestive	O
processes	O
as	O
well	O
as	O
reduce	O
the	O
symptoms	O
and	O
progression	O
of	O
different	O
diseases	O
.	O

Probiotics	O
have	O
shown	O
to	O
improve	O
dysbiosis	O
and	O
modulate	O
the	O
immune	O
response	O
of	O
the	O
host	O
by	O
interacting	O
with	O
different	O
cell	O
types	O
.	O

Probiotics	O
and	O
the	O
host	O
can	O
interact	O
in	O
a	O
direct	O
way	O
,	O
but	O
it	O
is	O
becoming	O
apparent	O
that	O
communication	O
occurs	O
also	O
through	O
extracellular	O
vesicles	O
(	O
EVs	O
)	O
derived	O
from	O
probiotics	O
.	O

EVs	O
are	O
key	O
for	O
bacteria	O
-	O
bacteria	O
and	O
bacteria	O
-	O
host	O
interactions	O
,	O
since	O
they	O
carry	O
a	O
wide	O
variety	O
of	O
components	O
that	O
can	O
modulate	O
different	O
signaling	O
pathways	O
,	O
including	O
those	O
involved	O
in	O
the	O
immune	O
response	O
.	O

Interestingly	O
,	O
EVs	O
are	O
recently	O
starting	O
to	O
be	O
considered	O
as	O
an	O
alternative	O
to	O
probiotics	O
in	O
those	O
cases	O
for	O
which	O
the	O
use	O
of	O
live	O
bacteria	O
could	O
be	O
dangerous	O
,	O
such	O
as	O
immunocompromised	O
individuals	O
or	O
situations	O
where	O
the	O
intestinal	O
barrier	O
is	O
impaired	O
.	O

EVs	O
can	O
spread	O
through	O
the	O
mucus	O
layer	O
and	O
interact	O
with	O
the	O
host	O
,	O
avoiding	O
the	O
risk	O
of	O
sepsis	O
.	O

This	O
review	O
summarizes	O
the	O
existing	O
knowledge	O
about	O
EVs	O
from	O
different	O
probiotic	O
strains	O
,	O
their	O
properties	O
,	O
and	O
their	O
potential	O
use	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
different	O
gastrointestinal	O
diseases	O
.	O

A	O
Distinct	O
Gut	O
Microbiota	O
Exists	O
Within	O
Crohn	O
'	O
s	O
Disease	O
-	O
Related	O
Perianal	O
Fistulae	O
.	O

BACKGROUND	O
:	O
Gut	O
bacteria	O
are	O
strongly	O
suspected	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
.	O

Studies	O
have	O
demonstrated	O
alterations	O
in	O
the	O
gut	O
microbiota	O
in	O
this	O
patient	O
population	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
gut	O
microbiota	O
of	O
fistulizing	O
perianal	O
CD	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Stool	O
and	O
fistula	O
samples	O
were	O
obtained	O
from	O
patients	O
undergoing	O
surgery	O
for	O
CD	O
-	O
related	O
anorectal	O
fistulae	O
.	O

Microbial	O
compositions	O
of	O
matched	O
stool	O
and	O
fistula	O
samples	O
were	O
characterized	O
using	O
16S	O
rRNA	O
gene	O
profiling	O
.	O

The	O
effect	O
of	O
sample	O
type	O
,	O
patient	O
gender	O
,	O
disease	O
classification	O
(	O
Montreal	O
A	O
/	O
B	O
)	O
,	O
disease	O
activity	O
(	O
Harvey	O
Bradshaw	O
Index	O
)	O
,	O
antibiotic	O
use	O
,	O
and	O
presence	O
of	O
active	O
proctitis	O
on	O
microbial	O
composition	O
was	O
assessed	O
.	O

RESULTS	O
:	O
Samples	O
were	O
obtained	O
from	O
18	O
patients	O
.	O

Bacteroides	B-bacteria
was	O
the	O
most	O
abundant	O
genera	O
across	O
all	O
samples	O
collected	O
,	O
followed	O
by	O
Streptococcus	B-bacteria
and	O
Bifidobacterium	B-bacteria
.	O

Bifidobacterium	B-bacteria
was	O
present	O
at	O
significantly	O
higher	O
levels	O
in	O
fecal	O
samples	O
than	O
fistula	O
samples	O
,	O
whereas	O
Achromobacter	B-bacteria
and	O
Corynebacterium	B-bacteria
were	O
present	O
at	O
significantly	O
higher	O
levels	O
in	O
fistula	O
samples	O
.	O

Antibiotic	O
,	O
but	O
not	O
thiopurine	O
or	O
antitumor	O
necrosis	O
factor	O
medication	O
,	O
exposure	O
affected	O
the	O
gut	O
microbial	O
composition	O
.	O

Patient	O
gender	O
,	O
disease	O
classification	O
,	O
disease	O
activity	O
,	O
and	O
presence	O
of	O
active	O
proctitis	O
did	O
not	O
alter	O
stool	O
or	O
fistula	O
microbiota	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
show	O
that	O
the	O
gut	O
microbiota	O
within	O
CD	O
-	O
related	O
anorectal	O
fistulae	O
is	O
distinct	O
from	O
that	O
in	O
stool	O
samples	O
obtained	O
from	O
the	O
same	O
patients	O
.	O

We	O
also	O
observe	O
a	O
dysbiosis	O
in	O
patients	O
treated	O
with	O
antibiotics	O
compared	O
with	O
those	O
not	O
treated	O
with	O
antibiotics	O
.	O

Metabolic	O
Effects	O
of	O
Bile	O
Acids	O
:	O
Potential	O
Role	O
in	O
Bariatric	O
Surgery	O
.	O

Bariatric	O
surgery	O
is	O
the	O
most	O
effective	O
and	O
durable	O
treatment	O
for	O
morbid	O
obesity	O
,	O
with	O
an	O
unexplained	O
yet	O
beneficial	O
side	O
effect	O
of	O
restoring	O
insulin	O
sensitivity	O
and	O
improving	O
glycemia	O
,	O
often	O
before	O
weight	O
loss	O
is	O
observed	O
.	O

Among	O
the	O
many	O
contributing	O
mechanisms	O
oft	O
cited	O
,	O
the	O
altered	O
handling	O
of	O
intestinal	O
bile	O
acids	O
is	O
of	O
considerable	O
therapeutic	O
interest	O
.	O

Here	O
,	O
we	O
review	O
a	O
growing	O
body	O
of	O
literature	O
examining	O
the	O
metabolic	O
effects	O
of	O
bile	O
acids	O
ranging	O
from	O
their	O
physical	O
roles	O
in	O
dietary	O
fat	O
handling	O
within	O
the	O
intestine	O
to	O
their	O
functions	O
as	O
endocrine	O
and	O
paracrine	O
hormones	O
in	O
potentiating	O
responses	O
to	O
bariatric	O
surgery	O
.	O

The	O
roles	O
of	O
two	O
important	O
bile	O
acid	O
receptors	O
,	O
TGR5	O
(	O
Takeda	O
G	O
-	O
protein	O
coupled	O
receptor	O
also	O
known	O
as	O
G	O
-	O
protein	O
coupled	O
bile	O
acid	O
receptor	O
,	O
Gpbar1	O
)	O
and	O
farnesoid	O
X	O
receptor	O
(	O
FXR	O
)	O
,	O
are	O
highlighted	O
as	O
is	O
downstream	O
signaling	O
through	O
glucagon	O
-	O
like	O
polypeptide	O
1	O
(	O
GLP	O
-	O
1	O
)	O
and	O
its	O
cognate	O
receptor	O
,	O
GLP	O
-	O
1R	O
(	O
GLP	O
-	O
1	O
receptor	O
)	O
.	O

Additional	O
improvements	O
in	O
other	O
phenotypes	O
as	O
well	O
as	O
potential	O
contributions	O
of	O
commensal	O
gut	O
bacteria	O
such	O
as	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
that	O
are	O
manifest	O
after	O
Roux	O
-	O
en	O
y	O
gastric	O
bypass	O
(	O
RYGB	O
)	O
and	O
other	O
emulations	O
such	O
as	O
gallbladder	O
bile	O
diversion	O
to	O
the	O
ileum	O
(	O
GB	O
-	O
IL	O
)	O
are	O
also	O
discussed	O
.	O

The	O
interactions	O
of	O
bile	O
acids	O
and	O
the	O
gut	O
microbiota	O
:	O
learning	O
from	O
the	O
differences	O
in	O
Clostridium	B-bacteria
difficile	I-bacteria
infection	O
between	O
children	O
and	O
adults	O
.	O

Bile	O
acids	O
and	O
microbiota	O
differ	O
significantly	O
in	O
the	O
gut	O
of	O
children	O
and	O
adults	O
.	O

In	O
the	O
first	O
three	O
years	O
of	O
life	O
,	O
intestinal	O
bile	O
consists	O
mostly	O
of	O
two	O
primary	O
bile	O
acids	O
,	O
cholic	O
acid	O
(	O
CA	O
)	O
and	O
chenodeoxycholic	O
acid	O
(	O
CDCA	O
)	O
;	O
however	O
,	O
in	O
adults	O
,	O
primary	O
bile	O
acids	O
are	O
transformed	O
into	O
the	O
secondary	O
bile	O
acids	O
,	O
deoxycholic	O
acid	O
(	O
DCA	O
)	O
and	O
lithocholic	O
acid	O
(	O
LCA	O
)	O
.	O

This	O
difference	O
has	O
a	O
major	O
impact	O
on	O
the	O
gut	O
microbiome	O
,	O
especially	O
on	O
anaerobic	O
spore	O
-	O
forming	O
bacteria	O
.	O

Cholic	O
acid	O
augments	O
germination	O
of	O
spores	O
in	O
the	O
terminal	O
ileum	O
.	O

On	O
the	O
other	O
hand	O
,	O
deoxycholic	O
acid	O
curtails	O
the	O
number	O
of	O
germinated	O
anaerobes	O
entering	O
the	O
cecum	O
from	O
the	O
terminal	O
ileum	O
.	O

The	O
control	O
mechanism	O
that	O
exists	O
in	O
the	O
adult	O
cecum	O
is	O
absent	O
in	O
the	O
young	O
child	O
and	O
results	O
in	O
unrestrained	O
proliferation	O
of	O
anaerobes	O
,	O
such	O
as	O
Clostridium	B-bacteria
difficile	I-bacteria
,	O
in	O
the	O
cecum	O
.	O

A	O
similar	O
situation	O
may	O
develop	O
during	O
antibiotic	O
therapy	O
when	O
an	O
antibiotic	O
eradicates	O
the	O
anaerobic	O
population	O
capable	O
of	O
converting	O
primary	O
bile	O
acids	O
into	O
secondary	O
bile	O
acids	O
.	O

The	O
Urinary	O
Microbiome	O
and	O
Anticancer	O
Immunotherapy	O
:	O
The	O
Potentially	O
Hidden	O
Role	O
of	O
Unculturable	O
Microbes	O
.	O

Several	O
urinary	O
disorders	O
,	O
including	O
overactive	O
bladder	O
,	O
urinary	O
incontinence	O
,	O
and	O
interstitial	O
cystitis	O
,	O
are	O
often	O
characterized	O
by	O
negative	O
urine	O
cultures	O
.	O

The	O
application	O
of	O
metagenomics	O
(	O
i	O
.	O
e	O
.	O
,	O
16S	O
rRNA	O
microbial	O
profiling	O
or	O
whole	O
-	O
genome	O
shotgun	O
sequencing	O
)	O
to	O
urine	O
samples	O
has	O
enabled	O
the	O
identification	O
of	O
previously	O
undetected	O
bacteria	O
,	O
contributing	O
to	O
the	O
discovery	O
and	O
characterization	O
of	O
the	O
urinary	O
microbiome	O
.	O

The	O
most	O
frequent	O
species	O
isolated	O
are	O
Lactobacillus	B-bacteria
(	O
15	O
%	O
)	O
,	O
Corynebacterium	B-bacteria
(	O
14	O
.	O
2	O
%	O
)	O
,	O
Streptococcus	B-bacteria
(	O
11	O
.	O
9	O
%	O
)	O
,	O
Actinomyces	B-bacteria
(	O
6	O
.	O
9	O
%	O
)	O
,	O
and	O
Staphylococcus	B-bacteria
(	O
6	O
.	O
9	O
%	O
)	O
.	O

Although	O
several	O
studies	O
are	O
emerging	O
in	O
this	O
context	O
,	O
the	O
role	O
of	O
urinary	O
microbiota	O
in	O
the	O
pathogenesis	O
of	O
infections	O
and	O
in	O
tumor	O
carcinogenesis	O
remains	O
unclear	O
.	O

Furthermore	O
,	O
data	O
on	O
the	O
activity	O
of	O
gut	O
microbiota	O
in	O
modulating	O
sensitivity	O
to	O
immune	O
checkpoint	O
inhibitors	O
in	O
advanced	O
cancer	O
patients	O
suggest	O
that	O
the	O
influence	O
of	O
urinary	O
microbiota	O
on	O
tumor	O
response	O
to	O
anticancer	O
therapy	O
should	O
also	O
be	O
investigated	O
.	O

Moreover	O
,	O
its	O
possible	O
relationship	O
with	O
tumor	O
mutational	O
burden	O
,	O
which	O
is	O
in	O
turn	O
correlated	O
with	O
response	O
to	O
immunotherapy	O
,	O
should	O
be	O
the	O
focus	O
of	O
future	O
studies	O
.	O

Of	O
note	O
,	O
the	O
effect	O
of	O
antibiotics	O
on	O
this	O
complex	O
scenario	O
seems	O
to	O
deserve	O
careful	O
consideration	O
.	O

Modulation	O
of	O
gut	O
microbiota	O
by	O
chlorogenic	O
acid	O
pretreatment	O
on	O
rats	O
with	O
adrenocorticotropic	O
hormone	O
induced	O
depression	O
-	O
like	O
behavior	O
.	O

Gut	O
microbiota	O
dysbiosis	O
has	O
been	O
implicated	O
as	O
a	O
vital	O
element	O
in	O
the	O
development	O
or	O
exacerbation	O
of	O
mental	O
disorders	O
,	O
such	O
as	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

Based	O
on	O
the	O
current	O
interest	O
in	O
the	O
gut	O
-	O
brain	O
axis	O
,	O
we	O
investigate	O
the	O
effects	O
of	O
chlorogenic	O
acid	O
(	O
CGA	O
)	O
on	O
gut	O
microbiota	O
in	O
a	O
rat	O
model	O
of	O
MDD	O
.	O

Depression	O
was	O
induced	O
by	O
the	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
,	O
100	O
mug	O
per	O
rat	O
)	O
in	O
male	O
Wistar	O
rats	O
,	O
which	O
were	O
intervened	O
with	O
using	O
saline	O
or	O
CGA	O
(	O
500	O
mg	O
kg	O
-	O
1	O
)	O
.	O

Behavioral	O
changes	O
and	O
serum	O
parameters	O
were	O
assessed	O
and	O
fecal	O
samples	O
were	O
analyzed	O
by	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

Our	O
studies	O
demonstrated	O
that	O
CGA	O
pretreatment	O
ameliorated	O
depression	O
-	O
like	O
behavior	O
(	O
SPT	O
,	O
FST	O
,	O
TST	O
,	O
and	O
OFT	O
)	O
and	O
serum	O
biochemical	O
levels	O
(	O
5	O
-	O
HT	O
,	O
DA	O
,	O
IL	O
-	O
6	O
,	O
and	O
TNF	O
-	O
alpha	O
)	O
in	O
ACTH	O
-	O
induced	O
depression	O
rats	O
.	O

In	O
addition	O
,	O
CGA	O
ameliorated	O
the	O
decrease	O
in	O
fecal	O
microbiota	O
diversity	O
in	O
ACTH	O
-	O
treated	O
rats	O
.	O

In	O
particular	O
,	O
at	O
the	O
genus	O
level	O
,	O
the	O
changes	O
in	O
the	O
relative	O
abundance	O
of	O
some	O
key	O
bacteria	O
such	O
as	O
Desulfovibrionales	B-bacteria
,	O
Desulfovibrio	B-bacteria
,	O
Klebsiella	B-bacteria
,	O
Burkholderiales	B-bacteria
,	O
and	O
Bifidobacterium	B-bacteria
were	O
modulated	O
by	O
CGA	O
pretreatment	O
.	O

These	O
results	O
indicated	O
that	O
CGA	O
could	O
modify	O
the	O
gut	O
microbial	O
community	O
structure	O
,	O
which	O
may	O
contribute	O
to	O
its	O
antidepressant	O
effects	O
.	O

Bacteriophages	O
of	O
the	O
lower	O
urinary	O
tract	O
.	O

The	O
discovery	O
of	O
bacteria	O
in	O
the	O
female	O
urinary	O
bladder	O
has	O
fundamentally	O
changed	O
current	O
dogma	O
regarding	O
the	O
urinary	O
tract	O
and	O
related	O
urinary	O
disorders	O
.	O

Previous	O
research	O
characterized	O
many	O
of	O
the	O
bacterial	O
components	O
of	O
the	O
female	O
urinary	O
tract	O
,	O
but	O
the	O
viral	O
fraction	O
of	O
this	O
community	O
is	O
largely	O
unknown	O
.	O

Viruses	O
within	O
the	O
human	O
microbiota	O
far	O
outnumber	O
bacterial	O
cells	O
,	O
with	O
the	O
most	O
abundant	O
viruses	O
being	O
those	O
that	O
infect	O
bacteria	O
(	O
bacteriophages	O
)	O
.	O

Similar	O
to	O
observations	O
within	O
the	O
microbiota	O
of	O
the	O
gut	O
and	O
oral	O
cavity	O
,	O
preliminary	O
surveys	O
of	O
the	O
urinary	O
tract	O
and	O
bladder	O
microbiota	O
indicate	O
a	O
rich	O
diversity	O
of	O
uncharacterized	O
bacteriophage	O
(	O
phage	O
)	O
species	O
.	O

Phages	O
are	O
vital	O
members	O
of	O
the	O
microbiota	O
,	O
having	O
critical	O
roles	O
in	O
shaping	O
bacterial	O
metabolism	O
and	O
community	O
structure	O
.	O

Although	O
phages	O
have	O
been	O
discovered	O
in	O
the	O
urinary	O
tract	O
,	O
such	O
as	O
phages	O
that	O
infect	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
sampling	O
them	O
is	O
challenging	O
owing	O
to	O
low	O
biomass	O
,	O
possible	O
contamination	O
when	O
using	O
non	O
-	O
invasive	O
methods	O
and	O
the	O
invasiveness	O
of	O
methods	O
that	O
reduce	O
the	O
potential	O
for	O
contamination	O
.	O

Phages	O
could	O
influence	O
bladder	O
health	O
,	O
but	O
an	O
understanding	O
of	O
the	O
association	O
between	O
phage	O
communities	O
,	O
bacterial	O
populations	O
and	O
bladder	O
health	O
is	O
in	O
its	O
infancy	O
.	O

However	O
,	O
evidence	O
suggests	O
that	O
phages	O
can	O
defend	O
the	O
host	O
against	O
pathogenic	O
bacteria	O
and	O
,	O
therefore	O
,	O
modulation	O
of	O
the	O
microbiome	O
using	O
phages	O
has	O
therapeutic	O
potential	O
for	O
lower	O
urinary	O
tract	O
symptoms	O
.	O

Furthermore	O
,	O
as	O
natural	O
predators	O
of	O
bacteria	O
,	O
phages	O
have	O
garnered	O
renewed	O
interest	O
for	O
their	O
use	O
as	O
antimicrobial	O
agents	O
,	O
for	O
instance	O
,	O
in	O
the	O
treatment	O
of	O
urinary	O
tract	O
infections	O
.	O

Bacteroides	O
-	O
Derived	O
Sphingolipids	O
Are	O
Critical	O
for	O
Maintaining	O
Intestinal	O
Homeostasis	O
and	O
Symbiosis	O
.	O

Sphingolipids	O
are	O
structural	O
membrane	O
components	O
and	O
important	O
eukaryotic	O
signaling	O
molecules	O
.	O

Sphingolipids	O
regulate	O
inflammation	O
and	O
immunity	O
and	O
were	O
recently	O
identified	O
as	O
the	O
most	O
differentially	O
abundant	O
metabolite	O
in	O
stool	O
from	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
patients	O
.	O

Commensal	O
bacteria	O
from	O
the	O
Bacteroidetes	B-bacteria
phylum	I-bacteria
also	O
produce	O
sphingolipids	O
,	O
but	O
the	O
impact	O
of	O
these	O
metabolites	O
on	O
host	O
pathways	O
is	O
largely	O
uncharacterized	O
.	O

To	O
determine	O
whether	O
bacterial	O
sphingolipids	O
modulate	O
intestinal	O
health	O
,	O
we	O
colonized	O
germ	O
-	O
free	O
mice	O
with	O
a	O
sphingolipid	O
-	O
deficient	O
Bacteroides	B-bacteria
thetaiotaomicron	I-bacteria
strain	I-bacteria
.	O

A	O
lack	O
of	O
Bacteroides	O
-	O
derived	O
sphingolipids	O
resulted	O
in	O
intestinal	O
inflammation	O
and	O
altered	O
host	O
ceramide	O
pools	O
in	O
mice	O
.	O

Using	O
lipidomic	O
analysis	O
,	O
we	O
described	O
a	O
sphingolipid	O
biosynthesis	O
pathway	O
and	O
revealed	O
a	O
variety	O
of	O
Bacteroides	O
-	O
derived	O
sphingolipids	O
including	O
ceramide	O
phosphoinositol	O
and	O
deoxy	O
-	O
sphingolipids	O
.	O

Annotating	O
Bacteroides	B-bacteria
sphingolipids	O
in	O
an	O
IBD	O
metabolomic	O
dataset	O
revealed	O
lower	O
abundances	O
in	O
IBD	O
and	O
negative	O
correlations	O
with	O
inflammation	O
and	O
host	O
sphingolipid	O
production	O
.	O

These	O
data	O
highlight	O
the	O
role	O
of	O
bacterial	O
sphingolipids	O
in	O
maintaining	O
homeostasis	O
and	O
symbiosis	O
in	O
the	O
gut	O
.	O

Vitamin	O
C	O
and	O
B3	O
as	O
New	O
Biomaterials	O
to	O
Alter	O
Intestinal	O
Stem	O
Cells	O
.	O

Vitamin	O
C	O
(	O
ascorbic	O
acid	O
)	O
and	O
vitamin	O
B3	O
(	O
niacin	O
)	O
have	O
been	O
extensively	O
studied	O
since	O
the	O
20th	O
century	O
.	O

In	O
the	O
area	O
of	O
stem	O
cell	O
biology	O
,	O
vitamin	O
C	O
has	O
shown	O
its	O
direct	O
impact	O
towards	O
homeostasis	O
and	O
epigenetic	O
changes	O
.	O

(	O
1	O
)	O
Vitamin	O
B3	O
aids	O
in	O
maintaining	O
healthy	O
intestinal	O
homeostasis	O
and	O
reducing	O
gut	O
inflammation	O
by	O
participating	O
in	O
the	O
rapamycin	O
signaling	O
pathway	O
.	O

(	O
2	O
)	O
In	O
this	O
study	O
,	O
vitamin	O
C	O
and	O
vitamin	O
B3	O
(	O
600	O
and	O
1200	O
mug	O
/	O
ml	O
)	O
have	O
been	O
explored	O
as	O
potential	O
new	O
biomaterials	O
to	O
study	O
their	O
effects	O
on	O
four	O
types	O
of	O
intestinal	O
stem	O
cells	O
which	O
are	O
isolated	O
from	O
mice	O
bearing	O
different	O
microbiota	O
.	O

We	O
observed	O
that	O
C3H	O
ASF	O
and	O
129	O
ASF	O
IL	O
-	O
10	O
are	O
more	O
sensitive	O
towards	O
600	O
mug	O
/	O
ml	O
vitamin	O
B3	O
and	O
1200	O
mug	O
/	O
ml	O
vitamin	O
C	O
.	O
The	O
lowest	O
growth	O
rate	O
and	O
viability	O
for	O
all	O
types	O
of	O
organoids	O
was	O
with	O
1200	O
mug	O
/	O
ml	O
vitamin	O
C	O
.	O
From	O
qPCR	O
analysis	O
(	O
quantitative	O
Polymerase	O
Chain	O
Reaction	O
analysis	O
)	O
,	O
MUC2	O
was	O
upregulated	O
for	O
129	O
ASF	O
and	O
C3H	O
Conv	O
when	O
exposed	O
to	O
600	O
mug	O
/	O
ml	O
and	O
1200	O
mug	O
/	O
ml	O
vitamin	O
C	O
.	O
It	O
suggests	O
that	O
large	O
amounts	O
of	O
glycoprotein	O
may	O
be	O
produced	O
after	O
adding	O
high	O
concentrations	O
of	O
vitamin	O
C	O
.	O
Since	O
inflammatory	O
bowel	O
disease	O
has	O
low	O
level	O
of	O
MUC2	O
,	O
this	O
finding	O
may	O
be	O
helpful	O
in	O
restoring	O
mucosal	O
health	O
by	O
upregulating	O
the	O
MUC2	O
gene	O
while	O
altering	O
patient	O
'	O
s	O
microbiota	O
.	O

(	O
3	O
)	O
These	O
results	O
are	O
expected	O
to	O
have	O
a	O
positive	O
translational	O
impact	O
because	O
this	O
bottom	O
-	O
up	O
strategy	O
would	O
be	O
instrumental	O
in	O
developing	O
Vitamin	O
C	O
and	O
B3	O
based	O
orally	O
available	O
therapeutic	O
strategies	O
and	O
formula	O
for	O
advancing	O
the	O
fields	O
of	O
gastrointestinal	O
regenerative	O
medicine	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Bile	O
salt	O
hydrolase	O
can	O
improve	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
survival	O
in	O
gastrointestinal	O
tract	O
by	O
enhancing	O
their	O
adhesion	O
ability	O
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
are	O
major	O
probiotics	O
in	O
food	O
supplements	O
.	O

Survival	O
in	O
gastrointestinal	O
(	O
GI	O
)	O
tract	O
is	O
important	O
for	O
the	O
effective	O
use	O
of	O
LAB	B-bacteria
as	O
probiotics	O
.	O

Bile	O
salt	O
hydrolase	O
(	O
BSH	O
)	O
,	O
which	O
catalyzes	O
the	O
conversion	O
of	O
conjugated	O
bile	O
salts	O
into	O
free	O
bile	O
salts	O
,	O
can	O
significantly	O
modulate	O
the	O
gut	O
microbiome	O
.	O

Here	O
,	O
we	O
hypothesize	O
that	O
BSH	O
is	O
important	O
for	O
LAB	B-bacteria
survival	O
and	O
adhesion	O
in	O
the	O
gut	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effect	O
of	O
BSH	O
on	O
the	O
survival	O
of	O
LAB	B-bacteria
in	O
the	O
GI	O
tract	O
.	O

A	O
panel	O
of	O
bsh	O
genes	O
from	O
murine	O
gut	O
microbiota	O
were	O
amplified	O
,	O
cloned	O
and	O
expressed	O
into	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
,	O
which	O
were	O
then	O
administered	O
to	O
mice	O
by	O
gavage	O
.	O

Our	O
data	O
indicated	O
that	O
the	O
survival	O
of	O
BSH	O
-	O
positive	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
was	O
significantly	O
prolonged	O
in	O
the	O
GI	O
tract	O
compared	O
with	O
wild	O
type	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
.	O

Furthermore	O
,	O
BSH	O
-	O
positive	O
strains	O
exhibited	O
increased	O
adhesion	O
to	O
Caco	O
-	O
2	O
intestinal	O
cells	O
than	O
BSH	O
-	O
deleted	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
.	O

Enhanced	O
adhesion	O
to	O
intestinal	O
cells	O
of	O
BSH	O
positive	O
LAB	B-bacteria
can	O
therefore	O
be	O
an	O
important	O
criterion	O
for	O
selecting	O
effective	O
probiotic	O
strains	O
in	O
food	O
industry	O
.	O

Antibiotic	O
-	O
Induced	O
Disruption	O
of	O
Gut	O
Microbiota	O
Alters	O
Local	O
Metabolomes	O
and	O
Immune	O
Responses	O
.	O

Gut	O
microbiome	O
plays	O
an	O
essential	O
role	O
in	O
modulating	O
host	O
immune	O
responses	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
interaction	O
of	O
microbiota	O
,	O
their	O
metabolites	O
and	O
relevant	O
inflammatory	O
responses	O
in	O
the	O
gut	O
.	O

By	O
treating	O
the	O
mice	O
with	O
three	O
different	O
antibiotics	O
(	O
enrofloxacin	O
,	O
vancomycin	O
,	O
and	O
polymixin	O
B	O
sulfate	O
)	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
different	O
antibiotics	O
exposure	O
on	O
gut	O
microbiota	O
,	O
microbial	O
metabolism	O
,	O
inflammation	O
responses	O
in	O
the	O
gut	O
,	O
and	O
most	O
importantly	O
,	O
pinpoint	O
the	O
underlying	O
interactions	O
between	O
them	O
.	O

Although	O
the	O
administration	O
of	O
different	O
antibiotics	O
can	O
lead	O
to	O
different	O
effects	O
on	O
mouse	O
models	O
,	O
the	O
treatment	O
did	O
not	O
affect	O
the	O
average	O
body	O
weight	O
of	O
the	O
mice	O
.	O

A	O
heavier	O
caecum	O
was	O
observed	O
in	O
vancomycin	O
treated	O
mice	O
.	O

Treatment	O
by	O
these	O
three	O
antibiotics	O
significantly	O
up	O
-	O
regulated	O
gene	O
expression	O
of	O
various	O
cytokines	O
in	O
the	O
colon	O
.	O

Enrofloxacin	O
treated	O
mice	O
seemed	O
to	O
have	O
an	O
increased	O
Th1	O
response	O
in	O
the	O
colon	O
.	O

However	O
,	O
such	O
a	O
difference	O
was	O
not	O
found	O
in	O
mice	O
treated	O
by	O
vancomycin	O
or	O
polymixin	O
B	O
sulfate	O
.	O

Vancomycin	O
treatment	O
induced	O
significant	O
changes	O
in	O
bacterial	O
composition	O
at	O
phylum	O
and	O
family	O
level	O
and	O
decreased	O
richness	O
and	O
diversity	O
at	O
species	O
level	O
.	O

Enrofloxacin	O
treatment	O
only	O
induced	O
changes	O
in	O
composition	O
at	O
family	O
presenting	O
as	O
an	O
increase	O
in	O
Prevotellaceae	B-bacteria
and	O
Rikenellaceae	B-bacteria
and	O
a	O
decrease	O
in	O
Bacteroidaceae	B-bacteria
.	O

However	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
after	O
polymixin	O
B	O
sulfate	O
treatment	O
.	O

When	O
compared	O
with	O
the	O
control	O
group	O
,	O
significant	O
metabolic	O
shift	O
was	O
found	O
in	O
the	O
enrofloxacin	O
and	O
vancomycin	O
treated	O
group	O
.	O

The	O
metabolic	O
changes	O
mainly	O
occurred	O
in	O
Valine	O
,	O
leucine	O
,	O
and	O
isoleucine	O
biosynthesis	O
pathway	O
and	O
beta	O
-	O
Alanine	O
metabolism	O
in	O
enrofloxacin	O
treated	O
group	O
.	O

For	O
vancomycin	O
treatment	O
metabolic	O
changes	O
were	O
mainly	O
found	O
in	O
beta	O
-	O
Alanine	O
metabolism	O
and	O
Alanine	O
,	O
aspartate	O
and	O
glutamate	O
metabolism	O
pathway	O
.	O

Moreover	O
,	O
modifications	O
observed	O
in	O
the	O
microbiota	O
compositions	O
were	O
correlated	O
with	O
the	O
metabolite	O
concentrations	O
.	O

For	O
example	O
,	O
concentration	O
of	O
pentadecanoic	O
acid	O
was	O
positively	O
correlated	O
with	O
richness	O
of	O
Rikenellaceae	B-bacteria
and	O
Prevotellaceae	B-bacteria
and	O
negatively	O
correlated	O
with	O
Enterobacteriaceae	B-bacteria
.	O

This	O
study	O
suggests	O
that	O
the	O
antibiotic	O
-	O
induced	O
changes	O
in	O
gut	O
microbiota	O
might	O
contribute	O
to	O
the	O
inflammation	O
responses	O
through	O
the	O
alternation	O
of	O
metabolic	O
status	O
,	O
providing	O
a	O
novel	O
insight	O
regarding	O
a	O
complex	O
network	O
that	O
integrates	O
the	O
different	O
interactions	O
between	O
gut	O
microbiota	O
,	O
metabolic	O
functions	O
,	O
and	O
immune	O
responses	O
in	O
host	O
.	O

Identifying	O
Gut	O
Microbiota	O
Associated	O
With	O
Colorectal	O
Cancer	O
Using	O
a	O
Zero	O
-	O
Inflated	O
Lognormal	O
Model	O
.	O

Colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
the	O
third	O
most	O
common	O
cancer	O
worldwide	O
.	O

Its	O
incidence	O
is	O
still	O
increasing	O
,	O
and	O
the	O
mortality	O
rate	O
is	O
high	O
.	O

New	O
therapeutic	O
and	O
prognostic	O
strategies	O
are	O
urgently	O
needed	O
.	O

It	O
became	O
increasingly	O
recognized	O
that	O
the	O
gut	O
microbiota	O
composition	O
differs	O
significantly	O
between	O
healthy	O
people	O
and	O
CRC	O
patients	O
.	O

Thus	O
,	O
identifying	O
the	O
difference	O
between	O
gut	O
microbiota	O
of	O
the	O
healthy	O
people	O
and	O
CRC	O
patients	O
is	O
fundamental	O
to	O
understand	O
these	O
microbes	O
'	O
functional	O
roles	O
in	O
the	O
development	O
of	O
CRC	O
.	O

We	O
studied	O
the	O
microbial	O
community	O
structure	O
of	O
a	O
CRC	O
metagenomic	O
dataset	O
of	O
156	O
patients	O
and	O
healthy	O
controls	O
,	O
and	O
analyzed	O
the	O
diversity	O
,	O
differentially	O
abundant	O
bacteria	O
,	O
and	O
co	O
-	O
occurrence	O
networks	O
.	O

We	O
applied	O
a	O
modified	O
zero	O
-	O
inflated	O
lognormal	O
(	O
ZIL	O
)	O
model	O
for	O
estimating	O
the	O
relative	O
abundance	O
.	O

We	O
found	O
that	O
the	O
abundance	O
of	O
genera	O
:	O
Anaerostipes	B-bacteria
,	O
Bilophila	B-bacteria
,	O
Catenibacterium	B-bacteria
,	O
Coprococcus	B-bacteria
,	O
Desulfovibrio	B-bacteria
,	O
Flavonifractor	B-bacteria
,	O
Porphyromonas	B-bacteria
,	O
Pseudoflavonifractor	B-bacteria
,	O
and	O
Weissella	B-bacteria
was	O
significantly	O
different	O
between	O
the	O
healthy	O
and	O
CRC	O
groups	O
.	O

We	O
also	O
found	O
that	O
bacteria	O
such	O
as	O
Streptococcus	B-bacteria
,	O
Parvimonas	B-bacteria
,	O
Collinsella	B-bacteria
,	O
and	O
Citrobacter	B-bacteria
were	O
uniquely	O
co	O
-	O
occurring	O
within	O
the	O
CRC	O
patients	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
the	O
microbial	O
diversity	O
of	O
healthy	O
controls	O
is	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
CRC	O
patients	O
,	O
which	O
indicated	O
a	O
significant	O
negative	O
correlation	O
between	O
gut	O
microbiota	O
diversity	O
and	O
the	O
stage	O
of	O
CRC	O
.	O

Collectively	O
,	O
our	O
results	O
strengthened	O
the	O
view	O
that	O
individual	O
microbes	O
as	O
well	O
as	O
the	O
overall	O
structure	O
of	O
gut	O
microbiota	O
were	O
co	O
-	O
evolving	O
with	O
CRC	O
.	O

Alpha	O
-	O
Synuclein	O
Pathology	O
and	O
the	O
Role	O
of	O
the	O
Microbiota	O
in	O
Parkinson	O
'	O
s	O
Disease	O
.	O

There	O
is	O
a	O
principle	O
in	O
science	O
,	O
known	O
as	O
Occam	O
'	O
s	O
razor	O
,	O
that	O
says	O
the	O
correct	O
solution	O
is	O
usually	O
the	O
one	O
with	O
the	O
simplest	O
explanation	O
.	O

The	O
microbiota	O
-	O
gut	O
-	O
brain	O
axis	O
,	O
an	O
interdependent	O
series	O
of	O
communication	O
loops	O
between	O
the	O
enteric	O
nervous	O
system	O
(	O
ENS	O
)	O
,	O
the	O
microbiota	O
,	O
the	O
gut	O
,	O
and	O
the	O
brain	O
,	O
offers	O
important	O
insight	O
into	O
how	O
changes	O
in	O
our	O
gut	O
affect	O
distant	O
organs	O
like	O
our	O
brains	O
.	O

The	O
inherent	O
complexity	O
of	O
this	O
axis	O
with	O
the	O
crosstalk	O
between	O
the	O
immune	O
system	O
,	O
inflammatory	O
states	O
,	O
and	O
the	O
thousands	O
of	O
bacteria	O
,	O
viral	O
,	O
and	O
fungal	O
species	O
that	O
together	O
make	O
up	O
the	O
microbiota	O
make	O
studying	O
the	O
interactions	O
that	O
govern	O
this	O
axis	O
difficult	O
and	O
far	O
from	O
parsimonious	O
.	O

It	O
is	O
becoming	O
increasingly	O
clear	O
that	O
the	O
microbiota	O
is	O
integral	O
to	O
this	O
axis	O
.	O

Disruption	O
of	O
the	O
healthy	O
flora	O
,	O
a	O
phenomenon	O
collectively	O
referred	O
to	O
as	O
dysbiosis	O
,	O
has	O
been	O
implicated	O
as	O
a	O
driver	O
for	O
several	O
diseases	O
such	O
as	O
irritable	O
bowel	O
syndrome	O
,	O
rheumatoid	O
arthritis	O
,	O
obesity	O
,	O
diabetes	O
,	O
liver	O
disease	O
,	O
and	O
neurological	O
disorders	O
such	O
as	O
depression	O
,	O
anxiety	O
,	O
and	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O

Teasing	O
apart	O
these	O
complex	O
interactions	O
as	O
they	O
pertain	O
to	O
PD	O
is	O
critical	O
for	O
our	O
understanding	O
of	O
this	O
debilitating	O
disease	O
,	O
but	O
more	O
importantly	O
,	O
for	O
the	O
development	O
of	O
future	O
treatments	O
.	O

So	O
far	O
,	O
treatments	O
have	O
been	O
unable	O
to	O
stop	O
this	O
neurodegenerative	O
disease	O
,	O
succeeding	O
only	O
in	O
briefly	O
dampening	O
symptoms	O
and	O
buying	O
patients	O
time	O
before	O
the	O
inevitable	O
loss	O
of	O
function	O
ensues	O
.	O

Given	O
that	O
the	O
10	O
years	O
prognosis	O
for	O
death	O
or	O
life	O
-	O
limiting	O
disability	O
with	O
someone	O
diagnosed	O
with	O
PD	O
is	O
upwards	O
of	O
80	O
%	O
,	O
there	O
is	O
a	O
desperate	O
need	O
for	O
curative	O
treatments	O
that	O
go	O
beyond	O
symptom	O
management	O
.	O

If	O
PD	O
does	O
begin	O
in	O
the	O
periphery	O
with	O
bidirectional	O
communication	O
between	O
the	O
microbiota	O
and	O
the	O
immune	O
system	O
,	O
as	O
recent	O
literature	O
suggests	O
,	O
there	O
is	O
an	O
exciting	O
possibility	O
that	O
progression	O
could	O
be	O
stopped	O
before	O
it	O
reaches	O
the	O
brain	O
.	O

This	O
systematic	O
review	O
assesses	O
the	O
current	O
literature	O
surrounding	O
the	O
role	O
of	O
the	O
microbiota	O
in	O
the	O
pathogenesis	O
of	O
alpha	O
-	O
synucleinopathies	O
and	O
explores	O
the	O
hypothesis	O
that	O
alpha	O
-	O
synuclein	O
folding	O
is	O
modulated	O
by	O
the	O
microbiota	O
.	O

Furthermore	O
,	O
we	O
discuss	O
how	O
changes	O
in	O
the	O
gut	O
environment	O
can	O
lead	O
to	O
pathology	O
and	O
outline	O
the	O
implications	O
that	O
advances	O
in	O
understanding	O
the	O
interactions	O
between	O
host	O
and	O
microbiota	O
will	O
have	O
on	O
future	O
research	O
and	O
the	O
development	O
of	O
potential	O
biomarkers	O
.	O

Mucosal	O
-	O
associated	O
invariant	O
T	O
cells	O
and	O
oral	O
microbiome	O
in	O
persistent	O
apical	O
periodontitis	O
.	O

Opportunistic	O
bacteria	O
in	O
apical	O
periodontitis	O
(	O
AP	O
)	O
may	O
pose	O
a	O
risk	O
for	O
systemic	O
dissemination	O
.	O

Mucosal	O
-	O
associated	O
invariant	O
T	O
(	O
MAIT	O
)	O
cells	O
are	O
innate	O
-	O
like	O
T	O
cells	O
with	O
a	O
broad	O
and	O
potent	O
antimicrobial	O
activity	O
important	O
for	O
gut	O
mucosal	O
integrity	O
.	O

It	O
was	O
recently	O
shown	O
that	O
MAIT	O
cells	O
are	O
present	O
in	O
the	O
oral	O
mucosal	O
tissue	O
,	O
but	O
the	O
involvement	O
of	O
MAIT	O
cells	O
in	O
AP	O
is	O
unknown	O
.	O

Here	O
,	O
comparison	O
of	O
surgically	O
resected	O
AP	O
and	O
gingival	O
tissues	O
demonstrated	O
that	O
AP	O
tissues	O
express	O
significantly	O
higher	O
levels	O
of	O
Valpha7	O
.	O
2	O
-	O
Jalpha33	O
,	O
Valpha7	O
.	O
2	O
-	O
Jalpha20	O
,	O
Valpha7	O
.	O
2	O
-	O
Jalpha12	O
,	O
Calpha	O
and	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
interferon	O
(	O
IFN	O
)	O
-	O
gamma	O
and	O
interleukin	O
(	O
IL	O
)	O
-	O
17A	O
transcripts	O
,	O
resembling	O
a	O
MAIT	O
cell	O
signature	O
.	O

Moreover	O
,	O
in	O
AP	O
tissues	O
the	O
MR1	O
-	O
restricted	O
MAIT	O
cells	O
positive	O
for	O
MR1	O
-	O
5	O
-	O
OP	O
-	O
RU	O
tetramer	O
staining	O
appeared	O
to	O
be	O
of	O
similar	O
levels	O
as	O
in	O
peripheral	O
blood	O
but	O
consisted	O
mainly	O
of	O
CD4	O
(	O
+	O
)	O
subset	O
.	O

Unlike	O
gingival	O
tissues	O
,	O
the	O
AP	O
microbiome	O
was	O
quantitatively	O
impacted	O
by	O
factors	O
like	O
fistula	O
and	O
high	O
patient	O
age	O
and	O
had	O
a	O
prominent	O
riboflavin	O
-	O
expressing	O
bacterial	O
feature	O
.	O

When	O
merged	O
in	O
an	O
integrated	O
view	O
,	O
the	O
examined	O
immune	O
and	O
microbiome	O
data	O
in	O
the	O
sparse	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
could	O
identify	O
bacterial	O
relative	O
abundances	O
that	O
negatively	O
correlated	O
with	O
Valpha7	O
.	O
2	O
-	O
Jalpha33	O
,	O
Calpha	O
,	O
and	O
IL	O
-	O
17A	O
transcript	O
expressions	O
in	O
AP	O
,	O
implying	O
that	O
MAIT	O
cells	O
could	O
play	O
a	O
role	O
in	O
the	O
local	O
defence	O
at	O
the	O
oral	O
tissue	O
barrier	O
.	O

In	O
conclusion	O
,	O
we	O
describe	O
the	O
presence	O
of	O
MAIT	O
cells	O
at	O
the	O
oral	O
site	O
where	O
translocation	O
of	O
oral	O
microbiota	O
could	O
take	O
place	O
.	O

These	O
findings	O
have	O
implications	O
for	O
understanding	O
the	O
immune	O
sensing	O
of	O
polymicrobial	O
-	O
related	O
oral	O
diseases	O
.	O

Obesity	O
,	O
Xenobiotic	O
Intake	O
and	O
Antimicrobial	O
-	O
Resistance	O
Genes	O
in	O
the	O
Human	O
Gastrointestinal	O
Tract	O
:	O
A	O
Comparative	O
Study	O
of	O
Eutrophic	O
,	O
Overweight	O
and	O
Obese	O
Individuals	O
.	O

Although	O
lifestyle	O
and	O
physiology	O
in	O
obese	O
individuals	O
are	O
accepted	O
to	O
lead	O
to	O
changes	O
in	O
the	O
intestinal	O
microbiota	O
,	O
uncertainty	O
remains	O
about	O
microbiota	O
dysbiosis	O
,	O
and	O
xenobiotics	O
intake	O
,	O
as	O
a	O
source	O
of	O
selective	O
pressure	O
,	O
independent	O
of	O
antimicrobial	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
occurrence	O
of	O
antimicrobial	O
resistance	O
genetic	O
markers	O
(	O
ARG	O
)	O
in	O
faecal	O
specimens	O
of	O
eutrophic	O
,	O
overweight	O
and	O
obese	O
individuals	O
,	O
and	O
their	O
correlation	O
with	O
xenobiotic	O
intake	O
and	O
gut	O
bacteria	O
density	O
.	O

Methods	O
:	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
case	O
-	O
controlled	O
study	O
including	O
72	O
adult	O
participants	O
with	O
no	O
record	O
of	O
intestinal	O
or	O
systemic	O
diseases	O
,	O
or	O
recent	O
use	O
of	O
antimicrobials	O
,	O
grouped	O
as	O
eutrophic	O
,	O
overweight	O
,	O
or	O
obese	O
.	O

Anthropometric	O
profile	O
,	O
eating	O
habits	O
and	O
oral	O
xenobiotics	O
intake	O
were	O
recorded	O
.	O

Faecal	O
metagenomic	O
DNA	O
was	O
used	O
to	O
screen	O
for	O
ARG	O
by	O
PCR	O
,	O
and	O
to	O
measure	O
bacterial	O
groups	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Student	O
'	O
s	O
t	O
and	O
Wilcoxon	O
tests	O
were	O
used	O
to	O
compare	O
means	O
and	O
differences	O
in	O
ARG	O
detection	O
(	O
95	O
%	O
confidence	O
intervals	O
)	O
.	O

Correlation	O
analyses	O
(	O
odds	O
ratio	O
)	O
and	O
relationships	O
between	O
bacteria	O
density	O
and	O
ARG	O
were	O
determined	O
.	O

Results	O
:	O
Increase	O
in	O
abdominal	O
circumference	O
,	O
waist	O
circumference	O
,	O
hip	O
,	O
waist	O
-	O
hip	O
ratio	O
,	O
BMI	O
,	O
carbohydrate	O
,	O
fibres	O
,	O
and	O
total	O
calorie	O
intakes	O
were	O
different	O
from	O
eutrophic	O
to	O
obese	O
participants	O
.	O

Habitual	O
use	O
of	O
antihypertensive	O
and	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
antacids	O
,	O
and	O
artificial	O
sweeteners	O
were	O
associated	O
mainly	O
with	O
obesity	O
and	O
overweight	O
.	O

Nutritional	O
supplements	O
were	O
associated	O
to	O
the	O
eutrophic	O
group	O
.	O

ARG	O
screening	O
showed	O
differences	O
being	O
more	O
frequent	O
among	O
obese	O
,	O
and	O
positive	O
for	O
27	O
genetic	O
markers	O
related	O
to	O
beta	O
-	O
lactams	O
,	O
tetracyclines	O
,	O
the	O
macrolide	O
lincosamide	O
and	O
streptogramin	O
group	O
,	O
quinolones	O
,	O
sulfonamides	O
,	O
aminoglycosides	O
,	O
and	O
efflux	O
pump	O
.	O

Positive	O
correlation	O
between	O
ARG	O
and	O
BMI	O
,	O
caloric	O
intake	O
,	O
and	O
intake	O
of	O
xenobiotics	O
,	O
was	O
observed	O
for	O
obese	O
individuals	O
.	O

Relationships	O
among	O
ARG	O
detection	O
and	O
bacteria	O
densities	O
were	O
also	O
different	O
.	O

Conclusions	O
:	O
This	O
study	O
reinforces	O
the	O
hypothesis	O
that	O
obese	O
individuals	O
may	O
harbour	O
an	O
altered	O
gut	O
microbiota	O
,	O
if	O
compared	O
to	O
eutrophic	O
.	O

The	O
overweight	O
individuals	O
display	O
a	O
transitional	O
gut	O
microbiota	O
which	O
seems	O
to	O
be	O
between	O
eutrophic	O
and	O
obese	O
.	O

Furthermore	O
,	O
the	O
increased	O
xenobiotic	O
intake	O
associated	O
to	O
obesity	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
antimicrobial	O
resistance	O
phenomenon	O
.	O

Responses	O
of	O
microbial	O
community	O
structure	O
in	O
turbot	O
(	O
Scophthalmus	O
maximus	O
)	O
larval	O
intestine	O
to	O
the	O
regulation	O
of	O
probiotic	O
introduced	O
through	O
live	O
feed	O
.	O

Various	O
bacteria	O
that	O
adhere	O
to	O
the	O
gut	O
are	O
important	O
for	O
the	O
health	O
of	O
fish	O
.	O

Regulating	O
the	O
microbial	O
community	O
in	O
a	O
desirable	O
direction	O
may	O
be	O
beneficial	O
in	O
aquaculture	O
for	O
preventing	O
and	O
controlling	O
the	O
diseases	O
caused	O
by	O
pathogenic	O
microbes	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
changes	O
in	O
the	O
microflora	O
in	O
the	O
intestinal	O
tracts	O
of	O
turbot	O
(	O
Scophthalmus	O
maximus	O
)	O
larvae	O
after	O
introducing	O
a	O
probiotic	O
(	O
Bacillus	B-bacteria
amyloliquefaciens	I-bacteria
)	O
after	O
the	O
first	O
feed	O
.	O

B	B-bacteria
.	I-bacteria
amyloliquefaciens	I-bacteria
was	O
added	O
as	O
part	O
of	O
a	O
nutrient	O
enrichment	O
system	O
in	O
live	O
feed	O
(	O
Branchionus	O
plicatilis	O
or	O
Artemia	O
sinica	O
)	O
,	O
so	O
it	O
passed	O
into	O
the	O
intestinal	O
tracts	O
of	O
the	O
newly	O
hatched	O
turbot	O
larvae	O
.	O

The	O
turbot	O
larvae	O
were	O
fed	O
on	O
live	O
feed	O
containing	O
B	B-bacteria
.	I-bacteria
amyloliquefaciens	I-bacteria
in	O
the	O
experimental	O
group	O
,	O
whereas	O
live	O
feed	O
without	O
the	O
probiotic	O
was	O
provided	O
to	O
larvae	O
in	O
the	O
control	O
group	O
.	O

The	O
total	O
bacterial	O
genomic	O
DNA	O
in	O
the	O
larval	O
guts	O
was	O
extracted	O
and	O
sequenced	O
with	O
an	O
Illumina	O
HiSeq	O
PE250	O
system	O
.	O

According	O
to	O
the	O
sequencing	O
results	O
,	O
the	O
abundances	O
of	O
microbial	O
species	O
and	O
the	O
microflora	O
diversity	O
were	O
lower	O
in	O
the	O
intestines	O
in	O
the	O
experimental	O
group	O
than	O
the	O
control	O
.	O

Throughout	O
development	O
,	O
the	O
microflora	O
structure	O
in	O
the	O
intestines	O
was	O
mainly	O
constructed	O
before	O
the	O
first	O
feed	O
and	O
the	O
composition	O
of	O
the	O
dominant	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
was	O
stable	O
,	O
where	O
the	O
abundances	O
of	O
OTU8	O
,	O
OTU124	O
,	O
OTU150	O
,	O
OTU107	O
,	O
and	O
OTU17	O
were	O
always	O
high	O
.	O

Compared	O
with	O
the	O
control	O
,	O
the	O
structures	O
of	O
the	O
microflora	O
in	O
the	O
intestines	O
were	O
similar	O
on	O
different	O
days	O
during	O
the	O
development	O
and	O
the	O
growth	O
of	O
larvae	O
in	O
the	O
experimental	O
group	O
.	O

However	O
,	O
the	O
similarity	O
of	O
the	O
microflora	O
structure	O
between	O
different	O
treatments	O
was	O
low	O
on	O
the	O
same	O
day	O
.	O

Furthermore	O
,	O
the	O
mean	O
proportion	O
of	O
common	O
OTUs	O
was	O
only	O
74	O
.	O
7	O
%	O
in	O
different	O
treatments	O
on	O
each	O
day	O
,	O
which	O
indicates	O
that	O
the	O
introduction	O
of	O
B	B-bacteria
.	I-bacteria
amyloliquefaciens	I-bacteria
in	O
the	O
live	O
feed	O
changed	O
the	O
microflora	O
structure	O
in	O
the	O
intestine	O
.	O

During	O
the	O
early	O
development	O
stage	O
(	O
days	O
3	O
-	O
30	O
)	O
,	O
the	O
average	O
abundance	O
of	O
Pseudomonas	B-bacteria
was	O
reduced	O
by	O
0	O
.	O
8	O
%	O
whereas	O
that	O
of	O
Lactococcus	B-bacteria
increased	O
by	O
3	O
.	O
5	O
%	O
in	O
the	O
experimental	O
group	O
.	O

Pseudomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
are	O
considered	O
potentially	O
pathogenic	O
bacteria	O
but	O
there	O
is	O
no	O
direct	O
evidence	O
for	O
the	O
pathogenicity	O
of	O
Lactococcus	B-bacteria
in	O
turbot	O
.	O

Moreover	O
,	O
several	O
Lactococcus	B-bacteria
species	I-bacteria
are	O
regarded	O
as	O
probiotics	O
in	O
aquaculture	O
.	O

Therefore	O
,	O
the	O
use	O
of	O
B	B-bacteria
.	I-bacteria
amyloliquefaciens	I-bacteria
could	O
be	O
beneficial	O
for	O
optimizing	O
the	O
microbial	O
community	O
structure	O
in	O
the	O
intestines	O
of	O
turbot	O
larvae	O
,	O
which	O
may	O
explain	O
the	O
probiotic	O
effect	O
of	O
B	B-bacteria
.	I-bacteria
amyloliquefaciens	I-bacteria
.	O

This	O
study	O
provides	O
a	O
theoretical	O
basis	O
for	O
the	O
biological	O
regulation	O
of	O
the	O
microflora	O
structure	O
in	O
the	O
intestinal	O
tract	O
during	O
turbot	O
breeding	O
.	O

Variations	O
of	O
the	O
intestinal	O
gut	O
microbiota	O
of	O
farmed	O
rainbow	O
trout	O
,	O
Oncorhynchus	O
mykiss	O
(	O
Walbaum	O
)	O
,	O
depending	O
on	O
the	O
infection	O
status	O
of	O
the	O
fish	O
.	O

AIMS	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
composition	O
of	O
the	O
intestinal	O
microbiota	O
during	O
the	O
acute	O
stage	O
of	O
a	O
bacterial	O
infection	O
to	O
understand	O
how	O
dysbiosis	O
of	O
the	O
gut	O
may	O
influence	O
overall	O
taxonomic	O
hierarchy	O
and	O
diversity	O
,	O
and	O
determine	O
if	O
there	O
exists	O
a	O
bacterial	O
taxon	O
(	O
s	O
)	O
that	O
serve	O
as	O
markers	O
for	O
healthy	O
or	O
diseased	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
From	O
July	O
to	O
September	O
2015	O
29	O
specimens	O
of	O
three	O
-	O
year	O
-	O
old	O
(	O
an	O
average	O
weight	O
from	O
240	O
.	O
9	O
+	O
/	O
-	O
37	O
.	O
7	O
to	O
850	O
.	O
7	O
+	O
/	O
-	O
70	O
.	O
1	O
g	O
)	O
rainbow	O
trout	O
Oncorhynchus	O
mykiss	O
were	O
studied	O
.	O

Next	O
-	O
generation	O
high	O
-	O
throughput	O
sequencing	O
of	O
the	O
16S	O
ribosomal	O
RNA	O
genes	O
was	O
applied	O
to	O
stomach	O
and	O
intestinal	O
samples	O
to	O
compare	O
the	O
impact	O
of	O
infection	O
status	O
on	O
the	O
microbiota	O
of	O
rainbow	O
trout	O
Oncorhynchus	O
mykiss	O
(	O
Walbaum	O
)	O
from	O
the	O
northwest	O
part	O
of	O
Eurasia	O
(	O
Karelian	O
region	O
,	O
Russia	O
)	O
.	O

The	O
alpha	O
diversity	O
(	O
Chao1	O
,	O
Simpson	O
and	O
Shannon	O
index	O
)	O
of	O
the	O
microbial	O
community	O
of	O
healthy	O
rainbow	O
trout	O
was	O
significantly	O
higher	O
than	O
in	O
unhealthy	O
fish	O
.	O

The	O
greatest	O
contribution	O
to	O
the	O
gut	O
microbial	O
composition	O
of	O
healthy	O
fish	O
was	O
made	O
by	O
OTU	O
'	O
s	O
belonging	O
to	O
Bacillus	B-bacteria
,	O
Serratia	B-bacteria
,	O
Pseudomonas	B-bacteria
,	O
Cetobacterium	B-bacteria
,	O
and	O
Lactobacillus	B-bacteria
.	O

Microbiota	O
of	O
unhealthy	O
fish	O
in	O
most	O
cases	O
was	O
represented	O
by	O
the	O
genera	O
Serratia	B-bacteria
,	O
Bacillus	B-bacteria
,	O
and	O
Pseudomonas	B-bacteria
.	O

In	O
microbiota	O
of	O
unhealthy	O
fish	O
there	O
were	O
also	O
registered	O
unique	O
taxa	O
such	O
as	O
bacteria	O
from	O
the	O
family	O
Mycoplasmataceae	B-bacteria
and	O
Renibacterium	B-bacteria
.	O

Analysis	O
of	O
similarities	O
(	O
ANOSIM	O
test	O
)	O
revealed	O
the	O
significant	O
dissimilarity	O
between	O
the	O
microbiota	O
of	O
stomach	O
and	O
intestine	O
(	O
p	O
<	O
/	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
A	O
substantial	O
finding	O
was	O
the	O
absence	O
of	O
differences	O
between	O
microbial	O
communities	O
of	O
the	O
stomach	O
and	O
intestine	O
in	O
the	O
unhealthy	O
groups	O
if	O
compared	O
with	O
healthy	O
fish	O
.	O

SIGNIFICANCE	O
AND	O
IMPACT	O
OF	O
STUDY	O
:	O
These	O
results	O
demonstrated	O
alterations	O
of	O
the	O
gut	O
microbiota	O
of	O
farmed	O
rainbow	O
trout	O
,	O
O	O
.	O
mykiss	O
during	O
co	O
-	O
infections	O
and	O
can	O
be	O
useful	O
for	O
the	O
development	O
of	O
new	O
strategies	O
for	O
disease	O
control	O
programs	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Inclusion	O
of	O
fish	O
waste	O
silage	O
in	O
broiler	O
diets	O
affects	O
gut	O
microflora	O
,	O
cecal	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
digestive	O
enzyme	O
activity	O
,	O
nutrient	O
digestibility	O
,	O
and	O
excreta	O
gas	O
emission	O
.	O

A	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
impacts	O
of	O
dietary	O
inclusion	O
of	O
fish	O
waste	O
silage	O
(	O
FWS	O
)	O
substituting	O
soybean	O
meal	O
(	O
SBM	O
)	O
on	O
the	O
performance	O
,	O
gut	O
microflora	O
,	O
cecal	O
short	O
-	O
chain	O
fatty	O
acid	O
,	O
apparent	O
ileal	O
digestibility	O
(	O
AID	O
)	O
,	O
digestive	O
enzyme	O
activity	O
,	O
and	O
excreta	O
noxious	O
gas	O
emission	O
in	O
broiler	O
chickens	O
.	O

A	O
total	O
of	O
720	O
-	O
day	O
-	O
old	O
male	O
broilers	O
(	O
Cobb	O
500	O
)	O
were	O
randomly	O
allocated	O
to	O
3	O
dietary	O
treatments	O
with	O
12	O
replicates	O
each	O
accommodating	O
20	O
birds	O
for	O
42	O
d	O
.	O
Birds	O
received	O
diets	O
as	O
follows	O
:	O
a	O
corn	O
-	O
SBM	O
-	O
based	O
diet	O
(	O
CON	O
)	O
and	O
2	O
diets	O
that	O
replaced	O
SBM	O
with	O
FWS	O
at	O
60	O
g	O
/	O
kg	O
(	O
FWS60	O
)	O
and	O
120	O
g	O
/	O
kg	O
(	O
FWS120	O
)	O
.	O

During	O
the	O
entire	O
period	O
,	O
replacing	O
SBM	O
with	O
FWS60	O
and	O
FWS120	O
increased	O
body	O
weight	O
gain	O
and	O
decreased	O
feed	O
conversion	O
ratio	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
lowest	O
pH	O
values	O
in	O
the	O
crop	O
,	O
proventriculus	O
,	O
duodenum	O
,	O
ileum	O
,	O
and	O
ceca	O
were	O
observed	O
in	O
birds	O
fed	O
diets	O
containing	O
FWS60	O
and	O
FWS120	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Likewise	O
,	O
birds	O
fed	O
FWS60	O
and	O
FWS120	O
had	O
lower	O
numbers	O
of	O
coliform	B-bacteria
and	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
higher	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
count	O
in	O
the	O
ceca	O
than	O
those	O
fed	O
CON	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Feeding	O
FWS60	O
and	O
FWS120	O
diets	O
increased	O
cecal	O
butyrate	O
and	O
lactic	O
acid	O
contents	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Birds	O
fed	O
FWS120	O
diets	O
had	O
greater	O
intestinal	O
amylase	O
and	O
protease	O
activity	O
than	O
birds	O
fed	O
CON	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
however	O
,	O
no	O
significant	O
differences	O
were	O
recorded	O
between	O
the	O
treatment	O
groups	O
for	O
digestive	O
enzymes	O
activity	O
in	O
the	O
pancreas	O
.	O

The	O
use	O
of	O
both	O
levels	O
of	O
FWS	O
in	O
broiler	O
diet	O
increased	O
AID	O
of	O
crude	O
protein	O
and	O
ether	O
extract	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
lowest	O
excreta	O
ammonia	O
concentration	O
was	O
recorded	O
in	O
birds	O
fed	O
FWS120	O
diet	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
inclusion	O
of	O
FWS	O
in	O
broiler	O
diets	O
could	O
improve	O
the	O
performance	O
by	O
enhancing	O
gut	O
function	O
,	O
derived	O
from	O
the	O
improved	O
digestive	O
enzyme	O
activity	O
and	O
nutrient	O
digestibility	O
,	O
as	O
well	O
as	O
by	O
elevating	O
the	O
population	O
of	O
beneficial	O
bacteria	O
and	O
short	O
-	O
chain	O
fatty	O
acid	O
contents	O
.	O

Therefore	O
,	O
the	O
biological	O
silage	O
can	O
be	O
considered	O
as	O
a	O
promising	O
option	O
for	O
recycling	O
and	O
recovery	O
of	O
fish	O
wastes	O
and	O
effectively	O
be	O
used	O
in	O
broiler	O
diets	O
.	O

Amorphous	O
cellulose	O
feed	O
supplement	O
alters	O
the	O
broiler	O
caecal	O
microbiome	O
.	O

The	O
grains	O
that	O
form	O
the	O
basis	O
of	O
most	O
commercial	O
chicken	O
diets	O
are	O
rich	O
in	O
cellulose	O
,	O
an	O
unbranched	O
beta	O
-	O
1	O
,	O
4	O
-	O
linked	O
D	O
-	O
glucopyranose	O
polymer	O
,	O
used	O
as	O
a	O
structural	O
molecule	O
in	O
plants	O
.	O

Although	O
it	O
is	O
a	O
predominant	O
polysaccharide	O
in	O
cereal	O
hulls	O
,	O
it	O
is	O
considered	O
an	O
inert	O
non	O
-	O
fermentable	O
fiber	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
analyze	O
the	O
effect	O
of	O
in	O
-	O
feed	O
supplementation	O
of	O
cellulose	O
on	O
the	O
gut	O
microbiota	O
composition	O
of	O
broilers	O
.	O

Administration	O
of	O
cellulose	O
to	O
chickens	O
,	O
on	O
top	O
of	O
a	O
wheat	O
-	O
based	O
diet	O
,	O
changed	O
the	O
caecal	O
microbiota	O
composition	O
,	O
as	O
determined	O
using	O
pyrosequencing	O
of	O
the	O
16S	O
rRNA	O
gene	O
.	O

At	O
day	O
26	O
,	O
a	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
higher	O
relative	O
abundance	O
of	O
the	O
Alistipes	B-bacteria
genus	I-bacteria
was	O
observed	O
in	O
the	O
caeca	O
of	O
broilers	O
fed	O
the	O
cellulose	O
-	O
supplemented	O
diet	O
,	O
compared	O
to	O
animals	O
fed	O
the	O
control	O
diet	O
.	O

An	O
in	O
vitro	O
batch	O
fermentation	O
assay	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
growth	O
stimulation	O
of	O
Alistipes	B-bacteria
finegoldii	I-bacteria
in	O
the	O
presence	O
of	O
cellulose	O
.	O

In	O
conclusion	O
,	O
in	O
-	O
feed	O
supplementation	O
of	O
cellulose	O
alters	O
the	O
microbiota	O
composition	O
at	O
the	O
level	O
of	O
the	O
phylum	O
Bacteroidetes	B-bacteria
,	O
specifically	O
the	O
Alistipes	B-bacteria
genus	I-bacteria
.	O

This	O
suggests	O
that	O
cellulose	O
is	O
not	O
essentially	O
inert	O
but	O
can	O
alter	O
the	O
gut	O
micro	O
-	O
environment	O
.	O

Dysbiosis	O
of	O
the	O
Gut	O
Microbiome	O
in	O
Lung	O
Cancer	O
.	O

Lung	O
cancer	O
(	O
LC	O
)	O
is	O
one	O
of	O
the	O
most	O
serious	O
malignant	O
tumors	O
,	O
which	O
has	O
the	O
fastest	O
growing	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

A	O
role	O
of	O
the	O
lung	O
microbiota	O
in	O
LC	O
pathogenesis	O
has	O
been	O
analyzed	O
,	O
but	O
a	O
comparable	O
role	O
of	O
the	O
gut	O
microbiota	O
has	O
not	O
yet	O
been	O
investigated	O
.	O

In	O
this	O
study	O
,	O
the	O
gut	O
microbiota	O
of	O
30	O
LC	O
patients	O
and	O
30	O
healthy	O
controls	O
were	O
examined	O
via	O
next	O
-	O
generation	O
sequencing	O
of	O
16S	O
rRNA	O
and	O
analyzed	O
for	O
diversity	O
and	O
biomarkers	O
.	O

We	O
found	O
that	O
there	O
was	O
no	O
decrease	O
in	O
significant	O
microbial	O
diversity	O
(	O
alpha	O
diversity	O
)	O
in	O
LC	O
patients	O
compared	O
to	O
controls	O
(	O
P	O
observed	O
=	O
0	O
.	O
1422	O
)	O
,	O
while	O
the	O
composition	O
(	O
beta	O
diversity	O
)	O
differed	O
significantly	O
between	O
patients	O
and	O
controls	O
(	O
phylum	O
[	O
stress	O
=	O
0	O
.	O
153	O
]	O
,	O
class	O
[	O
stress	O
=	O
0	O
.	O
16	O
]	O
,	O
order	O
[	O
stress	O
=	O
0	O
.	O
146	O
]	O
,	O
family	O
[	O
stress	O
=	O
0	O
.	O
153	O
]	O
)	O
.	O

Controls	O
had	O
a	O
higher	O
abundance	O
of	O
the	O
bacterial	O
phylum	O
Actinobacteria	B-bacteria
and	O
genus	O
Bifidobacterium	B-bacteria
,	O
while	O
patients	O
with	O
LC	O
showed	O
elevated	O
levels	O
of	O
Enterococcus	B-bacteria
.	O

These	O
bacteria	O
were	O
found	O
as	O
possible	O
biomarkers	O
for	O
LC	O
.	O

A	O
decline	O
of	O
normal	O
function	O
of	O
the	O
gut	O
microbiome	O
in	O
LC	O
patients	O
was	O
also	O
observed	O
.	O

These	O
results	O
provide	O
the	O
basic	O
guidance	O
for	O
a	O
systematic	O
,	O
multilayered	O
assessment	O
of	O
the	O
role	O
of	O
the	O
gut	O
microbiome	O
in	O
LC	O
,	O
which	O
has	O
a	O
promising	O
potential	O
for	O
early	O
prevention	O
and	O
targeted	O
intervention	O
.	O

Prospecting	O
prebiotics	O
,	O
innovative	O
evaluation	O
methods	O
,	O
and	O
their	O
health	O
applications	O
:	O
a	O
review	O
.	O

Prebiotics	O
are	O
necessary	O
natural	O
and	O
synthetic	O
food	O
ingredients	O
that	O
help	O
in	O
the	O
growth	O
and	O
development	O
of	O
gut	O
microflora	O
.	O

There	O
is	O
a	O
complex	O
relationship	O
between	O
gut	O
dysbiosis	O
and	O
microbes	O
,	O
so	O
alteration	O
in	O
both	O
probiotics	O
and	O
prebiotics	O
can	O
reduce	O
illness	O
of	O
gut	O
,	O
which	O
further	O
plays	O
a	O
decisive	O
role	O
in	O
human	O
health	O
.	O

The	O
prebiotic	O
efficiency	O
can	O
be	O
validated	O
using	O
various	O
in	O
vitro	O
and	O
in	O
vivo	O
experiments	O
,	O
and	O
this	O
gives	O
an	O
important	O
insight	O
to	O
this	O
field	O
.	O

This	O
review	O
focuses	O
on	O
these	O
aspects	O
including	O
the	O
standardized	O
assessment	O
of	O
prebiotics	O
and	O
its	O
metabolic	O
products	O
for	O
customary	O
applications	O
.	O

This	O
review	O
has	O
also	O
summarized	O
the	O
mechanism	O
of	O
their	O
beneficial	O
actions	O
such	O
as	O
immunomodulation	O
,	O
nutrient	O
absorption	O
,	O
pathogen	O
inhibition	O
,	O
etc	O
.	O
,	O
and	O
its	O
significance	O
in	O
human	O
nutrition	O
.	O

In	O
addition	O
to	O
this	O
,	O
some	O
fascinating	O
applications	O
of	O
prebiotics	O
in	O
health	O
-	O
related	O
disorders	O
have	O
also	O
discussed	O
,	O
with	O
current	O
challenges	O
in	O
this	O
facet	O
.	O

Heat	O
stress	O
directly	O
impairs	O
gut	O
integrity	O
and	O
recruits	O
distinct	O
immune	O
cell	O
populations	O
into	O
the	O
bovine	O
intestine	O
.	O

High	O
ambient	O
temperature	O
has	O
multiple	O
potential	O
effects	O
on	O
the	O
organism	O
such	O
as	O
hyperthermia	O
,	O
endotoxemia	O
,	O
and	O
/	O
or	O
systemic	O
inflammation	O
.	O

However	O
,	O
it	O
is	O
often	O
difficult	O
to	O
discriminate	O
between	O
cause	O
and	O
consequence	O
of	O
phenotypic	O
effects	O
,	O
such	O
as	O
the	O
indirect	O
influence	O
of	O
heat	O
stress	O
via	O
reduced	O
food	O
intake	O
.	O

Lactating	O
dairy	O
cows	O
are	O
a	O
particularly	O
sensitive	O
model	O
to	O
examine	O
the	O
effects	O
of	O
heat	O
stress	O
due	O
to	O
their	O
intensive	O
metabolic	O
heat	O
production	O
and	O
small	O
surface	O
:	O
volume	O
ratio	O
.	O

Results	O
from	O
this	O
model	O
show	O
heat	O
stress	O
directly	O
induced	O
a	O
so	O
-	O
far	O
unknown	O
infiltration	O
of	O
yet	O
uncategorized	O
cells	O
into	O
the	O
mucosa	O
and	O
submucosa	O
of	O
the	O
jejunum	O
.	O

Due	O
to	O
a	O
pair	O
-	O
feeding	O
design	O
,	O
we	O
can	O
exclude	O
this	O
effect	O
being	O
a	O
consequence	O
of	O
the	O
concurrent	O
heat	O
-	O
induced	O
reduction	O
in	O
feed	O
intake	O
.	O

Isolation	O
and	O
characterization	O
of	O
the	O
infiltrating	O
cells	O
using	O
laser	O
capture	O
microdissection	O
and	O
RNA	O
sequencing	O
indicated	O
a	O
myeloic	O
origin	O
and	O
macrophage	O
-	O
like	O
phenotype	O
.	O

Furthermore	O
,	O
targeted	O
transcriptome	O
analyses	O
provided	O
evidence	O
of	O
activated	O
immune	O
-	O
and	O
phagocytosis	O
-	O
related	O
pathways	O
with	O
LPS	O
and	O
cytokines	O
as	O
upstream	O
regulators	O
directly	O
associated	O
with	O
heat	O
stress	O
.	O

Finally	O
,	O
we	O
obtained	O
indication	O
that	O
heat	O
stress	O
may	O
directly	O
alter	O
jejunal	O
tight	O
junction	O
proteins	O
suggesting	O
an	O
impaired	O
intestinal	O
barrier	O
.	O

The	O
penetration	O
of	O
toxic	O
and	O
bacterial	O
compounds	O
during	O
heat	O
stress	O
may	O
have	O
triggered	O
a	O
modulated	O
immune	O
repertoire	O
and	O
induced	O
an	O
antioxidative	O
defense	O
mechanism	O
to	O
maintain	O
homeostasis	O
between	O
commensal	O
bacteria	O
and	O
the	O
jejunal	O
immune	O
system	O
.	O

Our	O
bovine	O
model	O
indicates	O
direct	O
effects	O
of	O
heat	O
stress	O
on	O
the	O
jejunum	O
of	O
mammals	O
already	O
at	O
moderately	O
elevated	O
ambient	O
temperature	O
.	O

These	O
results	O
need	O
to	O
be	O
considered	O
when	O
developing	O
concepts	O
to	O
combat	O
the	O
negative	O
consequences	O
of	O
heat	O
stress	O
.	O

Pre	O
-	O
existing	O
commensal	O
dysbiosis	O
is	O
a	O
host	O
-	O
intrinsic	O
regulator	O
of	O
tissue	O
inflammation	O
and	O
tumor	O
cell	O
dissemination	O
in	O
hormone	O
receptor	O
-	O
positive	O
breast	O
cancer	O
.	O

It	O
is	O
unknown	O
why	O
some	O
patients	O
with	O
hormone	O
receptor	O
-	O
positive	O
(	O
HR	O
+	O
)	O
breast	O
cancer	O
present	O
with	O
more	O
aggressive	O
and	O
invasive	O
disease	O
.	O

Metastatic	O
dissemination	O
occurs	O
early	O
in	O
disease	O
and	O
is	O
facilitated	O
by	O
crosstalk	O
between	O
the	O
tumor	O
and	O
tissue	O
environment	O
,	O
suggesting	O
that	O
undefined	O
host	O
-	O
intrinsic	O
factors	O
enhance	O
early	O
dissemination	O
and	O
the	O
probability	O
of	O
developing	O
metastatic	O
disease	O
.	O

Here	O
we	O
have	O
identified	O
commensal	O
dysbiosis	O
as	O
a	O
host	O
-	O
intrinsic	O
factor	O
associated	O
with	O
metastatic	O
dissemination	O
.	O

Using	O
a	O
mouse	O
model	O
of	O
HR	O
+	O
mammary	O
cancer	O
,	O
we	O
demonstrate	O
that	O
a	O
pre	O
-	O
established	O
disruption	O
of	O
commensal	O
homeostasis	O
results	O
in	O
enhanced	O
circulating	O
tumor	O
cells	O
and	O
subsequent	O
dissemination	O
to	O
the	O
tumor	O
-	O
draining	O
lymph	O
nodes	O
and	O
lungs	O
.	O

Commensal	O
dysbiosis	O
promoted	O
early	O
inflammation	O
within	O
the	O
mammary	O
gland	O
that	O
was	O
sustained	O
during	O
HR	O
+	O
mammary	O
tumor	O
progression	O
.	O

Furthermore	O
,	O
dysbiosis	O
enhanced	O
fibrosis	O
and	O
collagen	O
deposition	O
both	O
systemically	O
and	O
locally	O
within	O
the	O
tumor	O
microenvironment	O
and	O
induced	O
significant	O
myeloid	O
infiltration	O
into	O
the	O
mammary	O
gland	O
and	O
breast	O
tumor	O
.	O

These	O
effects	O
were	O
recapitulated	O
both	O
by	O
directly	O
targeting	O
gut	O
microbes	O
using	O
non	O
-	O
absorbable	O
antibiotics	O
and	O
by	O
fecal	O
microbiota	O
transplantation	O
of	O
dysbiotic	O
cecal	O
contents	O
,	O
demonstrating	O
the	O
direct	O
impact	O
of	O
gut	O
dysbiosis	O
on	O
mammary	O
tumor	O
dissemination	O
.	O

This	O
study	O
identifies	O
dysbiosis	O
as	O
a	O
pre	O
-	O
existing	O
,	O
host	O
-	O
intrinsic	O
regulator	O
of	O
tissue	O
inflammation	O
,	O
myeloid	O
recruitment	O
,	O
fibrosis	O
,	O
and	O
dissemination	O
of	O
tumor	O
cells	O
in	O
HR	O
+	O
breast	O
cancer	O
.	O

Alzheimer	O
'	O
s	O
Disease	O
Microbiome	O
Is	O
Associated	O
with	O
Dysregulation	O
of	O
the	O
Anti	O
-	O
Inflammatory	O
P	O
-	O
Glycoprotein	O
Pathway	O
.	O

The	O
microbiota	O
-	O
gut	O
-	O
brain	O
axis	O
is	O
a	O
bidirectional	O
communication	O
system	O
that	O
is	O
poorly	O
understood	O
.	O

Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
,	O
the	O
most	O
common	O
cause	O
of	O
dementia	O
,	O
has	O
long	O
been	O
associated	O
with	O
bacterial	O
infections	O
and	O
inflammation	O
-	O
causing	O
immunosenescence	O
.	O

Recent	O
studies	O
examining	O
the	O
intestinal	O
microbiota	O
of	O
AD	O
patients	O
revealed	O
that	O
their	O
microbiome	O
differs	O
from	O
that	O
of	O
subjects	O
without	O
dementia	O
.	O

In	O
this	O
work	O
,	O
we	O
prospectively	O
enrolled	O
108	O
nursing	O
home	O
elders	O
and	O
followed	O
each	O
for	O
up	O
to	O
5	O
months	O
,	O
collecting	O
longitudinal	O
stool	O
samples	O
from	O
which	O
we	O
performed	O
metagenomic	O
sequencing	O
and	O
in	O
vitro	O
T84	O
intestinal	O
epithelial	O
cell	O
functional	O
assays	O
for	O
P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
expression	O
,	O
a	O
critical	O
mediator	O
of	O
intestinal	O
homeostasis	O
.	O

Our	O
analysis	O
identified	O
clinical	O
parameters	O
as	O
well	O
as	O
numerous	O
microbial	O
taxa	O
and	O
functional	O
genes	O
that	O
act	O
as	O
predictors	O
of	O
AD	O
dementia	O
in	O
comparison	O
to	O
elders	O
without	O
dementia	O
or	O
with	O
other	O
dementia	O
types	O
.	O

We	O
further	O
demonstrate	O
that	O
stool	O
samples	O
from	O
elders	O
with	O
AD	O
can	O
induce	O
lower	O
P	O
-	O
gp	O
expression	O
levels	O
in	O
vitro	O
those	O
samples	O
from	O
elders	O
without	O
dementia	O
or	O
with	O
other	O
dementia	O
types	O
.	O

We	O
also	O
paired	O
functional	O
studies	O
with	O
machine	O
learning	O
approaches	O
to	O
identify	O
bacterial	O
species	O
differentiating	O
the	O
microbiome	O
of	O
AD	O
elders	O
from	O
that	O
of	O
elders	O
without	O
dementia	O
,	O
which	O
in	O
turn	O
are	O
accurate	O
predictors	O
of	O
the	O
loss	O
of	O
dysregulation	O
of	O
the	O
P	O
-	O
gp	O
pathway	O
.	O

We	O
observed	O
that	O
the	O
microbiome	O
of	O
AD	O
elders	O
shows	O
a	O
lower	O
proportion	O
and	O
prevalence	O
of	O
bacteria	O
with	O
the	O
potential	O
to	O
synthesize	O
butyrate	O
,	O
as	O
well	O
as	O
higher	O
abundances	O
of	O
taxa	O
that	O
are	O
known	O
to	O
cause	O
proinflammatory	O
states	O
.	O

Therefore	O
,	O
a	O
potential	O
nexus	O
between	O
the	O
intestinal	O
microbiome	O
and	O
AD	O
is	O
the	O
modulation	O
of	O
intestinal	O
homeostasis	O
by	O
increases	O
in	O
inflammatory	O
,	O
and	O
decreases	O
in	O
anti	O
-	O
inflammatory	O
,	O
microbial	O
metabolism	O
.	O
IMPORTANCE	O
Studies	O
of	O
the	O
intestinal	O
microbiome	O
and	O
AD	O
have	O
demonstrated	O
associations	O
with	O
microbiome	O
composition	O
at	O
the	O
genus	O
level	O
among	O
matched	O
cohorts	O
.	O

We	O
move	O
this	O
body	O
of	O
literature	O
forward	O
by	O
more	O
deeply	O
investigating	O
microbiome	O
composition	O
via	O
metagenomics	O
and	O
by	O
comparing	O
AD	O
patients	O
against	O
those	O
without	O
dementia	O
and	O
with	O
other	O
dementia	O
types	O
.	O

We	O
also	O
exploit	O
machine	O
learning	O
approaches	O
that	O
combine	O
both	O
metagenomic	O
and	O
clinical	O
data	O
.	O

Finally	O
,	O
our	O
functional	O
studies	O
using	O
stool	O
samples	O
from	O
elders	O
demonstrate	O
how	O
the	O
c	O
microbiome	O
of	O
AD	O
elders	O
can	O
affect	O
intestinal	O
health	O
via	O
dysregulation	O
of	O
the	O
P	O
-	O
glycoprotein	O
pathway	O
.	O

P	O
-	O
glycoprotein	O
dysregulation	O
contributes	O
directly	O
to	O
inflammatory	O
disorders	O
of	O
the	O
intestine	O
.	O

Since	O
AD	O
has	O
been	O
long	O
thought	O
to	O
be	O
linked	O
to	O
chronic	O
bacterial	O
infections	O
as	O
a	O
possible	O
etiology	O
,	O
our	O
findings	O
therefore	O
fill	O
a	O
gap	O
in	O
knowledge	O
in	O
the	O
field	O
of	O
AD	O
research	O
by	O
identifying	O
a	O
nexus	O
between	O
the	O
microbiome	O
,	O
loss	O
of	O
intestinal	O
homeostasis	O
,	O
and	O
inflammation	O
that	O
may	O
underlie	O
this	O
neurodegenerative	O
disorder	O
.	O

Intestinal	O
dysbacteriosis	O
mediates	O
the	O
reference	O
memory	O
deficit	O
induced	O
by	O
anaesthesia	O
/	O
surgery	O
in	O
aged	O
mice	O
.	O

BACKGROUND	O
:	O
Postoperative	O
cognitive	O
dysfunction	O
(	O
POCD	O
)	O
is	O
associated	O
with	O
increased	O
morbidity	O
and	O
mortality	O
and	O
has	O
become	O
a	O
major	O
concern	O
for	O
patients	O
and	O
caregivers	O
.	O

POCD	O
is	O
most	O
common	O
in	O
older	O
patients	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
gut	O
microbiome	O
affects	O
cognitive	O
function	O
and	O
behaviour	O
,	O
and	O
perioperative	O
factors	O
,	O
including	O
the	O
operation	O
itself	O
,	O
antibiotics	O
,	O
opioids	O
or	O
acid	O
-	O
inducing	O
drugs	O
,	O
affect	O
the	O
gut	O
microbiome	O
.	O

Thus	O
,	O
we	O
hypothesised	O
that	O
intestinal	O
dysbacteriosis	O
caused	O
by	O
anaesthesia	O
/	O
surgery	O
induces	O
POCD	O
.	O

METHODS	O
:	O
Tibial	O
fracture	O
internal	O
fixation	O
was	O
performed	O
in	O
18	O
-	O
month	O
-	O
old	O
C57BL	O
/	O
6	O
mice	O
under	O
isoflurane	O
anaesthesia	O
to	O
establish	O
the	O
POCD	O
model	O
.	O

The	O
Morris	O
water	O
maze	O
was	O
used	O
to	O
measure	O
reference	O
memory	O
after	O
anaesthesia	O
/	O
surgery	O
.	O

High	O
-	O
throughput	O
sequencing	O
of	O
16S	O
rRNA	O
from	O
faecal	O
samples	O
was	O
used	O
to	O
investigate	O
changes	O
in	O
the	O
abundance	O
of	O
intestinal	O
bacteria	O
after	O
anaesthesia	O
/	O
surgery	O
.	O

To	O
confirm	O
the	O
role	O
of	O
the	O
gut	O
microbiome	O
in	O
POCD	O
,	O
we	O
pretreated	O
mice	O
with	O
compound	O
antibiotics	O
or	O
mixed	O
probiotics	O
(	O
VSL	O
#	O
3	O
)	O
.	O

Anaesthesia	O
/	O
surgery	O
impaired	O
reference	O
memory	O
and	O
induced	O
intestinal	O
dysbacteriosis	O
in	O
aged	O
mice	O
.	O

RESULTS	O
:	O
The	O
16S	O
rRNA	O
sequencing	O
data	O
revealed	O
37	O
genera	O
(	O
18	O
families	O
)	O
of	O
bacteria	O
that	O
changed	O
in	O
abundance	O
after	O
anaesthesia	O
/	O
surgery	O
.	O

Pretreating	O
mice	O
with	O
compound	O
antibiotics	O
or	O
mixed	O
probiotics	O
(	O
VSL	O
#	O
3	O
)	O
prevented	O
the	O
learning	O
and	O
memory	O
deficits	O
induced	O
by	O
anaesthesia	O
/	O
surgery	O
.	O

We	O
further	O
conducted	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
of	O
22	O
common	O
types	O
of	O
bacteria	O
among	O
the	O
37	O
total	O
types	O
to	O
verify	O
the	O
results	O
of	O
bacterial	O
flora	O
changes	O
after	O
anaesthesia	O
/	O
surgery	O
.	O

Numbers	O
of	O
8	O
types	O
of	O
bacteria	O
changed	O
after	O
anaesthesia	O
/	O
surgery	O
but	O
returned	O
to	O
normal	O
after	O
treatment	O
with	O
a	O
mix	O
of	O
probiotics	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
deficits	O
in	O
reference	O
memory	O
induced	O
by	O
anaesthesia	O
/	O
surgery	O
are	O
mediated	O
by	O
intestinal	O
dysbacteriosis	O
.	O

Bacterial	O
TLR4	O
and	O
NOD2	O
signaling	O
linked	O
to	O
reduced	O
mitochondrial	O
energy	O
function	O
in	O
active	O
inflammatory	O
bowel	O
disease	O
.	O
,	O
p	O
<	O
.	O
001	O
)	O
.	O

Transcripts	O
from	O
this	O
panel	O
were	O
involved	O
in	O
diverse	O
biological	O
functions	O
including	O
regulation	O
of	O
mitochondrial	O
energy	O
(	O
lower	O
ATP	O
)	O
,	O
extracellular	O
matrix	O
,	O
cell	O
-	O
cell	O
contact	O
,	O
cytoskeleton	O
,	O
growth	O
,	O
metabolism	O
,	O
and	O
inflammation	O
.	O

Next	O
,	O
unsupervised	O
hierarchical	O
clustering	O
showed	O
that	O
the	O
Mito	O
-	O
0	O
panel	O
distinctly	O
separated	O
inflamed	O
IBD	O
from	O
non	O
-	O
inflamed	O
transcriptomes	O
,	O
which	O
was	O
also	O
supported	O
by	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
revealing	O
distinct	O
variation	O
between	O
sample	O
types	O
based	O
on	O
presence	O
of	O
the	O
Mito	O
-	O
0	O
signature	O
(	O
PCA	O
,	O
p	O
=	O
8	O
.	O
77e	O
(	O
-	O
09	O
)	O
)	O
.	O

Utilizing	O
three	O
independent	O
IBD	O
cohorts	O
,	O
we	O
validated	O
that	O
60	O
novel	O
transcripts	O
from	O
the	O
Mito	O
-	O
0	O
panel	O
were	O
significantly	O
increased	O
in	O
inflamed	O
tissue	O
.	O

Subsequently	O
,	O
KEGG	O
generated	O
bacterial	O
TLR4	O
and	O
NOD2	O
transcriptional	O
signatures	O
strongly	O
associated	O
with	O
inflamed	O
IBD	O
transcriptomes	O
and	O
with	O
the	O
Mito	O
-	O
0	O
signature	O
as	O
determined	O
by	O
Spearman	O
'	O
s	O
analysis	O
(	O
coefficient	O
of	O
correlation	O
,	O
r	O
=	O
0	O
.	O
92	O
,	O
p	O
<	O
.	O
05	O
)	O
.	O

Herein	O
,	O
using	O
a	O
comprehensive	O
analysis	O
we	O
demonstrated	O
existence	O
of	O
an	O
axis	O
between	O
bacteria	O
triggered	O
signaling	O
and	O
reduced	O
mitochondrial	O
energy	O
function	O
.	O

Furthermore	O
,	O
we	O
identified	O
and	O
validated	O
novel	O
transcripts	O
within	O
this	O
axis	O
as	O
potential	O
drivers	O
and	O
therapeutic	O
targets	O
for	O
human	O
IBD	O
.	O

Weeping	O
forsythia	O
extract	O
alleviates	O
dexamethasone	O
-	O
induced	O
oxidative	O
injury	O
of	O
breast	O
muscles	O
in	O
broilers	O
.	O

Antioxidants	O
have	O
been	O
always	O
used	O
to	O
improve	O
post	O
-	O
slaughter	O
meat	O
quality	O
in	O
broilers	O
subjected	O
to	O
stress	O
.	O

Forsythia	O
suspensa	O
extract	O
(	O
FSE	O
)	O
,	O
a	O
traditional	O
Chinese	O
herbal	O
medicine	O
,	O
is	O
generally	O
regarded	O
as	O
a	O
natural	O
source	O
of	O
antioxidants	O
.	O

Therefore	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
FSE	O
could	O
protect	O
post	O
-	O
slaughter	O
breast	O
muscles	O
against	O
oxidative	O
injury	O
induced	O
by	O
dexamethasone	O
(	O
DEX	O
)	O
mimicking	O
chronic	O
physiological	O
stress	O
in	O
poultry	O
production	O
.	O

Average	O
daily	O
gain	O
and	O
feed	O
efficiency	O
of	O
poultry	O
were	O
suppressed	O
by	O
DEX	O
and	O
improved	O
by	O
FSE	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
05	O
)	O
.	O

Dexamethasone	O
caused	O
the	O
decrease	O
in	O
the	O
redness	O
value	O
and	O
the	O
increase	O
in	O
the	O
lightness	O
and	O
yellowness	O
values	O
and	O
drip	O
loss	O
of	O
the	O
breast	O
muscles	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
05	O
)	O
,	O
and	O
FSE	O
had	O
the	O
converse	O
effects	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
05	O
)	O
.	O

Dietary	O
FSE	O
supplementation	O
decreased	O
monounsaturated	O
fatty	O
acid	O
(	O
FA	O
)	O
and	O
increased	O
polyunsaturated	O
FA	O
in	O
breast	O
muscles	O
of	O
broilers	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
FSE	O
decreased	O
malondialdehyde	O
and	O
carbonyl	O
content	O
in	O
the	O
breast	O
muscles	O
of	O
DEX	O
-	O
treated	O
broilers	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
05	O
)	O
.	O

The	O
inhibition	O
of	O
1	O
,	O
1	O
-	O
diphenyl	O
-	O
2	O
-	O
picryl	O
-	O
hydrazyl	O
in	O
the	O
breast	O
muscles	O
was	O
decreased	O
by	O
DEX	O
and	O
increased	O
by	O
FSE	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
05	O
)	O
.	O

Total	O
-	O
antioxidant	O
capacity	O
and	O
glutathione	O
peroxidase	O
activity	O
in	O
the	O
breast	O
muscles	O
were	O
decreased	O
in	O
birds	O
subjected	O
to	O
DEX	O
and	O
increased	O
in	O
birds	O
supplemented	O
with	O
FSE	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
05	O
)	O
.	O

Totally	O
,	O
DEX	O
suppressed	O
growth	O
performance	O
and	O
induced	O
breast	O
muscle	O
oxidative	O
injury	O
in	O
broilers	O
,	O
and	O
FSE	O
supplementation	O
improved	O
antioxidant	O
capacity	O
to	O
attenuate	O
these	O
adverse	O
effects	O
.	O

Therefore	O
,	O
FSE	O
could	O
be	O
a	O
potential	O
natural	O
antioxidant	O
to	O
alleviate	O
oxidative	O
injury	O
of	O
the	O
breast	O
muscles	O
in	O
broilers	O
and	O
to	O
improve	O
the	O
meat	O
quality	O
for	O
human	O
consumption	O
.	O

Oral	O
vitamin	O
B12	O
supplement	O
is	O
delivered	O
to	O
the	O
distal	O
gut	O
,	O
altering	O
the	O
corrinoid	O
profile	O
and	O
selectively	O
depleting	O
Bacteroides	B-bacteria
in	O
C57BL	O
/	O
6	O
mice	O
.	O

Vitamin	O
B12	O
is	O
a	O
critical	O
nutrient	O
for	O
humans	O
as	O
well	O
as	O
microbes	O
.	O

Due	O
to	O
saturable	O
uptake	O
,	O
high	O
dose	O
oral	O
B12	O
supplements	O
are	O
largely	O
unabsorbed	O
and	O
reach	O
the	O
distal	O
gut	O
where	O
they	O
are	O
available	O
to	O
interact	O
with	O
the	O
microbiota	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
oral	O
B12	O
supplementation	O
in	O
mice	O
alters	O
1	O
)	O
the	O
concentration	O
of	O
B12	O
and	O
related	O
corrinoids	O
in	O
the	O
distal	O
gut	O
,	O
2	O
)	O
the	O
fecal	O
microbiome	O
,	O
3	O
)	O
short	O
chain	O
fatty	O
acids	O
(	O
SCFA	O
)	O
,	O
and	O
4	O
)	O
susceptibility	O
to	O
experimental	O
colitis	O
.	O

C57BL	O
/	O
6	O
mice	O
(	O
up	O
to	O
24	O
animals	O
/	O
group	O
)	O
were	O
supplemented	O
with	O
oral	O
3	O
.	O
94	O
microg	O
/	O
ml	O
cyanocobalamin	O
(	O
B12	O
)	O
,	O
a	O
dose	O
selected	O
to	O
approximate	O
a	O
single	O
5	O
mg	O
supplement	O
for	O
a	O
human	O
.	O

Active	O
vitamin	O
B12	O
(	O
cobalamin	O
)	O
,	O
and	O
four	O
B12	O
-	O
analogues	O
(	O
[	O
ADE	O
]	O
CN	O
-	O
Cba	O
,	O
[	O
2Me	O
-	O
ADE	O
]	O
CN	O
-	O
Cba	O
,	O
[	O
2MeS	O
-	O
ADE	O
]	O
CN	O
-	O
Cba	O
,	O
CN	O
-	O
Cbi	O
)	O
were	O
analyzed	O
in	O
cecal	O
and	O
fecal	O
contents	O
using	O
liquid	O
chromatography	O
/	O
mass	O
spectrometry	O
(	O
LC	O
/	O
MS	O
)	O
,	O
in	O
parallel	O
with	O
evaluation	O
of	O
fecal	O
microbiota	O
,	O
cecal	O
SCFA	O
,	O
and	O
susceptibility	O
to	O
dextran	O
sodium	O
sulfate	O
(	O
DSS	O
)	O
colitis	O
.	O

At	O
baseline	O
,	O
active	O
B12	O
was	O
a	O
minor	O
constituent	O
of	O
overall	O
cecal	O
(	O
0	O
.	O
86	O
%	O
)	O
and	O
fecal	O
(	O
0	O
.	O
44	O
%	O
)	O
corrinoid	O
.	O

Oral	O
B12	O
supplementation	O
increased	O
active	O
B12	O
at	O
distal	O
sites	O
by	O
>	O
130	O
-	O
fold	O
(	O
cecal	O
B12	O
increased	O
from	O
0	O
.	O
08	O
to	O
10	O
.	O
60	O
ng	O
/	O
mg	O
,	O
fecal	O
B12	O
increased	O
from	O
0	O
.	O
06	O
to	O
7	O
.	O
81	O
ng	O
/	O
ml	O
)	O
and	O
reduced	O
microbe	O
-	O
derived	O
fecal	O
corrinoid	O
analogues	O
(	O
[	O
ADE	O
]	O
CN	O
-	O
Cba	O
,	O
[	O
2Me	O
-	O
ADE	O
]	O
CN	O
-	O
Cba	O
,	O
[	O
2MeS	O
-	O
ADE	O
]	O
CN	O
-	O
Cba	O
)	O
.	O

Oral	O
B12	O
had	O
no	O
effect	O
on	O
cecal	O
SCFA	O
.	O

Microbial	O
diversity	O
was	O
unaffected	O
by	O
this	O
intervention	O
,	O
however	O
a	O
selective	O
decrease	O
in	O
Bacteroides	B-bacteria
was	O
observed	O
with	O
B12	O
treatment	O
.	O

Lastly	O
,	O
no	O
difference	O
in	O
markers	O
of	O
DSS	O
-	O
induced	O
colitis	O
were	O
detected	O
with	O
B12	O
treatment	O
.	O

Identification	O
of	O
an	O
intestinal	O
microbiota	O
signature	O
associated	O
with	O
hospitalized	O
patients	O
with	O
diarrhea	O
.	O

As	O
an	O
important	O
global	O
health	O
challenge	O
,	O
diarrhea	O
kills	O
nearly	O
two	O
million	O
people	O
each	O
year	O
.	O

Postinfectious	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
usually	O
manifests	O
itself	O
as	O
the	O
diarrhea	O
-	O
predominant	O
subtype	O
.	O

Small	O
intestinal	O
bacterial	O
overgrowth	O
has	O
been	O
observed	O
more	O
frequently	O
in	O
patients	O
with	O
IBS	O
compared	O
to	O
healthy	O
controls	O
.	O

However	O
,	O
the	O
pathophysiology	O
of	O
IBS	O
is	O
not	O
fully	O
understood	O
,	O
and	O
based	O
on	O
recent	O
evidences	O
,	O
altered	O
gut	O
microbiota	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
IBS	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
microbiome	O
in	O
hospitalized	O
patients	O
with	O
diarrhea	O
and	O
healthy	O
individuals	O
.	O

Thirty	O
patients	O
and	O
10	O
healthy	O
controls	O
were	O
included	O
into	O
this	O
case	O
-	O
control	O
study	O
.	O

Microbial	O
count	O
was	O
performed	O
using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
method	O
using	O
bacterial	O
16S	O
rRNA	O
gene	O
.	O

Clostridium	B-bacteria
cluster	I-bacteria
IV	I-bacteria
and	O
Bacteroides	B-bacteria
were	O
significantly	O
more	O
frequent	O
in	O
the	O
patients	O
compared	O
with	O
the	O
healthy	O
individuals	O
(	O
p	O
=	O
0	O
.	O
02	O
and	O
0	O
.	O
023	O
,	O
respectively	O
)	O
.	O

However	O
,	O
the	O
quantity	O
of	O
Enterococcus	B-bacteria
and	O
Bifidobacterium	B-bacteria
groups	O
were	O
significantly	O
higher	O
in	O
healthy	O
controls	O
than	O
in	O
diarrheal	O
group	O
(	O
p	O
=	O
0	O
.	O
000076	O
and	O
0	O
.	O
001	O
,	O
respectively	O
)	O
.	O

The	O
results	O
showed	O
that	O
the	O
number	O
of	O
bacteria	O
in	O
all	O
bacterial	O
groups	O
was	O
significantly	O
different	O
between	O
healthy	O
individuals	O
and	O
diabetic	O
group	O
,	O
whereas	O
the	O
difference	O
between	O
the	O
healthy	O
group	O
and	O
IBS	O
was	O
not	O
significant	O
for	O
Bifidobacterium	B-bacteria
group	O
.	O

The	O
findings	O
of	O
this	O
study	O
outlined	O
the	O
relationship	O
between	O
diarrhea	O
,	O
IBS	O
,	O
and	O
diabetes	O
disease	O
and	O
bacterial	O
composition	O
.	O

It	O
could	O
be	O
concluded	O
that	O
modifying	O
the	O
bacterial	O
composition	O
by	O
probiotics	O
can	O
be	O
helpful	O
in	O
the	O
control	O
and	O
management	O
of	O
the	O
mentioned	O
disease	O
.	O

Evolving	O
trends	O
in	O
next	O
-	O
generation	O
probiotics	O
:	O
a	O
5W1H	O
perspective	O
.	O

In	O
recent	O
years	O
,	O
scientific	O
community	O
has	O
been	O
gathering	O
increasingly	O
more	O
insight	O
on	O
the	O
dynamics	O
that	O
are	O
at	O
play	O
in	O
metabolic	O
and	O
inflammatory	O
disorders	O
.	O

These	O
rapidly	O
growing	O
conditions	O
are	O
reaching	O
epidemic	O
proportions	O
,	O
bringing	O
clinicians	O
and	O
researcher	O
'	O
s	O
new	O
challenges	O
.	O

The	O
specific	O
roles	O
and	O
modulating	O
properties	O
that	O
beneficial	O
/	O
probiotic	O
bacteria	O
hold	O
in	O
the	O
context	O
of	O
the	O
gut	O
ecosystem	O
seem	O
to	O
be	O
key	O
to	O
avert	O
these	O
inflammatory	O
and	O
diet	O
-	O
related	O
disorders	O
.	O

Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
,	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
and	O
Eubacterium	B-bacteria
hallii	I-bacteria
have	O
been	O
identified	O
as	O
candidates	O
for	O
next	O
generation	O
probiotics	O
(	O
NGPs	O
)	O
with	O
exciting	O
potential	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
such	O
of	O
dysbiosis	O
-	O
associated	O
diseases	O
.	O

The	O
challenges	O
of	O
these	O
non	O
-	O
conventional	O
native	O
gut	O
bacteria	O
lie	O
mainly	O
on	O
their	O
extreme	O
sensitivity	O
to	O
O2	O
traces	O
.	O

If	O
these	O
strains	O
are	O
to	O
be	O
used	O
successfully	O
in	O
food	O
,	O
supplements	O
or	O
drugs	O
they	O
need	O
to	O
be	O
stable	O
and	O
active	O
in	O
humans	O
.	O

In	O
the	O
present	O
review	O
,	O
we	O
present	O
an	O
overall	O
perspective	O
of	O
the	O
most	O
updated	O
scientific	O
literature	O
on	O
the	O
newly	O
called	O
NGPs	O
through	O
the	O
5W1H	O
(	O
What	O
,	O
Why	O
,	O
Who	O
,	O
Where	O
,	O
When	O
,	O
and	O
How	O
)	O
method	O
,	O
an	O
innovative	O
and	O
attractive	O
problem	O
-	O
solving	O
approach	O
that	O
provides	O
the	O
reader	O
an	O
effective	O
understanding	O
of	O
the	O
issue	O
at	O
hand	O
.	O

Surface	O
glycan	O
-	O
binding	O
proteins	O
are	O
essential	O
for	O
cereal	O
beta	O
-	O
glucan	O
utilization	O
by	O
the	O
human	O
gut	O
symbiont	O
Bacteroides	B-bacteria
ovatus	I-bacteria
.	O

The	O
human	O
gut	O
microbiota	O
,	O
which	O
underpins	O
nutrition	O
and	O
systemic	O
health	O
,	O
is	O
compositionally	O
sensitive	O
to	O
the	O
availability	O
of	O
complex	O
carbohydrates	O
in	O
the	O
diet	O
.	O

The	O
Bacteroidetes	B-bacteria
comprise	O
a	O
dominant	O
phylum	O
in	O
the	O
human	O
gut	O
microbiota	O
whose	O
members	O
thrive	O
on	O
dietary	O
and	O
endogenous	O
glycans	O
by	O
employing	O
a	O
diversity	O
of	O
highly	O
specific	O
,	O
multi	O
-	O
gene	O
polysaccharide	O
utilization	O
loci	O
(	O
PUL	O
)	O
,	O
which	O
encode	O
a	O
variety	O
of	O
carbohydrases	O
,	O
transporters	O
,	O
and	O
sensor	O
/	O
regulators	O
.	O

PULs	O
invariably	O
also	O
encode	O
surface	O
glycan	O
-	O
binding	O
proteins	O
(	O
SGBPs	O
)	O
that	O
play	O
a	O
central	O
role	O
in	O
saccharide	O
capture	O
at	O
the	O
outer	O
membrane	O
.	O

Here	O
,	O
we	O
present	O
combined	O
biophysical	O
,	O
structural	O
,	O
and	O
in	O
vivo	O
characterization	O
of	O
the	O
two	O
SGBPs	O
encoded	O
by	O
the	O
Bacteroides	B-bacteria
ovatus	I-bacteria
mixed	O
-	O
linkage	O
beta	O
-	O
glucan	O
utilization	O
locus	O
(	O
MLGUL	O
)	O
,	O
thereby	O
elucidating	O
their	O
key	O
roles	O
in	O
the	O
metabolism	O
of	O
this	O
ubiquitous	O
dietary	O
cereal	O
polysaccharide	O
.	O

In	O
particular	O
,	O
molecular	O
insight	O
gained	O
through	O
several	O
crystallographic	O
complexes	O
of	O
SGBP	O
-	O
A	O
and	O
SGBP	O
-	O
B	O
with	O
oligosaccharides	O
reveals	O
that	O
unique	O
shape	O
complementarity	O
of	O
binding	O
platforms	O
underpins	O
specificity	O
for	O
the	O
kinked	O
MLG	O
backbone	O
vis	O
-	O
a	O
-	O
vis	O
linear	O
beta	O
-	O
glucans	O
.	O

Reverse	O
-	O
genetic	O
analysis	O
revealed	O
that	O
both	O
the	O
presence	O
and	O
binding	O
ability	O
of	O
the	O
SusD	O
homolog	O
BoSGBPMLG	O
-	O
A	O
are	O
essential	O
for	O
growth	O
on	O
MLG	O
,	O
whereas	O
the	O
divergent	O
,	O
multi	O
-	O
domain	O
BoSGBPMLG	O
-	O
B	O
is	O
dispensable	O
but	O
may	O
assist	O
in	O
oligosaccharide	O
scavenging	O
from	O
the	O
environment	O
.	O

The	O
synthesis	O
of	O
these	O
data	O
illuminates	O
the	O
critical	O
role	O
SGBPs	O
play	O
in	O
concert	O
with	O
other	O
MLGUL	O
components	O
,	O
reveals	O
new	O
structure	O
-	O
function	O
relationships	O
among	O
SGBPs	O
,	O
and	O
provides	O
fundamental	O
knowledge	O
to	O
inform	O
future	O
(	O
meta	O
)	O
genomic	O
,	O
biochemical	O
,	O
and	O
microbiological	O
analyses	O
of	O
the	O
human	O
gut	O
microbiota	O
.	O

Effect	O
of	O
a	O
Multistrain	O
Probiotic	O
on	O
Cognitive	O
Function	O
and	O
Risk	O
of	O
Falls	O
in	O
Patients	O
With	O
Cirrhosis	O
:	O
A	O
Randomized	O
Trial	O
.	O

Probiotics	O
can	O
modulate	O
gut	O
microbiota	O
,	O
intestinal	O
permeability	O
,	O
and	O
immune	O
response	O
and	O
could	O
therefore	O
improve	O
cognitive	O
dysfunction	O
and	O
help	O
avoid	O
potential	O
consequences	O
,	O
such	O
as	O
falls	O
,	O
in	O
patients	O
with	O
cirrhosis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
multistrain	O
probiotic	O
on	O
cognitive	O
function	O
,	O
risk	O
of	O
falls	O
,	O
and	O
inflammatory	O
response	O
in	O
patients	O
with	O
cirrhosis	O
.	O

Consecutive	O
outpatients	O
with	O
cirrhosis	O
and	O
cognitive	O
dysfunction	O
(	O
defined	O
by	O
a	O
Psychometric	O
Hepatic	O
Encephalopathy	O
Score	O
[	O
PHES	O
]	O
<	O
-	O
4	O
)	O
and	O
/	O
or	O
falls	O
in	O
the	O
previous	O
year	O
were	O
randomized	O
to	O
receive	O
either	O
a	O
sachet	O
of	O
a	O
high	O
-	O
concentration	O
multistrain	O
probiotic	O
containing	O
450	O
billion	O
bacteria	O
twice	O
daily	O
for	O
12	O
weeks	O
or	O
placebo	O
.	O

We	O
evaluated	O
the	O
changes	O
in	O
cognitive	O
function	O
(	O
PHES	O
)	O
;	O
risk	O
of	O
falls	O
(	O
Timed	O
Up	O
and	O
Go	O
[	O
TUG	O
]	O
test	O
,	O
gait	O
speed	O
,	O
and	O
incidence	O
of	O
falls	O
)	O
;	O
systemic	O
inflammatory	O
response	O
;	O
neutrophil	O
oxidative	O
burst	O
;	O
intestinal	O
barrier	O
integrity	O
(	O
serum	O
fatty	O
acid	O
-	O
binding	O
protein	O
6	O
[	O
FABP	O
-	O
6	O
]	O
and	O
2	O
[	O
FABP	O
-	O
2	O
]	O
and	O
zonulin	O
and	O
urinary	O
claudin	O
-	O
3	O
)	O
;	O
bacterial	O
translocation	O
(	O
lipopolysaccharide	O
-	O
binding	O
protein	O
[	O
LBP	O
]	O
)	O
;	O
and	O
fecal	O
microbiota	O
.	O

Thirty	O
-	O
six	O
patients	O
were	O
included	O
.	O

Patients	O
treated	O
with	O
the	O
probiotic	O
(	O
n	O
=	O
18	O
)	O
showed	O
an	O
improvement	O
in	O
the	O
PHES	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
,	O
TUG	O
time	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
and	O
gait	O
speed	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
and	O
a	O
trend	O
toward	O
a	O
lower	O
incidence	O
of	O
falls	O
during	O
follow	O
-	O
up	O
(	O
0	O
%	O
compared	O
with	O
22	O
.	O
2	O
%	O
in	O
the	O
placebo	O
group	O
[	O
n	O
=	O
18	O
]	O
;	O
P	O
=	O
0	O
.	O
10	O
)	O
.	O

In	O
the	O
probiotic	O
group	O
,	O
we	O
observed	O
a	O
decrease	O
in	O
C	O
-	O
reactive	O
protein	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
FABP	O
-	O
6	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
,	O
and	O
claudin	O
-	O
3	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
,	O
and	O
an	O
increase	O
in	O
poststimulation	O
neutrophil	O
oxidative	O
burst	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

Conclusion	O
:	O
The	O
multistrain	O
probiotic	O
improved	O
cognitive	O
function	O
,	O
risk	O
of	O
falls	O
,	O
and	O
inflammatory	O
response	O
in	O
patients	O
with	O
cirrhosis	O
and	O
cognitive	O
dysfunction	O
and	O
/	O
or	O
previous	O
falls	O
.	O

Intestinal	O
Permeability	O
Measured	O
by	O
Urinary	O
Sucrose	O
Excretion	O
Correlates	O
with	O
Serum	O
Zonulin	O
and	O
Faecal	O
Calprotectin	O
Concentrations	O
in	O
UC	O
Patients	O
in	O
Remission	O
.	O

Background	O
and	O
Aims	O
:	O
Ulcerative	O
colitis	O
(	O
UC	O
)	O
is	O
associated	O
with	O
an	O
increased	O
intestinal	O
permeability	O
,	O
possibly	O
through	O
a	O
dysbiosis	O
of	O
intestinal	O
bacteria	O
.	O

We	O
investigated	O
which	O
markers	O
are	O
most	O
relevant	O
to	O
assess	O
intestinal	O
permeability	O
in	O
UC	O
patients	O
and	O
whether	O
probiotics	O
had	O
an	O
effect	O
on	O
these	O
markers	O
.	O

Methods	O
:	O
In	O
this	O
twelve	O
-	O
week	O
placebo	O
-	O
controlled	O
randomized	O
double	O
-	O
blind	O
study	O
,	O
twenty	O
-	O
five	O
subjects	O
with	O
UC	O
in	O
remission	O
received	O
either	O
placebo	O
or	O
a	O
multispecies	O
probiotics	O
.	O

Samples	O
of	O
blood	O
,	O
urine	O
,	O
and	O
faeces	O
were	O
taken	O
at	O
baseline	O
,	O
week	O
6	O
,	O
and	O
week	O
12	O
to	O
assess	O
intestinal	O
permeability	O
and	O
inflammation	O
.	O

Diaries	O
and	O
Bristol	O
stool	O
scale	O
were	O
kept	O
to	O
record	O
stool	O
frequency	O
and	O
consistency	O
.	O

Quality	O
of	O
life	O
was	O
scored	O
from	O
32	O
-	O
224	O
with	O
the	O
inflammatory	O
bowel	O
disease	O
questionnaire	O
(	O
IBD	O
-	O
Q	O
)	O
.	O

Results	O
:	O
This	O
group	O
of	O
UC	O
patients	O
,	O
in	O
clinical	O
remission	O
,	O
did	O
not	O
show	O
increased	O
intestinal	O
permeability	O
at	O
baseline	O
of	O
this	O
study	O
.	O

During	O
the	O
study	O
,	O
no	O
significant	O
group	O
or	O
time	O
effects	O
were	O
found	O
for	O
intestinal	O
permeability	O
measured	O
by	O
the	O
5	O
-	O
sugar	O
absorption	O
test	O
,	O
serum	O
zonulin	O
,	O
and	O
faecal	O
zonulin	O
.	O

Likewise	O
,	O
the	O
inflammatory	O
markers	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
,	O
calprotectin	O
,	O
and	O
the	O
cytokines	O
IFNgamma	O
,	O
TNFalpha	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
10	O
were	O
not	O
significantly	O
affected	O
.	O

Stool	O
frequency	O
and	O
consistency	O
were	O
not	O
significantly	O
affected	O
either	O
.	O

The	O
IBD	O
-	O
Q	O
score	O
,	O
194	O
for	O
the	O
probiotics	O
group	O
and	O
195	O
for	O
the	O
placebo	O
group	O
,	O
remained	O
unaffected	O
.	O

Correlations	O
were	O
tested	O
between	O
all	O
outcomes	O
;	O
urinary	O
sucrose	O
excretion	O
was	O
significantly	O
correlated	O
with	O
serum	O
zonulin	O
(	O
r	O
=	O
0	O
.	O
62	O
)	O
and	O
faecal	O
calprotectin	O
(	O
r	O
=	O
0	O
.	O
55	O
)	O
.	O

Faecal	O
zonulin	O
was	O
not	O
significantly	O
correlated	O
with	O
any	O
of	O
the	O
other	O
markers	O
.	O

Conclusion	O
:	O
Serum	O
zonulin	O
may	O
be	O
a	O
more	O
relevant	O
biomarker	O
of	O
intestinal	O
permeability	O
than	O
faecal	O
zonulin	O
,	O
due	O
to	O
its	O
correlation	O
with	O
other	O
biomarkers	O
of	O
intestinal	O
permeability	O
.	O

UC	O
patients	O
in	O
remission	O
did	O
not	O
show	O
an	O
effect	O
of	O
the	O
probiotic	O
treatment	O
or	O
a	O
change	O
in	O
gut	O
permeability	O
.	O

This	O
should	O
not	O
discourage	O
further	O
studies	O
because	O
effects	O
might	O
be	O
present	O
during	O
active	O
disease	O
or	O
shortly	O
after	O
a	O
flare	O
up	O
.	O

Corrigendum	O
to	O
'	O
Phoenicibacter	B-bacteria
congonensis	I-bacteria
'	I-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
a	O
new	O
bacterium	O
isolated	O
from	O
the	O
human	O
gut	O
of	O
a	O
pygmy	O
woman	O
.	O

[	O
This	O
corrects	O
the	O
article	O
DOI	O
:	O
10	O
.	O
1016	O
/	O
j	O
.	O
nmni	O
.	O
2017	O
.	O
04	O
.	O
003	O
.	O

]	O
.	O

The	O
role	O
of	O
gut	O
microbiota	O
in	O
shaping	O
the	O
relapse	O
-	O
remitting	O
and	O
chronic	O
-	O
progressive	O
forms	O
of	O
multiple	O
sclerosis	O
in	O
mouse	O
models	O
.	O

Using	O
a	O
mouse	O
model	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
,	O
experimental	O
autoimmune	O
encephalitis	O
(	O
EAE	O
)	O
,	O
we	O
evaluated	O
the	O
role	O
of	O
gut	O
microbiota	O
in	O
modulating	O
chronic	O
-	O
progressive	O
(	O
CP	O
)	O
versus	O
relapse	O
-	O
remitting	O
(	O
RR	O
)	O
forms	O
of	O
the	O
disease	O
.	O

We	O
hypothesized	O
that	O
clinical	O
courses	O
of	O
EAE	O
may	O
be	O
shaped	O
by	O
differential	O
gut	O
microbiota	O
.	O

Metagenomic	O
sequencing	O
of	O
prokaryotic	O
16S	O
rRNA	O
present	O
in	O
feces	O
from	O
naive	O
mice	O
and	O
those	O
exhibiting	O
CP	O
-	O
EAE	O
or	O
RR	O
-	O
EAE	O
revealed	O
significantly	O
diverse	O
microbial	O
populations	O
.	O

Microbiota	O
composition	O
was	O
considerably	O
different	O
between	O
naive	O
strains	O
of	O
mice	O
,	O
suggesting	O
microbial	O
components	O
present	O
in	O
homeostatic	O
conditions	O
may	O
prime	O
mice	O
for	O
divergent	O
courses	O
of	O
disease	O
.	O

Additionally	O
,	O
there	O
were	O
differentially	O
abundant	O
bacteria	O
in	O
CP	O
and	O
RR	O
forms	O
of	O
EAE	O
,	O
indicating	O
a	O
potential	O
role	O
for	O
gut	O
microbiota	O
in	O
shaping	O
tolerant	O
or	O
remittance	O
-	O
favoring	O
,	O
and	O
pathogenic	O
or	O
pro	O
-	O
inflammatory	O
-	O
promoting	O
conditions	O
.	O

Furthermore	O
,	O
immunization	O
to	O
induce	O
EAE	O
led	O
to	O
significant	O
alterations	O
in	O
gut	O
microbiota	O
,	O
some	O
were	O
shared	O
between	O
disease	O
courses	O
and	O
others	O
were	O
course	O
-	O
specific	O
,	O
supporting	O
a	O
role	O
for	O
gut	O
microbial	O
composition	O
in	O
EAE	O
pathogenesis	O
.	O

Moreover	O
,	O
using	O
Linear	O
Discriminant	O
Analysis	O
(	O
LDA	O
)	O
coupled	O
with	O
effect	O
size	O
measurement	O
(	O
LEfSe	O
)	O
to	O
analyze	O
microbial	O
content	O
,	O
biomarkers	O
of	O
each	O
naive	O
and	O
disease	O
states	O
were	O
identified	O
.	O

Our	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
gut	O
microbiota	O
may	O
determine	O
the	O
susceptibility	O
to	O
CP	O
or	O
RR	O
forms	O
of	O
EAE	O
.	O

Chemical	O
Derivatization	O
Enables	O
MALDI	O
-	O
TOF	O
-	O
Based	O
High	O
-	O
Throughput	O
Screening	O
for	O
Microbial	O
Trimethylamine	O
(	O
TMA	O
)	O
-	O
Lyase	O
Inhibitors	O
.	O

Microbial	O
-	O
dependent	O
trimethylamine	O
(	O
TMA	O
)	O
generation	O
from	O
dietary	O
precursors	O
such	O
as	O
choline	O
was	O
recently	O
linked	O
to	O
cardiovascular	O
diseases	O
(	O
CVDs	O
)	O
as	O
well	O
as	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
.	O

Inhibition	O
of	O
TMA	O
-	O
generating	O
enzymes	O
in	O
gut	O
bacteria	O
would	O
be	O
an	O
innovative	O
approach	O
to	O
treat	O
these	O
diseases	O
.	O

The	O
potential	O
to	O
accurately	O
quantify	O
secreted	O
TMA	O
levels	O
highlights	O
the	O
capacity	O
of	O
mass	O
spectrometry	O
(	O
MS	O
)	O
for	O
tracking	O
microbial	O
TMA	O
-	O
lyase	O
activity	O
.	O

However	O
,	O
high	O
-	O
throughput	O
screening	O
(	O
HTS	O
)	O
by	O
conventional	O
MS	O
instrumentation	O
is	O
hampered	O
by	O
limited	O
sample	O
throughput	O
.	O

Recent	O
advancement	O
in	O
liquid	O
handling	O
and	O
instrumentation	O
of	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
MS	O
provides	O
an	O
HTS	O
-	O
compatible	O
MS	O
technology	O
.	O

The	O
deciphering	O
of	O
enzymatic	O
reactions	O
using	O
this	O
label	O
-	O
free	O
readout	O
has	O
been	O
successfully	O
applied	O
but	O
has	O
thus	O
far	O
been	O
limited	O
to	O
peptide	O
/	O
protein	O
-	O
centric	O
activity	O
assays	O
.	O

Here	O
,	O
we	O
demonstrate	O
the	O
versatile	O
applicability	O
of	O
MALDI	O
-	O
TOF	O
by	O
tracking	O
a	O
small	O
molecule	O
within	O
a	O
highly	O
complex	O
sample	O
background	O
.	O

The	O
key	O
to	O
success	O
for	O
this	O
concept	O
was	O
chemical	O
derivatization	O
of	O
the	O
target	O
molecule	O
enabling	O
quantitative	O
assessment	O
of	O
microbial	O
TMA	O
formation	O
.	O

Further	O
,	O
its	O
potential	O
was	O
demonstrated	O
in	O
a	O
side	O
-	O
by	O
-	O
side	O
comparison	O
to	O
RapidFire	O
-	O
MS	O
in	O
a	O
primary	O
screen	O
and	O
subsequent	O
dose	O
-	O
response	O
experiments	O
.	O

Overall	O
,	O
the	O
established	O
assay	O
enables	O
the	O
screening	O
for	O
microbial	O
TMA	O
-	O
lyase	O
inhibitors	O
and	O
serves	O
as	O
a	O
proof	O
of	O
concept	O
for	O
the	O
applicability	O
of	O
MALDI	O
-	O
TOF	O
for	O
demanding	O
assay	O
concepts	O
per	O
se	O
.	O

In	O
vitro	O
characterization	O
of	O
the	O
colibactin	O
-	O
activating	O
peptidase	O
ClbP	O
enables	O
development	O
of	O
a	O
fluorogenic	O
activity	O
probe	O
.	O

The	O
gut	O
bacterial	O
genotoxin	O
colibactin	O
is	O
linked	O
to	O
the	O
devel	O
-	O
opment	O
of	O
colorectal	O
cancer	O
.	O

In	O
the	O
final	O
stages	O
of	O
colibactin	O
'	O
s	O
biosynthesis	O
,	O
an	O
inactive	O
precursor	O
(	O
precolibactin	O
)	O
undergoes	O
proteolytic	O
cleavage	O
by	O
ClbP	O
,	O
an	O
unusual	O
inner	O
-	O
membrane	O
-	O
bound	O
periplasmic	O
peptidase	O
,	O
to	O
generate	O
the	O
active	O
genotoxin	O
.	O

This	O
enzyme	O
presents	O
an	O
opportunity	O
to	O
monitor	O
and	O
modu	O
-	O
late	O
colibactin	O
biosynthesis	O
,	O
but	O
its	O
active	O
form	O
has	O
not	O
been	O
studied	O
in	O
vitro	O
and	O
limited	O
tools	O
exist	O
to	O
measure	O
its	O
activity	O
.	O

Here	O
,	O
we	O
describe	O
the	O
in	O
vitro	O
biochemical	O
characterization	O
of	O
catalytically	O
active	O
,	O
full	O
-	O
length	O
ClbP	O
.	O

We	O
elucidate	O
its	O
substrate	O
preferences	O
and	O
use	O
this	O
information	O
to	O
develop	O
a	O
fluorogenic	O
activity	O
probe	O
.	O

This	O
tool	O
will	O
enable	O
the	O
discovery	O
of	O
ClbP	O
in	O
-	O
hibitors	O
and	O
streamline	O
identification	O
of	O
colibactin	O
-	O
producing	O
bacteria	O
.	O

Metabolism	O
of	O
Dietary	O
and	O
Microbial	O
Vitamin	O
B	O
Family	O
in	O
the	O
Regulation	O
of	O
Host	O
Immunity	O
.	O

Vitamins	O
are	O
micronutrients	O
that	O
have	O
physiological	O
effects	O
on	O
various	O
biological	O
responses	O
,	O
including	O
host	O
immunity	O
.	O

Therefore	O
,	O
vitamin	O
deficiency	O
leads	O
to	O
increased	O
risk	O
of	O
developing	O
infectious	O
,	O
allergic	O
,	O
and	O
inflammatory	O
diseases	O
.	O

Since	O
B	O
vitamins	O
are	O
synthesized	O
by	O
plants	O
,	O
yeasts	O
,	O
and	O
bacteria	O
,	O
but	O
not	O
by	O
mammals	O
,	O
mammals	O
must	O
acquire	O
B	O
vitamins	O
from	O
dietary	O
or	O
microbial	O
sources	O
,	O
such	O
as	O
the	O
intestinal	O
microbiota	O
.	O

Similarly	O
,	O
some	O
intestinal	O
bacteria	O
are	O
unable	O
to	O
synthesize	O
B	O
vitamins	O
and	O
must	O
acquire	O
them	O
from	O
the	O
host	O
diet	O
or	O
from	O
other	O
intestinal	O
bacteria	O
for	O
their	O
growth	O
and	O
survival	O
.	O

This	O
suggests	O
that	O
the	O
composition	O
and	O
function	O
of	O
the	O
intestinal	O
microbiota	O
may	O
affect	O
host	O
B	O
vitamin	O
usage	O
and	O
,	O
by	O
extension	O
,	O
host	O
immunity	O
.	O

Here	O
,	O
we	O
review	O
the	O
immunological	O
functions	O
of	O
B	O
vitamins	O
and	O
their	O
metabolism	O
by	O
intestinal	O
bacteria	O
with	O
respect	O
to	O
the	O
control	O
of	O
host	O
immunity	O
.	O

The	O
Effects	O
of	O
Vegetarian	O
and	O
Vegan	O
Diets	O
on	O
Gut	O
Microbiota	O
.	O

The	O
difference	O
in	O
gut	O
microbiota	O
composition	O
between	O
individuals	O
following	O
vegan	O
or	O
vegetarian	O
diets	O
and	O
those	O
following	O
omnivorous	O
diets	O
is	O
well	O
documented	O
.	O

A	O
plant	O
-	O
based	O
diet	O
appears	O
to	O
be	O
beneficial	O
for	O
human	O
health	O
by	O
promoting	O
the	O
development	O
of	O
more	O
diverse	O
and	O
stable	O
microbial	O
systems	O
.	O

Additionally	O
,	O
vegans	O
and	O
vegetarians	O
have	O
significantly	O
higher	O
counts	O
of	O
certain	O
Bacteroidetes	O
-	O
related	O
operational	O
taxonomic	O
units	O
compared	O
to	O
omnivores	O
.	O

Fibers	O
(	O
that	O
is	O
,	O
non	O
-	O
digestible	O
carbohydrates	O
,	O
found	O
exclusively	O
in	O
plants	O
)	O
most	O
consistently	O
increase	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
,	O
such	O
as	O
Ruminococcus	O
,	O
E	O
.	O
rectale	O
,	O
and	O
Roseburia	O
,	O
and	O
reduce	O
Clostridium	B-bacteria
and	O
Enterococcus	B-bacteria
species	I-bacteria
.	O

Polyphenols	O
,	O
also	O
abundant	O
in	O
plant	O
foods	O
,	O
increase	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
,	O
which	O
provide	O
anti	O
-	O
pathogenic	O
and	O
anti	O
-	O
inflammatory	O
effects	O
and	O
cardiovascular	O
protection	O
.	O

High	O
fiber	O
intake	O
also	O
encourages	O
the	O
growth	O
of	O
species	O
that	O
ferment	O
fiber	O
into	O
metabolites	O
as	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
including	O
acetate	O
,	O
propionate	O
,	O
and	O
butyrate	O
.	O

The	O
positive	O
health	O
effects	O
of	O
SCFAs	O
are	O
myriad	O
,	O
including	O
improved	O
immunity	O
against	O
pathogens	O
,	O
blood	O
-	O
brain	O
barrier	O
integrity	O
,	O
provision	O
of	O
energy	O
substrates	O
,	O
and	O
regulation	O
of	O
critical	O
functions	O
of	O
the	O
intestine	O
.	O

In	O
conclusion	O
,	O
the	O
available	O
literature	O
suggests	O
that	O
a	O
vegetarian	O
/	O
vegan	O
diet	O
is	O
effective	O
in	O
promoting	O
a	O
diverse	O
ecosystem	O
of	O
beneficial	O
bacteria	O
to	O
support	O
both	O
human	O
gut	O
microbiome	O
and	O
overall	O
health	O
.	O

This	O
review	O
will	O
focus	O
on	O
effects	O
of	O
different	O
diets	O
and	O
nutrient	O
contents	O
,	O
particularly	O
plant	O
-	O
based	O
diets	O
,	O
on	O
the	O
gut	O
microbiota	O
composition	O
and	O
production	O
of	O
microbial	O
metabolites	O
affecting	O
the	O
host	O
health	O
.	O

Gegen	O
Qinlian	O
Decoction	O
Treats	O
Diarrhea	O
in	O
Piglets	O
by	O
Modulating	O
Gut	O
Microbiota	O
and	O
Short	O
-	O
Chain	O
Fatty	O
Acids	O
.	O

Gut	O
microbiota	O
and	O
its	O
metabolites	O
,	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
play	O
important	O
roles	O
in	O
diarrheal	O
diseases	O
.	O

Gegen	O
Qinlian	O
decoction	O
(	O
GQD	O
)	O
,	O
a	O
Chinese	O
herb	O
formula	O
,	O
has	O
been	O
widely	O
used	O
to	O
treat	O
infectious	O
diarrhea	O
for	O
centuries	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanism	O
underlying	O
its	O
efficacy	O
and	O
whether	O
it	O
is	O
mediated	O
by	O
gut	O
microbiota	O
and	O
SCFAs	O
.	O

In	O
this	O
study	O
,	O
the	O
composition	O
of	O
gut	O
microbiota	O
from	O
bacterial	O
diarrheal	O
piglets	O
was	O
assessed	O
using	O
16S	O
rRNA	O
analysis	O
.	O

The	O
concentrations	O
of	O
fecal	O
SCFAs	O
were	O
determined	O
using	O
a	O
gas	O
chromatography	O
-	O
mass	O
spectrometer	O
(	O
GC	O
-	O
MS	O
)	O
.	O

The	O
expression	O
of	O
mucosal	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
the	O
colon	O
was	O
ascertained	O
.	O

Results	O
showed	O
that	O
GQD	O
reverses	O
the	O
reduction	O
in	O
the	O
richness	O
of	O
gut	O
microbiota	O
,	O
changes	O
its	O
structure	O
,	O
and	O
significantly	O
increases	O
the	O
relative	O
abundances	O
of	O
SCFA	O
-	O
producing	O
bacteria	O
,	O
including	O
Akkermansia	B-bacteria
,	O
Bacteroides	B-bacteria
,	O
Clostridium	B-bacteria
,	O
Ruminococcus	B-bacteria
,	O
and	O
Phascolarctobacterium	B-bacteria
.	O

Moreover	O
,	O
GQD	O
increased	O
the	O
levels	O
of	O
fecal	O
SCFAs	O
,	O
including	O
acetic	O
acid	O
,	O
propionic	O
acid	O
,	O
and	O
butyric	O
acid	O
.	O

GQD	O
thus	O
attenuates	O
diarrhea	O
in	O
piglets	O
.	O

Further	O
,	O
our	O
results	O
suggest	O
that	O
the	O
SCFAs	O
could	O
help	O
to	O
attenuate	O
mucosal	O
pro	O
-	O
inflammatory	O
responses	O
following	O
GQD	O
treatment	O
by	O
inhibiting	O
histone	O
deacetylase	O
and	O
the	O
NF	O
-	O
kappaB	O
pathway	O
.	O

We	O
thus	O
suggseted	O
that	O
gut	O
microbiota	O
play	O
an	O
important	O
role	O
during	O
diarrhea	O
treatment	O
,	O
an	O
effect	O
may	O
be	O
promoted	O
by	O
the	O
GQD	O
-	O
induced	O
structural	O
changes	O
of	O
the	O
gut	O
microbial	O
community	O
and	O
production	O
of	O
SCFAs	O
.	O

The	O
increased	O
levels	O
of	O
SCFAs	O
probably	O
provide	O
further	O
help	O
to	O
attenuate	O
mucosal	O
inflammation	O
and	O
diarrhea	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
might	O
provide	O
evidence	O
that	O
GQD	O
treats	O
diarrhea	O
maybe	O
involved	O
in	O
modulating	O
gut	O
microbiota	O
and	O
increasing	O
SCFA	O
levels	O
.	O

Is	O
It	O
First	O
the	O
Egg	O
or	O
the	O
Shrimp	O
?	O
-	O
Diversity	O
and	O
Variation	O
in	O
Microbial	O
Communities	O
Colonizing	O
Broods	O
of	O
the	O
Vent	O
Shrimp	O
Rimicaris	B-bacteria
exoculata	I-bacteria
During	O
Embryonic	O
Development	O
.	O

Rimicaris	O
exoculata	O
is	O
one	O
of	O
the	O
most	O
well	O
-	O
known	O
and	O
emblematic	O
species	O
of	O
endemic	O
vent	O
fauna	O
.	O

Like	O
many	O
other	O
species	O
from	O
these	O
ecosystems	O
,	O
Rimicaris	O
shrimps	O
host	O
important	O
communities	O
of	O
chemosynthetic	O
bacteria	O
living	O
in	O
symbiosis	O
with	O
their	O
host	O
inside	O
the	O
cephalothorax	O
and	O
gut	O
.	O

For	O
many	O
of	O
these	O
symbiotic	O
partners	O
,	O
the	O
mode	O
of	O
transmission	O
remains	O
to	O
be	O
elucidated	O
and	O
the	O
starting	O
point	O
of	O
the	O
symbiotic	O
relationship	O
is	O
not	O
yet	O
defined	O
,	O
but	O
could	O
begin	O
with	O
the	O
egg	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
proliferation	O
of	O
microbial	O
communities	O
on	O
R	O
.	O
exoculata	O
broods	O
through	O
embryonic	O
development	O
using	O
a	O
combination	O
of	O
NGS	O
sequencing	O
and	O
microscopy	O
approaches	O
.	O

Variations	O
in	O
abundance	O
and	O
diversity	O
of	O
egg	O
microbial	O
communities	O
were	O
analyzed	O
in	O
broods	O
at	O
different	O
developmental	O
stages	O
and	O
collected	O
from	O
mothers	O
at	O
two	O
distinct	O
vent	O
fields	O
on	O
the	O
Mid	O
-	O
Atlantic	O
Ridge	O
(	O
TAG	O
and	O
Snake	O
Pit	O
)	O
.	O

We	O
also	O
assessed	O
the	O
specificity	O
of	O
the	O
egg	O
microbiome	O
by	O
comparing	O
communities	O
developing	O
on	O
egg	O
surfaces	O
with	O
those	O
developing	O
on	O
the	O
cuticle	O
of	O
pleopods	O
,	O
which	O
are	O
thought	O
to	O
be	O
exposed	O
to	O
similar	O
environmental	O
conditions	O
because	O
the	O
brood	O
is	O
held	O
under	O
the	O
female	O
'	O
s	O
abdomen	O
.	O

In	O
terms	O
of	O
abundance	O
,	O
bacterial	O
colonization	O
clearly	O
increases	O
with	O
both	O
egg	O
developmental	O
stage	O
and	O
the	O
position	O
of	O
the	O
egg	O
within	O
the	O
brood	O
:	O
those	O
closest	O
to	O
the	O
exterior	O
having	O
a	O
higher	O
bacterial	O
coverage	O
.	O

Bacterial	O
biomass	O
increase	O
also	O
accompanies	O
an	O
increase	O
of	O
mineral	O
precipitations	O
and	O
thus	O
clearly	O
relates	O
to	O
the	O
degree	O
of	O
exposure	O
to	O
vent	O
fluids	O
.	O

In	O
terms	O
of	O
diversity	O
,	O
most	O
bacterial	O
lineages	O
were	O
found	O
in	O
all	O
samples	O
and	O
were	O
also	O
those	O
found	O
in	O
the	O
cephalothorax	O
of	O
adults	O
.	O

However	O
,	O
significant	O
variation	O
occurs	O
in	O
the	O
relative	O
abundance	O
of	O
these	O
lineages	O
,	O
most	O
of	O
this	O
variation	O
being	O
explained	O
by	O
body	O
surface	O
(	O
egg	O
vs	O
.	O
pleopod	O
)	O
,	O
vent	O
field	O
,	O
and	O
developmental	O
stage	O
.	O

The	O
occurrence	O
of	O
symbiont	O
-	O
related	O
lineages	O
of	O
Epsilonbacteraeota	B-bacteria
,	O
Gammaproteobacteria	B-bacteria
,	O
Zetaproteobacteria	B-bacteria
,	O
and	O
Mollicutes	B-bacteria
provide	O
a	O
basis	O
for	O
discussion	O
on	O
both	O
the	O
acquisition	O
of	O
symbionts	O
and	O
the	O
potential	O
roles	O
of	O
these	O
bacterial	O
communities	O
during	O
egg	O
development	O
.	O

Coexistence	O
of	O
Microbial	O
Species	O
in	O
Structured	O
Communities	O
by	O
Forming	O
a	O
Hawk	O
-	O
Dove	O
Game	O
Like	O
Interactive	O
Relationship	O
.	O

Microorganisms	O
evolve	O
kinds	O
of	O
elaborate	O
interaction	O
models	O
that	O
can	O
form	O
relatively	O
stable	O
communities	O
in	O
a	O
wide	O
range	O
of	O
ecosystems	O
.	O

It	O
is	O
recognized	O
that	O
the	O
spatial	O
genetic	O
structure	O
of	O
microbes	O
in	O
surface	O
-	O
attached	O
environments	O
lays	O
a	O
good	O
foundation	O
for	O
the	O
persistence	O
of	O
polymicrobial	O
communities	O
in	O
adverse	O
conditions	O
.	O

However	O
,	O
the	O
interacting	O
dynamics	O
of	O
microbes	O
in	O
facilitating	O
the	O
formation	O
and	O
stabilization	O
of	O
community	O
structure	O
still	O
remains	O
elusive	O
.	O

In	O
this	O
study	O
,	O
we	O
identify	O
a	O
hawk	O
-	O
dove	O
game	O
like	O
interspecific	O
relationship	O
between	O
the	O
two	O
Gram	O
-	O
negative	O
opportunistic	O
pathogens	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
and	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
,	O
which	O
naturally	O
coexist	O
in	O
insect	O
gut	O
and	O
can	O
cocolonize	O
human	O
tissues	O
.	O

Specifically	O
,	O
although	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
had	O
significant	O
competitive	O
advantage	O
over	O
cocultured	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
on	O
solid	O
medium	O
with	O
rich	O
nutrient	O
factors	O
,	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
could	O
resist	O
the	O
suppression	O
of	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
by	O
enhancing	O
the	O
expression	O
of	O
membrane	O
transporters	O
induced	O
by	O
the	O
extracellular	O
metabolites	O
of	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
.	O

By	O
contrast	O
,	O
under	O
the	O
condition	O
that	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
had	O
a	O
growth	O
advantage	O
but	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
met	O
a	O
metabolic	O
burden	O
in	O
producing	O
quorum	O
-	O
sensing	O
-	O
controlled	O
extracellular	O
products	O
,	O
the	O
frequency	O
of	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
would	O
be	O
slightly	O
higher	O
than	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
during	O
the	O
coexistence	O
because	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
was	O
also	O
capable	O
of	O
exploiting	O
the	O
extracellular	O
metabolite	O
from	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
.	O

In	O
addition	O
,	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
quorum	O
-	O
sensing	O
variant	O
could	O
reap	O
benefits	O
from	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
in	O
turn	O
and	O
reach	O
a	O
relatively	O
stable	O
two	O
species	O
equilibrium	O
.	O

These	O
findings	O
provide	O
an	O
explanation	O
for	O
the	O
formation	O
and	O
maintenance	O
of	O
polymicrobial	O
communities	O
in	O
different	O
spatially	O
structured	O
environments	O
,	O
and	O
thus	O
may	O
contribute	O
to	O
understanding	O
the	O
complex	O
interspecific	O
interactions	O
of	O
microbes	O
in	O
local	O
communities	O
and	O
shed	O
new	O
light	O
on	O
the	O
development	O
of	O
social	O
microbiology	O
.	O

The	O
Influence	O
of	O
the	O
Gut	O
Microbiome	O
on	O
Host	O
Metabolism	O
Through	O
the	O
Regulation	O
of	O
Gut	O
Hormone	O
Release	O
.	O

The	O
microbial	O
community	O
of	O
the	O
gut	O
conveys	O
significant	O
benefits	O
to	O
host	O
physiology	O
.	O

A	O
clear	O
relationship	O
has	O
now	O
been	O
established	O
between	O
gut	O
bacteria	O
and	O
host	O
metabolism	O
in	O
which	O
microbial	O
-	O
mediated	O
gut	O
hormone	O
release	O
plays	O
an	O
important	O
role	O
.	O

Within	O
the	O
gut	O
lumen	O
,	O
bacteria	O
produce	O
a	O
number	O
of	O
metabolites	O
and	O
contain	O
structural	O
components	O
that	O
act	O
as	O
signaling	O
molecules	O
to	O
a	O
number	O
of	O
cell	O
types	O
within	O
the	O
mucosa	O
.	O

Enteroendocrine	O
cells	O
within	O
the	O
mucosal	O
lining	O
of	O
the	O
gut	O
synthesize	O
and	O
secrete	O
a	O
number	O
of	O
hormones	O
including	O
CCK	O
,	O
PYY	O
,	O
GLP	O
-	O
1	O
,	O
GIP	O
,	O
and	O
5	O
-	O
HT	O
,	O
which	O
have	O
regulatory	O
roles	O
in	O
key	O
metabolic	O
processes	O
such	O
as	O
insulin	O
sensitivity	O
,	O
glucose	O
tolerance	O
,	O
fat	O
storage	O
,	O
and	O
appetite	O
.	O

Release	O
of	O
these	O
hormones	O
can	O
be	O
influenced	O
by	O
the	O
presence	O
of	O
bacteria	O
and	O
their	O
metabolites	O
within	O
the	O
gut	O
and	O
as	O
such	O
,	O
microbial	O
-	O
mediated	O
gut	O
hormone	O
release	O
is	O
an	O
important	O
component	O
of	O
microbial	O
regulation	O
of	O
host	O
metabolism	O
.	O

Dietary	O
or	O
pharmacological	O
interventions	O
which	O
alter	O
the	O
gut	O
microbiome	O
therefore	O
pose	O
as	O
potential	O
therapeutics	O
for	O
the	O
treatment	O
of	O
human	O
metabolic	O
disorders	O
.	O

This	O
review	O
aims	O
to	O
describe	O
the	O
complex	O
interaction	O
between	O
intestinal	O
microbiota	O
and	O
their	O
metabolites	O
and	O
gut	O
enteroendocrine	O
cells	O
,	O
and	O
highlight	O
how	O
the	O
gut	O
microbiome	O
can	O
influence	O
host	O
metabolism	O
through	O
the	O
regulation	O
of	O
gut	O
hormone	O
release	O
.	O

Fecal	O
Proteases	O
from	O
Pouchitis	O
Patients	O
Activate	O
Protease	O
Activating	O
Receptor	O
-	O
2	O
to	O
Disrupt	O
the	O
Epithelial	O
Barrier	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
The	O
pathogenesis	O
of	O
pouch	O
inflammation	O
may	O
involve	O
epithelial	O
barrier	O
disruption	O
.	O

We	O
investigated	O
whether	O
fecal	O
proteolytic	O
activity	O
is	O
increased	O
during	O
pouchitis	O
and	O
results	O
in	O
epithelial	O
barrier	O
dysfunction	O
through	O
protease	O
activating	O
receptor	O
(	O
PAR	O
)	O
activation	O
,	O
and	O
assessed	O
whether	O
the	O
intestinal	O
microbiome	O
may	O
be	O
the	O
source	O
of	O
the	O
proteases	O
.	O

METHODS	O
:	O
Fecal	O
samples	O
were	O
measured	O
for	O
protease	O
activity	O
using	O
a	O
fluorescein	O
isothiocyanate	O
(	O
FITC	O
)	O
-	O
casein	O
florescence	O
assay	O
.	O

Caco	O
-	O
2	O
cell	O
monolayers	O
were	O
exposed	O
to	O
fecal	O
supernatants	O
to	O
assess	O
permeability	O
to	O
FITC	O
-	O
dextran	O
.	O

Tight	O
junction	O
protein	O
integrity	O
and	O
PAR	O
activation	O
were	O
assessed	O
by	O
immunoblot	O
and	O
immunofluorescence	O
.	O

A	O
truncated	O
PAR2	O
protein	O
in	O
Caco	O
-	O
2	O
cells	O
was	O
achieved	O
by	O
stable	O
transfection	O
using	O
CRISPR	O
/	O
Cas9	O
plasmid	O
.	O

PAR2	O
activation	O
in	O
pouch	O
biopsies	O
was	O
examined	O
using	O
antibodies	O
directed	O
to	O
the	O
N	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

Microbial	O
composition	O
was	O
analyzed	O
using	O
Illumina	O
MiSeq	O
platform	O
of	O
the	O
16S	O
rRNA	O
gene	O
.	O

RESULTS	O
:	O
Ten	O
pouchitis	O
patients	O
,	O
6	O
normal	O
pouch	O
(	O
NP	O
)	O
patients	O
and	O
9	O
healthy	O
controls	O
(	O
HC	O
)	O
were	O
recruited	O
.	O

The	O
pouchitis	O
patients	O
exhibited	O
a	O
5	O
.	O
19	O
-	O
and	O
5	O
.	O
35	O
-	O
fold	O
higher	O
fecal	O
protease	O
(	O
FP	O
)	O
activity	O
(	O
p	O
<	O
/	O
=	O
0	O
.	O
05	O
)	O
compared	O
to	O
the	O
NP	O
and	O
HC	O
participants	O
,	O
respectively	O
.	O

The	O
Haemophilus	B-bacteria
species	I-bacteria
was	O
positively	O
associated	O
with	O
FP	O
activity	O
(	O
R	O
=	O
0	O
.	O
718	O
,	O
FDR	O
<	O
0	O
.	O
1	O
)	O
.	O
Fecal	O
supernatants	O
from	O
pouchitis	O
patients	O
activated	O
PAR2	O
on	O
Caco	O
-	O
2	O
monolayers	O
,	O
disrupted	O
TJ	O
proteins	O
,	O
and	O
increased	O
epithelial	O
permeability	O
.	O

PAR2	O
truncation	O
in	O
Caco	O
-	O
2	O
abrogated	O
fecal	O
protease	O
-	O
mediated	O
permeability	O
.	O

Pouch	O
biopsies	O
obtained	O
from	O
pouchitis	O
patients	O
,	O
but	O
not	O
from	O
NP	O
patients	O
,	O
displayed	O
PAR2	O
activation	O
.	O

CONCLUSIONS	O
:	O
Protease	O
-	O
producing	O
bacteria	O
may	O
increase	O
fecal	O
proteolytic	O
activity	O
that	O
results	O
in	O
pouch	O
inflammation	O
through	O
disruption	O
of	O
TJ	O
proteins	O
and	O
increased	O
epithelial	O
permeability	O
in	O
a	O
PAR2	O
-	O
dependent	O
manner	O
.	O

This	O
mechanism	O
may	O
initiate	O
or	O
propagate	O
pouch	O
inflammation	O
.	O

The	O
microbiota	O
profile	O
and	O
transcriptome	O
analysis	O
of	O
immune	O
response	O
during	O
metamorphosis	O
stages	O
in	O
orange	O
spotted	O
grouper	O
(	O
Epinephelus	O
coioides	O
)	O
.	O

Metamorphosis	O
is	O
a	O
transformation	O
process	O
in	O
larval	O
development	O
associated	O
with	O
changes	O
in	O
morphological	O
and	O
physiological	O
features	O
,	O
including	O
the	O
immune	O
system	O
.	O

The	O
gastrointestinal	O
tract	O
harbors	O
a	O
plethora	O
of	O
bacteria	O
,	O
which	O
might	O
affect	O
the	O
digestion	O
and	O
absorption	O
of	O
nutrients	O
,	O
immunity	O
,	O
and	O
gut	O
-	O
brain	O
crosstalk	O
in	O
the	O
host	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
performed	O
metagenomic	O
and	O
transcriptomic	O
analyses	O
on	O
the	O
intestines	O
of	O
grouper	O
at	O
the	O
pre	O
-	O
,	O
mid	O
-	O
and	O
post	O
-	O
metamorphosis	O
stages	O
.	O

The	O
sequencing	O
data	O
of	O
16S	O
rRNA	O
gene	O
showed	O
drastic	O
changes	O
in	O
the	O
microbial	O
communities	O
at	O
different	O
developmental	O
stages	O
.	O

The	O
transcriptomic	O
data	O
revealed	O
that	O
the	O
leukocyte	O
transendothelial	O
migration	O
and	O
the	O
phagosome	O
pathways	O
might	O
play	O
important	O
roles	O
in	O
mediating	O
immunity	O
in	O
grouper	O
at	O
the	O
three	O
developmental	O
stages	O
.	O

This	O
information	O
will	O
increase	O
our	O
understanding	O
of	O
the	O
metamorphosis	O
process	O
in	O
grouper	O
larvae	O
,	O
and	O
shed	O
light	O
on	O
the	O
development	O
of	O
antimicrobial	O
strategy	O
during	O
larval	O
development	O
.	O

Colonic	O
fermentation	O
of	O
water	O
soluble	O
fiber	O
fraction	O
extracted	O
from	O
sugarcane	O
(	O
Sacchurum	O
officinarum	O
L	O
.	O
)	O
bagasse	O
in	O
murine	O
models	O
.	O

Biochemical	O
effects	O
of	O
the	O
water	O
soluble	O
fiber	O
fraction	O
of	O
sugarcane	O
bagasse	O
(	O
BSF	O
)	O
fermented	O
in	O
the	O
colon	O
was	O
examined	O
to	O
evaluate	O
its	O
potential	O
health	O
promoting	O
effects	O
.	O

A	O
feeding	O
experiment	O
involving	O
Fischer	O
344	O
rats	O
,	O
was	O
conducted	O
with	O
3	O
experimental	O
diets	O
containing	O
,	O
cellulose	O
(	O
CON	O
)	O
,	O
a	O
commercial	O
xylo	O
-	O
oligosaccharide	O
(	O
XYO	O
)	O
and	O
BSF	O
(	O
BGS	O
)	O
.	O

Cumulative	O
feed	O
intake	O
was	O
significantly	O
lower	O
in	O
XYO	O
group	O
while	O
cecal	O
weight	O
was	O
significantly	O
higher	O
.	O

Acetic	O
and	O
propionic	O
acid	O
contents	O
in	O
the	O
cecal	O
content	O
were	O
significantly	O
higher	O
in	O
the	O
BGS	O
and	O
XYO	O
,	O
respectively	O
.	O

Total	O
short	O
chain	O
fatty	O
acid	O
content	O
was	O
significantly	O
higher	O
in	O
BGS	O
and	O
XYO	O
resulting	O
significantly	O
lower	O
cecal	O
pH	O
.	O

Beneficial	O
bacteria	O
such	O
as	O
Bifidobacterium	B-bacteria
,	O
Blautia	B-bacteria
,	O
Akkermansia	B-bacteria
and	O
Roseburia	B-bacteria
abundance	O
was	O
significantly	O
higher	O
in	O
the	O
XYO	O
and	O
BGS	O
groups	O
.	O

Further	O
,	O
mucin	O
and	O
immunoglobulin	O
-	O
A	O
contents	O
were	O
significantly	O
higher	O
in	O
BGS	O
group	O
compared	O
to	O
CON	O
group	O
.	O

Thus	O
,	O
BSF	O
exhibited	O
its	O
ability	O
to	O
enhance	O
the	O
intestinal	O
and	O
systemic	O
health	O
upon	O
fermentation	O
in	O
the	O
colon	O
.	O

Pectin	O
-	O
decorated	O
magnetite	O
nanoparticles	O
as	O
both	O
iron	O
delivery	O
systems	O
and	O
protective	O
matrices	O
for	O
probiotic	O
bacteria	O
.	O

The	O
goal	O
of	O
this	O
work	O
was	O
to	O
investigate	O
biophysical	O
stability	O
of	O
iron	O
-	O
pectin	O
nanoparticles	O
and	O
analyze	O
the	O
feasibility	O
of	O
using	O
them	O
as	O
delivery	O
systems	O
for	O
the	O
probiotic	O
strain	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
CIDCA	I-bacteria
83114	I-bacteria
.	O

Iron	O
oxide	O
(	O
Fe3O4	O
)	O
nanoparticles	O
were	O
synthesized	O
from	O
0	O
.	O
25M	O
FeCl2	O
/	O
0	O
.	O
5	O
M	O
FeCl3	O
.	O
6H2O	O
,	O
and	O
coated	O
with	O
citrus	O
pectins	O
.	O

Their	O
physico	O
-	O
chemical	O
properties	O
[	O
FTIR	O
,	O
X	O
-	O
ray	O
diffraction	O
(	O
XRD	O
)	O
,	O
zeta	O
-	O
potential	O
,	O
particle	O
size	O
,	O
SEM	O
,	O
TEM	O
]	O
and	O
their	O
effect	O
on	O
bacterial	O
stabilization	O
(	O
viability	O
after	O
freeze	O
-	O
drying	O
/	O
storage	O
,	O
stability	O
when	O
exposed	O
to	O
simulated	O
gastro	O
-	O
intestinal	O
conditions	O
)	O
were	O
assessed	O
.	O

XRD	O
indicated	O
the	O
almost	O
exclusive	O
presence	O
of	O
magnetite	O
crystalline	O
phases	O
.	O

FTIR	O
spectra	O
confirmed	O
the	O
adsorption	O
of	O
pectin	O
on	O
magnetite	O
nanoparticles	O
surface	O
.	O

SEM	O
and	O
TEM	O
images	O
evidenced	O
agglomerated	O
nanoparticles	O
,	O
and	O
a	O
morphological	O
surface	O
change	O
after	O
adsorption	O
of	O
pectin	O
.	O

DLS	O
and	O
zeta	O
-	O
potential	O
results	O
proved	O
the	O
solvation	O
of	O
the	O
ionizable	O
groups	O
in	O
the	O
hydrophilic	O
network	O
which	O
induced	O
chain	O
expansion	O
and	O
agglomeration	O
.	O

Iron	O
from	O
nanoparticles	O
demonstrated	O
to	O
be	O
non	O
-	O
toxic	O
for	O
microorganisms	O
up	O
to	O
1	O
.	O
00	O
mg	O
/	O
mL	O
.	O

Simulated	O
saliva	O
and	O
gastric	O
solutions	O
prevented	O
nanoparticles	O
from	O
dissolution	O
.	O

The	O
higher	O
pH	O
of	O
the	O
intestinal	O
conditions	O
(	O
solvated	O
-	O
COO	O
-	O
and	O
Fe	O
-	O
O	O
-	O
groups	O
)	O
facilitated	O
the	O
dispersion	O
and	O
partial	O
dissolution	O
of	O
nanoparticles	O
.	O

Pectins	O
adsorption	O
on	O
magnetite	O
nanoparticles	O
significantly	O
enhanced	O
electrostatic	O
repulsion	O
,	O
which	O
aided	O
the	O
solvation	O
of	O
ionized	O
iron	O
forms	O
.	O

The	O
soluble	O
species	O
diffused	O
out	O
from	O
the	O
aggregates	O
,	O
being	O
detected	O
in	O
the	O
simulated	O
intestinal	O
fluid	O
.	O

Regarding	O
bacterial	O
viability	O
,	O
no	O
decays	O
were	O
observed	O
neither	O
when	O
pectin	O
-	O
decorated	O
nanoparticles	O
were	O
exposed	O
to	O
simulated	O
fluids	O
nor	O
when	O
stored	O
at	O
4	O
degrees	O
C	O
for	O
60	O
days	O
.	O

The	O
composites	O
engineered	O
in	O
this	O
work	O
appear	O
as	O
adequate	O
delivery	O
systems	O
for	O
probiotic	O
bacteria	O
,	O
whose	O
target	O
is	O
the	O
gut	O
.	O

Polysaccharide	O
from	O
Spirulina	O
platensis	O
ameliorates	O
diphenoxylate	O
-	O
induced	O
constipation	O
symptoms	O
in	O
mice	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
probe	O
new	O
functions	O
of	O
a	O
polysaccharide	O
from	O
Spirulina	O
platensis	O
(	O
PSP	O
)	O
on	O
constipation	O
and	O
intestinal	O
microbiota	O
in	O
mice	O
.	O

Diphenoxylate	O
-	O
induced	O
constipation	O
in	O
mice	O
was	O
treated	O
with	O
different	O
doses	O
of	O
PSP	O
,	O
followed	O
by	O
examining	O
the	O
defecation	O
patterns	O
,	O
levels	O
of	O
acetyl	O
cholinesterase	O
(	O
AchE	O
)	O
,	O
nitric	O
oxide	O
(	O
NO	O
)	O
,	O
and	O
tissue	O
section	O
histopathology	O
.	O

The	O
composition	O
of	O
intestinal	O
microbiota	O
was	O
determined	O
by	O
genome	O
sequencing	O
analysis	O
of	O
the	O
16S	O
rDNA	O
.	O

This	O
study	O
found	O
that	O
the	O
average	O
molecular	O
weight	O
of	O
PSP	O
was	O
29	O
,	O
600Da	O
,	O
and	O
mainly	O
monosaccharides	O
of	O
PSP	O
were	O
rhamnose	O
(	O
24	O
.	O
7	O
%	O
)	O
,	O
glucose	O
(	O
16	O
.	O
15	O
%	O
)	O
and	O
galactose	O
(	O
13	O
.	O
32	O
%	O
)	O
.	O

The	O
beneficial	O
effects	O
of	O
PSP	O
treatment	O
include	O
defecation	O
improvement	O
,	O
increase	O
of	O
AchE	O
activity	O
,	O
reduction	O
of	O
NO	O
concentration	O
,	O
renovation	O
of	O
the	O
damaged	O
intestinal	O
villus	O
and	O
affection	O
on	O
the	O
expression	O
of	O
some	O
related	O
genes	O
in	O
the	O
constipated	O
mice	O
.	O

In	O
addition	O
,	O
PSP	O
had	O
significant	O
effects	O
on	O
the	O
gut	O
microbiota	O
,	O
showing	O
the	O
enhancement	O
in	O
abundance	O
of	O
beneficial	O
bacteria	O
including	O
Akkermansia	B-bacteria
,	O
Lactobacillus	B-bacteria
,	O
Butyricimonas	B-bacteria
,	O
Candidatus	B-bacteria
Arthromitus	I-bacteria
and	O
Prevotella	B-bacteria
,	O
and	O
the	O
reduction	O
in	O
abundance	O
of	O
harmful	O
bacteria	O
such	O
as	O
Clostridium	B-bacteria
and	O
Dorea	B-bacteria
.	O

The	O
present	O
s	O
uncovered	O
a	O
new	O
function	O
of	O
PSP	O
,	O
indicating	O
that	O
PSP	O
could	O
be	O
used	O
in	O
constipation	O
therapies	O
.	O

Naming	O
novel	O
prokaryotic	O
taxa	O
discovered	O
in	O
the	O
human	O
gut	O
.	O

Impact	O
of	O
Early	O
Exposure	O
to	O
Cefuroxime	O
on	O
the	O
Composition	O
of	O
the	O
Gut	O
Microbiota	O
in	O
Infants	O
Following	O
Cesarean	O
Delivery	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
in	O
mothers	O
giving	O
birth	O
by	O
cesarean	O
delivery	O
if	O
prophylactic	O
antibiotics	O
administered	O
either	O
before	O
skin	O
incision	O
or	O
immediately	O
after	O
cutting	O
the	O
umbilical	O
cord	O
influences	O
gut	O
microbiota	O
colonization	O
and	O
antibiotic	O
susceptibility	O
of	O
the	O
gut	O
bacteria	O
in	O
the	O
newborn	O
.	O

STUDY	O
DESIGN	O
:	O
Forty	O
-	O
two	O
pregnant	O
women	O
scheduled	O
for	O
elective	O
cesarean	O
delivery	O
were	O
recruited	O
at	O
Odense	O
University	O
Hospital	O
,	O
Denmark	O
,	O
and	O
randomly	O
assigned	O
to	O
receive	O
cefuroxime	O
either	O
before	O
skin	O
incision	O
or	O
immediately	O
after	O
the	O
umbilical	O
cord	O
was	O
cut	O
.	O

Fecal	O
samples	O
were	O
collected	O
from	O
all	O
infants	O
at	O
age	O
10	O
days	O
and	O
9	O
months	O
.	O

Composition	O
of	O
the	O
gut	O
microbiota	O
was	O
determined	O
by	O
16S	O
ribosomal	O
RNA	O
gene	O
amplicon	O
high	O
-	O
throughput	O
sequencing	O
.	O

Gram	O
-	O
positive	O
cocci	O
and	O
Enterobacteriaceae	B-bacteria
were	O
isolated	O
and	O
identified	O
before	O
antimicrobial	O
susceptibility	O
tests	O
were	O
performed	O
by	O
disk	O
diffusion	O
.	O

RESULTS	O
:	O
No	O
clear	O
difference	O
in	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
was	O
observed	O
between	O
infants	O
whose	O
mothers	O
received	O
cefuroxime	O
before	O
or	O
after	O
cesarean	O
delivery	O
at	O
neither	O
time	O
point	O
,	O
though	O
surprisingly	O
at	O
9	O
months	O
of	O
age	O
,	O
but	O
not	O
at	O
10	O
days	O
of	O
age	O
,	O
the	O
number	O
of	O
observed	O
species	O
was	O
higher	O
in	O
infants	O
where	O
mothers	O
received	O
cefuroxime	O
after	O
cord	O
clamping	O
.	O

No	O
differences	O
in	O
antimicrobial	O
susceptibility	O
of	O
Enterobacteriaceae	B-bacteria
,	O
Enterococcus	B-bacteria
spp	I-bacteria
,	O
and	O
Staphylococcus	B-bacteria
spp	I-bacteria
were	O
seen	O
at	O
10	O
days	O
.	O

CONCLUSIONS	O
:	O
Timing	O
of	O
cefuroxime	O
administration	O
to	O
mothers	O
undergoing	O
cesarean	O
delivery	O
does	O
not	O
have	O
a	O
major	O
effect	O
on	O
the	O
gut	O
microbiota	O
and	O
bacterial	O
antibiotic	O
resistance	O
traits	O
in	O
infants	O
.	O

TRIAL	O
REGISTRATION	O
:	O
Clinicaltrials	O
.	O
gov	O
:	O
NCT02072798	O
.	O

Intrauterine	O
Microbiota	O
:	O
Missing	O
,	O
or	O
the	O
Missing	O
Link	O
?	O

The	O
intrauterine	O
environment	O
provides	O
a	O
key	O
interface	O
between	O
the	O
mother	O
and	O
the	O
developing	O
fetus	O
during	O
pregnancy	O
,	O
and	O
is	O
a	O
target	O
for	O
investigating	O
mechanisms	O
of	O
fetal	O
programming	O
.	O

Studies	O
have	O
demonstrated	O
an	O
association	O
between	O
prenatal	O
stress	O
and	O
neurodevelopmental	O
disorders	O
.	O

The	O
role	O
of	O
the	O
intrauterine	O
environment	O
in	O
mediating	O
this	O
effect	O
is	O
still	O
being	O
elucidated	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
emerging	O
preclinical	O
and	O
clinical	O
evidence	O
suggesting	O
the	O
existence	O
of	O
microbial	O
communities	O
in	O
utero	O
.	O

We	O
also	O
outline	O
possible	O
mechanisms	O
of	O
bacterial	O
translocation	O
to	O
the	O
intrauterine	O
environment	O
and	O
immune	O
responses	O
to	O
the	O
presence	O
of	O
microbes	O
or	O
microbial	O
components	O
.	O

Lastly	O
,	O
we	O
overview	O
the	O
effects	O
of	O
intrauterine	O
inflammation	O
on	O
neurodevelopment	O
.	O

We	O
hypothesize	O
that	O
maternal	O
gestational	O
stress	O
leads	O
to	O
disruptions	O
in	O
the	O
maternal	O
oral	O
,	O
gut	O
,	O
and	O
vaginal	O
microbiome	O
that	O
may	O
lead	O
to	O
the	O
translocation	O
of	O
bacteria	O
to	O
the	O
intrauterine	O
environment	O
,	O
eliciting	O
an	O
inflammatory	O
response	O
and	O
resulting	O
in	O
deficits	O
in	O
neurodevelopment	O
.	O

The	O
combination	O
of	O
sport	O
and	O
sport	O
-	O
specific	O
diet	O
is	O
associated	O
with	O
characteristics	O
of	O
gut	O
microbiota	O
:	O
an	O
observational	O
study	O
.	O

BACKGROUND	O
:	O
Recently	O
,	O
gut	O
microbiota	O
have	O
been	O
studied	O
extensively	O
for	O
health	O
promotion	O
,	O
disease	O
prevention	O
,	O
disease	O
treatment	O
,	O
and	O
exercise	O
performance	O
.	O

It	O
is	O
recommended	O
that	O
athletes	O
avoid	O
dietary	O
fiber	O
and	O
resistant	O
starch	O
to	O
promote	O
gastric	O
emptying	O
and	O
reduce	O
gastrointestinal	O
distress	O
during	O
exercise	O
,	O
but	O
this	O
diet	O
may	O
reduce	O
microbial	O
diversity	O
and	O
compromise	O
the	O
health	O
of	O
the	O
athlete	O
'	O
s	O
gut	O
microbiota	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
compared	O
fecal	O
microbiota	O
characteristics	O
using	O
high	O
-	O
throughput	O
sequencing	O
among	O
healthy	O
sedentary	O
men	O
(	O
as	O
controls	O
)	O
,	O
bodybuilders	O
,	O
and	O
distance	O
runners	O
,	O
as	O
well	O
as	O
the	O
relationships	O
between	O
microbiota	O
characteristics	O
,	O
body	O
composition	O
,	O
and	O
nutritional	O
status	O
.	O

METHODS	O
:	O
Body	O
composition	O
was	O
measured	O
using	O
DXA	O
,	O
and	O
physical	O
activity	O
level	O
was	O
assessed	O
using	O
IPAQ	O
.	O

Dietary	O
intake	O
was	O
analyzed	O
with	O
the	O
computerized	O
nutritional	O
evaluation	O
program	O
.	O

The	O
DNA	O
of	O
fecal	O
samples	O
was	O
extracted	O
and	O
it	O
was	O
sequenced	O
for	O
the	O
analysis	O
of	O
gut	O
microbial	O
diversity	O
through	O
bioinformatics	O
cloud	O
platform	O
.	O

RESULTS	O
:	O
We	O
showed	O
that	O
exercise	O
type	O
was	O
associated	O
with	O
athlete	O
diet	O
patterns	O
(	O
bodybuilders	O
:	O
high	O
protein	O
,	O
high	O
fat	O
,	O
low	O
carbohydrate	O
,	O
and	O
low	O
dietary	O
fiber	O
diet	O
;	O
distance	O
runners	O
:	O
low	O
carbohydrate	O
and	O
low	O
dietary	O
fiber	O
diet	O
)	O
.	O

However	O
,	O
athlete	O
type	O
did	O
not	O
differ	O
in	O
regard	O
to	O
gut	O
microbiota	O
alpha	O
and	O
beta	O
diversity	O
.	O

Athlete	O
type	O
was	O
significantly	O
associated	O
with	O
the	O
relative	O
abundance	O
of	O
gut	O
microbiota	O
at	O
the	O
genus	O
and	O
species	O
level	O
:	O
Faecalibacterium	B-bacteria
,	O
Sutterella	B-bacteria
,	O
Clostridium	B-bacteria
,	O
Haemophilus	B-bacteria
,	O
and	O
Eisenbergiella	B-bacteria
were	O
the	O
highest	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
bodybuilders	O
,	O
while	O
Bifidobacterium	B-bacteria
and	O
Parasutterella	B-bacteria
were	O
the	O
lowest	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
the	O
species	O
level	O
,	O
intestinal	O
beneficial	O
bacteria	O
widely	O
used	O
as	O
probiotics	O
(	O
Bifidobacterium	B-bacteria
adolescentis	I-bacteria
group	O
,	O
Bifidobacterium	B-bacteria
longum	I-bacteria
group	O
,	O
Lactobacillus	B-bacteria
sakei	I-bacteria
group	O
)	O
and	O
those	O
producing	O
short	O
chain	O
fatty	O
acids	O
(	O
Blautia	B-bacteria
wexlerae	I-bacteria
,	O
Eubacterium	B-bacteria
hallii	I-bacteria
)	O
were	O
the	O
lowest	O
in	O
bodybuilders	O
and	O
the	O
highest	O
in	O
controls	O
.	O

In	O
addition	O
,	O
aerobic	O
or	O
resistance	O
exercise	O
training	O
with	O
an	O
unbalanced	O
intake	O
of	O
macronutrients	O
and	O
low	O
intake	O
of	O
dietary	O
fiber	O
led	O
to	O
similar	O
diversity	O
of	O
gut	O
microbiota	O
.	O

Specifically	O
,	O
daily	O
protein	O
intake	O
was	O
negatively	O
correlated	O
with	O
operation	O
taxonomic	O
unit	O
(	O
r	O
=	O
-	O
0	O
.	O
53	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
ACE	O
(	O
r	O
=	O
-	O
0	O
.	O
51	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
Shannon	O
index	O
(	O
r	O
=	O
-	O
0	O
.	O
64	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
distance	O
runners	O
.	O
.	O

CONCLUSION	O
:	O
Results	O
suggest	O
that	O
high	O
-	O
protein	O
diets	O
may	O
have	O
a	O
negative	O
impact	O
on	O
gut	O
microbiota	O
diversity	O
for	O
athletes	O
,	O
while	O
athletes	O
in	O
resistance	O
sports	O
that	O
carry	O
out	O
the	O
high	O
protein	O
low	O
carbohydrates	O
diet	O
demonstrate	O
a	O
decrease	O
in	O
short	O
chain	O
fatty	O
acid	O
-	O
producing	O
commensal	O
bacteria	O
.	O

Increases	O
in	O
Colonic	O
Bacterial	O
Diversity	O
after	O
omega	O
-	O
3	O
Fatty	O
Acid	O
Supplementation	O
Predict	O
Decreased	O
Colonic	O
Prostaglandin	O
E2	O
Concentrations	O
in	O
Healthy	O
Adults	O
.	O

BACKGROUND	O
:	O
The	O
intestinal	O
microbiome	O
is	O
an	O
important	O
determinant	O
of	O
inflammatory	O
balance	O
in	O
the	O
colon	O
that	O
may	O
affect	O
response	O
to	O
dietary	O
agents	O
.	O

OBJECTIVE	O
:	O
This	O
is	O
a	O
secondary	O
analysis	O
of	O
a	O
clinical	O
trial	O
,	O
the	O
Fish	O
Oil	O
Study	O
,	O
to	O
determine	O
whether	O
interindividual	O
differences	O
in	O
colonic	O
bacteria	O
are	O
associated	O
with	O
variability	O
in	O
the	O
reduction	O
of	O
colonic	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
concentrations	O
after	O
personalized	O
supplementation	O
with	O
omega	O
-	O
3	O
(	O
n	O
-	O
3	O
)	O
fatty	O
acids	O
.	O

METHODS	O
:	O
Forty	O
-	O
seven	O
healthy	O
adults	O
(	O
17	O
men	O
,	O
30	O
women	O
,	O
ages	O
26	O
-	O
75	O
y	O
)	O
provided	O
biopsy	O
samples	O
of	O
colonic	O
mucosa	O
and	O
luminal	O
stool	O
brushings	O
before	O
and	O
after	O
personalized	O
omega	O
-	O
3	O
fatty	O
acid	O
supplementation	O
that	O
was	O
based	O
on	O
blood	O
fatty	O
acid	O
responses	O
.	O

Samples	O
were	O
analyzed	O
using	O
16S	O
ribosomal	O
RNA	O
sequencing	O
.	O

The	O
data	O
analyses	O
focused	O
on	O
changes	O
in	O
bacterial	O
community	O
diversity	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
evaluate	O
factors	O
that	O
predict	O
a	O
reduction	O
in	O
colonic	O
PGE2	O
.	O

RESULTS	O
:	O
At	O
baseline	O
,	O
increased	O
bacterial	O
diversity	O
,	O
as	O
measured	O
by	O
the	O
Shannon	O
and	O
Inverse	O
Simpson	O
indexes	O
in	O
both	O
biopsy	O
and	O
luminal	O
brushing	O
samples	O
,	O
was	O
positively	O
correlated	O
with	O
dietary	O
fiber	O
intakes	O
and	O
negatively	O
correlated	O
with	O
fat	O
intakes	O
.	O

Dietary	O
supplementation	O
with	O
omega	O
-	O
3	O
fatty	O
acids	O
increased	O
the	O
Yue	O
and	O
Clayton	O
community	O
dis	O
-	O
similarity	O
index	O
between	O
the	O
microbiome	O
in	O
luminal	O
brushings	O
and	O
colon	O
biopsy	O
samples	O
post	O
-	O
supplementation	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
small	O
group	O
of	O
individuals	O
with	O
relatively	O
high	O
Prevotella	B-bacteria
abundance	O
who	O
were	O
resistant	O
to	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
omega	O
-	O
3	O
fatty	O
acid	O
supplementation	O
.	O

In	O
linear	O
regression	O
analyses	O
,	O
increases	O
in	O
diversity	O
of	O
the	O
bacteria	O
in	O
the	O
luminal	O
brushing	O
samples	O
,	O
but	O
not	O
in	O
the	O
biopsy	O
samples	O
,	O
were	O
significant	O
predictors	O
of	O
lower	O
colonic	O
PGE2	O
concentrations	O
post	O
-	O
supplementation	O
in	O
models	O
that	O
included	O
baseline	O
PGE2	O
,	O
baseline	O
body	O
mass	O
index	O
,	O
and	O
changes	O
in	O
colonic	O
eicosapentaenoic	O
acid	O
-	O
to	O
-	O
arachidonic	O
acid	O
ratios	O
.	O

The	O
changes	O
in	O
bacterial	O
diversity	O
contributed	O
to	O
6	O
-	O
8	O
%	O
of	O
the	O
interindividual	O
variance	O
in	O
change	O
in	O
colonic	O
PGE2	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
Dietary	O
supplementation	O
with	O
omega	O
-	O
3	O
fatty	O
acids	O
had	O
little	O
effect	O
on	O
intestinal	O
bacteria	O
in	O
healthy	O
humans	O
;	O
however	O
,	O
an	O
increase	O
in	O
diversity	O
in	O
the	O
luminal	O
brushings	O
significantly	O
predicted	O
reductions	O
in	O
colonic	O
PGE2	O
.	O

This	O
trial	O
was	O
registered	O
at	O
www	O
.	O
clinicaltrials	O
.	O
gov	O
as	O
NCT01860352	O
.	O

Enchained	O
growth	O
and	O
cluster	O
dislocation	O
:	O
A	O
possible	O
mechanism	O
for	O
microbiota	O
homeostasis	O
.	O

Immunoglobulin	O
A	O
is	O
a	O
class	O
of	O
antibodies	O
produced	O
by	O
the	O
adaptive	O
immune	O
system	O
and	O
secreted	O
into	O
the	O
gut	O
lumen	O
to	O
fight	O
pathogenic	O
bacteria	O
.	O

We	O
recently	O
demonstrated	O
that	O
the	O
main	O
physical	O
effect	O
of	O
these	O
antibodies	O
is	O
to	O
enchain	O
daughter	O
bacteria	O
,	O
i	O
.	O
e	O
.	O
to	O
cross	O
-	O
link	O
bacteria	O
into	O
clusters	O
as	O
they	O
divide	O
,	O
preventing	O
them	O
from	O
interacting	O
with	O
epithelial	O
cells	O
,	O
thus	O
protecting	O
the	O
host	O
.	O

These	O
links	O
between	O
bacteria	O
may	O
break	O
over	O
time	O
.	O

We	O
study	O
several	O
models	O
using	O
analytical	O
and	O
numerical	O
calculations	O
.	O

We	O
obtain	O
the	O
resulting	O
distribution	O
of	O
chain	O
sizes	O
,	O
that	O
we	O
compare	O
with	O
experimental	O
data	O
.	O

We	O
study	O
the	O
rate	O
of	O
increase	O
in	O
the	O
number	O
of	O
free	O
bacteria	O
as	O
a	O
function	O
of	O
the	O
replication	O
rate	O
of	O
bacteria	O
.	O

Our	O
models	O
show	O
robustly	O
that	O
at	O
higher	O
replication	O
rates	O
,	O
bacteria	O
replicate	O
before	O
the	O
link	O
between	O
daughter	O
bacteria	O
breaks	O
,	O
leading	O
to	O
growing	O
cluster	O
sizes	O
.	O

On	O
the	O
contrary	O
at	O
low	O
growth	O
rates	O
two	O
daughter	O
bacteria	O
have	O
a	O
high	O
probability	O
to	O
break	O
apart	O
.	O

Thus	O
the	O
gut	O
could	O
produce	O
IgA	O
against	O
all	O
the	O
bacteria	O
it	O
has	O
encountered	O
,	O
but	O
the	O
most	O
affected	O
bacteria	O
would	O
be	O
the	O
fast	O
replicating	O
ones	O
,	O
that	O
are	O
more	O
likely	O
to	O
destabilize	O
the	O
microbiota	O
.	O

Linking	O
the	O
effect	O
of	O
the	O
immune	O
effectors	O
(	O
here	O
the	O
clustering	O
)	O
with	O
a	O
property	O
directly	O
relevant	O
to	O
the	O
potential	O
bacterial	O
pathogeneicity	O
(	O
here	O
the	O
replication	O
rate	O
)	O
could	O
avoid	O
to	O
make	O
complex	O
decisions	O
about	O
which	O
bacteria	O
to	O
produce	O
effectors	O
against	O
.	O

Fluidic	O
resistance	O
control	O
enables	O
high	O
-	O
throughput	O
establishment	O
of	O
mixed	O
-	O
species	O
biofilms	O
.	O

Bacteria	O
often	O
live	O
in	O
communities	O
of	O
mixed	O
species	O
embedded	O
in	O
a	O
self	O
-	O
produced	O
extracellular	O
matrix	O
of	O
polysaccharides	O
,	O
proteins	O
and	O
DNA	O
,	O
termed	O
biofilms	O
.	O

The	O
BioFlux	O
microfluidic	O
flow	O
system	O
is	O
useful	O
for	O
studying	O
biofilm	O
formation	O
in	O
different	O
media	O
under	O
flow	O
.	O

However	O
,	O
analyzing	O
the	O
architecture	O
and	O
maturation	O
of	O
biofilms	O
under	O
flow	O
requires	O
a	O
proper	O
seeding	O
,	O
which	O
can	O
prove	O
difficult	O
when	O
working	O
with	O
bacteria	O
of	O
different	O
sizes	O
,	O
motile	O
bacteria	O
or	O
aiming	O
for	O
a	O
high	O
number	O
of	O
replicates	O
.	O

Here	O
we	O
developed	O
an	O
efficient	O
protocol	O
that	O
exploits	O
viscosity	O
tuning	O
and	O
seeding	O
indicator	O
dyes	O
to	O
improve	O
seeding	O
and	O
allow	O
for	O
high	O
-	O
throughput	O
examination	O
and	O
visualization	O
of	O
consistent	O
mono	O
-	O
and	O
mixed	O
-	O
species	O
biofilm	O
developments	O
under	O
flow	O
.	O

Changing	O
our	O
microbiome	O
:	O
Probiotics	O
in	O
dermatology	O
.	O

BACKGROUND	O
:	O
Commensal	O
bacteria	O
are	O
a	O
major	O
factor	O
in	O
human	O
health	O
and	O
disease	O
pathogenesis	O
.	O

Interest	O
has	O
recently	O
expanded	O
beyond	O
the	O
gastrointestinal	O
microflora	O
to	O
include	O
the	O
skin	O
microbiome	O
and	O
its	O
impact	O
on	O
various	O
skin	O
diseases	O
.	O

OBJECTIVES	O
:	O
Here	O
,	O
we	O
present	O
the	O
current	O
data	O
reviewing	O
the	O
role	O
of	O
the	O
microbiome	O
in	O
dermatology	O
,	O
considering	O
both	O
the	O
gut	O
and	O
skin	O
microflora	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
whether	O
the	O
clinical	O
data	O
support	O
the	O
utility	O
of	O
oral	O
and	O
topical	O
probiotics	O
for	O
certain	O
dermatologic	O
diseases	O
.	O

METHODS	O
:	O
The	O
PubMed	O
and	O
ClinicalTrials	O
.	O

gov	O
databases	O
were	O
searched	O
for	O
basic	O
science	O
,	O
translational	O
research	O
,	O
and	O
clinical	O
studies	O
that	O
investigated	O
the	O
differences	O
in	O
the	O
cutaneous	O
microbiome	O
and	O
the	O
impact	O
of	O
probiotics	O
in	O
patients	O
with	O
atopic	O
dermatitis	O
,	O
acne	O
vulgaris	O
,	O
psoriasis	O
,	O
chronic	O
wounds	O
,	O
seborrheic	O
dermatitis	O
,	O
and	O
cutaneous	O
neoplasms	O
.	O

RESULTS	O
:	O
Few	O
clinical	O
trials	O
exist	O
that	O
explore	O
the	O
utility	O
of	O
probiotics	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
dermatologic	O
diseases	O
,	O
with	O
the	O
exception	O
of	O
atopic	O
dermatitis	O
.	O

Most	O
studies	O
investigated	O
oral	O
probiotic	O
interventions	O
,	O
and	O
of	O
those	O
utilizing	O
topical	O
probiotics	O
,	O
few	O
included	O
skin	O
commensals	O
.	O

In	O
general	O
,	O
the	O
available	O
clinical	O
trials	O
yielded	O
positive	O
results	O
with	O
improvement	O
of	O
the	O
skin	O
conditions	O
after	O
probiotic	O
intervention	O
.	O

CONCLUSIONS	O
:	O
Oral	O
and	O
topical	O
probiotics	O
appear	O
to	O
be	O
effective	O
for	O
the	O
treatment	O
of	O
certain	O
inflammatory	O
skin	O
diseases	O
and	O
demonstrate	O
a	O
promising	O
role	O
in	O
wound	O
healing	O
and	O
skin	O
cancer	O
.	O

However	O
,	O
more	O
studies	O
are	O
needed	O
to	O
confirm	O
these	O
results	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Effects	O
of	O
egg	O
phosvitin	O
on	O
mucosal	O
transcriptional	O
profiles	O
and	O
luminal	O
microbiota	O
composition	O
in	O
murine	O
colon	O
.	O

Egg	O
phosvitin	O
has	O
been	O
traditionally	O
considered	O
as	O
a	O
nutritionally	O
negative	O
protein	O
for	O
its	O
low	O
digestibility	O
in	O
the	O
gastrointestinal	O
tract	O
.	O

Whether	O
it	O
could	O
exert	O
nutritional	O
functions	O
in	O
the	O
large	O
intestine	O
is	O
not	O
known	O
.	O

In	O
this	O
work	O
,	O
the	O
influence	O
of	O
phosvitin	O
on	O
luminal	O
microbiota	O
composition	O
and	O
mucosal	O
transcriptome	O
was	O
investigated	O
with	O
young	O
(	O
3	O
-	O
week	O
)	O
and	O
adult	O
(	O
8	O
-	O
week	O
)	O
mouse	O
models	O
.	O

In	O
young	O
groups	O
,	O
phosvitin	O
mainly	O
suppressed	O
genes	O
related	O
to	O
lipid	O
metabolism	O
,	O
whereas	O
the	O
regulated	O
genes	O
in	O
adult	O
individuals	O
encompassed	O
various	O
biological	O
processes	O
,	O
such	O
as	O
carbohydrate	O
metabolism	O
,	O
sigestive	O
system	O
and	O
others	O
.	O

Phosvitin	O
increased	O
the	O
proportion	O
of	O
Bifidobacterium	B-bacteria
in	O
the	O
young	O
group	O
,	O
and	O
reduced	O
amounts	O
of	O
pathogenic	O
microbes	O
in	O
the	O
adult	O
group	O
,	O
including	O
Helicobacter	B-bacteria
and	O
Mucispirillum	B-bacteria
.	O

There	O
was	O
a	O
close	O
relationship	O
between	O
gene	O
expression	O
changes	O
and	O
abundance	O
of	O
bacteria	O
.	O

Finally	O
,	O
phosvitin	O
reduced	O
the	O
ammonia	O
concentrations	O
in	O
feces	O
for	O
both	O
young	O
and	O
adult	O
groups	O
.	O

These	O
findings	O
suggested	O
that	O
phosvitin	O
modified	O
the	O
large	O
intestinal	O
ecosystem	O
,	O
exhibiting	O
potentially	O
beneficial	O
effects	O
on	O
gut	O
health	O
.	O

Risk	O
and	O
protection	O
in	O
the	O
gut	O
.	O

Effects	O
of	O
diet	O
on	O
gut	O
microbiota	O
of	O
soil	O
collembolans	O
.	O

The	O
importance	O
of	O
diet	O
in	O
regulating	O
the	O
gut	O
microbiome	O
of	O
globally	O
distributed	O
and	O
functionally	O
important	O
soil	O
generalist	O
invertebrates	O
such	O
as	O
collembolans	O
remain	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
studied	O
a	O
model	O
collembolan	O
(	O
Folsomia	O
candida	O
)	O
and	O
found	O
that	O
diet	O
(	O
bacteria	O
,	O
plant	O
litters	O
,	O
yeast	O
,	O
mixed	O
food	O
)	O
is	O
a	O
critical	O
factor	O
in	O
regulating	O
the	O
microbial	O
diversity	O
and	O
community	O
composition	O
of	O
this	O
important	O
soil	O
organism	O
.	O

Collembolans	O
fed	O
with	O
litter	O
exhibited	O
the	O
lowest	O
bacterial	O
diversity	O
and	O
were	O
dominated	O
by	O
Ochrobactrum	B-bacteria
.	O

Conversely	O
,	O
collembolans	O
fed	O
with	O
mixed	O
diets	O
resulted	O
in	O
the	O
highest	O
bacterial	O
diversity	O
.	O

Our	O
findings	O
further	O
suggest	O
that	O
microbial	O
communities	O
associated	O
with	O
different	O
diets	O
are	O
linked	O
to	O
different	O
levels	O
of	O
collembolan	O
fitness	O
.	O

For	O
example	O
,	O
the	O
relative	O
abundance	O
of	O
the	O
genera	O
of	O
unclassified	O
Thermogemmatisporaceae	B-bacteria
,	O
Brevibacillus	B-bacteria
,	O
and	O
Novosphingobium	B-bacteria
were	O
positively	O
correlated	O
with	O
growth	O
of	O
the	O
collembolans	O
.	O

Together	O
,	O
our	O
work	O
provides	O
evidence	O
that	O
diet	O
is	O
a	O
major	O
force	O
controlling	O
the	O
gut	O
microbiome	O
of	O
collembolans	O
,	O
and	O
is	O
a	O
good	O
environmental	O
predictor	O
for	O
collembolan	O
growth	O
,	O
with	O
implications	O
for	O
ecosystem	O
functioning	O
in	O
terrestrial	O
environments	O
.	O

Gut	O
Microbiome	O
in	O
Health	O
and	O
Disease	O
:	O
Emerging	O
Diagnostic	O
Opportunities	O
.	O

The	O
gut	O
microbiome	O
is	O
fundamental	O
to	O
human	O
health	O
and	O
development	O
.	O

Altered	O
microbiomes	O
have	O
been	O
associated	O
with	O
many	O
diseases	O
.	O

However	O
,	O
variation	O
between	O
individuals	O
,	O
environmental	O
effects	O
,	O
and	O
a	O
lack	O
of	O
standardization	O
across	O
studies	O
makes	O
differentiation	O
between	O
health	O
and	O
disease	O
challenging	O
.	O

Large	O
-	O
scale	O
population	O
cohorts	O
in	O
different	O
countries	O
will	O
be	O
required	O
to	O
match	O
disease	O
subjects	O
with	O
healthy	O
controls	O
,	O
whereas	O
standardized	O
,	O
reproducible	O
pipelines	O
for	O
analysis	O
are	O
required	O
to	O
compare	O
findings	O
between	O
studies	O
.	O

Despite	O
this	O
,	O
several	O
conditions	O
have	O
already	O
demonstrated	O
great	O
promise	O
for	O
developing	O
microbiome	O
-	O
based	O
biomarkers	O
as	O
well	O
as	O
providing	O
a	O
gateway	O
into	O
integrated	O
personalized	O
medicine	O
.	O

Relationship	O
between	O
intestinal	O
microorganisms	O
and	O
T	O
lymphocytes	O
in	O
colorectal	O
cancer	O
.	O

Colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
a	O
common	O
type	O
of	O
malignant	O
cancer	O
worldwide	O
.	O

Recent	O
studies	O
have	O
identified	O
the	O
gut	O
microbiota	O
as	O
the	O
origin	O
of	O
CRC	O
,	O
and	O
T	O
lymphocyte	O
-	O
mediated	O
immune	O
functions	O
have	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
this	O
disease	O
.	O

By	O
summarizing	O
previous	O
literature	O
,	O
we	O
found	O
that	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
may	O
protect	O
CRC	O
from	O
immune	O
cell	O
attack	O
by	O
inhibiting	O
T	O
cells	O
and	O
influencing	O
the	O
production	O
of	O
many	O
chemokines	O
and	O
cytokines	O
.	O

Some	O
bacterial	O
metabolites	O
and	O
probiotics	O
have	O
been	O
shown	O
to	O
participate	O
in	O
the	O
regulation	O
of	O
CRC	O
through	O
T	O
cell	O
-	O
mediated	O
molecular	O
pathways	O
.	O

To	O
visualize	O
the	O
relevant	O
data	O
,	O
an	O
association	O
network	O
of	O
intestinal	O
microorganisms	O
and	O
T	O
lymphocytes	O
associated	O
with	O
CRC	O
was	O
constructed	O
.	O

This	O
work	O
may	O
provide	O
direction	O
for	O
-	O
and	O
insight	O
into	O
-	O
further	O
research	O
on	O
the	O
relationship	O
between	O
intestinal	O
microorganisms	O
and	O
T	O
lymphocytes	O
in	O
CRC	O
.	O

Quantification	O
of	O
serine	O
protease	O
HtrA	O
molecules	O
secreted	O
by	O
the	O
foodborne	O
pathogen	O
Campylobacter	B-bacteria
jejuni	I-bacteria
.	O

Background	O
:	O
Campylobacter	B-bacteria
jejuni	I-bacteria
is	O
a	O
major	O
food	O
-	O
borne	O
pathogen	O
and	O
a	O
worldwide	O
health	O
threat	O
.	O

Utilizing	O
different	O
virulence	O
factors	O
,	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
invades	O
the	O
host	O
'	O
s	O
intestinal	O
epithelial	O
cell	O
layer	O
.	O

One	O
important	O
factor	O
in	O
this	O
process	O
is	O
the	O
serine	O
protease	O
HtrA	O
,	O
which	O
is	O
secreted	O
into	O
the	O
extracellular	O
space	O
,	O
and	O
helps	O
the	O
bacteria	O
to	O
transmigrate	O
across	O
the	O
gut	O
epithelium	O
by	O
cleaving	O
various	O
cell	O
-	O
cell	O
adhesion	O
proteins	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
quantify	O
the	O
amount	O
of	O
HtrA	O
molecules	O
secreted	O
per	O
bacterial	O
cell	O
in	O
liquid	O
culture	O
and	O
during	O
infection	O
.	O

Results	O
:	O
HtrA	O
protein	O
purification	O
and	O
quantitative	O
Western	O
blotting	O
were	O
used	O
to	O
determine	O
the	O
number	O
of	O
HtrA	O
molecules	O
secreted	O
by	O
two	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
model	O
strains	O
,	O
11168	O
and	O
81	O
-	O
176	O
,	O
in	O
liquid	O
culture	O
during	O
an	O
8	O
-	O
h	O
time	O
course	O
.	O

On	O
average	O
,	O
the	O
two	O
strains	O
yielded	O
similar	O
HtrA	O
secretion	O
rates	O
,	O
with	O
strain	O
11168	O
secreting	O
4314	O
+	O
/	O
-	O
949	O
molecules	O
and	O
81	O
-	O
176	O
secreting	O
5483	O
+	O
/	O
-	O
1246	O
per	O
bacterium	O
after	O
2	O
h	O
.	O
After	O
8	O
h	O
,	O
both	O
strains	O
showed	O
a	O
decrease	O
in	O
the	O
average	O
amount	O
of	O
HtrA	O
secreted	O
per	O
bacterial	O
cell	O
over	O
time	O
.	O

Secretion	O
of	O
HtrA	O
by	O
strain	O
11168	O
reduced	O
to	O
about	O
1772	O
+	O
/	O
-	O
520	O
molecules	O
and	O
only	O
2151	O
+	O
/	O
-	O
562	O
HtrA	O
molecules	O
were	O
secreted	O
by	O
strain	O
81	O
-	O
176	O
at	O
this	O
time	O
point	O
.	O

During	O
infection	O
of	O
gut	O
epithelial	O
cells	O
,	O
the	O
secretion	O
of	O
HtrA	O
is	O
slightly	O
higher	O
with	O
a	O
similar	O
secretion	O
pattern	O
over	O
time	O
compared	O
to	O
culturing	O
in	O
vitro	O
.	O

Conclusion	O
:	O
We	O
determined	O
the	O
number	O
of	O
HtrA	O
molecules	O
secreted	O
by	O
single	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
cells	O
over	O
time	O
.	O

The	O
results	O
suggest	O
that	O
HtrA	O
secretion	O
is	O
regulated	O
in	O
a	O
time	O
-	O
dependent	O
fashion	O
,	O
leading	O
to	O
increasing	O
accumulative	O
HtrA	O
concentrations	O
in	O
the	O
extracellular	O
medium	O
.	O

Antibiotic	O
Resistance	O
Gene	O
Diversity	O
and	O
Virulence	O
Gene	O
Diversity	O
Are	O
Correlated	O
in	O
Human	O
Gut	O
and	O
Environmental	O
Microbiomes	O
.	O

Human	O
beings	O
have	O
used	O
large	O
amounts	O
of	O
antibiotics	O
,	O
not	O
only	O
in	O
medical	O
contexts	O
but	O
also	O
,	O
for	O
example	O
,	O
as	O
growth	O
factors	O
in	O
agriculture	O
and	O
livestock	O
,	O
resulting	O
in	O
the	O
contamination	O
of	O
the	O
environment	O
.	O

Even	O
when	O
pathogenic	O
bacteria	O
are	O
the	O
targets	O
of	O
antibiotics	O
,	O
hundreds	O
of	O
nonpathogenic	O
bacterial	O
species	O
are	O
affected	O
as	O
well	O
.	O

Therefore	O
,	O
both	O
pathogenic	O
and	O
nonpathogenic	O
bacteria	O
have	O
gradually	O
become	O
resistant	O
to	O
antibiotics	O
.	O

We	O
tested	O
whether	O
there	O
is	O
still	O
cooccurrence	O
of	O
resistance	O
and	O
virulence	O
determinants	O
.	O

We	O
performed	O
a	O
comparative	O
study	O
of	O
environmental	O
and	O
human	O
gut	O
metagenomes	O
from	O
different	O
individuals	O
and	O
from	O
distinct	O
human	O
populations	O
across	O
the	O
world	O
.	O

We	O
found	O
a	O
great	O
diversity	O
of	O
antibiotic	O
resistance	O
determinants	O
(	O
AR	O
diversity	O
[	O
ARd	O
]	O
)	O
and	O
virulence	O
factors	O
(	O
VF	O
diversity	O
[	O
VFd	O
]	O
)	O
in	O
metagenomes	O
.	O

Importantly	O
there	O
is	O
a	O
correlation	O
between	O
ARd	O
and	O
VFd	O
,	O
even	O
after	O
correcting	O
for	O
protein	O
family	O
richness	O
.	O

In	O
the	O
human	O
gut	O
,	O
there	O
are	O
less	O
ARd	O
and	O
VFd	O
than	O
in	O
more	O
diversified	O
environments	O
,	O
and	O
yet	O
correlations	O
between	O
the	O
ARd	O
and	O
VFd	O
are	O
stronger	O
.	O

They	O
can	O
vary	O
from	O
very	O
high	O
in	O
Malawi	O
,	O
where	O
antibiotic	O
consumption	O
is	O
unattended	O
,	O
to	O
nonexistent	O
in	O
the	O
uncontacted	O
Amerindian	O
population	O
.	O

We	O
conclude	O
that	O
there	O
is	O
cooccurrence	O
of	O
resistance	O
and	O
virulence	O
determinants	O
in	O
human	O
gut	O
microbiomes	O
,	O
suggesting	O
a	O
possible	O
coselective	O
mechanism	O
.	O
IMPORTANCE	O
Every	O
year	O
,	O
thousands	O
of	O
tons	O
of	O
antibiotics	O
are	O
used	O
,	O
not	O
only	O
in	O
human	O
and	O
animal	O
health	O
but	O
also	O
as	O
growth	O
promoters	O
in	O
livestock	O
.	O

Consequently	O
,	O
during	O
the	O
last	O
75	O
years	O
,	O
antibiotic	O
-	O
resistant	O
bacterial	O
strains	O
have	O
been	O
selected	O
in	O
human	O
and	O
environmental	O
microbial	O
communities	O
.	O

This	O
implies	O
that	O
,	O
even	O
when	O
pathogenic	O
bacteria	O
are	O
the	O
targets	O
of	O
antibiotics	O
,	O
hundreds	O
of	O
nonpathogenic	O
bacterial	O
species	O
are	O
also	O
affected	O
.	O

Here	O
,	O
we	O
performed	O
a	O
comparative	O
study	O
of	O
environmental	O
and	O
human	O
gut	O
microbial	O
communities	O
issuing	O
from	O
different	O
individuals	O
and	O
from	O
distinct	O
human	O
populations	O
across	O
the	O
world	O
.	O

We	O
found	O
that	O
antibiotic	O
resistance	O
and	O
pathogenicity	O
are	O
correlated	O
and	O
speculate	O
that	O
,	O
by	O
selecting	O
for	O
resistant	O
bacteria	O
,	O
we	O
may	O
be	O
selecting	O
for	O
more	O
virulent	O
strains	O
as	O
a	O
side	O
effect	O
of	O
antimicrobial	O
therapy	O
.	O

The	O
impact	O
of	O
probiotics	O
and	O
lactoferrin	O
supplementation	O
on	O
piglet	O
gastrointestinal	O
microbial	O
communities	O
.	O

Probiotics	O
and	O
lactoferrin	O
are	O
currently	O
being	O
used	O
in	O
neonatal	O
intensive	O
care	O
units	O
in	O
the	O
hopes	O
of	O
reducing	O
rates	O
of	O
sepsis	O
and	O
necrotizing	O
enterocolitis	O
(	O
NEC	O
)	O
.	O

While	O
studies	O
have	O
shown	O
that	O
these	O
measures	O
can	O
be	O
clinically	O
beneficial	O
to	O
premature	O
babies	O
,	O
and	O
there	O
are	O
ongoing	O
trials	O
to	O
measure	O
their	O
impact	O
on	O
NEC	O
and	O
sepsis	O
rates	O
,	O
little	O
is	O
known	O
about	O
how	O
they	O
may	O
impact	O
microbiota	O
development	O
.	O

We	O
thus	O
employed	O
a	O
newborn	O
piglet	O
model	O
to	O
assess	O
the	O
impact	O
of	O
feeding	O
probiotics	O
or	O
a	O
combination	O
of	O
probiotics	O
and	O
lactoferrin	O
on	O
development	O
of	O
the	O
gastrointestinal	O
microbiota	O
.	O

Healthy	O
full	O
-	O
term	O
piglets	O
were	O
fed	O
either	O
probiotics	O
alone	O
or	O
probiotics	O
and	O
a	O
bovine	O
lactoferrin	O
supplement	O
over	O
the	O
first	O
weeks	O
of	O
life	O
,	O
and	O
their	O
microbiota	O
profiles	O
were	O
compared	O
with	O
unsupplemented	O
controls	O
.	O

We	O
found	O
that	O
both	O
probiotic	O
and	O
probiotic	O
plus	O
lactoferrin	O
treatments	O
impacted	O
the	O
microbial	O
composition	O
within	O
the	O
gastrointestinal	O
tract	O
,	O
with	O
differing	O
impacts	O
on	O
various	O
regions	O
within	O
the	O
gut	O
.	O

In	O
addition	O
,	O
the	O
impact	O
of	O
probiotics	O
was	O
often	O
reversed	O
by	O
the	O
presence	O
of	O
lactoferrin	O
and	O
both	O
feeding	O
interventions	O
altered	O
the	O
microbiota	O
'	O
s	O
genetic	O
propensity	O
to	O
use	O
ferric	O
versus	O
ferrous	O
ions	O
.	O

These	O
results	O
suggest	O
that	O
iron	O
availability	O
may	O
be	O
a	O
key	O
factor	O
to	O
consider	O
when	O
designing	O
feeding	O
interventions	O
that	O
target	O
the	O
microbiome	O
.	O

Author	O
Correction	O
:	O
Cream	O
Cheese	O
-	O
Derived	O
Lactococcus	B-bacteria
chungangensis	I-bacteria
CAU	O
28	O
Modulates	O
the	O
Gut	O
Microbiota	O
and	O
Alleviates	O
Atopic	O
Dermatitis	O
in	O
BALB	O
/	O
c	O
Mice	O
.	O

A	O
correction	O
to	O
this	O
article	O
has	O
been	O
published	O
and	O
is	O
linked	O
from	O
the	O
HTML	O
and	O
PDF	O
versions	O
of	O
this	O
paper	O
.	O

The	O
error	O
has	O
not	O
been	O
fixed	O
in	O
the	O
paper	O
.	O

Similar	O
Neural	O
Pathways	O
Control	O
Foraging	O
in	O
Mosquitoes	O
and	O
Worms	O
.	O

Female	O
Aedes	B-bacteria
aegypti	I-bacteria
mosquitoes	O
bite	O
human	O
hosts	O
to	O
obtain	O
a	O
blood	O
meal	O
and	O
,	O
in	O
the	O
process	O
,	O
act	O
as	O
vectors	O
for	O
many	O
disease	O
-	O
causing	O
viruses	O
,	O
including	O
the	O
dengue	O
,	O
chikungunya	O
,	O
yellow	O
fever	O
,	O
and	O
Zika	O
viruses	O
.	O

After	O
a	O
complete	O
meal	O
,	O
the	O
female	O
mosquitoes	O
lose	O
attraction	O
to	O
their	O
hosts	O
for	O
several	O
days	O
.	O

New	O
research	O
shows	O
that	O
pharmacological	O
activation	O
of	O
neuropeptide	O
Y	O
-	O
like	O
receptor	O
(	O
NPYLR	O
)	O
signaling	O
elicits	O
host	O
aversion	O
in	O
female	O
mosquitoes	O
.	O

This	O
behavior	O
of	O
mosquitoes	O
shows	O
remarkable	O
similarities	O
to	O
a	O
bacterial	O
-	O
aversion	O
behavior	O
of	O
the	O
nematode	O
Caenorhabditis	B-bacteria
elegans	I-bacteria
Feeding	O
on	O
pathogenic	O
bacteria	O
causes	O
bloating	O
of	O
the	O
gut	O
in	O
C	O
.	O
elegans	O
that	O
leads	O
to	O
activation	O
of	O
NPYLR	O
signaling	O
and	O
bacterial	O
aversion	O
.	O

Several	O
studies	O
suggest	O
that	O
this	O
newly	O
discovered	O
mechanism	O
underlying	O
foraging	O
may	O
be	O
conserved	O
across	O
a	O
large	O
number	O
of	O
species	O
.	O

A	O
better	O
understanding	O
of	O
the	O
regulation	O
of	O
NPYLR	O
signaling	O
pathways	O
could	O
provide	O
molecular	O
targets	O
for	O
the	O
control	O
of	O
eating	O
behaviors	O
in	O
different	O
animals	O
,	O
including	O
human	O
-	O
disease	O
vectors	O
.	O

Gut	O
bacteria	O
are	O
critical	O
for	O
optimal	O
muscle	O
function	O
:	O
a	O
potential	O
link	O
with	O
glucose	O
homeostasis	O
.	O

Gut	O
microbiota	O
is	O
involved	O
in	O
the	O
development	O
of	O
several	O
chronic	O
diseases	O
,	O
including	O
diabetes	O
,	O
obesity	O
and	O
cancer	O
,	O
through	O
its	O
interactions	O
with	O
the	O
host	O
organs	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
cross	O
-	O
talk	O
between	O
gut	O
microbiota	O
and	O
skeletal	O
muscle	O
plays	O
a	O
role	O
in	O
different	O
pathological	O
conditions	O
,	O
such	O
as	O
intestinal	O
chronic	O
inflammation	O
and	O
cachexia	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
whether	O
gut	O
microbiota	O
directly	O
influences	O
skeletal	O
muscle	O
function	O
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
the	O
impact	O
of	O
gut	O
microbiota	O
modulation	O
on	O
mice	O
skeletal	O
muscle	O
function	O
and	O
investigated	O
the	O
underlying	O
mechanisms	O
.	O

We	O
determined	O
the	O
consequences	O
of	O
gut	O
microbiota	O
depletion	O
after	O
treatment	O
with	O
a	O
mixture	O
of	O
broad	O
spectrum	O
antibiotics	O
for	O
21	O
days	O
and	O
after	O
10	O
-	O
days	O
natural	O
reseeding	O
.	O

We	O
found	O
that	O
in	O
gut	O
microbiota	O
-	O
depleted	O
mice	O
,	O
running	O
endurance	O
was	O
decreased	O
,	O
as	O
well	O
as	O
the	O
extensor	O
digitorum	O
longus	O
muscle	O
fatigue	O
index	O
in	O
an	O
ex	O
vivo	O
contractile	O
test	O
.	O

Importantly	O
,	O
the	O
muscle	O
endurance	O
capacity	O
was	O
efficiently	O
normalized	O
by	O
natural	O
reseeding	O
.	O

These	O
endurance	O
changes	O
were	O
not	O
related	O
to	O
variation	O
in	O
muscle	O
mass	O
,	O
fiber	O
typology	O
or	O
mitochondrial	O
function	O
.	O

However	O
,	O
several	O
pertinent	O
glucose	O
metabolism	O
markers	O
such	O
as	O
ileum	O
gene	O
expression	O
of	O
short	O
fatty	O
acid	O
chain	O
and	O
glucose	O
transporters	O
,	O
Gpr41	O
and	O
sglt1	O
and	O
muscle	O
glycogen	O
level	O
,	O
paralleled	O
the	O
muscle	O
endurance	O
changes	O
observed	O
after	O
ATB	O
treatment	O
and	O
reseeding	O
.	O

As	O
glycogen	O
is	O
a	O
key	O
energetic	O
substrate	O
for	O
prolonged	O
exercise	O
,	O
modulating	O
its	O
muscle	O
availability	O
via	O
gut	O
microbiota	O
represents	O
one	O
potent	O
mechanism	O
that	O
can	O
contribute	O
to	O
the	O
gut	O
microbiota	O
/	O
skeletal	O
muscle	O
axis	O
.	O

Taken	O
together	O
,	O
our	O
results	O
strongly	O
support	O
the	O
hypothesis	O
that	O
gut	O
bacteria	O
are	O
required	O
for	O
host	O
optimal	O
skeletal	O
muscle	O
function	O
.	O

Bacteriophage	O
versus	O
antibiotic	O
therapy	O
on	O
gut	O
bacterial	O
communities	O
of	O
juvenile	O
green	O
turtle	O
,	O
Chelonia	O
mydas	O
.	O

Green	O
turtles	O
are	O
endangered	O
marine	O
herbivorous	O
hindgut	O
fermenters	O
that	O
contribute	O
to	O
a	O
variety	O
of	O
marine	O
ecosystems	O
.	O

Debilitated	O
turtles	O
are	O
often	O
rehabilitated	O
in	O
turtle	O
hospitals	O
.	O

Since	O
accurate	O
diagnosis	O
of	O
disease	O
is	O
difficult	O
,	O
broad	O
-	O
spectrum	O
antibiotics	O
are	O
routinely	O
used	O
as	O
a	O
general	O
treatment	O
,	O
potentially	O
causing	O
collateral	O
damage	O
to	O
the	O
gut	O
microbiome	O
of	O
the	O
patient	O
.	O

Here	O
we	O
evaluated	O
the	O
concept	O
of	O
the	O
application	O
of	O
bacteriophage	O
(	O
phages	O
)	O
to	O
eliminate	O
targeted	O
intestinal	O
bacteria	O
as	O
an	O
alternative	O
to	O
a	O
broad	O
-	O
spectrum	O
antibiotic	O
(	O
enrofloxacin	O
)	O
in	O
clinically	O
healthy	O
,	O
captive	O
green	O
turtles	O
.	O

Additionally	O
,	O
the	O
impact	O
of	O
a	O
broad	O
-	O
spectrum	O
antibiotic	O
(	O
enrofloxacin	O
)	O
and	O
phage	O
therapy	O
on	O
the	O
gut	O
bacterial	O
communities	O
of	O
green	O
turtles	O
was	O
evaluated	O
.	O

Gut	O
bacterial	O
communities	O
in	O
faecal	O
samples	O
were	O
analyzed	O
by	O
sequencing	O
the	O
V1	O
-	O
V3	O
regions	O
of	O
the	O
bacterial	O
16S	O
rRNA	O
.	O

Bacteria	O
specific	O
phage	O
cocktails	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
reduced	O
targeted	O
Acinetobacter	B-bacteria
in	O
phage	O
-	O
treated	O
turtles	O
during	O
the	O
therapy	O
.	O

Compared	O
to	O
control	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
the	O
bacterial	O
diversity	O
and	O
compositions	O
in	O
phage	O
-	O
treated	O
turtles	O
.	O

In	O
contrast	O
,	O
bacterial	O
diversity	O
was	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
reduced	O
in	O
antibiotic	O
-	O
treated	O
turtles	O
at	O
day	O
15	O
and	O
throughout	O
the	O
trial	O
.	O

The	O
alteration	O
in	O
the	O
bacterial	O
microbiota	O
of	O
antibiotic	O
-	O
treated	O
turtles	O
was	O
largely	O
due	O
to	O
an	O
increase	O
in	O
abundance	O
of	O
Gram	O
-	O
positive	O
Firmicutes	B-bacteria
and	O
a	O
concurrent	O
decrease	O
in	O
Gram	O
-	O
negative	O
Bacteroidetes	B-bacteria
,	O
Proteobacteria	B-bacteria
and	O
Verrucomicrobia	B-bacteria
.	O

Additionally	O
,	O
we	O
observed	O
the	O
relative	O
abundance	O
of	O
several	O
bacteria	O
at	O
lower	O
taxonomic	O
level	O
was	O
much	O
less	O
affected	O
by	O
phages	O
than	O
by	O
antibiotics	O
.	O

These	O
data	O
offers	O
the	O
proof	O
of	O
concept	O
of	O
phage	O
therapy	O
to	O
manipulate	O
transient	O
as	O
well	O
as	O
indigenous	O
bacterial	O
flora	O
in	O
gut	O
-	O
related	O
dysbiosis	O
of	O
turtles	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Antibiotic	O
therapy	O
with	O
metronidazole	O
reduces	O
endometriosis	O
disease	O
progression	O
in	O
mice	O
:	O
a	O
potential	O
role	O
for	O
gut	O
microbiota	O
.	O

STUDY	O
QUESTION	O
:	O
Does	O
altering	O
gut	O
microbiota	O
with	O
antibiotic	O
treatment	O
have	O
any	O
impact	O
on	O
endometriosis	O
progression	O
?	O

SUMMARY	O
ANSWER	O
:	O
Antibiotic	O
therapy	O
reduces	O
endometriosis	O
progression	O
in	O
mice	O
,	O
possibly	O
by	O
reducing	O
specific	O
gut	O
bacteria	O
.	O

WHAT	O
IS	O
KNOWN	O
ALREADY	O
:	O
Endometriosis	O
,	O
a	O
chronic	O
condition	O
causing	O
abdominal	O
pain	O
and	O
infertility	O
,	O
afflicts	O
up	O
to	O
10	O
%	O
of	O
women	O
between	O
the	O
ages	O
of	O
25	O
and	O
40	O
,	O
~	O
5	O
million	O
women	O
in	O
the	O
USA	O
.	O

Current	O
treatment	O
strategies	O
,	O
including	O
hormone	O
therapy	O
and	O
surgery	O
,	O
have	O
significant	O
side	O
effects	O
and	O
do	O
not	O
prevent	O
recurrences	O
.	O

We	O
have	O
little	O
understanding	O
of	O
why	O
some	O
women	O
develop	O
endometriosis	O
and	O
others	O
do	O
not	O
.	O

STUDY	O
DESIGN	O
,	O
SIZE	O
,	O
DURATION	O
:	O
Mice	O
were	O
treated	O
with	O
broad	O
-	O
spectrum	O
antibiotics	O
or	O
metronidazole	O
,	O
subjected	O
to	O
surgically	O
-	O
induced	O
endometriosis	O
and	O
assayed	O
after	O
21	O
days	O
.	O

PARTICIPANTS	O
/	O
MATERIALS	O
,	O
SETTING	O
,	O
METHODS	O
:	O
The	O
volumes	O
and	O
weights	O
of	O
endometriotic	O
lesions	O
and	O
histological	O
signatures	O
were	O
analysed	O
.	O

Proliferation	O
and	O
inflammation	O
in	O
lesions	O
were	O
assessed	O
by	O
counting	O
cells	O
that	O
were	O
positive	O
for	O
the	O
proliferation	O
marker	O
Ki	O
-	O
67	O
and	O
the	O
macrophage	O
marker	O
Iba1	O
,	O
respectively	O
.	O

Differences	O
in	O
faecal	O
bacterial	O
composition	O
were	O
assessed	O
in	O
mice	O
with	O
and	O
without	O
endometriosis	O
,	O
and	O
faecal	O
microbiota	O
transfer	O
studies	O
were	O
performed	O
.	O

MAIN	O
RESULTS	O
AND	O
THE	O
ROLE	O
OF	O
CHANCE	O
:	O
In	O
mice	O
treated	O
with	O
broad	O
-	O
spectrum	O
antibiotics	O
(	O
vancomycin	O
,	O
neomycin	O
,	O
metronidazole	O
and	O
ampicillin	O
)	O
,	O
endometriotic	O
lesions	O
were	O
significantly	O
smaller	O
(	O
~	O
5	O
-	O
fold	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
with	O
fewer	O
proliferating	O
cells	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
than	O
those	O
in	O
mice	O
treated	O
with	O
vehicle	O
.	O

Additionally	O
,	O
inflammatory	O
responses	O
,	O
as	O
measured	O
by	O
the	O
macrophage	O
marker	O
Iba1	O
in	O
lesions	O
and	O
IL	O
-	O
1beta	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
and	O
TGF	O
-	O
beta1	O
in	O
peritoneal	O
fluid	O
,	O
were	O
significantly	O
reduced	O
in	O
mice	O
treated	O
with	O
broad	O
-	O
spectrum	O
antibiotics	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
mice	O
treated	O
with	O
metronidazole	O
only	O
,	O
but	O
not	O
in	O
those	O
treated	O
with	O
neomycin	O
,	O
ectopic	O
lesions	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
smaller	O
in	O
volume	O
than	O
those	O
from	O
vehicle	O
-	O
treated	O
mice	O
.	O

Finally	O
,	O
oral	O
gavage	O
of	O
faeces	O
from	O
mice	O
with	O
endometriosis	O
restored	O
the	O
endometriotic	O
lesion	O
growth	O
and	O
inflammation	O
(	O
P	O
<	O
0	O
.	O
05	O
and	O
P	O
<	O
0	O
.	O
01	O
,	O
respectively	O
)	O
in	O
metronidazole	O
-	O
treated	O
mice	O
.	O

LARGE	O
-	O
SCALE	O
DATA	O
:	O
N	O
/	O
A	O
.	O

LIMITATIONS	O
,	O
REASONS	O
FOR	O
CAUTION	O
:	O
These	O
findings	O
are	O
from	O
a	O
mouse	O
model	O
of	O
surgically	O
-	O
induced	O
endometriosis	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
mechanism	O
by	O
which	O
gut	O
bacteria	O
promote	O
inflammation	O
,	O
identify	O
bacterial	O
genera	O
or	O
species	O
that	O
promote	O
disease	O
progression	O
and	O
assess	O
the	O
translatability	O
of	O
these	O
findings	O
to	O
humans	O
.	O

WIDER	O
IMPLICATIONS	O
OF	O
THE	O
FINDINGS	O
:	O
Our	O
findings	O
suggest	O
that	O
gut	O
bacteria	O
promote	O
endometriosis	O
progression	O
in	O
mice	O
.	O

This	O
finding	O
if	O
translated	O
to	O
humans	O
,	O
could	O
aid	O
in	O
the	O
development	O
of	O
improved	O
diagnostic	O
tools	O
and	O
personalised	O
treatment	O
strategies	O
.	O

STUDY	O
FUNDING	O
AND	O
COMPETING	O
INTEREST	O
(	O
S	O
)	O
:	O
This	O
work	O
was	O
funded	O
,	O
in	O
part	O
,	O
by	O
:	O
a	O
National	O
Institutes	O
of	O
Health	O
(	O
NIH	O
)	O
/	O
National	O
Institute	O
of	O
Child	O
Health	O
and	O
Human	O
Development	O
(	O
NICHD	O
)	O
grant	O
(	O
R00HD080742	O
)	O
to	O
RK	O
;	O
Washington	O
University	O
School	O
of	O
Medicine	O
start	O
-	O
up	O
funds	O
to	O
RK	O
;	O
an	O
Endometriosis	O
Foundation	O
of	O
America	O
Research	O
Award	O
to	O
R	O
.	O
K	O
.	O
;	O
and	O
an	O
NIH	O
/	O
NICHD	O
grant	O
(	O
R01HD091218	O
)	O
to	O
IUM	O
.	O

The	O
authors	O
report	O
no	O
conflict	O
of	O
interest	O
.	O

Gut	O
microbiota	O
and	O
butyrate	O
level	O
changes	O
associated	O
with	O
the	O
long	O
-	O
term	O
administration	O
of	O
proton	O
pump	O
inhibitors	O
to	O
old	O
rats	O
.	O

The	O
association	O
between	O
adverse	O
effects	O
of	O
PPI	O
and	O
gut	O
microbiota	O
in	O
old	O
age	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

We	O
assessed	O
changes	O
in	O
the	O
gut	O
microbiota	O
and	O
butyrate	O
levels	O
following	O
the	O
long	O
-	O
term	O
administration	O
of	O
PPIs	O
to	O
old	O
rats	O
and	O
investigated	O
their	O
associations	O
.	O

F344	O
aged	O
male	O
rats	O
were	O
fed	O
a	O
PPI	O
-	O
supplemented	O
diet	O
for	O
50	O
weeks	O
.	O

The	O
ileal	O
microbiota	O
was	O
analysed	O
by	O
metagenomic	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
,	O
while	O
the	O
butyrate	O
concentration	O
was	O
measured	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

We	O
observed	O
a	O
significant	O
decrease	O
in	O
microbial	O
diversity	O
following	O
PPI	O
administration	O
in	O
the	O
2	O
-	O
year	O
-	O
old	O
rats	O
but	O
not	O
in	O
the	O
74	O
-	O
week	O
-	O
old	O
rats	O
.	O

PPI	O
treatment	O
reduced	O
both	O
commensal	O
bacteria	O
and	O
opportunistic	O
pathogens	O
,	O
particularly	O
in	O
the	O
2	O
-	O
year	O
-	O
old	O
rats	O
.	O

Enterotypes	O
comprising	O
the	O
majority	O
of	O
the	O
control	O
samples	O
were	O
enriched	O
in	O
Lactobacillus	B-bacteria
,	O
while	O
other	O
enterotypes	O
in	O
the	O
PPI	O
group	O
were	O
dominated	O
by	O
Turicibacter	B-bacteria
or	O
Romboutsia	B-bacteria
.	O

The	O
PPI	O
treatment	O
reduced	O
the	O
butyrate	O
concentrations	O
in	O
the	O
intestines	O
and	O
colons	O
of	O
74	O
-	O
week	O
-	O
old	O
rats	O
compared	O
to	O
the	O
control	O
group	O
.	O

The	O
abundance	O
of	O
Lactobacillus	B-bacteria
significantly	O
correlated	O
with	O
butyrate	O
concentrations	O
in	O
74	O
-	O
week	O
-	O
old	O
rats	O
.	O

In	O
conclusion	O
,	O
long	O
-	O
term	O
administration	O
of	O
PPIs	O
alters	O
the	O
gut	O
microbiota	O
and	O
butyrate	O
concentrations	O
in	O
rats	O
,	O
particularly	O
in	O
old	O
age	O
,	O
which	O
may	O
be	O
an	O
underlying	O
mechanism	O
of	O
PPI	O
-	O
induced	O
adverse	O
effects	O
such	O
as	O
pseudomembranous	O
colitis	O
.	O

Serine	O
-	O
rich	O
repeat	O
proteins	O
from	O
gut	O
microbes	O
.	O

Serine	O
-	O
rich	O
repeat	O
proteins	O
(	O
SRRPs	O
)	O
have	O
emerged	O
as	O
an	O
important	O
group	O
of	O
cell	O
surface	O
adhesins	O
found	O
in	O
a	O
growing	O
number	O
of	O
Gram	O
-	O
positive	O
bacteria	O
.	O

Studies	O
focused	O
on	O
SRRPs	O
from	O
streptococci	B-bacteria
and	O
staphylococci	B-bacteria
demonstrated	O
that	O
these	O
proteins	O
are	O
O	O
-	O
glycosylated	O
on	O
serine	O
or	O
threonine	O
residues	O
and	O
exported	O
via	O
an	O
accessory	O
secretion	O
(	O
aSec	O
)	O
system	O
.	O

In	O
pathogens	O
,	O
these	O
adhesins	O
contribute	O
to	O
disease	O
pathogenesis	O
and	O
represent	O
therapeutic	O
targets	O
.	O

Recently	O
,	O
the	O
non	O
-	O
canonical	O
aSec	O
system	O
has	O
been	O
identified	O
in	O
the	O
genomes	O
of	O
gut	O
microbes	O
and	O
characterization	O
of	O
their	O
associated	O
SRRPs	O
is	O
beginning	O
to	O
unfold	O
,	O
showing	O
their	O
role	O
in	O
mediating	O
attachment	O
and	O
biofilm	O
formation	O
.	O

Here	O
we	O
provide	O
an	O
update	O
of	O
the	O
occurrence	O
,	O
structure	O
,	O
and	O
function	O
of	O
SRRPs	O
across	O
bacteria	O
,	O
with	O
emphasis	O
on	O
the	O
molecular	O
and	O
biochemical	O
properties	O
of	O
SRRPs	O
from	O
gut	O
symbionts	O
,	O
particularly	O
Lactobacilli	B-bacteria
.	O

These	O
emerging	O
studies	O
underscore	O
the	O
range	O
of	O
ligands	O
recognized	O
by	O
these	O
adhesins	O
and	O
the	O
importance	O
of	O
SRRP	O
glycosylation	O
in	O
the	O
interaction	O
of	O
gut	O
microbes	O
with	O
the	O
host	O
.	O

Efficacy	O
and	O
Long	O
-	O
Term	O
Safety	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
Eradication	O
for	O
Gastric	O
Cancer	O
Prevention	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
(	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
)	O
has	O
been	O
shown	O
to	O
be	O
a	O
causal	O
factor	O
of	O
gastric	O
cancer	O
in	O
cohort	O
studies	O
and	O
animal	O
models	O
.	O

Meta	O
-	O
analysis	O
of	O
case	O
-	O
control	O
studies	O
nested	O
within	O
prospective	O
cohorts	O
showed	O
that	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
was	O
associated	O
with	O
a	O
5	O
.	O
9	O
-	O
fold	O
increased	O
risk	O
of	O
non	O
-	O
cardia	O
gastric	O
cancer	O
.	O

Prospective	O
cohort	O
studies	O
showed	O
that	O
gastric	O
cancer	O
developed	O
in	O
1	O
-	O
4	O
%	O
of	O
H	O
.	O
pylori	O
-	O
infected	O
subjects	O
.	O

Gastric	O
cancer	O
was	O
successfully	O
induced	O
in	O
Mongolian	O
gerbils	O
and	O
insulin	O
-	O
gastrin	O
(	O
INS	O
-	O
GAS	O
)	O
transgenic	O
mice	O
after	O
inoculation	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

Meta	O
-	O
analysis	O
of	O
randomized	O
control	O
trials	O
also	O
showed	O
that	O
eradication	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
may	O
reduce	O
the	O
risk	O
of	O
gastric	O
cancer	O
.	O

However	O
,	O
there	O
are	O
several	O
concerns	O
regarding	O
the	O
widespread	O
use	O
of	O
antibiotics	O
to	O
prevent	O
gastric	O
cancer	O
,	O
including	O
the	O
emergence	O
of	O
antibiotic	O
resistance	O
and	O
the	O
perturbation	O
of	O
gut	O
microbiota	O
after	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
.	O

Recent	O
studies	O
showed	O
that	O
eradication	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
resulted	O
in	O
an	O
increase	O
in	O
the	O
bacterial	O
diversity	O
and	O
restoration	O
of	O
the	O
relative	O
abundance	O
of	O
other	O
bacteria	O
to	O
levels	O
similar	O
to	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
non	O
-	O
infected	O
subjects	O
in	O
the	O
gastric	O
microbiota	O
.	O

The	O
administration	O
of	O
antibiotics	O
may	O
also	O
alter	O
the	O
composition	O
of	O
intestinal	O
microbiota	O
.	O

The	O
alpha	O
-	O
diversity	O
and	O
beta	O
-	O
diversity	O
of	O
fecal	O
microbiota	O
are	O
significantly	O
altered	O
immediately	O
after	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
but	O
are	O
gradually	O
restored	O
to	O
levels	O
similar	O
to	O
those	O
before	O
therapy	O
.	O

Yet	O
,	O
the	O
rate	O
of	O
recovery	O
varies	O
with	O
regimens	O
.	O

The	O
diversity	O
was	O
restored	O
at	O
week	O
8	O
after	O
triple	O
therapy	O
but	O
was	O
not	O
yet	O
fully	O
recovered	O
at	O
1	O
year	O
after	O
concomitant	O
and	O
quadruple	O
therapies	O
.	O

Some	O
studies	O
showed	O
that	O
supplementation	O
of	O
probiotics	O
may	O
reduce	O
the	O
dysbiosis	O
during	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
therapy	O
.	O

Although	O
some	O
earlier	O
studies	O
showed	O
high	O
levels	O
of	O
macrolide	O
resistance	O
after	O
triple	O
therapy	O
,	O
recent	O
studies	O
showed	O
that	O
the	O
increased	O
antibiotic	O
resistance	O
rate	O
may	O
be	O
restored	O
2	O
-	O
12	O
months	O
after	O
eradication	O
therapy	O
.	O

These	O
results	O
collectively	O
provide	O
evidence	O
of	O
the	O
long	O
-	O
term	O
safety	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
.	O

Yet	O
,	O
more	O
prospective	O
cohort	O
studies	O
and	O
randomized	O
trials	O
are	O
warranted	O
to	O
assess	O
the	O
efficacy	O
and	O
long	O
-	O
term	O
safety	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
for	O
gastric	O
cancer	O
prevention	O
.	O

Effects	O
of	O
single	O
and	O
combined	O
toxic	O
exposures	O
on	O
the	O
gut	O
microbiome	O
:	O
current	O
knowledge	O
and	O
future	O
directions	O
.	O

Human	O
populations	O
are	O
chronically	O
exposed	O
to	O
mixtures	O
of	O
toxic	O
chemicals	O
.	O

Predicting	O
the	O
health	O
effects	O
of	O
these	O
mixtures	O
require	O
a	O
large	O
amount	O
of	O
information	O
on	O
the	O
mode	O
of	O
action	O
of	O
their	O
components	O
.	O

Xenobiotic	O
metabolism	O
by	O
bacteria	O
inhabiting	O
the	O
gastrointestinal	O
tract	O
has	O
a	O
major	O
influence	O
on	O
human	O
health	O
.	O

Our	O
review	O
aims	O
to	O
explore	O
the	O
literature	O
for	O
studies	O
looking	O
to	O
characterize	O
the	O
different	O
modes	O
of	O
action	O
and	O
outcomes	O
of	O
major	O
chemical	O
pollutants	O
,	O
and	O
some	O
components	O
of	O
cosmetics	O
and	O
food	O
additives	O
,	O
on	O
gut	O
microbial	O
communities	O
in	O
order	O
to	O
facilitate	O
an	O
estimation	O
of	O
their	O
potential	O
mixture	O
effects	O
.	O

We	O
identified	O
good	O
evidence	O
that	O
exposure	O
to	O
heavy	O
metals	O
,	O
pesticides	O
,	O
nanoparticles	O
,	O
polycyclic	O
aromatic	O
hydrocarbons	O
,	O
dioxins	O
,	O
furans	O
,	O
polychlorinated	O
biphenyls	O
,	O
and	O
non	O
-	O
caloric	O
artificial	O
sweeteners	O
affect	O
the	O
gut	O
microbiome	O
and	O
which	O
is	O
associated	O
with	O
the	O
development	O
of	O
metabolic	O
,	O
malignant	O
,	O
inflammatory	O
,	O
or	O
immune	O
diseases	O
.	O

Answering	O
the	O
question	O
'	O
Who	O
is	O
there	O
?	O
'	O

is	O
not	O
sufficient	O
to	O
define	O
the	O
mode	O
of	O
action	O
of	O
a	O
toxicant	O
in	O
predictive	O
modeling	O
of	O
mixture	O
effects	O
.	O

Therefore	O
,	O
we	O
recommend	O
that	O
new	O
studies	O
focus	O
to	O
simulate	O
real	O
-	O
life	O
exposure	O
to	O
diverse	O
chemicals	O
(	O
toxicants	O
,	O
cosmetic	O
/	O
food	O
additives	O
)	O
,	O
including	O
as	O
mixtures	O
,	O
and	O
which	O
combine	O
metagenomics	O
,	O
metatranscriptomics	O
and	O
metabolomic	O
analytical	O
methods	O
achieving	O
in	O
that	O
way	O
a	O
comprehensive	O
evaluation	O
of	O
effects	O
on	O
human	O
health	O
.	O

Clostridium	B-bacteria
butyricum	I-bacteria
Strains	O
Suppress	O
Experimental	O
Acute	O
Pancreatitis	O
by	O
Maintaining	O
Intestinal	O
Homeostasis	O
.	O

SCOPE	O
:	O
Acute	O
pancreatitis	O
(	O
AP	O
)	O
is	O
a	O
common	O
abdominal	O
inflammatory	O
disease	O
.	O

Disturbed	O
gut	O
homeostasis	O
secondary	O
to	O
pancreatic	O
inflammation	O
aggravates	O
the	O
condition	O
retroactively	O
.	O

The	O
current	O
study	O
investigates	O
potential	O
beneficial	O
effects	O
of	O
Clostridium	B-bacteria
butyricum	I-bacteria
(	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
)	O
strains	O
on	O
AP	O
and	O
underlying	O
mechanisms	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
strains	I-bacteria
MIYAIRI	I-bacteria
588	I-bacteria
(	O
CBM588	B-bacteria
)	O
and	O
CGMCC0313	B-bacteria
.	I-bacteria
1	I-bacteria
(	O
CB0313	B-bacteria
.	I-bacteria
1	I-bacteria
)	O
were	O
supplemented	O
to	O
mice	O
for	O
three	O
weeks	O
before	O
experimental	O
AP	O
or	O
SAP	O
induction	O
.	O

Both	O
CBM588	O
and	O
CB0313	O
.	O
1	O
protected	O
against	O
AP	O
,	O
as	O
evidenced	O
by	O
reduced	O
serum	O
amylase	O
and	O
lipase	O
levels	O
,	O
pancreatic	O
edema	O
,	O
and	O
myeloperoxidase	O
activity	O
.	O

Amelioration	O
of	O
both	O
experimental	O
AP	O
and	O
SAP	O
by	O
CB0313	O
.	O
1	O
indicated	O
a	O
non	O
-	O
model	O
-	O
specific	O
effect	O
.	O

Moreover	O
,	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
inhibited	O
pancreatic	O
neutrophil	O
and	O
dendritic	O
cell	O
infiltration	O
,	O
nucleotide	O
-	O
binding	O
domain	O
leucine	O
-	O
rich	O
repeat	O
-	O
containing	O
family	O
,	O
pyrin	O
domain	O
-	O
containing	O
3	O
inflammasome	O
activation	O
,	O
and	O
pro	O
-	O
inflammatory	O
pathways	O
.	O

Additionally	O
in	O
the	O
gut	O
,	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
strains	I-bacteria
attenuated	O
AP	O
-	O
associated	O
intestinal	O
inflammation	O
and	O
barrier	O
dysfunction	O
,	O
accompanied	O
with	O
reduced	O
pathogenic	O
bacteria	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
Enterococcus	B-bacteria
penetration	O
into	O
pancreas	O
.	O

Gut	O
microbiome	O
analyses	O
further	O
revealed	O
that	O
beneficial	O
effects	O
of	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
on	O
pancreatic	O
-	O
gut	O
homeostasis	O
were	O
correlated	O
with	O
improved	O
dysbiosis	O
.	O

In	O
particular	O
,	O
relative	O
abundance	O
of	O
Desulfovibrionaceae	B-bacteria
decreased	O
,	O
and	O
Verrucomicrobiaceae	B-bacteria
Clostridiaceae	B-bacteria
and	O
Lactobacillaceae	B-bacteria
increased	O
.	O

CONCLUSIONS	O
:	O
For	O
the	O
first	O
time	O
,	O
a	O
protective	O
effect	O
of	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
in	O
AP	O
by	O
modulating	O
intestinal	O
homeostasis	O
is	O
demonstrated	O
.	O

Microbiome	O
and	O
Metabolome	O
Profiles	O
Associated	O
With	O
Different	O
Types	O
of	O
Short	O
Bowel	O
Syndrome	O
:	O
Implications	O
for	O
Treatment	O
.	O

BACKGROUND	O
:	O
The	O
gut	O
microbiome	O
and	O
metabolome	O
may	O
significantly	O
influence	O
clinical	O
outcomes	O
in	O
patients	O
with	O
short	O
bowel	O
syndrome	O
(	O
SBS	O
)	O
.	O

The	O
study	O
aimed	O
to	O
describe	O
specific	O
metagenomic	O
/	O
metabolomics	O
profiles	O
of	O
different	O
SBS	O
types	O
and	O
to	O
identify	O
possible	O
therapeutic	O
targets	O
.	O

METHODS	O
:	O
Fecal	O
microbiome	O
(	O
FM	O
)	O
,	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
,	O
and	O
bile	O
acid	O
(	O
BA	O
)	O
spectrum	O
were	O
analyzed	O
in	O
parenteral	O
nutrition	O
(	O
PN	O
)	O
-	O
dependent	O
SBS	O
I	O
,	O
SBS	O
II	O
,	O
and	O
PN	O
-	O
independent	O
(	O
non	O
-	O
PN	O
)	O
SBS	O
patients	O
.	O

RESULTS	O
:	O
FM	O
in	O
SBS	O
I	O
,	O
SBS	O
II	O
,	O
and	O
non	O
-	O
PN	O
SBS	O
shared	O
characteristic	O
features	O
(	O
depletion	O
of	O
beneficial	O
anaerobes	O
,	O
high	O
abundance	O
of	O
Lactobacilaceae	B-bacteria
and	O
Enterobacteriaceae	B-bacteria
)	O
.	O

SBS	O
I	O
patients	O
were	O
characterized	O
by	O
the	O
abundance	O
of	O
oxygen	O
-	O
tolerant	O
microrganisms	O
and	O
depletion	O
of	O
strict	O
anaerobes	O
.	O

Non	O
-	O
PN	O
SBS	O
subjects	O
showed	O
markers	O
of	O
partial	O
FM	O
normalization	O
.	O

FM	O
dysbiosis	O
was	O
translated	O
into	O
VOC	O
and	O
BA	O
profiles	O
characteristic	O
for	O
each	O
SBS	O
cohort	O
.	O

A	O
typical	O
signature	O
of	O
all	O
SBS	O
patients	O
comprised	O
high	O
saturated	O
aldehydes	O
and	O
medium	O
-	O
chain	O
fatty	O
acids	O
and	O
reduced	O
short	O
-	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
content	O
.	O

Particularly	O
,	O
SBS	O
I	O
and	O
II	O
exhibited	O
low	O
protein	O
metabolism	O
intermediate	O
(	O
indole	O
,	O
p	O
-	O
cresol	O
)	O
content	O
despite	O
the	O
hypothetical	O
presence	O
of	O
relevant	O
metabolism	O
pathways	O
.	O

Distinctive	O
non	O
-	O
PN	O
SBS	O
marker	O
was	O
high	O
phenol	O
content	O
.	O

SBS	O
patients	O
'	O
BA	O
fecal	O
spectrum	O
was	O
enriched	O
by	O
chenodeoxycholic	O
and	O
deoxycholic	O
acids	O
and	O
depleted	O
of	O
lithocholic	O
acid	O
.	O

CONCLUSIONS	O
:	O
Environmental	O
conditions	O
in	O
SBS	O
gut	O
significantly	O
affect	O
FM	O
composition	O
and	O
metabolic	O
activity	O
.	O

The	O
common	O
feature	O
of	O
diverse	O
SBS	O
subjects	O
is	O
the	O
altered	O
VOC	O
/	O
BA	O
profile	O
and	O
the	O
lack	O
of	O
important	O
products	O
of	O
microbial	O
metabolism	O
.	O

Strategies	O
oriented	O
on	O
the	O
microbiome	O
/	O
metabolome	O
reconstitution	O
and	O
targeted	O
delivery	O
of	O
key	O
compounds	O
may	O
represent	O
a	O
promising	O
therapeutic	O
strategy	O
in	O
SBS	O
patients	O
.	O

The	O
impacts	O
of	O
natural	O
polysaccharides	O
on	O
intestinal	O
microbiota	O
and	O
immune	O
responses	O
-	O
a	O
review	O
.	O

In	O
recent	O
years	O
,	O
natural	O
polysaccharides	O
have	O
received	O
increasing	O
attention	O
and	O
become	O
one	O
type	O
of	O
popular	O
dietary	O
nutrient	O
because	O
of	O
their	O
various	O
biological	O
functions	O
.	O

In	O
this	O
paper	O
,	O
the	O
sources	O
,	O
extraction	O
,	O
purification	O
and	O
structural	O
characterization	O
methods	O
of	O
natural	O
polysaccharides	O
are	O
introduced	O
.	O

Natural	O
polysaccharides	O
are	O
favorable	O
for	O
the	O
proliferation	O
of	O
short	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
-	O
producing	O
bacteria	O
,	O
the	O
presence	O
of	O
which	O
can	O
improve	O
the	O
intestinal	O
microenvironment	O
.	O

Natural	O
polysaccharides	O
can	O
not	O
only	O
enhance	O
immunity	O
,	O
but	O
also	O
suppress	O
excessive	O
immune	O
responses	O
caused	O
by	O
various	O
stimuli	O
.	O

In	O
particular	O
,	O
natural	O
polysaccharides	O
can	O
regulate	O
immunity	O
by	O
acting	O
directly	O
on	O
the	O
immune	O
cells	O
and	O
targeting	O
the	O
gut	O
microbiota	O
.	O

Natural	O
polysaccharides	O
can	O
enhance	O
immunity	O
by	O
promoting	O
beneficial	O
microorganisms	O
and	O
strengthening	O
the	O
function	O
of	O
immune	O
cells	O
.	O

However	O
,	O
natural	O
polysaccharides	O
can	O
also	O
suppress	O
excessive	O
inflammatory	O
responses	O
by	O
improving	O
the	O
intestinal	O
microbiota	O
composition	O
,	O
strengthening	O
intestinal	O
barrier	O
function	O
,	O
enhancing	O
antioxidant	O
activities	O
,	O
promoting	O
SCFA	O
production	O
and	O
reducing	O
pro	O
-	O
inflammatory	O
mediators	O
.	O

Therefore	O
,	O
a	O
comprehensive	O
review	O
is	O
presented	O
on	O
the	O
impacts	O
of	O
natural	O
polysaccharides	O
on	O
the	O
gut	O
microbiota	O
and	O
immune	O
responses	O
,	O
as	O
well	O
as	O
their	O
interactions	O
.	O

Comprehensive	O
Kinetic	O
Survey	O
of	O
Intestinal	O
,	O
Extra	O
-	O
Intestinal	O
and	O
Systemic	O
Sequelae	O
of	O
Murine	O
Ileitis	O
Following	O
Peroral	O
Low	O
-	O
Dose	O
Toxoplasma	O
gondii	O
Infection	O
.	O

We	O
have	O
recently	O
shown	O
that	O
following	O
peroral	O
low	O
-	O
dose	O
Toxoplasma	O
gondii	O
infection	O
susceptible	O
mice	O
develop	O
subacute	O
ileitis	O
within	O
10	O
days	O
.	O

Data	O
regarding	O
long	O
-	O
term	O
intestinal	O
and	O
extra	O
-	O
intestinal	O
sequelae	O
of	O
infection	O
are	O
scarce	O
,	O
however	O
.	O

We	O
therefore	O
challenged	O
conventional	O
C57BL	O
/	O
6	O
mice	O
with	O
one	O
cyst	O
of	O
T	B-bacteria
.	I-bacteria
gondii	I-bacteria
ME49	I-bacteria
strain	I-bacteria
by	O
gavage	O
and	O
performed	O
a	O
comprehensive	O
immunopathological	O
survey	O
10	O
,	O
36	O
,	O
and	O
57	O
days	O
later	O
.	O

As	O
early	O
as	O
10	O
days	O
post	O
-	O
infection	O
,	O
mice	O
were	O
suffering	O
from	O
subacute	O
ileitis	O
as	O
indicated	O
by	O
mild	O
-	O
to	O
-	O
moderate	O
histopathological	O
changes	O
of	O
the	O
ileal	O
mucosa	O
.	O

Furthermore	O
,	O
numbers	O
of	O
apoptotic	O
and	O
proliferating	O
/	O
regenerating	O
epithelial	O
cells	O
as	O
well	O
as	O
of	O
T	O
and	O
B	O
lymphocytes	O
in	O
the	O
mucosa	O
and	O
lamina	O
propria	O
of	O
the	O
ileum	O
were	O
highest	O
at	O
day	O
10	O
post	O
-	O
infection	O
,	O
but	O
declined	O
thereafter	O
,	O
and	O
were	O
accompanied	O
by	O
enhanced	O
pro	O
-	O
inflammatory	O
mediator	O
secretion	O
in	O
ileum	O
,	O
colon	O
and	O
mesenteric	O
lymph	O
nodes	O
that	O
was	O
most	O
pronounced	O
during	O
the	O
early	O
phase	O
of	O
infection	O
.	O

In	O
addition	O
,	O
subacute	O
ileitis	O
was	O
accompanied	O
by	O
distinct	O
shifts	O
in	O
the	O
commensal	O
gut	O
microbiota	O
composition	O
in	O
the	O
small	O
intestines	O
.	O

Remarkably	O
,	O
immunopathological	O
sequelae	O
of	O
T	B-bacteria
.	I-bacteria
gondii	I-bacteria
infection	O
were	O
not	O
restricted	O
to	O
the	O
intestines	O
,	O
but	O
could	O
also	O
be	O
observed	O
in	O
extra	O
-	O
intestinal	O
tissues	O
including	O
the	O
liver	O
,	O
kidneys	O
,	O
lungs	O
,	O
heart	O
and	O
strikingly	O
,	O
in	O
systemic	O
compartments	O
that	O
were	O
most	O
prominent	O
at	O
day	O
10	O
post	O
-	O
infection	O
.	O

We	O
conclude	O
that	O
the	O
here	O
provided	O
long	O
-	O
term	O
kinetic	O
survey	O
of	O
immunopathological	O
sequalae	O
following	O
peroral	O
low	O
-	O
dose	O
T	B-bacteria
.	I-bacteria
gondii	I-bacteria
infection	O
provides	O
valuable	O
corner	O
stones	O
for	O
a	O
better	O
understanding	O
of	O
the	O
complex	O
interactions	O
within	O
the	O
triangle	O
relationship	O
of	O
(	O
parasitic	O
)	O
pathogens	O
,	O
the	O
host	O
immunity	O
and	O
the	O
commensal	O
gut	O
microbiota	O
during	O
intestinal	O
inflammation	O
.	O

The	O
low	O
-	O
dose	O
T	B-bacteria
.	I-bacteria
gondii	I-bacteria
infection	O
model	O
may	O
be	O
applied	O
as	O
valuable	O
gut	O
inflammation	O
model	O
in	O
future	O
pre	O
-	O
clinical	O
studies	O
in	O
order	O
to	O
test	O
potential	O
treatment	O
options	O
for	O
intestinal	O
inflammatory	O
conditions	O
in	O
humans	O
.	O

Public	O
questions	O
spur	O
the	O
discovery	O
of	O
new	O
bacterial	O
species	O
associated	O
with	O
lignin	O
bioconversion	O
of	O
industrial	O
waste	O
.	O

A	O
citizen	O
science	O
project	O
found	O
that	O
the	O
greenhouse	O
camel	O
cricket	O
(	O
Diestrammena	O
asynamora	O
)	O
is	O
common	O
in	O
North	O
American	O
homes	O
.	O

Public	O
response	O
was	O
to	O
wonder	O
'	O
what	O
good	O
are	O
they	O
anyway	O
?	O
'	O

and	O
ecology	O
and	O
evolution	O
guided	O
the	O
search	O
for	O
potential	O
benefit	O
.	O

We	O
predicted	O
that	O
camel	O
crickets	O
and	O
similar	O
household	O
species	O
would	O
likely	O
host	O
bacteria	O
with	O
the	O
ability	O
to	O
degrade	O
recalcitrant	O
carbon	O
compounds	O
.	O

Lignocellulose	O
is	O
particularly	O
relevant	O
as	O
it	O
is	O
difficult	O
to	O
degrade	O
yet	O
is	O
an	O
important	O
feedstock	O
for	O
pulp	O
and	O
paper	O
,	O
chemical	O
and	O
biofuel	O
industries	O
.	O

We	O
screened	O
gut	O
bacteria	O
of	O
greenhouse	O
camel	O
crickets	O
and	O
another	O
household	O
insect	O
,	O
the	O
hide	O
beetle	O
(	O
Dermestes	O
maculatus	O
)	O
for	O
the	O
ability	O
to	O
grow	O
on	O
and	O
degrade	O
lignocellulose	O
components	O
as	O
well	O
as	O
the	O
lignocellulose	O
-	O
derived	O
industrial	O
waste	O
product	O
black	O
liquor	O
.	O

From	O
three	O
greenhouse	O
camel	O
crickets	O
and	O
three	O
hide	O
beetles	O
,	O
14	O
bacterial	O
strains	O
were	O
identified	O
that	O
were	O
capable	O
of	O
growth	O
on	O
lignocellulosic	O
components	O
,	O
including	O
lignin	O
.	O

Cedecea	B-bacteria
lapagei	I-bacteria
was	O
selected	O
for	O
further	O
study	O
due	O
to	O
growth	O
on	O
most	O
lignocellulose	O
components	O
.	O

The	O
C	B-bacteria
.	I-bacteria
lapagei	I-bacteria
secretome	O
was	O
identified	O
using	O
LC	O
/	O
MS	O
/	O
MS	O
analysis	O
.	O

This	O
work	O
demonstrates	O
a	O
novel	O
source	O
of	O
lignocellulose	O
-	O
degrading	O
bacteria	O
and	O
introduces	O
an	O
effective	O
workflow	O
to	O
identify	O
bacterial	O
enzymes	O
for	O
transforming	O
industrial	O
waste	O
into	O
value	O
-	O
added	O
products	O
.	O

More	O
generally	O
,	O
our	O
research	O
suggests	O
the	O
value	O
of	O
ecologically	O
guided	O
discovery	O
of	O
novel	O
organisms	O
.	O

Bacterial	O
communities	O
within	O
Phengaris	O
(	O
Maculinea	O
)	O
alcon	O
caterpillars	O
are	O
shifted	O
following	O
transition	O
from	O
solitary	O
living	O
to	O
social	O
parasitism	O
of	O
Myrmica	O
ant	O
colonies	O
.	O

Bacterial	O
symbionts	O
are	O
known	O
to	O
facilitate	O
a	O
wide	O
range	O
of	O
physiological	O
processes	O
and	O
ecological	O
interactions	O
for	O
their	O
hosts	O
.	O

In	O
spite	O
of	O
this	O
,	O
caterpillars	O
with	O
highly	O
diverse	O
life	O
histories	O
appear	O
to	O
lack	O
resident	O
microbiota	O
.	O

Gut	O
physiology	O
,	O
endogenous	O
digestive	O
enzymes	O
,	O
and	O
limited	O
social	O
interactions	O
may	O
contribute	O
to	O
this	O
pattern	O
,	O
but	O
the	O
consequences	O
of	O
shifts	O
in	O
social	O
activity	O
and	O
diet	O
on	O
caterpillar	O
microbiota	O
are	O
largely	O
unknown	O
.	O

Phengaris	O
alcon	O
caterpillars	O
undergo	O
particularly	O
dramatic	O
social	O
and	O
dietary	O
shifts	O
when	O
they	O
parasitize	O
Myrmica	O
ant	O
colonies	O
,	O
rapidly	O
transitioning	O
from	O
solitary	O
herbivory	O
to	O
ant	O
tending	O
(	O
i	O
.	O
e	O
.	O
,	O
receiving	O
protein	O
-	O
rich	O
regurgitations	O
through	O
trophallaxis	O
)	O
.	O

This	O
unique	O
life	O
history	O
provides	O
a	O
model	O
for	O
studying	O
interactions	O
between	O
social	O
living	O
,	O
diet	O
,	O
and	O
caterpillar	O
microbiota	O
.	O

Here	O
,	O
we	O
characterized	O
and	O
compared	O
bacterial	O
communities	O
within	O
P	O
.	O
alcon	O
caterpillars	O
before	O
and	O
after	O
their	O
association	O
with	O
ants	O
,	O
using	O
16S	O
rRNA	O
amplicon	O
sequencing	O
and	O
quantitative	O
PCR	O
.	O

After	O
being	O
adopted	O
by	O
ants	O
,	O
bacterial	O
communities	O
within	O
P	O
.	O
alcon	O
caterpillars	O
shifted	O
substantially	O
,	O
with	O
a	O
significant	O
increase	O
in	O
alpha	O
diversity	O
and	O
greater	O
consistency	O
in	O
bacterial	O
community	O
composition	O
in	O
terms	O
of	O
beta	O
dissimilarity	O
.	O

We	O
also	O
characterized	O
the	O
bacterial	O
communities	O
within	O
their	O
host	O
ants	O
(	O
Myrmica	O
schencki	O
)	O
,	O
food	O
plant	O
(	O
Gentiana	O
cruciata	O
)	O
,	O
and	O
soil	O
from	O
ant	O
nest	O
chambers	O
.	O

These	O
data	O
indicated	O
that	O
the	O
aforementioned	O
patterns	O
were	O
influenced	O
by	O
bacteria	O
derived	O
from	O
caterpillars	O
'	O
surrounding	O
environments	O
,	O
rather	O
than	O
through	O
transfers	O
from	O
ants	O
.	O

Thus	O
,	O
while	O
bacterial	O
communities	O
are	O
substantially	O
reorganized	O
over	O
the	O
life	O
cycle	O
of	O
P	O
.	O
alcon	O
caterpillars	O
,	O
it	O
appears	O
that	O
they	O
do	O
not	O
rely	O
on	O
transfers	O
of	O
bacteria	O
from	O
host	O
ants	O
to	O
complete	O
their	O
development	O
.	O

Microbiota	O
of	O
the	O
Gut	O
-	O
Lymph	O
Node	O
Axis	O
:	O
Depletion	O
of	O
Mucosa	O
-	O
Associated	O
Segmented	O
Filamentous	O
Bacteria	O
and	O
Enrichment	O
of	O
Methanobrevibacter	B-bacteria
by	O
Colistin	O
Sulfate	O
and	O
Linco	O
-	O
Spectin	O
in	O
Pigs	O
.	O

Microorganisms	O
are	O
translocated	O
from	O
the	O
gut	O
to	O
lymphatic	O
tissues	O
via	O
immune	O
cells	O
,	O
thereby	O
challenging	O
and	O
training	O
the	O
mammalian	O
immune	O
system	O
.	O

Antibiotics	O
alter	O
the	O
gut	O
microbiome	O
and	O
consecutively	O
might	O
also	O
affect	O
the	O
corresponding	O
translocation	O
processes	O
,	O
resulting	O
in	O
an	O
imbalanced	O
state	O
between	O
the	O
intestinal	O
microbiota	O
and	O
the	O
host	O
.	O

Hence	O
,	O
understanding	O
the	O
variant	O
effects	O
of	O
antibiotics	O
on	O
the	O
microbiome	O
of	O
gut	O
-	O
associated	O
tissues	O
is	O
of	O
vital	O
importance	O
for	O
maintaining	O
metabolic	O
homeostasis	O
and	O
animal	O
health	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
microbiome	O
of	O
(	O
i	O
)	O
pig	O
feces	O
,	O
ileum	O
,	O
and	O
ileocecal	O
lymph	O
nodes	O
under	O
the	O
influence	O
of	O
antibiotics	O
(	O
Linco	O
-	O
Spectin	O
and	O
Colistin	O
sulfate	O
)	O
using	O
16S	O
rRNA	O
gene	O
sequencing	O
for	O
high	O
-	O
resolution	O
community	O
profiling	O
and	O
(	O
ii	O
)	O
ileocecal	O
lymph	O
nodes	O
in	O
more	O
detail	O
with	O
two	O
additional	O
methodological	O
approaches	O
,	O
i	O
.	O
e	O
.	O
,	O
cultivation	O
of	O
ileocecal	O
lymph	O
node	O
samples	O
and	O
(	O
iii	O
)	O
metatranscriptome	O
sequencing	O
of	O
a	O
single	O
lymph	O
node	O
sample	O
.	O

Supplementation	O
of	O
medicated	O
feed	O
showed	O
a	O
local	O
effect	O
on	O
feces	O
and	O
ileal	O
mucosa	O
-	O
associated	O
microbiomes	O
.	O

Pigs	O
that	O
received	O
antibiotics	O
harbored	O
significantly	O
reduced	O
amounts	O
of	O
segmented	O
filamentous	O
bacteria	O
(	O
SFB	O
)	O
along	O
the	O
ileal	O
mucosa	O
(	O
p	O
=	O
0	O
.	O
048	O
;	O
199	O
.	O
17	O
-	O
fold	O
change	O
)	O
and	O
increased	O
amounts	O
of	O
Methanobrevibacter	B-bacteria
,	O
a	O
methanogenic	O
Euryarchaeote	O
in	O
fecal	O
samples	O
(	O
p	O
=	O
0	O
.	O
005	O
;	O
20	O
.	O
17	O
-	O
fold	O
change	O
)	O
compared	O
to	O
the	O
control	O
group	O
.	O

Analysis	O
of	O
the	O
porcine	O
ileocecal	O
lymph	O
node	O
microbiome	O
exposed	O
large	O
differences	O
between	O
the	O
viable	O
and	O
the	O
dead	O
fraction	O
of	O
microorganisms	O
and	O
the	O
microbiome	O
was	O
altered	O
to	O
a	O
lesser	O
extent	O
by	O
antibiotics	O
compared	O
with	O
feces	O
and	O
ileum	O
.	O

The	O
core	O
microbiome	O
of	O
lymph	O
nodes	O
was	O
constituted	O
mainly	O
of	O
Proteobacteria	B-bacteria
.	O

RNA	O
-	O
sequencing	O
of	O
a	O
single	O
lymph	O
node	O
sample	O
unveiled	O
transcripts	O
responsible	O
for	O
amino	O
acid	O
and	O
carbohydrate	O
metabolism	O
as	O
well	O
as	O
protein	O
turnover	O
,	O
DNA	O
replication	O
and	O
signal	O
transduction	O
.	O

The	O
study	O
presented	O
here	O
is	O
the	O
first	O
comparative	O
study	O
of	O
microbial	O
communities	O
in	O
feces	O
,	O
ileum	O
,	O
and	O
its	O
associated	O
ileocecal	O
lymph	O
nodes	O
.	O

In	O
each	O
analyzed	O
site	O
,	O
we	O
identified	O
specific	O
phylotypes	O
susceptible	O
to	O
antibiotic	O
treatment	O
that	O
can	O
have	O
profound	O
impacts	O
on	O
the	O
host	O
physiological	O
and	O
immunological	O
state	O
,	O
or	O
even	O
on	O
global	O
biogeochemical	O
cycles	O
.	O

Our	O
results	O
indicate	O
that	O
pathogenic	O
bacteria	O
,	O
e	O
.	O
g	O
.	O
,	O
enteropathogenic	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
,	O
could	O
escape	O
antibiotic	O
treatment	O
by	O
translocating	O
to	O
lymph	O
nodes	O
.	O

In	O
general	O
ileocecal	O
lymph	O
nodes	O
harbor	O
a	O
more	O
diverse	O
and	O
active	O
community	O
of	O
microorganisms	O
than	O
previously	O
assumed	O
.	O

Synergistic	O
effect	O
of	O
anti	O
-	O
Helicobacter	O
pylori	O
urease	O
immunoglobulin	O
Y	O
from	O
egg	O
yolk	O
of	O
immunized	O
hens	O
and	O
Lactobacillus	B-bacteria
johnsonii	I-bacteria
No	I-bacteria
.	I-bacteria
1088	I-bacteria
to	O
inhibit	O
the	O
growth	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
is	O
a	O
pathogenic	O
bacterium	O
that	O
infects	O
the	O
stomach	O
,	O
causing	O
chronic	O
gastritis	O
;	O
and	O
it	O
is	O
also	O
considered	O
to	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
gastric	O
cancers	O
.	O

Although	O
some	O
eradication	O
regimens	O
including	O
multiple	O
antibiotics	O
have	O
been	O
developed	O
,	O
the	O
emergence	O
of	O
resistance	O
to	O
antibiotics	O
becomes	O
problematic	O
.	O

Therefore	O
,	O
other	O
approaches	O
to	O
compensate	O
or	O
augment	O
the	O
effects	O
of	O
standard	O
regimens	O
are	O
needed	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
possible	O
synergistic	O
effects	O
of	O
anti	O
-	O
H	O
.	O
pylori	O
urease	O
IgY	O
and	O
Lactobacillus	B-bacteria
johnsonii	I-bacteria
No	I-bacteria
.	I-bacteria
1088	I-bacteria
(	O
LJ88	B-bacteria
)	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Anti	O
-	O
H	O
.	O
pylori	O
urease	O
IgY	O
was	O
purified	O
from	O
egg	O
yolks	O
laid	O
by	O
the	O
hens	O
immunized	O
with	O
urease	O
purified	O
from	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
.	O

LJ88	B-bacteria
is	O
a	O
unique	O
strain	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacterium	I-bacteria
isolated	O
from	O
human	O
gastric	O
juice	O
,	O
and	O
it	O
has	O
been	O
reported	O
to	O
inhibit	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
in	O
vitro	O
mixed	O
culture	O
study	O
showed	O
that	O
anti	O
-	O
H	O
.	O
pylori	O
urease	O
IgY	O
augmented	O
the	O
anti	O
-	O
H	O
.	O
pylori	O
activity	O
of	O
LJ88	O
against	O
both	O
clarithromycin	O
-	O
sensitive	O
and	O
-	O
resistant	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
strains	I-bacteria
.	O

In	O
a	O
germ	O
-	O
free	O
mice	O
infection	O
model	O
,	O
combined	O
administration	O
of	O
daily	O
anti	O
-	O
H	O
.	O
pylori	O
urease	O
IgY	O
and	O
weekly	O
living	O
LJ88	O
significantly	O
reduced	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infections	O
,	O
whereas	O
either	O
monotherapy	O
did	O
not	O
.	O

In	O
an	O
in	O
vivo	O
human	O
gut	O
microbiota	O
-	O
associated	O
mice	O
model	O
,	O
not	O
only	O
daily	O
administration	O
of	O
living	O
LJ88	O
but	O
also	O
heat	O
-	O
killed	O
one	O
significantly	O
reduced	O
an	O
H	O
.	O
pylori	O
infection	O
in	O
the	O
stomach	O
when	O
combined	O
with	O
anti	O
-	O
H	O
.	O
pylori	O
urease	O
IgY	O
.	O

The	O
extent	O
of	O
reduction	O
of	O
the	O
stomach	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
by	O
such	O
a	O
combination	O
therapy	O
was	O
larger	O
than	O
that	O
reported	O
for	O
LJ88	O
monotherapy	O
.	O

These	O
results	O
taken	O
together	O
revealed	O
a	O
synergistic	O
effect	O
of	O
anti	O
-	O
H	O
.	O
pylori	O
urease	O
IgY	O
and	O
living	O
or	O
heat	O
-	O
killed	O
LJ88	O
,	O
thus	O
suggesting	O
that	O
such	O
a	O
combination	O
might	O
be	O
a	O
promising	O
therapy	O
to	O
possibly	O
compensate	O
and	O
/	O
or	O
augment	O
standard	O
anti	O
-	O
H	O
.	O
pylori	O
regimens	O
.	O

Enzymatic	O
synthesis	O
of	O
beta	O
-	O
galactosyl	O
fucose	O
using	O
recombinant	O
bifidobacterial	O
beta	O
-	O
galactosidase	O
and	O
its	O
prebiotic	O
effect	O
.	O

Breast	O
-	O
fed	O
infants	O
have	O
Bifidobacterium	O
-	O
rich	O
gut	O
microbiota	O
compared	O
to	O
infants	O
fed	O
formula	O
.	O

Fucosylated	O
oligosaccharides	O
are	O
the	O
major	O
components	O
of	O
human	O
milk	O
oligosaccharide	O
(	O
HMO	O
)	O
which	O
confer	O
various	O
beneficial	O
effects	O
including	O
prebiotic	O
effect	O
and	O
protection	O
from	O
pathogenic	O
infection	O
on	O
the	O
host	O
.	O

A	O
novel	O
prebiotics	O
was	O
developed	O
using	O
bifidobacterial	O
beta	O
-	O
galactosidase	O
and	O
fucose	O
and	O
lactose	O
as	O
substrates	O
.	O

Structure	O
analysis	O
revealed	O
it	O
as	O
beta	O
-	O
D	O
-	O
galactopyranosyl	O
-	O
(	O
1	O
-	O
-	O
>	O
3	O
)	O
-	O
O	O
-	O
L	O
-	O
fucopyranose	O
named	O
as	O
beta	O
-	O
galactosyl	O
fucose	O
(	O
gal	O
-	O
fuc	O
)	O
,	O
which	O
is	O
different	O
from	O
common	O
fucosylated	O
HMOs	O
with	O
alpha1	O
-	O
2	O
,	O
alpha1	O
-	O
3	O
,	O
and	O
alpha1	O
-	O
4	O
linkages	O
.	O

Among	O
the	O
four	O
Lactobacillus	B-bacteria
strains	I-bacteria
examined	O
,	O
all	O
but	O
L	B-bacteria
.	I-bacteria
delbrueckii	I-bacteria
subsp	I-bacteria
.	I-bacteria
bilgaricus	I-bacteria
KCTC	I-bacteria
3635	I-bacteria
grew	O
better	O
on	O
gal	O
-	O
fuc	O
than	O
on	O
beta	O
-	O
GOS	O
.	O

Among	O
the	O
11	O
bifidobacterial	B-bacteria
species	I-bacteria
examined	O
,	O
all	O
except	O
for	O
B	B-bacteria
.	I-bacteria
bifium	I-bacteria
used	O
gal	O
-	O
fuc	O
as	O
much	O
as	O
GOS	O
.	O

Moreover	O
,	O
the	O
gal	O
-	O
fuc	O
was	O
noticeably	O
better	O
used	O
by	O
Bifidobacterium	B-bacteria
infantis	I-bacteria
,	O
the	O
major	O
intestinal	O
bacteria	O
of	O
breast	O
fed	O
infant	O
.	O

Among	O
15	O
non	O
-	O
probiotic	O
bacteria	O
,	O
only	O
4	O
strains	O
used	O
gal	O
-	O
fuc	O
better	O
than	O
beta	O
-	O
GOS	O
.	O

In	O
conclusion	O
,	O
a	O
novel	O
gal	O
-	O
fuc	O
is	O
expected	O
to	O
contribute	O
to	O
beneficial	O
changes	O
of	O
gut	O
microbiota	O
.	O

Graphical	O
abstract	O
A	O
novel	O
form	O
of	O
beta	O
-	O
galactosyl	O
fucose	O
with	O
an	O
improved	O
prebiotic	O
effect	O
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
isolated	O
from	O
dairy	O
products	O
as	O
potential	O
producers	O
of	O
lipolytic	O
,	O
proteolytic	O
and	O
antibacterial	O
proteins	O
.	O

Regular	O
consumption	O
of	O
fermented	O
dairy	O
products	O
helps	O
maintain	O
a	O
healthy	O
microbiota	O
and	O
prevent	O
gut	O
dysbiosis	O
-	O
linked	O
diseases	O
.	O

The	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
present	O
in	O
food	O
enhance	O
the	O
digestibility	O
of	O
proteins	O
,	O
moderate	O
the	O
release	O
of	O
fatty	O
acids	O
,	O
and	O
support	O
human	O
health	O
through	O
inhabiting	O
the	O
gastrointestinal	O
tract	O
.	O

These	O
desirable	O
properties	O
of	O
LAB	B-bacteria
are	O
attributed	O
,	O
in	O
part	O
,	O
to	O
their	O
metabolic	O
processes	O
involving	O
enzymes	O
such	O
as	O
lipases	O
,	O
proteases	O
,	O
and	O
antibacterial	O
proteins	O
.	O

The	O
LAB	B-bacteria
strains	I-bacteria
presenting	O
higher	O
enzymatic	O
activities	O
may	O
offer	O
improved	O
functionality	O
for	O
applications	O
in	O
foods	O
.	O

The	O
first	O
aim	O
of	O
this	O
work	O
was	O
to	O
isolate	O
and	O
identify	O
LAB	B-bacteria
from	O
diverse	O
dairy	O
products	O
and	O
select	O
those	O
with	O
enhanced	O
enzymatic	O
activities	O
.	O

Secondly	O
,	O
this	O
work	O
aimed	O
to	O
investigate	O
the	O
subcellular	O
organization	O
and	O
identity	O
of	O
these	O
enzymes	O
after	O
semi	O
-	O
purification	O
.	O

Out	O
of	O
the	O
total	O
137	O
LAB	B-bacteria
strains	I-bacteria
isolated	O
and	O
screened	O
,	O
50	O
.	O
3	O
%	O
and	O
61	O
.	O
3	O
%	O
of	O
the	O
strains	O
exhibited	O
lipolytic	O
and	O
proteolytic	O
activities	O
,	O
respectively	O
.	O

Seven	O
strains	O
displaying	O
high	O
enzymatic	O
activities	O
were	O
selected	O
and	O
further	O
characterized	O
for	O
the	O
cellular	O
organization	O
of	O
their	O
lipases	O
,	O
proteases	O
,	O
and	O
antibacterial	O
proteins	O
.	O

The	O
lipolytic	O
and	O
proteolytic	O
activities	O
were	O
exhibited	O
predominantly	O
in	O
the	O
extracellular	O
fraction	O
;	O
whereas	O
,	O
the	O
antibacterial	O
activities	O
were	O
found	O
in	O
various	O
cellular	O
fractions	O
and	O
were	O
capable	O
of	O
inhibiting	O
common	O
undesirable	O
microorganisms	O
in	O
foods	O
.	O

In	O
total	O
,	O
two	O
lipases	O
,	O
seven	O
proteases	O
,	O
and	O
three	O
antibacterial	O
proteins	O
were	O
identified	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
.	O

Characterization	O
of	O
LAB	B-bacteria
strains	I-bacteria
with	O
high	O
enzymatic	O
activity	O
has	O
potential	O
biotechnological	O
significance	O
in	O
fermentative	O
processes	O
and	O
in	O
human	O
health	O
as	O
they	O
may	O
improve	O
the	O
physicochemical	O
characteristics	O
of	O
foods	O
and	O
displace	O
strains	O
with	O
weaker	O
enzymatic	O
activities	O
in	O
the	O
human	O
gut	O
microbiota	O
.	O

High	O
-	O
Throughput	O
Sequencing	O
Reveals	O
the	O
Gut	O
Microbiome	O
of	O
the	O
Bactrian	O
Camel	O
in	O
Different	O
Ages	O
.	O

The	O
complex	O
gut	O
microbiota	O
plays	O
a	O
key	O
role	O
in	O
host	O
metabolism	O
and	O
health	O
.	O

However	O
,	O
the	O
core	O
microbial	O
communities	O
in	O
the	O
different	O
aged	O
Bactrian	O
camels	O
remain	O
totally	O
unclear	O
.	O

We	O
used	O
high	O
-	O
throughput	O
16S	O
rRNA	O
gene	O
sequencing	O
to	O
examine	O
the	O
temporal	O
variability	O
of	O
the	O
fecal	O
microbiota	O
in	O
Bactrian	O
camels	O
.	O

At	O
2	O
months	O
of	O
age	O
,	O
the	O
fecal	O
microbiota	O
was	O
composed	O
of	O
Firmicutes	B-bacteria
,	O
Proteobacteria	B-bacteria
,	O
and	O
Actinobacteria	B-bacteria
.	O

At	O
1	O
and	O
3	O
years	O
of	O
age	O
,	O
the	O
fecal	O
microbiota	O
was	O
dominated	O
by	O
Firmicutes	B-bacteria
,	O
Bacteroidetes	B-bacteria
,	O
and	O
Verrucomicrobia	B-bacteria
.	O

At	O
the	O
genus	O
level	O
,	O
Blautia	B-bacteria
,	O
Fusobacterium	B-bacteria
,	O
and	O
Bifidobacterium	B-bacteria
were	O
more	O
abundant	O
at	O
2	O
months	O
of	O
age	O
,	O
as	O
well	O
as	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
.	O

Ruminococcaceae	B-bacteria
_	I-bacteria
UCG	I-bacteria
-	I-bacteria
005	I-bacteria
,	O
Akkermansia	B-bacteria
,	O
and	O
Christensenellaceae	B-bacteria
_	O
R	O
-	O
7	O
_	O
group	O
were	O
the	O
most	O
abundant	O
at	O
1	O
and	O
3	O
years	O
of	O
age	O
.	O

Diversity	O
and	O
stability	O
of	O
the	O
gut	O
microbiota	O
increased	O
with	O
age	O
.	O

There	O
was	O
enrichment	O
for	O
genes	O
associated	O
with	O
immune	O
system	O
diseases	O
at	O
2	O
months	O
of	O
age	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
investigate	O
the	O
distribution	O
of	O
the	O
gut	O
microbiota	O
in	O
Bactrian	O
camels	O
with	O
different	O
ages	O
and	O
provide	O
a	O
baseline	O
for	O
future	O
camel	O
microbiology	O
research	O
.	O

Feeding	O
of	O
deoxynivalenol	O
increases	O
the	O
intestinal	O
paracellular	O
permeability	O
of	O
broiler	O
chickens	O
.	O

In	O
recent	O
years	O
,	O
the	O
deleterious	O
effects	O
attributed	O
to	O
mycotoxins	O
,	O
in	O
particular	O
on	O
the	O
intestine	O
,	O
faced	O
increased	O
attention	O
and	O
it	O
was	O
shown	O
that	O
deoxynivalenol	O
(	O
DON	O
)	O
causes	O
adverse	O
effects	O
on	O
gut	O
health	O
.	O

In	O
this	O
context	O
,	O
it	O
has	O
been	O
repeatedly	O
reported	O
that	O
DON	O
can	O
alter	O
the	O
intestinal	O
morphology	O
,	O
disrupt	O
the	O
intestinal	O
barrier	O
and	O
reduce	O
nutrient	O
absorption	O
.	O

The	O
underlying	O
mechanism	O
of	O
a	O
compromised	O
intestinal	O
barrier	O
caused	O
by	O
DON	O
in	O
chickens	O
has	O
yet	O
to	O
be	O
illustrated	O
.	O

Although	O
,	O
DON	O
is	O
rapidly	O
absorbed	O
from	O
the	O
upper	O
parts	O
of	O
the	O
small	O
intestine	O
,	O
the	O
effects	O
on	O
the	O
large	O
intestine	O
can	O
not	O
be	O
excluded	O
.	O

Additionally	O
,	O
a	O
damaging	O
effect	O
of	O
DON	O
on	O
the	O
gut	O
epithelium	O
might	O
decrease	O
the	O
resistance	O
of	O
the	O
gut	O
against	O
infectious	O
agents	O
.	O

Consequently	O
,	O
the	O
objectives	O
of	O
the	O
present	O
studies	O
were	O
:	O
(	O
1	O
)	O
to	O
investigate	O
the	O
impact	O
of	O
DON	O
on	O
the	O
epithelial	O
paracellular	O
permeability	O
by	O
demonstrating	O
the	O
mucosal	O
to	O
serosal	O
flux	O
of	O
(	O
14	O
)	O
C	O
-	O
mannitol	O
in	O
the	O
small	O
and	O
large	O
intestine	O
applying	O
Ussing	O
chambers	O
and	O
(	O
2	O
)	O
to	O
delineate	O
the	O
effects	O
of	O
DON	O
on	O
the	O
colonization	O
and	O
translocation	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

Both	O
parameters	O
are	O
well	O
suited	O
as	O
potential	O
indicators	O
for	O
gut	O
barrier	O
failure	O
.	O

For	O
this	O
,	O
a	O
total	O
of	O
75	O
one	O
-	O
day	O
-	O
old	O
Ross	O
308	O
broiler	O
chickens	O
were	O
housed	O
in	O
floor	O
pens	O
on	O
wood	O
shavings	O
with	O
feed	O
and	O
water	O
provided	O
ad	O
libitum	O
.	O

Birds	O
were	O
randomly	O
allocated	O
to	O
three	O
different	O
groups	O
(	O
n	O
=	O
25	O
with	O
5	O
replicates	O
/	O
group	O
)	O
and	O
were	O
fed	O
for	O
5	O
weeks	O
with	O
either	O
contaminated	O
diets	O
(	O
5	O
or	O
10	O
mg	O
DON	O
/	O
kg	O
feed	O
)	O
or	O
basal	O
diets	O
(	O
control	O
)	O
.	O

Body	O
weight	O
(	O
BW	O
)	O
and	O
BW	O
gain	O
of	O
birds	O
in	O
the	O
group	O
fed	O
with	O
10	O
mg	O
/	O
kg	O
DON	O
were	O
significantly	O
lower	O
than	O
in	O
group	O
with	O
5	O
mg	O
/	O
kg	O
DON	O
and	O
the	O
control	O
group	O
.	O

Moreover	O
,	O
the	O
mannitol	O
flux	O
in	O
jejunum	O
and	O
cecum	O
was	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
in	O
DON	O
-	O
fed	O
groups	O
compared	O
to	O
control	O
birds	O
.	O

Consistent	O
with	O
this	O
,	O
DON	O
enhanced	O
the	O
translocation	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
with	O
a	O
higher	O
number	O
of	O
bacteria	O
encountered	O
in	O
the	O
spleen	O
and	O
liver	O
.	O

Altogether	O
,	O
the	O
actual	O
results	O
verified	O
that	O
DON	O
can	O
alter	O
the	O
intestinal	O
paracellular	O
permeability	O
in	O
broiler	O
chickens	O
and	O
facilitates	O
the	O
translocation	O
of	O
enteric	O
microorganisms	O
such	O
as	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
to	O
extra	O
-	O
intestinal	O
organs	O
.	O

Considering	O
that	O
moderate	O
levels	O
of	O
DON	O
are	O
present	O
in	O
feed	O
,	O
the	O
consumption	O
of	O
DON	O
-	O
contaminated	O
feed	O
can	O
induce	O
an	O
intestinal	O
breakdown	O
with	O
negative	O
consequences	O
on	O
broiler	O
health	O
.	O

Human	O
intestinal	O
enteroids	O
with	O
inducible	O
neurogenin	O
-	O
3	O
expression	O
as	O
a	O
novel	O
model	O
of	O
gut	O
hormone	O
secretion	O
.	O

BACKGROUND	O
:	O
Enteroendocrine	O
cells	O
(	O
EECs	O
)	O
are	O
specialized	O
epithelial	O
cells	O
that	O
produce	O
molecules	O
vital	O
for	O
intestinal	O
homeostasis	O
,	O
but	O
due	O
to	O
their	O
limited	O
numbers	O
,	O
in	O
-	O
depth	O
functional	O
studies	O
have	O
remained	O
challenging	O
.	O

Human	O
intestinal	O
enteroids	O
(	O
HIEs	O
)	O
that	O
are	O
derived	O
from	O
intestinal	O
crypt	O
stem	O
cells	O
are	O
a	O
biologically	O
relevant	O
in	O
vitro	O
model	O
of	O
the	O
intestinal	O
epithelium	O
.	O

HIEs	O
contain	O
all	O
intestinal	O
epithelial	O
cell	O
types	O
;	O
however	O
,	O
like	O
the	O
intestine	O
,	O
HIEs	O
spontaneously	O
produce	O
few	O
EECs	O
,	O
which	O
limits	O
their	O
study	O
.	O

METHODS	O
:	O
To	O
increase	O
the	O
number	O
of	O
EECs	O
in	O
HIEs	O
,	O
we	O
used	O
lentivirus	O
transduction	O
to	O
stably	O
engineer	O
jejunal	O
HIEs	O
with	O
doxycycline	O
-	O
inducible	O
expression	O
of	O
neurogenin	O
-	O
3	O
(	O
NGN3	O
)	O
,	O
a	O
transcription	O
factor	O
that	O
drives	O
EEC	O
differentiation	O
(	O
tetNGN3	O
-	O
HIEs	O
)	O
.	O

We	O
examined	O
the	O
impact	O
of	O
NGN3	O
induction	O
on	O
EECs	O
by	O
quantifying	O
the	O
increase	O
in	O
the	O
enterochromaffin	O
cells	O
and	O
other	O
EEC	O
subtypes	O
.	O

We	O
functionally	O
assessed	O
secretion	O
of	O
serotonin	O
and	O
EEC	O
hormones	O
in	O
response	O
to	O
norepinephrine	O
and	O
rotavirus	O
infection	O
.	O

RESULTS	O
:	O
Treating	O
tetNGN3	O
-	O
HIEs	O
with	O
doxycycline	O
induced	O
a	O
dose	O
-	O
dependent	O
increase	O
of	O
chromogranin	O
A	O
(	O
ChgA	O
)	O
-	O
positive	O
and	O
serotonin	O
-	O
positive	O
cells	O
,	O
demonstrating	O
increased	O
enterochromaffin	O
cell	O
differentiation	O
.	O

Despite	O
increased	O
ChgA	O
-	O
positive	O
cells	O
,	O
other	O
differentiated	O
cell	O
types	O
of	O
the	O
epithelium	O
remained	O
largely	O
unchanged	O
by	O
gene	O
expression	O
and	O
immunostaining	O
.	O

RNA	O
sequencing	O
of	O
doxycycline	O
-	O
induced	O
tetNGN3	O
-	O
HIEs	O
identified	O
increased	O
expression	O
of	O
key	O
hormones	O
and	O
enzymes	O
associated	O
with	O
several	O
other	O
EEC	O
subtypes	O
.	O

Doxycycline	O
-	O
induced	O
tetNGN3	O
-	O
HIEs	O
secreted	O
serotonin	O
,	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
,	O
glucose	O
-	O
dependent	O
insulinotropic	O
peptide	O
,	O
peptide	O
YY	O
,	O
and	O
ghrelin	O
in	O
response	O
to	O
norepinephrine	O
and	O
rotavirus	O
infection	O
,	O
further	O
supporting	O
the	O
presence	O
of	O
multiple	O
EEC	O
types	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
combined	O
HIEs	O
and	O
inducible	O
-	O
NGN3	O
expression	O
to	O
establish	O
a	O
flexible	O
in	O
vitro	O
model	O
system	O
for	O
functional	O
studies	O
of	O
EECs	O
in	O
enteroids	O
and	O
advance	O
the	O
molecular	O
and	O
physiological	O
investigation	O
of	O
EECs	O
.	O

Comparative	O
genomics	O
of	O
the	O
transportome	O
of	O
Ten	O
Treponema	B-bacteria
species	I-bacteria
.	O

Treponema	B-bacteria
is	O
a	O
diverse	O
bacterial	O
genus	O
,	O
the	O
species	O
of	O
which	O
can	O
be	O
pathogenic	O
,	O
symbiotic	O
,	O
or	O
free	O
living	O
.	O

These	O
treponemes	B-bacteria
can	O
cause	O
various	O
diseases	O
in	O
humans	O
and	O
other	O
animals	O
,	O
such	O
as	O
periodontal	O
disease	O
,	O
bovine	O
digital	O
dermatitis	O
and	O
animal	O
skin	O
lesions	O
.	O

However	O
,	O
the	O
most	O
important	O
and	O
well	O
-	O
studied	O
disease	O
of	O
treponemes	B-bacteria
that	O
affects	O
humans	O
is	O
'	O
syphilis	O
'	O
.	O

This	O
disease	O
is	O
caused	O
by	O
Treponema	B-bacteria
pallidum	I-bacteria
subspecie	I-bacteria
pallidum	I-bacteria
with	O
11	O
-	O
12	O
million	O
new	O
cases	O
around	O
the	O
globe	O
on	O
an	O
annual	O
basis	O
.	O

In	O
this	O
study	O
we	O
analyze	O
the	O
transportome	O
of	O
ten	O
Treponema	B-bacteria
species	I-bacteria
,	O
with	O
emphasis	O
on	O
the	O
types	O
of	O
encoded	O
transport	O
proteins	O
and	O
their	O
substrates	O
.	O

Of	O
the	O
ten	O
species	O
examined	O
,	O
two	O
(	O
T	B-bacteria
.	I-bacteria
primitia	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
azonutricium	I-bacteria
)	O
reside	O
as	O
symbionts	O
in	O
the	O
guts	O
of	O
termites	O
;	O
six	O
(	O
T	B-bacteria
.	I-bacteria
pallidum	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
paraluiscuniculi	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
pedis	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
denticola	I-bacteria
,	O
T	B-bacteria
.	I-bacteria
putidum	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
brennaborense	I-bacteria
)	O
are	O
pathogens	O
of	O
either	O
humans	O
or	O
animals	O
,	O
and	O
T	B-bacteria
.	I-bacteria
caldarium	I-bacteria
and	O
T	B-bacteria
.	I-bacteria
succinifaciens	I-bacteria
are	O
avirulent	O
species	O
,	O
the	O
former	O
being	O
thermophilic	O
.	O

All	O
ten	O
species	O
have	O
a	O
repertoire	O
of	O
transport	O
proteins	O
that	O
assists	O
them	O
in	O
residing	O
in	O
their	O
respective	O
ecological	O
niches	O
.	O

For	O
instance	O
,	O
oral	O
pathogens	O
use	O
transport	O
proteins	O
that	O
take	O
up	O
nutrients	O
uniquely	O
present	O
in	O
their	O
ecosystem	O
;	O
they	O
also	O
encode	O
multiple	O
multidrug	O
/	O
macromolecule	O
exporters	O
that	O
protect	O
against	O
antimicrobials	O
and	O
aid	O
in	O
biofilm	O
formation	O
.	O

Proteins	O
of	O
termite	O
gut	O
symbionts	O
convert	O
cellulose	O
into	O
other	O
sugars	O
that	O
can	O
be	O
metabolized	O
by	O
the	O
host	O
.	O

As	O
often	O
observed	O
for	O
pathogens	O
and	O
symbionts	O
,	O
several	O
of	O
these	O
treponemes	B-bacteria
have	O
reduced	O
genome	O
sizes	O
,	O
and	O
their	O
small	O
genomes	O
correlate	O
with	O
their	O
dependencies	O
on	O
the	O
host	O
.	O

Overall	O
,	O
the	O
transportomes	O
of	O
T	B-bacteria
.	I-bacteria
pallidum	I-bacteria
and	O
other	O
pathogens	O
have	O
a	O
conglomerate	O
of	O
parasitic	O
lifestyle	O
-	O
assisting	O
proteins	O
.	O

For	O
example	O
,	O
a	O
T	B-bacteria
.	I-bacteria
pallidum	I-bacteria
repeat	O
protein	O
(	O
TprK	O
)	O
mediates	O
immune	O
evasion	O
;	O
outer	O
membrane	O
proteins	O
(	O
OMPs	O
)	O
allow	O
nutrient	O
uptake	O
and	O
end	O
product	O
export	O
,	O
and	O
several	O
ABC	O
transporters	O
catalyze	O
sugar	O
uptake	O
,	O
considered	O
pivotal	O
to	O
parasitic	O
lifestyles	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
yield	O
new	O
information	O
that	O
may	O
help	O
open	O
new	O
avenues	O
of	O
treponeme	B-bacteria
research	O
.	O

Supplementation	O
with	O
Bifidobacterium	B-bacteria
longum	I-bacteria
Bar33	I-bacteria
and	O
Lactobacillus	B-bacteria
helveticus	I-bacteria
Bar13	I-bacteria
mixture	O
improves	O
immunity	O
in	O
elderly	O
humans	O
(	O
over	O
75	O
years	O
)	O
and	O
aged	O
mice	O
.	O

OBJECTIVE	O
:	O
Aging	O
induces	O
several	O
physiologic	O
and	O
immune	O
changes	O
.	O

The	O
usefulness	O
of	O
probiotics	O
in	O
ameliorating	O
age	O
-	O
related	O
disorders	O
remains	O
largely	O
unexplored	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
a	O
Bifidobacterium	B-bacteria
longum	I-bacteria
Bar33	I-bacteria
and	O
Lactobacillus	B-bacteria
helveticus	I-bacteria
Bar13	I-bacteria
mixture	O
in	O
improving	O
the	O
physiologic	O
status	O
and	O
immunity	O
of	O
older	O
adults	O
(	O
over	O
75	O
years	O
)	O
.	O

Furthermore	O
,	O
the	O
possible	O
role	O
of	O
such	O
mixture	O
in	O
ameliorating	O
gut	O
immunity	O
in	O
aged	O
mice	O
was	O
investigated	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
was	O
conducted	O
with	O
98	O
adults	O
(	O
84	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
8	O
y	O
)	O
,	O
supplemented	O
for	O
30	O
d	O
with	O
a	O
biscuit	O
containing	O
a	O
probiotic	O
mixture	O
of	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
Bar33	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
helveticus	I-bacteria
Bar13	I-bacteria
(	O
1	O
:	O
1	O
)	O
,	O
or	O
no	O
probiotics	O
,	O
as	O
placebo	O
.	O

Blood	O
was	O
collected	O
for	O
analysis	O
of	O
biochemical	O
parameters	O
,	O
lymphocyte	O
subpopulations	O
,	O
natural	O
killer	O
activity	O
,	O
and	O
cytokine	O
release	O
.	O

Aged	O
Balb	O
/	O
c	O
mice	O
received	O
the	O
same	O
probiotic	O
mixture	O
or	O
placebo	O
daily	O
for	O
28	O
d	O
,	O
then	O
blood	O
and	O
intestinal	O
lymphocyte	O
subpopulations	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
The	O
probiotic	O
mixture	O
ameliorated	O
immune	O
response	O
in	O
older	O
adults	O
by	O
increasing	O
naive	O
,	O
activated	O
memory	O
,	O
regulatory	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
natural	O
killer	O
activity	O
and	O
decreasing	O
memory	O
T	O
cells	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
biochemical	O
parameters	O
did	O
not	O
change	O
after	O
probiotic	O
supplementation	O
.	O

In	O
the	O
gut	O
of	O
old	O
mice	O
,	O
the	O
two	O
probiotics	O
modulated	O
cells	O
crucial	O
for	O
gut	O
immune	O
homeostasis	O
by	O
increasing	O
regulatory	O
T	O
(	O
Treg	O
and	O
Tr1	O
)	O
and	O
decreasing	O
gammadelta	O
T	O
cells	O
compared	O
with	O
control	O
mice	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
B	O
cells	O
increased	O
in	O
the	O
gut	O
and	O
blood	O
of	O
probiotic	O
-	O
treated	O
mice	O
.	O

CONCLUSION	O
:	O
Results	O
from	O
the	O
present	O
study	O
data	O
indicated	O
that	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
Bar33	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
helveticus	I-bacteria
Bar13	I-bacteria
improve	O
immune	O
function	O
at	O
intestinal	O
and	O
peripheral	O
sites	O
in	O
aging	O
.	O

Agricultural	O
origins	O
of	O
a	O
highly	O
-	O
persistent	O
lineage	O
of	O
vancomycin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Enterococcus	I-bacteria
faecalis	I-bacteria
in	O
New	O
Zealand	O
.	O

Enterococcus	B-bacteria
faecalis	I-bacteria
and	O
Enterococcus	B-bacteria
faecium	I-bacteria
are	O
human	O
and	O
animal	O
gut	O
commensals	O
.	O

Vancomycin	B-bacteria
-	I-bacteria
resistant	I-bacteria
enterococci	I-bacteria
(	O
VRE	B-bacteria
)	O
are	O
important	O
opportunistic	O
pathogens	O
with	O
limited	O
treatment	O
options	O
.	O

Historically	O
,	O
the	O
glycopeptide	O
antibiotics	O
vancomycin	O
and	O
avoparcin	O
selected	O
for	O
the	O
emergence	O
of	O
vancomycin	O
resistance	O
in	O
human	O
and	O
animal	O
isolates	O
respectively	O
,	O
resulting	O
in	O
global	O
cessation	O
of	O
avoparcin	O
use	O
between	O
1997	O
and	O
2000	O
.	O

To	O
better	O
understand	O
human	O
and	O
animal	O
-	O
associated	O
VRE	B-bacteria
strains	I-bacteria
in	O
the	O
post	O
-	O
avoparcin	O
era	O
,	O
we	O
sequenced	O
the	O
genomes	O
of	O
231	O
VRE	B-bacteria
isolates	I-bacteria
from	O
New	O
Zealand	O
(	O
NZ	O
)	O
(	O
75	O
human	O
clinical	O
,	O
156	O
poultry	O
)	O
cultured	O
between	O
1998	O
and	O
2009	O
.	O

E	B-bacteria
.	I-bacteria
faecium	I-bacteria
lineages	O
and	O
their	O
antibiotic	O
resistance	O
carriage	O
patterns	O
strictly	O
delineated	O
between	O
agricultural	O
and	O
human	O
reservoirs	O
,	O
with	O
bacitracin	O
resistance	O
ubiquitous	O
in	O
poultry	O
but	O
absent	O
in	O
clinical	O
E	O
.	O
faecium	I-bacteria
strains	I-bacteria
.	O

In	O
contrast	O
,	O
one	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
lineage	O
(	O
ST108	B-bacteria
)	O
predominated	O
in	O
both	O
poultry	O
and	O
human	O
isolates	O
in	O
the	O
three	O
years	O
following	O
avoparcin	O
discontinuation	O
.	O

Both	O
phylogenetic	O
and	O
antimicrobial	O
susceptibility	O
(	O
i	O
.	O
e	O
.	O
ubiquitous	O
bacitracin	O
resistance	O
in	O
both	O
poultry	O
and	O
clinical	O
ST108	O
isolates	O
)	O
analyses	O
suggest	O
an	O
agricultural	O
origin	O
for	O
the	O
ST108	B-bacteria
lineage	O
.	O

VRE	B-bacteria
isolate	I-bacteria
resistomes	O
were	O
carried	O
on	O
multiple	O
,	O
heterogeneous	O
plasmids	O
.	O

In	O
some	O
isolate	O
genomes	O
,	O
bacitracin	O
,	O
erythromycin	O
,	O
and	O
vancomycin	O
resistance	O
elements	O
were	O
co	O
-	O
localized	O
,	O
indicating	O
multiple	O
potentially	O
-	O
linked	O
selection	O
mechanisms	O
.	O
Importance	O
:	O
Historical	O
antimicrobial	O
use	O
in	O
NZ	O
agriculture	O
has	O
driven	O
the	O
evolution	O
of	O
ST108	B-bacteria
,	O
a	O
VRE	B-bacteria
lineage	O
carrying	O
a	O
range	O
of	O
clinically	O
-	O
relevant	O
antimicrobial	O
resistances	O
.	O

The	O
persistence	O
of	O
this	O
lineage	O
in	O
NZ	O
for	O
over	O
a	O
decade	O
indicates	O
that	O
co	O
-	O
selection	O
may	O
be	O
an	O
important	O
stabilizing	O
mechanism	O
for	O
its	O
persistence	O
.	O

Adaptive	O
Evolution	O
within	O
Gut	O
Microbiomes	O
of	O
Healthy	O
People	O
.	O

Natural	O
selection	O
shapes	O
bacterial	O
evolution	O
in	O
all	O
environments	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
commensal	O
bacteria	O
diversify	O
and	O
adapt	O
within	O
the	O
human	O
gut	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
combine	O
culture	O
-	O
based	O
population	O
genomics	O
and	O
metagenomics	O
to	O
investigate	O
the	O
within	O
-	O
microbiome	O
evolution	O
of	O
Bacteroides	B-bacteria
fragilis	I-bacteria
.	O

We	O
find	O
that	O
intra	O
-	O
individual	O
B	B-bacteria
.	I-bacteria
fragilis	I-bacteria
populations	O
contain	O
substantial	O
de	O
novo	O
nucleotide	O
and	O
mobile	O
element	O
diversity	O
,	O
preserving	O
years	O
of	O
within	O
-	O
person	O
history	O
.	O

This	O
history	O
reveals	O
multiple	O
signatures	O
of	O
within	O
-	O
person	O
adaptation	O
,	O
including	O
parallel	O
evolution	O
in	O
sixteen	O
genes	O
.	O

Many	O
of	O
these	O
genes	O
are	O
implicated	O
in	O
cell	O
-	O
envelope	O
biosynthesis	O
and	O
polysaccharide	O
utilization	O
.	O

Tracking	O
evolutionary	O
trajectories	O
using	O
near	O
-	O
daily	O
metagenomic	O
sampling	O
,	O
we	O
find	O
evidence	O
for	O
years	O
-	O
long	O
coexistence	O
in	O
one	O
subject	O
despite	O
adaptive	O
dynamics	O
.	O

We	O
used	O
public	O
metagenomes	O
to	O
investigate	O
one	O
adaptive	O
mutation	O
common	O
in	O
our	O
cohort	O
and	O
found	O
that	O
it	O
emerges	O
frequently	O
in	O
Western	O
,	O
but	O
not	O
Chinese	O
,	O
microbiomes	O
.	O

Collectively	O
,	O
these	O
results	O
demonstrate	O
that	O
B	B-bacteria
.	I-bacteria
fragilis	I-bacteria
adapts	O
within	O
individual	O
microbiomes	O
,	O
pointing	O
to	O
factors	O
that	O
promote	O
long	O
-	O
term	O
gut	O
colonization	O
.	O

Mechanical	O
Skin	O
Injury	O
Promotes	O
Food	O
Anaphylaxis	O
by	O
Driving	O
Intestinal	O
Mast	O
Cell	O
Expansion	O
.	O

Mast	O
cell	O
(	O
MC	O
)	O
mediator	O
release	O
after	O
crosslinking	O
of	O
surface	O
-	O
bound	O
IgE	O
antibody	O
by	O
ingested	O
antigen	O
underlies	O
food	O
allergy	O
.	O

However	O
,	O
IgE	O
antibodies	O
are	O
not	O
uniformly	O
associated	O
with	O
food	O
allergy	O
,	O
and	O
intestinal	O
MC	O
load	O
is	O
an	O
important	O
determinant	O
.	O

Atopic	O
dermatitis	O
(	O
AD	O
)	O
,	O
characterized	O
by	O
pruritis	O
and	O
cutaneous	O
sensitization	O
to	O
allergens	O
,	O
including	O
foods	O
,	O
is	O
strongly	O
associated	O
with	O
food	O
allergy	O
.	O

Tape	O
stripping	O
mouse	O
skin	O
,	O
a	O
surrogate	O
for	O
scratching	O
,	O
caused	O
expansion	O
and	O
activation	O
of	O
small	O
intestinal	O
MCs	O
,	O
increased	O
intestinal	O
permeability	O
,	O
and	O
promoted	O
food	O
anaphylaxis	O
in	O
sensitized	O
mice	O
.	O

Tape	O
stripping	O
caused	O
keratinocytes	O
to	O
systemically	O
release	O
interleukin	O
-	O
33	O
(	O
IL	O
-	O
33	O
)	O
,	O
which	O
synergized	O
with	O
intestinal	O
tuft	O
-	O
cell	O
-	O
derived	O
IL	O
-	O
25	O
to	O
drive	O
the	O
expansion	O
and	O
activation	O
of	O
intestinal	O
type	O
-	O
2	O
innate	O
lymphoid	O
cells	O
(	O
ILC2s	O
)	O
.	O

These	O
provided	O
IL	O
-	O
4	O
,	O
which	O
targeted	O
MCs	O
to	O
expand	O
in	O
the	O
intestine	O
.	O

Duodenal	O
MCs	O
were	O
expanded	O
in	O
AD	O
.	O

In	O
addition	O
to	O
promoting	O
cutaneous	O
sensitization	O
to	O
foods	O
,	O
scratching	O
may	O
promote	O
food	O
anaphylaxis	O
in	O
AD	O
by	O
expanding	O
and	O
activating	O
intestinal	O
MCs	O
.	O

Alterations	O
in	O
the	O
gut	O
microbiome	O
and	O
metabolism	O
with	O
coronary	O
artery	O
disease	O
severity	O
.	O

BACKGROUND	O
:	O
Coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
is	O
associated	O
with	O
gut	O
microbiota	O
alterations	O
in	O
different	O
populations	O
.	O

Gut	O
microbe	O
-	O
derived	O
metabolites	O
have	O
been	O
proposed	O
as	O
markers	O
of	O
major	O
adverse	O
cardiac	O
events	O
.	O

However	O
,	O
the	O
relationship	O
between	O
the	O
gut	O
microbiome	O
and	O
the	O
different	O
stages	O
of	O
CAD	O
pathophysiology	O
remains	O
to	O
be	O
established	O
by	O
a	O
systematic	O
study	O
.	O

RESULTS	O
:	O
Based	O
on	O
multi	O
-	O
omic	O
analyses	O
(	O
sequencing	O
of	O
the	O
V3	O
-	O
V4	O
regions	O
of	O
the	O
16S	O
rRNA	O
gene	O
and	O
metabolomics	O
)	O
of	O
161	O
CAD	O
patients	O
and	O
40	O
healthy	O
controls	O
,	O
we	O
found	O
that	O
the	O
composition	O
of	O
both	O
the	O
gut	O
microbiota	O
and	O
metabolites	O
changed	O
significantly	O
with	O
CAD	O
severity	O
.	O

We	O
identified	O
29	O
metabolite	O
modules	O
that	O
were	O
separately	O
classified	O
as	O
being	O
positively	O
or	O
negatively	O
correlated	O
with	O
CAD	O
phenotypes	O
,	O
and	O
the	O
bacterial	O
co	O
-	O
abundance	O
group	O
(	O
CAG	O
)	O
with	O
characteristic	O
changes	O
at	O
different	O
stages	O
of	O
CAD	O
was	O
represented	O
by	O
Roseburia	B-bacteria
,	O
Klebsiella	B-bacteria
,	O
Clostridium	B-bacteria
IV	I-bacteria
and	O
Ruminococcaceae	B-bacteria
.	O

The	O
result	O
revealed	O
that	O
certain	O
bacteria	O
might	O
affect	O
atherosclerosis	O
by	O
modulating	O
the	O
metabolic	O
pathways	O
of	O
the	O
host	O
,	O
such	O
as	O
taurine	O
,	O
sphingolipid	O
and	O
ceramide	O
,	O
and	O
benzene	O
metabolism	O
.	O

Moreover	O
,	O
a	O
disease	O
classifier	O
based	O
on	O
differential	O
levels	O
of	O
microbes	O
and	O
metabolites	O
was	O
constructed	O
to	O
discriminate	O
cases	O
from	O
controls	O
and	O
was	O
even	O
able	O
to	O
distinguish	O
stable	O
coronary	O
artery	O
disease	O
from	O
acute	O
coronary	O
syndrome	O
accurately	O
.	O

CONCLUSION	O
:	O
Overall	O
,	O
the	O
composition	O
and	O
functions	O
of	O
the	O
gut	O
microbial	O
community	O
differed	O
from	O
healthy	O
controls	O
to	O
diverse	O
coronary	O
artery	O
disease	O
subtypes	O
.	O

Our	O
study	O
identified	O
the	O
relationships	O
between	O
the	O
features	O
of	O
the	O
gut	O
microbiota	O
and	O
circulating	O
metabolites	O
,	O
providing	O
a	O
new	O
direction	O
for	O
future	O
studies	O
aiming	O
to	O
understand	O
the	O
host	O
-	O
gut	O
microbiota	O
interplay	O
in	O
atherosclerotic	O
pathogenesis	O
.	O

Xenobiotics	O
Formed	O
during	O
Food	O
Processing	O
:	O
Their	O
Relation	O
with	O
the	O
Intestinal	O
Microbiota	O
and	O
Colorectal	O
Cancer	O
.	O

The	O
colonic	O
epithelium	O
is	O
exposed	O
to	O
a	O
mixture	O
of	O
compounds	O
through	O
diet	O
,	O
among	O
which	O
some	O
are	O
procarcinogens	O
,	O
whereas	O
others	O
have	O
a	O
protective	O
effect	O
.	O

Therefore	O
,	O
the	O
net	O
impact	O
of	O
these	O
compounds	O
on	O
human	O
health	O
depends	O
on	O
the	O
overall	O
balance	O
between	O
all	O
factors	O
involved	O
.	O

Strong	O
scientific	O
evidence	O
has	O
demonstrated	O
the	O
relationship	O
between	O
nitrosamines	O
(	O
NA	O
)	O
,	O
heterocyclic	O
amines	O
(	O
HCAs	O
)	O
,	O
and	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
,	O
which	O
are	O
the	O
major	O
genotoxins	O
derived	O
from	O
cooking	O
and	O
food	O
processing	O
,	O
and	O
cancer	O
.	O

The	O
mechanisms	O
of	O
the	O
relationship	O
between	O
dietary	O
toxic	O
xenobiotics	O
and	O
cancer	O
risk	O
are	O
not	O
yet	O
well	O
understood	O
,	O
but	O
it	O
has	O
been	O
suggested	O
that	O
differences	O
in	O
dietary	O
habits	O
affect	O
the	O
colonic	O
environment	O
by	O
increasing	O
or	O
decreasing	O
the	O
exposure	O
to	O
mutagens	O
directly	O
and	O
indirectly	O
through	O
changes	O
in	O
the	O
composition	O
and	O
activity	O
of	O
the	O
gut	O
microbiota	O
.	O

Several	O
changes	O
in	O
the	O
proportions	O
of	O
specific	O
microbial	O
groups	O
have	O
been	O
proposed	O
as	O
risk	O
factors	O
for	O
the	O
development	O
of	O
neoplastic	O
lesions	O
and	O
the	O
enrichment	O
of	O
enterotoxigenic	O
microbial	O
strains	O
in	O
stool	O
.	O

In	O
addition	O
,	O
changes	O
in	O
the	O
gut	O
microbiota	O
composition	O
and	O
activity	O
promoted	O
by	O
diet	O
may	O
modify	O
the	O
faecal	O
genotoxicity	O
/	O
cytotoxicity	O
,	O
which	O
can	O
be	O
associated	O
with	O
a	O
higher	O
or	O
lower	O
risk	O
of	O
developing	O
cancer	O
.	O

Therefore	O
,	O
the	O
interaction	O
between	O
dietary	O
components	O
and	O
intestinal	O
bacteria	O
may	O
be	O
a	O
modifiable	O
factor	O
for	O
the	O
development	O
of	O
colorectal	O
cancer	O
in	O
humans	O
and	O
deserves	O
more	O
attention	O
in	O
the	O
near	O
future	O
.	O

Effect	O
of	O
probiotic	O
supplementation	O
on	O
seizure	O
activity	O
and	O
cognitive	O
performance	O
in	O
PTZ	O
-	O
induced	O
chemical	O
kindling	O
.	O

Epilepsy	O
is	O
one	O
of	O
the	O
most	O
common	O
neurological	O
disorders	O
that	O
severely	O
affect	O
life	O
quality	O
of	O
many	O
people	O
worldwide	O
.	O

Ion	O
transport	O
in	O
the	O
neuronal	O
membrane	O
,	O
inhibitory	O
-	O
excitatory	O
mechanisms	O
,	O
and	O
regulatory	O
modulator	O
systems	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
epilepsy	O
.	O

A	O
bidirectional	O
communication	O
is	O
proposed	O
between	O
brain	O
and	O
gut	O
where	O
the	O
brain	O
modulates	O
the	O
gastrointestinal	O
tract	O
,	O
and	O
the	O
gut	O
can	O
affect	O
brain	O
function	O
and	O
behavior	O
.	O

The	O
gut	O
microbiome	O
takes	O
an	O
important	O
role	O
in	O
health	O
and	O
disease	O
where	O
dysbiosis	O
is	O
involved	O
in	O
several	O
neurological	O
disorders	O
.	O

Probiotics	O
as	O
living	O
microorganisms	O
are	O
beneficial	O
to	O
humans	O
and	O
animals	O
when	O
adequately	O
administered	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
a	O
probiotic	O
bacteria	O
mixture	O
on	O
seizure	O
activity	O
,	O
cognitive	O
function	O
,	O
and	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
,	O
nitric	O
oxide	O
(	O
NO	O
)	O
,	O
malondealdehyde	O
(	O
MDA	O
)	O
,	O
and	O
total	O
antioxidant	O
capacity	O
(	O
TAC	O
)	O
level	O
of	O
the	O
brain	O
tissue	O
in	O
the	O
pentylenetetrazole	O
(	O
PTZ	O
)	O
-	O
induced	O
kindled	O
rats	O
.	O

The	O
Racine	O
score	O
and	O
performance	O
in	O
water	O
maze	O
were	O
considered	O
as	O
indices	O
of	O
the	O
epileptic	O
severity	O
and	O
the	O
spatial	O
learning	O
and	O
memory	O
,	O
respectively	O
.	O

We	O
found	O
that	O
the	O
probiotic	O
supplementation	O
substantially	O
reduces	O
seizure	O
severity	O
so	O
that	O
almost	O
no	O
probiotic	O
-	O
treated	O
animals	O
showed	O
full	O
kindling	O
.	O

The	O
oral	O
bacteriotherapy	O
partially	O
improved	O
the	O
spatial	O
learning	O
and	O
memory	O
in	O
the	O
kindled	O
rats	O
.	O

The	O
intervention	O
decreased	O
NO	O
and	O
MDA	O
and	O
increased	O
TAC	O
concentration	O
of	O
the	O
brain	O
.	O

The	O
probiotic	O
treatment	O
also	O
increased	O
the	O
inhibitory	O
neurotransmitter	O
GABA	O
.	O

Our	O
findings	O
are	O
the	O
first	O
preclinical	O
report	O
to	O
show	O
positive	O
effect	O
of	O
probiotic	O
bacteria	O
on	O
seizure	O
-	O
induced	O
neurological	O
disorders	O
.	O

Further	O
investigation	O
is	O
required	O
to	O
answer	O
the	O
questions	O
raised	O
about	O
the	O
probable	O
mechanisms	O
involved	O
.	O

Inulin	O
Can	O
Alleviate	O
Metabolism	O
Disorders	O
in	O
ob	O
/	O
ob	O
Mice	O
by	O
Partially	O
Restoring	O
Leptin	O
-	O
related	O
Pathways	O
Mediated	O
by	O
Gut	O
Microbiota	O
.	O

Inulin	O
has	O
been	O
used	O
as	O
a	O
prebiotic	O
to	O
alleviate	O
glucose	O
and	O
lipid	O
metabolism	O
disorders	O
in	O
mice	O
and	O
humans	O
by	O
modulating	O
the	O
gut	O
microbiota	O
.	O

However	O
,	O
the	O
mechanism	O
underlying	O
the	O
alleviation	O
of	O
metabolic	O
disorders	O
by	O
inulin	O
through	O
interactions	O
between	O
the	O
gut	O
microbiota	O
and	O
host	O
cells	O
is	O
unclear	O
.	O

We	O
use	O
ob	O
/	O
ob	O
mice	O
as	O
a	O
model	O
to	O
study	O
the	O
effect	O
of	O
inulin	O
on	O
the	O
cecal	O
microbiota	O
by	O
16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
and	O
its	O
interaction	O
with	O
host	O
cells	O
by	O
transcriptomics	O
.	O

The	O
inulin	O
-	O
supplemented	O
diet	O
improved	O
glucose	O
and	O
lipid	O
metabolism	O
disorder	O
parameters	O
in	O
ob	O
/	O
ob	O
mice	O
,	O
alleviating	O
fat	O
accumulation	O
and	O
glucose	O
intolerance	O
.	O

The	O
alpha	O
diversity	O
of	O
gut	O
microbial	O
community	O
of	O
ob	O
/	O
ob	O
mice	O
was	O
reduced	O
after	O
inulin	O
treatment	O
,	O
while	O
the	O
beta	O
diversity	O
tended	O
to	O
return	O
to	O
the	O
level	O
of	O
wild	O
type	O
mice	O
.	O

Interestingly	O
,	O
Prevotellaceae	B-bacteria
UCG	I-bacteria
001	I-bacteria
(	O
family	O
Prevotellaceae	B-bacteria
)	O
was	O
obviously	O
enriched	O
after	O
inulin	O
treatment	O
.	O

A	O
comparative	O
analysis	O
of	O
the	O
gene	O
expression	O
profile	O
showed	O
that	O
the	O
cecal	O
transcriptome	O
was	O
changed	O
in	O
leptin	O
gene	O
deficiency	O
mice	O
,	O
whereas	O
the	O
inulin	O
-	O
supplemented	O
diet	O
partially	O
reversed	O
the	O
changes	O
in	O
leptin	O
gene	O
-	O
related	O
signaling	O
pathways	O
,	O
especially	O
AMPK	O
signaling	O
pathway	O
,	O
where	O
the	O
levels	O
of	O
gene	O
expression	O
became	O
comparable	O
to	O
those	O
in	O
wild	O
type	O
mice	O
.	O

Further	O
analysis	O
indicated	O
that	O
Prevotellaceae	B-bacteria
UCG	I-bacteria
001	I-bacteria
was	O
positively	O
correlated	O
with	O
the	O
AMPK	O
signaling	O
pathway	O
,	O
which	O
was	O
negatively	O
correlated	O
with	O
markers	O
of	O
glycolipid	O
metabolism	O
disorders	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
inulin	O
-	O
supplemented	O
diet	O
alleviates	O
glucose	O
and	O
lipid	O
metabolism	O
disorders	O
by	O
partially	O
restoring	O
leptin	O
related	O
pathways	O
mediated	O
by	O
gut	O
microbiota	O
.	O

Antibiotic	O
Treatment	O
Drives	O
the	O
Diversification	O
of	O
the	O
Human	O
Gut	O
Resistome	O
.	O

Despite	O
the	O
documented	O
antibiotic	O
-	O
induced	O
disruption	O
of	O
the	O
gut	O
microbiota	O
,	O
the	O
impact	O
of	O
antibiotic	O
intake	O
on	O
strain	O
-	O
level	O
dynamics	O
,	O
evolution	O
of	O
resistance	O
genes	O
,	O
and	O
factors	O
influencing	O
resistance	O
dissemination	O
potential	O
remains	O
poorly	O
understood	O
.	O

To	O
address	O
this	O
gap	O
we	O
analyzed	O
public	O
metagenomic	O
datasets	O
from	O
24	O
antibiotic	O
treated	O
subjects	O
and	O
controls	O
,	O
combined	O
with	O
an	O
in	O
-	O
depth	O
prospective	O
functional	O
study	O
with	O
two	O
subjects	O
investigating	O
the	O
bacterial	O
community	O
dynamics	O
based	O
on	O
cultivation	O
-	O
dependent	O
and	O
independent	O
methods	O
.	O

We	O
observed	O
that	O
short	O
-	O
term	O
antibiotic	O
treatment	O
shifted	O
and	O
diversified	O
the	O
resistome	O
composition	O
,	O
increased	O
the	O
average	O
copy	O
number	O
of	O
antibiotic	O
resistance	O
genes	O
,	O
and	O
altered	O
the	O
dominant	O
strain	O
genotypes	O
in	O
an	O
individual	O
-	O
specific	O
manner	O
.	O

More	O
than	O
30	O
%	O
of	O
the	O
resistance	O
genes	O
underwent	O
strong	O
differentiation	O
at	O
the	O
single	O
nucleotide	O
level	O
during	O
antibiotic	O
treatment	O
.	O

We	O
found	O
that	O
the	O
increased	O
potential	O
for	O
horizontal	O
gene	O
transfer	O
,	O
due	O
to	O
antibiotic	O
administration	O
,	O
was	O
approximately	O
3	O
-	O
fold	O
stronger	O
in	O
the	O
differentiated	O
resistance	O
genes	O
than	O
the	O
non	O
-	O
differentiated	O
ones	O
.	O

This	O
study	O
highlights	O
how	O
antibiotic	O
treatment	O
has	O
individualized	O
impacts	O
on	O
the	O
resistome	O
and	O
strain	O
level	O
composition	O
,	O
and	O
drives	O
the	O
adaptive	O
evolution	O
of	O
the	O
gut	O
microbiota	O
.	O

The	O
diversity	O
of	O
gut	O
microbiome	O
is	O
associated	O
with	O
favorable	O
responses	O
to	O
anti	O
-	O
PD	O
-	O
1	O
immunotherapy	O
in	O
Chinese	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
patients	O
.	O

PURPOSE	O
:	O
Gut	O
microbiome	O
affecting	O
the	O
responses	O
to	O
immune	O
checkpoint	O
inhibitors	O
(	O
ICIs	O
)	O
against	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
has	O
been	O
investigated	O
in	O
western	O
population	O
.	O

However	O
,	O
considering	O
preexisting	O
genetic	O
and	O
gut	O
microbiota	O
variation	O
,	O
the	O
relevance	O
remains	O
unknown	O
in	O
east	O
-	O
Asian	O
NSCLC	O
population	O
.	O

The	O
study	O
is	O
designed	O
to	O
explore	O
the	O
relationship	O
between	O
gut	O
microbiome	O
and	O
clinical	O
outcomes	O
in	O
Chinese	O
NSCLC	O
patients	O
treated	O
with	O
an	O
anti	O
-	O
PD	O
-	O
1	O
blockade	O
.	O

METHODS	O
:	O
37	O
advanced	O
NSCLC	O
patients	O
receiving	O
the	O
treatment	O
of	O
nivolumab	O
were	O
enrolled	O
in	O
the	O
study	O
from	O
the	O
clinical	O
trials	O
CheckMate	O
078	O
(	O
NCT02613507	O
)	O
and	O
CheckMate	O
870	O
(	O
NCT03195491	O
)	O
.	O

Fecal	O
samples	O
were	O
collected	O
at	O
the	O
starting	O
point	O
,	O
every	O
time	O
point	O
receiving	O
nivolumab	O
as	O
well	O
as	O
clinical	O
evaluation	O
and	O
that	O
with	O
disease	O
progression	O
.	O

16S	O
ribosome	O
RNA	O
gene	O
sequencing	O
was	O
applied	O
to	O
assess	O
gut	O
microbiota	O
profiles	O
.	O

Peripheral	O
immune	O
signatures	O
were	O
determined	O
by	O
multi	O
-	O
color	O
flow	O
cytometry	O
in	O
parallel	O
.	O

RESULTS	O
:	O
When	O
subgrouping	O
patients	O
into	O
responder	O
(	O
R	O
)	O
and	O
non	O
-	O
responder	O
(	O
NR	O
)	O
according	O
to	O
the	O
clinical	O
response	O
assessed	O
by	O
RECIST1	O
.	O
1	O
,	O
R	O
patients	O
harbored	O
higher	O
diversity	O
of	O
gut	O
microbiome	O
at	O
the	O
starting	O
point	O
with	O
stable	O
composition	O
during	O
the	O
treatment	O
.	O

Patients	O
with	O
high	O
microbiome	O
diversity	O
had	O
significantly	O
prolonged	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
when	O
compared	O
to	O
those	O
with	O
low	O
diversity	O
.	O

Compositional	O
difference	O
was	O
observed	O
between	O
two	O
groups	O
as	O
well	O
with	O
the	O
enrichment	O
of	O
Alistipes	B-bacteria
putredinis	I-bacteria
,	O
Bifidobacterium	B-bacteria
longum	I-bacteria
,	O
Prevotella	B-bacteria
copri	I-bacteria
in	O
R	O
whereas	O
Ruminococcus	B-bacteria
_	O
unclassified	O
in	O
NR	O
.	O

Analysis	O
of	O
systemic	O
immune	O
responses	O
using	O
multi	O
-	O
color	O
flow	O
cytometry	O
revealed	O
that	O
patients	O
with	O
high	O
abundance	O
of	O
microbiome	O
diversity	O
in	O
the	O
gut	O
had	O
more	O
frequencies	O
of	O
unique	O
memory	O
CD8	O
(	O
+	O
)	O
T	O
cell	O
and	O
NK	O
cell	O
subsets	O
in	O
the	O
periphery	O
in	O
response	O
to	O
anti	O
-	O
PD	O
-	O
1	O
therapy	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
reveal	O
strong	O
correlation	O
between	O
gut	O
microbiome	O
diversity	O
and	O
the	O
responses	O
to	O
anti	O
-	O
PD	O
-	O
1	O
immunotherapy	O
in	O
Chinese	O
advanced	O
NSCLC	O
patients	O
.	O

Patients	O
with	O
favorable	O
gut	O
microbiome	O
(	O
such	O
as	O
high	O
diversity	O
)	O
exhibit	O
enhanced	O
memory	O
T	O
cell	O
and	O
NK	O
cell	O
signatures	O
in	O
the	O
periphery	O
.	O

These	O
findings	O
provide	O
important	O
implications	O
for	O
the	O
prediction	O
and	O
the	O
evaluation	O
of	O
anti	O
-	O
PD	O
-	O
1	O
immunotherapy	O
against	O
NSCLC	O
in	O
Chinese	O
population	O
.	O

The	O
bumble	O
bee	O
microbiome	O
increases	O
survival	O
of	O
bees	O
exposed	O
to	O
selenate	O
toxicity	O
.	O

Bumble	O
bees	O
are	O
important	O
and	O
widespread	O
insect	O
pollinators	O
who	O
face	O
many	O
environmental	O
challenges	O
.	O

For	O
example	O
,	O
bees	O
are	O
exposed	O
to	O
the	O
metalloid	O
selenate	O
when	O
foraging	O
on	O
pollen	O
and	O
nectar	O
from	O
plants	O
growing	O
in	O
contaminated	O
soils	O
.	O

As	O
it	O
has	O
been	O
shown	O
that	O
the	O
microbiome	O
of	O
animals	O
reduces	O
metalloid	O
toxicity	O
,	O
we	O
assayed	O
the	O
ability	O
of	O
the	O
bee	O
microbiome	O
to	O
increase	O
survivorship	O
against	O
selenate	O
challenge	O
.	O

We	O
exposed	O
uninoculated	O
or	O
microbiota	O
-	O
inoculated	O
Bombus	O
impatiens	O
workers	O
to	O
a	O
field	O
-	O
realistic	O
dose	O
of	O
0	O
.	O
75	O
mg	O
/	O
L	O
selenate	O
and	O
found	O
that	O
microbiota	O
-	O
inoculated	O
bees	O
survive	O
slightly	O
,	O
but	O
significantly	O
longer	O
than	O
uninoculated	O
bees	O
.	O

Using	O
16S	O
rRNA	O
gene	O
sequencing	O
,	O
we	O
found	O
that	O
selenate	O
exposure	O
altered	O
gut	O
microbial	O
community	O
composition	O
and	O
relative	O
abundance	O
of	O
specific	O
core	O
bacteria	O
.	O

We	O
also	O
grew	O
two	O
core	O
bumble	O
bee	O
microbes	O
-	O
Snodgrassella	B-bacteria
alvi	I-bacteria
and	O
Lactobacillus	B-bacteria
bombicola	I-bacteria
-	O
in	O
selenate	O
-	O
spiked	O
media	O
and	O
found	O
that	O
these	O
bacteria	O
grew	O
in	O
the	O
tested	O
concentrations	O
of	O
0	O
.	O
001	O
mg	O
/	O
L	O
to	O
10	O
mg	O
/	O
L	O
selenate	O
.	O

Furthermore	O
,	O
the	O
genomes	O
of	O
these	O
microbes	O
harbor	O
genes	O
involved	O
in	O
selenate	O
detoxification	O
.	O

The	O
bumble	O
bee	O
microbiome	O
slightly	O
increases	O
survivorship	O
when	O
the	O
host	O
is	O
exposed	O
to	O
selenate	O
,	O
but	O
the	O
specific	O
mechanisms	O
and	O
colony	O
-	O
level	O
benefits	O
under	O
natural	O
settings	O
require	O
further	O
study	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Supplementation	O
with	O
compound	O
polysaccharides	O
contributes	O
to	O
the	O
development	O
and	O
metabolic	O
activity	O
of	O
young	O
rat	O
intestinal	O
microbiota	O
.	O

Dietary	O
intervention	O
during	O
early	O
life	O
has	O
a	O
significant	O
impact	O
on	O
colonization	O
of	O
the	O
gut	O
microbiota	O
.	O

In	O
addition	O
,	O
some	O
polysaccharides	O
have	O
the	O
potential	O
to	O
selectively	O
stimulate	O
the	O
growth	O
and	O
metabolic	O
activity	O
of	O
intestinal	O
bacteria	O
associated	O
with	O
health	O
and	O
well	O
-	O
being	O
.	O

However	O
,	O
less	O
is	O
known	O
about	O
the	O
effect	O
of	O
polysaccharides	O
on	O
the	O
development	O
of	O
gut	O
microbiota	O
in	O
younger	O
individuals	O
.	O

This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
health	O
effects	O
of	O
supplementation	O
with	O
dietary	O
compound	O
polysaccharides	O
(	O
Lycium	O
barbarum	O
polysaccharides	O
(	O
LBP	O
)	O
,	O
Poria	O
cocos	O
polysaccharides	O
(	O
PCPs	O
)	O
and	O
Lentinan	O
,	O
1	O
:	O
1	O
:	O
1	O
)	O
on	O
the	O
intestinal	O
microecosystem	O
and	O
metabolism	O
of	O
young	O
rats	O
.	O

Male	O
21	O
-	O
day	O
-	O
old	O
Sprague	O
-	O
Dawley	O
rats	O
received	O
daily	O
intragastric	O
administration	O
of	O
either	O
compound	O
polysaccharides	O
(	O
three	O
dosages	O
,	O
6	O
g	O
kg	O
-	O
1	O
,	O
12	O
g	O
kg	O
-	O
1	O
or	O
24	O
g	O
kg	O
-	O
1	O
)	O
or	O
saline	O
for	O
28	O
consecutive	O
days	O
.	O

1H	O
-	O
NMR	O
spectroscopy	O
integrated	O
with	O
multi	O
-	O
variate	O
pattern	O
recognition	O
analysis	O
was	O
applied	O
to	O
reveal	O
the	O
metabolism	O
of	O
the	O
host	O
and	O
microflora	O
,	O
while	O
16S	O
rRNA	O
gene	O
sequencing	O
was	O
used	O
to	O
monitor	O
the	O
dynamic	O
changes	O
in	O
the	O
gut	O
microbiota	O
.	O

The	O
relative	O
concentrations	O
of	O
35	O
urinary	O
metabolites	O
and	O
24	O
faecal	O
metabolites	O
were	O
significantly	O
changed	O
compared	O
with	O
the	O
control	O
group	O
.	O

16S	O
rRNA	O
analysis	O
showed	O
that	O
the	O
relative	O
abundances	O
of	O
4	O
bacterial	O
genera	O
(	O
Bifidobacterium	B-bacteria
,	O
Lactobacillus	B-bacteria
,	O
Allobaculum	B-bacteria
and	O
Oligella	B-bacteria
)	O
significantly	O
increased	O
,	O
whereas	O
the	O
relative	O
abundance	O
of	O
1	O
bacterial	O
genus	O
(	O
Enterococcus	B-bacteria
)	O
significantly	O
declined	O
in	O
the	O
compound	O
polysaccharide	O
-	O
treated	O
groups	O
compared	O
with	O
the	O
control	O
group	O
.	O

Meanwhile	O
,	O
dietary	O
compound	O
polysaccharide	O
treatment	O
promoted	O
the	O
functional	O
maturation	O
of	O
the	O
gut	O
bacterial	O
community	O
,	O
characterised	O
by	O
increased	O
basic	O
metabolism	O
(	O
amino	O
acid	O
metabolism	O
and	O
energy	O
metabolism	O
)	O
,	O
short	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
-	O
related	O
metabolism	O
and	O
nucleotide	O
metabolism	O
.	O

These	O
findings	O
suggest	O
that	O
compound	O
polysaccharides	O
may	O
help	O
to	O
promote	O
the	O
colonisation	O
and	O
functional	O
maturation	O
of	O
infant	O
intestinal	O
microbiota	O
and	O
maintain	O
the	O
health	O
of	O
the	O
intestinal	O
microecosystem	O
.	O

Gut	O
microbiome	O
composition	O
of	O
wild	O
western	O
lowland	O
gorillas	O
is	O
associated	O
with	O
individual	O
age	O
and	O
sex	O
factors	O
.	O

OBJECTIVES	O
:	O
Environmental	O
and	O
ecological	O
factors	O
,	O
such	O
as	O
geographic	O
range	O
,	O
anthropogenic	O
pressure	O
,	O
group	O
identity	O
,	O
and	O
feeding	O
behavior	O
are	O
known	O
to	O
influence	O
the	O
gastrointestinal	O
microbiomes	O
of	O
great	O
apes	O
.	O

However	O
,	O
the	O
influence	O
of	O
individual	O
host	O
traits	O
such	O
as	O
age	O
and	O
sex	O
,	O
given	O
specific	O
dietary	O
and	O
social	O
constraints	O
,	O
has	O
been	O
less	O
studied	O
.	O

The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
the	O
associations	O
between	O
an	O
individual	O
'	O
s	O
age	O
and	O
sex	O
on	O
the	O
diversity	O
and	O
composition	O
of	O
the	O
gut	O
microbiome	O
in	O
wild	O
western	O
lowland	O
gorillas	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Publicly	O
available	O
16S	O
rRNA	O
data	O
generated	O
from	O
fecal	O
samples	O
of	O
different	O
groups	O
of	O
Gorilla	O
gorilla	O
gorilla	O
in	O
the	O
Central	O
African	O
Republic	O
were	O
downloaded	O
and	O
bioinformatically	O
processed	O
.	O

The	O
groups	O
analyzed	O
included	O
habituated	O
,	O
partially	O
habituated	O
and	O
unhabituated	O
gorillas	O
,	O
sampled	O
during	O
low	O
fruit	O
(	O
dry	O
,	O
n	O
=	O
28	O
)	O
and	O
high	O
fruit	O
(	O
wet	O
,	O
n	O
=	O
82	O
)	O
seasons	O
.	O

Microbial	O
community	O
analyses	O
(	O
alpha	O
and	O
beta	O
diversity	O
and	O
analyses	O
of	O
discriminant	O
taxa	O
)	O
,	O
in	O
tandem	O
with	O
network	O
-	O
wide	O
approaches	O
,	O
were	O
used	O
to	O
(	O
a	O
)	O
mine	O
for	O
specific	O
age	O
and	O
sex	O
based	O
differences	O
in	O
gut	O
bacterial	O
community	O
composition	O
and	O
to	O
(	O
b	O
)	O
asses	O
for	O
gut	O
community	O
modularity	O
and	O
bacterial	O
taxa	O
with	O
potential	O
functional	O
roles	O
,	O
in	O
the	O
context	O
of	O
seasonal	O
food	O
variation	O
,	O
and	O
social	O
group	O
affiliation	O
.	O

RESULTS	O
:	O
Both	O
age	O
and	O
sex	O
significantly	O
influenced	O
gut	O
microbiome	O
diversity	O
and	O
composition	O
in	O
wild	O
western	O
lowland	O
gorillas	O
.	O

However	O
,	O
the	O
largest	O
differences	O
were	O
observed	O
between	O
infants	O
and	O
adults	O
in	O
habituated	O
groups	O
and	O
between	O
adults	O
and	O
immature	O
gorillas	O
within	O
all	O
groups	O
,	O
and	O
across	O
dry	O
and	O
wet	O
seasons	O
.	O

Specifically	O
,	O
although	O
adults	O
always	O
showed	O
greater	O
bacterial	O
richness	O
than	O
infants	O
and	O
immature	O
gorillas	O
,	O
network	O
-	O
wide	O
analyses	O
showed	O
higher	O
microbial	O
community	O
complexity	O
and	O
modularity	O
in	O
the	O
infant	O
gorilla	O
gut	O
.	O

Sex	O
-	O
based	O
microbiome	O
differences	O
were	O
not	O
evident	O
among	O
adults	O
,	O
being	O
only	O
detected	O
among	O
immature	O
gorillas	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
presented	O
point	O
to	O
a	O
dynamic	O
gut	O
microbiome	O
in	O
Gorilla	O
spp	I-bacteria
.	I-bacteria
,	O
associated	O
with	O
ontogeny	O
and	O
individual	O
development	O
.	O

Of	O
note	O
,	O
the	O
gut	O
microbiomes	O
of	O
breastfeeding	O
infants	O
seemed	O
to	O
reflect	O
early	O
exposure	O
to	O
complex	O
,	O
herbaceous	O
vegetation	O
.	O

Whether	O
increased	O
compositional	O
complexity	O
of	O
the	O
infant	O
gorilla	O
gut	O
microbiome	O
is	O
an	O
adaptive	O
response	O
to	O
an	O
energy	O
-	O
limited	O
diet	O
and	O
an	O
underdeveloped	O
gut	O
needs	O
to	O
be	O
further	O
tested	O
.	O

Overall	O
,	O
age	O
and	O
sex	O
based	O
gut	O
microbiome	O
differences	O
,	O
as	O
shown	O
here	O
,	O
maybe	O
mainly	O
attributed	O
to	O
access	O
to	O
specific	O
feeding	O
sources	O
,	O
and	O
social	O
interactions	O
between	O
individuals	O
within	O
groups	O
.	O

Gut	O
Microbiota	O
as	O
a	O
Positive	O
Potential	O
Therapeutic	O
Factor	O
in	O
Carcinogenesis	O
:	O
an	O
Overview	O
of	O
Microbiota	O
-	O
Targeted	O
Therapy	O
.	O

Cancer	O
therapeutic	O
methods	O
comprising	O
chemotherapy	O
,	O
radiotherapy	O
,	O
and	O
surgery	O
are	O
so	O
routine	O
in	O
cancer	O
treatment	O
.	O

Remarkably	O
,	O
there	O
are	O
several	O
personal	O
features	O
which	O
affect	O
the	O
effectiveness	O
of	O
such	O
treatments	O
including	O
nutrition	O
,	O
microbiome	O
diversity	O
,	O
and	O
physical	O
activity	O
which	O
has	O
distinct	O
significant	O
roles	O
during	O
and	O
after	O
therapies	O
along	O
with	O
their	O
bilateral	O
connections	O
.	O

In	O
this	O
way	O
,	O
the	O
ability	O
of	O
gut	O
microbiota36	O
in	O
modulating	O
the	O
efficacy	O
of	O
chemotherapeutic	O
medications	O
in	O
cancer	O
and	O
other	O
types	O
of	O
disorders	O
is	O
of	O
great	O
importance	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
dietary	O
,	O
probiotic	O
,	O
and	O
synthetically	O
engineered	O
bacteria	O
in	O
manipulating	O
and	O
optimizing	O
the	O
gut	O
microbiota	O
is	O
of	O
interest	O
.	O

Conspicuously	O
,	O
the	O
correlation	O
between	O
the	O
commensal	O
microbiota	O
and	O
also	O
host	O
can	O
regulate	O
the	O
physiological	O
activities	O
comprising	O
the	O
immunity	O
system	O
and	O
inflammatory	O
agents	O
and	O
it	O
is	O
scanned	O
in	O
the	O
category	O
of	O
cancers	O
.	O

Bacterial	O
species	O
have	O
been	O
employed	O
in	O
cancer	O
therapy	O
;	O
commensal	O
microbes	O
posse	O
a	O
key	O
beneficial	O
role	O
in	O
this	O
field	O
.	O

Practically	O
,	O
the	O
microbiota	O
has	O
this	O
potential	O
to	O
accelerate	O
and	O
modulates	O
a	O
certain	O
response	O
by	O
priming	O
in	O
order	O
to	O
release	O
the	O
pro	O
-	O
inflammatory	O
agents	O
.	O

We	O
would	O
like	O
to	O
discuss	O
these	O
vital	O
factors	O
in	O
this	O
review	O
as	O
gut	O
microbiota	O
has	O
the	O
potential	O
to	O
be	O
the	O
main	O
option	O
for	O
personalized	O
cancer	O
treatment	O
strategies	O
in	O
the	O
future	O
.	O

Meaning	O
,	O
this	O
novel	O
data	O
present	O
clinical	O
promising	O
feasibilities	O
of	O
modulating	O
cancer	O
therapy	O
with	O
using	O
microbiota	O
.	O

Human	O
gut	O
microbiota	O
transferred	O
to	O
germ	O
-	O
free	O
NOD	O
mice	O
modulate	O
the	O
progression	O
towards	O
type	O
1	O
diabetes	O
regardless	O
of	O
the	O
pace	O
of	O
beta	O
cell	O
function	O
loss	O
in	O
the	O
donor	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
This	O
study	O
aimed	O
to	O
assess	O
the	O
ability	O
of	O
human	O
gut	O
microbiota	O
to	O
delay	O
the	O
onset	O
of	O
type	O
1	O
diabetes	O
when	O
transferred	O
into	O
germ	O
-	O
free	O
NOD	O
mice	O
.	O

METHODS	O
:	O
Two	O
children	O
with	O
rapid	O
and	O
three	O
children	O
with	O
slow	O
beta	O
cell	O
function	O
loss	O
(	O
as	O
assessed	O
by	O
C	O
-	O
peptide	O
AUC	O
change	O
in	O
the	O
mixed	O
-	O
meal	O
tolerance	O
tests	O
performed	O
1	O
and	O
12	O
months	O
after	O
type	O
1	O
diabetes	O
onset	O
)	O
,	O
participating	O
in	O
an	O
ongoing	O
trial	O
with	O
gluten	O
-	O
free	O
diet	O
,	O
donated	O
faeces	O
,	O
which	O
were	O
transferred	O
into	O
germ	O
-	O
free	O
NOD	O
mice	O
.	O

The	O
mice	O
were	O
subsequently	O
followed	O
for	O
diabetes	O
incidence	O
.	O

RESULTS	O
:	O
The	O
bacterial	O
profiles	O
of	O
bacteriome	O
-	O
humanised	O
mice	O
had	O
significantly	O
(	O
p	O
<	O
10	O
(	O
-	O
5	O
)	O
)	O
lower	O
alpha	O
diversity	O
than	O
the	O
donor	O
material	O
,	O
with	O
marked	O
shifts	O
in	O
ratios	O
between	O
the	O
main	O
phyla	O
.	O

Diabetes	O
onset	O
was	O
significantly	O
delayed	O
in	O
all	O
bacteriome	O
-	O
humanised	O
colonies	O
vs	O
germ	O
-	O
free	O
NOD	O
mice	O
,	O
but	O
the	O
pace	O
of	O
beta	O
cell	O
loss	O
was	O
not	O
transferable	O
to	O
the	O
mouse	O
model	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
Germ	O
-	O
free	O
NOD	O
mice	O
colonised	O
with	O
human	O
gut	O
microbiome	O
are	O
able	O
to	O
adopt	O
a	O
large	O
proportion	O
of	O
transferred	O
bacterial	O
content	O
,	O
although	O
the	O
ratios	O
of	O
main	O
phyla	O
are	O
reproduced	O
only	O
suboptimally	O
.	O

The	O
recipient	O
mice	O
did	O
not	O
replicate	O
the	O
phenotype	O
of	O
the	O
stool	O
donor	O
in	O
relation	O
to	O
the	O
pace	O
towards	O
type	O
1	O
diabetes	O
.	O

TRIAL	O
REGISTRATION	O
:	O
ClinicalTrials	O
.	O
gov	O
NCT02867436	O
.	O

Host	O
-	O
and	O
Microbe	O
-	O
Dependent	O
Dietary	O
Lipid	O
Metabolism	O
in	O
the	O
Control	O
of	O
Allergy	O
,	O
Inflammation	O
,	O
and	O
Immunity	O
.	O

The	O
intestine	O
is	O
the	O
largest	O
immune	O
organ	O
in	O
the	O
body	O
,	O
provides	O
the	O
first	O
line	O
of	O
defense	O
against	O
pathogens	O
,	O
and	O
prevents	O
excessive	O
immune	O
reactions	O
to	O
harmless	O
or	O
beneficial	O
non	O
-	O
self	O
-	O
materials	O
,	O
such	O
as	O
food	O
and	O
intestinal	O
bacteria	O
.	O

Allergic	O
and	O
inflammatory	O
diseases	O
in	O
the	O
intestine	O
occur	O
as	O
a	O
result	O
of	O
dysregulation	O
of	O
immunological	O
homeostasis	O
mediated	O
by	O
intestinal	O
immunity	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
that	O
gut	O
environmental	O
factors	O
,	O
including	O
nutrition	O
and	O
intestinal	O
bacteria	O
,	O
play	O
important	O
roles	O
in	O
controlling	O
host	O
immune	O
responses	O
and	O
maintaining	O
homeostasis	O
.	O

Among	O
nutritional	O
factors	O
,	O
omega3	O
and	O
omega6	O
essential	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFAs	O
)	O
profoundly	O
influence	O
the	O
host	O
immune	O
system	O
.	O

Recent	O
advances	O
in	O
lipidomics	O
technology	O
have	O
led	O
to	O
the	O
identification	O
of	O
lipid	O
mediators	O
derived	O
from	O
omega3	O
-	O
and	O
omega6	O
-	O
PUFAs	O
.	O

In	O
particular	O
,	O
lipid	O
metabolites	O
from	O
omega3	O
-	O
PUFAs	O
(	O
e	O
.	O
g	O
.	O
,	O
eicosapentaenoic	O
acid	O
and	O
docosahexaenoic	O
acid	O
)	O
have	O
recently	O
been	O
shown	O
to	O
exert	O
anti	O
-	O
allergic	O
and	O
anti	O
-	O
inflammatory	O
responses	O
;	O
these	O
metabolites	O
include	O
resolvins	O
,	O
protectins	O
,	O
and	O
maresins	O
.	O

Furthermore	O
,	O
a	O
new	O
class	O
of	O
anti	O
-	O
allergic	O
and	O
anti	O
-	O
inflammatory	O
lipid	O
metabolites	O
of	O
17	O
,	O
18	O
-	O
epoxyeicosatetraenoic	O
acid	O
has	O
recently	O
been	O
identified	O
in	O
the	O
control	O
of	O
allergic	O
and	O
inflammatory	O
diseases	O
in	O
the	O
gut	O
and	O
skin	O
.	O

Although	O
these	O
lipid	O
metabolites	O
were	O
found	O
to	O
be	O
endogenously	O
generated	O
in	O
the	O
host	O
,	O
accumulating	O
evidence	O
indicates	O
that	O
intestinal	O
bacteria	O
also	O
participate	O
in	O
lipid	O
metabolism	O
and	O
thus	O
generate	O
bioactive	O
unique	O
lipid	O
mediators	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
production	O
machinery	O
of	O
lipid	O
metabolites	O
in	O
the	O
host	O
and	O
intestinal	O
bacteria	O
and	O
the	O
roles	O
of	O
these	O
metabolites	O
in	O
the	O
regulation	O
of	O
host	O
immunity	O
.	O

Group	O
3	O
ILCs	O
:	O
Peacekeepers	O
or	O
Troublemakers	O
?	O
What	O
'	O
s	O
Your	O
Gut	O
Telling	O
You	O
?	O
!	O

A	O
complex	O
network	O
of	O
interactions	O
exists	O
between	O
the	O
microbiome	O
,	O
the	O
epithelium	O
,	O
and	O
immune	O
cells	O
that	O
reside	O
along	O
the	O
walls	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

The	O
intestinal	O
immune	O
system	O
has	O
been	O
assigned	O
with	O
the	O
difficult	O
task	O
of	O
discriminating	O
between	O
commensal	O
,	O
harmless	O
bacteria	O
,	O
and	O
invading	O
pathogens	O
that	O
translocate	O
across	O
the	O
epithelial	O
monolayer	O
.	O

Importantly	O
,	O
it	O
is	O
trained	O
to	O
maintain	O
tolerance	O
against	O
commensals	O
,	O
and	O
initiate	O
protective	O
immune	O
responses	O
against	O
pathogens	O
to	O
secure	O
intestinal	O
homeostasis	O
.	O

Breakdown	O
of	O
this	O
fine	O
balance	O
between	O
the	O
host	O
and	O
its	O
intestinal	O
microbiota	O
can	O
lead	O
to	O
intestinal	O
inflammation	O
and	O
subsequently	O
to	O
development	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

A	O
decade	O
since	O
their	O
discovery	O
,	O
innate	O
lymphoid	O
cells	O
(	O
ILCs	O
)	O
are	O
now	O
recognized	O
as	O
important	O
regulators	O
of	O
intestinal	O
homeostasis	O
.	O

ILC3s	O
have	O
emerged	O
as	O
a	O
critical	O
subset	O
in	O
the	O
gut	O
.	O

They	O
are	O
the	O
most	O
phenotypically	O
diverse	O
ILC	O
population	O
and	O
interact	O
directly	O
with	O
numerous	O
different	O
cell	O
types	O
(	O
haematopoietic	O
and	O
non	O
-	O
haematopoeitic	O
)	O
,	O
as	O
well	O
as	O
interface	O
with	O
the	O
bacterial	O
flora	O
.	O

In	O
addition	O
to	O
their	O
contribution	O
to	O
intestinal	O
pathogen	O
immunity	O
,	O
they	O
also	O
mitigate	O
against	O
tissue	O
damage	O
occurring	O
following	O
acute	O
injury	O
,	O
by	O
facilitating	O
tissue	O
repair	O
and	O
regeneration	O
,	O
a	O
key	O
function	O
in	O
the	O
maintenance	O
of	O
intestinal	O
homeostasis	O
.	O

However	O
,	O
in	O
chronic	O
inflammation	O
the	O
tables	O
are	O
turned	O
and	O
ILC3s	O
may	O
acquire	O
a	O
pro	O
-	O
inflammatory	O
phenotype	O
in	O
the	O
gut	O
.	O

Chronic	O
ILC	O
activation	O
can	O
lead	O
to	O
persistent	O
inflammation	O
contributing	O
to	O
IBD	O
and	O
/	O
or	O
colorectal	O
cancer	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
current	O
knowledge	O
of	O
group	O
3	O
ILCs	O
and	O
their	O
contributions	O
to	O
intestinal	O
homeostasis	O
and	O
disease	O
leading	O
to	O
novel	O
therapeutic	O
targets	O
and	O
clinical	O
approaches	O
that	O
may	O
inform	O
novel	O
treatment	O
strategies	O
for	O
immune	O
-	O
mediated	O
disorders	O
,	O
including	O
IBD	O
.	O

Plasmacytoid	O
Dendritic	O
Cells	O
Provide	O
Protection	O
Against	O
Bacterial	O
-	O
Induced	O
Colitis	O
.	O

We	O
have	O
examined	O
the	O
influence	O
of	O
depleting	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	O
)	O
in	O
mice	O
on	O
the	O
immune	O
response	O
to	O
the	O
gut	O
pathogen	O
Citrobacter	B-bacteria
rodentium	I-bacteria
,	O
an	O
organism	O
that	O
is	O
a	O
model	O
for	O
human	O
attaching	O
effacing	O
pathogens	O
such	O
as	O
enterohaemorraghic	B-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
.	O

A	O
significantly	O
higher	O
number	O
of	O
C	B-bacteria
.	I-bacteria
rodentium	I-bacteria
were	O
found	O
in	O
mice	O
depleted	O
of	O
pDC	O
from	O
7	O
days	O
after	O
infection	O
and	O
pDC	O
depleted	O
mice	O
showed	O
increased	O
gut	O
pathology	O
and	O
higher	O
levels	O
of	O
mRNA	O
encoding	O
inflammatory	O
cytokines	O
in	O
the	O
colon	O
upon	O
infection	O
.	O

pDC	O
-	O
depletion	O
led	O
to	O
a	O
compromising	O
of	O
the	O
gut	O
mucosal	O
barrier	O
that	O
may	O
have	O
contributed	O
to	O
increased	O
numbers	O
of	O
C	B-bacteria
.	I-bacteria
rodentium	I-bacteria
in	O
systemic	O
organs	O
.	O

pDC	O
-	O
depleted	O
mice	O
infected	O
with	O
C	B-bacteria
.	I-bacteria
rodentium	I-bacteria
suffered	O
substantial	O
weight	O
loss	O
necessitating	O
euthanasia	O
.	O

A	O
number	O
of	O
observations	O
suggested	O
that	O
this	O
was	O
not	O
simply	O
the	O
result	O
of	O
dysregulation	O
of	O
immunity	O
in	O
the	O
colon	O
as	O
pDC	O
-	O
depleted	O
mice	O
infected	O
intravenously	O
with	O
C	B-bacteria
.	I-bacteria
rodentium	I-bacteria
also	O
exhibited	O
exacerbated	O
weight	O
loss	O
,	O
arguing	O
that	O
pDC	O
influence	O
systemic	O
immune	O
responses	O
.	O

Overall	O
,	O
these	O
data	O
indicate	O
that	O
pDC	O
contribute	O
at	O
multiple	O
levels	O
to	O
immunity	O
to	O
C	B-bacteria
.	I-bacteria
rodentium	I-bacteria
including	O
control	O
of	O
bacterial	O
numbers	O
in	O
the	O
colon	O
,	O
maintenance	O
of	O
colon	O
barrier	O
function	O
and	O
regulation	O
of	O
immune	O
responses	O
to	O
disseminated	O
bacteria	O
.	O

Response	O
of	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
WCFS1	I-bacteria
to	O
the	O
Gram	O
-	O
Negative	O
Pathogen	O
-	O
Associated	O
Quorum	O
Sensing	O
Molecule	O
N	O
-	O
3	O
-	O
Oxododecanoyl	O
Homoserine	O
Lactone	O
.	O

The	O
bacterial	O
quorum	O
sensing	O
phenomenon	O
has	O
been	O
well	O
studied	O
since	O
its	O
discovery	O
and	O
has	O
traditionally	O
been	O
considered	O
to	O
include	O
signaling	O
pathways	O
recognized	O
exclusively	O
within	O
either	O
Gram	O
-	O
positive	O
or	O
Gram	O
-	O
negative	O
bacteria	O
.	O

These	O
groups	O
of	O
bacteria	O
synthesize	O
structurally	O
distinct	O
signaling	O
molecules	O
to	O
mediate	O
quorum	O
sensing	O
,	O
where	O
Gram	O
-	O
positive	O
bacteria	O
traditionally	O
utilize	O
small	O
autoinducing	O
peptides	O
(	O
AIPs	O
)	O
and	O
Gram	O
-	O
negatives	O
use	O
small	O
molecules	O
such	O
as	O
acyl	O
-	O
homoserine	O
lactones	O
(	O
AHLs	O
)	O
.	O

The	O
structural	O
differences	O
between	O
the	O
types	O
of	O
signaling	O
molecules	O
have	O
historically	O
implied	O
a	O
lack	O
of	O
cross	O
-	O
talk	O
among	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
quorum	O
sensing	O
systems	O
.	O

Recent	O
investigations	O
,	O
however	O
,	O
have	O
demonstrated	O
the	O
ability	O
for	O
AIPs	O
and	O
AHLs	O
to	O
be	O
produced	O
by	O
non	O
-	O
canonical	O
organisms	O
,	O
implying	O
quorum	O
sensing	O
systems	O
may	O
be	O
more	O
universally	O
recognized	O
than	O
previously	O
hypothesized	O
.	O

With	O
that	O
in	O
mind	O
,	O
our	O
interests	O
were	O
piqued	O
by	O
the	O
organisms	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
,	O
a	O
Gram	O
-	O
positive	O
commensal	O
probiotic	O
known	O
to	O
participate	O
in	O
AIP	O
-	O
mediated	O
quorum	O
sensing	O
,	O
and	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
,	O
a	O
characterized	O
Gram	O
-	O
negative	O
pathogen	O
whose	O
virulence	O
is	O
in	O
part	O
controlled	O
by	O
AHL	O
-	O
mediated	O
quorum	O
sensing	O
.	O

Both	O
health	O
-	O
related	O
organisms	O
are	O
known	O
to	O
inhabit	O
the	O
human	O
gut	O
in	O
various	O
instances	O
,	O
both	O
are	O
characterized	O
to	O
elicit	O
distinct	O
effects	O
on	O
host	O
immunity	O
,	O
and	O
some	O
studies	O
hint	O
at	O
the	O
putative	O
ability	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
to	O
degrade	O
AHLs	O
produced	O
by	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
.	O

We	O
therefore	O
wanted	O
to	O
determine	O
if	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
cultures	O
would	O
respond	O
to	O
the	O
addition	O
of	O
N	O
-	O
(	O
3	O
-	O
oxododecanoyl	O
)	O
-	O
L	O
-	O
homoserine	O
lactone	O
(	O
3OC12	O
)	O
from	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
by	O
analyzing	O
changes	O
on	O
both	O
the	O
transcriptome	O
and	O
proteome	O
over	O
time	O
.	O

Based	O
on	O
the	O
observed	O
upregulation	O
of	O
various	O
two	O
-	O
component	O
systems	O
,	O
response	O
regulators	O
,	O
and	O
native	O
quorum	O
sensing	O
related	O
genes	O
,	O
the	O
resulting	O
data	O
provide	O
evidence	O
of	O
an	O
AHL	O
recognition	O
and	O
response	O
by	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
.	O

Major	O
Traditional	O
Probiotics	O
:	O
Comparative	O
Genomic	O
Analyses	O
and	O
Roles	O
in	O
Gut	O
Microbiome	O
of	O
Eight	O
Cohorts	O
.	O

Modulating	O
gut	O
microbiota	O
to	O
promote	O
host	O
health	O
is	O
well	O
recognized	O
.	O

Therefore	O
,	O
people	O
consume	O
dietary	O
products	O
containing	O
traditional	O
probiotics	O
in	O
wishing	O
to	O
improve	O
their	O
health	O
,	O
and	O
they	O
need	O
more	O
research	O
-	O
based	O
advices	O
on	O
how	O
to	O
select	O
products	O
with	O
suitable	O
probiotic	O
species	O
.	O

Probiotic	O
designers	O
are	O
sometimes	O
confused	O
about	O
how	O
to	O
design	O
precision	O
products	O
for	O
different	O
consumers	O
by	O
taking	O
advantages	O
of	O
different	O
probiotic	O
species	O
'	O
strengths	O
.	O

Additionally	O
,	O
large	O
-	O
scale	O
analyses	O
on	O
traditional	O
probiotic	O
complementarity	O
potentials	O
and	O
their	O
roles	O
in	O
gut	O
microbiome	O
related	O
to	O
common	O
diseases	O
are	O
not	O
well	O
understood	O
.	O

Here	O
,	O
we	O
comprehensively	O
analyzed	O
444	O
genomes	O
of	O
major	O
traditional	O
probiotic	O
(	O
sub	O
)	O
species	O
(	O
MTPS	O
,	O
n	O
=	O
15	O
)	O
by	O
combining	O
one	O
newly	O
sequenced	O
genome	O
with	O
all	O
of	O
the	O
public	O
NCBI	O
-	O
available	O
MTPS	O
-	O
related	O
genomes	O
.	O

The	O
public	O
human	O
fecal	O
metagenomic	O
data	O
(	O
n	O
=	O
1	O
,	O
815	O
)	O
of	O
eight	O
cohorts	O
were	O
used	O
to	O
evaluate	O
the	O
roles	O
of	O
MTPS	O
,	O
compared	O
to	O
other	O
main	O
gut	O
bacteria	O
,	O
in	O
disease	O
association	O
by	O
examining	O
the	O
species	O
enrichment	O
direction	O
in	O
disease	O
group	O
or	O
the	O
control	O
group	O
.	O

Our	O
work	O
provided	O
a	O
comprehensive	O
genetic	O
landscape	O
and	O
complementarity	O
relations	O
for	O
MTPS	O
and	O
shed	O
light	O
on	O
personalized	O
probiotic	O
supplements	O
for	O
consumers	O
with	O
different	O
health	O
status	O
and	O
the	O
necessity	O
that	O
researchers	O
and	O
manufactures	O
could	O
explore	O
novel	O
probiotics	O
as	O
well	O
as	O
traditional	O
ones	O
.	O

Author	O
Correction	O
:	O
Diversity	O
in	O
gut	O
bacterial	O
community	O
of	O
school	O
-	O
age	O
children	O
in	O
Asia	O
.	O

A	O
correction	O
has	O
been	O
published	O
and	O
is	O
appended	O
to	O
both	O
the	O
HTML	O
and	O
PDF	O
versions	O
of	O
this	O
paper	O
.	O

The	O
error	O
has	O
not	O
been	O
fixed	O
in	O
the	O
paper	O
.	O

Regulation	O
of	O
Phenotypic	O
Switching	O
and	O
Heterogeneity	O
in	O
Photorhabdus	O
luminescens	I-bacteria
Cell	O
Populations	O
.	O

Phenotypic	O
heterogeneity	O
in	O
bacterial	O
cell	O
populations	O
allows	O
genetically	O
identical	O
organisms	O
to	O
different	O
behavior	O
under	O
similar	O
environmental	O
conditions	O
.	O

The	O
Gram	O
-	O
negative	O
bacterium	O
Photorhabdus	B-bacteria
luminescens	I-bacteria
is	O
an	O
excellent	O
organism	O
to	O
study	O
phenotypic	O
heterogeneity	O
since	O
their	O
life	O
cycle	O
involves	O
a	O
symbiotic	O
interaction	O
with	O
soil	O
nematodes	O
as	O
well	O
as	O
a	O
pathogenic	O
association	O
with	O
insect	O
larvae	O
.	O

Phenotypic	O
heterogeneity	O
is	O
highly	O
distinct	O
in	O
P	B-bacteria
.	I-bacteria
luminescens	I-bacteria
.	O

The	O
bacteria	O
exist	O
in	O
two	O
phenotypic	O
forms	O
that	O
differ	O
in	O
various	O
morphologic	O
and	O
phenotypic	O
traits	O
and	O
are	O
therefore	O
distinguished	O
as	O
primary	O
(	O
1	O
degrees	O
)	O
and	O
secondary	O
(	O
2	O
degrees	O
)	O
cells	O
.	O

The	O
1	O
cells	O
are	O
bioluminescent	O
,	O
pigmented	O
,	O
produce	O
several	O
secondary	O
metabolites	O
and	O
exo	O
-	O
enzymes	O
,	O
and	O
support	O
nematode	O
growth	O
and	O
development	O
.	O

The	O
2	O
degrees	O
cells	O
lack	O
all	O
these	O
1	O
degrees	O
-	O
specific	O
phenotypes	O
.	O

The	O
entomopathogenic	O
nematodes	O
carry	O
1	O
degrees	O
cells	O
in	O
their	O
upper	O
gut	O
and	O
release	O
them	O
into	O
an	O
insect	O
'	O
s	O
body	O
after	O
slipping	O
inside	O
.	O

During	O
insect	O
infection	O
,	O
up	O
to	O
the	O
half	O
number	O
of	O
1	O
degrees	O
cells	O
undergo	O
phenotypic	O
switching	O
and	O
convert	O
to	O
2	O
degrees	O
cells	O
.	O

Since	O
the	O
2	O
degrees	O
cells	O
are	O
not	O
able	O
to	O
live	O
in	O
nematode	O
symbiosis	O
any	O
more	O
,	O
they	O
can	O
not	O
re	O
-	O
associate	O
with	O
their	O
symbiosis	O
partners	O
after	O
the	O
infection	O
and	O
remain	O
in	O
the	O
soil	O
.	O

Phenotypic	O
switching	O
in	O
P	B-bacteria
.	I-bacteria
luminescens	I-bacteria
has	O
to	O
be	O
tightly	O
regulated	O
since	O
a	O
high	O
switching	O
frequency	O
would	O
lead	O
to	O
a	O
complete	O
break	O
-	O
down	O
of	O
the	O
nematode	O
-	O
bacteria	O
life	O
cycle	O
.	O

Here	O
,	O
we	O
present	O
the	O
main	O
regulatory	O
mechanisms	O
known	O
to	O
-	O
date	O
that	O
are	O
important	O
for	O
phenotypic	O
switching	O
in	O
P	B-bacteria
.	I-bacteria
luminescens	I-bacteria
cell	O
populations	O
and	O
discuss	O
the	O
biological	O
reason	O
as	O
well	O
as	O
the	O
fate	O
of	O
the	O
2	O
degrees	O
cells	O
in	O
the	O
soil	O
.	O

Diversity	O
and	O
composition	O
of	O
the	O
gut	O
microbiota	O
of	O
Atlantic	O
salmon	O
(	O
Salmo	O
salar	O
)	O
farmed	O
in	O
Irish	O
waters	O
.	O

AIMS	O
:	O
Information	O
on	O
the	O
gut	O
microbiota	O
of	O
salmon	O
is	O
essential	O
for	O
optimising	O
nutrition	O
while	O
maintaining	O
host	O
health	O
and	O
welfare	O
.	O

This	O
study	O
'	O
s	O
objectives	O
were	O
to	O
characterize	O
the	O
microbiota	O
in	O
the	O
GI	O
tract	O
of	O
Atlantic	O
salmon	O
(	O
Salmo	O
salar	O
)	O
farmed	O
in	O
waters	O
off	O
the	O
west	O
coast	O
of	O
Ireland	O
and	O
to	O
investigate	O
whether	O
there	O
is	O
a	O
difference	O
in	O
microbiota	O
diversity	O
between	O
the	O
proximal	O
and	O
distal	O
regions	O
of	O
the	O
intestine	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
microbiota	O
from	O
the	O
proximal	O
and	O
distal	O
intestine	O
(	O
PI	O
and	O
DI	O
,	O
respectively	O
)	O
of	O
Atlantic	O
salmon	O
was	O
examined	O
using	O
MiSeq	O
Illumina	O
high	O
throughput	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
gene	O
.	O

The	O
PI	O
region	O
had	O
greater	O
bacterial	O
diversity	O
than	O
the	O
DI	O
region	O
.	O

Six	O
phyla	O
were	O
present	O
in	O
the	O
DI	O
samples	O
,	O
dominated	O
by	O
Tenericutes	B-bacteria
and	O
Firmicutes	B-bacteria
.	O

These	O
six	O
phyla	O
were	O
also	O
amongst	O
the	O
12	O
phyla	O
detected	O
in	O
the	O
PI	O
samples	O
.	O

The	O
PI	O
microbiota	O
was	O
dominated	O
by	O
Tenericutes	B-bacteria
,	O
Firmicutes	B-bacteria
,	O
Bacteroidetes	B-bacteria
and	O
Proteobacteria	B-bacteria
.	O

A	O
core	O
microbiota	O
of	O
20	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
common	O
to	O
both	O
regions	O
was	O
observed	O
.	O

CONCLUSIONS	O
:	O
It	O
was	O
concluded	O
that	O
Tenericutes	B-bacteria
were	O
the	O
dominant	O
phylum	O
in	O
both	O
PI	O
and	O
DI	O
samples	O
and	O
the	O
PI	O
region	O
had	O
greater	O
Shannon	O
and	O
Simpson	O
diversity	O
of	O
bacteria	O
.	O

However	O
further	O
work	O
is	O
required	O
to	O
identify	O
the	O
functionality	O
of	O
the	O
salmon	O
microbiota	O
.	O

SIGNIFICANCE	O
AND	O
IMPACT	O
OF	O
THE	O
STUDY	O
:	O
Our	O
study	O
determined	O
the	O
composition	O
and	O
diversity	O
of	O
the	O
intestinal	O
microbiota	O
in	O
adult	O
salmon	O
from	O
a	O
commercial	O
fishery	O
and	O
provides	O
data	O
to	O
improve	O
our	O
understanding	O
of	O
their	O
contributions	O
to	O
the	O
nutrition	O
,	O
health	O
and	O
welfare	O
of	O
Atlantic	O
salmon	O
farmed	O
in	O
Irish	O
waters	O
.	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Metagenomic	O
analysis	O
revealed	O
beneficial	O
effects	O
of	O
probiotics	O
in	O
improving	O
the	O
composition	O
and	O
function	O
of	O
the	O
gut	O
microbiota	O
in	O
dogs	O
with	O
diarrhoea	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
probiotics	O
on	O
the	O
composition	O
and	O
function	O
of	O
the	O
gut	O
microbiota	O
in	O
dogs	O
with	O
diarrhoea	O
.	O

Forty	O
dogs	O
with	O
diarrhoea	O
were	O
randomly	O
allocated	O
to	O
the	O
treatment	O
group	O
or	O
control	O
group	O
.	O

Probiotics	O
,	O
containing	O
Lactobacillus	B-bacteria
casei	I-bacteria
Zhang	I-bacteria
,	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
P	I-bacteria
-	I-bacteria
8	I-bacteria
,	O
and	O
Bifidobacterium	B-bacteria
animalis	I-bacteria
subsp	I-bacteria
.	I-bacteria
lactis	I-bacteria
V9	I-bacteria
,	O
were	O
only	O
fed	O
to	O
20	O
treated	O
dogs	O
for	O
60	O
days	O
.	O

The	O
faecal	O
samples	O
of	O
all	O
dogs	O
at	O
day	O
0	O
and	O
day	O
60	O
were	O
analyzed	O
using	O
a	O
metagenomic	O
approach	O
.	O

The	O
results	O
showed	O
a	O
significantly	O
higher	O
microbial	O
diversity	O
and	O
an	O
obvious	O
change	O
in	O
the	O
structure	O
of	O
the	O
gut	O
microbiota	O
in	O
the	O
treatment	O
group	O
.	O

There	O
was	O
also	O
an	O
increase	O
in	O
the	O
abundance	O
of	O
some	O
beneficial	O
bacteria	O
in	O
differently	O
aged	O
dogs	O
,	O
such	O
as	O
Lactobacillus	B-bacteria
johnsonii	I-bacteria
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
Butyricicoccus	B-bacteria
pullicaecorum	I-bacteria
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
a	O
reduction	O
in	O
the	O
abundance	O
of	O
many	O
opportunistic	O
pathogenic	O
bacteria	O
such	O
as	O
Clostridium	B-bacteria
perfringens	I-bacteria
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
Stenotrophomonas	B-bacteria
maltophilia	I-bacteria
(	O
P	O
<	O
0	O
.	O
05	O
)	O
with	O
the	O
supplementation	O
of	O
probiotics	O
.	O

Intriguingly	O
,	O
the	O
correlated	O
networks	O
among	O
some	O
pathogenic	O
bacteria	O
decreased	O
following	O
the	O
administration	O
of	O
probiotics	O
.	O

Additionally	O
,	O
metagenomic	O
analysis	O
revealed	O
the	O
upregulation	O
of	O
pathways	O
involved	O
in	O
the	O
metabolism	O
of	O
amino	O
acids	O
and	O
biosynthesis	O
of	O
secondary	O
metabolites	O
,	O
accompanied	O
by	O
the	O
downregulation	O
of	O
pathways	O
associated	O
with	O
virulence	O
of	O
pathogenic	O
bacteria	O
and	O
cell	O
signaling	O
,	O
suggesting	O
that	O
probiotics	O
could	O
improve	O
the	O
health	O
of	O
dogs	O
with	O
diarrhoea	O
through	O
regulation	O
of	O
the	O
gut	O
microbiota	O
.	O

Our	O
research	O
provides	O
new	O
information	O
relevant	O
to	O
the	O
treatment	O
of	O
diarrhoea	O
in	O
animals	O
and	O
humans	O
.	O

Composition	O
,	O
diversity	O
and	O
function	O
of	O
gastrointestinal	O
microbiota	O
in	O
wild	O
red	O
-	O
billed	O
choughs	O
(	O
Pyrrhocorax	O
pyrrhocorax	O
)	O
.	O

Hitherto	O
,	O
virtually	O
nothing	O
is	O
known	O
about	O
the	O
microbial	O
communities	O
related	O
to	O
the	O
bird	O
species	O
in	O
the	O
family	O
Corvidae	O
.	O

To	O
fill	O
this	O
gap	O
,	O
the	O
present	O
study	O
was	O
conducted	O
to	O
provide	O
a	O
baseline	O
description	O
of	O
the	O
gut	O
microbiota	O
of	O
wild	O
red	O
-	O
billed	O
choughs	O
(	O
Pyrrhocorax	O
pyrrhocorax	O
)	O
.	O

In	O
this	O
study	O
,	O
microbiota	O
from	O
four	O
gastrointestinal	O
locations	O
(	O
oropharynx	O
,	O
gizzard	O
,	O
small	O
intestine	O
,	O
and	O
large	O
intestine	O
)	O
of	O
three	O
wild	O
red	O
-	O
billed	O
choughs	O
were	O
analyzed	O
using	O
the	O
Illumina	O
MiSeq	O
sequencing	O
platform	O
by	O
targeting	O
the	O
V4	O
-	O
V5	O
regions	O
of	O
the	O
16S	O
rRNA	O
genes	O
.	O

The	O
gut	O
microbiota	O
of	O
the	O
red	O
-	O
billed	O
choughs	O
were	O
dominated	O
by	O
the	O
phylum	O
Firmicutes	B-bacteria
(	O
59	O
.	O
56	O
%	O
)	O
,	O
followed	O
by	O
Proteobacteria	B-bacteria
(	O
16	O
.	O
56	O
%	O
)	O
,	O
Bacteroidetes	B-bacteria
(	O
13	O
.	O
86	O
%	O
)	O
,	O
and	O
Actinobacteria	B-bacteria
(	O
7	O
.	O
03	O
%	O
)	O
,	O
which	O
were	O
commonly	O
detected	O
in	O
avian	O
gut	O
ecosystems	O
.	O

Genus	O
-	O
level	O
compositions	O
were	O
found	O
to	O
be	O
largely	O
dominated	O
by	O
Lactobacillus	B-bacteria
(	O
18	O
.	O
21	O
%	O
)	O
,	O
Weissella	B-bacteria
(	O
12	O
.	O
37	O
%	O
)	O
,	O
Erysipelatoclostridium	B-bacteria
(	O
6	O
.	O
94	O
%	O
)	O
,	O
Bacteroides	B-bacteria
(	O
6	O
.	O
63	O
%	O
)	O
,	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
(	O
5	O
.	O
15	O
%	O
)	O
,	O
Leuconostoc	B-bacteria
(	O
4	O
.	O
60	O
%	O
)	O
,	O
Proteus	B-bacteria
(	O
3	O
.	O
33	O
%	O
)	O
,	O
Carnobacterium	B-bacteria
(	O
2	O
.	O
71	O
%	O
)	O
,	O
Lactococcus	B-bacteria
(	O
1	O
.	O
69	O
%	O
)	O
,	O
and	O
Enterococcus	B-bacteria
(	O
1	O
.	O
63	O
%	O
)	O
.	O

The	O
overall	O
intestinal	O
microbiota	O
was	O
enriched	O
with	O
functions	O
related	O
to	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporters	O
,	O
DNA	O
repair	O
and	O
recombination	O
proteins	O
,	O
purine	O
metabolism	O
,	O
ribosome	O
,	O
transcription	O
factors	O
,	O
pyrimidine	O
metabolism	O
,	O
peptidases	O
,	O
and	O
two	O
-	O
component	O
system	O
.	O

In	O
terms	O
of	O
four	O
different	O
gastrointestinal	O
locations	O
,	O
hierarchical	O
clustering	O
analysis	O
and	O
principal	O
coordinate	O
analysis	O
showed	O
that	O
microbial	O
communities	O
of	O
the	O
oropharynx	O
,	O
gizzard	O
,	O
small	O
intestine	O
,	O
and	O
large	O
intestine	O
formed	O
four	O
separated	O
clusters	O
.	O

A	O
total	O
of	O
825	O
OTUs	O
and	O
382	O
genera	O
were	O
detected	O
in	O
all	O
four	O
gastrointestinal	O
locations	O
,	O
which	O
were	O
considered	O
as	O
the	O
major	O
microbes	O
in	O
the	O
intestines	O
of	O
red	O
-	O
billed	O
choughs	O
.	O

Coexistence	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
and	O
potential	O
pathogens	O
in	O
the	O
gut	O
environments	O
of	O
red	O
-	O
billed	O
choughs	O
required	O
further	O
investigations	O
.	O

Genetically	O
engineered	O
probiotic	O
Saccharomyces	O
cerevisiae	O
strains	O
mature	O
human	O
dendritic	O
cells	O
and	O
stimulate	O
Gag	O
-	O
specific	O
memory	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
ex	O
vivo	O
.	O

Recombinant	O
Saccharomyces	O
cerevisiae	O
strains	O
expressing	O
HIV	O
antigens	O
have	O
shown	O
promising	O
pre	O
-	O
clinical	O
results	O
.	O

Probiotic	O
S	B-bacteria
.	I-bacteria
cerevisiae	I-bacteria
strains	I-bacteria
naturally	O
induce	O
gut	O
immunity	O
;	O
thus	O
,	O
genetically	O
engineered	O
probiotic	O
strains	O
could	O
be	O
used	O
to	O
stimulate	O
immune	O
responses	O
against	O
HIV	O
in	O
the	O
mucosa	O
.	O

Probiotic	O
strains	O
have	O
a	O
higher	O
rate	O
of	O
heterologous	O
protein	O
production	O
,	O
meaning	O
higher	O
antigen	O
'	O
s	O
epitope	O
expression	O
levels	O
per	O
yeast	O
cell	O
.	O

We	O
expressed	O
HIV	O
-	O
1	O
Gag	O
protein	O
in	O
the	O
probiotic	O
yeasts	O
'	O
surface	O
,	O
which	O
was	O
eagerly	O
phagocytosed	O
by	O
and	O
induced	O
type	O
1	O
polarization	O
of	O
human	O
monocyte	O
-	O
derived	O
dendritic	O
cells	O
(	O
DCs	O
)	O
from	O
healthy	O
donors	O
in	O
vitro	O
.	O

We	O
further	O
matured	O
DCs	O
derived	O
from	O
HIV	O
-	O
1	O
(	O
+	O
)	O
donors	O
with	O
transformed	O
yeasts	O
and	O
incubated	O
them	O
with	O
autologous	O
T	O
cells	O
.	O

Only	O
DCs	O
matured	O
with	O
Gag	O
-	O
expressing	O
probiotic	O
strains	O
were	O
able	O
to	O
efficiently	O
present	O
antigen	O
to	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
and	O
induced	O
their	O
clonal	O
expansion	O
.	O

Our	O
results	O
show	O
that	O
genetically	O
engineered	O
probiotic	O
S	B-bacteria
.	I-bacteria
cerevisiae	I-bacteria
strains	I-bacteria
are	O
a	O
promising	O
vaccination	O
strategy	O
against	O
HIV	O
.	O

Rumen	O
fermentation	O
,	O
intramuscular	O
fat	O
fatty	O
acid	O
profiles	O
and	O
related	O
rumen	O
bacterial	O
populations	O
of	O
Holstein	O
bulls	O
fed	O
diets	O
with	O
different	O
energy	O
levels	O
.	O

The	O
dietary	O
energy	O
level	O
can	O
affect	O
ruminal	O
microbiota	O
,	O
and	O
further	O
can	O
affect	O
rumen	O
fermentation	O
and	O
fatty	O
acid	O
(	O
FA	O
)	O
synthesis	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
correlations	O
between	O
rumen	O
bacteria	O
and	O
rumen	O
fermentation	O
parameters	O
and	O
intramuscular	O
fat	O
(	O
IMF	O
)	O
FA	O
profiles	O
of	O
Holstein	O
bulls	O
fed	O
different	O
energy	O
diets	O
via	O
using	O
16S	O
rRNA	O
high	O
-	O
throughput	O
sequencing	O
and	O
gas	O
chromatography	O
.	O

The	O
results	O
showed	O
that	O
the	O
improved	O
dietary	O
energy	O
increased	O
propionate	O
,	O
isobutyrate	O
and	O
isovalerate	O
concentrations	O
,	O
and	O
decreased	O
acetate	O
concentration	O
and	O
the	O
acetate	O
/	O
propionate	O
ratio	O
.	O

Increased	O
dietary	O
energy	O
improved	O
beef	O
IMF	O
content	O
and	O
had	O
no	O
effects	O
on	O
cooking	O
loss	O
,	O
Warner	O
-	O
Bratzler	O
shear	O
force	O
,	O
water	O
holding	O
capacity	O
,	O
or	O
drip	O
loss	O
.	O

Increase	O
dietary	O
energy	O
also	O
decreased	O
C18	O
:	O
0	O
,	O
C18	O
:	O
1	O
trans	O
,	O
C22	O
:	O
0	O
,	O
C20	O
:	O
3n	O
-	O
3	O
,	O
C22	O
:	O
6n	O
-	O
3	O
,	O
and	O
saturated	O
fatty	O
acids	O
,	O
and	O
increased	O
C18	O
:	O
1	O
cis	O
-	O
9	O
,	O
C18	O
:	O
2n	O
-	O
6	O
trans	O
,	O
and	O
monounsaturated	O
fatty	O
acids	O
.	O

16S	O
rRNA	O
high	O
-	O
throughput	O
sequencing	O
analysis	O
revealed	O
that	O
dietary	O
energy	O
had	O
no	O
impact	O
on	O
alpha	O
diversity	O
or	O
the	O
relative	O
abundance	O
of	O
most	O
of	O
the	O
major	O
phyla	O
and	O
genera	O
in	O
rumen	O
.	O

In	O
all	O
dietary	O
treatment	O
groups	O
,	O
the	O
dominant	O
microbial	O
phyla	O
were	O
Bacteroidetes	B-bacteria
(	O
54	O
.	O
91	O
%	O
)	O
and	O
Firmicutes	B-bacteria
(	O
33	O
.	O
60	O
%	O
)	O
,	O
and	O
the	O
major	O
microbial	O
genus	O
was	O
Prevotella	B-bacteria
_	I-bacteria
1	I-bacteria
(	O
21	O
.	O
75	O
%	O
)	O
.	O

Improved	O
dietary	O
energy	O
decreased	O
the	O
abundances	O
of	O
Firmicutes	B-bacteria
and	O
Tenericutes	B-bacteria
and	O
increased	O
that	O
of	O
Proteobacteria	B-bacteria
at	O
the	O
phylum	O
level	O
,	O
while	O
decreasing	O
those	O
of	O
RC9	O
_	O
gut	O
_	O
group	O
,	O
and	O
increased	O
Prevotellaceae	B-bacteria
_	I-bacteria
UCG	I-bacteria
-	I-bacteria
004	I-bacteria
,	O
Phocaeicola	B-bacteria
,	O
Acetitomaculum	B-bacteria
,	O
Lachnoclostridium	B-bacteria
_	I-bacteria
1	I-bacteria
,	O
Prevotellaceae	B-bacteria
_	I-bacteria
UCG	I-bacteria
-	I-bacteria
003	I-bacteria
,	O
and	O
Anaerovibrio	O
at	O
the	O
genus	O
level	O
.	O

Spearman	O
correlation	O
analysis	O
showed	O
high	O
correlations	O
between	O
rumen	O
bacteria	O
and	O
fermentation	O
parameters	O
/	O
IMF	O
FA	O
profiles	O
.	O

Collectively	O
,	O
our	O
data	O
indicated	O
that	O
dietary	O
energy	O
affects	O
the	O
ruminal	O
microbiota	O
,	O
and	O
further	O
affects	O
ruminal	O
fermentation	O
and	O
IMF	O
FA	O
composition	O
.	O

Comparative	O
Transcriptomic	O
Profiling	O
of	O
Yersinia	B-bacteria
enterocolitica	I-bacteria
O	O
:	O
3	O
and	O
O	O
:	O
8	O
Reveals	O
Major	O
Expression	O
Differences	O
of	O
Fitness	O
-	O
and	O
Virulence	O
-	O
Relevant	O
Genes	O
Indicating	O
Ecological	O
Separation	O
.	O

Yersinia	B-bacteria
enterocolitica	I-bacteria
is	O
a	O
zoonotic	O
pathogen	O
and	O
an	O
important	O
cause	O
of	O
bacterial	O
gastrointestinal	O
infections	O
in	O
humans	O
.	O

Large	O
-	O
scale	O
population	O
genomic	O
analyses	O
revealed	O
genetic	O
and	O
phenotypic	O
diversity	O
of	O
this	O
bacterial	O
species	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
differences	O
in	O
the	O
transcriptome	O
organization	O
,	O
small	O
RNA	O
(	O
sRNA	O
)	O
repertoire	O
,	O
and	O
transcriptional	O
output	O
.	O

Here	O
,	O
we	O
present	O
the	O
first	O
comparative	O
high	O
-	O
resolution	O
transcriptome	O
analysis	O
of	O
Y	B-bacteria
.	I-bacteria
enterocolitica	I-bacteria
strains	I-bacteria
representing	O
highly	O
pathogenic	O
phylogroup	O
2	O
(	O
serotype	O
O	O
:	O
8	O
)	O
and	O
moderately	O
pathogenic	O
phylogroup	O
3	O
(	O
serotype	O
O	O
:	O
3	O
)	O
grown	O
under	O
four	O
infection	O
-	O
relevant	O
conditions	O
.	O

Our	O
transcriptome	O
sequencing	O
(	O
RNA	O
-	O
seq	O
)	O
approach	O
revealed	O
1	O
,	O
299	O
and	O
1	O
,	O
076	O
transcriptional	O
start	O
sites	O
and	O
identified	O
strain	O
-	O
specific	O
sRNAs	O
that	O
could	O
contribute	O
to	O
differential	O
regulation	O
among	O
the	O
phylogroups	O
.	O

Comparative	O
transcriptomics	O
further	O
uncovered	O
major	O
gene	O
expression	O
differences	O
,	O
in	O
particular	O
,	O
in	O
the	O
temperature	O
-	O
responsive	O
regulon	O
.	O

Multiple	O
virulence	O
-	O
relevant	O
genes	O
are	O
differentially	O
regulated	O
between	O
the	O
two	O
strains	O
,	O
supporting	O
an	O
ecological	O
separation	O
of	O
phylogroups	O
with	O
certain	O
niche	O
-	O
adapted	O
properties	O
.	O

Strong	O
upregulation	O
of	O
the	O
ystA	O
enterotoxin	O
gene	O
in	O
combination	O
with	O
constitutive	O
high	O
expression	O
of	O
cell	O
invasion	O
factor	O
InvA	O
further	O
showed	O
that	O
the	O
toxicity	O
of	O
recent	O
outbreak	O
O	O
:	O
3	O
strains	O
has	O
increased	O
.	O

Overall	O
,	O
our	O
report	O
provides	O
new	O
insights	O
into	O
the	O
specific	O
transcriptome	O
organization	O
of	O
phylogroups	O
2	O
and	O
3	O
and	O
reveals	O
gene	O
expression	O
differences	O
contributing	O
to	O
the	O
substantial	O
phenotypic	O
differences	O
that	O
exist	O
between	O
the	O
lineages	O
.	O

IMPORTANCE	O
Yersinia	B-bacteria
enterocolitica	I-bacteria
is	O
a	O
major	O
diarrheal	O
pathogen	O
and	O
is	O
associated	O
with	O
a	O
large	O
range	O
of	O
gut	O
-	O
associated	O
diseases	O
.	O

Members	O
of	O
this	O
species	O
have	O
evolved	O
into	O
different	O
phylogroups	O
with	O
genotypic	O
variations	O
.	O

We	O
performed	O
the	O
first	O
characterization	O
of	O
the	O
Y	B-bacteria
.	I-bacteria
enterocolitica	I-bacteria
transcriptional	O
landscape	O
and	O
tracked	O
the	O
consequences	O
of	O
the	O
genomic	O
variations	O
between	O
two	O
different	O
pathogenic	O
phylogroups	O
by	O
comparing	O
their	O
RNA	O
repertoire	O
,	O
promoter	O
usage	O
,	O
and	O
expression	O
profiles	O
under	O
four	O
different	O
virulence	O
-	O
relevant	O
conditions	O
.	O

Our	O
analysis	O
revealed	O
major	O
differences	O
in	O
the	O
transcriptional	O
outputs	O
of	O
the	O
closely	O
related	O
strains	O
,	O
pointing	O
to	O
an	O
ecological	O
separation	O
in	O
which	O
one	O
is	O
more	O
adapted	O
to	O
an	O
environmental	O
lifestyle	O
and	O
the	O
other	O
to	O
a	O
mostly	O
mammal	O
-	O
associated	O
lifestyle	O
.	O

Moreover	O
,	O
a	O
variety	O
of	O
pathoadaptive	O
alterations	O
,	O
including	O
alterations	O
in	O
acid	O
resistance	O
genes	O
,	O
colonization	O
factors	O
,	O
and	O
toxins	O
,	O
were	O
identified	O
which	O
affect	O
virulence	O
and	O
host	O
specificity	O
.	O

This	O
illustrates	O
that	O
comparative	O
transcriptomics	O
is	O
an	O
excellent	O
approach	O
to	O
discover	O
differences	O
in	O
the	O
functional	O
output	O
from	O
closely	O
related	O
genomes	O
affecting	O
niche	O
adaptation	O
and	O
virulence	O
,	O
which	O
can	O
not	O
be	O
directly	O
inferred	O
from	O
DNA	O
sequences	O
.	O

Two	O
putative	O
MmpL	O
homologs	O
contribute	O
to	O
antimicrobial	O
resistance	O
and	O
nephropathy	O
of	O
enterohemorrhagic	B-bacteria
E	B-bacteria
.	I-bacteria
coli	I-bacteria
O157	I-bacteria
:	I-bacteria
H7	I-bacteria
.	O

Background	O
:	O
The	O
serious	O
human	O
pathogen	O
,	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
serotype	I-bacteria
O157	I-bacteria
:	I-bacteria
H7	I-bacteria
,	O
continues	O
to	O
gain	O
antibiotic	O
resistance	O
,	O
posing	O
a	O
public	O
health	O
threat	O
.	O

While	O
this	O
serotype	O
'	O
s	O
genome	O
has	O
been	O
sequenced	O
,	O
the	O
role	O
of	O
25	O
%	O
of	O
its	O
genes	O
remains	O
unknown	O
,	O
including	O
genes	O
conferring	O
additional	O
resistance	O
.	O

A	O
prominent	O
bacterial	O
resistance	O
mechanism	O
is	O
acquiring	O
genes	O
encoding	O
efflux	O
pumps	O
,	O
among	O
which	O
are	O
the	O
mycobacterial	O
membrane	O
proteins	O
(	O
Mmp	O
)	O
,	O
which	O
contribute	O
to	O
virulence	O
and	O
membrane	O
transport	O
in	O
mycobacteria	B-bacteria
.	O

Here	O
,	O
we	O
identified	O
two	O
potential	O
mmp	O
homologs	O
(	O
z4861	O
and	O
yegN	O
)	O
in	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
O157	I-bacteria
:	I-bacteria
H7	I-bacteria
,	O
and	O
we	O
aimed	O
to	O
investigate	O
their	O
distribution	O
among	O
E	O
.	I-bacteria
coli	I-bacteria
strains	I-bacteria
and	O
their	O
potential	O
functions	O
.	O

Methods	O
and	O
results	O
:	O
By	O
screening	O
different	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
strains	I-bacteria
in	O
vitro	O
and	O
in	O
silico	O
,	O
we	O
observed	O
that	O
yegN	O
is	O
more	O
conserved	O
than	O
z4861	O
.	O

Using	O
knockout	O
mutants	O
lacking	O
either	O
or	O
both	O
genes	O
,	O
we	O
found	O
that	O
the	O
mutants	O
were	O
more	O
susceptible	O
to	O
fluoroquinolones	O
than	O
the	O
parent	O
strain	O
and	O
their	O
secretomes	O
included	O
fewer	O
virulence	O
-	O
related	O
proteins	O
.	O

Moreover	O
,	O
histopathological	O
examination	O
of	O
the	O
kidneys	O
of	O
CD	O
-	O
1	O
mice	O
infected	O
by	O
the	O
wild	O
-	O
type	O
or	O
knockout	O
strains	O
indicated	O
a	O
greater	O
impact	O
of	O
z4861	O
on	O
pathogenesis	O
and	O
kidney	O
damage	O
than	O
yegN	O
,	O
since	O
both	O
mutants	O
lacking	O
z4861	O
caused	O
less	O
severe	O
kidney	O
damage	O
.	O

The	O
growth	O
pattern	O
of	O
the	O
wild	O
-	O
type	O
was	O
similar	O
to	O
that	O
of	O
mutant	O
strains	O
under	O
aerobic	O
and	O
anaerobic	O
conditions	O
;	O
yet	O
,	O
the	O
mutant	O
strains	O
grew	O
less	O
when	O
treated	O
with	O
subinhibitory	O
dose	O
of	O
ciprofloxacin	O
.	O

Conclusion	O
:	O
The	O
previously	O
unannotated	O
gene	O
product	O
,	O
Z4861	O
,	O
and	O
its	O
more	O
conserved	O
homolog	O
,	O
YegN	O
,	O
contribute	O
to	O
the	O
kidney	O
damage	O
and	O
resistance	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
O157	I-bacteria
:	I-bacteria
H7	I-bacteria
.	O

The	O
Gut	O
Microbiome	O
on	O
a	O
Periodized	O
Low	O
-	O
Protein	O
Diet	O
Is	O
Associated	O
With	O
Improved	O
Metabolic	O
Health	O
.	O

A	O
periodized	O
(	O
14	O
days	O
on	O
/	O
14	O
days	O
off	O
)	O
5	O
%	O
low	O
protein	O
-	O
high	O
carbohydrate	O
(	O
pLPHC	O
)	O
diet	O
protects	O
against	O
weight	O
gain	O
,	O
improves	O
glucose	O
tolerance	O
in	O
mice	O
and	O
interacts	O
with	O
concurrent	O
voluntary	O
activity	O
wheel	O
training	O
on	O
several	O
parameters	O
including	O
weight	O
maintenance	O
and	O
liver	O
FGF21	O
secretion	O
.	O

The	O
gut	O
microbiome	O
(	O
GM	O
)	O
responds	O
to	O
both	O
diet	O
and	O
exercise	O
and	O
may	O
influence	O
host	O
metabolism	O
.	O

This	O
study	O
compared	O
the	O
cecal	O
GM	O
after	O
a	O
13	O
.	O
5	O
-	O
week	O
intervention	O
study	O
in	O
mice	O
on	O
a	O
variety	O
of	O
dietary	O
interventions	O
+	O
/	O
-	O
concurrent	O
voluntary	O
exercise	O
training	O
in	O
activity	O
wheels	O
.	O

The	O
diets	O
included	O
chronic	O
chow	O
diet	O
,	O
LPHC	O
diet	O
,	O
40	O
E	O
%	O
high	O
protein	O
-	O
low	O
carbohydrate	O
(	O
HPLC	O
)	O
diet	O
,	O
an	O
obesigenic	O
chronic	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
and	O
the	O
pLPHC	O
diet	O
.	O

Our	O
hypothesis	O
was	O
that	O
the	O
GM	O
changes	O
with	O
pLPHC	O
diet	O
would	O
generally	O
reflect	O
the	O
improved	O
metabolic	O
health	O
of	O
the	O
host	O
and	O
interact	O
with	O
concurrent	O
exercise	O
training	O
.	O

The	O
GM	O
analyses	O
revealed	O
greater	O
abundance	O
phylum	O
Bacteroidetes	B-bacteria
and	O
the	O
genus	O
Akkermansia	B-bacteria
on	O
chronic	O
and	O
periodized	O
LPHC	O
and	O
higher	O
abundance	O
of	O
Oscillospira	B-bacteria
and	O
Oscillibacter	B-bacteria
on	O
HFD	O
.	O

The	O
differences	O
in	O
diet	O
-	O
induced	O
GM	O
correlated	O
strongly	O
with	O
the	O
differences	O
in	O
a	O
range	O
of	O
host	O
metabolic	O
health	O
-	O
measures	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
effect	O
of	O
concurrent	O
exercise	O
training	O
was	O
observed	O
.	O

In	O
conclusion	O
,	O
pLPHC	O
diet	O
elicits	O
substantial	O
changes	O
in	O
the	O
GM	O
.	O

In	O
contrast	O
,	O
only	O
subtle	O
and	O
non	O
-	O
significant	O
effects	O
of	O
concurrent	O
activity	O
wheel	O
exercise	O
were	O
observed	O
.	O

The	O
pLPHC	O
-	O
associated	O
microbiome	O
may	O
contribute	O
to	O
the	O
healthier	O
host	O
phenotype	O
observed	O
in	O
these	O
mice	O
.	O

Nlrp3	O
inflammasome	O
activation	O
and	O
Gasdermin	O
D	O
-	O
driven	O
pyroptosis	O
are	O
immunopathogenic	O
upon	O
gastrointestinal	O
norovirus	O
infection	O
.	O

Norovirus	O
infection	O
is	O
the	O
leading	O
cause	O
of	O
food	O
-	O
borne	O
gastroenteritis	O
worldwide	O
,	O
being	O
responsible	O
for	O
over	O
200	O
,	O
000	O
deaths	O
annually	O
.	O

Studies	O
with	O
murine	O
norovirus	O
(	O
MNV	O
)	O
showed	O
that	O
protective	O
STAT1	O
signaling	O
controls	O
viral	O
replication	O
and	O
pathogenesis	O
,	O
but	O
the	O
immune	O
mechanisms	O
that	O
noroviruses	O
exploit	O
to	O
induce	O
pathology	O
are	O
elusive	O
.	O

Here	O
,	O
we	O
show	O
that	O
gastrointestinal	O
MNV	O
infection	O
leads	O
to	O
widespread	O
IL	O
-	O
1beta	O
maturation	O
in	O
MNV	O
-	O
susceptible	O
STAT1	O
-	O
deficient	O
mice	O
.	O

MNV	O
activates	O
the	O
canonical	O
Nlrp3	O
inflammasome	O
in	O
macrophages	O
,	O
leading	O
to	O
maturation	O
of	O
IL	O
-	O
1beta	O
and	O
to	O
Gasdermin	O
D	O
(	O
GSDMD	O
)	O
-	O
dependent	O
pyroptosis	O
.	O

STAT1	O
-	O
deficient	O
macrophages	O
displayed	O
increased	O
MAVS	O
-	O
mediated	O
expression	O
of	O
pro	O
-	O
IL	O
-	O
1beta	O
,	O
facilitating	O
elevated	O
Nlrp3	O
-	O
dependent	O
release	O
of	O
mature	O
IL	O
-	O
1beta	O
upon	O
MNV	O
infection	O
.	O

Accordingly	O
,	O
MNV	O
-	O
infected	O
Stat1	O
-	O
/	O
-	O
mice	O
showed	O
Nlrp3	O
-	O
dependent	O
maturation	O
of	O
IL	O
-	O
1beta	O
as	O
well	O
as	O
Nlrp3	O
-	O
dependent	O
pyroptosis	O
as	O
assessed	O
by	O
in	O
vivo	O
cleavage	O
of	O
GSDMD	O
to	O
its	O
active	O
N	O
-	O
terminal	O
fragment	O
.	O

While	O
MNV	O
-	O
induced	O
diarrheic	O
responses	O
were	O
not	O
affected	O
,	O
Stat1	O
-	O
/	O
-	O
mice	O
additionally	O
lacking	O
either	O
Nlrp3	O
or	O
GSDMD	O
displayed	O
lower	O
levels	O
of	O
the	O
fecal	O
inflammatory	O
marker	O
Lipocalin	O
-	O
2	O
as	O
well	O
as	O
delayed	O
lethality	O
after	O
gastrointestinal	O
MNV	O
infection	O
.	O

Together	O
,	O
these	O
results	O
uncover	O
new	O
insights	O
into	O
the	O
mechanisms	O
of	O
norovirus	O
-	O
induced	O
inflammation	O
and	O
cell	O
death	O
,	O
thereby	O
revealing	O
Nlrp3	O
inflammasome	O
activation	O
and	O
ensuing	O
GSDMD	O
-	O
driven	O
pyroptosis	O
as	O
contributors	O
to	O
MNV	O
-	O
induced	O
immunopathology	O
in	O
susceptible	O
STAT1	O
-	O
deficient	O
mice	O
.	O

Implication	O
of	O
the	O
whitefly	O
,	O
Bemisia	O
tabaci	O
,	O
collagen	O
protein	O
in	O
begomoviruses	O
acquisition	O
and	O
transmission	O
.	O

Begomoviruses	O
are	O
the	O
largest	O
group	O
of	O
plant	O
viruses	O
,	O
transmitted	O
exclusively	O
by	O
the	O
whitefly	O
,	O
Bemisia	O
tabaci	O
(	O
Gennadius	O
)	O
in	O
a	O
persistent	O
,	O
circulative	O
and	O
non	O
-	O
propagative	O
manner	O
.	O

Begomoviruses	O
,	O
in	O
association	O
with	O
B	B-bacteria
.	I-bacteria
tabaci	I-bacteria
cause	O
enormous	O
loss	O
to	O
world	O
agricultural	O
crops	O
.	O

Transmission	O
,	O
retention	O
and	O
circulation	O
of	O
begomovirus	O
in	O
B	B-bacteria
.	I-bacteria
tabaci	I-bacteria
are	O
facilitated	O
by	O
its	O
interaction	O
with	O
several	O
proteins	O
of	O
the	O
insect	O
and	O
its	O
endosymbionts	O
.	O

But	O
very	O
few	O
such	O
proteins	O
have	O
been	O
identified	O
from	O
B	B-bacteria
.	I-bacteria
tabaci	I-bacteria
which	O
are	O
involved	O
in	O
this	O
specific	O
interaction	O
.	O

Here	O
,	O
we	O
have	O
performed	O
yeast	O
two	O
-	O
hybrid	O
assay	O
between	O
B	B-bacteria
.	I-bacteria
tabaci	I-bacteria
cDNA	O
expression	O
library	O
and	O
the	O
coat	O
protein	O
(	O
CP	O
)	O
of	O
Tomato	O
leaf	O
curl	O
New	O
Delhi	O
virus	O
(	O
ToLCNDV	O
)	O
and	O
cotton	O
leaf	O
curl	O
Rajasthan	O
virus	O
(	O
CLCuV	O
)	O
.	O

Collagen	O
was	O
the	O
common	O
protein	O
found	O
to	O
be	O
interacting	O
with	O
both	O
the	O
viruses	O
.	O

The	O
collagen	O
protein	O
was	O
found	O
to	O
be	O
localized	O
in	O
gut	O
layers	O
of	O
B	B-bacteria
.	I-bacteria
tabaci	I-bacteria
.	O

Additionally	O
,	O
pull	O
-	O
down	O
and	O
dot	O
-	O
blot	O
assays	O
confirmed	O
the	O
association	O
of	O
endogenous	O
collagen	O
with	O
ToLCNDV	O
CP	O
.	O

Immunolocalization	O
analysis	O
also	O
showed	O
co	O
-	O
localization	O
of	O
ToLCNDV	O
particles	O
and	O
collagen	O
within	O
insect	O
'	O
s	O
gut	O
.	O

Finally	O
,	O
B	B-bacteria
.	I-bacteria
tabaci	I-bacteria
fed	O
on	O
anti	O
-	O
collagen	O
antibody	O
,	O
exhibited	O
~	O
46	O
%	O
reduction	O
in	O
ToLCNDV	O
transmission	O
,	O
suggesting	O
a	O
supportive	O
role	O
for	O
collagen	O
in	O
virus	O
transmission	O
.	O

Gut	O
bacteria	O
of	O
the	O
cowpea	O
beetle	O
mediate	O
its	O
resistance	O
to	O
dichlorvos	O
and	O
susceptibility	O
to	O
Lippia	O
adoensis	O
essential	O
oil	O
.	O

Bacteria	O
inhabiting	O
the	O
gut	O
of	O
insects	O
provide	O
many	O
benefits	O
to	O
their	O
hosts	O
,	O
such	O
as	O
aiding	O
in	O
food	O
digestion	O
,	O
reproduction	O
,	O
and	O
immunity	O
,	O
tissue	O
homeostasis	O
,	O
adaptation	O
to	O
environment	O
and	O
resistance	O
to	O
pathogen	O
and	O
pesticides	O
.	O

The	O
cowpea	O
beetle	O
,	O
Callosobruchus	O
maculatus	O
,	O
is	O
a	O
serious	O
cosmopolitan	O
pest	O
of	O
pulses	O
.	O

This	O
beetle	O
has	O
lent	O
itself	O
as	O
a	O
guinea	O
pig	O
for	O
several	O
ecological	O
studies	O
.	O

It	O
harbors	O
a	O
consortium	O
of	O
bacterial	O
communities	O
in	O
its	O
gut	O
,	O
but	O
the	O
evidence	O
for	O
their	O
role	O
in	O
its	O
physiology	O
is	O
fragmentary	O
.	O

In	O
this	O
work	O
,	O
we	O
hypothesized	O
that	O
gut	O
microbiota	O
mediates	O
C	O
.	O
maculatus	O
resistance	O
to	O
dichlorvos	O
(	O
DDVP	O
or	O
O	O
,	O
O	O
-	O
dimethyl	O
O	O
-	O
2	O
,	O
2	O
-	O
dichlorovinylphosphate	O
)	O
and	O
represent	O
the	O
target	O
of	O
Lippia	O
adoensis	O
(	O
Gambian	O
Tea	O
Bush	O
)	O
essential	O
oil	O
(	O
EO	O
)	O
.	O

Symbiotic	O
and	O
aposymbiotic	O
beetles	O
were	O
exposed	O
to	O
artificial	O
cowpea	O
seeds	O
earlier	O
treated	O
with	O
DDVP	O
or	O
EO	O
.	O

Adult	O
mortality	O
and	O
changes	O
in	O
gut	O
bacterial	O
community	O
composition	O
and	O
abundance	O
were	O
examined	O
at	O
F1	O
and	O
F5	O
generations	O
.	O

The	O
susceptibility	O
of	O
experimental	O
beetles	O
to	O
DDVP	O
was	O
significantly	O
affected	O
by	O
their	O
symbiotic	O
status	O
.	O

The	O
adult	O
mortality	O
decreased	O
across	O
generations	O
in	O
DDVP	O
treatments	O
,	O
and	O
remained	O
significantly	O
higher	O
in	O
aposymbiotic	O
groups	O
.	O

In	O
EO	O
treatments	O
,	O
the	O
mortality	O
was	O
consistent	O
irrespective	O
of	O
symbiotic	O
status	O
and	O
experimental	O
generations	O
.	O

When	O
compared	O
to	O
DDVP	O
and	O
the	O
Control	O
,	O
EO	O
treatments	O
had	O
significantly	O
lower	O
bacterial	O
richness	O
and	O
diversity	O
,	O
as	O
well	O
as	O
lower	O
abundance	O
of	O
Proteobacteria	B-bacteria
,	O
Firmicutes	B-bacteria
,	O
and	O
Bacteroidetes	B-bacteria
.	O

These	O
results	O
support	O
our	O
hypothesis	O
and	O
describe	O
the	O
responses	O
of	O
gut	O
microbial	O
communities	O
to	O
pesticide	O
treatments	O
.	O

This	O
could	O
be	O
of	O
interest	O
for	O
developing	O
new	O
management	O
strategies	O
of	O
this	O
pest	O
.	O

Physical	O
and	O
functional	O
interaction	O
between	O
A20	O
and	O
ATG16L1	O
-	O
WD40	O
domain	O
in	O
the	O
control	O
of	O
intestinal	O
homeostasis	O
.	O

Prevention	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
relies	O
on	O
tight	O
control	O
of	O
inflammatory	O
,	O
cell	O
death	O
and	O
autophagic	O
mechanisms	O
,	O
but	O
how	O
these	O
pathways	O
are	O
integrated	O
at	O
the	O
molecular	O
level	O
is	O
still	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
the	O
anti	O
-	O
inflammatory	O
protein	O
A20	O
and	O
the	O
critical	O
autophagic	O
mediator	O
Atg16l1	O
physically	O
interact	O
and	O
synergize	O
to	O
regulate	O
the	O
stability	O
of	O
the	O
intestinal	O
epithelial	O
barrier	O
.	O

A	O
proteomic	O
screen	O
using	O
the	O
WD40	O
domain	O
of	O
ATG16L1	O
(	O
WDD	O
)	O
identified	O
A20	O
as	O
a	O
WDD	O
-	O
interacting	O
protein	O
.	O

Loss	O
of	O
A20	O
and	O
Atg16l1	O
in	O
mouse	O
intestinal	O
epithelium	O
induces	O
spontaneous	O
IBD	O
-	O
like	O
pathology	O
,	O
as	O
characterized	O
by	O
severe	O
inflammation	O
and	O
increased	O
intestinal	O
epithelial	O
cell	O
death	O
in	O
both	O
small	O
and	O
large	O
intestine	O
.	O

Mechanistically	O
,	O
absence	O
of	O
A20	O
promotes	O
Atg16l1	O
accumulation	O
,	O
while	O
elimination	O
of	O
Atg16l1	O
or	O
expression	O
of	O
WDD	O
-	O
deficient	O
Atg16l1	O
stabilizes	O
A20	O
.	O

Collectively	O
our	O
data	O
show	O
that	O
A20	O
and	O
Atg16l1	O
cooperatively	O
control	O
intestinal	O
homeostasis	O
by	O
acting	O
at	O
the	O
intersection	O
of	O
inflammatory	O
,	O
autophagy	O
and	O
cell	O
death	O
pathways	O
.	O

The	O
role	O
of	O
gut	O
microbiota	O
in	O
obesity	O
,	O
diabetes	O
mellitus	O
,	O
and	O
effect	O
of	O
metformin	O
:	O
new	O
insights	O
into	O
old	O
diseases	O
.	O

There	O
is	O
a	O
recent	O
growing	O
evidence	O
that	O
abnormalities	O
in	O
the	O
microbiota	O
composition	O
can	O
have	O
a	O
major	O
role	O
in	O
the	O
development	O
of	O
obesity	O
and	O
diabetes	O
and	O
that	O
some	O
actions	O
of	O
metformin	O
may	O
be	O
mediated	O
by	O
gut	O
bacteria	O
.	O

Several	O
mechanisms	O
have	O
been	O
found	O
.	O

A	O
reduced	O
microbial	O
diversity	O
is	O
associated	O
to	O
inflammation	O
,	O
insulin	O
-	O
resistance	O
,	O
and	O
adiposity	O
.	O

In	O
particular	O
,	O
a	O
rise	O
in	O
the	O
Firmicutes	B-bacteria
/	O
Bacteroidetes	B-bacteria
ratio	O
is	O
related	O
to	O
a	O
low	O
-	O
grade	O
inflammation	O
and	O
to	O
an	O
increased	O
capability	O
of	O
harvesting	O
energy	O
from	O
food	O
.	O

Interestingly	O
,	O
high	O
-	O
fat	O
-	O
diet	O
favors	O
the	O
growth	O
of	O
bacteria	O
capable	O
of	O
extracting	O
more	O
energy	O
from	O
food	O
.	O

Changes	O
in	O
some	O
metabolites	O
,	O
such	O
as	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
produced	O
by	O
gut	O
microbiota	O
,	O
and	O
decreased	O
amounts	O
of	O
the	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
are	O
associated	O
with	O
the	O
presence	O
of	O
type	O
2	O
diabetes	O
.	O

Among	O
the	O
mechanisms	O
by	O
which	O
metformin	O
acts	O
on	O
glucose	O
metabolism	O
and	O
on	O
the	O
cardiovascular	O
risk	O
,	O
some	O
of	O
them	O
are	O
due	O
to	O
positive	O
effects	O
on	O
gut	O
microbiota	O
.	O

A	O
shift	O
toward	O
positive	O
SCFAs	O
produced	O
by	O
bacteria	O
,	O
an	O
increase	O
in	O
some	O
bacterial	O
strains	O
,	O
including	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
,	O
and	O
some	O
actions	O
on	O
bile	O
acids	O
mediated	O
by	O
microbiota	O
have	O
been	O
described	O
.	O

All	O
these	O
recent	O
advances	O
have	O
been	O
reported	O
and	O
discussed	O
.	O

Cancer	O
Immune	O
Checkpoint	O
Inhibitor	O
Therapy	O
and	O
the	O
Gut	O
Microbiota	O
.	O

The	O
past	O
decade	O
has	O
seen	O
tremendous	O
advances	O
in	O
both	O
our	O
understanding	O
of	O
cancer	O
immunosuppressive	O
microenvironments	O
and	O
colonic	O
bacteria	O
facilitated	O
by	O
immune	O
checkpoint	O
inhibitor	O
antibodies	O
and	O
next	O
generation	O
sequencing	O
,	O
respectively	O
.	O

Because	O
an	O
important	O
role	O
of	O
the	O
host	O
immune	O
system	O
is	O
to	O
communicate	O
with	O
and	O
regulate	O
the	O
gut	O
microbial	O
community	O
,	O
it	O
should	O
not	O
come	O
as	O
a	O
surprise	O
that	O
the	O
behavior	O
of	O
one	O
is	O
coupled	O
to	O
the	O
other	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
attempt	O
to	O
dissect	O
some	O
of	O
the	O
studies	O
demonstrating	O
cancer	O
immunotherapy	O
modulation	O
by	O
specific	O
gut	O
microbes	O
and	O
discuss	O
possible	O
molecular	O
mechanisms	O
for	O
this	O
effect	O
.	O

Antiobesity	O
Effects	O
of	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
LMT1	I-bacteria
-	I-bacteria
48	I-bacteria
Accompanied	O
by	O
Inhibition	O
of	O
Enterobacter	B-bacteria
cloacae	I-bacteria
in	O
the	O
Intestine	O
of	O
Diet	O
-	O
Induced	O
Obese	O
Mice	O
.	O

The	O
gut	O
microbiota	O
is	O
the	O
most	O
important	O
environmental	O
factor	O
that	O
plays	O
a	O
role	O
in	O
inducing	O
obesity	O
.	O

The	O
gram	O
-	O
negative	O
bacteria	O
,	O
Enterobacter	B-bacteria
cloacae	I-bacteria
strains	I-bacteria
,	O
recently	O
identified	O
in	O
obese	O
mice	O
are	O
considered	O
to	O
be	O
pathogenic	O
bacteria	O
in	O
the	O
gut	O
.	O

Probiotics	O
are	O
important	O
members	O
of	O
the	O
gut	O
microbiota	O
and	O
exert	O
beneficial	O
effects	O
,	O
including	O
inhibiting	O
the	O
growth	O
of	O
potential	O
pathogenic	O
bacteria	O
.	O

Therefore	O
,	O
we	O
isolated	O
a	O
total	O
of	O
230	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
from	O
traditional	O
,	O
Korean	O
fermented	O
foods	O
and	O
fecal	O
samples	O
from	O
newborn	O
infants	O
,	O
including	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
LMT1	I-bacteria
-	I-bacteria
48	I-bacteria
,	O
which	O
exhibited	O
maximal	O
antimicrobial	O
activity	O
against	O
E	B-bacteria
.	I-bacteria
cloacae	I-bacteria
.	O

We	O
next	O
investigated	O
the	O
functional	O
antiobesity	O
effects	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
LMT1	I-bacteria
-	I-bacteria
48	I-bacteria
in	O
an	O
E	O
.	O
cloacae	O
-	O
induced	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
fed	O
animal	O
obesity	O
model	O
.	O

To	O
this	O
end	O
,	O
the	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
LMT1	I-bacteria
-	I-bacteria
48	I-bacteria
showed	O
antiobesity	O
effects	O
,	O
including	O
body	O
weight	O
loss	O
and	O
reduction	O
of	O
abdominal	O
fat	O
volume	O
,	O
which	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
leptin	O
and	O
total	O
cholesterol	O
levels	O
in	O
E	O
.	O
cloacae	O
-	O
induced	O
HFD	O
-	O
fed	O
mice	O
.	O

Notably	O
,	O
gut	O
microbiota	O
diversity	O
also	O
increased	O
after	O
long	O
-	O
term	O
ingestion	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
LMT1	I-bacteria
-	I-bacteria
48	I-bacteria
,	O
resulting	O
in	O
amelioration	O
of	O
obesity	O
in	O
E	B-bacteria
.	I-bacteria
cloacae	I-bacteria
-	O
induced	O
HFD	O
-	O
fed	O
mice	O
.	O

Accordingly	O
,	O
results	O
suggest	O
that	O
dietary	O
intake	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
LMT1	I-bacteria
-	I-bacteria
48	I-bacteria
protects	O
against	O
the	O
onset	O
of	O
E	O
.	O
cloacae	O
-	O
induced	O
obesity	O
.	O

Household	O
composition	O
and	O
the	O
infant	O
fecal	O
microbiome	O
:	O
The	O
INSPIRE	O
study	O
.	O

OBJECTIVES	O
:	O
Establishment	O
and	O
development	O
of	O
the	O
infant	O
gastrointestinal	O
microbiome	O
(	O
GIM	O
)	O
varies	O
cross	O
-	O
culturally	O
and	O
is	O
thought	O
to	O
be	O
influenced	O
by	O
factors	O
such	O
as	O
gestational	O
age	O
,	O
birth	O
mode	O
,	O
diet	O
,	O
and	O
antibiotic	O
exposure	O
.	O

However	O
,	O
there	O
is	O
little	O
data	O
as	O
to	O
how	O
the	O
composition	O
of	O
infants	O
'	O
households	O
may	O
play	O
a	O
role	O
,	O
particularly	O
from	O
a	O
cross	O
-	O
cultural	O
perspective	O
.	O

Here	O
,	O
we	O
examined	O
relationships	O
between	O
infant	O
fecal	O
microbiome	O
(	O
IFM	O
)	O
diversity	O
/	O
composition	O
and	O
infants	O
'	O
household	O
size	O
,	O
number	O
of	O
siblings	O
,	O
and	O
number	O
of	O
other	O
household	O
members	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
analyzed	O
377	O
fecal	O
samples	O
from	O
healthy	O
,	O
breastfeeding	O
infants	O
across	O
11	O
sites	O
in	O
eight	O
different	O
countries	O
(	O
Ethiopia	O
,	O
The	O
Gambia	O
,	O
Ghana	O
,	O
Kenya	O
,	O
Peru	O
,	O
Spain	O
,	O
Sweden	O
,	O
and	O
the	O
United	O
States	O
)	O
.	O

Fecal	O
microbial	O
community	O
structure	O
was	O
determined	O
by	O
amplifying	O
,	O
sequencing	O
,	O
and	O
classifying	O
(	O
to	O
the	O
genus	O
level	O
)	O
the	O
V1	O
-	O
V3	O
region	O
of	O
the	O
bacterial	O
16S	O
rRNA	O
gene	O
.	O

Surveys	O
administered	O
to	O
infants	O
'	O
mothers	O
identified	O
household	O
members	O
and	O
composition	O
.	O

RESULTS	O
:	O
Our	O
results	O
indicated	O
that	O
household	O
composition	O
(	O
represented	O
by	O
the	O
number	O
of	O
cohabitating	O
siblings	O
and	O
other	O
household	O
members	O
)	O
did	O
not	O
have	O
a	O
measurable	O
impact	O
on	O
the	O
bacterial	O
diversity	O
,	O
evenness	O
,	O
or	O
richness	O
of	O
the	O
IFM	O
.	O

However	O
,	O
we	O
observed	O
that	O
variation	O
in	O
household	O
composition	O
categories	O
did	O
correspond	O
to	O
differential	O
relative	O
abundances	O
of	O
specific	O
taxa	O
,	O
namely	O
:	O
Lactobacillus	B-bacteria
,	O
Clostridium	B-bacteria
,	O
Enterobacter	B-bacteria
,	O
and	O
Klebsiella	B-bacteria
.	O

DISCUSSION	O
:	O
This	O
study	O
,	O
to	O
our	O
knowledge	O
,	O
is	O
the	O
largest	O
cross	O
-	O
cultural	O
study	O
to	O
date	O
examining	O
the	O
association	O
between	O
household	O
composition	O
and	O
the	O
IFM	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
social	O
environment	O
of	O
infants	O
(	O
represented	O
here	O
by	O
the	O
proxy	O
of	O
household	O
composition	O
)	O
may	O
influence	O
the	O
bacterial	O
composition	O
of	O
the	O
infant	O
GIM	O
,	O
although	O
the	O
mechanism	O
is	O
unknown	O
.	O

A	O
higher	O
number	O
and	O
diversity	O
of	O
cohabitants	O
and	O
potential	O
caregivers	O
may	O
facilitate	O
social	O
transmission	O
of	O
beneficial	O
bacteria	O
to	O
the	O
infant	O
gastrointestinal	O
tract	O
,	O
by	O
way	O
of	O
shared	O
environment	O
or	O
through	O
direct	O
physical	O
and	O
social	O
contact	O
between	O
the	O
maternal	O
-	O
infant	O
dyad	O
and	O
other	O
household	O
members	O
.	O

These	O
findings	O
contribute	O
to	O
the	O
discussion	O
concerning	O
ways	O
by	O
which	O
infants	O
are	O
influenced	O
by	O
their	O
social	O
environments	O
and	O
add	O
further	O
dimensionality	O
to	O
the	O
ongoing	O
exploration	O
of	O
social	O
transmission	O
of	O
gut	O
microbiota	O
and	O
the	O
`	O
`	O
old	O
friends	O
'	O
'	O
hypothesis	O
.	O

Gastrointestinal	O
microbiota	O
alteration	O
induced	O
by	O
Mucor	B-bacteria
circinelloides	I-bacteria
in	O
a	O
murine	O
model	O
.	O

Mucor	O
circinelloides	O
is	O
a	O
pathogenic	O
fungus	O
and	O
etiologic	O
agent	O
of	O
mucormycosis	O
.	O

In	O
2013	O
,	O
cases	O
of	O
gastrointestinal	O
illness	O
after	O
yogurt	O
consumption	O
were	O
reported	O
to	O
the	O
US	O
FDA	O
,	O
and	O
the	O
producer	O
found	O
that	O
its	O
products	O
were	O
contaminated	O
with	O
Mucor	O
.	O

A	O
previous	O
study	O
found	O
that	O
the	O
Mucor	B-bacteria
strain	I-bacteria
isolated	O
from	O
an	O
open	O
contaminated	O
yogurt	O
exhibited	O
virulence	O
in	O
a	O
murine	O
systemic	O
infection	O
model	O
and	O
showed	O
that	O
this	O
strain	O
is	O
capable	O
of	O
surviving	O
passage	O
through	O
the	O
gastrointestinal	O
tract	O
of	O
mice	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
another	O
Mucor	B-bacteria
strain	I-bacteria
from	O
an	O
unopened	O
yogurt	O
that	O
is	O
closely	O
related	O
but	O
distinct	O
from	O
the	O
first	O
Mucor	B-bacteria
strain	I-bacteria
and	O
subsequently	O
examined	O
if	O
Mucor	B-bacteria
alters	I-bacteria
the	O
gut	O
microbiota	O
in	O
a	O
murine	O
host	O
model	O
.	O

DNA	O
extracted	O
from	O
a	O
ten	O
-	O
day	O
course	O
of	O
stool	O
samples	O
was	O
used	O
to	O
analyze	O
the	O
microbiota	O
in	O
the	O
gastrointestinal	O
tracts	O
of	O
mice	O
exposed	O
via	O
ingestion	O
of	O
Mucor	O
spores	O
.	O

The	O
bacterial	O
16S	O
rRNA	O
gene	O
and	O
fungal	O
ITS1	O
sequences	O
obtained	O
were	O
used	O
to	O
identify	O
taxa	O
of	O
each	O
kingdom	O
.	O

Linear	O
regressions	O
revealed	O
that	O
there	O
are	O
changes	O
in	O
bacterial	O
and	O
fungal	O
abundance	O
in	O
the	O
gastrointestinal	O
tracts	O
of	O
mice	O
which	O
ingested	O
Mucor	O
.	O

Furthermore	O
,	O
we	O
found	O
an	O
increased	O
abundance	O
of	O
the	O
bacterial	O
genus	O
Bacteroides	B-bacteria
and	O
a	O
decreased	O
abundance	O
of	O
the	O
bacteria	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
in	O
the	O
gastrointestinal	O
tracts	O
of	O
exposed	O
mice	O
.	O

Measurements	O
of	O
abundances	O
show	O
shifts	O
in	O
relative	O
levels	O
of	O
multiple	O
bacterial	O
and	O
fungal	O
taxa	O
between	O
mouse	O
groups	O
.	O

These	O
findings	O
suggest	O
that	O
exposure	O
of	O
the	O
gastrointestinal	O
tract	O
to	O
Mucor	O
can	O
alter	O
the	O
microbiota	O
and	O
,	O
more	O
importantly	O
,	O
illustrate	O
an	O
interaction	O
between	O
the	O
intestinal	O
mycobiota	O
and	O
bacteriota	B-bacteria
.	O

In	O
addition	O
,	O
Mucor	O
was	O
able	O
to	O
induce	O
increased	O
permeability	O
in	O
epithelial	O
cell	O
monolayers	O
in	O
vitro	O
,	O
which	O
might	O
be	O
indicative	O
of	O
unstable	O
intestinal	O
barriers	O
.	O

Understanding	O
how	O
the	O
gut	O
microbiota	O
is	O
shaped	O
is	O
important	O
to	O
understand	O
the	O
basis	O
of	O
potential	O
methods	O
of	O
treatment	O
for	O
gastrointestinal	O
illness	O
.	O

How	O
the	O
gut	O
microbiota	O
changes	O
in	O
response	O
to	O
exposure	O
,	O
even	O
by	O
pathogens	O
not	O
considered	O
to	O
be	O
causative	O
agents	O
of	O
food	O
-	O
borne	O
illness	O
,	O
may	O
be	O
important	O
to	O
how	O
commercial	O
food	O
producers	O
prevent	O
and	O
respond	O
to	O
contamination	O
of	O
products	O
aimed	O
at	O
the	O
public	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
the	O
fungal	O
microbiota	O
,	O
though	O
understudied	O
,	O
may	O
play	O
an	O
important	O
role	O
in	O
diseases	O
of	O
the	O
human	O
gut	O
.	O

Improvement	O
of	O
growth	O
performance	O
and	O
parameters	O
of	O
intestinal	O
function	O
in	O
liquid	O
fed	O
early	O
weanling	O
pigs	O
.	O

Liquid	O
feeding	O
,	O
a	O
widely	O
used	O
technique	O
,	O
has	O
been	O
applied	O
as	O
a	O
feeding	O
technique	O
commonly	O
in	O
global	O
swine	O
production	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
liquid	O
feeding	O
on	O
growth	O
performance	O
,	O
nutrient	O
digestibility	O
,	O
and	O
intestinal	O
barrier	O
functions	O
during	O
the	O
early	O
weaning	O
period	O
in	O
pigs	O
.	O

Three	O
hundred	O
and	O
sixty	O
24	O
-	O
d	O
-	O
old	O
weanling	O
pigs	O
(	O
Duroc	O
x	O
Landrace	O
x	O
Yorkshire	O
)	O
with	O
BW	O
of	O
6	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
15	O
kg	O
were	O
randomly	O
assigned	O
to	O
a	O
control	O
diet	O
(	O
dry	O
fed	O
basal	O
diet	O
,	O
CON	O
)	O
or	O
as	O
meal	O
mixed	O
with	O
water	O
in	O
the	O
ratio	O
1	O
:	O
4	O
(	O
liquid	O
fed	O
basal	O
diet	O
,	O
LF	O
)	O
with	O
6	O
replicates	O
per	O
treatment	O
and	O
30	O
weanling	O
pigs	O
per	O
replicate	O
.	O

The	O
study	O
lasted	O
7	O
d	O
.	O
On	O
days	O
4	O
-	O
7	O
,	O
fresh	O
fecal	O
samples	O
were	O
collected	O
to	O
evaluate	O
apparent	O
total	O
tract	O
digestibility	O
(	O
ATTD	O
)	O
of	O
nutrients	O
.	O

After	O
7	O
d	O
,	O
2	O
weanling	O
pigs	O
per	O
pen	O
were	O
euthanized	O
and	O
physiological	O
samples	O
were	O
obtained	O
.	O

Results	O
showed	O
that	O
LF	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
ADG	O
(	O
281	O
g	O
vs	O
.	O
183	O
g	O
)	O
,	O
ADFI	O
(	O
374	O
g	O
vs	O
.	O
245	O
g	O
)	O
and	O
final	O
BW	O
(	O
8	O
.	O
95	O
kg	O
vs	O
.	O
8	O
.	O
26	O
kg	O
)	O
compared	O
to	O
CON	O
.	O

Compared	O
with	O
CON	O
,	O
LF	O
significantly	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
serum	O
cortisol	O
and	O
D	O
-	O
lactate	O
concentrations	O
as	O
well	O
as	O
the	O
activity	O
of	O
diamine	O
oxidase	O
,	O
enhanced	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
ATTD	O
of	O
ether	O
extract	O
and	O
ash	O
,	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
activities	O
of	O
amylase	O
,	O
lipase	O
and	O
lactase	O
in	O
the	O
jejunal	O
mucosa	O
.	O

Furthermore	O
,	O
LF	O
had	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
villus	O
height	O
and	O
villi	O
height	O
:	O
crypt	O
depth	O
,	O
and	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
mRNA	O
expressions	O
of	O
insulin	O
-	O
like	O
growth	O
factors	O
-	O
1	O
receptor	O
(	O
IGF1	O
-	O
R	O
)	O
,	O
claudin	O
-	O
2	O
(	O
CLDN	O
-	O
2	O
)	O
,	O
zonula	O
occludens	O
-	O
1	O
(	O
ZO	O
-	O
1	O
)	O
and	O
zonula	O
occludens	O
-	O
2	O
(	O
ZO	O
-	O
2	O
)	O
in	O
the	O
jejunum	O
.	O

Moreover	O
,	O
LF	O
had	O
lower	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
abundances	O
of	O
total	O
bacteria	O
and	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
concentrations	O
of	O
acetic	O
acid	O
and	O
butyric	O
acid	O
in	O
cecal	O
digesta	O
.	O

Altogether	O
,	O
the	O
results	O
indicated	O
that	O
liquid	O
feeding	O
not	O
only	O
promoted	O
growth	O
performance	O
but	O
also	O
improved	O
intestinal	O
health	O
by	O
enhancing	O
gut	O
barrier	O
functions	O
in	O
weanling	O
pigs	O
.	O

Changes	O
in	O
urinary	O
metabolome	O
related	O
to	O
body	O
fat	O
involve	O
intermediates	O
of	O
choline	O
processing	O
by	O
gut	O
microbiota	O
.	O

Countering	O
the	O
obesity	O
pandemic	O
will	O
require	O
better	O
understanding	O
of	O
disease	O
mechanisms	O
and	O
development	O
of	O
new	O
diagnostic	O
methods	O
.	O

Small	O
molecule	O
metabolites	O
excreted	O
in	O
urine	O
can	O
be	O
important	O
biomarkers	O
of	O
disease	O
progression	O
and	O
treatment	O
.	O

However	O
,	O
with	O
multiple	O
pathways	O
involved	O
,	O
it	O
has	O
been	O
challenging	O
to	O
identify	O
key	O
pathway	O
(	O
s	O
)	O
that	O
closely	O
follow	O
disease	O
features	O
such	O
as	O
body	O
fat	O
.	O

We	O
employed	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
mouse	O
model	O
of	O
obesity	O
with	O
the	O
goal	O
of	O
determining	O
changes	O
in	O
urinary	O
metabolite	O
profile	O
related	O
to	O
body	O
fat	O
using	O
proton	O
nuclear	O
magnetic	O
resonance	O
(	O
(	O
1	O
)	O
H	O
NMR	O
)	O
.	O

Several	O
urinary	O
metabolites	O
with	O
significantly	O
lower	O
levels	O
in	O
HFD	O
compared	O
to	O
control	O
mice	O
have	O
been	O
identified	O
.	O

Specifically	O
,	O
major	O
changes	O
were	O
found	O
in	O
metabolites	O
from	O
tricarboxylic	O
acid	O
(	O
TCA	O
)	O
cycle	O
,	O
amino	O
acid	O
,	O
nicotinamide	O
,	O
and	O
choline	O
metabolism	O
including	O
2	O
-	O
hydroxydlutarate	O
,	O
cis	O
-	O
aconitate	O
,	O
trans	O
-	O
aconitate	O
,	O
alanine	O
,	O
creatine	O
,	O
trigonelline	O
,	O
dimethylamine	O
,	O
and	O
trimethylamine	O
.	O

However	O
,	O
levels	O
of	O
only	O
two	O
metabolites	O
,	O
namely	O
dimethylamine	O
and	O
trimethylamine	O
,	O
showed	O
significant	O
reverse	O
correlation	O
with	O
total	O
body	O
fat	O
.	O

These	O
metabolites	O
derive	O
from	O
choline	O
processing	O
by	O
gut	O
microbiota	O
and	O
may	O
be	O
prospective	O
biomarkers	O
indicative	O
of	O
accumulation	O
of	O
body	O
fat	O
in	O
obesity	O
.	O

High	O
dietary	O
fat	O
intake	O
lowers	O
serum	O
equol	O
concentration	O
and	O
promotes	O
prostate	O
carcinogenesis	O
in	O
a	O
transgenic	O
mouse	O
prostate	O
model	O
.	O

Background	O
:	O
Consumption	O
of	O
diet	O
high	O
in	O
soy	O
products	O
is	O
suggested	O
to	O
contribute	O
to	O
lower	O
prostate	O
cancer	O
incidence	O
in	O
Asian	O
men	O
.	O

But	O
little	O
has	O
been	O
known	O
about	O
the	O
influences	O
of	O
dietary	O
patterns	O
on	O
gut	O
microbiota	O
and	O
microbiota	O
-	O
mediated	O
isoflavone	O
metabolism	O
.	O

Here	O
,	O
we	O
determined	O
the	O
influences	O
of	O
western	O
pattern	O
diet	O
on	O
prostate	O
carcinogenesis	O
,	O
gut	O
microbiota	O
and	O
microbiota	O
-	O
mediated	O
equol	O
metabolism	O
using	O
a	O
transgenic	O
adenocarcinoma	O
of	O
mouse	O
prostate	O
(	O
TRAMP	O
)	O
model	O
.	O

Methods	O
:	O
We	O
mimicked	O
the	O
western	O
pattern	O
diet	O
using	O
a	O
high	O
fat	O
diet	O
(	O
HFD	O
)	O
.	O

TRAMP	O
mice	O
were	O
fed	O
with	O
either	O
control	O
diet	O
(	O
CD	O
)	O
or	O
HFD	O
.	O

At	O
the	O
age	O
of	O
24	O
weeks	O
,	O
mice	O
were	O
orally	O
administered	O
daidzein	O
over	O
a	O
4	O
-	O
day	O
period	O
,	O
and	O
then	O
sacrificed	O
.	O

The	O
serum	O
daidzein	O
and	O
equol	O
were	O
analyzed	O
by	O
ultra	O
high	O
performance	O
liquid	O
chromatography	O
.	O

Fecal	O
microbiome	O
was	O
analyzed	O
with	O
fecal	O
16S	O
rRNA	O
pyrosequencing	O
,	O
and	O
prostate	O
was	O
dissected	O
and	O
performed	O
with	O
histopathology	O
.	O

Results	O
:	O
HFD	O
could	O
promote	O
prostate	O
carcinogenesis	O
in	O
TRAMP	O
mice	O
(	O
p	O
=	O
0	O
.	O
045	O
)	O
.	O

The	O
daidzein	O
showed	O
no	O
significant	O
differences	O
between	O
CD	O
and	O
HFD	O
groups	O
,	O
while	O
equol	O
was	O
significantly	O
decreased	O
in	O
HFD	O
group	O
(	O
p	O
=	O
0	O
.	O
019	O
)	O
.	O

Fecal	O
microbiotas	O
differed	O
between	O
the	O
two	O
groups	O
,	O
21	O
microbial	O
phylotypes	O
were	O
increased	O
and	O
11	O
phylotypes	O
were	O
decreased	O
in	O
abundance	O
in	O
HFD	O
group	O
,	O
including	O
decreased	O
abundance	O
of	O
equol	O
-	O
producing	O
bacterium	O
Adlercreutzia	B-bacteria
(	O
0	O
.	O
08	O
%	O
vs	O
.	O
0	O
.	O
27	O
%	O
)	O
.	O

Conclusions	O
:	O
HFD	O
may	O
promote	O
prostate	O
carcinogenesis	O
through	O
adversely	O
affecting	O
equol	O
-	O
producing	O
bacterium	O
.	O

Further	O
functional	O
validations	O
are	O
required	O
to	O
ascertain	O
the	O
mechanism	O
of	O
those	O
HFD	O
-	O
responsive	O
bacteria	O
in	O
carcinogenesis	O
.	O

Selection	O
of	O
carbohydrate	O
-	O
active	O
probiotics	O
from	O
the	O
gut	O
of	O
carnivorous	O
fish	O
fed	O
plant	O
-	O
based	O
diets	O
.	O

The	O
gastrointestinal	O
microbiota	O
plays	O
a	O
critical	O
role	O
on	O
host	O
health	O
and	O
metabolism	O
.	O

This	O
is	O
particularly	O
important	O
in	O
teleost	O
nutrition	O
,	O
because	O
fish	O
do	O
not	O
possess	O
some	O
of	O
the	O
necessary	O
enzymes	O
to	O
cope	O
with	O
the	O
dietary	O
challenges	O
of	O
aquaculture	O
production	O
.	O

A	O
main	O
difficulty	O
within	O
fish	O
nutrition	O
is	O
its	O
dependence	O
on	O
fish	O
meal	O
,	O
an	O
unsustainable	O
commodity	O
and	O
a	O
source	O
of	O
organic	O
pollutants	O
.	O

The	O
most	O
obvious	O
sustainable	O
alternatives	O
to	O
fish	O
meal	O
are	O
plant	O
feedstuffs	O
,	O
but	O
their	O
nutritive	O
value	O
is	O
limited	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
non	O
-	O
starch	O
polysaccharides	O
(	O
NSP	O
)	O
,	O
which	O
are	O
not	O
metabolized	O
by	O
fish	O
.	O

The	O
composition	O
of	O
fish	O
-	O
gut	O
microbial	O
communities	O
have	O
been	O
demonstrated	O
to	O
adapt	O
when	O
the	O
host	O
is	O
fed	O
different	O
ingredients	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
a	O
selective	O
pressure	O
of	O
plant	O
-	O
based	O
diets	O
on	O
fish	O
gut	O
microbiota	O
,	O
could	O
be	O
a	O
beneficial	O
strategy	O
for	O
an	O
enrichment	O
of	O
bacteria	O
with	O
a	O
secretome	O
able	O
to	O
mobilize	O
dietary	O
NSP	O
.	O

By	O
targeting	O
bacterial	O
sporulating	O
isolates	O
with	O
diverse	O
carbohydrase	O
activities	O
from	O
the	O
gut	O
of	O
European	O
sea	O
bass	O
,	O
we	O
have	O
obtained	O
isolates	O
with	O
high	O
probiotic	O
potential	O
.	O

By	O
inferring	O
the	O
adaptive	O
fitness	O
to	O
the	O
fish	O
gut	O
and	O
the	O
amenability	O
to	O
industrial	O
processing	O
,	O
we	O
identified	O
the	O
best	O
two	O
candidates	O
to	O
become	O
industrially	O
valuable	O
probiotics	O
.	O

This	O
potential	O
was	O
confirmed	O
in	O
vivo	O
,	O
since	O
one	O
of	O
the	O
select	O
isolates	O
lead	O
to	O
a	O
better	O
growth	O
and	O
feed	O
utilization	O
efficiency	O
in	O
fish	O
fed	O
probiotic	O
-	O
supplemented	O
plant	O
-	O
based	O
diets	O
,	O
thus	O
contributing	O
for	O
sustainable	O
and	O
more	O
cost	O
-	O
effective	O
aquaculture	O
practices	O
.	O

beta	O
-	O
xylosidase	O
and	O
beta	O
-	O
mannosidase	O
in	O
combination	O
improved	O
growth	O
performance	O
and	O
altered	O
microbial	O
profiles	O
in	O
weanling	O
pigs	O
fed	O
a	O
corn	O
-	O
soybean	O
meal	O
-	O
based	O
diet	O
.	O

Objective	O
:	O
In	O
this	O
study	O
,	O
two	O
glycosidases	O
(	O
XMosidases	O
)	O
,	O
beta	O
-	O
xylosidase	O
and	O
-	O
mannosidase	O
,	O
were	O
investigated	O
on	O
their	O
in	O
vitro	O
hydrolysis	O
activities	O
of	O
feed	O
and	O
on	O
the	O
improvement	O
of	O
growth	O
performance	O
in	O
vivo	O
in	O
weanling	O
pigs	O
.	O

Methods	O
:	O
Enzyme	O
activities	O
of	O
XMosidases	O
in	O
vitro	O
were	O
evaluated	O
in	O
test	O
tubes	O
and	O
simulation	O
of	O
gastric	O
and	O
small	O
intestinal	O
digestion	O
,	O
respectively	O
,	O
in	O
the	O
presence	O
of	O
NSPase	O
.	O

In	O
vivo	O
study	O
was	O
performed	O
in	O
108	O
weaned	O
piglets	O
in	O
a	O
28	O
-	O
d	O
treatment	O
.	O

Pigs	O
were	O
allotted	O
to	O
one	O
of	O
three	O
dietary	O
treatments	O
with	O
six	O
replicate	O
pens	O
in	O
each	O
treatment	O
.	O

The	O
three	O
treatment	O
groups	O
were	O
as	O
follows	O
:	O
i	O
)	O
Control	O
(	O
basal	O
diet	O
)	O
.	O

ii	O
)	O
CE	O
(	O
basal	O
diets	O
+	O
CE	O
)	O
;	O
iii	O
)	O
CE	O
-	O
Xmosidases	O
(	O
basal	O
diets	O
+	O
CE	O
+	O
beta	O
-	O
xylosidase	O
at	O
800U	O
/	O
kg	O
and	O
beta	O
-	O
mannosidase	O
at	O
40U	O
/	O
kg	O
)	O
.	O

CE	O
was	O
complex	O
enzymes	O
(	O
amylase	O
,	O
protease	O
,	O
xylanase	O
and	O
mannanase	O
)	O
.	O

Results	O
:	O
In	O
vitro	O
XMosidases	O
displayed	O
significant	O
activities	O
on	O
hydrolysis	O
of	O
corn	O
and	O
soybean	O
meal	O
in	O
the	O
presence	O
of	O
non	O
-	O
starch	O
polysaccharide	O
degrading	O
enzymes	O
(	O
xylanase	O
and	O
beta	O
-	O
mannanase	O
)	O
.	O

In	O
vitro	O
simulation	O
of	O
gastric	O
and	O
small	O
intestinal	O
digestion	O
by	O
XMosidases	O
showed	O
XMosidases	O
achieved	O
67	O
.	O
89	O
+	O
/	O
-	O
0	O
.	O
22	O
%	O
of	O
dry	O
matter	O
digestibility	O
and	O
63	O
.	O
12	O
+	O
/	O
-	O
0	O
.	O
21	O
%	O
of	O
energy	O
digestibility	O
at	O
40	O
degrees	O
C	O
for	O
5	O
hrs	O
.	O

In	O
weanling	O
pigs	O
,	O
additional	O
XMosidases	O
to	O
CE	O
in	O
feed	O
improved	O
ADG	O
,	O
F	O
:	O
G	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
ATTD	O
of	O
crude	O
protein	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
dry	O
matter	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

XMosidases	O
also	O
altered	O
the	O
gut	O
bacterial	O
diversity	O
and	O
composition	O
by	O
increasing	O
the	O
proportion	O
of	O
beneficial	O
bacteria	O
.	O

Conclusion	O
:	O
Addition	O
of	O
a	O
complex	O
enzyme	O
supplementation	O
(	O
contained	O
xylanase	O
,	O
beta	O
-	O
mannanase	O
,	O
protease	O
and	O
amylase	O
)	O
,	O
XMosidases	O
(	O
beta	O
-	O
xylosidase	O
and	O
beta	O
-	O
mannosidase	O
)	O
can	O
further	O
improve	O
the	O
growth	O
performance	O
and	O
nutrient	O
digestion	O
of	O
young	O
pigs	O
.	O

Orally	O
administered	O
Lactobacillus	B-bacteria
casei	I-bacteria
exhibited	O
several	O
probiotic	O
properties	O
in	O
artificially	O
suckling	O
rabbits	O
.	O

Objective	O
:	O
Lactobacilli	B-bacteria
in	O
rabbit	O
intestine	O
is	O
rare	O
and	O
its	O
function	O
on	O
rabbit	O
gut	O
health	O
is	O
not	O
fully	O
understood	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
in	O
vivo	O
the	O
probiotic	O
potential	O
of	O
Lactobacillus	B-bacteria
casei	I-bacteria
for	O
suckling	O
rabbits	O
.	O

Methods	O
:	O
Two	O
healthy	O
5	O
-	O
day	O
-	O
old	O
suckling	O
rabbits	O
with	O
similar	O
weights	O
from	O
each	O
of	O
12	O
New	O
Zealand	O
White	O
litters	O
were	O
selected	O
and	O
disturbed	O
to	O
control	O
group	O
and	O
treatment	O
group	O
.	O

All	O
rabbits	O
were	O
artificially	O
fed	O
.	O

The	O
treatment	O
group	O
had	O
been	O
supplemented	O
with	O
live	O
Lactobacillus	B-bacteria
casei	I-bacteria
in	O
the	O
milk	O
from	O
the	O
beginning	O
of	O
the	O
trial	O
to	O
13	O
days	O
of	O
age	O
.	O

At	O
15	O
days	O
of	O
age	O
,	O
healthy	O
paired	O
rabbits	O
were	O
slaughtered	O
to	O
collect	O
intestinal	O
samples	O
.	O

Results	O
:	O
1	O
)	O
Oral	O
administration	O
of	O
Lactobacillus	B-bacteria
casei	I-bacteria
significantly	O
increased	O
the	O
proportion	O
of	O
Lactobacilli	B-bacteria
in	O
the	O
total	O
intestinal	O
bacteria	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
obviously	O
reduced	O
that	O
of	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
(	O
P	O
<	O
0	O
.	O
01	O
)	O
;	O
2	O
)	O
treatment	O
increased	O
the	O
length	O
of	O
vermiform	O
appendix	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
3	O
)	O
a	O
higher	O
percentage	O
of	O
degranulated	O
paneth	O
cells	O
was	O
observed	O
in	O
the	O
duodenum	O
and	O
jejunum	O
when	O
rabbits	O
administered	O
with	O
Lactobacillus	B-bacteria
casei	I-bacteria
(	O
P	O
<	O
0	O
.	O
01	O
)	O
;	O
and	O
4	O
)	O
the	O
expression	O
of	O
toll	O
-	O
like	O
receptor	O
9	O
(	O
TLR9	O
)	O
,	O
Lysozyme	O
(	O
LYZ	O
)	O
and	O
defensin	O
-	O
7	O
-	O
like	O
(	O
DEFEN	O
)	O
in	O
the	O
duodenum	O
and	O
jejunum	O
was	O
stimulated	O
by	O
supplemented	O
Lactobacillus	B-bacteria
casei	I-bacteria
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Conclusion	O
:	O
orally	O
administered	O
Lactobacillus	B-bacteria
casei	I-bacteria
could	O
increase	O
the	O
abundance	O
of	O
intestinal	O
Lactobacilli	B-bacteria
,	O
decrease	O
the	O
relative	O
abundance	O
of	O
intestinal	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
,	O
promote	O
the	O
growth	O
of	O
appendix	O
vermiform	O
,	O
stimulate	O
the	O
degranulation	O
of	O
paneth	O
cells	O
and	O
induce	O
the	O
expression	O
of	O
defensin	O
-	O
7	O
-	O
like	O
and	O
Lysozyme	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
implied	O
that	O
Lactobacillus	B-bacteria
casei	I-bacteria
exhibited	O
probiotic	O
potential	O
for	O
suckling	O
rabbit	O
.	O

Evaluation	O
of	O
Phage	O
Therapy	O
in	O
the	O
Context	O
of	O
Enterococcus	B-bacteria
faecalis	I-bacteria
and	O
Its	O
Associated	O
Diseases	O
.	O

Bacteriophages	O
(	O
phages	O
)	O
or	O
bacterial	O
viruses	O
have	O
been	O
proposed	O
as	O
natural	O
antimicrobial	O
agents	O
to	O
fight	O
against	O
antibiotic	O
-	O
resistant	O
bacteria	O
associated	O
with	O
human	O
infections	O
.	O

Enterococcus	B-bacteria
faecalis	I-bacteria
is	O
a	O
gut	O
commensal	O
,	O
which	O
is	O
occasionally	O
found	O
in	O
the	O
mouth	O
and	O
vaginal	O
tract	O
,	O
and	O
does	O
not	O
usually	O
cause	O
clinical	O
problems	O
.	O

However	O
,	O
it	O
can	O
spread	O
to	O
other	O
areas	O
of	O
the	O
body	O
and	O
cause	O
life	O
-	O
threatening	O
infections	O
,	O
such	O
as	O
septicemia	O
,	O
endocarditis	O
,	O
or	O
meningitis	O
,	O
in	O
immunocompromised	O
hosts	O
.	O

Although	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
phage	O
cocktails	O
are	O
not	O
commercially	O
available	O
within	O
the	O
EU	O
or	O
USA	O
,	O
there	O
is	O
an	O
accumulated	O
evidence	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
that	O
have	O
shown	O
phage	O
efficacy	O
,	O
which	O
supports	O
the	O
idea	O
of	O
applying	O
phage	O
therapy	O
to	O
overcome	O
infections	O
associated	O
with	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
potency	O
of	O
bacteriophages	O
in	O
controlling	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
,	O
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
scenarios	O
.	O

E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
associated	O
bacteriophages	O
were	O
compared	O
at	O
the	O
genome	O
level	O
and	O
an	O
attempt	O
was	O
made	O
to	O
categorize	O
phages	O
with	O
respect	O
to	O
their	O
suitability	O
for	O
therapeutic	O
application	O
,	O
using	O
orthocluster	O
analysis	O
.	O

In	O
addition	O
,	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
phages	O
have	O
been	O
examined	O
for	O
the	O
presence	O
of	O
antibiotic	O
-	O
resistant	O
genes	O
,	O
to	O
ensure	O
their	O
safe	O
use	O
in	O
clinical	O
conditions	O
.	O

Finally	O
,	O
the	O
domain	O
architecture	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
phage	O
-	O
encoded	O
endolysins	O
are	O
discussed	O
.	O

From	O
Probiotics	O
to	O
Psychobiotics	O
:	O
Live	O
Beneficial	O
Bacteria	O
Which	O
Act	O
on	O
the	O
Brain	O
-	O
Gut	O
Axis	O
.	O

There	O
is	O
an	O
important	O
relationship	O
between	O
probiotics	O
,	O
psychobiotics	O
and	O
cognitive	O
and	O
behavioral	O
processes	O
,	O
which	O
include	O
neurological	O
,	O
metabolic	O
,	O
hormonal	O
and	O
immunological	O
signaling	O
pathways	O
;	O
the	O
alteration	O
in	O
these	O
systems	O
may	O
cause	O
alterations	O
in	O
behavior	O
(	O
mood	O
)	O
and	O
cognitive	O
level	O
(	O
learning	O
and	O
memory	O
)	O
.	O

Psychobiotics	O
have	O
been	O
considered	O
key	O
elements	O
in	O
affective	O
disorders	O
and	O
the	O
immune	O
system	O
,	O
in	O
addition	O
to	O
their	O
effect	O
encompassing	O
the	O
regulation	O
of	O
neuroimmune	O
regulation	O
and	O
control	O
axes	O
(	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
or	O
HPA	O
,	O
the	O
sympathetic	O
-	O
adrenal	O
-	O
medullary	O
axis	O
or	O
SAM	O
and	O
the	O
inflammatory	O
reflex	O
)	O
in	O
diseases	O
of	O
the	O
nervous	O
system	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
summarize	O
the	O
recent	O
findings	O
about	O
psychobiotics	O
,	O
the	O
brain	O
-	O
gut	O
axis	O
and	O
the	O
immune	O
system	O
.	O

The	O
review	O
focuses	O
on	O
a	O
very	O
new	O
and	O
interesting	O
field	O
that	O
relates	O
the	O
microbiota	O
of	O
the	O
intestine	O
with	O
diseases	O
of	O
the	O
nervous	O
system	O
and	O
its	O
possible	O
treatment	O
,	O
in	O
neuroimmunomodulation	O
area	O
.	O

Indeed	O
,	O
although	O
probiotic	O
bacteria	O
will	O
be	O
concentrated	O
after	O
ingestion	O
,	O
mainly	O
in	O
the	O
intestinal	O
epithelium	O
(	O
where	O
they	O
provide	O
the	O
host	O
with	O
essential	O
nutrients	O
and	O
modulation	O
of	O
the	O
immune	O
system	O
)	O
,	O
they	O
may	O
also	O
produce	O
neuroactive	O
substances	O
which	O
act	O
on	O
the	O
brain	O
-	O
gut	O
axis	O
.	O

Effects	O
of	O
Long	O
-	O
Term	O
Dietary	O
Protein	O
Restriction	O
on	O
Intestinal	O
Morphology	O
,	O
Digestive	O
Enzymes	O
,	O
Gut	O
Hormones	O
,	O
and	O
Colonic	O
Microbiota	O
in	O
Pigs	O
.	O

Using	O
protein	O
-	O
restriction	O
diets	O
becomes	O
a	O
potential	O
strategy	O
to	O
save	O
the	O
dietary	O
protein	O
resources	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
low	O
-	O
protein	O
diets	O
influencing	O
pigs	O
'	O
growth	O
performance	O
is	O
still	O
controversial	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
protein	O
-	O
restriction	O
diets	O
on	O
gastrointestinal	O
physiology	O
and	O
gut	O
microbiota	O
in	O
pigs	O
.	O

Eighteen	O
weaned	O
piglets	O
were	O
randomly	O
allocated	O
to	O
three	O
groups	O
with	O
different	O
dietary	O
protein	O
levels	O
.	O

After	O
a	O
16	O
-	O
week	O
trial	O
,	O
the	O
results	O
showed	O
that	O
feeding	O
a	O
low	O
-	O
protein	O
diet	O
to	O
pigs	O
impaired	O
the	O
epithelial	O
morphology	O
of	O
duodenum	O
and	O
jejunum	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
reduced	O
the	O
concentration	O
of	O
many	O
plasma	O
hormones	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
such	O
as	O
ghrelin	O
,	O
somatostatin	O
,	O
glucose	O
-	O
dependent	O
insulin	O
-	O
tropic	O
polypeptide	O
,	O
leptin	O
,	O
and	O
gastrin	O
.	O

The	O
relative	O
abundance	O
of	O
Streptococcus	B-bacteria
and	O
Lactobacillus	B-bacteria
in	O
colon	O
and	O
microbiota	O
metabolites	O
was	O
also	O
decreased	O
by	O
extreme	O
protein	O
-	O
restriction	O
diets	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
findings	O
suggested	O
that	O
long	O
-	O
term	O
ingestion	O
of	O
a	O
protein	O
-	O
restricted	O
diet	O
could	O
impair	O
intestinal	O
morphology	O
,	O
suppress	O
gut	O
hormone	O
secretion	O
,	O
and	O
change	O
the	O
microbial	O
community	O
and	O
fermentation	O
metabolites	O
in	O
pigs	O
,	O
while	O
the	O
moderately	O
low	O
-	O
protein	O
diet	O
had	O
a	O
minimal	O
effect	O
on	O
gut	O
function	O
and	O
did	O
not	O
impair	O
growth	O
performance	O
.	O

STAT2	O
dependent	O
Type	O
I	O
Interferon	O
response	O
promotes	O
dysbiosis	O
and	O
luminal	O
expansion	O
of	O
the	O
enteric	O
pathogen	O
Salmonella	B-bacteria
Typhimurium	I-bacteria
.	O

The	O
mechanisms	O
by	O
which	O
the	O
gut	O
luminal	O
environment	O
is	O
disturbed	O
by	O
the	O
immune	O
system	O
to	O
foster	O
pathogenic	O
bacterial	O
growth	O
and	O
survival	O
remain	O
incompletely	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
STAT2	O
dependent	O
type	O
I	O
IFN	O
signaling	O
contributes	O
to	O
the	O
inflammatory	O
environment	O
by	O
disrupting	O
hypoxia	O
enabling	O
the	O
pathogenic	O
S	B-bacteria
.	I-bacteria
Typhimurium	I-bacteria
to	O
outgrow	O
the	O
microbiota	O
.	O

Stat2	O
-	O
/	O
-	O
mice	O
infected	O
with	O
S	B-bacteria
.	I-bacteria
Typhimurium	I-bacteria
exhibited	O
impaired	O
type	O
I	O
IFN	O
induced	O
transcriptional	O
responses	O
in	O
cecal	O
tissue	O
and	O
reduced	O
bacterial	O
burden	O
in	O
the	O
intestinal	O
lumen	O
compared	O
to	O
infected	O
wild	O
-	O
type	O
mice	O
.	O

Although	O
inflammatory	O
pathology	O
was	O
similar	O
between	O
wild	O
-	O
type	O
and	O
Stat2	O
-	O
/	O
-	O
mice	O
,	O
we	O
observed	O
decreased	O
hypoxia	O
in	O
the	O
gut	O
tissue	O
of	O
Stat2	O
-	O
/	O
-	O
mice	O
.	O

Neutrophil	O
numbers	O
were	O
similar	O
in	O
wild	O
-	O
type	O
and	O
Stat2	O
-	O
/	O
-	O
mice	O
,	O
yet	O
Stat2	O
-	O
/	O
-	O
mice	O
showed	O
reduced	O
levels	O
of	O
myeloperoxidase	O
activity	O
.	O

In	O
vitro	O
,	O
the	O
neutrophils	O
from	O
Stat2	O
-	O
/	O
-	O
mice	O
produced	O
lower	O
levels	O
of	O
superoxide	O
anion	O
upon	O
stimulation	O
with	O
the	O
bacterial	O
ligand	O
N	O
-	O
formylmethionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
(	O
fMLP	O
)	O
in	O
the	O
presence	O
of	O
IFNalpha	O
compared	O
to	O
neutrophils	O
from	O
wild	O
-	O
type	O
mice	O
,	O
indicating	O
that	O
the	O
neutrophils	O
were	O
less	O
functional	O
in	O
Stat2	O
-	O
/	O
-	O
mice	O
.	O

Cytochrome	O
bd	O
-	O
II	O
oxidase	O
-	O
mediated	O
respiration	O
enhances	O
S	B-bacteria
.	I-bacteria
Typhimurium	I-bacteria
fitness	O
in	O
wild	O
-	O
type	O
mice	O
,	O
while	O
in	O
Stat2	O
-	O
/	O
-	O
deficiency	O
,	O
this	O
respiratory	O
pathway	O
did	O
not	O
provide	O
a	O
fitness	O
advantage	O
.	O

Furthermore	O
,	O
luminal	O
expansion	O
of	O
S	B-bacteria
.	I-bacteria
Typhimurium	I-bacteria
in	O
wild	O
-	O
type	O
mice	O
was	O
blunted	O
in	O
Stat2	O
-	O
/	O
-	O
mice	O
.	O

Compared	O
to	O
wild	O
-	O
type	O
mice	O
which	O
exhibited	O
a	O
significant	O
perturbation	O
in	O
Bacteroidetes	B-bacteria
abundance	O
,	O
Stat2	O
-	O
/	O
-	O
mice	O
exhibited	O
significantly	O
less	O
perturbation	O
and	O
higher	O
levels	O
of	O
Bacteroidetes	B-bacteria
upon	O
S	B-bacteria
.	I-bacteria
Typhimurium	I-bacteria
infection	O
.	O

Our	O
results	O
highlight	O
STAT2	O
dependent	O
type	O
I	O
IFN	O
mediated	O
inflammation	O
in	O
the	O
gut	O
as	O
a	O
novel	O
mechanism	O
promoting	O
luminal	O
expansion	O
of	O
S	B-bacteria
.	I-bacteria
Typhimurium	I-bacteria
.	O

The	O
Effect	O
of	O
Allogenic	O
Versus	O
Autologous	O
Fecal	O
Microbiota	O
Transfer	O
on	O
Symptoms	O
,	O
Visceral	O
Perception	O
and	O
Fecal	O
and	O
Mucosal	O
Microbiota	O
in	O
Irritable	O
Bowel	O
Syndrome	O
:	O
A	O
Randomized	O
Controlled	O
Study	O
.	O

OBJECTIVES	O
:	O
Fecal	O
microbiota	O
transfer	O
(	O
FMT	O
)	O
is	O
suggested	O
as	O
a	O
potential	O
treatment	O
for	O
patients	O
with	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
.	O

We	O
aimed	O
to	O
study	O
the	O
effect	O
of	O
allogenic	O
and	O
autologous	O
FMT	O
on	O
IBS	O
symptoms	O
,	O
visceral	O
sensitivity	O
,	O
and	O
compositional	O
changes	O
in	O
fecal	O
and	O
mucosa	O
-	O
adherent	O
microbiota	O
.	O

METHODS	O
:	O
Seventeen	O
patients	O
with	O
IBS	O
were	O
randomized	O
either	O
to	O
receive	O
fecal	O
material	O
from	O
a	O
healthy	O
donor	O
(	O
allogenic	O
)	O
or	O
to	O
receive	O
their	O
own	O
fecal	O
material	O
(	O
autologous	O
)	O
.	O

The	O
fecal	O
material	O
was	O
administered	O
into	O
the	O
cecum	O
by	O
whole	O
colonoscopy	O
after	O
bowel	O
cleansing	O
.	O

RESULTS	O
:	O
No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
allogenic	O
and	O
the	O
autologous	O
FMT	O
regarding	O
symptom	O
scores	O
.	O

However	O
,	O
symptom	O
scores	O
of	O
patients	O
receiving	O
allogenic	O
fecal	O
material	O
significantly	O
decreased	O
after	O
FMT	O
compared	O
with	O
baseline	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
which	O
was	O
not	O
the	O
case	O
in	O
the	O
autologous	O
group	O
(	O
P	O
=	O
0	O
.	O
16	O
)	O
.	O

Visceral	O
sensitivity	O
was	O
not	O
affected	O
except	O
for	O
a	O
small	O
beneficial	O
effect	O
on	O
urge	O
scores	O
in	O
the	O
autologous	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

While	O
both	O
fecal	O
and	O
mucosa	O
-	O
adherent	O
microbiota	O
of	O
some	O
patients	O
shifted	O
to	O
their	O
respective	O
donor	O
'	O
s	O
fecal	O
microbiota	O
,	O
some	O
patients	O
showed	O
no	O
relevant	O
microbial	O
changes	O
after	O
allogenic	O
FMT	O
.	O

Large	O
compositional	O
shifts	O
in	O
fecal	O
and	O
mucosa	O
-	O
adherent	O
microbiota	O
also	O
occurred	O
in	O
the	O
autologous	O
group	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
showed	O
that	O
a	O
single	O
FMT	O
by	O
colonoscopy	O
may	O
have	O
beneficial	O
effects	O
in	O
IBS	O
;	O
however	O
,	O
the	O
allogenic	O
fecal	O
material	O
was	O
not	O
superior	O
to	O
the	O
autologous	O
fecal	O
material	O
.	O

This	O
suggests	O
that	O
bowel	O
cleansing	O
prior	O
to	O
the	O
colonoscopy	O
and	O
/	O
or	O
processing	O
of	O
the	O
fecal	O
material	O
as	O
part	O
of	O
the	O
FMT	O
routine	O
contribute	O
to	O
symptoms	O
and	O
gut	O
microbiota	O
composition	O
changes	O
in	O
IBS	O
.	O

An	O
update	O
on	O
carbohydrases	O
:	O
growth	O
performance	O
and	O
intestinal	O
health	O
of	O
poultry	O
.	O

Poultry	O
is	O
an	O
imperative	O
domesticated	O
livestock	O
species	O
that	O
provides	O
high	O
quality	O
protein	O
and	O
micronutrients	O
as	O
meat	O
and	O
eggs	O
.	O

In	O
poultry	O
production	O
,	O
feed	O
is	O
the	O
single	O
major	O
input	O
constituting	O
70	O
-	O
75	O
%	O
of	O
total	O
production	O
cost	O
.	O

Feed	O
mainly	O
consists	O
of	O
cereal	O
grains	O
,	O
those	O
provide	O
energy	O
to	O
the	O
birds	O
.	O

However	O
,	O
these	O
grains	O
contain	O
different	O
levels	O
of	O
anti	O
-	O
nutritional	O
factors	O
such	O
as	O
non	O
-	O
starch	O
polysaccharides	O
(	O
NSP	O
)	O
.	O

These	O
NSP	O
are	O
indigestible	O
by	O
poultry	O
birds	O
due	O
to	O
the	O
lack	O
of	O
vital	O
endogenous	O
enzymes	O
(	O
carbohydrases	O
)	O
thus	O
increase	O
intestinal	O
viscosity	O
which	O
slower	O
the	O
migration	O
and	O
absorption	O
of	O
nutrients	O
.	O

Consequently	O
,	O
these	O
NSP	O
may	O
also	O
increase	O
the	O
chances	O
for	O
infection	O
by	O
inducing	O
competition	O
within	O
gut	O
microbiota	O
for	O
digestible	O
nutrients	O
.	O

This	O
affects	O
bird	O
'	O
s	O
health	O
and	O
increases	O
the	O
production	O
cost	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
need	O
to	O
find	O
efficient	O
and	O
effective	O
solutions	O
for	O
these	O
problems	O
.	O

Carbohydrases	O
supplementation	O
have	O
an	O
important	O
role	O
in	O
poultry	O
diets	O
with	O
high	O
NSP	O
contents	O
.	O

Feed	O
enzymes	O
are	O
being	O
used	O
from	O
years	O
to	O
enhance	O
growth	O
performance	O
and	O
digestibility	O
but	O
have	O
limited	O
activity	O
for	O
selective	O
ingredients	O
.	O

New	O
generation	O
carbohydrases	O
with	O
a	O
board	O
range	O
of	O
activity	O
and	O
stability	O
help	O
to	O
degrade	O
the	O
complex	O
substrates	O
and	O
improve	O
growth	O
performance	O
of	O
poultry	O
.	O

Present	O
review	O
summarizes	O
the	O
updated	O
literature	O
on	O
the	O
use	O
of	O
carbohydrases	O
to	O
improve	O
bird	O
'	O
s	O
performance	O
and	O
intestinal	O
health	O
.	O

Differences	O
in	O
Fecal	O
Gut	O
Microbiota	O
,	O
Short	O
-	O
Chain	O
Fatty	O
Acids	O
and	O
Bile	O
Acids	O
Link	O
Colorectal	O
Cancer	O
Risk	O
to	O
Dietary	O
Changes	O
Associated	O
with	O
Urbanization	O
Among	O
Zimbabweans	O
.	O

The	O
incidence	O
of	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
gradually	O
rising	O
in	O
sub	O
-	O
Saharan	O
Africa	O
.	O

This	O
may	O
be	O
due	O
to	O
dietary	O
changes	O
associated	O
with	O
urbanization	O
,	O
which	O
may	O
induce	O
tumor	O
-	O
promoting	O
gut	O
microbiota	O
composition	O
and	O
function	O
.	O

We	O
compared	O
fecal	O
microbiota	O
composition	O
and	O
activity	O
in	O
10	O
rural	O
and	O
10	O
urban	O
Zimbabweans	O
for	O
evidence	O
of	O
a	O
differential	O
CRC	O
risk	O
.	O

Dietary	O
intake	O
was	O
assessed	O
by	O
a	O
food	O
frequency	O
questionnaire	O
.	O

Fecal	O
microbiota	O
composition	O
,	O
metabolomic	O
profile	O
,	O
functional	O
microbial	O
genes	O
were	O
analyzed	O
,	O
and	O
bile	O
acids	O
and	O
short	O
chain	O
fatty	O
acids	O
quantified	O
.	O

Animal	O
protein	O
intake	O
was	O
higher	O
among	O
urban	O
volunteers	O
,	O
but	O
carbohydrate	O
and	O
fiber	O
intake	O
were	O
similar	O
.	O

Bacteria	O
related	O
to	O
Blautia	B-bacteria
obeum	I-bacteria
,	O
Streptococcus	B-bacteria
bovis	I-bacteria
,	O
and	O
Subdoligranulum	B-bacteria
variabile	I-bacteria
were	O
higher	O
in	O
urban	O
residents	O
,	O
whereas	O
bacteria	O
related	O
to	O
Oscillospira	B-bacteria
guillermondii	I-bacteria
and	O
Sporobacter	B-bacteria
termitidis	I-bacteria
were	O
higher	O
in	O
rural	O
volunteers	O
.	O

Fecal	O
levels	O
of	O
primary	O
bile	O
acids	O
,	O
cholic	O
acid	O
,	O
and	O
chenodeoxycholic	O
acid	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
secondary	O
bile	O
acids	O
,	O
deoxycholic	O
acid	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
ursodeoxycholic	O
acid	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
were	O
higher	O
in	O
urban	O
residents	O
.	O

Fecal	O
levels	O
of	O
acetate	O
and	O
propionate	O
,	O
but	O
not	O
butyrate	O
,	O
were	O
higher	O
in	O
urban	O
residents	O
.	O

The	O
gut	O
microbiota	O
composition	O
and	O
activity	O
among	O
rural	O
and	O
urban	O
Zimbabweans	O
retain	O
significant	O
homogeneity	O
(	O
possibly	O
due	O
to	O
retention	O
of	O
dietary	O
fiber	O
)	O
,	O
but	O
urban	O
residents	O
have	O
subtle	O
changes	O
,	O
which	O
may	O
indicate	O
a	O
higher	O
CRC	O
risk	O
.	O

Mucispirillum	B-bacteria
schaedleri	I-bacteria
Antagonizes	O
Salmonella	B-bacteria
Virulence	I-bacteria
to	O
Protect	O
Mice	O
against	O
Colitis	O
.	O

The	O
microbiota	O
and	O
the	O
gastrointestinal	O
mucus	O
layer	O
play	O
a	O
pivotal	O
role	O
in	O
protection	O
against	O
non	O
-	O
typhoidal	O
Salmonella	B-bacteria
enterica	I-bacteria
serovar	I-bacteria
Typhimurium	I-bacteria
(	O
S	B-bacteria
.	I-bacteria
Tm	I-bacteria
)	O
colitis	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
course	O
of	O
Salmonella	B-bacteria
colitis	I-bacteria
in	O
mice	O
lacking	O
a	O
functional	O
mucus	O
layer	O
in	O
the	O
gut	O
.	O

Unexpectedly	O
,	O
in	O
contrast	O
to	O
mucus	O
-	O
proficient	O
littermates	O
,	O
genetically	O
deficient	O
mice	O
were	O
protected	O
against	O
Salmonella	O
-	O
induced	O
gut	O
inflammation	O
in	O
the	O
streptomycin	O
colitis	O
model	O
.	O

This	O
correlated	O
with	O
microbiota	O
alterations	O
and	O
enrichment	O
of	O
the	O
bacterial	O
phylum	O
Deferribacteres	B-bacteria
.	O

Using	O
gnotobiotic	O
mice	O
associated	O
with	O
defined	O
bacterial	O
consortia	O
,	O
we	O
causally	O
linked	O
Mucispirillum	B-bacteria
schaedleri	I-bacteria
,	O
currently	O
the	O
sole	O
known	O
representative	O
of	O
Deferribacteres	B-bacteria
present	O
in	O
the	O
mammalian	O
microbiota	O
,	O
to	O
host	O
protection	O
against	O
S	B-bacteria
.	I-bacteria
Tm	I-bacteria
colitis	O
.	O

Inhibition	O
by	O
M	B-bacteria
.	I-bacteria
schaedleri	I-bacteria
involves	O
interference	O
with	O
S	B-bacteria
.	I-bacteria
Tm	I-bacteria
invasion	O
gene	O
expression	O
,	O
partly	O
by	O
competing	O
for	O
anaerobic	O
electron	O
acceptors	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
establishes	O
M	B-bacteria
.	I-bacteria
schaedleri	I-bacteria
,	O
a	O
core	O
member	O
of	O
the	O
murine	O
gut	O
microbiota	O
,	O
as	O
a	O
key	O
antagonist	O
of	O
S	B-bacteria
.	I-bacteria
Tm	I-bacteria
virulence	O
in	O
the	O
gut	O
.	O

A	O
Forward	O
Chemical	O
Genetic	O
Screen	O
Reveals	O
Gut	O
Microbiota	O
Metabolites	O
That	O
Modulate	O
Host	O
Physiology	O
.	O

The	O
intestinal	O
microbiota	O
produces	O
tens	O
of	O
thousands	O
of	O
metabolites	O
.	O

Here	O
,	O
we	O
used	O
host	O
sensing	O
of	O
small	O
molecules	O
by	O
G	O
-	O
protein	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
as	O
a	O
lens	O
to	O
illuminate	O
bioactive	O
microbial	O
metabolites	O
that	O
impact	O
host	O
physiology	O
.	O

We	O
screened	O
144	O
human	O
gut	O
bacteria	O
against	O
the	O
non	O
-	O
olfactory	O
GPCRome	O
and	O
identified	O
dozens	O
of	O
bacteria	O
that	O
activated	O
both	O
well	O
-	O
characterized	O
and	O
orphan	O
GPCRs	O
,	O
including	O
strains	O
that	O
converted	O
dietary	O
histidine	O
into	O
histamine	O
and	O
shaped	O
colonic	O
motility	O
;	O
a	O
prolific	O
producer	O
of	O
the	O
essential	O
amino	O
acid	O
L	O
-	O
Phe	O
,	O
which	O
we	O
identified	O
as	O
an	O
agonist	O
for	O
GPR56	O
and	O
GPR97	O
;	O
and	O
a	O
species	O
that	O
converted	O
L	O
-	O
Phe	O
into	O
the	O
potent	O
psychoactive	O
trace	O
amine	O
phenethylamine	O
,	O
which	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
triggers	O
lethal	O
phenethylamine	O
poisoning	O
after	O
monoamine	O
oxidase	O
inhibitor	O
administration	O
.	O

These	O
studies	O
establish	O
an	O
orthogonal	O
approach	O
for	O
parsing	O
the	O
microbiota	O
metabolome	O
and	O
uncover	O
multiple	O
biologically	O
relevant	O
host	O
-	O
microbiota	O
metabolome	O
interactions	O
.	O

Increasing	O
carbohydrate	O
availability	O
in	O
the	O
hindgut	O
promotes	O
hypothalamic	O
neurotransmitter	O
synthesis	O
:	O
aromatic	O
amino	O
acids	O
linking	O
the	O
microbiota	O
-	O
brain	O
axis	O
.	O

The	O
gut	O
microbiota	O
is	O
increasingly	O
recognized	O
to	O
modulate	O
brain	O
function	O
by	O
recent	O
studies	O
demonstrating	O
the	O
central	O
effects	O
of	O
various	O
gut	O
microbial	O
manipulation	O
strategies	O
.	O

Our	O
previous	O
study	O
demonstrated	O
that	O
antibiotics	O
-	O
induced	O
alterations	O
of	O
hindgut	O
microbiota	O
are	O
associated	O
with	O
changes	O
in	O
aromatic	O
amino	O
acid	O
(	O
AAA	O
)	O
metabolism	O
and	O
hypothalamic	O
neurochemistry	O
,	O
while	O
the	O
underlying	O
mechanism	O
insight	O
is	O
limited	O
.	O

Given	O
that	O
the	O
microbial	O
AAA	O
metabolism	O
can	O
be	O
affected	O
by	O
luminal	O
carbohydrate	O
availability	O
,	O
here	O
we	O
hypothesize	O
that	O
increasing	O
hindgut	O
carbohydrate	O
availability	O
affects	O
the	O
expression	O
of	O
neurotransmitters	O
in	O
the	O
porcine	O
hypothalamus	O
.	O

A	O
hindgut	O
microbiota	O
-	O
targeted	O
strategy	O
was	O
adopted	O
by	O
increasing	O
hindgut	O
carbohydrate	O
availability	O
in	O
a	O
cecal	O
-	O
cannulated	O
piglet	O
model	O
.	O

Mechanistic	O
involvement	O
of	O
AAAs	O
along	O
the	O
gut	O
microbiota	O
-	O
brain	O
axis	O
was	O
further	O
investigated	O
in	O
mice	O
and	O
neuronal	O
cells	O
.	O

Increasing	O
carbohydrate	O
availability	O
by	O
cecal	O
starch	O
infusion	O
led	O
to	O
a	O
decrease	O
in	O
hindgut	O
AAA	O
metabolism	O
,	O
and	O
an	O
increase	O
in	O
systemic	O
AAA	O
availability	O
,	O
central	O
AAA	O
-	O
derived	O
neurotransmitters	O
(	O
5	O
-	O
HT	O
,	O
dopamine	O
)	O
and	O
neurotrophin	O
BDNF	O
in	O
piglets	O
,	O
indicating	O
that	O
hindgut	O
microbiota	O
affect	O
hypothalamic	O
neurochemistry	O
in	O
an	O
AAA	O
-	O
dependent	O
manner	O
.	O

Single	O
AAA	O
i	O
.	O
p	O
.	O
injection	O
in	O
mice	O
revealed	O
that	O
an	O
increase	O
in	O
circulating	O
tryptophan	O
and	O
tyrosine	O
elevated	O
their	O
concentrations	O
in	O
brain	O
and	O
finally	O
promoted	O
the	O
expressions	O
of	O
5	O
-	O
HT	O
,	O
dopamine	O
,	O
and	O
BDNF	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Neuronal	O
cells	O
treated	O
with	O
single	O
AAAs	O
in	O
vitro	O
further	O
demonstrated	O
that	O
tryptophan	O
and	O
tyrosine	O
enhanced	O
5	O
-	O
HT	O
and	O
dopamine	O
synthesis	O
,	O
respectively	O
,	O
and	O
promoted	O
BDNF	O
expression	O
partly	O
through	O
the	O
5	O
-	O
HT1A	O
/	O
DRD1	O
-	O
CREB	O
pathway	O
.	O

Our	O
study	O
reveals	O
that	O
increasing	O
hindgut	O
carbohydrate	O
availability	O
promotes	O
hypothalamic	O
neurotransmitter	O
synthesis	O
and	O
that	O
circulating	O
AAAs	O
act	O
as	O
potential	O
mediators	O
between	O
hindgut	O
microbiota	O
and	O
brain	O
neurochemistry	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Protocol	O
for	O
the	O
Gut	O
Bugs	O
Trial	O
:	O
a	O
randomised	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
of	O
gut	O
microbiome	O
transfer	O
for	O
the	O
treatment	O
of	O
obesity	O
in	O
adolescents	O
.	O

INTRODUCTION	O
:	O
Animal	O
studies	O
showed	O
that	O
germ	O
-	O
free	O
mice	O
inoculated	O
with	O
normal	O
mouse	O
gut	O
bacteria	O
developed	O
obesity	O
,	O
insulin	O
resistance	O
and	O
higher	O
triglyceride	O
levels	O
,	O
despite	O
similar	O
food	O
intake	O
.	O

In	O
humans	O
,	O
an	O
association	O
has	O
been	O
found	O
between	O
obesity	O
and	O
gut	O
microbiome	O
dysbiosis	O
.	O

However	O
,	O
gut	O
microbiome	O
transfer	O
has	O
not	O
been	O
evaluated	O
for	O
the	O
treatment	O
of	O
human	O
obesity	O
.	O

We	O
will	O
examine	O
the	O
effectiveness	O
of	O
gut	O
microbiome	O
transfer	O
using	O
encapsulated	O
material	O
for	O
the	O
treatment	O
of	O
obesity	O
in	O
adolescents	O
.	O

METHODS	O
AND	O
ANALYSIS	O
:	O
A	O
two	O
-	O
arm	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomised	O
clinical	O
trial	O
of	O
a	O
single	O
course	O
of	O
gut	O
microbiome	O
transfer	O
will	O
be	O
conducted	O
in	O
80	O
obese	O
[	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
>	O
/	O
=	O
30	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
adolescents	O
(	O
males	O
and	O
females	O
,	O
aged	O
14	O
-	O
18	O
years	O
)	O
in	O
Auckland	O
,	O
New	O
Zealand	O
.	O

Healthy	O
lean	O
donors	O
(	O
males	O
and	O
females	O
,	O
aged	O
18	O
-	O
28	O
years	O
)	O
will	O
provide	O
fresh	O
stool	O
samples	O
from	O
which	O
bacteria	O
will	O
be	O
isolated	O
and	O
double	O
encapsulated	O
.	O

Participants	O
(	O
recipients	O
)	O
will	O
be	O
randomised	O
at	O
1	O
:	O
1	O
to	O
control	O
(	O
placebo	O
)	O
or	O
treatment	O
(	O
gut	O
microbiome	O
transfer	O
)	O
,	O
stratified	O
by	O
sex	O
.	O

Recipients	O
will	O
receive	O
28	O
capsules	O
over	O
two	O
consecutive	O
mornings	O
(	O
~	O
14	O
mL	O
of	O
frozen	O
microbial	O
suspension	O
or	O
saline	O
)	O
.	O

Clinical	O
assessments	O
will	O
be	O
performed	O
at	O
baseline	O
,	O
6	O
,	O
12	O
and	O
26	O
weeks	O
,	O
and	O
will	O
include	O
:	O
anthropometry	O
,	O
blood	O
pressure	O
,	O
fasting	O
metabolic	O
markers	O
,	O
dietary	O
intake	O
,	O
physical	O
activity	O
levels	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

Insulin	O
sensitivity	O
(	O
Matsuda	O
index	O
)	O
,	O
gut	O
microbiota	O
population	O
structure	O
characterised	O
by	O
16S	O
rRNA	O
amplicon	O
sequencing	O
and	O
body	O
composition	O
(	O
using	O
dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
)	O
will	O
be	O
assessed	O
at	O
baseline	O
,	O
6	O
,	O
12	O
and	O
26	O
weeks	O
.	O

24	O
-	O
hour	O
ambulatory	O
blood	O
pressure	O
monitoring	O
will	O
be	O
performed	O
at	O
baseline	O
and	O
at	O
6	O
weeks	O
.	O

The	O
primary	O
outcome	O
is	O
BMI	O
SD	O
scores	O
(	O
SDS	O
)	O
at	O
6	O
weeks	O
,	O
with	O
BMI	O
SDS	O
at	O
12	O
and	O
26	O
weeks	O
as	O
secondary	O
outcomes	O
.	O

Other	O
secondary	O
outcomes	O
include	O
insulin	O
sensitivity	O
,	O
adiposity	O
(	O
total	O
body	O
fat	O
percentage	O
)	O
and	O
gut	O
microbial	O
composition	O
at	O
6	O
,	O
12	O
and	O
26	O
weeks	O
.	O

Statistical	O
analysis	O
will	O
be	O
performed	O
on	O
the	O
principle	O
of	O
intention	O
to	O
treat	O
.	O

ETHICS	O
AND	O
DISSEMINATION	O
:	O
Ethics	O
approval	O
was	O
provided	O
by	O
the	O
Northern	O
A	O
Health	O
and	O
Disability	O
Ethics	O
Committee	O
(	O
Ministry	O
of	O
Health	O
,	O
New	O
Zealand	O
;	O
16	O
/	O
NTA	O
/	O
172	O
)	O
.	O

The	O
trial	O
results	O
will	O
be	O
published	O
in	O
peer	O
-	O
reviewed	O
journals	O
and	O
presented	O
at	O
international	O
conferences	O
.	O

TRIAL	O
REGISTRATION	O
NUMBER	O
:	O
ACTRN12615001351505	O
;	O
Pre	O
-	O
results	O
.	O

Momordica	O
charantia	O
(	O
bitter	O
melon	O
)	O
modulates	O
adipose	O
tissue	O
inflammasome	O
gene	O
expression	O
and	O
adipose	O
-	O
gut	O
inflammatory	O
cross	O
talk	O
in	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
fed	O
mice	O
.	O

Systemic	O
and	O
tissue	O
-	O
specific	O
inflammation	O
has	O
a	O
profound	O
influence	O
on	O
regulation	O
of	O
metabolism	O
,	O
and	O
therefore	O
,	O
strategies	O
to	O
reduce	O
inflammation	O
are	O
of	O
special	O
interest	O
in	O
prevention	O
and	O
treatment	O
of	O
obesity	O
and	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
.	O

Antiobesity	O
and	O
antidiabetic	O
properties	O
of	O
Momordica	O
charantia	O
(	O
bitter	O
melon	O
,	O
BM	O
)	O
have	O
been	O
linked	O
to	O
its	O
protective	O
effects	O
on	O
inflammation	O
and	O
gut	O
microbial	O
dysbiosis	O
.	O

We	O
investigated	O
the	O
mechanisms	O
by	O
which	O
freeze	O
-	O
driedBM	O
juice	O
reduces	O
adipose	O
inflammation	O
in	O
mice	O
fed	O
a	O
60	O
%	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
for	O
16	O
weeks	O
.	O

Although	O
earlier	O
studies	O
indicated	O
that	O
BM	O
inhibited	O
recruitment	O
of	O
macrophages	O
(	O
Mphi	O
)	O
infiltration	O
in	O
adipose	O
tissue	O
of	O
rodents	O
and	O
reduced	O
NF	O
-	O
kB	O
and	O
IL	O
-	O
1beta	O
secretions	O
,	O
the	O
mechanisms	O
remain	O
unknown	O
.	O

We	O
demonstrate	O
that	O
freeze	O
-	O
driedBM	O
juice	O
inhibits	O
recruitment	O
of	O
Mphi	O
into	O
adipose	O
tissue	O
and	O
its	O
polarization	O
to	O
inflammatory	O
phenotype	O
possibly	O
due	O
to	O
reduction	O
of	O
sphingokinase	O
1	O
(	O
SPK1	O
)	O
mRNA	O
in	O
HFD	O
-	O
fed	O
mice	O
.	O

Furthermore	O
,	O
reduction	O
of	O
IL	O
-	O
1beta	O
secretion	O
by	O
freeze	O
-	O
driedBM	O
juice	O
in	O
the	O
adipose	O
tissue	O
of	O
HFD	O
-	O
fed	O
mice	O
is	O
correlated	O
to	O
alleviation	O
of	O
NLRP3	O
inflammasome	O
components	O
and	O
their	O
downstream	O
signaling	O
targets	O
.	O

We	O
confirm	O
previous	O
observations	O
that	O
BM	O
inhibited	O
inflammation	O
of	O
colon	O
and	O
gut	O
microbial	O
dysbiosis	O
in	O
HFD	O
-	O
fed	O
mice	O
,	O
which	O
in	O
part	O
may	O
be	O
associated	O
with	O
the	O
observed	O
anti	O
-	O
inflammatory	O
effects	O
in	O
adipose	O
tissue	O
if	O
HFD	O
-	O
fed	O
mice	O
.	O

Overall	O
,	O
functional	O
foods	O
such	O
as	O
BM	O
may	O
offer	O
potential	O
dietary	O
interventions	O
that	O
may	O
impact	O
sterile	O
inflammatory	O
diseases	O
such	O
as	O
obesity	O
and	O
T2D	O
.	O

Stronger	O
anti	O
-	O
obesity	O
effect	O
of	O
white	O
ginseng	O
over	O
red	O
ginseng	O
and	O
the	O
potential	O
mechanisms	O
involving	O
chemically	O
structural	O
/	O
compositional	O
specificity	O
to	O
gut	O
microbiota	O
.	O

BACKGROUND	O
:	O
Ginseng	O
has	O
therapeutic	O
potential	O
for	O
treating	O
obesity	O
and	O
the	O
associated	O
gut	O
microbiota	O
dysbiosis	O
.	O

However	O
,	O
whether	O
white	O
ginseng	O
and	O
red	O
ginseng	O
,	O
the	O
two	O
kinds	O
of	O
commonly	O
used	O
processed	O
ginseng	O
,	O
possess	O
different	O
anti	O
-	O
obesity	O
effects	O
remains	O
unknown	O
.	O

PURPOSE	O
:	O
Anti	O
-	O
obesity	O
effects	O
of	O
water	O
extracts	O
of	O
white	O
ginseng	O
and	O
red	O
ginseng	O
(	O
WEWG	O
and	O
WERG	O
)	O
were	O
compared	O
,	O
and	O
the	O
potential	O
mechanisms	O
were	O
discussed	O
.	O

METHODS	O
:	O
Chemical	O
profiles	O
of	O
WEWG	O
and	O
WERG	O
were	O
characterized	O
by	O
ultra	O
-	O
high	O
performance	O
liquid	O
chromatography	O
-	O
tandem	O
triple	O
quadrupole	O
mass	O
spectrometry	O
(	O
UHPLC	O
-	O
QqQ	O
-	O
MS	O
/	O
MS	O
)	O
and	O
high	O
performance	O
liquid	O
chromatography	O
coupled	O
with	O
evaporative	O
light	O
scattering	O
detector	O
(	O
HPLC	O
-	O
ELSD	O
)	O
.	O

Anti	O
-	O
obesity	O
effects	O
of	O
WEWG	O
/	O
WERG	O
were	O
examined	O
by	O
determining	O
fat	O
accumulation	O
,	O
systemic	O
inflammation	O
,	O
enteric	O
metabolic	O
disorders	O
and	O
gut	O
microbiota	O
dysbiosis	O
in	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
fed	O
obese	O
mice	O
.	O

RESULTS	O
:	O
Both	O
WEWG	O
and	O
WERG	O
exerted	O
anti	O
-	O
obesity	O
effects	O
,	O
with	O
WEWG	O
stronger	O
than	O
WERG	O
.	O

Compared	O
to	O
WERG	O
,	O
WEWG	O
contained	O
less	O
contents	O
of	O
carbohydrates	O
(	O
polysaccharides	O
,	O
oligosaccharides	O
,	O
free	O
monosaccharides	O
)	O
and	O
ginsenosides	O
,	O
but	O
chemical	O
structures	O
or	O
compositions	O
of	O
these	O
components	O
in	O
WEWG	O
were	O
characteristic	O
,	O
i	O
.	O
e	O
.	O
narrower	O
molecular	O
weight	O
distribution	O
and	O
higher	O
molar	O
ratios	O
of	O
glucose	O
residues	O
of	O
polysaccharides	O
;	O
higher	O
content	O
ratios	O
of	O
oligosaccharides	O
DP2	O
-	O
3	O
(	O
di	O
-	O
/	O
tri	O
-	O
saccharides	O
)	O
-	O
to	O
-	O
oligosaccharides	O
DP4	O
-	O
7	O
(	O
tetra	O
-	O
/	O
penta	O
-	O
/	O
hexa	O
-	O
/	O
hepta	O
-	O
saccharides	O
)	O
,	O
sucrose	O
-	O
to	O
-	O
melibiose	O
,	O
maltose	O
-	O
to	O
-	O
trehalose	O
and	O
high	O
-	O
polar	O
-	O
to	O
-	O
low	O
-	O
polar	O
ginsenosides	O
.	O

WEWG	O
better	O
ameliorated	O
fat	O
accumulation	O
,	O
enteric	O
metabolic	O
disorders	O
and	O
gut	O
microbiota	O
dysbiosis	O
in	O
HFD	O
-	O
fed	O
obese	O
mice	O
than	O
WERG	O
.	O

CONCLUSION	O
:	O
The	O
stronger	O
anti	O
-	O
obesity	O
effect	O
of	O
white	O
ginseng	O
appears	O
to	O
correlate	O
with	O
differences	O
in	O
its	O
chemical	O
profile	O
as	O
compared	O
to	O
red	O
ginseng	O
.	O

The	O
carbohydrates	O
and	O
ginsenosides	O
in	O
WEWG	O
potentially	O
present	O
more	O
structural	O
and	O
compositional	O
specificity	O
to	O
the	O
obesity	O
-	O
associated	O
gut	O
bacteria	O
,	O
allowing	O
more	O
beneficial	O
effects	O
of	O
WEWG	O
on	O
the	O
gut	O
microbiota	O
dysbiosis	O
.	O

This	O
consequently	O
better	O
alleviates	O
the	O
enteric	O
metabolic	O
disorders	O
and	O
systemic	O
inflammation	O
,	O
thereby	O
contributing	O
to	O
the	O
stronger	O
anti	O
-	O
obesity	O
effect	O
of	O
WEWG	O
as	O
compared	O
to	O
WERG	O
.	O

Adaptive	O
responses	O
in	O
short	O
-	O
chain	O
fatty	O
acid	O
absorption	O
,	O
gene	O
expression	O
,	O
and	O
bacterial	O
community	O
of	O
the	O
bovine	O
rumen	O
epithelium	O
recovered	O
from	O
a	O
continuous	O
or	O
transient	O
high	O
-	O
grain	O
feeding	O
.	O

The	O
feeding	O
of	O
high	O
-	O
grain	O
diets	O
to	O
dairy	O
cows	O
commonly	O
results	O
in	O
lowered	O
pH	O
and	O
ruminal	O
dysbiosis	O
,	O
characterized	O
by	O
changes	O
in	O
absorption	O
dynamics	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFA	O
)	O
across	O
the	O
reticuloruminal	O
wall	O
,	O
epithelial	O
function	O
,	O
and	O
the	O
epithelial	O
bacteria	O
community	O
structure	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
evaluated	O
the	O
effect	O
of	O
high	O
-	O
grain	O
feeding	O
persistence	O
on	O
the	O
absorption	O
kinetics	O
of	O
reticuloruminal	O
SCFA	O
,	O
gene	O
expression	O
in	O
the	O
rumen	O
epithelium	O
,	O
and	O
the	O
associated	O
shifts	O
in	O
the	O
epithelial	O
bacteria	O
in	O
cows	O
recovering	O
from	O
either	O
a	O
long	O
-	O
term	O
continuous	O
high	O
-	O
grain	O
feeding	O
model	O
or	O
a	O
long	O
-	O
term	O
transient	O
high	O
-	O
grain	O
feeding	O
model	O
.	O

In	O
a	O
crossover	O
study	O
design	O
,	O
8	O
nonlactating	O
Holstein	O
cows	O
were	O
fed	O
60	O
%	O
concentrate	O
either	O
continuously	O
for	O
4	O
wk	O
(	O
continuous	O
)	O
or	O
with	O
a	O
1	O
-	O
wk	O
break	O
in	O
the	O
second	O
week	O
of	O
the	O
high	O
-	O
grain	O
feeding	O
(	O
transient	O
)	O
.	O

After	O
the	O
high	O
-	O
grain	O
feeding	O
,	O
all	O
animals	O
were	O
fed	O
a	O
diet	O
of	O
100	O
%	O
forage	O
(	O
recovery	O
)	O
for	O
an	O
additional	O
8	O
wk	O
.	O

Rumen	O
papilla	O
biopsies	O
and	O
SCFA	O
absorption	O
measurements	O
were	O
taken	O
at	O
the	O
start	O
of	O
the	O
trial	O
(	O
baseline	O
)	O
,	O
after	O
the	O
4	O
-	O
wk	O
high	O
-	O
grain	O
feeding	O
(	O
49	O
d	O
)	O
,	O
after	O
2	O
-	O
wk	O
recovery	O
forage	O
feeding	O
(	O
63	O
d	O
)	O
,	O
and	O
after	O
8	O
-	O
wk	O
recovery	O
forage	O
(	O
105	O
d	O
)	O
.	O

Absorption	O
of	O
SCFA	O
was	O
determined	O
in	O
vivo	O
using	O
the	O
washed	O
and	O
isolated	O
reticulorumen	O
technique	O
.	O

Rumen	O
papillae	O
biopsies	O
were	O
used	O
for	O
adherent	O
bacterial	O
DNA	O
and	O
host	O
RNA	O
extraction	O
.	O

The	O
epithelial	O
bacteria	O
were	O
determined	O
using	O
Illumina	O
MiSeq	O
(	O
Microsynth	O
AG	O
,	O
Balgach	O
,	O
Switzerland	O
)	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
gene	O
.	O

No	O
significant	O
effects	O
of	O
the	O
high	O
-	O
grain	O
feeding	O
model	O
were	O
seen	O
for	O
bacterial	O
diversity	O
.	O

However	O
,	O
bacterial	O
diversity	O
increased	O
with	O
time	O
spent	O
in	O
the	O
recovery	O
forage	O
feeding	O
period	O
regardless	O
of	O
feeding	O
model	O
.	O

The	O
relative	O
abundance	O
of	O
Acidobacteria	B-bacteria
phyla	I-bacteria
and	O
Acetivibrio	B-bacteria
spp	I-bacteria
.	I-bacteria
increased	O
when	O
animals	O
were	O
fed	O
a	O
transient	O
high	O
-	O
grain	O
feeding	O
model	O
.	O

A	O
trend	O
toward	O
increased	O
CLDN4	O
expression	O
was	O
observed	O
in	O
the	O
continuous	O
model	O
.	O

Furthermore	O
,	O
there	O
were	O
interactions	O
between	O
feeding	O
model	O
and	O
sampling	O
day	O
for	O
gene	O
targets	O
CD14	O
,	O
DRA	O
,	O
NHE2	O
,	O
NHE3	O
,	O
and	O
MCT2	O
.	O

When	O
comparing	O
length	O
of	O
recovery	O
,	O
in	O
the	O
continuous	O
model	O
increased	O
relative	O
absorption	O
of	O
SCFA	O
was	O
sustained	O
at	O
63	O
d	O
but	O
dropped	O
to	O
baseline	O
measurements	O
at	O
105	O
d	O
.	O
A	O
similar	O
pattern	O
was	O
found	O
with	O
the	O
transient	O
model	O
but	O
it	O
did	O
not	O
reach	O
significance	O
.	O

The	O
only	O
gene	O
target	O
that	O
was	O
found	O
to	O
significantly	O
correlate	O
to	O
relative	O
absorption	O
of	O
SCFA	O
was	O
DRA	O
(	O
correlation	O
coefficient	O
<	O
/	O
=	O
-	O
0	O
.	O
41	O
)	O
.	O

Whereas	O
,	O
genera	O
Alkalibaculum	B-bacteria
,	O
Anaerorhabdus	B-bacteria
,	O
Coprococcus	B-bacteria
,	O
and	O
Dethiobacter	B-bacteria
all	O
showed	O
positive	O
correlations	O
to	O
gene	O
targets	O
for	O
pH	O
regulation	O
(	O
NHE2	O
and	O
NHE3	O
)	O
and	O
SCFA	O
uptake	O
(	O
MCT1	O
)	O
but	O
negative	O
correlations	O
to	O
SCFA	O
absorption	O
.	O

We	O
conclude	O
that	O
while	O
the	O
rumen	O
absorption	O
and	O
epithelial	O
bacteria	O
were	O
able	O
to	O
recover	O
to	O
baseline	O
levels	O
after	O
8	O
-	O
wk	O
of	O
forage	O
feeding	O
,	O
the	O
time	O
needed	O
for	O
re	O
-	O
establishment	O
of	O
homeostasis	O
in	O
host	O
gene	O
expression	O
is	O
longer	O
,	O
especially	O
when	O
high	O
-	O
grain	O
feeding	O
is	O
interrupted	O
.	O

Comparative	O
analysis	O
of	O
intestinal	O
bacteria	O
among	O
venom	O
secretion	O
and	O
non	O
-	O
secrection	O
snakes	O
.	O

To	O
further	O
investigate	O
the	O
bacterial	O
community	O
and	O
identify	O
the	O
bacterial	O
biomarkers	O
between	O
venom	O
secretion	O
and	O
non	O
-	O
venom	O
secretion	O
snakes	O
,	O
50	O
intestinal	O
samples	O
(	O
25	O
large	O
intestine	O
,	O
25	O
small	O
intestine	O
)	O
were	O
obtained	O
from	O
29	O
snakes	O
(	O
13	O
gut	O
samples	O
from	O
Deinagkistrodon	O
,	O
26	O
from	O
Naja	O
and	O
11	O
from	O
Ptyas	O
mucosa	O
)	O
.	O

16S	O
rDNA	O
high	O
-	O
throughput	O
sequencing	O
results	O
showed	O
that	O
29	O
bacterial	O
phyla	O
,	O
545	O
bacterial	O
genera	O
,	O
and	O
1	O
,	O
725	O
OTUs	O
(	O
operational	O
taxonomic	O
units	O
)	O
were	O
identified	O
in	O
these	O
samples	O
.	O

OTU	O
numbers	O
and	O
the	O
Ace	O
,	O
Chao	O
,	O
Shannon	O
,	O
and	O
Simpson	O
indexes	O
were	O
very	O
similar	O
among	O
the	O
three	O
breeds	O
of	O
snakes	O
included	O
in	O
this	O
study	O
.	O

The	O
Bacteroidetes	B-bacteria
,	O
Firmicutes	B-bacteria
,	O
Fusobacteria	B-bacteria
and	O
Proteobacteria	B-bacteria
were	O
predominant	O
bacterial	O
phyla	O
.	O

The	O
relative	O
abundance	O
at	O
the	O
phylum	O
level	O
among	O
these	O
samples	O
was	O
similar	O
,	O
and	O
the	O
difference	O
between	O
small	O
and	O
large	O
intestinal	O
samples	O
was	O
not	O
obvious	O
.	O

However	O
,	O
at	O
the	O
genus	O
level	O
,	O
venom	O
secretion	O
snakes	O
Deinagkistrodon	O
and	O
Naja	O
clustered	O
together	O
according	O
to	O
different	O
breeds	O
.	O

27	O
,	O
24	O
,	O
and	O
16	O
genera	O
were	O
identified	O
as	O
core	O
microbes	O
for	O
Deinagkistrodon	O
,	O
Naja	O
,	O
and	O
Ptyas	O
mucosa	O
,	O
respectively	O
.	O

Interestingly	O
,	O
the	O
relative	O
abundances	O
of	O
genera	O
Hafnia	B-bacteria
_	I-bacteria
Obesumbacterium	I-bacteria
,	O
Providencia	B-bacteria
,	O
and	O
Ureaplasma	B-bacteria
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
non	O
-	O
venom	O
secretion	O
snakes	O
,	O
and	O
the	O
genera	O
Achromobacter	B-bacteria
,	O
Cetobacterium	B-bacteria
,	O
Clostridium	B-bacteria
innocuum	I-bacteria
group	O
,	O
Fusobacterium	B-bacteria
,	O
Lachnoclostridium	B-bacteria
,	O
Parabacteroides	B-bacteria
,	O
and	O
Romboutsia	B-bacteria
were	O
only	O
detected	O
in	O
venom	O
secretion	O
snakes	O
.	O

The	O
function	O
of	O
these	O
bacteria	O
in	O
venom	O
secretion	O
needs	O
to	O
be	O
further	O
studied	O
,	O
and	O
these	O
venom	O
secretion	O
related	O
genera	O
may	O
be	O
the	O
promising	O
target	O
to	O
improve	O
venom	O
production	O
.	O

Fungi	O
participate	O
in	O
the	O
dysbiosis	O
of	O
gut	O
microbiota	O
in	O
patients	O
with	O
primary	O
sclerosing	O
cholangitis	O
.	O

OBJECTIVE	O
:	O
Patients	O
with	O
primary	O
sclerosing	O
cholangitis	O
(	O
PSC	O
)	O
were	O
previously	O
shown	O
to	O
display	O
a	O
bacterial	O
gut	O
dysbiosis	O
but	O
fungal	O
microbiota	O
has	O
never	O
been	O
examined	O
in	O
these	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
fungal	O
gut	O
microbiota	O
in	O
patients	O
with	O
PSC	O
.	O

DESIGN	O
:	O
We	O
analysed	O
the	O
faecal	O
microbiota	O
of	O
patients	O
with	O
PSC	O
and	O
concomitant	O
IBD	O
(	O
n	O
=	O
27	O
)	O
,	O
patients	O
with	O
PSC	O
and	O
no	O
IBD	O
(	O
n	O
=	O
22	O
)	O
,	O
patients	O
with	O
IBD	O
and	O
no	O
PSC	O
(	O
n	O
=	O
33	O
)	O
and	O
healthy	O
subjects	O
(	O
n	O
=	O
30	O
)	O
.	O

Bacterial	O
and	O
fungal	O
composition	O
of	O
the	O
faecal	O
microbiota	O
was	O
determined	O
using	O
16S	O
and	O
ITS2	O
sequencing	O
,	O
respectively	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
patients	O
with	O
PSC	O
harboured	O
bacterial	O
dysbiosis	O
characterised	O
by	O
a	O
decreased	O
biodiversity	O
,	O
an	O
altered	O
composition	O
and	O
a	O
decreased	O
correlation	O
network	O
density	O
.	O

These	O
alterations	O
of	O
the	O
microbiota	O
were	O
associated	O
with	O
PSC	O
,	O
independently	O
of	O
IBD	O
status	O
.	O

For	O
the	O
first	O
time	O
,	O
we	O
showed	O
that	O
patients	O
with	O
PSC	O
displayed	O
a	O
fungal	O
gut	O
dysbiosis	O
,	O
characterised	O
by	O
a	O
relative	O
increase	O
in	O
biodiversity	O
and	O
an	O
altered	O
composition	O
.	O

Notably	O
,	O
we	O
observed	O
an	O
increased	O
proportion	O
of	O
Exophiala	O
and	O
a	O
decreased	O
proportion	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

Compared	O
with	O
patients	O
with	O
IBD	O
and	O
healthy	O
subjects	O
,	O
the	O
gut	O
microbiota	O
of	O
patients	O
with	O
PSC	O
exhibited	O
a	O
strong	O
disruption	O
in	O
bacteria	O
-	O
fungi	O
correlation	O
network	O
,	O
suggesting	O
an	O
alteration	O
in	O
the	O
interkingdom	O
crosstalk	O
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
bacteria	O
and	O
fungi	O
contribute	O
to	O
gut	O
dysbiosis	O
in	O
PSC	O
.	O

The	O
role	O
of	O
sphingosine	O
kinase	O
2	O
in	O
alcoholic	O
liver	O
disease	O
.	O

Alcoholic	O
liver	O
disease	O
(	O
ALD	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
liver	O
diseases	O
worldwide	O
.	O

However	O
,	O
the	O
exact	O
mechanisms	O
underlying	O
ALD	O
remain	O
unclear	O
.	O

Previous	O
studies	O
reported	O
that	O
sphingosine	O
kinase	O
2	O
(	O
SphK2	O
)	O
plays	O
an	O
essential	O
role	O
in	O
regulating	O
hepatic	O
lipid	O
metabolism	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
demonstrate	O
that	O
compared	O
to	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
,	O
SphK2	O
deficient	O
(	O
SphK2	O
(	O
-	O
/	O
-	O
)	O
)	O
mice	O
exhibited	O
a	O
greater	O
degree	O
of	O
liver	O
injury	O
and	O
hepatic	O
lipid	O
accumulation	O
after	O
feeding	O
with	O
an	O
alcohol	O
diet	O
for	O
60	O
days	O
.	O

This	O
is	O
accompanied	O
by	O
a	O
down	O
-	O
regulation	O
of	O
steroid	O
7	O
-	O
alpha	O
-	O
hydroxylase	O
(	O
Cyp7b1	O
)	O
and	O
an	O
up	O
-	O
regulation	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
(	O
Tnfalpha	O
,	O
F4	O
/	O
80	O
,	O
Il	O
-	O
1beta	O
)	O
.	O

In	O
vitro	O
experiments	O
showed	O
that	O
alcohol	O
induced	O
SphK2	O
expression	O
in	O
mouse	O
primary	O
hepatocytes	O
and	O
cultured	O
mouse	O
macrophages	O
.	O

Furthermore	O
,	O
alcohol	O
feeding	O
induced	O
a	O
more	O
severe	O
intestinal	O
barrier	O
dysfunction	O
in	O
SphK2	O
(	O
-	O
/	O
-	O
)	O
mice	O
than	O
WT	O
mice	O
.	O

Deficiency	O
of	O
SphK2	O
impaired	O
the	O
growth	O
of	O
intestinal	O
organoids	O
.	O

Finally	O
,	O
SphK2	O
expression	O
levels	O
were	O
down	O
-	O
regulated	O
in	O
the	O
livers	O
of	O
human	O
patients	O
with	O
alcoholic	O
cirrhosis	O
and	O
hepatocellular	O
carcinoma	O
compared	O
to	O
healthy	O
controls	O
.	O

In	O
summary	O
,	O
these	O
findings	O
suggest	O
that	O
SphK2	O
is	O
a	O
crucial	O
regulator	O
of	O
hepatic	O
lipid	O
metabolism	O
and	O
that	O
modulating	O
the	O
SphK2	O
-	O
mediated	O
signaling	O
pathway	O
may	O
represent	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
the	O
treatment	O
of	O
ALD	O
and	O
other	O
metabolic	O
liver	O
diseases	O
.	O

The	O
role	O
of	O
intestinal	O
microbiota	O
in	O
the	O
pathogenesis	O
of	O
colorectal	O
carcinoma	O
.	O

The	O
symbiotic	O
relationship	O
between	O
intestinal	O
microbiota	O
and	O
the	O
host	O
is	O
a	O
major	O
mechanism	O
of	O
prevention	O
against	O
the	O
development	O
of	O
chronic	O
and	O
metabolic	O
diseases	O
.	O

The	O
intestinal	O
microbiota	O
provides	O
several	O
physiological	O
functions	O
of	O
the	O
organism	O
from	O
the	O
creation	O
of	O
a	O
natural	O
functional	O
barrier	O
with	O
a	O
subsequent	O
immunostimulatory	O
activity	O
up	O
to	O
affecting	O
the	O
energy	O
metabolism	O
of	O
the	O
host	O
.	O

Disruption	O
of	O
physiological	O
intestinal	O
microbiota	O
is	O
reported	O
as	O
one	O
of	O
the	O
major	O
etiological	O
factors	O
of	O
initiation	O
and	O
progression	O
of	O
colorectal	O
carcinoma	O
(	O
CRC	O
)	O
.	O

Chronic	O
low	O
-	O
grade	O
inflammation	O
is	O
associated	O
with	O
the	O
development	O
of	O
CRC	O
,	O
through	O
the	O
production	O
of	O
inflammatory	O
cytokines	O
and	O
reactive	O
oxygen	O
species	O
.	O

CRC	O
occurs	O
in	O
association	O
with	O
high	O
-	O
protein	O
and	O
high	O
-	O
fat	O
diets	O
in	O
combination	O
with	O
low	O
-	O
fiber	O
intake	O
.	O

The	O
problem	O
of	O
intestinal	O
dysbiosis	O
and	O
oncological	O
diseases	O
is	O
a	O
multidisciplinary	O
problem	O
and	O
it	O
is	O
necessary	O
to	O
focus	O
on	O
several	O
fields	O
of	O
medicine	O
such	O
as	O
public	O
health	O
,	O
clinical	O
pharmacology	O
,	O
and	O
internal	O
medicine	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
describing	O
the	O
role	O
of	O
gut	O
dysbiosis	O
in	O
pathogenesis	O
of	O
colorectal	O
carcinoma	O
.	O

The	O
Gut	O
Microbiome	O
Signatures	O
Discriminate	O
Healthy	O
From	O
Pulmonary	O
Tuberculosis	O
Patients	O
.	O

Cross	O
talk	O
occurs	O
between	O
the	O
human	O
gut	O
and	O
the	O
lung	O
through	O
a	O
gut	O
-	O
lung	O
axis	O
involving	O
the	O
gut	O
microbiota	O
.	O

However	O
,	O
the	O
signatures	O
of	O
the	O
human	O
gut	O
microbiota	O
after	O
active	O
Mycobacterium	B-bacteria
tuberculosis	I-bacteria
infection	O
have	O
not	O
been	O
fully	O
understood	O
.	O

Here	O
,	O
we	O
investigated	O
changes	O
in	O
the	O
gut	O
microbiota	O
in	O
tuberculosis	O
(	O
TB	O
)	O
patients	O
by	O
shotgun	O
sequencing	O
the	O
gut	O
microbiomes	O
of	O
31	O
healthy	O
controls	O
and	O
46	O
patients	O
.	O

We	O
observed	O
a	O
dramatic	O
changes	O
in	O
gut	O
microbiota	O
in	O
tuberculosis	O
patients	O
as	O
reflected	O
by	O
significant	O
decreases	O
in	O
species	O
number	O
and	O
microbial	O
diversity	O
.	O

The	O
gut	O
microbiota	O
of	O
TB	O
patients	O
were	O
mostly	O
featured	O
by	O
the	O
striking	O
decrease	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
-	O
producingbacteria	O
as	O
well	O
as	O
associated	O
metabolic	O
pathways	O
.	O

A	O
classification	O
model	O
based	O
on	O
the	O
abundance	O
of	O
three	O
species	O
,	O
Haemophilus	B-bacteria
parainfluenzae	I-bacteria
,	O
Roseburia	B-bacteria
inulinivorans	I-bacteria
,	O
and	O
Roseburia	B-bacteria
hominis	I-bacteria
,	O
performed	O
well	O
for	O
discriminating	O
between	O
healthy	O
and	O
diseased	O
patients	O
.	O

Additionally	O
,	O
the	O
healthy	O
and	O
diseased	O
states	O
can	O
be	O
distinguished	O
by	O
SNPs	O
in	O
the	O
species	O
of	O
B	B-bacteria
.	I-bacteria
vulgatus	I-bacteria
.	O

We	O
present	O
a	O
comprehensive	O
profile	O
of	O
changes	O
in	O
the	O
microbiota	O
in	O
clinical	O
TB	O
patients	O
.	O

Our	O
findings	O
will	O
shed	O
light	O
on	O
the	O
design	O
of	O
future	O
diagnoses	O
and	O
treatments	O
for	O
M	B-bacteria
.	I-bacteria
tuberculosis	I-bacteria
infections	O
.	O

The	O
Preterm	O
Gut	O
Microbiota	O
:	O
An	O
Inconspicuous	O
Challenge	O
in	O
Nutritional	O
Neonatal	O
Care	O
.	O

The	O
nutritional	O
requirements	O
of	O
preterm	O
infants	O
are	O
unique	O
and	O
challenging	O
to	O
meet	O
in	O
neonatal	O
care	O
,	O
yet	O
crucial	O
for	O
their	O
growth	O
,	O
development	O
and	O
health	O
.	O

Normally	O
,	O
the	O
gut	O
microbiota	O
has	O
distinct	O
metabolic	O
capacities	O
,	O
making	O
their	O
role	O
in	O
metabolism	O
of	O
dietary	O
components	O
indispensable	O
.	O

In	O
preterm	O
infants	O
,	O
variation	O
in	O
microbiota	O
composition	O
is	O
introduced	O
while	O
facing	O
a	O
unique	O
set	O
of	O
environmental	O
conditions	O
.	O

However	O
,	O
the	O
effect	O
of	O
such	O
variation	O
on	O
the	O
microbiota	O
'	O
s	O
metabolic	O
capacity	O
and	O
on	O
the	O
preterm	O
infant	O
'	O
s	O
growth	O
and	O
development	O
remains	O
unresolved	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
provide	O
a	O
holistic	O
overview	O
on	O
the	O
development	O
of	O
the	O
preterm	O
gut	O
microbiota	O
and	O
the	O
unique	O
environmental	O
conditions	O
contributing	O
to	O
this	O
,	O
in	O
addition	O
to	O
maturation	O
of	O
the	O
gastrointestinal	O
tract	O
and	O
immune	O
system	O
in	O
preterm	O
infants	O
.	O

The	O
role	O
of	O
prematurity	O
,	O
as	O
well	O
as	O
the	O
role	O
of	O
human	O
milk	O
,	O
in	O
the	O
developmental	O
processes	O
is	O
emphasized	O
.	O

Current	O
research	O
stresses	O
the	O
early	O
life	O
gut	O
microbiota	O
as	O
cornerstone	O
for	O
simultaneous	O
development	O
of	O
the	O
gastrointestinal	O
tract	O
and	O
immune	O
system	O
.	O

Besides	O
that	O
,	O
literature	O
provides	O
clues	O
that	O
prematurity	O
affects	O
growth	O
and	O
development	O
.	O

As	O
such	O
,	O
this	O
review	O
is	O
concluded	O
with	O
our	O
hypothesis	O
that	O
prematurity	O
of	O
the	O
gut	O
microbiota	O
may	O
be	O
an	O
inconspicuous	O
clinical	O
challenge	O
in	O
achieving	O
optimal	O
feeding	O
besides	O
traditional	O
challenges	O
,	O
such	O
as	O
preterm	O
breast	O
milk	O
composition	O
,	O
high	O
nutritional	O
requirements	O
and	O
immaturity	O
of	O
the	O
gastrointestinal	O
tract	O
and	O
immune	O
system	O
.	O

A	O
better	O
understanding	O
of	O
the	O
metabolic	O
capacity	O
of	O
the	O
gut	O
microbiota	O
and	O
its	O
impact	O
on	O
gut	O
and	O
immune	O
maturation	O
in	O
preterm	O
infants	O
could	O
complement	O
current	O
feeding	O
regimens	O
in	O
future	O
neonatal	O
care	O
and	O
thereby	O
facilitate	O
growth	O
,	O
development	O
and	O
health	O
in	O
preterm	O
infants	O
.	O

Oral	O
Administration	O
of	O
Compound	O
Probiotics	O
Improved	O
Canine	O
Feed	O
Intake	O
,	O
Weight	O
Gain	O
,	O
Immunity	O
and	O
Intestinal	O
Microbiota	O
.	O

Probiotics	O
have	O
been	O
used	O
successfully	O
to	O
promote	O
human	O
and	O
animal	O
health	O
,	O
but	O
only	O
limited	O
studies	O
have	O
focused	O
on	O
using	O
probiotics	O
to	O
improve	O
the	O
health	O
of	O
hosts	O
of	O
different	O
age	O
.	O

Canine	O
microbiome	O
studies	O
may	O
be	O
predictive	O
of	O
results	O
in	O
humans	O
because	O
of	O
the	O
high	O
structural	O
and	O
functional	O
similarity	O
between	O
dog	O
and	O
human	O
microbiomes	O
.	O

A	O
total	O
of	O
90	O
dogs	O
were	O
divided	O
into	O
three	O
groups	O
based	O
on	O
dog	O
age	O
(	O
elderly	O
group	O
,	O
n	O
=	O
30	O
;	O
young	O
group	O
,	O
n	O
=	O
24	O
;	O
and	O
training	O
group	O
,	O
n	O
=	O
36	O
)	O
.	O

Each	O
group	O
was	O
subdivided	O
into	O
two	O
subgroups	O
,	O
with	O
and	O
without	O
receiving	O
daily	O
probiotic	O
feed	O
additive	O
.	O

The	O
probiotic	O
feed	O
additive	O
contained	O
three	O
different	O
bacterial	O
strains	O
,	O
namely	O
Lactobacillus	B-bacteria
casei	I-bacteria
Zhang	I-bacteria
,	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
P	I-bacteria
-	I-bacteria
8	I-bacteria
,	O
and	O
Bifdobacterium	B-bacteria
animalis	I-bacteria
subsp	I-bacteria
.	I-bacteria
lactis	I-bacteria
V9	I-bacteria
.	O

Serum	O
and	O
fecal	O
samples	O
were	O
collected	O
and	O
analyzed	O
at	O
four	O
different	O
time	O
points	O
,	O
i	O
.	O
e	O
.	O
,	O
days	O
0	O
,	O
30	O
,	O
and	O
60	O
of	O
probiotic	O
treatment	O
,	O
and	O
15	O
days	O
after	O
ceasing	O
probiotic	O
treatment	O
.	O

The	O
results	O
demonstrated	O
that	O
probiotics	O
significantly	O
promoted	O
the	O
average	O
daily	O
feed	O
intake	O
of	O
the	O
elderly	O
dogs	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
the	O
average	O
daily	O
weight	O
gain	O
of	O
all	O
dogs	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
enhanced	O
the	O
level	O
of	O
serum	O
IgG	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
IFN	O
-	O
alpha	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
fecal	O
SIgA	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
while	O
reduced	O
the	O
TNF	O
-	O
alpha	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Additionally	O
,	O
probiotics	O
could	O
change	O
the	O
gut	O
microbial	O
structure	O
of	O
elderly	O
dogs	O
and	O
significantly	O
increased	O
beneficial	O
bacteria	O
(	O
including	O
some	O
Lactobacillus	B-bacteria
species	I-bacteria
and	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
)	O
and	O
decreased	O
potentially	O
harmful	O
bacteria	O
(	O
including	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
Sutterella	B-bacteria
stercoricanisin	I-bacteria
)	O
,	O
and	O
the	O
elderly	O
dogs	O
showed	O
the	O
strongest	O
response	O
to	O
the	O
probiotics	O
;	O
the	O
relative	O
abundance	O
of	O
some	O
of	O
these	O
species	O
correlated	O
with	O
certain	O
immune	O
factors	O
and	O
physiological	O
parameters	O
,	O
suggesting	O
that	O
the	O
probiotic	O
treatment	O
improved	O
the	O
host	O
health	O
and	O
enhanced	O
the	O
host	O
immunity	O
by	O
stimulating	O
antibody	O
and	O
cytokine	O
secretion	O
through	O
regulating	O
canine	O
gut	O
microbiota	O
.	O

Furthermore	O
,	O
the	O
gut	O
microbiota	O
of	O
the	O
elderly	O
dogs	O
shifted	O
toward	O
a	O
younger	O
-	O
like	O
composition	O
at	O
day	O
60	O
of	O
probiotic	O
treatment	O
.	O

Our	O
findings	O
suggested	O
that	O
the	O
probiotic	O
treatment	O
effects	O
on	O
canine	O
health	O
and	O
immunity	O
were	O
age	O
-	O
related	O
and	O
have	O
provided	O
interesting	O
insights	O
into	O
future	O
development	O
of	O
probiotic	O
-	O
based	O
strategies	O
to	O
improve	O
animal	O
and	O
human	O
health	O
.	O

Saccharomyces	B-bacteria
boulardii	I-bacteria
Strain	I-bacteria
CNCM	B-bacteria
I	I-bacteria
-	I-bacteria
745	I-bacteria
Modifies	O
the	O
Mononuclear	O
Phagocytes	O
Response	O
in	O
the	O
Small	O
Intestine	O
of	O
Mice	O
Following	O
Salmonella	B-bacteria
Typhimurium	I-bacteria
Infection	O
.	O

Intestinal	O
mononuclear	O
phagocytes	O
(	O
MPs	O
)	O
comprise	O
dendritic	O
cells	O
(	O
DCs	O
)	O
and	O
macrophages	O
(	O
Mphis	O
)	O
that	O
play	O
different	O
roles	O
in	O
response	O
to	O
Salmonella	B-bacteria
infection	O
.	O

After	O
phagocytosis	O
,	O
DCs	O
expressing	O
CD103	O
transport	O
Salmonella	B-bacteria
from	O
the	O
intestinal	O
tract	O
to	O
the	O
mesenteric	O
lymph	O
nodes	O
(	O
MLN	O
)	O
and	O
induce	O
adaptive	O
immune	O
responses	O
whereas	O
resident	O
Mphis	O
expressing	O
CX3CR1	O
capture	O
bacteria	O
in	O
the	O
lumen	O
and	O
reside	O
in	O
the	O
lamina	O
propria	O
(	O
LP	O
)	O
where	O
they	O
induce	O
a	O
local	O
immune	O
response	O
.	O

CX3CR1	O
(	O
+	O
)	O
Mphis	O
are	O
generated	O
from	O
Ly6C	O
(	O
hi	O
)	O
monocytes	O
that	O
enter	O
the	O
colonic	O
mucosa	O
and	O
differentiate	O
locally	O
.	O

We	O
previously	O
demonstrated	O
that	O
the	O
probiotic	O
yeast	O
Saccharomyces	B-bacteria
boulardii	I-bacteria
CNCM	I-bacteria
I	I-bacteria
-	I-bacteria
745	I-bacteria
(	O
S	B-bacteria
.	I-bacteria
b	I-bacteria
)	O
prevents	O
infection	O
by	O
Salmonella	B-bacteria
enterica	I-bacteria
serovar	I-bacteria
Typhimurium	I-bacteria
(	O
ST	B-bacteria
)	O
,	O
decreases	O
ST	B-bacteria
translocation	O
to	O
the	O
peripheral	O
organs	O
and	O
modifies	O
the	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokine	O
profiles	O
in	O
the	O
gut	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
S	B-bacteria
.	I-bacteria
b	I-bacteria
on	O
the	O
migratory	O
CD103	O
(	O
+	O
)	O
DCs	O
and	O
the	O
resident	O
CX3CR1	O
(	O
+	O
)	O
Mphis	O
.	O

MPs	O
were	O
isolated	O
from	O
the	O
LP	O
of	O
streptomycin	O
-	O
treated	O
mice	O
infected	O
by	O
ST	O
with	O
or	O
without	O
S	B-bacteria
.	I-bacteria
b	I-bacteria
treatment	O
before	O
or	O
during	O
the	O
infection	O
.	O

In	O
S	O
.	O
b	O
-	O
pretreated	O
mice	O
,	O
we	O
observed	O
a	O
decrease	O
of	O
the	O
CD103	O
(	O
+	O
)	O
DCs	O
in	O
the	O
LP	O
that	O
was	O
associated	O
with	O
the	O
drop	O
of	O
ST	O
recovery	O
from	O
MLN	O
.	O

Interestingly	O
,	O
S	B-bacteria
.	I-bacteria
b	I-bacteria
induced	O
an	O
infiltration	O
of	O
LP	O
by	O
classical	O
Ly6C	O
(	O
hi	O
)	O
monocytes	O
,	O
and	O
S	B-bacteria
.	I-bacteria
b	I-bacteria
modified	O
the	O
monocyte	O
-	O
Mphi	O
maturation	O
process	O
in	O
ST	O
-	O
infected	O
mice	O
.	O

Our	O
results	O
showed	O
that	O
S	B-bacteria
.	I-bacteria
b	I-bacteria
treatment	O
induced	O
the	O
expansion	O
of	O
Ly6C	O
(	O
hi	O
)	O
monocytes	O
in	O
the	O
blood	O
as	O
well	O
as	O
in	O
the	O
bone	O
marrow	O
(	O
BM	O
)	O
of	O
mice	O
,	O
thus	O
contributing	O
to	O
the	O
Mphi	O
replenishment	O
in	O
LP	O
from	O
blood	O
monocytes	O
.	O

In	O
vitro	O
experiments	O
conducted	O
on	O
BM	O
cells	O
confirmed	O
that	O
S	B-bacteria
.	I-bacteria
b	I-bacteria
induced	O
the	O
expansion	O
of	O
CX3CR1	O
(	O
+	O
)	O
Mphis	O
and	O
concomitantly	O
ST	B-bacteria
phagocytosis	O
.	O

Altogether	O
,	O
these	O
data	O
demonstrate	O
that	O
Saccharomyces	B-bacteria
boulardii	I-bacteria
CNCM	I-bacteria
I	I-bacteria
-	I-bacteria
745	I-bacteria
modulates	O
the	O
innate	O
immune	O
response	O
.	O

Although	O
here	O
,	O
we	O
can	O
not	O
explicitly	O
delineate	O
direct	O
effects	O
on	O
ST	O
from	O
innate	O
immunity	O
,	O
S	O
.	O
b	O
-	O
amplified	O
innate	O
immunity	O
correlated	O
with	O
partial	O
protection	O
from	O
ST	O
infection	O
.	O

This	O
study	O
shows	O
that	O
S	B-bacteria
.	I-bacteria
b	I-bacteria
can	O
induce	O
the	O
expansion	O
of	O
classical	O
monocytes	O
that	O
are	O
precursors	O
of	O
resident	O
Mphis	O
in	O
the	O
LP	O
.	O

Egg	O
Protein	O
Transferrin	O
-	O
Derived	O
Peptides	O
IRW	O
and	O
IQW	O
Regulate	O
Citrobacter	O
rodentium	O
-	O
Induced	O
,	O
Inflammation	O
-	O
Related	O
Microbial	O
and	O
Metabolomic	O
Profiles	O
.	O

Bioactive	O
peptides	O
that	O
target	O
the	O
gastrointestinal	O
tract	O
can	O
strongly	O
affect	O
the	O
health	O
of	O
animals	O
and	O
humans	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
abilities	O
of	O
two	O
peptides	O
derived	O
from	O
egg	O
albumin	O
transferrin	O
,	O
IRW	O
and	O
IQW	O
,	O
to	O
treat	O
enteritis	O
in	O
a	O
mouse	O
model	O
of	O
Citrobacter	O
rodentium	O
-	O
induced	O
colitis	O
by	O
evaluating	O
serum	O
metabolomics	O
and	O
gut	O
microbes	O
.	O

Forty	O
-	O
eight	O
mice	O
were	O
randomly	O
assigned	O
to	O
six	O
groups	O
:	O
basal	O
diet	O
(	O
CTRL	O
)	O
,	O
intragastric	O
administration	O
Citrobacter	B-bacteria
rodentium	I-bacteria
(	O
CR	B-bacteria
)	O
,	O
basal	O
diet	O
with	O
0	O
.	O
03	O
%	O
IRW	O
(	O
IRW	O
)	O
,	O
CR	B-bacteria
with	O
0	O
.	O
03	O
%	O
IRW	O
(	O
IRW	O
+	O
CR	O
)	O
,	O
basal	O
diet	O
with	O
0	O
.	O
03	O
%	O
IQW	O
(	O
IQW	O
)	O
and	O
CR	B-bacteria
with	O
0	O
.	O
03	O
%	O
IQW	O
(	O
IQW	O
+	O
CR	O
)	O
.	O

CR	B-bacteria
administration	O
began	O
on	O
day	O
10	O
and	O
continued	O
for	O
7	O
days	O
.	O

After	O
14	O
days	O
of	O
IRW	O
and	O
IQW	O
treatment	O
,	O
serum	O
was	O
collected	O
and	O
subjected	O
to	O
a	O
metabolomics	O
analysis	O
.	O

The	O
length	O
and	O
weight	O
of	O
each	O
colon	O
were	O
measured	O
,	O
and	O
the	O
colon	O
contents	O
were	O
collected	O
for	O
16srRNA	O
sequencing	O
.	O

The	O
colons	O
were	O
significantly	O
longer	O
in	O
the	O
CR	B-bacteria
group	O
,	O
compared	O
to	O
the	O
CTRL	O
group	O
.	O

A	O
serum	O
metabolomics	O
analysis	O
revealed	O
no	O
significant	O
difference	O
in	O
microbial	O
diversity	O
between	O
the	O
six	O
groups	O
.	O

Compared	O
with	O
the	O
CTRL	O
group	O
,	O
the	O
proportions	O
of	O
Firmicutes	B-bacteria
and	O
Actinobacteria	B-bacteria
species	I-bacteria
decreased	O
significantly	O
and	O
the	O
proportions	O
of	O
Bacteroidetes	B-bacteria
and	O
Proteobacteria	B-bacteria
species	I-bacteria
increased	O
in	O
the	O
CR	O
group	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
CTRL	O
and	O
other	O
groups	O
.	O

The	O
serum	O
metabolomics	O
analysis	O
revealed	O
that	O
Infected	O
by	O
CR	O
increased	O
the	O
levels	O
of	O
oxalic	O
acid	O
,	O
homogentisic	O
acid	O
and	O
prostaglandin	O
but	O
decreased	O
the	O
levels	O
of	O
L	O
-	O
glutamine	O
,	O
L	O
-	O
acetyl	O
carnitine	O
,	O
1	O
-	O
methylhistidine	O
and	O
gentisic	O
acid	O
.	O

Therefore	O
,	O
treatment	O
with	O
IRW	O
and	O
IQW	O
was	O
shown	O
to	O
regulate	O
the	O
intestinal	O
microorganisms	O
associated	O
with	O
colonic	O
inflammation	O
and	O
serum	O
metabolite	O
levels	O
,	O
thus	O
improving	O
intestinal	O
health	O
.	O

Corrigendum	O
:	O
Bacteroides	B-bacteria
fragilis	I-bacteria
Prevents	O
Clostridium	B-bacteria
difficile	I-bacteria
Infection	O
in	O
a	O
Mouse	O
Model	O
by	O
Restoring	O
Gut	O
Barrier	O
and	O
Microbiome	O
Regulation	O
.	O

[	O
This	O
corrects	O
the	O
article	O
DOI	O
:	O
10	O
.	O
3389	O
/	O
fmicb	O
.	O
2018	O
.	O
02976	O
.	O

]	O
.	O

A	O
surface	O
exposed	O
GH26	O
beta	O
-	O
mannanase	O
from	O
Bacteroides	B-bacteria
ovatus	I-bacteria
:	O
structure	O
,	O
role	O
and	O
phylogenetic	O
analysis	O
of	O
BoMan26B	O
.	O

The	O
galactomannan	O
utilization	O
locus	O
(	O
BoManPUL	O
)	O
of	O
the	O
human	O
gut	O
bacterium	O
Bacteroides	B-bacteria
ovatus	I-bacteria
encodes	O
BoMan26B	O
,	O
a	O
cell	O
-	O
surface	O
exposed	O
endomannanase	O
whose	O
functional	O
and	O
structural	O
features	O
have	O
been	O
unclear	O
.	O

Our	O
study	O
now	O
places	O
BoMan26B	O
in	O
context	O
with	O
related	O
enzymes	O
and	O
reveals	O
the	O
structural	O
basis	O
for	O
its	O
specificity	O
.	O

BoMan26B	O
prefers	O
longer	O
substrates	O
and	O
is	O
less	O
restricted	O
by	O
galactose	O
side	O
-	O
groups	O
than	O
the	O
mannanase	O
BoMan26A	O
of	O
the	O
same	O
locus	O
.	O

Using	O
galactomannan	O
,	O
BoMan26B	O
generated	O
a	O
mixture	O
of	O
(	O
galactosyl	O
)	O
manno	O
-	O
oligosaccharides	O
shorter	O
than	O
mannohexaose	O
.	O

Three	O
defined	O
manno	O
-	O
oligosaccharides	O
had	O
affinity	O
for	O
the	O
SusD	O
-	O
like	O
surface	O
exposed	O
glycan	O
binding	O
protein	O
,	O
predicted	O
to	O
be	O
implicated	O
in	O
saccharide	O
transport	O
.	O

Co	O
-	O
incubation	O
of	O
BoMan26B	O
and	O
the	O
periplasmic	O
alpha	O
-	O
galactosidase	O
BoGal36A	O
increased	O
the	O
rate	O
of	O
galactose	O
release	O
by	O
about	O
ten	O
-	O
fold	O
compared	O
to	O
the	O
rate	O
without	O
BoMan26B	O
.	O

The	O
results	O
suggested	O
that	O
BoMan26B	O
performs	O
the	O
initial	O
attack	O
on	O
galactomannan	O
,	O
generating	O
oligosaccharides	O
that	O
after	O
transport	O
to	O
the	O
periplasm	O
are	O
processed	O
by	O
BoGal36A	O
.	O

A	O
crystal	O
structure	O
of	O
BoMan26B	O
with	O
galactosyl	O
-	O
mannotetraose	O
bound	O
in	O
subsites	O
-	O
5	O
to	O
-	O
2	O
revealed	O
an	O
open	O
and	O
long	O
active	O
site	O
cleft	O
with	O
Trp	O
-	O
112	O
in	O
subsite	O
-	O
5	O
concluded	O
to	O
be	O
involved	O
in	O
mannosyl	O
interaction	O
.	O

Moreover	O
,	O
Lys	O
-	O
149	O
in	O
the	O
-	O
4	O
subsite	O
interacted	O
with	O
the	O
galactosyl	O
side	O
-	O
group	O
of	O
the	O
ligand	O
.	O

A	O
phylogenetic	O
tree	O
consisting	O
of	O
GH26	O
enzymes	O
revealed	O
four	O
strictly	O
conserved	O
GH26	O
residues	O
and	O
disclosed	O
that	O
BoMan26A	O
and	O
BoMan26B	O
reside	O
on	O
two	O
distinct	O
phylogenetic	O
branches	O
(	O
A	O
and	O
B	O
)	O
.	O

The	O
three	O
other	O
branches	O
contain	O
lichenases	O
,	O
xylanases	O
or	O
enzymes	O
with	O
unknown	O
activities	O
.	O

Lys	O
-	O
149	O
is	O
conserved	O
in	O
a	O
narrow	O
part	O
of	O
branch	O
B	O
and	O
Trp	O
-	O
112	O
is	O
conserved	O
in	O
a	O
wider	O
group	O
within	O
branch	O
B	O
.	O

Genome	O
Sequences	O
of	O
Microviruses	O
Associated	O
with	O
Coptotermes	B-bacteria
formosanus	I-bacteria
.	O

Termites	O
have	O
a	O
unique	O
ability	O
to	O
effectively	O
digest	O
lignocellulose	O
with	O
the	O
help	O
of	O
mutualistic	O
symbionts	O
.	O

While	O
gut	O
bacteria	O
and	O
protozoa	O
have	O
been	O
relatively	O
well	O
characterized	O
in	O
termites	O
,	O
the	O
virome	O
remains	O
largely	O
unexplored	O
.	O

Here	O
,	O
we	O
report	O
two	O
genomes	O
of	O
microviruses	O
(	O
termite	O
-	O
associated	O
microvirus	O
-	O
1	O
[	O
TaMV	O
-	O
1	O
]	O
and	O
termite	O
-	O
associated	O
microvirus	O
-	O
2	O
[	O
TaMV	O
-	O
2	O
]	O
)	O
associated	O
with	O
the	O
gut	O
of	O
Coptotermes	B-bacteria
formosanus	I-bacteria
.	O

In	O
vitro	O
modulation	O
of	O
human	O
gut	O
microbiota	O
composition	O
and	O
metabolites	O
by	O
Bifidobacterium	B-bacteria
longum	I-bacteria
BB	I-bacteria
-	I-bacteria
46	I-bacteria
and	O
a	O
citric	O
pectin	O
.	O

The	O
gut	O
microbiota	O
composition	O
and	O
its	O
metabolites	O
have	O
high	O
impact	O
on	O
human	O
health	O
.	O

Exploitation	O
of	O
prebiotics	O
and	O
probiotics	O
for	O
modulation	O
of	O
gut	O
microbiota	O
can	O
lead	O
to	O
promising	O
outcomes	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
the	O
probiotic	O
strain	O
Bifidobacterium	B-bacteria
longum	I-bacteria
BB	I-bacteria
-	I-bacteria
46	I-bacteria
alone	O
and	O
in	O
combination	O
with	O
a	O
citric	O
pectin	O
from	O
lemon	O
on	O
the	O
gut	O
microbiota	O
from	O
healthy	O
adults	O
using	O
the	O
Simulator	O
of	O
Human	O
Intestinal	O
Microbial	O
Ecosystem	O
(	O
SHIME	O
(	O
(	O
R	O
)	O
)	O
)	O
.	O

Changes	O
in	O
microbiota	O
composition	O
and	O
in	O
metabolic	O
activity	O
were	O
assessed	O
by	O
the	O
16S	O
rRNA	O
gene	O
sequencing	O
and	O
by	O
analyses	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
and	O
ammonium	O
ions	O
(	O
NH4	O
(	O
+	O
)	O
)	O
.	O

An	O
increase	O
in	O
the	O
relative	O
abundances	O
of	O
Firmicutes	B-bacteria
(	O
especially	O
the	O
members	O
of	O
Lachnospiraceae	B-bacteria
and	O
Lactobacillaceae	B-bacteria
families	I-bacteria
)	O
and	O
Bacteroidetes	B-bacteria
was	O
observed	O
during	O
treatment	O
with	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
BB	I-bacteria
-	I-bacteria
46	I-bacteria
alone	O
in	O
all	O
compartments	O
of	O
the	O
colon	O
.	O

Treatment	O
with	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
BB	I-bacteria
-	I-bacteria
46	I-bacteria
and	O
pectin	O
stimulated	O
an	O
increase	O
in	O
the	O
proportions	O
of	O
genera	O
Faecalibacterium	B-bacteria
,	O
Eubacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
,	O
as	O
well	O
as	O
in	O
the	O
Ruminococcaceae	B-bacteria
family	O
in	O
the	O
transverse	O
and	O
descending	O
colons	O
.	O

Concurrently	O
,	O
the	O
butyrate	O
levels	O
increased	O
in	O
these	O
two	O
compartments	O
.	O

Additionally	O
,	O
the	O
combination	O
of	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
BB	I-bacteria
-	I-bacteria
46	I-bacteria
and	O
pectin	O
reduced	O
the	O
abundance	O
of	O
proteolytic	O
bacteria	O
Bacteroides	B-bacteria
,	O
Clostridium	B-bacteria
,	O
Peptoniphilus	B-bacteria
,	O
and	O
Streptococcus	B-bacteria
,	O
along	O
with	O
decreased	O
NH4	O
(	O
+	O
)	O
production	O
.	O

No	O
significant	O
changes	O
could	O
be	O
observed	O
on	O
NH4	O
(	O
+	O
)	O
production	O
by	O
treatment	O
with	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
BB	I-bacteria
-	I-bacteria
46	I-bacteria
,	O
nor	O
did	O
it	O
increase	O
the	O
amount	O
of	O
SCFAs	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
that	O
although	O
each	O
treatment	O
was	O
able	O
to	O
modulate	O
the	O
microbiota	O
,	O
the	O
combination	O
of	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
BB	I-bacteria
-	I-bacteria
46	I-bacteria
and	O
pectin	O
was	O
more	O
efficient	O
in	O
decreasing	O
the	O
intestinal	O
NH4	O
(	O
+	O
)	O
levels	O
and	O
in	O
increasing	O
butyric	O
acid	O
-	O
producing	O
bacteria	O
.	O

These	O
findings	O
indicate	O
that	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
BB	I-bacteria
-	I-bacteria
46	I-bacteria
,	O
especially	O
when	O
combined	O
with	O
the	O
specific	O
citric	O
pectin	O
,	O
might	O
have	O
beneficial	O
impact	O
on	O
human	O
health	O
.	O

Spatial	O
quorum	O
sensing	O
modelling	O
using	O
coloured	O
hybrid	O
Petri	O
nets	O
and	O
simulative	O
model	O
checking	O
.	O

BACKGROUND	O
:	O
Quorum	O
sensing	O
drives	O
biofilm	O
formation	O
in	O
bacteria	O
in	O
order	O
to	O
ensure	O
that	O
biofilm	O
formation	O
only	O
occurs	O
when	O
colonies	O
are	O
of	O
a	O
sufficient	O
size	O
and	O
density	O
.	O

This	O
spatial	O
behaviour	O
is	O
achieved	O
by	O
the	O
broadcast	O
communication	O
of	O
an	O
autoinducer	O
in	O
a	O
diffusion	O
scenario	O
.	O

This	O
is	O
of	O
interest	O
,	O
for	O
example	O
,	O
when	O
considering	O
the	O
role	O
of	O
gut	O
microbiota	O
in	O
gut	O
health	O
.	O

This	O
behaviour	O
occurs	O
within	O
the	O
context	O
of	O
the	O
four	O
phases	O
of	O
bacterial	O
growth	O
,	O
specifically	O
in	O
the	O
exponential	O
stage	O
(	O
phase	O
2	O
)	O
for	O
autoinducer	O
production	O
and	O
the	O
stationary	O
stage	O
(	O
phase	O
3	O
)	O
for	O
biofilm	O
formation	O
.	O

RESULTS	O
:	O
We	O
have	O
used	O
coloured	O
hybrid	O
Petri	O
nets	O
to	O
step	O
-	O
wise	O
develop	O
a	O
flexible	O
computational	O
model	O
for	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
biofilm	O
formation	O
driven	O
by	O
Autoinducer	O
2	O
(	O
AI	O
-	O
2	O
)	O
which	O
is	O
easy	O
to	O
configure	O
for	O
different	O
notions	O
of	O
space	O
.	O

The	O
model	O
describes	O
the	O
essential	O
components	O
of	O
gene	O
transcription	O
,	O
signal	O
transduction	O
,	O
extra	O
and	O
intra	O
cellular	O
transport	O
,	O
as	O
well	O
as	O
the	O
two	O
-	O
phase	O
nature	O
of	O
the	O
system	O
.	O

We	O
build	O
on	O
a	O
previously	O
published	O
non	O
-	O
spatial	O
stochastic	O
Petri	O
net	O
model	O
of	O
AI	O
-	O
2	O
production	O
,	O
keeping	O
the	O
assumptions	O
of	O
a	O
limited	O
nutritional	O
environment	O
,	O
and	O
our	O
spatial	O
hybrid	O
Petri	O
net	O
model	O
of	O
biofilm	O
formation	O
,	O
first	O
presented	O
at	O
the	O
NETTAB	O
2017	O
workshop	O
.	O

First	O
we	O
consider	O
the	O
two	O
models	O
separately	O
without	O
space	O
,	O
and	O
then	O
combined	O
,	O
and	O
finally	O
we	O
add	O
space	O
.	O

We	O
describe	O
in	O
detail	O
our	O
step	O
-	O
wise	O
model	O
development	O
and	O
validation	O
.	O

Our	O
simulation	O
results	O
support	O
the	O
expected	O
behaviour	O
that	O
biofilm	O
formation	O
is	O
increased	O
in	O
areas	O
of	O
higher	O
bacterial	O
colony	O
size	O
and	O
density	O
.	O

Our	O
analysis	O
techniques	O
include	O
behaviour	O
checking	O
based	O
on	O
linear	O
time	O
temporal	O
logic	O
.	O

CONCLUSIONS	O
:	O
The	O
advantages	O
of	O
our	O
modelling	O
and	O
analysis	O
approach	O
are	O
the	O
description	O
of	O
quorum	O
sensing	O
and	O
associated	O
biofilm	O
formation	O
over	O
two	O
phases	O
of	O
bacterial	O
growth	O
,	O
taking	O
into	O
account	O
bacterial	O
spatial	O
distribution	O
using	O
a	O
flexible	O
and	O
easy	O
to	O
maintain	O
computational	O
model	O
.	O

All	O
computational	O
results	O
are	O
reproducible	O
.	O

L	B-bacteria
.	I-bacteria
pseudomesenteroides	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
johnsonii	I-bacteria
isolated	O
from	O
yaks	O
in	O
Tibet	O
modulate	O
gut	O
microbiota	O
in	O
mice	O
to	O
ameliorate	O
enteroinvasive	O
Escherichia	O
coli	O
-	O
induced	O
diarrhea	O
.	O

Enteroinvasive	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
(	O
EIEC	B-bacteria
)	O
are	O
well	O
-	O
known	O
food	O
-	O
borne	O
pathogens	O
that	O
cause	O
animal	O
intestinal	O
diseases	O
.	O

Lactobacillus	B-bacteria
is	O
believed	O
to	O
inhibit	O
intestinal	O
pathogens	O
and	O
maintain	O
a	O
healthy	O
gut	O
microbiota	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
pre	O
-	O
supplementation	O
of	O
Lactobacillus	B-bacteria
from	O
yaks	O
(	O
4500m	O
)	O
to	O
prevent	O
the	O
clinical	O
symptoms	O
and	O
the	O
improvement	O
of	O
the	O
disordered	O
flora	O
caused	O
by	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
infection	O
.	O

Forty	O
healthy	O
mice	O
were	O
randomized	O
to	O
four	O
study	O
groups	O
(	O
n	O
=	O
10	O
)	O
;	O
Leuconostoc	B-bacteria
pseudomesenteroides	I-bacteria
(	O
LP1	B-bacteria
)	O
,	O
Lactobacillus	B-bacteria
johnsonii	I-bacteria
(	O
LJ1	B-bacteria
)	O
,	O
blank	O
control	O
,	O
and	O
control	O
groups	O
.	O

Mice	O
in	O
the	O
LP1	O
,	O
LJ1	O
,	O
and	O
control	O
groups	O
were	O
intraperitoneally	O
challenged	O
with	O
EIEC	O
O124	O
(	O
1x10	O
(	O
9	O
)	O
CFU	O
)	O
on	O
day	O
23	O
.	O

After	O
two	O
days	O
,	O
the	O
mice	O
in	O
control	O
group	O
were	O
recorded	O
for	O
high	O
mortality	O
.	O

The	O
diarrhea	O
in	O
LP1	O
and	O
LJ1	O
groups	O
was	O
much	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
,	O
and	O
no	O
death	O
was	O
recorded	O
.	O

In	O
histopathology	O
,	O
pre	O
-	O
supplementation	O
of	O
LJ1	O
and	O
LP1	O
relieved	O
the	O
damage	O
to	O
the	O
liver	O
,	O
spleen	O
and	O
duodenum	O
caused	O
by	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
.	O

In	O
addition	O
,	O
the	O
normal	O
intestinal	O
microecology	O
was	O
also	O
affected	O
by	O
infection	O
of	O
EIEC	O
,	O
including	O
an	O
increase	O
in	O
relative	O
abundance	O
of	O
Proteobacteria	B-bacteria
.	O

At	O
the	O
same	O
time	O
,	O
the	O
beneficial	O
bacteria	O
were	O
increased	O
and	O
harmful	O
bacteria	O
were	O
decreased	O
in	O
different	O
intestinal	O
segments	O
of	O
the	O
LJ1	O
and	O
LP1	O
groups	O
compared	O
to	O
the	O
control	O
group	O
.	O

In	O
conclusion	O
,	O
pre	O
-	O
supplementation	O
of	O
LP1	O
and	O
LJ1	O
can	O
mitigate	O
EIEC	O
-	O
induced	O
intestinal	O
flora	O
dysbiosis	O
and	O
can	O
also	O
reduce	O
EIEC	O
-	O
associated	O
diarrhea	O
.	O

Microbiota	O
and	O
gut	O
neuropeptides	O
:	O
a	O
dual	O
action	O
of	O
antimicrobial	O
activity	O
and	O
neuroimmune	O
response	O
.	O

The	O
gut	O
microbiota	O
is	O
comprised	O
of	O
a	O
vast	O
variety	O
of	O
microbes	O
that	O
colonize	O
the	O
gastrointestinal	O
tract	O
and	O
exert	O
crucial	O
roles	O
for	O
the	O
host	O
health	O
.	O

These	O
microorganisms	O
,	O
partially	O
via	O
their	O
breakdown	O
of	O
dietary	O
components	O
,	O
are	O
able	O
to	O
modulate	O
immune	O
response	O
,	O
mood	O
,	O
and	O
behavior	O
,	O
establishing	O
a	O
chemical	O
dialogue	O
in	O
the	O
microbiota	O
-	O
gut	O
-	O
brain	O
interphase	O
.	O

Changes	O
in	O
the	O
gut	O
microbiota	O
composition	O
and	O
functionality	O
are	O
associated	O
with	O
multiple	O
diseases	O
,	O
in	O
which	O
altered	O
levels	O
of	O
gut	O
-	O
associated	O
neuropeptides	O
are	O
also	O
detected	O
.	O

Gut	O
neuropeptides	O
are	O
strong	O
neuroimmune	O
modulators	O
;	O
they	O
mediate	O
the	O
communication	O
between	O
the	O
gut	O
microbiota	O
and	O
the	O
host	O
(	O
including	O
gut	O
-	O
brain	O
axis	O
)	O
and	O
have	O
also	O
recently	O
been	O
found	O
to	O
exert	O
antimicrobial	O
properties	O
.	O

This	O
highlights	O
the	O
importance	O
of	O
understanding	O
the	O
interplay	O
between	O
gut	O
neuropeptides	O
and	O
microbiota	O
and	O
their	O
implications	O
on	O
host	O
health	O
.	O

Here	O
,	O
we	O
will	O
discuss	O
how	O
gut	O
neuropeptides	O
help	O
to	O
maintain	O
a	O
balanced	O
microbiota	O
and	O
we	O
will	O
point	O
at	O
the	O
missing	O
gaps	O
that	O
need	O
to	O
be	O
further	O
investigated	O
in	O
order	O
to	O
elucidate	O
whether	O
these	O
molecules	O
are	O
related	O
to	O
neuropsychiatric	O
disorders	O
,	O
which	O
are	O
often	O
associated	O
with	O
gut	O
dysbiosis	O
and	O
altered	O
gut	O
neuropeptide	O
levels	O
.	O

The	O
gut	O
microflora	O
assay	O
in	O
patients	O
with	O
colorectal	O
cancer	O
:	O
in	O
feces	O
or	O
tissue	O
samples	O
?	O

Gut	O
microbiota	O
is	O
the	O
complex	O
community	O
of	O
microorganisms	O
that	O
live	O
in	O
the	O
digestive	O
tracts	O
of	O
humans	O
and	O
other	O
animals	O
,	O
including	O
insects	O
.	O

The	O
relationship	O
between	O
gut	O
microbiota	O
and	O
human	O
health	O
is	O
mutualistic	O
and	O
altered	O
bacterial	O
compositions	O
in	O
fecal	O
and	O
mucosal	O
specimens	O
of	O
colon	O
in	O
patients	O
with	O
cancer	O
compared	O
to	O
healthy	O
subjects	O
were	O
observed	O
.	O

Thereby	O
,	O
studying	O
the	O
gut	O
microbiota	O
,	O
their	O
interactions	O
with	O
the	O
host	O
and	O
their	O
alterations	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
patients	O
could	O
be	O
helpful	O
to	O
diagnose	O
and	O
treat	O
the	O
disease	O
in	O
earlier	O
stages	O
.	O

In	O
CRC	O
research	O
,	O
the	O
most	O
common	O
samples	O
are	O
feces	O
and	O
tumor	O
tissues	O
.	O

Interestingly	O
,	O
scientists	O
have	O
quite	O
different	O
views	O
regarding	O
gut	O
microbiota	O
composition	O
of	O
feces	O
and	O
tissues	O
.	O

Some	O
believe	O
bacterial	O
populations	O
in	O
feces	O
and	O
mucosa	O
are	O
completely	O
distinct	O
and	O
differ	O
in	O
composition	O
and	O
diversity	O
while	O
some	O
others	O
declare	O
similar	O
variations	O
.	O

Actually	O
,	O
both	O
types	O
of	O
specimens	O
have	O
some	O
advantages	O
and	O
disadvantages	O
in	O
survey	O
of	O
gut	O
microbiota	O
.	O

Fecal	O
samples	O
serve	O
as	O
a	O
noninvasive	O
approach	O
for	O
screening	O
tests	O
while	O
mucosal	O
associated	O
samples	O
are	O
more	O
powerful	O
for	O
identification	O
of	O
bacteria	O
with	O
adenoma	O
and	O
CRC	O
initiation	O
and	O
growth	O
.	O

Here	O
we	O
have	O
discussed	O
the	O
advantages	O
and	O
disadvantages	O
of	O
two	O
type	O
of	O
specimens	O
in	O
CRC	O
investigations	O
and	O
also	O
discussed	O
the	O
similarities	O
and	O
differences	O
of	O
microbial	O
composition	O
between	O
stool	O
and	O
tissue	O
specimens	O
.	O

Closely	O
-	O
related	O
Photobacterium	B-bacteria
strains	I-bacteria
comprise	O
the	O
majority	O
of	O
bacteria	O
in	O
the	O
gut	O
of	O
migrating	O
Atlantic	O
cod	O
(	O
Gadus	O
morhua	O
)	O
.	O

BACKGROUND	O
:	O
The	O
population	O
of	O
Atlantic	O
cod	O
(	O
Gadus	O
morhua	O
)	O
,	O
also	O
known	O
as	O
Northeast	O
Arctic	O
cod	O
,	O
migrating	O
Atlantic	O
cod	O
,	O
or	O
simply	O
`	O
`	O
skrei	O
,	O
'	O
'	O
lives	O
mainly	O
in	O
the	O
Barents	O
Sea	O
and	O
Svalbard	O
waters	O
and	O
migrates	O
in	O
annual	O
cycles	O
to	O
the	O
Norwegian	O
coast	O
in	O
order	O
to	O
spawn	O
eggs	O
during	O
late	O
winter	O
.	O

It	O
is	O
the	O
world	O
'	O
s	O
largest	O
population	O
of	O
Atlantic	O
cod	O
,	O
and	O
the	O
population	O
is	O
distinct	O
from	O
the	O
Norwegian	O
coastal	O
cod	O
(	O
or	O
`	O
`	O
fjord	O
'	O
'	O
cod	O
)	O
.	O

Despite	O
the	O
biological	O
,	O
economic	O
,	O
and	O
cultural	O
importance	O
of	O
migrating	O
Atlantic	O
cod	O
,	O
current	O
knowledge	O
on	O
the	O
associated	O
microbiota	O
is	O
very	O
limited	O
.	O

Using	O
shotgun	O
metagenomics	O
and	O
metaproteomics	O
approaches	O
,	O
we	O
present	O
here	O
the	O
gut	O
microbiota	O
,	O
metagenome	O
-	O
assembled	O
genomes	O
(	O
MAGs	O
)	O
of	O
the	O
most	O
abundant	O
bacterial	O
species	O
,	O
DNA	O
-	O
based	O
functional	O
profile	O
,	O
and	O
the	O
metaproteome	O
of	O
Atlantic	O
cod	O
specimens	O
caught	O
at	O
a	O
spawning	O
area	O
in	O
an	O
open	O
ocean	O
outside	O
of	O
Tromso	O
,	O
Norway	O
.	O

RESULTS	O
:	O
Our	O
analyses	O
identified	O
268	O
bacterial	O
families	O
in	O
DNA	O
isolated	O
from	O
feces	O
of	O
6	O
individual	O
migrating	O
Atlantic	O
cod	O
.	O

The	O
most	O
abundant	O
family	O
was	O
Vibrionaceae	B-bacteria
(	O
52	O
%	O
;	O
83	O
%	O
if	O
unclassified	O
reads	O
are	O
excluded	O
)	O
,	O
with	O
Photobacterium	B-bacteria
(	O
genus	O
)	O
representing	O
the	O
vast	O
majority	O
.	O

The	O
recovery	O
of	O
metagenome	O
-	O
assembled	O
genomes	O
provided	O
further	O
details	O
and	O
suggests	O
that	O
several	O
closely	O
related	O
Photobacterium	B-bacteria
strains	I-bacteria
from	O
the	O
Photobacterium	B-bacteria
phosphoreum	I-bacteria
clade	O
are	O
the	O
most	O
abundant	O
.	O

A	O
genomic	O
-	O
based	O
functional	O
profiling	O
showed	O
that	O
the	O
most	O
abundant	O
functional	O
subsystems	O
are	O
`	O
`	O
Carbohydrates	O
'	O
'	O
;	O
`	O
`	O
Amino	O
Acids	O
and	O
Derivatives	O
'	O
'	O
;	O
`	O
`	O
Protein	O
Metabolism	O
'	O
'	O
;	O
`	O
`	O
Cofactors	O
,	O
Vitamins	O
,	O
Prosthetic	O
,	O
Groups	O
,	O
and	O
Pigments	O
'	O
'	O
;	O
and	O
`	O
`	O
DNA	O
Metabolism	O
,	O
'	O
'	O
which	O
is	O
in	O
agreement	O
with	O
other	O
studies	O
of	O
gut	O
microbiomes	O
of	O
marine	O
organisms	O
.	O

Finally	O
,	O
the	O
MS	O
-	O
based	O
metaproteomic	O
dataset	O
revealed	O
that	O
the	O
functional	O
category	O
`	O
`	O
Protein	O
Metabolism	O
'	O
'	O
is	O
highly	O
overrepresented	O
(	O
3x	O
)	O
when	O
compared	O
to	O
the	O
genome	O
-	O
based	O
functional	O
profile	O
,	O
which	O
shows	O
that	O
ribosomal	O
proteins	O
are	O
rich	O
in	O
the	O
bacterial	O
cytosol	O
.	O

CONCLUSION	O
:	O
We	O
present	O
here	O
the	O
first	O
study	O
of	O
bacterial	O
diversity	O
of	O
the	O
gut	O
of	O
migrating	O
Atlantic	O
cod	O
using	O
shotgun	O
sequencing	O
and	O
metagenome	O
-	O
assembled	O
genomes	O
(	O
MAGs	O
)	O
.	O

The	O
most	O
abundant	O
bacteria	O
belong	O
to	O
the	O
Photobacterium	B-bacteria
genus	I-bacteria
(	O
Vibrionaceae	B-bacteria
family	I-bacteria
)	O
.	O

We	O
also	O
constructed	O
functional	O
profiles	O
of	O
the	O
gut	O
microbiome	O
.	O

These	O
may	O
be	O
used	O
in	O
future	O
studies	O
as	O
a	O
platform	O
for	O
mining	O
of	O
commercially	O
interesting	O
cold	O
-	O
active	O
enzymes	O
.	O

Progesterone	O
Increases	O
Bifidobacterium	B-bacteria
Relative	O
Abundance	O
during	O
Late	O
Pregnancy	O
.	O

Gestation	O
is	O
accompanied	O
by	O
alterations	O
in	O
the	O
microbial	O
repertoire	O
;	O
however	O
,	O
the	O
mechanisms	O
driving	O
these	O
changes	O
are	O
unknown	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
dramatic	O
shift	O
in	O
the	O
gut	O
microbial	O
composition	O
of	O
women	O
and	O
mice	O
during	O
late	O
pregnancy	O
,	O
including	O
an	O
increase	O
in	O
the	O
relative	O
abundance	O
of	O
Bifidobacterium	B-bacteria
.	O

Using	O
in	O
-	O
vivo	O
-	O
transplanted	O
pellets	O
,	O
we	O
found	O
that	O
progesterone	O
,	O
the	O
principal	O
gestation	O
hormone	O
,	O
affects	O
the	O
microbial	O
community	O
.	O

The	O
effect	O
of	O
progesterone	O
on	O
the	O
richness	O
of	O
several	O
bacteria	O
species	O
,	O
including	O
Bifidobacterium	B-bacteria
,	O
was	O
also	O
demonstrated	O
in	O
vitro	O
,	O
indicating	O
a	O
direct	O
effect	O
.	O

Altogether	O
,	O
our	O
results	O
delineate	O
a	O
model	O
in	O
which	O
progesterone	O
promotes	O
Bifidobacterium	B-bacteria
growth	O
during	O
late	O
pregnancy	O
.	O

Changing	O
paradigm	O
of	O
antibiotic	O
resistance	O
amongst	O
Escherichia	B-bacteria
coli	I-bacteria
isolates	I-bacteria
in	O
Indian	O
pediatric	O
population	O
.	O

Antimicrobial	O
resistance	O
happens	O
when	O
microorganisms	O
mutates	O
in	O
manners	O
that	O
render	O
the	O
drugs	O
like	O
antibacterial	O
,	O
antiviral	O
,	O
antiparasitic	O
and	O
antifungal	O
,	O
ineffective	O
.	O

The	O
normal	O
mutation	O
process	O
is	O
encouraged	O
by	O
the	O
improper	O
use	O
of	O
antibiotics	O
.	O

Mutations	O
leading	O
to	O
quinolone	O
resistance	O
occur	O
in	O
a	O
highly	O
conserved	O
region	O
of	O
the	O
quinolone	O
resistance	O
-	O
determining	O
region	O
(	O
QRDR	O
)	O
of	O
DNA	O
gyrAse	O
and	O
topoisomerase	O
IV	O
gene	O
.	O

We	O
analyzed	O
antibiotic	O
resistant	O
genes	O
and	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
gyrA	O
and	O
parC	O
genes	O
in	O
QRDR	O
in	O
120	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
isolates	I-bacteria
(	O
both	O
diarrheagenic	O
and	O
non	O
-	O
pathogenic	O
)	O
recovered	O
from	O
fresh	O
stool	O
samples	O
collected	O
from	O
children	O
aged	O
less	O
than	O
5	O
years	O
from	O
Delhi	O
,	O
India	O
.	O

Antibiotic	O
susceptibility	O
testing	O
was	O
performed	O
according	O
to	O
standard	O
clinical	O
and	O
laboratory	O
standards	O
institute	O
(	O
CLSI	O
)	O
guidelines	O
.	O

Phylogenetic	O
analysis	O
showed	O
the	O
clonal	O
diversity	O
and	O
phylogenetic	O
relationships	O
among	O
the	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
isolates	I-bacteria
.	O

The	O
SNP	O
analysis	O
depicted	O
mutations	O
in	O
gyrA	O
and	O
parC	O
genes	O
in	O
QRDR	O
.	O

The	O
sul1	O
gene	O
,	O
responsible	O
for	O
sulfonamide	O
resistance	O
,	O
was	O
present	O
in	O
almost	O
half	O
(	O
47	O
.	O
5	O
%	O
)	O
of	O
the	O
isolates	O
across	O
the	O
diseased	O
and	O
healthy	O
samples	O
.	O

The	O
presence	O
of	O
antibiotic	O
resistance	O
genes	O
in	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
isolates	I-bacteria
from	O
healthy	O
children	O
indicate	O
the	O
development	O
,	O
dissemination	O
and	O
carriage	O
of	O
antibiotic	O
resistance	O
in	O
their	O
gut	O
.	O

Our	O
observations	O
suggest	O
the	O
implementation	O
of	O
active	O
surveillance	O
and	O
stewardship	O
programs	O
to	O
promote	O
appropriate	O
antibiotic	O
use	O
and	O
minimizing	O
further	O
danger	O
.	O

Fermented	O
feed	O
regulates	O
growth	O
performance	O
and	O
the	O
cecal	O
microbiota	O
community	O
in	O
geese	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effects	O
of	O
fermented	O
feed	O
diets	O
on	O
the	O
growth	O
performance	O
and	O
cecal	O
microbial	O
community	O
in	O
geese	O
,	O
and	O
to	O
examine	O
associations	O
between	O
the	O
gut	O
microbiota	O
and	O
growth	O
performance	O
.	O

A	O
total	O
of	O
720	O
healthy	O
,	O
1	O
-	O
day	O
-	O
old	O
male	O
SanHua	O
geese	O
were	O
used	O
for	O
the	O
55	O
-	O
D	O
experiment	O
.	O

Geese	O
were	O
randomly	O
divided	O
into	O
4	O
groups	O
,	O
each	O
with	O
6	O
replicates	O
of	O
30	O
geese	O
.	O

Groups	O
were	O
fed	O
a	O
basal	O
diet	O
supplemented	O
with	O
0	O
.	O
0	O
,	O
2	O
.	O
5	O
,	O
5	O
.	O
0	O
,	O
or	O
7	O
.	O
5	O
%	O
fermented	O
feed	O
.	O

The	O
results	O
showed	O
that	O
7	O
.	O
5	O
%	O
fermented	O
feed	O
had	O
an	O
increasing	O
trend	O
in	O
the	O
body	O
weight	O
and	O
average	O
daily	O
gain	O
of	O
the	O
geese	O
;	O
however	O
,	O
there	O
was	O
no	O
significant	O
response	O
to	O
increasing	O
dietary	O
fermented	O
feed	O
level	O
with	O
regards	O
to	O
ADFI	O
and	O
FCR	O
.	O

In	O
addition	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
there	O
was	O
a	O
higher	O
abundance	O
of	O
bacteria	O
in	O
the	O
phylum	O
Bacteroidetes	B-bacteria
in	O
the	O
cecal	O
samples	O
of	O
geese	O
in	O
the	O
7	O
.	O
5	O
%	O
fermented	O
feed	O
group	O
(	O
53	O
.	O
18	O
%	O
vs	O
.	O
41	O
.	O
77	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
the	O
abundance	O
of	O
Firmicutes	B-bacteria
was	O
lower	O
in	O
the	O
7	O
.	O
5	O
%	O
fermented	O
feed	O
group	O
(	O
36	O
.	O
30	O
%	O
vs	O
.	O
44	O
.	O
13	O
%	O
,	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

At	O
the	O
genus	O
level	O
,	O
the	O
abundance	O
of	O
Bacteroides	B-bacteria
was	O
increased	O
by	O
adding	O
fermented	O
feed	O
to	O
geese	O
diets	O
,	O
whereas	O
the	O
abundances	O
of	O
Desulfovibrio	B-bacteria
,	O
Phascolarctobacterium	B-bacteria
,	O
Lachnospiraceae	B-bacteria
_	I-bacteria
uncultured	I-bacteria
,	O
Ruminiclostridium	B-bacteria
,	O
and	O
Oscillospira	B-bacteria
were	O
decreased	O
.	O

These	O
results	O
indicate	O
that	O
fermented	O
feeds	O
have	O
an	O
important	O
effect	O
on	O
the	O
cecal	O
microflora	O
composition	O
of	O
geese	O
,	O
and	O
may	O
affect	O
host	O
growth	O
,	O
nutritional	O
status	O
,	O
and	O
intestinal	O
health	O
.	O

virMine	O
:	O
automated	O
detection	O
of	O
viral	O
sequences	O
from	O
complex	O
metagenomic	O
samples	O
.	O

Metagenomics	O
has	O
enabled	O
sequencing	O
of	O
viral	O
communities	O
from	O
a	O
myriad	O
of	O
different	O
environments	O
.	O

Viral	O
metagenomic	O
studies	O
routinely	O
uncover	O
sequences	O
with	O
no	O
recognizable	O
homology	O
to	O
known	O
coding	O
regions	O
or	O
genomes	O
.	O

Nevertheless	O
,	O
complete	O
viral	O
genomes	O
have	O
been	O
constructed	O
directly	O
from	O
complex	O
community	O
metagenomes	O
,	O
often	O
through	O
tedious	O
manual	O
curation	O
.	O

To	O
address	O
this	O
,	O
we	O
developed	O
the	O
software	O
tool	O
virMine	O
to	O
identify	O
viral	O
genomes	O
from	O
raw	O
reads	O
representative	O
of	O
viral	O
or	O
mixed	O
(	O
viral	O
and	O
bacterial	O
)	O
communities	O
.	O

virMine	O
automates	O
sequence	O
read	O
quality	O
control	O
,	O
assembly	O
,	O
and	O
annotation	O
.	O

Researchers	O
can	O
easily	O
refine	O
their	O
search	O
for	O
a	O
specific	O
study	O
system	O
and	O
/	O
or	O
feature	O
(	O
s	O
)	O
of	O
interest	O
.	O

In	O
contrast	O
to	O
other	O
viral	O
genome	O
detection	O
tools	O
that	O
often	O
rely	O
on	O
the	O
recognition	O
of	O
viral	O
signature	O
sequences	O
,	O
virMine	O
is	O
not	O
restricted	O
by	O
the	O
insufficient	O
representation	O
of	O
viral	O
diversity	O
in	O
public	O
data	O
repositories	O
.	O

Rather	O
,	O
viral	O
genomes	O
are	O
identified	O
through	O
an	O
iterative	O
approach	O
,	O
first	O
omitting	O
non	O
-	O
viral	O
sequences	O
.	O

Thus	O
,	O
both	O
relatives	O
of	O
previously	O
characterized	O
viruses	O
and	O
novel	O
species	O
can	O
be	O
detected	O
,	O
including	O
both	O
eukaryotic	O
viruses	O
and	O
bacteriophages	O
.	O

Here	O
we	O
present	O
virMine	O
and	O
its	O
analysis	O
of	O
synthetic	O
communities	O
as	O
well	O
as	O
metagenomic	O
data	O
sets	O
from	O
three	O
distinctly	O
different	O
environments	O
:	O
the	O
gut	O
microbiota	O
,	O
the	O
urinary	O
microbiota	O
,	O
and	O
freshwater	O
viromes	O
.	O

Several	O
new	O
viral	O
genomes	O
were	O
identified	O
and	O
annotated	O
,	O
thus	O
contributing	O
to	O
our	O
understanding	O
of	O
viral	O
genetic	O
diversity	O
in	O
these	O
three	O
environments	O
.	O

Identification	O
of	O
the	O
Bacterial	O
Biosynthetic	O
Gene	O
Clusters	O
of	O
the	O
Oral	O
Microbiome	O
Illuminates	O
the	O
Unexplored	O
Social	O
Language	O
of	O
Bacteria	O
during	O
Health	O
and	O
Disease	O
.	O

Small	O
molecules	O
are	O
the	O
primary	O
communication	O
media	O
of	O
the	O
microbial	O
world	O
.	O

Recent	O
bioinformatic	O
studies	O
,	O
exploring	O
the	O
biosynthetic	O
gene	O
clusters	O
(	O
BGCs	O
)	O
which	O
produce	O
many	O
small	O
molecules	O
,	O
have	O
highlighted	O
the	O
incredible	O
biochemical	O
potential	O
of	O
the	O
signaling	O
molecules	O
encoded	O
by	O
the	O
human	O
microbiome	O
.	O

Thus	O
far	O
,	O
most	O
research	O
efforts	O
have	O
focused	O
on	O
understanding	O
the	O
social	O
language	O
of	O
the	O
gut	O
microbiome	O
,	O
leaving	O
crucial	O
signaling	O
molecules	O
produced	O
by	O
oral	O
bacteria	O
and	O
their	O
connection	O
to	O
health	O
versus	O
disease	O
in	O
need	O
of	O
investigation	O
.	O

In	O
this	O
study	O
,	O
a	O
total	O
of	O
4	O
,	O
915	O
BGCs	O
were	O
identified	O
across	O
461	O
genomes	O
representing	O
a	O
broad	O
taxonomic	O
diversity	O
of	O
oral	O
bacteria	O
.	O

Sequence	O
similarity	O
networking	O
provided	O
a	O
putative	O
product	O
class	O
for	O
more	O
than	O
100	O
unclassified	O
novel	O
BGCs	O
.	O

The	O
newly	O
identified	O
BGCs	O
were	O
cross	O
-	O
referenced	O
against	O
254	O
metagenomes	O
and	O
metatranscriptomes	O
derived	O
from	O
individuals	O
either	O
with	O
good	O
oral	O
health	O
or	O
with	O
dental	O
caries	O
or	O
periodontitis	O
.	O

This	O
analysis	O
revealed	O
2	O
,	O
473	O
BGCs	O
,	O
which	O
were	O
differentially	O
represented	O
across	O
the	O
oral	O
microbiomes	O
associated	O
with	O
health	O
versus	O
disease	O
.	O

Coabundance	O
network	O
analysis	O
identified	O
numerous	O
inverse	O
correlations	O
between	O
BGCs	O
and	O
specific	O
oral	O
taxa	O
.	O

These	O
correlations	O
were	O
present	O
in	O
healthy	O
individuals	O
but	O
greatly	O
reduced	O
in	O
individuals	O
with	O
dental	O
caries	O
,	O
which	O
may	O
suggest	O
a	O
defect	O
in	O
colonization	O
resistance	O
.	O

Finally	O
,	O
corroborating	O
mass	O
spectrometry	O
identified	O
several	O
compounds	O
with	O
homology	O
to	O
products	O
of	O
the	O
predicted	O
BGC	O
classes	O
.	O

Together	O
,	O
these	O
findings	O
greatly	O
expand	O
the	O
number	O
of	O
known	O
biosynthetic	O
pathways	O
present	O
in	O
the	O
oral	O
microbiome	O
and	O
provide	O
an	O
atlas	O
for	O
experimental	O
characterization	O
of	O
these	O
abundant	O
,	O
yet	O
poorly	O
understood	O
,	O
molecules	O
and	O
socio	O
-	O
chemical	O
relationships	O
,	O
which	O
impact	O
the	O
development	O
of	O
caries	O
and	O
periodontitis	O
,	O
two	O
of	O
the	O
world	O
'	O
s	O
most	O
common	O
chronic	O
diseases	O
.	O
IMPORTANCE	O
The	O
healthy	O
oral	O
microbiome	O
is	O
symbiotic	O
with	O
the	O
human	O
host	O
,	O
importantly	O
providing	O
colonization	O
resistance	O
against	O
potential	O
pathogens	O
.	O

Dental	O
caries	O
and	O
periodontitis	O
are	O
two	O
of	O
the	O
world	O
'	O
s	O
most	O
common	O
and	O
costly	O
chronic	O
infectious	O
diseases	O
and	O
are	O
caused	O
by	O
a	O
localized	O
dysbiosis	O
of	O
the	O
oral	O
microbiome	O
.	O

Bacterially	O
produced	O
small	O
molecules	O
,	O
often	O
encoded	O
by	O
BGCs	O
,	O
are	O
the	O
primary	O
communication	O
media	O
of	O
bacterial	O
communities	O
and	O
play	O
a	O
crucial	O
,	O
yet	O
largely	O
unknown	O
,	O
role	O
in	O
the	O
transition	O
from	O
health	O
to	O
dysbiosis	O
.	O

This	O
study	O
provides	O
a	O
comprehensive	O
mapping	O
of	O
the	O
BGC	O
repertoire	O
of	O
the	O
human	O
oral	O
microbiome	O
and	O
identifies	O
major	O
differences	O
in	O
health	O
compared	O
to	O
disease	O
.	O

Furthermore	O
,	O
BGC	O
representation	O
and	O
expression	O
is	O
linked	O
to	O
the	O
abundance	O
of	O
particular	O
oral	O
bacterial	O
taxa	O
in	O
health	O
versus	O
dental	O
caries	O
and	O
periodontitis	O
.	O

Overall	O
,	O
this	O
study	O
provides	O
a	O
significant	O
insight	O
into	O
the	O
chemical	O
communication	O
network	O
of	O
the	O
healthy	O
oral	O
microbiome	O
and	O
how	O
it	O
devolves	O
in	O
the	O
case	O
of	O
two	O
prominent	O
diseases	O
.	O

High	O
intake	O
of	O
dietary	O
fructose	O
in	O
overweight	O
/	O
obese	O
teenagers	O
associated	O
with	O
depletion	O
of	O
Eubacterium	B-bacteria
and	O
Streptococcus	B-bacteria
in	O
gut	O
microbiome	O
.	O

BACKGROUND	O
:	O
A	O
western	O
high	O
fat	O
,	O
high	O
carbohydrate	O
diet	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
decreased	O
gut	O
bacterial	O
diversity	O
and	O
reductions	O
in	O
beneficial	O
bacteria	O
.	O

This	O
gut	O
bacteria	O
dysbiosis	O
could	O
develop	O
in	O
early	O
life	O
and	O
contribute	O
to	O
chronic	O
disease	O
risk	O
such	O
as	O
obesity	O
,	O
type	O
2	O
diabetes	O
and	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
how	O
dietary	O
macronutrients	O
are	O
associated	O
with	O
the	O
relative	O
abundance	O
of	O
gut	O
bacteria	O
in	O
healthy	O
adolescents	O
.	O

METHODS	O
:	O
Fifty	O
-	O
two	O
obese	O
participants	O
(	O
12	O
-	O
19	O
years	O
)	O
from	O
two	O
studies	O
,	O
many	O
who	O
were	O
primarily	O
of	O
Hispanic	O
background	O
,	O
provided	O
fecal	O
samples	O
for	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

Dietary	O
macronutrients	O
were	O
assessed	O
using	O
24	O
-	O
hour	O
diet	O
recalls	O
and	O
body	O
composition	O
was	O
assessed	O
using	O
DEXA	O
.	O

General	O
regression	O
models	O
assuming	O
a	O
negative	O
binomial	O
distribution	O
were	O
used	O
to	O
examine	O
the	O
associations	O
between	O
gut	O
bacteria	O
and	O
dietary	O
fiber	O
,	O
saturated	O
fat	O
,	O
unsaturated	O
fats	O
,	O
protein	O
,	O
added	O
sugar	O
,	O
total	O
sugar	O
and	O
free	O
fructose	O
after	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
race	O
/	O
ethnicity	O
,	O
body	O
fat	O
percentage	O
,	O
study	O
and	O
caloric	O
intake	O
.	O

RESULTS	O
:	O
The	O
genera	O
Eubacterium	B-bacteria
(	O
Benjamini	O
-	O
Hochberg	O
(	O
BH	O
)	O
corrected	O
p	O
-	O
value	O
=	O
0	O
.	O
10	O
)	O
and	O
Streptococcus	B-bacteria
(	O
BH	O
corrected	O
p	O
-	O
value	O
=	O
0	O
.	O
04	O
)	O
were	O
inversely	O
associated	O
with	O
dietary	O
fructose	O
intake	O
.	O

There	O
were	O
no	O
other	O
significant	O
associations	O
between	O
abundances	O
of	O
gut	O
microbes	O
and	O
other	O
dietary	O
macronutrients	O
,	O
including	O
fiber	O
,	O
fat	O
,	O
protein	O
,	O
total	O
sugar	O
or	O
added	O
sugar	O
.	O

CONCLUSIONS	O
:	O
High	O
dietary	O
fructose	O
was	O
associated	O
with	O
lower	O
abundance	O
of	O
the	O
beneficial	O
microbes	O
Eubacterium	B-bacteria
and	O
Streptococcus	B-bacteria
,	O
which	O
are	O
involved	O
with	O
carbohydrate	O
metabolism	O
.	O

[	O
Research	O
progress	O
on	O
Chinese	O
herbal	O
medicine	O
fermentation	O
and	O
profile	O
of	O
active	O
substances	O
derived	O
]	O
.	O

Chinese	O
herbal	O
medicines	O
(	O
CHMs	O
)	O
are	O
a	O
class	O
of	O
preparations	O
made	O
from	O
natural	O
plants	O
that	O
pose	O
health	O
beneficial	O
properties	O
as	O
well	O
as	O
illness	O
prevention	O
functions	O
.	O

Thanks	O
to	O
a	O
panel	O
of	O
salutary	O
features	O
,	O
such	O
as	O
comprehensive	O
immunological	O
enhancement	O
and	O
inhibition	O
of	O
pathogenic	O
bacteria	O
,	O
negligible	O
side	O
-	O
effects	O
,	O
inappreciable	O
drug	O
-	O
resistance	O
,	O
CHMs	O
have	O
been	O
taken	O
as	O
one	O
of	O
the	O
costeffective	O
candidates	O
for	O
antibiotics	O
substitutions	O
.	O

Through	O
probiotics	O
fermentation	O
,	O
the	O
enzymatic	O
hydrolysis	O
of	O
matrixes	O
of	O
CHMs	O
enables	O
easier	O
release	O
of	O
the	O
active	O
ingredient	O
as	O
well	O
as	O
endows	O
less	O
toxicity	O
of	O
the	O
preparations	O
derived	O
.	O

During	O
fermentation	O
,	O
the	O
macromolecule	O
or	O
polymers	O
forms	O
of	O
the	O
active	O
ingredient	O
can	O
be	O
cut	O
down	O
to	O
smaller	O
molecule	O
,	O
which	O
favors	O
the	O
transmembrane	O
transport	O
and	O
improve	O
adsorption	O
of	O
the	O
active	O
ingredients	O
by	O
the	O
tissues	O
.	O

Other	O
than	O
the	O
enzymatic	O
benefits	O
,	O
probiotics	O
can	O
produce	O
metabolites	O
that	O
inhibit	O
pathogenic	O
bacteria	O
propagation	O
,	O
which	O
may	O
function	O
synergically	O
with	O
the	O
inhibitory	O
effects	O
of	O
the	O
CHMs	O
preparations	O
to	O
fight	O
the	O
target	O
pathogens	O
.	O

In	O
addition	O
,	O
the	O
oligosaccharide	O
like	O
components	O
of	O
CHMs	O
can	O
promote	O
the	O
growth	O
of	O
probiotics	O
in	O
intestinal	O
environment	O
which	O
may	O
largely	O
facilitate	O
the	O
gut	O
health	O
.	O

To	O
summarize	O
,	O
the	O
fermentation	O
of	O
CHMs	O
using	O
probiotics	O
brings	O
about	O
the	O
biochemical	O
reactions	O
and	O
elevates	O
the	O
health	O
beneficial	O
effects	O
by	O
synergy	O
of	O
the	O
microbial	O
and	O
herbal	O
activities	O
.	O

It	O
has	O
been	O
proved	O
to	O
be	O
one	O
of	O
promising	O
approaches	O
as	O
to	O
antibiotic	O
substitutions	O
,	O
particularly	O
in	O
livestock	O
and	O
poultry	O
breeding	O
industries	O
.	O

This	O
review	O
covered	O
the	O
recent	O
progress	O
of	O
CHMs	O
fermentation	O
on	O
the	O
aspects	O
of	O
microbial	O
strains	O
,	O
patterns	O
of	O
fermentation	O
and	O
active	O
substances	O
from	O
fermentation	O
of	O
CHMs	O
and	O
their	O
potency	O
,	O
respectively	O
.	O

Characterization	O
of	O
Bacterial	O
Communities	O
in	O
Breeding	O
Waters	O
of	O
Anopheles	O
darlingi	O
in	O
Manaus	O
in	O
the	O
Amazon	O
Basin	O
Malaria	O
-	O
Endemic	O
Area	O
.	O

The	O
microbiota	O
in	O
mosquito	O
breeding	O
waters	O
can	O
affect	O
ovipositing	O
mosquitoes	O
,	O
have	O
effects	O
on	O
larval	O
development	O
,	O
and	O
can	O
modify	O
adult	O
mosquito	O
-	O
gut	O
bacterial	O
composition	O
.	O

This	O
,	O
in	O
turn	O
,	O
can	O
affect	O
transmission	O
of	O
human	O
pathogens	O
such	O
as	O
malaria	O
parasites	O
.	O

Here	O
,	O
we	O
explore	O
the	O
microbiota	O
of	O
four	O
breeding	O
sites	O
for	O
Anopheles	O
darlingi	O
,	O
the	O
most	O
important	O
malaria	O
vector	O
in	O
Latin	O
America	O
.	O

The	O
sites	O
are	O
located	O
in	O
Manaus	O
in	O
the	O
Amazon	O
basin	O
in	O
Brazil	O
,	O
an	O
area	O
of	O
active	O
malaria	O
transmission	O
.	O

Using	O
16S	O
rRNA	O
gene	O
sequencing	O
by	O
MiSeq	O
,	O
we	O
found	O
that	O
all	O
sites	O
were	O
dominated	O
by	O
Proteobacteria	B-bacteria
and	O
Firmicutes	B-bacteria
and	O
that	O
94	O
%	O
of	O
the	O
total	O
number	O
of	O
reads	O
belonged	O
to	O
36	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
identified	O
in	O
all	O
sites	O
.	O

Of	O
these	O
,	O
the	O
most	O
common	O
OTUs	O
belonged	O
to	O
Escherichia	B-bacteria
/	O
Shigella	B-bacteria
,	O
Staphylococcus	B-bacteria
,	O
and	O
Pseudomonas	B-bacteria
.	O

Of	O
the	O
remaining	O
6	O
%	O
of	O
the	O
reads	O
,	O
the	O
OTUs	O
found	O
to	O
differentiate	O
between	O
the	O
four	O
sites	O
belonged	O
to	O
the	O
orders	O
Burkholderiales	B-bacteria
,	O
Actinomycetales	B-bacteria
,	O
and	O
Clostridiales	B-bacteria
.	O

We	O
conclude	O
that	O
An	O
.	O
darlingi	O
can	O
develop	O
in	O
breeding	O
waters	O
with	O
different	O
surface	O
-	O
water	O
bacteria	O
,	O
but	O
that	O
the	O
common	O
microbiota	O
found	O
in	O
all	O
breeding	O
sites	O
might	O
indicate	O
or	O
contribute	O
to	O
a	O
suitable	O
habitat	O
for	O
this	O
important	O
malaria	O
vector	O
.	O

Dissemination	O
of	O
multiple	O
carbapenem	O
resistance	O
genes	O
in	O
an	O
in	O
vitro	O
gut	O
model	O
simulating	O
the	O
human	O
colon	O
.	O

BACKGROUND	O
:	O
Carbapenemase	O
-	O
producing	O
Enterobacteriaceae	B-bacteria
(	O
CPE	O
)	O
pose	O
a	O
major	O
global	O
health	O
risk	O
.	O

Mobile	O
genetic	O
elements	O
account	O
for	O
much	O
of	O
the	O
increasing	O
CPE	O
burden	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
CPE	O
colonization	O
and	O
the	O
impact	O
of	O
antibiotic	O
exposure	O
on	O
subsequent	O
resistance	O
gene	O
dissemination	O
within	O
the	O
gut	O
microbiota	O
using	O
a	O
model	O
to	O
simulate	O
the	O
human	O
colon	O
.	O

METHODS	O
:	O
Gut	O
models	O
seeded	O
with	O
CPE	O
-	O
negative	O
human	O
faeces	O
[	O
screened	O
with	O
BioMerieux	O
chromID	O
(	O
R	O
)	O
CARBA	O
-	O
SMART	O
(	O
Carba	O
-	O
Smart	O
)	O
,	O
Cepheid	O
Xpert	O
(	O
R	O
)	O
Carba	O
-	O
R	O
assay	O
(	O
XCR	O
)	O
]	O
were	O
inoculated	O
with	O
distinct	O
carbapenemase	O
-	O
producing	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
strains	I-bacteria
(	O
KPC	O
,	O
NDM	O
)	O
and	O
challenged	O
with	O
imipenem	O
or	O
piperacillin	O
/	O
tazobactam	O
then	O
meropenem	O
.	O

Resistant	O
populations	O
were	O
enumerated	O
daily	O
on	O
selective	O
agars	O
(	O
Carba	O
-	O
Smart	O
)	O
;	O
CPE	O
genes	O
were	O
confirmed	O
by	O
PCR	O
(	O
XCR	O
,	O
Check	O
-	O
Direct	O
CPE	O
Screen	O
for	O
BD	O
MAX	O
)	O
.	O

CPE	O
gene	O
dissemination	O
was	O
tracked	O
using	O
PacBio	O
long	O
-	O
read	O
sequencing	O
.	O

RESULTS	O
:	O
CPE	O
populations	O
increased	O
during	O
inoculation	O
,	O
plateauing	O
at	O
approximately	O
105	O
log10	O
cfu	O
/	O
mL	O
in	O
both	O
models	O
and	O
persisting	O
throughout	O
the	O
experiments	O
(	O
>	O
65	O
days	O
)	O
,	O
with	O
no	O
evidence	O
of	O
CPE	O
'	O
washout	O
'	O
.	O

After	O
antibiotic	O
administration	O
,	O
there	O
was	O
evidence	O
of	O
interspecies	O
plasmid	O
transfer	O
of	O
blaKPC	O
-	O
2	O
(	O
111742	O
bp	O
IncFII	O
/	O
IncR	O
plasmid	O
,	O
99	O
%	O
identity	O
to	O
pKpQIL	O
-	O
D2	O
)	O
and	O
blaNDM	O
-	O
1	O
(	O
approximately	O
170	O
kb	O
IncFIB	O
/	O
IncFII	O
plasmid	O
)	O
,	O
and	O
CPE	O
populations	O
rose	O
from	O
<	O
0	O
.	O
01	O
%	O
to	O
>	O
45	O
%	O
of	O
the	O
total	O
lactose	O
-	O
fermenting	O
populations	O
in	O
the	O
KPC	O
model	O
.	O

Isolation	O
of	O
a	O
blaNDM	O
-	I-bacteria
1K	I-bacteria
.	I-bacteria
pneumoniae	I-bacteria
with	O
one	O
chromosomal	O
single	O
-	O
nucleotide	O
variant	O
compared	O
with	O
the	O
inoculated	O
strain	O
indicated	O
clonal	O
expansion	O
within	O
the	O
model	O
.	O

Antibiotic	O
administration	O
exposed	O
a	O
previously	O
undetected	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
encoding	O
blaOXA	O
-	O
232	O
(	O
KPC	O
model	O
)	O
.	O

CONCLUSIONS	O
:	O
CPE	O
exposure	O
can	O
lead	O
to	O
colonization	O
,	O
clonal	O
expansion	O
and	O
resistance	O
gene	O
transfer	O
within	O
intact	O
human	O
colonic	O
microbiota	O
.	O

Furthermore	O
,	O
under	O
antibiotic	O
selective	O
pressure	O
,	O
new	O
resistant	O
populations	O
emerge	O
,	O
emphasizing	O
the	O
need	O
to	O
control	O
exposure	O
to	O
antimicrobials	O
.	O

Dysbiosis	O
patterns	O
during	O
re	O
-	O
induction	O
/	O
salvage	O
versus	O
induction	O
chemotherapy	O
for	O
acute	O
leukemia	O
.	O

Acute	O
leukemia	O
(	O
AL	O
)	O
patients	O
undergoing	O
intensive	O
induction	O
chemotherapy	O
develop	O
severe	O
gut	O
dysbiosis	O
,	O
placing	O
them	O
at	O
heightened	O
risk	O
for	O
infectious	O
complications	O
.	O

Some	O
AL	O
patients	O
will	O
undergo	O
`	O
`	O
repeat	O
therapy	O
'	O
'	O
(	O
re	O
-	O
induction	O
or	O
salvage	O
)	O
due	O
to	O
persistent	O
or	O
relapsed	O
disease	O
.	O

We	O
hypothesized	O
that	O
prior	O
injury	O
to	O
the	O
microbiome	O
during	O
induction	O
may	O
influence	O
dysbiosis	O
patterns	O
during	O
repeat	O
therapy	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
analyzed	O
the	O
bacterial	O
microbiome	O
profiles	O
of	O
thrice	O
-	O
weekly	O
stool	O
samples	O
from	O
20	O
intensively	O
treated	O
AL	O
patients	O
(	O
first	O
induction	O
:	O
13	O
,	O
repeat	O
therapy	O
:	O
7	O
)	O
by	O
16S	O
rRNA	O
sequencing	O
.	O

In	O
mixed	O
-	O
effects	O
modeling	O
,	O
repeat	O
therapy	O
was	O
a	O
significant	O
predictor	O
of	O
Enterococcus	B-bacteria
expansion	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
,	O
independently	O
of	O
antibiotic	O
exposure	O
,	O
disease	O
type	O
,	O
feeding	O
mode	O
,	O
and	O
week	O
of	O
chemotherapy	O
.	O

Bayesian	O
analysis	O
of	O
longitudinal	O
data	O
demonstrated	O
larger	O
departures	O
of	O
microbial	O
communities	O
from	O
the	O
pre	O
-	O
chemotherapy	O
baseline	O
during	O
repeat	O
therapy	O
compared	O
to	O
induction	O
.	O

This	O
increased	O
ecosystem	O
instability	O
during	O
repeat	O
therapy	O
possibly	O
impairs	O
colonization	O
resistance	O
and	O
increases	O
vulnerability	O
to	O
Enterococcus	B-bacteria
outgrowth	O
.	O

Microbiota	O
restoration	O
therapies	O
at	O
the	O
end	O
of	O
induction	O
or	O
before	O
starting	O
subsequent	O
therapy	O
warrant	O
investigation	O
.	O

Effects	O
of	O
a	O
phytogenic	O
,	O
alone	O
and	O
associated	O
with	O
potassium	O
diformate	O
,	O
on	O
tilapia	O
growth	O
,	O
immunity	O
,	O
gut	O
microbiome	O
and	O
resistance	O
against	O
francisellosis	O
.	O

This	O
work	O
evaluated	O
the	O
effects	O
of	O
dietary	O
supplementation	O
of	O
A	O
-	O
Live	O
(	O
phytogenic	O
)	O
either	O
individually	O
or	O
in	O
combination	O
with	O
Aquaform	O
(	O
potassium	O
diformate	O
,	O
acidifier	O
)	O
on	O
juvenile	O
Nile	O
tilapia	O
(	O
Oreochromis	O
niloticus	O
)	O
growth	O
performance	O
,	O
innate	O
immune	O
parameters	O
,	O
gut	O
microbiome	O
,	O
and	O
resistance	O
against	O
Francisella	B-bacteria
noatunensis	I-bacteria
subsp	I-bacteria
.	I-bacteria
orientalis	I-bacteria
challenge	O
.	O

Each	O
experimental	O
group	O
contained	O
140	O
fishes	O
(	O
34	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
33	O
)	O
in	O
two	O
150L	O
tanks	O
.	O

The	O
experimental	O
design	O
consisted	O
of	O
five	O
groups	O
:	O
a	O
negative	O
control	O
;	O
treated	O
groups	O
(	O
G1	O
,	O
G2	O
,	O
G3	O
)	O
supplemented	O
with	O
different	O
concentrations	O
of	O
A	O
-	O
Live	O
and	O
Aquaform	O
in	O
the	O
feed	O
;	O
and	O
a	O
positive	O
control	O
(	O
PC	O
)	O
for	O
pathogen	O
infection	O
.	O

Groups	O
G1	O
,	O
G2	O
,	O
G3	O
,	O
and	O
PC	O
were	O
challenged	O
with	O
Francisella	B-bacteria
spp	I-bacteria
.	I-bacteria
after	O
15	O
days	O
.	O

After	O
infection	O
,	O
the	O
mortality	O
was	O
significantly	O
lower	O
in	O
groups	O
G1	O
,	O
G2	O
,	O
and	O
G3	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Furthermore	O
,	O
these	O
groups	O
showed	O
significant	O
increase	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
daily	O
weight	O
gain	O
,	O
feed	O
conversion	O
rate	O
,	O
and	O
specific	O
growth	O
rate	O
.	O

The	O
PC	O
group	O
presented	O
increase	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
leukocytes	O
and	O
neutrophils	O
number	O
.	O

Innate	O
immunity	O
parameters	O
showed	O
no	O
difference	O
between	O
treatments	O
after	O
infection	O
.	O

Microbiome	O
analysis	O
revealed	O
an	O
increased	O
number	O
of	O
bacteria	O
belonging	O
to	O
the	O
Vibrionaceae	B-bacteria
family	I-bacteria
after	O
pathogen	O
infection	O
suggesting	O
a	O
secondary	O
pathogen	O
function	O
of	O
these	O
bacteria	O
.	O

These	O
results	O
validate	O
the	O
beneficial	O
effects	O
of	O
these	O
products	O
in	O
tilapia	O
farming	O
.	O

Does	O
exercise	O
impact	O
gut	O
microbiota	O
composition	O
in	O
men	O
receiving	O
androgen	O
deprivation	O
therapy	O
for	O
prostate	O
cancer	O
?	O
A	O
single	O
-	O
blinded	O
,	O
two	O
-	O
armed	O
,	O
randomised	O
controlled	O
trial	O
.	O

INTRODUCTION	O
:	O
A	O
potential	O
link	O
exists	O
between	O
prostate	O
cancer	O
(	O
PCa	O
)	O
disease	O
and	O
treatment	O
and	O
increased	O
inflammatory	O
levels	O
from	O
gut	O
dysbiosis	O
.	O

This	O
study	O
aims	O
to	O
examine	O
if	O
exercise	O
favourably	O
alters	O
gut	O
microbiota	O
in	O
men	O
receiving	O
androgen	O
deprivation	O
therapy	O
(	O
ADT	O
)	O
for	O
PCa	O
.	O

Specifically	O
,	O
this	O
study	O
will	O
explore	O
whether	O
:	O
(	O
1	O
)	O
exercise	O
improves	O
the	O
composition	O
of	O
gut	O
microbiota	O
and	O
increases	O
the	O
abundance	O
of	O
bacteria	O
associated	O
with	O
health	O
promotion	O
and	O
(	O
2	O
)	O
whether	O
gut	O
health	O
correlates	O
with	O
favourable	O
inflammatory	O
status	O
,	O
bowel	O
function	O
,	O
continence	O
and	O
nausea	O
among	O
patients	O
participating	O
in	O
the	O
exercise	O
intervention	O
.	O

METHODS	O
AND	O
ANALYSIS	O
:	O
A	O
single	O
-	O
blinded	O
,	O
two	O
-	O
armed	O
,	O
randomised	O
controlled	O
trial	O
will	O
explore	O
the	O
influence	O
of	O
a	O
3	O
-	O
month	O
exercise	O
programme	O
(	O
3	O
days	O
/	O
week	O
)	O
for	O
men	O
with	O
high	O
-	O
risk	O
localised	O
PCa	O
receiving	O
ADT	O
.	O

Sixty	O
patients	O
will	O
be	O
randomly	O
assigned	O
to	O
either	O
exercise	O
intervention	O
or	O
usual	O
care	O
.	O

The	O
primary	O
endpoint	O
(	O
gut	O
health	O
and	O
function	O
assessed	O
via	O
feacal	O
samples	O
)	O
and	O
secondary	O
endpoints	O
(	O
self	O
-	O
reported	O
quality	O
of	O
life	O
via	O
standardised	O
questionnaires	O
,	O
blood	O
biomarkers	O
,	O
body	O
composition	O
and	O
physical	O
fitness	O
)	O
will	O
be	O
measured	O
at	O
baseline	O
and	O
following	O
the	O
intervention	O
.	O

A	O
variety	O
of	O
statistical	O
methods	O
will	O
be	O
used	O
to	O
understand	O
the	O
covariance	O
between	O
microbial	O
diversity	O
and	O
metabolomics	O
profile	O
across	O
time	O
and	O
intervention	O
.	O

An	O
intention	O
-	O
to	O
-	O
treat	O
approach	O
will	O
be	O
utilised	O
for	O
the	O
analyses	O
with	O
multiple	O
imputations	O
followed	O
by	O
a	O
secondary	O
sensitivity	O
analysis	O
to	O
ensure	O
data	O
robustness	O
using	O
a	O
complete	O
cases	O
approach	O
.	O

ETHICS	O
AND	O
DISSEMINATION	O
:	O
Ethics	O
approval	O
was	O
obtained	O
from	O
the	O
Human	O
Research	O
Ethics	O
Committee	O
of	O
Edith	O
Cowan	O
University	O
(	O
ID	O
:	O
19827	O
NEWTON	O
)	O
.	O

Findings	O
will	O
be	O
reported	O
in	O
peer	O
-	O
reviewed	O
publications	O
and	O
scientific	O
conferences	O
in	O
addition	O
to	O
working	O
with	O
national	O
support	O
groups	O
to	O
translate	O
findings	O
for	O
the	O
broader	O
community	O
.	O

If	O
exercise	O
is	O
shown	O
to	O
result	O
in	O
favourable	O
changes	O
in	O
gut	O
microbial	O
diversity	O
,	O
composition	O
and	O
metabolic	O
profile	O
,	O
and	O
reduce	O
gastrointestinal	O
complications	O
in	O
PCa	O
patients	O
receiving	O
ADT	O
,	O
this	O
study	O
will	O
form	O
the	O
basis	O
of	O
a	O
future	O
phase	O
III	O
trial	O
.	O

TRIAL	O
REGISTRATION	O
NUMBER	O
:	O
ANZCTR12618000280202	O
.	O

Genomic	O
Analyses	O
of	O
Bifidobacterium	B-bacteria
moukalabense	I-bacteria
Reveal	O
Adaptations	O
to	O
Frugivore	O
/	O
Folivore	O
Feeding	O
Behavior	O
.	O

Despite	O
the	O
essential	O
role	O
of	O
Bifidobacterium	B-bacteria
in	O
health	O
-	O
promoting	O
gut	O
bacteria	O
in	O
humans	O
,	O
little	O
is	O
known	O
about	O
their	O
functions	O
in	O
wild	O
animals	O
,	O
especially	O
non	O
-	O
human	O
primates	O
.	O

It	O
is	O
difficult	O
to	O
determine	O
in	O
vivo	O
the	O
function	O
of	O
Bifidobacterium	B-bacteria
in	O
wild	O
animals	O
due	O
to	O
the	O
limited	O
accessibility	O
of	O
studying	O
target	O
animals	O
in	O
natural	O
conditions	O
.	O

However	O
,	O
the	O
genomic	O
characteristics	O
of	O
Bifidobacterium	B-bacteria
obtained	O
from	O
the	O
feces	O
of	O
wild	O
animals	O
can	O
provide	O
insight	O
into	O
their	O
functionality	O
in	O
the	O
gut	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
whole	O
genomes	O
of	O
12	O
B	B-bacteria
.	I-bacteria
moukalabense	I-bacteria
strains	I-bacteria
isolated	O
from	O
seven	O
feces	O
samples	O
of	O
wild	O
western	O
lowland	O
gorillas	O
(	O
Gorilla	O
gorilla	O
gorilla	O
)	O
,	O
three	O
samples	O
of	O
wild	O
central	O
chimpanzees	O
(	O
Pan	O
troglodytes	O
troglodytes	O
)	O
and	O
two	O
samples	O
of	O
wild	O
forest	O
elephants	O
(	O
Loxodonta	O
cyclotis	O
)	O
in	O
Moukalaba	O
-	O
Doudou	O
National	O
Park	O
,	O
Gabon	O
.	O

In	O
addition	O
,	O
we	O
analyzed	O
the	O
fecal	O
bacterial	O
communities	O
of	O
six	O
wild	O
western	O
lowland	O
gorillas	O
by	O
meta	O
16S	O
rRNA	O
gene	O
analyses	O
with	O
next	O
generation	O
sequencing	O
.	O

Although	O
the	O
abundance	O
of	O
the	O
genus	O
Bifidobacterium	B-bacteria
was	O
as	O
low	O
as	O
0	O
.	O
2	O
%	O
in	O
the	O
total	O
reads	O
,	O
a	O
whole	O
genome	O
analysis	O
of	O
B	B-bacteria
.	I-bacteria
moukalabense	I-bacteria
suggested	O
its	O
contribution	O
digestion	O
of	O
food	O
and	O
nutrition	O
of	O
frugivore	O
/	O
folivore	O
animals	O
.	O

Specifically	O
,	O
the	O
whole	O
genome	O
analysis	O
indicated	O
the	O
involvement	O
of	O
B	B-bacteria
.	I-bacteria
moukalabense	I-bacteria
in	O
hemicellulose	O
degradation	O
for	O
short	O
chain	O
fatty	O
acid	O
production	O
and	O
nucleic	O
acid	O
utilization	O
as	O
nitrogen	O
resources	O
.	O

In	O
comparison	O
with	O
human	O
-	O
associated	O
Bifidobacterium	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
genes	O
for	O
carbohydrate	O
transport	O
and	O
metabolism	O
are	O
not	O
conserved	O
in	O
these	O
wild	O
species	O
.	O

In	O
particular	O
the	O
glycosidases	O
,	O
which	O
are	O
found	O
in	O
all	O
12	O
strains	O
of	O
B	B-bacteria
.	I-bacteria
moukalabense	I-bacteria
,	O
were	O
variably	O
detected	O
,	O
or	O
not	O
detected	O
,	O
in	O
human	O
-	O
associated	O
species	O
.	O

Use	O
of	O
bioengineered	O
human	O
commensal	O
gut	O
bacteria	O
-	O
derived	O
microvesicles	O
for	O
mucosal	O
plague	O
vaccine	O
delivery	O
and	O
immunization	O
.	O

Plague	O
caused	O
by	O
the	O
Gram	O
-	O
negative	O
bacterium	O
,	O
Yersinia	B-bacteria
pestis	I-bacteria
,	O
is	O
still	O
endemic	O
in	O
parts	O
of	O
the	O
world	O
today	O
.	O

Protection	O
against	O
pneumonic	O
plague	O
is	O
essential	O
to	O
prevent	O
the	O
development	O
and	O
spread	O
of	O
epidemics	O
.	O

Despite	O
this	O
,	O
there	O
are	O
currently	O
no	O
licensed	O
plague	O
vaccines	O
in	O
the	O
western	O
world	O
.	O

Here	O
we	O
describe	O
the	O
means	O
of	O
delivering	O
biologically	O
active	O
plague	O
vaccine	O
antigens	O
directly	O
to	O
mucosal	O
sites	O
of	O
plague	O
infection	O
using	O
highly	O
stable	O
microvesicles	O
(	O
outer	O
membrane	O
vesicles	O
;	O
OMVs	O
)	O
that	O
are	O
naturally	O
produced	O
by	O
the	O
abundant	O
and	O
harmless	O
human	O
commensal	O
gut	O
bacterium	O
Bacteroides	B-bacteria
thetaiotaomicron	I-bacteria
(	O
Bt	B-bacteria
)	O
.	O

Bt	B-bacteria
was	O
engineered	O
to	O
express	O
major	O
plague	O
protective	O
antigens	O
in	O
its	O
OMVs	O
,	O
specifically	O
Fraction	O
1	O
(	O
F1	O
)	O
in	O
the	O
outer	O
membrane	O
and	O
LcrV	O
(	O
V	O
antigen	O
)	O
in	O
the	O
lumen	O
,	O
for	O
targeted	O
delivery	O
to	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
and	O
respiratory	O
tracts	O
in	O
a	O
non	O
-	O
human	O
primate	O
(	O
NHP	O
)	O
host	O
.	O

Our	O
key	O
findings	O
were	O
that	O
Bt	O
OMVs	O
stably	O
expresses	O
F1	O
and	O
V	O
plague	O
antigens	O
,	O
particularly	O
the	O
V	O
antigen	O
,	O
in	O
the	O
correct	O
,	O
immunogenic	O
form	O
.	O

When	O
delivered	O
intranasally	O
V	O
-	O
OMVs	O
elicited	O
substantive	O
and	O
specific	O
immune	O
and	O
antibody	O
responses	O
,	O
both	O
in	O
the	O
serum	O
[	O
immunoglobulin	O
(	O
Ig	O
)	O
G	O
]	O
and	O
in	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
(	O
IgA	O
)	O
;	O
this	O
included	O
the	O
generation	O
of	O
serum	O
antibodies	O
able	O
to	O
kill	O
plague	O
bacteria	O
.	O

Our	O
results	O
also	O
showed	O
that	O
Bt	O
OMV	O
-	O
based	O
vaccines	O
had	O
many	O
desirable	O
characteristics	O
,	O
including	O
:	O
biosafety	O
and	O
an	O
absence	O
of	O
any	O
adverse	O
effects	O
,	O
pathology	O
or	O
gross	O
alteration	O
of	O
resident	O
microbial	O
communities	O
(	O
microbiotas	O
)	O
;	O
high	O
stability	O
and	O
thermo	O
-	O
tolerance	O
;	O
needle	O
-	O
free	O
delivery	O
;	O
intrinsic	O
adjuvanticity	O
;	O
the	O
ability	O
to	O
stimulate	O
both	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	O
responses	O
;	O
and	O
targeting	O
of	O
primary	O
sites	O
of	O
plague	O
infection	O
.	O

The	O
Effects	O
of	O
Intact	O
Cereal	O
Grain	O
Fibers	O
,	O
Including	O
Wheat	O
Bran	O
on	O
the	O
Gut	O
Microbiota	O
Composition	O
of	O
Healthy	O
Adults	O
:	O
A	O
Systematic	O
Review	O
.	O

The	O
human	O
microbiota	O
is	O
increasingly	O
recognized	O
as	O
a	O
major	O
factor	O
influencing	O
health	O
and	O
well	O
-	O
being	O
,	O
with	O
potential	O
benefits	O
as	O
diverse	O
as	O
improved	O
immunity	O
,	O
reduced	O
risk	O
of	O
obesity	O
,	O
Type	O
2	O
diabetes	O
,	O
and	O
improved	O
cognition	O
and	O
mood	O
.	O

Bacteria	O
inhabiting	O
the	O
gut	O
are	O
dependent	O
on	O
the	O
provision	O
of	O
fermentable	O
dietary	O
substrates	O
making	O
diet	O
a	O
major	O
factor	O
driving	O
the	O
composition	O
of	O
the	O
human	O
gut	O
microbiota	O
.	O

Dietary	O
fiber	O
may	O
modify	O
microbiota	O
abundance	O
,	O
diversity	O
,	O
and	O
metabolism	O
including	O
short	O
-	O
chain	O
fatty	O
acid	O
production	O
.	O

The	O
majority	O
of	O
research	O
to	O
date	O
has	O
explored	O
isolated	O
fibers	O
,	O
and	O
the	O
influence	O
of	O
habitual	O
fiber	O
consumption	O
is	O
less	O
well	O
-	O
established	O
.	O

The	O
aim	O
of	O
the	O
current	O
article	O
was	O
to	O
systematically	O
review	O
evidence	O
from	O
human	O
intervention	O
studies	O
for	O
the	O
effects	O
of	O
intact	O
cereal	O
fibers	O
,	O
and	O
their	O
active	O
sub	O
-	O
fractions	O
,	O
on	O
gut	O
microbiota	O
composition	O
in	O
healthy	O
adults	O
.	O

Studies	O
published	O
in	O
the	O
past	O
20	O
years	O
were	O
identified	O
through	O
the	O
PubMed	O
and	O
Cochrane	O
electronic	O
databases	O
.	O

Inclusion	O
criteria	O
were	O
:	O
healthy	O
adult	O
participants	O
(	O
>	O
18	O
years	O
)	O
,	O
inclusion	O
of	O
at	O
least	O
one	O
intact	O
cereal	O
fiber	O
,	O
or	O
its	O
sub	O
-	O
fraction	O
,	O
and	O
measurement	O
of	O
fecal	O
microbiota	O
related	O
outcomes	O
.	O

As	O
every	O
individual	O
has	O
a	O
unique	O
microbiota	O
many	O
trials	O
utilized	O
a	O
cross	O
-	O
over	O
design	O
where	O
individuals	O
acted	O
as	O
their	O
own	O
control	O
.	O

Outcome	O
measures	O
included	O
change	O
to	O
the	O
microbiota	O
,	O
species	O
diversity	O
,	O
or	O
species	O
abundance	O
,	O
or	O
metabolic	O
indicators	O
of	O
microbiota	O
fermentation	O
such	O
as	O
short	O
chain	O
fatty	O
acids	O
or	O
fecal	O
nitrogen	O
.	O

Two	O
hundred	O
and	O
twenty	O
three	O
publications	O
were	O
identified	O
and	O
40	O
included	O
in	O
the	O
final	O
review	O
.	O

In	O
discussing	O
the	O
findings	O
,	O
particular	O
attention	O
has	O
been	O
paid	O
to	O
the	O
effects	O
of	O
wheat	O
fiber	O
,	O
bran	O
,	O
and	O
arabinoxylans	O
(	O
AXOS	O
)	O
as	O
this	O
is	O
the	O
dominant	O
source	O
of	O
fiber	O
in	O
many	O
Western	O
countries	O
.	O

Thirty	O
-	O
nine	O
of	O
the	O
forty	O
-	O
two	O
studies	O
demonstrated	O
an	O
increase	O
in	O
microbiota	O
diversity	O
and	O
/	O
or	O
abundance	O
following	O
intact	O
cereal	O
fiber	O
consumption	O
,	O
with	O
effects	O
apparent	O
from	O
24	O
h	O
to	O
52	O
weeks	O
.	O

Increases	O
in	O
wheat	O
fiber	O
as	O
low	O
as	O
6	O
-	O
8	O
g	O
were	O
sufficient	O
to	O
generate	O
significant	O
effects	O
.	O

Study	O
duration	O
ranged	O
from	O
1	O
day	O
to	O
12	O
weeks	O
,	O
with	O
a	O
single	O
study	O
over	O
1	O
year	O
,	O
and	O
exploration	O
of	O
the	O
stability	O
of	O
the	O
microbiota	O
following	O
long	O
-	O
term	O
dietary	O
change	O
is	O
required	O
.	O

Increasing	O
cereal	O
fiber	O
consumption	O
should	O
be	O
encouraged	O
for	O
overall	O
good	O
health	O
and	O
for	O
gut	O
microbiota	O
diversity	O
.	O

Commensal	O
and	O
Pathogenic	O
Bacteria	O
Indirectly	O
Induce	O
IL	O
-	O
22	O
but	O
Not	O
IFNgamma	O
Production	O
From	O
Human	O
Colonic	O
ILC3s	O
via	O
Multiple	O
Mechanisms	O
.	O

Innate	O
lymphoid	O
cells	O
(	O
ILCs	O
)	O
are	O
a	O
diverse	O
family	O
of	O
cells	O
that	O
play	O
critical	O
roles	O
in	O
mucosal	O
immunity	O
.	O

One	O
subset	O
of	O
the	O
ILC	O
family	O
,	O
Group	O
3	O
ILCs	O
(	O
ILC3s	O
)	O
,	O
has	O
been	O
shown	O
to	O
aid	O
in	O
gut	O
homeostasis	O
through	O
the	O
production	O
of	O
IL	O
-	O
22	O
.	O

IL	O
-	O
22	O
promotes	O
gut	O
homeostasis	O
through	O
its	O
functional	O
effect	O
on	O
the	O
epithelial	O
barrier	O
.	O

When	O
gut	O
epithelial	O
barrier	O
integrity	O
is	O
compromised	O
,	O
such	O
as	O
in	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
)	O
infection	O
and	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
,	O
microbes	O
from	O
the	O
gut	O
lumen	O
translocate	O
into	O
the	O
lamina	O
propria	O
,	O
inducing	O
a	O
multitude	O
of	O
potentially	O
pathogenic	O
immune	O
responses	O
.	O

In	O
murine	O
models	O
of	O
bacterial	O
infection	O
,	O
there	O
is	O
evidence	O
that	O
bacteria	O
can	O
induce	O
pro	O
-	O
inflammatory	O
IFNgamma	O
production	O
in	O
ILC3s	O
.	O

However	O
,	O
the	O
impact	O
of	O
diverse	O
translocating	O
bacteria	O
,	O
particularly	O
commensal	O
bacteria	O
,	O
in	O
dictating	O
IFNgamma	O
versus	O
IL	O
-	O
22	O
production	O
by	O
human	O
gut	O
ILC3s	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
utilized	O
an	O
in	O
vitro	O
human	O
lamina	O
propria	O
mononuclear	O
cell	O
(	O
LPMC	O
)	O
model	O
to	O
evaluate	O
ILC3	O
cytokine	O
production	O
in	O
response	O
to	O
a	O
panel	O
of	O
enteric	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
commensal	O
and	O
pathogenic	O
bacteria	O
and	O
determined	O
potential	O
mechanisms	O
by	O
which	O
these	O
cytokine	O
responses	O
were	O
induced	O
.	O

The	O
percentages	O
of	O
IL	O
-	O
22	O
-	O
producing	O
ILC3s	O
,	O
but	O
not	O
IFNgamma	O
-	O
producing	O
ILC3s	O
,	O
were	O
significantly	O
increased	O
after	O
LPMC	O
exposure	O
to	O
both	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
commensal	O
or	O
pathogenic	O
bacterial	O
stimuli	O
.	O

Stimulation	O
of	O
IL	O
-	O
22	O
production	O
from	O
ILC3s	O
was	O
not	O
through	O
direct	O
recognition	O
of	O
bacterial	O
antigen	O
by	O
ILC3s	O
,	O
but	O
rather	O
required	O
the	O
help	O
of	O
accessory	O
cells	O
within	O
the	O
LPMC	O
population	O
.	O

CD11c	O
+	O
myeloid	O
dendritic	O
cells	O
generated	O
IL	O
-	O
23	O
and	O
IL	O
-	O
1beta	O
in	O
response	O
to	O
enteric	O
bacteria	O
and	O
contributed	O
to	O
ILC3	O
production	O
of	O
IL	O
-	O
22	O
.	O

Furthermore	O
,	O
ligation	O
of	O
the	O
natural	O
cytotoxicity	O
receptor	O
NKp44	O
on	O
ILC3s	O
in	O
response	O
to	O
bacteria	O
stimulation	O
also	O
significantly	O
increased	O
the	O
percentage	O
of	O
IL	O
-	O
22	O
-	O
producing	O
ILC3s	O
.	O

Overall	O
,	O
these	O
data	O
demonstrate	O
that	O
human	O
gut	O
microbiota	O
,	O
including	O
commensal	O
bacteria	O
,	O
indirectly	O
modulate	O
colonic	O
ILC3	O
function	O
to	O
induce	O
IL	O
-	O
22	O
,	O
but	O
additional	O
signals	O
are	O
likely	O
required	O
to	O
induce	O
IFNgamma	O
production	O
by	O
colonic	O
ILC3s	O
in	O
the	O
setting	O
of	O
inflammation	O
and	O
microbial	O
translocation	O
.	O

Interplay	O
of	O
Na	O
(	O
+	O
)	O
Balance	O
and	O
Immunobiology	O
of	O
Dendritic	O
Cells	O
.	O

Local	O
Na	O
(	O
+	O
)	O
balance	O
emerges	O
as	O
an	O
important	O
factor	O
of	O
tissue	O
microenvironment	O
.	O

On	O
the	O
one	O
hand	O
,	O
immune	O
cells	O
impact	O
on	O
local	O
Na	O
(	O
+	O
)	O
levels	O
.	O

On	O
the	O
other	O
hand	O
,	O
Na	O
(	O
+	O
)	O
availability	O
is	O
able	O
to	O
influence	O
immune	O
responses	O
.	O

In	O
contrast	O
to	O
macrophages	O
,	O
our	O
knowledge	O
of	O
dendritic	O
cells	O
(	O
DCs	O
)	O
in	O
this	O
state	O
of	O
affair	O
is	O
rather	O
limited	O
.	O

Current	O
evidence	O
suggests	O
that	O
the	O
impact	O
of	O
increased	O
Na	O
(	O
+	O
)	O
on	O
DCs	O
is	O
context	O
dependent	O
.	O

Moreover	O
,	O
it	O
is	O
conceivable	O
that	O
DC	O
immunobiology	O
might	O
also	O
be	O
influenced	O
by	O
Na	O
(	O
+	O
)	O
-	O
rich	O
-	O
diet	O
-	O
induced	O
changes	O
of	O
the	O
gut	O
microbiome	O
.	O

Prevotella	B-bacteria
histicola	I-bacteria
,	O
A	O
Human	O
Gut	O
Commensal	O
,	O
Is	O
as	O
Potent	O
as	O
COPAXONE	O
(	O
R	O
)	O
in	O
an	O
Animal	O
Model	O
of	O
Multiple	O
Sclerosis	O
.	O

Multiple	O
sclerosis	O
(	O
MS	O
)	O
is	O
a	O
demyelinating	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
there	O
is	O
enrichment	O
or	O
depletion	O
of	O
some	O
gut	O
bacteria	O
in	O
MS	O
patients	O
compared	O
to	O
healthy	O
controls	O
(	O
HC	O
)	O
,	O
suggesting	O
an	O
important	O
role	O
of	O
the	O
gut	O
bacteria	O
in	O
disease	O
pathogenesis	O
.	O

Thus	O
,	O
specific	O
gut	O
bacteria	O
that	O
are	O
lower	O
in	O
abundance	O
in	O
MS	B-bacteria
patients	O
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
option	O
for	O
this	O
disease	O
.	O

In	O
particular	O
,	O
we	O
and	O
others	O
have	O
shown	O
that	O
MS	B-bacteria
patients	O
have	O
a	O
lower	O
abundance	O
of	O
Prevotella	B-bacteria
compared	O
to	O
HC	O
,	O
whereas	O
the	O
abundance	O
of	O
Prevotella	B-bacteria
is	O
increased	O
in	O
patients	O
that	O
receive	O
disease	O
-	O
modifying	O
therapies	O
such	O
as	O
Copaxone	O
(	O
R	O
)	O
(	O
Glatiramer	O
acetate	O
-	O
GA	O
)	O
.	O

This	O
inverse	O
correlation	O
between	O
the	O
severity	O
of	O
MS	B-bacteria
disease	O
and	O
the	O
abundance	O
of	O
Prevotella	B-bacteria
suggests	O
its	O
potential	O
for	O
use	O
as	O
a	O
therapeutic	O
option	O
to	O
treat	O
MS	B-bacteria
.	O

Notably	O
we	O
have	O
previously	O
identified	O
a	O
specific	O
strain	O
,	O
Prevotella	B-bacteria
histicola	I-bacteria
(	O
P	B-bacteria
.	I-bacteria
histicola	I-bacteria
)	O
,	O
that	O
suppresses	O
disease	O
in	O
the	O
animal	O
model	O
of	O
MS	B-bacteria
,	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
compared	O
with	O
sham	O
treatment	O
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
whether	O
the	O
disease	O
suppressing	O
effects	O
of	O
P	B-bacteria
.	I-bacteria
histicola	I-bacteria
synergize	O
with	O
those	O
of	O
the	O
disease	O
-	O
modifying	O
drug	O
Copaxone	O
(	O
R	O
)	O
to	O
more	O
effectively	O
suppress	O
disease	O
compared	O
to	O
either	O
treatment	O
alone	O
.	O

Treatment	O
with	O
P	B-bacteria
.	O
histicola	I-bacteria
was	O
as	O
effective	O
in	O
suppressing	O
disease	O
as	O
treatment	O
with	O
Copaxone	O
(	O
R	O
)	O
,	O
whereas	O
the	O
combination	O
of	O
P	O
.	O
histicola	O
plus	O
Copaxone	O
(	O
R	O
)	O
was	O
not	O
more	O
effective	O
than	O
either	O
individual	O
treatment	O
.	O

P	O
.	O
histicola	O
-	O
treated	O
mice	O
had	O
an	O
increased	O
frequency	O
and	O
number	O
of	O
CD4	O
(	O
+	O
)	O
FoxP3	O
(	O
+	O
)	O
regulatory	O
T	O
cells	O
in	O
periphery	O
as	O
well	O
as	O
gut	O
and	O
a	O
decreased	O
frequency	O
of	O
pro	O
-	O
inflammatory	O
IFN	O
-	O
gamma	O
and	O
IL17	O
-	O
producing	O
CD4	O
T	O
cells	O
in	O
the	O
CNS	O
,	O
suggesting	O
P	B-bacteria
.	I-bacteria
histicola	I-bacteria
suppresses	O
disease	O
by	O
boosting	O
anti	O
-	O
inflammatory	O
immune	O
responses	O
and	O
inhibiting	O
pro	O
-	O
inflammatory	O
immune	O
responses	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
indicates	O
that	O
the	O
human	O
gut	O
commensal	O
P	B-bacteria
.	I-bacteria
histicola	I-bacteria
can	O
suppress	O
disease	O
as	O
efficiently	O
as	O
Copaxone	O
(	O
R	O
)	O
and	O
may	O
provide	O
an	O
alternative	O
treatment	O
option	O
for	O
MS	O
patients	O
.	O

Impacts	O
of	O
Duck	O
-	O
Origin	O
Parvovirus	O
Infection	O
on	O
Cherry	O
Valley	O
Ducklings	O
From	O
the	O
Perspective	O
of	O
Gut	O
Microbiota	O
.	O

Duck	O
-	O
origin	O
goose	O
parvovirus	O
(	O
D	O
-	O
GPV	O
)	O
is	O
the	O
causative	O
agent	O
of	O
beak	O
atrophy	O
and	O
dwarfism	O
syndrome	O
(	O
BADS	O
)	O
,	O
characterized	O
by	O
growth	O
retardation	O
,	O
skeletal	O
dysplasia	O
,	O
and	O
persistent	O
diarrhea	O
.	O

However	O
,	O
the	O
pathogenic	O
mechanism	O
of	O
D	O
-	O
GPV	O
remains	O
undefined	O
.	O

Here	O
,	O
we	O
first	O
reported	O
the	O
gut	O
microbiome	O
diversity	O
of	O
D	O
-	O
GPV	O
infected	O
Cherry	O
Valley	O
ducks	O
.	O

In	O
the	O
investigation	O
for	O
the	O
influence	O
of	O
D	O
-	O
GPV	O
infection	O
on	O
gut	O
microbiota	O
through	O
a	O
period	O
of	O
infection	O
,	O
we	O
found	O
that	O
D	O
-	O
GPV	O
infection	O
caused	O
gut	O
microbiota	O
dysbiosis	O
by	O
reducing	O
the	O
prevalence	O
of	O
the	O
dominant	O
genera	O
and	O
decreasing	O
microbial	O
diversity	O
.	O

Furthermore	O
,	O
exfoliation	O
of	O
the	O
intestinal	O
epithelium	O
,	O
proliferation	O
of	O
lymphocytes	O
,	O
up	O
-	O
regulated	O
mRNA	O
expression	O
of	O
pro	O
-	O
inflammatory	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
17A	O
,	O
and	O
IL	O
-	O
22	O
and	O
down	O
-	O
regulated	O
mRNA	O
expression	O
of	O
anti	O
-	O
inflammatory	O
IL	O
-	O
10	O
and	O
IL	O
-	O
4	O
occurred	O
when	O
D	O
-	O
GPV	O
targeted	O
in	O
cecal	O
epithelium	O
.	O

In	O
addition	O
,	O
the	O
content	O
of	O
short	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
in	O
cecal	O
contents	O
was	O
significantly	O
reduced	O
after	O
D	O
-	O
GPV	O
infection	O
.	O

Importantly	O
,	O
the	O
disorder	O
of	O
pro	O
-	O
inflammatory	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
was	O
associated	O
with	O
the	O
decrease	O
of	O
SCFAs	O
-	O
producing	O
bacteria	O
and	O
the	O
enrichment	O
of	O
opportunistic	O
pathogens	O
.	O

Collectively	O
,	O
the	O
decrease	O
of	O
SCFAs	O
and	O
the	O
enrichment	O
of	O
pathogen	O
-	O
containing	O
gut	O
communities	O
promoted	O
intestinal	O
inflammatory	O
injury	O
.	O

These	O
results	O
may	O
provide	O
a	O
new	O
insight	O
that	O
target	O
the	O
gut	O
microbiota	O
to	O
understand	O
the	O
progression	O
of	O
BADS	O
disease	O
and	O
to	O
research	O
the	O
pathogenic	O
mechanism	O
of	O
D	O
-	O
GPV	O
.	O

Intestinal	O
and	O
hepatic	O
microbiota	O
changes	O
associated	O
with	O
chronic	O
ethanol	O
administration	O
in	O
mice	O
.	O

Alcohol	O
-	O
induced	O
liver	O
disease	O
is	O
closely	O
related	O
to	O
translocation	O
of	O
bacterial	O
products	O
and	O
bacteria	O
from	O
the	O
intestine	O
to	O
the	O
liver	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
whether	O
bacterial	O
translocation	O
to	O
the	O
liver	O
depends	O
on	O
certain	O
intestinal	O
microbiota	O
changes	O
that	O
would	O
predispose	O
bacteria	O
to	O
translocate	O
to	O
the	O
liver	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
microbiota	O
in	O
the	O
jejunum	O
,	O
ileum	O
,	O
cecum	O
,	O
feces	O
and	O
liver	O
of	O
mice	O
subjected	O
to	O
chronic	O
ethanol	O
feeding	O
using	O
a	O
Lieber	O
DeCarli	O
diet	O
model	O
of	O
chronic	O
ethanol	O
feeding	O
for	O
8	O
weeks	O
.	O

We	O
demonstrate	O
that	O
chronic	O
ethanol	O
administration	O
changes	O
alpha	O
diversity	O
in	O
the	O
ileum	O
and	O
the	O
liver	O
and	O
leads	O
to	O
compositional	O
changes	O
especially	O
in	O
the	O
ileum	O
.	O

This	O
is	O
largely	O
driven	O
by	O
an	O
increase	O
in	O
gram	O
-	O
negative	O
phyla	O
-	O
the	O
source	O
of	O
endotoxins	O
.	O

Moreover	O
,	O
gram	O
-	O
negative	O
Prevotella	B-bacteria
not	O
only	O
increased	O
in	O
the	O
mucus	O
layer	O
of	O
the	O
ileum	O
but	O
also	O
in	O
liver	O
samples	O
.	O

These	O
results	O
suggest	O
that	O
bacterial	O
translocation	O
to	O
the	O
liver	O
might	O
be	O
associated	O
with	O
microbiota	O
changes	O
in	O
the	O
distal	O
gastrointestinal	O
tract	O
.	O

Influences	O
of	O
stress	O
hormones	O
on	O
microbial	O
infections	O
.	O

Stress	O
hormones	O
have	O
been	O
recently	O
suggested	O
to	O
influence	O
the	O
pathogenicity	O
of	O
bacteria	O
significantly	O
.	O

Stress	O
has	O
been	O
identified	O
as	O
part	O
of	O
the	O
factors	O
causing	O
an	O
outbreak	O
of	O
infections	O
in	O
the	O
aquaculture	O
industry	O
.	O

The	O
most	O
studied	O
neuroendocrine	O
hormonal	O
family	O
from	O
a	O
microbial	O
endocrinology	O
perspective	O
is	O
the	O
catecholamine	O
comprising	O
of	O
norepinephrine	O
,	O
epinephrine	O
,	O
and	O
dopamine	O
.	O

It	O
is	O
of	O
importance	O
that	O
catecholamine	O
affects	O
the	O
growth	O
and	O
virulence	O
of	O
bacteria	O
.	O

The	O
influence	O
of	O
stress	O
on	O
bacterial	O
infections	O
is	O
attributed	O
to	O
the	O
ability	O
of	O
catecholamines	O
to	O
suppress	O
the	O
immune	O
system	O
as	O
the	O
mode	O
of	O
action	O
for	O
increased	O
bacterial	O
growth	O
.	O

Catecholamines	O
have	O
increased	O
the	O
growth	O
of	O
bacteria	O
,	O
virulence	O
-	O
associated	O
factors	O
,	O
adhesions	O
,	O
and	O
biofilm	O
formation	O
and	O
consequently	O
influence	O
the	O
outcome	O
of	O
infections	O
by	O
these	O
bacteria	O
in	O
many	O
hosts	O
.	O

The	O
siderophores	O
and	O
the	O
ferric	O
iron	O
transport	O
system	O
plays	O
a	O
vital	O
role	O
in	O
the	O
mechanism	O
by	O
which	O
catecholamines	O
stimulates	O
growth	O
and	O
exposure	O
of	O
genes	O
to	O
stress	O
hormones	O
enhances	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
bacterial	O
virulence	O
.	O

In	O
recent	O
years	O
,	O
it	O
has	O
been	O
discovered	O
that	O
intestinal	O
microflora	O
takes	O
part	O
in	O
bidirectional	O
communication	O
between	O
the	O
gut	O
and	O
brain	O
.	O

The	O
rapidly	O
growing	O
field	O
of	O
microbiome	O
research	O
,	O
understanding	O
the	O
communities	O
of	O
bacteria	O
living	O
within	O
our	O
bodies	O
and	O
the	O
genes	O
they	O
contain	O
is	O
yielding	O
new	O
perspectives	O
.	O

This	O
review	O
reveals	O
catecholamines	O
effects	O
on	O
the	O
growth	O
and	O
virulence	O
of	O
bacteria	O
and	O
the	O
latest	O
trends	O
in	O
microbial	O
endocrinology	O
.	O

Overuse	O
of	O
antianaerobic	O
drug	O
is	O
associated	O
with	O
poor	O
postchemotherapy	O
prognosis	O
of	O
patients	O
with	O
hepatocellular	O
carcinoma	O
.	O

Overuse	O
of	O
antibiotic	O
drugs	O
alters	O
the	O
composition	O
of	O
gut	O
microbiota	O
and	O
has	O
detrimental	O
effects	O
on	O
the	O
host	O
.	O

In	O
our	O
study	O
,	O
we	O
investigated	O
association	O
of	O
gut	O
flora	O
and	O
antibiotics	O
in	O
the	O
prognosis	O
of	O
patients	O
with	O
liver	O
cancer	O
who	O
have	O
undergone	O
chemotherapy	O
by	O
analyzing	O
two	O
independent	O
clinical	O
studies	O
.	O

We	O
retrospectively	O
subanalyzed	O
a	O
previously	O
reported	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
on	O
hepatic	O
arterial	O
infusion	O
chemotherapy	O
in	O
patients	O
with	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
to	O
investigate	O
the	O
association	O
between	O
use	O
of	O
antibiotics	O
and	O
prognosis	O
.	O

In	O
the	O
other	O
study	O
,	O
we	O
prospectively	O
determined	O
the	O
abundance	O
of	O
specific	O
bacterial	O
genus	O
in	O
patients	O
with	O
HCC	O
by	O
sequencing	O
16S	O
ribosomal	O
RNA	O
and	O
assessed	O
its	O
association	O
with	O
survival	O
.	O

Subanalysis	O
of	O
the	O
RCT	O
data	O
showed	O
that	O
,	O
of	O
26	O
types	O
of	O
antibiotics	O
used	O
,	O
administration	O
of	O
carbapenem	O
before	O
or	O
during	O
chemotherapy	O
was	O
associated	O
with	O
poor	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
patients	O
with	O
HCC	O
(	O
carbapenem	O
+	O
vs	O
.	O
-	O
;	O
median	O
PFS	O
,	O
78	O
days	O
vs	O
.	O
154	O
days	O
,	O
p	O
=	O
0	O
.	O
0053	O
;	O
median	O
OS	O
,	O
177	O
days	O
vs	O
.	O
475	O
days	O
,	O
p	O
=	O
0	O
.	O
0003	O
)	O
.	O

Multivariate	O
analysis	O
revealed	O
that	O
antianaerobic	O
drug	O
use	O
is	O
an	O
independent	O
predictor	O
of	O
poor	O
prognosis	O
.	O

In	O
the	O
prospective	O
study	O
,	O
the	O
abundance	O
of	O
Blautia	B-bacteria
in	O
fecal	O
microbiota	O
correlated	O
positively	O
with	O
both	O
PFS	O
and	O
OS	O
of	O
patients	O
with	O
HCC	O
who	O
underwent	O
chemotherapy	O
.	O

Use	O
of	O
antibiotics	O
targeting	O
anaerobes	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
in	O
patients	O
with	O
HCC	O
who	O
have	O
undergone	O
chemotherapy	O
,	O
whereas	O
the	O
intestinal	O
anaerobic	O
bacteria	O
,	O
Blautia	B-bacteria
is	O
associated	O
with	O
a	O
good	O
prognosis	O
.	O

These	O
findings	O
might	O
indicate	O
the	O
need	O
for	O
caution	O
regarding	O
overuse	O
of	O
broad	O
-	O
spectrum	O
antibiotics	O
targeting	O
anaerobes	O
in	O
patients	O
with	O
HCC	O
.	O

Commensal	O
Escherichia	B-bacteria
coli	I-bacteria
aggravates	O
acute	O
necrotizing	O
pancreatitis	O
through	O
targeting	O
intestinal	O
epithelial	O
cells	O
.	O

An	O
increase	O
of	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
was	O
previously	O
reported	O
in	O
acute	O
necrotizing	O
pancreatitis	O
(	O
ANP	O
)	O
.	O

Here	O
we	O
aimed	O
to	O
investigate	O
whether	O
Escherichia	B-bacteria
coli	I-bacteria
(	I-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
)	I-bacteria
MG1655	I-bacteria
,	O
a	O
commensal	O
belonging	O
to	O
Escherichia	B-bacteria
,	O
increased	O
intestinal	O
injury	O
and	O
aggravated	O
ANP	O
in	O
rats	O
.	O

ANP	O
was	O
induced	O
by	O
retrograde	O
injection	O
of	O
3	O
.	O
5	O
%	O
sodium	O
taurocholate	O
into	O
the	O
biliopancreatic	O
duct	O
.	O

Using	O
the	O
gut	O
microbiota	O
-	O
depleted	O
rats	O
,	O
we	O
demonstrated	O
that	O
gut	O
microbiota	O
was	O
involved	O
in	O
the	O
pancreatic	O
injury	O
and	O
intestinal	O
barrier	O
dysfunction	O
in	O
ANP	O
.	O

Through	O
16S	O
rRNA	O
gene	O
sequencing	O
and	O
qPCR	O
,	O
we	O
found	O
intestinal	O
dysbiosis	O
and	O
a	O
significant	O
increase	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
MG1655	I-bacteria
in	O
ANP	O
.	O

Afterwards	O
,	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
MG1655	I-bacteria
gavage	O
to	O
gut	O
microbiota	O
-	O
depleted	O
rats	O
in	O
ANP	O
was	O
performed	O
.	O

We	O
observed	O
that	O
after	O
ANP	O
induction	O
,	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
MG1655	I-bacteria
-	O
monocolonized	O
rats	O
presented	O
more	O
severe	O
injury	O
in	O
the	O
pancreas	O
and	O
intestinal	O
barrier	O
function	O
than	O
those	O
in	O
the	O
gut	O
microbiota	O
-	O
depleted	O
rats	O
.	O

Furthermore	O
,	O
TLR4	O
/	O
MyD88	O
/	O
p38	O
MAPK	O
and	O
ERS	O
activation	O
in	O
intestinal	O
epithelial	O
cells	O
were	O
also	O
increased	O
more	O
significantly	O
in	O
the	O
MG1655	O
-	O
monocolonized	O
ANP	O
rats	O
.	O

In	O
vitro	O
,	O
the	O
rat	O
ileal	O
epithelial	O
cell	O
line	O
IEC	O
-	O
18	O
displayed	O
aggravated	O
TNFalpha	O
-	O
induced	O
inflammation	O
and	O
loss	O
of	O
tight	O
junction	O
proteins	O
in	O
co	O
-	O
culture	O
with	O
E	O
.	I-bacteria
coli	I-bacteria
MG1655	I-bacteria
,	O
as	O
well	O
as	O
TLR4	O
,	O
MyD88	O
and	O
Bip	O
up	O
-	O
regulation	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
shows	O
that	O
commensal	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
MG1655	I-bacteria
increases	O
TLR4	O
/	O
MyD88	O
/	O
p38	O
MAPK	O
and	O
ERS	O
signalling	O
-	O
induced	O
intestinal	O
epithelial	O
injury	O
and	O
aggravates	O
ANP	O
in	O
rats	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
describing	O
the	O
harmful	O
potential	O
of	O
commensal	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
in	O
ANP	O
.	O

IMPORTANCE	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
describing	O
the	O
harmful	O
potential	O
of	O
commensal	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
in	O
ANP	O
,	O
which	O
has	O
never	O
been	O
demonstrated	O
by	O
previous	O
studies	O
.	O

Our	O
work	O
provides	O
new	O
insights	O
into	O
the	O
gut	O
bacteria	O
-	O
ANP	O
crosstalk	O
,	O
suggesting	O
that	O
non	O
-	O
pathogenic	O
commensals	O
could	O
also	O
exhibit	O
adverse	O
effects	O
in	O
the	O
context	O
of	O
diseases	O
.	O

Fibroblasts	O
Impact	O
Goblet	O
Cell	O
Responses	O
to	O
Lactic	O
Acid	O
Bacteria	O
After	O
Exposure	O
to	O
Inflammatory	O
Cytokines	O
and	O
Mucus	O
Disruptors	O
.	O

SCOPE	O
:	O
Mucus	O
produced	O
by	O
goblet	O
cells	O
contributes	O
to	O
gut	O
barrier	O
function	O
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
have	O
been	O
shown	O
to	O
impact	O
mucus	O
production	O
.	O

It	O
is	O
not	O
completely	O
known	O
whether	O
mucus	O
production	O
is	O
influenced	O
by	O
the	O
abundantly	O
present	O
fibroblasts	O
in	O
the	O
intestine	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
influence	O
of	O
fibroblasts	O
on	O
mucus	O
-	O
related	O
genes	O
including	O
mucin	O
-	O
2	O
(	O
MUC2	O
)	O
,	O
trefoil	O
factor	O
3	O
(	O
TFF3	O
)	O
,	O
resistin	O
-	O
like	O
molecule	O
beta	O
(	O
RETNLB	O
)	O
,	O
carbohydrate	O
sulfotransferase	O
5	O
(	O
CHST5	O
)	O
,	O
and	O
galactose	O
-	O
3	O
-	O
O	O
-	O
sulfotransferase	O
2	O
(	O
GAL3ST2	O
)	O
is	O
examined	O
after	O
co	O
-	O
culture	O
of	O
LS174T	O
-	O
goblet	O
cells	O
and	O
CCD	O
-	O
18Co	O
colonic	O
fibroblasts	O
in	O
the	O
presence	O
and	O
absence	O
of	O
LAB	B-bacteria
-	I-bacteria
strains	I-bacteria
known	O
to	O
impact	O
mucus	O
function	O
.	O

This	O
is	O
also	O
tested	O
after	O
exposure	O
to	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
13	O
,	O
or	O
the	O
mucin	O
synthesis	O
inhibitor	O
tunicamycin	O
(	O
Tm	O
)	O
.	O

Effects	O
of	O
fibroblasts	O
are	O
treatment	O
duration	O
-	O
and	O
bacterial	O
species	O
-	O
dependent	O
under	O
homeostatic	O
conditions	O
.	O

During	O
TNF	O
-	O
alpha	O
challenge	O
,	O
fibroblasts	O
reverse	O
Lactobacillus	O
(	O
L	O
.	O
)	O
rhamnosus	O
CCFM237	O
-	O
elicited	O
declined	O
TFF3	O
expression	O
.	O

After	O
IL	O
-	O
13	O
exposure	O
,	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
CCFM237	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
CCFM787	I-bacteria
attenuate	O
enhanced	O
TFF3	O
and	O
RETNLB	O
expression	O
,	O
respectively	O
,	O
only	O
in	O
the	O
presence	O
of	O
fibroblasts	O
.	O

LAB	B-bacteria
has	O
no	O
effects	O
on	O
Tm	O
-	O
induced	O
decreased	O
expression	O
of	O
goblet	O
cell	O
-	O
related	O
genes	O
regardless	O
of	O
the	O
presence	O
of	O
fibroblasts	O
.	O

CONCLUSION	O
:	O
It	O
is	O
demonstrated	O
that	O
goblet	O
cell	O
-	O
fibroblast	O
crosstalk	O
impacts	O
mucus	O
synthesis	O
and	O
influences	O
the	O
effects	O
of	O
LAB	B-bacteria
on	O
goblet	O
cell	O
-	O
related	O
genes	O
.	O

Effects	O
are	O
LAB	B-bacteria
-	I-bacteria
species	I-bacteria
and	O
stressor	O
dependent	O
.	O

The	O
chemical	O
composition	O
of	O
a	O
cold	O
-	O
pressed	O
milk	O
thistle	O
seed	O
flour	O
extract	O
,	O
and	O
its	O
potential	O
health	O
beneficial	O
properties	O
.	O

Cold	O
-	O
pressed	O
milk	O
thistle	O
seed	O
flour	O
was	O
extracted	O
with	O
50	O
%	O
acetone	O
and	O
evaluated	O
for	O
its	O
phytochemical	O
composition	O
,	O
and	O
gut	O
microbiota	O
modulating	O
,	O
free	O
radical	O
scavenging	O
,	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
proliferative	O
capacities	O
.	O

UHPLC	O
-	O
MS	O
analysis	O
detected	O
fifteen	O
compounds	O
in	O
the	O
milk	O
thistle	O
seed	O
flour	O
extract	O
with	O
silychristin	O
as	O
the	O
primary	O
component	O
followed	O
by	O
silybin	O
B	O
and	O
isosilybins	O
A	O
&	O
B	O
.	O

The	O
milk	O
thistle	O
seed	O
flour	O
extract	O
enhanced	O
the	O
total	O
bacteria	O
number	O
and	O
altered	O
the	O
abundance	O
of	O
a	O
specific	O
bacterial	O
phylum	O
or	O
genus	O
under	O
the	O
experimental	O
conditions	O
.	O

The	O
extract	O
had	O
RDSC	O
,	O
ORAC	O
,	O
HOSC	O
,	O
and	O
ABTS	O
+	O
scavenging	O
capacities	O
of	O
49	O
,	O
634	O
,	O
10	O
420	O
and	O
116	O
mumol	O
Trolox	O
equivalents	O
(	O
TE	O
)	O
per	O
g	O
flour	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
milk	O
thistle	O
seed	O
flour	O
extract	O
suppressed	O
LPS	O
induced	O
IL	O
-	O
1beta	O
mRNA	O
expression	O
in	O
the	O
cultured	O
J774A	O
.	O
1	O
mouse	O
macrophages	O
and	O
the	O
proliferation	O
of	O
LNCaP	O
prostate	O
cancer	O
cells	O
.	O

The	O
results	O
suggest	O
milk	O
thistle	O
seed	O
flour	O
'	O
s	O
potential	O
health	O
benefits	O
in	O
functional	O
foods	O
.	O

Klebsiella	B-bacteria
and	O
Providencia	B-bacteria
emerge	O
as	O
lone	O
survivors	O
following	O
long	O
-	O
term	O
starvation	O
of	O
oral	O
microbiota	O
.	O

It	O
is	O
well	O
-	O
understood	O
that	O
many	O
bacteria	O
have	O
evolved	O
to	O
survive	O
catastrophic	O
events	O
using	O
a	O
variety	O
of	O
mechanisms	O
,	O
which	O
include	O
expression	O
of	O
stress	O
-	O
response	O
genes	O
,	O
quiescence	O
,	O
necrotrophy	O
,	O
and	O
metabolic	O
advantages	O
obtained	O
through	O
mutation	O
.	O

However	O
,	O
the	O
dynamics	O
of	O
individuals	O
leveraging	O
these	O
abilities	O
to	O
gain	O
a	O
competitive	O
advantage	O
in	O
an	O
ecologically	O
complex	O
setting	O
remain	O
unstudied	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
the	O
saliva	O
microbiome	O
throughout	O
the	O
ecological	O
perturbation	O
of	O
long	O
-	O
term	O
starvation	O
,	O
allowing	O
only	O
the	O
species	O
best	O
equipped	O
to	O
access	O
and	O
use	O
the	O
limited	O
resources	O
to	O
survive	O
.	O

During	O
the	O
first	O
several	O
days	O
,	O
the	O
community	O
underwent	O
a	O
death	O
phase	O
that	O
resulted	O
in	O
a	O
approximately	O
50	O
-	O
100	O
-	O
fold	O
reduction	O
in	O
the	O
number	O
of	O
viable	O
cells	O
.	O

Interestingly	O
,	O
after	O
this	O
death	O
phase	O
,	O
only	O
three	O
species	O
,	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
,	O
Klebsiella	B-bacteria
oxytoca	I-bacteria
,	O
and	O
Providencia	B-bacteria
alcalifaciens	I-bacteria
,	O
all	O
members	O
of	O
the	O
family	O
Enterobacteriaceae	B-bacteria
,	O
appeared	O
to	O
be	O
transcriptionally	O
active	O
and	O
recoverable	O
.	O

Klebsiella	B-bacteria
are	O
significant	O
human	O
pathogens	O
,	O
frequently	O
resistant	O
to	O
multiple	O
antibiotics	O
,	O
and	O
recently	O
,	O
ectopic	O
colonization	O
of	O
the	O
gut	O
by	O
oral	O
Klebsiella	B-bacteria
was	O
documented	O
to	O
induce	O
dysbiosis	O
and	O
inflammation	O
.	O

MetaOmics	O
analyses	O
provided	O
several	O
leads	O
for	O
further	O
investigation	O
regarding	O
the	O
ecological	O
success	O
of	O
the	O
Enterobacteriaceae	B-bacteria
.	O

The	O
isolates	O
accumulated	O
single	O
nucleotide	O
polymorphisms	O
in	O
known	O
growth	O
advantage	O
in	O
stationary	O
phase	O
alleles	O
and	O
produced	O
natural	O
products	O
closely	O
resembling	O
antimicrobial	O
cyclic	O
depsipeptides	O
.	O

The	O
results	O
presented	O
in	O
this	O
study	O
suggest	O
that	O
pathogenic	O
Enterobacteriaceae	B-bacteria
persist	O
much	O
longer	O
than	O
their	O
more	O
benign	O
neighbors	O
in	O
the	O
salivary	O
microbiome	O
when	O
faced	O
with	O
starvation	O
.	O

This	O
is	O
particularly	O
significant	O
,	O
given	O
that	O
hospital	O
surfaces	O
contaminated	O
with	O
oral	O
fluids	O
,	O
especially	O
sinks	O
and	O
drains	O
,	O
are	O
well	O
-	O
established	O
sources	O
of	O
outbreaks	O
of	O
drug	O
-	O
resistant	O
Enterobacteriaceae	B-bacteria
.	O

Sargassum	O
fusiforme	O
fucoidan	O
modifies	O
the	O
gut	O
microbiota	O
during	O
alleviation	O
of	O
streptozotocin	O
-	O
induced	O
hyperglycemia	O
in	O
mice	O
.	O

Diabetes	O
is	O
a	O
complicated	O
endocrine	O
and	O
metabolic	O
disorder	O
,	O
which	O
has	O
become	O
an	O
epidemic	O
health	O
issue	O
worldwide	O
.	O

Fucoidan	O
is	O
extensively	O
distributed	O
in	O
the	O
brown	O
algae	O
and	O
several	O
marine	O
invertebrates	O
exhibiting	O
diverse	O
biological	O
activities	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
physicochemical	O
property	O
of	O
Sargassum	O
fusiforme	O
fucoidan	O
(	O
SFF	O
)	O
and	O
its	O
effects	O
on	O
streptozotocin	O
(	O
STZ	O
)	O
-	O
induced	O
diabetic	O
mice	O
and	O
gut	O
microbiota	O
were	O
investigated	O
.	O

Diabetes	O
mice	O
not	O
only	O
showed	O
abnormal	O
blood	O
glucose	O
,	O
but	O
also	O
accompanied	O
by	O
multiple	O
symptoms	O
,	O
such	O
as	O
gradual	O
emaciation	O
,	O
decreased	O
body	O
weight	O
,	O
increased	O
food	O
and	O
water	O
intake	O
.	O

Compared	O
with	O
diabetic	O
mice	O
after	O
6	O
-	O
week	O
treatment	O
,	O
administration	O
of	O
SFF	O
significantly	O
decreased	O
the	O
fasting	O
blood	O
glucose	O
,	O
diet	O
and	O
water	O
intake	O
.	O

Furthermore	O
,	O
SFF	O
attenuated	O
the	O
pathological	O
change	O
in	O
the	O
heart	O
and	O
liver	O
,	O
improved	O
the	O
liver	O
function	O
,	O
and	O
suppressed	O
oxidative	O
stress	O
in	O
STZ	O
-	O
induced	O
diabetic	O
mice	O
.	O

Simultaneously	O
,	O
SFF	O
significantly	O
altered	O
the	O
gut	O
microbiota	O
in	O
the	O
faeces	O
of	O
diabetic	O
mice	O
,	O
decreased	O
the	O
relative	O
abundances	O
of	O
the	O
diabetes	O
-	O
related	O
intestinal	O
bacteria	O
,	O
which	O
is	O
a	O
potential	O
mechanism	O
for	O
relieving	O
the	O
symptoms	O
of	O
diabetes	O
.	O

Therefore	O
,	O
SFF	O
might	O
be	O
considered	O
as	O
one	O
of	O
the	O
promising	O
complementary	O
and	O
alternative	O
medicines	O
for	O
the	O
management	O
of	O
diabetes	O
mellitus	O
in	O
future	O
.	O

Dynamic	O
changes	O
in	O
rumen	O
fermentation	O
and	O
bacterial	O
community	O
following	O
rumen	O
fluid	O
transplantation	O
in	O
a	O
sheep	O
model	O
of	O
rumen	O
acidosis	O
:	O
implications	O
for	O
rumen	O
health	O
in	O
ruminants	O
.	O

Over	O
the	O
years	O
,	O
rumen	O
fluid	O
transplantation	O
(	O
RT	O
)	O
has	O
been	O
successfully	O
applied	O
to	O
treat	O
acute	O
rumen	O
acidosis	O
in	O
ruminants	O
,	O
but	O
how	O
it	O
functions	O
in	O
the	O
ruminal	O
microbial	O
homeostasis	O
and	O
host	O
function	O
remains	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
dynamic	O
changes	O
of	O
rumen	O
fermentation	O
and	O
bacterial	O
communities	O
following	O
RT	O
and	O
its	O
beneficial	O
effects	O
on	O
rumen	O
epithelial	O
morphology	O
and	O
function	O
in	O
a	O
sheep	O
model	O
of	O
rumen	O
acidosis	O
.	O

The	O
results	O
showed	O
that	O
RT	O
resulted	O
in	O
dynamic	O
changes	O
in	O
rumen	O
fermentation	O
and	O
increased	O
the	O
concentrations	O
of	O
total	O
volatile	O
fatty	O
acid	O
,	O
acetate	O
,	O
propionate	O
,	O
and	O
butyrate	O
,	O
but	O
it	O
decreased	O
the	O
levels	O
of	O
lactate	O
and	O
LPS	O
in	O
the	O
rumen	O
.	O

Illumina	O
MiSeq	O
Sequencing	O
data	O
showed	O
that	O
RT	O
facilitated	O
rapid	O
rebuilt	O
of	O
ruminal	O
bacterial	O
homeostasis	O
(	O
8	O
d	O
in	O
control	O
vs	O
.	O
2	O
d	O
in	O
RT	O
)	O
from	O
a	O
markedly	O
dysbiotic	O
acidosis	O
state	O
to	O
a	O
healthy	O
level	O
(	O
similar	O
with	O
those	O
of	O
donors	O
)	O
.	O

At	O
the	O
genus	O
level	O
,	O
RT	O
increased	O
the	O
relative	O
abundance	O
of	O
unclassified	O
Bacteroidales	B-bacteria
,	O
unclassified	O
Prevotellaceae	B-bacteria
,	O
unclassified	O
Ruminococcaceae	B-bacteria
,	O
and	O
Acetitomaculum	B-bacteria
.	O

Additionally	O
,	O
RT	O
also	O
accelerated	O
recovery	O
of	O
the	O
predicted	O
metagenomic	O
function	O
of	O
ruminal	O
bacteria	O
.	O

Rumen	O
papillae	O
morphology	O
results	O
showed	O
that	O
RT	O
alleviated	O
the	O
damage	O
of	O
rumen	O
epithelia	O
induced	O
by	O
acute	O
rumen	O
acidosis	O
and	O
increased	O
the	O
length	O
of	O
rumen	O
papillae	O
.	O

Furthermore	O
,	O
real	O
-	O
time	O
PCR	O
results	O
showed	O
that	O
RT	O
modulated	O
mRNA	O
expression	O
of	O
genes	O
related	O
to	O
cytokines	O
and	O
tight	O
junctions	O
in	O
the	O
rumen	O
epithelia	O
.	O

In	O
summary	O
,	O
these	O
results	O
reveal	O
that	O
RT	O
accelerates	O
recovery	O
of	O
rumen	O
fermentation	O
and	O
bacterial	O
homeostasis	O
and	O
modulates	O
rumen	O
epithelial	O
morphology	O
and	O
function	O
for	O
sheep	O
suffering	O
from	O
rumen	O
acidosis	O
.	O
-	O
Liu	O
,	O
J	O
.	O
,	O
Li	O
,	O
H	O
.	O
,	O
Zhu	O
,	O
W	O
.	O
,	O
Mao	O
,	O
S	O
.	O
Dynamic	O
changes	O
in	O
rumen	O
fermentation	O
and	O
bacterial	O
community	O
following	O
rumen	O
fluid	O
transplantation	O
in	O
a	O
sheep	O
model	O
of	O
rumen	O
acidosis	O
:	O
implications	O
for	O
rumen	O
health	O
in	O
ruminants	O
.	O

Upregulation	O
of	O
the	O
Intestinal	O
Paracellular	O
Pathway	O
with	O
Breakdown	O
of	O
Tight	O
and	O
Adherens	O
Junctions	O
in	O
Deficit	O
Schizophrenia	O
.	O

In	O
2001	O
,	O
the	O
first	O
author	O
of	O
this	O
paper	O
reported	O
that	O
schizophrenia	O
is	O
associated	O
with	O
an	O
increased	O
frequency	O
of	O
the	O
haptoglobin	O
(	O
Hp	O
)	O
-	O
2	O
gene	O
.	O

The	O
precursor	O
of	O
Hp	O
-	O
2	O
is	O
zonulin	O
,	O
a	O
molecule	O
that	O
affects	O
intercellular	O
tight	O
junction	O
integrity	O
.	O

Recently	O
,	O
we	O
reported	O
increased	O
plasma	O
IgA	O
/	O
IgM	O
responses	O
to	O
Gram	O
-	O
negative	O
bacteria	O
in	O
deficit	O
schizophrenia	O
indicating	O
leaky	O
gut	O
and	O
gut	O
dysbiosis	O
.	O

The	O
current	O
study	O
was	O
performed	O
to	O
examine	O
the	O
integrity	O
of	O
the	O
paracellular	O
(	O
tight	O
and	O
adherens	O
junctions	O
)	O
and	O
transcellular	O
(	O
cytoskeletal	O
proteins	O
)	O
pathways	O
in	O
deficit	O
versus	O
non	O
-	O
deficit	O
schizophrenia	O
.	O

We	O
measured	O
IgM	O
responses	O
to	O
zonulin	O
,	O
occludin	O
,	O
E	O
-	O
cadherin	O
,	O
talin	O
,	O
actin	O
,	O
and	O
vinculin	O
in	O
association	O
with	O
IgA	O
responses	O
to	O
Gram	O
-	O
negative	O
bacteria	O
,	O
CCL	O
-	O
11	O
,	O
IgA	O
responses	O
to	O
tryptophan	O
catabolites	O
(	O
TRYCATs	O
)	O
,	O
immune	O
activation	O
and	O
IgM	O
to	O
malondialdehyde	O
(	O
MDA	O
)	O
,	O
and	O
NO	O
-	O
cysteinyl	O
in	O
78	O
schizophrenia	O
patients	O
and	O
40	O
controls	O
.	O

We	O
found	O
that	O
the	O
ratio	O
of	O
IgM	O
to	O
zonulin	O
+	O
occludin	O
/	O
talin	O
+	O
actin	O
+	O
viculin	O
(	O
PARA	O
/	O
TRANS	O
)	O
was	O
significantly	O
greater	O
in	O
deficit	O
than	O
those	O
in	O
non	O
-	O
deficit	O
schizophrenia	O
and	O
higher	O
in	O
schizophrenia	O
than	O
those	O
in	O
controls	O
and	O
was	O
significantly	O
associated	O
with	O
increased	O
IgA	O
responses	O
to	O
Gram	O
-	O
negative	O
bacteria	O
.	O

IgM	O
responses	O
to	O
zonulin	O
were	O
positively	O
associated	O
with	O
schizophrenia	O
(	O
versus	O
controls	O
)	O
,	O
while	O
IgM	O
to	O
occludin	O
was	O
significantly	O
associated	O
with	O
deficit	O
schizophrenia	O
(	O
versus	O
non	O
-	O
deficit	O
schizophrenia	O
and	O
controls	O
)	O
.	O

A	O
large	O
part	O
of	O
the	O
variance	O
(	O
90	O
.	O
8	O
%	O
)	O
in	O
negative	O
and	O
PHEM	O
(	O
psychosis	O
,	O
hostility	O
,	O
excitation	O
,	O
and	O
mannerism	O
)	O
symptoms	O
was	O
explained	O
by	O
PARA	O
/	O
TRANS	O
ratio	O
,	O
IgA	O
to	O
Gram	O
-	O
negative	O
bacteria	O
,	O
IgM	O
to	O
E	O
-	O
cadherin	O
and	O
MDA	O
,	O
and	O
memory	O
dysfunctions	O
,	O
while	O
53	O
.	O
3	O
%	O
of	O
the	O
variance	O
in	O
the	O
latter	O
was	O
explained	O
by	O
PARA	O
/	O
TRANS	O
ratio	O
,	O
IgA	O
to	O
Gram	O
-	O
negative	O
bacteria	O
,	O
CCL	O
-	O
11	O
,	O
TRYCATs	O
,	O
and	O
immune	O
activation	O
.	O

The	O
results	O
show	O
an	O
upregulated	O
paracellular	O
pathway	O
with	O
breakdown	O
of	O
the	O
tight	O
and	O
adherens	O
junctions	O
and	O
increased	O
bacterial	O
translocation	O
in	O
deficit	O
schizophrenia	O
.	O

These	O
dysfunctions	O
in	O
the	O
intestinal	O
paracellular	O
route	O
together	O
with	O
lowered	O
natural	O
IgM	O
,	O
immune	O
activation	O
,	O
and	O
production	O
of	O
CCL	O
-	O
11	O
and	O
TRYCATs	O
contribute	O
to	O
the	O
phenomenology	O
of	O
deficit	O
schizophrenia	O
.	O

Dietary	O
Arginine	O
Regulates	O
Severity	O
of	O
Experimental	O
Colitis	O
and	O
Affects	O
the	O
Colonic	O
Microbiome	O
.	O

There	O
is	O
great	O
interest	O
in	O
safe	O
and	O
effective	O
alternative	O
therapies	O
that	O
could	O
benefit	O
patients	O
with	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
.	O

L	O
-	O
arginine	O
(	O
Arg	O
)	O
is	O
a	O
semi	O
-	O
essential	O
amino	O
acid	O
with	O
a	O
variety	O
of	O
physiological	O
effects	O
.	O

In	O
this	O
context	O
,	O
our	O
aim	O
was	O
to	O
investigate	O
the	O
role	O
of	O
dietary	O
Arg	O
in	O
experimental	O
colitis	O
.	O

We	O
used	O
two	O
models	O
of	O
colitis	O
in	O
C57BL	O
/	O
6	O
mice	O
,	O
the	O
dextran	O
sulfate	O
sodium	O
(	O
DSS	O
)	O
model	O
of	O
injury	O
and	O
repair	O
,	O
and	O
Citrobacter	B-bacteria
rodentium	I-bacteria
infection	O
.	O

Animals	O
were	O
given	O
diets	O
containing	O
(	O
1	O
)	O
no	O
Arg	O
(	O
Arg	O
(	O
0	O
)	O
)	O
,	O
6	O
.	O
4	O
g	O
/	O
kg	O
(	O
Arg	O
(	O
NL	O
)	O
)	O
,	O
or	O
24	O
.	O
6	O
g	O
/	O
kg	O
Arg	O
(	O
Arg	O
(	O
HIGH	O
)	O
)	O
;	O
or	O
(	O
2	O
)	O
the	O
amino	O
acids	O
downstream	O
of	O
Arg	O
:	O
28	O
g	O
/	O
kg	O
L	O
-	O
ornithine	O
(	O
Orn	O
(	O
HIGH	O
)	O
)	O
or	O
72	O
g	O
/	O
kg	O
L	O
-	O
proline	O
(	O
Pro	O
(	O
HIGH	O
)	O
)	O
.	O

Mice	O
with	O
DSS	O
colitis	O
receiving	O
the	O
Arg	O
(	O
HIGH	O
)	O
diet	O
had	O
increased	O
levels	O
of	O
Arg	O
,	O
Orn	O
,	O
and	O
Pro	O
in	O
the	O
colon	O
and	O
improved	O
body	O
weight	O
loss	O
,	O
colon	O
length	O
shortening	O
,	O
and	O
histological	O
injury	O
compared	O
to	O
Arg	O
(	O
NL	O
)	O
and	O
Arg	O
(	O
0	O
)	O
diets	O
.	O

Histology	O
was	O
improved	O
in	O
the	O
Arg	O
(	O
NL	O
)	O
vs	O
.	O
Arg	O
(	O
0	O
)	O
group	O
.	O

Orn	O
(	O
HIGH	O
)	O
or	O
Pro	O
(	O
HIGH	O
)	O
diets	O
did	O
not	O
provide	O
protection	O
.	O

Reduction	O
in	O
colitis	O
with	O
Arg	O
(	O
HIGH	O
)	O
diet	O
also	O
occurred	O
in	O
C	O
.	O
rodentium	O
-	O
infected	O
mice	O
.	O

Diversity	O
of	O
the	O
intestinal	O
microbiota	O
was	O
significantly	O
enhanced	O
in	O
mice	O
on	O
the	O
Arg	O
(	O
HIGH	O
)	O
diet	O
compared	O
to	O
the	O
Arg	O
(	O
NL	O
)	O
or	O
Arg	O
(	O
0	O
)	O
diets	O
,	O
with	O
increased	O
abundance	O
of	O
Bacteroidetes	B-bacteria
and	O
decreased	O
Verrucomicrobia	B-bacteria
.	O

In	O
conclusion	O
,	O
dietary	O
supplementation	O
of	O
Arg	O
is	O
protective	O
in	O
colitis	O
models	O
.	O

This	O
may	O
occur	O
by	O
restoring	O
overall	O
microbial	O
diversity	O
and	O
Bacteroidetes	B-bacteria
prevalence	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
Arg	O
as	O
an	O
adjunctive	O
therapy	O
in	O
IBD	O
.	O

The	O
Perturbation	O
of	O
Infant	O
Gut	O
Microbiota	O
Caused	O
by	O
Cesarean	O
Delivery	O
Is	O
Partially	O
Restored	O
by	O
Exclusive	O
Breastfeeding	O
.	O

Early	O
establishment	O
of	O
the	O
infant	O
gut	O
microbiome	O
has	O
been	O
attributed	O
to	O
various	O
environmental	O
factors	O
that	O
may	O
influence	O
long	O
-	O
term	O
health	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
single	O
and	O
combined	O
impacts	O
of	O
the	O
delivery	O
mode	O
,	O
feeding	O
pattern	O
and	O
postnatal	O
antibiotic	O
exposure	O
on	O
the	O
initial	O
establishment	O
of	O
infant	O
gut	O
microbiome	O
at	O
6	O
weeks	O
postpartum	O
.	O

A	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
at	O
a	O
single	O
center	O
in	O
China	O
.	O

Fecal	O
samples	O
were	O
collected	O
from	O
120	O
infants	O
at	O
6	O
weeks	O
postpartum	O
.	O

The	O
V3	O
-	O
V4	O
regions	O
of	O
16S	O
rRNA	O
gene	O
were	O
analyzed	O
by	O
Illumina	O
sequencing	O
,	O
and	O
clinical	O
information	O
was	O
obtained	O
from	O
medical	O
records	O
and	O
questionnaire	O
survey	O
.	O

Compared	O
with	O
vaginally	O
delivered	O
infants	O
,	O
the	O
gut	O
microbial	O
community	O
structure	O
of	O
cesarean	O
delivered	O
infants	O
were	O
significantly	O
different	O
(	O
P	O
=	O
0	O
.	O
044	O
)	O
,	O
in	O
parallel	O
with	O
the	O
decreased	O
relative	O
abundance	O
of	O
Bifidobacterium	B-bacteria
(	O
P	O
=	O
0	O
.	O
028	O
)	O
,	O
which	O
contrasts	O
with	O
the	O
normal	O
gut	O
microbial	O
establishment	O
.	O

Using	O
the	O
vaginally	O
delivered	O
and	O
exclusively	O
breastfed	O
(	O
VB	O
)	O
infants	O
as	O
a	O
reference	O
,	O
the	O
comparative	O
analysis	O
of	O
cesarean	O
delivered	O
and	O
exclusively	O
breastfed	O
(	O
CB	O
)	O
infants	O
with	O
cesarean	O
delivered	O
and	O
mixed	O
-	O
fed	O
(	O
CM	O
)	O
infants	O
showed	O
that	O
both	O
within	O
-	O
and	O
between	O
-	O
group	O
UniFrac	O
distance	O
were	O
significantly	O
smaller	O
in	O
CB	O
infants	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

LEfSe	O
analysis	O
showed	O
that	O
the	O
relative	O
abundances	O
of	O
Enterococcus	B-bacteria
,	O
Veillonella	B-bacteria
,	O
and	O
Faecalibacterium	B-bacteria
were	O
significantly	O
different	O
between	O
CB	O
and	O
CM	O
infants	O
,	O
whereas	O
the	O
relative	O
abundances	O
of	O
those	O
genera	O
in	O
VB	O
infants	O
were	O
close	O
to	O
those	O
of	O
CB	O
infants	O
,	O
and	O
distinct	O
from	O
those	O
of	O
CM	O
infants	O
.	O

Additionally	O
,	O
no	O
significant	O
difference	O
of	O
microbial	O
composition	O
,	O
alpha	O
diversity	O
,	O
or	O
community	O
structure	O
was	O
observed	O
between	O
postnatal	O
antibiotics	O
exposed	O
infants	O
and	O
unexposed	O
infants	O
.	O

In	O
summary	O
,	O
delivery	O
mode	O
had	O
a	O
significant	O
impact	O
on	O
the	O
infant	O
gut	O
microbial	O
community	O
structure	O
and	O
composition	O
,	O
and	O
the	O
gut	O
microbiota	O
was	O
disturbed	O
in	O
infants	O
delivered	O
by	O
cesarean	O
section	O
.	O

However	O
,	O
our	O
study	O
showed	O
that	O
this	O
disturbance	O
of	O
gut	O
microbiota	O
in	O
cesarean	O
delivered	O
infants	O
was	O
partially	O
restored	O
by	O
exclusive	O
breastfeeding	O
in	O
comparison	O
with	O
mixed	O
feeding	O
.	O

No	O
distinct	O
impact	O
of	O
postnatal	O
antibiotic	O
exposure	O
on	O
infant	O
gut	O
microbiome	O
was	O
found	O
at	O
6	O
weeks	O
of	O
age	O
.	O

Corrigendum	O
:	O
Elevated	O
Gut	O
Microbiome	O
-	O
Derived	O
Propionate	O
Levels	O
Are	O
Associated	O
With	O
Reduced	O
Sterile	O
Lung	O
Inflammation	O
and	O
Bacterial	O
Immunity	O
in	O
Mice	O
.	O

[	O
This	O
corrects	O
the	O
article	O
DOI	O
:	O
10	O
.	O
3389	O
/	O
fmicb	O
.	O
2019	O
.	O
00159	O
.	O

]	O
.	O

Mechanistic	O
Insights	O
Into	O
Probiotic	O
Properties	O
of	O
Lactic	O
Acid	O
Bacteria	O
Associated	O
With	O
Ethnic	O
Fermented	O
Dairy	O
Products	O
.	O

Gut	O
microbes	O
and	O
their	O
metabolites	O
maintain	O
the	O
health	O
and	O
homeostasis	O
of	O
the	O
host	O
by	O
communicating	O
with	O
the	O
host	O
via	O
various	O
biochemical	O
and	O
physical	O
factors	O
.	O

Changing	O
lifestyle	O
,	O
chronic	O
intake	O
of	O
foods	O
rich	O
in	O
refined	O
carbohydrates	O
and	O
fats	O
have	O
caused	O
intestinal	O
dysbiosis	O
and	O
other	O
lifestyle	O
-	O
based	O
diseases	O
.	O

Thus	O
,	O
supplementation	O
with	O
probiotics	O
has	O
gained	O
popularity	O
as	O
biotherapies	O
for	O
improving	O
gut	O
health	O
and	O
treating	O
disorders	O
.	O

Research	O
shows	O
that	O
probiotic	O
organisms	O
enhance	O
gastrointestinal	O
health	O
,	O
immunomodulation	O
,	O
generation	O
of	O
essential	O
micronutrients	O
,	O
and	O
prevention	O
of	O
cancer	O
.	O

Ethnically	O
fermented	O
milk	O
and	O
dairy	O
products	O
are	O
hotspots	O
for	O
novel	O
probiotic	O
organisms	O
and	O
bioactive	O
compounds	O
.	O

These	O
ethnic	O
fermented	O
foods	O
have	O
been	O
traditionally	O
prepared	O
by	O
indigenous	O
populations	O
,	O
and	O
have	O
preserved	O
unique	O
microflora	O
for	O
ages	O
.	O

To	O
apply	O
these	O
unique	O
microflora	O
for	O
amelioration	O
of	O
human	O
health	O
,	O
it	O
is	O
important	O
that	O
probiotic	O
properties	O
of	O
the	O
bacterial	O
species	O
are	O
well	O
studied	O
.	O

Majority	O
of	O
the	O
published	O
research	O
and	O
reviews	O
focus	O
on	O
the	O
probiotic	O
organisms	O
and	O
their	O
properties	O
,	O
fermented	O
food	O
products	O
,	O
isolation	O
techniques	O
,	O
and	O
animal	O
studies	O
with	O
their	O
health	O
pathologies	O
.	O

As	O
a	O
consequence	O
,	O
there	O
is	O
a	O
dearth	O
of	O
information	O
about	O
the	O
underlying	O
molecular	O
mechanism	O
behind	O
probiotics	O
associated	O
with	O
ethnically	O
prepared	O
dairy	O
foods	O
.	O

This	O
review	O
is	O
targeted	O
at	O
stimulating	O
research	O
on	O
understanding	O
these	O
mechanisms	O
of	O
bacterial	O
species	O
and	O
beneficial	O
attributes	O
of	O
ethnically	O
fermented	O
dairy	O
products	O
.	O

Impact	O
of	O
antibiotic	O
treatment	O
and	O
host	O
innate	O
immune	O
pressure	O
on	O
enterococcal	O
adaptation	O
in	O
the	O
human	O
bloodstream	O
.	O

Multidrug	B-bacteria
-	I-bacteria
resistant	I-bacteria
enterococcal	I-bacteria
strains	I-bacteria
emerged	O
in	O
the	O
early	O
1980s	O
and	O
are	O
now	O
among	O
the	O
leading	O
causes	O
of	O
drug	O
-	O
resistant	O
bacterial	O
infection	O
worldwide	O
.	O

We	O
used	O
functional	O
genomics	O
to	O
study	O
an	O
early	O
bacterial	O
outbreak	O
in	O
patients	O
in	O
a	O
Wisconsin	O
hospital	O
between	O
1984	O
and	O
1988	O
that	O
was	O
caused	O
by	O
multidrug	O
-	I-bacteria
resistant	I-bacteria
Enterococcus	I-bacteria
faecalis	I-bacteria
The	O
goal	O
was	O
to	O
determine	O
how	O
a	O
clonal	O
lineage	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
became	O
adapted	O
to	O
growth	O
and	O
survival	O
in	O
the	O
human	O
bloodstream	O
.	O

Genome	O
sequence	O
analysis	O
revealed	O
a	O
progression	O
of	O
increasingly	O
fixed	O
mutations	O
and	O
repeated	O
independent	O
occurrences	O
of	O
mutations	O
in	O
a	O
relatively	O
small	O
set	O
of	O
genes	O
.	O

Repeated	O
independent	O
mutations	O
suggested	O
selection	O
within	O
the	O
host	O
during	O
the	O
course	O
of	O
infection	O
in	O
response	O
to	O
pressures	O
such	O
as	O
host	O
immunity	O
and	O
antibiotic	O
treatment	O
.	O

We	O
observed	O
repeated	O
independent	O
mutations	O
in	O
a	O
small	O
number	O
of	O
loci	O
,	O
including	O
a	O
little	O
studied	O
polysaccharide	O
utilization	O
pathway	O
and	O
the	O
cydABDC	O
locus	O
.	O

Functional	O
studies	O
showed	O
that	O
mutating	O
these	O
loci	O
rendered	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
better	O
able	O
to	O
withstand	O
antibiotic	O
pressure	O
and	O
innate	O
immune	O
defenses	O
in	O
the	O
human	O
bloodstream	O
.	O

We	O
also	O
observed	O
a	O
shift	O
in	O
mutation	O
pattern	O
that	O
corresponded	O
to	O
the	O
introduction	O
of	O
carbapenem	O
antibiotics	O
in	O
1987	O
.	O

This	O
work	O
identifies	O
pathways	O
that	O
allow	O
enterococci	B-bacteria
to	O
survive	O
the	O
transition	O
from	O
the	O
human	O
gut	O
into	O
the	O
bloodstream	O
,	O
enabling	O
them	O
to	O
cause	O
severe	O
bacteremia	O
associated	O
with	O
high	O
mortality	O
.	O

[	O
Customised	O
infectiology	O
-	O
Fecal	O
microbiota	O
transplantation	O
:	O
following	O
the	O
Clostridioides	B-bacteria
difficile	I-bacteria
pathway	O
]	O
.	O

Fecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
raised	O
,	O
in	O
the	O
recent	O
years	O
,	O
a	O
growing	O
interest	O
,	O
mostly	O
in	O
Clostridioides	B-bacteria
difficile	I-bacteria
infections	O
(	O
CDI	O
)	O
.	O

The	O
concept	O
of	O
FMT	O
is	O
quite	O
simple	O
based	O
on	O
the	O
administration	O
of	O
fecal	O
matter	O
from	O
a	O
healthy	O
donor	O
to	O
a	O
patient	O
with	O
a	O
disease	O
related	O
to	O
the	O
gut	O
microbiota	O
imbalance	O
(	O
dysbiosis	O
)	O
.	O

Although	O
the	O
theory	O
seems	O
straightforward	O
,	O
the	O
fine	O
mechanisms	O
are	O
multiple	O
and	O
not	O
yet	O
completely	O
understood	O
.	O

In	O
Switzerland	O
,	O
FMT	O
is	O
considered	O
as	O
a	O
drug	O
under	O
the	O
pharmacist	O
responsibility	O
.	O

The	O
only	O
official	O
indication	O
for	O
FMT	O
is	O
multi	O
-	O
recurrent	O
CDI	O
.	O

For	O
practical	O
reasons	O
,	O
most	O
of	O
the	O
FMT	O
are	O
performed	O
with	O
fresh	O
stools	O
,	O
but	O
development	O
of	O
frozen	O
forms	O
and	O
capsules	O
should	O
considerably	O
enhance	O
treatment	O
delivery	O
.	O

Other	O
indications	O
are	O
currently	O
investigated	O
but	O
not	O
yet	O
in	O
the	O
clinical	O
routine	O
.	O

Characterisation	O
of	O
the	O
effect	O
of	O
day	O
length	O
,	O
and	O
associated	O
differences	O
in	O
dietary	O
intake	O
,	O
on	O
the	O
gut	O
microbiota	O
of	O
Soay	O
sheep	O
.	O

Differences	O
in	O
the	O
rumen	O
bacterial	O
community	O
have	O
been	O
previously	O
reported	O
for	O
Soay	O
sheep	O
housed	O
under	O
different	O
day	O
length	O
conditions	O
.	O

This	O
study	O
extends	O
this	O
previous	O
investigation	O
to	O
other	O
organs	O
of	O
the	O
digestive	O
tract	O
,	O
as	O
well	O
as	O
the	O
analysis	O
of	O
ciliated	O
protozoa	O
and	O
anaerobic	O
fungi	O
.	O

The	O
detectable	O
concentrations	O
of	O
ciliated	O
protozoa	O
and	O
anaerobic	O
fungi	O
decreased	O
with	O
increased	O
day	O
length	O
in	O
both	O
the	O
rumen	O
and	O
large	O
colon	O
,	O
unlike	O
those	O
of	O
bacteria	O
where	O
no	O
effect	O
was	O
observed	O
.	O

Conversely	O
,	O
bacterial	O
community	O
composition	O
was	O
affected	O
by	O
day	O
length	O
in	O
both	O
the	O
rumen	O
and	O
large	O
colon	O
,	O
but	O
the	O
community	O
composition	O
of	O
the	O
detectable	O
ciliated	O
protozoa	O
and	O
anaerobic	O
fungi	O
was	O
not	O
affected	O
.	O

Day	O
length	O
-	O
associated	O
differences	O
in	O
the	O
bacterial	O
community	O
composition	O
extended	O
to	O
all	O
of	O
the	O
organs	O
examined	O
,	O
with	O
the	O
exception	O
of	O
the	O
duodenum	O
and	O
the	O
jejunum	O
.	O

It	O
is	O
proposed	O
that	O
differences	O
in	O
rumen	O
fill	O
and	O
ruminal	O
'	O
by	O
-	O
pass	O
'	O
nutrients	O
together	O
with	O
endocrinological	O
changes	O
cause	O
the	O
observed	O
effects	O
of	O
day	O
length	O
on	O
the	O
different	O
gut	O
microbial	O
communities	O
.	O

Fecal	O
Microbiota	O
Transplantation	O
Decreases	O
Intestinal	O
Loads	O
of	O
Multi	B-bacteria
-	I-bacteria
Drug	I-bacteria
Resistant	I-bacteria
Pseudomonas	I-bacteria
aeruginosa	I-bacteria
in	O
Murine	O
Carriers	O
.	O

Intestinal	O
carriage	O
of	O
multi	O
-	O
drug	O
resistant	O
(	O
MDR	O
)	O
Gram	O
-	O
negative	O
bacteria	O
including	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
(	O
Psae	B-bacteria
)	O
constitutes	O
a	O
pivotal	O
prerequisite	O
for	O
subsequent	O
fatal	O
endogenous	O
infections	O
in	O
patients	O
at	O
risk	O
.	O

We	O
here	O
addressed	O
whether	O
fecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
could	O
effectively	O
combat	O
MDR	O
-	O
Psae	O
carriage	O
.	O

Therefore	O
,	O
secondary	O
abiotic	O
mice	O
were	O
challenged	O
with	O
MDR	O
-	O
Psae	O
by	O
gavage	O
.	O

One	O
week	O
later	O
,	O
mice	O
were	O
subjected	O
to	O
peroral	O
FMT	O
from	O
either	O
murine	O
or	O
human	O
donors	O
on	O
3	O
consecutive	O
days	O
.	O

Irrespective	O
of	O
murine	O
or	O
human	O
origin	O
of	O
fecal	O
transplant	O
,	O
intestinal	O
MDR	O
-	O
Psae	O
loads	O
decreased	O
as	O
early	O
as	O
24	O
h	O
after	O
the	O
initial	O
FMT	O
.	O

Remarkably	O
,	O
the	O
murine	O
FMT	O
could	O
lower	O
intestinal	O
MDR	O
-	O
Psae	O
burdens	O
by	O
approximately	O
4	O
log	O
orders	O
of	O
magnitude	O
within	O
1	O
week	O
.	O

In	O
another	O
intervention	O
study	O
,	O
mice	O
harboring	O
a	O
human	O
gut	O
microbiota	O
were	O
perorally	O
challenged	O
with	O
MDR	O
-	O
Psae	O
and	O
subjected	O
to	O
murine	O
FMT	O
on	O
3	O
consecutive	O
days	O
,	O
1	O
week	O
later	O
.	O

Strikingly	O
,	O
within	O
5	O
days	O
,	O
murine	O
FMT	O
resulted	O
in	O
lower	O
loads	O
and	O
carrier	O
rates	O
of	O
MDR	O
-	O
Psae	O
in	O
mice	O
with	O
a	O
human	O
gut	O
microbiota	O
.	O

In	O
conclusion	O
,	O
FMT	O
might	O
be	O
a	O
promising	O
antibiotics	O
-	O
independent	O
option	O
to	O
combat	O
intestinal	O
MDR	O
-	O
Psae	O
carriage	O
and	O
thus	O
prevent	O
from	O
future	O
endogenous	O
infections	O
of	O
patients	O
at	O
risk	O
.	O

Pituitary	O
Adenylate	O
Cyclase	O
-	O
Activating	O
Polypeptide	O
-	O
A	O
Neuropeptide	O
as	O
Novel	O
Treatment	O
Option	O
for	O
Subacute	O
Ileitis	O
in	O
Mice	O
Harboring	O
a	O
Human	O
Gut	O
Microbiota	O
.	O

The	O
neuropeptide	O
Pituitary	O
adenylate	O
cyclase	O
-	O
activating	O
polypeptide	O
(	O
PACAP	O
)	O
is	O
well	O
-	O
known	O
for	O
its	O
important	O
functions	O
in	O
immunity	O
and	O
inflammation	O
.	O

Data	O
regarding	O
anti	O
-	O
inflammatory	O
properties	O
of	O
PACAP	O
in	O
the	O
intestinal	O
tract	O
are	O
limited	O
,	O
however	O
.	O

In	O
our	O
present	O
preclinical	O
intervention	O
study	O
we	O
addressed	O
whether	O
PACAP	O
treatment	O
could	O
alleviate	O
experimental	O
subacute	O
ileitis	O
mimicking	O
human	O
gut	O
microbiota	O
conditions	O
.	O

Therefore	O
,	O
secondary	O
abioitic	O
mice	O
were	O
subjected	O
to	O
human	O
fecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
and	O
perorally	O
infected	O
with	O
low	O
-	O
dose	O
Toxoplasma	O
gondii	O
to	O
induce	O
subacute	O
ileitis	O
on	O
day	O
0	O
.	O

From	O
day	O
3	O
until	O
day	O
8	O
post	O
-	O
infection	O
,	O
mice	O
were	O
either	O
treated	O
with	O
synthetic	O
PACAP38	O
or	O
placebo	O
.	O

At	O
day	O
9	O
post	O
-	O
infection	O
,	O
placebo	O
,	O
but	O
not	O
PACAP	O
treated	O
mice	O
exhibited	O
overt	O
macroscopic	O
sequelae	O
of	O
intestinal	O
immunopathology	O
.	O

PACAP	O
treatment	O
further	O
resulted	O
in	O
less	O
distinct	O
apoptotic	O
responses	O
in	O
ileal	O
and	O
colonic	O
epithelia	O
that	O
were	O
accompanied	O
by	O
lower	O
T	O
cell	O
numbers	O
in	O
the	O
mucosa	O
and	O
lamina	O
propria	O
and	O
less	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
intestinal	O
ex	O
vivo	O
biopsies	O
.	O

Notably	O
,	O
ileitis	O
-	O
associated	O
gut	O
microbiota	O
shifts	O
were	O
less	O
distinct	O
in	O
PACAP	O
as	O
compared	O
to	O
placebo	O
treated	O
mice	O
.	O

Inflammation	O
-	O
ameliorating	O
effects	O
of	O
PACAP	O
were	O
not	O
restricted	O
to	O
the	O
intestines	O
,	O
but	O
could	O
also	O
be	O
observed	O
in	O
extra	O
-	O
intestinal	O
including	O
systemic	O
compartments	O
as	O
indicated	O
by	O
lower	O
apoptotic	O
cell	O
counts	O
and	O
less	O
pro	O
-	O
inflammatory	O
cytokine	O
secretion	O
in	O
liver	O
and	O
lungs	O
taken	O
from	O
PACAP	O
treated	O
as	O
compared	O
to	O
placebo	O
control	O
mice	O
,	O
which	O
also	O
held	O
true	O
for	O
markedly	O
lower	O
serum	O
TNF	O
and	O
IL	O
-	O
6	O
concentrations	O
in	O
the	O
former	O
as	O
compared	O
to	O
the	O
latter	O
.	O

Our	O
preclinical	O
intervention	O
study	O
provides	O
strong	O
evidence	O
that	O
synthetic	O
PACAP	O
alleviates	O
subacute	O
ileitis	O
and	O
extra	O
-	O
intestinal	O
including	O
systemic	O
sequelae	O
of	O
T	O
cell	O
-	O
driven	O
immunopathology	O
.	O

These	O
findings	O
further	O
support	O
PACAP	O
as	O
a	O
novel	O
treatment	O
option	O
for	O
intestinal	O
inflammation	O
including	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
.	O

Circulating	O
LPS	O
and	O
(	O
1	O
-	O
-	O
>	O
3	O
)	O
-	O
beta	O
-	O
D	O
-	O
Glucan	O
:	O
A	O
Folie	O
a	O
Deux	O
Contributing	O
to	O
HIV	O
-	O
Associated	O
Immune	O
Activation	O
.	O

Immune	O
activation	O
is	O
the	O
driving	O
force	O
behind	O
the	O
occurrence	O
of	O
AIDS	O
and	O
non	O
-	O
AIDS	O
events	O
,	O
and	O
is	O
only	O
partially	O
reduced	O
by	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
.	O

Soon	O
after	O
HIV	O
infection	O
,	O
intestinal	O
CD4	O
+	O
T	O
cells	O
are	O
depleted	O
leading	O
to	O
epithelial	O
gut	O
damage	O
and	O
subsequent	O
translocation	O
of	O
microbes	O
and	O
/	O
or	O
their	O
products	O
into	O
systemic	O
circulation	O
.	O

Bacteria	O
and	O
fungi	O
are	O
the	O
two	O
most	O
abundant	O
populations	O
of	O
the	O
gut	O
microbiome	O
.	O

Circulating	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
(	O
1	O
-	O
-	O
>	O
3	O
)	O
-	O
beta	O
-	O
D	O
-	O
Glucan	O
(	O
betaDG	O
)	O
,	O
major	O
components	O
of	O
bacterial	O
and	O
fungal	O
cell	O
walls	O
respectively	O
,	O
are	O
measured	O
as	O
markers	O
of	O
microbial	O
translocation	O
in	O
the	O
context	O
of	O
compromised	O
gut	O
barriers	O
.	O

While	O
LPS	O
is	O
a	O
well	O
-	O
known	O
inducer	O
of	O
innate	O
immune	O
activation	O
,	O
betaDG	O
is	O
emerging	O
as	O
a	O
significant	O
source	O
of	O
monocyte	O
and	O
NK	O
cell	O
activation	O
that	O
contributes	O
to	O
immune	O
dysfunction	O
.	O

Herein	O
,	O
we	O
critically	O
evaluated	O
recent	O
literature	O
to	O
untangle	O
the	O
respective	O
roles	O
of	O
LPS	O
and	O
betaDG	O
in	O
HIV	O
-	O
associated	O
immune	O
dysfunction	O
.	O

Furthermore	O
,	O
we	O
appraised	O
the	O
relevance	O
of	O
LPS	O
and	O
betaDG	O
as	O
biomarkers	O
of	O
disease	O
progression	O
and	O
immune	O
activation	O
on	O
ART	O
.	O

Understanding	O
the	O
consequences	O
of	O
elevated	O
LPS	O
and	O
betaDG	O
on	O
immune	O
activation	O
will	O
provide	O
insight	O
into	O
novel	O
therapeutic	O
strategies	O
against	O
the	O
occurrence	O
of	O
AIDS	O
and	O
non	O
-	O
AIDS	O
events	O
.	O

Antidepressants	O
affect	O
gut	O
microbiota	O
and	O
Ruminococcus	B-bacteria
flavefaciens	I-bacteria
is	O
able	O
to	O
abolish	O
their	O
effects	O
on	O
depressive	O
-	O
like	O
behavior	O
.	O

Accumulating	O
evidence	O
demonstrates	O
that	O
the	O
gut	O
microbiota	O
affects	O
brain	O
function	O
and	O
behavior	O
,	O
including	O
depressive	O
behavior	O
.	O

Antidepressants	O
are	O
the	O
main	O
drugs	O
used	O
for	O
treatment	O
of	O
depression	O
.	O

We	O
hypothesized	O
that	O
antidepressant	O
treatment	O
could	O
modify	O
gut	O
microbiota	O
which	O
can	O
partially	O
mediate	O
their	O
antidepressant	O
effects	O
.	O

Mice	O
were	O
chronically	O
treated	O
with	O
one	O
of	O
five	O
antidepressants	O
(	O
fluoxetine	O
,	O
escitalopram	O
,	O
venlafaxine	O
,	O
duloxetine	O
or	O
desipramine	O
)	O
,	O
and	O
gut	O
microbiota	O
was	O
analyzed	O
,	O
using	O
16s	O
rRNA	O
gene	O
sequencing	O
.	O

After	O
characterization	O
of	O
differences	O
in	O
the	O
microbiota	O
,	O
chosen	O
bacterial	O
species	O
were	O
supplemented	O
to	O
vehicle	O
and	O
antidepressant	O
-	O
treated	O
mice	O
,	O
and	O
depressive	O
-	O
like	O
behavior	O
was	O
assessed	O
to	O
determine	O
bacterial	O
effects	O
.	O

RNA	O
-	O
seq	O
analysis	O
was	O
performed	O
to	O
determine	O
effects	O
of	O
bacterial	O
treatment	O
in	O
the	O
brain	O
.	O

Antidepressants	O
reduced	O
richness	O
and	O
increased	O
beta	O
diversity	O
of	O
gut	O
bacteria	O
,	O
compared	O
to	O
controls	O
.	O

At	O
the	O
genus	O
level	O
,	O
antidepressants	O
reduced	O
abundances	O
of	O
Ruminococcus	B-bacteria
,	O
Adlercreutzia	B-bacteria
,	O
and	O
an	O
unclassified	O
Alphaproteobacteria	B-bacteria
.	O

To	O
examine	O
implications	O
of	O
the	O
dysregulated	O
bacteria	O
,	O
we	O
chose	O
one	O
of	O
antidepressants	O
(	O
duloxetine	O
)	O
and	O
investigated	O
if	O
its	O
antidepressive	O
effects	O
can	O
be	O
attenuated	O
by	O
simultaneous	O
treatment	O
with	O
Ruminococcus	B-bacteria
flavefaciens	I-bacteria
or	O
Adlercreutzia	B-bacteria
equolifaciens	I-bacteria
.	O

Supplementation	O
with	O
R	B-bacteria
.	I-bacteria
flavefaciens	I-bacteria
diminished	O
duloxetine	O
-	O
induced	O
decrease	O
in	O
depressive	O
-	O
like	O
behavior	O
,	O
while	O
A	B-bacteria
.	I-bacteria
equolifaciens	I-bacteria
had	O
no	O
such	O
effect	O
.	O

R	B-bacteria
.	I-bacteria
flavefaciens	I-bacteria
treatment	O
induced	O
changes	O
in	O
cortical	O
gene	O
expression	O
,	O
up	O
-	O
regulating	O
genes	O
involved	O
in	O
mitochondrial	O
oxidative	O
phosphorylation	O
,	O
while	O
down	O
-	O
regulating	O
genes	O
involved	O
in	O
neuronal	O
plasticity	O
.	O

Our	O
results	O
demonstrate	O
that	O
various	O
types	O
of	O
antidepressants	O
alter	O
gut	O
microbiota	O
composition	O
,	O
and	O
further	O
implicate	O
a	O
role	O
for	O
R	B-bacteria
.	I-bacteria
flavefaciens	I-bacteria
in	O
alleviating	O
depressive	O
-	O
like	O
behavior	O
.	O

Moreover	O
,	O
R	B-bacteria
.	I-bacteria
flavefaciens	I-bacteria
affects	O
gene	O
networks	O
in	O
the	O
brain	O
,	O
suggesting	O
a	O
mechanism	O
for	O
microbial	O
regulation	O
of	O
antidepressant	O
treatment	O
efficiency	O
.	O

Thinking	O
bigger	O
:	O
How	O
early	O
life	O
environmental	O
exposures	O
shape	O
the	O
gut	O
microbiome	O
and	O
influence	O
the	O
development	O
of	O
asthma	O
and	O
allergic	O
disease	O
.	O

Imbalance	O
,	O
or	O
dysbiosis	O
,	O
of	O
the	O
gut	O
microbiome	O
of	O
infants	O
has	O
been	O
linked	O
to	O
an	O
increased	O
risk	O
of	O
asthma	O
and	O
allergic	O
diseases	O
.	O

Most	O
studies	O
to	O
date	O
have	O
provided	O
a	O
wealth	O
of	O
data	O
showing	O
correlations	O
between	O
early	O
-	O
life	O
risk	O
factors	O
for	O
disease	O
and	O
changes	O
in	O
the	O
structure	O
of	O
the	O
gut	O
microbiome	O
that	O
disrupt	O
normal	O
immunoregulation	O
.	O

These	O
studies	O
have	O
typically	O
focused	O
on	O
one	O
specific	O
risk	O
factor	O
,	O
such	O
as	O
mode	O
of	O
delivery	O
or	O
early	O
-	O
life	O
antibiotic	O
use	O
.	O

Such	O
'	O
micro	O
-	O
level	O
'	O
exposures	O
have	O
a	O
considerable	O
impact	O
on	O
affected	O
individuals	O
but	O
not	O
necessarily	O
the	O
whole	O
population	O
.	O

In	O
this	O
Review	O
we	O
place	O
these	O
mechanisms	O
under	O
a	O
larger	O
lens	O
that	O
takes	O
into	O
account	O
the	O
influence	O
of	O
upstream	O
'	O
macro	O
-	O
level	O
'	O
environmental	O
factors	O
such	O
as	O
air	O
pollution	O
and	O
the	O
built	O
environment	O
.	O

While	O
these	O
exposures	O
likely	O
have	O
a	O
smaller	O
impact	O
on	O
the	O
microbiome	O
at	O
an	O
individual	O
level	O
,	O
their	O
ubiquitous	O
nature	O
confers	O
them	O
with	O
a	O
large	O
influence	O
at	O
the	O
population	O
level	O
.	O

We	O
focus	O
on	O
features	O
of	O
the	O
indoor	O
and	O
outdoor	O
human	O
-	O
made	O
environment	O
,	O
their	O
microbiomes	O
and	O
the	O
research	O
challenges	O
inherent	O
in	O
integrating	O
the	O
built	O
environment	O
microbiomes	O
with	O
the	O
early	O
-	O
life	O
gut	O
microbiome	O
.	O

We	O
argue	O
that	O
an	O
exposome	O
perspective	O
integrating	O
internal	O
and	O
external	O
microbiomes	O
with	O
macro	O
-	O
level	O
environmental	O
factors	O
can	O
provide	O
a	O
more	O
comprehensive	O
framework	O
to	O
define	O
how	O
environmental	O
exposures	O
can	O
shape	O
the	O
gut	O
microbiome	O
and	O
influence	O
the	O
development	O
of	O
allergic	O
disease	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Infection	O
-	O
generated	O
electric	O
field	O
in	O
gut	O
epithelium	O
drives	O
bidirectional	O
migration	O
of	O
macrophages	O
.	O

Many	O
bacterial	O
pathogens	O
hijack	O
macrophages	O
to	O
egress	O
from	O
the	O
port	O
of	O
entry	O
to	O
the	O
lymphatic	O
drainage	O
and	O
/	O
or	O
bloodstream	O
,	O
causing	O
dissemination	O
of	O
life	O
-	O
threatening	O
infections	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
are	O
not	O
well	O
understood	O
.	O

Here	O
,	O
we	O
report	O
that	O
Salmonella	B-bacteria
infection	O
generates	O
directional	O
electric	O
fields	O
(	O
EFs	O
)	O
in	O
the	O
follicle	O
-	O
associated	O
epithelium	O
of	O
mouse	O
cecum	O
.	O

In	O
vitro	O
application	O
of	O
an	O
EF	O
,	O
mimicking	O
the	O
infection	O
-	O
generated	O
electric	O
field	O
(	O
IGEF	O
)	O
,	O
induces	O
directional	O
migration	O
of	O
primary	O
mouse	O
macrophages	O
to	O
the	O
anode	O
,	O
which	O
is	O
reversed	O
to	O
the	O
cathode	O
upon	O
Salmonella	B-bacteria
infection	O
.	O

This	O
infection	O
-	O
dependent	O
directional	O
switch	O
is	O
independent	O
of	O
the	O
Salmonella	B-bacteria
pathogenicity	I-bacteria
island	I-bacteria
1	O
(	O
SPI	O
-	O
1	O
)	O
type	O
III	O
secretion	O
system	O
.	O

The	O
switch	O
is	O
accompanied	O
by	O
a	O
reduction	O
of	O
sialic	O
acids	O
on	O
glycosylated	O
surface	O
components	O
during	O
phagocytosis	O
of	O
bacteria	O
,	O
which	O
is	O
absent	O
in	O
macrophages	O
challenged	O
by	O
microspheres	O
.	O

Moreover	O
,	O
enzymatic	O
cleavage	O
of	O
terminally	O
exposed	O
sialic	O
acids	O
reduces	O
macrophage	O
surface	O
negativity	O
and	O
severely	O
impairs	O
directional	O
migration	O
of	O
macrophages	O
in	O
response	O
to	O
an	O
EF	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
propose	O
that	O
macrophages	O
are	O
attracted	O
to	O
the	O
site	O
of	O
infection	O
by	O
a	O
combination	O
of	O
chemotaxis	O
and	O
galvanotaxis	O
;	O
after	O
phagocytosis	O
of	O
bacteria	O
,	O
surface	O
electrical	O
properties	O
of	O
the	O
macrophage	O
change	O
,	O
and	O
galvanotaxis	O
directs	O
the	O
cells	O
away	O
from	O
the	O
site	O
of	O
infection	O
.	O

Effects	O
of	O
fermentation	O
products	O
of	O
the	O
commensal	O
bacterium	O
Clostridium	B-bacteria
ramosum	I-bacteria
on	O
motility	O
,	O
intracellular	O
pH	O
,	O
and	O
flagellar	O
synthesis	O
of	O
enterohemorrhagic	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
.	O

The	O
flagellum	O
and	O
motility	O
are	O
crucial	O
virulence	O
factors	O
for	O
many	O
pathogenic	O
bacteria	O
.	O

In	O
general	O
,	O
pathogens	O
invade	O
and	O
translocate	O
through	O
motility	O
and	O
adhere	O
to	O
specific	O
tissue	O
via	O
flagella	O
.	O

Therefore	O
,	O
the	O
motility	O
and	O
flagella	O
of	O
pathogens	O
are	O
effectual	O
targets	O
for	O
attenuation	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
fermentation	O
products	O
of	O
Clostridium	B-bacteria
ramosum	I-bacteria
,	O
a	O
commensal	O
intestinal	O
bacterium	O
,	O
decrease	O
the	O
intracellular	O
pH	O
of	O
enterohemorrhagic	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
(	O
EHEC	B-bacteria
)	O
and	O
influence	O
its	O
swimming	O
motility	O
.	O

Quantifications	O
of	O
flagellar	O
rotation	O
in	O
individual	O
EHEC	O
cells	O
showed	O
an	O
increase	O
in	O
reversal	O
frequency	O
and	O
a	O
decrease	O
in	O
rotation	O
rate	O
in	O
the	O
presence	O
of	O
C	B-bacteria
.	I-bacteria
ramosum	I-bacteria
fermentation	O
products	O
.	O

Furthermore	O
,	O
the	O
C	B-bacteria
.	I-bacteria
ramosum	I-bacteria
fermentation	O
products	O
affected	O
synthesis	O
of	O
flagellar	O
filaments	O
.	O

The	O
results	O
were	O
reproduced	O
by	O
a	O
combination	O
of	O
organic	O
acids	O
under	O
acidic	O
conditions	O
.	O

Short	O
-	O
chain	O
fatty	O
acids	O
produced	O
by	O
microbes	O
in	O
the	O
gut	O
flora	O
are	O
beneficial	O
for	O
the	O
host	O
,	O
e	O
.	O
g	O
.	O
they	O
prevent	O
infection	O
.	O

Thus	O
,	O
C	B-bacteria
.	I-bacteria
ramosum	I-bacteria
could	O
affect	O
the	O
physiologies	O
of	O
other	O
enteric	O
microbes	O
and	O
host	O
tissues	O
.	O

Genomic	O
analysis	O
of	O
multidrug	O
-	O
resistant	O
clinical	O
Enterococcus	B-bacteria
faecalis	I-bacteria
isolates	I-bacteria
for	O
antimicrobial	O
resistance	O
genes	O
and	O
virulence	O
factors	O
from	O
the	O
western	O
region	O
of	O
Saudi	O
Arabia	O
.	O

Background	O
:	O
Enterococcus	B-bacteria
faecalis	I-bacteria
is	O
a	O
ubiquitous	O
member	O
of	O
the	O
gut	O
microbiota	O
and	O
has	O
emerged	O
as	O
a	O
life	O
-	O
threatening	O
multidrug	O
-	O
resistant	O
(	O
MDR	O
)	O
nosocomial	O
pathogen	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
survey	O
the	O
prevalence	O
of	O
multidrug	O
-	O
resistant	O
and	O
epidemiologically	O
important	O
strains	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
in	O
the	O
western	O
region	O
of	O
Saudi	O
Arabia	O
using	O
phenotypic	O
and	O
whole	O
genome	O
sequencing	O
approaches	O
.	O

Methods	O
:	O
In	O
total	O
,	O
155	O
patients	O
positive	O
for	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
infection	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
isolates	O
were	O
identified	O
by	O
MALDI	O
-	O
TOF	O
,	O
and	O
screen	O
for	O
antimicrobial	O
resistance	O
using	O
VITEK	O
-	O
2	O
system	O
.	O

Genome	O
sequencing	O
was	O
performed	O
with	O
paired	O
-	O
end	O
strategy	O
using	O
MiSeq	O
platform	O
.	O

Results	O
:	O
Seventeen	O
sequence	O
types	O
(	O
STs	O
)	O
were	O
identified	O
through	O
multilocus	O
sequence	O
typing	O
(	O
MLST	O
)	O
analysis	O
of	O
the	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
genomes	O
,	O
including	O
two	O
novels	O
STs	O
(	O
ST862	B-bacteria
and	O
ST863	B-bacteria
)	O
.	O

The	O
most	O
common	O
STs	O
in	O
the	O
Saudi	O
patients	O
were	O
ST179	B-bacteria
and	O
ST16	B-bacteria
from	O
clonal	O
complex	O
16	O
(	O
CC16	O
)	O
.	O

Around	O
96	O
%	O
(	O
n	O
=	O
149	O
)	O
isolates	O
were	O
MDR	O
.	O

The	O
antibiotics	O
quinupristin	O
/	O
dalfopristin	O
,	O
clindamycin	O
,	O
and	O
erythromycin	O
demonstrated	O
almost	O
no	O
coverage	O
,	O
and	O
high	O
-	O
level	O
streptomycin	O
,	O
gentamycin	O
,	O
and	O
ciprofloxacin	O
demonstrated	O
suboptimal	O
coverage	O
.	O

Low	O
resistance	O
was	O
observed	O
against	O
vancomycin	O
,	O
linezolid	O
,	O
and	O
ampicillin	O
.	O

Moreover	O
,	O
34	O
antimicrobial	O
resistance	O
genes	O
and	O
variants	O
,	O
and	O
three	O
families	O
of	O
insertion	O
sequences	O
were	O
found	O
in	O
the	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
genomes	O
,	O
which	O
likely	O
contributed	O
to	O
the	O
observed	O
antimicrobial	O
resistance	O
.	O

Twenty	O
-	O
two	O
virulence	O
factors	O
,	O
which	O
were	O
mainly	O
associated	O
with	O
biofilm	O
formation	O
,	O
endocarditis	O
,	O
cell	O
adherence	O
,	O
and	O
colonization	O
,	O
were	O
detected	O
in	O
the	O
isolates	O
.	O

Conclusions	O
:	O
Diverse	O
STs	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
,	O
including	O
strains	O
associated	O
with	O
common	O
nosocomial	O
infections	O
are	O
circulating	O
in	O
the	O
healthcare	O
facility	O
of	O
Saudi	O
Arabia	O
and	O
carried	O
multi	O
-	O
drug	O
resistance	O
,	O
which	O
has	O
important	O
implications	O
for	O
infection	O
control	O
.	O

Ability	O
of	O
bifidobacteria	B-bacteria
to	O
metabolize	O
chitin	O
-	O
glucan	O
and	O
its	O
impact	O
on	O
the	O
gut	O
microbiota	O
.	O

Chitin	O
-	O
glucan	O
(	O
CG	O
)	O
represents	O
a	O
natural	O
carbohydrate	O
source	O
for	O
certain	O
microbial	O
inhabitants	O
of	O
the	O
human	O
gut	O
and	O
may	O
act	O
as	O
a	O
prebiotic	O
for	O
a	O
number	O
of	O
bacterial	O
taxa	O
.	O

However	O
,	O
the	O
bifidogenic	O
activity	O
of	O
this	O
substrate	O
is	O
still	O
unknown	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
chitin	O
-	O
glucan	O
to	O
influence	O
growth	O
of	O
100	O
bifidobacterial	B-bacteria
strains	I-bacteria
belonging	O
to	O
those	O
species	O
commonly	O
identified	O
within	O
the	O
bifidobacterial	O
communities	O
residing	O
in	O
the	O
infant	O
and	O
adult	O
human	O
gut	O
.	O

Such	O
analyses	O
were	O
coupled	O
with	O
transcriptome	O
experiments	O
directed	O
to	O
explore	O
the	O
transcriptional	O
effects	O
of	O
CG	O
on	O
Bifidobacterium	B-bacteria
breve	I-bacteria
2L	I-bacteria
,	O
which	O
was	O
shown	O
to	O
elicit	O
the	O
highest	O
growth	O
performance	O
on	O
this	O
natural	O
polysaccharide	O
.	O

In	O
addition	O
,	O
an	O
in	O
vivo	O
trial	O
involving	O
a	O
rat	O
model	O
revealed	O
how	O
the	O
colonization	O
efficiency	O
of	O
this	O
bifidobacterial	B-bacteria
strain	I-bacteria
was	O
enhanced	O
when	O
the	O
animals	O
were	O
fed	O
with	O
a	O
diet	O
containing	O
CG	O
.	O

Altogether	O
our	O
analyses	O
indicate	O
that	O
CG	O
is	O
a	O
valuable	O
novel	O
prebiotic	O
compound	O
that	O
may	O
be	O
added	O
to	O
the	O
human	O
diet	O
in	O
order	O
to	O
re	O
-	O
establish	O
/	O
reinforce	O
bifidobacteria	B-bacteria
colonization	O
in	O
the	O
mammalian	O
gut	O
.	O

Radical	O
-	O
mediated	O
C	O
-	O
S	O
bond	O
cleavage	O
in	O
C2	O
sulfonate	O
degradation	O
by	O
anaerobic	O
bacteria	O
.	O

Bacterial	O
degradation	O
of	O
organosulfonates	O
plays	O
an	O
important	O
role	O
in	O
sulfur	O
recycling	O
,	O
and	O
has	O
been	O
extensively	O
studied	O
.	O

However	O
,	O
this	O
process	O
in	O
anaerobic	O
bacteria	O
especially	O
gut	O
bacteria	O
is	O
little	O
known	O
despite	O
of	O
its	O
potential	O
significant	O
impact	O
on	O
human	O
health	O
with	O
the	O
production	O
of	O
toxic	O
H2S	O
.	O

Here	O
,	O
we	O
describe	O
the	O
structural	O
and	O
biochemical	O
characterization	O
of	O
an	O
oxygen	O
-	O
sensitive	O
enzyme	O
that	O
catalyzes	O
the	O
radical	O
-	O
mediated	O
C	O
-	O
S	O
bond	O
cleavage	O
of	O
isethionate	O
to	O
form	O
sulfite	O
and	O
acetaldehyde	O
.	O

We	O
demonstrate	O
its	O
involvement	O
in	O
pathways	O
that	O
enables	O
C2	O
sulfonates	O
to	O
be	O
used	O
as	O
terminal	O
electron	O
acceptors	O
for	O
anaerobic	O
respiration	O
in	O
sulfate	O
-	O
and	O
sulfite	O
-	O
reducing	O
bacteria	O
.	O

Furthermore	O
,	O
it	O
plays	O
a	O
key	O
role	O
in	O
converting	O
bile	O
salt	O
-	O
derived	O
taurine	O
into	O
H2S	O
in	O
the	O
disease	O
-	O
associated	O
gut	O
bacterium	O
Bilophila	B-bacteria
wadsworthia	I-bacteria
.	O

The	O
enzymes	O
and	O
transporters	O
in	O
these	O
anaerobic	O
pathways	O
expand	O
our	O
understanding	O
of	O
microbial	O
sulfur	O
metabolism	O
,	O
and	O
help	O
deciphering	O
the	O
complex	O
web	O
of	O
microbial	O
pathways	O
involved	O
in	O
the	O
transformation	O
of	O
sulfur	O
compounds	O
in	O
the	O
gut	O
.	O

Antigen	O
-	O
specific	O
CD4	O
(	O
+	O
)	O
T	O
cell	O
-	O
derived	O
IFNgamma	O
is	O
both	O
necessary	O
and	O
sufficient	O
for	O
clearing	O
Chlamydia	O
from	O
the	O
small	O
intestine	O
but	O
not	O
the	O
large	O
intestine	O
.	O

The	O
genital	O
tract	O
pathogen	O
Chlamydia	O
trachomatis	O
is	O
frequently	O
detected	O
in	O
the	O
gastrointestinal	O
tract	O
but	O
the	O
host	O
immunity	O
that	O
regulates	O
chlamydial	O
colonization	O
in	O
the	O
gut	O
remains	O
unclear	O
.	O

In	O
a	O
Chlamydia	O
muridarum	O
-	O
C57	O
mouse	O
model	O
,	O
chlamydial	O
organisms	O
are	O
cleared	O
from	O
the	O
genital	O
tract	O
in	O
approximately	O
4	O
weeks	O
but	O
the	O
genital	O
organisms	O
can	O
spread	O
to	O
the	O
gastrointestinal	O
tract	O
.	O

We	O
found	O
that	O
the	O
gastrointestinal	O
chlamydial	O
organisms	O
were	O
cleared	O
from	O
the	O
small	O
intestine	O
by	O
day	O
28	O
,	O
paralleling	O
their	O
infection	O
course	O
in	O
the	O
genital	O
tract	O
,	O
but	O
persisted	O
in	O
the	O
large	O
intestine	O
for	O
long	O
periods	O
of	O
time	O
.	O

Mice	O
deficient	O
in	O
alpha	O
/	O
beta	O
T	O
cells	O
or	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
but	O
not	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
permitted	O
chlamydial	O
persistence	O
in	O
the	O
small	O
intestine	O
,	O
indicating	O
a	O
critical	O
role	O
of	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
in	O
clearing	O
Chlamydia	O
from	O
the	O
small	O
intestine	O
.	O

The	O
CD4	O
(	O
+	O
)	O
T	O
cell	O
-	O
dependent	O
clearance	O
is	O
likely	O
mediated	O
by	O
IFNgamma	O
since	O
mice	O
deficient	O
in	O
IFNgamma	O
but	O
not	O
IL	O
-	O
22	O
signaling	O
pathways	O
rescued	O
chlamydial	O
colonization	O
in	O
the	O
small	O
intestine	O
.	O

Furthermore	O
,	O
exogenous	O
IFNgamma	O
was	O
sufficient	O
for	O
clearing	O
Chlamydia	O
from	O
the	O
small	O
intestine	O
but	O
not	O
the	O
large	O
intestine	O
.	O

Mice	O
deficient	O
in	O
developing	O
Chlamydia	O
-	O
specific	O
Th1	O
immunity	O
permitted	O
chlamydial	O
persistence	O
in	O
the	O
small	O
intestine	O
.	O

Finally	O
,	O
IFNgamma	O
-	O
producing	O
CD4	O
(	O
+	O
)	O
but	O
not	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
from	O
immunized	O
donor	O
mice	O
were	O
sufficient	O
for	O
eliminating	O
Chlamydia	O
from	O
the	O
small	O
intestine	O
but	O
not	O
the	O
large	O
intestine	O
of	O
recipient	O
mice	O
.	O

Thus	O
,	O
we	O
have	O
demonstrated	O
a	O
critical	O
role	O
of	O
Th1	O
immunity	O
in	O
clearing	O
Chlamydia	O
from	O
the	O
small	O
intestine	O
but	O
not	O
the	O
large	O
intestine	O
,	O
indicating	O
that	O
chlamydial	O
colonization	O
in	O
different	O
regions	O
of	O
the	O
gastrointestinal	O
tract	O
is	O
regulated	O
by	O
distinct	O
immune	O
mechanisms	O
.	O

Meta	O
-	O
transcriptomics	O
reveals	O
a	O
diverse	O
antibiotic	O
resistance	O
gene	O
pool	O
in	O
avian	O
microbiomes	O
.	O

BACKGROUND	O
:	O
Antibiotic	O
resistance	O
is	O
rendering	O
common	O
bacterial	O
infections	O
untreatable	O
.	O

Wildlife	O
can	O
incorporate	O
and	O
disperse	O
antibiotic	O
-	O
resistant	O
bacteria	O
in	O
the	O
environment	O
,	O
such	O
as	O
water	O
systems	O
,	O
which	O
in	O
turn	O
serve	O
as	O
reservoirs	O
of	O
resistance	O
genes	O
for	O
human	O
pathogens	O
.	O

Anthropogenic	O
activity	O
may	O
contribute	O
to	O
the	O
spread	O
of	O
bacterial	O
resistance	O
cycling	O
through	O
natural	O
environments	O
,	O
including	O
through	O
the	O
release	O
of	O
human	O
waste	O
,	O
as	O
sewage	O
treatment	O
only	O
partially	O
removes	O
antibiotic	O
-	O
resistant	O
bacteria	O
.	O

However	O
,	O
empirical	O
data	O
supporting	O
these	O
effects	O
are	O
currently	O
limited	O
.	O

Here	O
we	O
used	O
bulk	O
RNA	O
-	O
sequencing	O
(	O
meta	O
-	O
transcriptomics	O
)	O
to	O
assess	O
the	O
diversity	O
and	O
expression	O
levels	O
of	O
functionally	O
viable	O
resistance	O
genes	O
in	O
the	O
gut	O
microbiome	O
of	O
birds	O
with	O
aquatic	O
habits	O
in	O
diverse	O
locations	O
.	O

RESULTS	O
:	O
We	O
found	O
antibiotic	O
resistance	O
genes	O
in	O
birds	O
from	O
all	O
localities	O
,	O
from	O
penguins	O
in	O
Antarctica	O
to	O
ducks	O
in	O
a	O
wastewater	O
treatment	O
plant	O
in	O
Australia	O
.	O

Comparative	O
analysis	O
revealed	O
that	O
birds	O
feeding	O
at	O
the	O
wastewater	O
treatment	O
plant	O
carried	O
the	O
greatest	O
resistance	O
gene	O
burden	O
,	O
including	O
genes	O
typically	O
associated	O
with	O
multidrug	O
resistance	O
plasmids	O
as	O
the	O
aac	O
(	O
6	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
.	O

Differences	O
in	O
resistance	O
gene	O
burden	O
also	O
reflected	O
aspects	O
of	O
bird	O
ecology	O
,	O
taxonomy	O
,	O
and	O
microbial	O
function	O
.	O

Notably	O
,	O
ducks	O
,	O
which	O
feed	O
by	O
dabbling	O
,	O
carried	O
a	O
higher	O
abundance	O
and	O
diversity	O
of	O
resistance	O
genes	O
than	O
turnstones	O
,	O
avocets	O
,	O
and	O
penguins	O
,	O
which	O
usually	O
prey	O
on	O
more	O
pristine	O
waters	O
.	O

CONCLUSIONS	O
:	O
These	O
transcriptome	O
data	O
suggest	O
that	O
human	O
waste	O
,	O
even	O
if	O
it	O
undergoes	O
treatment	O
,	O
might	O
contribute	O
to	O
the	O
spread	O
of	O
antibiotic	O
resistance	O
genes	O
to	O
the	O
wild	O
.	O

Differences	O
in	O
microbiome	O
functioning	O
across	O
different	O
bird	O
lineages	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
antibiotic	O
resistance	O
burden	O
carried	O
by	O
wild	O
birds	O
.	O

In	O
summary	O
,	O
we	O
reveal	O
the	O
complex	O
factors	O
explaining	O
the	O
distribution	O
of	O
resistance	O
genes	O
and	O
their	O
exchange	O
routes	O
between	O
humans	O
and	O
wildlife	O
,	O
and	O
show	O
that	O
meta	O
-	O
transcriptomics	O
is	O
a	O
valuable	O
tool	O
to	O
access	O
functional	O
resistance	O
genes	O
in	O
whole	O
microbial	O
communities	O
.	O

Biostimulation	O
of	O
in	O
situ	O
microbial	O
degradation	O
processes	O
in	O
organically	O
-	O
enriched	O
sediments	O
mitigates	O
the	O
impact	O
of	O
aquaculture	O
.	O

Fish	O
farm	O
deposition	O
,	O
resulting	O
in	O
organic	O
matter	O
accumulation	O
on	O
bottom	O
sediments	O
,	O
has	O
been	O
identified	O
as	O
among	O
the	O
main	O
phenomena	O
causing	O
negative	O
environmental	O
impacts	O
in	O
aquaculture	O
.	O

An	O
in	O
situ	O
bioremediation	O
treatment	O
was	O
carried	O
out	O
in	O
order	O
to	O
reduce	O
the	O
organic	O
matter	O
accumulation	O
in	O
the	O
fish	O
farm	O
sediments	O
by	O
promoting	O
the	O
natural	O
microbial	O
biodegradation	O
processes	O
.	O

To	O
assess	O
the	O
effect	O
of	O
the	O
treatment	O
,	O
the	O
concentration	O
of	O
organic	O
matter	O
in	O
the	O
sediment	O
and	O
its	O
microbial	O
degradation	O
,	O
as	O
well	O
as	O
the	O
response	O
of	O
the	O
benthic	O
prokaryotic	O
community	O
,	O
were	O
investigated	O
.	O

The	O
results	O
showed	O
a	O
significant	O
effect	O
of	O
the	O
treatment	O
in	O
stimulating	O
microbial	O
degradation	O
rates	O
,	O
and	O
the	O
consequent	O
decrease	O
in	O
the	O
concentration	O
of	O
biochemical	O
components	O
beneath	O
the	O
cages	O
during	O
the	O
treatment	O
.	O

During	O
the	O
bioremediation	O
process	O
,	O
the	O
prokaryotic	O
community	O
in	O
the	O
fish	O
farm	O
sediment	O
responded	O
to	O
the	O
overall	O
improvement	O
of	O
the	O
sediment	O
conditions	O
by	O
showing	O
the	O
decrease	O
of	O
certain	O
anaerobic	O
taxa	O
(	O
e	O
.	O
g	O
.	O
Clostridiales	B-bacteria
,	O
Acidaminobacteraceae	B-bacteria
and	O
Caldilinaceae	B-bacteria
)	O
.	O

This	O
suggested	O
that	O
the	O
bioactivator	O
was	O
effective	O
in	O
promoting	O
a	O
shift	O
from	O
an	O
anaerobic	O
to	O
an	O
aerobic	O
metabolism	O
in	O
the	O
prokaryotic	O
community	O
.	O

However	O
,	O
the	O
larger	O
importance	O
of	O
Lachnospiraceae	B-bacteria
(	O
members	O
of	O
the	O
gut	O
and	O
faecal	O
microbiota	O
of	O
the	O
farmed	O
fishes	O
)	O
in	O
treated	O
compared	O
to	O
non	O
-	O
treated	O
sediments	O
suggested	O
that	O
the	O
bioactivator	O
was	O
not	O
efficient	O
in	O
reducing	O
the	O
accumulation	O
of	O
faecal	O
bacteria	O
from	O
the	O
farmed	O
fishes	O
.	O

Our	O
results	O
indicate	O
that	O
bioremediation	O
is	O
a	O
promising	O
tool	O
to	O
mitigate	O
the	O
aquaculture	O
impact	O
in	O
fish	O
farm	O
sediments	O
,	O
and	O
that	O
further	O
research	O
needs	O
to	O
be	O
oriented	O
to	O
identifying	O
more	O
successful	O
interventions	O
able	O
to	O
specifically	O
target	O
also	O
fish	O
-	O
faeces	O
related	O
microbes	O
.	O

Gut	O
microbiota	O
modulation	O
and	O
anti	O
-	O
inflammatory	O
properties	O
of	O
anthocyanins	O
from	O
the	O
fruits	O
of	O
Lycium	O
ruthenicum	O
Murray	O
in	O
dextran	O
sodium	O
sulfate	O
-	O
induced	O
colitis	O
in	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
therapeutic	O
effects	O
of	O
crude	O
anthocyanins	O
(	O
ACN	O
)	O
from	O
the	O
fruits	O
of	O
Lycium	O
ruthenicum	O
Murray	O
and	O
the	O
main	O
monomer	O
of	O
ACN	O
,	O
petunidin	O
3	O
-	O
O	O
-	O
[	O
rhamnopyranosyl	O
-	O
(	O
trans	O
-	O
p	O
-	O
coumaroyl	O
)	O
]	O
-	O
5	O
-	O
O	O
-	O
[	O
beta	O
-	O
d	O
-	O
glucopyranoside	O
]	O
(	O
P3G	O
)	O
,	O
on	O
the	O
dextran	O
sodium	O
sulfate	O
(	O
DSS	O
)	O
-	O
induced	O
colitis	O
in	O
mice	O
were	O
investigated	O
.	O

Both	O
ACN	O
and	O
P3G	O
showed	O
intestinal	O
anti	O
-	O
inflammatory	O
effects	O
,	O
evidenced	O
by	O
restoration	O
of	O
various	O
physical	O
signs	O
(	O
body	O
weight	O
,	O
feed	O
quantity	O
,	O
solid	O
fecal	O
weight	O
and	O
colon	O
length	O
were	O
increased	O
,	O
and	O
DAI	O
score	O
was	O
decreased	O
)	O
,	O
reduction	O
of	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
and	O
related	O
mRNA	O
(	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
1beta	O
and	O
IFN	O
-	O
gamma	O
)	O
,	O
and	O
promotion	O
of	O
the	O
intestinal	O
barrier	O
function	O
by	O
histological	O
and	O
immunofluorescence	O
analysis	O
(	O
proteins	O
such	O
as	O
ZO	O
-	O
1	O
,	O
occludin	O
and	O
claudin	O
-	O
1	O
were	O
increased	O
)	O
.	O

Furthermore	O
,	O
the	O
effects	O
on	O
gut	O
microbiota	O
community	O
of	O
DSS	O
-	O
induced	O
colitis	O
in	O
mice	O
have	O
been	O
investigated	O
.	O

It	O
was	O
found	O
that	O
Porphyromonadaceae	B-bacteria
,	O
Helicobacter	B-bacteria
,	O
Parasutterella	B-bacteria
,	O
Parabacteroides	B-bacteria
,	O
Oscillibacter	B-bacteria
and	O
Lachnospiraceae	B-bacteria
were	O
the	O
key	O
bacteria	O
associated	O
with	O
inflammatory	O
bowel	O
disease	O
.	O

Taken	O
together	O
,	O
P3G	O
and	O
ACN	O
ameliorated	O
DSS	O
-	O
induced	O
colitis	O
in	O
mice	O
through	O
three	O
aspects	O
including	O
blocking	O
proinflammatory	O
cytokines	O
,	O
increasing	O
tight	O
junction	O
protein	O
and	O
modulating	O
gut	O
microbiota	O
.	O

What	O
'	O
s	O
more	O
,	O
P3G	O
showed	O
better	O
anti	O
-	O
inflammatory	O
effects	O
than	O
ACN	O
.	O

APOE	O
genotype	O
influences	O
the	O
gut	O
microbiome	O
structure	O
and	O
function	O
in	O
humans	O
and	O
mice	O
:	O
relevance	O
for	O
Alzheimer	O
'	O
s	O
disease	O
pathophysiology	O
.	O

Apolipoprotein	O
E	O
(	O
APOE	O
)	O
genotype	O
is	O
the	O
strongest	O
prevalent	O
genetic	O
risk	O
factor	O
for	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

Numerous	O
studies	O
have	O
provided	O
insights	O
into	O
the	O
pathologic	O
mechanisms	O
.	O

However	O
,	O
a	O
comprehensive	O
understanding	O
of	O
the	O
impact	O
of	O
APOE	O
genotype	O
on	O
microflora	O
speciation	O
and	O
metabolism	O
is	O
completely	O
lacking	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
association	O
between	O
APOE	O
genotype	O
and	O
the	O
gut	O
microbiome	O
composition	O
in	O
human	O
and	O
APOE	O
-	O
targeted	O
replacement	O
(	O
TR	O
)	O
transgenic	O
mice	O
.	O

Fecal	O
microbiota	O
amplicon	O
sequencing	O
from	O
matched	O
individuals	O
with	O
different	O
APOE	O
genotypes	O
revealed	O
no	O
significant	O
differences	O
in	O
overall	O
microbiota	O
diversity	O
in	O
group	O
-	O
aggregated	O
human	O
APOE	O
genotypes	O
.	O

However	O
,	O
several	O
bacterial	O
taxa	O
showed	O
significantly	O
different	O
relative	O
abundance	O
between	O
APOE	O
genotypes	O
.	O

Notably	O
,	O
we	O
detected	O
an	O
association	O
of	O
Prevotellaceae	B-bacteria
and	O
Ruminococcaceae	B-bacteria
and	O
several	O
butyrate	O
-	O
producing	O
genera	O
abundances	O
with	O
APOE	O
genotypes	O
.	O

These	O
findings	O
were	O
confirmed	O
by	O
comparing	O
the	O
gut	O
microbiota	O
of	O
APOE	O
-	O
TR	O
mice	O
.	O

Furthermore	O
,	O
metabolomic	O
analysis	O
of	O
murine	O
fecal	O
water	O
detected	O
significant	O
differences	O
in	O
microbe	O
-	O
associated	O
amino	O
acids	O
and	O
short	O
-	O
chain	O
fatty	O
acids	O
between	O
APOE	O
genotypes	O
.	O

Together	O
,	O
these	O
findings	O
indicate	O
that	O
APOE	O
genotype	O
is	O
associated	O
with	O
specific	O
gut	O
microbiome	O
profiles	O
in	O
both	O
humans	O
and	O
APOE	O
-	O
TR	O
mice	O
.	O

This	O
suggests	O
that	O
the	O
gut	O
microbiome	O
is	O
worth	O
further	O
investigation	O
as	O
a	O
potential	O
target	O
to	O
mitigate	O
the	O
deleterious	O
impact	O
of	O
the	O
APOE4	O
allele	O
on	O
cognitive	O
decline	O
and	O
the	O
prevention	O
of	O
AD	O
.	O
-	O
Tran	O
,	O
T	O
.	O
T	O
.	O
T	O
.	O
,	O
Corsini	O
,	O
S	O
.	O
,	O
Kellingray	O
,	O
L	O
.	O
,	O
Hegarty	O
,	O
C	O
.	O
,	O
Le	O
Gall	O
,	O
G	O
.	O
,	O
Narbad	O
,	O
A	O
.	O
,	O
Muller	O
,	O
M	O
.	O
,	O
Tejera	O
,	O
N	O
.	O
,	O
O	O
'	O
Toole	O
,	O
P	O
.	O
W	O
.	O
,	O
Minihane	O
,	O
A	O
.	O
-	O
M	O
.	O
,	O
Vauzour	O
,	O
D	O
.	O
APOE	O
genotype	O
influences	O
the	O
gut	O
microbiome	O
structure	O
and	O
function	O
in	O
humans	O
and	O
mice	O
:	O
relevance	O
for	O
Alzheimer	O
'	O
s	O
disease	O
pathophysiology	O
.	O

FEATURES	O
OF	O
MICROBIOTA	O
IN	O
PSORIATIC	O
DISEASE	O
:	O
FROM	O
SKIN	O
AND	O
GUT	O
PERSPECTIVES	O
(	O
REVIEW	O
)	O
.	O

Psoriatic	O
disease	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
characterized	O
by	O
skin	O
lesions	O
.	O

Psoriasis	O
development	O
has	O
been	O
associated	O
both	O
with	O
genetic	O
and	O
environmental	O
factors	O
.	O

Though	O
skin	O
and	O
gut	O
microbiota	O
has	O
been	O
implicated	O
in	O
number	O
of	O
pathologies	O
including	O
atopic	O
dermatitis	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
Crohn	O
'	O
s	O
disease	O
,	O
allergy	O
,	O
and	O
obesity	O
,	O
its	O
role	O
has	O
been	O
poorly	O
studied	O
in	O
psoriatic	O
disease	O
,	O
which	O
incorporates	O
both	O
psoriasis	O
and	O
psoriatic	O
arthritis	O
.	O

This	O
literature	O
review	O
summarizes	O
the	O
most	O
recent	O
and	O
major	O
findings	O
on	O
microbiota	O
features	O
in	O
psoriatic	O
disease	O
.	O

Despite	O
conflicting	O
findings	O
,	O
psoriasis	O
patients	O
were	O
frequently	O
found	O
to	O
have	O
distinct	O
microbial	O
composition	O
in	O
both	O
skin	O
and	O
guts	O
especially	O
in	O
the	O
major	O
bacterial	O
phyla	O
,	O
Firmicutes	B-bacteria
,	O
Bacteroidetes	B-bacteria
,	O
and	O
genus	O
Akkermansia	B-bacteria
.	O

Furthermore	O
,	O
bacterial	O
DNA	O
has	O
been	O
found	O
in	O
psoriatic	O
patients	O
both	O
locally	O
and	O
systemically	O
,	O
and	O
altogether	O
suggesting	O
a	O
crucial	O
role	O
of	O
bacteria	O
in	O
psoriatic	O
disease	O
and	O
future	O
studies	O
in	O
this	O
field	O
.	O

Decoding	O
the	O
Fatty	O
Acid	O
Profile	O
of	O
Bacillus	B-bacteria
licheniformis	I-bacteria
I89	I-bacteria
and	O
Its	O
Adaptation	O
to	O
Different	O
Growth	O
Conditions	O
to	O
Investigate	O
Possible	O
Biotechnological	O
Applications	O
.	O

Bacillus	B-bacteria
licheniformis	I-bacteria
I89	I-bacteria
is	O
a	O
Gram	O
-	O
positive	O
bacterium	O
,	O
a	O
producer	O
of	O
the	O
lantibiotic	O
lichenicidin	O
.	O

No	O
information	O
is	O
available	O
on	O
its	O
fatty	O
acid	O
(	O
FA	O
)	O
composition	O
.	O

Bacillus	B-bacteria
species	I-bacteria
are	O
rich	O
in	O
branched	O
FA	O
(	O
BrFA	O
)	O
,	O
claimed	O
to	O
be	O
beneficial	O
to	O
human	O
health	O
and	O
to	O
treat	O
diseases	O
.	O

Herein	O
,	O
the	O
FA	O
profile	O
of	O
B	B-bacteria
.	I-bacteria
licheniformis	I-bacteria
I89	I-bacteria
was	O
evaluated	O
under	O
different	O
growth	O
conditions	O
:	O
at	O
two	O
growth	O
temperatures	O
(	O
37	O
and	O
50	O
degrees	O
C	O
)	O
and	O
at	O
different	O
growth	O
phases	O
(	O
lag	O
,	O
exponential	O
,	O
and	O
stationary	O
)	O
,	O
using	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

The	O
FA	O
profile	O
revealed	O
predominant	O
BrFA	O
of	O
the	O
iso	O
-	O
series	O
and	O
anteiso	O
-	O
series	O
(	O
i	O
-	O
15	O
:	O
0	O
,	O
ai	O
-	O
15	O
:	O
0	O
,	O
i	O
-	O
16	O
:	O
0	O
,	O
i	O
-	O
17	O
:	O
0	O
,	O
and	O
ai	O
-	O
17	O
:	O
0	O
)	O
and	O
low	O
amounts	O
of	O
saturated	O
FA	O
(	O
14	O
:	O
0	O
,	O
16	O
:	O
0	O
,	O
and	O
18	O
:	O
0	O
)	O
.	O

Comparing	O
the	O
FA	O
profiles	O
at	O
different	O
temperatures	O
,	O
in	O
the	O
lag	O
phase	O
,	O
at	O
50	O
degrees	O
C	O
,	O
there	O
was	O
a	O
decrease	O
of	O
ai	O
-	O
17	O
:	O
0	O
and	O
a	O
decrease	O
of	O
i	O
-	O
15	O
:	O
0	O
in	O
the	O
exponential	O
phase	O
,	O
in	O
comparison	O
with	O
37	O
degrees	O
C	O
.	O
In	O
all	O
growth	O
phases	O
,	O
there	O
was	O
a	O
decrease	O
of	O
ai	O
-	O
15	O
:	O
0	O
and	O
an	O
increase	O
of	O
i	O
-	O
17	O
:	O
0	O
.	O

From	O
the	O
lag	O
to	O
the	O
stationary	O
phase	O
,	O
at	O
50	O
degrees	O
C	O
,	O
there	O
was	O
a	O
decrease	O
of	O
ai	O
-	O
17	O
:	O
0	O
and	O
i	O
-	O
16	O
:	O
0	O
,	O
whereas	O
i	O
-	O
15	O
:	O
0	O
increased	O
,	O
while	O
at	O
37	O
degrees	O
C	O
,	O
there	O
was	O
an	O
increase	O
of	O
i	O
-	O
15	O
:	O
0	O
and	O
i	O
-	O
16	O
:	O
0	O
,	O
and	O
a	O
decrease	O
in	O
ai	O
-	O
15	O
:	O
0	O
and	O
ai	O
-	O
17	O
:	O
0	O
.	O

B	B-bacteria
.	I-bacteria
licheniformis	I-bacteria
I89	I-bacteria
can	O
adapt	O
its	O
FA	O
profile	O
,	O
at	O
moderate	O
temperatures	O
,	O
by	O
changing	O
the	O
iso	O
-	O
FA	O
and	O
anteiso	O
-	O
FA	O
composition	O
and	O
the	O
iso	O
/	O
anteiso	O
ratio	O
.	O

This	O
nonpathogenic	O
bacterium	O
species	O
can	O
be	O
used	O
as	O
a	O
source	O
of	O
BrFA	O
with	O
putative	O
beneficial	O
health	O
effects	O
for	O
gut	O
protection	O
and	O
with	O
reported	O
antitumor	O
properties	O
,	O
foreseeing	O
its	O
use	O
for	O
producing	O
compounds	O
with	O
biotechnological	O
applications	O
.	O

Gut	O
microbiota	O
in	O
obstructive	O
sleep	O
apnea	O
-	O
hypopnea	O
syndrome	O
:	O
disease	O
-	O
related	O
dysbiosis	O
and	O
metabolic	O
comorbidities	O
.	O

Gut	O
microbiota	O
alterations	O
manifest	O
as	O
intermittent	O
hypoxia	O
and	O
fragmented	O
sleep	O
,	O
thereby	O
mimicking	O
obstructive	O
sleep	O
apnea	O
-	O
hypopnea	O
syndrome	O
(	O
OSAHS	O
)	O
.	O

Here	O
,	O
we	O
sought	O
to	O
perform	O
the	O
first	O
direct	O
survey	O
of	O
gut	O
microbial	O
dysbiosis	O
over	O
a	O
range	O
of	O
apnea	O
-	O
hypopnea	O
indices	O
(	O
AHI	O
)	O
among	O
patients	O
with	O
OSAHS	O
.	O

We	O
obtained	O
fecal	O
samples	O
from	O
93	O
patients	O
with	O
OSAHS	O
[	O
5	O
<	O
AHI	O
<	O
/	O
=	O
15	O
(	O
n	O
=	O
40	O
)	O
,	O
15	O
<	O
AHI	O
<	O
/	O
=	O
30	O
(	O
n	O
=	O
23	O
)	O
,	O
and	O
AHI	O
>	O
/	O
=	O
30	O
(	O
n	O
=	O
30	O
)	O
]	O
and	O
20	O
controls	O
(	O
AHI	O
<	O
/	O
=	O
5	O
)	O
and	O
determined	O
the	O
microbiome	O
composition	O
via	O
16S	O
rRNA	O
pyrosequencing	O
and	O
bioinformatics	O
analysis	O
of	O
variable	O
regions	O
3	O
-	O
4	O
.	O

We	O
measured	O
fasting	O
levels	O
of	O
homocysteine	O
(	O
HCY	O
)	O
,	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
,	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

Results	O
revealed	O
gut	O
microbial	O
dysbiosis	O
in	O
several	O
patients	O
with	O
varying	O
severities	O
of	O
OSAHS	O
,	O
reliably	O
separating	O
them	O
from	O
controls	O
with	O
a	O
receiver	O
operating	O
characteristic	O
-	O
area	O
under	O
the	O
curve	O
(	O
ROC	O
-	O
AUC	O
)	O
of	O
0	O
.	O
789	O
.	O

Functional	O
analysis	O
in	O
the	O
microbiomes	O
of	O
patients	O
revealed	O
alterations	O
;	O
additionally	O
,	O
decreased	O
in	O
short	O
-	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
-	O
producing	O
bacteria	O
and	O
increased	O
pathogens	O
,	O
accompanied	O
by	O
elevated	O
levels	O
of	O
IL	O
-	O
6	O
.	O

Lactobacillus	B-bacteria
levels	O
correlated	O
with	O
HCY	O
levels	O
.	O

Stratification	O
analysis	O
revealed	O
that	O
the	O
Ruminococcus	B-bacteria
enterotype	I-bacteria
posed	O
the	O
highest	O
risk	O
for	O
patients	O
with	O
OSAHS	O
.	O

Our	O
results	O
show	O
that	O
the	O
presence	O
of	O
an	O
altered	O
microbiome	O
is	O
associated	O
with	O
HCY	O
among	O
OSAHS	O
patients	O
.	O

These	O
changes	O
in	O
the	O
levels	O
of	O
SCFA	O
affect	O
the	O
levels	O
of	O
pathogens	O
that	O
play	O
a	O
pathophysiological	O
role	O
in	O
OSAHS	O
and	O
related	O
metabolic	O
comorbidities	O
.	O

Lactobacillus	B-bacteria
fermentum	I-bacteria
and	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
increased	O
gut	O
microbiota	O
diversity	O
and	O
functionality	O
,	O
and	O
mitigated	O
Enterobacteriaceae	B-bacteria
,	O
in	O
a	O
mouse	O
model	O
.	O

Probiotics	O
should	O
bring	O
'	O
balance	O
'	O
to	O
the	O
intestinal	O
microbiota	O
by	O
stimulating	O
beneficial	O
bacteria	O
,	O
whilst	O
mitigating	O
adverse	O
ones	O
.	O

Balance	O
can	O
also	O
be	O
interpreted	O
as	O
high	O
alpha	O
-	O
diversity	O
.	O

Contrary	O
,	O
Escherichia	B-bacteria
coli	I-bacteria
is	O
often	O
regarded	O
as	O
an	O
adverse	O
component	O
of	O
the	O
resident	O
intestinal	O
microbiota	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
implement	O
a	O
mouse	O
model	O
for	O
in	O
vivo	O
screening	O
of	O
Lactobacillus	B-bacteria
-	I-bacteria
strains	I-bacteria
for	O
ability	O
to	O
increase	O
gut	O
-	O
microbiota	O
diversity	O
and	O
to	O
mitigate	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
.	O

Mice	O
were	O
divided	O
into	O
six	O
groups	O
,	O
two	O
dietary	O
control	O
-	O
groups	O
and	O
four	O
groups	O
administered	O
strains	O
of	O
Lactobacillus	B-bacteria
fermentum	I-bacteria
and	O
/	O
or	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
.	O

All	O
animals	O
were	O
pre	O
-	O
treated	O
with	O
antibiotics	O
,	O
and	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
in	O
order	O
to	O
equalise	O
the	O
microbiota	O
from	O
the	O
start	O
.	O

After	O
7	O
weeks	O
of	O
Lactobacillus	B-bacteria
administration	O
,	O
the	O
animals	O
were	O
sacrificed	O
:	O
DNA	O
was	O
extracted	O
from	O
caecum	O
tissue	O
,	O
and	O
the	O
microbiota	O
composition	O
was	O
analysed	O
with	O
terminal	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
T	O
-	O
RFLP	O
)	O
and	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

The	O
diversity	O
of	O
the	O
caecal	O
microbiota	O
decreased	O
when	O
the	O
dietary	O
carbohydrate	O
source	O
was	O
limited	O
to	O
corn	O
starch	O
.	O

Conversely	O
,	O
the	O
diversity	O
was	O
restored	O
by	O
Lactobacillus	O
-	O
supplements	O
.	O

The	O
tested	O
combinations	O
of	O
two	O
Lactobacillus	B-bacteria
strains	I-bacteria
exerted	O
different	O
influences	O
,	O
not	O
only	O
on	O
the	O
taxonomic	O
level	O
,	O
but	O
also	O
on	O
the	O
inferred	O
microbiome	O
functions	O
.	O

The	O
mixture	O
of	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
GOS47	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
GOS1	I-bacteria
showed	O
potential	O
for	O
anti	O
-	O
inflammatory	O
activity	O
and	O
short	O
chain	O
fatty	O
acid	O
production	O
.	O

On	O
the	O
other	O
hand	O
,	O
co	O
-	O
administration	O
of	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
GOS57	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
GOS42	I-bacteria
significantly	O
decreased	O
the	O
viable	O
count	O
of	O
Enterobacteriaceae	B-bacteria
.	O

These	O
results	O
warrant	O
further	O
investigation	O
of	O
the	O
tested	O
strains	O
as	O
candidates	O
for	O
probiotics	O
.	O

Furthermore	O
,	O
the	O
findings	O
demonstrated	O
that	O
the	O
current	O
experimental	O
animal	O
model	O
is	O
suitable	O
for	O
in	O
vivo	O
studies	O
of	O
the	O
effect	O
of	O
bacterial	O
supplements	O
on	O
the	O
gut	O
-	O
microbiota	O
.	O

Antibody	O
-	O
mediated	O
crosslinking	O
of	O
gut	O
bacteria	O
hinders	O
the	O
spread	O
of	O
antibiotic	O
resistance	O
.	O

The	O
body	O
is	O
home	O
to	O
a	O
diverse	O
microbiota	O
,	O
mainly	O
in	O
the	O
gut	O
.	O

Resistant	O
bacteria	O
are	O
selected	O
by	O
antibiotic	O
treatments	O
,	O
and	O
once	O
resistance	O
becomes	O
widespread	O
in	O
a	O
population	O
of	O
hosts	O
,	O
antibiotics	O
become	O
useless	O
.	O

Here	O
,	O
we	O
develop	O
a	O
multiscale	O
model	O
of	O
the	O
interaction	O
between	O
antibiotic	O
use	O
and	O
resistance	O
spread	O
in	O
a	O
host	O
population	O
,	O
focusing	O
on	O
an	O
important	O
aspect	O
of	O
within	O
-	O
host	O
immunity	O
.	O

Antibodies	O
secreted	O
in	O
the	O
gut	O
enchain	O
bacteria	O
upon	O
division	O
,	O
yielding	O
clonal	O
clusters	O
of	O
bacteria	O
.	O

We	O
demonstrate	O
that	O
immunity	O
-	O
driven	O
bacteria	O
clustering	O
can	O
hinder	O
the	O
spread	O
of	O
a	O
novel	O
resistant	O
bacterial	O
strain	O
in	O
a	O
host	O
population	O
.	O

We	O
quantify	O
this	O
effect	O
both	O
in	O
the	O
case	O
where	O
resistance	O
preexists	O
and	O
in	O
the	O
case	O
where	O
acquiring	O
a	O
new	O
resistance	O
mutation	O
is	O
necessary	O
for	O
the	O
bacteria	O
to	O
spread	O
.	O

We	O
further	O
show	O
that	O
the	O
reduction	O
of	O
spread	O
by	O
clustering	O
can	O
be	O
countered	O
when	O
immune	O
hosts	O
are	O
silent	O
carriers	O
,	O
and	O
are	O
less	O
likely	O
to	O
get	O
treated	O
,	O
and	O
/	O
or	O
have	O
more	O
contacts	O
.	O

We	O
demonstrate	O
the	O
robustness	O
of	O
our	O
findings	O
to	O
including	O
stochastic	O
within	O
-	O
host	O
bacterial	O
growth	O
,	O
a	O
fitness	O
cost	O
of	O
resistance	O
,	O
and	O
its	O
compensation	O
.	O

Our	O
results	O
highlight	O
the	O
importance	O
of	O
interactions	O
between	O
immunity	O
and	O
the	O
spread	O
of	O
antibiotic	O
resistance	O
,	O
and	O
argue	O
in	O
the	O
favor	O
of	O
vaccine	O
-	O
based	O
strategies	O
to	O
combat	O
antibiotic	O
resistance	O
.	O

Oral	O
LPS	O
Dosing	O
Induces	O
Local	O
Immunological	O
Changes	O
in	O
the	O
Pancreatic	O
Lymph	O
Nodes	O
in	O
Mice	O
.	O

Lacking	O
the	O
initial	O
contact	O
between	O
the	O
immune	O
system	O
and	O
microbial	O
-	O
associated	O
molecular	O
patterns	O
(	O
MAMPs	O
)	O
,	O
such	O
as	O
lipopolysaccharides	O
(	O
LPS	O
)	O
,	O
early	O
in	O
life	O
,	O
may	O
be	O
regarded	O
as	O
one	O
of	O
the	O
causal	O
factors	O
of	O
the	O
increasing	O
global	O
increase	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
,	O
such	O
as	O
type	O
1	O
diabetes	O
(	O
T1D	O
)	O
.	O

Previously	O
,	O
a	O
reduced	O
incidence	O
of	O
T1D	O
accompanied	O
by	O
dramatically	O
increased	O
abundances	O
of	O
both	O
the	O
mucin	O
-	O
metabolising	O
bacterium	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
,	O
and	O
LPS	O
-	O
carrying	O
Proteobacteria	B-bacteria
was	O
observed	O
,	O
when	O
vancomycin	O
was	O
given	O
to	O
pups	O
of	O
nonobese	O
diabetic	O
(	O
NOD	O
)	O
mice	O
.	O

While	O
the	O
T1D	O
incidence	O
reducing	O
effect	O
of	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
has	O
been	O
shown	O
in	O
further	O
studies	O
,	O
little	O
is	O
known	O
as	O
to	O
whether	O
the	O
increased	O
abundance	O
of	O
LPS	O
-	O
carrying	O
bacteria	O
also	O
has	O
a	O
protective	O
effect	O
.	O

Therefore	O
,	O
we	O
fed	O
NOD	O
pups	O
with	O
Eschericia	B-bacteria
coli	I-bacteria
LPS	O
orally	O
from	O
birth	O
to	O
weaning	O
,	O
which	O
decreased	O
the	O
gene	O
expressions	O
of	O
TNFalpha	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
6	O
,	O
IFNgamma	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
4	O
,	O
and	O
FoxP3	O
in	O
the	O
pancreatic	O
lymph	O
nodes	O
,	O
while	O
the	O
same	O
gene	O
expression	O
profile	O
in	O
the	O
spleen	O
was	O
unaffected	O
.	O

However	O
,	O
no	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
T1D	O
,	O
gut	O
microbiota	O
composition	O
,	O
or	O
ileum	O
expression	O
of	O
the	O
genetic	O
markers	O
of	O
gut	O
permeability	O
,	O
Claudin8	O
,	O
Occludin	O
,	O
Zonulin	O
-	O
1	O
(	O
Tjp1	O
)	O
,	O
Claudin15	O
,	O
Muc1	O
,	O
and	O
Muc2	O
were	O
observed	O
in	O
relation	O
to	O
LPS	O
ingestion	O
.	O

It	O
is	O
,	O
therefore	O
,	O
concluded	O
that	O
early	O
life	O
oral	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
LPS	O
has	O
an	O
impact	O
on	O
the	O
local	O
immune	O
response	O
,	O
which	O
,	O
however	O
,	O
did	O
not	O
influence	O
T1D	O
incidence	O
in	O
NOD	O
mice	O
later	O
in	O
life	O
.	O

Response	O
to	O
:	O
'	O
Circulating	O
microbiome	O
in	O
blood	O
of	O
different	O
circulatory	O
compartments	O
'	O
by	O
Schierwagen	O
et	O
al	O
.	O

Regulation	O
of	O
immune	O
and	O
tissue	O
homeostasis	O
by	O
Drosophila	O
POU	O
factors	O
.	O

The	O
innate	O
immune	O
system	O
of	O
insects	O
deploys	O
both	O
cellular	O
and	O
humoral	O
reactions	O
in	O
immunocompetent	O
tissues	O
for	O
protection	O
of	O
insects	O
against	O
a	O
variety	O
of	O
infections	O
,	O
including	O
bacteria	O
,	O
fungi	O
,	O
and	O
viruses	O
.	O

Transcriptional	O
regulation	O
of	O
genes	O
encoding	O
antimicrobial	O
peptides	O
(	O
AMPs	O
)	O
,	O
cytokines	O
,	O
and	O
other	O
immune	O
effectors	O
plays	O
a	O
pivotal	O
role	O
in	O
maintenance	O
of	O
immune	O
homeostasis	O
both	O
prior	O
to	O
and	O
after	O
infections	O
.	O

The	O
POU	O
/	O
Oct	O
transcription	O
factor	O
family	O
is	O
a	O
subclass	O
of	O
the	O
homeodomain	O
proteins	O
present	O
in	O
all	O
metazoans	O
.	O

POU	O
factors	O
are	O
involved	O
in	O
regulation	O
of	O
development	O
,	O
metabolism	O
and	O
immunity	O
.	O

Their	O
role	O
in	O
regulation	O
of	O
immune	O
functions	O
has	O
recently	O
become	O
evident	O
,	O
and	O
involves	O
control	O
of	O
tissue	O
-	O
specific	O
,	O
constitutive	O
expression	O
of	O
immune	O
effectors	O
in	O
barrier	O
epithelia	O
as	O
well	O
as	O
positive	O
and	O
negative	O
control	O
of	O
immune	O
responses	O
in	O
gut	O
and	O
fat	O
body	O
.	O

In	O
addition	O
,	O
they	O
have	O
been	O
shown	O
to	O
affect	O
the	O
composition	O
of	O
gut	O
microbiota	O
and	O
play	O
a	O
role	O
in	O
regulation	O
of	O
intestinal	O
stem	O
cell	O
activities	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
knowledge	O
of	O
how	O
POU	O
transcription	O
factors	O
control	O
Drosophila	O
immune	O
homeostasis	O
in	O
healthy	O
and	O
infected	O
insects	O
.	O

The	O
role	O
of	O
POU	O
factor	O
isoform	O
specific	O
regulation	O
of	O
stem	O
cell	O
activities	O
in	O
Drosophila	O
and	O
mammals	O
is	O
also	O
discussed	O
.	O

Absence	O
of	O
gut	O
microbiota	O
during	O
early	O
life	O
affects	O
anxiolytic	O
Behaviors	O
and	O
monoamine	O
neurotransmitters	O
system	O
in	O
the	O
hippocampal	O
of	O
mice	O
.	O

The	O
gut	O
microbiome	O
is	O
composed	O
of	O
an	O
enormous	O
number	O
of	O
microorganisms	O
,	O
generally	O
regarded	O
as	O
commensal	O
bacteria	O
.	O

Resident	O
gut	O
bacteria	O
are	O
an	O
important	O
contributor	O
to	O
health	O
and	O
significant	O
evidence	O
suggests	O
that	O
the	O
presence	O
of	O
healthy	O
and	O
diverse	O
gut	O
microbiota	O
is	O
important	O
for	O
normal	O
cognitive	O
and	O
emotional	O
processing	O
.	O

Here	O
we	O
measured	O
the	O
expression	O
of	O
monoamine	O
neurotransmitter	O
-	O
related	O
genes	O
in	O
the	O
hippocampus	O
of	O
germ	O
-	O
free	O
(	O
GF	O
)	O
mice	O
and	O
specific	O
-	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
mice	O
to	O
explore	O
the	O
effect	O
of	O
gut	O
microbiota	O
on	O
hippocampal	O
monoamine	O
functioning	O
.	O

In	O
total	O
,	O
19	O
differential	O
expressed	O
genes	O
(	O
Htr7	O
,	O
Htr1f	O
,	O
Htr3b	O
,	O
Drd3	O
,	O
Ddc	O
,	O
Maob	O
,	O
Tdo2	O
,	O
Fos	O
,	O
Creb1	O
,	O
Akt1	O
,	O
Gsk3a	O
,	O
Pik3ca	O
,	O
Pla2g5	O
,	O
Cyp2d22	O
,	O
Grk6	O
,	O
Ephb1	O
,	O
Slc18a1	O
,	O
Nr4a1	O
,	O
Gdnf	O
)	O
that	O
could	O
discriminate	O
between	O
the	O
two	O
groups	O
were	O
identified	O
.	O

Interestingly	O
,	O
GF	O
mice	O
displayed	O
anxiolytic	O
-	O
like	O
behavior	O
compared	O
to	O
SPF	O
mice	O
,	O
which	O
were	O
not	O
reversed	O
by	O
colonization	O
with	O
gut	O
microbiota	O
from	O
SPF	O
mice	O
.	O

Besides	O
,	O
colonization	O
of	O
adolescent	O
GF	O
mice	O
by	O
gut	O
microbiota	O
was	O
not	O
sufficient	O
to	O
reverse	O
the	O
altered	O
gene	O
expression	O
associated	O
with	O
their	O
GF	O
status	O
.	O

Taking	O
these	O
findings	O
together	O
,	O
the	O
absence	O
of	O
commensal	O
microbiota	O
during	O
early	O
life	O
markedly	O
affects	O
hippocampal	O
monoamine	O
gene	O
-	O
regulation	O
,	O
which	O
was	O
associated	O
with	O
anxiolytic	O
behaviors	O
and	O
monoamine	O
neurological	O
signs	O
.	O

Edgeworthia	O
gardneri	O
(	O
Wall	O
.	O
)	O
Meisn	O
.	O
water	O
extract	O
improves	O
diabetes	O
and	O
modulates	O
gut	O
microbiota	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
In	O
Chinese	O
folk	O
medicine	O
,	O
the	O
flower	O
of	O
Edgeworthia	O
gardneri	O
(	O
Wall	O
.	O
)	O
Meisn	O
.	O
is	O
used	O
to	O
treat	O
various	O
metabolic	O
diseases	O
,	O
such	O
as	O
hyperglycemia	O
,	O
hypertension	O
,	O
and	O
hyperlipidemia	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
This	O
study	O
aimed	O
to	O
explore	O
the	O
antidiabetes	O
potential	O
of	O
the	O
flower	O
of	O
E	O
.	O
gardneri	O
and	O
investigate	O
whether	O
it	O
can	O
benefit	O
the	O
entire	O
gut	O
bacteria	O
community	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Chemical	O
constituents	O
of	O
the	O
extract	O
were	O
analyzed	O
by	O
UHPLC	O
-	O
Q	O
Exactive	O
Mass	O
Spectrometer	O
(	O
UHPLC	O
-	O
QE	O
-	O
MS	O
)	O
.	O

The	O
antidiabetes	O
effect	O
of	O
the	O
water	O
extract	O
(	O
WAE	O
)	O
of	O
the	O
flower	O
of	O
E	O
.	O
gardneri	O
was	O
evaluated	O
in	O
diabetic	O
mice	O
induced	O
by	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
and	O
streptozotocin	O
(	O
STZ	O
)	O
(	O
six	O
groups	O
,	O
n	O
=	O
8	O
)	O
daily	O
at	O
doses	O
of	O
1	O
,	O
2	O
,	O
and	O
3g	O
/	O
kg	O
for	O
4	O
weeks	O
.	O

The	O
gut	O
microbiota	O
was	O
analyzed	O
using	O
high	O
-	O
throughput	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

Short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
in	O
the	O
fecal	O
were	O
also	O
investigated	O
.	O

RESULTS	O
:	O
UHPLC	O
-	O
QE	O
-	O
MS	O
analysis	O
identified	O
29	O
compounds	O
,	O
including	O
five	O
alkaloids	O
,	O
six	O
coumarins	O
,	O
four	O
flavonoids	O
,	O
11	O
organic	O
acids	O
,	O
and	O
three	O
additional	O
compounds	O
,	O
in	O
the	O
WAE	O
.	O

Results	O
showed	O
that	O
the	O
high	O
dose	O
of	O
WAE	O
considerably	O
decreased	O
the	O
blood	O
glucose	O
level	O
by	O
30	O
.	O
0	O
%	O
.	O

Furthermore	O
,	O
E	B-bacteria
.	I-bacteria
gardneri	I-bacteria
significantly	O
ameliorated	O
insulin	O
resistance	O
and	O
lipid	O
metabolism	O
dysfunction	O
and	O
repaired	O
islet	O
,	O
hepatic	O
,	O
and	O
white	O
fat	O
and	O
colon	O
histology	O
in	O
diabetic	O
mice	O
.	O

Diabetic	O
mice	O
treated	O
with	O
WAE	O
showed	O
apparent	O
changes	O
in	O
the	O
structure	O
and	O
composition	O
of	O
the	O
gut	O
microbiota	O
.	O

WAE	O
reversed	O
the	O
changes	O
in	O
Clostridiales	B-bacteria
,	O
Lachnospiraceae	B-bacteria
,	O
S24	B-bacteria
-	I-bacteria
7	I-bacteria
,	O
Rikenellaceae	B-bacteria
,	O
and	O
Dorea	B-bacteria
in	O
diabetic	O
mice	O
.	O

The	O
correlation	O
analysis	O
indicated	O
that	O
key	O
OTUs	O
were	O
related	O
to	O
diabetes	O
indices	O
.	O

The	O
amounts	O
of	O
SCFAs	O
,	O
including	O
acetic	O
,	O
propionic	O
,	O
and	O
valeric	O
acids	O
,	O
were	O
significantly	O
high	O
in	O
WAE	O
-	O
treated	O
diabetic	O
groups	O
.	O

CONCLUSIONS	O
:	O
E	B-bacteria
.	I-bacteria
gardneri	I-bacteria
treatment	O
improved	O
the	O
glucose	O
metabolism	O
and	O
reshaped	O
the	O
unbalanced	O
gut	O
microbiota	O
of	O
diabetic	O
mice	O
.	O

Our	O
study	O
provides	O
evidence	O
for	O
application	O
of	O
E	B-bacteria
.	I-bacteria
gardneri	I-bacteria
to	O
treatment	O
of	O
diabetes	O
mellitus	O
.	O

Characteristics	O
of	O
regulatory	O
T	O
-	O
cell	O
populations	O
before	O
and	O
after	O
Ty21a	O
typhoid	O
vaccination	O
in	O
children	O
and	O
adults	O
.	O

Typhoid	O
fever	O
,	O
caused	O
by	O
the	O
pathogen	O
Salmonella	B-bacteria
enterica	I-bacteria
serovar	I-bacteria
Typhi	I-bacteria
(	O
S	B-bacteria
.	I-bacteria
Typhi	I-bacteria
)	O
,	O
is	O
a	O
serious	O
global	O
health	O
concern	O
.	O

Challenge	O
studies	O
with	O
wild	O
type	O
S	B-bacteria
.	I-bacteria
Typhi	I-bacteria
identified	O
associations	O
between	O
gut	O
-	O
homing	O
regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
and	O
development	O
of	O
typhoid	O
disease	O
.	O

Whether	O
oral	O
live	O
-	O
attenuated	O
Ty21a	O
vaccination	O
induces	O
gut	O
-	O
homing	O
Treg	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
analyze	O
pediatric	O
and	O
adult	O
Treg	O
pre	O
-	O
and	O
post	O
-	O
Ty21a	O
vaccination	O
in	O
an	O
autologous	O
S	O
.	O
Typhi	O
-	O
antigen	O
presentation	O
model	O
to	O
address	O
this	O
knowledge	O
gap	O
.	O

We	O
show	O
that	O
peripheral	O
memory	O
Treg	O
populations	O
change	O
from	O
childhood	O
to	O
adulthood	O
,	O
but	O
not	O
following	O
Ty21a	O
vaccination	O
.	O

Unsupervised	O
dimensionality	O
reduction	O
with	O
t	O
-	O
distributed	O
stochastic	O
neighbor	O
embedding	O
(	O
tSNE	O
)	O
identifies	O
homing	O
,	O
memory	O
,	O
and	O
functional	O
features	O
which	O
evidence	O
age	O
-	O
associated	O
maturation	O
of	O
multifunctional	O
S	O
.	O
Typhi	O
-	O
responsive	O
Treg	O
,	O
which	O
were	O
not	O
impacted	O
by	O
Ty21a	O
vaccination	O
.	O

These	O
findings	O
improve	O
understanding	O
of	O
pediatric	O
regulatory	O
T	O
cells	O
,	O
while	O
identifying	O
age	O
-	O
related	O
differences	O
in	O
S	O
.	O
Typhi	O
-	O
responsive	O
Treg	O
,	O
which	O
may	O
aid	O
in	O
the	O
development	O
of	O
improved	O
pediatric	O
vaccination	O
strategies	O
against	O
S	B-bacteria
.	I-bacteria
Typhi	I-bacteria
.	O

Altered	O
gut	O
microbiota	O
and	O
endocannabinoid	O
system	O
tone	O
in	O
vitamin	O
D	O
deficiency	O
-	O
mediated	O
chronic	O
pain	O
.	O

Recent	O
evidence	O
points	O
to	O
the	O
gut	O
microbiota	O
as	O
a	O
regulator	O
of	O
brain	O
and	O
behavior	O
,	O
although	O
it	O
remains	O
to	O
be	O
determined	O
if	O
gut	O
bacteria	O
play	O
a	O
role	O
in	O
chronic	O
pain	O
.	O

The	O
endocannabinoid	O
system	O
is	O
implicated	O
in	O
inflammation	O
and	O
chronic	O
pain	O
processing	O
at	O
both	O
the	O
gut	O
and	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
levels	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
low	O
Vitamin	O
D	O
dietary	O
intake	O
in	O
mice	O
and	O
evaluated	O
possible	O
changes	O
in	O
gut	O
microbiota	O
,	O
pain	O
processing	O
and	O
endocannabinoid	O
system	O
signaling	O
.	O

Vitamin	O
D	O
deficiency	O
induced	O
a	O
lower	O
microbial	O
diversity	O
characterized	O
by	O
an	O
increase	O
in	O
Firmicutes	B-bacteria
and	O
a	O
decrease	O
in	O
Verrucomicrobia	B-bacteria
and	O
Bacteroidetes	B-bacteria
.	O

Concurrently	O
,	O
vitamin	O
D	O
deficient	O
mice	O
showed	O
tactile	O
allodynia	O
associated	O
with	O
neuronal	O
hyperexcitability	O
and	O
alterations	O
of	O
endocannabinoid	O
system	O
members	O
(	O
endogenous	O
mediators	O
and	O
their	O
receptors	O
)	O
at	O
the	O
spinal	O
cord	O
level	O
.	O

Changes	O
in	O
endocannabinoid	O
(	O
anandamide	O
and	O
2	O
-	O
arachidonoylglycerol	O
)	O
levels	O
were	O
also	O
observed	O
in	O
the	O
duodenum	O
and	O
colon	O
.	O

Remarkably	O
,	O
the	O
anti	O
-	O
inflammatory	O
anandamide	O
congener	O
,	O
palmitoylethanolamide	O
,	O
counteracted	O
both	O
the	O
pain	O
behaviour	O
and	O
spinal	O
biochemical	O
changes	O
in	O
vitamin	O
D	O
deficient	O
mice	O
,	O
whilst	O
increasing	O
the	O
levels	O
of	O
Akkermansia	B-bacteria
,	O
Eubacterium	B-bacteria
and	O
Enterobacteriaceae	B-bacteria
,	O
as	O
compared	O
with	O
vehicle	O
-	O
treated	O
mice	O
.	O

Finally	O
,	O
induction	O
of	O
spared	O
nerve	O
injury	O
in	O
normal	O
or	O
vitamin	O
D	O
deficient	O
mice	O
was	O
not	O
accompanied	O
by	O
changes	O
in	O
gut	O
microbiota	O
composition	O
.	O

Our	O
data	O
suggest	O
the	O
existence	O
of	O
a	O
link	O
between	O
Vitamin	O
D	O
deficiency	O
-	O
with	O
related	O
changes	O
in	O
gut	O
bacterial	O
composition	O
-	O
and	O
altered	O
nociception	O
,	O
possibly	O
via	O
molecular	O
mechanisms	O
involving	O
the	O
endocannabinoid	O
and	O
related	O
mediator	O
signaling	O
systems	O
.	O

Chronic	O
paradoxical	O
sleep	O
deprivation	O
-	O
induced	O
depression	O
-	O
like	O
behavior	O
,	O
energy	O
metabolism	O
and	O
microbial	O
changes	O
in	O
rats	O
.	O

AIMS	O
:	O
Given	O
the	O
lasting	O
impact	O
of	O
chronic	O
paradoxical	O
sleep	O
deprivation	O
(	O
PSD	O
)	O
on	O
behavior	O
and	O
organism	O
metabolic	O
alternations	O
,	O
along	O
with	O
the	O
role	O
of	O
the	O
microbiome	O
in	O
neurobehavioral	O
development	O
and	O
metabolism	O
,	O
we	O
sought	O
to	O
examine	O
the	O
relationship	O
between	O
the	O
microbiota	O
and	O
chronic	O
PSD	O
-	O
induced	O
behavioral	O
and	O
metabolic	O
changes	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Psychological	O
status	O
of	O
7	O
-	O
day	O
PSD	O
(	O
7d	O
-	O
PSD	O
)	O
male	O
rats	O
was	O
tested	O
by	O
behavioral	O
method	O
,	O
serum	O
inflammatory	O
cytokines	O
and	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
-	O
related	O
hormones	O
.	O

In	O
addition	O
,	O
GC	O
-	O
MS	O
based	O
urine	O
metabolomics	O
and	O
16S	O
rRNA	O
gene	O
sequencing	O
approaches	O
were	O
applied	O
to	O
estimate	O
the	O
influences	O
of	O
chronic	O
PSD	O
on	O
host	O
metabolism	O
and	O
gut	O
-	O
microbiota	O
.	O

Furtherly	O
,	O
microbial	O
functional	O
prediction	O
and	O
Spearman	O
'	O
s	O
correlation	O
analysis	O
were	O
implemented	O
to	O
manifest	O
the	O
relations	O
between	O
the	O
differential	O
urinary	O
metabolites	O
and	O
gut	O
microbiota	O
.	O

KEY	O
FINDINGS	O
:	O
7d	O
-	O
PSD	O
rats	O
displayed	O
depression	O
-	O
like	O
behavior	O
,	O
metabolic	O
and	O
microbial	O
changes	O
.	O

By	O
integrating	O
differential	O
gut	O
bacteria	O
with	O
indicators	O
of	O
depression	O
and	O
differential	O
metabolites	O
,	O
we	O
found	O
that	O
the	O
alterations	O
of	O
Akkermansia	B-bacteria
,	O
Oscillospira	B-bacteria
,	O
Ruminococcus	B-bacteria
,	O
Parabacteroides	B-bacteria
,	O
Aggregatibacter	B-bacteria
and	O
Phascolarctobacterium	B-bacteria
were	O
closely	O
related	O
to	O
abnormalities	O
of	O
depression	O
symptoms	O
and	O
inflammatory	O
cytokines	O
.	O

These	O
bacteria	O
also	O
had	O
close	O
connections	O
with	O
host	O
energy	O
metabolism	O
concerning	O
arginine	O
and	O
proline	O
metabolism	O
,	O
glycine	O
,	O
serine	O
and	O
threonine	O
metabolism	O
,	O
and	O
glyoxylate	O
and	O
dicarboxylate	O
metabolism	O
,	O
pyruvate	O
metabolism	O
,	O
which	O
overlapped	O
with	O
the	O
results	O
of	O
16S	O
rRNA	O
gene	O
function	O
annotation	O
.	O

SIGNIFICANCE	O
:	O
These	O
data	O
suggest	O
that	O
a	O
specific	O
situation	O
of	O
circadian	O
disturbance	O
,	O
chronic	O
PSD	O
-	O
induced	O
alterations	O
in	O
gut	O
microbiota	O
and	O
related	O
host	O
changes	O
in	O
metabolism	O
may	O
be	O
the	O
pathogenesis	O
of	O
depression	O
.	O

In	O
vivo	O
pharmacodynamic	O
and	O
pharmacokinetic	O
effects	O
of	O
metformin	O
mediated	O
by	O
the	O
gut	O
microbiota	O
in	O
rats	O
.	O

AIMS	O
:	O
The	O
gut	O
microbiota	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
efficacy	O
of	O
metformin	O
in	O
T2DM	O
treatment	O
.	O

We	O
evaluated	O
whether	O
the	O
pharmacodynamics	O
and	O
pharmacokinetics	O
of	O
metformin	O
are	O
mediated	O
by	O
gut	O
microbiota	O
.	O

MAIN	O
METHODS	O
:	O
We	O
used	O
conventional	O
diabetic	O
and	O
pseudo	O
-	O
germ	O
-	O
free	O
rats	O
.	O

After	O
6weeks	O
of	O
metformin	O
treatment	O
,	O
pharmacodynamic	O
indexes	O
were	O
determined	O
.	O

Metformin	O
concentrations	O
were	O
measured	O
with	O
a	O
validated	O
HPLC	O
-	O
MS	O
/	O
MS	O
method	O
after	O
the	O
first	O
oral	O
administration	O
.	O

KEY	O
FINDINGS	O
:	O
Most	O
endpoints	O
were	O
similar	O
between	O
vehicle	O
-	O
treated	O
diabetic	O
and	O
vehicle	O
-	O
treated	O
pseudo	O
-	O
germ	O
-	O
free	O
diabetic	O
rats	O
.	O

However	O
,	O
after	O
6weeks	O
of	O
metformin	O
treatment	O
,	O
compared	O
with	O
conventional	O
diabetic	O
rats	O
,	O
pseudo	O
-	O
germ	O
-	O
free	O
diabetic	O
rats	O
exhibited	O
significantly	O
increased	O
FBG	O
,	O
decreased	O
oral	O
glucose	O
,	O
reduced	O
GSP	O
,	O
worsened	O
insulin	O
resistance	O
,	O
increased	O
hyperlipidemia	O
,	O
and	O
increased	O
hepatic	O
steatosis	O
severity	O
.	O

Moreover	O
,	O
the	O
Cmax	O
of	O
pseudo	O
-	O
germ	O
-	O
free	O
rats	O
increased	O
significantly	O
,	O
while	O
the	O
t1	O
/	O
2alpha	O
decreased	O
significantly	O
.	O

These	O
pharmacodynamic	O
and	O
pharmacokinetic	O
changes	O
were	O
probably	O
due	O
to	O
a	O
decrease	O
in	O
Oct1	O
expression	O
in	O
the	O
liver	O
,	O
resulting	O
in	O
altered	O
hepatic	O
uptake	O
of	O
metformin	O
in	O
vivo	O
.	O

SIGNIFICANCE	O
:	O
These	O
results	O
implied	O
that	O
the	O
gut	O
microbiota	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pharmacodynamics	O
and	O
pharmacokinetics	O
of	O
metformin	O
and	O
that	O
the	O
changes	O
in	O
these	O
properties	O
are	O
probably	O
due	O
to	O
Oct1	O
downregulation	O
in	O
the	O
livers	O
of	O
pseudo	O
-	O
germ	O
-	O
free	O
rats	O
.	O

Culture	O
-	O
enriched	O
human	O
gut	O
microbiomes	O
reveal	O
core	O
and	O
accessory	O
resistance	O
genes	O
.	O

BACKGROUND	O
:	O
Low	O
-	O
abundance	O
microorganisms	O
of	O
the	O
gut	O
microbiome	O
are	O
often	O
referred	O
to	O
as	O
a	O
reservoir	O
for	O
antibiotic	O
resistance	O
genes	O
.	O

Unfortunately	O
,	O
these	O
less	O
-	O
abundant	O
bacteria	O
can	O
be	O
overlooked	O
by	O
deep	O
shotgun	O
sequencing	O
.	O

In	O
addition	O
,	O
it	O
is	O
a	O
challenge	O
to	O
associate	O
the	O
presence	O
of	O
resistance	O
genes	O
with	O
their	O
risk	O
of	O
acquisition	O
by	O
pathogens	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
liquid	O
culture	O
enrichment	O
of	O
stools	O
to	O
assemble	O
the	O
genome	O
of	O
lower	O
-	O
abundance	O
bacteria	O
from	O
fecal	O
samples	O
.	O

We	O
then	O
investigated	O
the	O
gene	O
content	O
recovered	O
from	O
these	O
culture	O
-	O
enriched	O
and	O
culture	O
-	O
independent	O
metagenomes	O
in	O
relation	O
with	O
their	O
taxonomic	O
origin	O
,	O
specifically	O
antibiotic	O
resistance	O
genes	O
.	O

We	O
finally	O
used	O
a	O
pangenome	O
approach	O
to	O
associate	O
resistance	O
genes	O
with	O
the	O
core	O
or	O
accessory	O
genome	O
of	O
Enterobacteriaceae	B-bacteria
and	O
inferred	O
their	O
propensity	O
to	O
horizontal	O
gene	O
transfer	O
.	O

RESULTS	O
:	O
Using	O
culture	O
-	O
enrichment	O
approaches	O
with	O
stools	O
allowed	O
assembly	O
of	O
187	O
bacterial	O
species	O
with	O
an	O
assembly	O
size	O
greater	O
than	O
1	O
million	O
nucleotides	O
.	O

Of	O
these	O
,	O
67	O
were	O
found	O
only	O
in	O
culture	O
-	O
enriched	O
conditions	O
,	O
and	O
22	O
only	O
in	O
culture	O
-	O
independent	O
microbiomes	O
.	O

These	O
assembled	O
metagenomes	O
allowed	O
the	O
evaluation	O
of	O
the	O
gene	O
content	O
of	O
specific	O
subcommunities	O
of	O
the	O
gut	O
microbiome	O
.	O

We	O
observed	O
that	O
differentially	O
distributed	O
metabolic	O
enzymes	O
were	O
associated	O
with	O
specific	O
culture	O
conditions	O
and	O
,	O
for	O
the	O
most	O
part	O
,	O
with	O
specific	O
taxa	O
.	O

Gene	O
content	O
differences	O
between	O
microbiomes	O
,	O
for	O
example	O
,	O
antibiotic	O
resistance	O
,	O
were	O
for	O
the	O
most	O
part	O
not	O
associated	O
with	O
metabolic	O
enzymes	O
,	O
but	O
with	O
other	O
functions	O
.	O

We	O
used	O
a	O
pangenome	O
approach	O
to	O
determine	O
if	O
the	O
resistance	O
genes	O
found	O
in	O
Enterobacteriaceae	B-bacteria
,	O
specifically	O
E	B-bacteria
.	I-bacteria
cloacae	I-bacteria
or	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
,	O
were	O
part	O
of	O
the	O
core	O
genome	O
or	O
of	O
the	O
accessory	O
genome	O
of	O
this	O
species	O
.	O

In	O
our	O
healthy	O
volunteer	O
cohort	O
,	O
we	O
found	O
that	O
E	B-bacteria
.	I-bacteria
cloacae	I-bacteria
contigs	O
harbored	O
resistance	O
genes	O
that	O
were	O
part	O
of	O
the	O
core	O
genome	O
of	O
the	O
species	O
,	O
while	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
had	O
a	O
large	O
accessory	O
resistome	O
proximal	O
to	O
mobile	O
elements	O
.	O

CONCLUSION	O
:	O
Liquid	O
culture	O
of	O
stools	O
contributed	O
to	O
an	O
improved	O
functional	O
and	O
comparative	O
genomics	O
study	O
of	O
less	O
-	O
abundant	O
gut	O
bacteria	O
,	O
specifically	O
those	O
associated	O
with	O
antibiotic	O
resistance	O
.	O

Defining	O
whether	O
a	O
gene	O
is	O
part	O
of	O
the	O
core	O
genome	O
of	O
a	O
species	O
helped	O
in	O
interpreting	O
the	O
genomes	O
recovered	O
from	O
culture	O
-	O
independent	O
or	O
culture	O
-	O
enriched	O
microbiomes	O
.	O

The	O
Interplay	O
between	O
Salmonella	B-bacteria
enterica	I-bacteria
Serovar	I-bacteria
Typhimurium	I-bacteria
and	O
the	O
Intestinal	O
Mucosa	O
during	O
Oral	O
Infection	O
.	O

Bacterial	O
infection	O
results	O
in	O
a	O
dynamic	O
interplay	O
between	O
the	O
pathogen	O
and	O
its	O
host	O
.	O

The	O
underlying	O
interactions	O
are	O
multilayered	O
,	O
and	O
the	O
cellular	O
responses	O
are	O
modulated	O
by	O
the	O
local	O
environment	O
.	O

The	O
intestine	O
is	O
a	O
particularly	O
interesting	O
tissue	O
regarding	O
host	O
-	O
pathogen	O
interaction	O
.	O

It	O
is	O
densely	O
colonized	O
by	O
commensal	O
microbes	O
and	O
a	O
portal	O
of	O
entry	O
for	O
ingested	O
pathogens	O
.	O

This	O
necessitates	O
constant	O
monitoring	O
of	O
microbial	O
stimuli	O
in	O
order	O
to	O
maintain	O
homeostasis	O
during	O
encounters	O
with	O
benign	O
microbiota	O
and	O
to	O
trigger	O
immune	O
defenses	O
in	O
response	O
to	O
bacterial	O
pathogens	O
.	O

Homeostasis	O
is	O
maintained	O
by	O
physical	O
barriers	O
(	O
the	O
mucus	O
layer	O
and	O
epithelium	O
)	O
,	O
chemical	O
defenses	O
(	O
antimicrobial	O
peptides	O
)	O
,	O
and	O
innate	O
immune	O
responses	O
(	O
NLRC4	O
inflammasome	O
)	O
,	O
which	O
keep	O
the	O
bacteria	O
from	O
reaching	O
the	O
sterile	O
lamina	O
propria	O
.	O

Intestinal	O
pathogens	O
represent	O
potent	O
experimental	O
tools	O
to	O
probe	O
these	O
barriers	O
and	O
decipher	O
how	O
pathogens	O
can	O
circumvent	O
them	O
.	O

The	O
streptomycin	O
mouse	O
model	O
of	O
oral	O
Salmonella	B-bacteria
enterica	I-bacteria
serovar	I-bacteria
Typhimurium	I-bacteria
infection	O
provides	O
a	O
well	O
-	O
characterized	O
,	O
robust	O
experimental	O
system	O
for	O
such	O
studies	O
.	O

Strikingly	O
,	O
each	O
stage	O
of	O
the	O
gut	O
tissue	O
infection	O
poses	O
a	O
different	O
set	O
of	O
challenges	O
to	O
the	O
pathogen	O
and	O
requires	O
tight	O
control	O
of	O
virulence	O
factor	O
expression	O
,	O
host	O
response	O
modulation	O
,	O
and	O
cooperation	O
between	O
phenotypic	O
subpopulations	O
.	O

Therefore	O
,	O
successful	O
infection	O
of	O
the	O
intestinal	O
tissue	O
relies	O
on	O
a	O
delicate	O
and	O
dynamic	O
balance	O
between	O
responses	O
of	O
the	O
pathogen	O
and	O
its	O
host	O
.	O

These	O
mechanisms	O
can	O
be	O
deciphered	O
to	O
their	O
full	O
extent	O
only	O
in	O
realistic	O
in	O
vivo	O
infection	O
models	O
.	O

Effect	O
of	O
stock	O
density	O
on	O
the	O
microbial	O
community	O
in	O
biofloc	O
water	O
and	O
Pacific	O
white	O
shrimp	O
(	O
Litopenaeus	O
vannamei	O
)	O
gut	O
microbiota	O
.	O

Biofloc	O
technology	O
is	O
an	O
efficient	O
approach	O
for	O
intensive	O
shrimp	O
culture	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
this	O
process	O
can	O
influence	O
the	O
composition	O
of	O
intestinal	O
microbial	O
community	O
is	O
still	O
unknown	O
.	O

Here	O
,	O
we	O
surveyed	O
the	O
shrimp	O
intestinal	O
bacteria	O
as	O
well	O
as	O
the	O
floc	O
water	O
from	O
three	O
biofloc	O
systems	O
with	O
different	O
stock	O
densities	O
.	O

Our	O
study	O
revealed	O
a	O
similar	O
variation	O
trend	O
in	O
phylum	O
taxonomy	O
level	O
between	O
floc	O
bacteria	O
and	O
gut	O
microbiota	O
.	O

Microbial	O
community	O
varied	O
notably	O
in	O
floc	O
water	O
from	O
different	O
stock	O
densities	O
,	O
while	O
a	O
core	O
genus	O
with	O
dominating	O
relative	O
abundance	O
was	O
detected	O
in	O
gut	O
samples	O
.	O

Extensive	O
variation	O
was	O
discovered	O
in	O
gut	O
microbiota	O
,	O
but	O
still	O
clustered	O
into	O
groups	O
according	O
to	O
stock	O
density	O
.	O

Our	O
results	O
indicated	O
that	O
shrimp	O
intestinal	O
microbiota	O
as	O
well	O
as	O
bacteria	O
aggregated	O
in	O
flocs	O
assembled	O
into	O
distinct	O
communities	O
from	O
different	O
stock	O
densities	O
,	O
and	O
the	O
intestinal	O
communities	O
were	O
more	O
similar	O
with	O
the	O
surrounding	O
environment	O
as	O
the	O
increase	O
of	O
stock	O
density	O
and	O
resulting	O
high	O
floc	O
biomass	O
.	O

The	O
high	O
stock	O
density	O
changed	O
the	O
core	O
gut	O
microbiota	O
by	O
reducing	O
the	O
relative	O
abundance	O
of	O
Paracoccus	B-bacteria
and	O
increasing	O
that	O
of	O
Nocardioides	B-bacteria
,	O
which	O
may	O
negatively	O
influence	O
shrimp	O
performance	O
.	O

Therefore	O
,	O
this	O
study	O
helps	O
us	O
to	O
understand	O
further	O
bacteria	O
and	O
host	O
interactions	O
in	O
biofloc	O
system	O
.	O

Alpha	O
-	O
galactosylceramide	O
enhances	O
mucosal	O
immunity	O
to	O
oral	O
whole	O
-	O
cell	O
cholera	O
vaccines	O
.	O

Cholera	O
is	O
a	O
severe	O
diarrheal	O
disease	O
caused	O
by	O
the	O
bacterium	O
Vibrio	B-bacteria
cholerae	I-bacteria
(	O
V	B-bacteria
.	I-bacteria
cholerae	I-bacteria
)	O
that	O
results	O
in	O
3	O
-	O
4	O
million	O
cases	O
globally	O
with	O
100	O
,	O
000	O
-	O
150	O
,	O
000	O
deaths	O
reported	O
annually	O
.	O

Mostly	O
confined	O
to	O
developing	O
nations	O
,	O
current	O
strategies	O
to	O
control	O
the	O
spread	O
of	O
cholera	O
include	O
the	O
provision	O
of	O
safe	O
drinking	O
water	O
and	O
improved	O
sanitation	O
and	O
hygiene	O
,	O
ideally	O
in	O
conjunction	O
with	O
oral	O
vaccination	O
.	O

However	O
,	O
difficulties	O
associated	O
with	O
the	O
costs	O
and	O
logistics	O
of	O
these	O
strategies	O
have	O
hampered	O
their	O
widespread	O
implementation	O
.	O

Specific	O
challenges	O
pertaining	O
to	O
oral	O
cholera	O
vaccines	O
(	O
OCVs	O
)	O
include	O
a	O
lack	O
of	O
safe	O
and	O
effective	O
adjuvants	O
to	O
further	O
enhance	O
gut	O
immune	O
responses	O
,	O
the	O
complex	O
and	O
costly	O
multicomponent	O
vaccine	O
manufacturing	O
,	O
limitations	O
of	O
conventional	O
liquid	O
formulation	O
and	O
the	O
lack	O
of	O
an	O
integrated	O
delivery	O
platform	O
.	O

Herein	O
we	O
describe	O
the	O
use	O
of	O
the	O
orally	O
active	O
adjuvant	O
alpha	O
-	O
Galactosylceramide	O
(	O
alpha	O
-	O
GalCer	O
)	O
to	O
strongly	O
enhance	O
intestinal	O
bacterium	O
-	O
and	O
toxin	O
-	O
specific	O
IgA	O
responses	O
to	O
the	O
OCV	O
,	O
Dukoral	O
(	O
(	O
R	O
)	O
)	O
in	O
C57BL	O
/	O
6	O
and	O
BALB	O
/	O
c	O
mice	O
.	O

We	O
further	O
demonstrate	O
the	O
mucosal	O
immunogenicity	O
of	O
a	O
novel	O
multi	O
-	O
antigen	O
,	O
single	O
-	O
component	O
whole	O
-	O
cell	O
killed	O
V	B-bacteria
.	I-bacteria
cholerae	I-bacteria
strain	I-bacteria
and	O
the	O
enhancement	O
of	O
its	O
immunogenicity	O
by	O
adding	O
alpha	O
-	O
GalCer	O
.	O

Finally	O
,	O
we	O
report	O
that	O
combining	O
these	O
components	O
and	O
recombinant	O
cholera	O
toxin	O
B	O
subunit	O
in	O
the	O
SmPill	O
(	O
(	O
R	O
)	O
)	O
minisphere	O
delivery	O
system	O
induced	O
strong	O
intestinal	O
and	O
systemic	O
antigen	O
-	O
specific	O
antibody	O
responses	O
.	O

The	O
parasitic	O
worm	O
product	O
ES	O
-	O
62	O
normalises	O
the	O
gut	O
microbiota	O
bone	O
marrow	O
axis	O
in	O
inflammatory	O
arthritis	O
.	O

The	O
human	O
immune	O
system	O
has	O
evolved	O
in	O
the	O
context	O
of	O
our	O
colonisation	O
by	O
bacteria	O
,	O
viruses	O
,	O
fungi	O
and	O
parasitic	O
helminths	O
.	O

Reflecting	O
this	O
,	O
the	O
rapid	O
eradication	O
of	O
pathogens	O
appears	O
to	O
have	O
resulted	O
in	O
reduced	O
microbiome	O
diversity	O
and	O
generation	O
of	O
chronically	O
activated	O
immune	O
systems	O
,	O
presaging	O
the	O
recent	O
rise	O
of	O
allergic	O
,	O
autoimmune	O
and	O
metabolic	O
disorders	O
.	O

Certainly	O
,	O
gastrointestinal	O
helminths	O
can	O
protect	O
against	O
gut	O
and	O
lung	O
mucosa	O
inflammatory	O
conditions	O
by	O
modulating	O
the	O
microbiome	O
and	O
suppressing	O
the	O
chronic	O
inflammation	O
associated	O
with	O
dysbiosis	O
.	O

Here	O
,	O
we	O
employ	O
ES	O
-	O
62	O
,	O
an	O
immunomodulator	O
secreted	O
by	O
tissue	O
-	O
dwelling	O
Acanthocheilonema	B-bacteria
viteae	I-bacteria
to	O
show	O
that	O
helminth	O
-	O
modulation	O
of	O
the	O
gut	O
microbiome	O
does	O
not	O
require	O
live	O
infection	O
with	O
gastrointestinal	O
-	O
based	O
worms	O
nor	O
is	O
protection	O
restricted	O
to	O
mucosal	O
diseases	O
.	O

Specifically	O
,	O
subcutaneous	O
administration	O
of	O
this	O
defined	O
immunomodulator	O
affords	O
protection	O
against	O
joint	O
disease	O
in	O
collagen	O
-	O
induced	O
arthritis	O
,	O
a	O
mouse	O
model	O
of	O
rheumatoid	O
arthritis	O
,	O
which	O
is	O
associated	O
with	O
normalisation	O
of	O
gut	O
microbiota	O
and	O
prevention	O
of	O
loss	O
of	O
intestinal	O
barrier	O
integrity	O
.	O

Anorexia	O
nervosa	O
:	O
Gut	O
microbiota	O
-	O
immune	O
-	O
brain	O
interactions	O
.	O

Anorexia	O
nervosa	O
is	O
a	O
psychiatric	O
disorder	O
defined	O
by	O
an	O
extremely	O
low	O
body	O
weight	O
,	O
a	O
devastating	O
fear	O
of	O
weight	O
gain	O
,	O
and	O
body	O
image	O
disturbance	O
,	O
however	O
the	O
etiopathogenesis	O
remains	O
unclear	O
.	O

The	O
objective	O
of	O
the	O
article	O
is	O
to	O
provide	O
a	O
comprehensive	O
review	O
on	O
the	O
potential	O
role	O
of	O
gut	O
microbiota	O
in	O
pathogenesis	O
of	O
anorexia	O
nervosa	O
.	O

Recent	O
advances	O
in	O
sequencing	O
techniques	O
used	O
for	O
microbial	O
detection	O
revealed	O
that	O
this	O
disease	O
is	O
associated	O
with	O
disruption	O
of	O
the	O
composition	O
of	O
normal	O
gut	O
microbiota	O
(	O
dysbiosis	O
)	O
,	O
manifested	O
by	O
low	O
microbial	O
diversity	O
and	O
taxonomic	O
differences	O
as	O
compared	O
to	O
healthy	O
individuals	O
.	O

Microorganisms	O
present	O
in	O
the	O
gut	O
represent	O
a	O
part	O
of	O
the	O
so	O
called	O
`	O
`	O
microbiota	O
-	O
gut	O
-	O
brain	O
'	O
'	O
axis	O
that	O
affect	O
the	O
central	O
nervous	O
system	O
and	O
thus	O
human	O
behavior	O
via	O
the	O
production	O
of	O
various	O
neuroactive	O
compounds	O
.	O

In	O
addition	O
,	O
cells	O
of	O
the	O
immune	O
system	O
are	O
equipped	O
with	O
receptors	O
for	O
these	O
neuroactive	O
substances	O
.	O

Microbiota	O
of	O
the	O
intestinal	O
system	O
also	O
represent	O
a	O
very	O
important	O
antigenic	O
source	O
.	O

These	O
antigens	O
can	O
mimic	O
some	O
host	O
neuropeptides	O
and	O
neurohormones	O
and	O
thus	O
trigger	O
the	O
production	O
of	O
autoantibodies	O
which	O
cross	O
-	O
react	O
with	O
these	O
compounds	O
.	O

The	O
levels	O
and	O
affinities	O
of	O
these	O
antibodies	O
are	O
thought	O
to	O
be	O
associated	O
with	O
neuropsychiatric	O
conditions	O
including	O
anxiety	O
,	O
depression	O
,	O
and	O
eating	O
and	O
sleep	O
disorders	O
.	O

The	O
study	O
of	O
microbiota	O
function	O
in	O
diseases	O
could	O
bring	O
new	O
insights	O
to	O
the	O
pathogenetic	O
mechanisms	O
.	O

Midbiotics	O
:	O
conjugative	O
plasmids	O
for	O
genetic	O
engineering	O
of	O
natural	O
gut	O
flora	O
.	O

The	O
possibility	O
to	O
modify	O
gut	O
bacterial	O
flora	O
has	O
become	O
an	O
important	O
goal	O
,	O
and	O
various	O
approaches	O
are	O
used	O
to	O
achieve	O
desirable	O
communities	O
.	O

However	O
,	O
the	O
genetic	O
engineering	O
of	O
existing	O
microbes	O
in	O
the	O
gut	O
,	O
which	O
are	O
already	O
compatible	O
with	O
the	O
rest	O
of	O
the	O
community	O
and	O
host	O
immune	O
system	O
,	O
has	O
not	O
received	O
much	O
attention	O
.	O

Here	O
,	O
we	O
discuss	O
and	O
experimentally	O
evaluate	O
the	O
possibility	O
to	O
use	O
modified	O
and	O
mobilizable	O
CRISPR	O
-	O
Cas9	O
-	O
endocing	O
plasmid	O
as	O
a	O
tool	O
to	O
induce	O
changes	O
in	O
bacterial	O
communities	O
.	O

This	O
plasmid	O
system	O
(	O
briefly	O
midbiotic	O
)	O
is	O
delivered	O
from	O
bacterial	O
vector	O
into	O
target	O
bacteria	O
via	O
conjugation	O
.	O

Compared	O
to	O
,	O
for	O
example	O
,	O
bacteriophage	O
-	O
based	O
applications	O
,	O
the	O
benefits	O
of	O
conjugative	O
plasmids	O
include	O
their	O
independence	O
of	O
any	O
particular	O
receptor	O
(	O
s	O
)	O
on	O
host	O
bacteria	O
and	O
their	O
relative	O
immunity	O
to	O
bacterial	O
defense	O
mechanisms	O
(	O
such	O
as	O
restriction	O
-	O
modification	O
systems	O
)	O
due	O
to	O
the	O
synthesis	O
of	O
the	O
complementary	O
strand	O
with	O
host	O
-	O
specific	O
epigenetic	O
modifications	O
.	O

We	O
show	O
that	O
conjugative	O
plasmid	O
in	O
association	O
with	O
a	O
mobilizable	O
antibiotic	O
resistance	O
gene	O
targeting	O
CRISPR	O
-	O
plasmid	O
efficiently	O
causes	O
ESBL	O
-	O
positive	O
transconjugants	O
to	O
lose	O
their	O
resistance	O
,	O
and	O
multiple	O
gene	O
types	O
can	O
be	O
targeted	O
simultaneously	O
by	O
introducing	O
several	O
CRISPR	O
RNA	O
encoding	O
segments	O
into	O
the	O
transferred	O
plasmids	O
.	O

In	O
the	O
rare	O
cases	O
where	O
the	O
midbiotic	O
plasmids	O
failed	O
to	O
resensitize	O
bacteria	O
to	O
antibiotics	O
,	O
the	O
CRISPR	O
spacer	O
(	O
s	O
)	O
and	O
their	O
adjacent	O
repeats	O
or	O
larger	O
regions	O
were	O
found	O
to	O
be	O
lost	O
.	O

Results	O
also	O
revealed	O
potential	O
caveats	O
in	O
the	O
design	O
of	O
conjugative	O
engineering	O
systems	O
as	O
well	O
as	O
workarounds	O
to	O
minimize	O
these	O
risks	O
.	O

Probiotics	O
in	O
the	O
next	O
-	O
generation	O
sequencing	O
era	O
.	O

Technological	O
developments	O
,	O
including	O
massively	O
parallel	O
DNA	O
sequencing	O
,	O
gnotobiotics	O
,	O
metabolomics	O
,	O
RNA	O
sequencing	O
and	O
culturomics	O
,	O
have	O
markedly	O
propelled	O
the	O
field	O
of	O
microbiome	O
research	O
in	O
recent	O
years	O
.	O

These	O
methodologies	O
can	O
be	O
harnessed	O
to	O
improve	O
our	O
in	O
-	O
depth	O
mechanistic	O
understanding	O
of	O
basic	O
concepts	O
related	O
to	O
consumption	O
of	O
probiotics	O
,	O
including	O
their	O
rules	O
of	O
engagement	O
with	O
the	O
indigenous	O
microbiome	O
and	O
impacts	O
on	O
the	O
human	O
host	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
even	O
during	O
probiotic	O
supplementation	O
,	O
resident	O
gut	O
bacteria	O
in	O
a	O
subset	O
of	O
individuals	O
resist	O
the	O
mucosal	O
presence	O
of	O
probiotic	O
strains	O
,	O
limiting	O
their	O
modulatory	O
effect	O
on	O
the	O
microbiome	O
and	O
on	O
the	O
host	O
gut	O
transcriptional	O
landscape	O
.	O

Resistance	O
is	O
partly	O
alleviated	O
by	O
antibiotics	O
treatment	O
,	O
which	O
enables	O
probiotics	O
to	O
interact	O
with	O
the	O
host	O
at	O
the	O
gut	O
mucosal	O
interface	O
,	O
although	O
rather	O
than	O
promoting	O
reconstitution	O
of	O
the	O
indigenous	O
microbiome	O
and	O
of	O
the	O
host	O
transcriptional	O
profile	O
,	O
they	O
inhibit	O
these	O
components	O
from	O
returning	O
to	O
their	O
naive	O
pre	O
-	O
antibiotic	O
configurations	O
.	O

In	O
this	O
commentary	O
,	O
we	O
discuss	O
our	O
findings	O
in	O
the	O
context	O
of	O
previous	O
and	O
recent	O
works	O
,	O
and	O
suggest	O
that	O
incorporating	O
the	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
methods	O
currently	O
utilized	O
in	O
microbiome	O
research	O
into	O
the	O
field	O
of	O
probiotics	O
may	O
lead	O
to	O
improved	O
understanding	O
of	O
their	O
mechanisms	O
of	O
activity	O
,	O
as	O
well	O
as	O
their	O
efficacy	O
and	O
long	O
-	O
term	O
safety	O
.	O

The	O
effect	O
of	O
diet	O
on	O
hypertensive	O
pathology	O
:	O
is	O
there	O
a	O
link	O
via	O
gut	O
microbiota	O
-	O
driven	O
immune	O
-	O
metabolism	O
?	O

Over	O
the	O
past	O
decade	O
,	O
the	O
immune	O
system	O
has	O
emerged	O
as	O
an	O
important	O
component	O
in	O
the	O
aetiology	O
of	O
hypertension	O
.	O

There	O
has	O
been	O
a	O
blooming	O
interest	O
in	O
the	O
contribution	O
of	O
the	O
gut	O
microbiota	O
,	O
the	O
microbes	O
that	O
inhabit	O
our	O
small	O
and	O
large	O
intestine	O
,	O
to	O
blood	O
pressure	O
(	O
BP	O
)	O
regulation	O
.	O

The	O
gastrointestinal	O
tract	O
houses	O
the	O
largest	O
number	O
of	O
immune	O
cells	O
in	O
our	O
body	O
,	O
thus	O
,	O
it	O
is	O
no	O
surprise	O
that	O
its	O
microbiota	O
plays	O
an	O
important	O
functional	O
role	O
in	O
the	O
appropriate	O
development	O
of	O
the	O
immune	O
system	O
through	O
a	O
coordinated	O
sequence	O
of	O
events	O
leading	O
to	O
immune	O
tolerance	O
of	O
commensal	O
bacteria	O
.	O

Importantly	O
,	O
recent	O
evidence	O
supports	O
that	O
the	O
gut	O
microbiota	O
can	O
protect	O
or	O
promote	O
the	O
development	O
of	O
experimental	O
hypertension	O
and	O
is	O
likely	O
to	O
have	O
a	O
role	O
in	O
human	O
hypertension	O
.	O

One	O
of	O
the	O
major	O
modulators	O
of	O
the	O
gut	O
microbiota	O
is	O
diet	O
:	O
diets	O
that	O
emphasise	O
high	O
fibre	O
intake	O
,	O
such	O
as	O
the	O
Mediterranean	O
diet	O
and	O
the	O
Dietary	O
Approaches	O
to	O
Stop	O
Hypertension	O
,	O
promote	O
expansion	O
of	O
protective	O
microbes	O
that	O
release	O
gut	O
metabolites	O
such	O
as	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
which	O
are	O
immune	O
-	O
,	O
BP	O
-	O
and	O
cardio	O
-	O
protective	O
,	O
likely	O
acting	O
through	O
G	O
-	O
coupled	O
protein	O
receptors	O
.	O

In	O
contrast	O
,	O
diets	O
lacking	O
fibre	O
or	O
high	O
in	O
salt	O
and	O
fat	O
,	O
such	O
as	O
the	O
Western	O
diet	O
,	O
reduce	O
prevalence	O
of	O
commensal	O
microbial	O
species	O
and	O
support	O
a	O
pathogenic	O
and	O
pro	O
-	O
inflammatory	O
environment	O
,	O
including	O
the	O
release	O
of	O
the	O
pro	O
-	O
atherosclerotic	O
trimethylamine	O
N	O
-	O
oxide	O
(	O
TMAO	O
)	O
.	O

Here	O
we	O
review	O
the	O
current	O
understanding	O
of	O
the	O
gut	O
microbiota	O
-	O
driven	O
immune	O
dysfunction	O
in	O
both	O
experimental	O
and	O
clinical	O
hypertension	O
,	O
and	O
how	O
these	O
changes	O
may	O
be	O
addressed	O
through	O
dietary	O
interventions	O
.	O

X	O
-	O
ray	O
structure	O
of	O
an	O
inactive	O
zymogen	O
clostripain	O
-	O
like	O
protease	O
from	O
Parabacteroides	B-bacteria
distasonis	I-bacteria
.	O

The	O
clostripain	O
-	O
like	O
(	O
C11	O
)	O
family	O
of	O
cysteine	O
proteases	O
are	O
ubiquitously	O
produced	O
by	O
the	O
vast	O
majority	O
of	O
the	O
bacterial	O
strains	O
that	O
make	O
up	O
the	O
human	O
distal	O
gut	O
microbiome	O
.	O

Recent	O
reports	O
show	O
that	O
some	O
C11	O
proteases	O
promote	O
host	O
immune	O
responses	O
and	O
bacterial	O
pathogenesis	O
,	O
including	O
the	O
induction	O
of	O
neutrophil	O
phagocytosis	O
and	O
the	O
activation	O
of	O
bacterial	O
pathogenic	O
toxins	O
,	O
respectively	O
.	O

The	O
crystal	O
structure	O
of	O
distapain	O
,	O
the	O
only	O
C11	O
protease	O
predicted	O
within	O
the	O
genome	O
of	O
the	O
commensal	O
bacterium	O
Parabacteroides	B-bacteria
distasonis	I-bacteria
,	O
was	O
determined	O
in	O
the	O
inactive	O
zymogen	O
state	O
to	O
1	O
.	O
65	O
A	O
resolution	O
.	O

This	O
is	O
the	O
first	O
C11	O
protease	O
structure	O
of	O
a	O
zymogen	O
,	O
and	O
the	O
structure	O
helped	O
to	O
uncover	O
key	O
unique	O
conformations	O
among	O
critical	O
active	O
-	O
site	O
residues	O
that	O
are	O
likely	O
to	O
assist	O
in	O
preserving	O
the	O
inactive	O
protease	O
.	O

His135	O
,	O
a	O
member	O
of	O
the	O
catalytic	O
dyad	O
,	O
is	O
repositioned	O
approximately	O
5	O
.	O
5	O
A	O
from	O
the	O
orientation	O
found	O
in	O
active	O
C11	O
structures	O
and	O
forms	O
a	O
hydrogen	O
bond	O
to	O
Asp180	O
and	O
a	O
pi	O
-	O
stacking	O
interaction	O
with	O
Trp133	O
.	O

The	O
structure	O
sheds	O
light	O
on	O
the	O
potential	O
importance	O
of	O
Asp180	O
and	O
Trp133	O
,	O
as	O
these	O
residues	O
are	O
highly	O
conserved	O
across	O
C11	O
proteases	O
.	O

Structure	O
elucidation	O
of	O
C11	O
proteases	O
will	O
ultimately	O
help	O
to	O
identify	O
new	O
ways	O
to	O
chemically	O
and	O
/	O
or	O
biologically	O
regulate	O
this	O
family	O
of	O
enzymes	O
,	O
which	O
represent	O
potential	O
drug	O
-	O
discovery	O
targets	O
in	O
microbiome	O
-	O
related	O
gastrointestinal	O
diseases	O
.	O

Probiotic	O
Bacteria	O
:	O
A	O
Promising	O
Tool	O
in	O
Cancer	O
Prevention	O
and	O
Therapy	O
.	O

Gut	O
microbiota	O
is	O
widely	O
considered	O
to	O
be	O
one	O
of	O
the	O
most	O
important	O
components	O
to	O
maintain	O
balanced	O
homeostasis	O
.	O

Looking	O
forward	O
,	O
probiotic	O
bacteria	O
have	O
been	O
shown	O
to	O
play	O
a	O
significant	O
role	O
in	O
immunomodulation	O
and	O
display	O
antitumour	O
properties	O
.	O

Bacterial	O
strains	O
could	O
be	O
responsible	O
for	O
detection	O
and	O
degradation	O
of	O
potential	O
carcinogens	O
and	O
production	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
which	O
affect	O
cell	O
death	O
and	O
proliferation	O
and	O
are	O
known	O
as	O
signaling	O
molecules	O
in	O
the	O
immune	O
system	O
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
present	O
in	O
the	O
gut	O
has	O
been	O
shown	O
to	O
have	O
a	O
role	O
in	O
regression	O
of	O
carcinogenesis	O
due	O
to	O
their	O
influence	O
on	O
immunomodulation	O
,	O
which	O
can	O
stand	O
as	O
a	O
proof	O
of	O
interaction	O
between	O
bacterial	O
metabolites	O
and	O
immune	O
and	O
epithelial	O
cells	O
.	O

Probiotic	O
bacteria	O
have	O
the	O
ability	O
to	O
both	O
increase	O
and	O
decrease	O
the	O
production	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
which	O
play	O
an	O
important	O
role	O
in	O
prevention	O
of	O
carcinogenesis	O
.	O

They	O
are	O
also	O
capable	O
of	O
activating	O
phagocytes	O
in	O
order	O
to	O
eliminate	O
early	O
-	O
stage	O
cancer	O
cells	O
.	O

Application	O
of	O
heat	O
-	O
killed	O
probiotic	O
bacteria	O
coupled	O
with	O
radiation	O
had	O
a	O
positive	O
influence	O
on	O
enhancing	O
immunological	O
recognition	O
of	O
cancer	O
cells	O
.	O

In	O
the	O
absence	O
of	O
active	O
microbiota	O
,	O
murine	O
immunity	O
to	O
carcinogens	O
has	O
been	O
decreased	O
.	O

There	O
are	O
numerous	O
cohort	O
studies	O
showing	O
the	O
correlation	O
between	O
ingestion	O
of	O
dairy	O
products	O
and	O
the	O
risk	O
of	O
colon	O
and	O
colorectal	O
cancer	O
.	O

An	O
idea	O
of	O
using	O
probiotic	O
bacteria	O
as	O
vectors	O
to	O
administer	O
drugs	O
has	O
emerged	O
lately	O
as	O
several	O
papers	O
presenting	O
successful	O
results	O
have	O
been	O
revealed	O
.	O

Within	O
the	O
next	O
few	O
years	O
,	O
probiotic	O
bacteria	O
as	O
well	O
as	O
gut	O
microbiota	O
are	O
likely	O
to	O
become	O
an	O
important	O
component	O
in	O
cancer	O
prevention	O
and	O
treatment	O
.	O

Early	O
Nutrition	O
Programming	O
(	O
in	O
ovo	O
and	O
Post	O
-	O
hatch	O
Feeding	O
)	O
as	O
a	O
Strategy	O
to	O
Modulate	O
Gut	O
Health	O
of	O
Poultry	O
.	O

Healthy	O
gastrointestinal	O
tract	O
(	O
GIT	O
)	O
is	O
crucial	O
for	O
optimum	O
performance	O
,	O
better	O
feed	O
efficiency	O
,	O
and	O
overall	O
health	O
of	O
poultry	O
.	O

In	O
the	O
past	O
,	O
antibiotic	O
growth	O
promoters	O
(	O
AGP	O
)	O
were	O
commonly	O
used	O
to	O
modulate	O
the	O
gut	O
health	O
of	O
animals	O
.	O

However	O
,	O
considering	O
the	O
public	O
health	O
concern	O
,	O
the	O
use	O
of	O
AGP	O
in	O
animal	O
feeding	O
is	O
banned	O
or	O
regulated	O
in	O
several	O
jurisdictions	O
around	O
the	O
world	O
.	O

This	O
necessitates	O
the	O
need	O
for	O
alternative	O
nutritional	O
strategies	O
to	O
produce	O
healthy	O
poultry	O
.	O

For	O
that	O
,	O
several	O
alternatives	O
to	O
AGP	O
have	O
been	O
attempted	O
with	O
some	O
success	O
.	O

However	O
,	O
effective	O
modulation	O
of	O
the	O
gut	O
health	O
parameters	O
depends	O
on	O
the	O
methods	O
and	O
timing	O
of	O
the	O
compound	O
being	O
available	O
to	O
host	O
animals	O
.	O

Routinely	O
,	O
the	O
alternatives	O
to	O
AGP	O
and	O
other	O
nutrients	O
are	O
provided	O
in	O
feed	O
or	O
water	O
to	O
poultry	O
.	O

However	O
,	O
the	O
GIT	O
of	O
the	O
newly	O
hatched	O
poultry	O
is	O
functionally	O
immature	O
,	O
despite	O
going	O
through	O
significant	O
morphological	O
,	O
cellular	O
,	O
and	O
molecular	O
changes	O
toward	O
the	O
end	O
of	O
incubation	O
.	O

Thus	O
,	O
early	O
growth	O
and	O
development	O
of	O
GIT	O
are	O
of	O
critical	O
importance	O
to	O
enhance	O
nutrients	O
utilization	O
and	O
optimize	O
the	O
growth	O
of	O
poultry	O
.	O

Early	O
nutrition	O
programming	O
using	O
both	O
in	O
ovo	O
and	O
post	O
-	O
hatch	O
feeding	O
has	O
been	O
used	O
as	O
a	O
means	O
to	O
modulate	O
the	O
early	O
growth	O
and	O
development	O
of	O
GIT	O
and	O
found	O
to	O
be	O
an	O
effective	O
strategy	O
but	O
with	O
inconsistent	O
results	O
.	O

This	O
review	O
summarizes	O
the	O
information	O
on	O
in	O
ovo	O
and	O
post	O
-	O
hatch	O
-	O
feeding	O
of	O
different	O
nutrients	O
and	O
feeds	O
additives	O
and	O
their	O
effects	O
on	O
gut	O
development	O
,	O
histomorphology	O
,	O
microbiology	O
,	O
and	O
immunology	O
.	O

Furthermore	O
,	O
this	O
review	O
will	O
provide	O
insight	O
on	O
the	O
future	O
of	O
early	O
nutrition	O
programming	O
as	O
a	O
strategy	O
to	O
enhance	O
gut	O
health	O
,	O
thereby	O
improving	O
overall	O
health	O
and	O
production	O
so	O
that	O
the	O
poultry	O
industry	O
can	O
benefit	O
from	O
this	O
technique	O
.	O

Microbiota	O
Landscape	O
of	O
Gut	O
System	O
of	O
Guppy	O
Fish	O
(	O
Poecilia	O
reticulata	O
)	O
Plays	O
an	O
Outstanding	O
Role	O
in	O
Adaptation	O
Mechanisms	O
.	O

Microbial	O
consortium	O
that	O
is	O
present	O
in	O
fish	O
gut	O
systems	O
works	O
together	O
to	O
achieve	O
unknown	O
specific	O
roles	O
.	O

Here	O
,	O
we	O
collected	O
guppy	O
fish	O
from	O
hydrocarbon	O
-	O
and	O
trace	O
metal	O
-	O
contaminated	O
wastewater	O
to	O
assess	O
the	O
relationships	O
between	O
gut	O
microbiota	O
and	O
host	O
fish	O
adaptation	O
.	O

Targeted	O
genes	O
and	O
16S	O
rRNA	O
amplicon	O
sequencing	O
have	O
been	O
used	O
to	O
identify	O
gut	O
bacteria	O
of	O
guppies	O
.	O

Mineral	O
-	O
conditioned	O
medium	O
contributes	O
to	O
identify	O
bacteria	O
with	O
the	O
ability	O
to	O
grow	O
and	O
/	O
or	O
to	O
tolerate	O
hydrocarbon	O
and	O
trace	O
metals	O
.	O

Additionally	O
,	O
trace	O
metals	O
'	O
tolerance	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
of	O
microbiota	O
was	O
evaluated	O
.	O

We	O
first	O
isolated	O
bacteria	O
from	O
the	O
gut	O
system	O
,	O
and	O
we	O
showed	O
that	O
Bacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Staphylococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Shigella	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Salmonella	B-bacteria
spp	I-bacteria
,	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	O
,	O
Citrobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Salmonella	B-bacteria
enterica	I-bacteria
ssp	I-bacteria
.	I-bacteria
arizonae	I-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Enterobacter	B-bacteria
spp	I-bacteria
,	O
and	O
Acinetobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
are	O
part	O
of	O
guppy	O
gut	O
microbiota	O
.	O

Some	O
representative	O
species	O
are	O
able	O
to	O
degrade	O
and	O
/	O
or	O
tolerate	O
gasoline	O
and	O
/	O
or	O
diesel	O
fuel	O
hydrocarbons	O
.	O

Tolerance	O
to	O
trace	O
metals	O
was	O
observed	O
in	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
.	O

We	O
showed	O
that	O
minimal	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
of	O
some	O
microbiota	O
isolated	O
from	O
gut	O
systems	O
has	O
been	O
found	O
including	O
for	O
mercury	O
(	O
Hg	O
)	O
between	O
2	O
and	O
4	O
per	O
thousand	O
,	O
cobalt	O
(	O
Co	O
)	O
Co	O
(	O
2	O
and	O
5	O
per	O
thousand	O
)	O
,	O
zinc	O
(	O
Zn	O
)	O
(	O
9	O
and	O
18	O
per	O
thousand	O
)	O
,	O
and	O
plomb	O
(	O
Pb	O
)	O
(	O
22	O
and	O
27	O
per	O
thousand	O
)	O
.	O

Zn	O
and	O
Pb	O
were	O
the	O
trace	O
metals	O
for	O
which	O
the	O
rate	O
of	O
tolerance	O
was	O
significantly	O
higher	O
.	O

Finally	O
,	O
we	O
showed	O
that	O
cytochrome	O
c	O
oxidase	O
is	O
not	O
interfering	O
in	O
presence	O
of	O
trace	O
metals	O
.	O

The	O
working	O
consortium	O
showed	O
that	O
bacteria	O
should	O
work	O
together	O
to	O
achieve	O
their	O
best	O
.	O

P2RX7	O
Deletion	O
in	O
T	O
Cells	O
Promotes	O
Autoimmune	O
Arthritis	O
by	O
Unleashing	O
the	O
Tfh	O
Cell	O
Response	O
.	O

Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
an	O
autoimmune	O
disease	O
that	O
affects	O
~	O
1	O
%	O
of	O
the	O
world	O
'	O
s	O
population	O
.	O

B	O
cells	O
and	O
autoantibodies	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
RA	O
.	O

The	O
P2RX7	O
receptor	O
is	O
an	O
ATP	O
-	O
gated	O
cation	O
channel	O
and	O
its	O
activation	O
results	O
in	O
the	O
release	O
of	O
pro	O
-	O
inflammatory	O
molecules	O
.	O

Thus	O
,	O
antagonists	O
of	O
P2RX7	O
have	O
been	O
considered	O
to	O
have	O
potential	O
as	O
novel	O
anti	O
-	O
inflammatory	O
therapies	O
.	O

Although	O
originally	O
identified	O
for	O
its	O
role	O
in	O
innate	O
immunity	O
,	O
P2RX7	O
has	O
recently	O
been	O
found	O
to	O
negatively	O
control	O
Peyer	O
'	O
s	O
patches	O
(	O
PP	O
)	O
T	O
follicular	O
helper	O
cells	O
(	O
Tfh	O
)	O
,	O
which	O
specialize	O
in	O
helping	O
B	O
cells	O
,	O
under	O
homeostatic	O
conditions	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
PP	O
Tfh	O
cells	O
are	O
required	O
for	O
the	O
augmentation	O
of	O
autoimmune	O
arthritis	O
mediated	O
by	O
gut	O
commensal	O
segmented	O
filamentous	O
bacteria	O
(	O
SFB	O
)	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
P2RX7	O
is	O
required	O
to	O
control	O
autoimmune	O
disease	O
by	O
keeping	O
the	O
Tfh	O
cell	O
response	O
in	O
check	O
.	O

To	O
test	O
our	O
hypothesis	O
,	O
we	O
analyzed	O
the	O
impact	O
of	O
P2RX7	O
deficiency	O
in	O
vivo	O
using	O
both	O
the	O
original	O
K	O
/	O
BxN	O
autoimmune	O
arthritis	O
model	O
and	O
T	O
cell	O
transfers	O
in	O
the	O
K	O
/	O
BxN	O
system	O
.	O

We	O
also	O
examined	O
the	O
impact	O
of	O
P2RX7	O
ablation	O
on	O
autoimmune	O
development	O
in	O
the	O
presence	O
of	O
the	O
gut	O
microbiota	O
SFB	O
.	O

Our	O
data	O
illustrate	O
that	O
contrary	O
to	O
exerting	O
an	O
anti	O
-	O
inflammatory	O
effect	O
,	O
P2RX7	O
deficiency	O
actually	O
enhances	O
autoimmune	O
arthritis	O
.	O

Interestingly	O
,	O
SFB	O
colonization	O
can	O
negate	O
the	O
difference	O
in	O
disease	O
severity	O
between	O
WT	O
and	O
P2RX7	O
-	O
deficient	O
mice	O
.	O

We	O
further	O
demonstrated	O
that	O
P2RX7	O
ablation	O
in	O
the	O
absence	O
of	O
SFB	O
caused	O
reduced	O
apoptotic	O
Tfh	O
cells	O
and	O
enhanced	O
the	O
Tfh	O
response	O
,	O
leading	O
to	O
an	O
increase	O
in	O
autoantibody	O
production	O
.	O

It	O
has	O
been	O
shown	O
that	O
activation	O
of	O
TIGIT	O
,	O
a	O
well	O
-	O
known	O
T	O
cell	O
exhaustion	O
marker	O
,	O
up	O
-	O
regulates	O
anti	O
-	O
apoptotic	O
molecules	O
and	O
promotes	O
T	O
cell	O
survival	O
.	O

We	O
demonstrated	O
that	O
the	O
reduced	O
apoptotic	O
phenotype	O
of	O
P2rx7	O
(	O
-	O
/	O
-	O
)	O
Tfh	O
cells	O
is	O
associated	O
with	O
their	O
increased	O
expression	O
of	O
TIGIT	O
.	O

This	O
suggested	O
that	O
while	O
P2RX7	O
was	O
regulating	O
the	O
Tfh	O
population	O
by	O
promoting	O
cell	O
death	O
,	O
TIGIT	O
may	O
have	O
been	O
opposing	O
P2RX7	O
by	O
inhibiting	O
cell	O
death	O
.	O

Together	O
,	O
these	O
results	O
demonstrated	O
that	O
systemic	O
administration	O
of	O
general	O
P2RX7	O
antagonists	O
may	O
have	O
detrimental	O
effects	O
in	O
autoimmune	O
therapies	O
,	O
especially	O
in	O
Tfh	O
cell	O
-	O
dependent	O
autoimmune	O
diseases	O
,	O
and	O
cell	O
-	O
specific	O
targeting	O
of	O
P2RX7	O
should	O
be	O
considered	O
in	O
order	O
to	O
achieve	O
efficacy	O
for	O
P2RX7	O
-	O
related	O
therapy	O
.	O

Gut	O
microbiota	O
profile	O
in	O
healthy	O
Indonesians	O
.	O

BACKGROUND	O
:	O
Recently	O
,	O
gut	O
microbiota	O
has	O
been	O
associated	O
with	O
various	O
diseases	O
other	O
than	O
intestinal	O
disease	O
.	O

Thus	O
,	O
there	O
has	O
been	O
rapid	O
growth	O
in	O
the	O
study	O
of	O
gut	O
microbiota	O
.	O

Considering	O
the	O
numerous	O
factors	O
influencing	O
gut	O
microbiota	O
such	O
as	O
age	O
,	O
diet	O
,	O
etc	O
.	O
,	O
area	O
-	O
based	O
research	O
is	O
required	O
.	O

Indonesia	O
has	O
numerous	O
different	O
tribes	O
and	O
each	O
of	O
these	O
tribes	O
have	O
different	O
lifestyles	O
.	O

Hence	O
,	O
it	O
is	O
expected	O
that	O
each	O
tribe	O
has	O
a	O
specific	O
gut	O
microbiota	O
.	O

A	O
deeper	O
insight	O
into	O
the	O
composition	O
of	O
gut	O
microbiota	O
can	O
be	O
used	O
to	O
determine	O
the	O
condition	O
of	O
gut	O
microbiota	O
in	O
Indonesians	O
and	O
to	O
consider	O
which	O
treatment	O
may	O
be	O
suitable	O
and	O
effective	O
to	O
improve	O
health	O
status	O
.	O

AIM	O
:	O
To	O
investigate	O
the	O
gut	O
microbiota	O
of	O
Indonesian	O
subjects	O
represented	O
by	O
Javanese	O
and	O
Balinese	O
tribes	O
by	O
analyzing	O
fecal	O
samples	O
.	O

METHODS	O
:	O
Fecal	O
samples	O
were	O
collected	O
from	O
a	O
total	O
of	O
80	O
individuals	O
with	O
20	O
in	O
each	O
of	O
the	O
young	O
groups	O
ranging	O
from	O
25	O
-	O
45	O
years	O
and	O
the	O
elderly	O
group	O
aged	O
70	O
years	O
or	O
more	O
from	O
two	O
different	O
regions	O
,	O
Yogyakarta	O
and	O
Bali	O
.	O

Fecal	O
sample	O
collection	O
was	O
performed	O
at	O
the	O
end	O
of	O
the	O
assessment	O
period	O
(	O
day	O
14	O
+	O
/	O
-	O
1	O
d	O
)	O
during	O
which	O
time	O
the	O
subjects	O
were	O
not	O
allowed	O
to	O
consume	O
probiotic	O
or	O
antibiotic	O
products	O
.	O

The	O
quantification	O
of	O
various	O
Clostridium	B-bacteria
subgroups	I-bacteria
,	O
Lactobacillus	B-bacteria
subgroups	I-bacteria
,	O
Enterococcus	B-bacteria
,	O
Streptococcus	B-bacteria
,	O
Staphylococcus	B-bacteria
,	O
Bacteroides	B-bacteria
fragilis	I-bacteria
group	I-bacteria
and	O
Prevotella	B-bacteria
,	O
Bifidobacterium	B-bacteria
and	O
Atopobium	B-bacteria
cluster	I-bacteria
,	O
Enterobacteriaceae	B-bacteria
and	O
Pseudomonas	B-bacteria
was	O
performed	O
using	O
the	O
Yakult	O
intestinal	O
flora	O
-	O
scan	O
(	O
YIF	O
-	O
SCAN	O
)	O
.	O

RESULTS	O
:	O
The	O
bacterial	O
population	O
in	O
younger	O
subjects	O
'	O
feces	O
was	O
higher	O
than	O
that	O
in	O
the	O
elderly	O
population	O
,	O
with	O
a	O
total	O
of	O
approximately	O
10	O
.	O
0	O
-	O
10	O
.	O
6	O
log10	O
bacterial	O
cells	O
/	O
g	O
feces	O
.	O

The	O
most	O
abundant	O
bacteria	O
in	O
all	O
groups	O
were	O
Clostridium	B-bacteria
,	O
followed	O
by	O
Prevotella	B-bacteria
,	O
Atopobium	B-bacteria
,	O
Bifidobacterium	B-bacteria
and	O
Bacteroides	B-bacteria
.	O

In	O
the	O
elderly	O
,	O
an	O
increase	O
in	O
Enterobacteriaceae	B-bacteria
,	O
Coliform	B-bacteria
and	O
Escherichia	B-bacteria
coli	I-bacteria
was	O
found	O
.	O

In	O
terms	O
of	O
bacterial	O
counts	O
in	O
Yogyakarta	O
,	O
total	O
bacteria	O
,	O
Clostridium	B-bacteria
coccoides	I-bacteria
(	O
C	B-bacteria
.	I-bacteria
coccoides	I-bacteria
)	O
group	O
,	O
Bifidobacterium	B-bacteria
,	O
Prevotella	B-bacteria
,	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
subgroup	I-bacteria
,	O
and	O
Streptococcus	B-bacteria
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
younger	O
than	O
elderly	O
subjects	O
,	O
while	O
the	O
Lactobacillus	B-bacteria
gasseri	I-bacteria
subgroup	O
,	O
Lactobacillus	B-bacteria
casei	I-bacteria
subgroup	I-bacteria
,	O
and	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
subgroup	O
counts	O
were	O
significantly	O
lower	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
younger	O
subjects	O
.	O

In	O
Balinese	O
subjects	O
,	O
total	O
bacteria	O
,	O
C	B-bacteria
.	I-bacteria
coccoides	I-bacteria
group	O
,	O
Clostridium	B-bacteria
leptum	I-bacteria
subgroup	I-bacteria
,	O
Bacteroides	B-bacteria
fragilis	I-bacteria
group	I-bacteria
,	O
and	O
Prevotella	B-bacteria
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
younger	O
compared	O
to	O
elderly	O
individuals	O
,	O
while	O
the	O
Lactobacillus	B-bacteria
ruminis	I-bacteria
subgroup	O
,	O
and	O
Enterobacteriaceae	B-bacteria
were	O
significantly	O
lower	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
younger	O
subjects	O
.	O

The	O
results	O
also	O
revealed	O
that	O
,	O
besides	O
the	O
C	B-bacteria
.	I-bacteria
coccoides	I-bacteria
group	O
and	O
Clostridium	B-bacteria
leptum	I-bacteria
group	O
being	O
the	O
most	O
abundant	O
gut	O
microbiota	O
in	O
both	O
Yogyakarta	O
and	O
Balinese	O
people	O
,	O
the	O
latter	O
was	O
indicated	O
by	O
a	O
higher	O
Clostridium	B-bacteria
perfringens	I-bacteria
count	O
,	O
which	O
was	O
almost	O
10	O
times	O
that	O
of	O
Yogyakarta	O
subjects	O
.	O

This	O
may	O
be	O
a	O
response	O
to	O
different	O
lifestyles	O
in	O
the	O
different	O
tribes	O
;	O
however	O
,	O
this	O
phenomenon	O
requires	O
further	O
extensive	O
study	O
.	O

CONCLUSION	O
:	O
Bacterial	O
populations	O
were	O
higher	O
in	O
younger	O
than	O
in	O
elderly	O
subjects	O
.	O

Most	O
abundant	O
bacterial	O
groups	O
were	O
Clostridium	B-bacteria
,	O
Prevotella	B-bacteria
,	O
Atopobium	B-bacteria
,	O
Bifidobacterium	B-bacteria
,	O
and	O
Bacteroides	B-bacteria
.	O

The	O
level	O
of	O
Clostridium	B-bacteria
perfringens	I-bacteria
in	O
Yogyakarta	O
subjects	O
was	O
lower	O
than	O
that	O
in	O
Balinese	O
subjects	O
.	O

Anti	O
-	O
tumor	O
necrosis	O
factor	O
alpha	O
therapy	O
associates	O
to	O
type	O
17	O
helper	O
T	O
lymphocytes	O
immunological	O
shift	O
and	O
significant	O
microbial	O
changes	O
in	O
dextran	O
sodium	O
sulphate	O
colitis	O
.	O

BACKGROUND	O
:	O
Anti	O
-	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	O
)	O
represents	O
the	O
best	O
therapeutic	O
option	O
to	O
induce	O
mucosal	O
healing	O
and	O
clinical	O
remission	O
in	O
patients	O
with	O
moderate	O
-	O
severe	O
ulcerative	O
colitis	O
.	O

On	O
the	O
other	O
side	O
gut	O
microbiota	O
plays	O
a	O
crucial	O
role	O
in	O
pathogenesis	O
of	O
ulcerative	O
colitis	O
but	O
few	O
information	O
exists	O
on	O
how	O
microbiota	O
changes	O
following	O
anti	O
-	O
TNFalpha	O
therapy	O
and	O
on	O
microbiota	O
role	O
in	O
mucosal	O
healing	O
.	O

AIM	O
:	O
To	O
elucidate	O
whether	O
gut	O
microbiota	O
and	O
immune	O
system	O
changes	O
appear	O
following	O
anti	O
TNFalpha	O
therapy	O
during	O
dextran	O
sulfate	O
sodium	O
(	O
DSS	O
)	O
colitis	O
.	O

METHODS	O
:	O
Eighty	O
C57BL	O
/	O
6	O
mice	O
were	O
divided	O
into	O
four	O
groups	O
:	O
`	O
`	O
No	O
DSS	O
'	O
'	O
,	O
`	O
`	O
No	O
DSS	O
+	O
anti	O
-	O
TNFalpha	O
'	O
'	O
,	O
`	O
`	O
DSS	O
'	O
'	O
and	O
`	O
`	O
DSS	O
+	O
anti	O
-	O
TNFalpha	O
'	O
'	O
.	O

`	O
`	O
DSS	O
'	O
'	O
and	O
`	O
`	O
DSS	O
+	O
anti	O
-	O
TNFalpha	O
'	O
'	O
were	O
treated	O
for	O
5	O
d	O
with	O
3	O
%	O
DSS	O
.	O

At	O
day	O
3	O
,	O
mice	O
whithin	O
`	O
`	O
No	O
DSS	O
+	O
anti	O
-	O
TNFalpha	O
'	O
'	O
and	O
`	O
`	O
DSS	O
+	O
anti	O
-	O
TNFalpha	O
'	O
'	O
group	O
received	O
5	O
mg	O
/	O
kg	O
of	O
an	O
anti	O
-	O
TNFalpha	O
agent	O
.	O

Forty	O
mice	O
were	O
sacrificed	O
at	O
day	O
5	O
,	O
forty	O
at	O
day	O
12	O
,	O
after	O
one	O
week	O
of	O
recovery	O
post	O
DSS	O
.	O

The	O
severity	O
of	O
colitis	O
was	O
assessed	O
by	O
a	O
clinical	O
score	O
(	O
Disease	O
Activity	O
Index	O
)	O
,	O
colon	O
length	O
and	O
histology	O
.	O

Bacteria	O
such	O
as	O
Bacteroides	B-bacteria
,	O
Clostridiaceae	B-bacteria
,	O
Enterococcaceae	B-bacteria
and	O
Fecalibacterium	B-bacteria
prausnitzii	I-bacteria
(	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
)	O
were	O
evaluated	O
by	O
quantitative	O
PCR	O
.	O

Type	O
1	O
helper	O
T	O
lymphocytes	O
(	O
Th1	O
)	O
,	O
type	O
17	O
helper	O
T	O
lymphocytes	O
(	O
Th17	O
)	O
and	O
CD4	O
(	O
+	O
)	O
regulatory	O
T	O
lymphocytes	O
(	O
Treg	O
)	O
distributions	O
in	O
the	O
mesenteric	O
lymph	O
node	O
(	O
MLN	O
)	O
were	O
studied	O
by	O
flow	O
cytometry	O
.	O

RESULTS	O
:	O
Bacteria	O
associated	O
with	O
a	O
healthy	O
state	O
(	O
i	O
.	O
e	O
.	O
,	O
such	O
as	O
Bacteroides	B-bacteria
,	O
Clostridiaceae	B-bacteria
and	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
)	O
decreased	O
during	O
colitis	O
and	O
increased	O
in	O
course	O
of	O
anti	O
-	O
TNFalpha	O
treatment	O
.	O

Conversely	O
,	O
microorganisms	O
belonging	O
to	O
Enterococcaceae	B-bacteria
genera	I-bacteria
,	O
which	O
are	O
linked	O
to	O
inflammatory	O
processes	O
,	O
showed	O
an	O
opposite	O
trend	O
.	O

Furthermore	O
,	O
in	O
colitic	O
mice	O
treated	O
with	O
anti	O
-	O
TNFalpha	O
microbial	O
changes	O
were	O
associated	O
with	O
an	O
initial	O
increase	O
(	O
day	O
5	O
of	O
the	O
colitis	O
)	O
in	O
Treg	O
cells	O
and	O
a	O
consequent	O
decrease	O
(	O
day	O
12	O
post	O
DSS	O
)	O
in	O
Th1	O
and	O
Th17	O
frequency	O
cells	O
.	O

Healthy	O
mice	O
treated	O
with	O
anti	O
-	O
TNFalpha	O
showed	O
the	O
same	O
histological	O
,	O
microbial	O
and	O
immune	O
features	O
of	O
untreated	O
colitic	O
mice	O
.	O

`	O
`	O
No	O
DSS	O
+	O
anti	O
-	O
TNFalpha	O
'	O
'	O
group	O
showed	O
a	O
lymphomononuclear	O
infiltrate	O
both	O
at	O
5	O
(	O
th	O
)	O
and	O
12	O
(	O
th	O
)	O
d	O
at	O
hematoxylin	O
and	O
eosin	O
staining	O
,	O
an	O
increase	O
of	O
in	O
Th1	O
and	O
Th17	O
frequency	O
at	O
day	O
12	O
,	O
an	O
increase	O
of	O
Enterococcaceae	B-bacteria
at	O
day	O
5	O
,	O
a	O
decrease	O
of	O
Bacteroides	B-bacteria
and	O
Clostridiaceae	B-bacteria
at	O
day	O
12	O
.	O

CONCLUSION	O
:	O
Anti	O
-	O
TNFalpha	O
treatment	O
in	O
experimental	O
model	O
of	O
colitis	O
improves	O
disease	O
activity	O
but	O
it	O
is	O
associated	O
to	O
an	O
increase	O
in	O
Th17	O
pathway	O
together	O
with	O
gut	O
microbiota	O
alteration	O
.	O

Heat	O
stress	O
,	O
Eimeria	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
C	B-bacteria
.	I-bacteria
perfringens	I-bacteria
infections	O
alone	O
or	O
in	O
combination	O
modify	O
gut	O
Th1	O
/	O
Th2	O
cytokine	O
balance	O
and	O
avian	O
necrotic	O
enteritis	O
pathogenesis	O
.	O

Information	O
on	O
the	O
dynamics	O
of	O
the	O
chicken	O
immune	O
system	O
during	O
bacterial	O
or	O
parasite	O
challenge	O
in	O
the	O
presence	O
or	O
absence	O
of	O
stressful	O
situations	O
may	O
provide	O
a	O
better	O
understanding	O
of	O
the	O
complex	O
mechanisms	O
behind	O
these	O
diseases	O
.	O

Necrotic	O
enteritis	O
(	O
NE	O
)	O
had	O
been	O
controlled	O
previously	O
by	O
the	O
proper	O
use	O
of	O
antimicrobial	O
agents	O
;	O
however	O
,	O
more	O
recently	O
,	O
NE	O
has	O
reemerged	O
in	O
many	O
countries	O
.	O

The	O
imposed	O
restrictions	O
on	O
antimicrobial	O
use	O
and	O
/	O
or	O
the	O
intensive	O
productive	O
programs	O
implemented	O
by	O
producers	O
are	O
challenges	O
the	O
birds	O
,	O
leading	O
to	O
large	O
host	O
adaptive	O
responses	O
that	O
in	O
many	O
instances	O
are	O
like	O
those	O
elicited	O
by	O
stressors	O
.	O

This	O
study	O
analyses	O
the	O
effects	O
of	O
heat	O
stress	O
on	O
Th1	O
/	O
Th2	O
cytokine	O
balance	O
,	O
pathological	O
features	O
,	O
and	O
Toll	O
-	O
like	O
receptor	O
expression	O
in	O
the	O
small	O
intestine	O
of	O
broiler	O
chickens	O
infected	O
with	O
Clostridium	B-bacteria
perfringens	I-bacteria
type	I-bacteria
A	I-bacteria
in	O
the	O
presence	O
or	O
absence	O
of	O
Eimeria	B-bacteria
spp	I-bacteria
.	I-bacteria
co	O
-	O
infection	O
.	O

This	O
co	O
-	O
infection	O
model	O
was	O
experimentally	O
used	O
because	O
it	O
reproduces	O
the	O
findings	O
commonly	O
observed	O
in	O
the	O
field	O
during	O
avian	O
NE	O
.	O

For	O
this	O
purpose	O
,	O
broiler	O
chickens	O
infected	O
with	O
C	B-bacteria
.	I-bacteria
perfringens	I-bacteria
and	O
/	O
or	O
Eimeria	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
reared	O
in	O
isolator	O
chambers	O
subjected	O
or	O
not	O
to	O
heat	O
stress	O
intermittently	O
.	O

It	O
was	O
observed	O
that	O
heat	O
stress	O
directs	O
the	O
expression	O
of	O
Th2	O
-	O
type	O
cytokines	O
,	O
increases	O
Toll	O
-	O
like	O
receptor	O
4	O
expression	O
in	O
the	O
intestine	O
and	O
reduces	O
the	O
disease	O
severity	O
induced	O
by	O
Eimeria	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
C	B-bacteria
.	I-bacteria
perfringens	I-bacteria
infections	O
alone	O
or	O
in	O
combination	O
,	O
most	O
likely	O
as	O
a	O
consequence	O
of	O
stress	O
-	O
induced	O
changes	O
in	O
brain	O
-	O
gut	O
axis	O
activity	O
.	O

Gut	O
microbiota	O
from	O
high	O
-	O
risk	O
men	O
who	O
have	O
sex	O
with	O
men	O
drive	O
immune	O
activation	O
in	O
gnotobiotic	O
mice	O
and	O
in	O
vitro	O
HIV	O
infection	O
.	O

Men	O
who	O
have	O
sex	O
with	O
men	O
(	O
MSM	O
)	O
have	O
differences	O
in	O
immune	O
activation	O
and	O
gut	O
microbiome	O
composition	O
compared	O
with	O
men	O
who	O
have	O
sex	O
with	O
women	O
(	O
MSW	O
)	O
,	O
even	O
in	O
the	O
absence	O
of	O
HIV	O
infection	O
.	O

Gut	O
microbiome	O
differences	O
associated	O
with	O
HIV	O
itself	O
when	O
controlling	O
for	O
MSM	O
,	O
as	O
assessed	O
by	O
16S	O
rRNA	O
sequencing	O
,	O
are	O
relatively	O
subtle	O
.	O

Understanding	O
whether	O
gut	O
microbiome	O
composition	O
impacts	O
immune	O
activation	O
in	O
HIV	O
-	O
negative	O
and	O
HIV	O
-	O
positive	O
MSM	O
has	O
important	O
implications	O
since	O
immune	O
activation	O
has	O
been	O
associated	O
with	O
HIV	O
acquisition	O
risk	O
and	O
disease	O
progression	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
MSM	O
and	O
HIV	O
-	O
associated	O
gut	O
microbiota	O
on	O
immune	O
activation	O
,	O
we	O
transplanted	O
feces	O
from	O
HIV	O
-	O
negative	O
MSW	O
,	O
HIV	O
-	O
negative	O
MSM	O
,	O
and	O
HIV	O
-	O
positive	O
untreated	O
MSM	O
to	O
gnotobiotic	O
mice	O
.	O

Following	O
transplant	O
,	O
16S	O
rRNA	O
gene	O
sequencing	O
determined	O
that	O
the	O
microbiomes	O
of	O
MSM	O
and	O
MSW	O
maintained	O
distinct	O
compositions	O
in	O
mice	O
and	O
that	O
specific	O
microbial	O
differences	O
between	O
MSM	O
and	O
MSW	O
were	O
replicated	O
.	O

Immunologically	O
,	O
HIV	O
-	O
negative	O
MSM	O
donors	O
had	O
higher	O
frequencies	O
of	O
blood	O
CD38	O
+	O
HLADR	O
+	O
and	O
CD103	O
+	O
T	O
cells	O
and	O
their	O
fecal	O
recipients	O
had	O
higher	O
frequencies	O
of	O
gut	O
CD69	O
+	O
and	O
CD103	O
+	O
T	O
cells	O
,	O
compared	O
with	O
HIV	O
-	O
negative	O
MSW	O
donors	O
and	O
recipients	O
,	O
respectively	O
.	O

Significant	O
microbiome	O
differences	O
were	O
not	O
detected	O
between	O
HIV	O
-	O
negative	O
and	O
HIV	O
-	O
positive	O
MSM	O
in	O
this	O
small	O
donor	O
cohort	O
,	O
and	O
immune	O
differences	O
between	O
their	O
recipients	O
were	O
trending	O
but	O
not	O
statistically	O
significant	O
.	O

A	O
larger	O
donor	O
cohort	O
may	O
therefore	O
be	O
needed	O
to	O
detect	O
immune	O
-	O
modulating	O
microbes	O
associated	O
with	O
HIV	O
.	O

To	O
investigate	O
whether	O
our	O
findings	O
in	O
mice	O
could	O
have	O
implications	O
for	O
HIV	O
replication	O
,	O
we	O
infected	O
primary	O
human	O
lamina	O
propria	O
cells	O
stimulated	O
with	O
isolated	O
fecal	O
microbiota	O
,	O
and	O
found	O
that	O
microbiota	O
from	O
MSM	O
stimulated	O
higher	O
frequencies	O
of	O
HIV	O
-	O
infected	O
cells	O
than	O
microbiota	O
from	O
MSW	O
.	O

Finally	O
,	O
we	O
identified	O
several	O
microbes	O
that	O
correlated	O
with	O
immune	O
readouts	O
in	O
both	O
fecal	O
recipients	O
and	O
donors	O
,	O
and	O
with	O
in	O
vitro	O
HIV	O
infection	O
,	O
which	O
suggests	O
a	O
role	O
for	O
gut	O
microbiota	O
in	O
immune	O
activation	O
and	O
potentially	O
HIV	O
acquisition	O
in	O
MSM	O
.	O

Domestic	O
canines	O
do	O
not	O
display	O
evidence	O
of	O
gut	O
microbial	O
dysbiosis	O
in	O
the	O
presence	O
of	O
Clostridioides	B-bacteria
(	I-bacteria
Clostridium	I-bacteria
)	I-bacteria
difficile	I-bacteria
,	O
despite	O
cellular	O
susceptibility	O
to	O
its	O
toxins	O
.	O

Clostridioides	B-bacteria
difficile	I-bacteria
infection	O
(	O
CDI	O
)	O
is	O
an	O
emerging	O
public	O
health	O
threat	O
and	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
is	O
the	O
most	O
common	O
cause	O
of	O
antimicrobial	O
-	O
associated	O
diarrhea	O
worldwide	O
and	O
the	O
leading	O
cause	O
of	O
hospital	O
-	O
associated	O
infections	O
in	O
the	O
US	O
,	O
yet	O
the	O
burden	O
of	O
community	O
-	O
acquired	O
infections	O
(	O
CAI	O
)	O
is	O
poorly	O
understood	O
.	O

Characterizing	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
isolated	O
from	O
canines	O
is	O
important	O
for	O
understanding	O
the	O
role	O
that	O
canines	O
may	O
play	O
in	O
CAI	O
.	O

In	O
addition	O
,	O
several	O
studies	O
have	O
suggested	O
that	O
canines	O
carry	O
toxigenic	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
asymptomatically	O
,	O
which	O
may	O
imply	O
that	O
there	O
are	O
mechanisms	O
responsible	O
for	O
resistance	O
to	O
CDI	O
in	O
canines	O
that	O
could	O
be	O
exploited	O
to	O
help	O
combat	O
human	O
CDI	O
.	O

To	O
assess	O
the	O
virulence	O
potential	O
of	O
canine	O
-	O
derived	O
C	O
.	O
difficile	O
,	O
we	O
tested	O
whether	O
toxins	O
TcdA	O
and	O
TcdB	O
(	O
hereafter	O
toxins	O
)	O
derived	O
from	O
a	O
canine	O
isolate	O
were	O
capable	O
of	O
causing	O
tight	O
junction	O
disruptions	O
to	O
colonic	O
epithelial	O
cells	O
.	O

Additionally	O
,	O
we	O
addressed	O
whether	O
major	O
differences	O
exist	O
between	O
human	O
and	O
canine	O
cells	O
regarding	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
pathogenicity	O
by	O
exposing	O
them	O
to	O
identical	O
toxins	O
.	O

We	O
then	O
examined	O
the	O
canine	O
gut	O
microbiome	O
associated	O
with	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
carriage	O
using	O
16S	O
rRNA	O
gene	O
sequencing	O
and	O
searched	O
for	O
deviations	O
from	O
homeostasis	O
as	O
an	O
indicator	O
of	O
CDI	O
.	O

Finally	O
,	O
we	O
queried	O
16S	O
rRNA	O
gene	O
sequences	O
for	O
bacterial	O
taxa	O
that	O
may	O
be	O
associated	O
with	O
resistance	O
to	O
CDI	O
in	O
canines	O
.	O

Clostridioides	B-bacteria
difficile	I-bacteria
isolated	O
from	O
a	O
canine	O
produced	O
toxins	O
that	O
reduced	O
tight	O
junction	O
integrity	O
in	O
both	O
human	O
and	O
canine	O
cells	O
in	O
vitro	O
.	O

However	O
,	O
canine	O
guts	O
were	O
not	O
dysbiotic	O
in	O
the	O
presence	O
of	O
C	O
.	O
difficile	O
.	O

These	O
findings	O
support	O
asymptomatic	O
carriage	O
in	O
canines	O
and	O
,	O
furthermore	O
,	O
suggest	O
that	O
there	O
are	O
features	O
of	O
the	O
gut	O
microbiome	O
and	O
/	O
or	O
a	O
canine	O
-	O
specific	O
immune	O
response	O
that	O
may	O
protect	O
canines	O
against	O
CDI	O
.	O

We	O
identified	O
two	O
biologically	O
relevant	O
bacteria	O
that	O
may	O
aid	O
in	O
CDI	O
resistance	O
in	O
canines	O
:	O
1	O
)	O
Clostridium	B-bacteria
hiranonis	I-bacteria
,	O
which	O
synthesizes	O
secondary	O
bile	O
acids	O
that	O
have	O
been	O
shown	O
to	O
provide	O
resistance	O
to	O
CDI	O
in	O
mice	O
;	O
and	O
2	O
)	O
Sphingobacterium	B-bacteria
faecium	I-bacteria
,	O
which	O
produces	O
sphingophospholipids	O
that	O
may	O
be	O
associated	O
with	O
regulating	O
homeostasis	O
in	O
the	O
canine	O
gut	O
.	O

Our	O
findings	O
suggest	O
that	O
canines	O
may	O
be	O
cryptic	O
reservoirs	O
for	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
and	O
,	O
furthermore	O
,	O
that	O
mechanisms	O
of	O
CDI	O
resistance	O
in	O
the	O
canine	O
gut	O
could	O
provide	O
insights	O
into	O
targeted	O
therapeutics	O
for	O
human	O
CDI	O
.	O

Fasting	O
breath	O
H2	O
and	O
gut	O
microbiota	O
metabolic	O
potential	O
are	O
associated	O
with	O
the	O
response	O
to	O
a	O
fermented	O
milk	O
product	O
in	O
irritable	O
bowel	O
syndrome	O
.	O

OBJECTIVES	O
:	O
Aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
a	O
fermented	O
milk	O
product	O
containing	O
Bifidobacterium	B-bacteria
lactis	I-bacteria
CNCM	I-bacteria
I	I-bacteria
-	I-bacteria
2494	I-bacteria
(	O
FMP	O
)	O
on	O
gastrointestinal	O
(	O
GI	O
)	O
symptoms	O
and	O
exhaled	O
H2	O
and	O
CH4	O
during	O
a	O
nutrient	O
and	O
lactulose	O
challenge	O
in	O
patients	O
with	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
.	O

METHODS	O
:	O
We	O
included	O
125	O
patients	O
with	O
IBS	O
(	O
Rome	O
III	O
)	O
.	O

Fasted	O
subjects	O
were	O
served	O
a	O
400ml	O
liquid	O
test	O
meal	O
containing	O
25g	O
lactulose	O
.	O

The	O
intensity	O
of	O
eight	O
GI	O
symptoms	O
and	O
the	O
amount	O
of	O
exhaled	O
H2	O
and	O
CH4	O
were	O
assessed	O
before	O
and	O
during	O
4h	O
after	O
meal	O
intake	O
.	O

The	O
challenge	O
was	O
repeated	O
after	O
14	O
days	O
consumption	O
of	O
FMP	O
or	O
a	O
control	O
product	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
parallel	O
design	O
.	O

The	O
metabolic	O
potential	O
of	O
fecal	O
microbiota	O
was	O
profiled	O
using	O
16S	O
MiSeq	O
analysis	O
of	O
samples	O
obtained	O
before	O
and	O
after	O
the	O
intervention	O
.	O

RESULTS	O
:	O
106	O
patients	O
with	O
IBS	O
were	O
randomized	O
.	O

No	O
difference	O
between	O
FMP	O
or	O
control	O
groups	O
was	O
found	O
on	O
GI	O
symptoms	O
or	O
breath	O
H2	O
and	O
CH4	O
in	O
the	O
whole	O
cohort	O
.	O

A	O
post	O
-	O
hoc	O
analysis	O
in	O
patients	O
stratified	O
according	O
to	O
their	O
fasting	O
H2	O
levels	O
showed	O
that	O
in	O
high	O
H2	O
producers	O
(	O
fasting	O
H2	O
level	O
>	O
/	O
=	O
10ppm	O
,	O
n	O
=	O
35	O
)	O
,	O
FMP	O
consumption	O
reduced	O
fasting	O
H2	O
levels	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
H2	O
production	O
during	O
the	O
challenge	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
and	O
tended	O
to	O
decrease	O
GI	O
discomfort	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
vs	O
.	O
control	O
product	O
.	O

The	O
Prevotella	B-bacteria
/	O
Bacteroides	B-bacteria
metabolic	O
potential	O
at	O
baseline	O
was	O
higher	O
in	O
high	O
H2	O
producers	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
vs	O
.	O
low	O
H2	O
producers	O
and	O
FMP	O
consumption	O
reduced	O
this	O
ratio	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
vs	O
.	O
control	O
product	O
.	O

CONCLUSIONS	O
:	O
The	O
response	O
to	O
a	O
fermented	O
milk	O
product	O
containing	O
Bifidobacterium	B-bacteria
lactis	I-bacteria
CNCM	I-bacteria
I	I-bacteria
-	I-bacteria
2494	I-bacteria
(	O
FMP	O
)	O
in	O
patients	O
with	O
IBS	O
seems	O
to	O
be	O
associated	O
with	O
the	O
metabolic	O
potential	O
of	O
the	O
gut	O
microbiota	O
.	O

TRIAL	O
REGISTRATION	O
:	O
ClinicalTrial	O
.	O
gov	O
NCT01252550	O
.	O

These	O
results	O
were	O
presented	O
as	O
congress	O
posters	O
at	O
Digestive	O
Disease	O
Week	O
2016	O
in	O
San	O
Diego	O
,	O
USA	O
and	O
United	O
European	O
Gastroenterology	O
Week	O
2016	O
in	O
Vienna	O
,	O
Austria	O
.	O

Multidonor	O
FMT	O
capsules	O
improve	O
symptoms	O
and	O
decrease	O
fecal	O
calprotectin	O
in	O
ulcerative	O
colitis	O
patients	O
while	O
treated	O
-	O
an	O
open	O
-	O
label	O
pilot	O
study	O
.	O

BACKGROUND	O
:	O
Growing	O
evidence	O
indicates	O
that	O
gut	O
dysbiosis	O
is	O
a	O
factor	O
in	O
the	O
pathogenesis	O
of	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
.	O

Fecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
appears	O
to	O
be	O
promising	O
in	O
inducing	O
UC	O
remission	O
,	O
but	O
there	O
are	O
no	O
reports	O
regarding	O
administration	O
using	O
capsules	O
.	O

METHODS	O
:	O
Seven	O
patients	O
with	O
active	O
UC	O
,	O
aged	O
27	O
-	O
50	O
years	O
,	O
were	O
treated	O
with	O
25	O
multidonor	O
FMT	O
capsules	O
daily	O
for	O
50	O
days	O
as	O
a	O
supplement	O
to	O
their	O
standard	O
treatment	O
in	O
an	O
open	O
-	O
label	O
pilot	O
study	O
.	O

The	O
primary	O
objective	O
was	O
to	O
follow	O
symptoms	O
through	O
the	O
Simple	O
Clinical	O
Colitis	O
Activity	O
Index	O
(	O
SCCAI	O
)	O
.	O

Secondary	O
objectives	O
were	O
to	O
follow	O
changes	O
in	O
fecal	O
calprotectin	O
and	O
microbial	O
diversity	O
through	O
fecal	O
samples	O
and	O
quality	O
of	O
life	O
through	O
the	O
Inflammatory	O
Bowel	O
Disease	O
Questionnaire	O
(	O
IBDQ	O
)	O
.	O

Participants	O
were	O
followed	O
through	O
regular	O
visits	O
for	O
six	O
months	O
.	O

RESULTS	O
:	O
From	O
a	O
median	O
of	O
6	O
at	O
baseline	O
,	O
the	O
SCCAI	O
of	O
all	O
participants	O
decreased	O
,	O
with	O
median	O
decreases	O
of	O
5	O
(	O
p	O
=	O
.	O
001	O
)	O
and	O
6	O
(	O
p	O
=	O
.	O
001	O
)	O
after	O
4	O
and	O
8	O
weeks	O
,	O
respectively	O
.	O

Three	O
of	O
the	O
seven	O
patients	O
had	O
flare	O
-	O
up	O
/	O
relapse	O
of	O
symptoms	O
after	O
the	O
active	O
treatment	O
period	O
.	O

The	O
median	O
F	O
-	O
calprotectin	O
of	O
>	O
/	O
=	O
1800	O
mg	O
/	O
kg	O
at	O
baseline	O
decreased	O
significantly	O
during	O
the	O
treatment	O
period	O
,	O
but	O
increased	O
again	O
in	O
the	O
follow	O
-	O
up	O
period	O
.	O

The	O
median	O
IBDQ	O
improved	O
at	O
all	O
visits	O
compared	O
to	O
baseline	O
.	O

The	O
fecal	O
microbiota	O
alpha	O
-	O
diversity	O
did	O
not	O
increase	O
in	O
the	O
study	O
period	O
compared	O
to	O
baseline	O
.	O

All	O
participants	O
completed	O
the	O
treatment	O
and	O
no	O
serious	O
adverse	O
events	O
were	O
reported	O
.	O

CONCLUSION	O
:	O
Fifty	O
days	O
of	O
daily	O
multidonor	O
FMT	O
capsules	O
temporarily	O
improved	O
symptoms	O
and	O
health	O
-	O
related	O
life	O
quality	O
and	O
decreased	O
F	O
-	O
calprotectin	O
in	O
patients	O
with	O
active	O
UC	O
.	O

Mucosal	O
and	O
systemic	O
immune	O
profiles	O
differ	O
during	O
early	O
and	O
late	O
phase	O
of	O
the	O
disease	O
in	O
patients	O
with	O
active	O
ulcerative	O
colitis	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
Alterations	O
in	O
the	O
immunopathogenesis	O
in	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
during	O
the	O
disease	O
course	O
have	O
been	O
proposed	O
.	O

We	O
therefore	O
aimed	O
to	O
determine	O
mucosal	O
and	O
systemic	O
immune	O
profiles	O
in	O
individual	O
patients	O
at	O
the	O
time	O
of	O
diagnosis	O
(	O
early	O
disease	O
)	O
and	O
after	O
10	O
years	O
(	O
late	O
disease	O
)	O
.	O

METHODS	O
:	O
Patients	O
with	O
UC	O
provided	O
serum	O
and	O
mucosal	O
biopsies	O
during	O
a	O
flare	O
at	O
early	O
and	O
late	O
disease	O
.	O

Serum	O
samples	O
were	O
analyzed	O
using	O
the	O
Olink	O
Proseek	O
Inflammation	O
panel	O
.	O

mRNA	O
gene	O
expression	O
of	O
biopsies	O
was	O
analyzed	O
using	O
the	O
Qiagen	O
RT2	O
Profiler	O
PCR	O
Arrays	O
Antibacterial	O
response	O
and	O
T	O
Helper	O
Cell	O
Differentiation	O
.	O

RESULTS	O
:	O
Orthogonal	O
projections	O
to	O
latent	O
structures	O
discriminant	O
analyses	O
(	O
OPLS	O
-	O
DA	O
)	O
demonstrated	O
that	O
the	O
profile	O
of	O
15	O
serum	O
proteins	O
discriminated	O
early	O
and	O
late	O
disease	O
(	O
R2	O
=	O
0	O
.	O
84	O
,	O
Q2	O
=	O
0	O
.	O
65	O
)	O
in	O
15	O
UC	O
patients	O
,	O
8	O
of	O
these	O
proteins	O
were	O
differently	O
expressed	O
between	O
the	O
groups	O
(	O
q	O
<	O
0	O
.	O
05	O
)	O
.	O

Further	O
,	O
OPLS	O
-	O
DA	O
of	O
the	O
mRNA	O
profiles	O
in	O
biopsies	O
strongly	O
discriminated	O
early	O
and	O
late	O
disease	O
with	O
high	O
predictability	O
(	O
R2	O
=	O
0	O
.	O
96	O
,	O
Q2	O
=	O
0	O
.	O
89	O
)	O
,	O
42	O
genes	O
were	O
differently	O
expressed	O
at	O
the	O
two	O
time	O
points	O
(	O
q	O
<	O
0	O
.	O
05	O
)	O
.	O

Finally	O
,	O
principal	O
component	O
analysis	O
showed	O
that	O
T	O
helper	O
(	O
Th	O
)	O
1	O
and	O
Th2	O
related	O
genes	O
were	O
associated	O
with	O
early	O
disease	O
and	O
late	O
disease	O
,	O
respectively	O
,	O
and	O
hierarchical	O
cluster	O
analysis	O
was	O
able	O
to	O
cluster	O
patients	O
with	O
early	O
from	O
late	O
disease	O
with	O
only	O
minor	O
overlap	O
.	O

CONCLUSIONS	O
:	O
Mucosal	O
and	O
systemic	O
immune	O
profiles	O
differ	O
between	O
early	O
and	O
late	O
disease	O
in	O
patients	O
with	O
active	O
UC	O
,	O
with	O
a	O
transition	O
from	O
a	O
Th1	O
to	O
a	O
Th2	O
driven	O
disease	O
in	O
the	O
intestine	O
.	O

Improved	O
understanding	O
of	O
the	O
variation	O
in	O
immunopathogenesis	O
during	O
the	O
disease	O
course	O
in	O
UC	O
is	O
important	O
to	O
guide	O
individualized	O
treatment	O
decision	O
-	O
making	O
.	O

IL	O
-	O
7	O
-	O
induced	O
proliferation	O
of	O
peripheral	O
Th17	O
cells	O
is	O
impaired	O
in	O
HAART	O
-	O
controlled	O
HIV	O
infection	O
.	O

OBJECTIVES	O
:	O
Th17	O
cells	O
are	O
key	O
regulators	O
of	O
functional	O
immunity	O
in	O
mucosal	O
tissues	O
,	O
including	O
the	O
gut	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
GALT	O
)	O
,	O
an	O
important	O
site	O
of	O
immune	O
impairment	O
in	O
HIV	O
infection	O
.	O

During	O
HIV	O
infection	O
,	O
Th17	O
cells	O
are	O
lost	O
in	O
large	O
numbers	O
from	O
the	O
GALT	O
.	O

Despite	O
the	O
recovery	O
of	O
peripheral	O
CD4	O
T	O
cells	O
that	O
accompanies	O
suppression	O
of	O
viral	O
replication	O
with	O
HAART	O
,	O
Th17	O
cells	O
in	O
GALT	O
are	O
not	O
completely	O
restored	O
.	O

IL	O
-	O
7	O
is	O
essential	O
for	O
the	O
survival	O
and	O
proliferation	O
of	O
T	O
cells	O
,	O
but	O
its	O
signaling	O
through	O
its	O
receptor	O
IL	O
-	O
7Ralpha	O
(	O
CD127	O
)	O
,	O
is	O
impaired	O
in	O
CD8	O
T	O
cells	O
and	O
thymocytes	O
during	O
HIV	O
infection	O
.	O

We	O
set	O
out	O
to	O
determine	O
if	O
decreased	O
CD127	O
expression	O
or	O
impaired	O
CD127	O
signaling	O
may	O
be	O
the	O
cause	O
of	O
Th17	O
impairment	O
in	O
HAART	O
-	O
controlled	O
HIV	O
infection	O
.	O

DESIGN	O
:	O
Healthy	O
and	O
HIV	O
donors	O
on	O
HAART	O
were	O
selected	O
for	O
this	O
study	O
of	O
Th17	O
cell	O
function	O
in	O
HIV	O
.	O

METHODS	O
:	O
Peripheral	O
CD4	O
T	O
cells	O
and	O
Th17	O
cells	O
were	O
isolated	O
using	O
magnetic	O
beads	O
,	O
then	O
stimulated	O
with	O
IL	O
-	O
7	O
.	O

CD127	O
expression	O
and	O
the	O
phosphorylation	O
of	O
signaling	O
molecules	O
was	O
determined	O
using	O
flow	O
cytometry	O
.	O

Proliferation	O
was	O
determined	O
with	O
a	O
CFSE	O
dilution	O
assay	O
.	O

RESULTS	O
:	O
CD127	O
was	O
not	O
decreased	O
on	O
Th17	O
cells	O
from	O
HAART	O
-	O
controlled	O
HIV	O
individuals	O
,	O
in	O
fact	O
,	O
the	O
percentage	O
of	O
Th17	O
cells	O
that	O
express	O
CD127	O
was	O
increased	O
in	O
treated	O
HIV	O
individuals	O
.	O

Furthermore	O
,	O
Th17	O
cells	O
from	O
HAART	O
-	O
controlled	O
individuals	O
,	O
have	O
normal	O
IL	O
-	O
7	O
-	O
induced	O
STAT5	O
and	O
Bcl	O
-	O
2	O
responses	O
,	O
but	O
vastly	O
decreased	O
proliferative	O
responses	O
.	O

CONCLUSION	O
:	O
This	O
reduced	O
IL	O
-	O
7	O
responsiveness	O
may	O
explain	O
the	O
lack	O
of	O
Th17	O
cell	O
recovery	O
and	O
ongoing	O
systemic	O
immune	O
activation	O
that	O
persists	O
despite	O
well	O
treated	O
HIV	O
infection	O
.	O

Food	O
processing	O
,	O
gut	O
microbiota	O
and	O
the	O
globesity	O
problem	O
.	O

In	O
the	O
context	O
of	O
diseases	O
of	O
affluence	O
,	O
western	O
diets	O
have	O
in	O
the	O
past	O
years	O
mainly	O
been	O
studied	O
on	O
their	O
fat	O
and	O
sugar	O
content	O
and	O
lack	O
of	O
dietary	O
fiber	O
.	O

Yet	O
,	O
the	O
more	O
general	O
aspect	O
of	O
food	O
processing	O
has	O
recently	O
sparked	O
scientific	O
interest	O
as	O
well	O
.	O

In	O
addition	O
,	O
the	O
gut	O
microbiota	O
have	O
been	O
put	O
forward	O
as	O
an	O
important	O
link	O
between	O
diet	O
,	O
obesity	O
and	O
non	O
-	O
communicable	O
diseases	O
(	O
NCD	O
)	O
.	O

Western	O
dietary	O
patterns	O
,	O
containing	O
large	O
amounts	O
of	O
processed	O
foods	O
might	O
create	O
an	O
imbalance	O
in	O
the	O
gut	O
system	O
by	O
affecting	O
gut	O
bacteria	O
and	O
their	O
metabolism	O
.	O

Here	O
we	O
discuss	O
what	O
has	O
been	O
already	O
published	O
regarding	O
the	O
relationship	O
between	O
several	O
recently	O
researched	O
features	O
of	O
processed	O
foods	O
and	O
the	O
etiology	O
of	O
obesity	O
and	O
NCD	O
.	O

The	O
addressed	O
features	O
concern	O
micronutrient	O
and	O
energy	O
density	O
,	O
several	O
types	O
of	O
food	O
additives	O
and	O
the	O
generation	O
of	O
advanced	O
glycation	O
end	O
products	O
by	O
thermal	O
treatment	O
during	O
food	O
processing	O
.	O

Overall	O
,	O
literature	O
indicates	O
that	O
all	O
discussed	O
aspects	O
can	O
be	O
linked	O
to	O
western	O
ailments	O
and	O
that	O
they	O
can	O
have	O
a	O
potential	O
negative	O
impact	O
on	O
human	O
microbiota	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
the	O
thesis	O
that	O
a	O
distressed	O
gut	O
microbiota	O
is	O
a	O
mechanism	O
that	O
might	O
explain	O
how	O
food	O
processing	O
features	O
could	O
harm	O
human	O
health	O
is	O
gaining	O
empirical	O
evidence	O
.	O

Future	O
research	O
will	O
need	O
to	O
address	O
the	O
question	O
whether	O
the	O
alteration	O
of	O
the	O
gut	O
microbiota	O
is	O
a	O
direct	O
or	O
an	O
indirect	O
(	O
via	O
the	O
host	O
)	O
effect	O
.	O

These	O
conclusions	O
are	O
important	O
assets	O
in	O
the	O
fight	O
against	O
the	O
continuing	O
worldwide	O
upsurge	O
of	O
obesity	O
and	O
NCD	O
.	O

Altered	O
Bacterial	O
-	O
Fungal	O
Interkingdom	O
Networks	O
in	O
the	O
Guts	O
of	O
Ankylosing	O
Spondylitis	O
Patients	O
.	O

Intestinal	O
bacterial	O
dysbiosis	O
has	O
been	O
increasingly	O
linked	O
to	O
ankylosing	O
spondylitis	O
(	O
AS	O
)	O
,	O
which	O
is	O
a	O
prototypic	O
and	O
best	O
studied	O
subtype	O
of	O
spondyloarthritis	O
(	O
SpA	O
)	O
.	O

Fungi	O
and	O
bacteria	O
coexist	O
in	O
the	O
human	O
gut	O
and	O
interact	O
with	O
each	O
other	O
.	O

Although	O
they	O
have	O
been	O
shown	O
to	O
contribute	O
actively	O
to	O
health	O
or	O
disease	O
,	O
no	O
studies	O
have	O
investigated	O
whether	O
the	O
fungal	O
microbiota	O
in	O
AS	O
patients	O
is	O
perturbed	O
.	O

In	O
this	O
study	O
,	O
fecal	O
samples	O
from	O
22	O
AS	O
patients	O
,	O
with	O
clinical	O
and	O
radiographic	O
assessments	O
,	O
and	O
16	O
healthy	O
controls	O
(	O
HCs	O
)	O
were	O
collected	O
to	O
systematically	O
characterize	O
the	O
gut	O
microbiota	O
and	O
mycobiota	O
in	O
AS	O
patients	O
by	O
16S	O
rRNA	O
gene	O
-	O
and	O
ITS2	O
-	O
based	O
DNA	O
sequencing	O
.	O

Our	O
results	O
showed	O
that	O
the	O
microbiota	O
of	O
AS	O
patients	O
was	O
characterized	O
by	O
increased	O
abundance	O
of	O
Proteobacteria	B-bacteria
and	O
decreased	O
Bacteroidetes	B-bacteria
,	O
which	O
was	O
contributed	O
by	O
enrichment	O
of	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
,	O
Veillonella	B-bacteria
,	O
Lachnospiraceae	B-bacteria
NK4A136	I-bacteria
group	O
,	O
and	O
reduction	O
of	O
Prevotella	B-bacteria
strain	I-bacteria
9	I-bacteria
,	O
Megamona	B-bacteria
,	O
and	O
Fusobacterium	B-bacteria
.	O

The	O
gut	O
mycobiota	O
of	O
AS	O
patients	O
was	O
characterized	O
by	O
higher	O
levels	O
of	O
Ascomycota	O
,	O
especially	O
the	O
class	O
of	O
Dothideomycetes	B-bacteria
,	O
and	O
decreased	O
abundance	O
of	O
Basidiomycota	B-bacteria
,	O
which	O
was	O
mainly	O
contributed	O
by	O
the	O
decease	O
of	O
Agaricales	O
.	O

Compared	O
to	O
HCs	O
,	O
decreased	O
ITS2	O
/	O
16S	O
biodiversity	O
ratios	O
and	O
altered	O
bacterial	O
-	O
fungal	O
interkingdom	O
networks	O
were	O
observed	O
in	O
AS	O
patients	O
.	O

Compared	O
with	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
treating	O
AS	O
patients	O
with	O
biological	O
agents	O
induced	O
obvious	O
changes	O
in	O
the	O
gut	O
mycobiota	O
,	O
and	O
this	O
result	O
was	O
highly	O
associated	O
with	O
disease	O
activity	O
indexes	O
,	O
including	O
AS	O
disease	O
activity	O
index	O
(	O
ASDAS	O
)	O
C	O
-	O
reactive	O
protein	O
(	O
asCRP	O
)	O
,	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
)	O
,	O
and	O
Bath	O
AS	O
disease	O
activity	O
index	O
(	O
BASDAI	O
)	O
.	O

In	O
addition	O
,	O
altered	O
mycobiota	O
in	O
AS	O
patients	O
was	O
also	O
found	O
associated	O
with	O
the	O
degree	O
of	O
radiographic	O
damage	O
.	O

IMPORTANCE	O
The	O
human	O
gut	O
is	O
colonized	O
by	O
diverse	O
fungi	O
(	O
mycobiota	O
)	O
,	O
and	O
fungi	O
have	O
long	O
been	O
suspected	O
in	O
the	O
pathogenesis	O
of	O
SpA	O
.	O

Our	O
study	O
unraveled	O
a	O
disease	O
-	O
specific	O
interkingdom	O
network	O
alteration	O
in	O
AS	O
,	O
suggesting	O
that	O
fungi	O
,	O
or	O
the	O
interkingdom	O
interactions	O
between	O
bacteria	O
and	O
fungi	O
,	O
may	O
play	O
an	O
essential	O
role	O
in	O
AS	O
development	O
.	O

However	O
,	O
our	O
study	O
is	O
limited	O
by	O
sample	O
size	O
,	O
and	O
in	O
-	O
depth	O
mechanism	O
studies	O
and	O
additional	O
large	O
-	O
scale	O
investigations	O
characterizing	O
the	O
gut	O
mycobiome	O
in	O
AS	O
patients	O
are	O
needed	O
to	O
form	O
a	O
foundation	O
for	O
research	O
into	O
the	O
relationship	O
between	O
mycobiota	O
dysbiosis	O
and	O
AS	O
development	O
.	O

Clostridium	B-bacteria
difficile	I-bacteria
Modulates	O
the	O
Gut	O
Microbiota	O
by	O
Inducing	O
the	O
Production	O
of	O
Indole	O
,	O
an	O
Interkingdom	O
Signaling	O
and	O
Antimicrobial	O
Molecule	O
.	O

Clostridium	B-bacteria
(	I-bacteria
Clostridioides	I-bacteria
)	I-bacteria
difficile	I-bacteria
infection	O
(	O
CDI	O
)	O
is	O
associated	O
with	O
dysbiosis	O
.	O

C	B-bacteria
.	I-bacteria
difficile	I-bacteria
has	O
a	O
characteristic	O
propensity	O
to	O
persist	O
and	O
recur	O
1	O
to	O
4	O
weeks	O
after	O
treatment	O
,	O
but	O
the	O
mechanism	O
is	O
unknown	O
.	O

We	O
hypothesized	O
that	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
may	O
persist	O
by	O
manipulating	O
the	O
intestinal	O
microenvironment	O
,	O
thereby	O
hampering	O
gut	O
microbiota	O
reconstitution	O
following	O
antibiotic	O
-	O
mediated	O
dysbiosis	O
.	O

By	O
screening	O
stools	O
from	O
CDI	O
patients	O
for	O
unique	O
markers	O
,	O
a	O
metabolite	O
identified	O
to	O
be	O
indole	O
by	O
mass	O
spectrometry	O
and	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
was	O
identified	O
.	O

The	O
average	O
fecal	O
indole	O
concentration	O
detected	O
in	O
CDI	O
patients	O
(	O
n	O
=	O
216	O
;	O
mean	O
,	O
1	O
,	O
684	O
.	O
0	O
+	O
/	O
-	O
84	O
.	O
4	O
microM	O
)	O
was	O
significantly	O
higher	O
than	O
in	O
stools	O
of	O
patients	O
with	O
non	O
-	O
C	O
.	O
difficile	O
diarrhea	O
(	O
n	O
=	O
204	O
;	O
mean	O
,	O
762	O
.	O
8	O
+	O
/	O
-	O
53	O
.	O
8	O
microM	O
)	O
.	O

Certain	O
intestinal	O
bacteria	O
,	O
but	O
not	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
,	O
produce	O
indole	O
,	O
a	O
potent	O
antimicrobial	O
antioxidant	O
.	O

Remarkably	O
,	O
C	O
.	O
difficile	O
induced	O
other	O
indole	O
-	O
producing	O
gut	O
microbes	O
to	O
produce	O
increasing	O
amounts	O
of	O
indole	O
.	O

Furthermore	O
,	O
a	O
C	O
.	O
difficile	O
accessory	O
gene	O
regulator	O
1	O
quorum	O
sensing	O
system	O
mutant	O
can	O
not	O
induce	O
indole	O
,	O
but	O
complementation	O
of	O
the	O
mutant	O
strain	O
with	O
the	O
wild	O
-	O
type	O
gene	O
restored	O
its	O
ability	O
to	O
induce	O
indole	O
production	O
.	O

Indole	O
tolerance	O
assays	O
indicated	O
that	O
the	O
amount	O
of	O
indole	O
required	O
to	O
inhibit	O
growth	O
of	O
most	O
gut	O
-	O
protective	O
bacteria	O
was	O
within	O
the	O
range	O
detected	O
in	O
the	O
CDI	O
stools	O
.	O

We	O
think	O
that	O
a	O
high	O
indole	O
level	O
limits	O
the	O
growth	O
of	O
beneficial	O
indole	O
-	O
sensitive	O
bacteria	O
in	O
the	O
colon	O
and	O
alters	O
colonization	O
resistance	O
and	O
this	O
might	O
allow	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
to	O
proliferate	O
and	O
persist	O
.	O

Together	O
,	O
these	O
results	O
reveal	O
a	O
unique	O
mechanism	O
of	O
C	O
.	O
difficile	O
persistence	O
and	O
provide	O
insight	O
into	O
complex	O
interactions	O
and	O
chemical	O
warfare	O
among	O
the	O
gut	O
microbiota	O
.	O

IMPORTANCE	O
Clostridium	B-bacteria
difficile	I-bacteria
infection	O
is	O
the	O
leading	O
cause	O
of	O
hospital	O
-	O
acquired	O
and	O
antibiotic	O
-	O
associated	O
diarrhea	O
worldwide	O
.	O

C	B-bacteria
.	I-bacteria
difficile	I-bacteria
flourishes	O
in	O
the	O
colon	O
after	O
the	O
diversity	O
of	O
the	O
beneficial	O
and	O
protective	O
gut	O
microbiota	O
have	O
been	O
altered	O
by	O
antibiotic	O
therapy	O
.	O

C	B-bacteria
.	I-bacteria
difficile	I-bacteria
tends	O
to	O
persist	O
,	O
as	O
does	O
dysbiosis	O
,	O
encouraging	O
recurrence	O
a	O
few	O
days	O
to	O
weeks	O
after	O
treatment	O
,	O
and	O
this	O
further	O
complicates	O
treatment	O
options	O
.	O

Here	O
,	O
we	O
show	O
that	O
C	O
.	O
difficile	O
might	O
persist	O
by	O
manipulating	O
the	O
indigenous	O
microbiota	O
to	O
produce	O
indole	O
,	O
a	O
bioactive	O
molecule	O
that	O
inhibits	O
the	O
growth	O
and	O
reconstitution	O
of	O
the	O
protective	O
gut	O
microbiota	O
during	O
infection	O
.	O

This	O
discovery	O
may	O
explain	O
a	O
unique	O
strategy	O
C	O
.	O
difficile	O
uses	O
to	O
control	O
other	O
bacteria	O
in	O
the	O
colon	O
and	O
provide	O
insight	O
into	O
the	O
complex	O
interactions	O
and	O
chemical	O
warfare	O
among	O
the	O
gut	O
microbiota	O
.	O

Immunomodulatory	O
nanogels	O
overcome	O
restricted	O
immunity	O
in	O
a	O
murine	O
model	O
of	O
gut	O
microbiome	O
-	O
mediated	O
metabolic	O
syndrome	O
.	O

Biomaterials	O
-	O
based	O
nanovaccines	O
,	O
such	O
as	O
those	O
made	O
of	O
poly	O
(	O
lactic	O
-	O
co	O
-	O
glycolic	O
acid	O
)	O
(	O
PLGA	O
)	O
,	O
can	O
induce	O
stronger	O
immunity	O
than	O
soluble	O
antigens	O
in	O
healthy	O
wild	O
-	O
type	O
mouse	O
models	O
.	O

However	O
,	O
whether	O
metabolic	O
syndrome	O
can	O
influence	O
the	O
immunological	O
responses	O
of	O
nanovaccines	O
remains	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
first	O
show	O
that	O
alteration	O
in	O
the	O
sensing	O
of	O
the	O
gut	O
microbiome	O
through	O
Toll	O
-	O
like	O
receptor	O
5	O
(	O
TLR5	O
)	O
and	O
the	O
resulting	O
metabolic	O
syndrome	O
in	O
TLR5	O
(	O
-	O
/	O
-	O
)	O
mice	O
diminish	O
the	O
germinal	O
center	O
immune	O
response	O
induced	O
by	O
PLGA	O
nanovaccines	O
.	O

The	O
PLGA	O
nanovaccines	O
,	O
unexpectedly	O
,	O
further	O
changed	O
gut	O
microbiota	O
.	O

By	O
chronically	O
treating	O
mice	O
with	O
antibiotics	O
,	O
we	O
show	O
that	O
disrupting	O
gut	O
microbiome	O
leads	O
to	O
poor	O
vaccine	O
response	O
in	O
an	O
obesity	O
-	O
independent	O
manner	O
.	O

We	O
next	O
demonstrate	O
that	O
the	O
low	O
immune	O
response	O
can	O
be	O
rescued	O
by	O
an	O
immunomodulatory	O
Pyr	O
-	O
pHEMA	O
nanogel	O
vaccine	O
,	O
which	O
functions	O
through	O
TLR2	O
stimulation	O
,	O
enhanced	O
trafficking	O
,	O
and	O
induced	O
stronger	O
germinal	O
center	O
response	O
than	O
alum	O
-	O
supplemented	O
PLGA	O
nanovaccines	O
.	O

The	O
study	O
highlights	O
the	O
potential	O
for	O
immunomodulation	O
under	O
gut	O
-	O
mediated	O
metabolic	O
syndrome	O
conditions	O
using	O
advanced	O
nanomaterials	O
.	O

Fatty	O
Liver	O
Disease	O
and	O
Gut	O
Microbiota	O
:	O
A	O
Comprehensive	O
Update	O
.	O

Nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
is	O
the	O
accumulation	O
of	O
fat	O
in	O
the	O
liver	O
in	O
the	O
absence	O
of	O
secondary	O
causes	O
.	O

NAFLD	O
is	O
a	O
multifactorial	O
disease	O
that	O
results	O
from	O
the	O
interaction	O
of	O
genetic	O
predisposition	O
and	O
metabolic	O
,	O
inflammatory	O
and	O
environmental	O
factors	O
.	O

Among	O
these	O
factors	O
,	O
dysregulation	O
of	O
gut	O
microbiome	O
has	O
been	O
linked	O
to	O
the	O
development	O
of	O
fatty	O
liver	O
disease	O
.	O

The	O
microbiome	O
composition	O
can	O
be	O
modified	O
by	O
dietary	O
habits	O
leading	O
to	O
gut	O
microbiome	O
dysbiosis	O
,	O
especially	O
when	O
a	O
diet	O
is	O
rich	O
in	O
saturated	O
fats	O
,	O
animal	O
products	O
and	O
fructose	O
sugars	O
.	O

Different	O
species	O
of	O
bacteria	O
in	O
the	O
gut	O
metabolize	O
nutrients	O
differently	O
,	O
triggering	O
different	O
pathways	O
that	O
contribute	O
to	O
the	O
accumulation	O
of	O
fat	O
within	O
the	O
liver	O
and	O
triggering	O
inflammatory	O
cascades	O
that	O
promote	O
liver	O
damage	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
understanding	O
of	O
the	O
roles	O
of	O
gut	O
microbiota	O
in	O
mediating	O
NAFLD	O
development	O
and	O
discuss	O
possible	O
gut	O
microbiota	O
-	O
targeted	O
therapies	O
for	O
NAFLD	O
.	O

We	O
summarize	O
experimental	O
and	O
clinical	O
evidence	O
,	O
and	O
draw	O
conclusions	O
on	O
the	O
therapeutic	O
potential	O
of	O
manipulating	O
gut	O
microbiota	O
to	O
decrease	O
the	O
incidence	O
and	O
prevalence	O
of	O
fatty	O
liver	O
disease	O
.	O

Worldwide	O
trends	O
in	O
scientific	O
publications	O
on	O
association	O
of	O
gut	O
microbiota	O
with	O
obesity	O
.	O

Objectives	O
:	O
Recent	O
evidence	O
has	O
shown	O
underlying	O
roles	O
of	O
gut	O
dysbiosis	O
and	O
metabolic	O
endotoxemia	O
in	O
obesity	O
and	O
its	O
complications	O
.	O

Despite	O
the	O
large	O
number	O
of	O
experimental	O
and	O
clinical	O
researches	O
performed	O
on	O
gut	O
microbiota	O
and	O
obesity	O
,	O
no	O
bibliometrics	O
'	O
study	O
has	O
been	O
conducted	O
so	O
far	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
trend	O
of	O
global	O
scientific	O
publications	O
in	O
the	O
field	O
of	O
gut	O
microbiota	O
and	O
obesity	O
.	O

Materials	O
and	O
Methods	O
:	O
The	O
bibliometrics	O
'	O
data	O
from	O
January	O
2000	O
to	O
April	O
2017	O
were	O
retrieved	O
based	O
on	O
Scopus	O
database	O
.	O

The	O
analysis	O
of	O
the	O
publication	O
year	O
,	O
main	O
source	O
,	O
citation	O
,	O
subject	O
area	O
,	O
co	O
-	O
authorship	O
network	O
,	O
and	O
geographical	O
distribution	O
were	O
carried	O
out	O
,	O
accordingly	O
.	O

The	O
data	O
were	O
analyzed	O
using	O
the	O
Scopus	O
analysis	O
tools	O
,	O
SPSS	O
version	O
15	O
and	O
Visualizing	O
Scientific	O
Landscapes	O
(	O
VOS	O
)	O
viewer	O
version	O
1	O
.	O
6	O
.	O
5	O
.	O

Results	O
:	O
Out	O
of	O
4384	O
documents	O
that	O
were	O
identified	O
,	O
the	O
United	O
States	O
published	O
the	O
highest	O
number	O
(	O
28	O
.	O
2	O
%	O
)	O
,	O
followed	O
by	O
China	O
and	O
United	O
Kingdom	O
.	O

The	O
number	O
of	O
publications	O
showed	O
an	O
increasing	O
trend	O
over	O
the	O
years	O
of	O
which	O
the	O
most	O
productive	O
year	O
was	O
2016	O
.	O

The	O
leading	O
subject	O
area	O
was	O
medicine	O
.	O

Most	O
of	O
published	O
scientific	O
documents	O
were	O
original	O
articles	O
and	O
the	O
top	O
source	O
was	O
`	O
`	O
PLoS	O
One	O
'	O
'	O
.	O

The	O
documents	O
were	O
cited	O
totally	O
153576	O
times	O
with	O
average	O
citations	O
per	O
article	O
as	O
35	O
.	O
03	O
,	O
and	O
h	O
-	O
index	O
of	O
159	O
.	O

Top	O
author	O
in	O
the	O
co	O
-	O
authorship	O
network	O
assessment	O
was	O
`	O
`	O
Wang	O
J	O
.	O
'	O
'	O
from	O
China	O
.	O

Conclusion	O
:	O
This	O
study	O
could	O
provide	O
practical	O
sources	O
to	O
researchers	O
to	O
find	O
highly	O
cited	O
studies	O
.	O

Moreover	O
,	O
the	O
study	O
could	O
pave	O
the	O
way	O
for	O
researchers	O
to	O
be	O
engaged	O
in	O
studies	O
which	O
potentially	O
lead	O
to	O
more	O
publication	O
in	O
the	O
field	O
.	O

Oral	O
Administration	O
of	O
Lactobacillus	B-bacteria
delbrueckii	I-bacteria
during	O
the	O
Suckling	O
Phase	O
Improves	O
Antioxidant	O
Activities	O
and	O
Immune	O
Responses	O
after	O
the	O
Weaning	O
Event	O
in	O
a	O
Piglet	O
Model	O
.	O

Early	O
colonization	O
in	O
the	O
gut	O
by	O
probiotics	O
influences	O
the	O
progressive	O
development	O
and	O
maturity	O
of	O
antioxidant	O
and	O
immune	O
system	O
functionality	O
in	O
the	O
future	O
.	O

This	O
study	O
investigated	O
the	O
impact	O
of	O
orally	O
administrated	O
Lactobacillus	B-bacteria
delbrueckii	I-bacteria
(	O
LAB	B-bacteria
)	O
during	O
the	O
suckling	O
phase	O
on	O
future	O
antioxidant	O
and	O
immune	O
responses	O
of	O
the	O
host	O
,	O
using	O
a	O
piglet	O
model	O
.	O

One	O
hundred	O
neonatal	O
piglets	O
received	O
saline	O
(	O
CON	O
)	O
or	O
LAB	B-bacteria
at	O
the	O
amounts	O
of	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
mL	O
at	O
1	O
,	O
3	O
,	O
7	O
,	O
and	O
14	O
d	O
of	O
age	O
,	O
respectively	O
.	O

The	O
piglets	O
were	O
weaned	O
at	O
the	O
age	O
of	O
21	O
d	O
and	O
fed	O
until	O
the	O
age	O
of	O
49	O
d	O
.	O
Serum	O
,	O
liver	O
,	O
and	O
intestinal	O
samples	O
were	O
obtained	O
at	O
21	O
,	O
28	O
,	O
and	O
49	O
d	O
of	O
age	O
.	O

The	O
results	O
showed	O
that	O
LAB	B-bacteria
tended	O
to	O
decrease	O
serum	O
8	O
-	O
hydroxy	O
-	O
2	O
-	O
deoxyguanosine	O
concentration	O
and	O
decreased	O
the	O
concentration	O
of	O
serum	O
and	O
hepatic	O
malondialdehyde	O
,	O
but	O
increased	O
the	O
activity	O
of	O
hepatic	O
glutathione	O
peroxidase	O
on	O
days	O
21	O
,	O
28	O
,	O
and	O
49	O
.	O

The	O
concentrations	O
of	O
secretory	O
immunoglobulin	O
A	O
and	O
some	O
inflammatory	O
cytokines	O
and	O
chemokines	O
were	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
intestinal	O
mucosa	O
of	O
LAB	O
-	O
treated	O
piglets	O
on	O
days	O
21	O
,	O
28	O
,	O
and	O
49	O
compared	O
to	O
that	O
of	O
CON	O
piglets	O
.	O

Likewise	O
,	O
protein	O
expression	O
of	O
cyclooxygenase	O
2	O
and	O
inducible	O
nitric	O
oxide	O
synthase	O
in	O
the	O
intestine	O
of	O
LAB	O
-	O
treated	O
piglets	O
was	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
during	O
the	O
whole	O
period	O
.	O

These	O
results	O
indicate	O
that	O
administration	O
of	O
LAB	B-bacteria
to	O
the	O
suckling	O
piglet	O
could	O
improve	O
antioxidant	O
capacity	O
and	O
stimulate	O
intestinal	O
immune	O
response	O
,	O
and	O
these	O
long	O
-	O
lasting	O
effects	O
are	O
also	O
observed	O
up	O
to	O
4	O
weeks	O
after	O
weaning	O
.	O

A	O
proper	O
utilization	O
of	O
LAB	B-bacteria
to	O
neonates	O
would	O
be	O
beneficial	O
to	O
human	O
and	O
animal	O
'	O
s	O
future	O
health	O
.	O

Aryl	O
hydrocarbon	O
receptor	O
agonist	O
indigo	O
protects	O
against	O
obesity	O
-	O
related	O
insulin	O
resistance	O
through	O
modulation	O
of	O
intestinal	O
and	O
metabolic	O
tissue	O
immunity	O
.	O

BACKGROUND	O
/	O
OBJECTIVES	O
:	O
Low	O
-	O
grade	O
chronic	O
inflammation	O
in	O
visceral	O
adipose	O
tissue	O
and	O
the	O
intestines	O
are	O
important	O
drivers	O
of	O
obesity	O
associated	O
insulin	O
resistance	O
.	O

Bioactive	O
compounds	O
derived	O
from	O
plants	O
are	O
an	O
important	O
source	O
of	O
potential	O
novel	O
therapies	O
for	O
the	O
treatment	O
of	O
chronic	O
diseases	O
.	O

In	O
search	O
for	O
new	O
immune	O
based	O
treatments	O
of	O
obesity	O
associated	O
insulin	O
resistance	O
,	O
we	O
screened	O
for	O
tissue	O
relevant	O
anti	O
-	O
inflammatory	O
properties	O
in	O
20	O
plant	O
-	O
based	O
extracts	O
.	O

METHODS	O
:	O
We	O
screened	O
20	O
plant	O
-	O
based	O
extracts	O
to	O
assess	O
for	O
preferential	O
production	O
of	O
IL	O
-	O
10	O
compared	O
to	O
TNFalpha	O
,	O
specifically	O
targetting	O
metabolic	O
tissues	O
,	O
including	O
the	O
visceral	O
adipose	O
tissue	O
.	O

We	O
assessed	O
the	O
therapeutic	O
potential	O
of	O
the	O
strongest	O
anti	O
-	O
inflammatory	O
compound	O
,	O
indigo	O
,	O
in	O
the	O
C57BL	O
/	O
6J	O
diet	O
-	O
induced	O
obesity	O
mouse	O
model	O
with	O
supplementation	O
for	O
up	O
to	O
16	O
weeks	O
by	O
measuring	O
changes	O
in	O
body	O
weight	O
,	O
glucose	O
and	O
insulin	O
tolerance	O
,	O
and	O
gut	O
barrier	O
function	O
.	O

We	O
also	O
utilized	O
flow	O
cytometry	O
,	O
quantitative	O
PCR	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
and	O
histology	O
to	O
measure	O
changes	O
to	O
immune	O
cells	O
populations	O
and	O
cytokine	O
profiles	O
in	O
the	O
intestine	O
,	O
visceral	O
adipose	O
tissue	O
(	O
VAT	O
)	O
,	O
and	O
liver	O
.	O

16SrRNA	O
sequencing	O
was	O
performed	O
to	O
examine	O
gut	O
microbial	O
differences	O
induced	O
by	O
indigo	O
supplementation	O
.	O

RESULTS	O
:	O
We	O
identifed	O
indigo	O
,	O
an	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
ligand	O
agonist	O
,	O
as	O
a	O
potent	O
inducer	O
of	O
IL	O
-	O
10	O
and	O
IL	O
-	O
22	O
,	O
which	O
protects	O
against	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
insulin	O
resistance	O
and	O
fatty	O
liver	O
disease	O
in	O
the	O
diet	O
-	O
induced	O
obesity	O
model	O
.	O

Therapeutic	O
actions	O
were	O
mechanistically	O
linked	O
to	O
decreased	O
inflammatory	O
immune	O
cell	O
tone	O
in	O
the	O
intestine	O
,	O
VAT	O
and	O
liver	O
.	O

Specifically	O
,	O
indigo	O
increased	O
Lactobacillus	B-bacteria
bacteria	I-bacteria
and	O
elicited	O
IL	O
-	O
22	O
production	O
in	O
the	O
gut	O
,	O
which	O
improved	O
intestinal	O
barrier	O
permeability	O
and	O
reduced	O
endotoxemia	O
.	O

These	O
changes	O
were	O
associated	O
with	O
increased	O
IL	O
-	O
10	O
production	O
by	O
immune	O
cells	O
residing	O
in	O
liver	O
and	O
VAT	O
.	O

CONCLUSIONS	O
:	O
Indigo	O
is	O
a	O
naturally	O
occurring	O
AhR	O
ligand	O
with	O
anti	O
-	O
inflammatory	O
properties	O
that	O
effectively	O
protects	O
against	O
HFD	O
-	O
induced	O
glucose	O
dysregulation	O
.	O

Compounds	O
derived	O
from	O
indigo	O
or	O
those	O
with	O
similar	O
properties	O
could	O
represent	O
novel	O
therapies	O
for	O
diseases	O
associated	O
with	O
obesity	O
-	O
related	O
metabolic	O
tissue	O
inflammation	O
.	O

Perinatal	O
factors	O
affect	O
the	O
gut	O
microbiota	O
up	O
to	O
four	O
years	O
after	O
birth	O
.	O

Perinatal	O
factors	O
impact	O
gut	O
microbiota	O
development	O
in	O
early	O
life	O
,	O
however	O
,	O
little	O
is	O
known	O
on	O
the	O
effects	O
of	O
these	O
factors	O
on	O
microbes	O
in	O
later	O
life	O
.	O

Here	O
we	O
sequence	O
DNA	O
from	O
faecal	O
samples	O
of	O
children	O
over	O
the	O
first	O
four	O
years	O
and	O
reveal	O
a	O
perpetual	O
evolution	O
of	O
the	O
gut	O
microbiota	O
during	O
this	O
period	O
.	O

The	O
significant	O
impact	O
of	O
gestational	O
age	O
at	O
birth	O
and	O
delivery	O
mode	O
on	O
gut	O
microbiota	O
progression	O
is	O
evident	O
in	O
the	O
first	O
four	O
years	O
of	O
life	O
,	O
while	O
no	O
measurable	O
effects	O
of	O
antibiotics	O
are	O
found	O
in	O
the	O
first	O
year	O
.	O

Microbiota	O
profiles	O
are	O
also	O
characteristic	O
in	O
children	O
dependant	O
on	O
gestational	O
age	O
and	O
maturity	O
.	O

Full	O
term	O
delivery	O
is	O
characterised	O
by	O
Bacteroides	B-bacteria
(	O
year	O
one	O
)	O
,	O
Parabacteroides	B-bacteria
(	O
year	O
two	O
)	O
and	O
Christensenellaceae	B-bacteria
(	O
year	O
four	O
)	O
.	O

Preterm	O
delivery	O
is	O
characterised	O
by	O
Lactobacillus	B-bacteria
(	O
year	O
one	O
)	O
,	O
Streptococcus	B-bacteria
(	O
year	O
two	O
)	O
and	O
Carnobacterium	B-bacteria
(	O
year	O
four	O
)	O
.	O

This	O
study	O
reveals	O
that	O
the	O
gut	O
retains	O
distinct	O
microbial	O
profiles	O
of	O
perinatal	O
factors	O
up	O
to	O
four	O
years	O
of	O
age	O
.	O

Mus	O
musculus	O
deficient	O
for	O
secretory	O
antibodies	O
show	O
delayed	O
growth	O
with	O
an	O
altered	O
urinary	O
metabolome	O
.	O

BACKGROUND	O
:	O
The	O
polymeric	O
immunoglobulin	O
receptor	O
(	O
pIgR	O
)	O
maintains	O
the	O
integrity	O
of	O
epithelial	O
barriers	O
by	O
transporting	O
polymeric	O
antibodies	O
and	O
antigens	O
through	O
the	O
epithelial	O
mucosa	O
into	O
the	O
lumen	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
role	O
of	O
pIgR	O
in	O
maintaining	O
gut	O
barrier	O
integrity	O
,	O
which	O
is	O
important	O
for	O
the	O
normal	O
development	O
in	O
mice	O
.	O

METHODS	O
:	O
Cohorts	O
of	O
pIgR	O
(	O
-	O
/	O
-	O
)	O
mice	O
and	O
their	O
wildtype	O
controls	O
were	O
housed	O
under	O
Specific	O
Pathogen	O
Free	O
(	O
SPF	O
)	O
conditions	O
and	O
monitored	O
for	O
weight	O
gain	O
as	O
an	O
indicator	O
of	O
development	O
over	O
time	O
.	O

The	O
general	O
physiology	O
of	O
the	O
gastrointestinal	O
tract	O
was	O
analysed	O
using	O
immunohistochemistry	O
in	O
young	O
(	O
8	O
-	O
12	O
weeks	O
of	O
age	O
)	O
and	O
aged	O
mice	O
(	O
up	O
to	O
18	O
months	O
of	O
age	O
)	O
,	O
and	O
the	O
observed	O
immunopathology	O
in	O
pIgR	O
(	O
-	O
/	O
-	O
)	O
mice	O
was	O
further	O
characterised	O
using	O
flow	O
cytometry	O
.	O

Urinary	O
metabolites	O
were	O
analysed	O
using	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
)	O
,	O
which	O
revealed	O
changes	O
in	O
metabolites	O
that	O
correlated	O
with	O
age	O
-	O
related	O
increase	O
in	O
gut	O
permeability	O
in	O
pIgR	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

RESULTS	O
:	O
We	O
observed	O
that	O
pIgR	O
(	O
-	O
/	O
-	O
)	O
mice	O
exhibited	O
delayed	O
growth	O
,	O
and	O
this	O
phenomenon	O
is	O
associated	O
with	O
low	O
-	O
grade	O
gut	O
inflammation	O
that	O
increased	O
with	O
ageing	O
.	O

The	O
gross	O
intraepithelial	O
lymphocytic	O
(	O
IEL	O
)	O
infiltration	O
characteristic	O
of	O
pIgR	O
(	O
-	O
/	O
-	O
)	O
mice	O
was	O
redefined	O
as	O
CD8alpha	O
(	O
+	O
)	O
alphabeta	O
(	O
+	O
)	O
T	O
cells	O
,	O
the	O
majority	O
of	O
which	O
expressed	O
high	O
levels	O
of	O
CD103	O
and	O
CD69	O
consistent	O
with	O
tissue	O
resident	O
memory	O
T	O
cells	O
(	O
TRM	O
)	O
.	O

Comparison	O
of	O
the	O
urinary	O
metabolome	O
between	O
pIgR	O
(	O
-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
mice	O
revealed	O
key	O
changes	O
in	O
urinary	O
biomarkers	O
fucose	O
,	O
glycine	O
and	O
Vitamin	O
B5	O
,	O
suggestive	O
of	O
altered	O
mucosal	O
permeability	O
.	O

A	O
significant	O
increase	O
in	O
gut	O
permeability	O
was	O
confirmed	O
by	O
analysing	O
the	O
site	O
-	O
specific	O
uptake	O
of	O
sugar	O
probes	O
in	O
different	O
parts	O
of	O
the	O
intestine	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
show	O
that	O
loss	O
of	O
the	O
secretory	O
antibody	O
system	O
in	O
mice	O
results	O
in	O
enhanced	O
accumulation	O
of	O
inflammatory	O
IELs	O
in	O
the	O
gut	O
,	O
which	O
likely	O
reflects	O
ongoing	O
inflammation	O
in	O
reaction	O
to	O
gut	O
microbiota	O
or	O
food	O
antigens	O
,	O
leading	O
to	O
delayed	O
growth	O
in	O
pIgR	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

We	O
demonstrate	O
that	O
this	O
leads	O
to	O
the	O
presence	O
of	O
a	O
unique	O
urinary	O
metabolome	O
profile	O
,	O
which	O
may	O
provide	O
a	O
biomarker	O
for	O
altered	O
gut	O
permeability	O
.	O

Gut	O
T	O
Cells	O
Feast	O
on	O
GLP	O
-	O
1	O
to	O
Modulate	O
Cardiometabolic	O
Disease	O
.	O

Glucagon	O
-	O
like	O
peptide	O
-	O
1	O
(	O
GLP	O
-	O
1	O
)	O
is	O
an	O
enteroendocrine	O
hormone	O
that	O
controls	O
insulin	O
secretion	O
,	O
intestinal	O
function	O
,	O
and	O
food	O
intake	O
.	O

Recently	O
in	O
Nature	O
,	O
He	O
et	O
al	O
.	O
(	O
2019	O
)	O
reported	O
that	O
gut	O
intraepithelial	O
T	O
cells	O
regulate	O
GLP	O
-	O
1	O
bioavailability	O
by	O
capturing	O
it	O
on	O
GLP	O
-	O
1	O
receptors	O
and	O
impacting	O
L	O
-	O
cell	O
numbers	O
.	O

This	O
study	O
delineates	O
a	O
novel	O
endocrine	O
-	O
immune	O
axis	O
through	O
which	O
intestinal	O
immune	O
cells	O
regulate	O
whole	O
-	O
body	O
metabolism	O
.	O

Rhodnius	B-bacteria
prolixus	I-bacteria
:	O
Identification	O
of	O
missing	O
components	O
of	O
the	O
IMD	O
immune	O
signaling	O
pathway	O
and	O
functional	O
characterization	O
of	O
its	O
role	O
in	O
eliminating	O
bacteria	O
.	O

The	O
innate	O
immune	O
system	O
in	O
insects	O
is	O
regulated	O
by	O
specific	O
signalling	O
pathways	O
.	O

Most	O
immune	O
related	O
pathways	O
were	O
identified	O
and	O
characterized	O
in	O
holometabolous	O
insects	O
such	O
as	O
Drosophila	O
melanogaster	O
,	O
and	O
it	O
was	O
assumed	O
they	O
would	O
be	O
highly	O
conserved	O
in	O
all	O
insects	O
.	O

The	O
hemimetabolous	O
insect	O
,	O
Rhodnius	O
prolixus	O
,	O
has	O
served	O
as	O
a	O
model	O
to	O
study	O
basic	O
insect	O
physiology	O
,	O
but	O
also	O
is	O
a	O
major	O
vector	O
of	O
the	O
human	O
parasite	O
,	O
Trypanosoma	O
cruzi	O
,	O
that	O
causes	O
10	O
,	O
000	O
deaths	O
annually	O
.	O

The	O
publication	O
of	O
the	O
R	B-bacteria
.	I-bacteria
prolixus	I-bacteria
genome	O
revealed	O
that	O
one	O
of	O
the	O
main	O
immune	O
pathways	O
,	O
the	O
Immune	O
-	O
deficiency	O
pathway	O
(	O
IMD	O
)	O
,	O
was	O
incomplete	O
and	O
probably	O
non	O
-	O
functional	O
,	O
an	O
observation	O
shared	O
with	O
other	O
hemimetabolous	O
insects	O
including	O
the	O
pea	O
aphid	O
(	O
Acyrthosiphon	B-bacteria
pisum	I-bacteria
)	O
and	O
the	O
bedbug	O
(	O
Cimex	B-bacteria
lectularius	I-bacteria
)	O
.	O

It	O
was	O
proposed	O
that	O
the	O
IMD	O
pathway	O
is	O
inactive	O
in	O
R	B-bacteria
.	I-bacteria
prolixus	I-bacteria
as	O
an	O
adaptation	O
to	O
prevent	O
eliminating	O
beneficial	O
symbiont	O
gut	O
bacteria	O
.	O

We	O
used	O
bioinformatic	O
analyses	O
based	O
on	O
reciprocal	O
BLAST	O
and	O
HMM	O
-	O
profile	O
searches	O
to	O
find	O
orthologs	O
for	O
most	O
of	O
the	O
`	O
`	O
missing	O
'	O
'	O
elements	O
of	O
the	O
IMD	O
pathway	O
and	O
provide	O
data	O
that	O
these	O
are	O
regulated	O
in	O
response	O
to	O
infection	O
with	O
Gram	O
-	O
negative	O
bacteria	O
.	O

We	O
used	O
RNAi	O
strategies	O
to	O
demonstrate	O
the	O
role	O
of	O
the	O
IMD	O
pathway	O
in	O
regulating	O
the	O
expression	O
of	O
specific	O
antimicrobial	O
peptides	O
(	O
AMPs	O
)	O
in	O
the	O
fat	O
body	O
of	O
R	O
.	O
prolixus	O
.	O

The	O
data	O
indicate	O
that	O
the	O
IMD	O
pathway	O
is	O
present	O
and	O
active	O
in	O
R	B-bacteria
.	I-bacteria
prolixus	I-bacteria
,	O
which	O
opens	O
up	O
new	O
avenues	O
of	O
research	O
on	O
R	O
.	O
prolixus	O
-	O
T	O
.	O
cruzi	O
interactions	O
.	O

Gut	O
microbiota	O
and	O
immunity	O
in	O
common	O
variable	O
immunodeficiency	O
:	O
crosstalk	O
with	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

In	O
recent	O
years	O
,	O
gut	O
microbiota	O
(	O
GM	O
)	O
has	O
emerged	O
as	O
a	O
key	O
factor	O
in	O
shaping	O
the	O
pathogenesis	O
of	O
a	O
vast	O
array	O
of	O
immune	O
-	O
mediated	O
diseases	O
,	O
as	O
well	O
as	O
in	O
the	O
response	O
to	O
immune	O
-	O
based	O
treatments	O
such	O
as	O
anti	O
PD	O
-	O
1	O
and	O
anti	O
-	O
CTLA4	O
therapy	O
or	O
influenza	O
vaccination	O
.	O

In	O
addition	O
,	O
GM	O
has	O
a	O
significant	O
role	O
in	O
the	O
immune	O
system	O
development	O
and	O
is	O
fundamental	O
in	O
developing	O
mucosal	O
immunity	O
.	O

Recent	O
data	O
suggest	O
that	O
GM	O
plays	O
an	O
important	O
role	O
in	O
the	O
immune	O
system	O
of	O
immune	O
deficient	O
patients	O
.	O

GM	O
status	O
has	O
a	O
remarkable	O
impact	O
on	O
the	O
immune	O
system	O
and	O
in	O
immune	O
deficient	O
patients	O
;	O
this	O
can	O
lead	O
to	O
important	O
consequences	O
.	O

Prebiotics	O
are	O
indeed	O
a	O
promising	O
candidate	O
in	O
restoring	O
GM	O
homeostasis	O
and	O
improving	O
immunity	O
.	O

Antibiotics	O
are	O
also	O
capable	O
of	O
altering	O
the	O
microbial	O
equilibrium	O
.	O

A	O
descriptive	O
analysis	O
of	O
gut	O
microbiota	O
composition	O
in	O
differentially	O
reared	O
infant	O
rhesus	O
monkeys	O
(	O
Macaca	O
mulatta	O
)	O
across	O
the	O
first	O
6	O
months	O
of	O
life	O
.	O

The	O
gastrointestinal	O
microbiome	O
is	O
recognized	O
as	O
a	O
critical	O
component	O
in	O
host	O
immune	O
function	O
,	O
physiology	O
,	O
and	O
behavior	O
.	O

Early	O
life	O
experiences	O
that	O
alter	O
diet	O
and	O
social	O
contact	O
also	O
influence	O
these	O
outcomes	O
.	O

Despite	O
the	O
growing	O
number	O
of	O
studies	O
in	O
this	O
area	O
,	O
no	O
studies	O
to	O
date	O
have	O
examined	O
the	O
contribution	O
of	O
early	O
life	O
experiences	O
on	O
the	O
gut	O
microbiome	O
in	O
infants	O
across	O
development	O
.	O

Such	O
studies	O
are	O
important	O
for	O
understanding	O
the	O
biological	O
and	O
environmental	O
factors	O
that	O
contribute	O
to	O
optimal	O
gut	O
microbial	O
colonization	O
and	O
subsequent	O
health	O
.	O

We	O
studied	O
infant	O
rhesus	O
monkeys	O
(	O
Macaca	O
mulatta	O
)	O
across	O
the	O
first	O
6	O
months	O
of	O
life	O
that	O
were	O
pseudo	O
-	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
different	O
rearing	O
conditions	O
at	O
birth	O
:	O
mother	O
-	O
peer	O
-	O
reared	O
(	O
MPR	O
)	O
,	O
in	O
which	O
infants	O
were	O
reared	O
in	O
social	O
groups	O
with	O
many	O
other	O
adults	O
and	O
peers	O
and	O
nursed	O
on	O
their	O
mothers	O
,	O
or	O
nursery	O
-	O
reared	O
(	O
NR	O
)	O
,	O
in	O
which	O
infants	O
were	O
reared	O
by	O
human	O
caregivers	O
,	O
fed	O
formula	O
,	O
and	O
given	O
daily	O
social	O
contact	O
with	O
peers	O
.	O

We	O
analyzed	O
the	O
microbiome	O
from	O
rectal	O
swabs	O
(	O
total	O
N	O
=	O
97	O
;	O
MPR	O
=	O
43	O
,	O
NR	O
=	O
54	O
)	O
taken	O
on	O
the	O
day	O
of	O
birth	O
and	O
at	O
postnatal	O
Days	O
14	O
,	O
30	O
,	O
90	O
,	O
and	O
180	O
using	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

Bacterial	O
composition	O
differences	O
were	O
evident	O
as	O
early	O
as	O
14	O
days	O
,	O
with	O
MPR	O
infants	O
exhibiting	O
a	O
lower	O
abundance	O
of	O
Bifidobacterium	B-bacteria
and	O
a	O
higher	O
abundance	O
of	O
Bacteroides	B-bacteria
than	O
NR	O
infants	O
.	O

The	O
most	O
marked	O
differences	O
were	O
observed	O
at	O
90	O
days	O
,	O
when	O
Bifidobacterium	B-bacteria
,	O
Lactobacillus	B-bacteria
,	O
Streptococcus	B-bacteria
,	O
Bacteroides	B-bacteria
,	O
Clostridium	B-bacteria
,	O
and	O
Prevotella	B-bacteria
differed	O
across	O
rearing	O
groups	O
.	O

By	O
Day	O
180	O
,	O
no	O
differences	O
in	O
the	O
relative	O
abundances	O
of	O
the	O
bacteria	O
of	O
interest	O
were	O
observed	O
.	O

These	O
novel	O
findings	O
in	O
developing	O
primate	O
neonates	O
indicate	O
that	O
the	O
early	O
social	O
environment	O
as	O
well	O
as	O
diet	O
influence	O
gut	O
microbiota	O
composition	O
very	O
early	O
in	O
life	O
.	O

These	O
results	O
also	O
lay	O
the	O
groundwork	O
for	O
mechanistic	O
studies	O
examining	O
the	O
effects	O
of	O
early	O
experiences	O
on	O
gut	O
microbiota	O
across	O
development	O
with	O
the	O
ultimate	O
goal	O
of	O
understanding	O
the	O
clinical	O
significance	O
of	O
developmental	O
changes	O
.	O

Gut	O
bacteria	O
of	O
animals	O
/	O
pests	O
living	O
in	O
polluted	O
environments	O
are	O
a	O
potential	O
source	O
of	O
antibacterials	O
.	O

The	O
morbidity	O
and	O
mortality	O
associated	O
with	O
bacterial	O
infections	O
have	O
remained	O
significant	O
despite	O
chemotherapeutic	O
advances	O
.	O

With	O
the	O
emergence	O
of	O
drug	O
-	O
resistant	O
bacterial	O
strains	O
,	O
the	O
situation	O
has	O
become	O
a	O
serious	O
threat	O
to	O
the	O
public	O
health	O
.	O

Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
identify	O
novel	O
antibacterials	O
.	O

The	O
majority	O
of	O
antibiotics	O
available	O
in	O
the	O
market	O
are	O
produced	O
by	O
bacteria	O
isolated	O
from	O
soil	O
.	O

However	O
,	O
the	O
low	O
-	O
hanging	O
fruit	O
has	O
been	O
picked	O
;	O
hence	O
,	O
there	O
is	O
a	O
need	O
to	O
mine	O
bacteria	O
from	O
unusual	O
sources	O
.	O

With	O
this	O
in	O
mind	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
animals	O
and	O
pests	O
such	O
as	O
cockroaches	O
,	O
snake	O
,	O
crocodiles	O
,	O
and	O
water	O
monitor	O
lizard	O
come	O
across	O
pathogenic	O
bacteria	O
regularly	O
,	O
yet	O
flourish	O
in	O
contaminated	O
environments	O
.	O

These	O
species	O
must	O
have	O
developed	O
methods	O
to	O
defend	O
themselves	O
to	O
counter	O
pathogens	O
.	O

Although	O
the	O
immune	O
system	O
is	O
known	O
to	O
possess	O
antiinfective	O
properties	O
,	O
gut	O
bacteria	O
of	O
animals	O
/	O
pests	O
may	O
also	O
offer	O
a	O
potential	O
source	O
of	O
novel	O
antibacterial	O
agents	O
,	O
and	O
it	O
is	O
the	O
subject	O
of	O
this	O
study	O
.	O

This	O
paper	O
discusses	O
our	O
current	O
knowledge	O
of	O
bacteria	O
isolated	O
from	O
land	O
and	O
marine	O
animals	O
with	O
antibacterial	O
properties	O
and	O
to	O
propose	O
untapped	O
sources	O
for	O
the	O
isolation	O
of	O
bacteria	O
to	O
mine	O
potentially	O
novel	O
antibiotic	O
molecules	O
.	O

A	O
prospective	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
dose	O
-	O
response	O
relationship	O
study	O
to	O
investigate	O
efficacy	O
of	O
fructo	O
-	O
oligosaccharides	O
(	O
FOS	O
)	O
on	O
human	O
gut	O
microflora	O
.	O

Fructo	O
-	O
oligosaccharides	O
(	O
FOS	O
)	O
,	O
a	O
prebiotic	O
supplement	O
,	O
is	O
known	O
for	O
its	O
Bifidogenic	O
capabilities	O
.	O

However	O
,	O
aspects	O
such	O
as	O
effect	O
of	O
variable	O
quantities	O
of	O
FOS	O
intake	O
on	O
gut	O
microbiota	O
,	O
and	O
temporal	O
dynamics	O
of	O
gut	O
microbiota	O
(	O
transitioning	O
through	O
basal	O
,	O
dosage	O
,	O
and	O
follow	O
-	O
up	O
phases	O
)	O
has	O
not	O
been	O
studied	O
in	O
detail	O
.	O

This	O
study	O
investigated	O
these	O
aspects	O
through	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
dose	O
-	O
response	O
relationship	O
study	O
.	O

The	O
study	O
involved	O
80	O
participants	O
being	O
administered	O
FOS	O
at	O
three	O
dose	O
levels	O
(	O
2	O
.	O
5	O
,	O
5	O
,	O
and	O
10	O
g	O
/	O
day	O
)	O
or	O
placebo	O
(	O
Maltodextrin	O
10	O
g	O
/	O
day	O
)	O
during	O
dosage	O
phase	O
.	O

Microbial	O
DNA	O
extracted	O
from	O
fecal	O
samples	O
collected	O
at	O
9	O
intervening	O
time	O
-	O
points	O
was	O
sequenced	O
and	O
analysed	O
.	O

Results	O
indicate	O
that	O
FOS	O
consumption	O
increased	O
the	O
relative	O
abundance	O
of	O
OTUs	O
belonging	O
to	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
.	O

Interestingly	O
,	O
higher	O
FOS	O
dosage	O
appears	O
to	O
promote	O
,	O
in	O
contrast	O
to	O
Maltodextrin	O
,	O
the	O
selective	O
proliferation	O
of	O
OTUs	O
belonging	O
to	O
Lactobacillus	B-bacteria
.	O

While	O
consumption	O
of	O
prebiotics	O
increased	O
bacterial	O
diversity	O
,	O
withdrawal	O
led	O
to	O
its	O
reduction	O
.	O

Apart	O
from	O
probiotic	O
bacteria	O
,	O
a	O
significant	O
change	O
was	O
also	O
observed	O
in	O
certain	O
butyrate	O
-	O
producing	O
microbes	O
like	O
Faecalibacterium	B-bacteria
,	O
Ruminococcus	B-bacteria
and	O
Oscillospira	B-bacteria
.	O

The	O
positive	O
impact	O
of	O
FOS	O
on	O
butyrate	O
-	O
producing	O
bacteria	O
and	O
FOS	O
-	O
mediated	O
increased	O
bacterial	O
diversity	O
reinforces	O
the	O
role	O
of	O
prebiotics	O
in	O
conferring	O
beneficial	O
functions	O
to	O
the	O
host	O
.	O

Azoreductase	O
activity	O
of	O
dye	O
-	O
decolorizing	O
bacteria	O
isolated	O
from	O
the	O
human	O
gut	O
microbiota	O
.	O

The	O
gut	O
microbiota	O
enriches	O
the	O
human	O
gene	O
pool	O
and	O
contributes	O
to	O
xenobiotic	O
metabolism	O
.	O

Microbial	O
azoreductases	O
modulate	O
the	O
reduction	O
of	O
azo	O
-	O
bonds	O
,	O
activating	O
produgs	O
and	O
azo	O
polymer	O
-	O
coated	O
dosage	O
forms	O
,	O
or	O
degrading	O
food	O
additives	O
.	O

Here	O
,	O
we	O
aimed	O
to	O
screen	O
the	O
healthy	O
human	O
gut	O
microbiota	O
for	O
food	O
colorant	O
-	O
reducing	O
activity	O
and	O
to	O
characterize	O
factors	O
modulating	O
it	O
.	O

Four	O
representative	O
isolates	O
from	O
screened	O
fecal	O
samples	O
were	O
identified	O
as	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
(	O
AZO	O
-	O
Ec	O
)	O
,	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
(	O
AZO	O
-	O
Ef	O
)	O
,	O
E	B-bacteria
.	I-bacteria
avium	I-bacteria
(	O
AZO	O
-	O
Ev	O
)	O
and	O
B	B-bacteria
.	I-bacteria
cereus	I-bacteria
(	O
AZO	O
-	O
Bc	O
)	O
.	O

Both	O
AZO	O
-	O
Ef	O
and	O
AZO	O
-	O
Ev	O
decolorized	O
amaranth	O
aerobically	O
and	O
microaerophilically	O
while	O
AZO	O
-	O
Ec	O
and	O
AZO	O
-	O
Bc	O
had	O
higher	O
aerobic	O
reduction	O
rates	O
.	O

The	O
isolates	O
varied	O
in	O
their	O
activities	O
against	O
different	O
dyes	O
,	O
and	O
the	O
azo	O
-	O
reduction	O
activity	O
mostly	O
followed	O
zero	O
-	O
order	O
reaction	O
kinetics	O
,	O
with	O
a	O
few	O
exceptions	O
.	O

Additionally	O
,	O
the	O
isolates	O
had	O
different	O
pH	O
dependence	O
,	O
e	O
.	O
g	O
.	O
,	O
AZO	O
-	O
Ec	O
was	O
not	O
affected	O
by	O
pH	O
variation	O
while	O
AZO	O
-	O
Bc	O
exhibited	O
variable	O
degradation	O
kinetics	O
at	O
different	O
pH	O
levels	O
.	O

Cell	O
-	O
free	O
extracts	O
showed	O
NADH	O
-	O
dependent	O
enzymatic	O
activities	O
14	O
-	O
19	O
times	O
higher	O
than	O
extracellular	O
fractions	O
.	O

FMN	O
did	O
not	O
affect	O
the	O
reducing	O
activity	O
of	O
AZO	O
-	O
Ef	O
cell	O
-	O
free	O
extract	O
,	O
whereas	O
AZO	O
-	O
Ec	O
,	O
AZO	O
-	O
Ev	O
and	O
AZO	O
-	O
Bc	O
had	O
significantly	O
higher	O
reduction	O
rates	O
in	O
its	O
presence	O
(	O
P	O
values	O
=	O
0	O
.	O
02	O
,	O
0	O
.	O
0001	O
and	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O

Using	O
Degenerate	O
primers	O
allowed	O
the	O
amplification	O
of	O
azoreductase	O
genes	O
,	O
whose	O
sequences	O
were	O
98	O
-	O
99	O
%	O
similar	O
to	O
genes	O
encoding	O
FMN	O
-	O
dependent	O
-	O
NADH	O
azoreductases	O
.	O

Gut	O
microbiota	O
dependent	O
anti	O
-	O
tumor	O
immunity	O
restricts	O
melanoma	O
growth	O
in	O
Rnf5	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Accumulating	O
evidence	O
points	O
to	O
an	O
important	O
role	O
for	O
the	O
gut	O
microbiome	O
in	O
anti	O
-	O
tumor	O
immunity	O
.	O

Here	O
,	O
we	O
show	O
that	O
altered	O
intestinal	O
microbiota	O
contributes	O
to	O
anti	O
-	O
tumor	O
immunity	O
,	O
limiting	O
tumor	O
expansion	O
.	O

Mice	O
lacking	O
the	O
ubiquitin	O
ligase	O
RNF5	O
exhibit	O
attenuated	O
activation	O
of	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
components	O
,	O
which	O
coincides	O
with	O
increased	O
expression	O
of	O
inflammasome	O
components	O
,	O
recruitment	O
and	O
activation	O
of	O
dendritic	O
cells	O
and	O
reduced	O
expression	O
of	O
antimicrobial	O
peptides	O
in	O
intestinal	O
epithelial	O
cells	O
.	O

Reduced	O
UPR	O
expression	O
is	O
also	O
seen	O
in	O
murine	O
and	O
human	O
melanoma	O
tumor	O
specimens	O
that	O
responded	O
to	O
immune	O
checkpoint	O
therapy	O
.	O

Co	O
-	O
housing	O
of	O
Rnf5	O
(	O
-	O
/	O
-	O
)	O
and	O
WT	O
mice	O
abolishes	O
the	O
anti	O
-	O
tumor	O
immunity	O
and	O
tumor	O
inhibition	O
phenotype	O
,	O
whereas	O
transfer	O
of	O
11	O
bacterial	O
strains	O
,	O
including	O
B	B-bacteria
.	I-bacteria
rodentium	I-bacteria
,	O
enriched	O
in	O
Rnf5	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
establishes	O
anti	O
-	O
tumor	O
immunity	O
and	O
restricts	O
melanoma	O
growth	O
in	O
germ	O
-	O
free	O
WT	O
mice	O
.	O

Altered	O
UPR	O
signaling	O
,	O
exemplified	O
in	O
Rnf5	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
coincides	O
with	O
altered	O
gut	O
microbiota	O
composition	O
and	O
anti	O
-	O
tumor	O
immunity	O
to	O
control	O
melanoma	O
growth	O
.	O

Effects	O
of	O
a	O
Novel	O
Probiotic	O
Combination	O
on	O
Pathogenic	O
Bacterial	O
-	O
Fungal	O
Polymicrobial	O
Biofilms	O
.	O

Dysbiosis	O
of	O
the	O
gut	O
microbiome	O
has	O
been	O
implicated	O
in	O
inflammatory	O
bowel	O
diseases	O
.	O

We	O
have	O
shown	O
that	O
levels	O
of	O
Candida	O
tropicalis	O
,	O
along	O
with	O
those	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
Serratia	B-bacteria
marcescens	I-bacteria
,	O
are	O
significantly	O
elevated	O
in	O
Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
patients	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
a	O
novel	O
probiotic	O
to	O
prevent	O
and	O
treat	O
polymicrobial	O
biofilms	O
(	O
PMB	O
)	O
formed	O
by	O
C	O
.	O
tropicalis	O
with	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
marcescens	I-bacteria
Since	O
Candida	O
albicans	O
has	O
been	O
reported	O
to	O
be	O
elevated	O
in	O
CD	O
patients	O
,	O
we	O
investigated	O
the	O
interactions	O
of	O
C	O
.	O
albicans	O
with	O
these	O
bacterial	O
species	O
in	O
biofilm	O
formation	O
.	O

We	O
determined	O
whether	O
the	O
interaction	O
between	O
Candida	O
spp	O
.	O
and	O
bacteria	O
is	O
specific	O
by	O
using	O
Trichosporon	O
inkin	O
and	O
Saccharomyces	O
fibuligera	O
as	O
comparators	O
.	O

Additionally	O
,	O
the	O
effects	O
of	O
probiotics	O
on	O
C	O
.	O
albicans	O
germination	O
and	O
biofilm	O
formation	O
were	O
determined	O
.	O

To	O
determine	O
the	O
ability	O
of	O
the	O
probiotic	O
to	O
prevent	O
or	O
treat	O
mature	O
biofilms	O
,	O
probiotic	O
filtrate	O
was	O
added	O
to	O
the	O
PMB	O
at	O
early	O
(	O
prevention	O
)	O
and	O
mature	O
(	O
treatment	O
)	O
phases	O
.	O

Biofilm	O
thickness	O
and	O
architecture	O
were	O
assessed	O
by	O
confocal	O
scanning	O
laser	O
microscopy	O
.	O

The	O
effects	O
of	O
the	O
probiotic	O
on	O
germination	O
were	O
evaluated	O
in	O
the	O
presence	O
of	O
serum	O
.	O

Exposure	O
of	O
C	O
.	O
tropicalis	O
PMB	O
to	O
probiotic	O
filtrate	O
reduced	O
biofilm	O
matrix	O
,	O
decreased	O
thickness	O
,	O
and	O
inhibited	O
hyphal	O
formation	O
.	O

We	O
showed	O
that	O
C	O
.	O
albicans	O
or	O
C	O
.	O
tropicalis	O
formed	O
significantly	O
thicker	O
PMB	O
than	O
control	O
biofilms	O
,	O
indicating	O
that	O
this	O
interaction	O
is	O
Candida	O
specific	O
.	O

Treatment	O
with	O
probiotic	O
filtrate	O
inhibited	O
C	O
.	O
albicans	O
germination	O
and	O
prevented	O
/	O
treated	O
C	O
.	O
albicans	O
PMB	O
.	O

The	O
designed	O
probiotic	O
may	O
have	O
utility	O
in	O
the	O
management	O
of	O
biofilm	O
-	O
associated	O
gastrointestinal	O
diseases	O
such	O
as	O
Crohn	O
'	O
s	O
and	O
colorectal	O
cancer	O
.	O
IMPORTANCE	O
The	O
effects	O
of	O
diversity	O
of	O
the	O
gut	O
microbiome	O
on	O
inflammation	O
have	O
centered	O
mainly	O
on	O
bacterial	O
flora	O
.	O

Recent	O
research	O
has	O
implicated	O
fungal	O
species	O
and	O
their	O
interactions	O
with	O
other	O
organisms	O
in	O
the	O
inflammatory	O
process	O
.	O

New	O
ways	O
to	O
restore	O
microbial	O
balance	O
in	O
the	O
gut	O
are	O
being	O
explored	O
.	O

Our	O
goal	O
was	O
to	O
identify	O
beneficial	O
probiotic	O
strains	O
that	O
would	O
antagonize	O
these	O
fungal	O
and	O
bacterial	O
pathogens	O
that	O
are	O
elevated	O
in	O
the	O
inflamed	O
gut	O
,	O
and	O
which	O
also	O
have	O
antibiofilm	O
activity	O
.	O

Fungus	O
-	O
bacterium	O
correlation	O
analysis	O
allowed	O
us	O
to	O
identify	O
candidate	O
probiotic	O
species	O
that	O
can	O
antagonize	O
microbial	O
pathogens	O
,	O
which	O
we	O
subsequently	O
incorporated	O
into	O
a	O
novel	O
probiotic	O
formulation	O
.	O

Amylase	O
,	O
which	O
is	O
known	O
to	O
have	O
some	O
antibiofilm	O
activity	O
,	O
was	O
also	O
added	O
to	O
the	O
probiotic	O
mixture	O
.	O

This	O
novel	O
probiotic	O
may	O
have	O
utility	O
for	O
the	O
management	O
of	O
inflammatory	O
bowel	O
diseases	O
by	O
disrupting	O
polymicrobial	O
biofilm	O
formation	O
.	O

Gut	O
Microbiota	O
in	O
Patients	O
With	O
Irritable	O
Bowel	O
Syndrome	O
-	O
a	O
Systematic	O
Review	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
is	O
common	O
but	O
difficult	O
to	O
treat	O
.	O

Altering	O
the	O
gut	O
microbiota	O
has	O
been	O
proposed	O
as	O
a	O
strategy	O
for	O
treatment	O
of	O
IBS	O
,	O
but	O
the	O
association	O
between	O
the	O
gut	O
microbiome	O
and	O
IBS	O
symptoms	O
has	O
not	O
been	O
well	O
established	O
.	O

We	O
performed	O
a	O
systematic	O
review	O
to	O
explore	O
evidence	O
for	O
this	O
association	O
.	O

METHODS	O
:	O
We	O
searched	O
databases	O
,	O
including	O
MEDLINE	O
,	O
EMBASE	O
,	O
Cochrane	O
CDSR	O
,	O
and	O
CENTRAL	O
,	O
through	O
April	O
2	O
,	O
2018	O
for	O
case	O
-	O
control	O
studies	O
comparing	O
the	O
fecal	O
or	O
colon	O
microbiomes	O
of	O
adult	O
or	O
pediatric	O
patients	O
with	O
IBS	O
with	O
microbiomes	O
of	O
healthy	O
individuals	O
(	O
controls	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
differences	O
in	O
specific	O
gut	O
microbes	O
between	O
patients	O
with	O
IBS	O
and	O
controls	O
.	O

RESULTS	O
:	O
The	O
search	O
identified	O
2631	O
citations	O
;	O
24	O
studies	O
from	O
22	O
articles	O
were	O
included	O
.	O

Most	O
studies	O
evaluated	O
adults	O
presenting	O
with	O
various	O
IBS	O
subtypes	O
.	O

Family	B-bacteria
Enterobacteriaceae	B-bacteria
(	O
phylum	O
Proteobacteria	B-bacteria
)	O
,	O
family	B-bacteria
Lactobacillaceae	B-bacteria
,	O
and	O
genus	B-bacteria
Bacteroides	I-bacteria
were	O
increased	O
in	O
patients	O
with	O
IBS	O
compared	O
with	O
controls	O
,	O
whereas	O
uncultured	O
Clostridiales	B-bacteria
I	I-bacteria
,	O
genus	B-bacteria
Faecalibacterium	I-bacteria
(	O
including	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
)	O
,	O
and	O
genus	O
Bifidobacterium	B-bacteria
were	O
decreased	O
in	O
patients	O
with	O
IBS	O
.	O

The	O
diversity	O
of	O
the	O
microbiota	O
was	O
either	O
decreased	O
or	O
not	O
different	O
in	O
IBS	O
patients	O
compared	O
with	O
controls	O
.	O

More	O
than	O
40	O
%	O
of	O
included	O
studies	O
did	O
not	O
state	O
whether	O
cases	O
and	O
controls	O
were	O
comparable	O
(	O
did	O
not	O
describe	O
sex	O
and	O
/	O
or	O
age	O
characteristics	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
a	O
systematic	O
review	O
,	O
we	O
identified	O
specific	O
bacteria	O
associated	O
with	O
microbiomes	O
of	O
patients	O
with	O
IBS	O
vs	O
controls	O
.	O

Studies	O
are	O
needed	O
to	O
determine	O
whether	O
these	O
microbes	O
are	O
a	O
product	O
or	O
cause	O
of	O
IBS	O
.	O

The	O
composition	O
and	O
abundance	O
of	O
bacterial	O
communities	O
residing	O
in	O
the	O
gut	O
of	O
Glossina	O
palpalis	O
palpalis	O
captured	O
in	O
two	O
sites	O
of	O
southern	O
Cameroon	O
.	O

BACKGROUND	O
:	O
A	O
number	O
of	O
reports	O
have	O
demonstrated	O
the	O
role	O
of	O
insect	O
bacterial	O
flora	O
on	O
their	O
host	O
'	O
s	O
physiology	O
and	O
metabolism	O
.	O

The	O
tsetse	O
host	O
and	O
vector	O
of	O
trypanosomes	O
responsible	O
for	O
human	O
sleeping	O
sickness	O
(	O
human	O
African	O
trypanosomiasis	O
,	O
HAT	O
)	O
and	O
nagana	O
in	O
animals	O
(	O
African	O
animal	O
trypanosomiasis	O
,	O
AAT	O
)	O
carry	O
bacteria	O
that	O
influence	O
its	O
diet	O
and	O
immune	O
processes	O
.	O

However	O
,	O
the	O
mechanisms	O
involved	O
in	O
these	O
processes	O
remain	O
poorly	O
documented	O
.	O

This	O
underscores	O
the	O
need	O
for	O
increased	O
research	O
into	O
the	O
bacterial	O
flora	O
composition	O
and	O
structure	O
of	O
tsetse	O
flies	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
diversity	O
and	O
relative	O
abundance	O
of	O
bacterial	O
genera	O
in	O
Glossina	O
palpalis	O
palpalis	O
flies	O
collected	O
in	O
two	O
trypanosomiasis	O
foci	O
in	O
Cameroon	O
.	O

METHODS	O
:	O
Samples	O
of	O
G	O
.	O
p	O
.	O
palpalis	O
which	O
were	O
either	O
negative	O
or	O
naturally	O
trypanosome	O
-	O
positive	O
were	O
collected	O
in	O
two	O
foci	O
located	O
in	O
southern	O
Cameroon	O
(	O
Campo	O
and	O
Bipindi	O
)	O
.	O

Using	O
the	O
V3V4	O
and	O
V4	O
variable	O
regions	O
of	O
the	O
small	O
subunit	O
of	O
the	O
16S	O
ribosomal	O
RNA	O
gene	O
,	O
we	O
analyzed	O
the	O
respective	O
bacteriome	O
of	O
the	O
flies	O
'	O
midguts	O
.	O

RESULTS	O
:	O
We	O
identified	O
ten	O
bacterial	O
genera	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
relative	O
abundance	O
of	O
the	O
obligate	O
endosymbiont	O
Wigglesworthia	O
was	O
highly	O
prominent	O
(	O
around	O
99	O
%	O
)	O
,	O
regardless	O
of	O
the	O
analyzed	O
region	O
.	O

The	O
remaining	O
genera	O
represented	O
approximately	O
1	O
%	O
of	O
the	O
bacterial	O
flora	O
,	O
and	O
were	O
composed	O
of	O
Salmonella	B-bacteria
,	O
Spiroplasma	B-bacteria
,	O
Sphingomonas	B-bacteria
,	O
Methylobacterium	B-bacteria
,	O
Acidibacter	B-bacteria
,	O
Tsukamurella	B-bacteria
,	O
Serratia	B-bacteria
,	O
Kluyvera	B-bacteria
and	O
an	O
unidentified	O
bacterium	O
.	O

The	O
genus	O
Sodalis	B-bacteria
was	O
present	O
but	O
with	O
a	O
very	O
low	O
abundance	O
.	O

Globally	O
,	O
no	O
statistically	O
significant	O
difference	O
was	O
found	O
between	O
the	O
bacterial	O
compositions	O
of	O
flies	O
from	O
the	O
two	O
foci	O
,	O
and	O
between	O
positive	O
and	O
trypanosome	O
-	O
negative	O
flies	O
.	O

However	O
,	O
Salmonella	B-bacteria
and	O
Serratia	B-bacteria
were	O
only	O
described	O
in	O
trypanosome	O
-	O
negative	O
flies	O
,	O
suggesting	O
a	O
potential	O
role	O
for	O
these	O
two	O
bacteria	O
in	O
fly	O
refractoriness	O
to	O
trypanosome	O
infection	O
.	O

In	O
addition	O
,	O
our	O
study	O
showed	O
the	O
V4	O
region	O
of	O
the	O
small	O
subunit	O
of	O
the	O
16S	O
ribosomal	O
RNA	O
gene	O
was	O
more	O
efficient	O
than	O
the	O
V3V4	O
region	O
at	O
describing	O
the	O
totality	O
of	O
the	O
bacterial	O
diversity	O
.	O

CONCLUSIONS	O
:	O
A	O
very	O
large	O
diversity	O
of	O
bacteria	O
was	O
identified	O
with	O
the	O
discovering	O
of	O
species	O
reported	O
to	O
secrete	O
anti	O
-	O
parasitic	O
compounds	O
or	O
to	O
modulate	O
vector	O
competence	O
in	O
other	O
insects	O
.	O

For	O
future	O
studies	O
,	O
the	O
analyses	O
should	O
be	O
enlarged	O
with	O
larger	O
sampling	O
including	O
foci	O
from	O
several	O
countries	O
.	O

Modulation	O
of	O
cancer	O
immunotherapy	O
efficacy	O
by	O
gut	O
microbiota	O
.	O

The	O
microbial	O
community	O
is	O
present	O
abundantly	O
in	O
mucosal	O
organs	O
including	O
the	O
intestine	O
,	O
the	O
oral	O
cavity	O
,	O
and	O
the	O
vagina	O
,	O
and	O
is	O
referred	O
to	O
as	O
the	O
microbiota	O
.	O

The	O
microbiota	O
is	O
composed	O
of	O
commensal	O
bacteria	O
and	O
other	O
microorganisms	O
.	O

Intestinal	O
colonization	O
by	O
commensal	O
microorganisms	O
is	O
essential	O
for	O
host	O
physiological	O
functions	O
from	O
the	O
maintenance	O
of	O
barrier	O
homeostasis	O
locally	O
to	O
the	O
regulation	O
of	O
metabolism	O
,	O
hematopoiesis	O
,	O
inflammation	O
,	O
immune	O
development	O
,	O
and	O
other	O
functions	O
systemically	O
.	O

Evidence	O
is	O
growing	O
that	O
the	O
gut	O
microbiota	O
can	O
modulate	O
the	O
host	O
response	O
to	O
cancer	O
immunotherapy	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
evidence	O
for	O
the	O
ability	O
of	O
the	O
microbiota	O
to	O
modulate	O
immunotherapy	O
,	O
their	O
mechanisms	O
of	O
action	O
,	O
and	O
the	O
possibility	O
of	O
altering	O
the	O
microbiota	O
to	O
improve	O
immunotherapy	O
efficacy	O
.	O

Hepatic	O
glycogen	O
storage	O
diseases	O
are	O
associated	O
to	O
microbial	O
dysbiosis	O
.	O

INTRODUCTION	O
:	O
The	O
gut	O
microbiome	O
has	O
been	O
related	O
to	O
several	O
features	O
present	O
in	O
Glycogen	O
Storage	O
Diseases	O
(	O
GSD	O
)	O
patients	O
including	O
obesity	O
,	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
and	O
liver	O
disease	O
.	O

OBJECTIVES	O
:	O
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
associations	O
between	O
GSD	O
and	O
the	O
gut	O
microbiota	O
.	O

METHODS	O
:	O
Twenty	O
-	O
four	O
GSD	O
patients	O
on	O
treatment	O
with	O
uncooked	O
cornstarch	O
(	O
UCCS	O
)	O
,	O
and	O
16	O
healthy	O
controls	O
had	O
their	O
faecal	O
microbiota	O
evaluated	O
through	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

Patients	O
and	O
controls	O
were	O
>	O
/	O
=	O
3	O
years	O
of	O
age	O
and	O
not	O
on	O
antibiotics	O
.	O

Faecal	O
pH	O
,	O
calprotectin	O
,	O
mean	O
daily	O
nutrient	O
intake	O
and	O
current	O
medications	O
were	O
recorded	O
and	O
correlated	O
with	O
gut	O
microbiome	O
.	O

RESULTS	O
:	O
Patients	O
'	O
group	O
presented	O
higher	O
intake	O
of	O
UCCS	O
,	O
higher	O
prevalence	O
of	O
IBD	O
(	O
n	O
=	O
04	O
/	O
24	O
)	O
and	O
obesity	O
/	O
overweight	O
(	O
n	O
=	O
18	O
/	O
24	O
)	O
compared	O
to	O
controls	O
(	O
n	O
=	O
0	O
and	O
06	O
/	O
16	O
,	O
respectively	O
)	O
.	O

Both	O
groups	O
differed	O
regarding	O
diet	O
(	O
in	O
patients	O
,	O
the	O
calories	O
'	O
source	O
was	O
mainly	O
the	O
UCSS	O
,	O
and	O
the	O
intake	O
of	O
fat	O
,	O
calcium	O
,	O
sodium	O
,	O
and	O
vitamins	O
was	O
lower	O
than	O
in	O
controls	O
)	O
,	O
use	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
(	O
patients	O
=	O
11	O
,	O
controls	O
=	O
0	O
;	O
p	O
-	O
value	O
=	O
0	O
.	O
001	O
)	O
multivitamins	O
(	O
patients	O
=	O
22	O
,	O
controls	O
=	O
01	O
;	O
p	O
-	O
value	O
=	O
0	O
.	O
001	O
)	O
,	O
and	O
mean	O
faecal	O
pH	O
(	O
patients	O
=	O
6	O
.	O
23	O
;	O
controls	O
=	O
7	O
.	O
41	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
GSD	O
microbiome	O
was	O
characterized	O
by	O
low	O
diversity	O
and	O
distinct	O
microbial	O
structure	O
.	O

The	O
operational	O
taxonomic	O
unit	O
(	O
OTU	O
)	O
abundance	O
was	O
significantly	O
influenced	O
by	O
faecal	O
pH	O
(	O
r	O
=	O
0	O
.	O
77	O
;	O
p	O
=	O
6	O
.	O
8e	O
-	O
09	O
)	O
,	O
total	O
carbohydrate	O
(	O
r	O
=	O
-	O
0	O
.	O
6	O
;	O
p	O
=	O
4	O
.	O
8e	O
-	O
05	O
)	O
and	O
sugar	O
(	O
r	O
=	O
0	O
.	O
057	O
;	O
p	O
=	O
0	O
.	O
00013	O
)	O
intakes	O
.	O

CONCLUSIONS	O
:	O
GSD	O
patients	O
presented	O
intestinal	O
dysbiosis	O
,	O
showing	O
low	O
faecal	O
microbial	O
diversity	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O

Those	O
findings	O
might	O
be	O
due	O
to	O
the	O
disease	O
per	O
se	O
,	O
and	O
/	O
or	O
to	O
the	O
different	O
diets	O
,	O
use	O
of	O
UCSS	O
and	O
of	O
medicines	O
,	O
and	O
obesity	O
rate	O
found	O
in	O
patients	O
.	O

Although	O
the	O
main	O
driver	O
of	O
these	O
differences	O
is	O
unknown	O
,	O
this	O
study	O
might	O
help	O
to	O
understand	O
how	O
the	O
nutritional	O
management	O
affects	O
GSD	O
patients	O
.	O

A	O
Highly	O
Divergent	O
Picornavirus	O
Infecting	O
the	O
Gut	O
Epithelia	O
of	O
Zebrafish	O
(	O
Danio	O
rerio	O
)	O
in	O
Research	O
Institutions	O
Worldwide	O
.	O

Zebrafish	O
have	O
been	O
extensively	O
used	O
as	O
a	O
model	O
system	O
for	O
research	O
in	O
vertebrate	O
development	O
and	O
pathogen	O
-	O
host	O
interactions	O
.	O

We	O
describe	O
the	O
complete	O
genome	O
of	O
a	O
novel	O
picornavirus	O
identified	O
during	O
a	O
viral	O
metagenomics	O
analysis	O
of	O
zebrafish	O
gut	O
tissue	O
.	O

The	O
closest	O
relatives	O
of	O
this	O
virus	O
showed	O
identity	O
of	O
<	O
20	O
%	O
in	O
their	O
P1	O
capsids	O
and	O
<	O
36	O
%	O
in	O
their	O
RdRp	O
qualifying	O
zebrafish	O
picornavirus	O
-	O
1	O
(	O
ZfPV	O
-	O
1	O
)	O
as	O
member	O
of	O
a	O
novel	O
genus	O
with	O
a	O
proposed	O
name	O
of	O
Cyprivirus	O
.	O

Reverse	O
transcription	O
(	O
RT	O
)	O
-	O
PCR	O
testing	O
of	O
zebrafish	O
from	O
North	O
America	O
,	O
Europe	O
,	O
and	O
Asia	O
showed	O
ZfPV	O
-	O
1	O
to	O
be	O
globally	O
distributed	O
,	O
being	O
detected	O
in	O
23	O
of	O
41	O
(	O
56	O
%	O
)	O
institutions	O
tested	O
.	O

In	O
situ	O
hybridization	O
of	O
whole	O
zebrafish	O
showed	O
viral	O
RNA	O
was	O
restricted	O
to	O
a	O
subset	O
of	O
enterocytes	O
and	O
cells	O
in	O
the	O
subjacent	O
lamina	O
propria	O
of	O
the	O
intestine	O
and	O
the	O
intestinal	O
mucosa	O
.	O

This	O
naturally	O
occurring	O
and	O
apparently	O
asymptomatic	O
infection	O
(	O
in	O
wild	O
-	O
type	O
zebrafish	O
lineage	O
AB	O
)	O
provides	O
a	O
natural	O
infection	O
system	O
to	O
study	O
picornavirus	O
-	O
host	O
interactions	O
in	O
an	O
advanced	O
vertebrate	O
model	O
organism	O
.	O

Whether	O
ZfPV	O
-	O
1	O
infection	O
affects	O
any	O
immunological	O
,	O
developmental	O
,	O
or	O
other	O
biological	O
processes	O
in	O
wild	O
-	O
type	O
or	O
mutant	O
zebrafish	O
lineages	O
remains	O
to	O
be	O
determined	O
.	O

Implicating	O
Dysbiosis	O
of	O
the	O
Gut	O
Fungal	O
Microbiome	O
in	O
Uveitis	O
,	O
an	O
Inflammatory	O
Disease	O
of	O
the	O
Eye	O
.	O

Purpose	O
:	O
In	O
this	O
study	O
,	O
the	O
gut	O
fungal	O
microbiome	O
of	O
uveitis	O
(	O
UVT	O
)	O
patients	O
was	O
generated	O
and	O
compared	O
with	O
healthy	O
controls	O
(	O
HC	O
)	O
to	O
identify	O
dysbiosis	O
in	O
UVT	O
patients	O
and	O
ascertain	O
the	O
role	O
of	O
gut	O
fungal	O
microbiome	O
in	O
disease	O
pathology	O
.	O

Methods	O
:	O
In	O
the	O
present	O
study	O
,	O
gut	O
fungal	O
microbiomes	O
were	O
analyzed	O
in	O
the	O
fecal	O
samples	O
of	O
HC	O
(	O
n	O
=	O
24	O
)	O
and	O
UVT	O
patients	O
(	O
n	O
=	O
14	O
)	O
using	O
high	O
-	O
throughput	O
Illumina	O
sequencing	O
of	O
ITS2	O
region	O
of	O
the	O
fungal	O
ribosomal	O
RNA	O
.	O

QIIME	O
and	O
R	O
software	O
were	O
used	O
for	O
data	O
analysis	O
.	O

Results	O
:	O
The	O
gut	O
fungal	O
richness	O
and	O
diversity	O
were	O
significantly	O
decreased	O
in	O
UVT	O
patients	O
compared	O
to	O
HC	O
.	O

Our	O
analyses	O
showed	O
enrichment	O
of	O
several	O
pathogenic	O
fungi	O
including	O
Malassezia	O
restricta	O
,	O
Candida	O
albicans	O
,	O
Candida	O
glabrata	O
,	O
and	O
Aspergillus	O
gracilis	O
in	O
UVT	O
patients	O
.	O

Heatmap	O
and	O
discriminatory	O
OTUs	O
further	O
confirmed	O
the	O
disparities	O
between	O
UVT	O
and	O
HC	O
microbiomes	O
.	O

Conclusions	O
:	O
This	O
is	O
the	O
first	O
study	O
demonstrating	O
dysbiosis	O
in	O
the	O
gut	O
fungal	O
communities	O
of	O
UVT	O
patients	O
indicating	O
the	O
importance	O
of	O
fungal	O
microbiome	O
in	O
the	O
disease	O
pathology	O
.	O

These	O
initial	O
findings	O
might	O
warrant	O
further	O
investigation	O
into	O
the	O
fungal	O
microbiome	O
,	O
especially	O
interactions	O
between	O
fungal	O
and	O
bacterial	O
that	O
then	O
might	O
give	O
further	O
insight	O
into	O
how	O
probiotics	O
or	O
fecal	O
transplants	O
might	O
benefit	O
.	O

ngrA	O
-	O
dependent	O
natural	O
products	O
are	O
required	O
for	O
interspecies	O
competition	O
and	O
virulence	O
in	O
the	O
insect	O
pathogenic	O
bacterium	O
Xenorhabdus	B-bacteria
szentirmaii	I-bacteria
.	O

Xenorhabdus	O
species	O
are	O
symbionts	O
of	O
entomopathogenic	O
nematodes	O
and	O
pathogens	O
of	O
susceptible	O
insects	O
.	O

Nematodes	O
enter	O
insect	O
hosts	O
and	O
perforate	O
the	O
midgut	O
to	O
invade	O
the	O
haemocoel	O
where	O
Xenorhabdus	B-bacteria
bacteria	I-bacteria
are	O
released	O
transitioning	O
to	O
their	O
pathogenic	O
stage	O
.	O

During	O
nematode	O
invasion	O
microbes	O
from	O
the	O
insect	O
gut	O
translocate	O
into	O
the	O
haemocoel	O
.	O

Different	O
species	O
of	O
nematodes	O
carrying	O
specific	O
strains	O
of	O
Xenorhabdus	O
can	O
also	O
invade	O
the	O
same	O
insect	O
.	O

Xenorhabdus	B-bacteria
species	I-bacteria
thereby	O
compete	O
for	O
nutrients	O
and	O
space	O
with	O
both	O
related	O
strains	O
and	O
non	O
-	O
related	O
gut	O
microbes	O
.	O

While	O
Xenorhabdus	B-bacteria
species	I-bacteria
produce	O
diverse	O
antimicrobial	O
compounds	O
in	O
complex	O
media	O
,	O
their	O
functions	O
in	O
insect	O
hosts	O
are	O
not	O
well	O
understood	O
.	O

We	O
show	O
that	O
Xenorhabdus	B-bacteria
szentirmaii	I-bacteria
produced	O
ngrA	O
-	O
dependent	O
antibiotics	O
that	O
were	O
active	O
against	O
both	O
gut	O
-	O
derived	O
microbes	O
and	O
Xenorhabdus	B-bacteria
nematophila	I-bacteria
whereas	O
antibiotics	O
of	O
X	B-bacteria
.	I-bacteria
nematophila	I-bacteria
were	O
not	O
active	O
against	O
X	B-bacteria
.	I-bacteria
szentirmaii	I-bacteria
.	O

X	B-bacteria
.	I-bacteria
nematophila	I-bacteria
growth	O
was	O
inhibited	O
in	O
co	O
-	O
cultures	O
with	O
wild	O
-	O
type	O
X	B-bacteria
.	I-bacteria
szentirmaii	I-bacteria
in	O
medium	O
that	O
mimics	O
insect	O
haemolymph	O
.	O

An	O
antibiotic	O
-	O
deficient	O
strain	O
of	O
X	B-bacteria
.	I-bacteria
szentirmaii	I-bacteria
was	O
created	O
by	O
inactivating	O
the	O
ngrA	O
gene	O
that	O
encodes	O
the	O
enzyme	O
that	O
attaches	O
the	O
4	O
'	O
phosphopantetheinyl	O
moiety	O
to	O
non	O
-	O
ribosomal	O
peptide	O
synthetases	O
involved	O
in	O
antibiotic	O
biosynthesis	O
.	O

X	B-bacteria
.	I-bacteria
nematophila	I-bacteria
growth	O
was	O
not	O
inhibited	O
in	O
co	O
-	O
cultures	O
with	O
the	O
ngrA	O
strain	O
.	O

The	O
growth	O
of	O
X	B-bacteria
.	I-bacteria
nematophila	I-bacteria
was	O
suppressed	O
in	O
Manduca	O
sexta	O
co	O
-	O
injected	O
with	O
wild	O
-	O
type	O
X	B-bacteria
.	I-bacteria
szentirmaii	I-bacteria
and	O
X	B-bacteria
.	I-bacteria
nematophila	I-bacteria
.	O

In	O
contrast	O
,	O
growth	O
of	O
X	B-bacteria
.	I-bacteria
nematophila	I-bacteria
was	O
not	O
suppressed	O
in	O
M	B-bacteria
.	I-bacteria
sexta	I-bacteria
co	O
-	O
injected	O
with	O
the	O
ngrA	O
strain	O
.	O

Two	O
unique	O
compounds	O
were	O
detected	O
by	O
MALDI	O
-	O
TOF	O
MS	O
analysis	O
in	O
haemolymph	O
infected	O
with	O
the	O
wild	O
-	O
type	O
but	O
not	O
with	O
the	O
ngrA	O
strain	O
.	O

Finally	O
,	O
killing	O
of	O
M	B-bacteria
.	I-bacteria
sexta	I-bacteria
was	O
delayed	O
in	O
insects	O
infected	O
with	O
the	O
ngrA	O
strain	O
.	O

These	O
findings	O
indicate	O
that	O
in	O
the	O
insect	O
host	O
X	B-bacteria
.	I-bacteria
szentirmaii	I-bacteria
produces	O
ngrA	O
-	O
dependent	O
products	O
involved	O
in	O
both	O
interspecies	O
competition	O
and	O
virulence	O
.	O

Feeding	O
modes	O
shape	O
the	O
acquisition	O
and	O
structure	O
of	O
the	O
initial	O
gut	O
microbiota	O
in	O
newborn	O
lambs	O
.	O

Early	O
gut	O
microbial	O
colonization	O
is	O
important	O
for	O
postnatal	O
metabolic	O
and	O
immune	O
development	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
different	O
feeding	O
modes	O
(	O
suckling	O
versus	O
bottle	O
-	O
feeding	O
)	O
or	O
microbial	O
sources	O
on	O
this	O
process	O
in	O
farm	O
animals	O
.	O

We	O
found	O
that	O
suckled	O
and	O
bottle	O
-	O
fed	O
newborn	O
lambs	O
had	O
their	O
own	O
distinct	O
gut	O
microbiota	O
.	O

Results	O
from	O
16S	O
rRNA	O
gene	O
sequencing	O
and	O
qPCR	O
showed	O
that	O
,	O
compared	O
with	O
suckling	O
,	O
bottle	O
feeding	O
significantly	O
increased	O
the	O
abundances	O
of	O
Escherichia	B-bacteria
/	O
Shigella	B-bacteria
,	O
Butyricicoccus	B-bacteria
,	O
and	O
Clostridium	B-bacteria
XlVa	B-bacteria
,	O
while	O
significantly	O
decreased	O
the	O
abundance	O
of	O
Clostridium	B-bacteria
XI	I-bacteria
.	O

The	O
higher	O
levels	O
of	O
Escherichia	B-bacteria
/	O
Shigella	B-bacteria
in	O
bottle	O
-	O
fed	O
lambs	O
suggest	O
that	O
artificial	O
feeding	O
may	O
increase	O
the	O
number	O
of	O
potential	O
pathogens	O
and	O
delay	O
the	O
establishment	O
of	O
the	O
anaerobic	O
environment	O
and	O
anaerobic	O
microbes	O
.	O

Feeding	O
modes	O
also	O
affected	O
the	O
direct	O
transmission	O
of	O
bacteria	O
from	O
the	O
mother	O
and	O
the	O
environment	O
to	O
newborns	O
.	O

The	O
SourceTracker	O
analysis	O
estimated	O
that	O
the	O
early	O
gut	O
microbes	O
of	O
suckled	O
lambs	O
were	O
mainly	O
derived	O
from	O
the	O
mother	O
'	O
s	O
teats	O
(	O
43	O
%	O
)	O
and	O
ambient	O
air	O
(	O
28	O
%	O
)	O
;	O
whereas	O
those	O
of	O
bottle	O
-	O
fed	O
lambs	O
were	O
dominated	O
by	O
bacteria	O
from	O
the	O
mother	O
'	O
s	O
vagina	O
(	O
46	O
%	O
)	O
,	O
ambient	O
air	O
(	O
31	O
%	O
)	O
,	O
and	O
the	O
sheep	O
pen	O
floor	O
(	O
12	O
%	O
)	O
.	O

These	O
findings	O
advance	O
our	O
understanding	O
of	O
gut	O
microbiota	O
in	O
early	O
life	O
and	O
may	O
help	O
design	O
techniques	O
to	O
improve	O
gut	O
microbiota	O
and	O
health	O
.	O

Spotlight	O
on	O
early	O
-	O
career	O
researchers	O
:	O
an	O
interview	O
with	O
Natalia	O
Castano	O
-	O
Rodriguez	O
.	O

Dr	O
.	O
Natalia	O
Castano	O
-	O
Rodriguez	O
is	O
a	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
Early	O
Career	O
Fellow	O
in	O
the	O
School	O
of	O
Biotechnology	O
and	O
Biomolecular	O
Sciences	O
at	O
the	O
University	O
of	O
New	O
South	O
Wales	O
.	O

Her	O
research	O
focuses	O
on	O
understanding	O
how	O
host	O
immunogenetic	O
factors	O
interact	O
with	O
bacterial	O
infection	O
and	O
gut	O
dysbiosis	O
to	O
regulate	O
tumorigenesis	O
and	O
chronic	O
inflammation	O
in	O
humans	O
,	O
using	O
molecular	O
biology	O
,	O
microbiology	O
,	O
genetics	O
,	O
and	O
bioinformatics	O
.	O

As	O
part	O
of	O
our	O
series	O
on	O
early	O
-	O
career	O
researchers	O
,	O
we	O
asked	O
Dr	O
.	O
Castano	O
-	O
Rodriguez	O
to	O
talk	O
to	O
us	O
about	O
her	O
research	O
and	O
career	O
path	O
.	O

She	O
also	O
shares	O
the	O
lesson	O
she	O
'	O
s	O
learned	O
from	O
studying	O
the	O
bacteria	O
colonizing	O
our	O
stomachs	O
.	O

The	O
gut	O
virome	O
:	O
the	O
'	O
missing	O
link	O
'	O
between	O
gut	O
bacteria	O
and	O
host	O
immunity	O
?	O

The	O
human	O
gut	O
virome	O
includes	O
a	O
diverse	O
collection	O
of	O
viruses	O
that	O
infect	O
our	O
own	O
cells	O
as	O
well	O
as	O
other	O
commensal	O
organisms	O
,	O
directly	O
impacting	O
on	O
our	O
well	O
-	O
being	O
.	O

Despite	O
its	O
predominance	O
,	O
the	O
virome	O
remains	O
one	O
of	O
the	O
least	O
understood	O
components	O
of	O
the	O
gut	O
microbiota	O
,	O
with	O
appropriate	O
analysis	O
toolkits	O
still	O
in	O
development	O
.	O

Based	O
on	O
its	O
interconnectivity	O
with	O
all	O
living	O
cells	O
,	O
it	O
is	O
clear	O
that	O
the	O
virome	O
can	O
not	O
be	O
studied	O
in	O
isolation	O
.	O

Here	O
we	O
review	O
the	O
current	O
understanding	O
of	O
the	O
human	O
gut	O
virome	O
,	O
specifically	O
in	O
relation	O
to	O
other	O
constituents	O
of	O
the	O
microbiome	O
,	O
its	O
evolution	O
and	O
life	O
-	O
long	O
association	O
with	O
its	O
host	O
,	O
and	O
our	O
current	O
understanding	O
in	O
the	O
context	O
of	O
inflammatory	O
bowel	O
disease	O
and	O
associated	O
therapies	O
.	O

We	O
propose	O
that	O
the	O
gut	O
virome	O
and	O
the	O
gut	O
bacterial	O
microbiome	O
share	O
similar	O
trajectories	O
and	O
interact	O
in	O
both	O
health	O
and	O
disease	O
and	O
that	O
future	O
microbiota	O
studies	O
should	O
in	O
parallel	O
characterize	O
the	O
gut	O
virome	O
to	O
uncover	O
its	O
role	O
in	O
health	O
and	O
disease	O
.	O

GABA	O
-	O
Producing	O
Natural	O
Dairy	O
Isolate	O
From	O
Artisanal	O
Zlatar	O
Cheese	O
Attenuates	O
Gut	O
Inflammation	O
and	O
Strengthens	O
Gut	O
Epithelial	O
Barrier	O
in	O
vitro	O
.	O

Probiotic	O
bacteria	O
are	O
recognized	O
for	O
their	O
health	O
-	O
promoting	O
properties	O
,	O
including	O
maintenance	O
of	O
gut	O
epithelial	O
integrity	O
and	O
host	O
immune	O
system	O
homeostasis	O
.	O

Taking	O
into	O
account	O
the	O
beneficial	O
health	O
-	O
promoting	O
effects	O
of	O
GABA	O
,	O
the	O
presence	O
of	O
the	O
gadB	O
gene	O
,	O
encoding	O
glutamate	O
decarboxylase	O
that	O
converts	O
L	O
-	O
glutamate	O
to	O
GABA	O
,	O
was	O
analyzed	O
in	O
Lactic	B-bacteria
Acid	I-bacteria
Bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
natural	O
isolates	O
from	O
Zlatar	O
cheese	O
.	O

The	O
results	O
revealed	O
that	O
52	O
%	O
of	O
tested	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
8	O
%	O
of	O
Lactococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
isolates	I-bacteria
harbor	O
the	O
gadB	O
gene	O
.	O

Qualitative	O
and	O
quantitative	O
analysis	O
of	O
GABA	O
production	O
performed	O
by	O
thin	O
-	O
layer	O
chromatography	O
(	O
TLC	O
)	O
and	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
revealed	O
the	O
highest	O
GABA	O
production	O
by	O
Lactobacillus	B-bacteria
brevis	I-bacteria
BGZLS10	I-bacteria
-	I-bacteria
17	I-bacteria
.	O

Since	O
high	O
GABA	O
-	O
producing	O
LAB	B-bacteria
natural	O
isolates	O
are	O
the	O
most	O
valuable	O
source	O
of	O
naturally	O
produced	O
GABA	O
,	O
the	O
probiotic	O
properties	O
of	O
BGZLS10	B-bacteria
-	I-bacteria
17	I-bacteria
were	O
characterized	O
.	O

This	O
study	O
demonstrated	O
high	O
adhesion	O
of	O
BGZLS10	B-bacteria
-	I-bacteria
17	I-bacteria
strain	I-bacteria
to	O
Caco	O
-	O
2	O
cells	O
and	O
the	O
ability	O
to	O
decrease	O
the	O
adhesion	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
ATCC25922	I-bacteria
and	O
Salmonella	B-bacteria
enterica	I-bacteria
C29039	I-bacteria
.	O

Treatment	O
of	O
differentiated	O
Caco	O
-	O
2	O
cells	O
monolayer	O
with	O
BGZLS10	O
-	O
17	O
supernatant	O
containing	O
GABA	O
alleviated	O
inflammation	O
(	O
production	O
of	O
IL	O
-	O
8	O
)	O
caused	O
by	O
IL	O
-	O
1beta	O
and	O
significantly	O
stimulated	O
the	O
expression	O
of	O
tight	O
junction	O
proteins	O
(	O
zonulin	O
,	O
occludin	O
,	O
and	O
claudin	O
4	O
)	O
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
TGF	O
-	O
beta	O
cytokine	O
leading	O
to	O
the	O
conclusion	O
that	O
immunosuppression	O
and	O
strengthening	O
the	O
tight	O
junctions	O
can	O
have	O
significant	O
role	O
in	O
the	O
maintenance	O
of	O
intestinal	O
epithelial	O
barrier	O
integrity	O
.	O

Taken	O
together	O
the	O
results	O
obtained	O
in	O
this	O
study	O
support	O
the	O
idea	O
that	O
using	O
of	O
GABA	O
producing	O
BGZLS10	B-bacteria
-	I-bacteria
17	I-bacteria
probiotic	O
strain	O
could	O
be	O
a	O
good	O
strategy	O
to	O
modulate	O
immunological	O
response	O
in	O
various	O
inflammatory	O
diseases	O
,	O
and	O
at	O
the	O
same	O
time	O
,	O
it	O
could	O
be	O
a	O
good	O
candidate	O
for	O
adjunct	O
starter	O
culture	O
for	O
production	O
of	O
GABA	O
-	O
enriched	O
dairy	O
foods	O
and	O
beverages	O
offering	O
new	O
perspectives	O
in	O
designing	O
the	O
novel	O
functional	O
foods	O
.	O

Metagenomic	O
analysis	O
of	O
colorectal	O
cancer	O
datasets	O
identifies	O
cross	O
-	O
cohort	O
microbial	O
diagnostic	O
signatures	O
and	O
a	O
link	O
with	O
choline	O
degradation	O
.	O

Several	O
studies	O
have	O
investigated	O
links	O
between	O
the	O
gut	O
microbiome	O
and	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
,	O
but	O
questions	O
remain	O
about	O
the	O
replicability	O
of	O
biomarkers	O
across	O
cohorts	O
and	O
populations	O
.	O

We	O
performed	O
a	O
meta	O
-	O
analysis	O
of	O
five	O
publicly	O
available	O
datasets	O
and	O
two	O
new	O
cohorts	O
and	O
validated	O
the	O
findings	O
on	O
two	O
additional	O
cohorts	O
,	O
considering	O
in	O
total	O
969	O
fecal	O
metagenomes	O
.	O

Unlike	O
microbiome	O
shifts	O
associated	O
with	O
gastrointestinal	O
syndromes	O
,	O
the	O
gut	O
microbiome	O
in	O
CRC	O
showed	O
reproducibly	O
higher	O
richness	O
than	O
controls	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
partially	O
due	O
to	O
expansions	O
of	O
species	O
typically	O
derived	O
from	O
the	O
oral	O
cavity	O
.	O

Meta	O
-	O
analysis	O
of	O
the	O
microbiome	O
functional	O
potential	O
identified	O
gluconeogenesis	O
and	O
the	O
putrefaction	O
and	O
fermentation	O
pathways	O
as	O
being	O
associated	O
with	O
CRC	O
,	O
whereas	O
the	O
stachyose	O
and	O
starch	O
degradation	O
pathways	O
were	O
associated	O
with	O
controls	O
.	O

Predictive	O
microbiome	O
signatures	O
for	O
CRC	O
trained	O
on	O
multiple	O
datasets	O
showed	O
consistently	O
high	O
accuracy	O
in	O
datasets	O
not	O
considered	O
for	O
model	O
training	O
and	O
independent	O
validation	O
cohorts	O
(	O
average	O
area	O
under	O
the	O
curve	O
,	O
0	O
.	O
84	O
)	O
.	O

Pooled	O
analysis	O
of	O
raw	O
metagenomes	O
showed	O
that	O
the	O
choline	O
trimethylamine	O
-	O
lyase	O
gene	O
was	O
overabundant	O
in	O
CRC	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
identifying	O
a	O
relationship	O
between	O
microbiome	O
choline	O
metabolism	O
and	O
CRC	O
.	O

The	O
combined	O
analysis	O
of	O
heterogeneous	O
CRC	O
cohorts	O
thus	O
identified	O
reproducible	O
microbiome	O
biomarkers	O
and	O
accurate	O
disease	O
-	O
predictive	O
models	O
that	O
can	O
form	O
the	O
basis	O
for	O
clinical	O
prognostic	O
tests	O
and	O
hypothesis	O
-	O
driven	O
mechanistic	O
studies	O
.	O

Meta	O
-	O
analysis	O
of	O
fecal	O
metagenomes	O
reveals	O
global	O
microbial	O
signatures	O
that	O
are	O
specific	O
for	O
colorectal	O
cancer	O
.	O

Association	O
studies	O
have	O
linked	O
microbiome	O
alterations	O
with	O
many	O
human	O
diseases	O
.	O

However	O
,	O
they	O
have	O
not	O
always	O
reported	O
consistent	O
results	O
,	O
thereby	O
necessitating	O
cross	O
-	O
study	O
comparisons	O
.	O

Here	O
,	O
a	O
meta	O
-	O
analysis	O
of	O
eight	O
geographically	O
and	O
technically	O
diverse	O
fecal	O
shotgun	O
metagenomic	O
studies	O
of	O
colorectal	O
cancer	O
(	O
CRC	O
,	O
n	O
=	O
768	O
)	O
,	O
which	O
was	O
controlled	O
for	O
several	O
confounders	O
,	O
identified	O
a	O
core	O
set	O
of	O
29	O
species	O
significantly	O
enriched	O
in	O
CRC	O
metagenomes	O
(	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
<	O
1	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
.	O

CRC	O
signatures	O
derived	O
from	O
single	O
studies	O
maintained	O
their	O
accuracy	O
in	O
other	O
studies	O
.	O

By	O
training	O
on	O
multiple	O
studies	O
,	O
we	O
improved	O
detection	O
accuracy	O
and	O
disease	O
specificity	O
for	O
CRC	O
.	O

Functional	O
analysis	O
of	O
CRC	O
metagenomes	O
revealed	O
enriched	O
protein	O
and	O
mucin	O
catabolism	O
genes	O
and	O
depleted	O
carbohydrate	O
degradation	O
genes	O
.	O

Moreover	O
,	O
we	O
inferred	O
elevated	O
production	O
of	O
secondary	O
bile	O
acids	O
from	O
CRC	O
metagenomes	O
,	O
suggesting	O
a	O
metabolic	O
link	O
between	O
cancer	O
-	O
associated	O
gut	O
microbes	O
and	O
a	O
fat	O
-	O
and	O
meat	O
-	O
rich	O
diet	O
.	O

Through	O
extensive	O
validations	O
,	O
this	O
meta	O
-	O
analysis	O
firmly	O
establishes	O
globally	O
generalizable	O
,	O
predictive	O
taxonomic	O
and	O
functional	O
microbiome	O
CRC	O
signatures	O
as	O
a	O
basis	O
for	O
future	O
diagnostics	O
.	O

Viral	O
complementation	O
of	O
immunodeficiency	O
confers	O
protection	O
against	O
enteric	O
pathogens	O
via	O
interferon	O
-	O
lambda	O
.	O

Commensal	O
microbes	O
profoundly	O
impact	O
host	O
immunity	O
to	O
enteric	O
viral	O
infections	O
(	O
1	O
)	O
.	O

We	O
have	O
shown	O
that	O
the	O
bacterial	O
microbiota	O
and	O
host	O
antiviral	O
cytokine	O
interferon	O
-	O
lambda	O
(	O
IFN	O
-	O
lambda	O
)	O
determine	O
the	O
persistence	O
of	O
murine	O
norovirus	O
in	O
the	O
gut	O
(	O
2	O
,	O
3	O
)	O
.	O

However	O
,	O
the	O
effects	O
of	O
the	O
virome	O
in	O
modulating	O
enteric	O
infections	O
remain	O
unexplored	O
.	O

Here	O
,	O
we	O
report	O
that	O
murine	O
astrovirus	O
can	O
complement	O
primary	O
immunodeficiency	O
to	O
protect	O
against	O
murine	O
norovirus	O
and	O
rotavirus	O
infections	O
.	O

Protection	O
against	O
infection	O
was	O
horizontally	O
transferable	O
between	O
immunocompromised	O
mouse	O
strains	O
by	O
co	O
-	O
housing	O
and	O
fecal	O
transplantation	O
.	O

Furthermore	O
,	O
protection	O
against	O
enteric	O
pathogens	O
corresponded	O
with	O
the	O
presence	O
of	O
a	O
specific	O
strain	O
of	O
murine	O
astrovirus	O
in	O
the	O
gut	O
,	O
and	O
this	O
complementation	O
of	O
immunodeficiency	O
required	O
IFN	O
-	O
lambda	O
signalling	O
in	O
gut	O
epithelial	O
cells	O
.	O

Our	O
study	O
demonstrates	O
that	O
elements	O
of	O
the	O
virome	O
can	O
protect	O
against	O
enteric	O
pathogens	O
in	O
an	O
immunodeficient	O
host	O
.	O

Single	O
cell	O
fluorescence	O
imaging	O
of	O
glycan	O
uptake	O
by	O
intestinal	O
bacteria	O
.	O

Microbes	O
in	O
the	O
intestines	O
of	O
mammals	O
degrade	O
dietary	O
glycans	O
for	O
energy	O
and	O
growth	O
.	O

The	O
pathways	O
required	O
for	O
polysaccharide	O
utilization	O
are	O
functionally	O
diverse	O
;	O
moreover	O
,	O
they	O
are	O
unequally	O
dispersed	O
between	O
bacterial	O
genomes	O
.	O

Hence	O
,	O
assigning	O
metabolic	O
phenotypes	O
to	O
genotypes	O
remains	O
a	O
challenge	O
in	O
microbiome	O
research	O
.	O

Here	O
we	O
demonstrate	O
that	O
glycan	O
uptake	O
in	O
gut	O
bacteria	O
can	O
be	O
visualized	O
with	O
fluorescent	O
glycan	O
conjugates	O
(	O
FGCs	O
)	O
using	O
epifluorescence	O
microscopy	O
.	O

Yeast	O
alpha	O
-	O
mannan	O
and	O
rhamnogalacturonan	O
-	O
II	O
,	O
two	O
structurally	O
distinct	O
glycans	O
from	O
the	O
cell	O
walls	O
of	O
yeast	O
and	O
plants	O
,	O
respectively	O
,	O
were	O
fluorescently	O
labeled	O
and	O
fed	O
to	O
Bacteroides	B-bacteria
thetaiotaomicron	I-bacteria
VPI	I-bacteria
-	I-bacteria
5482	I-bacteria
.	O

Wild	O
-	O
type	O
cells	O
rapidly	O
consumed	O
the	O
FGCs	O
and	O
became	O
fluorescent	O
;	O
whereas	O
,	O
strains	O
that	O
had	O
deleted	O
pathways	O
for	O
glycan	O
degradation	O
and	O
transport	O
were	O
non	O
-	O
fluorescent	O
.	O

Uptake	O
of	O
FGCs	O
,	O
therefore	O
,	O
is	O
direct	O
evidence	O
of	O
genetic	O
function	O
and	O
provides	O
a	O
direct	O
method	O
to	O
assess	O
specific	O
glycan	O
metabolism	O
in	O
intestinal	O
bacteria	O
at	O
the	O
single	O
cell	O
level	O
.	O

Antibiotic	O
resistance	O
gene	O
reservoir	O
in	O
live	O
poultry	O
markets	O
.	O

OBJECTIVES	O
:	O
The	O
heavy	O
use	O
of	O
antibiotics	O
in	O
farm	O
animals	O
contributes	O
to	O
the	O
enrichment	O
and	O
spread	O
of	O
antibiotic	O
resistance	O
genes	O
(	O
ARGs	O
)	O
in	O
`	O
`	O
one	O
-	O
health	O
'	O
'	O
settings	O
.	O

Numerous	O
ARGs	O
have	O
been	O
identified	O
in	O
livestock	O
-	O
associated	O
environments	O
but	O
not	O
in	O
Chinese	O
live	O
poultry	O
markets	O
(	O
LPMs	O
)	O
.	O

METHODS	O
:	O
We	O
collected	O
753	O
poultry	O
fecal	O
samples	O
from	O
LPMs	O
of	O
18	O
provinces	O
and	O
municipalities	O
in	O
China	O
and	O
sequenced	O
the	O
metagenomes	O
of	O
130	O
samples	O
.	O

Bioinformatic	O
tools	O
were	O
used	O
to	O
construct	O
the	O
gene	O
catalog	O
and	O
analyze	O
the	O
ARG	O
content	O
.	O

PCR	O
amplification	O
and	O
Sanger	O
sequencing	O
were	O
used	O
to	O
survey	O
the	O
distribution	O
of	O
mcr	O
-	O
1	O
gene	O
in	O
all	O
753	O
fecal	O
samples	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
a	O
low	O
number	O
of	O
genes	O
but	O
a	O
high	O
percentage	O
of	O
gene	O
functions	O
were	O
shared	O
among	O
the	O
poultry	O
,	O
human	O
and	O
pig	O
gut	O
gene	O
catalogs	O
.	O

The	O
poultry	O
gut	O
possessed	O
539	O
ARGs	O
which	O
were	O
classified	O
into	O
235	O
types	O
.	O

Both	O
the	O
ARG	O
number	O
and	O
abundance	O
were	O
significantly	O
higher	O
in	O
poultry	O
than	O
that	O
in	O
either	O
pigs	O
or	O
humans	O
.	O

Fourteen	O
ARG	O
types	O
were	O
found	O
present	O
in	O
all	O
130	O
samples	O
,	O
and	O
tetracycline	O
resistance	O
(	O
TcR	O
)	O
genes	O
were	O
the	O
most	O
abundant	O
ARGs	O
in	O
both	O
animals	O
and	O
humans	O
.	O

Moreover	O
,	O
59	O
.	O
63	O
%	O
LPM	O
samples	O
harbored	O
the	O
colistin	O
resistance	O
gene	O
mcr	O
-	O
1	O
,	O
and	O
other	O
mcr	O
gene	O
variants	O
were	O
also	O
found	O
.	O

CONCLUSIONS	O
:	O
We	O
demonstrated	O
that	O
the	O
Chinese	O
LPMs	O
is	O
a	O
repository	O
for	O
ARGs	O
,	O
posing	O
a	O
high	O
risk	O
for	O
ARG	O
dissemination	O
from	O
food	O
animals	O
to	O
humans	O
under	O
such	O
a	O
trade	O
system	O
,	O
which	O
has	O
not	O
been	O
addressed	O
before	O
.	O

Impact	O
of	O
Aquaculture	O
Practices	O
on	O
Intestinal	O
Bacterial	O
Profiles	O
of	O
Pacific	O
Whiteleg	O
Shrim	O
Litopenaeus	B-bacteria
vannamei	I-bacteria
.	O

Considering	O
the	O
crucial	O
role	O
of	O
the	O
gut	O
microbiome	O
in	O
animal	O
health	O
and	O
nutrition	O
,	O
solutions	O
to	O
shrimp	O
aquaculture	O
challenges	O
,	O
such	O
as	O
improving	O
disease	O
resistance	O
and	O
optimizing	O
growth	O
on	O
lower	O
cost	O
feeds	O
,	O
may	O
lie	O
in	O
manipulation	O
of	O
their	O
microbial	O
symbionts	O
.	O

However	O
,	O
achieving	O
this	O
goal	O
will	O
require	O
a	O
deeper	O
understanding	O
of	O
shrimp	O
microbial	O
communities	O
and	O
how	O
their	O
composition	O
is	O
influenced	O
by	O
diet	O
formulation	O
,	O
environmental	O
conditions	O
,	O
and	O
host	O
factors	O
.	O

In	O
this	O
context	O
,	O
the	O
current	O
study	O
investigated	O
the	O
intestinal	O
bacterial	O
communities	O
of	O
the	O
Pacific	O
whiteleg	O
shrimp	O
(	O
Litopenaeus	O
vannamei	O
-	O
the	O
most	O
widely	O
aquaculture	O
-	O
farmed	O
shrimp	O
worldwide	O
)	O
reared	O
in	O
indoor	O
aquaculture	O
facilities	O
and	O
outdoor	O
pond	O
systems	O
.	O

While	O
samples	O
showed	O
very	O
consistent	O
intestinal	O
bacterial	O
community	O
profiles	O
within	O
each	O
production	O
system	O
,	O
major	O
differences	O
were	O
uncovered	O
between	O
the	O
two	O
practices	O
.	O

Indeed	O
,	O
bacteria	O
affiliated	O
with	O
Rhodobacteraceae	B-bacteria
(	O
Proteobacteria	B-bacteria
)	O
and	O
Actinobacteria	B-bacteria
were	O
significantly	O
more	O
abundant	O
in	O
indoor	O
samples	O
(	O
84	O
.	O
4	O
%	O
vs	O
.	O
5	O
.	O
1	O
%	O
;	O
3	O
.	O
0	O
%	O
vs	O
.	O
0	O
.	O
06	O
%	O
,	O
respectively	O
)	O
,	O
while	O
Vibrionaceae	B-bacteria
(	O
Proteobacteria	B-bacteria
)	O
,	O
Firmicutes	B-bacteria
,	O
Fusobacteria	B-bacteria
and	O
Cyanobacteria	B-bacteria
were	O
predominant	O
in	O
pond	O
samples	O
(	O
0	O
.	O
03	O
%	O
vs	O
.	O
44	O
.	O
8	O
%	O
;	O
0	O
.	O
7	O
%	O
vs	O
.	O
36	O
.	O
0	O
%	O
;	O
0	O
.	O
0	O
%	O
vs	O
.	O
7	O
.	O
9	O
%	O
;	O
0	O
.	O
001	O
%	O
vs	O
.	O
1	O
.	O
6	O
%	O
,	O
respectively	O
)	O
.	O

Accordingly	O
,	O
the	O
abundance	O
of	O
11	O
of	O
the	O
12	O
most	O
prominent	O
Operational	O
Taxonomic	O
Units	O
(	O
OTUs	O
)	O
were	O
found	O
to	O
be	O
statistically	O
different	O
between	O
the	O
two	O
production	O
environments	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
aquaculture	O
practices	O
greatly	O
influence	O
the	O
intestinal	O
bacterial	O
profile	O
of	O
the	O
whiteleg	O
shrimp	O
,	O
and	O
further	O
suggest	O
that	O
bacterial	O
communities	O
of	O
this	O
economically	O
important	O
crustacean	O
could	O
be	O
effectively	O
manipulated	O
using	O
diet	O
composition	O
or	O
environmental	O
conditions	O
.	O

Microbiome	O
-	O
Microbial	O
Metabolome	O
-	O
Cancer	O
Cell	O
Interactions	O
in	O
Breast	O
Cancer	O
-	O
Familiar	O
,	O
but	O
Unexplored	O
.	O

Breast	O
cancer	O
is	O
a	O
leading	O
cause	O
of	O
death	O
among	O
women	O
worldwide	O
.	O

Dysbiosis	O
,	O
an	O
aberrant	O
composition	O
of	O
the	O
microbiome	O
,	O
characterizes	O
breast	O
cancer	O
.	O

In	O
this	O
review	O
we	O
discuss	O
the	O
changes	O
to	O
the	O
metabolism	O
of	O
breast	O
cancer	O
cells	O
,	O
as	O
well	O
as	O
the	O
composition	O
of	O
the	O
breast	O
and	O
gut	O
microbiome	O
in	O
breast	O
cancer	O
.	O

The	O
role	O
of	O
the	O
breast	O
microbiome	O
in	O
breast	O
cancer	O
is	O
unresolved	O
,	O
nevertheless	O
it	O
seems	O
that	O
the	O
gut	O
microbiome	O
does	O
have	O
a	O
role	O
in	O
the	O
pathology	O
of	O
the	O
disease	O
.	O

The	O
gut	O
microbiome	O
secretes	O
bioactive	O
metabolites	O
(	O
reactivated	O
estrogens	O
,	O
short	O
chain	O
fatty	O
acids	O
,	O
amino	O
acid	O
metabolites	O
,	O
or	O
secondary	O
bile	O
acids	O
)	O
that	O
modulate	O
breast	O
cancer	O
.	O

We	O
highlight	O
the	O
bacterial	O
species	O
or	O
taxonomical	O
units	O
that	O
generate	O
these	O
metabolites	O
,	O
we	O
show	O
their	O
mode	O
of	O
action	O
,	O
and	O
discuss	O
how	O
the	O
metabolites	O
affect	O
mitochondrial	O
metabolism	O
and	O
other	O
molecular	O
events	O
in	O
breast	O
cancer	O
.	O

These	O
metabolites	O
resemble	O
human	O
hormones	O
,	O
as	O
they	O
are	O
produced	O
in	O
a	O
`	O
`	O
gland	O
'	O
'	O
(	O
in	O
this	O
case	O
,	O
the	O
microbiome	O
)	O
and	O
they	O
are	O
subsequently	O
transferred	O
to	O
distant	O
sites	O
of	O
action	O
through	O
the	O
circulation	O
.	O

These	O
metabolites	O
appear	O
to	O
be	O
important	O
constituents	O
of	O
the	O
tumor	O
microenvironment	O
.	O

Finally	O
,	O
we	O
discuss	O
how	O
bacterial	O
dysbiosis	O
interferes	O
with	O
breast	O
cancer	O
treatment	O
through	O
interfering	O
with	O
chemotherapeutic	O
drug	O
metabolism	O
and	O
availability	O
.	O

Unique	O
Gene	O
Expression	O
Signatures	O
in	O
the	O
Intestinal	O
Mucosa	O
and	O
Organoids	O
Derived	O
from	O
Germ	O
-	O
Free	O
and	O
Monoassociated	O
Mice	O
.	O

Commensal	O
microbiota	O
contribute	O
to	O
gut	O
homeostasis	O
by	O
inducing	O
transcription	O
of	O
mucosal	O
genes	O
.	O

Analysis	O
of	O
the	O
impact	O
of	O
various	O
microbiota	O
on	O
intestinal	O
tissue	O
provides	O
an	O
important	O
insight	O
into	O
the	O
function	O
of	O
this	O
organ	O
.	O

We	O
used	O
cDNA	O
microarrays	O
to	O
determine	O
the	O
gene	O
expression	O
signature	O
of	O
mucosa	O
isolated	O
from	O
the	O
small	O
intestine	O
and	O
colon	O
of	O
germ	O
-	O
free	O
(	O
GF	O
)	O
mice	O
and	O
animals	O
monoassociated	O
with	O
two	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
strains	I-bacteria
.	O

The	O
results	O
were	O
compared	O
to	O
the	O
expression	O
data	O
obtained	O
in	O
conventionally	O
reared	O
(	O
CR	O
)	O
mice	O
.	O

In	O
addition	O
,	O
we	O
analyzed	O
gene	O
expression	O
in	O
colon	O
organoids	O
derived	O
from	O
CR	O
,	O
GF	O
,	O
and	O
monoassociated	O
animals	O
.	O

The	O
analysis	O
revealed	O
that	O
the	O
complete	O
absence	O
of	O
intestinal	O
microbiota	O
mainly	O
affected	O
the	O
mucosal	O
immune	O
system	O
,	O
which	O
was	O
not	O
restored	O
upon	O
monoassociation	O
.	O

The	O
most	O
important	O
expression	O
changes	O
observed	O
in	O
the	O
colon	O
mucosa	O
indicated	O
alterations	O
in	O
adipose	O
tissue	O
and	O
lipid	O
metabolism	O
.	O

In	O
the	O
comparison	O
of	O
differentially	O
expressed	O
genes	O
in	O
the	O
mucosa	O
or	O
organoids	O
obtained	O
from	O
GF	O
and	O
CR	O
mice	O
,	O
only	O
six	O
genes	O
were	O
common	O
for	O
both	O
types	O
of	O
samples	O
.	O

The	O
results	O
show	O
that	O
the	O
increased	O
expression	O
of	O
the	O
angiopoietin	O
-	O
like	O
4	O
(	O
Angptl4	O
)	O
gene	O
encoding	O
a	O
secreted	O
regulator	O
of	O
lipid	O
metabolism	O
indicates	O
the	O
GF	O
status	O
.	O

Phytate	O
degradation	O
,	O
intestinal	O
microbiota	O
,	O
microbial	O
metabolites	O
and	O
immune	O
values	O
are	O
changed	O
in	O
growing	O
pigs	O
fed	O
diets	O
with	O
varying	O
calcium	O
-	O
phosphorus	O
concentration	O
and	O
fermentable	O
substrates	O
.	O

The	O
present	O
study	O
assessed	O
effects	O
of	O
diets	O
containing	O
varying	O
calcium	O
-	O
phosphorus	O
(	O
CaP	O
)	O
concentration	O
and	O
fermentable	O
substrates	O
on	O
digestibility	O
of	O
diets	O
,	O
intestinal	O
microbiota	O
and	O
immune	O
system	O
using	O
32	O
crossbred	O
pigs	O
(	O
initial	O
BW	O
54	O
.	O
7	O
kg	O
)	O
.	O

In	O
a	O
2	O
x	O
2	O
factorial	O
arrangement	O
,	O
pigs	O
were	O
fed	O
either	O
a	O
corn	O
-	O
soybean	O
meal	O
(	O
CSB	O
)	O
or	O
corn	O
-	O
field	O
pea	O
(	O
CFP	O
)	O
diet	O
with	O
either	O
low	O
[	O
-	O
]	O
(	O
4	O
.	O
4	O
g	O
Ca	O
/	O
kg	O
;	O
4	O
.	O
2	O
g	O
total	O
P	O
/	O
kg	O
)	O
or	O
high	O
[	O
+	O
]	O
(	O
8	O
.	O
3	O
g	O
Ca	O
/	O
kg	O
;	O
7	O
.	O
5	O
g	O
total	O
P	O
/	O
kg	O
;	O
supplemented	O
with	O
monocalcium	O
phosphate	O
)	O
CaP	O
content	O
for	O
a	O
period	O
of	O
9	O
weeks	O
.	O

In	O
week	O
8	O
,	O
blood	O
samples	O
were	O
taken	O
,	O
and	O
at	O
the	O
end	O
of	O
the	O
trial	O
,	O
all	O
pigs	O
were	O
euthanized	O
to	O
collect	O
digesta	O
and	O
mesenteric	O
lymphoid	O
tissue	O
.	O

Apparent	O
total	O
tract	O
digestibility	O
(	O
ATTD	O
)	O
of	O
P	O
was	O
greater	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
for	O
pigs	O
fed	O
the	O
CaP	O
+	O
and	O
CFP	O
diets	O
than	O
CaP	O
-	O
and	O
CSB	O
diets	O
.	O

The	O
myo	O
-	O
inositol	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
-	O
hexakis	O
(	O
dihydrogen	O
phosphate	O
)	O
(	O
InsP6	O
)	O
concentration	O
in	O
jejunal	O
digesta	O
was	O
higher	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
for	O
CaP	O
+	O
than	O
in	O
CaP	O
-	O
fed	O
pigs	O
.	O

In	O
addition	O
,	O
caecal	O
and	O
faecal	O
InsP5	O
isomer	O
concentration	O
were	O
greater	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
for	O
CSB	O
than	O
CFP	O
diets	O
.	O

In	O
the	O
caecum	O
,	O
gene	O
copy	O
numbers	O
of	O
saccharolytic	O
bacteria	O
,	O
such	O
as	O
Eubacterium	B-bacteria
rectale	I-bacteria
and	O
Roseburia	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
as	O
well	O
as	O
SCFA	O
concentration	O
were	O
higher	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
for	O
CaP	O
+	O
than	O
CaP	O
-	O
diets	O
.	O

In	O
particular	O
,	O
innate	O
immune	O
cell	O
numbers	O
,	O
such	O
as	O
natural	O
killer	O
cells	O
,	O
dendritic	O
cells	O
,	O
monocytes	O
and	O
neutrophils	O
,	O
were	O
greater	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
for	O
CaP	O
+	O
than	O
CaP	O
-	O
fed	O
pigs	O
.	O

Diets	O
high	O
in	O
CaP	O
resulted	O
in	O
higher	O
abundance	O
of	O
potential	O
beneficial	O
bacteria	O
and	O
might	O
promote	O
the	O
first	O
line	O
of	O
defence	O
enhancing	O
the	O
activation	O
of	O
the	O
cellular	O
adaptive	O
immune	O
response	O
,	O
thereby	O
possibly	O
decreasing	O
the	O
risk	O
for	O
intestinal	O
disturbances	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
both	O
,	O
CaP	O
supply	O
and	O
dietary	O
ingredients	O
differing	O
in	O
fermentability	O
,	O
may	O
beneficially	O
affect	O
gut	O
health	O
through	O
increase	O
in	O
SCFA	O
-	O
producing	O
bacteria	O
and	O
/	O
or	O
bacteria	O
with	O
anti	O
-	O
inflammatory	O
properties	O
.	O

The	O
potential	O
probiotic	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
CNCM	I-bacteria
I	I-bacteria
-	I-bacteria
3690	I-bacteria
strain	I-bacteria
protects	O
the	O
intestinal	O
barrier	O
by	O
stimulating	O
both	O
mucus	O
production	O
and	O
cytoprotective	O
response	O
.	O

The	O
gut	O
barrier	O
plays	O
an	O
important	O
role	O
in	O
human	O
health	O
.	O

When	O
barrier	O
function	O
is	O
impaired	O
,	O
altered	O
permeability	O
and	O
barrier	O
dysfunction	O
can	O
occur	O
,	O
leading	O
to	O
inflammatory	O
bowel	O
diseases	O
,	O
irritable	O
bowel	O
syndrome	O
or	O
obesity	O
.	O

Several	O
bacteria	O
,	O
including	O
pathogens	O
and	O
commensals	O
,	O
have	O
been	O
found	O
to	O
directly	O
or	O
indirectly	O
modulate	O
intestinal	O
barrier	O
function	O
.	O

The	O
use	O
of	O
probiotic	O
strains	O
could	O
be	O
an	O
important	O
landmark	O
in	O
the	O
management	O
of	O
gut	O
dysfunction	O
with	O
a	O
clear	O
impact	O
on	O
the	O
general	O
population	O
.	O

Previously	O
,	O
we	O
found	O
that	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
CNCM	I-bacteria
I	I-bacteria
-	I-bacteria
3690	I-bacteria
can	O
protect	O
intestinal	O
barrier	O
functions	O
in	O
mice	O
inflammation	O
model	O
.	O

Here	O
,	O
we	O
investigated	O
its	O
mechanism	O
of	O
action	O
.	O

Our	O
results	O
show	O
that	O
CNCM	O
I	O
-	O
3690	O
can	O
(	O
i	O
)	O
physically	O
maintain	O
modulated	O
goblet	O
cells	O
and	O
the	O
mucus	O
layer	O
and	O
(	O
ii	O
)	O
counteract	O
changes	O
in	O
local	O
and	O
systemic	O
lymphocytes	O
.	O

Furthermore	O
,	O
mice	O
colonic	O
transcriptome	O
analysis	O
revealed	O
that	O
CNCM	O
I	O
-	O
3690	O
enhances	O
the	O
expression	O
of	O
genes	O
related	O
to	O
healthy	O
gut	O
permeability	O
:	O
motility	O
and	O
absorption	O
,	O
cell	O
proliferation	O
;	O
and	O
protective	O
functions	O
by	O
inhibiting	O
endogenous	O
proteases	O
.	O

Finally	O
,	O
SpaFED	O
pili	O
are	O
clearly	O
important	O
effectors	O
since	O
an	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
DeltaspaF	O
mutant	O
failed	O
to	O
provide	O
the	O
same	O
benefits	O
as	O
the	O
wild	O
type	O
strain	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
CNCM	O
I	O
-	O
3690	O
restores	O
impaired	O
intestinal	O
barrier	O
functions	O
via	O
anti	O
-	O
inflammatory	O
and	O
cytoprotective	O
responses	O
.	O

Metabolism	O
of	O
Milk	O
Oligosaccharides	O
in	O
Preterm	O
Pigs	O
Sensitive	O
to	O
Necrotizing	O
Enterocolitis	O
.	O

Human	O
milk	O
oligosaccharides	O
(	O
HMO	O
)	O
are	O
major	O
components	O
of	O
breast	O
milk	O
that	O
may	O
have	O
local	O
effects	O
in	O
the	O
gastrointestinal	O
tract	O
and	O
systemic	O
functions	O
after	O
being	O
absorbed	O
,	O
both	O
depending	O
on	O
their	O
metabolism	O
.	O

Using	O
preterm	O
pigs	O
,	O
we	O
investigated	O
the	O
metabolic	O
fate	O
of	O
HMO	O
in	O
three	O
experiments	O
with	O
two	O
different	O
HMO	O
blends	O
.	O

In	O
addition	O
,	O
we	O
examined	O
effects	O
on	O
the	O
colonic	O
microbiota	O
in	O
the	O
presence	O
or	O
absence	O
of	O
necrotizing	O
enterocolitis	O
(	O
NEC	O
)	O
.	O

Thus	O
,	O
preterm	O
pigs	O
(	O
n	O
=	O
112	O
)	O
were	O
fed	O
formula	O
without	O
or	O
with	O
HMO	O
supplementation	O
(	O
5	O
-	O
10	O
)	O
g	O
/	O
L	O
of	O
a	O
mixture	O
of	O
4	O
(	O
4	O
-	O
HMO	O
)	O
or	O
>	O
25	O
HMO	O
(	O
25	O
-	O
HMO	O
)	O
for	O
5	O
(	O
Experiment	O
1	O
and	O
2	O
)	O
or	O
11	O
days	O
(	O
Experiment	O
3	O
)	O
.	O

Individual	O
HMO	O
were	O
quantified	O
in	O
colon	O
contents	O
and	O
urine	O
using	O
MALDI	O
-	O
TOF	O
-	O
MS	O
(	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
mass	O
spectrometry	O
)	O
and	O
HPAEC	O
-	O
PAD	O
(	O
high	O
-	O
performance	O
anion	O
-	O
exchange	O
chromatography	O
with	O
pulsed	O
amperometric	O
detection	O
)	O
.	O

Microbial	O
colonization	O
was	O
analyzed	O
by	O
sequencing	O
of	O
16S	O
rRNA	O
gene	O
tags	O
.	O

Intestinal	O
permeability	O
was	O
measured	O
by	O
lactulose	O
to	O
mannitol	O
ratio	O
in	O
urine	O
.	O

HMO	O
supplemented	O
to	O
formula	O
were	O
detected	O
in	O
urine	O
and	O
colon	O
contents	O
in	O
preterm	O
piglets	O
after	O
5	O
and	O
11	O
days	O
in	O
all	O
three	O
experiments	O
.	O

The	O
amount	O
of	O
HMO	O
excreted	O
via	O
the	O
gut	O
or	O
the	O
kidneys	O
showed	O
large	O
individual	O
variations	O
.	O

Microbial	O
diversity	O
in	O
the	O
colon	O
changed	O
from	O
high	O
levels	O
of	O
Firmicutes	B-bacteria
(	O
dominated	O
by	O
Clostridium	B-bacteria
)	O
at	O
day	O
5	O
(	O
Exp	O
2	O
)	O
to	O
high	O
levels	O
of	O
Proteobacteria	B-bacteria
dominated	O
by	O
Helicobacter	B-bacteria
and	O
Campylobacter	B-bacteria
at	O
day	O
11	O
(	O
Exp	O
3	O
)	O
.	O

Colonic	O
microbiota	O
composition	O
as	O
well	O
as	O
HMO	O
excretion	O
pattern	O
varied	O
greatly	O
among	O
piglets	O
.	O

Interestingly	O
,	O
the	O
5	O
-	O
day	O
supplementation	O
of	O
the	O
complex	O
25	O
-	O
HMO	O
blend	O
led	O
to	O
low	O
concentrations	O
of	O
3	O
-	O
fucosyllactose	O
(	O
FL	O
)	O
and	O
lacto	O
-	O
N	O
-	O
fucopentaose	O
(	O
LNFP	O
)	O
I	O
in	O
colonic	O
contents	O
,	O
indicating	O
a	O
preferred	O
utilization	O
of	O
these	O
two	O
HMO	O
.	O

Although	O
the	O
interpretation	O
of	O
the	O
data	O
from	O
our	O
piglet	O
study	O
is	O
difficult	O
due	O
to	O
the	O
large	O
individual	O
variation	O
,	O
the	O
presence	O
of	O
Bifidobacteria	B-bacteria
,	O
although	O
low	O
in	O
total	O
numbers	O
,	O
was	O
correlated	O
with	O
total	O
HMO	O
contents	O
,	O
and	O
specifically	O
with	O
2	O
'	O
FL	O
levels	O
in	O
colonic	O
content	O
.	O

However	O
,	O
early	O
supplementation	O
of	O
formula	O
with	O
HMO	O
did	O
not	O
affect	O
NEC	O
incidence	O
.	O

Gut	O
Microbiota	O
,	O
Host	O
Organism	O
,	O
and	O
Diet	O
Trialogue	O
in	O
Diabetes	O
and	O
Obesity	O
.	O

The	O
gastrointestinal	O
tract	O
with	O
its	O
microbiota	O
is	O
a	O
complex	O
,	O
open	O
,	O
and	O
integrated	O
ecosystem	O
with	O
a	O
high	O
environmental	O
exposure	O
.	O

It	O
is	O
widely	O
accepted	O
that	O
the	O
healthy	O
gut	O
microbiotais	O
essential	O
for	O
host	O
homeostasis	O
and	O
immunostasis	O
,	O
harboring	O
an	O
enormous	O
number	O
and	O
variety	O
of	O
microorganisms	O
and	O
genes	O
tailored	O
by	O
hundreds	O
of	O
exogenous	O
and	O
intrinsic	O
host	O
factors	O
.	O

The	O
occurrence	O
of	O
dysbiosis	O
may	O
contribute	O
to	O
host	O
vulnerability	O
and	O
progression	O
to	O
a	O
large	O
spectrum	O
of	O
infectious	O
and	O
non	O
-	O
communicable	O
diseases	O
,	O
including	O
diabetes	O
and	O
obesity	O
,	O
two	O
metabolic	O
disorders	O
that	O
are	O
showing	O
an	O
endemic	O
trend	O
nowadays	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
efficient	O
strategies	O
to	O
prevent	O
and	O
treat	O
metabolic	O
disorders	O
such	O
as	O
diabetes	O
and	O
obesity	O
which	O
are	O
often	O
associated	O
with	O
serious	O
complications	O
.	O

In	O
this	O
paper	O
,	O
we	O
give	O
an	O
overview	O
on	O
the	O
implications	O
of	O
gut	O
microbiota	O
in	O
diabesity	O
,	O
with	O
a	O
focus	O
on	O
the	O
triangle	O
gut	O
microbiota	O
-	O
diet	O
-	O
host	O
metabolism	O
and	O
on	O
the	O
way	O
to	O
manipulate	O
the	O
gut	O
microbial	O
ecosystem	O
toward	O
achieving	O
novel	O
diagnosis	O
and	O
predictive	O
biomarkers	O
with	O
the	O
final	O
goal	O
of	O
reestablishing	O
the	O
healthy	O
metabolic	O
condition	O
.	O

The	O
current	O
research	O
data	O
regarding	O
the	O
precision	O
/	O
personalized	O
nutrition	O
suggest	O
that	O
dietary	O
interventions	O
,	O
including	O
administration	O
of	O
pre	O
-	O
,	O
pro	O
-	O
,	O
and	O
syn	O
-	O
biotics	O
,	O
as	O
well	O
as	O
antibiotic	O
treatment	O
should	O
be	O
individually	O
tailored	O
to	O
prevent	O
chronic	O
diseases	O
based	O
on	O
the	O
genetic	O
background	O
,	O
food	O
and	O
beverage	O
consumption	O
,	O
nutrient	O
intake	O
,	O
microbiome	O
,	O
metabolome	O
,	O
and	O
other	O
omic	O
profiles	O
.	O

Phage	O
Biocontrol	O
of	O
Campylobacter	B-bacteria
jejuni	I-bacteria
in	O
Chickens	O
Does	O
Not	O
Produce	O
Collateral	O
Effects	O
on	O
the	O
Gut	O
Microbiota	O
.	O

Bacteriophage	O
biocontrol	O
to	O
reduce	O
Campylobacter	B-bacteria
jejuni	I-bacteria
levels	O
in	O
chickens	O
can	O
reduce	O
human	O
exposure	O
and	O
disease	O
acquired	O
through	O
the	O
consumption	O
of	O
contaminated	O
poultry	O
products	O
.	O

Investigating	O
changes	O
in	O
the	O
chicken	O
microbiota	O
during	O
phage	O
treatment	O
has	O
not	O
previously	O
been	O
undertaken	O
but	O
is	O
crucial	O
to	O
understanding	O
the	O
system	O
-	O
wide	O
effects	O
of	O
such	O
treatments	O
to	O
establish	O
a	O
sustainable	O
application	O
.	O

A	O
phage	O
cocktail	O
containing	O
two	O
virulent	O
Campylobacter	B-bacteria
phages	O
was	O
used	O
to	O
treat	O
broiler	O
chickens	O
colonized	O
with	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
HPC5	I-bacteria
.	O

Campylobacter	B-bacteria
counts	O
from	O
cecal	O
contents	O
were	O
significantly	O
reduced	O
throughout	O
the	O
experimental	O
period	O
but	O
were	O
most	O
effective	O
2	O
days	O
post	O
-	O
treatment	O
showing	O
a	O
reduction	O
of	O
2	O
.	O
4	O
log10	O
CFU	O
g	O
(	O
-	O
1	O
)	O
relative	O
to	O
mock	O
-	O
treated	O
Campylobacter	B-bacteria
colonized	O
controls	O
.	O

The	O
administered	O
phages	O
replicated	O
in	O
vivo	O
to	O
establish	O
stable	O
populations	O
.	O

Bacteriophage	O
predation	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
was	O
not	O
found	O
to	O
affect	O
the	O
microbiota	O
structure	O
but	O
selectively	O
reduced	O
the	O
relative	O
abundance	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
without	O
affecting	O
other	O
bacteria	O
.	O

The	O
Effects	O
of	O
Unfermented	O
and	O
Fermented	O
Cow	O
and	O
Sheep	O
Milk	O
on	O
the	O
Gut	O
Microbiota	O
.	O

A	O
variety	O
of	O
fermented	O
foods	O
have	O
been	O
linked	O
to	O
improved	O
human	O
health	O
,	O
but	O
their	O
impacts	O
on	O
the	O
gut	O
microbiome	O
have	O
not	O
been	O
well	O
characterized	O
.	O

Dairy	O
products	O
are	O
one	O
of	O
the	O
most	O
popular	O
fermented	O
foods	O
and	O
are	O
commonly	O
consumed	O
worldwide	O
.	O

One	O
area	O
we	O
currently	O
lack	O
data	O
on	O
is	O
how	O
the	O
process	O
of	O
fermentation	O
changes	O
the	O
gut	O
microbiota	O
upon	O
digestion	O
.	O

What	O
is	O
even	O
less	O
well	O
characterized	O
are	O
the	O
possible	O
differences	O
between	O
cow	O
and	O
other	O
mammals	O
'	O
milks	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
the	O
impact	O
of	O
unfermented	O
skim	O
milk	O
and	O
fermented	O
skim	O
milk	O
products	O
(	O
milk	O
/	O
yogurt	O
)	O
originating	O
from	O
two	O
species	O
(	O
cow	O
/	O
sheep	O
)	O
on	O
the	O
gut	O
microbiome	O
using	O
a	O
rat	O
model	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
fed	O
a	O
dairy	O
-	O
free	O
diet	O
supplemented	O
with	O
one	O
of	O
four	O
treatment	O
dairy	O
drinks	O
(	O
cow	O
milk	O
,	O
cow	O
yogurt	O
,	O
sheep	O
milk	O
,	O
sheep	O
yogurt	O
)	O
for	O
2	O
weeks	O
.	O

The	O
viable	O
starter	O
culture	O
bacteria	O
in	O
the	O
yogurts	O
were	O
depleted	O
in	O
this	O
study	O
to	O
reduce	O
their	O
potential	O
influence	O
on	O
gut	O
bacterial	O
communities	O
.	O

At	O
the	O
end	O
of	O
the	O
study	O
,	O
cecal	O
samples	O
were	O
collected	O
and	O
the	O
bacterial	O
community	O
profiles	O
determined	O
via	O
16S	O
rRNA	O
high	O
-	O
throughput	O
sequencing	O
.	O

Fermentation	O
status	O
drove	O
the	O
composition	O
of	O
the	O
bacterial	O
communities	O
to	O
a	O
greater	O
extent	O
than	O
their	O
animal	O
origin	O
.	O

While	O
overall	O
community	O
alpha	O
diversity	O
did	O
not	O
change	O
among	O
treatment	O
groups	O
,	O
the	O
abundance	O
of	O
a	O
number	O
of	O
taxa	O
differed	O
.	O

The	O
cow	O
milk	O
supplemented	O
treatment	O
group	O
was	O
distinct	O
,	O
with	O
a	O
higher	O
intragroup	O
variability	O
and	O
a	O
distinctive	O
taxonomic	O
composition	O
.	O

Collinsella	B-bacteria
aerofaciens	I-bacteria
was	O
of	O
particularly	O
high	O
abundance	O
(	O
9	O
%	O
)	O
for	O
this	O
group	O
.	O

Taxa	O
such	O
as	O
Firmicutes	B-bacteria
and	O
Lactobacillus	B-bacteria
were	O
found	O
in	O
higher	O
abundance	O
in	O
communities	O
of	O
rats	O
fed	O
with	O
milk	O
,	O
while	O
Proteobacteria	B-bacteria
,	O
Bacteroidetes	B-bacteria
,	O
and	O
Parabacteroides	B-bacteria
were	O
higher	O
in	O
yogurt	O
fed	O
rats	O
.	O

Collinsella	B-bacteria
was	O
also	O
found	O
to	O
be	O
of	O
higher	O
abundance	O
in	O
both	O
milk	O
(	O
vs	O
.	O
yogurt	O
)	O
and	O
cows	O
(	O
vs	O
.	O
sheep	O
)	O
.	O

This	O
research	O
provides	O
new	O
insight	O
into	O
the	O
effects	O
of	O
unfermented	O
vs	O
.	O
fermented	O
milk	O
(	O
yogurt	O
)	O
and	O
animal	O
origin	O
on	O
gut	O
microbial	O
composition	O
in	O
a	O
healthy	O
host	O
.	O

A	O
number	O
of	O
differences	O
in	O
taxonomic	O
abundance	O
between	O
treatment	O
groups	O
were	O
observed	O
.	O

Most	O
were	O
associated	O
with	O
the	O
effects	O
of	O
fermentation	O
,	O
but	O
others	O
the	O
origin	O
species	O
,	O
or	O
in	O
the	O
case	O
of	O
cow	O
milk	O
,	O
unique	O
to	O
the	O
treatment	O
group	O
.	O

Future	O
studies	O
focusing	O
on	O
understanding	O
microbial	O
metabolism	O
and	O
interactions	O
,	O
should	O
help	O
unravel	O
what	O
drives	O
these	O
differences	O
.	O

The	O
gut	O
microbiota	O
community	O
and	O
antioxidant	O
enzymes	O
activity	O
of	O
barramundi	O
reared	O
at	O
seawater	O
and	O
freshwater	O
.	O

To	O
understand	O
the	O
physiological	O
responses	O
of	O
euryhaline	O
fish	O
to	O
reared	O
salinity	O
,	O
the	O
gut	O
microbiota	O
composition	O
and	O
antioxidant	O
enzymes	O
activity	O
of	O
same	O
batch	O
barramundi	O
Lates	O
calcarifer	O
reared	O
in	O
two	O
extreme	O
salinity	O
condition	O
(	O
seawater	O
and	O
freshwater	O
)	O
were	O
studied	O
,	O
under	O
laboratory	O
condition	O
.	O

The	O
gut	O
bacterial	O
composition	O
was	O
analyzed	O
using	O
high	O
-	O
throughput	O
Illumina	O
sequencing	O
.	O

Acid	O
phosphatase	O
(	O
ACP	O
)	O
,	O
catalase	O
(	O
CAT	O
)	O
,	O
glutathione	O
peroxidase	O
(	O
GSH	O
-	O
Px	O
)	O
,	O
lipid	O
peroxide	O
(	O
LPO	O
)	O
,	O
lysozyme	O
(	O
LZM	O
)	O
,	O
malonaldehyde	O
(	O
MDA	O
)	O
,	O
peroxidase	O
(	O
POD	O
)	O
,	O
and	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
were	O
used	O
as	O
biochemical	O
indicators	O
.	O

The	O
reared	O
salinity	O
did	O
not	O
change	O
the	O
major	O
composition	O
of	O
barramundi	O
gut	O
bacteria	O
under	O
circulating	O
aquaculture	O
system	O
.	O

Proteobacteria	B-bacteria
,	O
Firmicutes	B-bacteria
were	O
the	O
most	O
phylum	O
in	O
barramundi	B-bacteria
gut	O
microbiota	O
community	O
,	O
and	O
Exiguobacterium	B-bacteria
,	O
Citrobacter	B-bacteria
,	O
Acinetobacter	B-bacteria
,	O
Pseudomonas	B-bacteria
were	O
the	O
dominate	O
genus	O
.	O

CAT	O
and	O
ACP	O
activity	O
in	O
barramundi	O
liver	O
were	O
found	O
significantly	O
different	O
between	O
freshwater	O
and	O
seawater	O
group	O
.	O

GSH	O
-	O
Px	O
,	O
LZM	O
,	O
POD	O
,	O
SOD	O
activity	O
and	O
MDA	O
,	O
LPO	O
levels	O
were	O
not	O
significantly	O
affected	O
by	O
reared	O
salinity	O
.	O

This	O
study	O
is	O
the	O
first	O
high	O
-	O
throughput	O
analyses	O
of	O
the	O
gut	O
microbiota	O
diversity	O
in	O
barramundi	O
from	O
same	O
batch	O
of	O
siblings	O
reared	O
under	O
two	O
extreme	O
salinity	O
condition	O
.	O

And	O
the	O
findings	O
in	O
the	O
present	O
study	O
can	O
be	O
instructive	O
to	O
the	O
management	O
of	O
animal	O
health	O
in	O
barramundi	O
circulating	O
farming	O
activities	O
,	O
and	O
further	O
euryhaline	O
fish	O
gut	O
microecology	O
research	O
.	O

Pharmacologic	O
and	O
Nonpharmacologic	O
Therapies	O
for	O
the	O
Gut	O
Microbiota	O
in	O
Type	O
2	O
Diabetes	O
.	O

The	O
gut	O
microbiota	O
is	O
an	O
important	O
regulator	O
of	O
host	O
metabolism	O
.	O

Metagenome	O
analyses	O
have	O
demonstrated	O
that	O
the	O
gut	O
microbiota	O
differs	O
between	O
patients	O
with	O
type	O
2	O
diabetes	O
and	O
healthy	O
subjects	O
,	O
and	O
several	O
studies	O
have	O
shown	O
that	O
impaired	O
glucose	O
metabolism	O
is	O
associated	O
with	O
decreased	O
levels	O
of	O
butyrate	O
-	O
producing	O
bacteria	O
.	O

Gut	O
microbiota	O
-	O
produced	O
metabolites	O
,	O
such	O
as	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
amino	O
acid	O
derivatives	O
and	O
secondary	O
bile	O
acids	O
,	O
participate	O
in	O
metabolic	O
and	O
immunologic	O
processes	O
and	O
,	O
hence	O
,	O
pose	O
putative	O
links	O
between	O
the	O
gut	O
microbiota	O
and	O
glucose	O
homeostasis	O
.	O

Strategies	O
to	O
prevent	O
and	O
treat	O
type	O
2	O
diabetes	O
through	O
manipulation	O
of	O
the	O
gut	O
microbiota	O
are	O
being	O
developed	O
.	O

These	O
include	O
replacement	O
of	O
the	O
gut	O
microbiota	O
by	O
fecal	O
transplantation	O
,	O
consumption	O
of	O
fibres	O
to	O
promote	O
the	O
function	O
and	O
growth	O
of	O
beneficial	O
bacteria	O
and	O
treatment	O
with	O
probiotic	O
bacterial	O
strains	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
shown	O
that	O
many	O
drugs	O
,	O
including	O
drugs	O
used	O
for	O
treatment	O
of	O
diabetes	O
,	O
have	O
major	O
impacts	O
on	O
gut	O
microbiota	O
and	O
,	O
thereby	O
,	O
potentially	O
on	O
glucose	O
metabolism	O
.	O

In	O
particular	O
,	O
the	O
commonly	O
used	O
drug	O
metformin	O
has	O
been	O
shown	O
to	O
influence	O
the	O
functional	O
capacity	O
of	O
the	O
gut	O
microbiota	O
,	O
and	O
recent	O
evidence	O
indicates	O
that	O
this	O
may	O
contribute	O
to	O
the	O
antidiabetes	O
effect	O
of	O
metformin	O
.	O

The	O
Microbiome	O
in	O
Paediatric	O
Crohn	O
'	O
s	O
Disease	O
-	O
A	O
Longitudinal	O
,	O
Prospective	O
,	O
Single	O
-	O
Centre	O
Study	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
The	O
gut	O
mucosa	O
is	O
the	O
principal	O
site	O
where	O
Crohn	O
'	O
s	O
disease	O
[	O
CD	O
]	O
inflammation	O
occurs	O
.	O

Limited	O
information	O
is	O
available	O
about	O
the	O
gut	O
mucosal	O
microbiome	O
during	O
CD	O
relapse	O
and	O
remission	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
characterize	O
specific	O
changes	O
in	O
the	O
gut	O
microbiome	O
during	O
relapse	O
and	O
remission	O
in	O
a	O
large	O
single	O
-	O
centre	O
paediatric	O
CD	O
cohort	O
.	O

METHODS	O
:	O
We	O
analysed	O
the	O
microbiome	O
of	O
345	O
biopsies	O
from	O
204	O
patients	O
,	O
including	O
88	O
CD	O
first	O
diagnosis	O
[	O
CDFD	O
]	O
patients	O
,	O
38	O
relapse	O
[	O
CDRL	O
]	O
patients	O
,	O
12	O
remission	O
[	O
CDRM	O
]	O
patients	O
,	O
and	O
66	O
controls	O
.	O

Species	O
identification	O
was	O
conducted	O
using	O
oligotyping	O
in	O
combination	O
with	O
ARB	O
/	O
SILVA	O
taxonomic	O
annotation	O
.	O

RESULTS	O
:	O
We	O
observed	O
45	O
bacteria	O
to	O
differ	O
between	O
CDFD	O
samples	O
and	O
controls	O
with	O
statistical	O
significance	O
,	O
with	O
Fusobacterium	B-bacteria
being	O
the	O
most	O
implicated	O
species	O
in	O
CDFD	O
patients	O
.	O

We	O
also	O
identified	O
gender	O
-	O
specific	O
differences	O
in	O
CD	O
.	O

Five	O
species	O
showed	O
a	O
strong	O
association	O
with	O
CDRL	O
patients	O
and	O
10	O
species	O
with	O
CDRM	O
patients	O
.	O

Three	O
taxa	O
showed	O
a	O
positive	O
co	O
-	O
occurrence	O
across	O
the	O
two	O
groups	O
.	O

Hespellia	B-bacteria
porcina	I-bacteria
[	O
closest	O
taxonomic	O
neighbour	O
to	O
Clostridium	B-bacteria
oroticum	I-bacteria
]	O
was	O
the	O
most	O
strongly	O
associated	O
with	O
CDRL	O
samples	O
.	O

Interestingly	O
,	O
Fusobacterium	B-bacteria
was	O
not	O
part	O
of	O
the	O
CDRL	O
-	O
associated	O
taxa	O
group	O
.	O

Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
was	O
equally	O
present	O
in	O
CDFD	O
and	O
control	O
samples	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
study	O
that	O
has	O
investigated	O
the	O
gut	O
mucosal	O
microbiome	O
in	O
a	O
paediatric	O
CD	O
cohort	O
with	O
longitudinal	O
sampling	O
.	O

Importantly	O
,	O
the	O
microbiome	O
of	O
patients	O
in	O
CDRM	O
did	O
not	O
return	O
to	O
a	O
healthy	O
control	O
state	O
.	O

Neither	O
did	O
the	O
microbiome	O
of	O
patients	O
with	O
CDRL	O
return	O
to	O
the	O
profile	O
seen	O
at	O
CDFD	O
.	O

Similarly	O
in	O
depression	O
,	O
nuances	O
of	O
gut	O
microbiota	O
:	O
Evidences	O
from	O
a	O
shotgun	O
metagenomics	O
sequencing	O
study	O
on	O
major	O
depressive	O
disorder	O
versus	O
bipolar	O
disorder	O
with	O
current	O
major	O
depressive	O
episode	O
patients	O
.	O

BACKGROUND	O
:	O
To	O
probe	O
the	O
differences	O
of	O
gut	O
microbiota	O
among	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
,	O
bipolar	O
disorder	O
with	O
current	O
major	O
depressive	O
episode	O
(	O
BPD	O
)	O
and	O
health	O
participants	O
.	O

METHODS	O
:	O
Thirty	O
one	O
MDD	O
patients	O
,	O
thirty	O
BPD	O
patients	O
,	O
and	O
thirty	O
healthy	O
controls	O
(	O
HCs	O
)	O
were	O
recruited	O
.	O

All	O
the	O
faecal	O
samples	O
were	O
analyzed	O
by	O
shotgun	O
metagenomics	O
sequencing	O
.	O

Except	O
for	O
routine	O
analyses	O
of	O
alpha	O
diversity	O
,	O
we	O
specially	O
designed	O
a	O
new	O
indicator	O
,	O
the	O
Gm	O
coefficient	O
,	O
to	O
evaluate	O
the	O
inequality	O
of	O
relative	O
abundances	O
of	O
microbiota	O
for	O
each	O
participant	O
.	O

RESULTS	O
:	O
The	O
Gm	O
coefficients	O
are	O
significant	O
decreased	O
in	O
both	O
MDD	O
and	O
BPD	O
groups	O
.	O

The	O
relative	O
abundances	O
of	O
increased	O
phyla	O
Firmicutes	B-bacteria
and	O
Actinobacteria	B-bacteria
and	O
decreased	O
Bacteroidetes	B-bacteria
were	O
significantly	O
in	O
the	O
MDD	O
and	O
BPD	O
groups	O
.	O

At	O
genus	O
level	O
,	O
four	O
of	O
top	O
five	O
enriched	O
genera	O
(	O
Bacteroides	B-bacteria
,	O
Clostridium	B-bacteria
,	O
Bifidobacterium	B-bacteria
,	O
Oscillibacter	B-bacteria
and	O
Streptococcus	B-bacteria
)	O
were	O
found	O
increased	O
significantly	O
in	O
the	O
MDD	O
and	O
BPD	O
groups	O
compared	O
with	O
HCs	O
.	O

The	O
genera	O
Escherichia	B-bacteria
and	O
Klebsiella	B-bacteria
showed	O
significant	O
changes	O
in	O
abundances	O
only	O
between	O
the	O
BPD	O
and	O
HC	O
groups	O
.	O

At	O
the	O
species	O
level	O
,	O
compared	O
with	O
BPD	O
patients	O
,	O
MDD	O
patients	O
had	O
a	O
higher	O
abundance	O
of	O
Prevotellaceae	B-bacteria
including	O
Prevotella	B-bacteria
denticola	I-bacteria
F0289	I-bacteria
,	O
Prevotella	B-bacteria
intermedia	I-bacteria
17	I-bacteria
,	O
Prevotella	B-bacteria
ruminicola	I-bacteria
,	O
and	O
Prevotella	B-bacteria
intermedia	I-bacteria
.	O

Furthermore	O
,	O
the	O
abundance	O
of	O
Fusobacteriaceae	B-bacteria
,	O
Escherichia	B-bacteria
blattae	I-bacteria
DSM	I-bacteria
4481	I-bacteria
and	O
Klebsiella	B-bacteria
oxytoca	I-bacteria
were	O
significantly	O
increased	O
,	O
whereas	O
the	O
Bifidobacterium	B-bacteria
longum	I-bacteria
subsp	I-bacteria
.	I-bacteria
infantis	I-bacteria
ATCC	I-bacteria
15697	I-bacteria
=	O
JCM	B-bacteria
1222	I-bacteria
was	O
significantly	O
reduced	O
in	O
BPD	O
group	O
compared	O
with	O
MDD	O
group	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
suggested	O
that	O
gut	O
microbiota	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
both	O
MDD	O
and	O
BPD	O
patients	O
,	O
and	O
the	O
nuances	O
of	O
bacteria	O
may	O
have	O
the	O
potentiality	O
of	O
being	O
the	O
biomarkers	O
of	O
MDD	O
and	O
BPD	O
.	O

A	O
gut	O
microbiome	O
signature	O
for	O
cirrhosis	O
due	O
to	O
nonalcoholic	O
fatty	O
liver	O
disease	O
.	O

The	O
presence	O
of	O
cirrhosis	O
in	O
nonalcoholic	O
-	O
fatty	O
-	O
liver	O
-	O
disease	O
(	O
NAFLD	O
)	O
is	O
the	O
most	O
important	O
predictor	O
of	O
liver	O
-	O
related	O
mortality	O
.	O

Limited	O
data	O
exist	O
concerning	O
the	O
diagnostic	O
accuracy	O
of	O
gut	O
-	O
microbiome	O
-	O
derived	O
signatures	O
for	O
detecting	O
NAFLD	O
-	O
cirrhosis	O
.	O

Here	O
we	O
report	O
16S	O
gut	O
-	O
microbiome	O
compositions	O
of	O
203	O
uniquely	O
well	O
-	O
characterized	O
participants	O
from	O
a	O
prospective	O
twin	O
and	O
family	O
cohort	O
,	O
including	O
98	O
probands	O
encompassing	O
the	O
entire	O
spectrum	O
of	O
NAFLD	O
and	O
105	O
of	O
their	O
first	O
-	O
degree	O
relatives	O
,	O
assessed	O
by	O
advanced	O
magnetic	O
-	O
resonance	O
-	O
imaging	O
.	O

We	O
show	O
strong	O
familial	O
correlation	O
of	O
gut	O
-	O
microbiome	O
profiles	O
,	O
driven	O
by	O
shared	O
housing	O
.	O

We	O
report	O
a	O
panel	O
of	O
30	O
features	O
,	O
including	O
27	O
bacterial	O
features	O
with	O
discriminatory	O
ability	O
to	O
detect	O
NAFLD	O
-	O
cirrhosis	O
using	O
a	O
Random	O
Forest	O
classifier	O
model	O
.	O

In	O
a	O
derivation	O
cohort	O
of	O
probands	O
,	O
the	O
model	O
has	O
a	O
robust	O
diagnostic	O
accuracy	O
(	O
AUROC	O
of	O
0	O
.	O
92	O
)	O
for	O
detecting	O
NAFLD	O
-	O
cirrhosis	O
,	O
confirmed	O
in	O
a	O
validation	O
cohort	O
of	O
relatives	O
of	O
proband	O
with	O
NAFLD	O
-	O
cirrhosis	O
(	O
AUROC	O
of	O
0	O
.	O
87	O
)	O
.	O

This	O
study	O
provides	O
evidence	O
for	O
a	O
fecal	O
-	O
microbiome	O
-	O
derived	O
signature	O
to	O
detect	O
NAFLD	O
-	O
cirrhosis	O
.	O

Faecal	O
microbiota	O
transplantation	O
for	O
the	O
decolonization	O
of	O
antibiotic	O
-	O
resistant	O
bacteria	O
in	O
the	O
gut	O
:	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

Antibiotic	O
resistance	O
is	O
a	O
growing	O
global	O
problem	O
associated	O
with	O
increased	O
morbidity	O
and	O
mortality	O
,	O
and	O
presents	O
a	O
significant	O
financial	O
and	O
economic	O
burden	O
on	O
healthcare	O
.	O

Faecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
has	O
been	O
proven	O
effective	O
for	O
curing	O
recurrent	O
Clostridium	B-bacteria
difficile	I-bacteria
infections	O
,	O
however	O
no	O
systematic	O
review	O
to	O
date	O
has	O
addressed	O
its	O
effectiveness	O
for	O
decolonization	O
of	O
antibiotic	O
-	O
resistant	O
bacteria	O
from	O
the	O
gut	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
establish	O
whether	O
faecal	O
microbiota	O
transplantation	O
decolonizes	O
antibiotic	O
-	O
resistant	O
bacteria	O
from	O
the	O
gut	O
of	O
colonized	O
adults	O
.	O

A	O
systematic	O
review	O
was	O
performed	O
by	O
undertaking	O
a	O
comprehensive	O
search	O
on	O
MEDLINE	O
,	O
Embase	O
,	O
CENTRAL	O
,	O
PubMed	O
and	O
CINAHL	O
databases	O
for	O
evidence	O
up	O
until	O
May	O
2018	O
.	O

Randomized	O
and	O
non	O
-	O
randomized	O
studies	O
evaluating	O
the	O
effects	O
of	O
FMT	O
on	O
gut	O
colonization	O
of	O
antibiotic	O
-	O
resistant	O
bacteria	O
in	O
adults	O
were	O
eligible	O
.	O

Studies	O
were	O
assessed	O
using	O
the	O
Joanna	O
Briggs	O
Institution	O
critical	O
appraisal	O
checklists	O
.	O

Quality	O
of	O
reporting	O
was	O
assessed	O
using	O
PROCESS	O
and	O
CARE	O
checklists	O
.	O

Data	O
was	O
synthesized	O
narratively	O
,	O
along	O
with	O
a	O
meta	O
-	O
analysis	O
of	O
proportions	O
for	O
the	O
primary	O
outcome	O
.	O

Five	O
studies	O
with	O
a	O
total	O
number	O
of	O
52	O
participants	O
were	O
included	O
.	O

Evidence	O
of	O
low	O
quality	O
showed	O
that	O
decolonization	O
was	O
achieved	O
in	O
half	O
of	O
the	O
cases	O
one	O
month	O
after	O
FMT	O
with	O
higher	O
response	O
noted	O
in	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
,	O
and	O
lower	O
response	O
in	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
with	O
New	O
Delhi	O
metallo	O
-	O
beta	O
-	O
lactamase	O
1	O
(	O
NDM	O
-	O
1	O
)	O
and	O
extended	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
(	O
ESBL	O
)	O
mechanisms	O
of	O
resistance	O
.	O

In	O
successful	O
cases	O
,	O
70	O
%	O
of	O
decolonization	O
cases	O
occurred	O
within	O
the	O
first	O
week	O
after	O
FMT	O
.	O

Few	O
temporary	O
adverse	O
events	O
were	O
identified	O
.	O

Despite	O
the	O
limitations	O
of	O
the	O
included	O
studies	O
,	O
evidence	O
from	O
this	O
review	O
indicates	O
a	O
potential	O
benefit	O
of	O
FMT	O
as	O
a	O
decolonization	O
intervention	O
,	O
which	O
can	O
only	O
be	O
confirmed	O
by	O
future	O
well	O
-	O
designed	O
RCTs	O
.	O

Adaptive	O
Strategies	O
of	O
the	O
Candidate	O
Probiotic	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
Nissle	I-bacteria
in	O
the	O
Mammalian	O
Gut	O
.	O

Probiotics	O
are	O
living	O
microorganisms	O
that	O
are	O
increasingly	O
used	O
as	O
gastrointestinal	O
therapeutics	O
by	O
virtue	O
of	O
their	O
innate	O
or	O
engineered	O
genetic	O
function	O
.	O

Unlike	O
abiotic	O
therapeutics	O
,	O
probiotics	O
can	O
replicate	O
in	O
their	O
intended	O
site	O
,	O
subjecting	O
their	O
genomes	O
and	O
therapeutic	O
properties	O
to	O
natural	O
selection	O
.	O

We	O
exposed	O
the	O
candidate	O
probiotic	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
Nissle	I-bacteria
(	O
EcN	B-bacteria
)	O
to	O
the	O
mouse	O
gastrointestinal	O
tract	O
over	O
several	O
weeks	O
,	O
systematically	O
altering	O
the	O
diet	O
and	O
background	O
microbiota	O
complexity	O
.	O

In	O
-	O
transit	O
EcN	O
accumulates	O
genetic	O
mutations	O
that	O
modulate	O
carbohydrate	O
utilization	O
,	O
stress	O
response	O
,	O
and	O
adhesion	O
to	O
gain	O
competitive	O
fitness	O
,	O
while	O
previous	O
exposure	O
to	O
antibiotics	O
reveals	O
an	O
acquisition	O
of	O
resistance	O
.	O

We	O
then	O
leveraged	O
these	O
insights	O
to	O
generate	O
an	O
EcN	O
strain	O
that	O
shows	O
therapeutic	O
efficacy	O
in	O
a	O
mouse	O
model	O
of	O
phenylketonuria	O
and	O
found	O
that	O
it	O
was	O
genetically	O
stable	O
over	O
1	O
week	O
,	O
thereby	O
validating	O
EcN	O
'	O
s	O
utility	O
as	O
a	O
chassis	O
for	O
engineering	O
.	O

Collectively	O
,	O
we	O
demonstrate	O
a	O
generalizable	O
pipeline	O
that	O
can	O
be	O
applied	O
to	O
other	O
probiotics	O
to	O
better	O
understand	O
their	O
safety	O
and	O
engineering	O
potential	O
.	O

The	O
Transformative	O
Possibilities	O
of	O
the	O
Microbiota	O
and	O
Mycobiota	B-bacteria
for	O
Health	O
,	O
Disease	O
,	O
Aging	O
,	O
and	O
Technological	O
Innovation	O
.	O

The	O
gut	O
microbiota	O
is	O
extremely	O
important	O
for	O
the	O
health	O
of	O
the	O
host	O
across	O
its	O
lifespan	O
.	O
Recent	O
studies	O
have	O
elucidated	O
connections	O
between	O
the	O
gut	O
microbiota	O
and	O
neurological	O
diseaseand	O
disorders	O
such	O
as	O
depression	O
,	O
anxiety	O
,	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
,	O
autism	O
,	O
and	O
a	O
host	O
of	O
otherbrain	O
illnesses	O
.	O

Dysbiosis	O
of	O
the	O
normal	O
gut	O
flora	O
can	O
have	O
negative	O
consequences	O
for	O
humans	O
,	O
especially	O
throughout	O
key	O
periods	O
during	O
our	O
lifespan	O
as	O
the	O
gut	O
microbes	O
change	O
with	O
age	O
in	O
bothphenotype	O
and	O
number	O
of	O
bacterial	O
species	O
.	O

Neurologic	O
diseases	O
,	O
mental	O
disorders	O
,	O
and	O
euthymicstates	O
are	O
influenced	O
by	O
alterations	O
in	O
the	O
metabolites	O
produced	O
by	O
gut	O
microbial	O
milieu	O
.	O

Weintroduce	O
a	O
new	O
concept	O
,	O
namely	O
,	O
the	O
mycobiota	B-bacteria
and	O
microbiota	O
-	O
gut	O
-	O
brain	O
neuroendocrine	O
axis	O
anddiscuss	O
co	O
-	O
metabolism	O
with	O
emphasis	O
on	O
means	O
to	O
influence	O
or	O
correct	O
disruptions	O
to	O
normal	O
gutflora	O
throughout	O
the	O
lifespan	O
from	O
early	O
development	O
to	O
old	O
age	O
.	O

These	O
changes	O
involveinflammation	O
and	O
involve	O
the	O
permeability	O
of	O
barriers	O
,	O
such	O
as	O
the	O
intestine	O
blood	O
barrier	O
,	O
the	O
blood	O
(	O
-	O
)	O
brain	O
barrier	O
,	O
and	O
others	O
.	O

The	O
mycobiota	O
and	O
microbiota	O
(	O
-	O
)	O
gut	O
(	O
-	O
)	O
brain	O
axis	O
offer	O
new	O
research	O
horizonsand	O
represents	O
a	O
great	O
potential	O
target	O
for	O
new	O
therapeutics	O
,	O
including	O
approaches	O
based	O
aroundinflammatory	O
disruptive	O
process	O
,	O
genetically	O
engineered	O
drug	O
delivery	O
systems	O
,	O
diseased	O
cellculling	O
`	O
`	O
kill	O
switches	O
'	O
'	O
,	O
phage	O
-	O
like	O
therapies	O
,	O
medicinal	O
chemistry	O
,	O
or	O
microbial	O
parabiosis	O
to	O
namea	O
few	O
.	O

Aseptic	O
Rearing	O
and	O
Infection	O
with	O
Gut	O
Bacteria	O
Improve	O
the	O
Fitness	O
of	O
Transgenic	O
Diamondback	O
Moth	O
,	O
Plutella	B-bacteria
xylostella	I-bacteria
.	O

Mass	O
insect	O
rearing	O
can	O
have	O
a	O
range	O
of	O
applications	O
,	O
for	O
example	O
in	O
biological	O
control	O
of	O
pests	O
.	O

The	O
competitive	O
fitness	O
of	O
released	O
insects	O
is	O
extremely	O
important	O
in	O
a	O
number	O
of	O
applications	O
.	O

Here	O
,	O
we	O
investigated	O
how	O
to	O
improve	O
the	O
fitness	O
of	O
a	O
transgenic	O
diamondback	O
moth	O
,	O
which	O
has	O
shown	O
variation	O
in	O
mating	O
ability	O
when	O
reared	O
in	O
different	O
insectaries	O
.	O

Specifically	O
we	O
tested	O
whether	O
infection	O
with	O
a	O
gut	O
bacteria	O
,	O
Enterobacter	B-bacteria
cloacae	I-bacteria
,	O
and	O
aseptic	O
rearing	O
of	O
larvae	O
could	O
improve	O
insect	O
growth	O
and	O
male	O
performance	O
.	O

All	O
larvae	O
were	O
readily	O
infected	O
with	O
E	B-bacteria
.	I-bacteria
cloacae	I-bacteria
.	O

Under	O
aseptic	O
rearing	O
,	O
pupal	O
weights	O
were	O
reduced	O
and	O
there	O
was	O
a	O
marginal	O
reduction	O
in	O
larval	O
survival	O
.	O

However	O
,	O
aseptic	O
rearing	O
substantially	O
improved	O
the	O
fitness	O
of	O
transgenic	O
males	O
.	O

In	O
addition	O
,	O
under	O
aseptic	O
rearing	O
,	O
inoculation	O
with	O
E	B-bacteria
.	I-bacteria
cloacae	I-bacteria
increased	O
pupal	O
weights	O
and	O
male	O
fitness	O
,	O
increasing	O
the	O
proportion	O
of	O
transgenic	O
progeny	O
from	O
20	O
%	O
to	O
30	O
%	O
relative	O
to	O
uninfected	O
insects	O
.	O

Aseptic	O
conditions	O
may	O
improve	O
the	O
fitness	O
of	O
transgenic	O
males	O
by	O
excluding	O
microbial	O
contaminants	O
,	O
while	O
symbiont	O
inoculation	O
could	O
further	O
improve	O
fitness	O
by	O
providing	O
additional	O
protection	O
against	O
infection	O
,	O
or	O
by	O
normalizing	O
insect	O
physiology	O
.	O

The	O
simple	O
innovation	O
of	O
incorporating	O
antibiotic	O
into	O
diet	O
,	O
and	O
inoculating	O
insects	O
with	O
symbiotic	O
bacteria	O
that	O
are	O
resistant	O
to	O
that	O
antibiotic	O
,	O
could	O
provide	O
a	O
readily	O
transferable	O
tool	O
for	O
other	O
insect	O
rearing	O
systems	O
.	O

Curcumin	O
and	O
Resveratrol	O
Regulate	O
Intestinal	O
Bacteria	O
and	O
Alleviate	O
Intestinal	O
Inflammation	O
in	O
Weaned	O
Piglets	O
.	O

Human	O
infants	O
or	O
piglets	O
are	O
vulnerable	O
to	O
intestinal	O
microbe	O
-	O
caused	O
disorders	O
and	O
inflammation	O
due	O
to	O
their	O
rapidly	O
changing	O
gut	O
microbiota	O
and	O
immaturity	O
of	O
their	O
immune	O
systems	O
at	O
weaning	O
.	O

Resveratrol	O
and	O
curcumin	O
have	O
significant	O
anti	O
-	O
inflammatory	O
,	O
bacteria	O
-	O
regulating	O
and	O
immune	O
-	O
promoting	O
effects	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
dietary	O
supplementation	O
with	O
resveratrol	O
and	O
curcumin	O
can	O
change	O
the	O
intestinal	O
microbiota	O
and	O
alleviate	O
intestinal	O
inflammation	O
induced	O
by	O
weaning	O
in	O
piglets	O
.	O

One	O
hundred	O
eighty	O
piglets	O
weaned	O
at	O
21	O
+	O
/	O
-	O
2	O
d	O
were	O
fed	O
a	O
control	O
diet	O
(	O
CON	O
group	O
)	O
or	O
supplemented	O
diet	O
(	O
300	O
mg	O
/	O
kg	O
of	O
antibiotics	O
,	O
ANT	O
group	O
;	O
300	O
mg	O
/	O
kg	O
of	O
resveratrol	O
and	O
curcumin	O
,	O
respectively	O
,	O
HRC	O
group	O
;	O
100	O
mg	O
/	O
kg	O
of	O
resveratrol	O
and	O
curcumin	O
,	O
respectively	O
,	O
LRC	O
group	O
;	O
300	O
mg	O
/	O
kg	O
of	O
resveratrol	O
,	O
RES	O
group	O
;	O
300	O
mg	O
/	O
kg	O
of	O
curcumin	O
,	O
CUR	O
group	O
)	O
for	O
28	O
days	O
.	O

The	O
results	O
showed	O
that	O
compared	O
with	O
the	O
CON	O
group	O
,	O
curcumin	O
alone	O
and	O
antibiotics	O
decreased	O
the	O
copy	O
numbers	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

Both	O
curcumin	O
and	O
resveratrol	O
down	O
-	O
regulated	O
the	O
level	O
of	O
Toll	O
-	O
like	O
-	O
receptor	O
4	O
mRNA	O
and	O
protein	O
expression	O
in	O
the	O
intestine	O
to	O
inhibit	O
the	O
release	O
of	O
critical	O
inflammation	O
molecules	O
(	O
interleukin	O
-	O
1beta	O
,	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
)	O
,	O
and	O
increase	O
the	O
secretion	O
of	O
immunoglobulin	O
.	O

Our	O
results	O
suggested	O
that	O
curcumin	O
and	O
resveratrol	O
can	O
regulate	O
weaned	O
piglet	O
gut	O
microbiota	O
,	O
down	O
-	O
regulate	O
the	O
TLR4	O
signaling	O
pathway	O
,	O
alleviate	O
intestinal	O
inflammation	O
,	O
and	O
ultimately	O
increase	O
intestinal	O
immune	O
function	O
.	O

Gut	O
Prevotella	B-bacteria
as	O
a	O
possible	O
biomarker	O
of	O
diet	O
and	O
its	O
eubiotic	O
versus	O
dysbiotic	O
roles	O
-	O
A	O
comprehensive	O
literature	O
review	O
.	O

Gut	O
microbiota	O
has	O
a	O
profound	O
impact	O
on	O
human	O
health	O
.	O

Emerging	O
data	O
shows	O
that	O
dietary	O
patterns	O
are	O
associated	O
with	O
different	O
communities	O
of	O
bacterial	O
species	O
within	O
the	O
gut	O
.	O

Prevotella	B-bacteria
species	I-bacteria
have	O
been	O
correlated	O
with	O
plant	O
rich	O
diets	O
,	O
abundant	O
in	O
carbohydrates	O
and	O
fibres	O
.	O

Dysbiosis	O
within	O
the	O
gut	O
ecosystem	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
non	O
-	O
communicable	O
diseases	O
such	O
as	O
obesity	O
,	O
metabolic	O
syndrome	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
irritable	O
bowel	O
syndrome	O
,	O
colorectal	O
cancer	O
,	O
type	O
1	O
diabetes	O
,	O
allergies	O
and	O
other	O
diseases	O
.	O

The	O
purpose	O
of	O
this	O
comprehensive	O
literature	O
review	O
was	O
to	O
evaluate	O
the	O
available	O
data	O
on	O
the	O
impact	O
of	O
diet	O
on	O
Prevotella	B-bacteria
genus	I-bacteria
,	O
as	O
a	O
dietary	O
fibre	O
fermenter	O
in	O
the	O
gut	O
,	O
as	O
well	O
as	O
its	O
implications	O
as	O
a	O
potential	O
biomarker	O
for	O
homeostasis	O
or	O
disease	O
state	O
,	O
through	O
its	O
metabolite	O
signature	O
.	O

Studies	O
were	O
identified	O
by	O
conducting	O
PubMed	O
,	O
Web	O
of	O
Science	O
Core	O
Collection	O
and	O
Google	O
Scholar	O
electronic	O
searches	O
.	O

We	O
found	O
85	O
publications	O
reporting	O
the	O
impact	O
of	O
dietary	O
patterns	O
on	O
gut	O
microbial	O
communities	O
including	O
Prevotella	B-bacteria
or	O
Prevotella	B-bacteria
/	O
Bacteroides	B-bacteria
ratio	O
in	O
particular	O
.	O

Moreover	O
,	O
the	O
role	O
of	O
Prevotella	B-bacteria
species	I-bacteria
on	O
health	O
status	O
was	O
also	O
evaluated	O
.	O

Prevotella	B-bacteria
possess	O
a	O
high	O
genetic	O
diversity	O
,	O
representing	O
one	O
of	O
the	O
important	O
groups	O
found	O
in	O
the	O
oral	O
cavity	O
and	O
large	O
intestine	O
of	O
man	O
.	O

The	O
gut	O
commensal	O
Prevotella	B-bacteria
bacteria	I-bacteria
contribute	O
to	O
polysaccharide	O
breakdown	O
,	O
being	O
dominant	O
colonizers	O
of	O
agrarian	O
societies	O
.	O

However	O
,	O
studies	O
also	O
suggested	O
a	O
potential	O
role	O
of	O
Prevotella	B-bacteria
species	I-bacteria
as	O
intestinal	O
pathobionts	O
.	O

Further	O
metagenomic	O
studies	O
are	O
needed	O
in	O
order	O
to	O
reveal	O
health	O
-	O
or	O
disease	O
-	O
modulating	O
properties	O
of	O
Prevotella	B-bacteria
species	I-bacteria
.	O
in	O
the	O
gut	O
.	O

Amylose	O
resistant	O
starch	O
(	O
HAM	O
-	O
RS2	O
)	O
supplementation	O
increases	O
the	O
proportion	O
of	O
Faecalibacterium	B-bacteria
bacteria	I-bacteria
in	O
end	O
-	O
stage	O
renal	O
disease	O
patients	O
:	O
Microbial	O
analysis	O
from	O
a	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
.	O

INTRODUCTION	O
:	O
Many	O
of	O
the	O
deleterious	O
effects	O
associated	O
with	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
are	O
secondary	O
to	O
the	O
resultant	O
systemic	O
inflammation	O
.	O

The	O
gut	O
microbial	O
changes	O
caused	O
by	O
CKD	O
are	O
thought	O
to	O
perpetuate	O
systemic	O
inflammation	O
.	O

Therefore	O
,	O
strategies	O
aimed	O
at	O
modulating	O
the	O
gut	O
microbiota	O
may	O
be	O
helpful	O
in	O
reducing	O
complications	O
associated	O
with	O
CKD	O
.	O

We	O
hypothesized	O
that	O
supplementation	O
with	O
high	O
-	O
amylose	O
maize	O
resistant	O
starch	O
type	O
2	O
(	O
HAM	O
-	O
RS2	O
)	O
would	O
beneficially	O
alter	O
the	O
gut	O
microbiome	O
and	O
lead	O
to	O
lower	O
levels	O
of	O
systemic	O
inflammation	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
,	O
parallel	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
was	O
performed	O
comparing	O
dietary	O
supplementation	O
of	O
HAM	O
-	O
RS2	O
with	O
placebo	O
in	O
patients	O
with	O
end	O
-	O
stage	O
CKD	O
.	O

Fecal	O
microbial	O
data	O
were	O
obtained	O
from	O
a	O
subset	O
of	O
patients	O
after	O
DNA	O
extraction	O
and	O
16s	O
sequencing	O
.	O

FINDINGS	O
:	O
Supplementation	O
of	O
HAM	O
-	O
RS2	O
led	O
to	O
a	O
decrease	O
in	O
serum	O
urea	O
,	O
IL	O
-	O
6	O
,	O
TNFalpha	O
,	O
and	O
malondialdehyde	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
Faecalibacterium	B-bacteria
genus	I-bacteria
was	O
significantly	O
increased	O
in	O
relative	O
abundance	O
following	O
HAM	O
-	O
RS2	O
supplementation	O
(	O
HAM	O
-	O
RS2	O
-	O
Day	O
0	O
:	O
0	O
.	O
40	O
+	O
/	O
-	O
0	O
.	O
50	O
vs	O
.	O
HAM	O
-	O
RS2	O
-	O
Day	O
56	O
:	O
3	O
.	O
21	O
+	O
/	O
-	O
4	O
.	O
97	O
P	O
=	O
0	O
.	O
03	O
)	O
and	O
was	O
unchanged	O
by	O
placebo	O
(	O
Control	O
-	O
Day	O
0	O
:	O
0	O
.	O
72	O
+	O
/	O
-	O
0	O
.	O
72	O
vs	O
.	O
Control	O
-	O
Day	O
56	O
:	O
0	O
.	O
83	O
+	O
/	O
-	O
1	O
.	O
57	O
P	O
=	O
0	O
.	O
5	O
)	O
.	O

DISCUSSION	O
:	O
Supplementation	O
of	O
amylose	O
resistant	O
starch	O
,	O
HAM	O
-	O
RS2	O
,	O
in	O
patients	O
with	O
CKD	O
led	O
to	O
an	O
elevation	O
in	O
Faecalibacterium	B-bacteria
and	O
decrease	O
in	O
systemic	O
inflammation	O
.	O

Microbial	O
manipulation	O
in	O
CKD	O
patients	O
by	O
using	O
the	O
prebiotic	O
fiber	O
may	O
exert	O
an	O
anti	O
-	O
inflammatory	O
effect	O
through	O
an	O
elevation	O
in	O
the	O
bacterial	O
genera	O
Faecalibacterium	B-bacteria
.	O

Antibiotic	O
exposure	O
perturbs	O
the	O
bacterial	O
community	O
in	O
the	O
small	O
brown	O
planthopper	O
Laodelphax	O
striatellus	I-bacteria
.	O

Bacteria	O
symbionts	O
in	O
herbivores	O
play	O
an	O
important	O
role	O
in	O
host	O
biology	O
and	O
ecology	O
,	O
and	O
are	O
affected	O
by	O
environmental	O
factors	O
such	O
as	O
temperature	O
,	O
diet	O
,	O
habitat	O
,	O
antibiotics	O
and	O
so	O
on	O
.	O

However	O
,	O
the	O
effects	O
of	O
antibiotics	O
on	O
the	O
microbiome	O
of	O
the	O
small	O
brown	O
planthopper	O
Laodelphax	O
striatellus		O
(	O
SBPH	O
)	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
studied	O
the	O
effects	O
of	O
tetracycline	O
on	O
the	O
diversity	O
and	O
composition	O
of	O
bacterial	O
colonies	O
in	O
different	O
tissues	O
of	O
SBPH	O
using	O
high	O
throughput	O
sequencing	O
of	O
16S	O
ribosomal	O
RNA	O
amplicons	O
.	O

Our	O
results	O
show	O
that	O
Proteobacteria	B-bacteria
,	O
Firmicutes	B-bacteria
,	O
Bacteroidetes	B-bacteria
,	O
Actinobacteria	B-bacteria
were	O
most	O
abundant	O
in	O
SBPH	O
,	O
and	O
the	O
genera	O
Asaia	B-bacteria
and	O
Wolbachia	B-bacteria
were	O
most	O
abundant	O
in	O
all	O
body	O
parts	O
of	O
SBPH	O
.	O

Antibiotic	O
treatment	O
had	O
persistent	O
effects	O
on	O
the	O
composition	O
of	O
the	O
SBPH	O
microbiome	O
.	O

Tetracycline	O
depleted	O
the	O
population	O
of	O
Firmicutes	B-bacteria
,	O
Bacteroidetes	B-bacteria
,	O
Tenericutes	B-bacteria
and	O
Fusobacteria	B-bacteria
,	O
and	O
nearly	O
100	O
%	O
eliminated	O
Wolbachia	B-bacteria
,	O
Bacteroides	B-bacteria
and	O
Abiotrophia	B-bacteria
in	O
SBPH	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
antibiotic	O
exposure	O
affects	O
the	O
bacteria	O
symbionts	O
of	O
different	O
body	O
parts	O
in	O
SBPH	O
and	O
will	O
facilitate	O
future	O
studies	O
of	O
the	O
bacterial	O
symbionts	O
of	O
arthropod	O
hosts	O
.	O

Characterization	O
of	O
gut	O
microbiota	O
composition	O
in	O
HIV	O
-	O
infected	O
patients	O
with	O
metabolic	O
syndrome	O
.	O

The	O
presence	O
of	O
metabolic	O
syndrome	O
(	O
MS	O
)	O
per	O
se	O
or	O
its	O
separated	O
components	O
in	O
HIV	O
-	O
infected	O
patients	O
contributes	O
to	O
an	O
accelerated	O
aging	O
and	O
increased	O
cardiovascular	O
risk	O
.	O

Gut	O
microbiota	O
(	O
GM	O
)	O
dysbiosis	O
has	O
been	O
linked	O
with	O
chronic	O
inflammation	O
associated	O
with	O
MS	O
in	O
a	O
general	O
non	O
-	O
infected	O
population	O
.	O

However	O
,	O
no	O
studies	O
concerning	O
GM	O
have	O
been	O
performed	O
in	O
HIV	O
-	O
infected	O
patients	O
with	O
MS	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
bacterial	O
translocation	O
,	O
inflammation	O
,	O
and	O
GM	O
composition	O
in	O
HIV	O
-	O
infected	O
patients	O
with	O
and	O
without	O
MS	O
.	O

A	O
total	O
of	O
51	O
HIV	O
-	O
infected	O
patients	O
were	O
recruited	O
and	O
classified	O
according	O
to	O
the	O
presence	O
of	O
M	O
(	O
40	O
patients	O
without	O
MS	O
and	O
11	O
with	O
MS	O
)	O
.	O

Markers	O
of	O
bacterial	O
translocation	O
,	O
inflammation	O
,	O
and	O
cardiovascular	O
risk	O
were	O
measured	O
and	O
GM	O
was	O
analyzed	O
using	O
16S	O
rRNA	O
gene	O
deep	O
sequencing	O
.	O

No	O
differences	O
were	O
observed	O
among	O
both	O
HIV	O
-	O
infected	O
groups	O
in	O
the	O
bacterial	O
translocation	O
markers	O
LBP	O
and	O
sCD14	O
.	O

A	O
tendency	O
to	O
increase	O
the	O
inflammatory	O
markers	O
IL	O
-	O
6	O
(	O
p	O
=	O
0	O
.	O
069	O
)	O
and	O
MCP	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
067	O
)	O
was	O
observed	O
in	O
those	O
patients	O
suffering	O
from	O
MS	O
.	O

An	O
increase	O
in	O
the	O
cardiovascular	O
risk	O
markers	O
PAI	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
007	O
)	O
and	O
triglycerides	O
/	O
HDL	O
cholesterol	O
ratio	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
was	O
also	O
found	O
in	O
the	O
MS	O
group	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
at	O
phylum	O
level	O
although	O
a	O
decrease	O
in	O
the	O
abundance	O
of	O
seven	O
genera	O
and	O
seven	O
bacterial	O
species	O
,	O
including	O
some	O
anti	O
-	O
inflammatory	O
bacteria	O
,	O
was	O
observed	O
in	O
HIV	O
-	O
infected	O
patients	O
with	O
MS	O
.	O

To	O
summarize	O
,	O
the	O
presence	O
of	O
MS	O
was	O
not	O
accompanied	O
by	O
major	O
changes	O
in	O
GM	O
,	O
although	O
the	O
reduction	O
observed	O
in	O
some	O
anti	O
-	O
inflammatory	O
bacteria	O
may	O
be	O
clinically	O
useful	O
to	O
develop	O
strategies	O
to	O
minimize	O
inflammation	O
and	O
its	O
future	O
deleterious	O
consequences	O
in	O
these	O
HIV	O
-	O
infected	O
patients	O
.	O

A	O
thioredoxin	O
-	O
like	O
protein	O
of	O
Bemisia	O
tabaci	O
interacts	O
with	O
coat	O
protein	O
of	O
begomoviruses	O
.	O

Bemisia	O
tabaci	O
(	O
whitefly	O
)	O
is	O
the	O
sole	O
vector	O
of	O
begomoviruses	O
,	O
which	O
transmits	O
them	O
in	O
a	O
persistent	O
and	O
circulative	O
manner	O
from	O
infected	O
to	O
healthy	O
plants	O
.	O

During	O
this	O
process	O
,	O
begomoviruses	O
interact	O
with	O
various	O
proteins	O
in	O
the	O
insect	O
vector	O
B	B-bacteria
.	I-bacteria
tabaci	I-bacteria
that	O
would	O
play	O
a	O
specific	O
role	O
in	O
the	O
virus	O
transmission	O
.	O

Identification	O
and	O
characterization	O
of	O
such	O
proteins	O
are	O
important	O
to	O
understand	O
the	O
complete	O
process	O
of	O
virus	O
transmission	O
.	O

Coat	O
protein	O
(	O
CP	O
)	O
of	O
begomoviruses	O
is	O
the	O
only	O
protein	O
which	O
is	O
reported	O
to	O
interact	O
with	O
proteins	O
of	O
the	O
insect	O
vector	O
B	B-bacteria
.	I-bacteria
tabaci	I-bacteria
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
yeast	O
two	O
-	O
hybrid	O
assay	O
using	O
CP	O
of	O
cotton	O
leaf	O
curl	O
Rajasthan	O
virus	O
(	O
CLCuV	O
)	O
and	O
Tomato	O
leaf	O
curl	O
New	O
Delhi	O
virus	O
(	O
ToLCNDV	O
)	O
as	O
bait	O
in	O
separate	O
experiments	O
and	O
cDNA	O
prepared	O
from	O
total	O
RNA	O
of	O
B	B-bacteria
.	I-bacteria
tabaci	I-bacteria
was	O
used	O
as	O
prey	O
.	O

Yeast	O
two	O
-	O
hybrid	O
assay	O
resulted	O
in	O
identification	O
of	O
a	O
thioredoxin	O
-	O
like	O
protein	O
(	O
TLP	O
)	O
from	O
CLCuV	O
yeast	O
two	O
-	O
hybrid	O
library	O
.	O

Later	O
TLP	O
was	O
also	O
found	O
to	O
interact	O
with	O
CP	O
of	O
ToLCNDV	O
.	O

In	O
vitro	O
pull	O
-	O
down	O
assay	O
showed	O
TLP	O
interaction	O
with	O
CP	O
of	O
both	O
CLCuV	O
and	O
ToLCNDV	O
.	O

TLP	O
was	O
found	O
to	O
interact	O
with	O
ToLCNDV	O
virus	O
particles	O
isolated	O
from	O
tomato	O
leaves	O
.	O

Dietary	O
and	O
Gut	O
Microbiota	O
Polyamines	O
in	O
Obesity	O
-	O
and	O
Age	O
-	O
Related	O
Diseases	O
.	O

The	O
polyamines	O
putrescine	O
,	O
spermidine	O
,	O
and	O
spermine	O
are	O
widely	O
distributed	O
polycationic	O
compounds	O
essential	O
for	O
cellular	O
functions	O
.	O

Intracellular	O
polyamine	O
pools	O
are	O
tightly	O
regulated	O
by	O
a	O
complex	O
regulatory	O
mechanism	O
involving	O
de	O
novo	O
biosynthesis	O
,	O
catabolism	O
,	O
and	O
transport	O
across	O
the	O
plasma	O
membrane	O
.	O

In	O
mammals	O
,	O
both	O
the	O
production	O
of	O
polyamines	O
and	O
their	O
uptake	O
from	O
the	O
extracellular	O
space	O
are	O
controlled	O
by	O
a	O
set	O
of	O
proteins	O
named	O
antizymes	O
and	O
antizyme	O
inhibitors	O
.	O

Dysregulation	O
of	O
polyamine	O
levels	O
has	O
been	O
implicated	O
in	O
a	O
variety	O
of	O
human	O
pathologies	O
,	O
especially	O
cancer	O
.	O

Additionally	O
,	O
decreases	O
in	O
the	O
intracellular	O
and	O
circulating	O
polyamine	O
levels	O
during	O
aging	O
have	O
been	O
reported	O
.	O

The	O
differences	O
in	O
the	O
polyamine	O
content	O
existing	O
among	O
tissues	O
are	O
mainly	O
due	O
to	O
the	O
endogenous	O
polyamine	O
metabolism	O
.	O

In	O
addition	O
,	O
a	O
part	O
of	O
the	O
tissue	O
polyamines	O
has	O
its	O
origin	O
in	O
the	O
diet	O
or	O
their	O
production	O
by	O
the	O
intestinal	O
microbiome	O
.	O

Emerging	O
evidence	O
has	O
suggested	O
that	O
exogenous	O
polyamines	O
(	O
either	O
orally	O
administrated	O
or	O
synthetized	O
by	O
the	O
gut	O
microbiota	O
)	O
are	O
able	O
to	O
induce	O
longevity	O
in	O
mice	O
,	O
and	O
that	O
spermidine	O
supplementation	O
exerts	O
cardioprotective	O
effects	O
in	O
animal	O
models	O
.	O

Furthermore	O
,	O
the	O
administration	O
of	O
either	O
spermidine	O
or	O
spermine	O
has	O
been	O
shown	O
to	O
be	O
effective	O
for	O
improving	O
glucose	O
homeostasis	O
and	O
insulin	O
sensitivity	O
and	O
reducing	O
adiposity	O
and	O
hepatic	O
fat	O
accumulation	O
in	O
diet	O
-	O
induced	O
obesity	O
mouse	O
models	O
.	O

The	O
exogenous	O
addition	O
of	O
agmatine	O
,	O
a	O
cationic	O
molecule	O
produced	O
through	O
arginine	O
decarboxylation	O
by	O
bacteria	O
and	O
plants	O
,	O
also	O
exerts	O
significant	O
effects	O
on	O
glucose	O
metabolism	O
in	O
obese	O
models	O
,	O
as	O
well	O
as	O
cardioprotective	O
effects	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
some	O
aspects	O
of	O
polyamine	O
metabolism	O
and	O
transport	O
,	O
how	O
diet	O
can	O
affect	O
circulating	O
and	O
local	O
polyamine	O
levels	O
,	O
and	O
how	O
the	O
modulation	O
of	O
either	O
polyamine	O
intake	O
or	O
polyamine	O
production	O
by	O
gut	O
microbiota	O
can	O
be	O
used	O
for	O
potential	O
therapeutic	O
purposes	O
.	O

Gut	O
integrity	O
in	O
critical	O
illness	O
.	O

Background	O
:	O
The	O
gut	O
is	O
hypothesized	O
to	O
be	O
the	O
`	O
`	O
motor	O
'	O
'	O
of	O
critical	O
illness	O
.	O

Under	O
basal	O
conditions	O
,	O
the	O
gut	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
maintenance	O
of	O
health	O
.	O

However	O
,	O
in	O
critical	O
illness	O
,	O
all	O
elements	O
of	O
the	O
gut	O
are	O
injured	O
,	O
potentially	O
worsening	O
multiple	O
organ	O
dysfunction	O
syndrome	O
.	O

Main	O
body	O
:	O
Under	O
basal	O
conditions	O
,	O
the	O
intestinal	O
epithelium	O
absorbs	O
nutrients	O
and	O
plays	O
a	O
critical	O
role	O
as	O
the	O
first	O
-	O
line	O
protection	O
against	O
pathogenic	O
microbes	O
and	O
as	O
the	O
central	O
coordinator	O
of	O
mucosal	O
immunity	O
.	O

In	O
contrast	O
,	O
each	O
element	O
of	O
the	O
gut	O
is	O
impacted	O
in	O
critical	O
illness	O
.	O

In	O
the	O
epithelium	O
,	O
apoptosis	O
increases	O
,	O
proliferation	O
decreases	O
,	O
and	O
migration	O
slows	O
.	O

In	O
addition	O
,	O
gut	O
barrier	O
function	O
is	O
worsened	O
via	O
alterations	O
to	O
the	O
tight	O
junction	O
,	O
resulting	O
in	O
intestinal	O
hyperpermeability	O
.	O

This	O
is	O
associated	O
with	O
damage	O
to	O
the	O
mucus	O
that	O
separates	O
the	O
contents	O
of	O
the	O
intestinal	O
lumen	O
from	O
the	O
epithelium	O
.	O

Finally	O
,	O
the	O
microbiome	O
of	O
the	O
intestine	O
is	O
converted	O
into	O
a	O
pathobiome	O
,	O
with	O
an	O
increase	O
in	O
disease	O
-	O
promoting	O
bacteria	O
and	O
induction	O
of	O
virulence	O
factors	O
in	O
commensal	O
bacteria	O
.	O

Toxic	O
factors	O
can	O
then	O
leave	O
the	O
intestine	O
via	O
both	O
portal	O
blood	O
flow	O
and	O
mesenteric	O
lymph	O
to	O
cause	O
distant	O
organ	O
damage	O
.	O

Conclusion	O
:	O
The	O
gut	O
plays	O
a	O
complex	O
role	O
in	O
both	O
health	O
and	O
critical	O
illness	O
.	O

Here	O
,	O
we	O
review	O
gut	O
integrity	O
in	O
both	O
health	O
and	O
illness	O
and	O
highlight	O
potential	O
strategies	O
for	O
targeting	O
the	O
intestine	O
for	O
therapeutic	O
gain	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

Intestinal	O
Bacteria	O
Interplay	O
With	O
Bile	O
and	O
Cholesterol	O
Metabolism	O
:	O
Implications	O
on	O
Host	O
Physiology	O
.	O

Bile	O
is	O
a	O
biological	O
fluid	O
synthesized	O
in	O
the	O
liver	O
,	O
mainly	O
constituted	O
by	O
bile	O
acids	O
and	O
cholesterol	O
,	O
which	O
functions	O
as	O
a	O
biological	O
detergent	O
that	O
emulsifies	O
and	O
solubilizes	O
lipids	O
,	O
thereby	O
playing	O
an	O
essential	O
role	O
in	O
fat	O
digestion	O
.	O

Besides	O
,	O
bile	O
acids	O
are	O
important	O
signaling	O
molecules	O
that	O
regulate	O
key	O
functions	O
at	O
intestinal	O
and	O
systemic	O
levels	O
in	O
the	O
human	O
body	O
,	O
affecting	O
glucose	O
and	O
lipid	O
metabolism	O
,	O
and	O
immune	O
homeostasis	O
.	O

Apart	O
from	O
this	O
,	O
due	O
to	O
their	O
amphipathic	O
nature	O
,	O
bile	O
acids	O
are	O
toxic	O
for	O
bacterial	O
cells	O
and	O
,	O
thus	O
,	O
exert	O
a	O
strong	O
selective	O
pressure	O
on	O
the	O
microbial	O
populations	O
inhabiting	O
the	O
human	O
gut	O
,	O
decisively	O
shaping	O
the	O
microbial	O
profiles	O
of	O
our	O
gut	O
microbiota	O
,	O
which	O
has	O
been	O
recognized	O
as	O
a	O
metabolic	O
organ	O
playing	O
a	O
pivotal	O
role	O
in	O
host	O
health	O
.	O

Remarkably	O
,	O
bacteria	O
in	O
our	O
gut	O
also	O
display	O
a	O
range	O
of	O
enzymatic	O
activities	O
capable	O
of	O
acting	O
on	O
bile	O
acids	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
cholesterol	O
.	O

These	O
activities	O
can	O
have	O
a	O
direct	O
impact	O
on	O
host	O
physiology	O
as	O
they	O
influence	O
the	O
composition	O
of	O
the	O
intestinal	O
and	O
circulating	O
bile	O
acid	O
pool	O
in	O
the	O
host	O
,	O
affecting	O
bile	O
homeostasis	O
.	O

Given	O
that	O
bile	O
acids	O
are	O
important	O
signaling	O
molecules	O
in	O
the	O
human	O
body	O
,	O
changes	O
in	O
the	O
microbiota	O
-	O
residing	O
bile	O
biotransformation	O
ability	O
can	O
significantly	O
impact	O
host	O
physiology	O
and	O
health	O
status	O
.	O

Elucidating	O
ways	O
to	O
fine	O
-	O
tune	O
microbiota	O
-	O
bile	O
acids	O
-	O
host	O
interplay	O
are	O
promising	O
strategies	O
to	O
act	O
on	O
bile	O
and	O
cholesterol	O
-	O
related	O
disorders	O
.	O

This	O
manuscript	O
summarizes	O
the	O
current	O
knowledge	O
on	O
bile	O
and	O
cholesterol	O
metabolism	O
by	O
intestinal	O
bacteria	O
,	O
as	O
well	O
as	O
its	O
influence	O
on	O
host	O
physiology	O
,	O
identifying	O
knowledge	O
gaps	O
and	O
opportunities	O
to	O
guide	O
further	O
advances	O
in	O
the	O
field	O
.	O

Isolation	O
and	O
Characterisation	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
O1	I-bacteria
Producer	O
of	O
Plantaricin	O
as	O
Potential	O
Starter	O
Culture	O
for	O
the	O
Biopreservation	O
of	O
Aquatic	O
Food	O
Products	O
.	O

Lactobacillus	B-bacteria
plantarum	I-bacteria
O1	I-bacteria
was	O
isolated	O
from	O
the	O
gut	O
of	O
sea	O
bream	O
(	O
Sparus	O
aurata	O
)	O
and	O
identified	O
with	O
the	O
API	O
biochemical	O
test	O
and	O
MALDI	O
-	O
TOF	O
MS	O
.	O

This	O
strain	O
was	O
further	O
characterised	O
according	O
to	O
the	O
selection	O
criteria	O
for	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
as	O
starter	O
cultures	O
for	O
aquatic	O
food	O
production	O
.	O

L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
O1	I-bacteria
showed	O
good	O
antimicrobial	O
activity	O
against	O
pathogenic	O
test	O
microorganisms	O
.	O

Further	O
investigation	O
confirmed	O
it	O
as	O
the	O
producer	O
of	O
the	O
bacteriocin	O
plantaricin	O
.	O

This	O
strain	O
also	O
showed	O
good	O
growth	O
at	O
a	O
wide	O
range	O
of	O
temperatures	O
(	O
from	O
4	O
to	O
45	O
degrees	O
C	O
)	O
and	O
a	O
wide	O
range	O
of	O
pH	O
(	O
2	O
-	O
12	O
)	O
,	O
even	O
in	O
the	O
presence	O
of	O
3	O
.	O
5	O
%	O
NaCl	O
.	O

Its	O
viability	O
was	O
also	O
good	O
after	O
lyophilisation	O
and	O
in	O
simulated	O
gastric	O
and	O
small	O
intestinal	O
juice	O
.	O

The	O
strain	O
is	O
a	O
promising	O
probiotic	O
,	O
and	O
our	O
further	O
research	O
will	O
focus	O
on	O
its	O
application	O
in	O
the	O
biopreservation	O
of	O
fresh	O
fish	O
and	O
shellfish	O
.	O

Human	O
gut	O
bacterial	O
genome	O
reference	O
.	O

Reshaping	O
fecal	O
gut	O
microbiota	O
composition	O
by	O
growing	O
with	O
Polygonum	O
cuspidatum	O
,	O
Houttuynia	O
cordata	O
Thunb	O
,	O
and	O
Ipomoea	O
aquatica	O
Forsk	O
.	O

We	O
performed	O
sequencing	O
using	O
samples	O
cultivated	O
in	O
floating	O
beds	O
with	O
different	O
Chinese	O
medicinal	O
herbs	O
to	O
analyze	O
the	O
changes	O
in	O
the	O
gut	O
microbiota	O
composition	O
of	O
tilapia	O
feces	O
.	O

Fusobacteria	B-bacteria
(	O
ranging	O
from	O
49	O
.	O
0	O
%	O
to	O
73	O
.	O
3	O
%	O
)	O
,	O
Firmicutes	B-bacteria
(	O
12	O
.	O
3	O
%	O
~	O
37	O
.	O
8	O
%	O
)	O
,	O
and	O
Proteobacteria	B-bacteria
(	O
5	O
.	O
1	O
%	O
~	O
23	O
.	O
0	O
%	O
)	O
were	O
found	O
to	O
be	O
the	O
most	O
dominant	O
phyla	O
present	O
in	O
all	O
samples	O
.	O

The	O
operational	O
taxonomic	O
units	O
,	O
Ace	O
,	O
and	O
Chao1	O
indices	O
from	O
group	O
A	O
and	O
D	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
group	O
C	O
.	O

P	B-bacteria
.	I-bacteria
cuspidatum	I-bacteria
decreased	O
the	O
species	O
richness	O
and	O
diversity	O
of	O
microbial	O
communities	O
in	O
tilapia	O
intestinal	O
feces	O
.	O

The	O
phylum	O
WCHB1	B-bacteria
-	I-bacteria
60	I-bacteria
,	O
order	O
Enterobacteriales	B-bacteria
,	O
and	O
genus	O
Plesiomonas	B-bacteria
significantly	O
decreased	O
(	O
A	O
)	O
;	O
the	O
species	O
Plesiomonas	B-bacteria
shigelloides	I-bacteria
significantly	O
decreased	O
(	O
B	O
and	O
C	O
)	O
;	O
and	O
the	O
genus	O
Leucobacter	B-bacteria
significantly	O
increased	O
(	O
D	O
)	O
when	O
compared	O
to	O
the	O
controls	O
.	O

The	O
relative	O
abundance	O
of	O
the	O
class	O
Verrucomicrobiae	B-bacteria
(	O
B	O
vs	O
C	O
)	O
significantly	O
decreased	O
.	O

In	O
the	O
presence	O
of	O
I	O
.	O
aquatica	O
Forsk	O
,	O
the	O
phylum	O
Bacteroidetes	B-bacteria
significantly	O
decreased	O
,	O
while	O
the	O
genera	O
Leucobacter	B-bacteria
and	O
Pelotomaculum	B-bacteria
significantly	O
increased	O
.	O

The	O
ratio	O
of	O
Bacteroidetes	B-bacteria
:	O
Firmicutes	B-bacteria
was	O
significantly	O
higher	O
(	O
B	O
and	O
C	O
)	O
relative	O
to	O
the	O
controls	O
,	O
while	O
it	O
decreased	O
significantly	O
in	O
group	O
D	O
.	O
The	O
algae	O
(	O
i	O
.	O
e	O
.	O
,	O
Anabaena	B-bacteria
and	O
Microcystis	B-bacteria
)	O
and	O
beneficial	O
pathogenic	O
bacteria	O
decreased	O
in	O
groups	O
C	O
and	O
D	O
,	O
respectively	O
.	O

Microbes	O
and	O
the	O
Mind	O
:	O
How	O
Bacteria	O
Shape	O
Affect	O
,	O
Neurological	O
Processes	O
,	O
Cognition	O
,	O
Social	O
Relationships	O
,	O
Development	O
,	O
and	O
Pathology	O
.	O

Recent	O
data	O
suggest	O
that	O
the	O
human	O
body	O
is	O
not	O
so	O
exclusively	O
human	O
after	O
all	O
.	O

Specifically	O
,	O
humans	O
share	O
their	O
bodies	O
with	O
approximately	O
10	O
trillion	O
microorganisms	O
,	O
collectively	O
known	O
as	O
the	O
microbiome	O
.	O

Chief	O
among	O
these	O
microbes	O
are	O
bacteria	O
,	O
and	O
there	O
is	O
a	O
growing	O
consensus	O
that	O
they	O
are	O
critical	O
to	O
virtually	O
all	O
facets	O
of	O
normative	O
functioning	O
.	O

This	O
article	O
reviews	O
the	O
ways	O
in	O
which	O
bacteria	O
shape	O
affect	O
,	O
neurological	O
processes	O
,	O
cognition	O
,	O
social	O
relationships	O
,	O
development	O
,	O
and	O
psychological	O
pathology	O
.	O

To	O
date	O
,	O
the	O
vast	O
majority	O
of	O
research	O
on	O
interactions	O
between	O
microbes	O
and	O
humans	O
has	O
been	O
conducted	O
by	O
scientists	O
outside	O
the	O
field	O
of	O
psychology	O
,	O
despite	O
the	O
fact	O
that	O
psychological	O
scientists	O
are	O
experts	O
in	O
many	O
of	O
the	O
topics	O
being	O
explored	O
.	O

This	O
review	O
aims	O
to	O
orient	O
psychological	O
scientists	O
to	O
the	O
most	O
relevant	O
research	O
and	O
perspectives	O
regarding	O
the	O
microbiome	O
so	O
that	O
we	O
might	O
contribute	O
to	O
the	O
now	O
widespread	O
,	O
interdisciplinary	O
effort	O
to	O
understand	O
the	O
relationship	O
between	O
microbes	O
and	O
the	O
mind	O
.	O

Gut	O
microbiota	O
dysbiosis	O
in	O
a	O
cohort	O
of	O
psoriasis	O
patients	O
.	O

BACKGROUND	O
:	O
there	O
is	O
an	O
increasing	O
evidence	O
of	O
the	O
key	O
role	O
that	O
the	O
gut	O
microbiota	O
plays	O
on	O
inflammatory	O
diseases	O
.	O

OBJECTIVES	O
:	O
to	O
identify	O
differences	O
in	O
the	O
faecal	O
microbial	O
composition	O
of	O
psoriasis	O
patients	O
compared	O
to	O
healthy	O
individuals	O
in	O
order	O
to	O
unravel	O
the	O
microbiota	O
profiling	O
in	O
this	O
autoimmune	O
disease	O
.	O

METHODS	O
:	O
16S	O
rRNA	O
gene	O
sequencing	O
and	O
bioinformatic	O
analyses	O
were	O
performed	O
with	O
the	O
total	O
DNA	O
extracted	O
from	O
the	O
faecal	O
microbiota	O
of	O
nineteen	O
psoriasis	O
patients	O
and	O
twenty	O
healthy	O
individuals	O
from	O
the	O
same	O
geographic	O
location	O
.	O

RESULTS	O
:	O
gut	O
microbiota	O
composition	O
of	O
psoriasis	O
patients	O
displayed	O
lower	O
diversity	O
and	O
different	O
relative	O
abundance	O
of	O
certain	O
bacterial	O
taxa	O
compared	O
to	O
healthy	O
individuals	O
.	O

CONCLUSIONS	O
:	O
the	O
gut	O
microbiota	O
profile	O
of	O
psoriasis	O
patients	O
displayed	O
a	O
clear	O
dysbiosis	O
that	O
can	O
be	O
targeted	O
for	O
microbiome	O
-	O
based	O
therapeutic	O
approaches	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Smed	O
-	O
egfr	O
-	O
4	O
is	O
required	O
for	O
planarian	O
eye	O
regeneration	O
.	O

Planarians	O
are	O
remarkable	O
organisms	O
that	O
can	O
regenerate	O
their	O
entire	O
body	O
from	O
a	O
tiny	O
portion	O
thereof	O
.	O

This	O
capability	O
is	O
made	O
possible	O
by	O
the	O
persistence	O
throughout	O
the	O
lifespan	O
of	O
these	O
animals	O
of	O
a	O
population	O
of	O
pluripotent	O
stem	O
cells	O
known	O
as	O
neoblasts	O
.	O

Planarian	O
neoblasts	O
include	O
both	O
pluripotent	O
stem	O
cells	O
and	O
specialized	O
lineage	O
-	O
committed	O
progenitors	O
that	O
give	O
rise	O
to	O
all	O
mature	O
cell	O
types	O
during	O
regeneration	O
and	O
homeostatic	O
cell	O
turnover	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
that	O
regulate	O
neoblast	O
differentiation	O
.	O

A	O
recent	O
study	O
demonstrated	O
that	O
Smed	O
-	O
egfr	O
-	O
1	O
,	O
a	O
homologue	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
family	O
,	O
is	O
required	O
for	O
final	O
differentiation	O
,	O
but	O
not	O
specification	O
,	O
of	O
gut	O
progenitor	O
cells	O
into	O
mature	O
cells	O
.	O

Given	O
the	O
expression	O
by	O
planarians	O
of	O
several	O
EGFR	O
homologues	O
,	O
it	O
has	O
been	O
proposed	O
that	O
these	O
homologues	O
may	O
have	O
diverged	O
functionally	O
to	O
regulate	O
the	O
differentiation	O
of	O
distinct	O
cell	O
types	O
in	O
these	O
animals	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
Smed	O
-	O
egfr	O
-	O
4	O
in	O
eye	O
regeneration	O
.	O

Compared	O
with	O
controls	O
,	O
animals	O
in	O
which	O
this	O
gene	O
was	O
silenced	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
regenerated	O
smaller	O
eyes	O
.	O

Moreover	O
,	O
the	O
numbers	O
of	O
both	O
mature	O
eye	O
cell	O
types	O
,	O
photoreceptor	O
neurons	O
and	O
cells	O
of	O
the	O
pigment	O
cup	O
,	O
were	O
significantly	O
reduced	O
in	O
Smed	O
-	O
egfr	O
-	O
4	O
(	O
RNAi	O
)	O
animals	O
.	O

By	O
contrast	O
,	O
these	O
animals	O
exhibited	O
an	O
increase	O
in	O
the	O
numbers	O
of	O
eye	O
progenitor	O
cells	O
expressing	O
the	O
specific	O
markers	O
Smed	O
-	O
ovo	O
and	O
Smed	O
-	O
sp6	O
-	O
9	O
.	O

These	O
results	O
suggest	O
that	O
Smed	O
-	O
egfr	O
-	O
4	O
is	O
required	O
not	O
for	O
the	O
specification	O
of	O
eye	O
progenitor	O
cells	O
but	O
for	O
their	O
final	O
differentiation	O
,	O
and	O
support	O
the	O
view	O
that	O
in	O
planarians	O
the	O
EGFR	O
pathway	O
might	O
play	O
a	O
general	O
role	O
in	O
regulating	O
the	O
differentiation	O
of	O
lineage	O
-	O
committed	O
progenitors	O
.	O

Mind	O
and	O
gut	O
:	O
Associations	O
between	O
mood	O
and	O
gastrointestinal	O
distress	O
in	O
children	O
exposed	O
to	O
adversity	O
.	O

Gastrointestinal	O
and	O
mental	O
disorders	O
are	O
highly	O
comorbid	O
,	O
and	O
animal	O
models	O
have	O
shown	O
that	O
both	O
can	O
be	O
caused	O
by	O
early	O
adversity	O
(	O
e	O
.	O
g	O
.	O
,	O
parental	O
deprivation	O
)	O
.	O

Interactions	O
between	O
the	O
brain	O
and	O
bacteria	O
that	O
live	O
within	O
the	O
gastrointestinal	O
system	O
(	O
the	O
microbiome	O
)	O
underlie	O
adversity	O
-	O
gastrointestinal	O
-	O
anxiety	O
interactions	O
,	O
but	O
these	O
links	O
have	O
not	O
been	O
investigated	O
during	O
human	O
development	O
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
data	O
from	O
a	O
population	O
of	O
344	O
youth	O
(	O
3	O
-	O
18	O
years	O
old	O
)	O
who	O
were	O
raised	O
with	O
their	O
biological	O
parents	O
or	O
were	O
exposed	O
to	O
early	O
adverse	O
caregiving	O
experiences	O
(	O
i	O
.	O
e	O
.	O
,	O
institutional	O
or	O
foster	O
care	O
followed	O
by	O
international	O
adoption	O
)	O
to	O
explore	O
adversity	O
-	O
gastrointestinal	O
-	O
anxiety	O
associations	O
.	O

In	O
Study	O
1	O
,	O
we	O
demonstrated	O
that	O
previous	O
adverse	O
care	O
experiences	O
were	O
associated	O
with	O
increased	O
incidence	O
of	O
gastrointestinal	O
symptoms	O
in	O
youth	O
.	O

Gastrointestinal	O
symptoms	O
were	O
also	O
associated	O
with	O
concurrent	O
and	O
future	O
anxiety	O
(	O
measured	O
across	O
5	O
years	O
)	O
,	O
and	O
those	O
gastrointestinal	O
symptoms	O
mediated	O
the	O
adversity	O
-	O
anxiety	O
association	O
at	O
Time	O
1	O
.	O

In	O
a	O
subsample	O
of	O
children	O
who	O
provided	O
both	O
stool	O
samples	O
and	O
functional	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
brain	O
(	O
Study	O
2	O
,	O
which	O
was	O
a	O
`	O
`	O
proof	O
-	O
of	O
-	O
principle	O
'	O
'	O
)	O
,	O
adversity	O
was	O
associated	O
with	O
changes	O
in	O
diversity	O
(	O
both	O
alpha	O
and	O
beta	O
)	O
of	O
microbial	O
communities	O
,	O
and	O
bacteria	O
levels	O
(	O
adversity	O
-	O
associated	O
and	O
adversity	O
-	O
independent	O
)	O
were	O
correlated	O
with	O
prefrontal	O
cortex	O
activation	O
to	O
emotional	O
faces	O
.	O

Implications	O
of	O
these	O
data	O
for	O
supporting	O
youth	O
mental	O
health	O
are	O
discussed	O
.	O

Faecal	O
microbiota	O
from	O
patients	O
with	O
cirrhosis	O
has	O
a	O
low	O
capacity	O
to	O
ferment	O
non	O
-	O
digestible	O
carbohydrates	O
into	O
short	O
-	O
chain	O
fatty	O
acids	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
Cirrhosis	O
is	O
associated	O
with	O
dysbiosis	O
,	O
but	O
its	O
functional	O
consequences	O
are	O
still	O
largely	O
unknown	O
.	O

Short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
account	O
for	O
physiological	O
interactions	O
between	O
the	O
gut	O
microbiota	O
and	O
host	O
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
impact	O
of	O
cirrhotic	O
dysbiosis	O
on	O
the	O
production	O
of	O
SCFAs	O
.	O

METHODS	O
:	O
Seventeen	O
patients	O
with	O
cirrhosis	O
and	O
17	O
controls	O
were	O
selected	O
.	O

Microbiota	O
composition	O
in	O
faecal	O
samples	O
was	O
assessed	O
by	O
next	O
-	O
generation	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

SCFAs	O
were	O
measured	O
with	O
GC	O
-	O
MS	O
in	O
faecal	O
samples	O
and	O
after	O
in	O
vitro	O
batch	O
fermentations	O
using	O
arabinoxylan	O
,	O
resistant	O
starch	O
,	O
pectin	O
,	O
and	O
lactulose	O
as	O
substrates	O
.	O

RESULTS	O
:	O
Among	O
the	O
17	O
cirrhotic	O
patients	O
(	O
mean	O
age	O
58	O
,	O
eight	O
males	O
)	O
,	O
six	O
,	O
nine	O
and	O
two	O
were	O
,	O
respectively	O
,	O
Child	O
-	O
Pugh	O
class	O
A	O
,	O
B	O
and	O
C	O
.	O
Eleven	O
patients	O
were	O
on	O
oral	O
antibiotics	O
,	O
11	O
on	O
lactulose	O
and	O
13	O
on	O
proton	O
pump	O
inhibitors	O
.	O

Cirrhotic	O
patients	O
showed	O
marked	O
differences	O
in	O
the	O
composition	O
and	O
diversity	O
of	O
gut	O
microbiome	O
when	O
compared	O
to	O
controls	O
,	O
that	O
were	O
more	O
pronounced	O
with	O
increased	O
severity	O
.	O

Stool	O
samples	O
from	O
cirrhotic	O
patients	O
showed	O
lower	O
SCFAs	O
content	O
and	O
reduced	O
capacity	O
to	O
produce	O
SCFAs	O
in	O
batch	O
fermentations	O
,	O
with	O
butyrate	O
production	O
being	O
the	O
most	O
abnormal	O
.	O

These	O
functional	O
aberrancies	O
were	O
more	O
pronounced	O
with	O
greater	O
liver	O
disease	O
severity	O
.	O

Abundance	O
of	O
Ruminococcus	B-bacteria
faecis	I-bacteria
(	O
in	O
family	O
Ruminococcacea	B-bacteria
)	O
,	O
Faecalicatena	B-bacteria
fissicatena	I-bacteria
and	O
Fusicatenibacter	B-bacteria
saccharivorans	I-bacteria
(	O
in	O
family	O
Lachnospiraceae	B-bacteria
)	O
was	O
positively	O
correlated	O
with	O
the	O
SCFAs	O
production	O
.	O

CONCLUSION	O
:	O
Cirrhotic	O
dysbiosis	O
is	O
associated	O
with	O
a	O
decreased	O
capacity	O
to	O
ferment	O
non	O
-	O
digestible	O
carbohydrates	O
into	O
SCFAs	O
,	O
especially	O
into	O
butyrate	O
.	O

These	O
functional	O
abnormalities	O
are	O
more	O
pronounced	O
as	O
disease	O
progresses	O
.	O

These	O
results	O
might	O
inform	O
the	O
design	O
of	O
gut	O
-	O
targeted	O
therapies	O
for	O
cirrhosis	O
.	O

Fecal	O
microbiota	O
transplantation	O
prevents	O
Candida	O
albicans	O
from	O
colonizing	O
the	O
gastrointestinal	O
tract	O
.	O

Gut	O
microbes	O
symbiotically	O
colonize	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tract	O
,	O
interacting	O
with	O
each	O
other	O
and	O
their	O
host	O
to	O
maintain	O
GI	O
tract	O
homeostasis	O
.	O

Recent	O
reports	O
have	O
shown	O
that	O
gut	O
microbes	O
help	O
protect	O
the	O
gut	O
from	O
colonization	O
by	O
pathogenic	O
microbes	O
.	O

Here	O
,	O
we	O
report	O
that	O
commensal	O
microbes	O
prevent	O
colonization	O
of	O
the	O
pathogenic	O
fungus	O
,	O
Candida	O
albicans	O
,	O
in	O
the	O
GI	O
tract	O
.	O

Wild	O
-	O
type	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
mice	O
are	O
resistant	O
to	O
C	O
.	O
albicans	O
colonization	O
in	O
the	O
GI	O
tract	O
.	O

However	O
,	O
administering	O
certain	O
antibiotics	O
to	O
SPF	O
mice	O
enables	O
C	O
.	O
albicans	O
colonization	O
.	O

Quantitative	O
kinetics	O
of	O
commensal	O
bacteria	O
are	O
inversely	O
correlated	O
with	O
the	O
number	O
of	O
C	O
.	O
albicans	O
in	O
the	O
gut	O
.	O

Here	O
,	O
we	O
provide	O
further	O
evidence	O
that	O
fecal	O
microbiota	O
transplantation	O
effectively	O
prevents	O
Candida	O
colonization	O
in	O
the	O
GI	O
tract	O
.	O

These	O
data	O
demonstrate	O
the	O
importance	O
of	O
commensal	O
bacteria	O
as	O
a	O
barrier	O
of	O
the	O
GI	O
tract	O
surface	O
,	O
and	O
highlight	O
the	O
potential	O
clinical	O
applications	O
of	O
commensal	O
bacteria	O
for	O
preventing	O
pathogenic	O
fungal	O
infections	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Irinotecan	O
-	O
Induced	O
Mucositis	O
Is	O
Associated	O
with	O
Goblet	O
Cell	O
Dysregulation	O
and	O
Neural	O
Cell	O
Damage	O
in	O
a	O
Tumour	O
Bearing	O
DA	O
Rat	O
Model	O
.	O

Irinotecan	O
-	O
induced	O
mucositis	O
is	O
a	O
major	O
oncological	O
problem	O
.	O

Goblet	O
cells	O
secrete	O
mucus	O
,	O
protecting	O
the	O
intestinal	O
mucosa	O
,	O
with	O
secretion	O
altered	O
during	O
mucositis	O
.	O

The	O
enteric	O
nervous	O
system	O
is	O
involved	O
in	O
regulating	O
gut	O
motility	O
and	O
secretion	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
enteric	O
neural	O
cells	O
and	O
goblet	O
cells	O
are	O
altered	O
following	O
irinotecan	O
treatment	O
.	O

Tumour	O
-	O
bearing	O
Dark	O
Agouti	O
rats	O
were	O
administered	O
a	O
single	O
dose	O
of	O
175	O
mg	O
/	O
kg	O
of	O
irinotecan	O
intraperitoneally	O
and	O
0	O
.	O
01	O
mg	O
/	O
kg	O
atropine	O
subcutaneously	O
.	O

Experimental	O
and	O
untreated	O
control	O
rats	O
were	O
killed	O
at	O
times	O
6	O
,	O
24	O
,	O
48	O
,	O
72	O
,	O
96	O
and	O
120	O
h	O
after	O
treatment	O
.	O

Jejunum	O
and	O
colon	O
samples	O
were	O
formalin	O
fixed	O
.	O

Haematoxylin	O
and	O
eosin	O
staining	O
,	O
Alcian	O
Blue	O
-	O
PAS	O
staining	O
,	O
and	O
immunohistochemistry	O
with	O
S	O
-	O
100	O
antibody	O
(	O
neural	O
cell	O
marker	O
)	O
were	O
carried	O
out	O
.	O

Statistical	O
analyses	O
were	O
carried	O
out	O
using	O
Kruskal	O
-	O
Wallis	O
test	O
with	O
Dunns	O
post	O
test	O
,	O
Mann	O
Whitney	O
U	O
test	O
and	O
nonlinear	O
regression	O
.	O

Total	O
goblet	O
cells	O
decreased	O
at	O
72	O
h	O
compared	O
with	O
controls	O
in	O
the	O
colon	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
percentage	O
of	O
cavitated	O
goblet	O
cells	O
decreased	O
compared	O
to	O
all	O
other	O
time	O
points	O
at	O
120	O
h	O
in	O
the	O
colon	O
.	O

The	O
number	O
of	O
S	O
-	O
100	O
positive	O
cells	O
in	O
the	O
submucosal	O
plexus	O
decreased	O
in	O
the	O
colon	O
(	O
p	O
=	O
0	O
.	O
0046	O
)	O
and	O
in	O
the	O
myenteric	O
plexus	O
of	O
the	O
jejunum	O
and	O
colon	O
(	O
p	O
=	O
0	O
.	O
0058	O
and	O
p	O
=	O
0	O
.	O
0022	O
,	O
respectively	O
)	O
,	O
when	O
comparing	O
treated	O
with	O
control	O
.	O

Enteric	O
ganglia	O
in	O
the	O
myenteric	O
plexus	O
of	O
the	O
jejunum	O
decreased	O
at	O
24	O
h	O
and	O
96	O
h	O
.	O
Irinotecan	O
-	O
induced	O
mucositis	O
is	O
associated	O
with	O
increases	O
in	O
mucus	O
secretion	O
,	O
and	O
enteric	O
neural	O
cell	O
change	O
.	O

These	O
changes	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
mucositis	O
through	O
the	O
dysregulation	O
of	O
neural	O
signalling	O
.	O

Microbiota	O
Metabolite	O
Butyrate	O
Differentially	O
Regulates	O
Th1	O
and	O
Th17	O
Cells	O
'	O
Differentiation	O
and	O
Function	O
in	O
Induction	O
of	O
Colitis	O
.	O

BACKGROUND	O
:	O
How	O
the	O
gut	O
microbiota	O
regulates	O
intestinal	O
homeostasis	O
is	O
not	O
completely	O
clear	O
.	O

Gut	O
microbiota	O
metabolite	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
have	O
been	O
reported	O
to	O
regulate	O
T	O
-	O
cell	O
differentiation	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
SCFA	O
regulation	O
of	O
T	O
-	O
cell	O
differentiation	O
and	O
function	O
remain	O
to	O
be	O
investigated	O
.	O

METHODS	O
:	O
CBir1	O
,	O
an	O
immunodominant	O
microbiota	O
antigen	O
,	O
transgenic	O
T	O
cells	O
were	O
treated	O
with	O
butyrate	O
under	O
various	O
T	O
-	O
cell	O
polarization	O
conditions	O
to	O
investigate	O
butyrate	O
regulation	O
of	O
T	O
-	O
cell	O
differentiation	O
and	O
the	O
mechanism	O
involved	O
.	O

Transfer	O
of	O
butyrate	O
-	O
treated	O
CBir	O
T	O
cells	O
into	O
Rag1	O
-	O
/	O
-	O
mice	O
was	O
performed	O
to	O
study	O
the	O
in	O
vivo	O
role	O
of	O
such	O
T	O
cells	O
in	O
inducing	O
colitis	O
.	O

RESULTS	O
:	O
Although	O
butyrate	O
promoted	O
Th1	O
cell	O
development	O
by	O
promoting	O
IFN	O
-	O
gamma	O
and	O
T	O
-	O
bet	O
expression	O
,	O
it	O
inhibited	O
Th17	O
cell	O
development	O
by	O
suppressing	O
IL	O
-	O
17	O
,	O
Roralpha	O
,	O
and	O
Rorgammat	O
expression	O
.	O

Interestingly	O
,	O
butyrate	O
upregulated	O
IL	O
-	O
10	O
production	O
in	O
T	O
cells	O
both	O
under	O
Th1	O
and	O
Th17	O
cell	O
conditions	O
.	O

Furthermore	O
,	O
butyrate	O
induced	O
T	O
-	O
cell	O
B	O
-	O
lymphocyte	O
-	O
induced	O
maturation	O
protein	O
1	O
(	O
Blimp1	O
)	O
expression	O
,	O
and	O
deficiency	O
of	O
Blimp1	O
in	O
T	O
cells	O
impaired	O
the	O
butyrate	O
upregulation	O
of	O
IL	O
-	O
10	O
production	O
,	O
indicating	O
that	O
butyrate	O
promotes	O
T	O
-	O
cell	O
IL	O
-	O
10	O
production	O
at	O
least	O
partially	O
through	O
Blimp1	O
.	O

Rag1	O
-	O
/	O
-	O
mice	O
transferred	O
with	O
butyrate	O
-	O
treated	O
T	O
cells	O
demonstrated	O
less	O
severe	O
colitis	O
,	O
compared	O
with	O
transfer	O
of	O
untreated	O
T	O
cells	O
,	O
and	O
administration	O
of	O
anti	O
-	O
IL	O
-	O
10R	O
antibody	O
exacerbated	O
colitis	O
development	O
in	O
Rag	O
-	O
/	O
-	O
mice	O
that	O
had	O
received	O
butyrate	O
-	O
treated	O
T	O
cells	O
.	O

Mechanistically	O
,	O
the	O
effects	O
of	O
butyrate	O
on	O
the	O
development	O
of	O
Th1	O
cells	O
was	O
through	O
inhibition	O
of	O
histone	O
deacetylase	O
but	O
was	O
independent	O
of	O
GPR43	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
butyrate	O
controls	O
the	O
capacity	O
of	O
T	O
cells	O
in	O
the	O
induction	O
of	O
colitis	O
by	O
differentially	O
regulating	O
Th1	O
and	O
Th17	O
cell	O
differentiation	O
and	O
promoting	O
IL	O
-	O
10	O
production	O
,	O
providing	O
insights	O
into	O
butyrate	O
as	O
a	O
potential	O
therapeutic	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
.	O

Intestinal	O
CD103	O
+	O
CD4	O
+	O
and	O
CD103	O
+	O
CD8	O
+	O
T	O
-	O
Cell	O
Subsets	O
in	O
the	O
Gut	O
of	O
Inflammatory	O
Bowel	O
Disease	O
Patients	O
at	O
Diagnosis	O
and	O
During	O
Follow	O
-	O
up	O
.	O

BACKGROUND	O
:	O
The	O
integrin	O
CD103	O
is	O
proposed	O
to	O
be	O
a	O
potential	O
therapeutical	O
target	O
in	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
,	O
as	O
it	O
can	O
form	O
a	O
heterodimeric	O
integrin	O
with	O
beta7	O
(	O
Etrolizumab	O
,	O
anti	O
-	O
beta7	O
integrin	O
)	O
on	O
epithelial	O
T	O
cells	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
study	O
the	O
frequencies	O
of	O
different	O
intestinal	O
CD103	O
+	O
T	O
-	O
cell	O
subsets	O
,	O
both	O
CD4	O
+	O
and	O
CD8	O
+	O
,	O
in	O
newly	O
diagnosed	O
,	O
untreated	O
IBD	O
patients	O
at	O
baseline	O
and	O
during	O
follow	O
-	O
up	O
,	O
compared	O
with	O
healthy	O
controls	O
.	O

METHODS	O
:	O
Intestinal	O
biopsies	O
from	O
inflamed	O
segments	O
during	O
colonoscopy	O
and	O
peripheral	O
blood	O
samples	O
were	O
prospectively	O
taken	O
from	O
IBD	O
patients	O
at	O
diagnosis	O
and	O
during	O
follow	O
-	O
up	O
.	O

Blood	O
and	O
single	O
cell	O
suspensions	O
from	O
biopsies	O
were	O
analyzed	O
for	O
CD103	O
+	O
T	O
-	O
cell	O
subpopulations	O
by	O
flow	O
cytometry	O
and	O
expressed	O
as	O
median	O
percentages	O
of	O
the	O
total	O
T	O
-	O
cell	O
population	O
.	O

RESULTS	O
:	O
In	O
total	O
,	O
75	O
Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
patients	O
,	O
49	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
patients	O
,	O
and	O
16	O
healthy	O
controls	O
were	O
included	O
.	O

At	O
presentation	O
,	O
IBD	O
patients	O
displayed	O
lower	O
percentages	O
of	O
CD103	O
+	O
T	O
-	O
cell	O
subsets	O
in	O
inflamed	O
biopsies	O
:	O
3	O
%	O
(	O
1	O
to	O
5	O
)	O
CD103	O
+	O
CD4	O
+	O
in	O
IBD	O
vs	O
5	O
%	O
(	O
5	O
to	O
7	O
)	O
in	O
healthy	O
controls	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
9	O
%	O
(	O
4	O
to	O
15	O
)	O
CD103	O
+	O
CD8	O
+	O
compared	O
with	O
42	O
%	O
(	O
23	O
to	O
57	O
)	O
in	O
healthy	O
controls	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
majority	O
of	O
intestinal	O
T	O
cells	O
was	O
composed	O
of	O
CD103	O
-	O
CD4	O
+	O
T	O
cells	O
(	O
65	O
%	O
[	O
52	O
to	O
74	O
]	O
)	O
in	O
IBD	O
compared	O
with	O
30	O
%	O
(	O
21	O
to	O
50	O
)	O
in	O
healthy	O
controls	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

In	O
patients	O
with	O
endoscopic	O
remission	O
during	O
follow	O
-	O
up	O
(	O
n	O
=	O
27	O
)	O
,	O
frequencies	O
of	O
CD103	O
+	O
and	O
CD103	O
-	O
T	O
-	O
cell	O
subsets	O
were	O
comparable	O
with	O
healthy	O
controls	O
.	O

CONCLUSION	O
:	O
At	O
diagnosis	O
,	O
active	O
inflammation	O
in	O
IBD	O
was	O
associated	O
with	O
decreased	O
percentages	O
of	O
both	O
CD103	O
+	O
CD4	O
+	O
and	O
CD103	O
+	O
CD8	O
+	O
T	O
-	O
cell	O
subsets	O
in	O
colon	O
and	O
ileum	O
biopsies	O
.	O

In	O
active	O
disease	O
during	O
follow	O
-	O
up	O
,	O
these	O
T	O
-	O
cell	O
populations	O
remained	O
low	O
but	O
increased	O
in	O
remission	O
to	O
values	O
comparable	O
with	O
healthy	O
controls	O
.	O

A	O
shift	O
toward	O
more	O
CD103	O
-	O
T	O
cells	O
was	O
observed	O
during	O
active	O
inflammation	O
.	O

Linkage	O
of	O
microbiota	O
and	O
osteoporosis	O
:	O
A	O
mini	O
literature	O
review	O
.	O

The	O
gut	O
microbiota	O
(	O
GM	O
)	O
has	O
become	O
a	O
recent	O
topic	O
of	O
interest	O
in	O
the	O
role	O
of	O
many	O
disease	O
states	O
.	O

Assessing	O
patients	O
with	O
osteoporosis	O
(	O
OP	O
)	O
,	O
there	O
is	O
a	O
strong	O
correlation	O
between	O
gut	O
microbe	O
dysregulation	O
and	O
decreased	O
bone	O
density	O
.	O

Gut	O
dysbiosis	O
may	O
lead	O
to	O
inflammation	O
,	O
dysregulation	O
of	O
nutrient	O
and	O
calcium	O
transport	O
across	O
the	O
intestine	O
into	O
circulation	O
and	O
systemic	O
inflammation	O
.	O

Investigation	O
of	O
microbial	O
profile	O
relative	O
to	O
normal	O
gut	O
microbiomes	O
,	O
assessment	O
of	O
inflammatory	O
markers	O
such	O
as	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
,	O
IL	O
-	O
6	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
.	O

Therapies	O
to	O
normalize	O
GM	O
in	O
patients	O
with	O
OP	O
or	O
prevent	O
occurrence	O
of	O
OP	O
to	O
be	O
investigated	O
include	O
:	O
High	O
fiber	O
prebiotic	O
diets	O
to	O
promote	O
growth	O
of	O
normal	O
gut	O
bacteria	O
and	O
short	O
chain	O
fatty	O
acid	O
production	O
,	O
Probiotics	O
to	O
encourage	O
growth	O
of	O
normal	O
gut	O
microbes	O
,	O
and	O
antibiotic	O
treatment	O
followed	O
by	O
fecal	O
matter	O
transplant	O
.	O

New	O
species	O
of	O
gut	O
bacteria	O
associated	O
with	O
AS	O
.	O

Bacterial	O
AB5	O
toxins	O
inhibit	O
the	O
growth	O
of	O
gut	O
bacteria	O
by	O
targeting	O
ganglioside	O
-	O
like	O
glycoconjugates	O
.	O

The	O
AB5	O
toxins	O
cholera	O
toxin	O
(	O
CT	O
)	O
from	O
Vibrio	B-bacteria
cholerae	I-bacteria
and	O
heat	O
-	O
labile	O
enterotoxin	O
(	O
LT	O
)	O
from	O
enterotoxigenic	B-bacteria
Escherichia	B-bacteria
coli	I-bacteria
are	O
notorious	O
for	O
their	O
roles	O
in	O
diarrheal	O
disease	O
,	O
but	O
their	O
effect	O
on	O
other	O
intestinal	O
bacteria	O
remains	O
unexplored	O
.	O

Another	O
foodborne	O
pathogen	O
,	O
Campylobacter	B-bacteria
jejuni	I-bacteria
,	O
can	O
mimic	O
the	O
GM1	O
ganglioside	O
receptor	O
of	O
CT	O
and	O
LT	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
toxin	O
B	O
-	O
subunits	O
(	O
CTB	O
and	O
LTB	O
)	O
inhibit	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
growth	O
by	O
binding	O
to	O
GM1	O
-	O
mimicking	O
lipooligosaccharides	O
and	O
increasing	O
permeability	O
of	O
the	O
cell	O
membrane	O
.	O

Furthermore	O
,	O
incubation	O
of	O
CTB	O
or	O
LTB	O
with	O
a	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
isolate	I-bacteria
capable	O
of	O
altering	O
its	O
lipooligosaccharide	O
structure	O
selects	O
for	O
variants	O
lacking	O
the	O
GM1	O
mimic	O
.	O

Examining	O
the	O
chicken	O
GI	O
tract	O
with	O
immunofluorescence	O
microscopy	O
demonstrates	O
that	O
GM1	O
reactive	O
structures	O
are	O
abundant	O
on	O
epithelial	O
cells	O
and	O
commensal	O
bacteria	O
,	O
further	O
emphasizing	O
the	O
relevance	O
of	O
this	O
mimicry	O
.	O

Exposure	O
of	O
chickens	O
to	O
CTB	O
or	O
LTB	O
causes	O
shifts	O
in	O
the	O
gut	O
microbial	O
composition	O
,	O
providing	O
evidence	O
for	O
new	O
toxin	O
functions	O
in	O
bacterial	O
gut	O
competition	O
.	O

Gut	O
Microbial	O
Dynamics	O
during	O
Conventionalization	O
of	O
Germfree	O
Chicken	O
.	O

A	O
gnotobiotic	O
Gallus	O
gallus	O
(	O
chicken	O
)	O
model	O
was	O
developed	O
to	O
study	O
the	O
dynamics	O
of	O
intestinal	O
microflora	O
from	O
hatching	O
to	O
18	O
days	O
of	O
age	O
employing	O
metagenomics	O
.	O

Intestinal	O
samples	O
were	O
collected	O
from	O
a	O
local	O
population	O
of	O
feral	O
chickens	O
and	O
administered	O
orally	O
to	O
germfree	O
3	O
-	O
day	O
-	O
old	O
chicks	O
.	O

Animals	O
were	O
euthanized	O
on	O
days	O
9	O
and	O
18	O
postinoculation	O
,	O
and	O
intestinal	O
samples	O
were	O
collected	O
and	O
subjected	O
to	O
metagenomic	O
analysis	O
.	O

On	O
day	O
18	O
,	O
the	O
five	O
most	O
prevalent	O
phyla	O
were	O
Bacteroidetes	B-bacteria
(	O
43	O
.	O
03	O
+	O
/	O
-	O
3	O
.	O
19	O
%	O
)	O
,	O
Firmicutes	B-bacteria
(	O
38	O
.	O
51	O
+	O
/	O
-	O
2	O
.	O
67	O
%	O
)	O
,	O
Actinobacteria	B-bacteria
(	O
6	O
.	O
77	O
+	O
/	O
-	O
0	O
.	O
7	O
%	O
)	O
,	O
Proteobacteria	B-bacteria
(	O
6	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
7	O
%	O
)	O
,	O
and	O
Spirochaetes	B-bacteria
(	O
2	O
.	O
71	O
+	O
/	O
-	O
0	O
.	O
55	O
%	O
)	O
.	O

Principal	O
-	O
coordinate	O
analysis	O
showed	O
that	O
the	O
day	O
18	O
variables	O
clustered	O
more	O
closely	O
than	O
the	O
day	O
9	O
variables	O
,	O
suggesting	O
that	O
the	O
microbial	O
communities	O
had	O
changed	O
temporally	O
.	O

The	O
Morista	O
-	O
Horn	O
index	O
values	O
ranged	O
from	O
0	O
.	O
7	O
to	O
1	O
,	O
indicating	O
that	O
the	O
communities	O
in	O
the	O
inoculum	O
and	O
in	O
the	O
day	O
9	O
and	O
day	O
18	O
samples	O
were	O
more	O
similar	O
than	O
dissimilar	O
.	O

The	O
predicted	O
functional	O
profiles	O
of	O
the	O
microbiomes	O
of	O
the	O
inoculum	O
and	O
the	O
day	O
9	O
and	O
day	O
18	O
samples	O
were	O
also	O
similar	O
(	O
values	O
of	O
0	O
.	O
98	O
to	O
1	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
gnotobiotic	O
chicks	O
stably	O
maintained	O
the	O
phylogenetic	O
diversity	O
and	O
predicted	O
metabolic	O
functionality	O
of	O
the	O
inoculum	O
community	O
.	O
IMPORTANCE	O
The	O
domestic	O
chicken	O
is	O
the	O
cornerstone	O
of	O
animal	O
agriculture	O
worldwide	O
,	O
with	O
a	O
flock	O
population	O
exceeding	O
40	O
billion	O
birds	O
/	O
year	O
.	O

It	O
serves	O
as	O
an	O
economically	O
valuable	O
source	O
of	O
protein	O
globally	O
.	O

The	O
microbiome	O
of	O
poultry	O
has	O
important	O
effects	O
on	O
chicken	O
growth	O
,	O
feed	O
conversion	O
,	O
immune	O
status	O
,	O
and	O
pathogen	O
resistance	O
.	O

The	O
aim	O
of	O
our	O
research	O
was	O
to	O
develop	O
a	O
gnotobiotic	O
chicken	O
model	O
appropriate	O
for	O
the	O
study	O
chicken	O
gut	O
microbiota	O
function	O
.	O

Our	O
experimental	O
model	O
shows	O
that	O
young	O
germfree	O
chicks	O
are	O
able	O
to	O
colonize	O
diverse	O
sets	O
of	O
gut	O
bacteria	O
.	O

Therefore	O
,	O
besides	O
the	O
use	O
of	O
this	O
model	O
to	O
study	O
mechanisms	O
of	O
gut	O
microbiota	O
interactions	O
in	O
the	O
chicken	O
gut	O
,	O
it	O
could	O
be	O
also	O
used	O
for	O
applied	O
aspects	O
such	O
as	O
determining	O
the	O
safety	O
and	O
efficacy	O
of	O
new	O
probiotic	O
strains	O
derived	O
from	O
chicken	O
gut	O
microbiota	O
.	O

Stereoselective	O
Oxidation	O
Kinetics	O
of	O
Deoxycholate	O
in	O
Recombinant	O
and	O
Microsomal	O
CYP3A	O
Enzymes	O
:	O
Deoxycholate	O
19	O
-	O
Hydroxylation	O
Is	O
an	O
In	O
Vitro	O
Marker	O
of	O
CYP3A7	O
Activity	O
.	O

The	O
primary	O
bile	O
acids	O
(	O
BAs	O
)	O
synthesized	O
from	O
cholesterol	O
in	O
the	O
liver	O
are	O
converted	O
to	O
secondary	O
BAs	O
by	O
gut	O
microbiota	O
.	O

It	O
was	O
recently	O
disclosed	O
that	O
the	O
major	O
secondary	O
BA	O
,	O
deoxycholate	O
(	O
DCA	O
)	O
species	O
,	O
is	O
stereoselectively	O
oxidized	O
to	O
tertiary	O
BAs	O
exclusively	O
by	O
CYP3A	O
enzymes	O
.	O

This	O
work	O
subsequently	O
investigated	O
the	O
in	O
vitro	O
oxidation	O
kinetics	O
of	O
DCA	O
at	O
C	O
-	O
1beta	O
,	O
C	O
-	O
3beta	O
,	O
C	O
-	O
4beta	O
,	O
C	O
-	O
5beta	O
,	O
C	O
-	O
6alpha	O
,	O
C	O
-	O
6beta	O
,	O
and	O
C	O
-	O
19	O
in	O
recombinant	O
CYP3A	O
enzymes	O
and	O
naive	O
enzymes	O
in	O
human	O
liver	O
microsomes	O
(	O
HLMs	O
)	O
.	O

The	O
stereoselective	O
oxidation	O
of	O
DCA	O
fit	O
well	O
with	O
Hill	O
kinetics	O
at	O
1	O
-	O
300	O
muM	O
in	O
both	O
recombinant	O
CYP3A	O
enzymes	O
and	O
pooled	O
HLMs	O
.	O

With	O
no	O
contributions	O
or	O
trace	O
contributions	O
from	O
CYP3A5	O
,	O
CYP3A7	O
favors	O
oxidation	O
at	O
C	O
-	O
19	O
,	O
C	O
-	O
4beta	O
,	O
C	O
-	O
6alpha	O
,	O
C	O
-	O
3beta	O
,	O
and	O
C	O
-	O
1beta	O
,	O
whereas	O
CYP3A4	O
favors	O
the	O
oxidation	O
at	O
C	O
-	O
5beta	O
and	O
C	O
-	O
6beta	O
compared	O
with	O
each	O
other	O
.	O

Correlation	O
between	O
DCA	O
oxidation	O
and	O
testosterone	O
6beta	O
-	O
hydroxylation	O
in	O
14	O
adult	O
single	O
-	O
donor	O
HLMs	O
provided	O
proof	O
-	O
of	O
-	O
concept	O
evidence	O
that	O
DCA	O
19	O
-	O
hydroxylation	O
is	O
an	O
in	O
vitro	O
marker	O
reaction	O
for	O
CYP3A7	O
activity	O
,	O
whereas	O
oxidation	O
at	O
other	O
sites	O
represents	O
mixed	O
indicators	O
for	O
CYP3A4	O
and	O
CYP3A7	O
activities	O
.	O

Deactivation	O
caused	O
by	O
DCA	O
-	O
induced	O
cytochrome	O
P450	O
-	O
cytochrome	O
P420	O
conversion	O
,	O
as	O
shown	O
by	O
the	O
spectral	O
titrations	O
of	O
isolated	O
CYP3A	O
proteins	O
,	O
was	O
observed	O
when	O
DCA	O
levels	O
were	O
near	O
or	O
higher	O
than	O
the	O
critical	O
micelle	O
concentration	O
(	O
about	O
1500	O
muM	O
)	O
.	O

Unlike	O
CYP3A4	O
,	O
CYP3A7	O
showed	O
abnormally	O
elevated	O
activities	O
at	O
500	O
and	O
750	O
muM	O
,	O
which	O
might	O
be	O
associated	O
with	O
an	O
altered	O
affinity	O
for	O
DCA	O
multimers	O
.	O

The	O
disclosed	O
kinetic	O
and	O
functional	O
roles	O
of	O
CYP3A	O
isoforms	O
in	O
disposing	O
of	O
the	O
gut	O
bacteria	O
-	O
derived	O
DCA	O
may	O
help	O
in	O
understanding	O
the	O
structural	O
and	O
functional	O
mechanisms	O
of	O
CYP3A	O
.	O

Simplified	O
Intestinal	O
Microbiota	O
to	O
Study	O
Microbe	O
-	O
Diet	O
-	O
Host	O
Interactions	O
in	O
a	O
Mouse	O
Model	O
.	O

The	O
gut	O
microbiota	O
can	O
modulate	O
human	O
metabolism	O
through	O
interactions	O
with	O
macronutrients	O
.	O

However	O
,	O
microbiota	O
-	O
diet	O
-	O
host	O
interactions	O
are	O
difficult	O
to	O
study	O
because	O
bacteria	O
interact	O
in	O
complex	O
food	O
webs	O
in	O
concert	O
with	O
the	O
host	O
,	O
and	O
many	O
of	O
the	O
bacteria	O
are	O
not	O
yet	O
characterized	O
.	O

To	O
reduce	O
the	O
complexity	O
,	O
we	O
colonize	O
mice	O
with	O
a	O
simplified	O
intestinal	O
microbiota	O
(	O
SIM	O
)	O
composed	O
of	O
ten	O
sequenced	O
strains	O
isolated	O
from	O
the	O
human	O
gut	O
with	O
complementing	O
pathways	O
to	O
metabolize	O
dietary	O
fibers	O
.	O

We	O
feed	O
the	O
SIM	O
mice	O
one	O
of	O
three	O
diets	O
(	O
chow	O
[	O
fiber	O
rich	O
]	O
,	O
high	O
-	O
fat	O
/	O
high	O
-	O
sucrose	O
,	O
or	O
zero	O
-	O
fat	O
/	O
high	O
-	O
sucrose	O
diets	O
[	O
both	O
low	O
in	O
fiber	O
]	O
)	O
and	O
investigate	O
(	O
1	O
)	O
how	O
dietary	O
fiber	O
,	O
saturated	O
fat	O
,	O
and	O
sucrose	O
affect	O
the	O
abundance	O
and	O
transcriptome	O
of	O
the	O
SIM	O
community	O
,	O
(	O
2	O
)	O
the	O
effect	O
of	O
microbe	O
-	O
diet	O
interactions	O
on	O
circulating	O
metabolites	O
,	O
and	O
(	O
3	O
)	O
how	O
microbiota	O
-	O
diet	O
interactions	O
affect	O
host	O
metabolism	O
.	O

Our	O
SIM	O
model	O
can	O
be	O
used	O
in	O
future	O
studies	O
to	O
help	O
clarify	O
how	O
microbiota	O
-	O
diet	O
interactions	O
contribute	O
to	O
metabolic	O
diseases	O
.	O

Intestinal	O
short	O
-	O
chain	O
fatty	O
acid	O
composition	O
does	O
not	O
explain	O
gut	O
microbiota	O
-	O
mediated	O
effects	O
on	O
malaria	O
severity	O
.	O

Malaria	O
is	O
a	O
devastating	O
disease	O
resulting	O
in	O
significant	O
morbidity	O
and	O
mortality	O
,	O
especially	O
in	O
the	O
developing	O
world	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
gut	O
microbiome	O
modulates	O
severity	O
of	O
malaria	O
in	O
mice	O
,	O
though	O
the	O
exact	O
mechanism	O
was	O
unknown	O
.	O

One	O
well	O
-	O
studied	O
mechanism	O
by	O
which	O
the	O
intestinal	O
microbiota	O
exerts	O
an	O
effect	O
on	O
host	O
health	O
is	O
by	O
synthesis	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
.	O

SCFAs	O
have	O
pleiotropic	O
effects	O
on	O
the	O
host	O
,	O
including	O
modulating	O
the	O
immune	O
system	O
and	O
altering	O
susceptibility	O
to	O
pathogens	O
.	O

The	O
objective	O
of	O
the	O
current	O
work	O
was	O
to	O
explore	O
if	O
gut	O
microbiota	O
-	O
mediated	O
resistance	O
and	O
susceptibility	O
to	O
malaria	O
in	O
mice	O
is	O
through	O
differential	O
production	O
of	O
SCFAs	O
.	O

Of	O
the	O
eight	O
detected	O
SCFAs	O
,	O
only	O
propionic	O
acid	O
(	O
C3	O
)	O
was	O
different	O
between	O
two	O
groups	O
of	O
resistant	O
and	O
two	O
groups	O
of	O
susceptible	O
mice	O
,	O
with	O
higher	O
levels	O
in	O
feces	O
of	O
susceptible	O
mice	O
compared	O
to	O
resistant	O
mice	O
.	O

Nevertheless	O
,	O
subsequent	O
analysis	O
revealed	O
no	O
robust	O
correlation	O
between	O
malaria	O
severity	O
and	O
levels	O
of	O
fecal	O
propionic	O
acid	O
.	O

In	O
spite	O
of	O
the	O
broad	O
effect	O
of	O
SCFAs	O
on	O
host	O
physiology	O
,	O
including	O
host	O
immunity	O
,	O
this	O
study	O
shows	O
that	O
gut	O
microbiota	O
-	O
mediated	O
modulation	O
of	O
malaria	O
severity	O
in	O
mice	O
is	O
independent	O
of	O
fecal	O
SCFA	O
levels	O
.	O

Additionally	O
,	O
our	O
data	O
indicates	O
that	O
intestinal	O
SCFAs	O
do	O
not	O
function	O
as	O
biomarkers	O
for	O
prediction	O
of	O
malaria	O
disease	O
severity	O
.	O

Major	O
shifts	O
in	O
gut	O
microbiota	O
during	O
development	O
and	O
its	O
relationship	O
to	O
growth	O
in	O
ostriches	O
.	O

The	O
development	O
of	O
gut	O
microbiota	O
during	O
ontogeny	O
is	O
emerging	O
as	O
an	O
important	O
process	O
influencing	O
physiology	O
,	O
immunity	O
and	O
fitness	O
in	O
vertebrates	O
.	O

However	O
,	O
knowledge	O
of	O
how	O
bacteria	O
colonize	O
the	O
juvenile	O
gut	O
,	O
how	O
this	O
is	O
influenced	O
by	O
changes	O
in	O
the	O
diversity	O
of	O
gut	O
bacteria	O
and	O
to	O
what	O
extent	O
this	O
influences	O
host	O
fitness	O
,	O
particularly	O
in	O
nonmodel	O
organisms	O
,	O
is	O
lacking	O
.	O

Here	O
we	O
used	O
16S	O
rRNA	O
gene	O
sequencing	O
to	O
describe	O
the	O
successional	O
development	O
of	O
the	O
faecal	O
microbiome	O
in	O
ostriches	O
(	O
Struthio	O
camelus	O
,	O
n	O
=	O
66	O
,	O
repeatedly	O
sampled	O
)	O
over	O
the	O
first	O
3	O
months	O
of	O
life	O
and	O
its	O
relationship	O
to	O
growth	O
.	O

We	O
found	O
a	O
gradual	O
increase	O
in	O
microbial	O
diversity	O
with	O
age	O
that	O
involved	O
multiple	O
colonization	O
and	O
extinction	O
events	O
and	O
a	O
major	O
taxonomic	O
shift	O
in	O
bacteria	O
that	O
coincided	O
with	O
the	O
cessation	O
of	O
yolk	O
absorption	O
.	O

Comparisons	O
with	O
the	O
microbiota	O
of	O
adults	O
(	O
n	O
=	O
5	O
)	O
revealed	O
that	O
the	O
chicks	O
became	O
more	O
similar	O
in	O
their	O
microbial	O
diversity	O
and	O
composition	O
to	O
adults	O
as	O
they	O
aged	O
.	O

There	O
was	O
a	O
five	O
-	O
fold	O
difference	O
in	O
juvenile	O
growth	O
during	O
development	O
,	O
and	O
growth	O
during	O
the	O
first	O
week	O
of	O
age	O
was	O
strongly	O
positively	O
correlated	O
with	O
the	O
abundance	O
of	O
the	O
genus	O
Bacteroides	B-bacteria
and	O
negatively	O
correlated	O
with	O
Akkermansia	B-bacteria
.	O

After	O
the	O
first	O
week	O
,	O
the	O
abundances	O
of	O
six	O
phylogenetically	O
diverse	O
families	O
(	O
Peptococcaceae	B-bacteria
,	O
S24	B-bacteria
-	I-bacteria
7	I-bacteria
,	O
Verrucomicrobiae	B-bacteria
,	O
Anaeroplasmataceae	B-bacteria
,	O
Streptococcaceae	B-bacteria
,	O
Methanobacteriaceae	B-bacteria
)	O
were	O
associated	O
with	O
subsequent	O
reductions	O
in	O
chick	O
growth	O
in	O
an	O
age	O
-	O
specific	O
and	O
transient	O
manner	O
.	O

These	O
results	O
have	O
broad	O
implications	O
for	O
our	O
understanding	O
of	O
the	O
development	O
of	O
gut	O
microbiota	O
and	O
its	O
associations	O
with	O
animal	O
growth	O
.	O

Evaluation	O
and	O
entomopathogenicity	O
of	O
gut	O
bacteria	O
associated	O
with	O
dauer	O
juveniles	O
of	O
Oscheius	O
chongmingensis	O
(	O
Nematoda	O
:	O
Rhabditidae	O
)	O
.	O

The	O
nematodes	O
of	O
genus	O
Oscheius	B-bacteria
are	O
insect	O
parasites	O
with	O
a	O
potential	O
role	O
as	O
biological	O
control	O
agents	O
.	O

The	O
composition	O
of	O
gut	O
microbiota	O
and	O
its	O
potential	O
assistant	O
role	O
in	O
the	O
complex	O
pathogenic	O
mechanism	O
of	O
nematodes	O
have	O
been	O
poorly	O
illustrated	O
.	O

In	O
this	O
study	O
,	O
the	O
intestinal	O
bacteria	O
associated	O
with	O
dauer	O
juveniles	O
of	O
the	O
nematode	O
Oscheius	O
chongmingensis	O
Tumian	O
were	O
classified	O
by	O
16S	O
rDNA	O
high	O
-	O
throughput	O
sequencing	O
.	O

The	O
raw	O
reads	O
were	O
assigned	O
to	O
845	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
after	O
quality	O
filtering	O
.	O

The	O
results	O
showed	O
that	O
the	O
genus	O
Ochrobactrum	B-bacteria
,	O
with	O
a	O
proportion	O
of	O
59	O
.	O
82	O
%	O
,	O
was	O
the	O
most	O
abundant	O
genus	O
,	O
followed	O
by	O
7	O
.	O
13	O
%	O
Bacillus	B-bacteria
,	O
4	O
.	O
7	O
%	O
Albidiferax	B-bacteria
,	O
4	O
.	O
26	O
%	O
Acinetobacter	B-bacteria
,	O
and	O
3	O
.	O
09	O
%	O
Rhodococcus	B-bacteria
.	O

The	O
two	O
dominant	O
bacteria	O
,	O
Ochrobactrum	B-bacteria
and	O
Bacillus	B-bacteria
,	O
were	O
further	O
isolated	O
by	O
culturing	O
on	O
NBTA	O
and	O
LB	O
medium	O
respectively	O
,	O
and	O
then	O
identified	O
as	O
Ochrobactrum	B-bacteria
tritici	I-bacteria
and	O
Bacillus	B-bacteria
cereus	I-bacteria
by	O
morphological	O
and	O
16S	O
rDNA	O
sequence	O
analysis	O
.	O

Furthermore	O
,	O
the	O
entomopathogenicity	O
of	O
these	O
two	O
bacterial	O
species	O
was	O
studied	O
.	O

The	O
results	O
showed	O
that	O
O	O
.	O
tritici	O
caused	O
93	O
.	O
33	O
%	O
mortality	O
within	O
144	O
hr	O
in	O
the	O
4	O
(	O
th	O
)	O
-	O
instar	O
larvae	O
of	O
Galleria	O
mellonella	O
treated	O
with	O
2	O
x	O
10	O
(	O
9	O
)	O
CFU	O
/	O
ml	O
,	O
whereas	O
B	B-bacteria
.	I-bacteria
cereus	I-bacteria
showed	O
100	O
%	O
mortality	O
at	O
a	O
concentration	O
of	O
3	O
.	O
3	O
x	O
10	O
(	O
7	O
)	O
CFU	O
/	O
ml	O
within	O
48	O
hr	O
.	O

These	O
findings	O
,	O
especially	O
the	O
presence	O
of	O
O	O
.	O
tritici	O
,	O
which	O
had	O
not	O
been	O
found	O
in	O
other	O
nematode	O
species	O
in	O
the	O
genus	O
Oscheius	B-bacteria
,	O
indicate	O
that	O
the	O
associated	O
nematode	O
O	O
.	O
chongmingensis	O
may	O
have	O
particular	O
utility	O
as	O
a	O
biocontrol	O
agent	O
.	O

Small	O
intestinal	O
bacterial	O
overgrowth	O
and	O
nonalcoholic	O
fatty	O
liver	O
disease	O
.	O

The	O
gut	O
microbiota	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
major	O
environmental	O
factor	O
in	O
the	O
pathophysiology	O
of	O
several	O
human	O
diseases	O
.	O

The	O
anatomical	O
and	O
functional	O
association	O
existing	O
between	O
the	O
gut	O
and	O
the	O
liver	O
provides	O
the	O
theoretical	O
basis	O
to	O
assume	O
that	O
the	O
liver	O
is	O
a	O
major	O
target	O
for	O
gut	O
microbes	O
.	O

In	O
the	O
last	O
decades	O
,	O
many	O
studies	O
have	O
reported	O
an	O
altered	O
composition	O
of	O
gut	O
microbiota	O
in	O
patients	O
with	O
chronic	O
liver	O
diseases	O
and	O
liver	O
cirrhosis	O
,	O
suggesting	O
a	O
progressively	O
marked	O
dysbiosis	O
to	O
be	O
related	O
to	O
worsening	O
of	O
the	O
liver	O
disease	O
.	O

Modifications	O
of	O
microbiota	O
result	O
in	O
alteration	O
in	O
providing	O
signals	O
through	O
the	O
intestine	O
and	O
bacterial	O
products	O
,	O
as	O
well	O
as	O
hormones	O
produced	O
in	O
the	O
bowel	O
that	O
affect	O
metabolism	O
at	O
different	O
levels	O
including	O
the	O
liver	O
.	O

There	O
is	O
increasing	O
evidence	O
for	O
a	O
correlation	O
between	O
intestinal	O
microbiota	O
,	O
bacterial	O
translocation	O
and	O
hepatic	O
steatosis	O
.	O

Intestinal	O
microbiota	O
affects	O
nutrient	O
absorption	O
and	O
energy	O
homeostasis	O
.	O

Altered	O
intestinal	O
permeability	O
may	O
favor	O
the	O
passage	O
of	O
bacteria	O
derived	O
compounds	O
into	O
the	O
systemic	O
circulation	O
,	O
causing	O
a	O
systemic	O
inflammatory	O
state	O
,	O
characteristic	O
of	O
the	O
metabolic	O
syndrome	O
.	O

At	O
present	O
,	O
an	O
increasing	O
number	O
of	O
studies	O
indicate	O
a	O
close	O
relationship	O
between	O
dysbiosis	O
,	O
defined	O
as	O
abnormal	O
composition	O
and	O
the	O
amount	O
of	O
intestinal	O
bacteria	O
(	O
gut	O
microbiota	O
)	O
,	O
intestinal	O
permeability	O
and	O
some	O
metabolic	O
,	O
inflammatory	O
,	O
degenerative	O
and	O
even	O
psychiatric	O
diseases	O
.	O

Microbiota	O
pharmacological	O
modulation	O
seems	O
to	O
be	O
a	O
promising	O
tool	O
for	O
a	O
new	O
therapeutic	O
approach	O
to	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
and	O
in	O
prevention	O
of	O
cirrhosis	O
.	O

The	O
following	O
study	O
aims	O
to	O
briefly	O
discuss	O
the	O
role	O
of	O
microbiota	O
disorder	O
(	O
dysbiosis	O
)	O
,	O
and	O
in	O
particular	O
small	O
intestinal	O
bacterial	O
overgrowth	O
(	O
SIBO	O
)	O
,	O
in	O
the	O
pathogenesis	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
.	O

The	O
Impact	O
of	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
on	O
the	O
Gut	O
Microbiota	O
of	O
Mice	O
with	O
DSS	O
-	O
Induced	O
Colitis	O
.	O

The	O
pathogenesis	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
is	O
due	O
in	O
part	O
to	O
a	O
loss	O
of	O
equilibrium	O
among	O
the	O
gut	O
microbiota	O
,	O
epithelial	O
cells	O
,	O
and	O
resident	O
immune	O
cells	O
.	O

The	O
gut	O
microbiota	O
contains	O
a	O
large	O
proportion	O
of	O
probiotic	O
commensal	O
Lactobacillus	B-bacteria
species	I-bacteria
;	O
some	O
natural	O
microbiota	O
and	O
probiotics	O
confer	O
protection	O
against	O
IBD	O
.	O

In	O
this	O
study	O
,	O
mice	O
with	O
colitis	O
triggered	O
by	O
dextran	O
sodium	O
sulphate	O
(	O
DSS	O
)	O
were	O
given	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
orally	O
.	O

We	O
assessed	O
the	O
damage	O
caused	O
by	O
DSS	O
and	O
the	O
therapeutic	O
activity	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
.	O

The	O
colitis	O
triggered	O
by	O
DSS	O
was	O
less	O
severe	O
in	O
the	O
mice	O
that	O
received	O
the	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
treatment	O
,	O
which	O
also	O
diversified	O
the	O
microbe	O
species	O
in	O
the	O
colon	O
,	O
enhanced	O
the	O
ratio	O
of	O
Firmicutes	B-bacteria
to	O
Bacteroidetes	B-bacteria
,	O
and	O
diminished	O
the	O
relative	O
abundance	O
of	O
Lactobacillus	B-bacteria
.	O

The	O
taxonomic	O
units	O
of	O
greatest	O
diversity	O
in	O
the	O
DSS	O
and	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
groups	O
were	O
identified	O
using	O
a	O
linear	O
discriminant	O
and	O
effect	O
size	O
(	O
LEfSe	O
)	O
analysis	O
.	O

Aliihoeflea	O
was	O
established	O
to	O
be	O
the	O
genus	O
of	O
bacteria	O
that	O
was	O
affected	O
in	O
the	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
group	O
most	O
extensively	O
.	O

In	O
conclusion	O
,	O
gut	O
health	O
was	O
promoted	O
by	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
,	O
as	O
it	O
diversified	O
the	O
microbes	O
in	O
the	O
colon	O
and	O
restricted	O
the	O
activity	O
of	O
pathogenic	O
bacteria	O
in	O
the	O
intestine	O
.	O

Moreover	O
,	O
according	O
to	O
the	O
LEfSe	O
analysis	O
,	O
the	O
DSS	O
group	O
was	O
impacted	O
more	O
significantly	O
by	O
gut	O
microorganisms	O
than	O
the	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
group	O
,	O
suggesting	O
that	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
improved	O
the	O
stability	O
of	O
the	O
intestinal	O
tract	O
.	O

Intestinal	O
Bacteria	O
as	O
Powerful	O
Trapping	O
Lifeforms	O
for	O
the	O
Elimination	O
of	O
Radioactive	O
Cesium	O
.	O

In	O
March	O
2011	O
,	O
an	O
accident	O
at	O
the	O
Fukushima	O
Daiichi	O
Nuclear	O
Power	O
Plant	O
led	O
to	O
major	O
problems	O
,	O
including	O
the	O
release	O
of	O
radionuclides	O
such	O
as	O
Cesium	O
(	O
Cs	O
)	O
-	O
137	O
into	O
the	O
environment	O
.	O

Ever	O
since	O
this	O
accident	O
,	O
Cs	O
-	O
137	O
in	O
foods	O
has	O
become	O
a	O
serious	O
problem	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
concentration	O
of	O
Cs	O
-	O
137	O
in	O
the	O
feces	O
,	O
urine	O
,	O
and	O
ruminal	O
contents	O
of	O
cattle	O
and	O
demonstrated	O
the	O
possibility	O
of	O
its	O
elimination	O
from	O
the	O
body	O
by	O
intestinal	O
bacteria	O
.	O

The	O
results	O
revealed	O
a	O
high	O
Cs	O
-	O
137	O
concentration	O
in	O
the	O
feces	O
;	O
in	O
fact	O
,	O
this	O
concentration	O
was	O
higher	O
than	O
that	O
in	O
skeletal	O
muscles	O
and	O
other	O
samples	O
from	O
several	O
animals	O
.	O

Furthermore	O
,	O
intestinal	O
bacteria	O
were	O
able	O
to	O
trap	O
Cs	O
-	O
137	O
,	O
showing	O
an	O
uptake	O
ratio	O
within	O
the	O
range	O
of	O
38	O
-	O
81	O
%	O
in	O
vitro	O
.	O

This	O
uptake	O
appeared	O
to	O
be	O
mediated	O
through	O
the	O
sodium	O
-	O
potassium	O
(	O
Na	O
(	O
+	O
)	O
-	O
K	O
(	O
+	O
)	O
)	O
ion	O
pump	O
in	O
the	O
bacterial	O
cell	O
membrane	O
.	O

This	O
inference	O
was	O
drawn	O
based	O
on	O
the	O
fact	O
that	O
the	O
uptake	O
ratio	O
of	O
Cs	O
-	O
137	O
was	O
decreased	O
in	O
media	O
with	O
high	O
potassium	O
concentration	O
.	O

In	O
addition	O
,	O
it	O
was	O
demonstrated	O
that	O
intestinal	O
bacteria	O
hindered	O
the	O
trapping	O
of	O
Cs	O
-	O
137	O
by	O
the	O
animal	O
.	O

Cattle	O
feces	O
showed	O
high	O
concentration	O
of	O
Cs	O
-	O
137	O
and	O
intestinal	O
bacteria	O
trapped	O
Cs	O
-	O
137	O
.	O

This	O
study	O
is	O
the	O
first	O
report	O
showing	O
that	O
intestinal	O
bacteria	O
contribute	O
to	O
the	O
elimination	O
of	O
Cs	O
-	O
137	O
from	O
the	O
body	O
.	O

Short	O
Chain	O
Fatty	O
Acids	O
(	O
SCFAs	O
)	O
-	O
Mediated	O
Gut	O
Epithelial	O
and	O
Immune	O
Regulation	O
and	O
Its	O
Relevance	O
for	O
Inflammatory	O
Bowel	O
Diseases	O
.	O

Ulcerative	O
colitis	O
(	O
UC	O
)	O
and	O
Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
,	O
collectively	O
known	O
as	O
Inflammatory	O
Bowel	O
Diseases	O
(	O
IBD	O
)	O
,	O
are	O
caused	O
by	O
a	O
complex	O
interplay	O
between	O
genetic	O
,	O
immunologic	O
,	O
microbial	O
and	O
environmental	O
factors	O
.	O

Dysbiosis	O
of	O
the	O
gut	O
microbiome	O
is	O
increasingly	O
considered	O
to	O
be	O
causatively	O
related	O
to	O
IBD	O
and	O
is	O
strongly	O
affected	O
by	O
components	O
of	O
a	O
Western	O
life	O
style	O
.	O

Bacteria	O
that	O
ferment	O
fibers	O
and	O
produce	O
short	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
are	O
typically	O
reduced	O
in	O
mucosa	O
and	O
feces	O
of	O
patients	O
with	O
IBD	O
,	O
as	O
compared	O
to	O
healthy	O
individuals	O
.	O

SCFAs	O
,	O
such	O
as	O
acetate	O
,	O
propionate	O
and	O
butyrate	O
,	O
are	O
important	O
metabolites	O
in	O
maintaining	O
intestinal	O
homeostasis	O
.	O

Several	O
studies	O
have	O
indeed	O
shown	O
that	O
fecal	O
SCFAs	O
levels	O
are	O
reduced	O
in	O
active	O
IBD	O
.	O

SCFAs	O
are	O
an	O
important	O
fuel	O
for	O
intestinal	O
epithelial	O
cells	O
and	O
are	O
known	O
to	O
strengthen	O
the	O
gut	O
barrier	O
function	O
.	O

Recent	O
findings	O
,	O
however	O
,	O
show	O
that	O
SCFAs	O
,	O
and	O
in	O
particular	O
butyrate	O
,	O
also	O
have	O
important	O
immunomodulatory	O
functions	O
.	O

Absorption	O
of	O
SCFAs	O
is	O
facilitated	O
by	O
substrate	O
transporters	O
like	O
MCT1	O
and	O
SMCT1	O
to	O
promote	O
cellular	O
metabolism	O
.	O

Moreover	O
,	O
SCFAs	O
may	O
signal	O
through	O
cell	O
surface	O
G	O
-	O
protein	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
,	O
like	O
GPR41	O
,	O
GPR43	O
,	O
and	O
GPR109A	O
,	O
to	O
activate	O
signaling	O
cascades	O
that	O
control	O
immune	O
functions	O
.	O

Transgenic	O
mouse	O
models	O
support	O
the	O
key	O
role	O
of	O
these	O
GPCRs	O
in	O
controlling	O
intestinal	O
inflammation	O
.	O

Here	O
,	O
we	O
present	O
an	O
overview	O
of	O
microbial	O
SCFAs	O
production	O
and	O
their	O
effects	O
on	O
the	O
intestinal	O
mucosa	O
with	O
specific	O
emphasis	O
on	O
their	O
relevance	O
for	O
IBD	O
.	O

Moreover	O
,	O
we	O
discuss	O
the	O
therapeutic	O
potential	O
of	O
SCFAs	O
for	O
IBD	O
,	O
either	O
applied	O
directly	O
or	O
by	O
stimulating	O
SCFAs	O
-	O
producing	O
bacteria	O
through	O
pre	O
-	O
or	O
probiotic	O
approaches	O
.	O

Combined	O
Effects	O
of	O
Three	O
High	O
-	O
Energy	O
Charged	O
Particle	O
Beams	O
Important	O
for	O
Space	O
Flight	O
on	O
Brain	O
,	O
Behavioral	O
and	O
Cognitive	O
Endpoints	O
in	O
B6D2F1	O
Female	O
and	O
Male	O
Mice	O
.	O

The	O
radiation	O
environment	O
in	O
deep	O
space	O
includes	O
the	O
galactic	O
cosmic	O
radiation	O
with	O
different	O
proportions	O
of	O
all	O
naturally	O
occurring	O
ions	O
from	O
protons	O
to	O
uranium	O
.	O

Most	O
experimental	O
animal	O
studies	O
for	O
assessing	O
the	O
biological	O
effects	O
of	O
charged	O
particles	O
have	O
involved	O
acute	O
dose	O
delivery	O
for	O
single	O
ions	O
and	O
/	O
or	O
fractionated	O
exposure	O
protocols	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
behavioral	O
and	O
cognitive	O
performance	O
of	O
female	O
and	O
male	O
C57BL	O
/	O
6J	O
x	O
DBA2	O
/	O
J	O
F1	O
(	O
B6D2F1	O
)	O
mice	O
2	O
months	O
following	O
rapidly	O
delivered	O
,	O
sequential	O
irradiation	O
with	O
protons	O
(	O
1	O
GeV	O
,	O
60	O
%	O
)	O
,	O
(	O
16	O
)	O
O	O
(	O
250	O
MeV	O
/	O
n	O
,	O
20	O
%	O
)	O
,	O
and	O
(	O
28	O
)	O
Si	O
(	O
263	O
MeV	O
/	O
n	O
,	O
20	O
%	O
)	O
at	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
200	O
cGy	O
at	O
4	O
-	O
6	O
months	O
of	O
age	O
.	O

Cortical	O
BDNF	O
,	O
CD68	O
,	O
and	O
MAP	O
-	O
2	O
levels	O
were	O
analyzed	O
3	O
months	O
after	O
irradiation	O
or	O
sham	O
irradiation	O
.	O

During	O
the	O
dark	O
period	O
,	O
male	O
mice	O
irradiated	O
with	O
50	O
cGy	O
showed	O
higher	O
activity	O
levels	O
in	O
the	O
home	O
cage	O
than	O
sham	O
-	O
irradiated	O
mice	O
.	O

Mice	O
irradiated	O
with	O
50	O
cGy	O
also	O
showed	O
increased	O
depressive	O
behavior	O
in	O
the	O
forced	O
swim	O
test	O
.	O

When	O
cognitive	O
performance	O
was	O
assessed	O
,	O
sham	O
-	O
irradiated	O
mice	O
of	O
both	O
sexes	O
and	O
mice	O
irradiated	O
with	O
25	O
cGy	O
showed	O
normal	O
responses	O
to	O
object	O
recognition	O
and	O
novel	O
object	O
exploration	O
.	O

However	O
,	O
object	O
recognition	O
was	O
impaired	O
in	O
female	O
and	O
male	O
mice	O
irradiated	O
with	O
50	O
or	O
200	O
cGy	O
.	O

For	O
cortical	O
levels	O
of	O
the	O
neurotrophic	O
factor	O
BDNF	O
and	O
the	O
marker	O
of	O
microglial	O
activation	O
CD68	O
,	O
there	O
were	O
sex	O
x	O
radiation	O
interactions	O
.	O

In	O
females	O
,	O
but	O
not	O
males	O
,	O
there	O
were	O
increased	O
CD68	O
levels	O
following	O
irradiation	O
.	O

In	O
males	O
,	O
but	O
not	O
females	O
,	O
there	O
were	O
reduced	O
BDNF	O
levels	O
following	O
irradiation	O
.	O

A	O
significant	O
positive	O
correlation	O
between	O
BDNF	O
and	O
CD68	O
levels	O
was	O
observed	O
,	O
suggesting	O
a	O
role	O
for	O
activated	O
microglia	O
in	O
the	O
alterations	O
in	O
BDNF	O
levels	O
.	O

Finally	O
,	O
sequential	O
beam	O
irradiation	O
impacted	O
the	O
diversity	O
and	O
composition	O
of	O
the	O
gut	O
microbiome	O
.	O

These	O
included	O
dose	O
-	O
dependent	O
impacts	O
and	O
alterations	O
to	O
the	O
relative	O
abundance	O
of	O
several	O
gut	O
genera	O
,	O
such	O
as	O
Butyricicoccus	B-bacteria
and	O
Lachnospiraceae	B-bacteria
.	O

Thus	O
,	O
exposure	O
to	O
rapidly	O
delivered	O
sequential	O
proton	O
,	O
(	O
16	O
)	O
O	O
ion	O
,	O
and	O
(	O
28	O
)	O
Si	O
ion	O
irradiation	O
significantly	O
affects	O
behavioral	O
and	O
cognitive	O
performance	O
,	O
cortical	O
levels	O
of	O
CD68	O
and	O
BDNF	O
in	O
a	O
sex	O
-	O
dependent	O
fashion	O
,	O
and	O
the	O
gut	O
microbiome	O
.	O

[	O
Carcinogenesis	O
and	O
Gut	O
Microbiota	O
]	O
.	O

Recent	O
developments	O
in	O
techniques	O
of	O
metabologenomics	O
have	O
given	O
a	O
better	O
understanding	O
the	O
association	O
of	O
gut	O
microbiota	O
with	O
various	O
diseases	O
.	O

Gut	O
microbiota	O
has	O
a	O
strong	O
impact	O
on	O
host	O
immunostasis	O
and	O
homeostasis	O
of	O
gut	O
function	O
for	O
maintaining	O
the	O
health	O
condition	O
.	O

Dysbiosis	O
leads	O
to	O
an	O
increase	O
in	O
bacterial	O
populations	O
that	O
stimulate	O
tumorigenesis	O
,	O
and	O
contributes	O
to	O
epithelial	O
carcinogenesis	O
and	O
tumor	O
progression	O
by	O
altering	O
metabolic	O
properties	O
(	O
such	O
as	O
bile	O
acid	O
and	O
butyric	O
acid	O
)	O
and	O
inflammatory	O
process	O
.	O

Inflammation	O
aid	O
the	O
bacterial	O
translocation	O
into	O
the	O
neoplastic	O
tissue	O
,	O
which	O
in	O
turn	O
promotes	O
production	O
of	O
inflammatory	O
cytokines	O
subsequently	O
leading	O
to	O
tumor	O
growth	O
.	O

The	O
colonic	O
microbiota	O
such	O
as	O
enterotoxigenic	B-bacteria
Bacteroides	I-bacteria
fragilis	I-bacteria
(	O
ETBF	B-bacteria
)	O
may	O
also	O
promote	O
colorectal	O
cancer	O
by	O
stimulating	O
exaggerated	O
immune	O
responses	O
via	O
Th17	O
cells	O
.	O

Dysbiosis	O
caused	O
by	O
a	O
deficiency	O
of	O
the	O
NLRP6	O
inflammasome	O
promotes	O
cancer	O
development	O
via	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
-	O
induced	O
epithelial	O
proliferation	O
.	O

Emerging	O
data	O
suggest	O
that	O
certain	O
groups	O
of	O
bacteria	O
might	O
promote	O
whereas	O
others	O
might	O
protect	O
against	O
colon	O
cancer	O
.	O

Indeed	O
,	O
Fusobacteriumnucleatum	B-bacteria
(	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
)	O
seems	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
tumor	O
microenvironment	O
as	O
its	O
abundance	O
correlates	O
with	O
cancer	O
progression	O
as	O
well	O
as	O
the	O
dysbiotic	O
tumor	O
microbiota	O
composition	O
including	O
Bacteroides	B-bacteria
and	O
Prevotella	B-bacteria
species	I-bacteria
.	O

Moreover	O
,	O
gut	O
microbiota	O
not	O
only	O
plays	O
a	O
key	O
role	O
in	O
carcinogenesis	O
but	O
also	O
influences	O
the	O
efficacy	O
and	O
toxicity	O
of	O
cancer	O
immunotherapy	O
,	O
especially	O
immune	O
checkpoint	O
inhibitors	O
by	O
targeting	O
the	O
programmed	O
death	O
receptor	O
1	O
(	O
PD	O
-	O
1	O
)	O
and	O
the	O
cytotoxic	O
T	O
lymphocyte	O
antigen	O
4	O
(	O
CTLA	O
-	O
4	O
)	O
.	O

Gut	O
Microbiota	O
Metabolite	O
Indole	O
Propionic	O
Acid	O
Targets	O
Tryptophan	O
Biosynthesis	O
in	O
Mycobacterium	B-bacteria
tuberculosis	I-bacteria
.	O

Indole	O
propionic	O
acid	O
(	O
IPA	O
)	O
,	O
produced	O
by	O
the	O
gut	O
microbiota	O
,	O
is	O
active	O
against	O
Mycobacterium	B-bacteria
tuberculosis	I-bacteria
in	O
vitro	O
and	O
in	O
vivo	O
However	O
,	O
its	O
mechanism	O
of	O
action	O
is	O
unknown	O
.	O

IPA	O
is	O
the	O
deamination	O
product	O
of	O
tryptophan	O
(	O
Trp	O
)	O
and	O
thus	O
a	O
close	O
structural	O
analog	O
of	O
this	O
essential	O
aromatic	O
amino	O
acid	O
.	O

De	O
novo	O
Trp	O
biosynthesis	O
in	O
M	B-bacteria
.	I-bacteria
tuberculosis	I-bacteria
is	O
regulated	O
through	O
feedback	O
inhibition	O
:	O
Trp	O
acts	O
as	O
an	O
allosteric	O
inhibitor	O
of	O
anthranilate	O
synthase	O
TrpE	O
,	O
which	O
catalyzes	O
the	O
first	O
committed	O
step	O
in	O
the	O
Trp	O
biosynthesis	O
pathway	O
.	O

Hence	O
,	O
we	O
hypothesized	O
that	O
IPA	O
may	O
mimic	O
Trp	O
as	O
an	O
allosteric	O
inhibitor	O
of	O
TrpE	O
and	O
exert	O
its	O
antimicrobial	O
effect	O
by	O
blocking	O
synthesis	O
of	O
Trp	O
at	O
the	O
TrpE	O
catalytic	O
step	O
.	O

To	O
test	O
our	O
hypothesis	O
,	O
we	O
carried	O
out	O
metabolic	O
,	O
chemical	O
rescue	O
,	O
genetic	O
,	O
and	O
biochemical	O
analyses	O
.	O

Treatment	O
of	O
mycobacteria	B-bacteria
with	O
IPA	O
inhibited	O
growth	O
and	O
reduced	O
the	O
intracellular	O
level	O
of	O
Trp	O
,	O
an	O
effect	O
abrogated	O
upon	O
supplementation	O
of	O
Trp	O
in	O
the	O
medium	O
.	O

Missense	O
mutations	O
at	O
the	O
allosteric	O
Trp	O
binding	O
site	O
of	O
TrpE	O
eliminated	O
Trp	O
inhibition	O
and	O
caused	O
IPA	O
resistance	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
shown	O
that	O
IPA	O
blocks	O
Trp	O
biosynthesis	O
in	O
M	B-bacteria
.	I-bacteria
tuberculosis	I-bacteria
via	O
inhibition	O
of	O
TrpE	O
by	O
mimicking	O
the	O
physiological	O
allosteric	O
inhibitor	O
of	O
this	O
enzyme	O
.	O
IMPORTANCE	O
New	O
drugs	O
against	O
tuberculosis	O
are	O
urgently	O
needed	O
.	O

The	O
tryptophan	O
(	O
Trp	O
)	O
analog	O
indole	O
propionic	O
acid	O
(	O
IPA	O
)	O
is	O
the	O
first	O
antitubercular	O
metabolite	O
produced	O
by	O
human	O
gut	O
bacteria	O
.	O

Here	O
,	O
we	O
show	O
that	O
this	O
antibiotic	O
blocks	O
Trp	O
synthesis	O
,	O
an	O
in	O
vivo	O
essential	O
biosynthetic	O
pathway	O
in	O
M	B-bacteria
.	I-bacteria
tuberculosis	I-bacteria
Intriguingly	O
,	O
IPA	O
acts	O
by	O
decoupling	O
a	O
bacterial	O
feedback	O
regulatory	O
mechanism	O
:	O
it	O
mimics	O
Trp	O
as	O
allosteric	O
inhibitor	O
of	O
anthranilate	O
synthase	O
,	O
thereby	O
switching	O
off	O
Trp	O
synthesis	O
regardless	O
of	O
intracellular	O
Trp	O
levels	O
.	O

The	O
identification	O
of	O
IPA	O
'	O
s	O
target	O
paves	O
the	O
way	O
for	O
the	O
discovery	O
of	O
more	O
potent	O
TrpE	O
ligands	O
employing	O
rational	O
,	O
target	O
-	O
based	O
lead	O
optimization	O
.	O

An	O
IMD	O
-	O
like	O
pathway	O
mediates	O
the	O
intestinal	O
immunity	O
to	O
modulate	O
the	O
homeostasis	O
of	O
gut	O
microbiota	O
in	O
Rhynchophorus	O
ferrugineus	O
Olivier	O
(	O
Coleoptera	O
:	O
Dryophthoridae	O
)	O
.	O

Most	O
animals	O
have	O
established	O
the	O
mutualistic	O
interactions	O
with	O
their	O
intestinal	O
microbes	O
which	O
provide	O
multiple	O
benefits	O
to	O
their	O
host	O
physiology	O
.	O

However	O
,	O
the	O
mechanisms	O
behind	O
hosts	O
determine	O
the	O
load	O
and	O
composition	O
of	O
gut	O
microbiota	O
are	O
still	O
poorly	O
understood	O
outside	O
dipteran	O
insects	O
.	O

Here	O
,	O
the	O
gene	O
,	O
encoding	O
the	O
NF	O
-	O
kappaB	O
-	O
like	O
transcription	O
factor	O
Relish	O
,	O
being	O
designated	O
as	O
RfRelish	O
,	O
was	O
identified	O
and	O
analyzed	O
in	O
red	O
palm	O
weevil	O
(	O
RPW	O
)	O
,	O
Rhynchophorus	B-bacteria
ferrugineus	I-bacteria
Olivier	O
.	O

We	O
revealed	O
that	O
the	O
abundance	O
of	O
RfRelish	O
transcripts	O
in	O
the	O
fat	O
body	O
,	O
hemolymph	O
and	O
gut	O
are	O
significantly	O
higher	O
than	O
that	O
in	O
non	O
-	O
immunity	O
-	O
related	O
tissues	O
,	O
and	O
its	O
expression	O
level	O
can	O
be	O
markedly	O
induced	O
by	O
bacterial	O
challenges	O
.	O

When	O
RfRelish	O
was	O
silenced	O
,	O
the	O
ability	O
of	O
individuals	O
to	O
clear	O
the	O
pathogenic	O
bacteria	O
in	O
body	O
cavity	O
and	O
gut	O
was	O
significantly	O
compromised	O
,	O
suggesting	O
that	O
both	O
the	O
systemic	O
and	O
gut	O
local	O
immunity	O
were	O
impaired	O
dramatically	O
by	O
RfRelish	O
knockdown	O
.	O

Additionally	O
,	O
the	O
silenced	O
insects	O
exhibited	O
increased	O
gut	O
bacterial	O
load	O
,	O
and	O
the	O
relative	O
abundance	O
of	O
some	O
gut	O
bacteria	O
was	O
changed	O
as	O
compared	O
to	O
controls	O
.	O

Collectively	O
,	O
our	O
findings	O
demonstrate	O
that	O
the	O
IMD	O
-	O
like	O
pathway	O
restricts	O
the	O
proliferation	O
of	O
gut	O
bacteria	O
and	O
shapes	O
the	O
commensal	O
community	O
structure	O
in	O
the	O
intestine	O
of	O
R	B-bacteria
.	I-bacteria
ferrugineus	I-bacteria
by	O
mediating	O
the	O
secretion	O
of	O
antimicrobial	O
peptides	O
.	O

We	O
provide	O
a	O
striking	O
example	O
on	O
how	O
an	O
insect	O
pest	O
maintains	O
the	O
homeostasis	O
of	O
gut	O
microbiota	O
via	O
a	O
conserved	O
immune	O
pathway	O
without	O
compromising	O
the	O
advantages	O
of	O
the	O
mutualistic	O
relationships	O
.	O

Nutritional	O
impacts	O
of	O
dietary	O
oregano	O
and	O
Enviva	O
essential	O
oils	O
on	O
the	O
performance	O
,	O
gut	O
microbiota	O
and	O
blood	O
biochemicals	O
of	O
growing	O
ducks	O
.	O

Nowadays	O
,	O
there	O
is	O
much	O
legislation	O
in	O
the	O
world	O
devoted	O
to	O
restrict	O
the	O
use	O
of	O
synthetic	O
antibiotics	O
in	O
the	O
poultry	O
industry	O
,	O
which	O
could	O
reduce	O
performance	O
rate	O
and	O
production	O
profits	O
.	O

Various	O
phyto	O
-	O
biotic	O
growth	O
promoters	O
have	O
been	O
proposed	O
to	O
serve	O
as	O
antibiotic	O
alternatives	O
with	O
emphasis	O
on	O
plant	O
extracts	O
and	O
essential	O
oils	O
.	O

This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
impacts	O
of	O
using	O
the	O
oregano	O
essential	O
oil	O
(	O
OEO	O
)	O
(	O
comprised	O
of	O
5	O
%	O
thymol	O
and	O
65	O
%	O
carvacrol	O
)	O
and	O
Enviva	O
essential	O
oil	O
(	O
EEO	O
)	O
(	O
4	O
.	O
5	O
%	O
cinnamaldehyde	O
and	O
13	O
.	O
5	O
%	O
thymol	O
)	O
as	O
phytobiotic	O
feed	O
additives	O
(	O
PFA	O
)	O
on	O
growth	O
performance	O
,	O
cecal	O
microbiota	O
and	O
serum	O
biochemicals	O
of	O
growing	O
ducks	O
.	O

In	O
total	O
,	O
800	O
11	O
-	O
day	O
-	O
old	O
ducklings	O
,	O
housed	O
in	O
20	O
floor	O
pens	O
,	O
were	O
allotted	O
randomly	O
into	O
five	O
dietary	O
treatments	O
:	O
(	O
i	O
)	O
A	O
basal	O
diet	O
(	O
BD	O
)	O
(	O
control	O
)	O
,	O
(	O
ii	O
.	O
)	O

BD	O
+	O
50	O
mg	O
EEO	O
/	O
kg	O
,	O
(	O
iii	O
.	O
)	O

BD	O
+	O
100	O
mg	O
EEO	O
/	O
kg	O
,	O
(	O
iv	O
.	O
)	O

BD	O
+	O
150	O
mg	O
OEO	O
/	O
kg	O
and	O
(	O
v	O
.	O
)	O
BD	O
+	O
300	O
mg	O
OEO	O
/	O
kg	O
diet	O
.	O

The	O
growth	O
performance	O
traits	O
were	O
studied	O
between	O
11	O
and	O
42	O
days	O
of	O
age	O
.	O

At	O
the	O
experiment	O
end	O
,	O
40	O
ducks	O
were	O
slaughtered	O
(	O
eight	O
/	O
treatment	O
)	O
and	O
cecal	O
digesta	O
and	O
blood	O
samples	O
were	O
collected	O
to	O
estimate	O
the	O
cecal	O
bacterial	O
populations	O
and	O
serum	O
blood	O
biochemicals	O
.	O

The	O
results	O
indicated	O
that	O
the	O
tested	O
levels	O
of	O
OEO	O
and	O
EEO	O
did	O
not	O
display	O
any	O
significant	O
effect	O
(	O
P	O
&	O
gt	O
;	O
0	O
.	O
05	O
)	O
on	O
the	O
duck	O
'	O
s	O
final	O
BW	O
,	O
BW	O
gain	O
,	O
growth	O
rate	O
,	O
feed	O
intake	O
,	O
feed	O
conversion	O
ratio	O
or	O
survivability	O
rate	O
.	O

Besides	O
,	O
the	O
different	O
levels	O
of	O
EEO	O
and	O
OEO	O
decreased	O
the	O
cecal	O
populations	O
of	O
Coliforms	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
01	O
)	O
,	O
total	O
aerobes	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
01	O
)	O
and	O
lactose	B-bacteria
-	I-bacteria
negative	I-bacteria
Enterobacteria	I-bacteria
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
05	O
)	O
in	O
comparison	O
with	O
those	O
of	O
the	O
control	O
group	O
.	O

Finally	O
,	O
the	O
tested	O
EEO	O
and	O
OEO	O
levels	O
did	O
not	O
show	O
any	O
significant	O
effect	O
on	O
the	O
serum	O
variables	O
;	O
in	O
terms	O
of	O
total	O
protein	O
,	O
albumin	O
,	O
globulin	O
,	O
total	O
cholesterol	O
,	O
triglycerides	O
,	O
alanine	O
aminotransferase	O
and	O
aspartate	O
aminotransferase	O
.	O

In	O
conclusion	O
,	O
the	O
antimicrobial	O
effect	O
of	O
the	O
OEO	O
and	O
EEO	O
against	O
the	O
cecal	O
microbiota	O
has	O
been	O
proven	O
,	O
while	O
they	O
did	O
not	O
display	O
significant	O
effects	O
on	O
the	O
growth	O
performance	O
or	O
blood	O
variables	O
of	O
growing	O
ducks	O
.	O

Metagenomic	O
reconstructions	O
of	O
gut	O
microbial	O
metabolism	O
in	O
weanling	O
pigs	O
.	O

BACKGROUND	O
:	O
The	O
piglets	O
'	O
transition	O
from	O
milk	O
to	O
solid	O
feed	O
induces	O
a	O
succession	O
of	O
bacterial	O
communities	O
,	O
enhancing	O
the	O
hosts	O
'	O
ability	O
to	O
harvest	O
energy	O
from	O
dietary	O
carbohydrates	O
.	O

To	O
reconstruct	O
microbial	O
carbohydrate	O
metabolism	O
in	O
weanling	O
pigs	O
,	O
this	O
study	O
combined	O
16S	O
rRNA	O
gene	O
sequencing	O
(	O
n	O
=	O
191	O
)	O
and	O
shotgun	O
metagenomics	O
(	O
n	O
=	O
72	O
)	O
.	O

RESULTS	O
:	O
Time	O
and	O
wheat	O
content	O
in	O
feed	O
explained	O
most	O
of	O
the	O
variation	O
of	O
the	O
microbiota	O
as	O
assessed	O
by	O
16S	O
rRNA	O
gene	O
sequencing	O
in	O
weanling	O
pigs	O
.	O

De	O
novo	O
metagenomic	O
binning	O
reconstructed	O
360	O
high	O
-	O
quality	O
genomes	O
that	O
represented	O
11	O
prokaryotic	O
and	O
1	O
archaeal	O
phylum	O
.	O

Analysis	O
of	O
carbohydrate	O
metabolism	O
in	O
these	O
genomes	O
revealed	O
that	O
starch	O
fermentation	O
is	O
carried	O
out	O
by	O
a	O
consortium	O
of	O
Firmicutes	B-bacteria
expressing	O
extracellular	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
4	O
)	O
-	O
glucan	O
branching	O
enzyme	O
(	O
GH13	O
)	O
and	O
Bacteroidetes	B-bacteria
expressing	O
periplasmic	O
neopullulanase	O
(	O
GH13	O
)	O
and	O
alpha	O
-	O
glucosidase	O
(	O
GH97	O
)	O
.	O

Fructans	O
were	O
degraded	O
by	O
extracellular	O
GH32	O
enzymes	O
from	O
Bacteriodetes	B-bacteria
and	O
Lactobacillus	B-bacteria
.	O

Lactose	O
fermentation	O
by	O
beta	O
-	O
galactosidases	O
(	O
GH2	O
and	O
GH42	O
)	O
was	O
identified	O
in	O
Firmicutes	B-bacteria
.	O

In	O
conclusion	O
,	O
the	O
assembly	O
of	O
360	O
high	O
-	O
quality	O
genomes	O
as	O
the	O
first	O
metagenomic	O
reference	O
for	O
swine	O
intestinal	O
microbiota	O
allowed	O
identification	O
of	O
key	O
microbial	O
contributors	O
to	O
degradation	O
of	O
starch	O
,	O
fructans	O
,	O
and	O
lactose	O
.	O

CONCLUSIONS	O
:	O
Microbial	O
consortia	O
that	O
are	O
responsible	O
for	O
degradation	O
of	O
these	O
glycans	O
differ	O
substantially	O
from	O
the	O
microbial	O
consortia	O
that	O
degrade	O
the	O
same	O
glycans	O
in	O
humans	O
.	O

Our	O
study	O
thus	O
enables	O
improvement	O
of	O
feeding	O
models	O
with	O
higher	O
feed	O
efficiency	O
and	O
better	O
pathogen	O
control	O
for	O
weanling	O
pigs	O
.	O

Probiotics	O
to	O
prevent	O
Staphylococcus	B-bacteria
aureus	I-bacteria
disease	O
?	O

There	O
are	O
a	O
plethora	O
of	O
probiotic	O
formulae	O
that	O
supposedly	O
benefit	O
human	O
health	O
on	O
the	O
market	O
.	O

However	O
,	O
the	O
scientific	O
underpinnings	O
of	O
the	O
claimed	O
benefits	O
have	O
remained	O
poorly	O
established	O
.	O

Scientific	O
evidence	O
is	O
now	O
increasingly	O
being	O
provided	O
that	O
explains	O
those	O
benefits	O
,	O
for	O
example	O
,	O
by	O
immune	O
-	O
stimulatory	O
effects	O
or	O
inter	O
-	O
bacterial	O
competition	O
between	O
beneficial	O
and	O
pathogenic	O
bacteria	O
.	O

In	O
our	O
recent	O
study	O
(	O
Piewngam	O
et	O
al	O
.	O
Nature	O
2018	O
)	O
,	O
we	O
show	O
that	O
Bacillus	B-bacteria
colonization	O
of	O
the	O
human	O
intestine	O
is	O
negatively	O
correlated	O
with	O
that	O
of	O
the	O
human	O
pathogen	O
,	O
Staphylococcus	B-bacteria
aureus	I-bacteria
.	O

This	O
type	O
of	O
colonization	O
resistance	O
is	O
achieved	O
by	O
secretion	O
of	O
a	O
class	O
of	O
lipopeptides	O
by	O
Bacillus	B-bacteria
species	I-bacteria
that	O
inhibits	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
quorum	O
-	O
sensing	O
signaling	O
,	O
which	O
we	O
found	O
is	O
crucial	O
for	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
intestinal	O
colonization	O
.	O

Here	O
,	O
we	O
discuss	O
what	O
these	O
findings	O
imply	O
for	O
the	O
general	O
role	O
of	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
intestinal	O
colonization	O
,	O
the	O
role	O
of	O
quorum	O
-	O
sensing	O
in	O
that	O
process	O
,	O
and	O
potential	O
alternative	O
ways	O
to	O
control	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
infection	O
.	O

Gut	O
bacteria	O
signaling	O
to	O
mitochondria	O
in	O
intestinal	O
inflammation	O
and	O
cancer	O
.	O

The	O
gastrointestinal	O
microbiome	O
plays	O
a	O
pivotal	O
role	O
in	O
physiological	O
homeostasis	O
of	O
the	O
intestine	O
as	O
well	O
as	O
in	O
the	O
pathophysiology	O
of	O
diseases	O
including	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
and	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

Emerging	O
evidence	O
suggests	O
that	O
gut	O
microbiota	O
signal	O
to	O
the	O
mitochondria	O
of	O
mucosal	O
cells	O
,	O
including	O
epithelial	O
cells	O
and	O
immune	O
cells	O
.	O

Gut	O
microbiota	O
signaling	O
to	O
mitochondria	O
has	O
been	O
shown	O
to	O
alter	O
mitochondrial	O
metabolism	O
,	O
activate	O
immune	O
cells	O
,	O
induce	O
inflammasome	O
signaling	O
,	O
and	O
alter	O
epithelial	O
barrier	O
function	O
.	O

Both	O
dysbiosis	O
of	O
the	O
gut	O
microbiota	O
and	O
mitochondrial	O
dysfunction	O
are	O
associated	O
with	O
chronic	O
intestinal	O
inflammation	O
and	O
CRC	O
.	O

This	O
review	O
discusses	O
mitochondrial	O
metabolism	O
of	O
gut	O
mucosal	O
cells	O
,	O
mitochondrial	O
dysfunction	O
,	O
and	O
known	O
gut	O
microbiota	O
-	O
mediated	O
mitochondrial	O
alterations	O
during	O
IBD	O
and	O
CRC	O
.	O

Sucrose	O
6	O
(	O
F	O
)	O
-	O
phosphate	O
phosphorylase	O
:	O
a	O
novel	O
insight	O
in	O
the	O
human	O
gut	O
microbiome	O
.	O

The	O
human	O
gut	O
microbiome	O
plays	O
an	O
essential	O
role	O
in	O
maintaining	O
human	O
health	O
including	O
in	O
degradation	O
of	O
dietary	O
fibres	O
and	O
carbohydrates	O
further	O
used	O
as	O
nutrients	O
by	O
both	O
the	O
host	O
and	O
the	O
gut	O
bacteria	O
.	O

Previously	O
,	O
we	O
identified	O
a	O
polysaccharide	O
utilization	O
loci	O
(	O
PUL	O
)	O
involved	O
in	O
sucrose	O
and	O
raffinose	O
family	O
oligosaccharide	O
(	O
RFO	O
)	O
metabolism	O
from	O
one	O
of	O
the	O
most	O
common	O
Firmicutes	B-bacteria
present	O
in	O
individuals	O
,	O
Ruminococcus	B-bacteria
gnavus	I-bacteria
E1	I-bacteria
.	O

One	O
of	O
the	O
enzymes	O
encoded	O
by	O
this	O
PUL	O
was	O
annotated	O
as	O
a	O
putative	O
sucrose	O
phosphate	O
phosphorylase	O
(	O
RgSPP	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
in	O
-	O
depth	O
characterized	O
the	O
heterologously	O
expressed	O
RgSPP	O
as	O
sucrose	O
6	O
(	O
F	O
)	O
-	O
phosphate	O
phosphorylase	O
(	O
SPP	O
)	O
,	O
expanding	O
our	O
knowledge	O
of	O
the	O
glycoside	O
hydrolase	O
GH13	O
_	O
18	O
subfamily	O
.	O

Specifically	O
,	O
the	O
enzymatic	O
characterization	O
showed	O
a	O
selective	O
activity	O
on	O
sucrose	O
6	O
(	O
F	O
)	O
-	O
phosphate	O
(	O
S6	O
(	O
F	O
)	O
P	O
)	O
acting	O
both	O
in	O
phosphorolysis	O
releasing	O
alpha	O
-	O
d	O
-	O
glucose	O
-	O
1	O
-	O
phosphate	O
(	O
G1P	O
)	O
and	O
alpha	O
-	O
d	O
-	O
fructose	O
-	O
6	O
-	O
phosphate	O
(	O
F6P	O
)	O
,	O
and	O
in	O
reverse	O
phosphorolysis	O
from	O
G1P	O
and	O
F6P	O
to	O
S6	O
(	O
F	O
)	O
P	O
.	O
Interestingly	O
,	O
such	O
a	O
SPP	O
activity	O
had	O
never	O
been	O
observed	O
in	O
gut	O
bacteria	O
before	O
.	O

In	O
addition	O
,	O
a	O
phylogenetic	O
and	O
synteny	O
analysis	O
showed	O
a	O
clustering	O
and	O
a	O
strictly	O
conserved	O
PUL	O
organization	O
specific	O
to	O
gut	O
bacteria	O
.	O

However	O
,	O
a	O
wide	O
prevalence	O
and	O
abundance	O
study	O
with	O
a	O
human	O
metagenomic	O
library	O
showed	O
a	O
correlation	O
between	O
SPP	O
activity	O
and	O
the	O
geographical	O
origin	O
of	O
the	O
individuals	O
and	O
,	O
thus	O
,	O
most	O
likely	O
linked	O
to	O
diet	O
.	O

Rgspp	O
gene	O
overexpression	O
has	O
been	O
observed	O
in	O
mice	O
fed	O
with	O
a	O
high	O
-	O
fat	O
diet	O
suggesting	O
,	O
as	O
observed	O
for	O
humans	O
,	O
that	O
intestine	O
lipid	O
and	O
carbohydrate	O
microbial	O
metabolisms	O
are	O
intertwined	O
.	O

Finally	O
,	O
based	O
on	O
the	O
genomic	O
environment	O
analysis	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
,	O
results	O
provide	O
new	O
insights	O
into	O
the	O
gut	O
microbiota	O
catabolism	O
of	O
sucrose	O
,	O
RFOs	O
and	O
S6	O
(	O
F	O
)	O
P	O
.	O

Camporidines	O
A	O
and	O
B	O
:	O
Antimetastatic	O
and	O
Anti	O
-	O
inflammatory	O
Polyketide	O
Alkaloids	O
from	O
a	O
Gut	O
Bacterium	O
of	O
Camponotus	O
kiusiuensis	O
.	O

Chemical	O
studies	O
of	O
gut	O
bacteria	O
of	O
the	O
carpenter	O
ant	O
Camponotus	O
kiusiuensis	O
led	O
to	O
the	O
discovery	O
of	O
two	O
new	O
alkaloids	O
,	O
camporidines	O
A	O
and	O
B	O
(	O
1	O
and	O
2	O
)	O
,	O
from	O
Streptomyces	B-bacteria
sp	I-bacteria
.	I-bacteria
STA1	I-bacteria
.	O

The	O
structures	O
of	O
1	O
and	O
2	O
were	O
established	O
as	O
new	O
polyketide	O
alkaloids	O
bearing	O
a	O
piperidine	O
-	O
cyclopentene	O
-	O
epoxide	O
6	O
/	O
5	O
/	O
3	O
tricyclic	O
system	O
based	O
on	O
NMR	O
spectroscopic	O
and	O
mass	O
spectrometric	O
analysis	O
.	O

The	O
relative	O
configurations	O
of	O
the	O
camporidines	O
were	O
determined	O
by	O
their	O
(	O
1	O
)	O
H	O
-	O
(	O
1	O
)	O
H	O
NOESY	O
/	O
ROESY	O
and	O
1D	O
NOE	O
NMR	O
correlations	O
.	O

The	O
experimental	O
ECD	O
spectra	O
of	O
1	O
and	O
2	O
were	O
compared	O
with	O
their	O
calculated	O
ECD	O
spectra	O
to	O
assign	O
their	O
absolute	O
configurations	O
.	O

Camporidine	O
A	O
(	O
1	O
)	O
displayed	O
antimetastatic	O
activity	O
by	O
suppression	O
of	O
cell	O
invasion	O
against	O
the	O
metastatic	O
breast	O
cancer	O
cell	O
line	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
showed	O
an	O
anti	O
-	O
inflammatory	O
effect	O
by	O
suppressing	O
nitric	O
oxide	O
production	O
induced	O
by	O
lipopolysaccharide	O
.	O

In	O
addition	O
,	O
the	O
putative	O
biosynthetic	O
gene	O
cluster	O
of	O
the	O
camporidines	O
was	O
identified	O
,	O
and	O
the	O
biosynthetic	O
pathway	O
of	O
the	O
camporidines	O
was	O
proposed	O
based	O
on	O
bioinformatic	O
analysis	O
of	O
the	O
full	O
genome	O
of	O
Streptomyces	B-bacteria
sp	I-bacteria
.	I-bacteria
STA1	I-bacteria
.	O

Camporidines	O
A	O
and	O
B	O
(	O
1	O
and	O
2	O
)	O
could	O
be	O
biosynthesized	O
by	O
a	O
modular	O
type	O
I	O
PKS	O
containing	O
an	O
acyl	O
transferase	O
domain	O
that	O
accepts	O
an	O
unusual	O
extender	O
unit	O
,	O
which	O
becomes	O
the	O
(	O
C1	O
'	O
-	O
C6	O
'	O
)	O
hexyl	O
side	O
chain	O
.	O

The	O
post	O
-	O
PKS	O
modification	O
enzymes	O
were	O
predicted	O
to	O
perform	O
an	O
amination	O
and	O
an	O
oxidation	O
along	O
with	O
spontaneous	O
Schiff	O
base	O
formation	O
and	O
generate	O
the	O
unique	O
piperidine	O
-	O
cyclopentene	O
-	O
epoxide	O
6	O
/	O
5	O
/	O
3	O
tricyclic	O
framework	O
.	O

Importance	O
of	O
probiotics	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
colorectal	O
cancer	O
.	O

Colorectal	O
cancer	O
(	O
CRC	O
)	O
remains	O
one	O
of	O
the	O
most	O
common	O
and	O
deadly	O
cancers	O
.	O

Intestinal	O
gut	O
microflora	O
is	O
important	O
to	O
maintain	O
and	O
contributes	O
to	O
several	O
intestinal	O
functions	O
,	O
including	O
the	O
development	O
of	O
the	O
mucosal	O
immune	O
system	O
,	O
absorption	O
of	O
complex	O
macromolecules	O
,	O
synthesis	O
of	O
amino	O
acids	O
/	O
vitamins	O
and	O
the	O
protection	O
against	O
pathogenic	O
microorganisms	O
.	O

It	O
is	O
well	O
known	O
that	O
the	O
gut	O
microbiota	O
changes	O
or	O
dysbiosis	O
may	O
have	O
an	O
essential	O
impact	O
in	O
the	O
initiation	O
and	O
promotion	O
of	O
chronic	O
inflammatory	O
pathways	O
and	O
also	O
have	O
a	O
profound	O
different	O
genetic	O
and	O
epigenetic	O
alterations	O
leading	O
to	O
dysplasia	O
,	O
clonal	O
expansion	O
,	O
and	O
malignant	O
transformation	O
.	O

Probiotic	O
bacteria	O
has	O
antitumor	O
activity	O
with	O
various	O
mechanisms	O
such	O
as	O
nonspecific	O
physiological	O
and	O
immunological	O
mechanisms	O
.	O

This	O
review	O
evaluates	O
the	O
effects	O
of	O
microbiota	O
and	O
probiotics	O
in	O
clinical	O
trials	O
,	O
in	O
vitro	O
and	O
animal	O
model	O
studies	O
that	O
have	O
explored	O
how	O
probiotic	O
against	O
cancer	O
development	O
and	O
also	O
discusses	O
the	O
possible	O
immunomodulatory	O
mechanisms	O
.	O

Several	O
mechanisms	O
alteration	O
of	O
the	O
intestinal	O
microflora	O
;	O
inactivation	O
of	O
cancerogenic	O
compounds	O
;	O
competition	O
with	O
putrefactive	O
and	O
pathogenic	O
microbiota	O
;	O
improvement	O
of	O
the	O
host	O
'	O
s	O
immune	O
response	O
;	O
antiproliferative	O
effects	O
via	O
regulation	O
of	O
apoptosis	O
and	O
cell	O
differentiation	O
;	O
fermentation	O
of	O
undigested	O
food	O
;	O
inhibition	O
of	O
tyrosine	O
kinase	O
;	O
reduces	O
the	O
enteropathogenic	O
complications	O
before	O
and	O
after	O
colon	O
cancer	O
surgery	O
and	O
improve	O
diarrhea	O
and	O
it	O
'	O
s	O
have	O
been	O
able	O
to	O
create	O
the	O
integrity	O
of	O
gut	O
mucosal	O
and	O
have	O
stimulatory	O
effects	O
on	O
the	O
systemic	O
immune	O
system	O
and	O
prevent	O
the	O
CRC	O
metastasis	O
.	O

Research	O
in	O
clinical	O
trials	O
encouraging	O
findings	O
that	O
support	O
a	O
role	O
of	O
probiotics	O
in	O
CRC	O
prevention	O
and	O
improve	O
the	O
safety	O
and	O
effectiveness	O
of	O
cancer	O
therapy	O
even	O
though	O
additional	O
clinical	O
research	O
is	O
still	O
necessary	O
.	O

Inter	O
-	O
kingdom	O
signaling	O
between	O
gut	O
microbiota	O
and	O
their	O
host	O
.	O

The	O
crosstalk	O
between	O
prokaryotic	O
bacteria	O
and	O
eukaryotic	O
gut	O
epithelial	O
cells	O
has	O
opened	O
a	O
new	O
field	O
for	O
research	O
.	O

Quorum	O
sensing	O
system	O
(	O
QS	O
)	O
molecules	O
employed	O
by	O
gut	O
microbiota	O
may	O
play	O
an	O
essential	O
role	O
in	O
host	O
-	O
microbial	O
symbioses	O
of	O
the	O
gut	O
.	O

Recent	O
studies	O
on	O
the	O
gut	O
microbiome	O
will	O
unveil	O
evolved	O
mechanisms	O
of	O
the	O
host	O
to	O
affect	O
bacterial	O
QS	O
and	O
shape	O
bacterial	O
composition	O
.	O

Bacterial	O
autoinducers	O
(	O
AIs	O
)	O
could	O
talk	O
to	O
the	O
host	O
'	O
s	O
gut	O
by	O
eliciting	O
proinflammatory	O
effects	O
and	O
modulating	O
the	O
activities	O
of	O
T	O
lymphocyte	O
,	O
macrophage	O
,	O
dendritic	O
cells	O
,	O
and	O
neutrophils	O
.	O

In	O
addition	O
,	O
the	O
gut	O
mucosa	O
could	O
interfere	O
with	O
bacterial	O
AIs	O
by	O
degrading	O
them	O
or	O
secreting	O
AI	O
mimics	O
.	O

Moreover	O
,	O
bacterial	O
AIs	O
and	O
gut	O
hormones	O
epinephrine	O
and	O
noradrenaline	O
may	O
be	O
interchangeable	O
in	O
the	O
crosstalk	O
between	O
the	O
microbiota	O
and	O
human	O
gut	O
.	O

Therefore	O
,	O
inter	O
-	O
kingdom	O
signaling	O
between	O
gut	O
microbiota	O
and	O
host	O
may	O
provide	O
a	O
novel	O
target	O
in	O
the	O
management	O
of	O
gut	O
microbiota	O
-	O
related	O
conditions	O
or	O
diseases	O
in	O
the	O
future	O
.	O

Can	O
oral	O
bacteria	O
affect	O
the	O
microbiome	O
of	O
the	O
gut	O
?	O

Oral	O
bacteria	O
spreading	O
through	O
the	O
body	O
have	O
been	O
associated	O
with	O
a	O
number	O
of	O
systemic	O
diseases	O
.	O

The	O
gut	O
is	O
no	O
exception	O
.	O

Studies	O
in	O
animals	O
and	O
man	O
have	O
indicated	O
that	O
oral	O
bacteria	O
can	O
translocate	O
to	O
the	O
gut	O
and	O
change	O
its	O
microbiota	O
and	O
possibly	O
immune	O
defense	O
.	O

The	O
ectopic	O
displacement	O
of	O
oral	O
bacteria	O
particularly	O
occurs	O
in	O
severe	O
systemic	O
diseases	O
,	O
but	O
also	O
in	O
patients	O
with	O
`	O
`	O
chronic	O
'	O
'	O
periodontitis	O
.	O

Thus	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
which	O
creates	O
dysbiosis	O
in	O
the	O
subgingival	O
microbiota	O
and	O
immune	O
defense	O
,	O
may	O
also	O
cause	O
dysregulation	O
in	O
the	O
gut	O
.	O

A	O
dysbiotic	O
gut	O
microbiota	O
may	O
cause	O
diseases	O
elsewhere	O
in	O
the	O
body	O
.	O

The	O
fact	O
that	O
`	O
`	O
chronic	O
'	O
'	O
periodontitis	O
may	O
affect	O
the	O
gut	O
microbiota	O
could	O
imply	O
that	O
consideration	O
might	O
in	O
the	O
future	O
be	O
given	O
to	O
a	O
coordinated	O
approach	O
to	O
the	O
treatment	O
of	O
periodontitis	O
and	O
gastrointestinal	O
disease	O
.	O

This	O
area	O
of	O
investigation	O
,	O
which	O
is	O
in	O
its	O
infancy	O
,	O
may	O
represent	O
another	O
pathway	O
for	O
oral	O
bacteria	O
to	O
cause	O
systemic	O
diseases	O
and	O
deserves	O
more	O
research	O
.	O

Endogenous	O
Enterobacteriaceae	B-bacteria
underlie	O
variation	O
in	O
susceptibility	O
to	O
Salmonella	B-bacteria
infection	O
.	O

Lack	O
of	O
reproducibility	O
is	O
a	O
prominent	O
problem	O
in	O
biomedical	O
research	O
.	O

An	O
important	O
source	O
of	O
variation	O
in	O
animal	O
experiments	O
is	O
the	O
microbiome	O
,	O
but	O
little	O
is	O
known	O
about	O
specific	O
changes	O
in	O
the	O
microbiota	O
composition	O
that	O
cause	O
phenotypic	O
differences	O
.	O

Here	O
,	O
we	O
show	O
that	O
genetically	O
similar	O
laboratory	O
mice	O
obtained	O
from	O
four	O
different	O
commercial	O
vendors	O
exhibited	O
marked	O
phenotypic	O
variation	O
in	O
their	O
susceptibility	O
to	O
Salmonella	B-bacteria
infection	O
.	O

Faecal	O
microbiota	O
transplant	O
into	O
germ	O
-	O
free	O
mice	O
replicated	O
donor	O
susceptibility	O
,	O
revealing	O
that	O
variability	O
was	O
due	O
to	O
changes	O
in	O
the	O
gut	O
microbiota	O
composition	O
.	O

Co	O
-	O
housing	O
of	O
mice	O
only	O
partially	O
transferred	O
protection	O
against	O
Salmonella	B-bacteria
infection	O
,	O
suggesting	O
that	O
minority	O
species	O
within	O
the	O
gut	O
microbiota	O
might	O
confer	O
this	O
trait	O
.	O

Consistent	O
with	O
this	O
idea	O
,	O
we	O
identified	O
endogenous	O
Enterobacteriaceae	B-bacteria
,	O
a	O
low	O
-	O
abundance	O
taxon	O
,	O
as	O
a	O
keystone	O
species	O
responsible	O
for	O
variation	O
in	O
the	O
susceptibility	O
to	O
Salmonella	B-bacteria
infection	O
.	O

Protection	O
conferred	O
by	O
endogenous	O
Enterobacteriaceae	B-bacteria
could	O
be	O
modelled	O
by	O
inoculating	O
mice	O
with	O
probiotic	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
which	O
conferred	O
resistance	O
by	O
using	O
its	O
aerobic	O
metabolism	O
to	O
compete	O
with	O
Salmonella	B-bacteria
for	O
resources	O
.	O

We	O
conclude	O
that	O
a	O
mechanistic	O
understanding	O
of	O
phenotypic	O
variation	O
can	O
accelerate	O
development	O
of	O
strategies	O
for	O
enhancing	O
the	O
reproducibility	O
of	O
animal	O
experiments	O
.	O

Increased	O
expression	O
of	O
IL	O
-	O
32	O
correlates	O
with	O
IFN	O
-	O
gamma	O
,	O
Th1	O
and	O
Tc1	O
in	O
virologically	O
suppressed	O
HIV	O
-	O
1	O
-	O
infected	O
patients	O
.	O

Following	O
recent	O
attention	O
focused	O
on	O
IL	O
-	O
32	O
as	O
an	O
important	O
component	O
involved	O
in	O
the	O
inflammatory	O
cytokine	O
network	O
,	O
we	O
speculated	O
that	O
IL	O
-	O
32	O
'	O
s	O
action	O
on	O
IFN	O
-	O
gamma	O
and	O
IFN	O
-	O
gamma	O
secreting	O
T	O
cell	O
subsets	O
may	O
help	O
sustain	O
the	O
immune	O
activation	O
and	O
dysregulation	O
found	O
in	O
patients	O
with	O
HIV	O
-	O
1	O
achieving	O
viral	O
suppression	O
.	O

To	O
explore	O
this	O
hypothesis	O
,	O
transcript	O
levels	O
of	O
IL	O
-	O
32	O
and	O
IFN	O
-	O
gamma	O
were	O
evaluated	O
in	O
PBMC	O
from	O
139	O
virologically	O
suppressed	O
HIV	O
-	O
1	O
-	O
infected	O
patients	O
and	O
from	O
63	O
healthy	O
individuals	O
by	O
Real	O
Time	O
RT	O
-	O
PCR	O
assays	O
.	O

IL	O
-	O
32	O
and	O
IFN	O
-	O
gamma	O
mRNA	O
levels	O
were	O
also	O
analyzed	O
in	O
CD4	O
+	O
T	O
cells	O
,	O
CD14	O
+	O
monocytes	O
and	O
lamina	O
propria	O
lymphocytes	O
(	O
LPL	O
)	O
of	O
the	O
gut	O
district	O
in	O
a	O
subgroup	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
subjects	O
.	O

IFN	O
-	O
gamma	O
secreting	O
CD4	O
+	O
(	O
Th1	O
)	O
and	O
CD8	O
+	O
(	O
Tc1	O
)	O
T	O
cell	O
subset	O
frequencies	O
were	O
evaluated	O
in	O
LPL	O
by	O
multiparametric	O
flow	O
cytometry	O
.	O

Gene	O
expression	O
results	O
revealed	O
that	O
IL	O
-	O
32	O
and	O
IFN	O
-	O
gamma	O
levels	O
in	O
PBMC	O
from	O
HIV	O
-	O
1	O
-	O
positive	O
patients	O
were	O
significantly	O
elevated	O
compared	O
to	O
those	O
from	O
healthy	O
donors	O
,	O
correlated	O
with	O
each	O
other	O
and	O
increased	O
with	O
patient	O
age	O
.	O

Both	O
IL	O
-	O
32	O
and	O
IFN	O
-	O
gamma	O
genes	O
were	O
also	O
more	O
strongly	O
expressed	O
in	O
CD4	O
+	O
T	O
cells	O
than	O
in	O
CD14	O
+	O
monocytes	O
.	O

By	O
contrast	O
,	O
IL	O
-	O
32	O
levels	O
in	O
LPL	O
were	O
comparable	O
to	O
those	O
measured	O
in	O
PBMC	O
,	O
while	O
IFN	O
-	O
gamma	O
levels	O
were	O
higher	O
in	O
PBMC	O
than	O
those	O
in	O
LPL	O
.	O

Negative	O
correlations	O
were	O
found	O
between	O
IL	O
-	O
32	O
levels	O
and	O
the	O
frequencies	O
of	O
Th1	O
and	O
Tc1	O
subsets	O
in	O
gut	O
mucosa	O
.	O

Collectively	O
,	O
our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
IL	O
-	O
32	O
levels	O
remain	O
elevated	O
in	O
treated	O
HIV	O
-	O
1	O
-	O
infected	O
patients	O
and	O
correlate	O
with	O
IFN	O
-	O
gamma	O
,	O
Th1	O
and	O
Tc1	O
subsets	O
.	O

Targeted	O
interplay	O
between	O
bacterial	O
pathogens	O
and	O
host	O
autophagy	O
.	O

Due	O
to	O
the	O
critical	O
role	O
played	O
by	O
autophagy	O
in	O
pathogen	O
clearance	O
,	O
pathogens	O
have	O
developed	O
diverse	O
strategies	O
to	O
subvert	O
it	O
.	O

Despite	O
previous	O
key	O
findings	O
of	O
bacteria	O
-	O
autophagy	O
interplay	O
,	O
asystems	O
-	O
level	O
insight	O
into	O
selective	O
targeting	O
by	O
the	O
host	O
and	O
autophagy	O
modulation	O
by	O
the	O
pathogens	O
is	O
lacking	O
.	O

We	O
predicted	O
potential	O
interactions	O
between	O
human	O
autophagy	O
proteins	O
and	O
effector	O
proteins	O
from	O
56	O
pathogenic	O
bacterial	O
species	O
by	O
identifying	O
bacterial	O
proteins	O
predicted	O
to	O
have	O
recognition	O
motifs	O
for	O
selective	O
autophagy	O
receptors	O
SQSTM1	O
/	O
p62	O
,	O
CALCOCO2	O
/	O
NDP52	O
and	O
MAP1LC3	O
/	O
LC3	O
.	O

Using	O
structure	O
-	O
based	O
interaction	O
prediction	O
,	O
we	O
identified	O
bacterial	O
proteins	O
capable	O
to	O
modify	O
core	O
autophagy	O
components	O
.	O

Our	O
analysis	O
revealed	O
that	O
autophagy	O
receptors	O
in	O
general	O
potentially	O
target	O
mostly	O
genus	O
-	O
specific	O
proteins	O
,	O
and	O
not	O
those	O
present	O
in	O
multiple	O
genera	O
.	O

The	O
complementarity	O
between	O
the	O
predicted	O
SQSTM1	O
/	O
p62	O
and	O
CALCOCO2	O
/	O
NDP52	O
targets	O
,	O
which	O
has	O
been	O
shown	O
for	O
Salmonella	B-bacteria
,	O
Listeria	B-bacteria
and	O
Shigella	B-bacteria
,	O
could	O
be	O
observed	O
across	O
other	O
pathogens	O
.	O

This	O
complementarity	O
potentially	O
leaves	O
the	O
host	O
more	O
susceptible	O
to	O
chronic	O
infections	O
upon	O
the	O
mutation	O
of	O
autophagy	O
receptors	O
.	O

Proteins	O
derived	O
from	O
enterotoxigenic	O
and	O
non	O
-	O
toxigenic	O
Bacillus	B-bacteria
outer	O
membrane	O
vesicles	O
indicated	O
that	O
autophagy	O
targets	O
pathogenic	O
proteins	O
rather	O
than	O
non	O
-	O
pathogenic	O
ones	O
.	O

We	O
also	O
observed	O
apathogen	O
-	O
specific	O
pattern	O
as	O
to	O
which	O
autophagy	O
phase	O
could	O
be	O
modulated	O
by	O
specific	O
genera	O
.	O

We	O
found	O
intriguing	O
examples	O
of	O
bacterial	O
proteins	O
that	O
could	O
modulate	O
autophagy	O
,	O
and	O
in	O
turn	O
being	O
targeted	O
by	O
autophagy	O
as	O
ahost	O
defense	O
mechanism	O
.	O

We	O
confirmed	O
experimentally	O
an	O
interplay	O
between	O
a	O
Salmonella	B-bacteria
protease	O
,	O
YhjJ	O
and	O
autophagy	O
.	O

Our	O
comparative	O
meta	O
-	O
analysis	O
points	O
out	O
key	O
commonalities	O
and	O
differences	O
in	O
how	O
pathogens	O
could	O
affect	O
autophagy	O
and	O
how	O
autophagy	O
potentially	O
recognizes	O
these	O
pathogenic	O
effectors	O
.	O

Abbreviations	O
:	O
ATG5	O
:	O
autophagy	O
related	O
5	O
;	O
CALCOCO2	O
/	O
NDP52	O
:	O
calcium	O
binding	O
and	O
coiled	O
-	O
coil	O
domain	O
2	O
;	O
GST	O
:	O
glutathione	O
S	O
-	O
transferase	O
;	O
LIR	O
:	O
MAP1LC3	O
/	O
LC3	O
-	O
interacting	O
region	O
;	O
MAP1LC3	O
/	O
LC3	O
:	O
microtubule	O
associated	O
protein	O
1	O
light	O
chain	O
3	O
alpha	O
;	O
OMV	O
:	O
outer	O
membrane	O
vesicles	O
;	O
SQSTM1	O
/	O
p62	O
:	O
sequestosome	O
1	O
;	O
SCV	O
:	O
Salmonella	B-bacteria
containing	O
vesicle	O
;	O
TECPR1	O
:	O
tectonin	O
beta	O
-	O
propeller	O
repeat	O
containing	O
1	O
;	O
YhjJ	O
:	O
hypothetical	O
zinc	O
-	O
protease	O
.	O

Improvement	O
of	O
Colonic	O
Immune	O
Function	O
with	O
Soy	O
Isoflavones	O
in	O
High	O
-	O
Fat	O
Diet	O
-	O
Induced	O
Obese	O
Rats	O
.	O

Background	O
:	O
The	O
damage	O
to	O
intestinal	O
barrier	O
function	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
obesity	O
and	O
associated	O
diseases	O
.	O

Soy	O
isoflavones	O
are	O
effective	O
natural	O
active	O
components	O
for	O
controlling	O
obesity	O
and	O
reducing	O
the	O
level	O
of	O
blood	O
lipid	O
.	O

Here	O
,	O
we	O
explored	O
whether	O
these	O
effects	O
of	O
soy	O
isoflavones	O
were	O
associated	O
with	O
the	O
intestinal	O
barrier	O
function	O
.	O

Methods	O
and	O
Results	O
:	O
The	O
obese	O
rat	O
models	O
were	O
established	O
by	O
high	O
fat	O
diet	O
feeding	O
.	O

Then	O
,	O
those	O
obese	O
rats	O
were	O
supplemented	O
with	O
soy	O
isoflavones	O
at	O
different	O
doses	O
for	O
4	O
weeks	O
.	O

Our	O
results	O
showed	O
that	O
obesity	O
induced	O
the	O
expressions	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
decreased	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
(	O
IL	O
-	O
10	O
)	O
expression	O
,	O
elevated	O
intestinal	O
permeability	O
,	O
altered	O
gut	O
microbiota	O
and	O
exacerbated	O
oxidative	O
damages	O
in	O
colon	O
.	O

The	O
administration	O
of	O
soy	O
isoflavones	O
reversed	O
these	O
changes	O
in	O
obese	O
rats	O
,	O
presenting	O
as	O
the	O
improvement	O
of	O
intestinal	O
immune	O
function	O
and	O
permeability	O
,	O
attenuation	O
of	O
oxidative	O
damage	O
,	O
increase	O
in	O
the	O
fraction	O
of	O
beneficial	O
bacteria	O
producing	O
short	O
-	O
chain	O
fatty	O
acids	O
and	O
short	O
-	O
chain	O
fatty	O
acid	O
production	O
,	O
and	O
reduction	O
in	O
harmful	O
bacteria	O
.	O

Furthermore	O
,	O
soy	O
isoflavones	O
blocked	O
the	O
expressions	O
of	O
TLR4	O
and	O
NF	O
-	O
kappaB	O
in	O
the	O
colons	O
of	O
the	O
obese	O
rats	O
.	O

Conclusions	O
:	O
Soy	O
isoflavones	O
could	O
improve	O
obesity	O
through	O
the	O
attenuation	O
of	O
intestinal	O
oxidative	O
stress	O
,	O
recovery	O
of	O
immune	O
and	O
mucosal	O
barrier	O
,	O
as	O
well	O
as	O
re	O
-	O
balance	O
of	O
intestinal	O
gut	O
microbiota	O
.	O

The	O
deposit	O
feeder	O
Capitella	O
teleta	O
has	O
a	O
unique	O
and	O
relatively	O
complex	O
microbiome	O
likely	O
supporting	O
its	O
ability	O
to	O
degrade	O
pollutants	O
.	O

Capitella	O
teleta	O
is	O
a	O
sediment	O
-	O
dwelling	O
marine	O
polychaete	O
that	O
is	O
often	O
found	O
in	O
high	O
densities	O
in	O
association	O
with	O
organic	O
matter	O
and	O
pollutants	O
.	O

While	O
C	O
.	O
teleta	O
has	O
been	O
reported	O
to	O
transform	O
a	O
variety	O
of	O
aromatic	O
hydrocarbons	O
,	O
the	O
mechanisms	O
by	O
which	O
degradation	O
occurs	O
are	O
unknown	O
.	O

Moreover	O
,	O
there	O
is	O
continuing	O
debate	O
on	O
the	O
role	O
of	O
host	O
and	O
microbiota	O
in	O
degradation	O
activity	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
characterize	O
the	O
gut	O
microbiome	O
of	O
C	O
.	O
teleta	O
and	O
to	O
identify	O
microbiota	O
that	O
could	O
potentially	O
play	O
a	O
role	O
in	O
degradation	O
of	O
organic	O
matter	O
and	O
aromatic	O
hydrocarbons	O
.	O

Sequencing	O
analysis	O
of	O
the	O
16S	O
rRNA	O
genes	O
from	O
the	O
intestinal	O
tracts	O
of	O
adult	O
worms	O
revealed	O
a	O
unique	O
microbiome	O
that	O
was	O
distinct	O
from	O
that	O
of	O
the	O
worm	O
'	O
s	O
sediment	O
food	O
source	O
and	O
fecal	O
pellets	O
.	O

About	O
66	O
%	O
of	O
the	O
775	O
identified	O
OTUs	O
from	O
the	O
C	O
.	O
teleta	O
gut	O
microbiome	O
were	O
found	O
to	O
be	O
unique	O
to	O
the	O
worm	O
and	O
displayed	O
high	O
inter	O
-	O
individual	O
variability	O
.	O

The	O
gut	O
microbiome	O
was	O
dominated	O
by	O
members	O
of	O
the	O
genera	O
Arcobacter	B-bacteria
,	O
Pseudoalteromonas	B-bacteria
,	O
Methylobacterium	B-bacteria
,	O
and	O
Propionibacterium	B-bacteria
.	O

Functional	O
analyses	O
of	O
microbiota	O
revealed	O
that	O
hydrocarbon	O
treatment	O
led	O
to	O
a	O
proliferation	O
of	O
gene	O
classes	O
involved	O
in	O
chemoheterotrophy	O
and	O
aromatic	O
compound	O
degradation	O
.	O

Of	O
the	O
18	O
most	O
abundant	O
taxa	O
identified	O
,	O
50	O
%	O
were	O
members	O
of	O
genera	O
containing	O
hydrocarbon	O
(	O
PAH	O
)	O
-	O
degrading	O
members	O
,	O
including	O
Acinetobacter	B-bacteria
,	O
Thalassotalea	B-bacteria
,	O
and	O
Achromobacter	B-bacteria
.	O

Data	O
obtained	O
in	O
this	O
study	O
will	O
be	O
useful	O
to	O
understand	O
the	O
biology	O
of	O
this	O
marine	O
polychaete	O
and	O
to	O
elucidate	O
the	O
role	O
that	O
gut	O
bacteria	O
play	O
in	O
worm	O
catabolism	O
and	O
the	O
transformation	O
of	O
sediment	O
organic	O
pollutants	O
.	O

Microbiota	O
of	O
newborn	O
meconium	O
is	O
associated	O
with	O
maternal	O
anxiety	O
experienced	O
during	O
pregnancy	O
.	O

Little	O
is	O
known	O
about	O
whether	O
a	O
mother	O
'	O
s	O
psychological	O
state	O
during	O
pregnancy	O
influences	O
her	O
offspring	O
'	O
s	O
microbiome	O
.	O

This	O
study	O
examined	O
whether	O
maternal	O
anxiety	O
,	O
depression	O
,	O
and	O
stress	O
during	O
pregnancy	O
is	O
associated	O
with	O
the	O
diversity	O
of	O
meconium	O
microbiome	O
,	O
the	O
first	O
internal	O
discharge	O
,	O
in	O
75	O
newborns	O
from	O
an	O
existing	O
birth	O
cohort	O
study	O
.	O

The	O
meconium	O
microbiome	O
was	O
profiled	O
using	O
multibarcode16S	O
rRNA	O
sequencing	O
at	O
V3	O
-	O
V4	O
hypervariable	O
region	O
followed	O
by	O
taxonomic	O
assignment	O
to	O
the	O
green	O
gene	O
16S	O
references	O
at	O
97	O
%	O
similarity	O
and	O
diversity	O
analysis	O
at	O
the	O
genus	O
level	O
.	O

Results	O
showed	O
that	O
the	O
meconium	O
contained	O
diversified	O
microbiota	O
,	O
and	O
greater	O
pregnancy	O
-	O
related	O
anxiety	O
was	O
significantly	O
associated	O
with	O
a	O
less	O
diverse	O
meconium	O
microbiota	O
community	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

At	O
the	O
specific	O
taxa	O
level	O
,	O
greater	O
pregnancy	O
-	O
related	O
anxiety	O
was	O
correlated	O
with	O
a	O
lower	O
level	O
of	O
the	O
Enterococcaceae	B-bacteria
family	I-bacteria
(	O
p	O
=	O
2e	O
-	O
4	O
,	O
Spearman	O
rho	O
=	O
-	O
0	O
.	O
43	O
)	O
.	O

These	O
findings	O
support	O
a	O
significant	O
role	O
of	O
prenatal	O
maternal	O
mood	O
in	O
the	O
early	O
-	O
life	O
bacteria	O
colonization	O
of	O
their	O
offspring	O
.	O

Scalable	O
nonlinear	O
programming	O
framework	O
for	O
parameter	O
estimation	O
in	O
dynamic	O
biological	O
system	O
models	O
.	O

We	O
present	O
a	O
nonlinear	O
programming	O
(	O
NLP	O
)	O
framework	O
for	O
the	O
scalable	O
solution	O
of	O
parameter	O
estimation	O
problems	O
that	O
arise	O
in	O
dynamic	O
modeling	O
of	O
biological	O
systems	O
.	O

Such	O
problems	O
are	O
computationally	O
challenging	O
because	O
they	O
often	O
involve	O
highly	O
nonlinear	O
and	O
stiff	O
differential	O
equations	O
as	O
well	O
as	O
many	O
experimental	O
data	O
sets	O
and	O
parameters	O
.	O

The	O
proposed	O
framework	O
uses	O
cutting	O
-	O
edge	O
modeling	O
and	O
solution	O
tools	O
which	O
are	O
computationally	O
efficient	O
,	O
robust	O
,	O
and	O
easy	O
-	O
to	O
-	O
use	O
.	O

Specifically	O
,	O
our	O
framework	O
uses	O
a	O
time	O
discretization	O
approach	O
that	O
:	O
i	O
)	O
avoids	O
repetitive	O
simulations	O
of	O
the	O
dynamic	O
model	O
,	O
ii	O
)	O
enables	O
fully	O
algebraic	O
model	O
implementations	O
and	O
computation	O
of	O
derivatives	O
,	O
and	O
iii	O
)	O
enables	O
the	O
use	O
of	O
computationally	O
efficient	O
nonlinear	O
interior	O
point	O
solvers	O
that	O
exploit	O
sparse	O
and	O
structured	O
linear	O
algebra	O
techniques	O
.	O

We	O
demonstrate	O
these	O
capabilities	O
by	O
solving	O
estimation	O
problems	O
for	O
synthetic	O
human	O
gut	O
microbiome	O
community	O
models	O
.	O

We	O
show	O
that	O
an	O
instance	O
with	O
156	O
parameters	O
,	O
144	O
differential	O
equations	O
,	O
and	O
1	O
,	O
704	O
experimental	O
data	O
points	O
can	O
be	O
solved	O
in	O
less	O
than	O
3	O
minutes	O
using	O
our	O
proposed	O
framework	O
(	O
while	O
an	O
off	O
-	O
the	O
-	O
shelf	O
simulation	O
-	O
based	O
solution	O
framework	O
requires	O
over	O
7	O
hours	O
)	O
.	O

We	O
also	O
create	O
large	O
instances	O
to	O
show	O
that	O
the	O
proposed	O
framework	O
is	O
scalable	O
and	O
can	O
solve	O
problems	O
with	O
up	O
to	O
2	O
,	O
352	O
parameters	O
,	O
2	O
,	O
304	O
differential	O
equations	O
,	O
and	O
20	O
,	O
352	O
data	O
points	O
in	O
less	O
than	O
15	O
minutes	O
.	O

The	O
proposed	O
framework	O
is	O
flexible	O
and	O
easy	O
-	O
to	O
-	O
use	O
,	O
can	O
be	O
broadly	O
applied	O
to	O
dynamic	O
models	O
of	O
biological	O
systems	O
,	O
and	O
enables	O
the	O
implementation	O
of	O
sophisticated	O
estimation	O
techniques	O
to	O
quantify	O
parameter	O
uncertainty	O
,	O
to	O
diagnose	O
observability	O
/	O
uniqueness	O
issues	O
,	O
to	O
perform	O
model	O
selection	O
,	O
and	O
to	O
handle	O
outliers	O
.	O

Optimal	O
Dietary	O
Ferulic	O
Acid	O
for	O
Suppressing	O
the	O
Obesity	O
-	O
Related	O
Disorders	O
in	O
Leptin	O
-	O
Deficient	O
Obese	O
C57BL	O
/	O
6J	O
-	O
ob	O
/	O
ob	O
Mice	O
.	O

Ferulic	O
acid	O
(	O
FA	O
)	O
is	O
a	O
major	O
polyphenolic	O
compound	O
and	O
has	O
been	O
shown	O
to	O
improve	O
the	O
glucose	O
and	O
lipid	O
homeostasis	O
in	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obese	O
mice	O
.	O

Here	O
,	O
we	O
found	O
the	O
optimal	O
level	O
of	O
dietary	O
FA	O
to	O
ameliorate	O
obesity	O
and	O
obesity	O
-	O
correlated	O
disorders	O
,	O
and	O
identified	O
the	O
responses	O
of	O
gut	O
microbiota	O
to	O
dietary	O
FA	O
in	O
genetic	O
leptin	O
-	O
deficient	O
obese	O
(	O
ob	O
/	O
ob	O
)	O
mice	O
.	O

The	O
ob	O
/	O
ob	O
mice	O
exhibited	O
persistent	O
higher	O
body	O
weights	O
,	O
feed	O
efficiency	O
,	O
white	O
adipose	O
tissue	O
weights	O
,	O
and	O
hepatic	O
lipid	O
accumulation	O
,	O
compared	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
mice	O
.	O

However	O
,	O
0	O
.	O
5	O
%	O
dietary	O
FA	O
suppressed	O
these	O
symptoms	O
in	O
ob	O
/	O
ob	O
mice	O
.	O

The	O
diversity	O
of	O
gut	O
microbiota	O
and	O
the	O
total	O
abundance	O
of	O
obesity	O
-	O
and	O
anti	O
-	O
obesity	O
-	O
related	O
genera	O
were	O
not	O
influenced	O
after	O
FA	O
intervention	O
in	O
ob	O
/	O
ob	O
mice	O
.	O

These	O
data	O
suggest	O
that	O
sufficient	O
intake	O
of	O
FA	O
(	O
0	O
.	O
5	O
%	O
)	O
could	O
be	O
useful	O
for	O
treating	O
obesity	O
or	O
obesity	O
-	O
related	O
diseases	O
,	O
and	O
this	O
weight	O
-	O
control	O
effect	O
is	O
possibly	O
not	O
correlated	O
with	O
the	O
gut	O
-	O
brain	O
axis	O
.	O

Advances	O
in	O
understanding	O
the	O
molecular	O
mechanisms	O
of	O
venous	O
thrombosis	O
.	O

Venous	O
thromboembolism	O
(	O
VTE	O
)	O
represents	O
a	O
leading	O
cause	O
of	O
global	O
mortality	O
,	O
however	O
,	O
the	O
determinants	O
that	O
contribute	O
to	O
thrombus	O
development	O
remain	O
incompletely	O
understood	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
role	O
of	O
inherited	O
abnormalities	O
of	O
blood	O
coagulation	O
in	O
VTE	O
pathogenesis	O
.	O

In	O
addition	O
,	O
we	O
also	O
consider	O
recent	O
emerging	O
data	O
suggesting	O
other	O
molecular	O
and	O
cellular	O
determinants	O
may	O
also	O
contribute	O
.	O

Specifically	O
,	O
we	O
describe	O
the	O
role	O
played	O
by	O
the	O
inflamed	O
endothelium	O
,	O
and	O
the	O
dysregulated	O
responses	O
to	O
inflammatory	O
stimuli	O
that	O
create	O
a	O
platform	O
for	O
pathological	O
clot	O
formation	O
.	O

We	O
review	O
the	O
accumulating	O
evidence	O
that	O
blood	O
cells	O
,	O
contact	O
pathway	O
factors	O
and	O
protein	O
disulphide	O
isomerases	O
all	O
play	O
key	O
roles	O
in	O
VTE	O
development	O
.	O

Finally	O
,	O
we	O
discuss	O
new	O
insights	O
into	O
the	O
role	O
of	O
metabolites	O
arising	O
from	O
commensal	O
gut	O
bacteria	O
and	O
their	O
potential	O
role	O
in	O
facilitating	O
VTE	O
.	O

This	O
overview	O
provides	O
an	O
update	O
on	O
these	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
developments	O
and	O
the	O
opportunities	O
they	O
provide	O
for	O
new	O
antithrombotic	O
therapies	O
with	O
enhanced	O
efficacy	O
and	O
improved	O
safety	O
profiles	O
.	O

Pro	O
-	O
tumoral	O
role	O
of	O
gut	O
bacteria	O
:	O
sabotaging	O
immune	O
cell	O
recruitment	O
.	O

Interplay	O
between	O
heat	O
shock	O
proteins	O
,	O
inflammation	O
and	O
cancer	O
:	O
a	O
potential	O
cancer	O
therapeutic	O
target	O
.	O

The	O
historical	O
relationship	O
between	O
cancer	O
and	O
inflammation	O
has	O
long	O
been	O
evaluated	O
,	O
and	O
dates	O
back	O
to	O
the	O
early	O
work	O
of	O
Virchow	O
(	O
1863	O
)	O
,	O
where	O
he	O
hypothesised	O
that	O
chronic	O
inflammation	O
as	O
a	O
direct	O
cause	O
of	O
tissue	O
injury	O
and	O
infection	O
,	O
could	O
actually	O
promote	O
tissue	O
proliferation	O
.	O

At	O
that	O
period	O
in	O
time	O
however	O
,	O
the	O
exact	O
mechanisms	O
that	O
mediated	O
this	O
relationship	O
were	O
little	O
understood	O
.	O

Subsequent	O
studies	O
have	O
since	O
then	O
demonstrated	O
that	O
chronic	O
inflammation	O
plays	O
significant	O
roles	O
in	O
microenvironments	O
,	O
mostly	O
in	O
the	O
progression	O
of	O
tumours	O
,	O
probably	O
,	O
through	O
over	O
-	O
secretion	O
of	O
proinflammatory	O
cytokines	O
and	O
other	O
immune	O
-	O
killing	O
apparatus	O
such	O
as	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
which	O
cause	O
damage	O
to	O
normal	O
cells	O
leading	O
to	O
DNA	O
damage	O
and	O
increased	O
cellular	O
mutation	O
rates	O
.	O

Recently	O
,	O
the	O
identification	O
of	O
DNA	O
lesion	O
5	O
-	O
chlorocytosine	O
(	O
5	O
-	O
CIC	O
)	O
created	O
by	O
hypochlorous	O
acid	O
(	O
HOCl	O
)	O
secreted	O
to	O
nullify	O
or	O
kill	O
infectious	O
agents	O
and	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
-	O
mediated	O
chronic	O
inflammation	O
in	O
the	O
human	O
gut	O
,	O
has	O
become	O
the	O
latest	O
evidence	O
linking	O
inflammation	O
directly	O
to	O
cancer	O
.	O

The	O
key	O
to	O
cellular	O
survival	O
and	O
adaptation	O
under	O
unfavourable	O
or	O
pathological	O
conditions	O
is	O
the	O
expression	O
of	O
heat	O
shock	O
proteins	O
(	O
HSPs	O
)	O
also	O
called	O
molecular	O
chaperones	O
.	O

These	O
proteins	O
play	O
essential	O
roles	O
in	O
DNA	O
repair	O
processes	O
by	O
maintaining	O
membrane	O
integrity	O
,	O
orderliness	O
and	O
stability	O
of	O
client	O
proteins	O
that	O
play	O
prominent	O
roles	O
in	O
DNA	O
repair	O
mechanisms	O
.	O

More	O
so	O
,	O
HSPs	O
have	O
also	O
been	O
shown	O
to	O
modulate	O
the	O
effects	O
of	O
pro	O
-	O
inflammatory	O
/	O
apoptotic	O
cytokines	O
through	O
the	O
inhibition	O
of	O
cascades	O
leading	O
to	O
the	O
generation	O
of	O
ROS	O
-	O
mediated	O
DNA	O
damage	O
,	O
while	O
promoting	O
the	O
DNA	O
repair	O
mechanism	O
,	O
thus	O
playing	O
prominent	O
roles	O
in	O
various	O
stages	O
of	O
DNA	O
repair	O
and	O
cancer	O
progression	O
.	O

Hence	O
,	O
studies	O
targeting	O
HSPs	O
and	O
their	O
inhibitors	O
in	O
inflammation	O
,	O
DNA	O
damage	O
,	O
and	O
repair	O
,	O
could	O
improve	O
current	O
cancer	O
therapeutic	O
efficiency	O
.	O

Here	O
the	O
focus	O
will	O
be	O
on	O
the	O
relationship	O
between	O
HSPs	O
,	O
inflammation	O
and	O
cancer	O
,	O
as	O
well	O
as	O
roles	O
of	O
HSPs	O
in	O
DNA	O
damage	O
response	O
(	O
DDR	O
)	O
.	O

Breastmilk	O
and	O
NICU	O
surfaces	O
are	O
potential	O
sources	O
of	O
fungi	O
for	O
infant	O
mycobiomes	O
.	O

Surfaces	O
within	O
the	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
,	O
especially	O
those	O
handled	O
frequently	O
by	O
hospital	O
staff	O
,	O
provide	O
sources	O
of	O
gut	O
-	O
colonizing	O
bacteria	O
for	O
hospitalized	O
infants	O
,	O
in	O
addition	O
to	O
those	O
acquired	O
perinatally	O
from	O
maternal	O
sources	O
such	O
as	O
breastmilk	O
.	O

In	O
comparison	O
to	O
bacteria	O
,	O
very	O
little	O
is	O
known	O
about	O
potential	O
sources	O
of	O
colonizing	O
fungi	O
in	O
the	O
NICU	O
setting	O
.	O

Thus	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
characterize	O
fungal	O
communities	O
(	O
mycobiomes	O
)	O
of	O
potential	O
colonization	O
sources	O
for	O
neonates	O
hospitalized	O
in	O
a	O
large	O
university	O
NICU	O
.	O

We	O
hypothesized	O
that	O
the	O
unit	O
surfaces	O
would	O
contain	O
different	O
mycobiomes	O
than	O
those	O
of	O
human	O
-	O
associated	O
(	O
breastmilk	O
)	O
sources	O
.	O

We	O
characterized	O
mycobiomes	O
of	O
NICU	O
surfaces	O
of	O
multiple	O
individual	O
patient	O
care	O
areas	O
as	O
well	O
as	O
those	O
of	O
breastmilk	O
samples	O
by	O
sequencing	O
the	O
internal	O
transcribed	O
spacer	O
region	O
2	O
(	O
ITS2	O
)	O
of	O
the	O
fungal	O
rDNA	O
locus	O
.	O

We	O
found	O
that	O
,	O
across	O
all	O
samples	O
,	O
Candida	O
and	O
Saccharomyces	O
species	O
were	O
the	O
most	O
prevalent	O
taxa	O
and	O
had	O
the	O
greatest	O
relative	O
abundances	O
.	O

Breastmilk	O
samples	O
had	O
significantly	O
higher	O
fungal	O
alpha	O
-	O
diversities	O
than	O
NICU	O
surface	O
samples	O
and	O
fungal	O
community	O
compositions	O
(	O
beta	O
diversities	O
)	O
differed	O
significantly	O
between	O
the	O
two	O
sample	O
types	O
.	O

Mycobiome	O
compositions	O
were	O
predominantly	O
driven	O
by	O
the	O
relative	O
abundances	O
of	O
three	O
fungal	O
taxa	O
:	O
Candida	O
albicans	O
,	O
Candida	O
parapsilosis	O
,	O
and	O
Saccharomyces	O
cerevisiae	O
.	O

In	O
total	O
,	O
21	O
individual	O
fungal	O
taxa	O
showed	O
significantly	O
greater	O
relative	O
abundances	O
in	O
breastmilk	O
as	O
compared	O
to	O
NICU	O
surfaces	O
,	O
with	O
three	O
being	O
of	O
particular	O
interest	O
to	O
human	O
health	O
:	O
Candida	O
glabrata	O
,	O
Candida	O
tropicalis	O
,	O
and	O
Cryptococcus	B-bacteria
neoformans	I-bacteria
.	O

Since	O
no	O
fungal	O
DNA	O
was	O
detected	O
when	O
whole	O
breastmilk	O
was	O
used	O
as	O
the	O
DNA	O
template	O
,	O
as	O
opposed	O
to	O
breastmilk	O
subjected	O
to	O
cell	O
lysis	O
during	O
the	O
DNA	O
isolation	O
procedure	O
,	O
our	O
results	O
indicate	O
that	O
DNA	O
is	O
from	O
fungal	O
cells	O
and	O
is	O
not	O
cell	O
-	O
free	O
DNA	O
.	O

In	O
summary	O
,	O
both	O
NICU	O
surfaces	O
and	O
human	O
breastmilk	O
harbor	O
distinct	O
fungal	O
communities	O
that	O
could	O
provide	O
a	O
source	O
of	O
fungi	O
for	O
the	O
developing	O
infant	O
gut	O
mycobiota	O
.	O

In	O
particular	O
,	O
Candida	O
and	O
Saccharomyces	O
species	O
are	O
abundant	O
and	O
prevalent	O
for	O
both	O
of	O
these	O
potential	O
sources	O
that	O
infants	O
are	O
exposed	O
to	O
.	O

Editing	O
the	O
microbiome	O
the	O
CRISPR	O
way	O
.	O

Our	O
bodies	O
are	O
colonized	O
by	O
a	O
complex	O
ecosystem	O
of	O
bacteria	O
,	O
unicellular	O
eukaryotes	O
and	O
their	O
viruses	O
that	O
together	O
play	O
a	O
major	O
role	O
in	O
our	O
health	O
.	O

Over	O
the	O
past	O
few	O
years	O
tools	O
derived	O
from	O
the	O
prokaryotic	O
immune	O
system	O
known	O
as	O
CRISPR	O
-	O
Cas	O
have	O
empowered	O
researchers	O
to	O
modify	O
and	O
study	O
organisms	O
with	O
unprecedented	O
ease	O
and	O
efficiency	O
.	O

Here	O
we	O
discuss	O
how	O
various	O
types	O
of	O
CRISPR	O
-	O
Cas	O
systems	O
can	O
be	O
used	O
to	O
modify	O
the	O
genome	O
of	O
gut	O
microorganisms	O
and	O
bacteriophages	O
.	O

CRISPR	O
-	O
Cas	O
systems	O
can	O
also	O
be	O
delivered	O
to	O
bacterial	O
population	O
and	O
programmed	O
to	O
specifically	O
eliminate	O
members	O
of	O
the	O
microbiome	O
.	O

Finally	O
,	O
engineered	O
CRISPR	O
-	O
Cas	O
systems	O
can	O
be	O
used	O
to	O
control	O
gene	O
expression	O
and	O
modulate	O
the	O
production	O
of	O
metabolites	O
and	O
proteins	O
.	O

Together	O
these	O
tools	O
provide	O
exciting	O
opportunities	O
to	O
investigate	O
the	O
complex	O
interplay	O
between	O
members	O
of	O
the	O
microbiome	O
and	O
our	O
bodies	O
,	O
and	O
present	O
new	O
avenues	O
for	O
the	O
development	O
of	O
drugs	O
that	O
target	O
the	O
microbiome	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
discussion	O
meeting	O
issue	O
'	O
The	O
ecology	O
and	O
evolution	O
of	O
prokaryotic	O
CRISPR	O
-	O
Cas	O
adaptive	O
immune	O
systems	O
'	O
.	O

Increased	O
Cadmium	O
Excretion	O
Due	O
to	O
Oral	O
Administration	O
of	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
Strains	O
by	O
Regulating	O
Enterohepatic	O
Circulation	O
in	O
Mice	O
.	O

The	O
heavy	O
metal	O
cadmium	O
(	O
Cd	O
)	O
is	O
a	O
contaminant	O
widely	O
distributed	O
in	O
the	O
food	O
chain	O
.	O

In	O
the	O
present	O
study	O
,	O
8	O
-	O
week	O
oral	O
administration	O
of	O
a	O
probiotic	O
strain	O
,	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
CCFM8610	I-bacteria
,	O
markedly	O
decreased	O
blood	O
Cd	O
levels	O
in	O
volunteers	O
.	O

Further	O
animal	O
study	O
showed	O
that	O
three	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
strains	I-bacteria
administered	O
orally	O
exhibited	O
significantly	O
different	O
effects	O
on	O
the	O
regulation	O
of	O
bile	O
acid	O
(	O
BA	O
)	O
metabolism	O
and	O
Cd	O
excretion	O
in	O
mice	O
.	O

Among	O
the	O
strains	O
,	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
CCFM8610	I-bacteria
showed	O
the	O
most	O
significant	O
effects	O
on	O
enhancing	O
hepatic	O
BA	O
synthesis	O
,	O
biliary	O
glutathione	O
output	O
,	O
and	O
fecal	O
BA	O
excretion	O
.	O

Biliary	O
Cd	O
output	O
and	O
fecal	O
Cd	O
excretion	O
were	O
markedly	O
increased	O
after	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
CCFM8610	I-bacteria
administration	O
,	O
resulting	O
in	O
a	O
marked	O
reduction	O
in	O
tissue	O
Cd	O
levels	O
.	O

The	O
regulation	O
of	O
BA	O
homeostasis	O
and	O
Cd	O
excretion	O
was	O
due	O
to	O
the	O
suppression	O
of	O
the	O
enterohepatic	O
farnesoid	O
X	O
receptor	O
-	O
fibroblast	O
growth	O
factor	O
15	O
(	O
FXR	O
-	O
FGF15	O
)	O
axis	O
by	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
CCFM8610	I-bacteria
and	O
could	O
be	O
abolished	O
by	O
treatment	O
with	O
the	O
FXR	O
agonist	O
GW4064	O
.	O

The	O
regulatory	O
effects	O
were	O
also	O
related	O
to	O
the	O
gut	O
microbiota	O
,	O
as	O
antibiotic	O
pretreatment	O
reversed	O
L	O
.	O
plantarum	O
CCFM8610	O
-	O
induced	O
effects	O
in	O
BA	O
and	O
Cd	O
metabolism	O
.	O

Altered	O
diversity	O
and	O
composition	O
of	O
the	O
gut	O
microbiome	O
in	O
patients	O
with	O
cervical	O
cancer	O
.	O

Gut	O
microbiota	O
have	O
been	O
implicated	O
in	O
the	O
development	O
of	O
many	O
human	O
diseases	O
,	O
including	O
both	O
digestive	O
diseases	O
and	O
non	O
-	O
digestive	O
diseases	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
gut	O
bacteria	O
differed	O
in	O
cervical	O
cancer	O
(	O
CCa	O
)	O
patients	O
compared	O
with	O
healthy	O
controls	O
by	O
16S	O
rRNA	O
sequencing	O
analysis	O
.	O

Subjects	O
including	O
eight	O
CCa	O
and	O
five	O
healthy	O
controls	O
were	O
included	O
.	O

Microbiota	O
profiles	O
in	O
fecal	O
DNA	O
were	O
characterized	O
by	O
PCR	O
amplification	O
of	O
the	O
16S	O
rRNA	O
V4	O
variable	O
region	O
and	O
deep	O
sequencing	O
using	O
the	O
Illumina	O
HiSeq	O
platform	O
.	O

The	O
CCa	O
-	O
associated	O
gut	O
microbiota	O
had	O
an	O
increasing	O
trend	O
in	O
alpha	O
diversity	O
,	O
although	O
statistical	O
significance	O
was	O
not	O
reached	O
.	O

Inter	O
-	O
group	O
variability	O
in	O
community	O
structure	O
by	O
beta	O
diversity	O
analysis	O
showed	O
a	O
clear	O
separation	O
between	O
cancer	O
patients	O
and	O
healthy	O
controls	O
.	O

Gut	O
microbiota	O
profiles	O
were	O
different	O
between	O
patients	O
and	O
controls	O
;	O
namely	O
,	O
the	O
proportions	O
of	O
Proteobacteria	B-bacteria
phylum	I-bacteria
was	O
notably	O
higher	O
in	O
patients	O
with	O
CCa	O
(	O
rho	O
=	O
0	O
.	O
012	O
)	O
.	O

Seven	O
genera	O
differentiated	O
significantly	O
in	O
relative	O
abundance	O
between	O
CCa	O
and	O
controls	O
(	O
all	O
rho	O
<	O
0	O
.	O
05	O
)	O
,	O
including	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
,	O
Roseburia	B-bacteria
,	O
Pseudomonas	B-bacteria
,	O
Lachnoclostridium	B-bacteria
,	O
Lachnospiraceae	B-bacteria
_	I-bacteria
UCG	I-bacteria
-	I-bacteria
004	I-bacteria
,	O
Dorea	O
and	O
Succinivibrio	O
.	O

The	O
characteristic	O
microbiome	O
in	O
CCa	O
patients	O
was	O
also	O
identified	O
by	O
linear	O
discriminant	O
analysis	O
effect	O
size	O
(	O
LEfSe	O
)	O
.	O

The	O
phylum	O
Proteobacteria	B-bacteria
,	O
and	O
the	O
genus	O
Parabacteroides	B-bacteria
,	O
Escherichia	B-bacteria
_	I-bacteria
Shigells	I-bacteria
and	O
Roseburia	B-bacteria
may	O
provide	O
novel	O
potential	O
biomarkers	O
for	O
CCa	O
.	O

Taken	O
together	O
,	O
this	O
is	O
the	O
first	O
study	O
on	O
gut	O
microbiota	O
in	O
patients	O
with	O
CCa	O
,	O
and	O
demonstrated	O
the	O
significantly	O
altered	O
diversity	O
and	O
composition	O
.	O

Anesthesia	O
and	O
surgery	O
induce	O
cognitive	O
dysfunction	O
in	O
elderly	O
male	O
mice	O
:	O
the	O
role	O
of	O
gut	O
microbiota	O
.	O

It	O
is	O
well	O
known	O
that	O
the	O
incidence	O
of	O
postoperative	O
cognitive	O
dysfunction	O
(	O
POCD	O
)	O
is	O
high	O
in	O
elderly	O
patients	O
.	O

The	O
pathogenesis	O
and	O
therapeutic	O
mechanisms	O
of	O
POCD	O
,	O
however	O
,	O
have	O
not	O
yet	O
been	O
completely	O
elucidated	O
.	O

The	O
effects	O
of	O
gut	O
microbiota	O
,	O
particularly	O
in	O
terms	O
of	O
regulating	O
brain	O
function	O
,	O
have	O
gradually	O
attracted	O
increasing	O
attention	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
potential	O
role	O
of	O
gut	O
microbiota	O
in	O
POCD	O
in	O
aged	O
male	O
mice	O
and	O
attempted	O
to	O
determine	O
whether	O
alterations	O
in	O
gut	O
microbiota	O
would	O
be	O
helpful	O
in	O
the	O
diagnosis	O
of	O
POCD	O
.	O

POCD	O
and	O
non	O
-	O
POCD	O
mice	O
were	O
classified	O
by	O
hierarchical	O
cluster	O
analysis	O
of	O
behavioral	O
results	O
.	O

Additionally	O
,	O
alpha	O
-	O
and	O
beta	O
-	O
diversity	O
of	O
gut	O
microbiota	O
showed	O
a	O
differential	O
profile	O
between	O
the	O
groups	O
.	O

In	O
total	O
,	O
24	O
gut	O
bacteria	O
were	O
significantly	O
altered	O
in	O
POCD	O
mice	O
compared	O
with	O
those	O
in	O
non	O
-	O
POCD	O
mice	O
,	O
in	O
which	O
13	O
gut	O
bacteria	O
were	O
significantly	O
correlated	O
with	O
escape	O
latency	O
in	O
the	O
Morris	O
water	O
maze	O
test	O
(	O
MWMT	O
)	O
.	O

Remarkably	O
,	O
receiver	O
operating	O
characteristic	O
curves	O
revealed	O
that	O
the	O
Dehalobacteriaceae	B-bacteria
family	I-bacteria
and	O
Dehalobacterium	B-bacteria
genus	I-bacteria
are	O
potentially	O
important	O
bacteria	O
for	O
the	O
diagnosis	O
of	O
POCD	O
.	O

These	O
findings	O
indicate	O
that	O
alterations	O
in	O
the	O
composition	O
of	O
gut	O
microbiota	O
are	O
probably	O
involved	O
in	O
the	O
pathogenesis	O
of	O
POCD	O
in	O
aged	O
mice	O
.	O

Novel	O
therapeutic	O
strategies	O
regulating	O
specific	O
gut	O
bacteria	O
may	O
be	O
helpful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
POCD	O
.	O

Exposure	O
to	O
TiO2	O
nanoparticles	O
induces	O
shifts	O
in	O
the	O
microbiota	O
composition	O
of	O
Mytilus	B-bacteria
galloprovincialis	I-bacteria
hemolymph	O
.	O

It	O
is	O
now	O
recognized	O
that	O
host	O
microbiome	O
,	O
the	O
community	O
of	O
microorganisms	O
that	O
colonize	O
the	O
animal	O
body	O
(	O
e	O
.	O
g	O
.	O
microbiota	O
)	O
and	O
their	O
genomes	O
,	O
play	O
an	O
important	O
role	O
in	O
the	O
health	O
status	O
of	O
all	O
organisms	O
,	O
from	O
nutrient	O
processing	O
to	O
protection	O
from	O
disease	O
.	O

In	O
particular	O
,	O
the	O
complex	O
,	O
bilateral	O
interactions	O
between	O
the	O
host	O
innate	O
immune	O
system	O
and	O
the	O
microbiota	O
are	O
crucial	O
in	O
maintaining	O
whole	O
body	O
homeostasis	O
.	O

The	O
development	O
of	O
nanotechnology	O
is	O
raising	O
concern	O
on	O
the	O
potential	O
impact	O
of	O
nanoparticles	O
-	O
NPs	O
on	O
human	O
and	O
environmental	O
health	O
.	O

Titanium	O
dioxide	O
-	O
nTiO2	O
,	O
one	O
of	O
the	O
most	O
widely	O
NP	O
in	O
use	O
,	O
has	O
been	O
shown	O
to	O
affect	O
the	O
gut	O
microbiota	O
of	O
mammals	O
and	O
fish	O
,	O
as	O
well	O
as	O
to	O
potentially	O
alter	O
microbial	O
communities	O
.	O

In	O
the	O
marine	O
bivalve	O
Mytilus	B-bacteria
galloprovincialis	I-bacteria
,	O
nTiO2	O
has	O
been	O
previously	O
shown	O
to	O
interact	O
with	O
hemolymph	O
components	O
,	O
thus	O
resulting	O
in	O
immunomodulation	O
.	O

However	O
,	O
no	O
information	O
is	O
available	O
on	O
the	O
possible	O
impact	O
of	O
NPs	O
on	O
the	O
microbiome	O
of	O
marine	O
organisms	O
.	O

Bivalves	O
host	O
high	O
microbial	O
abundance	O
and	O
diversity	O
,	O
and	O
alteration	O
of	O
their	O
microbiota	O
,	O
in	O
both	O
tissues	O
and	O
hemolymph	O
,	O
in	O
response	O
to	O
stressful	O
conditions	O
has	O
been	O
linked	O
to	O
a	O
compromised	O
health	O
status	O
and	O
susceptibility	O
to	O
diseases	O
.	O

In	O
this	O
work	O
,	O
the	O
effects	O
of	O
nTiO2	O
exposure	O
(	O
100mug	O
/	O
L	O
,	O
4days	O
)	O
on	O
Mytilus	O
hemolymph	O
microbiota	O
were	O
investigated	O
by	O
16S	O
rRNA	O
gene	O
-	O
based	O
profiling	O
.	O

Immune	O
parameters	O
were	O
also	O
evaluated	O
.	O

Although	O
hemolymph	O
microbiota	O
of	O
control	O
and	O
nTiO2	O
-	O
treated	O
mussels	O
revealed	O
a	O
similar	O
core	O
composition	O
,	O
nTiO2	O
exposure	O
affected	O
the	O
abundance	O
of	O
different	O
genera	O
,	O
with	O
decreases	O
in	O
some	O
(	O
e	O
.	O
g	O
.	O
Shewanella	B-bacteria
,	O
Kistimonas	B-bacteria
,	O
Vibrio	B-bacteria
)	O
and	O
increases	O
in	O
others	O
(	O
e	O
.	O
g	O
.	O
Stenotrophomonas	B-bacteria
)	O
.	O

The	O
immunomodulatory	O
effects	O
of	O
nTiO2	O
were	O
confirmed	O
by	O
the	O
increase	O
in	O
the	O
bactericidal	O
activity	O
of	O
whole	O
hemolymph	O
.	O

These	O
represent	O
the	O
first	O
data	O
on	O
the	O
effects	O
of	O
NPs	O
on	O
the	O
microbiome	O
of	O
marine	O
invertebrates	O
,	O
and	O
suggest	O
that	O
the	O
shift	O
in	O
hemolymph	O
microbiome	O
composition	O
induced	O
by	O
nTiO2	O
may	O
result	O
from	O
the	O
interplay	O
between	O
the	O
microbiota	O
and	O
the	O
immune	O
system	O
.	O

Diet	O
-	O
induced	O
metabolic	O
changes	O
of	O
the	O
human	O
gut	O
microbiome	O
:	O
importance	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
methylamines	O
and	O
indoles	O
.	O

The	O
human	O
gut	O
is	O
a	O
home	O
for	O
more	O
than	O
100	O
trillion	O
bacteria	O
,	O
far	O
more	O
than	O
all	O
other	O
microbial	O
populations	O
resident	O
on	O
the	O
body	O
'	O
s	O
surface	O
.	O

The	O
human	O
gut	O
microbiome	O
is	O
considered	O
as	O
a	O
microbial	O
organ	O
symbiotically	O
operating	O
within	O
the	O
host	O
.	O

It	O
is	O
a	O
collection	O
of	O
different	O
cell	O
lineages	O
that	O
are	O
capable	O
of	O
communicating	O
with	O
each	O
other	O
and	O
the	O
host	O
and	O
has	O
an	O
ability	O
to	O
undergo	O
self	O
-	O
replication	O
for	O
its	O
repair	O
and	O
maintenance	O
.	O

As	O
the	O
gut	O
microbiota	O
is	O
involved	O
in	O
many	O
host	O
processes	O
including	O
growth	O
and	O
development	O
,	O
an	O
imbalance	O
in	O
its	O
ecological	O
composition	O
may	O
lead	O
to	O
disease	O
and	O
dysfunction	O
in	O
the	O
human	O
.	O

Gut	O
microbial	O
degradation	O
of	O
nutrients	O
produces	O
bioactive	O
metabolites	O
that	O
bind	O
target	O
receptors	O
,	O
activating	O
signalling	O
cascades	O
,	O
and	O
modulating	O
host	O
metabolism	O
.	O

This	O
review	O
covers	O
current	O
findings	O
on	O
the	O
nutritional	O
and	O
pharmacological	O
roles	O
of	O
selective	O
gut	O
microbial	O
metabolites	O
,	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
methylamines	O
and	O
indoles	O
,	O
as	O
well	O
as	O
discussing	O
nutritional	O
interventions	O
to	O
modulate	O
the	O
microbiome	O
.	O

Understanding	O
the	O
Link	O
Between	O
Gut	O
Microbiome	O
and	O
Urinary	O
Stone	O
Disease	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
With	O
recent	O
advances	O
in	O
sequencing	O
technologies	O
and	O
increasing	O
research	O
into	O
the	O
gut	O
microbiome	O
(	O
GMB	O
)	O
,	O
studies	O
have	O
revealed	O
associations	O
between	O
the	O
GMB	O
and	O
urinary	O
stone	O
disease	O
(	O
USD	O
)	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
the	O
evidence	O
pointed	O
towards	O
a	O
few	O
specific	O
gut	O
bacteria	O
or	O
the	O
broader	O
GMB	O
network	O
is	O
seemingly	O
responsible	O
for	O
this	O
relationship	O
.	O

RECENT	O
FINDINGS	O
:	O
Initially	O
,	O
Oxalobacter	B-bacteria
formigenes	I-bacteria
(	O
OF	O
)	O
was	O
pursued	O
as	O
the	O
main	O
link	O
between	O
GMB	O
and	O
USD	O
given	O
its	O
ability	O
to	O
degrade	O
oxalate	O
in	O
the	O
gut	O
.	O

However	O
,	O
the	O
latest	O
studies	O
consistently	O
suggest	O
that	O
the	O
entire	O
GMB	O
is	O
much	O
more	O
likely	O
to	O
be	O
involved	O
in	O
handling	O
oxalate	O
absorption	O
and	O
other	O
risk	O
factors	O
for	O
urinary	O
stone	O
formation	O
,	O
rather	O
than	O
just	O
a	O
few	O
microbiota	O
.	O

The	O
GMB	O
has	O
complex	O
networks	O
that	O
are	O
likely	O
involved	O
in	O
the	O
pathophysiology	O
of	O
USD	O
,	O
although	O
the	O
causal	O
mechanisms	O
remain	O
unclear	O
.	O

With	O
increasing	O
interest	O
and	O
research	O
,	O
potential	O
modalities	O
that	O
act	O
on	O
the	O
GMB	O
may	O
help	O
to	O
prevent	O
incidence	O
of	O
USD	O
.	O

Positive	O
effects	O
of	O
the	O
tea	O
catechin	O
(	O
-	O
)	O
-	O
epigallocatechin	O
-	O
3	O
-	O
gallate	O
on	O
gut	O
bacteria	O
and	O
fitness	O
of	O
Ectropis	O
obliqua	O
Prout	O
(	O
Lepidoptera	O
:	O
Geometridae	O
)	O
.	O

Ectropis	O
obliqua	O
Prout	O
(	O
Lepidoptera	O
:	O
Geometridae	O
)	O
is	O
the	O
most	O
devastating	O
insect	O
pest	O
of	O
tea	O
plants	O
in	O
China	O
and	O
infests	O
thousands	O
of	O
hectares	O
of	O
tea	O
plantations	O
in	O
China	O
annually	O
.	O

(	O
-	O
)	O
-	O
Epigallocatechin	O
-	O
3	O
-	O
gallate	O
(	O
EGCG	O
)	O
is	O
a	O
major	O
phenolic	O
compound	O
in	O
tea	O
leaves	O
and	O
has	O
a	O
strong	O
antibacterial	O
function	O
.	O

Here	O
,	O
we	O
show	O
that	O
EGCG	O
can	O
effectively	O
improve	O
the	O
fitness	O
of	O
E	B-bacteria
.	I-bacteria
obliqua	I-bacteria
larvae	O
and	O
present	O
the	O
reason	O
by	O
which	O
EGCG	O
promotes	O
larval	O
fitness	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
fitness	O
difference	O
among	O
Control	O
,	O
Antibiotic	O
and	O
Treatment	O
of	O
larvae	O
.	O

The	O
fitness	O
of	O
larvae	O
treated	O
with	O
EGCG	O
and	O
antibiotic	O
was	O
similar	O
and	O
better	O
than	O
that	O
of	O
control	O
group	O
.	O

We	O
also	O
demonstrated	O
that	O
EGCG	O
treatment	O
could	O
significantly	O
reduce	O
species	O
richness	O
and	O
abundance	O
of	O
gut	O
bacteria	O
in	O
E	B-bacteria
.	I-bacteria
obliqua	I-bacteria
larvae	O
.	O

Hence	O
that	O
we	O
speculate	O
that	O
EGCG	O
promotes	O
larval	O
fitness	O
and	O
is	O
associated	O
with	O
ECGG	O
antimicrobial	O
activity	O
.	O

In	O
short	O
,	O
our	O
study	O
provides	O
evidence	O
of	O
the	O
E	O
.	O
obliqua	O
larvae	O
have	O
adapted	O
to	O
secondary	O
compounds	O
found	O
in	O
tea	O
leaves	O
,	O
and	O
may	O
even	O
benefit	O
from	O
these	O
compounds	O
.	O

Our	O
study	O
also	O
contributes	O
to	O
a	O
greater	O
understanding	O
of	O
the	O
reason	O
involved	O
in	O
plant	O
-	O
insect	O
interactions	O
.	O

Drosophila	B-bacteria
Histone	O
Demethylase	O
KDM5	O
Regulates	O
Social	O
Behavior	O
through	O
Immune	O
Control	O
and	O
Gut	O
Microbiota	O
Maintenance	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
histone	O
demethylases	O
KDM5A	O
,	O
KDM5B	O
,	O
or	O
KDM5C	O
are	O
found	O
in	O
intellectual	O
disability	O
(	O
ID	O
)	O
and	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
patients	O
.	O

Here	O
,	O
we	O
use	O
the	O
model	O
organism	O
Drosophila	B-bacteria
melanogaster	I-bacteria
to	O
delineate	O
how	O
KDM5	O
contributes	O
to	O
ID	O
and	O
ASD	O
.	O

We	O
show	O
that	O
reducing	O
KDM5	O
causes	O
intestinal	O
barrier	O
dysfunction	O
and	O
changes	O
in	O
social	O
behavior	O
that	O
correlates	O
with	O
compositional	O
changes	O
in	O
the	O
gut	O
microbiota	O
.	O

Therapeutic	O
alteration	O
of	O
the	O
dysbiotic	O
microbiota	O
through	O
antibiotic	O
administration	O
or	O
feeding	O
with	O
a	O
probiotic	O
Lactobacillus	B-bacteria
strain	I-bacteria
partially	O
rescues	O
the	O
behavioral	O
,	O
lifespan	O
,	O
and	O
cellular	O
phenotypes	O
observed	O
in	O
kdm5	O
-	O
deficient	O
flies	O
.	O

Mechanistically	O
,	O
KDM5	O
was	O
found	O
to	O
transcriptionally	O
regulate	O
component	O
genes	O
of	O
the	O
immune	O
deficiency	O
(	O
IMD	O
)	O
signaling	O
pathway	O
and	O
subsequent	O
maintenance	O
of	O
host	O
-	O
commensal	O
bacteria	O
homeostasis	O
in	O
a	O
demethylase	O
-	O
dependent	O
manner	O
.	O

Together	O
,	O
our	O
study	O
uses	O
a	O
genetic	O
approach	O
to	O
dissect	O
the	O
role	O
of	O
KDM5	O
in	O
the	O
gut	O
-	O
microbiome	O
-	O
brain	O
axis	O
and	O
suggests	O
that	O
modifying	O
the	O
gut	O
microbiome	O
may	O
provide	O
therapeutic	O
benefits	O
for	O
ID	O
and	O
ASD	O
patients	O
.	O

Status	O
of	O
vaccine	O
research	O
and	O
development	O
for	O
Clostridium	B-bacteria
difficile	I-bacteria
.	O

Clostridium	B-bacteria
difficile	I-bacteria
associated	O
disease	O
is	O
fundamentally	O
associated	O
with	O
dysbiosis	O
of	O
the	O
gut	O
microbiome	O
as	O
a	O
consequence	O
of	O
antibiotic	O
use	O
.	O

This	O
is	O
because	O
this	O
sporulating	O
,	O
obligate	O
anaerobe	O
germinates	O
and	O
proliferates	O
rapidly	O
in	O
the	O
dysbiotic	O
gut	O
,	O
which	O
is	O
an	O
indirect	O
consequence	O
of	O
their	O
use	O
.	O

During	O
its	O
growth	O
,	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
produces	O
two	O
toxins	O
,	O
toxin	O
A	O
(	O
TcdA	O
)	O
and	O
toxin	O
B	O
(	O
TcdB	O
)	O
,	O
which	O
are	O
responsible	O
for	O
the	O
majority	O
of	O
clinical	O
symptoms	O
associated	O
with	O
the	O
disease	O
.	O

Three	O
parenterally	O
delivered	O
vaccines	O
,	O
based	O
on	O
detoxified	O
or	O
recombinant	O
forms	O
of	O
these	O
toxins	O
,	O
have	O
undergone	O
or	O
are	O
undergoing	O
clinical	O
trials	O
.	O

Each	O
offers	O
the	O
opportunity	O
to	O
generate	O
high	O
titres	O
of	O
toxin	O
neutralising	O
antibodies	O
.	O

Whilst	O
these	O
data	O
suggest	O
these	O
vaccines	O
may	O
reduce	O
primary	O
symptomatic	O
disease	O
,	O
they	O
do	O
not	O
in	O
their	O
current	O
form	O
reduce	O
the	O
capacity	O
of	O
the	O
organism	O
to	O
persist	O
and	O
shed	O
from	O
the	O
vaccinated	O
host	O
.	O

The	O
current	O
progress	O
of	O
vaccine	O
development	O
is	O
considered	O
with	O
advantages	O
and	O
limitations	O
of	O
each	O
highlighted	O
.	O

In	O
addition	O
,	O
several	O
alternative	O
approaches	O
are	O
described	O
that	O
seek	O
to	O
limit	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
germination	O
,	O
colonisation	O
and	O
persistence	O
.	O

It	O
may	O
yet	O
prove	O
that	O
the	O
most	O
effective	O
treatments	O
to	O
limit	O
infection	O
,	O
disease	O
and	O
spread	O
of	O
the	O
organism	O
will	O
require	O
a	O
combination	O
of	O
therapeutic	O
approaches	O
.	O

The	O
potential	O
use	O
and	O
efficacy	O
of	O
these	O
vaccines	O
in	O
low	O
and	O
middle	O
income	O
countries	O
will	O
be	O
depend	O
on	O
the	O
development	O
of	O
a	O
cost	O
effective	O
vaccine	O
and	O
greater	O
understanding	O
of	O
the	O
distribution	O
and	O
extent	O
of	O
disease	O
in	O
these	O
countries	O
.	O

Metaproteomic	O
and	O
16S	O
rRNA	O
Gene	O
Sequencing	O
Analysis	O
of	O
the	O
Infant	O
Fecal	O
Microbiome	O
.	O

A	O
metaproteomic	O
analysis	O
was	O
conducted	O
on	O
the	O
fecal	O
microbiome	O
of	O
eight	O
infants	O
to	O
characterize	O
global	O
protein	O
and	O
pathway	O
expression	O
.	O

Although	O
mass	O
spectrometry	O
-	O
based	O
proteomics	O
is	O
now	O
a	O
routine	O
tool	O
,	O
analysis	O
of	O
the	O
microbiome	O
presents	O
specific	O
technical	O
challenges	O
,	O
including	O
the	O
complexity	O
and	O
dynamic	O
range	O
of	O
member	O
taxa	O
,	O
the	O
need	O
for	O
well	O
-	O
annotated	O
metagenomic	O
databases	O
,	O
and	O
high	O
inter	O
-	O
protein	O
sequence	O
redundancy	O
and	O
similarity	O
.	O

In	O
this	O
study	O
,	O
an	O
approach	O
was	O
developed	O
for	O
assessment	O
of	O
biological	O
phenotype	O
and	O
metabolic	O
status	O
,	O
as	O
a	O
functional	O
complement	O
to	O
DNA	O
sequence	O
analysis	O
.	O

Fecal	O
samples	O
were	O
prepared	O
and	O
analysed	O
by	O
tandem	O
mass	O
spectrometry	O
and	O
a	O
homology	O
-	O
based	O
meta	O
-	O
clustering	O
strategy	O
was	O
used	O
to	O
combine	O
peptides	O
from	O
multiple	O
species	O
into	O
representative	O
proteins	O
.	O

In	O
total	O
,	O
15	O
,	O
250	O
unique	O
peptides	O
were	O
sequenced	O
and	O
assigned	O
to	O
2154	O
metaclusters	O
,	O
which	O
were	O
then	O
assigned	O
to	O
pathways	O
and	O
functional	O
groups	O
.	O

Differences	O
were	O
noted	O
in	O
several	O
pathways	O
,	O
consistent	O
with	O
the	O
dominant	O
genera	O
observed	O
in	O
different	O
subjects	O
.	O

Although	O
this	O
study	O
was	O
not	O
powered	O
to	O
draw	O
conclusions	O
from	O
the	O
comparisons	O
,	O
the	O
results	O
obtained	O
demonstrate	O
the	O
applicability	O
of	O
this	O
approach	O
and	O
provide	O
the	O
methods	O
needed	O
for	O
performing	O
semi	O
-	O
quantitative	O
comparisons	O
of	O
human	O
fecal	O
microbiome	O
composition	O
,	O
physiology	O
and	O
metabolism	O
,	O
as	O
well	O
as	O
a	O
more	O
detailed	O
assessment	O
of	O
microbial	O
composition	O
in	O
comparison	O
to	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

Autoimmunity	O
-	O
Associated	O
Gut	O
Commensals	O
Modulate	O
Gut	O
Permeability	O
and	O
Immunity	O
in	O
Humanized	O
Mice	O
.	O

OBJECTIVE	O
:	O
Although	O
the	O
etiology	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
unknown	O
,	O
recent	O
studies	O
have	O
led	O
to	O
the	O
concept	O
that	O
gut	O
dysbiosis	O
may	O
be	O
involved	O
in	O
onset	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
if	O
human	O
gut	O
commensals	O
modulate	O
the	O
immune	O
response	O
and	O
gut	O
epithelial	O
integrity	O
in	O
DQ8	O
mice	O
.	O

METHODS	O
:	O
DQ8	O
mice	O
were	O
orally	O
gavaged	O
with	O
RA	O
-	O
associated	O
(	O
Eggerthella	B-bacteria
lenta	I-bacteria
or	O
Collinsella	B-bacteria
aerofaciens	I-bacteria
)	O
and	O
non	O
-	O
associated	O
(	O
Prevotella	B-bacteria
histicola	I-bacteria
or	O
Bifidobacterium	B-bacteria
sp	I-bacteria
.	I-bacteria
)	O
on	O
alternate	O
days	O
for	O
1	O
week	O
in	O
naive	O
mice	O
.	O

Some	O
mice	O
were	O
immunized	O
with	O
type	O
II	O
collagen	O
and	O
oral	O
gavage	O
continued	O
for	O
6	O
weeks	O
and	O
followed	O
for	O
arthritis	O
.	O

Epithelial	O
integrity	O
was	O
done	O
by	O
FITC	O
-	O
Dextran	O
assay	O
.	O

In	O
addition	O
,	O
cytokines	O
were	O
measured	O
in	O
sera	O
by	O
ELISA	O
and	O
various	O
immune	O
cells	O
were	O
quantified	O
using	O
flow	O
cytometry	O
.	O

RESULTS	O
:	O
Gut	O
permeability	O
was	O
increased	O
by	O
the	O
RA	O
-	O
associated	O
bacteria	O
and	O
was	O
sex	O
and	O
age	O
-	O
dependent	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
observations	O
showed	O
that	O
the	O
RA	O
-	O
non	O
-	O
associated	O
bacteria	O
outgrow	O
the	O
RA	O
-	O
associated	O
bacteria	O
when	O
gavaged	O
or	O
cultured	O
together	O
.	O

Mice	O
gavaged	O
with	O
the	O
RA	O
-	O
non	O
-	O
associated	O
bacteria	O
produced	O
lower	O
levels	O
of	O
pro	O
-	O
inflammatory	O
MCP	O
-	O
1	O
and	O
MCP	O
-	O
3	O
and	O
had	O
lower	O
numbers	O
of	O
Inflammatory	O
monocytes	O
CD11c	O
+	O
Ly6c	O
+	O
,	O
when	O
compared	O
to	O
controls	O
.	O

E	B-bacteria
.	I-bacteria
lenta	I-bacteria
treated	O
naive	O
mice	O
produce	O
Th17	O
cytokines	O
.	O

CONCLUSIONS	O
:	O
Our	O
studies	O
suggest	O
that	O
gut	O
commensals	O
influence	O
immune	O
response	O
in	O
and	O
away	O
from	O
the	O
gut	O
by	O
changing	O
the	O
gut	O
permeability	O
and	O
immunity	O
.	O

Dysbiosis	O
helps	O
the	O
growth	O
of	O
RA	O
-	O
associated	O
bacteria	O
and	O
reduces	O
the	O
beneficial	O
bacteria	O
.	O

Comprehensive	O
Analysis	O
of	O
Serum	O
and	O
Fecal	O
Bile	O
Acid	O
Profiles	O
and	O
Interaction	O
with	O
Gut	O
Microbiota	O
in	O
Primary	O
Biliary	O
Cholangitis	O
.	O

Accumulation	O
of	O
bile	O
acids	O
(	O
BAs	O
)	O
contributes	O
significantly	O
to	O
the	O
pathogenesis	O
of	O
primary	O
biliary	O
cholangitis	O
(	O
PBC	O
)	O
.	O

Here	O
,	O
we	O
sought	O
to	O
systematically	O
characterize	O
the	O
serum	O
and	O
fecal	O
BA	O
profiles	O
and	O
the	O
linkage	O
between	O
BAs	O
and	O
gut	O
microbiota	O
in	O
PBC	O
.	O

The	O
serum	O
and	O
fecal	O
BAs	O
were	O
compared	O
between	O
65	O
UDCA	O
treatment	O
-	O
naive	O
PBC	O
and	O
109	O
healthy	O
controls	O
using	O
UPLC	O
-	O
MS	O
in	O
cross	O
-	O
sectional	O
study	O
.	O

In	O
a	O
prospective	O
study	O
,	O
a	O
subgroup	O
of	O
patients	O
was	O
enrolled	O
for	O
BA	O
and	O
microbiota	O
analysis	O
before	O
and	O
after	O
UDCA	O
therapy	O
.	O

BA	O
compositions	O
in	O
serum	O
and	O
feces	O
significantly	O
differed	O
between	O
treatment	O
-	O
naive	O
PBC	O
and	O
controls	O
.	O

Particularly	O
,	O
PBC	O
was	O
associated	O
with	O
decreased	O
conversions	O
of	O
conjugated	O
to	O
unconjugated	O
,	O
and	O
primary	O
to	O
secondary	O
BAs	O
,	O
indicating	O
impaired	O
microbial	O
metabolism	O
of	O
BAs	O
.	O

PBC	O
patients	O
at	O
advanced	O
stage	O
exhibited	O
a	O
more	O
abnormal	O
BA	O
profile	O
compared	O
with	O
early	O
-	O
stage	O
patients	O
.	O

UDCA	O
treatment	O
led	O
to	O
a	O
decreased	O
level	O
of	O
taurine	O
-	O
conjugated	O
BAs	O
,	O
thereby	O
reversing	O
the	O
conjugated	O
/	O
unconjugated	O
ratio	O
in	O
PBC	O
.	O

Moreover	O
,	O
the	O
level	O
of	O
secondary	O
BAs	O
such	O
as	O
DCA	O
and	O
conjugated	O
DCA	O
inversely	O
correlated	O
with	O
PBC	O
-	O
enriched	O
gut	O
microbes	O
(	O
e	O
.	O
g	O
.	O
,	O
Veillonella	B-bacteria
,	O
Klebsiella	B-bacteria
)	O
,	O
while	O
positively	O
correlated	O
with	O
control	O
-	O
enriched	O
microbes	O
(	O
e	O
.	O
g	O
.	O
,	O
Faecalibacterium	B-bacteria
,	O
Oscillospira	B-bacteria
)	O
.	O

Microbiota	O
analysis	O
also	O
revealed	O
a	O
significant	O
increase	O
of	O
taurine	O
-	O
metabolizing	O
bacteria	O
Bilophila	B-bacteria
spp	I-bacteria
.	I-bacteria
in	O
patients	O
after	O
UDCA	O
,	O
which	O
was	O
strongly	O
correlated	O
with	O
decreased	O
taurine	O
-	O
conjugated	O
BAs	O
.	O

In	O
addition	O
,	O
serum	O
FGF19	O
was	O
remarkably	O
increased	O
in	O
treatment	O
-	O
naive	O
PBC	O
and	O
decreased	O
after	O
UDCA	O
.	O

Our	O
study	O
established	O
specific	O
alterations	O
of	O
BA	O
compositions	O
in	O
serum	O
and	O
feces	O
of	O
PBC	O
,	O
suggesting	O
the	O
potential	O
for	O
using	O
BAs	O
for	O
diagnosis	O
,	O
and	O
highlighting	O
the	O
possibility	O
of	O
modulating	O
BA	O
profile	O
by	O
altering	O
gut	O
microbiota	O
.	O

Graphical	O
Abstract	O
.	O

Broiler	O
gut	O
microbiota	O
and	O
expressions	O
of	O
gut	O
barrier	O
genes	O
affected	O
by	O
cereal	O
type	O
and	O
phytogenic	O
inclusion	O
.	O

The	O
present	O
study	O
assessed	O
the	O
effects	O
of	O
cereal	O
type	O
and	O
the	O
inclusion	O
level	O
of	O
a	O
phytogenic	O
feed	O
additive	O
(	O
PFA	O
)	O
on	O
broiler	O
ileal	O
and	O
cecal	O
gut	O
microbiota	O
composition	O
,	O
volatile	O
fatty	O
acids	O
(	O
VFA	O
)	O
and	O
gene	O
expression	O
of	O
toll	O
like	O
receptors	O
(	O
TLR	O
)	O
,	O
tight	O
junction	O
proteins	O
,	O
mucin	O
2	O
(	O
MUC2	O
)	O
and	O
secretory	O
immunoglobulin	O
A	O
(	O
sIgA	O
)	O
.	O

Depending	O
on	O
cereal	O
type	O
(	O
i	O
.	O
e	O
.	O
maize	O
or	O
wheat	O
)	O
and	O
PFA	O
inclusion	O
level	O
(	O
i	O
.	O
e	O
.	O
0	O
,	O
100	O
and	O
150	O
mg	O
/	O
kg	O
diet	O
)	O
,	O
450	O
one	O
-	O
day	O
-	O
old	O
male	O
broilers	O
were	O
allocated	O
in	O
6	O
treatments	O
according	O
to	O
a	O
2	O
x	O
3	O
factorial	O
arrangement	O
with	O
5	O
replicates	O
of	O
15	O
broilers	O
each	O
,	O
for	O
42	O
d	O
.	O
Significant	O
interactions	O
(	O
P	O
<	O
/	O
=	O
0	O
.	O
05	O
)	O
between	O
cereal	O
type	O
and	O
PFA	O
were	O
shown	O
for	O
cecal	O
digesta	O
Bacteroides	B-bacteria
and	O
Clostridium	B-bacteria
cluster	I-bacteria
XIVa	I-bacteria
,	O
ileal	O
digesta	O
propionic	O
and	O
branched	O
VFA	O
,	O
ileal	O
sIgA	O
gene	O
expression	O
,	O
as	O
well	O
as	O
cecal	O
digesta	O
branched	O
and	O
other	O
VFA	O
molar	O
ratios	O
.	O

Cereal	O
type	O
affected	O
the	O
cecal	O
microbiota	O
composition	O
.	O

In	O
particular	O
,	O
wheat	O
-	O
fed	O
broilers	O
had	O
higher	O
levels	O
of	O
mucosa	O
-	O
associated	O
Lactobacillus	B-bacteria
(	O
P	O
CT	O
=	O
0	O
.	O
007	O
)	O
and	O
digesta	O
Bifidobacterium	B-bacteria
(	O
P	O
CT	O
<	O
0	O
.	O
001	O
)	O
,	O
as	O
well	O
as	O
lower	O
levels	O
of	O
total	O
bacteria	O
(	O
P	O
CT	O
=	O
0	O
.	O
004	O
)	O
and	O
Clostridia	B-bacteria
clusters	O
I	O
,	O
IV	O
and	O
XIVa	O
(	O
P	O
CT	O
<	O
/	O
=	O
0	O
.	O
05	O
)	O
,	O
compared	O
with	O
maize	O
-	O
fed	O
ones	O
.	O

In	O
addition	O
,	O
cereal	O
type	O
gave	O
differences	O
in	O
fermentation	O
intensity	O
(	O
P	O
CT	O
=	O
0	O
.	O
021	O
)	O
and	O
in	O
certain	O
individual	O
VFA	O
molar	O
ratios	O
.	O

Wheat	O
-	O
fed	O
broilers	O
had	O
higher	O
(	O
P	O
<	O
/	O
=	O
0	O
.	O
05	O
)	O
ileal	O
zonula	O
occluden	O
2	O
(	O
ZO	O
-	O
2	O
)	O
and	O
lower	O
ileal	O
and	O
cecal	O
TLR2	O
and	O
sIgA	O
levels	O
,	O
compared	O
with	O
maize	O
-	O
fed	O
broilers	O
.	O

On	O
the	O
other	O
hand	O
,	O
PFA	O
inclusion	O
at	O
150	O
mg	O
/	O
kg	O
had	O
a	O
stimulating	O
effect	O
on	O
microbial	O
fermentation	O
at	O
ileum	O
and	O
a	O
retarding	O
effect	O
in	O
ceca	O
with	O
additional	O
variable	O
VFA	O
molar	O
patterns	O
.	O

In	O
addition	O
,	O
PFA	O
inclusion	O
at	O
100	O
mg	O
/	O
kg	O
increased	O
the	O
ileal	O
mucosa	O
expression	O
of	O
claudin	O
5	O
(	O
CLDN5	O
)	O
(	O
P	O
PFA	O
=	O
0	O
.	O
023	O
)	O
and	O
MUC2	O
(	O
P	O
PFA	O
=	O
0	O
.	O
001	O
)	O
genes	O
,	O
and	O
at	O
150	O
mg	O
/	O
kg	O
decreased	O
cecal	O
TLR2	O
(	O
P	O
PFA	O
=	O
0	O
.	O
022	O
)	O
gene	O
expression	O
compared	O
with	O
the	O
un	O
-	O
supplemented	O
controls	O
.	O

In	O
conclusion	O
,	O
cereal	O
type	O
and	O
PFA	O
affected	O
in	O
combination	O
and	O
independently	O
broiler	O
gut	O
microbiota	O
composition	O
and	O
metabolic	O
activity	O
as	O
well	O
as	O
the	O
expression	O
of	O
critical	O
gut	O
barrier	O
genes	O
including	O
TLR2	O
.	O

Further	O
exploitation	O
of	O
these	O
properties	O
in	O
cases	O
of	O
stressor	O
challenges	O
is	O
warranted	O
.	O

Recent	O
advances	O
in	O
fermented	O
feeds	O
towards	O
improved	O
broiler	O
chicken	O
performance	O
,	O
gastrointestinal	O
tract	O
microecology	O
and	O
immune	O
responses	O
:	O
A	O
review	O
.	O

Previously	O
,	O
fermentation	O
has	O
been	O
associated	O
with	O
methods	O
that	O
improve	O
the	O
nutritional	O
value	O
of	O
unconventional	O
feed	O
ingredients	O
for	O
broilers	O
.	O

In	O
recent	O
decades	O
,	O
the	O
fermentation	O
process	O
has	O
been	O
employed	O
to	O
produce	O
functional	O
feeds	O
that	O
have	O
the	O
potential	O
to	O
improve	O
broiler	O
gastrointestinal	O
tract	O
microecology	O
,	O
health	O
and	O
production	O
performance	O
.	O

Some	O
of	O
the	O
functional	O
ingredients	O
found	O
in	O
fermented	O
feed	O
include	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
,	O
lactic	O
acid	O
and	O
other	O
organic	O
acids	O
,	O
and	O
appear	O
to	O
play	O
major	O
roles	O
in	O
determining	O
the	O
beneficial	O
effects	O
of	O
fermented	O
feed	O
on	O
broiler	O
gut	O
health	O
and	O
performance	O
.	O

Unlike	O
the	O
pig	O
,	O
the	O
available	O
literature	O
on	O
broiler	O
fermented	O
feed	O
is	O
still	O
rather	O
limited	O
.	O

This	O
review	O
describes	O
recent	O
advances	O
in	O
the	O
use	O
of	O
fermented	O
feed	O
(	O
on	O
the	O
basis	O
of	O
conventional	O
and	O
unconventional	O
feed	O
ingredients	O
)	O
in	O
broilers	O
.	O

Similarly	O
,	O
this	O
review	O
also	O
shows	O
that	O
additional	O
research	O
is	O
necessary	O
to	O
exploit	O
fermented	O
feed	O
as	O
a	O
viable	O
food	O
source	O
in	O
broiler	O
nutrition	O
.	O

Gut	O
microbiome	O
meta	O
-	O
analysis	O
reveals	O
dysbiosis	O
is	O
independent	O
of	O
body	O
mass	O
index	O
in	O
predicting	O
risk	O
of	O
obesity	O
-	O
associated	O
CRC	O
.	O

Objective	O
:	O
Obesity	O
is	O
a	O
risk	O
factor	O
for	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
,	O
accounting	O
for	O
more	O
than	O
14	O
%	O
of	O
CRC	O
incidence	O
.	O

Microbial	O
dysbiosis	O
and	O
chronic	O
inflammation	O
are	O
common	O
characteristics	O
in	O
both	O
obesity	O
and	O
CRC	O
.	O

Human	O
and	O
murine	O
studies	O
,	O
together	O
,	O
demonstrate	O
the	O
significant	O
impact	O
of	O
the	O
microbiome	O
in	O
governing	O
energy	O
metabolism	O
and	O
CRC	O
development	O
;	O
yet	O
,	O
little	O
is	O
understood	O
about	O
the	O
contribution	O
of	O
the	O
microbiome	O
to	O
development	O
of	O
obesity	O
-	O
associated	O
CRC	O
as	O
compared	O
to	O
individuals	O
who	O
are	O
not	O
obese	O
.	O

Design	O
:	O
In	O
this	O
study	O
,	O
we	O
conducted	O
a	O
meta	O
-	O
analysis	O
using	O
five	O
publicly	O
available	O
stool	O
and	O
tissue	O
-	O
based	O
16S	O
rRNA	O
and	O
whole	O
genome	O
sequencing	O
(	O
WGS	O
)	O
data	O
sets	O
of	O
CRC	O
microbiome	O
studies	O
.	O

High	O
-	O
resolution	O
analysis	O
was	O
employed	O
for	O
16S	O
rRNA	O
data	O
,	O
which	O
allowed	O
us	O
to	O
achieve	O
species	O
-	O
level	O
information	O
to	O
compare	O
with	O
WGS	O
.	O

Results	O
:	O
Characterisation	O
of	O
the	O
confounders	O
between	O
studies	O
,	O
16S	O
rRNA	O
variable	O
region	O
and	O
sequencing	O
method	O
did	O
not	O
reveal	O
any	O
significant	O
effect	O
on	O
alpha	O
diversity	O
in	O
CRC	O
prediction	O
.	O

Both	O
16S	O
rRNA	O
and	O
WGS	O
were	O
equally	O
variable	O
in	O
their	O
ability	O
to	O
predict	O
CRC	O
.	O

Results	O
from	O
diversity	O
analysis	O
confirmed	O
lower	O
diversity	O
in	O
obese	O
individuals	O
without	O
CRC	O
;	O
however	O
,	O
no	O
universal	O
differences	O
were	O
found	O
in	O
diversity	O
between	O
obese	O
and	O
non	O
-	O
obese	O
individuals	O
with	O
CRC	O
.	O

When	O
examining	O
taxonomic	O
differences	O
,	O
the	O
probability	O
of	O
being	O
classified	O
as	O
CRC	O
did	O
not	O
change	O
significantly	O
in	O
obese	O
individuals	O
for	O
all	O
taxa	O
tested	O
.	O

However	O
,	O
random	O
forest	O
classification	O
was	O
able	O
to	O
distinguish	O
CRC	O
and	O
non	O
-	O
CRC	O
stool	O
when	O
body	O
mass	O
index	O
was	O
added	O
to	O
the	O
model	O
.	O

Conclusion	O
:	O
Overall	O
,	O
microbial	O
dysbiosis	O
was	O
not	O
a	O
significant	O
factor	O
in	O
explaining	O
the	O
higher	O
risk	O
of	O
colon	O
cancer	O
among	O
individuals	O
with	O
obesity	O
.	O

Akkermansia	B-bacteria
muciniphila	I-bacteria
ameliorates	O
the	O
age	O
-	O
related	O
decline	O
in	O
colonic	O
mucus	O
thickness	O
and	O
attenuates	O
immune	O
activation	O
in	O
accelerated	O
aging	O
Ercc1	O
(	O
-	O
/	O
Delta7	O
)	O
mice	O
.	O

Background	O
:	O
The	O
use	O
of	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
as	O
potential	O
therapeutic	O
intervention	O
is	O
receiving	O
increasing	O
attention	O
.	O

Health	O
benefits	O
attributed	O
to	O
this	O
bacterium	O
include	O
an	O
improvement	O
of	O
metabolic	O
disorders	O
and	O
exerting	O
anti	O
-	O
inflammatory	O
effects	O
.	O

The	O
abundance	O
of	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
is	O
associated	O
with	O
a	O
healthy	O
gut	O
in	O
early	O
mid	O
-	O
and	O
later	O
life	O
.	O

However	O
,	O
the	O
effects	O
of	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
on	O
a	O
decline	O
in	O
intestinal	O
health	O
during	O
the	O
aging	O
process	O
are	O
not	O
investigated	O
yet	O
.	O

We	O
supplemented	O
accelerated	O
aging	O
Ercc1	O
(	O
-	O
/	O
Delta7	O
)	O
mice	O
with	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
for	O
10	O
weeks	O
and	O
investigated	O
histological	O
,	O
transcriptional	O
and	O
immunological	O
aspects	O
of	O
intestinal	O
health	O
.	O

Results	O
:	O
The	O
thickness	O
of	O
the	O
colonic	O
mucus	O
layer	O
increased	O
about	O
3	O
-	O
fold	O
after	O
long	O
-	O
term	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
supplementation	O
and	O
was	O
even	O
significantly	O
thicker	O
compared	O
to	O
mice	O
supplemented	O
with	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
WCFS1	I-bacteria
.	O

Colonic	O
gene	O
expression	O
profiles	O
pointed	O
towards	O
a	O
decreased	O
expression	O
of	O
genes	O
and	O
pathways	O
related	O
to	O
inflammation	O
and	O
immune	O
function	O
,	O
and	O
suggested	O
a	O
decreased	O
presence	O
of	O
B	O
cells	O
in	O
colon	O
.	O

Total	O
B	O
cell	O
frequencies	O
in	O
spleen	O
and	O
mesenteric	O
lymph	O
nodes	O
were	O
not	O
altered	O
after	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
supplementation	O
.	O

Mature	O
and	O
immature	O
B	O
cell	O
frequencies	O
in	O
bone	O
marrow	O
were	O
increased	O
,	O
whereas	O
B	O
cell	O
precursors	O
were	O
unaffected	O
.	O

These	O
findings	O
implicate	O
that	O
B	O
cell	O
migration	O
rather	O
than	O
production	O
was	O
affected	O
by	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
supplementation	O
.	O

Gene	O
expression	O
profiles	O
in	O
ileum	O
pointed	O
toward	O
a	O
decrease	O
in	O
metabolic	O
-	O
and	O
immune	O
-	O
related	O
processes	O
and	O
antimicrobial	O
peptide	O
production	O
after	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
supplementation	O
.	O

Besides	O
,	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
decreased	O
the	O
frequency	O
of	O
activated	O
CD80	O
(	O
+	O
)	O
CD273	O
(	O
-	O
)	O
B	O
cells	O
in	O
Peyer	O
'	O
s	O
patches	O
.	O

Additionally	O
,	O
the	O
increased	O
numbers	O
of	O
peritoneal	O
resident	O
macrophages	O
and	O
a	O
decrease	O
in	O
Ly6C	O
(	O
int	O
)	O
monocyte	O
frequencies	O
in	O
spleen	O
and	O
mesenteric	O
lymph	O
nodes	O
add	O
evidence	O
for	O
the	O
potentially	O
anti	O
-	O
inflammatory	O
properties	O
of	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
.	O

Conclusions	O
:	O
Altogether	O
,	O
we	O
show	O
that	O
supplementation	O
with	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
prevented	O
the	O
age	O
-	O
related	O
decline	O
in	O
thickness	O
of	O
the	O
colonic	O
mucus	O
layer	O
and	O
attenuated	O
inflammation	O
and	O
immune	O
-	O
related	O
processes	O
at	O
old	O
age	O
.	O

This	O
study	O
implies	O
that	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
supplementation	O
can	O
contribute	O
to	O
a	O
promotion	O
of	O
healthy	O
aging	O
.	O

Lactobacillus	B-bacteria
reuteri	I-bacteria
Reduces	O
the	O
Severity	O
of	O
Experimental	O
Autoimmune	O
Encephalomyelitis	O
in	O
Mice	O
by	O
Modulating	O
Gut	O
Microbiota	O
.	O

The	O
gut	O
microbiome	O
plays	O
an	O
important	O
role	O
in	O
immune	O
function	O
and	O
has	O
been	O
implicated	O
in	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

However	O
,	O
how	O
and	O
if	O
the	O
modulation	O
of	O
microbiota	O
can	O
prevent	O
or	O
treat	O
MS	O
remain	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
probiotic	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
DSM	I-bacteria
17938	I-bacteria
(	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
)	O
ameliorated	O
the	O
development	O
of	O
murine	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
,	O
a	O
widely	O
used	O
animal	O
model	O
of	O
MS	O
,	O
a	O
model	O
which	O
is	O
primarily	O
mediated	O
by	O
TH17	O
and	O
TH1	O
cells	O
.	O

We	O
discovered	O
that	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
treatment	O
reduced	O
TH1	O
/	O
TH17	O
cells	O
and	O
their	O
associated	O
cytokines	O
IFN	O
-	O
gamma	O
/	O
IL	O
-	O
17	O
in	O
EAE	O
mice	O
.	O

We	O
also	O
showed	O
that	O
the	O
loss	O
of	O
diversity	O
of	O
gut	O
microbiota	O
induced	O
by	O
EAE	O
was	O
largely	O
restored	O
by	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
treatment	O
.	O

Taxonomy	O
-	O
based	O
analysis	O
of	O
gut	O
microbiota	O
showed	O
that	O
three	O
`	O
`	O
beneficial	O
'	O
'	O
genera	O
Bifidobacterium	B-bacteria
,	O
Prevotella	B-bacteria
,	O
and	O
Lactobacillus	B-bacteria
were	O
negatively	O
correlated	O
with	O
EAE	O
clinical	O
severity	O
,	O
whereas	O
the	O
genera	O
Anaeroplasma	B-bacteria
,	O
Rikenellaceae	B-bacteria
,	O
and	O
Clostridium	B-bacteria
were	O
positively	O
correlated	O
with	O
disease	O
severity	O
.	O

Notably	O
,	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
treatment	O
coordinately	O
altered	O
the	O
relative	O
abundance	O
of	O
these	O
EAE	O
-	O
associated	O
taxa	O
.	O

In	O
conclusion	O
,	O
probiotic	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
changed	O
gut	O
microbiota	O
to	O
modulate	O
immune	O
responses	O
in	O
EAE	O
,	O
making	O
it	O
a	O
novel	O
candidate	O
in	O
future	O
studies	O
to	O
modify	O
the	O
severity	O
of	O
MS	O
.	O

Gut	O
microbiota	O
profile	O
in	O
children	O
affected	O
by	O
atopic	O
dermatitis	O
and	O
evaluation	O
of	O
intestinal	O
persistence	O
of	O
a	O
probiotic	O
mixture	O
.	O

Atopic	O
dermatitis	O
(	O
AD	O
)	O
has	O
been	O
hypothesised	O
to	O
be	O
associated	O
with	O
gut	O
microbiota	O
(	O
GM	O
)	O
composition	O
.	O

We	O
performed	O
a	O
comparative	O
study	O
of	O
the	O
GM	O
profile	O
of	O
19	O
AD	O
children	O
and	O
18	O
healthy	O
individuals	O
aimed	O
at	O
identifying	O
bacterial	O
biomarkers	O
associated	O
with	O
the	O
disease	O
.	O

The	O
effect	O
of	O
probiotic	O
intake	O
(	O
Bifidobacterium	B-bacteria
breve	I-bacteria
plus	O
Lactobacillus	B-bacteria
salivarius	I-bacteria
)	O
on	O
the	O
modulation	O
of	O
GM	O
and	O
the	O
probiotic	O
persistence	O
in	O
the	O
GM	O
were	O
also	O
evaluated	O
.	O

Faecal	O
samples	O
were	O
analysed	O
by	O
real	O
-	O
time	O
PCR	O
and	O
16S	O
rRNA	O
targeted	O
metagenomics	O
.	O

Although	O
the	O
probiotics	O
,	O
chosen	O
for	O
this	O
study	O
,	O
did	O
not	O
shape	O
the	O
entire	O
GM	O
profile	O
,	O
we	O
observed	O
the	O
ability	O
of	O
these	O
species	O
to	O
pass	O
through	O
the	O
gastrointestinal	O
tract	O
and	O
to	O
persist	O
(	O
only	O
B	B-bacteria
.	I-bacteria
breve	I-bacteria
)	O
in	O
the	O
GM	O
.	O

Moreover	O
,	O
the	O
GM	O
of	O
patients	O
compared	O
to	O
CTRLs	O
showed	O
a	O
dysbiotic	O
status	O
characterised	O
by	O
an	O
increase	O
of	O
Faecalibacterium	B-bacteria
,	O
Oscillospira	B-bacteria
,	O
Bacteroides	B-bacteria
,	O
Parabacteroides	B-bacteria
and	O
Sutterella	B-bacteria
and	O
a	O
reduction	O
of	O
short	O
-	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
-	O
producing	O
bacteria	O
(	O
i	O
.	O
e	O
.	O
,	O
Bifidobacterium	B-bacteria
,	O
Blautia	B-bacteria
,	O
Coprococcus	B-bacteria
,	O
Eubacterium	B-bacteria
and	O
Propionibacterium	B-bacteria
)	O
.	O

Taken	O
togheter	O
these	O
results	O
show	O
an	O
alteration	O
in	O
AD	O
microbiota	O
composition	O
with	O
the	O
depletion	O
or	O
absence	O
of	O
some	O
species	O
,	O
opening	O
the	O
way	O
to	O
future	O
probiotic	O
intervention	O
studies	O
.	O

Assessing	O
the	O
viability	O
of	O
transplanted	O
gut	O
microbiota	O
by	O
sequential	O
tagging	O
with	O
D	O
-	O
amino	O
acid	O
-	O
based	O
metabolic	O
probes	O
.	O

Currently	O
,	O
there	O
are	O
more	O
than	O
200	O
fecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
clinical	O
trials	O
worldwide	O
.	O

However	O
,	O
our	O
knowledge	O
of	O
this	O
microbial	O
therapy	O
is	O
still	O
limited	O
.	O

Here	O
we	O
develop	O
a	O
strategy	O
using	O
sequential	O
tagging	O
with	O
D	O
-	O
amino	O
acid	O
-	O
based	O
metabolic	O
probes	O
(	O
STAMP	O
)	O
for	O
assessing	O
the	O
viabilities	O
of	O
transplanted	O
microbiotas	O
.	O

A	O
fluorescent	O
D	O
-	O
amino	O
acid	O
(	O
FDAA	O
)	O
is	O
first	O
administered	O
to	O
donor	O
mice	O
to	O
metabolically	O
label	O
the	O
gut	O
microbiotas	O
in	O
vivo	O
.	O

The	O
labeled	O
microbiotas	O
are	O
transplanted	O
to	O
recipient	O
mice	O
,	O
which	O
receive	O
a	O
second	O
FDAA	O
with	O
a	O
different	O
color	O
.	O

The	O
surviving	O
transplants	O
should	O
incorporate	O
both	O
FDAAs	O
and	O
can	O
be	O
readily	O
distinguished	O
by	O
presenting	O
two	O
colors	O
simultaneously	O
.	O

Isolation	O
of	O
surviving	O
bacteria	O
and	O
16S	O
rDNA	O
sequencing	O
identify	O
several	O
enriched	O
genera	O
,	O
suggesting	O
the	O
importance	O
of	O
specific	O
bacteria	O
in	O
FMT	O
.	O

In	O
addition	O
,	O
using	O
STAMP	O
,	O
we	O
evaluate	O
the	O
effects	O
on	O
transplant	O
survival	O
of	O
pre	O
-	O
treating	O
recipients	O
using	O
different	O
antibiotics	O
.	O

We	O
propose	O
STAMP	O
as	O
a	O
versatile	O
tool	O
for	O
deciphering	O
the	O
complex	O
biology	O
of	O
FMT	O
,	O
and	O
potentially	O
improving	O
its	O
treatment	O
efficacy	O
.	O

Manipulation	O
of	O
gut	O
microbiota	O
blunts	O
the	O
ventilatory	O
response	O
to	O
hypercapnia	O
in	O
adult	O
rats	O
.	O

BACKGROUND	O
:	O
It	O
is	O
increasingly	O
evident	O
that	O
perturbations	O
to	O
the	O
diversity	O
and	O
composition	O
of	O
the	O
gut	O
microbiota	O
have	O
significant	O
consequences	O
for	O
the	O
regulation	O
of	O
integrative	O
physiological	O
systems	O
.	O

There	O
is	O
growing	O
interest	O
in	O
the	O
potential	O
contribution	O
of	O
microbiota	O
-	O
gut	O
-	O
brain	O
signalling	O
to	O
cardiorespiratory	O
control	O
in	O
health	O
and	O
disease	O
.	O

METHODS	O
:	O
In	O
adult	O
male	O
rats	O
,	O
we	O
sought	O
to	O
determine	O
the	O
cardiorespiratory	O
effects	O
of	O
manipulation	O
of	O
the	O
gut	O
microbiota	O
following	O
a	O
4	O
-	O
week	O
administration	O
of	O
a	O
cocktail	O
of	O
antibiotics	O
.	O

We	O
subsequently	O
explored	O
the	O
effects	O
of	O
administration	O
of	O
faecal	O
microbiota	O
from	O
pooled	O
control	O
(	O
vehicle	O
)	O
rat	O
faeces	O
,	O
given	O
by	O
gavage	O
to	O
vehicle	O
-	O
and	O
antibiotic	O
-	O
treated	O
rats	O
.	O

FINDINGS	O
:	O
Antibiotic	O
intervention	O
depressed	O
the	O
ventilatory	O
response	O
to	O
hypercapnic	O
stress	O
in	O
conscious	O
animals	O
,	O
owing	O
to	O
a	O
reduction	O
in	O
the	O
respiratory	O
frequency	O
response	O
to	O
carbon	O
dioxide	O
.	O

Baseline	O
frequency	O
,	O
respiratory	O
timing	O
variability	O
,	O
and	O
the	O
expression	O
of	O
apnoeas	O
and	O
sighs	O
were	O
normal	O
.	O

Microbiota	O
-	O
depleted	O
rats	O
had	O
decreased	O
systolic	O
blood	O
pressure	O
.	O

Faecal	O
microbial	O
transfer	O
to	O
vehicle	O
-	O
and	O
antibiotic	O
-	O
treated	O
animals	O
also	O
disrupted	O
the	O
gut	O
microbiota	O
composition	O
,	O
associated	O
with	O
depressed	O
ventilatory	O
responsiveness	O
to	O
hypercapnia	O
.	O

Chronic	O
antibiotic	O
intervention	O
or	O
faecal	O
microbial	O
transfer	O
both	O
caused	O
significant	O
disruptions	O
to	O
brainstem	O
monoamine	O
neurochemistry	O
,	O
with	O
increased	O
homovanillic	O
acid	O
:	O
dopamine	O
ratio	O
indicative	O
of	O
increased	O
dopamine	O
turnover	O
,	O
which	O
correlated	O
with	O
the	O
abundance	O
of	O
several	O
bacteria	O
of	O
six	O
different	O
phyla	O
.	O

INTERPRETATION	O
:	O
Chronic	O
antibiotic	O
administration	O
and	O
faecal	O
microbial	O
transfer	O
disrupt	O
gut	O
microbiota	O
,	O
brainstem	O
monoamine	O
concentrations	O
and	O
the	O
ventilatory	O
response	O
to	O
hypercapnia	O
.	O

We	O
suggest	O
that	O
aberrant	O
microbiota	O
-	O
gut	O
-	O
brain	O
axis	O
signalling	O
has	O
a	O
modulatory	O
influence	O
on	O
respiratory	O
behaviour	O
during	O
hypercapnic	O
stress	O
.	O

FUND	O
:	O
Department	O
of	O
Physiology	O
and	O
APC	O
Microbiome	O
Ireland	O
,	O
University	O
College	O
Cork	O
,	O
Ireland	O
.	O

Evidence	O
for	O
an	O
association	O
of	O
gut	O
microbial	O
Clostridia	B-bacteria
with	O
brain	O
functional	O
connectivity	O
and	O
gastrointestinal	O
sensorimotor	O
function	O
in	O
patients	O
with	O
irritable	O
bowel	O
syndrome	O
,	O
based	O
on	O
tripartite	O
network	O
analysis	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
Evidence	O
from	O
preclinical	O
and	O
clinical	O
studies	O
suggests	O
that	O
interactions	O
among	O
the	O
brain	O
,	O
gut	O
,	O
and	O
microbiota	O
may	O
affect	O
the	O
pathophysiology	O
of	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
.	O

As	O
disruptions	O
in	O
central	O
and	O
peripheral	O
serotonergic	O
signaling	O
pathways	O
have	O
been	O
found	O
in	O
patients	O
with	O
IBS	O
,	O
we	O
explored	O
the	O
hypothesis	O
that	O
the	O
abundance	O
of	O
serotonin	O
-	O
modulating	O
microbes	O
of	O
the	O
order	O
Clostridiales	B-bacteria
is	O
associated	O
with	O
functional	O
connectivity	O
of	O
somatosensory	O
brain	O
regions	O
and	O
gastrointestinal	O
(	O
GI	O
)	O
sensorimotor	O
function	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
prospective	O
study	O
of	O
65	O
patients	O
with	O
IBS	O
and	O
21	O
healthy	O
individuals	O
(	O
controls	O
)	O
recruited	O
from	O
2011	O
through	O
2013	O
at	O
a	O
secondary	O
/	O
tertiary	O
care	O
outpatient	O
clinic	O
in	O
Sweden	O
.	O

Study	O
participants	O
underwent	O
functional	O
brain	O
imaging	O
,	O
rectal	O
balloon	O
distension	O
,	O
a	O
nutrient	O
and	O
lactulose	O
challenge	O
test	O
,	O
and	O
assessment	O
of	O
oroanal	O
transit	O
time	O
within	O
a	O
month	O
.	O

They	O
also	O
submitted	O
stool	O
samples	O
,	O
which	O
were	O
analyzed	O
by	O
16S	O
ribosomal	O
RNA	O
gene	O
sequencing	O
.	O

A	O
tripartite	O
network	O
analysis	O
based	O
on	O
graph	O
theory	O
was	O
used	O
to	O
investigate	O
the	O
interactions	O
among	O
bacteria	O
in	O
the	O
order	O
Clostridiales	B-bacteria
,	O
connectivity	O
of	O
brain	O
regions	O
in	O
the	O
somatosensory	O
network	O
,	O
and	O
GI	O
sensorimotor	O
function	O
.	O

RESULTS	O
:	O
We	O
found	O
associations	O
between	O
GI	O
sensorimotor	O
function	O
and	O
gut	O
microbes	O
in	O
stool	O
samples	O
from	O
controls	O
,	O
but	O
not	O
in	O
samples	O
from	O
IBS	O
patients	O
.	O

The	O
largest	O
differences	O
between	O
controls	O
and	O
patients	O
with	O
IBS	O
were	O
observed	O
in	O
the	O
Lachnospiraceae	B-bacteria
incertae	I-bacteria
sedis	I-bacteria
,	O
Clostridium	B-bacteria
XIVa	I-bacteria
,	O
and	O
Coprococcus	B-bacteria
subnetworks	I-bacteria
.	O

We	O
found	O
connectivity	O
of	O
subcortical	O
(	O
thalamus	O
,	O
caudate	O
,	O
and	O
putamen	O
)	O
and	O
cortical	O
(	O
primary	O
and	O
secondary	O
somatosensory	O
cortices	O
)	O
regions	O
to	O
be	O
involved	O
in	O
mediating	O
interactions	O
among	O
these	O
networks	O
.	O

CONCLUSIONS	O
:	O
In	O
a	O
comparison	O
of	O
patients	O
with	O
IBS	O
and	O
controls	O
,	O
we	O
observed	O
disruptions	O
in	O
the	O
interactions	O
between	O
the	O
brain	O
,	O
gut	O
,	O
and	O
gut	O
microbial	O
metabolites	O
in	O
patients	O
with	O
IBS	O
-	O
these	O
involve	O
mainly	O
subcortical	O
but	O
also	O
cortical	O
regions	O
of	O
brain	O
.	O

These	O
disruptions	O
may	O
contribute	O
to	O
altered	O
perception	O
of	O
pain	O
in	O
patients	O
with	O
IBS	O
and	O
may	O
be	O
mediated	O
by	O
microbial	O
modulation	O
of	O
the	O
gut	O
serotonergic	O
system	O
.	O

Differential	O
Responses	O
of	O
Colorectal	O
Cancer	O
Cell	O
Lines	O
to	O
Enterococcus	B-bacteria
faecalis	I-bacteria
'	O
Strains	O
Isolated	O
from	O
Healthy	O
Donors	O
and	O
Colorectal	O
Cancer	O
Patients	O
.	O

The	O
metabolites	O
produced	O
by	O
the	O
host	O
'	O
s	O
gut	O
microbiota	O
have	O
an	O
important	O
role	O
in	O
the	O
maintenance	O
of	O
intestinal	O
homeostasis	O
,	O
but	O
can	O
also	O
act	O
as	O
toxins	O
and	O
induce	O
DNA	O
damage	O
in	O
colorectal	O
epithelial	O
cells	O
increasing	O
the	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
chance	O
.	O

In	O
this	O
scenario	O
,	O
the	O
impact	O
of	O
some	O
of	O
the	O
components	O
of	O
the	O
natural	O
human	O
gastrointestinal	O
microbiota	O
,	O
such	O
as	O
Enterococcus	B-bacteria
faecalis	I-bacteria
(	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
)	O
,	O
at	O
the	O
onset	O
of	O
CRC	O
progression	O
remains	O
controversial	O
.	O

Since	O
under	O
dysbiotic	O
conditions	O
it	O
could	O
turn	O
into	O
a	O
pathogen	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
'	I-bacteria
strains	I-bacteria
(	O
isolated	O
from	O
CRC	O
patients	O
and	O
healthy	O
subjects	O
'	O
stools	O
)	O
on	O
the	O
proliferation	O
of	O
different	O
colorectal	O
cells	O
lines	O
.	O

First	O
,	O
we	O
isolated	O
and	O
genotyping	O
characterized	O
the	O
Enterococcus	B-bacteria
faecalis	I-bacteria
'	O
strains	O
.	O

Then	O
,	O
we	O
analyzed	O
the	O
proliferation	O
index	O
(	O
by	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
Dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
2	O
,	O
5	O
-	O
Diphenyltetrazolium	O
Bromide	O
(	O
MTT	O
)	O
assay	O
)	O
of	O
three	O
tumor	O
and	O
one	O
normal	O
intestinal	O
cell	O
lines	O
,	O
previously	O
exposed	O
to	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
strains	I-bacteria
pre	O
-	O
cultured	O
medium	O
.	O

Stool	O
samples	O
of	O
CRC	O
patients	O
demonstrated	O
a	O
reduced	O
frequency	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
compared	O
to	O
healthy	O
subjects	O
.	O

In	O
addition	O
,	O
the	O
secreted	O
metabolites	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
'	I-bacteria
strains	I-bacteria
,	O
isolated	O
from	O
healthy	O
donors	O
,	O
decreased	O
the	O
human	O
ileocecal	O
adenocarcinoma	O
cell	O
line	O
HCT	O
-	O
8	O
and	O
human	O
colon	O
carcinoma	O
cell	O
line	O
HCT	O
-	O
116	O
cell	O
proliferation	O
without	O
effects	O
on	O
human	O
colorectal	O
adenocarcinoma	O
cell	O
line	O
SW620	O
and	O
on	O
normal	O
human	O
diploid	O
cell	O
line	O
CLR	O
-	O
1790	O
.	O

Notably	O
,	O
the	O
metabolites	O
of	O
the	O
strains	O
isolated	O
from	O
CRC	O
patients	O
did	O
not	O
influence	O
the	O
cell	O
growth	O
of	O
CRC	O
cell	O
lines	O
.	O

Our	O
results	O
demonstrated	O
a	O
new	O
point	O
of	O
view	O
in	O
the	O
investigation	O
of	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
'	O
role	O
in	O
CRC	O
development	O
,	O
which	O
raises	O
awareness	O
of	O
the	O
importance	O
of	O
not	O
only	O
associating	O
the	O
presence	O
/	O
absence	O
of	O
a	O
unique	O
microorganism	O
,	O
but	O
also	O
in	O
defining	O
the	O
specific	O
characteristics	O
of	O
the	O
different	O
investigated	O
strains	O
.	O

The	O
intestinal	O
microbiota	O
associated	O
with	O
cardiac	O
valve	O
calcification	O
differs	O
from	O
that	O
of	O
coronary	O
artery	O
disease	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
Although	O
most	O
risk	O
factors	O
for	O
cardiac	O
valve	O
calcification	O
(	O
VC	O
)	O
are	O
similar	O
to	O
those	O
for	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
,	O
they	O
differ	O
regarding	O
lesions	O
and	O
clinical	O
symptoms	O
.	O

Recently	O
,	O
increasing	O
evidence	O
suggests	O
that	O
intestinal	O
bacteria	O
play	O
essential	O
roles	O
in	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

It	O
is	O
plausible	O
that	O
the	O
gut	O
microbiota	O
is	O
linked	O
to	O
the	O
occurrence	O
of	O
different	O
CVDs	O
under	O
similar	O
risk	O
factors	O
.	O

Thus	O
,	O
we	O
aimed	O
to	O
explore	O
the	O
gut	O
microbiomes	O
in	O
patients	O
with	O
VC	O
or	O
CAD	O
and	O
determine	O
their	O
underlying	O
connections	O
.	O

METHODS	O
:	O
We	O
collected	O
samples	O
from	O
119	O
subjects	O
and	O
performed	O
16S	O
rRNA	O
gene	O
sequencing	O
to	O
analyze	O
the	O
gut	O
microbiomes	O
in	O
VC	O
and	O
CAD	O
patients	O
and	O
in	O
control	O
volunteers	O
.	O

RESULTS	O
:	O
The	O
gut	O
microbiomes	O
of	O
VC	O
and	O
CAD	O
patients	O
were	O
significantly	O
different	O
in	O
terms	O
of	O
beta	O
-	O
diversity	O
.	O

Bacteria	O
from	O
Veillonella	B-bacteria
dispar	I-bacteria
,	O
Bacteroides	B-bacteria
plebeius	I-bacteria
and	O
Fusobacterium	B-bacteria
were	O
enriched	O
in	O
the	O
VC	O
group	O
,	O
while	O
members	O
of	O
Collinsella	B-bacteria
aerofaciens	I-bacteria
,	O
Megamonas	B-bacteria
,	O
Enterococcus	B-bacteria
,	O
Megasphaera	B-bacteria
,	O
Dorea	B-bacteria
and	O
Blautia	O
were	O
decreased	O
.	O

According	O
to	O
the	O
association	O
with	O
dyslipidemia	O
,	O
seven	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
,	O
including	O
Parabacteroides	B-bacteria
distasonis	I-bacteria
,	O
Megamonas	B-bacteria
,	O
Fusobacterium	B-bacteria
,	O
Bacteroides	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Bacteroides	B-bacteria
plebeius	I-bacteria
,	O
Lactobacillus	B-bacteria
and	O
Prevotella	B-bacteria
copri	I-bacteria
,	O
were	O
regarded	O
as	O
potential	O
pathogens	O
for	O
CVDs	O
.	O

Additionally	O
,	O
Prevotella	B-bacteria
copri	I-bacteria
might	O
be	O
a	O
keystone	O
of	O
CVDs	O
,	O
especially	O
in	O
VC	O
patients	O
,	O
while	O
Collinsella	B-bacteria
aerofaciens	I-bacteria
is	O
a	O
possible	O
keystone	O
of	O
CAD	O
,	O
based	O
on	O
the	O
multi	O
-	O
correlations	O
of	O
these	O
bacteria	O
with	O
other	O
OTUs	O
in	O
microbial	O
communities	O
.	O

CONCLUSIONS	O
:	O
Patients	O
with	O
VC	O
and	O
CAD	O
suffer	O
from	O
different	O
gut	O
microbial	O
dysbiosis	O
.	O

The	O
gut	O
microbiomes	O
are	O
associated	O
with	O
the	O
clinical	O
characteristics	O
in	O
these	O
diseases	O
and	O
might	O
be	O
potential	O
therapeutic	O
targets	O
.	O

Resveratrol	O
modulates	O
the	O
gut	O
microbiota	O
to	O
prevent	O
murine	O
colitis	O
development	O
through	O
induction	O
of	O
Tregs	O
and	O
suppression	O
of	O
Th17	O
cells	O
.	O

Inflammatory	O
diseases	O
of	O
the	O
gastrointestinal	O
tract	O
are	O
often	O
associated	O
with	O
microbial	O
dysbiosis	O
.	O

Thus	O
,	O
dietary	O
interactions	O
with	O
intestinal	O
microbiota	O
,	O
to	O
maintain	O
homeostasis	O
,	O
play	O
a	O
crucial	O
role	O
in	O
regulation	O
of	O
clinical	O
disorders	O
such	O
as	O
colitis	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
if	O
resveratrol	O
,	O
a	O
polyphenol	O
found	O
in	O
a	O
variety	O
of	O
foods	O
and	O
beverages	O
,	O
would	O
reverse	O
microbial	O
dysbiosis	O
induced	O
during	O
colitis	O
.	O

Administration	O
of	O
resveratrol	O
attenuated	O
colonic	O
inflammation	O
and	O
clinical	O
symptoms	O
in	O
the	O
murine	O
model	O
of	O
2	O
,	O
4	O
,	O
6	O
-	O
trinitrobenzenesulfonic	O
acid	O
(	O
TNBS	O
)	O
-	O
induced	O
colitis	O
.	O

Resveratrol	O
treatment	O
in	O
mice	O
with	O
colitis	O
led	O
to	O
an	O
increase	O
in	O
CD4	O
(	O
+	O
)	O
FOXP3	O
(	O
+	O
)	O
and	O
CD4	O
(	O
+	O
)	O
IL	O
-	O
10	O
(	O
+	O
)	O
T	O
cells	O
,	O
and	O
a	O
decrease	O
in	O
CD4	O
(	O
+	O
)	O
IFN	O
-	O
gamma	O
(	O
+	O
)	O
and	O
CD4	O
(	O
+	O
)	O
IL	O
-	O
17	O
(	O
+	O
)	O
T	O
cells	O
.	O

16S	O
rRNA	O
gene	O
sequencing	O
to	O
investigate	O
alterations	O
in	O
the	O
gut	O
microbiota	O
revealed	O
that	O
TNBS	O
caused	O
significant	O
dysbiosis	O
,	O
which	O
was	O
reversed	O
following	O
resveratrol	O
treatment	O
.	O

Analysis	O
of	O
cecal	O
flush	O
revealed	O
that	O
TNBS	O
administration	O
led	O
to	O
an	O
increase	O
in	O
species	O
such	O
as	O
Bacteroides	B-bacteria
acidifaciens	I-bacteria
,	O
but	O
decrease	O
in	O
species	O
such	O
as	O
Ruminococcus	B-bacteria
gnavus	I-bacteria
and	O
Akkermansia	B-bacteria
mucinphilia	I-bacteria
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
SCFA	O
i	O
-	O
butyric	O
acid	O
.	O

However	O
,	O
resveratrol	O
treatment	O
restored	O
the	O
gut	O
bacteria	O
back	O
to	O
homeostatic	O
levels	O
,	O
and	O
increased	O
production	O
of	O
i	O
-	O
butyric	O
acid	O
.	O

Fecal	O
transfer	O
experiments	O
confirmed	O
the	O
protective	O
role	O
of	O
resveratrol	O
-	O
induced	O
microbiota	O
against	O
colitis	O
inasmuch	O
as	O
such	O
recipient	O
mice	O
were	O
more	O
resistant	O
to	O
TNBS	O
-	O
colitis	O
and	O
exhibited	O
polarization	O
toward	O
CD4	O
(	O
+	O
)	O
FOXP3	O
(	O
+	O
)	O
T	O
cells	O
and	O
decreases	O
in	O
CD4	O
(	O
+	O
)	O
IFN	O
-	O
gamma	O
(	O
+	O
)	O
and	O
CD4	O
(	O
+	O
)	O
IL	O
-	O
17	O
(	O
+	O
)	O
T	O
cells	O
.	O

Collectively	O
,	O
these	O
data	O
demonstrate	O
that	O
resveratrol	O
-	O
mediated	O
attenuation	O
of	O
colitis	O
results	O
from	O
reversal	O
of	O
microbial	O
dysbiosis	O
induced	O
during	O
colitis	O
and	O
such	O
microbiota	O
protect	O
the	O
host	O
from	O
colonic	O
inflammation	O
by	O
inducing	O
Tregs	O
while	O
suppressing	O
inflammatory	O
Th1	O
/	O
Th17	O
cells	O
.	O

Targeting	O
bacterial	O
quorum	O
sensing	O
shows	O
promise	O
in	O
improving	O
intestinal	O
barrier	O
function	O
following	O
burnsite	O
infection	O
.	O

Burnsite	O
infections	O
,	O
commonly	O
due	O
to	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
,	O
have	O
been	O
associated	O
with	O
deranged	O
intestinal	O
integrity	O
,	O
allowing	O
bacteria	O
and	O
their	O
products	O
to	O
translocate	O
from	O
the	O
gut	O
to	O
the	O
circulatory	O
system	O
.	O

The	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
quorum	O
sensing	O
(	O
QS	O
)	O
transcription	O
factor	O
MvfR	O
(	O
PqsR	O
)	O
controls	O
the	O
expression	O
of	O
numerous	O
virulence	O
factors	O
,	O
and	O
the	O
synthesis	O
of	O
several	O
toxic	O
products	O
.	O

However	O
,	O
the	O
role	O
of	O
QS	O
in	O
intestinal	O
integrity	O
alterations	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
has	O
not	O
been	O
previously	O
investigated	O
.	O

Using	O
a	O
proven	O
antiMvfR	O
,	O
antivirulence	O
agent	O
,	O
the	O
in	O
vivo	O
results	O
of	O
the	O
present	O
study	O
revealed	O
that	O
inhibition	O
of	O
MvfR	O
function	O
significantly	O
decreased	O
Fluorescein	O
IsothiocyanateDextran	O
(	O
FITCDextran	O
)	O
flow	O
from	O
the	O
intestine	O
to	O
the	O
systemic	O
circulation	O
,	O
diminished	O
bacterial	O
translocation	O
from	O
the	O
intestine	O
to	O
mesenteric	O
lymph	O
nodes	O
(	O
MLNs	O
)	O
,	O
and	O
improved	O
tight	O
junction	O
integrity	O
in	O
thermally	O
injured	O
and	O
infected	O
mice	O
.	O

In	O
addition	O
,	O
the	O
MvfR	O
antagonist	O
administration	O
alleviates	O
the	O
intestinal	O
inflammation	O
,	O
as	O
demonstrated	O
by	O
reduced	O
ileal	O
TNFalpha	O
and	O
fecal	O
lipocalin2	O
concentrations	O
.	O

In	O
addition	O
,	O
it	O
is	O
associated	O
with	O
lower	O
levels	O
of	O
circulating	O
endotoxin	O
and	O
decreased	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
dissemination	O
from	O
the	O
burn	O
wound	O
to	O
the	O
ileum	O
.	O

Collectively	O
,	O
these	O
results	O
hold	O
great	O
promise	O
that	O
the	O
inhibition	O
of	O
this	O
QS	O
system	O
mitigates	O
gut	O
hyperpermeability	O
by	O
attenuating	O
the	O
derangement	O
of	O
morphological	O
and	O
immune	O
aspects	O
of	O
the	O
intestinal	O
barrier	O
,	O
suggesting	O
that	O
MvfR	O
function	O
is	O
crucial	O
in	O
the	O
deterioration	O
of	O
intestinal	O
integrity	O
following	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
burnsite	O
infection	O
.	O

Therefore	O
,	O
an	O
antivirulence	O
approach	O
targeting	O
MvfR	O
,	O
could	O
potentially	O
offer	O
a	O
novel	O
therapeutic	O
approach	O
against	O
multidrug	O
resistant	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
infections	O
following	O
thermal	O
injuries	O
.	O

Since	O
this	O
approach	O
is	O
targeting	O
virulence	O
pathways	O
that	O
are	O
nonessential	O
for	O
growth	O
or	O
viability	O
,	O
our	O
strategy	O
is	O
hypothesized	O
to	O
minimize	O
the	O
development	O
of	O
bacterial	O
resistance	O
,	O
and	O
preserve	O
the	O
beneficial	O
enteric	O
microbes	O
,	O
while	O
improving	O
intestinal	O
integrity	O
that	O
is	O
deranged	O
as	O
a	O
result	O
of	O
burn	O
and	O
infection	O
.	O

A	O
Soluble	O
Immune	O
Effector	O
Binds	O
Both	O
Fungi	O
and	O
Bacteria	O
via	O
Separate	O
Functional	O
Domains	O
.	O

The	O
gut	O
microbiome	O
of	O
animals	O
consists	O
of	O
diverse	O
microorganisms	O
that	O
include	O
both	O
prokaryotes	O
and	O
eukaryotes	O
.	O

Complex	O
interactions	O
occur	O
among	O
these	O
inhabitants	O
,	O
as	O
well	O
as	O
with	O
the	O
immune	O
system	O
of	O
the	O
host	O
,	O
and	O
profoundly	O
influence	O
the	O
overall	O
health	O
of	O
both	O
the	O
host	O
and	O
its	O
microbial	O
symbionts	O
.	O

Despite	O
the	O
enormous	O
importance	O
for	O
the	O
host	O
to	O
regulate	O
its	O
gut	O
microbiome	O
,	O
the	O
extent	O
to	O
which	O
animals	O
generate	O
immune	O
-	O
related	O
molecules	O
with	O
the	O
capacity	O
to	O
directly	O
influence	O
polymicrobial	O
interactions	O
remains	O
unclear	O
.	O

The	O
urochordate	O
,	O
Ciona	O
robusta	O
,	O
is	O
a	O
model	O
organism	O
that	O
has	O
been	O
adapted	O
to	O
experimental	O
studies	O
of	O
host	O
/	O
microbiome	O
interactions	O
.	O

Ciona	O
variable	O
-	O
region	O
containing	O
chitin	O
-	O
binding	O
proteins	O
(	O
VCBPs	O
)	O
are	O
innate	O
immune	O
effectors	O
,	O
composed	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
variable	O
regions	O
and	O
a	O
chitin	O
-	O
binding	O
domain	O
(	O
CBD	O
)	O
and	O
are	O
expressed	O
in	O
high	O
abundance	O
in	O
the	O
gut	O
.	O

It	O
was	O
previously	O
shown	O
that	O
VCBP	O
-	O
C	O
binds	O
bacteria	O
and	O
influences	O
both	O
phagocytosis	O
by	O
granular	O
amoebocytes	O
and	O
biofilm	O
formation	O
via	O
its	O
Ig	O
domains	O
.	O

We	O
show	O
here	O
that	O
the	O
CBD	O
of	O
VCBP	O
-	O
C	O
independently	O
recognizes	O
chitin	O
molecules	O
present	O
in	O
the	O
cell	O
walls	O
,	O
sporangia	O
(	O
spore	O
-	O
forming	O
bodies	O
)	O
,	O
and	O
spores	O
of	O
a	O
diverse	O
set	O
of	O
filamentous	O
fungi	O
isolated	O
from	O
the	O
gut	O
of	O
Ciona	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
description	O
of	O
a	O
secreted	O
Ig	O
-	O
containing	O
immune	O
molecule	O
with	O
the	O
capacity	O
to	O
directly	O
promote	O
transkingdom	O
interactions	O
through	O
simultaneous	O
binding	O
by	O
independent	O
structural	O
domains	O
and	O
could	O
have	O
broad	O
implications	O
in	O
modulating	O
the	O
establishment	O
,	O
succession	O
,	O
and	O
homeostasis	O
of	O
gut	O
microbiomes	O
.	O

Combined	O
Genomic	O
,	O
Transcriptomic	O
,	O
Proteomic	O
,	O
and	O
Physiological	O
Characterization	O
of	O
the	O
Growth	O
of	O
Pecoramyces	B-bacteria
sp	I-bacteria
.	I-bacteria
F1	I-bacteria
in	O
Monoculture	O
and	O
Co	O
-	O
culture	O
With	O
a	O
Syntrophic	O
Methanogen	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
a	O
syntrophic	O
methanogen	O
on	O
the	O
growth	O
of	O
Pecoramyces	B-bacteria
sp	I-bacteria
.	I-bacteria
F1	I-bacteria
was	O
investigated	O
by	O
characterizing	O
fermentation	O
profiles	O
,	O
as	O
well	O
as	O
functional	O
genomic	O
,	O
transcriptomic	O
,	O
and	O
proteomic	O
analysis	O
.	O

The	O
estimated	O
genome	O
size	O
,	O
GC	O
content	O
,	O
and	O
protein	O
coding	O
regions	O
of	O
strain	O
F1	O
are	O
106	O
.	O
83	O
Mb	O
,	O
16	O
.	O
07	O
%	O
,	O
and	O
23	O
.	O
54	O
%	O
,	O
respectively	O
.	O

Comparison	O
of	O
the	O
fungal	O
monoculture	O
with	O
the	O
methanogen	O
co	O
-	O
culture	O
demonstrated	O
that	O
during	O
the	O
fermentation	O
of	O
glucose	O
,	O
the	O
co	O
-	O
culture	O
initially	O
expressed	O
and	O
then	O
down	O
-	O
regulated	O
a	O
large	O
number	O
of	O
genes	O
encoding	O
both	O
enzymes	O
involved	O
in	O
intermediate	O
metabolism	O
and	O
plant	O
cell	O
wall	O
degradation	O
.	O

However	O
,	O
the	O
number	O
of	O
up	O
-	O
regulated	O
proteins	O
doubled	O
at	O
the	O
late	O
-	O
growth	O
stage	O
in	O
the	O
co	O
-	O
culture	O
.	O

In	O
addition	O
,	O
we	O
provide	O
a	O
mechanistic	O
understanding	O
of	O
the	O
metabolism	O
of	O
this	O
fungus	O
in	O
co	O
-	O
culture	O
with	O
a	O
syntrophic	O
methanogen	O
.	O

Further	O
experiments	O
are	O
needed	O
to	O
explore	O
this	O
interaction	O
during	O
degradation	O
of	O
more	O
complex	O
plant	O
cell	O
wall	O
substrates	O
.	O

Characterization	O
of	O
the	O
gut	O
microbiota	O
of	O
invasive	O
Agrilus	O
mali	O
Matsumara	O
(	O
Coleoptera	O
:	O
Buprestidae	O
)	O
using	O
high	O
-	O
throughput	O
sequencing	O
:	O
uncovering	O
plant	O
cell	O
-	O
wall	O
degrading	O
bacteria	O
.	O

The	O
genus	O
Agrilus	O
comprises	O
diverse	O
exotic	O
and	O
agriculturally	O
important	O
wood	O
-	O
boring	O
insects	O
that	O
have	O
evolved	O
efficient	O
digestive	O
systems	O
.	O

Agrilus	O
mali	O
Matsumara	O
,	O
an	O
invasive	O
insect	O
,	O
is	O
causing	O
extensive	O
mortality	O
to	O
endangered	O
wild	O
apple	O
trees	O
in	O
Tianshan	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
an	O
in	O
-	O
depth	O
characterization	O
of	O
the	O
gut	O
microbiota	O
of	O
A	O
.		O
mali	O
based	O
on	O
high	O
-	O
throughput	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
gene	O
and	O
report	O
the	O
presence	O
of	O
lignocellulose	O
-	O
degrading	O
bacteria	O
.	O

Thirty	O
-	O
nine	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
were	O
characterized	O
from	O
the	O
larval	O
gut	O
.	O

OTUs	O
represented	O
6	O
phyla	O
,	O
10	O
classes	O
,	O
16	O
orders	O
,	O
20	O
families	O
,	O
and	O
20	O
genera	O
.	O

The	O
majority	O
of	O
bacterial	O
OTUs	O
belonged	O
to	O
the	O
order	O
Enterobacteriales	B-bacteria
which	O
was	O
the	O
most	O
abundant	O
taxa	O
in	O
the	O
larval	O
gut	O
.	O

Cultivable	O
bacteria	O
revealed	O
9	O
OTUs	O
that	O
all	O
belonged	O
to	O
Gammaproteobacteria	B-bacteria
.	O

Subsequently	O
,	O
we	O
examined	O
the	O
breakdown	O
of	O
plant	O
cell	O
-	O
wall	O
compounds	O
by	O
bacterial	O
isolates	O
.	O

Among	O
the	O
isolates	O
,	O
the	O
highest	O
efficiency	O
was	O
observed	O
in	O
Pantoea	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
which	O
was	O
able	O
to	O
synthesize	O
four	O
out	O
of	O
the	O
six	O
enzymes	O
(	O
cellulase	O
,	O
cellobiase	O
,	O
beta	O
-	O
xylanase	O
,	O
and	O
beta	O
-	O
gluconase	O
)	O
responsible	O
for	O
plant	O
-	O
cell	O
wall	O
degradation	O
.	O

One	O
isolate	O
identified	O
as	O
Pseudomonas	B-bacteria
orientalis	I-bacteria
exhibited	O
lignin	O
peroxidase	O
activity	O
.	O

Our	O
study	O
provides	O
the	O
first	O
characterization	O
of	O
the	O
gut	O
microbial	O
diversity	O
of	O
A	O
.	O
mali	O
larvae	O
and	O
shows	O
that	O
some	O
cultivable	O
bacteria	O
play	O
a	O
significant	O
role	O
in	O
the	O
digestive	O
tracts	O
of	O
larvae	O
by	O
providing	O
nutritional	O
needs	O
.	O

Metabolic	O
phenotypes	O
and	O
the	O
gut	O
microbiota	O
in	O
response	O
to	O
dietary	O
resistant	O
starch	O
type	O
2	O
in	O
normal	O
-	O
weight	O
subjects	O
:	O
a	O
randomized	O
crossover	O
trial	O
.	O

Resistant	O
starch	O
(	O
RS	O
)	O
has	O
been	O
reported	O
to	O
reduce	O
body	O
fat	O
in	O
obese	O
mice	O
.	O

However	O
,	O
this	O
effect	O
has	O
not	O
been	O
demonstrated	O
in	O
humans	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
RS	O
in	O
19	O
volunteers	O
with	O
normal	O
body	O
weights	O
.	O

A	O
randomized	O
,	O
double	O
-	O
blinded	O
and	O
crossover	O
design	O
clinical	O
trial	O
was	O
conducted	O
.	O

The	O
study	O
subjects	O
were	O
given	O
either	O
40	O
g	O
high	O
amylose	O
RS2	O
or	O
energy	O
-	O
matched	O
control	O
starch	O
with	O
three	O
identical	O
diets	O
per	O
day	O
throughout	O
the	O
study	O
.	O

The	O
effect	O
of	O
RS	O
was	O
evaluated	O
by	O
monitoring	O
body	O
fat	O
,	O
glucose	O
metabolism	O
,	O
gut	O
hormones	O
,	O
gut	O
microbiota	O
,	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
and	O
metabolites	O
.	O

The	O
visceral	O
and	O
subcutaneous	O
fat	O
areas	O
were	O
significantly	O
reduced	O
following	O
RS	O
intake	O
.	O

Acetate	O
and	O
early	O
-	O
phase	O
insulin	O
,	O
C	O
-	O
peptide	O
and	O
glucagon	O
-	O
like	O
peptide	O
-	O
1	O
(	O
GLP	O
-	O
1	O
)	O
secretion	O
were	O
increased	O
,	O
and	O
the	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
and	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
levels	O
were	O
decreased	O
after	O
the	O
RS	O
intervention	O
.	O

Based	O
on	O
16S	O
rRNA	O
sequencing	O
,	O
certain	O
gut	O
microbes	O
were	O
significantly	O
decreased	O
after	O
RS	O
supplementation	O
,	O
whereas	O
the	O
genus	O
Ruminococcaceae	B-bacteria
_	I-bacteria
UCG	I-bacteria
-	I-bacteria
005	I-bacteria
showed	O
an	O
increase	O
in	O
abundance	O
.	O

Other	O
potential	O
signatures	O
of	O
the	O
RS	O
intervention	O
included	O
Akkermansia	B-bacteria
,	O
Ruminococcus	B-bacteria
_	I-bacteria
2	I-bacteria
,	O
Victivallis	B-bacteria
,	O
and	O
Comamonas	B-bacteria
.	O

Moreover	O
,	O
the	O
baseline	O
abundance	O
of	O
the	O
genera	O
Streptococcus	B-bacteria
,	O
Ruminococcus	B-bacteria
_	I-bacteria
torques	I-bacteria
_	O
group	O
,	O
Eubacterium		B-bacteria
_	I-bacteria
hallii	I-bacteria
_	O
group	O
,	O
and	O
Eubacterium	B-bacteria
_	I-bacteria
eligens	I-bacteria
_	O
group	O
was	O
significantly	O
associated	O
with	O
the	O
hormonal	O
and	O
metabolic	O
effects	O
of	O
RS	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
daily	O
intake	O
of	O
40	O
g	O
of	O
RS	O
is	O
effective	O
in	O
modulating	O
body	O
fat	O
,	O
SCFAs	O
,	O
early	O
-	O
phase	O
insulin	O
and	O
GLP	O
-	O
1	O
secretion	O
and	O
the	O
gut	O
microbiota	O
in	O
normal	O
-	O
weight	O
subjects	O
.	O

Colonization	O
of	O
the	O
human	O
gut	O
by	O
bovine	O
bacteria	O
present	O
in	O
Parmesan	O
cheese	O
.	O

The	O
abilities	O
of	O
certain	O
microorganisms	O
to	O
be	O
transferred	O
across	O
the	O
food	O
production	O
chain	O
,	O
persist	O
in	O
the	O
final	O
product	O
and	O
,	O
potentially	O
,	O
colonize	O
the	O
human	O
gut	O
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
provide	O
strain	O
-	O
level	O
evidence	O
supporting	O
that	O
dairy	O
cattle	O
-	O
associated	O
bacteria	O
can	O
be	O
transferred	O
to	O
the	O
human	O
gut	O
via	O
consumption	O
of	O
Parmesan	O
cheese	O
.	O

We	O
characterize	O
the	O
microbial	O
communities	O
in	O
samples	O
taken	O
from	O
five	O
different	O
locations	O
across	O
the	O
Parmesan	O
cheese	O
production	O
chain	O
,	O
confirming	O
that	O
the	O
final	O
product	O
contains	O
microorganisms	O
derived	O
from	O
cattle	O
gut	O
,	O
milk	O
,	O
and	O
the	O
nearby	O
environment	O
.	O

In	O
addition	O
,	O
we	O
carry	O
out	O
a	O
human	O
pilot	O
study	O
showing	O
that	O
Bifidobacterium	B-bacteria
mongoliense	I-bacteria
strains	I-bacteria
from	O
cheese	O
can	O
transiently	O
colonize	O
the	O
human	O
gut	O
,	O
a	O
process	O
that	O
can	O
be	O
enhanced	O
by	O
cow	O
milk	O
consumption	O
.	O

Outbreak	O
of	O
Murine	O
Infection	O
with	O
Clostridium	B-bacteria
difficile	I-bacteria
Associated	O
with	O
the	O
Administration	O
of	O
a	O
Pre	O
-	O
and	O
Perinatal	O
Methyl	O
Donor	O
Diet	O
.	O

Between	O
October	O
2016	O
and	O
June	O
2017	O
,	O
a	O
C57BL	O
/	O
6J	O
mouse	O
colony	O
that	O
was	O
undergoing	O
a	O
pre	O
-	O
and	O
perinatal	O
methyl	O
donor	O
supplementation	O
diet	O
intervention	O
to	O
study	O
the	O
impact	O
of	O
parental	O
nutrition	O
on	O
offspring	O
susceptibility	O
to	O
disease	O
was	O
found	O
to	O
suffer	O
from	O
an	O
epizootic	O
of	O
unexpected	O
deaths	O
.	O

Necropsy	O
revealed	O
the	O
presence	O
of	O
severe	O
colitis	O
,	O
and	O
further	O
investigation	O
linked	O
these	O
outbreak	O
deaths	O
to	O
a	O
Clostridium	B-bacteria
difficile	I-bacteria
strain	I-bacteria
of	O
ribotype	O
027	I-bacteria
that	O
we	O
term	O
16N203	O
.	O

C	B-bacteria
.	I-bacteria
difficile	I-bacteria
infection	O
(	O
CDI	O
)	O
is	O
associated	O
with	O
antibiotic	O
use	O
in	O
humans	O
.	O

Current	O
murine	O
models	O
of	O
CDI	O
rely	O
on	O
antibiotic	O
pretreatment	O
to	O
establish	O
clinical	O
phenotypes	O
.	O

In	O
this	O
report	O
,	O
the	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
outbreak	O
occurs	O
in	O
F1	O
mice	O
linked	O
to	O
alterations	O
in	O
the	O
parental	O
diet	O
.	O

The	O
diagnosis	O
of	O
CDI	O
in	O
the	O
affected	O
mice	O
was	O
confirmed	O
by	O
cecal	O
/	O
colonic	O
histopathology	O
,	O
the	O
presence	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
bacteria	O
in	O
fecal	O
/	O
colonic	O
culture	O
,	O
and	O
detection	O
of	O
C	O
.	O
difficile	O
toxins	O
.	O

F1	O
mice	O
from	O
parents	O
fed	O
the	O
methyl	O
supplementation	O
diet	O
also	O
had	O
significantly	O
reduced	O
survival	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
compared	O
with	O
F1	O
mice	O
from	O
parents	O
fed	O
the	O
control	O
diet	O
.	O

When	O
we	O
tested	O
the	O
16N203	O
outbreak	O
strain	O
in	O
an	O
established	O
mouse	O
model	O
of	O
antibiotic	O
-	O
induced	O
CDI	O
,	O
we	O
confirmed	O
that	O
this	O
strain	O
is	O
pathogenic	O
.	O

Our	O
serendipitous	O
observations	O
from	O
this	O
spontaneous	O
outbreak	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
in	O
association	O
with	O
a	O
pre	O
-	O
and	O
perinatal	O
methyl	O
donor	O
diet	O
suggest	O
the	O
important	O
role	O
that	O
diet	O
may	O
play	O
in	O
host	O
defense	O
and	O
CDI	O
risk	O
factors	O
.	O
IMPORTANCE	O
Clostridium	B-bacteria
difficile	I-bacteria
infection	O
(	O
CDI	O
)	O
has	O
become	O
the	O
leading	O
cause	O
of	O
infectious	O
diarrhea	O
in	O
hospitals	O
worldwide	O
,	O
owing	O
its	O
preeminence	O
to	O
the	O
emergence	O
of	O
hyperendemic	O
strains	O
,	O
such	O
as	O
ribotype	O
027	O
(	O
RT027	O
)	O
.	O

A	O
major	O
CDI	O
risk	O
factor	O
is	O
antibiotic	O
exposure	O
,	O
which	O
alters	O
gut	O
microbiota	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
colonization	O
resistance	O
.	O

Current	O
murine	O
models	O
of	O
CDI	O
also	O
depend	O
on	O
pretreatment	O
of	O
animals	O
with	O
antibiotics	O
to	O
establish	O
disease	O
.	O

The	O
outbreak	O
that	O
we	O
report	O
here	O
is	O
unique	O
in	O
that	O
the	O
CDI	O
occurred	O
in	O
mice	O
with	O
no	O
antibiotic	O
exposure	O
and	O
is	O
associated	O
with	O
a	O
pre	O
-	O
and	O
perinatal	O
methyl	O
supplementation	O
donor	O
diet	O
intervention	O
study	O
.	O

Our	O
investigation	O
subsequently	O
reveals	O
that	O
the	O
outbreak	O
strain	O
that	O
we	O
term	O
16N203	O
is	O
an	O
RT027	O
strain	O
,	O
and	O
this	O
isolated	O
strain	O
is	O
also	O
pathogenic	O
in	O
an	O
established	O
murine	O
model	O
of	O
CDI	O
(	O
with	O
antibiotics	O
)	O
.	O

Our	O
report	O
of	O
this	O
spontaneous	O
outbreak	O
offers	O
additional	O
insight	O
into	O
the	O
importance	O
of	O
environmental	O
factors	O
,	O
such	O
as	O
diet	O
,	O
and	O
CDI	O
susceptibility	O
.	O

Characterization	O
of	O
gut	O
microbiota	O
composition	O
and	O
functions	O
in	O
patients	O
with	O
chronic	O
alcohol	O
overconsumption	O
.	O

Excessive	O
alcohol	O
intake	O
can	O
alter	O
the	O
gut	O
microbiota	O
,	O
which	O
may	O
underlie	O
the	O
pathophysiology	O
of	O
alcohol	O
-	O
related	O
diseases	O
.	O

We	O
examined	O
gut	O
microbiota	O
composition	O
and	O
functions	O
in	O
patients	O
with	O
alcohol	O
overconsumption	O
for	O
>	O
10	O
years	O
,	O
compared	O
to	O
a	O
control	O
group	O
of	O
patients	O
with	O
a	O
history	O
of	O
no	O
or	O
low	O
alcohol	O
intake	O
.	O

Faecal	O
microbiota	O
composition	O
was	O
assessed	O
by	O
16S	O
rRNA	O
sequencing	O
.	O

Gut	O
microbiota	O
functions	O
were	O
evaluated	O
by	O
quantification	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
and	O
predictive	O
metagenome	O
profiling	O
(	O
PICRUSt	O
)	O
.	O

Twenty	O
-	O
four	O
patients	O
,	O
mean	O
age	O
64	O
.	O
8	O
years	O
(	O
19	O
males	O
)	O
,	O
with	O
alcohol	O
overconsumption	O
,	O
and	O
18	O
control	O
patients	O
,	O
mean	O
age	O
58	O
.	O
2	O
years	O
(	O
14	O
males	O
)	O
were	O
included	O
.	O

The	O
two	O
groups	O
were	O
comparable	O
regarding	O
basic	O
clinical	O
variables	O
.	O

Nutritional	O
assessment	O
revealed	O
lower	O
total	O
score	O
on	O
the	O
screening	O
tool	O
Mini	O
Nutritional	O
Assessment	O
,	O
lower	O
muscle	O
mass	O
as	O
assessed	O
by	O
handgrip	O
strength	O
,	O
and	O
lower	O
plasma	O
vitamin	O
C	O
levels	O
in	O
the	O
alcohol	O
overconsumption	O
group	O
.	O

Bacteria	O
from	O
phylum	O
Proteobacteria	B-bacteria
were	O
found	O
in	O
higher	O
relative	O
abundance	O
,	O
while	O
bacteria	O
from	O
genus	O
Faecalibacterium	B-bacteria
were	O
found	O
in	O
lower	O
relative	O
abundance	O
in	O
the	O
group	O
of	O
alcohol	O
overconsumers	O
.	O

The	O
group	O
also	O
had	O
higher	O
levels	O
of	O
the	O
genera	O
Sutterella	B-bacteria
,	O
Holdemania	B-bacteria
and	O
Clostridium	B-bacteria
,	O
and	O
lower	O
concentration	O
and	O
percentage	O
of	O
butyric	O
acid	O
.	O

When	O
applying	O
PICRUSt	O
to	O
predict	O
the	O
metagenomic	O
composition	O
,	O
we	O
found	O
that	O
genes	O
related	O
to	O
invasion	O
of	O
epithelial	O
cells	O
were	O
more	O
common	O
in	O
the	O
group	O
of	O
alcohol	O
overconsumers	O
.	O

We	O
conclude	O
that	O
gut	O
microbiota	O
composition	O
and	O
functions	O
in	O
patients	O
with	O
alcohol	O
overconsumption	O
differ	O
from	O
patients	O
with	O
low	O
consumption	O
of	O
alcohol	O
,	O
and	O
seem	O
to	O
be	O
skewed	O
into	O
a	O
putative	O
pro	O
-	O
inflammatory	O
direction	O
.	O

Functional	O
and	O
Cognitive	O
Status	O
in	O
Clostridium	B-bacteria
difficile	I-bacteria
Infection	O
in	O
the	O
Hospitalized	O
Elderly	O
:	O
a	O
Retrospective	O
Study	O
of	O
Two	O
Sites	O
.	O

The	O
role	O
of	O
the	O
gut	O
microbiota	O
on	O
animal	O
model	O
reproducibility	O
.	O

The	O
gut	O
microbiota	O
is	O
composed	O
of	O
approximately	O
10	O
(	O
10	O
)	O
-	O
10	O
(	O
14	O
)	O
cells	O
,	O
including	O
fungi	O
,	O
bacteria	O
,	O
archaea	O
,	O
protozoa	O
,	O
viruses	O
,	O
and	O
bacteriophages	O
;	O
their	O
genes	O
and	O
their	O
various	O
metabolites	O
were	O
found	O
throughout	O
the	O
gastrointestinal	O
tract	O
.	O

It	O
has	O
co	O
-	O
evolved	O
with	O
each	O
species	O
to	O
assist	O
with	O
day	O
to	O
day	O
bodily	O
functions	O
,	O
such	O
as	O
digestion	O
,	O
metabolism	O
of	O
xenobiotics	O
,	O
development	O
of	O
mucosal	O
immunity	O
and	O
immunomodulation	O
,	O
and	O
protection	O
against	O
invading	O
pathogens	O
.	O

Because	O
of	O
the	O
significant	O
beneficial	O
impact	O
that	O
gut	O
microbiota	O
may	O
have	O
,	O
there	O
is	O
interest	O
in	O
learning	O
more	O
about	O
it	O
and	O
translating	O
these	O
findings	O
into	O
clinical	O
therapies	O
.	O

Results	O
from	O
recent	O
studies	O
characterizing	O
the	O
gut	O
microbiota	O
of	O
various	O
species	O
have	O
demonstrated	O
the	O
range	O
of	O
influences	O
that	O
may	O
affect	O
gut	O
microbiota	O
diversity	O
,	O
including	O
animal	O
strain	O
,	O
obesity	O
,	O
types	O
of	O
enrichment	O
used	O
,	O
bedding	O
and	O
housing	O
methods	O
,	O
treatment	O
with	O
antimicrobials	O
,	O
vendor	O
source	O
,	O
specific	O
animal	O
housing	O
,	O
diet	O
,	O
and	O
intercurrent	O
disease	O
.	O

Relatively	O
little	O
is	O
known	O
about	O
the	O
functional	O
consequences	O
of	O
alterations	O
of	O
the	O
gut	O
microbiota	O
and	O
exactly	O
how	O
changes	O
in	O
richness	O
and	O
diversity	O
of	O
the	O
microbiota	O
translate	O
into	O
changes	O
in	O
health	O
and	O
susceptibility	O
to	O
disease	O
.	O

Furthermore	O
,	O
questions	O
have	O
been	O
raised	O
as	O
to	O
whether	O
germ	O
-	O
free	O
or	O
even	O
ultraclean	O
,	O
barrier	O
-	O
raised	O
mice	O
are	O
relevant	O
models	O
of	O
human	O
disease	O
,	O
given	O
their	O
significantly	O
reduced	O
gut	O
microbiota	O
diversity	O
and	O
complexity	O
compared	O
with	O
conventionally	O
housed	O
mice	O
.	O

In	O
addition	O
,	O
evidence	O
suggests	O
that	O
the	O
specific	O
anatomical	O
location	O
selected	O
for	O
assessing	O
the	O
gut	O
microbiota	O
has	O
a	O
highly	O
significant	O
effect	O
on	O
study	O
outcomes	O
,	O
in	O
that	O
bacterial	O
phyla	O
change	O
significantly	O
along	O
the	O
gastrointestinal	O
tract	O
.	O

This	O
paper	O
will	O
explore	O
animal	O
model	O
reproducibility	O
in	O
light	O
of	O
this	O
information	O
about	O
the	O
gut	O
microbiota	O
.	O

Crosstalk	O
between	O
gut	O
microbiota	O
and	O
antidiabetic	O
drug	O
action	O
.	O

Type	O
2	O
diabetes	O
(	O
T2D	O
)	O
is	O
a	O
disorder	O
characterized	O
by	O
chronic	O
inflated	O
blood	O
glucose	O
levels	O
(	O
hyperglycemia	O
)	O
,	O
at	O
first	O
due	O
to	O
insulin	O
resistance	O
and	O
unregulated	O
insulin	O
secretion	O
but	O
with	O
tendency	O
towards	O
global	O
spreading	O
.	O

The	O
gut	O
microbiota	O
is	O
recognized	O
to	O
have	O
an	O
influence	O
on	O
T2D	O
,	O
although	O
surveys	O
have	O
not	O
formed	O
a	O
clear	O
overview	O
to	O
date	O
.	O

Because	O
of	O
the	O
interactions	O
between	O
gut	O
microbiota	O
and	O
host	O
homeostasis	O
,	O
intestinal	O
bacteria	O
are	O
believed	O
to	O
play	O
a	O
large	O
role	O
in	O
various	O
diseases	O
,	O
including	O
metabolic	O
syndrome	O
,	O
obesity	O
and	O
associated	O
disease	O
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
the	O
animal	O
and	O
human	O
studies	O
which	O
have	O
elucidated	O
the	O
roles	O
of	O
metformin	O
,	O
alpha	O
-	O
glucosidase	O
inhibitors	O
,	O
glucagon	O
-	O
like	O
peptide	O
-	O
1	O
agonists	O
,	O
peroxisome	O
proliferator	O
-	O
activated	O
receptors	O
gamma	O
agonists	O
,	O
inhibitors	O
of	O
dipeptidyl	O
peptidase	O
-	O
4	O
,	O
sodium	O
/	O
glucose	O
cotransporter	O
inhibitors	O
,	O
and	O
other	O
less	O
studied	O
medications	O
on	O
gut	O
microbiota	O
.	O

This	O
review	O
is	O
dedicated	O
to	O
one	O
of	O
the	O
most	O
widespread	O
diseases	O
,	O
T2D	O
,	O
and	O
the	O
currently	O
used	O
antidiabetic	O
drugs	O
and	O
most	O
promising	O
new	O
findings	O
.	O

In	O
general	O
,	O
the	O
gut	O
microbiota	O
has	O
been	O
shown	O
to	O
have	O
an	O
influence	O
on	O
host	O
metabolism	O
,	O
food	O
consumption	O
,	O
satiety	O
,	O
glucose	O
homoeostasis	O
,	O
and	O
weight	O
gain	O
.	O

Altered	O
intestinal	O
microbiota	O
composition	O
has	O
been	O
noticed	O
in	O
cardiovascular	O
diseases	O
,	O
colon	O
cancer	O
,	O
rheumatoid	O
arthritis	O
,	O
T2D	O
,	O
and	O
obesity	O
.	O

Therefore	O
,	O
the	O
main	O
effect	O
of	O
antidiabetic	O
drugs	O
is	O
on	O
the	O
microbiome	O
composition	O
,	O
basically	O
increasing	O
the	O
short	O
-	O
chain	O
fatty	O
acids	O
-	O
producing	O
bacteria	O
,	O
responsible	O
for	O
losing	O
weight	O
and	O
suppressing	O
inflammation	O
.	O

Reduced	O
CD27	O
(	O
-	O
)	O
IgD	O
(	O
-	O
)	O
B	O
Cells	O
in	O
Blood	O
and	O
Raised	O
CD27	O
(	O
-	O
)	O
IgD	O
(	O
-	O
)	O
B	O
Cells	O
in	O
Gut	O
-	O
Associated	O
Lymphoid	O
Tissue	O
in	O
Inflammatory	O
Bowel	O
Disease	O
.	O

The	O
intestinal	O
mucosa	O
in	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
contains	O
increased	O
frequencies	O
of	O
lymphocytes	O
and	O
a	O
disproportionate	O
increase	O
in	O
plasma	O
cells	O
secreting	O
immunoglobulin	O
(	O
Ig	O
)	O
G	O
relative	O
to	O
other	O
isotypes	O
compared	O
to	O
healthy	O
controls	O
.	O

Despite	O
consistent	O
evidence	O
of	O
B	O
lineage	O
cells	O
in	O
the	O
mucosa	O
in	O
IBD	O
,	O
little	O
is	O
known	O
of	O
B	O
cell	O
recruitment	O
to	O
the	O
gut	O
in	O
IBD	O
.	O

Here	O
we	O
analyzed	O
B	O
cells	O
in	O
blood	O
of	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
and	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
with	O
a	O
range	O
of	O
disease	O
activities	O
.	O

We	O
analyzed	O
the	O
frequencies	O
of	O
known	O
B	O
cell	O
subsets	O
in	O
blood	O
and	O
observed	O
a	O
consistent	O
reduction	O
in	O
the	O
proportion	O
of	O
CD27	O
(	O
-	O
)	O
IgD	O
(	O
-	O
)	O
B	O
cells	O
expressing	O
all	O
Ig	O
isotypes	O
in	O
the	O
blood	O
in	O
IBD	O
(	O
independent	O
of	O
severity	O
of	O
disease	O
and	O
treatment	O
)	O
compared	O
to	O
healthy	O
controls	O
.	O

Successful	O
treatment	O
of	O
patients	O
with	O
biologic	O
therapies	O
did	O
not	O
change	O
the	O
profile	O
of	O
B	O
cell	O
subsets	O
in	O
blood	O
.	O

By	O
mass	O
cytometry	O
we	O
demonstrated	O
that	O
CD27	O
(	O
-	O
)	O
IgD	O
(	O
-	O
)	O
B	O
cells	O
were	O
proportionately	O
enriched	O
in	O
the	O
gut	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
GALT	O
)	O
in	O
IBD	O
.	O

Since	O
production	O
of	O
TNFalpha	O
is	O
a	O
feature	O
of	O
IBD	O
relevant	O
to	O
therapies	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
B	O
cells	O
in	O
GALT	O
or	O
the	O
CD27	O
(	O
-	O
)	O
IgD	O
(	O
-	O
)	O
subset	O
in	O
particular	O
could	O
contribute	O
to	O
pathology	O
by	O
secretion	O
of	O
TNFalpha	O
or	O
IL	O
-	O
10	O
.	O

We	O
found	O
that	O
donor	O
matched	O
GALT	O
and	O
blood	O
B	O
cells	O
are	O
capable	O
of	O
producing	O
TNFalpha	O
as	O
well	O
as	O
IL	O
-	O
10	O
,	O
but	O
we	O
saw	O
no	O
evidence	O
that	O
CD27	O
(	O
-	O
)	O
IgD	O
(	O
-	O
)	O
B	O
cells	O
from	O
blood	O
expressed	O
more	O
TNFalpha	O
compared	O
to	O
other	O
subsets	O
.	O

The	O
reduced	O
proportion	O
of	O
CD27	O
(	O
-	O
)	O
IgD	O
(	O
-	O
)	O
B	O
cells	O
in	O
blood	O
and	O
the	O
increased	O
proportion	O
in	O
the	O
gut	O
implies	O
that	O
CD27	O
(	O
-	O
)	O
IgD	O
(	O
-	O
)	O
B	O
cells	O
are	O
recruited	O
from	O
the	O
blood	O
to	O
the	O
gut	O
in	O
IBD	O
.	O

CD27	O
(	O
-	O
)	O
IgD	O
(	O
-	O
)	O
B	O
cells	O
have	O
been	O
implicated	O
in	O
immune	O
responses	O
to	O
intestinal	O
bacteria	O
and	O
recruitment	O
to	O
GALT	O
,	O
and	O
may	O
contribute	O
to	O
the	O
intestinal	O
inflammatory	O
milieu	O
in	O
IBD	O
.	O

The	O
Formation	O
of	O
Glycan	O
-	O
Specific	O
Natural	O
Antibodies	O
Repertoire	O
in	O
GalT	O
-	O
KO	O
Mice	O
Is	O
Determined	O
by	O
Gut	O
Microbiota	O
.	O

Gut	O
commensal	O
bacteria	O
are	O
known	O
to	O
have	O
a	O
significant	O
role	O
in	O
regulating	O
the	O
innate	O
and	O
adaptive	O
immune	O
homeostasis	O
.	O

Alterations	O
in	O
the	O
intestinal	O
microbial	O
composition	O
have	O
been	O
associated	O
with	O
several	O
disease	O
states	O
,	O
including	O
autoimmune	O
and	O
inflammatory	O
conditions	O
.	O

However	O
,	O
it	O
is	O
not	O
entirely	O
clear	O
how	O
commensal	O
gut	O
microbiota	O
modulate	O
and	O
contribute	O
to	O
the	O
systemic	O
immunity	O
,	O
and	O
whether	O
circulating	O
elements	O
of	O
the	O
host	O
immune	O
system	O
could	O
regulate	O
the	O
microbiome	O
.	O

Thus	O
,	O
we	O
have	O
studied	O
the	O
diversity	O
and	O
abundance	O
of	O
specific	O
taxons	O
in	O
the	O
gut	O
microbiota	O
of	O
inbred	O
GalT	O
-	O
KO	O
mice	O
during	O
7	O
months	O
of	O
animal	O
life	O
by	O
metagenetic	O
high	O
-	O
throughput	O
sequencing	O
(	O
16S	O
rRNA	O
gene	O
,	O
variable	O
regions	O
V3	O
-	O
V5	O
)	O
.	O

The	O
repertoire	O
of	O
glycan	O
-	O
specific	O
natural	O
antibodies	O
,	O
obtained	O
by	O
printed	O
glycan	O
array	O
technology	O
,	O
was	O
then	O
associated	O
with	O
the	O
microbial	O
diversity	O
for	O
each	O
animal	O
by	O
metagenome	O
-	O
wide	O
association	O
studies	O
(	O
MWAS	O
)	O
.	O

Our	O
data	O
show	O
that	O
the	O
orders	O
clostridiales	B-bacteria
(	O
most	O
abundant	O
)	O
,	O
bacteriodales	B-bacteria
,	O
lactobacillales	B-bacteria
,	O
and	O
deferribacterales	B-bacteria
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
the	O
final	O
repertoire	O
of	O
natural	O
anti	O
-	O
glycan	O
antibodies	O
in	O
GalT	O
-	O
KO	O
mice	O
.	O

The	O
main	O
changes	O
in	O
microbiota	O
diversity	O
(	O
month	O
-	O
2	O
and	O
month	O
-	O
3	O
)	O
were	O
related	O
to	O
important	O
changes	O
in	O
levels	O
and	O
repertoire	O
of	O
natural	O
anti	O
-	O
glycan	O
antibodies	O
in	O
these	O
mice	O
.	O

Additionally	O
,	O
significant	O
positive	O
and	O
negative	O
associations	O
were	O
found	O
between	O
the	O
gut	O
microbiota	O
and	O
the	O
pattern	O
of	O
specific	O
anti	O
-	O
glycan	O
antibodies	O
.	O

Regarding	O
individual	O
features	O
,	O
the	O
gut	O
microbiota	O
and	O
the	O
corresponding	O
repertoire	O
of	O
natural	O
anti	O
-	O
glycan	O
antibodies	O
showed	O
differences	O
among	O
the	O
examined	O
animals	O
.	O

We	O
also	O
found	O
redundancy	O
in	O
different	O
taxa	O
associated	O
with	O
the	O
development	O
of	O
specific	O
anti	O
-	O
glycan	O
antibodies	O
.	O

Differences	O
in	O
microbial	O
diversity	O
did	O
not	O
,	O
therefore	O
,	O
necessarily	O
influence	O
the	O
overall	O
functional	O
output	O
of	O
the	O
gut	O
microbiome	O
of	O
GalT	O
-	O
KO	O
mice	O
.	O

In	O
summary	O
,	O
the	O
repertoire	O
of	O
natural	O
anti	O
-	O
carbohydrate	O
antibodies	O
may	O
be	O
partially	O
determined	O
by	O
the	O
continuous	O
antigenic	O
stimulation	O
produced	O
by	O
the	O
gut	O
bacterial	O
population	O
of	O
each	O
GalT	O
-	O
KO	O
mouse	O
.	O

Small	O
differences	O
in	O
gut	O
microbiota	O
diversity	O
could	O
determine	O
different	O
repertoire	O
and	O
levels	O
of	O
natural	O
anti	O
-	O
glycan	O
antibodies	O
and	O
consequently	O
might	O
induce	O
different	O
immune	O
responses	O
to	O
pathogens	O
or	O
other	O
potential	O
threats	O
.	O

The	O
Influence	O
of	O
Heat	O
-	O
Killed	O
Enterococcus	B-bacteria
faecium	I-bacteria
BGPAS1	I-bacteria
-	I-bacteria
3	I-bacteria
on	O
the	O
Tight	O
Junction	O
Protein	O
Expression	O
and	O
Immune	O
Function	O
in	O
Differentiated	O
Caco	O
-	O
2	O
Cells	O
Infected	O
With	O
Listeria	B-bacteria
monocytogenes	I-bacteria
ATCC	B-bacteria
19111	I-bacteria
.	O

Listeria	B-bacteria
monocytogenes	I-bacteria
,	O
the	O
common	O
foodborne	O
pathogenic	O
bacteria	O
species	O
,	O
compromises	O
the	O
intestinal	O
epithelial	O
barrier	O
,	O
leading	O
to	O
development	O
of	O
the	O
listeriosis	O
,	O
a	O
severe	O
disease	O
especially	O
among	O
immunocompromised	O
individuals	O
.	O

L	B-bacteria
.	I-bacteria
monocytogenes	I-bacteria
infection	O
usually	O
requires	O
antibiotic	O
treatment	O
,	O
however	O
,	O
excessive	O
use	O
of	O
antibiotics	O
promotes	O
emergence	O
of	O
antibiotic	O
resistance	O
and	O
the	O
destruction	O
of	O
gut	O
microbiota	O
.	O

Probiotics	O
,	O
including	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
,	O
have	O
been	O
repeatedly	O
proven	O
as	O
an	O
alternative	O
approach	O
for	O
the	O
treatment	O
of	O
various	O
infections	O
.	O

We	O
have	O
analyzed	O
the	O
potential	O
of	O
Enterococcus	B-bacteria
faecium	I-bacteria
BGPAS1	I-bacteria
-	I-bacteria
3	I-bacteria
,	O
a	O
dairy	O
isolate	O
exhibiting	O
strong	O
direct	O
antilisterial	O
effect	O
,	O
to	O
modulate	O
the	O
response	O
of	O
differentiated	O
Caco	O
-	O
2	O
intestinal	O
epithelial	O
cells	O
to	O
L	B-bacteria
.	I-bacteria
monocytogenes	I-bacteria
ATCC	I-bacteria
19111	I-bacteria
infection	O
.	O

We	O
showed	O
that	O
the	O
molecule	O
with	O
antilisterial	O
effect	O
is	O
a	O
bacterial	O
cell	O
-	O
wall	O
protein	O
that	O
is	O
highly	O
resistant	O
to	O
the	O
high	O
-	O
temperature	O
treatment	O
.	O

When	O
we	O
tested	O
the	O
antilisterial	O
potential	O
of	O
heat	O
-	O
killed	O
BGPAS1	O
-	O
3	O
,	O
we	O
found	O
that	O
it	O
could	O
prevent	O
tight	O
junction	O
disruption	O
in	O
differentiated	O
Caco	O
-	O
2	O
monolayer	O
infected	O
with	O
L	B-bacteria
.	I-bacteria
monocytogenes	I-bacteria
ATCC	I-bacteria
19111	I-bacteria
,	O
induce	O
antilisterial	O
host	O
response	O
mechanisms	O
,	O
and	O
stimulate	O
the	O
production	O
of	O
protective	O
TGF	O
-	O
beta	O
in	O
intestinal	O
epithelial	O
cells	O
.	O

We	O
also	O
showed	O
that	O
the	O
modulation	O
of	O
MyD88	O
dependent	O
TLR2	O
and	O
TLR4	O
pathways	O
by	O
BGPAS1	O
-	O
3	O
are	O
involved	O
in	O
host	O
response	O
against	O
L	B-bacteria
.	I-bacteria
monocytogenes	I-bacteria
ATCC	I-bacteria
19111	I-bacteria
.	O

Since	O
heat	O
-	O
killed	O
BGPAS1	O
-	O
3	O
possess	O
strong	O
antilisterial	O
effects	O
,	O
such	O
postbiotic	O
could	O
be	O
used	O
as	O
a	O
controllable	O
and	O
safe	O
therapeutic	O
.	O

Elevated	O
Gut	O
Microbiome	O
-	O
Derived	O
Propionate	O
Levels	O
Are	O
Associated	O
With	O
Reduced	O
Sterile	O
Lung	O
Inflammation	O
and	O
Bacterial	O
Immunity	O
in	O
Mice	O
.	O

Short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFA	O
)	O
are	O
important	O
dietary	O
and	O
microbiome	O
metabolites	O
that	O
can	O
have	O
roles	O
in	O
gut	O
immunity	O
as	O
well	O
as	O
further	O
afield	O
.	O

We	O
previously	O
observed	O
that	O
gut	O
microbiome	O
alteration	O
via	O
antibiotics	O
led	O
to	O
attenuated	O
lung	O
inflammatory	O
responses	O
.	O

The	O
rationale	O
for	O
this	O
study	O
was	O
to	O
identify	O
gut	O
microbiome	O
factors	O
that	O
regulate	O
lung	O
immune	O
homeostasis	O
.	O

We	O
first	O
investigated	O
key	O
factors	O
within	O
mouse	O
colonic	O
lumen	O
filtrates	O
(	O
CLF	O
)	O
which	O
could	O
elicit	O
direct	O
inflammatory	O
effects	O
in	O
vitro	O
.	O

We	O
identified	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
SCFAs	O
as	O
key	O
CLF	O
ingredients	O
whose	O
levels	O
and	O
inflammatory	O
capacity	O
changed	O
after	O
antibiotic	O
exposure	O
in	O
mice	O
.	O

Specifically	O
,	O
the	O
SCFA	O
propionate	O
appeared	O
to	O
be	O
a	O
key	O
regulator	O
of	O
LPS	O
responses	O
in	O
vitro	O
.	O

Elevated	O
propionate	O
:	O
acetate	O
ratios	O
,	O
as	O
seen	O
in	O
CLF	O
after	O
antibiotic	O
exposure	O
,	O
strongly	O
blunted	O
inflammatory	O
responses	O
in	O
vitro	O
.	O

In	O
vivo	O
,	O
exposure	O
of	O
lungs	O
to	O
high	O
dose	O
propionate	O
,	O
to	O
mimic	O
how	O
prior	O
antibiotic	O
exposure	O
changed	O
SCFA	O
levels	O
,	O
resulted	O
in	O
diminished	O
immune	O
containment	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
pneumonia	O
.	O

Finally	O
,	O
we	O
discovered	O
an	O
enrichment	O
of	O
propionate	O
-	O
producing	O
gut	O
bacteria	O
in	O
mice	O
with	O
reduced	O
lung	O
inflammation	O
following	O
lung	O
ischemia	O
reperfusion	O
injury	O
in	O
vivo	O
.	O

Overall	O
,	O
our	O
data	O
show	O
that	O
propionate	O
levels	O
can	O
distinctly	O
modulate	O
lung	O
immune	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
that	O
gut	O
microbiome	O
increased	O
production	O
of	O
propionate	O
is	O
associated	O
with	O
reduced	O
lung	O
inflammation	O
.	O

Effects	O
of	O
Early	O
Intervention	O
With	O
Maternal	O
Fecal	O
Bacteria	O
and	O
Antibiotics	O
on	O
Liver	O
Metabolome	O
and	O
Transcription	O
in	O
Neonatal	O
Pigs	O
.	O

The	O
establishment	O
of	O
a	O
stable	O
bacterial	O
flora	O
in	O
early	O
life	O
is	O
associated	O
with	O
host	O
metabolism	O
.	O

Studies	O
of	O
fecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
and	O
antibiotics	O
on	O
neonatal	O
pig	O
mainly	O
focused	O
on	O
intestinal	O
development	O
and	O
mucosal	O
immunity	O
,	O
but	O
the	O
information	O
on	O
metabolism	O
is	O
lacking	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
responses	O
of	O
metabolome	O
and	O
transcriptome	O
in	O
the	O
livers	O
of	O
neonatal	O
piglets	O
that	O
were	O
orally	O
inoculated	O
with	O
maternal	O
fecal	O
bacteria	O
suspension	O
and	O
amoxicillin	O
(	O
AM	O
)	O
solution	O
.	O

Five	O
litters	O
of	O
Duroc	O
x	O
Landrace	O
x	O
Yorkshire	O
neonatal	O
piglets	O
were	O
used	O
as	O
five	O
replicates	O
and	O
nine	O
piglets	O
in	O
each	O
litter	O
were	O
randomly	O
assigned	O
to	O
the	O
control	O
(	O
CO	O
)	O
,	O
AM	O
or	O
FMT	O
groups	O
.	O

Neonatal	O
piglets	O
in	O
three	O
groups	O
were	O
fed	O
with	O
3	O
mL	O
saline	O
(	O
0	O
.	O
9	O
%	O
)	O
,	O
AM	O
solution	O
(	O
6	O
.	O
94	O
mg	O
/	O
mL	O
)	O
or	O
fecal	O
bacteria	O
suspension	O
(	O
>	O
10	O
(	O
9	O
)	O
/	O
mL	O
)	O
,	O
respectively	O
,	O
on	O
days	O
1	O
-	O
6	O
.	O

At	O
the	O
age	O
of	O
7	O
and	O
21	O
days	O
,	O
one	O
piglet	O
from	O
each	O
group	O
in	O
each	O
litter	O
was	O
sacrificed	O
,	O
and	O
the	O
serum	O
and	O
liver	O
were	O
collected	O
for	O
analysis	O
.	O

The	O
RNA	O
sequencing	O
analysis	O
showed	O
that	O
the	O
mRNA	O
expressions	O
of	O
arachidonate	O
12	O
-	O
lipoxygenase	O
(	O
ALOX12	O
)	O
,	O
acetyl	O
-	O
CoA	O
acyltransferase	O
2	O
(	O
ACAA2	O
)	O
,	O
cytochrome	O
P450	O
family	O
1	O
subfamily	O
A	O
member	O
2	O
(	O
CYP1A2	O
)	O
,	O
glutamic	O
-	O
pyruvic	O
transaminase	O
2	O
(	O
GPT2	O
)	O
and	O
argininosuccinate	O
synthase	O
1	O
(	O
ASS1	O
)	O
were	O
downregulated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
by	O
AM	O
on	O
day	O
7	O
,	O
and	O
that	O
the	O
mRNA	O
expressions	O
of	O
arachidonate	O
15	O
-	O
lipoxygenase	O
(	O
ALOX15	O
)	O
,	O
CYP1A2	O
and	O
GPT2	O
were	O
downregulated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
by	O
FMT	O
on	O
day	O
7	O
.	O

GC	O
-	O
MS	O
analysis	O
showed	O
that	O
AM	O
and	O
FMT	O
treatments	O
mainly	O
affected	O
fatty	O
acid	O
metabolism	O
and	O
amino	O
acid	O
metabolism	O
on	O
days	O
7	O
and	O
21	O
.	O

AM	O
and	O
FMT	O
both	O
reduced	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
blood	O
levels	O
of	O
triglycerides	O
and	O
low	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
on	O
day	O
7	O
.	O

AM	O
reduced	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
blood	O
level	O
of	O
cholesterol	O
on	O
day	O
21	O
,	O
and	O
FMT	O
reduced	O
the	O
blood	O
levels	O
of	O
cholesterol	O
,	O
triglycerides	O
and	O
LDL	O
-	O
C	O
on	O
day	O
21	O
.	O

These	O
results	O
indicate	O
that	O
early	O
intervention	O
with	O
FMT	O
or	O
AM	O
can	O
reduce	O
fatty	O
acid	O
oxidative	O
catabolism	O
and	O
amino	O
acid	O
biosynthesis	O
of	O
neonatal	O
piglets	O
,	O
which	O
provides	O
a	O
reference	O
for	O
regulation	O
host	O
metabolism	O
through	O
early	O
intervention	O
in	O
animal	O
production	O
and	O
even	O
human	O
health	O
.	O

Common	O
miRNA	O
Patterns	O
of	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Parkinson	O
'	O
s	O
Disease	O
and	O
Their	O
Putative	O
Impact	O
on	O
Commensal	O
Gut	O
Microbiota	O
.	O

With	O
the	O
rise	O
of	O
Next	O
-	O
Generation	O
-	O
Sequencing	O
(	O
NGS	O
)	O
methods	O
,	O
Micro	O
-	O
RNAs	O
(	O
miRNAs	O
)	O
have	O
achieved	O
an	O
important	O
position	O
in	O
the	O
research	O
landscape	O
and	O
have	O
been	O
found	O
to	O
present	O
valuable	O
diagnostic	O
tools	O
in	O
various	O
diseases	O
such	O
as	O
multiple	O
sclerosis	O
or	O
lung	O
cancer	O
.	O

There	O
is	O
also	O
emerging	O
evidence	O
that	O
miRNAs	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
neurodegenerative	O
diseases	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
or	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O

Apparently	O
,	O
these	O
diseases	O
come	O
along	O
with	O
changes	O
in	O
miRNA	O
expression	O
patterns	O
which	O
led	O
to	O
attempts	O
from	O
researchers	O
to	O
use	O
these	O
small	O
RNA	O
species	O
from	O
several	O
body	O
fluids	O
for	O
a	O
better	O
diagnosis	O
and	O
in	O
order	O
to	O
observe	O
disease	O
progression	O
.	O

Additionally	O
,	O
it	O
became	O
evident	O
that	O
microbial	O
commensals	O
might	O
play	O
an	O
important	O
role	O
for	O
pathology	O
development	O
and	O
were	O
shown	O
to	O
have	O
a	O
significantly	O
different	O
composition	O
in	O
patients	O
suffering	O
from	O
neurodegeneration	O
compared	O
with	O
healthy	O
controls	O
.	O

As	O
it	O
could	O
recently	O
be	O
shown	O
that	O
secreted	O
miRNAs	O
are	O
able	O
to	O
enter	O
microbial	O
organisms	O
,	O
it	O
is	O
conceivable	O
that	O
the	O
host	O
'	O
s	O
miRNA	O
might	O
affect	O
the	O
gut	O
microbial	O
ecosystem	O
.	O

As	O
such	O
,	O
miRNAs	O
may	O
inherit	O
a	O
central	O
role	O
in	O
shaping	O
the	O
`	O
`	O
diseased	O
microbiome	O
'	O
'	O
and	O
thereby	O
mutually	O
act	O
on	O
the	O
characteristics	O
of	O
these	O
neurodegenerative	O
diseases	O
.	O

We	O
have	O
therefore	O
(	O
1	O
)	O
compiled	O
a	O
list	O
of	O
miRNAs	O
known	O
to	O
be	O
associated	O
with	O
AD	O
and	O
/	O
or	O
PD	O
,	O
(	O
2	O
)	O
performed	O
an	O
in	O
silico	O
target	O
screen	O
for	O
binding	O
sites	O
of	O
these	O
miRNA	O
on	O
human	O
gut	O
metagenome	O
sequences	O
and	O
(	O
3	O
)	O
evaluated	O
the	O
hit	O
list	O
for	O
interesting	O
matches	O
potentially	O
relevant	O
to	O
the	O
etiology	O
of	O
AD	O
and	O
or	O
PD	O
.	O

The	O
examination	O
of	O
protein	O
identifiers	O
connected	O
to	O
bacterial	O
secretion	O
system	O
,	O
lipopolysaccharide	O
biosynthesis	O
and	O
biofilm	O
formation	O
revealed	O
an	O
overlap	O
of	O
37	O
bacterial	O
proteins	O
that	O
were	O
targeted	O
by	O
human	O
miRNAs	O
.	O

The	O
identified	O
links	O
of	O
miRNAs	O
to	O
the	O
biological	O
processes	O
of	O
bacteria	O
connected	O
to	O
AD	O
and	O
PD	O
have	O
yet	O
to	O
be	O
validated	O
via	O
in	O
vivo	O
experiments	O
.	O

However	O
,	O
our	O
results	O
show	O
a	O
promising	O
new	O
approach	O
for	O
understanding	O
aspects	O
of	O
these	O
neurodegenerative	O
diseases	O
in	O
light	O
of	O
the	O
regulation	O
of	O
the	O
microbiome	O
.	O

Malassezia	B-bacteria
restricta	I-bacteria
plays	O
CARDs	O
in	O
the	O
gut	O
.	O

Modeling	O
gut	O
-	O
brain	O
interactions	O
in	O
zebrafish	O
.	O

Mounting	O
clinical	O
and	O
experimental	O
evidence	O
suggests	O
the	O
gut	O
-	O
brain	O
interplay	O
as	O
a	O
novel	O
important	O
paradigm	O
in	O
translational	O
neuroscience	O
,	O
including	O
the	O
critical	O
role	O
for	O
gut	O
microbiota	O
in	O
modulating	O
brain	O
development	O
and	O
behavior	O
,	O
as	O
well	O
as	O
neuroimmune	O
and	O
neuroendocrine	O
responses	O
.	O

Animal	O
models	O
are	O
an	O
indispensable	O
tool	O
in	O
studying	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
disorders	O
and	O
their	O
mechanisms	O
.	O

Recently	O
,	O
the	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
has	O
become	O
a	O
powerful	O
new	O
model	O
organism	O
in	O
neuroscience	O
,	O
including	O
studying	O
the	O
gut	O
-	O
brain	O
axis	O
.	O

Here	O
,	O
we	O
discuss	O
zebrafish	O
models	O
of	O
gut	O
-	O
brain	O
interplay	O
,	O
endocrine	O
and	O
toxicological	O
effects	O
of	O
zebrafish	O
microbiota	O
,	O
and	O
their	O
impact	O
on	O
neuroimmune	O
and	O
behavioral	O
processes	O
.	O

We	O
particularly	O
emphasize	O
the	O
growing	O
utility	O
of	O
zebrafish	O
models	O
in	O
gut	O
-	O
brain	O
research	O
,	O
as	O
they	O
foster	O
future	O
discoveries	O
of	O
new	O
interconnections	O
between	O
these	O
systems	O
.	O

Mining	O
,	O
analyzing	O
,	O
and	O
integrating	O
viral	O
signals	O
from	O
metagenomic	O
data	O
.	O

BACKGROUND	O
:	O
Viruses	O
are	O
important	O
components	O
of	O
microbial	O
communities	O
modulating	O
community	O
structure	O
and	O
function	O
;	O
however	O
,	O
only	O
a	O
couple	O
of	O
tools	O
are	O
currently	O
available	O
for	O
phage	O
identification	O
and	O
analysis	O
from	O
metagenomic	O
sequencing	O
data	O
.	O

Here	O
we	O
employed	O
the	O
random	O
forest	O
algorithm	O
to	O
develop	O
VirMiner	O
,	O
a	O
web	O
-	O
based	O
phage	O
contig	O
prediction	O
tool	O
especially	O
sensitive	O
for	O
high	O
-	O
abundances	O
phage	O
contigs	O
,	O
trained	O
and	O
validated	O
by	O
paired	O
metagenomic	O
and	O
phagenomic	O
sequencing	O
data	O
from	O
the	O
human	O
gut	O
flora	O
.	O

RESULTS	O
:	O
VirMiner	O
achieved	O
41	O
.	O
06	O
%	O
+	O
/	O
-	O
17	O
.	O
51	O
%	O
sensitivity	O
and	O
81	O
.	O
91	O
%	O
+	O
/	O
-	O
4	O
.	O
04	O
%	O
specificity	O
in	O
the	O
prediction	O
of	O
phage	O
contigs	O
.	O

In	O
particular	O
,	O
for	O
the	O
high	O
-	O
abundance	O
phage	O
contigs	O
,	O
VirMiner	O
outperformed	O
other	O
tools	O
(	O
VirFinder	O
and	O
VirSorter	O
)	O
with	O
much	O
higher	O
sensitivity	O
(	O
65	O
.	O
23	O
%	O
+	O
/	O
-	O
16	O
.	O
94	O
%	O
)	O
than	O
VirFinder	O
(	O
34	O
.	O
63	O
%	O
+	O
/	O
-	O
17	O
.	O
96	O
%	O
)	O
and	O
VirSorter	O
(	O
18	O
.	O
75	O
%	O
+	O
/	O
-	O
15	O
.	O
23	O
%	O
)	O
at	O
almost	O
the	O
same	O
specificity	O
.	O

Moreover	O
,	O
VirMiner	O
provides	O
the	O
most	O
comprehensive	O
phage	O
analysis	O
pipeline	O
which	O
is	O
comprised	O
of	O
metagenomic	O
raw	O
reads	O
processing	O
,	O
functional	O
annotation	O
,	O
phage	O
contig	O
identification	O
,	O
and	O
phage	O
-	O
host	O
relationship	O
prediction	O
(	O
CRISPR	O
-	O
spacer	O
recognition	O
)	O
and	O
supports	O
two	O
-	O
group	O
comparison	O
when	O
the	O
input	O
(	O
metagenomic	O
sequence	O
data	O
)	O
includes	O
different	O
conditions	O
(	O
e	O
.	O
g	O
.	O
,	O
case	O
and	O
control	O
)	O
.	O

Application	O
of	O
VirMiner	O
to	O
an	O
independent	O
cohort	O
of	O
human	O
gut	O
metagenomes	O
obtained	O
from	O
individuals	O
treated	O
with	O
antibiotics	O
revealed	O
that	O
122	O
KEGG	O
orthology	O
and	O
118	O
Pfam	O
groups	O
had	O
significantly	O
differential	O
abundance	O
in	O
the	O
pre	O
-	O
treatment	O
samples	O
compared	O
to	O
samples	O
at	O
the	O
end	O
of	O
antibiotic	O
administration	O
,	O
including	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR	O
)	O
,	O
multidrug	O
resistance	O
,	O
and	O
protein	O
transport	O
.	O

The	O
VirMiner	O
webserver	O
is	O
available	O
at	O
http	O
:	O
/	O
/	O
sbb	O
.	O
hku	O
.	O
hk	O
/	O
VirMiner	O
/	O
.	O

CONCLUSIONS	O
:	O
We	O
developed	O
a	O
comprehensive	O
tool	O
for	O
phage	O
prediction	O
and	O
analysis	O
for	O
metagenomic	O
samples	O
.	O

Compared	O
to	O
VirSorter	O
and	O
VirFinder	O
-	O
the	O
most	O
widely	O
used	O
tools	O
-	O
VirMiner	O
is	O
able	O
to	O
capture	O
more	O
high	O
-	O
abundance	O
phage	O
contigs	O
which	O
could	O
play	O
key	O
roles	O
in	O
infecting	O
bacteria	O
and	O
modulating	O
microbial	O
community	O
dynamics	O
.	O

TRIAL	O
REGISTRATION	O
:	O
The	O
European	O
Union	O
Clinical	O
Trials	O
Register	O
,	O
EudraCT	O
Number	O
:	O
2013	O
-	O
003378	O
-	O
28	O
.	O

Registered	O
on	O
9	O
April	O
2014	O
.	O

Decreased	O
Protein	O
Kinase	O
C	O
-	O
beta	O
Type	O
II	O
Associated	O
with	O
the	O
Prominent	O
Endotoxin	O
Exhaustion	O
in	O
the	O
Macrophage	O
of	O
FcGRIIb	O
-	O
/	O
-	O
Lupus	O
Prone	O
Mice	O
is	O
Revealed	O
by	O
Phosphoproteomic	O
Analysis	O
.	O

Dysfunction	O
of	O
FcGRIIb	O
,	O
the	O
only	O
inhibitory	O
receptor	O
of	O
the	O
FcGR	O
family	O
,	O
is	O
commonly	O
found	O
in	O
the	O
Asian	O
population	O
and	O
is	O
possibly	O
responsible	O
for	O
the	O
extreme	O
endotoxin	O
exhaustion	O
in	O
lupus	O
.	O

Here	O
,	O
the	O
mechanisms	O
of	O
prominent	O
endotoxin	O
(	O
LPS	O
)	O
tolerance	O
in	O
FcGRIIb	O
-	O
/	O
-	O
mice	O
were	O
explored	O
on	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
using	O
phosphoproteomic	O
analysis	O
.	O

As	O
such	O
,	O
LPS	O
tolerance	O
decreased	O
several	O
phosphoproteins	O
in	O
the	O
FcGRIIb	O
-	O
/	O
-	O
macrophage	O
,	O
including	O
protein	O
kinase	O
C	O
-	O
beta	O
type	O
II	O
(	O
PRKCB	O
)	O
,	O
which	O
was	O
associated	O
with	O
phagocytosis	O
function	O
.	O

Overexpression	O
of	O
PRKCB	O
attenuated	O
LPS	O
tolerance	O
in	O
RAW264	O
.	O
7	O
cells	O
,	O
supporting	O
the	O
role	O
of	O
this	O
gene	O
in	O
LPS	O
tolerance	O
.	O

In	O
parallel	O
,	O
LPS	O
tolerance	O
in	O
macrophages	O
and	O
in	O
mice	O
was	O
attenuated	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
administration	O
.	O

This	O
treatment	O
induced	O
several	O
protein	O
kinase	O
C	O
families	O
,	O
including	O
PRKCB	O
.	O

However	O
,	O
PMA	O
attenuated	O
the	O
severity	O
of	O
mice	O
with	O
cecal	O
ligation	O
and	O
puncture	O
on	O
LPS	O
tolerance	O
preconditioning	O
in	O
FcGRIIb	O
-	O
/	O
-	O
but	O
not	O
in	O
wild	O
-	O
type	O
cells	O
.	O

The	O
significant	O
reduction	O
of	O
PRKCB	O
in	O
the	O
FcGRIIb	O
-	O
/	O
-	O
macrophage	O
over	O
wild	O
-	O
type	O
cell	O
possibly	O
induced	O
the	O
more	O
severe	O
LPS	O
-	O
exhaustion	O
and	O
increased	O
the	O
infection	O
susceptibility	O
in	O
FcGRIIb	O
-	O
/	O
-	O
mice	O
.	O

PMA	O
induced	O
PRKCB	O
,	O
improved	O
LPS	O
-	O
tolerance	O
,	O
and	O
attenuated	O
sepsis	O
severity	O
,	O
predominantly	O
in	O
FcGRIIb	O
-	O
/	O
-	O
mice	O
.	O

PRKCB	O
enhancement	O
might	O
be	O
a	O
promising	O
strategy	O
to	O
improve	O
macrophage	O
functions	O
in	O
lupus	O
patients	O
with	O
LPS	O
-	O
tolerance	O
from	O
chronic	O
infection	O
.	O

Associations	O
of	O
Probiotic	O
Fermented	O
Milk	O
(	O
PFM	O
)	O
and	O
Yogurt	O
Consumption	O
with	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
Components	O
of	O
the	O
Gut	O
Microbiota	O
in	O
Healthy	O
Adults	O
.	O

The	O
current	O
study	O
investigates	O
whether	O
probiotic	O
fermented	O
milk	O
(	O
PFM	O
)	O
and	O
yogurt	O
consumption	O
(	O
YC	O
)	O
are	O
related	O
to	O
both	O
the	O
ingested	O
bacteria	O
taxa	O
and	O
the	O
overall	O
gut	O
microbiota	O
(	O
GM	O
)	O
composition	O
in	O
healthy	O
adults	O
.	O

PFM	O
and	O
YC	O
habits	O
were	O
analyzed	O
in	O
260	O
subjects	O
(	O
51	O
%	O
male	O
)	O
by	O
specific	O
questionnaires	O
,	O
and	O
the	O
following	O
groups	O
were	O
considered	O
:	O
(	O
1	O
)	O
PFM	O
groups	O
:	O
nonconsumers	O
(	O
PFM	O
-	O
NC	O
,	O
n	O
=	O
175	O
)	O
and	O
consumers	O
(	O
PFM	O
,	O
n	O
=	O
85	O
)	O
,	O
divided	O
as	O
follows	O
:	O
Bifidobacterium	O
-	O
containing	O
PFM	O
(	O
Bif	O
-	O
PFM	O
;	O
n	O
=	O
33	O
)	O
,	O
Lactobacillus	O
-	O
containing	O
PFM	O
(	O
Lb	O
-	O
PFM	O
;	O
n	O
=	O
14	O
)	O
,	O
and	O
mixed	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
-	O
containing	O
PFM	O
(	O
Mixed	O
-	O
PFM	O
;	O
n	O
=	O
38	O
)	O
;	O
(	O
2	O
)	O
PFM	O
-	O
NC	O
were	O
classified	O
as	O
:	O
yogurt	O
nonconsumers	O
(	O
Y	O
-	O
NC	O
;	O
n	O
=	O
40	O
)	O
and	O
yogurt	O
consumers	O
(	O
n	O
=	O
135	O
)	O
.	O

GM	O
was	O
analyzed	O
through	O
16S	O
rRNA	O
sequencing	O
.	O

PFM	O
consumers	O
showed	O
higher	O
Bifidobacteria	B-bacteria
taxa	I-bacteria
levels	O
compared	O
to	O
NC	O
,	O
from	O
phylum	O
through	O
to	O
species	O
.	O

Specifically	O
,	O
Bif	O
-	O
PFM	O
consumption	O
was	O
related	O
to	O
higher	O
B	B-bacteria
.	I-bacteria
animalis	I-bacteria
levels	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
whereas	O
Lb	O
-	O
PFM	O
consumption	O
was	O
associated	O
to	O
higher	O
levels	O
of	O
Bifidobacterium	B-bacteria
(	O
p	O
<	O
0	O
.	O
045	O
)	O
and	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
(	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

YC	O
was	O
related	O
to	O
higher	O
levels	O
of	O
the	O
yogurt	O
starter	O
Streptococcus	B-bacteria
thermophilus	I-bacteria
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Lactobacilli	B-bacteria
and	O
the	O
overall	O
GM	O
were	O
not	O
related	O
either	O
to	O
YC	O
or	O
PFM	O
consumption	O
.	O

According	O
to	O
these	O
results	O
,	O
healthy	O
adults	O
might	O
benefit	O
from	O
PFM	O
intake	O
by	O
increasing	O
Bifidobacterium	B-bacteria
levels	O
.	O

Evaluation	O
of	O
Prebiotic	O
Potential	O
of	O
Three	O
Marine	O
Algae	O
Oligosaccharides	O
from	O
Enzymatic	O
Hydrolysis	O
.	O

Alginate	O
oligosaccharides	O
(	O
AlgO	O
)	O
,	O
agarose	O
oligosaccharides	O
(	O
AO	O
)	O
,	O
and	O
kappa	O
-	O
carrageenan	O
oligosaccharides	O
(	O
KCO	O
)	O
were	O
obtained	O
by	O
specific	O
enzymatic	O
hydrolysis	O
method	O
.	O

The	O
molecular	O
weight	O
distributions	O
of	O
the	O
three	O
oligosaccharides	O
were	O
1	O
.	O
0	O
(	O
-	O
)	O
5	O
.	O
0	O
kDa	O
,	O
0	O
.	O
4	O
(	O
-	O
)	O
1	O
.	O
4	O
kDa	O
,	O
and	O
1	O
.	O
0	O
(	O
-	O
)	O
7	O
.	O
0	O
kDa	O
,	O
respectively	O
.	O

The	O
culture	O
medium	O
was	O
supplemented	O
with	O
the	O
three	O
oligosaccharides	O
and	O
fermented	O
by	O
pig	O
fecal	O
microbiota	O
in	O
vitro	O
,	O
for	O
24	O
h	O
.	O
Each	O
oligosaccharide	O
was	O
capable	O
of	O
increasing	O
the	O
concentration	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
especially	O
butyric	O
acid	O
,	O
and	O
altering	O
the	O
microbiota	O
composition	O
.	O

Linear	O
discriminant	O
analysis	O
effect	O
size	O
(	O
LEfSe	O
)	O
analysis	O
results	O
showed	O
that	O
the	O
opportunistic	O
pathogenic	O
bacteria	O
Escherichia	B-bacteria
,	O
Shigella	B-bacteria
,	O
and	O
Peptoniphilus	B-bacteria
,	O
were	O
significantly	O
decreased	O
in	O
AlgO	O
supplemented	O
medium	O
.	O

AO	O
could	O
improve	O
the	O
gut	O
microbiota	O
composition	O
by	O
enriching	O
the	O
abundance	O
of	O
Ruminococcaceae	B-bacteria
,	O
Coprococcus	B-bacteria
,	O
Roseburia	B-bacteria
,	O
and	O
Faecalibacterium	B-bacteria
.	O

Besides	O
,	O
KCO	O
could	O
increase	O
the	O
abundance	O
of	O
SCFA	O
microbial	O
producers	O
and	O
opportunistic	O
pathogenic	O
flora	O
.	O

Therefore	O
,	O
these	O
results	O
indicate	O
that	O
AlgO	O
and	O
AO	O
can	O
be	O
used	O
as	O
gut	O
microbial	O
regulators	O
and	O
can	O
potentially	O
improve	O
animal	O
/	O
human	O
gastrointestinal	O
health	O
and	O
prevent	O
gut	O
disease	O
,	O
whereas	O
the	O
physiological	O
function	O
of	O
KCO	O
needs	O
further	O
evaluation	O
.	O

Microbiome	O
patterns	O
reveal	O
the	O
transmission	O
of	O
pathogenic	O
bacteria	O
in	O
hilsa	O
fish	O
(	O
Tenualosa	O
ilisha	O
)	O
marketed	O
for	O
human	O
consumption	O
in	O
Bangladesh	O
.	O

AIMS	O
:	O
This	O
study	O
conducted	O
bacterial	O
community	O
,	O
virulence	O
and	O
antibiogram	O
profiling	O
inside	O
the	O
hindgut	O
and	O
skin	O
of	O
freshly	O
caught	O
hilsa	O
fish	O
and	O
those	O
sold	O
at	O
markets	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
results	O
of	O
16S	O
rRNA	O
-	O
based	O
high	O
-	O
throughput	O
sequencing	O
showed	O
a	O
higher	O
number	O
of	O
bacterial	O
genera	O
in	O
marketed	O
fish	O
samples	O
than	O
in	O
fresh	O
fish	O
samples	O
.	O

The	O
total	O
operational	O
taxonomic	O
units	O
,	O
genus	O
counts	O
and	O
diversity	O
index	O
were	O
significantly	O
higher	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
in	O
marketed	O
fish	O
,	O
which	O
also	O
had	O
abundant	O
pathogenic	O
bacterial	O
groups	O
.	O

Skin	O
samples	O
had	O
a	O
lower	O
profusion	O
of	O
pathogenic	O
bacteria	O
than	O
gut	O
samples	O
.	O

A	O
total	O
of	O
52	O
bacterial	O
isolates	O
from	O
nine	O
species	O
were	O
identified	O
in	O
this	O
study	O
,	O
of	O
which	O
25	O
were	O
from	O
a	O
Chittagong	O
market	O
and	O
22	O
were	O
from	O
a	O
Dhaka	O
market	O
,	O
whereas	O
only	O
five	O
were	O
from	O
fresh	O
hilsa	O
.	O

The	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
12	O
species	O
-	O
specific	O
virulence	O
genes	O
in	O
the	O
52	O
isolates	O
,	O
namely	O
,	O
aer	O
,	O
hly	O
,	O
chxA	O
,	O
toxB	O
,	O
rtxC	O
,	O
sfa	O
,	O
uge	O
,	O
norB	O
,	O
trx	O
,	O
toxA	O
,	O
ipaH	O
,	O
sigA	O
and	O
coa	O
,	O
indicated	O
a	O
high	O
number	O
of	O
positive	O
samples	O
containing	O
Vibrio	B-bacteria
cholerae	I-bacteria
,	O
Aeromonas	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
,	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
Staphylococcus	B-bacteria
aureus	I-bacteria
.	O

Antibiogram	O
profiling	O
of	O
these	O
bacteria	O
against	O
10	O
commercial	O
antibiotics	O
showed	O
high	O
-	O
resistance	O
patterns	O
of	O
the	O
isolates	O
against	O
sulfamethoxazole	O
,	O
kanamycin	O
,	O
neomycin	O
,	O
ampicillin	O
and	O
tetracycline	O
.	O

CONCLUSION	O
:	O
The	O
results	O
reveal	O
the	O
spread	O
of	O
multidrug	O
-	O
resistant	O
bacteria	O
in	O
hilsa	O
fish	O
marketed	O
for	O
human	O
consumption	O
in	O
Bangladesh	O
.	O

SIGNIFICANCE	O
AND	O
IMPACT	O
OF	O
THE	O
STUDY	O
:	O
This	O
study	O
highlights	O
the	O
risk	O
of	O
spreading	O
environmentally	O
and	O
clinically	O
pathogenic	O
bacteria	O
in	O
fish	O
sold	O
for	O
human	O
consumption	O
in	O
Bangladesh	O
.	O

Such	O
bacteria	O
come	O
from	O
aquatic	O
pollution	O
and	O
poor	O
handling	O
,	O
storage	O
and	O
transportation	O
practices	O
that	O
may	O
predispose	O
fish	O
to	O
major	O
outbreaks	O
of	O
infectious	O
and	O
waterborne	O
diseases	O
.	O

Probiotic	O
Activity	O
of	O
Enterococcus	B-bacteria
faecium	I-bacteria
and	O
Lactococcus	B-bacteria
lactis	I-bacteria
Isolated	O
from	O
Thai	O
Fermented	O
Sausages	O
and	O
Their	O
Protective	O
Effect	O
Against	O
Clostridium	B-bacteria
difficile	I-bacteria
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
,	O
Enterococcus	B-bacteria
faecium	I-bacteria
and	O
Lactococcus	B-bacteria
lactis	I-bacteria
,	O
previously	O
isolated	O
from	O
Thai	O
fermented	O
sausages	O
were	O
elucidated	O
their	O
probiotic	O
properties	O
especially	O
in	O
the	O
control	O
of	O
Clostridium	B-bacteria
difficile	I-bacteria
630	I-bacteria
.	O

Both	O
isolates	O
survived	O
in	O
simulated	O
gastric	O
solution	O
at	O
pH	O
3	O
followed	O
in	O
simulated	O
intestinal	O
solution	O
at	O
pH	O
8	O
.	O

The	O
presence	O
of	O
skimmed	O
milk	O
also	O
helped	O
the	O
bacteria	O
to	O
survive	O
through	O
acidic	O
and	O
alkaline	O
in	O
gastrointestinal	O
conditions	O
.	O

The	O
adhesion	O
properties	O
of	O
both	O
isolates	O
were	O
tested	O
using	O
a	O
human	O
colon	O
adenocarcinoma	O
cell	O
line	O
.	O

The	O
result	O
showed	O
that	O
both	O
isolates	O
exhibited	O
desirable	O
probiotic	O
properties	O
which	O
adhered	O
to	O
Caco	O
-	O
2	O
cells	O
.	O

The	O
neutralized	O
cell	O
-	O
free	O
supernatant	O
of	O
both	O
isolates	O
demonstrated	O
that	O
no	O
cytotoxicity	O
toward	O
Caco	O
-	O
2	O
cells	O
vice	O
versa	O
cell	O
-	O
free	O
supernatant	O
of	O
C	O
.	O
difficile	O
630	O
toward	O
Caco	O
-	O
2	O
cell	O
demonstrated	O
high	O
toxicity	O
.	O

The	O
immunomodulation	O
effect	O
in	O
response	O
to	O
bacterial	O
neutralized	O
cell	O
-	O
free	O
supernatant	O
and	O
cell	O
-	O
free	O
supernatant	O
was	O
also	O
studied	O
.	O

The	O
expression	O
level	O
of	O
pro	O
-	O
inflammatory	O
cytokine	O
of	O
Caco	O
-	O
2	O
cell	O
which	O
are	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
8	O
was	O
evaluated	O
using	O
quantitative	O
reverse	O
transcriptase	O
PCR	O
.	O

Both	O
isolates	O
were	O
able	O
to	O
diminish	O
the	O
expression	O
level	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
8	O
induced	O
by	O
the	O
cell	O
-	O
free	O
supernatant	O
of	O
C	O
.	O
difficile	O
630	O
.	O

Hence	O
,	O
these	O
isolates	O
would	O
be	O
able	O
to	O
improve	O
the	O
gut	O
health	O
through	O
counteracting	O
the	O
C	O
.	O
difficile	O
-	O
associated	O
intestinal	O
inflammation	O
in	O
human	O
cell	O
lines	O
.	O

These	O
results	O
may	O
contribute	O
to	O
the	O
development	O
of	O
the	O
isolates	O
using	O
as	O
probiotics	O
.	O

Understanding	O
the	O
gut	O
-	O
kidney	O
axis	O
among	O
biopsy	O
-	O
proven	O
diabetic	O
nephropathy	O
,	O
type	O
2	O
diabetes	O
mellitus	O
and	O
healthy	O
controls	O
:	O
an	O
analysis	O
of	O
the	O
gut	O
microbiota	O
composition	O
.	O

AIMS	O
:	O
Type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
has	O
a	O
rising	O
prevalence	O
and	O
gut	O
microbiota	O
involvement	O
is	O
increasingly	O
recognized	O
.	O

Diabetic	O
nephropathy	O
(	O
DN	O
)	O
is	O
a	O
major	O
complication	O
of	O
T2DM	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
understand	O
the	O
gut	O
-	O
kidney	O
axis	O
by	O
an	O
analysis	O
of	O
gut	O
microbiota	O
composition	O
among	O
biopsy	O
-	O
proven	O
DN	O
,	O
T2DM	O
without	O
kidney	O
disease	O
,	O
and	O
healthy	O
control	O
.	O

METHODS	O
:	O
Fecal	O
samples	O
were	O
collected	O
from	O
14	O
DNs	O
,	O
14	O
age	O
/	O
gender	O
-	O
matched	O
T2DMs	O
without	O
renal	O
diseases	O
(	O
DM	O
)	O
,	O
14	O
age	O
and	O
gender	O
-	O
matched	O
healthy	O
controls	O
(	O
HC	O
)	O
and	O
household	O
contacts	O
(	O
HH	O
)	O
of	O
DM	O
group	O
.	O

The	O
microbiota	O
composition	O
was	O
analyzed	O
by	O
16sRNA	O
microbial	O
profiling	O
approach	O
.	O

RESULTS	O
:	O
Substantial	O
differences	O
were	O
found	O
in	O
the	O
richness	O
of	O
gut	O
microbiota	O
and	O
the	O
variation	O
of	O
bacteria	O
population	O
in	O
DM	O
compared	O
to	O
HC	O
,	O
and	O
DN	O
compared	O
to	O
DM	O
,	O
respectively	O
.	O

DM	O
could	O
be	O
accurately	O
distinguished	O
from	O
age	O
/	O
gender	O
-	O
matched	O
healthy	O
controls	O
by	O
the	O
variable	O
of	O
genus	O
g	O
_	O
Prevotella	O
_	O
9	O
(	O
AUC	O
=	O
0	O
.	O
9	O
)	O
,	O
and	O
DN	O
patients	O
could	O
be	O
accurately	O
distinguished	O
from	O
age	O
/	O
gender	O
-	O
matched	O
DM	O
by	O
the	O
variables	O
of	O
two	O
genera	O
(	O
g	O
_	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
and	O
g	O
_	O
Prevotella	O
_	O
9	O
,	O
AUC	O
=	O
0	O
.	O
86	O
)	O
.	O

The	O
microbiota	O
composition	O
of	O
HH	O
group	O
was	O
close	O
to	O
that	O
of	O
HC	O
group	O
,	O
and	O
was	O
different	O
from	O
DM	O
group	O
.	O

Under	O
the	O
same	O
diet	O
,	O
DM	O
could	O
be	O
more	O
accurately	O
detected	O
by	O
the	O
same	O
genus	O
(	O
g	O
_	O
Prevotella	B-bacteria
_	I-bacteria
9	I-bacteria
,	O
AUC	O
=	O
0	O
.	O
92	O
)	O
.	O

CONCLUSION	O
:	O
Gut	O
microbiota	O
composition	O
was	O
explored	O
to	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
biopsy	O
-	O
proven	O
DN	O
from	O
DM	O
.	O

DM	O
could	O
be	O
distinguished	O
from	O
HC	O
by	O
detecting	O
g	B-bacteria
_	I-bacteria
Prevotella	I-bacteria
_	I-bacteria
9	I-bacteria
level	O
in	O
feces	O
,	O
while	O
DN	O
was	O
different	O
from	O
DM	O
by	O
the	O
variables	O
of	O
g	B-bacteria
_	I-bacteria
Escherichia	I-bacteria
-	I-bacteria
Shigella	I-bacteria
and	O
g	B-bacteria
_	I-bacteria
Prevotella	I-bacteria
_	I-bacteria
9	I-bacteria
,	O
which	O
potentially	O
contributed	O
to	O
the	O
physiopathological	O
diagnosis	O
of	O
DN	O
from	O
DM	O
.	O

Phage	O
therapy	O
:	O
What	O
factors	O
shape	O
phage	O
pharmacokinetics	O
and	O
bioavailability	O
?	O
Systematic	O
and	O
critical	O
review	O
.	O

Bacteriophages	O
are	O
not	O
forgotten	O
viruses	O
anymore	O
:	O
scientists	O
and	O
practitioners	O
seek	O
to	O
understand	O
phage	O
pharmacokinetics	O
in	O
animals	O
and	O
humans	O
,	O
investigating	O
bacteriophages	O
as	O
therapeutics	O
,	O
nanocarriers	O
or	O
microbiome	O
components	O
.	O

This	O
review	O
provides	O
a	O
comprehensive	O
overview	O
of	O
factors	O
that	O
determine	O
phage	O
circulation	O
,	O
penetration	O
,	O
and	O
clearance	O
,	O
and	O
that	O
in	O
consequence	O
determine	O
phage	O
applicability	O
for	O
medicine	O
.	O

It	O
makes	O
use	O
of	O
experimental	O
data	O
collected	O
by	O
the	O
phage	O
community	O
so	O
far	O
(	O
PubMed	O
1924	O
-	O
2016	O
,	O
including	O
non	O
-	O
English	O
reports	O
)	O
,	O
combining	O
elements	O
of	O
critical	O
and	O
systematic	O
review	O
.	O

This	O
study	O
covers	O
phage	O
ability	O
to	O
enter	O
a	O
system	O
by	O
various	O
routes	O
of	O
administration	O
,	O
how	O
(	O
and	O
if	O
)	O
the	O
phage	O
may	O
access	O
various	O
tissues	O
and	O
organs	O
,	O
and	O
finally	O
what	O
mechanisms	O
determine	O
the	O
courses	O
of	O
phage	O
clearance	O
.	O

The	O
systematic	O
review	O
method	O
was	O
applied	O
to	O
analyze	O
(	O
i	O
)	O
phage	O
survival	O
in	O
the	O
gut	O
(	O
gut	O
transit	O
)	O
and	O
(	O
ii	O
)	O
phage	O
ability	O
to	O
enter	O
the	O
mammalian	O
system	O
by	O
many	O
administration	O
routes	O
.	O

Aspects	O
that	O
have	O
not	O
yet	O
been	O
covered	O
by	O
a	O
sufficient	O
number	O
of	O
reports	O
for	O
mathematical	O
analysis	O
,	O
as	O
well	O
as	O
mechanisms	O
underlying	O
trends	O
,	O
are	O
discussed	O
in	O
the	O
form	O
of	O
a	O
critical	O
review	O
.	O

In	O
spite	O
of	O
the	O
extraordinary	O
diversity	O
of	O
bacteriophages	O
and	O
possible	O
phage	O
applications	O
,	O
the	O
analysis	O
revealed	O
that	O
phage	O
morphology	O
,	O
phage	O
specificity	O
,	O
phage	O
dose	O
,	O
presence	O
of	O
sensitive	O
bacteria	O
or	O
the	O
characteristics	O
of	O
treated	O
individuals	O
(	O
age	O
,	O
taxonomy	O
)	O
may	O
affect	O
phage	O
bioavailability	O
in	O
animals	O
and	O
humans	O
.	O

However	O
,	O
once	O
phages	O
successfully	O
enter	O
the	O
body	O
,	O
they	O
reach	O
most	O
organs	O
,	O
including	O
the	O
central	O
nervous	O
system	O
.	O

Bacteriophages	O
are	O
cleared	O
mainly	O
by	O
the	O
immune	O
system	O
:	O
innate	O
immunity	O
removes	O
phages	O
even	O
when	O
no	O
specific	O
response	O
to	O
bacteriophages	O
has	O
yet	O
developed	O
.	O

Gut	O
microbiota	O
from	O
infant	O
with	O
cow	O
'	O
s	O
milk	O
allergy	O
promotes	O
clinical	O
and	O
immune	O
features	O
of	O
atopy	O
in	O
a	O
murine	O
model	O
.	O

The	O
gut	O
microbiome	O
and	O
response	O
to	O
immune	O
checkpoint	O
inhibitors	O
:	O
preclinical	O
and	O
clinical	O
strategies	O
.	O

There	O
is	O
growing	O
interest	O
in	O
identifying	O
predictive	O
biomarkers	O
for	O
inhibitors	O
of	O
programmed	O
cell	O
death	O
protein	O
1	O
receptor	O
(	O
PD	O
-	O
1	O
)	O
,	O
programmed	O
death	O
ligand	O
1	O
(	O
PD	O
-	O
L1	O
)	O
,	O
and	O
cytotoxic	O
T	O
-	O
lymphocyte	O
associated	O
protein	O
4	O
(	O
CTLA	O
-	O
4	O
)	O
.	O

Given	O
the	O
links	O
between	O
the	O
stool	O
microbiota	O
,	O
anticancer	O
immunosurveillance	O
,	O
and	O
general	O
health	O
,	O
the	O
composition	O
of	O
the	O
gut	O
microbiome	O
has	O
recently	O
undergone	O
investigation	O
as	O
a	O
biomarker	O
for	O
immunotherapy	O
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
published	O
results	O
from	O
preclinical	O
and	O
clinical	O
studies	O
to	O
date	O
supporting	O
a	O
relationship	O
between	O
the	O
gut	O
microbiome	O
and	O
antitumor	O
efficacy	O
of	O
immune	O
checkpoint	O
inhibitors	O
.	O

Despite	O
the	O
promising	O
and	O
hypothesis	O
-	O
generating	O
findings	O
that	O
have	O
been	O
produced	O
in	O
this	O
arena	O
to	O
date	O
,	O
there	O
remain	O
some	O
inconsistencies	O
amongst	O
present	O
data	O
that	O
may	O
need	O
to	O
be	O
resolved	O
to	O
contribute	O
to	O
further	O
development	O
.	O

Among	O
these	O
,	O
a	O
better	O
understanding	O
of	O
the	O
immunomodulatory	O
function	O
of	O
the	O
microbiome	O
,	O
standardization	O
in	O
sampling	O
,	O
sequencing	O
techniques	O
,	O
and	O
data	O
analysis	O
,	O
and	O
ensuring	O
uniformity	O
across	O
various	O
aspects	O
of	O
study	O
design	O
are	O
warranted	O
in	O
conducting	O
future	O
prospective	O
studies	O
seeking	O
to	O
validate	O
the	O
gut	O
microbiome	O
as	O
a	O
potential	O
biomarker	O
of	O
response	O
to	O
checkpoint	O
blockade	O
.	O

Oxidative	O
Stress	O
in	O
the	O
Poultry	O
Gut	O
:	O
Potential	O
Challenges	O
and	O
Interventions	O
.	O

The	O
gastrointestinal	O
tract	O
(	O
GIT	O
)	O
provides	O
the	O
biological	O
environment	O
for	O
nutrient	O
digestion	O
and	O
absorption	O
,	O
and	O
protection	O
from	O
pathogens	O
and	O
toxins	O
.	O

Broilers	O
are	O
fast	O
growing	O
because	O
of	O
the	O
great	O
potential	O
of	O
intestinal	O
epithelia	O
for	O
nutrient	O
absorption	O
,	O
and	O
efficient	O
conversion	O
of	O
nutrient	O
to	O
muscle	O
.	O

Physiologically	O
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
reactive	O
nitrogen	O
species	O
(	O
RNS	O
)	O
are	O
generated	O
by	O
GIT	O
epithelial	O
cells	O
either	O
from	O
oxygen	O
metabolism	O
or	O
by	O
enteric	O
commensal	O
bacteria	O
and	O
regulate	O
gut	O
health	O
.	O

However	O
,	O
increased	O
production	O
of	O
ROS	O
elevates	O
free	O
radical	O
production	O
and	O
antioxidant	O
insults	O
resulting	O
in	O
oxidative	O
stress	O
.	O

Oxidative	O
stress	O
in	O
poultry	O
GIT	O
is	O
derived	O
from	O
nutritional	O
,	O
environmental	O
heat	O
stress	O
,	O
and	O
pathological	O
factors	O
,	O
which	O
alters	O
overall	O
performance	O
as	O
well	O
as	O
meat	O
and	O
egg	O
quality	O
.	O

Supplementation	O
of	O
exogenous	O
vitamins	O
,	O
antioxidants	O
,	O
and	O
plant	O
extract	O
having	O
antioxidant	O
properties	O
scavenge	O
ROS	O
and	O
are	O
beneficial	O
in	O
mitigating	O
oxidative	O
stress	O
in	O
the	O
GIT	O
.	O

This	O
review	O
highlights	O
the	O
involvement	O
of	O
oxidative	O
stress	O
in	O
the	O
gastrointestinal	O
functionality	O
of	O
poultry	O
and	O
potential	O
intervention	O
strategies	O
to	O
maintain	O
redox	O
balance	O
in	O
the	O
GIT	O
.	O

Dietary	O
Fiber	O
and	O
Intestinal	O
Health	O
of	O
Monogastric	O
Animals	O
.	O

Animal	O
performance	O
,	O
feed	O
efficiency	O
,	O
and	O
overall	O
health	O
are	O
heavily	O
dependent	O
on	O
gut	O
health	O
.	O

Changes	O
in	O
animal	O
production	O
systems	O
and	O
feed	O
regulations	O
away	O
from	O
the	O
use	O
of	O
antibiotic	O
growth	O
promoters	O
(	O
AGP	O
)	O
have	O
necessitated	O
the	O
identification	O
of	O
strategies	O
to	O
optimize	O
gut	O
health	O
in	O
novel	O
and	O
effective	O
ways	O
.	O

Among	O
alternatives	O
to	O
AGP	O
,	O
the	O
inclusion	O
of	O
dietary	O
fibers	O
(	O
DF	O
)	O
in	O
monogastric	O
diets	O
has	O
been	O
attempted	O
with	O
some	O
success	O
.	O

Alternative	O
feedstuffs	O
and	O
coproducts	O
are	O
typically	O
rich	O
in	O
fiber	O
and	O
can	O
be	O
used	O
in	O
the	O
diets	O
to	O
reduce	O
feed	O
costs	O
and	O
optimize	O
gut	O
health	O
.	O

DF	O
are	O
naturally	O
occurring	O
compounds	O
with	O
a	O
diverse	O
composition	O
and	O
are	O
present	O
in	O
all	O
plant	O
-	O
based	O
feedstuffs	O
.	O

DF	O
stimulate	O
the	O
growth	O
of	O
health	O
-	O
promoting	O
gut	O
bacteria	O
,	O
are	O
fermented	O
in	O
the	O
distal	O
small	O
intestine	O
and	O
large	O
intestine	O
to	O
short	O
-	O
chain	O
fatty	O
acids	O
and	O
have	O
beneficial	O
effects	O
on	O
the	O
immune	O
system	O
.	O

Maternal	O
DF	O
supplementation	O
is	O
one	O
novel	O
strategy	O
suggested	O
to	O
have	O
a	O
beneficial	O
programming	O
effect	O
on	O
the	O
microbial	O
and	O
immune	O
development	O
of	O
their	O
offspring	O
.	O

One	O
mechanism	O
by	O
which	O
DF	O
improves	O
gut	O
health	O
is	O
through	O
maintenance	O
of	O
an	O
anaerobic	O
intestinal	O
environment	O
that	O
subsequently	O
prevents	O
facultative	O
anaerobic	O
pathogens	O
from	O
flourishing	O
.	O

Studies	O
with	O
pigs	O
and	O
poultry	O
have	O
shown	O
that	O
fermentation	O
characteristics	O
and	O
their	O
beneficial	O
effects	O
on	O
gut	O
health	O
vary	O
widely	O
based	O
on	O
type	O
,	O
form	O
,	O
and	O
the	O
physico	O
-	O
chemical	O
properties	O
of	O
the	O
DF	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
have	O
information	O
on	O
the	O
different	O
types	O
of	O
DF	O
and	O
their	O
role	O
in	O
optimizing	O
gut	O
health	O
.	O

This	O
review	O
will	O
provide	O
information	O
and	O
updates	O
on	O
different	O
types	O
of	O
DF	O
used	O
in	O
monogastric	O
nutrition	O
and	O
its	O
contribution	O
to	O
gut	O
health	O
including	O
microbiology	O
,	O
fermentation	O
characteristics	O
,	O
and	O
innate	O
and	O
adaptive	O
immune	O
responses	O
.	O

Age	O
-	O
Associated	O
Heterogeneity	O
of	O
Ty21a	O
-	O
Induced	O
T	O
Cell	O
Responses	O
to	O
HLA	O
-	O
E	O
Restricted	O
Salmonella	B-bacteria
Typhi	I-bacteria
Antigen	O
Presentation	O
.	O

Human	O
-	O
restricted	O
Salmonella	B-bacteria
enterica	I-bacteria
serovar	I-bacteria
Typhi	I-bacteria
(	O
S	B-bacteria
.	I-bacteria
Typhi	I-bacteria
)	O
is	O
the	O
causative	O
agent	O
of	O
typhoid	O
fever	O
-	O
a	O
life	O
-	O
threatening	O
disease	O
of	O
great	O
global	O
health	O
significance	O
,	O
particularly	O
in	O
the	O
developing	O
world	O
.	O

Ty21a	B-bacteria
is	O
an	O
oral	O
live	O
-	O
attenuated	O
vaccine	O
that	O
protects	O
against	O
the	O
development	O
of	O
typhoid	O
disease	O
in	O
part	O
by	O
inducing	O
robust	O
T	O
cell	O
responses	O
,	O
among	O
which	O
multifunctional	O
CD8	O
(	O
+	O
)	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTL	O
)	O
play	O
an	O
important	O
role	O
.	O

Following	O
Ty21a	O
vaccination	O
,	O
a	O
significant	O
component	O
of	O
adult	O
CTL	O
have	O
shown	O
to	O
be	O
targeted	O
to	O
S	B-bacteria
.	I-bacteria
Typhi	I-bacteria
antigen	O
presented	O
by	O
the	O
conserved	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
Ib	O
molecule	O
,	O
human	O
leukocyte	O
antigen	O
-	O
E	O
(	O
HLA	O
-	O
E	O
)	O
.	O

S	B-bacteria
.	I-bacteria
Typhi	I-bacteria
challenge	O
studies	O
have	O
shown	O
that	O
baseline	O
,	O
multifunctional	O
HLA	O
-	O
E	O
responsive	O
T	O
cells	O
are	O
associated	O
with	O
protection	O
from	O
,	O
and	O
delayed	O
onset	O
of	O
,	O
typhoid	O
disease	O
.	O

However	O
,	O
despite	O
the	O
overwhelming	O
burden	O
of	O
typhoid	O
fever	O
in	O
school	O
-	O
aged	O
children	O
,	O
and	O
due	O
to	O
limited	O
availability	O
of	O
pediatric	O
samples	O
,	O
incomplete	O
information	O
is	O
available	O
regarding	O
these	O
important	O
HLA	O
-	O
E	O
-	O
restricted	O
responses	O
in	O
children	O
,	O
even	O
though	O
studies	O
have	O
shown	O
that	O
younger	O
children	O
may	O
be	O
less	O
likely	O
to	O
develop	O
protective	O
cell	O
mediated	O
immune	O
(	O
CMI	O
)	O
responses	O
than	O
adults	O
following	O
vaccination	O
.	O

To	O
address	O
this	O
gap	O
,	O
we	O
have	O
studied	O
this	O
phenomenon	O
in	O
depth	O
by	O
using	O
mass	O
cytometry	O
to	O
analyze	O
pediatric	O
and	O
adult	O
T	O
cell	O
responses	O
to	O
HLA	O
-	O
E	O
-	O
restricted	O
S	B-bacteria
.	I-bacteria
Typhi	I-bacteria
antigen	O
presentation	O
,	O
before	O
and	O
after	O
Ty21a	B-bacteria
vaccination	O
.	O

Herein	O
,	O
we	O
show	O
variable	O
responses	O
in	O
all	O
age	O
strata	O
following	O
vaccination	O
among	O
T	O
effector	O
memory	O
(	O
TEM	O
)	O
and	O
T	O
effector	O
memory	O
CD45RA	O
(	O
+	O
)	O
(	O
TEMRA	O
)	O
cells	O
based	O
on	O
conventional	O
gating	O
analysis	O
.	O

However	O
,	O
by	O
utilizing	O
the	O
dimensionality	O
reduction	O
tool	O
tSNE	O
(	O
t	O
-	O
distributed	O
Stochastic	O
Neighbor	O
Embedding	O
)	O
,	O
we	O
are	O
able	O
to	O
identify	O
diverse	O
,	O
highly	O
multifunctional	O
gut	O
-	O
homing	O
-	O
TEM	O
and	O
TEMRA	O
clusters	O
of	O
cells	O
which	O
are	O
more	O
abundant	O
in	O
adult	O
and	O
older	O
pediatric	O
participants	O
than	O
in	O
younger	O
children	O
.	O

These	O
findings	O
highlight	O
a	O
potential	O
age	O
-	O
associated	O
maturation	O
of	O
otherwise	O
conserved	O
HLA	O
-	O
E	O
restricted	O
T	O
cell	O
responses	O
.	O

Such	O
insights	O
,	O
coupled	O
with	O
the	O
marked	O
importance	O
of	O
multifunctional	O
T	O
cell	O
responses	O
to	O
combat	O
infection	O
,	O
may	O
better	O
inform	O
future	O
pediatric	O
vaccination	O
strategies	O
against	O
S	B-bacteria
.	I-bacteria
Typhi	I-bacteria
and	O
other	O
infectious	O
diseases	O
.	O

Diabetic	O
cats	O
have	O
decreased	O
gut	O
microbial	O
diversity	O
and	O
a	O
lack	O
of	O
butyrate	O
producing	O
bacteria	O
.	O

Obesity	O
and	O
inactivity	O
are	O
major	O
risk	O
factors	O
of	O
feline	O
diabetes	O
mellitus	O
(	O
FDM	O
)	O
and	O
human	O
type	O
II	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

In	O
recent	O
years	O
,	O
changes	O
in	O
the	O
gut	O
microbiota	O
have	O
been	O
suggested	O
as	O
a	O
contributing	O
factor	O
to	O
T2DM	O
.	O

Whether	O
the	O
gut	O
microbiota	O
(	O
GM	O
)	O
composition	O
plays	O
a	O
role	O
in	O
FDM	O
remains	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
firstly	O
a	O
cross	O
-	O
sectional	O
comparison	O
of	O
the	O
GM	O
of	O
diabetic	O
cats	O
,	O
to	O
that	O
of	O
lean	O
,	O
and	O
of	O
obese	O
/	O
overweight	O
non	O
-	O
diabetic	O
cats	O
of	O
a	O
similar	O
age	O
.	O

Specifically	O
,	O
fecal	O
samples	O
from	O
82	O
privately	O
-	O
owned	O
cats	O
from	O
Denmark	O
and	O
Switzerland	O
were	O
sequenced	O
using	O
16S	O
rRNA	O
gene	O
amplicon	O
metabarcoding	O
.	O

Secondly	O
dietary	O
intervention	O
data	O
was	O
generated	O
,	O
by	O
obtaining	O
additional	O
samples	O
from	O
a	O
subset	O
of	O
cats	O
after	O
placing	O
them	O
on	O
a	O
high	O
-	O
protein	O
diet	O
for	O
four	O
weeks	O
.	O

The	O
GM	O
diversity	O
of	O
diabetic	O
cats	O
was	O
lower	O
than	O
that	O
of	O
lean	O
cats	O
in	O
the	O
cross	O
-	O
sectional	O
study	O
,	O
and	O
lower	O
compared	O
to	O
lean	O
and	O
to	O
overweight	O
/	O
obese	O
cats	O
after	O
diet	O
intervention	O
.	O

Diabetic	O
cats	O
also	O
exhibited	O
fewer	O
Anaerotruncus	B-bacteria
,	O
Dialister	B-bacteria
,	O
and	O
unknown	O
Ruminococcaceae	B-bacteria
than	O
lean	O
cats	O
.	O

Serum	O
fructosamine	O
levels	O
correlated	O
negatively	O
with	O
Prevotellaceae	B-bacteria
abundance	O
and	O
positively	O
with	O
Enterobacteriaceae	B-bacteria
abundance	O
.	O

In	O
summary	O
the	O
intestinal	O
microbiota	O
of	O
diabetic	O
cats	O
was	O
characterized	O
by	O
decreased	O
GM	O
diversity	O
and	O
loss	O
of	O
butyrate	O
producing	O
bacterial	O
genera	O
.	O

Epigenetic	O
changes	O
induced	O
by	O
Bacteroides	B-bacteria
fragilis	I-bacteria
toxin	O
(	O
BFT	O
)	O
.	O

Enterotoxigenic	B-bacteria
Bacteroides	I-bacteria
fragilis	I-bacteria
(	O
ETBF	B-bacteria
)	O
is	O
a	O
gram	O
negative	O
,	O
obligate	O
anaerobe	O
member	O
of	O
the	O
gut	O
microbial	O
community	O
in	O
up	O
to	O
40	O
%	O
of	O
healthy	O
individuals	O
.	O

This	O
bacterium	O
is	O
found	O
more	O
frequently	O
in	O
people	O
with	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
and	O
causes	O
tumor	O
formation	O
in	O
the	O
distal	O
colon	O
of	O
Apc	O
(	O
min	O
/	O
+	O
)	O
mice	O
;	O
tumor	O
formation	O
is	O
dependent	O
on	O
ETBF	O
-	O
secreted	O
Bacteroides	B-bacteria
fragilis	I-bacteria
toxin	O
(	O
BFT	O
)	O
.	O

Because	O
of	O
the	O
extensive	O
data	O
connecting	O
alterations	O
in	O
the	O
epigenome	O
with	O
tumor	O
formation	O
,	O
initial	O
experiments	O
attempting	O
to	O
connect	O
BFT	O
-	O
induced	O
tumor	O
formation	O
with	O
methylation	O
in	O
colon	O
epithelial	O
cells	O
(	O
CECs	O
)	O
have	O
been	O
performed	O
,	O
but	O
the	O
effect	O
of	O
BFT	O
on	O
other	O
epigenetic	O
processes	O
,	O
such	O
as	O
chromatin	O
structure	O
,	O
remains	O
unexplored	O
.	O

Here	O
,	O
the	O
changes	O
in	O
gene	O
expression	O
(	O
RNA	O
-	O
seq	O
)	O
and	O
chromatin	O
accessibility	O
(	O
ATAC	O
-	O
seq	O
)	O
induced	O
by	O
treatment	O
of	O
HT29	O
/	O
C1	O
cells	O
with	O
BFT	O
for	O
24	O
and	O
48	O
hours	O
is	O
examined	O
.	O

Our	O
data	O
show	O
that	O
several	O
genes	O
are	O
differentially	O
expressed	O
after	O
BFT	O
treatment	O
and	O
these	O
changes	O
relate	O
to	O
the	O
interaction	O
between	O
bacteria	O
and	O
CECs	O
.	O

Further	O
,	O
sites	O
of	O
increased	O
chromatin	O
accessibility	O
are	O
associated	O
with	O
the	O
location	O
of	O
enhancers	O
in	O
CECs	O
and	O
binding	O
sites	O
of	O
transcription	O
factors	O
in	O
the	O
AP	O
-	O
1	O
/	O
ATF	O
family	O
;	O
they	O
are	O
also	O
enriched	O
for	O
common	O
differentially	O
methylated	O
regions	O
(	O
DMRs	O
)	O
in	O
CRC	O
.	O

These	O
data	O
provide	O
insight	O
into	O
the	O
mechanisms	O
by	O
which	O
BFT	O
induces	O
tumor	O
formation	O
and	O
lay	O
the	O
groundwork	O
for	O
future	O
in	O
vivo	O
studies	O
to	O
explore	O
the	O
impact	O
of	O
BFT	O
on	O
nuclear	O
structure	O
and	O
function	O
.	O

Fate	O
of	O
CMY	O
-	O
2	O
-	O
Encoding	O
Plasmids	O
Introduced	O
into	O
the	O
Human	O
Fecal	O
Microbiota	O
by	O
Exogenous	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

The	O
gut	O
is	O
a	O
hot	O
spot	O
for	O
transfer	O
of	O
antibiotic	O
resistance	O
genes	O
from	O
ingested	O
exogenous	O
bacteria	O
to	O
the	O
indigenous	O
microbiota	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
fate	O
of	O
two	O
nearly	O
identical	O
bla	O
CMY	O
-	O
2	O
-	O
harboring	O
plasmids	O
introduced	O
into	O
the	O
human	O
fecal	O
microbiota	O
by	O
two	O
Escherichia	O
coli	I-bacteria
strains	I-bacteria
isolated	O
from	O
a	O
human	O
and	O
from	O
poultry	O
meat	O
.	O

The	O
chromosome	O
and	O
the	O
CMY	O
-	O
2	O
-	O
encoding	O
plasmid	O
of	O
both	O
strains	O
were	O
labeled	O
with	O
distinct	O
fluorescent	O
markers	O
(	O
mCherry	O
and	O
green	O
fluorescent	O
protein	O
[	O
GFP	O
]	O
)	O
,	O
allowing	O
fluorescence	O
-	O
activated	O
cell	O
sorting	O
(	O
FACS	O
)	O
-	O
based	O
tracking	O
of	O
the	O
strain	O
and	O
the	O
resident	O
bacteria	O
that	O
have	O
acquired	O
its	O
plasmid	O
.	O

Each	O
strain	O
was	O
introduced	O
into	O
an	O
established	O
in	O
vitro	O
gut	O
model	O
(	O
CoMiniGut	O
)	O
inoculated	O
with	O
individual	O
feces	O
from	O
ten	O
healthy	O
volunteers	O
.	O

Fecal	O
samples	O
collected	O
2	O
,	O
6	O
,	O
and	O
24	O
h	O
after	O
strain	O
inoculation	O
were	O
analyzed	O
by	O
FACS	O
and	O
plate	O
counts	O
.	O

Although	O
the	O
human	O
strain	O
survived	O
better	O
than	O
the	O
poultry	O
meat	O
strain	O
,	O
both	O
strains	O
transferred	O
their	O
plasmids	O
to	O
the	O
fecal	O
microbiota	O
at	O
concentrations	O
as	O
low	O
as	O
10	O
(	O
2	O
)	O
CFU	O
/	O
ml	O
.	O

Strain	O
survival	O
and	O
plasmid	O
transfer	O
varied	O
significantly	O
depending	O
on	O
inoculum	O
concentration	O
and	O
individual	O
fecal	O
microbiota	O
.	O

Identification	O
of	O
transconjugants	O
by	O
16S	O
rRNA	O
gene	O
sequencing	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
-	O
time	O
of	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
MS	O
)	O
revealed	O
that	O
the	O
plasmids	O
were	O
predominantly	O
acquired	O
by	O
Enterobacteriaceae	B-bacteria
species	I-bacteria
,	O
such	O
as	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
Hafnia	B-bacteria
alvei	I-bacteria
Our	O
experimental	O
data	O
demonstrate	O
that	O
exogenous	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
of	O
human	O
or	O
animal	O
origin	O
can	O
readily	O
transfer	O
CMY	O
-	O
2	O
-	O
encoding	O
IncI1	O
plasmids	O
to	O
the	O
human	O
fecal	O
microbiota	O
.	O

Small	O
amounts	O
of	O
the	O
exogenous	O
strain	O
are	O
sufficient	O
to	O
ensure	O
plasmid	O
transfer	O
if	O
the	O
strain	O
is	O
able	O
to	O
survive	O
the	O
gastric	O
environment	O
.	O

Immunosuppression	O
-	O
induced	O
alterations	O
in	O
fish	O
gut	O
microbiota	O
may	O
increase	O
the	O
susceptibility	O
to	O
pathogens	O
.	O

Intestinal	O
bacteria	O
play	O
an	O
important	O
role	O
in	O
the	O
health	O
and	O
provide	O
a	O
variety	O
of	O
beneficial	O
effects	O
to	O
host	O
.	O

Immunosuppressant	O
can	O
reduce	O
the	O
immunity	O
of	O
host	O
and	O
increase	O
the	O
susceptibility	O
to	O
pathogens	O
.	O

But	O
it	O
is	O
not	O
clear	O
whether	O
the	O
increased	O
susceptibility	O
caused	O
by	O
immunosuppressant	O
is	O
related	O
to	O
changes	O
of	O
gut	O
microbiota	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
crucian	O
carp	O
administrated	O
with	O
dexamethasone	O
to	O
explore	O
the	O
effects	O
of	O
immunosuppressants	O
on	O
gut	O
microbial	O
communities	O
and	O
further	O
evaluate	O
the	O
potential	O
association	O
between	O
changes	O
in	O
gut	O
microbiota	O
and	O
susceptibility	O
to	O
pathogens	O
.	O

The	O
results	O
of	O
MANOVA	O
based	O
on	O
the	O
top	O
10	O
PCoA	O
axis	O
scores	O
from	O
unweighed	O
/	O
weighted	O
UniFrac	O
distances	O
showed	O
that	O
administration	O
of	O
dexamethasone	O
(	O
P	O
=	O
0	O
.	O
021	O
)	O
and	O
the	O
administration	O
time	O
(	O
P	O
=	O
0	O
.	O
027	O
)	O
had	O
a	O
significant	O
impact	O
on	O
the	O
gut	O
microbial	O
composition	O
,	O
regardless	O
of	O
pathogens	O
infection	O
status	O
(	O
P	O
=	O
0	O
.	O
35	O
)	O
.	O

After	O
administration	O
with	O
dexamethasone	O
,	O
the	O
fish	O
had	O
higher	O
abundance	O
of	O
Cetobacterium	B-bacteria
and	O
lower	O
abundance	O
of	O
Bacillus	B-bacteria
and	O
Lactococcus	B-bacteria
,	O
and	O
the	O
abundance	O
of	O
genus	O
Bacillus	B-bacteria
,	O
Pseudomonas	B-bacteria
and	O
Lactococcus	B-bacteria
decreased	O
along	O
with	O
prolong	O
administration	O
time	O
of	O
dexamethasone	O
.	O

The	O
results	O
may	O
help	O
us	O
understand	O
the	O
correlation	O
between	O
the	O
host	O
susceptibility	O
to	O
pathogenic	O
bacteria	O
and	O
gut	O
microbial	O
community	O
shift	O
,	O
and	O
extend	O
our	O
knowledge	O
regarding	O
the	O
role	O
of	O
gut	O
microbiota	O
in	O
keeping	O
the	O
balance	O
between	O
pathogenic	O
and	O
symbiotic	O
bacteria	O
.	O

Does	O
disease	O
start	O
in	O
the	O
mouth	O
,	O
the	O
gut	O
or	O
both	O
?	O

Oral	O
bacteria	O
colonize	O
the	O
gut	O
more	O
frequently	O
than	O
previously	O
thought	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
of	O
Lactobacillus	B-bacteria
strains	I-bacteria
and	O
comparative	O
genomic	O
analysis	O
of	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
CGMCC12436	I-bacteria
reveal	O
candidates	O
of	O
colonise	O
-	O
related	O
genes	O
.	O

The	O
presence	O
of	O
Lactobacillus	B-bacteria
strains	I-bacteria
in	O
dairy	O
products	O
and	O
the	O
intestinal	O
tracts	O
of	O
humans	O
and	O
animals	O
is	O
frequently	O
considered	O
to	O
have	O
beneficial	O
effects	O
on	O
gut	O
health	O
.	O

In	O
this	O
study	O
,	O
five	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
and	O
five	O
L	B-bacteria
.	I-bacteria
casei	I-bacteria
strains	I-bacteria
from	O
fermented	O
food	O
origin	O
were	O
isolated	O
and	O
compared	O
to	O
characterise	O
their	O
functional	O
properties	O
,	O
including	O
generation	O
time	O
,	O
survival	O
in	O
the	O
gastrointestinal	O
environmental	O
conditions	O
and	O
carbohydrate	O
utilisation	O
.	O

The	O
growth	O
rate	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
CGMCC12436	I-bacteria
was	O
the	O
same	O
level	O
with	O
that	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
strain	I-bacteria
ST	I-bacteria
-	I-bacteria
III	I-bacteria
.	O

The	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
CCFM605	I-bacteria
and	O
CGMCC12436	B-bacteria
maintained	O
the	O
similar	O
levels	O
of	O
cell	O
numbers	O
under	O
the	O
simulated	O
gastrointestinal	O
tract	O
,	O
which	O
were	O
comparable	O
to	O
the	O
cell	O
numbers	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
strain	I-bacteria
ST	I-bacteria
-	I-bacteria
III	O
.	O

The	O
L	B-bacteria
.	I-bacteria
casei	I-bacteria
CCFM236	I-bacteria
and	O
CGMCC12435	B-bacteria
exhibited	O
significant	O
higher	O
survival	O
rates	O
than	O
CCFM5	B-bacteria
in	O
the	O
duodenal	O
juice	O
.	O

The	O
evaluation	O
of	O
their	O
colonisation	O
in	O
the	O
mouse	O
gut	O
indicated	O
that	O
the	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
strain	I-bacteria
ST	I-bacteria
-	I-bacteria
III	I-bacteria
,	O
CCFM595	B-bacteria
and	O
CGMCC12436	B-bacteria
could	O
colonise	O
relatively	O
longer	O
than	O
other	O
tested	O
strains	O
.	O

Furthermore	O
,	O
two	O
strains	O
were	O
selected	O
for	O
characterisation	O
of	O
whole	O
genome	O
sequences	O
.	O

Among	O
the	O
identified	O
key	O
genes	O
responsible	O
for	O
the	O
functional	O
properties	O
,	O
we	O
found	O
that	O
the	O
cpsD	O
gene	O
cluster	O
in	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
CGMCC12436	I-bacteria
may	O
be	O
closely	O
associated	O
with	O
its	O
colonisation	O
ability	O
in	O
the	O
mouse	O
gut	O
during	O
and	O
after	O
discontinuing	O
the	O
strain	O
administration	O
.	O

In	O
conclusion	O
,	O
we	O
revealed	O
the	O
functional	O
properties	O
of	O
Lactobacillus	B-bacteria
strains	I-bacteria
in	O
vitro	O
assays	O
and	O
colonisation	O
properties	O
in	O
the	O
mouse	O
gut	O
,	O
and	O
elucidated	O
the	O
relevant	O
genes	O
involved	O
in	O
the	O
tolerance	O
or	O
colonisation	O
in	O
gut	O
using	O
comparative	O
genome	O
analysis	O
.	O

Probiotic	O
potential	O
of	O
a	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
cheese	O
isolate	O
and	O
its	O
effect	O
on	O
the	O
fecal	O
microbiota	O
of	O
healthy	O
volunteers	O
.	O

The	O
present	O
study	O
describes	O
an	O
in	O
vitro	O
characterization	O
of	O
strains	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
,	O
focusing	O
on	O
physiological	O
characters	O
of	O
probiotic	O
interest	O
,	O
and	O
a	O
subsequent	O
placebo	O
-	O
controlled	O
,	O
crossover	O
administration	O
trial	O
,	O
with	O
a	O
cohort	O
of	O
healthy	O
volunteers	O
.	O

The	O
strains	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
were	O
previously	O
isolated	O
from	O
a	O
fermented	O
food	O
(	O
ripened	O
cheese	O
)	O
and	O
several	O
ones	O
resulted	O
to	O
have	O
promising	O
probiotic	O
characteristics	O
.	O

Based	O
on	O
comprehensive	O
evaluation	O
of	O
the	O
data	O
obtained	O
,	O
one	O
strain	O
was	O
chosen	O
and	O
supplemented	O
in	O
a	O
fermented	O
milk	O
.	O

The	O
fermented	O
milk	O
was	O
then	O
used	O
in	O
the	O
administration	O
trial	O
with	O
the	O
goal	O
of	O
assessing	O
its	O
effect	O
on	O
the	O
composition	O
of	O
the	O
intestinal	O
microbiota	O
,	O
as	O
reflected	O
in	O
the	O
feces	O
.	O

The	O
fermented	O
milk	O
,	O
with	O
or	O
without	O
probiotic	O
,	O
had	O
an	O
effect	O
on	O
the	O
intestinal	O
microbiota	O
and	O
significant	O
inter	O
-	O
individual	O
differences	O
were	O
observed	O
in	O
response	O
to	O
the	O
intervention	O
.	O

A	O
common	O
trend	O
was	O
observed	O
related	O
to	O
two	O
important	O
populations	O
of	O
the	O
human	O
gut	O
microbiota	O
;	O
a	O
reduction	O
in	O
the	O
relative	O
abundance	O
of	O
Bacteroides	B-bacteria
and	O
increase	O
in	O
the	O
abundance	O
of	O
Prevotella	B-bacteria
in	O
subjects	O
during	O
treatment	O
compared	O
to	O
baseline	O
were	O
registered	O
.	O

In	O
silico	O
prediction	O
reveals	O
the	O
existence	O
of	O
potential	O
bioactive	O
neuropeptides	O
produced	O
by	O
the	O
human	O
gut	O
microbiota	O
.	O

This	O
work	O
reports	O
on	O
a	O
large	O
-	O
scale	O
potential	O
neuropeptide	O
activity	O
screening	O
in	O
human	O
gut	O
microbiomes	O
deposited	O
in	O
public	O
databases	O
.	O

In	O
our	O
experimental	O
approach	O
,	O
the	O
sequences	O
of	O
the	O
bioactive	O
peptides	O
collected	O
in	O
the	O
MAHMI	O
database	O
,	O
mainly	O
predicted	O
as	O
immunomodulatory	O
or	O
antitumoral	O
,	O
were	O
crossed	O
with	O
those	O
of	O
the	O
neuroactive	O
/	O
digestive	O
peptides	O
.	O

From	O
91	O
,	O
325	O
,	O
790	O
potential	O
bioactive	O
peptides	O
,	O
only	O
581	O
returned	O
a	O
match	O
when	O
crossed	O
against	O
the	O
5949	O
neuroactive	O
peptides	O
from	O
the	O
NeuroPep	O
database	O
and	O
the	O
15	O
digestive	O
hormones	O
.	O

Relevant	O
bacterial	O
taxa	O
,	O
such	O
as	O
Ruminococcus	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Clostridium	B-bacteria
sp	I-bacteria
.	O

were	O
found	O
among	O
the	O
main	O
producers	O
of	O
the	O
matching	O
sequences	O
,	O
and	O
many	O
of	O
the	O
matches	O
corresponded	O
to	O
adiponectin	O
and	O
the	O
hormone	O
produced	O
by	O
adipocites	O
,	O
which	O
is	O
involved	O
in	O
glucose	O
homeostasis	O
.	O

These	O
results	O
show	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
presence	O
of	O
potentially	O
bioactive	O
peptides	O
produced	O
by	O
gut	O
microbiota	O
members	O
over	O
the	O
nervous	O
cells	O
,	O
most	O
notably	O
,	O
peptides	O
with	O
already	O
predicted	O
immunomodulatory	O
or	O
anti	O
-	O
inflammatory	O
activity	O
.	O

Classical	O
(	O
Lactobacillus	B-bacteria
sp	I-bacteria
.	I-bacteria
)	O
and	O
next	O
-	O
generation	O
(	O
Faecalibacterium	B-bacteria
sp	I-bacteria
.	I-bacteria
)	O
probiotics	O
are	O
shown	O
to	O
produce	O
these	O
peptides	O
,	O
which	O
are	O
proposed	O
as	O
a	O
potential	O
mechanism	O
of	O
action	O
of	O
psychobiotics	O
.	O

Our	O
previous	O
experimental	O
results	O
showed	O
that	O
many	O
of	O
these	O
peptides	O
were	O
active	O
when	O
incubated	O
with	O
immune	O
cells	O
,	O
such	O
as	O
dendritic	O
cells	O
,	O
so	O
their	O
effect	O
over	O
the	O
nervous	O
system	O
innervating	O
the	O
gut	O
mucosa	O
holds	O
significant	O
potential	O
and	O
should	O
be	O
explored	O
.	O

Metaphire	O
guillelmi	O
gut	O
as	O
hospitable	O
micro	O
-	O
environment	O
for	O
the	O
potential	O
transmission	O
of	O
antibiotic	O
resistance	O
genes	O
.	O

Earthworm	O
gut	O
played	O
an	O
important	O
role	O
in	O
the	O
transformation	O
of	O
various	O
contaminants	O
in	O
the	O
soil	O
environments	O
.	O

With	O
the	O
increasing	O
application	O
of	O
organic	O
fertilizer	O
recently	O
,	O
the	O
ingestion	O
of	O
antibiotics	O
,	O
antibiotic	O
resistance	O
bacteria	O
(	O
ARB	O
)	O
,	O
and	O
antibiotic	O
resistance	O
genes	O
(	O
ARGs	O
)	O
made	O
the	O
earthworm	O
gut	O
a	O
potential	O
favorable	O
micro	O
-	O
environment	O
for	O
the	O
transmission	O
of	O
ARGs	O
in	O
the	O
soil	O
.	O

In	O
this	O
work	O
,	O
the	O
conventional	O
plate	O
incubation	O
and	O
high	O
-	O
throughput	O
sequencing	O
methods	O
were	O
both	O
employed	O
to	O
investigate	O
the	O
composition	O
of	O
the	O
cultivable	O
and	O
overall	O
ARB	O
/	O
ARGs	O
in	O
the	O
Metaphire	O
guillelmi	O
earthworm	O
gut	O
.	O

A	O
total	O
of	O
87	O
cultivable	O
isolates	O
that	O
resisted	O
tetracycline	O
(	O
TC	O
)	O
and	O
/	O
or	O
sulfadiazine	O
(	O
SD	O
)	O
were	O
obtained	O
,	O
most	O
of	O
which	O
belonged	O
to	O
phylum	O
Firmicutes	B-bacteria
,	O
genus	O
Bacillus	B-bacteria
.	O

Meanwhile	O
,	O
the	O
counts	O
of	O
isolates	O
with	O
TC	O
-	O
SD	O
dual	O
resistance	O
were	O
higher	O
than	O
those	O
with	O
sole	O
SD	O
or	O
TC	O
resistance	O
.	O

Moreover	O
,	O
higher	O
ARB	O
counts	O
and	O
diversity	O
were	O
detected	O
in	O
the	O
earthworm	O
gut	O
by	O
high	O
-	O
throughput	O
sequencing	O
technique	O
than	O
those	O
by	O
the	O
classical	O
plate	O
cultivation	O
.	O

Overall	O
,	O
the	O
combination	O
of	O
conventional	O
cultivable	O
bacteria	O
isolation	O
and	O
high	O
-	O
throughput	O
sequencing	O
methods	O
provided	O
a	O
comprehensive	O
understanding	O
of	O
the	O
ARB	O
composition	O
in	O
the	O
earthworm	O
gut	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
earthworm	O
gut	O
is	O
a	O
hospitable	O
micro	O
-	O
environment	O
for	O
ARB	O
colonization	O
.	O

The	O
potential	O
role	O
of	O
earthworm	O
intestinal	O
ARB	O
and	O
ARGs	O
proliferation	O
in	O
soil	O
environments	O
warrants	O
further	O
research	O
.	O

Black	O
soldier	O
fly	O
larvae	O
(	O
Hermetia	O
illucens	O
)	O
strengthen	O
the	O
metabolic	O
function	O
of	O
food	O
waste	O
biodegradation	O
by	O
gut	O
microbiome	O
.	O

Vermicomposting	O
using	O
black	O
soldier	O
fly	O
(	O
BSF	O
)	O
larvae	O
(	O
Hermetia	O
illucens	O
)	O
has	O
gradually	O
become	O
a	O
promising	O
biotechnology	O
for	O
waste	O
management	O
,	O
but	O
knowledge	O
about	O
the	O
larvae	O
gut	O
microbiome	O
is	O
sparse	O
.	O

In	O
this	O
study	O
,	O
16S	O
rRNA	O
sequencing	O
,	O
SourceTracker	O
,	O
and	O
network	O
analysis	O
were	O
leveraged	O
to	O
decipher	O
the	O
influence	O
of	O
larvae	O
gut	O
microbiome	O
on	O
food	O
waste	O
(	O
FW	O
)	O
biodegradation	O
.	O

The	O
microbial	O
community	O
structure	O
of	O
BSF	O
vermicompost	O
(	O
BC	O
)	O
changed	O
greatly	O
after	O
larvae	O
inoculation	O
,	O
with	O
a	O
peak	O
colonization	O
traceable	O
to	O
gut	O
bacteria	O
of	O
66	O
.	O
0	O
%	O
.	O

The	O
relative	O
abundance	O
of	O
11	O
out	O
of	O
21	O
metabolic	O
function	O
groups	O
in	O
BC	O
were	O
significantly	O
higher	O
than	O
that	O
in	O
natural	O
composting	O
(	O
NC	O
)	O
,	O
such	O
as	O
carbohydrate	O
-	O
active	O
enzymes	O
.	O

In	O
addition	O
,	O
36	O
.	O
5	O
%	O
of	O
the	O
functional	O
genes	O
in	O
BC	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
NC	O
.	O

The	O
changes	O
of	O
metabolic	O
functions	O
and	O
functional	O
genes	O
were	O
significantly	O
correlated	O
with	O
the	O
microbial	O
succession	O
.	O

Moreover	O
,	O
the	O
bacteria	O
that	O
proliferated	O
in	O
vermicompost	O
,	O
including	O
Corynebacterium	B-bacteria
,	O
Vagococcus	B-bacteria
,	O
and	O
Providencia	B-bacteria
,	O
had	O
strong	O
metabolic	O
abilities	O
.	O

Systematic	O
and	O
complex	O
interactions	O
between	O
the	O
BSF	O
gut	O
and	O
BC	O
bacteria	O
occurred	O
over	O
time	O
through	O
invasion	O
,	O
altered	O
the	O
microbial	O
community	O
structure	O
,	O
and	O
thus	O
evolved	O
into	O
a	O
new	O
intermediate	O
niche	O
favourable	O
for	O
FW	O
biodegradation	O
.	O

The	O
study	O
highlights	O
BSF	O
gut	O
microbiome	O
as	O
an	O
engine	O
for	O
FW	O
bioconversion	O
,	O
which	O
is	O
conducive	O
to	O
bioproducts	O
regeneration	O
from	O
wastes	O
.	O

Antibiotics	O
in	O
inflammatory	O
bowel	O
diseases	O
:	O
do	O
we	O
know	O
what	O
we	O
'	O
re	O
doing	O
?	O

Despite	O
the	O
revolution	O
in	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
treatment	O
over	O
the	O
past	O
two	O
decades	O
with	O
the	O
advent	O
of	O
biological	O
therapies	O
,	O
there	O
remains	O
a	O
substantial	O
proportion	O
of	O
patients	O
with	O
inadequate	O
or	O
unsustained	O
response	O
to	O
existent	O
therapies	O
.	O

The	O
overwhelming	O
focus	O
of	O
IBD	O
therapeutics	O
has	O
been	O
targeting	O
mucosal	O
immunity	O
,	O
however	O
with	O
the	O
developing	O
evidence	O
base	O
pointing	O
to	O
the	O
role	O
of	O
gut	O
microbes	O
in	O
the	O
inflammatory	O
process	O
,	O
renewed	O
focus	O
should	O
be	O
placed	O
on	O
the	O
impact	O
of	O
manipulating	O
the	O
microbiome	O
in	O
IBD	O
management	O
.	O

This	O
review	O
provides	O
an	O
overview	O
of	O
the	O
evidence	O
implicating	O
bacteria	O
in	O
the	O
pathogenesis	O
of	O
gut	O
inflammation	O
in	O
IBD	O
and	O
provides	O
an	O
overview	O
of	O
the	O
evidence	O
of	O
antibiotics	O
in	O
IBD	O
treatment	O
.	O

We	O
also	O
suggest	O
a	O
potential	O
role	O
of	O
antibiotics	O
in	O
clinical	O
practice	O
based	O
on	O
available	O
evidence	O
and	O
clinical	O
experience	O
.	O

Multidrug	B-bacteria
-	I-bacteria
resistant	I-bacteria
Enterobacteriaceae	I-bacteria
colonising	O
the	O
gut	O
of	O
adult	O
rural	O
population	O
in	O
South	O
India	O
.	O

Background	O
:	O
Multidrug	O
-	O
resistant	O
(	O
MDR	O
)	O
colonisers	O
act	O
as	O
a	O
reservoir	O
for	O
transmission	O
of	O
antibiotic	O
resistance	O
and	O
are	O
a	O
source	O
of	O
infection	O
.	O

Exposure	O
to	O
antibiotics	O
by	O
the	O
commensal	O
flora	O
renders	O
them	O
resistant	O
.	O

Antibiotic	O
consumption	O
and	O
hospitalisation	O
are	O
two	O
major	O
factors	O
influencing	O
this	O
.	O

We	O
studied	O
,	O
antibiotic	O
-	O
resistant	O
bacteria	O
colonising	O
rural	O
adult	O
population	O
who	O
had	O
restricted	O
access	O
to	O
health	O
care	O
and	O
presumably	O
had	O
low	O
consumption	O
of	O
antibiotics	O
.	O

Aim	O
:	O
Detection	O
of	O
multidrug	O
resistance	O
genes	O
of	O
extended	O
spectrum	O
beta	O
-	O
lactamase	O
(	O
ESBL	O
-	O
CTX	O
-	O
M	O
)	O
,	O
AmpC	O
beta	O
-	O
Lactamase	O
(	O
CIT	O
)	O
,	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
carbapenemase	O
(	O
KPC	O
)	O
and	O
New	O
Delhi	O
Metallo	O
beta	O
-	O
lactamase	O
(	O
NDM	O
)	O
in	O
Enterobacteriaceae	B-bacteria
colonising	O
the	O
gut	O
of	O
adult	O
population	O
in	O
a	O
South	O
Indian	O
rural	O
community	O
.	O

Methodology	O
:	O
Faecal	O
samples	O
of	O
154	O
healthy	O
volunteers	O
were	O
screened	O
for	O
Enterobacteriaceae	B-bacteria
resistant	O
to	O
commonly	O
used	O
antibiotics	O
by	O
standard	O
methods	O
,	O
followed	O
by	O
phenotypic	O
detection	O
of	O
ESBL	O
by	O
double	O
disk	O
synergy	O
method	O
,	O
AmpC	O
by	O
spot	O
inoculation	O
and	O
carbapenemases	O
by	O
imipenem	O
and	O
ethylenediaminetetraacetic	O
acid	O
+	O
imipenem	O
combined	O
E	O
-	O
test	O
strips	O
and	O
modified	O
Hodge	O
test	O
.	O

Polymerase	O
chain	O
reaction	O
was	O
done	O
to	O
detect	O
blaCTX	O
-	O
M	O
,	O
blaCIT	O
,	O
blaKPC	O
-	O
1	O
and	O
blaNDM	O
-	O
1	O
genes	O
coding	O
for	O
ESBL	O
,	O
AmpC	O
,	O
KPC	O
and	O
NDM	O
,	O
respectively	O
.	O

Results	O
:	O
Colonisation	O
rate	O
of	O
enteric	O
bacteria	O
with	O
MDR	O
genes	O
in	O
the	O
community	O
was	O
30	O
.	O
1	O
%	O
.	O

However	O
,	O
phenotypically	O
,	O
only	O
ESBL	O
(	O
3	O
.	O
2	O
%	O
)	O
and	O
NDM	O
(	O
0	O
.	O
65	O
%	O
)	O
were	O
detected	O
.	O

While	O
the	O
genes	O
coding	O
for	O
ESBL	O
,	O
AmpC	O
and	O
NDM	O
were	O
detected	O
in	O
35	O
.	O
6	O
%	O
,	O
17	O
.	O
8	O
%	O
and	O
4	O
.	O
4	O
%	O
of	O
the	O
MDR	O
isolates	O
,	O
respectively	O
.	O

Conclusions	O
:	O
Carriage	O
of	O
MDR	O
strains	O
with	O
a	O
potential	O
to	O
express	O
multidrug	O
resistance	O
poses	O
a	O
threat	O
of	O
dissemination	O
in	O
the	O
community	O
.	O

Awareness	O
for	O
restricted	O
use	O
of	O
antibiotics	O
and	O
proper	O
sanitation	O
can	O
contain	O
the	O
spread	O
of	O
resistant	O
bacteria	O
.	O

Role	O
of	O
inulin	O
as	O
prebiotics	O
on	O
inflammatory	O
bowel	O
disease	O
.	O

The	O
present	O
review	O
is	O
focused	O
on	O
the	O
prebiotic	O
impact	O
of	O
inulin	O
on	O
the	O
management	O
of	O
the	O
gastrointestinal	O
disorder	O
.	O

Prebiotics	O
can	O
be	O
described	O
as	O
`	O
`	O
non	O
-	O
digestible	O
food	O
ingredient	O
stimulating	O
the	O
growth	O
of	O
a	O
certain	O
number	O
of	O
bacteria	O
in	O
the	O
colon	O
,	O
which	O
can	O
improve	O
the	O
host	O
health	O
'	O
'	O
.	O

In	O
2004	O
this	O
definition	O
was	O
modernized	O
to	O
include	O
other	O
areas	O
that	O
may	O
benefit	O
from	O
selective	O
targeting	O
of	O
particular	O
microorganisms	O
:	O
`	O
`	O
selectively	O
fermented	O
ingredients	O
that	O
alter	O
the	O
configuration	O
and	O
activity	O
in	O
the	O
gastrointestinal	O
microbiota	O
that	O
confer	O
positive	O
effect	O
'	O
'	O
.	O

The	O
positive	O
impact	O
of	O
prebiotics	O
in	O
experimental	O
colitis	O
and	O
human	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
has	O
already	O
been	O
established	O
.	O

Prebiotics	O
shows	O
a	O
positive	O
effect	O
in	O
the	O
prevention	O
of	O
IBD	O
by	O
modulating	O
the	O
trophic	O
functions	O
of	O
the	O
flora	O
.	O

Inulin	O
enhances	O
the	O
growth	O
of	O
indigenous	O
lactobacilli	B-bacteria
and	O
/	O
or	O
bifidobacteria	B-bacteria
by	O
inducing	O
colonic	O
production	O
of	O
short	O
chain	O
fatty	O
acids	O
(	O
SCFA	O
'	O
s	O
)	O
and	O
these	O
properties	O
are	O
related	O
to	O
decreased	O
mucosal	O
lesion	O
scores	O
and	O
diminished	O
mucosal	O
inflammation	O
.	O

Inulin	O
shows	O
a	O
positive	O
approach	O
to	O
retain	O
microbial	O
populations	O
and	O
to	O
support	O
epithelial	O
barrier	O
function	O
by	O
their	O
prebiotic	O
effect	O
which	O
helps	O
in	O
the	O
host	O
defense	O
against	O
invasion	O
and	O
pathogens	O
translocation	O
(	O
endogenous	O
and	O
/	O
or	O
exogenous	O
)	O
and	O
in	O
the	O
inhibition	O
of	O
gastrointestinal	O
diseases	O
and	O
this	O
impact	O
should	O
be	O
verified	O
in	O
further	O
clinical	O
studies	O
.	O

In	O
the	O
present	O
review	O
,	O
we	O
discussed	O
the	O
positive	O
effect	O
of	O
prebiotics	O
in	O
rat	O
IBD	O
models	O
and	O
in	O
human	O
subjects	O
along	O
with	O
their	O
potential	O
protective	O
mechanisms	O
.	O

Preclinical	O
and	O
clinical	O
data	O
revealed	O
that	O
the	O
gut	O
mucosal	O
barrier	O
would	O
be	O
improved	O
by	O
the	O
use	O
of	O
prebiotics	O
in	O
IBD	O
.	O

Genetic	O
Factors	O
and	O
the	O
Intestinal	O
Microbiome	O
Guide	O
Development	O
of	O
Microbe	O
-	O
Based	O
Therapies	O
for	O
Inflammatory	O
Bowel	O
Diseases	O
.	O

The	O
intestinal	O
microbiota	O
is	O
a	O
dynamic	O
community	O
of	O
bacteria	O
,	O
fungi	O
,	O
and	O
viruses	O
that	O
mediates	O
mucosal	O
homeostasis	O
and	O
physiology	O
.	O

Imbalances	O
in	O
the	O
microbiome	O
and	O
aberrant	O
immune	O
responses	O
to	O
gut	O
bacteria	O
can	O
disrupt	O
homeostasis	O
and	O
are	O
associated	O
with	O
inflammatory	O
bowel	O
diseases	O
(	O
IBDs	O
)	O
in	O
humans	O
and	O
colitis	O
in	O
mice	O
.	O

We	O
review	O
genetic	O
variants	O
associated	O
with	O
IBD	O
and	O
their	O
effects	O
on	O
the	O
intestinal	O
microbiome	O
,	O
the	O
immune	O
response	O
,	O
and	O
disease	O
pathogenesis	O
.	O

The	O
intestinal	O
microbiome	O
,	O
which	O
includes	O
microbial	O
antigens	O
,	O
adjuvants	O
,	O
and	O
metabolic	O
products	O
,	O
affects	O
the	O
development	O
and	O
function	O
of	O
the	O
intestinal	O
mucosa	O
and	O
inflammatory	O
responses	O
in	O
the	O
gut	O
.	O

Therefore	O
,	O
strategies	O
to	O
manipulate	O
the	O
microbiome	O
might	O
be	O
used	O
in	O
treatment	O
of	O
IBD	O
.	O

We	O
review	O
microbe	O
-	O
based	O
therapies	O
for	O
IBD	O
and	O
the	O
potential	O
to	O
engineer	O
patients	O
'	O
intestinal	O
microbiota	O
.	O

We	O
discuss	O
how	O
studies	O
of	O
patients	O
with	O
IBD	O
and	O
mouse	O
models	O
have	O
advanced	O
our	O
understanding	O
of	O
the	O
interactions	O
between	O
genetic	O
factors	O
and	O
the	O
gut	O
microbiome	O
and	O
challenges	O
to	O
the	O
development	O
of	O
microbe	O
-	O
based	O
therapies	O
for	O
IBD	O
.	O

Circulating	O
(	O
1	O
-	O
-	O
>	O
3	O
)	O
-	O
beta	O
-	O
D	O
-	O
Glucan	O
is	O
associated	O
with	O
immune	O
activation	O
during	O
HIV	O
infection	O
.	O

BACKGROUND	O
:	O
Microbial	O
translocation	O
from	O
the	O
gut	O
to	O
circulation	O
contributes	O
to	O
immune	O
activation	O
during	O
HIV	O
infection	O
and	O
is	O
usually	O
assessed	O
by	O
measuring	O
plasma	O
levels	O
of	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Gut	O
fungal	O
colonization	O
increases	O
during	O
HIV	O
infection	O
and	O
elevated	O
systemic	O
levels	O
of	O
the	O
fungal	O
polysaccharide	O
(	O
13	O
)	O
-	O
-	O
D	O
-	O
Glucan	O
(	O
DG	O
)	O
have	O
been	O
reported	O
in	O
people	O
living	O
with	O
HIV	O
(	O
PLWH	O
)	O
.	O

We	O
assessed	O
plasma	O
DG	O
in	O
146	O
early	O
and	O
chronic	O
PLWH	O
and	O
investigated	O
its	O
contribution	O
to	O
systemic	O
immune	O
activation	O
.	O

METHODS	O
:	O
Cross	O
-	O
sectional	O
and	O
longitudinal	O
assessment	O
of	O
plasma	O
DG	O
levels	O
were	O
conducted	O
along	O
with	O
markers	O
of	O
HIV	O
disease	O
progression	O
,	O
epithelial	O
gut	O
damage	O
,	O
bacterial	O
translocation	O
,	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
and	O
DG	O
-	O
specific	O
receptor	O
expression	O
on	O
monocytes	O
and	O
NK	O
cells	O
.	O

RESULTS	O
:	O
Plasma	O
DG	O
levels	O
were	O
elevated	O
during	O
early	O
and	O
chronic	O
HIV	O
infection	O
and	O
persisted	O
despite	O
long	O
-	O
term	O
ART	O
.	O

DG	O
increased	O
over	O
24	O
-	O
months	O
without	O
ART	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
but	O
remained	O
unchanged	O
after	O
24	O
-	O
months	O
of	O
treatment	O
(	O
p	O
>	O
0	O
.	O
99	O
)	O
.	O

DG	O
correlated	O
negatively	O
with	O
CD4	O
T	O
-	O
cell	O
count	O
(	O
r	O
=	O
-	O
0	O
.	O
252	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
positively	O
with	O
time	O
to	O
ART	O
initiation	O
(	O
r	O
=	O
0	O
.	O
254	O
;	O
p	O
=	O
0	O
.	O
04	O
)	O
,	O
viral	O
load	O
(	O
r	O
=	O
0	O
.	O
350	O
;	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
I	O
-	O
FABP	O
(	O
r	O
=	O
0	O
.	O
384	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
LPS	O
(	O
r	O
=	O
0	O
.	O
267	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
sCD14	O
(	O
r	O
=	O
0	O
.	O
388	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Elevated	O
DG	O
correlated	O
positively	O
with	O
IDO	O
-	O
1	O
enzyme	O
activity	O
(	O
r	O
=	O
0	O
.	O
345	O
;	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
Tregs	O
frequency	O
(	O
r	O
=	O
0	O
.	O
410	O
;	O
p	O
=	O
0	O
.	O
006	O
)	O
,	O
activated	O
CD38	O
+	O
HLA	O
-	O
DR	O
+	O
CD4	O
(	O
r	O
=	O
0	O
.	O
652	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
CD8	O
T	O
-	O
cells	O
(	O
r	O
=	O
0	O
.	O
687	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
negatively	O
with	O
Dectin	O
-	O
1	O
(	O
r	O
=	O
-	O
0	O
.	O
474	O
;	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
NKp30	O
(	O
r	O
=	O
-	O
0	O
.	O
614	O
;	O
p	O
=	O
0	O
.	O
009	O
)	O
expression	O
on	O
monocytes	O
and	O
NK	O
cells	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
PLWH	O
have	O
elevated	O
plasma	O
DG	O
in	O
correlation	O
with	O
markers	O
of	O
disease	O
progression	O
,	O
gut	O
damage	O
,	O
bacterial	O
translocation	O
and	O
inflammation	O
.	O

Early	O
ART	O
initiation	O
prevents	O
further	O
DG	O
increase	O
.	O

This	O
fungal	O
antigen	O
contributes	O
to	O
immune	O
activation	O
and	O
represents	O
a	O
potential	O
therapeutic	O
target	O
to	O
prevent	O
non	O
-	O
AIDS	O
events	O
.	O

Recombinant	O
nodavirus	O
vaccine	O
produced	O
in	O
bacteria	O
and	O
administered	O
without	O
purification	O
elicits	O
humoral	O
immunity	O
and	O
protects	O
European	O
sea	O
bass	O
against	O
infection	O
.	O

Viral	O
necrosis	O
virus	O
(	O
NNV	O
)	O
or	O
nodavirus	O
causes	O
fish	O
viral	O
encephalopathy	O
and	O
retinopathy	O
worldwide	O
.	O

In	O
some	O
cases	O
,	O
mortalities	O
in	O
aquaculture	O
industry	O
can	O
reach	O
up	O
to	O
100	O
%	O
,	O
some	O
species	O
being	O
especially	O
sensitive	O
as	O
is	O
the	O
case	O
of	O
European	O
sea	O
bass	O
(	O
Dicentrarchus	O
labrax	O
)	O
,	O
one	O
of	O
the	O
main	O
cultured	O
species	O
in	O
the	O
Mediterranean	O
,	O
with	O
the	O
consequent	O
economical	O
loses	O
.	O

Development	O
of	O
new	O
vaccines	O
against	O
NNV	O
is	O
in	O
the	O
spotlight	O
though	O
few	O
researches	O
have	O
focused	O
in	O
European	O
sea	O
bass	O
.	O

In	O
this	O
study	O
we	O
have	O
generated	O
a	O
recombinant	O
NNV	O
(	O
rNNV	O
)	O
vaccine	O
produced	O
in	O
Escherichia	B-bacteria
coli	I-bacteria
expressing	O
the	O
capsid	O
protein	O
and	O
administered	O
it	O
to	O
European	O
sea	O
bass	O
juveniles	O
by	O
two	O
different	O
routes	O
(	O
intraperitoneal	O
and	O
oral	O
)	O
.	O

The	O
last	O
being	O
considered	O
non	O
-	O
stressful	O
and	O
desired	O
for	O
fish	O
farming	O
of	O
small	O
fish	O
,	O
which	O
in	O
fact	O
are	O
the	O
most	O
affected	O
by	O
NNV	O
.	O

Oral	O
vaccine	O
was	O
composed	O
of	O
feed	O
pellets	O
containing	O
the	O
recombinant	O
whole	O
bacteria	O
,	O
and	O
injected	O
vaccine	O
was	O
composed	O
of	O
recombinant	O
bacteria	O
previously	O
lysed	O
.	O

Our	O
results	O
revealed	O
production	O
of	O
specific	O
anti	O
-	O
NNV	O
IgM	O
following	O
the	O
two	O
vaccination	O
procedures	O
,	O
levels	O
that	O
were	O
further	O
increased	O
in	O
orally	O
-	O
vaccinated	O
group	O
after	O
challenge	O
with	O
NNV	O
.	O

Genes	O
related	O
to	O
interferon	O
(	O
IFN	O
)	O
,	O
T	O
-	O
cell	O
and	O
immunoglobulin	O
markers	O
were	O
scarcely	O
regulated	O
in	O
head	O
-	O
kidney	O
(	O
HK	O
)	O
,	O
gut	O
or	O
brain	O
.	O

Vaccination	O
by	O
either	O
route	O
elicited	O
a	O
relative	O
survival	O
response	O
of	O
100	O
%	O
after	O
NNV	O
challenge	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
recombinant	O
vaccine	O
followed	O
by	O
no	O
purification	O
steps	O
which	O
resulted	O
in	O
a	O
complete	O
protection	O
in	O
European	O
sea	O
bass	O
when	O
challenged	O
with	O
NNV	O
.	O

Intestinal	O
microbiome	O
as	O
a	O
novel	O
therapeutic	O
target	O
for	O
local	O
and	O
systemic	O
inflammation	O
.	O

Recently	O
,	O
the	O
pathogenesis	O
of	O
systemic	O
inflammatory	O
disease	O
such	O
as	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
,	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
,	O
systemic	O
inflammatory	O
arthritis	O
,	O
asthma	O
,	O
and	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
has	O
been	O
reported	O
to	O
be	O
related	O
to	O
the	O
dysbiosis	O
of	O
gut	O
microbiota	O
.	O

The	O
contribution	O
of	O
special	O
bacteria	O
for	O
the	O
development	O
of	O
those	O
diseases	O
has	O
been	O
elucidated	O
by	O
disease	O
animal	O
models	O
such	O
as	O
germ	O
-	O
free	O
mice	O
.	O

Besides	O
,	O
the	O
contribution	O
by	O
several	O
bacteria	O
for	O
the	O
pathogenesis	O
of	O
those	O
diseases	O
has	O
been	O
suggested	O
by	O
detailed	O
analysis	O
of	O
the	O
16	O
small	O
ribosomal	O
subunit	O
RNA	O
(	O
16S	O
rRNA	O
)	O
from	O
stool	O
samples	O
of	O
the	O
patients	O
.	O

Gut	O
microbiota	O
-	O
targeted	O
treatment	O
for	O
systemic	O
inflammatory	O
diseases	O
such	O
as	O
fecal	O
microbiota	O
transplant	O
(	O
FMT	O
)	O
,	O
and	O
probiotics	O
has	O
been	O
now	O
reported	O
.	O

Though	O
there	O
are	O
several	O
issues	O
to	O
be	O
understood	O
,	O
these	O
treatments	O
have	O
been	O
highlighted	O
as	O
an	O
innovative	O
approach	O
to	O
intractable	O
systemic	O
inflammatory	O
disease	O
.	O

In	O
the	O
present	O
review	O
,	O
recent	O
reports	O
regarding	O
the	O
relation	O
between	O
gut	O
microbiota	O
and	O
systemic	O
inflammatory	O
diseases	O
are	O
discussed	O
with	O
treatments	O
to	O
target	O
gut	O
microbiota	O
.	O

Unconjugated	O
and	O
secondary	O
bile	O
acid	O
profiles	O
in	O
response	O
to	O
higher	O
-	O
fat	O
,	O
lower	O
-	O
carbohydrate	O
diet	O
and	O
associated	O
with	O
related	O
gut	O
microbiota	O
:	O
A	O
6	O
-	O
month	O
randomized	O
controlled	O
-	O
feeding	O
trial	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Observational	O
studies	O
have	O
shown	O
that	O
diets	O
high	O
in	O
fat	O
and	O
low	O
in	O
dietary	O
fiber	O
,	O
might	O
have	O
an	O
unfavorable	O
impact	O
on	O
bile	O
acid	O
(	O
BA	O
)	O
profiles	O
,	O
which	O
might	O
further	O
affect	O
host	O
cardiometabolic	O
health	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
dietary	O
fat	O
content	O
on	O
BA	O
profiles	O
and	O
associated	O
gut	O
microbiota	O
,	O
and	O
their	O
correlates	O
with	O
cardiometabolic	O
risk	O
factors	O
.	O

METHODS	O
:	O
In	O
a	O
randomized	O
controlled	O
-	O
feeding	O
trial	O
,	O
healthy	O
young	O
adults	O
were	O
assigned	O
to	O
one	O
of	O
the	O
three	O
diets	O
:	O
a	O
lower	O
-	O
fat	O
diet	O
(	O
fat	O
20	O
%	O
,	O
carbohydrate	O
66	O
%	O
and	O
protein	O
14	O
%	O
)	O
,	O
a	O
moderate	O
-	O
fat	O
diet	O
(	O
fat	O
30	O
%	O
,	O
carbohydrate	O
56	O
%	O
and	O
protein	O
14	O
%	O
)	O
and	O
a	O
higher	O
-	O
fat	O
diet	O
(	O
fat	O
40	O
%	O
,	O
carbohydrate	O
46	O
%	O
and	O
protein	O
14	O
%	O
)	O
for	O
6	O
months	O
.	O

All	O
the	O
foods	O
were	O
provided	O
during	O
the	O
entire	O
intervention	O
period	O
.	O

The	O
BA	O
profiles	O
,	O
associated	O
gut	O
microbiota	O
and	O
markers	O
of	O
cardiometabolic	O
risk	O
factors	O
were	O
determined	O
before	O
and	O
after	O
intervention	O
.	O

RESULTS	O
:	O
The	O
higher	O
-	O
fat	O
diet	O
resulted	O
in	O
an	O
elevated	O
concentration	O
of	O
total	O
BAs	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
unconjugated	O
BAs	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
compared	O
with	O
lower	O
-	O
fat	O
diet	O
.	O

Secondary	O
BAs	O
,	O
such	O
as	O
deoxycholic	O
acid	O
(	O
DCA	O
)	O
,	O
taurodeoxycholic	O
acid	O
(	O
TDCA	O
)	O
,	O
12ketolithocholic	O
acid	O
(	O
12keto	O
-	O
LCA	O
)	O
,	O
3beta	O
-	O
DCA	O
and	O
taurolithocholic	O
acid	O
(	O
TLCA	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
after	O
FDR	O
correction	O
)	O
were	O
significantly	O
increased	O
in	O
the	O
higher	O
-	O
fat	O
diet	O
group	O
after	O
the	O
6	O
-	O
month	O
intervention	O
.	O

Consistently	O
,	O
the	O
abundances	O
of	O
gut	O
bacteria	O
(	O
Bacteroides	B-bacteria
,	O
Clostridium	B-bacteria
,	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
)	O
which	O
affect	O
bile	O
salt	O
hydrolase	O
gene	O
expression	O
were	O
significantly	O
increased	O
after	O
higher	O
-	O
fat	O
consumption	O
.	O

The	O
change	O
of	O
DCA	O
was	O
positively	O
associated	O
with	O
the	O
relative	O
abundance	O
of	O
Bacteroides	B-bacteria
(	O
r	O
=	O
0	O
.	O
31	O
,	O
p	O
=	O
0	O
.	O
08	O
after	O
FDR	O
correction	O
)	O
.	O

In	O
addition	O
,	O
the	O
changes	O
of	O
fecal	O
concentrations	O
of	O
DCA	O
and	O
12keto	O
-	O
LCA	O
were	O
positively	O
associated	O
with	O
serum	O
total	O
cholesterol	O
(	O
r	O
>	O
0	O
.	O
3	O
,	O
p	O
=	O
0	O
.	O
02	O
and	O
p	O
=	O
0	O
.	O
008	O
after	O
FDR	O
correction	O
,	O
respectively	O
)	O
.	O

In	O
line	O
with	O
these	O
findings	O
,	O
serum	O
fibroblast	O
growth	O
factor	O
19	O
(	O
FGF19	O
)	O
was	O
marginally	O
significantly	O
elevated	O
in	O
the	O
higher	O
-	O
fat	O
group	O
after	O
intervention	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
higher	O
-	O
fat	O
diet	O
resulted	O
in	O
an	O
alteration	O
of	O
BAs	O
,	O
especially	O
unconjugated	O
BAs	O
and	O
secondary	O
BAs	O
,	O
most	O
likely	O
through	O
actions	O
of	O
gut	O
microbiota	O
.	O

These	O
alterations	O
might	O
confer	O
potentially	O
unfavorable	O
impacts	O
on	O
colonic	O
and	O
host	O
cardiometabolic	O
health	O
in	O
healthy	O
young	O
adults	O
.	O

Clinical	O
trial	O
registry	O
number	O
:	O
NCT02355795	O
listed	O
on	O
NIH	O
website	O
:	O
ClinicalTrials	O
.	O
gov	O
.	O

Healthy	O
dietary	O
pattern	O
and	O
their	O
corresponding	O
gut	O
microbiota	O
profile	O
are	O
linked	O
to	O
a	O
lower	O
risk	O
of	O
type	O
2	O
diabetes	O
,	O
independent	O
of	O
the	O
presence	O
of	O
obesity	O
.	O

BACKGROUND	O
:	O
Prediabetes	O
and	O
old	O
age	O
are	O
both	O
high	O
risk	O
factors	O
for	O
developing	O
Type	O
2	O
Diabetes	O
(	O
T2D	O
)	O
,	O
while	O
obesity	O
is	O
one	O
of	O
the	O
most	O
important	O
factors	O
triggering	O
the	O
disease	O
.	O

Nutritional	O
interventions	O
are	O
the	O
most	O
effective	O
tool	O
for	O
preventing	O
T2D	O
,	O
as	O
they	O
improve	O
different	O
biochemical	O
and	O
anthropometric	O
outcomes	O
and	O
growth	O
-	O
promoting	O
/	O
inhibiting	O
gut	O
microbiota	O
populations	O
.	O

However	O
,	O
to	O
date	O
there	O
are	O
no	O
specific	O
dietary	O
recommendations	O
to	O
stop	O
the	O
development	O
of	O
T2D	O
in	O
elderly	O
groups	O
,	O
for	O
whom	O
hypocaloric	O
diets	O
and	O
other	O
commonly	O
used	O
weight	O
-	O
loss	O
programs	O
could	O
be	O
considered	O
dangerous	O
.	O

The	O
objective	O
of	O
our	O
study	O
,	O
thus	O
,	O
was	O
to	O
understand	O
the	O
impact	O
of	O
dietary	O
patterns	O
on	O
T2D	O
risk	O
as	O
related	O
to	O
gut	O
microbiota	O
profile	O
in	O
obese	O
and	O
non	O
-	O
obese	O
elderly	O
prediabetic	O
subjects	O
.	O

METHODS	O
:	O
A	O
cross	O
-	O
sectional	O
study	O
was	O
performed	O
in	O
182	O
subjects	O
>	O
/	O
=	O
65	O
years	O
old	O
with	O
prediabetes	O
,	O
divided	O
into	O
obese	O
(	O
OB	O
)	O
or	O
non	O
-	O
obese	O
(	O
NOB	O
)	O
subgroups	O
,	O
and	O
their	O
risk	O
of	O
developing	O
T2D	O
was	O
measured	O
according	O
to	O
FINDRISK	O
score	O
and	O
biochemical	O
parameters	O
.	O

Also	O
,	O
clusters	O
into	O
different	O
dietary	O
patterns	O
in	O
each	O
group	O
by	O
PCA	O
analysis	O
was	O
related	O
with	O
gut	O
microbiota	O
,	O
which	O
was	O
analyzed	O
from	O
stool	O
samples	O
by	O
qPCR	O
.	O

The	O
creation	O
of	O
clusters	O
was	O
used	O
to	O
re	O
-	O
evaluate	O
T2D	O
risk	O
.	O

RESULTS	O
:	O
OB	O
was	O
at	O
higher	O
risk	O
of	O
developing	O
T2D	O
and	O
showed	O
worse	O
metabolic	O
outcomes	O
.	O

Unhealthier	O
and	O
healthier	O
dietary	O
pattern	O
clusters	O
were	O
observed	O
for	O
both	O
OB	O
(	O
OB	O
-	O
6	O
and	O
OB	O
-	O
5	O
respectively	O
)	O
and	O
NOB	O
(	O
NOB	O
-	O
2	O
and	O
NOB	O
-	O
3	O
respectively	O
)	O
groups	O
.	O

Results	O
obtained	O
from	O
the	O
gut	O
microbiota	O
showed	O
that	O
only	O
Prevotella	B-bacteria
was	O
higher	O
in	O
NOB	O
,	O
but	O
when	O
comparisons	O
were	O
made	O
between	O
clusters	O
,	O
a	O
clear	O
relation	O
with	O
dietary	O
pattern	O
was	O
observed	O
;	O
showing	O
in	O
healthier	O
dietary	O
clusters	O
a	O
decrease	O
in	O
Prevotella	B-bacteria
,	O
an	O
increase	O
of	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
and	O
an	O
increase	O
in	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
.	O

T2D	O
risk	O
was	O
greater	O
in	O
the	O
obese	O
group	O
between	O
unhealthier	O
dietary	O
clusters	O
.	O

No	O
difference	O
between	O
healthier	O
dietary	O
clusters	O
was	O
observed	O
.	O

CONCLUSION	O
:	O
A	O
healthy	O
dietary	O
pattern	O
and	O
the	O
growth	O
-	O
promoting	O
beneficial	O
and	O
growth	O
-	O
inhibiting	O
disadvantageous	O
gut	O
microbiota	O
populations	O
linked	O
to	O
it	O
provide	O
protection	O
against	O
the	O
development	O
of	O
T2D	O
in	O
an	O
obese	O
population	O
with	O
advanced	O
age	O
and	O
preDM	O
.	O

Biotechnology	O
of	O
health	O
-	O
promoting	O
bacteria	O
.	O

Over	O
the	O
last	O
decade	O
,	O
there	O
has	O
been	O
an	O
increasing	O
scientific	O
and	O
public	O
interest	O
in	O
bacteria	O
that	O
may	O
positively	O
contribute	O
to	O
human	O
gut	O
health	O
and	O
well	O
-	O
being	O
.	O

This	O
interest	O
is	O
reflected	O
by	O
the	O
ever	O
-	O
increasing	O
number	O
of	O
developed	O
functional	O
food	O
products	O
containing	O
health	O
-	O
promoting	O
bacteria	O
and	O
reaching	O
the	O
market	O
place	O
as	O
well	O
as	O
by	O
the	O
growing	O
revenue	O
and	O
profits	O
of	O
notably	O
bacterial	O
supplements	O
worldwide	O
.	O

Traditionally	O
,	O
the	O
origin	O
of	O
probiotic	O
-	O
marketed	O
bacteria	O
was	O
limited	O
to	O
a	O
rather	O
small	O
number	O
of	O
bacterial	O
species	O
that	O
mostly	O
belong	O
to	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
and	O
bifidobacteria	B-bacteria
.	O

Intensifying	O
research	O
efforts	O
on	O
the	O
human	O
gut	O
microbiome	O
offered	O
novel	O
insights	O
into	O
the	O
role	O
of	O
human	O
gut	O
microbiota	O
in	O
health	O
and	O
disease	O
,	O
while	O
also	O
providing	O
a	O
deep	O
and	O
increasingly	O
comprehensive	O
understanding	O
of	O
the	O
bacterial	O
communities	O
present	O
in	O
this	O
complex	O
ecosystem	O
and	O
their	O
interactions	O
with	O
the	O
gut	O
-	O
liver	O
-	O
brain	O
axis	O
.	O

This	O
resulted	O
in	O
rational	O
and	O
systematic	O
approaches	O
to	O
select	O
novel	O
health	O
-	O
promoting	O
bacteria	O
or	O
to	O
engineer	O
existing	O
bacteria	O
with	O
enhanced	O
probiotic	O
properties	O
.	O

In	O
parallel	O
,	O
the	O
field	O
of	O
gut	O
microbiomics	O
developed	O
into	O
a	O
fertile	O
framework	O
for	O
the	O
identification	O
,	O
isolation	O
and	O
characterization	O
of	O
a	O
phylogenetically	O
diverse	O
array	O
of	O
health	O
-	O
promoting	O
bacterial	O
species	O
,	O
also	O
called	O
next	O
-	O
generation	O
therapeutic	O
bacteria	O
.	O

The	O
present	O
review	O
will	O
address	O
these	O
developments	O
with	O
specific	O
attention	O
for	O
the	O
selection	O
and	O
improvement	O
of	O
a	O
selected	O
number	O
of	O
health	O
-	O
promoting	O
bacterial	O
species	O
and	O
strains	O
that	O
are	O
extensively	O
studied	O
or	O
hold	O
promise	O
for	O
future	O
food	O
or	O
pharma	O
product	O
development	O
.	O

The	O
use	O
of	O
predictive	O
scores	O
in	O
the	O
management	O
of	O
patients	O
with	O
carbapenem	B-bacteria
-	I-bacteria
resistant	I-bacteria
Klebsiella	I-bacteria
pneumoniae	I-bacteria
infection	O
.	O

INTRODUCTION	O
:	O
Carbapenem	B-bacteria
-	I-bacteria
resistant	I-bacteria
Klebsiella	I-bacteria
pneumoniae	I-bacteria
(	O
CR	O
-	O
KPB	O
-	O
bacteria	O
)	O
infections	O
are	O
associated	O
with	O
high	O
morbidity	O
and	O
mortality	O
rates	O
.	O

A	O
therapeutic	O
approach	O
based	O
on	O
the	O
patient	O
risk	O
stratification	O
could	O
improve	O
outcome	O
and	O
avoid	O
antibiotic	O
misuse	O
.	O

Areas	O
covered	O
:	O
English	O
literature	O
search	O
,	O
from	O
2008	O
to	O
2018	O
,	O
was	O
done	O
using	O
PubMed	O
database	O
.	O

Risk	O
factors	O
for	O
developing	O
CR	O
-	O
KP	O
infection	O
in	O
several	O
settings	O
were	O
reviewed	O
.	O

Since	O
,	O
rectal	O
carriage	O
was	O
a	O
main	O
risk	O
factor	O
for	O
developing	O
infection	O
,	O
we	O
revised	O
in	O
deep	O
clinical	O
score	O
to	O
predict	O
infection	O
among	O
colonized	O
patients	O
.	O

Furthermore	O
,	O
we	O
investigated	O
overall	O
and	O
treatment	O
-	O
related	O
risk	O
factors	O
for	O
poor	O
outcome	O
in	O
patients	O
with	O
CR	O
-	O
KP	O
infection	O
,	O
in	O
particular	O
the	O
carbapenem	O
producing	O
Enterobacteriacieae	B-bacteria
(	O
CPE	O
)	O
-	O
INCREMENT	O
score	O
.	O

Finally	O
,	O
an	O
algorithm	O
,	O
based	O
on	O
such	O
scores	O
,	O
for	O
the	O
therapeutic	O
management	O
of	O
patients	O
with	O
CR	O
-	O
KP	O
colonization	O
was	O
commented	O
.	O

Expert	O
opinion	O
:	O
The	O
therapeutic	O
approach	O
analyzed	O
in	O
this	O
review	O
could	O
help	O
physicians	O
to	O
avoid	O
antibiotic	O
overuse	O
as	O
well	O
as	O
to	O
start	O
promptly	O
with	O
the	O
most	O
appropriate	O
antibiotic	O
regimen	O
.	O

However	O
,	O
it	O
has	O
to	O
be	O
validated	O
in	O
further	O
studies	O
,	O
mainly	O
among	O
special	O
population	O
such	O
as	O
immunocompromised	O
patients	O
.	O

The	O
availability	O
of	O
new	O
drugs	O
,	O
fast	O
microbiology	O
,	O
and	O
analysis	O
of	O
gut	O
microbiome	O
could	O
significantly	O
improve	O
the	O
management	O
of	O
CR	O
-	O
KP	O
colonized	O
and	O
/	O
or	O
infected	O
patients	O
.	O

Indoles	O
:	O
metabolites	O
produced	O
by	O
intestinal	O
bacteria	O
capable	O
of	O
controlling	O
liver	O
disease	O
manifestation	O
.	O

Alterations	O
in	O
the	O
bacteria	O
that	O
reside	O
in	O
our	O
gastrointestinal	O
tract	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
and	O
progression	O
of	O
many	O
disorders	O
including	O
liver	O
and	O
gastrointestinal	O
diseases	O
.	O

Both	O
qualitative	O
(	O
composition	O
)	O
and	O
quantitative	O
(	O
amount	O
)	O
changes	O
in	O
gut	O
microbes	O
are	O
associated	O
with	O
increased	O
susceptibility	O
to	O
liver	O
disease	O
.	O

Importantly	O
,	O
the	O
intestinal	O
microbiota	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
many	O
host	O
signalling	O
pathways	O
via	O
the	O
generation	O
of	O
different	O
metabolites	O
.	O

Hence	O
,	O
dysbiosis	O
influences	O
disease	O
development	O
and	O
progression	O
by	O
directly	O
affecting	O
the	O
host	O
-	O
bacteria	O
metabolic	O
interaction	O
.	O

Microbe	O
-	O
derived	O
harmful	O
metabolites	O
can	O
translocate	O
to	O
distant	O
organs	O
due	O
to	O
increased	O
intestinal	O
permeability	O
as	O
observed	O
during	O
dysbiosis	O
.	O

Contrary	O
,	O
certain	O
bacterial	O
metabolites	O
such	O
as	O
tryptophan	O
metabolites	O
contribute	O
to	O
intestinal	O
and	O
systemic	O
homeostasis	O
.	O

Here	O
,	O
we	O
provide	O
an	O
overview	O
of	O
current	O
evidence	O
describing	O
to	O
what	O
extent	O
microbial	O
metabolites	O
modulate	O
the	O
development	O
of	O
chronic	O
liver	O
diseases	O
such	O
as	O
alcoholic	O
steatohepatitis	O
and	O
nonalcoholic	O
fatty	O
liver	O
disease	O
with	O
a	O
special	O
emphasis	O
on	O
indoles	O
.	O

Effects	O
of	O
Dietary	O
Supplementation	O
With	O
Enterococcus	B-bacteria
faecium	I-bacteria
and	O
Clostridium	B-bacteria
butyricum	I-bacteria
,	O
Either	O
Alone	O
or	O
in	O
Combination	O
,	O
on	O
Growth	O
and	O
Fecal	O
Microbiota	O
Composition	O
of	O
Post	O
-	O
weaning	O
Pigs	O
at	O
a	O
Commercial	O
Farm	O
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
and	O
butyric	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
BAB	B-bacteria
)	O
are	O
commonly	O
used	O
as	O
probiotics	O
in	O
swine	O
production	O
.	O

However	O
,	O
their	O
combined	O
effect	O
on	O
post	O
-	O
weaning	O
pigs	O
has	O
not	O
been	O
assessed	O
.	O

Therefore	O
,	O
here	O
we	O
investigated	O
the	O
individual	O
and	O
combined	O
efficacy	O
of	O
dietary	O
Enterococcus	B-bacteria
faecium	I-bacteria
and	O
Clostridium	B-bacteria
butyricum	I-bacteria
on	O
the	O
growth	O
and	O
gut	O
microbiota	O
of	O
post	O
-	O
weaning	O
pigs	O
at	O
a	O
commercial	O
farm	O
.	O

Four	O
independent	O
trials	O
were	O
conducted	O
,	O
in	O
each	O
of	O
which	O
five	O
pens	O
containing	O
10	O
pigs	O
were	O
assigned	O
to	O
one	O
of	O
five	O
treatments	O
:	O
C	O
,	O
basal	O
diet	O
;	O
L	O
,	O
basal	O
diet	O
+	O
live	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
;	O
D	O
,	O
basal	O
diet	O
+	O
heat	O
-	O
killed	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
;	O
M	O
,	O
basal	O
diet	O
+	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
;	O
or	O
L	O
+	O
M	O
,	O
basal	O
diet	O
+	O
live	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
+	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
.	O

Each	O
trial	O
was	O
conducted	O
over	O
a	O
90	O
-	O
day	O
period	O
that	O
was	O
divided	O
into	O
two	O
phases	O
(	O
Phase	O
1	O
,	O
days	O
0	O
-	O
40	O
post	O
-	O
weaning	O
;	O
and	O
Phase	O
2	O
,	O
days	O
40	O
-	O
90	O
post	O
-	O
weaning	O
)	O
,	O
with	O
the	O
probiotics	O
being	O
supplemented	O
only	O
during	O
Phase	O
1	O
.	O

Ten	O
pigs	O
in	O
each	O
pen	O
were	O
used	O
for	O
body	O
weight	O
(	O
BW	O
)	O
analysis	O
and	O
fecal	O
samples	O
were	O
collected	O
from	O
five	O
or	O
six	O
of	O
these	O
pigs	O
.	O

In	O
addition	O
,	O
the	O
fecal	O
samples	O
from	O
one	O
randomly	O
selected	O
trial	O
were	O
used	O
for	O
gut	O
microbiota	O
analysis	O
.	O

We	O
found	O
that	O
pigs	O
in	O
the	O
L	O
,	O
D	O
,	O
and	O
L	O
+	O
M	O
treatment	O
groups	O
had	O
a	O
significantly	O
higher	O
BW	O
than	O
those	O
in	O
C	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
but	O
pigs	O
in	O
the	O
L	O
+	O
M	O
treatment	O
group	O
had	O
a	O
similar	O
BW	O
to	O
those	O
in	O
the	O
L	O
and	O
M	O
groups	O
.	O

Furthermore	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
alpha	O
diversity	O
among	O
the	O
treatments	O
but	O
the	O
beta	O
diversity	O
(	O
weighted	O
UniFrac	O
distances	O
)	O
showed	O
distinct	O
clustering	O
patterns	O
,	O
with	O
pigs	O
in	O
C	O
having	O
discrete	O
microbiota	O
from	O
those	O
in	O
all	O
of	O
the	O
probiotics	O
treatment	O
groups	O
except	O
D	O
(	O
C	O
vs	O
.	O
L	O
,	O
q	O
=	O
0	O
.	O
04	O
;	O
C	O
vs	O
.	O
M	O
,	O
q	O
=	O
0	O
.	O
06	O
;	O
C	O
vs	O
.	O
L	O
+	O
M	O
,	O
q	O
=	O
0	O
.	O
06	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
dietary	O
supplementation	O
with	O
live	O
or	O
heat	O
-	O
killed	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
enhances	O
growth	O
performance	O
in	O
pigs	O
but	O
there	O
is	O
no	O
synergistic	O
effect	O
when	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
is	O
used	O
in	O
combination	O
with	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
.	O

Furthermore	O
,	O
the	O
addition	O
of	O
live	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
and	O
C	B-bacteria
.	I-bacteria
butyricum	I-bacteria
to	O
the	O
diet	O
of	O
pigs	O
may	O
change	O
the	O
structure	O
of	O
the	O
gut	O
microbiota	O
.	O

Reciprocal	O
modulation	O
of	O
5	O
-	O
HT	O
and	O
octopamine	O
regulates	O
pumping	O
via	O
feedforward	O
and	O
feedback	O
circuits	O
in	O
C	O
.	I-bacteria
elegans	I-bacteria
.	O

Feeding	O
is	O
vital	O
for	O
animal	O
survival	O
and	O
is	O
tightly	O
regulated	O
by	O
the	O
endocrine	O
and	O
nervous	O
systems	O
.	O

To	O
study	O
the	O
mechanisms	O
of	O
humoral	O
regulation	O
of	O
feeding	O
behavior	O
,	O
we	O
investigated	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
and	O
octopamine	O
(	O
OA	O
)	O
signaling	O
in	O
Caenorhabditis	O
elegans	O
,	O
which	O
uses	O
pharyngeal	O
pumping	O
to	O
ingest	O
bacteria	O
into	O
the	O
gut	O
.	O

We	O
reveal	O
that	O
a	O
cross	O
-	O
modulation	O
mechanism	O
between	O
5	O
-	O
HT	O
and	O
OA	O
,	O
which	O
convey	O
feeding	O
and	O
fasting	O
signals	O
,	O
respectively	O
,	O
mainly	O
functions	O
in	O
regulating	O
the	O
pumping	O
and	O
secretion	O
of	O
both	O
neuromodulators	O
via	O
ADF	O
/	O
RIC	O
/	O
SIA	O
feedforward	O
neurocircuit	O
(	O
consisting	O
of	O
ADF	O
,	O
RIC	O
,	O
and	O
SIA	O
neurons	O
)	O
and	O
ADF	O
/	O
RIC	O
/	O
AWB	O
/	O
ADF	O
feedback	O
neurocircuit	O
(	O
consisting	O
of	O
ADF	O
,	O
RIC	O
,	O
AWB	O
,	O
and	O
ADF	O
neurons	O
)	O
under	O
conditions	O
of	O
food	O
supply	O
and	O
food	O
deprivation	O
,	O
respectively	O
.	O

Food	O
supply	O
stimulates	O
food	O
-	O
sensing	O
ADFs	O
to	O
release	O
more	O
5	O
-	O
HT	O
,	O
which	O
augments	O
pumping	O
via	O
inhibiting	O
OA	O
secretion	O
by	O
RIC	O
interneurons	O
and	O
,	O
thus	O
,	O
alleviates	O
pumping	O
suppression	O
by	O
OA	O
-	O
activated	O
SIA	O
interneurons	O
/	O
motoneurons	O
.	O

In	O
contrast	O
,	O
nutrient	O
deprivation	O
stimulates	O
RICs	O
to	O
secrete	O
OA	O
,	O
which	O
suppresses	O
pumping	O
via	O
activating	O
SIAs	O
and	O
maintains	O
basal	O
pumping	O
and	O
5	O
-	O
HT	O
production	O
activity	O
through	O
excitation	O
of	O
ADFs	O
relayed	O
by	O
AWB	O
sensory	O
neurons	O
.	O

Notably	O
,	O
the	O
feedforward	O
and	O
feedback	O
circuits	O
employ	O
distinct	O
modalities	O
of	O
neurosignal	O
integration	O
,	O
namely	O
,	O
disinhibition	O
and	O
disexcitation	O
,	O
respectively	O
.	O

Enrichment	O
of	O
oral	O
microbiota	O
in	O
early	O
cystic	O
precursors	O
to	O
invasive	O
pancreatic	O
cancer	O
.	O

OBJECTIVES	O
:	O
Intraductal	O
papillary	O
mucinous	O
neoplasms	O
(	O
IPMNs	O
)	O
are	O
pancreatic	O
cysts	O
that	O
can	O
progress	O
to	O
invasive	O
pancreatic	O
cancer	O
.	O

Associations	O
between	O
oncogenesis	O
and	O
oral	O
microbiome	O
alterations	O
have	O
been	O
reported	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
a	O
potential	O
intracystic	O
pancreatic	O
microbiome	O
in	O
a	O
pancreatic	O
cystic	O
neoplasm	O
(	O
PCN	O
)	O
surgery	O
patient	O
cohort	O
.	O

DESIGN	O
:	O
Paired	O
cyst	O
fluid	O
and	O
plasma	O
were	O
collected	O
at	O
pancreatic	O
surgery	O
from	O
patients	O
with	O
suspected	O
PCN	O
(	O
n	O
=	O
105	O
)	O
.	O

Quantitative	O
and	O
qualitative	O
assessment	O
of	O
bacterial	O
DNA	O
by	O
qPCR	O
,	O
PacBio	O
sequencing	O
(	O
n	O
=	O
35	O
)	O
,	O
and	O
interleukin	O
(	O
IL	O
)	O
-	O
1beta	O
quantification	O
was	O
performed	O
.	O

The	O
data	O
were	O
correlated	O
to	O
diagnosis	O
,	O
lesion	O
severity	O
and	O
clinical	O
and	O
laboratory	O
profile	O
,	O
including	O
proton	O
-	O
pump	O
inhibitor	O
(	O
PPI	O
)	O
usage	O
and	O
history	O
of	O
invasive	O
endoscopy	O
procedures	O
.	O

RESULTS	O
:	O
Intracystic	O
bacterial	O
16S	O
DNA	O
copy	O
number	O
and	O
IL	O
-	O
1beta	O
protein	O
quantity	O
were	O
significantly	O
higher	O
in	O
IPMN	O
with	O
high	O
-	O
grade	O
dysplasia	O
and	O
IPMN	O
with	O
cancer	O
compared	O
with	O
non	O
-	O
IPMN	O
PCNs	O
.	O

Despite	O
high	O
interpersonal	O
variation	O
of	O
intracystic	O
microbiota	O
composition	O
,	O
bacterial	O
network	O
and	O
linear	O
discriminant	O
analysis	O
effect	O
size	O
analyses	O
demonstrated	O
co	O
-	O
occurrence	O
and	O
enrichment	O
of	O
oral	O
bacterial	O
taxa	O
including	O
Fusobacterium	B-bacteria
nucleatum	I-bacteria
and	O
Granulicatella	B-bacteria
adiacens	I-bacteria
in	O
cyst	O
fluid	O
from	O
IPMN	O
with	O
high	O
-	O
grade	O
dysplasia	O
.	O

The	O
elevated	O
intracystic	O
bacterial	O
DNA	O
is	O
associated	O
with	O
,	O
but	O
not	O
limited	O
to	O
,	O
prior	O
exposure	O
to	O
invasive	O
endoscopic	O
procedures	O
,	O
and	O
is	O
independent	O
from	O
use	O
of	O
PPI	O
and	O
antibiotics	O
.	O

CONCLUSIONS	O
:	O
Collectively	O
,	O
these	O
findings	O
warrant	O
further	O
investigation	O
into	O
the	O
role	O
of	O
oral	O
bacteria	O
in	O
cystic	O
precursors	O
to	O
pancreatic	O
cancer	O
and	O
have	O
added	O
values	O
on	O
the	O
aetiopathology	O
as	O
well	O
as	O
the	O
management	O
of	O
pancreatic	O
cysts	O
.	O

Supplementation	O
of	O
dietary	O
non	O
-	O
digestible	O
oligosaccharides	O
from	O
birth	O
onwards	O
improve	O
social	O
and	O
reduce	O
anxiety	O
-	O
like	O
behaviour	O
in	O
male	O
BALB	O
/	O
c	O
mice	O
.	O

OBJECTIVE	O
:	O
The	O
intestinal	O
microbiota	O
is	O
acknowledged	O
to	O
be	O
essential	O
in	O
brain	O
development	O
and	O
behaviour	O
.	O

Their	O
composition	O
can	O
be	O
modulated	O
by	O
prebiotics	O
such	O
as	O
short	O
-	O
chain	O
galacto	O
-	O
oligosaccharides	O
(	O
scGOS	O
)	O
and	O
long	O
-	O
chain	O
fructo	O
-	O
oligosaccharide	O
(	O
lcFOS	O
)	O
.	O

Several	O
studies	O
reported	O
potential	O
health	O
benefit	O
of	O
prebiotics	O
on	O
behaviour	O
.	O

As	O
the	O
prebiotic	O
mixture	O
of	O
scGOS	O
and	O
lcFOS	O
is	O
included	O
in	O
infant	O
formula	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
dietary	O
supplementation	O
with	O
this	O
specific	O
mixture	O
from	O
the	O
day	O
of	O
birth	O
onwards	O
on	O
behaviour	O
and	O
intestinal	O
microbiota	O
development	O
in	O
mice	O
.	O

METHOD	O
:	O
Healthy	O
male	O
BALB	O
/	O
cByJ	O
mice	O
received	O
,	O
from	O
day	O
of	O
birth	O
,	O
a	O
dietary	O
supplement	O
with	O
or	O
without	O
3	O
%	O
scGOS	O
:	O
lcFOS	O
(	O
9	O
:	O
1	O
)	O
.	O

Behavioural	O
tests	O
were	O
performed	O
pre	O
-	O
weaning	O
,	O
in	O
adolescence	O
,	O
early	O
adulthood	O
and	O
adulthood	O
.	O

We	O
assessed	O
faecal	O
microbiota	O
compositions	O
over	O
time	O
,	O
caecal	O
short	O
-	O
chain	O
fatty	O
acids	O
as	O
well	O
as	O
brain	O
mRNA	O
expression	O
of	O
Htr1a	O
,	O
Htr1b	O
and	O
Tph2	O
and	O
monoamine	O
levels	O
.	O

RESULTS	O
:	O
Compared	O
to	O
control	O
fed	O
mice	O
,	O
scGOS	O
:	O
lcFOS	O
fed	O
mice	O
showed	O
reduced	O
anxiety	O
-	O
like	O
and	O
repetitive	O
behaviour	O
over	O
time	O
and	O
improved	O
social	O
behaviour	O
in	O
adulthood	O
.	O

The	O
serotonergic	O
system	O
in	O
the	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
and	O
somatosensory	O
cortex	O
(	O
SSC	O
)	O
was	O
affected	O
by	O
the	O
scGOS	O
:	O
lcFOS	O
.	O

In	O
the	O
PFC	O
,	O
mRNA	O
expression	O
of	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
Bdnf	O
)	O
was	O
enhanced	O
in	O
scGOS	O
:	O
lcFOS	O
fed	O
mice	O
.	O

Although	O
the	O
bacterial	O
diversity	O
of	O
the	O
intestinal	O
microbiota	O
was	O
unaffected	O
by	O
the	O
scGOS	O
:	O
lcFOS	O
diet	O
,	O
microbiota	O
composition	O
differed	O
between	O
the	O
scGOS	O
:	O
lcFOS	O
and	O
the	O
control	O
fed	O
mice	O
over	O
time	O
.	O

Moreover	O
,	O
an	O
increased	O
saccharolytic	O
and	O
decreased	O
proteolytic	O
fermentation	O
activity	O
were	O
observed	O
in	O
caecum	O
content	O
.	O

DISCUSSION	O
:	O
Supplementing	O
the	O
diet	O
with	O
scGOS	O
:	O
lcFOS	O
from	O
the	O
day	O
of	O
birth	O
is	O
associated	O
with	O
reduced	O
anxiety	O
-	O
like	O
and	O
improved	O
social	O
behaviour	O
during	O
the	O
developmental	O
period	O
and	O
later	O
in	O
life	O
,	O
and	O
modulates	O
the	O
composition	O
and	O
activity	O
of	O
the	O
intestinal	O
microbiota	O
in	O
healthy	O
male	O
BALB	O
/	O
c	O
mice	O
.	O

These	O
data	O
provide	O
further	O
evidence	O
of	O
the	O
potential	O
impact	O
of	O
scGOS	O
:	O
lcFOS	O
on	O
behaviour	O
at	O
several	O
developmental	O
stages	O
throughout	O
life	O
and	O
strengthen	O
the	O
insights	O
in	O
the	O
interplay	O
between	O
the	O
developing	O
intestine	O
and	O
brain	O
.	O

Nonalcoholic	O
fatty	O
liver	O
disease	O
and	O
the	O
gut	O
microbiome	O
:	O
Are	O
bacteria	O
responsible	O
for	O
fatty	O
liver	O
?	O

IMPACT	O
STATEMENT	O
:	O
This	O
invited	O
minireview	O
for	O
the	O
upcoming	O
thematic	O
issue	O
on	O
the	O
microbiome	O
addresses	O
the	O
role	O
of	O
the	O
microbiome	O
in	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
.	O

The	O
incidence	O
of	O
NAFLD	O
has	O
increased	O
greatly	O
in	O
recent	O
years	O
in	O
parallel	O
with	O
the	O
rise	O
in	O
obesity	O
and	O
is	O
now	O
believed	O
to	O
have	O
a	O
population	O
prevalence	O
of	O
20	O
-	O
40	O
%	O
.	O

It	O
is	O
anticipated	O
to	O
soon	O
become	O
the	O
primary	O
cause	O
of	O
liver	O
-	O
related	O
morbidity	O
and	O
mortality	O
,	O
and	O
unfortunately	O
,	O
there	O
are	O
few	O
treatment	O
options	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
critical	O
need	O
for	O
improved	O
understanding	O
of	O
NAFLD	O
pathophysiology	O
to	O
provide	O
new	O
avenues	O
for	O
therapeutic	O
intervention	O
.	O

In	O
this	O
paper	O
,	O
we	O
have	O
reviewed	O
evidence	O
from	O
human	O
and	O
animal	O
model	O
studies	O
that	O
have	O
associated	O
microbiome	O
composition	O
and	O
microbial	O
metabolites	O
with	O
development	O
and	O
progression	O
of	O
NAFLD	O
.	O

We	O
have	O
also	O
discussed	O
proposed	O
mechanisms	O
by	O
which	O
the	O
microbiome	O
could	O
contribute	O
to	O
NAFLD	O
pathogenesis	O
and	O
addressed	O
future	O
directions	O
for	O
this	O
field	O
.	O

Characterization	O
a	O
Novel	O
Butyric	O
Acid	O
-	O
Producing	O
Bacterium	O
Collinsella	B-bacteria
aerofaciens	I-bacteria
Subsp	I-bacteria
.	I-bacteria
Shenzhenensis	I-bacteria
Subsp	I-bacteria
.	I-bacteria
Nov	I-bacteria
.	O

Butyrate	O
-	O
producing	O
bacteria	O
can	O
biosynthesize	O
butyrate	O
and	O
alleviate	O
inflammatory	O
diseases	O
.	O

However	O
,	O
few	O
studies	O
have	O
reported	O
that	O
the	O
genus	O
Collinsella	B-bacteria
has	O
the	O
ability	O
to	O
produce	O
butyric	O
acid	O
.	O

Here	O
,	O
our	O
study	O
depicts	O
a	O
Collinsella	B-bacteria
strain	I-bacteria
,	O
which	O
is	O
a	O
rod	O
-	O
shaped	O
obligate	O
anaerobe	O
that	O
is	O
able	O
to	O
produce	O
butyric	O
acid	O
.	O

This	O
microorganism	O
was	O
isolated	O
from	O
a	O
human	O
gut	O
,	O
and	O
the	O
optimal	O
growth	O
conditions	O
were	O
found	O
to	O
be	O
37	O
degrees	O
C	O
on	O
PYG	O
medium	O
with	O
pH	O
6	O
.	O
5	O
.	O

The	O
16S	O
rRNA	O
gene	O
sequence	O
demonstrated	O
that	O
this	O
microorganism	O
shared	O
99	O
.	O
93	O
%	O
similarity	O
with	O
C	B-bacteria
.	I-bacteria
aerofaciens	I-bacteria
ATCC	I-bacteria
25986	I-bacteria
(	O
T	O
)	O
,	O
which	O
was	O
higher	O
than	O
the	O
threshold	O
(	O
98	O
.	O
65	O
%	O
)	O
for	O
differentiating	O
two	O
species	O
.	O

Digital	O
DNA	O
(	O
-	O
)	O
DNA	O
hybridization	O
and	O
average	O
nucleotide	O
identity	O
values	O
also	O
supported	O
that	O
this	O
microorganism	O
belonged	O
to	O
the	O
species	O
C	B-bacteria
.	I-bacteria
aerofaciens	I-bacteria
.	O

Distinct	O
phenotypic	O
characteristics	O
between	O
TF06	O
-		O
26	O
and	O
the	O
type	O
strain	O
of	O
C	B-bacteria
.	I-bacteria
aerofaciens	I-bacteria
,	O
such	O
as	O
the	O
fermentation	O
of	O
D	O
-	O
lactose	O
,	O
D	O
-	O
fructose	O
and	O
D	O
-	O
maltose	O
,	O
positive	O
growth	O
under	O
pH	O
5	O
and	O
0	O
.	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
cholate	O
,	O
suggested	O
this	O
strain	O
was	O
a	O
novel	O
subspecies	O
.	O

Comparative	O
genome	O
analysis	O
revealed	O
that	O
butyric	O
acid	O
kinase	O
and	O
phosphate	O
butyryltransferase	O
enzymes	O
were	O
coded	O
exclusively	O
by	O
this	O
strain	O
,	O
indicating	O
a	O
specific	O
butyric	O
acid	O
-	O
producing	O
function	O
of	O
this	O
C	O
.	I-bacteria
aerofaciens	I-bacteria
subspecies	I-bacteria
within	O
the	O
genus	O
Collinsella	B-bacteria
.	O

Thus	O
,	O
Collinsella	B-bacteria
aerofaciens	I-bacteria
subsp	I-bacteria
.	I-bacteria
shenzhenensis	I-bacteria
subsp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
was	O
proposed	O
,	O
with	O
set	O
strain	O
TF06	B-bacteria
-	I-bacteria
26	I-bacteria
(	O
T	O
)	O
(	O
=	O
CGMCC	B-bacteria
1	I-bacteria
.	I-bacteria
5216	I-bacteria
(	O
T	O
)	O
=	O
DSM	B-bacteria
105138	I-bacteria
(	O
T	O
)	O
)	O
as	O
the	O
type	O
strain	O
.	O

Dietary	O
Nutrients	O
Involved	O
in	O
One	O
-	O
Carbon	O
Metabolism	O
and	O
Colonic	O
Mucosa	O
-	O
Associated	O
Gut	O
Microbiome	O
in	O
Individuals	O
with	O
an	O
Endoscopically	O
Normal	O
Colon	O
.	O

One	O
carbon	O
(	O
1C	O
)	O
metabolism	O
nutrients	O
influence	O
epigenetic	O
regulation	O
and	O
they	O
are	O
supplied	O
by	O
diet	O
and	O
synthesized	O
by	O
gut	O
microbiota	O
.	O

We	O
examined	O
the	O
association	O
between	O
dietary	O
consumption	O
of	O
methyl	O
donors	O
(	O
methionine	O
,	O
betaine	O
and	O
choline	O
)	O
and	O
B	O
vitamins	O
(	O
folate	O
,	O
B2	O
,	O
B6	O
,	O
and	O
B12	O
)	O
and	O
the	O
community	O
composition	O
and	O
structure	O
of	O
the	O
colonic	O
mucosa	O
-	O
associated	O
gut	O
microbiota	O
determined	O
by	O
16S	O
rRNA	O
gene	O
sequencing	O
in	O
97	O
colonic	O
biopsies	O
of	O
35	O
men	O
.	O

We	O
used	O
the	O
food	O
frequency	O
questionnaire	O
to	O
assess	O
daily	O
consumption	O
of	O
nutrients	O
,	O
and	O
the	O
UPARSE	O
and	O
SILVA	O
databases	O
for	O
operational	O
taxonomic	O
unit	O
classification	O
.	O

The	O
difference	O
in	O
bacterial	O
diversity	O
and	O
taxonomic	O
relative	O
abundance	O
were	O
compared	O
between	O
low	O
versus	O
high	O
consumption	O
of	O
these	O
nutrients	O
.	O

False	O
discover	O
rate	O
(	O
FDR	O
)	O
adjusted	O
p	O
value	O
<	O
0	O
.	O
05	O
indicated	O
statistical	O
significance	O
.	O

The	O
bacterial	O
richness	O
and	O
composition	O
differed	O
significantly	O
by	O
the	O
consumption	O
of	O
folate	O
and	O
B	O
vitamins	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Compared	O
with	O
higher	O
consumption	O
,	O
a	O
lower	O
consumption	O
of	O
these	O
nutrients	O
was	O
associated	O
with	O
a	O
lower	O
abundance	O
of	O
Akkermansia	O
(	O
folate	O
)	O
,	O
Roseburia	O
(	O
vitamin	O
B2	O
)	O
,	O
and	O
Faecalibacterium	B-bacteria
(	O
vitamins	O
B2	O
,	O
B6	O
,	O
and	O
B12	O
)	O
but	O
a	O
higher	O
abundance	O
of	O
Erysipelatoclostridium	B-bacteria
(	O
vitamin	O
B2	O
)	O
(	O
FDR	O
p	O
values	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
community	O
composition	O
and	O
structure	O
of	O
the	O
colonic	O
bacteria	O
differed	O
significantly	O
by	O
dietary	O
consumption	O
of	O
folate	O
and	O
B	O
vitamins	O
.	O

Three	O
types	O
of	O
gut	O
bacteria	O
collaborating	O
to	O
improve	O
Kui	O
Jie	O
'	O
an	O
enema	O
treat	O
DSS	O
-	O
induced	O
colitis	O
in	O
mice	O
.	O

A	O
rising	O
amount	O
of	O
evidences	O
show	O
that	O
gut	O
microbiota	O
is	O
an	O
important	O
factor	O
in	O
mediating	O
the	O
growth	O
of	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
,	O
the	O
major	O
product	O
of	O
colon	O
bacteria	O
fermentation	O
butyrate	O
as	O
mediator	O
have	O
effects	O
on	O
the	O
mucosal	O
immune	O
system	O
by	O
expanding	O
regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
in	O
the	O
colon	O
.	O

Turkish	O
galls	O
,	O
an	O
insect	O
gall	O
parasitized	O
on	O
the	O
tree	O
branches	O
of	O
Quercus	O
infectoria	O
Oliv	O
.	O
,	O
exhibiting	O
the	O
promising	O
prospect	O
in	O
treating	O
the	O
remedy	O
of	O
UC	O
by	O
regulating	O
the	O
bacteria	O
,	O
whereas	O
its	O
mechanism	O
remains	O
unclear	O
.	O

Here	O
,	O
this	O
work	O
found	O
that	O
three	O
types	O
of	O
gut	O
bacteria	O
collaborating	O
to	O
improve	O
DSS	O
-	O
induced	O
UC	O
in	O
mice	O
after	O
Turkish	O
galls	O
intervention	O
,	O
including	O
putative	O
SCFAs	O
-	O
producing	O
bacteria	O
(	O
PCPB	O
)	O
,	O
anti	O
-	O
inflammatory	O
bacteria	O
and	O
harmful	O
bacteria	O
.	O

The	O
Helicobacter	B-bacteria
,	O
Bilophila	B-bacteria
,	O
Acinetobacter	B-bacteria
and	O
Odoribacter	B-bacteria
,	O
which	O
belong	O
to	O
the	O
harmful	O
bacteria	O
were	O
dramatically	O
increased	O
in	O
UC	O
group	O
,	O
whereas	O
the	O
harmful	O
bacteria	O
were	O
reduced	O
after	O
treatment	O
with	O
Turkish	O
galls	O
.	O

The	O
Allobaculum	B-bacteria
,	O
Bacteriodes	B-bacteria
,	O
Blautia	B-bacteria
,	O
Butyricimonas	B-bacteria
,	O
belonging	O
to	O
PCPB	O
,	O
were	O
significantly	O
increased	O
after	O
Turkish	O
galls	O
and	O
butyrate	O
intervention	O
,	O
and	O
we	O
also	O
observed	O
that	O
the	O
concentration	O
of	O
butyrate	O
increased	O
with	O
the	O
grows	O
of	O
PCPB	O
.	O

The	O
Bifidobacterium	B-bacteria
,	O
Lactococcus	B-bacteria
,	O
which	O
belong	O
to	O
the	O
anti	O
-	O
inflammatory	O
bacteria	O
,	O
were	O
also	O
significantly	O
increased	O
after	O
Turkish	O
galls	O
intervention	O
.	O

Meanwhile	O
,	O
rectal	O
administration	O
of	O
Turkish	O
galls	O
and	O
butyrate	O
could	O
increase	O
mucosa	O
inflammation	O
and	O
diarrhea	O
.	O

The	O
expression	O
of	O
cytokines	O
in	O
the	O
colon	O
was	O
improved	O
by	O
butyrate	O
and	O
Turkish	O
galls	O
treatment	O
group	O
.	O

The	O
percentage	O
of	O
Treg	O
out	O
of	O
CD4	O
(	O
+	O
)	O
population	O
was	O
evaluated	O
by	O
flow	O
cytometry	O
after	O
Turkish	O
galls	O
and	O
butyrate	O
intervention	O
.	O

The	O
results	O
suggested	O
that	O
Turkish	O
galls	O
alleviated	O
UC	O
by	O
modulating	O
three	O
types	O
of	O
the	O
gut	O
microbiota	O
,	O
and	O
butyrate	O
may	O
be	O
used	O
to	O
relieve	O
inflammatory	O
.	O

This	O
study	O
may	O
help	O
us	O
to	O
understand	O
the	O
mechanism	O
of	O
Turkish	O
galls	O
in	O
treating	O
UC	O
from	O
the	O
perspective	O
of	O
intestinal	O
flora	O
and	O
also	O
offered	O
a	O
mechanism	O
reference	O
for	O
UC	O
treatment	O
using	O
an	O
insect	O
gall	O
in	O
rich	O
of	O
polyphenolic	O
compounds	O
.	O

Candida	O
albicans	O
Morphogenesis	O
Programs	O
Control	O
the	O
Balance	O
between	O
Gut	O
Commensalism	O
and	O
Invasive	O
Infection	O
.	O

Candida	O
albicans	O
is	O
a	O
gut	O
commensal	O
and	O
opportunistic	O
pathogen	O
.	O

The	O
transition	O
between	O
yeast	O
and	O
invasive	O
hyphae	O
is	O
central	O
to	O
virulence	O
but	O
has	O
unknown	O
functions	O
during	O
commensal	O
growth	O
.	O

In	O
a	O
mouse	O
model	O
of	O
colonization	O
,	O
yeast	O
and	O
hyphae	O
co	O
-	O
occur	O
throughout	O
the	O
gastrointestinal	O
tract	O
.	O

However	O
,	O
competitive	O
infections	O
of	O
C	O
.	O
albicans	O
homozygous	O
gene	O
disruption	O
mutants	O
revealed	O
an	O
unanticipated	O
,	O
inhibitory	O
role	O
for	O
the	O
yeast	O
-	O
to	O
-	O
hypha	O
morphogenesis	O
program	O
on	O
commensalism	O
.	O

We	O
show	O
that	O
the	O
transcription	O
factor	O
Ume6	O
,	O
a	O
master	O
regulator	O
of	O
filamentation	O
,	O
inhibits	O
gut	O
colonization	O
,	O
not	O
by	O
effects	O
on	O
cell	O
shape	O
,	O
but	O
by	O
activating	O
the	O
expression	O
of	O
a	O
hypha	O
-	O
specific	O
pro	O
-	O
inflammatory	O
secreted	O
protease	O
,	O
Sap6	O
,	O
and	O
a	O
hyphal	O
cell	O
surface	O
adhesin	O
,	O
Hyr1	O
.	O

Like	O
a	O
ume6	O
mutant	O
,	O
strains	O
lacking	O
SAP6	O
exhibit	O
enhanced	O
colonization	O
fitness	O
,	O
whereas	O
SAP6	O
-	O
overexpression	O
strains	O
are	O
attenuated	O
in	O
the	O
gut	O
.	O

These	O
results	O
reveal	O
a	O
tradeoff	O
between	O
fungal	O
programs	O
supporting	O
commensalism	O
and	O
virulence	O
in	O
which	O
selection	O
against	O
hypha	O
-	O
specific	O
markers	O
limits	O
the	O
disease	O
-	O
causing	O
potential	O
of	O
this	O
ubiquitous	O
commensal	O
-	O
pathogen	O
.	O

Setting	O
Up	O
Home	O
:	O
Fungal	O
Rules	O
of	O
Commensalism	O
in	O
the	O
Mammalian	O
Gut	O
.	O

Candida	O
albicans	O
is	O
a	O
commensal	O
fungus	O
of	O
the	O
human	O
gut	O
,	O
but	O
also	O
causes	O
life	O
-	O
threatening	O
systemic	O
infections	O
.	O

Recent	O
studies	O
published	O
in	O
Cell	O
Host	O
&	O
Microbe	O
(	O
Witchley	O
et	O
al	O
.	O
,	O
2019	O
)	O
and	O
Science	O
(	O
Tso	O
et	O
al	O
.	O
,	O
2018	O
)	O
provide	O
insights	O
into	O
the	O
determinants	O
of	O
C	O
.	O
albicans	O
commensal	O
fitness	O
within	O
the	O
mammalian	O
gut	O
.	O

H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
with	O
antibiotic	O
treatment	O
causes	O
changes	O
in	O
glucose	O
homeostasis	O
related	O
to	O
modifications	O
in	O
the	O
gut	O
microbiota	O
.	O

BACKGROUND	O
:	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
and	O
eradication	O
cause	O
perturbations	O
of	O
the	O
gut	O
microbiome	O
.	O

The	O
gut	O
microbiota	O
has	O
been	O
identified	O
as	O
a	O
potential	O
contributor	O
to	O
metabolic	O
diseases	O
.	O

We	O
evaluate	O
whether	O
these	O
alterations	O
in	O
intestinal	O
microbiota	O
composition	O
produced	O
by	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
and	O
its	O
posterior	O
eradication	O
with	O
antibiotic	O
treatment	O
could	O
be	O
associated	O
with	O
glucose	O
homeostasis	O
in	O
metabolically	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
Forty	O
adult	O
patients	O
infected	O
with	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
and	O
20	O
control	O
subjects	O
were	O
recruited	O
.	O

The	O
infected	O
subjects	O
were	O
evaluated	O
before	O
and	O
two	O
months	O
after	O
eradication	O
treatment	O
(	O
omeprazole	O
,	O
clarithromycin	O
,	O
amoxicillin	O
)	O
.	O

The	O
microbiota	O
composition	O
in	O
fecal	O
samples	O
was	O
determined	O
by	O
16S	O
rRNA	O
gene	O
(	O
V3	O
-	O
V4	O
)	O
sequencing	O
using	O
Illumina	O
Miseq	O
.	O

RESULTS	O
:	O
Patients	O
(	O
pre	O
-	O
and	O
post	O
-	O
H	O
.	O
pylori	O
eradication	O
)	O
showed	O
a	O
decreased	O
bacterial	O
richness	O
and	O
diversity	O
with	O
respect	O
to	O
controls	O
.	O

There	O
was	O
an	O
improvement	O
in	O
glucose	O
homeostasis	O
in	O
subjects	O
two	O
months	O
after	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
treatment	O
.	O

Changes	O
in	O
the	O
amount	O
of	O
Rikenellaceae	B-bacteria
,	O
Butyricimonas	B-bacteria
,	O
E	B-bacteria
.	I-bacteria
biforme	I-bacteria
,	O
B	B-bacteria
.	I-bacteria
fragilis	I-bacteria
,	O
and	O
Megamonas	B-bacteria
were	O
inversely	O
associated	O
with	O
changes	O
in	O
the	O
glucose	O
level	O
or	O
related	O
parameters	O
(	O
Hb1ac	O
)	O
in	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
subjects	O
.	O

CONCLUSIONS	O
:	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
and	O
eradication	O
with	O
antibiotic	O
treatment	O
causes	O
alteration	O
of	O
the	O
human	O
gut	O
microbiome	O
.	O

The	O
increase	O
in	O
SCFA	O
-	O
producing	O
bacteria	O
and	O
glucose	O
-	O
removing	O
bacteria	O
,	O
specifically	O
members	O
of	O
Megamonas	B-bacteria
,	O
Rikenellaceae	B-bacteria
and	O
Butyricimonas	B-bacteria
,	O
has	O
been	O
related	O
with	O
an	O
improvement	O
in	O
glucose	O
homeostasis	O
after	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
eradication	O
with	O
antibiotic	O
treatment	O
.	O

Changes	O
of	O
intestinal	O
flora	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
in	O
northeast	O
China	O
.	O

OBJECTIVE	O
:	O
The	O
human	O
gut	O
harbors	O
diverse	O
microbes	O
that	O
play	O
a	O
fundamental	O
role	O
in	O
the	O
well	O
-	O
being	O
of	O
their	O
hosts	O
.	O

Microbes	O
can	O
cause	O
autoimmunity	O
,	O
trigger	O
autoimmunity	O
in	O
genetically	O
susceptible	O
individuals	O
or	O
prevent	O
autoimmunity	O
.	O

There	O
were	O
reports	O
about	O
intestinal	O
flora	O
changes	O
in	O
Systemic	O
Lupus	O
Erythematosus	O
(	O
SLE	O
)	O
patients	O
,	O
but	O
no	O
data	O
were	O
available	O
in	O
northeast	O
China	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
intestinal	O
flora	O
changes	O
of	O
SLE	O
patients	O
in	O
Heilongjiang	O
province	O
located	O
in	O
northeast	O
China	O
.	O

METHODS	O
:	O
Feces	O
from	O
16	O
SLE	O
patients	O
and	O
14	O
healthy	O
volunteers	O
were	O
employed	O
to	O
extract	O
bacterial	O
DNA	O
,	O
amplify	O
16s	O
RNA	O
of	O
bacteria	O
,	O
and	O
analyze	O
the	O
biological	O
information	O
by	O
sequencing	O
.	O

The	O
statistical	O
analysis	O
used	O
the	O
SPSS	O
version	O
of	O
17	O
.	O

RESULT	O
:	O
We	O
found	O
that	O
there	O
were	O
1	O
phylums	O
,	O
4	O
families	O
and	O
9	O
genera	O
in	O
the	O
intestinal	O
flora	O
of	O
SLE	O
patients	O
.	O

And	O
the	O
nine	O
differences	O
genera	O
can	O
be	O
used	O
to	O
distinguish	O
SLE	O
patients	O
from	O
normal	O
people	O
.	O

CONCLUSION	O
:	O
We	O
found	O
an	O
increase	O
of	O
Proteobacteria	B-bacteria
and	O
a	O
decrease	O
of	O
Ruminococcaceae	B-bacteria
in	O
SLE	O
patients	O
in	O
different	O
regions	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
some	O
proteins	O
,	O
enzymes	O
,	O
and	O
diseases	O
were	O
significantly	O
associated	O
with	O
SLE	O
.	O

Gut	O
microbe	O
-	O
generated	O
metabolite	O
trimethylamine	O
N	O
-	O
oxide	O
and	O
the	O
risk	O
of	O
diabetes	O
:	O
A	O
systematic	O
review	O
and	O
dose	O
-	O
response	O
meta	O
-	O
analysis	O
.	O

Elevated	O
circulating	O
concentrations	O
of	O
the	O
gut	O
bacteria	O
choline	O
metabolite	O
trimethylamine	O
N	O
-	O
oxide	O
(	O
TMAO	O
)	O
were	O
found	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

However	O
,	O
whether	O
a	O
high	O
level	O
of	O
TMAO	O
is	O
related	O
to	O
the	O
risk	O
of	O
diabetes	O
has	O
not	O
been	O
studied	O
.	O

We	O
aimed	O
to	O
synthesize	O
the	O
evidence	O
on	O
the	O
relation	O
between	O
TMAO	O
levels	O
and	O
the	O
risk	O
of	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
and	O
to	O
investigate	O
the	O
association	O
further	O
in	O
a	O
dose	O
-	O
response	O
meta	O
-	O
analysis	O
.	O

PubMed	O
,	O
Web	O
of	O
Science	O
,	O
and	O
Scopus	O
databases	O
were	O
searched	O
for	O
studies	O
from	O
inception	O
to	O
June	O
2018	O
.	O

A	O
total	O
of	O
12	O
clinical	O
studies	O
were	O
included	O
in	O
this	O
study	O
,	O
and	O
15	O
314	O
enrolled	O
subjects	O
were	O
included	O
.	O

A	O
meta	O
-	O
analysis	O
of	O
two	O
-	O
class	O
variables	O
and	O
continuous	O
variables	O
were	O
used	O
to	O
obtain	O
pooled	O
effects	O
.	O

Dose	O
-	O
response	O
meta	O
-	O
analysis	O
was	O
used	O
to	O
investigate	O
the	O
dose	O
-	O
response	O
relationship	O
between	O
TMAO	O
concentrations	O
and	O
the	O
risk	O
of	O
DM	O
.	O

Meta	O
-	O
regression	O
and	O
subgroup	O
analyses	O
were	O
applied	O
to	O
identify	O
the	O
source	O
of	O
heterogeneity	O
in	O
this	O
study	O
.	O

High	O
levels	O
of	O
circulating	O
TMAO	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
DM	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
1	O
.	O
89	O
)	O
using	O
the	O
two	O
-	O
class	O
meta	O
-	O
analysis	O
.	O

Plasma	O
levels	O
of	O
TMAO	O
in	O
patients	O
with	O
diabetes	O
were	O
higher	O
than	O
in	O
subjects	O
without	O
diabetes	O
(	O
standardized	O
mean	O
difference	O
[	O
SMD	O
]	O
:	O
0	O
.	O
36	O
)	O
using	O
a	O
meta	O
-	O
analysis	O
of	O
continuous	O
variables	O
.	O

The	O
OR	O
for	O
DM	O
prevalence	O
increased	O
by	O
54	O
%	O
per	O
5	O
mumol	O
L	O
(	O
-	O
1	O
)	O
increment	O
of	O
plasma	O
TMAO	O
(	O
OR	O
=	O
1	O
.	O
54	O
)	O
according	O
to	O
the	O
dose	O
-	O
response	O
meta	O
-	O
analysis	O
.	O

This	O
is	O
the	O
first	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
to	O
demonstrate	O
a	O
positive	O
dose	O
-	O
dependent	O
association	O
between	O
circulating	O
TMAO	O
levels	O
and	O
increased	O
diabetes	O
risk	O
.	O

Microbiome	O
programming	O
of	O
brain	O
development	O
:	O
implications	O
for	O
neurodevelopmental	O
disorders	O
.	O

During	O
the	O
last	O
decade	O
,	O
research	O
on	O
germ	O
-	O
free	O
mice	O
has	O
discovered	O
that	O
the	O
gut	O
microbiome	O
(	O
i	O
.	O
e	O
.	O
the	O
normal	O
bacteria	O
colonizing	O
the	O
gastrointestinal	O
tract	O
)	O
can	O
programme	O
brain	O
function	O
and	O
behaviour	O
during	O
early	O
development	O
.	O

At	O
the	O
same	O
time	O
a	O
growing	O
number	O
of	O
clinical	O
studies	O
have	O
shown	O
altered	O
gut	O
microflora	O
in	O
children	O
with	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
,	O
in	O
combination	O
with	O
altered	O
bacterial	O
metabolites	O
and	O
inflammatory	O
cytokines	O
being	O
part	O
of	O
the	O
gut	O
-	O
brain	O
axis	O
.	O

This	O
review	O
covers	O
the	O
concept	O
of	O
the	O
microbiome	O
;	O
how	O
it	O
is	O
established	O
during	O
childhood	O
;	O
how	O
it	O
is	O
affected	O
by	O
malnutrition	O
;	O
how	O
it	O
can	O
programme	O
the	O
development	O
of	O
the	O
brain	O
through	O
epigenetic	O
mechanisms	O
;	O
which	O
pathways	O
are	O
used	O
from	O
the	O
gut	O
to	O
the	O
brain	O
;	O
and	O
assesses	O
findings	O
that	O
suggest	O
the	O
gut	O
microbiome	O
may	O
be	O
involved	O
in	O
ASD	O
and	O
other	O
neurodevelopmental	O
disorders	O
.	O

This	O
is	O
a	O
new	O
research	O
field	O
with	O
a	O
number	O
of	O
exciting	O
,	O
but	O
so	O
far	O
fragmented	O
,	O
findings	O
indicating	O
the	O
important	O
role	O
of	O
the	O
normal	O
microbiome	O
in	O
shaping	O
the	O
brain	O
.	O

Research	O
also	O
suggests	O
that	O
disruptions	O
of	O
the	O
microbiome	O
may	O
be	O
involved	O
in	O
the	O
aetiology	O
of	O
neurodevelopmental	O
disorders	O
.	O

WHAT	O
THIS	O
PAPER	O
ADDS	O
:	O
The	O
gut	O
microbiome	O
shapes	O
the	O
brain	O
via	O
the	O
gut	O
-	O
brain	O
axis	O
.	O

The	O
microbiome	O
may	O
play	O
a	O
role	O
in	O
neurodevelopmental	O
disorders	O
.	O

Distinct	O
Roles	O
for	O
Peyer	O
'	O
s	O
Patch	O
B	O
Cells	O
for	O
Induction	O
of	O
Antigen	O
-	O
specific	O
IgA	O
Antibody	O
Responses	O
in	O
Mice	O
Administered	O
Oral	O
Recombinant	O
Salmonella	B-bacteria
.	O

Our	O
previous	O
study	O
demonstrated	O
an	O
indispensable	O
role	O
of	O
Peyer	O
'	O
s	O
patches	O
(	O
PPs	O
)	O
for	O
the	O
induction	O
of	O
antigen	O
-	O
specific	O
secretory	O
(	O
S	O
)	O
IgA	O
antibody	O
responses	O
after	O
oral	O
immunization	O
with	O
recombinant	O
Salmonella	B-bacteria
expressing	O
fragment	O
C	O
of	O
tetanus	O
toxin	O
(	O
rSalmonella	O
-	O
Tox	O
C	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
defined	O
the	O
PP	O
lymphoid	O
structures	O
and	O
immune	O
cells	O
required	O
for	O
the	O
induction	O
of	O
mucosal	O
SIgA	O
antibody	O
responses	O
.	O

Adoptive	O
transfer	O
of	O
mononuclear	O
cells	O
(	O
MNCs	O
)	O
from	O
PPs	O
into	O
PP	O
deficient	O
(	O
PP	O
-	O
null	O
)	O
mice	O
failed	O
to	O
elicit	O
tetanus	O
toxoid	O
(	O
TT	O
)	O
-	O
specific	O
mucosal	O
immunity	O
.	O

However	O
,	O
when	O
the	O
same	O
PP	O
MNCs	O
were	O
transferred	O
into	O
lethally	O
irradiated	O
PP	O
-	O
normal	O
recipient	O
mice	O
,	O
PP	O
MNCs	O
preferentially	O
emigrated	O
to	O
recipient	O
PPs	O
,	O
leading	O
to	O
PP	O
lymphoid	O
structures	O
and	O
TT	O
-	O
specific	O
SIgA	O
antibody	O
responses	O
.	O

Significantly	O
reduced	O
numbers	O
of	O
TT	O
-	O
specific	O
IgA	O
antibody	O
-	O
forming	O
cells	O
were	O
detected	O
in	O
the	O
mesenteric	O
lymph	O
nodes	O
(	O
MLNs	O
)	O
and	O
intestinal	O
lamina	O
propria	O
of	O
mice	O
when	O
surface	O
expression	O
of	O
the	O
sphingosine	O
1	O
-	O
phosphate	O
receptor	O
on	O
lymphocytes	O
was	O
inhibited	O
by	O
its	O
agonist	O
FTY720	O
.	O

However	O
,	O
FTY720	O
treatment	O
did	O
not	O
alter	O
dendritic	O
cell	O
(	O
DC	O
)	O
migration	O
or	O
Salmonella	B-bacteria
dissemination	O
into	O
these	O
tissues	O
.	O

When	O
rSalmonella	O
-	O
Tox	O
C	O
-	O
stimulated	O
CD4	O
+	O
T	O
cells	O
isolated	O
from	O
PPs	O
,	O
MLNs	O
and	O
the	O
spleen	O
were	O
co	O
-	O
cultured	O
with	O
B	O
cells	O
from	O
these	O
tissues	O
,	O
significantly	O
increased	O
levels	O
of	O
TT	O
-	O
specific	O
IgA	O
antibody	O
responses	O
were	O
exclusively	O
induced	O
in	O
cultures	O
containing	O
PP	O
B	O
cells	O
.	O

Furthermore	O
,	O
surface	O
IgA	O
+	O
PP	O
B	O
cells	O
produced	O
TT	O
-	O
specific	O
IgA	O
antibody	O
responses	O
in	O
vitro	O
.	O

These	O
findings	O
suggest	O
that	O
PP	O
lymphoid	O
structures	O
and	O
surface	O
IgA	O
+	O
PP	O
B	O
cells	O
are	O
essential	O
elements	O
for	O
the	O
induction	O
of	O
antigen	O
-	O
specific	O
intestinal	O
SIgA	O
antibody	O
responses	O
to	O
oral	O
Salmonella	B-bacteria
.	O

Alterations	O
in	O
the	O
gut	O
microbiota	O
of	O
patients	O
with	O
silica	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O

Silicosis	O
resulting	O
from	O
silica	O
exposure	O
is	O
a	O
global	O
occupational	O
disease	O
characterized	O
by	O
severe	O
pathological	O
changes	O
in	O
progressive	O
pulmonary	O
fibrosis	O
.	O

Previous	O
evidence	O
has	O
indicated	O
that	O
dysbiosis	O
of	O
the	O
gut	O
microbiota	O
occurs	O
after	O
environmental	O
dust	O
exposure	O
and	O
is	O
associated	O
with	O
certain	O
diseases	O
.	O

The	O
aims	O
of	O
this	O
study	O
are	O
to	O
elucidate	O
the	O
compositional	O
and	O
functional	O
characteristics	O
of	O
the	O
gut	O
microbiota	O
in	O
early	O
-	O
stage	O
silicosis	O
and	O
to	O
understand	O
their	O
influence	O
on	O
pulmonary	O
fibrosis	O
.	O

We	O
investigated	O
the	O
gut	O
microbial	O
composition	O
of	O
fecal	O
samples	O
from	O
18	O
patients	O
and	O
21	O
healthy	O
subjects	O
using	O
16S	O
rRNA	O
gene	O
sequencing	O
technology	O
.	O

Compared	O
with	O
the	O
healthy	O
subjects	O
,	O
reductions	O
in	O
the	O
levels	O
of	O
Firmicutes	B-bacteria
and	O
Actinobacteria	B-bacteria
were	O
noted	O
in	O
patients	O
with	O
silicosis	O
and	O
progressive	O
pulmonary	O
fibrosis	O
,	O
as	O
well	O
as	O
lower	O
levels	O
of	O
Devosia	B-bacteria
,	O
Clostridiales	B-bacteria
,	O
AlloprevotellaandRikenellaceae	B-bacteria
_	I-bacteria
RC9	I-bacteria
.	O

Lachnospiraceae	B-bacteria
and	O
Lachnoclostridium	B-bacteria
levels	O
were	O
increased	O
in	O
patients	O
with	O
silicosis	O
.	O

GOC	O
and	O
KEGG	O
analyses	O
were	O
used	O
to	O
predict	O
that	O
certain	O
bacteria	O
taxa	O
play	O
critical	O
roles	O
in	O
the	O
development	O
of	O
pulmonary	O
fibrosis	O
,	O
including	O
posttranslational	O
modification	O
,	O
amino	O
acid	O
transport	O
and	O
metabolism	O
,	O
nucleotide	O
transport	O
and	O
metabolism	O
,	O
and	O
ribosomal	O
structure	O
and	O
biogenesis	O
.	O

KEGG	O
analysis	O
showed	O
that	O
certain	O
taxa	O
participate	O
in	O
various	O
roles	O
including	O
cancer	O
,	O
endocrine	O
metabolism	O
,	O
immune	O
system	O
,	O
signaling	O
molecules	O
and	O
interaction	O
,	O
and	O
transcription	O
.	O

Collectively	O
,	O
in	O
this	O
pilot	O
study	O
,	O
microbiota	O
changes	O
have	O
been	O
represented	O
in	O
the	O
gut	O
of	O
patients	O
with	O
silicosis	O
.	O

Although	O
this	O
change	O
in	O
gut	O
microbiota	O
have	O
been	O
represented	O
,	O
caution	O
is	O
needed	O
when	O
interpreting	O
the	O
findings	O
since	O
this	O
is	O
observational	O
finding	O
,	O
not	O
necessarily	O
causative	O
.	O

More	O
studies	O
should	O
be	O
performed	O
in	O
the	O
expanding	O
population	O
to	O
be	O
verified	O
and	O
more	O
studies	O
underlying	O
biological	O
mechanisms	O
for	O
better	O
understanding	O
the	O
relationship	O
between	O
gut	O
microbiota	O
and	O
development	O
of	O
pulmonary	O
fibrosis	O
in	O
patients	O
with	O
silicosis	O
.	O

New	O
insights	O
from	O
uncultivated	O
genomes	O
of	O
the	O
global	O
human	O
gut	O
microbiome	O
.	O

The	O
genome	O
sequences	O
of	O
many	O
species	O
of	O
the	O
human	O
gut	O
microbiome	O
remain	O
unknown	O
,	O
largely	O
owing	O
to	O
challenges	O
in	O
cultivating	O
microorganisms	O
under	O
laboratory	O
conditions	O
.	O

Here	O
we	O
address	O
this	O
problem	O
by	O
reconstructing	O
60	O
,	O
664	O
draft	O
prokaryotic	O
genomes	O
from	O
3	O
,	O
810	O
faecal	O
metagenomes	O
,	O
from	O
geographically	O
and	O
phenotypically	O
diverse	O
humans	O
.	O

These	O
genomes	O
provide	O
reference	O
points	O
for	O
2	O
,	O
058	O
newly	O
identified	O
species	O
-	O
level	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
,	O
which	O
represents	O
a	O
50	O
%	O
increase	O
over	O
the	O
previously	O
known	O
phylogenetic	O
diversity	O
of	O
sequenced	O
gut	O
bacteria	O
.	O

On	O
average	O
,	O
the	O
newly	O
identified	O
OTUs	O
comprise	O
33	O
%	O
of	O
richness	O
and	O
28	O
%	O
of	O
species	O
abundance	O
per	O
individual	O
,	O
and	O
are	O
enriched	O
in	O
humans	O
from	O
rural	O
populations	O
.	O

A	O
meta	O
-	O
analysis	O
of	O
clinical	O
gut	O
-	O
microbiome	O
studies	O
pinpointed	O
numerous	O
disease	O
associations	O
for	O
the	O
newly	O
identified	O
OTUs	O
,	O
which	O
have	O
the	O
potential	O
to	O
improve	O
predictive	O
models	O
.	O

Finally	O
,	O
our	O
analysis	O
revealed	O
that	O
uncultured	O
gut	O
species	O
have	O
undergone	O
genome	O
reduction	O
that	O
has	O
resulted	O
in	O
the	O
loss	O
of	O
certain	O
biosynthetic	O
pathways	O
,	O
which	O
may	O
offer	O
clues	O
for	O
improving	O
cultivation	O
strategies	O
in	O
the	O
future	O
.	O

Impact	O
of	O
a	O
bathing	O
tradition	O
on	O
shared	O
gut	O
microbe	O
among	O
Japanese	O
families	O
.	O

Sharing	O
of	O
Bifidobacterium	B-bacteria
longum	I-bacteria
strains	I-bacteria
had	O
recently	O
been	O
shown	O
to	O
occur	O
among	O
Japanese	O
family	O
members	O
,	O
a	O
phenomenon	O
that	O
is	O
not	O
confined	O
to	O
mother	O
-	O
infant	O
pairs	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
if	O
bathtub	O
water	O
is	O
a	O
possible	O
vehicle	O
for	O
the	O
exchange	O
of	O
strains	O
as	O
a	O
consequence	O
of	O
a	O
Japanese	O
custom	O
to	O
share	O
bathtub	O
water	O
by	O
family	O
members	O
during	O
bathing	O
practices	O
.	O

A	O
total	O
of	O
twenty	O
-	O
one	O
subjects	O
from	O
five	O
Japanese	O
families	O
,	O
each	O
consisting	O
of	O
parents	O
with	O
either	O
2	O
or	O
3	O
children	O
,	O
were	O
enrolled	O
in	O
this	O
study	O
and	O
the	O
fecal	O
microbiota	O
of	O
all	O
participants	O
was	O
determined	O
.	O

Viable	O
bifidobacterial	B-bacteria
strains	I-bacteria
were	O
isolated	O
from	O
all	O
bathtub	O
water	O
samples	O
.	O

A	O
subsequent	O
comparative	O
genome	O
analysis	O
using	O
ninety	O
-	O
eight	O
strains	O
indicated	O
that	O
certain	O
strain	O
-	O
sets	O
,	O
which	O
were	O
isolated	O
from	O
feces	O
and	O
bathtub	O
water	O
,	O
share	O
near	O
identical	O
genome	O
sequences	O
,	O
including	O
CRISPR	O
/	O
Cas	O
protospacers	O
.	O

By	O
means	O
of	O
unweighted	O
UniFrac	O
distance	O
analysis	O
based	O
on	O
16S	O
rRNA	O
gene	O
analysis	O
of	O
59	O
subjects	O
from	O
sixteen	O
Japanese	O
families	O
,	O
we	O
showed	O
that	O
the	O
fecal	O
microbiota	O
composition	O
among	O
family	O
members	O
that	O
share	O
bathtub	O
water	O
is	O
significantly	O
closer	O
than	O
that	O
between	O
family	O
members	O
that	O
do	O
not	O
engage	O
in	O
this	O
practice	O
.	O

Our	O
results	O
indicate	O
that	O
bathtub	O
water	O
represents	O
a	O
vehicle	O
for	O
the	O
transmission	O
of	O
gut	O
bacteria	O
,	O
and	O
that	O
the	O
Japanese	O
custom	O
of	O
sharing	O
bathtub	O
water	O
contributes	O
to	O
the	O
exchange	O
of	O
gut	O
microbes	O
,	O
in	O
particular	O
bifidobacteria	B-bacteria
,	O
among	O
family	O
members	O
.	O

The	O
influence	O
of	O
the	O
host	O
microbiome	O
on	O
3	O
,	O
4	O
-	O
methylenedioxymethamphetamine	O
(	O
MDMA	O
)	O
-	O
induced	O
hyperthermia	O
and	O
vice	O
versa	O
.	O

Hyperthermia	O
induced	O
by	O
3	O
,	O
4	O
-	O
methylenedioxymethamphetamine	O
(	O
MDMA	O
)	O
can	O
be	O
life	O
-	O
threatening	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
the	O
gut	O
microbiome	O
and	O
TGR5	O
bile	O
acid	O
receptors	O
in	O
MDMA	O
-	O
mediated	O
hyperthermia	O
.	O

Fourteen	O
days	O
prior	O
to	O
treatment	O
with	O
MDMA	O
,	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
provided	O
water	O
or	O
water	O
treated	O
with	O
antibiotics	O
.	O

Animals	O
that	O
had	O
received	O
antibiotics	O
displayed	O
a	O
reduction	O
in	O
gut	O
bacteria	O
and	O
an	O
attenuated	O
hyperthermic	O
response	O
to	O
MDMA	O
.	O

MDMA	O
treated	O
animals	O
showed	O
increased	O
uncoupling	O
protein	O
1	O
(	O
UCP1	O
)	O
and	O
TGR5	O
expression	O
levels	O
in	O
brown	O
adipose	O
tissue	O
and	O
skeletal	O
muscle	O
while	O
increased	O
expression	O
of	O
UCP3	O
was	O
observed	O
only	O
in	O
skeletal	O
muscle	O
.	O

Antibiotics	O
prior	O
to	O
MDMA	O
administration	O
significantly	O
blunted	O
these	O
increases	O
in	O
gene	O
expression	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
the	O
TGR5	O
receptor	O
with	O
triamterene	O
or	O
of	O
deiodinase	O
II	O
downstream	O
of	O
the	O
TGR5	O
receptor	O
with	O
iopanoic	O
acid	O
also	O
resulted	O
in	O
the	O
attenuation	O
of	O
MDMA	O
-	O
induced	O
hyperthermia	O
.	O

MDMA	O
-	O
treatment	O
enriched	O
the	O
relative	O
proportion	O
of	O
a	O
Proteus	B-bacteria
mirabilis	I-bacteria
strain	I-bacteria
in	O
the	O
ceca	O
of	O
animals	O
not	O
pre	O
-	O
treated	O
with	O
antibiotics	O
.	O

These	O
findings	O
suggest	O
a	O
contributing	O
role	O
for	O
the	O
gut	O
microbiota	O
in	O
MDMA	O
-	O
mediated	O
hyperthermia	O
and	O
that	O
MDMA	O
treatment	O
can	O
trigger	O
a	O
rapid	O
remodeling	O
of	O
the	O
composition	O
of	O
the	O
gut	O
microbiome	O
.	O

Spatial	O
and	O
Temporal	O
Analysis	O
of	O
the	O
Stomach	O
and	O
Small	O
-	O
Intestinal	O
Microbiota	O
in	O
Fasted	O
Healthy	O
Humans	O
.	O

Although	O
the	O
microbiota	O
in	O
the	O
proximal	O
gastrointestinal	O
(	O
GI	O
)	O
tract	O
have	O
been	O
implicated	O
in	O
health	O
and	O
disease	O
,	O
much	O
about	O
these	O
microbes	O
remains	O
understudied	O
compared	O
to	O
those	O
in	O
the	O
distal	O
GI	O
tract	O
.	O

This	O
study	O
characterized	O
the	O
microbiota	O
across	O
multiple	O
proximal	O
GI	O
sites	O
over	O
time	O
in	O
healthy	O
individuals	O
.	O

As	O
part	O
of	O
a	O
study	O
of	O
the	O
pharmacokinetics	O
of	O
oral	O
mesalamine	O
administration	O
,	O
healthy	O
,	O
fasted	O
volunteers	O
(	O
n	O
=	O
8	O
;	O
10	O
observation	O
periods	O
total	O
)	O
were	O
orally	O
intubated	O
with	O
a	O
four	O
-	O
lumen	O
catheter	O
with	O
multiple	O
aspiration	O
ports	O
.	O

Samples	O
were	O
taken	O
from	O
stomach	O
,	O
duodenal	O
,	O
and	O
multiple	O
jejunal	O
sites	O
,	O
sampling	O
hourly	O
(	O
<	O
/	O
=	O
7	O
h	O
)	O
to	O
measure	O
mesalamine	O
(	O
administered	O
at	O
t	O
=	O
0	O
)	O
,	O
pH	O
,	O
and	O
16S	O
rRNA	O
gene	O
-	O
based	O
composition	O
.	O

We	O
observed	O
a	O
predominance	O
of	O
Firmicutes	B-bacteria
across	O
proximal	O
GI	O
sites	O
,	O
with	O
significant	O
variation	O
compared	O
to	O
stool	O
.	O

The	O
microbiota	O
was	O
more	O
similar	O
within	O
individuals	O
over	O
time	O
than	O
between	O
subjects	O
,	O
with	O
the	O
fecal	O
microbiota	O
being	O
unique	O
from	O
that	O
of	O
the	O
small	O
intestine	O
.	O

The	O
stomach	O
and	O
duodenal	O
microbiota	O
displayed	O
highest	O
intraindividual	O
variability	O
compared	O
to	O
jejunal	O
sites	O
,	O
which	O
were	O
more	O
stable	O
across	O
time	O
.	O

We	O
observed	O
significant	O
correlations	O
in	O
the	O
duodenal	O
microbial	O
composition	O
with	O
changes	O
in	O
pH	O
;	O
linear	O
mixed	O
models	O
identified	O
positive	O
correlations	O
with	O
multiple	O
Streptococcus	B-bacteria
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
and	O
negative	O
correlations	O
with	O
multiple	O
Prevotella	B-bacteria
and	O
Pasteurellaceae	B-bacteria
OTUs	O
.	O

Few	O
OTUs	O
correlated	O
with	O
mesalamine	O
concentration	O
.	O

The	O
stomach	O
and	O
duodenal	O
microbiota	O
exhibited	O
greater	O
compositional	O
dynamics	O
than	O
the	O
jejunum	O
.	O

Short	O
-	O
term	O
fluctuations	O
in	O
the	O
duodenal	O
microbiota	O
were	O
correlated	O
with	O
pH	O
.	O

Given	O
the	O
unique	O
characteristics	O
and	O
dynamics	O
of	O
the	O
proximal	O
GI	O
tract	O
microbiota	O
,	O
it	O
is	O
important	O
to	O
consider	O
these	O
local	O
environments	O
in	O
health	O
and	O
disease	O
states	O
.	O
IMPORTANCE	O
The	O
gut	O
microbiota	O
are	O
linked	O
to	O
a	O
variety	O
of	O
gastrointestinal	O
diseases	O
,	O
including	O
inflammatory	O
bowel	O
disease	O
.	O

Despite	O
this	O
importance	O
,	O
microbiota	O
dynamics	O
in	O
the	O
upper	O
gastrointestinal	O
tract	O
are	O
understudied	O
.	O

Our	O
article	O
seeks	O
to	O
understand	O
what	O
factors	O
impact	O
microbiota	O
dynamics	O
in	O
the	O
healthy	O
human	O
upper	O
gut	O
.	O

We	O
found	O
that	O
the	O
upper	O
gastrointestinal	O
tract	O
contains	O
consistently	O
prevalent	O
bacterial	O
OTUs	O
that	O
dominate	O
the	O
overall	O
community	O
.	O

Microbiota	O
variability	O
is	O
highest	O
in	O
the	O
stomach	O
and	O
duodenum	O
and	O
correlates	O
with	O
pH	O
.	O

The	O
Use	O
of	O
Defined	O
Microbial	O
Communities	O
To	O
Model	O
Host	O
-	O
Microbe	O
Interactions	O
in	O
the	O
Human	O
Gut	O
.	O

The	O
human	O
intestinal	O
ecosystem	O
is	O
characterized	O
by	O
a	O
complex	O
interplay	O
between	O
different	O
microorganisms	O
and	O
the	O
host	O
.	O

The	O
high	O
variation	O
within	O
the	O
human	O
population	O
further	O
complicates	O
the	O
quest	O
toward	O
an	O
adequate	O
understanding	O
of	O
this	O
complex	O
system	O
that	O
is	O
so	O
relevant	O
to	O
human	O
health	O
and	O
well	O
-	O
being	O
.	O

To	O
study	O
host	O
-	O
microbe	O
interactions	O
,	O
defined	O
synthetic	O
bacterial	O
communities	O
have	O
been	O
introduced	O
in	O
gnotobiotic	O
animals	O
or	O
in	O
sophisticated	O
in	O
vitro	O
cell	O
models	O
.	O

This	O
review	O
reinforces	O
that	O
our	O
limited	O
understanding	O
has	O
often	O
hampered	O
the	O
appropriate	O
design	O
of	O
defined	O
communities	O
that	O
represent	O
the	O
human	O
gut	O
microbiota	O
.	O

On	O
top	O
of	O
this	O
,	O
some	O
communities	O
have	O
been	O
applied	O
to	O
in	O
vivo	O
models	O
that	O
differ	O
appreciably	O
from	O
the	O
human	O
host	O
.	O

In	O
this	O
review	O
,	O
the	O
advantages	O
and	O
disadvantages	O
of	O
using	O
defined	O
microbial	O
communities	O
are	O
outlined	O
,	O
and	O
suggestions	O
for	O
future	O
improvement	O
of	O
host	O
-	O
microbe	O
interaction	O
models	O
are	O
provided	O
.	O

With	O
respect	O
to	O
the	O
host	O
,	O
technological	O
advances	O
,	O
such	O
as	O
the	O
development	O
of	O
a	O
gut	O
-	O
on	O
-	O
a	O
-	O
chip	O
system	O
and	O
intestinal	O
organoids	O
,	O
may	O
contribute	O
to	O
more	O
-	O
accurate	O
in	O
vitro	O
models	O
of	O
the	O
human	O
host	O
.	O

With	O
respect	O
to	O
the	O
microbiota	O
,	O
due	O
to	O
the	O
increasing	O
availability	O
of	O
representative	O
cultured	O
isolates	O
and	O
their	O
genomic	O
sequences	O
,	O
our	O
understanding	O
and	O
controllability	O
of	O
the	O
human	O
gut	O
`	O
`	O
core	O
microbiota	O
'	O
'	O
are	O
likely	O
to	O
increase	O
.	O

Taken	O
together	O
,	O
these	O
advancements	O
could	O
further	O
unravel	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
human	O
gut	O
microbiota	O
superorganism	O
.	O

Such	O
a	O
gain	O
of	O
insight	O
would	O
provide	O
a	O
solid	O
basis	O
for	O
the	O
improvement	O
of	O
pre	O
-	O
,	O
pro	O
-	O
,	O
and	O
synbiotics	O
as	O
well	O
as	O
the	O
development	O
of	O
new	O
therapeutic	O
microbes	O
.	O

Prebiotic	O
supplementation	O
in	O
frail	O
older	O
people	O
affects	O
specific	O
gut	O
microbiota	O
taxa	O
but	O
not	O
global	O
diversity	O
.	O

BACKGROUND	O
:	O
There	O
are	O
complex	O
interactions	O
between	O
aging	O
,	O
frailty	O
,	O
diet	O
,	O
and	O
the	O
gut	O
microbiota	O
;	O
modulation	O
of	O
the	O
gut	O
microbiota	O
by	O
diet	O
could	O
lead	O
to	O
healthier	O
aging	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
effect	O
of	O
diets	O
differing	O
in	O
sugar	O
,	O
fat	O
,	O
and	O
fiber	O
content	O
upon	O
the	O
gut	O
microbiota	O
of	O
mice	O
humanized	O
with	O
microbiota	O
from	O
healthy	O
or	O
frail	O
older	O
people	O
.	O

We	O
also	O
performed	O
a	O
6	O
-	O
month	O
dietary	O
fiber	O
supplementation	O
in	O
three	O
human	O
cohorts	O
representing	O
three	O
distinct	O
life	O
-	O
stages	O
.	O

METHODS	O
:	O
Mice	O
were	O
colonized	O
with	O
human	O
microbiota	O
and	O
then	O
underwent	O
an	O
8	O
-	O
week	O
dietary	O
intervention	O
with	O
either	O
a	O
high	O
-	O
fiber	O
/	O
low	O
-	O
fat	O
diet	O
typical	O
of	O
elderly	O
community	O
dwellers	O
or	O
a	O
low	O
-	O
fiber	O
/	O
high	O
-	O
fat	O
diet	O
typical	O
of	O
long	O
-	O
stay	O
residential	O
care	O
subjects	O
.	O

A	O
cross	O
-	O
over	O
design	O
was	O
used	O
where	O
the	O
diets	O
were	O
switched	O
after	O
4	O
weeks	O
to	O
the	O
other	O
diet	O
type	O
to	O
identify	O
responsive	O
taxa	O
and	O
innate	O
immunity	O
changes	O
.	O

In	O
the	O
human	O
intervention	O
,	O
the	O
subjects	O
supplemented	O
their	O
normal	O
diet	O
with	O
a	O
mix	O
of	O
five	O
prebiotics	O
(	O
wheat	O
dextrin	O
,	O
resistant	O
starch	O
,	O
polydextrose	O
,	O
soluble	O
corn	O
fiber	O
,	O
and	O
galactooligo	O
-	O
saccharide	O
)	O
at	O
10	O
g	O
/	O
day	O
combined	O
total	O
,	O
for	O
healthy	O
subjects	O
and	O
20	O
g	O
/	O
day	O
for	O
frail	O
subjects	O
,	O
or	O
placebo	O
(	O
10	O
g	O
/	O
day	O
maltodextrin	O
)	O
for	O
26	O
weeks	O
.	O

The	O
gut	O
microbiota	O
was	O
profiled	O
and	O
immune	O
responses	O
were	O
assayed	O
by	O
T	O
cell	O
markers	O
in	O
mice	O
,	O
and	O
serum	O
cytokines	O
in	O
humans	O
.	O

RESULTS	O
:	O
Humanized	O
mice	O
maintained	O
gut	O
microbiota	O
types	O
reflecting	O
the	O
respective	O
healthy	O
or	O
frail	O
human	O
donor	O
.	O

Changes	O
in	O
abundance	O
of	O
specific	O
taxa	O
occurred	O
with	O
the	O
diet	O
switch	O
.	O

In	O
mice	O
with	O
the	O
community	O
type	O
microbiota	O
,	O
the	O
observed	O
differences	O
reflected	O
compositions	O
previously	O
associated	O
with	O
higher	O
frailty	O
.	O

The	O
dominance	O
of	O
Prevotella	B-bacteria
present	O
initially	O
in	O
community	O
inoculated	O
mice	O
was	O
replaced	O
by	O
Bacteroides	B-bacteria
,	O
Alistipes	B-bacteria
,	O
and	O
Oscillibacter	B-bacteria
.	O

Frail	O
type	O
microbiota	O
showed	O
a	O
differential	O
effect	O
on	O
innate	O
immune	O
markers	O
in	O
both	O
conventional	O
and	O
germ	O
-	O
free	O
mice	O
,	O
but	O
a	O
moderate	O
number	O
of	O
taxonomic	O
changes	O
occurring	O
upon	O
diet	O
switch	O
with	O
an	O
increase	O
in	O
abundance	O
of	O
Parabacteroides	B-bacteria
,	O
Blautia	B-bacteria
,	O
Clostridium	B-bacteria
cluster	I-bacteria
IV	I-bacteria
,	O
and	O
Phascolarctobacterium	B-bacteria
.	O

In	O
the	O
human	O
intervention	O
,	O
prebiotic	O
supplementation	O
did	O
not	O
drive	O
any	O
global	O
changes	O
in	O
alpha	O
-	O
or	O
beta	O
-	O
diversity	O
,	O
but	O
the	O
abundance	O
of	O
certain	O
bacterial	O
taxa	O
,	O
particularly	O
Ruminococcaceae	B-bacteria
(	O
Clostridium	B-bacteria
cluster	I-bacteria
IV	I-bacteria
)	O
,	O
Parabacteroides	B-bacteria
,	O
Phascolarctobacterium	B-bacteria
,	O
increased	O
,	O
and	O
levels	O
of	O
the	O
chemokine	O
CXCL11	O
were	O
significantly	O
lower	O
in	O
the	O
frail	O
elderly	O
group	O
,	O
but	O
increased	O
during	O
the	O
wash	O
-	O
out	O
period	O
.	O

CONCLUSIONS	O
:	O
Switching	O
to	O
a	O
nutritionally	O
poorer	O
diet	O
has	O
a	O
profound	O
effect	O
on	O
the	O
microbiota	O
in	O
mouse	O
models	O
,	O
with	O
changes	O
in	O
the	O
gut	O
microbiota	O
from	O
healthy	O
donors	O
reflecting	O
previously	O
observed	O
differences	O
between	O
elderly	O
frail	O
and	O
non	O
-	O
frail	O
individuals	O
.	O

However	O
,	O
the	O
frailty	O
-	O
associated	O
gut	O
microbiota	O
did	O
not	O
reciprocally	O
switch	O
to	O
a	O
younger	O
healthy	O
-	O
subject	O
like	O
state	O
,	O
and	O
supplementation	O
with	O
prebiotics	O
was	O
associated	O
with	O
fewer	O
detected	O
effects	O
in	O
humans	O
than	O
diet	O
adjustment	O
in	O
animal	O
models	O
.	O

The	O
success	O
of	O
fecal	O
microbial	O
transplantation	O
in	O
Clostridium	B-bacteria
difficile	I-bacteria
infection	O
correlates	O
with	O
bacteriophage	O
relative	O
abundance	O
in	O
the	O
donor	O
:	O
a	O
retrospective	O
cohort	O
study	O
.	O

BACKGROUND	O
:	O
Fecal	O
microbial	O
transplantation	O
(	O
FMT	O
)	O
is	O
used	O
in	O
the	O
treatment	O
of	O
relapsing	O
Clostridium	B-bacteria
difficile	I-bacteria
infection	O
(	O
rCDI	O
)	O
.	O

Failure	O
rate	O
for	O
FMT	O
is	O
as	O
high	O
as	O
10	O
%	O
but	O
the	O
mechanisms	O
contributing	O
to	O
a	O
failed	O
FMT	O
are	O
not	O
understood	O
.	O

We	O
utilized	O
metagenomic	O
data	O
to	O
identify	O
the	O
role	O
of	O
bacteria	O
and	O
bacteriophages	O
on	O
FMT	O
success	O
.	O

RESULTS	O
:	O
Subjects	O
with	O
rCDI	O
(	O
n	O
=	O
19	O
)	O
received	O
FMT	O
from	O
volunteer	O
donors	O
(	O
n	O
=	O
7	O
)	O
via	O
colonoscopy	O
.	O

Twelve	O
patients	O
fully	O
recovered	O
after	O
a	O
single	O
FMT	O
,	O
while	O
seven	O
patients	O
required	O
a	O
subsequent	O
FMT	O
.	O

DNA	O
was	O
extracted	O
from	O
patient	O
and	O
donor	O
stool	O
samples	O
for	O
shotgun	O
metagenomic	O
analysis	O
.	O

Metagenomics	O
libraries	O
were	O
analyzed	O
focusing	O
on	O
bacterial	O
taxonomy	O
and	O
bacteriophage	O
sequences	O
.	O

Gammaproteobacteria	B-bacteria
were	O
dominant	O
in	O
rCDI	O
patients	O
prior	O
to	O
FMT	O
largely	O
due	O
to	O
elevated	O
levels	O
of	O
Klebsiella	B-bacteria
and	O
Escherichia	B-bacteria
.	O

A	O
successful	O
FMT	O
led	O
to	O
increased	O
levels	O
of	O
Clostridia	B-bacteria
and	O
Bacteroidia	B-bacteria
and	O
a	O
reduction	O
in	O
Gammaproteobacteria	B-bacteria
.	O

In	O
contrast	O
,	O
a	O
failed	O
FMT	O
led	O
to	O
no	O
significant	O
changes	O
in	O
bacterial	O
composition	O
.	O

Bacteriophages	O
were	O
classified	O
during	O
whole	O
metagenomic	O
analysis	O
of	O
each	O
sample	O
and	O
were	O
markedly	O
different	O
between	O
rCDI	O
patients	O
,	O
donors	O
,	O
and	O
a	O
healthy	O
control	O
cohort	O
(	O
n	O
=	O
96	O
)	O
.	O

Bacteriophage	O
sequence	O
reads	O
were	O
increased	O
in	O
CDI	O
patients	O
compared	O
with	O
donors	O
and	O
healthy	O
controls	O
.	O

Successful	O
FMT	O
donors	O
had	O
higher	O
bacteriophage	O
alpha	O
-	O
diversity	O
and	O
lower	O
relative	O
abundance	O
compared	O
to	O
the	O
donors	O
of	O
a	O
failed	O
initial	O
FMT	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
retrospective	O
analysis	O
,	O
FMTs	O
with	O
increased	O
bacteriophage	O
alpha	O
-	O
diversity	O
were	O
more	O
likely	O
to	O
successfully	O
treat	O
rCDI	O
.	O

In	O
addition	O
,	O
the	O
relative	O
number	O
of	O
bacteriophage	O
reads	O
was	O
lower	O
in	O
donations	O
leading	O
to	O
a	O
successful	O
FMT	O
.	O

These	O
results	O
suggest	O
that	O
bacteriophage	O
abundance	O
may	O
have	O
some	O
role	O
in	O
determining	O
the	O
relative	O
success	O
of	O
FMT	O
.	O

Childhood	O
obesity	O
:	O
current	O
situation	O
in	O
Mexico	O
.	O

Introduction	O
:	O
Mexico	O
has	O
reported	O
in	O
2016	O
a	O
combined	O
prevalence	O
of	O
obesity	O
and	O
overweight	O
of	O
33	O
.	O
2	O
%	O
in	O
children	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
make	O
a	O
literature	O
review	O
of	O
the	O
factors	O
associated	O
with	O
obesity	O
in	O
Mexican	O
children	O
,	O
such	O
as	O
genetic	O
factors	O
,	O
feeding	O
patterns	O
,	O
sedentary	O
lifestyle	O
and	O
gut	O
microbiota	O
.	O

We	O
found	O
that	O
in	O
Mexican	O
children	O
SNP	O
(	O
single	O
nucleotide	O
polymorphism	O
)	O
is	O
present	O
in	O
genes	O
such	O
as	O
MC4R	O
,	O
FTO	O
and	O
ADRB1	O
,	O
associated	O
with	O
obesity	O
,	O
and	O
that	O
PON	O
-	O
1192	O
polymorphism	O
increases	O
the	O
risk	O
of	O
suffering	O
insulin	O
resistance	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
variant	O
of	O
the	O
ADIPOR2	O
gene	O
(	O
rs11061971	O
)	O
protects	O
Mexican	O
children	O
against	O
obesity	O
,	O
as	O
well	O
as	O
a	O
greater	O
number	O
of	O
copies	O
of	O
the	O
AMY	O
gene	O
was	O
found	O
in	O
children	O
with	O
normal	O
weight	O
.	O

The	O
evidence	O
of	O
the	O
number	O
of	O
copies	O
is	O
very	O
important	O
,	O
since	O
the	O
current	O
diet	O
of	O
the	O
Mexican	O
population	O
is	O
rich	O
in	O
carbohydrates	O
and	O
fats	O
,	O
origin	O
of	O
a	O
nutritional	O
transition	O
that	O
includes	O
sedentary	O
activities	O
and	O
a	O
high	O
consumption	O
of	O
sugary	O
drinks	O
.	O

The	O
consumption	O
of	O
certain	O
foods	O
causes	O
important	O
changes	O
in	O
the	O
gut	O
microbiota	O
that	O
contribute	O
to	O
the	O
development	O
of	O
obesity	O
and	O
insulin	O
resistance	O
.	O

It	O
has	O
been	O
found	O
that	O
Mexican	O
children	O
with	O
obesity	O
have	O
a	O
higher	O
abundance	O
of	O
phylum	O
Firmicutes	B-bacteria
and	O
B	B-bacteria
.	I-bacteria
eggerhii	I-bacteria
bacteria	I-bacteria
.	O

Therefore	O
,	O
as	O
obesity	O
is	O
so	O
diverse	O
,	O
it	O
is	O
essential	O
to	O
diversify	O
the	O
treatment	O
in	O
which	O
government	O
authorities	O
,	O
parents	O
and	O
health	O
authorities	O
should	O
get	O
involved	O
,	O
as	O
well	O
as	O
reinforcing	O
nutrition	O
and	O
healthy	O
eating	O
issues	O
in	O
primary	O
education	O
in	O
the	O
country	O
in	O
order	O
to	O
reverse	O
the	O
prevalence	O
and	O
prevent	O
the	O
development	O
of	O
other	O
pathologies	O
in	O
Mexican	O
children	O
.	O

Chronic	O
Kidney	O
Disease	O
and	O
the	O
Gut	O
Microbiome	O
.	O

The	O
gut	O
microbiome	O
is	O
composed	O
of	O
a	O
diverse	O
population	O
of	O
bacteria	O
which	O
have	O
beneficial	O
and	O
adverse	O
effects	O
on	O
human	O
health	O
.	O

The	O
microbiome	O
has	O
recently	O
gained	O
attention	O
and	O
is	O
increasingly	O
noted	O
to	O
play	O
a	O
significant	O
role	O
in	O
health	O
and	O
a	O
number	O
of	O
disease	O
states	O
.	O

Increasing	O
urea	O
concentration	O
during	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
leads	O
to	O
alterations	O
in	O
the	O
intestinal	O
flora	O
that	O
can	O
increase	O
production	O
of	O
gut	O
-	O
derived	O
toxins	O
and	O
alter	O
the	O
intestinal	O
epithelial	O
barrier	O
.	O

These	O
changes	O
can	O
lead	O
to	O
an	O
acceleration	O
of	O
the	O
process	O
of	O
kidney	O
injury	O
.	O

A	O
number	O
of	O
strategies	O
have	O
been	O
proposed	O
to	O
interrupt	O
this	O
pathway	O
of	O
injury	O
in	O
CKD	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
summarize	O
the	O
role	O
of	O
the	O
gut	O
microbiome	O
in	O
chronic	O
kidney	O
disease	O
,	O
tools	O
used	O
to	O
study	O
this	O
microbial	O
population	O
,	O
and	O
attempts	O
to	O
alter	O
its	O
composition	O
for	O
therapeutic	O
purposes	O
.	O

Undernutrition	O
Shapes	O
the	O
Gut	O
Microbiota	O
and	O
Bile	O
Acid	O
Profile	O
in	O
Association	O
with	O
Altered	O
Gut	O
-	O
Liver	O
FXR	O
Signaling	O
in	O
Weaning	O
Pigs	O
.	O

Bile	O
acids	O
,	O
synthesized	O
in	O
the	O
liver	O
and	O
metabolized	O
by	O
microbiota	O
,	O
have	O
emerged	O
as	O
important	O
signaling	O
molecules	O
regulating	O
immune	O
responses	O
and	O
cell	O
proliferation	O
.	O

However	O
,	O
the	O
crosstalk	O
among	O
nutrition	O
,	O
microbiota	O
,	O
and	O
bile	O
acids	O
remains	O
unclear	O
.	O

Our	O
study	O
indicated	O
that	O
undernutrition	O
in	O
weaning	O
piglets	O
led	O
to	O
intestinal	O
atrophy	O
,	O
increased	O
colonic	O
production	O
,	O
and	O
systemic	O
accumulation	O
of	O
lithocholic	O
acid	O
(	O
LCA	O
)	O
,	O
deoxycholic	O
acid	O
(	O
DCA	O
)	O
,	O
or	O
their	O
conjugated	O
forms	O
,	O
which	O
might	O
be	O
associated	O
with	O
decreased	O
Lactobacillus	B-bacteria
abundance	O
.	O

Moreover	O
,	O
undernutrition	O
led	O
to	O
increased	O
portal	O
fibroblast	O
growth	O
factor	O
19	O
(	O
FGF19	O
)	O
level	O
,	O
upregulated	O
hepatic	O
heterodimer	O
partner	O
(	O
SHP	O
)	O
,	O
and	O
downregulated	O
cholesterol	O
7a	O
-	O
hydroxylase	O
(	O
CYP7A1	O
)	O
expression	O
.	O

The	O
detrimental	O
effects	O
of	O
DCA	O
and	O
LCA	O
on	O
proliferation	O
and	O
barrier	O
function	O
were	O
confirmed	O
in	O
porcine	O
enterocytes	O
,	O
whereas	O
their	O
roles	O
in	O
weaning	O
piglets	O
warrant	O
further	O
research	O
.	O

In	O
summary	O
,	O
undernutrition	O
in	O
weaning	O
piglets	O
led	O
to	O
increased	O
secondary	O
bile	O
acids	O
production	O
,	O
which	O
might	O
be	O
related	O
to	O
altered	O
gut	O
microbiome	O
and	O
enhanced	O
farnesoid	O
X	O
receptor	O
(	O
FXR	O
)	O
signaling	O
while	O
CYP7A1	O
expression	O
was	O
suppressed	O
.	O

Genomic	O
changes	O
underlying	O
host	O
specialization	O
in	O
the	O
bee	O
gut	O
symbiont	O
Lactobacillus	B-bacteria
Firm5	I-bacteria
.	O

Bacteria	O
that	O
engage	O
in	O
longstanding	O
associations	O
with	O
particular	O
hosts	O
are	O
expected	O
to	O
evolve	O
host	O
-	O
specific	O
adaptations	O
that	O
limit	O
their	O
capacity	O
to	O
thrive	O
in	O
other	O
environments	O
.	O

Consistent	O
with	O
this	O
,	O
many	O
gut	O
symbionts	O
seem	O
to	O
have	O
a	O
limited	O
host	O
range	O
,	O
based	O
on	O
community	O
profiling	O
and	O
phylogenomics	O
.	O

However	O
,	O
few	O
studies	O
have	O
experimentally	O
investigated	O
host	O
specialization	O
of	O
gut	O
symbionts	O
and	O
underlying	O
mechanisms	O
have	O
largely	O
remained	O
elusive	O
.	O

Here	O
,	O
we	O
studied	O
host	O
specialization	O
of	O
a	O
dominant	O
gut	O
symbiont	O
of	O
social	O
bees	O
,	O
Lactobacillus	B-bacteria
Firm5	I-bacteria
.	O

We	O
show	O
that	O
Firm5	B-bacteria
strains	I-bacteria
isolated	O
from	O
honey	O
bees	O
and	O
bumble	O
bees	O
separate	O
into	O
deep	O
-	O
branching	O
host	O
-	O
specific	O
phylogenetic	O
lineages	O
.	O

Despite	O
their	O
divergent	O
evolution	O
,	O
colonization	O
experiments	O
show	O
that	O
bumble	O
bee	O
strains	O
are	O
capable	O
of	O
colonizing	O
the	O
honey	O
bee	O
gut	O
.	O

However	O
,	O
they	O
were	O
less	O
successful	O
than	O
honey	O
bee	O
strains	O
,	O
and	O
competition	O
with	O
honey	O
bee	O
strains	O
completely	O
abolished	O
their	O
colonization	O
.	O

In	O
contrast	O
honey	O
bee	O
strains	O
of	O
divergent	O
phylogenetic	O
lineages	O
were	O
able	O
to	O
coexist	O
within	O
individual	O
bees	O
.	O

This	O
suggests	O
that	O
both	O
host	O
selection	O
and	O
interbacterial	O
competition	O
play	O
important	O
roles	O
for	O
host	O
specialization	O
.	O

Using	O
comparative	O
genomics	O
of	O
27	O
Firm5	B-bacteria
isolates	I-bacteria
,	O
we	O
found	O
that	O
the	O
genomes	O
of	O
honey	O
bee	O
strains	O
harbor	O
more	O
carbohydrate	O
-	O
related	O
functions	O
than	O
bumble	O
bee	O
strains	O
,	O
possibly	O
providing	O
a	O
competitive	O
advantage	O
in	O
the	O
honey	O
bee	O
gut	O
.	O

Remarkably	O
,	O
most	O
of	O
the	O
genes	O
encoding	O
carbohydrate	O
-	O
related	O
functions	O
were	O
not	O
conserved	O
among	O
the	O
honey	O
bee	O
strains	O
,	O
which	O
suggests	O
that	O
honey	O
bees	O
can	O
support	O
a	O
metabolically	O
more	O
diverse	O
community	O
of	O
Firm5	B-bacteria
strains	I-bacteria
than	O
bumble	O
bees	O
.	O

These	O
findings	O
advance	O
our	O
understanding	O
of	O
genomic	O
changes	O
underlying	O
host	O
specialization	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Gut	O
Leakage	O
of	O
Fungal	O
-	O
Derived	O
Inflammatory	O
Mediators	O
:	O
Part	O
of	O
a	O
Gut	O
-	O
Liver	O
-	O
Kidney	O
Axis	O
in	O
Bacterial	O
Sepsis	O
.	O

Sepsis	O
is	O
a	O
life	O
-	O
threatening	O
response	O
to	O
systemic	O
infection	O
.	O

In	O
addition	O
to	O
frank	O
gastrointestinal	O
(	O
GI	O
)	O
rupture	O
/	O
puncture	O
,	O
sepsis	O
can	O
also	O
be	O
exacerbated	O
by	O
translocation	O
of	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
(	O
PAMPs	O
)	O
from	O
the	O
GI	O
tract	O
to	O
the	O
systemic	O
circulation	O
(	O
gut	O
origin	O
of	O
sepsis	O
)	O
.	O

In	O
the	O
human	O
gut	O
,	O
Gram	O
-	O
negative	O
bacteria	O
and	O
Candida	O
albicans	O
are	O
abundant	O
,	O
along	O
with	O
their	O
major	O
PAMP	O
components	O
,	O
endotoxin	O
(	O
LPS	O
)	O
and	O
(	O
1	O
-	O
-	O
>	O
3	O
)	O
-	O
beta	O
-	O
D	O
-	O
glucan	O
(	O
BG	O
)	O
.	O

Whereas	O
the	O
influence	O
of	O
LPS	O
in	O
bacterial	O
sepsis	O
has	O
been	O
studied	O
extensively	O
,	O
exploration	O
of	O
the	O
role	O
of	O
BG	O
in	O
bacterial	O
sepsis	O
is	O
limited	O
.	O

Post	O
-	O
translocation	O
,	O
PAMPs	O
enter	O
the	O
circulation	O
through	O
lymphatics	O
and	O
the	O
portal	O
vein	O
,	O
and	O
are	O
detoxified	O
and	O
then	O
excreted	O
via	O
the	O
liver	O
and	O
the	O
kidney	O
.	O

Sepsis	O
-	O
induced	O
liver	O
and	O
kidney	O
injury	O
might	O
therefore	O
affect	O
the	O
kinetics	O
and	O
increase	O
circulating	O
PAMPs	O
.	O

In	O
this	O
article	O
,	O
we	O
discuss	O
the	O
current	O
knowledge	O
of	O
the	O
impact	O
of	O
PAMPs	O
from	O
both	O
gut	O
mycobiota	O
and	O
microbiota	O
,	O
including	O
epithelial	O
barrier	O
function	O
and	O
the	O
`	O
`	O
gut	O
-	O
liver	O
-	O
kidney	O
axis	O
,	O
'	O
'	O
on	O
bacterial	O
sepsis	O
severity	O
.	O

Colistin	O
resistance	O
in	O
Parisian	O
inpatient	O
faecal	O
Escherichia	B-bacteria
coli	I-bacteria
as	O
the	O
result	O
of	O
two	O
distinct	O
evolutionary	O
pathways	O
.	O

BACKGROUND	O
:	O
Beyond	O
plasmid	O
-	O
encoded	O
resistance	O
(	O
mcr	O
genes	O
)	O
prevalence	O
in	O
strain	O
collections	O
,	O
large	O
epidemiological	O
studies	O
to	O
estimate	O
the	O
human	O
burden	O
of	O
colistin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Escherichia	I-bacteria
coli	I-bacteria
gut	O
carriage	O
are	O
lacking	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
prevalence	O
of	O
colistin	B-bacteria
-	I-bacteria
resistant	I-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
carriage	O
in	O
inpatients	O
and	O
decipher	O
the	O
molecular	O
support	O
of	O
resistance	O
and	O
the	O
genetic	O
background	O
of	O
the	O
strains	O
.	O

METHODS	O
:	O
During	O
a	O
3	O
month	O
period	O
in	O
2017	O
,	O
we	O
prospectively	O
screened	O
patients	O
in	O
six	O
Parisian	O
hospitals	O
for	O
rectal	O
carriage	O
of	O
colistin	B-bacteria
-	I-bacteria
resistant	I-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
using	O
a	O
selective	O
medium	O
,	O
a	O
biochemical	O
confirmatory	O
test	O
and	O
MIC	O
determination	O
.	O

WGS	O
of	O
the	O
resistant	O
strains	O
and	O
their	O
corresponding	O
plasmids	O
was	O
performed	O
.	O

RESULTS	O
:	O
Among	O
the	O
1217	O
screened	O
patients	O
,	O
153	O
colistin	B-bacteria
-	I-bacteria
resistant	I-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
strains	I-bacteria
were	O
isolated	O
from	O
152	O
patients	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

The	O
mcr	O
-	O
1	O
gene	O
was	O
identified	O
in	O
only	O
seven	O
isolates	O
(	O
4	O
.	O
6	O
%	O
)	O
on	O
different	O
plasmid	O
scaffolds	O
.	O

The	O
genetic	O
background	O
of	O
these	O
MCR	O
-	O
1	O
producers	O
argued	O
for	O
an	O
animal	O
origin	O
.	O

Conversely	O
,	O
the	O
remaining	O
146	O
colistin	B-bacteria
-	I-bacteria
resistant	I-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
exhibited	O
a	O
phylogenetic	O
distribution	O
corresponding	O
to	O
human	O
gut	O
commensal	O
/	O
clinical	O
population	O
structure	O
(	O
B2	O
and	O
D	O
phylogroup	O
predominance	O
)	O
;	O
72	O
.	O
6	O
%	O
of	O
those	O
isolates	O
harboured	O
convergent	O
mutations	O
in	O
the	O
PmrA	O
and	O
PmrB	O
proteins	O
,	O
constituting	O
a	O
two	O
-	O
component	O
system	O
shown	O
to	O
be	O
associated	O
with	O
colistin	O
resistance	O
.	O

CONCLUSIONS	O
:	O
We	O
showed	O
that	O
the	O
occurrence	O
at	O
a	O
high	O
rate	O
of	O
colistin	O
resistance	O
in	O
human	O
faecal	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
is	O
the	O
result	O
of	O
two	O
distinct	O
evolutionary	O
pathways	O
,	O
i	O
.	O
e	O
.	O

the	O
occurrence	O
of	O
chromosomal	O
mutations	O
in	O
an	O
endogenous	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
population	O
and	O
the	O
rare	O
acquisition	O
of	O
exogenous	O
mcr	O
-	O
1	O
-	O
bearing	O
strains	O
probably	O
of	O
animal	O
origin	O
.	O

The	O
involved	O
selective	O
pressures	O
need	O
to	O
be	O
identified	O
in	O
order	O
to	O
develop	O
preventative	O
strategies	O
.	O

Phagocytosis	O
of	O
Gut	O
Bacteria	O
by	O
Entamoeba	B-bacteria
histolytica	I-bacteria
.	O

The	O
protist	O
parasite	O
Entamoeba	O
histolytica	O
causes	O
amoebiasis	O
,	O
a	O
major	O
public	O
health	O
problem	O
in	O
developing	O
countries	O
.	O

Only	O
a	O
small	O
fraction	O
of	O
patients	O
infected	O
with	O
the	O
parasite	O
display	O
invasive	O
disease	O
involving	O
colon	O
or	O
extra	O
intestinal	O
tissues	O
such	O
as	O
liver	O
.	O

E	B-bacteria
.	I-bacteria
histolytica	I-bacteria
exists	O
as	O
two	O
distinct	O
forms	O
,	O
cysts	O
,	O
the	O
infective	O
form	O
,	O
and	O
trophozoites	O
,	O
that	O
are	O
responsible	O
for	O
disease	O
pathology	O
.	O

The	O
latter	O
multiply	O
in	O
the	O
large	O
intestine	O
occasionally	O
causing	O
disease	O
.	O

The	O
large	O
intestine	O
in	O
humans	O
is	O
populated	O
by	O
a	O
number	O
of	O
different	O
bacterial	O
communities	O
and	O
amoebic	O
cells	O
grow	O
in	O
their	O
midst	O
using	O
some	O
as	O
food	O
material	O
.	O

Several	O
studies	O
have	O
shown	O
relationship	O
between	O
bacteria	O
and	O
E	B-bacteria
.	I-bacteria
histolytica	I-bacteria
growth	O
and	O
virulence	O
.	O

However	O
,	O
an	O
understanding	O
of	O
this	O
relationship	O
in	O
human	O
gut	O
environment	O
is	O
not	O
clear	O
.	O

We	O
have	O
investigated	O
the	O
possibility	O
that	O
there	O
may	O
be	O
specific	O
interaction	O
of	O
amoeba	O
with	O
different	O
bacteria	O
present	O
in	O
the	O
gut	O
environment	O
by	O
using	O
a	O
metagenomic	O
pipe	O
line	O
.	O

This	O
was	O
done	O
by	O
incubating	O
bacteria	O
isolated	O
from	O
human	O
fecal	O
material	O
with	O
E	B-bacteria
.	I-bacteria
histolytica	I-bacteria
and	O
then	O
identifying	O
the	O
bacterial	O
population	O
isolated	O
from	O
amoebic	O
cells	O
using	O
a	O
rRNA	O
based	O
metagenomic	O
approach	O
.	O

Our	O
results	O
show	O
that	O
the	O
parasite	O
prefers	O
a	O
few	O
bacterial	O
species	O
.	O

One	O
of	O
these	O
species	O
is	O
Lactobacillus	B-bacteria
ruminus	I-bacteria
which	O
has	O
never	O
shown	O
to	O
be	O
associated	O
with	O
E	B-bacteria
.	I-bacteria
histolytica	I-bacteria
.	O

Employing	O
toxin	O
-	O
antitoxin	O
genome	O
markers	O
for	O
identification	O
of	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
strains	I-bacteria
in	O
human	O
metagenomes	O
.	O

Recent	O
research	O
has	O
indicated	O
that	O
in	O
addition	O
to	O
the	O
unique	O
genotype	O
each	O
individual	O
may	O
also	O
have	O
a	O
unique	O
microbiota	O
composition	O
.	O

Difference	O
in	O
microbiota	O
composition	O
may	O
emerge	O
from	O
both	O
its	O
species	O
and	O
strain	O
constituents	O
.	O

It	O
is	O
important	O
to	O
know	O
the	O
precise	O
composition	O
especially	O
for	O
the	O
gut	O
microbiota	O
(	O
GM	O
)	O
,	O
since	O
it	O
can	O
contribute	O
to	O
the	O
health	O
assessment	O
,	O
personalized	O
treatment	O
,	O
and	O
disease	O
prevention	O
for	O
individuals	O
and	O
groups	O
(	O
cohorts	O
)	O
.	O

The	O
existing	O
methods	O
for	O
species	O
and	O
strain	O
composition	O
in	O
microbiota	O
are	O
not	O
always	O
precise	O
and	O
usually	O
not	O
so	O
easy	O
to	O
use	O
.	O

Probiotic	O
bacteria	O
of	O
the	O
genus	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
make	O
an	O
essential	O
component	O
of	O
human	O
GM	O
.	O

Previously	O
we	O
have	O
shown	O
that	O
in	O
certain	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
species	I-bacteria
the	O
RelBE	O
and	O
MazEF	O
superfamily	O
of	O
toxin	O
-	O
antitoxin	O
(	O
TA	O
)	O
systems	O
may	O
be	O
used	O
as	O
functional	O
biomarkers	O
to	O
differentiate	O
these	O
groups	O
of	O
bacteria	O
at	O
the	O
species	O
and	O
strain	O
levels	O
.	O

We	O
have	O
composed	O
a	O
database	O
of	O
TA	O
genes	O
of	O
these	O
superfamily	O
specific	O
for	O
all	O
lactobacilli	B-bacteria
and	O
bifidobacteria	B-bacteria
species	I-bacteria
with	O
complete	O
genome	O
sequence	O
and	O
confirmed	O
that	O
in	O
all	O
Lactobacillus	B-bacteria
and	O
Bifidobacterium	B-bacteria
species	O
TA	O
gene	O
composition	O
is	O
species	O
and	O
strain	O
specific	O
.	O

To	O
analyze	O
composition	O
of	O
species	O
and	O
strains	O
of	O
two	O
bacteria	O
genera	O
,	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
,	O
in	O
human	O
GM	O
we	O
developed	O
TAGMA	O
(	O
toxin	O
antitoxin	O
genes	O
for	O
metagenomes	O
analyses	O
)	O
software	O
based	O
on	O
polymorphism	O
in	O
TA	O
genes	O
.	O

TAGMA	O
was	O
tested	O
on	O
gut	O
metagenomic	O
samples	O
.	O

The	O
results	O
of	O
our	O
analysis	O
have	O
shown	O
that	O
TAGMA	O
can	O
be	O
used	O
to	O
characterize	O
species	O
and	O
strains	O
of	O
Lactobacillus	B-bacteria
and	O
Bifidobacterium	B-bacteria
in	O
metagenomes	O
.	O

Probiotic	O
Properties	O
of	O
Enterococcus	B-bacteria
Isolated	O
From	O
Artisanal	O
Dairy	O
Products	O
.	O

The	O
present	O
study	O
focused	O
on	O
probiotic	O
characterization	O
and	O
safety	O
evaluation	O
of	O
Enterococcus	B-bacteria
isolates	I-bacteria
from	O
different	O
artisanal	O
dairy	O
products	O
.	O

All	O
the	O
isolates	O
exhibited	O
inhibitory	O
activity	O
against	O
several	O
food	O
spoilage	O
bacteria	O
and	O
food	O
-	O
borne	O
pathogens	O
,	O
including	O
Shigella	B-bacteria
flexneri	I-bacteria
,	O
Staphylococcus	B-bacteria
aureus	I-bacteria
,	O
Listeria	B-bacteria
monocytogenes	I-bacteria
,	O
Yersinia	B-bacteria
enterocolitica	I-bacteria
,	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
,	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
and	O
Bacillus	B-bacteria
subtilis	I-bacteria
.	O

The	O
PCR	O
results	O
indicated	O
the	O
presence	O
of	O
at	O
least	O
one	O
enterocin	O
structural	O
gene	O
in	O
all	O
the	O
tested	O
strains	O
.	O

The	O
Enterococcus	B-bacteria
isolates	I-bacteria
were	O
further	O
evaluated	O
regarding	O
their	O
safety	O
properties	O
and	O
functional	O
features	O
.	O

The	O
isolates	O
were	O
susceptible	O
to	O
vancomycin	O
,	O
gentamycin	O
,	O
and	O
chloramphenicol	O
.	O

The	O
results	O
of	O
PCR	O
amplification	O
revealed	O
that	O
all	O
the	O
tested	O
isolates	O
harbored	O
none	O
of	O
the	O
tested	O
virulence	O
genes	O
except	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
(	O
ES9	O
)	O
,	O
which	O
showed	O
the	O
presence	O
of	O
esp	O
gene	O
.	O

The	O
Enterococcus	B-bacteria
isolates	I-bacteria
showed	O
cholesterol	O
lowering	O
properties	O
.	O

The	O
selected	O
isolates	O
showed	O
a	O
high	O
tolerance	O
to	O
low	O
pH	O
,	O
and	O
toward	O
bile	O
salts	O
.	O

They	O
also	O
demonstrated	O
hydrophobicity	O
activity	O
,	O
auto	O
-	O
aggregation	O
,	O
and	O
adhesion	O
ability	O
to	O
the	O
human	O
intestinal	O
Caco	O
-	O
2	O
cell	O
line	O
.	O

These	O
properties	O
may	O
contribute	O
the	O
bacteria	O
colonizing	O
the	O
gut	O
.	O

This	O
study	O
revealed	O
that	O
the	O
Enterococcus	B-bacteria
isolates	I-bacteria
,	O
especially	O
E	B-bacteria
.	I-bacteria
durans	I-bacteria
ES11	I-bacteria
,	O
ES20	B-bacteria
and	O
ES32	B-bacteria
,	O
might	O
be	O
excellent	O
candidates	O
for	O
production	O
of	O
functional	O
foods	O
to	O
promote	O
health	O
benefits	O
.	O

Reaction	O
of	O
antibodies	O
to	O
Campylobacter	B-bacteria
jejuni	I-bacteria
and	O
cytolethal	O
distending	O
toxin	O
B	O
with	O
tissues	O
and	O
food	O
antigens	O
.	O

BACKGROUND	O
:	O
The	O
bacteria	O
Campylobacter	B-bacteria
jejuni	I-bacteria
(	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
)	O
is	O
commonly	O
associated	O
with	O
Guillane	O
-	O
Barre	O
syndrome	O
(	O
GBS	O
)	O
and	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
,	O
but	O
studies	O
have	O
also	O
linked	O
it	O
with	O
Miller	O
Fisher	O
syndrome	O
,	O
reactive	O
arthritis	O
and	O
other	O
disorders	O
,	O
some	O
of	O
which	O
are	O
autoimmune	O
.	O

It	O
is	O
possible	O
that	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
and	O
its	O
toxins	O
may	O
be	O
cross	O
-	O
reactive	O
with	O
some	O
human	O
tissues	O
and	O
food	O
antigens	O
,	O
potentially	O
leading	O
to	O
autoimmune	O
responses	O
.	O

AIM	O
:	O
To	O
measure	O
the	O
immune	O
reactivity	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
and	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
cytolethal	O
distending	O
toxin	O
(	O
Cdt	O
)	O
antibodies	O
with	O
tissue	O
and	O
food	O
antigens	O
to	O
examine	O
their	O
role	O
in	O
autoimmunities	O
.	O

METHODS	O
:	O
Using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
methodology	O
,	O
specific	O
antibodies	O
made	O
against	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
and	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
Cdt	O
were	O
applied	O
to	O
a	O
variety	O
of	O
microwell	O
plates	O
coated	O
with	O
45	O
tissues	O
and	O
180	O
food	O
antigens	O
.	O

The	O
resulting	O
immunoreactivities	O
were	O
compared	O
to	O
reactions	O
with	O
control	O
wells	O
coated	O
with	O
human	O
serum	O
albumin	O
(	O
HSA	O
)	O
which	O
were	O
used	O
as	O
negative	O
controls	O
and	O
with	O
wells	O
coated	O
with	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
lysate	O
or	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
Cdt	O
which	O
served	O
as	O
positive	O
controls	O
.	O

RESULTS	O
:	O
At	O
3	O
SD	O
above	O
the	O
mean	O
of	O
control	O
wells	O
coated	O
with	O
HSA	O
or	O
0	O
.	O
41	O
OD	O
,	O
the	O
mouse	O
monoclonal	O
antibody	O
made	O
against	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
showed	O
moderate	O
to	O
high	O
reactions	O
with	O
zonulin	O
,	O
somatotropin	O
,	O
acetylcholine	O
receptor	O
,	O
beta	O
-	O
amyloid	O
and	O
presenilin	O
.	O

This	O
immune	O
reaction	O
was	O
low	O
with	O
an	O
additional	O
25	O
tissue	O
antigens	O
including	O
asialoganglioside	O
,	O
and	O
the	O
same	O
antibody	O
did	O
not	O
react	O
at	O
all	O
with	O
another	O
15	O
tissue	O
antigens	O
.	O

Examining	O
the	O
reaction	O
between	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
antibody	O
and	O
180	O
food	O
antigens	O
,	O
we	O
found	O
insignificant	O
reactions	O
with	O
163	O
foods	O
but	O
low	O
to	O
high	O
immune	O
reactions	O
with	O
17	O
food	O
antigens	O
.	O

Similarly	O
,	O
we	O
examined	O
the	O
reaction	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
Cdt	O
with	O
the	O
same	O
tissues	O
and	O
food	O
antigens	O
.	O

The	O
strongest	O
reactions	O
were	O
observed	O
with	O
zonulin	O
,	O
intrinsic	O
factor	O
and	O
somatotropin	O
.	O

The	O
reaction	O
was	O
moderate	O
with	O
9	O
different	O
tissue	O
antigens	O
including	O
thyroid	O
peroxidase	O
,	O
and	O
reaction	O
was	O
low	O
with	O
another	O
10	O
different	O
antigens	O
,	O
including	O
neuronal	O
antigens	O
.	O

The	O
reaction	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
Cdt	O
antibody	O
with	O
an	O
additional	O
23	O
tissue	O
antigens	O
was	O
insignificant	O
.	O

Regarding	O
the	O
reaction	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
Cdt	O
antibody	O
with	O
different	O
food	O
antigens	O
,	O
160	O
out	O
of	O
180	O
foods	O
showed	O
insignificant	O
reactions	O
,	O
while	O
20	O
foods	O
showed	O
reactions	O
ranging	O
from	O
low	O
to	O
high	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
indicate	O
that	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
and	O
its	O
Cdt	O
may	O
play	O
a	O
role	O
in	O
inflammation	O
and	O
autoimmunities	O
beyond	O
the	O
gut	O
.	O

A	O
More	O
Robust	O
Gut	O
Microbiota	O
in	O
Calorie	O
-	O
Restricted	O
Mice	O
Is	O
Associated	O
with	O
Attenuated	O
Intestinal	O
Injury	O
Caused	O
by	O
the	O
Chemotherapy	O
Drug	O
Cyclophosphamide	O
.	O

Cyclophosphamide	O
(	O
CTX	O
)	O
is	O
widely	O
used	O
in	O
cancer	O
chemotherapy	O
,	O
but	O
it	O
often	O
induces	O
mucositis	O
,	O
in	O
which	O
the	O
disruption	O
of	O
the	O
gut	O
microbiota	O
might	O
play	O
a	O
pivotal	O
role	O
.	O

Whether	O
the	O
manipulation	O
of	O
the	O
gut	O
microbiota	O
can	O
be	O
used	O
as	O
a	O
strategy	O
to	O
improve	O
CTX	O
-	O
induced	O
mucositis	O
remains	O
to	O
be	O
studied	O
.	O

Here	O
we	O
observed	O
the	O
effects	O
of	O
a	O
4	O
-	O
week	O
calorie	O
restriction	O
(	O
CR	O
)	O
on	O
CTX	O
-	O
induced	O
mucositis	O
.	O

Compared	O
with	O
ad	O
libitum	O
-	O
fed	O
mice	O
,	O
CR	O
mice	O
showed	O
significantly	O
less	O
mucositis	O
in	O
response	O
to	O
CTX	O
,	O
including	O
lower	O
intestinal	O
permeability	O
,	O
less	O
bacterial	O
translocation	O
,	O
higher	O
number	O
of	O
epithelial	O
stem	O
cells	O
,	O
and	O
less	O
epithelium	O
damage	O
.	O

CTX	O
induced	O
significant	O
shifts	O
of	O
the	O
gut	O
microbiota	O
of	O
the	O
gut	O
microbiota	O
in	O
ad	O
libitum	O
-	O
fed	O
control	O
mice	O
.	O

In	O
contrast	O
,	O
CR	O
mice	O
showed	O
no	O
significant	O
change	O
in	O
their	O
gut	O
microbiota	O
in	O
responding	O
to	O
CTX	O
treatment	O
.	O

CR	O
significantly	O
enriched	O
the	O
gut	O
microbiota	O
in	O
Lactobacillus	B-bacteria
and	O
Lachnospiraceae	B-bacteria
which	O
are	O
known	O
to	O
mitigate	O
inflammation	O
and	O
improve	O
gut	O
barrier	O
function	O
.	O

These	O
findings	O
suggest	O
that	O
CR	O
remodeled	O
gut	O
microbiota	O
is	O
more	O
robust	O
and	O
may	O
contribute	O
to	O
attenuate	O
the	O
side	O
effects	O
of	O
cyclophosphamide	O
,	O
which	O
supports	O
the	O
concept	O
that	O
cancer	O
chemotherapy	O
would	O
benefit	O
from	O
strategies	O
targeting	O
the	O
gut	O
microbiota	O
.	O
IMPORTANCE	O
Improving	O
the	O
gut	O
microbiota	O
via	O
calorie	O
restriction	O
is	O
beneficial	O
for	O
human	O
health	O
.	O

Our	O
findings	O
showed	O
differential	O
responses	O
between	O
calorie	O
-	O
restricted	O
mice	O
and	O
ad	O
libitum	O
-	O
fed	O
mice	O
.	O

Compared	O
with	O
the	O
ad	O
libitum	O
-	O
fed	O
mice	O
,	O
the	O
calorie	O
-	O
restricted	O
mice	O
were	O
less	O
susceptible	O
to	O
cyclophosphamide	O
side	O
effects	O
otherwise	O
observed	O
on	O
the	O
gut	O
integrity	O
and	O
its	O
microbiota	O
.	O

These	O
results	O
show	O
the	O
potential	O
benefits	O
of	O
manipulating	O
the	O
gut	O
microbiota	O
with	O
CR	O
prior	O
to	O
cancer	O
chemotherapy	O
.	O

Genome	O
-	O
Wide	O
Screening	O
for	O
Enteric	O
Colonization	O
Factors	O
in	O
Carbapenem	O
-	O
Resistant	O
ST258	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
.	O

A	O
diverse	O
,	O
antibiotic	O
-	O
naive	O
microbiota	O
prevents	O
highly	O
antibiotic	O
-	O
resistant	O
microbes	O
,	O
including	O
carbapenem	B-bacteria
-	I-bacteria
resistant	I-bacteria
Klebsiella	I-bacteria
pneumoniae	I-bacteria
(	O
CR	B-bacteria
-	I-bacteria
Kp	I-bacteria
)	O
,	O
from	O
achieving	O
dense	O
colonization	O
of	O
the	O
intestinal	O
lumen	O
.	O

Antibiotic	O
-	O
mediated	O
destruction	O
of	O
the	O
microbiota	O
leads	O
to	O
expansion	O
of	O
CR	B-bacteria
-	I-bacteria
Kp	I-bacteria
in	O
the	O
gut	O
,	O
markedly	O
increasing	O
the	O
risk	O
of	O
bacteremia	O
in	O
vulnerable	O
patients	O
.	O

While	O
preventing	O
dense	O
colonization	O
represents	O
a	O
rational	O
approach	O
to	O
reduce	O
intra	O
-	O
and	O
interpatient	O
dissemination	O
of	O
CR	B-bacteria
-	I-bacteria
Kp	I-bacteria
,	O
little	O
is	O
known	O
about	O
pathogen	O
-	O
associated	O
factors	O
that	O
enable	O
dense	O
growth	O
and	O
persistence	O
in	O
the	O
intestinal	O
lumen	O
.	O

To	O
identify	O
genetic	O
factors	O
essential	O
for	O
dense	O
colonization	O
of	O
the	O
gut	O
by	O
CR	B-bacteria
-	I-bacteria
Kp	I-bacteria
,	O
we	O
constructed	O
a	O
highly	O
saturated	O
transposon	O
mutant	O
library	O
with	O
>	O
150	O
,	O
000	O
unique	O
mutations	O
in	O
an	O
ST258	B-bacteria
strain	I-bacteria
of	O
CR	B-bacteria
-	I-bacteria
Kp	I-bacteria
and	O
screened	O
for	O
in	O
vitro	O
growth	O
and	O
in	O
vivo	O
intestinal	O
colonization	O
in	O
antibiotic	O
-	O
treated	O
mice	O
.	O

Stochastic	O
and	O
partially	O
reversible	O
fluctuations	O
in	O
the	O
representation	O
of	O
different	O
mutations	O
during	O
dense	O
colonization	O
revealed	O
the	O
dynamic	O
nature	O
of	O
intestinal	O
microbial	O
populations	O
.	O

We	O
identified	O
genes	O
that	O
are	O
crucial	O
for	O
early	O
and	O
late	O
stages	O
of	O
dense	O
gut	O
colonization	O
and	O
confirmed	O
their	O
role	O
by	O
testing	O
isogenic	O
mutants	O
in	O
in	O
vivo	O
competition	O
assays	O
with	O
wild	O
-	O
type	O
CR	O
-	O
Kp	O
Screening	O
of	O
the	O
transposon	O
library	O
also	O
identified	O
mutations	O
that	O
enhanced	O
in	O
vivo	O
CR	O
-	O
Kp	O
growth	O
.	O

These	O
newly	O
identified	O
colonization	O
factors	O
may	O
provide	O
novel	O
therapeutic	O
opportunities	O
to	O
reduce	O
intestinal	O
colonization	O
by	O
CR	B-bacteria
-	I-bacteria
Kp	I-bacteria
IMPORTANCE	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
is	O
a	O
common	O
cause	O
of	O
bloodstream	O
infections	O
in	O
immunocompromised	O
and	O
hospitalized	O
patients	O
,	O
and	O
over	O
the	O
last	O
2	O
decades	O
,	O
some	O
strains	O
have	O
acquired	O
resistance	O
to	O
nearly	O
all	O
available	O
antibiotics	O
,	O
including	O
broad	O
-	O
spectrum	O
carbapenems	O
.	O

The	O
U	O
.	O
S	O
.	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
has	O
listed	O
carbapenem	B-bacteria
-	I-bacteria
resistant	I-bacteria
K	I-bacteria
.	I-bacteria
pneumoniae	I-bacteria
(	O
CR	B-bacteria
-	I-bacteria
Kp	I-bacteria
)	O
as	O
an	O
urgent	O
public	O
health	O
threat	O
.	O

Dense	O
colonization	O
of	O
the	O
intestine	O
by	O
CR	B-bacteria
-	I-bacteria
Kp	I-bacteria
and	O
other	O
antibiotic	O
-	O
resistant	O
bacteria	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
bacteremia	O
.	O

Reducing	O
the	O
density	O
of	O
gut	O
colonization	O
by	O
CR	B-bacteria
-	I-bacteria
Kp	I-bacteria
is	O
likely	O
to	O
reduce	O
their	O
transmission	O
from	O
patient	O
to	O
patient	O
in	O
health	O
care	O
facilities	O
as	O
well	O
as	O
systemic	O
infections	O
.	O

How	O
CR	B-bacteria
-	I-bacteria
Kp	I-bacteria
expands	O
and	O
persists	O
in	O
the	O
gut	O
lumen	O
,	O
however	O
,	O
is	O
poorly	O
understood	O
.	O

Herein	O
,	O
we	O
generated	O
a	O
highly	O
saturated	O
mutant	O
library	O
in	O
a	O
multidrug	B-bacteria
-	I-bacteria
resistant	I-bacteria
K	I-bacteria
.	I-bacteria
pneumoniae	I-bacteria
strain	I-bacteria
and	O
identified	O
genetic	O
factors	O
that	O
are	O
associated	O
with	O
dense	O
gut	O
colonization	O
by	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
This	O
study	O
sheds	O
light	O
on	O
host	O
colonization	O
by	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
and	O
identifies	O
potential	O
colonization	O
factors	O
that	O
contribute	O
to	O
high	O
-	O
density	O
persistence	O
of	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
in	O
the	O
intestine	O
.	O

Effect	O
of	O
Dietary	O
Carbohydrate	O
-	O
to	O
-	O
Protein	O
Ratio	O
on	O
Gut	O
Microbiota	O
in	O
Atlantic	O
Salmon	O
(	O
Salmo	O
salar	O
)	O
.	O

Atlantic	O
salmon	O
(	O
Salmo	O
salar	O
)	O
is	O
a	O
carnivorous	O
fish	O
species	O
whose	O
productive	O
performance	O
tends	O
to	O
be	O
suboptimal	O
when	O
fed	O
low	O
-	O
cost	O
carbohydrate	O
rich	O
meals	O
.	O

It	O
is	O
of	O
interest	O
to	O
study	O
the	O
dynamics	O
of	O
gut	O
microbiota	O
communities	O
in	O
salmonids	O
fed	O
high	O
carbohydrate	O
diets	O
since	O
gut	O
microbes	O
are	O
referred	O
to	O
as	O
key	O
players	O
that	O
influence	O
the	O
metabolism	O
and	O
physiology	O
of	O
the	O
host	O
.	O

A	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
effect	O
of	O
feeding	O
a	O
high	O
carbohydrate	O
diet	O
to	O
Atlantic	O
salmon	O
in	O
gut	O
microbiota	O
communities	O
.	O

A	O
medium	O
carbohydrate	O
(	O
15	O
%	O
wheat	O
starch	O
)	O
/	O
medium	O
protein	O
(	O
MC	O
/	O
MP	O
)	O
diet	O
or	O
a	O
high	O
carbohydrate	O
(	O
30	O
%	O
wheat	O
starch	O
)	O
/	O
low	O
protein	O
(	O
HC	O
/	O
LP	O
)	O
diet	O
was	O
fed	O
to	O
triplicate	O
tanks	O
(	O
28	O
fish	O
each	O
)	O
during	O
four	O
weeks	O
.	O

We	O
conducted	O
an	O
in	O
-	O
depth	O
characterization	O
of	O
the	O
distal	O
intestine	O
digesta	O
microbiota	O
using	O
high	O
-	O
throughput	O
sequencing	O
of	O
the	O
V4	O
region	O
of	O
the	O
16S	O
rRNA	O
gene	O
.	O

Firmicutes	B-bacteria
,	O
Actinobacteria	B-bacteria
and	O
Proteobacteria	B-bacteria
were	O
the	O
major	O
phyla	O
determined	O
in	O
either	O
experimental	O
group	O
.	O

Phylum	B-bacteria
Planctomycetes	B-bacteria
,	O
class	O
Planctomycetia	B-bacteria
,	O
order	O
Planctomycetales	B-bacteria
and	O
genus	O
Lactococcus	B-bacteria
were	O
significantly	O
more	O
abundant	O
in	O
fish	O
fed	O
the	O
HC	O
/	O
LP	O
diet	O
compared	O
with	O
fish	O
fed	O
the	O
MC	O
/	O
MP	O
diet	O
.	O

Our	O
study	O
suggests	O
feeding	O
a	O
carbohydrate	O
rich	O
meal	O
to	O
salmon	O
exerts	O
a	O
low	O
impact	O
on	O
the	O
structure	O
of	O
gut	O
microbial	O
communities	O
,	O
affecting	O
mostly	O
low	O
-	O
abundance	O
bacteria	O
capable	O
of	O
metabolizing	O
anaerobically	O
carbohydrates	O
as	O
a	O
major	O
energy	O
-	O
yielding	O
substrate	O
.	O

Changes	O
in	O
Mouse	O
Gut	O
Microbial	O
Community	O
in	O
Response	O
to	O
the	O
Different	O
Types	O
of	O
Commonly	O
Consumed	O
Meat	O
.	O

The	O
consumption	O
of	O
various	O
meats	O
prevalent	O
throughout	O
the	O
world	O
affects	O
host	O
health	O
probably	O
by	O
associating	O
with	O
compositional	O
shifts	O
of	O
gut	O
microbiota	O
.	O

However	O
,	O
the	O
responses	O
of	O
gut	O
microbiota	O
to	O
different	O
types	O
of	O
meat	O
are	O
not	O
well	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
effects	O
of	O
cooked	O
fish	O
(	O
white	O
meat	O
)	O
,	O
and	O
pork	O
and	O
beef	O
(	O
red	O
meat	O
)	O
on	O
gut	O
microbiota	O
and	O
blood	O
lipid	O
metabolism	O
in	O
male	O
C57BL	O
/	O
6	O
mice	O
by	O
comparing	O
to	O
those	O
fed	O
laboratory	O
chow	O
.	O

Significant	O
differences	O
in	O
microbial	O
communities	O
were	O
observed	O
among	O
meat	O
-	O
and	O
chow	O
-	O
fed	O
mice	O
.	O

Compared	O
with	O
the	O
chow	O
group	O
,	O
the	O
red	O
and	O
white	O
meat	O
groups	O
obviously	O
increased	O
in	O
abundance	O
of	O
Clostridium	B-bacteria
,	O
and	O
decreased	O
in	O
Prevotella	B-bacteria
abundance	O
.	O

The	O
richness	O
and	O
diversity	O
of	O
gut	O
microbiota	O
were	O
markedly	O
decreased	O
in	O
the	O
two	O
red	O
meat	O
groups	O
,	O
with	O
lower	O
abundance	O
of	O
Oscillospira	B-bacteria
and	O
higher	O
abundance	O
of	O
Escherichia	B-bacteria
.	O

Meanwhile	O
,	O
there	O
were	O
significant	O
meat	O
-	O
related	O
differences	O
in	O
blood	O
lipid	O
metabolites	O
,	O
with	O
lower	O
levels	O
of	O
high	O
-	O
density	O
lipoprotein	O
,	O
low	O
-	O
density	O
lipoprotein	O
,	O
cholesterol	O
,	O
and	O
in	O
mice	O
fed	O
white	O
,	O
compared	O
with	O
red	O
,	O
meat	O
.	O

Lipopolysaccharide	O
-	O
binding	O
protein	O
was	O
significantly	O
lower	O
in	O
fish	O
-	O
fed	O
mice	O
.	O

Our	O
results	O
indicate	O
that	O
different	O
types	O
of	O
meat	O
potentially	O
influence	O
gut	O
microbial	O
compositions	O
and	O
blood	O
metabolic	O
profiles	O
,	O
suggesting	O
a	O
need	O
to	O
focus	O
on	O
clinically	O
relevant	O
bacteria	O
in	O
gut	O
microbiota	O
associated	O
with	O
increasing	O
meat	O
consumption	O
.	O

Indole	O
-	O
3	O
-	O
Propionic	O
Acid	O
,	O
a	O
Tryptophan	O
-	O
Derived	O
Bacterial	O
Metabolite	O
,	O
Reduces	O
Weight	O
Gain	O
in	O
Rats	O
.	O

Recent	O
evidence	O
suggests	O
that	O
tryptophan	O
,	O
an	O
essential	O
amino	O
acid	O
,	O
may	O
exert	O
biological	O
effects	O
by	O
means	O
of	O
tryptophan	O
-	O
derived	O
gut	O
bacteria	O
products	O
.	O

We	O
evaluated	O
the	O
potential	O
contribution	O
of	O
tryptophan	O
-	O
derived	O
bacterial	O
metabolites	O
to	O
body	O
weight	O
gain	O
.	O

The	O
study	O
comprised	O
three	O
experimental	O
series	O
performed	O
on	O
separate	O
groups	O
of	O
male	O
,	O
Sprague	O
-	O
Dawley	O
rats	O
:	O
(	O
i	O
)	O
rats	O
on	O
standard	O
laboratory	O
diet	O
treated	O
with	O
water	O
solution	O
of	O
neomycin	O
,	O
an	O
antibiotic	O
,	O
or	O
tap	O
water	O
(	O
controls	O
-	O
1	O
)	O
;	O
(	O
ii	O
)	O
rats	O
on	O
standard	O
diet	O
(	O
controls	O
-	O
2	O
)	O
or	O
tryptophan	O
-	O
high	O
(	O
TH	O
)	O
or	O
tryptophan	O
-	O
free	O
(	O
TF	O
)	O
diet	O
;	O
and	O
(	O
iii	O
)	O
rats	O
treated	O
with	O
indole	O
-	O
3	O
-	O
propionic	O
acid	O
(	O
I3P	O
)	O
,	O
a	O
bacterial	O
metabolite	O
of	O
tryptophan	O
,	O
or	O
a	O
vehicle	O
(	O
controls	O
-	O
3	O
)	O
.	O

(	O
i	O
)	O
Rats	O
treated	O
with	O
neomycin	O
showed	O
a	O
significantly	O
higher	O
weight	O
gain	O
but	O
lower	O
stool	O
and	O
blood	O
concentration	O
of	O
I3P	O
than	O
controls	O
-	O
1	O
.	O

(	O
ii	O
)	O
The	O
TH	O
group	O
showed	O
significantly	O
smaller	O
increases	O
in	O
body	O
weight	O
but	O
higher	O
stool	O
and	O
plasma	O
concentration	O
of	O
I3P	O
than	O
controls	O
-	O
2	O
.	O

In	O
contrast	O
,	O
the	O
TF	O
group	O
showed	O
a	O
decrease	O
in	O
body	O
weight	O
,	O
decreased	O
total	O
serum	O
protein	O
and	O
a	O
significant	O
increase	O
in	O
urine	O
output	O
.	O

(	O
iii	O
)	O
Rats	O
treated	O
with	O
I3P	O
showed	O
significantly	O
smaller	O
weight	O
gain	O
than	O
controls	O
-	O
3	O
.	O

Our	O
study	O
suggests	O
that	O
I3P	O
,	O
a	O
gut	O
bacteria	O
metabolite	O
of	O
tryptophan	O
,	O
contributes	O
to	O
changes	O
in	O
body	O
weight	O
gain	O
produced	O
by	O
antibiotics	O
and	O
tryptophan	O
-	O
rich	O
diet	O
.	O

From	O
isoniazid	O
to	O
psychobiotics	O
:	O
the	O
gut	O
microbiome	O
as	O
a	O
new	O
antidepressant	O
target	O
.	O

An	O
awareness	O
of	O
the	O
importance	O
of	O
the	O
gut	O
-	O
brain	O
axis	O
in	O
psychiatric	O
disorders	O
such	O
as	O
depression	O
is	O
increasing	O
.	O

The	O
gut	O
microbiome	O
is	O
a	O
key	O
component	O
of	O
this	O
axis	O
.	O

Gut	O
bacteria	O
can	O
communicate	O
with	O
the	O
brain	O
through	O
a	O
variety	O
of	O
pathways	O
including	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
,	O
immune	O
modulation	O
,	O
tryptophan	O
metabolism	O
and	O
the	O
production	O
of	O
various	O
neuroactive	O
compounds	O
.	O

Patients	O
with	O
depression	O
,	O
and	O
other	O
mood	O
and	O
anxiety	O
disorders	O
,	O
show	O
distinct	O
compositional	O
changes	O
in	O
their	O
gut	O
bacteria	O
profile	O
,	O
raising	O
the	O
question	O
about	O
a	O
possible	O
aetiological	O
role	O
for	O
the	O
microbiome	O
in	O
these	O
disorders	O
.	O

Evidence	O
is	O
emerging	O
that	O
the	O
gut	O
microbiome	O
may	O
represent	O
a	O
new	O
potential	O
antidepressant	O
target	O
and	O
the	O
term	O
'	O
psychobiotic	O
'	O
has	O
been	O
coined	O
to	O
describe	O
bacteria	O
which	O
confer	O
mental	O
health	O
benefits	O
.	O

Gut	O
bacteria	O
are	O
easily	O
accessible	O
and	O
can	O
be	O
altered	O
in	O
a	O
variety	O
of	O
ways	O
including	O
through	O
the	O
use	O
of	O
probiotics	O
,	O
prebiotics	O
and	O
dietary	O
change	O
.	O

Psychobiotics	O
containing	O
various	O
Lactobacillus	B-bacteria
and	O
Bifidobacterium	B-bacteria
species	I-bacteria
have	O
demonstrated	O
the	O
ability	O
to	O
improve	O
mood	O
,	O
reduce	O
anxiety	O
and	O
enhance	O
cognitive	O
function	O
in	O
both	O
healthy	O
populations	O
and	O
patient	O
groups	O
.	O

This	O
article	O
provides	O
an	O
overview	O
of	O
the	O
identification	O
and	O
development	O
of	O
antidepressant	O
psychobiotics	O
,	O
from	O
the	O
preclinical	O
evidence	O
in	O
the	O
laboratory	O
to	O
the	O
more	O
recent	O
encouraging	O
results	O
from	O
human	O
trials	O
.	O

Six	O
-	O
Week	O
High	O
-	O
Fat	O
Diet	O
Alters	O
the	O
Gut	O
Microbiome	O
and	O
Promotes	O
Cecal	O
Inflammation	O
,	O
Endotoxin	O
Production	O
,	O
and	O
Simple	O
Steatosis	O
without	O
Obesity	O
in	O
Male	O
Rats	O
.	O

Energy	O
-	O
dense	O
foods	O
can	O
alter	O
gut	O
microbial	O
diversity	O
.	O

However	O
,	O
the	O
physiological	O
effects	O
of	O
diet	O
-	O
induced	O
microbial	O
changes	O
on	O
the	O
development	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
remain	O
debatable	O
.	O

We	O
hypothesized	O
that	O
high	O
-	O
fat	O
intake	O
for	O
6	O
weeks	O
would	O
promote	O
intestinal	O
dysbiosis	O
by	O
increasing	O
gram	O
-	O
positive	O
bacteria	O
,	O
inducing	O
the	O
intestinal	O
production	O
of	O
proinflammatory	O
cytokines	O
and	O
subsequent	O
hepatic	O
lipid	O
infiltration	O
in	O
young	O
male	O
rats	O
.	O

Six	O
-	O
week	O
old	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
divided	O
into	O
two	O
groups	O
and	O
fed	O
either	O
a	O
standard	O
rodent	O
chow	O
or	O
a	O
60	O
%	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
for	O
6	O
weeks	O
.	O

Chromogenic	O
endotoxin	O
quantification	O
assays	O
indicate	O
an	O
increase	O
in	O
lipopolysaccharide	O
concentration	O
in	O
the	O
plasma	O
of	O
HFD	O
rats	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
.	O

Additionally	O
,	O
Western	O
blot	O
analyses	O
of	O
the	O
cecum	O
showed	O
significantly	O
greater	O
protein	O
expression	O
of	O
the	O
transcription	O
factor	O
,	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kB	O
)	O
,	O
(	O
p	O
=	O
0	O
.	O
037	O
)	O
and	O
the	O
proinflammatory	O
cytokine	O
,	O
interleukin	O
-	O
1beta	O
(	O
IL	O
-	O
1beta	O
)	O
,	O
(	O
p	O
=	O
0	O
.	O
042	O
)	O
in	O
rats	O
fed	O
HFD	O
.	O

Linear	O
discriminate	O
analysis	O
of	O
effect	O
size	O
(	O
LEfSe	O
)	O
showed	O
greater	O
abundance	O
of	O
Firmicutes	B-bacteria
and	O
Actinobacteria	B-bacteria
in	O
the	O
samples	O
collected	O
from	O
the	O
cecum	O
of	O
HFD	O
rats	O
compared	O
to	O
chow	O
.	O

Consistent	O
with	O
the	O
development	O
of	O
steatosis	O
,	O
the	O
Oil	O
-	O
Red	O
-	O
O	O
-	O
stained	O
area	O
was	O
increased	O
in	O
liver	O
sections	O
from	O
HFD	O
rats	O
.	O

Hepatic	O
triacylglycerol	O
concentrations	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
plasma	O
alanine	O
aminotransferase	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
were	O
significantly	O
increased	O
in	O
HFD	O
-	O
fed	O
animals	O
compared	O
to	O
chow	O
.	O

These	O
findings	O
show	O
that	O
a	O
short	O
duration	O
of	O
high	O
-	O
fat	O
consumption	O
can	O
have	O
profound	O
deleterious	O
effects	O
on	O
gastrointestinal	O
health	O
and	O
the	O
inflammatory	O
state	O
of	O
these	O
young	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

Beneficial	O
effects	O
of	O
ginger	O
on	O
prevention	O
of	O
obesity	O
through	O
modulation	O
of	O
gut	O
microbiota	O
in	O
mice	O
.	O

PURPOSE	O
:	O
Recent	O
evidence	O
has	O
demonstrated	O
that	O
the	O
gut	O
microbiota	O
plays	O
a	O
critical	O
role	O
in	O
the	O
treatment	O
of	O
obesity	O
and	O
other	O
metabolic	O
dysfunctions	O
.	O

Ginger	O
(	O
Zingiber	O
officinale	O
Roscoe	O
)	O
,	O
one	O
of	O
the	O
most	O
commonly	O
used	O
spices	O
and	O
dietary	O
supplements	O
,	O
has	O
been	O
shown	O
to	O
exert	O
beneficial	O
effects	O
against	O
obesity	O
and	O
related	O
disorders	O
.	O

However	O
,	O
to	O
date	O
,	O
the	O
mechanisms	O
linking	O
these	O
effects	O
to	O
the	O
gut	O
microbiota	O
remain	O
unclear	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
relationship	O
between	O
the	O
gut	O
microbiota	O
and	O
the	O
metabolic	O
adaptations	O
resulting	O
from	O
ginger	O
supplementation	O
in	O
mice	O
.	O

METHODS	O
:	O
Four	O
groups	O
of	O
mice	O
were	O
fed	O
a	O
normal	O
chow	O
diet	O
(	O
NCD	O
)	O
or	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
with	O
or	O
without	O
ginger	O
supplementation	O
for	O
16	O
weeks	O
.	O

Lipid	O
profiles	O
,	O
proinflammatory	O
cytokines	O
,	O
glucose	O
tolerance	O
,	O
microbiota	O
composition	O
and	O
short	O
-	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
concentrations	O
were	O
analyzed	O
at	O
the	O
end	O
of	O
the	O
experiment	O
.	O

In	O
addition	O
,	O
microbiota	O
-	O
depleted	O
mice	O
were	O
transplanted	O
with	O
the	O
fecal	O
microbiota	O
of	O
mice	O
fed	O
a	O
HFD	O
or	O
mice	O
fed	O
a	O
HFD	O
along	O
with	O
ginger	O
supplementation	O
.	O

Glucose	O
tolerance	O
and	O
microbiota	O
composition	O
were	O
assessed	O
after	O
a	O
8	O
-	O
week	O
fecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
.	O

RESULTS	O
:	O
We	O
observed	O
marked	O
decreases	O
in	O
body	O
weight	O
,	O
liver	O
steatosis	O
,	O
and	O
low	O
-	O
grade	O
inflammation	O
as	O
well	O
as	O
amelioration	O
of	O
insulin	O
resistance	O
in	O
the	O
HFD	O
-	O
fed	O
mice	O
treated	O
with	O
ginger	O
.	O

Furthermore	O
,	O
ginger	O
supplementation	O
modulated	O
the	O
gut	O
microbiota	O
composition	O
and	O
increased	O
species	O
belonging	O
to	O
the	O
Bifidobacterium	B-bacteria
genus	I-bacteria
and	O
SCFA	O
-	O
producing	O
bacteria	O
(	O
Alloprevotella	B-bacteria
and	O
Allobaculum	B-bacteria
)	O
,	O
along	O
with	O
increases	O
in	O
fecal	O
SCFA	O
concentrations	O
.	O

The	O
FMT	O
experiment	O
showed	O
anti	O
-	O
obesity	O
and	O
microbiota	O
-	O
modulating	O
effects	O
similar	O
to	O
those	O
observed	O
in	O
the	O
oral	O
ginger	O
-	O
feeding	O
experiment	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
suggests	O
that	O
modulation	O
of	O
the	O
gut	O
microbiota	O
as	O
a	O
result	O
of	O
ginger	O
supplementation	O
has	O
a	O
therapeutic	O
effect	O
on	O
obesity	O
in	O
mice	O
.	O

Shaping	O
the	O
Infant	O
Microbiome	O
With	O
Non	O
-	O
digestible	O
Carbohydrates	O
.	O

Natural	O
polysaccharides	O
with	O
health	O
benefits	O
are	O
characterized	O
by	O
a	O
large	O
structural	O
diversity	O
and	O
differ	O
in	O
building	O
blocks	O
,	O
linkages	O
,	O
and	O
lengths	O
.	O

They	O
contribute	O
to	O
human	O
health	O
by	O
functioning	O
as	O
anti	O
-	O
adhesives	O
preventing	O
pathogen	O
adhesion	O
,	O
stimulate	O
immune	O
maturation	O
and	O
gut	O
barrier	O
function	O
,	O
and	O
serve	O
as	O
fermentable	O
substrates	O
for	O
gut	O
bacteria	O
.	O

Examples	O
of	O
such	O
beneficial	O
carbohydrates	O
include	O
the	O
human	O
milk	O
oligosaccharides	O
(	O
HMOs	O
)	O
.	O

Also	O
,	O
specific	O
non	O
-	O
digestible	O
carbohydrates	O
(	O
NDCs	O
)	O
,	O
such	O
as	O
galacto	O
-	O
oligosaccharides	O
(	O
GOS	O
)	O
and	O
fructo	O
-	O
oligosaccharides	O
(	O
FOS	O
)	O
are	O
being	O
produced	O
with	O
this	O
purpose	O
in	O
mind	O
,	O
and	O
are	O
currently	O
added	O
to	O
infant	O
formula	O
to	O
stimulate	O
the	O
healthy	O
development	O
of	O
the	O
newborn	O
.	O

They	O
mimic	O
some	O
functions	O
of	O
HMO	O
,	O
but	O
not	O
all	O
.	O

Therefore	O
,	O
many	O
research	O
efforts	O
focus	O
on	O
identification	O
and	O
production	O
of	O
novel	O
types	O
of	O
NDCs	O
.	O

In	O
this	O
review	O
,	O
we	O
give	O
an	O
overview	O
of	O
the	O
few	O
NDCs	O
currently	O
available	O
[	O
GOS	O
,	O
FOS	O
,	O
polydextrose	O
(	O
PDX	O
)	O
]	O
,	O
and	O
outline	O
the	O
potential	O
of	O
alternative	O
oligosaccharides	O
,	O
such	O
as	O
pectins	O
,	O
(	O
arabino	O
)	O
xylo	O
-	O
oligosaccharides	O
,	O
and	O
microbial	O
exopolysaccharides	O
(	O
EPS	O
)	O
.	O

Moreover	O
,	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
techniques	O
to	O
generate	O
novel	O
types	O
of	O
dietary	O
glycans	O
,	O
including	O
sialylated	O
GOS	O
(	O
Sia	O
-	O
GOS	O
)	O
and	O
galactosylated	O
chitin	O
,	O
are	O
presented	O
as	O
a	O
way	O
to	O
obtain	O
novel	O
prebiotic	O
NDCs	O
that	O
help	O
shaping	O
the	O
infant	O
microbiome	O
.	O

Dynamic	O
Change	O
of	O
Gut	O
Microbiota	O
During	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Infection	O
in	O
Suckling	O
Piglets	O
.	O

Porcine	O
epidemic	O
diarrhea	O
(	O
PED	O
)	O
is	O
a	O
disease	O
that	O
has	O
a	O
devastating	O
effect	O
on	O
livestock	O
.	O

Currently	O
,	O
most	O
studies	O
are	O
focused	O
on	O
comparing	O
gut	O
microbiota	O
of	O
healthy	O
piglets	O
and	O
piglets	O
with	O
PED	O
,	O
resulting	O
in	O
gut	O
microbial	O
populations	O
related	O
to	O
dynamic	O
change	O
in	O
diarrheal	O
piglets	O
being	O
poorly	O
understood	O
.	O

The	O
current	O
study	O
analyzed	O
the	O
characteristics	O
of	O
gut	O
microbiota	O
in	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
-	O
infected	O
piglets	O
during	O
the	O
suckling	O
transition	O
stage	O
.	O

Fresh	O
fecal	O
samples	O
were	O
collected	O
from	O
1	O
to	O
3	O
-	O
week	O
-	O
old	O
healthy	O
piglets	O
(	O
n	O
=	O
20	O
)	O
and	O
PEDV	O
infected	O
piglets	O
(	O
n	O
=	O
18	O
)	O
from	O
the	O
same	O
swine	O
farm	O
.	O

Total	O
DNA	O
was	O
extracted	O
from	O
each	O
sample	O
and	O
the	O
V3	O
-	O
V4	O
hypervariable	O
region	O
of	O
the	O
16S	O
rRNA	O
gene	O
was	O
amplified	O
and	O
sequenced	O
using	O
the	O
Illumina	O
MiSeq	O
platform	O
.	O

Statistically	O
significant	O
differences	O
were	O
observed	O
in	O
bacterial	O
diversity	O
and	O
richness	O
between	O
the	O
healthy	O
and	O
diarrheal	O
piglets	O
.	O

Principal	O
coordinates	O
analysis	O
(	O
PCoA	O
)	O
showed	O
structural	O
segregation	O
between	O
diseased	O
and	O
healthy	O
groups	O
,	O
as	O
well	O
as	O
among	O
3	O
different	O
age	O
groups	O
.	O

The	O
abundance	O
of	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
,	O
Enterococcus	B-bacteria
,	O
Fusobacterium	B-bacteria
,	O
and	O
Veillonella	B-bacteria
increased	O
due	O
to	O
dysbiosis	O
induced	O
by	O
PEDV	O
infection	O
.	O

Notably	O
,	O
there	O
was	O
a	O
remarkable	O
age	O
-	O
related	O
increase	O
in	O
Fusobacterium	B-bacteria
and	O
Veillonella	B-bacteria
in	O
diarrheal	O
piglets	O
.	O

Certain	O
SCFA	O
-	O
producing	O
bacteria	O
,	O
such	O
as	O
Ruminococcaceae	B-bacteria
_	I-bacteria
UCG	I-bacteria
-	I-bacteria
002	I-bacteria
,	O
Butyricimonas	B-bacteria
,	O
and	O
Alistipes	B-bacteria
,	O
were	O
shared	O
by	O
all	O
healthy	O
piglets	O
,	O
but	O
were	O
not	O
identified	O
in	O
various	O
age	O
groups	O
of	O
diarrheal	O
piglets	O
.	O

In	O
addition	O
,	O
significant	O
differences	O
were	O
observed	O
between	O
clusters	O
of	O
orthologous	O
groups	O
(	O
COG	O
)	O
functional	O
categories	O
of	O
healthy	O
and	O
PEDV	O
-	O
infected	O
piglets	O
.	O

Our	O
findings	O
demonstrated	O
that	O
PEDV	O
infection	O
caused	O
severe	O
perturbations	O
in	O
porcine	O
gut	O
microbiota	O
.	O

Therefore	O
,	O
regulating	O
gut	O
microbiota	O
in	O
an	O
age	O
-	O
related	O
manner	O
may	O
be	O
a	O
promising	O
method	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
PEDV	O
.	O

The	O
dynamics	O
of	O
the	O
antibiotic	O
resistome	O
in	O
the	O
feces	O
of	O
freshly	O
weaned	O
pigs	O
following	O
therapeutic	O
administration	O
of	O
oxytetracycline	O
.	O

In	O
this	O
study	O
,	O
shotgun	O
metagenomics	O
was	O
employed	O
to	O
monitor	O
the	O
effect	O
of	O
oxytetracycline	O
,	O
administered	O
at	O
a	O
therapeutic	O
dose	O
,	O
on	O
the	O
dynamics	O
of	O
the	O
microbiota	O
and	O
resistome	O
in	O
the	O
feces	O
of	O
weaned	O
pigs	O
.	O

Sixteen	O
weaning	O
pigs	O
were	O
assigned	O
to	O
one	O
of	O
two	O
treatments	O
including	O
standard	O
starter	O
diet	O
for	O
21	O
days	O
or	O
antibiotic	O
-	O
supplemented	O
diet	O
(	O
10	O
g	O
oxytetracycline	O
/	O
100	O
kg	O
body	O
weight	O
/	O
day	O
)	O
for	O
7	O
days	O
,	O
followed	O
by	O
14	O
days	O
of	O
standard	O
starter	O
diet	O
.	O

Feces	O
were	O
collected	O
from	O
the	O
pigs	O
on	O
days	O
0	O
,	O
8	O
,	O
and	O
21	O
for	O
microbiota	O
and	O
resistome	O
profiling	O
.	O

Pigs	O
receiving	O
oxytetracycline	O
exhibited	O
a	O
significantly	O
greater	O
richness	O
(	O
ANOVA	O
,	O
P	O
=	O
0	O
.	O
034	O
)	O
and	O
diversity	O
(	O
ANOVA	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
of	O
antibiotic	O
resistance	O
genes	O
(	O
ARGs	O
)	O
than	O
the	O
control	O
pigs	O
.	O

Antibiotic	O
administration	O
significantly	O
enriched	O
the	O
abundances	O
of	O
41	O
ARGs	O
,	O
mainly	O
from	O
the	O
tetracycline	O
,	O
betalactam	O
and	O
multidrug	O
resistance	O
classes	O
.	O

Compositional	O
shifts	O
in	O
the	O
bacterial	O
communities	O
were	O
observed	O
following	O
7	O
days	O
of	O
antibiotic	O
adminstration	O
,	O
with	O
the	O
medicated	O
pigs	O
showing	O
an	O
increase	O
in	O
Escherichia	B-bacteria
(	O
Proteobacteria	B-bacteria
)	O
and	O
Prevotella	B-bacteria
(	O
Bacteroidetes	B-bacteria
)	O
populations	O
compared	O
with	O
the	O
nonmedicated	O
pigs	O
.	O

This	O
might	O
be	O
explained	O
by	O
the	O
potential	O
of	O
these	O
taxa	O
to	O
carry	O
ARGs	O
that	O
may	O
be	O
transferred	O
to	O
other	O
susceptible	O
bacteria	O
in	O
the	O
densely	O
populated	O
gut	O
environment	O
.	O

These	O
findings	O
will	O
help	O
in	O
the	O
optimization	O
of	O
therapeutic	O
schemes	O
involving	O
antibiotic	O
usage	O
in	O
swine	O
production	O
.	O

Host	O
genotype	O
and	O
early	O
life	O
microbiota	O
alterations	O
have	O
additive	O
effects	O
on	O
disease	O
susceptibility	O
.	O

Why	O
do	O
people	O
develop	O
chronic	O
inflammatory	O
illnesses	O
,	O
such	O
as	O
inflammatory	O
bowel	O
disease	O
and	O
auto	O
-	O
immunity	O
,	O
when	O
they	O
are	O
adults	O
?	O

Is	O
the	O
trigger	O
a	O
recent	O
exposure	O
or	O
may	O
the	O
seeds	O
of	O
the	O
problem	O
have	O
formed	O
much	O
earlier	O
in	O
life	O
?	O

What	O
is	O
the	O
role	O
of	O
genetic	O
susceptibility	O
in	O
such	O
processes	O
?	O
In	O
this	O
issue	O
of	O
Mucosal	O
Immunology	O
,	O
Goethel	O
et	O
al	O
.	O

(	O
Mucosal	O
Immunol	O
.	O

1	O
,	O
2019	O
)	O
developed	O
an	O
experimental	O
system	O
in	O
mice	O
to	O
provide	O
at	O
least	O
partial	O
answers	O
to	O
these	O
important	O
questions	O
,	O
in	O
a	O
model	O
relevant	O
to	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

To	O
examine	O
the	O
role	O
of	O
host	O
genotype	O
,	O
they	O
compared	O
wild	O
type	O
C57BL	O
/	O
6	O
mice	O
with	O
their	O
congenic	O
NOD2	O
knockouts	O
,	O
focusing	O
on	O
an	O
important	O
innate	O
immunity	O
gene	O
related	O
to	O
detection	O
of	O
bacterial	O
derived	O
ligands	O
and	O
regulation	O
of	O
inflammatory	O
immune	O
responses	O
(	O
Gut	O
Microbes	O
4	O
:	O
222	O
-	O
231	O
,	O
2013	O
)	O
.	O

To	O
examine	O
the	O
role	O
of	O
the	O
microbiota	O
,	O
mice	O
were	O
exposed	O
,	O
or	O
not	O
,	O
to	O
amoxicillin	O
,	O
an	O
antibiotic	O
with	O
broad	O
-	O
spectrum	O
activity	O
against	O
the	O
normal	O
constituents	O
of	O
the	O
mammalian	O
intestinal	O
microbiome	O
.	O

Further	O
,	O
to	O
examine	O
developmental	O
phenomena	O
related	O
to	O
host	O
age	O
,	O
mice	O
were	O
exposed	O
either	O
during	O
early	O
life	O
or	O
as	O
adults	O
.	O

Effects	O
of	O
bowel	O
preparation	O
on	O
the	O
human	O
gut	O
microbiome	O
and	O
metabolome	O
.	O

Large	O
bowel	O
preparation	O
may	O
cause	O
a	O
substantial	O
change	O
in	O
the	O
gut	O
microbiota	O
and	O
metabolites	O
.	O

Here	O
,	O
we	O
included	O
a	O
bowel	O
prep	O
group	O
and	O
a	O
no	O
-	O
procedure	O
control	O
group	O
and	O
evaluated	O
the	O
effects	O
of	O
bowel	O
prep	O
on	O
the	O
stability	O
of	O
the	O
gut	O
microbiome	O
and	O
metabolome	O
as	O
well	O
as	O
on	O
recovery	O
.	O

Gut	O
microbiota	O
and	O
metabolome	O
compositions	O
were	O
analyzed	O
by	O
16S	O
rRNA	O
sequencing	O
and	O
capillary	O
electrophoresis	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
,	O
respectively	O
.	O

Analysis	O
of	O
coefficients	O
at	O
the	O
genus	O
and	O
species	O
level	O
and	O
weighted	O
UniFrac	O
distance	O
showed	O
that	O
,	O
compared	O
with	O
controls	O
,	O
microbiota	O
composition	O
was	O
significantly	O
reduced	O
immediately	O
after	O
the	O
prep	O
but	O
not	O
at	O
14	O
days	O
after	O
it	O
.	O

For	O
the	O
gut	O
metabolome	O
profiles	O
,	O
correlation	O
coefficients	O
between	O
before	O
and	O
immediately	O
after	O
the	O
prep	O
were	O
significantly	O
lower	O
than	O
those	O
between	O
before	O
and	O
14	O
days	O
after	O
prep	O
and	O
were	O
not	O
significantly	O
different	O
compared	O
with	O
those	O
for	O
between	O
-	O
subject	O
differences	O
.	O

Thirty	O
-	O
two	O
metabolites	O
were	O
significantly	O
changed	O
before	O
and	O
immediately	O
after	O
the	O
prep	O
,	O
but	O
these	O
metabolites	O
recovered	O
within	O
14	O
days	O
.	O

In	O
conclusion	O
,	O
bowel	O
preparation	O
has	O
a	O
profound	O
effect	O
on	O
the	O
gut	O
microbiome	O
and	O
metabolome	O
,	O
but	O
the	O
overall	O
composition	O
recovers	O
to	O
baseline	O
within	O
14	O
days	O
.	O

To	O
properly	O
conduct	O
studies	O
of	O
the	O
human	O
gut	O
microbiome	O
and	O
metabolome	O
,	O
fecal	O
sampling	O
should	O
be	O
avoided	O
immediately	O
after	O
bowel	O
prep	O
.	O

Correction	O
to	O
:	O
Genomic	O
and	O
metatranscriptomic	O
analyses	O
of	O
carbon	O
remineralization	O
in	O
an	O
Antarctic	O
polynya	O
.	O

Following	O
publication	O
of	O
the	O
original	O
article	O
[	O
1	O
]	O
,	O
the	O
authors	O
identified	O
wrong	O
citations	O
in	O
the	O
maintext	O
.	O

Antiproliferative	O
and	O
Cytotoxic	O
Activity	O
of	O
Xanthohumol	O
and	O
Its	O
Non	O
-	O
Estrogenic	O
Derivatives	O
in	O
Colon	O
and	O
Hepatocellular	O
Carcinoma	O
Cell	O
Lines	O
.	O

Xanthohumol	O
(	O
XN	O
)	O
,	O
a	O
prenylated	O
flavonoid	O
found	O
in	O
hops	O
,	O
inhibits	O
growth	O
in	O
a	O
variety	O
of	O
cancer	O
cell	O
lines	O
;	O
however	O
,	O
its	O
use	O
raises	O
concerns	O
as	O
gut	O
microbiota	O
and	O
the	O
host	O
'	O
s	O
hepatic	O
cytochrome	O
P450	O
enzymes	O
metabolize	O
it	O
into	O
the	O
most	O
potent	O
phytoestrogen	O
known	O
,	O
8	O
-	O
prenylnaringenin	O
(	O
8	O
-	O
PN	O
)	O
.	O

The	O
XN	O
derivatives	O
dihydroxanthohumol	O
(	O
DXN	O
)	O
and	O
tetrahydroxanthohumol	O
(	O
TXN	O
)	O
are	O
not	O
metabolized	O
into	O
8	O
-	O
PN	O
and	O
they	O
show	O
higher	O
tissue	O
concentrations	O
in	O
vivo	O
compared	O
with	O
XN	O
when	O
orally	O
administered	O
to	O
mice	O
at	O
the	O
same	O
dose	O
.	O

Here	O
we	O
show	O
that	O
DXN	O
and	O
TXN	O
possess	O
improved	O
anti	O
-	O
proliferative	O
activity	O
compared	O
with	O
XN	O
in	O
two	O
colon	O
(	O
HCT116	O
,	O
HT29	O
)	O
and	O
two	O
hepatocellular	O
(	O
HepG2	O
,	O
Huh7	O
)	O
carcinoma	O
cell	O
lines	O
,	O
as	O
indicated	O
by	O
their	O
respective	O
IC50	O
values	O
.	O

Furthermore	O
,	O
XN	O
,	O
DXN	O
,	O
and	O
TXN	O
induce	O
extensive	O
apoptosis	O
in	O
all	O
these	O
carcinoma	O
cell	O
lines	O
.	O

Finally	O
,	O
TXN	O
induces	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
cell	O
cycle	O
arrest	O
in	O
the	O
colon	O
carcinoma	O
cell	O
line	O
HT29	O
.	O

Our	O
findings	O
suggest	O
that	O
DXN	O
and	O
TXN	O
could	O
show	O
promise	O
as	O
therapeutic	O
agents	O
against	O
colorectal	O
and	O
liver	O
cancer	O
in	O
preclinical	O
studies	O
without	O
the	O
drawback	O
of	O
metabolism	O
into	O
a	O
phytoestrogen	O
.	O

Dietary	O
Polyphenols	O
Targeting	O
Arterial	O
Stiffness	O
:	O
Interplay	O
of	O
Contributing	O
Mechanisms	O
and	O
Gut	O
Microbiome	O
-	O
Related	O
Metabolism	O
.	O

Increased	O
arterial	O
stiffness	O
is	O
a	O
degenerative	O
vascular	O
process	O
,	O
progressing	O
with	O
age	O
that	O
leads	O
to	O
a	O
reduced	O
capability	O
of	O
arteries	O
to	O
expand	O
and	O
contract	O
in	O
response	O
to	O
pressure	O
changes	O
.	O

This	O
progressive	O
degeneration	O
mainly	O
affects	O
the	O
extracellular	O
matrix	O
of	O
elastic	O
arteries	O
and	O
causes	O
loss	O
of	O
vascular	O
elasticity	O
.	O

Recent	O
studies	O
point	O
to	O
significant	O
interference	O
of	O
dietary	O
polyphenols	O
with	O
mechanisms	O
involved	O
in	O
the	O
pathophysiology	O
and	O
progression	O
of	O
arterial	O
stiffness	O
.	O

This	O
review	O
summarizes	O
data	O
from	O
epidemiological	O
and	O
interventional	O
studies	O
on	O
the	O
effect	O
of	O
polyphenols	O
on	O
vascular	O
stiffness	O
as	O
an	O
illustration	O
of	O
current	O
research	O
and	O
addresses	O
possible	O
etiological	O
factors	O
targeted	O
by	O
polyphenols	O
,	O
including	O
pathways	O
of	O
vascular	O
functionality	O
,	O
oxidative	O
status	O
,	O
inflammation	O
,	O
glycation	O
,	O
and	O
autophagy	O
.	O

Effects	O
can	O
either	O
be	O
inflicted	O
directly	O
by	O
the	O
dietary	O
polyphenols	O
or	O
indirectly	O
by	O
metabolites	O
originated	O
from	O
the	O
host	O
or	O
microbial	O
metabolic	O
processes	O
.	O

The	O
composition	O
of	O
the	O
gut	O
microbiome	O
,	O
therefore	O
,	O
determines	O
the	O
resulting	O
metabolome	O
and	O
,	O
as	O
a	O
consequence	O
,	O
the	O
observed	O
activity	O
.	O

On	O
the	O
other	O
hand	O
,	O
polyphenols	O
also	O
influence	O
the	O
intestinal	O
microbial	O
composition	O
,	O
and	O
therefore	O
the	O
metabolites	O
available	O
for	O
interaction	O
with	O
relevant	O
targets	O
.	O

As	O
such	O
,	O
targeting	O
the	O
gut	O
microbiome	O
is	O
another	O
potential	O
treatment	O
option	O
for	O
arterial	O
stiffness	O
.	O

Antibiotic	O
resistant	O
bacteria	O
are	O
widespread	O
in	O
songbirds	O
across	O
rural	O
and	O
urban	O
environments	O
.	O

The	O
widespread	O
use	O
of	O
antibiotics	O
in	O
human	O
and	O
veterinary	O
medicine	O
to	O
treat	O
pathogenic	O
bacteria	O
has	O
resulted	O
in	O
the	O
rapid	O
emergence	O
of	O
antibiotic	O
-	O
resistant	O
bacteria	O
(	O
ARB	O
)	O
.	O

Wild	O
animals	O
may	O
enable	O
the	O
spread	O
of	O
pathogenic	O
and	O
non	O
-	O
pathogenic	O
ARB	O
when	O
they	O
are	O
exposed	O
to	O
reservoirs	O
(	O
e	O
.	O
g	O
.	O
,	O
contaminated	O
soil	O
,	O
water	O
,	O
or	O
crops	O
)	O
and	O
carry	O
ARB	O
in	O
and	O
on	O
their	O
bodies	O
to	O
other	O
environments	O
.	O

We	O
tested	O
for	O
the	O
presence	O
of	O
ARB	O
in	O
four	O
songbird	O
species	O
in	O
southwest	O
Michigan	O
across	O
a	O
gradient	O
of	O
land	O
use	O
.	O

Our	O
specific	O
objectives	O
were	O
to	O
:	O
1	O
)	O
quantify	O
the	O
prevalence	O
of	O
ARB	O
found	O
in	O
the	O
gut	O
microbiome	O
of	O
birds	O
;	O
2	O
)	O
identify	O
the	O
specific	O
bacteria	O
exhibiting	O
resistance	O
;	O
3	O
)	O
assess	O
whether	O
ARB	O
prevalence	O
and	O
identity	O
varied	O
among	O
bird	O
species	O
;	O
and	O
4	O
)	O
assess	O
whether	O
anthropogenic	O
land	O
use	O
influenced	O
the	O
prevalence	O
and	O
identity	O
of	O
ARB	O
found	O
on	O
birds	O
.	O

We	O
sampled	O
birds	O
across	O
a	O
land	O
use	O
gradient	O
consisting	O
of	O
urban	O
,	O
agricultural	O
,	O
and	O
natural	O
land	O
covers	O
using	O
a	O
randomized	O
,	O
spatially	O
-	O
balanced	O
sampling	O
design	O
and	O
cultured	O
bacteria	O
from	O
fecal	O
samples	O
in	O
the	O
presence	O
of	O
three	O
different	O
antibiotics	O
(	O
amoxicillin	O
,	O
tetracycline	O
,	O
and	O
ciprofloxacin	O
)	O
.	O

Overall	O
prevalence	O
of	O
ARB	O
was	O
high	O
,	O
with	O
88	O
%	O
of	O
total	O
birds	O
carrying	O
ARB	O
resistant	O
to	O
one	O
of	O
three	O
antibiotics	O
that	O
we	O
tested	O
.	O

Resistance	O
to	O
amoxicillin	O
was	O
more	O
common	O
(	O
83	O
%	O
of	O
sampled	O
birds	O
)	O
than	O
resistance	O
to	O
tetracycline	O
(	O
15	O
%	O
)	O
or	O
ciprofloxacin	O
(	O
1	O
%	O
)	O
.	O

Identified	O
ARB	O
were	O
diverse	O
,	O
and	O
included	O
135	O
isolates	O
representing	O
5	O
bacterial	O
phyla	O
and	O
22	O
genera	O
.	O

There	O
was	O
no	O
effect	O
of	O
land	O
use	O
on	O
ARB	O
prevalence	O
,	O
with	O
90	O
%	O
of	O
sampled	O
birds	O
captured	O
in	O
rural	O
sites	O
and	O
85	O
%	O
of	O
sampled	O
birds	O
in	O
urban	O
sites	O
carrying	O
ARB	O
.	O

We	O
provide	O
the	O
first	O
analysis	O
of	O
ARB	O
prevalence	O
across	O
multiple	O
bird	O
species	O
and	O
land	O
uses	O
utilizing	O
a	O
spatially	O
-	O
balanced	O
,	O
randomized	O
study	O
design	O
.	O

Our	O
results	O
demonstrate	O
that	O
nearly	O
all	O
sampled	O
birds	O
carried	O
at	O
least	O
some	O
ARB	O
,	O
and	O
that	O
they	O
may	O
serve	O
as	O
important	O
dispersal	O
agents	O
of	O
ARB	O
across	O
large	O
spatial	O
scales	O
.	O

Lipopolysaccharide	O
from	O
Gut	O
Microbiota	O
Modulates	O
alpha	O
-	O
Synuclein	O
Aggregation	O
and	O
Alters	O
Its	O
Biological	O
Function	O
.	O

Altered	O
intestinal	O
permeability	O
has	O
been	O
correlated	O
with	O
Parkinson	O
'	O
s	O
pathophysiology	O
in	O
the	O
enteric	O
nervous	O
system	O
,	O
before	O
manifestations	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

The	O
inflammatory	O
endotoxin	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
released	O
by	O
gut	O
bacteria	O
is	O
known	O
to	O
modulate	O
alpha	O
-	O
synuclein	O
amyloidogenesis	O
through	O
the	O
formation	O
of	O
intermediate	O
nucleating	O
species	O
.	O

Here	O
,	O
biophysical	O
techniques	O
in	O
conjunction	O
with	O
microscopic	O
images	O
revealed	O
the	O
molecular	O
interaction	O
between	O
lipopolysaccharide	O
and	O
alpha	O
-	O
synuclein	O
that	O
induce	O
rapid	O
nucleation	O
events	O
.	O

This	O
heteromolecular	O
interaction	O
stabilizes	O
the	O
alpha	O
-	O
helical	O
intermediates	O
in	O
the	O
alpha	O
-	O
synuclein	O
aggregation	O
pathway	O
.	O

Multitude	O
NMR	O
studies	O
probed	O
the	O
residues	O
involved	O
in	O
the	O
LPS	O
-	O
binding	O
structural	O
motif	O
that	O
modulates	O
the	O
nucleating	O
forms	O
,	O
affecting	O
the	O
cellular	O
internalization	O
and	O
associated	O
cytotoxicity	O
.	O

Collectively	O
,	O
our	O
data	O
characterizes	O
this	O
heteromolecular	O
interaction	O
associated	O
with	O
an	O
alternative	O
pathway	O
in	O
Parkinson	O
'	O
s	O
disease	O
progression	O
.	O

CCL28	O
Is	O
Involved	O
in	O
Mucosal	O
IgA	O
Responses	O
,	O
Olfaction	O
,	O
and	O
Resistance	O
to	O
Enteric	O
Infections	O
.	O

CCL28	O
is	O
a	O
mucosal	O
chemokine	O
that	O
has	O
been	O
involved	O
in	O
various	O
responses	O
,	O
including	O
IgA	O
production	O
.	O

We	O
have	O
analyzed	O
its	O
production	O
in	O
human	O
tissues	O
using	O
a	O
comprehensive	O
microarray	O
database	O
.	O

Its	O
highest	O
expression	O
is	O
in	O
the	O
salivary	O
gland	O
,	O
indicating	O
that	O
it	O
is	O
an	O
important	O
component	O
of	O
saliva	O
.	O

It	O
is	O
also	O
expressed	O
in	O
the	O
trachea	O
,	O
bronchus	O
,	O
and	O
in	O
the	O
mammary	O
gland	O
upon	O
onset	O
of	O
lactation	O
.	O

We	O
have	O
also	O
characterized	O
a	O
Ccl28	O
(	O
-	O
/	O
-	O
)	O
mouse	O
that	O
exhibits	O
very	O
low	O
IgA	O
levels	O
in	O
milk	O
,	O
and	O
the	O
IgA	O
levels	O
in	O
feces	O
are	O
also	O
reduced	O
.	O

These	O
observations	O
confirm	O
a	O
role	O
for	O
the	O
CCL28	O
/	O
CCR10	O
chemokine	O
axis	O
in	O
the	O
recruitment	O
of	O
IgA	O
plasmablasts	O
to	O
the	O
lactating	O
mammary	O
gland	O
.	O

CCL28	O
is	O
also	O
expressed	O
in	O
the	O
vomeronasal	O
organ	O
.	O

We	O
also	O
detected	O
olfactory	O
defects	O
(	O
anosmia	O
)	O
in	O
a	O
Ccl28	O
(	O
-	O
/	O
-	O
)	O
mouse	O
suggesting	O
that	O
CCL28	O
is	O
involved	O
in	O
the	O
function	O
/	O
development	O
of	O
olfaction	O
.	O

Importantly	O
,	O
Ccl28	O
(	O
-	O
/	O
-	O
)	O
mice	O
are	O
highly	O
susceptible	O
to	O
Salmonella	B-bacteria
enterica	I-bacteria
serovar	I-bacteria
Typhimurium	I-bacteria
in	O
an	O
acute	O
model	O
of	O
infection	O
,	O
indicating	O
that	O
CCL28	O
plays	O
a	O
major	O
role	O
in	O
innate	O
immunity	O
against	O
Salmonella	B-bacteria
in	O
the	O
gut	O
.	O

Finally	O
,	O
microbiome	O
studies	O
revealed	O
modest	O
differences	O
in	O
the	O
gut	O
microbiota	O
between	O
Ccl28	O
(	O
-	O
/	O
-	O
)	O
mice	O
and	O
their	O
cohoused	O
wild	O
-	O
type	O
littermates	O
.	O

The	O
latter	O
observation	O
suggests	O
that	O
under	O
homeostatic	O
conditions	O
,	O
CCL28	O
plays	O
a	O
limited	O
role	O
in	O
shaping	O
the	O
gut	O
microbiome	O
.	O

Anti	O
-	O
inflammation	O
effects	O
of	O
fucosylated	O
chondroitin	O
sulphate	O
from	O
Acaudina	O
molpadioides	O
by	O
altering	O
gut	O
microbiota	O
in	O
obese	O
mice	O
.	O

This	O
study	O
evaluated	O
the	O
possible	O
prebiotic	O
effects	O
of	O
dietary	O
fucosylated	O
chondroitin	O
sulfate	O
from	O
Acaudina	O
molpadioides	O
(	O
Am	O
-	O
CHS	O
)	O
on	O
the	O
modulation	O
of	O
the	O
gut	O
microbiota	O
and	O
the	O
improvement	O
in	O
the	O
risk	O
factors	O
for	O
chronic	O
inflammation	O
in	O
high	O
fat	O
diet	O
-	O
fed	O
mice	O
.	O

The	O
results	O
showed	O
that	O
the	O
Am	O
-	O
CHS	O
treatment	O
greatly	O
modified	O
the	O
gut	O
microbiota	O
,	O
including	O
the	O
decrease	O
in	O
Bacteroidetes	B-bacteria
,	O
increase	O
in	O
Firmicutes	B-bacteria
,	O
elevation	O
in	O
Lactobacillus	B-bacteria
(	O
intestinal	O
barrier	O
protector	O
)	O
and	O
short	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
-	O
producing	O
bacteria	O
(	O
Lactobacillus	B-bacteria
,	O
Bifidobacterium	B-bacteria
,	O
and	O
Lachnospiraceae	B-bacteria
NK4A136	I-bacteria
group	O
)	O
,	O
and	O
reduction	O
in	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
producer	O
(	O
Escherichia	B-bacteria
coli	I-bacteria
)	O
.	O

This	O
modulation	O
inhibited	O
inflammatory	O
response	O
,	O
manifesting	O
the	O
decreases	O
in	O
circulating	O
proinflammatory	O
cytokines	O
and	O
their	O
mRNA	O
expression	O
,	O
and	O
the	O
increases	O
in	O
interleukin	O
-	O
10	O
.	O

Dietary	O
Am	O
-	O
CHS	O
caused	O
reductions	O
in	O
serum	O
and	O
fecal	O
LPS	O
concentrations	O
and	O
inhibition	O
of	O
transcription	O
of	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
and	O
its	O
downstream	O
proteins	O
.	O

In	O
addition	O
,	O
there	O
were	O
increases	O
in	O
the	O
portal	O
levels	O
of	O
fecal	O
SCFAs	O
,	O
which	O
probably	O
contributed	O
to	O
an	O
increase	O
in	O
the	O
adenosine	O
monophosphate	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
protein	O
in	O
Am	O
-	O
CHS	O
-	O
treated	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
modulation	O
of	O
gut	O
microbiota	O
by	O
Am	O
-	O
CHS	O
can	O
improve	O
chronic	O
inflammation	O
by	O
reducing	O
LPS	O
levels	O
and	O
TLR4	O
signaling	O
.	O

Modulation	O
also	O
appears	O
to	O
increase	O
the	O
levels	O
of	O
fecal	O
SCFAs	O
,	O
which	O
activates	O
AMPK	O
and	O
finally	O
leads	O
to	O
inflammation	O
resistance	O
.	O

Prospective	O
observational	O
study	O
of	O
vaginal	O
microbiota	O
pre	O
-	O
and	O
post	O
-	O
rescue	O
cervical	O
cerclage	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
relation	O
between	O
vaginal	O
microbiota	O
composition	O
and	O
outcome	O
of	O
rescue	O
cervical	O
cerclage	O
.	O

DESIGN	O
:	O
Prospective	O
observational	O
study	O
.	O

SETTING	O
:	O
Queen	O
Charlotte	O
'	O
s	O
and	O
Chelsea	O
Hospital	O
,	O
London	O
.	O

POPULATION	O
:	O
Twenty	O
singleton	O
pregnancies	O
undergoing	O
a	O
rescue	O
cervical	O
cerclage	O
.	O

METHODS	O
:	O
Vaginal	O
microbiota	O
composition	O
was	O
analysed	O
in	O
women	O
presenting	O
with	O
a	O
dilated	O
cervix	O
and	O
exposed	O
fetal	O
membranes	O
before	O
and	O
10	O
days	O
following	O
rescue	O
cervical	O
cerclage	O
and	O
was	O
correlated	O
with	O
clinical	O
outcomes	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Composition	O
of	O
vaginal	O
bacteria	O
was	O
characterised	O
by	O
culture	O
-	O
independent	O
next	O
generation	O
sequencing	O
.	O

Successful	O
cerclage	O
was	O
defined	O
as	O
that	O
resulting	O
in	O
the	O
birth	O
of	O
a	O
neonate	O
discharged	O
from	O
hospital	O
without	O
morbidity	O
.	O

Unsuccessful	O
cerclage	O
was	O
defined	O
as	O
procedures	O
culminating	O
in	O
miscarriage	O
,	O
intrauterine	O
death	O
,	O
neonatal	O
death	O
or	O
significant	O
neonatal	O
morbidity	O
.	O

RESULTS	O
:	O
Reduced	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
relative	O
abundance	O
was	O
observed	O
in	O
40	O
%	O
of	O
cases	O
prior	O
to	O
rescue	O
cerclage	O
compared	O
with	O
10	O
%	O
of	O
gestation	O
age	O
-	O
matched	O
controls	O
(	O
8	O
/	O
20	O
,	O
40	O
%	O
versus	O
3	O
/	O
30	O
,	O
10	O
%	O
,	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O

Gardnerella	B-bacteria
vaginalis	I-bacteria
was	O
over	O
-	O
represented	O
in	O
women	O
presenting	O
with	O
symptoms	O
(	O
3	O
/	O
7	O
,	O
43	O
%	O
versus	O
0	O
/	O
13	O
,	O
0	O
%	O
,	O
P	O
=	O
0	O
.	O
03	O
,	O
linear	O
discriminant	O
analysis	O
,	O
LDA	O
(	O
log	O
10	O
)	O
and	O
cases	O
culminating	O
in	O
miscarriage	O
(	O
3	O
/	O
6	O
,	O
50	O
%	O
versus	O
0	O
/	O
14	O
,	O
0	O
%	O
,	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O

In	O
the	O
majority	O
of	O
cases	O
(	O
10	O
/	O
14	O
,	O
71	O
%	O
)	O
bacterial	O
composition	O
was	O
unchanged	O
following	O
cerclage	O
insertion	O
and	O
perioperative	O
interventions	O
.	O

CONCLUSIONS	O
:	O
Reduced	O
relative	O
abundance	O
of	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
is	O
associated	O
with	O
premature	O
cervical	O
dilation	O
,	O
whereas	O
high	O
levels	O
of	O
G	B-bacteria
.	I-bacteria
vaginalis	I-bacteria
are	O
associated	O
with	O
unsuccessful	O
rescue	O
cerclage	O
cases	O
.	O

The	O
insertion	O
of	O
a	O
rescue	O
cerclage	O
does	O
not	O
affect	O
the	O
underlying	O
bacterial	O
composition	O
in	O
the	O
majority	O
of	O
cases	O
.	O

TWEETABLE	O
ABSTRACT	O
:	O
Preterm	O
cervical	O
dilatation	O
associates	O
with	O
reduced	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	O

Presence	O
of	O
Gardnerella	B-bacteria
vaginalis	I-bacteria
predicts	O
rescue	O
cerclage	O
failure	O
.	O

Myenteric	O
Denervation	O
of	O
the	O
Gut	O
with	O
Benzalkonium	O
Chloride	O
:	O
A	O
Review	O
of	O
Forty	O
Years	O
of	O
an	O
Experimental	O
Model	O
.	O

Experimental	O
denervation	O
of	O
organs	O
plays	O
a	O
key	O
role	O
in	O
understanding	O
the	O
functional	O
aspects	O
of	O
the	O
normal	O
innervation	O
as	O
well	O
as	O
the	O
diseases	O
related	O
to	O
them	O
.	O

In	O
1978	O
the	O
experimental	O
model	O
of	O
myenteric	O
denervation	O
of	O
the	O
rat	O
gut	O
by	O
serosal	O
application	O
of	O
benzalkonium	O
chloride	O
(	O
BAC	O
)	O
was	O
proposed	O
.	O

BAC	O
is	O
a	O
positively	O
charged	O
surface	O
-	O
active	O
alkylamine	O
and	O
is	O
a	O
powerful	O
cationic	O
detergent	O
,	O
which	O
destroys	O
bacteria	O
after	O
ionic	O
attraction	O
and	O
for	O
this	O
reason	O
is	O
largely	O
used	O
as	O
a	O
surgical	O
antiseptic	O
.	O

Since	O
its	O
initial	O
report	O
,	O
the	O
BAC	O
-	O
induced	O
myenteric	O
denervation	O
model	O
has	O
been	O
used	O
to	O
study	O
many	O
functional	O
and	O
pathological	O
aspects	O
of	O
the	O
enteric	O
nervous	O
system	O
.	O

So	O
far	O
this	O
is	O
the	O
only	O
pure	O
method	O
of	O
myenteric	O
denervation	O
available	O
for	O
research	O
in	O
this	O
area	O
.	O

Promising	O
reports	O
in	O
the	O
literature	O
have	O
shed	O
light	O
on	O
the	O
possibilities	O
for	O
the	O
development	O
of	O
new	O
uses	O
of	O
the	O
BAC	O
-	O
denervation	O
experimental	O
model	O
as	O
a	O
therapeutic	O
tool	O
in	O
some	O
pathological	O
situations	O
.	O

This	O
review	O
aims	O
to	O
shed	O
light	O
on	O
the	O
main	O
historical	O
and	O
recent	O
findings	O
provided	O
by	O
this	O
experimental	O
model	O
.	O

Interactions	O
between	O
a	O
pathogenic	O
Blastocystis	O
subtype	O
and	O
gut	O
microbiota	O
:	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
.	O

BACKGROUND	O
:	O
Blastocystis	O
is	O
a	O
common	O
gut	O
eukaryote	O
detected	O
in	O
humans	O
and	O
animals	O
.	O

It	O
has	O
been	O
associated	O
with	O
gastrointestinal	O
disease	O
in	O
the	O
past	O
although	O
recent	O
metagenomic	O
studies	O
also	O
suggest	O
that	O
it	O
is	O
a	O
member	O
of	O
normal	O
microbiota	O
.	O

This	O
study	O
investigates	O
interactions	O
between	O
pathogenic	O
human	O
isolates	O
belonging	O
to	O
Blastocystis	O
subtype	O
7	O
(	O
ST7	O
)	O
and	O
bacterial	O
representatives	O
of	O
the	O
gut	O
microbiota	O
.	O

RESULTS	O
:	O
Generally	O
,	O
Blastocystis	O
ST7	O
exerts	O
a	O
positive	O
effect	O
on	O
the	O
viability	O
of	O
representative	O
gut	O
bacteria	O
except	O
on	O
Bifidobacterium	B-bacteria
longum	I-bacteria
.	O

Gene	O
expression	O
analysis	O
and	O
flow	O
cytometry	O
indicate	O
that	O
the	O
bacterium	O
may	O
be	O
undergoing	O
oxidative	O
stress	O
in	O
the	O
presence	O
of	O
Blastocystis	O
.	O

In	O
vitro	O
assays	O
demonstrate	O
that	O
Blastocystis	O
-	O
induced	O
host	O
responses	O
are	O
able	O
to	O
decrease	O
Bifidobacterium	B-bacteria
counts	O
.	O

Mice	O
infected	O
with	O
Blastocystis	O
also	O
reveal	O
a	O
decrease	O
in	O
beneficial	O
bacteria	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
.	O

CONCLUSIONS	O
:	O
This	O
study	O
shows	O
that	O
particular	O
isolates	O
of	O
Blastocystis	O
ST7	O
cause	O
changes	O
in	O
microbiota	O
populations	O
and	O
potentially	O
lead	O
to	O
an	O
imbalance	O
of	O
the	O
gut	O
microbiota	O
.	O

This	O
study	O
suggests	O
that	O
certain	O
isolates	O
of	O
Blastocystis	O
exert	O
their	O
pathogenic	O
effects	O
through	O
disruption	O
of	O
the	O
gut	O
microbiota	O
and	O
provides	O
a	O
counterpoint	O
to	O
the	O
increasing	O
reports	O
indicating	O
the	O
commensal	O
nature	O
of	O
this	O
ubiquitous	O
parasite	O
.	O

Shape	O
of	O
gastrointestinal	O
immunity	O
with	O
non	O
-	O
genetically	O
modified	O
Lactococcus	B-bacteria
lactis	I-bacteria
particles	O
requires	O
commensal	O
bacteria	O
and	O
myeloid	O
cells	O
-	O
derived	O
TGF	O
-	O
beta1	O
.	O

Heat	O
-	O
killed	O
probiotics	O
or	O
microbial	O
autologous	O
components	O
show	O
multiple	O
activities	O
on	O
modulating	O
host	O
immune	O
responses	O
towards	O
tolerance	O
or	O
vice	O
versus	O
aggressiveness	O
.	O

Gram	O
-	O
positive	O
enhancer	O
matrix	O
particles	O
(	O
GEMs	O
)	O
,	O
the	O
non	O
-	O
genetically	O
modified	O
particles	O
which	O
composed	O
of	O
the	O
cell	O
wall	O
derived	O
from	O
Lactococcus	B-bacteria
lactis	I-bacteria
(	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
)	O
,	O
were	O
used	O
as	O
a	O
typical	O
microbial	O
molecule	O
to	O
investigate	O
the	O
mechanism	O
of	O
opposite	O
immune	O
responses	O
generated	O
in	O
disparate	O
scenarios	O
.	O

The	O
results	O
of	O
stool	O
16S	O
rRNA	O
Illumina	O
sequencing	O
suggested	O
that	O
the	O
overwhelming	O
number	O
of	O
mice	O
pre	O
-	O
administered	O
with	O
GEMs	O
showed	O
the	O
expansion	O
of	O
Bacteroidetes	B-bacteria
but	O
contraction	O
of	O
Verrucomicrobia	B-bacteria
.	O

Co	O
-	O
administration	O
GEMs	O
and	O
antibiotics	O
could	O
preserve	O
the	O
microbial	O
diversity	O
,	O
even	O
though	O
the	O
abundance	O
of	O
gut	O
microbes	O
was	O
largely	O
depleted	O
by	O
antibiotics	O
.	O

Additionally	O
,	O
dendritic	O
cells	O
(	O
DCs	O
)	O
from	O
mice	O
receiving	O
GEMs	O
rather	O
than	O
DCs	O
that	O
in	O
vitro	O
treated	O
with	O
GEMs	O
induced	O
the	O
expansion	O
of	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
,	O
witnessing	O
the	O
critical	O
role	O
of	O
gut	O
flora	O
alteration	O
.	O

Importantly	O
,	O
this	O
alteration	O
provided	O
protection	O
to	O
alleviate	O
dextran	O
sulfate	O
sodium	O
(	O
DSS	O
)	O
-	O
induced	O
intestinal	O
inflammation	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
the	O
context	O
of	O
Helicobacter	B-bacteria
felis	I-bacteria
(	O
H	B-bacteria
.	I-bacteria
felis	I-bacteria
)	O
infection	O
,	O
the	O
mice	O
pre	O
-	O
administrated	O
with	O
GEMs	O
exhibited	O
a	O
comparably	O
potent	O
gastric	O
immunity	O
with	O
the	O
elevated	O
expression	O
of	O
IFN	O
-	O
gamma	O
,	O
IL	O
-	O
17	O
,	O
and	O
multiple	O
anti	O
-	O
microbial	O
factors	O
,	O
leading	O
to	O
the	O
reduced	O
burden	O
of	O
H	B-bacteria
.	I-bacteria
felis	I-bacteria
.	O

However	O
,	O
tolerance	O
for	O
both	O
DSS	O
-	O
induced	O
intestinal	O
inflammation	O
and	O
immunity	O
against	O
H	B-bacteria
.	I-bacteria
felis	I-bacteria
was	O
depleted	O
in	O
a	O
mice	O
model	O
lacking	O
of	O
transforming	O
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
in	O
myeloid	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
GEMs	O
can	O
modulate	O
host	O
immune	O
responses	O
bidirectionally	O
according	O
to	O
context	O
,	O
and	O
may	O
serve	O
as	O
a	O
supplement	O
for	O
antibiotic	O
treatment	O
.	O

The	O
hepatoprotective	O
effect	O
of	O
polysaccharides	O
from	O
Pleurotus	O
ostreatus	O
on	O
carbon	O
tetrachloride	O
-	O
induced	O
acute	O
liver	O
injury	O
rats	O
.	O

This	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
hepatoprotective	O
effect	O
of	O
polysaccharides	O
from	O
Pleurotus	O
ostreatus	O
(	O
POP	O
)	O
on	O
carbon	O
tetrachloride	O
-	O
induced	O
acute	O
liver	O
injury	O
(	O
ALI	O
)	O
in	O
rats	O
.	O

The	O
hepatoprotective	O
effect	O
of	O
POP	O
against	O
ALI	O
was	O
reflected	O
by	O
the	O
decreased	O
alanine	O
transaminase	O
and	O
aspartate	O
transaminase	O
levels	O
in	O
blood	O
,	O
increased	O
superoxide	O
dismutase	O
,	O
catalase	O
,	O
and	O
glutathione	O
peroxidase	O
levels	O
,	O
and	O
decreased	O
malondialdehyde	O
levels	O
in	O
blood	O
and	O
liver	O
.	O

TUNEL	O
and	O
immunohistochemistry	O
analyses	O
showed	O
that	O
TUNEL	O
apoptosis	O
cell	O
rate	O
and	O
Bax	O
,	O
cytochrome	O
C	O
,	O
caspase	O
-	O
3	O
,	O
caspase	O
-	O
9	O
,	O
and	O
apoptosis	O
-	O
inducing	O
factor	O
expression	O
levels	O
were	O
obviously	O
decreased	O
,	O
whereas	O
Bcl	O
-	O
2	O
expression	O
levels	O
obviously	O
increased	O
after	O
POP	O
treatment	O
.	O

A	O
total	O
of	O
11	O
metabolites	O
belonging	O
to	O
energy	O
,	O
amino	O
acid	O
,	O
fatty	O
acid	O
,	O
and	O
gut	O
bacteria	O
metabolism	O
were	O
identified	O
as	O
biomarkers	O
by	O
using	O
metabolite	O
analysis	O
of	O
liver	O
homogenate	O
based	O
on	O
ultra	O
-	O
performance	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
.	O

POP	O
exhibited	O
hepatoprotective	O
effects	O
on	O
CCl4	O
-	O
induced	O
ALI	O
,	O
and	O
the	O
underlying	O
mechanism	O
is	O
correlated	O
with	O
antioxidants	O
that	O
regulate	O
metabolic	O
pathway	O
disorders	O
and	O
alleviate	O
liver	O
mitochondria	O
apoptosis	O
.	O

Different	O
host	O
-	O
specific	O
responses	O
in	O
thyroid	O
function	O
and	O
gut	O
microbiota	O
modulation	O
between	O
diet	O
-	O
induced	O
obese	O
and	O
normal	O
mice	O
given	O
the	O
same	O
dose	O
of	O
iodine	O
.	O

Iodine	O
is	O
an	O
important	O
trace	O
element	O
involved	O
in	O
thyroid	O
hormone	O
biosynthesis	O
,	O
while	O
diet	O
-	O
induced	O
obesity	O
is	O
reported	O
to	O
disturb	O
the	O
trace	O
element	O
metabolic	O
balance	O
.	O

Herein	O
,	O
we	O
studied	O
the	O
host	O
-	O
specific	O
responses	O
involved	O
in	O
modulating	O
thyroid	O
function	O
and	O
gut	O
microbiota	O
in	O
obese	O
mice	O
after	O
the	O
iodine	O
treatment	O
and	O
analyzed	O
the	O
possible	O
causes	O
for	O
these	O
responses	O
.	O

Obesity	O
in	O
the	O
mice	O
was	O
induced	O
by	O
a	O
high	O
-	O
fat	O
diet	O
,	O
and	O
the	O
obese	O
and	O
normal	O
mice	O
were	O
treated	O
with	O
the	O
same	O
iodine	O
dosage	O
(	O
18	O
mug	O
/	O
kg	O
/	O
day	O
)	O
continuously	O
for	O
8	O
weeks	O
.	O

Iodine	O
treatment	O
in	O
the	O
obese	O
mice	O
showed	O
a	O
weight	O
-	O
reducing	O
effect	O
,	O
increased	O
the	O
thyroid	O
hormone	O
concentrations	O
,	O
altered	O
the	O
transcriptions	O
of	O
genes	O
involved	O
in	O
thyroid	O
hormone	O
biosynthesis	O
,	O
and	O
modulated	O
the	O
gut	O
microbiota	O
with	O
an	O
increased	O
abundance	O
of	O
pathogenic	O
bacteria	O
and	O
decreased	O
the	O
proportion	O
of	O
beneficial	O
bacteria	O
.	O

However	O
,	O
completely	O
different	O
or	O
even	O
opposite	O
response	O
profiles	O
were	O
observed	O
in	O
the	O
normal	O
hosts	O
.	O

Our	O
work	O
indicated	O
that	O
obesity	O
may	O
exacerbate	O
the	O
risk	O
of	O
thyroid	O
disease	O
with	O
a	O
relatively	O
safe	O
dose	O
of	O
iodine	O
,	O
and	O
individual	O
differences	O
should	O
be	O
considered	O
with	O
trace	O
element	O
supplementation	O
.	O

Parasitoid	O
envenomation	O
alters	O
the	O
Galleria	O
mellonella	O
midgut	O
microbiota	O
and	O
immunity	O
,	O
thereby	O
promoting	O
fungal	O
infection	O
.	O

Gut	O
bacteria	O
influence	O
the	O
development	O
of	O
different	O
pathologies	O
caused	O
by	O
bacteria	O
,	O
fungi	O
and	O
parasitoids	O
in	O
insects	O
.	O

Wax	O
moth	O
larvae	O
became	O
more	O
susceptible	O
to	O
fungal	O
infections	O
after	O
envenomation	O
by	O
the	O
ectoparasitoid	O
Habrobracon	O
hebetor	O
.	O

In	O
addition	O
,	O
spontaneous	O
bacterioses	O
occurred	O
more	O
often	O
in	O
envenomated	O
larvae	O
.	O

We	O
analyzed	O
alterations	O
in	O
the	O
midgut	O
microbiota	O
and	O
immunity	O
of	O
the	O
wax	O
moth	O
in	O
response	O
to	O
H	O
.	O
hebetor	O
envenomation	O
and	O
topical	O
fungal	O
infection	O
(	O
Beauveria	O
bassiana	O
)	O
alone	O
or	O
in	O
combination	O
using	O
16S	O
rRNA	O
sequencing	O
,	O
an	O
analysis	O
of	O
cultivable	O
bacteria	O
and	O
a	O
qPCR	O
analysis	O
of	O
immunity	O
-	O
and	O
stress	O
-	O
related	O
genes	O
.	O

Envenomation	O
led	O
to	O
a	O
predominance	O
shift	O
from	O
enterococci	B-bacteria
to	O
enterobacteria	B-bacteria
,	O
an	O
increase	O
in	O
CFUs	O
and	O
the	O
upregulation	O
of	O
AMPs	O
in	O
wax	O
moth	O
midguts	O
.	O

Furthermore	O
,	O
mycosis	O
nonsignificantly	O
increased	O
the	O
abundance	O
of	O
enterobacteria	B-bacteria
and	O
the	O
expression	O
of	O
AMPs	O
in	O
the	O
midgut	O
.	O

Combined	O
treatment	O
led	O
to	O
a	O
significant	O
increase	O
in	O
the	O
abundance	O
of	O
Serratia	B-bacteria
and	O
a	O
greater	O
upregulation	O
of	O
gloverin	O
.	O

The	O
oral	O
administration	O
of	O
predominant	O
bacteria	O
(	O
Enterococcus	B-bacteria
faecalis	I-bacteria
,	O
Enterobacter	B-bacteria
sp	I-bacteria
.	I-bacteria
and	O
Serratia	B-bacteria
marcescens	I-bacteria
)	O
to	O
wax	O
moth	O
larvae	O
synergistically	O
increased	O
fungal	O
susceptibility	O
.	O

Thus	O
,	O
the	O
activation	O
of	O
midgut	O
immunity	O
might	O
prevent	O
the	O
bacterial	O
decomposition	O
of	O
envenomated	O
larvae	O
,	O
thus	O
permitting	O
the	O
development	O
of	O
fungal	O
infections	O
.	O

Moreover	O
,	O
changes	O
in	O
the	O
midgut	O
bacterial	O
community	O
may	O
promote	O
fungal	O
killing	O
.	O

Antibiotic	O
treatment	O
affects	O
the	O
expression	O
levels	O
of	O
copper	O
transporters	O
and	O
the	O
isotopic	O
composition	O
of	O
copper	O
in	O
the	O
colon	O
of	O
mice	O
.	O

Copper	O
is	O
a	O
critical	O
enzyme	O
cofactor	O
in	O
the	O
body	O
but	O
also	O
a	O
potent	O
cellular	O
toxin	O
when	O
intracellularly	O
unbound	O
.	O

Thus	O
,	O
there	O
is	O
a	O
delicate	O
balance	O
of	O
intracellular	O
copper	O
,	O
maintained	O
by	O
a	O
series	O
of	O
complex	O
interactions	O
between	O
the	O
metal	O
and	O
specific	O
copper	O
transport	O
and	O
binding	O
proteins	O
.	O

The	O
gastrointestinal	O
(	O
GI	O
)	O
tract	O
is	O
the	O
primary	O
site	O
of	O
copper	O
entry	O
into	O
the	O
body	O
and	O
there	O
has	O
been	O
considerable	O
progress	O
in	O
understanding	O
the	O
intricacies	O
of	O
copper	O
metabolism	O
in	O
this	O
region	O
.	O

The	O
GI	O
tract	O
is	O
also	O
host	O
to	O
diverse	O
bacterial	O
populations	O
,	O
and	O
their	O
role	O
in	O
copper	O
metabolism	O
is	O
not	O
well	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
isotopic	O
fractionation	O
of	O
copper	O
in	O
the	O
GI	O
tract	O
of	O
mice	O
with	O
intestinal	O
microbiota	O
significantly	O
depleted	O
by	O
antibiotic	O
treatment	O
to	O
that	O
in	O
mice	O
not	O
receiving	O
such	O
treatment	O
.	O

We	O
demonstrated	O
variability	O
in	O
copper	O
isotopic	O
composition	O
along	O
the	O
length	O
of	O
the	O
gut	O
.	O

A	O
significant	O
difference	O
,	O
approximately	O
1	O
.	O
0	O
per	O
thousand	O
,	O
in	O
copper	O
isotope	O
abundances	O
was	O
measured	O
in	O
the	O
proximal	O
colon	O
of	O
antibiotic	O
-	O
treated	O
mice	O
.	O

The	O
changes	O
in	O
copper	O
isotopic	O
composition	O
in	O
the	O
colon	O
are	O
accompanied	O
by	O
changes	O
in	O
copper	O
transporters	O
.	O

Both	O
CTR1	O
,	O
a	O
copper	O
importer	O
,	O
and	O
ATP7A	O
,	O
a	O
copper	O
transporter	O
across	O
membranes	O
,	O
were	O
significantly	O
down	O
-	O
regulated	O
in	O
the	O
colon	O
of	O
antibiotic	O
-	O
treated	O
mice	O
.	O

This	O
study	O
demonstrated	O
that	O
isotope	O
abundance	O
measurements	O
of	O
metals	O
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
changes	O
in	O
metabolic	O
processes	O
in	O
vivo	O
.	O

These	O
measurements	O
revealed	O
a	O
host	O
-	O
microbial	O
interaction	O
in	O
the	O
GI	O
tract	O
involved	O
in	O
the	O
regulation	O
of	O
copper	O
transport	O
.	O

New	O
Insights	O
into	O
the	O
Nature	O
of	O
Symbiotic	O
Associations	O
in	O
Aphids	O
:	O
Infection	O
Process	O
,	O
Biological	O
Effects	O
,	O
and	O
Transmission	O
Mode	O
of	O
Cultivable	O
Serratia	B-bacteria
symbiotica	I-bacteria
Bacteria	O
.	O

Symbiotic	O
microorganisms	O
are	O
widespread	O
in	O
nature	O
and	O
can	O
play	O
a	O
major	O
role	O
in	O
the	O
ecology	O
and	O
evolution	O
of	O
animals	O
.	O

The	O
aphid	O
-	O
Serratia	B-bacteria
symbiotica	I-bacteria
bacterium	I-bacteria
interaction	O
provides	O
a	O
valuable	O
model	O
to	O
study	O
the	O
mechanisms	O
behind	O
these	O
symbiotic	O
associations	O
.	O

The	O
recent	O
discovery	O
of	O
cultivable	O
S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
strains	I-bacteria
with	O
a	O
free	O
-	O
living	O
lifestyle	O
allowed	O
us	O
to	O
simulate	O
their	O
environmental	O
acquisition	O
by	O
aphids	O
to	O
examine	O
the	O
mechanisms	O
involved	O
in	O
this	O
infection	O
pathway	O
.	O

Here	O
,	O
after	O
oral	O
ingestion	O
,	O
we	O
analyzed	O
the	O
infection	O
dynamics	O
of	O
cultivable	O
S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
during	O
the	O
host	O
'	O
s	O
lifetime	O
using	O
quantitative	O
PCR	O
and	O
fluorescence	O
techniques	O
and	O
determined	O
the	O
immediate	O
fitness	O
consequences	O
of	O
these	O
bacteria	O
on	O
their	O
new	O
host	O
.	O

We	O
further	O
examined	O
the	O
transmission	O
behavior	O
and	O
phylogenetic	O
position	O
of	O
cultivable	O
strains	O
.	O

Our	O
study	O
revealed	O
that	O
cultivable	O
S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
bacteria	I-bacteria
are	O
predisposed	O
to	O
establish	O
a	O
symbiotic	O
association	O
with	O
a	O
new	O
aphid	O
host	O
,	O
settling	O
in	O
its	O
gut	O
.	O

We	O
show	O
that	O
cultivable	O
S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
bacteria	O
colonize	O
the	O
entire	O
aphid	O
digestive	O
tract	O
following	O
infection	O
,	O
after	O
which	O
the	O
bacteria	O
multiply	O
exponentially	O
during	O
aphid	O
development	O
.	O

Our	O
results	O
further	O
reveal	O
that	O
gut	O
colonization	O
by	O
the	O
bacteria	O
induces	O
a	O
fitness	O
cost	O
to	O
their	O
hosts	O
.	O

Nevertheless	O
,	O
it	O
appeared	O
that	O
the	O
bacteria	O
also	O
offer	O
an	O
immediate	O
protection	O
against	O
parasitoids	O
.	O

Interestingly	O
,	O
cultivable	O
S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
strains	I-bacteria
seem	O
to	O
be	O
extracellularly	O
transmitted	O
,	O
possibly	O
through	O
the	O
honeydew	O
,	O
while	O
S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
is	O
generally	O
considered	O
a	O
maternally	O
transmitted	O
bacterium	O
living	O
within	O
the	O
aphid	O
body	O
cavity	O
and	O
bringing	O
some	O
benefits	O
to	O
its	O
hosts	O
,	O
despite	O
its	O
costs	O
.	O

These	O
findings	O
provide	O
new	O
insights	O
into	O
the	O
nature	O
of	O
symbiosis	O
in	O
aphids	O
and	O
the	O
mechanisms	O
underpinning	O
these	O
interactions	O
.	O

IMPORTANCE	O
S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
is	O
one	O
of	O
the	O
most	O
common	O
symbionts	O
among	O
aphid	O
populations	O
and	O
includes	O
a	O
wide	O
variety	O
of	O
strains	O
whose	O
degree	O
of	O
interdependence	O
on	O
the	O
host	O
may	O
vary	O
considerably	O
.	O

S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
strains	I-bacteria
with	O
a	O
free	O
-	O
living	O
capacity	O
have	O
recently	O
been	O
isolated	O
from	O
aphids	O
.	O

By	O
using	O
these	O
strains	O
,	O
we	O
established	O
artificial	O
associations	O
by	O
simulating	O
new	O
bacterial	O
acquisitions	O
involved	O
in	O
aphid	O
gut	O
infections	O
to	O
decipher	O
their	O
infection	O
processes	O
and	O
biological	O
effects	O
on	O
their	O
new	O
hosts	O
.	O

Our	O
results	O
showed	O
the	O
early	O
stages	O
involved	O
in	O
this	O
route	O
of	O
infection	O
.	O

So	O
far	O
,	O
S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
has	O
been	O
considered	O
a	O
maternally	O
transmitted	O
aphid	O
endosymbiont	O
.	O

Nevertheless	O
,	O
we	O
show	O
that	O
our	O
cultivable	O
S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
strains	I-bacteria
occupy	O
and	O
replicate	O
in	O
the	O
aphid	O
gut	O
and	O
seem	O
to	O
be	O
transmitted	O
over	O
generations	O
through	O
an	O
environmental	O
transmission	O
mechanism	O
.	O

Moreover	O
,	O
cultivable	O
S	B-bacteria
.	I-bacteria
symbiotica	I-bacteria
bacteria	I-bacteria
are	O
both	O
parasites	O
and	O
mutualists	O
given	O
the	O
context	O
,	O
as	O
are	O
many	O
aphid	O
endosymbionts	O
.	O

Our	O
findings	O
give	O
new	O
perception	O
of	O
the	O
associations	O
involved	O
in	O
bacterial	O
mutualism	O
in	O
aphids	O
.	O

Malassezia	O
Is	O
Associated	O
with	O
Crohn	O
'	O
s	O
Disease	O
and	O
Exacerbates	O
Colitis	O
in	O
Mouse	O
Models	O
.	O

Inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
is	O
characterized	O
by	O
alterations	O
in	O
the	O
intestinal	O
microbiota	O
and	O
altered	O
immune	O
responses	O
to	O
gut	O
microbiota	O
.	O

Evidence	O
is	O
accumulating	O
that	O
IBD	O
is	O
influenced	O
by	O
not	O
only	O
commensal	O
bacteria	O
but	O
also	O
commensal	O
fungi	O
.	O

We	O
characterized	O
fungi	O
directly	O
associated	O
with	O
the	O
intestinal	O
mucosa	O
in	O
healthy	O
people	O
and	O
Crohn	O
'	O
s	O
disease	O
patients	O
and	O
identified	O
fungi	O
specifically	O
abundant	O
in	O
patients	O
.	O

One	O
of	O
these	O
,	O
the	O
common	O
skin	O
resident	O
fungus	O
Malassezia	O
restricta	O
,	O
is	O
also	O
linked	O
to	O
the	O
presence	O
of	O
an	O
IBD	O
-	O
associated	O
polymorphism	O
in	O
the	O
gene	O
for	O
CARD9	O
,	O
a	O
signaling	O
adaptor	O
important	O
for	O
anti	O
-	O
fungal	O
defense	O
.	O

M	O
.	O
restricta	O
elicits	O
innate	O
inflammatory	O
responses	O
largely	O
through	O
CARD9	O
and	O
is	O
recognized	O
by	O
Crohn	O
'	O
s	O
disease	O
patient	O
anti	O
-	O
fungal	O
antibodies	O
.	O

This	O
yeast	O
elicits	O
strong	O
inflammatory	O
cytokine	O
production	O
from	O
innate	O
cells	O
harboring	O
the	O
IBD	O
-	O
linked	O
polymorphism	O
in	O
CARD9	O
and	O
exacerbates	O
colitis	O
via	O
CARD9	O
in	O
mouse	O
models	O
of	O
disease	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
targeting	O
specific	O
commensal	O
fungi	O
may	O
be	O
a	O
therapeutic	O
strategy	O
for	O
IBD	O
.	O

Profound	O
mycobiome	O
differences	O
between	O
segregated	O
mouse	O
colonies	O
do	O
not	O
influence	O
Th17	O
responses	O
to	O
a	O
newly	O
introduced	O
gut	O
fungal	O
commensal	O
.	O

Gut	O
mycobiota	O
dysbiosis	O
can	O
negatively	O
impact	O
the	O
outcome	O
of	O
several	O
diseases	O
of	O
inflammatory	O
origin	O
,	O
suggesting	O
a	O
role	O
of	O
the	O
mycobiota	O
in	O
influencing	O
the	O
host	O
immunity	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
the	O
gut	O
mycobiota	O
composition	O
can	O
create	O
an	O
immune	O
environment	O
that	O
would	O
influence	O
the	O
immune	O
response	O
to	O
a	O
newly	O
introduced	O
intestinal	O
fungus	O
.	O

Using	O
ITS1	O
deep	O
sequencing	O
,	O
we	O
evaluated	O
the	O
mycobiome	O
structure	O
of	O
C57BL	O
/	O
6J	O
mice	O
acquired	O
from	O
Jackson	O
(	O
JAX	O
)	O
or	O
bred	O
in	O
a	O
controlled	O
environment	O
at	O
a	O
dedicated	O
room	O
in	O
our	O
own	O
mouse	O
facility	O
(	O
WCM	O
-	O
CE	O
)	O
for	O
several	O
generations	O
.	O

We	O
found	O
that	O
C57BL	O
/	O
6J	O
mice	O
from	O
these	O
segregated	O
mouse	O
colonies	O
harbor	O
dramatically	O
different	O
mycobiota	O
.	O

To	O
assess	O
whether	O
the	O
mycobiota	O
make	O
up	O
can	O
influence	O
immune	O
responses	O
to	O
colonization	O
with	O
a	O
fungus	O
foreign	O
to	O
the	O
murine	O
GI	O
tract	O
,	O
we	O
colonized	O
JAX	O
and	O
WCM	O
-	O
CE	O
mice	O
with	O
the	O
human	O
commensal	O
C	O
.	O
albicans	O
and	O
measured	O
Th17	O
responses	O
in	O
the	O
gut	O
.	O

We	O
found	O
that	O
independent	O
of	O
mycobiota	O
composition	O
,	O
mice	O
produced	O
strong	O
Th17	O
responses	O
to	O
gastrointestinal	O
C	O
.	O
albicans	O
colonization	O
.	O

Our	O
data	O
suggest	O
that	O
different	O
mouse	O
colonies	O
can	O
carry	O
dramatically	O
different	O
mycobiota	O
.	O

Nevertheless	O
,	O
strong	O
Th17	O
responses	O
to	O
a	O
newly	O
introduced	O
opportunistic	O
commensal	O
fungus	O
are	O
potently	O
induced	O
independent	O
of	O
the	O
mycobiota	O
background	O
in	O
this	O
experimental	O
setting	O
.	O
Genetic	O
effects	O
on	O
the	O
commensal	O
microbiota	O
in	O
inflammatory	O
bowel	O
disease	O
patients	O
.	O

Several	O
bacteria	O
in	O
the	O
gut	O
microbiota	O
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
,	O
and	O
dozens	O
of	O
IBD	O
genetic	O
variants	O
have	O
been	O
identified	O
in	O
genome	O
-	O
wide	O
association	O
studies	O
.	O

However	O
,	O
the	O
role	O
of	O
the	O
microbiota	O
in	O
the	O
etiology	O
of	O
IBD	O
in	O
terms	O
of	O
host	O
genetic	O
susceptibility	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
studied	O
the	O
association	O
between	O
four	O
major	O
genetic	O
variants	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
IBD	O
and	O
bacterial	O
taxa	O
in	O
up	O
to	O
633	O
IBD	O
cases	O
.	O

We	O
performed	O
systematic	O
screening	O
for	O
associations	O
,	O
identifying	O
and	O
replicating	O
associations	O
between	O
NOD2	O
variants	O
and	O
two	O
taxa	O
:	O
the	O
Roseburia	B-bacteria
genus	I-bacteria
and	O
the	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
species	I-bacteria
.	O

By	O
exploring	O
the	O
overall	O
association	O
patterns	O
between	O
genes	O
and	O
bacteria	O
,	O
we	O
found	O
that	O
IBD	O
risk	O
alleles	O
were	O
significantly	O
enriched	O
for	O
associations	O
concordant	O
with	O
bacteria	O
-	O
IBD	O
associations	O
.	O

To	O
understand	O
the	O
significance	O
of	O
this	O
pattern	O
in	O
terms	O
of	O
the	O
study	O
design	O
and	O
known	O
effects	O
from	O
the	O
literature	O
,	O
we	O
used	O
counterfactual	O
principles	O
to	O
assess	O
the	O
fitness	O
of	O
a	O
few	O
parsimonious	O
gene	O
-	O
bacteria	O
-	O
IBD	O
causal	O
models	O
.	O

Our	O
analyses	O
showed	O
evidence	O
that	O
the	O
disease	O
risk	O
of	O
these	O
genetic	O
variants	O
were	O
likely	O
to	O
be	O
partially	O
mediated	O
by	O
the	O
microbiome	O
.	O

We	O
confirmed	O
these	O
results	O
in	O
extensive	O
simulation	O
studies	O
and	O
sensitivity	O
analyses	O
using	O
the	O
association	O
between	O
NOD2	O
and	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
as	O
a	O
case	O
study	O
.	O

The	O
Gut	O
Microbiota	O
in	O
Causation	O
,	O
Detection	O
,	O
and	O
Treatment	O
of	O
Cancer	O
.	O

The	O
gut	O
microbiota	O
has	O
emerged	O
as	O
an	O
important	O
consideration	O
in	O
clinical	O
oncology	O
.	O

The	O
role	O
of	O
the	O
microbiome	O
in	O
cancer	O
extends	O
beyond	O
causation	O
and	O
cancer	O
risk	O
.	O

It	O
is	O
now	O
known	O
that	O
the	O
microbiome	O
not	O
only	O
acts	O
at	O
a	O
local	O
epithelial	O
level	O
in	O
the	O
gut	O
but	O
also	O
modifies	O
immune	O
responses	O
within	O
intestinal	O
and	O
extraintestinal	O
tumors	O
.	O

Microbial	O
signaling	O
influences	O
the	O
clinical	O
course	O
of	O
cancer	O
including	O
the	O
efficacy	O
,	O
bioavailability	O
,	O
and	O
toxicity	O
of	O
chemotherapeutic	O
and	O
immunotherapy	O
agents	O
.	O

This	O
has	O
focused	O
research	O
on	O
microbiota	O
profiling	O
in	O
different	O
cancer	O
states	O
with	O
an	O
aim	O
of	O
developing	O
prognostic	O
biomarkers	O
of	O
risk	O
.	O

The	O
potential	O
value	O
of	O
microbiome	O
manipulation	O
with	O
live	O
biotherapeutics	O
or	O
microbial	O
transplantation	O
has	O
also	O
become	O
a	O
realistic	O
consideration	O
.	O

Maintenance	O
of	O
microbial	O
diversity	O
in	O
patients	O
with	O
cancer	O
is	O
a	O
variable	O
challenge	O
given	O
the	O
modifying	O
influences	O
of	O
the	O
tumor	O
itself	O
,	O
chemotherapy	O
,	O
nutritional	O
status	O
,	O
and	O
sporadic	O
antimicrobial	O
therapy	O
.	O

Here	O
,	O
we	O
address	O
current	O
evidence	O
for	O
the	O
role	O
of	O
the	O
microbiome	O
in	O
cancer	O
therapy	O
.	O

Wild	O
bacterial	O
probiotics	O
fed	O
to	O
larvae	O
of	O
mass	O
-	O
reared	O
Queensland	O
fruit	O
fly	O
[	O
Bactrocera	O
tryoni	O
(	O
Froggatt	O
)	O
]	O
do	O
not	O
impact	O
long	O
-	O
term	O
survival	O
,	O
mate	O
selection	O
,	O
or	O
locomotor	O
activity	O
.	O

Queensland	O
fruit	O
fly	O
[	O
Bactrocera	O
tryoni	O
(	O
Froggatt	O
)	O
,	O
Diptera	O
,	O
Tephritidae	O
]	O
is	O
the	O
most	O
devastating	O
insect	O
pest	O
impacting	O
Australian	O
horticulture	O
.	O

The	O
Sterile	O
Insect	O
Technique	O
(	O
SIT	O
)	O
is	O
an	O
important	O
component	O
of	O
tephritid	O
pest	O
management	O
programs	O
.	O

However	O
,	O
mass	O
-	O
rearing	O
and	O
irradiation	O
(	O
to	O
render	O
insects	O
sterile	O
)	O
may	O
reduce	O
the	O
fitness	O
and	O
performance	O
of	O
the	O
insect	O
,	O
including	O
the	O
ability	O
of	O
sterile	O
males	O
to	O
successfully	O
compete	O
for	O
wild	O
females	O
.	O

Manipulation	O
of	O
the	O
gut	O
microbiome	O
,	O
including	O
the	O
supplementation	O
with	O
bacterial	O
probiotics	O
shows	O
promise	O
for	O
enhancing	O
the	O
quality	O
of	O
mass	O
-	O
reared	O
sterile	O
flies	O
,	O
however	O
there	O
are	O
fewer	O
published	O
studies	O
targeting	O
the	O
larval	O
stage	O
.	O

In	O
this	O
study	O
,	O
we	O
supplemented	O
the	O
larval	O
stage	O
of	O
mass	O
-	O
reared	O
B	B-bacteria
.	I-bacteria
tryoni	I-bacteria
with	O
bacterial	O
probiotics	O
.	O

We	O
tested	O
several	O
individual	O
bacteria	O
that	O
had	O
been	O
previously	O
isolated	O
and	O
characterized	O
from	O
the	O
gut	O
of	O
wild	O
B	B-bacteria
.	I-bacteria
tryoni	I-bacteria
larvae	O
including	O
Asaia	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Enterobacter	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Lactobacillus	B-bacteria
sp	I-bacteria
.	I-bacteria
,	O
Leuconostoc	B-bacteria
sp	I-bacteria
.	O

We	O
also	O
tested	O
a	O
consortium	O
of	O
all	O
four	O
of	O
these	O
bacterial	O
isolates	O
.	O

The	O
fitness	O
parameters	O
tested	O
included	O
adult	O
survival	O
in	O
field	O
cages	O
,	O
laboratory	O
mate	O
selection	O
of	O
bacteria	O
supplemented	O
males	O
by	O
bacteria	O
nonsupplemented	O
females	O
,	O
and	O
laboratory	O
locomotor	O
activity	O
of	O
adult	O
flies	O
.	O

None	O
of	O
the	O
bacterial	O
probiotic	O
treatments	O
in	O
the	O
current	O
study	O
was	O
significantly	O
different	O
to	O
the	O
control	O
for	O
field	O
survival	O
,	O
mate	O
selection	O
or	O
locomotor	O
activity	O
of	O
adult	O
B	B-bacteria
.	I-bacteria
tryoni	I-bacteria
,	O
which	O
agree	O
with	O
some	O
of	O
the	O
other	O
studies	O
regarding	O
bacterial	O
probiotics	O
fed	O
to	O
the	O
larval	O
stage	O
of	O
tephritids	O
.	O

Future	O
work	O
is	O
needed	O
to	O
determine	O
if	O
feeding	O
the	O
same	O
,	O
and	O
/	O
or	O
other	O
probiotics	O
to	O
adults	O
,	O
as	O
opposed	O
to	O
larvae	O
can	O
positively	O
impact	O
survival	O
,	O
mating	O
performance	O
,	O
mating	O
competitiveness	O
and	O
locomotor	O
activity	O
of	O
B	B-bacteria
.	I-bacteria
tryoni	I-bacteria
.	O

The	O
bacterial	O
group	O
(	O
s	O
)	O
and	O
function	O
of	O
bacterial	O
species	O
that	O
increase	O
fitness	O
and	O
competitiveness	O
is	O
also	O
of	O
interest	O
to	O
tephritid	O
mass	O
-	O
rearing	O
programs	O
.	O

From	O
germ	O
theory	O
to	O
germ	O
therapy	O
.	O

Germ	O
theory	O
of	O
disease	O
and	O
Koch	O
'	O
s	O
postulates	O
has	O
been	O
governing	O
our	O
understanding	O
of	O
the	O
role	O
of	O
microbes	O
in	O
human	O
health	O
since	O
19th	O
century	O
.	O

The	O
discovery	O
of	O
Helicobacter	B-bacteria
pylori	I-bacteria
(	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
)	O
and	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
associated	O
diseases	O
has	O
typically	O
represented	O
the	O
concept	O
and	O
framework	O
of	O
Koch	O
'	O
s	O
postulates	O
.	O

Eradication	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
to	O
prevent	O
peptic	O
ulcers	O
recurrence	O
and	O
gastric	O
cancer	O
is	O
the	O
triumph	O
of	O
this	O
microbiology	O
paradigm	O
.	O

Advances	O
of	O
next	O
generation	O
sequencing	O
provide	O
great	O
insight	O
into	O
the	O
unculturable	O
microbes	O
and	O
show	O
trillions	O
of	O
microbes	O
have	O
evolved	O
with	O
human	O
beings	O
.	O

Research	O
into	O
the	O
microbiome	O
-	O
the	O
microbial	O
communities	O
(	O
microbiota	O
)	O
and	O
the	O
host	O
environment	O
that	O
they	O
inhabit	O
-	O
has	O
changed	O
our	O
understanding	O
about	O
microbes	O
in	O
human	O
health	O
and	O
disease	O
.	O

The	O
gut	O
microbiota	O
,	O
the	O
largest	O
reservoir	O
of	O
the	O
microbiome	O
in	O
human	O
,	O
plays	O
a	O
critical	O
role	O
in	O
our	O
catabolic	O
-	O
metabolism	O
and	O
immunity	O
.	O

This	O
review	O
will	O
show	O
the	O
changes	O
of	O
the	O
view	O
of	O
microbes	O
on	O
human	O
health	O
.	O

We	O
will	O
briefly	O
discuss	O
dysbiosis	O
,	O
the	O
disruption	O
of	O
symbiotic	O
relationship	O
between	O
the	O
host	O
and	O
microbiota	O
,	O
and	O
the	O
associated	O
diseases	O
.	O

This	O
leads	O
to	O
an	O
idea	O
to	O
manipulate	O
the	O
microbiota	O
,	O
either	O
by	O
restoring	O
missing	O
functions	O
or	O
by	O
eliminating	O
harmful	O
functions	O
,	O
to	O
prevent	O
or	O
treat	O
a	O
variety	O
of	O
diseases	O
.	O

Current	O
evidences	O
of	O
two	O
common	O
germ	O
therapies	O
,	O
fecal	O
microbiota	O
transplantation	O
and	O
probiotics	O
,	O
in	O
treating	O
diseases	O
will	O
be	O
reviewed	O
.	O

From	O
Infection	O
to	O
the	O
Microbiome	O
:	O
An	O
Evolving	O
Role	O
of	O
Microbes	O
in	O
Schizophrenia	O
.	O

The	O
study	O
of	O
microorganisms	O
such	O
as	O
bacteria	O
,	O
viruses	O
,	O
archaea	O
,	O
fungi	O
,	O
and	O
protozoa	O
in	O
the	O
context	O
of	O
psychiatric	O
disorders	O
may	O
be	O
surprising	O
to	O
some	O
.	O

This	O
intersection	O
of	O
disciplines	O
,	O
however	O
,	O
has	O
a	O
rich	O
history	O
and	O
is	O
currently	O
revitalized	O
by	O
newfound	O
functions	O
of	O
the	O
microbiome	O
and	O
the	O
gut	O
-	O
brain	O
axis	O
in	O
human	O
diseases	O
.	O

Schizophrenia	O
,	O
in	O
particular	O
,	O
fits	O
this	O
model	O
as	O
a	O
disorder	O
with	O
gene	O
and	O
environmental	O
roots	O
that	O
may	O
be	O
anchored	O
in	O
the	O
immune	O
system	O
.	O

In	O
this	O
context	O
,	O
the	O
combination	O
of	O
a	O
precisely	O
timed	O
pathogen	O
exposure	O
in	O
a	O
person	O
with	O
genetically	O
encoded	O
altered	O
immunity	O
may	O
have	O
especially	O
destructive	O
consequences	O
for	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Furthermore	O
,	O
significant	O
components	O
of	O
immunity	O
,	O
such	O
as	O
the	O
development	O
of	O
the	O
immune	O
response	O
and	O
the	O
concept	O
of	O
immune	O
tolerance	O
,	O
are	O
largely	O
dictated	O
by	O
the	O
commensal	O
residents	O
of	O
the	O
microbiome	O
.	O

When	O
this	O
community	O
of	O
microbes	O
is	O
imbalanced	O
,	O
perhaps	O
as	O
the	O
result	O
of	O
a	O
pathogen	O
invasion	O
,	O
stress	O
,	O
or	O
immune	O
gene	O
deficiency	O
,	O
a	O
pathological	O
cycle	O
of	O
localized	O
inflammation	O
,	O
endothelial	O
barrier	O
compromise	O
,	O
translocation	O
of	O
gut	O
-	O
derived	O
products	O
,	O
and	O
systemic	O
inflammation	O
may	O
ensue	O
.	O

If	O
these	O
pathologies	O
enable	O
access	O
of	O
gut	O
and	O
microbial	O
metabolites	O
and	O
immune	O
molecules	O
to	O
the	O
CNS	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
,	O
and	O
studies	O
of	O
the	O
gut	O
-	O
brain	O
axis	O
support	O
this	O
hypothesis	O
,	O
a	O
worsening	O
of	O
cognitive	O
deficits	O
and	O
psychiatric	O
symptoms	O
is	O
predicted	O
to	O
occur	O
in	O
susceptible	O
individuals	O
with	O
schizophrenia	O
.	O

In	O
this	O
chapter	O
,	O
we	O
review	O
the	O
role	O
of	O
microbes	O
in	O
various	O
stages	O
of	O
this	O
model	O
and	O
how	O
these	O
organisms	O
may	O
contribute	O
to	O
documented	O
phenotypes	O
of	O
schizophrenia	O
.	O

An	O
increased	O
understanding	O
of	O
the	O
role	O
of	O
pathogens	O
and	O
the	O
microbiome	O
in	O
psychiatric	O
disorders	O
will	O
better	O
guide	O
the	O
development	O
of	O
microbial	O
and	O
immune	O
-	O
based	O
therapeutics	O
for	O
disease	O
prevention	O
and	O
treatment	O
.	O

Combinatory	O
biotechnological	O
intervention	O
for	O
gut	O
microbiota	O
.	O

Individual	O
'	O
s	O
colonization	O
of	O
microbes	O
in	O
the	O
gut	O
is	O
by	O
birth	O
,	O
and	O
there	O
is	O
a	O
complex	O
interaction	O
between	O
the	O
gut	O
microbiome	O
and	O
human	O
.	O

This	O
interaction	O
happens	O
at	O
various	O
levels	O
like	O
genes	O
,	O
transcripts	O
,	O
proteins	O
,	O
and	O
metabolites	O
of	O
different	O
microbes	O
present	O
in	O
the	O
gut	O
.	O

The	O
complete	O
understanding	O
of	O
gut	O
microflora	O
can	O
be	O
studied	O
using	O
systems	O
biology	O
.	O

Further	O
,	O
the	O
contemporaneous	O
information	O
revealed	O
by	O
systems	O
biology	O
can	O
be	O
used	O
for	O
metabolic	O
engineering	O
of	O
gut	O
microbes	O
.	O

The	O
engineered	O
microbes	O
having	O
more	O
pronounced	O
activity	O
helps	O
to	O
rejuvenate	O
the	O
gut	O
microflora	O
that	O
plays	O
a	O
significant	O
role	O
in	O
the	O
management	O
of	O
various	O
life	O
-	O
threatening	O
diseases	O
due	O
to	O
microbial	O
imbalance	O
.	O

This	O
review	O
highlights	O
various	O
systems	O
biology	O
and	O
metabolic	O
engineering	O
approaches	O
.	O

Moreover	O
,	O
this	O
review	O
can	O
also	O
emphasize	O
on	O
the	O
different	O
computational	O
simulation	O
models	O
which	O
can	O
be	O
further	O
used	O
in	O
the	O
efficient	O
engineering	O
of	O
gut	O
microbes	O
.	O

The	O
genetically	O
engineered	O
models	O
can	O
help	O
one	O
to	O
predict	O
the	O
significant	O
pathways	O
present	O
in	O
microbes	O
that	O
can	O
be	O
modified	O
towards	O
diseases	O
treatments	O
.	O

[	O
Microbiome	O
,	O
diabetes	O
and	O
heart	O
:	O
a	O
novel	O
link	O
?	O
]	O

Patients	O
with	O
type	O
2	O
diabetes	O
suffer	O
from	O
a	O
high	O
cardiovascular	O
risk	O
.	O

The	O
underlying	O
pathomechanisms	O
are	O
not	O
fully	O
understood	O
and	O
treatment	O
options	O
are	O
correspondingly	O
limited	O
.	O

The	O
gut	O
microbiome	O
could	O
be	O
a	O
new	O
important	O
player	O
in	O
cardiometabolic	O
diseases	O
.	O

Dysbiosis	O
of	O
the	O
intestinal	O
flora	O
has	O
been	O
associated	O
with	O
insulin	O
resistance	O
,	O
diabetes	O
mellitus	O
and	O
cardiovascular	O
diseases	O
,	O
such	O
as	O
atherosclerosis	O
and	O
heart	O
failure	O
.	O

The	O
negative	O
cardiovascular	O
effects	O
of	O
type	O
2	O
diabetes	O
mellitus	O
could	O
therefore	O
partly	O
be	O
mediated	O
by	O
gut	O
microbiota	O
.	O

This	O
review	O
article	O
discusses	O
specific	O
gut	O
microbiome	O
-	O
associated	O
mechanisms	O
,	O
which	O
are	O
modulated	O
in	O
both	O
type	O
2	O
diabetes	O
and	O
cardiovascular	O
diseases	O
.	O

It	O
is	O
presented	O
how	O
intestinal	O
bacteria	O
may	O
contribute	O
to	O
systemic	O
low	O
-	O
grade	O
inflammation	O
.	O

Furthermore	O
,	O
it	O
is	O
shown	O
how	O
the	O
intestinal	O
microbiome	O
as	O
a	O
complex	O
metabolic	O
organ	O
is	O
able	O
to	O
influence	O
the	O
cardiometabolic	O
phenotype	O
via	O
production	O
of	O
bioactive	O
metabolites	O
.	O

Further	O
studies	O
will	O
have	O
to	O
demonstrate	O
whether	O
these	O
mechanisms	O
contribute	O
to	O
the	O
high	O
cardiovascular	O
risk	O
in	O
type	O
2	O
diabetes	O
.	O

Symbiont	O
-	O
mediated	O
chemical	O
defense	O
in	O
the	O
invasive	O
ladybird	O
Harmonia	O
axyridis	O
.	O

The	O
volatile	O
alkylpyrazines	O
methyl	O
-	O
and	O
methoxypyrazines	O
(	O
MPs	O
)	O
present	O
in	O
the	O
reflex	O
bleeds	O
of	O
coccinellid	O
beetles	O
such	O
as	O
the	O
harlequin	O
ladybird	O
beetle	O
Harmonia	O
axyridis	O
are	O
important	O
semiochemicals	O
that	O
function	O
in	O
antipredatory	O
defense	O
behavior	O
.	O

Pyrazines	O
have	O
also	O
been	O
coadapted	O
from	O
a	O
primarily	O
defensive	O
role	O
into	O
pheromones	O
that	O
function	O
in	O
intraspecific	O
communication	O
,	O
attraction	O
,	O
and	O
aggregation	O
behavior	O
.	O

However	O
,	O
the	O
biosynthesis	O
of	O
MPs	O
in	O
ladybird	O
beetles	O
is	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
MPs	O
could	O
be	O
produced	O
by	O
microbial	O
symbionts	O
in	O
H	B-bacteria
.	I-bacteria
axyridis	I-bacteria
,	O
which	O
generates	O
four	O
different	O
MPs	O
.	O

The	O
evaluation	O
of	O
tissue	O
-	O
specific	O
MP	O
production	O
showed	O
that	O
MP	O
concentrations	O
were	O
highest	O
in	O
the	O
gut	O
tissue	O
and	O
hemolymph	O
of	O
the	O
beetles	O
rather	O
than	O
the	O
fat	O
body	O
tissue	O
as	O
the	O
presumed	O
site	O
of	O
MP	O
biosynthesis	O
.	O

Furthermore	O
,	O
manipulation	O
of	O
gut	O
microbiota	O
by	O
antibiotic	O
-	O
containing	O
diets	O
resulted	O
in	O
a	O
lower	O
MP	O
content	O
in	O
adult	O
beetles	O
.	O

The	O
analysis	O
of	O
the	O
bacterial	O
community	O
of	O
the	O
digestive	O
tract	O
revealed	O
the	O
presence	O
of	O
bacteria	O
of	O
the	O
genera	O
Serratia	B-bacteria
and	O
Lactococcus	B-bacteria
which	O
are	O
reportedly	O
able	O
to	O
produce	O
MPs	O
.	O

In	O
line	O
with	O
the	O
known	O
diet	O
-	O
dependent	O
production	O
of	O
MP	O
in	O
H	B-bacteria
.	I-bacteria
axyridis	I-bacteria
,	O
we	O
determined	O
that	O
the	O
presence	O
or	O
relative	O
abundance	O
of	O
some	O
of	O
the	O
potential	O
MP	O
producers	O
(	O
Enterococcus	B-bacteria
and	O
Staphylococcus	B-bacteria
)	O
is	O
also	O
diet	O
-	O
dependent	O
.	O

We	O
hypothesize	O
a	O
potential	O
role	O
of	O
the	O
microbiota	O
in	O
MP	O
production	O
in	O
H	B-bacteria
.	I-bacteria
axyridis	I-bacteria
as	O
a	O
possible	O
example	O
for	O
outsourcing	O
the	O
synthesis	O
of	O
ecologically	O
important	O
semiochemicals	O
to	O
its	O
gut	O
bacteria	O
.	O

Intensity	O
of	O
Nosema	O
ceranae	O
infection	O
is	O
associated	O
with	O
specific	O
honey	O
bee	O
gut	O
bacteria	O
and	O
weakly	O
associated	O
with	O
gut	O
microbiome	O
structure	O
.	O

The	O
honey	O
bee	O
,	O
Apis	O
mellifera	O
,	O
pollinates	O
a	O
wide	O
variety	O
of	O
essential	O
crops	O
in	O
numerous	O
ecosystems	O
around	O
the	O
world	O
but	O
faces	O
many	O
modern	O
challenges	O
.	O

Among	O
these	O
,	O
the	O
microsporidian	O
pathogen	O
Nosema	O
ceranae	O
is	O
one	O
of	O
the	O
primary	O
detriments	O
to	O
honey	O
bee	O
health	O
.	O

Nosema	O
infects	O
the	O
honey	O
bee	O
gut	O
,	O
which	O
harbors	O
a	O
highly	O
specific	O
,	O
coevolved	O
microbiota	O
heavily	O
involved	O
in	O
bee	O
immune	O
function	O
and	O
nutrition	O
.	O

Here	O
,	O
we	O
extend	O
previous	O
work	O
investigating	O
interactions	O
between	O
the	O
honey	O
bee	O
gut	O
microbiome	O
and	O
N	O
.	O
ceranae	O
by	O
studying	O
experimentally	O
infected	O
bees	O
that	O
were	O
returned	O
to	O
their	O
colonies	O
and	O
sampled	O
5	O
,	O
10	O
,	O
and	O
21	O
days	O
post	O
-	O
infection	O
.	O

We	O
measured	O
Nosema	O
load	O
with	O
quantitative	O
PCR	O
and	O
characterized	O
microbiota	O
with	O
16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
.	O

We	O
found	O
significant	O
colony	O
level	O
variation	O
in	O
infection	O
levels	O
,	O
and	O
subtle	O
differences	O
between	O
the	O
microbiota	O
of	O
colonies	O
with	O
high	O
infection	O
levels	O
versus	O
those	O
with	O
low	O
infection	O
levels	O
.	O

Two	O
exact	O
sequence	O
variants	O
of	O
Gilliamella	B-bacteria
,	O
a	O
core	O
gut	O
symbiont	O
that	O
has	O
previously	O
been	O
associated	O
with	O
gut	O
dysbiosis	O
,	O
were	O
significantly	O
more	O
abundant	O
in	O
bees	O
from	O
colonies	O
with	O
high	O
Nosema	O
loads	O
versus	O
those	O
with	O
low	O
Nosema	O
loads	O
.	O

These	O
bacteria	O
deserve	O
further	O
study	O
to	O
determine	O
if	O
they	O
facilitate	O
more	O
intense	O
infection	O
by	O
Nosema	O
ceranae	O
.	O

Endocytosis	O
of	O
commensal	O
antigens	O
by	O
intestinal	O
epithelial	O
cells	O
regulates	O
mucosal	O
T	O
cell	O
homeostasis	O
.	O

Commensal	O
bacteria	O
influence	O
host	O
physiology	O
,	O
without	O
invading	O
host	O
tissues	O
.	O

We	O
show	O
that	O
proteins	O
from	O
segmented	O
filamentous	O
bacteria	O
(	O
SFB	O
)	O
are	O
transferred	O
into	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
through	O
adhesion	O
-	O
directed	O
endocytosis	O
that	O
is	O
distinct	O
from	O
the	O
clathrin	O
-	O
dependent	O
endocytosis	O
of	O
invasive	O
pathogens	O
.	O

This	O
process	O
transfers	O
microbial	O
cell	O
wall	O
-	O
associated	O
proteins	O
,	O
including	O
an	O
antigen	O
that	O
stimulates	O
mucosal	O
T	O
helper	O
17	O
(	O
TH17	O
)	O
cell	O
differentiation	O
,	O
into	O
the	O
cytosol	O
of	O
IECs	O
in	O
a	O
cell	O
division	O
control	O
protein	O
42	O
homolog	O
(	O
CDC42	O
)	O
-	O
dependent	O
manner	O
.	O

Removal	O
of	O
CDC42	O
activity	O
in	O
vivo	O
led	O
to	O
disruption	O
of	O
endocytosis	O
induced	O
by	O
SFB	O
and	O
decreased	O
epithelial	O
antigen	O
acquisition	O
,	O
with	O
consequent	O
loss	O
of	O
mucosal	O
TH17	O
cells	O
.	O

Our	O
findings	O
demonstrate	O
direct	O
communication	O
between	O
a	O
resident	O
gut	O
microbe	O
and	O
the	O
host	O
and	O
show	O
that	O
under	O
physiological	O
conditions	O
,	O
IECs	O
acquire	O
antigens	O
from	O
commensal	O
bacteria	O
for	O
generation	O
of	O
T	O
cell	O
responses	O
to	O
the	O
resident	O
microbiota	O
.	O

Pollen	O
reverses	O
decreased	O
lifespan	O
,	O
altered	O
nutritional	O
metabolism	O
and	O
suppressed	O
immunity	O
in	O
honey	O
bees	O
(	O
Apis	O
mellifera	O
)	O
treated	O
with	O
antibiotics	O
.	O

Nutrition	O
is	O
involved	O
in	O
regulating	O
multiple	O
aspects	O
of	O
honey	O
bee	O
biology	O
such	O
as	O
caste	O
,	O
immunity	O
,	O
lifespan	O
,	O
growth	O
and	O
behavioral	O
development	O
.	O

Deformed	O
wing	O
virus	O
(	O
DWV	O
)	O
is	O
a	O
major	O
pathogenic	O
factor	O
which	O
threatens	O
honey	O
bee	O
populations	O
,	O
and	O
its	O
replication	O
is	O
regulated	O
by	O
the	O
nutrition	O
status	O
and	O
immune	O
response	O
of	O
honey	O
bees	O
.	O

The	O
alimentary	O
canal	O
of	O
the	O
honey	O
bee	O
is	O
home	O
to	O
a	O
diverse	O
microbial	O
community	O
that	O
provides	O
essential	O
nutrients	O
and	O
serves	O
to	O
bolster	O
immune	O
responses	O
.	O

However	O
,	O
to	O
what	O
extent	O
gut	O
bacteria	O
affect	O
honey	O
bee	O
nutrition	O
metabolism	O
and	O
immunity	O
with	O
respect	O
to	O
DWV	O
has	O
not	O
been	O
investigated	O
fully	O
.	O

In	O
this	O
study	O
,	O
newly	O
emerged	O
worker	O
bees	O
were	O
subjected	O
to	O
four	O
diets	O
that	O
contained	O
(	O
1	O
)	O
pollen	O
,	O
(	O
2	O
)	O
pollen	O
and	O
antibiotics	O
,	O
(	O
3	O
)	O
neither	O
pollen	O
nor	O
antibiotics	O
or	O
(	O
4	O
)	O
antibiotics	O
alone	O
.	O

The	O
expression	O
level	O
of	O
two	O
nutrition	O
genes	O
target	O
of	O
rapamycin	O
(	O
tor	O
)	O
and	O
insulin	O
like	O
peptide	O
(	O
ilp1	O
)	O
,	O
one	O
nutritional	O
marker	O
gene	O
vitellogenin	O
(	O
vg	O
)	O
,	O
five	O
major	O
royal	O
jelly	O
protein	O
genes	O
(	O
mrjp1	O
-	O
5	O
)	O
,	O
one	O
antimicrobial	O
peptide	O
regulating	O
gene	O
relish	O
(	O
rel	O
)	O
,	O
and	O
DWV	O
virus	O
titer	O
and	O
its	O
replication	O
intermediate	O
,	O
negative	O
RNA	O
strand	O
,	O
were	O
determined	O
by	O
qRT	O
-	O
PCR	O
from	O
the	O
honey	O
bees	O
at	O
7	O
days	O
post	O
-	O
antibiotic	O
treatment	O
.	O

Additionally	O
,	O
honey	O
bee	O
head	O
mass	O
and	O
survival	O
rate	O
were	O
measured	O
.	O

We	O
observed	O
that	O
antibiotics	O
decreased	O
the	O
expression	O
of	O
tor	O
and	O
rel	O
,	O
and	O
increased	O
DWV	O
titer	O
and	O
its	O
replication	O
activity	O
.	O

Expression	O
of	O
ilp1	O
,	O
mrjp1	O
-	O
5	O
and	O
vg	O
,	O
and	O
honey	O
bee	O
head	O
mass	O
were	O
also	O
reduced	O
compared	O
with	O
bees	O
on	O
a	O
pollen	O
diet	O
.	O

Antibiotics	O
also	O
caused	O
a	O
significant	O
drop	O
in	O
survivorship	O
,	O
which	O
could	O
be	O
rescued	O
by	O
addition	O
of	O
pollen	O
to	O
the	O
diet	O
.	O

Of	O
importance	O
,	O
pollen	O
could	O
partially	O
rescue	O
the	O
loss	O
of	O
vg	O
and	O
mrjp2	O
while	O
also	O
increasing	O
the	O
head	O
mass	O
of	O
antibiotic	O
-	O
treated	O
bees	O
.	O

Our	O
results	O
illuminate	O
the	O
roles	O
of	O
bacteria	O
in	O
honey	O
bee	O
nutrition	O
,	O
metabolism	O
and	O
immunity	O
,	O
which	O
confer	O
the	O
ability	O
to	O
inhibit	O
virus	O
replication	O
,	O
extend	O
honey	O
bee	O
lifespan	O
and	O
improve	O
overall	O
health	O
.	O

Phosphate	O
Binders	O
and	O
Nonphosphate	O
Effects	O
in	O
the	O
Gastrointestinal	O
Tract	O
.	O

Phosphate	O
binders	O
are	O
commonly	O
prescribed	O
in	O
patients	O
with	O
end	O
-	O
stage	O
kidney	O
disease	O
to	O
prevent	O
and	O
treat	O
hyperphosphatemia	O
.	O

These	O
binders	O
are	O
usually	O
associated	O
with	O
gastrointestinal	O
distress	O
,	O
may	O
bind	O
molecules	O
other	O
than	O
phosphate	O
,	O
and	O
may	O
alter	O
the	O
gut	O
microbiota	O
,	O
altogether	O
having	O
systemic	O
effects	O
unrelated	O
to	O
phosphate	O
control	O
.	O

Sevelamer	O
is	O
the	O
most	O
studied	O
of	O
the	O
available	O
binders	O
for	O
nonphosphate	O
-	O
related	O
effects	O
including	O
binding	O
to	O
bile	O
acids	O
,	O
endotoxins	O
,	O
gut	O
microbiota	O
-	O
derived	O
metabolites	O
,	O
and	O
advanced	O
glycation	O
end	O
products	O
.	O

Other	O
binders	O
(	O
calcium	O
-	O
and	O
noncalcium	O
-	O
based	O
binders	O
)	O
may	O
bind	O
vitamins	O
,	O
such	O
as	O
vitamin	O
K	O
and	O
folic	O
acid	O
.	O

Moreover	O
,	O
the	O
relatively	O
new	O
iron	O
-	O
based	O
phosphate	O
binders	O
may	O
alter	O
the	O
gut	O
microbiota	O
,	O
as	O
some	O
of	O
the	O
iron	O
or	O
organic	O
ligands	O
may	O
be	O
used	O
by	O
the	O
gastrointestinal	O
bacteria	O
.	O

The	O
objective	O
of	O
this	O
narrative	O
review	O
is	O
to	O
provide	O
the	O
current	O
evidence	O
for	O
the	O
nonphosphate	O
effects	O
of	O
phosphate	O
binders	O
on	O
gastrointestinal	O
function	O
,	O
nutrient	O
and	O
molecule	O
binding	O
,	O
and	O
the	O
gut	O
microbiome	O
.	O

Alterations	O
in	O
bacterial	O
communities	O
,	O
SCFA	O
and	O
biomarkers	O
in	O
an	O
elderly	O
HIV	O
-	O
positive	O
and	O
HIV	O
-	O
negative	O
population	O
in	O
western	O
Mexico	O
.	O

BACKGROUND	O
:	O
The	O
study	O
of	O
stool	O
microbiota	O
has	O
taken	O
great	O
relevance	O
in	O
the	O
last	O
years	O
,	O
given	O
its	O
role	O
in	O
the	O
maintenance	O
of	O
the	O
intestinal	O
metabolic	O
,	O
physiological	O
,	O
and	O
immunological	O
homeostasis	O
,	O
as	O
well	O
as	O
,	O
its	O
effect	O
over	O
HIV	O
biomarkers	O
levels	O
such	O
as	O
CD4	O
/	O
CD8	O
ratio	O
,	O
high	O
sensitivity	O
C	O
-	O
Reactive	O
Protein	O
(	O
hs	O
-	O
CRP	O
)	O
,	O
related	O
to	O
poor	O
outcomes	O
(	O
rapid	O
progression	O
to	O
AIDS	O
)	O
.	O

Several	O
efforts	O
have	O
been	O
made	O
to	O
characterize	O
the	O
gut	O
microbiome	O
.	O

In	O
HIV	O
infection	O
,	O
most	O
of	O
the	O
studies	O
report	O
the	O
presence	O
of	O
a	O
dysbiotic	O
pattern	O
;	O
however	O
,	O
few	O
of	O
them	O
have	O
made	O
an	O
approach	O
in	O
elderly	O
HIV	O
-	O
positive	O
subjects	O
despite	O
the	O
fact	O
that	O
nowadays	O
this	O
subgroup	O
is	O
rising	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
composition	O
of	O
faecal	O
microbiota	O
,	O
Short	O
Chain	O
Fatty	O
Acids	O
(	O
SCFAs	O
)	O
,	O
and	O
systemic	O
biomarkers	O
between	O
elderly	O
HIV	O
-	O
positive	O
and	O
HIV	O
-	O
negative	O
subjects	O
.	O

METHODS	O
:	O
A	O
cross	O
-	O
sectional	O
study	O
with	O
18	O
HIV	O
-	O
negative	O
controls	O
and	O
20	O
HIV	O
-	O
positive	O
patients	O
.	O

The	O
quantification	O
of	O
Bacteroidetes	B-bacteria
,	O
Firmicutes	B-bacteria
,	O
Proteobacteria	B-bacteria
,	O
Actinobacteria	B-bacteria
,	O
Lactobacillus	B-bacteria
,	O
Enterobacteriaceae	B-bacteria
,	O
Bifidobacterium	B-bacteria
,	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Clostridium	B-bacteria
leptum	I-bacteria
,	O
Clostridium	B-bacteria
coccoides	I-bacteria
was	O
performed	O
in	O
faecal	O
samples	O
by	O
qPCR	O
.	O

The	O
analysis	O
was	O
performed	O
by	O
calculating	O
the	O
DeltaCq	O
of	O
each	O
microorganism	O
using	O
16S	O
rDNA	O
as	O
a	O
reference	O
gene	O
.	O

Faecal	O
SCFAs	O
were	O
measured	O
by	O
HPLC	O
.	O

The	O
hs	O
-	O
CRP	O
and	O
sCD14	O
were	O
performed	O
by	O
ELISA	O
.	O

RESULTS	O
:	O
An	O
increase	O
in	O
the	O
Firmicutes	B-bacteria
/	O
Bacteroidetes	B-bacteria
ratio	O
,	O
coupled	O
with	O
a	O
significant	O
increase	O
in	O
the	O
proteobacteria	B-bacteria
phylum	O
was	O
detected	O
in	O
HIV	O
-	O
positive	O
subjects	O
.	O

In	O
contrast	O
,	O
a	O
decrease	O
in	O
the	O
Clostridium	B-bacteria
leptum	I-bacteria
group	O
was	O
observed	O
.	O

Nevertheless	O
,	O
these	O
elderly	O
HIV	O
-	O
positive	O
patients	O
showed	O
higher	O
levels	O
of	O
total	O
SCFAs	O
mainly	O
by	O
an	O
augmented	O
propionic	O
acid	O
values	O
,	O
compared	O
to	O
HIV	O
-	O
negative	O
subjects	O
.	O

Whereas	O
high	O
levels	O
of	O
hs	O
-	O
CRP	O
were	O
positively	O
correlated	O
with	O
sCD14	O
in	O
the	O
HIV	O
-	O
positive	O
group	O
.	O

CONCLUSIONS	O
:	O
Alterations	O
in	O
bacterial	O
communities	O
reveals	O
a	O
dysbiotic	O
state	O
related	O
to	O
an	O
unbalance	O
of	O
faecal	O
SCFAs	O
.	O

Therefore	O
,	O
these	O
intestinal	O
conditions	O
might	O
drive	O
an	O
increase	O
of	O
poor	O
prognostic	O
biomarkers	O
in	O
elderly	O
HIV	O
-	O
positive	O
subjects	O
.	O

An	O
overview	O
of	O
microbiome	O
based	O
strategies	O
on	O
anti	O
-	O
obesity	O
.	O

With	O
the	O
significant	O
global	O
obesity	O
epidemic	O
and	O
emerging	O
strong	O
scientific	O
evidence	O
that	O
connected	O
gut	O
microbiota	O
to	O
obesity	O
,	O
intervening	O
obesity	O
by	O
targeting	O
gut	O
microbiota	O
has	O
become	O
a	O
trendy	O
strategy	O
.	O

Particularly	O
the	O
application	O
of	O
probiotics	O
has	O
become	O
remarkably	O
popular	O
because	O
of	O
their	O
expected	O
association	O
with	O
gut	O
microbiota	O
modulation	O
.	O

Although	O
there	O
are	O
many	O
literatures	O
on	O
the	O
effects	O
of	O
probiotics	O
in	O
obese	O
animal	O
models	O
,	O
most	O
of	O
them	O
reported	O
the	O
effects	O
of	O
probiotic	O
bacteria	O
on	O
metabolic	O
indications	O
with	O
limited	O
information	O
on	O
anti	O
-	O
obesity	O
itself	O
.	O

Besides	O
,	O
some	O
probiotics	O
have	O
been	O
shown	O
to	O
reduce	O
certain	O
metabolic	O
symptoms	O
but	O
they	O
failed	O
to	O
achieve	O
weight	O
loss	O
.	O

This	O
report	O
reviewed	O
the	O
current	O
literatures	O
on	O
the	O
anti	O
-	O
obesity	O
effects	O
of	O
next	O
-	O
generation	O
probiotics	O
in	O
various	O
animal	O
obesity	O
models	O
and	O
discussed	O
the	O
beneficial	O
potential	O
of	O
fecal	O
microbiota	O
transplantation	O
in	O
treating	O
obesity	O
in	O
humans	O
.	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
help	O
guide	O
further	O
research	O
improve	O
the	O
probiotic	O
bacteria	O
experiments	O
in	O
more	O
precise	O
animal	O
obesity	O
models	O
by	O
standardizing	O
the	O
anti	O
-	O
obesogenesis	O
,	O
obesity	O
control	O
,	O
and	O
treatment	O
assays	O
and	O
hopefully	O
the	O
evidence	O
-	O
based	O
investigations	O
on	O
harnessing	O
gut	O
microbiota	O
through	O
next	O
-	O
generation	O
probiotics	O
or	O
fecal	O
microbiota	O
transplantation	O
will	O
develop	O
new	O
interventions	O
to	O
promote	O
and	O
achieve	O
anti	O
-	O
obesity	O
.	O

Dietary	O
coconut	O
oil	O
ameliorates	O
skin	O
contact	O
hypersensitivity	O
through	O
mead	O
acid	O
production	O
in	O
mice	O
.	O

Coconut	O
oil	O
is	O
used	O
as	O
a	O
dietary	O
oil	O
worldwide	O
,	O
and	O
its	O
healthy	O
effects	O
are	O
recognized	O
by	O
the	O
fact	O
that	O
coconut	O
oil	O
is	O
easy	O
to	O
digest	O
,	O
helps	O
in	O
weight	O
management	O
,	O
increases	O
healthy	O
cholesterol	O
,	O
and	O
provides	O
instant	O
energy	O
.	O

Although	O
topical	O
application	O
of	O
coconut	O
oil	O
is	O
known	O
to	O
reduce	O
skin	O
infection	O
and	O
inflammation	O
,	O
whether	O
dietary	O
coconut	O
oil	O
has	O
any	O
role	O
in	O
decreasing	O
skin	O
inflammation	O
is	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
the	O
impact	O
of	O
dietary	O
coconut	O
oil	O
in	O
allergic	O
skin	O
inflammation	O
by	O
using	O
a	O
mouse	O
model	O
of	O
contact	O
hypersensitivity	O
(	O
CHS	O
)	O
.	O

Mice	O
maintained	O
on	O
coconut	O
oil	O
showed	O
amelioration	O
of	O
skin	O
inflammation	O
and	O
increased	O
levels	O
of	O
cis	O
-	O
5	O
,	O
8	O
,	O
11	O
-	O
eicosatrienoic	O
acid	O
(	O
mead	O
acid	O
)	O
in	O
serum	O
.	O

Intraperitoneal	O
injection	O
of	O
mead	O
acid	O
inhibited	O
CHS	O
and	O
reduced	O
the	O
number	O
of	O
neutrophils	O
infiltrating	O
to	O
the	O
skin	O
.	O

Detailed	O
mechanistic	O
studies	O
unveiled	O
that	O
mead	O
acid	O
inhibited	O
the	O
directional	O
migration	O
of	O
neutrophils	O
by	O
inhibiting	O
the	O
filamentous	O
actin	O
polymerization	O
and	O
leukotriene	O
B4	O
production	O
required	O
for	O
secondary	O
recruitment	O
of	O
neutrophils	O
.	O

Our	O
findings	O
provide	O
valuable	O
insights	O
into	O
the	O
preventive	O
roles	O
of	O
coconut	O
oil	O
and	O
mead	O
acid	O
against	O
skin	O
inflammation	O
,	O
thereby	O
offering	O
attractive	O
therapeutic	O
possibilities	O
.	O

TarSynFlow	O
,	O
a	O
workflow	O
for	O
bacterial	O
genome	O
comparisons	O
that	O
revealed	O
genes	O
putatively	O
involved	O
in	O
the	O
probiotic	O
character	O
of	O
Shewanella	B-bacteria
putrefaciens	I-bacteria
strain	I-bacteria
Pdp11	I-bacteria
.	O

Probiotic	O
microorganisms	O
are	O
of	O
great	O
interest	O
in	O
clinical	O
,	O
livestock	O
and	O
aquaculture	O
.	O

Knowledge	O
of	O
the	O
genomic	O
basis	O
of	O
probiotic	O
characteristics	O
can	O
be	O
a	O
useful	O
tool	O
to	O
understand	O
why	O
some	O
strains	O
can	O
be	O
pathogenic	O
while	O
others	O
are	O
probiotic	O
in	O
the	O
same	O
species	O
.	O

An	O
automatized	O
workflow	O
called	O
TarSynFlow	O
(	O
Targeted	O
Synteny	O
Workflow	O
)	O
has	O
been	O
then	O
developed	O
to	O
compare	O
finished	O
or	O
draft	O
bacterial	O
genomes	O
based	O
on	O
a	O
set	O
of	O
proteins	O
.	O

When	O
used	O
to	O
analyze	O
the	O
finished	O
genome	O
of	O
the	O
probiotic	O
strain	O
Pdp11	B-bacteria
of	O
Shewanella	B-bacteria
putrefaciens	I-bacteria
and	O
genome	O
drafts	O
from	O
seven	O
known	O
non	O
-	O
probiotic	O
strains	O
of	O
the	O
same	O
species	O
obtained	O
in	O
this	O
work	O
,	O
15	O
genes	O
were	O
found	O
exclusive	O
of	O
Pdp11	O
.	O

Their	O
presence	O
was	O
confirmed	O
by	O
PCR	O
using	O
Pdp11	O
-	O
specific	O
primers	O
.	O

Functional	O
inspection	O
of	O
the	O
15	O
genes	O
allowed	O
us	O
to	O
hypothesize	O
that	O
Pdp11	O
underwent	O
genome	O
rearrangements	O
spurred	O
by	O
plasmids	O
and	O
mobile	O
elements	O
.	O

As	O
a	O
result	O
,	O
Pdp11	O
presents	O
specific	O
proteins	O
for	O
gut	O
colonization	O
,	O
bile	O
salt	O
resistance	O
and	O
gut	O
pathogen	O
adhesion	O
inhibition	O
,	O
which	O
can	O
explain	O
some	O
probiotic	O
features	O
of	O
Pdp11	O
.	O

The	O
microbiome	O
,	O
cancer	O
,	O
and	O
cancer	O
therapy	O
.	O

With	O
the	O
advent	O
of	O
next	O
-	O
generation	O
sequencing	O
,	O
we	O
have	O
an	O
unprecedented	O
ability	O
to	O
study	O
tumor	O
and	O
host	O
genomes	O
as	O
well	O
as	O
those	O
of	O
the	O
vast	O
array	O
of	O
microorganisms	O
that	O
exist	O
within	O
living	O
organisms	O
.	O

Evidence	O
now	O
suggests	O
that	O
these	O
microbes	O
may	O
confer	O
susceptibility	O
to	O
certain	O
cancers	O
and	O
may	O
also	O
influence	O
response	O
to	O
therapeutics	O
.	O

A	O
prime	O
example	O
of	O
this	O
is	O
seen	O
with	O
immunotherapy	O
,	O
for	O
which	O
gut	O
microbes	O
have	O
been	O
implicated	O
in	O
influencing	O
therapeutic	O
responses	O
in	O
preclinical	O
models	O
and	O
patient	O
cohorts	O
.	O

However	O
,	O
these	O
microbes	O
may	O
influence	O
responses	O
to	O
other	O
forms	O
of	O
therapy	O
as	O
well	O
and	O
may	O
also	O
affect	O
treatment	O
-	O
associated	O
toxicity	O
.	O

Based	O
on	O
these	O
influences	O
,	O
there	O
is	O
growing	O
interest	O
in	O
targeting	O
these	O
microbes	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
diseases	O
.	O

Yet	O
complexities	O
exist	O
,	O
and	O
a	O
deeper	O
understanding	O
of	O
host	O
-	O
microbiome	O
interactions	O
is	O
critical	O
to	O
realization	O
of	O
the	O
full	O
potential	O
of	O
such	O
approaches	O
.	O

These	O
concepts	O
and	O
the	O
means	O
through	O
which	O
such	O
findings	O
may	O
be	O
translated	O
into	O
the	O
clinic	O
will	O
be	O
discussed	O
herein	O
.	O

Gut	O
mucosal	O
virome	O
alterations	O
in	O
ulcerative	O
colitis	O
.	O

OBJECTIVE	O
:	O
The	O
pathogenesis	O
of	O
UC	O
relates	O
to	O
gut	O
microbiota	O
dysbiosis	O
.	O

We	O
postulate	O
that	O
alterations	O
in	O
the	O
viral	O
community	O
populating	O
the	O
intestinal	O
mucosa	O
play	O
an	O
important	O
role	O
in	O
UC	O
pathogenesis	O
.	O

This	O
study	O
aims	O
to	O
characterise	O
the	O
mucosal	O
virome	O
and	O
their	O
functions	O
in	O
health	O
and	O
UC	O
.	O

DESIGN	O
:	O
Deep	O
metagenomics	O
sequencing	O
of	O
virus	O
-	O
like	O
particle	O
preparations	O
and	O
bacterial	O
16S	O
rRNA	O
sequencing	O
were	O
performed	O
on	O
the	O
rectal	O
mucosa	O
of	O
167	O
subjects	O
from	O
three	O
different	O
geographical	O
regions	O
in	O
China	O
(	O
UC	O
=	O
91	O
;	O
healthy	O
controls	O
=	O
76	O
)	O
.	O

Virome	O
and	O
bacteriome	O
alterations	O
in	O
UC	O
mucosa	O
were	O
assessed	O
and	O
correlated	O
with	O
patient	O
metadata	O
.	O

We	O
applied	O
partition	O
around	O
medoids	O
clustering	O
algorithm	O
and	O
classified	O
mucosa	O
viral	O
communities	O
into	O
two	O
clusters	O
,	O
referred	O
to	O
as	O
mucosal	O
virome	O
metacommunities	O
1	O
and	O
2	O
.	O

RESULTS	O
:	O
In	O
UC	O
,	O
there	O
was	O
an	O
expansion	O
of	O
mucosa	O
viruses	O
,	O
particularly	O
Caudovirales	O
bacteriophages	O
,	O
and	O
a	O
decrease	O
in	O
mucosa	O
Caudovirales	O
diversity	O
,	O
richness	O
and	O
evenness	O
compared	O
with	O
healthy	O
controls	O
.	O

Altered	O
mucosal	O
virome	O
correlated	O
with	O
intestinal	O
inflammation	O
.	O

Interindividual	O
dissimilarity	O
between	O
mucosal	O
viromes	O
was	O
higher	O
in	O
UC	O
than	O
controls	O
.	O

Escherichia	B-bacteria
phage	O
and	O
Enterobacteria	B-bacteria
phage	O
were	O
more	O
abundant	O
in	O
the	O
mucosa	O
of	O
UC	O
than	O
controls	O
.	O

Compared	O
with	O
metacommunity	O
1	O
,	O
metacommunity	O
2	O
was	O
predominated	O
by	O
UC	O
subjects	O
and	O
displayed	O
a	O
significant	O
loss	O
of	O
various	O
viral	O
species	O
.	O

Patients	O
with	O
UC	O
showed	O
substantial	O
abrogation	O
of	O
diverse	O
viral	O
functions	O
,	O
whereas	O
multiple	O
viral	O
functions	O
,	O
particularly	O
functions	O
of	O
bacteriophages	O
associated	O
with	O
host	O
bacteria	O
fitness	O
and	O
pathogenicity	O
,	O
were	O
markedly	O
enriched	O
in	O
UC	O
mucosa	O
.	O

Intensive	O
transkingdom	O
correlations	O
between	O
mucosa	O
viruses	O
and	O
bacteria	O
were	O
significantly	O
depleted	O
in	O
UC	O
.	O

CONCLUSION	O
:	O
We	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
UC	O
is	O
characterised	O
by	O
substantial	O
alterations	O
of	O
the	O
mucosa	O
virobiota	O
with	O
functional	O
distortion	O
.	O

Enrichment	O
of	O
Caudovirales	O
bacteriophages	O
,	O
increased	O
phage	O
/	O
bacteria	O
virulence	O
functions	O
and	O
loss	O
of	O
viral	O
-	O
bacterial	O
correlations	O
in	O
the	O
UC	O
mucosa	O
highlight	O
that	O
mucosal	O
virome	O
may	O
play	O
an	O
important	O
role	O
in	O
UC	O
pathogenesis	O
.	O

Impact	O
of	O
Short	O
-	O
Term	O
Exposure	O
of	O
AuNCs	O
on	O
the	O
Gut	O
Microbiota	O
of	O
BALB	O
/	O
c	O
Mice	O
.	O

The	O
widespread	O
application	O
of	O
nanoparticles	O
causes	O
extensive	O
public	O
concern	O
on	O
their	O
biological	O
safety	O
.	O

However	O
,	O
up	O
to	O
date	O
,	O
few	O
reports	O
have	O
been	O
associated	O
with	O
the	O
impact	O
of	O
metal	O
nanoparticles	O
on	O
gut	O
microbiota	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
gold	O
nanoclusters	O
(	O
AuNCs	O
)	O
were	O
orally	O
administered	O
to	O
BALB	O
/	O
c	O
mice	O
for	O
7	O
days	O
,	O
and	O
the	O
dynamic	O
effects	O
of	O
AuNCs	O
on	O
gut	O
microbiota	O
were	O
investigated	O
at	O
0	O
h	O
,	O
4	O
h	O
,	O
8	O
h	O
,	O
1	O
d	O
,	O
3	O
d	O
and	O
7	O
d	O
,	O
respectively	O
.	O

Using	O
high	O
-	O
throughput	O
sequencing	O
of	O
V4	O
-	O
V5	O
regions	O
of	O
the	O
16S	O
rRNA	O
gene	O
on	O
the	O
Illumina	O
MiSeq	O
platform	O
,	O
we	O
found	O
that	O
gavage	O
of	O
AuNCs	O
did	O
not	O
significantly	O
change	O
the	O
gut	O
microbiota	O
diversity	O
and	O
community	O
at	O
the	O
initial	O
3	O
days	O
.	O

Bacteroidetes	B-bacteria
,	O
Firmicutes	B-bacteria
,	O
Proteobacteria	B-bacteria
,	O
Deferribacteres	B-bacteria
,	O
Tenericutes	B-bacteria
and	O
Actinobacteria	B-bacteria
were	O
the	O
six	O
most	O
abundant	O
phylum	O
in	O
the	O
control	O
and	O
AuNCs	O
groups	O
.	O

However	O
,	O
the	O
phylum	O
Proteobacteria	B-bacteria
was	O
significantly	O
increased	O
by	O
AuNCs	O
at	O
7	O
d	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
the	O
genus	O
level	O
,	O
Roseburia	B-bacteria
were	O
notably	O
decreased	O
while	O
Staphylococcus	B-bacteria
,	O
Ureaplasma	B-bacteria
and	O
Methylobacterium	B-bacteria
were	O
dramatically	O
increased	O
by	O
AuNCs	O
at	O
7	O
d	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Taken	O
together	O
,	O
gavage	O
of	O
AuNCs	O
shifted	O
the	O
bacterial	O
composition	O
at	O
7	O
d	O
.	O
This	O
is	O
the	O
first	O
research	O
to	O
investigate	O
the	O
toxicity	O
of	O
AuNCs	O
from	O
the	O
perspective	O
of	O
gut	O
microbiota	O
and	O
opens	O
up	O
a	O
new	O
avenue	O
for	O
the	O
safety	O
or	O
toxicity	O
evaluation	O
of	O
AuNCs	O
.	O

Effect	O
of	O
green	O
tea	O
and	O
mulberry	O
leaf	O
powders	O
on	O
the	O
gut	O
microbiota	O
of	O
chicken	O
.	O

BACKGROUND	O
:	O
The	O
gut	O
microbiota	O
is	O
closely	O
correlated	O
with	O
host	O
health	O
and	O
is	O
strongly	O
influenced	O
by	O
food	O
composition	O
.	O

Chinese	O
herbs	O
are	O
usually	O
used	O
as	O
natural	O
feed	O
additives	O
in	O
livestock	O
production	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
assessed	O
the	O
influence	O
of	O
diet	O
supplementation	O
with	O
green	O
tea	O
and	O
mulberry	O
leaf	O
powders	O
on	O
the	O
chicken	O
gut	O
microbiota	O
.	O

The	O
gut	O
microbiota	O
compositions	O
were	O
determined	O
using	O
16S	O
rDNA	O
sequencing	O
.	O

RESULTS	O
:	O
Enhanced	O
relative	O
abundances	O
of	O
Bacteroides	B-bacteria
,	O
Prevotella	B-bacteria
,	O
and	O
Megamonas	B-bacteria
were	O
found	O
in	O
the	O
chicken	O
gut	O
when	O
mulberry	O
leaf	O
powder	O
was	O
added	O
to	O
diet	O
.	O

Conversely	O
,	O
a	O
higher	O
abundance	O
of	O
potentially	O
pathogenic	O
Gallibacterium	B-bacteria
was	O
found	O
in	O
the	O
chicken	O
gut	O
when	O
the	O
diet	O
was	O
supplemented	O
with	O
green	O
tea	O
powder	O
.	O

These	O
results	O
indicated	O
that	O
green	O
tea	O
powder	O
and	O
mulberry	O
leaf	O
powder	O
can	O
greatly	O
affect	O
the	O
gut	O
microbiota	O
of	O
chickens	O
by	O
changing	O
their	O
compositions	O
.	O

CONCLUSIONS	O
:	O
It	O
is	O
imperative	O
to	O
examine	O
and	O
evaluate	O
the	O
effects	O
of	O
Chinese	O
herbs	O
on	O
animal	O
health	O
before	O
they	O
are	O
introduced	O
as	O
feed	O
additives	O
in	O
animal	O
production	O
.	O

A	O
Preventive	O
Prebiotic	O
Supplementation	O
Improves	O
the	O
Sweet	O
Taste	O
Perception	O
in	O
Diet	O
-	O
Induced	O
Obese	O
Mice	O
.	O

Orosensory	O
perception	O
of	O
sweet	O
stimulus	O
is	O
blunted	O
in	O
diet	O
-	O
induced	O
obese	O
(	O
DIO	O
)	O
rodents	O
.	O

Although	O
this	O
alteration	O
might	O
contribute	O
to	O
unhealthy	O
food	O
choices	O
,	O
its	O
origin	O
remains	O
to	O
be	O
understood	O
.	O

Cumulative	O
evidence	O
indicates	O
that	O
prebiotic	O
manipulations	O
of	O
the	O
gut	O
microbiota	O
are	O
associated	O
with	O
changes	O
in	O
food	O
intake	O
by	O
modulating	O
hedonic	O
and	O
motivational	O
drive	O
for	O
food	O
reward	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
explore	O
whether	O
a	O
prebiotic	O
supplementation	O
can	O
also	O
restore	O
the	O
taste	O
sensation	O
in	O
DIO	O
mice	O
.	O

The	O
preference	O
and	O
licking	O
behavior	O
in	O
response	O
to	O
various	O
sucrose	O
concentrations	O
were	O
determined	O
using	O
respectively	O
two	O
-	O
bottle	O
choice	O
tests	O
and	O
gustometer	O
analysis	O
in	O
lean	O
and	O
obese	O
mice	O
supplemented	O
or	O
not	O
with	O
10	O
%	O
inulin	O
-	O
type	O
fructans	O
prebiotic	O
(	O
P	O
)	O
in	O
a	O
preventive	O
manner	O
.	O

In	O
DIO	O
mice	O
,	O
P	O
addition	O
reduced	O
the	O
fat	O
mass	O
gain	O
and	O
energy	O
intake	O
,	O
limited	O
the	O
gut	O
dysbiosis	O
and	O
partially	O
improved	O
the	O
sweet	O
taste	O
perception	O
(	O
rise	O
both	O
of	O
sucrose	O
preference	O
and	O
number	O
of	O
licks	O
/	O
10	O
s	O
vs	O
.	O
non	O
-	O
supplemented	O
DIO	O
mice	O
)	O
.	O

No	O
clear	O
effect	O
on	O
orosensory	O
perception	O
of	O
sucrose	O
was	O
found	O
in	O
the	O
supplemented	O
control	O
mice	O
.	O

Therefore	O
,	O
a	O
preventive	O
P	O
supplementation	O
can	O
partially	O
correct	O
the	O
loss	O
of	O
sweet	O
taste	O
sensitivity	O
found	O
in	O
DIO	O
mice	O
,	O
with	O
the	O
efficiency	O
of	O
treatment	O
being	O
dependent	O
from	O
the	O
nutritional	O
status	O
of	O
mice	O
(	O
high	O
fat	O
diet	O
vs	O
.	O
regular	O
chow	O
)	O
.	O

Microbial	O
Colonization	O
at	O
Early	O
Life	O
Promotes	O
the	O
Development	O
of	O
Diet	O
-	O
Induced	O
CD8alphabeta	O
Intraepithelial	O
T	O
Cells	O
.	O

Intraepithelial	O
lymphocytes	O
(	O
IELs	O
)	O
develop	O
through	O
the	O
continuous	O
interaction	O
with	O
intestinal	O
antigens	O
such	O
as	O
commensal	O
microbiome	O
and	O
diet	O
.	O

However	O
,	O
their	O
respective	O
roles	O
and	O
mutual	O
interactions	O
in	O
the	O
development	O
of	O
IELs	O
are	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
showed	O
that	O
dietary	O
antigens	O
regulate	O
the	O
development	O
of	O
the	O
majority	O
of	O
CD8alphabeta	O
IELs	O
in	O
the	O
small	O
intestine	O
and	O
the	O
absence	O
of	O
commensal	O
microbiota	O
particularly	O
during	O
the	O
weaning	O
period	O
,	O
delay	O
the	O
development	O
of	O
IELs	O
.	O

When	O
we	O
tested	O
specific	O
dietary	O
components	O
,	O
such	O
as	O
wheat	O
or	O
combined	O
corn	O
,	O
soybean	O
and	O
yeast	O
,	O
they	O
were	O
dependent	O
on	O
commensal	O
bacteria	O
for	O
the	O
timely	O
development	O
of	O
diet	O
-	O
induced	O
CD8alphabeta	O
IELs	O
.	O

In	O
addition	O
,	O
supplementation	O
of	O
intestinal	O
antigens	O
later	O
in	O
life	O
was	O
inefficient	O
for	O
the	O
full	O
induction	O
of	O
CD8alphabeta	O
IELs	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
early	O
exposure	O
to	O
commensal	O
bacteria	O
is	O
important	O
for	O
the	O
proper	O
development	O
of	O
dietary	O
antigen	O
-	O
dependent	O
immune	O
repertoire	O
in	O
the	O
gut	O
.	O

Linseed	O
oil	O
and	O
heated	O
linseed	O
grain	O
supplements	O
have	O
different	O
effects	O
on	O
rumen	O
bacterial	O
community	O
structures	O
and	O
fatty	O
acid	O
profiles	O
in	O
cashmere	O
kids	O
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
dietary	O
supplementation	O
with	O
alternative	O
sources	O
of	O
alpha	O
-	O
linolenic	O
acid	O
on	O
growth	O
,	O
the	O
composition	O
of	O
rumen	O
microbiota	O
,	O
and	O
the	O
interactions	O
between	O
rumen	O
microbiota	O
and	O
long	O
-	O
chain	O
fatty	O
acid	O
concentrations	O
,	O
in	O
goat	O
kids	O
.	O

Sixty	O
4	O
-	O
month	O
-	O
old	O
castrated	O
male	O
Albas	O
white	O
cashmere	O
kids	O
(	O
average	O
BW	O
18	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
1	O
kg	O
)	O
were	O
randomly	O
allocated	O
among	O
three	O
dietary	O
treatments	O
:	O
1	O
)	O
basal	O
diet	O
without	O
supplementation	O
(	O
Control	O
)	O
;	O
2	O
)	O
basal	O
diet	O
supplemented	O
with	O
linseed	O
oil	O
(	O
LSO	O
)	O
;	O
3	O
)	O
basal	O
diet	O
supplemented	O
with	O
heated	O
linseed	O
grain	O
(	O
HLS	O
)	O
.	O

The	O
concentrate	O
:	O
forage	O
ratio	O
was	O
5	O
:	O
5	O
and	O
the	O
LSO	O
and	O
HLS	O
treatments	O
provided	O
the	O
kids	O
with	O
similar	O
dietary	O
FA	O
profiles	O
.	O

The	O
diets	O
were	O
fed	O
for	O
104	O
days	O
,	O
consisting	O
of	O
14	O
days	O
for	O
adaptation	O
followed	O
by	O
90	O
days	O
of	O
experimental	O
observation	O
.	O

Treatment	O
did	O
not	O
significantly	O
influence	O
body	O
weight	O
,	O
dry	O
matter	O
intake	O
,	O
or	O
bacterial	O
richness	O
or	O
diversity	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
relative	O
abundance	O
of	O
bacteria	O
participating	O
in	O
hydrogenation	O
differed	O
significantly	O
among	O
the	O
three	O
groups	O
:	O
the	O
Veillonellaceae	B-bacteria
and	O
Christensenellaceae	B-bacteria
were	O
more	O
abundant	O
in	O
LSO	O
kids	O
,	O
Prevotellaceae	B-bacteria
were	O
more	O
abundant	O
in	O
HLS	O
kids	O
,	O
and	O
the	O
Fibrobacteriaceae	B-bacteria
were	O
more	O
abundant	O
in	O
Control	O
kids	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Spearman	O
correlation	O
analysis	O
indicated	O
that	O
Ruminobacter	B-bacteria
,	O
Selenomonas	B-bacteria
_	I-bacteria
1	I-bacteria
,	O
Fretibacterium	B-bacteria
,	O
Prevotellaceae	B-bacteria
_	I-bacteria
UCG	I-bacteria
-	I-bacteria
001	I-bacteria
,	O
Succinimonas	B-bacteria
and	O
Ruminococcaceae	B-bacteria
_	I-bacteria
NK4A214	I-bacteria
_	O
group	O
were	O
the	O
genera	O
that	O
participated	O
in	O
hydrogenation	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
.	O

HLS	O
-	O
fed	O
kids	O
had	O
a	O
lower	O
relative	O
abundance	O
of	O
Ruminobacter	B-bacteria
,	O
but	O
a	O
higher	O
abundance	O
of	O
Prevotellaceae	B-bacteria
_	I-bacteria
UCG	I-bacteria
-	I-bacteria
001	I-bacteria
and	O
Fretibacterium	B-bacteria
than	O
LSO	O
-	O
fed	O
kids	O
.	O

These	O
changes	O
were	O
associated	O
with	O
greater	O
rumen	O
concentrations	O
of	O
C18	O
:	O
3n3	O
and	O
n	O
-	O
3	O
PUFA	O
,	O
but	O
lower	O
concentrations	O
of	O
n	O
-	O
6	O
PUFA	O
and	O
lower	O
n	O
-	O
6	O
/	O
n	O
-	O
3	O
ratios	O
,	O
in	O
HLS	O
-	O
than	O
in	O
LSO	O
-	O
fed	O
kids	O
.	O

In	O
conclusion	O
,	O
feeding	O
kids	O
with	O
heated	O
linseed	O
grain	O
increased	O
rumen	O
concentrations	O
of	O
C18	O
:	O
3n3	O
and	O
n	O
-	O
3	O
PUFA	O
,	O
but	O
decreased	O
the	O
n	O
-	O
6	O
/	O
n	O
-	O
3	O
ratio	O
by	O
decreasing	O
the	O
abundance	O
of	O
bacteria	O
that	O
hydrogenate	O
C18	O
:	O
3n3	O
and	O
increasing	O
the	O
abundance	O
of	O
bacteria	O
that	O
hydrogenate	O
C18	O
:	O
2n6	O
.	O

Sodium	O
butyrate	O
supplementation	O
in	O
high	O
-	O
soybean	O
meal	O
diets	O
for	O
turbot	O
(	O
Scophthalmus	O
maximus	O
L	O
.	O
)	O
:	O
Effects	O
on	O
inflammatory	O
status	O
,	O
mucosal	O
barriers	O
and	O
microbiota	O
in	O
the	O
intestine	O
.	O

A	O
12	O
-	O
week	O
feeding	O
trial	O
was	O
conducted	O
to	O
evaluate	O
the	O
effects	O
of	O
dietary	O
sodium	O
butyrate	O
(	O
NaBT	O
)	O
on	O
the	O
intestinal	O
health	O
of	O
juvenile	O
turbot	O
(	O
Scophthalmus	O
maximus	O
L	O
.	O
)	O
,	O
in	O
terms	O
of	O
inflammatory	O
status	O
,	O
mucosal	O
barriers	O
and	O
microbiota	O
.	O

Three	O
isonitrogenous	O
and	O
isolipidic	O
practical	O
diets	O
were	O
used	O
:	O
(	O
1	O
)	O
fish	O
meal	O
based	O
group	O
(	O
FM	O
)	O
;	O
(	O
2	O
)	O
soybean	O
meal	O
group	O
(	O
SBM	O
)	O
,	O
soy	O
protein	O
replacing	O
40	O
%	O
fish	O
meal	O
protein	O
in	O
FM	O
;	O
(	O
3	O
)	O
NaBT	O
group	O
,	O
0	O
.	O
2	O
%	O
NaBT	O
supplemented	O
in	O
SBM	O
.	O

Each	O
diet	O
was	O
fed	O
to	O
triplicate	O
tanks	O
(	O
30	O
fish	O
in	O
each	O
tank	O
)	O
.	O

The	O
current	O
results	O
showed	O
that	O
0	O
.	O
2	O
%	O
dietary	O
NaBT	O
improved	O
the	O
growth	O
performance	O
of	O
fish	O
and	O
alleviated	O
the	O
enteropathy	O
,	O
increasing	O
the	O
absorptive	O
surface	O
and	O
mitigating	O
the	O
infiltration	O
of	O
mixed	O
leukocytes	O
in	O
lamina	O
propria	O
.	O

Fish	O
fed	O
the	O
NaBT	O
diet	O
presented	O
increased	O
activities	O
of	O
intestinal	O
brush	O
border	O
enzyme	O
and	O
similar	O
nutrient	O
digestibility	O
with	O
the	O
FM	O
group	O
.	O

Compared	O
to	O
SBM	O
,	O
the	O
inclusion	O
of	O
0	O
.	O
2	O
%	O
NaBT	O
in	O
diet	O
significantly	O
up	O
-	O
regulated	O
the	O
intestinal	O
gene	O
expression	O
of	O
tight	O
junction	O
proteins	O
and	O
down	O
-	O
regulated	O
the	O
gene	O
expression	O
of	O
TNF	O
-	O
alpha	O
and	O
NF	O
-	O
kappaB	O
.	O

The	O
gut	O
microbial	O
communities	O
of	O
the	O
NaBT	O
group	O
were	O
closer	O
to	O
the	O
FM	O
group	O
than	O
to	O
the	O
SBM	O
group	O
,	O
in	O
terms	O
of	O
PCoA	O
,	O
UPGMA	O
and	O
Heatmap	O
analyses	O
based	O
on	O
weighted	O
Unifrac	O
distance	O
.	O

The	O
relative	O
abundance	O
of	O
several	O
dominant	O
bacteria	O
at	O
the	O
phylum	O
(	O
Proteobacteria	B-bacteria
,	O
Bacteroidetes	B-bacteria
,	O
Deinococcus	B-bacteria
-	I-bacteria
Thermus	I-bacteria
and	O
Actinobacteria	B-bacteria
)	O
and	O
genus	O
level	O
(	O
Thermus	B-bacteria
,	O
Acinetobacter	B-bacteria
,	O
Bacteroides	B-bacteria
and	O
Silanimonas	B-bacteria
)	O
were	O
altered	O
by	O
dietary	O
NaBT	O
.	O

In	O
conclusion	O
,	O
dietary	O
NaBT	O
had	O
positive	O
roles	O
in	O
protecting	O
the	O
intestinal	O
health	O
of	O
turbot	O
from	O
the	O
impairment	O
of	O
soybean	O
meal	O
.	O

Contact	O
with	O
adult	O
hen	O
affects	O
development	O
of	O
caecal	O
microbiota	O
in	O
newly	O
hatched	O
chicks	O
.	O

Chickens	O
in	O
commercial	O
production	O
are	O
hatched	O
in	O
a	O
clean	O
hatchery	O
environment	O
in	O
the	O
absence	O
of	O
any	O
contact	O
with	O
adult	O
hens	O
.	O

However	O
,	O
Gallus	O
gallus	O
evolved	O
to	O
be	O
hatched	O
in	O
a	O
nest	O
in	O
contact	O
with	O
an	O
adult	O
hen	O
which	O
may	O
act	O
as	O
a	O
donor	O
of	O
gut	O
microbiota	O
.	O

In	O
this	O
study	O
,	O
we	O
therefore	O
addressed	O
the	O
issue	O
of	O
microbiota	O
development	O
in	O
newly	O
hatched	O
chickens	O
with	O
or	O
without	O
contact	O
with	O
an	O
adult	O
hen	O
.	O

We	O
found	O
that	O
a	O
mere	O
24	O
-	O
hour	O
-	O
long	O
contact	O
between	O
a	O
hen	O
and	O
newly	O
hatched	O
chickens	O
was	O
long	O
enough	O
for	O
transfer	O
of	O
hen	O
gut	O
microbiota	O
to	O
chickens	O
.	O

Hens	O
were	O
efficient	O
donors	O
of	O
Bacteroidetes	B-bacteria
and	O
Actinobacteria	B-bacteria
.	O

However	O
,	O
except	O
for	O
genus	O
Faecalibacterium	B-bacteria
and	O
bacterial	O
species	O
belonging	O
to	O
class	O
Negativicutes	B-bacteria
,	O
hens	O
did	O
not	O
act	O
as	O
an	O
important	O
source	O
of	O
Gram	O
-	O
positive	O
Firmicutes	B-bacteria
.	O

Though	O
common	O
to	O
the	O
chicken	O
intestinal	O
tract	O
,	O
Lactobacilli	B-bacteria
and	O
isolates	O
from	O
families	O
Erysipelotrichaceae	B-bacteria
,	O
Lachnospiraceae	B-bacteria
and	O
Ruminococcaceae	B-bacteria
therefore	O
originated	O
from	O
environmental	O
sources	O
instead	O
of	O
from	O
the	O
hens	O
.	O

These	O
observation	O
may	O
have	O
considerable	O
consequences	O
for	O
the	O
evidence	O
-	O
based	O
design	O
of	O
the	O
new	O
generation	O
of	O
probiotics	O
for	O
poultry	O
.	O

Mutual	O
interactions	O
of	O
E	B-bacteria
.	I-bacteria
andrei	I-bacteria
earthworm	O
and	O
pathogens	O
during	O
the	O
process	O
of	O
vermicomposting	O
.	O

Vermicomposting	O
is	O
a	O
process	O
by	O
which	O
earthworms	O
together	O
with	O
microorganisms	O
degrade	O
organic	O
wastes	O
into	O
a	O
humus	O
-	O
like	O
material	O
called	O
vermicompost	O
.	O

This	O
process	O
does	O
not	O
include	O
a	O
thermophilic	O
stage	O
,	O
and	O
therefore	O
,	O
the	O
possible	O
presence	O
of	O
pathogens	O
represents	O
a	O
potential	O
health	O
hazard	O
.	O

To	O
elucidate	O
the	O
effect	O
of	O
earthworms	O
in	O
the	O
selective	O
reduction	O
of	O
pathogens	O
,	O
grape	O
marc	O
substrate	O
was	O
artificially	O
inoculated	O
with	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Enterococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
thermotolerant	B-bacteria
coliform	I-bacteria
bacteria	I-bacteria
(	O
TCB	B-bacteria
)	O
,	O
and	O
Salmonella	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
and	O
their	O
reduction	O
during	O
vermicomposting	O
was	O
monitored	O
.	O

Various	O
defense	O
mechanisms	O
eliminating	O
microorganisms	O
in	O
the	O
earthworm	O
gut	O
were	O
assumed	O
to	O
be	O
involved	O
in	O
the	O
process	O
of	O
pathogen	O
reduction	O
.	O

Therefore	O
,	O
we	O
followed	O
the	O
expression	O
of	O
three	O
pattern	O
recognition	O
receptors	O
(	O
coelomic	O
cytolytic	O
factor	O
(	O
CCF	O
)	O
,	O
lipopolysaccharide	O
-	O
binding	O
protein	O
(	O
LBP	O
)	O
,	O
and	O
Toll	O
-	O
like	O
receptor	O
(	O
v	O
-	O
TLR	O
)	O
)	O
,	O
two	O
antimicrobial	O
molecules	O
(	O
fetidin	O
/	O
lysenins	O
and	O
lysozyme	O
)	O
,	O
and	O
heat	O
shock	O
protein	O
HSP70	O
.	O

We	O
detected	O
the	O
significant	O
decrease	O
of	O
some	O
defense	O
molecules	O
(	O
fetidin	O
/	O
lysenins	O
and	O
LBP	O
)	O
in	O
all	O
pathogen	O
-	O
inoculated	O
substrates	O
,	O
and	O
the	O
increase	O
of	O
CCF	O
and	O
LBP	O
in	O
the	O
Salmonella	B-bacteria
spp	I-bacteria
.	I-bacteria
-	O
inoculated	O
substrate	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
reduction	O
of	O
pathogens	O
during	O
vermicomposting	O
was	O
assessed	O
.	O

We	O
observed	O
the	O
accelerated	O
reduction	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
,	O
Enterococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
and	O
TCB	O
in	O
pathogen	O
-	O
inoculated	O
substrates	O
with	O
earthworms	O
compared	O
to	O
that	O
without	O
earthworms	O
.	O

Moreover	O
,	O
the	O
differences	O
between	O
the	O
microbiome	O
of	O
grape	O
marc	O
substrate	O
and	O
earthworm	O
intestines	O
were	O
determined	O
by	O
high	O
throughput	O
sequencing	O
.	O

This	O
analysis	O
revealed	O
that	O
the	O
bacterial	O
composition	O
of	O
grape	O
marc	O
substrate	O
differed	O
from	O
the	O
composition	O
of	O
the	O
content	O
of	O
earthworm	O
intestines	O
,	O
suggesting	O
the	O
elimination	O
of	O
specific	O
bacterial	O
species	O
during	O
food	O
passage	O
through	O
the	O
gut	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
of	O
an	O
exopolysaccharide	O
produced	O
by	O
Lactobacillus	B-bacteria
helveticus	I-bacteria
KLDS1	I-bacteria
.	I-bacteria
8701	I-bacteria
for	O
the	O
alleviative	O
effect	O
on	O
oxidative	O
stress	O
.	O

Correlations	O
between	O
oxidative	O
stress	O
and	O
degenerative	O
diseases	O
have	O
been	O
gaining	O
increasing	O
attention	O
.	O

A	O
number	O
of	O
studies	O
affirm	O
that	O
exopolysaccharide	O
(	O
EPS	O
)	O
produced	O
by	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
can	O
alleviate	O
oxidative	O
stress	O
and	O
further	O
prevent	O
the	O
related	O
diseases	O
.	O

In	O
our	O
previous	O
study	O
,	O
Lactobacillus	B-bacteria
helveticus	I-bacteria
KLDS1	I-bacteria
.	I-bacteria
8701	I-bacteria
has	O
been	O
shown	O
to	O
possess	O
high	O
antioxidant	O
capacity	O
in	O
vitro	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
ameliorative	O
effects	O
of	O
EPS	O
produced	O
by	O
L	B-bacteria
.	I-bacteria
helveticus	I-bacteria
KLDS1	I-bacteria
.	I-bacteria
8701	I-bacteria
on	O
oxidative	O
stress	O
.	O

Firstly	O
,	O
EPS	O
was	O
isolated	O
from	O
the	O
culture	O
of	O
L	B-bacteria
.	I-bacteria
helveticus	I-bacteria
KLDS1	I-bacteria
.	I-bacteria
8701	I-bacteria
and	O
purified	O
using	O
DEAE	O
-	O
Sepharose	O
Fast	O
Flow	O
chromatography	O
.	O

Secondly	O
,	O
the	O
antioxidant	O
capacities	O
of	O
EPS	O
fractions	O
were	O
evaluated	O
using	O
in	O
vitro	O
methods	O
.	O

Thirdly	O
,	O
an	O
in	O
vivo	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
possible	O
protective	O
effects	O
of	O
EPS	O
on	O
d	O
-	O
galactose	O
(	O
d	O
-	O
gal	O
)	O
-	O
induced	O
liver	O
damage	O
and	O
gut	O
microbiota	O
disorder	O
.	O

In	O
vitro	O
antioxidant	O
activity	O
results	O
suggested	O
that	O
EPS	O
-	O
1	O
exhibited	O
strong	O
scavenging	O
properties	O
on	O
2	O
,	O
2	O
-	O
diphenyl	O
-	O
1	O
-	O
picrylhydrazyl	O
radical	O
,	O
superoxide	O
radical	O
,	O
hydroxyl	O
radical	O
,	O
and	O
chelating	O
activity	O
on	O
ferrous	O
ion	O
.	O

In	O
vivo	O
,	O
EPS	O
-	O
1	O
supplementation	O
significantly	O
attenuated	O
oxidative	O
status	O
such	O
as	O
decreased	O
organic	O
index	O
,	O
liver	O
injury	O
and	O
liver	O
oxidative	O
stress	O
.	O

EPS	O
-	O
1	O
supplementation	O
shifted	O
the	O
gut	O
microbiota	O
composition	O
to	O
that	O
of	O
the	O
control	O
group	O
.	O

In	O
addition	O
,	O
the	O
analysis	O
of	O
Spearman	O
'	O
s	O
rank	O
correlation	O
suggested	O
that	O
the	O
protective	O
effects	O
of	O
EPS	O
correlated	O
with	O
manipulating	O
the	O
gut	O
microbiota	O
composition	O
in	O
d	O
-	O
gal	O
-	O
induced	O
mice	O
.	O

These	O
results	O
implied	O
that	O
EPS	O
-	O
1	O
supplementation	O
could	O
mitigate	O
hepatic	O
oxidative	O
stress	O
via	O
manipulating	O
the	O
gut	O
microbiota	O
composition	O
and	O
be	O
used	O
as	O
a	O
potential	O
candidate	O
to	O
attenuate	O
oxidative	O
damage	O
.	O

Oral	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
LR06	I-bacteria
or	O
Bifidobacterium	B-bacteria
BL5b	I-bacteria
supplement	O
do	O
not	O
produce	O
analgesic	O
effects	O
on	O
neuropathic	O
and	O
inflammatory	O
pain	O
in	O
rats	O
.	O

BACKGROUND	O
:	O
Previous	O
studies	O
have	O
reported	O
that	O
certain	O
bacteria	O
exert	O
visceral	O
antinociceptive	O
activity	O
in	O
visceral	O
pain	O
and	O
may	O
also	O
help	O
to	O
relieve	O
neuropathic	O
and	O
inflammatory	O
pain	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
analgesic	O
effect	O
of	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
LR06	I-bacteria
(	O
LR06	B-bacteria
)	O
or	O
Bifidobacterium	B-bacteria
BL5b	I-bacteria
(	O
BL5b	B-bacteria
)	O
in	O
chronic	O
pain	O
in	O
vivo	O
.	O

DESIGN	O
:	O
Rats	O
were	O
randomly	O
assigned	O
into	O
four	O
groups	O
:	O
sham	O
,	O
Chronic	O
Constriction	O
Injury	O
(	O
CCI	O
)	O
/	O
Complete	O
Freund	O
'	O
s	O
Adjuvant	O
(	O
CFA	O
)	O
+	O
control	O
,	O
CCI	O
/	O
CFA	O
+	O
LR06	O
,	O
and	O
CCI	O
/	O
CFA	O
+	O
BL5b	O
.	O

Rats	O
from	O
the	O
probiotic	O
groups	O
were	O
treated	O
with	O
1	O
x	O
10	O
(	O
9	O
)	O
cfu	O
(	O
LR06	O
or	O
BL5b	O
)	O
daily	O
through	O
gavage	O
for	O
14	O
days	O
after	O
a	O
pain	O
model	O
was	O
successfully	O
established	O
.	O

Mechanical	O
and	O
thermal	O
hyperalgesia	O
were	O
used	O
to	O
assess	O
the	O
analgesic	O
effect	O
of	O
the	O
probiotics	O
.	O

Iba1	O
was	O
used	O
to	O
verify	O
the	O
microglial	O
inflammatory	O
reaction	O
in	O
the	O
different	O
groups	O
.	O

RESULTS	O
:	O
The	O
results	O
showed	O
that	O
probiotics	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
LR06	I-bacteria
or	O
Bifidobacterium	B-bacteria
BL5b	I-bacteria
had	O
no	O
significant	O
antinociception	O
effects	O
in	O
chronic	O
pain	O
rats	O
.	O

The	O
chronic	O
pain	O
-	O
induced	O
activation	O
of	O
microglia	O
(	O
Iba1	O
)	O
was	O
not	O
relieved	O
by	O
probiotics	O
in	O
CCI	O
/	O
CFA	O
-	O
induced	O
neuropathic	O
or	O
inflammatory	O
pain	O
rats	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggested	O
that	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
LR06	I-bacteria
or	O
Bifidobacterium	B-bacteria
BL5b	I-bacteria
had	O
no	O
antinociceptive	O
effects	O
on	O
CCI	O
-	O
induced	O
neuropathic	O
pain	O
and	O
CFA	O
-	O
induced	O
inflammatory	O
pain	O
in	O
rats	O
.	O

Infectious	O
Complications	O
Are	O
Associated	O
With	O
Alterations	O
in	O
the	O
Gut	O
Microbiome	O
in	O
Pediatric	O
Patients	O
With	O
Acute	O
Lymphoblastic	O
Leukemia	O
.	O

Acute	O
lymphoblastic	O
leukemia	O
is	O
the	O
most	O
common	O
pediatric	O
cancer	O
.	O

Fortunately	O
,	O
survival	O
rates	O
exceed	O
90	O
%	O
,	O
however	O
,	O
infectious	O
complications	O
remain	O
a	O
significant	O
issue	O
that	O
can	O
cause	O
reductions	O
in	O
the	O
quality	O
of	O
life	O
and	O
prognosis	O
of	O
patients	O
.	O

Recently	O
,	O
numerous	O
studies	O
have	O
linked	O
shifts	O
in	O
the	O
gut	O
microbiome	O
composition	O
to	O
infection	O
events	O
in	O
various	O
hematological	O
malignances	O
including	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O

These	O
studies	O
have	O
been	O
limited	O
to	O
observing	O
broad	O
taxonomic	O
changes	O
using	O
16S	O
rRNA	O
gene	O
profiling	O
,	O
while	O
missing	O
possible	O
differences	O
within	O
microbial	O
functions	O
encoded	O
by	O
individual	O
species	O
.	O

In	O
this	O
study	O
we	O
present	O
the	O
first	O
combined	O
16S	O
rRNA	O
gene	O
and	O
metagenomic	O
shotgun	O
sequencing	O
study	O
on	O
the	O
gut	O
microbiome	O
of	O
an	O
independent	O
pediatric	O
ALL	O
cohort	O
during	O
treatment	O
.	O

In	O
this	O
study	O
we	O
found	O
distinctive	O
differences	O
in	O
alpha	O
diversity	O
and	O
beta	O
diversity	O
in	O
samples	O
from	O
patients	O
with	O
infectious	O
complications	O
in	O
the	O
first	O
6	O
months	O
of	O
therapy	O
.	O

We	O
were	O
also	O
able	O
to	O
find	O
specific	O
species	O
and	O
functional	O
pathways	O
that	O
were	O
significantly	O
different	O
in	O
relative	O
abundance	O
between	O
samples	O
that	O
came	O
from	O
patients	O
with	O
infectious	O
complications	O
.	O

Finally	O
,	O
machine	O
learning	O
models	O
based	O
on	O
patient	O
metadata	O
and	O
bacterial	O
species	O
were	O
able	O
to	O
classify	O
samples	O
with	O
high	O
accuracy	O
(	O
84	O
.	O
09	O
%	O
)	O
,	O
with	O
bacterial	O
species	O
being	O
the	O
most	O
important	O
classifying	O
features	O
.	O

This	O
study	O
strengthens	O
our	O
understanding	O
of	O
the	O
association	O
between	O
infection	O
and	O
pediatric	O
acute	O
lymphoblastic	O
leukemia	O
treatment	O
and	O
warrants	O
further	O
investigation	O
in	O
the	O
future	O
.	O

Current	O
Understanding	O
of	O
Gut	O
Microbiota	O
in	O
Mood	O
Disorders	O
:	O
An	O
Update	O
of	O
Human	O
Studies	O
.	O

Gut	O
microbiota	O
plays	O
an	O
important	O
role	O
in	O
the	O
bidirectional	O
communication	O
between	O
the	O
gut	O
and	O
the	O
central	O
nervous	O
system	O
.	O

Mounting	O
evidence	O
suggests	O
that	O
gut	O
microbiota	O
can	O
influence	O
the	O
brain	O
function	O
via	O
neuroimmune	O
and	O
neuroendocrine	O
pathways	O
as	O
well	O
as	O
the	O
nervous	O
system	O
.	O

Advances	O
in	O
gene	O
sequencing	O
techniques	O
further	O
facilitate	O
investigating	O
the	O
underlying	O
relationship	O
between	O
gut	O
microbiota	O
and	O
psychiatric	O
disorders	O
.	O

In	O
recent	O
years	O
,	O
researchers	O
have	O
preliminarily	O
explored	O
the	O
gut	O
microbiota	O
in	O
patients	O
with	O
mood	O
disorders	O
.	O

The	O
current	O
review	O
aims	O
to	O
summarize	O
the	O
published	O
human	O
studies	O
of	O
gut	O
microbiota	O
in	O
mood	O
disorders	O
.	O

The	O
findings	O
showed	O
that	O
microbial	O
diversity	O
and	O
taxonomic	O
compositions	O
were	O
significantly	O
changed	O
compared	O
with	O
healthy	O
individuals	O
.	O

Most	O
of	O
these	O
findings	O
revealed	O
that	O
short	O
-	O
chain	O
fatty	O
acids	O
-	O
producing	O
bacterial	O
genera	O
were	O
decreased	O
,	O
while	O
pro	O
-	O
inflammatory	O
genera	O
and	O
those	O
involved	O
in	O
lipid	O
metabolism	O
were	O
increased	O
in	O
patients	O
with	O
depressive	O
episodes	O
.	O

Interestingly	O
,	O
the	O
abundance	O
of	O
Actinobacteria	B-bacteria
,	O
Enterobacteriaceae	B-bacteria
was	O
increased	O
and	O
Faecalibacterium	B-bacteria
was	O
decreased	O
consistently	O
in	O
patients	O
with	O
either	O
bipolar	O
disorder	O
or	O
major	O
depressive	O
disorder	O
.	O

Some	O
studies	O
further	O
indicated	O
that	O
specific	O
bacteria	O
were	O
associated	O
with	O
clinical	O
characteristics	O
,	O
inflammatory	O
profiles	O
,	O
metabolic	O
markers	O
,	O
and	O
pharmacological	O
treatment	O
.	O

These	O
studies	O
present	O
preliminary	O
evidence	O
of	O
the	O
important	O
role	O
of	O
gut	O
microbiota	O
in	O
mood	O
disorders	O
,	O
through	O
the	O
brain	O
-	O
gut	O
-	O
microbiota	O
axis	O
,	O
which	O
emerges	O
as	O
a	O
promising	O
target	O
for	O
disease	O
diagnosis	O
and	O
therapeutic	O
interventions	O
in	O
the	O
future	O
.	O

Substantial	O
Extracellular	O
Metabolic	O
Differences	O
Found	O
Between	O
Phylogenetically	O
Closely	O
Related	O
Probiotic	O
and	O
Pathogenic	O
Strains	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

Since	O
its	O
first	O
isolation	O
a	O
century	O
ago	O
,	O
the	O
gut	O
inhabitant	O
Escherichia	B-bacteria
coli	I-bacteria
strain	I-bacteria
Nissle	I-bacteria
1917	I-bacteria
has	O
been	O
shown	O
to	O
have	O
probiotic	O
activities	O
;	O
however	O
,	O
it	O
is	O
yet	O
not	O
fully	O
elucidated	O
which	O
differential	O
factors	O
play	O
key	O
roles	O
in	O
its	O
beneficial	O
interactions	O
with	O
the	O
host	O
.	O

To	O
date	O
,	O
no	O
metabolomics	O
studies	O
have	O
been	O
reported	O
investigating	O
the	O
potential	O
role	O
of	O
small	O
molecules	O
in	O
functional	O
strain	O
differentiation	O
of	O
Nissle	B-bacteria
from	O
its	O
genetically	O
close	O
neighbors	O
.	O

Here	O
,	O
we	O
present	O
results	O
of	O
liquid	O
chromatography	O
coupled	O
to	O
high	O
-	O
resolution	O
mass	O
spectrometry	O
characterization	O
of	O
extracellular	O
metabolomes	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
strains	I-bacteria
as	O
a	O
proxy	O
of	O
their	O
bioactivity	O
potential	O
.	O

We	O
found	O
that	O
phylogroup	O
B2	O
strains	O
exported	O
a	O
more	O
diverse	O
arsenal	O
of	O
metabolites	O
than	O
strains	O
of	O
other	O
phylogroups	O
.	O

Zooming	O
into	O
the	O
phylogroup	O
B2	O
metabolome	O
identified	O
consistent	O
substantial	O
differences	O
between	O
metabolic	O
output	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
Nissle	I-bacteria
and	O
other	O
strains	O
,	O
particularly	O
in	O
metabolites	O
associated	O
to	O
the	O
Argimine	O
biosynthesis	O
pathway	O
.	O

Nissle	O
was	O
found	O
to	O
release	O
higher	O
levels	O
of	O
Ornithine	O
and	O
Citrulline	O
whilst	O
depleting	O
greater	O
amounts	O
of	O
Arginine	O
from	O
the	O
medium	O
.	O

Moreover	O
,	O
a	O
novel	O
Nissle	O
-	O
specific	O
metabolite	O
not	O
reported	O
before	O
in	O
bacteria	O
,	O
5	O
-	O
(	O
Carbamoylamino	O
)	O
-	O
2	O
-	O
hydroxypentanoic	O
acid	O
(	O
Citrulline	O
/	O
Arginic	O
Acid	O
related	O
)	O
was	O
observed	O
.	O

Finally	O
,	O
Nissle	B-bacteria
,	O
CFT073	B-bacteria
and	O
NCTC12241	B-bacteria
/	O
ATCC25922	I-bacteria
shared	O
the	O
excretion	O
of	O
N5	O
-	O
Acetylornithine	O
,	O
whereas	O
other	O
strains	O
released	O
N2	O
-	O
Acetylornithine	O
or	O
no	O
N	O
-	O
Acetylornithine	O
at	O
all	O
.	O

Thus	O
,	O
we	O
found	O
substantial	O
metabolic	O
differences	O
in	O
phylogenetically	O
very	O
similar	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
strains	I-bacteria
,	O
an	O
observation	O
which	O
suggests	O
that	O
it	O
is	O
justified	O
to	O
further	O
investigate	O
roles	O
of	O
small	O
molecules	O
as	O
potential	O
modulators	O
of	O
the	O
gut	O
environment	O
by	O
probiotic	O
,	O
commensal	O
,	O
and	O
pathogenic	O
strains	O
,	O
including	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
Nissle	I-bacteria
1917	I-bacteria
.	O

Evaluation	O
of	O
the	O
Treatment	O
Effect	O
of	O
Aloe	O
vera	O
Fermentation	O
in	O
Burn	O
Injury	O
Healing	O
Using	O
a	O
Rat	O
Model	O
.	O

Burn	O
injury	O
is	O
a	O
growing	O
medical	O
problem	O
associated	O
with	O
public	O
health	O
,	O
and	O
few	O
effective	O
agents	O
are	O
available	O
for	O
treatment	O
of	O
this	O
disease	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
burn	O
injury	O
rat	O
model	O
was	O
developed	O
and	O
the	O
accelerated	O
effect	O
of	O
Aloe	O
vera	O
fermentation	O
on	O
burn	O
injury	O
healing	O
was	O
evaluated	O
.	O

Our	O
results	O
indicated	O
that	O
Aloe	O
vera	O
fermentation	O
could	O
markedly	O
reduce	O
the	O
DPPH	O
(	O
56	O
.	O
12	O
%	O
)	O
,	O
O	O
(	O
2	O
.	O
-	O
)	O
(	O
93	O
.	O
5	O
%	O
)	O
,	O
(	O
.	O

)	O
OH	O
(	O
76	O
.	O
12	O
%	O
)	O
,	O
Fe	O
(	O
2	O
+	O
)	O
chelation	O
(	O
82	O
%	O
)	O
,	O
and	O
oxygen	O
-	O
reduction	O
activity	O
(	O
0	O
.	O
28	O
mug	O
/	O
ml	O
)	O
and	O
significantly	O
inhibited	O
the	O
growth	O
of	O
pathogens	O
S	B-bacteria
.	I-bacteria
typhimurium	I-bacteria
ATCC	I-bacteria
13311	I-bacteria
(	O
inhibition	O
zone	O
diameter	O
:	O
14	O
mm	O
)	O
,	O
S	B-bacteria
.	I-bacteria
enteritidis	I-bacteria
ATCC13076	I-bacteria
(	O
IZD	O
:	O
13	O
mm	O
)	O
,	O
S	B-bacteria
.	I-bacteria
flexneri	I-bacteria
ATCC	I-bacteria
12022	I-bacteria
(	O
IZD	O
:	O
18	O
mm	O
)	O
,	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
44102	I-bacteria
(	O
IZD	O
:	O
10	O
mm	O
)	O
,	O
L	B-bacteria
.	I-bacteria
monocytogenes	I-bacteria
ATCC	I-bacteria
19111	I-bacteria
(	O
IZD	O
:	O
18	O
mm	O
)	O
,	O
S	B-bacteria
.	I-bacteria
dysenteriae	I-bacteria
301	I-bacteria
(	O
IZD	O
:	O
20	O
mm	O
)	O
,	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
COWAN1	I-bacteria
(	O
IZD	O
:	O
19	O
mm	O
)	O
,	O
and	O
P	B-bacteria
.	I-bacteria
acnes	I-bacteria
ATCC	I-bacteria
11827	I-bacteria
(	O
IZD	O
:	O
25	O
mm	O
)	O
in	O
vitro	O
.	O

The	O
in	O
vivo	O
results	O
indicated	O
that	O
Aloe	O
vera	O
fermentation	O
produced	O
more	O
eosinophils	O
and	O
fibroblasts	O
and	O
less	O
vessel	O
proliferation	O
compared	O
with	O
the	O
model	O
group	O
on	O
the	O
14	O
(	O
th	O
)	O
day	O
,	O
which	O
had	O
greatly	O
accelerated	O
burn	O
injury	O
healing	O
via	O
shedding	O
of	O
the	O
scab	O
and	O
promoting	O
hair	O
growth	O
.	O

ELISA	O
results	O
indicated	O
that	O
Aloe	O
vera	O
fermentation	O
had	O
significantly	O
reduced	O
the	O
production	O
of	O
proinflammatory	O
factors	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1beta	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
greatly	O
enhanced	O
the	O
yield	O
of	O
anti	O
-	O
inflammatory	O
factor	O
IL	O
-	O
4	O
in	O
animal	O
serum	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
the	O
high	O
-	O
throughput	O
sequencing	O
results	O
indicated	O
that	O
Aloe	O
vera	O
fermentation	O
obviously	O
increased	O
the	O
percentage	O
of	O
Firmicutes	B-bacteria
(	O
65	O
.	O
86	O
%	O
vs	O
.	O
49	O
.	O
76	O
%	O
)	O
,	O
while	O
reducing	O
the	O
number	O
of	O
Bacteroidetes	B-bacteria
(	O
27	O
.	O
60	O
%	O
vs	O
.	O
45	O
.	O
15	O
%	O
)	O
compared	O
with	O
the	O
M	O
group	O
at	O
the	O
phylum	O
level	O
.	O

At	O
the	O
genus	O
level	O
,	O
Aloe	O
vera	O
fermentation	O
increased	O
the	O
probiotic	O
bacteria	O
Lactobacillus	B-bacteria
(	O
3	O
.	O
13	O
%	O
vs	O
.	O
2	O
.	O
09	O
%	O
)	O
and	O
reduced	O
the	O
pathogens	O
Prevotella	O
(	O
10	O
.	O
60	O
%	O
vs	O
.	O
18	O
.	O
24	O
%	O
)	O
and	O
Blautia	O
(	O
2	O
.	O
91	O
%	O
vs	O
.	O
16	O
.	O
41	O
%	O
)	O
compared	O
with	O
the	O
M	O
group	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
the	O
use	O
of	O
Aloe	O
vera	O
fermentation	O
significantly	O
accelerates	O
burn	O
injury	O
healing	O
via	O
reduction	O
of	O
the	O
severity	O
of	O
inflammation	O
and	O
through	O
modification	O
of	O
gut	O
microbiota	O
.	O

Differential	O
Sensitivity	O
to	O
Plasmodium	B-bacteria
yoelii	I-bacteria
Infection	O
in	O
C57BL	O
/	O
6	O
Mice	O
Impacts	O
Gut	O
-	O
Liver	O
Axis	O
Homeostasis	O
.	O

Experimental	O
models	O
of	O
malaria	O
have	O
shown	O
that	O
infection	O
with	O
specific	O
Plasmodium	B-bacteria
species	I-bacteria
in	O
certain	O
mouse	O
strains	O
can	O
transiently	O
modulate	O
gut	O
microbiota	O
and	O
cause	O
intestinal	O
shortening	O
,	O
indicating	O
a	O
disruption	O
of	O
gut	O
homeostasis	O
.	O

Importantly	O
,	O
changes	O
in	O
gut	O
homeostasis	O
have	O
not	O
been	O
characterized	O
in	O
the	O
context	O
of	O
mild	O
versus	O
severe	O
malaria	O
.	O

We	O
show	O
that	O
severe	O
Plasmodium	B-bacteria
infection	O
in	O
mice	O
disrupts	O
homeostasis	O
along	O
the	O
gut	O
-	O
liver	O
axis	O
in	O
multiple	O
ways	O
compared	O
to	O
mild	O
infection	O
.	O

High	O
parasite	O
burden	O
results	O
in	O
a	O
larger	O
influx	O
of	O
immune	O
cells	O
in	O
the	O
lamina	O
propria	O
and	O
mice	O
with	O
high	O
parasitemia	O
display	O
specific	O
metabolomic	O
profiles	O
in	O
the	O
ceca	O
and	O
plasma	O
during	O
infection	O
compared	O
to	O
mice	O
with	O
mild	O
parasitemia	O
.	O

Liver	O
damage	O
was	O
also	O
more	O
pronounced	O
and	O
longer	O
lasting	O
during	O
severe	O
infection	O
,	O
with	O
concomitant	O
changes	O
in	O
bile	O
acids	O
in	O
the	O
gut	O
.	O

Finally	O
,	O
severe	O
Plasmodium	B-bacteria
infection	O
changes	O
the	O
functional	O
capacity	O
of	O
the	O
microbiota	O
,	O
enhancing	O
bacterial	O
motility	O
and	O
amino	O
acid	O
metabolism	O
in	O
mice	O
with	O
high	O
parasite	O
burden	O
compared	O
to	O
a	O
mild	O
infection	O
.	O

Taken	O
together	O
,	O
Plasmodium	B-bacteria
infections	O
have	O
diverse	O
effects	O
on	O
host	O
gut	O
homeostasis	O
relative	O
to	O
the	O
severity	O
of	O
infection	O
that	O
may	O
contribute	O
to	O
enteric	O
bacteremia	O
that	O
is	O
associated	O
with	O
malaria	O
.	O

A	O
theoretical	O
framework	O
for	O
controlling	O
complex	O
microbial	O
communities	O
.	O

Microbes	O
form	O
complex	O
communities	O
that	O
perform	O
critical	O
roles	O
for	O
the	O
integrity	O
of	O
their	O
environment	O
or	O
the	O
well	O
-	O
being	O
of	O
their	O
hosts	O
.	O

Controlling	O
these	O
microbial	O
communities	O
can	O
help	O
us	O
restore	O
natural	O
ecosystems	O
and	O
maintain	O
healthy	O
human	O
microbiota	O
.	O

However	O
,	O
the	O
lack	O
of	O
an	O
efficient	O
and	O
systematic	O
control	O
framework	O
has	O
limited	O
our	O
ability	O
to	O
manipulate	O
these	O
microbial	O
communities	O
.	O

Here	O
we	O
fill	O
this	O
gap	O
by	O
developing	O
a	O
control	O
framework	O
based	O
on	O
the	O
new	O
notion	O
of	O
structural	O
accessibility	O
.	O

Our	O
framework	O
uses	O
the	O
ecological	O
network	O
of	O
the	O
community	O
to	O
identify	O
minimum	O
sets	O
of	O
its	O
driver	O
species	O
,	O
manipulation	O
of	O
which	O
allows	O
controlling	O
the	O
whole	O
community	O
.	O

We	O
numerically	O
validate	O
our	O
control	O
framework	O
on	O
large	O
communities	O
,	O
and	O
then	O
we	O
demonstrate	O
its	O
application	O
for	O
controlling	O
the	O
gut	O
microbiota	O
of	O
gnotobiotic	O
mice	O
infected	O
with	O
Clostridium	B-bacteria
difficile	I-bacteria
and	O
the	O
core	O
microbiota	O
of	O
the	O
sea	O
sponge	O
Ircinia	O
oros	O
.	O

Our	O
results	O
provide	O
a	O
systematic	O
pipeline	O
to	O
efficiently	O
drive	O
complex	O
microbial	O
communities	O
towards	O
desired	O
states	O
.	O

Introducing	O
THOR	O
,	O
a	O
Model	O
Microbiome	O
for	O
Genetic	O
Dissection	O
of	O
Community	O
Behavior	O
.	O

The	O
quest	O
to	O
manipulate	O
microbiomes	O
has	O
intensified	O
,	O
but	O
many	O
microbial	O
communities	O
have	O
proven	O
to	O
be	O
recalcitrant	O
to	O
sustained	O
change	O
.	O

Developing	O
model	O
communities	O
amenable	O
to	O
genetic	O
dissection	O
will	O
underpin	O
successful	O
strategies	O
for	O
shaping	O
microbiomes	O
by	O
advancing	O
an	O
understanding	O
of	O
community	O
interactions	O
.	O

We	O
developed	O
a	O
model	O
community	O
with	O
representatives	O
from	O
three	O
dominant	O
rhizosphere	O
taxa	O
,	O
the	O
Firmicutes	B-bacteria
,	O
Proteobacteria	B-bacteria
,	O
and	O
Bacteroidetes	B-bacteria
We	O
chose	O
Bacillus	B-bacteria
cereus	I-bacteria
as	O
a	O
model	O
rhizosphere	O
firmicute	O
and	O
characterized	O
20	O
other	O
candidates	O
,	O
including	O
`	O
`	O
hitchhikers	O
'	O
'	O
that	O
coisolated	O
with	O
B	B-bacteria
.	I-bacteria
cereus	I-bacteria
from	O
the	O
rhizosphere	O
.	O

Pairwise	O
analysis	O
produced	O
a	O
hierarchical	O
interstrain	O
-	O
competition	O
network	O
.	O

We	O
chose	O
two	O
hitchhikers	O
,	O
Pseudomonas	B-bacteria
koreensis	I-bacteria
from	O
the	O
top	O
tier	O
of	O
the	O
competition	O
network	O
and	O
Flavobacterium	B-bacteria
johnsoniae	I-bacteria
from	O
the	O
bottom	O
of	O
the	O
network	O
,	O
to	O
represent	O
the	O
Proteobacteria	B-bacteria
and	O
Bacteroidetes	B-bacteria
,	O
respectively	O
.	O

The	O
model	O
community	O
has	O
several	O
emergent	O
properties	O
,	O
induction	O
of	O
dendritic	O
expansion	O
of	O
B	B-bacteria
.	I-bacteria
cereus	I-bacteria
colonies	O
by	O
either	O
of	O
the	O
other	O
members	O
,	O
and	O
production	O
of	O
more	O
robust	O
biofilms	O
by	O
the	O
three	O
members	O
together	O
than	O
individually	O
.	O

Moreover	O
,	O
P	O
.	O
koreensis	O
produces	O
a	O
novel	O
family	O
of	O
alkaloid	O
antibiotics	O
that	O
inhibit	O
growth	O
of	O
F	B-bacteria
.	I-bacteria
johnsoniae	I-bacteria
,	O
and	O
production	O
is	O
inhibited	O
by	O
B	B-bacteria
.	I-bacteria
cereus	I-bacteria
We	O
designate	O
this	O
community	O
THOR	O
,	O
because	O
the	O
members	O
are	O
the	O
hitchhikers	O
of	O
the	O
rhizosphere	O
.	O

The	O
genetic	O
,	O
genomic	O
,	O
and	O
biochemical	O
tools	O
available	O
for	O
dissection	O
of	O
THOR	O
provide	O
the	O
means	O
to	O
achieve	O
a	O
new	O
level	O
of	O
understanding	O
of	O
microbial	O
community	O
behavior	O
.	O
IMPORTANCE	O
The	O
manipulation	O
and	O
engineering	O
of	O
microbiomes	O
could	O
lead	O
to	O
improved	O
human	O
health	O
,	O
environmental	O
sustainability	O
,	O
and	O
agricultural	O
productivity	O
.	O

However	O
,	O
microbiomes	O
have	O
proven	O
difficult	O
to	O
alter	O
in	O
predictable	O
ways	O
,	O
and	O
their	O
emergent	O
properties	O
are	O
poorly	O
understood	O
.	O

The	O
history	O
of	O
biology	O
has	O
demonstrated	O
the	O
power	O
of	O
model	O
systems	O
to	O
understand	O
complex	O
problems	O
such	O
as	O
gene	O
expression	O
or	O
development	O
.	O

Therefore	O
,	O
a	O
defined	O
and	O
genetically	O
tractable	O
model	O
community	O
would	O
be	O
useful	O
to	O
dissect	O
microbiome	O
assembly	O
,	O
maintenance	O
,	O
and	O
processes	O
.	O

We	O
have	O
developed	O
a	O
tractable	O
model	O
rhizosphere	O
microbiome	O
,	O
designated	O
THOR	O
,	O
containing	O
Pseudomonas	B-bacteria
koreensis	I-bacteria
,	O
Flavobacterium	B-bacteria
johnsoniae	I-bacteria
,	O
and	O
Bacillus	B-bacteria
cereus	I-bacteria
,	O
which	O
represent	O
three	O
dominant	O
phyla	O
in	O
the	O
rhizosphere	O
,	O
as	O
well	O
as	O
in	O
soil	O
and	O
the	O
mammalian	O
gut	O
.	O

The	O
model	O
community	O
demonstrates	O
emergent	O
properties	O
,	O
and	O
the	O
members	O
are	O
amenable	O
to	O
genetic	O
dissection	O
.	O

We	O
propose	O
that	O
THOR	O
will	O
be	O
a	O
useful	O
model	O
for	O
investigations	O
of	O
community	O
-	O
level	O
interactions	O
.	O

Targeting	O
antibiotic	O
resistant	O
bacteria	O
with	O
phage	O
reduces	O
bacterial	O
density	O
in	O
an	O
insect	O
host	O
.	O

Phage	O
therapy	O
is	O
attracting	O
growing	O
interest	O
among	O
clinicians	O
as	O
antibiotic	O
resistance	O
continues	O
becoming	O
harder	O
to	O
control	O
.	O

However	O
,	O
clinical	O
trials	O
and	O
animal	O
model	O
studies	O
on	O
bacteriophage	O
treatment	O
are	O
still	O
scarce	O
and	O
results	O
on	O
the	O
efficacy	O
vary	O
.	O

Recent	O
research	O
suggests	O
that	O
using	O
traditional	O
antimicrobials	O
in	O
concert	O
with	O
phage	O
could	O
have	O
desirable	O
synergistic	O
effects	O
that	O
hinder	O
the	O
evolution	O
of	O
resistance	O
.	O

Here	O
,	O
we	O
present	O
a	O
novel	O
insect	O
gut	O
model	O
to	O
study	O
phage	O
-	O
antibiotic	O
interaction	O
in	O
a	O
system	O
where	O
antibiotic	O
resistance	O
initially	O
exists	O
in	O
very	O
low	O
frequency	O
and	O
phage	O
specifically	O
targets	O
the	O
resistance	O
bearing	O
cells	O
.	O

We	O
demonstrate	O
that	O
while	O
phage	O
therapy	O
could	O
not	O
reduce	O
the	O
frequency	O
of	O
target	O
bacteria	O
in	O
the	O
population	O
during	O
positive	O
selection	O
by	O
antibiotics	O
,	O
it	O
alleviated	O
the	O
antibiotic	O
induced	O
blooming	O
by	O
lowering	O
the	O
overall	O
load	O
of	O
resistant	O
cells	O
.	O

The	O
highly	O
structured	O
gut	O
environment	O
had	O
pharmacokinetic	O
effects	O
on	O
both	O
phage	O
and	O
antibiotic	O
dynamics	O
compared	O
with	O
in	O
vitro	O
:	O
antibiotics	O
did	O
not	O
reduce	O
the	O
overall	O
amount	O
of	O
bacteria	O
,	O
demonstrating	O
a	O
simple	O
turnover	O
of	O
gut	O
microbiota	O
from	O
non	O
-	O
resistant	O
to	O
resistant	O
population	O
with	O
little	O
cost	O
.	O

The	O
results	O
imply	O
moderate	O
potential	O
for	O
using	O
phage	O
as	O
an	O
aid	O
to	O
target	O
antibiotic	O
resistant	O
gut	O
infections	O
,	O
and	O
question	O
the	O
usefulness	O
of	O
in	O
vitro	O
inferences	O
.	O

Epithelial	O
-	O
microbial	O
diplomacy	O
:	O
escalating	O
border	O
tensions	O
drive	O
inflammation	O
in	O
inflammatory	O
bowel	O
disease	O
.	O

Inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
are	O
chronic	O
conditions	O
of	O
the	O
gastrointestinal	O
tract	O
-	O
the	O
main	O
site	O
of	O
host	O
-	O
microbial	O
interaction	O
in	O
the	O
body	O
.	O

Development	O
of	O
IBD	O
is	O
not	O
due	O
to	O
a	O
single	O
event	O
but	O
rather	O
is	O
a	O
multifactorial	O
process	O
where	O
a	O
patient	O
'	O
s	O
genetic	O
background	O
,	O
behavioral	O
habits	O
,	O
and	O
environmental	O
exposures	O
contribute	O
to	O
disease	O
pathogenesis	O
.	O

IBD	O
patients	O
exhibit	O
alterations	O
to	O
gut	O
bacterial	O
populations	O
`	O
`	O
dysbiosis	O
'	O
'	O
due	O
to	O
the	O
inflammatory	O
microenvironment	O
,	O
however	O
whether	O
this	O
alteration	O
of	O
the	O
gut	O
microbiota	O
precedes	O
inflammation	O
has	O
not	O
been	O
confirmed	O
.	O

Emerging	O
evidence	O
has	O
highlighted	O
the	O
important	O
role	O
of	O
gut	O
microbes	O
in	O
developing	O
measured	O
immune	O
responses	O
and	O
modulating	O
other	O
host	O
responses	O
such	O
as	O
metabolism	O
.	O

Much	O
of	O
the	O
work	O
on	O
the	O
gut	O
microbiota	O
has	O
been	O
correlative	O
and	O
there	O
is	O
an	O
increasing	O
need	O
to	O
understand	O
the	O
intimate	O
relationship	O
between	O
host	O
and	O
microbe	O
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
how	O
commensal	O
and	O
pathogenic	O
bacteria	O
interact	O
with	O
host	O
intestinal	O
epithelial	O
cells	O
and	O
explore	O
how	O
altered	O
microenvironments	O
impact	O
these	O
connections	O
.	O

Human	O
Gut	O
Microbiome	O
Response	O
Induced	O
by	O
Fermented	O
Dairy	O
Product	O
Intake	O
in	O
Healthy	O
Volunteers	O
.	O

Accumulated	O
data	O
suggests	O
that	O
the	O
gut	O
microbiome	O
can	O
rapidly	O
respond	O
to	O
changes	O
in	O
diet	O
.	O

Consumption	O
of	O
fermented	O
dairy	O
products	O
(	O
FDP	O
)	O
fortified	O
with	O
probiotic	O
microbes	O
may	O
be	O
associated	O
with	O
positive	O
impact	O
on	O
human	O
health	O
.	O

However	O
,	O
the	O
extent	O
and	O
details	O
of	O
the	O
possible	O
impact	O
of	O
FDP	O
consumption	O
on	O
gut	O
community	O
structure	O
tends	O
to	O
vary	O
across	O
individuals	O
.	O

We	O
used	O
microbiome	O
analysis	O
to	O
characterize	O
changes	O
in	O
gut	O
microbiota	O
composition	O
after	O
30	O
days	O
of	O
oral	O
intake	O
of	O
a	O
yoghurt	O
fortified	O
with	O
Bifidobacterium	B-bacteria
animalis	I-bacteria
subsp	I-bacteria
.	I-bacteria
lactis	I-bacteria
BB	I-bacteria
-	I-bacteria
12	I-bacteria
.	O

16S	O
rRNA	O
gene	O
sequencing	O
was	O
used	O
to	O
assess	O
the	O
gut	O
microbial	O
composition	O
before	O
and	O
after	O
FDP	O
consumption	O
in	O
healthy	O
adults	O
(	O
n	O
=	O
150	O
)	O
.	O

Paired	O
comparison	O
of	O
gut	O
microbial	O
content	O
demonstrated	O
an	O
increase	O
in	O
presence	O
of	O
potentially	O
beneficial	O
bacteria	O
,	O
particularly	O
,	O
Bifidobacterium	B-bacteria
genus	I-bacteria
,	O
as	O
well	O
as	O
Adlercreutzia	B-bacteria
equolifaciens	I-bacteria
and	O
Slackia	B-bacteria
isoflavoniconvertens	I-bacteria
.	O

At	O
a	O
functional	O
level	O
,	O
an	O
increased	O
capacity	O
to	O
metabolize	O
lactose	O
and	O
synthesize	O
amino	O
acids	O
was	O
observed	O
accompanied	O
by	O
a	O
lowered	O
potential	O
for	O
synthesis	O
of	O
lipopolysaccharides	O
.	O

Cluster	O
analysis	O
revealed	O
that	O
study	O
volunteers	O
segregated	O
into	O
two	O
groups	O
with	O
post	O
-	O
intervention	O
microbiota	O
response	O
that	O
was	O
dependent	O
on	O
the	O
baseline	O
microbial	O
community	O
structure	O
.	O

HIV	O
-	O
1	O
remission	O
following	O
CCR5Delta32	O
/	O
Delta32	O
haematopoietic	O
stem	O
-	O
cell	O
transplantation	O
.	O

A	O
cure	O
for	O
HIV	O
-	O
1	O
remains	O
unattainable	O
as	O
only	O
one	O
case	O
has	O
been	O
reported	O
,	O
a	O
decade	O
ago	O
(	O
1	O
,	O
2	O
)	O
.	O

The	O
individual	O
-	O
who	O
is	O
known	O
as	O
the	O
'	O
Berlin	O
patient	O
'	O
-	O
underwent	O
two	O
allogeneic	O
haematopoietic	O
stem	O
-	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
procedures	O
using	O
a	O
donor	O
with	O
a	O
homozygous	O
mutation	O
in	O
the	O
HIV	O
coreceptor	O
CCR5	O
(	O
CCR5Delta32	O
/	O
Delta32	O
)	O
to	O
treat	O
his	O
acute	O
myeloid	O
leukaemia	O
.	O

Total	O
body	O
irradiation	O
was	O
given	O
with	O
each	O
HSCT	O
.	O

Notably	O
,	O
it	O
is	O
unclear	O
which	O
treatment	O
or	O
patient	O
parameters	O
contributed	O
to	O
this	O
case	O
of	O
long	O
-	O
term	O
HIV	O
remission	O
.	O

Here	O
we	O
show	O
that	O
HIV	O
-	O
1	O
remission	O
may	O
be	O
possible	O
with	O
a	O
less	O
aggressive	O
and	O
toxic	O
approach	O
.	O

An	O
adult	O
infected	O
with	O
HIV	O
-	O
1	O
underwent	O
allogeneic	O
HSCT	O
for	O
Hodgkin	O
'	O
s	O
lymphoma	O
using	O
cells	O
from	O
a	O
CCR5Delta32	O
/	O
Delta32	O
donor	O
.	O

He	O
experienced	O
mild	O
gut	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
.	O

Antiretroviral	O
therapy	O
was	O
interrupted	O
16	O
months	O
after	O
transplantation	O
.	O

HIV	O
-	O
1	O
remission	O
has	O
been	O
maintained	O
over	O
a	O
further	O
18	O
months	O
.	O

Plasma	O
HIV	O
-	O
1	O
RNA	O
has	O
been	O
undetectable	O
at	O
less	O
than	O
one	O
copy	O
per	O
millilitre	O
along	O
with	O
undetectable	O
HIV	O
-	O
1	O
DNA	O
in	O
peripheral	O
CD4	O
T	O
lymphocytes	O
.	O

Quantitative	O
viral	O
outgrowth	O
assays	O
from	O
peripheral	O
CD4	O
T	O
lymphocytes	O
show	O
no	O
reactivatable	O
virus	O
using	O
a	O
total	O
of	O
24	O
million	O
resting	O
CD4	O
T	O
cells	O
.	O

CCR5	O
-	O
tropic	O
,	O
but	O
not	O
CXCR4	O
-	O
tropic	O
,	O
viruses	O
were	O
identified	O
in	O
HIV	O
-	O
1	O
DNA	O
from	O
CD4	O
T	O
cells	O
of	O
the	O
patient	O
before	O
the	O
transplant	O
.	O

CD4	O
T	O
cells	O
isolated	O
from	O
peripheral	O
blood	O
after	O
transplantation	O
did	O
not	O
express	O
CCR5	O
and	O
were	O
susceptible	O
only	O
to	O
CXCR4	O
-	O
tropic	O
virus	O
ex	O
vivo	O
.	O

HIV	O
-	O
1	O
Gag	O
-	O
specific	O
CD4	O
and	O
CD8	O
T	O
cell	O
responses	O
were	O
lost	O
after	O
transplantation	O
,	O
whereas	O
cytomegalovirus	O
-	O
specific	O
responses	O
were	O
detectable	O
.	O

Similarly	O
,	O
HIV	O
-	O
1	O
-	O
specific	O
antibodies	O
and	O
avidities	O
fell	O
to	O
levels	O
comparable	O
to	O
those	O
in	O
the	O
Berlin	O
patient	O
following	O
transplantation	O
.	O

Although	O
at	O
18	O
months	O
after	O
the	O
interruption	O
of	O
treatment	O
it	O
is	O
premature	O
to	O
conclude	O
that	O
this	O
patient	O
has	O
been	O
cured	O
,	O
these	O
data	O
suggest	O
that	O
a	O
single	O
allogeneic	O
HSCT	O
with	O
homozygous	O
CCR5Delta32	O
donor	O
cells	O
may	O
be	O
sufficient	O
to	O
achieve	O
HIV	O
-	O
1	O
remission	O
with	O
reduced	O
intensity	O
conditioning	O
and	O
no	O
irradiation	O
,	O
and	O
the	O
findings	O
provide	O
further	O
support	O
for	O
the	O
development	O
of	O
HIV	O
-	O
1	O
remission	O
strategies	O
based	O
on	O
preventing	O
CCR5	O
expression	O
.	O

Isolation	O
of	O
Desulfovibrio	B-bacteria
spp	I-bacteria
.	I-bacteria
from	O
human	O
gut	O
microbiota	O
using	O
a	O
next	O
-	O
generation	O
sequencing	O
directed	O
culture	O
method	O
.	O

Desulfovibrio	B-bacteria
spp	I-bacteria
.	I-bacteria
is	O
predominant	O
member	O
of	O
sulphate	O
-	O
reducing	O
bacteria	O
in	O
human	O
gut	O
microbiota	O
.	O

Previous	O
studies	O
indicated	O
that	O
the	O
isolation	O
of	O
Desulfovibrio	B-bacteria
strains	I-bacteria
from	O
human	O
faecal	O
samples	O
is	O
very	O
important	O
to	O
study	O
the	O
roles	O
of	O
human	O
intestinal	O
Desulfovibrio	B-bacteria
spp	I-bacteria
.	I-bacteria
in	O
maintaining	O
healthy	O
states	O
or	O
causing	O
diseases	O
,	O
as	O
well	O
as	O
defining	O
their	O
biological	O
characteristics	O
.	O

However	O
,	O
there	O
are	O
very	O
few	O
reports	O
describing	O
the	O
isolation	O
of	O
Desulfovibrio	B-bacteria
spp	I-bacteria
.	I-bacteria
from	O
human	O
faecal	O
samples	O
.	O

In	O
this	O
study	O
,	O
faecal	O
samples	O
were	O
inoculated	O
into	O
various	O
media	O
containing	O
different	O
components	O
.	O

The	O
enriched	O
culture	O
communities	O
were	O
identified	O
using	O
16S	O
rRNA	O
gene	O
high	O
-	O
throughput	O
sequencing	O
analysis	O
,	O
enabling	O
us	O
to	O
identify	O
the	O
specific	O
components	O
that	O
enable	O
the	O
enrichment	O
of	O
Desulfovibrio	B-bacteria
.	O

Using	O
this	O
information	O
,	O
we	O
developed	O
five	O
specific	O
media	O
and	O
identified	O
an	O
effective	O
enrichment	O
medium	O
that	O
produced	O
the	O
highest	O
relative	O
abundance	O
of	O
Desulfovibrio	B-bacteria
in	O
communities	O
cultured	O
from	O
four	O
faecal	O
samples	O
(	O
26	O
.	O
5	O
,	O
73	O
.	O
5	O
,	O
44	O
.	O
7	O
and	O
77	O
.	O
6	O
%	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
the	O
major	O
non	O
-	O
Desulfovibrio	B-bacteria
genera	I-bacteria
were	O
identified	O
.	O

Finally	O
,	O
three	O
species	O
of	O
Desulfovibrio	B-bacteria
,	O
D	B-bacteria
.	I-bacteria
desulfuricans	I-bacteria
,	O
D	B-bacteria
.	I-bacteria
piger	I-bacteria
and	O
D	B-bacteria
.	I-bacteria
legallii	I-bacteria
were	O
isolated	O
,	O
representing	O
the	O
first	O
time	O
that	O
has	O
D	B-bacteria
.	I-bacteria
legallii	I-bacteria
been	O
isolated	O
from	O
a	O
human	O
gastrointestinal	O
source	O
.	O

SIGNIFICANCE	O
AND	O
IMPACT	O
OF	O
THE	O
STUDY	O
:	O
ost	O
of	O
the	O
human	O
intestinal	O
bacteria	O
have	O
not	O
been	O
cultured	O
because	O
of	O
lack	O
of	O
appropriate	O
culture	O
method	O
and	O
appropriate	O
media	O
.	O

Desulfovibrio	B-bacteria
spp	I-bacteria
.	I-bacteria
is	O
associated	O
with	O
several	O
clinical	O
conditions	O
like	O
inflammatory	O
bowel	O
disease	O
,	O
but	O
until	O
now	O
there	O
are	O
very	O
few	O
reports	O
describing	O
the	O
isolation	O
of	O
Desulfovibrio	B-bacteria
spp	I-bacteria
.	I-bacteria
from	O
human	O
faecal	O
samples	O
.	O

In	O
this	O
study	O
,	O
16S	O
rRNA	O
gene	O
high	O
-	O
throughput	O
sequencing	O
analysis	O
was	O
applied	O
to	O
screen	O
appropriate	O
enrichment	O
media	O
and	O
selective	O
cultivation	O
of	O
Desulfovibrio	B-bacteria
.	O

This	O
sequencing	O
-	O
based	O
directed	O
culture	O
method	O
described	O
here	O
can	O
be	O
used	O
for	O
the	O
selective	O
cultivation	O
of	O
gut	O
bacteria	O
of	O
interest	O
.	O

X	O
-	O
ray	O
Structures	O
of	O
Two	O
Bacteroides	B-bacteria
thetaiotaomicron	I-bacteria
C11	I-bacteria
Proteases	O
in	O
Complex	O
with	O
Peptide	O
-	O
Based	O
Inhibitors	O
.	O

Commensal	O
bacteria	O
secrete	O
proteins	O
and	O
metabolites	O
to	O
influence	O
host	O
intestinal	O
homeostasis	O
,	O
and	O
proteases	O
represent	O
a	O
significant	O
constituent	O
of	O
the	O
components	O
at	O
the	O
host	O
:	O
microbiome	O
interface	O
.	O

Here	O
,	O
we	O
determined	O
the	O
structures	O
of	O
the	O
two	O
secreted	O
C11	O
cysteine	O
proteases	O
encoded	O
by	O
the	O
established	O
gut	O
commensal	O
Bacteroides	B-bacteria
thetaiotaomicron	I-bacteria
.	O

We	O
employed	O
mutational	O
analysis	O
to	O
demonstrate	O
the	O
two	O
proteases	O
,	O
termed	O
`	O
`	O
thetapain	O
'	O
'	O
and	O
`	O
`	O
iotapain	O
'	O
'	O
,	O
undergo	O
in	O
trans	O
autoactivation	O
after	O
lysine	O
and	O
/	O
or	O
arginine	O
residues	O
,	O
as	O
observed	O
for	O
other	O
C11	O
proteases	O
.	O

We	O
determined	O
the	O
structures	O
of	O
the	O
active	O
forms	O
of	O
thetapain	O
and	O
iotapain	O
in	O
complex	O
with	O
irreversible	O
peptide	O
inhibitors	O
,	O
Ac	O
-	O
VLTK	O
-	O
AOMK	O
and	O
biotin	O
-	O
VLTK	O
-	O
AOMK	O
,	O
respectively	O
.	O

Structural	O
comparisons	O
revealed	O
key	O
active	O
-	O
site	O
interactions	O
important	O
for	O
peptide	O
recognition	O
are	O
more	O
extensive	O
for	O
thetapain	O
;	O
however	O
,	O
both	O
proteases	O
employ	O
a	O
glutamate	O
residue	O
to	O
preferentially	O
bind	O
small	O
polar	O
residues	O
at	O
the	O
P2	O
position	O
.	O

Our	O
results	O
will	O
aid	O
in	O
the	O
design	O
of	O
protease	O
-	O
specific	O
probes	O
to	O
ultimately	O
understand	O
the	O
biological	O
role	O
of	O
C11	O
proteases	O
in	O
bacterial	O
fitness	O
,	O
elucidate	O
their	O
host	O
and	O
/	O
or	O
microbial	O
substrates	O
,	O
and	O
interrogate	O
their	O
involvement	O
in	O
microbiome	O
-	O
related	O
diseases	O
.	O

Impact	O
of	O
Preservation	O
Method	O
and	O
16S	O
rRNA	O
Hypervariable	O
Region	O
on	O
Gut	O
Microbiota	O
Profiling	O
.	O

Proper	O
preservation	O
of	O
stool	O
samples	O
to	O
minimize	O
microbial	O
community	O
shifts	O
and	O
inactivate	O
infectious	O
agents	O
is	O
important	O
for	O
self	O
-	O
collected	O
specimens	O
requiring	O
shipment	O
to	O
laboratories	O
when	O
cold	O
chain	O
transport	O
is	O
not	O
feasible	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
performance	O
of	O
six	O
preservation	O
solutions	O
(	O
Norgen	O
,	O
OMNI	O
,	O
RNAlater	O
,	O
CURNA	O
,	O
HEMA	O
,	O
and	O
Shield	O
)	O
for	O
these	O
aspects	O
.	O

Following	O
storage	O
of	O
human	O
stool	O
samples	O
with	O
these	O
preservatives	O
at	O
room	O
temperature	O
for	O
7	O
days	O
,	O
three	O
hypervariable	O
regions	O
of	O
the	O
bacterial	O
16S	O
rRNA	O
gene	O
(	O
V1	O
-	O
V2	O
,	O
V3	O
-	O
V4	O
,	O
and	O
V4	O
)	O
were	O
amplicon	O
sequenced	O
.	O

We	O
found	O
that	O
samples	O
collected	O
in	O
two	O
preservatives	O
,	O
Norgen	O
and	O
OMNI	O
,	O
showed	O
the	O
least	O
shift	O
in	O
community	O
composition	O
relative	O
to	O
-	O
80	O
degrees	O
C	O
standards	O
compared	O
with	O
other	O
storage	O
conditions	O
,	O
and	O
both	O
efficiently	O
inhibited	O
the	O
growth	O
of	O
aerobic	O
and	O
anaerobic	O
bacteria	O
.	O

RNAlater	O
did	O
not	O
prevent	O
bacterial	O
activity	O
and	O
exhibited	O
relatively	O
larger	O
community	O
shift	O
.	O

Although	O
the	O
effect	O
of	O
preservation	O
solution	O
was	O
small	O
compared	O
to	O
intersubject	O
variation	O
,	O
notable	O
changes	O
in	O
microbiota	O
composition	O
were	O
observed	O
,	O
which	O
could	O
create	O
biases	O
in	O
downstream	O
data	O
analysis	O
.	O

When	O
community	O
profiles	O
inferred	O
from	O
different	O
16S	O
rRNA	O
gene	O
hypervariable	O
regions	O
were	O
compared	O
,	O
we	O
found	O
differential	O
sensitivity	O
of	O
primer	O
sets	O
in	O
identifying	O
overall	O
microbial	O
community	O
and	O
certain	O
bacterial	O
taxa	O
.	O

For	O
example	O
,	O
reads	O
generated	O
by	O
the	O
V4	O
primer	O
pair	O
showed	O
a	O
higher	O
alpha	O
diversity	O
of	O
the	O
gut	O
microbial	O
community	O
.	O

The	O
degenerate	O
27f	O
-	O
YM	O
primer	O
failed	O
to	O
detect	O
the	O
majority	O
of	O
Bifidobacteriales	B-bacteria
.	O

Our	O
data	O
indicate	O
that	O
choice	O
of	O
preservation	O
solution	O
and	O
16S	O
rRNA	O
gene	O
primer	O
pair	O
are	O
critical	O
determinants	O
affecting	O
gut	O
microbiota	O
profiling	O
.	O

IMPORTANCE	O
Large	O
-	O
scale	O
human	O
microbiota	O
studies	O
require	O
specimens	O
collected	O
from	O
multiple	O
sites	O
and	O
/	O
or	O
time	O
points	O
to	O
maximize	O
detection	O
of	O
the	O
small	O
effects	O
in	O
microbe	O
-	O
host	O
interactions	O
.	O

However	O
,	O
batch	O
biases	O
caused	O
by	O
experimental	O
protocols	O
,	O
such	O
as	O
sample	O
collection	O
,	O
massively	O
parallel	O
sequencing	O
,	O
and	O
bioinformatics	O
analyses	O
,	O
remain	O
critical	O
and	O
should	O
be	O
minimized	O
.	O

This	O
work	O
evaluated	O
the	O
effects	O
of	O
preservation	O
solutions	O
and	O
bacterial	O
16S	O
rRNA	O
gene	O
primer	O
pairs	O
in	O
revealing	O
human	O
gut	O
microbiota	O
composition	O
.	O

Since	O
notable	O
changes	O
in	O
detecting	O
bacterial	O
composition	O
and	O
abundance	O
were	O
observed	O
among	O
choice	O
of	O
preservatives	O
and	O
primer	O
pairs	O
,	O
a	O
consistent	O
methodology	O
is	O
essential	O
in	O
minimizing	O
their	O
effects	O
to	O
facilitate	O
comparisons	O
between	O
data	O
sets	O
.	O

Procyanidin	O
B2	O
protects	O
against	O
diet	O
-	O
induced	O
obesity	O
and	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
via	O
the	O
modulation	O
of	O
the	O
gut	O
microbiota	O
in	O
rabbits	O
.	O

BACKGROUND	O
:	O
Procyanidins	O
have	O
beneficial	O
effects	O
on	O
metabolic	O
syndrome	O
and	O
antimicrobial	O
activity	O
,	O
but	O
the	O
mechanisms	O
underlying	O
these	O
effects	O
are	O
unclear	O
.	O

AIM	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
procyanidin	O
B2	O
(	O
PB2	O
)	O
on	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
and	O
to	O
explore	O
the	O
possible	O
mechanism	O
.	O

METHODS	O
:	O
Thirty	O
male	O
New	O
Zealand	O
white	O
rabbits	O
were	O
randomized	O
into	O
three	O
groups	O
.	O

All	O
of	O
them	O
were	O
fed	O
either	O
a	O
high	O
-	O
fat	O
-	O
cholesterol	O
diet	O
(	O
HCD	O
)	O
or	O
chow	O
diet	O
.	O

HCD	O
-	O
fed	O
rabbits	O
were	O
treated	O
with	O
vehicle	O
or	O
PB2	O
daily	O
for	O
12	O
wk	O
.	O

Body	O
weight	O
and	O
food	O
intake	O
were	O
evaluated	O
once	O
a	O
week	O
.	O

Serum	O
biomarkers	O
,	O
such	O
as	O
total	O
cholesterols	O
,	O
triglycerides	O
,	O
and	O
aspartate	O
transaminase	O
,	O
were	O
detected	O
.	O

All	O
rabbits	O
were	O
sacrificed	O
and	O
histological	O
parameters	O
of	O
liver	O
were	O
assessed	O
by	O
hematoxylin	O
and	O
eosin	O
-	O
stained	O
sections	O
.	O

Moreover	O
,	O
several	O
lipogenic	O
genes	O
and	O
gut	O
microbiota	O
(	O
by	O
16S	O
rRNA	O
sequencing	O
)	O
were	O
investigated	O
to	O
explore	O
the	O
possible	O
mechanism	O
.	O

RESULTS	O
:	O
The	O
HCD	O
group	O
had	O
higher	O
body	O
weight	O
,	O
liver	O
index	O
,	O
serum	O
lipid	O
profile	O
,	O
insulin	O
resistance	O
,	O
serum	O
glucose	O
,	O
and	O
hepatic	O
steatosis	O
compared	O
to	O
the	O
CHOW	O
group	O
.	O

PB2	O
treatment	O
prevented	O
HCD	O
-	O
induced	O
increases	O
in	O
body	O
weight	O
and	O
hypertriglyceridemia	O
in	O
association	O
with	O
triglyceride	O
accumulation	O
in	O
the	O
liver	O
.	O

PB2	O
also	O
ameliorated	O
low	O
-	O
grade	O
inflammation	O
,	O
which	O
was	O
reflected	O
by	O
serum	O
lipopolysaccharides	O
and	O
improved	O
insulin	O
resistance	O
.	O

In	O
rabbit	O
liver	O
,	O
PB2	O
prevented	O
the	O
upregulation	O
of	O
steroid	O
response	O
element	O
binding	O
protein	O
1c	O
and	O
fatty	O
acid	O
synthase	O
and	O
the	O
downregulation	O
of	O
carnitine	O
palmitoyltransferase	O
,	O
compared	O
to	O
the	O
HCD	O
group	O
.	O

Moreover	O
,	O
HCD	O
led	O
to	O
a	O
decrease	O
of	O
Bacteroidetes	B-bacteria
in	O
gut	O
microbiota	O
.	O

PB2	O
significantly	O
improved	O
the	O
proportions	O
of	O
Bacteroidetes	B-bacteria
at	O
the	O
phylum	O
level	O
and	O
Akkermansia	B-bacteria
at	O
the	O
genus	O
level	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
indicate	O
the	O
possible	O
mechanism	O
of	O
PB2	O
to	O
improve	O
HCD	O
-	O
induced	O
features	O
of	O
metabolic	O
syndrome	O
and	O
provide	O
a	O
new	O
dietary	O
supplement	O
.	O

BCR	O
affinity	O
differentially	O
regulates	O
colonization	O
of	O
the	O
subepithelial	O
dome	O
and	O
infiltration	O
into	O
germinal	O
centers	O
within	O
Peyer	O
'	O
s	O
patches	O
.	O

Gut	O
-	O
derived	O
antigens	O
trigger	O
immunoglobulin	O
A	O
(	O
IgA	O
)	O
immune	O
responses	O
that	O
are	O
initiated	O
by	O
cognate	O
B	O
cells	O
in	O
Peyer	O
'	O
s	O
patches	O
(	O
PPs	O
)	O
.	O

These	O
cells	O
colonize	O
the	O
subepithelial	O
domes	O
(	O
SEDs	O
)	O
of	O
the	O
PPs	O
and	O
subsequently	O
infiltrate	O
pre	O
-	O
existing	O
germinal	O
centers	O
(	O
GCs	O
)	O
.	O

Here	O
we	O
defined	O
the	O
pre	O
-	O
GC	O
events	O
and	O
the	O
micro	O
-	O
anatomical	O
site	O
at	O
which	O
affinity	O
-	O
based	O
B	O
cell	O
selection	O
occurred	O
in	O
PPs	O
.	O

Using	O
whole	O
-	O
organ	O
imaging	O
,	O
we	O
showed	O
that	O
the	O
affinity	O
of	O
the	O
B	O
cell	O
antigen	O
receptor	O
(	O
BCR	O
)	O
regulated	O
the	O
infiltration	O
of	O
antigen	O
-	O
specific	O
B	O
cells	O
into	O
GCs	O
but	O
not	O
clonal	O
competition	O
in	O
the	O
SED	O
.	O

Follicular	O
helper	O
-	O
like	O
T	O
cells	O
resided	O
in	O
the	O
SED	O
and	O
promoted	O
its	O
B	O
cell	O
colonization	O
,	O
independently	O
of	O
the	O
magnitude	O
of	O
BCR	O
affinity	O
.	O

Imaging	O
and	O
immunoglobulin	O
sequencing	O
indicated	O
that	O
selective	O
clonal	O
expansion	O
ensued	O
during	O
infiltration	O
into	O
GCs	O
.	O

Thus	O
,	O
in	O
contrast	O
to	O
the	O
events	O
in	O
draining	O
lymph	O
nodes	O
and	O
spleen	O
,	O
in	O
PPs	O
,	O
T	O
cells	O
promoted	O
mainly	O
the	O
population	O
expansion	O
of	O
B	O
cells	O
without	O
clonal	O
selection	O
during	O
pre	O
-	O
GC	O
events	O
.	O

These	O
findings	O
have	O
major	O
implications	O
for	O
the	O
design	O
of	O
oral	O
vaccines	O
.	O

Oral	O
bacteria	O
colonize	O
and	O
compete	O
with	O
gut	O
microbiota	O
in	O
gnotobiotic	O
mice	O
.	O

The	O
oral	O
microbiota	O
is	O
associated	O
with	O
oral	O
diseases	O
and	O
digestive	O
systemic	O
diseases	O
.	O

Nevertheless	O
,	O
the	O
causal	O
relationship	O
between	O
them	O
has	O
not	O
been	O
completely	O
elucidated	O
,	O
and	O
colonisation	O
of	O
the	O
gut	O
by	O
oral	O
bacteria	O
is	O
not	O
clear	O
due	O
to	O
the	O
limitations	O
of	O
existing	O
research	O
models	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
human	O
oral	O
microbiota	O
-	O
associated	O
(	O
HOMA	O
)	O
mouse	O
model	O
and	O
to	O
investigate	O
the	O
ecological	O
invasion	O
into	O
the	O
gut	O
.	O

By	O
transplanting	O
human	O
saliva	O
into	O
germ	O
-	O
free	O
(	O
GF	O
)	O
mice	O
,	O
a	O
HOMA	O
mouse	O
model	O
was	O
first	O
constructed	O
.	O

16S	O
rRNA	O
gene	O
sequencing	O
was	O
used	O
to	O
reveal	O
the	O
biogeography	O
of	O
oral	O
bacteria	O
along	O
the	O
cephalocaudal	O
axis	O
of	O
the	O
digestive	O
tract	O
.	O

In	O
the	O
HOMA	O
mice	O
,	O
84	O
.	O
78	O
%	O
of	O
the	O
detected	O
genus	O
-	O
level	O
taxa	O
were	O
specific	O
to	O
the	O
donor	O
.	O

Principal	O
component	O
analysis	O
(	O
PCA	O
)	O
revealed	O
that	O
the	O
donor	O
oral	O
microbiota	O
clustered	O
with	O
those	O
of	O
the	O
HOMA	O
mice	O
and	O
were	O
distinct	O
from	O
those	O
of	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
mice	O
.	O

In	O
HOMA	O
mice	O
,	O
OTU	O
counts	O
decreased	O
from	O
the	O
stomach	O
and	O
small	O
intestine	O
to	O
the	O
distal	O
gut	O
.	O

The	O
distal	O
gut	O
was	O
dominated	O
by	O
Streptococcus	B-bacteria
,	O
Veillonella	B-bacteria
,	O
Haemophilus	B-bacteria
,	O
Fusobacterium	B-bacteria
,	O
Trichococcus	B-bacteria
and	O
Actinomyces	B-bacteria
.	O

HOMA	O
mice	O
and	O
human	O
microbiota	O
-	O
associated	O
(	O
HMA	O
)	O
mice	O
along	O
with	O
the	O
GF	O
mice	O
were	O
then	O
cohoused	O
.	O

Microbial	O
communities	O
of	O
cohoused	O
mice	O
clustered	O
together	O
and	O
were	O
significantly	O
separated	O
from	O
those	O
of	O
HOMA	O
mice	O
and	O
HMA	O
mice	O
.	O

The	O
Source	O
Tracker	O
analysis	O
and	O
network	O
analysis	O
revealed	O
more	O
significant	O
ecological	O
invasion	O
from	O
oral	O
bacteria	O
in	O
the	O
small	O
intestines	O
,	O
compared	O
to	O
the	O
distal	O
gut	O
,	O
of	O
cohoused	O
mice	O
.	O

In	O
conclusion	O
,	O
a	O
HOMA	O
mouse	O
model	O
was	O
successfully	O
established	O
.	O

By	O
overcoming	O
the	O
physical	O
and	O
microbial	O
barrier	O
,	O
oral	O
bacteria	O
colonised	O
the	O
gut	O
and	O
profiled	O
the	O
gut	O
microbiota	O
,	O
especially	O
in	O
the	O
small	O
intestine	O
.	O

MetaCHIP	O
:	O
community	O
-	O
level	O
horizontal	O
gene	O
transfer	O
identification	O
through	O
the	O
combination	O
of	O
best	O
-	O
match	O
and	O
phylogenetic	O
approaches	O
.	O

BACKGROUND	O
:	O
Metagenomic	O
datasets	O
provide	O
an	O
opportunity	O
to	O
study	O
horizontal	O
gene	O
transfer	O
(	O
HGT	O
)	O
on	O
the	O
level	O
of	O
a	O
microbial	O
community	O
.	O

However	O
,	O
current	O
HGT	O
detection	O
methods	O
can	O
not	O
be	O
applied	O
to	O
community	O
-	O
level	O
datasets	O
or	O
require	O
reference	O
genomes	O
.	O

Here	O
,	O
we	O
present	O
MetaCHIP	O
,	O
a	O
pipeline	O
for	O
reference	O
-	O
independent	O
HGT	O
identification	O
at	O
the	O
community	O
level	O
.	O

RESULTS	O
:	O
Assessment	O
of	O
MetaCHIP	O
'	O
s	O
performance	O
on	O
simulated	O
datasets	O
revealed	O
that	O
it	O
can	O
predict	O
HGTs	O
with	O
various	O
degrees	O
of	O
genetic	O
divergence	O
from	O
metagenomic	O
datasets	O
.	O

The	O
results	O
also	O
indicated	O
that	O
the	O
detection	O
of	O
very	O
recent	O
gene	O
transfers	O
(	O
i	O
.	O
e	O
.	O

those	O
with	O
low	O
levels	O
of	O
genetic	O
divergence	O
)	O
from	O
metagenomics	O
datasets	O
is	O
largely	O
affected	O
by	O
the	O
read	O
assembly	O
step	O
.	O

Comparison	O
of	O
MetaCHIP	O
with	O
a	O
previous	O
analysis	O
on	O
soil	O
bacteria	O
showed	O
a	O
high	O
level	O
of	O
consistency	O
for	O
the	O
prediction	O
of	O
recent	O
HGTs	O
and	O
revealed	O
a	O
large	O
number	O
of	O
additional	O
non	O
-	O
recent	O
gene	O
transfers	O
,	O
which	O
can	O
provide	O
new	O
biological	O
and	O
ecological	O
insight	O
.	O

Assessment	O
of	O
MetaCHIP	O
'	O
s	O
performance	O
on	O
real	O
metagenomic	O
datasets	O
confirmed	O
the	O
role	O
of	O
HGT	O
in	O
the	O
spread	O
of	O
genes	O
related	O
to	O
antibiotic	O
resistance	O
in	O
the	O
human	O
gut	O
microbiome	O
.	O

Further	O
testing	O
also	O
showed	O
that	O
functions	O
related	O
to	O
energy	O
production	O
and	O
conversion	O
as	O
well	O
as	O
carbohydrate	O
transport	O
and	O
metabolism	O
are	O
frequently	O
transferred	O
among	O
free	O
-	O
living	O
microorganisms	O
.	O

CONCLUSION	O
:	O
MetaCHIP	O
provides	O
an	O
opportunity	O
to	O
study	O
HGTs	O
among	O
members	O
of	O
a	O
microbial	O
community	O
and	O
therefore	O
has	O
several	O
applications	O
in	O
the	O
field	O
of	O
microbial	O
ecology	O
and	O
evolution	O
.	O

MetaCHIP	O
is	O
implemented	O
in	O
Python	O
and	O
freely	O
available	O
at	O
https	O
:	O
/	O
/	O
github	O
.	O
com	O
/	O
songweizhi	O
/	O
MetaCHIP	O
.	O

Using	O
formalin	O
fixed	O
paraffin	O
embedded	O
tissue	O
to	O
characterize	O
the	O
preterm	O
gut	O
microbiota	O
in	O
necrotising	O
enterocolitis	O
and	O
spontaneous	O
isolated	O
perforation	O
using	O
marginal	O
and	O
diseased	O
tissue	O
.	O

BACKGROUND	O
:	O
Necrotising	O
enterocolitis	O
(	O
NEC	O
)	O
is	O
a	O
common	O
cause	O
of	O
death	O
in	O
preterm	O
infants	O
and	O
is	O
closely	O
linked	O
to	O
the	O
gut	O
microbiota	O
.	O

Spontaneous	O
intestinal	O
perforation	O
(	O
SIP	O
)	O
also	O
occurs	O
in	O
preterm	O
neonates	O
,	O
but	O
results	O
in	O
lower	O
mortality	O
and	O
less	O
adverse	O
neonatal	O
outcomes	O
than	O
NEC	O
.	O

Existing	O
studies	O
are	O
largely	O
limited	O
to	O
non	O
-	O
invasive	O
stool	O
samples	O
,	O
which	O
may	O
not	O
be	O
reflective	O
of	O
the	O
anatomical	O
site	O
of	O
disease	O
.	O

Therefore	O
,	O
we	O
analysed	O
historical	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
tissue	O
from	O
NEC	O
and	O
SIP	O
preterm	O
infants	O
.	O

A	O
total	O
of	O
13	O
NEC	O
and	O
16	O
SIP	O
infants	O
were	O
included	O
.	O

Extracted	O
DNA	O
from	O
FFPE	O
tissue	O
blocks	O
underwent	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

For	O
a	O
subset	O
of	O
infants	O
,	O
diseased	O
tissue	O
and	O
marginal	O
healthy	O
tissue	O
from	O
the	O
same	O
infant	O
were	O
compared	O
.	O

RESULTS	O
:	O
Xylene	O
provided	O
a	O
cost	O
and	O
time	O
effective	O
means	O
of	O
deparaffinization	O
.	O

Tissue	O
from	O
the	O
site	O
of	O
disease	O
was	O
highly	O
comparable	O
to	O
adjacent	O
healthier	O
tissue	O
.	O

Comparing	O
only	O
diseased	O
tissue	O
from	O
all	O
infants	O
showed	O
significantly	O
lower	O
Shannon	O
diversity	O
in	O
NEC	O
(	O
P	O
=	O
0	O
.	O
026	O
)	O
.	O

The	O
overall	O
bacterial	O
communities	O
were	O
also	O
significantly	O
different	O
in	O
NEC	O
samples	O
compared	O
to	O
SIP	O
(	O
P	O
=	O
0	O
.	O
038	O
)	O
,	O
and	O
large	O
variability	O
within	O
NEC	O
infants	O
was	O
observed	O
.	O

While	O
no	O
single	O
OTU	O
or	O
genus	O
was	O
significantly	O
associated	O
with	O
NEC	O
or	O
SIP	O
,	O
at	O
the	O
phylum	O
level	O
Proteobacteria	B-bacteria
(	O
P	O
=	O
0	O
.	O
045	O
)	O
and	O
Bacteroidetes	B-bacteria
(	O
P	O
=	O
0	O
.	O
024	O
)	O
were	O
significantly	O
higher	O
in	O
NEC	O
and	O
SIP	O
infants	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
Existing	O
banks	O
of	O
intestinal	O
FFPE	O
blocks	O
provide	O
a	O
robust	O
and	O
specific	O
sample	O
for	O
profiling	O
the	O
microbiota	O
at	O
the	O
site	O
of	O
disease	O
.	O

We	O
showed	O
preterm	O
infants	O
with	O
NEC	O
have	O
lower	O
diversity	O
and	O
different	O
bacterial	O
communities	O
when	O
compared	O
to	O
SIP	O
controls	O
.	O

Alterations	O
of	O
Bile	O
Acids	O
and	O
Gut	O
Microbiota	O
in	O
Obesity	O
Induced	O
by	O
High	O
Fat	O
Diet	O
in	O
Rat	O
Model	O
.	O

Obesity	O
has	O
become	O
a	O
worldwide	O
health	O
issue	O
and	O
has	O
attracted	O
much	O
public	O
attention	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
aim	O
to	O
elucidate	O
the	O
roles	O
of	O
bile	O
acids	O
and	O
their	O
associations	O
with	O
gut	O
microbiota	O
during	O
obesity	O
development	O
,	O
employing	O
high	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
obesity	O
in	O
a	O
rat	O
model	O
.	O

We	O
collected	O
feces	O
and	O
plasma	O
,	O
liver	O
tissues	O
,	O
and	O
segments	O
of	O
intestinal	O
tissues	O
and	O
a	O
developed	O
bile	O
acids	O
quantification	O
method	O
by	O
employing	O
an	O
ultraperformance	O
liquid	O
chromatography	O
coupled	O
with	O
mass	O
spectrometry	O
detection	O
(	O
UPLC	O
-	O
MS	O
)	O
strategy	O
.	O

We	O
then	O
assessed	O
bile	O
acids	O
fluxes	O
in	O
the	O
biological	O
matrixes	O
collected	O
.	O

We	O
found	O
that	O
,	O
irrespective	O
of	O
dietary	O
regimes	O
,	O
taurine	O
-	O
conjugated	O
bile	O
acids	O
were	O
the	O
dominant	O
species	O
in	O
the	O
liver	O
whereas	O
unconjugated	O
bile	O
acids	O
were	O
in	O
plasma	O
.	O

However	O
,	O
HFD	O
caused	O
slight	O
increases	O
in	O
the	O
total	O
bile	O
acids	O
pool	O
and	O
particularly	O
the	O
increases	O
in	O
the	O
levels	O
of	O
deoxycholic	O
acid	O
(	O
DCA	O
)	O
(	O
138	O
.	O
67	O
+	O
/	O
-	O
37	O
.	O
225	O
nmol	O
/	O
L	O
in	O
control	O
group	O
,	O
242	O
.	O
61	O
+	O
/	O
-	O
43	O
.	O
16	O
nmol	O
/	O
L	O
in	O
HFD	O
group	O
,	O
p	O
=	O
0	O
.	O
014	O
)	O
and	O
taurodeoxycholic	O
acid	O
(	O
TDCA	O
)	O
(	O
2	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
247	O
nmol	O
/	O
g	O
in	O
control	O
group	O
,	O
4	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
386	O
nmol	O
/	O
g	O
in	O
HFD	O
group	O
,	O
p	O
=	O
0	O
.	O
0018	O
)	O
in	O
plasma	O
and	O
liver	O
tissues	O
,	O
respectively	O
,	O
which	O
were	O
consistent	O
with	O
the	O
increased	O
levels	O
of	O
DCA	O
in	O
intestinal	O
tissues	O
and	O
feces	O
.	O

These	O
changes	O
are	O
correlated	O
to	O
an	O
increase	O
in	O
abundance	O
of	O
genera	O
Blautia	B-bacteria
,	O
Coprococcus	B-bacteria
,	O
Intestinimonas	B-bacteria
,	O
Lactococcus	B-bacteria
,	O
Roseburia	B-bacteria
,	O
and	O
Ruminococcus	B-bacteria
.	O

Our	O
investigation	O
revealed	O
the	O
fluxes	O
of	O
bile	O
acids	O
and	O
their	O
association	O
with	O
gut	O
microbiota	O
during	O
obesity	O
development	O
and	O
explicated	O
unfavorable	O
impact	O
of	O
HFD	O
on	O
health	O
.	O

Probiotics	O
and	O
Prebiotics	O
for	O
the	O
Amelioration	O
of	O
Type	O
1	O
Diabetes	O
:	O
Present	O
and	O
Future	O
Perspectives	O
.	O

Type	O
1	O
-	O
diabetes	O
(	O
T1D	O
)	O
is	O
an	O
autoimmune	O
disease	O
characterized	O
by	O
immune	O
-	O
mediated	O
destruction	O
of	O
pancreatic	O
beta	O
(	O
beta	O
)	O
-	O
cells	O
.	O

Genetic	O
and	O
environmental	O
interactions	O
play	O
an	O
important	O
role	O
in	O
immune	O
system	O
malfunction	O
by	O
priming	O
an	O
aggressive	O
adaptive	O
immune	O
response	O
against	O
beta	O
-	O
cells	O
.	O

The	O
microbes	O
inhabiting	O
the	O
human	O
intestine	O
closely	O
interact	O
with	O
the	O
enteric	O
mucosal	O
immune	O
system	O
.	O

Gut	O
microbiota	O
colonization	O
and	O
immune	O
system	O
maturation	O
occur	O
in	O
parallel	O
during	O
early	O
years	O
of	O
life	O
;	O
hence	O
,	O
perturbations	O
in	O
the	O
gut	O
microbiota	O
can	O
impair	O
the	O
functions	O
of	O
immune	O
cells	O
and	O
vice	O
-	O
versa	O
.	O

Abnormal	O
gut	O
microbiota	O
perturbations	O
(	O
dysbiosis	O
)	O
are	O
often	O
detected	O
in	O
T1D	O
subjects	O
,	O
particularly	O
those	O
diagnosed	O
as	O
multiple	O
-	O
autoantibody	O
-	O
positive	O
as	O
a	O
result	O
of	O
an	O
aggressive	O
and	O
adverse	O
immunoresponse	O
.	O

The	O
pathogenesis	O
of	O
T1D	O
involves	O
activation	O
of	O
self	O
-	O
reactive	O
T	O
-	O
cells	O
,	O
resulting	O
in	O
the	O
destruction	O
of	O
beta	O
-	O
cells	O
by	O
CD8	O
(	O
+	O
)	O
T	O
-	O
lymphocytes	O
.	O

It	O
is	O
also	O
becoming	O
clear	O
that	O
gut	O
microbes	O
interact	O
closely	O
with	O
T	O
-	O
cells	O
.	O

The	O
amelioration	O
of	O
gut	O
dysbiosis	O
using	O
specific	O
probiotics	O
and	O
prebiotics	O
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
decline	O
in	O
the	O
autoimmune	O
response	O
(	O
with	O
diminished	O
inflammation	O
)	O
and	O
gut	O
integrity	O
(	O
through	O
increased	O
expression	O
of	O
tight	O
-	O
junction	O
proteins	O
in	O
the	O
intestinal	O
epithelium	O
)	O
.	O

This	O
review	O
discusses	O
the	O
potential	O
interactions	O
between	O
gut	O
microbiota	O
and	O
immune	O
mechanisms	O
that	O
are	O
involved	O
in	O
the	O
progression	O
of	O
T1D	O
and	O
contemplates	O
the	O
potential	O
effects	O
and	O
prospects	O
of	O
gut	O
microbiota	O
modulators	O
,	O
including	O
probiotic	O
and	O
prebiotic	O
interventions	O
,	O
in	O
the	O
amelioration	O
of	O
T1D	O
pathology	O
,	O
in	O
both	O
human	O
and	O
animal	O
models	O
.	O

Immunomodulatory	O
potential	O
of	O
gut	O
microbiome	O
-	O
derived	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
.	O

Intestinal	O
microbiota	O
is	O
an	O
element	O
of	O
the	O
bacterial	O
ecosystem	O
in	O
all	O
mammalian	O
organisms	O
.	O

These	O
microorganisms	O
play	O
a	O
very	O
important	O
part	O
in	O
the	O
development	O
,	O
functioning	O
,	O
and	O
modulation	O
of	O
the	O
immune	O
system	O
from	O
the	O
moment	O
of	O
birth	O
.	O

In	O
recent	O
years	O
,	O
owing	O
to	O
the	O
use	O
of	O
modern	O
sequencing	O
techniques	O
,	O
the	O
microbiome	O
composition	O
in	O
healthy	O
people	O
has	O
been	O
identified	O
based	O
on	O
bacterial	O
16S	O
rRNA	O
analysis	O
.	O

Currently	O
,	O
more	O
and	O
more	O
attention	O
is	O
being	O
given	O
to	O
the	O
influence	O
of	O
microorganisms	O
on	O
the	O
host	O
'	O
s	O
cellular	O
metabolism	O
.	O

Analysis	O
of	O
microbial	O
metabolites	O
,	O
among	O
them	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
and	O
disruption	O
of	O
intestinal	O
microbiota	O
homeostasis	O
in	O
terms	O
of	O
their	O
effects	O
on	O
molecular	O
regulatory	O
mechanisms	O
of	O
immune	O
reactions	O
will	O
surely	O
improve	O
the	O
understanding	O
of	O
the	O
etiology	O
of	O
many	O
common	O
diseases	O
.	O

SCFAs	O
,	O
mainly	O
butyrate	O
,	O
propionate	O
,	O
and	O
acetate	O
,	O
occur	O
in	O
specific	O
amounts	O
,	O
and	O
their	O
proportions	O
can	O
change	O
,	O
depending	O
on	O
the	O
diet	O
,	O
age	O
and	O
diseases	O
.	O

The	O
levels	O
of	O
SCFAs	O
are	O
substantially	O
influenced	O
by	O
the	O
ratio	O
of	O
commensal	O
intestinal	O
bacteria	O
,	O
the	O
disturbance	O
of	O
which	O
(	O
dysbiosis	O
)	O
can	O
lead	O
to	O
a	O
disproportion	O
between	O
the	O
SCFAs	O
produced	O
.	O

SCFAs	O
are	O
regarded	O
as	O
mediators	O
in	O
the	O
communication	O
between	O
the	O
intestinal	O
microbiome	O
and	O
the	O
immune	O
system	O
.	O

The	O
signal	O
they	O
produce	O
is	O
transferred	O
,	O
among	O
others	O
,	O
in	O
immune	O
cells	O
via	O
free	O
fatty	O
acid	O
receptors	O
(	O
FFARs	O
)	O
,	O
which	O
belong	O
to	O
the	O
family	O
of	O
G	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
.	O

It	O
has	O
been	O
also	O
confirmed	O
that	O
SCFAs	O
inhibit	O
the	O
activity	O
of	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
-	O
an	O
enzyme	O
involved	O
in	O
post	O
-	O
translational	O
modifications	O
,	O
namely	O
the	O
process	O
of	O
deacetylation	O
and	O
,	O
what	O
is	O
new	O
,	O
the	O
process	O
of	O
histone	O
crotonylation	O
.	O

These	O
properties	O
of	O
SCFAs	O
have	O
an	O
effect	O
on	O
their	O
immunomodulatory	O
potential	O
i	O
.	O
e	O
.	O
maintaining	O
the	O
anti	O
/	O
pro	O
-	O
inflammatory	O
balance	O
.	O

SCFAs	O
act	O
not	O
only	O
locally	O
in	O
the	O
intestines	O
colonized	O
by	O
commensal	O
bacteria	O
,	O
but	O
also	O
influence	O
the	O
intestinal	O
immune	O
cells	O
,	O
and	O
modulate	O
immune	O
response	O
by	O
multi	O
-	O
protein	O
inflammasome	O
complexes	O
.	O

SCFAs	O
have	O
been	O
confirmed	O
to	O
contribute	O
to	O
the	O
maintenance	O
of	O
the	O
immune	O
homeostasis	O
of	O
the	O
urinary	O
system	O
(	O
kidneys	O
)	O
,	O
respiratory	O
system	O
(	O
lungs	O
)	O
,	O
central	O
nervous	O
system	O
,	O
and	O
the	O
sight	O
organ	O
.	O

A	O
decrease	O
in	O
iron	O
availability	O
to	O
human	O
gut	O
microbiome	O
reduces	O
the	O
growth	O
of	O
potentially	O
pathogenic	O
gut	O
bacteria	O
;	O
an	O
in	O
vitro	O
colonic	O
fermentation	O
study	O
.	O

Iron	O
supplements	O
are	O
widely	O
consumed	O
;	O
however	O
most	O
of	O
the	O
iron	O
is	O
not	O
absorbed	O
and	O
enters	O
the	O
colon	O
where	O
potentially	O
pathogenic	O
bacteria	O
can	O
utilise	O
it	O
for	O
growth	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
iron	O
availability	O
on	O
human	O
gut	O
microbial	O
composition	O
and	O
function	O
using	O
an	O
in	O
vitro	O
colonic	O
fermentation	O
model	O
inoculated	O
with	O
faecal	O
microbiota	O
from	O
healthy	O
adult	O
donors	O
,	O
as	O
well	O
as	O
examining	O
the	O
effect	O
of	O
iron	O
on	O
the	O
growth	O
of	O
individual	O
gut	O
bacteria	O
.	O

Batch	O
fermenters	O
were	O
seeded	O
with	O
fresh	O
faecal	O
material	O
and	O
supplemented	O
with	O
the	O
iron	O
chelator	O
,	O
bathophenanthroline	O
disulphonic	O
acid	O
(	O
BPDS	O
)	O
.	O

Samples	O
were	O
analysed	O
at	O
regular	O
intervals	O
to	O
assess	O
impact	O
on	O
the	O
gut	O
bacterial	O
communities	O
.	O

The	O
growth	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
Salmonella	B-bacteria
typhimurium	I-bacteria
was	O
significantly	O
impaired	O
when	O
cultured	O
independently	O
in	O
iron	O
-	O
deficient	O
media	O
.	O

In	O
contrast	O
,	O
depletion	O
of	O
iron	O
did	O
not	O
affect	O
the	O
growth	O
of	O
the	O
beneficial	O
species	O
,	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
,	O
when	O
cultured	O
independently	O
.	O

Analysis	O
of	O
the	O
microbiome	O
composition	O
via	O
16S	O
-	O
based	O
metataxonomics	O
indicated	O
that	O
under	O
conditions	O
of	O
iron	O
chelation	O
,	O
the	O
relative	O
abundance	O
decreased	O
for	O
several	O
taxa	O
,	O
including	O
a	O
10	O
%	O
decrease	O
in	O
Escherichia	B-bacteria
and	O
a	O
15	O
%	O
decrease	O
in	O
Bifidobacterium	B-bacteria
.	O

Metabolomics	O
analysis	O
using	O
(	O
1	O
)	O
H	O
-	O
NMR	O
indicated	O
that	O
the	O
production	O
of	O
SCFAs	O
was	O
reduced	O
under	O
iron	O
-	O
limited	O
conditions	O
.	O

These	O
results	O
support	O
previous	O
studies	O
demonstrating	O
the	O
essentiality	O
of	O
iron	O
for	O
microbial	O
growth	O
and	O
metabolism	O
,	O
but	O
,	O
in	O
addition	O
,	O
they	O
indicate	O
that	O
iron	O
chelation	O
changes	O
the	O
gut	O
microbiota	O
profile	O
and	O
influences	O
human	O
gut	O
microbial	O
homeostasis	O
through	O
both	O
compositional	O
and	O
functional	O
changes	O
.	O

Prebiotics	O
from	O
acorn	O
and	O
sago	O
prevent	O
high	O
-	O
fat	O
-	O
diet	O
-	O
induced	O
insulin	O
resistance	O
via	O
microbiome	O
-	O
gut	O
-	O
brain	O
axis	O
modulation	O
.	O

Role	O
of	O
gut	O
microbiome	O
in	O
obesity	O
and	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
became	O
apparent	O
from	O
several	O
independent	O
studies	O
indicating	O
that	O
gut	O
microbiome	O
modulators	O
like	O
prebiotics	O
may	O
improve	O
microbiome	O
perturbations	O
(	O
dysbiosis	O
)	O
to	O
ameliorate	O
metabolic	O
derangements	O
.	O

We	O
herein	O
isolate	O
water	O
soluble	O
,	O
nondigestible	O
polysaccharides	O
from	O
five	O
plant	O
-	O
based	O
foods	O
(	O
acorn	O
,	O
quinoa	O
,	O
sunflower	O
,	O
pumpkin	O
seeds	O
and	O
sago	O
)	O
and	O
assess	O
their	O
impact	O
on	O
human	O
fecal	O
microbiome	O
and	O
amelioration	O
of	O
high	O
-	O
fat	O
-	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
obesity	O
/	O
T2D	O
in	O
mice	O
.	O

During	O
polysaccharide	O
isolation	O
,	O
purification	O
,	O
biochemical	O
and	O
digestion	O
resistance	O
characterization	O
,	O
and	O
fermentation	O
pattern	O
by	O
human	O
fecal	O
microbiome	O
,	O
we	O
select	O
acorn	O
-	O
and	O
sago	O
-	O
derived	O
prebiotics	O
(	O
on	O
the	O
basis	O
of	O
relatively	O
higher	O
purity	O
and	O
yield	O
and	O
lower	O
protein	O
contamination	O
)	O
and	O
examine	O
their	O
effects	O
in	O
comparison	O
to	O
inulin	O
.	O

Prebiotics	O
treatments	O
in	O
human	O
fecal	O
microbiome	O
culture	O
system	O
not	O
only	O
preserve	O
microbial	O
diversity	O
but	O
also	O
appear	O
to	O
foster	O
beneficial	O
bacteria	O
and	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
.	O

Feeding	O
of	O
acorn	O
-	O
and	O
sago	O
-	O
derived	O
prebiotics	O
ameliorates	O
HFD	O
-	O
induced	O
glucose	O
intolerance	O
and	O
insulin	O
resistance	O
in	O
mice	O
,	O
with	O
effects	O
comparatively	O
superior	O
to	O
those	O
seen	O
in	O
inulin	O
-	O
fed	O
mice	O
.	O

Feeding	O
of	O
both	O
of	O
novel	O
prebiotics	O
as	O
well	O
as	O
inulin	O
increases	O
SCFAs	O
levels	O
in	O
the	O
mouse	O
gut	O
.	O

Interestingly	O
,	O
gut	O
hyperpermeability	O
and	O
mucosal	O
inflammatory	O
markers	O
were	O
significantly	O
reduced	O
upon	O
prebiotics	O
feeding	O
in	O
HFD	O
-	O
fed	O
mice	O
.	O

Hypothalamic	O
energy	O
signaling	O
in	O
terms	O
of	O
increased	O
expression	O
of	O
pro	O
-	O
opiomelanocortin	O
was	O
also	O
modulated	O
by	O
prebiotics	O
administration	O
.	O

Results	O
demonstrate	O
that	O
these	O
(	O
and	O
/	O
or	O
such	O
)	O
novel	O
prebiotics	O
can	O
ameliorate	O
HFD	O
-	O
induced	O
defects	O
in	O
glucose	O
metabolism	O
via	O
positive	O
modulation	O
of	O
gut	O
-	O
microbiome	O
-	O
brain	O
axis	O
and	O
hence	O
could	O
be	O
useful	O
in	O
preventing	O
/	O
treating	O
diet	O
-	O
induced	O
obesity	O
/	O
T2D	O
.	O

Interleukin	O
-	O
33	O
Promotes	O
REG3gamma	O
Expression	O
in	O
Intestinal	O
Epithelial	O
Cells	O
and	O
Regulates	O
Gut	O
Microbiota	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Regenerating	O
islet	O
-	O
derived	O
protein	O
(	O
REG3gamma	O
)	O
,	O
an	O
antimicrobial	O
peptide	O
,	O
typically	O
expressed	O
by	O
intestinal	O
epithelial	O
cells	O
(	O
IEC	O
)	O
,	O
plays	O
crucial	O
roles	O
in	O
intestinal	O
homeostasis	O
and	O
controlling	O
gut	O
microbiota	O
.	O

However	O
,	O
the	O
mechanisms	O
that	O
regulate	O
IEC	O
expression	O
of	O
REG3gamma	O
are	O
still	O
largely	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
and	O
how	O
interleukin	O
(	O
IL	O
)	O
33	O
,	O
an	O
alarmin	O
produced	O
by	O
IEC	O
in	O
response	O
to	O
injury	O
,	O
regulates	O
REG3gamma	O
expression	O
in	O
IEC	O
,	O
thus	O
contributing	O
to	O
intestinal	O
homeostasis	O
.	O

METHODS	O
:	O
IEC	O
were	O
isolated	O
from	O
wild	O
-	O
type	O
and	O
IL33	O
(	O
-	O
/	O
-	O
)	O
mice	O
to	O
determine	O
expression	O
of	O
REG3gamma	O
and	O
other	O
antimicrobial	O
peptides	O
by	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blot	O
.	O

IEC	O
cell	O
lines	O
were	O
used	O
for	O
mechanistic	O
studies	O
.	O

16S	O
rRNA	O
pyrosequencing	O
analysis	O
was	O
used	O
for	O
measuring	O
gut	O
microbiota	O
.	O

Citrobacter	B-bacteria
rodentium	I-bacteria
was	O
used	O
for	O
enteric	O
infections	O
.	O

RESULTS	O
:	O
The	O
expression	O
of	O
REG3gamma	O
,	O
but	O
not	O
beta	O
-	O
defensins	O
,	O
in	O
IECs	O
of	O
IL33	O
(	O
-	O
/	O
-	O
)	O
mice	O
was	O
significantly	O
lower	O
than	O
wild	O
-	O
type	O
mice	O
.	O

IL33	O
treatment	O
induced	O
IEC	O
expression	O
of	O
REG3gamma	O
in	O
both	O
mice	O
and	O
human	O
cell	O
lines	O
.	O

Mechanistically	O
,	O
IL33	O
activated	O
STAT3	O
,	O
mTOR	O
,	O
and	O
ERK1	O
/	O
2	O
in	O
IEC	O
.	O

Inhibition	O
of	O
these	O
pathways	O
abrogated	O
IL33	O
-	O
induction	O
of	O
REG3gamma	O
.	O

IL33	O
(	O
-	O
/	O
-	O
)	O
mice	O
demonstrated	O
higher	O
bacteria	O
loads	O
and	O
altered	O
microbiota	O
composition	O
.	O

IL33	O
did	O
not	O
directly	O
inhibit	O
bacterial	O
growth	O
,	O
but	O
promoted	O
wild	O
-	O
type	O
,	O
not	O
REG3gammaKO	O
,	O
IECs	O
to	O
kill	O
bacteria	O
in	O
vitro	O
.	O

Consistently	O
,	O
C	B-bacteria
rodentium	I-bacteria
infection	O
induced	O
IEC	O
IL33	O
expression	O
,	O
and	O
IL33	O
(	O
-	O
/	O
-	O
)	O
mice	O
demonstrated	O
an	O
impaired	O
bacterial	O
clearance	O
with	O
C	B-bacteria
rodentium	I-bacteria
infection	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
demonstrated	O
that	O
IL33	O
,	O
which	O
is	O
produced	O
by	O
IEC	O
in	O
response	O
to	O
injury	O
and	O
inflammatory	O
stimulation	O
,	O
in	O
turn	O
promotes	O
IEC	O
expression	O
of	O
REG3gamma	O
,	O
and	O
controls	O
the	O
gut	O
microbiota	O
of	O
the	O
host	O
.	O

The	O
altered	O
human	O
serum	O
metabolome	O
induced	O
by	O
a	O
marathon	O
.	O

INTRODUCTION	O
:	O
Endurance	O
races	O
have	O
been	O
associated	O
with	O
a	O
substantial	O
amount	O
of	O
adverse	O
effects	O
which	O
could	O
lead	O
to	O
chronic	O
disease	O
and	O
long	O
-	O
term	O
performance	O
impairment	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
holistic	O
metabolic	O
changes	O
occurring	O
within	O
the	O
serum	O
metabolome	O
of	O
athletes	O
after	O
the	O
completion	O
of	O
a	O
marathon	O
.	O

OBJECTIVES	O
:	O
Considering	O
this	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
better	O
characterize	O
the	O
acute	O
metabolic	O
changes	O
induced	O
by	O
a	O
marathon	O
.	O

METHODS	O
:	O
Using	O
an	O
untargeted	O
two	O
dimensional	O
gas	O
chromatography	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
metabolomics	O
approach	O
,	O
pre	O
-	O
and	O
post	O
-	O
marathon	O
serum	O
samples	O
of	O
31	O
athletes	O
were	O
analyzed	O
and	O
compared	O
to	O
identify	O
those	O
metabolites	O
varying	O
the	O
most	O
after	O
the	O
marathon	O
perturbation	O
.	O

RESULTS	O
:	O
Principle	O
component	O
analysis	O
of	O
the	O
comparative	O
groups	O
indicated	O
natural	O
differentiation	O
due	O
to	O
variation	O
in	O
the	O
total	O
metabolite	O
profiles	O
.	O

Elevated	O
concentrations	O
of	O
carbohydrates	O
,	O
fatty	O
acids	O
,	O
tricarboxylic	O
acid	O
cycle	O
intermediates	O
,	O
ketones	O
and	O
reduced	O
concentrations	O
of	O
amino	O
acids	O
indicated	O
a	O
metabolic	O
shift	O
between	O
various	O
fuel	O
substrate	O
systems	O
.	O

Additionally	O
,	O
elevated	O
odd	O
-	O
chain	O
fatty	O
acids	O
and	O
alpha	O
-	O
hydroxy	O
acids	O
indicated	O
the	O
utilization	O
of	O
alpha	O
-	O
oxidation	O
and	O
autophagy	O
as	O
alternative	O
energy	O
-	O
producing	O
mechanisms	O
.	O

Adaptations	O
in	O
gut	O
microbe	O
-	O
associated	O
markers	O
were	O
also	O
observed	O
and	O
correlated	O
with	O
the	O
metabolic	O
flexibility	O
of	O
the	O
athlete	O
.	O

CONCLUSION	O
:	O
From	O
these	O
results	O
it	O
is	O
evident	O
that	O
a	O
marathon	O
places	O
immense	O
strain	O
on	O
the	O
energy	O
-	O
producing	O
pathways	O
of	O
the	O
athlete	O
,	O
leading	O
to	O
extensive	O
protein	O
degradation	O
,	O
oxidative	O
stress	O
,	O
mammalian	O
target	O
of	O
rapamycin	O
complex	O
1	O
inhibition	O
and	O
autophagy	O
.	O

A	O
better	O
understanding	O
of	O
this	O
metabolic	O
shift	O
could	O
provide	O
new	O
insights	O
for	O
optimizing	O
athletic	O
performance	O
,	O
developing	O
more	O
efficient	O
nutrition	O
regimens	O
and	O
identify	O
strategies	O
to	O
improve	O
recovery	O
.	O

Administration	O
of	O
Candida	O
Albicans	O
to	O
Dextran	O
Sulfate	O
Solution	O
Treated	O
Mice	O
Causes	O
Intestinal	O
Dysbiosis	O
,	O
Emergence	O
and	O
Dissemination	O
of	O
Intestinal	O
Pseudomonas	B-bacteria
Aeruginosa	I-bacteria
and	O
Lethal	O
Sepsis	O
.	O

The	O
influence	O
of	O
gut	O
fungi	O
in	O
chronic	O
colitis	O
was	O
investigated	O
by	O
repeated	O
oral	O
administration	O
of	O
Candida	O
albicans	O
in	O
a	O
3	O
%	O
dextran	O
sulfate	O
solution	O
(	O
DSS	O
)	O
induced	O
-	O
colitis	O
mouse	O
model	O
.	O

Candida	O
administration	O
in	O
the	O
DSS	O
(	O
DSS	O
+	O
Candida	O
)	O
model	O
enhanced	O
the	O
mortality	O
rate	O
and	O
induced	O
bacteremia	O
(	O
without	O
candidemia	O
)	O
resulting	O
from	O
a	O
gut	O
perm	O
-	O
selectivity	O
defect	O
despite	O
similar	O
diarrheal	O
severity	O
in	O
mice	O
treated	O
with	O
DSS	O
alone	O
.	O

The	O
dominant	O
fecal	O
bacteria	O
in	O
DSS	O
+	O
Candida	O
and	O
DSS	O
alone	O
mice	O
were	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
and	O
Enterobacter	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
respectively	O
,	O
implying	O
that	O
Candida	O
induced	O
gut	O
dysbiosis	O
.	O

Interestingly	O
,	O
chloramphenicol	O
-	O
resistant	O
bacterial	O
colonies	O
,	O
predominantly	O
Pseudomonas	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
appeared	O
in	O
the	O
feces	O
and	O
blood	O
of	O
DSS	O
+	O
Candida	O
mice	O
(	O
not	O
the	O
DSS	O
alone	O
group	O
)	O
during	O
fungal	O
culture	O
.	O

These	O
antibiotic	O
-	O
resistant	O
bacteria	O
were	O
also	O
isolated	O
,	O
ex	O
vivo	O
,	O
by	O
incubating	O
mouse	O
feces	O
with	O
DSS	O
and	O
heat	O
-	O
killed	O
Candida	O
or	O
(	O
1	O
-	O
-	O
>	O
3	O
)	O
-	O
beta	O
-	O
D	O
-	O
glucan	O
,	O
suggesting	O
bacterial	O
fermentation	O
on	O
fungi	O
.	O

Administration	O
of	O
Pseudomonas	B-bacteria
aeruginosa	I-bacteria
isolated	O
from	O
chloramphenicol	O
-	O
resistant	O
bacteria	O
in	O
the	O
DSS	O
+	O
Candida	O
model	O
enhanced	O
the	O
severity	O
of	O
disease	O
,	O
and	O
increased	O
growth	O
of	O
isolated	O
P	B-bacteria
.	I-bacteria
aeruginosa	I-bacteria
in	O
blood	O
agar	O
containing	O
heat	O
-	O
killed	O
Candida	O
was	O
demonstrated	O
.	O

These	O
data	O
suggested	O
the	O
selection	O
of	O
a	O
highly	O
virulent	O
bacterial	O
strain	O
following	O
fecal	O
Candida	O
presentation	O
in	O
the	O
gut	O
.	O

Additionally	O
,	O
reduction	O
of	O
fecal	O
fungi	O
with	O
fluconazole	O
decreased	O
the	O
burden	O
of	O
chloramphenicol	O
-	O
resistant	O
bacteria	O
,	O
attenuating	O
the	O
severity	O
of	O
DSS	O
+	O
Candida	O
.	O

In	O
conclusion	O
,	O
gut	O
Candida	O
induced	O
bacteremia	O
in	O
the	O
DSS	O
model	O
through	O
an	O
inflammation	O
-	O
induced	O
gut	O
perm	O
-	O
selectivity	O
defect	O
and	O
facilitated	O
the	O
growth	O
of	O
some	O
gut	O
bacteria	O
.	O

Treatment	O
strategies	O
aimed	O
at	O
reducing	O
gut	O
fungi	O
could	O
attenuate	O
disease	O
severity	O
.	O

Further	O
investigation	O
of	O
gut	O
fungi	O
in	O
inflammatory	O
bowel	O
disease	O
is	O
warranted	O
.	O

Lipopolysaccharide	O
-	O
acylating	O
capacity	O
of	O
the	O
gut	O
microbiota	O
and	O
its	O
potential	O
impact	O
on	O
the	O
immunopathogenesis	O
of	O
HIV	O
infection	O
.	O

Vedolizumab	O
-	O
mediated	O
integrin	O
alpha4beta7	O
blockade	O
does	O
not	O
control	O
HIV	O
-	O
1SF162	O
rebound	O
after	O
combination	O
antiretroviral	O
therapy	O
interruption	O
in	O
humanized	O
mice	O
.	O

OBJECTIVE	O
:	O
The	O
combined	O
combination	O
antiretroviral	O
therapy	O
(	O
cART	O
)	O
and	O
anti	O
-	O
alpha4beta7	O
RM	O
-	O
Act	O
-	O
1	O
antibody	O
therapy	O
allows	O
macaques	O
to	O
durably	O
control	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
rebound	O
after	O
withdrawal	O
of	O
the	O
interventions	O
.	O

Here	O
,	O
we	O
aimed	O
to	O
investigate	O
whether	O
vedolizumab	O
(	O
VDZ	O
)	O
,	O
a	O
clinical	O
-	O
grade	O
humanized	O
anti	O
-	O
alpha4beta7	O
antibody	O
,	O
would	O
have	O
similar	O
effects	O
in	O
controlling	O
live	O
HIV	O
-	O
1	O
infection	O
in	O
humanized	O
mice	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
integrin	O
alpha4beta7	O
blockade	O
by	O
VDZ	O
was	O
evaluated	O
on	O
human	O
primary	O
memory	O
CD4	O
T	O
(	O
MEMT	O
)	O
cells	O
and	O
retinoic	O
acid	O
-	O
induced	O
gut	O
-	O
homing	O
alpha4beta7MEMT	O
cells	O
(	O
alpha4beta7MEMT	O
)	O
in	O
vitro	O
.	O

The	O
antiretroviral	O
activity	O
of	O
VDZ	O
was	O
determined	O
using	O
pseudotyped	O
R5	O
-	O
tropic	O
HIV	O
-	O
1SF162	O
,	O
which	O
displays	O
binding	O
activity	O
to	O
alpha4beta7	O
.	O

The	O
preventive	O
and	O
immunotherapeutic	O
efficacies	O
of	O
VDZ	O
were	O
further	O
investigated	O
in	O
humanized	O
mice	O
using	O
the	O
live	O
HIV	O
-	O
1SF162	O
strain	O
compared	O
with	O
RM	O
-	O
Act	O
-	O
1	O
.	O

RESULTS	O
:	O
VDZ	O
effectively	O
and	O
dose	O
-	O
dependently	O
blocked	O
the	O
binding	O
of	O
mucosal	O
vascular	O
addressin	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
MAdCAM	O
-	O
1	O
)	O
,	O
the	O
native	O
ligand	O
of	O
alpha4beta7	O
,	O
to	O
alpha4beta7MEMT	O
cells	O
.	O

HIV	O
-	O
1SF162	O
not	O
only	O
displayed	O
binding	O
capacity	O
to	O
alpha4beta7	O
-	O
expressing	O
cells	O
,	O
but	O
also	O
showed	O
an	O
increased	O
infectivity	O
in	O
retinoic	O
acid	O
-	O
induced	O
alpha4beta7MEMT	O
cells	O
pretreated	O
with	O
VDZ	O
.	O

Moreover	O
,	O
VDZ	O
failed	O
to	O
prevent	O
live	O
HIV	O
-	O
1SF162	O
infection	O
and	O
did	O
not	O
reduce	O
the	O
peak	O
viral	O
load	O
when	O
administrated	O
prior	O
to	O
viral	O
challenge	O
in	O
humanized	O
mice	O
.	O

Lastly	O
,	O
in	O
immunotherapeutic	O
settings	O
,	O
the	O
withdrawal	O
of	O
combined	O
cART	O
with	O
either	O
VDZ	O
or	O
RM	O
-	O
Act	O
-	O
1	O
resulted	O
in	O
an	O
uncontrolled	O
HIV	O
-	O
1SF162	O
rebound	O
in	O
humanized	O
mice	O
,	O
whereas	O
the	O
alpha4beta7	O
molecules	O
remained	O
significantly	O
blocked	O
on	O
circulating	O
CD4	O
T	O
cells	O
.	O

CONCLUSION	O
:	O
VDZ	O
neither	O
prevents	O
nor	O
controls	O
HIV	O
-	O
1SF162	O
infection	O
both	O
in	O
vitro	O
and	O
in	O
humanized	O
mice	O
.	O

Our	O
findings	O
have	O
significant	O
implications	O
to	O
the	O
clinical	O
application	O
of	O
VDZ	O
in	O
HIV	O
-	O
1	O
preventive	O
and	O
immunotherapeutic	O
interventions	O
.	O

Applying	O
Advanced	O
In	O
Vitro	O
Culturing	O
Technology	O
to	O
Study	O
the	O
Human	O
Gut	O
Microbiota	O
.	O

The	O
human	O
gut	O
microbiota	O
plays	O
a	O
vital	O
role	O
in	O
both	O
human	O
health	O
and	O
disease	O
.	O

Studying	O
the	O
gut	O
microbiota	O
using	O
an	O
in	O
vivo	O
model	O
,	O
is	O
difficult	O
due	O
to	O
its	O
complex	O
nature	O
,	O
and	O
its	O
diverse	O
association	O
with	O
mammalian	O
components	O
.	O

The	O
goal	O
of	O
this	O
protocol	O
is	O
to	O
culture	O
the	O
gut	O
microbiota	O
in	O
vitro	O
,	O
which	O
allows	O
for	O
the	O
study	O
of	O
the	O
gut	O
microbiota	O
dynamics	O
,	O
without	O
having	O
to	O
consider	O
the	O
contribution	O
of	O
the	O
mammalian	O
milieu	O
.	O

Using	O
in	O
vitro	O
culturing	O
technology	O
,	O
the	O
physiological	O
conditions	O
of	O
the	O
gastro	O
intestinal	O
tract	O
are	O
simulated	O
,	O
including	O
parameters	O
such	O
as	O
pH	O
,	O
temperature	O
,	O
anaerobiosis	O
,	O
and	O
transit	O
time	O
.	O

The	O
intestinal	O
surface	O
of	O
the	O
colon	O
is	O
simulated	O
by	O
adding	O
mucin	O
-	O
coated	O
carriers	O
,	O
creating	O
a	O
mucosal	O
phase	O
,	O
and	O
adding	O
further	O
dimension	O
.	O

The	O
gut	O
microbiota	O
is	O
introduced	O
by	O
inoculating	O
with	O
the	O
human	O
fecal	O
material	O
.	O

Upon	O
inoculation	O
with	O
this	O
complex	O
mixture	O
of	O
bacteria	O
,	O
specific	O
microbes	O
are	O
enriched	O
in	O
the	O
different	O
longitudinal	O
(	O
ascending	O
,	O
transverse	O
and	O
descending	O
colons	O
)	O
and	O
transversal	O
(	O
luminal	O
and	O
mucosal	O
)	O
environments	O
of	O
the	O
in	O
vitro	O
model	O
.	O

It	O
is	O
crucial	O
to	O
allow	O
the	O
system	O
to	O
reach	O
a	O
steady	O
state	O
,	O
in	O
which	O
the	O
community	O
and	O
the	O
metabolites	O
produced	O
remain	O
stable	O
.	O

The	O
experimental	O
results	O
in	O
this	O
manuscript	O
demonstrate	O
how	O
the	O
inoculated	O
gut	O
microbiota	O
community	O
develops	O
into	O
a	O
stable	O
community	O
over	O
time	O
.	O

Once	O
steady	O
state	O
is	O
achieved	O
,	O
the	O
system	O
can	O
be	O
used	O
to	O
analyze	O
bacterial	O
interactions	O
and	O
community	O
functions	O
or	O
to	O
test	O
the	O
effects	O
of	O
any	O
additives	O
on	O
the	O
gut	O
microbiota	O
,	O
such	O
as	O
food	O
,	O
food	O
components	O
,	O
or	O
pharmaceuticals	O
.	O

Thylakoids	O
:	O
A	O
Novel	O
Food	O
-	O
Derived	O
Supplement	O
for	O
Obesity	O
-	O
A	O
Mini	O
-	O
Review	O
.	O

Nowadays	O
,	O
overweight	O
and	O
obesity	O
are	O
major	O
epidemic	O
health	O
problems	O
that	O
can	O
bring	O
about	O
some	O
other	O
health	O
issues	O
such	O
as	O
cardiovascular	O
disease	O
which	O
is	O
the	O
first	O
cause	O
of	O
mortality	O
worldwide	O
.	O

Thylakoids	O
are	O
disc	O
-	O
like	O
membranes	O
responsible	O
for	O
photosynthetic	O
light	O
reactions	O
in	O
chloroplasts	O
of	O
green	O
plants	O
.	O

Although	O
only	O
a	O
few	O
animal	O
and	O
human	O
studies	O
have	O
been	O
conducted	O
regarding	O
the	O
impact	O
of	O
thylakoids	O
on	O
overweight	O
-	O
and	O
obesity	O
-	O
related	O
factors	O
,	O
all	O
of	O
them	O
have	O
resulted	O
in	O
positive	O
outcomes	O
.	O

These	O
outcomes	O
are	O
as	O
follows	O
:	O
increment	O
of	O
satiety	O
response	O
;	O
suppression	O
of	O
hunger	O
sensations	O
,	O
particularly	O
hedonic	O
hunger	O
;	O
reduction	O
of	O
body	O
weight	O
and	O
fat	O
;	O
promotion	O
of	O
glucose	O
homeostasis	O
;	O
decrease	O
in	O
serum	O
lipids	O
;	O
attenuation	O
of	O
oxidative	O
stress	O
and	O
inflammation	O
;	O
and	O
modulation	O
of	O
gut	O
microbiota	O
,	O
notably	O
by	O
increasing	O
some	O
helpful	O
bacteria	O
such	O
as	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
.	O

It	O
seems	O
that	O
some	O
of	O
these	O
useful	O
effects	O
are	O
related	O
to	O
retarded	O
absorption	O
of	O
dietary	O
fat	O
and	O
carbohydrate	O
caused	O
by	O
thylakoids	O
.	O

There	O
is	O
still	O
a	O
need	O
for	O
more	O
well	O
-	O
designed	O
studies	O
.	O

Spatiotemporal	O
successions	O
of	O
shrimp	O
gut	O
microbial	O
colonization	O
:	O
high	O
consistency	O
despite	O
distinct	O
species	O
pool	O
.	O

Aquatic	O
animals	O
encounter	O
suites	O
of	O
novel	O
planktonic	O
microbes	O
during	O
their	O
development	O
.	O

Although	O
hosts	O
have	O
been	O
shown	O
to	O
exert	O
strong	O
selection	O
on	O
their	O
gut	O
microbiota	O
from	O
surrounding	O
environment	O
,	O
to	O
what	O
extent	O
and	O
the	O
generality	O
that	O
the	O
gut	O
microbiota	O
and	O
the	O
underlying	O
ecological	O
processes	O
are	O
affected	O
by	O
biotic	O
and	O
abiotic	O
variations	O
are	O
largely	O
unclear	O
.	O

Here	O
,	O
these	O
concerns	O
were	O
explored	O
by	O
coupling	O
spatiotemporal	O
data	O
on	O
gut	O
and	O
rearing	O
water	O
bacterial	O
communities	O
with	O
environmental	O
variables	O
over	O
shrimp	O
life	O
stages	O
at	O
spatially	O
distant	O
locations	O
.	O

Shrimp	O
gut	O
microbiotas	O
significantly	O
changed	O
mirroring	O
their	O
development	O
,	O
as	O
evidenced	O
by	O
gut	O
bacterial	O
signatures	O
of	O
shrimp	O
life	O
stage	O
contributing	O
95	O
.	O
5	O
%	O
stratification	O
accuracy	O
.	O

Shrimp	O
sourced	O
little	O
(	O
2	O
.	O
6	O
%	O
-	O
15	O
.	O
8	O
%	O
)	O
of	O
their	O
gut	O
microbiota	O
from	O
their	O
rearing	O
water	O
.	O

This	O
microbial	O
resistance	O
was	O
reflected	O
by	O
weak	O
compositional	O
differences	O
between	O
shrimp	O
farming	O
spatially	O
distinct	O
locations	O
where	O
species	O
pools	O
were	O
distinct	O
.	O

Consistently	O
,	O
the	O
assembly	O
of	O
shrimp	O
gut	O
microbiota	O
was	O
not	O
adequately	O
explained	O
by	O
the	O
rearing	O
water	O
variables	O
and	O
bacterial	O
community	O
,	O
but	O
rather	O
by	O
host	O
-	O
age	O
-	O
associated	O
biotic	O
features	O
.	O

The	O
successions	O
of	O
shrimp	O
gut	O
microbiota	O
were	O
droved	O
by	O
replacement	O
(	O
betasim	O
)	O
,	O
rather	O
than	O
by	O
nestedness	O
(	O
betanes	O
)	O
,	O
while	O
those	O
of	O
bacterioplankton	O
communities	O
were	O
equally	O
governed	O
by	O
replacement	O
and	O
nestedness	O
.	O

Our	O
study	O
highlights	O
how	O
shrimp	O
gut	O
bacterial	O
community	O
assembly	O
is	O
coupled	O
to	O
their	O
development	O
,	O
rearing	O
species	O
pool	O
,	O
and	O
that	O
the	O
successional	O
pattern	O
of	O
host	O
-	O
associated	O
communities	O
is	O
differed	O
from	O
that	O
of	O
free	O
-	O
living	O
bacteria	O
.	O

Virulence	O
factors	O
,	O
prevalence	O
and	O
potential	O
transmission	O
of	O
extraintestinal	O
pathogenic	O
Escherichia	B-bacteria
coli	I-bacteria
isolated	O
from	O
different	O
sources	O
:	O
recent	O
reports	O
.	O

Extraintestinal	B-bacteria
pathogenic	I-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
(	O
ExPEC	B-bacteria
)	O
are	O
facultative	O
pathogens	O
that	O
are	O
part	O
of	O
the	O
normal	O
human	O
intestinal	O
flora	O
.	O

The	O
ExPEC	O
group	O
includes	O
uropathogenic	B-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
(	O
UPEC	B-bacteria
)	O
,	O
neonatal	O
meningitis	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
(	O
NMEC	O
)	O
,	O
sepsis	O
-	O
associated	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
(	O
SEPEC	O
)	O
,	O
and	O
avian	O
pathogenic	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
(	O
APEC	B-bacteria
)	O
.	O

Virulence	O
factors	O
(	O
VF	O
)	O
related	O
to	O
the	O
pathogenicity	O
of	O
ExPEC	O
are	O
numerous	O
and	O
have	O
a	O
wide	O
range	O
of	O
activities	O
,	O
from	O
those	O
related	O
to	O
bacteria	O
colonization	O
to	O
those	O
related	O
to	O
virulence	O
,	O
including	O
adhesins	O
,	O
toxins	O
,	O
iron	O
acquisition	O
factors	O
,	O
lipopolysaccharides	O
,	O
polysaccharide	O
capsules	O
,	O
and	O
invasins	O
,	O
which	O
are	O
usually	O
encoded	O
on	O
pathogenicity	O
islands	O
(	O
PAIs	O
)	O
,	O
plasmids	O
and	O
other	O
mobile	O
genetic	O
elements	O
.	O

Mechanisms	O
underlying	O
the	O
dynamics	O
of	O
ExPEC	O
transmission	O
and	O
the	O
selection	O
of	O
virulent	O
clones	O
are	O
still	O
poorly	O
understood	O
and	O
require	O
further	O
research	O
.	O

The	O
time	O
shift	O
between	O
colonization	O
of	O
ExPEC	O
and	O
the	O
development	O
of	O
infection	O
remains	O
problematic	O
in	O
the	O
context	O
of	O
establishing	O
the	O
relation	O
between	O
consumption	O
of	O
contaminated	O
food	O
and	O
the	O
appearance	O
of	O
first	O
disease	O
symptoms	O
.	O

What	O
appears	O
to	O
be	O
most	O
difficult	O
is	O
to	O
prove	O
that	O
ExPEC	B-bacteria
strains	I-bacteria
cause	O
disease	O
symptoms	O
and	O
to	O
examine	O
the	O
mechanism	O
of	O
transition	O
from	O
the	O
asymptomatic	O
colonization	O
of	O
the	O
intestines	O
to	O
the	O
spreading	O
of	O
the	O
bacteria	O
outside	O
the	O
digestive	O
system	O
.	O

A	O
significant	O
problem	O
for	O
researchers	O
who	O
are	O
trying	O
to	O
ascribe	O
ExPEC	B-bacteria
transmission	O
to	O
food	O
,	O
people	O
or	O
the	O
environment	O
is	O
to	O
draw	O
the	O
distinction	O
between	O
colonization	O
of	O
ExPEC	B-bacteria
and	O
infection	O
.	O

Food	O
safety	O
is	O
an	O
important	O
challenge	O
for	O
public	O
health	O
both	O
at	O
the	O
production	O
stage	O
and	O
in	O
the	O
course	O
of	O
its	O
processing	O
and	O
distribution	O
.	O

Examination	O
of	O
the	O
genetic	O
similarity	O
of	O
ExPEC	B-bacteria
strains	I-bacteria
will	O
allow	O
to	O
determine	O
their	O
origin	O
from	O
different	O
sources	O
.	O

Many	O
levels	O
of	O
genotyping	O
have	O
been	O
proposed	O
in	O
which	O
the	O
typing	O
of	O
strains	O
,	O
plasmids	O
and	O
genes	O
is	O
compared	O
in	O
order	O
to	O
obtain	O
a	O
more	O
complete	O
picture	O
of	O
this	O
complex	O
problem	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
characterize	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
strains	I-bacteria
isolated	O
from	O
humans	O
,	O
animals	O
and	O
food	O
for	O
the	O
presence	O
of	O
bacterial	O
genes	O
encoding	O
virulence	O
factors	O
such	O
as	O
toxins	O
,	O
and	O
iron	O
acquisition	O
systems	O
(	O
siderophores	O
)	O
in	O
the	O
context	O
of	O
an	O
increasing	O
spread	O
of	O
ExPEC	B-bacteria
infections	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
deficiency	O
-	O
induced	O
gut	O
microbial	O
dysbiosis	O
degrades	O
the	O
colonic	O
mucus	O
barrier	O
in	O
Cyp27b1	O
knockout	O
mouse	O
model	O
.	O

Background	O
:	O
The	O
relationship	O
between	O
disturbances	O
of	O
the	O
gut	O
microbiota	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
deficiency	O
has	O
been	O
established	O
both	O
in	O
humans	O
and	O
animal	O
models	O
with	O
a	O
vitamin	O
D	O
poor	O
diet	O
or	O
a	O
lack	O
of	O
sun	O
exposure	O
.	O

Our	O
prior	O
study	O
has	O
demonstrated	O
that	O
Cyp27b1	O
(	O
-	O
/	O
-	O
)	O
(	O
Cyp27b1	O
knockout	O
)	O
mice	O
that	O
could	O
not	O
produce	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
significant	O
colon	O
inflammation	O
phenotypes	O
.	O

However	O
,	O
whether	O
and	O
how	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
deficiency	O
due	O
to	O
the	O
genetic	O
deletion	O
controls	O
the	O
gut	O
homeostasis	O
and	O
modulates	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
remains	O
to	O
be	O
explored	O
.	O

Results	O
:	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
deficiency	O
impair	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
and	O
metabolite	O
in	O
Cyp27b1	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
including	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
,	O
Solitalea	B-bacteria
Canadensis	I-bacteria
,	O
Bacteroides	B-bacteria
-	I-bacteria
acidifaciens	I-bacteria
,	O
Bacteroides	B-bacteria
plebeius	I-bacteria
and	O
SCFA	O
production	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
deficiency	O
cause	O
the	O
thinner	O
colonic	O
mucus	O
layer	O
and	O
increase	O
the	O
translocation	O
of	O
the	O
bacteria	O
to	O
the	O
mesenteric	O
lymph	O
nodes	O
.	O

We	O
also	O
found	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
supplement	O
significantly	O
decreased	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
abundance	O
in	O
fecal	O
samples	O
of	O
Cyp27b1	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Conclusion	O
:	O
Deficiency	O
in	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
impairs	O
the	O
composition	O
of	O
gut	O
microbiota	O
leading	O
to	O
disruption	O
of	O
intestinal	O
epithelial	O
barrier	O
homeostasis	O
and	O
induction	O
of	O
colonic	O
inflammation	O
.	O

This	O
study	O
highlights	O
the	O
association	O
between	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
status	O
,	O
the	O
gut	O
microbiota	O
and	O
the	O
colonic	O
mucus	O
barrier	O
that	O
is	O
regarded	O
as	O
a	O
primary	O
defense	O
against	O
enteric	O
pathogens	O
.	O

T	O
-	O
Cell	O
-	O
Driven	O
Inflammation	O
as	O
a	O
Mediator	O
of	O
the	O
Gut	O
-	O
Brain	O
Axis	O
Involved	O
in	O
Parkinson	O
'	O
s	O
Disease	O
.	O

Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
is	O
a	O
neurodegenerative	O
disorder	O
affecting	O
mainly	O
the	O
dopaminergic	O
neurons	O
of	O
the	O
nigrostriatal	O
pathway	O
,	O
a	O
neuronal	O
circuit	O
involved	O
in	O
the	O
control	O
of	O
movements	O
,	O
thereby	O
the	O
main	O
manifestations	O
correspond	O
to	O
motor	O
impairments	O
.	O

The	O
major	O
molecular	O
hallmark	O
of	O
this	O
disease	O
corresponds	O
to	O
the	O
presence	O
of	O
pathological	O
protein	O
inclusions	O
called	O
Lewy	O
bodies	O
in	O
the	O
midbrain	O
of	O
patients	O
,	O
which	O
have	O
been	O
extensively	O
associated	O
with	O
neurotoxic	O
effects	O
.	O

Importantly	O
,	O
different	O
research	O
groups	O
have	O
demonstrated	O
that	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cells	O
infiltrate	O
into	O
the	O
substantia	O
nigra	O
of	O
PD	O
patients	O
and	O
animal	O
models	O
.	O

Moreover	O
,	O
several	O
studies	O
have	O
consistently	O
demonstrated	O
that	O
T	O
-	O
cell	O
deficiency	O
results	O
in	O
a	O
strong	O
attenuation	O
of	O
dopaminergic	O
neurodegeneration	O
in	O
animal	O
models	O
of	O
PD	O
,	O
thus	O
indicating	O
a	O
key	O
role	O
of	O
adaptive	O
immunity	O
in	O
the	O
neurodegenerative	O
process	O
.	O

Recent	O
evidence	O
has	O
shown	O
that	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
response	O
involved	O
in	O
PD	O
patients	O
is	O
directed	O
to	O
oxidised	O
forms	O
of	O
alpha	O
-	O
synuclein	O
,	O
one	O
of	O
the	O
main	O
constituents	O
of	O
Lewy	O
bodies	O
.	O

On	O
the	O
other	O
hand	O
,	O
most	O
PD	O
patients	O
present	O
a	O
number	O
of	O
non	O
-	O
motor	O
manifestations	O
.	O

Among	O
non	O
-	O
motor	O
manifestations	O
,	O
gastrointestinal	O
dysfunctions	O
result	O
especially	O
important	O
as	O
potential	O
early	O
biomarkers	O
of	O
PD	O
,	O
since	O
they	O
are	O
ubiquitously	O
found	O
among	O
confirmed	O
patients	O
and	O
occur	O
much	O
earlier	O
than	O
motor	O
symptoms	O
.	O

These	O
gastrointestinal	O
dysfunctions	O
include	O
constipation	O
and	O
inflammation	O
of	O
the	O
gut	O
mucosa	O
and	O
the	O
most	O
distinctive	O
pathologic	O
features	O
associated	O
are	O
the	O
loss	O
of	O
neurons	O
of	O
the	O
enteric	O
nervous	O
system	O
and	O
the	O
generation	O
of	O
Lewy	O
bodies	O
in	O
the	O
gut	O
.	O

Moreover	O
,	O
emerging	O
evidence	O
has	O
recently	O
shown	O
a	O
pivotal	O
role	O
of	O
gut	O
microbiota	O
in	O
triggering	O
the	O
development	O
of	O
PD	O
in	O
genetically	O
predisposed	O
individuals	O
.	O

Of	O
note	O
,	O
PD	O
has	O
been	O
positively	O
correlated	O
with	O
inflammatory	O
bowel	O
diseases	O
,	O
a	O
group	O
of	O
disorders	O
involving	O
a	O
T	O
-	O
cell	O
driven	O
inflammation	O
of	O
gut	O
mucosa	O
,	O
which	O
is	O
strongly	O
dependent	O
in	O
the	O
composition	O
of	O
gut	O
microbiota	O
.	O

Here	O
we	O
raised	O
the	O
hypothesis	O
that	O
T	O
-	O
cell	O
driven	O
inflammation	O
,	O
which	O
mediates	O
dopaminergic	O
neurodegeneration	O
in	O
PD	O
,	O
is	O
triggered	O
in	O
the	O
gut	O
mucosa	O
.	O

Accordingly	O
,	O
we	O
discuss	O
how	O
structural	O
components	O
of	O
commensal	O
bacteria	O
or	O
how	O
different	O
mediators	O
produced	O
by	O
gut	O
-	O
microbiota	O
,	O
including	O
short	O
-	O
chain	O
fatty	O
acids	O
and	O
dopamine	O
,	O
may	O
affect	O
the	O
behaviour	O
of	O
T	O
-	O
cells	O
,	O
triggering	O
the	O
development	O
of	O
T	O
-	O
cell	O
responses	O
against	O
Lewy	O
bodies	O
,	O
initially	O
confined	O
to	O
the	O
gut	O
mucosa	O
but	O
later	O
extended	O
to	O
the	O
brain	O
.	O

Potential	O
of	O
Pectins	O
to	O
Beneficially	O
Modulate	O
the	O
Gut	O
Microbiota	O
Depends	O
on	O
Their	O
Structural	O
Properties	O
.	O

Pectins	O
are	O
plant	O
cell	O
-	O
wall	O
polysaccharides	O
which	O
can	O
be	O
utilized	O
by	O
commensal	O
bacteria	O
in	O
the	O
gut	O
,	O
exhibiting	O
beneficial	O
properties	O
for	O
the	O
host	O
.	O

Knowledge	O
of	O
the	O
impact	O
of	O
pectins	O
on	O
intestinal	O
bacterial	O
communities	O
is	O
insufficient	O
and	O
limited	O
to	O
a	O
few	O
types	O
of	O
pectins	O
.	O

This	O
study	O
characterized	O
the	O
relationship	O
between	O
the	O
structural	O
properties	O
of	O
pectins	O
and	O
their	O
potential	O
to	O
modulate	O
composition	O
and	O
activity	O
of	O
the	O
gut	O
microbiota	O
in	O
a	O
beneficial	O
way	O
.	O

For	O
this	O
purpose	O
we	O
performed	O
in	O
vitro	O
fermentations	O
of	O
nine	O
structurally	O
diverse	O
pectins	O
from	O
citrus	O
fruits	O
and	O
sugar	O
beet	O
,	O
and	O
a	O
pectic	O
derivative	O
,	O
rhamnogalacturonan	O
I	O
(	O
RGI	O
)	O
,	O
using	O
a	O
TIM	O
-	O
2	O
colon	O
model	O
.	O

The	O
composition	O
of	O
microbiota	O
during	O
TIM	O
-	O
2	O
fermentations	O
was	O
assessed	O
by	O
16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
.	O

Both	O
general	O
and	O
pectin	O
-	O
specific	O
changes	O
were	O
observed	O
in	O
relative	O
abundances	O
of	O
numerous	O
bacterial	O
taxa	O
in	O
a	O
time	O
-	O
dependent	O
way	O
.	O

Bacterial	O
populations	O
associated	O
with	O
human	O
health	O
,	O
such	O
as	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
,	O
Coprococcus	B-bacteria
,	O
Ruminococcus	B-bacteria
,	O
Dorea	B-bacteria
,	O
Blautia	B-bacteria
,	O
Oscillospira	B-bacteria
,	O
Sutterella	B-bacteria
,	O
Bifidobacterium	B-bacteria
,	O
Christensenellaceae	B-bacteria
,	O
Prevotella	B-bacteria
copri	I-bacteria
,	O
and	O
Bacteroides	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
either	O
increased	O
or	O
decreased	O
depending	O
on	O
the	O
substrate	O
,	O
suggesting	O
that	O
these	O
bacteria	O
can	O
be	O
controlled	O
using	O
structurally	O
different	O
pectins	O
.	O

The	O
main	O
structural	O
features	O
linked	O
to	O
the	O
pectin	O
-	O
mediated	O
shifts	O
in	O
microbiota	O
included	O
degree	O
of	O
esterification	O
,	O
composition	O
of	O
neutral	O
sugars	O
,	O
distribution	O
of	O
homogalacturonan	O
and	O
rhamnogalacturonan	O
fractions	O
,	O
degree	O
of	O
branching	O
,	O
and	O
the	O
presence	O
of	O
amide	O
groups	O
.	O

Cumulative	O
production	O
of	O
the	O
total	O
short	O
chain	O
fatty	O
acids	O
and	O
propionate	O
was	O
largest	O
in	O
fermentations	O
of	O
the	O
high	O
methoxyl	O
pectins	O
.	O

Thus	O
,	O
this	O
study	O
indicates	O
that	O
microbial	O
communities	O
in	O
the	O
gut	O
can	O
be	O
specifically	O
modulated	O
by	O
pectins	O
and	O
identifies	O
the	O
features	O
in	O
pectin	O
molecules	O
linked	O
to	O
microbial	O
alterations	O
.	O

This	O
knowledge	O
can	O
be	O
used	O
to	O
define	O
preferred	O
dietary	O
pectins	O
,	O
targeting	O
beneficial	O
bacteria	O
,	O
and	O
favoring	O
more	O
balanced	O
microbiota	O
communities	O
in	O
the	O
gut	O
.	O

Metabolism	O
the	O
Difficile	O
Way	O
:	O
The	O
Key	O
to	O
the	O
Success	O
of	O
the	O
Pathogen	O
Clostridioides	B-bacteria
difficile	I-bacteria
.	O

Strains	O
of	O
Clostridioides	B-bacteria
difficile	I-bacteria
cause	O
detrimental	O
diarrheas	O
with	O
thousands	O
of	O
deaths	O
worldwide	O
.	O

The	O
infection	O
process	O
by	O
the	O
Gram	O
-	O
positive	O
,	O
strictly	O
anaerobic	O
gut	O
bacterium	O
is	O
directly	O
related	O
to	O
its	O
unique	O
metabolism	O
,	O
using	O
multiple	O
Stickland	O
-	O
type	O
amino	O
acid	O
fermentation	O
reactions	O
coupled	O
to	O
Rnf	O
complex	O
-	O
mediated	O
sodium	O
/	O
proton	O
gradient	O
formation	O
for	O
ATP	O
generation	O
.	O

Major	O
pathways	O
utilize	O
phenylalanine	O
,	O
leucine	O
,	O
glycine	O
and	O
proline	O
with	O
the	O
formation	O
of	O
3	O
-	O
phenylproprionate	O
,	O
isocaproate	O
,	O
butyrate	O
,	O
5	O
-	O
methylcaproate	O
,	O
valerate	O
and	O
5	O
-	O
aminovalerate	O
.	O

In	O
parallel	O
a	O
versatile	O
sugar	O
catabolism	O
including	O
pyruvate	O
formate	O
-	O
lyase	O
as	O
a	O
central	O
enzyme	O
and	O
an	O
incomplete	O
tricarboxylic	O
acid	O
cycle	O
to	O
prevent	O
unnecessary	O
NADH	O
formation	O
completes	O
the	O
picture	O
.	O

However	O
,	O
a	O
complex	O
gene	O
regulatory	O
network	O
that	O
carefully	O
mediates	O
the	O
continuous	O
adaptation	O
of	O
this	O
metabolism	O
to	O
changing	O
environmental	O
conditions	O
is	O
only	O
partially	O
elucidated	O
.	O

It	O
involves	O
the	O
pleiotropic	O
regulators	O
CodY	O
and	O
SigH	O
,	O
the	O
known	O
carbon	O
metabolism	O
regulator	O
CcpA	O
,	O
the	O
proline	O
regulator	O
PrdR	O
,	O
the	O
iron	O
regulator	O
Fur	O
,	O
the	O
small	O
regulatory	O
RNA	O
CsrA	O
and	O
potentially	O
the	O
NADH	O
-	O
responsive	O
regulator	O
Rex	O
.	O

Here	O
,	O
we	O
describe	O
the	O
current	O
knowledge	O
of	O
the	O
metabolic	O
principles	O
of	O
energy	O
generation	O
by	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
and	O
the	O
underlying	O
gene	O
regulatory	O
scenarios	O
.	O

Disentangling	O
What	O
We	O
Know	O
About	O
Microbes	O
and	O
Mental	O
Health	O
.	O

Much	O
has	O
been	O
written	O
in	O
recent	O
years	O
about	O
the	O
gut	O
-	O
brain	O
axis	O
.	O

Exciting	O
pilot	O
studies	O
suggest	O
probiotic	O
applications	O
to	O
the	O
gut	O
can	O
reduce	O
anxiety	O
and	O
depression	O
via	O
the	O
vagus	O
nerve	O
.	O

But	O
not	O
to	O
diminish	O
such	O
findings	O
,	O
much	O
still	O
needs	O
to	O
be	O
considered	O
,	O
including	O
the	O
fact	O
that	O
the	O
vagus	O
nerve	O
links	O
to	O
many	O
other	O
body	O
sites	O
that	O
also	O
host	O
a	O
microbiome	O
.	O

Questions	O
remain	O
that	O
touch	O
the	O
core	O
of	O
being	O
human	O
:	O
(	O
i	O
)	O
Do	O
our	O
microbes	O
influence	O
happiness	O
and	O
to	O
what	O
extent	O
?	O

(	O
ii	O
)	O
What	O
components	O
of	O
the	O
gut	O
microbiota	O
and	O
their	O
function	O
,	O
including	O
as	O
it	O
relates	O
to	O
mental	O
health	O
,	O
are	O
critical	O
and	O
how	O
do	O
they	O
differ	O
between	O
agile	O
,	O
fit	O
hunter	O
gatherers	O
and	O
obese	O
westerners	O
or	O
Danes	O
described	O
as	O
the	O
happiest	O
people	O
on	O
the	O
planet	O
?	O

(	O
iii	O
)	O
What	O
role	O
do	O
environmental	O
pollutants	O
play	O
in	O
this	O
microbes	O
-	O
host	O
ecosystem	O
?	O

While	O
approaching	O
life	O
from	O
a	O
reductionist	O
perspective	O
has	O
a	O
long	O
history	O
in	O
science	O
,	O
we	O
need	O
to	O
try	O
to	O
interrogate	O
these	O
health	O
and	O
disease	O
issues	O
from	O
a	O
wider	O
perspective	O
.	O

For	O
verification	O
of	O
a	O
link	O
between	O
the	O
gut	O
microbiota	O
and	O
brain	O
,	O
and	O
to	O
test	O
new	O
therapies	O
,	O
human	O
studies	O
are	O
needed	O
,	O
and	O
are	O
long	O
overdue	O
.	O

Modulation	O
of	O
the	O
intestinal	O
microbiota	O
of	O
dogs	O
by	O
kefir	O
as	O
a	O
functional	O
dairy	O
product	O
.	O

Kefir	O
is	O
a	O
traditional	O
dairy	O
product	O
with	O
multiple	O
probiotic	O
characteristics	O
derived	O
from	O
its	O
associated	O
microorganisms	O
,	O
including	O
more	O
than	O
50	O
species	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
and	O
yeast	O
.	O

For	O
centuries	O
,	O
many	O
people	O
have	O
produced	O
kefir	O
for	O
human	O
consumption	O
;	O
its	O
consumption	O
and	O
potential	O
role	O
as	O
a	O
probiotic	O
supplement	O
in	O
companion	O
animals	O
have	O
never	O
been	O
tested	O
.	O

The	O
present	O
study	O
explored	O
the	O
potential	O
application	O
of	O
kefir	O
as	O
a	O
probiotic	O
supplement	O
for	O
dogs	O
.	O

Kefir	O
was	O
orally	O
administered	O
to	O
healthy	O
adult	O
dogs	O
(	O
n	O
=	O
6	O
)	O
for	O
2	O
wk	O
.	O

On	O
d	O
0	O
and	O
14	O
(	O
before	O
and	O
after	O
kefir	O
consumption	O
,	O
respectively	O
)	O
,	O
gut	O
microbiota	O
was	O
analyzed	O
comprehensively	O
using	O
quantitative	O
PCR	O
and	O
16S	O
rDNA	O
amplicon	O
-	O
based	O
community	O
analysis	O
using	O
fresh	O
fecal	O
samples	O
.	O

The	O
16S	O
rDNA	O
amplicon	O
-	O
based	O
community	O
analysis	O
showed	O
that	O
the	O
relative	O
abundance	O
of	O
the	O
phylum	O
Fusobacteria	B-bacteria
was	O
significantly	O
decreased	O
after	O
kefir	O
consumption	O
.	O

Furthermore	O
,	O
the	O
relative	O
abundance	O
of	O
the	O
families	O
Prevotellaceae	B-bacteria
,	O
Selenomonadaceae	B-bacteria
,	O
and	O
Sutterellaceae	B-bacteria
increased	O
significantly	O
,	O
whereas	O
that	O
of	O
the	O
families	O
Clostridiaceae	B-bacteria
,	O
Fusobacteriaceae	B-bacteria
,	O
and	O
Ruminococcaceae	B-bacteria
decreased	O
significantly	O
.	O

The	O
quantitative	O
PCR	O
assay	O
showed	O
that	O
kefir	O
consumption	O
significantly	O
increased	O
the	O
population	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
and	O
the	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
:	O
Enterobacteriaceae	B-bacteria
ratio	O
and	O
significantly	O
decreased	O
the	O
Firmicutes	B-bacteria
:	O
Bacteroidetes	B-bacteria
ratio	O
.	O

In	O
summary	O
,	O
2	O
-	O
wk	O
kefir	O
administration	O
successfully	O
modified	O
the	O
gut	O
microbiota	O
without	O
causing	O
any	O
clinically	O
evident	O
adverse	O
effects	O
.	O

Therefore	O
,	O
kefir	O
could	O
be	O
further	O
developed	O
as	O
a	O
novel	O
probiotic	O
food	O
supplement	O
for	O
dogs	O
to	O
improve	O
the	O
quality	O
of	O
life	O
of	O
dogs	O
.	O

Lactobacillus	B-bacteria
johnsonii	I-bacteria
L531	I-bacteria
reduces	O
pathogen	O
load	O
and	O
helps	O
maintain	O
short	O
-	O
chain	O
fatty	O
acid	O
levels	O
in	O
the	O
intestines	O
of	O
pigs	O
challenged	O
with	O
Salmonella	B-bacteria
enterica	I-bacteria
Infantis	I-bacteria
.	O

In	O
the	O
current	O
study	O
,	O
we	O
screened	O
Lactobacillus	B-bacteria
strains	I-bacteria
isolated	O
from	O
the	O
colon	O
of	O
clinically	O
healthy	O
weaned	O
piglets	O
for	O
potential	O
probiotic	O
properties	O
and	O
isolated	O
Lactobacillus	B-bacteria
.	I-bacteria
johnsonii	I-bacteria
L531	I-bacteria
,	O
which	O
produced	O
high	O
levels	O
of	O
beneficial	O
metabolites	O
(	O
butyric	O
,	O
acetic	O
,	O
and	O
lactic	O
acid	O
)	O
in	O
vitro	O
.	O

We	O
also	O
evaluated	O
the	O
efficacy	O
of	O
this	O
metabolites	O
-	O
producing	O
probiotic	O
in	O
treating	O
Salmonella	B-bacteria
.	I-bacteria
Infantis	I-bacteria
infection	O
.	O

Oral	O
administration	O
of	O
L	B-bacteria
.	I-bacteria
johnsonii	I-bacteria
L531	I-bacteria
to	O
newly	O
weaned	O
piglets	O
significantly	O
decreased	O
levels	O
of	O
Salmonella	B-bacteria
colonization	O
in	O
colonic	O
and	O
jejunal	O
contents	O
,	O
accelerated	O
the	O
clearance	O
of	O
Salmonella	B-bacteria
in	O
feces	O
after	O
infection	O
,	O
and	O
reduced	O
S	B-bacteria
.	I-bacteria
Infantis	I-bacteria
translocation	O
to	O
the	O
spleen	O
.	O

Pretreatment	O
with	O
SCFAs	O
-	O
promoting	O
probiotic	O
L	B-bacteria
.	I-bacteria
johnsonii	I-bacteria
L531	I-bacteria
significantly	O
ameliorated	O
the	O
depletion	O
of	O
SCFAs	O
induced	O
by	O
S	B-bacteria
.	I-bacteria
Infantis	I-bacteria
infection	O
and	O
led	O
to	O
significantly	O
greater	O
weight	O
gain	O
and	O
better	O
feed	O
conversion	O
ratios	O
compared	O
to	O
piglets	O
challenged	O
only	O
with	O
S	B-bacteria
.	I-bacteria
Infantis	I-bacteria
.	O

These	O
data	O
provide	O
further	O
evidence	O
that	O
SCFAs	O
-	O
promoting	O
probiotic	O
L	B-bacteria
.	I-bacteria
johnsonii	I-bacteria
L531	I-bacteria
treatment	O
could	O
be	O
a	O
suitable	O
nonantibiotic	O
alternative	O
for	O
controlling	O
Salmonella	B-bacteria
infection	O
and	O
maintaining	O
metabolic	O
homeostasis	O
,	O
thereby	O
enhancing	O
the	O
gut	O
health	O
of	O
piglets	O
during	O
the	O
critical	O
weaning	O
period	O
.	O

Mechanisms	O
and	O
immunomodulatory	O
properties	O
of	O
pre	O
-	O
and	O
probiotics	O
.	O

The	O
human	O
body	O
is	O
exposed	O
to	O
many	O
xenobiotic	O
,	O
potentially	O
harmful	O
compounds	O
.	O

The	O
intestinal	O
immune	O
system	O
is	O
crucial	O
in	O
protecting	O
the	O
human	O
body	O
from	O
these	O
substances	O
.	O

Moreover	O
,	O
many	O
microorganisms	O
,	O
residing	O
in	O
the	O
gastrointestinal	O
tract	O
,	O
play	O
an	O
important	O
role	O
in	O
modulating	O
immune	O
responses	O
.	O

Pre	O
-	O
and	O
probiotics	O
may	O
have	O
beneficial	O
effects	O
on	O
the	O
microbial	O
composition	O
and	O
activity	O
within	O
the	O
human	O
gut	O
,	O
subsequently	O
affecting	O
the	O
immune	O
system	O
.	O

Prebiotics	O
can	O
exert	O
their	O
effects	O
via	O
different	O
mechanisms	O
,	O
like	O
selectively	O
stimulating	O
the	O
growth	O
of	O
bacteria	O
by	O
providing	O
substrates	O
or	O
via	O
direct	O
immune	O
stimulation	O
.	O

Probiotics	O
may	O
have	O
beneficial	O
health	O
effects	O
via	O
competition	O
with	O
pathogens	O
for	O
substrates	O
and	O
binding	O
intestinal	O
sites	O
,	O
bioconversions	O
of	O
for	O
example	O
sugars	O
into	O
fermentation	O
products	O
with	O
inhibitory	O
properties	O
,	O
production	O
of	O
growth	O
substrates	O
like	O
vitamins	O
for	O
the	O
host	O
,	O
direct	O
antagonism	O
of	O
pathogens	O
via	O
antimicrobial	O
peptide	O
production	O
,	O
reduction	O
of	O
inflammation	O
and	O
stimulation	O
of	O
immune	O
cells	O
.	O

This	O
review	O
focuses	O
on	O
the	O
different	O
mechanisms	O
via	O
which	O
the	O
pre	O
-	O
and	O
probiotics	O
exert	O
their	O
beneficial	O
effects	O
on	O
the	O
host	O
,	O
addressing	O
their	O
immunomodulatory	O
properties	O
in	O
particular	O
.	O

Metagenomic	O
insights	O
into	O
the	O
distribution	O
of	O
antibiotic	O
resistome	O
between	O
the	O
gut	O
-	O
associated	O
environments	O
and	O
the	O
pristine	O
environments	O
.	O

Antibiotic	O
resistance	O
genes	O
(	O
ARGs	O
)	O
in	O
the	O
environment	O
are	O
promoted	O
by	O
anthropogenic	O
activities	O
,	O
which	O
cause	O
potential	O
risks	O
to	O
human	O
health	O
.	O

However	O
,	O
large	O
-	O
scale	O
quantitative	O
data	O
on	O
antibiotic	O
resistome	O
from	O
the	O
pristine	O
and	O
anthropogenic	O
environments	O
remains	O
largely	O
unexplored	O
.	O

Here	O
,	O
we	O
used	O
metagenome	O
-	O
wide	O
analysis	O
to	O
investigate	O
the	O
share	O
and	O
divergence	O
in	O
ARG	O
profiles	O
and	O
their	O
potential	O
bacterial	O
hosts	O
between	O
the	O
pristine	O
and	O
gut	O
-	O
associated	O
environments	O
.	O

We	O
found	O
that	O
the	O
abundance	O
of	O
total	O
ARGs	O
in	O
gut	O
-	O
associated	O
environments	O
was	O
significantly	O
higher	O
than	O
the	O
pristine	O
environments	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
mcr	O
-	O
1	O
and	O
tetX	O
,	O
the	O
genes	O
resistant	O
to	O
the	O
last	O
resort	O
antibiotics	O
(	O
colistin	O
and	O
tigecycline	O
,	O
respectively	O
)	O
,	O
were	O
in	O
high	O
abundance	O
(	O
4	O
.	O
57	O
copies	O
/	O
Gb	O
and	O
3	O
.	O
39	O
copies	O
/	O
Gb	O
,	O
respectively	O
)	O
in	O
gut	O
-	O
associated	O
environments	O
,	O
suggesting	O
the	O
ARG	O
pollution	O
caused	O
by	O
anthropogenic	O
antibiotics	O
.	O

Metagenomic	O
assembly	O
-	O
based	O
host	O
-	O
tracking	O
analysis	O
identified	O
Escherichia	B-bacteria
,	O
Bacteroides	B-bacteria
,	O
and	O
Clostridium	B-bacteria
as	O
the	O
predominant	O
bacterial	O
hosts	O
of	O
ARGs	O
in	O
gut	O
-	O
associated	O
environments	O
,	O
while	O
Alteromonas	B-bacteria
,	O
Vibrio	B-bacteria
,	O
and	O
Proteobacteria	B-bacteria
as	O
the	O
predominant	O
bacterial	O
hosts	O
of	O
ARGs	O
in	O
pristine	O
environments	O
.	O

We	O
first	O
described	O
the	O
broad	O
diversity	O
of	O
ARG	B-bacteria
hosts	O
in	O
different	O
environments	O
using	O
metagenome	O
-	O
wide	O
analysis	O
.	O

Our	O
results	O
revealed	O
the	O
heterogeneous	O
distribution	O
of	O
ARGs	O
and	O
their	O
hosts	O
among	O
different	O
microbial	O
niches	O
in	O
gut	O
-	O
associated	O
environments	O
and	O
the	O
pristine	O
environments	O
.	O

Dietary	O
therapy	O
for	O
clostridium	B-bacteria
difficile	I-bacteria
colonization	O
:	O
A	O
case	O
series	O
.	O

Clostridium	B-bacteria
difficile	I-bacteria
(	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
)	O
is	O
an	O
important	O
nosocomial	O
pathogen	O
in	O
adults	O
and	O
children	O
.	O

Roughly	O
4	O
-	O
5	O
%	O
of	O
non	O
hospitalized	O
healthy	O
adults	O
carry	O
the	O
organism	O
in	O
their	O
intestinal	O
flora	O
while	O
adults	O
in	O
long	O
term	O
care	O
facilities	O
have	O
asymptomatic	O
carriage	O
rates	O
estimated	O
at	O
20	O
-	O
50	O
%	O
.	O

C	B-bacteria
.	I-bacteria
difficile	I-bacteria
colonization	O
results	O
in	O
a	O
spectrum	O
of	O
clinical	O
conditions	O
from	O
asymptomatic	O
carrier	O
state	O
to	O
fulminant	O
colitis	O
.	O

Changes	O
in	O
the	O
fecal	O
microbiome	O
are	O
central	O
in	O
the	O
development	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
colonization	O
and	O
disease	O
pathogenesis	O
.	O

C	B-bacteria
.	I-bacteria
difficile	I-bacteria
infection	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
reduced	O
biodiversity	O
of	O
the	O
gut	O
microbiome	O
and	O
intestinal	O
dysbiosis	O
.	O

With	O
the	O
importance	O
of	O
the	O
intestinal	O
microbiota	O
in	O
development	O
of	O
CDI	O
and	O
with	O
the	O
known	O
impact	O
of	O
diet	O
on	O
the	O
intestinal	O
microbiota	O
,	O
we	O
report	O
the	O
first	O
known	O
case	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
colonization	O
/	O
recurrence	O
successful	O
treated	O
by	O
dietary	O
modification	O
.	O

Reactive	O
mechanism	O
and	O
the	O
applications	O
of	O
bioactive	O
prebiotics	O
for	O
human	O
health	O
:	O
Review	O
.	O

Prebiotics	O
plays	O
an	O
important	O
role	O
in	O
improving	O
the	O
growth	O
of	O
gut	O
bacteria	O
and	O
it	O
majorly	O
found	O
in	O
various	O
natural	O
food	O
sources	O
such	O
as	O
fruits	O
and	O
vegetables	O
.	O

Nowadays	O
,	O
the	O
prebiotic	O
sources	O
are	O
added	O
as	O
a	O
supplement	O
in	O
various	O
food	O
products	O
such	O
as	O
dairy	O
products	O
,	O
beverages	O
,	O
health	O
drinks	O
,	O
infant	O
formulae	O
,	O
and	O
meat	O
products	O
.	O

The	O
presence	O
of	O
prebiotics	O
provides	O
various	O
health	O
benefits	O
such	O
as	O
improveing	O
calcium	O
and	O
magnesium	O
absorption	O
,	O
increases	O
bone	O
density	O
,	O
reduces	O
cancer	O
risk	O
,	O
decreases	O
cardiovascular	O
diseases	O
and	O
also	O
improves	O
the	O
immune	O
system	O
.	O

Antibacterial	O
substances	O
produced	O
by	O
pathogen	O
inhibitory	O
gut	O
bacteria	O
in	O
Labeo	O
rohita	O
:	O
Physico	O
-	O
chemical	O
characterization	O
,	O
purification	O
and	O
identification	O
through	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
.	O

Application	O
of	O
antibiotics	O
to	O
combat	O
bacterial	O
diseases	O
in	O
fish	O
has	O
been	O
criticized	O
due	O
to	O
likely	O
emergence	O
of	O
drug	O
resistance	O
.	O

Therefore	O
,	O
investigation	O
of	O
new	O
bioactive	O
compounds	O
from	O
natural	O
sources	O
has	O
been	O
taken	O
into	O
account	O
.	O

This	O
study	O
was	O
designed	O
to	O
purify	O
and	O
characterize	O
the	O
bioactive	O
compound	O
in	O
the	O
cell	O
free	O
supernatant	O
(	O
CFSs	O
)	O
of	O
autochthonous	O
gut	O
bacteria	O
(	O
Bacillus	B-bacteria
methylotrophicus	I-bacteria
KU556164	I-bacteria
,	O
B	B-bacteria
.	I-bacteria
amyloliquefaciens	B-bacteria
KU556165	I-bacteria
,	O
Pseudomonas	B-bacteria
fluorescens	I-bacteria
KU556166	I-bacteria
and	O
B	B-bacteria
.	I-bacteria
licheniformis	I-bacteria
KU556167	I-bacteria
)	O
isolated	O
from	O
rohu	O
,	O
Labeo	O
rohita	O
.	O

CFSs	O
were	O
antagonistic	O
to	O
fish	O
pathogenic	O
Aeromonas	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
moderately	O
thermo	O
-	O
tolerant	O
and	O
active	O
in	O
wide	O
range	O
of	O
pH	O
(	O
5	O
-	O
11	O
)	O
.	O

Antibacterial	O
activity	O
of	O
the	O
CFSs	O
was	O
reduced	O
by	O
the	O
action	O
of	O
proteases	O
(	O
e	O
.	O
g	O
.	O
,	O
Proteinase	O
K	O
and	O
Trypsin	O
)	O
,	O
indicating	O
proteinaceous	O
nature	O
of	O
the	O
bioactive	O
compound	O
like	O
the	O
bacteriocins	O
.	O

Three	O
-	O
step	O
purification	O
procedure	O
resulted	O
in	O
recovery	O
of	O
16	O
.	O
97	O
%	O
,	O
18	O
.	O
04	O
%	O
,	O
33	O
.	O
33	O
%	O
and	O
6	O
.	O
38	O
%	O
activity	O
of	O
the	O
antimicrobial	O
protein	O
produced	O
by	O
B	B-bacteria
.	I-bacteria
methylotrophicus	I-bacteria
,	O
B	B-bacteria
.	I-bacteria
amyloliquefaciens	I-bacteria
,	O
P	B-bacteria
.	I-bacteria
fluorescens	I-bacteria
and	O
B	B-bacteria
.	I-bacteria
licheniformis	I-bacteria
,	O
respectively	O
.	O

Purification	O
at	O
each	O
step	O
revealed	O
decrease	O
in	O
protein	O
content	O
with	O
gradual	O
increase	O
in	O
the	O
specific	O
activity	O
of	O
the	O
antimicrobial	O
protein	O
.	O

The	O
purified	O
antibacterial	O
compound	O
ranged	O
between	O
18	O
.	O
2	O
and	O
25	O
.	O
6kDa	O
.	O

Identification	O
through	O
MALDI	O
-	O
TOF	O
MS	O
/	O
MS	O
and	O
database	O
search	O
through	O
Mascot	O
search	O
engine	O
predicted	O
that	O
the	O
bactericidal	O
compound	O
belonged	O
to	O
either	O
alkaline	O
proteases	O
,	O
or	O
,	O
transcriptional	O
regulator	O
and	O
some	O
hypothetical	O
proteins	O
.	O

Apart	O
from	O
potential	O
technological	O
application	O
of	O
the	O
antibacterial	O
compound	O
,	O
the	O
present	O
study	O
might	O
show	O
promise	O
for	O
application	O
of	O
gut	O
-	O
associated	O
bacteriocinogenic	O
bacteria	O
to	O
control	O
diseases	O
in	O
fish	O
caused	O
by	O
pathogenic	O
bacteria	O
.	O

Hypoglycemic	O
activity	O
and	O
gut	O
microbiota	O
regulation	O
of	O
a	O
novel	O
polysaccharide	O
from	O
Grifola	O
frondosa	I-bacteria
in	O
type	O
2	O
diabetic	O
mice	O
.	O

GFP	O
-	O
N	O
,	O
a	O
novel	O
heteropolysaccharide	O
with	O
a	O
molecular	O
weight	O
of	O
1	O
.	O
26x10	O
(	O
7	O
)	O
Da	O
,	O
was	O
isolated	O
from	O
maitake	O
mushroom	O
and	O
purified	O
by	O
anion	O
-	O
exchange	O
chromatography	O
on	O
a	O
DEAE	O
cellulose	O
-	O
52	O
column	O
and	O
gel	O
-	O
filtration	O
chromatography	O
on	O
a	O
Sephadex	O
G	O
-	O
100	O
column	O
.	O

Its	O
structure	O
was	O
characterized	O
by	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
and	O
one	O
-	O
dimensional	O
(	O
(	O
1	O
)	O
H	O
-	O
and	O
(	O
13	O
)	O
C	O
-	O
)	O
NMR	O
spectra	O
,	O
(	O
1	O
)	O
H	O
(	O
1	O
)	O
H	O
correlation	O
spectroscopy	O
,	O
and	O
(	O
1	O
)	O
H	O
(	O
13	O
)	O
C	O
heteronuclear	O
single	O
-	O
quantum	O
coherence	O
spectroscopy	O
.	O

The	O
structure	O
of	O
GFP	O
-	O
N	O
consisted	O
of	O
L	O
-	O
arabinose	O
,	O
D	O
-	O
mannose	O
and	O
D	O
-	O
glucose	O
and	O
mainly	O
contained	O
three	O
kinds	O
of	O
linkage	O
type	O
units	O
as	O
-	O
-	O
>	O
2	O
,	O
6	O
)	O
-	O
alpha	O
-	O
D	O
-	O
Manp	O
-	O
(	O
1	O
-	O
-	O
>	O
4	O
,	O
alpha	O
-	O
L	O
-	O
Araf	O
-	O
C1	O
-	O
-	O
>	O
,	O
and	O
-	O
-	O
>	O
3	O
,	O
6	O
)	O
-	O
beta	O
-	O
D	O
-	O
Glcp	O
-	O
(	O
1	O
-	O
-	O
>	O
.	O

GFP	O
-	O
N	O
could	O
activate	O
insulin	O
receptor	O
substrate	O
1	O
,	O
phosphatidylinositol	O
-	O
3	O
-	O
kinase	O
,	O
and	O
glucose	O
transporter	O
4	O
and	O
inhibit	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
1	O
/	O
2	O
for	O
hypoglycemic	O
effects	O
in	O
diabetic	O
mouse	O
livers	O
.	O

This	O
is	O
also	O
the	O
first	O
report	O
of	O
the	O
regulatory	O
efficacy	O
of	O
Grifola	O
frondosa	O
polysaccharide	O
on	O
intestinal	O
microflora	O
in	O
vivo	O
using	O
single	O
-	O
molecule	O
real	O
-	O
time	O
sequencing	O
.	O

These	O
results	O
indicated	O
that	O
polysaccharide	O
from	O
maitake	O
mushroom	O
could	O
be	O
as	O
an	O
enhancer	O
to	O
improve	O
type	O
2	O
diabetes	O
and	O
a	O
healthy	O
food	O
option	O
to	O
help	O
regulate	O
gut	O
microbiota	O
in	O
diabetic	O
individuals	O
.	O

Type	O
VI	O
Secretion	O
Systems	O
and	O
the	O
Gut	O
Microbiota	O
.	O

The	O
human	O
colonic	O
microbiota	O
is	O
a	O
dense	O
ecosystem	O
comprised	O
of	O
numerous	O
microbes	O
,	O
including	O
bacteria	O
,	O
phage	O
,	O
fungi	O
,	O
archaea	O
,	O
and	O
protozoa	O
,	O
that	O
compete	O
for	O
nutrients	O
and	O
space	O
.	O

Studies	O
are	O
beginning	O
to	O
reveal	O
the	O
antagonistic	O
mechanisms	O
that	O
gut	O
bacteria	O
use	O
to	O
compete	O
with	O
other	O
members	O
of	O
this	O
ecosystem	O
.	O

In	O
the	O
healthy	O
human	O
colon	O
,	O
the	O
majority	O
of	O
the	O
Gram	O
-	O
negative	O
bacteria	O
are	O
of	O
the	O
order	O
Bacteroidales	B-bacteria
.	O

Proteobacteria	B-bacteria
,	O
such	O
as	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
are	O
numerically	O
fewer	O
but	O
confer	O
important	O
properties	O
to	O
the	O
host	O
,	O
such	O
as	O
colonization	O
resistance	O
.	O

Several	O
enteric	O
pathogens	O
use	O
type	O
VI	O
secretion	O
systems	O
(	O
T6SSs	O
)	O
to	O
antagonize	O
symbiotic	O
gut	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
,	O
facilitating	O
colonization	O
and	O
disease	O
progression	O
.	O

T6SS	O
loci	O
are	O
also	O
widely	O
distributed	O
in	O
human	O
gut	O
Bacteroidales	B-bacteria
,	O
which	O
includes	O
three	O
predominant	O
genera	O
:	O
Bacteroides	B-bacteria
,	O
Parabacteroides	B-bacteria
,	O
and	O
Prevotella	B-bacteria
.	O

There	O
are	O
three	O
distinct	O
genetic	O
architectures	O
of	O
T6SS	O
loci	O
among	O
the	O
gut	O
Bacteroidales	B-bacteria
,	O
termed	O
GA1	O
,	O
GA2	O
,	O
and	O
GA3	O
.	O

GA1	O
and	O
GA2	O
T6SS	O
loci	O
are	O
contained	O
on	O
integrative	O
and	O
conjugative	O
elements	O
and	O
are	O
the	O
first	O
T6SS	O
loci	O
shown	O
to	O
be	O
readily	O
transferred	O
in	O
the	O
human	O
gut	O
between	O
numerous	O
species	O
and	O
families	O
of	O
Bacteroidales	B-bacteria
.	O

In	O
contrast	O
,	O
the	O
GA3	O
T6SSs	O
are	O
present	O
exclusively	O
in	O
Bacteroides	B-bacteria
fragilis	I-bacteria
.	O

There	O
are	O
divergent	O
regions	O
in	O
all	O
three	O
T6SS	O
GAs	O
that	O
contain	O
genes	O
encoding	O
effector	O
and	O
immunity	O
proteins	O
,	O
many	O
of	O
which	O
function	O
by	O
unknown	O
mechanisms	O
.	O

To	O
date	O
,	O
only	O
the	O
GA3	O
T6SSs	O
have	O
been	O
shown	O
to	O
antagonize	O
bacteria	O
,	O
and	O
they	O
target	O
nearly	O
all	O
gut	O
Bacteroidales	B-bacteria
species	I-bacteria
analyzed	O
.	O

This	O
review	O
delves	O
more	O
deeply	O
into	O
properties	O
of	O
the	O
T6SSs	O
of	O
these	O
human	O
gut	O
bacteria	O
and	O
the	O
ecological	O
outcomes	O
of	O
their	O
synthesis	O
in	O
vivo	O
.	O

The	O
gut	O
mycobiota	O
:	O
insights	O
into	O
analysis	O
,	O
environmental	O
interactions	O
and	O
role	O
in	O
gastrointestinal	O
diseases	O
.	O

The	O
gut	O
microbiota	O
is	O
a	O
dense	O
and	O
diverse	O
ecosystem	O
that	O
is	O
involved	O
in	O
many	O
physiological	O
functions	O
as	O
well	O
as	O
in	O
disease	O
pathogenesis	O
.	O

It	O
is	O
dominated	O
by	O
bacteria	O
,	O
which	O
have	O
been	O
extensively	O
studied	O
in	O
the	O
past	O
15	O
years	O
;	O
however	O
,	O
other	O
microorganisms	O
,	O
such	O
as	O
fungi	O
,	O
phages	O
,	O
archaea	O
and	O
protists	O
,	O
are	O
also	O
present	O
in	O
the	O
gut	O
microbiota	O
.	O

Exploration	O
of	O
the	O
fungal	O
component	O
,	O
namely	O
,	O
the	O
mycobiota	O
,	O
is	O
at	O
an	O
early	O
stage	O
,	O
and	O
several	O
specific	O
technical	O
challenges	O
are	O
associated	O
with	O
mycobiota	O
analysis	O
.	O

The	O
number	O
of	O
fungi	O
in	O
the	O
lower	O
gastrointestinal	O
tract	O
is	O
far	O
lower	O
than	O
that	O
of	O
bacteria	O
,	O
but	O
fungal	O
cells	O
are	O
much	O
larger	O
and	O
much	O
more	O
complex	O
than	O
bacterial	O
cells	O
.	O

In	O
addition	O
,	O
a	O
role	O
of	O
the	O
mycobiota	O
in	O
disease	O
,	O
notably	O
in	O
IBD	O
,	O
is	O
indicated	O
by	O
both	O
descriptive	O
data	O
in	O
humans	O
and	O
mechanistic	O
data	O
in	O
mice	O
.	O

Interactions	O
between	O
bacteria	O
and	O
fungi	O
within	O
the	O
gut	O
,	O
their	O
functional	O
roles	O
and	O
their	O
interplay	O
with	O
the	O
host	O
and	O
its	O
immune	O
system	O
are	O
fascinating	O
areas	O
that	O
researchers	O
are	O
just	O
beginning	O
to	O
investigate	O
.	O

In	O
this	O
Review	O
,	O
we	O
discuss	O
the	O
newest	O
data	O
on	O
the	O
gut	O
mycobiota	O
and	O
explore	O
both	O
the	O
technical	O
aspects	O
of	O
its	O
study	O
and	O
its	O
role	O
in	O
health	O
and	O
gastrointestinal	O
diseases	O
.	O

Mycobiome	O
Profiles	O
in	O
Breast	O
Milk	O
from	O
Healthy	O
Women	O
Depend	O
on	O
Mode	O
of	O
Delivery	O
,	O
Geographic	O
Location	O
,	O
and	O
Interaction	O
with	O
Bacteria	O
.	O

Recent	O
studies	O
report	O
the	O
presence	O
of	O
fungal	O
species	O
in	O
breast	O
milk	O
of	O
healthy	O
mothers	O
,	O
suggesting	O
a	O
potential	O
role	O
in	O
infant	O
mycobiome	O
development	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
aimed	O
to	O
determine	O
whether	O
the	O
healthy	O
human	O
breast	O
milk	O
mycobiota	O
is	O
influenced	O
by	O
geographical	O
location	O
and	O
mode	O
of	O
delivery	O
,	O
as	O
well	O
as	O
to	O
investigate	O
its	O
interaction	O
with	O
bacterial	O
profiles	O
in	O
the	O
same	O
samples	O
.	O

A	O
total	O
of	O
80	O
mature	O
breast	O
milk	O
samples	O
from	O
4	O
different	O
countries	O
were	O
analyzed	O
by	O
Illumina	O
sequencing	O
of	O
the	O
internal	O
transcribed	O
spacer	O
1	O
(	O
ITS1	O
)	O
region	O
,	O
joining	O
the	O
18S	O
and	O
5	O
.	O
8S	O
regions	O
of	O
the	O
fungal	O
rRNA	O
region	O
.	O

Basidiomycota	B-bacteria
and	O
Ascomycota	B-bacteria
were	O
found	O
to	O
be	O
the	O
dominant	O
phyla	O
,	O
with	O
Malassezia	B-bacteria
and	O
Davidiella	B-bacteria
being	O
the	O
most	O
prevalent	O
genera	O
across	O
countries	O
.	O

A	O
core	O
formed	O
by	O
Malassezia	B-bacteria
,	O
Davidiella	B-bacteria
,	O
Sistotrema	B-bacteria
,	O
and	O
Penicillium	B-bacteria
was	O
shared	O
in	O
the	O
milk	O
samples	O
from	O
the	O
different	O
origins	O
,	O
although	O
specific	O
shifts	O
in	O
mycobiome	O
composition	O
were	O
associated	O
with	O
geographic	O
location	O
and	O
delivery	O
mode	O
.	O

The	O
presence	O
of	O
fungi	O
in	O
the	O
breast	O
milk	O
samples	O
was	O
further	O
confirmed	O
by	O
culture	O
and	O
isolate	O
characterization	O
,	O
and	O
fungal	O
loads	O
were	O
estimated	O
by	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
targeting	O
the	O
fungal	O
ITS1	O
region	O
.	O

Cooccurrence	O
network	O
analysis	O
of	O
bacteria	O
and	O
fungi	O
showed	O
complex	O
interactions	O
that	O
were	O
influenced	O
by	O
geographical	O
location	O
,	O
mode	O
of	O
delivery	O
,	O
maternal	O
age	O
,	O
and	O
pregestational	O
body	O
mass	O
index	O
.	O

The	O
presence	O
of	O
a	O
breast	O
milk	O
mycobiome	O
was	O
confirmed	O
in	O
all	O
samples	O
analyzed	O
,	O
regardless	O
of	O
the	O
geographic	O
origin	O
.	O
IMPORTANCE	O
During	O
recent	O
years	O
,	O
human	O
breast	O
milk	O
has	O
been	O
documented	O
as	O
a	O
potential	O
source	O
of	O
bacteria	O
for	O
the	O
newborn	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
the	O
presence	O
of	O
fungi	O
in	O
breast	O
milk	O
from	O
healthy	O
mothers	O
.	O

It	O
is	O
well	O
known	O
that	O
environmental	O
and	O
perinatal	O
factors	O
can	O
affect	O
milk	O
bacteria	O
;	O
however	O
,	O
the	O
impact	O
on	O
milk	O
fungi	O
is	O
still	O
unknown	O
.	O

The	O
current	O
report	O
describes	O
fungal	O
communities	O
(	O
mycobiota	O
)	O
in	O
breast	O
milk	O
samples	O
across	O
different	O
geographic	O
locations	O
and	O
the	O
influence	O
of	O
the	O
mode	O
of	O
delivery	O
.	O

We	O
also	O
provide	O
novel	O
insights	O
on	O
bacterium	O
-	O
fungus	O
interactions	O
,	O
taking	O
into	O
account	O
environmental	O
and	O
perinatal	O
factors	O
.	O

We	O
identified	O
a	O
core	O
of	O
four	O
genera	O
shared	O
across	O
locations	O
,	O
consisting	O
of	O
Malassezia	B-bacteria
,	O
Davidiella	B-bacteria
,	O
Sistotrema	B-bacteria
,	O
and	O
Penicillium	B-bacteria
,	O
which	O
have	O
been	O
reported	O
to	O
be	O
present	O
in	O
the	O
infant	O
gut	O
.	O

Our	O
data	O
confirm	O
the	O
presence	O
of	O
fungi	O
in	O
breast	O
milk	O
across	O
continents	O
and	O
support	O
the	O
potential	O
role	O
of	O
breast	O
milk	O
in	O
the	O
initial	O
seeding	O
of	O
fungal	O
species	O
in	O
the	O
infant	O
gut	O
.	O

Prebiotic	O
Supplementation	O
of	O
In	O
Vitro	O
Fecal	O
Fermentations	O
Inhibits	O
Proteolysis	O
by	O
Gut	O
Bacteria	O
,	O
and	O
Host	O
Diet	O
Shapes	O
Gut	O
Bacterial	O
Metabolism	O
and	O
Response	O
to	O
Intervention	O
.	O

Metabolism	O
of	O
protein	O
by	O
gut	O
bacteria	O
is	O
potentially	O
detrimental	O
due	O
to	O
the	O
production	O
of	O
toxic	O
metabolites	O
,	O
such	O
as	O
ammonia	O
,	O
amines	O
,	O
p	O
-	O
cresol	O
,	O
and	O
indole	O
.	O

The	O
consumption	O
of	O
prebiotic	O
carbohydrates	O
results	O
in	O
specific	O
changes	O
in	O
the	O
composition	O
and	O
/	O
or	O
activity	O
of	O
the	O
microbiota	O
that	O
may	O
confer	O
benefits	O
to	O
host	O
well	O
-	O
being	O
and	O
health	O
.	O

Here	O
,	O
we	O
have	O
studied	O
the	O
impact	O
of	O
prebiotics	O
on	O
proteolysis	O
within	O
the	O
gut	O
in	O
vitro	O
Anaerobic	O
stirred	O
batch	O
cultures	O
were	O
inoculated	O
with	O
feces	O
from	O
omnivores	O
(	O
n	O
=	O
3	O
)	O
and	O
vegetarians	O
(	O
n	O
=	O
3	O
)	O
and	O
four	O
protein	O
sources	O
(	O
casein	O
,	O
meat	O
,	O
mycoprotein	O
,	O
and	O
soy	O
protein	O
)	O
with	O
and	O
without	O
supplementation	O
by	O
an	O
oligofructose	O
-	O
enriched	O
inulin	O
.	O

Bacterial	O
counts	O
and	O
concentrations	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFA	O
)	O
,	O
ammonia	O
,	O
phenol	O
,	O
indole	O
,	O
and	O
p	O
-	O
cresol	O
were	O
monitored	O
during	O
fermentation	O
.	O

Addition	O
of	O
the	O
fructan	O
prebiotic	O
Synergy1	O
increased	O
levels	O
of	O
bifidobacteria	B-bacteria
(	O
P	O
=	O
0	O
.	O
000019	O
and	O
0	O
.	O
000013	O
for	O
omnivores	O
and	O
vegetarians	O
,	O
respectively	O
)	O
.	O

Branched	O
-	O
chain	O
fatty	O
acids	O
(	O
BCFA	O
)	O
were	O
significantly	O
lower	O
in	O
fermenters	O
with	O
vegetarians	O
'	O
feces	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
,	O
reduced	O
further	O
by	O
prebiotic	O
treatment	O
.	O

Ammonia	O
production	O
was	O
lower	O
with	O
Synergy1	O
.	O

Bacterial	O
adaptation	O
to	O
different	O
dietary	O
protein	O
sources	O
was	O
observed	O
through	O
different	O
patterns	O
of	O
ammonia	O
production	O
between	O
vegetarians	O
and	O
omnivores	O
.	O

In	O
volunteer	O
samples	O
with	O
high	O
baseline	O
levels	O
of	O
phenol	O
,	O
indole	O
,	O
p	O
-	O
cresol	O
,	O
and	O
skatole	O
,	O
Synergy1	O
fermentation	O
led	O
to	O
a	O
reduction	O
of	O
these	O
compounds	O
.	O
IMPORTANCE	O
Dietary	O
protein	O
intake	O
is	O
high	O
in	O
Western	O
populations	O
,	O
which	O
could	O
result	O
in	O
potentially	O
harmful	O
metabolites	O
in	O
the	O
gut	O
from	O
proteolysis	O
.	O

In	O
an	O
in	O
vitro	O
fermentation	O
model	O
,	O
the	O
addition	O
of	O
prebiotics	O
reduced	O
the	O
negative	O
consequences	O
of	O
high	O
protein	O
levels	O
.	O

Supplementation	O
with	O
a	O
prebiotic	O
resulted	O
in	O
a	O
reduction	O
of	O
proteolytic	O
metabolites	O
in	O
the	O
model	O
.	O

A	O
difference	O
was	O
seen	O
in	O
protein	O
fermentation	O
between	O
omnivore	O
and	O
vegetarian	O
gut	O
microbiotas	O
:	O
bacteria	O
from	O
vegetarian	O
donors	O
grew	O
more	O
on	O
soy	O
and	O
Quorn	O
than	O
on	O
meat	O
and	O
casein	O
,	O
with	O
reduced	O
ammonia	O
production	O
.	O

Bacteria	O
from	O
vegetarian	O
donors	O
produced	O
less	O
branched	O
-	O
chain	O
fatty	O
acids	O
(	O
BCFA	O
)	O
.	O

Differential	O
Effects	O
of	O
Breed	O
and	O
Nursing	O
on	O
Early	O
-	O
Life	O
Colonic	O
Microbiota	O
and	O
Immune	O
Status	O
as	O
Revealed	O
in	O
a	O
Cross	O
-	O
Fostering	O
Piglet	O
Model	O
.	O

Nursing	O
mother	O
and	O
breed	O
can	O
differently	O
regulate	O
early	O
-	O
life	O
microbiota	O
succession	O
in	O
pigs	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
whether	O
they	O
affect	O
gastrointestinal	O
microbiota	O
and	O
immune	O
status	O
,	O
which	O
are	O
critical	O
for	O
early	O
-	O
life	O
gut	O
health	O
.	O

Here	O
,	O
an	O
interspecific	O
cross	O
-	O
fostering	O
piglet	O
model	O
was	O
employed	O
by	O
fostering	O
neonatal	O
Yorkshire	O
and	O
Meishan	O
piglets	O
to	O
the	O
same	O
or	O
another	O
breed	O
of	O
sows	O
.	O

Jejunal	O
and	O
colonic	O
microbiotas	O
and	O
mucosal	O
immune	O
parameters	O
were	O
analyzed	O
at	O
postnatal	O
days	O
14	O
(	O
preweaning	O
)	O
and	O
49	O
(	O
postweaning	O
)	O
.	O

Nursing	O
mother	O
affected	O
10	O
genera	O
in	O
the	O
colon	O
and	O
3	O
minor	O
genera	O
in	O
the	O
jejunum	O
.	O

At	O
day	O
14	O
,	O
Meishan	O
sow	O
-	O
nursed	O
piglets	O
had	O
lower	O
Streptococcus	B-bacteria
suis	I-bacteria
and	O
higher	O
Cloacibacillus	B-bacteria
counts	O
in	O
the	O
colonic	O
digesta	O
and	O
larger	O
amounts	O
of	O
interleukin	O
10	O
and	O
Foxp3	O
-	O
positive	O
cells	O
in	O
the	O
colonic	O
mucosa	O
than	O
did	O
Yorkshire	O
sow	O
-	O
nursed	O
piglets	O
.	O

At	O
day	O
49	O
,	O
nursing	O
mother	O
had	O
no	O
significant	O
effects	O
on	O
cytokine	O
expression	O
.	O

Breed	O
effects	O
were	O
observed	O
;	O
Meishan	O
piglets	O
had	O
lower	O
relative	O
abundances	O
of	O
Prevotella	B-bacteria
and	O
lower	O
gene	O
expression	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
than	O
those	O
of	O
Yorkshire	O
piglets	O
at	O
days	O
14	O
and	O
49	O
.	O

Collectively	O
,	O
nursing	O
mother	O
mainly	O
affected	O
preweaning	O
colonic	O
microbiota	O
and	O
immune	O
status	O
,	O
while	O
breed	O
effects	O
persisted	O
after	O
weaning	O
.	O

Piglets	O
nursed	O
by	O
Meishan	O
sows	O
had	O
different	O
microbiota	O
compositions	O
and	O
inflammatory	O
cytokine	O
profiles	O
in	O
the	O
colon	O
compared	O
with	O
those	O
of	O
piglets	O
nursed	O
by	O
Yorkshire	O
sows	O
.	O

These	O
results	O
highlight	O
the	O
different	O
role	O
of	O
nursing	O
mother	O
and	O
breed	O
in	O
affecting	O
early	O
gut	O
microenvironment	O
.	O
IMPORTANCE	O
Early	O
-	O
life	O
gut	O
microbiota	O
and	O
immune	O
status	O
are	O
pivotal	O
for	O
postnatal	O
growth	O
.	O

By	O
using	O
an	O
interspecific	O
cross	O
-	O
fostering	O
piglet	O
model	O
,	O
we	O
find	O
that	O
change	O
in	O
nursing	O
mother	O
transiently	O
reshapes	O
preweaning	O
colon	O
microbiota	O
and	O
immune	O
status	O
,	O
while	O
breed	O
shows	O
persistent	O
effects	O
both	O
pre	O
-	O
and	O
postweaning	O
.	O

Piglets	O
nursed	O
by	O
Meishan	O
sows	O
had	O
lower	O
Streptococcus	B-bacteria
suis	I-bacteria
counts	O
and	O
higher	O
anti	O
-	O
inflammatory	O
cytokine	O
expression	O
.	O

These	O
results	O
highlight	O
the	O
significance	O
of	O
nursing	O
mother	O
in	O
regulating	O
early	O
-	O
life	O
gut	O
health	O
.	O

Farm	O
Stage	O
,	O
Bird	O
Age	O
,	O
and	O
Body	O
Site	O
Dominantly	O
Affect	O
the	O
Quantity	O
,	O
Taxonomic	O
Composition	O
,	O
and	O
Dynamics	O
of	O
Respiratory	O
and	O
Gut	O
Microbiota	O
of	O
Commercial	O
Layer	O
Chickens	O
.	O

The	O
digestive	O
and	O
respiratory	O
tracts	O
of	O
chickens	O
are	O
colonized	O
by	O
bacteria	O
that	O
are	O
believed	O
to	O
play	O
important	O
roles	O
in	O
the	O
overall	O
health	O
and	O
performance	O
of	O
the	O
birds	O
.	O

Most	O
of	O
the	O
current	O
research	O
on	O
the	O
commensal	O
bacteria	O
(	O
microbiota	O
)	O
of	O
chickens	O
has	O
focused	O
on	O
broilers	O
and	O
gut	O
microbiota	O
,	O
and	O
less	O
attention	O
has	O
been	O
given	O
to	O
layers	O
and	O
respiratory	O
microbiota	O
.	O

This	O
research	O
bias	O
has	O
left	O
significant	O
gaps	O
in	O
our	O
knowledge	O
of	O
the	O
layer	O
microbiome	O
.	O

This	O
study	O
was	O
conducted	O
to	O
define	O
the	O
core	O
microbiota	O
colonizing	O
the	O
upper	O
respiratory	O
tract	O
(	O
URT	O
)	O
and	O
lower	O
intestinal	O
tract	O
(	O
LIT	O
)	O
in	O
commercial	O
layers	O
under	O
field	O
conditions	O
.	O

One	O
hundred	O
eighty	O
-	O
one	O
chickens	O
were	O
sampled	O
from	O
a	O
flock	O
of	O
>	O
80	O
,	O
000	O
birds	O
at	O
nine	O
times	O
to	O
collect	O
samples	O
for	O
16S	O
rRNA	O
gene	O
-	O
based	O
bacterial	O
metabarcoding	O
.	O

Generally	O
,	O
the	O
body	O
site	O
and	O
age	O
/	O
farm	O
stage	O
had	O
very	O
dominant	O
effects	O
on	O
the	O
quantity	O
,	O
taxonomic	O
composition	O
,	O
and	O
dynamics	O
of	O
core	O
bacteria	O
.	O

Remarkably	O
,	O
ileal	O
and	O
URT	O
microbiota	O
were	O
compositionally	O
more	O
related	O
to	O
each	O
other	O
than	O
to	O
that	O
from	O
the	O
cecum	O
.	O

Unique	O
taxa	O
dominated	O
in	O
each	O
body	O
site	O
yet	O
some	O
taxa	O
overlapped	O
between	O
URT	O
and	O
LIT	O
sites	O
,	O
demonstrating	O
a	O
common	O
core	O
.	O

The	O
overlapping	O
bacteria	O
also	O
contained	O
various	O
levels	O
of	O
several	O
genera	O
with	O
well	O
-	O
recognized	O
avian	O
pathogens	O
.	O

Our	O
findings	O
suggest	O
that	O
significant	O
interaction	O
exists	O
between	O
gut	O
and	O
respiratory	O
microbiota	O
,	O
including	O
potential	O
pathogens	O
,	O
in	O
all	O
stages	O
of	O
the	O
farm	O
sequence	O
.	O

The	O
baseline	O
data	O
generated	O
in	O
this	O
study	O
can	O
be	O
useful	O
for	O
the	O
development	O
of	O
effective	O
microbiome	O
-	O
based	O
interventions	O
to	O
enhance	O
production	O
performance	O
and	O
to	O
prevent	O
and	O
control	O
disease	O
in	O
commercial	O
chicken	O
layers	O
.	O
IMPORTANCE	O
The	O
poultry	O
industry	O
is	O
faced	O
with	O
numerous	O
challenges	O
associated	O
with	O
infectious	O
diseases	O
and	O
suboptimal	O
performance	O
of	O
flocks	O
.	O

As	O
microbiome	O
research	O
continues	O
to	O
grow	O
,	O
it	O
is	O
becoming	O
clear	O
that	O
poultry	O
health	O
and	O
production	O
performance	O
are	O
partly	O
influenced	O
by	O
nonpathogenic	O
symbionts	O
that	O
occupy	O
different	O
habitats	O
within	O
the	O
bird	O
.	O

This	O
study	O
has	O
defined	O
the	O
baseline	O
composition	O
and	O
overlaps	O
between	O
respiratory	O
and	O
gut	O
bacteria	O
in	O
healthy	O
,	O
optimally	O
performing	O
chicken	O
layers	O
across	O
all	O
stages	O
of	O
the	O
commercial	O
farm	O
sequence	O
.	O

Consequently	O
,	O
the	O
study	O
has	O
set	O
the	O
groundwork	O
for	O
the	O
development	O
of	O
interventions	O
that	O
seek	O
to	O
enhance	O
production	O
performance	O
and	O
to	O
prevent	O
and	O
control	O
infectious	O
diseases	O
through	O
the	O
modulation	O
of	O
gut	O
and	O
respiratory	O
bacteria	O
.	O

Altered	O
gut	O
microbiome	O
after	O
bariatric	O
surgery	O
and	O
its	O
association	O
with	O
metabolic	O
benefits	O
:	O
A	O
systematic	O
review	O
.	O

Bariatric	O
surgery	O
is	O
currently	O
the	O
recommended	O
therapy	O
for	O
significant	O
weight	O
reduction	O
and	O
remission	O
of	O
type	O
2	O
diabetes	O
.	O

Different	O
types	O
of	O
bariatric	O
surgery	O
result	O
in	O
dramatic	O
changes	O
to	O
gut	O
bacteria	O
but	O
the	O
contribution	O
of	O
such	O
changes	O
to	O
the	O
metabolic	O
benefits	O
achieved	O
is	O
still	O
unclear	O
.	O

This	O
systematic	O
review	O
of	O
14	O
clinical	O
studies	O
,	O
incorporating	O
222	O
participants	O
(	O
146	O
patients	O
with	O
Roux	O
-	O
en	O
-	O
Y	O
gastric	O
bypass	O
,	O
25	O
with	O
sleeve	O
gastrectomy	O
,	O
30	O
with	O
biliointestinal	O
bypass	O
,	O
7	O
with	O
vertical	O
banded	O
gastroplasty	O
,	O
and	O
14	O
with	O
an	O
adjustable	O
gastric	O
band	O
)	O
reveals	O
generally	O
increased	O
microbial	O
diversity	O
and	O
gene	O
richness	O
after	O
surgery	O
.	O

Major	O
species	O
-	O
level	O
changes	O
include	O
a	O
decrease	O
in	O
the	O
relative	O
abundance	O
of	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
and	O
increase	O
in	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

Decreases	O
in	O
the	O
relative	O
abundance	O
of	O
Firmicutes	B-bacteria
after	O
sleeve	O
gastrectomy	O
and	O
increases	O
in	O
Bacteroidetes	B-bacteria
and	O
Proteobacteria	B-bacteria
after	O
Roux	O
-	O
en	O
-	O
Y	O
gastric	O
bypass	O
were	O
seen	O
.	O

Microbial	O
changes	O
after	O
surgery	O
are	O
discussed	O
in	O
the	O
context	O
of	O
potential	O
confounding	O
effects	O
of	O
baseline	O
diet	O
,	O
medications	O
,	O
and	O
type	O
2	O
diabetes	O
,	O
with	O
recommendations	O
to	O
consider	O
these	O
factors	O
in	O
future	O
studies	O
,	O
to	O
identify	O
potentially	O
causal	O
associations	O
with	O
observed	O
metabolic	O
benefits	O
.	O

Impact	O
of	O
microbiota	O
on	O
central	O
nervous	O
system	O
and	O
neurological	O
diseases	O
:	O
the	O
gut	O
-	O
brain	O
axis	O
.	O

Development	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
is	O
regulated	O
by	O
both	O
intrinsic	O
and	O
peripheral	O
signals	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
environmental	O
factors	O
affect	O
neurological	O
activities	O
under	O
both	O
physiological	O
and	O
pathological	O
conditions	O
.	O

Although	O
there	O
is	O
anatomical	O
separation	O
,	O
emerging	O
evidence	O
has	O
indicated	O
the	O
existence	O
of	O
bidirectional	O
interaction	O
between	O
gut	O
microbiota	O
,	O
i	O
.	O
e	O
.	O
,	O
(	O
diverse	O
microorganisms	O
colonizing	O
human	O
intestine	O
)	O
,	O
and	O
brain	O
.	O

The	O
cross	O
-	O
talk	O
between	O
gut	O
microbiota	O
and	O
brain	O
may	O
have	O
crucial	O
impact	O
during	O
basic	O
neurogenerative	O
processes	O
,	O
in	O
neurodegenerative	O
disorders	O
and	O
tumors	O
of	O
CNS	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
biological	O
interplay	O
between	O
gut	O
-	O
brain	O
axis	O
,	O
and	O
further	O
explore	O
how	O
this	O
communication	O
may	O
be	O
dysregulated	O
in	O
neurological	O
diseases	O
.	O

Further	O
,	O
we	O
highlight	O
new	O
insights	O
in	O
modification	O
of	O
gut	O
microbiota	O
composition	O
,	O
which	O
may	O
emerge	O
as	O
a	O
promising	O
therapeutic	O
approach	O
to	O
treat	O
CNS	O
disorders	O
.	O

Probiotics	O
and	O
Colon	O
Cancer	O
.	O

Literature	O
has	O
recently	O
highlighted	O
the	O
enormous	O
scientific	O
interest	O
on	O
the	O
relationship	O
between	O
the	O
gut	O
microbiota	O
and	O
colon	O
cancer	O
,	O
and	O
how	O
the	O
use	O
of	O
some	O
selected	O
probiotics	O
can	O
have	O
a	O
future	O
impact	O
on	O
the	O
adverse	O
events	O
which	O
occur	O
during	O
this	O
disease	O
.	O

Although	O
there	O
is	O
no	O
clear	O
evidence	O
to	O
claim	O
that	O
probiotics	O
are	O
effective	O
in	O
people	O
with	O
cancer	O
,	O
recent	O
reviews	O
have	O
found	O
that	O
probiotics	O
can	O
significantly	O
reduce	O
the	O
incidence	O
of	O
diarrhea	O
and	O
the	O
average	O
frequency	O
of	O
daily	O
bowel	O
movements	O
.	O

However	O
,	O
most	O
of	O
this	O
evidence	O
needs	O
to	O
be	O
more	O
clinically	O
convincing	O
and	O
further	O
discussed	O
.	O

Undoubtedly	O
,	O
some	O
probiotics	O
,	O
when	O
properly	O
dosed	O
and	O
administered	O
,	O
can	O
have	O
a	O
strong	O
rebalance	O
effect	O
on	O
the	O
gut	O
microbiota	O
and	O
as	O
a	O
consequence	O
a	O
possible	O
positive	O
action	O
on	O
immune	O
modulation	O
of	O
the	O
gastrointestinal	O
tract	O
and	O
on	O
inflammation	O
of	O
the	O
intestinal	O
mucosa	O
.	O

Many	O
recent	O
findings	O
indeed	O
support	O
the	O
hypothesis	O
that	O
the	O
daily	O
use	O
of	O
some	O
selected	O
probiotics	O
can	O
be	O
a	O
feasible	O
approach	O
to	O
effectively	O
protect	O
patients	O
against	O
the	O
risk	O
of	O
some	O
severe	O
consequences	O
due	O
to	O
radiation	O
therapy	O
or	O
chemotherapy	O
.	O

This	O
paper	O
aims	O
to	O
review	O
the	O
most	O
recent	O
articles	O
in	O
order	O
to	O
consider	O
a	O
possible	O
adjuvant	O
approach	O
for	O
the	O
use	O
of	O
certain	O
well	O
-	O
balanced	O
probiotics	O
to	O
help	O
prevent	O
colon	O
cancer	O
and	O
the	O
adverse	O
effects	O
caused	O
by	O
related	O
therapies	O
.	O

Gut	O
phages	O
at	O
the	O
centre	O
.	O

Bugs	O
,	O
drugs	O
,	O
and	O
cancer	O
:	O
can	O
the	O
microbiome	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
cancer	O
management	O
?	O

Outnumbering	O
our	O
own	O
cells	O
over	O
ten	O
times	O
,	O
gut	O
microbes	O
can	O
even	O
be	O
considered	O
an	O
additional	O
organ	O
.	O

Several	O
studies	O
have	O
explored	O
the	O
association	O
between	O
microbiomes	O
and	O
antitumor	O
drug	O
response	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
presence	O
of	O
specific	O
bacteria	O
might	O
modulate	O
cancer	O
progression	O
and	O
the	O
efficacy	O
of	O
anticancer	O
therapeutics	O
.	O

Bacteria	O
-	O
targeting	O
intervention	O
can	O
provide	O
crucial	O
guidance	O
for	O
the	O
design	O
of	O
next	O
-	O
generation	O
antitumor	O
drugs	O
.	O

Here	O
,	O
we	O
review	O
previous	O
findings	O
elucidating	O
the	O
impact	O
of	O
gut	O
microbiomes	O
on	O
cancer	O
treatment	O
and	O
the	O
possible	O
underlying	O
mechanisms	O
.	O

In	O
addition	O
,	O
we	O
examine	O
the	O
role	O
of	O
microbiome	O
manipulation	O
in	O
controlling	O
tumor	O
growth	O
.	O

Finally	O
,	O
we	O
discuss	O
concerns	O
regarding	O
the	O
alteration	O
of	O
the	O
microbiome	O
composition	O
,	O
and	O
the	O
potential	O
approaches	O
to	O
surpass	O
existing	O
limitations	O
.	O

Protective	O
effects	O
of	O
oral	O
immunization	O
with	O
formalin	O
-	O
inactivated	O
whole	O
-	O
cell	O
Citrobacter	B-bacteria
rodentium	I-bacteria
on	O
Citrobacter	B-bacteria
rodentium	I-bacteria
infection	O
in	O
mice	O
.	O

Evaluation	O
of	O
the	O
efficacy	O
of	O
vaccine	O
candidates	O
that	O
prevent	O
enteropathogenic	O
and	O
enterohemorrhagic	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
(	O
EPEC	B-bacteria
/	O
EHEC	B-bacteria
)	O
infection	O
in	O
mouse	O
models	O
is	O
difficult	O
due	O
to	O
their	O
limited	O
pathogenicity	O
in	O
mice	O
.	O

Citrobacter	B-bacteria
rodentium	I-bacteria
,	O
a	O
murine	O
pathogenic	O
bacterium	O
that	O
shares	O
its	O
infection	O
strategy	O
and	O
virulence	O
genes	O
with	O
EPEC	O
/	O
EHEC	O
,	O
has	O
been	O
used	O
as	O
a	O
model	O
pathogen	O
to	O
develop	O
novel	O
vaccine	O
strategies	O
or	O
platforms	O
for	O
these	O
bacteria	O
.	O

However	O
,	O
there	O
are	O
few	O
reports	O
on	O
the	O
comparative	O
effectiveness	O
of	O
novel	O
vaccine	O
platforms	O
as	O
no	O
C	B-bacteria
.	I-bacteria
rodentium	I-bacteria
vaccines	O
have	O
yet	O
been	O
prepared	O
by	O
standard	O
methods	O
such	O
as	O
bacteria	O
attenuation	O
or	O
inactivation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
protective	O
effect	O
of	O
the	O
oral	O
administration	O
of	O
formalin	O
-	O
inactivated	O
C	O
.	O
rodentium	O
(	O
Fo	O
-	O
CR	O
)	O
on	O
C	O
.	O
rodentium	O
infection	O
in	O
two	O
mouse	O
strains	O
,	O
C57BL	O
/	O
6	O
and	O
C3H	O
/	O
HeN	O
,	O
as	O
these	O
strains	O
have	O
different	O
degrees	O
of	O
susceptibility	O
to	O
infection	O
.	O

In	O
C57BL	O
/	O
6	O
mice	O
,	O
administration	O
of	O
Fo	O
-	O
CR	O
induced	O
significant	O
C	O
.	O
rodentium	O
-	O
specific	O
mucosal	O
and	O
systemic	O
antibody	O
responses	O
,	O
promoted	O
bacterial	O
clearance	O
from	O
the	O
gut	O
and	O
inhibited	O
colonic	O
hyperplasia	O
.	O

Furthermore	O
,	O
in	O
C3H	O
/	O
HeN	O
mice	O
,	O
the	O
administration	O
followed	O
by	O
lethal	O
C	B-bacteria
.	I-bacteria
rodentium	I-bacteria
infection	O
induced	O
significantly	O
high	O
avidity	O
serum	O
IgG	O
specific	O
to	O
C	B-bacteria
.	I-bacteria
rodentium	I-bacteria
and	O
inhibited	O
death	O
,	O
body	O
weight	O
loss	O
,	O
and	O
bacterial	O
invasion	O
to	O
visceral	O
organs	O
.	O

In	O
conclusion	O
,	O
the	O
oral	O
administration	O
of	O
Fo	O
-	O
CR	O
resulted	O
in	O
the	O
protection	O
of	O
mice	O
from	O
C	B-bacteria
.	I-bacteria
rodentium	I-bacteria
infection	O
,	O
indicating	O
that	O
it	O
serves	O
as	O
a	O
reference	O
method	O
for	O
evaluating	O
the	O
efficacy	O
of	O
novel	O
oral	O
vaccine	O
candidates	O
or	O
platforms	O
.	O

Colonization	O
of	O
the	O
tsetse	O
fly	O
midgut	O
with	O
commensal	O
Kosakonia	O
cowanii	O
Zambiae	O
inhibits	O
trypanosome	O
infection	O
establishment	O
.	O

Tsetse	O
flies	O
(	O
Glossina	O
spp	O
.	O
)	O

vector	O
pathogenic	O
trypanosomes	O
(	O
Trypanosoma	O
spp	O
.	O
)	O

in	O
sub	O
-	O
Saharan	O
Africa	O
.	O

These	O
parasites	O
cause	O
human	O
and	O
animal	O
African	O
trypanosomiases	O
,	O
which	O
are	O
debilitating	O
diseases	O
that	O
inflict	O
an	O
enormous	O
socio	O
-	O
economic	O
burden	O
on	O
inhabitants	O
of	O
endemic	O
regions	O
.	O

Current	O
disease	O
control	O
strategies	O
rely	O
primarily	O
on	O
treating	O
infected	O
animals	O
and	O
reducing	O
tsetse	O
population	O
densities	O
.	O

However	O
,	O
relevant	O
programs	O
are	O
costly	O
,	O
labor	O
intensive	O
and	O
difficult	O
to	O
sustain	O
.	O

As	O
such	O
,	O
novel	O
strategies	O
aimed	O
at	O
reducing	O
tsetse	O
vector	O
competence	O
require	O
development	O
.	O

Herein	O
we	O
investigated	O
whether	O
Kosakonia	O
cowanii	O
Zambiae	O
(	O
Kco	O
_	O
Z	O
)	O
,	O
which	O
confers	O
Anopheles	O
gambiae	O
with	O
resistance	O
to	O
Plasmodium	O
,	O
is	O
able	O
to	O
colonize	O
tsetse	O
and	O
induce	O
a	O
trypanosome	O
refractory	O
phenotype	O
in	O
the	O
fly	O
.	O

Kco	O
_	O
Z	O
established	O
stable	O
infections	O
in	O
tsetse	O
'	O
s	O
gut	O
and	O
exhibited	O
no	O
adverse	O
effect	O
on	O
the	O
fly	O
'	O
s	O
survival	O
.	O

Flies	O
with	O
established	O
Kco	O
_	O
Z	O
infections	O
in	O
their	O
gut	O
were	O
significantly	O
more	O
refractory	O
to	O
infection	O
with	O
two	O
distinct	O
trypanosome	O
species	O
(	O
T	O
.	O
congolense	O
,	O
6	O
%	O
infection	O
;	O
T	O
.	O
brucei	O
,	O
32	O
%	O
infection	O
)	O
than	O
were	O
age	O
-	O
matched	O
flies	O
that	O
did	O
not	O
house	O
the	O
exogenous	O
bacterium	O
(	O
T	O
.	O
congolense	O
,	O
36	O
%	O
infected	O
;	O
T	O
brucei	O
,	O
70	O
%	O
infected	O
)	O
.	O

Additionally	O
,	O
52	O
%	O
of	O
Kco	O
_	O
Z	O
colonized	O
tsetse	O
survived	O
infection	O
with	O
entomopathogenic	O
Serratia	B-bacteria
marcescens	I-bacteria
,	O
compared	O
with	O
only	O
9	O
%	O
of	O
their	O
wild	O
-	O
type	O
counterparts	O
.	O

These	O
parasite	O
and	O
pathogen	O
refractory	O
phenotypes	O
result	O
from	O
the	O
fact	O
that	O
Kco	O
_	O
Z	O
acidifies	O
tsetse	O
'	O
s	O
midgut	O
environment	O
,	O
which	O
inhibits	O
trypanosome	O
and	O
Serratia	B-bacteria
growth	O
and	O
thus	O
infection	O
establishment	O
.	O

Finally	O
,	O
we	O
determined	O
that	O
Kco	O
_	O
Z	O
infection	O
does	O
not	O
impact	O
the	O
fecundity	O
of	O
male	O
or	O
female	O
tsetse	O
,	O
nor	O
the	O
ability	O
of	O
male	O
flies	O
to	O
compete	O
with	O
their	O
wild	O
-	O
type	O
counterparts	O
for	O
mates	O
.	O

We	O
propose	O
that	O
Kco	O
_	O
Z	O
could	O
be	O
used	O
as	O
one	O
component	O
of	O
an	O
integrated	O
strategy	O
aimed	O
at	O
reducing	O
the	O
ability	O
of	O
tsetse	O
to	O
transmit	O
pathogenic	O
trypanosomes	O
.	O

Specific	O
Gut	O
and	O
Salivary	O
Microbiota	O
Patterns	O
Are	O
Linked	O
With	O
Different	O
Cognitive	O
Testing	O
Strategies	O
in	O
Minimal	O
Hepatic	O
Encephalopathy	O
.	O

OBJECTIVES	O
:	O
Minimal	O
hepatic	O
encephalopathy	O
(	O
MHE	O
)	O
is	O
epidemic	O
in	O
cirrhosis	O
,	O
but	O
testing	O
strategies	O
often	O
have	O
poor	O
concordance	O
.	O

Altered	O
gut	O
/	O
salivary	O
microbiota	O
occur	O
in	O
cirrhosis	O
and	O
could	O
be	O
related	O
to	O
MHE	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
microbial	O
signatures	O
of	O
individual	O
cognitive	O
tests	O
and	O
define	O
the	O
role	O
of	O
microbiota	O
in	O
the	O
diagnosis	O
of	O
MHE	O
.	O

METHODS	O
:	O
Outpatients	O
with	O
cirrhosis	O
underwent	O
stool	O
collection	O
and	O
MHE	O
testing	O
with	O
psychometric	O
hepatic	O
encephalopathy	O
score	O
(	O
PHES	O
)	O
,	O
inhibitory	O
control	O
test	O
,	O
and	O
EncephalApp	O
Stroop	O
.	O

A	O
subset	O
provided	O
saliva	O
samples	O
.	O

Minimal	O
hepatic	O
encephalopathy	O
diagnosis	O
/	O
concordance	O
between	O
tests	O
was	O
compared	O
.	O

Stool	O
/	O
salivary	O
microbiota	O
were	O
analyzed	O
using	O
16srRNA	O
sequencing	O
.	O

Microbial	O
profiles	O
were	O
compared	O
between	O
patients	O
with	O
/	O
without	O
MHE	O
on	O
individual	O
tests	O
.	O

Logistic	O
regression	O
was	O
used	O
to	O
evaluate	O
clinical	O
and	O
microbial	O
predictors	O
of	O
MHE	O
diagnosis	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
forty	O
-	O
seven	O
patients	O
with	O
cirrhosis	O
(	O
123	O
prior	O
overt	O
HE	O
,	O
MELD	O
13	O
)	O
underwent	O
stool	O
collection	O
and	O
PHES	O
testing	O
;	O
175	O
underwent	O
inhibitory	O
control	O
test	O
and	O
125	O
underwent	O
Stroop	O
testing	O
.	O

One	O
hundred	O
twelve	O
patients	O
also	O
provided	O
saliva	O
samples	O
.	O

Depending	O
on	O
the	O
modality	O
,	O
59	O
%	O
-	O
82	O
%	O
of	O
patients	O
had	O
MHE	O
.	O

Intertest	O
Kappa	O
for	O
MHE	O
was	O
0	O
.	O
15	O
-	O
0	O
.	O
35	O
.	O

Stool	O
and	O
salivary	O
microbiota	O
profiles	O
with	O
MHE	O
were	O
different	O
from	O
those	O
without	O
MHE	O
.	O

Individual	O
microbiota	O
signatures	O
were	O
associated	O
with	O
MHE	O
in	O
specific	O
modalities	O
.	O

However	O
,	O
the	O
relative	O
abundance	O
of	O
Lactobacillaceae	B-bacteria
in	O
the	O
stool	O
and	O
saliva	O
samples	O
was	O
higher	O
in	O
MHE	O
,	O
regardless	O
of	O
the	O
modality	O
used	O
,	O
whereas	O
autochthonous	O
Lachnospiraceae	B-bacteria
were	O
higher	O
in	O
those	O
without	O
MHE	O
,	O
especially	O
on	O
PHES	O
.	O

On	O
logistic	O
regression	O
,	O
stool	O
and	O
salivary	O
Lachnospiraceae	B-bacteria
genera	I-bacteria
(	O
Ruminococcus	B-bacteria
and	O
Clostridium	B-bacteria
XIVb	I-bacteria
)	O
were	O
associated	O
with	O
good	O
cognition	O
independent	O
of	O
clinical	O
variables	O
.	O

CONCLUSIONS	O
:	O
Specific	O
stool	O
and	O
salivary	O
microbial	O
signatures	O
exist	O
for	O
individual	O
cognitive	O
testing	O
strategies	O
in	O
MHE	O
.	O

The	O
presence	O
of	O
specific	O
taxa	O
associated	O
with	O
good	O
cognitive	O
function	O
regardless	O
of	O
modality	O
could	O
potentially	O
be	O
used	O
to	O
circumvent	O
MHE	O
testing	O
.	O

Fructooligosaccharides	O
Ameliorating	O
Cognitive	O
Deficits	O
and	O
Neurodegeneration	O
in	O
APP	O
/	O
PS1	O
Transgenic	O
Mice	O
through	O
Modulating	O
Gut	O
Microbiota	O
.	O

Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
is	O
closely	O
related	O
to	O
gut	O
microbial	O
alteration	O
.	O

Prebiotic	O
fructooligosaccharides	O
(	O
FOS	O
)	O
play	O
major	O
roles	O
by	O
regulating	O
gut	O
microbiota	O
.	O

The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
effect	O
and	O
mechanism	O
of	O
FOS	O
protection	O
against	O
AD	O
via	O
regulating	O
gut	O
microbiota	O
.	O

Male	O
Apse	O
/	O
PSEN	O
1dE9	O
(	O
APP	O
/	O
PS1	O
)	O
transgenic	O
(	O
Tg	O
)	O
mice	O
were	O
administrated	O
with	O
FOS	O
for	O
6	O
weeks	O
.	O

Cognitive	O
deficits	O
and	O
amyloid	O
deposition	O
were	O
evaluated	O
.	O

The	O
levels	O
of	O
synaptic	O
plasticity	O
markers	O
including	O
postsynaptic	O
density	O
protein	O
95	O
(	O
PSD	O
-	O
95	O
)	O
and	O
synapsin	O
I	O
,	O
as	O
well	O
as	O
phosphorylation	O
of	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
were	O
determined	O
.	O

The	O
intestinal	O
microbial	O
constituent	O
was	O
detected	O
by	O
16S	O
rRNA	O
sequencing	O
.	O

Moreover	O
,	O
the	O
levels	O
of	O
glucagon	O
-	O
like	O
peptide	O
-	O
1	O
(	O
GLP	O
-	O
1	O
)	O
in	O
the	O
gut	O
and	O
GLP	O
-	O
1	O
receptor	O
(	O
GLP	O
-	O
1R	O
)	O
in	O
the	O
brain	O
were	O
measured	O
.	O

The	O
results	O
indicated	O
that	O
FOS	O
treatment	O
ameliorated	O
cognitive	O
deficits	O
and	O
pathological	O
changes	O
in	O
the	O
Tg	O
mice	O
.	O

FOS	O
significantly	O
upregulated	O
the	O
expression	O
levels	O
of	O
synapsin	O
I	O
and	O
PSD	O
-	O
95	O
,	O
as	O
well	O
as	O
decreased	O
phosphorylated	O
level	O
of	O
JNK	O
.	O

The	O
sequencing	O
results	O
showed	O
that	O
FOS	O
reversed	O
the	O
altered	O
microbial	O
composition	O
.	O

Furthermore	O
,	O
FOS	O
increased	O
the	O
level	O
of	O
GLP	O
-	O
1	O
and	O
decreased	O
the	O
level	O
of	O
GLP	O
-	O
1R	O
in	O
the	O
Tg	O
mice	O
.	O

These	O
findings	O
indicated	O
that	O
FOS	O
exerted	O
beneficial	O
effects	O
against	O
AD	O
via	O
regulating	O
the	O
gut	O
microbiota	O
-	O
GLP	O
-	O
1	O
/	O
GLP	O
-	O
1R	O
pathway	O
.	O

Diversity	O
of	O
probiotic	O
adhesion	O
genes	O
in	O
the	O
gastrointestinal	O
tract	O
of	O
goats	O
.	O

Gastrointestinal	O
(	O
GI	O
)	O
microflora	O
is	O
an	O
important	O
system	O
in	O
the	O
host	O
,	O
as	O
it	O
has	O
both	O
pathogenic	O
and	O
probiotic	O
bacteria	O
.	O

Most	O
of	O
the	O
studies	O
were	O
focused	O
on	O
the	O
human	O
gut	O
microflora	O
and	O
the	O
available	O
information	O
on	O
the	O
intestinal	O
microflora	O
of	O
goats	O
was	O
limited	O
.	O

This	O
urged	O
the	O
need	O
to	O
inspect	O
the	O
impacts	O
of	O
the	O
goat	O
'	O
s	O
gut	O
microflora	O
.	O

Metagenomic	O
investigation	O
of	O
probiotic	O
bacteria	O
in	O
the	O
GI	O
tract	O
of	O
goat	O
is	O
one	O
of	O
the	O
challenging	O
streams	O
because	O
of	O
the	O
less	O
available	O
data	O
of	O
the	O
uncultivable	O
bacteria	O
.	O

In	O
our	O
report	O
,	O
comparative	O
analysis	O
of	O
metagenomic	O
and	O
enrichment	O
samples	O
of	O
goat	O
intestinal	O
content	O
was	O
done	O
and	O
this	O
approach	O
will	O
be	O
helpful	O
in	O
analyzing	O
the	O
identification	O
of	O
uncultivable	O
and	O
cultivable	O
probiotic	O
bacteria	O
.	O

This	O
study	O
mainly	O
focused	O
on	O
three	O
key	O
probiotic	O
adhesion	O
genes	O
,	O
such	O
as	O
EF	O
-	O
Tu	O
,	O
mapA	O
,	O
and	O
mub	O
.	O

The	O
GI	O
of	O
four	O
different	O
goats	O
were	O
investigated	O
for	O
these	O
genes	O
.	O

The	O
data	O
from	O
this	O
study	O
showed	O
that	O
there	O
is	O
a	O
wide	O
diversity	O
of	O
these	O
genes	O
among	O
goat	O
intestinal	O
samples	O
.	O

The	O
Human	O
Fecal	O
Microbiota	O
Metabolizes	O
Foodborne	O
Heterocyclic	O
Aromatic	O
Amines	O
by	O
Reuterin	O
Conjugation	O
and	O
Further	O
Transformations	O
.	O

SCOPE	O
:	O
Heterocyclic	O
aromatic	O
amines	O
(	O
HAAs	O
)	O
are	O
process	O
-	O
induced	O
food	O
contaminants	O
with	O
high	O
mutagenic	O
and	O
/	O
or	O
carcinogenic	O
potential	O
.	O

Although	O
the	O
human	O
gut	O
microbiota	O
is	O
known	O
to	O
affect	O
the	O
metabolism	O
of	O
dietary	O
constituents	O
,	O
its	O
impact	O
on	O
HAA	O
metabolism	O
and	O
toxicity	O
has	O
been	O
little	O
studied	O
.	O

Here	O
,	O
the	O
glycerol	O
-	O
dependent	O
metabolism	O
of	O
seven	O
foodborne	O
HAAs	O
(	O
AalphaC	O
,	O
Trp	O
-	O
P	O
-	O
1	O
,	O
harman	O
,	O
norharman	O
,	O
PhIP	O
,	O
MeIQx	O
,	O
and	O
MeIQ	O
)	O
by	O
the	O
human	O
fecal	O
microbiota	O
is	O
investigated	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
As	O
analyzed	O
by	O
HPLC	O
-	O
DAD	O
/	O
FLD	O
,	O
the	O
extent	O
of	O
conversion	O
is	O
strongly	O
dependent	O
on	O
glycerol	O
supplementation	O
and	O
HAA	O
structure	O
.	O

AalphaC	O
(	O
60	O
-	O
100	O
%	O
)	O
and	O
the	O
2	O
-	O
aminoimidazoazarenes	O
(	O
up	O
to	O
58	O
%	O
)	O
are	O
especially	O
prone	O
to	O
microbial	O
conversion	O
.	O

Based	O
on	O
high	O
-	O
resolution	O
MS	O
and	O
/	O
or	O
NMR	O
spectroscopy	O
data	O
,	O
70	O
fecal	O
metabolites	O
are	O
identified	O
in	O
total	O
,	O
mainly	O
formed	O
by	O
chemical	O
reactions	O
with	O
one	O
or	O
two	O
molecules	O
of	O
microbially	O
derived	O
reuterin	O
.	O

Moreover	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
human	O
fecal	O
microbiota	O
can	O
further	O
transform	O
reuterin	O
adducts	O
by	O
reduction	O
and	O
/	O
or	O
hydroxylation	O
reactions	O
.	O

Upon	O
isolation	O
,	O
some	O
reuterin	O
-	O
induced	O
HAA	O
metabolites	O
appear	O
to	O
be	O
partially	O
unstable	O
,	O
complicating	O
structural	O
identification	O
.	O

CONCLUSION	O
:	O
The	O
formation	O
of	O
microbial	O
metabolites	O
needs	O
to	O
be	O
incorporated	O
into	O
risk	O
assessment	O
considerations	O
for	O
HAAs	O
in	O
human	O
health	O
.	O

In	O
this	O
study	O
,	O
several	O
HAA	O
metabolites	O
,	O
mainly	O
reuterin	O
-	O
dependent	O
,	O
are	O
identified	O
in	O
vitro	O
,	O
providing	O
the	O
basis	O
for	O
future	O
human	O
studies	O
investigating	O
microbial	O
HAA	O
metabolism	O
.	O

Distinct	O
Gut	O
Virome	O
Profile	O
of	O
Pregnant	O
Women	O
With	O
Type	O
1	O
Diabetes	O
in	O
the	O
ENDIA	O
Study	O
.	O

Background	O
:	O
The	O
importance	O
of	O
gut	O
bacteria	O
in	O
human	O
physiology	O
,	O
immune	O
regulation	O
,	O
and	O
disease	O
pathogenesis	O
is	O
well	O
established	O
.	O

In	O
contrast	O
,	O
the	O
composition	O
and	O
dynamics	O
of	O
the	O
gut	O
virome	O
are	O
largely	O
unknown	O
;	O
particularly	O
lacking	O
are	O
studies	O
in	O
pregnancy	O
.	O

We	O
used	O
comprehensive	O
virome	O
capture	O
sequencing	O
to	O
characterize	O
the	O
gut	O
virome	O
of	O
pregnant	O
women	O
with	O
and	O
without	O
type	O
1	O
diabetes	O
(	O
T1D	O
)	O
,	O
longitudinally	O
followed	O
in	O
the	O
Environmental	O
Determinants	O
of	O
Islet	O
Autoimmunity	O
study	O
.	O

Methods	O
:	O
In	O
total	O
,	O
61	O
pregnant	O
women	O
(	O
35	O
with	O
T1D	O
and	O
26	O
without	O
)	O
from	O
Australia	O
were	O
examined	O
.	O

Nucleic	O
acid	O
was	O
extracted	O
from	O
serial	O
fecal	O
specimens	O
obtained	O
at	O
prenatal	O
visits	O
,	O
and	O
viral	O
genomes	O
were	O
sequenced	O
by	O
virome	O
capture	O
enrichment	O
.	O

The	O
frequency	O
,	O
richness	O
,	O
and	O
abundance	O
of	O
viruses	O
were	O
compared	O
between	O
women	O
with	O
and	O
without	O
T1D	O
.	O

Results	O
:	O
Two	O
viruses	O
were	O
more	O
prevalent	O
in	O
pregnant	O
women	O
with	O
T1D	O
:	O
picobirnaviruses	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
4	O
.	O
2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
0	O
-	O
17	O
.	O
1	O
;	O
P	O
=	O
.	O
046	O
)	O
and	O
tobamoviruses	O
(	O
OR	O
,	O
3	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
9	O
.	O
3	O
;	O
P	O
=	O
.	O
037	O
)	O
.	O

The	O
abundance	O
of	O
77	O
viruses	O
significantly	O
differed	O
between	O
the	O
2	O
maternal	O
groups	O
(	O
>	O
/	O
=	O
2	O
-	O
fold	O
difference	O
;	O
P	O
<	O
.	O
02	O
)	O
,	O
including	O
8	O
Enterovirus	O
B	O
types	O
present	O
at	O
a	O
higher	O
abundance	O
in	O
women	O
with	O
T1D	O
.	O

Conclusions	O
:	O
These	O
findings	O
provide	O
novel	O
insight	O
into	O
the	O
composition	O
of	O
the	O
gut	O
virome	O
during	O
pregnancy	O
and	O
demonstrate	O
a	O
distinct	O
profile	O
of	O
viruses	O
in	O
women	O
with	O
T1D	O
.	O

The	O
influence	O
of	O
probiotic	O
bacteria	O
and	O
human	O
gut	O
microorganisms	O
causing	O
opportunistic	O
infections	O
on	O
Blastocystis	O
ST3		O
.	O

Background	O
:	O
Blastocystis	O
subtype	O
3	O
is	O
an	O
intestinal	O
protist	O
present	O
in	O
humans	O
throughout	O
the	O
world	O
with	O
a	O
controversial	O
pathogenic	O
potential	O
.	O

It	O
has	O
been	O
suggested	O
that	O
probiotic	O
bacteria	O
inhibit	O
the	O
multiplication	O
of	O
gut	O
protozoans	O
,	O
while	O
others	O
are	O
beneficial	O
for	O
their	O
development	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
the	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
,	O
Lactococcus	B-bacteria
lactis	I-bacteria
and	O
Enterococcus	B-bacteria
faecium	I-bacteria
in	O
Blastocystis	O
ST3	O
eradication	O
and	O
the	O
relevance	O
of	O
the	O
intestinal	O
microorganisms	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Candida	O
albicans	O
and	O
Candida	O
glabrata	O
in	O
protozoan	O
proliferation	O
.	O

Blastocystis	O
xenic	O
and	O
axenic	O
culture	O
was	O
co	O
-	O
incubated	O
with	O
the	O
above	O
-	O
mentioned	O
microorganisms	O
and	O
their	O
cell	O
free	O
supernatants	O
at	O
different	O
concentrations	O
in	O
vitro	O
.	O

The	O
number	O
of	O
protozoan	O
cells	O
was	O
counted	O
every	O
day	O
.	O

Results	O
:	O
Both	O
experiments	O
,	O
with	O
xenic	O
and	O
axenic	O
cultures	O
,	O
showed	O
Blastocystis	O
inhibition	O
by	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
and	O
their	O
supernatants	O
from	O
the	O
2nd	O
day	O
of	O
co	O
-	O
incubation	O
.	O

Furthermore	O
,	O
co	O
-	O
incubation	O
with	O
both	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
and	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
showed	O
a	O
beneficial	O
influence	O
on	O
Blastocystis	O
during	O
the	O
first	O
2	O
days	O
.	O

Only	O
after	O
3	O
days	O
did	O
the	O
above	O
-	O
mentioned	O
bacteria	O
start	O
to	O
inhibit	O
Blastocystis	O
growth	O
in	O
both	O
cultures	O
.	O

The	O
supernatant	O
containing	O
the	O
metabolites	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
was	O
effective	O
to	O
a	O
lesser	O
degree	O
.	O

Compared	O
to	O
the	O
control	O
samples	O
,	O
co	O
-	O
incubation	O
with	O
both	O
C	O
.	O
albicans	O
and	O
C	O
.	O
glabrata	O
showed	O
a	O
faster	O
decrease	O
in	O
Blastocystis	O
proliferation	O
,	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
.	O

Conclusions	O
:	O
This	O
study	O
has	O
shown	O
the	O
potential	O
of	O
using	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
,	O
as	O
well	O
as	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
as	O
a	O
prophylactic	O
treatment	O
against	O
Blastocystis	O
colonization	O
or	O
as	O
an	O
additional	O
treatment	O
regimen	O
in	O
combination	O
with	O
standard	O
drugs	O
.	O

Ganoderma	O
lucidum	O
polysaccharide	O
improves	O
rat	O
DSS	O
-	O
induced	O
colitis	O
by	O
altering	O
cecal	O
microbiota	O
and	O
gene	O
expression	O
of	O
colonic	O
epithelial	O
cells	O
.	O

Background	O
:	O
The	O
effects	O
of	O
beta	O
-	O
glucan	O
on	O
colitis	O
mice	O
are	O
contradictory	O
in	O
previous	O
reports	O
.	O

As	O
a	O
result	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
there	O
is	O
an	O
anti	O
-	O
colitis	O
effect	O
in	O
Ganoderma	O
lucidum	O
polysaccharide	O
(	O
GLP	O
)	O
,	O
which	O
is	O
mainly	O
composed	O
of	O
beta	O
-	O
glucan	O
.	O

Moreover	O
,	O
the	O
association	O
between	O
GLP	O
function	O
and	O
gut	O
microbiota	O
remains	O
to	O
be	O
elucidated	O
.	O

Objective	O
:	O
This	O
study	O
aimed	O
to	O
investigate	O
whether	O
GLP	O
consumption	O
improved	O
rat	O
dextran	O
sodium	O
sulfate	O
(	O
DSS	O
)	O
-	O
induced	O
colitis	O
by	O
regulating	O
gut	O
microbiota	O
and	O
altering	O
colonic	O
epithelial	O
expression	O
.	O

Design	O
:	O
The	O
disease	O
activity	O
index	O
(	O
DAI	O
)	O
scores	O
and	O
the	O
cecal	O
short	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
levels	O
of	O
DSS	O
-	O
induced	O
colitis	O
rats	O
fed	O
with	O
a	O
GLP	O
diet	O
(	O
Group	O
GLP	O
,	O
n	O
=	O
6	O
)	O
and	O
a	O
control	O
diet	O
(	O
Group	O
Con	O
,	O
n	O
=	O
6	O
)	O
were	O
investigated	O
and	O
analyzed	O
.	O

Moreover	O
,	O
the	O
profiles	O
of	O
gut	O
microbiota	O
and	O
colonic	O
epithelial	O
expression	O
were	O
analyzed	O
using	O
metagenomics	O
and	O
transcriptomics	O
.	O

Results	O
:	O
GLP	O
consumption	O
significantly	O
lowered	O
animal	O
DAI	O
scores	O
by	O
producing	O
more	O
SCFAs	O
by	O
increasing	O
SCFA	O
-	O
producing	O
bacteria	O
such	O
as	O
Ruminococcus	B-bacteria
_	I-bacteria
1	I-bacteria
and	O
reducing	O
pathogens	O
such	O
as	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
in	O
both	O
the	O
small	O
intestine	O
and	O
cecum	O
of	O
rat	O
.	O

Moreover	O
,	O
GLP	O
consumption	O
regulated	O
11	O
genes	O
,	O
including	O
six	O
upregulated	O
(	O
Ccl5	O
,	O
Cd3e	O
,	O
Cd8a	O
,	O
Il21r	O
,	O
Lck	O
,	O
and	O
Trbv	O
)	O
and	O
five	O
downregulated	O
(	O
Ccl3	O
,	O
Gro	O
,	O
Il11	O
,	O
Mhc2	O
,	O
and	O
Ptgs	O
)	O
genes	O
enriched	O
in	O
six	O
inflammation	O
-	O
related	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
pathways	O
,	O
resulting	O
in	O
enhancement	O
of	O
immunity	O
and	O
reduction	O
of	O
inflammatory	O
response	O
and	O
colonic	O
cancer	O
risk	O
.	O

Conclusions	O
:	O
GLP	O
consumption	O
alleviated	O
DSS	O
-	O
induced	O
colitis	O
and	O
may	O
have	O
potential	O
for	O
ulcerative	O
colitis	O
relief	O
.	O

Role	O
of	O
intestinal	O
microecology	O
in	O
the	O
regulation	O
of	O
energy	O
metabolism	O
by	O
dietary	O
polyphenols	O
and	O
their	O
metabolites	O
.	O

Background	O
:	O
Polyphenols	O
are	O
a	O
class	O
of	O
plant	O
secondary	O
metabolites	O
with	O
a	O
variety	O
of	O
physiological	O
functions	O
.	O

Polyphenols	O
and	O
their	O
intestinal	O
metabolites	O
could	O
greatly	O
affect	O
host	O
energy	O
metabolism	O
via	O
multiple	O
mechanisms	O
.	O

Objective	O
:	O
The	O
objective	O
of	O
this	O
review	O
was	O
to	O
elaborate	O
the	O
role	O
of	O
intestinal	O
microecology	O
in	O
the	O
regulatory	O
effects	O
of	O
dietary	O
polyphenols	O
and	O
their	O
metabolites	O
on	O
energy	O
metabolism	O
.	O

Methods	O
:	O
In	O
this	O
review	O
,	O
we	O
illustrated	O
the	O
potential	O
mechanisms	O
of	O
energy	O
metabolism	O
regulated	O
by	O
the	O
crosstalk	O
between	O
polyphenols	O
and	O
intestinal	O
microecology	O
including	O
intestinal	O
microbiota	O
,	O
intestinal	O
epithelial	O
cells	O
,	O
and	O
mucosal	O
immune	O
system	O
.	O

Results	O
:	O
Polyphenols	O
can	O
selectively	O
regulate	O
the	O
growth	O
of	O
susceptible	O
microorganisms	O
(	O
eg	O
.	O
reducing	O
the	O
ratio	O
of	O
Firmicutes	B-bacteria
to	O
Bacteroides	B-bacteria
,	O
promoting	O
the	O
growth	O
of	O
beneficial	O
bacteria	O
and	O
inhibiting	O
pathogenic	O
bacteria	O
)	O
as	O
well	O
as	O
alter	O
bacterial	O
enzyme	O
activity	O
.	O

Moreover	O
,	O
polyphenols	O
can	O
influence	O
the	O
absorption	O
and	O
secretion	O
of	O
intestinal	O
epithelial	O
cells	O
,	O
and	O
alter	O
the	O
intestinal	O
mucosal	O
immune	O
system	O
.	O

Conclusion	O
:	O
The	O
intestinal	O
microecology	O
play	O
a	O
crucial	O
role	O
for	O
the	O
regulation	O
of	O
energy	O
metabolism	O
by	O
dietary	O
polyphenols	O
.	O

Anti	O
-	O
coccidial	O
properties	O
and	O
mechanisms	O
of	O
an	O
edible	O
herb	O
,	O
Bidens	O
pilosa	O
,	O
and	O
its	O
active	O
compounds	O
for	O
coccidiosis	O
.	O

Avian	O
coccidiosis	O
is	O
an	O
economically	O
important	O
disease	O
in	O
the	O
poultry	O
industry	O
.	O

In	O
view	O
of	O
the	O
disadvantages	O
of	O
anti	O
-	O
coccidial	O
drugs	O
in	O
chickens	O
,	O
edible	O
plants	O
and	O
their	O
compounds	O
are	O
re	O
-	O
emerging	O
as	O
an	O
alternative	O
strategy	O
to	O
combat	O
this	O
disease	O
.	O

A	O
previous	O
publication	O
reported	O
that	O
the	O
edible	O
plant	O
B	O
.	O
pilosa	O
showed	O
promise	O
for	O
use	O
against	O
coccidiosis	O
.	O

Here	O
,	O
we	O
first	O
investigated	O
into	O
the	O
anti	O
-	O
coccidial	O
effects	O
of	O
B	O
.	O
pilosa	O
.	O

We	O
found	O
that	O
B	O
.	O
pilosa	O
at	O
100	O
ppm	O
or	O
more	O
significantly	O
suppressed	O
E	O
.	O
tenella	O
as	O
evidenced	O
by	O
reduction	O
in	O
mortality	O
rate	O
,	O
oocyst	O
excretion	O
and	O
gut	O
pathological	O
severity	O
in	O
chickens	O
and	O
its	O
minimum	O
prophylactic	O
duration	O
was	O
3	O
days	O
.	O

Next	O
,	O
we	O
explored	O
the	O
mode	O
of	O
action	O
of	O
anti	O
-	O
coccidial	O
mechanism	O
of	O
B	O
.	O
pilosa	O
.	O

The	O
E	O
.	O
tenella	O
oocysts	O
were	O
not	O
directly	O
killed	O
by	O
B	O
.	O
pilosa	O
;	O
however	O
,	O
administration	O
of	O
the	O
plant	O
suppressed	O
oocyst	O
sporulation	O
,	O
sporozoite	O
invasion	O
,	O
and	O
schizonts	O
in	O
the	O
life	O
cycle	O
of	O
E	O
.	O
tenella	O
.	O

Besides	O
,	O
B	O
.	O
pilosa	O
boosted	O
T	O
cell	O
-	O
mediated	O
immunity	O
.	O

Finally	O
,	O
we	O
characterized	O
the	O
related	O
anti	O
-	O
coccidial	O
phytochemicals	O
and	O
their	O
mode	O
of	O
action	O
.	O

One	O
of	O
three	O
potent	O
polyynes	O
present	O
in	O
B	O
.	O
pilsoa	O
,	O
Compound	O
1	O
(	O
cytopiloyne	O
)	O
,	O
acted	O
against	O
coccidiosis	O
in	O
chickens	O
in	O
a	O
similar	O
manner	O
to	O
B	O
.	O
pilosa	O
.	O

These	O
data	O
illustrate	O
the	O
anti	O
-	O
coccidial	O
potency	O
and	O
mechanism	O
of	O
B	O
.	O
pilosa	O
and	O
one	O
of	O
its	O
active	O
compounds	O
,	O
and	O
provide	O
a	O
cornerstone	O
for	O
development	O
of	O
novel	O
herbal	O
remedies	O
for	O
avian	O
coccidiosis	O
.	O

Environmental	O
toxicants	O
in	O
breast	O
milk	O
of	O
Norwegian	O
mothers	O
and	O
gut	O
bacteria	O
composition	O
and	O
metabolites	O
in	O
their	O
infants	O
at	O
1	O
month	O
.	O

BACKGROUND	O
:	O
Early	O
disruption	O
of	O
the	O
microbial	O
community	O
may	O
influence	O
life	O
-	O
long	O
health	O
.	O

Environmental	O
toxicants	O
can	O
contaminate	O
breast	O
milk	O
and	O
the	O
developing	O
infant	O
gut	O
microbiome	O
is	O
directly	O
exposed	O
.	O

We	O
investigated	O
whether	O
environmental	O
toxicants	O
in	O
breastmilk	O
affect	O
the	O
composition	O
and	O
function	O
of	O
the	O
infant	O
gut	O
microbiome	O
at	O
1	O
month	O
.	O

We	O
measured	O
environmental	O
toxicants	O
in	O
breastmilk	O
,	O
fecal	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
and	O
gut	O
microbial	O
composition	O
from	O
16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
using	O
samples	O
from	O
267	O
mother	O
-	O
child	O
pairs	O
in	O
the	O
Norwegian	O
Microbiota	O
Cohort	O
(	O
NoMIC	O
)	O
.	O

We	O
tested	O
28	O
chemical	O
exposures	O
:	O
polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
,	O
polybrominated	O
flame	O
retardants	O
(	O
PBDEs	O
)	O
,	O
per	O
-	O
and	O
polyfluoroalkyl	O
substances	O
(	O
PFASs	O
)	O
,	O
and	O
organochlorine	O
pesticides	O
.	O

We	O
assessed	O
chemical	O
exposure	O
and	O
alpha	O
diversity	O
/	O
SCFAs	O
using	O
elastic	O
net	O
regression	O
modeling	O
and	O
generalized	O
linear	O
models	O
,	O
adjusting	O
for	O
confounders	O
,	O
and	O
variation	O
in	O
beta	O
diversity	O
(	O
UniFrac	O
)	O
,	O
taxa	O
abundance	O
(	O
ANCOM	O
)	O
,	O
and	O
predicted	O
metagenomes	O
(	O
PiCRUSt	O
)	O
in	O
low	O
,	O
medium	O
,	O
and	O
high	O
exposed	O
groups	O
.	O

RESULTS	O
:	O
PBDE	O
-	O
28	O
and	O
the	O
surfactant	O
perfluorooctanesulfonic	O
acid	O
(	O
PFOS	O
)	O
were	O
associated	O
with	O
less	O
microbiome	O
diversity	O
.	O

Some	O
sub	O
-	O
OTUs	O
of	O
Lactobacillus	B-bacteria
,	O
an	O
important	O
genus	O
in	O
early	O
life	O
,	O
were	O
lower	O
in	O
abundance	O
in	O
samples	O
from	O
infants	O
with	O
relative	O
`	O
`	O
high	O
'	O
'	O
(	O
>	O
80th	O
percentile	O
)	O
vs	O
.	O
`	O
`	O
low	O
'	O
'	O
(	O
<	O
20th	O
percentile	O
)	O
toxicant	O
exposure	O
in	O
this	O
cohort	O
.	O

Moreover	O
,	O
breast	O
milk	O
toxicants	O
were	O
associated	O
with	O
microbiome	O
functionality	O
,	O
explaining	O
up	O
to	O
34	O
%	O
of	O
variance	O
in	O
acetic	O
and	O
propionic	O
SCFAs	O
,	O
essential	O
signaling	O
molecules	O
.	O

Per	O
one	O
standard	O
deviation	O
of	O
exposure	O
,	O
PBDE	O
-	O
28	O
was	O
associated	O
with	O
less	O
propionic	O
acid	O
(	O
-	O
24	O
%	O
[	O
95	O
%	O
CI	O
-	O
35	O
%	O
to	O
-	O
14	O
%	O
]	O
relative	O
to	O
the	O
mean	O
)	O
,	O
and	O
PCB	O
-	O
209	O
with	O
less	O
acetic	O
acid	O
(	O
-	O
15	O
%	O
[	O
95	O
%	O
CI	O
-	O
29	O
%	O
to	O
-	O
0	O
.	O
4	O
%	O
]	O
)	O
.	O

Conversely	O
,	O
PFOA	O
and	O
dioxin	O
-	O
like	O
PCB	O
-	O
167	O
were	O
associated	O
with	O
61	O
%	O
(	O
95	O
%	O
CI	O
35	O
%	O
to	O
87	O
%	O
)	O
and	O
22	O
%	O
(	O
95	O
%	O
CI	O
8	O
%	O
to	O
35	O
%	O
)	O
more	O
propionic	O
and	O
acetic	O
acid	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
Environmental	O
toxicant	O
exposure	O
may	O
influence	O
infant	O
gut	O
microbial	O
function	O
during	O
a	O
critical	O
developmental	O
window	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
replicate	O
these	O
novel	O
findings	O
and	O
investigate	O
whether	O
this	O
has	O
any	O
impact	O
on	O
child	O
health	O
.	O

Inhibition	O
of	O
Tumor	O
Growth	O
by	O
Dietary	O
Indole	O
-	O
3	O
-	O
Carbinol	O
in	O
a	O
Prostate	O
Cancer	O
Xenograft	O
Model	O
May	O
Be	O
Associated	O
with	O
Disrupted	O
Gut	O
Microbial	O
Interactions	O
.	O

Accumulated	O
evidence	O
suggests	O
that	O
the	O
cruciferous	O
vegetables	O
-	O
derived	O
compound	O
indole	O
-	O
3	O
-	O
carbinol	O
(	O
I3C	O
)	O
may	O
protect	O
against	O
prostate	O
cancer	O
,	O
but	O
the	O
precise	O
mechanisms	O
underlying	O
its	O
action	O
remain	O
unclear	O
.	O

This	O
study	O
aimed	O
to	O
verify	O
the	O
hypothesis	O
that	O
the	O
beneficial	O
effect	O
of	O
dietary	O
I3C	O
may	O
be	O
due	O
to	O
its	O
modulatory	O
effect	O
on	O
the	O
gut	O
microbiome	O
of	O
mice	O
.	O

Athymic	O
nude	O
mice	O
(	O
5	O
(	O
-	O
)	O
7	O
weeks	O
old	O
,	O
male	O
,	O
Balb	O
c	O
/	O
c	O
nu	O
/	O
nu	O
)	O
with	O
established	O
tumor	O
xenografts	O
were	O
fed	O
a	O
basal	O
diet	O
(	O
AIN	O
-	O
93	O
)	O
with	O
or	O
without	O
1	O
micromoles	O
I3C	O
/	O
g	O
for	O
9	O
weeks	O
.	O

The	O
effects	O
of	O
dietary	O
I3C	O
on	O
gut	O
microbial	O
composition	O
and	O
microbial	O
species	O
interactions	O
were	O
then	O
examined	O
by	O
16s	O
rRNA	O
gene	O
-	O
based	O
sequencing	O
and	O
co	O
-	O
occurrence	O
network	O
analysis	O
.	O

I3C	O
supplementation	O
significantly	O
inhibited	O
tumor	O
growth	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
altered	O
the	O
structure	O
of	O
gut	O
microbiome	O
.	O

The	O
abundance	O
of	O
the	O
phylum	O
Deferribacteres	B-bacteria
,	O
more	O
specifically	O
,	O
Mucispirillum	B-bacteria
schaedleri	I-bacteria
,	O
was	O
significantly	O
increased	O
by	O
dietary	O
I3C	O
.	O

Additionally	O
,	O
I3C	O
consumption	O
also	O
changed	O
gut	O
microbial	O
co	O
-	O
occurrence	O
patterns	O
.	O

One	O
of	O
the	O
network	O
modules	O
in	O
the	O
control	O
group	O
,	O
consisting	O
of	O
seven	O
bacteria	O
in	O
family	O
S	O
-	O
27	O
,	O
was	O
positively	O
correlated	O
with	O
tumor	O
size	O
(	O
p	O
<	O
0	O
.	O
009	O
)	O
.	O

Moreover	O
,	O
dietary	O
I3C	O
disrupted	O
microbial	O
interactions	O
and	O
altered	O
this	O
association	O
between	O
specific	O
microbial	O
network	O
and	O
tumor	O
development	O
.	O

Our	O
results	O
unraveled	O
complex	O
relationships	O
among	O
I3C	O
ingestion	O
,	O
gut	O
microbiota	O
,	O
and	O
prostate	O
tumor	O
development	O
and	O
may	O
provide	O
a	O
novel	O
insight	O
into	O
the	O
mechanism	O
for	O
the	O
chemopreventive	O
effect	O
of	O
dietary	O
I3C	O
on	O
prostate	O
cancer	O
.	O

Gut	O
commensal	O
bacteria	O
in	O
biological	O
invasions	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Convergence	O
,	O
constraint	O
and	O
the	O
potential	O
for	O
mutualism	O
between	O
ants	O
and	O
gut	O
microbes	O
.	O

Ants	O
are	O
a	O
hugely	O
diverse	O
family	O
of	O
eusocial	O
insects	O
that	O
dominate	O
terrestrial	O
ecosystems	O
all	O
over	O
the	O
planet	O
.	O

Did	O
mutualistic	O
gut	O
microbes	O
help	O
ants	O
to	O
achieve	O
their	O
diversity	O
and	O
ecological	O
dominance	O
?	O

Initial	O
studies	O
suggested	O
the	O
potential	O
for	O
widespread	O
convergence	O
in	O
ant	O
gut	O
bacterial	O
communities	O
based	O
on	O
dietary	O
niche	O
,	O
but	O
it	O
now	O
seems	O
possible	O
that	O
dedicated	O
bacterial	O
symbionts	O
are	O
restricted	O
to	O
a	O
minority	O
of	O
ant	O
lineages	O
(	O
Russell	O
et	O
al	O
.	O
,	O
)	O
.	O

Nevertheless	O
,	O
as	O
most	O
ants	O
are	O
omnivores	O
,	O
the	O
evidence	O
so	O
far	O
has	O
suggested	O
a	O
broad	O
,	O
positive	O
correlation	O
between	O
the	O
evolution	O
of	O
dietary	O
specialization	O
and	O
ant	O
investment	O
in	O
nutrient	O
-	O
provisioning	O
gut	O
bacteria	O
.	O

In	O
this	O
issue	O
of	O
Molecular	O
Ecology	O
,	O
Sapountzis	O
et	O
al	O
.	O

(	O
)	O
and	O
Rubin	O
et	O
al	O
.	O

(	O
)	O
examine	O
the	O
evolution	O
of	O
gut	O
bacterial	O
communities	O
in	O
two	O
iconic	O
ant	O
taxa	O
-	O
the	O
attine	O
fungus	O
farmers	O
and	O
the	O
Pseudomyrmex	O
plant	O
bodyguards	O
,	O
respectively	O
-	O
in	O
a	O
comparative	O
context	O
.	O

By	O
comparing	O
gut	O
bacteria	O
between	O
ant	O
species	O
of	O
differing	O
dietary	O
specialization	O
within	O
each	O
taxon	O
,	O
these	O
studies	O
demonstrate	O
a	O
hint	O
of	O
convergence	O
in	O
the	O
midst	O
of	O
widespread	O
apparent	O
constraints	O
.	O

These	O
results	O
raise	O
numerous	O
interesting	O
questions	O
about	O
the	O
nature	O
of	O
these	O
apparent	O
constraints	O
and	O
whether	O
they	O
are	O
causes	O
or	O
consequences	O
of	O
varying	O
investment	O
by	O
ants	O
to	O
mutualism	O
with	O
their	O
gut	O
microbes	O
.	O

Incidence	O
of	O
Virulence	O
Determinants	O
Among	O
Enterococcal	O
Clinical	O
Isolates	O
in	O
Egypt	O
and	O
Its	O
Association	O
with	O
Biofilm	O
Formation	O
.	O

BACKGROUND	O
:	O
Although	O
Enterococci	B-bacteria
compromise	O
an	O
essential	O
part	O
of	O
normal	O
gut	O
microbiota	O
of	O
both	O
animals	O
and	O
humans	O
,	O
they	O
have	O
emerged	O
as	O
a	O
leading	O
opportunistic	O
pathogen	O
causing	O
infections	O
.	O

The	O
pathogenesis	O
of	O
enterococci	B-bacteria
is	O
attributed	O
to	O
an	O
array	O
of	O
virulence	O
determinants	O
.	O

OBJECTIVES	O
:	O
This	O
study	O
aims	O
to	O
explore	O
the	O
prevalence	O
and	O
characteristics	O
of	O
enterococcal	O
clinical	O
isolates	O
collected	O
from	O
Mansoura	O
University	O
Hospitals	O
,	O
Egypt	O
,	O
assess	O
their	O
ability	O
to	O
form	O
biofilm	O
,	O
and	O
the	O
correlation	O
with	O
virulence	O
determinants	O
and	O
antimicrobial	O
resistance	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
70	O
Enterococcal	O
clinical	O
isolates	O
were	O
collected	O
from	O
different	O
clinical	O
sources	O
between	O
June	O
and	O
December	O
2016	O
.	O

Biofilm	O
formation	O
capacity	O
was	O
assessed	O
,	O
and	O
characterization	O
of	O
virulence	O
factors	O
and	O
antibiotic	O
susceptibility	O
was	O
performed	O
.	O

Clonal	O
relatedness	O
between	O
isolates	O
was	O
assessed	O
using	O
enterobacterial	O
repetitive	O
intergenic	O
consensus	O
-	O
PCR	O
(	O
ERIC	O
-	O
PCR	O
)	O
approach	O
.	O

RESULTS	O
AND	O
CONCLUSION	O
:	O
The	O
molecular	O
analysis	O
demonstrated	O
high	O
genetic	O
diversity	O
among	O
enterococcal	O
clinical	O
isolates	O
.	O

The	O
gelE	O
was	O
the	O
most	O
frequently	O
detected	O
gene	O
(	O
91	O
.	O
4	O
%	O
)	O
,	O
followed	O
by	O
asa1	O
(	O
70	O
%	O
)	O
,	O
esp	O
(	O
65	O
.	O
7	O
%	O
)	O
,	O
and	O
cylA	O
(	O
17	O
.	O
1	O
%	O
)	O
,	O
while	O
hyl	O
was	O
not	O
detected	O
in	O
any	O
isolate	O
.	O

Gelatinase	O
activity	O
was	O
detected	O
in	O
35	O
.	O
7	O
%	O
,	O
while	O
hemolysin	O
and	O
lipase	O
activity	O
was	O
detected	O
in	O
12	O
.	O
9	O
%	O
and	O
78	O
.	O
5	O
%	O
,	O
respectively	O
.	O

Most	O
of	O
the	O
enterococcal	B-bacteria
isolates	I-bacteria
were	O
biofilm	O
producers	O
,	O
of	O
which	O
67	O
.	O
1	O
%	O
were	O
strong	O
/	O
moderate	O
biofilm	O
producers	O
.	O

All	O
linezolid	O
-	O
resistant	O
isolates	O
exhibited	O
strong	O
/	O
moderate	O
biofilm	O
formation	O
capacity	O
.	O

Strong	O
/	O
moderate	O
biofilm	O
formation	O
was	O
more	O
frequently	O
observed	O
among	O
esp	O
-	O
positive	O
(	O
esp	O
+	O
)	O
and	O
gelatinase	O
nonproducing	O
(	O
gelatinase	O
-	O
)	O
enterococcal	B-bacteria
isolates	I-bacteria
.	O

Multiple	O
regression	O
analysis	O
denoted	O
that	O
esp	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
5	O
.	O
371	O
,	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
gelatinase	O
production	O
(	O
OR	O
0	O
.	O
264	O
,	O
p	O
=	O
0	O
.	O
015	O
)	O
were	O
associated	O
with	O
strong	O
/	O
moderate	O
biofilm	O
formation	O
capacity	O
.	O

These	O
findings	O
suggest	O
that	O
esp	O
gene	O
positivity	O
and	O
gelatinase	O
production	O
may	O
affect	O
biofilm	O
formation	O
capacity	O
among	O
enterococcal	O
clinical	O
isolates	O
.	O

Probiotic	O
mixture	O
of	O
Lactobacillus	B-bacteria
helveticus	I-bacteria
R0052	I-bacteria
and	O
Bifidobacterium	B-bacteria
longum	I-bacteria
R0175	I-bacteria
attenuates	O
hippocampal	O
apoptosis	O
induced	O
by	O
lipopolysaccharide	O
in	O
rats	O
.	O

In	O
recent	O
years	O
,	O
the	O
beneficial	O
impact	O
of	O
targeted	O
gut	O
microbiota	O
manipulation	O
in	O
various	O
neurological	O
disorders	O
has	O
become	O
more	O
evident	O
.	O

Therefore	O
,	O
probiotics	O
have	O
been	O
considered	O
as	O
a	O
promising	O
approach	O
to	O
modulate	O
brain	O
gene	O
expression	O
and	O
neuronal	O
pathways	O
even	O
in	O
some	O
neurodegenerative	O
diseases	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
probiotic	O
biotherapy	O
with	O
combination	O
of	O
Lactobacillus	B-bacteria
helveticus	I-bacteria
R0052	I-bacteria
and	O
Bifidobacterium	B-bacteria
longum	I-bacteria
R0175	I-bacteria
on	O
the	O
expression	O
levels	O
of	O
proteins	O
critical	O
to	O
neuronal	O
apoptosis	O
in	O
hippocampus	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
exposed	O
rats	O
.	O

Four	O
groups	O
of	O
animals	O
(	O
Control	O
,	O
LPS	O
,	O
Probiotic	O
+	O
LPS	O
,	O
and	O
Probiotic	O
)	O
were	O
treated	O
with	O
maltodextrin	O
(	O
placebo	O
)	O
or	O
probiotic	O
(	O
10	O
(	O
9	O
)	O
CFU	O
/	O
ml	O
/	O
rat	O
)	O
for	O
2	O
weeks	O
by	O
gavage	O
.	O

On	O
the	O
15th	O
day	O
,	O
a	O
single	O
intraperitoneal	O
dose	O
of	O
saline	O
or	O
LPS	O
(	O
1	O
mg	O
/	O
kg	O
)	O
was	O
injected	O
and	O
4	O
h	O
later	O
,	O
protein	O
assessment	O
was	O
performed	O
by	O
western	O
blotting	O
in	O
hippocampal	O
tissues	O
.	O

LPS	O
significantly	O
increased	O
the	O
Bax	O
,	O
Bax	O
/	O
Bcl	O
-	O
2	O
ratio	O
,	O
and	O
cleaved	O
caspase	O
-	O
3	O
expression	O
along	O
with	O
decreased	O
the	O
Bcl	O
-	O
2	O
and	O
procaspase	O
-	O
3	O
protein	O
levels	O
.	O

However	O
,	O
probiotic	O
pretreatment	O
(	O
L	B-bacteria
.	I-bacteria
helveticus	I-bacteria
R0052	I-bacteria
+	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
R0175	I-bacteria
)	O
significantly	O
downregulated	O
the	O
Bax	O
and	O
Bax	O
/	O
Bcl	O
-	O
2	O
ratio	O
accompanied	O
with	O
upregulated	O
Bcl	O
-	O
2	O
expression	O
.	O

Prophylactic	O
treatment	O
with	O
these	O
bacteria	O
also	O
attenuated	O
LPS	O
-	O
induced	O
caspase	O
-	O
3	O
activation	O
by	O
remarkably	O
increasing	O
the	O
expression	O
of	O
procaspase	O
-	O
3	O
while	O
reducing	O
the	O
level	O
of	O
cleaved	O
caspase	O
-	O
3	O
in	O
target	O
tissues	O
.	O

Our	O
data	O
indicate	O
that	O
probiotic	O
formulation	O
(	O
L	B-bacteria
.	I-bacteria
helveticus	I-bacteria
R0052	I-bacteria
+	O
B	B-bacteria
.	I-bacteria
longum	I-bacteria
R0175	I-bacteria
)	O
alleviated	O
hippocampal	O
apoptosis	O
induced	O
by	O
LPS	O
in	O
rats	O
via	O
the	O
gut	O
-	O
brain	O
axis	O
and	O
suggest	O
that	O
this	O
probiotic	O
could	O
play	O
a	O
beneficial	O
role	O
in	O
some	O
neurodegenerative	O
conditions	O
.	O

Isolation	O
and	O
Characterization	O
of	O
Novel	O
Lignolytic	O
,	O
Cellulolytic	O
,	O
and	O
Hemicellulolytic	O
Bacteria	O
from	O
Wood	O
-	O
Feeding	O
Termite	O
Cryptotermes	O
brevis	O
.	O

In	O
a	O
natural	O
ecosystem	O
,	O
various	O
organisms	O
digest	O
and	O
hydrolyze	O
lignocellulose	O
biomass	O
efficiently	O
.	O

Termites	O
are	O
one	O
of	O
them	O
.	O

They	O
digest	O
lignocellulose	O
biomass	O
with	O
the	O
help	O
of	O
symbiotic	O
microorganisms	O
in	O
their	O
gut	O
.	O

Therefore	O
,	O
termites	O
gut	O
may	O
harbor	O
potential	O
sources	O
of	O
microorganisms	O
capable	O
to	O
degrade	O
lignocellulose	O
biomass	O
.	O

In	O
this	O
study	O
,	O
termite	O
gut	O
microbiomes	O
of	O
Cryptotermes	B-bacteria
brevis	I-bacteria
species	I-bacteria
were	O
isolated	O
and	O
identified	O
for	O
their	O
capability	O
to	O
degrade	O
lignin	O
and	O
polysaccharides	O
.	O

Alkali	O
lignin	O
,	O
carboxymethylcellulose	O
,	O
and	O
xylan	O
were	O
used	O
as	O
the	O
only	O
carbon	O
sources	O
in	O
the	O
medium	O
to	O
isolate	O
lignin	O
-	O
,	O
cellulose	O
-	O
,	O
and	O
hemicellulose	O
-	O
degrading	O
bacteria	O
.	O

By	O
this	O
method	O
,	O
two	O
bacteria	O
strains	O
,	O
Bacillus	B-bacteria
sp	I-bacteria
.	I-bacteria
BMP01	I-bacteria
and	O
Ochrobactrum	B-bacteria
oryzae	I-bacteria
BMP03	I-bacteria
strain	I-bacteria
were	O
isolated	O
and	O
identified	O
.	O

Bacillus	B-bacteria
sp	I-bacteria
.	I-bacteria
BMP01	I-bacteria
strain	I-bacteria
has	O
capabilities	O
to	O
hydrolyze	O
carboxymethylcellulose	O
and	O
xylan	O
to	O
glucose	O
and	O
xylose	O
,	O
respectively	O
.	O

This	O
strain	O
showed	O
high	O
xylanase	O
activity	O
(	O
about	O
0	O
.	O
21	O
U	O
/	O
ml	O
)	O
and	O
carboxymethyl	O
cellulase	O
activity	O
(	O
about	O
0	O
.	O
25	O
U	O
/	O
ml	O
)	O
.	O

The	O
ability	O
to	O
hydrolyze	O
both	O
carboxymethylcellulose	O
and	O
xylan	O
makes	O
it	O
superior	O
to	O
other	O
known	O
cellulolytic	O
bacteria	O
.	O

Ochrobactrum	B-bacteria
oryzae	I-bacteria
BMP03	I-bacteria
strain	I-bacteria
showed	O
laccase	O
activity	O
,	O
which	O
indicates	O
its	O
ability	O
to	O
depolymerize	O
lignin	O
.	O

Lignocellulose	O
-	O
degrading	O
bacteria	O
play	O
a	O
vital	O
role	O
in	O
the	O
biological	O
conversion	O
of	O
lignocellulose	O
biomass	O
to	O
biofuel	O
.	O

Overall	O
,	O
this	O
study	O
shows	O
that	O
termite	O
'	O
s	O
gut	O
microbiomes	O
are	O
potential	O
sources	O
of	O
lignocellulose	O
-	O
degrading	O
bacteria	O
that	O
can	O
be	O
cultured	O
and	O
used	O
in	O
the	O
biological	O
conversion	O
of	O
lignocellulose	O
biomass	O
to	O
biofuel	O
.	O

The	O
human	O
microbiome	O
in	O
health	O
and	O
disease	O
:	O
hype	O
or	O
hope	O
.	O

OBJECTIVES	O
:	O
The	O
prognostic	O
,	O
diagnostic	O
,	O
and	O
therapeutic	O
potential	O
of	O
the	O
human	O
gut	O
microbiota	O
is	O
widely	O
recognised	O
.	O

However	O
,	O
translation	O
of	O
microbiome	O
findings	O
to	O
clinical	O
practice	O
is	O
challenging	O
.	O

Here	O
,	O
we	O
discuss	O
current	O
knowledge	O
and	O
applications	O
in	O
the	O
field	O
.	O

METHODS	O
:	O
We	O
revisit	O
some	O
recent	O
advances	O
in	O
the	O
field	O
of	O
faecal	O
microbiome	O
analyses	O
with	O
a	O
focus	O
on	O
covariate	O
analyses	O
and	O
ecological	O
interpretation	O
.	O

RESULTS	O
:	O
Population	O
-	O
level	O
characterization	O
of	O
gut	O
microbiota	O
variation	O
among	O
healthy	O
volunteers	O
has	O
allowed	O
identifying	O
microbiome	O
covariates	O
required	O
for	O
clinical	O
studies	O
.	O

Currently	O
,	O
microbiome	O
research	O
is	O
moving	O
from	O
relative	O
to	O
quantitative	O
approaches	O
that	O
will	O
shed	O
a	O
new	O
light	O
on	O
microbiota	O
-	O
host	O
interactions	O
in	O
health	O
and	O
disease	O
.	O

CONCLUSIONS	O
:	O
Covariate	O
characterization	O
and	O
technical	O
advances	O
increase	O
reproducibility	O
of	O
microbiome	O
research	O
.	O

Targeted	O
in	O
vitro	O
/	O
in	O
vivo	O
intervention	O
studies	O
will	O
accelerate	O
clinical	O
implementation	O
of	O
microbiota	O
findings	O
.	O

Influence	O
of	O
short	O
-	O
term	O
changes	O
in	O
dietary	O
sulfur	O
on	O
the	O
relative	O
abundances	O
of	O
intestinal	O
sulfate	O
-	O
reducing	O
bacteria	O
.	O

High	O
-	O
protein	O
diets	O
may	O
be	O
linked	O
to	O
gut	O
inflammation	O
due	O
to	O
increased	O
production	O
of	O
hydrogen	O
sulfide	O
(	O
H2S	O
)	O
,	O
a	O
potential	O
toxin	O
,	O
as	O
an	O
end	O
product	O
of	O
microbial	O
fermentation	O
in	O
the	O
colon	O
by	O
sulfidogenic	O
sulfate	B-bacteria
-	I-bacteria
reducing	I-bacteria
bacteria	I-bacteria
(	O
SRB	B-bacteria
)	O
.	O

We	O
hypothesized	O
that	O
dietary	O
content	O
of	O
sulfur	O
-	O
containing	O
amino	O
acids	O
(	O
SAA	O
)	O
leads	O
to	O
variation	O
in	O
the	O
relative	O
abundances	O
of	O
intestinal	O
SRB	B-bacteria
,	O
which	O
include	O
Desulfovibrio	B-bacteria
and	O
Bilophila	B-bacteria
taxa	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
performed	O
a	O
pilot	O
crossover	O
study	O
in	O
four	O
healthy	O
volunteers	O
,	O
who	O
consumed	O
two	O
interventional	O
diets	O
for	O
10	O
-	O
14	O
days	O
,	O
containing	O
high	O
or	O
low	O
SAA	O
content	O
.	O

The	O
total	O
energy	O
intake	O
was	O
similar	O
between	O
the	O
two	O
dietary	O
extremes	O
.	O

Microbial	O
communities	O
were	O
characterized	O
by	O
16S	O
rRNA	O
gene	O
amplicon	O
and	O
shotgun	O
next	O
-	O
generation	O
DNA	O
sequencing	O
.	O

While	O
the	O
relative	O
abundance	O
of	O
Desulfovibrio	B-bacteria
differed	O
among	O
participants	O
(	O
ANOVA	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
we	O
could	O
not	O
detect	O
a	O
change	O
with	O
dietary	O
treatments	O
.	O

Similarly	O
,	O
no	O
differences	O
in	O
Bilophila	B-bacteria
abundance	O
were	O
observed	O
among	O
individuals	O
or	O
dietary	O
arms	O
.	O

Inter	O
-	O
personal	O
differences	O
in	O
microbial	O
community	O
composition	O
and	O
functional	O
gene	O
categories	O
differed	O
between	O
subjects	O
and	O
these	O
differences	O
were	O
maintained	O
over	O
the	O
course	O
of	O
the	O
study	O
.	O

These	O
observations	O
are	O
consistent	O
with	O
re	O
-	O
analysis	O
of	O
two	O
previously	O
published	O
dietary	O
intervention	O
studies	O
.	O

Finally	O
,	O
we	O
found	O
that	O
inter	O
-	O
personal	O
differences	O
in	O
the	O
taxonomic	O
composition	O
of	O
fecal	O
microbiota	O
,	O
including	O
the	O
relative	O
abundances	O
of	O
SRB	B-bacteria
,	O
were	O
maintained	O
over	O
time	O
in	O
19	O
healthy	O
individuals	O
in	O
our	O
stool	O
donor	O
program	O
.	O

These	O
results	O
suggest	O
that	O
the	O
use	O
of	O
dietary	O
interventions	O
alone	O
may	O
be	O
insufficient	O
for	O
rapid	O
therapeutic	O
targeting	O
of	O
SRB	B-bacteria
.	O

Nevertheless	O
,	O
these	O
pilot	O
data	O
provide	O
a	O
foundation	O
to	O
inform	O
future	O
,	O
statistically	O
powered	O
,	O
studies	O
.	O

Dietary	O
Intake	O
of	O
Whole	O
Strawberry	O
Inhibited	O
Colonic	O
Inflammation	O
in	O
Dextran	O
-	O
Sulfate	O
-	O
Sodium	O
-	O
Treated	O
Mice	O
via	O
Restoring	O
Immune	O
Homeostasis	O
and	O
Alleviating	O
Gut	O
Microbiota	O
Dysbiosis	O
.	O

Strawberry	O
(	O
Fragaria	O
chiloensis	O
)	O
is	O
a	O
major	O
edible	O
berry	O
with	O
various	O
potential	O
health	O
benefits	O
.	O

This	O
study	O
determined	O
the	O
protective	O
effects	O
of	O
whole	O
strawberry	O
(	O
WS	O
)	O
against	O
dextran	O
-	O
sulfate	O
-	O
sodium	O
-	O
induced	O
colitis	O
in	O
mice	O
.	O

In	O
colitic	O
mice	O
,	O
dietary	O
WS	O
reduced	O
the	O
disease	O
activity	O
index	O
,	O
prevented	O
the	O
colon	O
shortening	O
and	O
spleen	O
enlargement	O
,	O
and	O
alleviated	O
the	O
colonic	O
tissue	O
damages	O
.	O

The	O
abundance	O
of	O
proinflammatory	O
immune	O
cells	O
was	O
reduced	O
by	O
dietary	O
WS	O
in	O
the	O
colonic	O
mucosa	O
,	O
which	O
was	O
accompanied	O
by	O
the	O
suppression	O
of	O
overproduction	O
of	O
proinflammatory	O
cytokines	O
.	O

Western	O
blotting	O
and	O
immunohistochemical	O
analysis	O
revealed	O
that	O
dietary	O
WS	O
decreased	O
the	O
expression	O
of	O
proinflammatory	O
proteins	O
in	O
the	O
colonic	O
mucosa	O
.	O

Moreover	O
,	O
dietary	O
WS	O
partially	O
reversed	O
the	O
alteration	O
of	O
gut	O
microbiota	O
in	O
the	O
colitic	O
mice	O
by	O
increasing	O
the	O
abundance	O
of	O
potential	O
beneficial	O
bacteria	O
,	O
e	O
.	O
g	O
.	O
,	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
,	O
and	O
decreasing	O
the	O
abundance	O
of	O
potential	O
harmful	O
bacteria	O
,	O
e	O
.	O
g	O
.	O
,	O
Dorea	B-bacteria
and	O
Bilophila	B-bacteria
.	O

Dietary	O
WS	O
also	O
restored	O
the	O
decreased	O
production	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
in	O
the	O
cecum	O
of	O
the	O
colitic	O
mice	O
.	O

The	O
results	O
revealed	O
the	O
anti	O
-	O
inflammatory	O
effects	O
and	O
mechanisms	O
of	O
dietary	O
WS	O
in	O
the	O
colon	O
,	O
which	O
is	O
critical	O
for	O
the	O
rational	O
utilization	O
of	O
strawberry	O
for	O
the	O
prevention	O
of	O
inflammation	O
-	O
driven	O
diseases	O
.	O

Germ	O
-	O
Free	O
Mice	O
Exhibit	O
Mast	O
Cells	O
With	O
Impaired	O
Functionality	O
and	O
Gut	O
Homing	O
and	O
Do	O
Not	O
Develop	O
Food	O
Allergy	O
.	O

Background	O
:	O
Mucosal	O
mast	O
cells	O
(	O
MC	O
)	O
are	O
key	O
players	O
in	O
IgE	O
-	O
mediated	O
food	O
allergy	O
(	O
FA	O
)	O
.	O

The	O
evidence	O
on	O
the	O
interaction	O
between	O
gut	O
microbiota	O
,	O
MC	O
and	O
susceptibility	O
to	O
FA	O
is	O
contradictory	O
.	O

Objective	O
:	O
We	O
tested	O
the	O
hypothesis	O
that	O
commensal	O
bacteria	O
are	O
essential	O
for	O
MC	O
migration	O
to	O
the	O
gut	O
and	O
their	O
maturation	O
impacting	O
the	O
susceptibility	O
to	O
FA	O
.	O

Methods	O
:	O
The	O
development	O
and	O
severity	O
of	O
FA	O
symptoms	O
was	O
studied	O
in	O
sensitized	O
germ	O
-	O
free	O
(	O
GF	O
)	O
,	O
conventional	O
(	O
CV	O
)	O
,	O
and	O
mice	O
mono	O
-	O
colonized	O
with	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
WCFS1	I-bacteria
or	O
co	O
-	O
housed	O
with	O
CV	O
mice	O
.	O

MC	O
were	O
phenotypically	O
and	O
functionally	O
characterized	O
.	O

Results	O
:	O
Systemic	O
sensitization	O
and	O
oral	O
challenge	O
of	O
GF	O
mice	O
with	O
ovalbumin	O
led	O
to	O
increased	O
levels	O
of	O
specific	O
IgE	O
in	O
serum	O
compared	O
to	O
CV	O
mice	O
.	O

Remarkably	O
,	O
despite	O
the	O
high	O
levels	O
of	O
sensitization	O
,	O
GF	O
mice	O
did	O
not	O
develop	O
diarrhea	O
or	O
anaphylactic	O
hypothermia	O
,	O
common	O
symptoms	O
of	O
FA	O
.	O

In	O
the	O
gut	O
,	O
GF	O
mice	O
expressed	O
low	O
levels	O
of	O
the	O
MC	O
tissue	O
-	O
homing	O
markers	O
CXCL1	O
and	O
CXCL2	O
,	O
and	O
harbored	O
fewer	O
MC	O
which	O
exhibited	O
lower	O
levels	O
of	O
MC	O
protease	O
-	O
1	O
after	O
challenge	O
.	O

Additionally	O
,	O
MC	O
in	O
GF	O
mice	O
were	O
less	O
mature	O
as	O
confirmed	O
by	O
flow	O
-	O
cytometry	O
and	O
their	O
functionality	O
was	O
impaired	O
as	O
shown	O
by	O
reduced	O
edema	O
formation	O
after	O
injection	O
of	O
degranulation	O
-	O
provoking	O
compound	O
48	O
/	O
80	O
.	O

Co	O
-	O
housing	O
of	O
GF	O
mice	O
with	O
CV	O
mice	O
fully	O
restored	O
their	O
susceptibility	O
to	O
develop	O
FA	O
.	O

However	O
,	O
this	O
did	O
not	O
occur	O
when	O
mice	O
were	O
mono	O
-	O
colonized	O
with	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
.	O

Conclusion	O
:	O
Our	O
results	O
demonstrate	O
that	O
microbiota	O
-	O
induced	O
maturation	O
and	O
gut	O
-	O
homing	O
of	O
MC	O
is	O
a	O
critical	O
step	O
for	O
the	O
development	O
of	O
symptoms	O
of	O
experimental	O
FA	O
.	O

This	O
new	O
mechanistic	O
insight	O
into	O
microbiota	O
-	O
MC	O
-	O
FA	O
axis	O
can	O
be	O
exploited	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
FA	O
in	O
humans	O
.	O

Cuts	O
Both	O
Ways	O
:	O
Proteases	O
Modulate	O
Virulence	O
of	O
Enterohemorrhagic	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
.	O

Enterohemorrhagic	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
(	O
EHEC	B-bacteria
)	O
is	O
a	O
major	O
cause	O
of	O
foodborne	O
gastrointestinal	O
illness	O
.	O

EHEC	O
uses	O
a	O
specialized	O
type	O
III	O
secretion	O
system	O
(	O
T3SS	O
)	O
to	O
form	O
attaching	O
and	O
effacing	O
lesions	O
in	O
the	O
colonic	O
epithelium	O
and	O
outcompete	O
commensal	O
gut	O
microbiota	O
to	O
cause	O
disease	O
.	O

A	O
recent	O
report	O
in	O
mBio	O
(	O
E	O
.	O
A	O
.	O
Cameron	O
,	O
M	O
.	O
M	O
.	O
Curtis	O
,	O
A	O
.	O
Kumar	O
,	O
G	O
.	O
M	O
.	O
Dunny	O
,	O
et	O
al	O
.	O
,	O
mBio	O
9	O
:	O
e02204	O
-	O
18	O
,	O
2018	O
,	O
https	O
:	O
/	O
/	O
doi	O
.	O
org	O
/	O
10	O
.	O
1128	O
/	O
mBio	O
.	O
02204	O
-	O
18	O
)	O
describes	O
a	O
new	O
role	O
for	O
gut	O
commensals	O
in	O
potentiating	O
disease	O
caused	O
by	O
EHEC	O
.	O

Proteases	O
produced	O
by	O
EHEC	O
and	O
the	O
prevalent	O
human	O
commensal	O
Bacteroides	B-bacteria
thetaiotaomicron	I-bacteria
cleave	O
proteins	O
in	O
the	O
EHEC	O
T3SS	O
translocon	O
that	O
modulate	O
T3SS	O
function	O
.	O

B	B-bacteria
.	I-bacteria
thetaiotaomicron	I-bacteria
protease	O
activity	O
promotes	O
translocation	O
of	O
bacterial	O
effectors	O
required	O
for	O
lesion	O
formation	O
.	O

These	O
results	O
describe	O
a	O
new	O
role	O
for	O
the	O
microbiota	O
in	O
gastrointestinal	O
disease	O
that	O
could	O
uncover	O
future	O
treatments	O
to	O
prevent	O
the	O
spread	O
of	O
gastroenteritis	O
.	O

Impact	O
of	O
5	O
fluorouracil	O
chemotherapy	O
on	O
gut	O
inflammation	O
,	O
functional	O
parameters	O
,	O
and	O
gut	O
microbiota	O
.	O

Emerging	O
evidence	O
suggests	O
that	O
gut	O
microbiota	O
may	O
influence	O
the	O
response	O
to	O
chemotherapy	O
.	O

We	O
sought	O
to	O
characterize	O
the	O
effects	O
of	O
5	O
fluorouracil	O
(	O
5FU	O
)	O
chemotherapy	O
on	O
colon	O
inflammation	O
and	O
functional	O
measures	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
and	O
to	O
further	O
determine	O
whether	O
gut	O
microbiota	O
can	O
influence	O
this	O
response	O
.	O

50	O
C57BL	O
/	O
6	O
were	O
randomized	O
into	O
four	O
groups	O
;	O
Control	O
+	O
Vehicle	O
(	O
n	O
=	O
10	O
)	O
,	O
Control	O
+	O
5FU	O
(	O
n	O
=	O
10	O
)	O
,	O
AOM	O
/	O
DSS	O
+	O
Vehicle	O
(	O
n	O
=	O
15	O
)	O
,	O
and	O
AOM	O
/	O
DSS	O
+	O
5FU	O
(	O
n	O
=	O
15	O
)	O
.	O

CRC	O
was	O
induced	O
chemically	O
by	O
a	O
single	O
10mg	O
/	O
kg	O
injection	O
of	O
azoxymethane	O
(	O
AOM	O
)	O
followed	O
by	O
two	O
cycles	O
(	O
2	O
%	O
and	O
1	O
%	O
)	O
of	O
dextran	O
sodium	O
sulfate	O
(	O
DSS	O
)	O
.	O

Mice	O
were	O
then	O
treated	O
with	O
3	O
cycles	O
of	O
vehicle	O
or	O
5FU	O
(	O
cycle	O
1	O
:	O
40mg	O
/	O
kg	O
,	O
cycle	O
2	O
+	O
3	O
:	O
20mg	O
/	O
kg	O
)	O
.	O

Functional	O
tests	O
(	O
grip	O
strength	O
and	O
run	O
-	O
to	O
-	O
fatigue	O
)	O
were	O
performed	O
prior	O
to	O
5FU	O
treatment	O
(	O
baseline	O
)	O
and	O
at	O
the	O
completion	O
of	O
the	O
second	O
cycle	O
of	O
5FU	O
.	O

Following	O
the	O
third	O
5FU	O
cycle	O
,	O
mice	O
were	O
euthanized	O
and	O
the	O
colon	O
was	O
evaluated	O
for	O
expression	O
of	O
inflammatory	O
genes	O
using	O
RT	O
-	O
qPCR	O
and	O
stool	O
samples	O
were	O
profiled	O
using	O
16S	O
rRNA	O
sequencing	O
.	O

A	O
second	O
experiment	O
used	O
fecal	O
microbiota	O
transplantation	O
from	O
5FU	O
treated	O
mice	O
to	O
control	O
mice	O
(	O
n	O
=	O
10	O
-	O
15	O
/	O
group	O
)	O
to	O
determine	O
whether	O
5FU	O
associated	O
changes	O
in	O
the	O
microbiota	O
could	O
influence	O
functional	O
measures	O
and	O
colon	O
inflammation	O
.	O

5FU	O
reduced	O
grip	O
strength	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
caused	O
a	O
trending	O
decrease	O
in	O
run	O
-	O
to	O
-	O
fatigue	O
performance	O
in	O
cancer	O
mice	O
(	O
p	O
=	O
0	O
.	O
06	O
)	O
.	O

Select	O
intestinal	O
inflammatory	O
genes	O
were	O
significantly	O
elevated	O
with	O
5FU	O
treatment	O
and	O
this	O
was	O
further	O
exacerbated	O
with	O
cancer	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Microbiota	O
analysis	O
revealed	O
increased	O
dissimilarity	O
and	O
alterations	O
in	O
bacterial	O
taxonomy	O
in	O
5FU	O
and	O
AOM	O
/	O
DSS	O
-	O
treated	O
mice	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Fecal	O
transplant	O
from	O
5FU	O
treated	O
mice	O
reduced	O
functional	O
performance	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
altered	O
select	O
colon	O
inflammatory	O
markers	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

This	O
study	O
provides	O
evidence	O
of	O
an	O
effect	O
of	O
5FU	O
on	O
inflammatory	O
responses	O
and	O
functional	O
measures	O
in	O
a	O
mouse	O
model	O
of	O
CRC	O
and	O
suggests	O
that	O
gut	O
microbes	O
may	O
play	O
a	O
role	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
5FU	O
related	O
perturbations	O
.	O

The	O
anti	O
-	O
diabetic	O
activities	O
,	O
gut	O
microbiota	O
composition	O
,	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
Scutellaria	O
-	O
coptis	O
herb	O
couple	O
against	O
insulin	O
resistance	O
-	O
model	O
of	O
diabetes	O
involving	O
the	O
toll	O
-	O
like	O
receptor	O
4	O
signaling	O
pathway	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Scutellaria	O
-	O
coptis	O
herb	O
couple	O
(	O
SC	O
)	O
is	O
one	O
of	O
the	O
well	O
-	O
known	O
herb	O
couples	O
in	O
many	O
traditional	O
Chinese	O
compound	O
formulas	O
used	O
for	O
the	O
treatment	O
of	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
,	O
which	O
has	O
been	O
used	O
to	O
treat	O
DM	O
for	O
thousands	O
of	O
years	O
in	O
China	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
Few	O
studies	O
have	O
confirmed	O
in	O
detail	O
the	O
anti	O
-	O
diabetic	O
activities	O
of	O
SC	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
present	O
investigations	O
aimed	O
to	O
evaluate	O
the	O
anti	O
-	O
diabetic	O
activity	O
of	O
SC	O
in	O
type	O
2	O
diabetic	O
KK	O
-	O
Ay	O
mice	O
and	O
in	O
RAW264	O
.	O
7	O
macrophages	O
to	O
understand	O
its	O
possible	O
mechanism	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
High	O
-	O
performance	O
liquid	O
chromatography	O
with	O
ultraviolet	O
detection	O
(	O
HPLC	O
-	O
UV	O
)	O
and	O
LC	O
-	O
LTQ	O
-	O
Orbitrap	O
Pro	O
mass	O
spectrometry	O
were	O
used	O
to	O
analyze	O
the	O
active	O
ingredients	O
of	O
SC	O
extracts	O
and	O
control	O
the	O
quality	O
.	O

A	O
type	O
2	O
diabetic	O
KK	O
-	O
Ay	O
mice	O
model	O
was	O
established	O
by	O
high	O
-	O
fat	O
diet	O
.	O

Body	O
weight	O
,	O
fasting	O
blood	O
glucose	O
levels	O
,	O
fasting	O
blood	O
insulin	O
levels	O
,	O
glycosylated	O
hemoglobin	O
and	O
glycosylated	O
serum	O
protein	O
were	O
measured	O
.	O

The	O
effects	O
of	O
SC	O
on	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
and	O
triglyceride	O
(	O
TG	O
)	O
levels	O
were	O
examined	O
.	O

The	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
and	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
levels	O
were	O
measured	O
.	O

Gut	O
microbial	O
communities	O
were	O
assayed	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
PCR	O
-	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
PCR	O
-	O
DGGE	O
)	O
methods	O
.	O

The	O
expressions	O
of	O
Toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
and	O
MyD88	O
protein	O
in	O
the	O
colons	O
were	O
measured	O
by	O
western	O
blot	O
.	O

In	O
RAW264	O
.	O
7	O
macrophages	O
,	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
alpha	O
,	O
TLR4	O
and	O
MyD88	O
protein	O
levels	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kits	O
or	O
western	O
blot	O
,	O
and	O
the	O
mRNA	O
expression	O
of	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
alpha	O
and	O
TLR4	O
was	O
examined	O
by	O
the	O
real	O
time	O
PCR	O
.	O

RESULTS	O
:	O
The	O
present	O
results	O
showed	O
that	O
the	O
SC	O
significantly	O
increased	O
blood	O
HDL	O
and	O
significantly	O
reduced	O
fasting	O
blood	O
glucose	O
,	O
fasting	O
blood	O
insulin	O
,	O
glycosylated	O
hemoglobin	O
,	O
glycosylated	O
serum	O
protein	O
,	O
TC	O
,	O
TG	O
,	O
LPS	O
,	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
alpha	O
levels	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
type	O
-	O
2	O
diabetic	O
KK	O
-	O
Ay	O
mice	O
.	O

Furthermore	O
,	O
SC	O
could	O
regulate	O
the	O
structure	O
of	O
intestinal	O
flora	O
.	O

Additionally	O
,	O
the	O
expressions	O
of	O
TLR4	O
and	O
MyD88	O
protein	O
in	O
the	O
colons	O
were	O
significantly	O
decreased	O
in	O
the	O
model	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

However	O
,	O
SC	O
had	O
no	O
significant	O
effect	O
on	O
weight	O
gain	O
.	O

In	O
RAW264	O
.	O
7	O
macrophages	O
,	O
SC	O
containing	O
serum	O
(	O
SC	O
-	O
CS	O
)	O
(	O
5	O
%	O
,	O
10	O
%	O
and	O
20	O
%	O
)	O
significantly	O
decreased	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
alpha	O
,	O
TLR4	O
and	O
MyD88	O
protein	O
levels	O
and	O
the	O
mRNA	O
expression	O
of	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
alpha	O
and	O
TLR4	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
anti	O
-	O
diabetic	O
effects	O
of	O
SC	O
were	O
attributed	O
to	O
its	O
regulation	O
of	O
intestinal	O
flora	O
and	O
anti	O
-	O
inflammation	O
involving	O
the	O
TLR4	O
signaling	O
pathway	O
.	O

These	O
findings	O
provide	O
a	O
new	O
insight	O
into	O
the	O
anti	O
-	O
diabetic	O
application	O
for	O
SC	O
in	O
clinical	O
settings	O
and	O
display	O
the	O
potential	O
of	O
SC	O
in	O
the	O
treatment	O
of	O
DM	O
.	O

Psychotropics	O
and	O
the	O
Microbiome	O
:	O
a	O
Chamber	O
of	O
Secrets	O
.	O
.	O
.	O
.	O

The	O
human	O
gut	O
contains	O
trillions	O
of	O
symbiotic	O
bacteria	O
that	O
play	O
a	O
key	O
role	O
in	O
programming	O
different	O
aspects	O
of	O
host	O
physiology	O
in	O
health	O
and	O
disease	O
.	O

Psychotropic	O
medications	O
act	O
on	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
are	O
used	O
in	O
the	O
treatment	O
of	O
various	O
psychiatric	O
disorders	O
.	O

There	O
is	O
increasing	O
emphasis	O
on	O
the	O
bidirectional	O
interaction	O
between	O
drugs	O
and	O
the	O
gut	O
microbiome	O
.	O

An	O
expanding	O
body	O
of	O
evidence	O
supports	O
the	O
notion	O
that	O
microbes	O
can	O
metabolise	O
drugs	O
and	O
vice	O
versa	O
drugs	O
can	O
modify	O
the	O
gut	O
microbiota	O
composition	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
first	O
give	O
a	O
comprehensive	O
introduction	O
about	O
this	O
bidirectional	O
interaction	O
,	O
then	O
we	O
will	O
take	O
into	O
consideration	O
different	O
classes	O
of	O
psychotropics	O
including	O
antipsychotics	O
,	O
antidepressants	O
,	O
antianxiety	O
drugs	O
,	O
anticonvulsants	O
/	O
mood	O
stabilisers	O
,	O
opioid	O
analgesics	O
,	O
drugs	O
of	O
abuse	O
,	O
alcohol	O
,	O
nicotine	O
and	O
xanthines	O
.	O

The	O
varying	O
effects	O
of	O
these	O
widely	O
used	O
medications	O
on	O
microorganisms	O
are	O
becoming	O
apparent	O
from	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
.	O

This	O
has	O
important	O
implications	O
for	O
the	O
future	O
of	O
psychopharmacology	O
pipelines	O
that	O
will	O
routinely	O
need	O
to	O
consider	O
the	O
host	O
microbiome	O
during	O
drug	O
discovery	O
and	O
development	O
.	O

Review	O
:	O
Microbial	O
endocrinology	O
:	O
intersection	O
of	O
microbiology	O
and	O
neurobiology	O
matters	O
to	O
swine	O
health	O
from	O
infection	O
to	O
behavior	O
.	O

From	O
birth	O
to	O
slaughter	O
,	O
pigs	O
are	O
in	O
constant	O
interaction	O
with	O
microorganisms	O
.	O

Exposure	O
of	O
the	O
skin	O
,	O
gastrointestinal	O
and	O
respiratory	O
tracts	O
,	O
and	O
other	O
systems	O
allows	O
microorganisms	O
to	O
affect	O
the	O
developmental	O
trajectory	O
and	O
function	O
of	O
porcine	O
physiology	O
as	O
well	O
as	O
impact	O
behavior	O
.	O

These	O
routes	O
of	O
communication	O
are	O
bi	O
-	O
directional	O
,	O
allowing	O
the	O
swine	O
host	O
to	O
likewise	O
influence	O
microbial	O
survival	O
,	O
function	O
and	O
community	O
composition	O
.	O

Microbial	O
endocrinology	O
is	O
the	O
study	O
of	O
the	O
bi	O
-	O
directional	O
dialogue	O
between	O
host	O
and	O
microbe	O
.	O

Indeed	O
,	O
the	O
landmark	O
discovery	O
of	O
host	O
neuroendocrine	O
systems	O
as	O
hubs	O
of	O
host	O
-	O
microbe	O
communication	O
revealed	O
neurochemicals	O
act	O
as	O
an	O
inter	O
-	O
kingdom	O
evolutionary	O
-	O
based	O
language	O
between	O
microorganism	O
and	O
host	O
.	O

Several	O
such	O
neurochemicals	O
are	O
stress	O
catecholamines	O
,	O
which	O
have	O
been	O
shown	O
to	O
drastically	O
increase	O
host	O
susceptibility	O
to	O
infection	O
and	O
augment	O
virulence	O
of	O
important	O
swine	O
pathogens	O
,	O
including	O
Clostridium	B-bacteria
perfringens	I-bacteria
.	O

Catecholamines	O
,	O
the	O
production	O
of	O
which	O
increase	O
in	O
response	O
to	O
stress	O
,	O
reach	O
the	O
epithelium	O
of	O
multiple	O
tissues	O
,	O
including	O
the	O
gastrointestinal	O
tract	O
and	O
lung	O
,	O
where	O
they	O
initiate	O
diverse	O
responses	O
by	O
members	O
of	O
the	O
microbiome	O
as	O
well	O
as	O
transient	O
microorganisms	O
,	O
including	O
pathogens	O
and	O
opportunistic	O
pathogens	O
.	O

Multiple	O
laboratories	O
have	O
confirmed	O
the	O
evolutionary	O
role	O
of	O
microbial	O
endocrinology	O
in	O
infectious	O
disease	O
pathogenesis	O
extending	O
from	O
animals	O
to	O
even	O
plants	O
.	O

More	O
recent	O
investigations	O
have	O
now	O
shown	O
that	O
microbial	O
endocrinology	O
also	O
plays	O
a	O
role	O
in	O
animal	O
behavior	O
through	O
the	O
microbiota	O
-	O
gut	O
-	O
brain	O
axis	O
.	O

As	O
stress	O
and	O
disease	O
are	O
ever	O
-	O
present	O
,	O
intersecting	O
concerns	O
during	O
each	O
stage	O
of	O
swine	O
production	O
,	O
novel	O
strategies	O
utilizing	O
a	O
microbial	O
endocrinology	O
-	O
based	O
approach	O
will	O
likely	O
prove	O
invaluable	O
to	O
the	O
swine	O
industry	O
.	O

Nutritional	O
modulation	O
of	O
the	O
antioxidant	O
capacities	O
in	O
poultry	O
:	O
the	O
case	O
of	O
vitamin	O
E	O
.	O

Commercial	O
poultry	O
production	O
is	O
associated	O
with	O
a	O
range	O
of	O
stresses	O
,	O
including	O
environmental	O
,	O
technological	O
,	O
nutritional	O
,	O
and	O
internal	O
/	O
biological	O
ones	O
,	O
responsible	O
for	O
decreased	O
productive	O
and	O
reproductive	O
performance	O
of	O
poultry	O
.	O

At	O
the	O
molecular	O
level	O
,	O
most	O
of	O
them	O
are	O
associated	O
with	O
oxidative	O
stress	O
and	O
damages	O
to	O
important	O
biological	O
molecules	O
.	O

Poultry	O
feed	O
contains	O
a	O
range	O
of	O
feed	O
-	O
derived	O
and	O
supplemented	O
antioxidants	O
and	O
,	O
among	O
them	O
,	O
vitamin	O
E	O
is	O
considered	O
as	O
the	O
`	O
`	O
headquarters	O
'	O
'	O
of	O
the	O
antioxidant	O
defense	O
network	O
.	O

It	O
is	O
well	O
-	O
established	O
that	O
dietary	O
supplementation	O
of	O
selenium	O
,	O
vitamin	O
E	O
,	O
and	O
carotenoids	O
can	O
modulate	O
antioxidant	O
defenses	O
in	O
poultry	O
.	O

The	O
aim	O
of	O
the	O
present	O
paper	O
is	O
to	O
present	O
evidence	O
related	O
to	O
modulation	O
of	O
the	O
antioxidant	O
capacities	O
in	O
poultry	O
by	O
vitamin	O
E	O
.	O
Using	O
3	O
model	O
systems	O
including	O
poultry	O
breeders	O
/	O
males	O
,	O
semen	O
,	O
and	O
chicken	O
embryo	O
/	O
postnatal	O
chickens	O
,	O
the	O
possibility	O
of	O
modulation	O
of	O
the	O
antioxidant	O
defense	O
mechanisms	O
has	O
been	O
clearly	O
demonstrated	O
.	O

It	O
was	O
shown	O
that	O
increased	O
vitamin	O
E	O
supplementation	O
in	O
the	O
breeder	O
'	O
s	O
or	O
cockerel	O
'	O
s	O
diet	O
increased	O
their	O
resistance	O
to	O
various	O
stresses	O
,	O
including	O
high	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFA	O
)	O
,	O
mycotoxin	O
,	O
or	O
heat	O
stress	O
.	O

Increased	O
vitamin	O
E	O
supplementation	O
of	O
poultry	O
males	O
was	O
shown	O
to	O
be	O
associated	O
with	O
significant	O
increases	O
in	O
alpha	O
-	O
tocopherol	O
level	O
in	O
semen	O
associated	O
with	O
an	O
increased	O
resistance	O
to	O
oxidative	O
stress	O
imposed	O
by	O
various	O
external	O
stressors	O
.	O

Similarly	O
,	O
increased	O
vitamin	O
E	O
concentration	O
in	O
the	O
egg	O
yolk	O
due	O
to	O
dietary	O
supplementation	O
was	O
shown	O
to	O
be	O
associated	O
with	O
increased	O
alpha	O
-	O
tocopherol	O
concentration	O
in	O
the	O
tissues	O
of	O
the	O
developing	O
embryos	O
and	O
newly	O
hatched	O
chicks	O
resulting	O
in	O
increased	O
antioxidant	O
defenses	O
and	O
decreased	O
lipid	O
peroxidation	O
.	O

Furthermore	O
,	O
increased	O
vitamin	O
E	O
transfer	O
from	O
the	O
feed	O
to	O
egg	O
yolk	O
and	O
further	O
to	O
the	O
developing	O
embryo	O
was	O
shown	O
to	O
be	O
associated	O
with	O
upregulation	O
of	O
antioxidant	O
enzymes	O
reflecting	O
antioxidant	O
system	O
regulation	O
and	O
adaptation	O
.	O

The	O
role	O
of	O
vitamin	O
E	O
in	O
cell	O
signaling	O
and	O
gene	O
expression	O
as	O
well	O
as	O
in	O
interaction	O
with	O
microbiota	O
and	O
maintaining	O
gut	O
health	O
in	O
poultry	O
awaits	O
further	O
investigation	O
.	O

Morphological	O
and	O
molecular	O
response	O
of	O
small	O
intestine	O
to	O
lactulose	O
and	O
hydrogen	O
-	O
rich	O
water	O
in	O
female	O
piglets	O
fed	O
Fusarium	O
mycotoxins	O
contaminated	O
diet	O
.	O

Background	O
:	O
Following	O
the	O
intake	O
of	O
Fusarium	O
mycotoxin	O
-	O
contaminated	O
feed	O
,	O
small	O
intestines	O
may	O
be	O
exposed	O
to	O
high	O
levels	O
of	O
toxic	O
substances	O
that	O
can	O
potentially	O
damage	O
intestinal	O
functions	O
in	O
livestock	O
.	O

It	O
is	O
well	O
known	O
that	O
Fusarium	O
mycotoxins	O
will	O
lead	O
a	O
breakdown	O
of	O
the	O
normally	O
impeccable	O
epithelial	O
barrier	O
,	O
resulting	O
in	O
the	O
development	O
of	O
a	O
`	O
`	O
leaky	O
'	O
'	O
gut	O
.	O

H2	O
administration	O
with	O
different	O
methods	O
has	O
been	O
proved	O
definitely	O
potentials	O
to	O
prevent	O
serious	O
intestinal	O
diseases	O
.	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
roles	O
of	O
lactulose	O
(	O
LAC	O
)	O
and	O
hydrogen	O
-	O
rich	O
water	O
(	O
HRW	O
)	O
in	O
preventing	O
intestinal	O
dysfunction	O
in	O
piglets	O
fed	O
Fusarium	O
mycotoxin	O
-	O
contaminated	O
feed	O
.	O

Methods	O
:	O
A	O
total	O
of	O
24	O
female	O
piglets	O
were	O
evenly	O
assigned	O
to	O
4	O
groups	O
:	O
negative	O
control	O
(	O
NC	O
)	O
group	O
,	O
mycotoxin	O
-	O
contaminated	O
(	O
MC	O
)	O
feed	O
group	O
,	O
MC	O
feed	O
with	O
LAC	O
treatment	O
(	O
MC	O
+	O
LAC	O
)	O
,	O
and	O
MC	O
feed	O
with	O
HRW	O
treatment	O
(	O
MC	O
+	O
HRW	O
)	O
,	O
respectively	O
.	O

Piglets	O
in	O
the	O
NC	O
group	O
were	O
fed	O
uncontaminated	O
control	O
diet	O
,	O
while	O
remaining	O
piglets	O
were	O
fed	O
Fusarium	O
mycotoxin	O
-	O
contaminated	O
diet	O
.	O

For	O
the	O
NC	O
and	O
MC	O
groups	O
,	O
10	O
mL	O
/	O
kg	O
body	O
weight	O
(	O
BW	O
)	O
of	O
hydrogen	O
-	O
free	O
water	O
(	O
HFW	O
)	O
was	O
orally	O
administrated	O
to	O
piglets	O
twice	O
daily	O
;	O
while	O
in	O
the	O
MC	O
+	O
LAC	O
and	O
MC	O
+	O
HRW	O
groups	O
,	O
piglets	O
were	O
treated	O
with	O
the	O
same	O
dose	O
of	O
LAC	O
solution	O
(	O
500	O
mg	O
/	O
kg	O
BW	O
)	O
and	O
HRW	O
twice	O
daily	O
,	O
respectively	O
.	O

On	O
d	O
25	O
,	O
serum	O
was	O
collected	O
and	O
used	O
for	O
biochemical	O
analysis	O
.	O

Intestinal	O
tissues	O
were	O
sampled	O
for	O
morphological	O
examination	O
as	O
well	O
as	O
relative	O
genes	O
and	O
protein	O
expression	O
analysis	O
.	O

Results	O
:	O
Our	O
data	O
showed	O
that	O
Fusarium	O
mycotoxins	O
induced	O
higher	O
serum	O
diamine	O
oxidase	O
(	O
DAO	O
)	O
activities	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
D	O
-	O
lactic	O
acid	O
levels	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
endotoxin	O
status	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
lower	O
villus	O
height	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
ratio	O
of	O
villus	O
height	O
to	O
crypt	O
depth	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
small	O
intestine	O
,	O
greater	O
apoptosis	O
index	O
and	O
higher	O
mRNA	O
expression	O
related	O
to	O
tight	O
junctions	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
the	O
distribution	O
and	O
down	O
-	O
regulation	O
of	O
claudin	O
-	O
3	O
(	O
CLDN3	O
)	O
protein	O
in	O
the	O
small	O
intestinal	O
was	O
also	O
observed	O
.	O

As	O
expected	O
,	O
oral	O
administrations	O
of	O
HRW	O
and	O
LAC	O
were	O
found	O
to	O
remarkably	O
provide	O
beneficial	O
effects	O
against	O
Fusarium	O
mycotoxin	O
-	O
induced	O
apoptosis	O
and	O
intestinal	O
leaking	O
.	O

Moreover	O
,	O
either	O
HRW	O
or	O
LAC	O
treatments	O
were	O
also	O
revealed	O
to	O
prevent	O
abnormal	O
intestinal	O
morphological	O
changes	O
,	O
disintegrate	O
tight	O
junctions	O
,	O
and	O
restore	O
the	O
expression	O
and	O
distribution	O
of	O
CLDN3	O
protein	O
in	O
the	O
small	O
intestinal	O
mucosal	O
layer	O
in	O
female	O
piglets	O
that	O
were	O
fed	O
Fusarium	O
mycotoxins	O
contaminated	O
diet	O
.	O

Conclusions	O
:	O
Our	O
data	O
suggest	O
that	O
orally	O
administrations	O
of	O
HRW	O
and	O
LAC	O
result	O
in	O
less	O
Fusarium	O
mycotoxin	O
-	O
induced	O
apoptosis	O
and	O
leak	O
in	O
the	O
small	O
intestine	O
.	O

Either	O
HRW	O
or	O
LAC	O
treatments	O
could	O
prevent	O
the	O
abnormal	O
changes	O
of	O
intestinal	O
morphology	O
and	O
molecular	O
response	O
of	O
tight	O
junctions	O
as	O
well	O
as	O
restore	O
the	O
distribution	O
and	O
expression	O
of	O
CLDN3	O
protein	O
of	O
small	O
intestinal	O
mucosa	O
layer	O
in	O
female	O
piglets	O
that	O
were	O
fed	O
Fusarium	O
mycotoxins	O
contaminated	O
diet	O
.	O

Campylobacter	B-bacteria
jejuni	I-bacteria
enters	O
gut	O
epithelial	O
cells	O
and	O
impairs	O
intestinal	O
barrier	O
function	O
through	O
cleavage	O
of	O
occludin	O
by	O
serine	O
protease	O
HtrA	O
.	O

Campylobacter	B-bacteria
jejuni	I-bacteria
secretes	O
HtrA	O
(	O
high	O
temperature	O
requirement	O
protein	O
A	O
)	O
,	O
a	O
serine	O
protease	O
that	O
is	O
involved	O
in	O
virulence	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
interaction	O
of	O
HtrA	O
with	O
the	O
host	O
protein	O
occludin	O
,	O
a	O
tight	O
junction	O
strand	O
component	O
.	O

Immunofluorescence	O
studies	O
demonstrated	O
that	O
infection	O
of	O
polarized	O
intestinal	O
Caco	O
-	O
2	O
cells	O
with	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
strain	I-bacteria
81	I-bacteria
-	I-bacteria
176	I-bacteria
resulted	O
in	O
a	O
redistribution	O
of	O
occludin	O
away	O
from	O
the	O
tight	O
junctions	O
into	O
the	O
cytoplasm	O
,	O
an	O
effect	O
that	O
was	O
also	O
observed	O
in	O
human	O
biopsies	O
during	O
acute	O
campylobacteriosis	O
.	O

Occludin	O
knockout	O
Caco	O
-	O
2	O
cells	O
were	O
generated	O
by	O
CRISPR	O
/	O
Cas9	O
technology	O
.	O

Inactivation	O
of	O
this	O
gene	O
affected	O
the	O
polarization	O
of	O
the	O
cells	O
in	O
monolayers	O
and	O
transepithelial	O
electrical	O
resistance	O
(	O
TER	O
)	O
was	O
reduced	O
,	O
compared	O
to	O
wild	O
-	O
type	O
Caco	O
-	O
2	O
cells	O
.	O

Although	O
tight	O
junctions	O
were	O
still	O
being	O
formed	O
,	O
occludin	O
deficiency	O
resulted	O
in	O
a	O
slight	O
decrease	O
of	O
the	O
tight	O
junction	O
plaque	O
protein	O
ZO	O
-	O
1	O
,	O
which	O
was	O
redistributed	O
off	O
the	O
tight	O
junction	O
into	O
the	O
lateral	O
plasma	O
membrane	O
.	O

Adherence	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
to	O
Caco	O
-	O
2	O
cell	O
monolayers	O
was	O
similar	O
between	O
the	O
occludin	O
knockout	O
compared	O
to	O
wild	O
-	O
type	O
cells	O
,	O
but	O
invasion	O
was	O
enhanced	O
,	O
indicating	O
that	O
deletion	O
of	O
occludin	O
allowed	O
larger	O
numbers	O
of	O
bacteria	O
to	O
pass	O
the	O
tight	O
junctions	O
and	O
to	O
reach	O
basal	O
membranes	O
to	O
target	O
the	O
fibronectin	O
receptor	O
followed	O
by	O
cell	O
entry	O
.	O

Finally	O
,	O
we	O
discovered	O
that	O
purified	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
HtrA	O
cleaves	O
recombinant	O
occludin	O
in	O
vitro	O
to	O
release	O
a	O
37	O
kDa	O
carboxy	O
-	O
terminal	O
fragment	O
.	O

The	O
same	O
cleavage	O
fragment	O
was	O
observed	O
in	O
Western	O
blots	O
upon	O
infection	O
of	O
polarized	O
Caco	O
-	O
2	O
cells	O
with	O
wild	O
-	O
type	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
,	O
but	O
not	O
with	O
isogenic	O
DeltahtrA	O
mutants	O
.	O

HtrA	O
cleavage	O
was	O
mapped	O
to	O
the	O
second	O
extracellular	O
loop	O
of	O
occludin	O
,	O
and	O
a	O
putative	O
cleavage	O
site	O
was	O
identified	O
.	O

In	O
conclusion	O
,	O
HtrA	O
functions	O
as	O
a	O
secreted	O
protease	O
targeting	O
the	O
tight	O
junctions	O
,	O
which	O
enables	O
the	O
bacteria	O
by	O
cleaving	O
occludin	O
and	O
subcellular	O
redistribution	O
of	O
other	O
tight	O
junction	O
proteins	O
to	O
transmigrate	O
using	O
a	O
paracellular	O
mechanism	O
and	O
subsequently	O
invade	O
epithelial	O
cells	O
.	O

High	O
contiguity	O
genome	O
sequence	O
of	O
a	O
multidrug	O
-	O
resistant	O
hospital	O
isolate	O
of	O
Enterobacter	B-bacteria
hormaechei	I-bacteria
.	O

Background	O
:	O
Enterobacter	B-bacteria
hormaechei	I-bacteria
is	O
an	O
important	O
emerging	O
pathogen	O
and	O
a	O
key	O
member	O
of	O
the	O
highly	O
diverse	O
Enterobacter	B-bacteria
cloacae	I-bacteria
complex	I-bacteria
.	O

E	B-bacteria
.	I-bacteria
hormaechei	I-bacteria
strains	I-bacteria
can	O
persist	O
and	O
spread	O
in	O
nosocomial	O
environments	O
,	O
and	O
often	O
exhibit	O
resistance	O
to	O
multiple	O
clinically	O
important	O
antibiotics	O
.	O

However	O
,	O
the	O
genomic	O
regions	O
that	O
harbour	O
resistance	O
determinants	O
are	O
typically	O
highly	O
repetitive	O
and	O
impossible	O
to	O
resolve	O
with	O
standard	O
short	O
-	O
read	O
sequencing	O
technologies	O
.	O

Results	O
:	O
Here	O
we	O
used	O
both	O
short	O
-	O
and	O
long	O
-	O
read	O
methods	O
to	O
sequence	O
the	O
genome	O
of	O
a	O
multidrug	O
-	O
resistant	O
hospital	O
isolate	O
(	O
C15117	O
)	O
,	O
which	O
we	O
identified	O
as	O
E	B-bacteria
.	I-bacteria
hormaechei	I-bacteria
.	O

Hybrid	O
assembly	O
generated	O
a	O
complete	O
circular	O
chromosome	O
of	O
4	O
,	O
739	O
,	O
272	O
bp	O
and	O
a	O
fully	O
resolved	O
plasmid	O
of	O
339	O
,	O
920	O
bp	O
containing	O
several	O
antibiotic	O
resistance	O
genes	O
.	O

The	O
strain	O
also	O
harboured	O
a	O
34	O
,	O
857	O
bp	O
repeat	O
encoding	O
copper	O
resistance	O
,	O
which	O
was	O
present	O
in	O
both	O
the	O
chromosome	O
and	O
plasmid	O
.	O

Long	O
reads	O
that	O
unambiguously	O
spanned	O
this	O
repeat	O
were	O
required	O
to	O
resolve	O
the	O
chromosome	O
and	O
plasmid	O
into	O
separate	O
replicons	O
.	O

Conclusion	O
:	O
This	O
study	O
provides	O
important	O
insights	O
into	O
the	O
evolution	O
and	O
potential	O
spread	O
of	O
antimicrobial	O
resistance	O
in	O
a	O
nosocomial	O
E	B-bacteria
.	I-bacteria
hormaechei	I-bacteria
strain	I-bacteria
.	O

More	O
broadly	O
,	O
it	O
further	O
exemplifies	O
the	O
power	O
of	O
long	O
-	O
read	O
sequencing	O
technologies	O
,	O
particularly	O
the	O
Oxford	O
Nanopore	O
platform	O
,	O
for	O
the	O
characterisation	O
of	O
bacteria	O
with	O
complex	O
resistance	O
loci	O
and	O
large	O
repeat	O
elements	O
.	O

Significant	O
Differences	O
in	O
Bacterial	O
and	O
Potentially	O
Pathogenic	O
Communities	O
Between	O
Sympatric	O
Hooded	O
Crane	O
and	O
Greater	O
White	O
-	O
Fronted	O
Goose	O
.	O

The	O
gut	O
microbiota	O
of	O
vertebrates	O
play	O
a	O
crucial	O
role	O
in	O
shaping	O
the	O
health	O
of	O
their	O
hosts	O
.	O

However	O
,	O
knowledge	O
of	O
the	O
avian	O
intestinal	O
microbiota	O
has	O
arguably	O
lagged	O
behind	O
that	O
of	O
many	O
other	O
vertebrates	O
.	O

Here	O
,	O
we	O
examine	O
the	O
intestinal	O
bacterial	O
communities	O
of	O
the	O
hooded	O
crane	O
and	O
the	O
greater	O
white	O
-	O
fronted	O
goose	O
at	O
the	O
Shengjin	O
Lake	O
of	O
China	O
,	O
using	O
high	O
-	O
throughput	O
sequencing	O
(	O
Illumina	O
Mi	O
-	O
Seq	O
)	O
,	O
and	O
infer	O
the	O
potential	O
pathogens	O
associated	O
with	O
each	O
species	O
.	O

Intestinal	O
bacterial	O
alpha	O
-	O
diversity	O
in	O
the	O
greater	O
white	O
-	O
fronted	O
goose	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
hooded	O
crane	O
.	O

The	O
intestinal	O
bacterial	O
community	O
compositions	O
were	O
significantly	O
different	O
between	O
the	O
two	O
hosts	O
,	O
suggesting	O
that	O
host	O
interactions	O
with	O
specific	O
communities	O
might	O
have	O
profound	O
implications	O
.	O

In	O
addition	O
,	O
potential	O
pathogens	O
were	O
detected	O
in	O
both	O
guts	O
of	O
the	O
two	O
hosts	O
,	O
suggesting	O
that	O
these	O
wild	O
birds	O
might	O
be	O
at	O
risk	O
of	O
disease	O
and	O
probably	O
spread	O
infectious	O
disease	O
to	O
other	O
sympatric	O
vertebrates	O
.	O

The	O
gut	O
of	O
hooded	O
crane	O
carried	O
more	O
potential	O
pathogens	O
than	O
that	O
of	O
the	O
greater	O
white	O
-	O
fronted	O
goose	O
.	O

The	O
potentially	O
pathogenic	O
community	O
compositions	O
were	O
also	O
significantly	O
different	O
between	O
the	O
two	O
hosts	O
,	O
suggesting	O
the	O
divergence	O
of	O
potentially	O
pathogenic	O
communities	O
between	O
hooded	O
crane	O
,	O
and	O
greater	O
white	O
-	O
fronted	O
goose	O
.	O

Finally	O
,	O
bacterial	O
and	O
potentially	O
pathogenic	O
structures	O
showed	O
strong	O
evidence	O
of	O
phylogenic	O
clustering	O
in	O
both	O
hosts	O
,	O
further	O
demonstrating	O
that	O
each	O
host	O
was	O
associated	O
with	O
preferential	O
and	O
defined	O
bacterial	O
and	O
potentially	O
pathogenic	O
communities	O
.	O

Our	O
results	O
argue	O
that	O
more	O
attention	O
should	O
be	O
paid	O
to	O
investigate	O
avian	O
intestinal	O
pathogens	O
which	O
might	O
increase	O
disease	O
risks	O
for	O
conspecifics	O
and	O
other	O
mixed	O
species	O
,	O
and	O
even	O
poultry	O
and	O
human	O
beings	O
.	O

Development	O
of	O
a	O
Bioelectrochemical	O
System	O
as	O
a	O
Tool	O
to	O
Enrich	O
H2	O
-	O
Producing	O
Syntrophic	O
Bacteria	O
.	O

Syntrophic	O
microbial	O
partnerships	O
are	O
found	O
in	O
many	O
environments	O
and	O
play	O
critical	O
roles	O
in	O
wastewater	O
treatment	O
,	O
global	O
nutrient	O
cycles	O
,	O
and	O
gut	O
systems	O
.	O

An	O
important	O
type	O
of	O
syntrophy	O
for	O
the	O
anaerobic	O
conversion	O
of	O
carboxylic	O
acids	O
is	O
H2	O
syntrophy	O
.	O

In	O
this	O
type	O
of	O
microbial	O
partnership	O
,	O
dissolved	O
H2	O
is	O
produced	O
by	O
a	O
bacterium	O
and	O
rapidly	O
consumed	O
by	O
an	O
archeon	O
(	O
methanogen	O
)	O
,	O
resulting	O
in	O
methane	O
gas	O
.	O

This	O
is	O
referred	O
to	O
as	O
interspecies	O
H2	O
transfer	O
,	O
and	O
some	O
conversions	O
rely	O
on	O
this	O
mechanism	O
to	O
become	O
thermodynamically	O
feasible	O
.	O

For	O
this	O
reason	O
,	O
syntrophic	O
partners	O
are	O
often	O
not	O
possible	O
to	O
separate	O
in	O
the	O
lab	O
,	O
which	O
hampers	O
the	O
full	O
understanding	O
of	O
their	O
physiology	O
.	O

Bioelectrochemical	O
systems	O
(	O
BESs	O
)	O
may	O
show	O
promise	O
to	O
ultimately	O
separate	O
and	O
study	O
the	O
behavior	O
of	O
the	O
syntrophic	O
bacterium	O
by	O
employing	O
an	O
abiotic	O
H2	O
oxidation	O
reaction	O
at	O
the	O
anode	O
,	O
actively	O
removing	O
dissolved	O
H2	O
.	O

Here	O
,	O
we	O
performed	O
a	O
proof	O
-	O
of	O
-	O
concept	O
study	O
to	O
ascertain	O
whether	O
an	O
H2	O
-	O
removing	O
anode	O
can	O
:	O
(	O
1	O
)	O
provide	O
a	O
growth	O
advantage	O
for	O
the	O
syntrophic	O
bacterium	O
;	O
and	O
(	O
2	O
)	O
compete	O
with	O
the	O
methanogenic	O
partner	O
.	O

A	O
mathematical	O
model	O
was	O
developed	O
to	O
design	O
a	O
BES	O
to	O
perform	O
competition	O
experiments	O
.	O

Indeed	O
,	O
the	O
operated	O
BES	O
demonstrated	O
the	O
ability	O
to	O
provide	O
a	O
growth	O
advantage	O
to	O
the	O
syntrophic	O
bacterium	O
Syntrophus	B-bacteria
aciditrophicus	I-bacteria
compared	O
to	O
its	O
methanogenic	O
partner	O
Methanospirillum	B-bacteria
hungatei	I-bacteria
when	O
grown	O
in	O
co	O
-	O
culture	O
.	O

Further	O
,	O
the	O
BES	O
provided	O
the	O
never	O
-	O
before	O
isolated	O
Syntrophomonas	B-bacteria
zehnderi	I-bacteria
with	O
a	O
growth	O
advantage	O
compared	O
to	O
Methanobacterium	B-bacteria
formicicum	I-bacteria
.	O

Our	O
results	O
demonstrate	O
a	O
potential	O
to	O
use	O
this	O
BES	O
to	O
enrich	O
H2	O
-	O
sensitive	O
syntrophic	O
bacteria	O
,	O
and	O
gives	O
prospects	O
for	O
the	O
development	O
of	O
an	O
effective	O
method	O
for	O
the	O
separation	O
of	O
obligate	O
syntrophs	O
.	O

Lactobacillus	B-bacteria
plantarum	I-bacteria
PFM	I-bacteria
105	I-bacteria
Promotes	O
Intestinal	O
Development	O
Through	O
Modulation	O
of	O
Gut	O
Microbiota	O
in	O
Weaning	O
Piglets	O
.	O

Lactobacillus	B-bacteria
plantarum	I-bacteria
is	O
a	O
widespread	O
bacterial	O
species	O
and	O
is	O
commonly	O
used	O
as	O
a	O
probiotic	O
.	O

L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
PFM105	I-bacteria
was	O
isolated	O
from	O
the	O
rectum	O
of	O
a	O
healthy	O
sow	O
.	O

Here	O
we	O
found	O
that	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
PFM105	I-bacteria
showed	O
probiotic	O
effect	O
on	O
weaning	O
piglets	O
in	O
which	O
intestinal	O
inflammation	O
and	O
unbalanced	O
gut	O
microbiota	O
happened	O
frequently	O
.	O

L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
PFM105	I-bacteria
was	O
identified	O
to	O
improve	O
the	O
growth	O
of	O
weaning	O
piglet	O
and	O
promote	O
the	O
development	O
of	O
small	O
intestinal	O
villi	O
.	O

Antibiotics	O
are	O
often	O
used	O
in	O
weaning	O
piglet	O
to	O
prevent	O
intestinal	O
infection	O
and	O
promote	O
the	O
growth	O
of	O
animal	O
.	O

We	O
found	O
that	O
weaning	O
piglets	O
feeding	O
with	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
PFM105	I-bacteria
showed	O
similar	O
growth	O
promotion	O
but	O
decreased	O
diarrhea	O
incidence	O
compared	O
with	O
those	O
feeding	O
with	O
antibiotics	O
.	O

High	O
-	O
throughput	O
sequencing	O
was	O
used	O
to	O
analyze	O
the	O
gut	O
microbiota	O
in	O
weaning	O
piglets	O
treated	O
with	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
PFM105	I-bacteria
or	O
antibiotics	O
.	O

The	O
relative	O
abundance	O
of	O
beneficial	O
microbes	O
Prevotellaceae	B-bacteria
and	O
Bifidobacteriaceae	B-bacteria
were	O
increased	O
in	O
colon	O
of	O
weaning	O
piglet	O
feeding	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
PFM105	I-bacteria
,	O
while	O
antibiotics	O
increased	O
the	O
relative	O
abundance	O
of	O
bacteria	O
associated	O
with	O
pathogenicity	O
,	O
such	O
as	O
Spirochaeta	B-bacteria
and	O
Campylobacteraceae	B-bacteria
.	O

L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
PFM	I-bacteria
105	I-bacteria
increased	O
indicators	O
of	O
intestinal	O
health	O
including	O
serum	O
levels	O
of	O
IgM	O
,	O
IL	O
-	O
10	O
,	O
and	O
TGF	O
-	O
beta	O
,	O
and	O
colonic	O
levels	O
of	O
SCFAs	O
.	O

We	O
found	O
strong	O
correlations	O
between	O
the	O
alterations	O
in	O
gut	O
microbiota	O
composition	O
caused	O
by	O
feeding	O
antibiotics	O
and	O
probiotics	O
and	O
the	O
measured	O
growth	O
and	O
health	O
parameters	O
in	O
weaning	O
piglets	O
.	O

The	O
addition	O
of	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
PFM105	I-bacteria
could	O
significantly	O
increase	O
the	O
relative	O
abundance	O
of	O
metabolic	O
genes	O
which	O
may	O
important	O
to	O
intestinal	O
microbiota	O
maturation	O
.	O

Altogether	O
,	O
we	O
demonstrated	O
here	O
that	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
PFM	I-bacteria
105	I-bacteria
could	O
promote	O
intestinal	O
development	O
through	O
modulation	O
of	O
gut	O
microbiota	O
in	O
weaning	O
piglets	O
.	O

Gut	O
microbiota	O
of	O
the	O
European	O
Brown	O
Hare	O
(	O
Lepus	O
europaeus	O
)	O
.	O

Diseases	O
of	O
the	O
gastrointestinal	O
tract	O
due	O
to	O
changes	O
in	O
the	O
bacterial	O
flora	O
have	O
been	O
described	O
with	O
increasing	O
incidence	O
in	O
the	O
European	O
brown	O
hare	O
.	O

Despite	O
extensive	O
demographic	O
and	O
phylogeographic	O
research	O
,	O
little	O
is	O
known	O
about	O
the	O
composition	O
of	O
its	O
gut	O
microbiota	O
and	O
how	O
it	O
might	O
vary	O
based	O
on	O
potential	O
environmental	O
or	O
host	O
factors	O
.	O

We	O
analysed	O
the	O
intestinal	O
and	O
faecal	O
microbiota	O
of	O
3	O
hare	O
populations	O
by	O
Illumina	O
MiSeq	O
16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
.	O

The	O
phyla	O
and	O
OTU	O
abundance	O
composition	O
differed	O
significantly	O
between	O
intestinal	O
and	O
faecal	O
samples	O
(	O
PERMANOVA	O
:	O
P	O
=	O
0	O
.	O
002	O
and	O
P	O
=	O
0	O
.	O
031	O
,	O
respectively	O
)	O
,	O
but	O
in	O
both	O
sample	O
types	O
Firmicutes	B-bacteria
and	O
Bacteroidetes	B-bacteria
dominated	O
the	O
microbial	O
community	O
composition	O
(	O
45	O
.	O
51	O
%	O
and	O
19	O
.	O
30	O
%	O
relative	O
abundance	O
)	O
.	O

Intestinal	O
samples	O
contained	O
an	O
enrichment	O
of	O
Proteobacteria	B-bacteria
compared	O
with	O
faecal	O
samples	O
(	O
15	O
.	O
71	O
-	O
fold	O
change	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

At	O
OTU	O
level	O
,	O
a	O
significant	O
enrichment	O
with	O
best	O
BLAST	O
hits	O
to	O
the	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
group	O
,	O
Eubacterium	B-bacteria
limosum	I-bacteria
,	O
Sphingomonas	B-bacteria
kyeonggiensis	I-bacteria
,	O
Flintibacter	B-bacteria
butyricus	I-bacteria
and	O
Blautia	B-bacteria
faecis	I-bacteria
were	O
detected	O
in	O
intestinal	O
samples	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
our	O
statistical	O
model	O
,	O
geographic	O
location	O
and	O
possibly	O
associated	O
environmental	O
factors	O
had	O
a	O
greater	O
impact	O
on	O
the	O
microbiota	O
composition	O
than	O
host	O
factors	O
.	O

Population	O
had	O
a	O
significant	O
effect	O
on	O
the	O
composition	O
of	O
abundant	O
intestinal	O
and	O
faecal	O
OTUs	O
,	O
and	O
on	O
the	O
abundance	O
of	O
potential	O
pathogenic	O
bacteria	O
of	O
the	O
family	O
Enterobacteriaceae	B-bacteria
,	O
regularly	O
associated	O
with	O
intestinal	O
dysbiosis	O
in	O
hares	O
,	O
in	O
faecal	O
samples	O
.	O

Our	O
study	O
is	O
the	O
first	O
to	O
describe	O
the	O
microbiota	O
in	O
brown	O
hares	O
and	O
provides	O
a	O
foundation	O
to	O
generate	O
hypothesis	O
aiming	O
to	O
test	O
the	O
role	O
of	O
gut	O
health	O
in	O
population	O
fluctuations	O
of	O
the	O
species	O
.	O

Educational	O
intervention	O
improves	O
fruit	O
and	O
vegetable	O
intake	O
in	O
young	O
adults	O
with	O
metabolic	O
syndrome	O
components	O
.	O

The	O
FRUVEDomics	O
study	O
investigates	O
the	O
effect	O
of	O
a	O
diet	O
intervention	O
focused	O
on	O
increasing	O
fruit	O
and	O
vegetable	O
intake	O
on	O
the	O
gut	O
microbiome	O
and	O
cardiovascular	O
health	O
of	O
young	O
adults	O
with	O
/	O
at	O
risk	O
for	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
.	O

It	O
was	O
hypothesized	O
that	O
the	O
recommended	O
diet	O
would	O
result	O
in	O
metabolic	O
and	O
gut	O
microbiome	O
changes	O
.	O

The	O
9	O
-	O
week	O
dietary	O
intervention	O
adhered	O
to	O
the	O
US	O
Department	O
of	O
Agriculture	O
Dietary	O
Guidelines	O
for	O
Americans	O
and	O
focused	O
on	O
increasing	O
fruit	O
and	O
vegetable	O
intake	O
to	O
equal	O
half	O
of	O
the	O
diet	O
.	O

Seventeen	O
eligible	O
young	O
adults	O
with	O
/	O
or	O
at	O
high	O
risk	O
of	O
MetS	O
consented	O
and	O
completed	O
preintervention	O
and	O
postintervention	O
measurements	O
,	O
including	O
anthropometric	O
,	O
body	O
composition	O
,	O
cardiovascular	O
,	O
complete	O
blood	O
lipid	O
panel	O
,	O
and	O
collection	O
of	O
stool	O
sample	O
for	O
microbial	O
analysis	O
.	O

Participants	O
attended	O
weekly	O
consultations	O
to	O
assess	O
food	O
logs	O
,	O
food	O
receipts	O
,	O
and	O
adherence	O
to	O
the	O
diet	O
.	O

Following	O
intention	O
-	O
to	O
-	O
treat	O
guidelines	O
,	O
all	O
17	O
individuals	O
were	O
included	O
in	O
the	O
dietary	O
,	O
clinical	O
,	O
and	O
anthropometric	O
analysis	O
.	O

Fruit	O
and	O
vegetable	O
intake	O
increased	O
from	O
1	O
.	O
6	O
to	O
3	O
.	O
4	O
cups	O
of	O
fruits	O
and	O
vegetables	O
(	O
P	O
<	O
.	O
001	O
)	O
daily	O
.	O

Total	O
fiber	O
(	O
P	O
=	O
.	O
02	O
)	O
and	O
insoluble	O
fiber	O
(	O
P	O
<	O
.	O
0001	O
)	O
also	O
increased	O
.	O

Clinical	O
laboratory	O
changes	O
included	O
an	O
increase	O
in	O
sodium	O
(	O
P	O
=	O
.	O
0006	O
)	O
and	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
P	O
=	O
.	O
04	O
)	O
.	O

In	O
the	O
fecal	O
microbiome	O
,	O
Erysipelotrichaceae	B-bacteria
(	O
phylum	O
Firmicutes	B-bacteria
)	O
decreased	O
(	O
log2	O
fold	O
change	O
:	O
-	O
1	O
.	O
78	O
,	O
P	O
=	O
.	O
01	O
)	O
and	O
Caulobacteraceae	B-bacteria
(	O
phylum	O
Proteobacteria	B-bacteria
)	O
increased	O
(	O
log2	O
fold	O
change	O
=	O
1	O
.	O
07	O
,	O
P	O
=	O
.	O
01	O
)	O
.	O

Implementing	O
a	O
free	O
-	O
living	O
9	O
-	O
week	O
diet	O
,	O
with	O
intensive	O
education	O
and	O
accountability	O
,	O
gave	O
young	O
adults	O
at	O
high	O
risk	O
for	O
/	O
or	O
diagnosed	O
with	O
MetS	O
the	O
knowledge	O
,	O
skills	O
,	O
and	O
feedback	O
to	O
improve	O
diet	O
.	O

To	O
yield	O
greater	O
impact	O
,	O
a	O
longer	O
diet	O
intervention	O
may	O
be	O
needed	O
in	O
this	O
population	O
.	O

No	O
evidence	O
that	O
gut	O
microbiota	O
impose	O
a	O
net	O
cost	O
on	O
their	O
butterfly	O
host	O
.	O

Gut	O
microbes	O
are	O
believed	O
to	O
play	O
a	O
critical	O
role	O
in	O
most	O
animal	O
life	O
,	O
yet	O
fitness	O
effects	O
and	O
cost	O
-	O
benefit	O
trade	O
-	O
offs	O
incurred	O
by	O
the	O
host	O
are	O
poorly	O
understood	O
.	O

Unlike	O
most	O
hosts	O
studied	O
to	O
date	O
,	O
butterflies	O
largely	O
acquire	O
their	O
nutrients	O
from	O
larval	O
feeding	O
,	O
leaving	O
relatively	O
little	O
opportunity	O
for	O
nutritive	O
contributions	O
by	O
the	O
adult	O
'	O
s	O
microbiota	O
.	O

This	O
provides	O
an	O
opportunity	O
to	O
measure	O
whether	O
hosting	O
gut	O
microbiota	O
comes	O
at	O
a	O
net	O
nutritional	O
price	O
.	O

Because	O
host	O
and	O
bacteria	O
may	O
compete	O
for	O
sugars	O
,	O
we	O
hypothesized	O
that	O
gut	O
flora	O
would	O
be	O
nutritionally	O
neutral	O
to	O
adult	O
butterflies	O
with	O
plentiful	O
food	O
,	O
but	O
detrimental	O
to	O
semistarved	O
hosts	O
,	O
especially	O
when	O
at	O
high	O
density	O
.	O

We	O
held	O
field	O
-	O
caught	O
adult	O
Speyeria	B-bacteria
mormonia	I-bacteria
under	O
abundant	O
or	O
restricted	O
food	O
conditions	O
.	O

Because	O
antibiotic	O
treatments	O
did	O
not	O
generate	O
consistent	O
variation	O
in	O
their	O
gut	O
microbiota	O
,	O
we	O
used	O
interindividual	O
variability	O
in	O
bacterial	O
loads	O
and	O
operational	O
taxonomic	O
unit	O
abundances	O
to	O
examine	O
correlations	O
between	O
host	O
fitness	O
and	O
the	O
abdominal	O
microbiota	O
present	O
upon	O
natural	O
death	O
.	O

We	O
detected	O
strikingly	O
few	O
relationships	O
between	O
microbial	O
flora	O
and	O
host	O
fitness	O
.	O

Neither	O
total	O
bacterial	O
load	O
nor	O
the	O
abundances	O
of	O
dominant	O
bacterial	O
taxa	O
were	O
related	O
to	O
butterfly	O
fecundity	O
,	O
egg	O
mass	O
or	O
egg	O
chemical	O
content	O
.	O

Increased	O
abundance	O
of	O
a	O
Commensalibacter	B-bacteria
species	I-bacteria
did	O
correlate	O
with	O
longer	O
host	O
life	O
span	O
,	O
while	O
increased	O
abundance	O
of	O
a	O
Rhodococcus	B-bacteria
species	I-bacteria
correlated	O
with	O
shorter	O
life	O
span	O
.	O

Contrary	O
to	O
our	O
expectations	O
,	O
these	O
relationships	O
were	O
unchanged	O
by	O
food	O
availability	O
to	O
the	O
host	O
and	O
were	O
unrelated	O
to	O
reproductive	O
output	O
.	O

Our	O
results	O
suggest	O
the	O
butterfly	O
microbiota	O
comprises	O
parasitic	O
,	O
commensal	O
and	O
beneficial	O
taxa	O
that	O
together	O
do	O
not	O
impose	O
a	O
net	O
reproductive	O
cost	O
,	O
even	O
under	O
caloric	O
stress	O
.	O

EtOAc	O
extract	O
of	O
H	O
.	O
attenuatum	O
Choisy	O
inhibits	O
inflammation	O
by	O
suppressing	O
the	O
NF	O
-	O
kappaB	O
and	O
MAPK	O
pathways	O
and	O
modulating	O
the	O
gut	O
microbiota	O
.	O

BACKGROUND	O
:	O
Hypericum	O
attenuatum	O
Choisy	O
,	O
a	O
traditional	O
Chinese	O
herb	O
,	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
inflammation	O
and	O
has	O
been	O
used	O
to	O
treat	O
rheumatic	O
arthritis	O
in	O
China	O
for	O
centuries	O
.	O

However	O
,	O
the	O
underlying	O
mechanism	O
of	O
its	O
anti	O
-	O
inflammatory	O
effect	O
is	O
poorly	O
understood	O
.	O

HYPOTHESIS	O
/	O
PURPOSE	O
:	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
anti	O
-	O
inflammatory	O
mechanisms	O
of	O
EtOAc	O
fractions	O
of	O
H	O
.	O
attenuatum	O
Choisy	O
(	O
Ha	O
-	O
EtOAc	O
)	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
RAW264	O
.	O
7	O
macrophage	O
inflammation	O
and	O
hypothesized	O
that	O
Ha	O
-	O
EtOAc	O
could	O
attenuate	O
inflammation	O
in	O
the	O
colon	O
.	O

STUDY	O
DESIGN	O
:	O
LPS	O
was	O
utilized	O
to	O
induce	O
RAW264	O
.	O
7	O
cells	O
inflammation	O
.	O

The	O
anti	O
-	O
inflammatory	O
effect	O
of	O
Ha	O
-	O
EtOAc	O
in	O
RAW264	O
.	O
7	O
cells	O
was	O
evaluated	O
by	O
measuring	O
the	O
inhibition	O
ratio	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
.	O

Murine	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
was	O
induced	O
by	O
treatment	O
with	O
2	O
.	O
5	O
%	O
dextran	O
sulfate	O
sodium	O
(	O
DSS	O
)	O
.	O

The	O
basic	O
indexes	O
of	O
the	O
mice	O
,	O
including	O
body	O
weight	O
,	O
food	O
intake	O
and	O
hematochezia	O
,	O
were	O
recorded	O
during	O
mice	O
experiments	O
.	O

METHODS	O
:	O
The	O
expression	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
1beta	O
,	O
were	O
measured	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
western	O
blot	O
.	O

Additionally	O
,	O
the	O
influences	O
of	O
Ha	O
-	O
EtOAc	O
on	O
the	O
NF	O
-	O
kappaB	O
and	O
MAPK	O
signaling	O
pathways	O
were	O
determined	O
by	O
western	O
blot	O
and	O
immunofluorescence	O
assays	O
.	O

In	O
addition	O
,	O
the	O
impact	O
of	O
Ha	O
-	O
EtOAc	O
on	O
gut	O
microbiota	O
of	O
mice	O
with	O
UC	O
was	O
detected	O
by	O
16S	O
rDNA	O
sequencing	O
.	O

RESULTS	O
:	O
Ha	O
-	O
EtOAc	O
inhibited	O
the	O
LPS	O
-	O
induced	O
production	O
of	O
NO	O
and	O
decreased	O
the	O
release	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
1beta	O
in	O
RAW264	O
.	O
7	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
pretreatment	O
with	O
Ha	O
-	O
EtOAc	O
could	O
suppress	O
the	O
nuclear	O
translocation	O
of	O
p65	O
and	O
the	O
phosphorylation	O
of	O
Erk1	O
/	O
2	O
,	O
p38	O
and	O
JNK	O
.	O

Ha	O
-	O
EtOAc	O
treatment	O
ameliorated	O
murine	O
UC	O
,	O
as	O
reflected	O
by	O
a	O
reduced	O
body	O
weight	O
loss	O
,	O
improved	O
colon	O
shortening	O
,	O
alleviated	O
mucosal	O
damage	O
and	O
decreased	O
releases	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Furthermore	O
,	O
Ha	O
-	O
EtOAc	O
could	O
modulate	O
the	O
composition	O
of	O
microbial	O
communities	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
demonstrated	O
that	O
Ha	O
-	O
EtOAc	O
exhibited	O
anti	O
-	O
inflammatory	O
effects	O
mainly	O
by	O
suppressing	O
the	O
NF	O
-	O
kappaB	O
and	O
MAPK	O
pathways	O
,	O
and	O
Ha	O
-	O
EtOAc	O
treatment	O
may	O
be	O
a	O
potent	O
therapy	O
for	O
the	O
treatment	O
of	O
ulcerative	O
colitis	O
.	O

Manipulation	O
of	O
microbiota	O
reveals	O
altered	O
callosal	O
myelination	O
and	O
white	O
matter	O
plasticity	O
in	O
a	O
model	O
of	O
Huntington	O
disease	O
.	O

Structural	O
and	O
molecular	O
myelination	O
deficits	O
represent	O
early	O
pathological	O
features	O
of	O
Huntington	O
disease	O
(	O
HD	O
)	O
.	O

Recent	O
evidence	O
from	O
germ	O
-	O
free	O
(	O
GF	O
)	O
animals	O
suggests	O
a	O
role	O
for	O
microbiota	O
-	O
gut	O
-	O
brain	O
bidirectional	O
communication	O
in	O
the	O
regulation	O
of	O
myelination	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
impact	O
of	O
microbiota	O
on	O
myelin	O
plasticity	O
and	O
oligodendroglial	O
population	O
dynamics	O
in	O
the	O
mixed	O
-	O
sex	O
BACHD	O
mouse	O
model	O
of	O
HD	O
.	O

Ultrastructural	O
analysis	O
of	O
myelin	O
in	O
the	O
corpus	O
callosum	O
revealed	O
alterations	O
of	O
myelin	O
thickness	O
in	O
BACHD	O
GF	O
compared	O
to	O
specific	O
-	O
pathogen	O
free	O
(	O
SPF	O
)	O
mice	O
,	O
whereas	O
no	O
differences	O
were	O
observed	O
between	O
wild	O
-	O
type	O
(	O
WT	O
)	O
groups	O
.	O

In	O
contrast	O
,	O
myelin	O
compaction	O
was	O
altered	O
in	O
all	O
groups	O
when	O
compared	O
to	O
WT	O
SPF	O
animals	O
.	O

Levels	O
of	O
myelin	O
-	O
related	O
proteins	O
were	O
generally	O
reduced	O
,	O
and	O
the	O
number	O
of	O
mature	O
oligodendrocytes	O
was	O
decreased	O
in	O
the	O
prefrontal	O
cortex	O
under	O
GF	O
compared	O
to	O
SPF	O
conditions	O
,	O
regardless	O
of	O
genotype	O
.	O

Minor	O
differences	O
in	O
commensal	O
bacteria	O
at	O
the	O
family	O
and	O
genera	O
levels	O
were	O
found	O
in	O
the	O
gut	O
microbiota	O
of	O
BACHD	O
and	O
WT	O
animals	O
housed	O
in	O
standard	O
living	O
conditions	O
.	O

Our	O
findings	O
indicate	O
complex	O
effects	O
of	O
a	O
germ	O
-	O
free	O
status	O
on	O
myelin	O
-	O
related	O
characteristics	O
,	O
and	O
highlight	O
the	O
adaptive	O
properties	O
of	O
myelination	O
as	O
a	O
result	O
of	O
environmental	O
manipulation	O
.	O

Lactobacilli	B-bacteria
Degrade	O
Wheat	O
Amylase	O
Trypsin	O
Inhibitors	O
to	O
Reduce	O
Intestinal	O
Dysfunction	O
Induced	O
by	O
Immunogenic	O
Wheat	O
Proteins	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Wheat	O
-	O
related	O
disorders	O
,	O
a	O
spectrum	O
of	O
conditions	O
induced	O
by	O
the	O
ingestion	O
of	O
gluten	O
-	O
containing	O
cereals	O
,	O
have	O
been	O
increasing	O
in	O
prevalence	O
.	O

Patients	O
with	O
celiac	O
disease	O
have	O
gluten	O
-	O
specific	O
immune	O
responses	O
,	O
but	O
the	O
contribution	O
of	O
non	O
-	O
gluten	O
proteins	O
to	O
symptoms	O
in	O
patients	O
with	O
celiac	O
disease	O
or	O
other	O
wheat	O
-	O
related	O
disorders	O
is	O
controversial	O
.	O

METHODS	O
:	O
C57BL	O
/	O
6	O
(	O
control	O
)	O
,	O
Myd88	O
(	O
-	O
/	O
-	O
,	O
)	O
Ticam1	O
(	O
-	O
/	O
-	O
)	O
,	O
and	O
Il15	O
(	O
-	O
/	O
-	O
)	O
mice	O
were	O
placed	O
on	O
diets	O
that	O
lacked	O
wheat	O
or	O
gluten	O
,	O
with	O
or	O
without	O
wheat	O
amylase	O
trypsin	O
inhibitors	O
(	O
ATIs	O
)	O
,	O
for	O
1	O
week	O
.	O

Small	O
intestine	O
tissues	O
were	O
collected	O
and	O
intestinal	O
intraepithelial	O
lymphocytes	O
(	O
IELs	O
)	O
were	O
measured	O
;	O
we	O
also	O
investigated	O
gut	O
permeability	O
and	O
intestinal	O
transit	O
.	O

Control	O
mice	O
fed	O
ATIs	O
for	O
1	O
week	O
were	O
gavaged	O
daily	O
with	O
Lactobacillus	B-bacteria
strains	I-bacteria
that	O
had	O
high	O
or	O
low	O
ATI	O
-	O
degrading	O
capacity	O
.	O

Nonobese	O
diabetic	O
/	O
DQ8	O
mice	O
were	O
sensitized	O
to	O
gluten	O
and	O
fed	O
an	O
ATI	O
diet	O
,	O
a	O
gluten	O
-	O
containing	O
diet	O
or	O
a	O
diet	O
with	O
ATIs	O
and	O
gluten	O
for	O
2	O
weeks	O
.	O

Mice	O
were	O
also	O
treated	O
with	O
Lactobacillus	B-bacteria
strains	I-bacteria
that	O
had	O
high	O
or	O
low	O
ATI	O
-	O
degrading	O
capacity	O
.	O

Intestinal	O
tissues	O
were	O
collected	O
and	O
IELs	O
,	O
gene	O
expression	O
,	O
gut	O
permeability	O
and	O
intestinal	O
microbiota	O
profiles	O
were	O
measured	O
.	O

RESULTS	O
:	O
In	O
intestinal	O
tissues	O
from	O
control	O
mice	O
,	O
ATIs	O
induced	O
an	O
innate	O
immune	O
response	O
by	O
activation	O
of	O
Toll	O
-	O
like	O
receptor	O
4	O
signaling	O
to	O
MD2	O
and	O
CD14	O
,	O
and	O
caused	O
barrier	O
dysfunction	O
in	O
the	O
absence	O
of	O
mucosal	O
damage	O
.	O

Administration	O
of	O
ATIs	O
to	O
gluten	O
-	O
sensitized	O
mice	O
expressing	O
HLA	O
-	O
DQ8	O
increased	O
intestinal	O
inflammation	O
in	O
response	O
to	O
gluten	O
in	O
the	O
diet	O
.	O

We	O
found	O
ATIs	O
to	O
be	O
degraded	O
by	O
Lactobacillus	B-bacteria
,	O
which	O
reduced	O
the	O
inflammatory	O
effects	O
of	O
ATIs	O
.	O

CONCLUSIONS	O
:	O
ATIs	O
mediate	O
wheat	O
-	O
induced	O
intestinal	O
dysfunction	O
in	O
wild	O
-	O
type	O
mice	O
and	O
exacerbate	O
inflammation	O
to	O
gluten	O
in	O
susceptible	O
mice	O
.	O

Microbiome	O
-	O
modulating	O
strategies	O
,	O
such	O
as	O
administration	O
of	O
bacteria	O
with	O
ATI	O
-	O
degrading	O
capacity	O
,	O
may	O
be	O
effective	O
in	O
patients	O
with	O
wheat	O
-	O
sensitive	O
disorders	O
.	O

Pradoshia	B-bacteria
eiseniae	I-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
a	O
spore	O
-	O
forming	O
member	O
of	O
the	O
family	O
Bacillaceae	B-bacteria
capable	O
of	O
assimilating	O
3	O
-	O
nitropropionic	O
acid	O
,	O
isolated	O
from	O
the	O
anterior	O
gut	O
of	O
the	O
earthworm	O
Eisenia	O
fetida	O
.	O

A	O
Gram	O
-	O
stain	O
-	O
positive	O
,	O
spore	O
-	O
forming	O
bacterium	O
,	O
EAG3	B-bacteria
(	O
T	O
)	O
,	O
capable	O
of	O
growing	O
on	O
3	O
-	O
nitropropionic	O
acid	O
as	O
the	O
sole	O
source	O
of	O
carbon	O
,	O
nitrogen	O
and	O
energy	O
,	O
was	O
isolated	O
from	O
the	O
anterior	O
gut	O
of	O
an	O
earthworm	O
(	O
Eisenia	O
fetida	O
)	O
reared	O
at	O
the	O
Centre	O
of	O
Floriculture	O
and	O
Agribusiness	O
Management	O
of	O
the	O
University	O
of	O
North	O
Bengal	O
at	O
Siliguri	O
(	O
26	O
.	O
7072	O
degrees	O
N	O
,	O
88	O
.	O
3558	O
degrees	O
E	O
)	O
,	O
West	O
Bengal	O
,	O
India	O
.	O

The	O
DNA	O
G	O
+	O
C	O
content	O
of	O
strain	O
EAG3	B-bacteria
(	O
T	O
)	O
was	O
42	O
.	O
5	O
mol	O
%	O
.	O

Strain	O
EAG3	B-bacteria
(	O
T	O
)	O
contained	O
MK	O
-	O
7	O
and	O
MK	O
-	O
8	O
as	O
predominant	O
menaquinones	O
.	O

The	O
predominant	O
polar	O
lipids	O
were	O
phosphatidylglycerol	O
,	O
diphosphatidylglycerol	O
and	O
phosphatidylethanolamine	O
.	O

The	O
major	O
cellular	O
fatty	O
acids	O
were	O
13	O
-	O
methyltetradecanoic	O
acid	O
,	O
(	O
9Z	O
)	O
-	O
9	O
-	O
hexadecen	O
-	O
1	O
-	O
ol	O
,	O
12	O
-	O
methyltetradecanoic	O
acid	O
and	O
14	O
-	O
methylpentadecanoic	O
acid	O
.	O

The	O
draft	O
genome	O
of	O
strain	O
EAG3	B-bacteria
(	O
T	O
)	O
,	O
distributed	O
in	O
57	O
contigs	O
,	O
was	O
found	O
to	O
be	O
3	O
.	O
8	O
Mb	O
.	O

A	O
total	O
of	O
3811	O
potential	O
coding	O
sequences	O
or	O
genes	O
were	O
predicted	O
,	O
including	O
3672	O
protein	O
-	O
coding	O
and	O
108	O
RNA	O
-	O
coding	O
ones	O
together	O
with	O
31	O
pseudogenes	O
.	O

One	O
hundred	O
and	O
thirty	O
-	O
five	O
genes	O
encoded	O
hypothetical	O
proteins	O
with	O
no	O
meaningful	O
homologies	O
with	O
known	O
proteins	O
.	O

The	O
EAG3	B-bacteria
(	O
T	O
)	O
genome	O
encompassed	O
two	O
nitronate	O
monooxygenase	O
and	O
one	O
methylmalonate	O
-	O
semialdehyde	O
dehydrogenase	O
(	O
CoA	O
acylating	O
)	O
homologues	O
.	O

16S	O
rRNA	O
gene	O
sequence	O
-	O
based	O
phylogeny	O
revealed	O
that	O
the	O
closest	O
relative	O
of	O
strain	O
EAG3	B-bacteria
(	O
T	O
)	O
was	O
Bacillus	B-bacteria
methanolicus	I-bacteria
NCIMB	I-bacteria
13113	I-bacteria
(	O
T	O
)	O
(	O
95	O
.	O
7	O
%	O
similarity	O
)	O
.	O

Phylogenetic	O
,	O
physiological	O
and	O
biochemical	O
characteristics	O
differentiated	O
strain	O
EAG3	B-bacteria
(	O
T	O
)	O
from	O
B	B-bacteria
.	I-bacteria
methanolicus	I-bacteria
,	O
as	O
well	O
as	O
from	O
the	O
other	O
close	O
taxonomic	O
relatives	O
Planococcus	B-bacteria
rifietoensis	I-bacteria
M8	I-bacteria
(	O
T	O
)	O
,	O
Bhargavaea	B-bacteria
cecembensis	I-bacteria
DSE10	I-bacteria
(	O
T	O
)	O
,	O
Planomicrobium	B-bacteria
flavidum	I-bacteria
ISL	I-bacteria
-	I-bacteria
41	I-bacteria
(	O
T	O
)	O
and	O
Fermentibacilluspolygoni	B-bacteria
IEB3	I-bacteria
(	O
T	O
)	O
,	O
with	O
which	O
strain	O
EAG3	B-bacteria
(	O
T	O
)	O
had	O
93	O
.	O
3	O
-	O
94	O
.	O
2	O
%	O
16S	O
rRNA	O
gene	O
sequence	O
similarities	O
.	O

The	O
new	O
isolate	O
,	O
therefore	O
,	O
was	O
considered	O
as	O
representing	O
a	O
novel	O
genus	O
of	O
family	O
Bacillaceae	O
,	O
for	O
which	O
the	O
name	O
Pradoshia	B-bacteria
eiseniae	I-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
is	O
proposed	O
,	O
with	O
EAG3	B-bacteria
(	O
T	O
)	O
(	O
=	O
LMG	B-bacteria
30312	I-bacteria
(	O
T	O
)	O
=	O
JCM	B-bacteria
32460	I-bacteria
(	O
T	O
)	O
)	O
as	O
the	O
type	O
strain	O
.	O

Sequential	O
Changes	O
in	O
the	O
Mesenteric	O
Lymph	O
Node	O
Microbiome	O
and	O
Immune	O
Response	O
during	O
Cirrhosis	O
Induction	O
in	O
Rats	O
.	O

Whether	O
the	O
interaction	O
between	O
the	O
gut	O
microbiota	O
and	O
the	O
immune	O
response	O
influences	O
the	O
evolution	O
of	O
cirrhosis	O
is	O
poorly	O
understood	O
.	O

We	O
aimed	O
to	O
investigate	O
modifications	O
of	O
the	O
microbiome	O
and	O
the	O
immune	O
response	O
during	O
the	O
progression	O
of	O
cirrhosis	O
.	O

Rats	O
were	O
treated	O
with	O
carbon	O
tetrachloride	O
(	O
CCl4	O
)	O
to	O
induce	O
cirrhosis	O
.	O

We	O
then	O
assessed	O
microbiome	O
load	O
and	O
composition	O
in	O
stool	O
,	O
ileocecal	O
contents	O
(	O
ICCs	O
)	O
,	O
mesenteric	O
lymph	O
nodes	O
(	O
MLNs	O
)	O
,	O
blood	O
,	O
and	O
ascitic	O
fluids	O
(	O
AFs	O
)	O
at	O
6	O
,	O
8	O
,	O
and	O
10	O
weeks	O
or	O
ascites	O
production	O
and	O
measured	O
cytokine	O
production	O
in	O
MLNs	O
and	O
blood	O
.	O

The	O
microbiome	O
of	O
MLN	O
,	O
blood	O
,	O
and	O
AF	O
showed	O
a	O
distinct	O
composition	O
compared	O
to	O
that	O
of	O
stool	O
and	O
ICCs	O
.	O

Betaproteobacteria	B-bacteria
(	O
Sutterella	B-bacteria
)	O
were	O
found	O
associated	O
with	O
the	O
appearance	O
of	O
a	O
decompensated	O
state	O
of	O
cirrhosis	O
.	O

Microbial	O
load	O
increased	O
and	O
showed	O
a	O
positive	O
correlation	O
with	O
the	O
relative	O
abundance	O
of	O
pathobionts	O
in	O
the	O
MLN	O
of	O
decompensated	O
rats	O
.	O

Among	O
several	O
genera	O
,	O
Escherichia	B-bacteria
and	O
`	O
`	O
Candidatus	B-bacteria
Arthromitus	I-bacteria
'	O
'	O
positively	O
correlated	O
with	O
elevated	O
levels	O
of	O
systemic	O
proinflammatory	O
cytokines	O
.	O

`	O
`	O
Candidatus	O
Arthromitus	O
,	O
'	O
'	O
a	O
segmented	O
filamentous	O
bacteria	O
,	O
was	O
detected	O
in	O
ICC	O
,	O
MLN	O
,	O
and	O
AF	O
samples	O
,	O
suggesting	O
a	O
possible	O
translocation	O
from	O
the	O
gut	O
to	O
the	O
AF	O
through	O
the	O
lymphatic	O
system	O
,	O
whereas	O
Escherichia	B-bacteria
was	O
detected	O
in	O
ICC	O
,	O
MLN	O
,	O
AF	O
,	O
and	O
blood	O
,	O
suggesting	O
a	O
possible	O
translocation	O
from	O
the	O
gut	O
to	O
the	O
AF	O
through	O
the	O
bloodstream	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
microbiome	O
changes	O
in	O
distinct	O
intestinal	O
sites	O
are	O
associated	O
with	O
microbial	O
shifts	O
in	O
the	O
MLNs	O
as	O
well	O
as	O
an	O
increase	O
in	O
cytokine	O
production	O
,	O
providing	O
further	O
evidence	O
of	O
the	O
role	O
the	O
gut	O
-	O
liver	O
-	O
immunity	O
axis	O
plays	O
in	O
the	O
progression	O
of	O
cirrhosis	O
.	O

IMPORTANCE	O
Cirrhosis	O
severity	O
in	O
patients	O
was	O
previously	O
shown	O
to	O
be	O
associated	O
with	O
progressive	O
changes	O
in	O
the	O
fecal	O
microbiome	O
in	O
a	O
longitudinal	O
setting	O
.	O

Recent	O
evidence	O
shows	O
that	O
bacterial	O
translocation	O
from	O
the	O
gut	O
to	O
the	O
extraintestinal	O
sites	O
could	O
play	O
a	O
major	O
role	O
in	O
poor	O
disease	O
outcome	O
and	O
patient	O
survival	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
involving	O
the	O
microbiota	O
in	O
the	O
disease	O
progression	O
are	O
not	O
well	O
understood	O
.	O

Here	O
,	O
using	O
an	O
animal	O
model	O
of	O
cirrhosis	O
in	O
a	O
longitudinal	O
and	O
multibody	O
sites	O
setting	O
,	O
we	O
showed	O
the	O
presence	O
of	O
a	O
distinct	O
composition	O
of	O
the	O
microbiome	O
in	O
mesenteric	O
lymph	O
nodes	O
,	O
blood	O
,	O
and	O
ascitic	O
fluid	O
compared	O
to	O
that	O
in	O
feces	O
and	O
ileocecal	O
content	O
,	O
suggesting	O
compartmentalization	O
of	O
the	O
gut	O
microbiome	O
.	O

We	O
also	O
demonstrate	O
that	O
microbiome	O
changes	O
in	O
intestinal	O
sites	O
are	O
associated	O
with	O
shifts	O
in	O
specific	O
microbial	O
groups	O
in	O
the	O
mesenteric	O
lymph	O
nodes	O
as	O
well	O
as	O
an	O
increase	O
in	O
systemic	O
cytokine	O
production	O
,	O
linking	O
inflammation	O
to	O
decompensated	O
cirrhosis	O
in	O
the	O
gut	O
-	O
liver	O
-	O
immunity	O
axis	O
.	O

Helminth	O
-	O
Based	O
Product	O
and	O
the	O
Microbiome	O
of	O
Mice	O
with	O
Lupus	O
.	O

The	O
hygiene	O
hypothesis	O
claims	O
that	O
the	O
lack	O
of	O
exposure	O
to	O
microorganisms	O
in	O
developed	O
countries	O
correlates	O
with	O
a	O
rise	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
.	O

It	O
was	O
also	O
found	O
that	O
helminths	O
are	O
able	O
to	O
modulate	O
the	O
immune	O
response	O
in	O
hosts	O
in	O
order	O
to	O
survive	O
.	O

Consequently	O
,	O
several	O
successful	O
trials	O
using	O
helminths	O
as	O
a	O
treatment	O
for	O
autoimmune	O
patients	O
have	O
been	O
reported	O
.	O

The	O
helminth	O
derivative	O
,	O
phosphorylcholine	O
(	O
PC	O
)	O
,	O
was	O
discovered	O
as	O
an	O
immunomodulatory	O
molecule	O
.	O

We	O
have	O
recently	O
shown	O
in	O
a	O
murine	O
model	O
that	O
when	O
a	O
conjugate	O
of	O
tuftsin	O
and	O
PC	O
,	O
termed	O
TPC	O
,	O
is	O
prophylactically	O
administered	O
before	O
the	O
onset	O
of	O
glomerulonephritis	O
,	O
it	O
attenuates	O
the	O
development	O
of	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
.	O

The	O
current	O
study	O
aimed	O
to	O
examine	O
the	O
TPC	O
effect	O
on	O
the	O
gut	O
microbiome	O
in	O
a	O
mouse	O
model	O
of	O
lupus	O
.	O

TPC	O
treatment	O
altered	O
the	O
gut	O
composition	O
in	O
the	O
mice	O
with	O
active	O
lupus	O
,	O
in	O
correlation	O
with	O
a	O
significant	O
decrease	O
in	O
glomerulonephritis	O
,	O
followed	O
by	O
an	O
increased	O
level	O
of	O
anti	O
-	O
inflammatory	O
interleukin	O
10	O
(	O
IL	O
-	O
10	O
)	O
,	O
decreased	O
levels	O
of	O
proinflammatory	O
mediators	O
,	O
and	O
expansion	O
of	O
the	O
T	O
regulatory	O
cell	O
population	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
TPC	O
treatment	O
altered	O
the	O
mouse	O
gut	O
microbiome	O
composition	O
,	O
in	O
correlation	O
with	O
a	O
significant	O
decrease	O
in	O
protein	O
secretion	O
and	O
improved	O
disease	O
parameters	O
.	O

The	O
major	O
effects	O
of	O
TPC	O
treatment	O
on	O
the	O
gut	O
microbiome	O
included	O
decreased	O
abundances	O
of	O
Akkermansia	B-bacteria
and	O
increased	O
abundance	O
of	O
several	O
genera	O
,	O
including	O
Turicibacter	B-bacteria
,	O
Bifidobacterium	B-bacteria
,	O
unclassified	O
Mogibacteriaceae	B-bacteria
,	O
unclassified	O
Clostridiaceae	B-bacteria
,	O
Adlercreutzia	B-bacteria
,	O
Allobaculum	B-bacteria
,	O
and	O
Anaeroplasma	B-bacteria
.	O

Overall	O
,	O
our	O
results	O
associate	O
microbial	O
changes	O
with	O
the	O
immunomodulation	O
of	O
glomerulonephritis	O
in	O
mice	O
with	O
lupus	O
.	O

IMPORTANCE	O
Recently	O
,	O
several	O
papers	O
referred	O
to	O
the	O
association	O
of	O
different	O
bacteria	O
with	O
lupus	O
in	O
mice	O
and	O
humans	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
demonstrate	O
the	O
effect	O
of	O
a	O
compound	O
derived	O
from	O
helminths	O
on	O
the	O
induction	O
of	O
remission	O
in	O
mice	O
with	O
lupus	O
and	O
its	O
association	O
with	O
a	O
bacterial	O
change	O
.	O

We	O
show	O
that	O
several	O
genera	O
,	O
including	O
Akkermansia	B-bacteria
,	O
are	O
associated	O
with	O
clinical	O
and	O
serological	O
parameters	O
of	O
lupus	O
,	O
while	O
other	O
genera	O
,	O
including	O
butyrate	O
-	O
producing	O
bacteria	O
,	O
are	O
associated	O
with	O
amelioration	O
of	O
disease	O
following	O
tuftsin	O
and	O
phosphorylcholine	O
treatment	O
.	O

A	O
Combined	O
Metabolomic	O
and	O
Proteomic	O
Study	O
Revealed	O
the	O
Difference	O
in	O
Metabolite	O
and	O
Protein	O
Expression	O
Profiles	O
in	O
Ruminal	O
Tissue	O
From	O
Goats	O
Fed	O
Hay	O
or	O
High	O
-	O
Grain	O
Diets	O
.	O

Currently	O
,	O
knowledge	O
about	O
the	O
impact	O
of	O
high	O
-	O
grain	O
(	O
HG	O
)	O
feeding	O
on	O
metabolite	O
and	O
protein	O
expression	O
profiles	O
in	O
ruminal	O
tissue	O
is	O
limited	O
.	O

In	O
this	O
study	O
,	O
a	O
combination	O
of	O
proteomic	O
and	O
metabolomic	O
approaches	O
was	O
applied	O
to	O
evaluate	O
metabolic	O
and	O
proteomic	O
changes	O
of	O
the	O
rumen	O
epithelium	O
in	O
goats	O
fed	O
a	O
hay	O
diet	O
(	O
Hay	O
)	O
or	O
HG	O
diet	O
.	O

At	O
the	O
metabolome	O
level	O
,	O
results	O
from	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
and	O
PLS	O
-	O
DA	O
revealed	O
clear	O
differences	O
in	O
the	O
biochemical	O
composition	O
of	O
ruminal	O
tissue	O
of	O
the	O
control	O
(	O
Hay	O
)	O
and	O
the	O
grain	O
-	O
fed	O
groups	O
,	O
demonstrating	O
the	O
evident	O
impact	O
of	O
HG	O
feeding	O
on	O
metabolite	O
profile	O
of	O
ruminal	O
epithelial	O
tissues	O
.	O

As	O
compared	O
with	O
the	O
Hay	O
group	O
,	O
HG	O
feeding	O
increased	O
the	O
levels	O
of	O
eight	O
metabolites	O
and	O
decreased	O
the	O
concentrations	O
of	O
seven	O
metabolites	O
in	O
ruminal	O
epithelial	O
tissues	O
.	O

HG	O
feeding	O
mainly	O
altered	O
starch	O
and	O
sucrose	O
metabolism	O
,	O
purine	O
metabolism	O
,	O
glyoxylate	O
and	O
dicarboxylate	O
metabolism	O
,	O
glycerolipid	O
metabolism	O
,	O
pyruvate	O
metabolism	O
,	O
glycolysis	O
or	O
gluconeogenesis	O
,	O
galactose	O
metabolism	O
,	O
glycine	O
,	O
serine	O
and	O
threonine	O
metabolism	O
,	O
and	O
arginine	O
and	O
proline	O
metabolism	O
in	O
ruminal	O
epithelium	O
.	O

At	O
the	O
proteome	O
level	O
,	O
35	O
differentially	O
expressed	O
proteins	O
were	O
found	O
in	O
the	O
rumen	O
epithelium	O
between	O
the	O
Hay	O
and	O
HG	O
groups	O
,	O
with	O
12	O
upregulated	O
and	O
23	O
downregulated	O
proteins	O
.	O

The	O
downregulated	O
proteins	O
were	O
related	O
to	O
fatty	O
acid	O
metabolism	O
,	O
carbohydrate	O
metabolic	O
processes	O
and	O
nucleoside	O
metabolic	O
processes	O
,	O
while	O
most	O
of	O
upregulated	O
proteins	O
were	O
involved	O
in	O
oxidative	O
stress	O
and	O
detoxification	O
.	O

In	O
general	O
,	O
our	O
findings	O
revealed	O
that	O
HG	O
feeding	O
resulted	O
in	O
differential	O
proteomic	O
and	O
metabolomic	O
profiles	O
in	O
the	O
rumen	O
epithelia	O
of	O
goats	O
,	O
which	O
may	O
contribute	O
to	O
better	O
understanding	O
how	O
rumen	O
epithelium	O
adapt	O
to	O
HG	O
feeding	O
.	O

Effect	O
of	O
the	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
strain	I-bacteria
GG	I-bacteria
and	O
tagatose	O
as	O
a	O
synbiotic	O
combination	O
in	O
a	O
dextran	O
sulfate	O
sodium	O
-	O
induced	O
colitis	O
murine	O
model	O
.	O

Synbiotics	O
,	O
a	O
combination	O
of	O
prebiotics	O
and	O
probiotics	O
,	O
produce	O
synergistic	O
effects	O
to	O
promote	O
gastrointestinal	O
health	O
.	O

Herein	O
,	O
we	O
investigated	O
the	O
synbiotic	O
interaction	O
between	O
the	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
strain	I-bacteria
GG	I-bacteria
(	O
LGG	B-bacteria
;	O
a	O
probiotic	O
strain	O
)	O
and	O
tagatose	O
(	O
a	O
prebiotic	O
)	O
in	O
a	O
dextran	O
sulfate	O
sodium	O
(	O
DSS	O
)	O
-	O
induced	O
colitis	O
murine	O
model	O
.	O

Initially	O
,	O
body	O
weight	O
,	O
food	O
intake	O
,	O
and	O
clinical	O
features	O
were	O
dramatically	O
decreased	O
after	O
treatment	O
with	O
DSS	O
,	O
and	O
the	O
addition	O
of	O
LGG	B-bacteria
,	O
tagatose	O
,	O
or	O
both	O
ameliorated	O
these	O
effects	O
.	O

In	O
our	O
pyrosequencing	O
analysis	O
of	O
fecal	O
microbiota	O
,	O
DSS	O
treatment	O
increased	O
the	O
abundance	O
of	O
Proteobacteria	B-bacteria
and	O
decreased	O
that	O
of	O
Firmicutes	B-bacteria
.	O

When	O
LGG	B-bacteria
and	O
tagatose	O
were	O
administered	O
as	O
synbiotics	O
,	O
the	O
gut	O
microbiota	O
composition	O
recovered	O
from	O
the	O
dysbiosis	O
caused	O
by	O
DSS	O
treatment	O
.	O

In	O
particular	O
,	O
the	O
abundance	O
of	O
Bacteroides	B-bacteria
,	O
Lactobacillus	B-bacteria
,	O
and	O
Akkermansia	B-bacteria
was	O
significantly	O
associated	O
with	O
probiotic	O
,	O
prebiotic	O
,	O
and	O
synbiotic	O
treatments	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
LGG	B-bacteria
and	O
tagatose	O
as	O
synbiotics	O
can	O
alleviate	O
colitis	O
,	O
and	O
synbiotics	O
could	O
be	O
applied	O
as	O
dietary	O
supplements	O
in	O
dairy	O
foods	O
such	O
as	O
yogurt	O
and	O
cheese	O
.	O

Nucleic	O
Acid	O
Sensing	O
Perturbation	O
:	O
How	O
Aberrant	O
Recognition	O
of	O
Self	O
-	O
Nucleic	O
Acids	O
May	O
Contribute	O
to	O
Autoimmune	O
and	O
Autoinflammatory	O
Diseases	O
.	O

Bacteria	O
and	O
mammalian	O
cells	O
have	O
developed	O
sophisticated	O
sensing	O
mechanisms	O
to	O
detect	O
and	O
eliminate	O
foreign	O
genetic	O
material	O
or	O
to	O
restrict	O
its	O
expression	O
and	O
replication	O
.	O

Progress	O
has	O
been	O
made	O
in	O
the	O
understanding	O
of	O
these	O
mechanisms	O
,	O
which	O
keep	O
foreign	O
or	O
unwanted	O
nucleic	O
acids	O
in	O
check	O
.	O

The	O
complex	O
of	O
mechanisms	O
involved	O
in	O
RNA	O
and	O
DNA	O
sensing	O
is	O
part	O
of	O
a	O
system	O
which	O
is	O
now	O
appreciated	O
as	O
`	O
`	O
immune	O
sensing	O
of	O
nucleic	O
acids	O
'	O
'	O
or	O
better	O
`	O
`	O
nucleic	O
acid	O
immunity	O
.	O
'	O
'	O

Nucleic	O
acids	O
,	O
which	O
are	O
critical	O
components	O
for	O
inheriting	O
genetic	O
information	O
in	O
all	O
species	O
,	O
including	O
pathogens	O
,	O
are	O
key	O
structures	O
recognized	O
by	O
the	O
innate	O
immune	O
system	O
.	O

However	O
,	O
while	O
nucleic	O
acid	O
recognition	O
is	O
required	O
for	O
host	O
defense	O
against	O
pathogens	O
,	O
there	O
is	O
a	O
potential	O
risk	O
of	O
self	O
-	O
nucleic	O
acids	O
recognition	O
.	O

In	O
fact	O
,	O
besides	O
its	O
essential	O
contribution	O
to	O
antiviral	O
or	O
microbial	O
defense	O
and	O
restriction	O
of	O
endogenous	O
retro	O
elements	O
,	O
deregulation	O
of	O
nucleic	O
acid	O
immunity	O
can	O
also	O
lead	O
to	O
human	O
diseases	O
due	O
to	O
erroneous	O
detection	O
and	O
response	O
to	O
self	O
-	O
nucleic	O
acids	O
,	O
causing	O
sterile	O
inflammation	O
and	O
autoimmunity	O
.	O

In	O
this	O
review	O
we	O
will	O
discuss	O
the	O
roles	O
of	O
nucleic	O
acid	O
receptors	O
in	O
guarding	O
against	O
pathogen	O
invasion	O
,	O
and	O
how	O
the	O
microbial	O
environment	O
could	O
interfere	O
or	O
influence	O
immune	O
sensing	O
in	O
discriminating	O
between	O
self	O
and	O
non	O
-	O
self	O
and	O
how	O
this	O
may	O
contribute	O
to	O
autoimmunity	O
or	O
inflammatory	O
diseases	O
.	O

Intestinal	O
Barrier	O
Function	O
-	O
Non	O
-	O
alcoholic	O
Fatty	O
Liver	O
Disease	O
Interactions	O
and	O
Possible	O
Role	O
of	O
Gut	O
Microbiota	O
.	O

Non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
is	O
a	O
metabolic	O
stress	O
liver	O
injury	O
that	O
is	O
closely	O
related	O
to	O
obesity	O
,	O
insulin	O
resistance	O
,	O
type	O
2	O
diabetes	O
,	O
atherosclerosis	O
,	O
and	O
metabolic	O
syndrome	O
.	O

The	O
pathological	O
features	O
are	O
diffuse	O
hepatic	O
vesicular	O
steatosis	O
,	O
including	O
non	O
-	O
alcoholic	O
steatohepatitis	O
,	O
liver	O
fibrosis	O
,	O
and	O
even	O
liver	O
cancer	O
.	O

A	O
variety	O
of	O
pathological	O
outcomes	O
cause	O
serious	O
harm	O
to	O
human	O
health	O
.	O

At	O
present	O
,	O
an	O
increasing	O
number	O
of	O
researchers	O
are	O
investigating	O
the	O
pathogenesis	O
of	O
NAFLD	O
from	O
the	O
perspective	O
of	O
changes	O
in	O
the	O
function	O
of	O
the	O
intestinal	O
barrier	O
.	O

The	O
physical	O
,	O
chemical	O
,	O
immunological	O
,	O
and	O
microbiological	O
barriers	O
in	O
the	O
intestinal	O
tract	O
constitute	O
the	O
complete	O
intestinal	O
barrier	O
,	O
which	O
plays	O
an	O
important	O
defensive	O
role	O
against	O
the	O
invasion	O
of	O
harmful	O
substances	O
from	O
the	O
intestines	O
.	O

Protecting	O
the	O
function	O
of	O
the	O
intestinal	O
barrier	O
is	O
a	O
new	O
way	O
to	O
treat	O
NAFLD	O
and	O
its	O
related	O
diseases	O
.	O

In	O
this	O
perspective	O
,	O
we	O
summarized	O
the	O
current	O
knowledge	O
of	O
the	O
role	O
of	O
the	O
intestinal	O
barrier	O
in	O
NAFLD	O
.	O

Combating	O
tigecycline	B-bacteria
resistant	I-bacteria
Acinetobacter	I-bacteria
baumannii	I-bacteria
:	O
A	O
leap	O
forward	O
towards	O
multi	O
-	O
epitope	O
based	O
vaccine	O
discovery	O
.	O

Global	O
emergence	O
of	O
Tigecycline	B-bacteria
resistant	I-bacteria
Acinetobacter	I-bacteria
baumannii	I-bacteria
(	O
TRAB	B-bacteria
)	O
is	O
on	O
the	O
horizon	O
and	O
poses	O
a	O
very	O
serious	O
threat	O
to	O
human	O
health	O
.	O

There	O
is	O
a	O
pressing	O
demand	O
for	O
suitable	O
therapeutics	O
against	O
this	O
pathogen	O
,	O
particularly	O
a	O
vaccine	O
to	O
protect	O
against	O
TRAB	O
infections	O
.	O

We	O
present	O
a	O
comprehensive	O
investigation	O
of	O
the	O
complete	O
proteome	O
of	O
a	O
TRAB	B-bacteria
AB031	I-bacteria
strain	I-bacteria
to	O
predict	O
promiscuous	O
antigenic	O
,	O
non	O
-	O
allergenic	O
,	O
virulent	O
B	O
-	O
cell	O
derived	O
T	O
-	O
cell	O
epitopes	O
and	O
formulate	O
a	O
multi	O
-	O
epitope	O
vaccine	O
against	O
the	O
pathogen	O
.	O

We	O
identified	O
epitopes	O
from	O
three	O
proteins	O
:	O
outer	O
membrane	O
protein	O
assembly	O
factor	O
(	O
BamA	O
)	O
,	O
fimbrial	O
biogenesis	O
outer	O
membrane	O
usher	O
protein	O
(	O
FimD	O
)	O
and	O
type	O
IV	O
secretion	O
protein	O
(	O
Rhs	O
)	O
that	O
are	O
appropriate	O
for	O
vaccine	O
design	O
.	O

These	O
proteins	O
constitute	O
the	O
core	O
proteome	O
of	O
the	O
pathogen	O
,	O
are	O
essential	O
,	O
localized	O
at	O
the	O
pathogen	O
surface	O
,	O
non	O
-	O
homologous	O
to	O
humans	O
,	O
mice	O
and	O
to	O
the	O
beneficial	O
probiotic	O
bacteria	O
that	O
reside	O
the	O
human	O
gut	O
.	O

Moreover	O
,	O
these	O
proteins	O
are	O
ideal	O
candidates	O
for	O
experimental	O
investigation	O
as	O
they	O
have	O
favorable	O
physicochemical	O
properties	O
and	O
have	O
strong	O
cellular	O
interacting	O
networks	O
.	O

The	O
predicted	O
epitopes	O
:	O
FPLNDKPGD	O
(	O
BamA	O
)	O
,	O
FVHAEEAAA	O
(	O
FimD	O
)	O
and	O
YVVAGTAAA	O
(	O
Rhs	O
)	O
have	O
exo	O
-	O
membrane	O
topology	O
for	O
efficient	O
recognition	O
of	O
the	O
host	O
immune	O
system	O
and	O
high	O
affinity	O
for	O
the	O
most	O
prevalent	O
allele	O
in	O
human	O
populations	O
,	O
the	O
DRB	O
*	O
0101	O
.	O

These	O
epitopes	O
were	O
linked	O
and	O
attached	O
to	O
an	O
adjuvant	O
to	O
enhance	O
its	O
antigenicity	O
.	O

The	O
multi	O
-	O
epitope	O
vaccine	O
-	O
construct	O
was	O
docked	O
with	O
the	O
TLR4	O
receptor	O
to	O
assess	O
its	O
affinity	O
for	O
the	O
protein	O
and	O
thus	O
its	O
presentation	O
to	O
the	O
host	O
immune	O
system	O
.	O

Docking	O
results	O
were	O
validated	O
through	O
molecular	O
dynamics	O
simulations	O
and	O
binding	O
free	O
energies	O
were	O
calculated	O
using	O
the	O
molecular	O
mechanics	O
/	O
generalized	O
Born	O
(	O
MM	O
-	O
GBSA	O
)	O
method	O
.	O

In	O
conclusion	O
,	O
we	O
expect	O
the	O
designed	O
chimeric	O
vaccine	O
is	O
highly	O
likely	O
to	O
be	O
effective	O
against	O
infections	O
caused	O
by	O
TRAB	O
.	O

Role	O
of	O
putative	O
virulence	O
traits	O
of	O
Campylobacter	B-bacteria
jejuni	I-bacteria
in	O
regulating	O
differential	O
host	O
immune	O
responses	O
.	O

Among	O
the	O
major	O
enteric	O
pathogens	O
,	O
Campylobacter	B-bacteria
jejuni	I-bacteria
is	O
considered	O
an	O
important	O
source	O
of	O
diarrheal	O
illness	O
in	O
humans	O
.	O

In	O
contrast	O
to	O
the	O
acute	O
gastroenteritis	O
in	O
humans	O
,	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
exhibits	O
prolonged	O
cecal	O
colonization	O
at	O
a	O
high	O
level	O
with	O
little	O
or	O
no	O
pathology	O
in	O
chickens	O
.	O

Although	O
several	O
known	O
virulence	O
determinants	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
a	O
higher	O
degree	O
of	O
pathogenesis	O
in	O
humans	O
,	O
to	O
date	O
,	O
little	O
is	O
known	O
about	O
their	O
functions	O
in	O
the	O
persistent	O
colonization	O
of	O
chickens	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
assess	O
the	O
role	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
in	O
imparting	O
differential	O
host	O
immune	O
responses	O
in	O
human	O
and	O
chicken	O
cells	O
.	O

Based	O
on	O
the	O
abundance	O
of	O
major	O
genes	O
encoding	O
virulence	O
factors	O
(	O
GEVFs	O
)	O
,	O
we	O
used	O
a	O
particular	O
isolate	O
that	O
harbors	O
the	O
cadF	O
,	O
flaA	O
,	O
peb1	O
,	O
racR	O
,	O
ciaB	O
,	O
cdtB	O
,	O
and	O
hcp	O
genes	O
.	O

This	O
study	O
showed	O
that	O
hypervirulent	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
isolate	I-bacteria
that	O
encodes	O
a	O
functional	O
type	O
VI	O
secretion	O
system	O
(	O
T6SS	O
)	O
has	O
a	O
greater	O
ability	O
to	O
invade	O
and	O
create	O
characteristic	O
`	O
`	O
attaching	O
and	O
effacing	O
'	O
'	O
lesions	O
in	O
human	O
INT407	O
compared	O
to	O
primary	O
chicken	O
embryo	O
intestinal	O
cells	O
(	O
CEICs	O
)	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
the	O
higher	O
bacterial	O
invasion	O
in	O
human	O
INT407	O
triggered	O
higher	O
levels	O
of	O
expression	O
of	O
major	O
proinflammatory	O
cytokines	O
,	O
such	O
as	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
6	O
,	O
and	O
significant	O
downregulation	O
of	O
IL	O
-	O
17A	O
gene	O
expression	O
(	O
P	O
<	O
/	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
findings	O
of	O
the	O
present	O
study	O
suggest	O
that	O
the	O
enhanced	O
ability	O
of	O
C	B-bacteria
.	I-bacteria
jejuni	I-bacteria
to	O
invade	O
human	O
cells	O
is	O
tightly	O
regulated	O
by	O
proinflammatory	O
cytokines	O
in	O
the	O
gut	O
and	O
possibly	O
holds	O
the	O
keys	O
to	O
the	O
observed	O
differences	O
in	O
pathogenesis	O
between	O
human	O
and	O
chicken	O
cells	O
.	O

Alterations	O
in	O
intestinal	O
microbiota	O
of	O
colorectal	O
cancer	O
patients	O
receiving	O
radical	O
surgery	O
combined	O
with	O
adjuvant	O
CapeOx	O
therapy	O
.	O

An	O
intricate	O
relationship	O
exists	O
and	O
interactions	O
occur	O
between	O
gut	O
microbiota	O
and	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

Radical	O
surgery	O
combined	O
with	O
adjuvant	O
chemotherapy	O
(	O
AC	O
)	O
serves	O
as	O
the	O
mainstream	O
therapeutic	O
scheme	O
for	O
most	O
CRC	O
patients	O
.	O

The	O
current	O
research	O
was	O
conducted	O
to	O
assess	O
the	O
effect	O
of	O
surgery	O
or	O
chemotherapy	O
on	O
gut	O
microbiota	O
.	O

Forty	O
-	O
three	O
CRC	O
patients	O
who	O
received	O
radical	O
surgery	O
and	O
AC	O
were	O
enrolled	O
.	O

Fecal	O
samples	O
were	O
collected	O
preoperatively	O
,	O
postoperatively	O
,	O
and	O
after	O
the	O
first	O
to	O
fifth	O
cycles	O
of	O
postoperative	O
chemotherapy	O
.	O

The	O
microbial	O
community	O
of	O
each	O
sample	O
was	O
analyzed	O
using	O
high	O
throughput	O
16S	O
rRNA	O
amplicon	O
sequencing	O
.	O

Compared	O
with	O
preoperative	O
samples	O
,	O
fecal	O
samples	O
collected	O
postoperatively	O
exhibited	O
a	O
significant	O
decrease	O
of	O
obligate	O
anaerobes	O
,	O
tumor	O
-	O
related	O
bacteria	O
,	O
and	O
butyric	O
acid	O
-	O
producing	O
bacteria	O
.	O

However	O
,	O
a	O
significant	O
increase	O
of	O
some	O
conditional	O
pathogens	O
was	O
observed	O
.	O

In	O
addition	O
,	O
the	O
AC	O
regimen	O
(	O
CapeOx	O
)	O
was	O
found	O
to	O
alter	O
intestinal	O
microbiota	O
dramatically	O
.	O

In	O
particular	O
,	O
several	O
changes	O
were	O
observed	O
after	O
chemotherapy	O
including	O
an	O
increase	O
of	O
pathogenic	O
bacteria	O
,	O
the	O
`	O
`	O
rebound	O
effect	O
'	O
'	O
of	O
chemotherapy	O
-	O
adapted	O
bacteria	O
,	O
the	O
shift	O
of	O
lactate	O
-	O
utilizing	O
microbiota	O
from	O
Veillonella	B-bacteria
to	O
Butyricimonas	B-bacteria
and	O
Butyricicoccus	B-bacteria
,	O
as	O
well	O
as	O
the	O
decrease	O
of	O
probiotics	O
.	O

Both	O
radical	O
surgery	O
and	O
CapeOx	O
chemotherapy	O
exert	O
a	O
non	O
-	O
negligible	O
effect	O
on	O
the	O
gut	O
microbiota	O
of	O
CRC	O
patients	O
.	O

Microbiota	O
-	O
based	O
intervention	O
may	O
be	O
beneficial	O
for	O
patients	O
during	O
postoperative	O
clinical	O
management	O
.	O

Biosolids	O
and	O
Tillage	O
Practices	O
Influence	O
Soil	O
Bacterial	O
Communities	O
in	O
Dryland	O
Wheat	O
.	O

Class	O
B	O
biosolids	O
are	O
used	O
in	O
dryland	O
wheat	O
(	O
Triticum	O
aestivum	O
L	O
.	O
)	O
production	O
in	O
eastern	O
Washington	O
as	O
a	O
source	O
of	O
nutrients	O
and	O
to	O
increase	O
soil	O
organic	O
matter	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
effects	O
on	O
bacterial	O
communities	O
and	O
potential	O
for	O
harboring	O
human	O
pathogens	O
.	O

Moreover	O
,	O
conservation	O
tillage	O
is	O
promoted	O
to	O
reduce	O
erosion	O
and	O
soil	O
degradation	O
.	O

We	O
explored	O
the	O
impacts	O
of	O
biosolids	O
or	O
synthetic	O
fertilizer	O
in	O
combination	O
with	O
traditional	O
(	O
conventional	O
)	O
or	O
conservation	O
tillage	O
on	O
soil	O
bacterial	O
communities	O
.	O

Bacterial	O
communities	O
were	O
characterized	O
from	O
fresh	O
biosolids	O
,	O
biosolid	O
aggregates	O
embedded	O
in	O
soil	O
,	O
and	O
soil	O
after	O
a	O
second	O
application	O
of	O
biosolids	O
using	O
high	O
-	O
throughput	O
amplicon	O
sequencing	O
.	O

Biosolid	O
application	O
significantly	O
affected	O
bacterial	O
communities	O
,	O
even	O
4	O
years	O
after	O
their	O
application	O
.	O

Bacteria	O
in	O
the	O
families	O
Clostridiaceae	B-bacteria
,	O
Norcardiaceae	B-bacteria
,	O
Anaerolinaceae	B-bacteria
,	O
Dietziaceae	B-bacteria
,	O
and	O
Planococcaceae	B-bacteria
were	O
more	O
abundant	O
in	O
fresh	O
biosolids	O
,	O
biosolid	O
aggregates	O
,	O
and	O
soils	O
treated	O
with	O
biosolids	O
than	O
in	O
synthetically	O
fertilized	O
soils	O
.	O

Taxa	O
identified	O
as	O
Turcibacte	B-bacteria
,	O
Dietzia	B-bacteria
,	O
Clostridiaceae	B-bacteria
,	O
and	O
Anaerolineaceae	B-bacteria
were	O
highly	O
abundant	O
in	O
biosolid	O
aggregates	O
in	O
the	O
soil	O
and	O
likely	O
originated	O
from	O
the	O
biosolids	O
.	O

In	O
contrast	O
,	O
Oxalobacteriaceae	B-bacteria
,	O
Streptomyceteaceae	B-bacteria
,	O
Janthinobacterium	B-bacteria
,	O
Pseudomonas	B-bacteria
,	O
Kribbella	B-bacteria
,	O
and	O
Bacillus	B-bacteria
were	O
rare	O
in	O
the	O
fresh	O
biosolids	O
,	O
but	O
relatively	O
abundant	O
in	O
biosolid	O
aggregates	O
in	O
the	O
soil	O
,	O
and	O
probably	O
originated	O
from	O
the	O
soil	O
to	O
colonize	O
the	O
substrate	O
.	O

However	O
,	O
tillage	O
had	O
relatively	O
minor	O
effects	O
on	O
bacterial	O
communities	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
taxa	O
differing	O
in	O
relative	O
abundance	O
between	O
traditional	O
and	O
conventional	O
tillage	O
.	O

Although	O
biosolid	O
-	O
associated	O
bacteria	O
persisted	O
in	O
soil	O
,	O
potentially	O
pathogenic	O
taxa	O
were	O
extremely	O
rare	O
and	O
no	O
toxin	O
genes	O
for	O
key	O
groups	O
(	O
Salmonella	B-bacteria
,	O
Clostridium	B-bacteria
)	O
were	O
detectable	O
,	O
suggesting	O
that	O
although	O
fecal	O
contamination	O
was	O
apparent	O
via	O
indicator	O
taxa	O
,	O
pathogen	O
populations	O
had	O
declined	O
to	O
low	O
levels	O
.	O

Thus	O
,	O
biosolid	O
amendments	O
had	O
profound	O
effects	O
on	O
soil	O
bacterial	O
communities	O
both	O
by	O
introducing	O
gut	O
-	O
or	O
digester	O
-	O
derived	O
bacteria	O
and	O
by	O
enriching	O
potentially	O
beneficial	O
indigenous	O
soil	O
populations	O
.	O

The	O
human	O
gut	O
Firmicute	B-bacteria
Roseburia	B-bacteria
intestinalis	I-bacteria
is	O
a	O
primary	O
degrader	O
of	O
dietary	O
beta	O
-	O
mannans	O
.	O

beta	O
-	O
Mannans	O
are	O
plant	O
cell	O
wall	O
polysaccharides	O
that	O
are	O
commonly	O
found	O
in	O
human	O
diets	O
.	O

However	O
,	O
a	O
mechanistic	O
understanding	O
into	O
the	O
key	O
populations	O
that	O
degrade	O
this	O
glycan	O
is	O
absent	O
,	O
especially	O
for	O
the	O
dominant	O
Firmicutes	B-bacteria
phylum	I-bacteria
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
prominent	O
butyrate	O
-	O
producing	O
Firmicute	O
Roseburia	O
intestinalis	O
expresses	O
two	O
loci	O
conferring	O
metabolism	O
of	O
beta	O
-	O
mannans	O
.	O

We	O
combine	O
multi	O
-	O
'	O
'	O
omic	O
'	O
'	O
analyses	O
and	O
detailed	O
biochemical	O
studies	O
to	O
comprehensively	O
characterize	O
loci	O
-	O
encoded	O
proteins	O
that	O
are	O
involved	O
in	O
beta	O
-	O
mannan	O
capturing	O
,	O
importation	O
,	O
de	O
-	O
branching	O
and	O
degradation	O
into	O
monosaccharides	O
.	O

In	O
mixed	O
cultures	O
,	O
R	B-bacteria
.	I-bacteria
intestinalis	I-bacteria
shares	O
the	O
available	O
beta	O
-	O
mannan	O
with	O
Bacteroides	B-bacteria
ovatus	I-bacteria
,	O
demonstrating	O
that	O
the	O
apparatus	O
allows	O
coexistence	O
in	O
a	O
competitive	O
environment	O
.	O

In	O
murine	O
experiments	O
,	O
beta	O
-	O
mannan	O
selectively	O
promotes	O
beneficial	O
gut	O
bacteria	O
,	O
exemplified	O
by	O
increased	O
R	B-bacteria
.	I-bacteria
intestinalis	I-bacteria
,	O
and	O
reduction	O
of	O
mucus	O
-	O
degraders	O
.	O

Our	O
findings	O
highlight	O
that	O
R	B-bacteria
.	I-bacteria
intestinalis	I-bacteria
is	O
a	O
primary	O
degrader	O
of	O
this	O
dietary	O
fiber	O
and	O
that	O
this	O
metabolic	O
capacity	O
could	O
be	O
exploited	O
to	O
selectively	O
promote	O
key	O
members	O
of	O
the	O
healthy	O
microbiota	O
using	O
beta	O
-	O
mannan	O
-	O
based	O
therapeutic	O
interventions	O
.	O

Response	O
to	O
the	O
letter	O
:	O
Identification	O
of	O
trimethylamine	O
N	O
-	O
oxide	O
(	O
TMAO	O
)	O
-	O
producer	O
phenotype	O
is	O
interesting	O
,	O
but	O
is	O
it	O
helpful	O
?	O

In	O
-	O
feed	O
resin	O
acids	O
reduce	O
matrix	O
metalloproteinase	O
activity	O
in	O
the	O
ileal	O
mucosa	O
of	O
healthy	O
broilers	O
without	O
inducing	O
major	O
effects	O
on	O
the	O
gut	O
microbiota	O
.	O

The	O
chicken	O
gut	O
is	O
constantly	O
exposed	O
to	O
harmful	O
molecules	O
and	O
microorganisms	O
which	O
endanger	O
the	O
integrity	O
of	O
the	O
intestinal	O
wall	O
.	O

Strengthening	O
intestinal	O
mucosal	O
integrity	O
is	O
a	O
key	O
target	O
for	O
feed	O
additives	O
that	O
aim	O
to	O
promote	O
intestinal	O
health	O
in	O
broilers	O
.	O

Recently	O
,	O
dietary	O
inclusion	O
of	O
resin	O
-	O
based	O
products	O
has	O
been	O
shown	O
to	O
increase	O
broiler	O
performance	O
.	O

However	O
,	O
the	O
mode	O
of	O
action	O
is	O
still	O
largely	O
unexplored	O
.	O

Coniferous	O
resin	O
acids	O
are	O
known	O
for	O
their	O
anti	O
-	O
microbial	O
,	O
anti	O
-	O
inflammatory	O
and	O
wound	O
-	O
healing	O
properties	O
,	O
all	O
properties	O
that	O
might	O
support	O
broiler	O
intestinal	O
health	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
effect	O
of	O
pure	O
resin	O
acids	O
on	O
broiler	O
intestinal	O
health	O
was	O
explored	O
.	O

Ross	O
308	O
broilers	O
were	O
fed	O
a	O
diet	O
supplemented	O
with	O
coniferous	O
resin	O
acids	O
for	O
22	O
days	O
,	O
after	O
which	O
the	O
effect	O
on	O
both	O
the	O
intestinal	O
microbiota	O
as	O
well	O
as	O
on	O
the	O
intestinal	O
tissue	O
morphology	O
and	O
activity	O
of	O
host	O
collagenases	O
was	O
assessed	O
.	O

Dietary	O
inclusion	O
of	O
resin	O
acids	O
did	O
not	O
alter	O
the	O
morphology	O
of	O
the	O
healthy	O
intestine	O
and	O
only	O
minor	O
effects	O
on	O
the	O
intestinal	O
microbiota	O
were	O
observed	O
.	O

However	O
,	O
resin	O
acids	O
-	O
supplementation	O
reduced	O
both	O
duodenal	O
inflammatory	O
T	O
cell	O
infiltration	O
and	O
small	O
intestinal	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
activity	O
towards	O
collagen	O
type	O
I	O
and	O
type	O
IV	O
.	O

Reduced	O
breakdown	O
of	O
collagen	O
type	O
I	O
and	O
IV	O
might	O
indicate	O
a	O
protective	O
effect	O
of	O
resin	O
acids	O
on	O
intestinal	O
barrier	O
integrity	O
by	O
preservation	O
of	O
the	O
basal	O
membrane	O
and	O
the	O
extracellular	O
matrix	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
explore	O
the	O
protective	O
effects	O
of	O
resin	O
acids	O
on	O
broiler	O
intestinal	O
health	O
under	O
sub	O
-	O
optimal	O
conditions	O
and	O
to	O
elaborate	O
our	O
knowledge	O
on	O
the	O
mechanisms	O
behind	O
the	O
observed	O
effects	O
.	O

Resistance	O
towards	O
metronidazole	O
in	O
Blastocystis	B-bacteria
sp	I-bacteria
.	I-bacteria
:	O
A	O
pathogenic	O
consequence	O
.	O

Blastocsytis	O
sp	O
.	O
is	O
a	O
protozoan	O
parasite	O
that	O
has	O
been	O
linked	O
to	O
common	O
gastrointestinal	O
illnesses	O
.	O

Metronidazole	O
,	O
the	O
first	O
line	O
therapy	O
,	O
was	O
reported	O
to	O
show	O
frequent	O
inefficacy	O
.	O

Previously	O
,	O
Blastocystis	O
sp	O
.	O
isolated	O
from	O
different	O
population	O
showed	O
varying	O
metronidazole	O
resistance	O
.	O

However	O
,	O
the	O
effect	O
of	O
metronidazole	O
treatment	O
on	O
pathogenic	O
potentials	O
of	O
Blastocystis	O
sp	O
.	O
isolated	O
from	O
different	O
populations	O
,	O
which	O
is	O
known	O
to	O
have	O
different	O
gut	O
environment	O
,	O
is	O
unclear	O
.	O

This	O
study	O
investigates	O
the	O
in	O
vitro	O
effect	O
of	O
metronidazole	O
on	O
the	O
pathogenic	O
potentials	O
of	O
Blastocystis	O
sp	O
.	O
isolated	O
from	O
urban	O
and	O
orang	O
asli	O
individuals	O
.	O

Blastocystis	O
sp	O
.	O
ST	O
3	O
isolated	O
from	O
symptomatic	O
and	O
asymptomatic	O
individuals	O
were	O
treated	O
with	O
a	O
range	O
of	O
metronidazole	O
concentration	O
.	O

The	O
parasites	O
'	O
growth	O
characteristics	O
,	O
apoptotic	O
rate	O
,	O
specific	O
protease	O
activity	O
and	O
the	O
ability	O
to	O
proliferate	O
cancer	O
cells	O
were	O
analyzed	O
upon	O
treatment	O
with	O
0	O
.	O
001	O
mg	O
/	O
l	O
metronidazole	O
.	O

The	O
study	O
demonstrates	O
that	O
Blastocystis	O
sp	O
.	O
isolates	O
showed	O
increase	O
in	O
the	O
parasite	O
numbers	O
especially	O
the	O
amoebic	O
forms	O
(	O
only	O
in	O
urban	O
isolates	O
)	O
after	O
treating	O
with	O
metronidazole	O
at	O
the	O
concentration	O
of	O
0	O
.	O
001	O
mg	O
/	O
ml	O
.	O

High	O
number	O
of	O
cells	O
in	O
post	O
-	O
treated	O
isolates	O
coincided	O
with	O
increase	O
of	O
apoptosis	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
cysteine	O
protease	O
of	O
Blastocystis	O
sp	O
.	O
isolates	O
upon	O
treatment	O
despite	O
the	O
initial	O
predominance	O
of	O
serine	O
protease	O
in	O
asymptomatic	O
isolates	O
.	O

Metronidazole	O
resistant	O
Blastocystis	O
sp	O
.	O
also	O
showed	O
significant	O
increase	O
in	O
cancer	O
cell	O
proliferation	O
.	O

Resistance	O
to	O
metronidazole	O
did	O
not	O
show	O
significant	O
different	O
influence	O
on	O
the	O
pathogenicity	O
between	O
Blastocystis	O
sp	O
.	O
isolated	O
from	O
urban	O
and	O
orang	O
asli	O
individual	O
.	O

However	O
,	O
an	O
increase	O
in	O
parasite	O
numbers	O
,	O
higher	O
amoebic	O
forms	O
,	O
cysteine	O
protease	O
and	O
ability	O
to	O
proliferate	O
cancer	O
cells	O
implicates	O
a	O
pathogenic	O
role	O
.	O

The	O
study	O
provides	O
evidence	O
for	O
the	O
first	O
time	O
,	O
the	O
effect	O
of	O
metronidazole	O
towards	O
enhancing	O
pathogenic	O
potentials	O
in	O
Blastocystis	O
sp	O
.	O
when	O
isolated	O
from	O
different	O
gut	O
environment	O
.	O

This	O
necessitates	O
the	O
need	O
for	O
reassessment	O
of	O
metronidazole	O
treatment	O
modalities	O
.	O

Ecological	O
and	O
Evolutionary	O
Consequences	O
of	O
Viral	O
Plasticity	O
.	O

Viruses	O
use	O
the	O
host	O
machinery	O
to	O
replicate	O
,	O
and	O
their	O
performance	O
thus	O
depends	O
on	O
the	O
host	O
'	O
s	O
physiological	O
state	O
.	O

For	O
bacteriophages	O
,	O
this	O
link	O
between	O
host	O
and	O
viral	O
performance	O
has	O
been	O
characterized	O
empirically	O
and	O
with	O
intracellular	O
theories	O
.	O

Such	O
theories	O
are	O
too	O
detailed	O
to	O
be	O
included	O
in	O
models	O
that	O
study	O
host	O
-	O
phage	O
interactions	O
in	O
the	O
long	O
term	O
,	O
which	O
hinders	O
our	O
understanding	O
of	O
systems	O
that	O
range	O
from	O
pathogens	O
infecting	O
gut	O
bacteria	O
to	O
marine	O
phage	O
shaping	O
the	O
oceans	O
.	O

Here	O
,	O
we	O
combined	O
data	O
and	O
models	O
to	O
study	O
the	O
short	O
-	O
and	O
long	O
-	O
term	O
consequences	O
that	O
host	O
physiology	O
has	O
on	O
bacteriophage	O
performance	O
.	O

We	O
compiled	O
data	O
showing	O
the	O
dependence	O
of	O
lytic	O
-	O
phage	O
traits	O
on	O
host	O
growth	O
rate	O
(	O
referred	O
to	O
as	O
viral	O
phenotypic	O
plasticity	O
)	O
to	O
deduce	O
simple	O
expressions	O
that	O
represent	O
such	O
plasticity	O
.	O

Including	O
these	O
expressions	O
in	O
a	O
standard	O
host	O
-	O
phage	O
model	O
allowed	O
us	O
to	O
understand	O
mechanistically	O
how	O
viral	O
plasticity	O
affects	O
emergent	O
evolutionary	O
strategies	O
and	O
the	O
population	O
dynamics	O
associated	O
with	O
different	O
environmental	O
scenarios	O
including	O
,	O
for	O
example	O
,	O
nutrient	O
pulses	O
or	O
host	O
starvation	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
plasticity	O
on	O
the	O
offspring	O
number	O
drives	O
the	O
phage	O
ecological	O
and	O
evolutionary	O
dynamics	O
by	O
reinforcing	O
feedbacks	O
between	O
host	O
,	O
virus	O
,	O
and	O
environment	O
.	O

Standard	O
models	O
neglect	O
viral	O
plasticity	O
,	O
which	O
therefore	O
handicaps	O
their	O
predictive	O
ability	O
in	O
realistic	O
scenarios	O
.	O

Our	O
results	O
highlight	O
the	O
importance	O
of	O
viral	O
plasticity	O
to	O
unravel	O
host	O
-	O
phage	O
interactions	O
and	O
the	O
need	O
of	O
laboratory	O
and	O
field	O
experiments	O
to	O
characterize	O
viral	O
plastic	O
responses	O
across	O
systems	O
.	O

Gut	O
microbiota	O
metabolizes	O
nabumetone	O
in	O
vitro	O
:	O
Consequences	O
for	O
its	O
bioavailability	O
in	O
vivo	O
in	O
the	O
rodents	O
with	O
altered	O
gut	O
microbiome	O
.	O

1	O
.	O

The	O
underlying	O
microbial	O
metabolic	O
activity	O
toward	O
xenobiotics	O
is	O
among	O
the	O
least	O
explored	O
factors	O
contributing	O
to	O
the	O
inter	O
-	O
individual	O
variability	O
in	O
drug	O
response	O
.	O

2	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
effect	O
of	O
microbiota	O
on	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
nabumetone	O
.	O

3	O
.	O

First	O
,	O
we	O
cultivated	O
the	O
drug	O
with	O
the	O
selected	O
gut	O
commensal	O
and	O
probiotic	O
bacteria	O
under	O
both	O
aerobic	O
and	O
anaerobic	O
conditions	O
and	O
analyzed	O
its	O
metabolites	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
with	O
UV	O
detection	O
.	O

To	O
analyze	O
the	O
effect	O
of	O
microbiota	O
on	O
nabumetone	O
pharmacokinetics	O
in	O
vivo	O
,	O
we	O
administered	O
a	O
single	O
oral	O
dose	O
of	O
nabumetone	O
to	O
rodents	O
with	O
intentionally	O
altered	O
gut	O
microbiome	O
-	O
either	O
rats	O
treated	O
for	O
three	O
days	O
with	O
the	O
antibiotic	O
imipenem	O
or	O
to	O
germ	O
-	O
free	O
mice	O
.	O

Plasma	O
levels	O
of	O
its	O
main	O
active	O
metabolite	O
6	O
methoxy	O
-	O
2	O
-	O
naphthylacetic	O
acid	O
(	O
6	O
-	O
MNA	O
)	O
were	O
analyzed	O
at	O
pre	O
-	O
specified	O
time	O
intervals	O
using	O
HPLC	O
with	O
UV	O
/	O
fluorescence	O
detection	O
.	O

4	O
.	O

We	O
found	O
that	O
nabumetone	O
is	O
metabolized	O
by	O
bacteria	O
to	O
its	O
non	O
-	O
active	O
metabolites	O
and	O
that	O
this	O
effect	O
is	O
stronger	O
under	O
anaerobic	O
conditions	O
.	O

Although	O
in	O
vivo	O
,	O
none	O
of	O
the	O
pharmacokinetic	O
parameters	O
of	O
6	O
-	O
MNA	O
was	O
significantly	O
altered	O
,	O
there	O
was	O
a	O
clear	O
trend	O
towards	O
an	O
increase	O
of	O
the	O
AUC	O
,	O
Cmax	O
and	O
t1	O
/	O
2	O
in	O
rats	O
with	O
reduced	O
microbiota	O
and	O
germ	O
-	O
free	O
mice	O
.	O

Metabolic	O
and	O
Gut	O
Microbial	O
Characterization	O
of	O
Obesity	O
-	O
Prone	O
Mice	O
under	O
a	O
High	O
-	O
Fat	O
Diet	O
.	O

Obesity	O
is	O
characterized	O
with	O
high	O
heterogeneity	O
due	O
to	O
genetic	O
abnormality	O
,	O
energy	O
imbalance	O
,	O
gut	O
dysbiosis	O
,	O
or	O
a	O
combination	O
of	O
all	O
three	O
.	O

Obesity	O
-	O
prone	O
(	O
OP	O
)	O
and	O
-	O
resistant	O
(	O
OR	O
)	O
phenotypes	O
are	O
frequently	O
observed	O
in	O
rodents	O
,	O
even	O
in	O
those	O
given	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
are	O
largely	O
unknown	O
.	O

Male	O
C57BL	O
/	O
6J	O
mice	O
were	O
fed	O
with	O
chow	O
or	O
a	O
HFD	O
for	O
8	O
weeks	O
.	O

OP	O
and	O
OR	O
mice	O
were	O
defined	O
based	O
on	O
body	O
weight	O
gain	O
,	O
and	O
integrated	O
serum	O
metabolic	O
and	O
gut	O
microbial	O
profiling	O
was	O
performed	O
by	O
the	O
gas	O
chromatography	O
-	O
mass	O
spectroscopy	O
-	O
based	O
metabolomic	O
sequencing	O
and	O
pyrosequencing	O
of	O
16S	O
rDNA	O
of	O
cecum	O
contents	O
.	O

A	O
total	O
of	O
60	O
differential	O
metabolites	O
were	O
identified	O
in	O
comparisons	O
among	O
Con	O
,	O
OP	O
,	O
and	O
OR	O
groups	O
,	O
in	O
which	O
27	O
were	O
OP	O
-	O
related	O
.	O

These	O
differential	O
metabolites	O
are	O
mainly	O
involved	O
in	O
glycolysis	O
,	O
lipids	O
,	O
and	O
amino	O
acids	O
metabolism	O
and	O
the	O
TCA	O
cycle	O
.	O

Meanwhile	O
,	O
OP	O
mice	O
had	O
a	O
distinct	O
profile	O
in	O
gut	O
microbiota	O
compared	O
to	O
those	O
of	O
OR	O
or	O
Con	O
mice	O
,	O
which	O
showed	O
a	O
reduced	O
ratio	O
of	O
Firmicutes	B-bacteria
to	O
Bacteroidetes	B-bacteria
and	O
increased	O
Proteobacteria	B-bacteria
.	O

Moreover	O
,	O
the	O
gut	O
microbial	O
alteration	O
of	O
OP	O
mice	O
was	O
correlated	O
with	O
the	O
changes	O
of	O
the	O
key	O
serum	O
metabolites	O
.	O

OP	O
-	O
enriched	O
Parasutterella	B-bacteria
from	O
the	O
Proteobacteria	B-bacteria
phylum	I-bacteria
correlated	O
to	O
most	O
of	O
metabolites	O
,	O
suggesting	O
that	O
it	O
was	O
essential	O
in	O
obesity	O
.	O

OP	O
mice	O
are	O
distinct	O
in	O
metabolic	O
and	O
gut	O
microbial	O
profiles	O
,	O
and	O
OP	O
-	O
related	O
metabolites	O
and	O
bacteria	O
are	O
of	O
significance	O
for	O
understanding	O
obesity	O
development	O
.	O

Changes	O
in	O
Gut	O
Microbiota	O
and	O
Hormones	O
After	O
Bariatric	O
Surgery	O
:	O
a	O
Bench	O
-	O
to	O
-	O
Bedside	O
Review	O
.	O

Overweight	O
and	O
obesity	O
are	O
among	O
the	O
most	O
prevalent	O
non	O
-	O
communicable	O
diseases	O
which	O
are	O
generally	O
treated	O
successfully	O
by	O
bariatric	O
or	O
sleeve	O
surgery	O
.	O

There	O
are	O
evidences	O
affirming	O
that	O
sleeve	O
surgery	O
can	O
manipulate	O
the	O
pH	O
of	O
the	O
stomach	O
and	O
interact	O
with	O
the	O
metabolism	O
of	O
fatty	O
acids	O
,	O
carbohydrates	O
,	O
and	O
bile	O
acid	O
transfer	O
,	O
leading	O
to	O
the	O
overgrowth	O
of	O
gut	O
microbiota	O
.	O

Therefore	O
,	O
this	O
study	O
aims	O
to	O
review	O
the	O
changes	O
in	O
gut	O
microbiota	O
and	O
hormones	O
after	O
bariatric	O
surgery	O
.	O

A	O
Robust	O
Longitudinal	O
Co	O
-	O
culture	O
of	O
Obligate	O
Anaerobic	O
Gut	O
Microbiome	O
With	O
Human	O
Intestinal	O
Epithelium	O
in	O
an	O
Anoxic	O
-	O
Oxic	O
Interface	O
-	O
on	O
-	O
a	O
-	O
Chip	O
.	O

The	O
majority	O
of	O
human	O
gut	O
microbiome	O
is	O
comprised	O
of	O
obligate	O
anaerobic	O
bacteria	O
that	O
exert	O
essential	O
metabolic	O
functions	O
in	O
the	O
human	O
colon	O
.	O

These	O
anaerobic	O
gut	O
bacteria	O
constantly	O
crosstalk	O
with	O
the	O
colonic	O
epithelium	O
in	O
a	O
mucosal	O
anoxic	O
-	O
oxic	O
interface	O
(	O
AOI	O
)	O
.	O

However	O
,	O
in	O
vitro	O
recreation	O
of	O
the	O
metabolically	O
mismatched	O
colonic	O
AOI	O
has	O
been	O
technically	O
challenging	O
.	O

Furthermore	O
,	O
stable	O
co	O
-	O
culture	O
of	O
the	O
obligate	O
anaerobic	O
commensal	O
microbiome	O
and	O
epithelial	O
cells	O
in	O
a	O
mechanically	O
dynamic	O
condition	O
is	O
essential	O
for	O
demonstrating	O
the	O
host	O
-	O
gut	O
microbiome	O
crosstalk	O
.	O

Here	O
,	O
we	O
developed	O
an	O
anoxic	O
-	O
oxic	O
interface	O
-	O
on	O
-	O
a	O
-	O
chip	O
(	O
AOI	O
Chip	O
)	O
by	O
leveraging	O
a	O
modified	O
human	O
gut	O
-	O
on	O
-	O
a	O
-	O
chip	O
to	O
demonstrate	O
a	O
controlled	O
oxygen	O
gradient	O
in	O
the	O
lumen	O
-	O
capillary	O
transepithelial	O
interface	O
by	O
flowing	O
anoxic	O
and	O
oxic	O
culture	O
medium	O
at	O
various	O
physiological	O
milieus	O
.	O

Computational	O
simulation	O
and	O
experimental	O
results	O
revealed	O
that	O
the	O
presence	O
of	O
the	O
epithelial	O
cell	O
layer	O
and	O
the	O
flow	O
-	O
dependent	O
conditioning	O
in	O
the	O
lumen	O
microchannel	O
is	O
necessary	O
and	O
sufficient	O
to	O
create	O
the	O
steady	O
-	O
state	O
vertical	O
oxygen	O
gradient	O
in	O
the	O
AOI	O
Chip	O
.	O

We	O
confirmed	O
that	O
the	O
created	O
AOI	O
does	O
not	O
compromise	O
the	O
viability	O
,	O
barrier	O
function	O
,	O
mucin	O
production	O
,	O
and	O
the	O
expression	O
and	O
localization	O
of	O
tight	O
junction	O
proteins	O
in	O
the	O
3D	O
intestinal	O
epithelial	O
layer	O
.	O

Two	O
obligate	O
anaerobic	O
commensal	O
gut	O
microbiome	O
,	O
Bifidobacterium	B-bacteria
adolescentis	I-bacteria
and	O
Eubacterium	B-bacteria
hallii	I-bacteria
,	O
that	O
exert	O
metabolic	O
cross	O
-	O
feeding	O
in	O
vivo	O
,	O
were	O
independently	O
co	O
-	O
cultured	O
with	O
epithelial	O
cells	O
in	O
the	O
AOI	O
Chip	O
for	O
up	O
to	O
a	O
week	O
without	O
compromising	O
any	O
cell	O
viability	O
.	O

Our	O
new	O
protocol	O
for	O
creating	O
an	O
AOI	O
in	O
a	O
microfluidic	O
gut	O
-	O
on	O
-	O
a	O
-	O
chip	O
may	O
enable	O
to	O
demonstrate	O
the	O
key	O
physiological	O
interactions	O
of	O
obligate	O
anaerobic	O
gut	O
microbiome	O
with	O
the	O
host	O
cells	O
associated	O
with	O
intestinal	O
metabolism	O
,	O
homeostasis	O
,	O
and	O
immune	O
regulation	O
.	O

Fight	O
them	O
or	O
feed	O
them	O
:	O
how	O
the	O
intestinal	O
mucus	O
layer	O
manages	O
the	O
gut	O
microbiota	O
.	O

The	O
intestinal	O
tract	O
is	O
inhabited	O
by	O
a	O
tremendous	O
number	O
of	O
microorganisms	O
,	O
termed	O
the	O
gut	O
microbiota	O
.	O

These	O
microorganisms	O
live	O
in	O
a	O
mutualistic	O
relationship	O
with	O
their	O
host	O
and	O
assist	O
in	O
the	O
degradation	O
of	O
complex	O
carbohydrates	O
.	O

Although	O
the	O
gut	O
microbiota	O
is	O
generally	O
considered	O
beneficial	O
,	O
the	O
vast	O
number	O
of	O
microbial	O
cells	O
also	O
form	O
a	O
permanent	O
threat	O
to	O
the	O
host	O
.	O

Thus	O
,	O
the	O
intestinal	O
epithelium	O
is	O
covered	O
with	O
a	O
dense	O
layer	O
of	O
mucus	O
to	O
prevent	O
translocation	O
of	O
the	O
gut	O
microbiota	O
into	O
underlying	O
tissues	O
.	O

Intestinal	O
mucus	O
is	O
an	O
organized	O
glycoprotein	O
network	O
with	O
a	O
host	O
-	O
specific	O
glycan	O
structure	O
.	O

While	O
the	O
mucus	O
layer	O
has	O
long	O
been	O
considered	O
a	O
passive	O
,	O
host	O
-	O
designed	O
barrier	O
,	O
recent	O
studies	O
showed	O
that	O
maturation	O
and	O
function	O
of	O
the	O
mucus	O
layer	O
are	O
strongly	O
influenced	O
by	O
the	O
gut	O
microbiota	O
.	O

In	O
return	O
,	O
the	O
glycan	O
repertoire	O
of	O
mucins	O
can	O
select	O
for	O
distinct	O
mucosa	O
-	O
associated	O
bacteria	O
that	O
are	O
able	O
to	O
bind	O
or	O
degrade	O
specific	O
mucin	O
glycans	O
as	O
a	O
nutrient	O
source	O
.	O

Because	O
the	O
intestinal	O
mucus	O
layer	O
is	O
at	O
the	O
crucial	O
interface	O
between	O
host	O
and	O
microbes	O
,	O
its	O
breakdown	O
leads	O
to	O
gut	O
bacterial	O
encroachment	O
that	O
can	O
eventually	O
cause	O
inflammation	O
and	O
infection	O
.	O

Accordingly	O
,	O
a	O
dysfunctional	O
mucus	O
layer	O
has	O
been	O
observed	O
in	O
colitis	O
in	O
mice	O
and	O
humans	O
.	O

Moreover	O
,	O
the	O
increased	O
consumption	O
of	O
a	O
low	O
-	O
fiber	O
Western	O
-	O
style	O
diet	O
in	O
our	O
modern	O
society	O
has	O
recently	O
been	O
demonstrated	O
to	O
cause	O
bacteria	O
-	O
mediated	O
defects	O
of	O
the	O
intestinal	O
mucus	O
layer	O
.	O

Here	O
,	O
I	O
will	O
review	O
current	O
knowledge	O
on	O
the	O
interaction	O
between	O
gut	O
bacteria	O
and	O
the	O
intestinal	O
mucus	O
layer	O
in	O
health	O
and	O
disease	O
.	O

Understanding	O
the	O
molecular	O
details	O
of	O
this	O
host	O
-	O
microbe	O
interaction	O
may	O
contribute	O
to	O
the	O
development	O
of	O
novel	O
treatment	O
options	O
for	O
diseases	O
involving	O
a	O
dysfunctional	O
mucus	O
layer	O
,	O
such	O
as	O
ulcerative	O
colitis	O
.	O

D	O
-	O
methionine	O
alleviates	O
cisplatin	O
-	O
induced	O
mucositis	O
by	O
restoring	O
the	O
gut	O
microbiota	O
structure	O
and	O
improving	O
intestinal	O
inflammation	O
.	O

Background	O
:	O
There	O
are	O
close	O
links	O
between	O
chemotherapy	O
-	O
induced	O
intestinal	O
mucositis	O
and	O
microbiota	O
dysbiosis	O
.	O

Previous	O
studies	O
indicated	O
that	O
D	O
-	O
methionine	O
was	O
an	O
excellent	O
candidate	O
for	O
a	O
chemopreventive	O
agent	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
D	O
-	O
methionine	O
on	O
cisplatin	O
-	O
induced	O
mucositis	O
.	O

Materials	O
and	O
methods	O
:	O
Male	O
Wistar	O
rats	O
(	O
176	O
-	O
200	O
g	O
,	O
6	O
weeks	O
old	O
)	O
were	O
given	O
cisplatin	O
(	O
5	O
mg	O
/	O
kg	O
)	O
and	O
treated	O
with	O
D	O
-	O
methionine	O
(	O
300	O
mg	O
/	O
kg	O
)	O
.	O

Histopathological	O
,	O
digestive	O
enzymes	O
activity	O
,	O
oxidative	O
/	O
antioxidant	O
status	O
,	O
proinflammatory	O
/	O
anti	O
-	O
inflammatory	O
cytokines	O
in	O
intestinal	O
tissues	O
were	O
measured	O
.	O

Next	O
-	O
generation	O
sequencing	O
technologies	O
were	O
also	O
performed	O
to	O
investigate	O
the	O
gut	O
microbial	O
ecology	O
.	O

Results	O
:	O
D	O
-	O
methionine	O
administration	O
increased	O
villus	O
length	O
and	O
crypt	O
depth	O
and	O
improved	O
digestive	O
enzyme	O
(	O
leucine	O
aminopeptidase	O
,	O
sucrose	O
and	O
alkaline	O
phosphatase	O
)	O
activities	O
in	O
the	O
brush	O
-	O
border	O
membrane	O
of	O
cisplatin	O
-	O
treated	O
rats	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
D	O
-	O
methionine	O
significantly	O
attenuated	O
oxidative	O
stress	O
and	O
inflammatory	O
reaction	O
and	O
increased	O
interleukin	O
-	O
10	O
levels	O
in	O
cisplatin	O
-	O
induced	O
intestinal	O
mucositis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Cisplatin	O
administration	O
resulted	O
in	O
high	O
relative	O
abundances	O
of	O
Deferribacteres	B-bacteria
and	O
Proteobacteria	B-bacteria
and	O
a	O
low	O
diversity	O
of	O
the	O
microbiota	O
when	O
compared	O
with	O
control	O
groups	O
,	O
D	O
-	O
methionine	O
only	O
and	O
cisplatin	O
plus	O
D	O
-	O
methionine	O
.	O

Cisplatin	O
markedly	O
increased	O
comparative	O
abundances	O
of	O
Bacteroides	B-bacteria
caccae	I-bacteria
,	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Mucispirillum	B-bacteria
schaedleri	I-bacteria
,	O
Bacteroides	B-bacteria
uniformis	I-bacteria
and	O
Desulfovibrio	B-bacteria
C21	I-bacteria
-	I-bacteria
c20	I-bacteria
,	O
while	O
Lactobacillus	B-bacteria
was	O
almost	O
completely	O
depleted	O
,	O
compared	O
with	O
the	O
control	O
group	O
.	O

There	O
were	O
higher	O
abundances	O
of	O
Lactobacillus	B-bacteria
,	O
Lachnospiraceae	B-bacteria
,	O
and	O
Clostridium	B-bacteria
butyrium	I-bacteria
in	O
cisplatin	O
plus	O
D	O
-	O
methionine	O
rats	O
than	O
in	O
cisplatin	O
rats	O
.	O

D	O
-	O
methionine	O
treatment	O
alone	O
significantly	O
increased	O
the	O
number	O
of	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
.	O

Conclusion	O
:	O
D	O
-	O
methionine	O
protects	O
against	O
cisplatin	O
-	O
induced	O
intestinal	O
damage	O
through	O
antioxidative	O
and	O
anti	O
-	O
inflammatory	O
effects	O
.	O

By	O
enhancing	O
growth	O
of	O
beneficial	O
bacteria	O
(	O
Lachnospiraceae	B-bacteria
and	O
Lactobacillus	B-bacteria
)	O
,	O
D	O
-	O
methionine	O
attenuates	O
gut	O
microbiome	O
imbalance	O
caused	O
by	O
cisplatin	O
and	O
maintains	O
gut	O
homeostasis	O
.	O

Synbiotic	O
-	O
driven	O
improvement	O
of	O
metabolic	O
disturbances	O
is	O
associated	O
with	O
changes	O
in	O
the	O
gut	O
microbiome	O
in	O
diet	O
-	O
induced	O
obese	O
mice	O
.	O

OBJECTIVE	O
:	O
The	O
gut	O
microbiota	O
is	O
an	O
important	O
influencing	O
factor	O
of	O
metabolic	O
health	O
.	O

Although	O
dietary	O
interventions	O
with	O
probiotics	O
,	O
prebiotics	O
,	O
and	O
synbiotics	O
can	O
be	O
effective	O
means	O
to	O
regulate	O
obesity	O
and	O
associated	O
comorbidities	O
,	O
the	O
underlying	O
shifts	O
in	O
gut	O
microbial	O
communities	O
,	O
especially	O
at	O
the	O
functional	O
level	O
,	O
have	O
not	O
been	O
characterized	O
in	O
great	O
details	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
investigate	O
the	O
effects	O
of	O
synbiotics	O
on	O
the	O
regulation	O
of	O
gut	O
microbiota	O
and	O
the	O
alleviation	O
of	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
metabolic	O
disorders	O
in	O
mice	O
.	O

METHODS	O
:	O
Specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
male	O
C57BL	O
/	O
6J	O
mice	O
were	O
fed	O
diets	O
with	O
either	O
10	O
%	O
(	O
normal	O
diet	O
,	O
ND	O
)	O
or	O
60	O
%	O
(	O
high	O
-	O
fat	O
diet	O
,	O
HFD	O
)	O
of	O
total	O
calories	O
from	O
fat	O
(	O
lard	O
)	O
.	O

Dietary	O
interventions	O
in	O
the	O
HFD	O
-	O
fed	O
mice	O
included	O
(	O
i	O
)	O
probiotic	O
(	O
Bifidobacterium	B-bacteria
animalis	I-bacteria
subsp	I-bacteria
.	I-bacteria
lactis	I-bacteria
and	O
Lactobacillus	B-bacteria
paracasei	I-bacteria
subsp	I-bacteria
.	I-bacteria
paracasei	I-bacteria
DSM	I-bacteria
46331	I-bacteria
)	O
,	O
(	O
ii	O
)	O
prebiotic	O
(	O
oat	O
beta	O
-	O
glucan	O
)	O
,	O
and	O
(	O
iii	O
)	O
synbiotic	O
(	O
a	O
mixture	O
of	O
i	O
and	O
ii	O
)	O
treatments	O
for	O
12	O
weeks	O
.	O

Besides	O
detailed	O
characterization	O
of	O
host	O
metabolic	O
parameters	O
,	O
a	O
multi	O
-	O
omics	O
approach	O
was	O
used	O
to	O
systematically	O
profile	O
the	O
microbial	O
signatures	O
at	O
both	O
the	O
phylogenetic	O
and	O
functional	O
levels	O
using	O
16S	O
rRNA	O
gene	O
sequencing	O
,	O
metaproteomics	O
and	O
targeted	O
metabolomics	O
analysis	O
.	O

RESULTS	O
:	O
The	O
synbiotic	O
intervention	O
significantly	O
reduced	O
body	O
weight	O
gain	O
and	O
alleviated	O
features	O
of	O
metabolic	O
complications	O
.	O

At	O
the	O
phylogenetic	O
level	O
,	O
the	O
synbiotic	O
treatment	O
significantly	O
reversed	O
HFD	O
-	O
induced	O
changes	O
in	O
microbial	O
populations	O
,	O
both	O
in	O
terms	O
of	O
richness	O
and	O
the	O
relative	O
abundance	O
of	O
specific	O
taxa	O
.	O

Potentially	O
important	O
species	O
such	O
as	O
Faecalibaculum	B-bacteria
rodentium	I-bacteria
and	O
Alistipes	B-bacteria
putredinis	I-bacteria
that	O
might	O
mediate	O
the	O
beneficial	O
effects	O
of	O
the	O
synbiotic	O
were	O
identified	O
.	O

At	O
the	O
functional	O
level	O
,	O
short	O
-	O
chain	O
fatty	O
acid	O
and	O
bile	O
acid	O
profiles	O
revealed	O
that	O
all	O
dietary	O
interventions	O
significantly	O
restored	O
cecal	O
levels	O
of	O
acetate	O
,	O
propionate	O
,	O
and	O
butyrate	O
,	O
while	O
the	O
synbiotic	O
treatment	O
reduced	O
the	O
bile	O
acid	O
pools	O
most	O
efficiently	O
.	O

Metaproteomics	O
revealed	O
that	O
the	O
effects	O
of	O
the	O
synbiotic	O
intervention	O
might	O
be	O
mediated	O
through	O
metabolic	O
pathways	O
involved	O
in	O
carbohydrate	O
,	O
amino	O
acid	O
,	O
and	O
energy	O
metabolisms	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggested	O
that	O
dietary	O
intervention	O
using	O
the	O
novel	O
synbiotic	O
can	O
alleviate	O
HFD	O
-	O
induced	O
weight	O
gain	O
and	O
restore	O
gut	O
microbial	O
ecosystem	O
homeostasis	O
phylogenetically	O
and	O
functionally	O
.	O

Daidzein	O
Intake	O
Is	O
Associated	O
with	O
Equol	O
Producing	O
Status	O
through	O
an	O
Increase	O
in	O
the	O
Intestinal	O
Bacteria	O
Responsible	O
for	O
Equol	O
Production	O
.	O

Equol	O
is	O
a	O
metabolite	O
of	O
isoflavone	O
daidzein	O
and	O
has	O
an	O
affinity	O
to	O
estrogen	O
receptors	O
.	O

Although	O
equol	O
is	O
produced	O
by	O
intestinal	O
bacteria	O
,	O
the	O
association	O
between	O
the	O
status	O
of	O
equol	O
production	O
and	O
the	O
gut	O
microbiota	O
has	O
not	O
been	O
fully	O
investigated	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
intestinal	O
bacteria	O
responsible	O
for	O
equol	O
production	O
in	O
gut	O
microbiota	O
between	O
equol	O
producer	O
and	O
non	O
-	O
producer	O
subjects	O
regarding	O
the	O
intake	O
of	O
daidzein	O
.	O

A	O
total	O
of	O
1044	O
adult	O
subjects	O
who	O
participated	O
in	O
a	O
health	O
survey	O
in	O
Hirosaki	O
city	O
were	O
examined	O
.	O

The	O
concentration	O
of	O
equol	O
in	O
urine	O
was	O
measured	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

The	O
relative	O
abundances	O
of	O
8	O
bacterial	O
species	O
responsible	O
for	O
equol	O
production	O
in	O
the	O
gut	O
microbiota	O
was	O
assessed	O
using	O
16S	O
rRNA	O
amplification	O
.	O

There	O
were	O
458	O
subjects	O
identified	O
as	O
equol	O
producers	O
.	O

The	O
proportion	O
of	O
equol	O
production	O
status	O
and	O
the	O
intake	O
of	O
daidzein	O
increased	O
with	O
age	O
.	O

Daily	O
intake	O
of	O
daidzein	O
was	O
larger	O
in	O
equol	O
-	O
producer	O
.	O

The	O
intestinal	O
bacteria	O
,	O
which	O
convert	O
daidzein	O
to	O
equol	O
were	O
present	O
in	O
both	O
equol	O
producers	O
and	O
non	O
-	O
producers	O
.	O

However	O
,	O
the	O
relative	O
abundance	O
and	O
the	O
prevalence	O
of	O
Asaccharobacter	B-bacteria
celatus	I-bacteria
and	O
Slackia	B-bacteria
isoflavoniconvertens	I-bacteria
were	O
significantly	O
higher	O
in	O
equol	O
producers	O
than	O
those	O
in	O
equol	O
non	O
-	O
producers	O
.	O

The	O
intestinal	O
bacteria	O
that	O
convert	O
daidzein	O
to	O
equol	O
are	O
present	O
in	O
not	O
only	O
the	O
equol	O
producers	O
but	O
also	O
in	O
the	O
non	O
-	O
producers	O
.	O

The	O
daidzein	O
intake	O
is	O
associated	O
with	O
the	O
equol	O
production	O
status	O
through	O
an	O
increase	O
of	O
A	B-bacteria
.	I-bacteria
celatus	I-bacteria
and	O
S	B-bacteria
.	I-bacteria
isoflavoniconvertens	I-bacteria
in	O
the	O
gut	O
microbiota	O
.	O

Effect	O
of	O
Selected	O
Stilbenoids	O
on	O
Human	O
Fecal	O
Microbiota	O
.	O

Dietary	O
phenolics	O
or	O
polyphenols	O
are	O
mostly	O
metabolized	O
by	O
the	O
human	O
gut	O
microbiota	O
.	O

These	O
metabolites	O
appear	O
to	O
confer	O
the	O
beneficial	O
health	O
effects	O
attributed	O
to	O
phenolics	O
.	O

Microbial	O
composition	O
affects	O
the	O
type	O
of	O
metabolites	O
produced	O
.	O

Reciprocally	O
,	O
phenolics	O
modulate	O
microbial	O
composition	O
.	O

Understanding	O
this	O
relationship	O
could	O
be	O
used	O
to	O
positively	O
impact	O
health	O
by	O
phenolic	O
supplementation	O
and	O
thus	O
create	O
favorable	O
colonic	O
conditions	O
.	O

This	O
study	O
explored	O
the	O
effect	O
of	O
six	O
stilbenoids	O
(	O
batatasin	O
III	O
,	O
oxyresveratrol	O
,	O
piceatannol	O
,	O
pinostilbene	O
,	O
resveratrol	O
,	O
thunalbene	O
)	O
on	O
the	O
gut	O
microbiota	O
composition	O
.	O

Stilbenoids	O
were	O
anaerobically	O
fermented	O
with	O
fecal	O
bacteria	O
from	O
four	O
donors	O
,	O
samples	O
were	O
collected	O
at	O
0	O
and	O
24	O
h	O
,	O
and	O
effects	O
on	O
the	O
microbiota	O
were	O
assessed	O
by	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

Statistical	O
tests	O
identified	O
affected	O
microbes	O
at	O
three	O
taxonomic	O
levels	O
.	O

Observed	O
microbial	O
composition	O
modulation	O
by	O
stilbenoids	O
included	O
a	O
decrease	O
in	O
the	O
Firmicutes	B-bacteria
to	O
Bacteroidetes	B-bacteria
ratio	O
,	O
a	O
decrease	O
in	O
the	O
relative	O
abundance	O
of	O
strains	O
from	O
the	O
genus	O
Clostridium	B-bacteria
,	O
and	O
effects	O
on	O
the	O
family	O
Lachnospiraceae	B-bacteria
.	O

A	O
frequently	O
observed	O
effect	O
was	O
a	O
further	O
decrease	O
of	O
the	O
relative	O
abundance	O
when	O
compared	O
to	O
the	O
control	O
.	O

An	O
opposite	O
effect	O
to	O
the	O
control	O
was	O
observed	O
for	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
,	O
whose	O
relative	O
abundance	O
increased	O
.	O

Observed	O
effects	O
were	O
more	O
frequently	O
attributed	O
to	O
resveratrol	O
and	O
piceatannol	O
,	O
followed	O
by	O
thunalbene	O
and	O
batatasin	O
III	O
.	O

Construction	O
of	O
a	O
Model	O
Culture	O
System	O
of	O
Human	O
Colonic	O
Microbiota	O
to	O
Detect	O
Decreased	O
Lachnospiraceae	B-bacteria
Abundance	O
and	O
Butyrogenesis	O
in	O
the	O
Feces	O
of	O
Ulcerative	O
Colitis	O
Patients	O
.	O

Compositional	O
alteration	O
of	O
the	O
gut	O
microbiota	O
is	O
associated	O
with	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
.	O

Here	O
,	O
a	O
model	O
culture	O
system	O
is	O
established	O
for	O
the	O
in	O
vitro	O
human	O
colonic	O
microbiota	O
of	O
UC	O
,	O
which	O
will	O
be	O
helpful	O
for	O
determining	O
medical	O
interventions	O
.	O

16S	O
ribosomal	O
RNA	O
sequencing	O
confirms	O
that	O
UC	O
models	O
are	O
successfully	O
developed	O
from	O
fecal	O
inoculum	O
and	O
retain	O
the	O
bacterial	O
species	O
biodiversity	O
of	O
UC	O
feces	O
.	O

The	O
UC	O
models	O
closely	O
reproduce	O
the	O
microbial	O
components	O
and	O
successfully	O
preserve	O
distinct	O
clusters	O
from	O
the	O
healthy	O
subjects	O
(	O
HS	O
)	O
,	O
as	O
observed	O
in	O
the	O
feces	O
.	O

The	O
relative	O
abundance	O
of	O
bacteria	O
belonging	O
to	O
the	O
family	O
Lachnospiraceae	B-bacteria
significantly	O
decreases	O
in	O
the	O
UC	O
models	O
compared	O
to	O
that	O
in	O
HS	O
,	O
as	O
observed	O
in	O
the	O
feces	O
.	O

The	O
system	O
detects	O
significantly	O
lower	O
butyrogenesis	O
in	O
the	O
UC	O
models	O
than	O
that	O
in	O
HS	O
,	O
correlating	O
with	O
the	O
decreased	O
abundance	O
of	O
Lachnospiraceae	B-bacteria
.	O

Interestingly	O
,	O
the	O
relative	O
abundance	O
of	O
Lachnospiraceae	B-bacteria
does	O
not	O
correlate	O
with	O
disease	O
activity	O
(	O
defined	O
as	O
partial	O
Mayo	O
score	O
)	O
,	O
suggesting	O
that	O
Lachnospiraceae	B-bacteria
persists	O
in	O
UC	O
patients	O
at	O
a	O
decreased	O
level	O
,	O
irrespective	O
of	O
the	O
alteration	O
in	O
disease	O
activity	O
.	O

Moreover	O
,	O
the	O
system	O
shows	O
that	O
administration	O
of	O
Clostridium	B-bacteria
butyricum	I-bacteria
MIYAIRI	O
restores	O
butyrogenesis	O
in	O
the	O
UC	O
model	O
.	O

Hence	O
,	O
the	O
model	O
detects	O
deregulation	O
in	O
the	O
intestinal	O
environment	O
in	O
UC	O
patients	O
and	O
may	O
be	O
useful	O
for	O
simulating	O
the	O
effect	O
of	O
probiotics	O
.	O

Immune	O
tolerance	O
attenuates	O
gut	O
dysbiosis	O
,	O
dysregulated	O
uterine	O
gene	O
expression	O
and	O
high	O
-	O
fat	O
diet	O
potentiated	O
preterm	O
birth	O
in	O
mice	O
.	O

BACKGROUND	O
:	O
Preterm	O
delivery	O
accounts	O
for	O
85	O
%	O
of	O
perinatal	O
morbidity	O
and	O
mortality	O
.	O

Although	O
the	O
consumption	O
of	O
a	O
high	O
-	O
fat	O
diet	O
leads	O
to	O
exaggerated	O
proinflammatory	O
responses	O
and	O
,	O
in	O
pregnant	O
women	O
,	O
increased	O
rates	O
of	O
spontaneous	O
preterm	O
birth	O
,	O
the	O
underlying	O
mechanisms	O
remain	O
unclear	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
elucidate	O
the	O
mechanisms	O
by	O
which	O
maternal	O
consumption	O
of	O
a	O
high	O
-	O
fat	O
diet	O
leads	O
to	O
a	O
dysregulated	O
immune	O
response	O
and	O
,	O
subsequently	O
,	O
spontaneous	O
preterm	O
birth	O
.	O

STUDY	O
DESIGN	O
:	O
We	O
performed	O
16S	O
ribosomal	O
RNA	O
sequencing	O
of	O
DNA	O
extracted	O
and	O
amplified	O
from	O
stool	O
samples	O
and	O
compared	O
the	O
gut	O
microbiomes	O
of	O
lipopolysaccharide	O
-	O
induced	O
pregnant	O
mice	O
that	O
were	O
maintained	O
on	O
a	O
high	O
-	O
fat	O
diet	O
compared	O
to	O
a	O
normal	O
control	O
diet	O
.	O

Next	O
,	O
we	O
sequenced	O
the	O
uterine	O
transcriptomes	O
of	O
the	O
mice	O
.	O

To	O
test	O
the	O
effect	O
of	O
dampening	O
of	O
the	O
immune	O
response	O
on	O
the	O
microbiome	O
,	O
transcriptome	O
,	O
and	O
risk	O
of	O
spontaneous	O
preterm	O
birth	O
,	O
we	O
induced	O
immune	O
tolerance	O
with	O
repetitive	O
subclinical	O
doses	O
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
/	O
week	O
for	O
8	O
weeks	O
)	O
of	O
endotoxin	O
and	O
performed	O
16S	O
ribosomal	O
RNA	O
and	O
uterine	O
transcriptome	O
sequencing	O
on	O
these	O
immunotolerized	O
mice	O
.	O

RESULTS	O
:	O
High	O
-	O
fat	O
diet	O
potentiates	O
lipopolysaccharide	O
-	O
induced	O
preterm	O
birth	O
by	O
affecting	O
the	O
maternal	O
gut	O
microbiome	O
and	O
uterine	O
transcriptome	O
and	O
reduces	O
antioxidant	O
capacity	O
in	O
a	O
murine	O
model	O
.	O

High	O
-	O
fat	O
diet	O
consumption	O
also	O
increases	O
the	O
colonization	O
of	O
the	O
gut	O
by	O
5	O
immunogenic	O
bacteria	O
and	O
decreases	O
colonization	O
by	O
Lachnospiraceae	B-bacteria
_	O
NK4A136	I-bacteria
_	O
group	O
.	O

Uteri	O
from	O
high	O
-	O
fat	O
diet	O
mice	O
had	O
increased	O
expression	O
of	O
genes	O
that	O
stimulate	O
the	O
inflammatory	O
-	O
oxidative	O
stress	O
axis	O
,	O
autophagy	O
/	O
apoptosis	O
,	O
and	O
smooth	O
muscle	O
contraction	O
.	O

Repetitive	O
endotoxin	O
priming	O
protects	O
high	O
-	O
fat	O
diet	O
dams	O
from	O
spontaneous	O
preterm	O
birth	O
,	O
increases	O
colonization	O
of	O
the	O
gut	O
by	O
Lachnospiraceae	B-bacteria
_	I-bacteria
NK4A136	I-bacteria
_	I-bacteria
group	I-bacteria
,	O
decreases	O
levels	O
of	O
immunogenic	O
bacteria	O
in	O
the	O
gut	O
microbiome	O
,	O
and	O
reduces	O
the	O
number	O
of	O
dysregulated	O
genes	O
after	O
high	O
-	O
fat	O
diet	O
consumption	O
from	O
994	O
to	O
74	O
.	O

CONCLUSION	O
:	O
High	O
-	O
fat	O
diet	O
-	O
potentiated	O
spontaneous	O
preterm	O
birth	O
is	O
mediated	O
by	O
increased	O
inflammation	O
,	O
oxidative	O
stress	O
,	O
and	O
gut	O
dysbiosis	O
.	O

The	O
induction	O
of	O
immune	O
tolerance	O
via	O
endotoxin	O
priming	O
reverses	O
these	O
effects	O
and	O
protects	O
high	O
-	O
fat	O
diet	O
dams	O
from	O
spontaneous	O
preterm	O
birth	O
.	O

Based	O
on	O
this	O
work	O
,	O
the	O
role	O
of	O
immunomodulation	O
as	O
a	O
novel	O
therapeutic	O
approach	O
to	O
prevent	O
preterm	O
birth	O
among	O
women	O
who	O
consume	O
high	O
-	O
fat	O
diets	O
should	O
be	O
explored	O
.	O

Fecal	O
transplant	O
modifies	O
urine	O
chemistry	O
risk	O
factors	O
for	O
urinary	O
stone	O
disease	O
.	O

Urinary	O
stone	O
disease	O
(	O
USD	O
)	O
is	O
a	O
major	O
health	O
concern	O
.	O

There	O
is	O
a	O
need	O
for	O
new	O
treatment	O
modalities	O
.	O

Recently	O
,	O
our	O
group	O
provided	O
evidence	O
for	O
an	O
association	O
between	O
the	O
GMB	O
composition	O
and	O
USD	O
.	O

The	O
accessibility	O
of	O
the	O
Gut	O
Microbiome	O
(	O
GMB	O
)	O
makes	O
it	O
an	O
attractive	O
target	O
for	O
investigation	O
and	O
therefore	O
,	O
in	O
these	O
studies	O
we	O
have	O
evaluated	O
the	O
extent	O
to	O
which	O
the	O
whole	O
gut	O
microbial	O
community	O
in	O
fecal	O
transplants	O
can	O
affect	O
urinary	O
stone	O
risk	O
parameters	O
in	O
an	O
animal	O
model	O
.	O

Fresh	O
fecal	O
pellets	O
were	O
collected	O
from	O
Zucker	O
lean	O
rats	O
,	O
homogenized	O
in	O
PBS	O
(	O
100	O
mg	O
/	O
mL	O
)	O
,	O
filtered	O
through	O
a	O
70	O
mum	O
strainer	O
and	O
then	O
orally	O
gavaged	O
into	O
C57BL	O
/	O
6NTac	O
germ	O
-	O
free	O
mice	O
.	O

Twenty	O
-	O
four	O
hours	O
urine	O
collections	O
and	O
GMB	O
analysis	O
were	O
performed	O
over	O
time	O
for	O
1	O
month	O
.	O

Kidney	O
and	O
gut	O
tissue	O
were	O
harvested	O
from	O
transplanted	O
mice	O
for	O
western	O
blot	O
analysis	O
of	O
expression	O
levels	O
of	O
the	O
Slc26a6	O
transporter	O
involved	O
in	O
oxalate	O
balance	O
.	O

Urinary	O
calcium	O
decreased	O
after	O
fecal	O
transplant	O
by	O
55	O
%	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Urinary	O
oxalate	O
levels	O
were	O
on	O
average	O
24	O
%	O
lower	O
than	O
baseline	O
levels	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Clostridiaceae	B-bacteria
family	I-bacteria
was	O
negatively	O
correlated	O
with	O
urinary	O
oxalate	O
at	O
4	O
weeks	O
after	O
transplant	O
(	O
r	O
=	O
-	O
0	O
.	O
83	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
a	O
0	O
.	O
6	O
unit	O
average	O
increase	O
in	O
urinary	O
pH	O
from	O
a	O
baseline	O
of	O
5	O
.	O
85	O
(	O
SE	O
+	O
/	O
-	O
0	O
.	O
028	O
)	O
to	O
6	O
.	O
49	O
(	O
SE	O
+	O
/	O
-	O
0	O
.	O
04	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
after	O
transplant	O
.	O

There	O
was	O
a	O
concomitant	O
29	O
%	O
increase	O
in	O
gastrointestinal	O
alkali	O
absorption	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
4	O
-	O
weeks	O
after	O
fecal	O
transplant	O
.	O

Slc26a6	O
expression	O
increased	O
by	O
90	O
%	O
in	O
the	O
cecum	O
after	O
transplant	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
gut	O
microbiome	O
may	O
impact	O
metabolism	O
,	O
alters	O
urinary	O
chemistry	O
,	O
and	O
thereby	O
may	O
influence	O
USD	O
;	O
the	O
accessibility	O
of	O
the	O
GMB	O
can	O
potentially	O
be	O
leveraged	O
for	O
therapeutic	O
interventions	O
.	O

Enhanced	O
emergence	O
of	O
antibiotic	O
-	O
resistant	O
pathogenic	O
bacteria	O
after	O
in	O
vitro	O
induction	O
with	O
cancer	O
chemotherapy	O
drugs	O
.	O

BACKGROUND	O
:	O
Infections	O
with	O
antibiotic	O
-	O
resistant	O
pathogens	O
in	O
cancer	O
patients	O
are	O
a	O
leading	O
cause	O
of	O
mortality	O
.	O

Cancer	O
patients	O
are	O
treated	O
with	O
compounds	O
that	O
can	O
damage	O
bacterial	O
DNA	O
,	O
potentially	O
triggering	O
the	O
SOS	O
response	O
,	O
which	O
in	O
turn	O
enhances	O
the	O
bacterial	O
mutation	O
rate	O
.	O

Antibiotic	O
resistance	O
readily	O
occurs	O
after	O
mutation	O
of	O
bacterial	O
core	O
genes	O
.	O

Thus	O
,	O
we	O
tested	O
whether	O
cancer	O
chemotherapy	O
drugs	O
enhance	O
the	O
emergence	O
of	O
resistant	O
mutants	O
in	O
commensal	O
bacteria	O
.	O

METHODS	O
:	O
Induction	O
of	O
the	O
SOS	O
response	O
was	O
tested	O
after	O
the	O
incubation	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
biosensors	O
with	O
39	O
chemotherapeutic	O
drugs	O
at	O
therapeutic	O
concentrations	O
.	O

The	O
mutation	O
frequency	O
was	O
assessed	O
after	O
induction	O
with	O
the	O
SOS	O
-	O
inducing	O
chemotherapeutic	O
drugs	O
.	O

We	O
then	O
tested	O
the	O
ability	O
of	O
the	O
three	O
most	O
highly	O
inducing	O
drugs	O
to	O
drive	O
the	O
emergence	O
of	O
resistant	O
mutants	O
of	O
major	O
bacterial	O
pathogens	O
to	O
first	O
-	O
line	O
antibiotics	O
.	O

RESULTS	O
:	O
Ten	O
chemotherapeutic	O
drugs	O
activated	O
the	O
SOS	O
response	O
.	O

Among	O
them	O
,	O
eight	O
accelerated	O
the	O
evolution	O
of	O
the	O
major	O
commensal	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
,	O
mostly	O
through	O
activation	O
of	O
the	O
SOS	O
response	O
,	O
with	O
dacarbazine	O
,	O
azacitidine	O
and	O
streptozotocin	O
enhancing	O
the	O
mutation	O
rate	O
21	O
.	O
3	O
-	O
fold	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
101	O
.	O
7	O
-	O
fold	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
1158	O
.	O
7	O
-	O
fold	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
respectively	O
.	O

These	O
three	O
compounds	O
also	O
spurred	O
the	O
emergence	O
of	O
imipenem	O
-	I-bacteria
resistant	I-bacteria
Pseudomonas	I-bacteria
aeruginosa	I-bacteria
(	O
up	O
to	O
6	O
.	O
21	O
-	O
fold	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
,	O
ciprofloxacin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Staphylococcus	I-bacteria
aureus	I-bacteria
(	O
up	O
to	O
57	O
.	O
72	O
-	O
fold	O
;	O
P	O
=	O
0	O
.	O
016	O
)	O
and	O
cefotaxime	B-bacteria
-	I-bacteria
resistant	I-bacteria
Enterobacteria	I-bacteria
cloacae	I-bacteria
(	O
up	O
to	O
4	O
.	O
57	O
-	O
fold	O
;	O
P	O
=	O
0	O
.	O
018	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
chemotherapy	O
could	O
accelerate	O
evolution	O
of	O
the	O
microbiota	O
and	O
drive	O
the	O
emergence	O
of	O
antibiotic	O
-	O
resistant	O
mutants	O
from	O
bacterial	O
commensals	O
in	O
patients	O
.	O

This	O
reveals	O
an	O
additional	O
level	O
of	O
complexity	O
of	O
the	O
interactions	O
between	O
cancer	O
,	O
chemotherapy	O
and	O
the	O
gut	O
microbiota	O
.	O

Transition	O
metals	O
and	O
host	O
-	O
microbe	O
interactions	O
in	O
the	O
inflamed	O
intestine	O
.	O

Host	O
-	O
associated	O
microbial	O
communities	O
provide	O
critical	O
functions	O
for	O
their	O
hosts	O
.	O

Transition	O
metals	O
are	O
essential	O
for	O
both	O
the	O
mammalian	O
host	O
and	O
the	O
majority	O
of	O
commensal	O
bacteria	O
.	O

As	O
such	O
,	O
access	O
to	O
transition	O
metals	O
is	O
an	O
important	O
component	O
of	O
host	O
-	O
microbe	O
interactions	O
in	O
the	O
gastrointestinal	O
tract	O
.	O

In	O
mammals	O
,	O
transition	O
metal	O
ions	O
are	O
often	O
sequestered	O
by	O
metal	O
binding	O
proteins	O
to	O
limit	O
microbial	O
access	O
under	O
homeostatic	O
conditions	O
.	O

In	O
response	O
to	O
invading	O
pathogens	O
,	O
the	O
mammalian	O
host	O
further	O
decreases	O
availability	O
of	O
these	O
micronutrients	O
by	O
regulating	O
their	O
trafficking	O
or	O
releasing	O
high	O
-	O
affinity	O
metal	O
chelating	O
proteins	O
,	O
a	O
process	O
termed	O
nutritional	O
immunity	O
.	O

Bacterial	O
pathogens	O
have	O
evolved	O
several	O
mechanisms	O
to	O
subvert	O
nutritional	O
immunity	O
.	O

Here	O
,	O
we	O
provide	O
an	O
overview	O
on	O
how	O
metal	O
ion	O
availability	O
shapes	O
host	O
-	O
microbe	O
interactions	O
in	O
the	O
gut	O
with	O
a	O
particular	O
focus	O
on	O
intestinal	O
inflammatory	O
diseases	O
.	O

Human	O
cathelicidin	O
improves	O
colonic	O
epithelial	O
defenses	O
against	O
Salmonella	B-bacteria
typhimurium	I-bacteria
by	O
modulating	O
bacterial	O
invasion	O
,	O
TLR4	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

The	O
intestinal	O
mucosa	O
contributes	O
to	O
frontline	O
gut	O
defenses	O
by	O
forming	O
a	O
barrier	O
(	O
physical	O
and	O
biochemical	O
)	O
and	O
preventing	O
the	O
entry	O
of	O
pathogenic	O
microbes	O
.	O

One	O
innate	O
role	O
of	O
the	O
human	O
colonic	O
epithelium	O
is	O
to	O
secrete	O
cathelicidin	O
,	O
a	O
peptide	O
with	O
broad	O
antimicrobial	O
and	O
immunomodulatory	O
functions	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
cathelicidin	O
in	O
the	O
maintenance	O
of	O
epithelial	O
integrity	O
,	O
Toll	O
-	O
like	O
receptor	O
recognition	O
,	O
bacterial	O
invasion	O
and	O
initiation	O
of	O
inflammatory	O
response	O
against	O
Salmonella	B-bacteria
typhimurium	I-bacteria
is	O
investigated	O
in	O
cultured	O
human	O
colonic	O
epithelium	O
.	O

We	O
found	O
exogenous	O
human	O
cathelicidin	O
restores	O
the	O
epithelial	O
integrity	O
in	O
S	O
.	O
typhimurium	O
-	O
infected	O
colonic	O
epithelial	O
(	O
T84	O
)	O
cells	O
by	O
mostly	O
post	O
-	O
translational	O
effects	O
associated	O
with	O
reorganization	O
of	O
zonula	O
occludens	O
(	O
ZO	O
)	O
-	O
1	O
tight	O
junction	O
proteins	O
.	O

Endogenous	O
cathelicidin	O
prevents	O
S	B-bacteria
.	I-bacteria
typhimurium	I-bacteria
internalization	O
as	O
shown	O
in	O
colonic	O
epithelial	O
cells	O
genetically	O
deficient	O
in	O
the	O
only	O
human	O
cathelicidin	O
,	O
LL	O
-	O
37	O
(	O
shLL	O
-	O
37	O
)	O
.	O

Moreover	O
,	O
supplementation	O
of	O
shLL	O
-	O
37	O
cells	O
with	O
synthetic	O
LL	O
-	O
37	O
reduces	O
the	O
grade	O
of	O
S	B-bacteria
.	I-bacteria
typhimurium	I-bacteria
internalization	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Mechanistically	O
,	O
shLL	O
-	O
37	O
cells	O
have	O
lower	O
gene	O
expression	O
of	O
TLR4	O
and	O
pro	O
-	O
inflammatory	O
cytokine	O
IL	O
-	O
1beta	O
in	O
response	O
to	O
S	B-bacteria
.	I-bacteria
typhimurium	I-bacteria
.	O

Thus	O
,	O
human	O
cathelicidin	O
aids	O
in	O
the	O
early	O
colonic	O
epithelial	O
defenses	O
against	O
enteric	O
S	B-bacteria
.	I-bacteria
typhimurium	I-bacteria
by	O
preventing	O
bacterial	O
invasion	O
and	O
maintaining	O
epithelial	O
barrier	O
integrity	O
,	O
likely	O
to	O
occur	O
due	O
to	O
the	O
production	O
of	O
sensing	O
TLR4	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
Skews	O
Human	O
DC	O
to	O
Prime	O
IL10	O
-	O
Producing	O
T	O
Cells	O
Through	O
TLR2	O
/	O
6	O
/	O
JNK	O
Signaling	O
and	O
IL	O
-	O
10	O
,	O
IL	O
-	O
27	O
,	O
CD39	O
,	O
and	O
IDO	O
-	O
1	O
Induction	O
.	O

The	O
human	O
colonic	O
mucosa	O
contains	O
regulatory	O
type	O
1	O
-	O
like	O
(	O
Tr1	O
-	O
like	O
,	O
i	O
.	O
e	O
.	O
,	O
IL	O
-	O
10	O
-	O
secreting	O
and	O
Foxp3	O
-	O
negative	O
)	O
T	O
cells	O
specific	O
for	O
the	O
gut	O
Clostridium	B-bacteria
Faecalibacterium	I-bacteria
prausnitzii	I-bacteria
(	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
)	O
,	O
which	O
are	O
both	O
decreased	O
in	O
Crohn	O
'	O
s	O
disease	O
patients	O
.	O

These	O
data	O
,	O
together	O
with	O
the	O
demonstration	O
,	O
in	O
mice	O
,	O
that	O
colonic	O
regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
induced	O
by	O
Clostridium	B-bacteria
bacteria	I-bacteria
are	O
key	O
players	O
in	O
colon	O
homeostasis	O
,	O
support	O
a	O
similar	O
role	O
for	O
F	O
.	O
prausnitzii	O
-	O
specific	O
Treg	O
in	O
the	O
human	O
colon	O
.	O

Here	O
we	O
assessed	O
the	O
mechanisms	O
whereby	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
induces	O
human	O
colonic	O
Treg	O
.	O

We	O
demonstrated	O
that	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
,	O
but	O
not	O
related	O
Clostridia	B-bacteria
,	O
skewed	O
human	O
dendritic	O
cells	O
to	O
prime	O
IL	O
-	O
10	O
-	O
secreting	O
T	O
cells	O
.	O

Accordingly	O
,	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
induced	O
dendritic	O
cells	O
to	O
express	O
a	O
unique	O
array	O
of	O
potent	O
Tr1	O
/	O
Treg	O
polarizing	O
molecules	O
:	O
IL	O
-	O
10	O
,	O
IL	O
-	O
27	O
,	O
CD39	O
,	O
IDO	O
-	O
1	O
,	O
and	O
PDL	O
-	O
1	O
and	O
,	O
following	O
TLR4	O
stimulation	O
,	O
inhibited	O
their	O
up	O
-	O
regulation	O
of	O
costimulation	O
molecules	O
as	O
well	O
as	O
their	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	O
-	O
12	O
(	O
p35	O
and	O
p40	O
)	O
and	O
TNFalpha	O
.	O

We	O
further	O
showed	O
that	O
these	O
potent	O
tolerogenic	O
effects	O
relied	O
on	O
F	O
.	O
prausnitzii	O
-	O
induced	O
TLR2	O
/	O
6	O
triggering	O
,	O
JNK	O
signaling	O
and	O
CD39	O
ectonucleotidase	O
activity	O
,	O
which	O
was	O
induced	O
by	O
IDO	O
-	O
1	O
and	O
IL	O
-	O
27	O
.	O

These	O
data	O
,	O
together	O
with	O
the	O
presence	O
of	O
F	O
.	O
prausnitzii	O
-	O
specific	O
Tr1	O
-	O
like	O
Treg	O
in	O
the	O
human	O
colon	O
,	O
point	O
out	O
to	O
dendritic	O
cells	O
polarization	O
by	O
F	O
.	O
prausnitzii	O
as	O
the	O
first	O
described	O
cellular	O
mechanism	O
whereby	O
the	O
microbiota	O
composition	O
may	O
affect	O
human	O
colon	O
homeostasis	O
.	O

Identification	O
of	O
F	O
.	O
prausnitzii	O
-	O
induced	O
mediators	O
involved	O
in	O
Tr1	O
-	O
like	O
Treg	O
induction	O
by	O
dendritic	O
cells	O
opens	O
therapeutic	O
avenues	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
diseases	O
.	O

Dietary	O
Lysozyme	O
Alters	O
Sow	O
'	O
s	O
Gut	O
Microbiota	O
,	O
Serum	O
Immunity	O
and	O
Milk	O
Metabolite	O
Profile	O
.	O

The	O
aim	O
of	O
current	O
study	O
was	O
to	O
determine	O
variations	O
in	O
sow	O
'	O
s	O
gut	O
microbiota	O
,	O
serum	O
immunity	O
,	O
and	O
milk	O
metabolite	O
profile	O
mediated	O
by	O
lysozyme	O
supplementation	O
.	O

Twenty	O
-	O
four	O
pregnant	O
sows	O
were	O
assigned	O
to	O
a	O
control	O
group	O
without	O
supplementation	O
and	O
two	O
treatments	O
with	O
0	O
.	O
5	O
kg	O
/	O
t	O
and	O
1	O
.	O
0	O
kg	O
/	O
t	O
lysozyme	O
provided	O
in	O
formula	O
feed	O
for	O
21	O
days	O
(	O
n	O
=	O
8	O
per	O
treatment	O
)	O
.	O

Microbiota	O
analysis	O
and	O
metagenomic	O
predictions	O
were	O
based	O
on	O
16s	O
RNA	O
high	O
-	O
throughput	O
sequencing	O
.	O

Milk	O
metabolome	O
was	O
assessed	O
by	O
untargeted	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
.	O

Serum	O
biochemical	O
indicators	O
and	O
immunoglobulins	O
were	O
also	O
determined	O
.	O

Gut	O
microbial	O
diversity	O
of	O
sows	O
receiving	O
1	O
.	O
0	O
kg	O
/	O
t	O
lysozyme	O
treatment	O
was	O
significantly	O
reduced	O
after	O
the	O
trial	O
.	O

Spirochaetes	B-bacteria
,	O
Euryarchaeota	B-bacteria
,	O
and	O
Actinobacteria	B-bacteria
significantly	O
increased	O
while	O
Firmicutes	B-bacteria
showed	O
a	O
remarkable	O
reduction	O
in	O
1	O
.	O
0	O
kg	O
/	O
t	O
group	O
compared	O
with	O
control	O
.	O

Lysozyme	O
addition	O
rebuilt	O
sow	O
'	O
s	O
gut	O
microbiota	O
to	O
beneficial	O
composition	O
identified	O
by	O
reduced	O
richness	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
increased	O
abundance	O
of	O
Lactobacillus	B-bacteria
amylovorus	I-bacteria
.	O

Accordingly	O
,	O
microbial	O
metabolic	O
functions	O
including	O
pyrimidine	O
metabolism	O
,	O
purine	O
metabolism	O
,	O
and	O
amino	O
acid	O
related	O
enzymes	O
were	O
significantly	O
up	O
-	O
regulated	O
in	O
1	O
.	O
0	O
kg	O
/	O
t	O
group	O
.	O

Microbial	O
metabolic	O
phenotypes	O
like	O
the	O
richness	O
of	O
Gram	O
-	O
positive	O
bacteria	O
and	O
oxidative	O
stress	O
tolerance	O
were	O
also	O
significantly	O
reduced	O
by	O
lysozyme	O
treatment	O
.	O

Serum	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
activity	O
and	O
IgA	O
levels	O
were	O
significantly	O
down	O
-	O
regulated	O
in	O
the	O
1	O
.	O
0	O
kg	O
/	O
t	O
group	O
compared	O
with	O
control	O
,	O
but	O
IgM	O
levels	O
showed	O
a	O
significantly	O
increase	O
in	O
1	O
.	O
0	O
kg	O
/	O
t	O
group	O
.	O

Milk	O
metabolites	O
such	O
as	O
L	O
-	O
glutamine	O
,	O
creatine	O
,	O
and	O
L	O
-	O
arginine	O
showed	O
significantly	O
dose	O
-	O
dependent	O
changes	O
after	O
treatment	O
.	O

Overall	O
,	O
lysozyme	O
supplementation	O
could	O
effectively	O
improve	O
the	O
composition	O
,	O
metabolic	O
functions	O
,	O
and	O
phenotypes	O
of	O
sow	O
'	O
s	O
gut	O
microbiota	O
and	O
it	O
also	O
benefit	O
sows	O
with	O
better	O
serum	O
immunity	O
and	O
milk	O
composition	O
.	O

This	O
research	O
could	O
provide	O
theoretical	O
support	O
for	O
further	O
application	O
of	O
lysozyme	O
in	O
promoting	O
animal	O
gut	O
health	O
and	O
prevent	O
pathogenic	O
infections	O
in	O
livestock	O
production	O
.	O

Genomic	O
and	O
metatranscriptomic	O
analyses	O
of	O
carbon	O
remineralization	O
in	O
an	O
Antarctic	O
polynya	O
.	O

BACKGROUND	O
:	O
Polynyas	O
in	O
the	O
Southern	O
Ocean	O
are	O
regions	O
of	O
intense	O
primary	O
production	O
,	O
mainly	O
by	O
Phaeocystis	B-bacteria
antarctica	I-bacteria
.	O

Carbon	O
fixed	O
by	O
phytoplankton	O
in	O
the	O
water	O
column	O
is	O
transferred	O
to	O
higher	O
trophic	O
levels	O
,	O
and	O
finally	O
,	O
to	O
the	O
deep	O
ocean	O
.	O

However	O
,	O
in	O
the	O
Amundsen	O
Sea	O
,	O
most	O
of	O
this	O
organic	O
carbon	O
does	O
not	O
reach	O
the	O
sediment	O
but	O
is	O
degraded	O
in	O
the	O
water	O
column	O
due	O
to	O
high	O
bacterial	O
heterotrophic	O
activity	O
.	O

RESULTS	O
:	O
We	O
reconstructed	O
12	O
key	O
bacterial	O
genomes	O
from	O
different	O
phases	O
of	O
bloom	O
and	O
analyzed	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
organic	O
carbon	O
remineralization	O
.	O

A	O
high	O
correlation	O
of	O
gene	O
expression	O
between	O
the	O
peak	O
and	O
decline	O
phases	O
was	O
observed	O
in	O
an	O
individual	O
genome	O
bin	O
-	O
based	O
pairwise	O
comparison	O
of	O
gene	O
expression	O
.	O

Polaribacter	B-bacteria
belonging	O
to	O
Bacteroidetes	B-bacteria
was	O
found	O
to	O
be	O
dominant	O
in	O
the	O
peak	O
phase	O
,	O
and	O
its	O
transcriptional	O
activity	O
was	O
high	O
(	O
48	O
.	O
9	O
%	O
of	O
the	O
total	O
mRNA	O
reads	O
)	O
.	O

Two	O
dominant	O
Polaribacter	B-bacteria
bins	O
had	O
the	O
potential	O
to	O
utilize	O
major	O
polymers	O
in	O
P	B-bacteria
.	I-bacteria
antarctica	I-bacteria
,	O
chrysolaminarin	O
and	O
xylan	O
,	O
with	O
a	O
distinct	O
set	O
of	O
glycosyl	O
hydrolases	O
.	O

In	O
the	O
decline	O
phase	O
,	O
Gammaproteobacteria	B-bacteria
(	O
Ant4D3	B-bacteria
,	O
SUP05	B-bacteria
,	O
and	O
SAR92	B-bacteria
)	O
,	O
with	O
the	O
potential	O
to	O
utilize	O
low	O
molecular	O
weight	O
-	O
dissolved	O
organic	O
matter	O
(	O
LMW	O
-	O
DOM	O
)	O
including	O
compatible	O
solutes	O
,	O
was	O
increased	O
.	O

The	O
versatility	O
of	O
Gammaproteobacteria	B-bacteria
may	O
contribute	O
to	O
their	O
abundance	O
in	O
organic	O
carbon	O
-	O
rich	O
polynya	O
waters	O
,	O
while	O
the	O
SAR11	B-bacteria
clade	O
was	O
found	O
to	O
be	O
predominant	O
in	O
the	O
sea	O
ice	O
-	O
covered	O
oligotrophic	O
ocean	O
.	O

SAR92	O
clade	O
showed	O
transcriptional	O
activity	O
for	O
utilization	O
of	O
both	O
polysaccharides	O
and	O
LMW	O
-	O
DOM	O
;	O
this	O
may	O
account	O
for	O
their	O
abundance	O
both	O
in	O
the	O
peak	O
and	O
decline	O
phases	O
.	O

Ant4D3	O
clade	O
was	O
dominant	O
in	O
all	O
phases	O
of	O
the	O
polynya	O
bloom	O
,	O
implicating	O
the	O
crucial	O
roles	O
of	O
this	O
clade	O
in	O
LMW	O
-	O
DOM	O
remineralization	O
in	O
the	O
Antarctic	O
polynyas	O
.	O

CONCLUSIONS	O
:	O
Genomic	O
reconstruction	O
and	O
in	O
situ	O
gene	O
expression	O
analyses	O
revealed	O
the	O
unique	O
metabolic	O
potential	O
of	O
dominant	O
bacteria	O
of	O
the	O
Antarctic	O
polynya	O
at	O
a	O
finer	O
taxonomic	O
level	O
.	O

The	O
information	O
can	O
be	O
used	O
to	O
predict	O
temporal	O
community	O
succession	O
linked	O
to	O
the	O
availability	O
of	O
substrates	O
derived	O
from	O
the	O
P	B-bacteria
.	I-bacteria
antarctica	I-bacteria
bloom	O
.	O

Global	O
warming	O
has	O
resulted	O
in	O
compositional	O
changes	O
in	O
phytoplankton	O
from	O
P	B-bacteria
.	I-bacteria
antarctica	I-bacteria
to	O
diatoms	O
,	O
and	O
thus	O
,	O
repeated	O
parallel	O
studies	O
in	O
various	O
polynyas	O
are	O
required	O
to	O
predict	O
global	O
warming	O
-	O
related	O
changes	O
in	O
carbon	O
remineralization	O
.	O

Is	O
it	O
true	O
that	O
gut	O
microbiota	O
is	O
considered	O
as	O
panacea	O
in	O
cancer	O
therapy	O
?	O

Recent	O
studies	O
demonstrated	O
that	O
a	O
combination	O
of	O
the	O
gut	O
microbiome	O
has	O
the	O
vital	O
effect	O
on	O
the	O
efficacy	O
of	O
anticancer	O
immune	O
therapies	O
.	O

Regulatory	O
effects	O
of	O
microbiota	O
have	O
been	O
shown	O
in	O
different	O
types	O
of	O
cancer	O
therapies	O
such	O
as	O
chemotherapy	O
and	O
immunotherapy	O
.	O

Immune	O
-	O
checkpoint	O
-	O
blocked	O
therapies	O
are	O
the	O
recent	O
efficient	O
cancer	O
immunotherapy	O
strategies	O
.	O

The	O
target	O
of	O
immune	O
-	O
checkpoint	O
blocking	O
is	O
cytotoxic	O
T	O
lymphocyte	O
protein	O
-	O
4	O
(	O
CTLA	O
-	O
4	O
)	O
or	O
blockade	O
of	O
programmed	O
death	O
-	O
1	O
(	O
PD	O
-	O
1	O
)	O
protein	O
and	O
its	O
ligand	O
programmed	O
death	O
ligand	O
1	O
(	O
PD	O
-	O
L1	O
)	O
that	O
they	O
have	O
been	O
considered	O
as	O
cancer	O
immunotherapy	O
in	O
recent	O
years	O
.	O

In	O
the	O
latest	O
studies	O
,	O
it	O
have	O
been	O
demonstrated	O
that	O
several	O
gut	O
bacteria	O
such	O
as	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
,	O
Bifidobacterium	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
Faecalibacterium	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
and	O
Bacteroides	B-bacteria
fragilis	I-bacteria
have	O
the	O
regulatory	O
effects	O
on	O
PD	O
-	O
1	O
,	O
PD	O
-	O
L1	O
,	O
and	O
CTLA	O
-	O
4	O
blocked	O
anticancer	O
therapy	O
outcome	O
.	O

Microcapillary	O
sampling	O
of	O
Baltic	O
Sea	O
copepod	O
gut	O
microbiomes	O
indicates	O
high	O
variability	O
among	O
individuals	O
and	O
the	O
potential	O
for	O
methane	O
production	O
.	O

The	O
paradox	O
of	O
methane	O
oversaturation	O
in	O
oxygenated	O
surface	O
water	O
has	O
been	O
described	O
in	O
many	O
pelagic	O
systems	O
and	O
still	O
raises	O
the	O
question	O
of	O
the	O
source	O
.	O

Temora	O
sp	O
.	O
and	O
Acartia	O
sp	O
.	O
commonly	O
dominate	O
the	O
surface	O
and	O
subsurface	O
waters	O
of	O
the	O
central	O
Baltic	O
Sea	O
.	O

It	O
is	O
hypothesised	O
that	O
their	O
gut	O
microbiome	O
at	O
least	O
partly	O
contributes	O
to	O
the	O
methane	O
anomaly	O
in	O
this	O
ecosystem	O
.	O

However	O
,	O
the	O
potential	O
pathway	O
for	O
this	O
methane	O
production	O
remains	O
unclear	O
.	O

Using	O
a	O
microcapillary	O
technique	O
,	O
we	O
successfully	O
overcame	O
the	O
challenge	O
of	O
sampling	O
the	O
gut	O
microbiome	O
of	O
copepods	O
<	O
1	O
mm	O
.	O

16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
revealed	O
differences	O
among	O
the	O
dominant	O
bacterial	O
communities	O
associated	O
with	O
Temora	O
sp	O
.	O
(	O
Actinobacteria	B-bacteria
,	O
Betaproteobacteria	B-bacteria
and	O
Flavobacteriia	B-bacteria
)	O
and	O
Acartia	O
sp	O
.	O
(	O
Actinobacteria	B-bacteria
,	O
Alphaproteobacteria	B-bacteria
and	O
Betaproteobacteria	B-bacteria
)	O
and	O
the	O
surrounding	O
water	O
(	O
Proteobacteria	B-bacteria
,	O
Cyanobacteria	B-bacteria
and	O
Verrucomicrobia	B-bacteria
)	O
,	O
but	O
also	O
intraspecific	O
variability	O
.	O

In	O
both	O
copepods	O
,	O
gut	O
-	O
specific	O
prokaryotic	O
taxa	O
and	O
indicative	O
species	O
for	O
methane	O
production	O
pathways	O
(	O
methanogenesis	O
,	O
dimethylsulfoniopropionate	O
or	O
methylphosphonate	O
)	O
were	O
present	O
.	O

The	O
relative	O
abundance	O
of	O
archaea	O
and	O
methanogens	O
was	O
investigated	O
using	O
droplet	O
digital	O
polymerase	O
chain	O
reaction	O
and	O
showed	O
a	O
high	O
variability	O
among	O
copepod	O
individuals	O
,	O
underlining	O
intra	O
-	O
and	O
interspecific	O
differences	O
in	O
copepod	O
-	O
associated	O
prokaryotic	O
communities	O
.	O

Overall	O
,	O
this	O
work	O
highlights	O
that	O
the	O
guts	O
of	O
Temora	O
sp	O
.	O
and	O
Acartia	O
sp	O
.	O
have	O
the	O
potential	O
for	O
methane	O
production	O
but	O
are	O
probably	O
no	O
hotspot	O
.	O

Journal	O
of	O
Nutritional	O
Biochemistry	O
Special	O
Issue	O
:	O
nutritional	O
modulation	O
of	O
the	O
gut	O
microbiome	O
in	O
gastrointestinal	O
and	O
metabolic	O
disease	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
infection	O
and	O
gastric	O
cancer	O
biology	O
:	O
tempering	O
a	O
double	O
-	O
edged	O
sword	O
.	O

Helicobacter	B-bacteria
pylori	I-bacteria
(	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
)	O
infection	O
affects	O
an	O
estimated	O
4	O
.	O
4	O
billion	O
people	O
globally	O
.	O

Moreover	O
,	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
presents	O
the	O
most	O
significant	O
risk	O
factor	O
for	O
gastric	O
cancer	O
and	O
low	O
-	O
grade	O
mucosa	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
MALT	O
)	O
lymphoma	O
,	O
and	O
it	O
is	O
the	O
first	O
example	O
of	O
bacterial	O
infection	O
linked	O
to	O
carcinogenesis	O
.	O

Here	O
,	O
we	O
contend	O
that	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
research	O
,	O
which	O
focuses	O
on	O
a	O
cancer	O
-	O
causing	O
pathogen	O
resident	O
in	O
a	O
relatively	O
accessible	O
organ	O
,	O
the	O
stomach	O
,	O
could	O
constitute	O
an	O
exemplar	O
for	O
microbial	O
-	O
related	O
carcinogenesis	O
in	O
less	O
tractable	O
organs	O
,	O
such	O
as	O
the	O
pancreas	O
and	O
lung	O
.	O

In	O
this	O
context	O
,	O
molecular	O
biological	O
approaches	O
that	O
could	O
reap	O
rewards	O
are	O
reviewed	O
,	O
including	O
:	O
(	O
1	O
)	O
gastric	O
cancer	O
dynamics	O
,	O
particularly	O
the	O
role	O
of	O
stem	O
cells	O
and	O
the	O
heterogeneity	O
of	O
neoplastic	O
cells	O
,	O
which	O
are	O
currently	O
being	O
investigated	O
at	O
the	O
single	O
-	O
cell	O
sequencing	O
level	O
;	O
(	O
2	O
)	O
mechanobiology	O
,	O
and	O
the	O
role	O
of	O
three	O
-	O
dimensional	O
organoids	O
and	O
matrix	O
metalloproteases	O
;	O
and	O
(	O
3	O
)	O
the	O
connection	O
between	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
and	O
host	O
pathophysiology	O
and	O
the	O
gut	O
microbiome	O
.	O

In	O
the	O
context	O
of	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
'	O
s	O
contribution	O
to	O
gastric	O
cancer	O
,	O
several	O
important	O
conundrums	O
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

From	O
among	O
them	O
,	O
this	O
article	O
discusses	O
(	O
1	O
)	O
why	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
infection	O
,	O
which	O
causes	O
both	O
gastric	O
and	O
duodenal	O
inflammation	O
,	O
is	O
only	O
linked	O
to	O
gastric	O
cancer	O
;	O
(	O
2	O
)	O
whether	O
a	O
`	O
`	O
precision	O
oncomicrobiology	O
'	O
'	O
approach	O
could	O
enable	O
a	O
fine	O
-	O
tuning	O
of	O
the	O
expression	O
of	O
only	O
cancer	O
-	O
implicated	O
H	B-bacteria
.	I-bacteria
pylori	I-bacteria
genes	O
while	O
maintaining	O
beneficial	O
H	O
.	O
pylori	O
-	O
mediated	O
factors	O
in	O
extra	O
-	O
gastric	O
tissues	O
;	O
and	O
(	O
3	O
)	O
the	O
feasibility	O
of	O
using	O
antibiotics	O
targeting	O
the	O
microbial	O
DNA	O
damage	O
system	O
,	O
which	O
shares	O
commonalities	O
with	O
mechanisms	O
for	O
human	O
cell	O
replication	O
,	O
as	O
chemopreventives	O
.	O

Additional	O
therapeutic	O
perspectives	O
are	O
also	O
discussed	O
.	O

Intestinal	O
dysbiosis	O
compromises	O
alveolar	O
macrophage	O
immunity	O
to	O
Mycobacterium	B-bacteria
tuberculosis	I-bacteria
.	O

Current	O
treatments	O
for	O
tuberculosis	O
(	O
TB	O
)	O
are	O
effective	O
in	O
controlling	O
Mycobacterium	B-bacteria
tuberculosis	I-bacteria
(	O
Mtb	B-bacteria
)	O
growth	O
,	O
yet	O
have	O
significant	O
side	O
effects	O
and	O
do	O
not	O
prevent	O
reinfection	O
.	O

Therefore	O
,	O
it	O
is	O
critical	O
to	O
understand	O
why	O
our	O
host	O
defense	O
system	O
is	O
unable	O
to	O
generate	O
permanent	O
immunity	O
to	O
Mtb	O
despite	O
prolonged	O
anti	O
-	O
tuberculosis	O
therapy	O
(	O
ATT	O
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
treatment	O
of	O
mice	O
with	O
the	O
most	O
widely	O
used	O
anti	O
-	O
TB	O
drugs	O
,	O
rifampicin	O
(	O
RIF	O
)	O
or	O
isoniazid	O
(	O
INH	O
)	O
and	O
pyrazinamide	O
(	O
PYZ	O
)	O
,	O
significantly	O
altered	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
.	O

Unexpectedly	O
,	O
treatment	O
of	O
mice	O
with	O
the	O
pro	O
-	O
Mtb	O
drugs	O
INH	O
and	O
PYZ	O
,	O
but	O
not	O
RIF	O
,	O
prior	O
to	O
Mtb	O
infection	O
resulted	O
in	O
an	O
increased	O
bacterial	O
burden	O
,	O
an	O
effect	O
that	O
was	O
reversible	O
by	O
fecal	O
transplantation	O
from	O
untreated	O
animals	O
.	O

Mechanistically	O
,	O
susceptibility	O
of	O
INH	O
/	O
PYZ	O
-	O
treated	O
mice	O
was	O
associated	O
with	O
impaired	O
metabolism	O
of	O
alveolar	O
macrophages	O
and	O
defective	O
bactericidal	O
activity	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
dysbiosis	O
induced	O
by	O
ATT	O
administered	O
to	O
millions	O
of	O
individuals	O
worldwide	O
may	O
have	O
adverse	O
effects	O
on	O
the	O
anti	O
-	O
Mtb	O
response	O
of	O
alveolar	O
macrophages	O
.	O

Gut	O
microbiota	O
regulates	O
lacteal	O
integrity	O
by	O
inducing	O
VEGF	O
-	O
C	O
in	O
intestinal	O
villus	O
macrophages	O
.	O

A	O
lacteal	O
is	O
a	O
blunt	O
-	O
ended	O
,	O
long	O
,	O
tube	O
-	O
like	O
lymphatic	O
vessel	O
located	O
in	O
the	O
center	O
of	O
each	O
intestinal	O
villus	O
that	O
provides	O
a	O
unique	O
route	O
for	O
drainage	O
of	O
absorbed	O
lipids	O
from	O
the	O
small	O
intestine	O
.	O

However	O
,	O
key	O
regulators	O
for	O
maintaining	O
lacteal	O
integrity	O
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
explore	O
whether	O
and	O
how	O
the	O
gut	O
microbiota	O
regulates	O
lacteal	O
integrity	O
.	O

Germ	O
depletion	O
by	O
antibiotic	O
treatment	O
triggers	O
lacteal	O
regression	O
during	O
adulthood	O
and	O
delays	O
lacteal	O
maturation	O
during	O
the	O
postnatal	O
period	O
.	O

In	O
accordance	O
with	O
compromised	O
lipid	O
absorption	O
,	O
the	O
button	O
-	O
like	O
junction	O
between	O
lymphatic	O
endothelial	O
cells	O
,	O
which	O
is	O
ultrastructurally	O
open	O
to	O
permit	O
free	O
entry	O
of	O
dietary	O
lipids	O
into	O
lacteals	O
,	O
is	O
significantly	O
reduced	O
in	O
lacteals	O
of	O
germ	O
-	O
depleted	O
mice	O
.	O

Lacteal	O
defects	O
are	O
also	O
found	O
in	O
germ	O
-	O
free	O
mice	O
,	O
but	O
conventionalization	O
of	O
germ	O
-	O
free	O
mice	O
leads	O
to	O
normalization	O
of	O
lacteals	O
.	O

Mechanistically	O
,	O
VEGF	O
-	O
C	O
secreted	O
from	O
villus	O
macrophages	O
upon	O
MyD88	O
-	O
dependent	O
recognition	O
of	O
microbes	O
and	O
their	O
products	O
is	O
a	O
main	O
factor	O
in	O
lacteal	O
integrity	O
.	O

Collectively	O
,	O
we	O
conclude	O
that	O
the	O
gut	O
microbiota	O
is	O
a	O
crucial	O
regulator	O
for	O
lacteal	O
integrity	O
by	O
endowing	O
its	O
unique	O
microenvironment	O
and	O
regulating	O
villus	O
macrophages	O
in	O
small	O
intestine	O
.	O

Antibiotic	O
resistance	O
in	O
grass	O
and	O
soil	O
.	O

Antibiotic	O
resistance	O
is	O
currently	O
one	O
of	O
the	O
greatest	O
threats	O
to	O
human	O
health	O
.	O

The	O
global	O
overuse	O
of	O
antibiotics	O
in	O
human	O
medicine	O
and	O
in	O
agriculture	O
has	O
resulted	O
in	O
the	O
proliferation	O
and	O
dissemination	O
of	O
a	O
multitude	O
of	O
antibiotic	O
resistance	O
genes	O
(	O
ARGs	O
)	O
.	O

Despite	O
a	O
large	O
proportion	O
of	O
antibiotics	O
being	O
used	O
in	O
agriculture	O
,	O
little	O
is	O
understood	O
about	O
how	O
this	O
may	O
contribute	O
to	O
the	O
overall	O
antibiotic	O
resistance	O
crisis	O
.	O

The	O
use	O
of	O
manure	O
in	O
agriculture	O
is	O
a	O
traditional	O
and	O
widespread	O
practice	O
and	O
is	O
essential	O
for	O
returning	O
nutrients	O
to	O
the	O
soil	O
;	O
however	O
,	O
the	O
impact	O
of	O
continuous	O
manure	O
application	O
on	O
the	O
environmental	O
microbiome	O
and	O
resistome	O
is	O
unknown	O
.	O

The	O
use	O
of	O
antibiotics	O
in	O
animal	O
husbandry	O
in	O
therapeutic	O
and	O
sub	O
-	O
therapeutic	O
doses	O
creates	O
a	O
selective	O
pressure	O
for	O
ARGs	O
in	O
the	O
gut	O
microbiome	O
of	O
the	O
animal	O
,	O
which	O
is	O
then	O
excreted	O
in	O
the	O
faeces	O
.	O

Therefore	O
,	O
the	O
application	O
of	O
manure	O
to	O
agricultural	O
land	O
is	O
a	O
potential	O
route	O
for	O
the	O
transmission	O
of	O
antibiotic	O
-	O
resistant	O
bacteria	O
from	O
livestock	O
to	O
crops	O
,	O
animals	O
and	O
humans	O
.	O

It	O
is	O
of	O
vital	O
importance	O
to	O
understand	O
the	O
mechanisms	O
behind	O
ARG	O
enrichment	O
and	O
its	O
maintenance	O
both	O
on	O
the	O
plant	O
and	O
within	O
the	O
soil	O
microbiome	O
to	O
mitigate	O
the	O
spread	O
of	O
this	O
resistance	O
to	O
animals	O
and	O
humans	O
.	O

Understanding	O
this	O
link	O
between	O
human	O
health	O
,	O
animal	O
health	O
,	O
plant	O
health	O
and	O
the	O
environment	O
is	O
crucial	O
to	O
inform	O
implementation	O
of	O
new	O
regulations	O
and	O
practice	O
regarding	O
antibiotic	O
use	O
in	O
agriculture	O
and	O
manure	O
application	O
,	O
aimed	O
at	O
ensuring	O
the	O
antibiotic	O
resistance	O
crisis	O
is	O
not	O
aggravated	O
.	O

Innate	O
lymphoid	O
cell	O
type	O
3	O
-	O
derived	O
interleukin	O
-	O
22	O
boosts	O
lipocalin	O
-	O
2	O
production	O
in	O
intestinal	O
epithelial	O
cells	O
via	O
synergy	O
between	O
STAT3	O
and	O
NF	O
-	O
kappaB	O
.	O

Escherichia	B-bacteria
coli	I-bacteria
and	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
are	O
opportunistic	O
pathogens	O
that	O
are	O
commonly	O
associated	O
with	O
infections	O
at	O
mucosal	O
surfaces	O
,	O
such	O
as	O
the	O
lung	O
or	O
the	O
gut	O
.	O

The	O
host	O
response	O
against	O
these	O
types	O
of	O
infections	O
includes	O
the	O
release	O
of	O
epithelial	O
-	O
derived	O
antimicrobial	O
factors	O
such	O
as	O
lipocalin	O
-	O
2	O
(	O
LCN	O
-	O
2	O
)	O
,	O
a	O
protein	O
that	O
specifically	O
inhibits	O
the	O
iron	O
acquisition	O
of	O
Enterobacteriaceae	B-bacteria
by	O
binding	O
and	O
neutralizing	O
the	O
bacterial	O
iron	O
-	O
scavenging	O
molecule	O
enterobactin	O
.	O

Regulation	O
of	O
epithelial	O
antimicrobial	O
responses	O
,	O
including	O
the	O
release	O
of	O
LCN	O
-	O
2	O
,	O
has	O
previously	O
been	O
shown	O
to	O
depend	O
on	O
IL	O
-	O
22	O
,	O
a	O
cytokine	O
produced	O
by	O
innate	O
lymphoid	O
cells	O
type	O
3	O
(	O
ILC3	O
)	O
during	O
Enterobacteriaceae	B-bacteria
infections	O
.	O

However	O
,	O
much	O
remains	O
unknown	O
about	O
the	O
extent	O
to	O
which	O
antimicrobial	O
responses	O
are	O
regulated	O
by	O
IL	O
-	O
22	O
and	O
how	O
IL	O
-	O
22	O
regulates	O
the	O
expression	O
and	O
production	O
of	O
LCN	O
-	O
2	O
in	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
.	O

Our	O
study	O
demonstrates	O
how	O
IL	O
-	O
22	O
-	O
induced	O
activation	O
of	O
STAT3	O
synergizes	O
with	O
NF	O
-	O
kappaB	O
-	O
activating	O
cytokines	O
to	O
enhance	O
LCN	O
-	O
2	O
expression	O
in	O
human	O
IECs	O
and	O
elucidates	O
how	O
ILC3	O
are	O
involved	O
in	O
LCN	O
-	O
2	O
-	O
mediated	O
host	O
defense	O
against	O
Enterobacteriaceae	B-bacteria
.	O

Together	O
,	O
these	O
results	O
provide	O
new	O
insight	O
into	O
the	O
role	O
of	O
ILC3	O
in	O
regulating	O
LCN	O
-	O
2	O
expression	O
in	O
human	O
IECs	O
and	O
could	O
prove	O
useful	O
in	O
future	O
studies	O
aimed	O
at	O
understanding	O
the	O
host	O
response	O
against	O
Enterobacteriaceae	B-bacteria
as	O
well	O
as	O
for	O
the	O
development	O
of	O
antimicrobial	O
therapies	O
against	O
Enterobacteriaceae	O
-	O
related	O
infections	O
.	O

Effects	O
of	O
dietary	O
fat	O
on	O
gut	O
microbiota	O
and	O
faecal	O
metabolites	O
,	O
and	O
their	O
relationship	O
with	O
cardiometabolic	O
risk	O
factors	O
:	O
a	O
6	O
-	O
month	O
randomised	O
controlled	O
-	O
feeding	O
trial	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
whether	O
diets	O
differing	O
in	O
fat	O
content	O
alter	O
the	O
gut	O
microbiota	O
and	O
faecal	O
metabolomic	O
profiles	O
,	O
and	O
to	O
determine	O
their	O
relationship	O
with	O
cardiometabolic	O
risk	O
factors	O
in	O
healthy	O
adults	O
whose	O
diet	O
is	O
in	O
a	O
transition	O
from	O
a	O
traditional	O
low	O
-	O
fat	O
diet	O
to	O
a	O
diet	O
high	O
in	O
fat	O
and	O
reduced	O
in	O
carbohydrate	O
.	O

METHODS	O
:	O
In	O
a	O
6	O
-	O
month	O
randomised	O
controlled	O
-	O
feeding	O
trial	O
,	O
217	O
healthy	O
young	O
adults	O
(	O
aged	O
18	O
-	O
35	O
years	O
;	O
body	O
mass	O
index	O
<	O
28	O
kg	O
/	O
m	O
(	O
2	O
)	O
;	O
52	O
%	O
women	O
)	O
who	O
completed	O
the	O
whole	O
trial	O
were	O
included	O
.	O

All	O
the	O
foods	O
were	O
provided	O
during	O
the	O
intervention	O
period	O
.	O

The	O
three	O
isocaloric	O
diets	O
were	O
:	O
a	O
lower	O
-	O
fat	O
diet	O
(	O
fat	O
20	O
%	O
energy	O
)	O
,	O
a	O
moderate	O
-	O
fat	O
diet	O
(	O
fat	O
30	O
%	O
energy	O
)	O
and	O
a	O
higher	O
-	O
fat	O
diet	O
(	O
fat	O
40	O
%	O
energy	O
)	O
.	O

The	O
effects	O
of	O
the	O
dietary	O
interventions	O
on	O
the	O
gut	O
microbiota	O
,	O
faecal	O
metabolomics	O
and	O
plasma	O
inflammatory	O
factors	O
were	O
investigated	O
.	O

RESULTS	O
:	O
The	O
lower	O
-	O
fat	O
diet	O
was	O
associated	O
with	O
increased	O
alpha	O
-	O
diversity	O
assessed	O
by	O
the	O
Shannon	O
index	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
increased	O
abundance	O
of	O
Blautia	B-bacteria
(	O
p	O
=	O
0	O
.	O
007	O
)	O
and	O
Faecalibacterium	B-bacteria
(	O
p	O
=	O
0	O
.	O
04	O
)	O
,	O
whereas	O
the	O
higher	O
-	O
fat	O
diet	O
was	O
associated	O
with	O
increased	O
Alistipes	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
,	O
Bacteroides	B-bacteria
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
decreased	O
Faecalibacterium	B-bacteria
(	O
p	O
=	O
0	O
.	O
04	O
)	O
.	O

The	O
concentration	O
of	O
total	O
short	O
-	O
chain	O
fatty	O
acids	O
was	O
significantly	O
decreased	O
in	O
the	O
higher	O
-	O
fat	O
diet	O
group	O
in	O
comparison	O
with	O
the	O
other	O
groups	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
cometabolites	O
p	O
-	O
cresol	O
and	O
indole	O
,	O
known	O
to	O
be	O
associated	O
with	O
host	O
metabolic	O
disorders	O
,	O
were	O
decreased	O
in	O
the	O
lower	O
-	O
fat	O
diet	O
group	O
.	O

In	O
addition	O
,	O
the	O
higher	O
-	O
fat	O
diet	O
was	O
associated	O
with	O
faecal	O
enrichment	O
in	O
arachidonic	O
acid	O
and	O
the	O
lipopolysaccharide	O
biosynthesis	O
pathway	O
as	O
well	O
as	O
elevated	O
plasma	O
proinflammatory	O
factors	O
after	O
the	O
intervention	O
.	O

CONCLUSION	O
:	O
Higher	O
-	O
fat	O
consumption	O
by	O
healthy	O
young	O
adults	O
whose	O
diet	O
is	O
in	O
a	O
state	O
of	O
nutrition	O
transition	O
appeared	O
to	O
be	O
associated	O
with	O
unfavourable	O
changes	O
in	O
gut	O
microbiota	O
,	O
faecal	O
metabolomic	O
profiles	O
and	O
plasma	O
proin	O
fl	O
ammatory	O
factors	O
,	O
which	O
might	O
confer	O
adverse	O
consequences	O
for	O
long	O
-	O
term	O
health	O
outcomes	O
.	O

TRIAL	O
REGISTRATION	O
NUMBER	O
:	O
NCT02355795	O
;	O
Results	O
.	O

Ameliorative	O
effect	O
of	O
probiotics	O
(	O
Lactobacillus	B-bacteria
paracaseii	I-bacteria
and	O
Protexin	O
(	O
R	O
)	O
)	O
and	O
prebiotics	O
(	O
propolis	O
and	O
bee	O
pollen	O
)	O
on	O
clindamycin	O
and	O
propionic	O
acid	O
-	O
induced	O
oxidative	O
stress	O
and	O
altered	O
gut	O
microbiota	O
in	O
a	O
rodent	O
model	O
of	O
autism	O
.	O

Colonization	O
by	O
toxin	O
-	O
producing	O
bacteria	O
in	O
the	O
gut	O
plays	O
a	O
major	O
role	O
in	O
bowel	O
problems	O
in	O
autistic	O
patients	O
.	O

Prebiotics	O
can	O
inhibit	O
the	O
growth	O
of	O
these	O
pathogenic	O
microbes	O
by	O
nourishing	O
beneficial	O
bacteria	O
,	O
while	O
probiotics	O
-	O
-	O
live	O
microorganisms	O
-	O
-	O
can	O
balance	O
the	O
gut	O
bacteria	O
;	O
thus	O
,	O
both	O
together	O
can	O
maintain	O
healthy	O
bacteria	O
in	O
the	O
gut	O
.	O

The	O
present	O
study	O
was	O
conducted	O
to	O
find	O
the	O
effect	O
of	O
probiotics	O
and	O
prebiotics	O
in	O
balancing	O
the	O
gut	O
flora	O
in	O
a	O
rodent	O
model	O
of	O
autism	O
linked	O
with	O
a	O
clindamycin	O
-	O
induced	O
altered	O
gut	O
.	O

The	O
effects	O
of	O
probiotics	O
and	O
prebiotics	O
on	O
oxidative	O
stress	O
markers	O
in	O
the	O
brain	O
were	O
also	O
evaluated	O
.	O

Eight	O
groups	O
of	O
hamsters	O
were	O
assigned	O
,	O
with	O
Group	O
I	O
serving	O
as	O
the	O
control	O
;	O
Group	O
II	O
,	O
as	O
the	O
autistic	O
model	O
,	O
was	O
treated	O
with	O
250	O
mg	O
propionic	O
acid	O
/	O
kg	O
BW	O
/	O
day	O
for	O
3	O
days	O
;	O
Group	O
III	O
was	O
treated	O
with	O
clindamycin	O
30	O
mg	O
/	O
kg	O
BW	O
for	O
3	O
days	O
;	O
Groups	O
IV	O
and	O
V	O
were	O
treated	O
with	O
bee	O
pollen	O
and	O
propolis	O
(	O
supposed	O
prebiotics	O
)	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
BW	O
/	O
day	O
for	O
28	O
days	O
;	O
Group	O
VI	O
and	O
Group	O
VII	O
were	O
treated	O
with	O
Lactobacillus	B-bacteria
paracaseii	I-bacteria
and	O
Protexin	O
(	O
R	O
)	O
(	O
supposed	O
probiotics	O
)	O
for	O
28	O
days	O
;	O
and	O
finally	O
,	O
Group	O
VIII	O
was	O
anorectally	O
transplanted	O
with	O
stool	O
from	O
normal	O
animals	O
for	O
5	O
days	O
.	O

Remarkable	O
changes	O
were	O
measured	O
in	O
oxidative	O
stress	O
markers	O
,	O
primarily	O
glutathione	O
and	O
vitamin	O
C	O
,	O
in	O
the	O
brains	O
of	O
hamsters	O
in	O
the	O
propionic	O
acid	O
-	O
and	O
clindamycin	O
-	O
treated	O
group	O
.	O

All	O
probiotic	O
/	O
prebiotic	O
treatments	O
showed	O
ameliorative	O
effects	O
;	O
however	O
,	O
lactobacillus	B-bacteria
had	O
the	O
strongest	O
effect	O
.	O

We	O
conclude	O
that	O
pro	O
-	O
and	O
prebiotic	O
supplements	O
may	O
be	O
effective	O
to	O
revive	O
healthy	O
digestive	O
system	O
function	O
in	O
autistic	O
patients	O
.	O

The	O
disappointing	O
results	O
of	O
the	O
fecal	O
transplants	O
suggest	O
that	O
further	O
study	O
is	O
needed	O
to	O
develop	O
an	O
appropriate	O
technique	O
.	O

Sequence	O
and	O
cultivation	O
study	O
of	O
Muribaculaceae	B-bacteria
reveals	O
novel	O
species	O
,	O
host	O
preference	O
,	O
and	O
functional	O
potential	O
of	O
this	O
yet	O
undescribed	O
family	O
.	O

BACKGROUND	O
:	O
Bacteria	O
within	O
family	O
S24	O
-	I-bacteria
7	O
(	O
phylum	O
Bacteroidetes	B-bacteria
)	O
are	O
dominant	O
in	O
the	O
mouse	O
gut	O
microbiota	O
and	O
detected	O
in	O
the	O
intestine	O
of	O
other	O
animals	O
.	O

Because	O
they	O
had	O
not	O
been	O
cultured	O
until	O
recently	O
and	O
the	O
family	O
classification	O
is	O
still	O
ambiguous	O
,	O
interaction	O
with	O
their	O
host	O
was	O
difficult	O
to	O
study	O
and	O
confusion	O
still	O
exists	O
regarding	O
sequence	O
data	O
annotation	O
.	O

METHODS	O
:	O
We	O
investigated	O
family	O
S24	O
-	O
7	O
by	O
combining	O
data	O
from	O
large	O
-	O
scale	O
16S	O
rRNA	O
gene	O
analysis	O
and	O
from	O
functional	O
and	O
taxonomic	O
studies	O
of	O
metagenomic	O
and	O
cultured	O
species	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
685	O
species	O
was	O
inferred	O
by	O
full	O
-	O
length	O
16S	O
rRNA	O
gene	O
sequence	O
clustering	O
.	O

While	O
many	O
species	O
could	O
not	O
be	O
assigned	O
ecological	O
habitats	O
(	O
93	O
,	O
045	O
samples	O
analyzed	O
)	O
,	O
the	O
mouse	O
was	O
the	O
most	O
commonly	O
identified	O
host	O
(	O
average	O
of	O
20	O
%	O
relative	O
abundance	O
and	O
nine	O
co	O
-	O
occurring	O
species	O
)	O
.	O

Shotgun	O
metagenomics	O
allowed	O
reconstruction	O
of	O
59	O
molecular	O
species	O
,	O
of	O
which	O
34	O
were	O
representative	O
of	O
the	O
16S	O
rRNA	O
gene	O
-	O
derived	O
species	O
clusters	O
.	O

In	O
addition	O
,	O
cultivation	O
efforts	O
allowed	O
isolating	O
five	O
strains	O
representing	O
three	O
species	O
,	O
including	O
two	O
novel	O
taxa	O
.	O

Genome	O
analysis	O
revealed	O
that	O
S24	O
-	O
7	O
spp	O
.	I-bacteria
are	O
functionally	O
distinct	O
from	O
neighboring	O
families	O
and	O
versatile	O
with	O
respect	O
to	O
complex	O
carbohydrate	O
degradation	O
.	O

CONCLUSIONS	O
:	O
We	O
provide	O
novel	O
data	O
on	O
the	O
diversity	O
,	O
ecology	O
,	O
and	O
description	O
of	O
bacterial	O
family	O
S24	O
-	O
7	O
,	O
for	O
which	O
the	O
name	O
Muribaculaceae	B-bacteria
is	O
proposed	O
.	O

Brain	O
Aging	O
and	O
Gut	O
(	O
-	O
)	O
Brain	O
Axis	O
.	O

In	O
the	O
last	O
decade	O
,	O
the	O
microbiome	O
in	O
general	O
and	O
the	O
gut	O
microbiome	O
in	O
particular	O
have	O
been	O
associated	O
not	O
only	O
to	O
brain	O
development	O
and	O
function	O
,	O
but	O
also	O
to	O
the	O
pathophysiology	O
of	O
brain	O
aging	O
and	O
to	O
neurodegenerative	O
disorders	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
,	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
,	O
depression	O
,	O
or	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
[	O
.	O
.	O
.	O
]	O
.	O

Gut	O
Mucosal	O
Proteins	O
and	O
Bacteriome	O
Are	O
Shaped	O
by	O
the	O
Saturation	O
Index	O
of	O
Dietary	O
Lipids	O
.	O

The	O
dynamics	O
of	O
the	O
tripartite	O
relationship	O
between	O
the	O
host	O
,	O
gut	O
bacteria	O
and	O
diet	O
in	O
the	O
gut	O
is	O
relatively	O
unknown	O
.	O

An	O
imbalance	O
between	O
harmful	O
and	O
protective	O
gut	O
bacteria	O
,	O
termed	O
dysbiosis	O
,	O
has	O
been	O
linked	O
to	O
many	O
diseases	O
and	O
has	O
most	O
often	O
been	O
attributed	O
to	O
high	O
-	O
fat	O
dietary	O
intake	O
.	O

However	O
,	O
we	O
recently	O
clarified	O
that	O
the	O
type	O
of	O
fat	O
,	O
not	O
calories	O
,	O
were	O
important	O
in	O
the	O
development	O
of	O
murine	O
colitis	O
.	O

To	O
further	O
understand	O
the	O
host	O
-	O
microbe	O
dynamic	O
in	O
response	O
to	O
dietary	O
lipids	O
,	O
we	O
fed	O
mice	O
isocaloric	O
high	O
-	O
fat	O
diets	O
containing	O
either	O
milk	O
fat	O
,	O
corn	O
oil	O
or	O
olive	O
oil	O
and	O
performed	O
16S	O
rRNA	O
gene	O
sequencing	O
of	O
the	O
colon	O
microbiome	O
and	O
mass	O
spectrometry	O
-	O
based	O
relative	O
quantification	O
of	O
the	O
colonic	O
metaproteome	O
.	O

The	O
corn	O
oil	O
diet	O
,	O
rich	O
in	O
omega	O
-	O
6	O
polyunsaturated	O
fatty	O
acids	O
,	O
increased	O
the	O
potential	O
for	O
pathobiont	O
survival	O
and	O
invasion	O
in	O
an	O
inflamed	O
,	O
oxidized	O
and	O
damaged	O
gut	O
while	O
saturated	O
fatty	O
acids	O
promoted	O
compensatory	O
inflammatory	O
responses	O
involved	O
in	O
tissue	O
healing	O
.	O

We	O
conclude	O
that	O
various	O
lipids	O
uniquely	O
alter	O
the	O
host	O
-	O
microbe	O
interaction	O
in	O
the	O
gut	O
.	O

While	O
high	O
-	O
fat	O
consumption	O
has	O
a	O
distinct	O
impact	O
on	O
the	O
gut	O
microbiota	O
,	O
the	O
type	O
of	O
fatty	O
acids	O
alters	O
the	O
relative	O
microbial	O
abundances	O
and	O
predicted	O
functions	O
.	O

These	O
results	O
support	O
that	O
the	O
type	O
of	O
fat	O
are	O
key	O
to	O
understanding	O
the	O
biological	O
effects	O
of	O
high	O
-	O
fat	O
diets	O
on	O
gut	O
health	O
.	O

Enhanced	O
bioconversion	O
of	O
dairy	O
and	O
chicken	O
manure	O
by	O
the	O
interaction	O
of	O
exogenous	O
bacteria	O
and	O
black	O
soldier	O
fly	O
larvae	O
.	O

Generation	O
of	O
insects	O
'	O
biomass	O
from	O
lignocellulose	O
rich	O
organic	O
wastes	O
is	O
of	O
significant	O
challenges	O
in	O
reducing	O
the	O
environmental	O
impact	O
of	O
wastes	O
and	O
in	O
sustaining	O
feed	O
and	O
food	O
security	O
.	O

This	O
research	O
looked	O
at	O
the	O
effects	O
of	O
lignocellulotic	O
exogenous	O
bacteria	O
in	O
the	O
black	O
soldier	O
fly	O
(	O
BSF	O
)	O
organic	O
waste	O
conversion	O
system	O
for	O
biomass	O
production	O
and	O
lignocellulose	O
biodegradation	O
of	O
dairy	O
and	O
chicken	O
manures	O
.	O

Six	O
exogenous	O
bacteria	O
were	O
investigated	O
for	O
cellulolytic	O
activity	O
with	O
carboxymethyl	O
cellulose	O
and	O
found	O
that	O
these	O
tested	O
bacterial	O
strains	O
degrade	O
the	O
cellulose	O
.	O

In	O
this	O
study	O
;	O
a	O
co	O
-	O
conversion	O
process	O
using	O
Hermetia	B-bacteria
illucens	I-bacteria
larvae	O
to	O
convert	O
the	O
previously	O
studied	O
best	O
mixing	O
ratio	O
of	O
dairy	O
manure	O
(	O
DM	O
)	O
and	O
chicken	O
manure	O
(	O
CHM	O
)	O
(	O
2	O
:	O
3	O
)	O
and	O
cellulose	O
degrading	O
bacteria	O
was	O
established	O
to	O
enhance	O
the	O
larval	O
biomass	O
production	O
,	O
waste	O
reduction	O
and	O
manure	O
nutrient	O
degradation	O
.	O

BSF	O
larvae	O
assisted	O
by	O
MRO2	O
(	O
R5	O
)	O
has	O
the	O
best	O
outcome	O
measures	O
:	O
survival	O
rate	O
(	O
99	O
.	O
1	O
%	O
)	O
,	O
development	O
time	O
(	O
19	O
.	O
0d	O
)	O
,	O
manure	O
reduction	O
rate	O
(	O
48	O
.	O
7	O
%	O
)	O
,	O
bioconversion	O
rate	O
(	O
10	O
.	O
8	O
%	O
)	O
,	O
food	O
conversion	O
ratio	O
(	O
4	O
.	O
5	O
)	O
,	O
efficiency	O
of	O
conversion	O
of	O
ingestion	O
(	O
22	O
.	O
3	O
)	O
,	O
cellulose	O
(	O
72	O
.	O
9	O
%	O
)	O
,	O
hemicellulose	O
(	O
68	O
.	O
5	O
%	O
)	O
,	O
lignin	O
(	O
32	O
.	O
8	O
%	O
)	O
,	O
and	O
nutrient	O
utilization	O
(	O
protein	O
,	O
71	O
.	O
2	O
%	O
and	O
fat	O
,	O
67	O
.	O
8	O
%	O
)	O
.	O

By	O
analyzing	O
the	O
fiber	O
structural	O
changes	O
by	O
scanning	O
electron	O
microscopy	O
and	O
Fourier	O
-	O
transformed	O
infrared	O
spectroscopy	O
(	O
FT	O
-	O
IR	O
)	O
,	O
we	O
assume	O
that	O
exogenous	O
bacteria	O
assist	O
the	O
BSF	O
larvae	O
that	O
trigger	O
lead	O
to	O
structural	O
and	O
chemical	O
modification	O
of	O
fibers	O
.	O

We	O
hypothesized	O
that	O
these	O
surface	O
and	O
textural	O
changes	O
are	O
beneficial	O
to	O
the	O
associated	O
gut	O
bacteria	O
,	O
thereby	O
helping	O
to	O
larval	O
growth	O
and	O
reduce	O
waste	O
.	O

The	O
finding	O
of	O
the	O
investigation	O
showed	O
that	O
enhanced	O
conversion	O
of	O
DM	O
and	O
CHM	O
by	O
BSF	O
larvae	O
assisted	O
with	O
lignocellulotic	O
exogenous	O
bacteria	O
could	O
play	O
key	O
role	O
in	O
the	O
manure	O
management	O
.	O

Cyclic	O
Dinucleotides	O
Inhibit	O
Osteoclast	O
Differentiation	O
Through	O
STING	O
-	O
Mediated	O
Interferon	O
-	O
beta	O
Signaling	O
.	O

Cyclic	O
dinucleotides	O
(	O
CDNs	O
)	O
,	O
such	O
as	O
cyclic	O
diadenylate	O
monophosphate	O
and	O
cyclic	O
diguanylate	O
monophosphate	O
,	O
are	O
commensal	O
bacteria	O
-	O
derived	O
second	O
messengers	O
in	O
the	O
gut	O
that	O
modulate	O
bacterial	O
survival	O
,	O
colonization	O
,	O
and	O
biofilm	O
formation	O
.	O

Recently	O
,	O
CDNs	O
have	O
been	O
discovered	O
to	O
have	O
an	O
immunomodulatory	O
activity	O
by	O
inducing	O
the	O
expression	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
through	O
STING	O
signaling	O
pathway	O
in	O
macrophages	O
.	O

Because	O
CDNs	O
are	O
possibly	O
absorbed	O
and	O
delivered	O
into	O
the	O
bone	O
marrow	O
,	O
where	O
bone	O
-	O
resorbing	O
osteoclasts	O
are	O
derived	O
from	O
monocyte	O
/	O
macrophage	O
lineages	O
,	O
CDNs	O
could	O
affect	O
bone	O
metabolism	O
by	O
regulating	O
osteoclast	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
CDNs	O
on	O
the	O
differentiation	O
and	O
function	O
of	O
osteoclasts	O
and	O
osteoblasts	O
.	O

When	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
(	O
BMMs	O
)	O
were	O
differentiated	O
into	O
osteoclasts	O
with	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
and	O
receptor	O
activator	O
of	O
NF	O
-	O
kappaB	O
ligand	O
(	O
RANKL	O
)	O
in	O
the	O
presence	O
of	O
CDNs	O
,	O
the	O
differentiation	O
was	O
inhibited	O
by	O
CDNs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
contrast	O
,	O
CDNs	O
did	O
not	O
influence	O
the	O
differentiation	O
of	O
committed	O
osteoclasts	O
or	O
osteoblast	O
precursors	O
.	O

STING	O
signaling	O
pathway	O
appeared	O
to	O
be	O
critical	O
for	O
CDNs	O
-	O
mediated	O
inhibition	O
of	O
osteoclast	O
differentiation	O
since	O
CDNs	O
induced	O
the	O
phosphorylation	O
of	O
TBK1	O
and	O
IRF3	O
,	O
a	O
representative	O
feature	O
of	O
STING	O
activation	O
,	O
and	O
osteoclast	O
differentiation	O
was	O
restored	O
in	O
STING	O
knockdown	O
BMMs	O
with	O
siRNA	O
.	O

Moreover	O
,	O
CDNs	O
increased	O
the	O
mRNA	O
expression	O
of	O
STING	O
-	O
meditated	O
IFN	O
-	O
beta	O
,	O
which	O
is	O
a	O
negative	O
regulator	O
of	O
osteoclastogenesis	O
.	O

In	O
addition	O
,	O
CDNs	O
also	O
induced	O
the	O
phosphorylation	O
of	O
STAT1	O
,	O
which	O
mediates	O
IFN	O
-	O
alpha	O
/	O
beta	O
receptor	O
(	O
IFNAR	O
)	O
signal	O
transduction	O
.	O

The	O
inhibitory	O
effects	O
of	O
CDNs	O
on	O
osteoclast	O
differentiation	O
were	O
not	O
observed	O
in	O
the	O
presence	O
of	O
antibody	O
blocking	O
IFNAR	O
or	O
in	O
macrophages	O
derived	O
from	O
IFNAR1	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Experiments	O
using	O
a	O
mouse	O
calvarial	O
implantation	O
model	O
showed	O
that	O
RANKL	O
-	O
induced	O
bone	O
resorption	O
was	O
inhibited	O
by	O
CDNs	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
CDNs	O
inhibit	O
osteoclast	O
differentiation	O
and	O
bone	O
resorption	O
through	O
induction	O
of	O
IFN	O
-	O
beta	O
via	O
the	O
STING	O
signaling	O
pathway	O
.	O

(	O
c	O
)	O
2019	O
American	O
Society	O
for	O
Bone	O
and	O
Mineral	O
Research	O
.	O

Low	O
rate	O
of	O
gut	O
colonization	O
by	O
extended	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
producing	O
Enterobacteriaceae	B-bacteria
in	O
HIV	O
infected	O
persons	O
as	O
compared	O
to	O
healthy	O
individuals	O
in	O
Nepal	O
.	O

A	O
worldwide	O
increase	O
in	O
the	O
gastrointestinal	O
colonization	O
by	O
extended	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
(	O
ESBL	O
)	O
-	O
producing	O
bacteria	O
has	O
been	O
observed	O
.	O

Their	O
prevalence	O
amongst	O
Healthy	O
People	O
Living	O
with	O
HIV	O
(	O
HPLWH	O
)	O
has	O
not	O
been	O
investigated	O
adequately	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
and	O
compare	O
the	O
rates	O
of	O
and	O
risk	O
factors	O
for	O
intestinal	O
carriage	O
and	O
acquisition	O
of	O
extended	B-bacteria
-	I-bacteria
spectrum	I-bacteria
beta	I-bacteria
-	I-bacteria
lactamase	I-bacteria
producing	I-bacteria
Enterobacteriaceae	I-bacteria
(	O
ESBL	B-bacteria
-	I-bacteria
E	I-bacteria
)	O
and	O
carbapenemase	B-bacteria
-	I-bacteria
producing	I-bacteria
Enterobacteriaceae	I-bacteria
(	O
CPE	B-bacteria
)	O
among	O
healthy	O
people	O
living	O
with	O
HIV	O
(	O
HPLWH	O
)	O
and	O
healthy	O
HIV	O
negative	O
population	O
in	O
the	O
community	O
.	O

A	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
.	O

Rectal	O
swabs	O
from	O
HPLWH	O
(	O
n	O
=	O
119	O
)	O
and	O
HIV	O
negative	O
individuals	O
(	O
n	O
=	O
357	O
)	O
from	O
the	O
community	O
were	O
screened	O
for	O
ESBL	O
and	O
CPE	O
.	O

Phenotypically	O
confirmed	O
ESBL	O
-	O
E	O
strains	O
were	O
genotyped	O
by	O
multiplex	O
PCR	O
.	O

The	O
risk	O
factors	O
associated	O
with	O
ESBL	O
-	O
E	O
colonization	O
were	O
analyzed	O
by	O
a	O
multivariable	O
conditional	O
logistic	O
regression	O
analysis	O
.	O

Specimen	O
from	O
357	O
healthy	O
volunteers	O
(	O
213	O
female	O
and	O
144	O
male	O
)	O
and	O
119	O
HPLWH	O
(	O
82	O
female	O
and	O
37	O
male	O
)	O
with	O
a	O
median	O
age	O
of	O
30	O
[	O
IQR	O
11	O
-	O
50	O
]	O
years	O
were	O
included	O
in	O
the	O
study	O
.	O

ESBL	O
colonization	O
were	O
found	O
in	O
45	O
(	O
37	O
.	O
82	O
%	O
[	O
CI	O
29	O
.	O
09	O
,	O
47	O
.	O
16	O
]	O
)	O
and	O
246	O
(	O
68	O
.	O
91	O
%	O
[	O
CI	O
63	O
.	O
93	O
,	O
73	O
.	O
49	O
]	O
)	O
,	O
HPLWH	O
and	O
healthy	O
HIV	O
negative	O
participants	O
respectively	O
.	O

HPLWH	O
had	O
lower	O
ESBL	O
carriage	O
rate	O
(	O
odds	O
ratio	O
0	O
.	O
274	O
[	O
CI	O
0	O
.	O
178	O
,	O
0	O
.	O
423	O
]	O
)	O
compared	O
to	O
healthy	O
HIV	O
negative	O
subject	O
'	O
s	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
this	O
study	O
,	O
no	O
carbapenemase	O
-	O
producing	O
bacteria	O
were	O
isolated	O
.	O
CTX	O
-	O
M	O
-	O
15	O
type	O
was	O
the	O
most	O
predominant	O
genotype	O
in	O
both	O
groups	O
.	O

Livestock	O
contact	O
and	O
over	O
-	O
the	O
-	O
counter	O
medications	O
were	O
significantly	O
associated	O
with	O
a	O
higher	O
ESBL	O
-	O
E	O
carriage	O
rate	O
among	O
healthy	O
subjects	O
.	O

This	O
is	O
the	O
first	O
study	O
in	O
Nepal	O
that	O
has	O
demonstrated	O
a	O
high	O
rate	O
of	O
gut	O
colonization	O
by	O
ESBL	O
-	O
E	O
in	O
the	O
community	O
,	O
predominantly	O
of	O
blaCTX	O
-	O
M	O
-	O
15	O
genotype	O
.	O

This	O
study	O
divulges	O
the	O
low	O
fecal	O
carriage	O
rate	O
of	O
ESBL	O
producing	O
bacteria	O
in	O
HPLWH	O
group	O
compared	O
to	O
healthy	O
individuals	O
in	O
western	O
Nepal	O
.	O

The	O
factors	O
responsible	O
for	O
this	O
inverse	O
relationship	O
of	O
HIV	O
status	O
and	O
gut	O
colonization	O
by	O
ESBL	O
-	O
E	O
are	O
unidentified	O
and	O
require	O
further	O
large	O
-	O
scale	O
study	O
.	O

The	O
Gut	O
Microbiota	O
and	O
Ageing	O
.	O

Understanding	O
how	O
the	O
human	O
gut	O
microbiota	O
might	O
influence	O
ageing	O
is	O
challenging	O
.	O

The	O
gut	O
microbiota	O
is	O
a	O
hugely	O
complex	O
ecology	O
of	O
organisms	O
that	O
varies	O
greatly	O
with	O
individuals	O
and	O
time	O
,	O
making	O
age	O
-	O
related	O
changes	O
difficult	O
to	O
measure	O
.	O

However	O
,	O
elderly	O
and	O
younger	O
populations	O
do	O
show	O
differences	O
in	O
gut	O
microbe	O
composition	O
.	O

The	O
key	O
question	O
is	O
whether	O
these	O
differences	O
only	O
reflect	O
age	O
-	O
related	O
changes	O
in	O
host	O
physiology	O
and	O
diet	O
,	O
or	O
if	O
microbes	O
can	O
drive	O
host	O
ageing	O
?	O

Model	O
organisms	O
allow	O
this	O
question	O
to	O
be	O
addressed	O
.	O

Longitudinal	O
analyses	O
in	O
the	O
fruit	O
fly	O
Drosophila	B-bacteria
melanogaster	I-bacteria
show	O
that	O
changes	O
in	O
microbial	O
composition	O
precedes	O
intestinal	O
and	O
host	O
ageing	O
,	O
and	O
antibiotic	O
treatment	O
increases	O
lifespan	O
,	O
implicating	O
microbes	O
in	O
accelerating	O
ageing	O
.	O

Antibiotics	O
also	O
extend	O
the	O
lifespan	O
of	O
middle	O
-	O
aged	O
killifish	O
but	O
additional	O
transplantation	O
of	O
gut	O
microbes	O
from	O
young	O
killifish	O
extends	O
lifespan	O
further	O
,	O
suggesting	O
a	O
positive	O
effect	O
of	O
microbes	O
associated	O
with	O
young	O
animals	O
.	O

Microbes	O
from	O
old	O
,	O
but	O
not	O
young	O
,	O
mice	O
induce	O
inflammation	O
when	O
added	O
to	O
germ	O
-	O
free	O
mice	O
suggesting	O
that	O
microbes	O
become	O
more	O
harmful	O
to	O
the	O
host	O
with	O
age	O
.	O

These	O
studies	O
implicate	O
broad	O
classes	O
of	O
bacteria	O
,	O
particularly	O
members	O
of	O
the	O
phylum	O
Proteobacteria	B-bacteria
,	O
as	O
drivers	O
of	O
ageing	O
in	O
a	O
feed	O
-	O
forward	O
loop	O
with	O
intestinal	O
degradation	O
and	O
inflammation	O
.	O

The	O
nematode	O
Caenorhabditis	B-bacteria
elegans	I-bacteria
can	O
be	O
associated	O
with	O
single	O
strains	O
of	O
genetically	O
-	O
tractable	O
bacteria	O
,	O
and	O
this	O
simplified	O
system	O
has	O
revealed	O
specific	O
interventions	O
in	O
bacterial	O
metabolism	O
,	O
such	O
as	O
inhibition	O
of	O
bacterial	O
folate	O
synthesis	O
,	O
that	O
extend	O
animal	O
lifespan	O
.	O

Transferring	O
this	O
understanding	O
to	O
the	O
human	O
microbiota	O
is	O
challenging	O
but	O
promises	O
to	O
reveal	O
how	O
manipulation	O
of	O
the	O
gut	O
microbiota	O
might	O
be	O
a	O
route	O
to	O
maintain	O
health	O
in	O
old	O
age	O
.	O

Dietary	O
supplementation	O
with	O
fermented	O
Mao	O
-	O
tai	O
lees	O
beneficially	O
affects	O
gut	O
microbiota	O
structure	O
and	O
function	O
in	O
pigs	O
.	O

Gut	O
microbiota	O
positively	O
contribute	O
to	O
livestock	O
nutrition	O
and	O
metabolism	O
.	O

The	O
manipulation	O
of	O
these	O
microbes	O
may	O
improve	O
animal	O
health	O
.	O

Some	O
feed	O
additives	O
improve	O
livestock	O
health	O
and	O
metabolism	O
by	O
regulating	O
gut	O
microbiota	O
composition	O
and	O
activity	O
.	O

We	O
fed	O
hybrid	O
pigs	O
diets	O
supplemented	O
with	O
0	O
%	O
(	O
control	O
)	O
,	O
5	O
%	O
(	O
treat	O
1	O
)	O
,	O
10	O
%	O
(	O
treat	O
2	O
)	O
,	O
or	O
15	O
%	O
(	O
treat	O
3	O
)	O
fermented	O
Mao	O
-	O
tai	O
lees	O
(	O
FML	O
)	O
for	O
90	O
days	O
.	O

Short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
bioamines	O
,	O
and	O
microbial	O
communities	O
found	O
in	O
colonic	O
contents	O
were	O
analyzed	O
to	O
investigate	O
microbiota	O
composition	O
and	O
metabolic	O
profiles	O
.	O

Concentrations	O
of	O
straight	O
-	O
chain	O
fatty	O
acids	O
(	O
e	O
.	O
g	O
.	O
,	O
acetate	O
,	O
propionate	O
,	O
and	O
butyrate	O
)	O
and	O
tyramine	O
increased	O
with	O
FML	O
supplementation	O
content	O
.	O

Contrary	O
to	O
the	O
minor	O
effects	O
of	O
5	O
%	O
and	O
10	O
%	O
FML	O
on	O
gut	O
microbiota	O
,	O
15	O
%	O
FML	O
influenced	O
beta	O
diversity	O
(	O
Jaccard	O
or	O
Bray	O
-	O
Curtis	O
dissimilarity	O
)	O
but	O
not	O
alpha	O
diversity	O
(	O
number	O
of	O
operational	O
taxonomic	O
units	O
and	O
Shannon	O
diversity	O
)	O
of	O
pig	O
gut	O
microbial	O
communities	O
compared	O
to	O
the	O
control	O
group	O
.	O

Notably	O
,	O
15	O
%	O
FML	O
animals	O
were	O
characterized	O
by	O
a	O
higher	O
abundance	O
of	O
potentially	O
beneficial	O
bacteria	O
(	O
Lactobacillus	B-bacteria
and	O
Akkermansia	B-bacteria
)	O
but	O
lower	O
abundances	O
of	O
potential	O
pathogens	O
(	O
Escherichia	B-bacteria
)	O
.	O

Numerous	O
genes	O
associated	O
with	O
metabolism	O
(	O
e	O
.	O
g	O
.	O
,	O
starch	O
,	O
sucrose	O
,	O
and	O
sulfur	O
-	O
compounds	O
metabolism	O
)	O
showed	O
a	O
higher	O
relative	O
abundance	O
in	O
the	O
15	O
%	O
FML	O
than	O
in	O
the	O
control	O
group	O
.	O

Additionally	O
,	O
most	O
Phascolarctobacterium	B-bacteria
,	O
Treponema	B-bacteria
,	O
Prevotella	B-bacteria
,	O
and	O
Faecalibacterium	B-bacteria
bacterial	O
markers	O
in	O
the	O
15	O
%	O
FML	O
group	O
were	O
positively	O
correlated	O
with	O
straight	O
-	O
chain	O
fatty	O
acid	O
concentrations	O
,	O
suggesting	O
that	O
these	O
bacteria	O
are	O
likely	O
associated	O
with	O
SCFA	O
production	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
demonstrate	O
the	O
beneficial	O
effects	O
of	O
15	O
%	O
FML	O
on	O
fermentation	O
of	O
undigested	O
compounds	O
and	O
gut	O
microbiota	O
composition	O
in	O
the	O
colon	O
.	O

Thus	O
,	O
15	O
%	O
FML	O
supplementation	O
in	O
pig	O
feed	O
may	O
possibly	O
represent	O
a	O
way	O
to	O
optimize	O
pig	O
colon	O
health	O
for	O
livestock	O
farming	O
.	O

Intestinal	O
nerve	O
cell	O
injury	O
occurs	O
prior	O
to	O
insulin	O
resistance	O
in	O
female	O
mice	O
ingesting	O
a	O
high	O
-	O
fat	O
diet	O
.	O

Diabetic	O
patients	O
suffer	O
from	O
gastrointestinal	O
disorders	O
associated	O
with	O
dysmotility	O
,	O
enteric	O
neuropathy	O
and	O
dysbiosis	O
of	O
gut	O
microbiota	O
;	O
however	O
,	O
gender	O
differences	O
are	O
not	O
fully	O
known	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
causes	O
type	O
two	O
diabetes	O
(	O
T2D	O
)	O
in	O
male	O
mice	O
after	O
4	O
-	O
8	O
weeks	O
but	O
only	O
does	O
so	O
in	O
female	O
mice	O
after	O
16	O
weeks	O
.	O

This	O
study	O
seeks	O
to	O
determine	O
whether	O
sex	O
influences	O
the	O
development	O
of	O
intestinal	O
dysmotility	O
,	O
enteric	O
neuropathy	O
and	O
dysbiosis	O
in	O
mice	O
fed	O
HFD	O
.	O

We	O
fed	O
8	O
-	O
week	O
-	O
old	O
C57BL6	O
male	O
and	O
female	O
mice	O
a	O
standard	O
chow	O
diet	O
(	O
SCD	O
)	O
or	O
a	O
72	O
%	O
kcal	O
HFD	O
for	O
8	O
weeks	O
.	O

We	O
analyzed	O
the	O
associations	O
between	O
sex	O
and	O
intestinal	O
dysmotility	O
,	O
neuropathy	O
and	O
dysbiosis	O
using	O
motility	O
assays	O
,	O
immunohistochemistry	O
and	O
next	O
-	O
generation	O
sequencing	O
.	O

HFD	O
ingestion	O
caused	O
obesity	O
,	O
glucose	O
intolerance	O
and	O
insulin	O
resistance	O
in	O
male	O
but	O
not	O
female	O
mice	O
.	O

However	O
,	O
HFD	O
ingestion	O
slowed	O
intestinal	O
propulsive	O
motility	O
in	O
both	O
male	O
and	O
female	O
mice	O
.	O

This	O
was	O
associated	O
with	O
decreased	O
inhibitory	O
neuromuscular	O
transmission	O
,	O
loss	O
of	O
myenteric	O
inhibitory	O
motor	O
neurons	O
and	O
axonal	O
swelling	O
and	O
loss	O
of	O
cytoskeletal	O
filaments	O
.	O

HFD	O
induced	O
dysbiosis	O
and	O
changed	O
the	O
abundance	O
of	O
specific	O
bacteria	O
,	O
especially	O
Allobaculum	B-bacteria
,	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
,	O
which	O
correlated	O
with	O
dysmotility	O
and	O
neuropathy	O
.	O

Female	O
mice	O
had	O
higher	O
immunoreactivity	O
and	O
numbers	O
of	O
myenteric	O
inhibitory	O
motor	O
neurons	O
,	O
matching	O
larger	O
amplitudes	O
of	O
inhibitory	O
junction	O
potentials	O
.	O

This	O
study	O
suggests	O
that	O
sex	O
influences	O
the	O
development	O
of	O
HFD	O
-	O
induced	O
metabolic	O
syndrome	O
but	O
dysmotility	O
,	O
neuropathy	O
and	O
dysbiosis	O
occur	O
independent	O
of	O
sex	O
and	O
prior	O
to	O
T2D	O
conditions	O
.	O

Gastrointestinal	O
dysmotility	O
,	O
neuropathy	O
and	O
dysbiosis	O
might	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathophysiology	O
of	O
T2D	O
in	O
humans	O
irrespective	O
of	O
sex	O
.	O

Associations	O
of	O
prenatal	O
exposure	O
to	O
polybrominated	O
diphenyl	O
ethers	O
and	O
polychlorinated	O
biphenyls	O
with	O
long	O
-	O
term	O
gut	O
microbiome	O
structure	O
:	O
a	O
pilot	O
study	O
.	O

Background	O
:	O
The	O
gut	O
microbiome	O
is	O
influenced	O
by	O
early	O
-	O
life	O
exposures	O
,	O
but	O
-	O
despite	O
potentially	O
enormous	O
implications	O
for	O
child	O
health	O
-	O
is	O
understudied	O
in	O
environmental	O
epidemiology	O
.	O

This	O
pilot	O
study	O
is	O
one	O
of	O
the	O
first	O
to	O
explore	O
in	O
utero	O
exposures	O
and	O
long	O
-	O
term	O
gut	O
microbiome	O
profiles	O
.	O

We	O
examined	O
the	O
association	O
between	O
exposure	O
to	O
polybrominated	O
diphenyl	O
ethers	O
(	O
PBDEs	O
)	O
and	O
polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
during	O
pregnancy	O
and	O
the	O
mid	O
-	O
childhood	O
gut	O
microbiome	O
.	O

Methods	O
:	O
We	O
measured	O
levels	O
of	O
PBDE	O
-	O
47	O
,	O
-	O
99	O
,	O
-	O
100	O
,	O
and	O
-	O
153	O
and	O
PCB	O
-	O
138	O
,	O
-	O
153	O
,	O
and	O
-	O
180	O
in	O
maternal	O
plasma	O
during	O
early	O
pregnancy	O
(	O
n	O
=	O
18	O
)	O
and	O
at	O
delivery	O
(	O
n	O
=	O
25	O
)	O
in	O
women	O
of	O
European	O
descent	O
who	O
breastfed	O
the	O
child	O
participant	O
of	O
the	O
Gestation	O
and	O
Environment	O
cohort	O
in	O
Sherbrooke	O
,	O
Quebec	O
(	O
recruited	O
2007	O
-	O
2009	O
)	O
.	O

Bacteria	O
in	O
the	O
mid	O
-	O
childhood	O
(	O
6	O
-	O
8	O
years	O
)	O
fecal	O
microbiome	O
were	O
detected	O
with	O
16S	O
rRNA	O
sequencing	O
.	O

To	O
test	O
for	O
differences	O
at	O
the	O
taxon	O
level	O
,	O
we	O
used	O
the	O
Microbiome	O
Comprehensive	O
Association	O
Mapping	O
algorithm	O
.	O

Results	O
:	O
Early	O
pregnancy	O
PCB	O
-	O
153	O
,	O
-	O
180	O
,	O
and	O
the	O
sum	O
of	O
PCBs	O
(	O
Sigma3PCB	O
)	O
concentrations	O
were	O
associated	O
with	O
a	O
higher	O
relative	O
abundance	O
of	O
Propionibacteriales	B-bacteria
and	O
Propionibacteriaceae	B-bacteria
in	O
mid	O
-	O
childhood	O
.	O

Higher	O
PCB	O
-	O
180	O
and	O
Sigma3PCB	O
were	O
associated	O
with	O
higher	O
relative	O
abundance	O
of	O
Bacillales	O
Family	O
XI	O
.	O

Higher	O
PBDE	O
-	O
99	O
exposure	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
uncultured	O
bacteria	O
within	O
the	O
Ruminococcaceae	B-bacteria
NK4A214	I-bacteria
group	O
and	O
PBDE	O
-	O
47	O
was	O
associated	O
with	O
differences	O
in	O
Ruminococcus	B-bacteria
2	I-bacteria
.	O

These	O
taxon	O
-	O
level	O
changes	O
did	O
not	O
result	O
in	O
differences	O
in	O
within	O
-	O
or	O
between	O
-	O
subject	O
diversity	O
.	O

Exposures	O
at	O
delivery	O
were	O
not	O
associated	O
with	O
differences	O
in	O
taxa	O
.	O

Conclusions	O
:	O
Prenatal	O
exposure	O
to	O
PCBs	O
and	O
PBDEs	O
is	O
associated	O
with	O
mid	O
-	O
childhood	O
gut	O
microbiome	O
profiles	O
.	O

Larger	O
studies	O
are	O
needed	O
to	O
confirm	O
these	O
results	O
and	O
explore	O
health	O
implications	O
.	O

Bacterial	O
Dysbiosis	O
and	O
Translocation	O
in	O
Psoriasis	O
Vulgaris	O
.	O

Psoriasis	O
vulgaris	O
is	O
a	O
chronic	O
inflammatory	O
skin	O
condition	O
,	O
associated	O
with	O
both	O
a	O
physical	O
and	O
a	O
psychological	O
burden	O
.	O

Our	O
understanding	O
of	O
the	O
etiology	O
of	O
this	O
disease	O
remains	O
incomplete	O
.	O

Conventionally	O
,	O
psoriasis	O
has	O
been	O
viewed	O
as	O
a	O
condition	O
that	O
manifests	O
solely	O
in	O
the	O
skin	O
.	O

However	O
,	O
the	O
systemic	O
inflammatory	O
nature	O
of	O
this	O
disease	O
has	O
been	O
confirmed	O
by	O
the	O
presence	O
of	O
a	O
wide	O
array	O
of	O
dysregulated	O
cytokines	O
and	O
inflammatory	O
markers	O
in	O
the	O
serum	O
of	O
these	O
patients	O
.	O

Both	O
dysregulated	O
gut	O
and	O
skin	O
microbiomes	O
have	O
been	O
found	O
in	O
association	O
with	O
psoriasis	O
.	O

An	O
evident	O
association	O
also	O
exists	O
between	O
inflammatory	O
bowel	O
disease	O
and	O
this	O
condition	O
.	O

Regarding	O
the	O
skin	O
microbiome	O
,	O
changes	O
have	O
been	O
observed	O
in	O
the	O
relative	O
abundance	O
of	O
Firmicutes	B-bacteria
,	O
Actinobacteria	B-bacteria
,	O
and	O
Proteobacteria	B-bacteria
.	O

Additionally	O
,	O
Staphylococcus	B-bacteria
and	O
Streptococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
detected	O
more	O
frequently	O
in	O
lesional	O
skin	O
.	O

Alterations	O
in	O
the	O
gut	O
microbiome	O
have	O
been	O
characterized	O
by	O
a	O
decrease	O
in	O
the	O
Bacteroidetes	B-bacteria
phylum	I-bacteria
and	O
an	O
increase	O
in	O
the	O
Faecalibacterium	B-bacteria
genus	I-bacteria
.	O

We	O
suggest	O
that	O
dysbiosis	O
of	O
the	O
skin	O
and	O
gut	O
microbiota	O
may	O
contribute	O
to	O
psoriasis	O
,	O
by	O
promoting	O
the	O
translocation	O
of	O
microbes	O
from	O
these	O
sites	O
into	O
the	O
bloodstream	O
.	O

Consistent	O
with	O
the	O
Iron	O
Dysregulation	O
and	O
Dormant	O
Microbes	O
hypothesis	O
,	O
these	O
microorganisms	O
are	O
in	O
a	O
physiologically	O
dormant	O
state	O
,	O
but	O
may	O
be	O
awakened	O
periodically	O
and	O
shed	O
their	O
cell	O
wall	O
components	O
,	O
such	O
as	O
lipopolysaccharide	O
and	O
lipoteichoic	O
acid	O
.	O

Both	O
of	O
these	O
inflammagens	O
may	O
contribute	O
significantly	O
to	O
maintaining	O
a	O
chronic	O
inflammatory	O
state	O
in	O
the	O
host	O
,	O
such	O
as	O
is	O
seen	O
in	O
individuals	O
diagnosed	O
with	O
psoriasis	O
.	O

Higher	O
Risk	O
of	O
Stroke	O
Is	O
Correlated	O
With	O
Increased	O
Opportunistic	O
Pathogen	O
Load	O
and	O
Reduced	O
Levels	O
of	O
Butyrate	O
-	O
Producing	O
Bacteria	O
in	O
the	O
Gut	O
.	O

Objective	O
:	O
Gut	O
microbiota	O
is	O
a	O
newly	O
identified	O
risk	O
factor	O
for	O
stroke	O
,	O
and	O
there	O
are	O
no	O
large	O
prospective	O
studies	O
linking	O
the	O
baseline	O
gut	O
microbiome	O
to	O
long	O
-	O
term	O
risk	O
of	O
stroke	O
.	O

We	O
present	O
here	O
the	O
correlation	O
between	O
the	O
gut	O
microbiota	O
and	O
stroke	O
risk	O
in	O
people	O
with	O
no	O
prior	O
stroke	O
history	O
.	O

Methods	O
:	O
A	O
total	O
of	O
141	O
participants	O
aged	O
>	O
/	O
=	O
60	O
years	O
without	O
prior	O
history	O
of	O
stroke	O
were	O
recruited	O
and	O
divided	O
into	O
low	O
-	O
risk	O
,	O
medium	O
-	O
risk	O
,	O
and	O
high	O
-	O
risk	O
groups	O
based	O
on	O
known	O
risk	O
factors	O
and	O
whether	O
they	O
were	O
suffering	O
from	O
chronic	O
diseases	O
.	O

The	O
composition	O
of	O
their	O
gut	O
microbiomes	O
was	O
compared	O
using	O
16S	O
rRNA	O
gene	O
amplicon	O
next	O
-	O
generation	O
-	O
sequencing	O
and	O
Quantitative	O
Insights	O
into	O
Microbial	O
Ecology	O
(	O
QIIME	O
)	O
analysis	O
.	O

Levels	O
of	O
fecal	O
short	O
-	O
chain	O
fatty	O
acids	O
were	O
measured	O
using	O
gas	O
chromatography	O
.	O

Results	O
:	O
We	O
found	O
that	O
opportunistic	O
pathogens	O
(	O
e	O
.	O
g	O
.	O
,	O
Enterobacteriaceae	B-bacteria
and	O
Veillonellaceae	B-bacteria
)	O
and	O
lactate	O
-	O
producing	O
bacteria	O
(	O
e	O
.	O
g	O
.	O
,	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
)	O
were	O
enriched	O
,	O
while	O
butyrate	O
-	O
producing	O
bacteria	O
(	O
e	O
.	O
g	O
.	O
,	O
Lachnospiraceae	B-bacteria
and	O
Ruminococcaceae	B-bacteria
)	O
were	O
depleted	O
,	O
in	O
the	O
high	O
-	O
risk	O
group	O
compared	O
to	O
the	O
low	O
-	O
risk	O
group	O
.	O

Butyrate	O
concentrations	O
were	O
also	O
lower	O
in	O
the	O
fecal	O
samples	O
obtained	O
from	O
the	O
high	O
-	O
risk	O
group	O
than	O
from	O
the	O
low	O
-	O
risk	O
group	O
.	O

The	O
concentrations	O
of	O
other	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
e	O
.	O
g	O
.	O
,	O
acetate	O
,	O
propionate	O
,	O
isobutyrate	O
,	O
isovalerate	O
,	O
and	O
valerate	O
)	O
in	O
the	O
gut	O
were	O
comparable	O
among	O
the	O
three	O
groups	O
.	O

Conclusion	O
:	O
Participants	O
at	O
high	O
risk	O
of	O
stroke	O
were	O
characterized	O
by	O
the	O
enrichment	O
of	O
opportunistic	O
pathogens	O
,	O
low	O
abundance	O
of	O
butyrate	O
-	O
producing	O
bacteria	O
,	O
and	O
reduced	O
concentrations	O
of	O
fecal	O
butyrate	O
.	O

More	O
researches	O
into	O
the	O
gut	O
microbiota	O
as	O
a	O
risk	O
factor	O
in	O
stroke	O
should	O
be	O
carried	O
out	O
in	O
the	O
near	O
future	O
.	O

MAIT	O
Cells	O
Upregulate	O
alpha4beta7	O
in	O
Response	O
to	O
Acute	O
Simian	O
Immunodeficiency	O
Virus	O
/	O
Simian	O
HIV	O
Infection	O
but	O
Are	O
Resistant	O
to	O
Peripheral	O
Depletion	O
in	O
Pigtail	O
Macaques	O
.	O

Mucosal	O
-	O
associated	O
invariant	O
T	O
(	O
MAIT	O
)	O
cells	O
are	O
nonconventional	O
T	O
lymphocytes	O
that	O
recognize	O
bacterial	O
metabolites	O
presented	O
by	O
MR1	O
.	O

Whereas	O
gut	O
bacterial	O
translocation	O
and	O
the	O
loss	O
/	O
dysfunction	O
of	O
peripheral	O
MAIT	O
cells	O
in	O
HIV	O
infection	O
is	O
well	O
described	O
,	O
MAIT	O
cells	O
in	O
nonhuman	O
primate	O
models	O
are	O
poorly	O
characterized	O
.	O

We	O
generated	O
a	O
pigtail	O
macaque	O
(	O
PTM	O
)	O
-	O
specific	O
MR1	O
tetramer	O
and	O
characterized	O
MAIT	O
cells	O
in	O
serial	O
samples	O
from	O
naive	O
and	O
SIV	O
-	O
or	O
simian	O
HIV	O
-	O
infected	O
PTM	O
.	O

Although	O
PTM	O
MAIT	O
cells	O
generally	O
resemble	O
the	O
phenotype	O
and	O
transcriptional	O
profile	O
of	O
human	O
MAIT	O
cells	O
,	O
they	O
exhibited	O
uniquely	O
low	O
expression	O
of	O
the	O
gut	O
-	O
homing	O
marker	O
alpha4beta7	O
and	O
were	O
not	O
enriched	O
at	O
the	O
gut	O
mucosa	O
.	O

PTM	O
MAIT	O
cells	O
responded	O
to	O
SIV	O
/	O
simian	O
HIV	O
infection	O
by	O
proliferating	O
and	O
upregulating	O
alpha4beta7	O
,	O
coinciding	O
with	O
increased	O
MAIT	O
cell	O
frequency	O
in	O
the	O
rectum	O
.	O

By	O
36	O
wk	O
of	O
infection	O
,	O
PTM	O
MAIT	O
cells	O
were	O
activated	O
and	O
exhibited	O
a	O
loss	O
of	O
Tbet	O
expression	O
but	O
were	O
not	O
depleted	O
as	O
in	O
HIV	O
infection	O
.	O

Our	O
data	O
suggest	O
the	O
following	O
:	O
1	O
)	O
MAIT	O
cell	O
activation	O
and	O
exhaustion	O
is	O
uncoupled	O
from	O
the	O
hallmark	O
depletion	O
of	O
MAIT	O
cells	O
during	O
HIV	O
infection	O
;	O
and	O
2	O
)	O
the	O
lack	O
of	O
PTM	O
MAIT	O
cell	O
enrichment	O
at	O
the	O
gut	O
mucosa	O
may	O
prevent	O
depletion	O
during	O
chronic	O
infection	O
,	O
providing	O
a	O
model	O
to	O
assess	O
potential	O
immunotherapeutic	O
approaches	O
to	O
modify	O
MAIT	O
cell	O
trafficking	O
during	O
HIV	O
infection	O
.	O

Microbiota	O
Metabolism	O
Promotes	O
Synthesis	O
of	O
the	O
Human	O
Ah	O
Receptor	O
Agonist	O
2	O
,	O
8	O
-	O
Dihydroxyquinoline	O
.	O

The	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AHR	O
)	O
is	O
a	O
major	O
regulator	O
of	O
immune	O
function	O
within	O
the	O
gastrointestinal	O
tract	O
.	O

Resident	O
microbiota	O
are	O
capable	O
of	O
influencing	O
AHR	O
-	O
dependent	O
signaling	O
pathways	O
via	O
production	O
of	O
an	O
array	O
of	O
bioactive	O
molecules	O
that	O
act	O
as	O
AHR	O
agonists	O
,	O
such	O
as	O
indole	O
or	O
indole	O
-	O
3	O
-	O
aldehyde	O
.	O

Bacteria	O
produce	O
a	O
number	O
of	O
quinoline	O
derivatives	O
,	O
of	O
which	O
some	O
function	O
as	O
quorum	O
-	O
sensing	O
molecules	O
.	O

Thus	O
,	O
we	O
screened	O
relevant	O
hydroxyquinoline	O
derivatives	O
for	O
AHR	O
activity	O
using	O
AHR	O
responsive	O
reporter	O
cell	O
lines	O
.	O

2	O
,	O
8	O
-	O
Dihydroxyquinoline	O
(	O
2	O
,	O
8	O
-	O
DHQ	O
)	O
was	O
identified	O
as	O
a	O
species	O
-	O
specific	O
AHR	O
agonist	O
that	O
exhibits	O
full	O
AHR	O
agonist	O
activity	O
in	O
human	O
cell	O
lines	O
,	O
but	O
only	O
induces	O
modest	O
AHR	O
activity	O
in	O
mouse	O
cells	O
.	O

Additional	O
dihydroxylated	O
quinolines	O
tested	O
failed	O
to	O
activate	O
the	O
human	O
AHR	O
.	O

Nanomolar	O
concentrations	O
of	O
2	O
,	O
8	O
-	O
DHQ	O
significantly	O
induced	O
CYP1A1	O
expression	O
and	O
,	O
upon	O
cotreatment	O
with	O
cytokines	O
,	O
synergistically	O
induced	O
IL6	O
expression	O
.	O

Ligand	O
binding	O
competition	O
studies	O
subsequently	O
confirmed	O
2	O
,	O
8	O
-	O
DHQ	O
to	O
be	O
a	O
human	O
AHR	O
ligand	O
.	O

Several	O
dihydroxyquinolines	O
were	O
detected	O
in	O
human	O
fecal	O
samples	O
,	O
with	O
concentrations	O
of	O
2	O
,	O
8	O
-	O
DHQ	O
ranging	O
between	O
0	O
and	O
3	O
.	O
4	O
pmol	O
/	O
mg	O
feces	O
.	O

Additionally	O
,	O
in	O
mice	O
the	O
microbiota	O
was	O
necessary	O
for	O
the	O
presence	O
of	O
DHQ	O
in	O
cecal	O
contents	O
.	O

These	O
results	O
suggest	O
that	O
microbiota	O
-	O
derived	O
2	O
,	O
8	O
-	O
DHQ	O
would	O
contribute	O
to	O
AHR	O
activation	O
in	O
the	O
human	O
gut	O
,	O
and	O
thus	O
participate	O
in	O
the	O
protective	O
and	O
homeostatic	O
effects	O
observed	O
with	O
gastrointestinal	O
AHR	O
activation	O
.	O

Analysis	O
of	O
immune	O
response	O
in	O
the	O
sea	O
urchin	O
larva	O
.	O

Sea	O
urchin	O
larvae	O
deploy	O
a	O
complex	O
immune	O
system	O
in	O
the	O
context	O
of	O
relatively	O
simple	O
morphology	O
.	O

Several	O
types	O
of	O
phagocytic	O
or	O
granular	O
immune	O
cells	O
respond	O
rapidly	O
to	O
microbes	O
and	O
microbial	O
components	O
within	O
the	O
body	O
cavity	O
.	O

Many	O
of	O
these	O
cells	O
also	O
respond	O
to	O
microbial	O
disturbances	O
in	O
the	O
gut	O
lumen	O
.	O

In	O
the	O
course	O
of	O
immune	O
response	O
,	O
hundreds	O
of	O
genes	O
are	O
up	O
-	O
and	O
downregulated	O
,	O
many	O
of	O
which	O
have	O
homologs	O
involved	O
in	O
immunity	O
in	O
other	O
species	O
.	O

Thus	O
,	O
the	O
larval	O
sea	O
urchin	O
provides	O
an	O
experimentally	O
advantageous	O
model	O
for	O
investigating	O
the	O
response	O
to	O
immune	O
challenge	O
at	O
the	O
level	O
of	O
cell	O
behavior	O
and	O
gene	O
regulatory	O
networks	O
.	O

Importantly	O
,	O
the	O
morphological	O
simplicity	O
and	O
optical	O
clarity	O
of	O
these	O
larvae	O
allow	O
studies	O
to	O
be	O
carried	O
out	O
within	O
the	O
intact	O
animal	O
.	O

Here	O
,	O
we	O
outline	O
techniques	O
to	O
probe	O
and	O
visualize	O
the	O
immune	O
system	O
of	O
the	O
feeding	O
sea	O
urchin	O
larva	O
,	O
particularly	O
for	O
quantifying	O
gene	O
expression	O
and	O
cell	O
migration	O
as	O
the	O
animal	O
responds	O
to	O
both	O
pathogens	O
and	O
symbionts	O
.	O

Techniques	O
addressed	O
in	O
this	O
chapter	O
include	O
(	O
1	O
)	O
exposure	O
of	O
larvae	O
to	O
microbes	O
and	O
microbial	O
products	O
in	O
sea	O
water	O
and	O
by	O
blastocoelar	O
microinjection	O
,	O
(	O
2	O
)	O
time	O
-	O
lapse	O
imaging	O
of	O
immune	O
response	O
,	O
(	O
3	O
)	O
isolation	O
of	O
culturable	O
bacteria	O
associated	O
with	O
feeding	O
larvae	O
,	O
(	O
4	O
)	O
quantification	O
of	O
larval	O
associations	O
with	O
isolated	O
bacterial	O
strains	O
and	O
(	O
5	O
)	O
preparation	O
of	O
secreted	O
products	O
from	O
isolated	O
bacteria	O
for	O
testing	O
in	O
larval	O
culture	O
.	O

Gut	O
microbiome	O
patterns	O
correlate	O
with	O
higher	O
postoperative	O
complication	O
rates	O
after	O
pancreatic	O
surgery	O
.	O

BACKGROUND	O
:	O
Postoperative	O
complications	O
are	O
of	O
great	O
relevance	O
in	O
daily	O
clinical	O
practice	O
,	O
and	O
the	O
gut	O
microbiome	O
might	O
play	O
an	O
important	O
role	O
by	O
preventing	O
pathogens	O
from	O
crossing	O
the	O
intestinal	O
barrier	O
.	O

The	O
two	O
aims	O
of	O
this	O
prospective	O
clinical	O
pilot	O
study	O
were	O
:	O
(	O
1	O
)	O
to	O
examine	O
changes	O
in	O
the	O
gut	O
microbiome	O
following	O
pancreatic	O
surgery	O
,	O
and	O
(	O
2	O
)	O
to	O
correlate	O
these	O
changes	O
with	O
the	O
postoperative	O
course	O
of	O
the	O
patient	O
.	O

RESULTS	O
:	O
In	O
total	O
,	O
116	O
stool	O
samples	O
of	O
32	O
patients	O
undergoing	O
pancreatic	O
surgery	O
were	O
analysed	O
by	O
16S	O
-	O
rRNA	O
gene	O
next	O
-	O
generation	O
sequencing	O
.	O

One	O
sample	O
per	O
patient	O
was	O
collected	O
preoperatively	O
in	O
order	O
to	O
determine	O
the	O
baseline	O
gut	O
microbiome	O
without	O
exposure	O
to	O
surgical	O
stress	O
and	O
/	O
or	O
antibiotic	O
use	O
.	O

At	O
least	O
two	O
further	O
samples	O
were	O
obtained	O
within	O
the	O
first	O
10	O
days	O
following	O
the	O
surgical	O
procedure	O
to	O
observe	O
longitudinal	O
changes	O
in	O
the	O
gut	O
microbiome	O
.	O

Whenever	O
complications	O
occurred	O
,	O
further	O
samples	O
were	O
examined	O
.	O

Based	O
on	O
the	O
structure	O
of	O
the	O
gut	O
microbiome	O
,	O
the	O
samples	O
could	O
be	O
allocated	O
into	O
three	O
different	O
microbial	O
communities	O
(	O
A	O
,	O
B	O
and	O
C	O
)	O
.	O

Community	O
B	O
showed	O
an	O
increase	O
in	O
Akkermansia	B-bacteria
,	O
Enterobacteriaceae	B-bacteria
and	O
Bacteroidales	B-bacteria
as	O
well	O
as	O
a	O
decrease	O
in	O
Lachnospiraceae	B-bacteria
,	O
Prevotella	B-bacteria
and	O
Bacteroides	B-bacteria
.	O

Patients	O
showing	O
a	O
microbial	O
composition	O
resembling	O
community	O
B	O
at	O
least	O
once	O
during	O
the	O
observation	O
period	O
were	O
found	O
to	O
have	O
a	O
significantly	O
higher	O
risk	O
for	O
developing	O
postoperative	O
complications	O
(	O
B	O
vs	O
.	O
A	O
,	O
odds	O
ratio	O
=	O
4	O
.	O
96	O
,	O
p	O
<	O
0	O
.	O
01	O
*	O
*	O
;	O
B	O
vs	O
.	O
C	O
,	O
odds	O
ratio	O
=	O
2	O
.	O
89	O
,	O
p	O
=	O
0	O
.	O
019	O
*	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
structure	O
of	O
the	O
gut	O
microbiome	O
is	O
associated	O
with	O
the	O
development	O
of	O
postoperative	O
complications	O
.	O

Prebiotic	O
supplementation	O
over	O
a	O
cold	O
season	O
and	O
during	O
antibiotic	O
treatment	O
specifically	O
modulates	O
the	O
gut	O
microbiota	O
composition	O
of	O
3	O
-	O
6	O
year	O
-	O
old	O
children	O
.	O

Supplementing	O
kindergarten	O
children	O
during	O
a	O
cold	O
season	O
with	O
a	O
prebiotic	O
inulin	O
-	O
type	O
fructans	O
product	O
with	O
shorter	O
and	O
longer	O
fructan	O
chains	O
has	O
been	O
shown	O
to	O
reduce	O
febrile	O
episodes	O
requiring	O
medical	O
attention	O
and	O
to	O
lower	O
the	O
incidence	O
of	O
sinusitis	O
.	O

These	O
beneficial	O
effects	O
may	O
be	O
connected	O
to	O
the	O
specific	O
modulation	O
of	O
children	O
'	O
s	O
gut	O
microbiota	O
.	O

By	O
applying	O
quantitative	O
and	O
qualitative	O
microbiota	O
analysis	O
this	O
study	O
aimed	O
at	O
characterising	O
the	O
gut	O
microbiota	O
composition	O
and	O
at	O
exploring	O
effects	O
of	O
prebiotic	O
intervention	O
on	O
the	O
gut	O
microbiota	O
during	O
a	O
24	O
-	O
weeks	O
intervention	O
and	O
during	O
antibiotic	O
treatment	O
in	O
healthy	O
children	O
.	O

The	O
study	O
was	O
a	O
randomised	O
,	O
placebo	O
-	O
controlled	O
trial	O
with	O
258	O
healthy	O
children	O
aged	O
3	O
to	O
6	O
years	O
consuming	O
6	O
g	O
/	O
day	O
prebiotic	O
inulin	O
-	O
type	O
fructans	O
or	O
maltodextrin	O
.	O

During	O
the	O
course	O
of	O
the	O
study	O
,	O
faecal	O
samples	O
were	O
collected	O
and	O
subject	O
to	O
targeted	O
qPCR	O
analysis	O
and	O
phylogenetic	O
profiling	O
by	O
multiplexed	O
high	O
throughput	O
sequencing	O
of	O
the	O
prokaryotic	O
16S	O
rRNA	O
gene	O
PCR	O
amplicons	O
.	O

The	O
microbiota	O
composition	O
of	O
the	O
cohort	O
could	O
be	O
clustered	O
into	O
three	O
distinct	O
constellations	O
(	O
enterotypes	O
)	O
.	O

Prebiotic	O
intake	O
resulted	O
in	O
a	O
selective	O
modulation	O
of	O
the	O
gut	O
microbiota	O
composition	O
.	O

Relative	O
abundance	O
of	O
Bifidobacterium	B-bacteria
was	O
significantly	O
higher	O
in	O
the	O
prebiotic	O
group	O
(	O
n	O
=	O
104	O
)	O
compared	O
to	O
control	O
group	O
(	O
n	O
=	O
105	O
)	O
and	O
this	O
effect	O
was	O
found	O
for	O
all	O
three	O
enterotypes	O
.	O

Antibiotic	O
administration	O
decreased	O
the	O
relative	O
abundance	O
of	O
Bifidobacterium	B-bacteria
in	O
both	O
groups	O
.	O

Nonetheless	O
,	O
children	O
of	O
the	O
prebiotic	O
group	O
receiving	O
antibiotic	O
treatment	O
displayed	O
significantly	O
higher	O
levels	O
of	O
Bifidobacterium	B-bacteria
than	O
children	O
receiving	O
the	O
placebo	O
control	O
.	O

Prebiotic	O
supplementation	O
induced	O
specific	O
changes	O
in	O
the	O
gut	O
microbiota	O
composition	O
of	O
children	O
aged	O
3	O
to	O
6	O
years	O
.	O

Moreover	O
,	O
it	O
attenuated	O
antibiotic	O
-	O
induced	O
disturbances	O
in	O
the	O
gut	O
microbiota	O
composition	O
as	O
shown	O
by	O
higher	O
relative	O
abundance	O
of	O
bifidobacteria	B-bacteria
at	O
the	O
end	O
of	O
the	O
antibiotic	O
treatment	O
in	O
the	O
prebiotic	O
group	O
.	O

With	O
the	O
previously	O
reported	O
benefits	O
on	O
immune	O
function	O
,	O
the	O
study	O
contributes	O
to	O
the	O
evidence	O
on	O
the	O
immune	O
-	O
modulating	O
effects	O
of	O
prebiotics	O
through	O
gut	O
microbiota	O
modifications	O
.	O

The	O
study	O
was	O
registered	O
as	O
NCT03241355	O
(	O
https	O
:	O
/	O
/	O
clinicaltrials	O
.	O
gov	O
/	O
show	O
/	O
NCT03241355	O
)	O
.	O

A	O
pilot	O
study	O
on	O
clinicopathological	O
features	O
and	O
intestinal	O
microflora	O
changes	O
in	O
colorectal	O
cancer	O
patients	O
born	O
over	O
a	O
nine	O
-	O
year	O
period	O
encompassing	O
three	O
years	O
before	O
and	O
after	O
the	O
Great	O
Chinese	O
famine	O
.	O

BACKGROUND	O
:	O
Exposure	O
to	O
energy	O
restriction	O
during	O
childhood	O
is	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
developing	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

To	O
date	O
,	O
the	O
association	O
between	O
this	O
critical	O
period	O
of	O
growth	O
and	O
prognosis	O
of	O
CRC	O
has	O
rarely	O
been	O
investigated	O
.	O

Changes	O
in	O
microbiota	O
and	O
epigenetic	O
dysregulation	O
may	O
be	O
key	O
underlying	O
mechanisms	O
.	O

METHODOLOGY	O
:	O
Tissues	O
collected	O
from	O
patients	O
born	O
between	O
1956	O
and	O
1964	O
were	O
grouped	O
based	O
on	O
time	O
-	O
period	O
.	O

The	O
differences	O
in	O
overall	O
survival	O
among	O
patients	O
from	O
the	O
three	O
time	O
-	O
periods	O
were	O
examined	O
via	O
univariate	O
analysis	O
.	O

The	O
16S	O
rRNA	O
gene	O
sequencing	O
approach	O
was	O
to	O
determine	O
differences	O
in	O
microbiota	O
among	O
the	O
groups	O
.	O

Samples	O
were	O
randomly	O
selected	O
to	O
detect	O
BRAF	O
mutations	O
,	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
and	O
promoter	O
CpG	O
island	O
methylator	O
phenotype	O
(	O
CIMP	O
)	O
status	O
.	O

The	O
chi	O
-	O
square	O
test	O
was	O
to	O
assess	O
the	O
relationship	O
between	O
alterations	O
in	O
these	O
molecules	O
and	O
microbiota	O
differences	O
.	O

RESULTS	O
:	O
Patients	O
from	O
the	O
three	O
groups	O
differed	O
in	O
terms	O
of	O
location	O
of	O
CRC	O
(	O
P	O
=	O
0	O
.	O
034	O
)	O
and	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
level	O
(	O
P	O
=	O
0	O
.	O
036	O
)	O
.	O

A	O
survival	O
advantage	O
was	O
observed	O
in	O
the	O
famine	O
group	O
compared	O
with	O
the	O
other	O
two	O
groups	O
.	O

Fusobacterium	B-bacteria
nucleatum	I-bacteria
,	O
Bacteroides	B-bacteria
fragilis	I-bacteria
and	O
Escherichia	B-bacteria
coli	I-bacteria
were	O
more	O
abundant	O
in	O
the	O
two	O
comparing	O
groups	O
.	O

Abundance	O
of	O
B	B-bacteria
.	I-bacteria
fragilis	I-bacteria
was	O
associated	O
with	O
BRAF	O
mutations	O
,	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
and	O
abundance	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
.	O

Moreover	O
,	O
the	O
incidence	O
of	O
CIMP	O
and	O
MSI	O
was	O
higher	O
in	O
patients	O
with	O
greater	O
abundance	O
of	O
F	B-bacteria
.	I-bacteria
nucleatum	I-bacteria
.	O

CONCLUSIONS	O
:	O
Limitation	O
of	O
energy	O
intake	O
during	O
childhood	O
may	O
affect	O
the	O
composition	O
of	O
gut	O
microbiota	O
,	O
resulting	O
in	O
persistent	O
epigenetic	O
changes	O
that	O
subsequently	O
influence	O
the	O
prognosis	O
of	O
patients	O
with	O
CRC	O
.	O

Isolation	O
,	O
characterization	O
,	O
and	O
genome	O
insights	O
into	O
an	O
anaerobic	O
sulfidogenic	O
Tissierella	B-bacteria
bacterium	I-bacteria
from	O
Cu	O
-	O
bearing	O
coins	O
.	O

Recent	O
reports	O
on	O
antimicrobial	O
effects	O
of	O
metallic	O
Cu	O
prompted	O
this	O
study	O
of	O
anaerobic	O
microbial	O
communities	O
on	O
copper	O
surfaces	O
.	O

Widely	O
circulating	O
copper	O
-	O
containing	O
coinage	O
was	O
used	O
as	O
a	O
potential	O
source	O
for	O
microorganisms	O
that	O
had	O
had	O
human	O
contact	O
and	O
were	O
tolerant	O
to	O
copper	O
.	O

This	O
study	O
reports	O
on	O
the	O
isolation	O
,	O
characterization	O
,	O
and	O
genome	O
of	O
an	O
anaerobicn	O
sulfidogenicn	O
Tissierella	B-bacteria
sp	I-bacteria
.	I-bacteria
P1from	I-bacteria
copper	O
-	O
containing	O
brass	O
coinage	O
.	O

Dissimilatory	O
(	O
bi	O
)	O
sulfite	O
reductase	O
dsrAB	O
present	O
in	O
strain	O
P1	B-bacteria
genome	O
and	O
the	O
visible	O
absorbance	O
around	O
630nm	O
in	O
the	O
cells	O
suggested	O
the	O
presence	O
of	O
a	O
desulfoviridin	O
-	O
type	O
protein	O
.	O

However	O
,	O
the	O
sulfate	O
reduction	O
rate	O
measurements	O
with	O
(	O
35	O
)	O
SO4	O
(	O
2	O
-	O
)	O
did	O
not	O
confirm	O
the	O
dissimilatory	O
sulfate	O
reduction	O
by	O
the	O
strain	O
.	O

The	O
P1	O
genome	O
lacks	O
APS	O
reductase	O
,	O
sulfate	O
adenylyltransferase	O
,	O
DsrC	O
,	O
and	O
DsrMK	O
necessary	O
for	O
dissimilatory	O
sulfate	O
reduction	O
.	O

The	O
isolate	O
produced	O
up	O
to	O
0	O
.	O
79mMH2S	O
during	O
growth	O
,	O
possibly	O
due	O
to	O
cysteine	O
synthase	O
(	O
CysK	O
)	O
and	O
/	O
or	O
cysteine	O
desulfhydrase	O
(	O
CdsH	O
)	O
activities	O
,	O
encoded	O
in	O
the	O
genome	O
.	O

The	O
strain	O
can	O
tolerate	O
up	O
to	O
2	O
.	O
4mM	O
Cu	O
(	O
2	O
+	O
)	O
(	O
150mg	O
/	O
l	O
)	O
in	O
liquid	O
medium	O
,	O
shows	O
affinity	O
to	O
metallic	O
copper	O
,	O
and	O
can	O
survive	O
on	O
copper	O
-	O
containing	O
coins	O
up	O
to	O
three	O
days	O
under	O
ambient	O
air	O
and	O
dry	O
conditions	O
.	O

The	O
genome	O
sequence	O
of	O
strain	O
P1	O
contained	O
cutC	O
,	O
encoding	O
a	O
copper	O
resistance	O
protein	O
,	O
which	O
distinguishes	O
it	O
from	O
all	O
other	O
Tissierella	B-bacteria
strains	I-bacteria
with	O
published	O
genomes	O
.	O

Ameliorating	O
gut	O
microenvironment	O
through	O
staphylococcal	O
nuclease	O
-	O
mediated	O
intestinal	O
NETs	O
degradation	O
for	O
prevention	O
of	O
type	O
1	O
diabetes	O
in	O
NOD	O
mice	O
.	O

AIMS	O
:	O
Recent	O
studies	O
have	O
revealed	O
that	O
neutrophil	O
extracellular	O
traps	O
(	O
NETs	O
)	O
provide	O
negative	O
feedback	O
in	O
the	O
progression	O
to	O
chronic	O
inflammation	O
and	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
multiple	O
autoimmune	O
diseases	O
including	O
type	O
1	O
diabetes	O
(	O
T1D	O
)	O
.	O

In	O
addition	O
,	O
accumulating	O
evidences	O
suggest	O
that	O
gut	O
immunity	O
play	O
a	O
key	O
role	O
in	O
T1D	O
pathogenesis	O
.	O

Our	O
study	O
aimed	O
to	O
evaluate	O
whether	O
staphylococcal	O
nuclease	O
(	O
SNase	O
)	O
targeting	O
intestinal	O
NETs	O
can	O
ameliorate	O
the	O
intestinal	O
inflammatory	O
environment	O
and	O
protect	O
against	O
T1D	O
development	O
in	O
non	O
-	O
obese	O
diabetic	O
(	O
NOD	O
)	O
mice	O
.	O

MAIN	O
METHODS	O
:	O
Degradation	O
of	O
NETs	O
with	O
SNase	O
in	O
vitro	O
was	O
examined	O
using	O
SYTOX	O
green	O
assay	O
.	O

NOD	O
/	O
LtJ	O
mice	O
were	O
oral	O
administration	O
of	O
Lactococcus	B-bacteria
lactisl	I-bacteria
(	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
)	O
pCYT	O
:	O
SNase	O
and	O
blood	O
glucose	O
levels	O
were	O
monitored	O
weekly	O
.	O

Several	O
biomarkers	O
of	O
NETs	O
formation	O
,	O
gut	O
leakage	O
and	O
inflammation	O
were	O
determined	O
using	O
a	O
commercial	O
ELISA	O
kit	O
.	O

T	O
Cell	O
phenotypes	O
in	O
peripheral	O
immune	O
system	O
were	O
analyzed	O
in	O
flow	O
cytometry	O
and	O
fecal	O
samples	O
were	O
isolated	O
to	O
investigate	O
intestinal	O
microbiota	O
.	O

KEY	O
FINDINGS	O
:	O
The	O
oral	O
delivery	O
of	O
SNase	O
by	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
can	O
decrease	O
the	O
NETs	O
levels	O
and	O
ameliorate	O
inflammation	O
both	O
in	O
the	O
intestine	O
and	O
pancreatic	O
islets	O
and	O
finally	O
effectively	O
regulate	O
the	O
blood	O
glucose	O
levels	O
of	O
NOD	O
mice	O
.	O

Meanwhile	O
,	O
zonulin	O
and	O
lipopolysaccharide	O
levels	O
also	O
reduced	O
in	O
SNase	O
-	O
fed	O
NOD	O
mice	O
,	O
suggesting	O
SNase	O
could	O
improve	O
gut	O
barrier	O
function	O
via	O
intestinal	O
NETs	O
degradation	O
.	O

Furthermore	O
,	O
the	O
abundances	O
of	O
the	O
intestinal	O
microbiota	O
and	O
butyrate	O
-	O
producing	O
gut	O
bacteria	O
were	O
also	O
increased	O
with	O
SNase	O
treatment	O
.	O

SIGNIFICANCE	O
:	O
SNase	O
shows	O
potential	O
for	O
intestinal	O
NETs	O
to	O
prevent	O
T1D	O
based	O
on	O
the	O
gut	O
-	O
pancreas	O
axis	O
.	O

Analysis	O
of	O
pH	O
Dose	O
-	O
dependent	O
Growth	O
of	O
Sulfate	O
-	O
reducing	O
Bacteria	O
.	O

Lower	O
intraluminal	O
colonic	O
pH	O
is	O
an	O
indication	O
for	O
the	O
development	O
of	O
inflammatory	O
bowel	O
disease	O
including	O
active	O
ulcerative	O
colitis	O
.	O

Involvement	O
of	O
intestinal	O
sulfate	O
-	O
reducing	O
bacteria	O
in	O
decreasing	O
bowel	O
pH	O
by	O
the	O
production	O
of	O
H2S	O
and	O
acetate	O
as	O
well	O
as	O
their	O
sensitivity	O
has	O
never	O
been	O
reported	O
before	O
.	O

The	O
study	O
of	O
the	O
relative	O
pH	O
and	O
survival	O
of	O
Desulfovibrio	B-bacteria
piger	I-bacteria
Vib	I-bacteria
-	I-bacteria
7	I-bacteria
by	O
monitoring	O
sulfate	O
reduction	O
parameters	O
was	O
the	O
aim	O
of	O
this	O
work	O
.	O

Monitoring	O
was	O
done	O
through	O
the	O
measurement	O
of	O
bacterial	O
growth	O
(	O
biomass	O
)	O
,	O
dissimilatory	O
sulfate	O
reduction	O
parameters	O
:	O
sulfate	O
consumption	O
,	O
lactate	O
oxidation	O
,	O
hydrogen	O
sulfide	O
and	O
acetate	O
production	O
.	O

According	O
to	O
our	O
results	O
,	O
we	O
observed	O
that	O
lower	O
pH	O
(	O
<	O
5	O
)	O
significantly	O
inhibited	O
D	O
.	O
piger	O
Vib	O
-	O
7	O
growth	O
.	O

This	O
inhibition	O
was	O
also	O
noticed	O
when	O
alkaline	O
media	O
(	O
>	O
9	O
pH	O
)	O
was	O
used	O
,	O
though	O
the	O
reduction	O
was	O
not	O
at	O
the	O
rate	O
as	O
in	O
media	O
with	O
pH	O
of	O
4	O
.	O

The	O
research	O
indicates	O
that	O
the	O
growth	O
of	O
D	O
.	O
piger	O
Vib	O
-	O
7	O
is	O
inhibited	O
at	O
pH	O
of	O
4	O
which	O
is	O
not	O
as	O
low	O
as	O
the	O
pH	O
found	O
in	O
people	O
with	O
severely	O
developed	O
inflammatory	O
bowel	O
diseases	O
such	O
as	O
ulcerative	O
colitis	O
.	O

Certainly	O
the	O
interaction	O
(	O
synergistic	O
effect	O
)	O
between	O
both	O
hydrogen	O
sulfide	O
and	O
acetate	O
accumulation	O
can	O
also	O
play	O
an	O
important	O
etiological	O
role	O
in	O
the	O
development	O
of	O
bowel	O
inflammation	O
in	O
humans	O
and	O
animals	O
.	O

Neonatal	O
sepsis	O
due	O
to	O
glycopeptide	B-bacteria
resistant	I-bacteria
Enterococcus	I-bacteria
faecium	I-bacteria
from	O
colonized	O
maternal	O
gut	O
-	O
rare	O
case	O
evidence	O
.	O

Background	O
:	O
Vancomycin	O
-	O
resistant	O
enterococcal	O
infections	O
in	O
the	O
neonatal	O
ICU	O
are	O
growing	O
global	O
problems	O
.	O

We	O
report	O
a	O
case	O
of	O
neonatal	O
septicemia	O
by	O
multidrug	O
-	O
resistant	O
vancomycin	I-bacteria
-	I-bacteria
resistant	I-bacteria
Enterococcus	I-bacteria
faecium	I-bacteria
(	O
VRE	B-bacteria
)	O
,	O
the	O
source	O
of	O
infection	O
being	O
the	O
mother	O
'	O
s	O
gut	O
.	O

Case	O
presentation	O
:	O
A	O
newborn	O
male	O
child	O
admitted	O
to	O
the	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
was	O
diagnosed	O
to	O
have	O
mild	O
meconium	O
aspiration	O
syndrome	O
,	O
early	O
onset	O
neonatal	O
septicemia	O
,	O
and	O
bacteremia	O
by	O
multidrug	O
and	O
vancomycin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Enterococcus	I-bacteria
faecium	I-bacteria
.	O

Screening	O
of	O
gut	O
flora	O
of	O
the	O
baby	O
and	O
the	O
mother	O
were	O
carried	O
out	O
to	O
trace	O
the	O
source	O
of	O
infection	O
.	O

Stool	O
cultures	O
of	O
the	O
mother	O
and	O
the	O
baby	O
yielded	O
Vancomycin	B-bacteria
-	I-bacteria
Resistant	I-bacteria
Enterococcus	I-bacteria
faecium	I-bacteria
.	O

All	O
three	O
isolates	O
of	O
Enterococcus	B-bacteria
faecium	I-bacteria
had	O
similar	O
antibiogram	O
,	O
harbored	O
the	O
vanA	O
gene	O
and	O
similar	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
pattern	O
.	O

Baby	O
responded	O
to	O
the	O
1	O
week	O
therapy	O
with	O
oral	O
linezolid	O
suspension	O
20	O
mg	O
/	O
kg	O
/	O
day	O
,	O
1	O
ml	O
/	O
t	O
.	O
d	O
.	O
s	O
.	O

No	O
VRE	B-bacteria
was	O
isolated	O
from	O
baby	O
on	O
a	O
repeat	O
stool	O
culture	O
1	O
week	O
after	O
the	O
linezolid	O
therapy	O
.	O

He	O
was	O
discharged	O
with	O
the	O
advice	O
for	O
the	O
continuance	O
of	O
linezolid	O
for	O
seven	O
more	O
days	O
.	O

Conclusion	O
:	O
Isolation	O
of	O
MDR	O
-	O
VRE	O
from	O
the	O
blood	O
culture	O
of	O
the	O
baby	O
and	O
stool	O
specimens	O
of	O
the	O
mother	O
and	O
the	O
baby	O
with	O
the	O
same	O
antibiogram	O
profile	O
and	O
clonal	O
similarities	O
reveals	O
that	O
maternal	O
gut	O
colonization	O
was	O
responsible	O
for	O
neonatal	O
sepsis	O
.	O

Optimal	O
infection	O
control	O
measures	O
and	O
the	O
development	O
of	O
guidelines	O
for	O
monitoring	O
VRE	B-bacteria
colonization	O
in	O
pregnant	O
women	O
might	O
be	O
useful	O
in	O
reducing	O
the	O
occurrence	O
of	O
neonatal	O
sepsis	O
.	O

Functional	O
gastrointestinal	O
disorders	O
and	O
gut	O
-	O
brain	O
axis	O
:	O
What	O
does	O
the	O
future	O
hold	O
?	O

Despite	O
their	O
high	O
prevalence	O
,	O
lack	O
of	O
understanding	O
of	O
the	O
exact	O
pathophysiology	O
of	O
the	O
functional	O
gastrointestinal	O
disorders	O
has	O
restricted	O
us	O
to	O
symptomatic	O
diagnostic	O
tools	O
and	O
therapies	O
.	O

Complex	O
mechanisms	O
underlying	O
the	O
disturbances	O
in	O
the	O
bidirectional	O
communication	O
between	O
the	O
gastrointestinal	O
tract	O
and	O
the	O
brain	O
have	O
a	O
vital	O
role	O
in	O
the	O
pathogenesis	O
and	O
are	O
key	O
to	O
our	O
understanding	O
of	O
the	O
disease	O
phenomenon	O
.	O

Although	O
we	O
have	O
come	O
a	O
long	O
way	O
in	O
our	O
understanding	O
of	O
these	O
complex	O
disorders	O
with	O
the	O
help	O
of	O
studies	O
on	O
animals	O
especially	O
rodents	O
,	O
there	O
need	O
to	O
be	O
more	O
studies	O
in	O
humans	O
,	O
especially	O
to	O
identify	O
the	O
therapeutic	O
targets	O
.	O

This	O
review	O
study	O
looks	O
at	O
the	O
anatomical	O
features	O
of	O
the	O
gut	O
-	O
brain	O
axis	O
in	O
order	O
to	O
discuss	O
the	O
different	O
factors	O
and	O
underlying	O
molecular	O
mechanisms	O
that	O
may	O
have	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
functional	O
gastrointestinal	O
disorders	O
.	O

These	O
molecules	O
and	O
their	O
receptors	O
can	O
be	O
targeted	O
in	O
future	O
for	O
further	O
studies	O
and	O
possible	O
therapeutic	O
interventions	O
.	O

The	O
article	O
also	O
discusses	O
the	O
potential	O
role	O
of	O
artificial	O
intelligence	O
and	O
machine	O
learning	O
and	O
its	O
possible	O
role	O
in	O
our	O
understanding	O
of	O
these	O
scientifically	O
challenging	O
disorders	O
.	O

Methods	O
for	O
Studying	O
Gut	O
Microbiota	O
:	O
A	O
Primer	O
for	O
Physicians	O
.	O

Human	O
gastrointestinal	O
tract	O
contains	O
a	O
large	O
variety	O
of	O
microbes	O
,	O
in	O
particular	O
bacteria	O
.	O

Studies	O
in	O
recent	O
years	O
have	O
strongly	O
suggested	O
a	O
role	O
for	O
these	O
microbes	O
,	O
collectively	O
referred	O
to	O
as	O
gut	O
microbiota	O
,	O
in	O
the	O
maintenance	O
of	O
homeostasis	O
during	O
health	O
.	O

In	O
addition	O
,	O
alterations	O
in	O
gut	O
microbiota	O
have	O
been	O
reported	O
in	O
several	O
diseases	O
,	O
including	O
those	O
related	O
to	O
the	O
gastrointestinal	O
tract	O
and	O
several	O
systemic	O
conditions	O
,	O
and	O
are	O
believed	O
to	O
play	O
a	O
pathogenetic	O
role	O
in	O
at	O
least	O
some	O
of	O
these	O
.	O

Given	O
the	O
close	O
association	O
between	O
the	O
human	O
gut	O
and	O
liver	O
,	O
the	O
association	O
with	O
gut	O
microbiota	O
appears	O
to	O
be	O
particularly	O
strong	O
for	O
a	O
wide	O
variety	O
of	O
liver	O
diseases	O
.	O

This	O
piece	O
,	O
aimed	O
primarily	O
at	O
physicians	O
,	O
reviews	O
in	O
brief	O
the	O
methods	O
used	O
to	O
study	O
gut	O
microbiota	O
,	O
with	O
particular	O
emphasis	O
on	O
those	O
that	O
use	O
sequences	O
of	O
bacterial	O
16S	O
rRNA	O
gene	O
or	O
its	O
components	O
.	O

Prebiotic	O
oligosaccharides	O
in	O
early	O
life	O
alter	O
gut	O
microbiome	O
development	O
in	O
male	O
mice	O
while	O
supporting	O
influenza	O
vaccination	O
responses	O
.	O

Beneficial	O
modulation	O
of	O
the	O
gut	O
microbiota	O
is	O
an	O
attractive	O
therapeutic	O
approach	O
to	O
improve	O
the	O
efficacy	O
of	O
vaccine	O
-	O
induced	O
immunity	O
.	O

In	O
this	O
study	O
,	O
mice	O
were	O
supplemented	O
with	O
the	O
prebiotic	O
milk	O
oligosaccharide	O
2	O
'	O
-	O
fucosyllactose	O
(	O
2	O
'	O
FL	O
)	O
as	O
well	O
as	O
a	O
complex	O
mixture	O
of	O
immune	O
modulatory	O
prebiotic	O
short	O
-	O
chain	O
galacto	O
-	O
oligosaccharides	O
and	O
long	O
-	O
chain	O
fructo	O
-	O
oligosaccharides	O
(	O
scGOS	O
/	O
lcFOS	O
)	O
from	O
different	O
stages	O
in	O
early	O
life	O
.	O

Adult	O
mice	O
were	O
vaccinated	O
with	O
trivalent	O
influenza	O
vaccine	O
(	O
TIV	O
)	O
and	O
both	O
development	O
of	O
the	O
gut	O
microbiota	O
and	O
antibody	O
-	O
mediated	O
vaccine	O
responses	O
were	O
followed	O
over	O
time	O
.	O

Within	O
the	O
control	O
group	O
,	O
female	O
mice	O
demonstrated	O
a	O
larger	O
antibody	O
response	O
to	O
TIV	O
vaccination	O
than	O
male	O
mice	O
,	O
which	O
was	O
accompanied	O
by	O
enhanced	O
cytokine	O
production	O
by	O
splenocytes	O
and	O
a	O
higher	O
percentage	O
of	O
plasma	O
cells	O
in	O
skin	O
draining	O
lymph	O
nodes	O
.	O

In	O
addition	O
,	O
the	O
prebiotic	O
diet	O
improved	O
vaccine	O
-	O
specific	O
antibody	O
responses	O
in	O
male	O
mice	O
.	O

Introduction	O
of	O
prebiotics	O
into	O
the	O
diet	O
modulated	O
the	O
gut	O
microbiota	O
composition	O
and	O
at	O
the	O
genus	O
level	O
several	O
bacterial	O
groups	O
showed	O
a	O
significant	O
interaction	O
effect	O
which	O
potentially	O
contributed	O
to	O
the	O
immunological	O
effects	O
observed	O
.	O

This	O
study	O
provides	O
insight	O
in	O
the	O
effect	O
of	O
scGOS	O
/	O
lcFOS	O
/	O
2	O
'	O
FL	O
in	O
influenza	O
vaccination	O
antibody	O
production	O
.	O

Distinctive	O
subpopulations	O
of	O
the	O
intestinal	O
microbiota	O
are	O
present	O
in	O
women	O
with	O
unexplained	O
chronic	O
anovulation	O
.	O

RESEARCH	O
QUESTION	O
:	O
Do	O
gut	O
microbiota	O
associate	O
with	O
the	O
ovulatory	O
cycle	O
in	O
women	O
showing	O
normogonadotrophic	O
anovulation	O
?	O

In	O
humans	O
,	O
the	O
gut	O
microbiota	O
affects	O
diverse	O
physiological	O
functions	O
and	O
dysbiosis	O
(	O
microbial	O
imbalance	O
)	O
may	O
lead	O
to	O
pathological	O
syndromes	O
.	O

However	O
,	O
there	O
is	O
comparatively	O
little	O
information	O
on	O
the	O
relevance	O
of	O
gut	O
microbiota	O
to	O
reproductive	O
functions	O
in	O
women	O
.	O

Here	O
,	O
a	O
group	O
of	O
women	O
with	O
idiopathic	O
chronic	O
anovulation	O
were	O
examined	O
,	O
who	O
do	O
not	O
exhibit	O
any	O
apparent	O
endocrinological	O
disorder	O
,	O
as	O
they	O
are	O
suitable	O
for	O
investigating	O
the	O
relationship	O
between	O
intestinal	O
bacteria	O
and	O
ovulatory	O
disorders	O
.	O

DESIGN	O
:	O
A	O
prospective	O
observational	O
cohort	O
study	O
was	O
performed	O
on	O
two	O
groups	O
of	O
women	O
who	O
did	O
not	O
exhibit	O
apparent	O
endocrinological	O
disorders	O
but	O
showed	O
either	O
irregular	O
menstrual	O
cycles	O
(	O
IMC	O
group	O
)	O
or	O
normal	O
menstrual	O
cycles	O
(	O
controls	O
)	O
.	O

The	O
bacterial	O
composition	O
of	O
faeces	O
from	O
rectal	O
swabs	O
from	O
the	O
women	O
was	O
analysed	O
using	O
next	O
-	O
generation	O
sequencing	O
based	O
on	O
bacterial	O
16SrRNA	O
genes	O
.	O

RESULTS	O
:	O
A	O
metagenomic	O
analysis	O
indicated	O
that	O
the	O
two	O
groups	O
of	O
women	O
had	O
significant	O
differences	O
in	O
28	O
bacterial	O
taxa	O
in	O
their	O
faeces	O
.	O

Prevotella	O
-	O
enriched	O
microbiomes	O
were	O
more	O
abundant	O
in	O
the	O
IMC	O
group	O
,	O
whereas	O
Clostridiales	B-bacteria
,	O
Ruminococcus	B-bacteria
and	O
Lachnospiraceae	B-bacteria
(	O
butyrate	O
-	O
producing	O
bacteria	O
)	O
were	O
present	O
at	O
lower	O
levels	O
in	O
the	O
IMC	O
group	O
.	O

CONCLUSIONS	O
:	O
Distinctive	O
subpopulations	O
of	O
intestinal	O
microbiota	O
were	O
identified	O
in	O
women	O
with	O
unexplained	O
chronic	O
anovulation	O
.	O

The	O
results	O
indicate	O
that	O
gut	O
microbiota	O
could	O
be	O
associated	O
with	O
ovarian	O
functions	O
.	O

Oral	O
administration	O
of	O
antibiotics	O
increased	O
the	O
potential	O
mobility	O
of	O
bacterial	O
resistance	O
genes	O
in	O
the	O
gut	O
of	O
the	O
fish	O
Piaractus	O
mesopotamicus	O
.	O

BACKGROUND	O
:	O
Aquaculture	O
is	O
on	O
the	O
rise	O
worldwide	O
,	O
and	O
the	O
use	O
of	O
antibiotics	O
is	O
fostering	O
higher	O
production	O
intensity	O
.	O

However	O
,	O
recent	O
findings	O
suggest	O
that	O
the	O
use	O
of	O
antibiotics	O
comes	O
at	O
the	O
price	O
of	O
increased	O
antibiotic	O
resistance	O
.	O

Yet	O
,	O
the	O
effect	O
of	O
the	O
oral	O
administration	O
of	O
antibiotics	O
on	O
the	O
mobility	O
of	O
microbial	O
resistance	O
genes	O
in	O
the	O
fish	O
gut	O
is	O
not	O
well	O
understood	O
.	O

In	O
the	O
present	O
study	O
,	O
Piaractus	O
mesopotamicus	O
was	O
used	O
as	O
a	O
model	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
antimicrobial	O
florfenicol	O
on	O
the	O
diversity	O
of	O
the	O
gut	O
microbiome	O
as	O
well	O
as	O
antibiotic	O
resistance	O
genes	O
(	O
ARGs	O
)	O
and	O
mobile	O
genetic	O
elements	O
(	O
MGEs	O
)	O
using	O
a	O
metagenomic	O
approach	O
.	O

RESULTS	O
:	O
The	O
total	O
relative	O
abundance	O
of	O
ARGs	O
and	O
MGEs	O
significantly	O
increased	O
during	O
the	O
antibiotic	O
exposure	O
.	O

Additionally	O
,	O
phage	O
integrases	O
,	O
transposases	O
,	O
and	O
transposons	O
flanking	O
ARGs	O
accumulated	O
in	O
the	O
gut	O
microbiome	O
of	O
P	O
.	O
mesopotamicus	O
because	O
of	O
the	O
antibiotic	O
exposure	O
.	O

MGEs	O
co	O
-	O
occurring	O
with	O
ARGs	O
showed	O
a	O
significant	O
positive	O
correlation	O
with	O
the	O
total	O
ARGs	O
found	O
.	O

Furthermore	O
,	O
shifts	O
in	O
the	O
gut	O
microbiome	O
towards	O
well	O
-	O
known	O
putative	O
pathogens	O
such	O
as	O
Salmonella	B-bacteria
,	O
Plesiomonas	B-bacteria
,	O
and	O
Citrobacter	B-bacteria
were	O
observed	O
following	O
florfenicol	O
treatment	O
.	O

Mainly	O
Plesiomonas	B-bacteria
and	O
Citrobacter	B-bacteria
harbored	O
genes	O
that	O
code	O
for	O
multidrug	O
and	O
phenicol	O
efflux	O
pumps	O
.	O

Moreover	O
,	O
several	O
genes	O
related	O
to	O
RNA	O
processing	O
and	O
modification	O
,	O
cell	O
motility	O
,	O
SOS	O
response	O
,	O
and	O
extracellular	O
structure	O
were	O
enriched	O
due	O
to	O
the	O
antibiotic	O
application	O
.	O

The	O
observed	O
effects	O
were	O
visible	O
during	O
the	O
complete	O
application	O
phase	O
and	O
disappeared	O
at	O
the	O
post	O
-	O
exposure	O
phase	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
suggest	O
that	O
the	O
oral	O
administration	O
of	O
antibiotics	O
increases	O
the	O
potential	O
for	O
MGE	O
-	O
mediated	O
exchange	O
of	O
ARGs	O
in	O
the	O
gut	O
of	O
fish	O
and	O
could	O
contribute	O
to	O
the	O
enrichment	O
and	O
dispersion	O
of	O
ARGs	O
in	O
aquaculture	O
systems	O
.	O

Importantly	O
,	O
this	O
increase	O
in	O
the	O
potential	O
for	O
ARGs	O
exchange	O
could	O
be	O
an	O
effect	O
of	O
changes	O
in	O
community	O
structure	O
and	O
/	O
or	O
ARG	O
mobilization	O
.	O

Broccoli	O
ingestion	O
increases	O
the	O
glucosinolate	O
hydrolysis	O
activity	O
of	O
microbiota	O
in	O
the	O
mouse	O
gut	O
.	O

After	O
consuming	O
broccoli	O
,	O
isothiocyanates	O
can	O
be	O
produced	O
by	O
the	O
hydrolytic	O
action	O
of	O
myrosinase	O
from	O
plant	O
and	O
/	O
or	O
microbiota	O
.	O

Using	O
male	O
C57BL	O
/	O
6	O
mice	O
,	O
the	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
broccoli	O
ingestion	O
on	O
the	O
myrosinase	O
-	O
like	O
activity	O
,	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
1	O
(	O
NQO1	O
)	O
activity	O
,	O
diversity	O
and	O
composition	O
of	O
the	O
gut	O
microbiota	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
continuously	O
feeding	O
raw	O
or	O
hydrolysed	O
broccoli	O
increased	O
the	O
myrosinase	O
-	O
like	O
activities	O
of	O
the	O
colon	O
and	O
caecum	O
contents	O
,	O
and	O
also	O
improved	O
the	O
NQO1	O
activity	O
of	O
the	O
colon	O
mucosa	O
.	O

Significant	O
difference	O
between	O
the	O
broccoli	O
and	O
control	O
feeding	O
groups	O
were	O
found	O
.	O

16S	O
rRNA	O
gene	O
sequencing	O
indicated	O
that	O
broccoli	O
ingestion	O
profoundly	O
affected	O
the	O
composition	O
of	O
the	O
gut	O
bacteria	O
community	O
.	O

The	O
correlation	O
between	O
the	O
gut	O
bacterial	O
community	O
composition	O
and	O
microbiota	O
myrosinase	O
-	O
like	O
activity	O
was	O
also	O
studied	O
.	O

However	O
,	O
one	O
type	O
of	O
glucosinolate	O
,	O
sinigrin	O
,	O
had	O
no	O
effect	O
on	O
these	O
activities	O
,	O
indicating	O
that	O
broccoli	O
component	O
(	O
s	O
)	O
,	O
other	O
than	O
glucosinolate	O
,	O
had	O
increased	O
the	O
NQO1	O
and	O
myrosinase	O
-	O
like	O
activities	O
.	O

PROFIT	O
,	O
a	O
PROspective	O
,	O
randomised	O
placebo	O
controlled	O
feasibility	O
trial	O
of	O
Faecal	O
mIcrobiota	O
Transplantation	O
in	O
cirrhosis	O
:	O
study	O
protocol	O
for	O
a	O
single	O
-	O
blinded	O
trial	O
.	O

INTRODUCTION	O
:	O
Patients	O
with	O
advanced	O
cirrhosis	O
have	O
enteric	O
bacterial	O
dysbiosis	O
and	O
translocation	O
of	O
bacteria	O
and	O
their	O
products	O
across	O
the	O
gut	O
epithelial	O
barrier	O
.	O

This	O
culminates	O
in	O
systemic	O
inflammation	O
and	O
endotoxaemia	O
,	O
inducing	O
innate	O
immune	O
dysfunction	O
which	O
predisposes	O
to	O
infection	O
,	O
and	O
development	O
of	O
complications	O
such	O
as	O
bleeding	O
,	O
sepsis	O
and	O
hepatic	O
encephalopathy	O
.	O

This	O
feasibility	O
study	O
aims	O
to	O
assess	O
the	O
safety	O
of	O
administering	O
faecal	O
microbiota	O
transplantion	O
to	O
patients	O
with	O
cirrhosis	O
and	O
explore	O
the	O
effect	O
of	O
the	O
intervention	O
on	O
their	O
prognosis	O
by	O
achieving	O
restoration	O
of	O
a	O
healthy	O
gut	O
microbiome	O
.	O

METHODS	O
AND	O
ANALYSIS	O
:	O
A	O
PROspective	O
,	O
randomised	O
placebo	O
controlled	O
feasibility	O
trial	O
of	O
Faecal	O
mIcrobiota	O
Transplantation	O
is	O
a	O
single	O
-	O
centre	O
,	O
randomised	O
,	O
single	O
-	O
blinded	O
,	O
placebo	O
-	O
controlled	O
study	O
evaluating	O
faecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
against	O
placebo	O
.	O

Patients	O
with	O
advanced	O
but	O
stable	O
cirrhosis	O
with	O
a	O
Model	O
for	O
End	O
-	O
Stage	O
Liver	O
Disease	O
score	O
between	O
10	O
and	O
16	O
will	O
be	O
recruited	O
.	O

Twenty	O
-	O
four	O
patients	O
will	O
be	O
randomised	O
to	O
FMT	O
plus	O
standard	O
of	O
care	O
(	O
as	O
per	O
our	O
institutional	O
practice	O
)	O
and	O
eight	O
patients	O
to	O
placebo	O
in	O
a	O
ratio	O
of	O
3	O
:	O
1	O
.	O

Patients	O
will	O
be	O
evaluated	O
at	O
baseline	O
before	O
the	O
study	O
intervention	O
is	O
administered	O
and	O
at	O
7	O
,	O
30	O
and	O
90	O
days	O
post	O
-	O
intervention	O
to	O
assess	O
safety	O
and	O
adverse	O
events	O
.	O

FMT	O
/	O
placebo	O
will	O
be	O
administered	O
into	O
the	O
jejunum	O
within	O
7	O
days	O
of	O
baseline	O
.	O

The	O
primary	O
outcome	O
measure	O
will	O
be	O
safety	O
and	O
feasibility	O
as	O
assessed	O
by	O
recruitment	O
rates	O
,	O
tolerability	O
and	O
safety	O
of	O
FMT	O
treatment	O
.	O

Results	O
will	O
be	O
disseminated	O
via	O
peer	O
-	O
reviewed	O
journals	O
and	O
international	O
conferences	O
.	O

The	O
recruitment	O
of	O
the	O
first	O
patient	O
occurred	O
on	O
23	O
May	O
2018	O
.	O

ETHICS	O
AND	O
DISSEMINATION	O
:	O
Research	O
Ethics	O
approval	O
was	O
given	O
by	O
the	O
London	O
South	O
East	O
Research	O
Ethics	O
committee	O
(	O
ref	O
17	O
/	O
LO	O
/	O
2081	O
)	O
.	O

TRIAL	O
REGISTRATION	O
NUMBER	O
:	O
NCT02862249	O
and	O
EudraCT	O
2017	O
-	O
003629	O
-	O
13	O
.	O

Non	O
-	O
alcoholic	O
liver	O
disease	O
and	O
gut	O
bacteria	O
.	O

Dietary	O
supplementation	O
with	O
strawberry	O
induces	O
marked	O
changes	O
in	O
the	O
composition	O
and	O
functional	O
potential	O
of	O
the	O
gut	O
microbiome	O
in	O
diabetic	O
mice	O
.	O

Gut	O
microbiota	O
contributes	O
to	O
the	O
biological	O
activities	O
of	O
berry	O
anthocyanins	O
by	O
transforming	O
them	O
into	O
bioactive	O
metabolites	O
,	O
and	O
anthocyanins	O
support	O
the	O
growth	O
of	O
specific	O
bacteria	O
,	O
indicating	O
a	O
two	O
-	O
way	O
relationship	O
between	O
anthocyanins	O
and	O
microbiota	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
strawberry	O
supplementation	O
alters	O
gut	O
microbial	O
ecology	O
in	O
diabetic	O
db	O
/	O
db	O
mice	O
.	O

Control	O
(	O
db	O
/	O
+	O
)	O
and	O
diabetic	O
(	O
db	O
/	O
db	O
)	O
mice	O
(	O
7	O
weeks	O
old	O
)	O
consumed	O
standard	O
diet	O
or	O
diet	O
supplemented	O
with	O
2	O
.	O
35	O
%	O
freeze	O
-	O
dried	O
strawberry	O
(	O
db	O
/	O
db	O
+	O
SB	O
)	O
for	O
10	O
weeks	O
.	O

Colon	O
contents	O
were	O
used	O
to	O
isolate	O
bacterial	O
DNA	O
.	O

V4	O
variable	O
region	O
of	O
16S	O
rRNA	O
gene	O
was	O
amplified	O
.	O

Data	O
analyses	O
were	O
performed	O
using	O
standardized	O
pipelines	O
(	O
QIIME	O
1	O
.	O
9	O
and	O
R	O
packages	O
)	O
.	O

Differences	O
in	O
predictive	O
metagenomics	O
function	O
were	O
identified	O
by	O
PICRUSt	O
.	O

Principal	O
coordinate	O
analyses	O
confirmed	O
that	O
the	O
microbial	O
composition	O
was	O
significantly	O
influenced	O
by	O
both	O
host	O
genotype	O
and	O
strawberry	O
consumption	O
.	O

Further	O
,	O
alpha	O
-	O
diversity	O
indices	O
and	O
beta	O
-	O
diversity	O
were	O
different	O
at	O
the	O
phylum	O
and	O
genus	O
levels	O
,	O
and	O
genus	O
and	O
operational	O
taxonomical	O
units	O
levels	O
,	O
respectively	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

At	O
the	O
phylum	O
level	O
,	O
strawberry	O
supplementation	O
decreased	O
the	O
abundance	O
of	O
Verrucomicrobia	B-bacteria
in	O
db	O
/	O
db	O
+	O
SB	O
vs	O
.	O
db	O
/	O
db	O
mice	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

At	O
the	O
genus	O
level	O
,	O
db	O
/	O
db	O
mice	O
exhibited	O
a	O
decrease	O
in	O
the	O
abundance	O
of	O
Bifidobacterium	B-bacteria
,	O
and	O
strawberry	O
supplementation	O
increased	O
Bifidobacterium	B-bacteria
in	O
db	O
/	O
db	O
+	O
SB	O
vs	O
.	O
db	O
/	O
db	O
mice	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

PICRUSt	O
revealed	O
significant	O
differences	O
in	O
45	O
predicted	O
metabolic	O
functions	O
among	O
the	O
3	O
groups	O
.	O

Our	O
study	O
provides	O
evidence	O
for	O
marked	O
changes	O
in	O
the	O
composition	O
and	O
functional	O
potential	O
of	O
the	O
gut	O
microbiome	O
with	O
strawberry	O
supplementation	O
in	O
diabetic	O
mice	O
.	O

Importantly	O
,	O
strawberry	O
supplementation	O
increased	O
the	O
abundance	O
of	O
beneficial	O
bacteria	O
Bifidobacterium	B-bacteria
which	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
metabolism	O
of	O
anthocyanins	O
.	O

Depletion	O
of	O
Gram	O
-	O
Positive	O
Bacteria	O
Impacts	O
Hepatic	O
Biological	O
Functions	O
During	O
the	O
Light	O
Phase	O
.	O

Living	O
organisms	O
display	O
internal	O
biological	O
rhythms	O
,	O
which	O
are	O
an	O
evolutionarily	O
conserved	O
adaptation	O
to	O
the	O
environment	O
that	O
drives	O
their	O
rhythmic	O
behavioral	O
and	O
physiological	O
activities	O
.	O

The	O
gut	O
microbiota	O
has	O
been	O
proposed	O
,	O
in	O
association	O
with	O
diet	O
,	O
to	O
regulate	O
the	O
intestinal	O
peripheral	O
clock	O
.	O

However	O
,	O
the	O
effect	O
of	O
gut	O
dysbiosis	O
on	O
liver	O
remains	O
elusive	O
,	O
despite	O
that	O
germfree	O
mice	O
show	O
alterations	O
in	O
liver	O
metabolic	O
functions	O
and	O
the	O
hepatic	O
daily	O
rhythm	O
.	O

We	O
analyzed	O
whether	O
the	O
disruption	O
of	O
gut	O
microbial	O
populations	O
with	O
various	O
antibiotics	O
would	O
differentially	O
impact	O
liver	O
functions	O
in	O
mice	O
.	O

Our	O
results	O
support	O
the	O
notion	O
of	O
an	O
impact	O
on	O
the	O
hepatic	O
biological	O
rhythm	O
by	O
gram	O
-	O
positive	O
bacteria	O
.	O

In	O
addition	O
,	O
we	O
provide	O
evidence	O
for	O
differential	O
roles	O
of	O
gut	O
microbiota	O
spectra	O
in	O
xenobiotic	O
metabolism	O
that	O
could	O
protect	O
against	O
the	O
harmful	O
pharmacological	O
effects	O
of	O
drugs	O
.	O

Our	O
results	O
underscore	O
a	O
possible	O
link	O
between	O
liver	O
cell	O
proliferation	O
and	O
gram	O
-	O
positive	O
bacteria	O
.	O

High	O
dietary	O
fat	O
intake	O
induces	O
a	O
microbiota	O
signature	O
that	O
promotes	O
food	O
allergy	O
.	O

BACKGROUND	O
:	O
Diet	O
-	O
induced	O
obesity	O
and	O
food	O
allergies	O
increase	O
in	O
tandem	O
,	O
but	O
a	O
potential	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
these	O
diseases	O
of	O
affluence	O
remains	O
to	O
be	O
tested	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
test	O
the	O
role	O
of	O
high	O
dietary	O
fat	O
intake	O
,	O
diet	O
-	O
induced	O
obesity	O
,	O
and	O
associated	O
changes	O
in	O
gut	O
microbial	O
community	O
structure	O
on	O
food	O
allergy	O
pathogenesis	O
.	O

METHODS	O
:	O
Mice	O
were	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
for	O
12	O
weeks	O
before	O
food	O
allergen	O
sensitization	O
on	O
an	O
atopic	O
dermatitis	O
-	O
like	O
skin	O
lesion	O
,	O
followed	O
by	O
intragastric	O
allergen	O
challenge	O
to	O
induce	O
experimental	O
food	O
allergy	O
.	O

Germ	O
-	O
free	O
animals	O
were	O
colonized	O
with	O
a	O
signature	O
HFD	O
or	O
lean	O
microbiota	O
for	O
8	O
weeks	O
before	O
induction	O
of	O
food	O
allergy	O
.	O

Food	O
-	O
induced	O
allergic	O
responses	O
were	O
quantified	O
by	O
using	O
a	O
clinical	O
allergy	O
score	O
,	O
serum	O
IgE	O
levels	O
,	O
serum	O
mouse	O
mast	O
cell	O
protease	O
1	O
concentrations	O
,	O
and	O
type	O
2	O
cytokine	O
responses	O
.	O

Accumulation	O
of	O
intestinal	O
mast	O
cells	O
was	O
examined	O
by	O
using	O
flow	O
cytometry	O
and	O
chloroacetate	O
esterase	O
tissue	O
staining	O
.	O

Changes	O
in	O
the	O
gut	O
microbial	O
community	O
structure	O
were	O
assessed	O
by	O
using	O
high	O
-	O
throughput	O
16S	O
ribosomal	O
DNA	O
gene	O
sequencing	O
.	O

RESULTS	O
:	O
HFD	O
-	O
induced	O
obesity	O
potentiates	O
food	O
-	O
induced	O
allergic	O
responses	O
associated	O
with	O
dysregulated	O
intestinal	O
effector	O
mast	O
cell	O
responses	O
,	O
increased	O
intestinal	O
permeability	O
,	O
and	O
gut	O
dysbiosis	O
.	O

An	O
HFD	O
-	O
associated	O
microbiome	O
was	O
transmissible	O
to	O
germ	O
-	O
free	O
mice	O
,	O
with	O
the	O
gut	O
microbial	O
community	O
structure	O
of	O
recipients	O
segregating	O
according	O
to	O
the	O
microbiota	O
input	O
source	O
.	O

Independent	O
of	O
an	O
obese	O
state	O
,	O
an	O
HFD	O
-	O
associated	O
gut	O
microbiome	O
was	O
sufficient	O
to	O
confer	O
enhanced	O
susceptibility	O
to	O
food	O
allergy	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
identify	O
HFD	O
-	O
induced	O
microbial	O
alterations	O
as	O
risk	O
factors	O
for	O
experimental	O
food	O
allergy	O
and	O
uncouple	O
a	O
pathogenic	O
role	O
of	O
an	O
HFD	O
-	O
associated	O
microbiome	O
from	O
obesity	O
.	O

Postdieting	O
microbiome	O
alterations	O
caused	O
by	O
overindulgence	O
of	O
dietary	O
fat	O
might	O
increase	O
susceptibility	O
to	O
food	O
allergy	O
.	O

NLRC5	O
deficiency	O
has	O
a	O
moderate	O
impact	O
on	O
immunodominant	O
CD8	O
(	O
+	O
)	O
T	O
-	O
cell	O
responses	O
during	O
rotavirus	O
infection	O
of	O
adult	O
mice	O
.	O

The	O
NOD	O
-	O
like	O
receptor	O
(	O
NLR	O
)	O
family	O
plays	O
an	O
important	O
role	O
in	O
innate	O
immunity	O
.	O

Class	O
II	O
transactivator	O
and	O
NOD	O
-	O
like	O
receptor	O
caspase	O
activation	O
and	O
recruitment	O
domain	O
CARD	O
containing	O
5	O
(	O
NLRC5	O
)	O
are	O
unusual	O
members	O
of	O
the	O
NLR	O
family	O
that	O
instead	O
of	O
recognizing	O
pathogen	O
-	O
associated	O
or	O
damage	O
-	O
associated	O
molecular	O
patterns	O
,	O
form	O
enhanceosomes	O
with	O
adaptor	O
molecules	O
and	O
modulate	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
and	O
MHC	O
class	O
I	O
expression	O
,	O
respectively	O
.	O

While	O
NLRC5	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
during	O
intracellular	O
pathogen	O
infection	O
and	O
tumor	O
cell	O
immune	O
evasion	O
,	O
its	O
role	O
in	O
regulating	O
antigen	O
-	O
specific	O
CD8	O
(	O
+	O
)	O
T	O
-	O
cell	O
responses	O
at	O
the	O
intestinal	O
mucosa	O
has	O
not	O
been	O
investigated	O
.	O

Here	O
,	O
we	O
take	O
advantage	O
of	O
the	O
rotavirus	O
model	O
in	O
adult	O
mice	O
to	O
dissect	O
the	O
impact	O
of	O
NLRC5	O
on	O
CD8	O
(	O
+	O
)	O
T	O
-	O
cell	O
responses	O
to	O
this	O
viral	O
infection	O
at	O
the	O
gut	O
mucosa	O
.	O

We	O
show	O
that	O
while	O
Nlrc5	O
(	O
-	O
/	O
-	O
)	O
mice	O
exhibited	O
normal	O
proportions	O
of	O
T	O
-	O
cell	O
subpopulations	O
in	O
the	O
intraepithelial	O
and	O
lamina	O
propria	O
compartments	O
,	O
these	O
mice	O
had	O
decreased	O
baseline	O
MHC	O
class	O
I	O
expression	O
on	O
various	O
immune	O
cells	O
in	O
the	O
lamina	O
propria	O
.	O

Upon	O
rotavirus	O
infection	O
,	O
Nlrc5	O
deficiency	O
resulted	O
in	O
impaired	O
H2	O
-	O
K	O
(	O
b	O
)	O
-	O
restricted	O
antigen	O
-	O
specific	O
CD8	O
(	O
+	O
)	O
T	O
-	O
cell	O
responses	O
,	O
which	O
were	O
recapitulated	O
in	O
mice	O
deficient	O
for	O
Nlrc5	O
within	O
the	O
dendritic	O
cell	O
compartment	O
.	O

The	O
impaired	O
CD8	O
(	O
+	O
)	O
T	O
-	O
cell	O
response	O
in	O
Nlrc5	O
(	O
-	O
/	O
-	O
)	O
mice	O
was	O
not	O
significant	O
enough	O
to	O
impact	O
viral	O
titers	O
,	O
suggesting	O
compensation	O
in	O
Nlrc5	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
perhaps	O
as	O
a	O
result	O
of	O
higher	O
numbers	O
of	O
activated	O
B	O
cells	O
in	O
the	O
mesenteric	O
lymph	O
nodes	O
and	O
normal	O
rotavirus	O
-	O
specific	O
immunoglobulin	O
A	O
responses	O
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
a	O
minor	O
role	O
for	O
NLRC5	O
in	O
modulating	O
H2	O
-	O
K	O
(	O
b	O
)	O
-	O
restricted	O
antigen	O
-	O
specific	O
CD8	O
(	O
+	O
)	O
T	O
-	O
cell	O
responses	O
in	O
the	O
small	O
intestine	O
during	O
rotavirus	O
infection	O
in	O
adult	O
mice	O
.	O

The	O
Alternate	O
Consumption	O
of	O
Quercetin	O
and	O
Alliin	O
in	O
the	O
Traditional	O
Asian	O
Diet	O
Reshaped	O
Microbiota	O
and	O
Altered	O
Gene	O
Expression	O
of	O
Colonic	O
Epithelial	O
Cells	O
in	O
Rats	O
.	O

The	O
diet	O
of	O
traditional	O
Asian	O
is	O
similar	O
to	O
the	O
Mediterranean	O
that	O
was	O
considered	O
as	O
a	O
healthy	O
dietary	O
pattern	O
.	O

The	O
report	O
was	O
scarce	O
on	O
whether	O
different	O
plant	O
-	O
derived	O
components	O
with	O
similar	O
anti	O
-	O
oxidative	O
and	O
anti	O
-	O
inflammatory	O
function	O
such	O
as	O
quercetin	O
and	O
alliin	O
in	O
traditional	O
Asian	O
diet	O
consumed	O
in	O
an	O
alternate	O
style	O
cooperatively	O
affect	O
health	O
including	O
the	O
growth	O
of	O
host	O
and	O
the	O
status	O
of	O
the	O
gut	O
microbiota	O
and	O
colonic	O
epithelial	O
immunity	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
alternate	O
consumption	O
of	O
quercetin	O
and	O
alliin	O
on	O
host	O
health	O
judging	O
by	O
the	O
profile	O
of	O
gut	O
microbiota	O
and	O
gene	O
expression	O
of	O
colonic	O
epithelial	O
cells	O
were	O
investigated	O
with	O
the	O
Illumina	O
MiSeq	O
sequencing	O
(	O
16S	O
rRNA	O
genes	O
)	O
and	O
Illumina	O
HiSeq	O
(	O
RNA	O
-	O
seq	O
)	O
technique	O
,	O
respectively	O
.	O

The	O
results	O
showed	O
that	O
the	O
alternate	O
consumption	O
significantly	O
increased	O
the	O
rat	O
body	O
weight	O
and	O
reshaped	O
the	O
gut	O
microbiota	O
composition	O
.	O

At	O
the	O
phylum	O
level	O
,	O
it	O
significantly	O
increased	O
the	O
relative	O
abundance	O
of	O
fecal	O
Firmicutes	B-bacteria
and	O
Cyanobacteria	B-bacteria
but	O
decreased	O
that	O
of	O
Bacteroidetes	B-bacteria
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
increased	O
the	O
relative	O
abundance	O
of	O
Candidatus	B-bacteria
Arthromitus	I-bacteria
,	O
Lactococcus	B-bacteria
,	O
Geobacillus	B-bacteria
,	O
and	O
Ruminococcus	B-bacteria
at	O
the	O
genus	O
level	O
that	O
benefits	O
the	O
host	O
'	O
s	O
health	O
.	O

The	O
alternate	O
consumption	O
of	O
quercetin	O
and	O
alliin	O
also	O
altered	O
13	O
genes	O
expression	O
involved	O
in	O
the	O
KEGG	O
pathways	O
of	O
complement	O
and	O
coagulation	O
cascades	O
and	O
hematopoietic	O
cell	O
lineage	O
to	O
improve	O
the	O
gut	O
immunity	O
.	O

Therefore	O
,	O
the	O
alternate	O
consumption	O
of	O
quercetin	O
and	O
alliin	O
in	O
traditional	O
Asian	O
diet	O
can	O
contribute	O
beneficial	O
metabolic	O
effects	O
by	O
optimizing	O
gut	O
microbiota	O
and	O
altering	O
the	O
immunologic	O
function	O
of	O
colonic	O
epithelial	O
cells	O
,	O
resulting	O
in	O
its	O
potential	O
to	O
improve	O
the	O
sub	O
-	O
health	O
status	O
.	O

Impact	O
of	O
a	O
sustained	O
consumption	O
of	O
grape	O
extract	O
on	O
digestion	O
,	O
gut	O
microbial	O
metabolism	O
and	O
intestinal	O
barrier	O
in	O
broiler	O
chickens	O
.	O

The	O
effect	O
of	O
dietary	O
supplementation	O
with	O
grape	O
extract	O
(	O
GE	O
)	O
at	O
2	O
.	O
5	O
and	O
5	O
.	O
0	O
g	O
kg	O
-	O
1	O
of	O
feed	O
on	O
intestinal	O
utilization	O
of	O
polyphenols	O
and	O
gut	O
health	O
of	O
broiler	O
chickens	O
was	O
determined	O
.	O

The	O
ileal	O
digestibility	O
of	O
grape	O
polyphenols	O
was	O
higher	O
for	O
flavan	O
-	O
3	O
-	O
ol	O
monomers	O
[	O
(	O
+	O
)	O
-	O
catechin	O
and	O
(	O
-	O
)	O
-	O
epicatechin	O
]	O
than	O
for	O
dimers	O
(	O
Procyanidins	O
B1	O
and	O
B2	O
)	O
and	O
galloylated	O
compounds	O
[	O
(	O
-	O
)	O
-	O
epicatechingallate	O
]	O
and	O
no	O
differences	O
among	O
2	O
.	O
5	O
and	O
5	O
.	O
0	O
g	O
GE	O
per	O
kg	O
dietary	O
treatments	O
were	O
observed	O
.	O

The	O
excreta	O
concentration	O
of	O
benzoic	O
,	O
phenylacetic	O
,	O
phenylpropionic	O
,	O
and	O
cinnamic	O
acids	O
and	O
phenyl	O
-	O
gamma	O
-	O
valerolactone	O
phenolic	O
metabolites	O
was	O
higher	O
in	O
birds	O
fed	O
GE	O
,	O
confirming	O
hence	O
the	O
microbial	O
metabolism	O
of	O
grape	O
polyphenols	O
to	O
a	O
relevant	O
extent	O
.	O

Gut	O
morphology	O
and	O
the	O
total	O
ileal	O
mucin	O
content	O
were	O
not	O
modified	O
by	O
the	O
dietary	O
inclusion	O
of	O
GE	O
,	O
but	O
a	O
lower	O
sialic	O
acid	O
concentration	O
was	O
observed	O
in	O
those	O
birds	O
fed	O
a	O
higher	O
concentration	O
of	O
GE	O
.	O

Escherichia	B-bacteria
coli	I-bacteria
and	O
lactic	B-bacteria
-	I-bacteria
acid	I-bacteria
bacteria	I-bacteria
ileal	O
counts	O
were	O
reduced	O
in	O
birds	O
fed	O
GE	O
.	O

Overall	O
,	O
these	O
results	O
prove	O
the	O
extensive	O
intestinal	O
utilization	O
and	O
microbial	O
metabolism	O
of	O
grape	O
polyphenols	O
in	O
broiler	O
chickens	O
.	O

Some	O
antimicrobial	O
and	O
mucin	O
-	O
modulation	O
effects	O
were	O
also	O
observed	O
after	O
a	O
sustained	O
consumption	O
of	O
grape	O
polyphenols	O
during	O
21	O
days	O
.	O

Citroniella	B-bacteria
saccharovorans	I-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
a	O
member	O
of	O
the	O
family	O
Peptoniphilaceae	B-bacteria
isolated	O
from	O
a	O
human	O
fecal	O
sample	O
from	O
a	O
coastal	O
traditional	O
community	O
member	O
.	O

A	O
novel	O
Gram	O
-	O
stain	O
-	O
positive	O
,	O
non	O
-	O
motile	O
,	O
non	O
-	O
spore	O
-	O
forming	O
coccus	O
-	O
shaped	O
obligately	O
anaerobic	O
bacterium	O
was	O
recovered	O
from	O
a	O
fecal	O
sample	O
obtained	O
from	O
an	O
individual	O
from	O
a	O
traditional	O
community	O
located	O
on	O
the	O
southern	O
coast	O
of	O
Peru	O
.	O

The	O
results	O
of	O
analysis	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequencing	O
indicated	O
the	O
novel	O
bacterium	O
to	O
be	O
phylogenetically	O
distinct	O
from	O
other	O
genera	O
of	O
members	O
of	O
the	O
Peptoniphilaceae	B-bacteria
family	I-bacteria
,	O
sharing	O
a	O
loose	O
affinity	O
with	O
the	O
genera	O
Ezakiella	B-bacteria
,	O
Finegoldia	B-bacteria
,	O
Gallicola	B-bacteria
and	O
Parvimonas	B-bacteria
.	O

The	O
major	O
cellular	O
fatty	O
acids	O
of	O
the	O
novel	O
isolate	O
were	O
determined	O
to	O
be	O
C16	O
:	O
0	O
,	O
C17	O
:	O
1omega8c	O
,	O
and	O
C18	O
:	O
1omega9c	O
.	O

The	O
DNA	O
G	O
+	O
C	O
content	O
was	O
29	O
.	O
9	O
mol	O
%	O
.	O

End	O
products	O
of	O
metabolism	O
from	O
peptone	O
yeast	O
glucose	O
broth	O
(	O
PYG	O
)	O
were	O
determined	O
to	O
be	O
acetate	O
and	O
methyl	O
succinate	O
.	O

The	O
diagnostic	O
diamino	O
acid	O
present	O
in	O
the	O
cell	O
wall	O
was	O
lysine	O
.	O

On	O
the	O
basis	O
of	O
the	O
phenotypic	O
,	O
chemotaxonomic	O
and	O
phylogenetic	O
results	O
the	O
organism	O
is	O
a	O
member	O
of	O
a	O
novel	O
genus	O
belonging	O
to	O
the	O
family	O
Peptoniphilaceae	B-bacteria
for	O
which	O
the	O
name	O
Citroniella	B-bacteria
saccharovorans	I-bacteria
gen	I-bacteria
nov	I-bacteria
.	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
is	O
proposed	O
.	O

The	O
type	O
strain	O
is	O
M6	B-bacteria
.	I-bacteria
X9	I-bacteria
(	O
T	O
)	O
(	O
DSM	B-bacteria
29873	I-bacteria
(	O
T	O
)	O
=	O
CCUG	B-bacteria
66799	I-bacteria
(	O
T	O
)	O
)	O
.	O

Gut	O
microbiota	O
in	O
liver	O
disease	O
:	O
too	O
much	O
is	O
harmful	O
,	O
nothing	O
at	O
all	O
is	O
not	O
helpful	O
either	O
.	O

The	O
intestinal	O
microbiome	O
plays	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
liver	O
disease	O
,	O
with	O
a	O
hallmark	O
event	O
being	O
dysbiosis	O
,	O
or	O
an	O
imbalance	O
of	O
pathobionts	O
and	O
beneficial	O
bacteria	O
with	O
the	O
associated	O
deleterious	O
effects	O
on	O
their	O
host	O
.	O

Reducing	O
the	O
number	O
of	O
intestinal	O
bacteria	O
with	O
antibiotic	O
treatment	O
is	O
generally	O
advantageous	O
in	O
experimental	O
liver	O
diseases	O
.	O

Complete	O
absence	O
of	O
intestinal	O
microbiota	O
as	O
in	O
germ	O
-	O
free	O
rodents	O
can	O
be	O
protective	O
in	O
autoimmune	O
hepatitis	O
and	O
hepatic	O
tumors	O
induced	O
by	O
chemicals	O
,	O
or	O
it	O
can	O
exacerbate	O
disease	O
as	O
in	O
acute	O
toxic	O
liver	O
injury	O
and	O
liver	O
fibrosis	O
/	O
cirrhosis	O
.	O

In	O
alcoholic	O
liver	O
disease	O
,	O
nonalcoholic	O
fatty	O
liver	O
disease	O
,	O
and	O
autoimmune	O
cholangiopathies	O
,	O
germ	O
-	O
free	O
status	O
can	O
be	O
associated	O
with	O
worsened	O
or	O
improved	O
hepatic	O
phenotype	O
depending	O
on	O
the	O
experimental	O
model	O
and	O
type	O
of	O
rodent	O
.	O

Some	O
of	O
the	O
unexpected	O
outcomes	O
can	O
be	O
explained	O
by	O
the	O
limitations	O
of	O
rodents	O
raised	O
in	O
a	O
germ	O
-	O
free	O
environment	O
including	O
a	O
deficient	O
immune	O
system	O
and	O
an	O
altered	O
metabolism	O
of	O
lipids	O
,	O
cholesterol	O
,	O
xenobiotics	O
/	O
toxins	O
,	O
and	O
bile	O
acids	O
.	O

Given	O
these	O
limitations	O
and	O
to	O
advance	O
understanding	O
of	O
the	O
interactions	O
between	O
host	O
and	O
intestinal	O
microbiota	O
,	O
simplified	O
model	O
systems	O
such	O
as	O
humanized	O
gnotobiotic	O
mice	O
,	O
or	O
gnotobiotic	O
mice	O
monoassociated	O
with	O
a	O
single	O
bacterial	O
strain	O
or	O
colonized	O
with	O
a	O
defined	O
set	O
of	O
microbes	O
,	O
are	O
unique	O
and	O
useful	O
models	O
for	O
investigation	O
of	O
liver	O
disease	O
in	O
a	O
complex	O
ecosystem	O
.	O

Optimizing	O
Gastrointestinal	O
Integrity	O
in	O
Poultry	O
:	O
The	O
Role	O
of	O
Nutrients	O
and	O
Feed	O
Additives	O
.	O

Immunomodulation	O
of	O
the	O
immune	O
system	O
by	O
stimulating	O
or	O
suppressing	O
one	O
or	O
both	O
arms	O
,	O
is	O
an	O
emerging	O
concept	O
driven	O
by	O
the	O
understanding	O
of	O
the	O
host	O
defense	O
system	O
.	O

In	O
particular	O
,	O
the	O
gastrointestinal	O
tract	O
(	O
GIT	O
)	O
functions	O
not	O
only	O
as	O
a	O
site	O
for	O
digestion	O
and	O
absorption	O
of	O
nutrients	O
but	O
also	O
acts	O
as	O
a	O
metabolic	O
and	O
immunological	O
organ	O
.	O

This	O
serves	O
as	O
a	O
barrier	O
against	O
abnormal	O
presentation	O
of	O
luminal	O
constituents	O
,	O
caused	O
by	O
dysfunctional	O
intestinal	O
epithelial	O
barrier	O
,	O
to	O
the	O
mucosal	O
immune	O
system	O
.	O

Invasion	O
by	O
pathogens	O
in	O
the	O
case	O
of	O
disease	O
or	O
stress	O
or	O
a	O
massive	O
influx	O
of	O
commensal	O
bacteria	O
overcomes	O
the	O
defensive	O
mechanisms	O
,	O
resulting	O
in	O
the	O
full	O
activation	O
of	O
local	O
dendritic	O
cells	O
and	O
the	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

A	O
growing	O
body	O
of	O
literature	O
demonstrates	O
the	O
immune	O
benefits	O
of	O
increasing	O
the	O
intake	O
of	O
specific	O
nutrients	O
.	O

This	O
strategy	O
involves	O
formulating	O
diets	O
that	O
encompass	O
the	O
bioavailability	O
and	O
utilization	O
of	O
nutrients	O
from	O
various	O
food	O
sources	O
and	O
understanding	O
the	O
dynamics	O
of	O
the	O
macro	O
and	O
micronutrients	O
to	O
support	O
all	O
physiological	O
functions	O
as	O
well	O
as	O
maintaining	O
the	O
function	O
of	O
the	O
immune	O
cells	O
.	O

The	O
nature	O
and	O
type	O
of	O
feed	O
ingredients	O
may	O
also	O
play	O
some	O
roles	O
on	O
the	O
integrity	O
of	O
the	O
GIT	O
of	O
birds	O
.	O

Because	O
dietary	O
intake	O
or	O
nutritional	O
status	O
as	O
well	O
as	O
nutrient	O
requirements	O
may	O
be	O
altered	O
as	O
a	O
result	O
of	O
disease	O
or	O
stress	O
,	O
this	O
may	O
eventually	O
alter	O
the	O
gut	O
microflora	O
and	O
intestinal	O
mucosal	O
integrity	O
,	O
resulting	O
in	O
a	O
compromised	O
barrier	O
of	O
the	O
intestinal	O
epithelium	O
.	O

The	O
weakening	O
of	O
the	O
intestinal	O
integrity	O
could	O
result	O
in	O
an	O
increase	O
in	O
bacterial	O
adherence	O
to	O
the	O
mucosa	O
,	O
bacterial	O
translocation	O
,	O
susceptibility	O
to	O
opportunistic	O
bacterial	O
infection	O
,	O
and	O
mis	O
-	O
appropriation	O
of	O
nutrients	O
.	O

In	O
this	O
chapter	O
,	O
we	O
will	O
discuss	O
the	O
role	O
of	O
dietary	O
energy	O
and	O
nutrients	O
as	O
substrates	O
that	O
have	O
the	O
potential	O
to	O
influence	O
GIT	O
'	O
s	O
health	O
and	O
integrity	O
and	O
their	O
roles	O
,	O
directly	O
or	O
indirectly	O
,	O
in	O
modulating	O
bird	O
'	O
s	O
ability	O
to	O
be	O
resilient	O
or	O
resist	O
infection	O
.	O

Predictable	O
Molecular	O
Adaptation	O
of	O
Coevolving	O
Enterococcus	B-bacteria
faecium	I-bacteria
and	O
Lytic	O
Phage	O
EfV12	O
-	O
phi1	O
.	O

Bacteriophages	O
are	O
highly	O
abundant	O
in	O
human	O
microbiota	O
where	O
they	O
coevolve	O
with	O
resident	O
bacteria	O
.	O

Phage	O
predation	O
can	O
drive	O
the	O
evolution	O
of	O
bacterial	O
resistance	O
,	O
which	O
can	O
then	O
drive	O
reciprocal	O
evolution	O
in	O
the	O
phage	O
to	O
overcome	O
that	O
resistance	O
.	O

Such	O
coevolutionary	O
dynamics	O
have	O
not	O
been	O
extensively	O
studied	O
in	O
human	O
gut	O
bacteria	O
,	O
and	O
are	O
of	O
particular	O
interest	O
for	O
both	O
understanding	O
and	O
eventually	O
manipulating	O
the	O
human	O
gut	O
microbiome	O
.	O

We	O
performed	O
experimental	O
evolution	O
of	O
an	O
Enterococcus	B-bacteria
faecium	I-bacteria
isolate	I-bacteria
from	O
healthy	O
human	O
stool	O
in	O
the	O
absence	O
and	O
presence	O
of	O
a	O
single	O
infecting	O
Myoviridae	O
bacteriophage	O
,	O
EfV12	O
-	O
phi1	O
.	O

Four	O
replicates	O
of	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
and	O
phage	O
were	O
grown	O
with	O
twice	O
daily	O
serial	O
transfers	O
for	O
8	O
days	O
.	O

Genome	O
sequencing	O
revealed	O
that	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
evolved	O
resistance	O
to	O
phage	O
through	O
mutations	O
in	O
the	O
yqwD2	O
gene	O
involved	O
in	O
exopolysaccharide	O
biogenesis	O
and	O
export	O
,	O
and	O
the	O
rpoC	O
gene	O
which	O
encodes	O
the	O
RNA	O
polymerase	O
beta	O
'	O
subunit	O
.	O

In	O
response	O
to	O
bacterial	O
resistance	O
,	O
phage	O
EfV12	O
-	O
phi1	O
evolved	O
varying	O
numbers	O
of	O
1	O
.	O
8	O
kb	O
tandem	O
duplications	O
within	O
a	O
putative	O
tail	O
fiber	O
gene	O
.	O

Host	O
range	O
assays	O
indicated	O
that	O
coevolution	O
of	O
this	O
phage	O
-	O
host	O
pair	O
resulted	O
in	O
arms	O
race	O
dynamics	O
in	O
which	O
bacterial	O
resistance	O
and	O
phage	O
infectivity	O
increased	O
over	O
time	O
.	O

Tracking	O
mutations	O
from	O
population	O
sequencing	O
of	O
experimental	O
coevolution	O
can	O
quickly	O
illuminate	O
phage	O
entry	O
points	O
along	O
with	O
resistance	O
strategies	O
in	O
both	O
phage	O
and	O
host	O
-	O
critical	O
information	O
for	O
using	O
phage	O
to	O
manipulate	O
microbial	O
communities	O
.	O

Serotonin	O
Transporter	O
Deficiency	O
is	O
Associated	O
with	O
Dysbiosis	O
and	O
Changes	O
in	O
Metabolic	O
Function	O
of	O
the	O
Mouse	O
Intestinal	O
Microbiome	O
.	O

Serotonin	O
transporter	O
(	O
SERT	O
)	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
extracellular	O
availability	O
of	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
in	O
the	O
gut	O
and	O
brain	O
.	O

Mice	O
with	O
deletion	O
of	O
SERT	O
develop	O
metabolic	O
syndrome	O
as	O
they	O
age	O
.	O

Changes	O
in	O
the	O
gut	O
microbiota	O
are	O
being	O
increasingly	O
implicated	O
in	O
Metabolic	O
Syndrome	O
and	O
Diabetes	O
.	O

To	O
investigate	O
the	O
relationship	O
between	O
the	O
gut	O
microbiome	O
and	O
SERT	O
,	O
this	O
study	O
assessed	O
the	O
fecal	O
and	O
cecal	O
microbiome	O
profile	O
of	O
11	O
to	O
12	O
week	O
-	O
old	O
SERT	O
(	O
+	O
/	O
+	O
)	O
and	O
SERT	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Microbial	O
DNA	O
was	O
isolated	O
,	O
processed	O
for	O
metagenomics	O
shotgun	O
sequencing	O
,	O
and	O
taxonomic	O
and	O
functional	O
profiles	O
were	O
assessed	O
.	O

34	O
differentially	O
abundant	O
bacterial	O
species	O
were	O
identified	O
between	O
SERT	O
(	O
+	O
/	O
+	O
)	O
and	O
SERT	O
(	O
-	O
/	O
-	O
)	O
.	O

SERT	O
(	O
-	O
/	O
-	O
)	O
mice	O
displayed	O
higher	O
abundances	O
of	O
Bacilli	B-bacteria
species	I-bacteria
including	O
genera	O
Lactobacillus	B-bacteria
,	O
Streptococcus	B-bacteria
,	O
Enterococcus	B-bacteria
,	O
and	O
Listeria	B-bacteria
.	O

Furthermore	O
,	O
SERT	O
(	O
-	O
/	O
-	O
)	O
mice	O
exhibited	O
significantly	O
lower	O
abundances	O
of	O
Bifidobacterium	B-bacteria
species	I-bacteria
and	O
Akkermansia	B-bacteria
muciniphilia	I-bacteria
.	O

Bacterial	O
community	O
structure	O
was	O
altered	O
in	O
SERT	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Differential	O
abundance	O
of	O
bacteria	O
was	O
correlated	O
with	O
changes	O
in	O
host	O
gene	O
expression	O
.	O

Bifidobacterium	B-bacteria
and	O
Bacilli	B-bacteria
species	I-bacteria
exhibited	O
significant	O
associations	O
with	O
host	O
genes	O
involved	O
in	O
lipid	O
metabolism	O
pathways	O
.	O

Our	O
results	O
show	O
that	O
SERT	O
deletion	O
is	O
associated	O
with	O
dysbiosis	O
similar	O
to	O
that	O
observed	O
in	O
obesity	O
.	O

This	O
study	O
contributes	O
to	O
the	O
understanding	O
as	O
to	O
how	O
changes	O
in	O
gut	O
microbiota	O
are	O
associated	O
with	O
metabolic	O
phenotype	O
seen	O
in	O
SERT	O
deficiency	O
.	O

Enrichment	O
of	O
bacteria	O
and	O
alginate	O
lyase	O
genes	O
potentially	O
involved	O
in	O
brown	O
alga	O
degradation	O
in	O
the	O
gut	O
of	O
marine	O
gastropods	O
.	O

Gut	O
bacteria	O
of	O
phytophagous	O
and	O
omnivorous	O
marine	O
invertebrates	O
often	O
possess	O
alginate	O
lyases	O
(	O
ALGs	O
)	O
,	O
which	O
are	O
key	O
enzymes	O
for	O
utilizing	O
macroalgae	O
as	O
carbon	O
neutral	O
biomass	O
.	O

We	O
hypothesized	O
that	O
the	O
exclusive	O
feeding	O
of	O
a	O
target	O
alga	O
to	O
marine	O
invertebrates	O
would	O
shift	O
the	O
gut	O
bacterial	O
diversity	O
suitable	O
for	O
degrading	O
the	O
algal	O
components	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
reared	O
sea	O
hare	O
(	O
Dolabella	O
auricularia	O
)	O
and	O
sea	O
snail	O
(	O
Batillus	O
cornutus	O
)	O
for	O
two	O
to	O
four	O
weeks	O
with	O
exclusive	O
feeding	O
of	O
a	O
brown	O
alga	O
(	O
Ecklonia	O
cava	O
)	O
.	O

Pyrosequencing	O
analysis	O
of	O
the	O
gut	O
bacterial	O
16S	O
rRNA	O
genes	O
revealed	O
shifts	O
in	O
the	O
gut	O
microbiota	O
after	O
rearing	O
,	O
mainly	O
due	O
to	O
a	O
decrease	O
in	O
the	O
variety	O
of	O
bacterial	O
members	O
.	O

Significant	O
increases	O
in	O
six	O
and	O
four	O
16S	O
rRNA	O
gene	O
phylotypes	O
were	O
observed	O
in	O
the	O
reared	O
sea	O
hares	O
and	O
sea	O
snails	O
,	O
respectively	O
,	O
and	O
some	O
of	O
them	O
were	O
phylogenetically	O
close	O
to	O
known	O
alginate	O
-	O
degrading	O
bacteria	O
.	O

Clone	O
library	O
analysis	O
of	O
PL7	O
family	O
ALG	O
genes	O
using	O
newly	O
designed	O
degenerate	O
primer	O
sets	O
detected	O
a	O
total	O
of	O
50	O
ALG	O
gene	O
phylotypes	O
based	O
on	O
90	O
%	O
amino	O
acid	O
identity	O
.	O

The	O
number	O
of	O
ALG	O
gene	O
phylotypes	O
increased	O
in	O
the	O
reared	O
sea	O
hare	O
but	O
decreased	O
in	O
reared	O
sea	O
snail	O
samples	O
,	O
and	O
no	O
phylotype	O
was	O
shared	O
between	O
them	O
.	O

Out	O
of	O
the	O
50	O
phylotypes	O
,	O
15	O
were	O
detected	O
only	O
after	O
the	O
feeding	O
procedure	O
.	O

Thus	O
,	O
controlled	O
feeding	O
strategy	O
may	O
be	O
valid	O
and	O
useful	O
for	O
the	O
efficient	O
screening	O
of	O
genes	O
suitable	O
for	O
target	O
alga	O
fermentation	O
.	O

The	O
Food	O
Additive	O
Maltodextrin	O
Promotes	O
Endoplasmic	O
Reticulum	O
Stress	O
-	O
Driven	O
Mucus	O
Depletion	O
and	O
Exacerbates	O
Intestinal	O
Inflammation	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Food	O
additives	O
,	O
such	O
as	O
emulsifiers	O
,	O
stabilizers	O
,	O
or	O
bulking	O
agents	O
,	O
are	O
present	O
in	O
the	O
Western	O
diet	O
and	O
their	O
consumption	O
is	O
increasing	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
their	O
potential	O
effects	O
on	O
intestinal	O
homeostasis	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
effect	O
of	O
some	O
of	O
these	O
food	O
additives	O
on	O
gut	O
inflammation	O
.	O

METHODS	O
:	O
Mice	O
were	O
given	O
drinking	O
water	O
containing	O
maltodextrin	O
(	O
MDX	O
)	O
,	O
propylene	O
glycol	O
,	O
or	O
animal	O
gelatin	O
,	O
and	O
then	O
challenged	O
with	O
dextran	O
sulfate	O
sodium	O
or	O
indomethacin	O
.	O

In	O
parallel	O
,	O
mice	O
fed	O
a	O
MDX	O
-	O
enriched	O
diet	O
were	O
given	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
inhibitor	O
tauroursodeoxycholic	O
acid	O
(	O
TUDCA	O
)	O
.	O

Transcriptomic	O
analysis	O
,	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
,	O
mucin	O
-	O
2	O
expression	O
,	O
phosphorylated	O
p38	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
quantification	O
,	O
and	O
H	O
&	O
E	O
staining	O
was	O
performed	O
on	O
colonic	O
tissues	O
.	O

Mucosa	O
-	O
associated	O
microbiota	O
composition	O
was	O
characterized	O
by	O
16S	O
ribosomal	O
RNA	O
sequencing	O
.	O

For	O
the	O
in	O
vitro	O
experiments	O
,	O
murine	O
intestinal	O
crypts	O
and	O
the	O
human	O
mucus	O
-	O
secreting	O
HT29	O
-	O
methotrexate	O
treated	O
cell	O
line	O
were	O
stimulated	O
with	O
MDX	O
in	O
the	O
presence	O
or	O
absence	O
of	O
TUDCA	O
or	O
a	O
p38	O
MAP	O
kinase	O
inhibitor	O
.	O

RESULTS	O
:	O
Diets	O
enriched	O
in	O
MDX	O
,	O
but	O
not	O
propylene	O
glycol	O
or	O
animal	O
gelatin	O
,	O
exacerbated	O
intestinal	O
inflammation	O
in	O
both	O
models	O
.	O

Analysis	O
of	O
the	O
mechanisms	O
underlying	O
the	O
detrimental	O
effect	O
of	O
MDX	O
showed	O
up	O
-	O
regulation	O
of	O
inositol	O
requiring	O
protein	O
1beta	O
,	O
a	O
sensor	O
of	O
ER	O
stress	O
,	O
in	O
goblet	O
cells	O
,	O
and	O
a	O
reduction	O
of	O
mucin	O
-	O
2	O
expression	O
with	O
no	O
significant	O
change	O
in	O
mucosa	O
-	O
associated	O
microbiota	O
.	O

Stimulation	O
of	O
murine	O
intestinal	O
crypts	O
and	O
HT29	O
-	O
methotrexate	O
treated	O
cell	O
line	O
cells	O
with	O
MDX	O
induced	O
inositol	O
requiring	O
protein	O
1beta	O
via	O
a	O
p38	O
MAP	O
kinase	O
-	O
dependent	O
mechanism	O
.	O

Treatment	O
of	O
mice	O
with	O
TUDCA	O
prevented	O
mucin	O
-	O
2	O
depletion	O
and	O
attenuated	O
colitis	O
in	O
MDX	O
-	O
fed	O
mice	O
.	O

CONCLUSIONS	O
:	O
MDX	O
increases	O
ER	O
stress	O
in	O
gut	O
epithelial	O
cells	O
with	O
the	O
downstream	O
effect	O
of	O
reducing	O
mucus	O
production	O
and	O
enhancing	O
colitis	O
susceptibility	O
.	O

Reduced	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
and	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
levels	O
in	O
the	O
gut	O
microbiota	O
of	O
children	O
with	O
allergic	O
asthma	O
.	O

INTRODUCTION	O
AND	O
OBJECTIVES	O
:	O
The	O
amounts	O
of	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
and	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
in	O
gut	O
microbiota	O
are	O
reduced	O
in	O
patients	O
with	O
allergic	O
diseases	O
compared	O
to	O
healthy	O
controls	O
.	O

We	O
aimed	O
to	O
quantify	O
levels	O
of	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
amounts	O
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
in	O
the	O
gut	O
microbiota	O
of	O
children	O
with	O
allergic	O
asthma	O
and	O
in	O
healthy	O
controls	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
In	O
total	O
,	O
92	O
children	O
between	O
the	O
ages	O
of	O
three	O
and	O
eight	O
who	O
were	O
diagnosed	O
with	O
asthma	O
and	O
88	O
healthy	O
children	O
were	O
included	O
in	O
the	O
study	O
and	O
bacterial	O
DNA	O
was	O
isolated	O
from	O
the	O
stool	O
samples	O
using	O
the	O
stool	O
DNA	O
isolation	O
Kit	O
.	O

qPCR	O
assays	O
were	O
studied	O
with	O
the	O
microbial	O
DNA	O
qPCR	O
Kit	O
for	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
and	O
microbial	O
DNA	O
qPCR	O
Kit	O
for	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
.	O

RESULTS	O
:	O
Both	O
bacterial	O
species	O
showed	O
a	O
reduction	O
in	O
the	O
patient	O
group	O
compared	O
to	O
healthy	O
controls	O
.	O

A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
were	O
found	O
to	O
be	O
5	O
.	O
45	O
+	O
/	O
-	O
0	O
.	O
004	O
,	O
6	O
.	O
74	O
+	O
/	O
-	O
0	O
.	O
01	O
and	O
5	O
.	O
71	O
+	O
/	O
-	O
0	O
.	O
002	O
,	O
7	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
009	O
in	O
the	O
stool	O
samples	O
of	O
the	O
asthma	O
and	O
healthy	O
control	O
groups	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
and	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
may	O
have	O
induced	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	O
-	O
10	O
and	O
prevented	O
the	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
like	O
IL	O
-	O
12	O
.	O

These	O
findings	O
suggest	O
that	O
A	B-bacteria
.	I-bacteria
muciniphila	I-bacteria
and	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
may	O
suppress	O
inflammation	O
through	O
its	O
secreted	O
metabolites	O
.	O

Gut	O
microbiota	O
diversity	O
is	O
associated	O
with	O
cardiorespiratory	O
fitness	O
in	O
post	O
-	O
primary	O
treatment	O
breast	O
cancer	O
survivors	O
.	O

NEW	O
FINDINGS	O
:	O
What	O
is	O
the	O
central	O
question	O
of	O
this	O
study	O
?	O

Does	O
the	O
link	O
between	O
cardiorespiratory	O
fitness	O
and	O
gut	O
microbiota	O
diversity	O
persist	O
after	O
adjusting	O
for	O
the	O
potential	O
effects	O
of	O
percentage	O
body	O
fat	O
and	O
activity	O
-	O
related	O
energy	O
expenditure	O
(	O
AEE	O
)	O
?	O

What	O
is	O
the	O
main	O
finding	O
and	O
its	O
importance	O
?	O

This	O
is	O
the	O
first	O
study	O
to	O
examine	O
the	O
link	O
between	O
cardiorespiratory	O
fitness	O
and	O
gut	O
microbiota	O
diversity	O
while	O
accounting	O
for	O
the	O
underlying	O
effects	O
of	O
percentage	O
body	O
fat	O
and	O
free	O
-	O
living	O
AEE	O
.	O

Results	O
from	O
the	O
present	O
work	O
suggest	O
that	O
cardiorespiratory	O
fitness	O
,	O
not	O
physical	O
activity	O
,	O
is	O
a	O
superior	O
correlate	O
of	O
gut	O
microbiota	O
diversity	O
among	O
post	O
-	O
primary	O
treatment	O
,	O
non	O
-	O
metastatic	O
breast	O
cancer	O
survivors	O
.	O

ABSTRACT	O
:	O
Cancer	O
treatment	O
uniquely	O
triggers	O
multiple	O
physiological	O
shifts	O
detrimental	O
to	O
overall	O
health	O
.	O

Although	O
previous	O
research	O
indicates	O
a	O
link	O
between	O
the	O
gut	O
microbiota	O
and	O
cardiorespiratory	O
fitness	O
,	O
it	O
is	O
unclear	O
whether	O
these	O
findings	O
are	O
attributable	O
to	O
potential	O
underlying	O
effects	O
of	O
percentage	O
body	O
fat	O
or	O
free	O
-	O
living	O
activity	O
energy	O
expenditure	O
(	O
AEE	O
)	O
.	O

The	O
microbe	O
composition	O
of	O
faecal	O
specimens	O
from	O
37	O
breast	O
cancer	O
survivors	O
was	O
determined	O
using	O
16S	O
microbiome	O
analyses	O
.	O

Individual	O
-	O
sample	O
microbiota	O
diversity	O
(	O
alpha	O
-	O
diversity	O
)	O
and	O
between	O
-	O
sample	O
community	O
differences	O
(	O
beta	O
-	O
diversity	O
)	O
were	O
examined	O
.	O

Peak	O
oxygen	O
uptake	O
(	O
V	O
O	O
2	O
peak	O
)	O
was	O
estimated	O
from	O
a	O
graded	O
exercise	O
test	O
consistent	O
with	O
the	O
modified	O
Naughton	O
protocol	O
,	O
in	O
which	O
exercise	O
terminates	O
at	O
85	O
%	O
of	O
age	O
-	O
predicted	O
maximal	O
heart	O
rate	O
.	O

The	O
AEE	O
was	O
measured	O
over	O
10	O
days	O
using	O
doubly	O
labelled	O
water	O
,	O
wherein	O
the	O
percentage	O
body	O
fat	O
was	O
calculated	O
from	O
total	O
body	O
water	O
.	O

Pearson	O
correlations	O
revealed	O
alpha	O
-	O
diversity	O
indices	O
(	O
Chao1	O
,	O
observed	O
species	O
,	O
PD	O
whole	O
tree	O
and	O
Shannon	O
)	O
to	O
be	O
positively	O
associated	O
with	O
V	O
O	O
2	O
peak	O
(	O
r	O
=	O
0	O
.	O
34	O
-	O
0	O
.	O
51	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
the	O
percentage	O
of	O
maximal	O
heart	O
rate	O
during	O
stages	O
1	O
-	O
4	O
of	O
the	O
graded	O
exercise	O
test	O
(	O
r	O
=	O
-	O
0	O
.	O
34	O
to	O
-	O
0	O
.	O
50	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
percentage	O
body	O
fat	O
(	O
r	O
=	O
-	O
0	O
.	O
32	O
to	O
-	O
0	O
.	O
41	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
negatively	O
associated	O
with	O
the	O
same	O
alpha	O
-	O
diversity	O
indices	O
.	O

Multiple	O
linear	O
regression	O
models	O
showed	O
that	O
V	O
O	O
2	O
peak	O
accounted	O
for	O
22	O
and	O
26	O
%	O
of	O
the	O
variance	O
in	O
taxonomic	O
richness	O
(	O
observed	O
species	O
)	O
and	O
phylogenic	O
diversity	O
after	O
adjustment	O
for	O
percentage	O
body	O
fat	O
and	O
menopausal	O
status	O
.	O

Unweighted	O
UniFrac	O
(	O
beta	O
-	O
diversity	O
)	O
was	O
significant	O
for	O
several	O
outcomes	O
involving	O
cardiorespiratory	O
fitness	O
,	O
and	O
significant	O
taxa	O
comparisons	O
were	O
found	O
.	O

Associations	O
between	O
gut	O
microbiota	O
and	O
free	O
-	O
living	O
AEE	O
were	O
not	O
found	O
.	O

Results	O
from	O
the	O
present	O
work	O
suggest	O
that	O
cardiorespiratory	O
fitness	O
,	O
not	O
physical	O
activity	O
,	O
is	O
a	O
superior	O
correlate	O
of	O
gut	O
microbiota	O
diversity	O
.	O

Prebiotic	O
reduction	O
of	O
brain	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
activity	O
and	O
olanzapine	O
-	O
mediated	O
weight	O
gain	O
in	O
rats	O
,	O
are	O
acetate	O
independent	O
.	O

The	O
intestinal	O
microbiome	O
is	O
emerging	O
as	O
a	O
novel	O
therapeutic	O
target	O
owing	O
to	O
the	O
wide	O
range	O
of	O
potential	O
health	O
benefits	O
that	O
could	O
result	O
by	O
manipulating	O
the	O
microbiota	O
composition	O
through	O
relatively	O
simple	O
interventions	O
.	O

Ingestion	O
of	O
the	O
prebiotic	O
Bimuno	O
galacto	O
-	O
oligosaccharide	O
(	O
B	O
-	O
GOS	O
(	O
(	O
R	O
)	O
)	O
)	O
is	O
one	O
such	O
intervention	O
that	O
has	O
been	O
shown	O
to	O
attenuate	O
olanzapine	O
-	O
induced	O
weight	O
gain	O
and	O
improve	O
cognitive	O
flexibility	O
in	O
rats	O
,	O
potentially	O
through	O
mechanisms	O
involving	O
acetate	O
,	O
the	O
major	O
short	O
-	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
that	O
is	O
produced	O
by	O
B	O
-	O
GOS	O
(	O
(	O
R	O
)	O
)	O
fermentation	O
.	O

The	O
present	O
study	O
investigated	O
the	O
individual	O
influences	O
of	O
B	O
-	O
GOS	O
(	O
(	O
R	O
)	O
)	O
and	O
sodium	O
acetate	O
intake	O
on	O
brain	O
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
and	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
activities	O
,	O
cortical	O
and	O
hippocampal	O
expression	O
of	O
HDAC1	O
-	O
4	O
and	O
N	O
-	O
methyl	O
-	O
d	O
-	O
aspartate	O
receptor	O
subunits	O
in	O
saline	O
or	O
olanzapine	O
injected	O
female	O
rats	O
.	O

The	O
effect	O
of	O
sodium	O
acetate	O
on	O
olanzapine	O
-	O
induced	O
weight	O
gain	O
was	O
also	O
investigated	O
.	O

Daily	O
ingestion	O
of	O
B	O
-	O
GOS	O
(	O
(	O
R	O
)	O
)	O
for	O
21	O
days	O
,	O
reduced	O
HDAC	O
activity	O
and	O
hippocampal	O
HDAC	O
-	O
4	O
,	O
and	O
elevated	O
levels	O
of	O
cortical	O
HDAC	O
-	O
1	O
and	O
HDAC	O
-	O
3	O
mRNAs	O
.	O

Sodium	O
acetate	O
supplementation	O
significantly	O
decreased	O
HAT	O
,	O
but	O
not	O
HDAC	O
,	O
activity	O
and	O
increased	O
hippocampal	O
HDAC	O
-	O
3	O
and	O
HDAC	O
-	O
4	O
mRNAs	O
.	O

Olanzapine	O
-	O
induced	O
weight	O
gain	O
and	O
fourteen	O
genera	O
of	O
intestinal	O
bacteria	O
,	O
were	O
not	O
influenced	O
by	O
sodium	O
acetate	O
intake	O
.	O

Together	O
these	O
data	O
suggests	O
the	O
effects	O
of	O
B	O
-	O
GOS	O
(	O
(	O
R	O
)	O
)	O
in	O
rats	O
can	O
not	O
be	O
replicated	O
by	O
acetate	O
ingestion	O
,	O
and	O
that	O
mechanisms	O
beyond	O
the	O
production	O
of	O
this	O
SCFA	O
are	O
likely	O
to	O
underlie	O
the	O
psychotropic	O
and	O
metabolic	O
actions	O
of	O
this	O
prebiotic	O
.	O

Composition	O
and	O
Variation	O
of	O
the	O
Human	O
Milk	O
Microbiota	O
Are	O
Influenced	O
by	O
Maternal	O
and	O
Early	O
-	O
Life	O
Factors	O
.	O

Breastmilk	O
contains	O
a	O
complex	O
community	O
of	O
bacteria	O
that	O
may	O
help	O
seed	O
the	O
infant	O
gut	O
microbiota	O
.	O

The	O
composition	O
and	O
determinants	O
of	O
milk	O
microbiota	O
are	O
poorly	O
understood	O
.	O

Among	O
393	O
mother	O
-	O
infant	O
dyads	O
from	O
the	O
CHILD	O
cohort	O
,	O
we	O
found	O
that	O
milk	O
microbiota	O
at	O
3	O
-	O
4	O
months	O
postpartum	O
was	O
dominated	O
by	O
inversely	O
correlated	O
Proteobacteria	B-bacteria
and	O
Firmicutes	B-bacteria
,	O
and	O
exhibited	O
discrete	O
compositional	O
patterns	O
.	O

Milk	O
microbiota	O
composition	O
and	O
diversity	O
were	O
associated	O
with	O
maternal	O
factors	O
(	O
BMI	O
,	O
parity	O
,	O
and	O
mode	O
of	O
delivery	O
)	O
,	O
breastfeeding	O
practices	O
,	O
and	O
other	O
milk	O
components	O
in	O
a	O
sex	O
-	O
specific	O
manner	O
.	O

Causal	O
modeling	O
identified	O
mode	O
of	O
breastfeeding	O
as	O
a	O
key	O
determinant	O
of	O
milk	O
microbiota	O
composition	O
.	O

Specifically	O
,	O
providing	O
pumped	O
breastmilk	O
was	O
consistently	O
associated	O
with	O
multiple	O
microbiota	O
parameters	O
including	O
enrichment	O
of	O
potential	O
pathogens	O
and	O
depletion	O
of	O
bifidobacteria	B-bacteria
.	O

Further	O
,	O
these	O
data	O
support	O
the	O
retrograde	O
inoculation	O
hypothesis	O
,	O
whereby	O
the	O
infant	O
oral	O
cavity	O
impacts	O
the	O
milk	O
microbiota	O
.	O

Collectively	O
,	O
these	O
results	O
identify	O
features	O
and	O
determinants	O
of	O
human	O
milk	O
microbiota	O
composition	O
,	O
with	O
potential	O
implications	O
for	O
infant	O
health	O
and	O
development	O
.	O

Expansion	O
of	O
Bacteriophages	O
Is	O
Linked	O
to	O
Aggravated	O
Intestinal	O
Inflammation	O
and	O
Colitis	O
.	O

Bacteriophages	O
are	O
the	O
most	O
abundant	O
members	O
of	O
the	O
microbiota	O
and	O
have	O
the	O
potential	O
to	O
shape	O
gut	O
bacterial	O
communities	O
.	O

Changes	O
to	O
bacteriophage	O
composition	O
are	O
associated	O
with	O
disease	O
,	O
but	O
how	O
phages	O
impact	O
mammalian	O
health	O
remains	O
unclear	O
.	O

We	O
noted	O
an	O
induction	O
of	O
host	O
immunity	O
when	O
experimentally	O
treating	O
bacterially	O
driven	O
cancer	O
,	O
leading	O
us	O
to	O
test	O
whether	O
bacteriophages	O
alter	O
immune	O
responses	O
.	O

Treating	O
germ	O
-	O
free	O
mice	O
with	O
bacteriophages	O
leads	O
to	O
immune	O
cell	O
expansion	O
in	O
the	O
gut	O
.	O

Lactobacillus	B-bacteria
,	O
Escherichia	B-bacteria
,	O
and	O
Bacteroides	B-bacteria
bacteriophages	I-bacteria
and	O
phage	O
DNA	O
stimulated	O
IFN	O
-	O
gamma	O
via	O
the	O
nucleotide	O
-	O
sensing	O
receptor	O
TLR9	O
.	O

The	O
resultant	O
immune	O
responses	O
were	O
both	O
phage	O
and	O
bacteria	O
specific	O
.	O

Additionally	O
,	O
increasing	O
bacteriophage	O
levels	O
exacerbated	O
colitis	O
via	O
TLR9	O
and	O
IFN	O
-	O
gamma	O
.	O

Similarly	O
,	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
patients	O
responsive	O
to	O
fecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
have	O
reduced	O
phages	O
compared	O
to	O
non	O
-	O
responders	O
,	O
and	O
mucosal	O
IFN	O
-	O
gamma	O
positively	O
correlates	O
with	O
bacteriophage	O
levels	O
.	O

Bacteriophages	O
from	O
active	O
UC	O
patients	O
induced	O
more	O
IFN	O
-	O
gamma	O
compared	O
to	O
healthy	O
individuals	O
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
bacteriophages	O
can	O
alter	O
mucosal	O
immunity	O
to	O
impact	O
mammalian	O
health	O
.	O

Virome	O
Diversity	O
Correlates	O
with	O
Intestinal	O
Microbiome	O
Diversity	O
in	O
Adult	O
Monozygotic	O
Twins	O
.	O

The	O
virome	O
is	O
one	O
of	O
the	O
most	O
variable	O
components	O
of	O
the	O
human	O
gut	O
microbiome	O
.	O

Within	O
twin	O
pairs	O
,	O
viromes	O
have	O
been	O
shown	O
to	O
be	O
similar	O
for	O
infants	O
,	O
but	O
not	O
for	O
adults	O
,	O
indicating	O
that	O
as	O
twins	O
age	O
and	O
their	O
environments	O
and	O
microbiomes	O
diverge	O
,	O
so	O
do	O
their	O
viromes	O
.	O

The	O
degree	O
to	O
which	O
the	O
microbiome	O
drives	O
the	O
vast	O
virome	O
diversity	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
examine	O
the	O
relationship	O
between	O
microbiome	O
and	O
virome	O
diversity	O
in	O
21	O
adult	O
monozygotic	O
twin	O
pairs	O
selected	O
for	O
high	O
or	O
low	O
microbiome	O
concordance	O
.	O

Viromes	O
derived	O
from	O
virus	O
-	O
like	O
particles	O
are	O
unique	O
to	O
each	O
individual	O
,	O
are	O
dominated	O
by	O
Caudovirales	O
and	O
Microviridae	O
,	O
and	O
exhibit	O
a	O
small	O
core	O
that	O
includes	O
crAssphage	O
.	O

Microbiome	O
-	O
discordant	O
twins	O
display	O
more	O
dissimilar	O
viromes	O
compared	O
to	O
microbiome	O
-	O
concordant	O
twins	O
,	O
and	O
the	O
richer	O
the	O
microbiomes	O
,	O
the	O
richer	O
the	O
viromes	O
.	O

These	O
patterns	O
are	O
driven	O
by	O
bacteriophages	O
,	O
not	O
eukaryotic	O
viruses	O
.	O

Collectively	O
,	O
these	O
observations	O
support	O
a	O
strong	O
role	O
of	O
the	O
microbiome	O
in	O
patterning	O
for	O
the	O
virome	O
.	O

Bacteriophages	O
of	O
the	O
Human	O
Gut	O
:	O
The	O
`	O
`	O
Known	O
Unknown	O
'	O
'	O
of	O
the	O
Microbiome	O
.	O

The	O
human	O
gut	O
microbiome	O
is	O
a	O
dense	O
and	O
taxonomically	O
diverse	O
consortium	O
of	O
microorganisms	O
.	O

While	O
the	O
bacterial	O
components	O
of	O
the	O
microbiome	O
have	O
received	O
considerable	O
attention	O
,	O
comparatively	O
little	O
is	O
known	O
about	O
the	O
composition	O
and	O
physiological	O
significance	O
of	O
human	O
gut	O
-	O
associated	O
bacteriophage	O
populations	O
(	O
phageome	O
)	O
.	O

By	O
extrapolating	O
our	O
knowledge	O
of	O
phage	O
-	O
host	O
interactions	O
from	O
other	O
environments	O
,	O
one	O
could	O
expect	O
that	O
>	O
10	O
(	O
12	O
)	O
viruses	O
reside	O
in	O
the	O
human	O
gut	O
,	O
and	O
we	O
can	O
predict	O
that	O
they	O
play	O
important	O
roles	O
in	O
regulating	O
the	O
complex	O
microbial	O
networks	O
operating	O
in	O
this	O
habitat	O
.	O

Before	O
delving	O
into	O
their	O
function	O
,	O
we	O
need	O
to	O
first	O
overcome	O
the	O
challenges	O
associated	O
with	O
studying	O
and	O
characterizing	O
the	O
phageome	O
.	O

In	O
this	O
Review	O
,	O
we	O
summarize	O
the	O
available	O
methods	O
and	O
main	O
findings	O
regarding	O
taxonomic	O
composition	O
,	O
community	O
structure	O
,	O
and	O
population	O
dynamics	O
in	O
the	O
human	O
gut	O
phageome	O
.	O

We	O
also	O
discuss	O
the	O
main	O
challenges	O
in	O
the	O
field	O
and	O
identify	O
promising	O
avenues	O
for	O
future	O
research	O
.	O

The	O
Innate	O
Sense	O
of	O
Bacteriophages	O
.	O

Perturbation	O
of	O
the	O
gut	O
microbiota	O
is	O
associated	O
with	O
inflammatory	O
bowel	O
disease	O
,	O
obesity	O
,	O
and	O
even	O
cancer	O
.	O

In	O
this	O
issue	O
of	O
Cell	O
Host	O
&	O
Microbe	O
,	O
Gogokhia	O
et	O
al	O
.	O

2019	O
sought	O
to	O
kill	O
cancer	O
-	O
causing	O
bacteria	O
with	O
bacteriophages	O
.	O

However	O
,	O
the	O
bacteriophages	O
themselves	O
directly	O
stimulated	O
an	O
immune	O
response	O
,	O
which	O
worsened	O
inflammatory	O
bowel	O
disease	O
pathogenesis	O
.	O

Mucosal	O
cell	O
populations	O
may	O
contribute	O
to	O
peripheral	O
immune	O
abnormalities	O
in	O
HIV	O
-	O
infected	O
subjects	O
introducing	O
cART	O
with	O
moderate	O
immune	O
-	O
suppression	O
.	O

HIV	O
infection	O
causes	O
the	O
progressive	O
depletion	O
of	O
CD4	O
+	O
T	O
-	O
lymphocytes	O
and	O
profound	O
modifications	O
of	O
T	O
-	O
cell	O
homeostasis	O
,	O
which	O
persist	O
despite	O
virologically	O
-	O
suppressive	O
treatment	O
and	O
have	O
been	O
linked	O
to	O
a	O
worse	O
clinical	O
outcome	O
.	O

Enduring	O
alterations	O
of	O
the	O
gastrointestinal	O
tract	O
may	O
represent	O
the	O
underlying	O
pathogenic	O
mechanisms	O
of	O
these	O
phenomena	O
.	O

Twenty	O
-	O
six	O
HIV	O
-	O
infected	O
subjects	O
were	O
assessed	O
over	O
a	O
12	O
-	O
month	O
period	O
following	O
the	O
introduction	O
of	O
antiretroviral	O
therapy	O
.	O

18	O
uninfected	O
individuals	O
were	O
enrolled	O
as	O
controls	O
.	O

Parameters	O
of	O
peripheral	O
T	O
-	O
cell	O
homeostasis	O
(	O
activation	O
,	O
maturation	O
)	O
,	O
gastrointestinal	O
function	O
(	O
microbial	O
translocation	O
,	O
gut	O
inflammation	O
,	O
fecal	O
microbiota	O
composition	O
)	O
and	O
mucosal	O
immunity	O
(	O
CD4	O
+	O
CCR6	O
+	O
CD161	O
+	O
,	O
CD4	O
+	O
CCR9	O
+	O
alpha4beta7	O
+	O
,	O
stem	O
cell	O
memory	O
CD4	O
+	O
/	O
CD8	O
+	O
T	O
-	O
cells	O
)	O
were	O
assessed	O
.	O

CD4	O
+	O
CCR6	O
+	O
CD161	O
+	O
cells	O
were	O
depleted	O
in	O
HIV	O
-	O
infected	O
untreated	O
subjects	O
and	O
maintained	O
significantly	O
lower	O
levels	O
compared	O
to	O
controls	O
,	O
despite	O
the	O
introduction	O
of	O
effective	O
antiviral	O
treatment	O
.	O

The	O
frequency	O
of	O
gut	O
-	O
homing	O
CD4	O
+	O
CCR9	O
+	O
alpha4beta7	O
+	O
cells	O
was	O
also	O
impaired	O
in	O
untreated	O
infection	O
and	O
correlated	O
with	O
the	O
HIV	O
RNA	O
load	O
and	O
CD4	O
+	O
HLADR	O
+	O
CD38	O
+	O
;	O
during	O
therapy	O
,	O
we	O
observed	O
a	O
contraction	O
of	O
this	O
pool	O
in	O
the	O
peripheral	O
blood	O
and	O
the	O
loss	O
of	O
its	O
correlation	O
with	O
antigenic	O
exposure	O
/	O
immune	O
activation	O
.	O

A	O
partial	O
correction	O
of	O
the	O
balance	O
between	O
stem	O
cell	O
memory	O
pools	O
and	O
T	O
-	O
cell	O
homeostasis	O
was	O
registered	O
following	O
treatment	O
.	O

In	O
HIV	O
-	O
infected	O
subjects	O
with	O
moderate	O
immune	O
-	O
suppression	O
,	O
antiretroviral	O
therapy	O
has	O
a	O
marginal	O
impact	O
on	O
mucosal	O
immune	O
populations	O
which	O
feature	O
distinctive	O
kinetics	O
in	O
the	O
periphery	O
,	O
possibly	O
reflecting	O
their	O
diverse	O
recruitment	O
from	O
the	O
blood	O
to	O
the	O
mucosa	O
.	O

The	O
persistent	O
defects	O
in	O
mucosal	O
immunity	O
may	O
fuel	O
peripheral	O
T	O
-	O
cell	O
abnormalities	O
through	O
diverse	O
mechanisms	O
,	O
including	O
the	O
production	O
of	O
IL	O
-	O
17	O
/	O
IL	O
-	O
22	O
,	O
cellular	O
permissiveness	O
to	O
infection	O
and	O
regulation	O
of	O
T	O
-	O
lymphocyte	O
maturation	O
.	O

HIV	O
-	O
exposed	O
uninfected	O
compared	O
with	O
unexposed	O
infants	O
show	O
the	O
presence	O
of	O
leucocytes	O
,	O
lower	O
lactoferrin	O
levels	O
and	O
antimicrobial	O
-	O
resistant	O
micro	O
-	O
organisms	O
in	O
the	O
stool	O
.	O

BACKGROUND	O
:	O
HIV	O
-	O
exposed	O
uninfected	O
(	O
HEU	O
)	O
-	O
infants	O
have	O
been	O
shown	O
to	O
be	O
particularly	O
vulnerable	O
to	O
infections	O
.	O

In	O
this	O
population	O
,	O
disturbance	O
of	O
the	O
gut	O
micro	O
-	O
environment	O
might	O
increase	O
their	O
susceptibility	O
to	O
enteric	O
diseases	O
and	O
even	O
favour	O
the	O
translocation	O
of	O
bacteria	O
in	O
the	O
bloodstream	O
.	O

METHODS	O
:	O
The	O
gastro	O
-	O
intestinal	O
micro	O
-	O
environment	O
was	O
explored	O
in	O
22	O
HEU	O
infants	O
and	O
16	O
HIV	O
-	O
unexposed	O
(	O
HU	O
)	O
infants	O
aged	O
6	O
-	O
24	O
weeks	O
.	O

Faecal	O
leucocytes	O
,	O
firmicutes	B-bacteria
(	O
gram	O
-	O
positive	O
bacteria	O
)	O
and	O
gracilicutes	B-bacteria
(	O
gram	O
-	O
negative	O
bacteria	O
)	O
were	O
assessed	O
by	O
cytology	O
.	O

Faecal	O
lactoferrin	O
and	O
sIgA	O
were	O
measured	O
by	O
ELISA	O
.	O

The	O
spectrum	O
of	O
micro	O
-	O
organisms	O
in	O
infants	O
'	O
stool	O
was	O
analysed	O
by	O
culturing	O
.	O

RESULTS	O
:	O
HEU	O
infants	O
were	O
14	O
times	O
more	O
likely	O
to	O
have	O
leucocytes	O
in	O
their	O
stool	O
than	O
HU	O
infants	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

The	O
lactoferrin	O
level	O
was	O
significantly	O
lower	O
in	O
HEU	O
infants	O
than	O
in	O
HU	O
infants	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

Potentially	O
pathogenic	O
bacteria	O
such	O
as	O
Escherichia	B-bacteria
coli	I-bacteria
were	O
more	O
prevalent	O
in	O
HEU	O
than	O
in	O
HU	O
infants	O
(	O
64	O
%	O
vs	O
23	O
.	O
5	O
%	O
)	O
.	O

Also	O
,	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
strains	I-bacteria
resistant	O
to	O
key	O
antibiotics	O
including	O
co	O
-	O
trimoxazole	O
,	O
beta	O
-	O
lactam	O
(	O
cephalosporins	O
included	O
)	O
and	O
tetraclines	O
were	O
observed	O
in	O
some	O
HEU	O
infants	O
.	O

CONCLUSION	O
:	O
HEU	O
infants	O
are	O
more	O
likely	O
to	O
present	O
an	O
inflamed	O
digestive	O
tract	O
as	O
highlighted	O
by	O
the	O
presence	O
of	O
leucocytes	O
.	O

In	O
addition	O
,	O
there	O
is	O
a	O
real	O
risk	O
of	O
colonisation	O
of	O
HEU	O
infants	O
'	O
microbiota	O
by	O
resistant	O
micro	O
-	O
organisms	O
.	O

Draft	O
genome	O
sequence	O
data	O
and	O
analysis	O
of	O
Brachybacterium	B-bacteria
sp	I-bacteria
.	I-bacteria
strain	I-bacteria
EE	I-bacteria
-	I-bacteria
P12	I-bacteria
isolated	O
from	O
a	O
laboratory	O
-	O
scale	O
anaerobic	O
reactor	O
.	O

The	O
species	O
of	O
the	O
genus	O
Brachybacterium	B-bacteria
belonging	O
to	O
the	O
family	O
Dermabacteraceae	B-bacteria
within	O
the	O
phylum	O
Actinobacteria	B-bacteria
are	O
gram	O
-	O
positive	O
,	O
facultatively	O
anaerobic	O
or	O
aerobic	O
,	O
nonmotile	O
and	O
nonsporeforming	O
bacteria	O
.	O

Cells	O
of	O
Brachybacterium	B-bacteria
spp	I-bacteria
.	I-bacteria
vary	O
in	O
shape	O
from	O
coccoid	O
forms	O
(	O
stationary	O
phase	O
)	O
to	O
rods	O
(	O
exponential	O
phase	O
)	O
.	O

Brachybacterium	B-bacteria
species	I-bacteria
can	O
be	O
isolated	O
from	O
numerous	O
sources	O
such	O
as	O
poultry	O
deep	O
litter	O
,	O
human	O
gut	O
,	O
soil	O
,	O
food	O
products	O
.	O

Here	O
we	O
describe	O
the	O
draft	O
genome	O
sequence	O
of	O
Brachybacterium	B-bacteria
sp	I-bacteria
.	I-bacteria
EE	I-bacteria
-	I-bacteria
P12	I-bacteria
that	O
was	O
isolated	O
from	O
a	O
laboratory	O
-	O
scale	O
anaerobic	O
digester	O
.	O

The	O
genome	O
sequencing	O
generated	O
3	O
,	O
964	O
,	O
988bp	O
,	O
with	O
a	O
G	O
+	O
C	O
content	O
of	O
72	O
.	O
2	O
%	O
.	O

This	O
draft	O
genome	O
data	O
has	O
been	O
deposited	O
at	O
DDBJ	O
/	O
ENA	O
/	O
GenBank	O
under	O
the	O
accession	O
number	O
QXCP00000000	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
nuccore	O
/	O
QXCP00000000	O
)	O
.	O

Two	O
Strains	O
of	O
Lactobacilli	B-bacteria
Effectively	O
Decrease	O
the	O
Colonization	O
of	O
VRE	O
in	O
a	O
Mouse	O
Model	O
.	O

Vancomycin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Enterococcus	I-bacteria
(	O
VRE	B-bacteria
)	O
infection	O
is	O
a	O
serious	O
challenge	O
for	O
clinical	O
management	O
and	O
there	O
is	O
no	O
effective	O
treatment	O
at	O
present	O
.	O

Fecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
and	O
probiotic	O
intervention	O
have	O
been	O
shown	O
to	O
be	O
promising	O
approaches	O
for	O
reducing	O
the	O
colonization	O
of	O
certain	O
pathogenic	O
bacteria	O
in	O
the	O
gastrointestinal	O
tract	O
,	O
however	O
,	O
no	O
such	O
studies	O
have	O
been	O
done	O
on	O
VRE	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
FMT	O
and	O
two	O
Lactobacillus	B-bacteria
strains	I-bacteria
(	O
Y74	B-bacteria
and	O
HT121	B-bacteria
)	O
on	O
the	O
colonization	O
of	O
VRE	O
in	O
a	O
VRE	O
-	O
infection	O
mouse	O
model	O
.	O

We	O
found	O
that	O
both	O
Lactobacilli	B-bacteria
strains	I-bacteria
reduced	O
VRE	B-bacteria
colonization	O
rapidly	O
.	O

Fecal	O
microbiota	O
and	O
colon	O
mRNA	O
expression	O
analyses	O
further	O
showed	O
that	O
mice	O
in	O
FMT	O
and	O
the	O
two	O
Lactobacilli	B-bacteria
treatment	O
groups	O
restored	O
their	O
intestinal	O
microbiota	O
diversity	O
faster	O
than	O
those	O
in	O
the	O
phosphate	O
buffer	O
saline	O
(	O
PBS	O
)	O
treated	O
group	O
.	O

Administration	O
of	O
Lactobacilli	B-bacteria
restored	O
Firmicutes	B-bacteria
more	O
quickly	O
to	O
the	O
normal	O
level	O
,	O
compared	O
to	O
FMT	O
or	O
PBS	O
treatment	O
,	O
but	O
restored	O
Bacteroides	B-bacteria
to	O
their	O
normal	O
level	O
less	O
quickly	O
than	O
FMT	O
did	O
.	O

Furthermore	O
,	O
these	O
treatments	O
also	O
had	O
an	O
impact	O
on	O
the	O
relative	O
abundance	O
of	O
intestinal	O
microbiota	O
composition	O
from	O
phylum	O
to	O
species	O
level	O
.	O

RNA	O
-	O
seq	O
showed	O
that	O
FMT	O
treatment	O
induced	O
the	O
expression	O
of	O
more	O
genes	O
in	O
the	O
colon	O
,	O
compared	O
to	O
the	O
Lactobacilli	B-bacteria
treatment	O
.	O

Defense	O
-	O
related	O
genes	O
such	O
as	O
defensin	O
alpha	O
,	O
Apoa1	O
,	O
and	O
RegIII	O
were	O
down	O
-	O
regulated	O
in	O
both	O
FMT	O
and	O
the	O
two	O
Lactobacilli	B-bacteria
treatment	O
groups	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
both	O
FMT	O
and	O
Lactobacilli	B-bacteria
treatments	O
were	O
effective	O
in	O
decreasing	O
the	O
colonization	O
of	O
VRE	O
in	O
the	O
gut	O
.	O

Type	O
3	O
ILCs	O
in	O
Lung	O
Disease	O
.	O

The	O
lungs	O
represent	O
a	O
complex	O
immune	O
setting	O
,	O
balancing	O
external	O
environmental	O
signals	O
with	O
a	O
poised	O
immune	O
response	O
that	O
must	O
protect	O
from	O
infection	O
,	O
mediate	O
tissue	O
repair	O
,	O
and	O
maintain	O
lung	O
function	O
.	O

Innate	O
lymphoid	O
cells	O
(	O
ILCs	O
)	O
play	O
a	O
central	O
role	O
in	O
tissue	O
repair	O
and	O
homeostasis	O
,	O
and	O
mediate	O
protective	O
immunity	O
in	O
a	O
variety	O
of	O
mucosal	O
tissues	O
,	O
including	O
the	O
lung	O
.	O

All	O
three	O
ILC	O
subsets	O
are	O
present	O
in	O
the	O
airways	O
of	O
both	O
mice	O
and	O
humans	O
;	O
and	O
ILC2s	O
shown	O
to	O
have	O
pivotal	O
roles	O
in	O
asthma	O
,	O
airway	O
hyper	O
-	O
responsiveness	O
,	O
and	O
parasitic	O
worm	O
infection	O
.	O

The	O
involvement	O
of	O
ILC3s	O
in	O
respiratory	O
diseases	O
is	O
less	O
well	O
-	O
defined	O
,	O
but	O
they	O
are	O
known	O
to	O
be	O
critical	O
in	O
homeostasis	O
,	O
infection	O
and	O
inflammation	O
at	O
other	O
mucosal	O
barriers	O
,	O
such	O
as	O
the	O
gut	O
.	O

Moreover	O
,	O
they	O
are	O
important	O
players	O
in	O
the	O
IL17	O
/	O
IL22	O
axis	O
,	O
which	O
is	O
key	O
to	O
lung	O
health	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
emerging	O
role	O
of	O
ILC3s	O
in	O
the	O
context	O
of	O
infectious	O
and	O
inflammatory	O
lung	O
diseases	O
,	O
with	O
a	O
focus	O
on	O
data	O
from	O
human	O
subjects	O
.	O

Cigarette	O
Smoke	O
Induces	O
Intestinal	O
Inflammation	O
via	O
a	O
Th17	O
Cell	O
-	O
Neutrophil	O
Axis	O
.	O

Epidemiological	O
evidence	O
finds	O
cigarette	O
smoking	O
is	O
a	O
common	O
risk	O
factor	O
for	O
a	O
number	O
of	O
diseases	O
,	O
not	O
only	O
in	O
the	O
lung	O
but	O
also	O
in	O
other	O
tissues	O
,	O
such	O
as	O
the	O
gastrointestinal	O
tract	O
.	O

While	O
it	O
is	O
well	O
-	O
documented	O
that	O
smoking	O
directly	O
drives	O
lung	O
inflammatory	O
disease	O
,	O
how	O
it	O
promotes	O
disease	O
in	O
peripheral	O
tissues	O
is	O
incompletely	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
a	O
mouse	O
model	O
of	O
short	O
-	O
term	O
smoke	O
exposure	O
and	O
found	O
increased	O
Th17	O
cells	O
and	O
neutrophilia	O
in	O
the	O
lung	O
as	O
well	O
as	O
in	O
the	O
circulation	O
.	O

Following	O
intestinal	O
inflammatory	O
challenge	O
,	O
smoke	O
exposed	O
mice	O
showed	O
increased	O
pathology	O
which	O
corresponds	O
to	O
enhanced	O
intestinal	O
Th17	O
cells	O
,	O
ILC3	O
and	O
neutrophils	O
within	O
intestinal	O
tissue	O
.	O

Using	O
cellular	O
depletion	O
and	O
genetic	O
deficiencies	O
,	O
we	O
define	O
a	O
cellular	O
loop	O
by	O
which	O
IL	O
-	O
17A	O
and	O
downstream	O
neutrophils	O
drive	O
cigarette	O
smoke	O
-	O
enhanced	O
intestinal	O
inflammation	O
.	O

Collectively	O
,	O
cigarette	O
smoke	O
induced	O
local	O
lung	O
Th17	O
responses	O
lead	O
to	O
increased	O
systemic	O
susceptibility	O
to	O
inflammatory	O
insult	O
through	O
enhanced	O
circulating	O
neutrophils	O
.	O

These	O
data	O
demonstrate	O
a	O
cellular	O
pathway	O
by	O
which	O
inflammatory	O
challenge	O
in	O
the	O
lung	O
can	O
sensitize	O
the	O
intestine	O
to	O
enhanced	O
pathological	O
innate	O
and	O
adaptive	O
immune	O
responses	O
.	O

Multidrug	B-bacteria
-	I-bacteria
Resistant	I-bacteria
Pseudomonas	I-bacteria
aeruginosa	I-bacteria
Accelerate	O
Intestinal	O
,	O
Extra	O
-	O
Intestinal	O
,	O
and	O
Systemic	O
Inflammatory	O
Responses	O
in	O
Human	O
Microbiota	O
-	O
Associated	O
Mice	O
With	O
Subacute	O
Ileitis	O
.	O

The	O
globally	O
rising	O
incidences	O
of	O
multidrug	B-bacteria
-	I-bacteria
resistant	I-bacteria
(	I-bacteria
MDR	I-bacteria
)	I-bacteria
Pseudomonas	I-bacteria
aeruginosa	I-bacteria
(	O
Psae	B-bacteria
)	O
in	O
humans	O
and	O
live	O
-	O
stock	O
animals	O
has	O
prompted	O
the	O
World	O
Health	O
Organization	O
to	O
rate	O
MDR	B-bacteria
Psae	I-bacteria
as	O
serious	O
threat	O
for	O
human	O
health	O
.	O

Only	O
little	O
is	O
known	O
,	O
however	O
,	O
regarding	O
factors	O
facilitating	O
gastrointestinal	O
Psae	O
-	O
acquisition	O
by	O
the	O
vertebrate	O
host	O
and	O
subsequently	O
induced	O
inflammatory	O
sequelae	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
addressed	O
whether	O
subacute	O
ileitis	O
predisposed	O
mice	O
harboring	O
a	O
human	O
gut	O
microbiota	O
for	O
intestinal	O
MDR	O
Psae	O
carriage	O
and	O
whether	O
inflammatory	O
responses	O
might	O
be	O
induced	O
following	O
peroral	O
challenge	O
with	O
the	O
opportunistic	O
pathogen	O
.	O

To	O
accomplish	O
this	O
,	O
secondary	O
abiotic	O
mice	O
were	O
associated	O
with	O
a	O
human	O
gut	O
microbiota	O
by	O
fecal	O
microbiota	O
transplantation	O
.	O

Ten	O
days	O
later	O
(	O
i	O
.	O
e	O
.	O
,	O
on	O
day	O
0	O
)	O
,	O
subacute	O
ileitis	O
was	O
induced	O
in	O
human	O
microbiota	O
associated	O
(	O
hma	O
)	O
mice	O
by	O
peroral	O
low	O
-	O
dose	O
Toxoplasma	O
gondii	O
infection	O
.	O

On	O
day	O
5	O
post	O
-	O
infection	O
,	O
mice	O
were	O
perorally	O
challenged	O
with	O
10	O
(	O
9	O
)	O
colony	O
forming	O
units	O
of	O
a	O
clinical	O
MDR	B-bacteria
Psae	I-bacteria
isolate	I-bacteria
by	O
gavage	O
and	O
the	O
fecal	O
bacterial	O
loads	O
surveyed	O
thereafter	O
.	O

Four	O
days	O
post	O
-	O
peroral	O
challenge	O
,	O
only	O
approximately	O
one	O
third	O
of	O
mice	O
with	O
a	O
human	O
gut	O
microbiota	O
and	O
subacute	O
ileitis	O
harbored	O
the	O
opportunistic	O
pathogen	O
in	O
the	O
intestinal	O
tract	O
.	O

Notably	O
,	O
the	O
gut	O
microbiota	O
composition	O
was	O
virtually	O
unaffected	O
by	O
the	O
Psae	O
-	O
carriage	O
status	O
during	O
subacute	O
ileitis	O
of	O
hma	O
mice	O
.	O

The	O
Psae	O
challenge	O
resulted	O
,	O
however	O
,	O
in	O
more	O
pronounced	O
intestinal	O
epithelial	O
apoptotic	O
cell	O
and	O
T	O
lymphocyte	O
responses	O
upon	O
ileitis	O
induction	O
that	O
were	O
not	O
restricted	O
to	O
the	O
ileum	O
,	O
but	O
also	O
affected	O
the	O
large	O
intestines	O
.	O

Higher	O
Psae	O
-	O
induced	O
abundances	O
of	O
T	O
cells	O
could	O
additionally	O
be	O
observed	O
in	O
extra	O
-	O
intestinal	O
compartments	O
including	O
liver	O
,	O
kidney	O
,	O
lung	O
,	O
and	O
heart	O
of	O
hma	O
mice	O
with	O
subacute	O
ileitis	O
.	O

Furthermore	O
,	O
higher	O
apoptotic	O
cell	O
numbers	O
,	O
but	O
lower	O
anti	O
-	O
inflammatory	O
IL	O
-	O
10	O
concentrations	O
were	O
assessed	O
in	O
the	O
liver	O
of	O
Psae	O
as	O
compared	O
to	O
mock	O
treated	O
mice	O
with	O
ileitis	O
.	O

Remarkably	O
,	O
Psae	O
-	O
challenge	O
was	O
accompanied	O
by	O
even	O
more	O
pronounced	O
systemic	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
TNF	O
and	O
IL	O
-	O
6	O
at	O
day	O
9	O
post	O
ileitis	O
induction	O
.	O

In	O
conclusion	O
,	O
whereas	O
in	O
one	O
third	O
of	O
hma	O
mice	O
with	O
subacute	O
ileitis	O
Psae	B-bacteria
could	O
be	O
isolated	O
from	O
the	O
intestines	O
upon	O
peroral	O
challenge	O
,	O
the	O
opportunistic	O
pathogen	O
was	O
responsible	O
for	O
inflammatory	O
sequelae	O
in	O
intestinal	O
,	O
extra	O
-	O
intestinal	O
,	O
and	O
even	O
systemic	O
compartments	O
and	O
thus	O
worsened	O
subacute	O
ileitis	O
outcome	O
irrespective	O
of	O
the	O
Psae	O
-	O
carrier	O
status	O
.	O

Intestinal	O
Microbiota	O
as	O
a	O
Host	O
Defense	O
Mechanism	O
to	O
Infectious	O
Threats	O
.	O

The	O
intestinal	O
microbiota	O
is	O
a	O
complex	O
microbial	O
community	O
,	O
with	O
diverse	O
and	O
stable	O
populations	O
hosted	O
by	O
the	O
gastrointestinal	O
tract	O
since	O
birth	O
.	O

This	O
ecosystem	O
holds	O
multiple	O
anti	O
-	O
infectious	O
,	O
anti	O
-	O
inflammatory	O
,	O
and	O
immune	O
modulating	O
roles	O
decisive	O
for	O
intestinal	O
homeostasis	O
.	O

Among	O
these	O
,	O
colonization	O
resistance	O
refers	O
to	O
the	O
dynamic	O
antagonistic	O
interactions	O
between	O
commensals	O
and	O
pathogenic	O
flora	O
.	O

Hence	O
,	O
gut	O
bacteria	O
compete	O
for	O
the	O
same	O
intestinal	O
niches	O
and	O
substrates	O
,	O
while	O
also	O
releasing	O
antimicrobial	O
substances	O
such	O
as	O
bacteriocines	O
and	O
changing	O
the	O
environmental	O
conditions	O
.	O

Short	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
generated	O
in	O
anaerobic	O
conditions	O
prompt	O
epigenetic	O
regulatory	O
mechanisms	O
that	O
favor	O
a	O
tolerogenic	O
immune	O
response	O
.	O

In	O
addition	O
,	O
the	O
commensal	O
flora	O
is	O
involved	O
in	O
the	O
synthesis	O
of	O
bactericidal	O
products	O
,	O
namely	O
secondary	O
biliary	O
acids	O
or	O
antimicrobial	O
peptides	O
(	O
AMPs	O
)	O
such	O
as	O
cathellicidin	O
-	O
LL37	O
,	O
an	O
immunomodulatory	O
,	O
antimicrobial	O
,	O
and	O
wound	O
healing	O
peptide	O
.	O

Gut	O
microbiota	O
is	O
protected	O
through	O
symbiotic	O
relations	O
with	O
the	O
hosting	O
organism	O
and	O
by	O
quorum	O
sensing	O
,	O
a	O
specific	O
cell	O
-	O
to	O
-	O
cell	O
communication	O
system	O
.	O

Any	O
alterations	O
of	O
these	O
relationships	O
favor	O
the	O
uncontrollable	O
multiplication	O
of	O
the	O
resident	O
pathobionts	O
or	O
external	O
entero	O
-	O
pathogens	O
,	O
prompting	O
systemic	O
translocations	O
,	O
inflammatory	O
reactions	O
,	O
or	O
exacerbations	O
of	O
bacterial	O
virulence	O
mechanisms	O
(	O
T6SS	O
,	O
T3SS	O
)	O
and	O
ultimately	O
lead	O
to	O
gastrointestinal	O
or	O
systemic	O
infections	O
.	O

The	O
article	O
describes	O
the	O
metabolic	O
and	O
immunological	O
mechanisms	O
through	O
which	O
the	O
intestinal	O
microbiota	O
is	O
both	O
an	O
ally	O
of	O
the	O
organism	O
against	O
enteric	O
pathogens	O
and	O
an	O
enemy	O
that	O
favors	O
the	O
development	O
of	O
infections	O
.	O

Eating	O
for	O
3	O
.	O
8	O
x	O
10	O
(	O
13	O
)	O
:	O
Examining	O
the	O
Impact	O
of	O
Diet	O
and	O
Nutrition	O
on	O
the	O
Microbiota	O
-	O
Gut	O
-	O
Brain	O
Axis	O
Through	O
the	O
Lens	O
of	O
Microbial	O
Endocrinology	O
.	O

The	O
study	O
of	O
host	O
-	O
microbe	O
neuroendocrine	O
crosstalk	O
,	O
termed	O
microbial	O
endocrinology	O
,	O
suggests	O
the	O
impact	O
of	O
diet	O
on	O
host	O
health	O
and	O
microbial	O
viability	O
is	O
,	O
in	O
part	O
,	O
reliant	O
upon	O
nutritional	O
modulation	O
of	O
shared	O
host	O
-	O
microbe	O
neuroendocrine	O
axes	O
.	O

In	O
the	O
1990	O
'	O
s	O
it	O
was	O
first	O
recognized	O
that	O
neuroendocrine	O
pathways	O
are	O
major	O
components	O
of	O
the	O
microbiota	O
-	O
gut	O
-	O
brain	O
axis	O
,	O
and	O
that	O
diet	O
-	O
induced	O
changes	O
in	O
the	O
gut	O
microbiota	O
were	O
correlated	O
with	O
changes	O
in	O
host	O
behavior	O
and	O
cognition	O
.	O

A	O
causative	O
link	O
,	O
however	O
,	O
between	O
nutritional	O
-	O
induced	O
shifts	O
in	O
microbiota	O
composition	O
and	O
change	O
in	O
host	O
behavior	O
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
.	O

Substrates	O
found	O
in	O
food	O
which	O
are	O
utilized	O
by	O
bacteria	O
in	O
the	O
production	O
of	O
microbial	O
-	O
derived	O
neurochemicals	O
,	O
which	O
are	O
structurally	O
identical	O
to	O
those	O
made	O
by	O
the	O
host	O
,	O
likely	O
represent	O
a	O
microbial	O
endocrinology	O
-	O
based	O
route	O
by	O
which	O
the	O
microbiota	O
causally	O
influence	O
the	O
host	O
and	O
microbial	O
community	O
dynamics	O
via	O
diet	O
.	O

For	O
example	O
,	O
food	O
safety	O
is	O
strongly	O
impacted	O
by	O
the	O
microbial	O
production	O
of	O
biogenic	O
amines	O
.	O

While	O
microbial	O
-	O
produced	O
tyramine	O
found	O
in	O
cheese	O
can	O
elicit	O
hypertensive	O
crises	O
,	O
microorganisms	O
which	O
are	O
common	O
inhabitants	O
of	O
the	O
human	O
intestinal	O
tract	O
can	O
convert	O
L	O
-	O
histidine	O
found	O
in	O
common	O
foodstuffs	O
to	O
histamine	O
and	O
thereby	O
precipitate	O
allergic	O
reactions	O
.	O

Hence	O
,	O
there	O
is	O
substantial	O
evidence	O
suggesting	O
a	O
microbial	O
endocrinology	O
-	O
based	O
role	O
by	O
which	O
the	O
gastrointestinal	O
microbiota	O
can	O
utilize	O
host	O
dietary	O
components	O
to	O
produce	O
neuroactive	O
molecules	O
that	O
causally	O
impact	O
the	O
host	O
.	O

Conversely	O
,	O
little	O
is	O
known	O
regarding	O
the	O
reverse	O
scenario	O
whereby	O
nutrition	O
-	O
mediated	O
changes	O
in	O
host	O
neuroendocrine	O
production	O
affect	O
microbial	O
viability	O
,	O
composition	O
,	O
and	O
/	O
or	O
function	O
.	O

Mechanisms	O
in	O
the	O
direction	O
of	O
brain	O
-	O
to	O
-	O
gut	O
,	O
such	O
as	O
how	O
host	O
production	O
of	O
catecholamines	O
drives	O
diverse	O
changes	O
in	O
microbial	O
growth	O
and	O
functionality	O
within	O
the	O
gut	O
,	O
require	O
greater	O
examination	O
considering	O
well	O
-	O
known	O
nutritional	O
effects	O
on	O
host	O
stress	O
physiology	O
.	O

As	O
dietary	O
intake	O
mediates	O
changes	O
in	O
host	O
stress	O
,	O
such	O
as	O
the	O
effects	O
of	O
caffeine	O
on	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
,	O
it	O
is	O
likely	O
that	O
nutrition	O
can	O
impact	O
host	O
neuroendocrine	O
production	O
to	O
affect	O
the	O
microbiota	O
.	O

Likewise	O
,	O
the	O
plasticity	O
of	O
the	O
microbiota	O
to	O
changes	O
in	O
host	O
diet	O
has	O
been	O
hypothesized	O
to	O
drive	O
microbial	O
regulation	O
of	O
host	O
food	O
preference	O
via	O
a	O
host	O
-	O
microbe	O
feedback	O
loop	O
.	O

This	O
review	O
will	O
focus	O
on	O
food	O
as	O
concerns	O
microbial	O
endocrinology	O
with	O
emphasis	O
given	O
to	O
nutrition	O
as	O
a	O
mediator	O
of	O
host	O
-	O
microbe	O
bi	O
-	O
directional	O
neuroendocrine	O
crosstalk	O
and	O
its	O
impact	O
on	O
microbial	O
viability	O
and	O
host	O
health	O
.	O

The	O
gut	O
microbiome	O
and	O
mental	O
health	O
.	O

Mucosa	O
-	O
associated	O
microbiota	O
drives	O
pathogenic	O
functions	O
in	O
IBD	O
-	O
derived	O
intestinal	O
iNKT	O
cells	O
.	O

Inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
pathogenesis	O
has	O
been	O
linked	O
to	O
the	O
aberrant	O
activation	O
of	O
the	O
Gut	O
-	O
associated	O
lymphoid	O
tissues	O
against	O
components	O
of	O
the	O
intestinal	O
microbiota	O
.	O

Although	O
the	O
contribution	O
of	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
cells	O
to	O
inflammatory	O
processes	O
is	O
being	O
increasingly	O
acknowledged	O
,	O
the	O
functional	O
engagement	O
of	O
human	O
invariant	O
natural	O
killer	O
T	O
(	O
iNKT	O
)	O
cells	O
is	O
still	O
poorly	O
defined	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
functional	O
characteristics	O
of	O
intestinal	O
iNKT	O
cells	O
during	O
IBD	O
pathogenesis	O
and	O
to	O
exploit	O
the	O
role	O
of	O
mucosa	O
-	O
associated	O
microbiota	O
recognition	O
in	O
triggering	O
iNKT	O
cells	O
'	O
pro	O
-	O
inflammatory	O
responses	O
in	O
vivo	O
.	O

Lamina	O
propria	O
iNKT	O
cells	O
,	O
isolated	O
from	O
surgical	O
specimens	O
of	O
active	O
ulcerative	O
colitis	O
and	O
Crohn	O
'	O
s	O
disease	O
patients	O
and	O
non	O
-	O
IBD	O
donors	O
,	O
were	O
phenotypically	O
and	O
functionally	O
analyzed	O
ex	O
vivo	O
,	O
and	O
stable	O
cell	O
lines	O
and	O
clones	O
were	O
generated	O
for	O
in	O
vitro	O
functional	O
assays	O
.	O

iNKT	O
cells	O
expressing	O
a	O
pro	O
-	O
inflammatory	O
cytokine	O
profile	O
were	O
enriched	O
in	O
the	O
lamina	O
propria	O
of	O
IBD	O
patients	O
,	O
and	O
their	O
exposure	O
to	O
the	O
mucosa	O
-	O
associated	O
microbiota	O
drives	O
pro	O
-	O
inflammatory	O
activation	O
,	O
inducing	O
direct	O
pathogenic	O
activities	O
against	O
the	O
epithelial	O
barrier	O
integrity	O
.	O

These	O
observations	O
suggest	O
that	O
iNKT	O
cell	O
pro	O
-	O
inflammatory	O
functions	O
may	O
contribute	O
to	O
the	O
fuelling	O
of	O
intestinal	O
inflammation	O
in	O
IBD	O
patients	O
.	O

The	O
Impact	O
of	O
Low	O
-	O
FODMAPs	O
,	O
Gluten	O
-	O
Free	O
,	O
and	O
Ketogenic	O
Diets	O
on	O
Gut	O
Microbiota	O
Modulation	O
in	O
Pathological	O
Conditions	O
.	O

The	O
gut	O
microbiota	O
performs	O
several	O
essential	O
protective	O
,	O
structural	O
,	O
and	O
metabolic	O
functions	O
for	O
host	O
health	O
.	O

The	O
maintenance	O
of	O
a	O
beneficial	O
microbiota	O
requires	O
a	O
homeostatic	O
equilibrium	O
within	O
microbial	O
communities	O
,	O
and	O
between	O
the	O
microorganisms	O
and	O
the	O
host	O
.	O

The	O
gut	O
microbiota	O
composition	O
may	O
be	O
affected	O
by	O
external	O
factors	O
,	O
among	O
them	O
diet	O
habits	O
may	O
be	O
considered	O
most	O
important	O
.	O

In	O
some	O
pathological	O
conditions	O
such	O
as	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
,	O
celiac	O
disease	O
(	O
CD	O
)	O
,	O
or	O
neurological	O
disorders	O
(	O
ND	O
)	O
,	O
specific	O
dietary	O
regimens	O
as	O
low	O
-	O
fermentable	O
,	O
oligo	O
-	O
,	O
di	O
-	O
,	O
mono	O
-	O
saccharides	O
and	O
polyols	O
(	O
FODMAPs	O
)	O
,	O
ketogenic	O
(	O
KD	O
)	O
,	O
and	O
gluten	O
-	O
free	O
(	O
GFD	O
)	O
diets	O
are	O
considered	O
therapeutic	O
.	O

These	O
kinds	O
of	O
diets	O
are	O
characterized	O
by	O
a	O
reduction	O
or	O
exclusion	O
of	O
a	O
specific	O
nutrient	O
from	O
the	O
entire	O
dietary	O
pattern	O
.	O

Despite	O
these	O
alimentary	O
regimens	O
showing	O
beneficial	O
effects	O
on	O
disease	O
symptoms	O
,	O
they	O
can	O
affect	O
microbiota	O
composition	O
,	O
especially	O
if	O
they	O
are	O
protracted	O
for	O
a	O
long	O
time	O
.	O

To	O
date	O
,	O
only	O
a	O
few	O
studies	O
have	O
reported	O
the	O
effects	O
of	O
these	O
diets	O
on	O
gut	O
microbiota	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
effects	O
of	O
low	O
-	O
FODMAPs	O
,	O
KD	O
,	O
and	O
GFD	O
on	O
gut	O
microbiota	O
modulation	O
in	O
pathological	O
conditions	O
,	O
advancing	O
the	O
possibility	O
of	O
depicting	O
a	O
balanced	O
diet	O
and	O
developing	O
personalized	O
dietary	O
intervention	O
protocols	O
.	O

Maternal	O
Influence	O
and	O
Murine	O
Housing	O
Confound	O
Impact	O
of	O
NLRP1	O
Inflammasome	O
on	O
Microbiome	O
Composition	O
.	O

The	O
NLRP1	O
inflammasome	O
attenuates	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
progression	O
and	O
colitis	O
-	O
associated	O
tumorigenesis	O
.	O

A	O
possible	O
mechanism	O
postulates	O
that	O
the	O
lack	O
of	O
the	O
NLRP1	O
inflammasome	O
creates	O
permissive	O
niches	O
in	O
the	O
gut	O
for	O
pathogenic	O
bacteria	O
to	O
flourish	O
,	O
causing	O
dysbiosis	O
and	O
increased	O
IBD	O
susceptibility	O
.	O

To	O
evaluate	O
this	O
hypothesis	O
,	O
we	O
characterized	O
the	O
gut	O
microbiome	O
of	O
wild	O
-	O
type	O
,	O
Nlrp1b	O
-	O
/	O
-	O
,	O
and	O
Asc	O
-	O
/	O
-	O
mice	O
under	O
naive	O
conditions	O
by	O
sequencing	O
the	O
V3	O
region	O
of	O
the	O
16s	O
rRNA	O
gene	O
.	O

For	O
both	O
genetically	O
modified	O
mouse	O
lines	O
,	O
the	O
microbiome	O
composition	O
reflected	O
overrepresentation	O
of	O
bacteria	O
associated	O
with	O
dysbiosis	O
relative	O
to	O
wild	O
-	O
type	O
animals	O
.	O

Measurement	O
of	O
short	O
-	O
and	O
medium	O
-	O
chain	O
fatty	O
acids	O
by	O
mass	O
spectrometry	O
further	O
revealed	O
significant	O
differences	O
between	O
genotypes	O
.	O

However	O
,	O
prior	O
to	O
concluding	O
that	O
the	O
NLRP1	O
inflammasome	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
composition	O
of	O
the	O
microbiome	O
,	O
we	O
evaluated	O
two	O
additional	O
strategies	O
for	O
cohousing	O
wild	O
-	O
type	O
and	O
Nlrp1b	O
-	O
/	O
-	O
mice	O
:	O
breeding	O
homozygous	O
parents	O
and	O
cohousing	O
at	O
weaning	O
,	O
and	O
breeding	O
from	O
heterozygous	O
parents	O
and	O
cohousing	O
littermates	O
.	O

We	O
found	O
that	O
maternal	O
influence	O
was	O
the	O
greater	O
predictor	O
of	O
microbiome	O
composition	O
rather	O
than	O
genotype	O
.	O

With	O
the	O
rise	O
in	O
microbiome	O
research	O
across	O
disciplines	O
,	O
our	O
study	O
should	O
be	O
viewed	O
as	O
a	O
cautionary	O
example	O
that	O
illustrates	O
the	O
importance	O
of	O
careful	O
breeding	O
and	O
housing	O
strategies	O
when	O
evaluating	O
host	O
-	O
microbiome	O
interactions	O
.	O

Critical	O
Evaluation	O
of	O
CrAssphage	O
as	O
a	O
Molecular	O
Marker	O
for	O
Human	O
-	O
Derived	O
Wastewater	O
Contamination	O
in	O
the	O
Aquatic	O
Environment	O
.	O

The	O
discharge	O
of	O
human	O
-	O
derived	O
wastewater	O
represents	O
a	O
major	O
threat	O
to	O
water	O
quality	O
with	O
the	O
potential	O
for	O
waterborne	O
disease	O
outbreaks	O
mainly	O
associated	O
with	O
enteric	O
viruses	O
.	O

To	O
prevent	O
illnesses	O
,	O
indicators	O
associated	O
with	O
fecal	O
contamination	O
are	O
monitored	O
in	O
polluted	O
areas	O
,	O
however	O
,	O
their	O
prevalence	O
often	O
does	O
not	O
correlate	O
well	O
with	O
viral	O
pathogens	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
crAssphage	O
,	O
a	O
recently	O
discovered	O
human	O
-	O
specific	O
gut	O
-	O
associated	O
bacteriophage	O
,	O
for	O
the	O
surveillance	O
of	O
wastewater	O
-	O
derived	O
viral	O
contamination	O
.	O

Untreated	O
and	O
treated	O
wastewater	O
,	O
surface	O
water	O
,	O
sediment	O
and	O
mussel	O
samples	O
were	O
collected	O
monthly	O
over	O
1	O
year	O
from	O
the	O
Conwy	O
River	O
and	O
estuary	O
(	O
UK	O
)	O
and	O
were	O
analyzed	O
for	O
crAssphage	O
marker	O
by	O
quantitative	O
PCR	O
.	O

This	O
is	O
the	O
first	O
long	O
-	O
term	O
catchment	O
-	O
to	O
-	O
coast	O
scale	O
study	O
of	O
environmental	O
crAssphage	O
concentrations	O
.	O

CrAssphage	O
was	O
detected	O
in	O
all	O
sample	O
types	O
and	O
showed	O
no	O
distinct	O
seasonal	O
pattern	O
.	O

CrAssphage	O
concentrations	O
were	O
2	O
x	O
10	O
(	O
5	O
)	O
-	O
10	O
(	O
9	O
)	O
genome	O
copies	O
(	O
gc	O
)	O
/	O
L	O
in	O
all	O
untreated	O
wastewater	O
influent	O
and	O
10	O
(	O
7	O
)	O
-	O
10	O
(	O
8	O
)	O
gc	O
/	O
L	O
in	O
secondary	O
treated	O
effluent	O
samples	O
,	O
3	O
x	O
10	O
(	O
3	O
)	O
gc	O
/	O
L	O
-	O
3	O
x	O
10	O
(	O
7	O
)	O
gc	O
/	O
L	O
in	O
surface	O
water	O
samples	O
(	O
94	O
%	O
positive	O
)	O
and	O
2	O
x	O
10	O
(	O
2	O
)	O
-	O
10	O
(	O
4	O
)	O
gc	O
/	O
g	O
sediment	O
(	O
68	O
%	O
positive	O
)	O
and	O
mussel	O
digestive	O
tissue	O
(	O
79	O
%	O
positive	O
)	O
.	O

CrAssphage	O
concentrations	O
were	O
1	O
-	O
5	O
log10	O
higher	O
than	O
human	O
enteric	O
virus	O
titers	O
(	O
norovirus	O
,	O
sapovirus	O
,	O
adenovirus	O
,	O
polyomavirus	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
crAssphage	O
is	O
well	O
suited	O
to	O
tracking	O
human	O
wastewater	O
contamination	O
and	O
pollution	O
risk	O
assessment	O
in	O
aquatic	O
environments	O
.	O

The	O
gut	O
microbiome	O
and	O
the	O
potentials	O
of	O
probiotics	O
:	O
an	O
interview	O
with	O
Simon	O
Gaisford	O
.	O

In	O
this	O
exclusive	O
interview	O
,	O
Simon	O
Gaisford	O
discusses	O
his	O
current	O
research	O
into	O
gut	O
dysbiosis	O
and	O
its	O
possible	O
relevance	O
to	O
disease	O
states	O
,	O
as	O
well	O
as	O
the	O
efficacy	O
of	O
probiotic	O
supplementation	O
and	O
its	O
possible	O
use	O
as	O
treatment	O
.	O

This	O
interview	O
was	O
conducted	O
by	O
Ellen	O
Colvin	O
,	O
Commissioning	O
Editor	O
of	O
Future	O
Microbiology	O
.	O

Professor	O
Simon	O
Gaisford	O
is	O
the	O
Head	O
of	O
Department	O
at	O
UCL	O
School	O
of	O
Pharmacy	O
,	O
University	O
College	O
London	O
.	O

He	O
uses	O
isothermal	O
microcalorimetry	O
to	O
monitor	O
the	O
growth	O
and	O
interactions	O
of	O
bacteria	O
,	O
with	O
his	O
research	O
-	O
interest	O
focus	O
on	O
the	O
use	O
of	O
probiotic	O
supplements	O
to	O
improve	O
general	O
health	O
and	O
well	O
-	O
being	O
,	O
ameliorate	O
symptoms	O
of	O
disease	O
and	O
eradicate	O
gut	O
pathogens	O
.	O

He	O
has	O
published	O
120	O
papers	O
,	O
four	O
books	O
and	O
eight	O
book	O
chapters	O
.	O

Digestion	O
and	O
Colonic	O
Fermentation	O
of	O
Raw	O
and	O
Cooked	O
Opuntia	O
ficus	O
-	O
indica	O
Cladodes	O
Impacts	O
Bioaccessibility	O
and	O
Bioactivity	O
.	O

The	O
bioactivity	O
of	O
(	O
poly	O
)	O
phenols	O
from	O
a	O
food	O
is	O
an	O
interplay	O
between	O
the	O
cooking	O
methods	O
applied	O
and	O
the	O
interaction	O
of	O
the	O
food	O
with	O
the	O
gastrointestinal	O
tract	O
.	O

The	O
(	O
poly	O
)	O
phenolic	O
profile	O
and	O
biological	O
activity	O
of	O
raw	O
and	O
cooked	O
cactus	O
(	O
Opuntia	O
ficus	O
-	O
indica	O
Mill	O
.	O
)	O

cladodes	O
following	O
in	O
vitro	O
digestion	O
and	O
colonic	O
fermentation	O
were	O
evaluated	O
.	O

Twenty	O
-	O
seven	O
(	O
poly	O
)	O
phenols	O
were	O
identified	O
and	O
quantified	O
by	O
HPLC	O
-	O
ESI	O
-	O
MS	O
,	O
with	O
piscidic	O
acid	O
being	O
the	O
most	O
abundant	O
.	O

Throughout	O
the	O
colonic	O
fermentation	O
,	O
flavonoids	O
showed	O
more	O
degradation	O
than	O
phenolic	O
acids	O
,	O
and	O
eucomic	O
acid	O
remained	O
the	O
most	O
relevant	O
after	O
24	O
h	O
.	O
The	O
catabolite	O
3	O
-	O
(	O
4	O
-	O
hydroxyphenyl	O
)	O
propionic	O
acid	O
was	O
generated	O
after	O
24	O
h	O
of	O
fermentation	O
.	O

Cytotoxicity	O
,	O
genotoxicity	O
,	O
and	O
cell	O
cycle	O
analyses	O
were	O
performed	O
in	O
HT29	O
cells	O
.	O

Cactus	O
colonic	O
fermentates	O
showed	O
higher	O
cell	O
viability	O
(	O
>	O
/	O
=	O
80	O
%	O
)	O
in	O
comparison	O
to	O
the	O
control	O
fermentation	O
with	O
no	O
cactus	O
and	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
reduced	O
H2O2	O
-	O
induced	O
DNA	O
damage	O
in	O
HT29	O
cells	O
.	O

Results	O
suggest	O
that	O
,	O
although	O
phenolic	O
compounds	O
were	O
degraded	O
during	O
the	O
colonic	O
fermentation	O
,	O
the	O
biological	O
activity	O
is	O
retained	O
in	O
colon	O
cells	O
.	O

Methane	O
Emission	O
,	O
Rumen	O
Fermentation	O
,	O
and	O
Microbial	O
Community	O
Response	O
to	O
a	O
Nitrooxy	O
Compound	O
in	O
Low	O
-	O
Quality	O
Forage	O
Fed	O
Hu	O
Sheep	O
.	O

The	O
effects	O
of	O
nitroglycerine	O
(	O
NG	O
)	O
on	O
the	O
rumen	O
methane	O
emission	O
,	O
fermentation	O
,	O
and	O
microbial	O
community	O
of	O
Hu	O
sheep	O
were	O
investigated	O
.	O

Eight	O
sheep	O
were	O
fed	O
NG	O
(	O
100	O
mg	O
/	O
head	O
/	O
day	O
)	O
;	O
another	O
eight	O
sheep	O
served	O
as	O
controls	O
.	O

NG	O
decreased	O
methane	O
emission	O
of	O
Hu	O
sheep	O
by	O
~	O
19	O
.	O
3	O
%	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
without	O
adversely	O
affecting	O
the	O
production	O
performance	O
or	O
rumen	O
fermentation	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
alpha	O
and	O
beta	O
diversity	O
indexes	O
of	O
the	O
bacterial	O
and	O
archaeal	O
community	O
showed	O
no	O
significant	O
differences	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
dominant	O
methanogenic	O
species	O
was	O
the	O
Methanobrevibacter	B-bacteria
gottschalkii	I-bacteria
clade	O
,	O
accounting	O
for	O
~	O
60	O
%	O
,	O
followed	O
by	O
the	O
Methanobrevibacter	B-bacteria
boviskoreani	I-bacteria
and	O
Methanobrevibacter	B-bacteria
ruminantium	I-bacteria
clades	O
.	O

Prevotella	B-bacteria
1	I-bacteria
was	O
the	O
most	O
dominant	O
bacterial	O
genus	O
,	O
accounting	O
for	O
~	O
42	O
%	O
,	O
followed	O
by	O
the	O
Rikenellaceae	B-bacteria
RC9	I-bacteria
and	O
Bacteroidales	B-bacteria
BS11	I-bacteria
gut	O
groups	O
.	O

In	O
addition	O
,	O
pearson	O
correlation	O
analysis	O
showed	O
a	O
few	O
Methanomassiliicoccales	B-bacteria
species	I-bacteria
significantly	O
correlated	O
with	O
several	O
bacterial	O
genera	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Quantifying	O
and	O
Interpreting	O
the	O
Association	O
between	O
Early	O
-	O
Life	O
Gut	O
Microbiota	O
Composition	O
and	O
Childhood	O
Obesity	O
.	O

Moderate	O
-	O
intensity	O
aerobic	O
and	O
resistance	O
exercise	O
is	O
safe	O
and	O
favorably	O
influences	O
body	O
composition	O
in	O
patients	O
with	O
quiescent	O
Inflammatory	O
Bowel	O
Disease	O
:	O
a	O
randomized	O
controlled	O
cross	O
-	O
over	O
trial	O
.	O

BACKGROUND	O
:	O
Overweight	O
and	O
metabolic	O
problems	O
now	O
add	O
to	O
the	O
burden	O
of	O
illness	O
in	O
patients	O
with	O
Inflammatory	O
Bowel	O
Disease	O
.	O

We	O
aimed	O
to	O
determine	O
if	O
a	O
program	O
of	O
aerobic	O
and	O
resistance	O
exercise	O
could	O
safely	O
achieve	O
body	O
composition	O
changes	O
in	O
patients	O
with	O
Inflammatory	O
Bowel	O
Disease	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
cross	O
-	O
over	O
trial	O
of	O
eight	O
weeks	O
combined	O
aerobic	O
and	O
resistance	O
training	O
on	O
body	O
composition	O
assessed	O
by	O
Dual	O
Energy	O
X	O
-	O
ray	O
Absorptiometry	O
was	O
performed	O
.	O

Patients	O
in	O
clinical	O
remission	O
and	O
physically	O
inactive	O
with	O
a	O
mean	O
age	O
of	O
25	O
+	O
/	O
-	O
6	O
.	O
5	O
years	O
and	O
Body	O
Mass	O
Index	O
of	O
28	O
.	O
9	O
+	O
/	O
-	O
3	O
.	O
8	O
were	O
recruited	O
from	O
a	O
dedicated	O
Inflammatory	O
Bowel	O
Disease	O
clinic	O
.	O

Serum	O
cytokines	O
were	O
quantified	O
,	O
and	O
microbiota	O
assessed	O
using	O
metagenomic	O
sequencing	O
.	O

RESULTS	O
:	O
Improved	O
physical	O
fitness	O
was	O
demonstrated	O
in	O
the	O
exercise	O
group	O
by	O
increases	O
in	O
median	O
estimated	O
VO2max	O
(	O
Baseline	O
:	O
43	O
.	O
41mls	O
/	O
kg	O
/	O
min	O
;	O
post	O
-	O
intervention	O
:	O
46	O
.	O
01mls	O
/	O
kg	O
/	O
min	O
;	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

Improvement	O
in	O
body	O
composition	O
was	O
achieved	O
by	O
the	O
intervention	O
group	O
(	O
n	O
=	O
13	O
)	O
with	O
a	O
median	O
decrease	O
of	O
2	O
.	O
1	O
%	O
body	O
fat	O
compared	O
with	O
a	O
non	O
-	O
exercising	O
group	O
(	O
n	O
=	O
7	O
)	O
(	O
0	O
.	O
1	O
%	O
increase	O
;	O
p	O
=	O
0	O
.	O
022	O
)	O
.	O

Lean	O
tissue	O
mass	O
increased	O
by	O
a	O
median	O
of	O
1	O
.	O
59	O
kg	O
and	O
fat	O
mass	O
decreased	O
by	O
a	O
median	O
of	O
1	O
.	O
52	O
kg	O
in	O
the	O
exercising	O
group	O
.	O

No	O
patients	O
experienced	O
a	O
deterioration	O
in	O
disease	O
activity	O
scores	O
during	O
the	O
exercise	O
intervention	O
.	O

No	O
clinically	O
significant	O
alterations	O
in	O
the	O
alpha	O
-	O
and	O
beta	O
-	O
diversity	O
of	O
gut	O
microbiota	O
and	O
associated	O
metabolic	O
pathways	O
were	O
evident	O
.	O

CONCLUSIONS	O
:	O
Moderate	O
-	O
intensity	O
combined	O
aerobic	O
and	O
resistance	O
training	O
is	O
safe	O
in	O
physically	O
unfit	O
patients	O
with	O
quiescent	O
Inflammatory	O
Bowel	O
Disease	O
and	O
can	O
quickly	O
achieve	O
favourable	O
body	O
compositional	O
changes	O
without	O
adverse	O
effects	O
.	O

TRIAL	O
REGISTRATION	O
:	O
The	O
study	O
was	O
registered	O
at	O
ClinicalTrials	O
.	O
gov	O
;	O
Trial	O
number	O
:	O
NCT02463916	O
.	O

Mechanisms	O
linking	O
preterm	O
birth	O
to	O
onset	O
of	O
cardiovascular	O
disease	O
later	O
in	O
adulthood	O
.	O

Cardiovascular	O
disease	O
(	O
CVD	O
)	O
rates	O
in	O
adulthood	O
are	O
high	O
in	O
premature	O
infants	O
;	O
unfortunately	O
,	O
the	O
underlying	O
mechanisms	O
are	O
not	O
well	O
defined	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
potential	O
pathways	O
that	O
could	O
lead	O
to	O
CVD	O
in	O
premature	O
babies	O
.	O

Studies	O
show	O
intense	O
oxidant	O
stress	O
and	O
inflammation	O
at	O
tissue	O
levels	O
in	O
these	O
neonates	O
.	O

Alterations	O
in	O
lipid	O
profile	O
,	O
foetal	O
epigenomics	O
,	O
and	O
gut	O
microbiota	O
in	O
these	O
infants	O
may	O
also	O
underlie	O
the	O
development	O
of	O
CVD	O
.	O

Recently	O
,	O
probiotic	O
bacteria	O
,	O
such	O
as	O
the	O
mucin	O
-	O
degrading	O
bacterium	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
have	O
been	O
shown	O
to	O
reduce	O
inflammation	O
and	O
prevent	O
heart	O
disease	O
in	O
animal	O
models	O
.	O

All	O
this	O
information	O
might	O
enable	O
scientists	O
and	O
clinicians	O
to	O
target	O
pathways	O
to	O
act	O
early	O
to	O
curtail	O
the	O
adverse	O
effects	O
of	O
prematurity	O
on	O
the	O
cardiovascular	O
system	O
.	O

This	O
could	O
lead	O
to	O
primary	O
and	O
secondary	O
prevention	O
of	O
CVD	O
and	O
improve	O
survival	O
among	O
preterm	O
neonates	O
later	O
in	O
adult	O
life	O
.	O

Microbial	O
Diversity	O
and	O
Organic	O
Acid	O
Production	O
of	O
Guinea	O
Pig	O
Faecal	O
Samples	O
.	O

The	O
guinea	O
pig	O
(	O
Cavia	O
porcellus	O
)	O
or	O
cavy	O
is	O
a	O
grass	O
-	O
eating	O
rodent	O
.	O

Its	O
main	O
diet	O
consists	O
of	O
grass	O
or	O
hay	O
,	O
which	O
comprises	O
cellulose	O
,	O
hemicellulose	O
,	O
lignin	O
and	O
their	O
derivatives	O
.	O

Here	O
,	O
the	O
microbial	O
diversity	O
of	O
faecal	O
samples	O
of	O
two	O
guinea	O
pigs	O
and	O
microbial	O
enrichments	O
made	O
with	O
substrates	O
,	O
including	O
starch	O
waste	O
and	O
dried	O
grass	O
,	O
were	O
investigated	O
along	O
with	O
organic	O
acid	O
production	O
profiles	O
.	O

The	O
microbial	O
communities	O
of	O
the	O
faecal	O
samples	O
were	O
dominated	O
by	O
the	O
phyla	O
Bacteroidetes	B-bacteria
(	O
40	O
%	O
)	O
and	O
Firmicutes	B-bacteria
(	O
36	O
%	O
)	O
.	O

Bacteroidales	B-bacteria
S24	I-bacteria
-	I-bacteria
7	I-bacteria
(	O
11	O
%	O
in	O
Cavy	O
1	O
and	O
21	O
%	O
in	O
Cavy	O
2	O
)	O
was	O
the	O
most	O
abundant	O
order	O
.	O

At	O
genus	O
level	O
,	O
many	O
microorganisms	O
remained	O
unclassified	O
.	O

Different	O
carbon	O
sources	O
were	O
used	O
for	O
organic	O
acid	O
production	O
in	O
faecal	O
enrichments	O
.	O

The	O
dominant	O
bacterial	O
groups	O
in	O
the	O
secondary	O
enrichments	O
with	O
dried	O
grass	O
,	O
starch	O
waste	O
and	O
xylose	O
were	O
closely	O
related	O
to	O
Prevotella	B-bacteria
and	O
Blautia	B-bacteria
.	O

Acetate	O
was	O
the	O
predominant	O
organic	O
acid	O
from	O
all	O
enrichments	O
.	O

The	O
organic	O
acid	O
production	O
profiles	O
corresponded	O
to	O
a	O
mixed	O
acid	O
fermentation	O
but	O
differed	O
depending	O
on	O
the	O
substrate	O
.	O

Eight	O
phylogenetically	O
different	O
isolates	O
were	O
obtained	O
,	O
including	O
a	O
novel	O
Streptococcus	B-bacteria
species	I-bacteria
,	O
strain	O
Cavy	O
grass	O
6	O
.	O

This	O
strain	O
had	O
a	O
low	O
abundance	O
(	O
1	O
%	O
)	O
in	O
one	O
of	O
the	O
faecal	O
samples	O
but	O
was	O
enriched	O
in	O
the	O
dried	O
grass	O
enrichment	O
(	O
3	O
%	O
)	O
.	O

Cavy	O
grass	O
6	O
,	O
a	O
fast	O
-	O
growing	O
heterolactic	O
bacterium	O
,	O
ferments	O
cellobiose	O
to	O
lactate	O
,	O
acetate	O
,	O
formate	O
and	O
ethanol	O
.	O

Our	O
results	O
show	O
that	O
cavy	O
faecal	O
samples	O
can	O
be	O
applied	O
as	O
microbial	O
source	O
for	O
organic	O
acid	O
production	O
from	O
complex	O
organic	O
substrates	O
.	O

The	O
cavy	O
gut	O
contains	O
many	O
as	O
-	O
yet	O
-	O
uncultivated	O
bacteria	O
which	O
may	O
be	O
appropriate	O
targets	O
for	O
future	O
studies	O
.	O

Extensive	O
transmission	O
of	O
microbes	O
along	O
the	O
gastrointestinal	O
tract	O
.	O

The	O
gastrointestinal	O
tract	O
is	O
abundantly	O
colonized	O
by	O
microbes	O
,	O
yet	O
the	O
translocation	O
of	O
oral	O
species	O
to	O
the	O
intestine	O
is	O
considered	O
a	O
rare	O
aberrant	O
event	O
,	O
and	O
a	O
hallmark	O
of	O
disease	O
.	O

By	O
studying	O
salivary	O
and	O
fecal	O
microbial	O
strain	O
populations	O
of	O
310	O
species	O
in	O
470	O
individuals	O
from	O
five	O
countries	O
,	O
we	O
found	O
that	O
transmission	O
to	O
,	O
and	O
subsequent	O
colonization	O
of	O
,	O
the	O
large	O
intestine	O
by	O
oral	O
microbes	O
is	O
common	O
and	O
extensive	O
among	O
healthy	O
individuals	O
.	O

We	O
found	O
evidence	O
for	O
a	O
vast	O
majority	O
of	O
oral	O
species	O
to	O
be	O
transferable	O
,	O
with	O
increased	O
levels	O
of	O
transmission	O
in	O
colorectal	O
cancer	O
and	O
rheumatoid	O
arthritis	O
patients	O
and	O
,	O
more	O
generally	O
,	O
for	O
species	O
described	O
as	O
opportunistic	O
pathogens	O
.	O

This	O
establishes	O
the	O
oral	O
cavity	O
as	O
an	O
endogenous	O
reservoir	O
for	O
gut	O
microbial	O
strains	O
,	O
and	O
oral	O
-	O
fecal	O
transmission	O
as	O
an	O
important	O
process	O
that	O
shapes	O
the	O
gastrointestinal	O
microbiome	O
in	O
health	O
and	O
disease	O
.	O

The	O
Effect	O
of	O
Multispecies	O
Probiotic	O
Supplementation	O
on	O
Iron	O
Status	O
in	O
Rats	O
.	O

A	O
range	O
of	O
interactions	O
between	O
gut	O
microbiota	O
and	O
iron	O
(	O
Fe	O
)	O
metabolism	O
is	O
described	O
.	O

Oral	O
probiotics	O
ameliorate	O
host	O
'	O
s	O
iron	O
status	O
.	O

However	O
,	O
this	O
has	O
been	O
proven	O
for	O
single	O
-	O
strain	O
probiotic	O
supplements	O
.	O

Dose	O
-	O
dependence	O
of	O
beneficial	O
probiotic	O
supplementation	O
effect	O
on	O
iron	O
turnover	O
remains	O
unexplored	O
.	O

Our	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
oral	O
multispecies	O
probiotic	O
supplementation	O
in	O
two	O
doses	O
on	O
iron	O
status	O
in	O
rats	O
.	O

Thirty	O
rats	O
were	O
randomized	O
into	O
three	O
groups	O
receiving	O
multispecies	O
probiotic	O
supplement	O
at	O
a	O
daily	O
dose	O
of	O
2	O
.	O
5	O
x	O
10	O
(	O
9	O
)	O
CFU	O
(	O
PA	O
group	O
,	O
n	O
=	O
10	O
)	O
and	O
1	O
x	O
10	O
(	O
10	O
)	O
CFU	O
(	O
PB	O
group	O
,	O
n	O
=	O
10	O
)	O
or	O
placebo	O
(	O
KK	O
group	O
,	O
n	O
=	O
10	O
)	O
.	O

After	O
6	O
weeks	O
,	O
rats	O
were	O
sacrificed	O
for	O
analysis	O
,	O
blood	O
samples	O
,	O
and	O
organs	O
(	O
the	O
liver	O
,	O
heart	O
,	O
kidneys	O
,	O
spleen	O
,	O
pancreas	O
,	O
femur	O
,	O
testicles	O
,	O
duodenum	O
,	O
and	O
hair	O
)	O
were	O
collected	O
.	O

The	O
total	O
fecal	O
bacteria	O
content	O
was	O
higher	O
in	O
the	O
PB	O
group	O
vs	O
.	O
PA	O
group	O
.	O

Unsaturated	O
iron	O
-	O
binding	O
capacity	O
was	O
higher	O
in	O
the	O
PB	O
group	O
vs	O
.	O
KK	O
group	O
.	O

Serum	O
Fe	O
was	O
lower	O
in	O
both	O
PA	O
and	O
PB	O
vs	O
.	O
KK	O
group	O
.	O

Iron	O
content	O
in	O
the	O
liver	O
was	O
higher	O
in	O
the	O
PB	O
group	O
vs	O
.	O
KK	O
group	O
;	O
in	O
the	O
pancreas	O
,	O
this	O
was	O
higher	O
in	O
the	O
PB	O
group	O
vs	O
.	O
the	O
KK	O
and	O
PA	O
group	O
,	O
and	O
in	O
the	O
duodenum	O
,	O
it	O
was	O
higher	O
in	O
both	O
supplemented	O
groups	O
vs	O
.	O
the	O
KK	O
group	O
.	O

A	O
range	O
of	O
alterations	O
in	O
zinc	O
and	O
copper	O
status	O
and	O
correlations	O
between	O
analyzed	O
parameters	O
were	O
found	O
.	O

Oral	O
multispecies	O
probiotic	O
supplementation	O
exerts	O
dose	O
-	O
independent	O
and	O
beneficial	O
effect	O
on	O
iron	O
bioavailability	O
and	O
duodenal	O
iron	O
absorption	O
in	O
the	O
rat	O
model	O
,	O
induces	O
a	O
dose	O
-	O
independent	O
iron	O
shift	O
from	O
serum	O
and	O
intensifies	O
dose	O
-	O
dependent	O
pancreatic	O
and	O
liver	O
iron	O
uptake	O
.	O

The	O
effects	O
of	O
polyphenols	O
and	O
other	O
bioactives	O
on	O
human	O
health	O
.	O

Although	O
deficiencies	O
in	O
polyphenol	O
intake	O
do	O
not	O
result	O
in	O
specific	O
deficiency	O
diseases	O
,	O
adequate	O
intake	O
of	O
polyphenols	O
could	O
confer	O
health	O
benefits	O
,	O
especially	O
with	O
regard	O
to	O
chronic	O
diseases	O
.	O

Tea	O
,	O
cocoa	O
,	O
fruits	O
,	O
and	O
berries	O
,	O
as	O
well	O
as	O
vegetables	O
,	O
are	O
rich	O
in	O
polyphenols	O
.	O

Flavan	O
-	O
3	O
-	O
ols	O
from	O
cocoa	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
stroke	O
,	O
myocardial	O
infarction	O
,	O
and	O
diabetes	O
,	O
as	O
well	O
as	O
improvements	O
in	O
lipids	O
,	O
endothelial	O
-	O
dependent	O
blood	O
flow	O
and	O
blood	O
pressure	O
,	O
insulin	O
resistance	O
,	O
and	O
systemic	O
inflammation	O
.	O

The	O
flavonoid	O
quercetin	O
and	O
the	O
stilbene	O
resveratrol	O
have	O
also	O
been	O
associated	O
with	O
cardiometabolic	O
health	O
.	O

Although	O
polyphenols	O
have	O
been	O
associated	O
with	O
improved	O
cerebral	O
blood	O
flow	O
,	O
evidence	O
of	O
an	O
impact	O
on	O
cognition	O
is	O
more	O
limited	O
.	O

The	O
ability	O
of	O
dietary	O
polyphenols	O
to	O
produce	O
clinical	O
effects	O
may	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
bi	O
-	O
directional	O
relationship	O
with	O
the	O
gut	O
microbiota	O
.	O

Polyphenols	O
can	O
impact	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
(	O
which	O
are	O
independently	O
associated	O
with	O
health	O
benefits	O
)	O
,	O
and	O
gut	O
bacteria	O
metabolize	O
polyphenols	O
into	O
bioactive	O
compounds	O
that	O
produce	O
clinical	O
benefits	O
.	O

Another	O
critical	O
interaction	O
is	O
that	O
of	O
polyphenols	O
with	O
other	O
phytochemicals	O
,	O
which	O
could	O
be	O
relevant	O
to	O
interpreting	O
the	O
health	O
parameter	O
effects	O
of	O
polyphenols	O
assayed	O
as	O
purified	O
extracts	O
,	O
whole	O
foods	O
,	O
or	O
whole	O
food	O
extracts	O
.	O

A	O
new	O
genomic	O
blueprint	O
of	O
the	O
human	O
gut	O
microbiota	O
.	O

The	O
composition	O
of	O
the	O
human	O
gut	O
microbiota	O
is	O
linked	O
to	O
health	O
and	O
disease	O
,	O
but	O
knowledge	O
of	O
individual	O
microbial	O
species	O
is	O
needed	O
to	O
decipher	O
their	O
biological	O
roles	O
.	O

Despite	O
extensive	O
culturing	O
and	O
sequencing	O
efforts	O
,	O
the	O
complete	O
bacterial	O
repertoire	O
of	O
the	O
human	O
gut	O
microbiota	O
remains	O
undefined	O
.	O

Here	O
we	O
identify	O
1	O
,	O
952	O
uncultured	O
candidate	O
bacterial	O
species	O
by	O
reconstructing	O
92	O
,	O
143	O
metagenome	O
-	O
assembled	O
genomes	O
from	O
11	O
,	O
850	O
human	O
gut	O
microbiomes	O
.	O

These	O
uncultured	O
genomes	O
substantially	O
expand	O
the	O
known	O
species	O
repertoire	O
of	O
the	O
collective	O
human	O
gut	O
microbiota	O
,	O
with	O
a	O
281	O
%	O
increase	O
in	O
phylogenetic	O
diversity	O
.	O

Although	O
the	O
newly	O
identified	O
species	O
are	O
less	O
prevalent	O
in	O
well	O
-	O
studied	O
populations	O
compared	O
to	O
reference	O
isolate	O
genomes	O
,	O
they	O
improve	O
classification	O
of	O
understudied	O
African	O
and	O
South	O
American	O
samples	O
by	O
more	O
than	O
200	O
%	O
.	O

These	O
candidate	O
species	O
encode	O
hundreds	O
of	O
newly	O
identified	O
biosynthetic	O
gene	O
clusters	O
and	O
possess	O
a	O
distinctive	O
functional	O
capacity	O
that	O
might	O
explain	O
their	O
elusive	O
nature	O
.	O

Our	O
work	O
expands	O
the	O
known	O
diversity	O
of	O
uncultured	O
gut	O
bacteria	O
,	O
which	O
provides	O
unprecedented	O
resolution	O
for	O
taxonomic	O
and	O
functional	O
characterization	O
of	O
the	O
intestinal	O
microbiota	O
.	O

Dynamics	O
of	O
Resistance	O
Plasmids	O
in	O
Extended	O
-	O
Spectrum	O
-	O
beta	O
-	O
Lactamase	O
-	O
Producing	O
Enterobacteriaceae	B-bacteria
during	O
Postinfection	O
Colonization	O
.	O

Extended	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
-	O
producing	O
Enterobacteriaceae	B-bacteria
(	O
EPE	B-bacteria
)	O
are	O
a	O
major	O
cause	O
of	O
bloodstream	O
infections	O
,	O
and	O
the	O
colonization	O
rate	O
of	O
EPE	O
in	O
the	O
gut	O
microbiota	O
of	O
individuals	O
lacking	O
prior	O
hospitalization	O
or	O
comorbidities	O
is	O
increasing	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
an	O
in	O
-	O
depth	O
investigation	O
of	O
the	O
temporal	O
dynamics	O
of	O
EPE	O
and	O
their	O
plasmids	O
during	O
one	O
year	O
by	O
collecting	O
fecal	O
samples	O
from	O
three	O
patients	O
initially	O
seeking	O
medical	O
care	O
for	O
urinary	O
tract	O
infections	O
.	O

In	O
two	O
of	O
the	O
patients	O
,	O
the	O
same	O
strain	O
that	O
caused	O
the	O
urinary	O
tract	O
infection	O
(	O
UTI	O
)	O
was	O
found	O
at	O
all	O
consecutive	O
samplings	O
from	O
the	O
gut	O
microbiota	O
,	O
and	O
no	O
other	O
EPEs	O
were	O
detected	O
,	O
while	O
in	O
the	O
third	O
patient	O
the	O
UTI	O
strain	O
was	O
only	O
found	O
in	O
the	O
initial	O
UTI	O
sample	O
.	O

Instead	O
,	O
this	O
patient	O
presented	O
a	O
complex	O
situation	O
where	O
a	O
mixed	O
microbiota	O
of	O
different	O
EPE	B-bacteria
strain	I-bacteria
types	O
,	O
including	O
three	O
different	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
ST131	I-bacteria
variants	O
,	O
as	O
well	O
as	O
different	O
bacterial	O
species	O
,	O
was	O
identified	O
over	O
the	O
course	O
of	O
the	O
study	O
.	O

Different	O
plasmid	O
dynamics	O
were	O
displayed	O
in	O
each	O
of	O
the	O
patients	O
,	O
including	O
the	O
spread	O
of	O
plasmids	O
between	O
different	O
strain	O
types	O
over	O
time	O
and	O
the	O
transposition	O
of	O
bla	O
CTX	O
-	O
M	O
-	O
15	O
from	O
the	O
chromosome	O
to	O
a	O
plasmid	O
,	O
followed	O
by	O
subsequent	O
loss	O
through	O
homologous	O
recombination	O
.	O

Small	O
cryptic	O
plasmids	O
were	O
found	O
in	O
all	O
isolates	O
from	O
all	O
patients	O
,	O
and	O
they	O
appear	O
to	O
move	O
frequently	O
between	O
different	O
strains	O
in	O
the	O
microbiota	O
.	O

In	O
conclusion	O
,	O
we	O
could	O
demonstrate	O
an	O
extensive	O
variation	O
of	O
EPE	O
strain	O
types	O
,	O
plasmid	O
composition	O
,	O
rearrangements	O
,	O
and	O
horizontal	O
gene	O
transfer	O
of	O
genetic	O
material	O
illustrating	O
the	O
high	O
dynamics	O
nature	O
and	O
interactive	O
environment	O
of	O
the	O
gut	O
microbiota	O
during	O
post	O
-	O
UTI	O
carriage	O
.	O

Isolation	O
,	O
characterization	O
and	O
mode	O
of	O
action	O
of	O
a	O
larvicidal	O
compound	O
,	O
22	O
-	O
hydroxyhopane	O
from	O
Adiantum	O
latifolium	O
Lam	O
.	O
against	O
Oryctes	O
rhinoceros	O
Linn	O
.	O

Orycte	O
rhinoceros	O
Linn	O
.	O
is	O
one	O
of	O
the	O
most	O
serious	O
pests	O
of	O
coconuts	O
and	O
other	O
palms	O
.	O

Following	O
bioassay	O
guided	O
method	O
,	O
a	O
larvicidal	O
compound	O
,	O
22	O
-	O
hydroxyhopane	O
has	O
been	O
isolated	O
for	O
the	O
first	O
time	O
from	O
methanol	O
extract	O
of	O
leaves	O
of	O
Adiantum	O
latifolium	O
Lam	O
.	O

against	O
the	O
pest	O
(	O
LC50	O
value	O
20	O
.	O
81mug	O
/	O
g	O
)	O
.	O

It	O
is	O
a	O
hopanoid	O
triterpene	O
with	O
molecular	O
mass	O
of	O
442	O
.	O
42g	O
/	O
mol	O
.	O

The	O
compound	O
exhibited	O
antibacterial	O
activity	O
against	O
symbiotic	O
gut	O
bacteria	O
,	O
caused	O
histolysis	O
of	O
midgut	O
tissues	O
and	O
inhibited	O
secretion	O
of	O
digestive	O
enzymes	O
such	O
as	O
protease	O
,	O
amylase	O
and	O
trehalase	O
resulting	O
in	O
weight	O
loss	O
of	O
larvae	O
.	O

Enzyme	O
immunoassay	O
showed	O
an	O
elevation	O
of	O
20	O
-	O
hydroxyecdysone	O
level	O
in	O
haemolymph	O
causing	O
disruption	O
of	O
metamorphosis	O
of	O
larvae	O
.	O

Organophosphorus	O
pesticide	O
chlorpyrifos	O
intake	O
promotes	O
obesity	O
and	O
insulin	O
resistance	O
through	O
impacting	O
gut	O
and	O
gut	O
microbiota	O
.	O

BACKGROUND	O
:	O
Disruption	O
of	O
the	O
gut	O
microbiota	O
homeostasis	O
may	O
induce	O
low	O
-	O
grade	O
inflammation	O
leading	O
to	O
obesity	O
-	O
associated	O
diseases	O
.	O

A	O
major	O
protective	O
mechanism	O
is	O
to	O
use	O
the	O
multi	O
-	O
layered	O
mucus	O
structures	O
to	O
keep	O
a	O
safe	O
distance	O
between	O
gut	O
epithelial	O
cells	O
and	O
microbiota	O
.	O

To	O
investigate	O
whether	O
pesticides	O
would	O
induce	O
insulin	O
resistance	O
/	O
obesity	O
through	O
interfering	O
with	O
mucus	O
-	O
bacterial	O
interactions	O
,	O
we	O
conducted	O
a	O
study	O
to	O
determine	O
how	O
long	O
-	O
term	O
exposure	O
to	O
chlorpyrifos	O
affected	O
C57Bl	O
/	O
6	O
and	O
CD	O
-	O
1	O
(	O
ICR	O
)	O
mice	O
fed	O
high	O
-	O
or	O
normal	O
-	O
fat	O
diets	O
.	O

To	O
further	O
investigate	O
the	O
effects	O
of	O
chlorpyrifos	O
-	O
altered	O
microbiota	O
,	O
antibiotic	O
treatment	O
and	O
microbiota	O
transplantation	O
experiments	O
were	O
conducted	O
.	O

RESULTS	O
:	O
The	O
results	O
showed	O
that	O
chlorpyrifos	O
caused	O
broken	O
integrity	O
of	O
the	O
gut	O
barrier	O
,	O
leading	O
to	O
increased	O
lipopolysaccharide	O
entry	O
into	O
the	O
body	O
and	O
finally	O
low	O
-	O
grade	O
inflammation	O
,	O
while	O
genetic	O
background	O
and	O
diet	O
pattern	O
have	O
limited	O
influence	O
on	O
the	O
chlorpyrifos	O
-	O
induced	O
results	O
.	O

Moreover	O
,	O
the	O
mice	O
given	O
chlorpyrifos	O
-	O
altered	O
microbiota	O
had	O
gained	O
more	O
fat	O
and	O
lower	O
insulin	O
sensitivity	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
widespread	O
use	O
of	O
pesticides	O
may	O
contribute	O
to	O
the	O
worldwide	O
epidemic	O
of	O
inflammation	O
-	O
related	O
diseases	O
.	O

Metaproteomics	O
reveals	O
persistent	O
and	O
phylum	O
-	O
redundant	O
metabolic	O
functional	O
stability	O
in	O
adult	O
human	O
gut	O
microbiomes	O
of	O
Crohn	O
'	O
s	O
remission	O
patients	O
despite	O
temporal	O
variations	O
in	O
microbial	O
taxa	O
,	O
genomes	O
,	O
and	O
proteomes	O
.	O

BACKGROUND	O
:	O
The	O
gut	O
microbiome	O
plays	O
a	O
fundamental	O
role	O
in	O
the	O
human	O
host	O
'	O
s	O
overall	O
health	O
by	O
contributing	O
key	O
biological	O
functions	O
such	O
as	O
expanded	O
metabolism	O
and	O
pathogen	O
defense	O
/	O
immune	O
control	O
.	O

In	O
a	O
healthy	O
individual	O
,	O
the	O
gut	O
microbiome	O
co	O
-	O
exists	O
within	O
the	O
human	O
host	O
in	O
a	O
symbiotic	O
,	O
non	O
-	O
inflammatory	O
relationship	O
that	O
enables	O
mutual	O
benefits	O
,	O
such	O
as	O
microbial	O
degradation	O
of	O
indigestible	O
food	O
products	O
into	O
small	O
molecules	O
that	O
the	O
host	O
can	O
utilize	O
,	O
and	O
enhanced	O
pathogen	O
defense	O
.	O

In	O
abnormal	O
conditions	O
,	O
such	O
as	O
Crohn	O
'	O
s	O
disease	O
,	O
this	O
favorable	O
metabolic	O
relationship	O
breaks	O
down	O
and	O
a	O
variety	O
of	O
undesirable	O
activities	O
result	O
,	O
including	O
chronic	O
inflammation	O
and	O
other	O
health	O
-	O
related	O
issues	O
.	O

It	O
has	O
been	O
difficult	O
,	O
however	O
,	O
to	O
elucidate	O
the	O
overall	O
functional	O
characteristics	O
of	O
this	O
relationship	O
because	O
the	O
microbiota	O
can	O
vary	O
substantially	O
in	O
composition	O
for	O
healthy	O
humans	O
and	O
possibly	O
even	O
more	O
in	O
individuals	O
with	O
gut	O
disease	O
conditions	O
such	O
as	O
Crohn	O
'	O
s	O
disease	O
.	O

Overall	O
,	O
this	O
suggests	O
that	O
microbial	O
membership	O
composition	O
may	O
not	O
be	O
the	O
best	O
way	O
to	O
characterize	O
a	O
phenotype	O
.	O

Alternatively	O
,	O
it	O
seems	O
to	O
be	O
more	O
informative	O
to	O
examine	O
and	O
characterize	O
the	O
functional	O
composition	O
of	O
a	O
gut	O
microbiome	O
.	O

Towards	O
that	O
end	O
,	O
this	O
study	O
examines	O
25	O
metaproteomes	O
measured	O
in	O
several	O
Crohn	O
'	O
s	O
disease	O
patients	O
'	O
post	O
-	O
resection	O
surgery	O
across	O
the	O
course	O
of	O
1	O
year	O
,	O
in	O
order	O
to	O
examine	O
persistence	O
of	O
microbial	O
taxa	O
,	O
genes	O
,	O
proteins	O
,	O
and	O
metabolic	O
functional	O
distributions	O
across	O
time	O
in	O
individuals	O
whose	O
microbiome	O
might	O
be	O
more	O
variable	O
due	O
to	O
the	O
gut	O
disease	O
condition	O
.	O

RESULTS	O
:	O
The	O
measured	O
metaproteomes	O
were	O
highly	O
personalized	O
,	O
with	O
all	O
the	O
temporally	O
-	O
related	O
metaproteomes	O
clustering	O
most	O
closely	O
by	O
individual	O
.	O

In	O
general	O
,	O
the	O
metaproteomes	O
were	O
remarkably	O
distinct	O
between	O
individuals	O
and	O
to	O
a	O
lesser	O
extent	O
within	O
individuals	O
.	O

This	O
prompted	O
a	O
need	O
to	O
characterize	O
the	O
metaproteome	O
at	O
a	O
higher	O
functional	O
level	O
,	O
which	O
was	O
achieved	O
by	O
annotating	O
identified	O
protein	O
groups	O
with	O
KEGG	O
orthologous	O
groups	O
to	O
infer	O
metabolic	O
modules	O
.	O

At	O
this	O
level	O
,	O
similar	O
and	O
redundant	O
metabolic	O
functions	O
across	O
multiple	O
phyla	O
were	O
observed	O
across	O
time	O
and	O
between	O
individuals	O
.	O

Tracking	O
through	O
these	O
various	O
metabolic	O
modules	O
revealed	O
a	O
clear	O
path	O
from	O
carbohydrate	O
,	O
lipid	O
,	O
and	O
amino	O
acid	O
degradation	O
to	O
central	O
metabolism	O
and	O
finally	O
the	O
production	O
of	O
fermentation	O
products	O
.	O

CONCLUSIONS	O
:	O
The	O
human	O
gut	O
metaproteome	O
can	O
vary	O
quite	O
substantially	O
across	O
time	O
and	O
individuals	O
.	O

However	O
,	O
despite	O
substantial	O
intra	O
-	O
individual	O
variation	O
in	O
the	O
metaproteomes	O
,	O
there	O
is	O
a	O
clear	O
persistence	O
of	O
conserved	O
metabolic	O
functions	O
across	O
time	O
and	O
individuals	O
.	O

Additionally	O
,	O
the	O
persistence	O
of	O
these	O
core	O
functions	O
is	O
redundant	O
across	O
multiple	O
phyla	O
but	O
is	O
not	O
always	O
observable	O
in	O
the	O
same	O
sample	O
.	O

Finally	O
,	O
the	O
gut	O
microbiome	O
'	O
s	O
metabolism	O
is	O
not	O
driven	O
by	O
a	O
set	O
of	O
discrete	O
linear	O
pathways	O
but	O
a	O
web	O
of	O
interconnected	O
reactions	O
facilitated	O
by	O
a	O
network	O
of	O
enzymes	O
that	O
connect	O
multiple	O
molecules	O
across	O
multiple	O
pathways	O
.	O

The	O
Relationship	O
between	O
Platelet	O
Count	O
and	O
Host	O
Gut	O
Microbiota	O
:	O
A	O
Population	O
-	O
Based	O
Retrospective	O
Cross	O
-	O
Sectional	O
Study	O
.	O

Platelet	O
count	O
reflects	O
the	O
severity	O
and	O
prognosis	O
of	O
multiple	O
diseases	O
.	O

Additionally	O
,	O
alterations	O
in	O
gut	O
microbiota	O
have	O
been	O
linked	O
to	O
several	O
chronic	O
diseases	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
gut	O
microbiota	O
and	O
platelet	O
count	O
.	O

We	O
selected	O
1268	O
subjects	O
with	O
fecal	O
16S	O
RNA	O
gene	O
sequencing	O
data	O
from	O
a	O
Healthcare	O
Screening	O
Center	O
cohort	O
.	O

Based	O
on	O
the	O
third	O
quartile	O
of	O
platelets	O
(	O
277	O
x	O
10	O
(	O
8	O
)	O
/	O
L	O
)	O
,	O
we	O
compared	O
the	O
gut	O
microbiota	O
between	O
the	O
upper	O
quartile	O
(	O
n	O
=	O
321	O
)	O
and	O
lower	O
three	O
quartiles	O
groups	O
(	O
n	O
=	O
947	O
)	O
.	O

The	O
upper	O
quartile	O
group	O
had	O
lower	O
alpha	O
diversity	O
based	O
on	O
observed	O
amplicon	O
sequence	O
variants	O
(	O
q	O
=	O
0	O
.	O
004	O
)	O
and	O
phylogenetic	O
index	O
(	O
q	O
<	O
0	O
.	O
001	O
)	O
than	O
the	O
lower	O
three	O
quartiles	O
group	O
.	O

Significant	O
differences	O
were	O
also	O
found	O
in	O
the	O
weighted	O
UniFrac	O
distance	O
(	O
q	O
=	O
0	O
.	O
001	O
)	O
and	O
Jaccard	O
dissimilarity	O
(	O
q	O
=	O
0	O
.	O
047	O
)	O
beta	O
diversity	O
measures	O
between	O
the	O
two	O
groups	O
.	O

Compared	O
with	O
the	O
lower	O
three	O
quartiles	O
group	O
,	O
the	O
upper	O
quartile	O
group	O
exhibited	O
decreased	O
relative	O
abundances	O
of	O
the	O
genus	O
Faecalibacterium	B-bacteria
,	O
which	O
was	O
also	O
inversely	O
correlated	O
with	O
the	O
platelet	O
count	O
.	O

Increased	O
platelet	O
count	O
was	O
associated	O
with	O
reduced	O
diversity	O
in	O
gut	O
microbiota	O
and	O
lower	O
abundances	O
of	O
Faecalibacterium	B-bacteria
with	O
beneficial	O
gut	O
bacteria	O
spices	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
,	O
suggesting	O
that	O
an	O
increased	O
platelet	O
count	O
,	O
even	O
within	O
normal	O
range	O
,	O
may	O
adversely	O
affect	O
gut	O
microbial	O
diversity	O
and	O
composition	O
.	O

Infant	O
Complementary	O
Feeding	O
of	O
Prebiotics	O
for	O
theMicrobiome	O
and	O
Immunity	O
.	O

Complementary	O
feeding	O
transitions	O
infants	O
from	O
a	O
milk	O
-	O
based	O
diet	O
to	O
solid	O
foods	O
,	O
providing	O
essential	O
nutrients	O
to	O
the	O
infant	O
and	O
the	O
developing	O
gut	O
microbiome	O
while	O
influencing	O
immune	O
development	O
.	O

Some	O
of	O
the	O
earliest	O
microbial	O
colonisers	O
readily	O
ferment	O
select	O
oligosaccharides	O
,	O
influencing	O
the	O
ongoing	O
establishment	O
of	O
the	O
microbiome	O
.	O

Non	O
-	O
digestible	O
oligosaccharides	O
in	O
prebiotic	O
-	O
supplemented	O
formula	O
and	O
human	O
milk	O
oligosaccharides	O
promote	O
commensal	O
immune	O
-	O
modulating	O
bacteria	O
such	O
as	O
Bifidobacterium	B-bacteria
,	O
which	O
decrease	O
in	O
abundance	O
during	O
weaning	O
.	O

Incorporating	O
complex	O
,	O
bifidogenic	O
,	O
non	O
-	O
digestible	O
carbohydrates	O
during	O
the	O
transition	O
to	O
solid	O
foods	O
may	O
present	O
an	O
opportunity	O
to	O
feed	O
commensal	O
bacteria	O
and	O
promote	O
balanced	O
concentrations	O
of	O
beneficial	O
short	O
chain	O
fatty	O
acid	O
concentrations	O
and	O
vitamins	O
that	O
support	O
gut	O
barrier	O
maturation	O
and	O
immunity	O
throughout	O
the	O
complementary	O
feeding	O
window	O
.	O

Bifidobacterium	B-bacteria
with	O
the	O
role	O
of	O
5	O
-	O
hydroxytryptophan	O
synthesis	O
regulation	O
alleviates	O
the	O
symptom	O
of	O
depression	O
and	O
related	O
microbiota	O
dysbiosis	O
.	O

Depression	O
disorder	O
is	O
rapidly	O
advancing	O
worldwide	O
,	O
and	O
therapeutic	O
strategy	O
through	O
gut	O
-	O
brain	O
axis	O
has	O
been	O
proven	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
.	O

Here	O
we	O
studied	O
the	O
effect	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
treatment	O
on	O
depression	O
.	O

C57BL	O
/	O
6J	O
mice	O
were	O
administered	O
with	O
LAB	B-bacteria
during	O
a	O
5	O
-	O
week	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

Bifidobacterium	B-bacteria
longum	I-bacteria
subsp	I-bacteria
.	I-bacteria
infantis	I-bacteria
E41	I-bacteria
and	O
Bifidobacterium	B-bacteria
breve	I-bacteria
M2CF22M7	I-bacteria
,	O
which	O
improved	O
the	O
expression	O
of	O
Tph1	O
and	O
secretion	O
of	O
5	O
-	O
hydroxytryptophan	O
(	O
5	O
-	O
HTP	O
)	O
in	O
RIN14B	O
cells	O
,	O
significantly	O
reduced	O
depressive	O
behaviors	O
of	O
mice	O
in	O
the	O
forced	O
swim	O
test	O
,	O
sucrose	O
preference	O
test	O
and	O
step	O
-	O
down	O
test	O
,	O
as	O
well	O
as	O
increased	O
the	O
level	O
of	O
5	O
-	O
hydroxytryptamine	O
and	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
concentration	O
in	O
brain	O
.	O

Besides	O
,	O
M2CF22M7	O
reduced	O
the	O
serum	O
corticosterone	O
level	O
.	O

E41	O
increased	O
cecal	O
butyrate	O
level	O
,	O
which	O
significantly	O
and	O
positively	O
correlated	O
with	O
some	O
depression	O
-	O
related	O
indexes	O
.	O

Using	O
16S	O
rRNA	O
-	O
amplicon	O
sequencing	O
of	O
faces	O
,	O
E41	O
and	O
M2CF22M7	O
were	O
found	O
to	O
improve	O
the	O
chronic	O
-	O
stress	O
-	O
induced	O
microbial	O
dysbiosis	O
.	O

They	O
also	O
normalized	O
the	O
host	O
'	O
s	O
pathways	O
involving	O
metabolism	O
and	O
gene	O
information	O
processing	O
.	O

These	O
results	O
indicate	O
that	O
Bifidobacterium	B-bacteria
E41	I-bacteria
and	O
M2CF22M7	B-bacteria
have	O
an	O
antidepressant	O
effect	O
in	O
mice	O
partly	O
in	O
a	O
5	O
-	O
HTP	O
dependent	O
and	O
microbiota	O
-	O
regulating	O
manner	O
.	O

Nurturing	O
the	O
gut	O
microbiota	O
with	O
these	O
strains	O
may	O
become	O
an	O
emerging	O
therapeutic	O
way	O
for	O
mood	O
disorder	O
.	O

Proliferation	O
dynamics	O
of	O
WSSV	O
in	O
crayfish	O
,	O
Procambarus	O
clarkii	O
,	O
and	O
the	O
host	O
responses	O
at	O
different	O
temperatures	O
.	O

The	O
replication	O
profile	O
of	O
white	O
spot	O
syndrome	O
virus	O
(	O
WSSV	O
)	O
in	O
crayfish	O
,	O
Procambarus	O
clarkii	O
,	O
at	O
different	O
water	O
temperature	O
was	O
investigated	O
in	O
this	O
study	O
.	O

The	O
WSSV	O
detections	O
were	O
negative	O
at	O
15	O
+	O
/	O
-	O
1	O
degrees	O
C	O
,	O
and	O
the	O
natural	O
infection	O
ratio	O
increased	O
at	O
19	O
+	O
/	O
-	O
1	O
degrees	O
C	O
(	O
24	O
.	O
2	O
%	O
+	O
/	O
-	O
2	O
.	O
25	O
%	O
)	O
,	O
reached	O
100	O
%	O
at	O
25	O
+	O
/	O
-	O
1	O
degrees	O
C	O
and	O
decreased	O
at	O
30	O
+	O
/	O
-	O
1	O
degrees	O
C	O
(	O
93	O
.	O
2	O
%	O
+	O
/	O
-	O
3	O
.	O
37	O
%	O
)	O
.	O

The	O
WSSV	O
genome	O
copies	O
number	O
was	O
much	O
higher	O
at	O
25	O
+	O
/	O
-	O
1	O
degrees	O
C	O
(	O
>	O
/	O
=	O
5	O
x	O
10	O
(	O
6	O
.	O
45	O
+	O
/	O
-	O
0	O
.	O
35	O
)	O
/	O
mg	O
)	O
than	O
at	O
15	O
+	O
/	O
-	O
1	O
degrees	O
C	O
(	O
<	O
/	O
=	O
5	O
x	O
10	O
(	O
1	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
12	O
)	O
/	O
mg	O
)	O
,	O
19	O
+	O
/	O
-	O
1	O
degrees	O
C	O
(	O
<	O
/	O
=	O
5	O
x	O
10	O
(	O
2	O
.	O
74	O
+	O
/	O
-	O
0	O
.	O
48	O
)	O
/	O
mg	O
)	O
and	O
32	O
+	O
/	O
-	O
1	O
degrees	O
C	O
(	O
<	O
/	O
=	O
5	O
x	O
10	O
(	O
3	O
.	O
18	O
+	O
/	O
-	O
0	O
.	O
27	O
)	O
/	O
mg	O
)	O
.	O

Meanwhile	O
,	O
the	O
significant	O
transcription	O
signals	O
of	O
immediate	O
early	O
gene	O
ie1	O
and	O
late	O
gene	O
vp28	O
and	O
a	O
large	O
number	O
of	O
virus	O
particles	O
were	O
detected	O
in	O
epitheliums	O
of	O
stomach	O
,	O
gut	O
and	O
gill	O
,	O
hepatopancreas	O
,	O
heart	O
and	O
muscle	O
cells	O
at	O
25	O
+	O
/	O
-	O
1	O
degrees	O
C	O
by	O
using	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
and	O
transmission	O
electron	O
microscopy	O
.	O

The	O
experimental	O
infection	O
of	O
P	O
.	O
clarkii	O
with	O
WSSV	O
infection	O
showed	O
reduced	O
mortality	O
and	O
lower	O
virus	O
copies	O
number	O
at	O
19	O
+	O
/	O
-	O
1	O
degrees	O
C	O
(	O
23	O
.	O
51	O
%	O
+	O
/	O
-	O
0	O
.	O
84	O
%	O
,	O
<	O
/	O
=	O
5	O
x	O
10	O
(	O
3	O
.	O
41	O
+	O
/	O
-	O
0	O
.	O
11	O
)	O
/	O
mg	O
)	O
and	O
32	O
+	O
/	O
-	O
1	O
degrees	O
C	O
(	O
38	O
.	O
42	O
%	O
(	O
+	O
/	O
-	O
)	O
1	O
.	O
21	O
%	O
,	O
<	O
/	O
=	O
5	O
x	O
10	O
(	O
3	O
.	O
72	O
+	O
/	O
-	O
0	O
.	O
13	O
)	O
/	O
mg	O
)	O
compared	O
to	O
25	O
+	O
/	O
-	O
1	O
degrees	O
C	O
(	O
100	O
%	O
,	O
>	O
/	O
=	O
5	O
x	O
10	O
(	O
4	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
24	O
)	O
/	O
mg	O
)	O
.	O

The	O
water	O
temperature	O
regulated	O
the	O
transcription	O
of	O
immune	O
-	O
related	O
genes	O
(	O
crustin2	O
,	O
prophenoloxidase	O
(	O
proPO	O
)	O
and	O
heat	O
shock	O
protein70	O
(	O
Hsp70	O
)	O
)	O
,	O
with	O
some	O
differences	O
between	O
WSSV	O
treatments	O
and	O
control	O
treatments	O
.	O

These	O
results	O
demonstrate	O
that	O
water	O
temperature	O
has	O
effect	O
on	O
WSSV	O
proliferation	O
,	O
which	O
may	O
due	O
to	O
transcriptional	O
response	O
of	O
immune	O
-	O
related	O
genes	O
to	O
temperature	O
.	O

Comparative	O
cytology	O
,	O
physiology	O
and	O
transcriptomics	O
of	O
Burkholderia	B-bacteria
insecticola	I-bacteria
in	O
symbiosis	O
with	O
the	O
bean	O
bug	O
Riptortus	O
pedestris	O
and	O
in	O
culture	O
.	O

In	O
the	O
symbiosis	O
of	O
the	O
bean	O
bug	O
Riptortus	O
pedestris	I-bacteria
with	O
Burkholderia	B-bacteria
insecticola	I-bacteria
,	O
the	O
bacteria	O
occupy	O
an	O
exclusive	O
niche	O
in	O
the	O
insect	O
midgut	O
and	O
favor	O
insect	O
development	O
and	O
reproduction	O
.	O

In	O
order	O
to	O
understand	O
how	O
the	O
symbiotic	O
bacteria	O
stably	O
colonize	O
the	O
midgut	O
crypts	O
and	O
which	O
services	O
they	O
provide	O
to	O
the	O
host	O
,	O
we	O
compared	O
the	O
cytology	O
,	O
physiology	O
,	O
and	O
transcriptomics	O
of	O
free	O
-	O
living	O
and	O
midgut	O
-	O
colonizing	O
B	B-bacteria
.	I-bacteria
insecticola	I-bacteria
.	O

The	O
analyses	O
revealed	O
that	O
midgut	O
-	O
colonizing	O
bacteria	O
were	O
smaller	O
in	O
size	O
and	O
had	O
lower	O
DNA	O
content	O
,	O
they	O
had	O
increased	O
stress	O
sensitivity	O
,	O
lost	O
motility	O
,	O
and	O
an	O
altered	O
cell	O
surface	O
.	O

Transcriptomics	O
revealed	O
what	O
kinds	O
of	O
nutrients	O
are	O
provided	O
by	O
the	O
bean	O
bug	O
to	O
the	O
Burkholderia	B-bacteria
symbiont	I-bacteria
.	O

Transporters	O
and	O
metabolic	O
pathways	O
of	O
diverse	O
sugars	O
such	O
as	O
rhamnose	O
and	O
ribose	O
,	O
and	O
sulfur	O
compounds	O
like	O
sulfate	O
and	O
taurine	O
were	O
upregulated	O
in	O
the	O
midgut	O
-	O
colonizing	O
symbionts	O
.	O

Moreover	O
,	O
pathways	O
enabling	O
the	O
assimilation	O
of	O
insect	O
nitrogen	O
wastes	O
,	O
i	O
.	O
e	O
.	O

allantoin	O
and	O
urea	O
,	O
were	O
also	O
upregulated	O
.	O

The	O
data	O
further	O
suggested	O
that	O
the	O
midgut	O
-	O
colonizing	O
symbionts	O
produced	O
all	O
essential	O
amino	O
acids	O
and	O
B	O
vitamins	O
,	O
some	O
of	O
which	O
are	O
scarce	O
in	O
the	O
soybean	O
food	O
of	O
the	O
host	O
insect	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
Burkholderia	B-bacteria
symbiont	I-bacteria
is	O
fed	O
with	O
specific	O
nutrients	O
and	O
also	O
recycles	O
host	O
metabolic	O
wastes	O
in	O
the	O
insect	O
gut	O
,	O
and	O
in	O
return	O
,	O
the	O
bacterial	O
symbiont	O
provides	O
the	O
host	O
with	O
essential	O
nutrients	O
limited	O
in	O
the	O
insect	O
food	O
,	O
contributing	O
to	O
the	O
rapid	O
growth	O
and	O
enhanced	O
reproduction	O
of	O
the	O
bean	O
bug	O
host	O
.	O

Higher	O
abundance	O
of	O
enterovirus	O
A	O
species	O
in	O
the	O
gut	O
of	O
children	O
with	O
islet	O
autoimmunity	O
.	O

Enteroviruses	O
(	O
EVs	O
)	O
are	O
prime	O
candidate	O
environmental	O
triggers	O
of	O
islet	O
autoimmunity	O
(	O
IA	O
)	O
,	O
with	O
potential	O
as	O
vaccine	O
targets	O
for	O
type	O
1	O
diabetes	O
prevention	O
.	O

However	O
,	O
the	O
use	O
of	O
targeted	O
virus	O
detection	O
methods	O
and	O
the	O
selective	O
focus	O
on	O
EVs	O
by	O
most	O
studies	O
increases	O
the	O
risk	O
for	O
substantial	O
investigation	O
bias	O
and	O
an	O
overestimated	O
association	O
between	O
EV	O
and	O
type	O
1	O
diabetes	O
.	O

Here	O
we	O
performed	O
comprehensive	O
virome	O
-	O
capture	O
sequencing	O
to	O
examine	O
all	O
known	O
vertebrate	O
-	O
infecting	O
viruses	O
without	O
bias	O
in	O
182	O
specimens	O
(	O
faeces	O
and	O
plasma	O
)	O
collected	O
before	O
or	O
at	O
seroconversion	O
from	O
45	O
case	O
children	O
with	O
IA	O
and	O
48	O
matched	O
controls	O
.	O

From	O
>	O
2	O
.	O
6	O
billion	O
reads	O
,	O
28	O
genera	O
of	O
viruses	O
were	O
detected	O
and	O
62	O
%	O
of	O
children	O
(	O
58	O
/	O
93	O
)	O
were	O
positive	O
for	O
>	O
/	O
=	O
1	O
vertebrate	O
-	O
infecting	O
virus	O
.	O

We	O
identified	O
129	O
viruses	O
as	O
differentially	O
abundant	O
between	O
the	O
gut	O
of	O
cases	O
and	O
controls	O
,	O
including	O
5	O
EV	O
-	O
A	O
types	O
significantly	O
more	O
abundant	O
in	O
the	O
cases	O
.	O

Our	O
findings	O
further	O
support	O
EV	O
'	O
s	O
hypothesised	O
contribution	O
to	O
IA	O
and	O
corroborate	O
the	O
proposal	O
that	O
viral	O
load	O
may	O
be	O
an	O
important	O
parameter	O
in	O
disease	O
pathogenesis	O
.	O

Furthermore	O
,	O
our	O
data	O
indicate	O
a	O
previously	O
unrecognised	O
association	O
of	O
IA	O
with	O
higher	O
EV	O
-	O
A	O
abundance	O
in	O
the	O
gut	O
of	O
children	O
and	O
provide	O
a	O
catalog	O
of	O
viruses	O
to	O
be	O
interrogated	O
further	O
to	O
determine	O
a	O
causal	O
link	O
between	O
virus	O
infection	O
and	O
type	O
1	O
diabetes	O
.	O

Clothianidin	O
seed	O
-	O
treatment	O
has	O
no	O
detectable	O
negative	O
impact	O
on	O
honeybee	O
colonies	O
and	O
their	O
pathogens	O
.	O

Interactions	O
between	O
multiple	O
stressors	O
have	O
been	O
implicated	O
in	O
elevated	O
honeybee	O
colony	O
losses	O
.	O

Here	O
,	O
we	O
extend	O
our	O
landscape	O
-	O
scale	O
study	O
on	O
the	O
effects	O
of	O
placement	O
at	O
clothianidin	O
seed	O
-	O
treated	O
oilseed	O
rape	O
fields	O
on	O
honeybees	O
with	O
an	O
additional	O
year	O
and	O
new	O
data	O
on	O
honeybee	O
colony	O
development	O
,	O
swarming	O
,	O
mortality	O
,	O
pathogens	O
and	O
immune	O
gene	O
expression	O
.	O

Clothianidin	O
residues	O
in	O
pollen	O
,	O
nectar	O
and	O
honeybees	O
were	O
consistently	O
higher	O
at	O
clothianidin	O
-	O
treated	O
fields	O
,	O
with	O
large	O
differences	O
between	O
fields	O
and	O
years	O
.	O

We	O
found	O
large	O
variations	O
in	O
colony	O
development	O
and	O
microbial	O
composition	O
and	O
no	O
observable	O
negative	O
impact	O
of	O
placement	O
at	O
clothianidin	O
-	O
treated	O
fields	O
.	O

Clothianidin	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
brood	O
,	O
adult	O
bees	O
and	O
Gilliamella	O
apicola	O
(	O
beneficial	O
gut	O
symbiont	O
)	O
and	O
a	O
decrease	O
in	O
Aphid	O
lethal	O
paralysis	O
virus	O
and	O
Black	O
queen	O
cell	O
virus	O
-	O
particularly	O
in	O
the	O
second	O
year	O
.	O

The	O
results	O
suggest	O
that	O
at	O
colony	O
level	O
,	O
honeybees	O
are	O
relatively	O
robust	O
to	O
the	O
effects	O
of	O
clothianidin	O
in	O
real	O
-	O
world	O
agricultural	O
landscapes	O
,	O
with	O
moderate	O
,	O
natural	O
disease	O
pressure	O
.	O

Lactococcus	B-bacteria
Lactis	I-bacteria
Subsp	I-bacteria
.	I-bacteria
cremoris	I-bacteria
Is	O
an	O
Efficacious	O
Beneficial	O
Bacterium	O
that	O
Limits	O
Tissue	O
Injury	O
in	O
the	O
Intestine	O
.	O

The	O
use	O
of	O
beneficial	O
bacteria	O
to	O
promote	O
health	O
is	O
widely	O
practiced	O
.	O

However	O
,	O
experimental	O
evidence	O
corroborating	O
the	O
efficacy	O
of	O
bacteria	O
promoted	O
with	O
such	O
claims	O
remains	O
limited	O
.	O

We	O
address	O
this	O
gap	O
by	O
identifying	O
a	O
beneficial	O
bacterium	O
that	O
protects	O
against	O
tissue	O
damage	O
and	O
injury	O
-	O
induced	O
inflammation	O
in	O
the	O
gut	O
.	O

We	O
first	O
employed	O
the	O
Drosophila	O
animal	O
model	O
to	O
screen	O
for	O
the	O
capacity	O
of	O
candidate	O
beneficial	O
bacteria	O
to	O
protect	O
the	O
fly	O
gut	O
against	O
injury	O
.	O

From	O
this	O
screen	O
,	O
we	O
identified	O
Lactococcus	B-bacteria
lactis	I-bacteria
subsp	I-bacteria
.	I-bacteria
cremoris	I-bacteria
as	O
a	O
bacterium	O
that	O
elicited	O
potent	O
cytoprotective	O
activity	O
.	O

Then	O
,	O
in	O
a	O
murine	O
model	O
,	O
we	O
demonstrated	O
that	O
the	O
same	O
strain	O
confers	O
powerful	O
cytoprotective	O
influences	O
against	O
radiological	O
damage	O
,	O
as	O
well	O
as	O
anti	O
-	O
inflammatory	O
activity	O
in	O
a	O
gut	O
colitis	O
model	O
.	O

In	O
summary	O
,	O
we	O
demonstrate	O
the	O
positive	O
salutary	O
effects	O
of	O
a	O
beneficial	O
bacterium	O
,	O
namely	O
,	O
L	B-bacteria
.	I-bacteria
lactis	I-bacteria
subsp	I-bacteria
.	I-bacteria
cremoris	I-bacteria
on	O
intestinal	O
tissue	O
and	O
propose	O
the	O
use	O
of	O
this	O
strain	O
as	O
a	O
therapeutic	O
to	O
promote	O
intestinal	O
health	O
.	O

Potential	O
in	O
vivo	O
transfer	O
of	O
a	O
blaCTX	O
-	O
M14	O
-	O
harbouring	O
plasmid	O
established	O
by	O
combining	O
long	O
-	O
and	O
short	O
-	O
read	O
sequencing	O
.	O

Horizontal	O
transfer	O
of	O
plasmid	O
-	O
mediated	O
antibiotic	O
resistance	O
has	O
rarely	O
been	O
documented	O
in	O
vivo	O
.	O

Utilizing	O
long	O
-	O
read	O
(	O
Oxford	O
Nanopore	O
)	O
and	O
short	O
-	O
read	O
(	O
Illumina	O
)	O
sequencing	O
,	O
we	O
confirmed	O
that	O
a	O
gut	O
-	O
colonizing	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
a	O
hypervirulent	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
ST23	I-bacteria
,	O
isolated	O
from	O
a	O
surgical	O
site	O
culture	O
of	O
a	O
patient	O
receiving	O
cefuroxime	O
therapy	O
,	O
harboured	O
a	O
100	O
%	O
identical	O
blaCTX	O
-	O
M	O
-	O
14	O
-	O
harbouring	O
plasmid	O
,	O
indicative	O
of	O
a	O
potential	O
transfer	O
in	O
vivo	O
.	O

Kazachstania	B-bacteria
turicensis	I-bacteria
CAU	I-bacteria
Y1706	I-bacteria
ameliorates	O
atopic	O
dermatitis	O
by	O
regulation	O
of	O
the	O
gut	O
-	O
skin	O
axis	O
.	O

Atopic	O
dermatitis	O
(	O
AD	O
)	O
causes	O
chronic	O
inflammatory	O
skin	O
disease	O
that	O
results	O
in	O
a	O
considerable	O
economic	O
expense	O
and	O
social	O
burden	O
.	O

Certain	O
Lactobacillus	B-bacteria
strains	I-bacteria
ameliorate	O
AD	O
,	O
but	O
the	O
effects	O
of	O
probiotic	O
yeast	O
on	O
AD	O
have	O
not	O
been	O
investigated	O
to	O
date	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
Kazachstania	B-bacteria
turicensis	I-bacteria
CAU	I-bacteria
Y1706	I-bacteria
,	O
commonly	O
known	O
as	O
a	O
kefir	O
yeast	O
,	O
and	O
evaluated	O
its	O
mitigating	O
effects	O
using	O
an	O
ovalbumin	O
-	O
sensitized	O
AD	O
mouse	O
model	O
.	O

Overall	O
,	O
K	B-bacteria
.	I-bacteria
turicensis	I-bacteria
CAU	I-bacteria
Y1706	I-bacteria
was	O
generally	O
effective	O
against	O
AD	O
.	O

Oral	O
administration	O
of	O
K	B-bacteria
.	I-bacteria
turicensis	I-bacteria
CAU	I-bacteria
Y1706	I-bacteria
suppressed	O
T	O
helper	O
type	O
2	O
immune	O
response	O
factors	O
by	O
regulatory	O
T	O
cells	O
and	O
upregulation	O
of	O
T	O
helper	O
type	O
1	O
cytokine	O
levels	O
.	O

Kazachstania	B-bacteria
turicensis	I-bacteria
CAU	I-bacteria
Y1706	I-bacteria
also	O
reduced	O
IgE	O
levels	O
as	O
well	O
as	O
the	O
number	O
of	O
eosinophil	O
and	O
mast	O
cells	O
.	O

Furthermore	O
,	O
feces	O
from	O
K	B-bacteria
.	I-bacteria
turicensis	I-bacteria
CAU	I-bacteria
Y1706	I-bacteria
-	O
treated	O
mice	O
had	O
more	O
butyrate	O
-	O
producing	O
bacteria	O
,	O
such	O
as	O
Lactobacillus	B-bacteria
,	O
Bacteroides	B-bacteria
,	O
Ruminococcus	B-bacteria
,	O
and	O
Akkermansia	B-bacteria
,	O
although	O
the	O
level	O
of	O
Fecalibacterium	B-bacteria
was	O
significantly	O
reduced	O
.	O

Therefore	O
,	O
K	B-bacteria
.	I-bacteria
turicensis	I-bacteria
CAU	I-bacteria
Y1706	I-bacteria
modulates	O
immune	O
responses	O
as	O
well	O
as	O
gut	O
microbiota	O
,	O
thus	O
indicating	O
that	O
it	O
has	O
potential	O
for	O
application	O
as	O
a	O
supplement	O
for	O
alleviation	O
of	O
AD	O
.	O

MLKL	O
deficiency	O
inhibits	O
DSS	O
-	O
induced	O
colitis	O
independent	O
of	O
intestinal	O
microbiota	O
.	O

The	O
maintenance	O
of	O
intestinal	O
tissue	O
homeostasis	O
is	O
vital	O
for	O
the	O
resistance	O
against	O
inflammatory	O
bowel	O
diseases	O
(	O
IBDs	O
)	O
.	O

Necroptosis	O
is	O
identified	O
as	O
an	O
alternative	O
mode	O
of	O
regulated	O
cell	O
death	O
,	O
which	O
plays	O
a	O
pivotal	O
role	O
in	O
tissue	O
homeostasis	O
.	O

Thus	O
,	O
the	O
roles	O
of	O
RIP3	O
-	O
mediated	O
necroptosis	O
in	O
intestinal	O
inflammation	O
have	O
been	O
extensively	O
studied	O
.	O

However	O
,	O
the	O
biological	O
implications	O
of	O
the	O
mixed	O
lineage	O
kinase	O
-	O
like	O
protein	O
(	O
MLKL	O
)	O
,	O
a	O
molecule	O
downstream	O
of	O
RIP3	O
in	O
gut	O
remain	O
unclear	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
MLKL	O
in	O
DSS	O
-	O
induced	O
colitis	O
was	O
examined	O
,	O
and	O
the	O
contribution	O
of	O
gut	O
microbiota	O
was	O
also	O
determined	O
.	O

Compared	O
with	O
non	O
-	O
littermate	O
WT	O
mice	O
,	O
the	O
survival	O
rate	O
,	O
clinical	O
score	O
,	O
intestinal	O
damage	O
and	O
intestinal	O
mucosal	O
barrier	O
integrity	O
of	O
non	O
-	O
littermate	O
MLKL	O
-	O
deficient	O
mice	O
are	O
significantly	O
improved	O
.	O

MLKL	O
deficiency	O
prevents	O
inflammatory	O
cytokines	O
production	O
and	O
MAPK	O
signaling	O
activation	O
.	O

Hence	O
,	O
MLKL	O
deficiency	O
inhibits	O
DSS	O
-	O
induced	O
colitis	O
.	O

Moreover	O
,	O
we	O
proved	O
that	O
DSS	O
susceptibility	O
difference	O
between	O
two	O
genotypes	O
is	O
not	O
driven	O
by	O
intestinal	O
microbiota	O
based	O
on	O
the	O
co	O
-	O
housing	O
of	O
two	O
non	O
-	O
littermate	O
genotypes	O
and	O
qPCR	O
detection	O
of	O
fecal	O
dominant	O
bacterial	O
taxa	O
.	O

Diet	O
modulates	O
colonic	O
T	O
cell	O
responses	O
by	O
regulating	O
the	O
expression	O
of	O
a	O
Bacteroides	B-bacteria
thetaiotaomicron	I-bacteria
antigen	O
.	O

T	O
cell	O
responses	O
to	O
symbionts	O
in	O
the	O
intestine	O
drive	O
tolerance	O
or	O
inflammation	O
depending	O
on	O
the	O
genetic	O
background	O
of	O
the	O
host	O
.	O

These	O
symbionts	O
in	O
the	O
gut	O
sense	O
the	O
available	O
nutrients	O
and	O
adapt	O
their	O
metabolic	O
programs	O
to	O
use	O
these	O
nutrients	O
efficiently	O
.	O

Here	O
,	O
we	O
ask	O
whether	O
diet	O
can	O
alter	O
the	O
expression	O
of	O
a	O
bacterial	O
antigen	O
to	O
modulate	O
adaptive	O
immune	O
responses	O
.	O

We	O
generated	O
a	O
CD4	O
(	O
+	O
)	O
T	O
cell	O
hybridoma	O
,	O
BthetaOM	O
,	O
specific	O
for	O
Bacteroides	B-bacteria
thetaiotaomicron	I-bacteria
(	O
B	B-bacteria
.	I-bacteria
theta	I-bacteria
)	O
.	O

Adoptively	O
transferred	O
transgenic	O
T	O
cells	O
expressing	O
the	O
BthetaOM	O
TCR	O
proliferated	O
in	O
the	O
colon	O
,	O
colon	O
-	O
draining	O
lymph	O
node	O
,	O
and	O
spleen	O
in	O
B	O
.	O
theta	O
-	O
colonized	O
healthy	O
mice	O
and	O
differentiated	O
into	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
and	O
effector	O
T	O
cells	O
(	O
Teffs	O
)	O
.	O

Depletion	O
of	O
B	O
.	O
theta	O
-	O
specific	O
Tregs	O
resulted	O
in	O
colitis	O
,	O
showing	O
that	O
a	O
single	O
protein	O
expressed	O
by	O
B	B-bacteria
.	I-bacteria
theta	I-bacteria
can	O
drive	O
differentiation	O
of	O
Tregs	O
that	O
self	O
-	O
regulate	O
Teffs	O
to	O
prevent	O
disease	O
.	O

We	O
found	O
that	O
BthetaOM	O
T	O
cells	O
recognized	O
a	O
peptide	O
derived	O
from	O
a	O
single	O
B	B-bacteria
.	I-bacteria
theta	I-bacteria
protein	O
,	O
BT4295	O
,	O
whose	O
expression	O
is	O
regulated	O
by	O
nutrients	O
,	O
with	O
glucose	O
being	O
a	O
strong	O
catabolite	O
repressor	O
.	O

Mice	O
fed	O
a	O
high	O
-	O
glucose	O
diet	O
had	O
a	O
greatly	O
reduced	O
activation	O
of	O
BthetaOM	O
T	O
cells	O
in	O
the	O
colon	O
.	O

These	O
studies	O
establish	O
that	O
the	O
immune	O
response	O
to	O
specific	O
bacterial	O
antigens	O
can	O
be	O
modified	O
by	O
changes	O
in	O
the	O
diet	O
by	O
altering	O
antigen	O
expression	O
in	O
the	O
microbe	O
.	O

Clostridium	B-bacteria
scindens	I-bacteria
ATCC	I-bacteria
35704	I-bacteria
:	O
Integration	O
of	O
Nutritional	O
Requirements	O
,	O
the	O
Complete	O
Genome	O
Sequence	O
,	O
and	O
Global	O
Transcriptional	O
Responses	O
to	O
Bile	O
Acids	O
.	O

In	O
the	O
human	O
gut	O
,	O
Clostridium	B-bacteria
scindens	I-bacteria
ATCC	I-bacteria
35704	I-bacteria
is	O
a	O
predominant	O
bacterium	O
and	O
one	O
of	O
the	O
major	O
bile	O
acid	O
7alpha	O
-	O
dehydroxylating	O
anaerobes	O
.	O

While	O
this	O
organism	O
is	O
well	O
-	O
studied	O
relative	O
to	O
bile	O
acid	O
metabolism	O
,	O
little	O
is	O
known	O
about	O
the	O
basic	O
nutrition	O
and	O
physiology	O
of	O
C	B-bacteria
.	I-bacteria
scindens	I-bacteria
ATCC	I-bacteria
35704	I-bacteria
.	O

To	O
determine	O
the	O
amino	O
acid	O
and	O
vitamin	O
requirements	O
of	O
C	B-bacteria
.	I-bacteria
scindens	I-bacteria
,	O
the	O
leave	O
-	O
one	O
-	O
out	O
(	O
one	O
amino	O
acid	O
group	O
or	O
vitamin	O
)	O
technique	O
was	O
used	O
to	O
eliminate	O
the	O
nonessential	O
amino	O
acids	O
and	O
vitamins	O
.	O

With	O
this	O
approach	O
,	O
the	O
amino	O
acid	O
tryptophan	O
and	O
three	O
vitamins	O
(	O
riboflavin	O
,	O
pantothenate	O
,	O
and	O
pyridoxal	O
)	O
were	O
found	O
to	O
be	O
required	O
for	O
the	O
growth	O
of	O
C	O
.	O
scindens	I-bacteria
In	O
the	O
newly	O
developed	O
defined	O
medium	O
,	O
C	B-bacteria
.	I-bacteria
scindens	I-bacteria
fermented	O
glucose	O
mainly	O
to	O
ethanol	O
,	O
acetate	O
,	O
formate	O
,	O
and	O
H2	O
.	O

The	O
genome	O
of	O
C	B-bacteria
.	I-bacteria
scindens	I-bacteria
ATCC	I-bacteria
35704	I-bacteria
was	O
completed	O
through	O
PacBio	O
sequencing	O
.	O

Pathway	O
analysis	O
of	O
the	O
genome	O
sequence	O
coupled	O
with	O
transcriptome	O
sequencing	O
(	O
RNA	O
-	O
Seq	O
)	O
under	O
defined	O
culture	O
conditions	O
revealed	O
consistency	O
with	O
the	O
growth	O
requirements	O
and	O
end	O
products	O
of	O
glucose	O
metabolism	O
.	O

Induction	O
with	O
bile	O
acids	O
revealed	O
complex	O
and	O
differential	O
responses	O
to	O
cholic	O
acid	O
and	O
deoxycholic	O
acid	O
,	O
including	O
the	O
expression	O
of	O
potentially	O
novel	O
bile	O
acid	O
-	O
inducible	O
genes	O
involved	O
in	O
cholic	O
acid	O
metabolism	O
.	O

Responses	O
to	O
toxic	O
deoxycholic	O
acid	O
included	O
expression	O
of	O
genes	O
predicted	O
to	O
be	O
involved	O
in	O
DNA	O
repair	O
,	O
oxidative	O
stress	O
,	O
cell	O
wall	O
maintenance	O
/	O
metabolism	O
,	O
chaperone	O
synthesis	O
,	O
and	O
downregulation	O
of	O
one	O
-	O
third	O
of	O
the	O
genome	O
.	O

These	O
analyses	O
provide	O
valuable	O
insight	O
into	O
the	O
overall	O
biology	O
of	O
C	B-bacteria
.	I-bacteria
scindens	I-bacteria
which	O
may	O
be	O
important	O
in	O
treatment	O
of	O
disease	O
associated	O
with	O
increased	O
colonic	O
secondary	O
bile	O
acids	O
.	O

IMPORTANCE	O
C	B-bacteria
.	I-bacteria
scindens	I-bacteria
is	O
one	O
of	O
a	O
few	O
identified	O
gut	O
bacterial	O
species	O
capable	O
of	O
converting	O
host	O
cholic	O
acid	O
into	O
disease	O
-	O
associated	O
secondary	O
bile	O
acids	O
such	O
as	O
deoxycholic	O
acid	O
.	O

The	O
current	O
work	O
represents	O
an	O
important	O
advance	O
in	O
understanding	O
the	O
nutritional	O
requirements	O
and	O
response	O
to	O
bile	O
acids	O
of	O
the	O
medically	O
important	O
human	O
gut	O
bacterium	O
,	O
C	B-bacteria
.	I-bacteria
scindens	I-bacteria
ATCC	I-bacteria
35704	I-bacteria
.	O

A	O
defined	O
medium	O
has	O
been	O
developed	O
which	O
will	O
further	O
the	O
understanding	O
of	O
bile	O
acid	O
metabolism	O
in	O
the	O
context	O
of	O
growth	O
substrates	O
,	O
cofactors	O
,	O
and	O
other	O
metabolites	O
in	O
the	O
vertebrate	O
gut	O
.	O

Analysis	O
of	O
the	O
complete	O
genome	O
supports	O
the	O
nutritional	O
requirements	O
reported	O
here	O
.	O

Genome	O
-	O
wide	O
transcriptomic	O
analysis	O
of	O
gene	O
expression	O
in	O
the	O
presence	O
of	O
cholic	O
acid	O
and	O
deoxycholic	O
acid	O
provides	O
a	O
unique	O
insight	O
into	O
the	O
complex	O
response	O
of	O
C	B-bacteria
.	I-bacteria
scindens	I-bacteria
ATCC	I-bacteria
35704	O
to	O
primary	O
and	O
secondary	O
bile	O
acids	O
.	O

Also	O
revealed	O
are	O
genes	O
with	O
the	O
potential	O
to	O
function	O
in	O
bile	O
acid	O
transport	O
and	O
metabolism	O
.	O

Unveiling	O
Genomic	O
Diversity	O
among	O
Members	O
of	O
the	O
Species	O
Bifidobacterium	B-bacteria
pseudolongum	I-bacteria
,	O
a	O
Widely	O
Distributed	O
Gut	O
Commensal	O
of	O
the	O
Animal	O
Kingdom	O
.	O

Bifidobacteria	B-bacteria
are	O
commensals	O
of	O
the	O
animal	O
gut	O
and	O
are	O
commonly	O
found	O
in	O
mammals	O
,	O
birds	O
,	O
and	O
social	O
insects	O
.	O

Specifically	O
,	O
strains	O
of	O
Bifidobacterium	B-bacteria
adolescentis	I-bacteria
,	O
Bifidobacterium	B-bacteria
bifidum	I-bacteria
,	O
Bifidobacterium	B-bacteria
longum	I-bacteria
,	O
and	O
Bifidobacterium	B-bacteria
pseudolongum	I-bacteria
are	O
widely	O
distributed	O
in	O
the	O
mammalian	O
gut	O
.	O

In	O
this	O
context	O
,	O
we	O
investigated	O
the	O
genetic	O
variability	O
and	O
metabolic	O
abilities	O
of	O
the	O
B	B-bacteria
.	I-bacteria
pseudolongum	I-bacteria
taxon	O
,	O
whose	O
genomic	O
characterization	O
has	O
so	O
far	O
not	O
received	O
much	O
attention	O
.	O

Phylogenomic	O
analysis	O
of	O
the	O
genome	O
sequences	O
of	O
60	O
B	B-bacteria
.	I-bacteria
pseudolongum	I-bacteria
strains	I-bacteria
revealed	O
that	O
B	B-bacteria
.	I-bacteria
pseudolongum	I-bacteria
subsp	I-bacteria
.	I-bacteria
globosum	I-bacteria
and	O
B	B-bacteria
.	I-bacteria
pseudolongum	I-bacteria
subsp	I-bacteria
.	I-bacteria
pseudolongum	I-bacteria
may	O
actually	O
represent	O
two	O
distinct	O
bifidobacterial	B-bacteria
species	I-bacteria
.	O

Furthermore	O
,	O
our	O
analysis	O
highlighted	O
metabolic	O
differences	O
between	O
members	O
of	O
these	O
two	O
subspecies	O
.	O

Moreover	O
,	O
comparative	O
analyses	O
of	O
genetic	O
strategies	O
to	O
prevent	O
invasion	O
of	O
foreign	O
DNA	O
revealed	O
that	O
the	O
B	B-bacteria
.	I-bacteria
pseudolongum	I-bacteria
subsp	I-bacteria
.	I-bacteria
globosum	I-bacteria
group	O
exhibits	O
greater	O
genome	O
plasticity	O
.	O

In	O
fact	O
,	O
the	O
obtained	O
findings	O
indicate	O
that	O
B	B-bacteria
.	I-bacteria
pseudolongum	I-bacteria
subsp	I-bacteria
.	I-bacteria
globosum	I-bacteria
is	O
more	O
adaptable	O
to	O
different	O
ecological	O
niches	O
such	O
as	O
the	O
mammalian	O
and	O
avian	O
gut	O
than	O
is	O
B	B-bacteria
.	I-bacteria
pseudolongum	I-bacteria
subsp	I-bacteria
.	I-bacteria
pseudolongum	I-bacteria
IMPORTANCE	O
Currently	O
,	O
little	O
information	O
exists	O
on	O
the	O
genetics	O
of	O
the	O
B	B-bacteria
.	I-bacteria
pseudolongum	I-bacteria
taxon	O
due	O
to	O
the	O
limited	O
number	O
of	O
sequenced	O
genomes	O
belonging	O
to	O
this	O
species	O
.	O

In	O
order	O
to	O
survey	O
genome	O
variability	O
within	O
this	O
species	O
and	O
explore	O
how	O
members	O
of	O
this	O
taxon	O
evolved	O
as	O
commensals	O
of	O
the	O
animal	O
gut	O
,	O
we	O
isolated	O
and	O
decoded	O
the	O
genomes	O
of	O
51	O
newly	O
isolated	O
strains	O
.	O

Comparative	O
genomics	O
coupled	O
with	O
growth	O
profiles	O
on	O
different	O
carbohydrates	O
has	O
further	O
provided	O
insights	O
concerning	O
the	O
genotype	O
and	O
phenotype	O
of	O
members	O
of	O
the	O
B	B-bacteria
.	I-bacteria
pseudolongum	I-bacteria
taxon	O
.	O

The	O
Foodborne	O
Strain	O
Lactobacillus	B-bacteria
fermentum	I-bacteria
MBC2	I-bacteria
Triggers	O
pept	O
-	O
1	O
-	O
Dependent	O
Pro	O
-	O
Longevity	O
Effects	O
in	O
Caenorhabditis	O
elegans	O
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
are	O
involved	O
in	O
several	O
food	O
fermentations	O
and	O
many	O
of	O
them	O
provide	O
strain	O
-	O
specific	O
health	O
benefits	O
.	O

Herein	O
,	O
the	O
probiotic	O
potential	O
of	O
the	O
foodborne	O
strain	O
Lactobacillus	B-bacteria
fermentum	I-bacteria
MBC2	I-bacteria
was	O
investigated	O
through	O
in	O
vitro	O
and	O
in	O
vivo	O
approaches	O
.	O

Caenorhabditis	O
elegans	O
was	O
used	O
as	O
an	O
in	O
vivo	O
model	O
to	O
analyze	O
pro	O
-	O
longevity	O
and	O
anti	O
-	O
aging	O
effects	O
.	O

L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
MBC2	I-bacteria
showed	O
a	O
high	O
gut	O
colonization	O
capability	O
compared	O
to	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
OP50	I-bacteria
(	O
OP50	O
)	O
or	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
GG	I-bacteria
(	O
LGG	B-bacteria
)	O
.	O

Moreover	O
,	O
analysis	O
of	O
pumping	O
rate	O
,	O
lipofuscin	O
accumulation	O
,	O
and	O
body	O
bending	O
showed	O
anti	O
-	O
aging	O
effects	O
in	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
MBC2	O
-	O
fed	O
worms	O
.	O

Studies	O
on	O
PEPT	O
-	O
1	O
mutants	O
demonstrated	O
that	O
pept	O
-	O
1	O
gene	O
was	O
involved	O
in	O
the	O
anti	O
-	O
aging	O
processes	O
mediated	O
by	O
this	O
bacterial	O
strain	O
through	O
DAF	O
-	O
16	O
,	O
whereas	O
the	O
oxidative	O
stress	O
protection	O
was	O
PEPT	O
-	O
1	O
independent	O
.	O

Moreover	O
,	O
analysis	O
of	O
acid	O
tolerance	O
,	O
bile	O
tolerance	O
,	O
and	O
antibiotic	O
susceptibility	O
were	O
evaluated	O
.	O

L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
MBC2	I-bacteria
exerted	O
beneficial	O
effects	O
on	O
nematode	O
lifespan	O
,	O
influencing	O
energy	O
metabolism	O
and	O
oxidative	O
stress	O
resistance	O
,	O
resulted	O
in	O
being	O
tolerant	O
to	O
acidic	O
pH	O
and	O
able	O
to	O
adhere	O
to	O
Caco	O
-	O
2	O
cells	O
.	O

Overall	O
,	O
these	O
findings	O
provide	O
new	O
insight	O
for	O
application	O
of	O
this	O
strain	O
in	O
the	O
food	O
industry	O
as	O
a	O
newly	O
isolated	O
functional	O
starter	O
.	O

Furthermore	O
,	O
these	O
results	O
will	O
also	O
shed	O
light	O
on	O
C	O
.	O
elegans	O
molecular	O
players	O
involved	O
in	O
host	O
-	O
microbe	O
interactions	O
.	O

Impact	O
of	O
SchisandraChinensis	O
Bee	O
Pollen	O
on	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
and	O
Gut	O
Microbiota	O
in	O
HighFat	O
Diet	O
Induced	O
Obese	O
Mice	O
.	O

Schisandrachinensisbee	O
pollen	O
has	O
been	O
used	O
as	O
a	O
health	O
food	O
in	O
China	O
for	O
centuries	O
;	O
however	O
,	O
its	O
bioactive	O
constituents	O
and	O
functions	O
are	O
not	O
very	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
phenolic	O
compounds	O
of	O
Schisandrachinensisbee	O
pollen	O
extract	O
(	O
SCPE	O
)	O
by	O
UHPLC	O
-	O
Q	O
-	O
Orbitrap	O
-	O
HRMS	O
/	O
HPLC	O
-	O
DAD	O
-	O
ECD	O
and	O
its	O
prevention	O
from	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
and	O
modulation	O
of	O
gut	O
microbiota	O
in	O
high	O
fat	O
diet	O
induced	O
obese	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
results	O
showed	O
that	O
12	O
phenolic	O
compounds	O
were	O
identified	O
in	O
SCPE	O
,	O
and	O
naringenin	O
,	O
rutin	O
and	O
chrysin	O
were	O
the	O
main	O
constituents	O
.	O

The	O
content	O
of	O
naringenin	O
reached	O
1	O
.	O
89	O
mg	O
/	O
g	O
,	O
and	O
total	O
phenolic	O
content	O
(	O
TPC	O
)	O
of	O
SCPE	O
were	O
101	O
.	O
83	O
mg	O
GA	O
/	O
g	O
.	O

After	O
obese	O
mice	O
were	O
administrated	O
with	O
SCPE	O
at	O
7	O
.	O
86	O
and	O
15	O
.	O
72	O
g	O
/	O
kg	O
BW	O
for	O
8	O
weeks	O
,	O
body	O
weight	O
gains	O
were	O
reduced	O
by	O
18	O
.	O
23	O
%	O
and	O
19	O
.	O
37	O
%	O
.	O

SCPE	O
could	O
decrease	O
fasting	O
blood	O
glucose	O
,	O
cut	O
down	O
the	O
lipid	O
accumulation	O
in	O
serum	O
and	O
liver	O
,	O
lessen	O
oxidative	O
injury	O
and	O
inflammation	O
in	O
obesity	O
mice	O
.	O

Moreover	O
,	O
SCPE	O
could	O
effectively	O
inhibit	O
the	O
formation	O
of	O
NAFLD	O
by	O
inhibition	O
of	O
LXR	O
-	O
alpha	O
,	O
SREBP	O
-	O
1c	O
and	O
FAS	O
genes	O
expression	O
,	O
and	O
modulate	O
the	O
structural	O
alteration	O
of	O
gut	O
microbiota	O
in	O
obesity	O
mice	O
.	O

These	O
findings	O
suggested	O
that	O
SCPE	O
could	O
attenuate	O
the	O
features	O
of	O
the	O
metabolism	O
syndrome	O
in	O
obesity	O
mice	O
,	O
which	O
can	O
be	O
used	O
to	O
prevent	O
obesity	O
and	O
NAFLD	O
of	O
human	O
beings	O
.	O

Effects	O
of	O
polyethylene	O
microplastics	O
on	O
the	O
gut	O
microbial	O
community	O
,	O
reproduction	O
and	O
avoidance	O
behaviors	O
of	O
the	O
soil	O
springtail	O
,	O
Folsomia	O
candida	O
.	O

Microplastics	O
(	O
MPs	O
)	O
are	O
an	O
emerging	O
contaminant	O
and	O
are	O
confirmed	O
to	O
be	O
ubiquitous	O
in	O
the	O
environment	O
.	O

Adverse	O
effects	O
of	O
MPs	O
on	O
aquatic	O
organisms	O
have	O
been	O
widely	O
studied	O
,	O
whereas	O
little	O
research	O
has	O
focused	O
on	O
soil	O
invertebrates	O
.	O

We	O
exposed	O
the	O
soil	O
springtail	O
Folsomia	O
candida	O
to	O
artificial	O
soils	O
contaminated	O
with	O
polyethylene	O
MPs	O
(	O
<	O
500mum	O
)	O
for	O
28d	O
to	O
explore	O
the	O
effects	O
of	O
MPs	O
on	O
avoidance	O
,	O
reproduction	O
,	O
and	O
gut	O
microbiota	O
.	O

Springtails	O
exhibited	O
avoidance	O
behaviors	O
at	O
0	O
.	O
5	O
%	O
and	O
1	O
%	O
MPs	O
(	O
w	O
/	O
w	O
in	O
dry	O
soil	O
)	O
,	O
and	O
the	O
avoidance	O
rate	O
was	O
59	O
%	O
and	O
69	O
%	O
,	O
respectively	O
.	O

Reproduction	O
was	O
inhibited	O
when	O
the	O
concentration	O
of	O
MPs	O
reached	O
0	O
.	O
1	O
%	O
and	O
was	O
reduced	O
by	O
70	O
.	O
2	O
%	O
at	O
the	O
highest	O
concentration	O
of	O
1	O
%	O
MPs	O
compared	O
to	O
control	O
.	O

The	O
half	O
-	O
maximal	O
effective	O
concentration	O
(	O
EC50	O
)	O
value	O
based	O
on	O
reproduction	O
for	O
F	O
.	O
candida	O
was	O
0	O
.	O
29	O
%	O
MPs	O
.	O

At	O
concentrations	O
of	O
0	O
.	O
5	O
%	O
dry	O
weight	O
in	O
the	O
soil	O
,	O
MPs	O
significantly	O
altered	O
the	O
microbial	O
community	O
and	O
decreased	O
bacterial	O
diversity	O
in	O
the	O
springtail	O
gut	O
.	O

Specifically	O
,	O
the	O
relative	O
abundance	O
of	O
Wolbachia	O
significantly	O
decreased	O
while	O
the	O
relative	O
abundance	O
of	O
Bradyrhizobiaceae	B-bacteria
,	O
Ensifer	B-bacteria
and	O
Stenotrophomonas	B-bacteria
significantly	O
increased	O
.	O

Our	O
results	O
demonstrated	O
that	O
MPs	O
exerted	O
a	O
significant	O
toxic	O
effect	O
on	O
springtails	O
and	O
can	O
change	O
their	O
gut	O
microbial	O
community	O
.	O

This	O
can	O
provide	O
useful	O
information	O
for	O
risk	O
assessment	O
of	O
MPs	O
in	O
terrestrial	O
ecosystems	O
.	O

A	O
Fruitful	O
Discovery	O
:	O
Can	O
Gut	O
Bacteria	O
Control	O
Hyperactive	O
Behavior	O
?	O

In	O
a	O
recent	O
publication	O
in	O
Nature	O
,	O
Schretter	O
et	O
al	O
.	O
(	O
2018	O
)	O
demonstrated	O
in	O
the	O
fruit	O
fly	O
Drosophila	O
melanogaster	O
how	O
an	O
enzyme	O
from	O
specific	O
gut	O
bacteria	O
(	O
Lactobacillus	B-bacteria
brevis	O
)	O
regulates	O
locomotor	O
behavior	O
through	O
carbohydrate	O
metabolism	O
.	O

Effects	O
of	O
Eclipta	O
prostrata	O
on	O
gut	O
microbiota	O
of	O
SAMP6	O
mice	O
with	O
osteoporosis	O
.	O

PURPOSE	O
:	O
Traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
has	O
been	O
extensively	O
studied	O
for	O
its	O
preventive	O
and	O
treatment	O
properties	O
toward	O
osteoporosis	O
(	O
OP	O
)	O
.	O

Pharmacological	O
studies	O
have	O
shown	O
that	O
TCM	O
Eclipta	O
prostrata	O
induce	O
anti	O
-	O
OP	O
effects	O
.	O

Considering	O
the	O
growing	O
evidence	O
demonstrating	O
that	O
gut	O
microbiota	O
(	O
GM	O
)	O
is	O
related	O
to	O
OP	O
,	O
we	O
aimed	O
to	O
study	O
the	O
GM	O
-	O
dependent	O
function	O
and	O
mechanism	O
of	O
E	O
.	O
prostrata	O
for	O
preventing	O
OP	O
in	O
mice	O
.	O

METHODOLOGY	O
:	O
Bone	O
micro	O
-	O
structure	O
was	O
obtained	O
using	O
micro	O
-	O
computed	O
tomography	O
(	O
micro	O
-	O
CT	O
)	O
and	O
bone	O
-	O
relating	O
factors	O
were	O
detected	O
by	O
molecular	O
biological	O
test	O
.	O

High	O
-	O
throughput	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
V4	O
region	O
was	O
performed	O
for	O
GM	O
diversity	O
analysis	O
.	O

Growth	O
effects	O
of	O
E	O
.	O
prostrata	O
on	O
potential	O
targeted	O
strains	O
Lactobacillus	B-bacteria
and	O
Lactococcus	B-bacteria
were	O
investigated	O
by	O
in	O
vitro	O
bacterial	O
assay	O
.	O

By	O
feeding	O
Lactobacillus	B-bacteria
and	O
Lactococcus	B-bacteria
in	O
mice	O
,	O
GM	O
and	O
bone	O
condition	O
were	O
analysed	O
.	O

RESULTS	O
:	O
Bone	O
micro	O
-	O
structure	O
was	O
significantly	O
improved	O
by	O
E	O
.	O
prostrata	O
with	O
a	O
potential	O
mechanism	O
of	O
inhibiting	O
osteoclast	O
,	O
increasing	O
the	O
number	O
of	O
osteoblasts	O
and	O
regulating	O
the	O
dynamic	O
balance	O
of	O
bone	O
absorption	O
and	O
formation	O
.	O

Sequencing	O
results	O
indicated	O
that	O
E	O
.	O
prostrata	O
altered	O
the	O
bacterial	O
community	O
.	O

The	O
abundance	O
of	O
bacteria	O
genera	O
Lactobacillus	B-bacteria
and	O
Lactococcus	B-bacteria
was	O
markedly	O
decreased	O
in	O
individuals	O
with	O
OP	O
and	O
positively	O
correlated	O
with	O
high	O
dose	O
of	O
E	O
.	O
prostrata	O
.	O

GM	O
of	O
the	O
low	O
-	O
dose	O
E	O
.	O
prostrata	O
-	O
fed	O
group	O
did	O
not	O
significantly	O
differ	O
from	O
that	O
of	O
the	O
chow	O
-	O
fed	O
OP	O
group	O
,	O
which	O
was	O
consistent	O
with	O
bone	O
structure	O
test	O
results	O
.	O

Moreover	O
,	O
E	O
.	O
prostrata	O
could	O
promote	O
Lactobacillus	B-bacteria
and	O
Lactococcus	B-bacteria
growth	O
in	O
vitro	O
.	O

GM	O
was	O
altered	O
and	O
bone	O
condition	O
was	O
improved	O
via	O
bacterial	O
feeding	O
in	O
vivo	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggested	O
that	O
E	O
.	O
prostrata	O
might	O
be	O
a	O
novel	O
therapy	O
for	O
OP	O
prevention	O
by	O
targeting	O
GM	O
.	O

Gut	O
bacteria	O
linked	O
to	O
mental	O
well	O
-	O
being	O
and	O
depression	O
.	O

Fecal	O
microbiota	O
transplantation	O
before	O
or	O
after	O
allogeneic	O
hematopoietic	O
transplantation	O
in	O
patients	O
with	O
hematological	O
malignancies	O
carrying	O
multidrug	O
-	O
resistance	O
bacteria	O
.	O

Fecal	O
microbiota	O
transplantation	O
is	O
an	O
effective	O
treatment	O
in	O
recurrent	O
Clostridium	B-bacteria
difficile	I-bacteria
infection	O
.	O

Promising	O
results	O
to	O
eradicate	O
multidrug	O
-	O
resistant	O
bacteria	O
have	O
also	O
been	O
reported	O
with	O
this	O
procedure	O
,	O
but	O
there	O
are	O
safety	O
concerns	O
in	O
immunocompromised	O
patients	O
.	O

We	O
report	O
results	O
in	O
10	O
adult	O
patients	O
colonized	O
with	O
multidrug	O
-	O
resistant	O
bacteria	O
,	O
undergoing	O
fecal	O
microbiota	O
transplantation	O
before	O
(	O
n	O
=	O
4	O
)	O
or	O
after	O
(	O
n	O
=	O
6	O
)	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
for	O
hematologic	O
malignancies	O
.	O

Stools	O
were	O
obtained	O
from	O
healthy	O
related	O
or	O
unrelated	O
donors	O
.	O

Fecal	O
material	O
was	O
delivered	O
either	O
by	O
enema	O
or	O
via	O
nasogastric	O
tube	O
.	O

Patients	O
were	O
colonized	O
or	O
had	O
infections	O
from	O
either	O
carbapenemase	O
-	O
producing	O
bacteria	O
(	O
n	O
=	O
8	O
)	O
or	O
vancomycin	B-bacteria
-	I-bacteria
resistant	I-bacteria
enterococci	I-bacteria
(	O
n	O
=	O
2	O
)	O
.	O

The	O
median	O
age	O
at	O
fecal	O
microbiota	O
transplantation	O
was	O
48	O
(	O
range	O
16	O
-	O
64	O
)	O
years	O
.	O

Three	O
patients	O
needed	O
a	O
second	O
transplant	O
from	O
the	O
same	O
donor	O
,	O
due	O
to	O
initial	O
failure	O
of	O
the	O
procedure	O
.	O

With	O
a	O
median	O
follow	O
-	O
up	O
of	O
13	O
(	O
range	O
4	O
-	O
40	O
)	O
months	O
,	O
decolonization	O
was	O
achieved	O
in	O
seven	O
out	O
of	O
ten	O
patients	O
.	O

In	O
all	O
patients	O
,	O
fecal	O
microbiota	O
transplantation	O
was	O
safe	O
:	O
one	O
patient	O
presented	O
with	O
constipation	O
during	O
the	O
first	O
5	O
days	O
after	O
FMT	O
and	O
2	O
patients	O
had	O
grade	O
I	O
diarrhea	O
.	O

One	O
case	O
of	O
gut	O
grade	O
III	O
acute	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
occurred	O
after	O
fecal	O
microbiota	O
transplantation	O
.	O

In	O
patients	O
carrying	O
or	O
infected	O
by	O
multidrug	O
-	O
resistant	O
bacteria	O
,	O
fecal	O
microbiota	O
transplantation	O
is	O
an	O
effective	O
and	O
safe	O
decolonization	O
strategy	O
,	O
even	O
in	O
those	O
with	O
hematologic	O
malignancies	O
undergoing	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

Pinning	O
down	O
the	O
role	O
of	O
common	O
luminal	O
intestinal	O
parasitic	O
protists	O
in	O
human	O
health	O
and	O
disease	O
-	O
status	O
and	O
challenges	O
.	O

While	O
some	O
single	O
-	O
celled	O
intestinal	O
parasites	O
are	O
direct	O
causes	O
of	O
diarrhoea	O
and	O
other	O
types	O
of	O
intestinal	O
pathology	O
,	O
the	O
impact	O
of	O
other	O
gut	O
micro	O
-	O
eukaryotes	O
on	O
human	O
health	O
remains	O
elusive	O
.	O

The	O
fact	O
that	O
some	O
common	O
luminal	O
intestinal	O
parasitic	O
protists	O
(	O
CLIPPs	O
)	O
have	O
lately	O
been	O
found	O
more	O
often	O
in	O
healthy	O
than	O
in	O
diseased	O
individuals	O
has	O
fuelled	O
the	O
hypothesis	O
that	O
some	O
parasites	O
might	O
in	O
fact	O
be	O
protective	O
against	O
disease	O
.	O

To	O
this	O
end	O
,	O
the	O
use	O
of	O
new	O
DNA	O
technologies	O
has	O
helped	O
us	O
investigate	O
trans	O
-	O
kingdom	O
relationships	O
in	O
the	O
gut	O
.	O

However	O
,	O
research	O
into	O
these	O
relationships	O
is	O
currently	O
hampered	O
by	O
the	O
limited	O
data	O
available	O
on	O
the	O
genetic	O
diversity	O
within	O
the	O
CLIPPs	O
genera	O
,	O
which	O
results	O
in	O
limited	O
efficacy	O
of	O
publicly	O
available	O
DNA	O
sequence	O
databases	O
for	O
taxonomic	O
annotation	O
of	O
sequences	O
belonging	O
to	O
the	O
eukaryotic	O
component	O
of	O
the	O
gut	O
microbiota	O
.	O

In	O
this	O
paper	O
,	O
I	O
give	O
a	O
brief	O
overview	O
of	O
the	O
status	O
on	O
CLIPPs	O
in	O
human	O
health	O
and	O
disease	O
and	O
challenges	O
related	O
to	O
the	O
mapping	O
of	O
intestinal	O
eukaryotic	O
diversity	O
of	O
the	O
human	O
gut	O
.	O

Dynamics	O
of	O
the	O
Gut	O
Microbiota	O
in	O
Children	O
Receiving	O
Selective	O
or	O
Total	O
Gut	O
Decontamination	O
Treatment	O
during	O
Hematopoietic	O
Stem	O
Cell	O
Transplantation	O
.	O

Bloodstream	O
infections	O
and	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
are	O
common	O
complications	O
after	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
procedures	O
,	O
associated	O
with	O
the	O
gut	O
microbiota	O
that	O
acts	O
as	O
a	O
reservoir	O
for	O
opportunistic	O
pathogens	O
.	O

Selective	O
gut	O
decontamination	O
(	O
SGD	O
)	O
and	O
total	O
gut	O
decontamination	O
(	O
TGD	O
)	O
during	O
HSCT	O
have	O
been	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
developing	O
these	O
complications	O
after	O
transplantation	O
.	O

However	O
,	O
because	O
studies	O
have	O
shown	O
conflicting	O
results	O
,	O
the	O
use	O
of	O
these	O
treatments	O
remains	O
subject	O
of	O
debate	O
.	O

In	O
addition	O
,	O
their	O
impact	O
on	O
the	O
gut	O
microbiota	O
is	O
not	O
well	O
studied	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
dynamics	O
of	O
the	O
microbiota	O
during	O
and	O
after	O
TGD	O
and	O
to	O
compare	O
these	O
with	O
the	O
dynamics	O
of	O
SGD	O
.	O

In	O
this	O
prospective	O
,	O
observational	O
,	O
single	O
-	O
center	O
study	O
fecal	O
samples	O
were	O
longitudinally	O
collected	O
from	O
19	O
children	O
eligible	O
for	O
allogenic	O
HSCT	O
(	O
TGD	O
,	O
n	O
=	O
12	O
;	O
SGD	O
,	O
n	O
=	O
7	O
)	O
,	O
weekly	O
during	O
hospital	O
admission	O
and	O
monthly	O
after	O
discharge	O
.	O

In	O
addition	O
,	O
fecal	O
samples	O
were	O
collected	O
from	O
3	O
family	O
stem	O
cell	O
donors	O
.	O

Fecal	O
microbiota	O
structure	O
of	O
patients	O
and	O
donors	O
was	O
determined	O
by	O
16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
.	O

Microbiota	O
richness	O
and	O
diversity	O
markedly	O
decreased	O
during	O
SGD	O
and	O
TGD	O
and	O
gradually	O
increased	O
after	O
cessation	O
of	O
decontamination	O
treatment	O
.	O

During	O
SGD	O
,	O
gut	O
microbiota	O
composition	O
was	O
relatively	O
stable	O
and	O
dominated	O
by	O
Bacteroides	B-bacteria
,	O
whereas	O
it	O
showed	O
high	O
inter	O
-	O
and	O
intraindividual	O
variation	O
and	O
low	O
Bacteroides	B-bacteria
abundance	O
during	O
TGD	O
.	O

In	O
some	O
children	O
TGD	O
allowed	O
the	O
genera	O
Enterococcus	B-bacteria
and	O
Streptococcus	B-bacteria
to	O
thrive	O
during	O
treatment	O
.	O

A	O
gut	O
microbiota	O
dominated	O
by	O
Bacteroides	B-bacteria
was	O
associated	O
with	O
increased	O
predicted	O
activity	O
of	O
several	O
metabolic	O
processes	O
.	O

Comparing	O
the	O
microbiota	O
of	O
recipients	O
and	O
their	O
donors	O
indicated	O
that	O
receiving	O
an	O
SCT	O
did	O
not	O
alter	O
the	O
patient	O
'	O
s	O
microbiota	O
to	O
become	O
more	O
similar	O
to	O
that	O
of	O
its	O
donor	O
.	O

Overall	O
,	O
our	O
findings	O
indicate	O
that	O
SGD	O
and	O
TGD	O
affect	O
gut	O
microbiota	O
structure	O
in	O
a	O
treatment	O
-	O
specific	O
manner	O
.	O

Whether	O
these	O
treatments	O
affect	O
clinical	O
outcomes	O
via	O
interference	O
with	O
the	O
gut	O
microbiota	O
needs	O
to	O
be	O
further	O
elucidated	O
.	O

Assessing	O
intestinal	O
permeability	O
in	O
Crohn	O
'	O
s	O
disease	O
patients	O
using	O
orally	O
administered	O
52Cr	O
-	O
EDTA	O
.	O

BACKGROUND	O
:	O
Intestinal	O
permeability	O
can	O
be	O
assessed	O
by	O
monitoring	O
renal	O
excretion	O
of	O
orally	O
administered	O
radioactively	O
51Cr	O
-	O
labeled	O
ethylenediaminetetraacetic	O
acid	O
(	O
51Cr	O
-	O
EDTA	O
)	O
.	O

Although	O
considered	O
safe	O
,	O
patient	O
participation	O
in	O
using	O
radio	O
-	O
labeled	O
tracers	O
is	O
low	O
.	O

Here	O
,	O
we	O
used	O
orally	O
administered	O
52Cr	O
-	O
EDTA	O
as	O
non	O
-	O
radioactive	O
alternative	O
to	O
assess	O
intestinal	O
permeability	O
in	O
CD	O
and	O
analyzed	O
the	O
association	O
with	O
disease	O
activity	O
,	O
disease	O
location	O
and	O
gut	O
microbial	O
dysbiosis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
60	O
CD	O
patients	O
with	O
low	O
(	O
n	O
=	O
25	O
)	O
and	O
increased	O
(	O
n	O
=	O
35	O
)	O
fecal	O
calprotectin	O
levels	O
(	O
cut	O
-	O
off	O
:	O
100	O
mug	O
/	O
g	O
feces	O
)	O
ingested	O
20	O
mL	O
52Cr	O
-	O
EDTA	O
(	O
20	O
mmol	O
/	O
L	O
)	O
solution	O
whereafter	O
24	O
-	O
h	O
urine	O
was	O
collected	O
.	O

Urinary	O
52Cr	O
-	O
EDTA	O
concentrations	O
were	O
quantified	O
using	O
Inductively	O
Coupled	O
Plasma	O
Mass	O
Spectrometry	O
(	O
ICP	O
-	O
MS	O
)	O
.	O

Fecal	O
Enterobacteriaceae	B-bacteria
and	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
were	O
quantified	O
using	O
FISH	O
.	O

Correlations	O
between	O
urinary	O
52Cr	O
-	O
EDTA	O
excretion	O
and	O
other	O
parameters	O
were	O
established	O
using	O
nonparametric	O
Spearman	O
'	O
s	O
correlation	O
coefficients	O
(	O
rho	O
)	O
.	O

RESULTS	O
:	O
CD	O
patients	O
with	O
increased	O
fecal	O
calprotectin	O
levels	O
(	O
>	O
100	O
mug	O
/	O
g	O
)	O
demonstrated	O
an	O
elevated	O
urinary	O
52Cr	O
-	O
EDTA	O
/	O
creatinine	O
ratio	O
(	O
772	O
vs	O
.	O
636	O
mumol	O
/	O
mol	O
,	O
P	O
=	O
0	O
.	O
132	O
)	O
.	O

Patients	O
with	O
primarily	O
colonic	O
disease	O
showed	O
the	O
highest	O
52Cr	O
-	O
EDTA	O
excretion	O
.	O

Importantly	O
,	O
a	O
positive	O
correlation	O
was	O
observed	O
for	O
the	O
urinary	O
52Cr	O
-	O
EDTA	O
/	O
creatinine	O
ratio	O
and	O
fecal	O
calprotectin	O
levels	O
(	O
rho	O
=	O
0	O
.	O
325	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Finally	O
,	O
urinary	O
52Cr	O
-	O
EDTA	O
/	O
creatinine	O
ratio	O
negatively	O
correlated	O
with	O
the	O
relative	O
abundance	O
of	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
(	O
rho	O
=	O
-	O
0	O
.	O
221	O
,	O
P	O
=	O
0	O
.	O
092	O
)	O
,	O
while	O
positively	O
correlating	O
with	O
Enterobacteriaceae	B-bacteria
(	O
rho	O
=	O
0	O
.	O
202	O
,	O
P	O
=	O
0	O
.	O
126	O
)	O
.	O

CONCLUSIONS	O
:	O
Orally	O
administered	O
and	O
renal	O
excreted	O
52Cr	O
-	O
EDTA	O
may	O
be	O
used	O
to	O
assess	O
intestinal	O
permeability	O
in	O
CD	O
and	O
correlates	O
with	O
fecal	O
calprotectin	O
levels	O
and	O
bacterial	O
species	O
relevant	O
to	O
CD	O
.	O

This	O
test	O
may	O
improve	O
non	O
-	O
invasive	O
detection	O
of	O
disease	O
exacerbations	O
and	O
help	O
monitor	O
disease	O
activity	O
.	O

Selecting	O
a	O
Single	O
Stereocenter	O
:	O
The	O
Molecular	O
Nuances	O
That	O
Differentiate	O
beta	O
-	O
Hexuronidases	O
in	O
the	O
Human	O
Gut	O
Microbiome	O
.	O

The	O
human	O
gut	O
microbiome	O
is	O
a	O
ripe	O
space	O
for	O
the	O
discovery	O
of	O
new	O
proteins	O
and	O
novel	O
functions	O
.	O

Many	O
genes	O
in	O
the	O
gut	O
microbiome	O
encode	O
glycoside	O
hydrolases	O
that	O
help	O
bacteria	O
scavenge	O
sugars	O
present	O
in	O
the	O
human	O
gut	O
.	O

Glycoside	O
hydrolase	O
family	O
2	O
(	O
GH2	O
)	O
is	O
one	O
group	O
of	O
sugar	O
-	O
scavenging	O
proteins	O
,	O
which	O
includes	O
beta	O
-	O
glucuronidases	O
(	O
GUS	O
)	O
and	O
beta	O
-	O
galacturonidases	O
(	O
GalAses	O
)	O
,	O
enzymes	O
that	O
cleave	O
the	O
sugar	O
conjugates	O
of	O
the	O
epimers	O
glucuronate	O
and	O
galacturonate	O
.	O

Here	O
we	O
structurally	O
and	O
functionally	O
characterize	O
a	O
GH2	O
GalAse	O
and	O
a	O
hybrid	O
GUS	O
/	O
GalAse	O
,	O
which	O
reveal	O
the	O
molecular	O
details	O
that	O
enable	O
these	O
GHs	O
to	O
differentiate	O
a	O
single	O
stereocenter	O
.	O

First	O
,	O
we	O
characterized	O
a	O
previously	O
annotated	O
GUS	O
from	O
Eisenbergiella	B-bacteria
tayi	I-bacteria
and	O
demonstrated	O
that	O
it	O
is	O
,	O
in	O
fact	O
,	O
a	O
GalAse	O
.	O

We	O
determined	O
the	O
crystal	O
structure	O
of	O
this	O
GalAse	O
,	O
identified	O
the	O
key	O
residue	O
that	O
confers	O
GalAse	O
activity	O
,	O
and	O
convert	O
this	O
GalAse	O
into	O
a	O
GUS	O
by	O
mutating	O
a	O
single	O
residue	O
.	O

We	O
performed	O
bioinformatic	O
analysis	O
of	O
279	O
putative	O
GUS	O
enzymes	O
from	O
the	O
human	O
gut	O
microbiome	O
and	O
identified	O
12	O
additional	O
putative	O
GH2	O
GalAses	O
,	O
one	O
of	O
which	O
we	O
characterized	O
and	O
confirmed	O
is	O
a	O
GalAse	O
.	O

Lastly	O
,	O
we	O
report	O
the	O
structure	O
of	O
a	O
hybrid	O
GUS	O
/	O
GalAse	O
from	O
Fusicatenibacter	B-bacteria
saccharivorans	I-bacteria
,	O
which	O
revealed	O
a	O
unique	O
hexamer	O
that	O
positions	O
the	O
N	O
-	O
terminus	O
of	O
adjacent	O
protomers	O
in	O
the	O
aglycone	O
binding	O
site	O
.	O

Taken	O
together	O
,	O
these	O
data	O
reveal	O
a	O
new	O
class	O
of	O
bacterial	O
GalAses	O
in	O
the	O
human	O
gut	O
microbiome	O
and	O
unravel	O
the	O
structural	O
details	O
that	O
differentiate	O
GH2	O
GUSs	O
and	O
GalAses	O
.	O

Characterization	O
of	O
a	O
phospholipid	O
-	O
regulated	O
beta	O
-	O
galactosidase	O
from	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
involved	O
in	O
mucin	O
degradation	O
.	O

The	O
gut	O
microbe	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
is	O
important	O
for	O
the	O
human	O
health	O
as	O
the	O
occurrence	O
of	O
the	O
organism	O
is	O
inversely	O
correlated	O
with	O
different	O
metabolic	O
disorders	O
.	O

The	O
metabolism	O
of	O
the	O
organism	O
includes	O
the	O
degradation	O
of	O
intestinal	O
mucins	O
.	O

Thus	O
,	O
the	O
gut	O
health	O
-	O
promoting	O
properties	O
are	O
not	O
immediately	O
obvious	O
and	O
mechanisms	O
of	O
bacteria	O
-	O
host	O
interactions	O
are	O
mostly	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
a	O
novel	O
extracellular	O
beta	O
-	O
galactosidase	O
(	O
Amuc	O
_	O
1686	O
)	O
with	O
a	O
preference	O
for	O
linkages	O
from	O
the	O
type	O
Galbeta1	O
-	O
3GalNAc	O
.	O

Additionally	O
,	O
Amuc	O
_	O
1686	O
possesses	O
a	O
discoidin	O
-	O
like	O
domain	O
,	O
which	O
enables	O
the	O
interaction	O
with	O
anionic	O
phospholipids	O
.	O

We	O
detected	O
a	O
strong	O
inhibition	O
by	O
phosphatidylserine	O
,	O
phosphatidylglycerol	O
,	O
phosphatidic	O
acid	O
,	O
and	O
lysophosphatidic	O
acid	O
while	O
phosphatidylcholine	O
and	O
phosphatidylethanolamine	O
had	O
no	O
influence	O
.	O

Amuc	O
_	O
1686	O
is	O
the	O
first	O
example	O
of	O
a	O
prokaryotic	O
hydrolase	O
that	O
is	O
strongly	O
inhibited	O
by	O
certain	O
phospholipids	O
.	O

These	O
inhibiting	O
phospholipids	O
have	O
important	O
signal	O
functions	O
in	O
immune	O
response	O
and	O
cell	O
clearance	O
processes	O
.	O

Hence	O
,	O
Amuc	O
_	O
1686	O
might	O
be	O
regulated	O
based	O
on	O
the	O
health	O
status	O
of	O
the	O
large	O
intestine	O
and	O
could	O
therefore	O
contribute	O
to	O
the	O
mutualistic	O
relationship	O
between	O
the	O
microbe	O
and	O
the	O
host	O
on	O
a	O
molecular	O
level	O
.	O

In	O
this	O
sense	O
,	O
Amuc	O
_	O
1686	O
could	O
act	O
as	O
an	O
altruistic	O
enzyme	O
that	O
does	O
not	O
attack	O
the	O
mucin	O
layer	O
of	O
apoptotic	O
epithelial	O
cells	O
to	O
ensure	O
tissue	O
regeneration	O
,	O
for	O
example	O
,	O
in	O
areas	O
with	O
inflammatory	O
damages	O
.	O

Mast	O
cells	O
participate	O
in	O
regulation	O
of	O
lung	O
-	O
gut	O
axis	O
during	O
Staphylococcus	B-bacteria
aureus	I-bacteria
pneumonia	O
.	O

OBJECTIVES	O
:	O
The	O
lung	O
-	O
gut	O
axis	O
is	O
known	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Staphylococcus	B-bacteria
aureus	I-bacteria
pneumonia	I-bacteria
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
remain	O
unclear	O
.	O

We	O
examined	O
the	O
role	O
of	O
pulmonary	O
mast	O
cells	O
(	O
MCs	O
)	O
in	O
the	O
regulation	O
of	O
the	O
lung	O
-	O
gut	O
axis	O
during	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
pneumonia	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
created	O
a	O
mouse	O
model	O
of	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
pneumonia	O
using	O
MC	O
-	O
deficient	O
mice	O
(	O
Kit	O
(	O
W	O
-	O
sh	O
/	O
W	O
-	O
sh	O
)	O
)	O
and	O
examined	O
the	O
level	O
of	O
inflammation	O
,	O
bacterial	O
burden	O
,	O
expression	O
of	O
cathelicidin	O
-	O
related	O
antimicrobial	O
peptide	O
(	O
CRAMP	O
)	O
and	O
composition	O
of	O
the	O
gut	O
microbiota	O
.	O

We	O
further	O
evaluated	O
anti	O
-	O
bacterial	O
immunity	O
by	O
administering	O
bone	O
marrow	O
MCs	O
(	O
BMMCs	O
)	O
or	O
CRAMP	O
into	O
the	O
lungs	O
of	O
Kit	O
(	O
W	O
-	O
sh	O
/	O
W	O
-	O
sh	O
)	O
mice	O
.	O

RESULTS	O
:	O
After	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
challenge	O
,	O
the	O
MC	O
-	O
deficient	O
mice	O
,	O
compared	O
with	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
,	O
displayed	O
attenuated	O
lung	O
inflammation	O
,	O
decreased	O
expression	O
of	O
CRAMP	O
,	O
higher	O
bacterial	O
lung	O
load	O
and	O
disturbance	O
of	O
the	O
intestinal	O
microbiota	O
.	O

Adoptive	O
transfer	O
of	O
BMMCs	O
into	O
the	O
lung	O
effectively	O
reconstituted	O
the	O
host	O
defence	O
against	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
in	O
Kit	O
(	O
W	O
-	O
sh	O
/	O
W	O
-	O
sh	O
)	O
mice	O
,	O
thus	O
resulting	O
in	O
recovery	O
of	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
pneumonia	O
-	O
induced	O
intestinal	O
dysfunction	O
.	O

Similarly	O
,	O
exogenous	O
administration	O
of	O
CRAMP	O
significantly	O
enhanced	O
anti	O
-	O
bacterial	O
immunity	O
in	O
the	O
lungs	O
of	O
MC	O
-	O
deficient	O
mice	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
evidence	O
for	O
the	O
involvement	O
of	O
MCs	O
in	O
the	O
regulation	O
of	O
the	O
lung	O
-	O
gut	O
axis	O
during	O
S	B-bacteria
.	I-bacteria
aureus	I-bacteria
pneumonia	O
.	O

In	O
vitro	O
fermentation	O
of	O
arabinoxylan	O
from	O
oat	O
(	O
Avena	O
sativa	O
L	O
.	O
)	O
by	O
Pekin	O
duck	O
intestinal	O
microbiota	O
.	O

Arabinoxylan	O
(	O
AX	O
)	O
is	O
abundant	O
in	O
cereal	O
grains	O
used	O
as	O
feed	O
for	O
ducks	O
.	O

However	O
,	O
the	O
duck	O
intestinal	O
microbes	O
responsible	O
for	O
the	O
degradation	O
of	O
AX	O
are	O
not	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
oat	O
AX	O
was	O
degraded	O
and	O
utilized	O
by	O
different	O
duck	O
intestinal	O
microbiota	O
in	O
vitro	O
.	O

Changes	O
in	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
branch	O
-	O
chain	O
fatty	O
acids	O
,	O
and	O
the	O
pH	O
resulted	O
from	O
a	O
72	O
-	O
h	O
AX	O
fermentation	O
in	O
intestinal	O
samples	O
were	O
measured	O
.	O

The	O
addition	O
of	O
AX	O
increased	O
the	O
concentration	O
of	O
isobutyric	O
acid	O
and	O
decreased	O
the	O
concentrations	O
of	O
SCFAs	O
.	O

The	O
pH	O
values	O
decreased	O
significantly	O
in	O
the	O
intestinal	O
samples	O
.	O

Gut	O
microbiota	O
were	O
assessed	O
using	O
high	O
-	O
throughput	O
sequencing	O
of	O
the	O
16S	O
ribosomal	O
RNA	O
gene	O
,	O
and	O
the	O
results	O
indicated	O
that	O
AX	O
stimulated	O
the	O
growth	O
of	O
Megamonas	B-bacteria
and	O
Bifidobacterium	B-bacteria
species	I-bacteria
,	O
with	O
Megamonas	B-bacteria
exhibiting	O
the	O
greatest	O
stimulation	O
.	O

Overall	O
,	O
the	O
results	O
suggest	O
that	O
oat	O
AX	O
is	O
utilized	O
by	O
specific	O
bacteria	O
in	O
duck	O
intestines	O
,	O
providing	O
the	O
theoretical	O
basis	O
for	O
the	O
impacts	O
of	O
AX	O
on	O
animal	O
health	O
.	O

Prevalence	O
and	O
molecular	O
determinants	O
of	O
colistin	O
resistance	O
among	O
commensal	O
Enterobacteriaceae	B-bacteria
isolated	O
from	O
poultry	O
in	O
northwest	O
of	O
Iran	O
.	O

Background	O
:	O
The	O
emergence	O
of	O
colistin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Enterobacteriaceae	I-bacteria
from	O
human	O
and	O
animal	O
sources	O
is	O
a	O
public	O
health	O
concern	O
as	O
this	O
antibiotic	O
is	O
considered	O
to	O
be	O
the	O
last	O
line	O
therapeutic	O
option	O
for	O
infections	O
caused	O
by	O
multidrug	O
-	O
resistant	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Here	O
we	O
aimed	O
to	O
determine	O
the	O
prevalence	O
of	O
colistin	O
resistance	O
,	O
among	O
enterobacteria	B-bacteria
isolated	O
from	O
poultry	O
and	O
the	O
possible	O
underlying	O
colistin	O
resistance	O
mechanisms	O
.	O

Methods	O
:	O
A	O
collection	O
of	O
944	O
cloacal	O
samples	O
were	O
obtained	O
from	O
poultry	O
and	O
screened	O
for	O
colistin	O
resistance	O
.	O

To	O
uncover	O
the	O
molecular	O
mechanism	O
behind	O
colistin	O
resistance	O
,	O
the	O
presence	O
of	O
plasmid	O
encoded	O
colistin	O
resistance	O
genes	O
mcr	O
-	O
1	O
,	O
mcr	O
-	O
2	O
,	O
mcr	O
-	O
3	O
and	O
mcr	O
-	O
4	O
was	O
examined	O
by	O
PCR	O
.	O

The	O
nucleotide	O
sequences	O
of	O
the	O
mgrB	O
,	O
pmrA	O
,	O
pmrB	O
,	O
phoP	O
,	O
phoQ	O
,	O
crrA	O
and	O
crrB	O
genes	O
were	O
determined	O
.	O

The	O
genetic	O
relatedness	O
of	O
the	O
colistin	O
resistant	O
(	O
ColR	O
)	O
isolates	O
was	O
evaluated	O
by	O
Multilocus	O
sequence	O
typing	O
.	O

Three	O
ColR	O
mutants	O
were	O
generated	O
in	O
vitro	O
by	O
repetitive	O
drug	O
exposure	O
.	O

Results	O
:	O
Overall	O
from	O
931	O
enteric	O
bacteria	O
isolated	O
from	O
poultry	O
samples	O
obtained	O
from	O
131	O
farms	O
,	O
nine	O
ColR	O
bacteria	O
(	O
0	O
.	O
96	O
%	O
)	O
with	O
high	O
level	O
colistin	O
resistance	O
(	O
MICs	O
>	O
/	O
=	O
64	O
mg	O
/	O
L	O
)	O
were	O
detected	O
all	O
being	O
identified	O
as	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
.	O

The	O
9	O
ColR	O
bacteria	O
originated	O
from	O
different	O
farms	O
and	O
belonged	O
to	O
7	O
distinct	O
Sequence	O
types	O
including	O
ST11	B-bacteria
(	O
22	O
.	O
2	O
%	O
)	O
and	O
ST726	B-bacteria
(	O
22	O
.	O
2	O
%	O
)	O
being	O
the	O
most	O
prevalent	O
STs	O
followed	O
by	O
ST37	O
,	O
ST74	O
,	O
ST485	O
,	O
ST525	O
and	O
novel	O
sequence	O
type	O
3380	O
(	O
11	O
.	O
1	O
%	O
each	O
)	O
.	O

mcr	O
-	O
type	O
genes	O
were	O
not	O
detected	O
in	O
any	O
isolate	O
.	O

In	O
88	O
.	O
8	O
%	O
of	O
the	O
isolates	O
(	O
n	O
=	O
8	O
)	O
,	O
MgrB	O
was	O
inactivated	O
by	O
Insertion	O
of	O
IS	O
elements	O
(	O
IS1	O
-	O
like	O
,	O
IS3	O
-	O
like	O
,	O
IS5	O
-	O
like	O
families	O
,	O
positions	O
+	O
75	O
,	O
+	O
113	O
,	O
+	O
117	O
,	O
+	O
135	O
)	O
and	O
nonsense	O
mutations	O
at	O
codons	O
8	O
,	O
16	O
,	O
30	O
.	O

All	O
ColR	O
isolates	O
harboured	O
wild	O
type	O
PmrA	O
,	O
PhoP	O
,	O
PhoQ	O
or	O
polymorphic	O
variants	O
of	O
PmrB	O
.	O

Sequence	O
analysis	O
of	O
the	O
CrrB	O
revealed	O
a	O
familiar	O
S195N	O
and	O
4	O
novel	O
I27V	O
,	O
T150R	O
,	O
F303S	O
and	O
K325R	O
substitutions	O
.	O

PmrB	O
T93N	O
substitution	O
and	O
mgrB	O
locus	O
deletion	O
were	O
identified	O
in	O
two	O
laboratory	O
induced	O
ColR	O
mutants	O
and	O
one	O
mutant	O
lacked	O
alteration	O
in	O
the	O
studied	O
loci	O
.	O

In	O
one	O
ColR	O
isolate	O
with	O
wild	O
type	O
MgrB	O
an	O
A83V	O
substitution	O
was	O
detected	O
in	O
CrrA	O
.	O

Conclusion	O
:	O
It	O
is	O
concluded	O
from	O
our	O
results	O
that	O
colistin	O
resistance	O
in	O
the	O
studied	O
avian	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
isolates	I-bacteria
was	O
mostly	O
linked	O
to	O
alterations	O
identified	O
within	O
the	O
mgrB	O
gene	O
.	O

Genomic	O
insights	O
from	O
Monoglobus	B-bacteria
pectinilyticus	I-bacteria
:	O
a	O
pectin	O
-	O
degrading	O
specialist	O
bacterium	O
in	O
the	O
human	O
colon	O
.	O

Pectin	O
is	O
abundant	O
in	O
modern	O
day	O
diets	O
,	O
as	O
it	O
comprises	O
the	O
middle	O
lamellae	O
and	O
one	O
-	O
third	O
of	O
the	O
dry	O
carbohydrate	O
weight	O
of	O
fruit	O
and	O
vegetable	O
cell	O
walls	O
.	O

Currently	O
there	O
is	O
no	O
specialized	O
model	O
organism	O
for	O
studying	O
pectin	O
fermentation	O
in	O
the	O
human	O
colon	O
,	O
as	O
our	O
collective	O
understanding	O
is	O
informed	O
by	O
versatile	O
glycan	O
-	O
degrading	O
bacteria	O
rather	O
than	O
by	O
specialist	O
pectin	O
degraders	O
.	O

Here	O
we	O
show	O
that	O
the	O
genome	O
of	O
Monoglobus	B-bacteria
pectinilyticus	I-bacteria
possesses	O
a	O
highly	O
specialized	O
glycobiome	O
for	O
pectin	O
degradation	O
,	O
unique	O
amongst	O
Firmicutes	B-bacteria
known	O
to	O
be	O
in	O
the	O
human	O
gut	O
.	O

Its	O
genome	O
encodes	O
a	O
simple	O
set	O
of	O
metabolic	O
pathways	O
relevant	O
to	O
pectin	O
sugar	O
utilization	O
,	O
and	O
its	O
predicted	O
glycobiome	O
comprises	O
an	O
unusual	O
distribution	O
of	O
carbohydrate	O
-	O
active	O
enzymes	O
(	O
CAZymes	O
)	O
with	O
numerous	O
extracellular	O
methyl	O
/	O
acetyl	O
esterases	O
and	O
pectate	O
lyases	O
.	O

We	O
predict	O
the	O
M	B-bacteria
.	I-bacteria
pectinilyticus	I-bacteria
degradative	O
process	O
is	O
facilitated	O
by	O
cell	O
-	O
surface	O
S	O
-	O
layer	O
homology	O
(	O
SLH	O
)	O
domain	O
-	O
containing	O
proteins	O
,	O
which	O
proteomics	O
analysis	O
shows	O
are	O
differentially	O
expressed	O
in	O
response	O
to	O
pectin	O
.	O

Some	O
of	O
these	O
abundant	O
cell	O
surface	O
proteins	O
of	O
M	B-bacteria
.	I-bacteria
pectinilyticus	I-bacteria
share	O
unique	O
modular	O
organizations	O
rarely	O
observed	O
in	O
human	O
gut	O
bacteria	O
,	O
featuring	O
pectin	O
-	O
specific	O
CAZyme	O
domains	O
and	O
the	O
cell	O
wall	O
-	O
anchoring	O
SLH	O
motifs	O
.	O

We	O
observed	O
M	B-bacteria
.	I-bacteria
pectinilyticus	I-bacteria
degrades	O
various	O
pectins	O
,	O
RG	O
-	O
I	O
,	O
and	O
galactan	O
to	O
produce	O
polysaccharide	O
degradation	O
products	O
(	O
PDPs	O
)	O
which	O
are	O
presumably	O
shared	O
with	O
other	O
inhabitants	O
of	O
the	O
human	O
gut	O
microbiome	O
(	O
HGM	O
)	O
.	O

This	O
strain	O
occupies	O
a	O
new	O
ecological	O
niche	O
for	O
a	O
primary	O
degrader	O
specialized	O
in	O
foraging	O
a	O
habitually	O
consumed	O
plant	O
glycan	O
,	O
thereby	O
enriching	O
our	O
understanding	O
of	O
the	O
diverse	O
community	O
profile	O
of	O
the	O
HGM	O
.	O

The	O
Glucoamylase	O
Inhibitor	O
Acarbose	O
Has	O
a	O
Diet	O
-	O
Dependent	O
and	O
Reversible	O
Effect	O
on	O
the	O
Murine	O
Gut	O
Microbiome	O
.	O

Acarbose	O
is	O
a	O
safe	O
and	O
effective	O
medication	O
for	O
type	O
2	O
diabetes	O
that	O
inhibits	O
host	O
glucoamylases	O
to	O
prevent	O
starch	O
digestion	O
in	O
the	O
small	O
intestines	O
and	O
thus	O
decrease	O
postprandial	O
blood	O
glucose	O
levels	O
.	O

This	O
results	O
in	O
an	O
increase	O
in	O
dietary	O
starch	O
in	O
the	O
distal	O
intestine	O
,	O
where	O
it	O
becomes	O
food	O
for	O
the	O
gut	O
bacterial	O
community	O
.	O

Here	O
,	O
we	O
examined	O
the	O
effect	O
of	O
acarbose	O
therapy	O
on	O
the	O
gut	O
community	O
structure	O
in	O
mice	O
fed	O
either	O
a	O
high	O
-	O
starch	O
(	O
HS	O
)	O
or	O
high	O
-	O
fiber	O
diet	O
rich	O
in	O
plant	O
polysaccharides	O
(	O
PP	O
)	O
.	O

The	O
fecal	O
microbiota	O
of	O
animals	O
consuming	O
a	O
low	O
dose	O
of	O
acarbose	O
(	O
25	O
ppm	O
)	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
control	O
animals	O
that	O
did	O
not	O
receive	O
acarbose	O
.	O

However	O
,	O
a	O
high	O
dose	O
of	O
acarbose	O
(	O
400	O
ppm	O
)	O
with	O
the	O
HS	O
diet	O
resulted	O
in	O
a	O
substantial	O
change	O
to	O
the	O
microbiota	O
structure	O
.	O

Most	O
notably	O
,	O
the	O
HS	O
diet	O
with	O
a	O
high	O
dose	O
of	O
acarbose	O
lead	O
to	O
an	O
expansion	O
of	O
the	O
Bacteroidaceae	B-bacteria
and	O
Bifidobacteriaceae	B-bacteria
and	O
a	O
decrease	O
in	O
the	O
Verrucomicrobiaceae	B-bacteria
(	O
such	O
as	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
)	O
and	O
the	O
Bacteroidales	B-bacteria
S24	I-bacteria
-	I-bacteria
7	I-bacteria
.	O

Once	O
acarbose	O
treatment	O
ceased	O
,	O
the	O
community	O
composition	O
quickly	O
reverted	O
to	O
mirror	O
that	O
of	O
the	O
control	O
group	O
,	O
suggesting	O
that	O
acarbose	O
does	O
not	O
irreversibly	O
alter	O
the	O
gut	O
community	O
.	O

The	O
high	O
dose	O
of	O
acarbose	O
in	O
the	O
PP	O
diet	O
resulted	O
in	O
a	O
distinct	O
community	O
structure	O
with	O
increased	O
representation	O
of	O
Bifidobacteriaceae	B-bacteria
and	O
Lachnospiraceae	B-bacteria
Short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
measured	O
from	O
stool	O
samples	O
were	O
increased	O
,	O
especially	O
butyrate	O
,	O
as	O
a	O
result	O
of	O
acarbose	O
treatment	O
in	O
both	O
diets	O
.	O

These	O
data	O
demonstrate	O
the	O
potential	O
of	O
acarbose	O
to	O
change	O
the	O
gut	O
community	O
structure	O
and	O
increase	O
beneficial	O
SCFA	O
output	O
in	O
a	O
diet	O
-	O
dependent	O
manner	O
.	O
IMPORTANCE	O
The	O
gut	O
microbial	O
community	O
has	O
a	O
profound	O
influence	O
on	O
host	O
physiology	O
in	O
both	O
health	O
and	O
disease	O
.	O

In	O
diabetic	O
individuals	O
,	O
the	O
gut	O
microbiota	O
can	O
affect	O
the	O
course	O
of	O
disease	O
,	O
and	O
some	O
medications	O
for	O
diabetes	O
,	O
including	O
metformin	O
,	O
seem	O
to	O
elicit	O
some	O
of	O
their	O
benefits	O
via	O
an	O
interaction	O
with	O
the	O
microbiota	O
.	O

Here	O
,	O
we	O
report	O
that	O
acarbose	O
,	O
a	O
glucoamylase	O
inhibitor	O
for	O
type	O
2	O
diabetes	O
,	O
changes	O
the	O
murine	O
gut	O
bacterial	O
community	O
structure	O
in	O
a	O
reversible	O
and	O
diet	O
-	O
dependent	O
manner	O
.	O

In	O
both	O
high	O
-	O
starch	O
and	O
high	O
-	O
fiber	O
diet	O
backgrounds	O
,	O
acarbose	O
treatment	O
results	O
in	O
increased	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
particularly	O
butyrate	O
,	O
as	O
measured	O
in	O
stool	O
samples	O
.	O

As	O
we	O
learn	O
more	O
about	O
how	O
human	O
disease	O
is	O
affected	O
by	O
the	O
intestinal	O
bacterial	O
community	O
,	O
the	O
interplay	O
between	O
medications	O
such	O
as	O
acarbose	O
and	O
the	O
diet	O
will	O
become	O
increasingly	O
important	O
to	O
evaluate	O
.	O

Coronavirus	O
Endoribonuclease	O
Activity	O
in	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Suppresses	O
Type	O
I	O
and	O
Type	O
III	O
Interferon	O
Responses	O
.	O

Identifying	O
viral	O
antagonists	O
of	O
innate	O
immunity	O
and	O
determining	O
if	O
they	O
contribute	O
to	O
pathogenesis	O
are	O
critical	O
for	O
developing	O
effective	O
strategies	O
to	O
control	O
emerging	O
viruses	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
an	O
endoribonuclease	O
(	O
EndoU	O
)	O
encoded	O
by	O
murine	O
coronavirus	O
plays	O
a	O
pivotal	O
role	O
in	O
evasion	O
of	O
host	O
innate	O
immune	O
defenses	O
in	O
macrophages	O
.	O

Here	O
,	O
we	O
asked	O
if	O
the	O
EndoU	O
activity	O
of	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
(	O
PEDV	O
)	O
,	O
which	O
causes	O
acute	O
diarrhea	O
in	O
swine	O
,	O
plays	O
a	O
role	O
in	O
antagonizing	O
the	O
innate	O
response	O
in	O
porcine	O
epithelial	O
cells	O
and	O
macrophages	O
,	O
the	O
sites	O
of	O
viral	O
replication	O
.	O

We	O
constructed	O
an	O
infectious	O
clone	O
of	O
PEDV	O
-	O
Colorado	O
strain	O
(	O
icPEDV	O
-	O
wt	O
)	O
and	O
an	O
EndoU	O
-	O
mutant	O
PEDV	O
(	O
icPEDV	O
-	O
EnUmt	O
)	O
by	O
changing	O
the	O
codon	O
for	O
a	O
catalytic	O
histidine	O
residue	O
of	O
EndoU	O
to	O
alanine	O
(	O
His226Ala	O
)	O
.	O

We	O
found	O
that	O
both	O
icPEDV	O
-	O
wt	O
and	O
icPEDV	O
-	O
EnUmt	O
propagated	O
efficiently	O
in	O
interferon	O
(	O
IFN	O
)	O
-	O
deficient	O
Vero	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
propagation	O
of	O
icPEDV	O
-	O
EnUmt	O
was	O
impaired	O
in	O
porcine	O
epithelial	O
cells	O
(	O
LLC	O
-	O
PK1	O
)	O
,	O
where	O
we	O
detected	O
an	O
early	O
and	O
robust	O
transcriptional	O
activation	O
of	O
type	O
I	O
and	O
type	O
III	O
IFNs	O
.	O

Infection	O
of	O
piglets	O
with	O
the	O
parental	O
Colorado	O
strain	O
,	O
icPEDV	O
-	O
wt	O
,	O
or	O
icPEDV	O
-	O
EnUmt	O
revealed	O
that	O
all	O
viruses	O
replicated	O
in	O
the	O
gut	O
and	O
induced	O
diarrhea	O
;	O
however	O
,	O
there	O
was	O
reduced	O
viral	O
shedding	O
and	O
mortality	O
in	O
the	O
icPEDV	O
-	O
EnUmt	O
-	O
infected	O
animals	O
.	O

These	O
results	O
demonstrate	O
that	O
EndoU	O
activity	O
is	O
not	O
required	O
for	O
PEDV	O
replication	O
in	O
immortalized	O
,	O
IFN	O
-	O
deficient	O
Vero	O
cells	O
,	O
but	O
is	O
important	O
for	O
suppressing	O
the	O
IFN	O
response	O
in	O
epithelial	O
cells	O
and	O
macrophages	O
,	O
which	O
facilitates	O
replication	O
,	O
shedding	O
,	O
and	O
pathogenesis	O
in	O
vivo	O
We	O
conclude	O
that	O
PEDV	O
EndoU	O
activity	O
is	O
a	O
key	O
virulence	O
factor	O
that	O
suppresses	O
both	O
type	O
I	O
and	O
type	O
III	O
IFN	O
responses	O
.	O
IMPORTANCE	O
Coronaviruses	O
(	O
CoVs	O
)	O
can	O
emerge	O
from	O
an	O
animal	O
reservoir	O
into	O
a	O
naive	O
host	O
species	O
to	O
cause	O
pandemic	O
respiratory	O
or	O
gastrointestinal	O
diseases	O
with	O
significant	O
mortality	O
in	O
humans	O
or	O
domestic	O
animals	O
.	O

Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
,	O
an	O
alphacoronavirus	O
(	O
alpha	O
-	O
CoV	O
)	O
,	O
infects	O
gut	O
epithelial	O
cells	O
and	O
macrophages	O
,	O
inducing	O
diarrhea	O
and	O
resulting	O
in	O
high	O
mortality	O
in	O
piglets	O
.	O

How	O
PEDV	O
suppresses	O
the	O
innate	O
immune	O
response	O
was	O
unknown	O
.	O

We	O
found	O
that	O
mutating	O
a	O
viral	O
endoribonuclease	O
,	O
EndoU	O
,	O
results	O
in	O
a	O
virus	O
that	O
activates	O
both	O
the	O
type	O
I	O
interferon	O
response	O
and	O
the	O
type	O
III	O
interferon	O
response	O
in	O
macrophages	O
and	O
epithelial	O
cells	O
.	O

This	O
activation	O
of	O
interferon	O
resulted	O
in	O
limited	O
viral	O
replication	O
in	O
epithelial	O
cell	O
cultures	O
and	O
was	O
associated	O
with	O
reduced	O
virus	O
shedding	O
and	O
mortality	O
in	O
piglets	O
.	O

This	O
study	O
reveals	O
a	O
role	O
for	O
EndoU	O
activity	O
as	O
a	O
virulence	O
factor	O
in	O
PEDV	O
infection	O
and	O
provides	O
an	O
approach	O
for	O
generating	O
live	O
-	O
attenuated	O
vaccine	O
candidates	O
for	O
emerging	O
coronaviruses	O
.	O

Caspase	O
-	O
3	O
cleavage	O
of	O
Salmonella	B-bacteria
type	I-bacteria
III	O
secreted	O
effector	O
protein	O
SifA	O
is	O
required	O
for	O
localization	O
of	O
functional	O
domains	O
and	O
bacterial	O
dissemination	O
.	O

SifA	O
is	O
a	O
bi	O
-	O
functional	O
Type	O
III	O
Secretion	O
System	O
(	O
T3SS	O
)	O
effector	O
protein	O
that	O
plays	O
an	O
important	O
role	O
in	O
Salmonella	B-bacteria
virulence	O
.	O

The	O
N	O
-	O
terminal	O
domain	O
of	O
SifA	O
binds	O
SifA	O
-	O
Kinesin	O
-	O
Interacting	O
-	O
Protein	O
(	O
SKIP	O
)	O
,	O
and	O
via	O
an	O
interaction	O
with	O
kinesin	O
,	O
forms	O
tubular	O
membrane	O
extensions	O
called	O
Sif	O
filaments	O
(	O
Sifs	O
)	O
that	O
emanate	O
from	O
the	O
Salmonella	B-bacteria
Containing	O
Vacuole	O
(	O
SCV	O
)	O
.	O

The	O
C	O
-	O
terminal	O
domain	O
of	O
SifA	O
harbors	O
a	O
WxxxE	O
motif	O
that	O
functions	O
to	O
mimic	O
active	O
host	O
cell	O
GTPases	O
.	O

Taken	O
together	O
,	O
SifA	O
functions	O
in	O
inducing	O
endosomal	O
tubulation	O
in	O
order	O
to	O
maintain	O
the	O
integrity	O
of	O
the	O
SCV	O
and	O
promote	O
bacterial	O
dissemination	O
.	O

Since	O
SifA	O
performs	O
multiple	O
,	O
unrelated	O
functions	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
how	O
each	O
functional	O
domain	O
of	O
SifA	O
becomes	O
processed	O
.	O

Our	O
work	O
demonstrates	O
that	O
a	O
linker	O
region	O
containing	O
a	O
caspase	O
-	O
3	O
cleavage	O
motif	O
separates	O
the	O
two	O
functional	O
domains	O
of	O
SifA	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
processing	O
of	O
SifA	O
by	O
caspase	O
-	O
3	O
at	O
this	O
particular	O
site	O
is	O
required	O
for	O
function	O
and	O
proper	O
localization	O
of	O
the	O
effector	O
protein	O
domains	O
,	O
we	O
developed	O
two	O
tracking	O
methods	O
to	O
analyze	O
the	O
intracellular	O
localization	O
of	O
SifA	O
.	O

We	O
first	O
adapted	O
a	O
fluorescent	O
tag	O
called	O
phiLOV	O
that	O
allowed	O
for	O
type	O
-	O
III	O
secretion	O
system	O
(	O
T3SS	O
)	O
mediated	O
delivery	O
of	O
SifA	O
and	O
observation	O
of	O
its	O
intracellular	O
colocalization	O
with	O
caspase	O
-	O
3	O
.	O

Additionally	O
,	O
we	O
created	O
a	O
dual	O
-	O
tagging	O
strategy	O
that	O
permitted	O
tracking	O
of	O
each	O
of	O
the	O
SifA	O
functional	O
domains	O
following	O
caspase	O
-	O
3	O
cleavage	O
to	O
different	O
subcellular	O
locations	O
.	O

The	O
results	O
of	O
this	O
study	O
reveal	O
that	O
caspase	O
-	O
3	O
cleavage	O
of	O
SifA	O
is	O
required	O
for	O
the	O
proper	O
localization	O
of	O
functional	O
domains	O
and	O
bacterial	O
dissemination	O
.	O

Considering	O
the	O
importance	O
of	O
these	O
events	O
in	O
Salmonella	B-bacteria
pathogenesis	O
,	O
we	O
conclude	O
that	O
caspase	O
-	O
3	O
cleavage	O
of	O
effector	O
proteins	O
is	O
a	O
more	O
broadly	O
applicable	O
effector	O
processing	O
mechanism	O
utilized	O
by	O
Salmonella	B-bacteria
to	O
invade	O
and	O
persist	O
during	O
infection	O
.	O

Gas	O
Gangrene	O

Gas	O
gangrene	O
is	O
synonymous	O
with	O
myonecrosis	O
and	O
is	O
a	O
highly	O
lethal	O
infection	O
of	O
deep	O
soft	O
tissue	O
,	O
caused	O
by	O
Clostridium	B-bacteria
species	I-bacteria
,	O
with	O
Clostridium	B-bacteria
perfringens	I-bacteria
being	O
the	O
most	O
common	O
.	O

Clostridial	B-bacteria
myonecrosis	I-bacteria
historically	O
was	O
a	O
common	O
war	O
wound	O
infection	O
with	O
an	O
incidence	O
of	O
5	O
%	O
,	O
but	O
with	O
improvement	O
in	O
wound	O
care	O
,	O
antisepsis	O
and	O
the	O
use	O
of	O
antibiotics	O
,	O
the	O
incidence	O
has	O
fallen	O
to	O
0	O
.	O
1	O
%	O
of	O
war	O
-	O
related	O
wound	O
infections	O
since	O
the	O
Vietnam	O
war	O
era	O
.	O

Puncture	O
wounds	O
and	O
surgical	O
wounds	O
,	O
especially	O
GI	O
surgeries	O
done	O
on	O
the	O
biliary	O
tract	O
or	O
intestinal	O
surgeries	O
,	O
are	O
causes	O
of	O
clostridial	O
infections	O
due	O
to	O
inadvertent	O
inoculation	O
of	O
the	O
surgical	O
wound	O
with	O
gut	O
bacteria	O
.	O

[	O
1	O
]	O
[	O
0	O
]	O

Dietary	O
-	O
induced	O
modulation	O
of	O
the	O
hindgut	O
microbiota	O
is	O
related	O
to	O
behavioral	O
responses	O
during	O
stressful	O
events	O
in	O
horses	O
.	O

The	O
bidirectional	O
communication	O
between	O
the	O
central	O
and	O
the	O
enteric	O
nervous	O
system	O
named	O
the	O
gut	O
-	O
brain	O
axis	O
has	O
been	O
widely	O
recognized	O
.	O

The	O
gut	O
microbiota	O
has	O
been	O
implicated	O
in	O
a	O
variety	O
of	O
stress	O
-	O
related	O
conditions	O
including	O
anxiety	O
,	O
depression	O
and	O
irritable	O
bowel	O
syndrome	O
based	O
on	O
rodent	O
studies	O
or	O
correlative	O
analysis	O
in	O
human	O
patients	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
to	O
what	O
extent	O
changes	O
in	O
behavior	O
during	O
stressful	O
events	O
and	O
in	O
the	O
microbial	O
composition	O
of	O
the	O
colonic	O
ecosystem	O
were	O
associated	O
in	O
horses	O
.	O

The	O
microbiota	O
alterations	O
were	O
induced	O
by	O
a	O
change	O
from	O
a	O
high	O
-	O
fiber	O
diet	O
(	O
100	O
%	O
hay	O
,	O
H	O
diet	O
)	O
to	O
a	O
progressive	O
low	O
-	O
fiber	O
and	O
high	O
-	O
starch	O
diet	O
(	O
56	O
%	O
hay	O
and	O
44	O
%	O
barley	O
,	O
HB	O
diet	O
)	O
on	O
six	O
fistulated	O
horses	O
.	O

Colonic	O
total	O
anaerobic	O
,	O
cellulolytic	O
,	O
amylolytic	O
and	O
lactate	O
-	O
utilizing	O
bacteria	O
were	O
enumerated	O
once	O
on	O
H	O
diet	O
and	O
once	O
on	O
HB	O
diet	O
.	O

Bacterial	O
richness	O
,	O
diversity	O
and	O
structure	O
at	O
family	O
and	O
genus	O
level	O
were	O
also	O
determined	O
.	O

The	O
behavior	O
of	O
horses	O
was	O
assessed	O
through	O
two	O
standardized	O
stressful	O
tests	O
:	O
a	O
novelty	O
test	O
and	O
an	O
umbrella	O
test	O
.	O

The	O
different	O
alterations	O
measured	O
in	O
the	O
colonic	O
microbiota	O
demonstrated	O
a	O
lower	O
fibrolytic	O
capacity	O
and	O
a	O
higher	O
amylolytic	O
capacity	O
of	O
the	O
ecosystem	O
when	O
horses	O
received	O
HB	O
compared	O
to	O
H	O
diet	O
.	O

During	O
the	O
novelty	O
test	O
,	O
the	O
frequency	O
of	O
blowing	O
was	O
significantly	O
higher	O
in	O
HB	O
than	O
in	O
H	O
diet	O
and	O
was	O
positively	O
correlated	O
with	O
the	O
concentration	O
of	O
amylolytic	O
bacteria	O
and	O
the	O
Succinivibrionaceae	B-bacteria
relative	O
abundance	O
.	O

During	O
the	O
umbrella	O
test	O
,	O
behavioral	O
variables	O
were	O
not	O
significantly	O
different	O
between	O
the	O
diets	O
but	O
the	O
colonic	O
content	O
pH	O
was	O
negatively	O
correlated	O
with	O
the	O
frequency	O
of	O
startle	O
response	O
.	O

Behavioral	O
responses	O
of	O
anxiety	O
were	O
related	O
to	O
hindgut	O
microbiota	O
indicators	O
of	O
a	O
high	O
-	O
starch	O
diet	O
.	O

Dietary	O
-	O
induced	O
modulation	O
of	O
the	O
gut	O
microbiota	O
composition	O
may	O
have	O
changed	O
the	O
horses	O
'	O
behavioral	O
reactions	O
in	O
stressful	O
situations	O
.	O

Dietary	O
polysaccharides	O
:	O
fermentation	O
potentials	O
of	O
a	O
primitive	O
gut	O
ecosystem	O
.	O

The	O
alimentary	O
canal	O
of	O
the	O
earthworm	O
is	O
representative	O
of	O
primitive	O
gut	O
ecosystems	O
,	O
and	O
gut	O
fermenters	O
capable	O
of	O
degrading	O
ingested	O
biomass	O
-	O
derived	O
polysaccharides	O
might	O
contribute	O
to	O
the	O
environmental	O
impact	O
and	O
survival	O
of	O
this	O
terrestrial	O
invertebrate	O
.	O

Thus	O
,	O
this	O
study	O
evaluated	O
the	O
postulation	O
that	O
gut	O
microbiota	O
of	O
the	O
model	O
earthworm	O
Lumbricus	O
terrestris	O
ferment	O
diverse	O
biomass	O
-	O
derived	O
polysaccharides	O
.	O

Structural	O
polysaccharides	O
(	O
e	O
.	O
g	O
.	O
cellulose	O
,	O
chitin	O
)	O
had	O
marginal	O
impact	O
on	O
fermentation	O
in	O
anoxic	O
gut	O
content	O
treatments	O
.	O

In	O
contrast	O
,	O
nonstructural	O
polysaccharides	O
(	O
e	O
.	O
g	O
.	O
starch	O
,	O
glycogen	O
)	O
greatly	O
stimulated	O
(	O
a	O
)	O
the	O
formation	O
of	O
diverse	O
fermentation	O
products	O
(	O
e	O
.	O
g	O
.	O
H2	O
,	O
ethanol	O
,	O
fatty	O
acids	O
)	O
and	O
(	O
b	O
)	O
the	O
facultatively	O
fermentative	O
families	O
Aeromonadaceae	B-bacteria
and	O
Enterobacteriaceae	B-bacteria
.	O

Despite	O
these	O
contrasting	O
results	O
with	O
different	O
polysaccharides	O
,	O
most	O
saccharides	O
derived	O
from	O
these	O
biopolymers	O
(	O
e	O
.	O
g	O
.	O
glucose	O
,	O
N	O
-	O
acetylglucosamine	O
)	O
greatly	O
stimulated	O
fermentation	O
,	O
yielding	O
16S	O
rRNA	O
gene	O
-	O
based	O
signatures	O
of	O
Aeromonadaceae	B-bacteria
-	O
,	O
Enterobacteriaceae	B-bacteria
-	O
and	O
Fusobacteriaceae	B-bacteria
-	O
affiliated	O
phylotypes	O
.	O

Roots	O
and	O
litter	O
are	O
dietary	O
substrates	O
of	O
the	O
earthworm	O
,	O
and	O
as	O
proof	O
-	O
of	O
-	O
principle	O
,	O
gut	O
-	O
associated	O
fermenters	O
responded	O
rapidly	O
to	O
root	O
-	O
and	O
litter	O
-	O
derived	O
nutrients	O
including	O
saccharides	O
.	O

These	O
findings	O
suggest	O
that	O
(	O
a	O
)	O
hydrolysis	O
of	O
certain	O
ingested	O
structural	O
polysaccharides	O
may	O
be	O
a	O
limiting	O
factor	O
in	O
the	O
ability	O
of	O
gut	O
fermenters	O
to	O
utilize	O
them	O
and	O
(	O
b	O
)	O
nonstructural	O
polysaccharides	O
of	O
disrupted	O
biomass	O
are	O
subject	O
to	O
rapid	O
fermentation	O
by	O
gut	O
microbes	O
and	O
yield	O
fatty	O
acids	O
that	O
can	O
be	O
utilized	O
by	O
the	O
earthworm	O
.	O

Spent	O
Coffee	O
Grounds	O
Extract	O
,	O
Rich	O
in	O
Mannooligosaccharides	O
,	O
Promotes	O
a	O
Healthier	O
Gut	O
Microbial	O
Community	O
in	O
a	O
Dose	O
-	O
Dependent	O
Manner	O
.	O

Coffee	O
is	O
one	O
of	O
the	O
most	O
consumed	O
beverages	O
around	O
the	O
world	O
,	O
and	O
as	O
a	O
consequence	O
,	O
spent	O
coffee	O
grounds	O
are	O
a	O
massively	O
produced	O
residue	O
that	O
is	O
causing	O
environmental	O
problems	O
.	O

Reusing	O
them	O
is	O
a	O
major	O
focus	O
of	O
interest	O
presently	O
.	O

We	O
extracted	O
mannooligosaccharides	O
(	O
MOS	O
)	O
from	O
spent	O
coffee	O
grounds	O
and	O
submitted	O
them	O
to	O
an	O
in	O
vitro	O
fermentation	O
with	O
human	O
feces	O
.	O

Results	O
obtained	O
suggest	O
that	O
MOS	O
are	O
able	O
to	O
exert	O
a	O
prebiotic	O
effect	O
on	O
gut	O
microbiota	O
by	O
stimulating	O
the	O
growth	O
of	O
some	O
beneficial	O
genera	O
,	O
such	O
as	O
Barnesiella	B-bacteria
,	O
Odoribacter	B-bacteria
,	O
Coprococcus	B-bacteria
,	O
Butyricicoccus	B-bacteria
,	O
Intestinimonas	B-bacteria
,	O
Pseudoflavonifractor	B-bacteria
,	O
and	O
Veillonella	B-bacteria
.	O

Moreover	O
,	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFA	O
)	O
production	O
also	O
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

However	O
,	O
we	O
observed	O
that	O
5	O
-	O
(	O
hydroxymethyl	O
)	O
furfural	O
,	O
furfural	O
,	O
and	O
polyphenols	O
(	O
which	O
are	O
either	O
produced	O
or	O
released	O
from	O
the	O
spent	O
coffee	O
grounds	O
matrix	O
during	O
hydrolysis	O
)	O
could	O
have	O
an	O
inhibitory	O
effect	O
on	O
other	O
beneficial	O
genera	O
,	O
such	O
as	O
Faecalibacterium	B-bacteria
,	O
Ruminococcus	B-bacteria
,	O
Blautia	B-bacteria
,	O
Butyricimonas	B-bacteria
,	O
Dialister	B-bacteria
,	O
Collinsella	B-bacteria
,	O
and	O
Anaerostipes	B-bacteria
,	O
which	O
could	O
negatively	O
affect	O
the	O
prebiotic	O
activity	O
of	O
MOS	O
.	O

Publisher	O
Correction	O
:	O
Genomic	O
variation	O
and	O
strain	O
-	O
specific	O
functional	O
adaptation	O
in	O
the	O
human	O
gut	O
microbiome	O
during	O
early	O
life	O
.	O

In	O
the	O
version	O
of	O
this	O
Article	O
originally	O
published	O
,	O
in	O
the	O
first	O
sentence	O
of	O
the	O
second	O
paragraph	O
of	O
the	O
Discussion	O
section	O
,	O
the	O
word	O
`	O
`	O
operingrationally	O
'	O
'	O
should	O
have	O
read	O
`	O
`	O
operationally	O
'	O
'	O
.	O

This	O
has	O
now	O
been	O
amended	O
in	O
all	O
versions	O
of	O
the	O
Article	O
.	O

Age	O
-	O
associated	O
Impairment	O
of	O
the	O
Mucus	O
Barrier	O
Function	O
is	O
Associated	O
with	O
Profound	O
Changes	O
in	O
Microbiota	O
and	O
Immunity	O
.	O

Aging	O
significantly	O
increases	O
the	O
vulnerability	O
to	O
gastrointestinal	O
(	O
GI	O
)	O
disorders	O
but	O
there	O
are	O
few	O
studies	O
investigating	O
the	O
key	O
factors	O
in	O
aging	O
that	O
affect	O
the	O
GI	O
tract	O
.	O

To	O
address	O
this	O
knowledge	O
gap	O
,	O
we	O
used	O
10	O
-	O
week	O
-	O
and	O
19	O
-	O
month	O
-	O
old	O
litter	O
-	O
mate	O
mice	O
to	O
investigate	O
microbiota	O
and	O
host	O
gene	O
expression	O
changes	O
in	O
association	O
with	O
ageing	O
.	O

In	O
aged	O
mice	O
the	O
thickness	O
of	O
the	O
colonic	O
mucus	O
layer	O
was	O
reduced	O
about	O
6	O
-	O
fold	O
relative	O
to	O
young	O
mice	O
,	O
and	O
more	O
easily	O
penetrable	O
by	O
luminal	O
bacteria	O
.	O

This	O
was	O
linked	O
to	O
increased	O
apoptosis	O
of	O
goblet	O
cells	O
in	O
the	O
upper	O
part	O
of	O
the	O
crypts	O
.	O

The	O
barrier	O
function	O
of	O
the	O
small	O
intestinal	O
mucus	O
was	O
also	O
compromised	O
and	O
the	O
microbiota	O
were	O
frequently	O
observed	O
in	O
contact	O
with	O
the	O
villus	O
epithelium	O
.	O

Antimicrobial	O
Paneth	O
cell	O
factors	O
Ang4	O
and	O
lysozyme	O
were	O
expressed	O
in	O
significantly	O
reduced	O
amounts	O
.	O

These	O
barrier	O
defects	O
were	O
accompanied	O
by	O
major	O
changes	O
in	O
the	O
faecal	O
microbiota	O
and	O
significantly	O
decreased	O
abundance	O
of	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
which	O
is	O
strongly	O
and	O
negatively	O
affected	O
by	O
old	O
age	O
in	O
humans	O
.	O

Transcriptomics	O
revealed	O
age	O
-	O
associated	O
decreases	O
in	O
the	O
expression	O
of	O
immunity	O
and	O
other	O
genes	O
in	O
intestinal	O
mucosal	O
tissue	O
,	O
including	O
decreased	O
T	O
cell	O
-	O
specific	O
transcripts	O
and	O
T	O
cell	O
signalling	O
pathways	O
.	O

The	O
physiological	O
and	O
immunological	O
changes	O
we	O
observed	O
in	O
the	O
intestine	O
in	O
old	O
age	O
,	O
could	O
have	O
major	O
consequences	O
beyond	O
the	O
gut	O
.	O

TGFbeta	O
/	O
BMP	O
immune	O
signaling	O
affects	O
abundance	O
and	O
function	O
of	O
C	O
.	O
elegans	O
gut	O
commensals	O
.	O

The	O
gut	O
microbiota	O
contributes	O
to	O
host	O
health	O
and	O
fitness	O
,	O
and	O
imbalances	O
in	O
its	O
composition	O
are	O
associated	O
with	O
pathology	O
.	O

However	O
,	O
what	O
shapes	O
microbiota	O
composition	O
is	O
not	O
clear	O
,	O
in	O
particular	O
the	O
role	O
of	O
genetic	O
factors	O
.	O

Previous	O
work	O
in	O
Caenorhabditis	O
elegans	O
defined	O
a	O
characteristic	O
worm	O
gut	O
microbiota	O
significantly	O
influenced	O
by	O
host	O
genetics	O
.	O

The	O
current	O
work	O
explores	O
the	O
role	O
of	O
central	O
regulators	O
of	O
host	O
immunity	O
and	O
stress	O
resistance	O
,	O
employing	O
qPCR	O
and	O
CFU	O
counts	O
to	O
measure	O
abundance	O
of	O
core	O
microbiota	O
taxa	O
in	O
mutants	O
raised	O
on	O
synthetic	O
communities	O
of	O
previously	O
-	O
isolated	O
worm	O
gut	O
commensals	O
.	O

This	O
revealed	O
a	O
bloom	O
,	O
specifically	O
of	O
Enterobacter	B-bacteria
species	I-bacteria
,	O
in	O
immune	O
-	O
compromised	O
TGFbeta	O
/	O
BMP	O
mutants	O
.	O

Imaging	O
of	O
fluorescently	O
labeled	O
Enterobacter	B-bacteria
showed	O
that	O
TGFbeta	O
/	O
BMP	O
-	O
exerted	O
control	O
operated	O
primarily	O
in	O
the	O
anterior	O
gut	O
and	O
depended	O
on	O
multi	O
-	O
tissue	O
contributions	O
.	O

Enterobacter	B-bacteria
commensals	O
are	O
common	O
in	O
the	O
worm	O
gut	O
,	O
contributing	O
to	O
infection	O
resistance	O
.	O

However	O
,	O
disruption	O
of	O
TGFbeta	O
/	O
BMP	O
signaling	O
turned	O
a	O
normally	O
beneficial	O
Enterobacter	B-bacteria
commensal	O
to	O
pathogenic	O
.	O

These	O
results	O
demonstrate	O
specificity	O
in	O
gene	O
-	O
microbe	O
interactions	O
underlying	O
gut	O
microbial	O
homeostasis	O
and	O
highlight	O
the	O
pathogenic	O
potential	O
of	O
their	O
disruption	O
.	O

The	O
13th	O
International	O
Double	O
-	O
Stranded	O
RNA	O
Virus	O
Symposium	O
,	O
Houffalize	O
,	O
Belgium	O
,	O
24	O
to	O
28	O
September	O
2018	O
.	O

The	O
triennial	O
International	O
Double	O
-	O
Stranded	O
RNA	O
Virus	O
Symposium	O
,	O
this	O
year	O
organized	O
by	O
J	O
.	O
Matthijnssens	O
,	O
J	O
.	O
S	O
.	O
L	O
.	O
Parker	O
,	O
P	O
.	O
Danthi	O
,	O
and	O
P	O
.	O
Van	O
Damme	O
in	O
Belgium	O
,	O
gathered	O
over	O
200	O
scientists	O
to	O
discuss	O
novel	O
observations	O
and	O
hypotheses	O
in	O
the	O
field	O
.	O

The	O
keynote	O
lecture	O
on	O
functional	O
interactions	O
of	O
bacteria	O
and	O
viruses	O
in	O
the	O
gut	O
microbiome	O
was	O
presented	O
by	O
Julie	O
Pfeiffer	O
.	O

Workshops	O
were	O
held	O
on	O
viral	O
diversity	O
,	O
molecular	O
epidemiology	O
,	O
molecular	O
virology	O
,	O
immunity	O
and	O
pathogenesis	O
,	O
virus	O
structure	O
,	O
the	O
viral	O
use	O
and	O
abuse	O
of	O
cellular	O
pathways	O
,	O
and	O
applied	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
virology	O
.	O

The	O
establishment	O
of	O
a	O
plasmid	O
only	O
-	O
based	O
reverse	O
genetics	O
system	O
for	O
rotaviruses	O
by	O
several	O
Japanese	O
research	O
groups	O
in	O
2017	O
has	O
now	O
been	O
reproduced	O
by	O
various	O
other	O
research	O
groups	O
and	O
was	O
discussed	O
in	O
detail	O
.	O

The	O
visualization	O
of	O
dsRNA	O
virus	O
replication	O
steps	O
in	O
living	O
cells	O
received	O
much	O
attention	O
.	O

Mechanisms	O
of	O
the	O
cellular	O
innate	O
immune	O
response	O
to	O
virus	O
infection	O
and	O
of	O
viral	O
pathogenesis	O
were	O
explored	O
.	O

Knowledge	O
of	O
the	O
gut	O
microbiome	O
'	O
s	O
influence	O
on	O
specific	O
immune	O
responses	O
has	O
increased	O
rapidly	O
,	O
also	O
due	O
to	O
the	O
availability	O
of	O
relevant	O
animal	O
models	O
of	O
virus	O
infection	O
.	O

The	O
method	O
of	O
cryo	O
-	O
electron	O
microscopic	O
(	O
cryo	O
-	O
EM	O
)	O
tomography	O
has	O
elucidated	O
various	O
asymmetric	O
structures	O
in	O
viral	O
particles	O
.	O

The	O
use	O
of	O
orthoreoviruses	O
for	O
oncolytic	O
virotherapy	O
was	O
critically	O
assessed	O
.	O

The	O
application	O
of	O
llama	O
-	O
derived	O
single	O
chain	O
nanobodies	O
for	O
passive	O
immunotherapy	O
was	O
considered	O
attractive	O
.	O

In	O
a	O
satellite	O
symposium	O
the	O
introduction	O
,	O
impact	O
and	O
further	O
developments	O
of	O
rotavirus	O
vaccines	O
were	O
reviewed	O
.	O

The	O
Jean	O
Cohen	O
Lecturer	O
of	O
this	O
meeting	O
was	O
Harry	O
B	O
.	O
Greenberg	O
,	O
who	O
presented	O
aspects	O
of	O
his	O
research	O
on	O
rotaviruses	O
over	O
a	O
period	O
of	O
more	O
than	O
40	O
years	O
.	O

He	O
was	O
also	O
interviewed	O
at	O
the	O
meeting	O
by	O
Vincent	O
Racaniello	O
for	O
the	O
513th	O
session	O
of	O
This	O
Week	O
in	O
Virology	O
.	O

Emerging	O
roles	O
of	O
metabolites	O
of	O
omega3	O
and	O
omega6	O
essential	O
fatty	O
acids	O
in	O
the	O
control	O
of	O
intestinal	O
inflammation	O
.	O

The	O
gastrointestinal	O
tract	O
is	O
continuously	O
exposed	O
to	O
the	O
external	O
environment	O
,	O
which	O
contains	O
numerous	O
non	O
-	O
self	O
antigens	O
,	O
including	O
food	O
materials	O
and	O
commensal	O
micro	O
-	O
organisms	O
.	O

For	O
the	O
maintenance	O
of	O
mucosal	O
homeostasis	O
,	O
the	O
intestinal	O
epithelial	O
layer	O
and	O
mucosal	O
immune	O
system	O
simultaneously	O
provide	O
the	O
first	O
line	O
of	O
defense	O
against	O
pathogens	O
and	O
are	O
tightly	O
regulated	O
to	O
prevent	O
their	O
induction	O
of	O
inflammatory	O
responses	O
to	O
non	O
-	O
pathogenic	O
antigens	O
.	O

Defects	O
in	O
mucosal	O
homeostasis	O
lead	O
to	O
the	O
development	O
of	O
inflammatory	O
and	O
associated	O
intestinal	O
diseases	O
,	O
such	O
as	O
Crohn	O
'	O
s	O
disease	O
,	O
ulcerative	O
colitis	O
,	O
food	O
allergy	O
and	O
colorectal	O
cancer	O
.	O

The	O
recent	O
discovery	O
of	O
novel	O
dietary	O
omega3	O
and	O
omega6	O
lipid	O
-	O
derived	O
metabolites	O
-	O
such	O
as	O
resolvin	O
,	O
protectin	O
,	O
maresin	O
,	O
17	O
,	O
18	O
-	O
epoxy	O
-	O
eicosatetraenoic	O
acid	O
and	O
microbe	O
-	O
dependent	O
10	O
-	O
hydroxy	O
-	O
cis	O
-	O
12	O
-	O
octadecenoic	O
acid	O
-	O
and	O
their	O
potent	O
biologic	O
effects	O
on	O
the	O
regulation	O
of	O
inflammation	O
have	O
initiated	O
a	O
new	O
era	O
of	O
nutritional	O
immunology	O
.	O

In	O
this	O
review	O
,	O
we	O
update	O
our	O
understanding	O
of	O
the	O
role	O
of	O
lipid	O
metabolites	O
in	O
intestinal	O
inflammation	O
.	O

Mechanisms	O
of	O
Action	O
of	O
Probiotics	O
.	O

Probiotics	O
are	O
living	O
microorganisms	O
that	O
confer	O
health	O
benefits	O
to	O
the	O
host	O
when	O
administered	O
in	O
adequate	O
amounts	O
;	O
however	O
,	O
dead	O
bacteria	O
and	O
their	O
components	O
can	O
also	O
exhibit	O
probiotic	O
properties	O
.	O

Bifidobacterium	B-bacteria
and	O
strains	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
are	O
the	O
most	O
widely	O
used	O
bacteria	O
that	O
exhibit	O
probiotic	O
properties	O
and	O
are	O
included	O
in	O
many	O
functional	O
foods	O
and	O
dietary	O
supplements	O
.	O

Probiotics	O
have	O
been	O
shown	O
to	O
prevent	O
and	O
ameliorate	O
the	O
course	O
of	O
digestive	O
disorders	O
such	O
as	O
acute	O
,	O
nosocomial	O
,	O
and	O
antibiotic	O
-	O
associated	O
diarrhea	O
;	O
allergic	O
disorders	O
such	O
as	O
atopic	O
dermatitis	O
(	O
eczema	O
)	O
and	O
allergic	O
rhinitis	O
in	O
infants	O
;	O
and	O
Clostridium	O
difficile	O
-	O
associated	O
diarrhea	O
and	O
some	O
inflammatory	O
bowel	O
disorders	O
in	O
adults	O
.	O

In	O
addition	O
,	O
probiotics	O
may	O
be	O
of	O
interest	O
as	O
coadjuvants	O
in	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
,	O
including	O
obesity	O
,	O
metabolic	O
syndrome	O
,	O
nonalcoholic	O
fatty	O
liver	O
disease	O
,	O
and	O
type	O
2	O
diabetes	O
.	O

However	O
,	O
the	O
mechanisms	O
of	O
action	O
of	O
probiotics	O
,	O
which	O
are	O
diverse	O
,	O
heterogeneous	O
,	O
and	O
strain	O
specific	O
,	O
have	O
received	O
little	O
attention	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
work	O
was	O
to	O
review	O
the	O
main	O
mechanisms	O
of	O
action	O
of	O
probiotics	O
,	O
including	O
colonization	O
and	O
normalization	O
of	O
perturbed	O
intestinal	O
microbial	O
communities	O
in	O
children	O
and	O
adults	O
;	O
competitive	O
exclusion	O
of	O
pathogens	O
and	O
bacteriocin	O
production	O
;	O
modulation	O
of	O
fecal	O
enzymatic	O
activities	O
associated	O
with	O
the	O
metabolization	O
of	O
biliary	O
salts	O
and	O
inactivation	O
of	O
carcinogens	O
and	O
other	O
xenobiotics	O
;	O
production	O
of	O
short	O
-	O
chain	O
and	O
branched	O
-	O
chain	O
fatty	O
acids	O
,	O
which	O
,	O
in	O
turn	O
,	O
have	O
wide	O
effects	O
not	O
only	O
in	O
the	O
intestine	O
but	O
also	O
in	O
peripheral	O
tissues	O
via	O
interactions	O
with	O
short	O
-	O
chain	O
fatty	O
acid	O
receptors	O
,	O
modulating	O
mainly	O
tissue	O
insulin	O
sensitivity	O
;	O
cell	O
adhesion	O
and	O
mucin	O
production	O
;	O
modulation	O
of	O
the	O
immune	O
system	O
,	O
which	O
results	O
mainly	O
in	O
the	O
differentiation	O
of	O
T	O
-	O
regulatory	O
cells	O
and	O
upregulation	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
and	O
growth	O
factors	O
,	O
i	O
.	O
e	O
.	O
,	O
interleukin	O
-	O
10	O
and	O
transforming	O
growth	O
factor	O
;	O
and	O
interaction	O
with	O
the	O
brain	O
-	O
gut	O
axis	O
by	O
regulation	O
of	O
endocrine	O
and	O
neurologic	O
functions	O
.	O

Further	O
research	O
to	O
elucidate	O
the	O
precise	O
molecular	O
mechanisms	O
of	O
action	O
of	O
probiotics	O
is	O
warranted	O
.	O

Modulation	O
of	O
Gut	O
Microbiota	O
by	O
Soybean	O
7S	O
Globulin	O
Peptide	O
That	O
Involved	O
Lipopolysaccharide	O
-	O
Peptide	O
Interaction	O
.	O

Soybean	O
protein	O
exhibits	O
nutritional	O
significance	O
for	O
the	O
control	O
of	O
metabolic	O
syndrome	O
,	O
and	O
evidence	O
suggests	O
that	O
gut	O
microbiota	O
are	O
implicated	O
in	O
the	O
control	O
of	O
metabolic	O
disorders	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
modulation	O
of	O
pepsin	O
-	O
released	O
peptides	O
of	O
soybean	O
7S	O
globulin	O
on	O
gut	O
microbiota	O
and	O
possible	O
association	O
between	O
changes	O
of	O
gut	O
microbiota	O
composition	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
peptide	O
interaction	O
.	O

In	O
vitro	O
fermentation	O
experiments	O
showed	O
that	O
the	O
extension	O
region	O
(	O
ER	O
)	O
fragments	O
of	O
soybean	O
7S	O
globulin	O
selectively	O
suppressed	O
proinflammatory	O
Gram	O
-	O
negative	O
bacteria	O
.	O

ER	O
peptides	O
also	O
promoted	O
the	O
highest	O
production	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
which	O
were	O
associated	O
with	O
increase	O
of	O
the	O
relative	O
abundance	O
of	O
Lachnospiraceae	B-bacteria
and	O
Lactobacillaceae	B-bacteria
.	O

Isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
and	O
Langmuir	O
monolayer	O
studies	O
demonstrated	O
that	O
ER	O
peptides	O
exhibited	O
high	O
affinity	O
to	O
LPS	O
in	O
the	O
presence	O
of	O
Ca	O
(	O
2	O
+	O
)	O
and	O
developed	O
into	O
beta	O
-	O
sheet	O
-	O
rich	O
aggregate	O
structures	O
,	O
thus	O
weakening	O
the	O
stability	O
of	O
LPS	O
monolayers	O
.	O

This	O
finding	O
supplies	O
a	O
possible	O
explanation	O
for	O
improvement	O
of	O
the	O
effects	O
of	O
soybean	O
7S	O
globulin	O
on	O
metabolic	O
disease	O
.	O

A	O
randomised	O
trial	O
of	O
probiotics	O
to	O
reduce	O
severity	O
of	O
physiological	O
and	O
microbial	O
disorders	O
induced	O
by	O
partial	O
gastrectomy	O
for	O
patients	O
with	O
gastric	O
cancer	O
.	O

Gastrectomy	O
has	O
been	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
gastric	O
cancer	O
,	O
and	O
the	O
severity	O
of	O
physiological	O
and	O
microbial	O
disorders	O
has	O
greatly	O
harmed	O
the	O
health	O
of	O
patients	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
probiotic	O
combination	O
containing	O
Bifidobacterium	B-bacteria
infantis	I-bacteria
,	O
Lactobacillus	B-bacteria
acidophilus	I-bacteria
,	O
Enterococcus	B-bacteria
faecalis	I-bacteria
and	O
Bacillus	B-bacteria
cereus	I-bacteria
was	O
used	O
to	O
reduce	O
the	O
physiological	O
disorders	O
induced	O
by	O
gastrectomy	O
via	O
monitoring	O
the	O
blood	O
index	O
and	O
microbial	O
diversity	O
using	O
high	O
-	O
throughput	O
sequencing	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
probiotic	O
combination	O
had	O
significantly	O
reduced	O
the	O
inflammation	O
indexes	O
(	O
leukocyte	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
it	O
markedly	O
enhanced	O
the	O
immunity	O
indexes	O
(	O
lymphocyte	O
)	O
and	O
nutrition	O
indexes	O
(	O
albumin	O
and	O
total	O
protein	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
gastric	O
cancer	O
had	O
a	O
strong	O
influence	O
on	O
the	O
microbial	O
diversity	O
of	O
the	O
stomach	O
via	O
enhancing	O
the	O
number	O
of	O
pathogens	O
of	O
Streptococcus	B-bacteria
,	O
Peptostreptococcus	B-bacteria
and	O
Prevotella	B-bacteria
,	O
and	O
reducing	O
the	O
percentage	O
of	O
the	O
probiotic	O
Bifidobacterium	B-bacteria
.	O

Although	O
partial	O
gastrectomy	O
markedly	O
changed	O
intestinal	O
microbial	O
diversity	O
,	O
the	O
taking	O
of	O
the	O
probiotic	O
combination	O
greatly	O
reduced	O
the	O
ratio	O
of	O
Firmicutes	B-bacteria
/	O
Bacteroidetes	B-bacteria
compared	O
with	O
patients	O
taking	O
no	O
probiotics	O
at	O
the	O
phylum	O
level	O
.	O

At	O
the	O
genus	O
level	O
,	O
the	O
probiotic	O
combination	O
significantly	O
enhanced	O
the	O
numbers	O
of	O
the	O
probiotic	O
bacteria	O
Bacteroides	B-bacteria
,	O
Faecalibacterium	B-bacteria
and	O
Akkermansia	B-bacteria
and	O
lowered	O
the	O
richness	O
of	O
Streptococcus	B-bacteria
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
the	O
taking	O
of	O
the	O
probiotic	O
combination	O
significantly	O
enhances	O
the	O
immune	O
response	O
of	O
patients	O
and	O
reduces	O
the	O
severity	O
of	O
inflammation	O
through	O
modification	O
of	O
gut	O
microbiota	O
.	O

IL	O
-	O
10	O
produced	O
by	O
macrophages	O
regulates	O
epithelial	O
integrity	O
in	O
the	O
small	O
intestine	O
.	O

Macrophages	O
(	O
Mvarphis	O
)	O
are	O
known	O
to	O
be	O
major	O
producers	O
of	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
in	O
the	O
intestine	O
,	O
thus	O
playing	O
an	O
important	O
role	O
in	O
maintaining	O
gastrointestinal	O
homeostasis	O
.	O

Mvarphis	O
that	O
reside	O
in	O
the	O
small	O
intestine	O
(	O
SI	O
)	O
have	O
been	O
previously	O
shown	O
to	O
be	O
regulated	O
by	O
dietary	O
antigens	O
,	O
while	O
colonic	O
Mvarphis	O
are	O
regulated	O
by	O
the	O
microbiota	O
.	O

However	O
,	O
the	O
role	O
which	O
resident	O
Mvarphis	O
play	O
in	O
SI	O
homeostasis	O
has	O
not	O
yet	O
been	O
fully	O
elucidated	O
.	O

Here	O
,	O
we	O
show	O
that	O
SI	O
Mvarphis	O
regulate	O
the	O
integrity	O
of	O
the	O
epithelial	O
barrier	O
via	O
secretion	O
of	O
IL	O
-	O
10	O
.	O

We	O
used	O
an	O
animal	O
model	O
of	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
-	O
induced	O
SI	O
epithelial	O
injury	O
to	O
show	O
that	O
IL	O
-	O
10	O
is	O
mainly	O
produced	O
by	O
MHCII	O
(	O
+	O
)	O
CD64	O
(	O
+	O
)	O
Ly6C	O
(	O
low	O
)	O
Mvarphis	O
early	O
in	O
injury	O
and	O
that	O
it	O
is	O
involved	O
in	O
the	O
restoration	O
of	O
the	O
epithelial	O
barrier	O
.	O

We	O
found	O
that	O
a	O
lack	O
of	O
IL	O
-	O
10	O
,	O
particularly	O
its	O
secretion	O
by	O
Mvarphis	O
,	O
compromised	O
the	O
recovery	O
of	O
SI	O
epithelial	O
barrier	O
.	O

IL	O
-	O
10	O
production	O
by	O
MHCII	O
(	O
+	O
)	O
CD64	O
(	O
+	O
)	O
Ly6C	O
(	O
low	O
)	O
Mvarphis	O
in	O
the	O
SI	O
is	O
not	O
regulated	O
by	O
the	O
gut	O
microbiota	O
,	O
hence	O
depletion	O
of	O
the	O
microbiota	O
did	O
not	O
influence	O
epithelial	O
regeneration	O
in	O
the	O
SI	O
.	O

Collectively	O
,	O
these	O
results	O
highlight	O
the	O
critical	O
role	O
IL	O
-	O
10	O
-	O
producing	O
Mvarphis	O
play	O
in	O
recovery	O
from	O
intestinal	O
epithelial	O
injury	O
induced	O
by	O
NSAID	O
.	O

A	O
human	O
gut	O
bacterial	O
genome	O
and	O
culture	O
collection	O
for	O
improved	O
metagenomic	O
analyses	O
.	O

Understanding	O
gut	O
microbiome	O
functions	O
requires	O
cultivated	O
bacteria	O
for	O
experimental	O
validation	O
and	O
reference	O
bacterial	O
genome	O
sequences	O
to	O
interpret	O
metagenome	O
datasets	O
and	O
guide	O
functional	O
analyses	O
.	O

We	O
present	O
the	O
Human	O
Gastrointestinal	O
Bacteria	O
Culture	O
Collection	O
(	O
HBC	O
)	O
,	O
a	O
comprehensive	O
set	O
of	O
737	O
whole	O
-	O
genome	O
-	O
sequenced	O
bacterial	O
isolates	O
,	O
representing	O
273	O
species	O
(	O
105	O
novel	O
species	O
)	O
from	O
31	O
families	O
found	O
in	O
the	O
human	O
gastrointestinal	O
microbiota	O
.	O

The	O
HBC	O
increases	O
the	O
number	O
of	O
bacterial	O
genomes	O
derived	O
from	O
human	O
gastrointestinal	O
microbiota	O
by	O
37	O
%	O
.	O

The	O
resulting	O
global	O
Human	O
Gastrointestinal	O
Bacteria	O
Genome	O
Collection	O
(	O
HGG	O
)	O
classifies	O
83	O
%	O
of	O
genera	O
by	O
abundance	O
across	O
13	O
,	O
490	O
shotgun	O
-	O
sequenced	O
metagenomic	O
samples	O
,	O
improves	O
taxonomic	O
classification	O
by	O
61	O
%	O
compared	O
to	O
the	O
Human	O
Microbiome	O
Project	O
(	O
HMP	O
)	O
genome	O
collection	O
and	O
achieves	O
subspecies	O
-	O
level	O
classification	O
for	O
almost	O
50	O
%	O
of	O
sequences	O
.	O

The	O
improved	O
resource	O
of	O
gastrointestinal	O
bacterial	O
reference	O
sequences	O
circumvents	O
dependence	O
on	O
de	O
novo	O
assembly	O
of	O
metagenomes	O
and	O
enables	O
accurate	O
and	O
cost	O
-	O
effective	O
shotgun	O
metagenomic	O
analyses	O
of	O
human	O
gastrointestinal	O
microbiota	O
.	O

1	O
,	O
520	O
reference	O
genomes	O
from	O
cultivated	O
human	O
gut	O
bacteria	O
enable	O
functional	O
microbiome	O
analyses	O
.	O

Reference	O
genomes	O
are	O
essential	O
for	O
metagenomic	O
analyses	O
and	O
functional	O
characterization	O
of	O
the	O
human	O
gut	O
microbiota	O
.	O

We	O
present	O
the	O
Culturable	O
Genome	O
Reference	O
(	O
CGR	O
)	O
,	O
a	O
collection	O
of	O
1	O
,	O
520	O
nonredundant	O
,	O
high	O
-	O
quality	O
draft	O
genomes	O
generated	O
from	O
>	O
6	O
,	O
000	O
bacteria	O
cultivated	O
from	O
fecal	O
samples	O
of	O
healthy	O
humans	O
.	O

Of	O
the	O
1	O
,	O
520	O
genomes	O
,	O
which	O
were	O
chosen	O
to	O
cover	O
all	O
major	O
bacterial	O
phyla	O
and	O
genera	O
in	O
the	O
human	O
gut	O
,	O
264	O
are	O
not	O
represented	O
in	O
existing	O
reference	O
genome	O
catalogs	O
.	O

We	O
show	O
that	O
this	O
increase	O
in	O
the	O
number	O
of	O
reference	O
bacterial	O
genomes	O
improves	O
the	O
rate	O
of	O
mapping	O
metagenomic	O
sequencing	O
reads	O
from	O
50	O
%	O
to	O
>	O
70	O
%	O
,	O
enabling	O
higher	O
-	O
resolution	O
descriptions	O
of	O
the	O
human	O
gut	O
microbiome	O
.	O

We	O
use	O
the	O
CGR	O
genomes	O
to	O
annotate	O
functions	O
of	O
338	O
bacterial	O
species	O
,	O
showing	O
the	O
utility	O
of	O
this	O
resource	O
for	O
functional	O
studies	O
.	O

We	O
also	O
carry	O
out	O
a	O
pan	O
-	O
genome	O
analysis	O
of	O
38	O
important	O
human	O
gut	O
species	O
,	O
which	O
reveals	O
the	O
diversity	O
and	O
specificity	O
of	O
functional	O
enrichment	O
between	O
their	O
core	O
and	O
dispensable	O
genomes	O
.	O

The	O
neuroactive	O
potential	O
of	O
the	O
human	O
gut	O
microbiota	O
in	O
quality	O
of	O
life	O
and	O
depression	O
.	O

The	O
relationship	O
between	O
gut	O
microbial	O
metabolism	O
and	O
mental	O
health	O
is	O
one	O
of	O
the	O
most	O
intriguing	O
and	O
controversial	O
topics	O
in	O
microbiome	O
research	O
.	O

Bidirectional	O
microbiota	O
-	O
gut	O
-	O
brain	O
communication	O
has	O
mostly	O
been	O
explored	O
in	O
animal	O
models	O
,	O
with	O
human	O
research	O
lagging	O
behind	O
.	O

Large	O
-	O
scale	O
metagenomics	O
studies	O
could	O
facilitate	O
the	O
translational	O
process	O
,	O
but	O
their	O
interpretation	O
is	O
hampered	O
by	O
a	O
lack	O
of	O
dedicated	O
reference	O
databases	O
and	O
tools	O
to	O
study	O
the	O
microbial	O
neuroactive	O
potential	O
.	O

Surveying	O
a	O
large	O
microbiome	O
population	O
cohort	O
(	O
Flemish	O
Gut	O
Flora	O
Project	O
,	O
n	O
=	O
1	O
,	O
054	O
)	O
with	O
validation	O
in	O
independent	O
data	O
sets	O
(	O
ntotal	O
=	O
1	O
,	O
070	O
)	O
,	O
we	O
studied	O
how	O
microbiome	O
features	O
correlate	O
with	O
host	O
quality	O
of	O
life	O
and	O
depression	O
.	O

Butyrate	O
-	O
producing	O
Faecalibacterium	B-bacteria
and	O
Coprococcus	B-bacteria
bacteria	I-bacteria
were	O
consistently	O
associated	O
with	O
higher	O
quality	O
of	O
life	O
indicators	O
.	O

Together	O
with	O
Dialister	B-bacteria
,	O
Coprococcus	B-bacteria
spp	I-bacteria
.	I-bacteria
were	O
also	O
depleted	O
in	O
depression	O
,	O
even	O
after	O
correcting	O
for	O
the	O
confounding	O
effects	O
of	O
antidepressants	O
.	O

Using	O
a	O
module	O
-	O
based	O
analytical	O
framework	O
,	O
we	O
assembled	O
a	O
catalogue	O
of	O
neuroactive	O
potential	O
of	O
sequenced	O
gut	O
prokaryotes	O
.	O

Gut	O
-	O
brain	O
module	O
analysis	O
of	O
faecal	O
metagenomes	O
identified	O
the	O
microbial	O
synthesis	O
potential	O
of	O
the	O
dopamine	O
metabolite	O
3	O
,	O
4	O
-	O
dihydroxyphenylacetic	O
acid	O
as	O
correlating	O
positively	O
with	O
mental	O
quality	O
of	O
life	O
and	O
indicated	O
a	O
potential	O
role	O
of	O
microbial	O
gamma	O
-	O
aminobutyric	O
acid	O
production	O
in	O
depression	O
.	O

Our	O
results	O
provide	O
population	O
-	O
scale	O
evidence	O
for	O
microbiome	O
links	O
to	O
mental	O
health	O
,	O
while	O
emphasizing	O
confounder	O
importance	O
.	O

Clostridium	B-bacteria
ramosum	I-bacteria
regulates	O
enterochromaffin	O
cell	O
development	O
and	O
serotonin	O
release	O
.	O

Peripheral	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
:	O
5	O
-	O
HT	O
)	O
synthesized	O
in	O
the	O
intestine	O
by	O
enterochromaffin	O
cells	O
(	O
ECs	O
)	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
peristaltic	O
of	O
the	O
gut	O
,	O
epithelial	O
secretion	O
and	O
promotes	O
the	O
development	O
and	O
maintenance	O
of	O
the	O
enteric	O
neurons	O
.	O

Recent	O
studies	O
showed	O
that	O
the	O
indigenous	O
gut	O
microbiota	O
modulates	O
5	O
-	O
HT	O
signalling	O
and	O
that	O
ECs	O
use	O
sensory	O
receptors	O
to	O
detect	O
dietary	O
and	O
microbiota	O
-	O
derived	O
signals	O
from	O
the	O
lumen	O
to	O
subsequently	O
transduce	O
the	O
information	O
to	O
the	O
nervous	O
system	O
.	O

We	O
hypothesized	O
that	O
Clostridium	B-bacteria
ramosum	I-bacteria
by	O
increasing	O
gut	O
5	O
-	O
HT	O
availability	O
consequently	O
contributes	O
to	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obesity	O
.	O

Using	O
germ	O
-	O
free	O
mice	O
and	O
mice	O
monoassociated	O
with	O
C	B-bacteria
.	I-bacteria
ramosum	I-bacteria
,	O
intestinal	O
cell	O
lines	O
and	O
mouse	O
organoids	O
,	O
we	O
demonstrated	O
that	O
bacterial	O
cell	O
components	O
stimulate	O
host	O
5	O
-	O
HT	O
secretion	O
and	O
program	O
the	O
differentiation	O
of	O
colonic	O
intestinal	O
stem	O
progenitors	O
toward	O
the	O
secretory	O
5	O
-	O
HT	O
-	O
producing	O
lineage	O
.	O

An	O
elevated	O
5	O
-	O
HT	O
level	O
regulates	O
the	O
expression	O
of	O
major	O
proteins	O
involved	O
in	O
intestinal	O
fatty	O
acid	O
absorption	O
in	O
vitro	O
,	O
suggesting	O
that	O
the	O
presence	O
of	O
C	O
.	I-bacteria
ramosum	I-bacteria
in	O
the	O
gut	O
promotes	O
5	O
-	O
HT	O
secretion	O
and	O
thereby	O
could	O
facilitates	O
intestinal	O
lipid	O
absorption	O
and	O
the	O
development	O
of	O
obesity	O
.	O

A	O
glycyl	O
radical	O
enzyme	O
enables	O
hydrogen	O
sulfide	O
production	O
by	O
the	O
human	O
intestinal	O
bacterium	O
Bilophila	B-bacteria
wadsworthia	I-bacteria
.	O

Hydrogen	O
sulfide	O
(	O
H2S	O
)	O
production	O
in	O
the	O
intestinal	O
microbiota	O
has	O
many	O
contributions	O
to	O
human	O
health	O
and	O
disease	O
.	O

An	O
important	O
source	O
of	O
H2S	O
in	O
the	O
human	O
gut	O
is	O
anaerobic	O
respiration	O
of	O
sulfite	O
released	O
from	O
the	O
abundant	O
dietary	O
and	O
host	O
-	O
derived	O
organic	O
sulfonate	O
substrate	O
in	O
the	O
gut	O
,	O
taurine	O
(	O
2	O
-	O
aminoethanesulfonate	O
)	O
.	O

However	O
,	O
the	O
enzymes	O
that	O
allow	O
intestinal	O
bacteria	O
to	O
access	O
sulfite	O
from	O
taurine	O
have	O
not	O
yet	O
been	O
identified	O
.	O

Here	O
we	O
decipher	O
the	O
complete	O
taurine	O
desulfonation	O
pathway	O
in	O
Bilophila	B-bacteria
wadsworthia	I-bacteria
3	I-bacteria
.	I-bacteria
1	I-bacteria
.	I-bacteria
6	I-bacteria
using	O
differential	O
proteomics	O
,	O
in	O
vitro	O
reconstruction	O
with	O
heterologously	O
produced	O
enzymes	O
,	O
and	O
identification	O
of	O
critical	O
intermediates	O
.	O

An	O
initial	O
deamination	O
of	O
taurine	O
to	O
sulfoacetaldehyde	O
by	O
a	O
known	O
taurine	O
:	O
pyruvate	O
aminotransferase	O
is	O
followed	O
,	O
unexpectedly	O
,	O
by	O
reduction	O
of	O
sulfoacetaldehyde	O
to	O
isethionate	O
(	O
2	O
-	O
hydroxyethanesulfonate	O
)	O
by	O
an	O
NADH	O
-	O
dependent	O
reductase	O
.	O

Isethionate	O
is	O
then	O
cleaved	O
to	O
sulfite	O
and	O
acetaldehyde	O
by	O
a	O
previously	O
uncharacterized	O
glycyl	O
radical	O
enzyme	O
(	O
GRE	O
)	O
,	O
isethionate	O
sulfite	O
-	O
lyase	O
(	O
IslA	O
)	O
.	O

The	O
acetaldehyde	O
produced	O
is	O
oxidized	O
to	O
acetyl	O
-	O
CoA	O
by	O
a	O
dehydrogenase	O
,	O
and	O
the	O
sulfite	O
is	O
reduced	O
to	O
H2S	O
by	O
dissimilatory	O
sulfite	O
reductase	O
.	O

This	O
unique	O
GRE	O
is	O
also	O
found	O
in	O
Desulfovibrio	B-bacteria
desulfuricans	I-bacteria
DSM642	I-bacteria
and	O
Desulfovibrio	B-bacteria
alaskensis	I-bacteria
G20	I-bacteria
,	O
which	O
use	O
isethionate	O
but	O
not	O
taurine	O
;	O
corresponding	O
knockout	O
mutants	O
of	O
D	B-bacteria
.	I-bacteria
alaskensis	I-bacteria
G20	I-bacteria
did	O
not	O
grow	O
with	O
isethionate	O
as	O
the	O
terminal	O
electron	O
acceptor	O
.	O

In	O
conclusion	O
,	O
the	O
novel	O
radical	O
-	O
based	O
C	O
-	O
S	O
bond	O
-	O
cleavage	O
reaction	O
catalyzed	O
by	O
IslA	O
diversifies	O
the	O
known	O
repertoire	O
of	O
GRE	O
superfamily	O
enzymes	O
and	O
enables	O
the	O
energy	O
metabolism	O
of	O
B	B-bacteria
.	I-bacteria
wadsworthia	I-bacteria
This	O
GRE	O
is	O
widely	O
distributed	O
in	O
gut	O
bacterial	O
genomes	O
and	O
may	O
represent	O
a	O
novel	O
target	O
for	O
control	O
of	O
intestinal	O
H2S	O
production	O
.	O

Convergent	O
gene	O
losses	O
illuminate	O
metabolic	O
and	O
physiological	O
changes	O
in	O
herbivores	O
and	O
carnivores	O
.	O

The	O
repeated	O
evolution	O
of	O
dietary	O
specialization	O
represents	O
a	O
hallmark	O
of	O
mammalian	O
ecology	O
.	O

To	O
detect	O
genomic	O
changes	O
that	O
are	O
associated	O
with	O
dietary	O
adaptations	O
,	O
we	O
performed	O
a	O
systematic	O
screen	O
for	O
convergent	O
gene	O
losses	O
associated	O
with	O
an	O
obligate	O
herbivorous	O
or	O
carnivorous	O
diet	O
in	O
31	O
placental	O
mammals	O
.	O

For	O
herbivores	O
,	O
our	O
screen	O
discovered	O
the	O
repeated	O
loss	O
of	O
the	O
triglyceride	O
lipase	O
inhibitor	O
PNLIPRP1	O
,	O
suggesting	O
enhanced	O
triglyceride	O
digestion	O
efficiency	O
.	O

Furthermore	O
,	O
several	O
herbivores	O
lost	O
the	O
pancreatic	O
exocytosis	O
factor	O
SYCN	O
,	O
providing	O
an	O
explanation	O
for	O
continuous	O
pancreatic	O
zymogen	O
secretion	O
in	O
these	O
species	O
.	O

For	O
carnivores	O
,	O
we	O
discovered	O
the	O
repeated	O
loss	O
of	O
the	O
hormone	O
-	O
receptor	O
pair	O
INSL5	O
-	O
RXFP4	O
that	O
regulates	O
appetite	O
and	O
glucose	O
homeostasis	O
,	O
which	O
likely	O
relates	O
to	O
irregular	O
feeding	O
patterns	O
and	O
constant	O
gluconeogenesis	O
.	O

Furthermore	O
,	O
reflecting	O
the	O
reduced	O
need	O
to	O
metabolize	O
plant	O
-	O
derived	O
xenobiotics	O
,	O
several	O
carnivores	O
lost	O
the	O
xenobiotic	O
receptors	O
NR1I3	O
and	O
NR1I2	O
Finally	O
,	O
the	O
carnivore	O
-	O
associated	O
loss	O
of	O
the	O
gastrointestinal	O
host	O
defense	O
gene	O
NOX1	O
could	O
be	O
related	O
to	O
a	O
reduced	O
gut	O
microbiome	O
diversity	O
.	O

By	O
revealing	O
convergent	O
gene	O
losses	O
associated	O
with	O
differences	O
in	O
dietary	O
composition	O
,	O
feeding	O
patterns	O
,	O
and	O
gut	O
microbiomes	O
,	O
our	O
study	O
contributes	O
to	O
understanding	O
how	O
similar	O
dietary	O
specializations	O
evolved	O
repeatedly	O
in	O
mammals	O
.	O

Green	O
,	O
Yellow	O
,	O
and	O
Red	O
Fluorescent	O
Proteins	O
as	O
Markers	O
for	O
Bacterial	O
Isolates	O
from	O
Mosquito	O
Midguts	O
.	O

The	O
growing	O
awareness	O
that	O
microbial	O
symbionts	O
residing	O
in	O
mosquito	O
midguts	O
can	O
interrupt	O
transmission	O
of	O
vector	O
-	O
borne	O
diseases	O
has	O
stimulated	O
interest	O
in	O
understanding	O
their	O
potential	O
role	O
in	O
mosquito	O
biology	O
.	O

Fluorescent	O
proteins	O
are	O
powerful	O
molecular	O
markers	O
that	O
provide	O
for	O
detailed	O
analysis	O
of	O
the	O
function	O
and	O
behavior	O
of	O
specific	O
midgut	O
bacterial	O
isolates	O
without	O
disturbing	O
the	O
normal	O
gut	O
microbiota	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
label	O
bacterial	O
isolates	O
from	O
the	O
midgut	O
of	O
Ochlerotatus	B-bacteria
triseriatus	I-bacteria
,	O
the	O
primary	O
vector	O
of	O
La	O
Crosse	O
virus	O
,	O
with	O
green	O
,	O
yellow	O
,	O
and	O
red	O
fluorescent	O
proteins	O
(	O
GFP	O
,	O
YFP	O
,	O
RFP	O
)	O
via	O
electroporation	O
.	O

We	O
also	O
assessed	O
the	O
stability	O
of	O
GFP	O
-	O
,	O
YFP	O
-	O
,	O
and	O
RFP	O
-	O
bearing	O
plasmids	O
and	O
their	O
effect	O
on	O
bacterial	O
growth	O
.	O

Seven	O
of	O
eleven	O
bacterial	O
species	O
could	O
not	O
be	O
labeled	O
despite	O
several	O
attempts	O
.	O

Labeling	O
of	O
Escherichia	B-bacteria
coli	I-bacteria
and	O
Enterobacter	B-bacteria
cloacae	I-bacteria
was	O
successfully	O
achieved	O
with	O
all	O
three	O
fluorescent	O
proteins	O
.	O

In	O
contrast	O
,	O
labeling	O
of	O
Aerococcus	B-bacteria
viridans	I-bacteria
was	O
achieved	O
with	O
GFP	O
only	O
and	O
labeling	O
of	O
Aeromonas	B-bacteria
hydrophila	I-bacteria
was	O
achieved	O
with	O
GFP	O
and	O
YFP	O
only	O
.	O

The	O
stability	O
of	O
GFP	O
plasmid	O
varied	O
among	O
bacterial	O
species	O
with	O
A	B-bacteria
.	I-bacteria
hydrophila	I-bacteria
followed	O
by	O
E	B-bacteria
.	I-bacteria
cloacae	I-bacteria
having	O
the	O
most	O
stable	O
GFP	O
label	O
.	O

In	O
contrast	O
,	O
YFP	O
and	O
RFP	O
plasmids	O
were	O
very	O
stable	O
in	O
all	O
bacterial	O
species	O
possessing	O
these	O
labels	O
.	O

GFP	O
plasmid	O
reduced	O
the	O
growth	O
of	O
labeled	O
strains	O
relative	O
to	O
wild	O
type	O
but	O
this	O
effect	O
was	O
not	O
evident	O
in	O
YFP	O
and	O
RFP	O
plasmids	O
.	O

These	O
findings	O
suggest	O
that	O
some	O
mosquito	O
midgut	O
bacterial	O
isolates	O
can	O
effectively	O
be	O
labeled	O
with	O
GFP	O
,	O
YFP	O
and	O
RFP	O
plasmids	O
allowing	O
non	O
-	O
destructive	O
studies	O
on	O
their	O
functions	O
within	O
the	O
vector	O
.	O

Diet	O
-	O
Gut	O
Microbiota	O
Interactions	O
and	O
Gestational	O
Diabetes	O
Mellitus	O
(	O
GDM	O
)	O
.	O

Medical	O
nutritional	O
therapy	O
is	O
the	O
first	O
-	O
line	O
approach	O
in	O
managing	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
.	O

Diet	O
is	O
also	O
a	O
powerful	O
modulator	O
of	O
the	O
gut	O
microbiota	O
,	O
whose	O
impact	O
on	O
insulin	O
resistance	O
and	O
the	O
inflammatory	O
response	O
in	O
the	O
host	O
are	O
well	O
known	O
.	O

Changes	O
in	O
the	O
gut	O
microbiota	O
composition	O
have	O
been	O
described	O
in	O
pregnancies	O
either	O
before	O
the	O
onset	O
of	O
GDM	O
or	O
after	O
its	O
diagnosis	O
.	O

The	O
possible	O
modulation	O
of	O
the	O
gut	O
microbiota	O
by	O
dietary	O
interventions	O
in	O
pregnancy	O
is	O
a	O
topic	O
of	O
emerging	O
interest	O
,	O
in	O
consideration	O
of	O
the	O
potential	O
effects	O
on	O
maternal	O
and	O
consequently	O
neonatal	O
health	O
.	O

To	O
date	O
,	O
very	O
few	O
data	O
from	O
observational	O
studies	O
are	O
available	O
about	O
the	O
associations	O
between	O
diet	O
and	O
the	O
gut	O
microbiota	O
in	O
pregnancy	O
complicated	O
by	O
GDM	O
.	O

In	O
this	O
review	O
,	O
we	O
analyzed	O
the	O
available	O
data	O
and	O
discussed	O
the	O
current	O
knowledge	O
about	O
diet	O
manipulation	O
in	O
order	O
to	O
shape	O
the	O
gut	O
microbiota	O
in	O
pregnancy	O
.	O

Hesperidin	O
Effects	O
on	O
Gut	O
Microbiota	O
and	O
Gut	O
-	O
Associated	O
Lymphoid	O
Tissue	O
in	O
Healthy	O
Rats	O
.	O

Hesperidin	O
,	O
found	O
in	O
citrus	O
fruits	O
,	O
has	O
shown	O
a	O
wide	O
range	O
of	O
biological	O
properties	O
.	O

Nonetheless	O
,	O
a	O
more	O
in	O
-	O
depth	O
investigation	O
is	O
required	O
on	O
the	O
effects	O
on	O
the	O
immune	O
system	O
,	O
and	O
in	O
particular	O
,	O
on	O
the	O
gut	O
-	O
associated	O
lymphoid	O
tissue	O
,	O
together	O
with	O
its	O
relationship	O
with	O
the	O
gut	O
microbiota	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
establish	O
the	O
influence	O
of	O
oral	O
hesperidin	O
administration	O
on	O
the	O
intestinal	O
lymphoid	O
tissue	O
and	O
on	O
the	O
gut	O
microbiota	O
composition	O
in	O
healthy	O
animals	O
.	O

Lewis	O
rats	O
were	O
orally	O
administrated	O
100	O
or	O
200	O
mg	O
/	O
kg	O
hesperidin	O
three	O
times	O
per	O
week	O
for	O
four	O
weeks	O
.	O

Microbiota	O
composition	O
and	O
IgA	O
-	O
coated	O
bacteria	O
were	O
determined	O
in	O
caecal	O
content	O
.	O

Mesenteric	O
lymph	O
node	O
lymphocyte	O
(	O
MLNL	O
)	O
composition	O
and	O
functionality	O
were	O
assessed	O
.	O

IgA	O
,	O
cytokines	O
,	O
and	O
gene	O
expression	O
in	O
the	O
small	O
intestine	O
were	O
quantified	O
.	O

Hesperidin	O
administration	O
resulted	O
in	O
a	O
higher	O
number	O
of	O
bacteria	O
and	O
IgA	O
-	O
coated	O
bacteria	O
,	O
with	O
changes	O
in	O
microbiota	O
composition	O
such	O
as	O
higher	O
Lactobacillus	B-bacteria
proportion	O
.	O

Hesperidin	O
was	O
also	O
able	O
to	O
increase	O
the	O
small	O
intestine	O
IgA	O
content	O
.	O

These	O
changes	O
in	O
the	O
small	O
intestine	O
were	O
accompanied	O
by	O
a	O
decrease	O
in	O
interferon	O
-	O
gamma	O
and	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
concentration	O
.	O

In	O
addition	O
,	O
hesperidin	O
increased	O
the	O
relative	O
proportion	O
of	O
TCRalphabeta	O
+	O
lymphocytes	O
in	O
MLNL	O
.	O

These	O
results	O
show	O
the	O
immunomodulatory	O
actions	O
of	O
hesperidin	O
on	O
the	O
gut	O
-	O
associated	O
lymphoid	O
tissue	O
and	O
reinforce	O
its	O
role	O
as	O
a	O
prebiotic	O
.	O

Sex	O
-	O
Specific	O
Changes	O
in	O
Gut	O
Microbiome	O
Composition	O
following	O
Blueberry	O
Consumption	O
in	O
C57BL	O
/	O
6J	O
Mice	O
.	O

The	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
properties	O
of	O
blueberries	O
improve	O
vascular	O
function	O
and	O
insulin	O
sensitivity	O
.	O

However	O
,	O
the	O
bioavailability	O
of	O
the	O
active	O
compounds	O
in	O
blueberries	O
is	O
largely	O
dependent	O
on	O
the	O
gut	O
microbiota	O
,	O
which	O
may	O
themselves	O
be	O
altered	O
by	O
blueberry	O
components	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
explore	O
a	O
possible	O
sex	O
-	O
dependent	O
modulation	O
of	O
the	O
gut	O
microbiota	O
following	O
supplementation	O
with	O
blueberries	O
in	O
adult	O
mice	O
.	O

Eight	O
-	O
week	O
-	O
old	O
C57BL	O
/	O
6J	O
mice	O
(	O
n	O
=	O
7	O
(	O
-	O
)	O
10	O
/	O
group	O
)	O
were	O
provided	O
with	O
control	O
or	O
blueberry	O
-	O
containing	O
diets	O
(	O
5	O
%	O
freeze	O
-	O
dried	O
powder	O
)	O
for	O
4	O
weeks	O
.	O

Body	O
weight	O
,	O
composition	O
,	O
and	O
food	O
intake	O
were	O
measured	O
weekly	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
cecal	O
contents	O
for	O
16S	O
rRNA	O
sequencing	O
.	O

Blueberry	O
feeding	O
decreased	O
a	O
-	O
diversity	O
(	O
operational	O
taxonomical	O
unit	O
&	O
nbsp	O
;	O
abundance	O
)	O
and	O
altered	O
b	O
-	O
diversity	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
the	O
phylum	O
level	O
,	O
the	O
Firmicutes	B-bacteria
to	O
Bacteroidetes	B-bacteria
ratio	O
was	O
significantly	O
lower	O
in	O
the	O
blueberry	O
-	O
fed	O
groups	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
along	O
with	O
increased	O
Tenericutes	B-bacteria
and	O
decreased	O
Deferribacteres	B-bacteria
.	O

At	O
the	O
genus	O
level	O
,	O
blueberry	O
feeding	O
led	O
to	O
sexually	O
-	O
dimorphic	O
differences	O
,	O
which	O
were	O
associated	O
with	O
predicted	O
metabolic	O
pathways	O
.	O

Pathways	O
such	O
as	O
fatty	O
acid	O
and	O
lipid	O
metabolism	O
were	O
significantly	O
different	O
and	O
demonstrated	O
a	O
stronger	O
association	O
with	O
microbes	O
in	O
the	O
male	O
.	O

To	O
summarize	O
,	O
blueberry	O
supplementation	O
led	O
to	O
sexually	O
-	O
dimorphic	O
global	O
changes	O
in	O
the	O
gut	O
microbiome	O
,	O
which	O
could	O
possibly	O
contribute	O
to	O
physiological	O
changes	O
in	O
mice	O
.	O

Fecal	O
Microbiota	O
Analysis	O
in	O
Patients	O
Going	O
through	O
a	O
Depressive	O
Episode	O
during	O
Treatment	O
in	O
a	O
Psychiatric	O
Hospital	O
Setting	O
.	O

RATIONALE	O
:	O
There	O
is	O
a	O
worldwide	O
prevalence	O
of	O
generalized	O
anxiety	O
and	O
major	O
depressive	O
disorders	O
(	O
MDD	O
)	O
.	O

Gut	O
(	O
-	O
)	O
brain	O
axis	O
dysfunction	O
,	O
antibacterial	O
activity	O
,	O
and	O
modulatory	O
effects	O
of	O
antidepressants	O
toward	O
intestinal	O
bacteria	O
have	O
been	O
shown	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

OBJECTIVES	O
:	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
hospital	O
stay	O
,	O
including	O
escitalopram	O
administration	O
,	O
on	O
gut	O
microbiota	O
in	O
patients	O
with	O
depressive	O
episodes	O
.	O

METHODS	O
:	O
After	O
admission	O
to	O
the	O
hospital	O
and	O
7	O
-	O
days	O
washout	O
from	O
all	O
medications	O
the	O
composition	O
of	O
fecal	O
microbiota	O
samples	O
was	O
evaluated	O
at	O
baseline	O
(	O
W0	O
)	O
and	O
after	O
6	O
weeks	O
(	O
W6	O
)	O
,	O
using	O
16S	O
rRNA	O
sequencing	O
.	O

The	O
study	O
was	O
conducted	O
on	O
17	O
inpatients	O
(	O
52	O
.	O
9	O
%	O
females	O
)	O
,	O
who	O
followed	O
the	O
same	O
daily	O
hospital	O
routine	O
,	O
including	O
a	O
standard	O
diet	O
and	O
received	O
5	O
(	O
-	O
)	O
20	O
mg	O
daily	O
doses	O
of	O
escitalopram	O
.	O

RESULTS	O
:	O
At	O
the	O
end	O
of	O
treatment	O
(	O
W6	O
)	O
,	O
no	O
change	O
was	O
observed	O
in	O
the	O
Chao1	O
index	O
.	O

However	O
,	O
Shannon	O
(	O
median	O
(	O
Q1	O
(	O
-	O
)	O
Q3	O
)	O
:	O
W0	O
2	O
.	O
78	O
(	O
2	O
.	O
67	O
(	O
-	O
)	O
3	O
.	O
02	O
)	O
vs	O
.	O
W6	O
3	O
.	O
11	O
(	O
2	O
.	O
80	O
(	O
-	O
)	O
3	O
.	O
30	O
)	O
)	O
,	O
and	O
inverse	O
Simpson	O
(	O
median	O
(	O
Q1	O
(	O
-	O
)	O
Q3	O
)	O
:	O
W0	O
9	O
.	O
26	O
(	O
7	O
.	O
26	O
(	O
-	O
)	O
13	O
.	O
76	O
)	O
vs	O
.	O
W6	O
12	O
.	O
13	O
(	O
9	O
.	O
17	O
(	O
-	O
)	O
15	O
.	O
73	O
)	O
)	O
indices	O
increased	O
significantly	O
compared	O
to	O
baseline	O
values	O
(	O
False	O
Discovery	O
Rate	O
p	O
(	O
q	O
)	O
=	O
0	O
.	O
031	O
and	O
q	O
=	O
0	O
.	O
011	O
,	O
respectively	O
)	O
.	O

We	O
also	O
found	O
that	O
between	O
-	O
subject	O
W0	O
Bray	O
(	O
-	O
)	O
Curtis	O
dissimilarities	O
were	O
significantly	O
higher	O
than	O
W0	O
(	O
-	O
)	O
W6	O
within	O
-	O
subject	O
dissimilarities	O
(	O
median	O
(	O
Q1	O
(	O
-	O
)	O
Q3	O
)	O
:	O
0	O
.	O
68	O
(	O
0	O
.	O
56	O
(	O
-	O
)	O
0	O
.	O
77	O
)	O
vs	O
.	O
0	O
.	O
38	O
(	O
0	O
.	O
35	O
(	O
-	O
)	O
0	O
.	O
52	O
)	O
,	O
two	O
sided	O
Mann	O
(	O
-	O
)	O
Whitney	O
test	O
p	O
<	O
0	O
.	O
00001	O
.	O

The	O
within	O
-	O
subject	O
dissimilarities	O
did	O
not	O
depend	O
on	O
sex	O
,	O
age	O
,	O
BMI	O
,	O
illness	O
duration	O
and	O
a	O
daily	O
dose	O
of	O
escitalopram	O
.	O

No	O
significant	O
differences	O
between	O
taxa	O
levels	O
,	O
at	O
the	O
studied	O
time	O
points	O
,	O
were	O
observed	O
when	O
adjusted	O
for	O
multiple	O
hypotheses	O
testing	O
procedures	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
a	O
six	O
-	O
week	O
treatment	O
in	O
a	O
psychiatric	O
hospital	O
setting	O
resulted	O
in	O
increased	O
alpha	O
biodiversity	O
in	O
fecal	O
microbiota	O
,	O
however	O
its	O
causal	O
relationship	O
with	O
patients	O
'	O
mental	O
health	O
was	O
not	O
proved	O
.	O

We	O
have	O
also	O
found	O
that	O
individual	O
microbiome	O
stability	O
was	O
not	O
affected	O
by	O
hospitalization	O
.	O

Efficacy	O
and	O
Safety	O
of	O
Lactobacillus	B-bacteria
Plantarum	I-bacteria
C29	I-bacteria
-	O
Fermented	O
Soybean	O
(	O
DW2009	O
)	O
in	O
Individuals	O
with	O
Mild	O
Cognitive	O
Impairment	O
:	O
A	O
12	O
-	O
Week	O
,	O
Multi	O
-	O
Center	O
,	O
Randomized	O
,	O
Double	O
-	O
Blind	O
,	O
Placebo	O
-	O
Controlled	O
Clinical	O
Trial	O
.	O

Early	O
intervention	O
using	O
dietary	O
supplements	O
may	O
be	O
effective	O
in	O
alleviating	O
cognitive	O
impairment	O
among	O
individuals	O
with	O
mild	O
cognitive	O
impairment	O
(	O
MCI	O
)	O
.	O

This	O
study	O
investigated	O
the	O
efficacy	O
and	O
safety	O
of	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
C29	I-bacteria
-	O
fermented	O
soybean	O
(	O
DW2009	O
)	O
as	O
a	O
nutritional	O
supplement	O
for	O
cognitive	O
enhancement	O
.	O

One	O
hundred	O
individuals	O
with	O
MCI	O
were	O
randomly	O
assigned	O
to	O
take	O
DW2009	O
(	O
800	O
mg	O
/	O
day	O
,	O
n	O
=	O
50	O
)	O
or	O
placebo	O
(	O
800	O
mg	O
/	O
day	O
,	O
n	O
=	O
50	O
)	O
for	O
12	O
weeks	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
change	O
in	O
the	O
composite	O
score	O
of	O
cognitive	O
functions	O
related	O
to	O
memory	O
and	O
attention	O
,	O
measured	O
by	O
computerized	O
neurocognitive	O
function	O
tests	O
.	O

Associations	O
between	O
changes	O
in	O
serum	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
levels	O
and	O
cognitive	O
performance	O
for	O
each	O
treatment	O
group	O
were	O
evaluated	O
.	O

Compared	O
to	O
the	O
placebo	O
group	O
,	O
the	O
DW2009	O
group	O
showed	O
greater	O
improvements	O
in	O
the	O
combined	O
cognitive	O
functions	O
(	O
z	O
=	O
2	O
.	O
36	O
,	O
p	O
for	O
interaction	O
=	O
0	O
.	O
02	O
)	O
,	O
especially	O
in	O
the	O
attention	O
domain	O
(	O
z	O
=	O
2	O
.	O
34	O
,	O
p	O
for	O
interaction	O
=	O
0	O
.	O
02	O
)	O
.	O

Cognitive	O
improvement	O
was	O
associated	O
with	O
increased	O
serum	O
BDNF	O
levels	O
after	O
consumption	O
of	O
DW2009	O
(	O
t	O
=	O
2	O
.	O
83	O
,	O
p	O
=	O
0	O
.	O
007	O
)	O
.	O

The	O
results	O
of	O
this	O
clinical	O
trial	O
suggest	O
that	O
DW2009	O
can	O
be	O
safely	O
administered	O
to	O
enhance	O
cognitive	O
function	O
in	O
individuals	O
with	O
MCI	O
.	O

Increased	O
serum	O
BDNF	O
levels	O
after	O
administering	O
DW2009	O
may	O
provide	O
preliminary	O
insight	O
into	O
the	O
underlying	O
effects	O
of	O
cognitive	O
improvement	O
,	O
which	O
suggests	O
the	O
importance	O
of	O
the	O
gut	O
-	O
brain	O
axis	O
in	O
ameliorating	O
cognitive	O
deficits	O
in	O
MCI	O
.	O

Synbiotic	O
meal	O
decreases	O
uremic	O
toxins	O
in	O
hemodialysis	O
individuals	O
:	O
A	O
placebo	O
-	O
controlled	O
trial	O
.	O

Generation	O
of	O
uremic	O
toxins	O
p	O
-	O
cresylsulfate	O
(	O
p	O
-	O
CS	O
)	O
,	O
indoxyl	O
sulfate	O
(	O
IS	O
)	O
and	O
indole	O
3	O
-	O
acetic	O
acid	O
(	O
IAA	O
)	O
in	O
hemodialysis	O
(	O
HD	O
)	O
individuals	O
may	O
be	O
associated	O
with	O
the	O
gut	O
flora	O
and	O
recognized	O
markers	O
of	O
disease	O
progression	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
synbiotic	O
meal	O
on	O
uremic	O
toxins	O
in	O
HD	O
individuals	O
.	O

We	O
conducted	O
randomized	O
singleblind	O
and	O
placebo	O
-	O
controlled	O
intervention	O
study	O
with	O
58	O
HD	O
subjects	O
(	O
20F	O
/	O
38M	O
,	O
63	O
.	O
1	O
+	O
/	O
-	O
10	O
.	O
9	O
-	O
old	O
)	O
who	O
were	O
randomly	O
allocated	O
in	O
synbiotic	O
group	O
(	O
SG	O
,	O
40g	O
of	O
extruded	O
sorghum	O
plus	O
100mL	O
of	O
unfermented	O
probiotic	O
milk	O
)	O
or	O
control	O
group	O
(	O
CG	O
,	O
40g	O
of	O
extruded	O
corn	O
plus	O
100mL	O
of	O
pasteurized	O
milk	O
)	O
,	O
during	O
7	O
-	O
wk	O
Metabolic	O
markers	O
and	O
uremic	O
toxins	O
,	O
fecal	O
concentration	O
of	O
short	O
chain	O
fatty	O
acid	O
and	O
pH	O
value	O
was	O
determined	O
.	O

The	O
SG	O
group	O
had	O
decreased	O
serum	O
p	O
-	O
CS	O
and	O
IS	O
,	O
as	O
well	O
as	O
decreased	O
urea	O
concentration	O
(	O
p	O
<	O
.	O
05	O
)	O
compared	O
to	O
CG	O
.	O

SG	O
showed	O
higher	O
fecal	O
butyric	O
acid	O
and	O
lower	O
pH	O
compared	O
to	O
baseline	O
and	O
SC	O
(	O
p	O
<	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
serum	O
p	O
-	O
CS	O
and	O
fecal	O
pH	O
were	O
positively	O
correlated	O
to	O
urea	O
concentration	O
in	O
SG	O
participants	O
at	O
the	O
endpoint	O
.	O

The	O
consumption	O
of	O
the	O
synbiotic	O
meal	O
during	O
7	O
-	O
wk	O
reduced	O
colonic	O
pH	O
,	O
and	O
reduced	O
serum	O
uremic	O
(	O
p	O
-	O
CS	O
and	O
IS	O
)	O
toxins	O
and	O
urea	O
in	O
HD	O
subjects	O
.	O

Conjugal	O
transfer	O
of	O
erm	O
(	O
B	O
)	O
and	O
multiple	O
tet	O
genes	O
from	O
Lactobacillus	B-bacteria
spp	I-bacteria
.	I-bacteria
to	O
bacterial	O
pathogens	O
in	O
animal	O
gut	O
,	O
in	O
vitro	O
and	O
during	O
food	O
fermentation	O
.	O

Three	O
strains	O
of	O
Lactobacillus	B-bacteria
comprising	O
Lactobacillus	B-bacteria
salivarius	I-bacteria
(	O
CHS	O
-	O
1E	O
and	O
CH7	O
-	O
1E	O
)	O
and	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
(	O
CH2	O
-	O
2	O
)	O
previously	O
isolated	O
from	O
chicken	O
meat	O
were	O
analyzed	O
for	O
their	O
transferability	O
of	O
antibiotic	O
resistance	O
(	O
AR	O
)	O
genes	O
to	O
pathogenic	O
strains	O
under	O
in	O
vivo	O
,	O
in	O
vitro	O
,	O
and	O
during	O
food	O
fermentation	O
.	O

For	O
in	O
vivo	O
model	O
,	O
Albino	O
Wistar	O
rats	O
were	O
inoculated	O
with	O
10	O
(	O
10	O
)	O
CFU	O
/	O
g	O
/	O
ml	O
of	O
Enterococcus	B-bacteria
faecalis	I-bacteria
JH2	I-bacteria
-	I-bacteria
2	I-bacteria
(	O
recipient	O
)	O
.	O

After	O
7days	O
,	O
either	O
of	O
two	O
donors	O
L	B-bacteria
.	I-bacteria
salivarius	I-bacteria
CH7	I-bacteria
-	I-bacteria
1E	I-bacteria
or	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
[	O
harbouring	O
erythromycin	O
and	O
tetracycline	O
resistance	O
genes	O
]	O
were	O
introduced	O
at	O
a	O
concentration	O
of	O
10	O
(	O
9	O
)	O
CFU	O
/	O
ml	O
daily	O
for	O
1week	O
.	O

Two	O
days	O
after	O
donor	O
introduction	O
,	O
there	O
was	O
a	O
stable	O
increase	O
in	O
the	O
number	O
of	O
transconjugants	O
in	O
the	O
animal	O
faeces	O
from	O
10	O
(	O
2	O
)	O
to	O
10	O
(	O
3	O
)	O
CFU	O
/	O
g	O
and	O
presented	O
erm	O
(	O
B	O
)	O
,	O
tet	O
(	O
M	O
)	O
,	O
tet	O
(	O
L	O
)	O
and	O
tet	O
(	O
W	O
)	O
in	O
their	O
genome	O
like	O
donor	O
strains	O
.	O

Similar	O
observations	O
were	O
made	O
with	O
in	O
vitro	O
filter	O
mating	O
between	O
CHS	O
-	O
1E	O
,	O
CH2	O
-	O
2	O
and	O
CH7	O
-	O
1E	O
and	O
E	B-bacteria
.	I-bacteria
faecalis	I-bacteria
JH2	I-bacteria
-	I-bacteria
2	I-bacteria
with	O
transfer	O
frequencies	O
of	O
1x10	O
(	O
-	O
4	O
)	O
,	O
3	O
.	O
8x10	O
(	O
-	O
3	O
)	O
and	O
2x10	O
(	O
-	O
3	O
)	O
per	O
donor	O
cell	O
respectively	O
.	O

With	O
the	O
results	O
obtained	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
the	O
AR	O
transferability	O
of	O
donor	O
strains	O
was	O
estimated	O
during	O
food	O
fermentation	O
(	O
chicken	O
sausage	O
,	O
fermented	O
milk	O
or	O
idli	O
batter	O
)	O
with	O
pathogenic	O
recipient	O
strains	O
added	O
as	O
contaminants	O
.	O

At	O
the	O
end	O
of	O
mating	O
period	O
,	O
phenotypic	O
resistance	O
to	O
erythromycin	O
and	O
tetracycline	O
in	O
Listeria	B-bacteria
monocytogenes	I-bacteria
and	O
Yersinia	B-bacteria
enterocolitica	I-bacteria
strains	I-bacteria
was	O
observed	O
.	O

This	O
study	O
showed	O
the	O
ability	O
of	O
food	O
borne	O
Lactobacillus	B-bacteria
in	O
diffusing	O
their	O
AR	O
traits	O
in	O
diverse	O
natural	O
environments	O
increasing	O
their	O
concern	O
of	O
AR	O
dissemination	O
in	O
the	O
food	O
chain	O
when	O
used	O
as	O
food	O
additives	O
and	O
/	O
or	O
probiotics	O
.	O

Effect	O
of	O
Delivery	O
Mode	O
and	O
Nutrition	O
on	O
Gut	O
Microbiota	O
in	O
Neonates	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
The	O
mode	O
of	O
delivery	O
(	O
vaginal	O
or	O
cesarean	O
section	O
)	O
and	O
feeding	O
type	O
(	O
breastfeeding	O
or	O
formula	O
feeding	O
)	O
of	O
neonates	O
are	O
considered	O
the	O
most	O
influential	O
factors	O
in	O
the	O
development	O
of	O
gut	O
microbiota	O
.	O

OBJECTIVES	O
:	O
This	O
study	O
investigated	O
the	O
effect	O
of	O
prebiotic	O
-	O
rich	O
breast	O
milk	O
on	O
overcoming	O
gut	O
microbiota	O
dysbiosis	O
.	O

METHOD	O
:	O
Stool	O
samples	O
from	O
36	O
healthy	O
Japanese	O
neonates	O
were	O
obtained	O
at	O
4	O
days	O
and	O
1	O
month	O
of	O
age	O
,	O
and	O
divided	O
into	O
4	O
groups	O
based	O
on	O
mode	O
of	O
delivery	O
and	O
feeding	O
type	O
.	O

The	O
gut	O
microbiota	O
composition	O
and	O
bacterial	O
diversity	O
were	O
assessed	O
using	O
16S	O
rRNA	O
sequencing	O
.	O

RESULTS	O
:	O
At	O
4	O
days	O
old	O
,	O
vaginally	O
delivered	O
neonates	O
had	O
a	O
significantly	O
higher	O
diversity	O
of	O
bacteria	O
than	O
those	O
born	O
by	O
cesarean	O
section	O
.	O

Bacteroidales	B-bacteria
and	O
Enterobacteriales	B-bacteria
were	O
overrepresented	O
in	O
vaginally	O
delivered	O
neonates	O
(	O
p	O
=	O
0	O
.	O
0031	O
and	O
p	O
=	O
0	O
.	O
011	O
)	O
,	O
while	O
Bacillales	B-bacteria
and	O
Lactobacillales	B-bacteria
were	O
overrepresented	O
in	O
caesarean	O
section	O
delivered	O
neonates	O
(	O
p	O
=	O
0	O
.	O
012	O
and	O
p	O
=	O
0	O
.	O
0016	O
)	O
.	O

However	O
,	O
there	O
was	O
little	O
difference	O
in	O
bacterial	O
diversity	O
and	O
bacterial	O
relative	O
abundance	O
at	O
1	O
month	O
of	O
age	O
between	O
groups	O
.	O

CONCLUSIONS	O
:	O
Cesarean	O
section	O
delivery	O
appeared	O
to	O
reduce	O
the	O
diversity	O
of	O
neonate	O
gut	O
microbiota	O
,	O
resulting	O
in	O
dysbiosis	O
,	O
but	O
this	O
improved	O
to	O
the	O
equivalent	O
level	O
seen	O
in	O
vaginally	O
delivered	O
infants	O
by	O
1	O
month	O
of	O
age	O
.	O

Breastfeeding	O
,	O
even	O
for	O
short	O
periods	O
,	O
may	O
therefore	O
improve	O
neonate	O
gut	O
dysbiosis	O
.	O

Modulation	O
of	O
Gut	O
Microbiota	O
Composition	O
by	O
Serotonin	O
Signaling	O
Influences	O
Intestinal	O
Immune	O
Response	O
and	O
Susceptibility	O
to	O
Colitis	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
[	O
5	O
-	O
HT	O
]	O
)	O
is	O
synthesized	O
mainly	O
within	O
enterochromaffin	O
(	O
EC	O
)	O
cells	O
in	O
the	O
gut	O
,	O
and	O
tryptophan	O
hydroxylase	O
1	O
(	O
Tph1	O
)	O
is	O
the	O
rate	O
-	O
limiting	O
enzyme	O
for	O
5	O
-	O
HT	O
synthesis	O
in	O
EC	O
cells	O
.	O

Accumulating	O
evidence	O
suggests	O
the	O
importance	O
of	O
gut	O
microbiota	O
in	O
intestinal	O
inflammation	O
.	O

Considering	O
the	O
close	O
proximity	O
of	O
EC	O
cells	O
and	O
the	O
microbes	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
gut	O
-	O
derived	O
5	O
-	O
HT	O
on	O
the	O
microbiota	O
and	O
the	O
susceptibility	O
to	O
colitis	O
.	O

METHODS	O
:	O
Gut	O
microbiota	O
of	O
Tph1	O
(	O
-	O
/	O
-	O
)	O
and	O
Tph1	O
(	O
+	O
/	O
-	O
)	O
mice	O
were	O
investigated	O
by	O
deep	O
sequencing	O
.	O

Direct	O
influence	O
of	O
5	O
-	O
HT	O
on	O
bacteria	O
was	O
assessed	O
by	O
using	O
in	O
vitro	O
system	O
of	O
isolated	O
commensals	O
.	O

The	O
indirect	O
influence	O
of	O
5	O
-	O
HT	O
on	O
microbiota	O
was	O
assessed	O
by	O
measuring	O
antimicrobial	O
peptides	O
,	O
specifically	O
beta	O
-	O
defensins	O
,	O
in	O
the	O
colon	O
of	O
mice	O
and	O
HT	O
-	O
29	O
colonic	O
epithelial	O
cells	O
.	O

The	O
impact	O
of	O
gut	O
microbiota	O
on	O
the	O
development	O
of	O
dextran	O
sulfate	O
sodium	O
-	O
induced	O
colitis	O
was	O
assessed	O
by	O
transferring	O
gut	O
microbiota	O
from	O
Tph1	O
(	O
-	O
/	O
-	O
)	O
mice	O
to	O
Tph1	O
(	O
+	O
/	O
-	O
)	O
littermates	O
and	O
vice	O
versa	O
,	O
as	O
well	O
as	O
in	O
germ	O
-	O
free	O
mice	O
.	O

RESULTS	O
:	O
A	O
significant	O
difference	O
in	O
microbial	O
composition	O
between	O
Tph1	O
(	O
-	O
/	O
-	O
)	O
and	O
Tph1	O
(	O
+	O
/	O
-	O
)	O
littermates	O
was	O
observed	O
.	O

5	O
-	O
HT	O
directly	O
stimulated	O
and	O
inhibited	O
the	O
growth	O
of	O
commensal	O
bacteria	O
in	O
vitro	O
,	O
exhibiting	O
a	O
concentration	O
-	O
dependent	O
and	O
species	O
-	O
specific	O
effect	O
.	O

5	O
-	O
HT	O
also	O
inhibited	O
beta	O
-	O
defensin	O
production	O
by	O
HT	O
-	O
29	O
cells	O
.	O

Microbial	O
transfer	O
from	O
Tph1	O
(	O
-	O
/	O
-	O
)	O
to	O
Tph1	O
(	O
+	O
/	O
-	O
)	O
littermates	O
and	O
vice	O
versa	O
altered	O
colitis	O
severity	O
,	O
with	O
microbiota	O
from	O
Tph1	O
(	O
-	O
/	O
-	O
)	O
mice	O
mediating	O
the	O
protective	O
effects	O
.	O

Furthermore	O
,	O
germ	O
-	O
free	O
mice	O
colonized	O
with	O
microbiota	O
from	O
Tph1	O
(	O
-	O
/	O
-	O
)	O
mice	O
exhibited	O
less	O
severe	O
dextran	O
sulfate	O
sodium	O
-	O
induced	O
colitis	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
demonstrate	O
a	O
novel	O
role	O
of	O
gut	O
-	O
derived	O
5	O
-	O
HT	O
in	O
shaping	O
gut	O
microbiota	O
composition	O
in	O
relation	O
to	O
susceptibility	O
to	O
colitis	O
,	O
identifying	O
5	O
-	O
HT	O
-	O
microbiota	O
axis	O
as	O
a	O
potential	O
new	O
therapeutic	O
target	O
in	O
intestinal	O
inflammatory	O
disorders	O
.	O

Prospective	O
surveillance	O
of	O
bacterial	O
colonization	O
and	O
primary	O
sepsis	O
:	O
findings	O
of	O
a	O
tertiary	O
neonatal	O
intensive	O
and	O
intermediate	O
care	O
unit	O
.	O

BACKGROUND	O
:	O
Preterm	O
infants	O
and	O
critically	O
ill	O
neonates	O
are	O
predisposed	O
to	O
nosocomial	O
infections	O
as	O
sepsis	O
.	O

Moreover	O
,	O
these	O
infants	O
acquire	O
commensal	O
bacteria	O
,	O
which	O
might	O
become	O
potentially	O
harmful	O
.	O

On	O
-	O
ward	O
transmission	O
of	O
these	O
bacteria	O
can	O
cause	O
outbreaks	O
.	O

AIM	O
:	O
To	O
report	O
the	O
findings	O
of	O
a	O
prospective	O
surveillance	O
of	O
bacterial	O
colonization	O
and	O
primary	O
sepsis	O
in	O
preterm	O
infants	O
and	O
neonates	O
.	O

METHODS	O
:	O
The	O
results	O
of	O
the	O
surveillance	O
of	O
bacterial	O
colonization	O
of	O
the	O
gut	O
and	O
the	O
respiratory	O
tract	O
,	O
targeting	O
meticillin	B-bacteria
-	I-bacteria
resistant	I-bacteria
Staphylococcus	I-bacteria
aureus	I-bacteria
(	O
MRSA	B-bacteria
)	O
,	O
vancomycin	B-bacteria
-	I-bacteria
resistant	I-bacteria
enterococci	I-bacteria
(	O
VRE	B-bacteria
)	O
and	O
Gram	O
-	O
negative	O
bacteria	O
from	O
November	O
2016	O
to	O
March	O
2018	O
were	O
analysed	O
.	O

Bacterial	O
colonization	O
was	O
compared	O
to	O
surveillance	O
of	O
sepsis	O
.	O

FINDINGS	O
:	O
Six	O
-	O
hundred	O
and	O
seventy	O
-	O
one	O
patients	O
were	O
admitted	O
and	O
87	O
.	O
0	O
%	O
(	O
N	O
=	O
584	O
)	O
of	O
the	O
patients	O
were	O
screened	O
;	O
48	O
.	O
3	O
%	O
(	O
N	O
=	O
282	O
)	O
of	O
the	O
patients	O
screened	O
were	O
colonized	O
with	O
at	O
least	O
one	O
of	O
the	O
bacteria	O
included	O
in	O
the	O
screening	O
;	O
26	O
.	O
2	O
%	O
of	O
them	O
(	O
N	O
=	O
74	O
)	O
had	O
multi	O
-	O
drug	O
-	O
resistant	O
strains	O
.	O

A	O
total	O
of	O
534	O
bacterial	O
isolates	O
were	O
found	O
.	O

The	O
most	O
frequently	O
found	O
species	O
were	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
Enterobacter	B-bacteria
cloacae	I-bacteria
,	O
Klebsiella	B-bacteria
oxytoca	I-bacteria
and	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
.	O

Three	O
MRSA	B-bacteria
but	O
no	O
VRE	B-bacteria
were	O
detected	O
.	O

The	O
surveillance	O
detected	O
a	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
cluster	O
involving	O
nine	O
patients	O
.	O

There	O
were	O
23	O
blood	O
-	O
culture	O
-	O
confirmed	O
sepsis	O
episodes	O
;	O
60	O
.	O
9	O
%	O
(	O
N	O
=	O
14	O
)	O
were	O
caused	O
by	O
staphylococci	B-bacteria
.	O

Gram	O
-	O
negative	O
bacteria	O
(	O
one	O
Klebsiella	B-bacteria
aerogenes	I-bacteria
and	O
two	O
E	B-bacteria
.	I-bacteria
cloacae	I-bacteria
)	O
caused	O
three	O
sepsis	O
episodes	O
which	O
were	O
preceded	O
by	O
colonization	O
with	O
the	O
respective	O
isolates	O
.	O

CONCLUSIONS	O
:	O
Surveillance	O
of	O
colonization	O
provided	O
a	O
comprehensive	O
overview	O
of	O
species	O
and	O
antibiotic	O
resistance	O
patterns	O
.	O

It	O
allowed	O
early	O
detection	O
of	O
a	O
colonization	O
cluster	O
.	O

Knowledge	O
of	O
colonization	O
and	O
surveillance	O
of	O
sepsis	O
is	O
useful	O
for	O
guiding	O
infection	O
control	O
measures	O
and	O
antibiotic	O
treatment	O
.	O

Utilizing	O
longitudinal	O
microbiome	O
taxonomic	O
profiles	O
to	O
predict	O
food	O
allergy	O
via	O
Long	O
Short	O
-	O
Term	O
Memory	O
networks	O
.	O

Food	O
allergy	O
is	O
usually	O
difficult	O
to	O
diagnose	O
in	O
early	O
life	O
,	O
and	O
the	O
inability	O
to	O
diagnose	O
patients	O
with	O
atopic	O
diseases	O
at	O
an	O
early	O
age	O
may	O
lead	O
to	O
severe	O
complications	O
.	O

Numerous	O
studies	O
have	O
suggested	O
an	O
association	O
between	O
the	O
infant	O
gut	O
microbiome	O
and	O
development	O
of	O
allergy	O
.	O

In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
capacity	O
of	O
Long	O
Short	O
-	O
Term	O
Memory	O
(	O
LSTM	O
)	O
networks	O
to	O
predict	O
food	O
allergies	O
in	O
early	O
life	O
(	O
0	O
-	O
3	O
years	O
)	O
from	O
subjects	O
'	O
longitudinal	O
gut	O
microbiome	O
profiles	O
.	O

Using	O
the	O
DIABIMMUNE	O
dataset	O
,	O
we	O
show	O
an	O
increase	O
in	O
predictive	O
power	O
using	O
our	O
model	O
compared	O
to	O
Hidden	O
Markov	O
Model	O
,	O
Multi	O
-	O
Layer	O
Perceptron	O
Neural	O
Network	O
,	O
Support	O
Vector	O
Machine	O
,	O
Random	O
Forest	O
,	O
and	O
LASSO	O
regression	O
.	O

We	O
further	O
evaluated	O
whether	O
the	O
training	O
of	O
LSTM	O
networks	O
benefits	O
from	O
reduced	O
representations	O
of	O
microbial	O
features	O
.	O

We	O
considered	O
sparse	O
autoencoder	O
for	O
extraction	O
of	O
potential	O
latent	O
representations	O
in	O
addition	O
to	O
standard	O
feature	O
selection	O
procedures	O
based	O
on	O
Minimum	O
Redundancy	O
Maximum	O
Relevance	O
(	O
mRMR	O
)	O
and	O
variance	O
prior	O
to	O
the	O
training	O
of	O
LSTM	O
networks	O
.	O

The	O
comprehensive	O
evaluation	O
reveals	O
that	O
LSTM	O
networks	O
with	O
the	O
mRMR	O
selected	O
features	O
achieve	O
significantly	O
better	O
performance	O
compared	O
to	O
the	O
other	O
tested	O
machine	O
learning	O
models	O
.	O

Vaginal	O
microbiota	O
transplantation	O
for	O
the	O
treatment	O
of	O
bacterial	O
vaginosis	O
:	O
a	O
conceptual	O
analysis	O
.	O

Bacterial	O
vaginosis	O
(	O
BV	O
)	O
,	O
caused	O
by	O
the	O
vaginal	O
dysbacteriosis	O
as	O
well	O
as	O
the	O
excessive	O
growth	O
of	O
pathogenic	O
bacteria	O
,	O
is	O
a	O
pathological	O
condition	O
of	O
the	O
vagina	O
;	O
its	O
treatment	O
using	O
the	O
antibiotics	O
metronidazole	O
or	O
clindamycin	O
often	O
causes	O
high	O
recurrence	O
rates	O
.	O

Considering	O
the	O
similar	O
physiological	O
environments	O
of	O
the	O
intestinal	O
tract	O
and	O
vaginal	O
tract	O
,	O
as	O
well	O
as	O
the	O
pathological	O
mechanism	O
of	O
intestinal	O
infection	O
and	O
vaginal	O
infection	O
,	O
we	O
first	O
propose	O
the	O
conception	O
of	O
vaginal	O
microbiota	O
transplantation	O
(	O
VMT	O
)	O
and	O
discuss	O
its	O
potential	O
use	O
in	O
BV	O
.	O

This	O
review	O
focuses	O
on	O
the	O
pathology	O
of	O
BV	O
and	O
the	O
side	O
effects	O
caused	O
by	O
its	O
standardised	O
treatment	O
.	O

The	O
extremely	O
dynamic	O
and	O
diverse	O
gut	O
microbiota	O
forms	O
the	O
most	O
intensive	O
microbial	O
system	O
and	O
also	O
plays	O
a	O
significant	O
role	O
in	O
human	O
body	O
,	O
and	O
Lactobacilli	B-bacteria
dominate	O
in	O
the	O
vaginal	O
tract	O
of	O
women	O
,	O
keeping	O
them	O
healthy	O
.	O

Accordingly	O
,	O
we	O
also	O
propose	O
the	O
concept	O
of	O
VMT	O
based	O
on	O
the	O
effects	O
of	O
faecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
in	O
treating	O
intestinal	O
infections	O
,	O
and	O
list	O
the	O
potential	O
hurdles	O
for	O
the	O
implementation	O
of	O
VMT	O
.	O

Roux	O
-	O
en	O
-	O
Y	O
gastric	O
bypass	O
decreases	O
endotoxemia	O
and	O
inflammatory	O
stress	O
in	O
association	O
with	O
improvements	O
in	O
gut	O
permeability	O
in	O
obese	O
diabetic	O
rats	O
.	O

BACKGROUND	O
:	O
Postoperative	O
modulation	O
of	O
the	O
gut	O
microbiome	O
has	O
been	O
suggested	O
to	O
contribute	O
to	O
the	O
metabolic	O
benefits	O
after	O
metabolic	O
surgery	O
,	O
but	O
the	O
mechanisms	O
underlying	O
these	O
metabolic	O
benefits	O
remain	O
unknown	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
Roux	O
-	O
en	O
-	O
Y	O
gastric	O
bypass	O
(	O
RYGB	O
)	O
surgery	O
in	O
Zucker	O
diabetic	O
fatty	O
(	O
ZDF	O
)	O
rats	O
increased	O
the	O
abundance	O
of	O
Proteobacteria	B-bacteria
and	O
Gammaproteobacteria	B-bacteria
.	O

However	O
,	O
theoretically	O
,	O
these	O
Gram	O
-	O
negative	O
bacteria	O
may	O
elevate	O
lipopolysaccharide	O
(	O
LPS	O
)	O
levels	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
we	O
further	O
investigated	O
the	O
potential	O
mechanisms	O
by	O
which	O
RYGB	O
improves	O
glucose	O
homeostasis	O
,	O
endotoxemia	O
,	O
and	O
inflammatory	O
stress	O
in	O
ZDF	O
rats	O
.	O

METHODS	O
:	O
Rats	O
were	O
divided	O
into	O
three	O
groups	O
:	O
(	O
a	O
)	O
an	O
RYGB	O
group	O
(	O
RY	O
)	O
;	O
(	O
b	O
)	O
a	O
sham	O
-	O
operated	O
group	O
pair	O
-	O
fed	O
with	O
the	O
RY	O
group	O
;	O
and	O
(	O
c	O
)	O
a	O
sham	O
-	O
operated	O
group	O
fed	O
ad	O
libitum	O
.	O

Changes	O
in	O
LPS	O
,	O
cytokine	O
levels	O
,	O
intestinal	O
permeability	O
(	O
evaluated	O
using	O
the	O
fluorescein	O
isothiocyanate	O
-	O
dextran	O
method	O
)	O
,	O
and	O
intestinal	O
epithelial	O
tight	O
junction	O
proteins	O
zona	O
occludins	O
(	O
ZO	O
)	O
-	O
1	O
,	O
occludin	O
,	O
and	O
claudin	O
-	O
1	O
were	O
assessed	O
10	O
weeks	O
postoperatively	O
.	O

RESULTS	O
:	O
Rats	O
that	O
underwent	O
RYGB	O
exhibited	O
sustained	O
weight	O
loss	O
and	O
reduced	O
glucose	O
,	O
as	O
well	O
as	O
lower	O
cytokine	O
and	O
LPS	O
concentrations	O
,	O
than	O
rats	O
in	O
the	O
control	O
groups	O
.	O

In	O
the	O
colonic	O
epithelium	O
,	O
ZO1	O
and	O
claudin	O
-	O
1	O
(	O
Cldn1	O
)	O
mRNA	O
levels	O
were	O
higher	O
in	O
the	O
RY	O
than	O
control	O
groups	O
.	O

Intestinal	O
permeability	O
declined	O
in	O
the	O
RY	O
group	O
and	O
was	O
positively	O
correlated	O
with	O
LPS	O
levels	O
and	O
negatively	O
correlated	O
with	O
ZO	O
-	O
1	O
,	O
occludin	O
,	O
and	O
claudin	O
-	O
1	O
expression	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
demonstrate	O
that	O
RYGB	O
can	O
reduce	O
the	O
extent	O
of	O
endotoxemia	O
and	O
inflammation	O
,	O
which	O
is	O
associated	O
with	O
improved	O
tight	O
junction	O
integrity	O
and	O
intestinal	O
barrier	O
strength	O
.	O

These	O
effects	O
may	O
explain	O
why	O
a	O
low	O
level	O
of	O
inflammation	O
is	O
maintained	O
after	O
RYGB	O
and	O
the	O
postoperative	O
increase	O
in	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Suppressive	O
effect	O
of	O
Lactobacillus	B-bacteria
fermentum	I-bacteria
Lim2	I-bacteria
on	O
Clostridioides	B-bacteria
difficile	I-bacteria
027	I-bacteria
toxin	O
production	O
.	O

Clostridioides	B-bacteria
difficile	I-bacteria
is	O
a	O
spore	O
-	O
forming	O
,	O
Gram	O
-	O
positive	O
,	O
anaerobic	O
pathogen	O
that	O
caused	O
gastrointestinal	O
illness	O
.	O

During	O
dysbiosis	O
,	O
overgrowth	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
resulting	O
in	O
higher	O
levels	O
of	O
toxin	O
production	O
.	O

Since	O
Lactobacillus	B-bacteria
has	O
been	O
commonly	O
used	O
to	O
alleviate	O
gastrointestinal	O
discomfort	O
,	O
this	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
Lactobacillus	B-bacteria
isolated	O
from	O
kimchi	O
on	O
the	O
quorum	O
-	O
sensing	O
and	O
virulence	O
factors	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
027	I-bacteria
.	O

Among	O
the	O
isolated	O
Lactobacillus	B-bacteria
strains	I-bacteria
,	O
the	O
acid	O
and	O
bile	O
tolerant	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
Lim2	I-bacteria
was	O
only	O
able	O
to	O
reduce	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
027	I-bacteria
growth	O
by	O
one	O
log10	O
CFU	O
per	O
ml	O
.	O

In	O
keeping	O
with	O
this	O
finding	O
,	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
027	I-bacteria
growth	O
was	O
unaffected	O
by	O
either	O
untreated	O
or	O
heat	O
-	O
inactivated	O
cell	O
extracts	O
from	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
Lim2	I-bacteria
.	O

Both	O
untreated	O
and	O
heat	O
-	O
inactivated	O
cell	O
extracts	O
did	O
,	O
however	O
,	O
significantly	O
reduce	O
the	O
autoinducer	O
-	O
2	O
(	O
AI	O
-	O
2	O
)	O
activity	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
027	I-bacteria
,	O
with	O
the	O
most	O
prominent	O
suppression	O
effect	O
(	O
654	O
-	O
fold	O
)	O
being	O
found	O
from	O
100	O
mg	O
ml	O
(	O
-	O
1	O
)	O
of	O
heat	O
-	O
inactivated	O
cell	O
extract	O
.	O

A	O
gene	O
expression	O
analysis	O
indicated	O
that	O
in	O
the	O
presence	O
of	O
100	O
mg	O
ml	O
(	O
-	O
1	O
)	O
heat	O
-	O
inactivated	O
cell	O
extract	O
,	O
the	O
quorum	O
-	O
sensing	O
(	O
luxS	O
)	O
and	O
the	O
virulence	O
factors	O
(	O
tcdA	O
,	O
tcdB	O
and	O
tcdE	O
)	O
were	O
significantly	O
suppressed	O
,	O
whereas	O
the	O
negative	O
regulator	O
gene	O
(	O
tcdC	O
)	O
was	O
significantly	O
up	O
-	O
regulated	O
.	O

Taken	O
together	O
,	O
the	O
significant	O
anti	O
-	O
pathogenic	O
effect	O
from	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
Lim2	I-bacteria
could	O
potentially	O
be	O
used	O
to	O
treat	O
C	O
.	O
difficile	O
-	O
infections	O
.	O

SIGNIFICANCE	O
AND	O
IMPACT	O
OF	O
THE	O
STUDY	O
:	O
Clostridioides	B-bacteria
difficile	I-bacteria
is	O
a	O
Gram	O
-	O
positive	O
pathogenic	O
bacteria	O
that	O
caused	O
gastrointestinal	O
illness	O
via	O
toxic	O
production	O
.	O

The	O
emergence	O
of	O
highly	O
virulence	O
and	O
foodborne	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
strains	I-bacteria
has	O
further	O
increased	O
the	O
incident	O
and	O
severity	O
of	O
C	O
.	O
difficile	O
-	O
infections	O
(	O
CDIs	O
)	O
.	O

Numerous	O
studies	O
have	O
reported	O
the	O
immunomodulatory	O
activity	O
of	O
Lactobacillus	B-bacteria
,	O
a	O
member	O
of	O
healthy	O
gut	O
microbiota	O
,	O
to	O
maintain	O
gastrointestinal	O
health	O
.	O

Here	O
,	O
we	O
successfully	O
isolated	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
Lim2	I-bacteria
from	O
kimchi	O
,	O
and	O
identified	O
a	O
promising	O
anti	O
-	O
pathogenic	O
effect	O
against	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
027	I-bacteria
,	O
from	O
the	O
heat	O
-	O
inactivated	O
L	B-bacteria
.	I-bacteria
fermentum	I-bacteria
cell	O
extract	O
via	O
suppression	O
on	O
the	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
027	I-bacteria
quorum	O
-	O
sensing	O
system	O
and	O
toxin	O
production	O
,	O
which	O
could	O
potentially	O
be	O
used	O
to	O
treat	O
and	O
prevent	O
CDIs	O
.	O

The	O
Effect	O
of	O
Density	O
-	O
Dependent	O
Phase	O
on	O
the	O
Locust	O
Gut	O
Bacterial	O
Composition	O
.	O

The	O
desert	O
locust	O
demonstrates	O
density	O
-	O
dependent	O
phase	O
polyphenism	O
:	O
For	O
extended	O
periods	O
it	O
appears	O
in	O
a	O
non	O
-	O
aggregating	O
,	O
non	O
-	O
migrating	O
phenotype	O
,	O
known	O
as	O
the	O
solitary	O
phase	O
.	O

When	O
circumstances	O
change	O
,	O
solitary	O
individuals	O
may	O
aggregate	O
and	O
transform	O
to	O
the	O
gregarious	O
phenotype	O
,	O
which	O
have	O
a	O
strong	O
propensity	O
for	O
generating	O
large	O
swarms	O
.	O

Previous	O
reports	O
have	O
suggested	O
a	O
role	O
for	O
gut	O
-	O
bacteria	O
derived	O
volatiles	O
in	O
the	O
swarming	O
phenomenon	O
,	O
and	O
suggested	O
that	O
locusts	O
are	O
capable	O
of	O
manipulating	O
their	O
gut	O
microbiome	O
according	O
to	O
their	O
density	O
-	O
dependent	O
phases	O
.	O

Here	O
,	O
we	O
directly	O
tested	O
this	O
hypothesis	O
for	O
the	O
first	O
time	O
.	O

Using	O
locusts	O
of	O
both	O
phases	O
from	O
well	O
-	O
controlled	O
laboratory	O
cultures	O
as	O
well	O
as	O
gregarious	O
field	O
-	O
collected	O
individuals	O
;	O
and	O
high	O
-	O
throughput	O
sequencing	O
.	O

We	O
characterized	O
the	O
hindgut	O
bacterial	O
community	O
composition	O
in	O
the	O
two	O
phases	O
of	O
the	O
desert	O
locust	O
.	O

Our	O
findings	O
demonstrate	O
that	O
laboratory	O
-	O
reared	O
gregarious	O
and	O
solitary	O
locusts	O
maintain	O
a	O
stable	O
core	O
of	O
Enterobacter	B-bacteria
.	O

However	O
,	O
while	O
different	O
generations	O
of	O
gregarious	O
locust	O
experience	O
shifts	O
in	O
their	O
Enterobacter	B-bacteria
'	O
s	O
relative	O
abundance	O
;	O
the	O
solitary	O
locusts	O
maintain	O
a	O
stable	O
gut	O
microbiome	O
,	O
highly	O
similar	O
to	O
that	O
of	O
the	O
field	O
-	O
collected	O
locusts	O
.	O

Tentative	O
phase	O
differences	O
in	O
wild	O
populations	O
'	O
microbiome	O
may	O
thus	O
be	O
an	O
indirect	O
effect	O
of	O
environmental	O
or	O
other	O
factors	O
that	O
push	O
the	O
swarming	O
individuals	O
to	O
homogenous	O
gut	O
bacteria	O
.	O

We	O
therefore	O
conclude	O
that	O
there	O
are	O
phase	O
-	O
related	O
differences	O
in	O
the	O
population	O
dynamics	O
of	O
the	O
locust	O
hindgut	O
bacterial	O
composition	O
,	O
but	O
there	O
is	O
no	O
intrinsic	O
density	O
-	O
dependent	O
mechanism	O
directly	O
affecting	O
the	O
gut	O
microbiome	O
.	O

Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
Counts	O
in	O
the	O
Gut	O
Microbiota	O
of	O
Patients	O
With	O
Bipolar	O
Disorder	O
and	O
Healthy	O
Controls	O
.	O

Background	O
:	O
Although	O
the	O
pathophysiology	O
of	O
bipolar	O
disorder	O
remains	O
elusive	O
,	O
growing	O
evidence	O
suggests	O
the	O
beneficial	O
effects	O
of	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
in	O
the	O
gut	O
microbiota	O
on	O
stress	O
response	O
and	O
depressive	O
symptoms	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
counts	O
for	O
association	O
with	O
bipolar	O
disorder	O
and	O
serum	O
cortisol	O
levels	O
.	O

Methods	O
:	O
Bacterial	O
counts	O
in	O
fecal	O
samples	O
were	O
examined	O
in	O
39	O
patients	O
with	O
bipolar	O
disorder	O
according	O
to	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
4th	O
edn	O
.	O

and	O
58	O
healthy	O
controls	O
using	O
bacterial	O
rRNA	O
-	O
targeted	O
reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
.	O

Results	O
:	O
No	O
significant	O
difference	O
was	O
found	O
in	O
either	O
bacterial	O
counts	O
between	O
the	O
two	O
groups	O
.	O

However	O
,	O
we	O
found	O
a	O
significantly	O
negative	O
correlation	O
between	O
Lactobacillus	B-bacteria
counts	O
and	O
sleep	O
(	O
rho	O
=	O
-	O
0	O
.	O
45	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

Furthermore	O
,	O
a	O
significant	O
negative	O
correlation	O
was	O
found	O
between	O
Bifidobacterium	B-bacteria
counts	O
and	O
cortisol	O
levels	O
(	O
rho	O
=	O
-	O
0	O
.	O
39	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
in	O
the	O
patients	O
,	O
although	O
such	O
a	O
correlation	O
was	O
not	O
found	O
for	O
Lactobacillus	B-bacteria
counts	O
.	O

Conclusions	O
:	O
Our	O
results	O
suggest	O
that	O
Bifidobacterium	B-bacteria
or	O
Lactobacillus	B-bacteria
counts	O
may	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
pathophysiology	O
of	O
bipolar	O
disorder	O
in	O
our	O
sample	O
.	O

However	O
,	O
the	O
observed	O
negative	O
correlation	O
between	O
Lactobacillus	B-bacteria
counts	O
and	O
sleep	O
and	O
that	O
between	O
Bifidobacterium	B-bacteria
counts	O
and	O
serum	O
cortisol	O
levels	O
point	O
to	O
the	O
possible	O
roles	O
of	O
these	O
bacteria	O
in	O
sleep	O
and	O
stress	O
response	O
of	O
the	O
patients	O
.	O

Effects	O
and	O
immune	O
responses	O
of	O
probiotic	O
treatment	O
in	O
ruminants	O
.	O

Gut	O
microbial	O
colonization	O
and	O
establishment	O
are	O
vital	O
to	O
ruminant	O
health	O
and	O
production	O
.	O

This	O
review	O
article	O
focuses	O
on	O
current	O
knowledge	O
and	O
methods	O
used	O
to	O
understand	O
and	O
manipulate	O
the	O
gut	O
microbial	O
community	O
in	O
ruminant	O
animals	O
,	O
with	O
a	O
special	O
focus	O
on	O
probiotics	O
treatment	O
.	O

This	O
review	O
highlights	O
the	O
most	O
promising	O
of	O
studies	O
in	O
this	O
area	O
,	O
including	O
gut	O
microbial	O
colonization	O
and	O
establishment	O
,	O
effect	O
of	O
gastrointestinal	O
tract	O
microbial	O
community	O
on	O
host	O
mucosal	O
innate	O
immune	O
function	O
,	O
impact	O
of	O
feeding	O
strategies	O
on	O
gut	O
microbial	O
community	O
,	O
current	O
probiotic	O
treatments	O
in	O
ruminants	O
,	O
methods	O
to	O
manipulate	O
the	O
gut	O
microbiota	O
and	O
associated	O
antimicrobial	O
compounds	O
,	O
and	O
models	O
and	O
cell	O
lines	O
used	O
in	O
understanding	O
the	O
host	O
immune	O
response	O
to	O
probiotic	O
treatments	O
.	O

As	O
a	O
lot	O
of	O
work	O
in	O
this	O
area	O
was	O
done	O
in	O
humans	O
and	O
mice	O
,	O
this	O
review	O
article	O
also	O
includes	O
up	O
-	O
to	O
-	O
date	O
knowledge	O
from	O
relevant	O
studies	O
in	O
human	O
and	O
mouse	O
models	O
.	O

This	O
review	O
is	O
a	O
useful	O
resource	O
for	O
scientists	O
working	O
in	O
the	O
areas	O
of	O
ruminant	O
nutrition	O
and	O
health	O
,	O
and	O
to	O
researchers	O
investigating	O
the	O
microbial	O
ecology	O
and	O
its	O
relation	O
to	O
animal	O
health	O
.	O

A	O
murine	O
model	O
of	O
diarrhea	O
,	O
growth	O
impairment	O
and	O
metabolic	O
disturbances	O
with	O
Shigella	B-bacteria
flexneri	I-bacteria
infection	O
and	O
the	O
role	O
of	O
zinc	O
deficiency	O
.	O

Shigella	B-bacteria
is	O
one	O
of	O
the	O
major	O
enteric	O
pathogens	O
worldwide	O
.	O

We	O
present	O
a	O
murine	O
model	O
of	O
S	B-bacteria
.	I-bacteria
flexneri	I-bacteria
infection	O
and	O
investigate	O
the	O
role	O
of	O
zinc	O
deficiency	O
(	O
ZD	O
)	O
.	O

C57BL	O
/	O
6	O
mice	O
fed	O
either	O
standard	O
chow	O
(	O
HC	O
)	O
or	O
ZD	O
diets	O
were	O
pretreated	O
with	O
an	O
antibiotic	O
cocktail	O
and	O
received	O
S	B-bacteria
.	I-bacteria
flexneri	I-bacteria
strain	I-bacteria
2457T	I-bacteria
orally	O
.	O

Antibiotic	O
pre	O
-	O
treated	O
ZD	O
mice	O
showed	O
higher	O
S	B-bacteria
.	I-bacteria
flexneri	I-bacteria
colonization	O
than	O
non	O
-	O
treated	O
mice	O
.	O

ZD	O
mice	O
showed	O
persistent	O
colonization	O
for	O
at	O
least	O
50	O
days	O
post	O
-	O
infection	O
(	O
pi	O
)	O
.	O

S	O
.	O
flexneri	O
-	O
infected	O
mice	O
showed	O
significant	O
weight	O
loss	O
,	O
diarrhea	O
and	O
increased	O
levels	O
of	O
fecal	O
MPO	O
and	O
LCN	O
in	O
both	O
HC	O
and	O
ZD	O
fed	O
mice	O
.	O

S	B-bacteria
.	I-bacteria
flexneri	I-bacteria
preferentially	O
colonized	O
the	O
colon	O
,	O
caused	O
epithelial	O
disruption	O
and	O
inflammatory	O
cell	O
infiltrate	O
,	O
and	O
promoted	O
cytokine	O
production	O
which	O
correlated	O
with	O
weight	O
loss	O
and	O
histopathological	O
changes	O
.	O

Infection	O
with	O
S	B-bacteria
.	I-bacteria
flexneri	I-bacteria
DeltamxiG	O
(	O
critical	O
for	O
type	O
3	O
secretion	O
system	O
)	O
did	O
not	O
cause	O
weight	O
loss	O
or	O
diarrhea	O
,	O
and	O
had	O
decreased	O
stool	O
shedding	O
duration	O
and	O
tissue	O
burden	O
.	O

Several	O
biochemical	O
changes	O
related	O
to	O
energy	O
,	O
inflammation	O
and	O
gut	O
-	O
microbial	O
metabolism	O
were	O
observed	O
.	O

Zinc	O
supplementation	O
increased	O
weight	O
gains	O
and	O
reduced	O
intestinal	O
inflammation	O
and	O
stool	O
shedding	O
in	O
ZD	O
infected	O
mice	O
.	O

In	O
conclusion	O
,	O
young	O
antibiotic	O
-	O
treated	O
mice	O
provide	O
a	O
new	O
model	O
of	O
oral	O
S	B-bacteria
.	I-bacteria
flexneri	I-bacteria
infection	O
,	O
with	O
ZD	O
promoting	O
prolonged	O
infection	O
outcomes	O
.	O

Complex	O
dietary	O
polysaccharide	O
modulates	O
gut	O
immune	O
function	O
and	O
microbiota	O
,	O
and	O
promotes	O
protection	O
from	O
autoimmune	O
diabetes	O
.	O

The	O
dietary	O
supplement	O
and	O
prebiotic	O
values	O
of	O
beta	O
-	O
glucan	O
-	O
rich	O
products	O
have	O
been	O
widely	O
recognized	O
and	O
dietary	O
approaches	O
for	O
modulating	O
autoimmunity	O
have	O
been	O
increasingly	O
explored	O
,	O
we	O
assess	O
the	O
impact	O
of	O
oral	O
administration	O
of	O
high	O
-	O
purity	O
yeast	O
beta	O
-	O
glucan	O
(	O
YBG	O
)	O
on	O
gut	O
immune	O
function	O
,	O
microbiota	O
and	O
type	O
1	O
diabetes	O
(	O
T1D	O
)	O
using	O
mouse	O
models	O
.	O

Oral	O
administration	O
of	O
this	O
non	O
-	O
digestible	O
complex	O
polysaccharide	O
caused	O
a	O
dectin	O
-	O
1	O
-	O
dependent	O
immune	O
response	O
involving	O
increased	O
expression	O
of	O
interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
,	O
retinaldehyde	O
dehydrogenase	O
(	O
Raldh	O
)	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
the	O
gut	O
mucosa	O
.	O

YBG	O
-	O
exposed	O
intestinal	O
dendritic	O
cells	O
induced	O
/	O
expanded	O
primarily	O
Foxp3	O
(	O
+	O
)	O
,	O
IL	O
-	O
10	O
(	O
+	O
)	O
and	O
IL	O
-	O
17	O
(	O
+	O
)	O
T	O
cells	O
,	O
ex	O
vivo	O
.	O

Importantly	O
,	O
prolonged	O
oral	O
administration	O
of	O
low	O
-	O
dose	O
YBG	O
at	O
pre	O
-	O
diabetic	O
stage	O
suppressed	O
insulitis	O
and	O
significantly	O
delayed	O
the	O
appearance	O
of	O
T1D	O
in	O
non	O
-	O
obese	O
diabetic	O
(	O
NOD	O
)	O
mice	O
.	O

Further	O
,	O
prolonged	O
treatment	O
with	O
YBG	O
showed	O
increased	O
Foxp3	O
(	O
+	O
)	O
T	O
-	O
cell	O
frequencies	O
,	O
and	O
a	O
significant	O
change	O
in	O
the	O
gut	O
microbiota	O
,	O
particularly	O
an	O
increase	O
in	O
the	O
abundance	O
of	O
Bacteroidetes	B-bacteria
and	O
a	O
decrease	O
in	O
the	O
Firmicute	O
members	O
.	O

Oral	O
administration	O
of	O
YBG	O
,	O
together	O
with	O
Raldh	O
-	O
substrate	O
and	O
beta	O
-	O
cell	O
antigen	O
,	O
resulted	O
in	O
better	O
protection	O
of	O
NOD	O
mice	O
from	O
T1D	O
.	O

These	O
observations	O
suggest	O
that	O
YBG	O
not	O
only	O
has	O
a	O
prebiotic	O
property	O
,	O
but	O
also	O
an	O
oral	O
tolerogenic	O
-	O
adjuvant	O
-	O
like	O
effect	O
,	O
and	O
these	O
features	O
could	O
be	O
exploited	O
for	O
modulating	O
autoimmunity	O
in	O
T1D	O
.	O

Coupled	O
changes	O
of	O
bacterial	O
community	O
and	O
function	O
in	O
the	O
gut	O
of	O
mud	O
crab	O
(	O
Scylla	O
Paramamosain	O
)	O
in	O
response	O
to	O
Baimang	O
disease	O
.	O

Increasing	O
evidence	O
has	O
revealed	O
a	O
close	O
association	O
between	O
intestinal	O
bacterial	O
community	O
and	O
hosts	O
health	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
and	O
what	O
extend	O
Baimang	O
disease	O
alters	O
the	O
intestinal	O
microbiota	O
in	O
mud	O
crab	O
(	O
Scylla	O
paramamosain	O
)	O
.	O

Here	O
,	O
we	O
conducted	O
intestinal	O
contents	O
Illumina	O
sequencing	O
of	O
healthy	O
and	O
Baimang	O
diseased	O
mud	O
crab	O
(	O
S	O
.	O
paramamosain	O
)	O
to	O
understand	O
bacterial	O
community	O
variations	O
among	O
health	O
status	O
.	O

In	O
addition	O
,	O
bacterial	O
functional	O
predication	O
was	O
used	O
to	O
investigate	O
whether	O
and	O
how	O
the	O
bacteria	O
variations	O
further	O
change	O
their	O
functions	O
?	O

The	O
phyla	O
of	O
Proteobacteria	B-bacteria
,	O
Fusobacteria	B-bacteria
,	O
Cyanobacteria	B-bacteria
,	O
Tenericutes	B-bacteria
,	O
Firmicutes	B-bacteria
,	O
Bacteroidetes	B-bacteria
,	O
and	O
Spirochaetae	B-bacteria
constituted	O
over	O
96	O
.	O
44	O
%	O
of	O
the	O
total	O
intestinal	O
bacteria	O
,	O
with	O
being	O
the	O
dominant	O
taxa	O
.	O

The	O
7	O
most	O
significantly	O
different	O
orders	O
,	O
including	O
the	O
increased	O
four	O
orders	O
of	O
Clostridiales	B-bacteria
,	O
Entomoplasmatales	B-bacteria
,	O
Bacteroidales	B-bacteria
,	O
and	O
Mycoplasmatales	B-bacteria
and	O
the	O
decreased	O
three	O
orders	O
of	O
Vibrionales	B-bacteria
,	O
Campylobacterales	B-bacteria
,	O
and	O
Fusobacteriales	B-bacteria
,	O
accounted	O
for	O
61	O
.	O
14	O
%	O
dissimilarity	O
,	O
probably	O
being	O
the	O
indicator	O
taxa	O
of	O
Baimang	O
disease	O
.	O

Accordingly	O
,	O
12	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
orthologies	O
in	O
level	O
3	O
shifted	O
significantly	O
at	O
the	O
diseased	O
crabs	O
.	O

Especially	O
,	O
bacterial	O
secretion	O
system	O
,	O
secretion	O
system	O
,	O
lipopolysaccharide	O
biosynthesis	O
proteins	O
and	O
Vibrio	B-bacteria
cholerae	I-bacteria
pathogenic	O
cycle	O
,	O
being	O
related	O
to	O
bacterial	O
virulence	O
,	O
were	O
reduced	O
.	O

In	O
addition	O
,	O
the	O
reduced	O
butanoate	O
metabolism	O
,	O
and	O
induced	O
methane	O
metabolism	O
and	O
one	O
carbon	O
pool	O
by	O
folate	O
were	O
important	O
metabolic	O
processes	O
of	O
probiotic	O
,	O
such	O
as	O
Bacteroides	B-bacteria
spp	I-bacteria
.	O
and	O
Clostridium	B-bacteria
spp	I-bacteria
.	I-bacteria
,	O
with	O
playing	O
critical	O
roles	O
in	O
host	O
health	O
.	O

This	O
study	O
suggests	O
that	O
Baimang	O
disease	O
coupled	O
altered	O
the	O
intestinal	O
bacterial	O
communities	O
and	O
functions	O
,	O
providing	O
timely	O
information	O
for	O
further	O
analysis	O
the	O
influencing	O
mechanism	O
of	O
Baimang	O
disease	O
in	O
mud	O
crab	O
(	O
S	B-bacteria
.	I-bacteria
paramamosain	I-bacteria
)	O
.	O

Puerariae	O
Lobatae	O
Radix	O
with	O
chuanxiong	O
Rhizoma	O
for	O
treatment	O
of	O
cerebral	O
ischemic	O
stroke	O
by	O
remodeling	O
gut	O
microbiota	O
to	O
regulate	O
the	O
brain	O
-	O
gut	O
barriers	O
.	O

The	O
combination	O
of	O
Puerariae	O
Lobatae	O
Radix	O
(	O
PLR	O
)	O
and	O
Chuanxiong	O
Rhizoma	O
(	O
CXR	O
)	O
is	O
commonly	O
used	O
to	O
treat	O
cerebrovascular	O
diseases	O
.	O

This	O
work	O
aimed	O
to	O
clarify	O
the	O
mechanisms	O
of	O
their	O
action	O
in	O
treating	O
cerebral	O
ischemic	O
stroke	O
from	O
the	O
perspective	O
of	O
gut	O
microecology	O
.	O

The	O
PLR	O
and	O
CXR	O
combination	O
effectively	O
improved	O
the	O
neurological	O
function	O
,	O
reduced	O
the	O
cerebral	O
infarction	O
and	O
relieved	O
the	O
complications	O
of	O
cerebral	O
ischemic	O
stroke	O
,	O
including	O
dyslipidemia	O
,	O
increased	O
blood	O
viscosity	O
and	O
thrombotic	O
risk	O
.	O

Cerebral	O
ischemic	O
stroke	O
triggered	O
gut	O
microbial	O
disturbances	O
by	O
enriching	O
pathogens	O
and	O
opportunistic	O
microorganisms	O
,	O
including	O
Bacteroides	B-bacteria
,	O
Escherichia	B-bacteria
_	I-bacteria
Shigella	I-bacteria
,	O
Haemophilus	B-bacteria
,	O
Eubacterium	B-bacteria
_	I-bacteria
nodatum	I-bacteria
_	I-bacteria
group	I-bacteria
,	O
Collinsella	B-bacteria
,	O
Enterococcus	B-bacteria
,	O
Proteus	B-bacteria
,	O
Alistipes	B-bacteria
,	O
Klebsiella	B-bacteria
,	O
Shuttleworthia	B-bacteria
and	O
Faecalibacterium	B-bacteria
.	O

Cerebral	O
ischemic	O
stroke	O
also	O
increased	O
the	O
intestinal	O
permeability	O
,	O
disrupted	O
the	O
gut	O
barrier	O
and	O
caused	O
intestinal	O
microbial	O
translocation	O
.	O

Occludin	O
,	O
claudin	O
-	O
5	O
and	O
ZO	O
-	O
1	O
levels	O
in	O
the	O
brain	O
-	O
gut	O
barriers	O
showed	O
a	O
high	O
positive	O
correlation	O
.	O

However	O
,	O
the	O
combination	O
remodeled	O
the	O
gut	O
microecology	O
by	O
modulating	O
endogenous	O
bacteria	O
whose	O
effects	O
may	O
mitigate	O
cerebral	O
damage	O
,	O
such	O
as	O
Alloprevotella	B-bacteria
,	O
Ruminococcaceae	B-bacteria
,	O
Oscillospira	B-bacteria
,	O
Lachnospiraceae	B-bacteria
_	I-bacteria
NK4B4	I-bacteria
_	I-bacteria
group	I-bacteria
,	O
Akkermansia	B-bacteria
and	O
Megasphaera	B-bacteria
,	O
protected	O
the	O
brain	O
-	O
gut	O
barriers	O
by	O
increasing	O
claudin	O
-	O
5	O
and	O
ZO	O
-	O
1	O
levels	O
;	O
and	O
weakened	O
the	O
gut	O
microbiota	O
translocation	O
by	O
decreasing	O
diamine	O
oxidase	O
,	O
lipopolysaccharide	O
and	O
d	O
-	O
lactate	O
.	O

Although	O
nimodipine	O
effectively	O
reduced	O
the	O
cerebral	O
infarction	O
,	O
it	O
did	O
not	O
relieve	O
the	O
gut	O
microbiota	O
dysbiosis	O
and	O
instead	O
aggravated	O
the	O
gut	O
barrier	O
disruption	O
and	O
microbiota	O
translocation	O
.	O

In	O
conclusion	O
,	O
cerebral	O
ischemic	O
stroke	O
caused	O
gut	O
microbiota	O
dysbiosis	O
,	O
increased	O
intestinal	O
permeability	O
,	O
disrupted	O
the	O
gut	O
barrier	O
and	O
triggered	O
gut	O
microbiota	O
translocation	O
.	O

The	O
PLR	O
and	O
CXR	O
combination	O
was	O
an	O
effective	O
treatment	O
for	O
cerebral	O
ischemic	O
stroke	O
that	O
relieved	O
the	O
gut	O
microbiota	O
dysbiosis	O
and	O
brain	O
-	O
gut	O
barriers	O
disruption	O
.	O

Neuropods	O
.	O

Enteroendocrine	O
cells	O
(	O
EECs	O
)	O
are	O
sensory	O
cells	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

Most	O
EECs	O
reside	O
in	O
the	O
mucosal	O
lining	O
of	O
the	O
stomach	O
or	O
intestine	O
and	O
sense	O
food	O
in	O
the	O
gut	O
lumen	O
.	O

Food	O
signals	O
stimulate	O
the	O
release	O
of	O
hormones	O
into	O
the	O
paracellular	O
space	O
where	O
they	O
either	O
act	O
locally	O
or	O
are	O
taken	O
up	O
into	O
the	O
blood	O
and	O
circulate	O
to	O
distant	O
organs	O
.	O

It	O
recently	O
was	O
recognized	O
that	O
many	O
EECs	O
possess	O
basal	O
processes	O
known	O
as	O
neuropods	O
that	O
not	O
only	O
contain	O
hormones	O
but	O
also	O
connect	O
to	O
nerves	O
.	O

This	O
review	O
describes	O
how	O
neuropods	O
contribute	O
to	O
EEC	O
function	O
beyond	O
typical	O
hormonal	O
actions	O
.	O

For	O
example	O
,	O
gastrointestinal	O
hormones	O
not	O
only	O
act	O
on	O
distant	O
organs	O
,	O
but	O
,	O
through	O
neuropods	O
,	O
some	O
act	O
locally	O
to	O
stimulate	O
other	O
mucosal	O
cells	O
such	O
as	O
intestinal	O
stem	O
cells	O
,	O
enterocytes	O
,	O
or	O
other	O
EECs	O
.	O

With	O
the	O
recent	O
discovery	O
that	O
EECs	O
communicate	O
directly	O
with	O
enteric	O
nerves	O
,	O
EECs	O
not	O
only	O
have	O
the	O
ability	O
to	O
sense	O
food	O
and	O
bacteria	O
in	O
the	O
gastrointestinal	O
tract	O
,	O
but	O
can	O
communicate	O
these	O
signals	O
directly	O
to	O
the	O
nervous	O
system	O
.	O

PAD4	O
-	O
dependent	O
NETs	O
generation	O
are	O
indispensable	O
for	O
intestinal	O
clearance	O
of	O
Citrobacter	B-bacteria
rodentium	I-bacteria
.	O

Peptidyl	O
arginine	O
deiminase	O
-	O
4	O
(	O
PAD4	O
)	O
is	O
indispensable	O
for	O
generation	O
of	O
neutrophil	O
extracellular	O
traps	O
(	O
NETs	O
)	O
,	O
which	O
can	O
provide	O
antimicrobial	O
effects	O
during	O
host	O
innate	O
immune	O
response	O
;	O
however	O
,	O
the	O
role	O
of	O
PAD4	O
against	O
gastrointestinal	O
infection	O
is	O
largely	O
unknown	O
.	O

Herein	O
,	O
we	O
challenged	O
PAD4	O
-	O
deficient	O
(	O
Pad4	O
(	O
-	O
/	O
-	O
)	O
)	O
mice	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
littermates	O
with	O
Citrobacter	B-bacteria
rodentium	I-bacteria
(	O
CR	B-bacteria
)	O
,	O
and	O
investigated	O
bacteria	O
clearance	O
and	O
gut	O
pathology	O
.	O

Luminal	O
colonization	O
of	O
CR	B-bacteria
in	O
Pad4	O
(	O
-	O
/	O
-	O
)	O
mice	O
peaked	O
between	O
11	O
-	O
14	O
days	O
post	O
-	O
infection	O
,	O
whereas	O
WT	O
mice	O
suppressed	O
the	O
infection	O
by	O
14	O
days	O
.	O

We	O
demonstrated	O
that	O
Pad4	O
(	O
-	O
/	O
-	O
)	O
mice	O
were	O
unable	O
to	O
form	O
NETs	O
,	O
whereas	O
WT	O
mice	O
showed	O
increased	O
NETs	O
formation	O
in	O
the	O
colon	O
during	O
infection	O
.	O

Pad4	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
aggravated	O
CR	O
-	O
associated	O
inflammation	O
as	O
indicated	O
by	O
elevated	O
systemic	O
and	O
colonic	O
pro	O
-	O
inflammatory	O
markers	O
.	O

Histological	O
analysis	O
revealed	O
that	O
transmissible	O
colonic	O
hyperplasia	O
,	O
goblet	O
cell	O
depletion	O
,	O
and	O
apoptotic	O
cell	O
death	O
were	O
more	O
pronounced	O
in	O
the	O
colon	O
of	O
CR	O
-	O
infected	O
Pad4	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Treating	O
WT	O
mice	O
with	O
deoxyribonuclease	O
I	O
,	O
which	O
can	O
disrupt	O
NETs	O
generation	O
,	O
recapitulated	O
the	O
exacerbated	O
CR	O
infection	O
and	O
gut	O
pathology	O
associated	O
with	O
the	O
loss	O
of	O
PAD4	O
.	O

Administration	O
of	O
the	O
PAD4	O
inhibitor	O
,	O
Cl	O
-	O
amidine	O
also	O
aggravated	O
CR	O
infection	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
highlight	O
the	O
importance	O
of	O
PAD4	O
in	O
the	O
mucosal	O
clearance	O
of	O
CR	O
and	O
in	O
resolving	O
gut	O
-	O
associated	O
inflammation	O
.	O

Trait	O
-	O
based	O
community	O
assembly	O
and	O
succession	O
of	O
the	O
infant	O
gut	O
microbiome	O
.	O

The	O
human	O
gut	O
microbiome	O
develops	O
over	O
early	O
childhood	O
and	O
aids	O
in	O
food	O
digestion	O
and	O
immunomodulation	O
,	O
but	O
the	O
mechanisms	O
driving	O
its	O
development	O
remain	O
elusive	O
.	O

Here	O
we	O
use	O
data	O
curated	O
from	O
literature	O
and	O
online	O
repositories	O
to	O
examine	O
trait	O
-	O
based	O
patterns	O
of	O
gut	O
microbiome	O
succession	O
in	O
56	O
infants	O
over	O
their	O
first	O
three	O
years	O
of	O
life	O
.	O

We	O
also	O
develop	O
a	O
new	O
phylogeny	O
-	O
based	O
approach	O
of	O
inferring	O
trait	O
values	O
that	O
can	O
extend	O
readily	O
to	O
other	O
microbial	O
systems	O
and	O
questions	O
.	O

Trait	O
-	O
based	O
patterns	O
suggest	O
that	O
infant	O
gut	O
succession	O
begins	O
with	O
a	O
functionally	O
variable	O
cohort	O
of	O
taxa	O
,	O
adept	O
at	O
proliferating	O
rapidly	O
within	O
hosts	O
,	O
which	O
gradually	O
matures	O
into	O
a	O
more	O
functionally	O
uniform	O
cohort	O
of	O
taxa	O
adapted	O
to	O
thrive	O
in	O
the	O
anoxic	O
gut	O
and	O
disperse	O
between	O
anoxic	O
patches	O
as	O
oxygen	O
-	O
tolerant	O
spores	O
.	O

Trait	O
-	O
based	O
composition	O
stabilizes	O
after	O
the	O
first	O
year	O
,	O
while	O
taxonomic	O
turnover	O
continues	O
unabated	O
,	O
suggesting	O
functional	O
redundancy	O
in	O
the	O
traits	O
examined	O
.	O

Trait	O
-	O
based	O
approaches	O
powerfully	O
complement	O
taxonomy	O
-	O
based	O
approaches	O
to	O
understanding	O
the	O
mechanisms	O
of	O
microbial	O
community	O
assembly	O
and	O
succession	O
.	O

Association	O
of	O
HLA	O
-	O
dependent	O
islet	O
autoimmunity	O
with	O
systemic	O
antibody	O
responses	O
to	O
intestinal	O
commensal	O
bacteria	O
in	O
children	O
.	O

Microbiome	O
sequence	O
analyses	O
have	O
suggested	O
that	O
changes	O
in	O
gut	O
bacterial	O
composition	O
are	O
associated	O
with	O
autoimmune	O
disease	O
in	O
humans	O
and	O
animal	O
models	O
.	O

However	O
,	O
little	O
is	O
known	O
of	O
the	O
mechanisms	O
through	O
which	O
the	O
gut	O
microbiota	O
influences	O
autoimmune	O
responses	O
to	O
distant	O
tissues	O
.	O

Here	O
,	O
we	O
evaluated	O
systemic	O
antibody	O
responses	O
against	O
cultured	O
human	O
gut	O
bacterial	O
strains	O
to	O
determine	O
whether	O
observed	O
patterns	O
of	O
anticommensal	O
antibody	O
(	O
ACAb	O
)	O
responses	O
are	O
associated	O
with	O
type	O
1	O
diabetes	O
(	O
T1D	O
)	O
in	O
two	O
cohorts	O
of	O
pediatric	O
study	O
participants	O
.	O

In	O
the	O
first	O
cohort	O
,	O
ACAb	O
responses	O
in	O
sera	O
collected	O
from	O
participants	O
within	O
6	O
months	O
of	O
T1D	O
diagnosis	O
were	O
compared	O
with	O
age	O
-	O
matched	O
healthy	O
controls	O
and	O
also	O
with	O
patients	O
with	O
recent	O
onset	O
Crohn	O
'	O
s	O
disease	O
.	O

ACAb	O
responses	O
against	O
multiple	O
bacterial	O
species	O
discriminated	O
among	O
these	O
three	O
groups	O
.	O

In	O
the	O
second	O
cohort	O
,	O
we	O
asked	O
whether	O
ACAb	O
responses	O
present	O
before	O
diagnosis	O
were	O
associated	O
with	O
later	O
T1D	O
development	O
and	O
with	O
HLA	O
genotype	O
in	O
participants	O
who	O
were	O
discordant	O
for	O
subsequent	O
progression	O
to	O
diabetes	O
.	O

Serum	O
IgG2	O
antibodies	O
against	O
Roseburia	B-bacteria
faecis	I-bacteria
and	O
against	O
a	O
bacterial	O
consortium	O
were	O
associated	O
with	O
future	O
T1D	O
diagnosis	O
in	O
an	O
HLA	O
DR3	O
/	O
DR4	O
haplotype	O
-	O
dependent	O
manner	O
.	O

These	O
analyses	O
reveal	O
associations	O
between	O
antibody	O
responses	O
to	O
intestinal	O
microbes	O
and	O
HLA	O
-	O
DR	O
genotype	O
and	O
islet	O
autoantibody	O
specificity	O
and	O
with	O
a	O
future	O
diagnosis	O
of	O
T1D	O
.	O

Further	O
,	O
we	O
present	O
a	O
platform	O
to	O
investigate	O
antibacterial	O
antibodies	O
in	O
biological	O
fluids	O
that	O
is	O
applicable	O
to	O
studies	O
of	O
autoimmune	O
diseases	O
and	O
responses	O
to	O
therapeutic	O
interventions	O
.	O

Dissecting	O
the	O
Evolutionary	O
Development	O
of	O
the	O
Species	O
Bifidobacterium	B-bacteria
animalis	I-bacteria
through	O
Comparative	O
Genomics	O
Analyses	O
.	O

Bifidobacteria	B-bacteria
are	O
members	O
of	O
the	O
gut	O
microbiota	O
of	O
animals	O
,	O
including	O
mammals	O
,	O
birds	O
,	O
and	O
social	O
insects	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
and	O
determined	O
the	O
pangenome	O
of	O
Bifidobacterium	B-bacteria
animalis	I-bacteria
species	I-bacteria
,	O
encompassing	O
B	B-bacteria
.	I-bacteria
animalis	I-bacteria
subsp	I-bacteria
.	I-bacteria
animalis	I-bacteria
and	O
the	O
B	B-bacteria
.	I-bacteria
animalis	I-bacteria
subsp	I-bacteria
.	I-bacteria
lactis	I-bacteria
taxon	O
,	O
which	O
is	O
one	O
of	O
the	O
most	O
intensely	O
exploited	O
probiotic	O
bifidobacterial	B-bacteria
species	I-bacteria
.	O

In	O
order	O
to	O
reveal	O
differences	O
within	O
the	O
B	B-bacteria
.	I-bacteria
animalis	I-bacteria
species	I-bacteria
,	O
detailed	O
comparative	O
genomics	O
and	O
phylogenomics	O
analyses	O
were	O
performed	O
,	O
indicating	O
that	O
these	O
two	O
subspecies	O
recently	O
arose	O
through	O
divergent	O
evolutionary	O
events	O
.	O

A	O
subspecies	O
-	O
specific	O
core	O
genome	O
was	O
identified	O
for	O
both	O
B	B-bacteria
.	I-bacteria
animalis	I-bacteria
subspecies	I-bacteria
,	O
revealing	O
the	O
existence	O
of	O
subspecies	O
-	O
defining	O
genes	O
involved	O
in	O
carbohydrate	O
metabolism	O
.	O

Notably	O
,	O
these	O
in	O
silico	O
analyses	O
coupled	O
with	O
carbohydrate	O
profiling	O
assays	O
suggest	O
genetic	O
adaptations	O
toward	O
a	O
distinct	O
glycan	O
milieu	O
for	O
each	O
member	O
of	O
the	O
B	B-bacteria
.	I-bacteria
animalis	I-bacteria
subspecies	I-bacteria
,	O
resulting	O
in	O
a	O
divergent	O
evolutionary	O
development	O
of	O
the	O
two	O
subspecies	O
.	O
IMPORTANCE	O
The	O
majority	O
of	O
characterized	O
B	B-bacteria
.	I-bacteria
animalis	I-bacteria
strains	I-bacteria
have	O
been	O
isolated	O
from	O
human	O
fecal	O
samples	O
.	O

In	O
order	O
to	O
explore	O
genome	O
variability	O
within	O
this	O
species	O
,	O
we	O
isolated	O
15	O
novel	O
strains	O
from	O
the	O
gastrointestinal	O
tracts	O
of	O
different	O
animals	O
,	O
including	O
mammals	O
and	O
birds	O
.	O

The	O
present	O
study	O
allowed	O
us	O
to	O
reconstruct	O
the	O
pangenome	O
of	O
this	O
taxon	O
,	O
including	O
the	O
genome	O
contents	O
of	O
56	O
B	B-bacteria
.	I-bacteria
animalis	I-bacteria
strains	I-bacteria
.	O

Through	O
careful	O
assessment	O
of	O
subspecies	O
-	O
specific	O
core	O
genes	O
of	O
the	O
B	B-bacteria
.	I-bacteria
animalis	I-bacteria
subsp	I-bacteria
.	I-bacteria
animalis	I-bacteria
/	I-bacteria
lactis	I-bacteria
taxon	O
,	O
we	O
identified	O
genes	O
encoding	O
enzymes	O
involved	O
in	O
carbohydrate	O
transport	O
and	O
metabolism	O
,	O
while	O
unveiling	O
specific	O
gene	O
acquisition	O
and	O
loss	O
events	O
that	O
caused	O
the	O
evolutionary	O
emergence	O
of	O
these	O
two	O
subspecies	O
.	O

Potential	O
Role	O
for	O
the	O
Gut	O
Microbiota	O
in	O
Modulating	O
Host	O
Circadian	O
Rhythms	O
and	O
Metabolic	O
Health	O
.	O

This	O
article	O
reviews	O
the	O
current	O
evidence	O
associating	O
gut	O
microbiota	O
with	O
factors	O
that	O
impact	O
host	O
circadian	O
-	O
metabolic	O
axis	O
,	O
such	O
as	O
light	O
/	O
dark	O
cycles	O
,	O
sleep	O
/	O
wake	O
cycles	O
,	O
diet	O
,	O
and	O
eating	O
patterns	O
.	O

We	O
examine	O
how	O
gut	O
bacteria	O
possess	O
their	O
own	O
daily	O
rhythmicity	O
in	O
terms	O
of	O
composition	O
,	O
their	O
localization	O
to	O
intestinal	O
niches	O
,	O
and	O
functions	O
.	O

We	O
review	O
evidence	O
that	O
gut	O
bacteria	O
modulate	O
host	O
rhythms	O
via	O
microbial	O
metabolites	O
such	O
as	O
butyrate	O
,	O
polyphenolic	O
derivatives	O
,	O
vitamins	O
,	O
and	O
amines	O
.	O

Lifestyle	O
stressors	O
such	O
as	O
altered	O
sleep	O
and	O
eating	O
patterns	O
that	O
may	O
disturb	O
the	O
host	O
circadian	O
system	O
also	O
influence	O
the	O
gut	O
microbiome	O
.	O

The	O
consequent	O
disruptions	O
to	O
microbiota	O
-	O
mediated	O
functions	O
such	O
as	O
decreased	O
conjugation	O
of	O
bile	O
acids	O
or	O
increased	O
production	O
of	O
hydrogen	O
sulfide	O
and	O
the	O
resultant	O
decreased	O
production	O
of	O
butyrate	O
,	O
in	O
turn	O
affect	O
substrate	O
oxidation	O
and	O
energy	O
regulation	O
in	O
the	O
host	O
.	O

Thus	O
,	O
disturbances	O
in	O
microbiome	O
rhythms	O
may	O
at	O
least	O
partially	O
contribute	O
to	O
an	O
increased	O
risk	O
of	O
obesity	O
and	O
metabolic	O
syndrome	O
associated	O
with	O
insufficient	O
sleep	O
and	O
circadian	O
misalignment	O
.	O

Good	O
sleep	O
and	O
a	O
healthy	O
diet	O
appear	O
to	O
be	O
essential	O
for	O
maintaining	O
gut	O
microbial	O
balance	O
.	O

Manipulating	O
daily	O
rhythms	O
of	O
gut	O
microbial	O
abundance	O
and	O
activity	O
may	O
therefore	O
hold	O
promise	O
for	O
a	O
chrononutrition	O
-	O
based	O
approach	O
to	O
consolidate	O
host	O
circadian	O
rhythms	O
and	O
metabolic	O
homeorhesis	O
.	O

Wastewater	O
microbial	O
community	O
structure	O
and	O
functional	O
traits	O
change	O
over	O
short	O
timescales	O
.	O

Wastewater	O
contains	O
microorganisms	O
coming	O
from	O
various	O
sources	O
,	O
e	O
.	O
g	O
.	O
feces	O
discharges	O
,	O
soil	O
infiltrations	O
and	O
sewer	O
biofilms	O
and	O
sediments	O
.	O

The	O
primary	O
objective	O
of	O
this	O
work	O
was	O
to	O
determine	O
if	O
end	O
-	O
of	O
-	O
pipe	O
wastewater	O
microbial	O
community	O
structures	O
exhibits	O
short	O
-	O
timescale	O
variation	O
,	O
and	O
assess	O
possible	O
microbial	O
origins	O
.	O

To	O
this	O
end	O
,	O
we	O
measured	O
hourly	O
physicochemical	O
characteristics	O
of	O
wastewater	O
influent	O
for	O
2days	O
and	O
analyzed	O
the	O
microbial	O
community	O
at	O
4	O
-	O
h	O
intervals	O
using	O
16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
.	O

Results	O
showed	O
large	O
variations	O
in	O
the	O
microbial	O
community	O
composition	O
at	O
phylum	O
and	O
genus	O
levels	O
,	O
i	O
.	O
e	O
.	O
Proteobacteria	B-bacteria
ranged	O
from	O
44	O
to	O
63	O
%	O
of	O
the	O
total	O
relative	O
abundance	O
and	O
Arcobacter	B-bacteria
ranged	O
from	O
11	O
to	O
22	O
%	O
.	O

Diurnal	O
patterns	O
were	O
observed	O
in	O
the	O
alpha	O
-	O
diversity	O
,	O
beta	O
-	O
diversity	O
and	O
the	O
prevalence	O
of	O
several	O
taxa	O
.	O

Wastewater	O
physicochemical	O
characteristics	O
explained	O
61	O
%	O
of	O
the	O
total	O
microbial	O
community	O
variance	O
by	O
Canonical	O
Correspondence	O
Analysis	O
(	O
CCA	O
)	O
,	O
with	O
flow	O
rate	O
being	O
the	O
main	O
explanatory	O
variable	O
exhibiting	O
a	O
clear	O
diurnal	O
profile	O
.	O

Comparison	O
with	O
public	O
databases	O
using	O
closed	O
reference	O
OTUs	O
revealed	O
that	O
only	O
7	O
.	O
3	O
%	O
of	O
the	O
sequences	O
were	O
shared	O
with	O
human	O
gut	O
microbiota	O
and	O
21	O
.	O
7	O
%	O
with	O
soil	O
microbiota	O
,	O
the	O
majority	O
being	O
from	O
the	O
sewer	O
biofilms	O
and	O
sediments	O
.	O

The	O
functional	O
trait	O
,	O
weighted	O
average	O
ribosomal	O
RNA	O
operon	O
(	O
rrn	O
)	O
copy	O
number	O
per	O
genome	O
,	O
was	O
found	O
to	O
be	O
relatively	O
high	O
in	O
the	O
wastewater	O
microbiota	O
(	O
average	O
3	O
.	O
6	O
,	O
soil	O
2	O
.	O
1	O
,	O
and	O
human	O
gut	O
2	O
.	O
6	O
)	O
and	O
significantly	O
correlated	O
with	O
flow	O
,	O
inferring	O
active	O
microbial	O
enrichments	O
in	O
the	O
sewer	O
.	O

The	O
prevalence	O
of	O
Methylophilaceae	B-bacteria
,	O
methanol	O
oxidation	O
genes	O
and	O
denitrification	O
genes	O
were	O
related	O
to	O
high	O
influent	O
methanol	O
and	O
NO3	O
(	O
-	O
)	O
concentration	O
in	O
the	O
influent	O
wastewater	O
.	O

These	O
functional	O
organisms	O
and	O
genes	O
indicate	O
important	O
carbon	O
and	O
nutrient	O
removal	O
related	O
functions	O
in	O
the	O
sewer	O
.	O

Together	O
,	O
the	O
observed	O
temporal	O
patterns	O
of	O
the	O
microbial	O
community	O
and	O
functional	O
traits	O
suggest	O
that	O
high	O
wastewater	O
flow	O
causes	O
greater	O
transport	O
of	O
active	O
sewer	O
microorganisms	O
which	O
are	O
functionally	O
important	O
.	O

Long	O
-	O
term	O
effects	O
of	O
oxytetracycline	O
exposure	O
in	O
zebrafish	O
:	O
A	O
multi	O
-	O
level	O
perspective	O
.	O

Oxytetracycline	O
(	O
OTC	O
)	O
is	O
a	O
broad	O
-	O
spectrum	O
antibiotic	O
widely	O
used	O
in	O
livestock	O
production	O
.	O

Like	O
many	O
other	O
pharmaceuticals	O
,	O
OTC	O
is	O
not	O
completely	O
metabolized	O
by	O
the	O
organism	O
and	O
thus	O
,	O
increasing	O
amounts	O
of	O
the	O
compound	O
are	O
being	O
detected	O
in	O
the	O
aquatic	O
environment	O
.	O

The	O
assessment	O
of	O
the	O
environmental	O
risk	O
of	O
pharmaceuticals	O
is	O
hindered	O
by	O
their	O
very	O
low	O
concentrations	O
and	O
specific	O
modes	O
of	O
action	O
and	O
thus	O
relevant	O
exposure	O
scenarios	O
and	O
sensitive	O
endpoints	O
are	O
needed	O
.	O

Thus	O
,	O
this	O
work	O
aimed	O
to	O
study	O
the	O
long	O
-	O
term	O
effect	O
of	O
OTC	O
exposure	O
in	O
zebrafish	O
(	O
at	O
behavior	O
and	O
biochemical	O
levels	O
)	O
and	O
associated	O
bacterial	O
communities	O
(	O
fish	O
gut	O
and	O
water	O
bacterial	O
communities	O
)	O
.	O

Results	O
revealed	O
that	O
at	O
behavioral	O
level	O
,	O
boldness	O
increase	O
(	O
manifested	O
by	O
increased	O
exploratory	O
behavior	O
of	O
a	O
new	O
environment	O
)	O
was	O
observed	O
in	O
fish	O
exposed	O
to	O
low	O
OTC	O
concentrations	O
.	O

Moreover	O
,	O
changes	O
in	O
fish	O
swimming	O
pattern	O
were	O
observed	O
in	O
light	O
periods	O
(	O
increased	O
stress	O
response	O
:	O
hyperactivity	O
and	O
freezing	O
)	O
probably	O
due	O
to	O
photo	O
-	O
sensibility	O
conferred	O
by	O
OTC	O
exposure	O
.	O

Effects	O
at	O
biochemical	O
level	O
suggest	O
that	O
long	O
-	O
term	O
exposure	O
to	O
OTC	O
interfere	O
with	O
cellular	O
energy	O
allocation	O
mainly	O
by	O
reducing	O
lipids	O
levels	O
and	O
increasing	O
energy	O
consumption	O
.	O

Moreover	O
,	O
evidences	O
of	O
oxidative	O
damage	O
were	O
also	O
observed	O
(	O
reduced	O
levels	O
of	O
TG	O
,	O
GST	O
and	O
CAT	O
)	O
.	O

The	O
analysis	O
of	O
water	O
and	O
gut	O
microbiome	O
revealed	O
changes	O
in	O
the	O
structure	O
and	O
diversity	O
of	O
bacterial	O
communities	O
potentially	O
leading	O
to	O
changes	O
in	O
communities	O
'	O
biological	O
function	O
.	O

Some	O
of	O
the	O
effects	O
were	O
observed	O
at	O
the	O
lowest	O
concentration	O
tested	O
,	O
0	O
.	O
1mug	O
/	O
L	O
which	O
is	O
a	O
concentration	O
already	O
detected	O
in	O
the	O
environment	O
and	O
thus	O
clearly	O
demonstrating	O
the	O
need	O
of	O
a	O
serious	O
ecotoxicological	O
assessment	O
of	O
OTC	O
effects	O
on	O
non	O
-	O
target	O
organisms	O
.	O

Hydrolyzed	O
fumonisin	O
B1	O
induces	O
less	O
inflammatory	O
responses	O
than	O
fumonisin	O
B1	O
in	O
the	O
co	O
-	O
culture	O
model	O
of	O
porcine	O
intestinal	O
epithelial	O
and	O
immune	O
cells	O
.	O

Fumonisin	O
B1	O
(	O
FB1	O
)	O
,	O
mainly	O
produced	O
by	O
Fusarium	B-bacteria
verticillioides	I-bacteria
and	O
Fusarium	B-bacteria
proliferatum	I-bacteria
,	O
can	O
be	O
converted	O
to	O
the	O
less	O
toxic	O
metabolite	O
hydrolyzed	O
FB1	O
(	O
HFB1	O
)	O
by	O
enzymatic	O
degradation	O
.	O

The	O
application	O
of	O
an	O
FB1degrading	O
enzyme	O
as	O
a	O
feed	O
additive	O
is	O
a	O
strategy	O
to	O
reduce	O
fumonisin	O
exposure	O
of	O
animals	O
.	O

However	O
,	O
the	O
difference	O
between	O
the	O
effect	O
of	O
FB1	O
and	O
HFB1	O
on	O
porcine	O
intestinal	O
immunity	O
is	O
poorly	O
documented	O
.	O

We	O
investigated	O
the	O
toxic	O
effects	O
of	O
FB1	O
and	O
HFB1	O
exposure	O
on	O
porcine	O
gut	O
barrier	O
function	O
and	O
intestinal	O
immunity	O
by	O
using	O
a	O
co	O
-	O
culture	O
model	O
of	O
intestinal	O
porcine	O
epithelial	O
cells	O
(	O
IPEC	O
-	O
J2	O
)	O
and	O
porcine	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
.	O

First	O
,	O
we	O
confirmed	O
that	O
Fusarium	O
mycotoxin	O
(	O
deoxynivalenol	O
;	O
DON	O
)	O
,	O
in	O
the	O
presence	O
of	O
an	O
endotoxin	O
(	O
lipopolysaccharide	O
:	O
LPS	O
)	O
,	O
disrupted	O
gut	O
permeability	O
of	O
IPEC	O
-	O
J2	O
and	O
induced	O
inflammatory	O
response	O
in	O
the	O
co	O
-	O
culture	O
system	O
.	O

FB1	O
induced	O
additional	O
damage	O
to	O
gut	O
barrier	O
function	O
and	O
promoted	O
pro	O
-	O
inflammatory	O
responses	O
in	O
the	O
presence	O
of	O
LPS	O
and	O
DON	O
compared	O
to	O
only	O
LPS	O
/	O
DON	O
treatment	O
.	O

In	O
the	O
co	O
-	O
culture	O
system	O
,	O
FB1	O
/	O
LPS	O
/	O
DON	O
induced	O
increased	O
cell	O
death	O
of	O
PBMCs	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
than	O
LPS	O
/	O
DON	O
treatment	O
.	O

In	O
contrast	O
,	O
the	O
application	O
of	O
HFB1	O
resulted	O
in	O
reduced	O
levels	O
of	O
chemokines	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
together	O
with	O
marginal	O
immune	O
cell	O
death	O
compared	O
to	O
FB1	O
/	O
LPS	O
/	O
DON	O
in	O
the	O
IPEC	O
-	O
J2	O
/	O
PBMC	O
co	O
-	O
culture	O
system	O
.	O

These	O
findings	O
suggest	O
that	O
FB1	O
aggravates	O
LPS	O
/	O
DON	O
-	O
induced	O
intestinal	O
inflammation	O
,	O
and	O
HFB1	O
showed	O
less	O
toxicity	O
to	O
immune	O
response	O
.	O

Therefore	O
,	O
enzymatic	O
degradation	O
of	O
FB1	O
to	O
HFB1	O
could	O
be	O
an	O
effective	O
strategy	O
to	O
reduce	O
intestinal	O
inflammation	O
in	O
pigs	O
.	O

Screening	O
and	O
identification	O
of	O
gut	O
anaerobes	O
(	O
Bacteroidetes	B-bacteria
)	O
from	O
human	O
diabetic	O
stool	O
samples	O
with	O
and	O
without	O
retinopathy	O
in	O
comparison	O
to	O
control	O
subjects	O
.	O

Studies	O
have	O
reported	O
a	O
reciprocal	O
interaction	O
between	O
metabolic	O
disorders	O
and	O
the	O
human	O
gut	O
microbial	O
composition	O
.	O

However	O
,	O
more	O
information	O
is	O
still	O
needed	O
concerning	O
the	O
gut	O
microbiome	O
related	O
to	O
metabolic	O
disorders	O
such	O
as	O
Diabetes	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
reveal	O
whether	O
stool	O
samples	O
collected	O
from	O
normal	O
individuals	O
and	O
from	O
diabetic	O
subjects	O
with	O
or	O
without	O
retinopathy	O
differ	O
in	O
their	O
gut	O
microbial	O
composition	O
.	O

Data	O
showed	O
higher	O
Bacteroides	B-bacteria
ratio	O
in	O
diabetic	O
groups	O
gut	O
composition	O
with	O
no	O
significant	O
difference	O
of	O
bacterial	O
strains	O
in	O
diabetic	O
subjects	O
with	O
or	O
without	O
retinopathy	O
compared	O
to	O
lean	O
(	O
control	O
)	O
individuals	O
gut	O
microbiota	O
.	O

These	O
findings	O
indicated	O
that	O
the	O
gut	O
microbiota	O
is	O
altered	O
in	O
accordance	O
to	O
the	O
presence	O
of	O
metabolic	O
disorders	O
.	O

However	O
,	O
further	O
studies	O
have	O
to	O
be	O
elaborated	O
in	O
terms	O
of	O
gut	O
microbial	O
composition	O
with	O
diabetes	O
.	O

Gut	O
microbiota	O
analysis	O
and	O
its	O
significance	O
in	O
vasovagal	O
syncope	O
in	O
children	O
.	O

BACKGROUND	O
:	O
Vasovagal	O
syncope	O
(	O
VVS	O
)	O
is	O
common	O
in	O
children	O
and	O
greatly	O
affect	O
both	O
physical	O
and	O
mental	O
health	O
.	O

But	O
the	O
mechanisms	O
have	O
not	O
been	O
completely	O
explained	O
.	O

This	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
gut	O
microbiota	O
in	O
children	O
with	O
VVS	O
and	O
explore	O
its	O
clinical	O
significance	O
.	O

METHODS	O
:	O
Fecal	O
samples	O
from	O
20	O
VVS	O
children	O
and	O
20	O
matched	O
controls	O
were	O
collected	O
,	O
and	O
the	O
microbiota	O
were	O
analyzed	O
by	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

The	O
diversity	O
and	O
microbiota	O
compositions	O
of	O
the	O
VVS	O
cases	O
and	O
controls	O
were	O
compared	O
with	O
the	O
independent	O
sample	O
t	O
test	O
or	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

The	O
correlation	O
between	O
the	O
predominant	O
bacteria	O
and	O
clinical	O
symptoms	O
was	O
analyzed	O
using	O
Pearson	O
or	O
Spearman	O
correlation	O
test	O
.	O

RESULTS	O
:	O
No	O
significant	O
differences	O
in	O
diversity	O
were	O
evident	O
between	O
VVS	O
and	O
controls	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

At	O
the	O
family	O
level	O
,	O
the	O
relative	O
abundance	O
of	O
Ruminococcaceae	B-bacteria
was	O
significantly	O
higher	O
in	O
VVS	O
children	O
than	O
in	O
controls	O
(	O
median	O
[	O
Q1	O
,	O
Q3	O
]	O
:	O
22	O
.	O
10	O
%	O
[	O
16	O
.	O
89	O
%	O
,	O
27	O
.	O
36	O
%	O
]	O
vs	O
.	O
13	O
.	O
92	O
%	O
[	O
10	O
.	O
31	O
%	O
,	O
20	O
.	O
18	O
%	O
]	O
,	O
Z	O
=	O
-	O
2	O
.	O
40	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
LEfSe	O
analysis	O
revealed	O
Ruminococcaceae	B-bacteria
as	O
a	O
discriminative	O
feature	O
(	O
linear	O
discriminant	O
analysis	O
[	O
LDA	O
]	O
score	O
>	O
4	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
relative	O
abundance	O
of	O
Ruminococcaceae	B-bacteria
in	O
VVS	O
patients	O
was	O
positively	O
correlated	O
with	O
the	O
frequency	O
of	O
syncope	O
(	O
r	O
=	O
0	O
.	O
616	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
terms	O
of	O
its	O
correlation	O
with	O
hemodynamics	O
,	O
we	O
showed	O
that	O
relative	O
abundance	O
of	O
Ruminococcaceae	B-bacteria
was	O
negatively	O
correlated	O
with	O
the	O
systolic	O
and	O
diastolic	O
pressure	O
reduction	O
at	O
the	O
positive	O
response	O
in	O
head	O
-	O
up	O
tilt	O
test	O
(	O
HUTT	O
;	O
r	O
=	O
-	O
0	O
.	O
489	O
and	O
-	O
0	O
.	O
448	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
was	O
positively	O
correlated	O
with	O
the	O
mean	O
pressure	O
drop	O
and	O
decline	O
rate	O
(	O
r	O
=	O
0	O
.	O
489	O
and	O
0	O
.	O
467	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
as	O
well	O
as	O
diastolic	O
pressure	O
drop	O
and	O
decline	O
rate	O
at	O
the	O
HUTT	O
positive	O
response	O
(	O
r	O
=	O
0	O
.	O
579	O
and	O
0	O
.	O
589	O
,	O
all	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
VVS	O
patients	O
.	O

CONCLUSION	O
:	O
Ruminococcaceae	B-bacteria
was	O
the	O
predominant	O
gut	O
bacteria	O
and	O
was	O
associated	O
with	O
the	O
clinical	O
symptoms	O
and	O
hemodynamics	O
of	O
VVS	O
,	O
suggesting	O
that	O
gut	O
microbiota	O
might	O
be	O
involved	O
in	O
the	O
development	O
of	O
VVS	O
.	O

The	O
germ	O
-	O
free	O
mice	O
monocolonization	O
with	O
Bacteroides	B-bacteria
fragilis	I-bacteria
improves	O
azoxymethane	O
/	O
dextran	O
sulfate	O
sodium	O
induced	O
colitis	O
-	O
associated	O
colorectal	O
cancer	O
.	O

OBJECTIVE	O
:	O
Inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
is	O
generally	O
considered	O
as	O
a	O
major	O
risk	O
factor	O
in	O
the	O
progression	O
of	O
colitis	O
-	O
associated	O
colorectal	O
cancer	O
(	O
CAC	O
)	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
the	O
composition	O
of	O
gut	O
microflora	O
may	O
be	O
involved	O
in	O
CAC	O
induction	O
and	O
progress	O
.	O

Bacteroides	B-bacteria
fragilis	I-bacteria
(	O
BF	B-bacteria
)	O
is	O
a	O
Gram	O
-	O
negative	O
anaerobe	O
belonging	O
to	O
colonic	O
symbiotic	O
bacteria	O
of	O
the	O
host	O
.	O

This	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
protective	O
role	O
of	O
BF	O
in	O
a	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
model	O
induced	O
by	O
azoxymethane	O
(	O
AOM	O
)	O
and	O
dextran	O
sulfate	O
sodium	O
(	O
DSS	O
)	O
in	O
germ	O
-	O
free	O
(	O
GF	O
)	O
mice	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Total	O
22	O
GF	O
mice	O
were	O
divided	O
into	O
two	O
groups	O
:	O
GF	O
and	O
BF	O
group	O
.	O

Half	O
of	O
the	O
GF	O
mice	O
were	O
colonized	O
with	O
BF	O
for	O
28	O
days	O
before	O
CRC	O
induction	O
by	O
AOM	O
/	O
DSS	O
.	O

RESULTS	O
:	O
BF	O
colonization	O
increased	O
animal	O
survival	O
(	O
100	O
%	O
)	O
.	O

Cecum	O
weight	O
and	O
cecum	O
/	O
body	O
weight	O
ratio	O
significantly	O
decreased	O
in	O
BF	O
/	O
AOM	O
/	O
DSS	O
group	O
.	O

Interestingly	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
tumor	O
number	O
and	O
tumor	O
incidence	O
in	O
the	O
BF	O
/	O
AOM	O
/	O
DSS	O
group	O
as	O
compared	O
to	O
the	O
GF	O
/	O
AOM	O
/	O
DSS	O
group	O
.	O

The	O
adenocarcinoma	O
/	O
adenoma	O
incidence	O
and	O
histologic	O
score	O
were	O
also	O
decreased	O
in	O
the	O
BF	O
/	O
AOM	O
/	O
DSS	O
group	O
.	O

In	O
addition	O
,	O
immunohistochemistry	O
staining	O
found	O
decreased	O
numbers	O
of	O
cell	O
proliferation	O
(	O
PCNA	O
)	O
and	O
inflammatory	O
cell	O
(	O
granulocytes	O
)	O
infiltration	O
in	O
the	O
colon	O
mucosa	O
of	O
the	O
BF	O
group	O
.	O

The	O
beta	O
-	O
catenin	O
staining	O
in	O
the	O
BF	O
/	O
AOM	O
/	O
DSS	O
group	O
had	O
fewer	O
and	O
weaker	O
positive	O
signal	O
expressions	O
.	O

Taking	O
together	O
,	O
the	O
BF	O
colonization	O
significantly	O
ameliorated	O
AOM	O
/	O
DSS	O
-	O
induced	O
CRC	O
by	O
suppressing	O
the	O
activity	O
of	O
cell	O
proliferation	O
-	O
related	O
molecules	O
and	O
reducing	O
the	O
number	O
of	O
inflammatory	O
cells	O
.	O

CONCLUSIONS	O
:	O
Symbiotic	O
BF	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
maintaining	O
the	O
gastrointestinal	O
immunophysiologic	O
balance	O
and	O
regulating	O
anti	O
-	O
tumorigenesis	O
responses	O
.	O

IgA	O
-	O
enhancing	O
effects	O
of	O
membrane	O
vesicles	O
derived	O
from	O
Lactobacillus	B-bacteria
sakei	I-bacteria
subsp	I-bacteria
.	I-bacteria
sakei	I-bacteria
NBRC15893	I-bacteria
.	O

Immunoglobulin	O
(	O
Ig	O
)	O
A	O
in	O
the	O
mucus	O
of	O
the	O
intestinal	O
tract	O
plays	O
an	O
important	O
role	O
in	O
preventing	O
the	O
invasion	O
of	O
pathogenic	O
microorganisms	O
and	O
regulating	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
.	O

Several	O
strains	O
of	O
probiotic	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
are	O
known	O
to	O
promote	O
intestinal	O
IgA	O
production	O
.	O

Bacteria	O
are	O
also	O
known	O
to	O
naturally	O
release	O
spherical	O
membrane	O
vesicles	O
(	O
MVs	O
)	O
that	O
are	O
involved	O
in	O
various	O
biological	O
functions	O
such	O
as	O
quorum	O
sensing	O
,	O
pathogenesis	O
,	O
and	O
host	O
immunomodulation	O
.	O

However	O
,	O
the	O
production	O
of	O
MVs	O
by	O
LAB	B-bacteria
and	O
their	O
effects	O
on	O
host	O
immunity	O
remain	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
MV	O
production	O
by	O
Lactobacillus	B-bacteria
sakei	I-bacteria
subsp	I-bacteria
.	I-bacteria
sakei	I-bacteria
NBRC15893	I-bacteria
isolated	O
from	O
kimoto	O
,	O
the	O
traditional	O
seed	O
mash	O
used	O
for	O
brewing	O
sake	O
.	O

MVs	O
were	O
separated	O
from	O
the	O
culture	O
broth	O
of	O
L	B-bacteria
.	I-bacteria
sakei	I-bacteria
NBRC15893	I-bacteria
through	O
filtration	O
and	O
density	O
gradient	O
ultracentrifugation	O
and	O
were	O
observed	O
by	O
transmission	O
electron	O
microscopy	O
.	O

The	O
MVs	O
showed	O
a	O
spherical	O
morphology	O
,	O
with	O
a	O
diameter	O
of	O
30	O
-	O
400	O
nm	O
,	O
and	O
contained	O
proteins	O
and	O
nucleic	O
acids	O
.	O

In	O
addition	O
,	O
both	O
the	O
LAB	B-bacteria
cells	O
and	O
purified	O
MVs	O
promoted	O
IgA	O
production	O
by	O
murine	O
Peyer	O
'	O
s	O
patch	O
cells	O
.	O

This	O
MV	O
-	O
and	O
cell	O
-	O
induced	O
IgA	O
production	O
was	O
suppressed	O
by	O
neutralization	O
of	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
2	O
,	O
which	O
recognizes	O
cell	O
wall	O
components	O
of	O
gram	O
-	O
positive	O
bacteria	O
,	O
using	O
an	O
anti	O
-	O
TLR2	O
antibody	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
MVs	O
released	O
from	O
L	B-bacteria
.	I-bacteria
sakei	I-bacteria
NBRC15893	I-bacteria
enhance	O
IgA	O
production	O
by	O
activating	O
host	O
TLR2	O
signaling	O
through	O
its	O
cell	O
wall	O
components	O
.	O

Thus	O
,	O
it	O
is	O
important	O
to	O
consider	O
novel	O
interactions	O
between	O
gut	O
microbiota	O
and	O
hosts	O
via	O
MVs	O
,	O
and	O
MVs	O
derived	O
from	O
probiotic	O
bacteria	O
could	O
have	O
promising	O
applications	O
as	O
safe	O
adjuvants	O
.	O

Multi	O
-	O
Method	O
Characterization	O
of	O
the	O
Human	O
Circulating	O
Microbiome	O
.	O

The	O
term	O
microbiome	O
describes	O
the	O
genetic	O
material	O
encoding	O
the	O
various	O
microbial	O
populations	O
that	O
inhabit	O
our	O
body	O
.	O

Whilst	O
colonization	O
of	O
various	O
body	O
niches	O
(	O
e	O
.	O
g	O
.	O
,	O
the	O
gut	O
)	O
by	O
dynamic	O
communities	O
of	O
microorganisms	O
is	O
now	O
universally	O
accepted	O
,	O
the	O
existence	O
of	O
microbial	O
populations	O
in	O
other	O
`	O
`	O
classically	O
sterile	O
'	O
'	O
locations	O
,	O
including	O
the	O
blood	O
,	O
is	O
a	O
relatively	O
new	O
concept	O
.	O

The	O
presence	O
of	O
bacteria	O
-	O
specific	O
DNA	O
in	O
the	O
blood	O
has	O
been	O
reported	O
in	O
the	O
literature	O
for	O
some	O
time	O
,	O
yet	O
the	O
true	O
origin	O
of	O
this	O
is	O
still	O
the	O
subject	O
of	O
much	O
deliberation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phenomenon	O
of	O
a	O
`	O
`	O
blood	O
microbiome	O
'	O
'	O
by	O
providing	O
a	O
comprehensive	O
description	O
of	O
bacterially	O
derived	O
nucleic	O
acids	O
using	O
a	O
range	O
of	O
complementary	O
molecular	O
and	O
classical	O
microbiological	O
techniques	O
.	O

For	O
this	O
purpose	O
we	O
utilized	O
a	O
set	O
of	O
plasma	O
samples	O
from	O
healthy	O
subjects	O
(	O
n	O
=	O
5	O
)	O
and	O
asthmatic	O
subjects	O
(	O
n	O
=	O
5	O
)	O
.	O

DNA	O
-	O
level	O
analyses	O
involved	O
the	O
amplification	O
and	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
gene	O
.	O

RNA	O
-	O
level	O
analyses	O
were	O
based	O
upon	O
the	O
de	O
novo	O
assembly	O
of	O
unmapped	O
mRNA	O
reads	O
and	O
subsequent	O
taxonomic	O
identification	O
.	O

Molecular	O
studies	O
were	O
complemented	O
by	O
viability	O
data	O
from	O
classical	O
aerobic	O
and	O
anaerobic	O
microbial	O
culture	O
experiments	O
.	O

At	O
the	O
phylum	O
level	O
,	O
the	O
blood	O
microbiome	O
was	O
predominated	O
by	O
Proteobacteria	B-bacteria
,	O
Actinobacteria	B-bacteria
,	O
Firmicutes	B-bacteria
,	O
and	O
Bacteroidetes	B-bacteria
.	O

The	O
key	O
phyla	O
detected	O
were	O
consistent	O
irrespective	O
of	O
molecular	O
method	O
(	O
DNA	O
vs	O
.	O
RNA	O
)	O
,	O
and	O
consistent	O
with	O
the	O
results	O
of	O
other	O
published	O
studies	O
.	O

In	O
silico	O
comparison	O
of	O
our	O
data	O
with	O
that	O
of	O
the	O
Human	O
Microbiome	O
Project	O
revealed	O
that	O
members	O
of	O
the	O
blood	O
microbiome	O
were	O
most	O
likely	O
to	O
have	O
originated	O
from	O
the	O
oral	O
or	O
skin	O
communities	O
.	O

To	O
our	O
surprise	O
,	O
aerobic	O
and	O
anaerobic	O
cultures	O
were	O
positive	O
in	O
eight	O
of	O
out	O
the	O
ten	O
donor	O
samples	O
investigated	O
,	O
and	O
we	O
reflect	O
upon	O
their	O
source	O
.	O

Our	O
data	O
provide	O
further	O
evidence	O
of	O
a	O
core	O
blood	O
microbiome	O
,	O
and	O
provide	O
insight	O
into	O
the	O
potential	O
source	O
of	O
the	O
bacterial	O
DNA	O
/	O
RNA	O
detected	O
in	O
the	O
blood	O
.	O

Further	O
,	O
data	O
reveal	O
the	O
importance	O
of	O
robust	O
experimental	O
procedures	O
,	O
and	O
identify	O
areas	O
for	O
future	O
consideration	O
.	O

Aflatoxin	O
B1	O
Degradation	O
and	O
Detoxification	O
by	O
Escherichia	B-bacteria
coli	I-bacteria
CG1061	I-bacteria
Isolated	O
From	O
Chicken	O
Cecum	O
.	O

Aflatoxin	O
B1	O
(	O
AFB1	O
)	O
is	O
one	O
of	O
the	O
most	O
hazardous	O
mycotoxins	O
contamination	O
in	O
food	O
and	O
feed	O
products	O
,	O
which	O
leads	O
to	O
hepatocellular	O
carcinoma	O
in	O
humans	O
and	O
animals	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
isolated	O
and	O
characterized	O
an	O
AFB1	O
degrading	O
bacteria	O
CG1061	B-bacteria
from	O
chicken	O
cecum	O
,	O
exhibited	O
an	O
93	O
.	O
7	O
%	O
AFB1	O
degradation	O
rate	O
by	O
HPLC	O
.	O

16S	O
rRNA	O
gene	O
sequence	O
analysis	O
and	O
a	O
multiplex	O
PCR	O
experiment	O
demonstrated	O
that	O
CG1061	O
was	O
a	O
non	O
-	O
pathogenic	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

The	O
culture	O
supernatant	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
CG1061	I-bacteria
showed	O
an	O
61	O
.	O
8	O
%	O
degradation	O
rate	O
,	O
whereas	O
the	O
degradation	O
rates	O
produced	O
by	O
the	O
intracellular	O
extracts	O
was	O
only	O
17	O
.	O
6	O
%	O
,	O
indicating	O
that	O
the	O
active	O
component	O
was	O
constitutively	O
secreted	O
into	O
the	O
extracellular	O
space	O
.	O

The	O
degradation	O
rate	O
decreased	O
from	O
61	O
.	O
8	O
to	O
37	O
.	O
5	O
%	O
when	O
the	O
culture	O
supernatant	O
was	O
treated	O
with	O
1	O
mg	O
/	O
mL	O
proteinase	O
K	O
,	O
and	O
remained	O
51	O
.	O
3	O
%	O
when	O
that	O
treated	O
with	O
100	O
degrees	O
C	O
for	O
20	O
min	O
.	O

We	O
postulated	O
that	O
AFB1	O
degradation	O
was	O
mediated	O
by	O
heat	O
-	O
resistant	O
proteins	O
.	O

The	O
content	O
of	O
AFB1	O
decreased	O
rapidly	O
when	O
it	O
was	O
incubated	O
with	O
the	O
culture	O
supernatant	O
during	O
the	O
first	O
24	O
h	O
.	O
The	O
optimal	O
incubation	O
pH	O
and	O
temperature	O
were	O
pH	O
8	O
.	O
5	O
and	O
55	O
degrees	O
C	O
respectively	O
.	O

According	O
to	O
the	O
UPLC	O
Q	O
-	O
TOF	O
MS	O
analysis	O
,	O
AFB1	O
was	O
bio	O
-	O
transformed	O
to	O
the	O
product	O
C16H14O5	O
and	O
other	O
metabolites	O
.	O

Based	O
on	O
the	O
results	O
of	O
in	O
vitro	O
experiments	O
on	O
chicken	O
hepatocellular	O
carcinoma	O
(	O
LMH	O
)	O
cells	O
and	O
in	O
vivo	O
experiments	O
on	O
mice	O
,	O
we	O
confirmed	O
that	O
CG1061	O
-	O
degraded	O
AFB1	O
are	O
less	O
toxic	O
than	O
the	O
standard	O
AFB1	O
.	O

E	B-bacteria
.	I-bacteria
coli	I-bacteria
CG1061	I-bacteria
isolated	O
from	O
healthy	O
chicken	O
cerum	O
is	O
more	O
likely	O
to	O
colonize	O
the	O
animal	O
gut	O
,	O
which	O
might	O
be	O
an	O
excellent	O
candidate	O
for	O
the	O
detoxification	O
of	O
AFB1	O
in	O
food	O
and	O
feed	O
industry	O
.	O

The	O
microbiome	O
and	O
immunodeficiencies	O
:	O
Lessons	O
from	O
rare	O
diseases	O
.	O

Primary	O
immunodeficiencies	O
(	O
PIDs	O
)	O
are	O
inherited	O
disorders	O
of	O
the	O
immune	O
system	O
,	O
associated	O
with	O
a	O
considerable	O
increase	O
in	O
susceptibility	O
to	O
infections	O
.	O

PIDs	O
can	O
also	O
predispose	O
to	O
malignancy	O
,	O
inflammation	O
and	O
autoimmunity	O
.	O

There	O
is	O
increasing	O
awareness	O
that	O
some	O
aspects	O
of	O
the	O
immune	O
dysregulation	O
in	O
PIDs	O
may	O
be	O
linked	O
to	O
intestinal	O
microbiota	O
.	O

Indeed	O
,	O
the	O
gut	O
microbiota	O
and	O
its	O
metabolites	O
have	O
been	O
shown	O
to	O
influence	O
immune	O
functions	O
and	O
immune	O
homeostasis	O
both	O
locally	O
and	O
systemically	O
.	O

Recent	O
studies	O
have	O
indicated	O
that	O
genetic	O
defects	O
causing	O
PIDs	O
lead	O
to	O
perturbations	O
in	O
the	O
conventional	O
mechanisms	O
underlying	O
homeostasis	O
in	O
the	O
gut	O
,	O
resulting	O
in	O
poor	O
immune	O
surveillance	O
at	O
the	O
intestinal	O
barrier	O
,	O
which	O
associates	O
with	O
altered	O
intestinal	O
permeability	O
and	O
bacterial	O
translocation	O
.	O

Consistently	O
,	O
a	O
substantial	O
proportion	O
of	O
PID	O
patients	O
presents	O
with	O
clinically	O
challenging	O
IBD	O
-	O
like	O
pathology	O
.	O

Here	O
,	O
we	O
describe	O
the	O
current	O
body	O
of	O
literature	O
reporting	O
on	O
dysbiosis	O
of	O
the	O
gut	O
microbiota	O
in	O
different	O
PIDs	O
and	O
how	O
this	O
can	O
be	O
either	O
the	O
result	O
or	O
cause	O
of	O
immune	O
dysregulation	O
.	O

Further	O
,	O
we	O
report	O
how	O
infections	O
in	O
PIDs	O
enhance	O
pathobionts	O
colonization	O
and	O
speculate	O
how	O
,	O
in	O
turn	O
,	O
pathobionts	O
may	O
be	O
responsible	O
for	O
increased	O
disease	O
susceptibility	O
and	O
secondary	O
infections	O
in	O
these	O
patients	O
.	O

The	O
potential	O
relationship	O
between	O
the	O
microbial	O
composition	O
in	O
the	O
intestine	O
and	O
other	O
sites	O
,	O
such	O
as	O
the	O
oral	O
cavity	O
and	O
skin	O
,	O
is	O
also	O
highlighted	O
.	O

Finally	O
,	O
we	O
provide	O
evidence	O
,	O
in	O
preclinical	O
models	O
of	O
PIDs	O
,	O
for	O
the	O
efficacy	O
of	O
microbiota	O
manipulation	O
to	O
ameliorate	O
disease	O
complications	O
,	O
and	O
suggest	O
that	O
the	O
potential	O
use	O
of	O
dietary	O
intervention	O
to	O
correct	O
dysbiotic	O
flora	O
in	O
PID	O
patients	O
may	O
hold	O
promise	O
.	O

The	O
Microbiome	O
and	O
Eating	O
Disorders	O
.	O

Growing	O
interest	O
exists	O
in	O
the	O
association	O
of	O
gut	O
bacteria	O
with	O
diseases	O
,	O
such	O
as	O
diabetes	O
,	O
obesity	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
and	O
psychiatric	O
disorders	O
.	O

Gut	O
microbiota	O
influence	O
the	O
fermentation	O
of	O
nutrients	O
,	O
body	O
-	O
weight	O
regulation	O
,	O
gut	O
permeability	O
,	O
hormones	O
,	O
inflammation	O
,	O
immunology	O
,	O
and	O
behavior	O
(	O
gut	O
-	O
brain	O
axis	O
)	O
.	O

Regarding	O
anorexia	O
nervosa	O
(	O
AN	O
)	O
,	O
altered	O
microbial	O
diversity	O
and	O
taxa	O
abundance	O
were	O
found	O
and	O
associated	O
with	O
depressive	O
,	O
anxious	O
,	O
and	O
eating	O
disorder	O
symptoms	O
.	O

Potential	O
mechanisms	O
involve	O
increased	O
gut	O
permeability	O
,	O
low	O
-	O
grade	O
inflammation	O
,	O
autoantibodies	O
,	O
and	O
reduced	O
brain	O
cell	O
neogenesis	O
and	O
learning	O
.	O

Gut	O
microbiome	O
is	O
strongly	O
influenced	O
by	O
refeeding	O
practices	O
.	O

Microbiota	O
-	O
modulating	O
strategies	O
like	O
nutritional	O
interventions	O
or	O
psychobiotics	O
application	O
could	O
become	O
relevant	O
additions	O
to	O
AN	O
treatment	O
.	O

An	O
insoluble	O
polysaccharide	O
from	O
the	O
sclerotium	O
of	O
Poria	O
cocos	O
improves	O
hyperglycemia	O
,	O
hyperlipidemia	O
and	O
hepatic	O
steatosis	O
in	O
ob	O
/	O
ob	O
mice	O
via	O
modulation	O
of	O
gut	O
microbiota	O
.	O

Metabolic	O
syndrome	O
characterized	O
by	O
obesity	O
,	O
hyperglycemia	O
and	O
liver	O
steatosis	O
is	O
becoming	O
prevalent	O
all	O
over	O
the	O
world	O
.	O

Herein	O
,	O
a	O
water	O
insoluble	O
polysaccharide	O
(	O
WIP	O
)	O
was	O
isolated	O
and	O
identified	O
from	O
the	O
sclerotium	O
of	O
Poria	O
cocos	O
,	O
a	O
widely	O
used	O
Traditional	O
Chinese	O
Medicine	O
.	O

WIP	O
was	O
confirmed	O
to	O
be	O
a	O
(	O
1	O
-	O
3	O
)	O
-	O
beta	O
-	O
D	O
-	O
glucan	O
with	O
an	O
average	O
Mw	O
of	O
4	O
.	O
486	O
x	O
10	O
(	O
6	O
)	O
Da	O
by	O
NMR	O
and	O
SEC	O
-	O
RI	O
-	O
MALLS	O
analyses	O
.	O

Furthermore	O
,	O
oral	O
treatment	O
with	O
WIP	O
from	O
P	O
.	O
cocos	O
significantly	O
improved	O
glucose	O
and	O
lipid	O
metabolism	O
and	O
alleviated	O
hepatic	O
steatosis	O
in	O
ob	O
/	O
ob	O
mice	O
.	O

16S	O
DNA	O
sequencing	O
analysis	O
of	O
cecum	O
content	O
from	O
WIP	O
-	O
treated	O
mice	O
indicated	O
the	O
increase	O
of	O
butyrate	O
-	O
producing	O
bacteria	O
Lachnospiracea	B-bacteria
,	O
Clostridium	B-bacteria
.	O

It	O
was	O
also	O
observed	O
that	O
WIP	O
treatment	O
elevated	O
the	O
level	O
of	O
butyrate	O
in	O
gut	O
,	O
improved	O
the	O
gut	O
mucosal	O
integrity	O
and	O
activated	O
the	O
intestinal	O
PPAR	O
-	O
gamma	O
pathway	O
.	O

Fecal	O
transplantation	O
experiments	O
definitely	O
confirmed	O
the	O
causative	O
role	O
of	O
gut	O
microbiota	O
in	O
mediating	O
the	O
benefits	O
of	O
WIP	O
.	O

It	O
is	O
the	O
first	O
report	O
that	O
the	O
water	O
insoluble	O
polysaccharide	O
from	O
the	O
sclerotium	O
of	O
P	O
.	O
cocos	O
modulates	O
gut	O
microbiota	O
to	O
improve	O
hyperglycemia	O
and	O
hyperlipidemia	O
.	O

Thereby	O
,	O
WIP	O
from	O
P	O
.	O
cocos	O
,	O
as	O
a	O
prebiotic	O
,	O
has	O
the	O
potential	O
for	O
the	O
prevention	O
or	O
cure	O
of	O
metabolic	O
diseases	O
and	O
may	O
elucidate	O
new	O
mechanism	O
for	O
the	O
efficacies	O
of	O
this	O
traditional	O
herbal	O
medicine	O
on	O
the	O
regulation	O
of	O
lipid	O
and	O
glucose	O
metabolism	O
.	O

Modeling	O
Clostridium	B-bacteria
difficile	I-bacteria
in	O
a	O
hospital	O
setting	O
:	O
control	O
and	O
admissions	O
of	O
colonized	O
and	O
symptomatic	O
patients	O
.	O

BACKGROUND	O
:	O
Clostridium	B-bacteria
difficile	I-bacteria
(	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
)	O
infection	O
is	O
an	O
important	O
cause	O
of	O
healthcare	O
-	O
associated	O
diarrhea	O
.	O

Several	O
factors	O
such	O
as	O
admission	O
of	O
colonized	O
patients	O
,	O
levels	O
of	O
serum	O
antibodies	O
in	O
patients	O
,	O
and	O
control	O
strategies	O
may	O
involve	O
in	O
determining	O
the	O
prevalence	O
and	O
the	O
persistence	O
of	O
C	O
.	O
difficile	O
in	O
a	O
hospital	O
unit	O
.	O

METHODS	O
:	O
We	O
develop	O
mathematical	O
models	O
based	O
on	O
deterministic	O
and	O
stochastic	O
frameworks	O
to	O
investigate	O
the	O
effects	O
of	O
control	O
strategies	O
for	O
colonized	O
and	O
symptomatic	O
patients	O
and	O
admissions	O
of	O
colonized	O
and	O
symptomatic	O
patients	O
on	O
the	O
prevalence	O
and	O
the	O
persistence	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
.	O

RESULTS	O
:	O
Our	O
findings	O
suggest	O
that	O
control	O
strategies	O
and	O
admissions	O
of	O
colonized	O
and	O
symptomatic	O
patients	O
play	O
important	O
roles	O
in	O
determining	O
the	O
prevalence	O
and	O
the	O
persistence	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
.	O

Improving	O
control	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
in	O
colonized	O
and	O
symptomatic	O
patients	O
may	O
generally	O
help	O
reduce	O
the	O
prevalence	O
and	O
the	O
persistence	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
.	O

However	O
,	O
if	O
admission	O
rates	O
of	O
colonized	O
and	O
symptomatic	O
patients	O
are	O
high	O
,	O
the	O
prevalence	O
of	O
C	O
.	O
difficile	O
may	O
remain	O
high	O
in	O
a	O
patient	O
population	O
even	O
though	O
strict	O
control	O
policies	O
are	O
applied	O
.	O

CONCLUSION	O
:	O
Control	O
strategies	O
and	O
admissions	O
of	O
colonized	O
and	O
symptomatic	O
patients	O
are	O
important	O
determinants	O
of	O
the	O
prevalence	O
and	O
the	O
persistence	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
.	O

Exercise	O
influence	O
on	O
the	O
microbiome	O
-	O
gut	O
-	O
brain	O
axis	O
.	O

The	O
microbiome	O
in	O
the	O
gut	O
is	O
a	O
diverse	O
environment	O
,	O
housing	O
the	O
majority	O
of	O
our	O
bacterial	O
microbes	O
.	O

This	O
microecosystem	O
has	O
a	O
symbiotic	O
relationship	O
with	O
the	O
surrounding	O
multicellular	O
organism	O
,	O
and	O
a	O
balance	O
and	O
diversity	O
of	O
specific	O
phyla	O
of	O
bacteria	O
support	O
general	O
health	O
.	O

When	O
gut	O
bacteria	O
diversity	O
diminishes	O
,	O
there	O
are	O
systemic	O
consequences	O
,	O
such	O
as	O
gastrointestinal	O
and	O
psychological	O
distress	O
.	O

This	O
pathway	O
of	O
communication	O
is	O
known	O
as	O
the	O
microbiome	O
-	O
gut	O
-	O
brain	O
axis	O
.	O

Interventions	O
such	O
as	O
probiotic	O
supplementation	O
that	O
influence	O
microbiome	O
also	O
improve	O
both	O
gut	O
and	O
brain	O
disorders	O
.	O

Recent	O
evidence	O
suggests	O
that	O
aerobic	O
exercise	O
improves	O
the	O
diversity	O
and	O
abundance	O
of	O
genera	O
from	O
the	O
Firmcutes	B-bacteria
phylum	I-bacteria
,	O
which	O
may	O
be	O
the	O
link	O
between	O
the	O
positive	O
effects	O
of	O
exercise	O
on	O
the	O
gut	O
and	O
brain	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
explain	O
the	O
complex	O
communication	O
pathway	O
of	O
the	O
microbiome	O
-	O
gut	O
-	O
brain	O
axis	O
and	O
further	O
examine	O
the	O
role	O
of	O
exercise	O
on	O
influencing	O
this	O
communication	O
highway	O
.	O

Is	O
stool	O
frequency	O
associated	O
with	O
the	O
richness	O
and	O
community	O
composition	O
of	O
gut	O
microbiota	O
?	O

Background	O
/	O
Aims	O
:	O
Recently	O
,	O
a	O
number	O
of	O
studies	O
have	O
reported	O
that	O
the	O
gut	O
microbiota	O
could	O
contribute	O
to	O
human	O
conditions	O
,	O
including	O
obesity	O
,	O
inflammation	O
,	O
cancer	O
development	O
,	O
and	O
behavior	O
.	O

We	O
hypothesized	O
that	O
the	O
composition	O
and	O
distribution	O
of	O
gut	O
microbiota	O
are	O
different	O
according	O
to	O
stool	O
frequency	O
,	O
and	O
attempted	O
to	O
identify	O
the	O
association	O
between	O
gut	O
microbiota	O
and	O
stool	O
frequency	O
.	O

Methods	O
:	O
We	O
collected	O
fecal	O
samples	O
from	O
healthy	O
individuals	O
divided	O
into	O
3	O
groups	O
according	O
to	O
stool	O
frequency	O
:	O
group	O
1	O
,	O
a	O
small	O
number	O
of	O
defecation	O
(	O
<	O
/	O
=	O
2	O
times	O
/	O
wk	O
)	O
;	O
group	O
2	O
,	O
normal	O
defecation	O
(	O
1	O
time	O
/	O
day	O
or	O
1	O
time	O
/	O
2	O
day	O
)	O
;	O
and	O
group	O
3	O
,	O
a	O
large	O
number	O
of	O
defecation	O
(	O
>	O
/	O
=	O
2	O
-	O
3	O
times	O
/	O
day	O
)	O
.	O

We	O
evaluated	O
the	O
composition	O
and	O
distribution	O
of	O
the	O
gut	O
microbiota	O
in	O
each	O
group	O
via	O
16S	O
rRNA	O
-	O
based	O
taxonomic	O
profiling	O
of	O
the	O
fecal	O
samples	O
.	O

Results	O
:	O
Fecal	O
samples	O
were	O
collected	O
from	O
a	O
total	O
of	O
60	O
individuals	O
(	O
31	O
men	O
and	O
29	O
women	O
,	O
aged	O
34	O
.	O
1	O
+	O
/	O
-	O
5	O
.	O
88	O
years	O
)	O
,	O
and	O
each	O
group	O
comprised	O
20	O
individuals	O
.	O

The	O
microbial	O
richness	O
of	O
group	O
1	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
group	O
3	O
and	O
tended	O
to	O
decrease	O
with	O
increasing	O
number	O
of	O
defecation	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
biological	O
community	O
composition	O
was	O
fairly	O
different	O
according	O
to	O
the	O
number	O
of	O
defecation	O
,	O
and	O
Bacteroidetes	B-bacteria
to	O
Firmicutes	B-bacteria
ratio	O
was	O
higher	O
in	O
group	O
1	O
than	O
in	O
the	O
other	O
groups	O
.	O

Moreover	O
,	O
we	O
found	O
specific	O
strains	O
at	O
the	O
family	O
and	O
genus	O
levels	O
in	O
groups	O
1	O
and	O
3	O
.	O

Conclusions	O
:	O
Bacteroidetes	B-bacteria
to	O
Firmicutes	B-bacteria
ratio	O
and	O
the	O
abundance	O
of	O
Bifidobacterium	B-bacteria
were	O
different	O
according	O
to	O
the	O
stool	O
frequency	O
,	O
and	O
specific	O
bacteria	O
were	O
identified	O
in	O
the	O
subjects	O
with	O
large	O
and	O
small	O
numbers	O
of	O
defecation	O
,	O
respectively	O
.	O

These	O
findings	O
suggest	O
that	O
stool	O
frequency	O
might	O
be	O
associated	O
with	O
the	O
richness	O
and	O
community	O
composition	O
of	O
the	O
gut	O
microbiota	O
.	O

Resistant	O
Starch	O
Attenuates	O
Bone	O
Loss	O
in	O
Ovariectomised	O
Mice	O
by	O
Regulating	O
the	O
Intestinal	O
Microbiota	O
and	O
Bone	O
-	O
Marrow	O
Inflammation	O
.	O

The	O
intestinal	O
microbiota	O
may	O
regulate	O
bone	O
metabolism	O
by	O
reducing	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
and	O
T	O
cells	O
in	O
bone	O
tissues	O
of	O
oestrogen	O
-	O
deficient	O
mice	O
have	O
been	O
reported	O
.	O

Resistant	O
starch	O
(	O
RS	O
)	O
is	O
a	O
type	O
of	O
dietary	O
fibre	O
and	O
results	O
in	O
changes	O
in	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
RS	O
supplemented	O
in	O
diets	O
on	O
intestinal	O
microbial	O
composition	O
,	O
bone	O
mineral	O
density	O
,	O
and	O
inflammatory	O
-	O
gene	O
expression	O
in	O
the	O
colon	O
and	O
bone	O
marrow	O
of	O
ovariectomised	O
(	O
OVX	O
)	O
mice	O
.	O

OVX	O
mice	O
were	O
divided	O
randomly	O
into	O
three	O
groups	O
:	O
OVX	O
control	O
,	O
OVX	O
fed	O
a	O
20	O
%	O
high	O
amylose	O
corn	O
starch	O
(	O
HAS	O
)	O
diet	O
,	O
and	O
OVX	O
fed	O
a	O
20	O
%	O
acid	O
-	O
hydrolysed	O
HAS	O
(	O
AH	O
-	O
HAS	O
)	O
diet	O
.	O

HAS	O
and	O
AH	O
-	O
HAS	O
diets	O
contained	O
6	O
.	O
8	O
%	O
and	O
12	O
%	O
of	O
RS	O
,	O
respectively	O
.	O

After	O
6	O
weeks	O
,	O
treatment	O
with	O
HAS	O
or	O
AH	O
-	O
HAS	O
increased	O
the	O
abundance	O
of	O
Bifidobacterium	B-bacteria
spp	I-bacteria
.	I-bacteria
in	O
faeces	O
.	O

The	O
AH	O
-	O
HAS	O
diet	O
tended	O
to	O
upregulate	O
mRNA	O
expression	O
of	O
interleukin	O
(	O
IL	O
)	O
-	O
10	O
in	O
the	O
colon	O
,	O
and	O
downregulate	O
expression	O
of	O
receptor	O
activator	O
of	O
nuclear	O
factor	O
kappa	O
-	O
B	O
ligand	O
and	O
IL	O
-	O
7	O
receptor	O
genes	O
in	O
the	O
bone	O
marrow	O
of	O
OVX	O
mice	O
.	O

AH	O
-	O
HAS	O
treatment	O
attenuated	O
ovariectomy	O
-	O
induced	O
bone	O
loss	O
.	O

These	O
findings	O
suggest	O
that	O
AH	O
-	O
HAS	O
might	O
change	O
the	O
microbiota	O
and	O
immune	O
status	O
of	O
the	O
bone	O
marrow	O
,	O
resulting	O
in	O
attenuated	O
bone	O
resorption	O
in	O
OVX	O
mice	O
.	O

The	O
Effects	O
of	O
Glucosamine	O
and	O
Chondroitin	O
Sulfate	O
on	O
Gut	O
Microbial	O
Composition	O
:	O
A	O
Systematic	O
Review	O
of	O
Evidence	O
from	O
Animal	O
and	O
Human	O
Studies	O
.	O

Oral	O
glucosamine	O
sulfate	O
(	O
GS	O
)	O
and	O
chondroitin	O
sulfate	O
(	O
CS	O
)	O
,	O
while	O
widely	O
marketed	O
as	O
joint	O
-	O
protective	O
supplements	O
,	O
have	O
limited	O
intestinal	O
absorption	O
and	O
are	O
predominantly	O
utilized	O
by	O
gut	O
microbiota	O
.	O

Hence	O
the	O
effects	O
of	O
these	O
supplements	O
on	O
the	O
gut	O
microbiome	O
are	O
of	O
great	O
interest	O
,	O
and	O
may	O
clarify	O
their	O
mode	O
of	O
action	O
,	O
or	O
explain	O
heterogeneity	O
in	O
therapeutic	O
responses	O
.	O

We	O
conducted	O
a	O
systematic	O
review	O
of	O
animal	O
and	O
human	O
studies	O
reporting	O
the	O
effects	O
of	O
GS	O
or	O
CS	O
on	O
gut	O
microbial	O
composition	O
.	O

We	O
searched	O
MEDLINE	O
,	O
EMBASE	O
,	O
and	O
Scopus	O
databases	O
for	O
journal	O
articles	O
in	O
English	O
from	O
database	O
inception	O
until	O
July	O
2018	O
,	O
using	O
search	O
terms	O
microbiome	O
,	O
microflora	O
,	O
intestinal	O
microbiota	O
/	O
flora	O
,	O
gut	O
microbiota	O
/	O
flora	O
and	O
glucosamine	O
or	O
chondroitin	O
.	O

Eight	O
original	O
articles	O
reported	O
the	O
effects	O
of	O
GS	O
or	O
CS	O
on	O
microbiome	O
composition	O
in	O
adult	O
humans	O
(	O
four	O
articles	O
)	O
or	O
animals	O
(	O
four	O
articles	O
)	O
.	O

Studies	O
varied	O
significantly	O
in	O
design	O
,	O
supplementation	O
protocols	O
,	O
and	O
microbiome	O
assessment	O
methods	O
.	O

There	O
was	O
moderate	O
-	O
quality	O
evidence	O
for	O
an	O
association	O
between	O
CS	O
exposure	O
and	O
increased	O
abundance	O
of	O
genus	B-bacteria
Bacteroides	I-bacteria
in	O
the	O
murine	O
and	O
human	O
gut	O
,	O
and	O
low	O
-	O
quality	O
evidence	O
for	O
an	O
association	O
between	O
CS	O
exposure	O
and	O
an	O
increase	O
in	O
Desulfovibrio	B-bacteria
piger	I-bacteria
species	I-bacteria
,	O
an	O
increase	O
in	O
Bacteroidales	B-bacteria
S24	I-bacteria
-	I-bacteria
7	I-bacteria
family	I-bacteria
,	O
and	O
a	O
decrease	O
in	O
Lactobacillus	B-bacteria
.	O

We	O
discuss	O
the	O
possible	O
metabolic	O
implications	O
of	O
these	O
changes	O
for	O
the	O
host	O
.	O

For	O
GS	O
,	O
evidence	O
of	O
effects	O
on	O
gut	O
microbiome	O
was	O
limited	O
to	O
one	O
low	O
-	O
quality	O
study	O
.	O

This	O
review	O
highlights	O
the	O
importance	O
of	O
considering	O
the	O
potential	O
influence	O
of	O
oral	O
CS	O
supplements	O
on	O
gut	O
microbiota	O
when	O
evaluating	O
their	O
effects	O
and	O
safety	O
for	O
the	O
host	O
.	O

Structural	O
elucidation	O
of	O
a	O
glucan	O
from	O
Crataegus	O
pinnatifida	O
and	O
its	O
bioactivity	O
on	O
intestinal	O
bacteria	O
strains	O
.	O

Crataegus	O
pinnatifida	O
is	O
widely	O
used	O
as	O
functional	O
food	O
and	O
traditional	O
medicine	O
in	O
China	O
for	O
various	O
applications	O
.	O

Polysaccharides	O
may	O
contribute	O
to	O
health	O
benefits	O
,	O
such	O
as	O
modulating	O
human	O
gut	O
microbiota	O
(	O
HGM	O
)	O
.	O

To	O
investigate	O
structure	O
features	O
of	O
polysaccharides	O
from	O
this	O
plant	O
,	O
fruits	O
of	O
C	O
.	O
pinnatifida	O
were	O
extracted	O
with	O
boiling	O
water	O
,	O
yielding	O
crude	O
polysaccharides	O
HAW	O
.	O

A	O
novel	O
polysaccharide	O
,	O
named	O
HAW1	O
-	O
1	O
,	O
was	O
pooled	O
by	O
DEAE	O
Sepharose	O
Fast	O
Flow	O
column	O
and	O
further	O
purified	O
by	O
Sephacryl	O
S	O
-	O
100	O
HR	O
column	O
.	O

The	O
molecular	O
weight	O
of	O
HAW1	O
-	O
1	O
was	O
42	O
.	O
35kDa	O
.	O

The	O
carbohydrate	O
content	O
of	O
HAW1	O
-	O
1	O
was	O
99	O
.	O
42	O
%	O
and	O
no	O
protein	O
was	O
detected	O
.	O

The	O
monosaccharide	O
analysis	O
showed	O
this	O
polysaccharide	O
was	O
only	O
composed	O
of	O
glucose	O
.	O

According	O
to	O
the	O
partial	O
acid	O
hydrolysis	O
,	O
methylation	O
analysis	O
and	O
NMR	O
spectra	O
,	O
the	O
backbone	O
of	O
HAW1	O
-	O
1	O
was	O
consisted	O
of	O
1	O
,	O
4	O
-	O
linked	O
alpha	O
-	O
D	O
-	O
glucan	O
and	O
1	O
,	O
4	O
,	O
6	O
-	O
linked	O
alpha	O
-	O
D	O
-	O
glucan	O
.	O

The	O
side	O
chains	O
were	O
composed	O
of	O
1	O
,	O
6	O
-	O
linked	O
alpha	O
-	O
D	O
-	O
glucan	O
and	O
terminal	O
-	O
linked	O
alpha	O
-	O
D	O
-	O
glucan	O
.	O

The	O
bioactivity	O
tests	O
showed	O
that	O
HAW1	O
-	O
1	O
could	O
promote	O
the	O
growth	O
of	O
three	O
species	O
of	O
intestinal	O
Bacteroides	B-bacteria
and	O
produce	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
.	O

The	O
results	O
suggested	O
that	O
HAW1	O
-	O
1	O
might	O
be	O
a	O
potential	O
prebiotic	O
candidate	O
to	O
maintain	O
intestinal	O
homeostasis	O
and	O
improve	O
human	O
gut	O
health	O
.	O

Effect	O
of	O
TMAO	O
,	O
a	O
Gut	O
-	O
Bacteria	O
Metabolite	O
,	O
on	O
Dry	O
Eye	O
in	O
a	O
Rat	O
Model	O
.	O

PURPOSE	O
Trimethylamine	O
oxide	O
(	O
TMAO	O
)	O
is	O
an	O
osmolyte	O
used	O
by	O
saltwater	O
animals	O
to	O
protect	O
their	O
cells	O
from	O
hyperosmotic	O
environment	O
.	O

Here	O
,	O
we	O
studied	O
if	O
TMAO	O
may	O
exert	O
beneficial	O
effect	O
in	O
dry	O
eye	O
disease	O
(	O
DED	O
)	O
which	O
results	O
from	O
hyperosmotic	O
tear	O
film	O
.	O

MATERIALS	O
AND	O
METHODS	O
Female	O
,	O
12	O
-	O
week	O
-	O
old	O
Sprague	O
-	O
Dawley	O
rats	O
underwent	O
either	O
removal	O
of	O
extra	O
-	O
and	O
infraorbital	O
lacrimal	O
glands	O
(	O
dry	O
eye	O
group	O
)	O
or	O
sham	O
surgery	O
(	O
sham	O
group	O
)	O
.	O

A	O
1	O
-	O
week	O
topical	O
treatment	O
with	O
either	O
0	O
.	O
9	O
%	O
NaCl	O
(	O
control	O
)	O
or	O
1	O
%	O
TMAO	O
in	O
0	O
.	O
9	O
%	O
NaCl	O
solution	O
was	O
started	O
4	O
weeks	O
after	O
the	O
surgery	O
.	O

Fluorescein	O
score	O
(	O
FS	O
)	O
,	O
blink	O
rate	O
(	O
BR	O
)	O
,	O
and	O
histological	O
picture	O
of	O
cornea	O
were	O
assessed	O
.	O

RESULTS	O
At	O
baseline	O
,	O
corneas	O
did	O
not	O
stain	O
with	O
fluorescein	O
and	O
there	O
was	O
no	O
difference	O
between	O
the	O
groups	O
in	O
BR	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
FS	O
and	O
BR	O
after	O
the	O
removal	O
of	O
lacrimal	O
glands	O
(	O
p	O
<	O
0	O
.	O
0001	O
and	O
p	O
=	O
0	O
.	O
0003	O
,	O
respectively	O
)	O
.	O

Accordingly	O
,	O
the	O
dry	O
eye	O
group	O
showed	O
significantly	O
higher	O
FS	O
and	O
BR	O
than	O
the	O
sham	O
group	O
(	O
p	O
=	O
0	O
.	O
0003	O
and	O
p	O
=	O
0	O
.	O
0005	O
,	O
respectively	O
)	O
.	O

Treatment	O
with	O
TMAO	O
but	O
not	O
with	O
0	O
.	O
9	O
%	O
NaCl	O
significantly	O
reduced	O
FS	O
and	O
BR	O
(	O
p	O
=	O
0	O
.	O
01	O
and	O
p	O
=	O
0	O
.	O
005	O
,	O
respectively	O
)	O
;	O
however	O
,	O
FS	O
and	O
BR	O
did	O
not	O
return	O
to	O
baseline	O
(	O
p	O
=	O
0	O
.	O
0045	O
and	O
p	O
=	O
0	O
.	O
0065	O
,	O
respectively	O
)	O
.	O

In	O
comparison	O
to	O
the	O
control	O
group	O
,	O
treatment	O
with	O
TMAO	O
did	O
not	O
affect	O
epithelial	O
thickness	O
or	O
the	O
number	O
of	O
layers	O
of	O
epithelium	O
layers	O
.	O

CONCLUSIONS	O
We	O
have	O
found	O
that	O
in	O
a	O
rat	O
model	O
of	O
DED	O
,	O
the	O
topical	O
treatment	O
with	O
TMAO	O
improves	O
clinical	O
picture	O
,	O
however	O
does	O
not	O
lead	O
to	O
the	O
evident	O
histopathological	O
recovery	O
.	O

On	O
-	O
chip	O
stool	O
liquefaction	O
via	O
acoustofluidics	O
.	O

Microfluidic	O
-	O
based	O
portable	O
devices	O
for	O
stool	O
analysis	O
are	O
important	O
for	O
detecting	O
established	O
biomarkers	O
for	O
gastrointestinal	O
disorders	O
and	O
understanding	O
the	O
relationship	O
between	O
gut	O
microbiota	O
imbalances	O
and	O
various	O
health	O
conditions	O
,	O
ranging	O
from	O
digestive	O
disorders	O
to	O
neurodegenerative	O
diseases	O
.	O

However	O
,	O
the	O
challenge	O
of	O
processing	O
stool	O
samples	O
in	O
microfluidic	O
devices	O
hinders	O
the	O
development	O
of	O
a	O
standalone	O
platform	O
.	O

Here	O
,	O
we	O
present	O
the	O
first	O
microfluidic	O
chip	O
that	O
can	O
liquefy	O
stool	O
samples	O
via	O
acoustic	O
streaming	O
.	O

With	O
an	O
acoustic	O
transducer	O
actively	O
generating	O
strong	O
micro	O
-	O
vortex	O
streaming	O
,	O
stool	O
samples	O
and	O
buffers	O
in	O
microchannel	O
can	O
be	O
homogenized	O
at	O
a	O
flow	O
rate	O
up	O
to	O
30	O
muL	O
min	O
-	O
1	O
.	O

After	O
homogenization	O
,	O
an	O
array	O
of	O
100	O
mum	O
wide	O
micropillars	O
can	O
further	O
purify	O
stool	O
samples	O
by	O
filtering	O
out	O
large	O
debris	O
.	O

A	O
favorable	O
biocompatibility	O
was	O
also	O
demonstrated	O
for	O
our	O
acoustofluidic	O
-	O
based	O
stool	O
liquefaction	O
chip	O
by	O
examining	O
bacteria	O
morphology	O
and	O
viability	O
.	O

Moreover	O
,	O
stool	O
samples	O
with	O
different	O
consistencies	O
were	O
liquefied	O
.	O

Our	O
acoustofluidic	O
chip	O
offers	O
a	O
miniaturized	O
,	O
robust	O
,	O
and	O
biocompatible	O
solution	O
for	O
stool	O
sample	O
preparation	O
in	O
a	O
microfluidic	O
environment	O
and	O
can	O
be	O
potentially	O
integrated	O
with	O
stool	O
analysis	O
units	O
for	O
designing	O
portable	O
stool	O
diagnostics	O
platforms	O
.	O

Effect	O
of	O
Dahuang	O
Danpi	O
Decoction	O
on	O
Lactobacillus	B-bacteria
bulgaricus	I-bacteria
growth	O
and	O
metabolism	O
:	O
In	O
vitro	O
study	O
.	O

Gut	O
flora	O
plays	O
an	O
essential	O
role	O
in	O
disease	O
and	O
health	O
.	O

A	O
traditional	O
Chinese	O
herb	O
formula	O
,	O
Dahuang	O
Danpi	O
Decoction	O
(	O
DDD	O
)	O
can	O
alleviate	O
several	O
gastrointestinal	O
diseases	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
DDD	O
on	O
the	O
growth	O
and	O
metabolism	O
of	O
Lactobacillus	B-bacteria
bulgaricus	I-bacteria
.	O

L	B-bacteria
bulgaricus	I-bacteria
was	O
cultured	O
in	O
MRS	O
with	O
40	O
mg	O
/	O
ml	O
(	O
high	O
)	O
,	O
10	O
mg	O
/	O
ml	O
(	O
medium	O
)	O
,	O
and	O
2	O
.	O
5	O
mg	O
/	O
ml	O
(	O
low	O
)	O
of	O
DDD	O
,	O
Ceftriaxone	O
and	O
blank	O
(	O
control	O
)	O
.	O

The	O
growth	O
of	O
L	B-bacteria
bulgaricus	I-bacteria
was	O
measured	O
by	O
optical	O
density	O
.	O

The	O
levels	O
of	O
L	O
-	O
lactic	O
acid	O
and	O
D	O
-	O
lactic	O
acid	O
were	O
also	O
measured	O
.	O
Compared	O
to	O
the	O
control	O
group	O
,	O
the	O
concentrations	O
of	O
L	O
bulgaricus	O
in	O
the	O
medium	O
and	O
the	O
high	O
concentrations	O
DDD	O
groups	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
.	O
001	O
for	O
all	O
)	O
,	O
while	O
the	O
concentrations	O
of	O
L	B-bacteria
bulgaricus	I-bacteria
in	O
the	O
ceftriaxone	O
groups	O
were	O
significantly	O
lower	O
.	O

In	O
the	O
3	O
DDD	O
groups	O
,	O
the	O
L	O
-	O
lactic	O
acid	O
levels	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
control	O
group	O
and	O
the	O
ceftriaxone	O
groups	O
(	O
P	O
<	O
.	O
001	O
for	O
all	O
)	O
,	O
and	O
the	O
L	O
-	O
lactic	O
acid	O
level	O
was	O
the	O
highest	O
in	O
the	O
high	O
DDD	O
group	O
.	O

Similarly	O
,	O
the	O
D	O
-	O
lactic	O
acid	O
level	O
in	O
the	O
high	O
concentration	O
DDD	O
group	O
was	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
medium	O
and	O
low	O
concentration	O
DDD	O
groups	O
,	O
the	O
control	O
group	O
and	O
the	O
ceftriaxone	O
groups	O
.	O

Both	O
the	O
L	O
-	O
lactic	O
acid	O
and	O
D	O
-	O
lactic	O
acid	O
levels	O
were	O
lower	O
than	O
those	O
in	O
the	O
control	O
group	O
and	O
the	O
DDD	O
groups	O
.	O
DDD	O
could	O
dose	O
-	O
dependently	O
promote	O
the	O
growth	O
of	O
L	O
bulgaricus	O
and	O
enhance	O
the	O
secretion	O
of	O
L	O
-	O
lactic	O
acid	O
and	O
D	O
-	O
lactic	O
acid	O
,	O
which	O
suggests	O
DDD	O
may	O
be	O
able	O
to	O
interact	O
with	O
the	O
probiotics	O
,	O
improve	O
the	O
gut	O
microbiota	O
,	O
and	O
serve	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
dysbiosis	O
.	O

Noncontiguous	O
finished	O
genome	O
sequence	O
and	O
description	O
of	O
Raoultibacter	B-bacteria
massiliensis	I-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
and	O
Raoultibacter	B-bacteria
timonensis	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
,	O
two	O
new	O
bacterial	O
species	O
isolated	O
from	O
the	O
human	O
gut	O
.	O

As	O
part	O
of	O
the	O
culturomics	O
project	O
aiming	O
at	O
describing	O
the	O
human	O
microbiota	O
,	O
we	O
report	O
in	O
this	O
study	O
the	O
description	O
of	O
the	O
new	O
bacterial	O
genus	O
Raoultibacter	B-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	O
that	O
includes	O
two	O
new	O
species	O
,	O
that	O
is	O
,	O
R	B-bacteria
.	I-bacteria
massiliensis	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
and	O
R	B-bacteria
.	I-bacteria
timonensis	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	O

The	O
R	B-bacteria
.	I-bacteria
massiliensis	I-bacteria
type	O
strain	O
Marseille	B-bacteria
-	I-bacteria
P2849	I-bacteria
(	O
T	O
)	O
was	O
isolated	O
from	O
the	O
fecal	O
specimen	O
of	O
a	O
healthy	O
19	O
-	O
year	O
-	O
old	O
Saudi	O
Bedouin	O
,	O
while	O
R	B-bacteria
.	I-bacteria
timonensis	I-bacteria
type	O
strain	O
Marseille	B-bacteria
-	I-bacteria
P3277	I-bacteria
(	O
T	O
)	O
was	O
isolated	O
from	O
the	O
feces	O
of	O
an	O
11	O
-	O
year	O
-	O
old	O
pygmy	O
female	O
living	O
in	O
Congo	O
.	O

Strain	O
Marseille	B-bacteria
-	I-bacteria
P2849	I-bacteria
(	O
T	O
)	O
exhibited	O
91	O
.	O
4	O
%	O
16S	O
rRNA	O
sequence	O
similarity	O
with	O
Gordonibacter	B-bacteria
urolithinfaciens	I-bacteria
,	O
its	O
phylogenetic	O
closest	O
neighbor	O
with	O
standing	O
in	O
nomenclature	O
.	O

As	O
well	O
,	O
strain	O
Marseille	B-bacteria
-	I-bacteria
P3277	I-bacteria
(	O
T	O
)	O
exhibited	O
97	O
.	O
96	O
%	O
16S	O
rRNA	O
similarity	O
with	O
strain	O
Marseille	B-bacteria
-	I-bacteria
P2849	I-bacteria
(	O
T	O
)	O
.	O

Both	O
strains	O
were	O
Gram	O
-	O
positive	O
,	O
motile	O
,	O
nonspore	O
-	O
forming	O
rod	O
and	O
form	O
transparent	O
microcolonies	O
on	O
blood	O
agar	O
in	O
both	O
anaerobic	O
and	O
microaerophilic	O
atmospheres	O
.	O

The	O
genome	O
sizes	O
of	O
strain	O
Marseille	B-bacteria
-	I-bacteria
P2849	I-bacteria
(	O
T	O
)	O
and	O
strain	O
Marseille	B-bacteria
-	I-bacteria
P3277	I-bacteria
(	O
T	O
)	O
were	O
3	O
,	O
657	O
,	O
161	O
bp	O
and	O
4	O
,	O
000	O
,	O
215	O
bp	O
,	O
respectively	O
.	O

Using	O
a	O
taxono	O
-	O
genomic	O
approach	O
combining	O
the	O
phenotypic	O
,	O
biochemical	O
,	O
and	O
genomic	O
characteristics	O
,	O
we	O
propose	O
the	O
genus	O
Raoultibacter	B-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
which	O
contains	O
strains	O
Marseille	O
-	O
P2849	O
(	O
T	O
)	O
(	O
=	O
CSUR	B-bacteria
P2849	I-bacteria
(	O
T	O
)	O
,	O
=	O
DSM	B-bacteria
103407	I-bacteria
(	O
T	O
)	O
)	O
and	O
Marseille	O
-	O
P3277	O
(	O
T	O
)	O
(	O
=	O
CCUG	O
70680	I-bacteria
(	O
T	O
)	O
,	O
=	O
CSUR	B-bacteria
P3277	I-bacteria
(	O
T	O
)	O
)	O
as	O
type	O
strains	O
of	O
the	O
species	O
R	B-bacteria
.	I-bacteria
massiliensis	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
and	O
R	B-bacteria
.	I-bacteria
timonensis	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
respectively	O
.	O

Mechanistic	O
elucidation	O
of	O
amphetamine	O
metabolism	O
by	O
tyramine	O
oxidase	O
from	O
human	O
gut	O
microbiota	O
using	O
molecular	O
dynamics	O
simulations	O
.	O

The	O
human	O
gut	O
harbors	O
diverse	O
bacterial	O
species	O
in	O
the	O
gut	O
,	O
which	O
play	O
an	O
important	O
role	O
in	O
the	O
metabolism	O
of	O
food	O
and	O
host	O
health	O
.	O

Recent	O
studies	O
have	O
also	O
revealed	O
their	O
role	O
in	O
altering	O
the	O
pharmacological	O
properties	O
and	O
efficacy	O
of	O
oral	O
drugs	O
through	O
promiscuous	O
metabolism	O
.	O

However	O
,	O
the	O
atomistic	O
details	O
of	O
the	O
enzyme	O
-	O
drug	O
interactions	O
of	O
gut	O
bacterial	O
enzymes	O
which	O
can	O
potentially	O
carry	O
out	O
the	O
metabolism	O
of	O
drug	O
molecules	O
are	O
still	O
scarce	O
.	O

A	O
well	O
-	O
known	O
example	O
is	O
the	O
FDA	O
drug	O
amphetamine	O
(	O
a	O
central	O
nervous	O
system	O
stimulant	O
)	O
,	O
which	O
has	O
been	O
predicted	O
to	O
undergo	O
promiscuous	O
metabolism	O
by	O
gut	O
bacteria	O
.	O

Therefore	O
,	O
to	O
understand	O
the	O
atomistic	O
details	O
and	O
energy	O
landscape	O
of	O
the	O
gut	O
microbial	O
enzyme	O
-	O
mediated	O
metabolism	O
of	O
this	O
drug	O
,	O
molecular	O
dynamics	O
studies	O
were	O
performed	O
.	O

It	O
was	O
observed	O
that	O
amphetamine	O
binds	O
to	O
tyramine	O
oxidase	O
from	O
the	O
Escherichia	B-bacteria
coli	I-bacteria
strain	I-bacteria
present	O
in	O
the	O
human	O
gut	O
microbiota	O
at	O
the	O
binding	O
site	O
harboring	O
polar	O
and	O
nonpolar	O
amino	O
acids	O
.	O

The	O
stability	O
analysis	O
of	O
amphetamine	O
at	O
the	O
binding	O
site	O
showed	O
that	O
the	O
binding	O
is	O
stable	O
and	O
the	O
free	O
energy	O
for	O
the	O
binding	O
of	O
amphetamine	O
was	O
found	O
to	O
be	O
~	O
-	O
51	O
.	O
71	O
kJ	O
/	O
mol	O
.	O

The	O
insights	O
provided	O
by	O
this	O
study	O
on	O
promiscuous	O
metabolism	O
of	O
amphetamine	O
by	O
a	O
gut	O
enzyme	O
will	O
be	O
very	O
useful	O
to	O
improve	O
the	O
efficacy	O
of	O
the	O
drug	O
.	O

Supplementation	O
with	O
dairy	O
matrices	O
impacts	O
on	O
homocysteine	O
levels	O
and	O
gut	O
microbiota	O
composition	O
of	O
hyperhomocysteinemic	O
mice	O
.	O

PURPOSE	O
:	O
Several	O
studies	O
highlighted	O
a	O
correlation	O
between	O
folic	O
acid	O
deficiency	O
and	O
high	O
plasma	O
homocysteine	O
concentration	O
,	O
considered	O
a	O
risk	O
factor	O
for	O
multifactorial	O
diseases	O
.	O

Natural	O
folates	O
represent	O
an	O
emerging	O
alternative	O
strategy	O
to	O
supplementation	O
with	O
synthetic	O
folic	O
acid	O
,	O
whose	O
effects	O
are	O
controversial	O
.	O

The	O
present	O
work	O
was	O
,	O
therefore	O
,	O
performed	O
in	O
hyperhomocysteinemic	O
mice	O
to	O
study	O
the	O
impact	O
of	O
supplementation	O
with	O
dairy	O
matrices	O
containing	O
natural	O
folates	O
on	O
plasma	O
homocysteine	O
levels	O
and	O
faecal	O
microbiota	O
composition	O
.	O

METHODS	O
:	O
Forty	O
mice	O
were	O
divided	O
into	O
six	O
groups	O
,	O
two	O
of	O
which	O
fed	O
control	O
or	O
folic	O
acid	O
deficient	O
(	O
FD	O
)	O
diets	O
for	O
10	O
weeks	O
.	O

The	O
remaining	O
four	O
groups	O
were	O
fed	O
FD	O
diet	O
for	O
the	O
first	O
5	O
weeks	O
and	O
then	O
shifted	O
to	O
a	O
standard	O
control	O
diet	O
containing	O
synthetic	O
folic	O
acid	O
(	O
R	O
)	O
or	O
a	O
FD	O
diet	O
supplemented	O
with	O
folate	O
-	O
enriched	O
fermented	O
milk	O
(	O
FFM	O
)	O
produced	O
by	O
selected	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
,	O
fermented	O
milk	O
(	O
FM	O
)	O
,	O
or	O
milk	O
(	O
M	O
)	O
,	O
for	O
additional	O
5	O
weeks	O
.	O

RESULTS	O
:	O
Supplementation	O
with	O
dairy	O
matrices	O
restored	O
homocysteine	O
levels	O
in	O
FD	O
mice	O
,	O
although	O
impacting	O
differently	O
on	O
hepatic	O
S	O
-	O
adenosyl	O
-	O
methionine	O
levels	O
.	O

In	O
particular	O
,	O
FFM	O
restored	O
both	O
homocysteine	O
and	O
S	O
-	O
adenosyl	O
-	O
methionine	O
levels	O
to	O
the	O
control	O
conditions	O
,	O
in	O
comparison	O
with	O
FM	O
and	O
M	O
.	O
Next	O
generation	O
sequencing	O
analysis	O
revealed	O
that	O
faecal	O
microbiota	O
of	O
mice	O
supplemented	O
with	O
FFM	O
,	O
FM	O
and	O
M	O
were	O
characterised	O
by	O
a	O
higher	O
richness	O
of	O
bacterial	O
species	O
in	O
comparison	O
with	O
C	O
,	O
FD	O
and	O
R	O
groups	O
.	O

Analysis	O
of	O
beta	O
diversity	O
highlighted	O
that	O
the	O
three	O
dairy	O
matrices	O
determined	O
specific	O
,	O
significant	O
variations	O
of	O
faecal	O
microbiota	O
composition	O
,	O
while	O
hyperhomocysteinemia	O
was	O
not	O
associated	O
with	O
significant	O
changes	O
.	O

CONCLUSIONS	O
:	O
Overall	O
,	O
the	O
results	O
represent	O
a	O
promising	O
starting	O
point	O
for	O
the	O
applicability	O
of	O
food	O
matrices	O
enriched	O
in	O
natural	O
folates	O
to	O
manage	O
hyperhomocysteinemia	O
.	O

Alterations	O
in	O
Gut	O
Glutamate	O
Metabolism	O
Associated	O
with	O
Changes	O
in	O
Gut	O
Microbiota	O
Composition	O
in	O
Children	O
with	O
Autism	O
Spectrum	O
Disorder	O
.	O

Changes	O
in	O
the	O
gut	O
microenvironment	O
may	O
influence	O
the	O
pathogenesis	O
of	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
and	O
metabolites	O
in	O
children	O
with	O
ASD	O
.	O

Ninety	O
-	O
two	O
children	O
with	O
ASD	O
and	O
42	O
age	O
-	O
matched	O
children	O
exhibiting	O
typical	O
development	O
(	O
TD	O
)	O
were	O
enrolled	O
in	O
the	O
two	O
-	O
stage	O
study	O
.	O

In	O
the	O
discovery	O
stage	O
,	O
shotgun	O
metagenomic	O
sequencing	O
and	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
)	O
were	O
performed	O
simultaneously	O
on	O
fecal	O
samples	O
obtained	O
from	O
43	O
children	O
in	O
the	O
ASD	O
group	O
and	O
31	O
children	O
in	O
the	O
TD	O
group	O
.	O

Systematic	O
bioinformatic	O
analyses	O
were	O
performed	O
to	O
identify	O
gut	O
metabolites	O
associated	O
with	O
altered	O
gut	O
microbiota	O
composition	O
.	O

At	O
the	O
validation	O
stage	O
,	O
differential	O
metabolites	O
were	O
tested	O
using	O
LC	O
-	O
MS	O
with	O
an	O
additional	O
49	O
and	O
11	O
children	O
in	O
the	O
ASD	O
and	O
TD	O
groups	O
,	O
respectively	O
.	O

Altered	O
glutamate	O
metabolites	O
were	O
found	O
in	O
the	O
ASD	O
group	O
,	O
along	O
with	O
a	O
decline	O
in	O
2	O
-	O
keto	O
-	O
glutaramic	O
acid	O
and	O
an	O
abundance	O
of	O
microbiota	O
associated	O
with	O
glutamate	O
metabolism	O
.	O

These	O
changes	O
in	O
glutamate	O
metabolism	O
were	O
correlated	O
with	O
lower	O
levels	O
of	O
the	O
highly	O
abundant	O
bacteria	O
Bacteroides	B-bacteria
vulgatus	I-bacteria
and	O
higher	O
levels	O
of	O
the	O
potentially	O
harmful	O
Eggerthella	O
lenta	O
and	O
Clostridium	B-bacteria
botulinum	I-bacteria
.	O

Lower	O
gut	O
cortisol	O
levels	O
have	O
also	O
been	O
identified	O
in	O
the	O
ASD	O
group	O
and	O
associated	O
with	O
changes	O
in	O
gut	O
microbiota	O
glutamate	O
metabolism	O
.	O

Finally	O
,	O
gut	O
2	O
-	O
keto	O
-	O
glutaramic	O
acid	O
was	O
validated	O
as	O
a	O
potential	O
biomarker	O
for	O
ASD	O
.	O

The	O
significant	O
changes	O
in	O
the	O
gut	O
microenvironment	O
in	O
children	O
with	O
ASD	O
may	O
provide	O
new	O
insight	O
into	O
the	O
cause	O
of	O
ASD	O
and	O
aid	O
in	O
the	O
search	O
for	O
diagnostic	O
and	O
therapeutic	O
approaches	O
.	O

IMPORTANCE	O
Multiple	O
lines	O
of	O
evidence	O
suggest	O
that	O
the	O
gut	O
microbiota	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
ASD	O
,	O
but	O
the	O
specific	O
mechanism	O
is	O
still	O
unclear	O
.	O

Through	O
a	O
comprehensive	O
gut	O
metagenomic	O
and	O
metabolome	O
study	O
of	O
children	O
with	O
ASD	O
,	O
alterations	O
in	O
gut	O
metabolite	O
composition	O
were	O
found	O
in	O
children	O
with	O
ASD	O
,	O
and	O
these	O
alterations	O
were	O
linked	O
to	O
changes	O
in	O
gut	O
microbiota	O
composition	O
.	O

This	O
may	O
give	O
us	O
a	O
deeper	O
understanding	O
of	O
the	O
role	O
of	O
gut	O
microbiota	O
in	O
the	O
pathogenesis	O
of	O
ASD	O
.	O

Isolation	O
of	O
wheat	O
bran	O
-	O
colonizing	O
and	O
metabolizing	O
species	O
from	O
the	O
human	O
fecal	O
microbiota	O
.	O

Undigestible	O
,	O
insoluble	O
food	O
particles	O
,	O
such	O
as	O
wheat	O
bran	O
,	O
are	O
important	O
dietary	O
constituents	O
that	O
serve	O
as	O
a	O
fermentation	O
substrate	O
for	O
the	O
human	O
gut	O
microbiota	O
.	O

The	O
first	O
step	O
in	O
wheat	O
bran	O
fermentation	O
involves	O
the	O
poorly	O
studied	O
solubilization	O
of	O
fibers	O
from	O
the	O
complex	O
insoluble	O
wheat	O
bran	O
structure	O
.	O

Attachment	O
of	O
bacteria	O
has	O
been	O
suggested	O
to	O
promote	O
the	O
efficient	O
hydrolysis	O
of	O
insoluble	O
substrates	O
,	O
but	O
the	O
mechanisms	O
and	O
drivers	O
of	O
this	O
microbial	O
attachment	O
and	O
colonization	O
,	O
as	O
well	O
as	O
subsequent	O
fermentation	O
remain	O
to	O
be	O
elucidated	O
.	O

We	O
have	O
previously	O
shown	O
that	O
an	O
individually	O
dependent	O
subset	O
of	O
gut	O
bacteria	O
is	O
able	O
to	O
colonize	O
the	O
wheat	O
bran	O
residue	O
.	O

Here	O
,	O
we	O
isolated	O
these	O
bran	O
-	O
attached	O
microorganisms	O
,	O
which	O
can	O
then	O
be	O
used	O
to	O
gain	O
mechanistic	O
insights	O
in	O
future	O
pure	O
culture	O
experiments	O
.	O

Four	O
healthy	O
fecal	O
donors	O
were	O
screened	O
to	O
account	O
for	O
inter	O
-	O
individual	O
differences	O
in	O
gut	O
microbiota	O
composition	O
.	O

A	O
combination	O
of	O
a	O
direct	O
plating	O
and	O
enrichment	O
method	O
resulted	O
in	O
the	O
isolation	O
of	O
a	O
phylogenetically	O
diverse	O
set	O
of	O
species	O
,	O
belonging	O
to	O
the	O
Bacteroidetes	B-bacteria
,	O
Firmicutes	B-bacteria
,	O
Proteobacteria	B-bacteria
and	O
Actinobacteria	B-bacteria
phyla	I-bacteria
.	O

A	O
comparison	O
with	O
16S	O
rRNA	O
gene	O
sequences	O
that	O
were	O
found	O
enriched	O
on	O
wheat	O
bran	O
particles	O
in	O
previous	O
studies	O
,	O
however	O
,	O
showed	O
that	O
the	O
isolates	O
do	O
not	O
yet	O
cover	O
the	O
entire	O
diversity	O
of	O
wheat	O
-	O
bran	O
colonizing	O
species	O
,	O
comprising	O
among	O
others	O
a	O
broad	O
range	O
of	O
Prevotella	B-bacteria
,	O
Bacteroides	B-bacteria
and	O
Clostridium	B-bacteria
cluster	I-bacteria
XIVa	I-bacteria
species	I-bacteria
.	O

We	O
,	O
therefore	O
,	O
suggest	O
several	O
modifications	O
to	O
the	O
experiment	O
set	O
-	O
up	O
to	O
further	O
expand	O
the	O
array	O
of	O
isolated	O
species	O
.	O

The	O
ketogenic	O
diet	O
influences	O
taxonomic	O
and	O
functional	O
composition	O
of	O
the	O
gut	O
microbiota	O
in	O
children	O
with	O
severe	O
epilepsy	O
.	O

The	O
gut	O
microbiota	O
has	O
been	O
linked	O
to	O
various	O
neurological	O
disorders	O
via	O
the	O
gut	O
-	O
brain	O
axis	O
.	O

Diet	O
influences	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
.	O

The	O
ketogenic	O
diet	O
(	O
KD	O
)	O
is	O
a	O
high	O
-	O
fat	O
,	O
adequate	O
-	O
protein	O
,	O
low	O
-	O
carbohydrate	O
diet	O
established	O
for	O
treatment	O
of	O
therapy	O
-	O
resistant	O
epilepsy	O
in	O
children	O
.	O

Its	O
efficacy	O
in	O
reducing	O
seizures	O
has	O
been	O
confirmed	O
,	O
but	O
the	O
mechanisms	O
remain	O
elusive	O
.	O

The	O
diet	O
has	O
also	O
shown	O
positive	O
effects	O
in	O
a	O
wide	O
range	O
of	O
other	O
diseases	O
,	O
including	O
Alzheimer	O
'	O
s	O
,	O
depression	O
,	O
autism	O
,	O
cancer	O
,	O
and	O
type	O
2	O
diabetes	O
.	O

We	O
collected	O
fecal	O
samples	O
from	O
12	O
children	O
with	O
therapy	O
-	O
resistant	O
epilepsy	O
before	O
starting	O
KD	O
and	O
after	O
3	O
months	O
on	O
the	O
diet	O
.	O

Parents	O
did	O
not	O
start	O
KD	O
and	O
served	O
as	O
diet	O
controls	O
.	O

Applying	O
shotgun	O
metagenomic	O
DNA	O
sequencing	O
,	O
both	O
taxonomic	O
and	O
functional	O
profiles	O
were	O
established	O
.	O

Here	O
we	O
report	O
that	O
alpha	O
diversity	O
is	O
not	O
changed	O
significantly	O
during	O
the	O
diet	O
,	O
but	O
differences	O
in	O
both	O
taxonomic	O
and	O
functional	O
composition	O
are	O
detected	O
.	O

Relative	O
abundance	O
of	O
bifidobacteria	B-bacteria
as	O
well	O
as	O
E	B-bacteria
.	I-bacteria
rectale	I-bacteria
and	O
Dialister	B-bacteria
is	O
significantly	O
diminished	O
during	O
the	O
intervention	O
.	O

An	O
increase	O
in	O
relative	O
abundance	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
is	O
observed	O
on	O
KD	O
.	O

Functional	O
analysis	O
revealed	O
changes	O
in	O
29	O
SEED	O
subsystems	O
including	O
the	O
reduction	O
of	O
seven	O
pathways	O
involved	O
in	O
carbohydrate	O
metabolism	O
.	O

Decomposition	O
of	O
these	O
shifts	O
indicates	O
that	O
bifidobacteria	B-bacteria
and	O
Escherichia	B-bacteria
are	O
important	O
contributors	O
to	O
the	O
observed	O
functional	O
shifts	O
.	O

As	O
relative	O
abundance	O
of	O
health	O
-	O
promoting	O
,	O
fiber	O
-	O
consuming	O
bacteria	O
becomes	O
less	O
abundant	O
during	O
KD	O
,	O
we	O
raise	O
concern	O
about	O
the	O
effects	O
of	O
the	O
diet	O
on	O
the	O
gut	O
microbiota	O
and	O
overall	O
health	O
.	O

Further	O
studies	O
need	O
to	O
investigate	O
whether	O
these	O
changes	O
are	O
necessary	O
for	O
the	O
therapeutic	O
effect	O
of	O
KD	O
.	O

Lactobacillus	B-bacteria
Dominate	O
in	O
the	O
Intestine	O
of	O
Atlantic	O
Salmon	O
Fed	O
Dietary	O
Probiotics	O
.	O

Probiotics	O
,	O
the	O
live	O
microbial	O
strains	O
incorporated	O
as	O
dietary	O
supplements	O
,	O
are	O
known	O
to	O
provide	O
health	O
benefits	O
to	O
the	O
host	O
.	O

These	O
live	O
microbes	O
manipulate	O
the	O
gut	O
microbial	O
community	O
by	O
suppressing	O
the	O
growth	O
of	O
certain	O
intestinal	O
microbes	O
while	O
enhancing	O
the	O
establishment	O
of	O
some	O
others	O
.	O

Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
have	O
been	O
widely	O
studied	O
as	O
probiotics	O
;	O
in	O
this	O
study	O
we	O
have	O
elucidated	O
the	O
effects	O
of	O
two	O
fish	O
-	O
derived	O
LAB	B-bacteria
types	O
(	O
RII	O
and	O
RIII	O
)	O
on	O
the	O
distal	O
intestinal	O
microbial	O
communities	O
of	O
Atlantic	O
salmon	O
(	O
Salmo	O
salar	O
)	O
.	O

We	O
employed	O
high	O
-	O
throughput	O
16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
to	O
investigate	O
the	O
bacterial	O
communities	O
in	O
the	O
distal	O
intestinal	O
content	O
and	O
mucus	O
of	O
Atlantic	O
salmon	O
fed	O
diets	O
coated	O
with	O
the	O
LABs	B-bacteria
or	O
that	O
did	O
not	O
have	O
microbes	O
included	O
in	O
it	O
.	O

Our	O
results	O
show	O
that	O
the	O
supplementation	O
of	O
the	O
microbes	O
shifts	O
the	O
intestinal	O
microbial	O
profile	O
differentially	O
.	O

LAB	B-bacteria
supplementation	O
did	O
not	O
cause	O
any	O
significant	O
alterations	O
in	O
the	O
alpha	O
diversity	O
of	O
the	O
intestinal	O
content	O
bacteria	O
but	O
RIII	O
feeding	O
increased	O
the	O
bacterial	O
diversity	O
in	O
the	O
intestinal	O
mucus	O
of	O
the	O
fish	O
.	O

Beta	O
diversity	O
analysis	O
revealed	O
significant	O
differences	O
between	O
the	O
bacterial	O
compositions	O
of	O
the	O
control	O
and	O
LAB	O
-	O
fed	O
groups	O
.	O

Lactobacillus	B-bacteria
was	O
the	O
dominant	O
genus	O
in	O
LAB	O
-	O
fed	O
fish	O
.	O

A	O
few	O
members	O
of	O
the	O
phyla	O
Tenericutes	B-bacteria
,	O
Proteobacteria	B-bacteria
,	O
Actinobacteria	B-bacteria
,	O
and	O
Spirochaetes	B-bacteria
were	O
also	O
found	O
to	O
be	O
abundant	O
in	O
the	O
LAB	O
-	O
fed	O
groups	O
.	O

Furthermore	O
,	O
the	O
bacterial	O
association	O
network	O
analysis	O
showed	O
that	O
the	O
co	O
-	O
occurrence	O
pattern	O
of	O
bacteria	O
of	O
the	O
three	O
study	O
groups	O
were	O
different	O
.	O

Dietary	O
probiotics	O
can	O
modulate	O
the	O
composition	O
and	O
interaction	O
of	O
the	O
intestinal	O
microbiota	O
of	O
Atlantic	O
salmon	O
.	O

Loss	O
of	O
function	O
dysbiosis	O
associated	O
with	O
antibiotics	O
and	O
high	O
fat	O
,	O
high	O
sugar	O
diet	O
.	O

The	O
incidence	O
of	O
urinary	O
stone	O
disease	O
(	O
USD	O
)	O
has	O
increased	O
four	O
-	O
fold	O
in	O
50	O
years	O
.	O

Oxalate	O
,	O
which	O
is	O
degraded	O
exclusively	O
by	O
gut	O
bacteria	O
,	O
is	O
an	O
important	O
constituent	O
in	O
80	O
%	O
of	O
urinary	O
stones	O
.	O

We	O
quantified	O
the	O
effects	O
of	O
antibiotics	O
and	O
a	O
high	O
fat	O
/	O
high	O
sugar	O
(	O
HFHS	O
)	O
diet	O
on	O
the	O
microbial	O
metabolism	O
of	O
oxalate	O
in	O
the	O
gut	O
.	O

High	O
and	O
low	O
oxalate	O
-	O
degrading	O
mouse	O
models	O
were	O
developed	O
by	O
administering	O
fecal	O
transplants	O
from	O
either	O
the	O
wild	O
mammalian	O
rodent	O
Neotoma	O
albigula	O
or	O
Swiss	O
-	O
Webster	O
mice	O
to	O
Swiss	O
-	O
Webster	O
mice	O
,	O
which	O
produces	O
a	O
microbiota	O
with	O
or	O
without	O
the	O
bacteria	O
necessary	O
for	O
persistent	O
oxalate	O
metabolism	O
,	O
respectively	O
.	O

Antibiotics	O
led	O
to	O
an	O
acute	O
loss	O
of	O
both	O
transplant	O
bacteria	O
and	O
associated	O
oxalate	O
metabolism	O
.	O

Transplant	O
bacteria	O
exhibited	O
some	O
recovery	O
over	O
time	O
but	O
oxalate	O
metabolism	O
did	O
not	O
.	O

In	O
contrast	O
,	O
a	O
HFHS	O
diet	O
led	O
to	O
an	O
acute	O
loss	O
of	O
function	O
coupled	O
with	O
a	O
gradual	O
loss	O
of	O
transplant	O
bacteria	O
,	O
indicative	O
of	O
a	O
shift	O
in	O
overall	O
microbial	O
metabolism	O
.	O

Thus	O
,	O
the	O
effects	O
of	O
oral	O
antibiotics	O
on	O
the	O
microbiome	O
form	O
and	O
function	O
were	O
greater	O
than	O
the	O
effects	O
of	O
diet	O
.	O

Results	O
indicate	O
that	O
both	O
antibiotics	O
and	O
diet	O
strongly	O
influence	O
microbial	O
oxalate	O
metabolism	O
.	O

Analysis	O
of	O
the	O
relationship	O
between	O
the	O
gut	O
microbiome	O
and	O
dementia	O
:	O
a	O
cross	O
-	O
sectional	O
study	O
conducted	O
in	O
Japan	O
.	O

Dysregulation	O
of	O
the	O
gut	O
microbiome	O
is	O
associated	O
with	O
several	O
life	O
-	O
threatening	O
conditions	O
and	O
thus	O
might	O
represent	O
a	O
useful	O
target	O
for	O
the	O
prevention	O
of	O
dementia	O
.	O

However	O
,	O
the	O
relationship	O
between	O
the	O
gut	O
microbial	O
population	O
and	O
dementia	O
has	O
not	O
yet	O
been	O
fully	O
clarified	O
.	O

We	O
recruited	O
outpatients	O
visiting	O
our	O
memory	O
clinic	O
to	O
participate	O
in	O
this	O
study	O
.	O

Information	O
on	O
patient	O
demographics	O
,	O
risk	O
factors	O
,	O
and	O
activities	O
of	O
daily	O
living	O
was	O
collected	O
,	O
and	O
cognitive	O
function	O
was	O
assessed	O
using	O
neuropsychological	O
tests	O
and	O
brain	O
magnetic	O
resonance	O
imaging	O
scans	O
.	O

Faecal	O
samples	O
were	O
obtained	O
,	O
and	O
the	O
gut	O
microbiome	O
was	O
assessed	O
by	O
terminal	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
T	O
-	O
RFLP	O
)	O
analysis	O
,	O
one	O
of	O
the	O
most	O
well	O
-	O
established	O
and	O
reliable	O
16S	O
ribosomal	O
RNA	O
-	O
based	O
methods	O
for	O
classifying	O
gut	O
microbiota	O
.	O

Patients	O
were	O
divided	O
into	O
two	O
groups	O
,	O
demented	O
and	O
non	O
-	O
demented	O
.	O

Multivariable	O
logistic	O
regression	O
models	O
were	O
used	O
to	O
identify	O
the	O
variables	O
independently	O
associated	O
with	O
dementia	O
.	O

The	O
T	O
-	O
RFLP	O
analysis	O
revealed	O
differences	O
in	O
the	O
composition	O
of	O
the	O
gut	O
microbiome	O
:	O
the	O
number	O
of	O
Bacteroides	B-bacteria
(	O
enterotype	O
I	O
)	O
was	O
lower	O
and	O
the	O
number	O
of	O
'	O
other	O
'	O
bacteria	O
(	O
enterotype	O
III	O
)	O
was	O
higher	O
in	O
demented	O
than	O
non	O
-	O
demented	O
patients	O
.	O

Multivariable	O
analyses	O
showed	O
that	O
the	O
populations	O
of	O
enterotype	O
I	O
and	O
enterotype	O
III	O
bacteria	O
were	O
strongly	O
associated	O
with	O
dementia	O
,	O
independent	O
of	O
the	O
traditional	O
dementia	O
biomarkers	O
.	O

Further	O
studies	O
of	O
the	O
metabolites	O
of	O
gut	O
microbes	O
are	O
needed	O
to	O
determine	O
the	O
mechanism	O
underlying	O
this	O
association	O
.	O

HBV	O
infection	O
-	O
induced	O
liver	O
cirrhosis	O
development	O
in	O
dual	O
-	O
humanised	O
mice	O
with	O
human	O
bone	O
mesenchymal	O
stem	O
cell	O
transplantation	O
.	O

OBJECTIVE	O
:	O
Developing	O
a	O
small	O
animal	O
model	O
that	O
accurately	O
delineates	O
the	O
natural	O
history	O
of	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
and	O
immunopathophysiology	O
is	O
necessary	O
to	O
clarify	O
the	O
mechanisms	O
of	O
host	O
-	O
virus	O
interactions	O
and	O
to	O
identify	O
intervention	O
strategies	O
for	O
HBV	O
-	O
related	O
liver	O
diseases	O
.	O

This	O
study	O
aimed	O
to	O
develop	O
an	O
HBV	O
-	O
induced	O
chronic	O
hepatitis	O
and	O
cirrhosis	O
mouse	O
model	O
through	O
transplantation	O
of	O
human	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
hBMSCs	O
)	O
.	O

DESIGN	O
:	O
Transplantation	O
of	O
hBMSCs	O
into	O
Fah	O
(	O
-	O
/	O
-	O
)	O
Rag2	O
(	O
-	O
/	O
-	O
)	O
IL	O
-	O
2Rgammac	O
(	O
-	O
/	O
-	O
)	O
SCID	O
(	O
FRGS	O
)	O
mice	O
with	O
fulminant	O
hepatic	O
failure	O
(	O
FHF	O
)	O
induced	O
by	O
hamster	O
-	O
anti	O
-	O
mouse	O
CD95	O
antibody	O
JO2	O
generated	O
a	O
liver	O
and	O
immune	O
cell	O
dual	O
-	O
humanised	O
(	O
hBMSC	O
-	O
FRGS	O
)	O
mouse	O
.	O

The	O
generated	O
hBMSC	O
-	O
FRGS	O
mice	O
were	O
subjected	O
to	O
assessments	O
of	O
sustained	O
viremia	O
,	O
specific	O
immune	O
and	O
inflammatory	O
responses	O
and	O
liver	O
pathophysiological	O
injury	O
to	O
characterise	O
the	O
progression	O
of	O
chronic	O
hepatitis	O
and	O
cirrhosis	O
after	O
HBV	O
infection	O
.	O

RESULTS	O
:	O
The	O
implantation	O
of	O
hBMSCs	O
rescued	O
FHF	O
mice	O
,	O
as	O
demonstrated	O
by	O
robust	O
proliferation	O
and	O
transdifferentiation	O
of	O
functional	O
human	O
hepatocytes	O
and	O
multiple	O
immune	O
cell	O
lineages	O
,	O
including	O
B	O
cells	O
,	O
T	O
cells	O
,	O
natural	O
killer	O
cells	O
,	O
dendritic	O
cells	O
and	O
macrophages	O
.	O

After	O
HBV	O
infection	O
,	O
the	O
hBMSC	O
-	O
FRGS	O
mice	O
developed	O
sustained	O
viremia	O
and	O
specific	O
immune	O
and	O
inflammatory	O
responses	O
and	O
showed	O
progression	O
to	O
chronic	O
hepatitis	O
and	O
liver	O
cirrhosis	O
at	O
a	O
frequency	O
of	O
55	O
%	O
after	O
54	O
weeks	O
.	O

CONCLUSION	O
:	O
This	O
new	O
humanised	O
mouse	O
model	O
recapitulates	O
the	O
liver	O
cirrhosis	O
induced	O
by	O
human	O
HBV	O
infection	O
,	O
thus	O
providing	O
research	O
opportunities	O
for	O
understanding	O
viral	O
immune	O
pathophysiology	O
and	O
testing	O
antiviral	O
therapies	O
in	O
vivo	O
.	O

The	O
Gut	O
Microbiota	O
Is	O
Associated	O
with	O
Clearance	O
of	O
Clostridium	B-bacteria
difficile	I-bacteria
Infection	O
Independent	O
of	O
Adaptive	O
Immunity	O
.	O

Clostridium	B-bacteria
(	I-bacteria
Clostridioides	I-bacteria
)	I-bacteria
difficile	I-bacteria
,	O
a	O
Gram	O
-	O
positive	O
,	O
anaerobic	O
bacterium	O
,	O
is	O
the	O
leading	O
single	O
cause	O
of	O
nosocomial	O
infections	O
in	O
the	O
United	O
States	O
.	O

A	O
major	O
risk	O
factor	O
for	O
Clostridium	B-bacteria
difficile	I-bacteria
infection	O
(	O
CDI	O
)	O
is	O
prior	O
exposure	O
to	O
antibiotics	O
,	O
as	O
they	O
increase	O
susceptibility	O
to	O
CDI	O
by	O
altering	O
the	O
membership	O
of	O
the	O
microbial	O
community	O
enabling	O
colonization	O
.	O

The	O
importance	O
of	O
the	O
gut	O
microbiota	O
in	O
providing	O
protection	O
from	O
CDI	O
is	O
underscored	O
by	O
the	O
reported	O
80	O
to	O
90	O
%	O
success	O
rate	O
of	O
fecal	O
microbial	O
transplants	O
in	O
treating	O
recurrent	O
infections	O
.	O

Adaptive	O
immunity	O
,	O
specifically	O
humoral	O
immunity	O
,	O
is	O
also	O
sufficient	O
to	O
protect	O
from	O
both	O
acute	O
and	O
recurrent	O
CDI	O
.	O

However	O
,	O
the	O
role	O
of	O
the	O
adaptive	O
immune	O
system	O
in	O
mediating	O
clearance	O
of	O
C	O
.	O
difficile	O
has	O
yet	O
to	O
be	O
resolved	O
.	O

Using	O
murine	O
models	O
of	O
CDI	O
,	O
we	O
found	O
that	O
adaptive	O
immunity	O
is	O
dispensable	O
for	O
clearance	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
However	O
,	O
random	O
forest	O
analysis	O
using	O
only	O
two	O
members	O
of	O
the	O
resident	O
bacterial	O
community	O
correctly	O
identified	O
animals	O
that	O
would	O
go	O
on	O
to	O
clear	O
the	O
infection	O
with	O
66	O
.	O
7	O
%	O
accuracy	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
indigenous	O
gut	O
microbiota	O
independent	O
of	O
adaptive	O
immunity	O
facilitates	O
clearance	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
from	O
the	O
murine	O
gastrointestinal	O
tract	O
.	O

IMPORTANCE	O
Clostridium	B-bacteria
difficile	I-bacteria
infection	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
hospitalized	O
patients	O
in	O
the	O
United	O
States	O
.	O

Currently	O
,	O
the	O
role	O
of	O
the	O
adaptive	O
immune	O
response	O
in	O
modulating	O
levels	O
of	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
colonization	O
is	O
unresolved	O
.	O

This	O
work	O
suggests	O
that	O
the	O
indigenous	O
gut	O
microbiota	O
is	O
a	O
main	O
factor	O
that	O
promotes	O
clearance	O
of	O
C	O
.	O
difficile	O
from	O
the	O
GI	O
tract	O
.	O

Our	O
results	O
show	O
that	O
clearance	O
of	O
C	O
.	O
difficile	O
can	O
occur	O
without	O
contributions	O
from	O
the	O
adaptive	O
immune	O
response	O
.	O

This	O
study	O
also	O
has	O
implications	O
for	O
the	O
design	O
of	O
preclinical	O
studies	O
testing	O
the	O
efficacy	O
of	O
vaccines	O
on	O
clearance	O
of	O
bacterial	O
pathogens	O
,	O
as	O
inherent	O
differences	O
in	O
the	O
baseline	O
community	O
structure	O
of	O
animals	O
may	O
bias	O
findings	O
.	O

Interspecies	O
Social	O
Spreading	O
:	O
Interaction	O
between	O
Two	O
Sessile	O
Soil	O
Bacteria	O
Leads	O
to	O
Emergence	O
of	O
Surface	O
Motility	O
.	O

Bacteria	O
often	O
live	O
in	O
complex	O
communities	O
in	O
which	O
they	O
interact	O
with	O
other	O
organisms	O
.	O

Consideration	O
of	O
the	O
social	O
environment	O
of	O
bacteria	O
can	O
reveal	O
emergent	O
traits	O
and	O
behaviors	O
that	O
would	O
be	O
overlooked	O
by	O
studying	O
bacteria	O
in	O
isolation	O
.	O

Here	O
we	O
characterize	O
a	O
social	O
trait	O
which	O
emerges	O
upon	O
interaction	O
between	O
the	O
distantly	O
related	O
soil	O
bacteria	O
Pseudomonas	B-bacteria
fluorescens	I-bacteria
Pf0	I-bacteria
-	I-bacteria
1	I-bacteria
and	O
Pedobacter	B-bacteria
sp	I-bacteria
.	I-bacteria
strain	I-bacteria
V48	I-bacteria
.	O

On	O
hard	O
agar	O
,	O
which	O
is	O
not	O
permissive	O
for	O
motility	O
of	O
the	O
monoculture	O
of	O
either	O
species	O
,	O
coculture	O
reveals	O
an	O
emergent	O
phenotype	O
that	O
we	O
term	O
`	O
`	O
interspecies	O
social	O
spreading	O
,	O
'	O
'	O
where	O
the	O
mixed	O
colony	O
spreads	O
across	O
the	O
hard	O
surface	O
.	O

We	O
show	O
that	O
initiation	O
of	O
social	O
spreading	O
requires	O
close	O
association	O
between	O
the	O
two	O
species	O
of	O
bacteria	O
.	O

Both	O
species	O
remain	O
associated	O
throughout	O
the	O
spreading	O
colony	O
,	O
with	O
reproducible	O
and	O
nonhomogenous	O
patterns	O
of	O
distribution	O
.	O

The	O
nutritional	O
environment	O
influences	O
social	O
spreading	O
:	O
no	O
social	O
behavior	O
is	O
observed	O
under	O
high	O
-	O
nutrient	O
conditions	O
,	O
but	O
low	O
-	O
nutrient	O
conditions	O
are	O
insufficient	O
to	O
promote	O
social	O
spreading	O
without	O
high	O
salt	O
concentrations	O
.	O

This	O
simple	O
two	O
-	O
species	O
consortium	O
is	O
a	O
tractable	O
model	O
system	O
that	O
will	O
facilitate	O
mechanistic	O
investigations	O
of	O
interspecies	O
interactions	O
and	O
provide	O
insight	O
into	O
emergent	O
properties	O
of	O
interacting	O
species	O
.	O

These	O
studies	O
will	O
contribute	O
to	O
the	O
broader	O
knowledge	O
of	O
how	O
bacterial	O
interactions	O
influence	O
the	O
functions	O
of	O
communities	O
they	O
inhabit	O
.	O
IMPORTANCE	O
The	O
wealth	O
of	O
studies	O
on	O
microbial	O
communities	O
has	O
revealed	O
the	O
complexity	O
and	O
dynamics	O
of	O
the	O
composition	O
of	O
communities	O
in	O
many	O
ecological	O
settings	O
.	O

Fewer	O
studies	O
probe	O
the	O
functional	O
interactions	O
of	O
the	O
community	O
members	O
.	O

Function	O
of	O
the	O
community	O
as	O
a	O
whole	O
may	O
not	O
be	O
fully	O
revealed	O
by	O
characterizing	O
the	O
individuals	O
.	O

In	O
our	O
two	O
-	O
species	O
model	O
community	O
,	O
we	O
find	O
an	O
emergent	O
trait	O
resulting	O
from	O
the	O
interaction	O
of	O
the	O
soil	O
bacteria	O
Pseudomonas	B-bacteria
fluorescens	I-bacteria
Pf0	I-bacteria
-	I-bacteria
1	I-bacteria
and	O
Pedobacter	B-bacteria
sp	I-bacteria
.	I-bacteria
V48	I-bacteria
.	O

Observation	O
of	O
emergent	O
traits	O
suggests	O
there	O
may	O
be	O
many	O
functions	O
of	O
a	O
community	O
that	O
are	O
not	O
predicted	O
based	O
on	O
a	O
priori	O
knowledge	O
of	O
the	O
community	O
members	O
.	O

These	O
types	O
of	O
studies	O
will	O
provide	O
a	O
more	O
holistic	O
understanding	O
of	O
microbial	O
communities	O
,	O
allowing	O
us	O
to	O
connect	O
information	O
about	O
community	O
composition	O
with	O
behaviors	O
determined	O
by	O
interspecific	O
interactions	O
.	O

These	O
studies	O
increase	O
our	O
ability	O
to	O
understand	O
communities	O
,	O
such	O
as	O
the	O
soil	O
microbiome	O
,	O
plant	O
-	O
root	O
microbiome	O
,	O
and	O
human	O
gut	O
microbiome	O
,	O
with	O
the	O
final	O
goal	O
of	O
being	O
able	O
to	O
manipulate	O
and	O
rationally	O
improve	O
these	O
communities	O
.	O

Escherichia	B-bacteria
coli	I-bacteria
Pathobionts	O
Associated	O
with	O
Inflammatory	O
Bowel	O
Disease	O
.	O

Gut	O
bacteria	O
play	O
a	O
key	O
role	O
in	O
initiating	O
and	O
maintaining	O
the	O
inflammatory	O
process	O
in	O
the	O
gut	O
tissues	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
patients	O
,	O
by	O
supplying	O
antigens	O
or	O
other	O
stimulatory	O
factors	O
that	O
trigger	O
immune	O
cell	O
activation	O
.	O

Changes	O
in	O
the	O
composition	O
of	O
the	O
intestinal	O
microbiota	O
in	O
IBD	O
patients	O
compared	O
to	O
that	O
in	O
healthy	O
controls	O
and	O
a	O
reduced	O
diversity	O
of	O
intestinal	O
microbial	O
species	O
are	O
linked	O
to	O
the	O
pathogenesis	O
of	O
IBD	O
.	O

Adherent	B-bacteria
invasive	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
(	O
AIEC	B-bacteria
)	O
has	O
been	O
linked	O
to	O
Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
patients	O
,	O
while	O
diffusely	O
adherent	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
(	O
DAEC	O
)	O
has	O
been	O
associated	O
with	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
.	O

Bacteriological	O
analysis	O
of	O
intestinal	O
biopsy	O
specimens	O
and	O
fecal	O
samples	O
from	O
IBD	O
patients	O
shows	O
an	O
increased	O
number	O
of	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
strains	I-bacteria
belonging	O
to	O
the	O
B2	O
phylogenetic	O
group	O
,	O
which	O
are	O
typically	O
known	O
as	O
extraintestinal	B-bacteria
pathogenic	I-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
(	O
ExPEC	B-bacteria
)	O
.	O

Results	O
from	O
studies	O
of	O
both	O
cell	O
cultures	O
and	O
animal	O
models	O
reveal	O
pathogenic	O
features	O
of	O
these	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
pathobionts	O
,	O
which	O
may	O
link	O
them	O
to	O
IBD	O
pathogenesis	O
.	O

This	O
suggests	O
that	O
IBD	O
-	O
associated	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
strains	I-bacteria
play	O
a	O
facilitative	O
role	O
during	O
IBD	O
flares	O
.	O

In	O
this	O
review	O
,	O
we	O
explain	O
IBD	O
-	O
associated	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
its	O
role	O
in	O
IBD	O
pathogenesis	O
.	O

Culture	O
of	O
fecal	O
indicator	O
bacteria	O
from	O
snail	O
intestinal	O
tubes	O
as	O
a	O
tool	O
for	O
assessing	O
the	O
risk	O
of	O
Opisthorchis	O
viverrini	O
infection	O
in	O
Bithynia	O
snail	O
habitat	O
.	O

BACKGROUND	O
:	O
Like	O
many	O
trematodes	O
of	O
human	O
health	O
significance	O
,	O
the	O
carcinogenic	O
liver	O
fluke	O
,	O
Opisthorchis	O
viverrini	O
,	O
is	O
spread	O
via	O
fecal	O
contamination	O
of	O
snail	O
habitat	O
.	O

Methods	O
for	O
assessing	O
snail	O
exposure	O
to	O
fecal	O
waste	O
can	O
improve	O
our	O
ability	O
to	O
identify	O
snail	O
infection	O
hotspots	O
and	O
potential	O
sources	O
of	O
snail	O
infections	O
.	O

We	O
evaluated	O
the	O
feasibility	O
of	O
culturing	O
fecal	O
indicator	O
bacteria	O
from	O
Bithynia	O
snail	O
intestinal	O
tubes	O
as	O
a	O
method	O
for	O
assessing	O
snail	O
exposure	O
to	O
fecal	O
waste	O
.	O

Snails	O
and	O
water	O
samples	O
were	O
collected	O
from	O
a	O
site	O
with	O
a	O
historically	O
high	O
prevalence	O
of	O
O	O
.	O
viverrini	O
infected	O
snails	O
(	O
`	O
`	O
hotspot	O
'	O
'	O
site	O
)	O
and	O
a	O
site	O
with	O
historically	O
no	O
infected	O
snails	O
(	O
`	O
`	O
non	O
-	O
hotspot	O
'	O
'	O
site	O
)	O
on	O
two	O
sampling	O
days	O
.	O

Snails	O
were	O
tested	O
for	O
O	O
.	O
viverrini	O
and	O
a	O
stratified	O
random	O
sample	O
of	O
snails	O
from	O
each	O
site	O
was	O
selected	O
for	O
intestinal	O
tube	O
removal	O
and	O
culture	O
of	O
gut	O
contents	O
for	O
the	O
fecal	O
indicator	O
bacteria	O
,	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

Water	O
samples	O
were	O
tested	O
for	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
and	O
nearby	O
households	O
were	O
surveyed	O
to	O
assess	O
sources	O
of	O
fecal	O
contamination	O
.	O

RESULTS	O
:	O
At	O
the	O
hotspot	O
site	O
,	O
26	O
of	O
2833	O
Bithynia	O
siamensis	O
goniomphalos	O
snails	O
were	O
infected	O
with	O
O	O
.	O
viverrini	O
compared	O
to	O
0	O
of	O
1421	O
snails	O
at	O
the	O
non	O
-	O
hotspot	O
site	O
.	O

A	O
total	O
of	O
186	O
snails	O
were	O
dissected	O
and	O
cultured	O
.	O

Escherichia	B-bacteria
coli	I-bacteria
were	O
detected	O
in	O
the	O
guts	O
of	O
20	O
%	O
of	O
uninfected	O
snails	O
,	O
4	O
%	O
of	O
O	O
.	O
viverrini	O
-	O
positive	O
snails	O
and	O
8	O
%	O
of	O
snails	O
not	O
examined	O
for	O
cercarial	O
infection	O
at	O
the	O
hotspot	O
site	O
.	O

Only	O
one	O
of	O
75	O
snails	O
from	O
the	O
non	O
-	O
hotspot	O
site	O
was	O
positive	O
for	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
.	O

Accounting	O
for	O
sampling	O
weights	O
,	O
snails	O
at	O
the	O
hotspot	O
site	O
were	O
more	O
likely	O
to	O
have	O
gut	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
than	O
snails	O
from	O
the	O
non	O
-	O
hotspot	O
site	O
.	O

The	O
concentration	O
of	O
fecal	O
indicator	O
bacteria	O
in	O
surface	O
water	O
was	O
higher	O
at	O
the	O
hotspot	O
vs	O
non	O
-	O
hotspot	O
site	O
on	O
only	O
the	O
first	O
sampling	O
day	O
.	O

CONCLUSIONS	O
:	O
Fecal	O
indicator	O
bacteria	O
can	O
be	O
detected	O
in	O
the	O
intestinal	O
tubes	O
of	O
Bithynia	O
snails	O
.	O

The	O
presence	O
of	O
fecal	O
indicator	O
bacteria	O
in	O
Bithynia	O
snail	O
guts	O
may	O
indicate	O
risk	O
of	O
O	O
.	O
viverrini	O
infection	O
in	O
snail	O
populations	O
.	O

This	O
method	O
has	O
the	O
potential	O
to	O
aid	O
in	O
identifying	O
locations	O
and	O
time	O
windows	O
of	O
peak	O
snail	O
infection	O
risk	O
and	O
may	O
be	O
applicable	O
to	O
other	O
trematodes	O
of	O
human	O
-	O
health	O
significance	O
.	O

Revisiting	O
an	O
old	O
antibiotic	O
:	O
bacitracin	O
neutralizes	O
binary	O
bacterial	O
toxins	O
and	O
protects	O
cells	O
from	O
intoxication	O
.	O

The	O
antibiotic	O
bacitracin	O
(	O
Bac	O
)	O
inhibits	O
cell	O
wall	O
synthesis	O
of	O
gram	O
-	O
positive	O
bacteria	O
.	O

Here	O
,	O
we	O
discovered	O
a	O
totally	O
different	O
activity	O
of	O
Bac	O
:	O
the	O
neutralization	O
of	O
bacterial	O
exotoxins	O
.	O

Bac	O
prevented	O
intoxication	O
of	O
mammalian	O
cells	O
with	O
the	O
binary	O
enterotoxins	O
Clostridium	B-bacteria
botulinum	I-bacteria
C2	O
,	O
C	B-bacteria
.	I-bacteria
perfringens	I-bacteria
iota	O
,	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
transferase	O
(	O
CDT	O
)	O
,	O
and	O
Bacillus	B-bacteria
anthracis	I-bacteria
lethal	O
toxin	O
.	O

The	O
transport	O
(	O
B	O
)	O
subunits	O
of	O
these	O
toxins	O
deliver	O
their	O
respective	O
enzyme	O
(	O
A	O
)	O
subunits	O
into	O
cells	O
.	O

Following	O
endocytosis	O
,	O
the	O
B	O
subunits	O
form	O
pores	O
in	O
membranes	O
of	O
endosomes	O
,	O
which	O
mediate	O
translocation	O
of	O
the	O
A	O
subunits	O
into	O
the	O
cytosol	O
.	O

Bac	O
inhibited	O
formation	O
of	O
such	O
B	O
pores	O
in	O
lipid	O
bilayers	O
in	O
vitro	O
and	O
in	O
living	O
cells	O
,	O
thereby	O
preventing	O
translocation	O
of	O
the	O
A	O
subunit	O
into	O
the	O
cytosol	O
.	O

Bac	O
preserved	O
the	O
epithelial	O
integrity	O
of	O
toxin	O
-	O
treated	O
CaCo	O
-	O
2	O
monolayers	O
,	O
a	O
model	O
for	O
the	O
human	O
gut	O
epithelium	O
.	O

In	O
conclusion	O
,	O
Bac	O
should	O
be	O
discussed	O
as	O
a	O
therapeutic	O
option	O
against	O
infections	O
with	O
medically	O
relevant	O
toxin	O
-	O
producing	O
bacteria	O
,	O
including	O
C	B-bacteria
.	I-bacteria
difficile	I-bacteria
and	O
B	B-bacteria
.	I-bacteria
anthracis	I-bacteria
,	O
because	O
it	O
inhibits	O
bacterial	O
growth	O
and	O
neutralizes	O
the	O
secreted	O
toxins	O
.	O
-	O
Schnell	O
,	O
L	O
.	O
,	O
Felix	O
,	O
I	O
.	O
,	O
Muller	O
,	O
B	O
.	O
,	O
Sadi	O
,	O
M	O
.	O
,	O
von	O
Bank	O
,	O
F	O
.	O
,	O
Papatheodorou	O
,	O
P	O
.	O
,	O
Popoff	O
,	O
M	O
.	O
R	O
.	O
,	O
Aktories	O
,	O
K	O
.	O
,	O
Waltenberger	O
,	O
E	O
.	O
,	O
Benz	O
,	O
R	O
.	O
,	O
Weichbrodt	O
,	O
C	O
.	O
,	O
Fauler	O
,	O
M	O
.	O
,	O
Frick	O
,	O
M	O
.	O
,	O
Barth	O
,	O
H	O
.	O
Revisiting	O
an	O
old	O
antibiotic	O
:	O
bacitracin	O
neutralizes	O
binary	O
bacterial	O
toxins	O
and	O
protects	O
cells	O
from	O
intoxication	O
.	O

Social	O
dynamics	O
modeling	O
of	O
chrono	O
-	O
nutrition	O
.	O

Gut	O
microbiota	O
and	O
human	O
relationships	O
are	O
strictly	O
connected	O
to	O
each	O
other	O
.	O

What	O
we	O
eat	O
reflects	O
our	O
body	O
-	O
mind	O
connection	O
and	O
synchronizes	O
with	O
people	O
around	O
us	O
.	O

However	O
,	O
how	O
this	O
impacts	O
on	O
gut	O
microbiota	O
and	O
,	O
conversely	O
,	O
how	O
gut	O
bacteria	O
influence	O
our	O
dietary	O
behaviors	O
has	O
not	O
been	O
explored	O
yet	O
.	O

To	O
quantify	O
the	O
complex	O
dynamics	O
of	O
this	O
interplay	O
between	O
gut	O
and	O
human	O
behaviors	O
we	O
explore	O
the	O
`	O
`	O
gut	O
-	O
human	O
behavior	O
axis	O
'	O
'	O
and	O
its	O
evolutionary	O
dynamics	O
in	O
a	O
real	O
-	O
world	O
scenario	O
represented	O
by	O
the	O
social	O
multiplex	O
network	O
.	O

We	O
consider	O
a	O
dual	O
type	O
of	O
similarity	O
,	O
homophily	O
and	O
gut	O
similarity	O
,	O
other	O
than	O
psychological	O
and	O
unconscious	O
biases	O
.	O

We	O
analyze	O
the	O
dynamics	O
of	O
social	O
and	O
gut	O
microbial	O
communities	O
,	O
quantifying	O
the	O
impact	O
of	O
human	O
behaviors	O
on	O
diets	O
and	O
gut	O
microbial	O
composition	O
and	O
,	O
backwards	O
,	O
through	O
a	O
control	O
mechanism	O
.	O

Meal	O
timing	O
mechanisms	O
and	O
`	O
`	O
chrono	O
-	O
nutrition	O
'	O
'	O
play	O
a	O
crucial	O
role	O
in	O
feeding	O
behaviors	O
,	O
along	O
with	O
the	O
quality	O
and	O
quantity	O
of	O
food	O
intake	O
.	O

Considering	O
a	O
population	O
of	O
shift	O
workers	O
,	O
we	O
explore	O
the	O
dynamic	O
interplay	O
between	O
their	O
eating	O
behaviors	O
and	O
gut	O
microbiota	O
,	O
modeling	O
the	O
social	O
dynamics	O
of	O
chrono	O
-	O
nutrition	O
in	O
a	O
multiplex	O
network	O
.	O

Our	O
findings	O
allow	O
us	O
to	O
quantify	O
the	O
relation	O
between	O
human	O
behaviors	O
and	O
gut	O
microbiota	O
through	O
the	O
methodological	O
introduction	O
of	O
gut	O
metabolic	O
modeling	O
and	O
statistical	O
estimators	O
,	O
able	O
to	O
capture	O
their	O
dynamic	O
interplay	O
.	O

Moreover	O
,	O
we	O
find	O
that	O
the	O
timing	O
of	O
gut	O
microbial	O
communities	O
is	O
slower	O
than	O
social	O
interactions	O
and	O
shift	O
-	O
working	O
,	O
and	O
the	O
impact	O
of	O
shift	O
-	O
working	O
on	O
the	O
dynamics	O
of	O
chrono	O
-	O
nutrition	O
is	O
a	O
fluctuation	O
of	O
strategies	O
with	O
a	O
major	O
propensity	O
for	O
defection	O
(	O
e	O
.	O
g	O
.	O

high	O
-	O
fat	O
meals	O
)	O
.	O

A	O
deeper	O
understanding	O
of	O
the	O
relation	O
between	O
gut	O
microbiota	O
and	O
the	O
dietary	O
behavioral	O
patterns	O
,	O
by	O
embedding	O
also	O
the	O
related	O
social	O
aspects	O
,	O
allows	O
improving	O
the	O
overall	O
knowledge	O
about	O
metabolic	O
models	O
and	O
their	O
implications	O
for	O
human	O
health	O
,	O
opening	O
the	O
possibility	O
to	O
design	O
promising	O
social	O
therapeutic	O
dietary	O
interventions	O
.	O

Metaproteomics	O
reveals	O
potential	O
mechanisms	O
by	O
which	O
dietary	O
resistant	O
starch	O
supplementation	O
attenuates	O
chronic	O
kidney	O
disease	O
progression	O
in	O
rats	O
.	O

BACKGROUND	O
:	O
Resistant	O
starch	O
is	O
a	O
prebiotic	O
metabolized	O
by	O
the	O
gut	O
bacteria	O
.	O

It	O
has	O
been	O
shown	O
to	O
attenuate	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
progression	O
in	O
rats	O
.	O

Previous	O
studies	O
employed	O
taxonomic	O
analysis	O
using	O
16S	O
rRNA	O
sequencing	O
and	O
untargeted	O
metabolomics	O
profiling	O
.	O

Here	O
we	O
expand	O
these	O
studies	O
by	O
metaproteomics	O
,	O
gaining	O
new	O
insight	O
into	O
the	O
host	O
-	O
microbiome	O
interaction	O
.	O

METHODS	O
:	O
Differences	O
between	O
cecum	O
contents	O
in	O
CKD	O
rats	O
fed	O
a	O
diet	O
containing	O
resistant	O
starch	O
with	O
those	O
fed	O
a	O
diet	O
containing	O
digestible	O
starch	O
were	O
examined	O
by	O
comparative	O
metaproteomics	O
analysis	O
.	O

Taxonomic	O
information	O
was	O
obtained	O
using	O
unique	O
protein	O
sequences	O
.	O

Our	O
methodology	O
results	O
in	O
quantitative	O
data	O
covering	O
both	O
host	O
and	O
bacterial	O
proteins	O
.	O

RESULTS	O
:	O
5	O
,	O
834	O
proteins	O
were	O
quantified	O
,	O
with	O
947	O
proteins	O
originating	O
from	O
the	O
host	O
organism	O
.	O

Taxonomic	O
information	O
derived	O
from	O
metaproteomics	O
data	O
surpassed	O
previous	O
16S	O
RNA	O
analysis	O
,	O
and	O
reached	O
species	O
resolutions	O
for	O
moderately	O
abundant	O
taxonomic	O
groups	O
.	O

In	O
particular	O
,	O
the	O
Ruminococcaceae	B-bacteria
family	I-bacteria
becomes	O
well	O
resolved	O
-	O
with	O
butyrate	O
producers	O
and	O
amylolytic	O
species	O
such	O
as	O
R	B-bacteria
.	I-bacteria
bromii	I-bacteria
clearly	O
visible	O
and	O
significantly	O
higher	O
while	O
fibrolytic	O
species	O
such	O
as	O
R	B-bacteria
.	I-bacteria
flavefaciens	I-bacteria
are	O
significantly	O
lower	O
with	O
resistant	O
starch	O
feeding	O
.	O

The	O
observed	O
changes	O
in	O
protein	O
patterns	O
are	O
consistent	O
with	O
fiber	O
-	O
associated	O
improvement	O
in	O
CKD	O
phenotype	O
.	O

Several	O
known	O
host	O
CKD	O
-	O
associated	O
proteins	O
and	O
biomarkers	O
of	O
impaired	O
kidney	O
function	O
were	O
significantly	O
reduced	O
with	O
resistant	O
starch	O
supplementation	O
.	O

Data	O
are	O
available	O
via	O
ProteomeXchange	O
with	O
identifier	O
PXD008845	O
.	O

CONCLUSIONS	O
:	O
Metaproteomics	O
analysis	O
of	O
cecum	O
contents	O
of	O
CKD	O
rats	O
with	O
and	O
without	O
resistant	O
starch	O
supplementation	O
reveals	O
changes	O
within	O
gut	O
microbiota	O
at	O
unprecedented	O
resolution	O
,	O
providing	O
both	O
functional	O
and	O
taxonomic	O
information	O
.	O

Proteins	O
and	O
organisms	O
differentially	O
abundant	O
with	O
RS	B-bacteria
supplementation	O
point	O
toward	O
a	O
shift	O
from	O
mucin	O
degraders	O
to	O
butyrate	O
producers	O
.	O

Isolation	O
and	O
Characterization	O
of	O
Human	O
Gut	O
Bacteria	O
Capable	O
of	O
Extracellular	O
Electron	O
Transport	O
by	O
Electrochemical	O
Techniques	O
.	O

Microorganisms	O
are	O
known	O
to	O
exhibit	O
extracellular	O
electron	O
transfer	O
(	O
EET	O
)	O
in	O
a	O
wide	O
variety	O
of	O
habitats	O
.	O

However	O
,	O
as	O
for	O
the	O
human	O
microbiome	O
which	O
significantly	O
impacts	O
our	O
health	O
,	O
the	O
role	O
and	O
importance	O
of	O
EET	O
has	O
not	O
been	O
widely	O
investigated	O
.	O

In	O
this	O
study	O
,	O
we	O
enriched	O
and	O
isolated	O
the	O
EET	O
-	O
capable	O
bacteria	O
from	O
human	O
gut	O
microbes	O
using	O
an	O
electrochemical	O
enrichment	O
method	O
and	O
examined	O
whether	O
the	O
isolates	O
couple	O
EET	O
with	O
anaerobic	O
respiration	O
or	O
fermentation	O
.	O

Upon	O
the	O
use	O
of	O
energy	O
-	O
rich	O
or	O
minimum	O
media	O
(	O
with	O
acetate	O
or	O
lactate	O
)	O
for	O
electrochemical	O
enrichment	O
with	O
the	O
human	O
gut	O
sample	O
at	O
an	O
electrode	O
potential	O
of	O
+	O
0	O
.	O
4	O
V	O
[	O
vs	O
.	O
the	O
standard	O
hydrogen	O
electrode	O
(	O
SHE	O
)	O
]	O
,	O
both	O
culture	O
conditions	O
showed	O
significant	O
current	O
production	O
.	O

However	O
,	O
EET	O
-	O
capable	O
pure	O
strains	O
were	O
enriched	O
specifically	O
with	O
minimum	O
media	O
,	O
and	O
subsequent	O
incubation	O
using	O
the	O
delta	O
-	O
MnO2	O
-	O
agar	O
plate	O
with	O
lactate	O
or	O
acetate	O
led	O
to	O
the	O
isolation	O
of	O
two	O
EET	O
-	O
capable	O
microbial	O
strains	O
,	O
Gut	O
-	O
S1	O
and	O
Gut	O
-	O
S2	O
,	O
having	O
99	O
%	O
of	O
16S	O
rRNA	O
gene	O
sequence	O
identity	O
with	O
Enterococcus	B-bacteria
avium	I-bacteria
(	O
E	B-bacteria
.	I-bacteria
avium	I-bacteria
)	O
and	O
Klebsiella	B-bacteria
pneumoniae	I-bacteria
(	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
)	O
,	O
respectively	O
.	O

While	O
the	O
enrichment	O
involved	O
anaerobic	O
respiration	O
with	O
acetate	O
and	O
lactate	O
,	O
further	O
electrochemistry	O
with	O
E	B-bacteria
.	I-bacteria
avium	I-bacteria
and	O
K	B-bacteria
.	I-bacteria
pneumoniae	I-bacteria
revealed	O
that	O
the	O
glucose	O
fermentation	O
was	O
also	O
coupled	O
with	O
EET	O
.	O

These	O
results	O
indicate	O
that	O
EET	O
couples	O
not	O
only	O
with	O
anaerobic	O
respiration	O
as	O
found	O
in	O
environmental	O
bacteria	O
,	O
but	O
also	O
with	O
fermentation	O
in	O
the	O
human	O
gut	O
.	O

Oral	O
neonatal	O
antibiotic	O
treatment	O
perturbs	O
gut	O
microbiota	O
and	O
aggravates	O
central	O
nervous	O
system	O
autoimmunity	O
in	O
Dark	O
Agouti	O
rats	O
.	O

Gut	O
microbiota	O
dysbiosis	O
has	O
been	O
considered	O
the	O
essential	O
element	O
in	O
the	O
pathogenesis	O
of	O
multiple	O
sclerosis	O
and	O
its	O
animal	O
model	O
,	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
.	O

Antibiotics	O
were	O
administered	O
orally	O
to	O
Dark	O
Agouti	O
(	O
DA	O
)	O
rats	O
early	O
in	O
their	O
life	O
with	O
the	O
aim	O
of	O
perturbing	O
gut	O
microbiota	O
and	O
investigating	O
the	O
effects	O
of	O
such	O
intervention	O
on	O
the	O
course	O
of	O
EAE	O
.	O

As	O
a	O
result	O
,	O
the	O
diversity	O
of	O
the	O
gut	O
microbiota	O
was	O
reduced	O
under	O
the	O
influence	O
of	O
antibiotics	O
.	O

Mainly	O
,	O
Firmicutes	B-bacteria
and	O
Actinobacteria	B-bacteria
were	O
replaced	O
by	O
Proteobacteria	B-bacteria
and	O
Bacteroidetes	B-bacteria
,	O
while	O
decreased	O
proportions	O
of	O
Clostridia	B-bacteria
and	O
Bacilli	B-bacteria
classes	I-bacteria
were	O
accompanied	O
by	O
an	O
increase	O
in	O
Gamma	B-bacteria
-	I-bacteria
Proteobacteria	I-bacteria
in	O
antibiotic	O
-	O
treated	O
animals	O
.	O

Interestingly	O
,	O
a	O
notable	O
decrease	O
in	O
the	O
Helicobacteraceae	B-bacteria
,	O
Spirochaetaceae	B-bacteria
and	O
Turicibacteriaceae	B-bacteria
was	O
scored	O
in	O
antibiotic	O
-	O
treated	O
groups	O
.	O

Also	O
,	O
levels	O
of	O
short	O
chain	O
fatty	O
acids	O
were	O
reduced	O
in	O
the	O
faeces	O
of	O
antibiotic	O
-	O
treated	O
rats	O
.	O

Consequently	O
,	O
aggravation	O
of	O
EAE	O
,	O
paralleled	O
with	O
stronger	O
immune	O
response	O
in	O
lymph	O
nodes	O
draining	O
the	O
site	O
of	O
immunization	O
,	O
and	O
increased	O
inflammation	O
within	O
the	O
CNS	O
,	O
were	O
observed	O
in	O
antibiotic	O
-	O
treated	O
DA	O
rats	O
.	O

Thus	O
,	O
the	O
alteration	O
of	O
gut	O
microbiota	O
leads	O
to	O
an	O
escalation	O
of	O
CNS	O
-	O
directed	O
autoimmunity	O
in	O
DA	O
rats	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
antibiotic	O
use	O
in	O
early	O
life	O
may	O
have	O
subsequent	O
unfavourable	O
effects	O
on	O
the	O
regulation	O
of	O
the	O
immune	O
system	O
.	O

Mixed	O
Viral	O
-	O
Bacterial	O
Infections	O
and	O
Their	O
Effects	O
on	O
Gut	O
Microbiota	O
and	O
Clinical	O
Illnesses	O
in	O
Children	O
.	O

Acute	O
gastroenteritis	O
remains	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
among	O
young	O
children	O
worldwide	O
.	O

It	O
accounts	O
for	O
approximately	O
1	O
.	O
34	O
million	O
deaths	O
annually	O
in	O
children	O
younger	O
than	O
five	O
years	O
.	O

Infection	O
can	O
be	O
caused	O
by	O
viral	O
,	O
bacterial	O
and	O
/	O
or	O
parasitic	O
microorganisms	O
.	O

Dysbiosis	O
due	O
to	O
such	O
infections	O
could	O
dramatically	O
affect	O
disease	O
prognosis	O
as	O
well	O
as	O
development	O
of	O
chronic	O
illness	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
gut	O
microbiome	O
and	O
clinical	O
outcomes	O
in	O
young	O
children	O
suffering	O
from	O
viral	O
or	O
mixed	O
viral	O
-	O
bacterial	O
infection	O
.	O

We	O
evaluated	O
gut	O
microbiota	O
composition	O
in	O
children	O
suffering	O
from	O
viral	O
or	O
mixed	O
viral	O
-	O
bacterial	O
infection	O
with	O
two	O
major	O
viruses	O
rotavirus	O
(	O
RV	O
)	O
and	O
norovirus	O
(	O
NoV	O
)	O
and	O
two	O
pathogenic	O
bacteria	O
[	O
Enteroaggregative	B-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
(	O
EAEC	B-bacteria
)	O
,	O
and	O
Enteropathogenic	B-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
(	O
EPEC	B-bacteria
)	O
]	O
.	O

We	O
sequenced	O
16S	O
ribosomal	O
RNA	O
(	O
V4	O
region	O
)	O
genes	O
using	O
Illumina	O
MiSeq	O
in	O
70	O
hospitalized	O
children	O
suffering	O
from	O
gastroenteric	O
infections	O
plus	O
nine	O
healthy	O
controls	O
.	O

The	O
study	O
summarized	O
Operational	O
Taxonomic	O
Unit	O
(	O
OTU	O
)	O
abundances	O
with	O
the	O
Bray	O
-	O
Curtis	O
index	O
and	O
performed	O
a	O
non	O
-	O
metric	O
multidimensional	O
scaling	O
analysis	O
to	O
visualize	O
microbiome	O
similarities	O
.	O

We	O
used	O
a	O
permutational	O
multivariate	O
analyses	O
of	O
variance	O
to	O
test	O
the	O
significance	O
of	O
group	O
differences	O
.	O

We	O
also	O
analyzed	O
the	O
correlation	O
between	O
microbiome	O
changes	O
and	O
clinical	O
outcomes	O
.	O

Our	O
data	O
demonstrated	O
a	O
significant	O
increase	O
in	O
the	O
severity	O
score	O
in	O
children	O
with	O
viral	O
-	O
bacterial	O
mixed	O
infections	O
compared	O
to	O
those	O
with	O
virus	O
infections	O
alone	O
.	O

Statistical	O
analysis	O
by	O
overall	O
relative	O
abundance	O
denoted	O
lesser	O
proportions	O
of	O
Bacteroides	B-bacteria
in	O
the	O
infected	O
children	O
,	O
whereas	O
Bifidobacteriaceae	B-bacteria
richness	O
was	O
more	O
prominent	O
in	O
the	O
bacterial	O
-	O
viral	O
mixed	O
infections	O
.	O

Pairwise	O
differences	O
of	O
gut	O
microbiota	O
were	O
significantly	O
higher	O
in	O
RV	O
+	O
EAEC	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
and	O
NoV	O
+	O
EAEC	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
co	O
-	O
infections	O
,	O
compared	O
to	O
EPEC	O
mixed	O
infection	O
with	O
both	O
,	O
RV	O
(	O
P	O
=	O
0	O
.	O
045	O
)	O
and	O
NoV	O
(	O
P	O
=	O
0	O
.	O
188	O
)	O
.	O

Shannon	O
diversity	O
index	O
showed	O
considerable	O
more	O
variation	O
in	O
microbiome	O
diversity	O
in	O
children	O
infected	O
with	O
RV	O
cohort	O
compared	O
to	O
NoV	O
cohort	O
.	O

Our	O
results	O
highlight	O
that	O
richness	O
of	O
Bifidobacteriaceae	B-bacteria
,	O
which	O
acts	O
as	O
probiotics	O
,	O
increased	O
with	O
the	O
severity	O
of	O
the	O
viral	O
-	O
bacterial	O
mixed	O
infections	O
.	O

As	O
expected	O
,	O
significant	O
reduction	O
of	O
relative	O
numbers	O
of	O
Bacteroides	B-bacteria
was	O
characterized	O
in	O
both	O
RV	O
and	O
NoV	O
infections	O
,	O
with	O
more	O
reduction	O
observed	O
in	O
co	O
-	O
infection	O
pathogenic	O
E	O
.	O
coli	I-bacteria
.	O

Although	O
mixed	O
infection	O
with	O
EAEC	O
resulted	O
in	O
significant	O
microbiota	O
differences	O
compared	O
to	O
viral	O
infection	O
only	O
or	O
mixed	O
infection	O
with	O
EPEC	O
,	O
the	O
clinical	O
condition	O
of	O
the	O
children	O
were	O
worsened	O
with	O
both	O
pathogenic	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
co	O
-	O
infections	O
.	O

Further	O
,	O
in	O
comparison	O
with	O
RV	O
cohort	O
,	O
augmented	O
number	O
of	O
differential	O
abundant	O
pathogenic	O
OTUs	O
were	O
peculiarly	O
noticed	O
only	O
with	O
NoV	O
mixed	O
infection	O
.	O

Structure	O
,	O
function	O
,	O
and	O
inhibition	O
of	O
drug	O
reactivating	O
human	O
gut	O
microbial	O
beta	O
-	O
glucuronidases	O
.	O

Bacterial	O
beta	O
-	O
glucuronidase	O
(	O
GUS	O
)	O
enzymes	O
cause	O
drug	O
toxicity	O
by	O
reversing	O
Phase	O
II	O
glucuronidation	O
in	O
the	O
gastrointestinal	O
tract	O
.	O

While	O
many	O
human	O
gut	O
microbial	O
GUS	O
enzymes	O
have	O
been	O
examined	O
with	O
model	O
glucuronide	O
substrates	O
like	O
p	O
-	O
nitrophenol	O
-	O
beta	O
-	O
D	O
-	O
glucuronide	O
(	O
pNPG	O
)	O
,	O
the	O
GUS	O
orthologs	O
that	O
are	O
most	O
efficient	O
at	O
processing	O
drug	O
-	O
glucuronides	O
remain	O
unclear	O
.	O

Here	O
we	O
present	O
the	O
crystal	O
structures	O
of	O
GUS	O
enzymes	O
from	O
human	O
gut	O
commensals	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
,	O
Ruminococcus	B-bacteria
gnavus	I-bacteria
,	O
and	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
that	O
possess	O
an	O
active	O
site	O
loop	O
(	O
Loop	O
1	O
;	O
L1	O
)	O
analogous	O
to	O
that	O
found	O
in	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
GUS	O
,	O
which	O
processes	O
drug	O
substrates	O
.	O

We	O
also	O
resolve	O
the	O
structure	O
of	O
the	O
No	O
Loop	O
GUS	O
from	O
Bacteroides	B-bacteria
dorei	I-bacteria
.	O

We	O
then	O
compare	O
the	O
pNPG	O
and	O
diclofenac	O
glucuronide	O
processing	O
abilities	O
of	O
a	O
panel	O
of	O
twelve	O
structurally	O
diverse	O
GUS	O
proteins	O
,	O
and	O
find	O
that	O
the	O
new	O
L1	O
GUS	O
enzymes	O
presented	O
here	O
process	O
small	O
glucuronide	O
substrates	O
inefficiently	O
compared	O
to	O
previously	O
characterized	O
L1	O
GUS	O
enzymes	O
like	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
GUS	O
.	O

We	O
further	O
demonstrate	O
that	O
our	O
GUS	O
inhibitors	O
,	O
which	O
are	O
effective	O
against	O
some	O
L1	O
enzymes	O
,	O
are	O
not	O
potent	O
towards	O
all	O
.	O

Our	O
findings	O
pinpoint	O
active	O
site	O
structural	O
features	O
necessary	O
for	O
the	O
processing	O
of	O
drug	O
-	O
glucuronide	O
substrates	O
and	O
the	O
inhibition	O
of	O
such	O
processing	O
.	O

Urogenital	O
schistosomiasis	O
is	O
associated	O
with	O
signatures	O
of	O
microbiome	O
dysbiosis	O
in	O
Nigerian	O
adolescents	O
.	O

Urogenital	O
schistosomiasis	O
is	O
a	O
neglected	O
tropical	O
disease	O
caused	O
by	O
the	O
parasite	O
Schistosoma	O
haematobium	O
,	O
which	O
resides	O
in	O
the	O
vasculature	O
surrounding	O
the	O
urogenital	O
system	O
.	O

Previous	O
work	O
has	O
suggested	O
that	O
helminthic	O
infections	O
can	O
affect	O
the	O
intestinal	O
microbiome	O
,	O
and	O
we	O
hypothesized	O
that	O
S	O
.	O
haematobium	O
infection	O
could	O
result	O
in	O
an	O
alteration	O
of	O
immune	O
system	O
-	O
microbiota	O
homeostasis	O
and	O
impact	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
compared	O
the	O
fecal	O
microbiomes	O
of	O
infected	O
and	O
uninfected	O
schoolchildren	O
from	O
the	O
Argungu	O
Local	O
Government	O
Area	O
of	O
Kebbi	O
State	O
,	O
Nigeria	O
,	O
detecting	O
significant	O
differences	O
in	O
community	O
composition	O
between	O
the	O
two	O
groups	O
.	O

Most	O
remarkably	O
,	O
we	O
observed	O
a	O
decreased	O
abundance	O
of	O
Firmicutes	B-bacteria
and	O
increased	O
abundance	O
of	O
Proteobacteria	B-bacteria
-	O
a	O
shift	O
in	O
community	O
structure	O
which	O
has	O
been	O
previously	O
associated	O
with	O
dysbiosis	O
.	O

More	O
specifically	O
,	O
we	O
detected	O
a	O
number	O
of	O
changes	O
in	O
lower	O
taxa	O
reminiscent	O
of	O
inflammation	O
-	O
associated	O
dysbiosis	O
,	O
including	O
decreases	O
in	O
Clostridiales	B-bacteria
and	O
increases	O
in	O
Moraxellaceae	B-bacteria
,	O
Veillonellaceae	B-bacteria
,	O
Pasteurellaceae	B-bacteria
,	O
and	O
Desulfovibrionaceae	B-bacteria
.	O

Functional	O
potential	O
analysis	O
also	O
revealed	O
an	O
enrichment	O
in	O
orthologs	O
of	O
urease	O
,	O
which	O
has	O
been	O
linked	O
to	O
dysbiosis	O
and	O
inflammation	O
.	O

Overall	O
,	O
our	O
analysis	O
indicates	O
that	O
S	O
.	O
haematobium	O
infection	O
is	O
associated	O
with	O
perturbations	O
in	O
the	O
gut	O
microbiota	O
and	O
may	O
point	O
to	O
microbiome	O
disruption	O
as	O
an	O
additional	O
consequence	O
of	O
schistosome	O
infection	O
.	O

Identification	O
of	O
novel	O
autoinducer	O
-	O
2	O
receptors	O
in	O
Clostridia	B-bacteria
reveals	O
plasticity	O
in	O
the	O
binding	O
site	O
of	O
the	O
LsrB	O
receptor	O
family	O
.	O

Autoinducer	O
-	O
2	O
(	O
AI	O
-	O
2	O
)	O
is	O
unique	O
among	O
quorum	O
-	O
sensing	O
signaling	O
molecules	O
,	O
as	O
it	O
is	O
produced	O
and	O
recognized	O
by	O
a	O
wide	O
variety	O
of	O
bacteria	O
and	O
thus	O
facilitates	O
interspecies	O
communication	O
.	O

To	O
date	O
,	O
two	O
classes	O
of	O
AI	O
-	O
2	O
receptors	O
have	O
been	O
identified	O
:	O
the	O
LuxP	O
-	O
type	O
,	O
present	O
in	O
the	O
Vibrionales	B-bacteria
,	O
and	O
the	O
LsrB	O
-	O
type	O
,	O
found	O
in	O
a	O
number	O
of	O
phylogenetically	O
distinct	O
bacterial	O
families	O
.	O

Recently	O
,	O
AI	O
-	O
2	O
was	O
shown	O
to	O
affect	O
the	O
colonization	O
levels	O
of	O
a	O
variety	O
of	O
bacteria	O
in	O
the	O
microbiome	O
of	O
the	O
mouse	O
gut	O
,	O
including	O
members	O
of	O
the	O
genus	O
Clostridium	B-bacteria
,	O
but	O
no	O
AI	O
-	O
2	O
receptor	O
had	O
been	O
identified	O
in	O
this	O
genus	O
.	O

Here	O
,	O
we	O
identify	O
a	O
noncanonical	O
,	O
functional	O
LsrB	O
-	O
type	O
receptor	O
in	O
Clostridium	B-bacteria
saccharobutylicum	I-bacteria
.	O

This	O
novel	O
LsrB	O
-	O
like	O
receptor	O
is	O
the	O
first	O
one	O
reported	O
with	O
variations	O
in	O
the	O
binding	O
-	O
site	O
amino	O
acid	O
residues	O
that	O
interact	O
with	O
AI	O
-	O
2	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
C	B-bacteria
.	I-bacteria
saccharobutylicum	I-bacteria
receptor	O
determined	O
at	O
1	O
.	O
35	O
A	O
resolution	O
revealed	O
that	O
it	O
binds	O
the	O
same	O
form	O
of	O
AI	O
-	O
2	O
as	O
the	O
other	O
known	O
LsrB	O
-	O
type	O
receptors	O
,	O
and	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
assays	O
showed	O
that	O
binding	O
of	O
AI	O
-	O
2	O
occurs	O
at	O
a	O
submicromolar	O
concentration	O
.	O

Using	O
phylogenetic	O
analysis	O
,	O
we	O
inferred	O
that	O
the	O
newly	O
identified	O
noncanonical	O
LsrB	O
receptor	O
shares	O
a	O
common	O
ancestor	O
with	O
known	O
LsrB	O
receptors	O
and	O
that	O
noncanonical	O
receptors	O
are	O
present	O
in	O
bacteria	O
from	O
different	O
phyla	O
.	O

This	O
led	O
us	O
to	O
identify	O
putative	O
AI	O
-	O
2	O
receptors	O
in	O
bacterial	O
species	O
in	O
which	O
no	O
receptors	O
were	O
known	O
,	O
as	O
in	O
bacteria	O
belonging	O
to	O
the	O
Spirochaetes	B-bacteria
and	O
Actinobacteria	B-bacteria
phyla	I-bacteria
.	O

Thus	O
,	O
this	O
work	O
represents	O
a	O
significant	O
step	O
toward	O
understanding	O
how	O
AI	O
-	O
2	O
-	O
mediated	O
quorum	O
sensing	O
influences	O
bacterial	O
interactions	O
in	O
complex	O
biological	O
niches	O
.	O

Dynamics	O
of	O
Human	O
Gut	O
Microbiota	O
and	O
Short	O
-	O
Chain	O
Fatty	O
Acids	O
in	O
Response	O
to	O
Dietary	O
Interventions	O
with	O
Three	O
Fermentable	O
Fibers	O
.	O

Production	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
especially	O
butyrate	O
,	O
in	O
the	O
gut	O
microbiome	O
is	O
required	O
for	O
optimal	O
health	O
but	O
is	O
frequently	O
limited	O
by	O
the	O
lack	O
of	O
fermentable	O
fiber	O
in	O
the	O
diet	O
.	O

We	O
attempted	O
to	O
increase	O
butyrate	O
production	O
by	O
supplementing	O
the	O
diets	O
of	O
174	O
healthy	O
young	O
adults	O
for	O
2	O
weeks	O
with	O
resistant	O
starch	O
from	O
potatoes	O
(	O
RPS	O
)	O
,	O
resistant	O
starch	O
from	O
maize	O
(	O
RMS	O
)	O
,	O
inulin	O
from	O
chicory	O
root	O
,	O
or	O
an	O
accessible	O
corn	O
starch	O
control	O
.	O

RPS	O
resulted	O
in	O
the	O
greatest	O
increase	O
in	O
total	O
SCFAs	O
,	O
including	O
butyrate	O
.	O

Although	O
the	O
majority	O
of	O
microbiomes	O
responded	O
to	O
RPS	O
with	O
increases	O
in	O
the	O
relative	O
abundance	O
of	O
bifidobacteria	B-bacteria
,	O
those	O
that	O
responded	O
with	O
an	O
increase	O
in	O
Ruminococcus	B-bacteria
bromii	I-bacteria
or	O
Clostridium	B-bacteria
chartatabidum	I-bacteria
were	O
more	O
likely	O
to	O
yield	O
higher	O
butyrate	O
concentrations	O
,	O
especially	O
when	O
their	O
microbiota	O
were	O
replete	O
with	O
populations	O
of	O
the	O
butyrate	O
-	O
producing	O
species	O
Eubacterium	B-bacteria
rectale	I-bacteria
RMS	O
and	O
inulin	O
induced	O
different	O
changes	O
in	O
fecal	O
communities	O
,	O
but	O
they	O
did	O
not	O
generate	O
significant	O
increases	O
in	O
fecal	O
butyrate	O
levels	O
.	O
IMPORTANCE	O
These	O
results	O
reveal	O
that	O
not	O
all	O
fermentable	O
fibers	O
are	O
equally	O
capable	O
of	O
stimulating	O
SCFA	O
production	O
,	O
and	O
they	O
highlight	O
the	O
importance	O
of	O
the	O
composition	O
of	O
an	O
individual	O
'	O
s	O
microbiota	O
in	O
determining	O
whether	O
or	O
not	O
they	O
respond	O
to	O
a	O
specific	O
dietary	O
supplement	O
.	O

In	O
particular	O
,	O
R	B-bacteria
.	I-bacteria
bromii	I-bacteria
or	O
C	B-bacteria
.	I-bacteria
chartatabidum	I-bacteria
may	O
be	O
required	O
for	O
enhanced	O
butyrate	O
production	O
in	O
response	O
to	O
RS	B-bacteria
.	O

Bifidobacteria	B-bacteria
,	O
though	O
proficient	O
at	O
degrading	O
RS	O
and	O
inulin	O
,	O
may	O
not	O
contribute	O
to	O
the	O
butyrogenic	O
effect	O
of	O
those	O
fermentable	O
fibers	O
in	O
the	O
short	O
term	O
.	O

Megaphages	O
infect	O
Prevotella	B-bacteria
and	O
variants	O
are	O
widespread	O
in	O
gut	O
microbiomes	O
.	O

Bacteriophages	O
(	O
phages	O
)	O
dramatically	O
shape	O
microbial	O
community	O
composition	O
,	O
redistribute	O
nutrients	O
via	O
host	O
lysis	O
and	O
drive	O
evolution	O
through	O
horizontal	O
gene	O
transfer	O
.	O

Despite	O
their	O
importance	O
,	O
much	O
remains	O
to	O
be	O
learned	O
about	O
phages	O
in	O
the	O
human	O
microbiome	O
.	O

We	O
investigated	O
the	O
gut	O
microbiomes	O
of	O
humans	O
from	O
Bangladesh	O
and	O
Tanzania	O
,	O
two	O
African	O
baboon	O
social	O
groups	O
and	O
Danish	O
pigs	O
;	O
many	O
of	O
these	O
microbiomes	O
contain	O
phages	O
belonging	O
to	O
a	O
clade	O
with	O
genomes	O
>	O
540	O
kilobases	O
in	O
length	O
,	O
the	O
largest	O
yet	O
reported	O
in	O
the	O
human	O
microbiome	O
and	O
close	O
to	O
the	O
maximum	O
size	O
ever	O
reported	O
for	O
phages	O
.	O

We	O
refer	O
to	O
these	O
as	O
Lak	O
phages	O
.	O

CRISPR	O
spacer	O
targeting	O
indicates	O
that	O
Lak	O
phages	O
infect	O
bacteria	O
of	O
the	O
genus	O
Prevotella	B-bacteria
.	O

We	O
manually	O
curated	O
to	O
completion	O
15	O
distinct	O
Lak	O
phage	O
genomes	O
recovered	O
from	O
metagenomes	O
.	O

The	O
genomes	O
display	O
several	O
interesting	O
features	O
,	O
including	O
use	O
of	O
an	O
alternative	O
genetic	O
code	O
,	O
large	O
intergenic	O
regions	O
that	O
are	O
highly	O
expressed	O
and	O
up	O
to	O
35	O
putative	O
transfer	O
RNAs	O
,	O
some	O
of	O
which	O
contain	O
enigmatic	O
introns	O
.	O

Different	O
individuals	O
have	O
distinct	O
phage	O
genotypes	O
,	O
and	O
shifts	O
in	O
variant	O
frequencies	O
over	O
consecutive	O
sampling	O
days	O
reflect	O
changes	O
in	O
the	O
relative	O
abundance	O
of	O
phage	O
subpopulations	O
.	O

Recent	O
homologous	O
recombination	O
has	O
resulted	O
in	O
extensive	O
genome	O
admixture	O
of	O
nine	O
baboon	O
Lak	O
phage	O
populations	O
.	O

We	O
infer	O
that	O
Lak	O
phages	O
are	O
widespread	O
in	O
gut	O
communities	O
that	O
contain	O
the	O
Prevotella	B-bacteria
species	I-bacteria
,	O
and	O
conclude	O
that	O
megaphages	O
,	O
with	O
fascinating	O
and	O
underexplored	O
biology	O
,	O
may	O
be	O
common	O
but	O
largely	O
overlooked	O
components	O
of	O
human	O
and	O
animal	O
gut	O
microbiomes	O
.	O

Transcriptomics	O
analysis	O
of	O
host	O
liver	O
and	O
meta	O
-	O
transcriptome	O
analysis	O
of	O
rumen	O
epimural	O
microbial	O
community	O
in	O
young	O
calves	O
treated	O
with	O
artificial	O
dosing	O
of	O
rumen	O
content	O
from	O
adult	O
donor	O
cow	O
.	O

In	O
mammals	O
,	O
microbial	O
colonization	O
of	O
the	O
digestive	O
tract	O
(	O
GIT	O
)	O
occurs	O
right	O
after	O
birth	O
by	O
several	O
bacterial	O
phyla	O
.	O

Numerous	O
human	O
and	O
mouse	O
studies	O
have	O
reported	O
the	O
importance	O
of	O
early	O
gut	O
microbial	O
inhabitants	O
on	O
host	O
health	O
.	O

However	O
,	O
few	O
attempts	O
have	O
been	O
undertaken	O
to	O
directly	O
interrogate	O
the	O
role	O
of	O
early	O
gut	O
/	O
rumen	O
microbial	O
colonization	O
on	O
GIT	O
development	O
or	O
host	O
health	O
in	O
neonatal	O
ruminants	O
through	O
artificial	O
manipulation	O
of	O
the	O
rumen	O
microbiome	O
.	O

Thus	O
,	O
the	O
molecular	O
changes	O
associated	O
with	O
bacterial	O
colonization	O
are	O
largely	O
unknown	O
in	O
cattle	O
.	O

In	O
this	O
study	O
,	O
we	O
dosed	O
young	O
calves	O
with	O
exogenous	O
rumen	O
fluid	O
obtained	O
from	O
an	O
adult	O
donor	O
cow	O
,	O
starting	O
at	O
birth	O
,	O
and	O
repeated	O
every	O
other	O
week	O
until	O
six	O
weeks	O
of	O
age	O
.	O

Eight	O
Holstein	O
bull	O
calves	O
were	O
included	O
in	O
this	O
study	O
and	O
were	O
separated	O
into	O
two	O
groups	O
of	O
four	O
:	O
the	O
first	O
group	O
was	O
treated	O
with	O
rumen	O
content	O
freshly	O
extracted	O
from	O
an	O
adult	O
cow	O
,	O
and	O
the	O
second	O
group	O
was	O
treated	O
with	O
sterilized	O
rumen	O
content	O
.	O

Using	O
whole	O
-	O
transcriptome	O
RNA	O
-	O
sequencing	O
,	O
we	O
investigated	O
the	O
transcriptional	O
changes	O
in	O
the	O
host	O
liver	O
,	O
which	O
is	O
a	O
major	O
metabolic	O
organ	O
and	O
vital	O
to	O
the	O
calf	O
'	O
s	O
growth	O
performance	O
.	O

Additionally	O
,	O
the	O
comparison	O
of	O
rumen	O
epimural	O
microbial	O
communities	O
between	O
the	O
treatment	O
groups	O
was	O
performed	O
using	O
the	O
rRNA	O
reads	O
generated	O
by	O
sequencing	O
.	O

Liver	O
transcriptome	O
changes	O
were	O
enriched	O
with	O
genes	O
involved	O
in	O
cell	O
signaling	O
and	O
protein	O
phosphorylation	O
.	O

Specifically	O
,	O
up	O
-	O
regulation	O
of	O
SGPL1	O
suggests	O
a	O
potential	O
increase	O
in	O
the	O
metabolism	O
of	O
sphingolipids	O
,	O
an	O
essential	O
molecular	O
signal	O
for	O
bacterial	O
survival	O
in	O
digestive	O
tracts	O
.	O

Notably	O
,	O
eight	O
genera	O
,	O
belonging	O
to	O
four	O
phyla	O
,	O
had	O
significant	O
increases	O
in	O
abundance	O
in	O
treated	O
calves	O
.	O

Our	O
study	O
provides	O
insight	O
into	O
host	O
liver	O
transcriptome	O
changes	O
associated	O
with	O
early	O
colonization	O
of	O
the	O
microbial	O
communities	O
in	O
neonatal	O
calves	O
.	O

Such	O
knowledge	O
provides	O
a	O
foundation	O
for	O
future	O
probiotics	O
-	O
based	O
research	O
in	O
microbial	O
organism	O
mediated	O
rumen	O
development	O
and	O
nutrition	O
in	O
ruminants	O
.	O

Intestinal	O
epithelial	O
N	O
-	O
acylphosphatidylethanolamine	O
phospholipase	O
D	O
links	O
dietary	O
fat	O
to	O
metabolic	O
adaptations	O
in	O
obesity	O
and	O
steatosis	O
.	O

Variations	O
in	O
N	O
-	O
acylethanolamines	O
(	O
NAE	O
)	O
levels	O
are	O
associated	O
with	O
obesity	O
and	O
metabolic	O
comorbidities	O
.	O

Their	O
role	O
in	O
the	O
gut	O
remains	O
unclear	O
.	O

Therefore	O
,	O
we	O
generated	O
a	O
mouse	O
model	O
of	O
inducible	O
intestinal	O
epithelial	O
cell	O
(	O
IEC	O
)	O
-	O
specific	O
deletion	O
of	O
N	O
-	O
acylphosphatidylethanolamine	O
phospholipase	O
D	O
(	O
NAPE	O
-	O
PLD	O
)	O
,	O
a	O
key	O
enzyme	O
involved	O
in	O
NAE	O
biosynthesis	O
(	O
Napepld	O
(	O
IEC	O
)	O
)	O
.	O

We	O
discovered	O
that	O
Napepld	O
(	O
IEC	O
)	O
mice	O
are	O
hyperphagic	O
upon	O
first	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
exposure	O
,	O
and	O
develop	O
exacerbated	O
obesity	O
and	O
steatosis	O
.	O

These	O
mice	O
display	O
hypothalamic	O
Pomc	O
neurons	O
dysfunctions	O
and	O
alterations	O
in	O
intestinal	O
and	O
plasma	O
NAE	O
and	O
2	O
-	O
acylglycerols	O
.	O

After	O
long	O
-	O
term	O
HFD	O
,	O
Napepld	O
(	O
IEC	O
)	O
mice	O
present	O
reduced	O
energy	O
expenditure	O
.	O

The	O
increased	O
steatosis	O
is	O
associated	O
with	O
higher	O
gut	O
and	O
liver	O
lipid	O
absorption	O
.	O

Napepld	O
(	O
IEC	O
)	O
mice	O
display	O
altered	O
gut	O
microbiota	O
.	O

Akkermansia	B-bacteria
muciniphila	I-bacteria
administration	O
partly	O
counteracts	O
the	O
IEC	O
NAPE	O
-	O
PLD	O
deletion	O
effects	O
.	O

In	O
conclusion	O
,	O
intestinal	O
NAPE	O
-	O
PLD	O
is	O
a	O
key	O
sensor	O
in	O
nutritional	O
adaptation	O
to	O
fat	O
intake	O
,	O
gut	O
-	O
to	O
-	O
brain	O
axis	O
and	O
energy	O
homeostasis	O
and	O
thereby	O
constitutes	O
a	O
novel	O
target	O
to	O
tackle	O
obesity	O
and	O
related	O
disorders	O
.	O

Identification	O
of	O
a	O
Fifth	O
Antibacterial	O
Toxin	O
Produced	O
by	O
a	O
Single	O
Bacteroides	B-bacteria
fragilis	I-bacteria
Strain	I-bacteria
.	O

Bacteroidales	B-bacteria
are	O
the	O
most	O
abundant	O
Gram	O
-	O
negative	O
bacteria	O
of	O
the	O
healthy	O
human	O
colonic	O
microbiota	O
,	O
comprising	O
nearly	O
50	O
%	O
of	O
the	O
colonic	O
bacteria	O
in	O
many	O
individuals	O
.	O

Numerous	O
species	O
and	O
strains	O
of	O
gut	O
Bacteroidales	B-bacteria
are	O
present	O
simultaneously	O
at	O
high	O
concentrations	O
in	O
this	O
ecosystem	O
.	O

Studies	O
are	O
revealing	O
that	O
gut	O
Bacteroides	B-bacteria
has	O
numerous	O
antibacterial	O
weapons	O
to	O
antagonize	O
closely	O
related	O
members	O
.	O

In	O
this	O
study	O
,	O
we	O
identify	O
a	O
new	O
diffusible	O
antibacterial	O
toxin	O
produced	O
by	O
Bacteroides	B-bacteria
fragilis	I-bacteria
638R	I-bacteria
,	O
designated	O
BSAP	O
-	O
4	O
.	O

This	O
is	O
the	O
fifth	O
antibacterial	O
toxin	O
produced	O
by	O
this	O
strain	O
and	O
the	O
second	O
toxin	O
of	O
this	O
strain	O
with	O
a	O
membrane	O
attack	O
complex	O
/	O
perforin	O
domain	O
(	O
MACPF	O
)	O
.	O

We	O
identify	O
the	O
target	O
molecule	O
of	O
sensitive	O
cells	O
as	O
a	O
beta	O
-	O
barrel	O
outer	O
membrane	O
protein	O
(	O
OMP	O
)	O
with	O
calycin	O
-	O
like	O
domains	O
.	O

As	O
with	O
other	O
MACPF	O
toxins	O
,	O
the	O
gene	O
encoding	O
the	O
target	O
in	O
sensitive	O
strains	O
is	O
in	O
the	O
same	O
genetic	O
region	O
as	O
bsap	O
-	O
4	O
in	O
producing	O
strains	O
.	O

A	O
comparison	O
of	O
B	B-bacteria
.	I-bacteria
fragilis	I-bacteria
strains	I-bacteria
showed	O
there	O
are	O
two	O
sensitive	O
variants	O
of	O
this	O
OMP	O
that	O
are	O
87	O
%	O
similar	O
to	O
each	O
other	O
and	O
50	O
%	O
similar	O
to	O
the	O
resistant	O
OMP	O
.	O

Unlike	O
other	O
MACPF	O
toxins	O
,	O
there	O
are	O
numerous	O
B	B-bacteria
.	I-bacteria
fragilis	I-bacteria
strains	I-bacteria
that	O
harbor	O
the	O
resistant	O
OMP	O
without	O
bsap	O
-	O
4	O
Several	O
OMP	O
variants	O
from	O
strains	O
that	O
are	O
BSAP	O
-	O
4	O
resistant	O
under	O
the	O
conditions	O
of	O
our	O
assay	O
confer	O
BSAP	O
-	O
4	O
sensitivity	O
to	O
Bacteroides	B-bacteria
thetaiotaomicron	I-bacteria
when	O
constitutively	O
expressed	O
.	O

Using	O
a	O
reporter	O
assay	O
,	O
we	O
show	O
that	O
the	O
BSAP	O
-	O
4	O
receptor	O
gene	O
is	O
differentially	O
expressed	O
in	O
sensitive	O
and	O
resistant	O
strains	O
leading	O
to	O
apparent	O
BSAP	O
-	O
4	O
resistance	O
under	O
the	O
conditions	O
of	O
our	O
assay	O
,	O
despite	O
harboring	O
the	O
BSAP	O
-	O
4	O
target	O
gene	O
.	O
IMPORTANCE	O
The	O
intestinal	O
microbiota	O
is	O
a	O
diverse	O
microbial	O
ecosystem	O
that	O
provides	O
numerous	O
benefits	O
to	O
humans	O
.	O

The	O
factors	O
that	O
govern	O
its	O
establishment	O
and	O
stability	O
are	O
just	O
beginning	O
to	O
be	O
elucidated	O
.	O

Identification	O
and	O
characterization	O
of	O
antimicrobial	O
toxins	O
produced	O
by	O
its	O
members	O
and	O
their	O
killing	O
range	O
are	O
essential	O
to	O
understanding	O
the	O
role	O
of	O
antagonism	O
in	O
community	O
composition	O
and	O
stability	O
.	O

Here	O
,	O
we	O
identify	O
a	O
fifth	O
antimicrobial	O
toxin	O
produced	O
by	O
a	O
single	O
Bacteroides	B-bacteria
fragilis	I-bacteria
strain	I-bacteria
and	O
identify	O
its	O
target	O
.	O

The	O
finding	O
of	O
such	O
a	O
large	O
number	O
of	O
toxins	O
that	O
antagonize	O
competing	O
members	O
suggests	O
that	O
this	O
feature	O
substantially	O
contributes	O
to	O
the	O
fitness	O
of	O
these	O
bacteria	O
.	O

In	O
addition	O
,	O
these	O
toxins	O
may	O
have	O
applications	O
in	O
genetically	O
engineered	O
gut	O
bacteria	O
to	O
allow	O
engraftment	O
or	O
to	O
antagonize	O
a	O
potentially	O
pathogenic	O
member	O
.	O

Microbiome	O
in	O
Mechanisms	O
of	O
Asthma	O
.	O

The	O
lung	O
and	O
gut	O
microbiome	O
are	O
factors	O
in	O
asthma	O
risk	O
or	O
protection	O
.	O

Relevant	O
elements	O
of	O
the	O
microbiome	O
within	O
both	O
niches	O
include	O
the	O
importance	O
of	O
the	O
early	O
life	O
window	O
for	O
microbiome	O
establishment	O
,	O
the	O
diversity	O
of	O
bacteria	O
,	O
richness	O
of	O
bacteria	O
,	O
and	O
effect	O
of	O
those	O
bacteria	O
on	O
the	O
local	O
epithelium	O
and	O
immune	O
system	O
.	O

Mechanisms	O
of	O
protection	O
include	O
direct	O
anti	O
-	O
inflammatory	O
action	O
or	O
induction	O
of	O
non	O
-	O
type	O
2	O
inflammation	O
by	O
certain	O
bacterial	O
colonies	O
.	O

The	O
gut	O
microbiome	O
further	O
impacts	O
asthma	O
risk	O
through	O
the	O
contribution	O
of	O
metabolic	O
products	O
.	O

This	O
article	O
reviews	O
the	O
mechanisms	O
that	O
connect	O
the	O
lung	O
and	O
gut	O
microbiota	O
to	O
asthma	O
development	O
and	O
severity	O
.	O

Choice	O
of	O
assembly	O
software	O
has	O
a	O
critical	O
impact	O
on	O
virome	O
characterisation	O
.	O

BACKGROUND	O
:	O
The	O
viral	O
component	O
of	O
microbial	O
communities	O
plays	O
a	O
vital	O
role	O
in	O
driving	O
bacterial	O
diversity	O
,	O
facilitating	O
nutrient	O
turnover	O
and	O
shaping	O
community	O
composition	O
.	O

Despite	O
their	O
importance	O
,	O
the	O
vast	O
majority	O
of	O
viral	O
sequences	O
are	O
poorly	O
annotated	O
and	O
share	O
little	O
or	O
no	O
homology	O
to	O
reference	O
databases	O
.	O

As	O
a	O
result	O
,	O
investigation	O
of	O
the	O
viral	O
metagenome	O
(	O
virome	O
)	O
relies	O
heavily	O
on	O
de	O
novo	O
assembly	O
of	O
short	O
sequencing	O
reads	O
to	O
recover	O
compositional	O
and	O
functional	O
information	O
.	O

Metagenomic	O
assembly	O
is	O
particularly	O
challenging	O
for	O
virome	O
data	O
,	O
often	O
resulting	O
in	O
fragmented	O
assemblies	O
and	O
poor	O
recovery	O
of	O
viral	O
community	O
members	O
.	O

Despite	O
the	O
essential	O
role	O
of	O
assembly	O
in	O
virome	O
analysis	O
and	O
difficulties	O
posed	O
by	O
these	O
data	O
,	O
current	O
assembly	O
comparisons	O
have	O
been	O
limited	O
to	O
subsections	O
of	O
virome	O
studies	O
or	O
bacterial	O
datasets	O
.	O

DESIGN	O
:	O
This	O
study	O
presents	O
the	O
most	O
comprehensive	O
virome	O
assembly	O
comparison	O
to	O
date	O
,	O
featuring	O
16	O
metagenomic	O
assembly	O
approaches	O
which	O
have	O
featured	O
in	O
human	O
virome	O
studies	O
.	O

Assemblers	O
were	O
assessed	O
using	O
four	O
independent	O
virome	O
datasets	O
,	O
namely	O
,	O
simulated	O
reads	O
,	O
two	O
mock	O
communities	O
,	O
viromes	O
spiked	O
with	O
a	O
known	O
phage	O
and	O
human	O
gut	O
viromes	O
.	O

RESULTS	O
:	O
Assembly	O
performance	O
varied	O
significantly	O
across	O
all	O
test	O
datasets	O
,	O
with	O
SPAdes	O
(	O
meta	O
)	O
performing	O
consistently	O
well	O
.	O

Performance	O
of	O
MIRA	O
and	O
VICUNA	O
varied	O
,	O
highlighting	O
the	O
importance	O
of	O
using	O
a	O
range	O
of	O
datasets	O
when	O
comparing	O
assembly	O
programs	O
.	O

It	O
was	O
also	O
found	O
that	O
while	O
some	O
assemblers	O
addressed	O
the	O
challenges	O
of	O
virome	O
data	O
better	O
than	O
others	O
,	O
all	O
assemblers	O
had	O
limitations	O
.	O

Low	O
read	O
coverage	O
and	O
genomic	O
repeats	O
resulted	O
in	O
assemblies	O
with	O
poor	O
genome	O
recovery	O
,	O
high	O
degrees	O
of	O
fragmentation	O
and	O
low	O
-	O
accuracy	O
contigs	O
across	O
all	O
assemblers	O
.	O

These	O
limitations	O
must	O
be	O
considered	O
when	O
setting	O
thresholds	O
for	O
downstream	O
analysis	O
and	O
when	O
drawing	O
conclusions	O
from	O
virome	O
data	O
.	O

Probiotic	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
Prevents	O
Postantibiotic	O
Bone	O
Loss	O
by	O
Reducing	O
Intestinal	O
Dysbiosis	O
and	O
Preventing	O
Barrier	O
Disruption	O
.	O

Antibiotic	O
treatment	O
,	O
commonly	O
prescribed	O
for	O
bacterial	O
infections	O
,	O
depletes	O
and	O
subsequently	O
causes	O
long	O
-	O
term	O
alterations	O
in	O
intestinal	O
microbiota	O
composition	O
.	O

Knowing	O
the	O
importance	O
of	O
the	O
microbiome	O
in	O
the	O
regulation	O
of	O
bone	O
density	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
postantibiotic	O
treatment	O
on	O
gut	O
and	O
bone	O
health	O
.	O

Intestinal	O
microbiome	O
repopulation	O
at	O
4	O
-	O
weeks	O
postantibiotic	O
treatment	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
Firmicutes	B-bacteria
:	O
Bacteroidetes	B-bacteria
ratio	O
,	O
increased	O
intestinal	O
permeability	O
,	O
and	O
notably	O
reduced	O
femoral	O
trabecular	O
bone	O
volume	O
(	O
approximately	O
30	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Treatment	O
with	O
a	O
mucus	O
supplement	O
(	O
a	O
high	O
-	O
molecular	O
-	O
weight	O
polymer	O
,	O
MDY	O
-	O
1001	O
[	O
MDY	O
]	O
)	O
prevented	O
the	O
postantibiotic	O
-	O
induced	O
barrier	O
break	O
as	O
well	O
as	O
bone	O
loss	O
,	O
indicating	O
a	O
mechanistic	O
link	O
between	O
increased	O
intestinal	O
permeability	O
and	O
bone	O
loss	O
.	O

A	O
link	O
between	O
the	O
microbiome	O
composition	O
and	O
bone	O
density	O
was	O
demonstrated	O
by	O
supplementing	O
the	O
mice	O
with	O
probiotic	O
bacteria	O
.	O

Specifically	O
,	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
,	O
but	O
not	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
GG	I-bacteria
or	O
nonpathogenic	O
Escherichia	B-bacteria
coli	I-bacteria
,	O
reduced	O
the	O
postantibiotic	O
elevation	O
of	O
the	O
Firmicutes	B-bacteria
:	O
Bacteroidetes	B-bacteria
ratio	O
and	O
prevented	O
femoral	O
and	O
vertebral	O
trabecular	O
bone	O
loss	O
.	O

Consistent	O
with	O
causing	O
bone	O
loss	O
,	O
postantibiotic	O
-	O
induced	O
dysbiosis	O
decreased	O
osteoblast	O
and	O
increased	O
osteoclast	O
activities	O
,	O
changes	O
that	O
were	O
prevented	O
by	O
both	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
and	O
MDY	O
.	O

These	O
data	O
underscore	O
the	O
importance	O
of	O
microbial	O
dysbiosis	O
in	O
the	O
regulation	O
of	O
intestinal	O
permeability	O
and	O
bone	O
health	O
,	O
as	O
well	O
as	O
identify	O
L	B-bacteria
.	I-bacteria
reuteri	I-bacteria
and	O
MDY	O
as	O
novel	O
therapies	O
for	O
preventing	O
these	O
adverse	O
effects	O
.	O

(	O
c	O
)	O
2018	O
American	O
Society	O
for	O
Bone	O
and	O
Mineral	O
Research	O
.	O

Microplastics	O
induce	O
intestinal	O
inflammation	O
,	O
oxidative	O
stress	O
,	O
and	O
disorders	O
of	O
metabolome	O
and	O
microbiome	O
in	O
zebrafish	O
.	O

Microplastics	O
(	O
MPs	O
)	O
can	O
be	O
ingested	O
by	O
a	O
variety	O
of	O
species	O
and	O
mainly	O
accumulate	O
in	O
the	O
gut	O
.	O

However	O
,	O
the	O
consequences	O
of	O
MPs	O
exposure	O
in	O
the	O
gut	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
evaluated	O
the	O
impacts	O
of	O
MPs	O
exposure	O
in	O
zebrafish	O
gut	O
.	O

Animals	O
were	O
experimentally	O
exposed	O
to	O
polystyrene	O
MPs	O
(	O
5	O
-	O
mum	O
beads	O
;	O
50mug	O
/	O
L	O
and	O
500mug	O
/	O
L	O
)	O
for	O
21days	O
and	O
monitored	O
for	O
alterations	O
in	O
tissue	O
histology	O
,	O
enzymatic	O
biomarkers	O
,	O
gut	O
microbiome	O
and	O
metabolomic	O
responses	O
.	O

Inflammation	O
and	O
oxidative	O
stress	O
were	O
observed	O
in	O
the	O
zebrafish	O
gut	O
after	O
exposed	O
to	O
MPs	O
.	O

Furthermore	O
,	O
significant	O
alterations	O
in	O
the	O
gut	O
microbiome	O
and	O
tissue	O
metabolic	O
profiles	O
were	O
observed	O
,	O
with	O
most	O
of	O
these	O
were	O
associated	O
with	O
oxidative	O
stress	O
,	O
inflammation	O
and	O
lipid	O
metabolism	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
MPs	O
exposure	O
causes	O
gut	O
damage	O
as	O
well	O
as	O
alterations	O
in	O
gut	O
metabolome	O
and	O
microbiome	O
,	O
yielding	O
novel	O
insights	O
into	O
the	O
consequences	O
of	O
MPs	O
exposure	O
.	O

N	O
-	O
3	O
polyunsaturated	O
fatty	O
acids	O
:	O
An	O
innovative	O
strategy	O
against	O
obesity	O
and	O
related	O
metabolic	O
disorders	O
,	O
intestinal	O
alteration	O
and	O
gut	O
microbiota	O
dysbiosis	O
.	O

Obesity	O
is	O
now	O
widely	O
recognized	O
to	O
be	O
associated	O
with	O
low	O
-	O
grade	O
systemic	O
inflammation	O
.	O

It	O
has	O
been	O
shown	O
that	O
high	O
-	O
fat	O
feeding	O
modulates	O
gut	O
microbiota	O
which	O
strongly	O
increased	O
intestinal	O
permeability	O
leading	O
to	O
lipopolysaccharide	O
absorption	O
causing	O
metabolic	O
endotoxemia	O
that	O
triggers	O
inflammation	O
and	O
metabolic	O
disorders	O
.	O

N	O
-	O
3	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFAs	O
)	O
have	O
been	O
shown	O
associated	O
with	O
anti	O
-	O
obesity	O
properties	O
,	O
but	O
results	O
still	O
remain	O
heterogeneous	O
and	O
very	O
few	O
studies	O
underlined	O
the	O
metabolic	O
pathways	O
involved	O
.	O

Thus	O
,	O
the	O
use	O
of	O
Fat	O
-	O
1	O
transgenic	O
mice	O
allows	O
to	O
better	O
understanding	O
whether	O
endogenous	O
n	O
-	O
3	O
PUFAs	O
enrichment	O
contributes	O
to	O
obesity	O
and	O
associated	O
metabolic	O
disorders	O
prevention	O
.	O

It	O
specially	O
evidence	O
that	O
such	O
effects	O
occur	O
through	O
modulations	O
of	O
gut	O
microbiota	O
and	O
intestinal	O
permeability	O
.	O

Then	O
,	O
by	O
remodeling	O
gut	O
microbiota	O
,	O
endogenous	O
n	O
-	O
3	O
PUFAs	O
improve	O
HF	O
/	O
HS	O
-	O
diet	O
induced	O
features	O
of	O
the	O
metabolic	O
syndrome	O
which	O
in	O
turn	O
affects	O
host	O
metabolism	O
.	O

Thus	O
,	O
increasing	O
anti	O
-	O
obesogenic	O
microbial	O
species	O
in	O
the	O
gut	O
microbiota	O
population	O
(	O
i	O
.	O
e	O
Akkermansia	B-bacteria
)	O
by	O
appropriate	O
n	O
-	O
3	O
PUFAs	O
may	O
represent	O
a	O
promising	O
strategy	O
to	O
control	O
or	O
prevent	O
metabolic	O
diseases	O
.	O

Motilimonas	B-bacteria
pumila	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
isolated	O
from	O
the	O
gut	O
of	O
sea	O
cucumber	O
Apostichopus	O
japonicus	O
.	O

A	O
facultatively	O
anaerobic	O
and	O
Gram	O
-	O
negative	O
bacterium	O
,	O
designated	O
strain	O
PLHSC7	B-bacteria
-	I-bacteria
2	I-bacteria
(	O
T	O
)	O
,	O
was	O
isolated	O
from	O
the	O
gut	O
of	O
sea	O
cucumber	O
Apostichopusjaponicus	O
that	O
had	O
been	O
collected	O
from	O
the	O
coastal	O
area	O
of	O
Yantai	O
,	O
China	O
.	O

The	O
cells	O
were	O
rod	O
-	O
shaped	O
and	O
motile	O
by	O
means	O
of	O
polar	O
flagella	O
.	O

The	O
novel	O
isolate	O
grew	O
optimally	O
at	O
28	O
-	O
30	O
degrees	O
C	O
,	O
in	O
the	O
presence	O
of	O
2	O
.	O
0	O
-	O
3	O
.	O
0	O
%	O
(	O
w	O
/	O
v	O
)	O
NaCl	O
and	O
at	O
pH	O
7	O
.	O
0	O
-	O
7	O
.	O
5	O
.	O

The	O
sole	O
respiratory	O
quinone	O
was	O
Q	O
-	O
8	O
and	O
the	O
major	O
fatty	O
acids	O
were	O
summed	O
feature	O
3	O
(	O
C16	O
:	O
1omega7c	O
and	O
/	O
or	O
C16	O
:	O
1omega6c	O
)	O
,	O
C16	O
:	O
0	O
and	O
C17	O
:	O
0	O
.	O

The	O
predominant	O
polar	O
lipids	O
were	O
phosphatidylethanolamine	O
,	O
phosphatidylglycerol	O
and	O
diphosphatidylglycerol	O
.	O

Phylogenetic	O
analyses	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequences	O
showed	O
that	O
strain	O
PLHSC7	B-bacteria
-	I-bacteria
2	I-bacteria
(	O
T	O
)	O
was	O
phylogenetically	O
affiliated	O
with	O
the	O
genus	O
Motilimonas	B-bacteria
,	O
and	O
exhibited	O
sequence	O
similarity	O
of	O
96	O
.	O
2	O
%	O
toMotilimonas	O
eburnea	I-bacteria
YH6	I-bacteria
(	O
T	O
)	O
.	O

The	O
DNA	O
G	O
+	O
C	O
content	O
was	O
45	O
.	O
5	O
mol	O
%	O
.	O

On	O
the	O
basis	O
of	O
phenotypic	O
,	O
phylogenetic	O
and	O
genetic	O
distinctiveness	O
,	O
strain	O
PLHSC7	B-bacteria
-	I-bacteria
2	I-bacteria
(	O
T	O
)	O
(	O
=	O
MCCC	B-bacteria
1K03522	I-bacteria
(	O
T	O
)	O
=	O
KCTC	B-bacteria
62589	I-bacteria
(	O
T	O
)	O
)	O
was	O
classified	O
as	O
a	O
novel	O
species	O
within	O
the	O
genus	O
Motilimonas	B-bacteria
,	O
for	O
which	O
the	O
name	O
Motilimonas	B-bacteria
pumila	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
is	O
proposed	O
.	O

Endocrine	O
organs	O
of	O
cardiovascular	O
diseases	O
:	O
Gut	O
microbiota	O
.	O

Gut	O
microbiota	O
(	O
GM	O
)	O
is	O
a	O
collection	O
of	O
bacteria	O
,	O
fungi	O
,	O
archaea	O
,	O
viruses	O
and	O
protozoa	O
,	O
etc	O
.	O

They	O
inhabit	O
human	O
intestines	O
and	O
play	O
an	O
essential	O
role	O
in	O
human	O
health	O
and	O
disease	O
.	O

Close	O
information	O
exchange	O
between	O
the	O
intestinal	O
microbes	O
and	O
the	O
host	O
performs	O
a	O
vital	O
role	O
in	O
digestion	O
,	O
immune	O
defence	O
,	O
nervous	O
system	O
regulation	O
,	O
especially	O
metabolism	O
,	O
maintaining	O
a	O
delicate	O
balance	O
between	O
itself	O
and	O
the	O
human	O
host	O
.	O

Studies	O
have	O
shown	O
that	O
the	O
composition	O
of	O
GM	O
and	O
its	O
metabolites	O
are	O
firmly	O
related	O
to	O
the	O
occurrence	O
of	O
various	O
diseases	O
.	O

More	O
and	O
more	O
researchers	O
have	O
demonstrated	O
that	O
the	O
intestinal	O
microbiota	O
is	O
a	O
virtual	O
'	O
organ	O
'	O
with	O
endocrine	O
function	O
and	O
the	O
bioactive	O
metabolites	O
produced	O
by	O
it	O
can	O
affect	O
the	O
physiological	O
role	O
of	O
the	O
host	O
.	O

With	O
deepening	O
researches	O
in	O
recent	O
years	O
,	O
clinical	O
data	O
indicated	O
that	O
the	O
GM	O
has	O
a	O
significant	O
effect	O
on	O
the	O
occurrence	O
and	O
development	O
of	O
cardiovascular	O
diseases	O
(	O
CVD	O
)	O
.	O

This	O
article	O
systematically	O
elaborated	O
the	O
relationship	O
between	O
metabolites	O
of	O
GM	O
and	O
its	O
effects	O
,	O
the	O
relationship	O
between	O
intestinal	O
dysbacteriosis	O
and	O
cardiovascular	O
risk	O
factors	O
,	O
coronary	O
heart	O
disease	O
,	O
myocardial	O
infarction	O
,	O
heart	O
failure	O
and	O
hypertension	O
and	O
the	O
possible	O
pathogenic	O
mechanisms	O
.	O

Regulating	O
the	O
GM	O
is	O
supposed	O
to	O
be	O
a	O
potential	O
new	O
therapeutic	O
target	O
for	O
CVD	O
.	O

A	O
2	O
.	O
08	O
A	O
resolution	O
structure	O
of	O
HLB5	O
,	O
a	O
novel	O
cellulase	O
from	O
the	O
anaerobic	O
gut	O
bacterium	O
Parabacteroides	B-bacteria
johnsonii	I-bacteria
DSM	I-bacteria
18315	I-bacteria
.	O

Cellulases	O
play	O
a	O
significant	O
role	O
in	O
the	O
degradation	O
of	O
complex	O
carbohydrates	O
.	O

In	O
the	O
human	O
gut	O
,	O
anaerobic	O
bacteria	O
are	O
essential	O
to	O
the	O
well	O
-	O
being	O
of	O
the	O
host	O
by	O
producing	O
these	O
essential	O
enzymes	O
that	O
convert	O
plant	O
polymers	O
into	O
simple	O
sugars	O
that	O
can	O
then	O
be	O
further	O
metabolized	O
by	O
the	O
host	O
.	O

Here	O
,	O
we	O
report	O
the	O
2	O
.	O
08	O
A	O
resolution	O
structure	O
of	O
HLB5	O
,	O
a	O
chemically	O
verified	O
cellulase	O
that	O
was	O
identified	O
previously	O
from	O
an	O
anaerobic	O
gut	O
bacterium	O
and	O
that	O
has	O
no	O
structural	O
cellulase	O
homologues	O
in	O
PDB	O
nor	O
possesses	O
any	O
conserved	O
region	O
typical	O
for	O
glycosidases	O
.	O

We	O
anticipate	O
that	O
the	O
information	O
presented	O
here	O
will	O
facilitate	O
the	O
identification	O
of	O
additional	O
cellulases	O
for	O
which	O
no	O
homologues	O
have	O
been	O
identified	O
to	O
date	O
and	O
enhance	O
our	O
understanding	O
how	O
these	O
novel	O
cellulases	O
bind	O
and	O
hydrolyze	O
their	O
substrates	O
.	O

Entamoeba	O
histolytica	O
Cyclooxygenase	O
-	O
Like	O
Protein	O
Regulates	O
Cysteine	O
Protease	O
Expression	O
and	O
Virulence	O
.	O

The	O
intestinal	O
protozoan	O
parasite	O
Entamoeba	O
histolytica	O
(	O
Eh	O
)	O
causes	O
amebiasis	O
associated	O
with	O
severe	O
diarrhea	O
and	O
/	O
or	O
liver	O
abscess	O
.	O

Eh	O
pathogenesis	O
is	O
multifactorial	O
requiring	O
both	O
parasite	O
virulent	O
molecules	O
and	O
host	O
-	O
induced	O
innate	O
immune	O
responses	O
.	O

Eh	O
-	O
induced	O
host	O
pro	O
-	O
inflammatory	O
responses	O
plays	O
a	O
critical	O
role	O
in	O
disease	O
pathogenesis	O
by	O
causing	O
damage	O
to	O
tissues	O
allowing	O
parasites	O
access	O
to	O
systemic	O
sites	O
.	O

Eh	O
cyclooxygenase	O
(	O
EhCox	O
)	O
derived	O
prostaglandin	O
E2	O
stimulates	O
the	O
chemokine	O
IL	O
-	O
8	O
from	O
mucosal	O
epithelial	O
cells	O
that	O
recruits	O
neutrophils	O
to	O
the	O
site	O
of	O
infection	O
to	O
exacerbate	O
disease	O
.	O

At	O
present	O
,	O
it	O
is	O
not	O
known	O
how	O
EhCox	O
is	O
regulated	O
or	O
whether	O
it	O
affects	O
the	O
expression	O
of	O
other	O
proteins	O
in	O
Eh	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
gene	O
silencing	O
of	O
EhCox	O
(	O
EhCoxgs	O
)	O
markedly	O
increased	O
endogenous	O
cysteine	O
protease	O
(	O
CP	O
)	O
protein	O
expression	O
and	O
virulence	O
without	O
altering	O
CP	O
gene	O
transcripts	O
.	O

Live	O
virulent	O
Eh	O
pretreated	O
with	O
arachidonic	O
acid	O
substrate	O
to	O
enhance	O
PGE2	O
production	O
or	O
aspirin	O
to	O
inhibit	O
EhCox	O
enzyme	O
activity	O
or	O
addition	O
of	O
exogenous	O
PGE2	O
to	O
Eh	O
had	O
no	O
effect	O
on	O
EhCP	O
activity	O
.	O

Increased	O
CP	O
enzyme	O
activity	O
in	O
EhCoxgs	O
was	O
stable	O
and	O
significantly	O
enhanced	O
erythrophagocytosis	O
,	O
cytopathic	O
effects	O
on	O
colonic	O
epithelial	O
cells	O
and	O
elicited	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
mice	O
colonic	O
loops	O
.	O

Acute	O
infection	O
with	O
EhCoxgs	O
in	O
colonic	O
loops	O
increased	O
inflammation	O
associated	O
with	O
high	O
levels	O
of	O
myeloperoxidase	O
activity	O
.	O

This	O
study	O
has	O
identified	O
EhCox	O
protein	O
as	O
one	O
of	O
the	O
important	O
endogenous	O
regulators	O
of	O
cysteine	O
protease	O
activity	O
.	O

Alterations	O
of	O
CP	O
activity	O
in	O
response	O
to	O
Cox	O
gene	O
silencing	O
may	O
be	O
a	O
negative	O
feedback	O
mechanism	O
in	O
Eh	O
to	O
limit	O
proteolytic	O
activity	O
during	O
colonization	O
that	O
can	O
inadvertently	O
trigger	O
inflammation	O
in	O
the	O
gut	O
.	O

Enteropathogens	O
:	O
Tuning	O
Their	O
Gene	O
Expression	O
for	O
Hassle	O
-	O
Free	O
Survival	O
.	O

Enteropathogenic	O
bacteria	O
have	O
been	O
the	O
cause	O
of	O
the	O
majority	O
of	O
foodborne	O
illnesses	O
.	O

Much	O
of	O
the	O
research	O
has	O
been	O
focused	O
on	O
elucidating	O
the	O
mechanisms	O
by	O
which	O
these	O
pathogens	O
evade	O
the	O
host	O
immune	O
system	O
.	O

One	O
of	O
the	O
ways	O
in	O
which	O
they	O
achieve	O
the	O
successful	O
establishment	O
of	O
a	O
niche	O
in	O
the	O
gut	O
microenvironment	O
and	O
survive	O
is	O
by	O
a	O
chain	O
of	O
elegantly	O
regulated	O
gene	O
expression	O
patterns	O
.	O

Studies	O
have	O
shown	O
that	O
this	O
process	O
is	O
very	O
elaborate	O
and	O
is	O
also	O
regulated	O
by	O
several	O
factors	O
.	O

Pathogens	O
like	O
,	O
enteropathogenic	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
(	O
EPEC	B-bacteria
)	O
,	O
Salmonella	B-bacteria
Typhimurium	I-bacteria
,	O
Shigella	B-bacteria
flexneri	I-bacteria
,	O
Yersinia	B-bacteria
sp	I-bacteria
.	I-bacteria
have	O
been	O
seen	O
to	O
employ	O
various	O
regulated	O
gene	O
expression	O
strategies	O
.	O

These	O
include	O
toxin	O
-	O
antitoxin	O
systems	O
,	O
quorum	O
sensing	O
systems	O
,	O
expression	O
controlled	O
by	O
nucleoid	O
-	O
associated	O
proteins	O
(	O
NAPs	O
)	O
,	O
several	O
regulons	O
and	O
operons	O
specific	O
to	O
these	O
pathogens	O
.	O

In	O
the	O
following	O
review	O
,	O
we	O
have	O
tried	O
to	O
discuss	O
the	O
common	O
gene	O
regulatory	O
systems	O
of	O
enteropathogenic	O
bacteria	O
as	O
well	O
as	O
pathogen	O
-	O
specific	O
regulatory	O
mechanisms	O
.	O

The	O
Microbiome	O
Stress	O
Project	O
:	O
Toward	O
a	O
Global	O
Meta	O
-	O
Analysis	O
of	O
Environmental	O
Stressors	O
and	O
Their	O
Effects	O
on	O
Microbial	O
Communities	O
.	O

Microbial	O
community	O
structure	O
is	O
highly	O
sensitive	O
to	O
natural	O
(	O
e	O
.	O
g	O
.	O
,	O
drought	O
,	O
temperature	O
,	O
fire	O
)	O
and	O
anthropogenic	O
(	O
e	O
.	O
g	O
.	O
,	O
heavy	O
metal	O
exposure	O
,	O
land	O
-	O
use	O
change	O
)	O
stressors	O
.	O

However	O
,	O
despite	O
an	O
immense	O
amount	O
of	O
data	O
generated	O
,	O
systematic	O
,	O
cross	O
-	O
environment	O
analyses	O
of	O
microbiome	O
responses	O
to	O
multiple	O
disturbances	O
are	O
lacking	O
.	O

Here	O
,	O
we	O
present	O
the	O
Microbiome	O
Stress	O
Project	O
,	O
an	O
open	O
-	O
access	O
database	O
of	O
environmental	O
and	O
host	O
-	O
associated	O
16S	O
rRNA	O
amplicon	O
sequencing	O
studies	O
collected	O
to	O
facilitate	O
cross	O
-	O
study	O
analyses	O
of	O
microbiome	O
responses	O
to	O
stressors	O
.	O

This	O
database	O
will	O
comprise	O
published	O
and	O
unpublished	O
datasets	O
re	O
-	O
processed	O
from	O
the	O
raw	O
sequences	O
into	O
exact	O
sequence	O
variants	O
using	O
our	O
standardized	O
computational	O
pipeline	O
.	O

Our	O
database	O
will	O
provide	O
insight	O
into	O
general	O
response	O
patterns	O
of	O
microbiome	O
diversity	O
,	O
structure	O
,	O
and	O
stability	O
to	O
environmental	O
stressors	O
.	O

It	O
will	O
also	O
enable	O
the	O
identification	O
of	O
cross	O
-	O
study	O
associations	O
between	O
single	O
or	O
multiple	O
stressors	O
and	O
specific	O
microbial	O
clades	O
.	O

Here	O
,	O
we	O
present	O
a	O
proof	O
-	O
of	O
-	O
concept	O
meta	O
-	O
analysis	O
of	O
606	O
microbiomes	O
(	O
from	O
nine	O
studies	O
)	O
to	O
assess	O
microbial	O
community	O
responses	O
to	O
:	O
(	O
1	O
)	O
one	O
stressor	O
in	O
one	O
environment	O
:	O
soil	O
warming	O
across	O
a	O
variety	O
of	O
soil	O
types	O
,	O
(	O
2	O
)	O
a	O
range	O
of	O
stressors	O
in	O
one	O
environment	O
:	O
soil	O
microbiome	O
responses	O
to	O
a	O
comprehensive	O
set	O
of	O
stressors	O
(	O
incl	O
.	O
temperature	O
,	O
diesel	O
,	O
antibiotics	O
,	O
land	O
use	O
change	O
,	O
drought	O
,	O
and	O
heavy	O
metals	O
)	O
,	O
(	O
3	O
)	O
one	O
stressor	O
across	O
a	O
range	O
of	O
environments	O
:	O
copper	O
exposure	O
effects	O
on	O
soil	O
,	O
sediment	O
,	O
activated	O
-	O
sludge	O
reactors	O
,	O
and	O
gut	O
environments	O
,	O
and	O
(	O
4	O
)	O
the	O
general	O
trends	O
of	O
microbiome	O
stressor	O
responses	O
.	O

Overall	O
,	O
we	O
found	O
that	O
stressor	O
exposure	O
significantly	O
decreases	O
microbiome	O
alpha	O
diversity	O
and	O
increases	O
beta	O
diversity	O
(	O
community	O
dispersion	O
)	O
across	O
a	O
range	O
of	O
environments	O
and	O
stressor	O
types	O
.	O

We	O
observed	O
a	O
hump	O
-	O
shaped	O
relationship	O
between	O
microbial	O
community	O
resistance	O
to	O
stressors	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
average	O
pairwise	O
similarity	O
score	O
between	O
the	O
control	O
and	O
stressed	O
communities	O
)	O
and	O
alpha	O
diversity	O
.	O

We	O
used	O
Phylofactor	O
to	O
identify	O
microbial	O
clades	O
and	O
individual	O
taxa	O
as	O
potential	O
bioindicators	O
of	O
copper	O
contamination	O
across	O
different	O
environments	O
.	O

Using	O
standardized	O
computational	O
and	O
statistical	O
methods	O
,	O
the	O
Microbiome	O
Stress	O
Project	O
will	O
leverage	O
thousands	O
of	O
existing	O
datasets	O
to	O
build	O
a	O
general	O
framework	O
for	O
how	O
microbial	O
communities	O
respond	O
to	O
environmental	O
stress	O
.	O

Effects	O
of	O
Attenuated	O
S	B-bacteria
.	I-bacteria
agalactiae	I-bacteria
Strain	I-bacteria
YM001	I-bacteria
on	O
Intestinal	O
Microbiota	O
of	O
Tilapia	O
Are	O
Recoverable	O
.	O

Previously	O
,	O
we	O
constructed	O
and	O
characterized	O
the	O
vaccine	O
efficacy	O
of	O
attenuated	O
S	B-bacteria
.	I-bacteria
agalactiae	I-bacteria
strain	I-bacteria
YM001	I-bacteria
in	O
tilapia	O
.	O

In	O
this	O
study	O
,	O
the	O
potential	O
impacts	O
of	O
YM001	B-bacteria
on	O
the	O
tilapia	O
intestinal	O
microbiota	O
were	O
assessed	O
by	O
qPCR	O
and	O
16S	O
rRNA	O
sequencing	O
methods	O
.	O

The	O
results	O
showed	O
that	O
YM001	B-bacteria
distributed	O
unevenly	O
in	O
different	O
parts	O
of	O
intestine	O
,	O
peaked	O
in	O
the	O
intestine	O
at	O
12	O
h	O
after	O
oral	O
administration	O
,	O
and	O
then	O
declined	O
gradually	O
.	O

YM001	B-bacteria
caused	O
0	O
%	O
mortality	O
of	O
fish	O
during	O
the	O
entire	O
experimental	O
period	O
,	O
while	O
the	O
referent	O
strain	O
HN016	B-bacteria
caused	O
100	O
%	O
mortality	O
at	O
3	O
d	O
after	O
oral	O
administration	O
.	O

However	O
,	O
the	O
intestinal	O
microbiota	O
could	O
be	O
changed	O
by	O
YM001	B-bacteria
,	O
the	O
diversity	O
of	O
intestinal	O
microbiota	O
decreased	O
first	O
and	O
gradually	O
recovered	O
after	O
oral	O
administration	O
.	O

The	O
diversity	O
of	O
intestinal	O
microbiota	O
of	O
tilapia	O
was	O
negatively	O
correlated	O
with	O
the	O
content	O
of	O
HN016	O
in	O
the	O
intestinal	O
tract	O
.	O

The	O
oral	O
YM001	B-bacteria
mainly	O
changed	O
the	O
abundance	O
of	O
Streptococcus	B-bacteria
,	O
Cetobacterium	B-bacteria
,	O
Akkermansia	B-bacteria
,	O
Romboutsia	B-bacteria
,	O
Bacteroides	B-bacteria
,	O
Brevinema	B-bacteria
,	O
Lachnospiraceae	B-bacteria
_	I-bacteria
NK4A136	I-bacteria
-	I-bacteria
group	I-bacteria
,	O
coprothermobactter	B-bacteria
,	O
presiomonas	B-bacteria
,	O
and	O
Roseburia	O
in	O
intestine	O
.	O

The	O
present	O
study	O
indicate	O
that	O
oral	O
administration	O
of	O
YM001	B-bacteria
altered	O
the	O
diversity	O
and	O
composition	O
of	O
intestinal	O
microbiota	O
in	O
tilapia	O
,	O
but	O
these	O
change	O
were	O
only	O
temporary	O
,	O
non	O
-	O
lethal	O
,	O
and	O
recoverable	O
.	O

The	O
results	O
provide	O
a	O
more	O
comprehensive	O
experimental	O
basis	O
for	O
the	O
safety	O
of	O
oral	O
YM001	B-bacteria
vaccines	O
.	O

A	O
Fungal	O
World	O
:	O
Could	O
the	O
Gut	O
Mycobiome	O
Be	O
Involved	O
in	O
Neurological	O
Disease	O
?	O

The	O
human	O
microbiome	O
has	O
received	O
decades	O
of	O
attention	O
from	O
scientific	O
and	O
medical	O
research	O
communities	O
.	O

The	O
human	O
gastrointestinal	O
tract	O
is	O
host	O
to	O
immense	O
populations	O
of	O
microorganisms	O
including	O
bacteria	O
,	O
viruses	O
,	O
archaea	O
,	O
and	O
fungi	O
(	O
the	O
gut	O
microbiota	O
)	O
.	O

High	O
-	O
throughput	O
sequencing	O
and	O
computational	O
advancements	O
provide	O
unprecedented	O
ability	O
to	O
investigate	O
the	O
structure	O
and	O
function	O
of	O
microbial	O
communities	O
associated	O
with	O
the	O
human	O
body	O
in	O
health	O
and	O
disease	O
.	O

Most	O
research	O
to	O
date	O
has	O
largely	O
focused	O
on	O
elucidating	O
the	O
bacterial	O
component	O
of	O
the	O
human	O
gut	O
microbiota	O
.	O

Study	O
of	O
the	O
gut	O
`	O
`	O
mycobiota	O
,	O
'	O
'	O
which	O
refers	O
to	O
the	O
diverse	O
array	O
of	O
fungal	O
species	O
,	O
is	O
a	O
relatively	O
new	O
and	O
rapidly	O
progressing	O
field	O
.	O

Though	O
omnipresent	O
,	O
the	O
number	O
and	O
abundance	O
of	O
fungi	O
occupying	O
the	O
human	O
gut	O
is	O
orders	O
of	O
magnitude	O
smaller	O
than	O
that	O
of	O
bacteria	O
.	O

Recent	O
insights	O
however	O
,	O
have	O
suggested	O
that	O
the	O
gut	O
mycobiota	O
may	O
be	O
intricately	O
linked	O
to	O
health	O
and	O
disease	O
.	O

Evaluation	O
of	O
the	O
gut	O
mycobiota	O
has	O
shown	O
that	O
not	O
only	O
are	O
the	O
fungal	O
communities	O
altered	O
in	O
disease	O
,	O
but	O
they	O
also	O
play	O
a	O
role	O
in	O
maintaining	O
intestinal	O
homeostasis	O
and	O
influencing	O
systemic	O
immunity	O
.	O

In	O
addition	O
,	O
it	O
is	O
now	O
widely	O
accepted	O
that	O
host	O
-	O
fungi	O
and	O
bacteria	O
-	O
fungi	O
associations	O
are	O
critical	O
to	O
host	O
health	O
.	O

While	O
research	O
of	O
the	O
gut	O
mycobiota	O
in	O
health	O
and	O
disease	O
is	O
on	O
the	O
rise	O
,	O
little	O
research	O
has	O
been	O
performed	O
in	O
the	O
context	O
of	O
neuroimmune	O
and	O
neurodegenerative	O
conditions	O
.	O

Gut	O
microbiota	O
dysbiosis	O
(	O
specifically	O
bacteria	O
and	O
archaea	O
)	O
have	O
been	O
reported	O
in	O
neurological	O
diseases	O
such	O
as	O
multiple	O
sclerosis	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
and	O
Alzheimer	O
'	O
s	O
,	O
among	O
others	O
.	O

Given	O
the	O
widely	O
accepted	O
bacteria	O
-	O
fungi	O
associations	O
and	O
paucity	O
of	O
mycobiota	O
-	O
specific	O
studies	O
in	O
neurological	O
disease	O
,	O
this	O
review	O
discusses	O
the	O
potential	O
role	O
fungi	O
may	O
play	O
in	O
multiple	O
sclerosis	O
and	O
other	O
neurological	O
diseases	O
.	O

Herein	O
,	O
we	O
provide	O
an	O
overview	O
of	O
recent	O
advances	O
in	O
gut	O
mycobiome	O
research	O
and	O
discuss	O
the	O
plausible	O
role	O
of	O
both	O
intestinal	O
and	O
non	O
-	O
intestinal	O
fungi	O
in	O
the	O
context	O
of	O
neuroimmune	O
and	O
neurodegenerative	O
conditions	O
.	O

Bovine	O
colostrum	O
-	O
driven	O
modulation	O
of	O
intestinal	O
epithelial	O
cells	O
for	O
increased	O
commensal	O
colonisation	O
.	O

Nutritional	O
intake	O
may	O
influence	O
the	O
intestinal	O
epithelial	O
glycome	O
and	O
in	O
turn	O
the	O
available	O
attachment	O
sites	O
for	O
bacteria	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
bovine	O
colostrum	O
may	O
influence	O
the	O
intestinal	O
cell	O
surface	O
and	O
in	O
turn	O
the	O
attachment	O
of	O
commensal	O
organisms	O
.	O

Human	O
HT	O
-	O
29	O
intestinal	O
cells	O
were	O
exposed	O
to	O
a	O
bovine	O
colostrum	O
fraction	O
(	O
BCF	O
)	O
rich	O
in	O
free	O
oligosaccharides	O
.	O

The	O
adherence	O
of	O
several	O
commensal	O
bacteria	O
,	O
comprising	O
mainly	O
bifidobacteria	B-bacteria
,	O
to	O
the	O
intestinal	O
cells	O
was	O
significantly	O
enhanced	O
(	O
up	O
to	O
52	O
-	O
fold	O
)	O
for	O
all	O
strains	O
tested	O
which	O
spanned	O
species	O
that	O
are	O
found	O
across	O
the	O
human	O
lifespan	O
.	O

Importantly	O
,	O
the	O
changes	O
to	O
the	O
HT	O
-	O
29	O
cell	O
surface	O
did	O
not	O
support	O
enhanced	O
adhesion	O
of	O
the	O
enteric	O
pathogens	O
tested	O
.	O

The	O
gene	O
expression	O
profile	O
of	O
the	O
HT	O
-	O
29	O
cells	O
following	O
treatment	O
with	O
the	O
BCF	O
was	O
evaluated	O
by	O
microarray	O
analysis	O
.	O

Many	O
so	O
called	O
`	O
`	O
glyco	O
-	O
genes	O
'	O
'	O
(	O
glycosyltransferases	O
and	O
genes	O
involved	O
in	O
the	O
complex	O
biosynthetic	O
pathways	O
of	O
glycans	O
)	O
were	O
found	O
to	O
be	O
differentially	O
regulated	O
suggesting	O
modulation	O
of	O
the	O
enzymatic	O
addition	O
of	O
sugars	O
to	O
glycoconjugate	O
proteins	O
.	O

The	O
microarray	O
data	O
was	O
further	O
validated	O
by	O
means	O
of	O
real	O
-	O
time	O
PCR	O
.	O

The	O
current	O
findings	O
provide	O
an	O
insight	O
into	O
how	O
commensal	O
microorganisms	O
colonise	O
the	O
human	O
gut	O
and	O
highlight	O
the	O
potential	O
of	O
colostrum	O
and	O
milk	O
components	O
as	O
functional	O
ingredients	O
that	O
can	O
potentially	O
increase	O
commensal	O
numbers	O
in	O
individuals	O
with	O
lower	O
counts	O
of	O
health	O
-	O
promoting	O
bacteria	O
.	O

Gut	O
permeability	O
and	O
mimicry	O
of	O
the	O
Glutamate	O
Ionotropic	O
Receptor	O
NMDA	O
type	O
Subunit	O
Associated	O
with	O
protein	O
1	O
(	O
GRINA	O
)	O
as	O
potential	O
mechanisms	O
related	O
to	O
a	O
subgroup	O
of	O
people	O
with	O
schizophrenia	O
with	O
elevated	O
antigliadin	O
antibodies	O
(	O
AGA	O
IgG	O
)	O
.	O

About	O
one	O
third	O
of	O
people	O
with	O
schizophrenia	O
have	O
elevated	O
IgG	O
antibodies	O
to	O
gliadin	O
(	O
AGA	O
IgG	O
)	O
and	O
increased	O
inflammation	O
.	O

Understanding	O
the	O
mechanism	O
by	O
which	O
this	O
immune	O
response	O
occurs	O
is	O
critical	O
to	O
the	O
development	O
of	O
personalized	O
treatments	O
.	O

We	O
examined	O
gut	O
permeability	O
and	O
mimicry	O
to	O
the	O
glutamate	O
receptor	O
as	O
possible	O
mechanisms	O
related	O
to	O
high	O
gliadin	O
antibodies	O
(	O
AGA	O
IgG	O
)	O
seen	O
in	O
some	O
people	O
with	O
schizophrenia	O
.	O

The	O
Glutamate	O
Ionotropic	O
Receptor	O
NMDA	O
type	O
Subunit	O
Associated	O
with	O
protein	O
1	O
(	O
GRINA	O
)	O
has	O
a	O
similar	O
protein	O
structure	O
to	O
gliadin	O
representing	O
a	O
potential	O
target	O
for	O
cross	O
reactivity	O
or	O
mimicry	O
.	O

In	O
a	O
population	O
of	O
schizophrenia	O
subjects	O
(	O
N	O
=	O
160	O
)	O
and	O
healthy	O
controls	O
(	O
N	O
=	O
80	O
)	O
we	O
analyzed	O
serum	O
samples	O
for	O
both	O
GRINA	O
and	O
Anti	O
-	O
Saccharomyces	O
Cerevisiae	O
antibodies	O
(	O
ASCA	O
)	O
,	O
related	O
to	O
gut	O
permeability	O
.	O

Schizophrenia	O
patients	O
compared	O
to	O
controls	O
had	O
a	O
higher	O
prevalence	O
of	O
positivity	O
to	O
ASCA	O
IgA	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
and	O
IgG	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Multinomial	O
logistic	O
regression	O
showed	O
an	O
association	O
between	O
AGA	O
IgG	O
and	O
ASCA	O
IgG	O
in	O
schizophrenia	O
(	O
p	O
=	O
0	O
.	O
05	O
for	O
the	O
estimated	O
regression	O
coefficient	O
)	O
but	O
not	O
in	O
healthy	O
controls	O
(	O
p	O
=	O
0	O
.	O
13	O
)	O
.	O

GRINA	O
IgG	O
was	O
higher	O
in	O
schizophrenia	O
patients	O
than	O
in	O
healthy	O
controls	O
(	O
0	O
.	O
43	O
+	O
/	O
-	O
0	O
.	O
30	O
vs	O
.	O
0	O
.	O
22	O
+	O
/	O
-	O
0	O
.	O
24	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Logistic	O
regressions	O
showed	O
an	O
association	O
between	O
AGA	O
IgG	O
and	O
GRINA	O
IgG	O
in	O
schizophrenia	O
(	O
p	O
=	O
0	O
.	O
016	O
for	O
the	O
estimated	O
regression	O
coefficient	O
)	O
but	O
not	O
for	O
the	O
controls	O
(	O
p	O
=	O
0	O
.	O
471	O
)	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
mimicry	O
through	O
the	O
presence	O
of	O
cross	O
-	O
reactivity	O
between	O
gliadin	O
and	O
GRINA	O
might	O
disrupt	O
the	O
functions	O
of	O
the	O
glutamate	O
system	O
and	O
relate	O
to	O
illness	O
pathophysiology	O
in	O
those	O
with	O
schizophrenia	O
and	O
elevated	O
AGA	O
IgG	O
.	O

Among	O
older	O
adults	O
,	O
age	O
-	O
related	O
changes	O
in	O
the	O
stool	O
microbiome	O
differ	O
by	O
HIV	O
-	O
1	O
serostatus	O
.	O

BACKGROUND	O
:	O
HIV	O
-	O
1	O
infection	O
and	O
physiological	O
aging	O
are	O
independently	O
linked	O
to	O
elevated	O
systemic	O
inflammation	O
and	O
changes	O
in	O
enteric	O
microbial	O
communities	O
(	O
dysbiosis	O
)	O
.	O

However	O
,	O
knowledge	O
of	O
the	O
direct	O
effect	O
of	O
HIV	O
infection	O
on	O
the	O
aging	O
microbiome	O
and	O
potential	O
links	O
to	O
systemic	O
inflammation	O
is	O
lacking	O
.	O

METHODS	O
:	O
In	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
older	O
people	O
living	O
with	O
HIV	O
(	O
PLWH	O
)	O
(	O
median	O
age	O
61	O
.	O
5years	O
,	O
N	O
=	O
14	O
)	O
and	O
uninfected	O
controls	O
(	O
median	O
58years	O
,	O
n	O
=	O
22	O
)	O
we	O
compared	O
stool	O
microbiota	O
,	O
levels	O
of	O
microbial	O
metabolites	O
(	O
short	O
-	O
chain	O
fatty	O
acid	O
levels	O
,	O
SCFA	O
)	O
and	O
systemic	O
inflammatory	O
biomarkers	O
by	O
HIV	O
serostatus	O
and	O
age	O
.	O

FINDINGS	O
:	O
HIV	O
and	O
age	O
were	O
independently	O
associated	O
with	O
distinct	O
changes	O
in	O
the	O
stool	O
microbiome	O
.	O

For	O
example	O
,	O
abundances	O
of	O
Enterobacter	B-bacteria
and	O
Paraprevotella	B-bacteria
were	O
higher	O
and	O
Eggerthella	B-bacteria
and	O
Roseburia	B-bacteria
lower	O
among	O
PLWH	O
compared	O
to	O
uninfected	O
controls	O
.	O

Age	O
-	O
related	O
microbiome	O
changes	O
also	O
differed	O
by	O
HIV	O
serostatus	O
.	O

Some	O
bacteria	O
with	O
inflammatory	O
potential	O
(	O
e	O
.	O
g	O
.	O
Escherichia	B-bacteria
)	O
increased	O
with	O
age	O
among	O
PLWH	O
,	O
but	O
not	O
controls	O
.	O

Stool	O
SCFA	O
levels	O
were	O
similar	O
between	O
the	O
two	O
groups	O
yet	O
patterns	O
of	O
associations	O
between	O
individual	O
microbial	O
taxa	O
and	O
SCFA	O
levels	O
differed	O
.	O

Abundance	O
of	O
various	O
genera	O
including	O
Escherichia	B-bacteria
and	O
Bifidobacterium	B-bacteria
positively	O
associated	O
with	O
inflammatory	O
biomarkers	O
(	O
e	O
.	O
g	O
.	O
soluble	O
Tumor	O
Necrosis	O
Factor	O
Receptors	O
)	O
among	O
PLWH	O
,	O
but	O
not	O
among	O
controls	O
.	O

INTERPRETATION	O
:	O
The	O
age	O
effect	O
on	O
the	O
gut	O
microbiome	O
and	O
associations	O
between	O
microbiota	O
and	O
microbial	O
metabolites	O
or	O
systemic	O
inflammation	O
differed	O
based	O
on	O
HIV	O
serostatus	O
,	O
raising	O
important	O
implications	O
for	O
the	O
impact	O
of	O
therapeutic	O
interventions	O
,	O
dependent	O
on	O
HIV	O
serostatus	O
or	O
age	O
.	O

The	O
Microbiome	O
-	O
Host	O
Interaction	O
as	O
a	O
Potential	O
Driver	O
of	O
Anastomotic	O
Leak	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
The	O
goal	O
of	O
this	O
paper	O
is	O
to	O
review	O
current	O
literature	O
on	O
the	O
gut	O
microbiome	O
within	O
the	O
context	O
of	O
host	O
response	O
to	O
surgery	O
and	O
subsequent	O
risk	O
of	O
developing	O
complications	O
,	O
particularly	O
anastomotic	O
leak	O
.	O

We	O
provide	O
background	O
on	O
the	O
relationship	O
between	O
host	O
and	O
gut	O
microbiota	O
with	O
description	O
of	O
the	O
role	O
of	O
the	O
intestinal	O
mucus	O
layer	O
as	O
an	O
important	O
regulator	O
of	O
host	O
health	O
.	O

RECENT	O
FINDINGS	O
:	O
Despite	O
improvements	O
in	O
surgical	O
technique	O
and	O
adherence	O
to	O
the	O
tenets	O
of	O
creating	O
a	O
tension	O
-	O
free	O
anastomosis	O
with	O
adequate	O
blood	O
flow	O
,	O
the	O
surgical	O
community	O
has	O
been	O
unable	O
to	O
decrease	O
rates	O
of	O
anastomotic	O
leak	O
using	O
the	O
current	O
paradigm	O
.	O

Rather	O
than	O
adhere	O
to	O
empirical	O
strategies	O
of	O
decontamination	O
,	O
it	O
is	O
imperative	O
to	O
focus	O
on	O
the	O
interaction	O
between	O
the	O
human	O
host	O
and	O
the	O
gut	O
microbiota	O
that	O
live	O
within	O
us	O
.	O

The	O
gut	O
microbiome	O
has	O
been	O
found	O
to	O
play	O
a	O
potential	O
role	O
in	O
development	O
of	O
post	O
-	O
operative	O
complications	O
,	O
including	O
but	O
not	O
limited	O
to	O
anastomotic	O
leak	O
.	O

Evidence	O
suggests	O
that	O
peri	O
-	O
operative	O
interventions	O
may	O
have	O
a	O
role	O
in	O
instigating	O
or	O
mitigating	O
the	O
impact	O
of	O
the	O
gut	O
microbiota	O
via	O
disruption	O
of	O
the	O
protective	O
mucus	O
layer	O
,	O
use	O
of	O
multiple	O
medications	O
,	O
and	O
activation	O
of	O
virulence	O
factors	O
.	O

The	O
microbiome	O
plays	O
a	O
potential	O
role	O
in	O
the	O
development	O
of	O
surgical	O
complications	O
and	O
can	O
be	O
modulated	O
by	O
peri	O
-	O
operative	O
interventions	O
.	O

As	O
such	O
,	O
further	O
research	O
into	O
this	O
relationship	O
is	O
urgently	O
needed	O
.	O

The	O
links	O
between	O
the	O
gut	O
microbiome	O
and	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
.	O

NAFLD	O
is	O
currently	O
the	O
main	O
cause	O
of	O
chronic	O
liver	O
disease	O
in	O
developed	O
countries	O
,	O
and	O
the	O
number	O
of	O
NAFLD	O
patients	O
is	O
growing	O
worldwide	O
.	O

NAFLD	O
often	O
has	O
similar	O
symptoms	O
to	O
other	O
metabolic	O
disorders	O
,	O
including	O
type	O
2	O
diabetes	O
and	O
obesity	O
.	O

Recently	O
,	O
the	O
role	O
of	O
the	O
gut	O
microbiota	O
in	O
the	O
pathophysiology	O
of	O
many	O
diseases	O
has	O
been	O
revealed	O
.	O

Regarding	O
NAFLD	O
,	O
experiments	O
using	O
gut	O
microbiota	O
transplants	O
to	O
germ	O
-	O
free	O
animal	O
models	O
showed	O
that	O
fatty	O
liver	O
disease	O
development	O
is	O
determined	O
by	O
gut	O
bacteria	O
.	O

Moreover	O
,	O
the	O
perturbation	O
of	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
has	O
been	O
observed	O
in	O
patients	O
suffering	O
from	O
NAFLD	O
.	O

Numerous	O
mechanisms	O
relating	O
the	O
gut	O
microbiome	O
to	O
NAFLD	O
have	O
been	O
proposed	O
,	O
including	O
the	O
dysbiosis	O
-	O
induced	O
dysregulation	O
of	O
gut	O
endothelial	O
barrier	O
function	O
that	O
allows	O
for	O
the	O
translocation	O
of	O
bacterial	O
components	O
and	O
leads	O
to	O
hepatic	O
inflammation	O
.	O

In	O
addition	O
,	O
the	O
various	O
metabolites	O
produced	O
by	O
the	O
gut	O
microbiota	O
may	O
impact	O
the	O
liver	O
and	O
thus	O
modulate	O
NAFLD	O
susceptibility	O
.	O

Therefore	O
,	O
the	O
manipulation	O
of	O
the	O
gut	O
microbiome	O
by	O
probiotics	O
,	O
prebiotics	O
or	O
synbiotics	O
was	O
shown	O
to	O
improve	O
liver	O
phenotype	O
in	O
NAFLD	O
patients	O
as	O
well	O
as	O
in	O
rodent	O
models	O
.	O

Hence	O
,	O
further	O
knowledge	O
about	O
the	O
interactions	O
among	O
dysbiosis	O
,	O
environmental	O
factors	O
,	O
and	O
diet	O
and	O
their	O
impacts	O
on	O
the	O
gut	O
-	O
liver	O
axis	O
can	O
improve	O
the	O
treatment	O
of	O
this	O
life	O
-	O
threatening	O
liver	O
disease	O
and	O
its	O
related	O
disorders	O
.	O

A	O
gut	O
punch	O
fights	O
cancer	O
and	O
infection	O
.	O

T6SS	O
contributes	O
to	O
gut	O
microbiome	O
invasion	O
and	O
killing	O
of	O
an	O
herbivorous	O
pest	O
insect	O
by	O
plant	O
-	O
beneficial	O
Pseudomonas	B-bacteria
protegens	I-bacteria
.	O

Pseudomonas	B-bacteria
protegens	I-bacteria
are	O
multi	O
-	O
talented	O
plant	O
-	O
colonizing	O
bacteria	O
that	O
suppress	O
plant	O
pathogens	O
and	O
stimulate	O
plant	O
defenses	O
.	O

In	O
addition	O
,	O
they	O
are	O
capable	O
of	O
invading	O
and	O
killing	O
agriculturally	O
important	O
plant	O
pest	O
insects	O
that	O
makes	O
them	O
promising	O
candidates	O
for	O
biocontrol	O
applications	O
.	O

Here	O
we	O
assessed	O
the	O
role	O
of	O
type	O
VI	O
secretion	O
system	O
(	O
T6SS	O
)	O
components	O
of	O
type	O
strain	O
CHA0	B-bacteria
during	O
interaction	O
with	O
larvae	O
of	O
the	O
cabbage	O
pest	O
Pieris	O
brassicae	O
.	O

We	O
show	O
that	O
the	O
T6SS	O
core	O
apparatus	O
and	O
two	O
VgrG	O
modules	O
,	O
encompassing	O
the	O
respective	O
T6SS	O
spikes	O
(	O
VgrG1a	O
and	O
VgrG1b	O
)	O
and	O
associated	O
effectors	O
(	O
RhsA	O
and	O
Ghh1	O
)	O
,	O
contribute	O
significantly	O
to	O
insect	O
pathogenicity	O
of	O
P	B-bacteria
.	I-bacteria
protegens	I-bacteria
in	O
oral	O
infection	O
assays	O
but	O
not	O
when	O
bacteria	O
are	O
injected	O
directly	O
into	O
the	O
hemolymph	O
.	O

Monitoring	O
of	O
the	O
colonization	O
levels	O
of	O
P	B-bacteria
.	I-bacteria
protegens	I-bacteria
in	O
the	O
gut	O
,	O
hemolymph	O
,	O
and	O
excrements	O
of	O
the	O
insect	O
larvae	O
revealed	O
that	O
the	O
invader	O
relies	O
on	O
T6SS	O
and	O
VgrG1a	O
module	O
function	O
to	O
promote	O
hemocoel	O
invasion	O
.	O

A	O
16S	O
metagenomic	O
analysis	O
demonstrated	O
that	O
T6SS	O
-	O
supported	O
invasion	O
by	O
P	B-bacteria
.	I-bacteria
protegens	I-bacteria
induces	O
significant	O
changes	O
in	O
the	O
insect	O
gut	O
microbiome	O
affecting	O
notably	O
Enterobacteriaceae	B-bacteria
,	O
a	O
dominant	O
group	O
of	O
the	O
commensal	O
gut	O
bacteria	O
.	O

Our	O
study	O
supports	O
the	O
concept	O
that	O
pathogens	O
deploy	O
T6SS	O
-	O
based	O
strategies	O
to	O
disrupt	O
the	O
commensal	O
microbiota	O
in	O
order	O
to	O
promote	O
host	O
colonization	O
and	O
pathogenesis	O
.	O

Genomic	O
diversity	O
landscape	O
of	O
the	O
honey	O
bee	O
gut	O
microbiota	O
.	O

The	O
structure	O
and	O
distribution	O
of	O
genomic	O
diversity	O
in	O
natural	O
microbial	O
communities	O
is	O
largely	O
unexplored	O
.	O

Here	O
,	O
we	O
used	O
shotgun	O
metagenomics	O
to	O
assess	O
the	O
diversity	O
of	O
the	O
honey	O
bee	O
gut	O
microbiota	O
,	O
a	O
community	O
consisting	O
of	O
few	O
bacterial	O
phylotypes	O
.	O

Our	O
results	O
show	O
that	O
most	O
phylotypes	O
are	O
composed	O
of	O
sequence	O
-	O
discrete	O
populations	O
,	O
which	O
co	O
-	O
exist	O
in	O
individual	O
bees	O
and	O
show	O
age	O
-	O
specific	O
abundance	O
profiles	O
.	O

In	O
contrast	O
,	O
strains	O
present	O
within	O
these	O
sequence	O
-	O
discrete	O
populations	O
were	O
found	O
to	O
segregate	O
into	O
individual	O
bees	O
.	O

Consequently	O
,	O
despite	O
a	O
conserved	O
phylotype	O
composition	O
,	O
each	O
honey	O
bee	O
harbors	O
a	O
distinct	O
community	O
at	O
the	O
functional	O
level	O
.	O

While	O
ecological	O
differentiation	O
seems	O
to	O
facilitate	O
coexistence	O
at	O
higher	O
taxonomic	O
levels	O
,	O
our	O
findings	O
suggest	O
that	O
,	O
at	O
the	O
level	O
of	O
strains	O
,	O
priority	O
effects	O
during	O
community	O
assembly	O
result	O
in	O
individualized	O
profiles	O
,	O
despite	O
the	O
social	O
lifestyle	O
of	O
the	O
host	O
.	O

Our	O
study	O
underscores	O
the	O
need	O
to	O
move	O
beyond	O
phylotype	O
-	O
level	O
characterizations	O
to	O
understand	O
the	O
function	O
of	O
this	O
community	O
,	O
and	O
illustrates	O
its	O
potential	O
for	O
strain	O
-	O
level	O
analysis	O
.	O

Bifidobacterium	B-bacteria
bifidum	I-bacteria
ATCC	I-bacteria
15696	I-bacteria
and	O
Bifidobacterium	B-bacteria
breve	I-bacteria
24b	I-bacteria
Metabolic	O
Interaction	O
Based	O
on	O
2	O
'	O
-	O
O	O
-	O
Fucosyl	O
-	O
Lactose	O
Studied	O
in	O
Steady	O
-	O
State	O
Cultures	O
in	O
a	O
Freter	O
-	O
Style	O
Chemostat	O
.	O

Infants	O
fed	O
breast	O
milk	O
harbor	O
a	O
gut	O
microbiota	O
in	O
which	O
bifidobacteria	B-bacteria
are	O
generally	O
predominant	O
.	O

The	O
metabolic	O
interactions	O
of	O
bifidobacterial	B-bacteria
species	I-bacteria
need	O
investigation	O
because	O
they	O
may	O
offer	O
insight	O
into	O
the	O
colonization	O
of	O
the	O
gut	O
in	O
early	O
life	O
.	O

Bifidobacterium	B-bacteria
bifidum	I-bacteria
ATCC	I-bacteria
15696	I-bacteria
hydrolyzes	O
2	O
'	O
-	O
O	O
-	O
fucosyl	O
-	O
lactose	O
(	O
2FL	O
;	O
a	O
major	O
fucosylated	O
human	O
milk	O
oligosaccharide	O
)	O
but	O
does	O
not	O
use	O
fucose	O
released	O
into	O
the	O
culture	O
medium	O
.	O

However	O
,	O
fucose	O
is	O
a	O
growth	O
substrate	O
for	O
Bifidobacterium	B-bacteria
breve	I-bacteria
24b	I-bacteria
,	O
and	O
both	O
strains	O
utilize	O
lactose	O
for	O
growth	O
.	O

The	O
provision	O
of	O
fucose	O
and	O
lactose	O
by	O
B	B-bacteria
.	I-bacteria
bifidum	I-bacteria
(	O
the	O
donor	O
)	O
allowing	O
the	O
growth	O
of	O
B	B-bacteria
.	I-bacteria
breve	I-bacteria
(	O
the	O
beneficiary	O
)	O
conforms	O
to	O
the	O
concept	O
of	O
syntrophy	O
,	O
but	O
both	O
strains	O
will	O
compete	O
for	O
lactose	O
to	O
multiply	O
.	O

To	O
determine	O
the	O
metabolic	O
impact	O
of	O
this	O
syntrophic	O
/	O
competitive	O
relationship	O
on	O
the	O
donor	O
,	O
the	O
transcriptomes	O
of	O
B	B-bacteria
.	I-bacteria
bifidum	I-bacteria
were	O
determined	O
and	O
compared	O
in	O
steady	O
-	O
state	O
monoculture	O
and	O
coculture	O
using	O
transcriptome	O
sequencing	O
(	O
RNA	O
-	O
seq	O
)	O
and	O
reverse	O
transcription	O
-	O
quantitative	O
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
.	O

B	B-bacteria
.	I-bacteria
bifidum	I-bacteria
genes	O
upregulated	O
in	O
coculture	O
included	O
those	O
encoding	O
alpha	O
-	O
l	O
-	O
fucosidase	O
and	O
carbohydrate	O
transporters	O
and	O
those	O
involved	O
in	O
energy	O
production	O
and	O
conversion	O
.	O

B	B-bacteria
.	I-bacteria
bifidum	I-bacteria
abundance	O
was	O
the	O
same	O
in	O
coculture	O
as	O
in	O
monoculture	O
,	O
but	O
B	B-bacteria
.	I-bacteria
breve	I-bacteria
dominated	O
the	O
coculture	O
numerically	O
.	O

Cocultures	O
during	O
steady	O
-	O
state	O
growth	O
in	O
2FL	O
medium	O
produced	O
mostly	O
acetate	O
with	O
little	O
lactate	O
(	O
acetate	O
:	O
lactate	O
molar	O
ratio	O
,	O
8	O
:	O
1	O
)	O
compared	O
to	O
that	O
in	O
monobatch	O
cultures	O
containing	O
lactose	O
(	O
2	O
:	O
1	O
)	O
,	O
which	O
reflected	O
the	O
maintenance	O
of	O
steady	O
-	O
state	O
cells	O
in	O
log	O
-	O
phase	O
growth	O
.	O

Darwinian	O
competition	O
is	O
an	O
implicit	O
feature	O
of	O
bacterial	O
communities	O
,	O
but	O
syntrophy	O
is	O
a	O
phenomenon	O
putatively	O
based	O
on	O
cooperation	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
regulation	O
of	O
syntrophy	O
,	O
in	O
addition	O
to	O
competition	O
,	O
may	O
shape	O
bacterial	O
communities	O
.	O
IMPORTANCE	O
This	O
study	O
addresses	O
the	O
microbiology	O
and	O
function	O
of	O
a	O
natural	O
ecosystem	O
(	O
the	O
infant	O
bowel	O
)	O
using	O
in	O
vitro	O
experimentation	O
with	O
bacterial	O
cultures	O
maintained	O
under	O
controlled	O
growth	O
and	O
environmental	O
conditions	O
.	O

We	O
studied	O
the	O
growth	O
of	O
bifidobacteria	B-bacteria
whose	O
nutrition	O
centered	O
on	O
the	O
hydrolysis	O
of	O
a	O
human	O
milk	O
oligosaccharide	O
.	O

The	O
results	O
revealed	O
responses	O
relating	O
to	O
metabolism	O
occurring	O
in	O
a	O
Bifidobacterium	B-bacteria
bifidum	I-bacteria
strain	I-bacteria
when	O
it	O
provided	O
nutrients	O
that	O
allowed	O
the	O
growth	O
of	O
Bifidobacterium	B-bacteria
breve	I-bacteria
,	O
and	O
so	O
discovered	O
biochemical	O
features	O
of	O
these	O
bifidobacteria	B-bacteria
in	O
relation	O
to	O
metabolic	O
interaction	O
in	O
the	O
shared	O
environment	O
.	O

These	O
kinds	O
of	O
experiments	O
are	O
essential	O
in	O
developing	O
concepts	O
of	O
bifidobacterial	O
ecology	O
that	O
relate	O
to	O
the	O
development	O
of	O
the	O
gut	O
microbiota	O
in	O
early	O
life	O
.	O

Host	O
-	O
Specific	O
Adaptive	O
Diversification	O
of	O
Crohn	O
'	O
s	O
Disease	O
-	O
Associated	O
Adherent	O
-	O
Invasive	O
Escherichia	B-bacteria
coli	I-bacteria
.	O

Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
is	O
an	O
inflammatory	O
bowel	O
disease	O
influenced	O
by	O
bacteria	O
.	O

Adherent	B-bacteria
-	I-bacteria
invasive	I-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
(	O
AIEC	B-bacteria
)	O
is	O
associated	O
with	O
CD	O
,	O
yet	O
the	O
adaptations	O
facilitating	O
AIEC	B-bacteria
gut	O
colonization	O
are	O
unknown	O
.	O

AIEC	B-bacteria
isolates	I-bacteria
exhibit	O
high	O
genetic	O
diversity	O
,	O
suggesting	O
strains	O
evolve	O
independently	O
across	O
different	O
gut	O
environments	O
.	O

We	O
tracked	O
the	O
adaptive	O
evolution	O
of	O
AIEC	O
in	O
a	O
murine	O
model	O
of	O
chronic	O
colonization	O
across	O
multiple	O
hosts	O
and	O
transmission	O
events	O
.	O

We	O
detected	O
evolved	O
lineages	O
that	O
outcompeted	O
the	O
ancestral	O
strain	O
in	O
the	O
host	O
through	O
independent	O
mechanisms	O
.	O

One	O
lineage	O
was	O
hypermotile	O
because	O
of	O
a	O
mobile	O
insertion	O
sequence	O
upstream	O
of	O
the	O
master	O
flagellar	O
regulator	O
,	O
flhDC	O
,	O
which	O
enhanced	O
AIEC	O
invasion	O
and	O
establishment	O
of	O
a	O
mucosal	O
niche	O
.	O

Another	O
lineage	O
outcompeted	O
the	O
ancestral	O
strain	O
through	O
improved	O
use	O
of	O
acetate	O
,	O
a	O
short	O
-	O
chain	O
fatty	O
acid	O
in	O
the	O
gut	O
.	O

The	O
presence	O
of	O
hypermotile	O
and	O
acetate	O
-	O
consuming	O
lineages	O
discriminated	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
isolated	O
from	O
CD	O
patients	O
from	O
healthy	O
controls	O
,	O
suggesting	O
an	O
evolutionary	O
trajectory	O
that	O
distinguishes	O
AIEC	B-bacteria
from	O
commensal	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
.	O

Antibiotic	O
treatment	O
triggers	O
gut	O
dysbiosis	O
and	O
modulates	O
metabolism	O
in	O
a	O
chicken	O
model	O
of	O
gastro	O
-	O
intestinal	O
infection	O
.	O

BACKGROUND	O
:	O
Infection	O
of	O
the	O
digestive	O
track	O
by	O
gastro	O
-	O
intestinal	O
pathogens	O
results	O
in	O
the	O
development	O
of	O
symptoms	O
ranging	O
from	O
mild	O
diarrhea	O
to	O
more	O
severe	O
clinical	O
signs	O
such	O
as	O
dysentery	O
,	O
severe	O
dehydration	O
and	O
potentially	O
death	O
.	O

Although	O
,	O
antibiotics	O
are	O
efficient	O
to	O
tackle	O
infections	O
,	O
they	O
also	O
trigger	O
dysbiosis	O
that	O
has	O
been	O
suggested	O
to	O
result	O
in	O
variation	O
in	O
weight	O
gain	O
in	O
animal	O
production	O
systems	O
.	O

RESULTS	O
:	O
Here	O
is	O
the	O
first	O
study	O
demonstrating	O
the	O
metabolic	O
impact	O
of	O
infection	O
by	O
a	O
gastro	O
-	O
intestinal	O
pathogen	O
(	O
Brachyspira	B-bacteria
pilosicoli	I-bacteria
)	O
and	O
its	O
resolution	O
by	O
antibiotic	O
treatment	O
(	O
tiamulin	O
)	O
on	O
the	O
host	O
(	O
chicken	O
)	O
systemic	O
metabolism	O
and	O
gut	O
microbiota	O
composition	O
using	O
high	O
-	O
resolution	O
(	O
1	O
)	O
H	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectroscopy	O
and	O
16S	O
rDNA	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
.	O

Clear	O
systemic	O
metabolic	O
markers	O
of	O
infections	O
such	O
as	O
glycerol	O
and	O
betaine	O
were	O
identified	O
.	O

Weight	O
loss	O
in	O
untreated	O
animals	O
was	O
in	O
part	O
explained	O
by	O
the	O
observation	O
of	O
a	O
modification	O
of	O
systemic	O
host	O
energy	O
metabolism	O
characterized	O
by	O
the	O
utilization	O
of	O
glycerol	O
as	O
a	O
glucose	O
precursor	O
.	O

However	O
,	O
antibiotic	O
treatment	O
triggered	O
an	O
increased	O
VLDL	O
/	O
HDL	O
ratio	O
in	O
plasma	O
that	O
may	O
contribute	O
to	O
reducing	O
weight	O
loss	O
observed	O
in	O
treated	O
birds	O
.	O

All	O
metabolic	O
responses	O
co	O
-	O
occurred	O
with	O
significant	O
shift	O
of	O
the	O
microbiota	O
upon	O
infection	O
or	O
antibiotic	O
treatment	O
.	O

CONCLUSION	O
:	O
This	O
study	O
indicates	O
that	O
infection	O
and	O
antibiotic	O
treatment	O
trigger	O
dysbiosis	O
that	O
may	O
impact	O
host	O
systemic	O
energy	O
metabolism	O
and	O
cause	O
phenotypic	O
and	O
health	O
modifications	O
.	O

The	O
Effects	O
of	O
Dietary	O
Pattern	O
during	O
Intensified	O
Training	O
on	O
Stool	O
Microbiota	O
of	O
Elite	O
Race	O
Walkers	O
.	O

We	O
investigated	O
extreme	O
changes	O
in	O
diet	O
patterns	O
on	O
the	O
gut	O
microbiota	O
of	O
elite	O
race	O
walkers	O
undertaking	O
intensified	O
training	O
and	O
its	O
possible	O
links	O
with	O
athlete	O
performance	O
.	O

Numerous	O
studies	O
with	O
sedentary	O
subjects	O
have	O
shown	O
that	O
diet	O
and	O
/	O
or	O
exercise	O
can	O
exert	O
strong	O
selective	O
pressures	O
on	O
the	O
gut	O
microbiota	O
.	O

Similar	O
studies	O
with	O
elite	O
athletes	O
are	O
relatively	O
scant	O
,	O
despite	O
the	O
recognition	O
that	O
diet	O
is	O
an	O
important	O
contributor	O
to	O
sports	O
performance	O
.	O

In	O
this	O
study	O
,	O
stool	O
samples	O
were	O
collected	O
from	O
the	O
cohort	O
at	O
the	O
beginning	O
(	O
baseline	O
;	O
BL	O
)	O
and	O
end	O
(	O
post	O
-	O
treatment	O
;	O
PT	O
)	O
of	O
a	O
three	O
-	O
week	O
intensified	O
training	O
program	O
during	O
which	O
athletes	O
were	O
assigned	O
to	O
a	O
High	O
Carbohydrate	O
(	O
HCHO	O
)	O
,	O
Periodised	O
Carbohydrate	O
(	O
PCHO	O
)	O
or	O
ketogenic	O
Low	O
Carbohydrate	O
High	O
Fat	O
(	O
LCHF	O
)	O
diet	O
(	O
post	O
treatment	O
)	O
.	O

Microbial	O
community	O
profiles	O
were	O
determined	O
by	O
16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
.	O

The	O
microbiota	O
profiles	O
at	O
BL	O
could	O
be	O
separated	O
into	O
distinct	O
`	O
`	O
enterotypes	O
,	O
'	O
'	O
with	O
either	O
a	O
Prevotella	B-bacteria
or	O
Bacteroides	B-bacteria
dominated	O
enterotype	O
.	O

While	O
enterotypes	O
were	O
relatively	O
stable	O
and	O
remained	O
evident	O
post	O
treatment	O
,	O
the	O
LCHF	O
diet	O
resulted	O
in	O
a	O
greater	O
relative	O
abundance	O
of	O
Bacteroides	B-bacteria
and	O
Dorea	B-bacteria
and	O
a	O
reduction	O
of	O
Faecalibacterium	B-bacteria
.	O

Significant	O
negative	O
correlations	O
were	O
observed	O
between	O
Bacteroides	B-bacteria
and	O
fat	O
oxidation	O
and	O
between	O
Dorea	O
and	O
economy	O
test	O
following	O
LCHF	O
intervention	O
.	O

The	O
Interplay	O
between	O
Immunity	O
and	O
Microbiota	O
at	O
Intestinal	O
Immunological	O
Niche	O
:	O
The	O
Case	O
of	O
Cancer	O
.	O

The	O
gut	O
microbiota	O
is	O
central	O
to	O
the	O
pathogenesis	O
of	O
several	O
inflammatory	O
and	O
autoimmune	O
diseases	O
.	O

While	O
multiple	O
mechanisms	O
are	O
involved	O
,	O
the	O
immune	O
system	O
clearly	O
plays	O
a	O
special	O
role	O
.	O

Indeed	O
,	O
the	O
breakdown	O
of	O
the	O
physiological	O
balance	O
in	O
gut	O
microbial	O
composition	O
leads	O
to	O
dysbiosis	O
,	O
which	O
is	O
then	O
able	O
to	O
enhance	O
inflammation	O
and	O
to	O
influence	O
gene	O
expression	O
.	O

At	O
the	O
same	O
time	O
,	O
there	O
is	O
an	O
intense	O
cross	O
-	O
talk	O
between	O
the	O
microbiota	O
and	O
the	O
immunological	O
niche	O
in	O
the	O
intestinal	O
mucosa	O
.	O

These	O
interactions	O
may	O
pave	O
the	O
way	O
to	O
the	O
development	O
,	O
growth	O
and	O
spreading	O
of	O
cancer	O
,	O
especially	O
in	O
the	O
gastro	O
-	O
intestinal	O
system	O
.	O

Here	O
,	O
we	O
review	O
the	O
changes	O
in	O
microbiota	O
composition	O
,	O
how	O
they	O
relate	O
to	O
the	O
immunological	O
imbalance	O
,	O
influencing	O
the	O
onset	O
of	O
different	O
types	O
of	O
cancer	O
and	O
the	O
impact	O
of	O
these	O
mechanisms	O
on	O
the	O
efficacy	O
of	O
traditional	O
and	O
upcoming	O
cancer	O
treatments	O
.	O

Role	O
of	O
gut	O
metabolism	O
of	O
adrenal	O
corticosteroids	O
and	O
hypertension	O
:	O
clues	O
gut	O
-	O
cleansing	O
antibiotics	O
give	O
us	O
.	O

Intestinal	O
bacteria	O
can	O
metabolize	O
sterols	O
,	O
bile	O
acids	O
,	O
steroid	O
hormones	O
,	O
dietary	O
proteins	O
,	O
fiber	O
,	O
foodstuffs	O
,	O
and	O
short	O
chain	O
fatty	O
acids	O
.	O

The	O
metabolic	O
products	O
generated	O
by	O
some	O
of	O
these	O
intestinal	O
bacteria	O
have	O
been	O
linked	O
to	O
a	O
number	O
of	O
systemic	O
diseases	O
including	O
obesity	O
with	O
Type	O
2	O
diabetes	O
mellitus	O
,	O
some	O
forms	O
of	O
inflammation	O
,	O
and	O
more	O
recently	O
,	O
systemic	O
hypertension	O
.	O

In	O
this	O
review	O
,	O
we	O
primarily	O
focus	O
on	O
the	O
potential	O
role	O
selected	O
gut	O
bacteria	O
play	O
in	O
metabolizing	O
the	O
endogenous	O
glucocorticoids	O
corticosterone	O
and	O
cortisol	O
.	O

Those	O
generated	O
steroid	O
metabolites	O
,	O
when	O
reabsorbed	O
in	O
the	O
intestine	O
back	O
into	O
the	O
circulation	O
,	O
produce	O
biological	O
effects	O
most	O
notably	O
as	O
inhibitors	O
of	O
11beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
(	O
11beta	O
-	O
HSD	O
)	O
types	O
1	O
and	O
2	O
.	O

Inhibition	O
of	O
the	O
dehydrogenase	O
actions	O
of	O
11beta	O
-	O
HSD	O
,	O
particularly	O
in	O
kidney	O
and	O
vascular	O
tissue	O
,	O
allows	O
both	O
corticosterone	O
and	O
cortisol	O
the	O
ability	O
to	O
bind	O
to	O
and	O
activate	O
mineralocorticoid	O
receptors	O
with	O
attended	O
changes	O
in	O
sodium	O
handling	O
and	O
vascular	O
resistance	O
leading	O
to	O
increases	O
in	O
blood	O
pressure	O
.	O

In	O
several	O
animal	O
models	O
of	O
hypertension	O
,	O
administration	O
of	O
gut	O
-	O
cleansing	O
antibiotics	O
results	O
in	O
transient	O
resolution	O
of	O
hypertension	O
and	O
transfer	O
of	O
intestinal	O
contents	O
from	O
a	O
hypertensive	O
animal	O
to	O
a	O
normotensive	O
animal	O
produces	O
hypertension	O
in	O
the	O
recipient	O
.	O

Moreover	O
,	O
fecal	O
samples	O
from	O
hypertensive	O
humans	O
transplanted	O
into	O
germ	O
-	O
free	O
mice	O
resulted	O
in	O
hypertension	O
in	O
the	O
recipient	O
mice	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
intestinal	O
microbiome	O
may	O
not	O
just	O
be	O
an	O
innocent	O
bystander	O
but	O
certain	O
perturbations	O
in	O
the	O
type	O
and	O
number	O
of	O
bacteria	O
may	O
directly	O
or	O
indirectly	O
affect	O
hypertension	O
and	O
other	O
diseases	O
.	O

Geographical	O
location	O
specific	O
composition	O
of	O
cultured	O
microbiota	O
and	O
Lactobacillus	B-bacteria
occurrence	O
in	O
human	O
breast	O
milk	O
in	O
China	O
.	O

Breast	O
milk	O
bacteria	O
play	O
an	O
important	O
role	O
in	O
the	O
early	O
development	O
of	O
the	O
gut	O
microbiota	O
and	O
the	O
immune	O
system	O
.	O

Dominant	O
living	O
bacteria	O
of	O
89	O
healthy	O
Chinese	O
women	O
from	O
11	O
cities	O
in	O
five	O
regions	O
were	O
analysed	O
by	O
broad	O
-	O
range	O
yeast	O
extract	O
,	O
casitone	O
,	O
and	O
fatty	O
acid	O
and	O
de	O
Man	O
,	O
Rogosa	O
,	O
and	O
Sharpe	O
-	O
based	O
culturing	O
coupled	O
with	O
16S	O
rRNA	O
sequence	O
and	O
quantitative	O
polymerase	O
chain	O
reaction	O
.	O

Principal	O
coordinate	O
analysis	O
showed	O
that	O
human	O
breast	O
milk	O
samples	O
were	O
classified	O
into	O
three	O
groups	O
,	O
driven	O
by	O
Enterococcus	B-bacteria
(	O
abundance	O
in	O
group	O
1	O
,	O
63	O
.	O
13	O
%	O
)	O
,	O
Streptococcus	B-bacteria
(	O
abundance	O
in	O
group	O
2	O
,	O
68	O
.	O
16	O
%	O
)	O
and	O
Staphylococcus	B-bacteria
(	O
abundance	O
in	O
group	O
3	O
,	O
55	O
.	O
17	O
%	O
)	O
.	O

The	O
microbiota	O
profile	O
was	O
highly	O
region	O
-	O
specific	O
.	O

Samples	O
from	O
the	O
Northwest	O
and	O
North	O
of	O
China	O
showed	O
higher	O
alpha	O
diversity	O
compared	O
to	O
other	O
regions	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Staphylococcus	B-bacteria
,	O
Streptococcus	B-bacteria
,	O
and	O
Enterococcus	B-bacteria
were	O
the	O
dominant	O
genera	O
in	O
all	O
samples	O
.	O

Lactobacillus	B-bacteria
had	O
a	O
high	O
occurrence	O
in	O
samples	O
from	O
the	O
Northwest	O
and	O
North	O
,	O
dominated	O
by	O
Lactobacillus	B-bacteria
reuteri	I-bacteria
and	O
Lactobacillus	B-bacteria
gasseri	I-bacteria
.	O

Samples	O
of	O
mothers	O
with	O
a	O
high	O
postpartum	O
body	O
mass	O
index	O
showed	O
more	O
Staphylococcus	B-bacteria
and	O
less	O
Lactobacillus	B-bacteria
and	O
Streptococcus	B-bacteria
.	O

Staphylococcus	B-bacteria
was	O
negatively	O
correlated	O
with	O
Lactobacillus	B-bacteria
and	O
Streptococcus	B-bacteria
.	O

The	O
mode	O
of	O
delivery	O
also	O
affected	O
the	O
composition	O
of	O
microbiota	O
,	O
even	O
after	O
culture	O
.	O

These	O
findings	O
indicate	O
differences	O
between	O
the	O
North	O
and	O
South	O
,	O
provide	O
effective	O
information	O
for	O
collection	O
of	O
samples	O
in	O
which	O
Lactobacillus	B-bacteria
is	O
the	O
predominant	O
genus	O
,	O
and	O
lower	O
the	O
detection	O
limit	O
for	O
small	O
amounts	O
of	O
bacteria	O
.	O

Abnormal	O
composition	O
of	O
gut	O
microbiota	O
contributes	O
to	O
delirium	O
-	O
like	O
behaviors	O
after	O
abdominal	O
surgery	O
in	O
mice	O
.	O

AIMS	O
:	O
Anesthesia	O
and	O
surgery	O
can	O
cause	O
delirium	O
-	O
like	O
symptoms	O
postoperatively	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
gut	O
microbiota	O
is	O
a	O
physiological	O
regulator	O
of	O
the	O
brain	O
.	O

Herein	O
,	O
we	O
investigated	O
whether	O
gut	O
microbiota	O
plays	O
a	O
role	O
in	O
postoperative	O
delirium	O
(	O
POD	O
)	O
.	O

METHODS	O
:	O
Mice	O
were	O
separated	O
into	O
non	O
-	O
POD	O
and	O
POD	O
phenotypes	O
after	O
abdominal	O
surgery	O
by	O
applying	O
hierarchical	O
clustering	O
analysis	O
to	O
behavioral	O
tests	O
.	O

Fecal	O
samples	O
were	O
collected	O
,	O
and	O
16S	O
ribosomal	O
RNA	O
gene	O
sequencing	O
was	O
performed	O
to	O
detect	O
differences	O
in	O
gut	O
microbiota	O
composition	O
among	O
sham	O
,	O
non	O
-	O
POD	O
,	O
and	O
POD	O
mice	O
.	O

Fecal	O
bacteria	O
from	O
non	O
-	O
POD	O
and	O
POD	O
mice	O
were	O
transplanted	O
into	O
antibiotics	O
-	O
induced	O
pseudo	O
-	O
germ	O
-	O
free	O
mice	O
to	O
investigate	O
the	O
effects	O
on	O
behaviors	O
.	O

RESULTS	O
:	O
alpha	O
-	O
diversity	O
and	O
beta	O
-	O
diversity	O
indicated	O
differences	O
in	O
gut	O
microbiota	O
composition	O
between	O
the	O
non	O
-	O
POD	O
and	O
POD	O
mice	O
.	O

At	O
the	O
phylum	O
level	O
,	O
the	O
non	O
-	O
POD	O
mice	O
had	O
significantly	O
higher	O
levels	O
of	O
Tenericutes	B-bacteria
,	O
which	O
were	O
not	O
detected	O
in	O
the	O
POD	O
mice	O
.	O

At	O
the	O
class	O
level	O
,	O
levels	O
of	O
Gammaproteobacteria	B-bacteria
were	O
higher	O
in	O
the	O
POD	O
mice	O
,	O
whereas	O
the	O
non	O
-	O
POD	O
mice	O
had	O
significantly	O
higher	O
levels	O
of	O
Mollicutes	B-bacteria
,	O
which	O
were	O
not	O
detected	O
in	O
the	O
POD	O
mice	O
.	O

A	O
total	O
of	O
20	O
gut	O
bacteria	O
differed	O
significantly	O
between	O
the	O
POD	O
and	O
non	O
-	O
POD	O
mice	O
.	O

Interestingly	O
,	O
the	O
pseudo	O
-	O
germ	O
-	O
free	O
mice	O
showed	O
abnormal	O
behaviors	O
prior	O
to	O
transplant	O
.	O

The	O
pseudo	O
-	O
germ	O
-	O
free	O
mice	O
that	O
received	O
fecal	O
bacteria	O
transplants	O
from	O
non	O
-	O
POD	O
mice	O
but	O
not	O
from	O
POD	O
mice	O
showed	O
improvements	O
in	O
behaviors	O
.	O

CONCLUSIONS	O
:	O
Abnormal	O
gut	O
microbiota	O
composition	O
after	O
abdominal	O
surgery	O
may	O
contribute	O
to	O
the	O
development	O
of	O
POD	O
.	O

A	O
therapeutic	O
strategy	O
that	O
targets	O
gut	O
microbiota	O
could	O
provide	O
a	O
novel	O
alterative	O
for	O
POD	O
treatment	O
.	O

Metagenomic	O
dissection	O
of	O
the	O
canine	O
gut	O
microbiota	O
:	O
insights	O
into	O
taxonomic	O
,	O
metabolic	O
and	O
nutritional	O
features	O
.	O

Domestication	O
of	O
dogs	O
from	O
wolves	O
is	O
the	O
oldest	O
known	O
example	O
of	O
ongoing	O
animal	O
selection	O
,	O
responsible	O
for	O
generating	O
more	O
than	O
300	O
dog	O
breeds	O
worldwide	O
.	O

In	O
order	O
to	O
investigate	O
the	O
taxonomic	O
and	O
functional	O
evolution	O
of	O
the	O
canine	O
gut	O
microbiota	O
,	O
a	O
multi	O
-	O
omics	O
approach	O
was	O
applied	O
to	O
six	O
wild	O
wolves	O
and	O
169	O
dog	O
faecal	O
samples	O
,	O
the	O
latter	O
encompassing	O
51	O
breeds	O
,	O
which	O
fully	O
covers	O
currently	O
known	O
canine	O
genetic	O
biodiversity	O
.	O

Specifically	O
,	O
16S	O
rRNA	O
gene	O
and	O
bifidobacterial	O
Internally	O
Transcribed	O
Spacer	O
(	O
ITS	O
)	O
profiling	O
were	O
employed	O
to	O
reconstruct	O
and	O
then	O
compare	O
the	O
canine	O
core	O
gut	O
microbiota	O
to	O
those	O
of	O
wolves	O
and	O
humans	O
,	O
revealing	O
that	O
artificial	O
selection	O
and	O
subsequent	O
cohabitation	O
of	O
dogs	O
with	O
their	O
owners	O
influenced	O
the	O
microbial	O
population	O
of	O
canine	O
gut	O
through	O
loss	O
and	O
acquisition	O
of	O
specific	O
bacterial	O
taxa	O
.	O

Moreover	O
,	O
comparative	O
analysis	O
of	O
the	O
intestinal	O
bacterial	O
population	O
of	O
dogs	O
fed	O
on	O
Bones	O
and	O
Raw	O
Food	O
(	O
BARF	O
)	O
or	O
commercial	O
food	O
(	O
CF	O
)	O
diet	O
,	O
coupled	O
with	O
shotgun	O
metagenomics	O
,	O
highlighted	O
that	O
both	O
bacterial	O
composition	O
and	O
metabolic	O
repertoire	O
of	O
the	O
canine	O
gut	O
microbiota	O
have	O
evolved	O
to	O
adapt	O
to	O
high	O
-	O
protein	O
or	O
high	O
-	O
carbohydrates	O
intake	O
.	O

Altogether	O
,	O
these	O
data	O
indicate	O
that	O
artificial	O
selection	O
and	O
domestication	O
not	O
only	O
affected	O
the	O
canine	O
genome	O
,	O
but	O
also	O
shaped	O
extensively	O
the	O
bacterial	O
population	O
harboured	O
by	O
the	O
canine	O
gut	O
.	O

Necrotizing	O
Enterocolitis	O
and	O
the	O
Preterm	O
Infant	O
Microbiome	O
.	O

Bacterial	O
colonization	O
patterns	O
in	O
preterm	O
infants	O
differ	O
from	O
those	O
of	O
their	O
term	O
counterparts	O
due	O
to	O
maternal	O
microbial	O
diversity	O
,	O
delivery	O
mode	O
,	O
feeding	O
methods	O
,	O
antibiotic	O
use	O
,	O
and	O
exposure	O
to	O
commensal	O
microbiota	O
and	O
pathogens	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
.	O

Early	O
gut	O
microbiome	O
dysbiosis	O
predisposes	O
neonates	O
to	O
necrotizing	O
enterocolitis	O
(	O
NEC	O
)	O
,	O
a	O
devastating	O
intestinal	O
disease	O
with	O
high	O
morbidity	O
and	O
mortality	O
.	O

Though	O
mechanisms	O
of	O
NEC	O
pathogenesis	O
are	O
not	O
fully	O
understood	O
,	O
the	O
microbiome	O
is	O
a	O
promising	O
therapy	O
target	O
for	O
prevention	O
and	O
treatment	O
.	O

Direct	O
administration	O
of	O
probiotics	O
to	O
preterm	O
infants	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
incidence	O
of	O
NEC	O
,	O
but	O
is	O
not	O
without	O
risk	O
.	O

The	O
immature	O
immune	O
systems	O
of	O
preterm	O
infants	O
leave	O
them	O
vulnerable	O
to	O
even	O
beneficial	O
bacteria	O
.	O

Further	O
research	O
is	O
required	O
to	O
investigate	O
both	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
effects	O
of	O
probiotic	O
administration	O
to	O
preterm	O
infants	O
.	O

Other	O
methods	O
of	O
altering	O
the	O
preterm	O
infant	O
microbiome	O
must	O
also	O
be	O
considered	O
,	O
including	O
breastfeeding	O
,	O
prebiotics	O
,	O
and	O
targeting	O
the	O
maternal	O
microbiome	O
.	O

Dynamics	O
of	O
the	O
gut	O
microbiota	O
in	O
developmental	O
stages	O
of	O
Litopenaeus	O
vannamei	O
reveal	O
its	O
association	O
with	O
body	O
weight	O
.	O

Increasing	O
evidences	O
have	O
revealed	O
a	O
close	O
interaction	O
between	O
the	O
intestinal	O
microbes	O
and	O
host	O
growth	O
performance	O
.	O

The	O
shrimp	O
(	O
Litopenaeus	O
vannamei	O
)	O
gut	O
harbors	O
a	O
diverse	O
microbial	O
community	O
,	O
yet	O
its	O
associations	O
with	O
dietary	O
,	O
body	O
weight	O
and	O
weaning	O
age	O
remain	O
a	O
matter	O
of	O
debate	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
different	O
dietary	O
(	O
fishmeal	O
group	O
(	O
NC	O
)	O
,	O
krill	O
meal	O
group	O
(	O
KM	O
)	O
)	O
and	O
different	O
growth	O
stages	O
(	O
age	O
from	O
42	O
day	O
-	O
old	O
to	O
98	O
day	O
-	O
old	O
)	O
of	O
the	O
shrimp	O
on	O
the	O
intestinal	O
microbiota	O
.	O

High	O
throughput	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
genes	O
of	O
shrimp	O
intestinal	O
microbes	O
determined	O
the	O
novelty	O
of	O
bacteria	O
in	O
the	O
shrimp	O
gut	O
microbiota	O
and	O
a	O
core	O
of	O
58	O
Operation	O
Taxonomic	O
Units	O
(	O
OTUs	O
)	O
was	O
present	O
among	O
the	O
shrimp	O
gut	O
samples	O
.	O

Analysis	O
results	O
indicated	O
that	O
the	O
development	O
of	O
the	O
shrimp	O
gut	O
microbiota	O
is	O
a	O
dynamic	O
process	O
with	O
three	O
stages	O
across	O
the	O
age	O
according	O
to	O
the	O
gut	O
microbiota	O
compositions	O
.	O

Furthermore	O
,	O
the	O
dietary	O
of	O
KM	O
group	O
did	O
not	O
significantly	O
change	O
the	O
intestinal	O
microbiota	O
of	O
the	O
shrimps	O
compared	O
with	O
NC	O
group	O
.	O

Intriguingly	O
,	O
compared	O
to	O
NC	O
group	O
,	O
we	O
observed	O
in	O
KM	O
group	O
that	O
a	O
fluctuation	O
of	O
the	O
shrimp	O
gut	O
microbiota	O
coincided	O
with	O
the	O
shrimp	O
body	O
weight	O
gain	O
between	O
weeks	O
6	O
-	O
7	O
.	O

Six	O
OTUs	O
associated	O
with	O
the	O
microbiota	O
change	O
in	O
KM	O
group	O
were	O
identified	O
.	O

This	O
finding	O
strongly	O
suggests	O
that	O
the	O
shrimp	O
gut	O
microbiota	O
may	O
be	O
correlated	O
with	O
the	O
shrimp	O
body	O
weight	O
likely	O
by	O
influencing	O
nutrient	O
uptake	O
in	O
the	O
gut	O
.	O

The	O
results	O
obtained	O
from	O
this	O
study	O
potentially	O
will	O
be	O
guidelines	O
for	O
manipulation	O
to	O
provide	O
novel	O
shrimp	O
feed	O
management	O
approaches	O
.	O

Identification	O
of	O
the	O
novel	O
role	O
of	O
butyrate	O
as	O
AhR	O
ligand	O
in	O
human	O
intestinal	O
epithelial	O
cells	O
.	O

The	O
ligand	O
activated	O
transcription	O
factor	O
,	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
emerged	O
as	O
a	O
critical	O
regulator	O
of	O
immune	O
and	O
metabolic	O
processes	O
in	O
the	O
gastrointestinal	O
tract	O
.	O

In	O
the	O
gut	O
,	O
a	O
main	O
source	O
of	O
AhR	O
ligands	O
derives	O
from	O
commensal	O
bacteria	O
.	O

However	O
,	O
many	O
of	O
the	O
reported	O
microbiota	O
-	O
derived	O
ligands	O
have	O
been	O
restricted	O
to	O
indolyl	O
metabolites	O
.	O

Here	O
,	O
by	O
screening	O
commensal	O
bacteria	O
supernatants	O
on	O
an	O
AhR	O
reporter	O
system	O
expressed	O
in	O
human	O
intestinal	O
epithelial	O
cell	O
line	O
(	O
IEC	O
)	O
,	O
we	O
found	O
that	O
the	O
short	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
butyrate	O
induced	O
AhR	O
activity	O
and	O
the	O
transcription	O
of	O
AhR	O
-	O
dependent	O
genes	O
in	O
IECs	O
.	O

We	O
showed	O
that	O
AhR	O
ligand	O
antagonists	O
reduced	O
the	O
effects	O
of	O
butyrate	O
on	O
IEC	O
suggesting	O
that	O
butyrate	O
could	O
act	O
as	O
a	O
ligand	O
of	O
AhR	O
,	O
which	O
was	O
supported	O
by	O
the	O
nuclear	O
translocation	O
of	O
AhR	O
induced	O
by	O
butyrate	O
and	O
in	O
silico	O
structural	O
modelling	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
suggest	O
that	O
(	O
i	O
)	O
butyrate	O
activates	O
AhR	O
pathway	O
and	O
AhR	O
-	O
dependent	O
genes	O
in	O
human	O
intestinal	O
epithelial	O
cell	O
-	O
lines	O
(	O
ii	O
)	O
butyrate	O
is	O
a	O
potential	O
ligand	O
for	O
AhR	O
which	O
is	O
an	O
original	O
mechanism	O
of	O
gene	O
regulation	O
by	O
SCFA	O
.	O

Close	O
social	O
relationships	O
correlate	O
with	O
human	O
gut	O
microbiota	O
composition	O
.	O

Social	O
relationships	O
shape	O
human	O
health	O
and	O
mortality	O
via	O
behavioral	O
,	O
psychosocial	O
,	O
and	O
physiological	O
mechanisms	O
,	O
including	O
inflammatory	O
and	O
immune	O
responses	O
.	O

Though	O
not	O
tested	O
in	O
human	O
studies	O
,	O
recent	O
primate	O
studies	O
indicate	O
that	O
the	O
gut	O
microbiome	O
may	O
also	O
be	O
a	O
biological	O
mechanism	O
linking	O
relationships	O
to	O
health	O
.	O

Integrating	O
microbiota	O
data	O
into	O
the	O
60	O
-	O
year	O
-	O
old	O
Wisconsin	O
Longitudinal	O
Study	O
,	O
we	O
found	O
that	O
socialness	O
with	O
family	O
and	O
friends	O
is	O
associated	O
with	O
differences	O
in	O
the	O
human	O
fecal	O
microbiota	O
.	O

Analysis	O
of	O
spouse	O
(	O
N	O
=	O
94	O
)	O
and	O
sibling	O
pairs	O
(	O
N	O
=	O
83	O
)	O
further	O
revealed	O
that	O
spouses	O
have	O
more	O
similar	O
microbiota	O
and	O
more	O
bacterial	O
taxa	O
in	O
common	O
than	O
siblings	O
,	O
with	O
no	O
observed	O
differences	O
between	O
sibling	O
and	O
unrelated	O
pairs	O
.	O

These	O
differences	O
held	O
even	O
after	O
accounting	O
for	O
dietary	O
factors	O
.	O

The	O
differences	O
between	O
unrelated	O
individuals	O
and	O
married	O
couples	O
was	O
driven	O
entirely	O
by	O
couples	O
who	O
reported	O
close	O
relationships	O
;	O
there	O
were	O
no	O
differences	O
in	O
similarity	O
between	O
couples	O
reporting	O
somewhat	O
close	O
relationships	O
and	O
unrelated	O
individuals	O
.	O

Moreover	O
,	O
married	O
individuals	O
harbor	O
microbial	O
communities	O
of	O
greater	O
diversity	O
and	O
richness	O
relative	O
to	O
those	O
living	O
alone	O
,	O
with	O
the	O
greatest	O
diversity	O
among	O
couples	O
reporting	O
close	O
relationships	O
,	O
which	O
is	O
notable	O
given	O
decades	O
of	O
research	O
documenting	O
the	O
health	O
benefits	O
of	O
marriage	O
.	O

These	O
results	O
suggest	O
that	O
human	O
interactions	O
,	O
especially	O
sustained	O
,	O
close	O
marital	O
relationships	O
,	O
influence	O
the	O
gut	O
microbiota	O
.	O

Cream	O
Cheese	O
-	O
Derived	O
Lactococcus	B-bacteria
chungangensis	I-bacteria
CAU	O
28	O
Modulates	O
the	O
Gut	O
Microbiota	O
and	O
Alleviates	O
Atopic	O
Dermatitis	O
in	O
BALB	O
/	O
c	O
Mice	O
.	O

Atopic	O
dermatitis	O
(	O
AD	O
)	O
has	O
a	O
drastic	O
impact	O
on	O
human	O
health	O
owing	O
to	O
complex	O
skin	O
,	O
gut	O
microbiota	O
,	O
and	O
immune	O
responses	O
.	O

Some	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
(	O
LAB	B-bacteria
)	O
are	O
effective	O
in	O
ameliorating	O
AD	O
;	O
however	O
,	O
the	O
alleviative	O
effects	O
of	O
dairy	O
products	O
derived	O
from	O
these	O
LAB	B-bacteria
remain	O
unclear	O
.	O

In	O
this	O
study	O
,	O
the	O
efficacies	O
of	O
Lactococcus	B-bacteria
chungangensis	I-bacteria
CAU	I-bacteria
28	I-bacteria
(	O
CAU	B-bacteria
28	I-bacteria
)	O
cream	O
cheese	O
and	O
L	O
.	O
chungangensis	O
CAU	O
28	O
dry	O
cells	O
were	O
evaluated	O
for	O
treating	O
AD	O
in	O
an	O
AD	O
mouse	O
model	O
.	O

Overall	O
,	O
CAU	B-bacteria
28	I-bacteria
cream	O
cheese	O
administration	O
was	O
more	O
effective	O
against	O
AD	O
than	O
L	B-bacteria
.	I-bacteria
chungangensis	I-bacteria
CAU	I-bacteria
28	I-bacteria
dry	O
cells	O
.	O

Faeces	O
from	O
CAU	B-bacteria
28	I-bacteria
cream	O
cheese	O
-	O
administered	O
mice	O
had	O
increased	O
short	O
chain	O
fatty	O
acid	O
,	O
butyrate	O
,	O
acetate	O
,	O
and	O
lactic	O
acid	O
levels	O
,	O
as	O
well	O
as	O
butyrate	O
-	O
producing	O
bacteria	O
,	O
including	O
Akkermansia	B-bacteria
,	O
Bacteroides	B-bacteria
,	O
Lactobacillus	B-bacteria
,	O
and	O
Ruminococcus	B-bacteria
.	O

Furthermore	O
,	O
oral	O
CAU	B-bacteria
28	I-bacteria
cream	O
cheese	O
administration	O
resulted	O
in	O
regulatory	O
T	O
cell	O
(	O
Treg	O
)	O
-	O
mediated	O
suppression	O
of	O
T	O
helper	O
type	O
2	O
(	O
Th2	O
)	O
immune	O
responses	O
in	O
serum	O
and	O
mRNA	O
expression	O
levels	O
in	O
the	O
ileum	O
.	O

Oral	O
CAU	O
28	O
cream	O
cheese	O
further	O
reduced	O
IgE	O
levels	O
,	O
in	O
addition	O
to	O
eosinophil	O
and	O
mast	O
cell	O
numbers	O
.	O

Therefore	O
,	O
CAU	O
28	O
cream	O
cheese	O
administration	O
induced	O
a	O
coordinated	O
immune	O
response	O
involving	O
short	O
-	O
chain	O
fatty	O
acids	O
and	O
gut	O
microbiota	O
,	O
indicating	O
its	O
potential	O
for	O
use	O
as	O
a	O
supplement	O
for	O
AD	O
mitigation	O
.	O

Molecular	O
ontogeny	O
of	O
the	O
stomach	O
in	O
the	O
catshark	O
Scyliorhinus	O
canicula	O
.	O

The	O
origin	O
of	O
extracellular	O
digestion	O
in	O
metazoans	O
was	O
accompanied	O
by	O
structural	O
and	O
physiological	O
alterations	O
of	O
the	O
gut	O
.	O

These	O
adaptations	O
culminated	O
in	O
the	O
differentiation	O
of	O
a	O
novel	O
digestive	O
structure	O
in	O
jawed	O
vertebrates	O
,	O
the	O
stomach	O
.	O

Specific	O
endoderm	O
/	O
mesenchyme	O
signalling	O
is	O
required	O
for	O
stomach	O
differentiation	O
,	O
involving	O
the	O
growth	O
and	O
transcription	O
factors	O
:	O
1	O
)	O
Shh	O
and	O
Bmp4	O
,	O
required	O
for	O
stomach	O
outgrowth	O
;	O
2	O
)	O
Barx1	O
,	O
Sfrps	O
and	O
Sox2	O
,	O
required	O
for	O
gastric	O
epithelium	O
development	O
and	O
3	O
)	O
Cdx1	O
and	O
Cdx2	O
,	O
involved	O
in	O
intestinal	O
versus	O
gastric	O
identity	O
.	O

Thus	O
,	O
modulation	O
of	O
endoderm	O
/	O
mesenchyme	O
signalling	O
emerges	O
as	O
a	O
plausible	O
mechanism	O
linked	O
to	O
the	O
origin	O
of	O
the	O
stomach	O
.	O

In	O
order	O
to	O
gain	O
insight	O
into	O
the	O
ancient	O
mechanisms	O
capable	O
of	O
generating	O
this	O
structure	O
in	O
jawed	O
vertebrates	O
,	O
we	O
characterised	O
the	O
development	O
of	O
the	O
gut	O
in	O
the	O
catshark	O
Scyliorhinus	O
canicula	O
.	O

As	O
chondrichthyans	O
,	O
these	O
animals	O
retained	O
plesiomorphic	O
features	O
of	O
jawed	O
vertebrates	O
,	O
including	O
a	O
well	O
-	O
differentiated	O
stomach	O
.	O

We	O
identified	O
a	O
clear	O
molecular	O
regionalization	O
of	O
their	O
embryonic	O
gut	O
,	O
characterised	O
by	O
the	O
expression	O
of	O
barx1	O
and	O
sox2	O
in	O
the	O
prospective	O
stomach	O
region	O
and	O
expression	O
of	O
cdx1	O
and	O
cdx2	O
in	O
the	O
prospective	O
intestine	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
gastric	O
gland	O
development	O
occurs	O
close	O
to	O
hatching	O
,	O
accompanied	O
by	O
the	O
onset	O
of	O
gastric	O
proton	O
pump	O
activity	O
.	O

Our	O
findings	O
favour	O
a	O
scenario	O
in	O
which	O
the	O
developmental	O
mechanisms	O
involved	O
in	O
the	O
origin	O
of	O
the	O
stomach	O
were	O
present	O
in	O
the	O
common	O
ancestor	O
of	O
chondrichthyans	O
and	O
osteichthyans	O
.	O

Gut	O
microbiota	O
affects	O
development	O
and	O
olfactory	O
behavior	O
in	O
Drosophila	O
melanogaster	O
.	O

It	O
has	O
been	O
shown	O
that	O
gut	O
microbes	O
are	O
very	O
important	O
for	O
the	O
behavior	O
and	O
development	O
of	O
Drosophila	O
,	O
as	O
the	O
beneficial	O
microbes	O
are	O
involved	O
in	O
the	O
identification	O
of	O
suitable	O
feeding	O
and	O
egg	O
-	O
laying	O
locations	O
.	O

However	O
,	O
in	O
what	O
way	O
these	O
associated	O
gut	O
microbes	O
influence	O
the	O
fitness	O
-	O
related	O
behaviors	O
of	O
Drosophila	B-bacteria
melanogaster	I-bacteria
remains	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
D	B-bacteria
.	I-bacteria
melanogaster	I-bacteria
exhibits	O
different	O
behavioral	O
preferences	O
towards	O
gut	O
microbes	O
.	O

Both	O
adults	O
and	O
larvae	O
were	O
attracted	O
by	O
the	O
volatile	O
compounds	O
of	O
Saccharomyces	O
cerevisiae	O
and	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
,	O
but	O
were	O
repelled	O
by	O
Acetobacter	B-bacteria
malorum	I-bacteria
in	O
behavioral	O
assays	O
,	O
indicating	O
that	O
an	O
olfactory	O
mechanism	O
is	O
involved	O
in	O
these	O
preference	O
behaviors	O
.	O

While	O
the	O
attraction	O
to	O
yeast	O
was	O
governed	O
by	O
olfactory	O
sensory	O
neurons	O
expressing	O
the	O
odorant	O
co	O
-	O
receptor	O
Orco	O
,	O
the	O
observed	O
behaviors	O
towards	O
the	O
other	O
microbes	O
were	O
retained	O
in	O
flies	O
lacking	O
this	O
co	O
-	O
receptor	O
.	O

By	O
experimentally	O
manipulating	O
the	O
microbiota	O
of	O
the	O
flies	O
,	O
we	O
found	O
that	O
flies	O
did	O
not	O
strive	O
for	O
a	O
diverse	O
microbiome	O
by	O
increasing	O
their	O
preference	O
towards	O
gut	O
microbes	O
that	O
they	O
had	O
not	O
experienced	O
previously	O
.	O

Instead	O
,	O
in	O
some	O
cases	O
,	O
the	O
flies	O
even	O
increased	O
preference	O
for	O
the	O
microbes	O
on	O
which	O
they	O
were	O
reared	O
.	O

Furthermore	O
,	O
exposing	O
Drosophila	O
larvae	O
to	O
all	O
three	O
microbes	O
promoted	O
Drosophila	B-bacteria
development	O
,	O
while	O
exposure	O
to	O
only	O
S	B-bacteria
.	I-bacteria
cerevisiae	I-bacteria
and	O
A	B-bacteria
.	I-bacteria
malorum	I-bacteria
resulted	O
in	O
the	O
development	O
of	O
larger	O
ovaries	O
and	O
in	O
increased	O
egg	O
numbers	O
in	O
an	O
oviposition	O
assay	O
.	O

Thus	O
,	O
our	O
study	O
provides	O
a	O
better	O
understanding	O
of	O
how	O
gut	O
microbes	O
affect	O
insect	O
behavior	O
and	O
development	O
,	O
and	O
offers	O
an	O
ecological	O
rationale	O
for	O
preferences	O
of	O
flies	O
for	O
different	O
microbes	O
in	O
their	O
natural	O
environment	O
.	O

Microbial	O
Ecology	O
of	O
Fermented	O
Vegetables	O
and	O
Non	O
-	O
Alcoholic	O
Drinks	O
and	O
Current	O
Knowledge	O
on	O
Their	O
Impact	O
on	O
Human	O
Health	O
.	O

Fermented	O
foods	O
are	O
currently	O
experiencing	O
a	O
re	O
-	O
discovery	O
,	O
largely	O
driven	O
by	O
numerous	O
health	O
benefits	O
claims	O
.	O

While	O
fermented	O
dairy	O
,	O
beer	O
,	O
and	O
wine	O
(	O
and	O
other	O
alcoholic	O
fermented	O
beverages	O
)	O
have	O
been	O
the	O
subject	O
of	O
intensive	O
research	O
,	O
other	O
plant	O
-	O
based	O
fermented	O
foods	O
that	O
are	O
in	O
some	O
case	O
widely	O
consumed	O
(	O
kimchi	O
/	O
sauerkraut	O
,	O
pickles	O
,	O
kombucha	O
)	O
have	O
received	O
less	O
scientific	O
attention	O
.	O

In	O
this	O
chapter	O
,	O
the	O
current	O
knowledge	O
on	O
the	O
microbiology	O
and	O
potential	O
health	O
benefits	O
of	O
such	O
plant	O
-	O
based	O
fermented	O
foods	O
are	O
presented	O
.	O

Kimchi	O
is	O
the	O
most	O
studied	O
,	O
characterized	O
by	O
primarily	O
acidic	O
fermentation	O
by	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
.	O

Anti	O
-	O
obesity	O
and	O
anti	O
-	O
hypertension	O
properties	O
have	O
been	O
reported	O
for	O
kimchi	O
and	O
other	O
pickled	O
vegetables	O
.	O

Kombucha	O
is	O
the	O
most	O
popular	O
non	O
-	O
alcoholic	O
fermented	O
drink	O
.	O

Kombucha	O
'	O
s	O
microbiology	O
is	O
remarkable	O
as	O
it	O
involves	O
all	O
fermenters	O
described	O
in	O
known	O
fermented	O
foods	O
:	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
,	O
acetic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
,	O
fungi	O
,	O
and	O
yeasts	O
.	O

While	O
kombucha	O
is	O
often	O
hyped	O
as	O
a	O
`	O
`	O
super	O
-	O
food	O
,	O
'	O
'	O
only	O
antioxidant	O
and	O
antimicrobial	O
properties	O
toward	O
foodborne	O
pathogens	O
are	O
well	O
established	O
;	O
and	O
it	O
is	O
unknown	O
if	O
these	O
properties	O
incur	O
beneficial	O
impact	O
,	O
even	O
in	O
vitro	O
or	O
in	O
animal	O
models	O
.	O

The	O
mode	O
of	O
action	O
that	O
has	O
been	O
studied	O
and	O
demonstrated	O
the	O
most	O
is	O
the	O
probiotic	O
one	O
.	O

However	O
,	O
it	O
can	O
be	O
expected	O
that	O
fermentation	O
metabolites	O
may	O
be	O
prebiotic	O
,	O
or	O
influence	O
host	O
health	O
directly	O
.	O

To	O
conclude	O
,	O
plant	O
-	O
based	O
fermented	O
foods	O
and	O
drinks	O
are	O
usually	O
safe	O
products	O
;	O
few	O
negative	O
reports	O
can	O
be	O
found	O
,	O
but	O
more	O
research	O
,	O
especially	O
human	O
dietary	O
intervention	O
studies	O
,	O
are	O
warranted	O
to	O
substantiate	O
any	O
health	O
claim	O
.	O

A	O
longitudinal	O
assessment	O
of	O
host	O
-	O
microbe	O
-	O
parasite	O
interactions	O
resolves	O
the	O
zebrafish	O
gut	O
microbiome	O
'	O
s	O
link	O
to	O
Pseudocapillaria	O
tomentosa	O
infection	O
and	O
pathology	O
.	O

BACKGROUND	O
:	O
Helminth	O
parasites	O
represent	O
a	O
significant	O
threat	O
to	O
the	O
health	O
of	O
human	O
and	O
animal	O
populations	O
,	O
and	O
there	O
is	O
a	O
growing	O
need	O
for	O
tools	O
to	O
treat	O
,	O
diagnose	O
,	O
and	O
prevent	O
these	O
infections	O
.	O

Recent	O
work	O
has	O
turned	O
to	O
the	O
gut	O
microbiome	O
as	O
a	O
utilitarian	O
agent	O
in	O
this	O
regard	O
;	O
components	O
of	O
the	O
microbiome	O
may	O
interact	O
with	O
parasites	O
to	O
influence	O
their	O
success	O
in	O
the	O
gut	O
,	O
meaning	O
that	O
the	O
microbiome	O
may	O
encode	O
new	O
anthelmintic	O
drugs	O
.	O

Moreover	O
,	O
parasite	O
infections	O
may	O
restructure	O
the	O
microbiome	O
'	O
s	O
composition	O
in	O
consistent	O
ways	O
,	O
implying	O
that	O
the	O
microbiome	O
may	O
be	O
useful	O
for	O
diagnosing	O
infection	O
.	O

The	O
innovation	O
of	O
these	O
utilities	O
requires	O
foundational	O
knowledge	O
about	O
how	O
parasitic	O
infection	O
,	O
as	O
well	O
as	O
its	O
ultimate	O
success	O
in	O
the	O
gut	O
and	O
impact	O
on	O
the	O
host	O
,	O
relates	O
to	O
the	O
gut	O
microbiome	O
.	O

In	O
particular	O
,	O
we	O
currently	O
possess	O
limited	O
insight	O
into	O
how	O
the	O
microbiome	O
,	O
host	O
pathology	O
,	O
and	O
parasite	O
burden	O
covary	O
during	O
infection	O
.	O

Identifying	O
interactions	O
between	O
these	O
parameters	O
may	O
uncover	O
novel	O
putative	O
methods	O
of	O
disrupting	O
parasite	O
success	O
.	O

RESULTS	O
:	O
To	O
identify	O
interactions	O
between	O
parasite	O
success	O
and	O
the	O
microbiome	O
,	O
we	O
quantified	O
longitudinal	O
associations	O
between	O
an	O
intestinal	O
helminth	O
of	O
zebrafish	O
,	O
Pseudocapillaria	O
tomentosa	O
,	O
and	O
the	O
gut	O
microbiome	O
in	O
210	O
4	O
-	O
month	O
-	O
old	O
5D	O
line	O
zebrafish	O
.	O

Parasite	O
burden	O
and	O
parasite	O
-	O
associated	O
pathology	O
varied	O
in	O
severity	O
throughout	O
the	O
experiment	O
in	O
parasite	O
-	O
exposed	O
fish	O
,	O
with	O
intestinal	O
pathologic	O
changes	O
becoming	O
severe	O
at	O
late	O
time	O
points	O
.	O

Parasite	O
exposure	O
,	O
burden	O
,	O
and	O
intestinal	O
lesions	O
were	O
correlated	O
with	O
gut	O
microbial	O
diversity	O
.	O

Robust	O
generalized	O
linear	O
regression	O
identified	O
several	O
individual	O
taxa	O
whose	O
abundance	O
predicted	O
parasite	O
burden	O
,	O
suggesting	O
that	O
gut	O
microbiota	O
may	O
influence	O
P	O
.	O
tomentosa	O
success	O
.	O

Numerous	O
associations	O
between	O
taxon	O
abundance	O
,	O
burden	O
,	O
and	O
gut	O
pathologic	O
changes	O
were	O
also	O
observed	O
,	O
indicating	O
that	O
the	O
magnitude	O
of	O
microbiome	O
disruption	O
during	O
infection	O
varies	O
with	O
infection	O
severity	O
.	O

Finally	O
,	O
a	O
random	O
forest	O
classifier	O
accurately	O
predicted	O
a	O
fish	O
'	O
s	O
exposure	O
to	O
the	O
parasite	O
based	O
on	O
the	O
abundance	O
of	O
gut	O
phylotypes	O
,	O
which	O
underscores	O
the	O
potential	O
for	O
using	O
the	O
gut	O
microbiome	O
to	O
diagnose	O
intestinal	O
parasite	O
infection	O
.	O

CONCLUSIONS	O
:	O
These	O
experiments	O
demonstrate	O
that	O
P	O
.	O
tomentosa	O
infection	O
disrupts	O
zebrafish	O
gut	O
microbiome	O
composition	O
and	O
identifies	O
potential	O
interactions	O
between	O
the	O
gut	O
microbiota	O
and	O
parasite	O
success	O
.	O

The	O
microbiome	O
may	O
also	O
provide	O
a	O
diagnostic	O
that	O
would	O
enable	O
non	O
-	O
destructive	O
passive	O
sampling	O
for	O
P	O
.	O
tomentosa	O
and	O
other	O
intestinal	O
pathogens	O
in	O
zebrafish	O
facilities	O
.	O

Probiotics	O
:	O
How	O
Effective	O
Are	O
They	O
in	O
the	O
Fight	O
against	O
Obesity	O
?	O

Obesity	O
has	O
been	O
associated	O
with	O
structural	O
and	O
functional	O
changes	O
in	O
the	O
gut	O
microbiota	O
.	O

The	O
abundance	O
in	O
,	O
and	O
diversity	O
of	O
,	O
certain	O
bacteria	O
may	O
favor	O
energy	O
harvest	O
and	O
metabolic	O
pathways	O
leading	O
to	O
obesity	O
.	O

Therefore	O
,	O
gut	O
microbiota	O
has	O
become	O
a	O
potential	O
target	O
that	O
can	O
be	O
manipulated	O
to	O
obtain	O
optimal	O
health	O
.	O

Probiotics	O
have	O
been	O
shown	O
to	O
influence	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
,	O
improve	O
gut	O
integrity	O
,	O
and	O
restore	O
the	O
microbial	O
shifts	O
characteristic	O
of	O
obesity	O
.	O

Based	O
on	O
physical	O
and	O
biochemical	O
parameters	O
,	O
metabolic	O
and	O
inflammatory	O
markers	O
,	O
and	O
alterations	O
in	O
gut	O
microbe	O
diversity	O
,	O
animal	O
studies	O
revealed	O
beneficial	O
results	O
in	O
obese	O
models	O
whereas	O
the	O
results	O
in	O
humans	O
are	O
sparse	O
and	O
inconsistent	O
.	O

Thus	O
,	O
the	O
purpose	O
of	O
this	O
review	O
is	O
to	O
present	O
evidence	O
from	O
animal	O
studies	O
and	O
human	O
clinical	O
trials	O
demonstrating	O
the	O
effects	O
of	O
various	O
probiotic	O
strains	O
and	O
their	O
potential	O
efficacy	O
in	O
improving	O
obesity	O
and	O
associated	O
metabolic	O
dysfunctions	O
.	O

Furthermore	O
,	O
the	O
review	O
discusses	O
current	O
gaps	O
in	O
our	O
understanding	O
of	O
how	O
probiotics	O
modulate	O
gut	O
microflora	O
to	O
protect	O
against	O
obesity	O
.	O

Finally	O
,	O
we	O
propose	O
future	O
studies	O
and	O
methodological	O
approaches	O
that	O
may	O
shed	O
light	O
on	O
the	O
challenges	O
facing	O
the	O
scientific	O
community	O
in	O
deciphering	O
the	O
host	O
(	O
-	O
)	O
bacteria	O
interaction	O
in	O
obesity	O
.	O

Impact	O
of	O
Grain	O
Sorghum	O
Polyphenols	O
on	O
Microbiota	O
of	O
Normal	O
Weight	O
and	O
Overweight	O
/	O
Obese	O
Subjects	O
during	O
In	O
Vitro	O
Fecal	O
Fermentation	O
.	O

The	O
human	O
gut	O
microbiota	O
is	O
considered	O
as	O
a	O
crucial	O
mediator	O
between	O
diet	O
and	O
gut	O
homeostasis	O
and	O
body	O
weight	O
.	O

The	O
unique	O
polyphenolic	O
profile	O
of	O
sorghum	O
bran	O
may	O
promote	O
gastrointestinal	O
health	O
by	O
modulating	O
the	O
microbiota	O
.	O

This	O
study	O
evaluated	O
gut	O
microbiota	O
and	O
modulation	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFA	O
)	O
by	O
sorghum	O
bran	O
polyphenols	O
in	O
in	O
vitro	O
batch	O
fermentation	O
derived	O
from	O
normal	O
weight	O
(	O
NW	O
,	O
n	O
=	O
11	O
)	O
and	O
overweight	O
/	O
obese	O
(	O
OO	O
,	O
n	O
=	O
11	O
)	O
subjects	O
'	O
fecal	O
samples	O
.	O

Six	O
separate	O
treatments	O
were	O
applied	O
on	O
each	O
batch	O
fermentation	O
:	O
negative	O
control	O
(	O
NC	O
)	O
,	O
fructooligosaccharides	O
(	O
FOS	O
)	O
,	O
black	O
sorghum	O
bran	O
extract	O
(	O
BSE	O
)	O
,	O
sumac	O
sorghum	O
bran	O
extract	O
(	O
SSE	O
)	O
,	O
FOS	O
+	O
BSE	O
,	O
or	O
FOS	O
+	O
SSE	O
;	O
and	O
samples	O
were	O
collected	O
before	O
and	O
after	O
24	O
h	O
.	O
No	O
significant	O
differences	O
in	O
total	O
and	O
individual	O
SCFA	O
production	O
were	O
observed	O
between	O
NW	O
and	O
OO	O
subjects	O
.	O

Differential	O
responses	O
to	O
treatment	O
according	O
to	O
weight	O
class	O
were	O
observed	O
in	O
both	O
phyla	O
and	O
genera	O
.	O

Sorghum	O
bran	O
polyphenols	O
worked	O
with	O
FOS	O
to	O
enhance	O
Bifidobacterium	B-bacteria
and	O
Lactobacillus	B-bacteria
,	O
and	O
independently	O
stimulated	O
Roseburia	B-bacteria
and	O
Prevotella	B-bacteria
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
sorghum	O
bran	O
polyphenols	O
have	O
differential	O
effects	O
on	O
gut	O
health	O
and	O
may	O
positively	O
impact	O
gut	O
ecology	O
,	O
with	O
responses	O
varying	O
depending	O
on	O
weight	O
class	O
.	O

Dietary	O
Advanced	O
Glycation	O
End	O
Products	O
:	O
Digestion	O
,	O
Metabolism	O
and	O
Modulation	O
of	O
Gut	O
Microbial	O
Ecology	O
.	O

The	O
formation	O
of	O
advanced	O
glycation	O
end	O
products	O
(	O
AGEs	O
)	O
in	O
foods	O
is	O
accelerated	O
with	O
heat	O
treatment	O
,	O
particularly	O
within	O
foods	O
that	O
are	O
cooked	O
at	O
high	O
temperatures	O
for	O
long	O
periods	O
of	O
time	O
using	O
dry	O
heat	O
.	O

The	O
modern	O
processed	O
diet	O
is	O
replete	O
with	O
AGEs	O
,	O
and	O
excessive	O
AGE	O
consumption	O
is	O
thought	O
to	O
be	O
associated	O
with	O
a	O
number	O
of	O
negative	O
health	O
effects	O
.	O

Many	O
dietary	O
AGEs	O
have	O
high	O
molecular	O
weight	O
and	O
are	O
not	O
absorbed	O
in	O
the	O
intestine	O
,	O
and	O
instead	O
pass	O
through	O
to	O
the	O
colon	O
,	O
where	O
they	O
are	O
available	O
for	O
metabolism	O
by	O
the	O
colonic	O
bacteria	O
.	O

Recent	O
studies	O
have	O
been	O
conducted	O
to	O
explore	O
the	O
effects	O
of	O
AGEs	O
on	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
as	O
well	O
as	O
the	O
production	O
of	O
beneficial	O
microbial	O
metabolites	O
,	O
in	O
particular	O
,	O
short	O
-	O
chain	O
fatty	O
acids	O
.	O

However	O
,	O
there	O
is	O
conflicting	O
evidence	O
regarding	O
the	O
impact	O
of	O
dietary	O
AGEs	O
on	O
gut	O
microbiota	O
reshaping	O
,	O
which	O
may	O
be	O
due	O
,	O
in	O
part	O
,	O
to	O
the	O
formation	O
of	O
alternate	O
compounds	O
during	O
the	O
thermal	O
treatment	O
of	O
foods	O
.	O

This	O
review	O
summarises	O
the	O
current	O
evidence	O
regarding	O
dietary	O
sources	O
of	O
AGEs	O
,	O
their	O
gastrointestinal	O
absorption	O
and	O
role	O
in	O
gut	O
microbiota	O
reshaping	O
,	O
provides	O
a	O
brief	O
overview	O
of	O
the	O
health	O
implications	O
of	O
dietary	O
AGEs	O
and	O
highlights	O
knowledge	O
gaps	O
and	O
avenues	O
for	O
future	O
study	O
.	O

Translocation	O
of	O
dead	O
or	O
alive	O
bacteria	O
from	O
mucosa	O
to	O
joints	O
and	O
epiphyseal	O
bone	O
-	O
marrow	O
:	O
facts	O
and	O
hypotheses	O
.	O

The	O
recent	O
demonstration	O
that	O
DNA	O
from	O
several	O
mucosal	O
bacteria	O
,	O
including	O
Prevotella	B-bacteria
spp	I-bacteria
,	O
could	O
be	O
found	O
in	O
numerous	O
tissues	O
(	O
mesenteric	O
lymph	O
nodes	O
,	O
spleen	O
,	O
serum	O
,	O
liver	O
,	O
lung	O
,	O
eye	O
and	O
ankle	O
joints	O
)	O
,	O
either	O
in	O
HLA	O
-	O
B27	O
rats	O
with	O
or	O
without	O
arthritis	O
,	O
or	O
control	O
rats	O
without	O
HLA	O
-	O
B27	O
,	O
could	O
be	O
a	O
revolution	O
in	O
our	O
understanding	O
of	O
spondyloarthritis	O
and	O
close	O
disorders	O
,	O
including	O
rheumatoid	O
arthritis	O
.	O

Indeed	O
,	O
similar	O
translocations	O
of	O
dead	O
or	O
alive	O
bacteria	O
or	O
fungi	O
from	O
mucosa	O
to	O
joints	O
,	O
could	O
contribute	O
to	O
the	O
onset	O
and	O
flares	O
of	O
inflammatory	O
rheumatisms	O
.	O

This	O
state	O
of	O
the	O
art	O
article	O
addresses	O
six	O
questions	O
revived	O
by	O
this	O
finding	O
:	O
1	O
-	O
How	O
does	O
this	O
bacterial	O
DNA	O
or	O
living	O
bacteria	O
traffic	O
from	O
mucosa	O
to	O
joints	O
?	O

2	O
-	O
Can	O
some	O
mucosal	O
bacteria	O
remain	O
alive	O
in	O
those	O
tissues	O
,	O
including	O
joints	O
?	O

3	O
-	O
Could	O
bacteria	O
from	O
the	O
gut	O
microbiota	O
(	O
'	O
self	O
-	O
bacteria	O
'	O
)	O
protect	O
the	O
host	O
cells	O
from	O
invasion	O
by	O
more	O
pathogenic	O
bacteria	O
(	O
like	O
dog	O
-	O
shepherds	O
protect	O
from	O
wolves	O
)	O
?	O

4	O
-	O
Does	O
the	O
composition	O
of	O
the	O
joint	O
or	O
bone	O
marrow	O
microbiota	O
depends	O
on	O
local	O
metabolism	O
,	O
which	O
might	O
differ	O
from	O
gut	O
metabolism	O
?	O

5	O
-	O
Could	O
bacterial	O
antigens	O
from	O
mucosal	O
microbiota	O
be	O
sufficient	O
to	O
trigger	O
trained	O
immunity	O
of	O
presenting	O
cells	O
in	O
joints	O
,	O
or	O
does	O
such	O
phenomenon	O
(	O
with	O
lasting	O
epigenetic	O
changes	O
of	O
presenting	O
cells	O
)	O
require	O
intra	O
-	O
cellular	O
infection	O
of	O
presenting	O
cells	O
or	O
their	O
ancestors	O
?	O

6	O
-	O
In	O
which	O
subsets	O
of	O
cells	O
could	O
living	O
bacteria	O
preferentially	O
persist	O
for	O
a	O
long	O
period	O
in	O
the	O
joint	O
area	O
?	O

Transient	O
or	O
dormant	O
infections	O
within	O
bone	O
-	O
marrow	O
mesenchymal	O
stem	O
cells	O
leading	O
to	O
trained	O
immunity	O
of	O
some	O
of	O
their	O
daughter	O
cells	O
in	O
joints	O
or	O
enthesis	O
,	O
lasting	O
after	O
clearance	O
or	O
the	O
invader	O
,	O
is	O
an	O
attractive	O
hypothesis	O
to	O
test	O
.	O

Effects	O
of	O
Tylosin	O
Administration	O
Routes	O
on	O
the	O
Prevalence	O
of	O
Antimicrobial	O
Resistance	O
Among	O
Fecal	O
Enterococci	B-bacteria
of	O
Finishing	O
Swine	O
.	O

Antibiotics	O
can	O
be	O
administered	O
orally	O
or	O
parenterally	O
in	O
swine	O
production	O
,	O
which	O
may	O
influence	O
antimicrobial	O
resistance	O
(	O
AMR	O
)	O
development	O
in	O
gut	O
bacteria	O
.	O

A	O
total	O
of	O
40	O
barrows	O
and	O
40	O
gilts	O
were	O
used	O
to	O
determine	O
the	O
effects	O
of	O
tylosin	O
administration	O
route	O
on	O
growth	O
performance	O
and	O
fecal	O
enterococcal	O
AMR	O
.	O

The	O
antibiotic	O
treatments	O
followed	O
Food	O
and	O
Drug	O
Administration	O
label	O
directions	O
and	O
were	O
as	O
follows	O
:	O
(	O
1	O
)	O
no	O
antibiotic	O
(	O
CON	O
)	O
,	O
(	O
2	O
)	O
110	O
mg	O
tylosin	O
per	O
kg	O
feed	O
for	O
21	O
d	O
(	O
IN	O
-	O
FEED	O
)	O
,	O
(	O
3	O
)	O
8	O
.	O
82	O
mg	O
tylosin	O
per	O
kg	O
body	O
weight	O
through	O
intramuscular	O
injection	O
twice	O
daily	O
for	O
the	O
first	O
3	O
d	O
of	O
each	O
week	O
for	O
3	O
weeks	O
(	O
IM	O
)	O
,	O
and	O
(	O
4	O
)	O
66	O
mg	O
tylosin	O
per	O
liter	O
of	O
drinking	O
water	O
(	O
IN	O
-	O
WATER	O
)	O
.	O

Antibiotics	O
were	O
administered	O
during	O
d	O
0	O
to	O
21	O
and	O
all	O
pigs	O
were	O
then	O
fed	O
the	O
CON	O
diet	O
from	O
d	O
21	O
to	O
35	O
.	O

Fecal	O
samples	O
were	O
collected	O
on	O
d	O
0	O
,	O
21	O
,	O
and	O
35	O
.	O

Antimicrobial	O
susceptibility	O
was	O
determined	O
by	O
microbroth	O
dilution	O
method	O
.	O

No	O
evidence	O
of	O
route	O
x	O
sex	O
interaction	O
(	O
p	O
>	O
0	O
.	O
55	O
)	O
was	O
observed	O
for	O
growth	O
performance	O
.	O

From	O
d	O
0	O
to	O
21	O
,	O
pigs	O
receiving	O
CON	O
and	O
IN	O
-	O
FEED	O
had	O
greater	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
average	O
daily	O
gain	O
(	O
ADG	O
)	O
than	O
those	O
receiving	O
IM	O
,	O
with	O
the	O
IN	O
-	O
WATER	O
group	O
showing	O
intermediate	O
ADG	O
.	O

Pigs	O
receiving	O
CON	O
had	O
greater	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
gain	O
-	O
to	O
-	O
feed	O
ratio	O
(	O
G	O
:	O
F	O
)	O
than	O
IM	O
and	O
IN	O
-	O
WATER	O
,	O
but	O
were	O
not	O
different	O
from	O
pigs	O
receiving	O
IN	O
-	O
FEED	O
.	O

Overall	O
,	O
enterococcal	B-bacteria
isolates	I-bacteria
collected	O
from	O
pigs	O
receiving	O
IN	O
-	O
FEED	O
or	O
IM	O
were	O
more	O
resistant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
to	O
erythromycin	O
and	O
tylosin	O
than	O
CON	O
and	O
IN	O
-	O
WATER	O
groups	O
.	O

Regardless	O
of	O
administration	O
route	O
,	O
the	O
estimated	O
probability	O
of	O
AMR	O
to	O
these	O
two	O
antibiotics	O
was	O
greater	O
on	O
d	O
21	O
and	O
35	O
than	O
on	O
d	O
0	O
.	O

In	O
summary	O
,	O
IM	O
tylosin	O
decreased	O
ADG	O
and	O
G	O
:	O
F	O
in	O
finishing	O
pigs	O
,	O
which	O
may	O
be	O
because	O
of	O
a	O
response	O
to	O
the	O
handling	O
during	O
injection	O
administration	O
.	O

Tylosin	O
administration	O
through	O
injection	O
and	O
feed	O
resulted	O
in	O
greater	O
probability	O
of	O
enterococcal	O
AMR	O
to	O
erythromycin	O
and	O
tylosin	O
compared	O
with	O
in	O
-	O
water	O
treatment	O
.	O

Alteration	O
in	O
gut	O
microbiota	O
associated	O
with	O
hepatitis	O
B	O
and	O
non	O
-	O
hepatitis	O
virus	O
related	O
hepatocellular	O
carcinoma	O
.	O

Background	O
:	O
The	O
onset	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
ranked	O
fifth	O
malignancies	O
all	O
over	O
the	O
world	O
.	O

Increasing	O
evidences	O
showed	O
that	O
the	O
distribution	O
of	O
HCC	O
was	O
related	O
to	O
the	O
incidence	O
of	O
chronic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
and	O
other	O
factors	O
,	O
such	O
as	O
alcoholism	O
,	O
aflatoxin	O
B1	O
ingestion	O
and	O
obesity	O
.	O

Recent	O
studies	O
demonstrated	O
that	O
gut	O
dysbiosis	O
plays	O
an	O
important	O
role	O
in	O
liver	O
diseases	O
.	O

However	O
,	O
the	O
researches	O
on	O
gut	O
microbiota	O
of	O
HBV	O
and	O
non	O
-	O
HBV	O
non	O
-	O
HCV	O
related	O
HCC	O
have	O
not	O
been	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
differences	O
between	O
the	O
gut	O
microbiota	O
of	O
HBV	O
related	O
HCC	O
(	O
B	O
-	O
HCC	O
)	O
and	O
non	O
-	O
HBV	O
non	O
-	O
HCV	O
related	O
HCC	O
(	O
NBNC	O
-	O
HCC	O
)	O
,	O
finally	O
found	O
some	O
potential	O
bacteria	O
,	O
linking	O
different	O
pathological	O
mechanism	O
of	O
both	O
types	O
of	O
HCCs	O
.	O

Results	O
:	O
We	O
carried	O
out	O
16S	O
rRNA	O
analyses	O
in	O
a	O
cohort	O
of	O
33	O
healthy	O
controls	O
,	O
35	O
individuals	O
with	O
HBV	O
related	O
HCC	O
(	O
B	O
-	O
HCC	O
)	O
and	O
22	O
individuals	O
with	O
non	O
-	O
HBV	O
non	O
-	O
HCV	O
(	O
NBNC	O
)	O
related	O
HCC	O
(	O
NBNC	O
-	O
HCC	O
)	O
.	O

We	O
found	O
that	O
the	O
species	O
richness	O
of	O
fecal	O
microbiota	O
of	O
B	O
-	O
HCC	O
patients	O
was	O
much	O
higher	O
than	O
other	O
two	O
groups	O
.	O

Interestingly	O
,	O
the	O
feces	O
of	O
NBNC	O
-	O
HCC	O
patients	O
harbored	O
more	O
potential	O
pro	O
-	O
inflammatory	O
bacteria	O
(	O
Escherichia	B-bacteria
-	I-bacteria
Shigella	I-bacteria
,	O
Enterococcus	B-bacteria
)	O
and	O
reduced	O
levels	O
of	O
Faecalibacterium	B-bacteria
,	O
Ruminococcus	B-bacteria
,	O
Ruminoclostridium	B-bacteria
which	O
results	O
in	O
decrease	O
potential	O
of	O
anti	O
-	O
inflammatory	O
short	O
-	O
chain	O
fatty	O
acids	O
.	O

The	O
feces	O
of	O
NBNC	O
-	O
HCC	O
patients	O
had	O
relatively	O
fewer	O
abundance	O
of	O
multiple	O
biological	O
pathways	O
related	O
to	O
amino	O
acid	O
and	O
glucose	O
metabolism	O
,	O
but	O
high	O
level	O
of	O
transport	O
and	O
secretion	O
in	O
some	O
types	O
.	O

However	O
,	O
the	O
B	O
-	O
HCC	O
patients	O
had	O
opposite	O
results	O
of	O
bacterial	O
composition	O
and	O
associated	O
multiple	O
biological	O
pathways	O
versus	O
NBNC	O
-	O
HCC	O
patients	O
.	O

Meanwhile	O
,	O
we	O
found	O
that	O
aberrant	O
network	O
of	O
gut	O
microbiota	O
occurred	O
differently	O
in	O
B	O
-	O
HCC	O
and	O
NBNC	O
-	O
HCC	O
patients	O
.	O

Conclusions	O
:	O
Our	O
study	O
indicated	O
that	O
B	O
-	O
HCC	O
and	O
NBNC	O
-	O
HCC	O
patients	O
showed	O
differential	O
abundance	O
of	O
bacteria	O
involved	O
in	O
different	O
functions	O
or	O
biological	O
pathways	O
.	O

We	O
suggested	O
the	O
modification	O
of	O
specific	O
gut	O
microbiota	O
may	O
provide	O
the	O
therapeutic	O
benefit	O
for	O
B	O
-	O
HCC	O
and	O
NBNC	O
-	O
HCC	O
.	O

A	O
defined	O
commensal	O
consortium	O
elicits	O
CD8	O
T	O
cells	O
and	O
anti	O
-	O
cancer	O
immunity	O
.	O

There	O
is	O
a	O
growing	O
appreciation	O
for	O
the	O
importance	O
of	O
the	O
gut	O
microbiota	O
as	O
a	O
therapeutic	O
target	O
in	O
various	O
diseases	O
.	O

However	O
,	O
there	O
are	O
only	O
a	O
handful	O
of	O
known	O
commensal	O
strains	O
that	O
can	O
potentially	O
be	O
used	O
to	O
manipulate	O
host	O
physiological	O
functions	O
.	O

Here	O
we	O
isolate	O
a	O
consortium	O
of	O
11	O
bacterial	O
strains	O
from	O
healthy	O
human	O
donor	O
faeces	O
that	O
is	O
capable	O
of	O
robustly	O
inducing	O
interferon	O
-	O
gamma	O
-	O
producing	O
CD8	O
T	O
cells	O
in	O
the	O
intestine	O
.	O

These	O
11	O
strains	O
act	O
together	O
to	O
mediate	O
the	O
induction	O
without	O
causing	O
inflammation	O
in	O
a	O
manner	O
that	O
is	O
dependent	O
on	O
CD103	O
(	O
+	O
)	O
dendritic	O
cells	O
and	O
major	O
histocompatibility	O
(	O
MHC	O
)	O
class	O
Ia	O
molecules	O
.	O

Colonization	O
of	O
mice	O
with	O
the	O
11	O
-	O
strain	O
mixture	O
enhances	O
both	O
host	O
resistance	O
against	O
Listeria	B-bacteria
monocytogenes	I-bacteria
infection	O
and	O
the	O
therapeutic	O
efficacy	O
of	O
immune	O
checkpoint	O
inhibitors	O
in	O
syngeneic	O
tumour	O
models	O
.	O

The	O
11	O
strains	O
primarily	O
represent	O
rare	O
,	O
low	O
-	O
abundance	O
components	O
of	O
the	O
human	O
microbiome	O
,	O
and	O
thus	O
have	O
great	O
potential	O
as	O
broadly	O
effective	O
biotherapeutics	O
.	O

Administration	O
of	O
N	O
-	O
Acyl	O
-	O
Phosphatidylethanolamine	O
Expressing	O
Bacteria	O
to	O
Low	O
Density	O
Lipoprotein	O
Receptor	O
(	O
-	O
/	O
-	O
)	O
Mice	O
Improves	O
Indices	O
of	O
Cardiometabolic	O
Disease	O
.	O

Obesity	O
increases	O
the	O
risk	O
for	O
cardiometabolic	O
diseases	O
.	O

N	O
-	O
acyl	O
phosphatidylethanolamines	O
(	O
NAPEs	O
)	O
are	O
precursors	O
of	O
N	O
-	O
acylethanolamides	O
,	O
which	O
are	O
endogenous	O
lipid	O
satiety	O
factors	O
.	O

Incorporating	O
engineered	O
bacteria	O
expressing	O
NAPEs	O
into	O
the	O
gut	O
microbiota	O
retards	O
development	O
of	O
diet	O
induced	O
obesity	O
in	O
wild	O
-	O
type	O
mice	O
.	O

Because	O
NAPEs	O
can	O
also	O
exert	O
anti	O
-	O
inflammatory	O
effects	O
,	O
we	O
hypothesized	O
that	O
administering	O
NAPE	O
-	O
expressing	O
bacteria	O
to	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
(	O
Ldlr	O
)	O
(	O
-	O
/	O
-	O
)	O
mice	O
fed	O
a	O
Western	O
diet	O
would	O
improve	O
various	O
indices	O
of	O
cardiometabolic	O
disease	O
manifested	O
by	O
these	O
mice	O
.	O

NAPE	O
-	O
expressing	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
Nissle	I-bacteria
1917	I-bacteria
(	O
pNAPE	O
-	O
EcN	O
)	O
,	O
control	O
Nissle	B-bacteria
1917	I-bacteria
(	O
pEcN	O
)	O
,	O
or	O
vehicle	O
(	O
veh	O
)	O
were	O
given	O
via	O
drinking	O
water	O
to	O
Ldlr	O
(	O
-	O
/	O
-	O
)	O
mice	O
for	O
12	O
weeks	O
.	O

Compared	O
to	O
pEcN	O
or	O
veh	O
treatment	O
,	O
pNAPE	O
-	O
EcN	O
significantly	O
reduced	O
body	O
weight	O
and	O
adiposity	O
,	O
hepatic	O
triglycerides	O
,	O
fatty	O
acid	O
synthesis	O
genes	O
,	O
and	O
increased	O
expression	O
of	O
fatty	O
acid	O
oxidation	O
genes	O
.	O

pNAPE	O
-	O
EcN	O
also	O
significantly	O
reduced	O
markers	O
for	O
hepatic	O
inflammation	O
and	O
early	O
signs	O
of	O
fibrotic	O
development	O
.	O

Serum	O
cholesterol	O
was	O
reduced	O
with	O
pNAPE	O
-	O
EcN	O
,	O
but	O
atherosclerotic	O
lesion	O
size	O
showed	O
only	O
a	O
non	O
-	O
significant	O
trend	O
for	O
reduction	O
.	O

However	O
,	O
pNAPE	O
-	O
EcN	O
treatment	O
reduced	O
lesion	O
necrosis	O
by	O
69	O
%	O
indicating	O
an	O
effect	O
on	O
preventing	O
macrophage	O
inflammatory	O
death	O
.	O

Our	O
results	O
suggest	O
that	O
incorporation	O
of	O
NAPE	O
expressing	O
bacteria	O
into	O
the	O
gut	O
microbiota	O
can	O
potentially	O
serve	O
as	O
an	O
adjuvant	O
therapy	O
to	O
retard	O
development	O
of	O
cardiometabolic	O
disease	O
.	O

Gut	O
Virome	O
Analysis	O
of	O
Cameroonians	O
Reveals	O
High	O
Diversity	O
of	O
Enteric	O
Viruses	O
,	O
Including	O
Potential	O
Interspecies	O
Transmitted	O
Viruses	O
.	O

Diarrhea	O
remains	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
deaths	O
in	O
children	O
.	O

A	O
limited	O
number	O
of	O
studies	O
have	O
investigated	O
the	O
prevalence	O
of	O
enteric	O
pathogens	O
in	O
Cameroon	O
,	O
and	O
as	O
in	O
many	O
other	O
African	O
countries	O
,	O
the	O
cause	O
of	O
many	O
diarrheal	O
episodes	O
remains	O
unexplained	O
.	O

A	O
proportion	O
of	O
these	O
unknown	O
cases	O
of	O
diarrhea	O
are	O
likely	O
caused	O
by	O
yet	O
-	O
unidentified	O
viral	O
agents	O
,	O
some	O
of	O
which	O
could	O
be	O
the	O
result	O
of	O
(	O
recent	O
)	O
interspecies	O
transmission	O
from	O
animal	O
reservoirs	O
,	O
like	O
bats	O
.	O

Using	O
viral	O
metagenomics	O
,	O
we	O
screened	O
fecal	O
samples	O
of	O
221	O
humans	O
(	O
almost	O
all	O
with	O
gastroenteritis	O
symptoms	O
)	O
between	O
0	O
and	O
89	O
years	O
of	O
age	O
with	O
different	O
degrees	O
of	O
bat	O
contact	O
.	O

We	O
identified	O
viruses	O
belonging	O
to	O
families	O
that	O
are	O
known	O
to	O
cause	O
gastroenteritis	O
such	O
as	O
Adenoviridae	B-bacteria
,	O
Astroviridae	B-bacteria
,	O
Caliciviridae	B-bacteria
,	O
Picornaviridae	B-bacteria
,	O
and	O
Reoviridae	B-bacteria
Interestingly	O
,	O
a	O
mammalian	O
orthoreovirus	O
,	O
picobirnaviruses	O
,	O
a	O
smacovirus	O
,	O
and	O
a	O
pecovirus	O
were	O
also	O
found	O
.	O

Although	O
there	O
was	O
no	O
evidence	O
of	O
interspecies	O
transmission	O
of	O
the	O
most	O
common	O
human	O
gastroenteritis	O
-	O
related	O
viruses	O
(	O
Astroviridae	O
,	O
Caliciviridae	O
,	O
and	O
Reoviridae	O
)	O
,	O
the	O
phylogenies	O
of	O
the	O
identified	O
orthoreovirus	O
,	O
picobirnavirus	O
,	O
and	O
smacovirus	O
indicate	O
a	O
genetic	O
relatedness	O
of	O
these	O
viruses	O
identified	O
in	O
stools	O
of	O
humans	O
and	O
those	O
of	O
bats	O
and	O
/	O
or	O
other	O
animals	O
.	O

These	O
findings	O
points	O
out	O
the	O
possibility	O
of	O
interspecies	O
transmission	O
or	O
simply	O
a	O
shared	O
host	O
of	O
these	O
viruses	O
(	O
bacterial	O
,	O
fungal	O
,	O
parasitic	O
,	O
.	O
.	O
.	O
)	O
present	O
in	O
both	O
animals	O
(	O
bats	O
)	O
and	O
humans	O
.	O

Further	O
screening	O
of	O
bat	O
viruses	O
in	O
humans	O
or	O
vice	O
versa	O
will	O
elucidate	O
the	O
epidemiological	O
potential	O
threats	O
of	O
animal	O
viruses	O
to	O
human	O
health	O
.	O

Furthermore	O
,	O
this	O
study	O
showed	O
a	O
huge	O
diversity	O
of	O
highly	O
divergent	O
novel	O
phages	O
,	O
thereby	O
expanding	O
the	O
existing	O
phageome	O
considerably	O
.	O
IMPORTANCE	O
Despite	O
the	O
availability	O
of	O
diagnostic	O
tools	O
for	O
different	O
enteric	O
viral	O
pathogens	O
,	O
a	O
large	O
fraction	O
of	O
human	O
cases	O
of	O
gastroenteritis	O
remains	O
unexplained	O
.	O

This	O
could	O
be	O
due	O
to	O
pathogens	O
not	O
tested	O
for	O
or	O
novel	O
divergent	O
viruses	O
of	O
potential	O
animal	O
origin	O
.	O

Fecal	O
virome	O
analyses	O
of	O
Cameroonians	O
showed	O
a	O
very	O
diverse	O
group	O
of	O
viruses	O
,	O
some	O
of	O
which	O
are	O
genetically	O
related	O
to	O
those	O
identified	O
in	O
animals	O
.	O

This	O
is	O
the	O
first	O
attempt	O
to	O
describe	O
the	O
gut	O
virome	O
of	O
humans	O
from	O
Cameroon	O
.	O

Therefore	O
,	O
the	O
data	O
represent	O
a	O
baseline	O
for	O
future	O
studies	O
on	O
enteric	O
viral	O
pathogens	O
in	O
this	O
area	O
and	O
contribute	O
to	O
our	O
knowledge	O
of	O
the	O
world	O
'	O
s	O
virome	O
.	O

The	O
studies	O
also	O
highlight	O
the	O
fact	O
that	O
more	O
viruses	O
may	O
be	O
associated	O
with	O
diarrhea	O
than	O
the	O
typical	O
known	O
ones	O
.	O

Hence	O
,	O
it	O
provides	O
meaningful	O
epidemiological	O
information	O
on	O
diarrhea	O
-	O
related	O
viruses	O
in	O
this	O
area	O
.	O

Wood	O
-	O
Derived	O
Dietary	O
Fibers	O
Promote	O
Beneficial	O
Human	O
Gut	O
Microbiota	O
.	O

Woody	O
biomass	O
is	O
a	O
sustainable	O
and	O
virtually	O
unlimited	O
source	O
of	O
hemicellulosic	O
polysaccharides	O
.	O

The	O
predominant	O
hemicelluloses	O
in	O
softwood	O
and	O
hardwood	O
are	O
galactoglucomannan	O
(	O
GGM	O
)	O
and	O
arabinoglucuronoxylan	O
(	O
AGX	O
)	O
,	O
respectively	O
.	O

Based	O
on	O
the	O
structure	O
similarity	O
with	O
common	O
dietary	O
fibers	O
,	O
GGM	O
and	O
AGX	O
may	O
be	O
postulated	O
to	O
have	O
prebiotic	O
properties	O
,	O
conferring	O
a	O
health	O
benefit	O
on	O
the	O
host	O
through	O
specific	O
modulation	O
of	O
the	O
gut	O
microbiota	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
prebiotic	O
potential	O
of	O
acetylated	O
GGM	O
(	O
AcGGM	O
)	O
and	O
highly	O
acetylated	O
AGX	O
(	O
AcAGX	O
)	O
obtained	O
from	O
Norwegian	O
lignocellulosic	O
feedstocks	O
in	O
vitro	O
In	O
pure	O
culture	O
,	O
both	O
substrates	O
selectively	O
promoted	O
the	O
growth	O
of	O
Bifidobacterium	B-bacteria
,	O
Lactobacillus	B-bacteria
,	O
and	O
Bacteroides	B-bacteria
species	I-bacteria
in	O
a	O
manner	O
consistent	O
with	O
the	O
presence	O
of	O
genetic	O
loci	O
for	O
the	O
utilization	O
of	O
beta	O
-	O
manno	O
-	O
oligosaccharides	O
/	O
beta	O
-	O
mannans	O
and	O
xylo	O
-	O
oligosaccharides	O
/	O
xylans	O
.	O

The	O
prebiotic	O
potential	O
of	O
AcGGM	O
and	O
AcAGX	O
was	O
further	O
assessed	O
in	O
a	O
pH	O
-	O
controlled	O
batch	O
culture	O
fermentation	O
system	O
inoculated	O
with	O
healthy	O
adult	O
human	O
feces	O
.	O

Results	O
were	O
compared	O
with	O
those	O
obtained	O
with	O
a	O
commercial	O
fructo	O
-	O
oligosaccharide	O
(	O
FOS	O
)	O
mixture	O
.	O

Similarly	O
to	O
FOS	O
,	O
both	O
substrates	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
Bifidobacterium	B-bacteria
population	O
.	O

Other	O
bacterial	O
groups	O
enumerated	O
were	O
unaffected	O
with	O
the	O
exception	O
of	O
an	O
increase	O
in	O
the	O
growth	O
of	O
members	O
of	O
the	O
Bacteroides	B-bacteria
-	I-bacteria
Prevotella	I-bacteria
group	O
,	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
,	O
and	O
clostridial	B-bacteria
cluster	I-bacteria
IX	I-bacteria
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Compared	O
to	O
the	O
other	O
substrates	O
,	O
AcGGM	O
promoted	O
butyrogenic	O
fermentation	O
whereas	O
AcAGX	O
was	O
more	O
propiogenic	O
.	O

Although	O
further	O
in	O
vivo	O
confirmation	O
is	O
necessary	O
,	O
these	O
results	O
demonstrate	O
that	O
both	O
AcGGM	O
and	O
AcAGX	O
from	O
lignocellulosic	O
feedstocks	O
can	O
be	O
used	O
to	O
direct	O
the	O
promotion	O
of	O
beneficial	O
bacteria	O
,	O
thus	O
exhibiting	O
a	O
promising	O
prebiotic	O
ability	O
to	O
improve	O
or	O
restore	O
gut	O
health	O
.	O
IMPORTANCE	O
The	O
architecture	O
of	O
the	O
gut	O
bacterial	O
ecosystem	O
has	O
a	O
profound	O
effect	O
on	O
the	O
physiology	O
and	O
well	O
-	O
being	O
of	O
the	O
host	O
.	O

Modulation	O
of	O
the	O
gut	O
microbiota	O
and	O
the	O
intestinal	O
microenvironment	O
via	O
administration	O
of	O
prebiotics	O
represents	O
a	O
valuable	O
strategy	O
to	O
promote	O
host	O
health	O
.	O

This	O
work	O
provides	O
insights	O
into	O
the	O
ability	O
of	O
two	O
novel	O
wood	O
-	O
derived	O
preparations	O
,	O
AcGGM	O
and	O
AcAGX	O
,	O
to	O
influence	O
human	O
gut	O
microbiota	O
composition	O
and	O
activity	O
.	O

These	O
compounds	O
were	O
selectively	O
fermented	O
by	O
commensal	O
bacteria	O
such	O
as	O
Bifidobacterium	B-bacteria
,	O
Bacteroides	B-bacteria
-	I-bacteria
Prevotella	I-bacteria
,	O
F	B-bacteria
.	I-bacteria
prausnitzii	I-bacteria
,	O
and	O
clostridial	B-bacteria
cluster	I-bacteria
IX	I-bacteria
spp	I-bacteria
.	O

This	O
promoted	O
the	O
microbial	O
synthesis	O
of	O
acetate	O
,	O
propionate	O
,	O
and	O
butyrate	O
,	O
which	O
are	O
bene	O
fi	O
cial	O
to	O
the	O
microbial	O
ecosystem	O
and	O
host	O
colonic	O
epithelial	O
cells	O
.	O

Thus	O
,	O
our	O
results	O
demonstrate	O
potential	O
prebiotic	O
properties	O
for	O
both	O
AcGGM	O
and	O
AcAGX	O
from	O
lignocellulosic	O
feedstocks	O
.	O

These	O
findings	O
represent	O
pivotal	O
requirements	O
for	O
rationally	O
designing	O
intervention	O
strategies	O
based	O
on	O
the	O
dietary	O
supplementation	O
of	O
AcGGM	O
and	O
AcAGX	O
to	O
improve	O
or	O
restore	O
gut	O
health	O
.	O

GARP	O
Dampens	O
Cancer	O
Immunity	O
by	O
Sustaining	O
Function	O
and	O
Accumulation	O
of	O
Regulatory	O
T	O
Cells	O
in	O
the	O
Colon	O
.	O

Activated	O
regulatory	O
T	O
(	O
Treg	O
)	O
cells	O
express	O
the	O
surface	O
receptor	O
glycoprotein	O
-	O
A	O
repetitions	O
predominant	O
(	O
GARP	O
)	O
,	O
which	O
binds	O
and	O
activates	O
latent	O
TGFbeta	O
.	O

How	O
GARP	O
modulates	O
Treg	O
function	O
in	O
inflammation	O
and	O
cancer	O
remains	O
unclear	O
.	O

Here	O
we	O
demonstrate	O
that	O
loss	O
of	O
GARP	O
in	O
Treg	O
cells	O
leads	O
to	O
spontaneous	O
inflammation	O
with	O
highly	O
activated	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
and	O
development	O
of	O
enteritis	O
.	O

Treg	O
cells	O
lacking	O
GARP	O
were	O
unable	O
to	O
suppress	O
pathogenic	O
T	O
-	O
cell	O
responses	O
in	O
multiple	O
models	O
of	O
inflammation	O
,	O
including	O
T	O
-	O
cell	O
transfer	O
colitis	O
.	O

GARP	O
(	O
-	O
/	O
-	O
)	O
Treg	O
cells	O
were	O
significantly	O
reduced	O
in	O
the	O
gut	O
and	O
exhibited	O
a	O
reduction	O
in	O
CD103	O
expression	O
,	O
a	O
colon	O
-	O
specific	O
migratory	O
marker	O
.	O

In	O
the	O
colitis	O
-	O
associated	O
colon	O
cancer	O
model	O
,	O
GARP	O
on	O
Treg	O
cells	O
dampened	O
immune	O
surveillance	O
,	O
and	O
mice	O
with	O
GARP	O
(	O
-	O
/	O
-	O
)	O
Treg	O
cells	O
exhibited	O
improved	O
antitumor	O
immunity	O
.	O

Thus	O
,	O
GARP	O
empowers	O
the	O
functionality	O
of	O
Treg	O
cells	O
and	O
their	O
tissue	O
-	O
specific	O
accumulation	O
,	O
highlighting	O
the	O
importance	O
of	O
cell	O
surface	O
TGFbeta	O
in	O
Treg	O
function	O
and	O
GARP	O
as	O
a	O
potential	O
therapeutic	O
target	O
for	O
colorectal	O
cancer	O
therapy	O
.	O
Significance	O
:	O
These	O
findings	O
uncover	O
functions	O
of	O
membrane	O
-	O
bound	O
TGFbeta	O
and	O
GARP	O
that	O
tune	O
the	O
activity	O
of	O
Treg	O
cells	O
,	O
highlighting	O
a	O
potential	O
treatment	O
strategy	O
in	O
autoimmune	O
diseases	O
and	O
cancer	O
.	O

Taxonomic	O
profiling	O
and	O
populational	O
patterns	O
of	O
bacterial	O
bile	O
salt	O
hydrolase	O
(	O
BSH	O
)	O
genes	O
based	O
on	O
worldwide	O
human	O
gut	O
microbiome	O
.	O

BACKGROUND	O
:	O
Bile	O
salt	O
hydrolase	O
plays	O
an	O
important	O
role	O
in	O
bile	O
acid	O
-	O
mediated	O
signaling	O
pathways	O
,	O
which	O
regulate	O
lipid	O
absorption	O
,	O
glucose	O
metabolism	O
,	O
and	O
energy	O
homeostasis	O
.	O

Several	O
reports	O
suggest	O
that	O
changes	O
in	O
the	O
composition	O
of	O
bile	O
acids	O
are	O
found	O
in	O
many	O
diseases	O
caused	O
by	O
dysbacteriosis	O
.	O

RESULTS	O
:	O
Here	O
,	O
we	O
present	O
the	O
taxonomic	O
identification	O
of	O
bile	O
salt	O
hydrolase	O
(	O
BSH	O
)	O
in	O
human	O
microbiota	O
and	O
elucidate	O
the	O
abundance	O
and	O
activity	O
differences	O
of	O
various	O
bacterial	O
BSH	O
among	O
11	O
different	O
populations	O
from	O
six	O
continents	O
.	O

For	O
the	O
first	O
time	O
,	O
we	O
revealed	O
that	O
bile	O
salt	O
hydrolase	O
protein	O
sequences	O
(	O
BSHs	O
)	O
are	O
distributed	O
in	O
591	O
intestinal	O
bacterial	O
strains	O
within	O
117	O
genera	O
in	O
human	O
microbiota	O
,	O
and	O
27	O
.	O
52	O
%	O
of	O
these	O
bacterial	O
strains	O
containing	O
BSH	O
paralogs	O
.	O

Significant	O
variations	O
are	O
observed	O
in	O
BSH	O
distribution	O
patterns	O
among	O
different	O
populations	O
.	O

Based	O
on	O
phylogenetic	O
analysis	O
,	O
we	O
reclassified	O
these	O
BSHs	O
into	O
eight	O
phylotypes	O
and	O
investigated	O
the	O
abundance	O
patterns	O
of	O
these	O
phylotypes	O
among	O
different	O
populations	O
.	O

From	O
the	O
inspection	O
of	O
enzyme	O
activity	O
among	O
different	O
BSH	O
phylotypes	O
,	O
BSH	O
-	O
T3	O
showed	O
the	O
highest	O
enzyme	O
activity	O
and	O
is	O
only	O
found	O
in	O
Lactobaclillus	B-bacteria
.	O

The	O
phylotypes	O
of	O
BSH	O
-	O
T5	O
and	O
BSH	O
-	O
T6	O
mainly	O
from	O
Bacteroides	B-bacteria
with	O
high	O
percentage	O
of	O
paralogs	O
exhibit	O
different	O
enzyme	O
activity	O
and	O
deconjugation	O
activity	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
there	O
were	O
significant	O
differences	O
between	O
healthy	O
individuals	O
and	O
patients	O
with	O
atherosclerosis	O
and	O
diabetes	O
in	O
some	O
phylotypes	O
of	O
BSHs	O
though	O
the	O
correlations	O
were	O
pleiotropic	O
.	O

CONCLUSION	O
:	O
This	O
study	O
revealed	O
the	O
taxonomic	O
and	O
abundance	O
profiling	O
of	O
BSH	O
in	O
human	O
gut	O
microbiome	O
and	O
provided	O
a	O
phylogenetic	O
-	O
based	O
system	O
to	O
assess	O
BSHs	O
activity	O
by	O
classifying	O
the	O
target	O
sequence	O
into	O
specific	O
phylotype	O
.	O

Furthermore	O
,	O
the	O
present	O
work	O
disclosed	O
the	O
variation	O
patterns	O
of	O
BSHs	O
among	O
different	O
populations	O
of	O
geographical	O
regions	O
and	O
health	O
/	O
disease	O
cohorts	O
,	O
which	O
is	O
essential	O
to	O
understand	O
the	O
role	O
of	O
BSH	O
in	O
the	O
development	O
and	O
progression	O
of	O
related	O
diseases	O
.	O

Characterization	O
of	O
the	O
bacterial	O
microbiome	O
in	O
first	O
-	O
pass	O
meconium	O
using	O
propidium	O
monoazide	O
(	O
PMA	O
)	O
to	O
exclude	O
nonviable	O
bacterial	O
DNA	O
.	O

Numerous	O
studies	O
have	O
reported	O
bacterial	O
DNA	O
in	O
first	O
-	O
pass	O
meconium	O
samples	O
,	O
suggesting	O
that	O
the	O
human	O
gut	O
microbiome	O
is	O
seeded	O
prior	O
to	O
birth	O
.	O

However	O
,	O
these	O
studies	O
have	O
not	O
been	O
able	O
to	O
discriminate	O
between	O
DNA	O
from	O
living	O
bacterial	O
cells	O
,	O
DNA	O
from	O
dead	O
bacterial	O
cells	O
or	O
cell	O
-	O
free	O
DNA	O
.	O

Here	O
we	O
have	O
used	O
propidium	O
monoazide	O
(	O
PMA	O
)	O
together	O
with	O
16S	O
rRNA	O
gene	O
sequencing	O
to	O
determine	O
whether	O
there	O
are	O
intact	O
bacterial	O
cells	O
in	O
the	O
fetal	O
gut	O
.	O

DNA	O
was	O
extracted	O
from	O
first	O
-	O
pass	O
meconium	O
(	O
n	O
=	O
5	O
)	O
and	O
subjected	O
to	O
16S	O
rRNA	O
gene	O
sequencing	O
with	O
/	O
without	O
PMA	O
treatment	O
.	O

All	O
meconium	O
samples	O
,	O
regardless	O
of	O
PMA	O
treatment	O
,	O
contained	O
detectable	O
levels	O
of	O
bacterial	O
DNA	O
;	O
however	O
,	O
treatment	O
with	O
PMA	O
prior	O
to	O
DNA	O
extraction	O
decreased	O
the	O
DNA	O
yield	O
by	O
approximately	O
20	O
%	O
.	O

PMA	O
-	O
treated	O
meconium	O
samples	O
did	O
not	O
differ	O
significantly	O
from	O
untreated	O
samples	O
in	O
terms	O
of	O
observed	O
number	O
of	O
OTUs	O
(	O
P	O
=	O
0	O
.	O
945	O
)	O
;	O
although	O
they	O
did	O
differ	O
taxonomically	O
,	O
with	O
around	O
one	O
quarter	O
of	O
OTUs	O
identified	O
in	O
untreated	O
samples	O
only	O
,	O
suggesting	O
that	O
they	O
have	O
originated	O
from	O
cell	O
-	O
free	O
/	O
nonviable	O
DNA	O
.	O

The	O
mean	O
Sorensen	O
coefficient	O
for	O
treated	O
vs	O
untreated	O
samples	O
was	O
0	O
.	O
527	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
fetal	O
gut	O
is	O
seeded	O
with	O
intact	O
bacterial	O
cells	O
prior	O
to	O
birth	O
.	O

This	O
is	O
an	O
important	O
finding	O
,	O
as	O
exposure	O
to	O
live	O
bacteria	O
during	O
gestation	O
might	O
have	O
a	O
significant	O
impact	O
on	O
the	O
developing	O
fetus	O
.	O

SIGNIFICANCE	O
AND	O
IMPACT	O
OF	O
THE	O
STUDY	O
:	O
DNA	O
-	O
based	O
microbiome	O
studies	O
performed	O
using	O
16S	O
rRNA	O
gene	O
sequencing	O
are	O
limited	O
by	O
their	O
inability	O
to	O
discriminate	O
between	O
live	O
bacterial	O
cells	O
,	O
dead	O
bacterial	O
cells	O
and	O
cell	O
-	O
free	O
DNA	O
.	O

Here	O
we	O
use	O
propidium	O
monoazide	O
(	O
PMA	O
)	O
to	O
exclude	O
nonviable	O
bacteria	O
from	O
microbiome	O
analysis	O
of	O
first	O
-	O
pass	O
meconium	O
samples	O
and	O
thereby	O
reveal	O
that	O
the	O
majority	O
of	O
the	O
purported	O
fetal	O
gut	O
microbiome	O
is	O
from	O
intact	O
bacterial	O
cells	O
.	O

This	O
work	O
demonstrates	O
the	O
importance	O
of	O
excluding	O
nonviable	O
bacteria	O
when	O
analysing	O
the	O
microbial	O
community	O
in	O
low	O
-	O
biomass	O
samples	O
such	O
as	O
meconium	O
.	O

Evolutionary	O
dynamics	O
of	O
bacteria	O
in	O
the	O
gut	O
microbiome	O
within	O
and	O
across	O
hosts	O
.	O

Gut	O
microbiota	O
are	O
shaped	O
by	O
a	O
combination	O
of	O
ecological	O
and	O
evolutionary	O
forces	O
.	O

While	O
the	O
ecological	O
dynamics	O
have	O
been	O
extensively	O
studied	O
,	O
much	O
less	O
is	O
known	O
about	O
how	O
species	O
of	O
gut	O
bacteria	O
evolve	O
over	O
time	O
.	O

Here	O
,	O
we	O
introduce	O
a	O
model	O
-	O
based	O
framework	O
for	O
quantifying	O
evolutionary	O
dynamics	O
within	O
and	O
across	O
hosts	O
using	O
a	O
panel	O
of	O
metagenomic	O
samples	O
.	O

We	O
use	O
this	O
approach	O
to	O
study	O
evolution	O
in	O
approximately	O
40	O
prevalent	O
species	O
in	O
the	O
human	O
gut	O
.	O

Although	O
the	O
patterns	O
of	O
between	O
-	O
host	O
diversity	O
are	O
consistent	O
with	O
quasi	O
-	O
sexual	O
evolution	O
and	O
purifying	O
selection	O
on	O
long	O
timescales	O
,	O
we	O
identify	O
new	O
genealogical	O
signatures	O
that	O
challenge	O
standard	O
population	O
genetic	O
models	O
of	O
these	O
processes	O
.	O

Within	O
hosts	O
,	O
we	O
find	O
that	O
genetic	O
differences	O
that	O
accumulate	O
over	O
6	O
-	O
month	O
timescales	O
are	O
only	O
rarely	O
attributable	O
to	O
replacement	O
by	O
distantly	O
related	O
strains	O
.	O

Instead	O
,	O
the	O
resident	O
strains	O
more	O
commonly	O
acquire	O
a	O
smaller	O
number	O
of	O
putative	O
evolutionary	O
changes	O
,	O
in	O
which	O
nucleotide	O
variants	O
or	O
gene	O
gains	O
or	O
losses	O
rapidly	O
sweep	O
to	O
high	O
frequency	O
.	O

By	O
comparing	O
these	O
mutations	O
with	O
the	O
typical	O
between	O
-	O
host	O
differences	O
,	O
we	O
find	O
evidence	O
that	O
some	O
sweeps	O
may	O
be	O
seeded	O
by	O
recombination	O
,	O
in	O
addition	O
to	O
new	O
mutations	O
.	O

However	O
,	O
comparisons	O
of	O
adult	O
twins	O
suggest	O
that	O
replacement	O
eventually	O
overwhelms	O
evolution	O
over	O
multi	O
-	O
decade	O
timescales	O
,	O
hinting	O
at	O
fundamental	O
limits	O
to	O
the	O
extent	O
of	O
local	O
adaptation	O
.	O

Together	O
,	O
our	O
results	O
suggest	O
that	O
gut	O
bacteria	O
can	O
evolve	O
on	O
human	O
-	O
relevant	O
timescales	O
,	O
and	O
they	O
highlight	O
the	O
connections	O
between	O
these	O
short	O
-	O
term	O
evolutionary	O
dynamics	O
and	O
longer	O
-	O
term	O
evolution	O
across	O
hosts	O
.	O

Beneficial	O
Effects	O
of	O
Probiotic	O
Consumption	O
on	O
the	O
Immune	O
System	O
.	O

BACKGROUND	O
:	O
The	O
gastrointestinal	O
tract	O
is	O
one	O
of	O
the	O
most	O
microbiologically	O
active	O
ecosystems	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
working	O
of	O
the	O
mucosal	O
immune	O
system	O
(	O
MIS	O
)	O
.	O

In	O
this	O
ecosystem	O
,	O
the	O
consumed	O
probiotics	O
stimulate	O
the	O
immune	O
system	O
and	O
induce	O
a	O
network	O
of	O
signals	O
mediated	O
by	O
the	O
whole	O
bacteria	O
or	O
their	O
cell	O
wall	O
structure	O
.	O

This	O
review	O
is	O
aimed	O
at	O
describing	O
the	O
immunological	O
mechanisms	O
of	O
probiotics	O
and	O
their	O
beneficial	O
effects	O
on	O
the	O
host	O
.	O

SUMMARY	O
:	O
Once	O
administered	O
,	O
oral	O
probiotic	O
bacteria	O
interact	O
with	O
the	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
or	O
immune	O
cells	O
associated	O
with	O
the	O
lamina	O
propria	O
,	O
through	O
Toll	O
-	O
like	O
receptors	O
,	O
and	O
induce	O
the	O
production	O
of	O
different	O
cytokines	O
or	O
chemokines	O
.	O

Macrophage	O
chemoattractant	O
protein	O
1	O
,	O
produced	O
by	O
the	O
IECs	O
,	O
sends	O
signals	O
to	O
other	O
immune	O
cells	O
leading	O
to	O
the	O
activation	O
of	O
the	O
MIS	O
,	O
characterized	O
by	O
an	O
increase	O
in	O
immunoglobulin	O
A	O
+	O
cells	O
of	O
the	O
intestine	O
,	O
bronchus	O
and	O
mammary	O
glands	O
,	O
and	O
the	O
activation	O
of	O
T	O
cells	O
.	O

Specifically	O
,	O
probiotics	O
activate	O
regulatory	O
T	O
cells	O
that	O
release	O
IL	O
-	O
10	O
.	O

Interestingly	O
,	O
probiotics	O
reinforce	O
the	O
intestinal	O
barrier	O
by	O
an	O
increase	O
of	O
the	O
mucins	O
,	O
the	O
tight	O
junction	O
proteins	O
and	O
the	O
Goblet	O
and	O
Paneth	O
cells	O
.	O

Another	O
proposed	O
mechanism	O
of	O
probiotics	O
is	O
the	O
modulation	O
of	O
intestinal	O
microbiota	O
by	O
maintaining	O
the	O
balance	O
and	O
suppressing	O
the	O
growth	O
of	O
potential	O
pathogenic	O
bacteria	O
in	O
the	O
gut	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
long	O
-	O
term	O
probiotics	O
consumption	O
does	O
not	O
affect	O
the	O
intestinal	O
homeostasis	O
.	O

The	O
viability	O
of	O
probiotics	O
is	O
crucial	O
in	O
the	O
interaction	O
with	O
IECs	O
and	O
macrophages	O
favoring	O
,	O
mainly	O
,	O
the	O
innate	O
immune	O
response	O
.	O

Macrophages	O
and	O
Dendritic	O
cells	O
(	O
DCs	O
)	O
play	O
an	O
important	O
role	O
in	O
this	O
immune	O
response	O
without	O
inducing	O
an	O
inflammatory	O
pattern	O
,	O
just	O
a	O
slight	O
increase	O
in	O
the	O
cellularity	O
of	O
the	O
lamina	O
propria	O
.	O

Besides	O
,	O
as	O
part	O
of	O
the	O
machinery	O
that	O
probiotics	O
activate	O
to	O
protect	O
against	O
different	O
pathogens	O
,	O
an	O
increase	O
in	O
the	O
microbicidal	O
activity	O
of	O
peritoneal	O
and	O
spleen	O
macrophages	O
has	O
been	O
reported	O
.	O

In	O
malnutrition	O
models	O
,	O
such	O
as	O
undernourishment	O
and	O
obesity	O
,	O
probiotic	O
was	O
able	O
to	O
increase	O
the	O
intestinal	O
and	O
systemic	O
immune	O
response	O
.	O

Furthermore	O
,	O
probiotics	O
contribute	O
to	O
recover	O
the	O
histology	O
of	O
both	O
the	O
intestine	O
and	O
the	O
thymus	O
damaged	O
in	O
these	O
conditions	O
.	O

Probiotic	O
bacteria	O
are	O
emerging	O
as	O
a	O
safe	O
and	O
natural	O
strategy	O
for	O
allergy	O
prevention	O
and	O
treatment	O
.	O

Different	O
mechanisms	O
such	O
as	O
the	O
generation	O
of	O
cytokines	O
from	O
activated	O
pro	O
-	O
T	O
-	O
helper	O
type	O
1	O
,	O
which	O
favor	O
the	O
production	O
of	O
IgG	O
instead	O
of	O
IgE	O
,	O
have	O
been	O
proposed	O
.	O

Key	O
Messages	O
:	O
Probiotic	O
bacteria	O
,	O
their	O
cell	O
walls	O
or	O
probiotic	O
fermented	O
milk	O
have	O
significant	O
effects	O
on	O
the	O
functionality	O
of	O
the	O
mucosal	O
and	O
systemic	O
immune	O
systems	O
through	O
the	O
activation	O
of	O
multiple	O
immune	O
mechanisms	O
.	O

Oxygen	O
and	O
contact	O
with	O
human	O
intestinal	O
epithelium	O
independently	O
stimulate	O
virulence	O
gene	O
expression	O
in	O
enteroaggregative	B-bacteria
Escherichia	B-bacteria
coli	I-bacteria
.	O

Enteroaggregative	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
(	O
EAEC	B-bacteria
)	O
are	O
important	O
intestinal	O
pathogens	O
causing	O
acute	O
and	O
persistent	O
diarrhoeal	O
illness	O
worldwide	O
.	O

Although	O
many	O
putative	O
EAEC	B-bacteria
virulence	O
factors	O
have	O
been	O
identified	O
,	O
their	O
association	O
with	O
pathogenesis	O
remains	O
unclear	O
.	O

As	O
environmental	O
cues	O
can	O
modulate	O
bacterial	O
virulence	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
oxygen	O
and	O
human	O
intestinal	O
epithelium	O
on	O
EAEC	O
virulence	O
gene	O
expression	O
to	O
determine	O
the	O
involvement	O
of	O
respective	O
gene	O
products	O
in	O
intestinal	O
colonisation	O
and	O
pathogenesis	O
.	O

Using	O
in	O
vitro	O
organ	O
culture	O
of	O
human	O
intestinal	O
biopsies	O
,	O
we	O
established	O
the	O
colonic	O
epithelium	O
as	O
the	O
major	O
colonisation	O
site	O
of	O
EAEC	B-bacteria
strains	I-bacteria
042	I-bacteria
and	O
17	O
-	O
2	O
.	O

We	O
subsequently	O
optimised	O
a	O
vertical	O
diffusion	O
chamber	O
system	O
with	O
polarised	O
T84	O
colon	O
carcinoma	O
cells	O
for	O
EAEC	O
infection	O
and	O
showed	O
that	O
oxygen	O
induced	O
expression	O
of	O
the	O
global	O
regulator	O
AggR	O
,	O
aggregative	O
adherence	O
fimbriae	O
,	O
E	B-bacteria
.	I-bacteria
coli	I-bacteria
common	O
pilus	O
,	O
EAST	O
-	O
1	O
toxin	O
,	O
and	O
dispersin	O
in	O
EAEC	B-bacteria
strain	I-bacteria
042	I-bacteria
but	O
not	O
in	O
17	O
-	O
2	O
.	O

Furthermore	O
,	O
the	O
presence	O
of	O
T84	O
epithelia	O
stimulated	O
additional	O
expression	O
of	O
the	O
mucinase	O
Pic	O
and	O
the	O
toxins	O
HlyE	O
and	O
Pet	O
.	O

This	O
induction	O
was	O
dependent	O
on	O
physical	O
host	O
cell	O
contact	O
and	O
did	O
not	O
require	O
AggR	O
.	O

Overall	O
,	O
these	O
findings	O
suggest	O
that	O
EAEC	B-bacteria
virulence	O
in	O
the	O
human	O
gut	O
is	O
modulated	O
by	O
environmental	O
signals	O
including	O
oxygen	O
and	O
the	O
intestinal	O
epithelium	O
.	O

Advanced	O
Age	O
Impairs	O
Intestinal	O
Antimicrobial	O
Peptide	O
Response	O
and	O
Worsens	O
Fecal	O
Microbiome	O
Dysbiosis	O
Following	O
Burn	O
Injury	O
in	O
Mice	O
.	O

Maintenance	O
of	O
the	O
commensal	O
bacteria	O
that	O
comprise	O
the	O
gut	O
microbiome	O
is	O
essential	O
to	O
both	O
gut	O
and	O
systemic	O
health	O
.	O

Traumatic	O
injury	O
,	O
such	O
as	O
burn	O
,	O
elicits	O
a	O
number	O
of	O
changes	O
in	O
the	O
gut	O
,	O
including	O
a	O
shift	O
in	O
the	O
composition	O
of	O
the	O
microbiome	O
(	O
dysbiosis	O
)	O
,	O
increased	O
gut	O
leakiness	O
,	O
and	O
bacterial	O
translocation	O
into	O
the	O
lymphatic	O
system	O
and	O
bloodstream	O
.	O

These	O
effects	O
are	O
believed	O
to	O
contribute	O
to	O
devastating	O
secondary	O
complications	O
following	O
burn	O
,	O
including	O
pneumonia	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
multi	O
-	O
organ	O
failure	O
,	O
and	O
septic	O
shock	O
.	O

Clinical	O
studies	O
demonstrate	O
that	O
advanced	O
age	O
causes	O
a	O
significant	O
increase	O
in	O
mortality	O
following	O
burn	O
,	O
but	O
the	O
role	O
of	O
the	O
gut	O
in	O
this	O
age	O
-	O
dependent	O
susceptibility	O
has	O
not	O
been	O
investigated	O
.	O

In	O
this	O
study	O
,	O
we	O
combined	O
our	O
well	O
-	O
established	O
murine	O
model	O
of	O
scald	O
burn	O
injury	O
with	O
bacterial	O
16S	O
-	O
rRNA	O
gene	O
sequencing	O
to	O
investigate	O
how	O
burn	O
injury	O
affects	O
the	O
fecal	O
microbiome	O
in	O
aged	O
versus	O
young	O
mice	O
.	O

Of	O
our	O
treatment	O
groups	O
,	O
the	O
most	O
substantial	O
shift	O
in	O
gut	O
microbial	O
populations	O
was	O
observed	O
in	O
aged	O
mice	O
that	O
underwent	O
burn	O
injury	O
.	O

We	O
then	O
profiled	O
anti	O
-	O
microbial	O
peptides	O
(	O
AMPs	O
)	O
in	O
the	O
ileum	O
and	O
found	O
that	O
burn	O
injury	O
stimulated	O
a	O
20	O
-	O
fold	O
rise	O
in	O
levels	O
of	O
regenerating	O
islet	O
-	O
derived	O
protein	O
3	O
gamma	O
(	O
Reg3gamma	O
)	O
,	O
a	O
16	O
-	O
fold	O
rise	O
in	O
regenerating	O
islet	O
-	O
derived	O
protein	O
3	O
beta	O
(	O
Reg3beta	O
)	O
,	O
and	O
an	O
8	O
-	O
fold	O
rise	O
in	O
Cathelicidin	O
-	O
related	O
antimicrobial	O
peptide	O
(	O
Cramp	O
)	O
in	O
young	O
,	O
but	O
not	O
aged	O
mice	O
.	O

Advanced	O
age	O
alone	O
elicited	O
5	O
-	O
fold	O
higher	O
levels	O
of	O
alpha	O
defensin	O
related	O
sequence1	O
(	O
Defa	O
-	O
rs1	O
)	O
in	O
the	O
ileum	O
,	O
but	O
this	O
increase	O
was	O
lost	O
following	O
burn	O
.	O

Comparison	O
of	O
bacterial	O
genera	O
abundance	O
and	O
AMP	O
expression	O
across	O
treatment	O
groups	O
revealed	O
distinct	O
correlation	O
patterns	O
between	O
AMPs	O
and	O
individual	O
genera	O
.	O

Our	O
results	O
reveal	O
that	O
burn	O
injury	O
drives	O
microbiome	O
dysbiosis	O
and	O
altered	O
AMP	O
expression	O
in	O
an	O
age	O
-	O
dependent	O
fashion	O
,	O
and	O
highlight	O
potential	O
mechanistic	O
targets	O
contributing	O
to	O
the	O
increased	O
morbidity	O
and	O
mortality	O
observed	O
in	O
elderly	O
burn	O
patients	O
.	O

Crystal	O
toxins	O
and	O
the	O
volunteer	O
'	O
s	O
dilemma	O
in	O
bacteria	O
.	O

The	O
growth	O
and	O
virulence	O
of	O
the	O
bacteria	O
Bacillus	B-bacteria
thuringiensis	I-bacteria
depend	O
on	O
the	O
production	O
of	O
Cry	O
toxins	O
,	O
which	O
are	O
used	O
to	O
perforate	O
the	O
gut	O
of	O
its	O
host	O
.	O

Successful	O
invasion	O
of	O
the	O
host	O
relies	O
on	O
producing	O
a	O
threshold	O
amount	O
of	O
toxin	O
,	O
after	O
which	O
there	O
is	O
no	O
benefit	O
from	O
producing	O
more	O
toxin	O
.	O

Consequently	O
,	O
the	O
production	O
of	O
Cry	O
toxin	O
appears	O
to	O
be	O
a	O
different	O
type	O
of	O
social	O
problem	O
compared	O
with	O
the	O
public	O
goods	O
scenarios	O
that	O
bacteria	O
usually	O
encounter	O
.	O

We	O
show	O
that	O
selection	O
for	O
toxin	O
production	O
is	O
a	O
volunteer	O
'	O
s	O
dilemma	O
.	O

We	O
make	O
specific	O
predictions	O
that	O
(	O
a	O
)	O
selection	O
for	O
toxin	O
production	O
depends	O
upon	O
an	O
interplay	O
between	O
the	O
number	O
of	O
bacterial	O
cells	O
that	O
each	O
host	O
ingests	O
and	O
the	O
genetic	O
relatedness	O
between	O
those	O
cells	O
;	O
(	O
b	O
)	O
cheats	O
that	O
do	O
not	O
produce	O
toxin	O
gain	O
an	O
advantage	O
when	O
at	O
low	O
frequencies	O
,	O
and	O
at	O
high	O
bacterial	O
density	O
,	O
allowing	O
them	O
to	O
be	O
maintained	O
in	O
a	O
population	O
alongside	O
toxin	O
-	O
producing	O
cells	O
.	O

More	O
generally	O
,	O
our	O
results	O
emphasize	O
the	O
diversity	O
of	O
the	O
social	O
games	O
that	O
bacteria	O
play	O
.	O

A	O
correlation	O
between	O
intestinal	O
microbiota	O
dysbiosis	O
and	O
osteoarthritis	O
.	O

Osteoarthritis	O
(	O
OA	O
)	O
is	O
a	O
degenerative	O
disease	O
of	O
the	O
articular	O
cartilage	O
,	O
resulting	O
in	O
pain	O
and	O
total	O
joint	O
disability	O
.	O

Recent	O
studies	O
focused	O
on	O
the	O
role	O
of	O
the	O
metabolic	O
syndrome	O
in	O
inducing	O
or	O
worsening	O
joint	O
damage	O
suggest	O
that	O
chronic	O
low	O
-	O
grade	O
systemic	O
inflammation	O
may	O
represent	O
a	O
possible	O
linking	O
factor	O
.	O

This	O
finding	O
supports	O
the	O
concept	O
of	O
a	O
new	O
phenotype	O
of	O
OA	O
,	O
a	O
metabolic	O
OA	O
.	O

The	O
gut	O
microbiome	O
is	O
fundamental	O
for	O
human	O
physiology	O
and	O
immune	O
system	O
development	O
,	O
among	O
the	O
other	O
important	O
functions	O
.	O

Manipulation	O
of	O
the	O
gut	O
microbiome	O
is	O
considered	O
an	O
important	O
topic	O
for	O
the	O
individual	O
health	O
in	O
different	O
medical	O
fields	O
such	O
as	O
medical	O
biology	O
,	O
nutrition	O
,	O
sports	O
,	O
preventive	O
and	O
rehabilitative	O
medicine	O
.	O

Since	O
intestinal	O
microbiota	O
dysbiosis	O
is	O
strongly	O
associated	O
with	O
the	O
pathogenesis	O
of	O
several	O
metabolic	O
and	O
inflammatory	O
diseases	O
,	O
it	O
is	O
conceivable	O
that	O
also	O
the	O
pathogenesis	O
of	O
OA	O
might	O
be	O
related	O
to	O
it	O
.	O

However	O
,	O
the	O
mechanisms	O
and	O
the	O
contribution	O
of	O
intestinal	O
microbiota	O
metabolites	O
in	O
OA	O
pathogenesis	O
are	O
still	O
not	O
clear	O
.	O

The	O
aim	O
of	O
this	O
narrative	O
review	O
is	O
to	O
review	O
recent	O
literature	O
concerning	O
the	O
possible	O
contribution	O
of	O
dysbiosis	O
to	O
OA	O
onset	O
and	O
to	O
discuss	O
the	O
importance	O
of	O
gut	O
microbiome	O
homeostasis	O
maintenance	O
for	O
optimal	O
general	O
health	O
preservation	O
.	O

Modulation	O
of	O
the	O
Gut	O
Microbiota	O
in	O
Rats	O
by	O
Hugan	O
Qingzhi	O
Tablets	O
during	O
the	O
Treatment	O
of	O
High	O
-	O
Fat	O
-	O
Diet	O
-	O
Induced	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
.	O

Background	O
:	O
Accumulative	O
evidence	O
showed	O
that	O
gut	O
microbiota	O
was	O
important	O
in	O
regulating	O
the	O
development	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
.	O

Hugan	O
Qingzhi	O
tablet	O
(	O
HQT	O
)	O
,	O
a	O
lipid	O
-	O
lowering	O
and	O
anti	O
-	O
inflammatory	O
medicinal	O
formula	O
,	O
has	O
been	O
used	O
to	O
prevent	O
and	O
treat	O
NAFLD	O
.	O

However	O
,	O
its	O
mechanism	O
of	O
action	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
confirm	O
whether	O
HQT	O
reversed	O
the	O
gut	O
microbiota	O
dysbiosis	O
in	O
NAFLD	O
rats	O
.	O

Methods	O
:	O
We	O
established	O
an	O
NAFLD	O
model	O
of	O
rats	O
fed	O
with	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
,	O
which	O
was	O
given	O
different	O
interventions	O
,	O
and	O
measured	O
the	O
level	O
of	O
liver	O
biochemical	O
indices	O
and	O
inflammatory	O
factors	O
.	O

Liver	O
tissues	O
were	O
stained	O
with	O
hematoxylin	O
-	O
eosin	O
and	O
oil	O
red	O
O	O
.	O

Changes	O
in	O
the	O
gut	O
microbiota	O
composition	O
were	O
analyzed	O
using	O
16S	O
rRNA	O
sequencing	O
.	O

Results	O
:	O
The	O
hepatic	O
histology	O
and	O
biochemical	O
data	O
displayed	O
that	O
HQT	O
exhibited	O
protective	O
effects	O
on	O
HFD	O
-	O
induced	O
rats	O
.	O

Moreover	O
,	O
HQT	O
also	O
reduced	O
the	O
abundance	O
of	O
the	O
Firmicutes	B-bacteria
/	O
Bacteroidetes	B-bacteria
ratio	O
in	O
HFD	O
-	O
fed	O
rats	O
and	O
modified	O
the	O
gut	O
microbial	O
species	O
at	O
the	O
genus	O
level	O
,	O
increasing	O
the	O
abundances	O
of	O
gut	O
microbiota	O
which	O
were	O
reported	O
to	O
have	O
an	O
effect	O
on	O
relieving	O
NAFLD	O
,	O
such	O
as	O
Ruminococcaceae	B-bacteria
,	O
Bacteroidales	B-bacteria
_	I-bacteria
S24	I-bacteria
-	I-bacteria
7	I-bacteria
_	I-bacteria
group	I-bacteria
,	O
Bifidobacteria	B-bacteria
,	O
Alistipes	B-bacteria
,	O
and	O
Anaeroplasma	B-bacteria
,	O
and	O
significantly	O
inhibiting	O
the	O
relative	O
abundance	O
of	O
Enterobacteriaceae	B-bacteria
,	O
Streptococcus	B-bacteria
,	O
Holdemanella	B-bacteria
,	O
Allobaculum	B-bacteria
,	O
and	O
Blautia	B-bacteria
,	O
which	O
were	O
reported	O
to	O
be	O
potentially	O
related	O
to	O
NAFLD	O
.	O

Spearman	O
'	O
s	O
correlation	O
analysis	O
found	O
that	O
[	B-bacteria
Ruminococcus	I-bacteria
]	I-bacteria
_	I-bacteria
gauvreauii	I-bacteria
_	I-bacteria
group	I-bacteria
,	O
Lachnoclostridium	B-bacteria
,	O
Blautia	B-bacteria
,	O
Allobaculum	B-bacteria
,	O
and	O
Holdemanella	B-bacteria
exhibited	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
positive	O
correlations	O
with	O
triglyceride	O
,	O
cholesterol	O
,	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
,	O
interleukin	O
-	O
6	O
,	O
interleukin	O
-	O
1beta	O
,	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
and	O
body	O
weight	O
and	O
negative	O
correlations	O
with	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
norank	O
_	O
f	O
_	O
_	O
Bacteroidales	O
_	O
S24	O
-	O
7	O
_	O
group	O
and	O
Alistipes	O
showed	O
an	O
opposite	O
trend	O
.	O

Moreover	O
,	O
the	O
HQT	O
could	O
promote	O
flavonoid	O
biosynthesis	O
compared	O
with	O
the	O
HFD	O
group	O
.	O

Conclusion	O
:	O
In	O
summary	O
,	O
the	O
HQT	O
has	O
potential	O
applications	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
NAFLD	O
,	O
which	O
may	O
be	O
closely	O
related	O
to	O
its	O
modulatory	O
effect	O
on	O
the	O
gut	O
microbiota	O
.	O

Gegen	O
Qinlian	O
Decoction	O
Attenuates	O
High	O
-	O
Fat	O
Diet	O
-	O
Induced	O
Steatohepatitis	O
in	O
Rats	O
via	O
Gut	O
Microbiota	O
.	O

Gut	O
microbiota	O
play	O
an	O
important	O
role	O
in	O
modulating	O
energy	O
contribution	O
,	O
metabolism	O
,	O
and	O
inflammation	O
,	O
and	O
disruption	O
of	O
the	O
microbiome	O
population	O
is	O
closely	O
associated	O
with	O
chronic	O
metabolic	O
diseases	O
,	O
such	O
as	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
.	O

Gegen	O
Qinlian	O
decoction	O
(	O
GGQLD	O
)	O
,	O
a	O
well	O
-	O
known	O
traditional	O
Chinese	O
herbal	O
medicine	O
(	O
CHM	O
)	O
,	O
was	O
previously	O
found	O
to	O
regulate	O
lipid	O
metabolism	O
and	O
attenuate	O
inflammation	O
during	O
NAFLD	O
pathogenesis	O
.	O

However	O
,	O
the	O
underlying	O
mechanism	O
of	O
this	O
process	O
,	O
as	O
well	O
as	O
how	O
the	O
gut	O
microbiome	O
is	O
involved	O
,	O
remains	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
varying	O
doses	O
of	O
GGQLD	O
on	O
the	O
total	O
amount	O
and	O
distribution	O
of	O
gut	O
bacteria	O
in	O
rats	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
for	O
8	O
weeks	O
.	O

Our	O
analysis	O
indicates	O
that	O
Oscillibacter	B-bacteria
and	O
Ruminococcaceae	B-bacteria
_	O
g	O
_	O
unclassified	O
are	O
the	O
dominant	O
families	O
in	O
the	O
HFD	O
group	O
.	O

Further	O
,	O
HFD	O
-	O
dependent	O
differences	O
at	O
the	O
phylum	O
,	O
class	O
,	O
and	O
genus	O
levels	O
appear	O
to	O
lead	O
to	O
dysbiosis	O
,	O
characterized	O
by	O
an	O
increase	O
in	O
the	O
Firmicutes	B-bacteria
/	O
Bacteroidetes	B-bacteria
ratio	O
and	O
a	O
dramatic	O
increase	O
in	O
the	O
Oscillibacter	B-bacteria
genus	I-bacteria
compared	O
to	O
the	O
control	O
group	O
.	O

Treatment	O
with	O
GGQLD	O
,	O
especially	O
the	O
GGQLL	O
dose	O
,	O
improved	O
these	O
HFD	O
-	O
induced	O
changes	O
in	O
intestinal	O
flora	O
,	O
leading	O
to	O
increased	O
levels	O
of	O
Firmicutes	B-bacteria
,	O
Clostridia	B-bacteria
,	O
Lactobacillus	B-bacteria
,	O
bacilli	B-bacteria
,	O
and	O
Erysipelotrichales	B-bacteria
that	O
were	O
similar	O
to	O
the	O
controls	O
.	O

Taken	O
together	O
,	O
our	O
data	O
highlight	O
the	O
efficacy	O
of	O
GGQLD	O
in	O
treating	O
NAFLD	O
and	O
support	O
its	O
clinical	O
use	O
as	O
a	O
treatment	O
for	O
NAFLD	O
/	O
NASH	O
patients	O
.	O

The	O
Inflammatory	O
Response	O
to	O
Enterotoxigenic	B-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
and	O
Probiotic	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
in	O
a	O
Coculture	O
Model	O
of	O
Porcine	O
Intestinal	O
Epithelial	O
and	O
Dendritic	O
Cells	O
.	O

The	O
gut	O
epithelium	O
constitutes	O
an	O
interface	O
between	O
the	O
intestinal	O
contents	O
and	O
the	O
underlying	O
gut	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
GALT	O
)	O
including	O
dendritic	O
cells	O
(	O
DC	O
)	O
.	O

Interactions	O
of	O
intestinal	O
epithelial	O
cells	O
(	O
IEC	O
)	O
and	O
resident	O
DC	O
are	O
characterized	O
by	O
bidirectional	O
crosstalk	O
mediated	O
by	O
various	O
factors	O
,	O
such	O
as	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
and	O
thymic	O
stromal	O
lymphopoietin	O
(	O
TSLP	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
(	O
1	O
)	O
to	O
model	O
the	O
interplay	O
of	O
both	O
cell	O
types	O
in	O
a	O
porcine	O
in	O
vitro	O
coculture	O
consisting	O
of	O
IEC	O
(	O
cell	O
line	O
IPEC	O
-	O
J2	O
)	O
and	O
monocyte	O
-	O
derived	O
DC	O
(	O
MoDC	O
)	O
and	O
(	O
2	O
)	O
to	O
assess	O
whether	O
immune	O
responses	O
to	O
bacteria	O
are	O
altered	O
because	O
of	O
the	O
interplay	O
between	O
IPEC	O
-	O
J2	O
cells	O
and	O
MoDC	O
.	O

With	O
regard	O
to	O
the	O
latter	O
,	O
we	O
focused	O
on	O
the	O
inflammasome	O
pathway	O
.	O

Here	O
,	O
we	O
propose	O
caspase	O
-	O
13	O
as	O
a	O
promising	O
candidate	O
for	O
the	O
noncanonical	O
inflammasome	O
activation	O
in	O
pigs	O
.	O

We	O
conducted	O
challenge	O
experiments	O
with	O
enterotoxigenic	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
(	O
ETEC	B-bacteria
)	O
and	O
probiotic	O
Enterococcus	B-bacteria
faecium	I-bacteria
(	O
E	B-bacteria
.	I-bacteria
faecium	I-bacteria
)	O
NCIMB	B-bacteria
10415	I-bacteria
.	O

As	O
potential	O
mediators	O
of	O
IEC	O
/	O
DC	O
interactions	O
,	O
TGF	O
-	O
beta	O
and	O
TSLP	O
were	O
selected	O
for	O
analyses	O
.	O

Cocultured	O
MoDC	O
showed	O
attenuated	O
ETEC	O
-	O
induced	O
inflammasome	O
-	O
related	O
and	O
proinflammatory	O
interleukin	O
(	O
IL	O
)	O
-	O
8	O
reactions	O
compared	O
with	O
MoDC	O
monocultures	O
.	O

Caspase	O
-	O
13	O
was	O
more	O
strongly	O
expressed	O
in	O
IPEC	O
-	O
J2	O
cells	O
cocultured	O
with	O
MoDC	O
and	O
upon	O
ETEC	O
incubation	O
.	O

We	O
found	O
that	O
IPEC	O
-	O
J2	O
cells	O
and	O
MoDC	O
were	O
capable	O
of	O
releasing	O
TSLP	O
.	O

The	O
latter	O
cells	O
secreted	O
greater	O
amounts	O
of	O
TSLP	O
when	O
cocultured	O
with	O
IPEC	O
-	O
J2	O
cells	O
.	O

TGF	O
-	O
beta	O
was	O
not	O
modulated	O
under	O
the	O
present	O
experimental	O
conditions	O
in	O
either	O
cell	O
types	O
.	O

We	O
conclude	O
that	O
,	O
in	O
the	O
presence	O
of	O
IPEC	O
-	O
J2	O
cells	O
,	O
porcine	O
MoDC	O
exhibited	O
a	O
more	O
tolerogenic	O
phenotype	O
,	O
which	O
might	O
be	O
partially	O
regulated	O
by	O
autocrine	O
TSLP	O
production	O
.	O

Noncanonical	O
inflammasome	O
signaling	O
appeared	O
to	O
be	O
modulated	O
in	O
IPEC	O
-	O
J2	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
reciprocal	O
interplay	O
of	O
the	O
intestinal	O
epithelium	O
and	O
GALT	O
is	O
essential	O
for	O
promoting	O
balanced	O
immune	O
responses	O
.	O

Role	O
of	O
diet	O
and	O
gut	O
microbiota	O
on	O
colorectal	O
cancer	O
immunomodulation	O
.	O

Colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
one	O
of	O
the	O
most	O
commonly	O
diagnosed	O
cancers	O
,	O
and	O
it	O
is	O
characterized	O
by	O
genetic	O
and	O
epigenetic	O
alterations	O
,	O
as	O
well	O
as	O
by	O
inflammatory	O
cell	O
infiltration	O
among	O
malignant	O
and	O
stromal	O
cells	O
.	O

However	O
,	O
this	O
dynamic	O
infiltration	O
can	O
be	O
influenced	O
by	O
the	O
microenvironment	O
to	O
promote	O
tumor	O
proliferation	O
,	O
survival	O
and	O
metastasis	O
or	O
cancer	O
inhibition	O
.	O

In	O
particular	O
,	O
the	O
cancer	O
microenvironment	O
metabolites	O
can	O
regulate	O
the	O
inflammatory	O
cells	O
to	O
induce	O
a	O
chronic	O
inflammatory	O
response	O
that	O
can	O
be	O
a	O
predisposing	O
condition	O
for	O
CRC	O
retention	O
.	O

In	O
addition	O
,	O
some	O
nutritional	O
components	O
might	O
contribute	O
to	O
a	O
chronic	O
inflammatory	O
condition	O
by	O
regulating	O
various	O
immune	O
and	O
inflammatory	O
pathways	O
.	O

Besides	O
that	O
,	O
diet	O
strongly	O
modulates	O
the	O
gut	O
microbiota	O
composition	O
,	O
which	O
has	O
a	O
key	O
role	O
in	O
maintaining	O
gut	O
homeostasis	O
and	O
is	O
associated	O
with	O
the	O
modulation	O
of	O
host	O
inflammatory	O
and	O
immune	O
responses	O
.	O

Therefore	O
,	O
diet	O
has	O
a	O
fundamental	O
role	O
in	O
CRC	O
initiation	O
,	O
progression	O
and	O
prevention	O
.	O

In	O
particular	O
,	O
functional	O
foods	O
such	O
as	O
probiotics	O
,	O
prebiotics	O
and	O
symbiotics	O
can	O
have	O
a	O
potentially	O
positive	O
effect	O
on	O
health	O
beyond	O
basic	O
nutrition	O
and	O
have	O
anti	O
-	O
inflammatory	O
effects	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
influence	O
of	O
diet	O
on	O
gut	O
microbiota	O
composition	O
,	O
focusing	O
on	O
its	O
role	O
on	O
gut	O
inflammation	O
and	O
immunity	O
.	O

Finally	O
,	O
we	O
describe	O
the	O
potential	O
benefits	O
of	O
using	O
probiotics	O
and	O
prebiotics	O
to	O
modulate	O
the	O
host	O
inflammatory	O
response	O
,	O
as	O
well	O
as	O
its	O
application	O
in	O
CRC	O
prevention	O
and	O
treatment	O
.	O

Altered	O
gut	O
microbiota	O
and	O
short	O
chain	O
fatty	O
acids	O
in	O
Chinese	O
children	O
with	O
autism	O
spectrum	O
disorder	O
.	O

Autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
is	O
a	O
neurodevelopmental	O
disorder	O
that	O
is	O
characterized	O
by	O
impairments	O
in	O
social	O
interactions	O
and	O
communication	O
,	O
restricted	O
interests	O
and	O
repetitive	O
behaviors	O
.	O

Several	O
studies	O
report	O
a	O
high	O
prevalence	O
of	O
gastrointestinal	O
(	O
GI	O
)	O
symptoms	O
in	O
autistic	O
individuals	O
.	O

Cumulative	O
evidence	O
reveals	O
that	O
the	O
gut	O
microbiota	O
and	O
its	O
metabolites	O
(	O
especially	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
SCFAs	O
)	O
play	O
an	O
important	O
role	O
in	O
GI	O
disorders	O
and	O
the	O
pathogenesis	O
of	O
ASD	O
.	O

However	O
,	O
the	O
composition	O
of	O
the	O
gut	O
microbiota	O
and	O
its	O
association	O
with	O
fecal	O
SCFAs	O
and	O
GI	O
symptoms	O
of	O
autistic	O
children	O
remain	O
largely	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
sequenced	O
the	O
bacterial	O
16S	O
rRNA	O
gene	O
,	O
detected	O
fecal	O
SCFAs	O
,	O
assessed	O
GI	O
symptoms	O
and	O
analyzed	O
the	O
relationship	O
between	O
the	O
gut	O
microbiome	O
and	O
fecal	O
SCFAs	O
in	O
autistic	O
and	O
neurotypical	O
individuals	O
.	O

The	O
results	O
showed	O
that	O
the	O
compositions	O
of	O
the	O
gut	O
microbiota	O
and	O
SCFAs	O
were	O
altered	O
in	O
ASD	O
individuals	O
.	O

We	O
found	O
lower	O
levels	O
of	O
fecal	O
acetic	O
acid	O
and	O
butyrate	O
and	O
a	O
higher	O
level	O
of	O
fecal	O
valeric	O
acid	O
in	O
ASD	O
subjects	O
.	O

We	O
identified	O
decreased	O
abundances	O
of	O
key	O
butyrate	O
-	O
producing	O
taxa	O
(	O
Ruminococcaceae	B-bacteria
,	O
Eubacterium	B-bacteria
,	O
Lachnospiraceae	B-bacteria
and	O
Erysipelotrichaceae	B-bacteria
)	O
and	O
an	O
increased	O
abundance	O
of	O
valeric	O
acid	O
associated	O
bacteria	O
(	O
Acidobacteria	B-bacteria
)	O
among	O
autistic	O
individuals	O
.	O

Constipation	O
was	O
the	O
only	O
GI	O
disorder	O
in	O
ASD	O
children	O
in	O
the	O
present	O
study	O
.	O

We	O
also	O
found	O
enriched	O
Fusobacterium	B-bacteria
,	O
Barnesiella	B-bacteria
,	O
Coprobacter	B-bacteria
and	O
valeric	O
acid	O
-	O
associated	O
bacteria	O
(	O
Actinomycetaceae	B-bacteria
)	O
and	O
reduced	O
butyrate	O
-	O
producing	O
taxa	O
in	O
constipated	O
autistic	O
subjects	O
.	O

It	O
is	O
suggested	O
that	O
the	O
gut	O
microbiota	O
contributes	O
to	O
fecal	O
SCFAs	O
and	O
constipation	O
in	O
autism	O
.	O

Modulating	O
the	O
gut	O
microbiota	O
,	O
especially	O
butyrate	O
-	O
producing	O
bacteria	O
,	O
could	O
be	O
a	O
promising	O
strategy	O
in	O
the	O
search	O
for	O
alternatives	O
for	O
the	O
treatment	O
of	O
autism	O
spectrum	O
disorder	O
.	O

Microbiota	O
fermentation	O
-	O
NLRP3	O
axis	O
shapes	O
the	O
impact	O
of	O
dietary	O
fibres	O
on	O
intestinal	O
inflammation	O
.	O

OBJECTIVE	O
:	O
Diets	O
rich	O
in	O
fermentable	O
fibres	O
provide	O
an	O
array	O
of	O
health	O
benefits	O
;	O
however	O
,	O
many	O
patients	O
with	O
IBD	O
report	O
poor	O
tolerance	O
to	O
fermentable	O
fibre	O
-	O
rich	O
foods	O
.	O

Intervention	O
studies	O
with	O
dietary	O
fibres	O
in	O
murine	O
models	O
of	O
colonic	O
inflammation	O
have	O
yielded	O
conflicting	O
results	O
on	O
whether	O
fibres	O
ameliorate	O
or	O
exacerbate	O
IBD	O
.	O

Herein	O
,	O
we	O
examined	O
how	O
replacing	O
the	O
insoluble	O
fibre	O
,	O
cellulose	O
,	O
with	O
the	O
fermentable	O
fibres	O
,	O
inulin	O
or	O
pectin	O
,	O
impacted	O
murine	O
colitis	O
resulting	O
from	O
immune	O
dysregulation	O
via	O
inhibition	O
of	O
interleukin	O
(	O
IL	O
)	O
-	O
10	O
signalling	O
and	O
/	O
or	O
innate	O
immune	O
deficiency	O
(	O
Tlr5KO	O
)	O
.	O

DESIGN	O
:	O
Mice	O
were	O
fed	O
with	O
diet	O
containing	O
either	O
cellulose	O
,	O
inulin	O
or	O
pectin	O
and	O
subjected	O
to	O
weekly	O
injections	O
of	O
an	O
IL	O
-	O
10	O
receptor	O
(	O
alphaIL	O
-	O
10R	O
)	O
neutralising	O
antibody	O
.	O

Colitis	O
development	O
was	O
examined	O
by	O
serological	O
,	O
biochemical	O
,	O
histological	O
and	O
immunological	O
parameters	O
.	O

RESULTS	O
:	O
Inulin	O
potentiated	O
the	O
severity	O
of	O
alphaIL10R	O
-	O
induced	O
colitis	O
,	O
while	O
pectin	O
ameliorated	O
the	O
disease	O
.	O

Such	O
exacerbation	O
of	O
colitis	O
following	O
inulin	O
feeding	O
was	O
associated	O
with	O
enrichment	O
of	O
butyrate	O
-	O
producing	O
bacteria	O
and	O
elevated	O
levels	O
of	O
caecal	O
butyrate	O
.	O

Blockade	O
of	O
butyrate	O
production	O
by	O
either	O
metronidazole	O
or	O
hops	O
beta	O
-	O
acids	O
ameliorated	O
colitis	O
severity	O
in	O
inulin	O
-	O
fed	O
mice	O
,	O
whereas	O
augmenting	O
caecal	O
butyrate	O
via	O
tributyrin	O
increased	O
colitis	O
severity	O
in	O
cellulose	O
containing	O
diet	O
-	O
fed	O
mice	O
.	O

Elevated	O
butyrate	O
levels	O
were	O
associated	O
with	O
increased	O
IL	O
-	O
1beta	O
activity	O
,	O
while	O
inhibition	O
of	O
the	O
NOD	O
-	O
like	O
receptor	O
protein	O
3	O
by	O
genetic	O
,	O
pharmacologic	O
or	O
dietary	O
means	O
markedly	O
reduced	O
colitis	O
.	O

CONCLUSION	O
:	O
These	O
results	O
not	O
only	O
support	O
the	O
notion	O
that	O
fermentable	O
fibres	O
have	O
the	O
potential	O
to	O
ameliorate	O
colitis	O
but	O
also	O
caution	O
that	O
,	O
in	O
some	O
contexts	O
,	O
prebiotic	O
fibres	O
can	O
lead	O
to	O
gut	O
dysbiosis	O
and	O
surfeit	O
colonic	O
butyrate	O
that	O
might	O
exacerbate	O
IBD	O
.	O

Role	O
of	O
the	O
microbiome	O
in	O
human	O
development	O
.	O

The	O
host	O
-	O
microbiome	O
supraorganism	O
appears	O
to	O
have	O
coevolved	O
and	O
the	O
unperturbed	O
microbial	O
component	O
of	O
the	O
dyad	O
renders	O
host	O
health	O
sustainable	O
.	O

This	O
coevolution	O
has	O
likely	O
shaped	O
evolving	O
phenotypes	O
in	O
all	O
life	O
forms	O
on	O
this	O
predominantly	O
microbial	O
planet	O
.	O

The	O
microbiota	O
seems	O
to	O
exert	O
effects	O
on	O
the	O
next	O
generation	O
from	O
gestation	O
,	O
via	O
maternal	O
microbiota	O
and	O
immune	O
responses	O
.	O

The	O
microbiota	O
ecosystems	O
develop	O
,	O
restricted	O
to	O
their	O
epithelial	O
niches	O
by	O
the	O
host	O
immune	O
system	O
,	O
concomitantly	O
with	O
the	O
host	O
chronological	O
development	O
,	O
providing	O
early	O
modulation	O
of	O
physiological	O
host	O
development	O
and	O
functions	O
for	O
nutrition	O
,	O
immunity	O
and	O
resistance	O
to	O
pathogens	O
at	O
all	O
ages	O
.	O

Here	O
,	O
we	O
review	O
the	O
role	O
of	O
the	O
microbiome	O
in	O
human	O
development	O
,	O
including	O
evolutionary	O
considerations	O
,	O
and	O
the	O
maternal	O
/	O
fetal	O
relationships	O
,	O
contributions	O
to	O
nutrition	O
and	O
growth	O
.	O

We	O
also	O
discuss	O
what	O
constitutes	O
a	O
healthy	O
microbiota	O
,	O
how	O
antimicrobial	O
modern	O
practices	O
are	O
impacting	O
the	O
human	O
microbiota	O
,	O
the	O
associations	O
between	O
microbiota	O
perturbations	O
,	O
host	O
responses	O
and	O
diseases	O
rocketing	O
in	O
urban	O
societies	O
and	O
potential	O
for	O
future	O
restoration	O
.	O

Comparative	O
biocontrol	O
ability	O
of	O
chitinases	O
from	O
bacteria	O
and	O
recombinant	O
chitinases	O
from	O
the	O
thermophilic	O
fungus	O
Thermomyces	O
lanuginosus	O
.	O

Microbial	O
chitinases	O
(	O
EC	O
3	O
.	O
2	O
.	O
1	O
.	O
14	O
)	O
are	O
known	O
to	O
hydrolyse	O
the	O
chitinous	O
gut	O
epithelium	O
of	O
insects	O
and	O
cell	O
walls	O
of	O
many	O
fungi	O
.	O

In	O
this	O
study	O
,	O
seven	O
chitinases	O
from	O
different	O
bacteria	O
and	O
fungi	O
were	O
produced	O
,	O
characterized	O
and	O
their	O
biocontrol	O
abilities	O
against	O
graminaceous	O
stem	O
borers	O
Eldana	O
saccharina	O
,	O
Chilo	O
partellus	O
and	O
Sesamia	O
calamistis	O
were	O
assessed	O
.	O

All	O
chitinases	O
were	O
stable	O
over	O
broad	O
ranges	O
of	O
pH	O
and	O
temperature	O
,	O
however	O
,	O
recombinant	O
fungal	O
chitinases	O
were	O
more	O
acid	O
-	O
stable	O
than	O
the	O
bacterial	O
counterparts	O
.	O

Chitinases	O
from	O
the	O
thermophilic	O
filamentous	O
fungi	O
Thermomyces	O
lanuginosus	O
SSBP	O
(	O
Chit1	O
)	O
and	O
from	O
Bacillus	B-bacteria
licheniformis	I-bacteria
(	O
Chit	O
lic	O
)	O
caused	O
70	O
%	O
and	O
80	O
%	O
mortality	O
,	O
respectively	O
,	O
in	O
second	O
instar	O
larvae	O
of	O
E	O
.	O
saccharina	O
.	O

Six	O
of	O
the	O
seven	O
partially	O
-	O
purified	O
microbial	O
chitinases	O
inhibited	O
Aspergillus	O
niger	O
,	O
A	O
.	O
flavus	O
,	O
A	O
.	O
alliaceus	O
,	O
A	O
.	O
ochraceus	O
,	O
Fusarium	O
verticillioides	O
and	O
Mucor	O
sp	O
.	O

Overall	O
,	O
microbial	O
chitinases	O
show	O
promise	O
as	O
biocontrol	O
agents	O
of	O
fungi	O
and	O
stalk	O
-	O
boring	O
lepidopterans	O
.	O

Targeting	O
obesity	O
management	O
through	O
gut	O
microbiota	O
modulation	O
by	O
herbal	O
products	O
:	O
A	O
systematic	O
review	O
.	O

OBJECTIVES	O
:	O
The	O
gut	O
dysbiosis	O
has	O
been	O
implicated	O
as	O
a	O
mediator	O
to	O
obesity	O
and	O
its	O
manipulation	O
could	O
be	O
an	O
appropriate	O
approach	O
to	O
sustainable	O
weight	O
loss	O
.	O

In	O
this	O
systematic	O
review	O
,	O
our	O
primary	O
objective	O
was	O
to	O
assess	O
the	O
potential	O
manipulation	O
of	O
gut	O
microbiota	O
by	O
herbal	O
products	O
in	O
obesity	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
did	O
a	O
comprehensive	O
search	O
in	O
PubMed	O
,	O
Web	O
of	O
Science	O
,	O
Scopus	O
and	O
Cochrane	O
databases	O
for	O
all	O
clinical	O
trials	O
and	O
animal	O
studies	O
exploring	O
the	O
effects	O
of	O
various	O
herbal	O
products	O
on	O
gut	O
microbiota	O
composition	O
in	O
obesity	O
documented	O
up	O
to	O
May	O
2017	O
.	O

RESULTS	O
:	O
Our	O
initial	O
search	O
yielded	O
2766	O
articles	O
.	O

After	O
screening	O
abstracts	O
and	O
full	O
texts	O
,	O
68	O
articles	O
were	O
included	O
(	O
55	O
animal	O
studies	O
and	O
13	O
clinical	O
trials	O
)	O
.	O

The	O
studies	O
differed	O
in	O
their	O
methodologies	O
,	O
type	O
of	O
interventions	O
and	O
intervention	O
lengths	O
.	O

The	O
weight	O
loss	O
was	O
only	O
reported	O
in	O
23	O
%	O
of	O
trials	O
and	O
in	O
64	O
%	O
of	O
animal	O
studies	O
.	O

An	O
increasing	O
tendency	O
in	O
Bifidobacterium	B-bacteria
species	I-bacteria
and	O
butyrate	O
-	O
producing	O
bacteria	O
such	O
as	O
Faecalibacterium	B-bacteria
prausnitzii	I-bacteria
were	O
observed	O
after	O
consuming	O
non	O
-	O
digestible	O
carbohydrates	O
,	O
although	O
these	O
changes	O
did	O
not	O
always	O
correlate	O
with	O
weight	O
loss	O
.	O

Supplementation	O
with	O
high	O
concentration	O
of	O
polyphenols	O
reduced	O
body	O
weight	O
gain	O
in	O
animal	O
studies	O
and	O
inhibited	O
growth	O
of	O
detrimental	O
species	O
such	O
as	O
Clostridia	B-bacteria
and	O
Enterobacteria	B-bacteria
while	O
the	O
growth	O
of	O
Lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
and	O
Akkermansia	B-bacteria
muciniphila	I-bacteria
is	O
enriched	O
.	O

CONCLUSIONS	O
:	O
Alteration	O
of	O
gut	O
microbiota	O
after	O
interventions	O
has	O
been	O
affected	O
by	O
the	O
baseline	O
composition	O
of	O
gut	O
microbiota	O
.	O

This	O
systematic	O
review	O
shows	O
that	O
consumption	O
of	O
herbal	O
products	O
might	O
have	O
beneficial	O
effects	O
on	O
restoring	O
healthy	O
gut	O
microbiome	O
besides	O
body	O
fat	O
reduction	O
.	O

Oral	O
Delivery	O
of	O
Cholic	O
Acid	O
-	O
Derived	O
Amphiphile	O
Helps	O
in	O
Combating	O
Salmonella	O
-	O
Mediated	O
Gut	O
Infection	O
and	O
Inflammation	O
.	O

A	O
major	O
impediment	O
to	O
developing	O
effective	O
antimicrobials	O
against	O
Gram	O
-	O
negative	O
bacteria	O
like	O
Salmonella	B-bacteria
is	O
the	O
ability	O
of	O
the	O
bacteria	O
to	O
develop	O
resistance	O
against	O
existing	O
antibiotics	O
and	O
the	O
inability	O
of	O
the	O
antimicrobials	O
to	O
clear	O
the	O
intracellular	O
bacteria	O
residing	O
in	O
the	O
gastrointestinal	O
tract	O
.	O

As	O
the	O
critical	O
balance	O
of	O
charge	O
and	O
hydrophobicity	O
is	O
required	O
for	O
effective	O
membrane	O
-	O
targeting	O
antimicrobials	O
without	O
causing	O
any	O
toxicity	O
to	O
mammalian	O
cells	O
,	O
herein	O
we	O
report	O
the	O
synthesis	O
and	O
antibacterial	O
properties	O
of	O
cholic	O
acid	O
-	O
derived	O
amphiphiles	O
conjugated	O
with	O
alkyl	O
chains	O
of	O
varied	O
hydrophobicity	O
.	O

Relative	O
to	O
other	O
hydrophobic	O
counterparts	O
,	O
a	O
compound	O
with	O
hexyl	O
chain	O
(	O
6	O
)	O
acted	O
as	O
an	O
effective	O
antimicrobial	O
against	O
different	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Apart	O
from	O
its	O
ability	O
to	O
permeate	O
the	O
outer	O
and	O
inner	O
membranes	O
of	O
bacteria	O
;	O
compound	O
6	O
can	O
cross	O
the	O
cellular	O
and	O
lysosomal	O
barriers	O
of	O
epithelial	O
cells	O
and	O
macrophages	O
and	O
kill	O
the	O
facultative	O
intracellular	O
bacteria	O
without	O
disrupting	O
the	O
mammalian	O
cell	O
membranes	O
.	O

Oral	O
delivery	O
of	O
compound	O
6	O
was	O
able	O
to	O
clear	O
the	O
Salmonella	O
-	O
mediated	O
gut	O
infection	O
and	O
inflammation	O
,	O
and	O
was	O
able	O
to	O
combat	O
persistent	O
,	O
stationary	O
,	O
and	O
multi	O
-	O
drug	O
-	O
resistant	O
clinical	O
strains	O
.	O

Therefore	O
,	O
our	O
study	O
reveals	O
the	O
ability	O
of	O
cholic	O
acid	O
-	O
derived	O
amphiphiles	O
to	O
clear	O
intracellular	O
bacteria	O
and	O
Salmonella	O
-	O
mediated	O
gut	O
infection	O
and	O
inflammation	O
.	O

Hydrogen	O
Indirectly	O
Suppresses	O
Increases	O
in	O
Hydrogen	O
Peroxide	O
in	O
Cytoplasmic	O
Hydroxyl	O
Radical	O
-	O
Induced	O
Cells	O
and	O
Suppresses	O
Cellular	O
Senescence	O
.	O

Bacteria	O
inhabiting	O
the	O
human	O
gut	O
metabolize	O
microbiota	O
-	O
accessible	O
carbohydrates	O
(	O
MAC	O
)	O
contained	O
in	O
plant	O
fibers	O
and	O
subsequently	O
release	O
metabolic	O
products	O
.	O

Gut	O
bacteria	O
produce	O
hydrogen	O
(	O
H	O
(	O
2	O
)	O
)	O
,	O
which	O
scavenges	O
the	O
hydroxyl	O
radical	O
(	O
*	O
OH	O
)	O
.	O

Because	O
H	O
(	O
2	O
)	O
diffuses	O
within	O
the	O
cell	O
,	O
it	O
is	O
hypothesized	O
that	O
H	O
(	O
2	O
)	O
scavenges	O
cytoplasmic	O
*	O
OH	O
(	O
cyto	O
*	O
OH	O
)	O
and	O
suppresses	O
cellular	O
senescence	O
.	O

However	O
,	O
the	O
mechanisms	O
of	O
cyto	O
*	O
OH	O
-	O
induced	O
cellular	O
senescence	O
and	O
the	O
physiological	O
role	O
of	O
gut	O
bacteria	O
-	O
secreted	O
H	O
(	O
2	O
)	O
have	O
not	O
been	O
elucidated	O
.	O

Based	O
on	O
the	O
pyocyanin	O
-	O
stimulated	O
cyto	O
*	O
OH	O
-	O
induced	O
cellular	O
senescence	O
model	O
,	O
the	O
mechanism	O
by	O
which	O
cyto	O
*	O
OH	O
causes	O
cellular	O
senescence	O
was	O
investigated	O
by	O
adding	O
a	O
supersaturated	O
concentration	O
of	O
H	O
(	O
2	O
)	O
into	O
the	O
cell	O
culture	O
medium	O
.	O

Cyto	O
*	O
OH	O
-	O
generated	O
lipid	O
peroxide	O
caused	O
glutathione	O
(	O
GSH	O
)	O
and	O
heme	O
shortage	O
,	O
increased	O
hydrogen	O
peroxide	O
(	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
)	O
,	O
and	O
induced	O
cellular	O
senescence	O
via	O
the	O
phosphorylation	O
of	O
ataxia	O
telangiectasia	O
mutated	O
kinase	O
serine	O
1981	O
(	O
p	O
-	O
ATM	O
(	O
ser1981	O
)	O
)	O
/	O
p53	O
serine	O
15	O
(	O
p	O
-	O
p53	O
(	O
ser15	O
)	O
)	O
/	O
p21	O
and	O
phosphorylation	O
of	O
heme	O
-	O
regulated	O
inhibitor	O
(	O
p	O
-	O
HRI	O
)	O
/	O
phospho	O
-	O
eukaryotic	O
translation	O
initiation	O
factor	O
2	O
subunit	O
alpha	O
serine	O
51	O
(	O
p	O
-	O
eIF2alpha	O
)	O
/	O
activating	O
transcription	O
factor	O
4	O
(	O
ATF4	O
)	O
/	O
p16	O
pathways	O
.	O

Further	O
,	O
H	O
(	O
2	O
)	O
suppressed	O
increased	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
by	O
suppressing	O
cyto	O
*	O
OH	O
-	O
mediated	O
lipid	O
peroxide	O
formation	O
and	O
cellular	O
senescence	O
induction	O
via	O
two	O
pathways	O
.	O

H	O
(	O
2	O
)	O
produced	O
by	O
gut	O
bacteria	O
diffuses	O
throughout	O
the	O
body	O
to	O
scavenge	O
cyto	O
*	O
OH	O
in	O
cells	O
.	O

Therefore	O
,	O
it	O
is	O
highly	O
likely	O
that	O
gut	O
bacteria	O
-	O
produced	O
H	O
(	O
2	O
)	O
is	O
involved	O
in	O
intracellular	O
maintenance	O
of	O
the	O
redox	O
state	O
,	O
thereby	O
suppressing	O
cellular	O
senescence	O
and	O
individual	O
aging	O
.	O

Hence	O
,	O
H	O
(	O
2	O
)	O
produced	O
by	O
intestinal	O
bacteria	O
may	O
be	O
involved	O
in	O
the	O
suppression	O
of	O
aging	O
.	O

Metabolomics	O
and	O
Microbiomes	O
as	O
Potential	O
Tools	O
to	O
Evaluate	O
the	O
Effects	O
of	O
the	O
Mediterranean	O
Diet	O
.	O

The	O
approach	O
to	O
studying	O
diet	O
(	O
-	O
)	O
health	O
relationships	O
has	O
progressively	O
shifted	O
from	O
individual	O
dietary	O
components	O
to	O
overall	O
dietary	O
patterns	O
that	O
affect	O
the	O
interaction	O
and	O
balance	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
metabolites	O
(	O
metabolome	O
)	O
and	O
host	O
-	O
enteric	O
mic	O
{	O
Citation	O
}	O
robial	O
ecology	O
(	O
microbiome	O
)	O
.	O

Even	O
though	O
the	O
Mediterranean	O
diet	O
(	O
MedDiet	O
)	O
has	O
been	O
recognized	O
as	O
a	O
powerful	O
strategy	O
to	O
improve	O
health	O
,	O
the	O
accurate	O
assessment	O
of	O
exposure	O
to	O
the	O
MedDiet	O
has	O
been	O
a	O
major	O
challenge	O
in	O
epidemiological	O
and	O
clinical	O
studies	O
.	O

Interestingly	O
,	O
while	O
the	O
effects	O
of	O
individual	O
dietary	O
components	O
on	O
the	O
metabolome	O
have	O
been	O
described	O
,	O
studies	O
investigating	O
metabolomic	O
profiles	O
in	O
response	O
to	O
overall	O
dietary	O
patterns	O
(	O
including	O
the	O
MedDiet	O
)	O
,	O
although	O
limited	O
,	O
have	O
been	O
gaining	O
attention	O
.	O

Similarly	O
,	O
the	O
beneficial	O
effects	O
of	O
the	O
MedDiet	O
on	O
cardiometabolic	O
outcomes	O
may	O
be	O
mediated	O
through	O
gut	O
microbial	O
changes	O
.	O

Accumulating	O
evidence	O
linking	O
food	O
ingestion	O
and	O
enteric	O
microbiome	O
alterations	O
merits	O
the	O
evaluation	O
of	O
the	O
microbiome	O
-	O
mediated	O
effects	O
of	O
the	O
MedDiet	O
on	O
metabolic	O
pathways	O
implicated	O
in	O
disease	O
.	O

In	O
this	O
narrative	O
review	O
,	O
we	O
aimed	O
to	O
summarize	O
the	O
current	O
evidence	O
from	O
observational	O
and	O
clinical	O
trials	O
involving	O
the	O
MedDiet	O
by	O
(	O
1	O
)	O
assessing	O
changes	O
in	O
the	O
metabolome	O
and	O
microbiome	O
for	O
the	O
measurement	O
of	O
diet	O
pattern	O
adherence	O
and	O
(	O
2	O
)	O
assessing	O
health	O
outcomes	O
related	O
to	O
the	O
MedDiet	O
through	O
alterations	O
to	O
human	O
metabolomics	O
and	O
/	O
or	O
the	O
microbiome	O
.	O

Simultaneous	O
Intake	O
of	O
Euglena	O
gracilis	O
and	O
Vegetables	O
Exerts	O
Synergistic	O
Anti	O
-	O
Obesity	O
and	O
Anti	O
-	O
Inflammatory	O
Effects	O
by	O
Modulating	O
the	O
Gut	O
Microbiota	O
in	O
Diet	O
-	O
Induced	O
Obese	O
Mice	O
.	O

We	O
determined	O
whether	O
the	O
anti	O
-	O
obesity	O
effect	O
provided	O
by	O
the	O
consumption	O
of	O
Euglena	O
gracilis	O
(	O
Euglena	O
)	O
,	O
which	O
is	O
rich	O
in	O
insoluble	O
dietary	O
fiber	O
,	O
could	O
be	O
enhanced	O
by	O
the	O
co	O
-	O
consumption	O
of	O
vegetables	O
with	O
an	O
abundance	O
of	O
soluble	O
dietary	O
fiber	O
.	O

Nine	O
-	O
week	O
-	O
old	O
male	O
C57BL	O
/	O
6J	O
mice	O
were	O
divided	O
into	O
five	O
groups	O
as	O
follows	O
:	O
group	O
1	O
received	O
a	O
normal	O
diet	O
,	O
group	O
2	O
received	O
a	O
high	O
-	O
fat	O
diet	O
,	O
and	O
groups	O
3	O
,	O
4	O
,	O
and	O
5	O
received	O
high	O
fat	O
diets	O
containing	O
0	O
.	O
3	O
%	O
paramylon	O
,	O
1	O
.	O
0	O
%	O
Euglena	O
,	O
or	O
1	O
.	O
0	O
%	O
Euglena	O
plus	O
0	O
.	O
3	O
%	O
vegetables	O
(	O
barley	O
leaf	O
,	O
kale	O
,	O
and	O
ashitaba	O
)	O
,	O
respectively	O
.	O

Mice	O
were	O
fed	O
ad	O
libitum	O
until	O
18	O
weeks	O
of	O
age	O
.	O

Euglena	O
intake	O
significantly	O
reduced	O
visceral	O
fat	O
accumulation	O
in	O
obese	O
mice	O
,	O
and	O
co	O
-	O
consumption	O
of	O
vegetables	O
enhanced	O
this	O
effect	O
.	O

Consumption	O
of	O
Euglena	O
with	O
vegetables	O
reduced	O
adipocyte	O
area	O
,	O
suppressed	O
the	O
expression	O
of	O
genes	O
related	O
to	O
fatty	O
acid	O
synthesis	O
,	O
upregulated	O
genes	O
related	O
to	O
adipocyte	O
lipolysis	O
,	O
and	O
suppressed	O
serum	O
markers	O
of	O
inflammation	O
.	O

Notably	O
,	O
we	O
also	O
observed	O
an	O
increase	O
in	O
the	O
fraction	O
of	O
short	O
-	O
chain	O
fatty	O
acid	O
-	O
producing	O
beneficial	O
bacteria	O
,	O
a	O
reduction	O
in	O
harmful	O
bacteria	O
that	O
cause	O
inflammation	O
,	O
and	O
an	O
increase	O
in	O
short	O
-	O
chain	O
fatty	O
acid	O
production	O
.	O

Therefore	O
,	O
the	O
co	O
-	O
consumption	O
of	O
vegetables	O
enhanced	O
the	O
anti	O
-	O
obesity	O
and	O
anti	O
-	O
inflammatory	O
effects	O
of	O
Euglena	O
,	O
likely	O
by	O
modulating	O
the	O
gut	O
microbiota	O
composition	O
.	O

Gut	O
Microbiota	O
and	O
Predicted	O
Metabolic	O
Pathways	O
in	O
a	O
Sample	O
of	O
Mexican	O
Women	O
Affected	O
by	O
Obesity	O
and	O
Obesity	O
Plus	O
Metabolic	O
Syndrome	O
.	O

Obesity	O
is	O
an	O
excessive	O
fat	O
accumulation	O
that	O
could	O
lead	O
to	O
complications	O
like	O
metabolic	O
syndrome	O
.	O

There	O
are	O
reports	O
on	O
gut	O
microbiota	O
and	O
metabolic	O
syndrome	O
in	O
relation	O
to	O
dietary	O
,	O
host	O
genetics	O
,	O
and	O
other	O
environmental	O
factors	O
;	O
however	O
,	O
it	O
is	O
necessary	O
to	O
explore	O
the	O
role	O
of	O
the	O
gut	O
microbiota	O
metabolic	O
pathways	O
in	O
populations	O
like	O
Mexicans	O
,	O
where	O
the	O
prevalence	O
of	O
obesity	O
and	O
metabolic	O
syndrome	O
is	O
high	O
.	O

This	O
study	O
identify	O
alterations	O
of	O
the	O
gut	O
microbiota	O
in	O
a	O
sample	O
of	O
healthy	O
Mexican	O
women	O
(	O
CO	O
)	O
,	O
women	O
with	O
obesity	O
(	O
OB	O
)	O
,	O
and	O
women	O
with	O
obesity	O
plus	O
metabolic	O
syndrome	O
(	O
OMS	O
)	O
.	O

We	O
studied	O
67	O
women	O
,	O
characterizing	O
their	O
anthropometric	O
and	O
biochemical	O
parameters	O
along	O
with	O
their	O
gut	O
bacterial	O
diversity	O
by	O
high	O
-	O
throughput	O
DNA	O
sequencing	O
.	O

Our	O
results	O
indicate	O
that	O
in	O
OB	O
or	O
OMS	O
women	O
,	O
Firmicutes	B-bacteria
was	O
the	O
most	O
abundant	O
bacterial	O
phylum	O
.	O

We	O
observed	O
significant	O
changes	O
in	O
abundances	O
of	O
bacteria	O
belonging	O
to	O
the	O
Ruminococcaceae	B-bacteria
,	O
Lachnospiraceae	B-bacteria
,	O
and	O
Erysipelotrichaceae	B-bacteria
families	I-bacteria
and	O
significant	O
enrichment	O
of	O
gut	O
bacteria	O
from	O
16	O
different	O
taxa	O
that	O
might	O
explain	O
the	O
observed	O
metabolic	O
alterations	O
between	O
the	O
groups	O
.	O

Finally	O
,	O
the	O
predicted	O
functional	O
metagenome	O
of	O
the	O
gut	O
microbiota	O
found	O
in	O
each	O
category	O
shows	O
differences	O
in	O
metabolic	O
pathways	O
related	O
to	O
lipid	O
metabolism	O
.	O

We	O
demonstrate	O
that	O
Mexican	O
women	O
have	O
a	O
particular	O
bacterial	O
gut	O
microbiota	O
characteristic	O
of	O
each	O
phenotype	O
.	O

There	O
are	O
bacteria	O
that	O
potentially	O
explain	O
the	O
observed	O
metabolic	O
differences	O
between	O
the	O
groups	O
,	O
and	O
gut	O
bacteria	O
in	O
OMS	O
and	O
OB	O
conditions	O
carry	O
more	O
genes	O
of	O
metabolic	O
pathways	O
implicated	O
in	O
lipid	O
metabolism	O
.	O

The	O
Effect	O
of	O
Psyllium	O
Husk	O
on	O
Intestinal	O
Microbiota	O
in	O
Constipated	O
Patients	O
and	O
Healthy	O
Controls	O
.	O

Psyllium	O
is	O
a	O
widely	O
used	O
treatment	O
for	O
constipation	O
.	O

It	O
traps	O
water	O
in	O
the	O
intestine	O
increasing	O
stool	O
water	O
,	O
easing	O
defaecation	O
and	O
altering	O
the	O
colonic	O
environment	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
psyllium	O
on	O
faecal	O
microbiota	O
,	O
whose	O
key	O
role	O
in	O
gut	O
physiology	O
is	O
being	O
increasingly	O
recognised	O
.	O

We	O
performed	O
two	O
randomised	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blinded	O
trials	O
comparing	O
7	O
days	O
of	O
psyllium	O
with	O
a	O
placebo	O
(	O
maltodextrin	O
)	O
in	O
8	O
healthy	O
volunteers	O
and	O
16	O
constipated	O
patients	O
respectively	O
.	O

We	O
measured	O
the	O
patients	O
'	O
gastrointestnal	O
(	O
GI	O
)	O
transit	O
,	O
faecal	O
water	O
content	O
,	O
short	O
-	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
and	O
the	O
stool	O
microbiota	O
composition	O
.	O

While	O
psyllium	O
supplement	O
had	O
a	O
small	O
but	O
significant	O
effect	O
on	O
the	O
microbial	O
composition	O
of	O
healthy	O
adults	O
(	O
increasing	O
Veillonella	B-bacteria
and	O
decreasing	O
Subdoligranulum	B-bacteria
)	O
,	O
in	O
constipated	O
subjects	O
there	O
were	O
greater	O
effects	O
on	O
the	O
microbial	O
composition	O
(	O
increased	O
Lachnospira	B-bacteria
,	O
Faecalibacterium	B-bacteria
,	O
Phascolarctobacterium	B-bacteria
,	O
Veillonella	B-bacteria
and	O
Sutterella	B-bacteria
and	O
decreased	O
uncultured	O
Coriobacteria	B-bacteria
and	O
Christensenella	B-bacteria
)	O
and	O
alterations	O
in	O
the	O
levels	O
of	O
acetate	O
and	O
propionate	O
.	O

We	O
found	O
several	O
taxa	O
to	O
be	O
associated	O
with	O
altered	O
GI	O
transit	O
,	O
SCFAs	O
and	O
faecal	O
water	O
content	O
in	O
these	O
patients	O
.	O

Significant	O
increases	O
in	O
three	O
genera	O
known	O
to	O
produce	O
butyrate	O
,	O
Lachnospira	B-bacteria
,	O
Roseburia	B-bacteria
and	O
Faecalibacterium	B-bacteria
,	O
correlated	O
with	O
increased	O
faecal	O
water	O
.	O

In	O
summary	O
,	O
psyllium	O
supplementation	O
increased	O
stool	O
water	O
and	O
this	O
was	O
associated	O
with	O
significant	O
changes	O
in	O
microbiota	O
,	O
most	O
marked	O
in	O
constipated	O
patients	O
.	O

A	O
Cell	O
-	O
Surface	O
GH9	O
Endo	O
-	O
Glucanase	O
Coordinates	O
with	O
Surface	O
Glycan	O
-	O
Binding	O
Proteins	O
to	O
Mediate	O
Xyloglucan	O
Uptake	O
in	O
the	O
Gut	O
Symbiont	O
Bacteroides	B-bacteria
ovatus	I-bacteria
.	O

Dietary	O
fiber	O
is	O
an	O
important	O
food	O
source	O
for	O
members	O
of	O
the	O
human	O
gut	O
microbiome	O
.	O

Members	O
of	O
the	O
dominant	O
Bacteroidetes	B-bacteria
phylum	I-bacteria
capture	O
diverse	O
polysaccharides	O
via	O
the	O
action	O
of	O
multiple	O
cell	O
surface	O
proteins	O
encoded	O
within	O
polysaccharide	O
utilization	O
loci	O
(	O
PUL	O
)	O
.	O

The	O
independent	O
activities	O
of	O
PUL	O
-	O
encoded	O
glycoside	O
hydrolases	O
(	O
GHs	O
)	O
and	O
surface	O
glycan	O
-	O
binding	O
proteins	O
(	O
SGBPs	O
)	O
for	O
the	O
harvest	O
of	O
various	O
glycans	O
have	O
been	O
studied	O
in	O
detail	O
,	O
but	O
how	O
these	O
proteins	O
work	O
together	O
to	O
coordinate	O
uptake	O
is	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
combine	O
genetic	O
and	O
biochemical	O
approaches	O
to	O
discern	O
the	O
interplay	O
between	O
the	O
BoGH9	O
endoglucanase	O
and	O
the	O
xyloglucan	O
-	O
binding	O
proteins	O
SGBP	O
-	O
A	O
and	O
SGBP	O
-	O
B	O
from	O
the	O
Bacteroides	B-bacteria
ovatus	I-bacteria
xyloglucan	O
utilization	O
locus	O
(	O
XyGUL	O
)	O
.	O

The	O
expression	O
of	O
BoGH9	O
,	O
a	O
weakly	O
active	O
xyloglucanase	O
in	O
isolation	O
,	O
is	O
required	O
in	O
a	O
strain	O
that	O
expresses	O
a	O
non	O
-	O
binding	O
version	O
of	O
SGBP	O
-	O
A	O
(	O
SGBP	O
-	O
A	O
*	O
)	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
BoGH9	O
enzyme	O
suggests	O
the	O
molecular	O
basis	O
for	O
its	O
robust	O
activity	O
on	O
mixed	O
-	O
linkage	O
beta	O
-	O
glucan	O
compared	O
to	O
xyloglucan	O
.	O

However	O
,	O
catalytically	O
inactive	O
site	O
-	O
directed	O
mutants	O
of	O
BoGH9	O
fail	O
to	O
complement	O
the	O
deletion	O
of	O
the	O
active	O
BoGH9	O
in	O
a	O
SGBP	O
-	O
A	O
*	O
strain	O
.	O

We	O
also	O
find	O
that	O
SGBP	O
-	O
B	O
is	O
needed	O
in	O
an	O
SGBP	O
-	O
A	O
*	O
background	O
to	O
support	O
growth	O
on	O
xyloglucan	O
,	O
but	O
that	O
the	O
non	O
-	O
binding	O
SGBP	O
-	O
B	O
*	O
protein	O
acts	O
in	O
a	O
dominant	O
negative	O
manner	O
to	O
inhibit	O
growth	O
on	O
xyloglucan	O
.	O

We	O
postulate	O
a	O
model	O
whereby	O
the	O
SGBP	O
-	O
A	O
,	O
SGBP	O
-	O
B	O
,	O
and	O
BoGH9	O
work	O
together	O
at	O
the	O
cell	O
surface	O
,	O
likely	O
within	O
a	O
discrete	O
complex	O
,	O
and	O
that	O
xyloglucan	O
binding	O
by	O
SGBP	O
-	O
B	O
and	O
BoGH9	O
may	O
facilitate	O
the	O
orientation	O
of	O
the	O
xyloglucan	O
for	O
transfer	O
across	O
the	O
outer	O
membrane	O
.	O

Bacillus	B-bacteria
subtilis	I-bacteria
29784	I-bacteria
induces	O
a	O
shift	O
in	O
broiler	O
gut	O
microbiome	O
toward	O
butyrate	O
-	O
producing	O
bacteria	O
and	O
improves	O
intestinal	O
histomorphology	O
and	O
animal	O
performance	O
.	O

The	O
study	O
reports	O
the	O
effects	O
of	O
Bacillus	B-bacteria
subtilis	I-bacteria
29784	I-bacteria
on	O
broiler	O
performance	O
.	O

A	O
total	O
of	O
1	O
,	O
600	O
one	O
-	O
day	O
-	O
old	O
Cobb	O
500	O
male	O
broiler	O
chicks	O
received	O
either	O
a	O
control	O
diet	O
or	O
the	O
same	O
diet	O
to	O
which	O
B	B-bacteria
.	I-bacteria
subtilis	I-bacteria
29784	I-bacteria
spores	O
were	O
added	O
(	O
1E8	O
CFU	O
/	O
kg	O
of	O
feed	O
)	O
.	O

The	O
birds	O
were	O
slaughtered	O
at	O
42	O
D	O
of	O
age	O
.	O

Ileal	O
and	O
cecal	O
tissues	O
and	O
content	O
were	O
collected	O
for	O
histomorphological	O
analysis	O
and	O
16S	O
rRNA	O
gene	O
sequencing	O
,	O
respectively	O
.	O

The	O
inclusion	O
of	O
B	B-bacteria
.	I-bacteria
subtilis	I-bacteria
29784	I-bacteria
led	O
to	O
an	O
increase	O
of	O
final	O
body	O
weight	O
gain	O
of	O
broilers	O
(	O
+	O
5	O
.	O
7	O
%	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
an	O
improvement	O
in	O
feed	O
conversion	O
ratio	O
(	O
-	O
5	O
.	O
4	O
%	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Higher	O
feed	O
efficiency	O
in	O
the	O
Bacillus	O
-	O
fed	O
group	O
was	O
correlated	O
with	O
a	O
significant	O
increase	O
in	O
intestinal	O
microvilli	O
length	O
(	O
+	O
18	O
%	O
in	O
ileum	O
and	O
+	O
17	O
%	O
in	O
cecum	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Among	O
the	O
differences	O
revealed	O
by	O
16S	O
rRNA	O
analysis	O
,	O
Ruminococcus	B-bacteria
,	O
Lachnoclostridium	B-bacteria
,	O
and	O
Anaerostipes	B-bacteria
were	O
found	O
in	O
higher	O
relative	O
abundance	O
in	O
Bacillus	O
-	O
treated	O
birds	O
at	O
the	O
cecal	O
level	O
.	O

These	O
bacterial	O
genera	O
include	O
species	O
that	O
produce	O
butyrate	O
,	O
the	O
main	O
source	O
of	O
energy	O
for	O
enterocytes	O
and	O
known	O
to	O
be	O
an	O
immune	O
modulator	O
.	O

There	O
was	O
also	O
a	O
slight	O
increase	O
in	O
the	O
Butyrivibrio	B-bacteria
genus	I-bacteria
in	O
the	O
cecum	O
,	O
which	O
is	O
known	O
to	O
be	O
an	O
important	O
player	O
in	O
the	O
production	O
of	O
conjugated	O
linoleic	O
acid	O
,	O
also	O
considered	O
an	O
anti	O
-	O
inflammatory	O
compound	O
.	O

In	O
conclusion	O
,	O
dietary	O
supplementation	O
of	O
B	B-bacteria
.	I-bacteria
subtilis	I-bacteria
29784	I-bacteria
significantly	O
improved	O
the	O
growth	O
performance	O
of	O
broilers	O
,	O
likely	O
through	O
beneficial	O
effects	O
on	O
microbiota	O
and	O
host	O
.	O

In	O
vitro	O
inhibition	O
of	O
avian	O
pathogenic	O
Enterococcus	B-bacteria
cecorum	I-bacteria
isolates	I-bacteria
by	O
probiotic	O
Bacillus	B-bacteria
strains	I-bacteria
.	O

Enterococcus	B-bacteria
cecorum	I-bacteria
is	O
a	O
commensal	O
bacteria	O
and	O
opportunistic	O
pathogen	O
that	O
can	O
cause	O
outbreaks	O
of	O
Enterococcal	B-bacteria
spondylitis	I-bacteria
(	O
`	O
`	O
kinky	O
back	O
'	O
'	O
)	O
in	O
poultry	O
,	O
with	O
a	O
growing	O
concern	O
worldwide	O
.	O

Numerous	O
Bacillus	O
-	O
based	O
probiotic	O
strains	O
are	O
commercially	O
available	O
with	O
proven	O
effects	O
in	O
supporting	O
gut	O
health	O
and	O
growth	O
performance	O
,	O
but	O
efficacy	O
against	O
pathogenic	O
E	B-bacteria
.	I-bacteria
cecorum	I-bacteria
is	O
unknown	O
.	O

This	O
study	O
compared	O
the	O
in	O
vitro	O
inhibitory	O
potential	O
of	O
cell	O
-	O
free	O
supernatants	O
(	O
CFSs	O
)	O
of	O
18	O
Bacillus	B-bacteria
strains	I-bacteria
(	O
14	O
commercial	O
probiotic	O
strains	O
,	O
1	O
internal	O
negative	O
control	O
and	O
3	O
type	O
strains	O
)	O
on	O
the	O
growth	O
of	O
9	O
clinical	O
E	B-bacteria
.	I-bacteria
cecorum	I-bacteria
isolates	I-bacteria
.	O

Standardized	O
biomass	O
cultures	O
of	O
live	O
Bacillus	B-bacteria
were	O
harvested	O
and	O
filtered	O
to	O
obtain	O
CFSs	O
.	O

Inhibitory	O
potential	O
against	O
E	B-bacteria
.	I-bacteria
cecorum	I-bacteria
isolates	I-bacteria
was	O
assessed	O
via	O
a	O
microdilution	O
assay	O
in	O
which	O
the	O
final	O
pathogen	O
concentration	O
was	O
approximately	O
104	O
CFU	O
/	O
mL	O
.	O

Absorbance	O
(	O
OD	O
)	O
was	O
measured	O
every	O
15	O
min	O
for	O
15	O
h	O
and	O
used	O
to	O
calculate	O
percentage	O
growth	O
inhibition	O
at	O
an	O
OD	O
equivalent	O
to	O
0	O
.	O
4	O
in	O
the	O
positive	O
control	O
(	O
PC	O
)	O
(	O
pathogen	O
but	O
no	O
CFS	O
)	O
,	O
and	O
growth	O
delay	O
vs	O
.	O
PC	O
.	O

Growth	O
kinetic	O
responses	O
of	O
pathogen	O
isolate	O
-	O
Bacillus	B-bacteria
strain	I-bacteria
combinations	O
ranged	O
from	O
total	O
pathogen	O
inhibition	O
to	O
partial	O
inhibition	O
,	O
lag	O
in	O
growth	O
,	O
no	O
effect	O
,	O
or	O
increased	O
growth	O
vs	O
.	O
PC	O
.	O

Percentage	O
inhibition	O
of	O
individual	O
isolates	O
varied	O
markedly	O
among	O
Bacillus	B-bacteria
strains	I-bacteria
,	O
from	O
100	O
%	O
to	O
-	O
100	O
%	O
(	O
growth	O
promotion	O
as	O
recorded	O
for	O
the	O
type	O
strain	O
)	O
(	O
B	B-bacteria
.	I-bacteria
amyloliquefaciens	I-bacteria
DSM7T	I-bacteria
)	O
.	O

Five	O
B	B-bacteria
.	I-bacteria
amyloliquefaciens	I-bacteria
CFSs	O
produced	O
higher	O
average	O
inhibition	O
rates	O
(	O
>	O
75	O
%	O
)	O
than	O
2	O
out	O
of	O
3	O
Bacillus	B-bacteria
licheniformis	I-bacteria
CFSs	O
(	O
-	O
2	O
.	O
5	O
,	O
and	O
-	O
8	O
.	O
39	O
%	O
vs	O
.	O
PC	O
,	O
respectively	O
)	O
and	O
1	O
out	O
of	O
2	O
Bacillus	B-bacteria
subtilis	I-bacteria
CFSs	O
(	O
7	O
.	O
3	O
%	O
vs	O
.	O
PC	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Commercial	O
strain	O
3AP4	B-bacteria
exhibited	O
the	O
highest	O
average	O
percentage	O
inhibition	O
vs	O
.	O
PC	O
(	O
85	O
.	O
0	O
%	O
+	O
/	O
-	O
7	O
.	O
9	O
)	O
and	O
the	O
most	O
consistent	O
inhibitory	O
effect	O
across	O
pathogen	O
isolates	O
.	O

The	O
findings	O
indicate	O
that	O
some	O
commercially	O
available	O
poultry	O
probiotic	O
Bacillus	B-bacteria
strains	I-bacteria
are	O
effective	O
at	O
inhibiting	O
pathogenic	O
E	B-bacteria
.	I-bacteria
cecorum	I-bacteria
in	O
vitro	O
,	O
but	O
effects	O
are	O
highly	O
strain	O
and	O
pathogen	O
isolate	O
-	O
dependent	O
.	O

Further	O
work	O
is	O
required	O
to	O
confirm	O
effects	O
in	O
vivo	O
and	O
isolate	O
the	O
inhibitory	O
substances	O
.	O

Modulation	O
of	O
the	O
Gut	O
Microbiota	O
by	O
Resistant	O
Starch	O
as	O
a	O
Treatment	O
of	O
Chronic	O
Kidney	O
Diseases	O
:	O
Evidence	O
of	O
Efficacy	O
and	O
Mechanistic	O
Insights	O
.	O

Chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
has	O
been	O
associated	O
with	O
changes	O
in	O
gut	O
microbial	O
ecology	O
,	O
or	O
`	O
`	O
dysbiosis	O
,	O
'	O
'	O
which	O
may	O
contribute	O
to	O
disease	O
progression	O
.	O

Recent	O
studies	O
have	O
focused	O
on	O
dietary	O
approaches	O
to	O
favorably	O
alter	O
the	O
composition	O
of	O
the	O
gut	O
microbial	O
communities	O
as	O
a	O
treatment	O
method	O
in	O
CKD	O
.	O

Resistant	O
starch	O
(	O
RS	O
)	O
,	O
a	O
prebiotic	O
that	O
promotes	O
proliferation	O
of	O
gut	O
bacteria	O
such	O
as	O
Bifidobacteria	B-bacteria
and	O
Lactobacilli	B-bacteria
,	O
increases	O
the	O
production	O
of	O
metabolites	O
including	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
which	O
confer	O
a	O
number	O
of	O
health	O
-	O
promoting	O
benefits	O
.	O

However	O
,	O
there	O
is	O
a	O
lack	O
of	O
mechanistic	O
insight	O
into	O
how	O
these	O
metabolites	O
can	O
positively	O
influence	O
renal	O
health	O
.	O

Emerging	O
evidence	O
shows	O
that	O
microbiota	O
-	O
derived	O
metabolites	O
can	O
regulate	O
the	O
incretin	O
axis	O
and	O
mitigate	O
inflammation	O
via	O
expansion	O
of	O
regulatory	O
T	O
cells	O
.	O

Studies	O
from	O
animal	O
models	O
and	O
patients	O
with	O
CKD	O
show	O
that	O
RS	O
supplementation	O
attenuates	O
the	O
concentrations	O
of	O
uremic	O
retention	O
solutes	O
,	O
including	O
indoxyl	O
sulfate	O
and	O
p	O
-	O
cresyl	O
sulfate	O
.	O

Here	O
,	O
we	O
present	O
the	O
current	O
state	O
of	O
knowledge	O
linking	O
the	O
microbiome	O
to	O
CKD	O
,	O
we	O
explore	O
the	O
efficacy	O
of	O
RS	O
in	O
animal	O
models	O
of	O
CKD	O
and	O
in	O
humans	O
with	O
the	O
condition	O
,	O
and	O
we	O
discuss	O
how	O
RS	O
supplementation	O
could	O
be	O
a	O
promising	O
dietary	O
approach	O
for	O
slowing	O
CKD	O
progression	O
.	O

microRNA	O
-	O
Mediated	O
Tumor	O
-	O
Microbiota	O
Metabolic	O
Interactions	O
in	O
Colorectal	O
Cancer	O
.	O

Worldwide	O
,	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
cancer	O
-	O
related	O
deaths	O
.	O

Recent	O
advances	O
in	O
high	O
-	O
throughput	O
technologies	O
have	O
shown	O
that	O
the	O
gut	O
microbiota	O
may	O
have	O
a	O
major	O
influence	O
on	O
human	O
health	O
,	O
including	O
CRC	O
.	O

Nonetheless	O
,	O
how	O
the	O
gut	O
microbiota	O
interacts	O
with	O
tumor	O
cells	O
in	O
CRC	O
patients	O
is	O
largely	O
unknown	O
.	O

Studies	O
have	O
shown	O
that	O
the	O
microbiota	O
fills	O
in	O
a	O
variety	O
of	O
niche	O
metabolic	O
pathways	O
that	O
the	O
host	O
does	O
not	O
possess	O
.	O

For	O
example	O
,	O
the	O
microbiota	O
produces	O
butyrate	O
,	O
which	O
provides	O
the	O
colon	O
'	O
s	O
epithelial	O
cells	O
with	O
about	O
70	O
%	O
of	O
their	O
energy	O
needs	O
.	O

The	O
typically	O
fast	O
proliferation	O
of	O
tumor	O
cells	O
in	O
CRC	O
patients	O
drastically	O
alters	O
the	O
tumor	O
'	O
s	O
nutrient	O
microenvironment	O
.	O

Those	O
alterations	O
correspond	O
to	O
the	O
microbiota	O
composition	O
and	O
functional	O
changes	O
.	O

In	O
tumor	O
cells	O
,	O
a	O
central	O
mediator	O
of	O
metabolic	O
changes	O
is	O
the	O
aberrant	O
expression	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
recent	O
insights	O
into	O
metabolic	O
interactions	O
between	O
the	O
microbiota	O
and	O
tumor	O
cells	O
in	O
CRC	O
pathobiology	O
,	O
focusing	O
on	O
the	O
role	O
of	O
miRNAs	O
.	O

These	O
observations	O
support	O
our	O
view	O
that	O
miRNAs	O
may	O
also	O
serve	O
as	O
mediators	O
of	O
the	O
metabolites	O
'	O
effects	O
.	O

Green	O
Tea	O
Polyphenols	O
Modify	O
the	O
Gut	O
Microbiome	O
in	O
db	O
/	O
db	O
Mice	O
as	O
Co	O
-	O
Abundance	O
Groups	O
Correlating	O
with	O
the	O
Blood	O
Glucose	O
Lowering	O
Effect	O
.	O

SCOPE	O
:	O
The	O
effects	O
of	O
green	O
tea	O
polyphenols	O
,	O
Polyphenon	O
E	O
(	O
PPE	O
)	O
,	O
and	O
black	O
tea	O
polyphenols	O
,	O
theaflavins	O
(	O
TFs	O
)	O
,	O
on	O
gut	O
microbiota	O
and	O
development	O
of	O
diabetes	O
in	O
db	O
/	O
db	O
mice	O
are	O
investigated	O
and	O
compared	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Supplementation	O
of	O
PPE	O
(	O
0	O
.	O
1	O
%	O
)	O
in	O
the	O
diet	O
of	O
female	O
db	O
/	O
db	O
mice	O
for	O
7	O
weeks	O
decreases	O
fasting	O
blood	O
glucose	O
levels	O
and	O
mesenteric	O
fat	O
while	O
increasing	O
the	O
serum	O
level	O
of	O
insulin	O
,	O
possibly	O
through	O
protection	O
against	O
beta	O
-	O
cell	O
damage	O
.	O

However	O
,	O
TFs	O
are	O
less	O
or	O
not	O
effective	O
.	O

Microbiome	O
analysis	O
through	O
16S	O
rRNA	O
gene	O
sequencing	O
shows	O
that	O
PPE	O
and	O
TFs	O
treatments	O
significantly	O
alter	O
the	O
bacterial	O
community	O
structure	O
in	O
the	O
cecum	O
and	O
colon	O
,	O
but	O
not	O
in	O
the	O
ileum	O
.	O

The	O
key	O
bacterial	O
phylotypes	O
responding	O
to	O
the	O
treatments	O
are	O
then	O
clustered	O
into	O
11	O
co	O
-	O
abundance	O
groups	O
(	O
CAGs	O
)	O
.	O

CAGs	O
6	O
and	O
7	O
,	O
significantly	O
increased	O
by	O
PPE	O
but	O
not	O
by	O
TFs	O
,	O
are	O
negatively	O
associated	O
with	O
blood	O
glucose	O
levels	O
.	O

The	O
operational	O
taxonomic	O
units	O
in	O
these	O
CAGs	O
are	O
from	O
two	O
different	O
phyla	O
,	O
Firmicutes	B-bacteria
and	O
Bacteroidetes	B-bacteria
.	O

CAG	O
10	O
,	O
decreased	O
by	O
PPE	O
and	O
TFs	O
,	O
is	O
positively	O
associated	O
with	O
blood	O
glucose	O
levels	O
.	O

CONCLUSION	O
:	O
Gut	O
microbiota	O
respond	O
to	O
tea	O
polyphenol	O
treatments	O
as	O
CAGs	O
instead	O
of	O
taxa	O
.	O

Some	O
of	O
the	O
CAGs	O
associated	O
with	O
the	O
blood	O
glucose	O
lowering	O
effect	O
are	O
enriched	O
by	O
PPE	O
,	O
but	O
not	O
TFs	O
.	O

Effects	O
of	O
chronic	O
exercise	O
on	O
gut	O
microbiota	O
and	O
intestinal	O
barrier	O
in	O
human	O
with	O
type	O
2	O
diabetes	O
.	O

BACKGROUND	O
:	O
Intestinal	O
dysbiosis	O
has	O
been	O
proposed	O
as	O
a	O
possible	O
contributor	O
of	O
the	O
development	O
of	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
.	O

Indeed	O
,	O
commensal	O
fungi	O
and	O
opportunistic	O
bacteria	O
stimulate	O
the	O
local	O
immune	O
system	O
,	O
altering	O
intestinal	O
permeability	O
with	O
consequent	O
leaky	O
gut	O
,	O
which	O
in	O
turn	O
activates	O
systemic	O
inflammation	O
responsible	O
for	O
insulin	O
resistance	O
.	O

It	O
is	O
also	O
well	O
known	O
that	O
chronic	O
exercise	O
improves	O
glucose	O
control	O
and	O
diabetes	O
-	O
induced	O
damage	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
chronic	O
exercise	O
on	O
gut	O
flora	O
composition	O
and	O
leaky	O
gut	O
in	O
T2D	O
stable	O
patients	O
.	O

METHODS	O
:	O
Thirty	O
clinically	O
stable	O
patients	O
with	O
T2D	O
were	O
studied	O
before	O
and	O
after	O
a	O
six	O
months	O
program	O
of	O
endurance	O
,	O
resistance	O
and	O
flexibility	O
training	O
.	O

Metabolic	O
and	O
anthropometric	O
evaluations	O
were	O
carried	O
out	O
.	O

Gut	O
flora	O
and	O
intestinal	O
permeability	O
were	O
measured	O
in	O
stools	O
by	O
selective	O
agar	O
culture	O
medium	O
and	O
molecular	O
biology	O
measurements	O
of	O
zonulin	O
,	O
which	O
is	O
the	O
protein	O
that	O
modulates	O
enterocyte	O
tight	O
junctions	O
.	O

RESULTS	O
:	O
Diabetes	O
causes	O
significant	O
intestinal	O
mycetes	O
overgrowth	O
,	O
increased	O
intestinal	O
permeability	O
and	O
systemic	O
low	O
-	O
grade	O
inflammation	O
.	O

However	O
,	O
exercise	O
improved	O
glycemia	O
,	O
functional	O
and	O
anthropometric	O
variables	O
.	O

Moreover	O
,	O
chronic	O
exercise	O
reduced	O
intestinal	O
mycetes	O
overgrowth	O
,	O
leaky	O
gut	O
,	O
and	O
systemic	O
inflammation	O
.	O

Interestingly	O
,	O
these	O
variables	O
are	O
closely	O
correlated	O
.	O

CONCLUSIONS	O
:	O
Exercise	O
controls	O
diabetes	O
by	O
also	O
modifying	O
intestinal	O
microbiota	O
composition	O
and	O
gut	O
barrier	O
function	O
.	O

This	O
data	O
shows	O
an	O
additional	O
mechanism	O
of	O
chronic	O
exercise	O
and	O
suggests	O
that	O
improving	O
gut	O
flora	O
could	O
be	O
an	O
important	O
step	O
in	O
tailored	O
therapies	O
of	O
T2D	O
.	O

Influence	O
of	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
in	O
gut	O
microbiota	O
of	O
streptozotocin	O
-	O
induced	O
diabetic	O
mice	O
.	O

OBJECTIVES	O
:	O
Increasing	O
evidence	O
suggests	O
that	O
periodontitis	O
can	O
exacerbate	O
diabetes	O
,	O
and	O
gut	O
bacterial	O
dysbiosis	O
appears	O
to	O
be	O
linked	O
with	O
the	O
diabetic	O
condition	O
.	O

The	O
present	O
study	O
examined	O
the	O
effects	O
of	O
oral	O
administration	O
of	O
the	O
periodontopathic	O
bacterium	O
,	O
Porphyromonas	B-bacteria
gingivalis	I-bacteria
,	O
on	O
the	O
gut	O
microbiota	O
and	O
systemic	O
conditions	O
in	O
streptozotocin	O
-	O
induced	O
diabetic	O
mice	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Diabetes	O
was	O
induced	O
by	O
streptozotocin	O
injection	O
in	O
C57BL	O
/	O
6J	O
male	O
mice	O
(	O
STZ	O
)	O
.	O

STZ	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
were	O
orally	O
administered	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
(	O
STZPg	O
,	O
WTPg	O
)	O
or	O
saline	O
(	O
STZco	O
,	O
WTco	O
)	O
.	O

Feces	O
were	O
collected	O
,	O
and	O
the	O
gut	O
microbiome	O
was	O
examined	O
by	O
16S	O
rRNA	O
gene	O
sequencing	O
.	O

The	O
expression	O
of	O
genes	O
related	O
to	O
inflammation	O
,	O
epithelial	O
tight	O
junctions	O
,	O
and	O
glucose	O
/	O
fatty	O
acid	O
metabolism	O
in	O
the	O
ileum	O
or	O
liver	O
were	O
examined	O
by	O
quantitative	O
PCR	O
.	O

RESULTS	O
:	O
The	O
relative	O
abundance	O
of	O
several	O
genera	O
,	O
including	O
Brevibacterium	B-bacteria
,	O
Corynebacterium	B-bacteria
,	O
and	O
Facklamia	B-bacteria
,	O
was	O
significantly	O
increased	O
in	O
STZco	O
mice	O
compared	O
to	O
WTco	O
mice	O
.	O

The	O
relative	O
abundances	O
of	O
Staphylococcus	B-bacteria
and	O
Turicibacter	B-bacteria
in	O
the	O
gut	O
microbiome	O
were	O
altered	O
by	O
oral	O
administration	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
in	O
STZ	O
mice	O
.	O

STZPg	O
mice	O
showed	O
higher	O
concentrations	O
of	O
fasting	O
blood	O
glucose	O
and	O
inflammatory	O
genes	O
levels	O
in	O
the	O
ileum	O
,	O
compared	O
to	O
STZco	O
mice	O
.	O

CONCLUSIONS	O
:	O
Oral	O
administration	O
of	O
P	B-bacteria
.	I-bacteria
gingivalis	I-bacteria
altered	O
the	O
gut	O
microbiota	O
and	O
aggravated	O
glycemic	O
control	O
in	O
streptozotocin	O
-	O
induced	O
diabetic	O
mice	O
.	O

The	O
Crohn	O
'	O
s	O
disease	O
polymorphism	O
,	O
ATG16L1	O
T300A	O
,	O
alters	O
the	O
gut	O
microbiota	O
and	O
enhances	O
the	O
local	O
Th1	O
/	O
Th17	O
response	O
.	O

Inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
is	O
driven	O
by	O
dysfunction	O
between	O
host	O
genetics	O
,	O
the	O
microbiota	O
,	O
and	O
immune	O
system	O
.	O

Knowledge	O
gaps	O
remain	O
regarding	O
how	O
IBD	O
genetic	O
risk	O
loci	O
drive	O
gut	O
microbiota	O
changes	O
.	O

The	O
Crohn	O
'	O
s	O
disease	O
risk	O
allele	O
ATG16L1	O
T300A	O
results	O
in	O
abnormal	O
Paneth	O
cells	O
due	O
to	O
decreased	O
selective	O
autophagy	O
,	O
increased	O
cytokine	O
release	O
,	O
and	O
decreased	O
intracellular	O
bacterial	O
clearance	O
.	O

To	O
unravel	O
the	O
effects	O
of	O
ATG16L1	O
T300A	O
on	O
the	O
microbiota	O
and	O
immune	O
system	O
,	O
we	O
employed	O
a	O
gnotobiotic	O
model	O
using	O
human	O
fecal	O
transfers	O
into	O
ATG16L1	O
T300A	O
knock	O
-	O
in	O
mice	O
.	O

We	O
observed	O
increases	O
in	O
Bacteroides	B-bacteria
ovatus	I-bacteria
and	O
Th1	O
and	O
Th17	O
cells	O
in	O
ATG16L1	O
T300A	O
mice	O
.	O

Association	O
of	O
altered	O
Schaedler	O
flora	O
mice	O
with	O
B	B-bacteria
.	I-bacteria
ovatus	I-bacteria
specifically	O
increased	O
Th17	O
cells	O
selectively	O
in	O
ATG16L1	O
T300A	O
knock	O
-	O
in	O
mice	O
.	O

Changes	O
occur	O
before	O
disease	O
onset	O
,	O
suggesting	O
that	O
ATG16L1	O
T300A	O
contributes	O
to	O
dysbiosis	O
and	O
immune	O
infiltration	O
prior	O
to	O
disease	O
symptoms	O
.	O

Our	O
work	O
provides	O
insight	O
for	O
future	O
studies	O
on	O
IBD	O
subtypes	O
,	O
IBD	O
patient	O
treatment	O
and	O
diagnostics	O
.	O

Gut	O
microbiota	O
density	O
influences	O
host	O
physiology	O
and	O
is	O
shaped	O
by	O
host	O
and	O
microbial	O
factors	O
.	O

To	O
identify	O
factors	O
that	O
regulate	O
gut	O
microbiota	O
density	O
and	O
the	O
impact	O
of	O
varied	O
microbiota	O
density	O
on	O
health	O
,	O
we	O
assayed	O
this	O
fundamental	O
ecosystem	O
property	O
in	O
fecal	O
samples	O
across	O
mammals	O
,	O
human	O
disease	O
,	O
and	O
therapeutic	O
interventions	O
.	O

Physiologic	O
features	O
of	O
the	O
host	O
(	O
carrying	O
capacity	O
)	O
and	O
the	O
fitness	O
of	O
the	O
gut	O
microbiota	O
shape	O
microbiota	O
density	O
.	O

Therapeutic	O
manipulation	O
of	O
microbiota	O
density	O
in	O
mice	O
altered	O
host	O
metabolic	O
and	O
immune	O
homeostasis	O
.	O

In	O
humans	O
,	O
gut	O
microbiota	O
density	O
was	O
reduced	O
in	O
Crohn	O
'	O
s	O
disease	O
,	O
ulcerative	O
colitis	O
,	O
and	O
ileal	O
pouch	O
-	O
anal	O
anastomosis	O
.	O

The	O
gut	O
microbiota	O
in	O
recurrent	O
Clostridium	B-bacteria
difficile	I-bacteria
infection	O
had	O
lower	O
density	O
and	O
reduced	O
fitness	O
that	O
were	O
restored	O
by	O
fecal	O
microbiota	O
transplantation	O
.	O

Understanding	O
the	O
interplay	O
between	O
microbiota	O
and	O
disease	O
in	O
terms	O
of	O
microbiota	O
density	O
,	O
host	O
carrying	O
capacity	O
,	O
and	O
microbiota	O
fitness	O
provide	O
new	O
insights	O
into	O
microbiome	O
structure	O
and	O
microbiome	O
targeted	O
therapeutics	O
.	O

Editorial	O
note	O
:	O
This	O
article	O
has	O
been	O
through	O
an	O
editorial	O
process	O
in	O
which	O
the	O
authors	O
decide	O
how	O
to	O
respond	O
to	O
the	O
issues	O
raised	O
during	O
peer	O
review	O
.	O

The	O
Reviewing	O
Editor	O
'	O
s	O
assessment	O
is	O
that	O
all	O
the	O
issues	O
have	O
been	O
addressed	O
(	O
see	O
decision	O
letter	O
)	O
.	O

Oral	O
administration	O
of	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
GG	I-bacteria
to	O
newborn	O
piglets	O
augments	O
gut	O
barrier	O
function	O
in	O
pre	O
-	O
weaning	O
piglets	O
.	O

To	O
understand	O
the	O
effects	O
of	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
GG	I-bacteria
(	O
ATCC	B-bacteria
53103	I-bacteria
)	O
on	O
intestinal	O
barrier	O
function	O
in	O
pre	O
-	O
weaning	O
piglets	O
under	O
normal	O
conditions	O
,	O
twenty	O
-	O
four	O
newborn	O
littermate	O
piglets	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

Piglets	O
in	O
the	O
control	O
group	O
were	O
orally	O
administered	O
with	O
2	O
mL	O
0	O
.	O
1	O
g	O
/	O
mL	O
sterilized	O
skim	O
milk	O
while	O
the	O
treatment	O
group	O
was	O
administered	O
the	O
same	O
volume	O
of	O
sterilized	O
skim	O
milk	O
with	O
the	O
addition	O
of	O
viable	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
at	O
the	O
1st	O
,	O
3rd	O
,	O
and	O
5th	O
days	O
after	O
birth	O
.	O

The	O
feeding	O
trial	O
was	O
conducted	O
for	O
25	O
d	O
.	O
Results	O
showed	O
that	O
piglets	O
in	O
the	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
group	O
exhibited	O
increased	O
weaning	O
weight	O
and	O
average	O
daily	O
weight	O
gain	O
,	O
whereas	O
diarrhea	O
incidence	O
was	O
decreased	O
.	O

The	O
bacterial	O
abundance	O
and	O
composition	O
of	O
cecal	O
contents	O
,	O
especially	O
Firmicutes	B-bacteria
,	O
Bacteroidetes	B-bacteria
,	O
and	O
Fusobacteria	B-bacteria
,	O
were	O
altered	O
by	O
probiotic	O
treatment	O
.	O

In	O
addition	O
,	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
increased	O
the	O
jejunal	O
permeability	O
and	O
promoted	O
the	O
immunologic	O
barrier	O
through	O
regulating	O
antimicrobial	O
peptides	O
,	O
cytokines	O
,	O
and	O
chemokines	O
via	O
Toll	O
-	O
like	O
receptors	O
.	O

Our	O
findings	O
indicate	O
that	O
oral	O
administration	O
of	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
GG	I-bacteria
to	O
newborn	O
piglets	O
is	O
beneficial	O
for	O
intestinal	O
health	O
of	O
pre	O
-	O
weaning	O
piglets	O
by	O
improving	O
the	O
biological	O
,	O
physical	O
,	O
and	O
immunologic	O
barriers	O
of	O
intestinal	O
mucosa	O
.	O

Phoenicibacter	B-bacteria
congonensis	I-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	O
a	O
new	O
genus	O
isolated	O
from	O
the	O
human	O
gut	O
and	O
its	O
description	O
using	O
a	O
taxonogenomic	O
approach	O
.	O

Culturomics	O
has	O
recently	O
allowed	O
the	O
isolation	O
and	O
description	O
of	O
previously	O
uncultured	O
bacteria	O
from	O
the	O
human	O
microbiome	O
at	O
different	O
body	O
sites	O
.	O

As	O
part	O
of	O
a	O
project	O
aiming	O
to	O
describe	O
the	O
human	O
gut	O
microbiota	O
by	O
culturomics	O
,	O
Phoenicibacter	B-bacteria
congonensis	I-bacteria
strain	I-bacteria
Marseille	I-bacteria
-	I-bacteria
P3241	I-bacteria
(	O
T	O
)	O
was	O
isolated	O
from	O
the	O
gut	O
of	O
a	O
45	O
years	O
old	O
Pygmy	O
female	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
aim	O
to	O
describe	O
this	O
strain	O
via	O
the	O
taxonogenomics	O
approach	O
.	O

The	O
major	O
phenotypic	O
,	O
genomic	O
and	O
biochemical	O
characteristics	O
of	O
this	O
strain	O
were	O
analysed	O
.	O

Strain	O
Marseille	B-bacteria
-	O
P3241	B-bacteria
(	O
T	O
)	O
is	O
an	O
anaerobic	O
,	O
Gram	O
-	O
positive	O
and	O
motile	O
coccobacillus	B-bacteria
that	O
grows	O
optimally	O
at	O
37	O
degrees	O
C	O
.	O
The	O
genome	O
of	O
strain	O
Marseille	O
-	O
P3241	O
(	O
T	O
)	O
is	O
1	O
,	O
447	O
,	O
956	O
bp	O
long	O
with	O
43	O
.	O
44	O
%	O
GC	O
content	O
and	O
its	O
16S	O
rRNA	O
gene	O
sequence	O
exhibited	O
89	O
%	O
sequence	O
similarity	O
with	O
that	O
of	O
Denitrobacterium	B-bacteria
detoxificans	I-bacteria
strain	I-bacteria
NPOH1	I-bacteria
(	O
T	O
)	O
,	O
the	O
phylogenetically	O
closest	O
related	O
species	O
with	O
current	O
standing	O
in	O
nomenclature	O
.	O

After	O
performing	O
a	O
phylogenetic	O
and	O
genomic	O
analysis	O
,	O
we	O
conclude	O
that	O
strain	O
Marseille	B-bacteria
-	I-bacteria
P3241	I-bacteria
(	O
T	O
)	O
(	O
=	O
CCUG	B-bacteria
70681	I-bacteria
(	O
T	O
)	O
=	O
CSUR	B-bacteria
P3241	I-bacteria
(	O
T	O
)	O
)	O
represents	O
the	O
type	O
species	O
of	O
a	O
new	O
genus	O
,	O
for	O
which	O
we	O
propose	O
the	O
name	O
Phoenicibacter	B-bacteria
congonensis	I-bacteria
gen	I-bacteria
.	I-bacteria
nov	I-bacteria
.	I-bacteria
,	I-bacteria
sp	I-bacteria
.	I-bacteria
nov	I-bacteria
.	O

Identification	O
of	O
Specific	O
Oral	O
and	O
Gut	O
Pathogens	O
in	O
Full	O
Thickness	O
Colon	O
of	O
Colitis	O
Patients	O
:	O
Implications	O
for	O
Colon	O
Motility	O
.	O

Impaired	O
colon	O
motility	O
is	O
one	O
of	O
the	O
leading	O
problems	O
associated	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

An	O
expanding	O
body	O
of	O
evidence	O
supports	O
the	O
role	O
of	O
microbiome	O
in	O
normal	O
gut	O
function	O
and	O
in	O
progression	O
of	O
IBD	O
.	O

The	O
objective	O
of	O
this	O
work	O
is	O
to	O
determine	O
whether	O
diseased	O
full	O
thickness	O
colon	O
specimens	O
,	O
including	O
the	O
neuromuscular	O
region	O
(	O
critical	O
for	O
colon	O
motility	O
function	O
)	O
,	O
contain	O
specific	O
oral	O
and	O
gut	O
pathogens	O
.	O

In	O
addition	O
,	O
we	O
compared	O
the	O
differences	O
in	O
colon	O
microbiome	O
between	O
Caucasians	O
(	O
CA	O
)	O
and	O
African	O
Americans	O
(	O
AA	O
)	O
.	O

Thirty	O
-	O
nine	O
human	O
full	O
thickness	O
colon	O
(	O
diseased	O
colon	O
and	O
adjacent	O
healthy	O
colon	O
)	O
specimens	O
were	O
collected	O
from	O
Crohn	O
'	O
s	O
Colitis	O
(	O
CC	O
)	O
or	O
Ulcerative	O
Colitis	O
(	O
UC	O
)	O
patients	O
while	O
they	O
underwent	O
elective	O
colon	O
surgeries	O
.	O

We	O
isolated	O
and	O
analyzed	O
bacterial	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
from	O
colon	O
specimens	O
by	O
amplicon	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
gene	O
region	O
.	O

The	O
microbiome	O
proportions	O
were	O
quantified	O
into	O
Operational	O
Taxonomic	O
Units	O
(	O
OTUs	O
)	O
by	O
analysis	O
with	O
Quantitative	O
Insights	O
Into	O
Microbial	O
ecology	O
(	O
QIIME	O
)	O
platform	O
.	O

Two	O
hundred	O
twenty	O
-	O
eight	O
different	O
bacterial	O
species	O
were	O
identified	O
by	O
QIIME	O
analysis	O
.	O

However	O
,	O
we	O
could	O
only	O
decipher	O
the	O
species	O
name	O
of	O
fifty	O
-	O
three	O
bacteria	O
.	O

Our	O
results	O
show	O
that	O
proportion	O
of	O
non	O
-	O
detrimental	O
bacteria	O
in	O
CC	O
or	O
UC	O
colon	O
samples	O
were	O
altered	O
compared	O
to	O
adjacent	O
healthy	O
colon	O
specimens	O
.	O

We	O
further	O
show	O
,	O
for	O
the	O
first	O
time	O
in	O
full	O
thickness	O
colon	O
specimens	O
,	O
that	O
microbiome	O
of	O
CC	O
and	O
UC	O
diseased	O
specimens	O
is	O
dominated	O
by	O
putative	O
oral	O
pathogens	O
belonging	O
to	O
the	O
Phyla	O
Firmicutes	B-bacteria
(	O
Streptococcus	B-bacteria
,	O
Staphylococcus	B-bacteria
,	O
Peptostreptococcus	B-bacteria
)	O
,	O
and	O
Fusobacteria	B-bacteria
(	O
Fusobacterium	B-bacteria
)	O
.	O

In	O
addition	O
,	O
we	O
have	O
identified	O
patterns	O
of	O
differences	O
in	O
microbiome	O
levels	O
between	O
CA	O
and	O
AA	O
specimens	O
with	O
potential	O
implications	O
for	O
health	O
disparities	O
research	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
a	O
significant	O
association	O
between	O
oral	O
and	O
gut	O
microbes	O
in	O
the	O
modulation	O
of	O
colon	O
motility	O
in	O
colitis	O
patients	O
.	O

Population	O
structure	O
of	O
human	O
gut	O
bacteria	O
in	O
a	O
diverse	O
cohort	O
from	O
rural	O
Tanzania	O
and	O
Botswana	O
.	O

BACKGROUND	O
:	O
Gut	O
microbiota	O
from	O
individuals	O
in	O
rural	O
,	O
non	O
-	O
industrialized	O
societies	O
differ	O
from	O
those	O
in	O
individuals	O
from	O
industrialized	O
societies	O
.	O

Here	O
,	O
we	O
use	O
16S	O
rRNA	O
sequencing	O
to	O
survey	O
the	O
gut	O
bacteria	O
of	O
seven	O
non	O
-	O
industrialized	O
populations	O
from	O
Tanzania	O
and	O
Botswana	O
.	O

These	O
include	O
populations	O
practicing	O
traditional	O
hunter	O
-	O
gatherer	O
,	O
pastoralist	O
,	O
and	O
agropastoralist	O
subsistence	O
lifestyles	O
and	O
a	O
comparative	O
urban	O
cohort	O
from	O
the	O
greater	O
Philadelphia	O
region	O
.	O

RESULTS	O
:	O
We	O
find	O
that	O
bacterial	O
diversity	O
per	O
individual	O
and	O
within	O
-	O
population	O
phylogenetic	O
dissimilarity	O
differs	O
between	O
Botswanan	O
and	O
Tanzanian	O
populations	O
,	O
with	O
Tanzania	O
generally	O
having	O
higher	O
diversity	O
per	O
individual	O
and	O
lower	O
dissimilarity	O
between	O
individuals	O
.	O

Among	O
subsistence	O
groups	O
,	O
the	O
gut	O
bacteria	O
of	O
hunter	O
-	O
gatherers	O
are	O
phylogenetically	O
distinct	O
from	O
both	O
agropastoralists	O
and	O
pastoralists	O
,	O
but	O
that	O
of	O
agropastoralists	O
and	O
pastoralists	O
were	O
not	O
significantly	O
different	O
from	O
each	O
other	O
.	O

Nearly	O
half	O
of	O
the	O
Bantu	O
-	O
speaking	O
agropastoralists	O
from	O
Botswana	O
have	O
gut	O
bacteria	O
that	O
are	O
very	O
similar	O
to	O
the	O
Philadelphian	O
cohort	O
.	O

Based	O
on	O
imputed	O
metagenomic	O
content	O
,	O
US	O
samples	O
have	O
a	O
relative	O
enrichment	O
of	O
genes	O
found	O
in	O
pathways	O
for	O
degradation	O
of	O
several	O
common	O
industrial	O
pollutants	O
.	O

Within	O
two	O
African	O
populations	O
,	O
we	O
find	O
evidence	O
that	O
bacterial	O
composition	O
correlates	O
with	O
the	O
genetic	O
relatedness	O
between	O
individuals	O
.	O

CONCLUSIONS	O
:	O
Across	O
the	O
cohort	O
,	O
similarity	O
in	O
bacterial	O
presence	O
/	O
absence	O
compositions	O
between	O
people	O
increases	O
with	O
both	O
geographic	O
proximity	O
and	O
genetic	O
relatedness	O
,	O
while	O
abundance	O
weighted	O
bacterial	O
composition	O
varies	O
more	O
significantly	O
with	O
geographic	O
proximity	O
than	O
with	O
genetic	O
relatedness	O
.	O

Retention	O
of	O
Microbiota	O
Diversity	O
by	O
Lactose	O
-	O
Free	O
Milk	O
in	O
a	O
Mouse	O
Model	O
of	O
Elderly	O
Gut	O
Microbiota	O
.	O

Prebiotics	O
may	O
improve	O
aging	O
-	O
related	O
dysbiosis	O
.	O

Milk	O
is	O
a	O
source	O
of	O
nutrients	O
including	O
oligosaccharides	O
whose	O
prebiotic	O
potential	O
remains	O
largely	O
unexplored	O
.	O

We	O
used	O
a	O
murine	O
model	O
to	O
explore	O
the	O
effect	O
of	O
milk	O
products	O
on	O
high	O
diversity	O
and	O
lower	O
diversity	O
faecal	O
microbiota	O
from	O
healthy	O
and	O
frail	O
elderly	O
subjects	O
,	O
respectively	O
.	O

Mice	O
were	O
treated	O
with	O
antibiotics	O
and	O
subsequently	O
`	O
`	O
humanized	O
'	O
'	O
with	O
human	O
faecal	O
microbiota	O
.	O

The	O
mice	O
received	O
lactose	O
-	O
free	O
or	O
whole	O
milk	O
,	O
glycomacropeptide	O
,	O
or	O
soy	O
protein	O
(	O
control	O
)	O
supplemented	O
diets	O
for	O
one	O
month	O
.	O

The	O
faecal	O
microbiota	O
was	O
analyzed	O
by	O
16S	O
rRNA	O
gene	O
amplicon	O
sequencing	O
.	O

Lactose	O
-	O
free	O
milk	O
diet	O
was	O
as	O
efficient	O
as	O
the	O
control	O
diet	O
in	O
retaining	O
faecal	O
microbiota	O
diversity	O
in	O
mice	O
.	O

Both	O
milk	O
diets	O
had	O
a	O
significant	O
effect	O
on	O
the	O
relative	O
abundance	O
of	O
health	O
-	O
relevant	O
taxa	O
(	O
e	O
.	O
g	O
.	O
,	O
Ruminococcaceae	B-bacteria
,	O
Lachnospiraceae	B-bacteria
)	O
.	O

The	O
glycomacropeptide	O
prebiotic	O
activity	O
previously	O
observed	O
in	O
vitro	O
was	O
not	O
replicated	O
in	O
vivo	O
.	O

However	O
,	O
these	O
data	O
indicate	O
the	O
novel	O
prebiotic	O
potential	O
of	O
bovine	O
milk	O
for	O
human	O
nutrition	O
.	O

Systemic	O
antibody	O
responses	O
to	O
gut	O
commensal	O
bacteria	O
:	O
How	O
and	O
why	O
do	O
I	O
know	O
you	O
?	O

Inferring	O
bacterial	O
recombination	O
rates	O
from	O
large	O
-	O
scale	O
sequencing	O
datasets	O
.	O

We	O
present	O
a	O
robust	O
,	O
computationally	O
efficient	O
method	O
(	O
https	O
:	O
/	O
/	O
github	O
.	O
com	O
/	O
kussell	O
-	O
lab	O
/	O
mcorr	O
)	O
for	O
inferring	O
the	O
parameters	O
of	O
homologous	O
recombination	O
in	O
bacteria	O
,	O
which	O
can	O
be	O
applied	O
in	O
diverse	O
datasets	O
,	O
from	O
whole	O
-	O
genome	O
sequencing	O
to	O
metagenomic	O
shotgun	O
sequencing	O
data	O
.	O

Using	O
correlation	O
profiles	O
of	O
synonymous	O
substitutions	O
,	O
we	O
determine	O
recombination	O
rates	O
and	O
diversity	O
levels	O
of	O
the	O
shared	O
gene	O
pool	O
that	O
has	O
contributed	O
to	O
a	O
given	O
sample	O
.	O

We	O
validated	O
the	O
recombination	O
parameters	O
using	O
data	O
from	O
laboratory	O
experiments	O
.	O

We	O
determined	O
the	O
recombination	O
parameters	O
for	O
a	O
wide	O
range	O
of	O
bacterial	O
species	O
,	O
and	O
inferred	O
the	O
distribution	O
of	O
shared	O
gene	O
pools	O
for	O
global	O
Helicobacter	B-bacteria
pylori	I-bacteria
isolates	I-bacteria
.	O

Using	O
metagenomics	O
data	O
of	O
the	O
infant	O
gut	O
microbiome	O
,	O
we	O
measured	O
the	O
recombination	O
parameters	O
of	O
multidrug	B-bacteria
-	I-bacteria
resistant	I-bacteria
Escherichia	I-bacteria
coli	I-bacteria
ST131	I-bacteria
.	O

Lastly	O
,	O
we	O
analyzed	O
ancient	O
samples	O
of	O
bacterial	O
DNA	O
from	O
the	O
Copper	O
Age	O
'	O
Iceman	O
'	O
mummy	O
and	O
from	O
14th	O
century	O
victims	O
of	O
the	O
Black	O
Death	O
,	O
obtaining	O
measurements	O
of	O
bacterial	O
recombination	O
rates	O
and	O
gene	O
pool	O
diversity	O
of	O
earlier	O
eras	O
.	O

Bacteroides	B-bacteria
ovatus	I-bacteria
ATCC	I-bacteria
8483	I-bacteria
monotherapy	O
is	O
superior	O
to	O
traditional	O
fecal	O
transplant	O
and	O
multi	O
-	O
strain	O
bacteriotherapy	O
in	O
a	O
murine	O
colitis	O
model	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
Bacteriotherapy	O
aimed	O
at	O
addressing	O
dysbiosis	O
may	O
be	O
therapeutic	O
for	O
Inflammatory	O
Bowel	O
Diseases	O
(	O
IBDs	O
)	O
.	O

We	O
sought	O
to	O
determine	O
if	O
defined	O
Bacteroides	O
-	O
based	O
bacteriotherapy	O
could	O
be	O
an	O
effective	O
and	O
consistent	O
alternative	O
to	O
fecal	O
microbiota	O
transplantation	O
(	O
FMT	O
)	O
in	O
a	O
murine	O
model	O
of	O
IBD	O
.	O

METHODS	O
:	O
We	O
induced	O
experimental	O
colitis	O
in	O
8	O
-	O
12	O
-	O
week	O
-	O
old	O
C57BL	O
/	O
6	O
mice	O
using	O
2	O
-	O
3	O
%	O
dextran	O
sodium	O
sulfate	O
.	O

Mice	O
were	O
simultaneously	O
treated	O
by	O
oral	O
gavage	O
with	O
a	O
triple	O
-	O
Bacteroides	O
cocktail	O
,	O
individual	O
Bacteroides	B-bacteria
strains	I-bacteria
,	O
FMT	O
using	O
stool	O
from	O
healthy	O
donor	O
mice	O
,	O
or	O
their	O
own	O
stool	O
as	O
a	O
control	O
.	O

Survival	O
,	O
weight	O
loss	O
and	O
markers	O
of	O
inflammation	O
(	O
histology	O
,	O
serum	O
amyloid	O
A	O
,	O
cytokine	O
production	O
)	O
were	O
correlated	O
to	O
16S	O
rRNA	O
gene	O
profiling	O
of	O
fecal	O
and	O
mucosal	O
microbiomes	O
.	O

RESULTS	O
:	O
Triple	O
-	O
Bacteroides	O
combination	O
therapy	O
was	O
more	O
protective	O
against	O
weight	O
loss	O
and	O
mortality	O
than	O
traditional	O
FMT	O
therapy	O
.	O

B	B-bacteria
.	I-bacteria
ovatus	I-bacteria
ATCC8483	I-bacteria
was	O
more	O
effective	O
than	O
any	O
individual	O
strain	O
,	O
or	O
a	O
combination	O
of	O
strains	O
,	O
in	O
preventing	O
weight	O
loss	O
,	O
decreasing	O
histological	O
damage	O
,	O
dampening	O
inflammatory	O
response	O
,	O
and	O
stimulating	O
epithelial	O
recovery	O
.	O

Irrespective	O
of	O
the	O
treatment	O
group	O
,	O
overall	O
Bacteroides	B-bacteria
abundance	O
associated	O
with	O
treatment	O
success	O
and	O
decreased	O
cytokine	O
production	O
while	O
the	O
presence	O
of	O
Akkermansia	B-bacteria
correlated	O
with	O
treatment	O
failure	O
.	O

However	O
,	O
the	O
therapeutic	O
benefit	O
associated	O
with	O
high	O
Bacteroides	B-bacteria
abundance	O
was	O
negated	O
in	O
the	O
presence	O
of	O
Streptococcus	B-bacteria
.	O

CONCLUSIONS	O
:	O
Bacteroides	B-bacteria
ovatus	I-bacteria
monotherapy	O
was	O
more	O
consistent	O
and	O
effective	O
than	O
traditional	O
FMT	O
at	O
ameliorating	O
colitis	O
and	O
stimulating	O
epithelial	O
recovery	O
in	O
a	O
murine	O
model	O
of	O
IBD	O
.	O

Given	O
the	O
tolerability	O
of	O
Bacteroides	B-bacteria
ovatus	I-bacteria
ATCC	I-bacteria
8483	I-bacteria
in	O
an	O
active	O
,	O
on	O
-	O
going	O
human	O
study	O
,	O
this	O
therapy	O
may	O
be	O
repurposed	O
for	O
the	O
management	O
of	O
IBD	O
in	O
a	O
clinically	O
expedient	O
timeline	O
.	O

Lipopolysaccharide	O
promoted	O
proliferation	O
and	O
adipogenesis	O
of	O
preadipocytes	O
through	O
JAK	O
/	O
STAT	O
and	O
AMPK	O
-	O
regulated	O
cPLA2	O
expression	O
.	O

The	O
proliferation	O
and	O
adipogenesis	O
of	O
preadipocytes	O
played	O
important	O
roles	O
in	O
the	O
development	O
of	O
adipose	O
tissue	O
and	O
contributed	O
much	O
to	O
the	O
processes	O
of	O
obesity	O
.	O

On	O
the	O
other	O
hand	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
also	O
known	O
as	O
endotoxin	O
,	O
is	O
a	O
key	O
outer	O
membrane	O
component	O
of	O
gram	O
-	O
negative	O
bacteria	O
in	O
the	O
gut	O
microbiota	O
,	O
and	O
has	O
a	O
dominant	O
role	O
in	O
linking	O
inflammation	O
to	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
metabolic	O
syndrome	O
.	O

Studies	O
suggested	O
the	O
potential	O
roles	O
of	O
LPS	O
in	O
hepatic	O
steatosis	O
and	O
in	O
obese	O
mice	O
models	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
LPS	O
-	O
regulated	O
obesity	O
remained	O
largely	O
unknown	O
.	O

Here	O
we	O
reported	O
that	O
LPS	O
stimulated	O
expression	O
of	O
cyosolic	O
phospholipase	O
A2	O
(	O
cPLA2	O
)	O
,	O
one	O
of	O
inflammation	O
regulators	O
of	O
obesity	O
,	O
in	O
the	O
preadipocytes	O
.	O

Pretreatment	O
the	O
inhibitors	O
of	O
JAK2	O
,	O
STAT3	O
,	O
STAT5	O
or	O
AMPK	O
significantly	O
reduced	O
LPS	O
-	O
increased	O
mRNA	O
and	O
protein	O
expression	O
of	O
cPLA2	O
together	O
with	O
phosphorylation	O
of	O
JAK2	O
,	O
STAT3	O
,	O
STAT5	O
and	O
AMPK	O
,	O
separately	O
.	O

Similarly	O
,	O
transfection	O
of	O
siRNA	O
against	O
JAK2	O
or	O
AMPK	O
abolished	O
expression	O
of	O
cPLA2	O
and	O
phosphorylation	O
of	O
JAK2	O
or	O
AMPK	O
together	O
with	O
downregulated	O
expression	O
of	O
JAK2	O
and	O
AMPK	O
protein	O
.	O

LPS	O
enhanced	O
activation	O
of	O
STAT3	O
and	O
STAT5	O
via	O
JAK2	O
-	O
dependent	O
manner	O
in	O
the	O
preadipocytes	O
.	O

Transfection	O
of	O
JAK2	O
or	O
AMPK	O
siRNA	O
further	O
proofed	O
the	O
independence	O
of	O
JAK2	O
and	O
AMPK	O
in	O
LPS	O
-	O
treated	O
preadipocytes	O
.	O

In	O
addition	O
,	O
LPS	O
-	O
increased	O
DNA	O
synthesis	O
,	O
cell	O
numbers	O
and	O
cell	O
viability	O
of	O
preadipocytes	O
were	O
attenuated	O
by	O
AACOCF3	O
,	O
AG490	O
,	O
BML	O
-	O
275	O
,	O
cPLA2	O
siRNA	O
,	O
JAK2	O
siRNA	O
or	O
AMPK	O
siRNA	O
.	O

Attenuation	O
JAK2	O
/	O
STAT	O
or	O
AMPK	O
-	O
dependent	O
cPLA2	O
expression	O
reduced	O
LPS	O
-	O
mediated	O
adipogenesis	O
of	O
preadipocytes	O
.	O

Stimulation	O
of	O
arachidonic	O
acid	O
or	O
AMPK	O
activator	O
,	O
A	O
-	O
769662	O
,	O
increased	O
cell	O
numbers	O
and	O
cell	O
viability	O
and	O
promoted	O
differentiation	O
of	O
preadipocytes	O
.	O

Collectively	O
,	O
these	O
results	O
indicated	O
that	O
LPS	O
increased	O
preadipocytes	O
proliferation	O
and	O
adipogenesis	O
via	O
JAK	O
/	O
STAT	O
and	O
AMPK	O
-	O
dependent	O
cPLA2	O
expression	O
.	O

The	O
mechanisms	O
of	O
LPS	O
-	O
stimulated	O
cPLA2	O
expression	O
may	O
be	O
a	O
link	O
between	O
bacteria	O
and	O
obesity	O
and	O
provides	O
the	O
molecular	O
basis	O
for	O
preventing	O
metabolic	O
syndrome	O
or	O
hyperplasic	O
obesity	O
.	O

The	O
diabetes	O
pandemic	O
and	O
associated	O
infections	O
:	O
suggestions	O
for	O
clinical	O
microbiology	O
.	O

There	O
are	O
425	O
million	O
people	O
with	O
diabetes	O
mellitus	O
in	O
the	O
world	O
.	O

By	O
2045	O
,	O
this	O
figure	O
will	O
grow	O
to	O
over	O
600	O
million	O
.	O

Diabetes	O
mellitus	O
is	O
classified	O
among	O
noncommunicable	O
diseases	O
.	O

Evidence	O
points	O
to	O
a	O
key	O
role	O
of	O
microbes	O
in	O
diabetes	O
mellitus	O
,	O
both	O
as	O
infectious	O
agents	O
associated	O
with	O
the	O
diabetic	O
status	O
and	O
as	O
possible	O
causative	O
factors	O
of	O
diabetes	O
mellitus	O
.	O

This	O
review	O
takes	O
into	O
account	O
the	O
different	O
forms	O
of	O
diabetes	O
mellitus	O
,	O
the	O
genetic	O
determinants	O
that	O
predispose	O
to	O
type	O
1	O
and	O
type	O
2	O
diabetes	O
mellitus	O
(	O
especially	O
those	O
with	O
possible	O
immunologic	O
impact	O
)	O
,	O
the	O
immune	O
dysfunctions	O
that	O
have	O
been	O
documented	O
in	O
diabetes	O
mellitus	O
.	O

Common	O
infections	O
occurring	O
more	O
frequently	O
in	O
diabetic	O
vs	O
.	O
nondiabetic	O
individuals	O
are	O
reviewed	O
.	O

Infectious	O
agents	O
that	O
are	O
suspected	O
of	O
playing	O
an	O
etiologic	O
/	O
triggering	O
role	O
in	O
diabetes	O
mellitus	O
are	O
presented	O
,	O
with	O
emphasis	O
on	O
enteroviruses	O
,	O
the	O
hygiene	O
hypothesis	O
,	O
and	O
the	O
environment	O
.	O

Among	O
biological	O
agents	O
possibly	O
linked	O
to	O
diabetes	O
mellitus	O
,	O
the	O
gut	O
microbiome	O
,	O
hepatitis	O
C	O
virus	O
,	O
and	O
prion	O
-	O
like	O
protein	O
aggregates	O
are	O
discussed	O
.	O

Finally	O
,	O
preventive	O
vaccines	O
recommended	O
in	O
the	O
management	O
of	O
diabetic	O
patients	O
are	O
considered	O
,	O
including	O
the	O
bacillus	O
calmette	O
-	O
Guerin	O
vaccine	O
that	O
is	O
being	O
tested	O
for	O
type	O
1	O
diabetes	O
mellitus	O
.	O

Evidence	O
supports	O
the	O
notion	O
that	O
attenuation	O
of	O
immune	O
defenses	O
(	O
both	O
congenital	O
and	O
secondary	O
to	O
metabolic	O
disturbances	O
as	O
well	O
as	O
to	O
microangiopathy	O
and	O
neuropathy	O
)	O
makes	O
diabetic	O
people	O
more	O
prone	O
to	O
certain	O
infections	O
.	O

Attentive	O
microbiologic	O
monitoring	O
of	O
diabetic	O
patients	O
is	O
thus	O
recommendable	O
.	O

As	O
genetic	O
predisposition	O
can	O
not	O
be	O
changed	O
,	O
research	O
needs	O
to	O
identify	O
the	O
biological	O
agents	O
that	O
may	O
have	O
an	O
etiologic	O
role	O
in	O
diabetes	O
mellitus	O
,	O
and	O
to	O
envisage	O
curative	O
and	O
preventive	O
ways	O
to	O
limit	O
the	O
diabetes	O
pandemic	O
.	O

Effect	O
of	O
administering	O
kefir	O
on	O
the	O
changes	O
in	O
fecal	O
microbiota	O
and	O
symptoms	O
of	O
inflammatory	O
bowel	O
disease	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Kefir	O
is	O
a	O
kind	O
of	O
fermented	O
probiotic	O
dairy	O
product	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
kefir	O
consumption	O
on	O
the	O
fecal	O
microflora	O
and	O
symptoms	O
of	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Kefir	O
was	O
serially	O
diluted	O
and	O
inoculated	O
into	O
de	O
Man	O
,	O
Rogosa	O
,	O
and	O
Sharpe	O
agar	O
and	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
48	O
to	O
72	O
h	O
under	O
anaerobic	O
conditions	O
.	O

This	O
was	O
a	O
single	O
-	O
center	O
,	O
prospective	O
,	O
open	O
-	O
label	O
randomized	O
controlled	O
trial	O
.	O

Forty	O
-	O
five	O
patients	O
with	O
IBD	O
were	O
classified	O
into	O
two	O
groups	O
:	O
25	O
for	O
treatment	O
and	O
20	O
for	O
control	O
.	O

A	O
400	O
mL	O
/	O
day	O
kefir	O
was	O
administered	O
to	O
the	O
patients	O
for	O
4	O
weeks	O
day	O
and	O
night	O
.	O

Their	O
stool	O
Lactobacillus	B-bacteria
,	O
Lactobacillus	B-bacteria
kefiri	I-bacteria
,	O
content	O
was	O
quantitated	O
by	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
before	O
and	O
after	O
consumption	O
.	O

Abdominal	O
pain	O
,	O
bloating	O
,	O
stool	O
frequency	O
,	O
stool	O
consistency	O
,	O
and	O
feeling	O
good	O
scores	O
were	O
recorded	O
in	O
diaries	O
daily	O
by	O
the	O
patients	O
.	O

RESULTS	O
:	O
A	O
5x107	O
CFU	O
/	O
mL	O
count	O
of	O
lactic	B-bacteria
acid	I-bacteria
bacteria	I-bacteria
colony	O
forming	O
units	O
was	O
found	O
in	O
a	O
kefir	O
sample	O
as	O
the	O
total	O
average	O
count	O
.	O

Lactobacillus	B-bacteria
bacterial	O
load	O
of	O
feces	O
of	O
all	O
subjects	O
in	O
the	O
treatment	O
group	O
was	O
between	O
104	O
and	O
109	O
CFU	O
/	O
g	O
,	O
and	O
the	O
first	O
and	O
last	O
measurements	O
were	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
001	O
in	O
ulcerative	O
colitis	O
and	O
p	O
=	O
0	O
.	O
005	O
in	O
Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
)	O
.	O

The	O
L	B-bacteria
.	I-bacteria
kefiri	I-bacteria
bacterial	O
load	O
in	O
the	O
stool	O
of	O
17	O
subjects	O
was	O
measured	O
as	O
between	O
104	O
and	O
106	O
CFU	O
/	O
g	O
.	O

For	O
patients	O
with	O
CD	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
erythrocyte	O
sedimentation	O
rate	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
whereas	O
hemoglobin	O
increased	O
,	O
and	O
for	O
the	O
last	O
2	O
weeks	O
,	O
bloating	O
scores	O
were	O
significantly	O
reduced	O
(	O
p	O
=	O
0	O
.	O
012	O
)	O
,	O
and	O
feeling	O
good	O
scores	O
increased	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
.	O

CONCLUSION	O
:	O
According	O
to	O
our	O
data	O
,	O
kefir	O
consumption	O
may	O
modulate	O
gut	O
microbiota	O
,	O
and	O
regular	O
consumption	O
of	O
kefir	O
may	O
improve	O
the	O
patient	O
'	O
s	O
quality	O
of	O
life	O
in	O
the	O
short	O
term	O
.	O

Relationship	O
between	O
intestinal	O
microbial	O
dysbiosis	O
and	O
primary	O
liver	O
cancer	O
.	O

BACKGROUND	O
:	O
Intestinal	O
microbial	O
dysbiosis	O
is	O
involved	O
in	O
liver	O
disease	O
pathogenesis	O
.	O

However	O
,	O
its	O
role	O
in	O
primary	O
liver	O
cancer	O
(	O
PLC	O
)	O
,	O
particularly	O
in	O
hepatocarcinogenesis	O
remains	O
unclear	O
.	O

The	O
present	O
study	O
aimed	O
to	O
study	O
the	O
changes	O
in	O
intestinal	O
flora	O
at	O
various	O
stages	O
of	O
PLC	O
and	O
clarify	O
the	O
relationship	O
between	O
intestinal	O
microbes	O
and	O
PLC	O
.	O

METHODS	O
:	O
Twenty	O
-	O
four	O
patients	O
with	O
PLC	O
(	O
PLC	O
group	O
)	O
,	O
24	O
patients	O
with	O
liver	O
cirrhosis	O
(	O
LC	O
group	O
)	O
,	O
and	O
23	O
healthy	O
control	O
individuals	O
(	O
HC	O
group	O
)	O
were	O
enrolled	O
from	O
October	O
2016	O
to	O
October	O
2017	O
.	O

Stool	O
specimens	O
of	O
the	O
participants	O
were	O
collected	O
and	O
the	O
genomic	O
DNA	O
of	O
fecal	O
bacteria	O
was	O
isolated	O
.	O

High	O
-	O
throughput	O
pyrosequencing	O
of	O
16S	O
rDNA	O
was	O
used	O
to	O
identify	O
differences	O
in	O
gut	O
bacterial	O
diversity	O
among	O
HC	O
,	O
LC	O
,	O
and	O
PLC	O
groups	O
.	O

We	O
also	O
analyzed	O
the	O
relationship	O
between	O
clinical	O
factors	O
and	O
intestinal	O
microorganisms	O
in	O
LC	O
and	O
PLC	O
groups	O
.	O

RESULTS	O
:	O
Diversity	O
of	O
Firmicutes	B-bacteria
tended	O
to	O
decrease	O
from	O
the	O
HC	O
to	O
LC	O
and	O
PLC	O
groups	O
at	O
the	O
phylum	O
level	O
.	O

Among	O
species	O
,	O
Enterobacter	B-bacteria
ludwigii	I-bacteria
displayed	O
an	O
increasing	O
trend	O
in	O
the	O
PLC	O
group	O
,	O
wherein	O
the	O
relative	O
abundance	O
of	O
Enterobacter	B-bacteria
ludwigii	I-bacteria
in	O
the	O
PLC	O
group	O
was	O
100	O
times	O
greater	O
than	O
that	O
in	O
the	O
HC	O
and	O
LC	O
groups	O
.	O

The	O
ratio	O
of	O
Firmicutes	B-bacteria
/	O
Bacteroidetes	B-bacteria
was	O
significantly	O
decreased	O
with	O
the	O
disease	O
progression	O
.	O

In	O
addition	O
,	O
the	O
linear	O
discriminant	O
analysis	O
effect	O
size	O
method	O
indicated	O
that	O
Clostridia	B-bacteria
were	O
predominant	O
in	O
the	O
gut	O
microbiota	O
of	O
the	O
HC	O
group	O
,	O
whereas	O
Enterococcaceae	B-bacteria
,	O
Lactobacillales	B-bacteria
,	O
Bacilli	B-bacteria
and	O
Gammaproteobacteria	B-bacteria
may	O
be	O
used	O
as	O
diagnostic	O
markers	O
of	O
PLC	O
.	O

Redundancy	O
analysis	O
showed	O
a	O
correlation	O
between	O
intestinal	O
microbial	O
diversity	O
and	O
clinical	O
factors	O
AST	O
,	O
ALT	O
,	O
and	O
AFP	O
.	O

Veillonella	B-bacteria
showed	O
a	O
significant	O
positive	O
correlation	O
with	O
AFP	O
in	O
the	O
PLC	O
group	O
,	O
whereas	O
Subdoligranulum	B-bacteria
showed	O
a	O
negative	O
correlation	O
with	O
AFP	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
indicates	O
that	O
dysbiosis	O
of	O
the	O
gut	O
microbiota	O
might	O
be	O
involved	O
in	O
PLC	O
development	O
and	O
progression	O
.	O

Crossing	O
the	O
Intestinal	O
Barrier	O
via	O
Listeria	B-bacteria
Adhesion	O
Protein	O
and	O
Internalin	O
A	O
.	O

The	O
intestinal	O
epithelial	O
cell	O
lining	O
provides	O
the	O
first	O
line	O
of	O
defense	O
,	O
yet	O
foodborne	O
pathogens	O
such	O
as	O
Listeria	B-bacteria
monocytogenes	I-bacteria
can	O
overcome	O
this	O
barrier	O
;	O
however	O
,	O
the	O
underlying	O
mechanism	O
is	O
not	O
well	O
understood	O
.	O

Though	O
the	O
host	O
M	O
cells	O
in	O
Peyer	O
'	O
s	O
patch	O
and	O
the	O
bacterial	O
invasion	O
protein	O
internalin	O
A	O
(	O
InlA	O
)	O
are	O
involved	O
,	O
L	B-bacteria
.	I-bacteria
monocytogenes	I-bacteria
can	O
cross	O
the	O
gut	O
barrier	O
in	O
their	O
absence	O
.	O

The	O
interaction	O
of	O
Listeria	B-bacteria
adhesion	O
protein	O
(	O
LAP	O
)	O
with	O
the	O
host	O
cell	O
receptor	O
(	O
heat	O
shock	O
protein	O
60	O
)	O
disrupts	O
the	O
epithelial	O
barrier	O
,	O
promoting	O
bacterial	O
translocation	O
.	O

InlA	O
aids	O
L	B-bacteria
.	I-bacteria
monocytogenes	I-bacteria
transcytosis	O
via	O
interaction	O
with	O
the	O
E	O
-	O
cadherin	O
receptor	O
,	O
which	O
is	O
facilitated	O
by	O
epithelial	O
cell	O
extrusion	O
and	O
goblet	O
cell	O
exocytosis	O
;	O
however	O
,	O
LAP	O
-	O
induced	O
cell	O
junction	O
opening	O
may	O
be	O
an	O
alternative	O
bacterial	O
strategy	O
for	O
InlA	O
access	O
to	O
E	O
-	O
cadherin	O
and	O
its	O
translocation	O
.	O

Here	O
,	O
we	O
summarize	O
the	O
strategies	O
that	O
L	B-bacteria
.	I-bacteria
monocytogenes	I-bacteria
employs	O
to	O
circumvent	O
the	O
intestinal	O
epithelial	O
barrier	O
and	O
compare	O
and	O
contrast	O
these	O
strategies	O
with	O
other	O
enteric	O
bacterial	O
pathogens	O
.	O

Additionally	O
,	O
we	O
provide	O
implications	O
of	O
recent	O
findings	O
for	O
food	O
safety	O
regulations	O
.	O

Comparison	O
of	O
the	O
Gut	O
Microbiota	O
of	O
Centenarians	O
in	O
Longevity	O
Villages	O
of	O
South	O
Korea	O
with	O
Those	O
of	O
Other	O
Age	O
Groups	O
.	O

Several	O
studies	O
have	O
attempted	O
to	O
identify	O
factors	O
associated	O
with	O
longevity	O
and	O
maintenance	O
of	O
health	O
in	O
centenarians	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
and	O
compared	O
the	O
gut	O
microbiota	O
of	O
centenarians	O
in	O
longevity	O
villages	O
with	O
the	O
elderly	O
and	O
adults	O
in	O
the	O
same	O
region	O
and	O
urbanized	O
towns	O
.	O

Fecal	O
samples	O
were	O
collected	O
from	O
centenarians	O
,	O
elderly	O
,	O
and	O
young	O
adults	O
in	O
longevity	O
villages	O
,	O
and	O
the	O
gut	O
microbiota	O
sequences	O
of	O
elderly	O
and	O
young	O
adults	O
in	O
urbanized	O
towns	O
of	O
Korea	O
were	O
obtained	O
from	O
public	O
databases	O
.	O

The	O
relative	O
abundance	O
of	O
Firmicutes	B-bacteria
was	O
found	O
to	O
be	O
considerably	O
higher	O
in	O
subjects	O
from	O
longevity	O
villages	O
than	O
those	O
from	O
urbanized	O
towns	O
,	O
whereas	O
Bacteroidetes	B-bacteria
was	O
lower	O
.	O

Age	O
-	O
related	O
rearrangement	O
of	O
gut	O
microbiota	O
was	O
observed	O
in	O
centenarians	O
,	O
such	O
as	O
reduced	O
proportions	O
of	O
Faecalibacterium	B-bacteria
and	O
Prevotella	B-bacteria
,	O
and	O
increased	O
proportion	O
of	O
Escherichia	B-bacteria
,	O
along	O
with	O
higher	O
abundances	O
of	O
Akkermansia	B-bacteria
,	O
Clostridium	B-bacteria
,	O
Collinsella	B-bacteria
,	O
and	O
uncultured	O
Christensenellaceae	B-bacteria
.	O

Gut	O
microbiota	O
of	O
centenarians	O
in	O
rehabilitation	O
hospital	O
were	O
also	O
different	O
to	O
those	O
residing	O
at	O
home	O
.	O

These	O
differences	O
could	O
be	O
due	O
to	O
differences	O
in	O
diet	O
patterns	O
and	O
living	O
environments	O
.	O

In	O
addition	O
,	O
phosphatidylinositol	O
signaling	O
system	O
,	O
glycosphingolipid	O
biosynthesis	O
,	O
and	O
various	O
types	O
of	O
N	O
-	O
glycan	O
biosynthesis	O
were	O
predicted	O
to	O
be	O
higher	O
in	O
the	O
gut	O
microbiota	O
of	O
centenarians	O
(	O
corrected	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
three	O
metabolic	O
pathways	O
of	O
gut	O
microbiota	O
can	O
be	O
associated	O
with	O
the	O
immune	O
status	O
and	O
healthy	O
gut	O
environment	O
of	O
centenarians	O
.	O

Although	O
further	O
studies	O
are	O
necessary	O
to	O
validate	O
the	O
function	O
of	O
microbiota	O
between	O
groups	O
,	O
this	O
study	O
provides	O
valuable	O
information	O
on	O
centenarians	O
'	O
gut	O
microbiota	O
.	O

The	O
Gut	O
Microbiome	O
as	O
a	O
Target	O
for	O
IBD	O
Treatment	O
:	O
Are	O
We	O
There	O
Yet	O
?	O

PURPOSE	O
OF	O
REVIEW	O
:	O
This	O
review	O
aims	O
to	O
highlight	O
recent	O
research	O
on	O
the	O
gut	O
microbiome	O
in	O
IBD	O
and	O
the	O
application	O
of	O
microbiome	O
-	O
modulating	O
therapies	O
for	O
the	O
treatment	O
of	O
IBD	O
including	O
the	O
use	O
of	O
the	O
microbiome	O
as	O
an	O
indicator	O
for	O
disease	O
severity	O
and	O
treatment	O
response	O
.	O

RECENT	O
FINDINGS	O
:	O
Despite	O
the	O
high	O
number	O
of	O
gut	O
microbiome	O
studies	O
and	O
emerging	O
evidence	O
supporting	O
the	O
gut	O
microbiome	O
'	O
s	O
involvement	O
in	O
disease	O
pathogenesis	O
,	O
no	O
single	O
microorganism	O
has	O
been	O
identified	O
as	O
a	O
pathogenic	O
agent	O
in	O
IBD	O
.	O

Retrospective	O
studies	O
and	O
meta	O
-	O
analyses	O
on	O
antibiotic	O
use	O
in	O
ulcerative	O
colitis	O
and	O
Crohn	O
'	O
s	O
disease	O
and	O
long	O
-	O
term	O
outcomes	O
are	O
conflicting	O
.	O

Similarly	O
,	O
the	O
use	O
of	O
probiotics	O
for	O
the	O
treatment	O
of	O
IBD	O
remains	O
inconclusive	O
;	O
however	O
,	O
some	O
encouraging	O
results	O
are	O
emerging	O
as	O
microbial	O
concoctions	O
are	O
optimized	O
to	O
include	O
beneficial	O
bacterial	O
strains	O
.	O

Fecal	O
microbial	O
transplantation	O
(	O
FMT	O
)	O
is	O
currently	O
emerging	O
as	O
one	O
of	O
the	O
more	O
promising	O
microbiome	O
-	O
modulating	O
IBD	O
therapies	O
.	O

FMT	O
studies	O
in	O
ulcerative	O
colitis	O
have	O
shown	O
improved	O
remission	O
rates	O
compared	O
to	O
placebo	O
;	O
however	O
,	O
relatively	O
small	O
study	O
sample	O
sizes	O
and	O
varied	O
treatment	O
methods	O
,	O
limit	O
definitive	O
conclusions	O
.	O

With	O
clear	O
evidence	O
of	O
an	O
IBD	O
gut	O
dysbiosis	O
,	O
novel	O
therapies	O
to	O
treat	O
and	O
prevent	O
disease	O
relapse	O
will	O
undoubtedly	O
require	O
a	O
microbiome	O
-	O
modulating	O
approach	O
.	O

The	O
complexity	O
and	O
variability	O
of	O
IBD	O
disease	O
pathogenesis	O
(	O
disease	O
phenotype	O
,	O
gut	O
microbiome	O
,	O
host	O
genetic	O
susceptibility	O
,	O
and	O
environmental	O
factors	O
)	O
will	O
likely	O
require	O
a	O
personalized	O
and	O
multidimensional	O
treatment	O
approach	O
where	O
microbiome	O
-	O
modulating	O
therapy	O
is	O
coupled	O
with	O
other	O
therapies	O
to	O
target	O
other	O
IBD	O
disease	O
components	O
.	O

Characterization	O
of	O
GH2	O
and	O
GH42	O
beta	O
-	O
galactosidases	O
derived	O
from	O
bifidobacterial	O
infant	O
isolates	O
.	O

Bifidobacteria	B-bacteria
are	O
among	O
the	O
first	O
and	O
most	O
abundant	O
bacterial	O
colonizers	O
of	O
the	O
gastrointestinal	O
tract	O
of	O
(	O
breast	O
-	O
fed	O
)	O
healthy	O
infants	O
.	O

Their	O
success	O
of	O
colonising	O
the	O
infant	O
gut	O
is	O
believed	O
to	O
be	O
,	O
at	O
least	O
partly	O
,	O
due	O
to	O
their	O
ability	O
to	O
metabolize	O
available	O
carbon	O
sources	O
by	O
means	O
of	O
secreted	O
or	O
intracellular	O
glycosyl	O
hydrolases	O
(	O
GHs	O
)	O
.	O

Among	O
these	O
,	O
beta	O
-	O
galactosidases	O
are	O
particularly	O
relevant	O
as	O
they	O
allow	O
bifidobacteria	B-bacteria
to	O
grow	O
on	O
beta	O
-	O
galactosyl	O
-	O
linked	O
saccharidic	O
substrates	O
,	O
which	O
are	O
present	O
in	O
copious	O
amounts	O
in	O
the	O
milk	O
-	O
based	O
diet	O
of	O
their	O
infant	O
host	O
(	O
e	O
.	O
g	O
.	O
lactose	O
and	O
human	O
milk	O
oligosaccharides	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
employed	O
an	O
in	O
silico	O
analysis	O
to	O
identify	O
GH	O
family	O
2	O
and	O
42	O
beta	O
-	O
galactosidases	O
encoded	O
by	O
typical	O
infant	O
-	O
associated	O
bifidobacteria	B-bacteria
.	O

Comparative	O
genome	O
analysis	O
followed	O
by	O
characterisation	O
of	O
selected	O
beta	O
-	O
galactosidases	O
revealed	O
how	O
these	O
GH2	O
and	O
GH42	O
members	O
are	O
distributed	O
among	O
these	O
infant	O
-	O
associated	O
bifidobacteria	B-bacteria
,	O
while	O
their	O
hydrolytic	O
activity	O
towards	O
growth	O
substrates	O
commonly	O
available	O
in	O
the	O
infant	O
gut	O
were	O
also	O
assessed	O
.	O

Earthworms	O
and	O
cadmium	O
-	O
Heavy	O
metal	O
resistant	O
gut	O
bacteria	O
as	O
indicators	O
for	O
heavy	O
metal	O
pollution	O
in	O
soils	O
?	O

Preservation	O
of	O
the	O
soil	O
resources	O
stability	O
is	O
of	O
high	O
importance	O
for	O
ecosystems	O
,	O
particularly	O
in	O
the	O
current	O
era	O
of	O
environmental	O
change	O
,	O
which	O
presents	O
a	O
severe	O
pollution	O
burden	O
(	O
e	O
.	O
g	O
.	O
by	O
heavy	O
metals	O
)	O
to	O
soil	O
fauna	O
.	O

Gut	O
microbiomes	O
are	O
becoming	O
recognized	O
as	O
important	O
players	O
in	O
organism	O
health	O
,	O
with	O
comprehension	O
of	O
their	O
perturbations	O
in	O
the	O
polluted	O
environment	O
offering	O
new	O
insights	O
into	O
the	O
nature	O
and	O
extent	O
of	O
heavy	O
metal	O
effects	O
on	O
the	O
health	O
of	O
soil	O
biota	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
environmentally	O
relevant	O
heavy	O
metal	O
concentrations	O
of	O
cadmium	O
(	O
Cd	O
)	O
on	O
the	O
earthworm	O
(	O
Lumbricus	O
terrestris	O
)	O
gut	O
microbiota	O
.	O

Our	O
results	O
revealed	O
that	O
Cd	O
exposure	O
led	O
to	O
perturbations	O
of	O
earthworm	O
gut	O
microbiota	O
with	O
an	O
increase	O
in	O
bacteria	O
previously	O
described	O
as	O
heavy	O
metal	O
resistant	O
or	O
able	O
to	O
bind	O
heavy	O
metals	O
,	O
revealing	O
the	O
potential	O
of	O
the	O
earthworm	O
-	O
gut	O
microbiota	O
system	O
in	O
overcoming	O
human	O
-	O
caused	O
heavy	O
metal	O
pollution	O
.	O

Furthermore	O
,	O
an	O
'	O
indicator	O
species	O
analysis	O
'	O
linked	O
the	O
bacterial	O
genera	O
Paenibacillus	B-bacteria
,	O
Flavobacterium	B-bacteria
and	O
Pseudomonas	B-bacteria
,	O
with	O
Cd	O
treatment	O
,	O
suggesting	O
these	O
bacterial	O
taxa	O
as	O
biomarkers	O
of	O
exposure	O
in	O
earthworms	O
inhabiting	O
Cd	O
-	O
stressed	O
soils	O
.	O

The	O
results	O
of	O
this	O
study	O
help	O
to	O
understand	O
the	O
impact	O
of	O
anthropogenic	O
disturbance	O
on	O
soil	O
fauna	O
health	O
and	O
will	O
have	O
implications	O
for	O
environmental	O
monitoring	O
and	O
protection	O
of	O
soil	O
resources	O
.	O

Interactions	O
between	O
gut	O
microbiota	O
and	O
non	O
-	O
alcoholic	O
liver	O
disease	O
:	O
The	O
role	O
of	O
microbiota	O
-	O
derived	O
metabolites	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
the	O
intestinal	O
microbiota	O
plays	O
a	O
mechanistic	O
role	O
in	O
the	O
etiology	O
of	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
.	O

Animal	O
and	O
human	O
studies	O
have	O
linked	O
small	O
molecule	O
metabolites	O
produced	O
by	O
commensal	O
bacteria	O
in	O
the	O
gut	O
contribute	O
to	O
not	O
only	O
intestinal	O
inflammation	O
,	O
but	O
also	O
to	O
hepatic	O
inflammation	O
.	O

These	O
immunomodulatory	O
metabolites	O
are	O
capable	O
of	O
engaging	O
host	O
cellular	O
receptors	O
,	O
and	O
may	O
mediate	O
the	O
observed	O
association	O
between	O
gut	O
dysbiosis	O
and	O
NAFLD	O
.	O

This	O
review	O
focuses	O
on	O
the	O
effects	O
and	O
potential	O
mechanisms	O
of	O
three	O
specific	O
classes	O
of	O
metabolites	O
that	O
synthesized	O
or	O
modified	O
by	O
gut	O
bacteria	O
:	O
short	O
chain	O
fatty	O
acids	O
,	O
amino	O
acid	O
catabolites	O
,	O
and	O
bile	O
acids	O
.	O

In	O
particular	O
,	O
we	O
discuss	O
their	O
role	O
as	O
ligands	O
for	O
cell	O
surface	O
and	O
nuclear	O
receptors	O
regulating	O
metabolic	O
and	O
inflammatory	O
pathways	O
in	O
the	O
intestine	O
and	O
liver	O
.	O

Studies	O
reveal	O
that	O
the	O
metabolites	O
can	O
both	O
agonize	O
and	O
antagonize	O
their	O
cognate	O
receptors	O
to	O
reduce	O
or	O
exacerbate	O
liver	O
steatosis	O
and	O
inflammation	O
,	O
and	O
that	O
the	O
effects	O
are	O
metabolite	O
-	O
and	O
context	O
-	O
specific	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
more	O
comprehensively	O
understand	O
bacterial	O
metabolite	O
-	O
mediated	O
gut	O
-	O
liver	O
in	O
NAFLD	O
.	O

This	O
understanding	O
could	O
help	O
identify	O
novel	O
therapeutics	O
and	O
therapeutic	O
targets	O
to	O
intervene	O
in	O
the	O
disease	O
through	O
the	O
gut	O
microbiota	O
.	O

Acid	O
-	O
happy	O
:	O
Survival	O
and	O
recovery	O
of	O
enteropathogenic	B-bacteria
Escherichia	I-bacteria
coli	I-bacteria
(	O
EPEC	B-bacteria
)	O
in	O
simulated	O
gastric	O
fluid	O
.	O

BACKGROUND	O
:	O
Gastric	O
fluid	O
pH	O
serves	O
an	O
important	O
function	O
as	O
an	O
ecological	O
filter	O
to	O
kill	O
unwanted	O
microbial	O
taxa	O
that	O
would	O
otherwise	O
colonise	O
the	O
intestines	O
,	O
thereby	O
shaping	O
the	O
diversity	O
and	O
composition	O
of	O
microbial	O
communities	O
found	O
in	O
the	O
gut	O
.	O

The	O
typical	O
American	O
-	O
based	O
diet	O
causes	O
the	O
gastric	O
pH	O
to	O
increase	O
to	O
pH	O
4	O
to	O
5	O
,	O
and	O
it	O
takes	O
approximately	O
2h	O
to	O
return	O
to	O
pH	O
1	O
.	O
5	O
(	O
normal	O
)	O
.	O

This	O
window	O
of	O
increased	O
gastric	O
pH	O
may	O
allow	O
potential	O
pathogens	O
to	O
negotiate	O
the	O
hostile	O
environment	O
of	O
the	O
stomach	O
.	O

Another	O
factor	O
to	O
consider	O
is	O
that	O
in	O
developing	O
countries	O
many	O
people	O
experience	O
hypochlorhydria	O
related	O
to	O
malnutrition	O
and	O
various	O
gastric	O
diseases	O
.	O

Enteropathogenic	B-bacteria
E	I-bacteria
.	I-bacteria
coli	I-bacteria
(	O
EPEC	B-bacteria
)	O
is	O
a	O
leading	O
cause	O
of	O
infantile	O
diarrhoea	O
and	O
has	O
a	O
high	O
incidence	O
in	O
the	O
developing	O
world	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
survival	O
and	O
recovery	O
of	O
non	O
-	O
acid	O
adapted	O
EPEC	O
exposed	O
to	O
simulated	O
gastric	O
fluid	O
(	O
SGF	O
)	O
over	O
a	O
period	O
of	O
180min	O
.	O

RESULTS	O
:	O
EPEC	O
were	O
grown	O
in	O
nutrient	O
-	O
rich	O
medium	O
and	O
acid	O
challenged	O
in	O
SGF	O
at	O
pH	O
1	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
3	O
.	O
5	O
and	O
4	O
.	O
5	O
.	O

Culturability	O
was	O
evaluated	O
using	O
a	O
standard	O
plate	O
count	O
method	O
,	O
and	O
metabolic	O
viability	O
was	O
assessed	O
via	O
cellular	O
energy	O
(	O
adenosine	O
triphosphate	O
[	O
ATP	O
]	O
assay	O
)	O
and	O
respiratory	O
activity	O
(	O
3	O
-	O
bis	O
(	O
2	O
-	O
methyloxy	O
-	O
4	O
-	O
nitro	O
-	O
5	O
-	O
sulfophenyl	O
)	O
-	O
5	O
-	O
[	O
(	O
phenylamino	O
)	O
carbonyl	O
]	O
-	O
2H	O
-	O
tetrazoliu	O
m	O
hydroxide	O
[	O
XTT	O
]	O
assay	O
)	O
,	O
and	O
recovery	O
and	O
proliferation	O
by	O
means	O
of	O
optical	O
density	O
in	O
liquid	O
cultures	O
.	O

Sampling	O
was	O
performed	O
at	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180min	O
post	O
-	O
SGF	O
exposure	O
.	O

The	O
results	O
of	O
this	O
study	O
showed	O
that	O
EPEC	O
is	O
remarkably	O
acid	O
resistant	O
and	O
was	O
able	O
to	O
survive	O
a	O
simulated	O
gastric	O
environment	O
for	O
up	O
to	O
3h	O
(	O
180min	O
)	O
at	O
various	O
pH	O
(	O
1	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
3	O
.	O
5	O
,	O
and	O
4	O
.	O
5	O
)	O
.	O

EPEC	O
was	O
culturable	O
at	O
all	O
pH	O
(	O
1	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
3	O
.	O
5	O
and	O
4	O
.	O
5	O
)	O
at	O
the	O
higher	O
inoculum	O
size	O
of	O
5	O
.	O
4	O
-	O
7	O
.	O
1x10	O
(	O
6	O
)	O
CFU	O
/	O
ml	O
,	O
and	O
at	O
all	O
pH	O
except	O
pH	O
1	O
.	O
5at	O
the	O
lower	O
inoculums	O
of	O
5	O
.	O
4	O
-	O
7	O
.	O
1x10	O
(	O
3	O
)	O
CFU	O
/	O
ml	O
or	O
5	O
.	O
4	O
-	O
7	O
.	O
1x10	O
(	O
1	O
)	O
CFU	O
/	O
ml	O
.	O

The	O
organism	O
remained	O
metabolically	O
viable	O
at	O
pH	O
1	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
3	O
.	O
5	O
,	O
and	O
4	O
.	O
5	O
and	O
was	O
able	O
to	O
recover	O
and	O
proliferate	O
once	O
placed	O
in	O
a	O
neutral	O
,	O
nutrient	O
-	O
rich	O
environment	O
.	O

CONCLUSION	O
:	O
In	O
this	O
study	O
,	O
EPEC	O
demonstrated	O
remarkable	O
acid	O
resistance	O
and	O
recovery	O
at	O
low	O
pH	O
without	O
prior	O
acid	O
adaptation	O
,	O
which	O
could	O
prove	O
to	O
be	O
problematic	O
even	O
in	O
healthy	O
people	O
.	O

In	O
individuals	O
with	O
decreased	O
gastric	O
acidity	O
,	O
there	O
is	O
a	O
higher	O
probability	O
of	O
pathogen	O
colonization	O
and	O
a	O
resulting	O
change	O
in	O
the	O
gut	O
microbiome	O
.	O

The	O
results	O
highlight	O
the	O
potential	O
increase	O
of	O
food	O
-	O
and	O
waterborne	O
diseases	O
in	O
persons	O
with	O
compromised	O
gastric	O
function	O
,	O
or	O
who	O
are	O
malnourished	O
or	O
immunocompromised	O
.	O

The	O
data	O
herein	O
may	O
possibly	O
help	O
in	O
calculating	O
more	O
precisely	O
the	O
risk	O
associated	O
with	O
consuming	O
bacterial	O
contaminated	O
food	O
and	O
water	O
in	O
these	O
individuals	O
.	O

Effect	O
of	O
3	O
lactobacilli	B-bacteria
on	O
immunoregulation	O
and	O
intestinal	O
microbiota	O
in	O
a	O
beta	O
-	O
lactoglobulin	O
-	O
induced	O
allergic	O
mouse	O
model	O
.	O

Milk	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
common	O
allergen	O
sources	O
in	O
the	O
world	O
,	O
with	O
beta	O
-	O
lactoglobulin	O
representing	O
a	O
major	O
allergen	O
protein	O
.	O

Numerous	O
studies	O
have	O
reported	O
that	O
probiotics	O
exert	O
antiallergic	O
and	O
anti	O
-	O
inflammatory	O
effects	O
.	O

Here	O
,	O
we	O
examined	O
the	O
effects	O
of	O
3	O
strains	O
of	O
Lactobacillus	B-bacteria
on	O
immunomodulatory	O
functions	O
,	O
intestinal	O
barrier	O
functions	O
,	O
and	O
intestinal	O
microbiota	O
through	O
a	O
beta	O
-	O
lactoglobulin	O
-	O
induced	O
allergic	O
mouse	O
model	O
.	O

We	O
found	O
that	O
the	O
oral	O
administration	O
of	O
Lactobacillus	B-bacteria
plantarum	I-bacteria
ZDY2013	I-bacteria
and	O
Lactobacillus	B-bacteria
rhamnosus	I-bacteria
GG	I-bacteria
suppressed	O
allergic	O
response	O
,	O
attenuating	O
serum	O
IgE	O
and	O
relieving	O
anaphylaxis	O
symptoms	O
.	O

The	O
3	O
strains	O
of	O
Lactobacillus	B-bacteria
could	O
induce	O
T	O
helper	O
(	O
Th	O
)	O
1	O
or	O
T	O
regulatory	O
cells	O
to	O
differentiate	O
to	O
inhibit	O
the	O
Th2	O
-	O
biased	O
response	O
for	O
regulating	O
Th1	O
/	O
Th2	O
immune	O
balance	O
.	O

Furthermore	O
,	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
ZDY2013	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
rhamnosus	I-bacteria
GG	I-bacteria
enhanced	O
intestinal	O
barrier	O
function	O
through	O
the	O
regulation	O
of	O
tight	O
junction	O
.	O

We	O
also	O
found	O
that	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
ZDY2013	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
WLPL04	I-bacteria
could	O
regulate	O
alterations	O
in	O
intestinal	O
microbiota	O
caused	O
by	O
allergies	O
.	O

In	O
particular	O
,	O
Rikenella	B-bacteria
,	O
Ruminiclostridium	B-bacteria
,	O
and	O
Lachnospiraceae	B-bacteria
UCG	I-bacteria
-	I-bacteria
006	I-bacteria
were	O
considerably	O
reduced	O
after	O
treatment	O
with	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
ZDY2013	I-bacteria
and	O
L	B-bacteria
.	I-bacteria
plantarum	I-bacteria
WLPL04	I-bacteria
.	O

These	O
results	O
suggested	O
that	O
3	O
Lactobacillus	B-bacteria
strains	I-bacteria
may	O
serve	O
as	O
an	O
effective	O
tool	O
for	O
the	O
treatment	O
of	O
food	O
allergies	O
by	O
regulating	O
immune	O
and	O
gut	O
microbiota	O
.	O

Dose	O
-	O
dependent	O
impact	O
of	O
oxytetracycline	O
on	O
the	O
veal	O
calf	O
microbiome	O
and	O
resistome	O
.	O

BACKGROUND	O
:	O
Antibiotic	O
therapy	O
is	O
commonly	O
used	O
in	O
animal	O
agriculture	O
.	O

Antibiotics	O
excreted	O
by	O
the	O
animals	O
can	O
contaminate	O
farming	O
environments	O
,	O
resulting	O
in	O
long	O
term	O
exposure	O
of	O
animals	O
to	O
sub	O
-	O
inhibitory	O
levels	O
of	O
antibiotics	O
.	O

Little	O
is	O
known	O
on	O
the	O
effect	O
of	O
this	O
exposure	O
on	O
antibiotic	O
resistance	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
long	O
term	O
effects	O
of	O
sub	O
-	O
inhibitory	O
levels	O
of	O
antibiotics	O
on	O
the	O
gut	O
microbiota	O
composition	O
and	O
resistome	O
of	O
veal	O
calves	O
in	O
vivo	O
.	O

Forty	O
-	O
two	O
veal	O
calves	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
.	O

The	O
first	O
group	O
(	O
OTC	O
-	O
high	O
)	O
received	O
therapeutic	O
oral	O
dosages	O
of	O
1	O
g	O
oxytetracycline	O
(	O
OTC	O
)	O
,	O
twice	O
per	O
day	O
,	O
during	O
5	O
days	O
.	O

The	O
second	O
group	O
(	O
OTC	O
-	O
low	O
)	O
received	O
an	O
oral	O
dose	O
of	O
OTC	O
of	O
100	O
-	O
200	O
mug	O
per	O
day	O
during	O
7	O
weeks	O
,	O
mimicking	O
animal	O
exposure	O
to	O
environmental	O
contamination	O
.	O

The	O
third	O
group	O
(	O
CTR	O
)	O
did	O
not	O
receive	O
OTC	O
,	O
serving	O
as	O
unexposed	O
control	O
.	O

Antibiotic	O
residue	O
levels	O
were	O
determined	O
over	O
time	O
.	O

The	O
temporal	O
effects	O
on	O
the	O
gut	O
microbiota	O
and	O
antibiotic	O
resistance	O
gene	O
abundance	O
was	O
analysed	O
by	O
metagenomic	O
sequencing	O
.	O

RESULTS	O
:	O
In	O
the	O
therapeutic	O
group	O
,	O
OTC	O
levels	O
exceeded	O
MIC	O
values	O
.	O

The	O
low	O
group	O
remained	O
at	O
sub	O
-	O
inhibitory	O
levels	O
.	O

The	O
control	O
group	O
did	O
not	O
reach	O
any	O
significant	O
OTC	O
levels	O
.	O

16S	O
rRNA	O
gene	O
-	O
based	O
analysis	O
revealed	O
significant	O
changes	O
in	O
the	O
calf	O
gut	O
microbiota	O
.	O

Time	O
-	O
related	O
changes	O
accounted	O
for	O
most	O
of	O
the	O
variation	O
in	O
the	O
sequence	O
data	O
.	O

Therapeutic	O
application	O
of	O
OTC	O
had	O
transient	O
effect	O
,	O
significantly	O
impacting	O
gut	O
microbiota	O
composition	O
between	O
day	O
0	O
and	O
day	O
2	O
.	O

By	O
metagenomic	O
sequence	O
analysis	O
we	O
identified	O
six	O
antibiotic	O
resistance	O
genes	O
representing	O
three	O
gene	O
classes	O
(	O
tetM	O
,	O
floR	O
and	O
mel	O
)	O
that	O
differed	O
in	O
relative	O
abundance	O
between	O
any	O
of	O
the	O
intervention	O
groups	O
and	O
the	O
control	O
.	O

qPCR	O
was	O
used	O
to	O
validate	O
observations	O
made	O
by	O
metagenomic	O
sequencing	O
,	O
revealing	O
a	O
peak	O
of	O
tetM	O
abundance	O
at	O
day	O
28	O
-	O
35	O
in	O
the	O
OTC	O
-	O
high	O
group	O
.	O

No	O
increase	O
in	O
resistance	O
genes	O
abundance	O
was	O
seen	O
in	O
the	O
OTC	O
-	O
low	O
group	O
.	O

CONCLUSIONS	O
:	O
Under	O
the	O
conditions	O
tested	O
,	O
sub	O
-	O
therapeutic	O
administration	O
of	O
OTC	O
did	O
not	O
result	O
in	O
increased	O
tetM	O
resistance	O
levels	O
as	O
observed	O
in	O
the	O
therapeutic	O
group	O
.	O

